Effect	NN	O
of	IN	O
duloxetine	NN	O
on	IN	O
pain	NN	O
,	,	O
function	NN	O
,	,	O
and	CC	O
quality	NN	O
of	IN	O
life	NN	O
among	IN	O
patients	NNS	O
with	IN	O
chemotherapy-induced	JJ	C
painful	JJ	C
peripheral	JJ	C
neuropathy	NN	C
:	:	O
a	DT	O
randomized	JJ	O
clinical	JJ	O
trial	NN	O
.	.	O

IMPORTANCE	NNP	O
There	EX	O
are	VBP	O
no	DT	O
known	JJ	O
effective	JJ	O
treatments	NNS	O
for	IN	O
painful	JJ	O
chemotherapy-induced	JJ	O
peripheral	JJ	O
neuropathy	NN	O
.	.	O

OBJECTIVE	UH	O
To	TO	O
determine	VB	O
the	DT	O
effect	NN	O
of	IN	O
duloxetine	NN	O
,	,	O
60	CD	O
mg	JJ	O
daily	RB	O
,	,	O
on	IN	O
average	JJ	O
pain	NN	O
severity	NN	O
.	.	O

DESIGN	NNP	O
,	,	O
SETTING	NNP	O
,	,	O
AND	NNP	O
PATIENTS	NNP	O
Randomized	NNP	O
,	,	O
double-blind	NN	O
,	,	O
placebo-controlled	JJ	O
crossover	NN	O
trial	NN	O
at	IN	O
8	CD	O
National	NNP	O
Cancer	NNP	O
Institute	NNP	O
(	(	O
NCI	NNP	O
)	)	O
-funded	VBD	O
cooperative	JJ	O
research	NN	O
networks	NNS	O
that	WDT	O
enrolled	VBD	O
231	CD	C
patients	NNS	O
who	WP	O
were	VBD	O
25	CD	O
years	NNS	O
or	CC	O
older	JJR	O
being	VBG	O
treated	VBN	O
at	IN	O
community	NN	O
and	CC	O
academic	JJ	O
settings	NNS	O
between	IN	O
April	NNP	O
2008	CD	O
and	CC	O
March	NNP	O
2011	CD	O
.	.	O

Study	NNP	O
follow-up	NN	O
was	VBD	O
completed	VBN	O
July	NNP	O
2012	CD	O
.	.	O

Stratified	VBN	O
by	IN	O
chemotherapeutic	JJ	O
drug	NN	O
and	CC	O
comorbid	NN	O
pain	NN	O
risk	NN	O
,	,	O
patients	NNS	O
were	VBD	O
randomized	VBN	O
to	TO	O
receive	VB	O
either	DT	O
duloxetine	NN	O
followed	VBN	O
by	IN	O
placebo	NN	O
or	CC	O
placebo	NN	O
followed	VBN	O
by	IN	O
duloxetine	NN	O
.	.	O

Eligibility	NN	O
required	VBD	O
that	IN	O
patients	NNS	O
have	VBP	O
grade	VBN	C
1	CD	C
or	CC	C
higher	JJR	C
sensory	NN	C
neuropathy	JJ	C
according	VBG	O
to	TO	O
the	DT	O
NCI	NNP	O
Common	NNP	O
Terminology	NNP	O
Criteria	NNP	O
for	IN	O
Adverse	NNP	O
Events	NNS	O
and	CC	O
at	IN	O
least	JJS	O
4	CD	C
on	IN	C
a	DT	C
scale	NN	C
of	IN	C
0	CD	C
to	TO	C
10	CD	C
,	,	C
representing	VBG	C
average	JJ	C
chemotherapy-induced	JJ	C
pain	NN	C
,	,	O
after	IN	O
paclitaxel	NN	O
,	,	O
other	JJ	O
taxane	NN	O
,	,	O
or	CC	O
oxaliplatin	JJ	O
treatment	NN	O
.	.	O

INTERVENTIONS	VBZ	O
The	DT	O
initial	JJ	O
treatment	NN	O
consisted	VBN	O
of	IN	O
taking	VBG	O
1	CD	O
capsule	JJ	O
daily	RB	O
of	IN	O
either	CC	O
30	CD	O
mg	NN	O
of	IN	O
duloxetine	NN	O
or	CC	O
placebo	NN	O
for	IN	O
the	DT	O
first	JJ	O
week	NN	O
and	CC	O
2	CD	O
capsules	NNS	O
of	IN	O
either	DT	O
30	CD	O
mg	NN	O
of	IN	O
duloxetine	NN	O
or	CC	O
placebo	JJ	O
daily	JJ	O
for	IN	O
4	CD	O
additional	JJ	O
weeks	NNS	O
.	.	O

MAIN	NNP	O
OUTCOME	NNP	O
MEASURES	NNP	O
The	DT	O
primary	JJ	O
hypothesis	NN	O
was	VBD	O
that	IN	O
duloxetine	NN	O
would	MD	O
be	VB	O
more	RBR	O
effective	JJ	O
than	IN	O
placebo	NN	O
in	IN	O
decreasing	VBG	O
chemotherapy-induced	JJ	O
peripheral	JJ	O
neuropathic	JJ	O
pain	NN	O
.	.	O

Pain	NNP	O
severity	NN	O
was	VBD	O
assessed	VBN	O
using	VBG	O
the	DT	O
Brief	JJ	O
Pain	NNP	O
Inventory-Short	NNP	O
Form	NNP	O
average	NN	O
pain	NN	O
item	NN	O
with	IN	O
0	CD	O
representing	VBG	O
no	DT	O
pain	NN	O
and	CC	O
10	CD	O
representing	VBG	O
as	RB	O
bad	JJ	O
as	IN	O
can	MD	O
be	VB	O
imagined	VBN	O
.	.	O

RESULTS	JJ	O
Individuals	NNS	O
receiving	VBG	O
duloxetine	NN	O
as	IN	O
their	PRP$	O
initial	JJ	O
5-week	JJ	O
treatment	NN	O
reported	VBD	O
a	DT	O
mean	JJ	O
decrease	NN	O
in	IN	O
average	JJ	O
pain	NN	O
of	IN	O
1.06	CD	O
(	(	O
95	CD	O
%	NN	O
CI	NNP	O
,	,	O
0.72-1.40	NNP	O
)	)	O
vs	VBZ	O
0.34	CD	O
(	(	O
95	CD	O
%	NN	O
CI	NNP	O
,	,	O
0.01-0.66	NNP	O
)	)	O
among	IN	O
those	DT	O
who	WP	O
received	VBD	O
placebo	NN	O
(	(	O
P	NNP	O
=	NNP	O
.003	NNP	O
;	:	O
effect	NN	O
size	NN	O
,	,	O
0.513	CD	O
)	)	O
.	.	O

The	DT	O
observed	JJ	O
mean	JJ	O
difference	NN	O
in	IN	O
the	DT	O
average	JJ	O
pain	NN	O
score	NN	O
between	IN	O
duloxetine	NN	O
and	CC	O
placebo	NN	O
was	VBD	O
0.73	CD	O
(	(	O
95	CD	O
%	NN	O
CI	NNP	O
,	,	O
0.26-1.20	NN	O
)	)	O
.	.	O

Fifty-nine	JJ	O
percent	NN	O
of	IN	O
those	DT	O
initially	RB	O
receiving	VBG	O
duloxetine	NN	O
vs	FW	O
38	CD	O
%	NN	O
of	IN	O
those	DT	O
initially	RB	O
receiving	VBG	O
placebo	NN	O
reported	VBD	O
decreased	JJ	O
pain	NN	O
of	IN	O
any	DT	O
amount	NN	O
.	.	O

CONCLUSION	NNP	O
AND	CC	O
RELEVANCE	NNP	O
Among	IN	O
patients	NNS	O
with	IN	O
painful	JJ	C
chemotherapy-induced	JJ	C
peripheral	JJ	C
neuropathy	NN	C
,	,	O
the	DT	O
use	NN	O
of	IN	O
duloxetine	NN	O
compared	VBN	O
with	IN	O
placebo	NN	O
for	IN	O
5	CD	O
weeks	NNS	O
resulted	VBD	O
in	IN	O
a	DT	O
greater	JJR	O
reduction	NN	O
in	IN	O
pain	NN	O
.	.	O

TRIAL	NNP	O
REGISTRATION	NNP	O
clinicaltrials.gov	NN	O
Identifier	NNP	O
:	:	O
NCT00489411	NN	O
.	.	O

Need	NN	O
for	IN	O
insulin	NN	O
therapy	NN	O
in	IN	O
type	NN	C
II	NNP	C
diabetes	VBZ	C
mellitus	NN	C
.	.	O

A	DT	O
randomized	JJ	O
trial	NN	O
.	.	O

To	TO	O
identify	VB	O
patients	NNS	O
with	IN	O
type	JJ	C
II	NNP	C
diabetes	VBZ	C
mellitus	NN	C
for	IN	O
whom	WP	O
insulin	NN	O
therapy	NN	O
is	VBZ	O
most	RBS	O
beneficial	JJ	O
,	,	O
we	PRP	O
conducted	VBD	O
a	DT	O
randomized	VBN	O
controlled	VBN	O
trial	NN	O
in	IN	O
the	DT	O
general	JJ	O
medicine	NN	O
clinic	NN	O
of	IN	O
a	DT	O
university	NN	O
hospital	NN	O
.	.	O

Asymptomatic	NNP	O
,	,	O
obese	JJ	C
,	,	O
insulin-treated	JJ	O
patients	NNS	O
were	VBD	O
given	VBN	O
diet	JJ	O
and	CC	O
diabetes	VBZ	O
education	NN	O
and	CC	O
,	,	O
in	IN	O
half	NN	O
of	IN	O
these	DT	O
patients	NNS	O
,	,	O
insulin	JJ	O
therapy	NN	O
was	VBD	O
withdrawn	VBN	O
.	.	O

Over	IN	O
six	CD	O
months	NNS	O
,	,	O
patients	NNS	O
developing	VBG	O
hyperglycemic	JJ	O
symptoms	NNS	O
or	CC	O
acetonemia	NN	O
were	VBD	O
counted	VBN	O
as	IN	O
study	NN	O
failures	NNS	O
.	.	O

Failure	NN	O
criteria	NNS	O
developed	VBD	O
in	IN	O
13	CD	O
of	IN	O
25	CD	SS
insulin-withdrawal	JJ	SS
patients	NNS	O
,	,	O
at	IN	O
a	DT	O
median	NN	O
of	IN	O
four	CD	O
weeks	NNS	O
after	IN	O
withdrawal	NN	O
,	,	O
compared	VBN	O
with	IN	O
two	CD	O
of	IN	O
24	CD	SS
control	NN	O
subjects	NNS	O
.	.	O

Elevated	VBN	O
stimulated	VBD	O
glucose	JJ	O
levels	NNS	O
predicted	VBD	O
the	DT	O
need	NN	O
for	IN	O
insulin	JJ	O
therapy	NN	O
.	.	O

Hyperglycemia	NNP	O
worsened	VBD	O
in	IN	O
insulin-withdrawal	JJ	O
patients	NNS	O
who	WP	O
did	VBD	O
not	RB	O
meet	VB	O
study	JJ	O
failure	NN	O
criteria	NNS	O
,	,	O
but	CC	O
it	PRP	O
improved	VBD	O
in	IN	O
control	NN	O
patients	NNS	O
.	.	O

Study	NNP	O
patients	NNS	O
were	VBD	O
insulin	JJ	O
deficient	NN	O
as	IN	O
shown	VBN	O
by	IN	O
low	JJ	O
baseline	NN	O
C	NNP	O
peptide	NN	O
values	NNS	O
(	(	O
0.43	CD	O
+/-	JJ	O
0.05	CD	O
nmol/L	NN	O
)	)	O
.	.	O

The	DT	O
prompt	JJ	O
metabolic	JJ	O
decompensation	NN	O
precipitated	VBN	O
by	IN	O
insulin	NN	O
withdrawal	NN	O
suggests	VBZ	O
that	IN	O
insulin-deficient	JJ	O
patients	NNS	O
may	MD	O
benefit	VB	O
from	IN	O
insulin	NN	O
therapy	NN	O
and	CC	O
may	MD	O
need	VB	O
it	PRP	O
to	TO	O
prevent	VB	O
symptomatic	JJ	O
hyperglycemia	NN	O
.	.	O

Short-term	JJ	O
effects	NNS	O
of	IN	O
prednisolone	NN	O
and	CC	O
dexamethasone	NN	O
on	IN	O
circulating	VBG	O
concentrations	NNS	O
of	IN	O
leptin	NN	O
and	CC	O
sex	NN	O
hormone-binding	JJ	O
globulin	NN	O
in	IN	O
children	NNS	A
being	VBG	O
treated	VBN	O
for	IN	O
acute	JJ	C
lymphoblastic	JJ	C
leukaemia	NN	C
.	.	O

OBJECTIVE	NNP	O
Disturbances	NNPS	O
in	IN	O
body	NN	O
weight	JJ	O
regulation	NN	O
are	VBP	O
often	RB	O
encountered	VBN	O
during	IN	O
glucocorticoid	JJ	O
treatment	NN	O
and	CC	O
are	VBP	O
associated	VBN	O
with	IN	O
increased	JJ	O
insulin	NN	O
resistance	NN	O
and	CC	O
truncal	JJ	O
fat	NN	O
accumulation	NN	O
.	.	O

Children	NNP	A
were	VBD	O
investigated	VBN	O
who	WP	O
were	VBD	O
receiving	VBG	O
glucocorticoid	JJ	O
treatment	NN	O
for	IN	O
acute	JJ	C
lymphoblastic	JJ	C
leukaemia	NN	C
(	(	C
ALL	DT	C
)	)	C
.	.	O

They	PRP	O
were	VBD	O
randomized	VBN	O
to	TO	O
receive	VB	O
either	CC	O
prednisolone	VB	O
or	CC	O
dexamethasone	VB	O
as	IN	O
part	NN	O
of	IN	O
induction	NN	O
of	IN	O
remission	NN	O
.	.	O

This	DT	O
randomization	NN	O
process	NN	O
provided	VBD	O
a	DT	O
suitable	JJ	O
opportunity	NN	O
to	TO	O
compare	VB	O
the	DT	O
effects	NNS	O
of	IN	O
these	DT	O
two	CD	O
administered	VBD	O
steroid	NN	O
on	IN	O
surrogate	JJ	O
markers	NNS	O
of	IN	O
adipocyte	NN	O
activity	NN	O
(	(	O
leptin	NN	O
)	)	O
and	CC	O
hyperinsulinaemia/insulin	JJ	O
resistance	NN	O
(	(	O
SHBG	NNP	O
)	)	O
.	.	O

DESIGN	NNP	O
AND	CC	O
PATIENTS	NNP	O
Prospective	NNP	O
study	NN	O
over	IN	O
16	CD	O
weeks	NNS	O
of	IN	O
children	NNS	A
randomized	VBN	O
to	TO	O
receive	VB	O
prednisolone	NN	O
(	(	O
40	CD	O
mg/m2	NN	O
)	)	O
or	CC	O
dexamethasone	NN	O
(	(	O
6.5	CD	O
mg/m2	NN	O
)	)	O
as	IN	O
part	NN	O
of	IN	O
the	DT	O
MRC-ALL97/99	NNP	O
induction	NN	O
chemotherapy	NN	O
for	IN	O
ALL	NNP	O
.	.	O

Nineteen	NNP	SS
children	NNS	A
(	(	O
8	CD	SS
male	NN	SE
,	,	O
11	CD	SS
female	NN	SE
)	)	O
with	IN	O
a	DT	O
median	JJ	O
age	NN	O
5.9	CD	A
years	NNS	A
(	(	O
range	VB	O
2.6-13	CD	A
years	NNS	O
)	)	O
were	VBD	O
recruited	VBN	O
into	IN	O
the	DT	O
study	NN	O
.	.	O

Main	NNP	O
outcome	JJ	O
measures	NNS	O
were	VBD	O
body	JJ	O
mass	NN	O
index	NN	O
(	(	O
BMI	NNP	O
)	)	O
,	,	O
serum	JJ	O
leptin	NN	O
and	CC	O
sex	NN	O
hormone	NN	O
binding	VBG	O
globulin	NN	O
(	(	O
SHBG	NNP	O
)	)	O
.	.	O

RESULTS	NNP	O
Glucocorticoid	NNP	O
administration	NN	O
for	IN	O
5	CD	O
weeks	NNS	O
resulted	VBD	O
in	IN	O
significant	JJ	O
(	(	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
increases	NNS	O
in	IN	O
BMI	NNP	O
,	,	O
leptin	NN	O
(	(	O
corrected	VBN	O
for	IN	O
BMI	NNP	O
)	)	O
and	CC	O
the	DT	O
leptin	NN	O
:	:	O
SHBG	NNP	O
ratio	NN	O
and	CC	O
lowering	NN	O
of	IN	O
SHBG	NNP	O
.	.	O

Dose	NNP	O
for	IN	O
dose	NN	O
,	,	O
dexamethasone	NN	O
was	VBD	O
significantly	RB	O
more	RBR	O
potent	JJ	O
than	IN	O
prednisolone	NN	O
in	IN	O
altering	VBG	O
these	DT	O
parameters	NNS	O
.	.	O

CONCLUSIONS	NNP	O
Short-term	JJ	O
glucocorticoid	NN	O
treatment	NN	O
has	VBZ	O
significant	JJ	O
effects	NNS	O
on	IN	O
BMI	NNP	O
,	,	O
leptin	NN	O
and	CC	O
SHBG	NNP	O
.	.	O

The	DT	O
leptin	NN	O
:	:	O
SHBG	NNP	O
ratio	NN	O
increase	NN	O
indicates	VBZ	O
that	IN	O
this	DT	O
may	MD	O
be	VB	O
a	DT	O
novel	JJ	O
and	CC	O
sensitive	JJ	O
biochemical	JJ	O
marker	NN	O
of	IN	O
metabolic	JJ	O
change	NN	O
.	.	O

Our	PRP$	O
results	NNS	O
suggest	VBP	O
that	IN	O
glucocorticoid	JJ	O
treatment	NN	O
regimens	NNS	O
should	MD	O
be	VB	O
kept	VBN	O
as	RB	O
short	JJ	O
as	IN	O
possible	JJ	O
to	TO	O
avoid	VB	O
possible	JJ	O
detrimental	JJ	O
effects	NNS	O
associated	VBN	O
with	IN	O
increased	JJ	O
adiposity	NN	O
and	CC	O
insulin	NN	O
resistance	NN	O
.	.	O

Safety	NN	O
of	IN	O
ferumoxytol	NN	O
in	IN	O
patients	NNS	O
with	IN	O
anemia	NN	C
and	CC	O
CKD	NNP	C
.	.	O

BACKGROUND	NNP	O
Iron	NNP	O
deficiency	NN	O
anemia	NN	O
is	VBZ	O
a	DT	O
common	JJ	O
complication	NN	O
in	IN	O
patients	NNS	O
with	IN	O
chronic	JJ	C
kidney	NN	C
disease	NN	C
(	(	C
CKD	NNP	C
)	)	C
.	.	O

Currently	NNP	O
available	JJ	O
intravenous	JJ	O
(	(	O
IV	NNP	O
)	)	O
iron	NN	O
replacement	NN	O
therapies	NNS	O
have	VBP	O
either	DT	O
inconvenient	JJ	O
regimens	NNS	O
of	IN	O
administration	NN	O
or	CC	O
adverse	JJ	O
event	NN	O
profiles	NNS	O
that	WDT	O
limit	VBP	O
their	PRP$	O
utility	NN	O
in	IN	O
the	DT	O
outpatient	JJ	O
setting	NN	O
.	.	O

Ferumoxytol	NNP	O
is	VBZ	O
a	DT	O
novel	NN	O
,	,	O
semisynthetic	JJ	O
,	,	O
carbohydrate-coated	JJ	O
,	,	O
superparamagnetic	JJ	O
iron	NN	O
oxide	NN	O
nanoparticle	NN	O
that	WDT	O
is	VBZ	O
administered	VBN	O
IV	NNP	O
as	IN	O
an	DT	O
injection	NN	O
.	.	O

The	DT	O
main	JJ	O
objective	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
assess	VB	O
the	DT	O
safety	NN	O
of	IN	O
ferumoxytol	NN	O
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
patients	NNS	O
with	IN	O
CKD	NNP	C
stages	VBZ	C
1	CD	C
to	TO	C
5	CD	C
and	CC	C
5D	CD	C
.	.	O

STUDY	NNP	O
DESIGN	NNP	O
Phase	NNP	O
3	CD	O
,	,	O
randomized	VBN	O
,	,	O
double-blind	JJ	O
,	,	O
placebo-controlled	JJ	O
,	,	O
crossover	NN	O
,	,	O
multicenter	NN	O
study	NN	O
of	IN	O
a	DT	O
single	JJ	O
510-mg	JJ	O
dose	NN	O
of	IN	O
ferumoxytol	JJ	O
versus	NN	O
saline	NN	O
as	IN	O
placebo	NN	O
.	.	O

SETTING	NNP	O
&	CC	O
PARTICIPANTS	NNP	O
750	CD	SS
patients	NNS	O
with	IN	O
CKD	NNP	C
stages	VBZ	C
1	CD	C
to	TO	C
5	CD	C
and	CC	C
5D	CD	C
.	.	O

INTERVENTION	NNP	O
An	DT	O
IV	NNP	O
injection	NN	O
of	IN	O
either	CC	O
17	CD	O
mL	NN	O
of	IN	O
ferumoxytol	NN	O
or	CC	O
saline	NN	O
placebo	NN	O
over	IN	O
17	CD	O
seconds	NNS	O
on	IN	O
day	NN	O
0	CD	O
and	CC	O
the	DT	O
alternate	NN	O
agent	NN	O
on	IN	O
day	NN	O
7	CD	O
.	.	O

OUTCOMES	NNP	O
&	CC	O
MEASUREMENTS	NNP	O
Descriptive	NNP	O
comparison	NN	O
of	IN	O
adverse	JJ	O
events	NNS	O
,	,	O
laboratory	NN	O
tests	NNS	O
,	,	O
and	CC	O
vital	JJ	O
signs	NNS	O
.	.	O

RESULTS	NNP	O
Of	IN	O
750	CD	SS
randomly	NNS	O
assigned	VBD	O
patients	NNS	O
with	IN	O
CKD	NNP	C
,	,	O
60	CD	O
%	NN	O
were	VBD	O
not	RB	O
on	IN	O
dialysis	NN	O
therapy	NN	O
.	.	O

713	CD	O
patients	NNS	O
received	VBD	O
ferumoxytol	JJ	O
,	,	O
and	CC	O
711	CD	SS
received	VBD	O
placebo	NN	O
.	.	O

There	EX	O
were	VBD	O
420	CD	O
adverse	JJ	O
events	NNS	O
reported	VBD	O
;	:	O
242	CD	O
in	IN	O
152	CD	SS
patients	NNS	O
(	(	O
21.3	CD	O
%	NN	O
)	)	O
with	IN	O
ferumoxytol	NN	O
and	CC	O
178	CD	O
in	IN	O
119	CD	SS
patients	NNS	O
(	(	O
16.7	CD	O
%	NN	O
)	)	O
with	IN	O
placebo	NN	O
.	.	O

The	DT	O
incidence	NN	O
of	IN	O
related	JJ	O
adverse	JJ	O
events	NNS	O
was	VBD	O
5.2	CD	O
%	NN	O
with	IN	O
ferumoxytol	NN	O
and	CC	O
4.5	CD	O
%	NN	O
with	IN	O
placebo	NN	O
.	.	O

The	DT	O
most	RBS	O
common	JJ	O
related	JJ	O
adverse	JJ	O
events	NNS	O
after	IN	O
each	DT	O
treatment	NN	O
included	VBD	O
symptoms	NNS	O
related	VBN	O
to	TO	O
the	DT	O
injection/infusion	NN	O
site	NN	O
,	,	O
dizziness	NN	O
,	,	O
pruritus	NN	O
,	,	O
headache	NN	O
,	,	O
fatigue	NN	O
,	,	O
and	CC	O
nausea	NN	O
.	.	O

Serious	JJ	O
adverse	JJ	O
events	NNS	O
occurred	VBD	O
in	IN	O
21	CD	O
patients	NNS	O
(	(	O
2.9	CD	O
%	NN	O
)	)	O
after	IN	O
ferumoxytol	NN	O
and	CC	O
13	CD	O
patients	NNS	O
(	(	O
1.8	CD	O
%	NN	O
)	)	O
after	IN	O
placebo	NN	O
.	.	O

Serious	JJ	O
related	JJ	O
adverse	JJ	O
events	NNS	O
were	VBD	O
observed	VBN	O
in	IN	O
1	CD	O
patient	NN	O
(	(	O
0.1	CD	O
%	NN	O
)	)	O
after	IN	O
each	DT	O
treatment	NN	O
.	.	O

There	EX	O
was	VBD	O
no	DT	O
meaningful	JJ	O
decrease	NN	O
in	IN	O
blood	NN	O
pressure	NN	O
after	IN	O
administration	NN	O
of	IN	O
ferumoxytol	NN	O
or	CC	O
placebo	NN	O
.	.	O

LIMITATIONS	NNP	O
Follow-up	NNP	O
was	VBD	O
7	CD	O
days	NNS	O
after	IN	O
each	DT	O
study	NN	O
treatment	NN	O
.	.	O

CONCLUSIONS	NNP	O
Ferumoxytol	NNP	O
is	VBZ	O
well	RB	O
tolerated	VBN	O
and	CC	O
has	VBZ	O
a	DT	O
safety	NN	O
profile	NN	O
similar	JJ	O
to	TO	O
placebo	VB	O
in	IN	O
anemic	JJ	C
patients	NNS	O
with	IN	O
CKD	NNP	C
stages	VBZ	C
1	CD	C
to	TO	C
5	CD	C
and	CC	O
5D	CD	O
.	.	O

[	JJ	O
Efficacy	NNP	O
of	IN	O
naftopidil	NN	O
in	IN	O
patients	NNS	O
with	IN	O
overactive	JJ	C
bladder	NN	C
associated	VBN	C
with	IN	C
benign	JJ	C
prostatic	JJ	C
hyperplasia	NN	C
:	:	O
prospective	JJ	O
randomized	NN	O
controlled	VBD	O
study	NN	O
to	TO	O
compare	VB	O
differences	NNS	O
in	IN	O
efficacy	NN	O
between	IN	O
morning	NN	O
and	CC	O
evening	VBG	O
medication	NN	O
]	NNP	O
.	.	O

A	NNP	O
total	NN	O
of	IN	O
100	CD	SS
patients	NNS	O
with	IN	O
benign	JJ	C
prostatic	JJ	C
hyperplasia	NN	C
(	(	C
BPH	NNP	C
)	)	C
and	CC	C
overactive	JJ	C
bladder	NN	C
(	(	C
OAB	NNP	C
)	)	C
symptoms	NNS	O
(	(	O
BPH/OAB	NNP	O
)	)	O
,	,	O
enrolled	VBN	O
between	IN	O
June	NNP	O
2006	CD	O
to	TO	O
March	NNP	O
2008	CD	O
,	,	O
were	VBD	O
randomly	RB	O
divided	VBN	O
into	IN	O
2	CD	O
groups	NNS	O
of	IN	O
morning	NN	O
medication	NN	O
(	(	O
M	NNP	O
)	)	O
and	CC	O
evening	VBG	O
medication	NN	O
(	(	O
E	NNP	O
)	)	O
groups	NNS	O
,	,	O
then	RB	O
50	CD	O
mg	NN	O
of	IN	O
naftopidil	NN	O
was	VBD	O
given	VBN	O
once	RB	O
a	DT	O
day	NN	O
after	IN	O
breakfast	NN	O
or	CC	O
supper	NN	O
for	IN	O
8	CD	O
weeks	NNS	O
.	.	O

Data	NNS	O
were	VBD	O
available	JJ	O
for	IN	O
efficacy	NN	O
analysis	NN	O
on	IN	O
80	CD	O
patients	NNS	O
(	(	O
M	NNP	O
group	NN	O
;	:	O
43	CD	O
,	,	O
E	NNP	O
group	NN	O
;	:	O
37	CD	O
)	)	O
.	.	O

Naftopidil	NNP	O
significantly	RB	O
improved	VBD	O
the	DT	O
overall	JJ	O
international	JJ	O
prostatic	JJ	O
symptom	NN	O
score	NN	O
;	:	O
from	IN	O
19.2?7.9	CD	O
to	TO	O
11.7?5.8	CD	O
in	IN	O
the	DT	O
M	NNP	O
group	NN	O
and	CC	O
from	IN	O
19.4?6.4	CD	O
to	TO	O
12.3?6.8	CD	O
in	IN	O
the	DT	O
E	NNP	O
group	NN	O
(	(	O
p	JJ	O
<	NNP	O
0.0001	CD	O
)	)	O
,	,	O
QOL	NNP	O
score	NN	O
from	IN	O
4.9?0.8	CD	O
to	TO	O
3.2?1.4	CD	O
in	IN	O
the	DT	O
M	NNP	O
group	NN	O
and	CC	O
from	IN	O
5.0?0.8	CD	O
to	TO	O
3.6?1.3	CD	O
in	IN	O
the	DT	O
E	NNP	O
group	NN	O
(	(	O
p	JJ	O
<	NNP	O
0.0001	CD	O
)	)	O
,	,	O
and	CC	O
OAB	NNP	O
symptom	VBD	O
score	NN	O
from	IN	O
7.8?2.6	CD	O
to	TO	O
5.0?2.5	CD	O
in	IN	O
the	DT	O
M	NNP	O
group	NN	O
(	(	O
p	JJ	O
<	NNP	O
0.0001	CD	O
)	)	O
and	CC	O
from	IN	O
8.6?2.9	CD	O
to	TO	O
5.8?	CD	O
3.3	CD	O
in	IN	O
the	DT	O
E	NNP	O
group	NN	O
(	(	O
p	JJ	O
<	NNP	O
0.0001	CD	O
)	)	O
.	.	O

There	EX	O
was	VBD	O
no	DT	O
significant	JJ	O
difference	NN	O
in	IN	O
the	DT	O
incidence	NN	O
of	IN	O
adverse	JJ	O
effects	NNS	O
between	IN	O
the	DT	O
M	NNP	O
group	NN	O
(	(	O
6.1	CD	O
%	NN	O
)	)	O
and	CC	O
E	NNP	O
group	NN	O
(	(	O
2.2	CD	O
%	NN	O
)	)	O
.	.	O

These	DT	O
results	NNS	O
suggest	VBP	O
that	IN	O
naftopidil	JJ	O
improves	NNS	O
storage	NN	O
symptoms	NNS	O
as	RB	O
well	RB	O
as	IN	O
voiding	VBG	O
symptoms	NNS	O
regardless	RB	O
of	IN	O
timing	NN	O
of	IN	O
administration	NN	O
.	.	O

Early	JJ	O
combination	NN	O
disease-modifying	JJ	O
antirheumatic	JJ	O
drug	NN	O
therapy	NN	O
and	CC	O
tight	JJ	O
disease	NN	O
control	NN	O
improve	VB	O
long-term	JJ	O
radiologic	JJ	O
outcome	NN	O
in	IN	O
patients	NNS	C
with	IN	C
early	JJ	C
rheumatoid	NN	C
arthritis	NN	C
:	:	C
the	DT	O
11-year	JJ	O
results	NNS	O
of	IN	O
the	DT	O
Finnish	NNP	O
Rheumatoid	NNP	O
Arthritis	NNP	O
Combination	NNP	O
Therapy	NNP	O
trial	NN	O
.	.	O

INTRODUCTION	NNP	O
Early	NNP	O
treatment	NN	O
of	IN	O
rheumatoid	NN	C
arthritis	NN	C
(	(	C
RA	NNP	C
)	)	C
has	VBZ	O
been	VBN	O
shown	VBN	O
to	TO	O
retard	VB	O
the	DT	O
development	NN	O
of	IN	O
joint	JJ	O
damage	NN	O
for	IN	O
a	DT	O
period	NN	O
of	IN	O
up	IN	O
to	TO	O
5	CD	O
years	NNS	O
.	.	O

The	DT	O
aim	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
evaluate	VB	O
the	DT	O
radiologic	JJ	O
progression	NN	O
beyond	IN	O
that	DT	O
time	NN	O
in	IN	O
patients	NNS	C
with	IN	C
early	JJ	C
RA	NNP	C
initially	RB	C
treated	VBD	C
with	IN	C
a	DT	C
combination	NN	C
of	IN	C
three	CD	C
disease-modifying	JJ	C
antirheumatic	JJ	C
drugs	NNS	C
(	(	C
DMARDs	NNP	C
)	)	C
or	CC	C
a	DT	C
single	JJ	C
DMARD	NNP	C
.	.	C

METHODS	NNP	O
A	NNP	O
cohort	NN	O
of	IN	O
199	CD	O
patients	NNS	O
with	IN	O
early	JJ	O
active	JJ	O
RA	NNP	O
were	VBD	O
initially	RB	O
randomized	VBN	O
to	TO	O
receive	VB	O
treatment	NN	O
with	IN	O
a	DT	O
combination	NN	O
of	IN	O
methotrexate	NN	O
,	,	O
sulfasalazine	NN	O
,	,	O
and	CC	O
hydroxychloroquine	NN	O
with	IN	O
prednisolone	NN	O
(	(	O
FIN-RACo	NNP	O
)	)	O
,	,	O
or	CC	O
treatment	NN	O
with	IN	O
a	DT	O
single	JJ	O
DMARD	NNP	O
(	(	O
initially	RB	O
,	,	O
sulfasalazine	NN	O
)	)	O
with	IN	O
or	CC	O
without	IN	O
prednisolone	NN	O
(	(	O
SINGLE	NNP	O
)	)	O
.	.	O

After	IN	O
2	CD	O
years	NNS	O
,	,	O
the	DT	O
drug-treatment	JJ	O
strategy	NN	O
became	VBD	O
unrestricted	JJ	O
,	,	O
but	CC	O
still	RB	O
targeted	VBN	O
remission	NN	O
.	.	O

The	DT	O
radiographs	NN	O
of	IN	O
hands	NNS	O
and	CC	O
feet	NNS	O
were	VBD	O
analyzed	VBN	O
by	IN	O
using	VBG	O
the	DT	O
Larsen	NNP	O
score	NN	O
at	IN	O
baseline	NN	O
,	,	O
2	CD	O
,	,	O
5	CD	O
,	,	O
and	CC	O
11	CD	O
years	NNS	O
,	,	O
and	CC	O
the	DT	O
radiographs	NN	O
of	IN	O
large	JJ	O
joints	NNS	O
,	,	O
at	IN	O
11	CD	O
years	NNS	O
.	.	O

RESULTS	VB	O
Sixty-five	JJ	O
patients	NNS	O
in	IN	O
the	DT	O
FIN-RACo	NNP	O
and	CC	O
65	CD	O
in	IN	O
the	DT	O
SINGLE	NNP	O
group	NN	O
had	VBD	O
radiographs	NN	O
of	IN	O
hands	NNS	O
and	CC	O
feet	NNS	O
available	JJ	O
at	IN	O
baseline	NN	O
and	CC	O
at	IN	O
11	CD	O
years	NNS	O
.	.	O

The	DT	O
mean	JJ	O
change	NN	O
from	IN	O
baseline	NN	O
to	TO	O
11	CD	O
years	NNS	O
in	IN	O
Larsen	NNP	O
score	NN	O
was	VBD	O
17	CD	O
(	(	O
95	CD	O
%	NN	O
CI	NNP	O
,	,	O
12	CD	O
to	TO	O
26	CD	O
)	)	O
in	IN	O
the	DT	O
FIN-RACo	NNP	O
group	NN	O
and	CC	O
27	CD	O
(	(	O
95	CD	O
%	NN	O
CI	NNP	O
,	,	O
22	CD	O
to	TO	O
33	CD	O
)	)	O
in	IN	O
the	DT	O
SINGLE	NNP	O
group	NN	O
(	(	O
P=0.037	NNP	O
)	)	O
.	.	O

In	IN	O
total	JJ	O
,	,	O
87	CD	O
%	NN	O
(	(	O
95	CD	O
%	NN	O
CI	NNP	O
,	,	O
74	CD	O
to	TO	O
94	CD	O
)	)	O
and	CC	O
72	CD	O
%	NN	O
(	(	O
95	CD	O
%	NN	O
CI	NNP	O
,	,	O
58	CD	O
to	TO	O
84	CD	O
)	)	O
of	IN	O
the	DT	O
patients	NNS	O
in	IN	O
the	DT	O
FIN-RACo	NNP	O
and	CC	O
the	DT	O
SINGLE	NNP	O
treatment	NN	O
arms	NNS	O
,	,	O
respectively	RB	O
,	,	O
had	VBD	O
no	DT	O
erosive	JJ	O
changes	NNS	O
in	IN	O
large	JJ	O
joints	NNS	O
at	IN	O
11	CD	O
years	NNS	O
.	.	O

CONCLUSIONS	NNP	O
Targeting	VBG	O
to	TO	O
remission	NN	O
with	IN	O
tight	JJ	O
clinical	JJ	O
controls	NNS	O
results	NNS	O
in	IN	O
low	JJ	O
radiologic	JJ	O
progression	NN	O
in	IN	O
most	JJS	O
RA	JJ	SS
patients	NNS	SS
.	.	SS

Patients	NNS	O
treated	VBD	O
initially	RB	O
with	IN	O
a	DT	O
combination	NN	O
of	IN	O
DMARDs	NNP	O
have	VBP	O
less	RBR	O
long-term	JJ	O
radiologic	NN	O
damage	NN	O
than	IN	O
do	VBP	O
those	DT	O
treated	VBN	O
initially	RB	O
with	IN	O
DMARD	NNP	O
monotherapy	NN	O
.	.	O

TRIAL	NNP	O
REGISTRATION	NNP	O
Current	NNP	O
Controlled	NNP	O
Trials	NNP	O
ISRCTN18445519	NNP	O
.	.	O

A	DT	O
30-month	JJ	O
longitudinal	JJ	O
study	NN	O
of	IN	O
the	DT	O
effects	NNS	O
of	IN	O
some	DT	O
oral	JJ	O
hygiene	NN	O
measures	NNS	O
on	IN	O
Streptococcus	NNP	O
mutans	NNS	O
and	CC	O
approximal	JJ	O
dental	JJ	O
caries	NNS	O
.	.	O

The	DT	O
effects	NNS	O
of	IN	O
some	DT	O
oral	JJ	O
hygiene	NN	O
measures	NNS	O
on	IN	O
Streptococcus	NNP	O
mutants	NNS	O
and	CC	O
approximal	JJ	O
dental	JJ	O
caries	NNS	O
were	VBD	O
evaluated	VBN	O
.	.	O

One	CD	O
hundred	CD	O
and	CC	O
eighty-seven	JJ	O
13-year-old	JJ	O
individuals	NNS	O
with	IN	O
high	JJ	O
levels	NNS	O
of	IN	O
salivary	JJ	O
S.	NNP	O
mutans	NNS	O
(	(	O
greater	JJR	O
than	IN	O
10	CD	O
(	(	O
6	CD	O
)	)	O
/mL	NN	O
)	)	O
were	VBD	O
selected	VBN	O
.	.	O

They	PRP	O
were	VBD	O
randomly	RB	O
distributed	VBN	O
into	IN	O
three	CD	O
groups	NNS	O
.	.	O

Group	NNP	O
I	PRP	O
initially	RB	O
received	VBD	O
professional	JJ	O
mechanical	JJ	O
tooth-cleaning	NN	O
,	,	O
tongue-scraping	NN	O
,	,	O
chlorhexidine	NN	O
treatment	NN	O
,	,	O
and	CC	O
oral	JJ	O
hygiene	NN	O
instructions	NNS	O
concentrated	VBD	O
on	IN	O
the	DT	O
approximal	JJ	O
surfaces	NNS	O
most	RBS	O
colonized	VBN	O
by	IN	O
S.	NNP	O
mutans	NNS	O
.	.	O

The	DT	O
treatment	NN	O
was	VBD	O
given	VBN	O
four	CD	O
times	NNS	O
with	IN	O
intervals	NNS	O
of	IN	O
two	CD	O
days	NNS	O
,	,	O
followed	VBN	O
by	IN	O
one	CD	O
single	JJ	O
treatment	NN	O
every	DT	O
six	CD	O
months	NNS	O
throughout	IN	O
the	DT	O
experimental	JJ	O
period	NN	O
.	.	O

The	DT	O
initial	JJ	O
treatment	NN	O
period	NN	O
for	IN	O
group	NN	O
II	NNP	O
,	,	O
also	RB	O
consisting	VBG	O
of	IN	O
four	CD	O
visits	NNS	O
,	,	O
included	VBD	O
the	DT	O
same	JJ	O
oral	JJ	O
hygiene	NN	O
instructions	NNS	O
as	IN	O
for	IN	O
group	NN	O
I	PRP	O
.	.	O

The	DT	O
instructions	NNS	O
were	VBD	O
repeated	VBN	O
every	DT	O
six	CD	O
months	NNS	O
.	.	O

Group	NNP	O
III	NNP	O
was	VBD	O
maintained	VBN	O
in	IN	O
the	DT	O
preventive	JJ	O
program	NN	O
provided	VBN	O
by	IN	O
the	DT	O
local	JJ	O
Dental	NNP	O
Health	NNP	O
Office	NNP	O
,	,	O
based	VBN	O
on	IN	O
mechanical	JJ	O
plaque	NN	O
control	NN	O
and	CC	O
topical	JJ	O
use	NN	O
of	IN	O
fluorides	NNS	O
and	CC	O
chlorhexidine	NN	O
at	IN	O
individualized	JJ	O
intervals	NNS	O
.	.	O

Group	NNP	O
I	PRP	O
showed	VBD	O
a	DT	O
significant	JJ	O
immediate	JJ	O
reduction	NN	O
of	IN	O
S.	NNP	O
mutans	NNS	O
in	IN	O
saliva	NN	O
as	RB	O
well	RB	O
as	IN	O
an	DT	O
approximal	JJ	O
tooth	NN	O
surfaces	NNS	O
.	.	O

After	IN	O
six	CD	O
months	NNS	O
,	,	O
there	EX	O
were	VBD	O
no	DT	O
differences	NNS	O
among	IN	O
the	DT	O
three	CD	O
groups	NNS	O
regarding	VBG	O
these	DT	O
variables	NNS	O
.	.	O

Compared	VBN	O
with	IN	O
baseline	NN	O
,	,	O
there	EX	O
was	VBD	O
a	DT	O
significant	JJ	O
reduction	NN	O
of	IN	O
S.	NNP	O
mutans	NNS	O
in	IN	O
all	DT	O
groups	NNS	O
.	.	O

There	EX	O
was	VBD	O
no	DT	O
significant	JJ	O
difference	NN	O
in	IN	O
caries	NNS	O
progression	NN	O
among	IN	O
the	DT	O
three	CD	O
groups	NNS	O
.	.	O

However	RB	O
,	,	O
the	DT	O
selected	VBN	O
high-risk	JJ	O
individuals	NNS	O
in	IN	O
group	NN	O
I	PRP	O
developed	VBD	O
0.25	CD	O
new	JJ	O
manifest	NN	O
caries	NNS	O
lesions	NNS	O
approximally/year	VBP	O
,	,	O
compared	VBN	O
with	IN	O
0.27	CD	O
for	IN	O
all	DT	O
children	NNS	O
of	IN	O
the	DT	O
same	JJ	O
age	NN	O
group	NN	O
in	IN	O
the	DT	O
area	NN	O
.	.	O

Seventeen	JJ	O
individuals	NNS	O
had	VBD	O
approximal	JJ	O
surfaces	NNS	O
with	IN	O
consistently	RB	O
high	JJ	O
or	CC	O
consistently	RB	O
low	JJ	O
S.	NNP	O
mutans	NN	O
levels	NNS	O
.	.	O

Forty-six	CD	O
percent	NN	O
of	IN	O
the	DT	O
surfaces	NNS	O
with	IN	O
high	JJ	O
values	NNS	O
developed	VBD	O
new	JJ	O
or	CC	O
progressive	JJ	O
caries	NNS	O
,	,	O
compared	VBN	O
with	IN	O
2	CD	O
%	NN	O
of	IN	O
the	DT	O
surfaces	NNS	O
with	IN	O
low	JJ	O
values	NNS	O
.	.	O

Safety	NN	O
and	CC	O
efficacy	NN	O
of	IN	O
donepezil	NN	O
in	IN	O
children	NNS	O
and	CC	O
adolescents	NNS	O
with	IN	O
autism	NN	O
:	:	O
neuropsychological	JJ	O
measures	NNS	O
.	.	O

OBJECTIVE	NNP	O
There	EX	O
has	VBZ	O
been	VBN	O
recent	JJ	O
interest	NN	O
in	IN	O
the	DT	O
use	NN	O
of	IN	O
cognitive	JJ	O
enhancing	VBG	O
drugs	NNS	O
,	,	O
such	JJ	O
as	IN	O
cholinesterase	NN	O
inhibitors	NNS	O
,	,	O
as	IN	O
a	DT	O
possible	JJ	O
treatment	NN	O
for	IN	O
executive	NN	O
functioning	NN	O
(	(	O
EF	NNP	O
)	)	O
deficits	NNS	O
in	IN	O
autism	NN	O
spectrum	NN	O
disorder	NN	O
(	(	O
ASD	NNP	O
)	)	O
.	.	O

The	DT	O
goal	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
assess	VB	O
the	DT	O
tolerability	NN	O
,	,	O
safety	NN	O
,	,	O
and	CC	O
efficacy	NN	O
of	IN	O
donepezil	NN	O
on	IN	O
EF	NNP	O
in	IN	O
a	DT	O
sample	NN	O
of	IN	O
children	NNS	O
and	CC	O
adolescents	NNS	O
with	IN	O
ASD	NNP	O
.	.	O

METHOD	NNP	O
Thirty-four	JJ	O
children	NNS	O
and	CC	O
adolescents	NNS	O
with	IN	O
ASD	NNP	O
(	(	O
age	NN	O
range	NN	O
8-17	CD	O
years	NNS	O
;	:	O
IQ	NNP	O
>	NNP	O
75	CD	O
)	)	O
were	VBD	O
enrolled	VBN	O
in	IN	O
a	DT	O
10-week	JJ	O
,	,	O
double-blind	JJ	O
,	,	O
placebo-controlled	JJ	O
trial	NN	O
of	IN	O
donepezil	NN	O
(	(	O
doses	NNS	O
of	IN	O
5	CD	O
and	CC	O
10	CD	O
mg	NN	O
)	)	O
,	,	O
followed	VBN	O
by	IN	O
a	DT	O
10-week	JJ	O
open	JJ	O
label	NN	O
trial	NN	O
for	IN	O
placebo	NN	O
nonresponders	NNS	O
.	.	O

RESULTS	VB	O
The	DT	O
effect	NN	O
of	IN	O
donepezil	NN	O
treatment	NN	O
on	IN	O
EF	NNP	O
was	VBD	O
examined	VBN	O
.	.	O

Despite	IN	O
improvement	NN	O
on	IN	O
a	DT	O
number	NN	O
of	IN	O
EF	NNP	O
measures	NNS	O
,	,	O
no	DT	O
statistically	RB	O
significant	JJ	O
between-group	JJ	O
differences	NNS	O
were	VBD	O
found	VBN	O
(	(	O
with	IN	O
gains	NNS	O
observed	VBN	O
for	IN	O
both	DT	O
the	DT	O
placebo	NN	O
and	CC	O
donepezil	NN	O
groups	NNS	O
)	)	O
.	.	O

CONCLUSIONS	VB	O
The	DT	O
results	NNS	O
suggest	VBP	O
that	IN	O
short-term	JJ	O
treatment	NN	O
with	IN	O
donepezil	NN	O
may	MD	O
have	VB	O
limited	VBN	O
impact	NN	O
on	IN	O
cognitive	JJ	O
functioning	NN	O
in	IN	O
ASD	NNP	O
.	.	O

Future	NNP	O
controlled	VBD	O
trials	NNS	O
may	MD	O
need	VB	O
to	TO	O
consider	VB	O
a	DT	O
longer	RBR	O
treatment	NN	O
period	NN	O
to	TO	O
detect	VB	O
significant	JJ	O
gains	NNS	O
on	IN	O
EF	NNP	O
measures	NNS	O
.	.	O

Right	RB	O
ventricular	JJ	O
function	NN	O
during	IN	O
high-frequency	JJ	O
oscillatory	JJ	O
ventilation	NN	O
in	IN	O
adults	NNS	O
with	IN	O
acute	JJ	O
respiratory	NN	O
distress	NN	O
syndrome	NN	O
.	.	O

OBJECTIVE	UH	O
To	TO	O
evaluate	VB	O
the	DT	O
effect	NN	O
of	IN	O
mean	JJ	O
airway	JJ	O
pressure	NN	O
under	IN	O
high-frequency	NN	O
oscillatory	NN	O
ventilation	NN	O
on	IN	O
right	JJ	O
ventricular	JJ	O
function	NN	O
.	.	O

DESIGN	NNP	O
Prospective	NNP	O
randomized	VBD	O
study	NN	O
.	.	O

SETTING	NNP	O
Intensive	NNP	O
care	NN	O
unit	NN	O
of	IN	O
a	DT	O
tertiary	JJ	O
care	NN	O
hospital	NN	O
.	.	O

PATIENTS	NNP	O
Sixteen	NNP	O
consecutive	JJ	O
patients	NNS	O
within	IN	O
the	DT	O
first	JJ	O
48	CD	O
hrs	NN	O
of	IN	O
mainly	RB	O
pulmonary	JJ	O
acute	NN	O
respiratory	NN	O
distress	JJ	O
syndrome	NN	O
.	.	O

INTERVENTIONS	NNP	O
After	IN	O
a	DT	O
6-hr-period	JJ	O
of	IN	O
protective	JJ	O
conventional	JJ	O
mechanical	JJ	O
ventilation	NN	O
,	,	O
patients	NNS	O
were	VBD	O
submitted	VBN	O
to	TO	O
three	CD	O
1-hr	JJ	O
periods	NNS	O
of	IN	O
high-frequency	NN	O
oscillatory	NN	O
ventilation	NN	O
(	(	O
+5	JJ	O
,	,	O
+10	NNP	O
,	,	O
+15	NNP	O
)	)	O
in	IN	O
a	DT	O
randomized	JJ	O
order	NN	O
,	,	O
with	IN	O
a	DT	O
mean	JJ	O
airway	NN	O
pressure	NN	O
level	NN	O
determined	VBN	O
by	IN	O
adding	VBG	O
5	CD	O
,	,	O
10	CD	O
,	,	O
or	CC	O
15	CD	O
cm	NNS	O
H2O	NNP	O
to	TO	O
the	DT	O
mean	JJ	O
airway	NN	O
pressure	NN	O
recorded	VBN	O
during	IN	O
conventional	JJ	O
mechanical	JJ	O
ventilation	NN	O
.	.	O

MEASUREMENTS	NNP	O
AND	CC	O
MAIN	NNP	O
RESULTS	NNP	O
Mean	NNP	O
airway	JJ	O
pressure	NN	O
was	VBD	O
18?3	CD	O
cm	JJ	O
H2O	NNP	O
during	IN	O
conventional	JJ	O
mechanical	JJ	O
ventilation	NN	O
and	CC	O
was	VBD	O
increased	VBN	O
until	IN	O
33?3	CD	O
cm	NNS	O
H2O	NNP	O
at	IN	O
high-frequency	NN	O
oscillatory	NN	O
ventilation+15	NN	O
.	.	O

Right	NNP	O
ventricular	JJ	O
function	NN	O
was	VBD	O
assessed	VBN	O
using	VBG	O
transesophageal	JJ	O
echocardiography	NN	O
.	.	O

During	IN	O
conventional	JJ	O
mechanical	JJ	O
ventilation	NN	O
,	,	O
nine	CD	O
patients	NNS	O
presented	VBD	O
a	DT	O
right	JJ	O
ventricular	NN	O
dysfunction	NN	O
(	(	O
right	JJ	O
ventricular	NN	O
end-diastolic	JJ	O
area/left	NN	O
ventricular	JJ	O
end-diastolic	JJ	O
area	NN	O
ratio	NN	O
>	NNP	O
0.6	CD	O
)	)	O
of	IN	O
whom	WP	O
four	CD	O
patients	NNS	O
had	VBD	O
a	DT	O
right	JJ	O
ventricular	NN	O
failure	NN	O
(	(	O
right	JJ	O
ventricular	NN	O
end-diastolic	JJ	O
area/left	NN	O
ventricular	JJ	O
end-diastolic	JJ	O
area	NN	O
ratio	NN	O
>	NNP	O
0.9	CD	O
)	)	O
.	.	O

High-frequency	NNP	O
oscillatory	JJ	O
ventilation+10	NN	O
and	CC	O
+15	VB	O
further	RB	O
worsened	VBN	O
right	JJ	O
ventricular	NN	O
function	NN	O
,	,	O
resulting	VBG	O
in	IN	O
about	IN	O
a	DT	O
40	CD	O
%	NN	O
increase	NN	O
in	IN	O
right	JJ	O
ventricular	JJ	O
end-diastolic	JJ	O
area/left	NN	O
ventricular	JJ	O
end-diastolic	JJ	O
area	NN	O
ratio	NN	O
and	CC	O
a	DT	O
30	CD	O
%	NN	O
increase	NN	O
in	IN	O
end-diastolic	JJ	O
eccentricity	NN	O
index	NN	O
when	WRB	O
compared	VBN	O
with	IN	O
conventional	JJ	O
mechanical	JJ	O
ventilation	NN	O
or	CC	O
high-frequency	NN	O
oscillatory	NN	O
ventilation+5	NN	O
periods	NNS	O
.	.	O

At	IN	O
high-frequency	JJ	O
oscillatory	NN	O
ventilation+15	NN	O
,	,	O
15	CD	O
patients	NNS	O
had	VBD	O
right	JJ	O
ventricular	JJ	O
dysfunction	NN	O
and	CC	O
nine	CD	O
had	VBD	O
right	JJ	O
ventricular	JJ	O
failure	NN	O
.	.	O

High-frequency	NNP	O
oscillatory	JJ	O
ventilation	NN	O
did	VBD	O
not	RB	O
improve	VB	O
oxygenation	NN	O
whatever	IN	O
the	DT	O
mean	JJ	O
airway	NN	O
pressure	NN	O
level	NN	O
.	.	O

A	DT	O
significant	JJ	O
redistribution	NN	O
of	IN	O
tidal	JJ	O
variation	NN	O
to	TO	O
the	DT	O
posterior	JJ	O
parts	NNS	O
of	IN	O
the	DT	O
lung	NN	O
was	VBD	O
observed	VBN	O
on	IN	O
electrical	JJ	O
impedance	NN	O
tomography	NN	O
measurements	NNS	O
when	WRB	O
increasing	VBG	O
mean	VB	O
airway	JJ	O
pressure	NN	O
.	.	O

However	RB	O
,	,	O
this	DT	O
redistribution	NN	O
was	VBD	O
not	RB	O
observed	VBN	O
in	IN	O
patients	NNS	O
who	WP	O
presented	VBD	O
a	DT	O
worsening	NN	O
of	IN	O
right	JJ	O
ventricular	JJ	O
function	NN	O
(	(	O
right	JJ	O
ventricular	NN	O
end-diastolic	JJ	O
area/left	NN	O
ventricular	JJ	O
end-diastolic	JJ	O
area	NN	O
increase	NN	O
>	VBD	O
40	CD	O
%	NN	O
)	)	O
at	IN	O
high-frequency	NN	O
oscillatory	NN	O
ventilation+15	NN	O
.	.	O

CONCLUSIONS	NNP	O
In	IN	O
patients	NNS	O
with	IN	O
mainly	RB	O
pulmonary	JJ	O
acute	NN	O
respiratory	NN	O
distress	NN	O
syndrome	NN	O
,	,	O
using	VBG	O
high	JJ	O
mean	JJ	O
airway	NN	O
pressure	NN	O
under	IN	O
high-frequency	NN	O
oscillatory	JJ	O
ventilation	NN	O
can	MD	O
worsen	VB	O
right	JJ	O
ventricular	NN	O
function	NN	O
when	WRB	O
compared	VBN	O
with	IN	O
protective	JJ	O
conventional	JJ	O
mechanical	JJ	O
ventilation	NN	O
,	,	O
notably	RB	O
in	IN	O
patients	NNS	O
in	IN	O
whom	WP	O
high-frequency	NN	O
oscillatory	NN	O
ventilation	NN	O
produced	VBD	O
less	JJR	O
alveolar	JJ	O
recruitment	NN	O
of	IN	O
the	DT	O
posterior	JJ	O
parts	NNS	O
of	IN	O
the	DT	O
lungs	NNS	O
.	.	O

This	DT	O
study	NN	O
highlights	VBZ	O
the	DT	O
interest	NN	O
of	IN	O
monitoring	VBG	O
right	JJ	O
ventricular	JJ	O
function	NN	O
during	IN	O
high-frequency	JJ	O
oscillatory	JJ	O
ventilation	NN	O
.	.	O

The	DT	O
instruction	NN	O
to	TO	O
refrain	VB	O
from	IN	O
blinking	VBG	O
affects	NNS	O
auditory	JJ	O
P3	NNP	O
and	CC	O
N1	NNP	O
amplitudes	NNS	O
.	.	O

Often	NNP	O
subjects	VBZ	O
have	VBP	O
been	VBN	O
instructed	VBN	O
to	TO	O
refrain	VB	O
from	IN	O
blinking	VBG	O
lest	JJS	O
their	PRP$	O
evoked	JJ	O
EEG	NNP	O
potentials	NNS	O
should	MD	O
be	VB	O
distorted	VBN	O
.	.	O

We	PRP	O
studied	VBD	O
whether	IN	O
these	DT	O
very	RB	O
instructions	NNS	O
have	VBP	O
any	DT	O
impact	NN	O
on	IN	O
P3	NNP	O
amplitude	NN	O
.	.	O

Two	CD	O
tones	NNS	O
were	VBD	O
presented	VBN	O
in	IN	O
random	JJ	O
order	NN	O
,	,	O
and	CC	O
subjects	NNS	O
had	VBD	O
to	TO	O
count	VB	O
the	DT	O
high-pitched	JJ	O
tones	NNS	O
.	.	O

Half	PDT	O
the	DT	O
subjects	NNS	O
were	VBD	O
instructed	VBN	O
not	RB	C
to	TO	C
blink	VB	C
,	,	O
whereas	IN	O
this	DT	O
instruction	NN	O
was	VBD	O
omitted	VBN	O
for	IN	O
the	DT	O
other	JJ	O
subjects	NNS	O
.	.	O

Target	NNP	O
tones	NNS	O
evoked	VBD	O
larger	JJR	O
P3s	NNP	O
than	IN	O
non-targets	NNS	O
in	IN	O
the	DT	O
latter	JJ	O
group	NN	O
but	CC	O
not	RB	O
in	IN	O
the	DT	O
former	JJ	O
,	,	O
in	IN	O
particular	JJ	O
not	RB	O
in	IN	O
those	DT	O
subjects	NNS	O
that	WDT	O
actually	RB	O
blinked	VBD	O
rarely	RB	O
.	.	O

The	DT	O
groups	NNS	O
also	RB	O
differed	VBN	O
in	IN	O
their	PRP$	O
N1	NNP	O
amplitudes	NNS	O
.	.	O

These	DT	O
findings	NNS	O
might	MD	O
be	VB	O
relevant	JJ	O
to	TO	O
P3	NNP	O
studies	NNS	O
working	VBG	O
with	IN	O
patients	NNS	O
and	CC	O
controls	NNS	O
:	:	O
the	DT	O
harder	NN	O
some	DT	O
frequently	RB	O
blinking	JJ	O
subjects	NNS	O
try	VBP	O
to	TO	O
refrain	VB	O
from	IN	O
blinking	NN	O
,	,	O
the	DT	O
smaller	JJR	O
might	MD	O
become	VB	O
their	PRP$	O
P3	NNP	O
amplitudes	NNS	O
.	.	O

Omitting	VBG	O
the	DT	O
instruction	NN	O
and	CC	O
using	VBG	O
off-line	JJ	O
blink	NN	O
subtraction	NN	O
procedures	NNS	O
seems	VBZ	O
a	DT	O
viable	JJ	O
alternative	NN	O
.	.	O

This	DT	O
study	NN	O
was	VBD	O
actually	RB	O
motivated	VBN	O
by	IN	O
discrepant	JJ	O
findings	NNS	O
on	IN	O
the	DT	O
effects	NNS	O
of	IN	O
the	DT	O
preceding	VBG	O
tone	NN	O
sequence	NN	O
on	IN	O
P3	NNP	O
.	.	O

These	DT	O
discrepancies	NNS	O
could	MD	O
be	VB	O
largely	RB	O
resolved	VBN	O
by	IN	O
the	DT	O
instructional	JJ	O
variable	NN	O
,	,	O
in	IN	O
conjunction	NN	O
with	IN	O
different	JJ	O
tone	NN	O
intensities	NNS	O
.	.	O

It	PRP	O
is	VBZ	O
suggested	VBN	O
that	IN	O
subjects	NNS	O
who	WP	O
are	VBP	O
discouraged	VBN	O
from	IN	O
blinking	VBG	O
try	NN	O
to	TO	O
protect	VB	O
themselves	PRP	O
against	IN	O
the	DT	O
arousing	JJ	O
effects	NNS	O
of	IN	O
stimuli	NN	O
.	.	O

The	DT	O
impact	NN	O
of	IN	O
a	DT	O
psychological	JJ	O
intervention	NN	O
on	IN	O
quality	NN	O
of	IN	O
life	NN	O
in	IN	O
non-metastatic	JJ	C
breast	NN	C
cancer	NN	C
.	.	O

The	DT	O
aim	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
determine	VB	O
whether	IN	O
psychological	JJ	O
intervention	NN	O
had	VBD	O
a	DT	O
beneficial	JJ	O
effect	NN	O
on	IN	O
the	DT	O
quality	NN	O
of	IN	O
life	NN	O
and	CC	O
behaviour	NN	O
of	IN	O
women	NNS	SE
diagnosed	VBN	O
with	IN	O
breast	NN	C
cancer	NN	C
.	.	O

36	CD	SS
consecutive	JJ	O
patients	NNS	O
with	IN	O
non-metastatic	JJ	C
breast	NN	C
cancer	NN	C
assigned	VBD	O
to	TO	O
surgery	VB	O
and	CC	O
systemic	VB	O
chemotherapy	NN	O
were	VBD	O
randomised	VBN	O
to	TO	O
receive	VB	O
either	DT	O
psychological	JJ	O
intervention	NN	O
(	(	O
weekly	JJ	O
cognitive	VBP	O
individual	JJ	O
psychotherapy	NN	O
and	CC	O
bimonthly	JJ	O
family	NN	O
counselling	VBG	O
)	)	O
or	CC	O
standard	JJ	O
follow-up	NN	O
.	.	O

Personality	NNP	O
(	(	O
16-PF	JJ	O
and	CC	O
IIQ	NNP	O
)	)	O
,	,	O
quality	NN	O
of	IN	O
life	NN	O
(	(	O
FLIC	NNP	O
)	)	O
,	,	O
and	CC	O
depression	NN	O
(	(	O
BDI	NNP	O
)	)	O
scores	NNS	O
were	VBD	O
the	DT	O
endpoints	NNS	O
for	IN	O
this	DT	O
study	NN	O
,	,	O
and	CC	O
the	DT	O
questionnaires	NNS	O
were	VBD	O
completed	VBN	O
by	IN	O
the	DT	O
patients	NNS	O
at	IN	O
diagnosis	NN	O
,	,	O
and	CC	O
up	RB	O
to	TO	O
9	CD	O
months	NNS	O
after	IN	O
diagnosis	NN	O
.	.	O

Cognitive	JJ	O
psychotherapy	NN	O
and	CC	O
family	NN	O
counselling	NN	O
improved	VBD	O
both	DT	O
depression	NN	O
and	CC	O
quality	NN	O
of	IN	O
life	NN	O
indexes	NNS	O
compared	VBN	O
with	IN	O
the	DT	O
control	NN	O
group	NN	O
.	.	O

Better	NNP	O
emotional	JJ	O
coping	NN	O
behaviours	NNS	O
were	VBD	O
also	RB	O
revealed	VBN	O
by	IN	O
some	DT	O
changes	NNS	O
in	IN	O
personality	NN	O
traits	NNS	O
in	IN	O
the	DT	O
intervention	NN	O
group	NN	O
.	.	O

[	JJ	O
European	JJ	O
topic	NN	O
:	:	O
liver	NN	O
surgery	NN	O
II	NNP	O
--	:	O
regional	JJ	O
chemotherapy	NN	O
]	NN	O
.	.	O

The	DT	O
most	RBS	O
important	JJ	O
methods	NNS	O
of	IN	O
regional	JJ	O
chemotherapy	NN	O
are	VBP	O
exemplified	VBN	O
by	IN	O
657	CD	O
cases	NNS	O
of	IN	O
primary	JJ	O
and	CC	O
secondary	JJ	O
liver	NN	O
only	RB	O
malignancies	VBZ	O
.	.	O

I	PRP	O
.	.	O

Adjuvant	JJ	O
portal	JJ	O
therapy	NN	O
of	IN	O
the	DT	O
liver	NN	O
with	IN	O
resection	NN	O
of	IN	O
the	DT	O
colorectal	JJ	O
primary	JJ	O
malignancy	NN	O
seems	VBZ	O
to	TO	O
be	VB	O
advantageous	JJ	O
for	IN	O
advanced	JJ	O
tumors	NNS	O
.	.	O

II	NNP	O
.	.	O

It	PRP	O
is	VBZ	O
still	RB	O
unresolved	JJ	O
whether	IN	O
survival	NN	O
is	VBZ	O
prolonged	VBN	O
by	IN	O
adjuvant	JJ	O
treatment	NN	O
of	IN	O
the	DT	O
liver	NN	O
following	VBG	O
curative	JJ	O
resection	NN	O
of	IN	O
colorectal	JJ	O
liver	NN	O
metastases	NNS	O
.	.	O

III	NNP	O
.	.	O

The	DT	O
median	JJ	O
survival	NN	O
time	NN	O
(	(	O
FUDR	NNP	O
,	,	O
pump	NN	O
)	)	O
is	VBZ	O
17	CD	O
months	NNS	O
for	IN	O
palliative	JJ	O
local	JJ	O
chemotherapy	NN	O
of	IN	O
unresectable	JJ	O
colorectal	JJ	O
liver	NN	O
metastases	NNS	O
.	.	O

IV	NNP	O
.	.	O

Primary	NNP	O
non-resectable	JJ	O
liver	NN	O
malignancies	NNS	O
show	VBP	O
the	DT	O
best	JJS	O
results	NNS	O
after	IN	O
chemoembolisation	NN	O
(	(	O
Frankfurt	NNP	O
method	NN	O
)	)	O
.	.	O

Green	JJ	O
banana-supplemented	JJ	O
diet	NN	O
in	IN	O
the	DT	O
home	NN	O
management	NN	O
of	IN	O
acute	NN	O
and	CC	O
prolonged	JJ	C
diarrhoea	NN	C
in	IN	O
children	NNS	A
:	:	O
a	DT	O
community-based	JJ	O
trial	NN	O
in	IN	O
rural	JJ	O
Bangladesh	NNP	O
.	.	O

SUMMARY	NNP	O
OBJECTIVE	NNP	O
To	TO	O
determine	VB	O
the	DT	O
effectiveness	NN	O
of	IN	O
green	JJ	O
banana	NN	O
in	IN	O
the	DT	O
home	NN	O
management	NN	O
of	IN	O
acute	NN	O
(	(	O
<	JJ	O
7	CD	O
days	NNS	O
)	)	O
or	CC	O
prolonged	VBN	O
(	(	O
?	.	O
7	CD	O
days	NNS	O
)	)	O
diarrhoea	VBP	O
at	IN	O
the	DT	O
community	NN	O
level	NN	O
.	.	O

METHODS	NNP	O
A	NNP	O
cluster	NN	O
randomized	VBD	O
field	NN	O
trial	NN	O
was	VBD	O
conducted	VBN	O
among	IN	O
2968	CD	SS
Bangladeshi	NNP	O
rural	JJ	O
children	NNS	O
6-36	JJ	A
months	NNS	A
old	JJ	A
.	.	O

Wards	NNP	O
(	(	O
villages	NNS	O
)	)	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
either	CC	O
a	DT	O
standard	JJ	O
care	NN	O
group	NN	O
or	CC	O
a	DT	O
standard	JJ	O
care	NN	O
plus	CC	O
green	JJ	O
banana	NN	O
group	NN	O
where	WRB	O
mothers	NNS	O
were	VBD	O
instructed	VBN	O
to	TO	O
add	VB	O
cooked	JJ	O
green	JJ	O
banana	NN	O
to	TO	O
the	DT	O
diets	NNS	O
of	IN	O
diarrhoeal	JJ	O
children	NNS	O
.	.	O

Through	IN	O
a	DT	O
village-based	JJ	O
surveillance	NN	O
system	NN	O
,	,	O
diarrhoeal	JJ	O
morbidity	NN	O
data	NNS	O
(	(	O
severity	NN	O
,	,	O
duration	NN	O
,	,	O
compliance	NN	O
)	)	O
were	VBD	O
collected	VBN	O
for	IN	O
14	CD	O
days	NNS	O
.	.	O

Treatment	JJ	O
effects	NNS	O
were	VBD	O
determined	VBN	O
by	IN	O
analysing	VBG	O
cumulative	JJ	O
probability	NN	O
of	IN	O
cure	NN	O
by	IN	O
testing	VBG	O
Cox	NNP	O
proportional	JJ	O
hazards	NNS	O
models	NNS	O
and	CC	O
relative	JJ	O
risk	NN	O
(	(	O
RR	NNP	O
)	)	O
.	.	O

RESULTS	VB	O
The	DT	O
cumulative	JJ	O
probability	NN	O
of	IN	O
cure	NN	O
was	VBD	O
significantly	RB	O
(	(	O
P	NNP	O
<	NNP	O
0.001	CD	O
)	)	O
different	JJ	O
in	IN	O
children	NNS	O
receiving	VBG	O
GB	NNP	O
for	IN	O
both	DT	O
acute	JJ	O
[	NNP	O
hazard	NN	O
ratio	NN	O
(	(	O
HR	NNP	O
)	)	O
=	VBZ	O
0.63	CD	O
(	(	O
95	CD	O
%	NN	O
CI	NNP	O
:	:	O
0.56-0.67	NN	O
)	)	O
]	NN	O
and	CC	O
prolonged	VBD	O
diarrhoea	NNS	O
[	NNP	O
HR	NNP	O
=	VBZ	O
0.38	CD	O
(	(	O
95	CD	O
%	NN	O
CI	NNP	O
:	:	O
0.26-0.59	NN	O
)	)	O
]	NN	O
.	.	O

The	DT	O
recovery	NN	O
rates	NNS	O
of	IN	O
children	NNS	O
with	IN	O
acute	JJ	O
diarrhoea	NN	O
receiving	VBG	O
GB	NNP	O
(	(	O
vs.	FW	O
control	NN	O
)	)	O
were	VBD	O
significantly	RB	O
more	JJR	O
by	IN	O
day	NN	O
3	CD	O
:	:	O
79.9	CD	O
%	NN	O
vs	NN	O
.	.	O

53.3	CD	O
%	NN	O
[	NN	O
(	(	O
RR	NNP	O
)	)	O
=	VBD	O
0.47	CD	O
,	,	O
95	CD	O
%	NN	O
CI	NNP	O
:	:	O
0.41-0.55	JJ	O
]	NN	O
,	,	O
(	(	O
P	NNP	O
<	NNP	O
0.001	CD	O
)	)	O
and	CC	O
day	NN	O
7	CD	O
:	:	O
96.6	CD	O
%	NN	O
vs	NN	O
.	.	O

89.1	CD	O
%	NN	O
(	(	O
RR	NNP	O
=	NNP	O
0.32	CD	O
;	:	O
0.22-0.46	JJ	O
)	)	O
,	,	O
(	(	O
P	NNP	O
<	NNP	O
0.001	CD	O
)	)	O
.	.	O

Children	NNP	O
with	IN	O
prolonged	JJ	O
diarrhoea	NN	O
receiving	VBG	O
green	JJ	O
banana	NN	O
had	VBD	O
significantly	RB	O
higher	JJR	O
recovery	NN	O
rates	NNS	O
by	IN	O
day	NN	O
10	CD	O
:	:	O
79.8	CD	O
%	NN	O
vs	NN	O
.	.	O

51.9	CD	O
%	NN	O
(	(	O
RR	NNP	O
=	NNP	O
0.42	CD	O
;	:	O
0.23-0.73	JJ	O
)	)	O
,	,	O
(	(	O
P	NNP	O
<	NNP	O
0.001	CD	O
)	)	O
and	CC	O
day	NN	O
14	CD	O
:	:	O
93.6	CD	O
%	NN	O
vs	NN	O
.	.	O

67.2	CD	O
%	NN	O
(	(	O
RR	NNP	O
=	NNP	O
0.22	CD	O
;	:	O
0.08-0.54	JJ	O
)	)	O
,	,	O
(	(	O
P	NNP	O
<	NNP	O
0.001	CD	O
)	)	O
.	.	O

CONCLUSION	VB	O
A	DT	O
green	JJ	O
banana-supplemented	JJ	O
diet	NN	O
hastened	VBD	O
recovery	NN	O
of	IN	O
acute	NN	O
and	CC	O
prolonged	VBD	O
childhood	NN	O
diarrhoea	NN	O
managed	VBD	O
at	IN	O
home	NN	O
in	IN	O
rural	JJ	O
Bangladesh	NNP	O
.	.	O

Brief	JJ	O
report	NN	O
:	:	O
effect	NN	O
of	IN	O
a	DT	O
focused	JJ	O
imitation	NN	O
intervention	NN	O
on	IN	O
social	JJ	O
functioning	NN	O
in	IN	O
children	NNS	A
with	IN	O
autism	NN	C
.	.	O

Imitation	NNP	O
is	VBZ	O
an	DT	O
early	JJ	O
skill	NN	O
thought	VBN	O
to	TO	O
play	VB	O
a	DT	O
role	NN	O
in	IN	O
social	JJ	O
development	NN	O
,	,	O
leading	VBG	O
some	DT	O
to	TO	O
suggest	VB	O
that	IN	O
teaching	VBG	O
imitation	NN	O
to	TO	O
children	NNS	A
with	IN	O
autism	NN	C
should	MD	O
lead	VB	O
to	TO	O
improvements	NNS	O
in	IN	O
social	JJ	O
functioning	NN	O
.	.	O

This	DT	O
study	NN	O
used	VBD	O
a	DT	O
randomized	JJ	O
controlled	VBN	O
trial	NN	O
to	TO	O
evaluate	VB	O
the	DT	O
effect	NN	O
of	IN	O
a	DT	O
focused	JJ	O
imitation	NN	O
intervention	NN	O
on	IN	O
initiation	NN	O
of	IN	O
joint	JJ	O
attention	NN	O
and	CC	O
social-emotional	JJ	O
functioning	NN	O
in	IN	O
27	CD	SS
young	JJ	A
children	NNS	A
with	IN	O
autism	NN	C
.	.	O

Results	NNS	O
indicated	VBD	O
the	DT	O
treatment	NN	O
group	NN	O
made	VBD	O
significantly	RB	O
more	RBR	O
gains	NNS	O
in	IN	O
joint	JJ	O
attention	NN	O
initiations	NNS	O
at	IN	O
post-treatment	JJ	O
and	CC	O
follow-up	JJ	O
and	CC	O
social-emotional	JJ	O
functioning	NN	O
at	IN	O
follow-up	NN	O
than	IN	O
the	DT	O
control	NN	O
group	NN	O
.	.	O

Although	IN	O
gains	NNS	O
in	IN	O
social	JJ	O
functioning	NN	O
were	VBD	O
associated	VBN	O
with	IN	O
treatment	NN	O
,	,	O
a	DT	O
mediation	NN	O
analysis	NN	O
did	VBD	O
not	RB	O
support	VB	O
imitation	NN	O
as	IN	O
the	DT	O
mechanism	NN	O
of	IN	O
action	NN	O
.	.	O

These	DT	O
findings	NNS	O
suggest	VBP	O
the	DT	O
intervention	NN	O
improves	VBZ	O
social	JJ	O
functioning	NN	O
in	IN	O
children	NNS	A
with	IN	O
ASD	NNP	C
.	.	O

Effect	NN	O
of	IN	O
a	DT	O
synthetic	JJ	O
appeasing	VBG	O
pheromone	NN	O
on	IN	O
behavioral	JJ	O
,	,	O
neuroendocrine	JJ	O
,	,	O
immune	JJ	O
,	,	O
and	CC	O
acute-phase	JJ	O
perioperative	JJ	O
stress	NN	O
responses	NNS	O
in	IN	O
dogs	NNS	O
.	.	O

OBJECTIVE	NNP	O
To	TO	O
study	VB	O
the	DT	O
effects	NNS	O
of	IN	O
a	DT	O
synthetic	JJ	O
,	,	O
dog-appeasing	JJ	O
pheromone	NN	O
(	(	O
sDAP	NN	O
)	)	O
on	IN	O
the	DT	O
behavioral	JJ	O
,	,	O
neuroendocrine	JJ	O
,	,	O
immune	JJ	O
,	,	O
and	CC	O
acute-phase	JJ	O
perioperative	JJ	O
stress	NN	O
responses	NNS	O
in	IN	O
dogs	NNS	O
undergoing	VBG	O
elective	JJ	O
orchiectomy	NN	O
or	CC	O
ovariohysterectomy	NN	O
.	.	O

DESIGN	NNP	O
Randomized	NNP	O
,	,	O
controlled	VBD	O
clinical	JJ	O
trial	NN	O
.	.	O

ANIMALS	$	O
46	CD	SS
dogs	NNS	SS
housed	VBN	O
in	IN	O
animal	NN	O
shelters	NNS	O
and	CC	O
undergoing	VBG	O
elective	JJ	O
orchiectomy	NN	O
or	CC	O
ovariohysterectomy	NN	O
.	.	O

PROCEDURES	NNP	O
Intensive	NNP	O
care	NN	O
unit	NN	O
cages	NNS	O
were	VBD	O
sprayed	VBN	O
with	IN	O
sDAP	JJ	O
solution	NN	O
or	CC	O
sham	NN	O
treated	VBN	O
with	IN	O
the	DT	O
carrier	NN	O
used	VBN	O
in	IN	O
the	DT	O
solution	NN	O
20	CD	O
minutes	NNS	O
prior	RB	O
to	TO	O
use	VB	O
.	.	O

Dogs	NNS	O
(	(	O
n	JJ	O
=	NN	O
24	CD	O
and	CC	O
22	CD	O
in	IN	O
the	DT	O
sDAP	NN	O
and	CC	O
sham	JJ	O
treatment	NN	O
exposure	NN	O
groups	NNS	O
,	,	O
respectively	RB	O
)	)	O
were	VBD	O
placed	VBN	O
in	IN	O
treated	JJ	O
cages	NNS	O
for	IN	O
30	CD	O
minutes	NNS	O
before	IN	O
and	CC	O
after	IN	O
surgery	NN	O
.	.	O

Indicators	NNS	O
of	IN	O
stress	NN	O
(	(	O
ie	NN	O
,	,	O
alterations	NNS	O
in	IN	O
behavioral	JJ	O
,	,	O
neuroendocrine	JJ	O
,	,	O
immune	JJ	O
,	,	O
and	CC	O
acute-phase	JJ	O
responses	NNS	O
)	)	O
were	VBD	O
evaluated	VBN	O
perioperatively	RB	O
.	.	O

Behavioral	JJ	O
response	NN	O
variables	NNS	O
,	,	O
salivary	JJ	O
cortisol	NN	O
concentration	NN	O
,	,	O
WBC	NNP	O
count	NN	O
,	,	O
and	CC	O
serum	JJ	O
concentrations	NNS	O
of	IN	O
glucose	NN	O
,	,	O
prolactin	NN	O
,	,	O
haptoglobin	NN	O
,	,	O
and	CC	O
C-reactive	JJ	O
protein	NN	O
were	VBD	O
analyzed	VBN	O
.	.	O

RESULTS	NNP	O
Behavioral	NNP	O
response	NN	O
variables	NNS	O
and	CC	O
serum	NN	O
prolactin	NN	O
concentration	NN	O
were	VBD	O
influenced	VBN	O
by	IN	O
sDAP	NN	O
exposure	NN	O
.	.	O

Dogs	NNS	O
exposed	VBD	O
to	TO	O
sDAP	VB	O
were	VBD	O
more	RBR	O
likely	JJ	O
to	TO	O
have	VB	O
alertness	NN	O
and	CC	O
visual	JJ	O
exploration	NN	O
behaviors	NNS	O
after	IN	O
surgery	NN	O
than	IN	O
were	VBD	O
dogs	NNS	O
exposed	VBN	O
to	TO	O
sham	VB	O
treatment	NN	O
.	.	O

Decreases	VBZ	O
in	IN	O
serum	NN	O
prolactin	NN	O
concentrations	NNS	O
in	IN	O
response	NN	O
to	TO	O
perioperative	JJ	O
stress	NN	O
were	VBD	O
significantly	RB	O
smaller	JJR	O
in	IN	O
dogs	NNS	O
exposed	VBN	O
to	TO	O
sDAP	VB	O
,	,	O
compared	VBN	O
with	IN	O
findings	NNS	O
in	IN	O
dogs	NNS	O
exposed	VBN	O
to	TO	O
the	DT	O
sham	NN	O
treatment	NN	O
.	.	O

Variables	NNS	O
examined	VBD	O
to	TO	O
evaluate	VB	O
the	DT	O
hypothalamic-pituitary-adrenal	JJ	O
axis	NN	O
,	,	O
immune	JJ	O
system	NN	O
,	,	O
and	CC	O
acute-phase	JJ	O
responses	NNS	O
were	VBD	O
unaffected	VBN	O
by	IN	O
treatment	NN	O
.	.	O

CONCLUSIONS	NNP	O
AND	NNP	O
CLINICAL	NNP	O
RELEVANCE	NNP	O
sDAP	NN	O
appeared	VBD	O
to	TO	O
affect	VB	O
behavioral	JJ	O
and	CC	O
neuroendocrine	JJ	O
perioperative	JJ	O
stress	NN	O
responses	NNS	O
by	IN	O
modification	NN	O
of	IN	O
lactotropic	JJ	O
axis	NN	O
activity	NN	O
.	.	O

Use	NN	O
of	IN	O
sDAP	NN	O
in	IN	O
a	DT	O
clinical	JJ	O
setting	NN	O
may	MD	O
improve	VB	O
the	DT	O
recovery	NN	O
and	CC	O
welfare	NN	O
of	IN	O
dogs	NNS	O
undergoing	VBG	O
surgery	NN	O
.	.	O

Virtual	JJ	O
reality	NN	O
intervention	NN	O
for	IN	O
older	JJR	A
women	NNS	SE
with	IN	O
breast	NN	C
cancer	NN	C
.	.	O

This	DT	O
study	NN	O
examined	VBD	O
the	DT	O
effects	NNS	O
of	IN	O
a	DT	O
virtual	JJ	O
reality	NN	O
distraction	NN	O
intervention	NN	O
on	IN	O
chemotherapy-related	JJ	O
symptom	NN	O
distress	NN	O
levels	NNS	O
in	IN	O
16	CD	SS
women	NNS	C
aged	VBD	O
50	CD	A
and	CC	A
older	JJR	A
.	.	O

A	DT	O
cross-over	JJ	O
design	NN	O
was	VBD	O
used	VBN	O
to	TO	O
answer	VB	O
the	DT	O
following	JJ	O
research	NN	O
questions	NNS	O
:	:	O
(	(	O
1	CD	O
)	)	O
Is	VBZ	O
virtual	JJ	O
reality	NN	O
an	DT	O
effective	JJ	O
distraction	NN	O
intervention	NN	O
for	IN	O
reducing	VBG	O
chemotherapy-related	JJ	O
symptom	NN	O
distress	NN	O
levels	NNS	O
in	IN	O
older	JJR	O
women	NNS	C
with	IN	O
breast	NN	C
cancer	NN	C
?	.	O
(	(	O
2	CD	O
)	)	O
Does	NNP	O
virtual	JJ	O
reality	NN	O
have	VBP	O
a	DT	O
lasting	JJ	O
effect	NN	O
?	.	O
Chemotherapy	NN	O
treatments	NNS	O
are	VBP	O
intensive	JJ	O
and	CC	O
difficult	JJ	O
to	TO	O
endure	VB	O
.	.	O

One	CD	O
way	NN	O
to	TO	O
cope	VB	O
with	IN	O
chemotherapy-related	JJ	O
symptom	NN	O
distress	NN	O
is	VBZ	O
through	IN	O
the	DT	O
use	NN	O
of	IN	O
distraction	NN	O
.	.	O

For	IN	O
this	DT	O
study	NN	O
,	,	O
a	DT	O
head-mounted	JJ	O
display	NN	O
(	(	O
Sony	NNP	O
PC	NNP	O
Glasstron	NNP	O
PLM	NNP	O
-	:	O
S700	NN	O
)	)	O
was	VBD	O
used	VBN	O
to	TO	O
display	VB	O
encompassing	VBG	O
images	NNS	O
and	CC	O
block	NN	O
competing	VBG	O
stimuli	NNS	O
during	IN	O
chemotherapy	JJ	O
infusions	NNS	O
.	.	O

The	DT	O
Symptom	NNP	O
Distress	NNP	O
Scale	NNP	O
(	(	O
SDS	NNP	O
)	)	O
,	,	O
Revised	VBN	O
Piper	NNP	O
Fatigue	NNP	O
Scale	NNP	O
(	(	O
PFS	NNP	O
)	)	O
,	,	O
and	CC	O
the	DT	O
State	NNP	O
Anxiety	NNP	O
Inventory	NNP	O
(	(	O
SAI	NNP	O
)	)	O
were	VBD	O
used	VBN	O
to	TO	O
measure	VB	O
symptom	JJ	O
distress	NN	O
.	.	O

For	IN	O
two	CD	O
matched	JJ	O
chemotherapy	NN	O
treatments	NNS	O
,	,	O
one	CD	O
pre-test	NN	O
and	CC	O
two	CD	O
post-test	JJ	O
measures	NNS	O
were	VBD	O
employed	VBN	O
.	.	O

Participants	NNS	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
receive	VB	O
the	DT	O
VR	NNP	O
distraction	NN	O
intervention	NN	O
during	IN	O
one	CD	O
chemotherapy	NN	O
treatment	NN	O
and	CC	O
received	VBD	O
no	DT	O
distraction	NN	O
intervention	NN	O
(	(	O
control	VB	O
condition	NN	O
)	)	O
during	IN	O
an	DT	O
alternate	JJ	O
chemotherapy	NN	O
treatment	NN	O
.	.	O

Analysis	NN	O
using	VBG	O
paired	VBN	O
t-tests	NNS	O
demonstrated	VBD	O
a	DT	O
significant	JJ	O
decrease	NN	O
in	IN	O
the	DT	O
SAI	NNP	O
(	(	O
p	JJ	O
=	NNP	O
0.10	CD	O
)	)	O
scores	NNS	O
immediately	RB	O
following	VBG	O
chemotherapy	NN	O
treatments	NNS	O
when	WRB	O
participants	NNS	O
used	VBD	O
VR	NNP	O
.	.	O

No	NNP	O
significant	JJ	O
changes	NNS	O
were	VBD	O
found	VBN	O
in	IN	O
SDS	NNP	O
or	CC	O
PFS	NNP	O
values	NNS	O
.	.	O

There	EX	O
was	VBD	O
a	DT	O
consistent	JJ	O
trend	NN	O
toward	IN	O
improved	VBN	O
symptoms	NNS	O
on	IN	O
all	DT	O
measures	NNS	O
48	CD	O
h	NN	O
following	VBG	O
completion	NN	O
of	IN	O
chemotherapy	NN	O
.	.	O

Evaluation	NN	O
of	IN	O
the	DT	O
intervention	NN	O
indicated	VBD	O
that	IN	O
women	NNS	O
thought	VBD	O
the	DT	O
head	NN	O
mounted	VBD	O
device	NN	O
was	VBD	O
easy	JJ	O
to	TO	O
use	VB	O
,	,	O
they	PRP	O
experienced	VBD	O
no	DT	O
cybersickness	NN	O
,	,	O
and	CC	O
100	CD	O
%	NN	O
would	MD	O
use	VB	O
VR	NNP	O
again	RB	O
.	.	O

Primary	JJ	O
prophylaxis	NN	O
with	IN	O
pyrimethamine	NN	O
for	IN	O
toxoplasmic	JJ	O
encephalitis	NN	O
in	IN	O
patients	NNS	O
with	IN	O
advanced	JJ	O
human	JJ	O
immunodeficiency	NN	O
virus	NN	O
disease	NN	O
:	:	O
results	NNS	O
of	IN	O
a	DT	O
randomized	JJ	O
trial	NN	O
.	.	O

Terry	NNP	O
Beirn	NNP	O
Community	NNP	O
Programs	NNP	O
for	IN	O
Clinical	NNP	O
Research	NNP	O
on	IN	O
AIDS	NNP	O
.	.	O

Pyrimethamine	NNP	O
,	,	O
25	CD	O
mg	NN	O
thrice	NN	O
weekly	RB	O
,	,	O
was	VBD	O
evaluated	VBN	O
as	IN	O
primary	JJ	O
prophylaxis	NN	O
for	IN	O
toxoplasmic	JJ	O
encephalitis	NN	O
(	(	O
TE	NNP	O
)	)	O
in	IN	O
a	DT	O
double-blind	NN	O
,	,	O
randomized	VBD	O
clinical	JJ	O
trial	NN	O
in	IN	O
patients	NNS	O
with	IN	O
human	JJ	O
immunodeficiency	NN	O
virus	NN	O
(	(	O
HIV	NNP	O
)	)	O
disease	NN	O
,	,	O
absolute	JJ	O
CD4	NNP	O
lymphocyte	NN	O
count	NN	O
of	IN	O
<	$	O
200/microL	CD	O
(	(	O
or	CC	O
prior	RB	O
AIDS-defining	NNP	O
opportunistic	JJ	O
infection	NN	O
)	)	O
,	,	O
and	CC	O
the	DT	O
presence	NN	O
of	IN	O
serum	NN	O
IgG	NNP	O
to	TO	O
Toxoplasma	NNP	O
gondii	NN	O
.	.	O

Leucovorin	NNP	O
was	VBD	O
coadministered	VBN	O
only	RB	O
for	IN	O
hematologic	JJ	O
toxicity	NN	O
.	.	O

There	EX	O
was	VBD	O
a	DT	O
significantly	RB	O
higher	JJR	O
death	NN	O
rate	NN	O
among	IN	O
patients	NNS	O
receiving	VBG	O
pyrimethamine	NN	O
(	(	O
relative	JJ	O
risk	NN	O
[	NNP	O
RR	NNP	O
]	NNP	O
,	,	O
2.5	CD	O
;	:	O
95	CD	O
%	NN	O
confidence	NN	O
interval	NN	O
[	NNP	O
CI	NNP	O
]	NNP	O
,	,	O
1.3-4.8	JJ	O
;	:	O
P	NNP	O
=	NNP	O
.006	NNP	O
)	)	O
,	,	O
even	RB	O
after	IN	O
adjusting	VBG	O
for	IN	O
factors	NNS	O
predictive	CD	O
of	IN	O
survival	NN	O
.	.	O

The	DT	O
TE	NNP	O
event	NN	O
rate	NN	O
was	VBD	O
low	JJ	O
in	IN	O
both	DT	O
treatment	NN	O
groups	NNS	O
(	(	O
not	RB	O
significant	JJ	O
)	)	O
.	.	O

Only	RB	O
1	CD	O
of	IN	O
218	CD	O
patients	NNS	O
taking	VBG	O
trimethoprim-sulfamethoxazole	JJ	O
but	CC	O
7	CD	O
of	IN	O
117	CD	O
taking	VBG	O
aerosolized	JJ	O
pentamidine	NN	O
for	IN	O
prophylaxis	NN	O
against	IN	O
Pneumocystis	NNP	O
carinii	NN	O
pneumonia	NN	O
developed	VBD	O
TE	NNP	O
(	(	O
adjusted	VBN	O
RR	NNP	O
for	IN	O
the	DT	O
trimethoprim-sulfamethoxazole	JJ	O
group	NN	O
,	,	O
0.16	CD	O
;	:	O
95	CD	O
%	NN	O
CI	NNP	O
,	,	O
0.01-1.79	NNP	O
;	:	O
P	NNP	O
=	NNP	O
.14	NNP	O
)	)	O
.	.	O

Thus	RB	O
,	,	O
for	IN	O
HIV-infected	JJ	O
patients	NNS	O
receiving	VBG	O
trimethoprim-sulfamethoxazole	JJ	O
,	,	O
additional	JJ	O
prophylaxis	NN	O
for	IN	O
TE	NNP	O
appears	VBZ	O
unnecessary	JJ	O
.	.	O

Comparison	NNP	O
of	IN	O
maintenance	NN	O
treatment	NN	O
regimens	NNS	O
for	IN	O
first	JJ	O
central	JJ	C
nervous	JJ	C
system	NN	C
relapse	NN	C
in	IN	O
children	NNS	A
with	IN	O
acute	JJ	C
lymphocytic	JJ	C
leukemia	NN	C
.	.	O

A	DT	O
Pediatric	NNP	O
Oncology	NNP	O
Group	NNP	O
study	NN	O
.	.	O

Eighty-seven	JJ	SS
children	NNS	O
with	IN	O
central	JJ	C
nervous	JJ	C
system	NN	C
(	(	C
CNS	NNP	C
)	)	C
leukemia	NN	C
were	VBD	O
randomized	VBN	O
to	TO	O
receive	VB	O
either	DT	O
induction	NN	O
intrathecal	JJ	O
chemotherapy	NN	O
(	(	O
ITC	NNP	O
)	)	O
and	CC	O
cranial	JJ	O
irradiation	NN	O
(	(	O
CRT	NNP	O
)	)	O
plus	CC	O
maintenance	NN	O
ITC	NNP	O
,	,	O
or	CC	O
induction	NN	O
ITC	NNP	O
and	CC	O
craniospinal	JJ	O
irradiation	NN	O
(	(	O
CSpRT	NNP	O
)	)	O
with	IN	O
no	DT	O
maintenance	NN	O
ITC	NNP	O
.	.	O

ITC	NNP	O
consisted	VBD	O
of	IN	O
six	CD	O
weekly	JJ	O
injections	NNS	O
of	IN	O
methotrexate	NN	O
,	,	O
hydrocortisone	NN	O
,	,	O
and	CC	O
arabinosylcytosine	NN	O
.	.	O

Also	RB	O
,	,	O
intensification	NN	O
of	IN	O
systemic	JJ	O
induction	NN	O
and	CC	O
maintenance	NN	O
chemotherapy	NN	O
was	VBD	O
given	VBN	O
.	.	O

CRT	NNP	O
+	NNP	O
ITC	NNP	O
was	VBD	O
given	VBN	O
as	IN	O
CRT	NNP	O
,	,	O
2400	CD	O
rad	NN	O
in	IN	O
12	CD	O
fractions	NNS	O
followed	VBN	O
by	IN	O
ITC	NNP	O
maintenance	NN	O
bimonthly	NN	O
for	IN	O
2	CD	O
years	NNS	O
.	.	O

Craniospinal	JJ	O
irradiation	NN	O
consisted	VBD	O
of	IN	O
CRT	NNP	O
+	NNP	O
1400	CD	O
rad	NN	O
in	IN	O
ten	JJ	O
fractions	NNS	O
to	TO	O
the	DT	O
spine	NN	O
.	.	O

Randomization	NN	O
was	VBD	O
stratified	VBN	O
according	VBG	O
to	TO	O
whether	IN	O
CNS	NNP	O
leukemia	NN	O
occurred	VBD	O
at	IN	O
initial	JJ	O
diagnosis	NN	O
of	IN	O
acute	JJ	O
lymphocytic	JJ	O
leukemia	NN	O
(	(	O
ALL	DT	O
)	)	O
(	(	O
Stratum	NNP	O
I	PRP	O
,	,	O
15	CD	O
patients	NNS	O
)	)	O
,	,	O
during	IN	O
first	JJ	O
bone	NN	O
marrow	NN	O
(	(	O
BM	NNP	O
)	)	O
remission	NN	O
(	(	O
Stratum	NNP	O
II	NNP	O
,	,	O
49	CD	O
patients	NNS	O
)	)	O
,	,	O
simultaneous	JJ	O
with	IN	O
first	JJ	O
BM	NNP	O
relapse	NN	O
(	(	O
Stratum	NNP	O
III	NNP	O
,	,	O
12	CD	O
patients	NNS	O
)	)	O
,	,	O
or	CC	O
during	IN	O
second	JJ	O
BM	NNP	O
remission	NN	O
(	(	O
Stratum	NNP	O
IV	NNP	O
,	,	O
11	CD	O
patients	NNS	O
)	)	O
.	.	O

The	DT	O
median	JJ	O
follow-up	NN	O
for	IN	O
patients	NNS	O
who	WP	O
remain	VBP	O
at	IN	O
risk	NN	O
is	VBZ	O
15	CD	O
+	JJ	O
months	NNS	O
.	.	O

Eight	NNP	O
children	NNS	O
(	(	O
seven	CD	O
on	IN	O
CRT	NNP	O
+	NNP	O
ITC	NNP	O
,	,	O
one	CD	O
on	IN	O
CSpRT	NNP	O
)	)	O
developed	VBD	O
presumed	VBN	O
therapy	RB	O
related	VBN	O
encephalopathy	NN	O
.	.	O

In	IN	O
Stratum	NNP	O
II	NNP	O
,	,	O
16	CD	O
of	IN	O
29	CD	O
(	(	O
55	CD	O
%	NN	O
)	)	O
patients	NNS	O
receiving	VBG	O
CRT	NNP	O
+	NNP	O
ITC	NNP	O
experienced	VBD	O
adverse	JJ	O
events	NNS	O
:	:	O
3	CD	O
deaths	NNS	O
during	IN	O
continuous	JJ	O
complete	JJ	O
remission	NN	O
(	(	O
CCR	NNP	O
)	)	O
and	CC	O
13	CD	O
relapses	NNS	O
(	(	O
2	CD	O
CNS	NNP	O
,	,	O
1	CD	O
CNS	NNP	O
+	NNP	O
BM	NNP	O
,	,	O
1	CD	O
BM	NNP	O
+	NNP	O
testes	VBZ	O
,	,	O
and	CC	O
2	CD	O
testes	NNS	O
)	)	O
as	IN	O
compared	VBN	O
with	IN	O
only	RB	O
5	CD	O
relapses	NNS	O
in	IN	O
20	CD	O
(	(	O
25	CD	O
%	NN	O
)	)	O
patients	NNS	O
on	IN	O
CSpRT	NNP	O
(	(	O
1	CD	O
CNS	NNP	O
,	,	O
1	CD	O
CNS	NNP	O
+	NNP	O
BM	NNP	O
,	,	O
1	CD	O
BM	NNP	O
,	,	O
and	CC	O
2	CD	O
testes	NNS	O
)	)	O
.	.	O

The	DT	O
children	NNS	O
on	IN	O
both	DT	O
regimens	NNS	O
were	VBD	O
comparable	JJ	O
for	IN	O
sex	NN	O
,	,	O
race	NN	O
,	,	O
age	NN	O
at	IN	O
initial	JJ	O
ALL	NNP	O
diagnosis	NN	O
,	,	O
time	NN	O
from	IN	O
ALL	NNP	O
diagnosis	NN	O
to	TO	O
first	JJ	O
episode	NN	O
of	IN	O
CNS	NNP	O
leukemia	NN	O
,	,	O
systemic	JJ	O
therapy	NN	O
both	DT	O
before	IN	O
and	CC	O
after	IN	O
CNS	NNP	O
relapse	NN	O
,	,	O
and	CC	O
number	NN	O
of	IN	O
blasts	NNS	O
in	IN	O
the	DT	O
spinal	JJ	O
fluid	NN	O
at	IN	O
diagnosis	NN	O
of	IN	O
CNS	NNP	O
leukemia	NN	O
.	.	O

The	DT	O
conclusion	NN	O
is	VBZ	O
that	IN	O
children	NNS	O
with	IN	O
isolated	JJ	O
CNS	NNP	O
leukemia	NN	O
can	MD	O
achieve	VB	O
prolonged	JJ	O
survival	NN	O
with	IN	O
aggressive	JJ	O
therapy	NN	O
,	,	O
and	CC	O
that	IN	O
CSpRT	NNP	O
is	VBZ	O
possibly	RB	O
less	RBR	O
toxic	JJ	O
and	CC	O
more	RBR	O
likely	JJ	O
than	IN	O
is	VBZ	O
CRT	NNP	O
+	NNP	O
ITC	NNP	O
to	TO	O
prevent	VB	O
subsequent	JJ	O
BM	NNP	O
and	CC	O
testicular	JJ	O
relapse	NN	O
(	(	O
P	NNP	O
less	JJR	O
than	IN	O
0.02	CD	O
)	)	O
,	,	O
but	CC	O
not	RB	O
subsequent	JJ	O
CNS	NNP	O
relapse	NN	O
(	(	O
P	NNP	O
=	NNP	O
0.7	CD	O
)	)	O
.	.	O

A	DT	O
possible	JJ	O
systemic	JJ	O
therapy	NN	O
effect	NN	O
of	IN	O
spinal	JJ	O
irradiation	NN	O
is	VBZ	O
postulated	VBN	O
to	TO	O
explain	VB	O
the	DT	O
superiority	NN	O
of	IN	O
CSpRT	NNP	O
.	.	O

Hypnosis	NNP	O
treatment	NN	O
for	IN	O
severe	JJ	O
irritable	JJ	O
bowel	NN	O
syndrome	NN	O
:	:	O
investigation	NN	O
of	IN	O
mechanism	NN	O
and	CC	O
effects	NNS	O
on	IN	O
symptoms	NNS	O
.	.	O

Hypnosis	NNP	O
improves	VBZ	O
irritable	JJ	O
bowel	NN	O
syndrome	NN	O
(	(	O
IBS	NNP	O
)	)	O
,	,	O
but	CC	O
the	DT	O
mechanism	NN	O
is	VBZ	O
unknown	JJ	O
.	.	O

Possible	JJ	O
physiological	JJ	O
and	CC	O
psychological	JJ	O
mechanisms	NNS	O
were	VBD	O
investigated	VBN	O
in	IN	O
two	CD	O
studies	NNS	O
.	.	O

Patients	NNS	O
with	IN	O
severe	JJ	O
irritable	JJ	O
bowel	NN	O
syndrome	NN	O
received	VBD	O
seven	CD	O
biweekly	JJ	O
hypnosis	NN	O
sessions	NNS	O
and	CC	O
used	VBD	O
hypnosis	NN	O
audiotapes	NNS	O
at	IN	O
home	NN	O
.	.	O

Rectal	JJ	O
pain	NN	O
thresholds	NNS	O
and	CC	O
smooth	JJ	O
muscle	NN	O
tone	NN	O
were	VBD	O
measured	VBN	O
with	IN	O
a	DT	O
barostat	NN	O
before	IN	O
and	CC	O
after	IN	O
treatment	NN	O
in	IN	O
18	CD	O
patients	NNS	O
(	(	O
study	VB	O
I	PRP	O
)	)	O
,	,	O
and	CC	O
treatment	NN	O
changes	NNS	O
in	IN	O
heart	NN	O
rate	NN	O
,	,	O
blood	NN	O
pressure	NN	O
,	,	O
skin	JJ	O
conductance	NN	O
,	,	O
finger	NN	O
temperature	NN	O
,	,	O
and	CC	O
forehead	JJ	O
electromyographic	JJ	O
activity	NN	O
were	VBD	O
assessed	VBN	O
in	IN	O
24	CD	O
patients	NNS	O
(	(	O
study	VB	O
II	NNP	O
)	)	O
.	.	O

Somatization	NN	O
,	,	O
anxiety	NN	O
,	,	O
and	CC	O
depression	NN	O
were	VBD	O
also	RB	O
measured	VBN	O
.	.	O

All	DT	O
central	JJ	O
IBS	NNP	O
symptoms	NNS	O
improved	VBN	O
substantially	RB	O
from	IN	O
treatment	NN	O
in	IN	O
both	DT	O
studies	NNS	O
.	.	O

Rectal	JJ	O
pain	NN	O
thresholds	NNS	O
,	,	O
rectal	JJ	O
smooth	JJ	O
muscle	NN	O
tone	NN	O
,	,	O
and	CC	O
autonomic	JJ	O
functioning	NN	O
(	(	O
except	IN	O
sweat	NN	O
gland	VBP	O
reactivity	NN	O
)	)	O
were	VBD	O
unaffected	VBN	O
by	IN	O
hypnosis	NN	O
treatment	NN	O
.	.	O

However	RB	O
,	,	O
somatization	NN	O
and	CC	O
psychological	JJ	O
distress	NN	O
showed	VBD	O
large	JJ	O
decreases	NNS	O
.	.	O

In	IN	O
conclusion	NN	O
,	,	O
hypnosis	NN	O
improves	NNS	O
IBS	NNP	O
symptoms	NNS	O
through	IN	O
reductions	NNS	O
in	IN	O
psychological	JJ	O
distress	NN	O
and	CC	O
somatization	NN	O
.	.	O

Improvements	NNS	O
were	VBD	O
unrelated	JJ	O
to	TO	O
changes	NNS	O
in	IN	O
the	DT	O
physiological	JJ	O
parameters	NNS	O
measured	VBD	O
.	.	O

Menopausal	NNP	O
quality	NN	O
of	IN	O
life	NN	O
:	:	O
RCT	NNP	O
of	IN	O
yoga	NN	O
,	,	O
exercise	NN	O
,	,	O
and	CC	O
omega-3	JJ	O
supplements	NNS	O
.	.	O

OBJECTIVE	IN	O
The	DT	O
purpose	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
determine	VB	O
the	DT	O
efficacy	NN	O
of	IN	O
3	CD	O
nonhormonal	JJ	O
therapies	NNS	O
for	IN	O
the	DT	O
improvement	NN	O
of	IN	O
menopause-related	JJ	O
quality	NN	O
of	IN	O
life	NN	O
in	IN	O
women	NNS	O
with	IN	O
vasomotor	NN	O
symptoms	NNS	O
.	.	O

STUDY	NNP	O
DESIGN	NNP	O
We	PRP	O
conducted	VBD	O
a	DT	O
12-week	JJ	O
3	CD	O
?	.	O
2	CD	O
randomized	VBD	O
,	,	O
controlled	VBD	O
,	,	O
factorial	JJ	O
design	NN	O
trial	NN	O
.	.	O

Peri-	NN	O
and	CC	O
postmenopausal	JJ	O
women	NNS	O
,	,	O
40-62	JJ	O
years	NNS	O
old	JJ	O
,	,	O
were	VBD	O
assigned	VBN	O
randomly	RB	O
to	TO	O
yoga	VB	O
(	(	O
n	JJ	O
=	NNP	O
107	CD	O
)	)	O
,	,	O
exercise	NN	O
(	(	O
n	JJ	O
=	NNP	O
106	CD	O
)	)	O
,	,	O
or	CC	O
usual	JJ	O
activity	NN	O
(	(	O
n	JJ	O
=	NNP	O
142	CD	O
)	)	O
and	CC	O
also	RB	O
assigned	VBD	O
randomly	RB	O
to	TO	O
a	DT	O
double-blind	JJ	O
comparison	NN	O
of	IN	O
omega-3	JJ	O
(	(	O
n	JJ	O
=	NNP	O
177	CD	O
)	)	O
or	CC	O
placebo	NN	O
(	(	O
n	JJ	O
=	NNP	O
178	CD	O
)	)	O
capsules	NNS	O
.	.	O

We	PRP	O
performed	VBD	O
the	DT	O
following	JJ	O
interventions	NNS	O
:	:	O
(	(	O
1	CD	O
)	)	O
weekly	JJ	O
90-minute	CD	O
yoga	NN	O
classes	NNS	O
with	IN	O
daily	JJ	O
at-home	JJ	O
practice	NN	O
,	,	O
(	(	O
2	CD	O
)	)	O
individualized	VBN	O
facility-based	JJ	O
aerobic	JJ	O
exercise	NN	O
training	NN	O
3	CD	O
times/week	NN	O
,	,	O
and	CC	O
(	(	O
3	CD	O
)	)	O
0.615	CD	O
g	JJ	O
omega-3	JJ	O
supplement	NN	O
,	,	O
3	CD	O
times/day	NN	O
.	.	O

The	DT	O
outcomes	NNS	O
were	VBD	O
assessed	VBN	O
with	IN	O
the	DT	O
following	JJ	O
scores	NNS	O
:	:	O
Menopausal	NNP	O
Quality	NNP	O
of	IN	O
Life	NNP	O
Questionnaire	NNP	O
(	(	O
MENQOL	NNP	O
)	)	O
total	NN	O
and	CC	O
domain	NN	O
(	(	O
vasomotor	NN	O
symptoms	NNS	O
,	,	O
psychosocial	JJ	O
,	,	O
physical	JJ	O
and	CC	O
sexual	JJ	O
)	)	O
.	.	O

RESULTS	NNP	O
Among	IN	O
355	CD	O
randomly	NNS	O
assigned	VBN	O
women	NNS	O
who	WP	O
average	VBP	O
age	NN	O
was	VBD	O
54.7	CD	O
years	NNS	O
,	,	O
338	CD	O
women	NNS	O
(	(	O
95	CD	O
%	NN	O
)	)	O
completed	VBD	O
12-week	JJ	O
assessments	NNS	O
.	.	O

Mean	NNP	O
baseline	NN	O
vasomotor	NN	O
symptoms	JJ	O
frequency	NN	O
was	VBD	O
7.6/day	CD	O
,	,	O
and	CC	O
the	DT	O
mean	JJ	O
baseline	NN	O
total	JJ	O
MENQOL	NNP	O
score	NN	O
was	VBD	O
3.8	CD	O
(	(	O
range	NN	O
,	,	O
1-8	CD	O
from	IN	O
better	JJR	O
to	TO	O
worse	VB	O
)	)	O
with	IN	O
no	DT	O
between-group	JJ	O
differences	NNS	O
.	.	O

For	IN	O
yoga	NN	O
compared	VBN	O
to	TO	O
usual	JJ	O
activity	NN	O
,	,	O
baseline	NN	O
to	TO	O
12-week	JJ	O
improvements	NNS	O
were	VBD	O
seen	VBN	O
for	IN	O
MENQOL	NNP	O
total	JJ	O
-0.3	NNP	O
(	(	O
95	CD	O
%	NN	O
confidence	NN	O
interval	NN	O
,	,	O
-0.6	VBP	O
to	TO	O
0	CD	O
;	:	O
P	NNP	O
=	NNP	O
.02	NNP	O
)	)	O
,	,	O
vasomotor	NN	O
symptom	NN	O
domain	NN	O
(	(	O
P	NNP	O
=	NNP	O
.02	NNP	O
)	)	O
,	,	O
and	CC	O
sexuality	NN	O
domain	NN	O
(	(	O
P	NNP	O
=	NNP	O
.03	NNP	O
)	)	O
scores	VBZ	O
.	.	O

For	IN	O
women	NNS	O
who	WP	O
underwent	VBP	O
exercise	NN	O
and	CC	O
omega-3	JJ	O
therapy	NN	O
compared	VBN	O
with	IN	O
control	NN	O
subjects	NNS	O
,	,	O
improvements	NNS	O
in	IN	O
baseline	NN	O
to	TO	O
12-week	JJ	O
total	JJ	O
MENQOL	NNP	O
scores	NNS	O
were	VBD	O
not	RB	O
observed	VBN	O
.	.	O

Exercise	NN	O
showed	VBD	O
benefit	NN	O
in	IN	O
the	DT	O
MENQOL	NNP	O
physical	JJ	O
domain	NN	O
score	NN	O
at	IN	O
12	CD	O
weeks	NNS	O
(	(	O
P	NNP	O
=	NNP	O
.02	NNP	O
)	)	O
.	.	O

CONCLUSION	NNP	O
All	NNP	O
women	NNS	O
become	VBP	O
menopausal	JJ	O
,	,	O
and	CC	O
many	JJ	O
of	IN	O
them	PRP	O
seek	VBP	O
medical	JJ	O
advice	NN	O
on	IN	O
ways	NNS	O
to	TO	O
improve	VB	O
quality	NN	O
of	IN	O
life	NN	O
;	:	O
little	JJ	O
evidence-based	JJ	O
information	NN	O
exists	NNS	O
.	.	O

We	PRP	O
found	VBD	O
that	IN	O
,	,	O
among	IN	O
healthy	JJ	O
sedentary	JJ	O
menopausal	NN	O
women	NNS	O
,	,	O
yoga	NN	O
appears	VBZ	O
to	TO	O
improve	VB	O
menopausal	NN	O
quality	NN	O
of	IN	O
life	NN	O
;	:	O
the	DT	O
clinical	JJ	O
significance	NN	O
of	IN	O
our	PRP$	O
finding	NN	O
is	VBZ	O
uncertain	JJ	O
because	IN	O
of	IN	O
the	DT	O
modest	JJ	O
effect	NN	O
.	.	O

Environmental	JJ	O
enrichment	NN	O
as	IN	O
an	DT	O
effective	JJ	O
treatment	NN	O
for	IN	O
autism	NN	O
:	:	O
a	DT	O
randomized	NN	O
controlled	VBN	O
trial	NN	O
.	.	O

Enriched	NNP	O
sensorimotor	NN	O
environments	NNS	O
enable	JJ	O
rodents	NNS	O
to	TO	O
compensate	VB	O
for	IN	O
a	DT	O
wide	JJ	O
range	NN	O
of	IN	O
neurological	JJ	O
challenges	NNS	O
,	,	O
including	VBG	O
those	DT	O
induced	VBN	O
in	IN	O
animal	JJ	O
models	NNS	O
of	IN	O
autism	NN	O
.	.	O

Given	VBN	O
the	DT	O
sensorimotor	NN	O
deficits	NNS	O
in	IN	O
most	JJS	O
children	NNS	O
with	IN	O
autism	NN	C
,	,	O
we	PRP	O
attempted	VBD	O
to	TO	O
translate	VB	O
that	DT	O
approach	NN	O
to	TO	O
their	PRP$	O
treatment	NN	O
.	.	O

In	IN	O
a	DT	O
randomized	NN	O
controlled	VBN	O
trial	NN	O
,	,	O
3-12	JJ	A
year-old	JJ	A
children	NNS	A
with	IN	O
autism	NN	C
were	VBD	O
assigned	VBN	O
to	TO	O
either	VB	O
a	DT	O
sensorimotor	NN	O
enrichment	NN	O
group	NN	O
,	,	O
which	WDT	O
received	VBD	O
daily	RB	O
olfactory/tactile	JJ	O
stimulation	NN	O
along	IN	O
with	IN	O
exercises	NNS	O
that	WDT	O
stimulated	VBD	O
other	JJ	O
paired	JJ	O
sensory	JJ	O
modalities	NNS	O
,	,	O
or	CC	O
to	TO	O
a	DT	O
control	NN	O
group	NN	O
.	.	O

We	PRP	O
administered	VBD	O
tests	NNS	O
of	IN	O
cognitive	JJ	O
performance	NN	O
and	CC	O
autism	NN	O
severity	NN	O
to	TO	O
both	DT	O
groups	NNS	O
at	IN	O
the	DT	O
initiation	NN	O
of	IN	O
the	DT	O
study	NN	O
and	CC	O
after	IN	O
6	CD	O
months	NNS	O
.	.	O

Severity	NNP	O
of	IN	O
autism	NN	O
,	,	O
as	IN	O
assessed	VBN	O
with	IN	O
the	DT	O
Childhood	NNP	O
Autism	NNP	O
Rating	NNP	O
Scale	NNP	O
,	,	O
improved	VBN	O
significantly	RB	O
in	IN	O
the	DT	O
enriched	JJ	O
group	NN	O
compared	VBN	O
to	TO	O
controls	NNS	O
.	.	O

Indeed	RB	O
,	,	O
42	CD	O
%	NN	O
of	IN	O
the	DT	O
enriched	VBN	O
group	NN	O
and	CC	O
only	RB	O
7	CD	O
%	NN	O
of	IN	O
the	DT	O
control	NN	O
group	NN	O
had	VBD	O
what	WP	O
we	PRP	O
considered	VBD	O
to	TO	O
be	VB	O
a	DT	O
clinically	RB	O
significant	JJ	O
improvement	NN	O
of	IN	O
5	CD	O
points	NNS	O
on	IN	O
that	DT	O
scale	NN	O
.	.	O

Sensorimotor	NNP	O
enrichment	NN	O
also	RB	O
produced	VBD	O
a	DT	O
clear	JJ	O
improvement	NN	O
in	IN	O
cognition	NN	O
,	,	O
as	IN	O
determined	VBN	O
by	IN	O
their	PRP$	O
Leiter-R	JJ	O
Visualization	NNP	O
and	CC	O
Reasoning	NNP	O
scores	NNS	O
.	.	O

At	IN	O
6	CD	O
months	NNS	O
,	,	O
the	DT	O
change	NN	O
in	IN	O
average	JJ	O
scores	NNS	O
for	IN	O
the	DT	O
enriched	JJ	O
group	NN	O
was	VBD	O
11.3	CD	O
points	NNS	O
higher	JJR	O
than	IN	O
that	DT	O
for	IN	O
the	DT	O
control	NN	O
group	NN	O
.	.	O

Finally	RB	O
,	,	O
69	CD	O
%	NN	O
of	IN	O
parents	NNS	O
in	IN	O
the	DT	O
enriched	JJ	O
group	NN	O
and	CC	O
31	CD	O
%	NN	O
of	IN	O
parents	NNS	O
in	IN	O
the	DT	O
control	NN	O
group	NN	O
reported	VBD	O
improvement	NN	O
in	IN	O
their	PRP$	O
child	NN	O
over	IN	O
the	DT	O
6-month	JJ	O
study	NN	O
.	.	O

Environmental	JJ	O
enrichment	NN	O
therefore	RB	O
appears	VBZ	O
to	TO	O
be	VB	O
effective	JJ	O
in	IN	O
ameliorating	VBG	O
some	DT	O
of	IN	O
the	DT	O
symptoms	NNS	O
of	IN	O
autism	NN	O
in	IN	O
children	NNS	O
.	.	O

Divalproex	NNP	O
sodium	NN	O
vs.	FW	O
placebo	NN	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
repetitive	JJ	O
behaviours	NNS	O
in	IN	O
autism	NN	C
spectrum	NN	C
disorder	NN	C
.	.	O

Autism	NNP	O
is	VBZ	O
a	DT	O
neurodevelopmental	JJ	O
disorder	NN	O
characterized	VBN	O
by	IN	O
impairment	NN	O
in	IN	O
three	CD	O
core	NN	O
symptom	NN	O
domains	NNS	O
:	:	O
socialization	NN	O
,	,	O
communication	NN	O
,	,	O
and	CC	O
repetitive/stereotyped	VBD	O
behaviours	NNS	O
.	.	O

Other	JJ	O
associated	JJ	O
symptom	NN	O
domains	NNS	O
are	VBP	O
also	RB	O
affected	JJ	O
including	VBG	O
impulsivity/aggression	NN	O
,	,	O
self-injury	NN	O
,	,	O
anxiety	NN	O
,	,	O
and	CC	O
mood	NN	O
lability	NN	O
.	.	O

Divalproex	NNP	O
has	VBZ	O
been	VBN	O
shown	VBN	O
to	TO	O
have	VB	O
efficacy	NN	O
in	IN	O
treating	VBG	O
epilepsy	NN	O
,	,	O
bipolar	JJ	O
disorder	NN	O
,	,	O
mood	NN	O
lability	NN	O
,	,	O
and	CC	O
impulsive	JJ	O
aggression	NN	O
.	.	O

The	DT	O
present	JJ	O
study	NN	O
evaluated	VBD	O
the	DT	O
use	NN	O
of	IN	O
divalproex	NN	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
repetitive	JJ	O
,	,	O
compulsive-like	JJ	C
symptoms	NNS	C
of	IN	O
autism	NN	C
spectrum	NN	C
disorder	NN	C
(	(	C
ASD	NNP	C
)	)	C
.	.	O

Thirteen	JJ	SS
individuals	NNS	O
with	IN	O
ASD	NNP	C
participated	VBD	O
in	IN	O
an	DT	O
8-wk	JJ	O
,	,	O
double-blind	JJ	O
,	,	O
placebo-controlled	JJ	O
trial	NN	O
of	IN	O
divalproex	NN	O
sodium	NN	O
vs.	FW	O
placebo	NN	O
.	.	O

There	EX	O
was	VBD	O
a	DT	O
significant	JJ	O
group	NN	O
difference	NN	O
on	IN	O
improvement	NN	O
in	IN	O
repetitive	JJ	O
behaviours	NNS	O
as	IN	O
measured	VBN	O
by	IN	O
the	DT	O
Children	NNP	O
's	POS	O
Yale-Brown	JJ	O
Obsessive	NNP	O
Compulsive	NNP	O
Scale	NNP	O
(	(	O
C-YBOCS	NNP	O
)	)	O
(	(	O
p=0.037	NN	O
)	)	O
and	CC	O
a	DT	O
large	JJ	O
effect	NN	O
size	NN	O
(	(	O
d=1.616	NN	O
)	)	O
.	.	O

This	DT	O
study	NN	O
provides	VBZ	O
preliminary	JJ	O
support	NN	O
for	IN	O
the	DT	O
use	NN	O
of	IN	O
divalproex	NN	O
in	IN	O
treating	VBG	O
repetitive	JJ	O
behaviours	NNS	O
in	IN	O
ASD	NNP	O
.	.	O

Further	NNP	O
research	NN	O
is	VBZ	O
needed	VBN	O
to	TO	O
evaluate	VB	O
the	DT	O
specificity	NN	O
and	CC	O
mechanism	NN	O
of	IN	O
action	NN	O
of	IN	O
these	DT	O
findings	NNS	O
.	.	O

Randomized	VBN	O
trial	NN	O
comparing	VBG	O
induction	NN	O
chemotherapy	NN	O
versus	NN	O
induction	NN	O
chemotherapy	NN	O
followed	VBN	O
by	IN	O
maintenance	NN	O
chemotherapy	NN	O
in	IN	O
small-cell	JJ	C
lung	NN	C
cancer	NN	C
.	.	O

European	JJ	O
Lung	NNP	O
Cancer	NNP	O
Working	NNP	O
Party	NNP	O
.	.	O

PURPOSE	NNP	O
AND	CC	O
METHODS	NNP	O
The	DT	O
European	NNP	O
Lung	NNP	O
Cancer	NNP	O
Working	NNP	O
Party	NNP	O
(	(	O
ELCWP	NNP	O
)	)	O
performed	VBD	O
a	DT	O
randomized	JJ	O
trial	NN	O
with	IN	O
the	DT	O
primary	JJ	O
end	NN	O
point	NN	O
to	TO	O
determine	VB	O
if	IN	O
maintenance	NN	O
chemotherapy	NN	O
with	IN	O
12	CD	O
courses	NNS	O
of	IN	O
etoposide	NN	O
(	(	O
120	CD	O
mg/m2	NN	O
on	IN	O
days	NNS	O
1	CD	O
and	CC	O
3	CD	O
)	)	O
and	CC	O
vindesine	NN	O
(	(	O
3	CD	O
mg/m2	NN	O
on	IN	O
day	NN	O
3	CD	O
)	)	O
could	MD	O
improve	VB	O
progression-free	JJ	O
survival	NN	O
in	IN	O
small-cell	JJ	O
lung	NN	O
cancer	NN	O
(	(	O
SCLC	NNP	O
)	)	O
patients	NNS	O
who	WP	O
responded	VBD	O
to	TO	O
six	CD	O
courses	NNS	O
of	IN	O
induction	NN	O
chemotherapy	NN	O
with	IN	O
ifosfamide	NN	O
,	,	O
etoposide	RB	O
,	,	O
and	CC	O
an	DT	O
anthracycline	NN	O
(	(	O
doxorubicin	NN	O
or	CC	O
epirubicin	NN	O
)	)	O
.	.	O

RESULTS	NNP	O
Among	IN	O
235	CD	SS
eligible	JJ	O
patients	NNS	O
initially	RB	O
registered	VBD	O
,	,	O
91	CD	SS
were	VBD	O
randomized	VBN	O
to	TO	O
receive	VB	O
maintenance	NN	O
therapy	NN	O
,	,	O
including	VBG	O
seven	CD	SS
patients	NNS	O
who	WP	O
were	VBD	O
no	RB	O
longer	RBR	O
responding	VBG	O
.	.	O

Among	IN	O
84	CD	O
randomized	JJ	O
responders	NNS	O
,	,	O
progression-free	JJ	O
survival	NN	O
was	VBD	O
significantly	RB	O
improved	VBN	O
(	(	O
P	NNP	O
=	NNP	O
.003	NNP	O
)	)	O
by	IN	O
maintenance	NN	O
therapy	NN	O
,	,	O
with	IN	O
median	JJ	O
durations	NNS	O
(	(	O
maintenance	NN	O
v	IN	O
follow-up	JJ	O
)	)	O
of	IN	O
25	CD	O
versus	NNS	O
12	CD	O
weeks	NNS	O
after	IN	O
the	DT	O
second	JJ	O
randomization	NN	O
,	,	O
but	CC	O
survival	NN	O
was	VBD	O
not	RB	O
significantly	RB	O
increased	VBN	O
(	(	O
P	NNP	O
=	NNP	O
.10	NNP	O
)	)	O
,	,	O
with	IN	O
median	JJ	O
durations	NNS	O
of	IN	O
48	CD	O
and	CC	O
38	CD	O
weeks	NNS	O
.	.	O

However	RB	O
,	,	O
in	IN	O
a	DT	O
multi-variate	JJ	O
analysis	NN	O
that	WDT	O
took	VBD	O
into	IN	O
account	NN	O
disease	NN	O
extent	NN	O
,	,	O
maintenance	NN	O
therapy	NN	O
,	,	O
Karnofsky	NNP	O
performance	NN	O
status	NN	O
(	(	O
PS	NNP	O
)	)	O
,	,	O
and	CC	O
absolute	JJ	O
dose-intensity	NN	O
(	(	O
ADI	NNP	O
)	)	O
of	IN	O
anthracycline	NN	O
given	VBN	O
during	IN	O
induction	NN	O
,	,	O
limited	JJ	O
disease	NN	O
(	(	O
LD	NNP	O
)	)	O
and	CC	O
maintenance	NN	O
were	VBD	O
found	VBN	O
to	TO	O
be	VB	O
independent	JJ	O
positive	JJ	O
predictors	NNS	O
of	IN	O
survival	NN	O
.	.	O

CONCLUSION	NNP	O
We	PRP	O
conclude	VBP	O
that	DT	O
maintenance	NN	O
chemotherapy	NN	O
in	IN	O
responding	VBG	O
patients	NNS	O
is	VBZ	O
beneficial	JJ	O
in	IN	O
SCLC	NNP	O
.	.	O

Comparison	NNP	O
of	IN	O
arbutamine	NN	O
and	CC	O
exercise	NN	O
echocardiography	NN	O
in	IN	O
diagnosing	VBG	C
myocardial	JJ	C
ischemia	NN	C
.	.	C

Arbutamine	NNP	O
is	VBZ	O
a	DT	O
new	JJ	O
catecholamine	NN	O
designed	VBN	O
for	IN	O
use	NN	O
as	IN	O
a	DT	O
pharmacologic	JJ	O
stress	NN	O
agent	NN	O
.	.	O

This	DT	O
study	NN	O
compared	VBN	O
the	DT	O
sensitivity	NN	O
of	IN	O
arbutamine	NN	O
with	IN	O
symptom-limited	JJ	O
exercise	NN	O
to	TO	O
induce	VB	O
echocardiographic	JJ	O
signs	NNS	O
of	IN	O
ischemia	NN	O
.	.	O

Arbutamine	NNP	O
was	VBD	O
administered	VBN	O
by	IN	O
a	DT	O
computerized	JJ	O
closed-loop	NN	O
delivery	NN	O
system	NN	O
that	WDT	O
controls	VBZ	O
the	DT	O
infusion	NN	O
rate	NN	O
of	IN	O
arbutamine	NN	O
toward	IN	O
a	DT	O
predefined	JJ	O
rate	NN	O
of	IN	O
heart	NN	O
rate	NN	O
increase	NN	O
and	CC	O
maximum	JJ	O
heart	NN	O
rate	NN	O
limit	NN	O
.	.	O

Beta	NNP	O
blockers	NNS	O
were	VBD	O
stopped	VBN	O
>	CD	O
or	CC	O
=	VB	O
48	CD	O
hours	NNS	O
before	IN	O
both	DT	O
tests	NNS	O
.	.	O

Stress	NN	O
was	VBD	O
stopped	VBN	O
for	IN	O
intolerable	JJ	O
symptoms	NNS	O
,	,	O
or	CC	O
clinical	JJ	O
,	,	O
electrocardiographic	JJ	O
or	CC	O
echocardiographic	JJ	O
signs	NNS	O
of	IN	O
ischemia	NN	O
(	(	O
new	JJ	O
or	CC	O
worsening	VBG	O
wall	JJ	O
motion	NN	O
abnormality	NN	O
)	)	O
,	,	O
target	VB	O
heart	NN	O
rate	NN	O
(	(	O
>	CD	O
or	CC	O
=	VB	O
85	CD	O
%	NN	O
age	NN	O
predicted	VBD	O
maximum	JJ	O
heart	NN	O
rate	NN	O
)	)	O
,	,	O
or	CC	O
plateau	NN	O
of	IN	O
heart	NN	O
rate	NN	O
response	NN	O
.	.	O

Thirty-seven	JJ	O
patients	NNS	O
were	VBD	O
entered	VBN	O
into	IN	O
the	DT	O
study	NN	O
(	(	O
35	CD	O
arbutamine	NN	O
and	CC	O
exercise	NN	O
,	,	O
1	CD	O
arbutamine	NN	O
only	RB	O
,	,	O
1	CD	O
exercise	NN	O
only	RB	O
)	)	O
,	,	O
of	IN	O
which	WDT	O
30	CD	O
had	VBD	O
angiographic	JJ	O
evidence	NN	O
of	IN	O
coronary	JJ	O
artery	NN	O
disease	NN	O
(	(	O
>	CD	O
or	CC	O
=	VB	O
50	CD	O
%	NN	O
lumen	NNS	O
diameter	RB	O
narrowing	VBG	O
)	)	O
.	.	O

Rate-pressure	JJ	O
product	NN	O
increased	VBN	O
significantly	RB	O
in	IN	O
response	NN	O
to	TO	O
both	DT	O
stress	JJ	O
modalities	NNS	O
(	(	O
p	JJ	O
<	NNP	O
0.001	CD	O
)	)	O
and	CC	O
was	VBD	O
significantly	RB	O
greater	JJR	O
with	IN	O
exercise	NN	O
(	(	O
11,308	CD	O
+/-	JJ	O
2,443	CD	O
)	)	O
than	IN	O
with	IN	O
arbutamine	NN	O
(	(	O
9,486	CD	O
+/-	JJ	O
2,479	CD	O
,	,	O
p	NN	O
<	NNP	O
0.001	CD	O
)	)	O
.	.	O

The	DT	O
time	NN	O
to	TO	O
maximum	VB	O
heart	NN	O
rate	NN	O
was	VBD	O
longer	RBR	O
during	IN	O
arbutamine	JJ	O
stress	NN	O
echocardiography	NN	O
than	IN	O
during	IN	O
exercise	NN	O
testing	NN	O
(	(	O
17.3	CD	O
+/-	JJ	O
9.4	CD	O
versus	NN	O
9.3	CD	O
+/-	JJ	O
4.2	CD	O
minutes	NNS	O
,	,	O
respectively	RB	O
,	,	O
p	JJ	O
<	NNP	O
0.001	CD	O
)	)	O
.	.	O

There	EX	O
were	VBD	O
more	JJR	O
patients	NNS	O
with	IN	O
interpretable	JJ	O
echo	NN	O
data	NNS	O
for	IN	O
arbutamine	NN	O
(	(	O
82	CD	O
%	NN	O
)	)	O
than	IN	O
for	IN	O
exercise	NN	O
(	(	O
67	CD	O
%	NN	O
)	)	O
.	.	O

Sensitivity	NN	O
for	IN	O
recognition	NN	O
of	IN	O
myocardial	JJ	O
ischemia	NN	O
was	VBD	O
94	CD	O
%	NN	O
(	(	O
95	CD	O
%	NN	O
confidence	NN	O
interval	JJ	O
70	CD	O
%	NN	O
to	TO	O
100	CD	O
%	NN	O
)	)	O
and	CC	O
88	CD	O
%	NN	O
(	(	O
95	CD	O
%	NN	O
confidence	NN	O
interval	JJ	O
62	CD	O
%	NN	O
to	TO	O
98	CD	O
%	NN	O
)	)	O
,	,	O
respectively	RB	O
.	.	O

The	DT	O
most	RBS	O
frequent	JJ	O
adverse	JJ	O
events	NNS	O
during	IN	O
arbutamine	NN	O
(	(	O
n	JJ	O
=	NNP	O
36	CD	O
)	)	O
were	VBD	O
dyspnea	VBN	O
(	(	O
5.6	CD	O
%	NN	O
)	)	O
and	CC	O
tremor	NN	O
(	(	O
5.6	CD	O
%	NN	O
)	)	O
.	.	O

Two	CD	O
arbutamine	JJ	O
stress	NN	O
tests	NNS	O
were	VBD	O
discontinued	VBN	O
due	JJ	O
to	TO	O
arrhythmias	VB	O
:	:	O
1	CD	O
patient	NN	O
had	VBD	O
premature	JJ	O
atrial	JJ	O
and	CC	O
ventricular	JJ	O
beats	NNS	O
,	,	O
and	CC	O
the	DT	O
other	JJ	O
had	VBD	O
premature	JJ	O
atrial	JJ	O
contractions	NNS	O
and	CC	O
atrial	JJ	O
fibrillation	NN	O
.	.	O

Arrhythmias	NNP	O
were	VBD	O
well	RB	O
tolerated	VBN	O
and	CC	O
resolved	VBN	O
without	IN	O
sequelae	NN	O
.	.	O

In	IN	O
conclusion	NN	O
,	,	O
the	DT	O
sensitivity	NN	O
of	IN	O
arbutamine	NN	O
to	TO	O
induce	VB	O
echocardiographic	JJ	O
signs	NNS	O
of	IN	O
ischemia	NN	O
was	VBD	O
similar	JJ	O
to	TO	O
that	DT	O
of	IN	O
exercise	NN	O
despite	IN	O
a	DT	O
lower	JJR	O
rate-pressure	NN	O
product	NN	O
.	.	O

Arbutamine	NNP	O
was	VBD	O
well	RB	O
tolerated	JJ	O
and	CC	O
provides	VBZ	O
a	DT	O
reliable	JJ	O
alternative	NN	O
to	TO	O
exercise	VB	O
echocardiography	NN	O
.	.	O

Comparison	NNP	O
of	IN	O
three	CD	O
solutions	NNS	O
of	IN	O
ropivacaine/fentanyl	NN	O
for	IN	O
postoperative	JJ	O
patient-controlled	JJ	O
epidural	JJ	O
analgesia	NN	O
.	.	O

BACKGROUND	NNP	O
Ropivacaine	NNP	O
,	,	O
0.2	CD	O
%	NN	O
,	,	O
is	VBZ	O
a	DT	O
new	JJ	O
local	JJ	O
anesthetic	JJ	O
approved	VBN	O
for	IN	O
epidural	JJ	O
analgesia	NN	O
.	.	O

The	DT	O
addition	NN	O
of	IN	O
4	CD	O
microg/ml	NNS	O
fentanyl	JJ	O
improves	NNS	O
analgesia	VBP	O
from	IN	O
epidural	JJ	O
ropivacaine	NN	O
.	.	O

Use	NNP	O
of	IN	O
a	DT	O
lower	JJR	O
concentration	NN	O
of	IN	O
ropivacaine-fentanyl	NN	O
may	MD	O
further	VB	O
improve	VB	O
analgesia	NN	O
or	CC	O
decrease	JJ	O
side	NN	O
effects	NNS	O
.	.	O

METHODS	NNP	O
Thirty	NNP	O
patients	NNS	O
undergoing	VBG	O
lower	JJR	O
abdominal	JJ	O
surgery	NN	O
were	VBD	O
randomized	VBN	O
in	IN	O
a	DT	O
double-blinded	JJ	O
manner	NN	O
to	TO	O
receive	VB	O
one	CD	O
of	IN	O
three	CD	O
solutions	NNS	O
:	:	O
0.2	CD	O
%	NN	O
ropivacaine-4	JJ	O
microg	NN	O
fentanyl	VBD	O
0.1	CD	O
%	NN	O
ropivacaine-2	JJ	O
microg	NN	O
fentanyl	NN	O
,	,	O
or	CC	O
0.05	CD	O
%	NN	O
ropivacaine-1	JJ	O
microg	NN	O
fentanyl	NN	O
for	IN	O
patient-controlled	JJ	O
epidural	JJ	O
analgesia	NN	O
after	IN	O
standardized	VBN	O
combined	JJ	O
epidural	JJ	O
and	CC	O
general	JJ	O
anesthesia	NN	O
.	.	O

Patient-controlled	JJ	O
epidural	JJ	O
analgesia	NN	O
settings	NNS	O
and	CC	O
adjustments	NNS	O
for	IN	O
the	DT	O
three	CD	O
solutions	NNS	O
were	VBD	O
standardized	VBN	O
to	TO	O
deliver	VB	O
equivalent	JJ	O
drug	NN	O
doses	NNS	O
.	.	O

Pain	NN	O
scores	NNS	O
(	(	O
rest	NN	O
,	,	O
cough	NN	O
,	,	O
and	CC	O
ambulation	NN	O
)	)	O
,	,	O
side	JJ	O
effects	NNS	O
(	(	O
nausea	NN	O
,	,	O
pruritus	NN	O
,	,	O
sedation	NN	O
,	,	O
motor	NN	O
block	NN	O
,	,	O
hypotension	NN	O
,	,	O
and	CC	O
orthostasis	NN	O
)	)	O
,	,	O
and	CC	O
patient-controlled	JJ	O
epidural	JJ	O
analgesia	NN	O
consumption	NN	O
were	VBD	O
measured	VBN	O
for	IN	O
48	CD	O
h.	JJ	O
RESULTS	NNP	O
All	NNP	O
three	CD	O
solutions	NNS	O
produced	VBD	O
equivalent	JJ	O
analgesia	NN	O
.	.	O

Motor	NNP	O
block	NN	O
was	VBD	O
significantly	RB	O
more	JJR	O
common	JJ	O
(	(	O
30	CD	O
vs.	FW	O
0	CD	O
%	NN	O
)	)	O
and	CC	O
more	JJR	O
intense	JJ	O
with	IN	O
the	DT	O
0.2	CD	O
%	NN	O
ropivacaine-4	JJ	O
microg	NN	O
fentanyl	JJ	O
solution	NN	O
.	.	O

Other	JJ	O
side	NN	O
effects	NNS	O
were	VBD	O
equivalent	JJ	O
between	IN	O
solutions	NNS	O
and	CC	O
mild	NN	O
in	IN	O
severity	NN	O
.	.	O

A	DT	O
significantly	RB	O
smaller	JJR	O
volume	NN	O
of	IN	O
0.2	CD	O
%	NN	O
ropivacaine-4	JJ	O
microg	NN	O
fentanyl	JJ	O
solution	NN	O
was	VBD	O
used	VBN	O
,	,	O
whereas	IN	O
the	DT	O
0.1	CD	O
%	NN	O
ropivacaine-2	JJ	O
microg	NN	O
fentanyl	NN	O
group	NN	O
used	VBD	O
a	DT	O
significantly	RB	O
greater	JJR	O
amount	NN	O
of	IN	O
ropivacaine	NN	O
and	CC	O
fentanyl	NN	O
.	.	O

CONCLUSIONS	NNP	O
Lesser	NNP	O
concentrations	NNS	O
of	IN	O
ropivacaine	NN	O
and	CC	O
fentanyl	JJ	O
provide	NN	O
comparable	JJ	O
analgesia	NN	O
with	IN	O
less	JJR	O
motor	NN	O
block	NN	O
despite	IN	O
the	DT	O
use	NN	O
of	IN	O
similar	JJ	O
amounts	NNS	O
of	IN	O
ropivacaine	NN	O
and	CC	O
fentanyl	NN	O
.	.	O

This	DT	O
finding	NN	O
suggests	VBZ	O
that	IN	O
concentration	NN	O
of	IN	O
local	JJ	O
anesthetic	JJ	O
solution	NN	O
at	IN	O
low	JJ	O
doses	NNS	O
is	VBZ	O
a	DT	O
primary	JJ	O
determinant	NN	O
of	IN	O
motor	NN	O
block	NN	O
with	IN	O
patient-controlled	JJ	O
epidural	JJ	O
analgesia	NN	O
after	IN	O
lower	JJR	O
abdominal	JJ	O
surgery	NN	O
.	.	O

Behavioral	NNP	O
and	CC	O
physiological	JJ	O
effects	NNS	O
of	IN	O
remifentanil	NN	O
and	CC	O
alfentanil	NN	O
in	IN	O
healthy	JJ	C
volunteers	NNS	O
.	.	O

BACKGROUND	IN	O
The	DT	O
subjective	JJ	O
and	CC	O
psychomotor	JJ	O
effects	NNS	O
of	IN	O
remifentanil	NNS	O
have	VBP	O
not	RB	O
been	VBN	O
evaluated	VBN	O
.	.	O

Accordingly	RB	O
,	,	O
the	DT	O
authors	NNS	O
used	VBD	O
mood	NN	O
inventories	NNS	O
and	CC	O
psychomotor	NN	O
tests	NNS	O
to	TO	O
characterize	VB	O
the	DT	O
effects	NNS	O
of	IN	O
remifentanil	NN	O
in	IN	O
healthy	JJ	O
,	,	O
non-drug-abusing	JJ	C
volunteers	NNS	O
.	.	O

Alfentanil	NNP	O
was	VBD	O
used	VBN	O
as	IN	O
a	DT	O
comparator	NN	O
drug	NN	O
.	.	O

METHODS	NNP	O
Ten	NNP	O
healthy	JJ	O
volunteers	NNS	O
were	VBD	O
enrolled	VBN	O
in	IN	O
a	DT	O
randomized	JJ	O
,	,	O
double-blinded	JJ	O
,	,	O
placebo-controlled	JJ	O
,	,	O
crossover	JJ	O
trial	NN	O
in	IN	O
which	WDT	O
they	PRP	O
received	VBD	O
an	DT	O
infusion	NN	O
of	IN	O
saline	NN	O
,	,	O
remifentanil	NN	O
,	,	O
or	CC	O
alfentanil	NN	O
for	IN	O
120	CD	O
min	NN	O
.	.	O

The	DT	O
age-	JJ	O
and	CC	O
weight-adjusted	JJ	O
infusions	NNS	O
(	(	O
determined	VBN	O
with	IN	O
STANPUMP	NNP	O
,	,	O
a	DT	O
computer	NN	O
modeling	VBG	O
software	NN	O
package	NN	O
)	)	O
were	VBD	O
given	VBN	O
to	TO	O
achieve	VB	O
three	CD	O
predicted	VBN	O
constant	JJ	O
plasma	NN	O
levels	NNS	O
for	IN	O
40	CD	O
min	NNS	O
each	DT	O
of	IN	O
remifentanil	NN	O
(	(	O
0.75	CD	O
,	,	O
1.5	CD	O
,	,	O
and	CC	O
3	CD	O
ng/ml	NN	O
)	)	O
and	CC	O
alfentanil	NN	O
(	(	O
16	CD	O
,	,	O
32	CD	O
,	,	O
and	CC	O
64	CD	O
ng/ml	NN	O
)	)	O
.	.	O

Mood	NN	O
forms	NNS	O
and	CC	O
psychomotor	NN	O
tests	NNS	O
were	VBD	O
completed	VBN	O
,	,	O
and	CC	O
miosis	NN	O
was	VBD	O
assessed	VBN	O
,	,	O
during	IN	O
and	CC	O
after	IN	O
the	DT	O
infusions	NNS	O
.	.	O

In	IN	O
addition	NN	O
,	,	O
analgesia	NN	O
was	VBD	O
tested	VBN	O
at	IN	O
each	DT	O
dose	JJ	O
level	NN	O
using	VBG	O
a	DT	O
cold-pressor	JJ	O
test	NN	O
.	.	O

RESULTS	NNP	O
Remifentanil	NNP	O
had	VBD	O
prototypic	VBN	O
micro-like	JJ	O
opioid	JJ	O
subjective	JJ	O
effects	NNS	O
,	,	O
impaired	JJ	O
psychomotor	NN	O
performance	NN	O
,	,	O
and	CC	O
produced	VBD	O
analgesia	NN	O
.	.	O

Alfentanil	NNP	O
at	IN	O
the	DT	O
dose	JJ	O
range	NN	O
tested	VBD	O
had	VBD	O
more	RBR	O
mild	JJ	O
effects	NNS	O
on	IN	O
these	DT	O
measures	NNS	O
,	,	O
and	CC	O
the	DT	O
analgesia	NN	O
data	NNS	O
indicated	VBD	O
that	IN	O
a	DT	O
40:1	CD	O
potency	NN	O
ratio	NN	O
,	,	O
rather	RB	O
than	IN	O
the	DT	O
20:1	CD	O
ratio	NN	O
we	PRP	O
used	VBD	O
,	,	O
may	MD	O
exist	VB	O
between	IN	O
remifentanil	NN	O
and	CC	O
alfentanil	NN	O
.	.	O

A	DT	O
psychomotor	NN	O
test	NN	O
administered	VBD	O
60	CD	O
min	NN	O
after	IN	O
the	DT	O
remifentanil	NN	O
infusion	NN	O
was	VBD	O
discontinued	VBN	O
showed	VBD	O
that	IN	O
the	DT	O
volunteers	NNS	O
were	VBD	O
still	RB	O
impaired	VBN	O
,	,	O
although	IN	O
they	PRP	O
reported	VBD	O
feeling	VBG	O
no	DT	O
drug	NN	O
effects	NNS	O
.	.	O

CONCLUSIONS	VB	O
The	DT	O
notion	NN	O
that	IN	O
the	DT	O
pharmacodynamic	JJ	O
effects	NNS	O
of	IN	O
remifentanil	NN	O
are	VBP	O
extremely	RB	O
short-lived	JJ	O
after	IN	O
the	DT	O
drug	NN	O
is	VBZ	O
no	DT	O
longer	RB	O
administered	VBN	O
must	MD	O
be	VB	O
questioned	VBN	O
given	VBN	O
our	PRP$	O
findings	NNS	O
that	IN	O
psychomotor	NN	O
effects	NNS	O
were	VBD	O
still	RB	O
apparent	JJ	O
1	CD	O
h	NN	O
after	IN	O
the	DT	O
infusion	NN	O
was	VBD	O
discontinued	VBN	O
.	.	O

Dexamethasone	NNP	O
effectively	RB	O
reduces	VBZ	O
postoperative	JJ	O
nausea	NN	O
and	CC	O
vomiting	NN	O
in	IN	O
a	DT	O
general	JJ	O
surgical	JJ	O
adult	NN	O
patient	JJ	O
population	NN	O
.	.	O

BACKGROUND	NNP	O
Postoperative	NNP	O
nausea	NN	O
and	CC	O
vomiting	NN	O
(	(	O
PONV	NNP	O
)	)	O
is	VBZ	O
still	RB	O
a	DT	O
common	JJ	O
and	CC	O
major	JJ	O
complication	NN	O
for	IN	O
surgical	JJ	O
patients	NNS	O
,	,	O
which	WDT	O
may	MD	O
delay	VB	O
post-anesthetic	JJ	O
care	NN	O
unit	NN	O
discharge	NN	O
,	,	O
prolong	JJ	O
hospital	NN	O
stay	NN	O
and	CC	O
thus	RB	O
increase	VB	O
the	DT	O
cost	NN	O
of	IN	O
hospitalization	NN	O
.	.	O

It	PRP	O
is	VBZ	O
understood	JJ	O
that	IN	O
PONV	NNP	O
is	VBZ	O
a	DT	O
multi-factorial	JJ	O
outcome	NN	O
and	CC	O
occurs	VBZ	O
more	RBR	O
often	RB	O
with	IN	O
general	JJ	O
anesthesia	NN	O
than	IN	O
with	IN	O
other	JJ	O
anesthetic	JJ	O
methods	NNS	O
.	.	O

Prophylactic	JJ	O
administration	NN	O
of	IN	O
antihistamines	NNS	O
,	,	O
antidopaminergics	NNS	O
,	,	O
anticholinergics	NNS	O
,	,	O
phenothiazines	NNS	O
,	,	O
serotonin	JJ	O
antagonist	NN	O
,	,	O
steroids	NNS	O
and	CC	O
even	RB	O
acupuncture	NN	O
has	VBZ	O
been	VBN	O
shown	VBN	O
to	TO	O
be	VB	O
effective	JJ	O
.	.	O

However	RB	O
,	,	O
expenses	NNS	O
and	CC	O
side	JJ	O
effects	NNS	O
of	IN	O
these	DT	O
agents	NNS	O
have	VBP	O
also	RB	O
been	VBN	O
a	DT	O
concern	NN	O
for	IN	O
clinical	JJ	O
doctors	NNS	O
.	.	O

The	DT	O
aim	NN	O
for	IN	O
this	DT	O
prospective	JJ	O
study	NN	O
was	VBD	O
to	TO	O
find	VB	O
an	DT	O
agent	NN	O
that	WDT	O
is	VBZ	O
cost	RBS	O
effective	JJ	O
and	CC	O
side	JJ	O
effect	NN	O
free	JJ	O
(	(	O
or	CC	O
at	IN	O
least	JJS	O
with	IN	O
a	DT	O
low	JJ	O
incidence	NN	O
of	IN	O
side	JJ	O
effects	NNS	O
)	)	O
for	IN	O
the	DT	O
prevention	NN	O
of	IN	O
PONV	NNP	O
.	.	O

METHODS	NNP	O
A	NNP	O
total	NN	O
of	IN	O
700	CD	O
adult	NN	O
surgical	JJ	O
patients	NNS	O
who	WP	O
planned	VBD	O
to	TO	O
have	VB	O
surgery	NN	O
under	IN	O
general	JJ	O
anesthesia	NN	O
were	VBD	O
enrolled	VBN	O
in	IN	O
this	DT	O
double-blinded	JJ	O
,	,	O
randomized	JJ	O
and	CC	O
placebo-controlled	JJ	O
study	NN	O
.	.	O

Group	NNP	O
P	NNP	O
received	VBD	O
the	DT	O
placebo	NN	O
(	(	O
0.9	CD	O
%	NN	O
normal	JJ	O
saline	JJ	O
2	CD	O
ml	NN	O
)	)	O
and	CC	O
Group	NNP	O
D	NNP	O
received	VBD	O
10	CD	O
mg	NNS	O
dexamethasone	RB	O
intravenously	RB	O
right	JJ	O
before	IN	O
the	DT	O
induction	NN	O
of	IN	O
anesthesia	NN	O
.	.	O

RESULTS	NNP	O
We	PRP	O
found	VBD	O
that	IN	O
during	IN	O
the	DT	O
postoperative	JJ	O
period	NN	O
of	IN	O
1-8	JJ	O
h	NN	O
,	,	O
patients	NNS	O
in	IN	O
Group	NNP	O
D	NNP	O
reported	VBD	O
a	DT	O
lower	JJR	O
incidence	NN	O
of	IN	O
PONV	NNP	O
(	(	O
24	CD	O
%	NN	O
)	)	O
than	IN	O
those	DT	O
in	IN	O
Group	NNP	O
P	NNP	O
(	(	O
39	CD	O
%	NN	O
,	,	O
p	NN	O
<	NNP	O
0.001	CD	O
)	)	O
.	.	O

Patients	NNS	O
in	IN	O
Group	NNP	O
D	NNP	O
also	RB	O
requested	VBD	O
less	JJR	O
rescue	JJ	O
anti-emetic	JJ	O
(	(	O
17	CD	O
%	NN	O
)	)	O
than	IN	O
those	DT	O
in	IN	O
Group	NNP	O
P	NNP	O
(	(	O
30	CD	O
%	NN	O
,	,	O
p	NN	O
<	NNP	O
0.05	CD	O
)	)	O
.	.	O

The	DT	O
same	JJ	O
phenomenon	NN	O
was	VBD	O
also	RB	O
noted	VBN	O
in	IN	O
the	DT	O
8-to-24-hour	JJ	O
interval	NN	O
(	(	O
PONV	NNP	O
4	CD	O
%	NN	O
vs.	FW	O
12	CD	O
%	NN	O
,	,	O
p	NN	O
<	VBD	O
0.05	CD	O
and	CC	O
rescue	VB	O
anti-emetic	JJ	O
3	CD	O
%	NN	O
vs.	FW	O
9	CD	O
%	NN	O
,	,	O
p	NN	O
<	VBD	O
0.05	CD	O
in	IN	O
Group	NNP	O
D	NNP	O
vs.	FW	O
Group	NNP	O
P	NNP	O
,	,	O
respectively	RB	O
.	.	O

)	)	O
CONCLUSIONS	IN	O
We	PRP	O
conclude	VBP	O
that	IN	O
the	DT	O
prophylactic	JJ	O
intravenous	JJ	O
administration	NN	O
of	IN	O
10	CD	O
mg	NNS	O
dexamethasone	VBP	O
immediately	RB	O
before	IN	O
the	DT	O
induction	NN	O
of	IN	O
anesthesia	NN	O
is	VBZ	O
effective	JJ	O
in	IN	O
preventing	VBG	O
PONV	NNP	O
in	IN	O
the	DT	O
general	JJ	O
surgical	JJ	O
adult	NN	O
patient	JJ	O
population	NN	O
.	.	O

Effect	NN	O
of	IN	O
micronutrient	NN	O
supplement	NN	O
on	IN	O
health	NN	O
and	CC	O
nutritional	JJ	O
status	NN	O
of	IN	O
schoolchildren	NNS	O
:	:	O
study	NN	O
design	NN	O
.	.	O

OBJECTIVE	IN	O
We	PRP	O
tested	VBD	O
the	DT	O
hypothesis	NN	O
that	WDT	O
supplementation	NN	O
with	IN	O
a	DT	O
micronutrient-fortified	JJ	O
beverage	NN	O
improves	VBZ	O
micronutrient	JJ	O
status	NN	O
and	CC	O
physical	JJ	O
and	CC	O
mental	JJ	O
development	NN	O
in	IN	O
apparently	RB	O
healthy	JJ	O
schoolchildren	NNS	O
.	.	O

METHODS	NNP	O
The	DT	O
study	NN	O
was	VBD	O
carried	VBN	O
out	RP	O
in	IN	O
middle-income	JJ	O
students	NNS	O
in	IN	O
two	CD	O
residential	JJ	O
schools	NNS	O
that	WDT	O
catered	VBD	O
to	TO	O
children	NNS	O
from	IN	O
a	DT	O
semi-urban	JJ	O
population	NN	O
near	IN	O
Hyderabad	NNP	O
,	,	O
India	NNP	O
.	.	O

Included	NNP	O
were	VBD	O
869	CD	O
children	NNS	O
who	WP	O
were	VBD	O
6	CD	O
to	TO	O
16	CD	O
y	NN	O
of	IN	O
age	NN	O
in	IN	O
grades	NNS	O
1	CD	O
to	TO	O
10	CD	O
.	.	O

Because	IN	O
children	NNS	O
at	IN	O
each	DT	O
grade	NN	O
were	VBD	O
distributed	VBN	O
across	IN	O
two	CD	O
classrooms	NNS	O
(	(	O
clusters	NNS	O
)	)	O
and	CC	O
were	VBD	O
homogeneous	JJ	O
,	,	O
each	DT	O
grade	NN	O
was	VBD	O
considered	VBN	O
to	TO	O
consist	VB	O
of	IN	O
a	DT	O
matched	JJ	O
pair	NN	O
.	.	O

There	EX	O
were	VBD	O
thus	RB	O
10	CD	O
pairs	NNS	O
available	JJ	O
for	IN	O
the	DT	O
study	NN	O
.	.	O

Classes	NNS	O
in	IN	O
each	DT	O
grade	NN	O
were	VBD	O
randomized	VBN	O
to	TO	O
receive	VB	O
a	DT	O
micronutrient-enriched	JJ	O
beverage	NN	O
or	CC	O
a	DT	O
placebo	NN	O
without	IN	O
added	JJ	O
micronutrients	NNS	O
.	.	O

The	DT	O
study	NN	O
was	VBD	O
double	RB	O
blinded	VBN	O
and	CC	O
the	DT	O
duration	NN	O
was	VBD	O
14	CD	O
mo	NN	O
,	,	O
with	IN	O
supervised	JJ	O
feeding	NN	O
of	IN	O
the	DT	O
micronutrient-enriched	JJ	O
beverage	NN	O
.	.	O

The	DT	O
effect	NN	O
of	IN	O
the	DT	O
micronutrients	NNS	O
on	IN	O
the	DT	O
outcome	NN	O
variables	NNS	O
growth	NN	O
,	,	O
biochemical	JJ	O
status	NN	O
,	,	O
mental	JJ	O
function	NN	O
,	,	O
and	CC	O
bone	NN	O
health	NN	O
were	VBD	O
assessed	VBN	O
.	.	O

RESULTS	VB	O
The	DT	O
number	NN	O
of	IN	O
matched	JJ	O
pairs	NNS	O
varied	VBD	O
between	IN	O
seven	CD	O
and	CC	O
eight	CD	O
,	,	O
and	CC	O
the	DT	O
required	JJ	O
number	NN	O
of	IN	O
children	NNS	O
per	IN	O
treatment	NN	O
group	NN	O
ranged	VBD	O
from	IN	O
32	CD	O
in	IN	O
the	DT	O
case	NN	O
of	IN	O
bone	NN	O
heath	NN	O
to	TO	O
177	CD	O
for	IN	O
body	NN	O
weight	NN	O
.	.	O

The	DT	O
power	NN	O
of	IN	O
the	DT	O
outcome	NN	O
variables	NNS	O
ranged	VBD	O
from	IN	O
74	CD	O
%	NN	O
to	TO	O
100	CD	O
%	NN	O
and	CC	O
was	VBD	O
adequate	NN	O
for	IN	O
successful	JJ	O
pairing	NN	O
.	.	O

The	DT	O
effect	NN	O
assessed	VBD	O
at	IN	O
the	DT	O
end	NN	O
of	IN	O
supplementation	NN	O
showed	VBD	O
that	IN	O
the	DT	O
intervention	NN	O
was	VBD	O
beneficial	JJ	O
.	.	O

CONCLUSIONS	NNP	O
Designing	VBG	O
an	DT	O
intervention	NN	O
,	,	O
choosing	VBG	O
outcome	NN	O
variables	NNS	O
,	,	O
and	CC	O
implementing	VBG	O
the	DT	O
protocol	NN	O
in	IN	O
a	DT	O
typical	JJ	O
Indian	JJ	O
school	NN	O
setting	VBG	O
were	VBD	O
achieved	VBN	O
.	.	O

Family	RB	O
economic	JJ	O
empowerment	NN	O
and	CC	O
mental	JJ	O
health	NN	O
among	IN	O
AIDS-affected	JJ	O
children	NNS	O
living	VBG	O
in	IN	O
AIDS-impacted	JJ	O
communities	NNS	O
:	:	O
evidence	NN	O
from	IN	O
a	DT	O
randomised	JJ	O
evaluation	NN	O
in	IN	O
southwestern	JJ	O
Uganda	NNP	O
.	.	O

OBJECTIVE	CC	O
The	DT	O
authors	NNS	O
examine	VBP	O
whether	IN	O
an	DT	O
innovative	JJ	O
family	NN	O
economic	JJ	O
empowerment	NN	O
intervention	NN	O
addresses	VBZ	O
mental	JJ	O
health	NN	O
functioning	NN	O
of	IN	O
AIDS-affected	JJ	O
children	NNS	O
in	IN	O
communities	NNS	O
heavily	RB	O
impacted	VBN	O
by	IN	O
HIV/AIDS	NNP	O
in	IN	O
Uganda	NNP	O
.	.	O

METHODS	NNP	O
A	NNP	O
cluster	NN	O
randomised	VBD	O
controlled	VBN	O
trial	NN	O
consisting	VBG	O
of	IN	O
two	CD	O
study	NN	O
arms	NNS	O
,	,	O
a	DT	O
treatment	NN	O
condition	NN	O
(	(	O
n=179	JJ	O
)	)	O
and	CC	O
a	DT	O
control	NN	O
condition	NN	O
(	(	O
n=118	JJ	O
)	)	O
,	,	O
was	VBD	O
used	VBN	O
to	TO	O
examine	VB	O
the	DT	O
impact	NN	O
of	IN	O
the	DT	O
family	NN	O
economic	JJ	O
empowerment	NN	O
intervention	NN	O
on	IN	O
children	NNS	O
's	POS	O
levels	NNS	O
of	IN	O
hopelessness	NN	O
and	CC	O
depression	NN	O
.	.	O

The	DT	O
intervention	NN	O
comprised	VBD	O
matched	JJ	O
children	NNS	O
savings	NNS	O
accounts	NNS	O
,	,	O
financial	JJ	O
management	NN	O
workshops	NNS	O
and	CC	O
mentorship	NN	O
.	.	O

Data	NNS	O
were	VBD	O
collected	VBN	O
at	IN	O
baseline	NN	O
and	CC	O
12	CD	O
months	NNS	O
post-intervention	NN	O
.	.	O

RESULTS	NNP	O
Using	VBG	O
multivariate	JJ	O
analysis	NN	O
with	IN	O
several	JJ	O
socioeconomic	JJ	O
controls	NNS	O
,	,	O
the	DT	O
authors	NNS	O
find	VBP	O
that	IN	O
children	NNS	O
in	IN	O
the	DT	O
treatment	NN	O
condition	NN	O
(	(	O
receiving	VBG	O
the	DT	O
intervention	NN	O
)	)	O
report	NN	O
significant	JJ	O
improvement	NN	O
in	IN	O
their	PRP$	O
mental	JJ	O
health	NN	O
functioning	NN	O
.	.	O

Specifically	RB	O
,	,	O
the	DT	O
intervention	NN	O
reduces	VBZ	O
hopelessness	NN	O
and	CC	O
depression	NN	O
levels	NNS	O
.	.	O

On	IN	O
the	DT	O
other	JJ	O
hand	NN	O
,	,	O
children	NNS	O
in	IN	O
the	DT	O
control	NN	O
condition	NN	O
(	(	O
not	RB	O
receiving	VBG	O
the	DT	O
intervention	NN	O
)	)	O
report	NN	O
no	DT	O
changes	NNS	O
on	IN	O
both	DT	O
measures	NNS	O
.	.	O

CONCLUSIONS	VB	O
The	DT	O
findings	NNS	O
indicate	VBP	O
that	IN	O
children	NNS	O
with	IN	O
poor	JJ	O
mental	JJ	O
health	NN	O
functioning	VBG	O
living	NN	O
in	IN	O
communities	NNS	O
affected	VBN	O
by	IN	O
HIV/AIDS	NNP	O
may	MD	O
benefit	VB	O
from	IN	O
innovative	JJ	O
family	NN	O
economic	JJ	O
empowerment	NN	O
interventions	NNS	O
.	.	O

As	IN	O
measures	NNS	O
of	IN	O
mental	JJ	O
health	NN	O
functioning	NN	O
,	,	O
both	DT	O
hopelessness	NN	O
and	CC	O
depression	NN	O
have	VBP	O
long-term	JJ	O
negative	JJ	O
psychosocial	NN	O
and	CC	O
developmental	JJ	O
impacts	NNS	O
on	IN	O
children	NNS	O
.	.	O

These	DT	O
findings	NNS	O
have	VBP	O
implications	NNS	O
for	IN	O
public	JJ	O
health	NN	O
programmes	NNS	O
intended	VBN	O
for	IN	O
long-term	JJ	O
care	NN	O
and	CC	O
support	NN	O
of	IN	O
children	NNS	O
living	VBG	O
in	IN	O
resource	JJ	O
poor	JJ	O
AIDS-impacted	JJ	O
communities	NNS	O
.	.	O

Effect	NN	O
of	IN	O
prophylactic	JJ	O
amiodarone	NN	O
in	IN	O
patients	NNS	O
with	IN	O
rheumatic	JJ	O
valve	NNS	O
disease	NN	O
undergoing	VBG	O
valve	JJ	O
replacement	NN	O
surgery	NN	O
.	.	O

The	DT	O
study	NN	O
was	VBD	O
carried	VBN	O
out	IN	O
to	TO	O
evaluate	VB	O
the	DT	O
effect	NN	O
of	IN	O
prophylactic	JJ	O
single-dose	JJ	O
intravenous	JJ	O
amiodarone	NN	O
in	IN	O
patients	NNS	O
undergoing	VBG	O
valve	JJ	O
replacement	NN	O
surgery	NN	O
.	.	O

Maintenance	NN	O
of	IN	O
sinus	NN	O
rhythm	NN	O
is	VBZ	O
better	JJR	O
than	IN	O
maintenance	NN	O
of	IN	O
fixed	JJ	O
ventricular	JJ	O
rate	NN	O
in	IN	O
atrial	JJ	O
fibrillation	NN	O
(	(	O
AF	NNP	O
)	)	O
especially	RB	O
in	IN	O
the	DT	O
presence	NN	O
of	IN	O
irritable	JJ	O
left	NN	O
or	CC	O
right	JJ	O
atrium	NN	O
because	IN	O
of	IN	O
enlargement	NN	O
.	.	O

Fifty-six	JJ	O
patients	NNS	O
with	IN	O
valvular	JJ	O
heart	NN	O
disease	NN	O
with	IN	O
or	CC	O
without	IN	O
AF	NNP	O
were	VBD	O
randomly	RB	O
divided	VBN	O
into	IN	O
two	CD	O
groups	NNS	O
.	.	O

Group	NNP	O
I	PRP	O
or	CC	O
the	DT	O
amiodarone	NN	O
group	NN	O
(	(	O
n=28	NN	O
)	)	O
received	VBD	O
amiodarone	NN	O
(	(	O
3	CD	O
mg/kg	NN	O
in	IN	O
100	CD	O
ml	NNS	O
normal	JJ	O
saline	NN	O
)	)	O
and	CC	O
group	NN	O
II	NNP	O
or	CC	O
the	DT	O
control	NN	O
group	NN	O
received	VBD	O
same	JJ	O
volume	NN	O
of	IN	O
normal	JJ	O
saline	NN	O
.	.	O

The	DT	O
standardized	JJ	O
protocol	NN	O
for	IN	O
cardiopulmonary	JJ	O
bypass	NN	O
was	VBD	O
maintained	VBN	O
for	IN	O
all	PDT	O
the	DT	O
patients	NNS	O
.	.	O

AF	NNP	O
occurred	VBD	O
in	IN	O
7.14	CD	O
%	NN	O
patients	NNS	O
in	IN	O
group	NN	O
I	PRP	O
,	,	O
and	CC	O
in	IN	O
group	NN	O
II	NNP	O
,	,	O
28.57	CD	O
%	NN	O
(	(	O
P=0.035	NNP	O
)	)	O
;	:	O
ventricular	JJ	O
tachycardia/fibrillation	NN	O
was	VBD	O
observed	VBN	O
in	IN	O
21.43	CD	O
%	NN	O
patients	NNS	O
in	IN	O
group	NN	O
I	PRP	O
and	CC	O
46.43	CD	O
%	NN	O
patients	NNS	O
in	IN	O
group	NN	O
II	NNP	O
(	(	O
P=0.089	NNP	O
)	)	O
after	IN	O
release	NN	O
of	IN	O
aortic	JJ	O
clamp	NN	O
.	.	O

Most	JJS	O
of	IN	O
the	DT	O
patients	NNS	O
in	IN	O
group	NN	O
I	PRP	O
(	(	O
92.86	CD	O
%	NN	O
)	)	O
maintained	VBD	O
sinus	JJ	O
rhythm	NN	O
without	IN	O
cardioversion	NN	O
or	CC	O
defibrillation	NN	O
after	IN	O
release	NN	O
of	IN	O
aortic	JJ	O
cross	NN	O
clamp	NN	O
(	(	O
P=0.002	NNP	O
)	)	O
.	.	O

Defibrillation	NN	O
or	CC	O
cardio	NN	O
version	NN	O
was	VBD	O
needed	VBN	O
in	IN	O
7.14	CD	O
%	NN	O
patients	NNS	O
in	IN	O
group	NN	O
I	PRP	O
and	CC	O
28.57	CD	O
%	NN	O
patients	NNS	O
in	IN	O
group	NN	O
II	NNP	O
(	(	O
P=0.078	NNP	O
)	)	O
.	.	O

A	DT	O
single	JJ	O
prophylactic	JJ	O
intraoperative	NN	O
dose	NN	O
of	IN	O
intravenous	JJ	O
amiodarone	NN	O
decreased	VBD	O
post	NN	O
bypass	NN	O
arrhythmia	NN	O
in	IN	O
this	DT	O
study	NN	O
in	IN	O
comparison	NN	O
to	TO	O
the	DT	O
control	NN	O
group	NN	O
.	.	O

Single	NNP	O
dose	NN	O
of	IN	O
intraoperative	JJ	O
amiodarone	NN	O
may	MD	O
be	VB	O
used	VBN	O
to	TO	O
decrease	VB	O
postoperative	JJ	O
arrhythmia	NN	O
in	IN	O
open	JJ	O
heart	NN	O
surgery	NN	O
.	.	O

A	DT	O
web-based	JJ	O
patient	NN	O
activation	NN	O
intervention	NN	O
to	TO	O
improve	VB	O
hypertension	NN	O
care	NN	O
:	:	O
study	NN	O
design	NN	O
and	CC	O
baseline	NN	O
characteristics	NNS	O
in	IN	O
the	DT	O
web	NN	O
hypertension	NN	O
study	NN	O
.	.	O

BACKGROUND	NNP	O
Despite	IN	O
the	DT	O
known	JJ	O
health	NN	O
risks	NNS	O
of	IN	O
hypertension	NN	O
,	,	O
many	JJ	O
hypertensive	JJ	C
patients	NNS	O
still	RB	O
have	VBP	O
uncontrolled	VBN	O
blood	NN	O
pressure	NN	O
.	.	O

Clinical	JJ	O
inertia	NN	O
,	,	O
the	DT	O
tendency	NN	O
of	IN	O
physicians	NNS	O
not	RB	O
to	TO	O
intensify	VB	O
treatment	NN	O
,	,	O
is	VBZ	O
a	DT	O
common	JJ	O
barrier	NN	O
in	IN	O
controlling	VBG	O
chronic	JJ	O
diseases	NNS	O
.	.	O

This	DT	O
trial	NN	O
is	VBZ	O
aimed	VBN	O
at	IN	O
determining	VBG	O
the	DT	O
impact	NN	O
of	IN	O
activating	VBG	O
patients	NNS	O
to	TO	O
ask	VB	O
providers	NNS	O
to	TO	O
make	VB	O
changes	NNS	O
to	TO	O
their	PRP$	O
care	NN	O
through	IN	O
tailored	VBN	O
feedback	NN	O
.	.	O

METHODS	NNP	O
Diagnosed	VBD	O
hypertensive	JJ	C
patients	NNS	O
were	VBD	O
enrolled	VBN	O
in	IN	O
this	DT	O
RCT	NNP	O
and	CC	O
randomized	VBN	O
to	TO	O
one	CD	O
of	IN	O
two	CD	O
study	NN	O
groups	NNS	O
:	:	O
(	(	O
1	CD	O
)	)	O
the	DT	O
intervention	NN	O
condition	NN	O
--	:	O
Web-based	JJ	O
hypertension	NN	O
feedback	NN	O
,	,	O
based	VBN	O
on	IN	O
the	DT	O
individual	JJ	O
patient	NN	O
's	POS	O
self-report	NN	O
of	IN	O
health	NN	O
variables	NNS	O
and	CC	O
previous	JJ	O
BP	NNP	O
measurements	NNS	O
,	,	O
to	TO	O
prompt	VB	O
them	PRP	O
to	TO	O
ask	VB	O
questions	NNS	O
during	IN	O
their	PRP$	O
next	JJ	O
physician	NN	O
's	POS	O
visit	NN	O
about	IN	O
hypertension	NN	O
care	NN	O
(	(	O
2	CD	O
)	)	O
the	DT	O
control	NN	O
condition	NN	O
--	:	O
Web-based	JJ	O
preventive	JJ	O
health	NN	O
feedback	NN	O
,	,	O
based	VBN	O
on	IN	O
the	DT	O
individual	NN	O
's	POS	O
self-report	NN	O
of	IN	O
receiving	VBG	O
preventive	JJ	O
care	NN	O
(	(	O
e.g.	UH	O
,	,	O
pap	JJ	O
testing	VBG	O
)	)	O
,	,	O
to	TO	O
prompt	VB	O
them	PRP	O
to	TO	O
ask	VB	O
questions	NNS	O
during	IN	O
their	PRP$	O
next	JJ	O
physician	NN	O
's	POS	O
visit	NN	O
about	IN	O
preventive	JJ	O
care	NN	O
.	.	O

The	DT	O
primary	JJ	O
outcome	NN	O
of	IN	O
the	DT	O
study	NN	O
is	VBZ	O
change	VBN	O
in	IN	O
blood	NN	O
pressure	NN	O
and	CC	O
change	NN	O
in	IN	O
the	DT	O
percentage	NN	O
of	IN	O
patients	NNS	O
in	IN	O
each	DT	O
group	NN	O
with	IN	O
controlled	VBN	O
blood	NN	O
pressure	NN	O
.	.	O

CONCLUSION	NNP	O
Five	CD	SS
hundred	VBD	SS
participants	NNS	O
were	VBD	O
enrolled	VBN	O
and	CC	O
baseline	JJ	O
characteristics	NNS	O
include	VBP	O
a	DT	O
mean	JJ	O
age	NN	O
of	IN	O
60.0	CD	A
years	NNS	A
;	:	O
57.6	CD	O
%	NN	O
female	NN	SE
;	:	O
and	CC	O
77.6	CD	O
%	NN	O
white	JJ	O
.	.	O

Overall	JJ	O
37.7	CD	O
%	NN	O
participants	NNS	O
had	VBD	O
uncontrolled	VBN	C
blood	NN	C
pressure	NN	C
;	:	O
the	DT	O
mean	NN	O
body	NN	O
mass	NN	O
index	NN	O
(	(	O
BMI	NNP	O
)	)	O
was	VBD	O
in	IN	O
the	DT	O
obese	JJ	O
range	NN	O
(	(	O
32.4	CD	O
)	)	O
and	CC	O
21.8	CD	O
%	NN	O
had	VBD	O
diabetes	NNS	C
.	.	O

By	IN	O
activating	VBG	O
patients	NNS	O
to	TO	O
become	VB	O
involved	VBN	O
in	IN	O
their	PRP$	O
own	JJ	O
care	NN	O
,	,	O
we	PRP	O
believe	VBP	O
the	DT	O
addition	NN	O
of	IN	O
the	DT	O
web-based	JJ	O
intervention	NN	O
will	MD	O
improve	VB	O
blood	NN	O
pressure	NN	O
control	NN	O
compared	VBN	O
to	TO	O
a	DT	O
control	NN	O
group	NN	O
who	WP	O
receive	VBP	O
web-based	JJ	O
preventive	JJ	O
messages	NNS	O
unrelated	VBN	O
to	TO	O
hypertension	NN	O
.	.	O

Anecortave	NNP	O
acetate	NN	O
treatment	NN	O
for	IN	O
retinal	JJ	O
angiomatous	JJ	O
proliferation	NN	O
:	:	O
a	DT	O
pilot	NN	O
study	NN	O
.	.	O

PURPOSE	VB	O
The	DT	O
purpose	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
evaluate	VB	O
anecortave	JJ	O
acetate	JJ	O
treatment	NN	O
of	IN	O
retinal	JJ	O
angiomatous	JJ	O
proliferation	NN	O
(	(	O
RAP	NNP	O
)	)	O
,	,	O
a	DT	O
neovascular	JJ	O
form	NN	O
of	IN	O
age-related	JJ	O
macular	JJ	O
degeneration	NN	O
,	,	O
with	IN	O
specific	JJ	O
regard	NN	O
to	TO	O
inhibition	NN	O
of	IN	O
neovascularization	NN	O
and	CC	O
maintenance	NN	O
of	IN	O
vision	NN	O
.	.	O

METHODS	NNP	O
Thirty-four	JJ	O
patients	NNS	O
with	IN	O
RAP	NNP	O
with	IN	O
any	DT	O
stage	NN	O
of	IN	O
neovascularization	NN	O
were	VBD	O
randomized	VBN	O
1:1:1	CD	O
for	IN	O
treatment	NN	O
with	IN	O
three	CD	O
different	JJ	O
quantities	NNS	O
(	(	O
30	CD	O
mg	NN	O
,	,	O
15	CD	O
mg	NN	O
,	,	O
3	CD	O
mg	NN	O
)	)	O
of	IN	O
anecortave	NN	O
acetate	NN	O
sterile	JJ	O
suspension	NN	O
for	IN	O
juxtascleral	JJ	O
administration	NN	O
.	.	O

Best-corrected	JJ	O
visual	JJ	O
acuity	NN	O
(	(	O
Early	JJ	O
Treatment	NNP	O
Diabetic	NNP	O
Retinopathy	NNP	O
Study	NNP	O
chart	NN	O
)	)	O
,	,	O
intraocular	JJ	O
pressure	NN	O
measurement	NN	O
,	,	O
biomicroscopy	NN	O
,	,	O
funduscopy	NN	O
,	,	O
digital	JJ	O
fluorescein	NN	O
,	,	O
and	CC	O
indocyanine	NN	O
green	JJ	O
angiography	NN	O
were	VBD	O
recorded	VBN	O
at	IN	O
baseline	NN	O
and	CC	O
at	IN	O
3	CD	O
months	NNS	O
.	.	O

A	DT	O
6-month	JJ	O
retreatment	NN	O
interval	NN	O
was	VBD	O
established	VBN	O
for	IN	O
this	DT	O
study	NN	O
with	IN	O
a	DT	O
follow-up	NN	O
of	IN	O
12	CD	O
months	NNS	O
.	.	O

In	IN	O
selected	JJ	O
patients	NNS	O
optical	JJ	O
coherence	NN	O
tomography	NN	O
was	VBD	O
performed	VBN	O
.	.	O

The	DT	O
outcomes	NNS	O
were	VBD	O
mean	JJ	O
changes	NNS	O
in	IN	O
visual	JJ	O
acuity	NN	O
and	CC	O
lesion	NN	O
size	NN	O
at	IN	O
1	CD	O
year	NN	O
.	.	O

RESULTS	VB	O
The	DT	O
detachment	NN	O
of	IN	O
the	DT	O
neurosensory	JJ	O
retina	NN	O
and	CC	O
retinal	JJ	O
pigment	NN	O
epithelium	NN	O
improved	VBN	O
in	IN	O
all	DT	O
eyes	NNS	O
,	,	O
but	CC	O
all	DT	O
neovascular	JJ	O
lesions	NNS	O
increased	VBD	O
in	IN	O
size	NN	O
.	.	O

Vision	NNP	O
loss	NN	O
occurred	VBD	O
in	IN	O
the	DT	O
majority	NN	O
of	IN	O
study	NN	O
eyes	NNS	O
(	(	O
22	CD	O
out	IN	O
of	IN	O
34	CD	O
eyes	NNS	O
,	,	O
64.7	CD	O
%	NN	O
)	)	O
independent	JJ	O
of	IN	O
the	DT	O
concentration	NN	O
administered	VBD	O
.	.	O

CONCLUSION	NNP	O
The	DT	O
results	NNS	O
suggest	VBP	O
that	IN	O
a	DT	O
posterior	JJ	O
juxtascleral	JJ	O
injection	NN	O
of	IN	O
anecortave	JJ	O
acetate	NN	O
reduces	NNS	O
capillary	JJ	O
permeability	NN	O
in	IN	O
patients	NNS	O
with	IN	O
RAP	NNP	O
.	.	O

However	RB	O
,	,	O
in	IN	O
spite	NN	O
of	IN	O
improvement	NN	O
of	IN	O
the	DT	O
exudation	NN	O
there	EX	O
is	VBZ	O
a	DT	O
progression	NN	O
of	IN	O
neovascularization	NN	O
and	CC	O
a	DT	O
significant	JJ	O
loss	NN	O
of	IN	O
vision	NN	O
in	IN	O
all	PDT	O
these	DT	O
patients	NNS	O
.	.	O

Like	IN	O
other	JJ	O
monotherapeutic	JJ	O
methods	NNS	O
used	VBN	O
to	TO	O
treat	VB	O
this	DT	O
variant	NN	O
of	IN	O
neovascular	JJ	O
age-related	JJ	O
macular	JJ	O
degeneration	NN	O
,	,	O
anecortave	VBP	O
acetate	JJ	O
alone	RB	O
does	VBZ	O
not	RB	O
appear	VB	O
to	TO	O
benefit	VB	O
these	DT	O
patients	NNS	O
.	.	O

Future	JJ	O
studies	NNS	O
should	MD	O
investigate	VB	O
a	DT	O
combination	NN	O
form	NN	O
of	IN	O
therapy	NN	O
.	.	O

Clinical	JJ	O
hypnosis	NN	O
versus	NN	O
cognitive	JJ	O
behavioral	JJ	O
training	NN	O
for	IN	O
pain	NN	O
management	NN	O
with	IN	O
pediatric	JJ	O
cancer	NN	C
patients	NNS	C
undergoing	VBG	C
bone	NN	C
marrow	NN	C
aspirations	NNS	C
.	.	C

A	DT	O
randomized	JJ	O
controlled	JJ	O
trial	NN	O
was	VBD	O
conducted	VBN	O
to	TO	O
compare	VB	O
the	DT	O
efficacy	NN	O
of	IN	O
clinical	JJ	O
hypnosis	NN	O
versus	NN	O
cognitive	JJ	O
behavioral	NN	O
(	(	O
CB	NNP	O
)	)	O
coping	VBG	O
skills	NNS	O
training	VBG	O
in	IN	O
alleviating	VBG	O
the	DT	O
pain	NN	O
and	CC	O
distress	NN	O
of	IN	O
30	CD	SS
pediatric	JJ	O
cancer	NN	O
patients	NNS	O
(	(	O
age	NN	A
5	CD	A
to	TO	A
15	CD	A
years	NNS	A
)	)	O
undergoing	VBG	O
bone	NN	O
marrow	NN	O
aspirations	NNS	O
.	.	O

Patients	NNS	O
were	VBD	O
randomized	VBN	O
to	TO	O
one	CD	O
of	IN	O
three	CD	O
groups	NNS	O
:	:	O
hypnosis	NN	O
,	,	O
a	DT	O
package	NN	O
of	IN	O
CB	NNP	O
coping	VBG	O
skills	NNS	O
,	,	O
and	CC	O
no	DT	O
intervention	NN	O
.	.	O

Patients	NNS	O
who	WP	O
received	VBD	O
either	CC	O
hypnosis	NN	O
or	CC	O
CB	NNP	O
reported	VBD	O
less	JJR	O
pain	NN	O
and	CC	O
pain-related	JJ	O
anxiety	NN	O
than	IN	O
did	VBD	O
control	VB	O
patients	NNS	O
and	CC	O
less	JJR	O
pain	NN	O
and	CC	O
anxiety	NN	O
than	IN	O
at	IN	O
their	PRP$	O
own	JJ	O
baseline	NN	O
.	.	O

Hypnosis	NNP	O
and	CC	O
CB	NNP	O
were	VBD	O
similarly	RB	O
effective	JJ	O
in	IN	O
the	DT	O
relief	NN	O
of	IN	O
pain	NN	O
.	.	O

Results	NNP	O
also	RB	O
indicated	VBD	O
that	IN	O
children	NNS	O
reported	VBD	O
more	RBR	O
anxiety	NN	O
and	CC	O
exhibited	VBD	O
more	RBR	O
behavioral	JJ	O
distress	NN	O
in	IN	O
the	DT	O
CB	NNP	O
group	NN	O
than	IN	O
in	IN	O
the	DT	O
hypnosis	NN	O
group	NN	O
.	.	O

It	PRP	O
is	VBZ	O
concluded	VBN	O
that	IN	O
hypnosis	NN	O
and	CC	O
CB	NNP	O
coping	VBG	O
skills	NNS	O
are	VBP	O
effective	JJ	O
in	IN	O
preparing	VBG	O
pediatric	JJ	O
oncology	NN	O
patients	NNS	O
for	IN	O
bone	NN	O
marrow	NN	O
aspiration	NN	O
.	.	O

MDM2	NNP	O
and	CC	O
Ki-67	NNP	O
predict	NN	O
for	IN	O
distant	JJ	O
metastasis	NN	O
and	CC	O
mortality	NN	O
in	IN	O
men	NNS	O
treated	VBN	O
with	IN	O
radiotherapy	NN	O
and	CC	O
androgen	NN	O
deprivation	NN	O
for	IN	O
prostate	JJ	O
cancer	NN	O
:	:	O
RTOG	NNP	O
92-02	CD	O
.	.	O

PURPOSE	NNP	O
MDM2	NNP	O
regulates	VBZ	O
p53	NN	O
,	,	O
which	WDT	O
controls	VBZ	O
cell	NN	O
cycle	NN	O
arrest	NN	O
and	CC	O
apoptosis	NN	O
.	.	O

Both	DT	O
proteins	NNS	O
,	,	O
along	IN	O
with	IN	O
Ki-67	NNP	O
,	,	O
which	WDT	O
is	VBZ	O
an	DT	O
established	VBN	O
strong	JJ	O
determinant	NN	O
of	IN	O
metastasis	NN	O
,	,	O
have	VBP	O
shown	VBN	O
promise	NN	O
in	IN	O
predicting	VBG	O
the	DT	O
outcome	NN	O
of	IN	O
men	NNS	O
treated	VBN	O
with	IN	O
radiation	NN	O
therapy	NN	O
(	(	O
RT	NNP	O
)	)	O
with	IN	O
or	CC	O
without	IN	O
short-term	JJ	O
androgen	NN	O
deprivation	NN	O
(	(	O
STAD	NNP	O
)	)	O
.	.	O

This	DT	O
report	NN	O
compares	VBZ	O
the	DT	O
utility	NN	O
of	IN	O
abnormal	JJ	O
expression	NN	O
of	IN	O
these	DT	O
biomarkers	NNS	O
in	IN	O
estimating	VBG	O
progression	NN	O
in	IN	O
a	DT	O
cohort	NN	O
of	IN	O
men	NNS	O
treated	VBN	O
on	IN	O
RTOG	NNP	O
92-02	CD	O
.	.	O

PATIENTS	NNPS	O
AND	CC	O
METHODS	NNP	O
Adequate	NNP	O
tissue	NN	O
for	IN	O
immunohistochemistry	NN	O
was	VBD	O
available	JJ	O
for	IN	O
p53	NN	O
,	,	O
Ki-67	NNP	O
,	,	O
and	CC	O
MDM2	NNP	O
analyses	NNS	O
in	IN	O
478	CD	O
patient	JJ	O
cases	NNS	O
.	.	O

The	DT	O
percentage	NN	O
of	IN	O
tumor	NN	O
nuclei	NN	O
staining	VBG	O
positive	JJ	O
(	(	O
PSP	NNP	O
)	)	O
was	VBD	O
quantified	VBN	O
manually	RB	O
or	CC	O
by	IN	O
image	NN	O
analysis	NN	O
,	,	O
and	CC	O
the	DT	O
per-sample	JJ	O
mean	JJ	O
intensity	NN	O
score	NN	O
(	(	O
MIS	NNP	O
)	)	O
was	VBD	O
quantified	VBN	O
by	IN	O
image	NN	O
analysis	NN	O
.	.	O

Cox	NNP	O
regression	NN	O
models	NNS	O
were	VBD	O
used	VBN	O
to	TO	O
estimate	VB	O
overall	JJ	O
mortality	NN	O
(	(	O
OM	NNP	O
)	)	O
,	,	O
and	CC	O
Fine	NNP	O
and	CC	O
Gray	NNP	O
's	POS	O
regressions	NNS	O
were	VBD	O
applied	VBN	O
to	TO	O
the	DT	O
end	NN	O
points	NNS	O
of	IN	O
distant	JJ	O
metastasis	NN	O
(	(	O
DM	NNP	O
)	)	O
and	CC	O
cause-specific	JJ	O
mortality	NN	O
(	(	O
CSM	NNP	O
)	)	O
.	.	O

Results	NNS	O
In	IN	O
multivariate	JJ	O
analyses	NNS	O
that	WDT	O
adjusted	VBD	O
for	IN	O
all	DT	O
markers	NNS	O
and	CC	O
treatment	NN	O
covariates	NNS	O
,	,	O
MDM2	NNP	O
overexpression	NN	O
was	VBD	O
significantly	RB	O
related	VBN	O
to	TO	O
DM	NNP	O
(	(	O
P	NNP	O
=	NNP	O
.02	NNP	O
)	)	O
and	CC	O
OM	NNP	O
(	(	O
P	NNP	O
=	NNP	O
.003	NNP	O
)	)	O
,	,	O
and	CC	O
Ki-67	NNP	O
overexpression	NN	O
was	VBD	O
significantly	RB	O
related	VBN	O
to	TO	O
DM	NNP	O
(	(	O
P	NNP	O
<	NNP	O
.0001	NNP	O
)	)	O
,	,	O
CSM	NNP	O
(	(	O
P	NNP	O
=	NNP	O
.0007	NNP	O
)	)	O
,	,	O
and	CC	O
OM	NNP	O
(	(	O
P	NNP	O
=	NNP	O
.01	NNP	O
)	)	O
.	.	O

P53	NNP	O
overexpression	NN	O
was	VBD	O
significantly	RB	O
related	VBN	O
to	TO	O
OM	NNP	O
(	(	O
P	NNP	O
=	NNP	O
.02	NNP	O
)	)	O
.	.	O

When	WRB	O
considered	VBN	O
in	IN	O
combination	NN	O
,	,	O
the	DT	O
overexpression	NN	O
of	IN	O
both	DT	O
Ki-67	NNP	O
and	CC	O
MDM2	NNP	O
at	IN	O
high	JJ	O
levels	NNS	O
was	VBD	O
associated	VBN	O
with	IN	O
significantly	RB	O
increased	VBN	O
failure	NN	O
rates	NNS	O
for	IN	O
all	DT	O
end	NN	O
points	NNS	O
(	(	O
P	NNP	O
<	NNP	O
.001	NNP	O
for	IN	O
DM	NNP	O
,	,	O
CSM	NNP	O
,	,	O
and	CC	O
OM	NNP	O
)	)	O
.	.	O

CONCLUSION	NNP	O
Combined	VBD	O
MDM2	NNP	O
and	CC	O
Ki-67	NNP	O
expression	NN	O
levels	NNS	O
were	VBD	O
independently	RB	O
related	VBN	O
to	TO	O
distant	JJ	O
metastasis	NN	O
and	CC	O
mortality	NN	O
and	CC	O
,	,	O
if	IN	O
validated	VBN	O
,	,	O
could	MD	O
be	VB	O
considered	VBN	O
for	IN	O
risk	NN	O
stratification	NN	O
of	IN	O
patients	NNS	O
with	IN	O
prostate	JJ	O
cancer	NN	O
in	IN	O
clinical	JJ	O
trials	NNS	O
.	.	O

The	DT	O
effect	NN	O
of	IN	O
surgical	JJ	O
trauma	NN	O
and	CC	O
insulin	NN	O
on	IN	O
whole-body	NN	O
protein	NN	O
turnover	NN	O
in	IN	O
parenterally-fed	JJ	O
undernourished	JJ	C
patients	NNS	O
.	.	O

Ten	CD	SS
undernourished	JJ	C
patients	NNS	O
receiving	VBG	O
total	JJ	O
parenteral	JJ	O
nutrition	NN	O
and	CC	O
undergoing	JJ	O
major	JJ	O
intestinal	JJ	O
surgery	NN	O
were	VBD	O
restarted	VBN	O
on	IN	O
intravenous	JJ	O
feeds	NNS	O
identical	JJ	O
to	TO	O
their	PRP$	O
pre-operative	JJ	O
regimens	NNS	O
within	IN	O
24	CD	O
h	NNS	O
of	IN	O
their	PRP$	O
operation	NN	O
.	.	O

Five	CD	O
,	,	O
chosen	VBN	O
at	IN	O
random	NN	O
,	,	O
received	VBD	O
post-operatively	RB	O
1-2	JJ	O
units	NNS	O
insulin/kg	VBP	O
body	NN	O
weight/24	JJ	O
h	NN	O
with	IN	O
their	PRP$	O
feed	NN	O
,	,	O
while	IN	O
the	DT	O
other	JJ	O
five	CD	O
received	VBD	O
the	DT	O
feed	NN	O
only	RB	O
.	.	O

Pre-operatively	RB	O
,	,	O
and	CC	O
2	CD	O
h	NN	O
after	IN	O
commencing	VBG	O
their	PRP$	O
post-operative	JJ	O
feeds	NNS	O
,	,	O
rates	NNS	O
of	IN	O
whole-body	NN	O
protein	NN	O
synthesis	NN	O
and	CC	O
breakdown	NN	O
were	VBD	O
measured	VBN	O
over	IN	O
a	DT	O
9-h	JJ	O
period	NN	O
following	VBG	O
intravenous	JJ	O
injection	NN	O
of	IN	O
a	DT	O
single	JJ	O
tracer	NN	O
dose	NN	O
of	IN	O
15N-glycine	JJ	O
by	IN	O
the	DT	O
ammonia	NN	O
and	CC	O
urea	JJ	O
end-product	NN	O
methods	NNS	O
.	.	O

During	IN	O
these	DT	O
9-h	CD	O
study	NN	O
periods	NNS	O
measurements	NNS	O
were	VBD	O
also	RB	O
made	VBN	O
of	IN	O
blood	NN	O
glucose	NN	O
,	,	O
plasma	JJ	O
insulin	NN	O
and	CC	O
glucagon	NN	O
,	,	O
urinary	JJ	O
ammonia	NN	O
,	,	O
nitrogen	NN	O
,	,	O
creatinine	NN	O
and	CC	O
3-methylhistidine	JJ	O
.	.	O

Blood	NNP	O
glucose	NN	O
and	CC	O
plasma	JJ	O
insulin	NN	O
and	CC	O
glucagon	NN	O
concentrations	NNS	O
rose	VBD	O
post-operatively	RB	O
whether	IN	O
or	CC	O
not	RB	O
insulin	NN	O
was	VBD	O
given	VBN	O
,	,	O
but	CC	O
the	DT	O
increment	NN	O
in	IN	O
insulin	NN	O
concentration	NN	O
was	VBD	O
significantly	RB	O
greater	JJR	O
when	WRB	O
insulin	NN	O
was	VBD	O
given	VBN	O
.	.	O

Apparent	JJ	O
nitrogen	NN	O
balance	NN	O
was	VBD	O
positive	JJ	O
pre-operatively	RB	O
and	CC	O
became	VBD	O
less	RBR	O
so	RB	O
post-operatively	RB	O
whether	IN	O
insulin	NN	O
was	VBD	O
given	VBN	O
or	CC	O
not	RB	O
.	.	O

Similarly	RB	O
,	,	O
post-operative	JJ	O
increments	NNS	O
in	IN	O
urinary	JJ	O
excretion	NN	O
of	IN	O
ammonia	NN	O
,	,	O
creatinine	NN	O
and	CC	O
3-methylhistidine	JJ	O
were	VBD	O
not	RB	O
altered	VBN	O
by	IN	O
addition	NN	O
of	IN	O
insulin	NN	O
.	.	O

Protein	NNP	O
turnover	NN	O
,	,	O
as	IN	O
estimated	VBN	O
by	IN	O
the	DT	O
ammonia	JJ	O
end-product	NN	O
method	NN	O
,	,	O
tended	VBD	O
to	TO	O
rise	VB	O
post-operatively	RB	O
,	,	O
but	CC	O
there	EX	O
was	VBD	O
no	DT	O
significant	JJ	O
difference	NN	O
between	IN	O
the	DT	O
increases	NNS	O
observed	VBD	O
with	IN	O
or	CC	O
without	IN	O
insulin	NN	O
.	.	O

The	DT	O
urea	JJ	O
end-product	NN	O
method	NN	O
suggested	VBD	O
that	IN	O
there	EX	O
was	VBD	O
no	DT	O
change	NN	O
in	IN	O
whole-body	NN	O
protein	NN	O
turnover	NN	O
after	IN	O
surgery	NN	O
,	,	O
whether	IN	O
or	CC	O
not	RB	O
insulin	NN	O
was	VBD	O
given	VBN	O
.	.	O

This	DT	O
study	NN	O
does	VBZ	O
not	RB	O
support	VB	O
the	DT	O
clinical	JJ	O
use	NN	O
of	IN	O
insulin	NN	O
as	IN	O
a	DT	O
means	NN	O
of	IN	O
modifying	VBG	O
protein	JJ	O
metabolic	JJ	O
losses	NNS	O
after	IN	O
major	JJ	O
surgery	NN	O
.	.	O

Approval	JJ	O
summary	NN	O
:	:	O
imatinib	JJ	O
mesylate	NN	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
metastatic	JJ	O
and/or	NN	O
unresectable	JJ	O
malignant	JJ	C
gastrointestinal	JJ	C
stromal	JJ	C
tumors	NNS	C
.	.	O

The	DT	O
purpose	NN	O
of	IN	O
the	DT	O
present	JJ	O
application	NN	O
was	VBD	O
to	TO	O
fulfill	VB	O
a	DT	O
postmarketing	NN	O
commitment	NN	O
to	TO	O
provide	VB	O
long-term	JJ	O
efficacy	NN	O
and	CC	O
safety	NN	O
data	NNS	O
on	IN	O
treatment	NN	O
with	IN	O
imatinib	JJ	O
mesylate	NN	O
(	(	O
Gleevec	NNP	O
;	:	O
Novartis	NNP	O
Pharmaceuticals	NNP	O
,	,	O
East	NNP	O
Hanover	NNP	O
,	,	O
NJ	NNP	O
)	)	O
in	IN	O
patients	NNS	O
with	IN	O
CD117	NNP	O
(	(	O
+	NNP	O
)	)	O
unresectable	JJ	O
and/or	JJ	O
metastatic	JJ	O
malignant	JJ	O
gastrointestinal	JJ	O
stromal	NN	O
tumors	NNS	O
(	(	O
GISTs	NNP	C
)	)	O
.	.	O

In	IN	O
addition	NN	O
,	,	O
this	DT	O
application	NN	O
also	RB	O
provides	VBZ	O
evidence	NN	O
to	TO	O
support	VB	O
a	DT	O
change	NN	O
in	IN	O
the	DT	O
label	NN	O
to	TO	O
allow	VB	O
for	IN	O
an	DT	O
escalation	NN	O
of	IN	O
imatinib	NN	O
dosing	VBG	O
to	TO	O
800	CD	O
mg/day	NN	O
for	IN	O
patients	NNS	O
with	IN	O
progressive	JJ	O
disease	NN	O
on	IN	O
a	DT	O
lower	JJR	O
dose	NN	O
.	.	O

Two	CD	O
open-label	JJ	O
,	,	O
controlled	VBN	O
,	,	O
multicenter	NN	O
,	,	O
intergroup	NN	O
,	,	O
international	JJ	O
,	,	O
randomized	JJ	O
phase	NN	O
III	NNP	O
studies	NNS	O
were	VBD	O
submitted	VBN	O
--	:	O
one	CD	O
conducted	VBN	O
by	IN	O
the	DT	O
European	JJ	O
Organization	NNP	O
for	IN	O
Research	NNP	O
and	CC	O
Treatment	NNP	O
of	IN	O
Cancer	NNP	O
(	(	O
n	JJ	O
=	NNP	O
946	CD	SS
)	)	O
and	CC	O
the	DT	O
other	JJ	O
by	IN	O
the	DT	O
Southwest	NNP	O
Oncology	NNP	O
Group	NNP	O
(	(	O
n	JJ	O
=	NNP	O
746	CD	SS
)	)	O
.	.	O

These	DT	O
studies	NNS	O
compared	VBN	O
400	CD	O
mg/day	NN	O
of	IN	O
imatinib	NN	O
with	IN	O
800	CD	O
mg/day	NN	O
of	IN	O
imatinib	NN	O
.	.	O

A	DT	O
combined	JJ	O
analysis	NN	O
of	IN	O
the	DT	O
two	CD	O
studies	NNS	O
was	VBD	O
prospectively	RB	O
defined	VBN	O
and	CC	O
agreed	VBN	O
to	TO	O
by	IN	O
both	DT	O
groups	NNS	O
.	.	O

Both	DT	O
protocols	NNS	O
allowed	VBD	O
patients	NNS	O
randomized	VBN	O
to	TO	O
the	DT	O
400-mg/day	JJ	O
imatinib	NN	O
arm	NN	O
to	TO	O
cross	VB	O
over	IN	O
to	TO	O
800	CD	O
mg/day	NN	O
imatinib	NN	O
at	IN	O
progression	NN	O
.	.	O

Objective	JJ	O
responses	NNS	O
were	VBD	O
achieved	VBN	O
in	IN	O
>	JJ	O
50	CD	O
%	NN	O
of	IN	O
patients	NNS	O
receiving	VBG	O
either	CC	O
imatinib	JJ	O
dose	NN	O
.	.	O

The	DT	O
median	JJ	O
progression-free	JJ	O
survival	NN	O
time	NN	O
was	VBD	O
approximately	RB	O
20	CD	O
months	NNS	O
and	CC	O
the	DT	O
median	JJ	O
overall	JJ	O
survival	NN	O
(	(	O
OS	NNP	O
)	)	O
time	NN	O
was	VBD	O
approximately	RB	O
49	CD	O
months	NNS	O
.	.	O

In	IN	O
the	DT	O
combined	JJ	O
analysis	NN	O
,	,	O
347	CD	O
patients	NNS	O
crossed	VBN	O
over	IN	O
to	TO	O
800	CD	O
mg/day	NN	O
imatinib	NN	O
at	IN	O
the	DT	O
time	NN	O
of	IN	O
progression	NN	O
.	.	O

The	DT	O
median	JJ	O
OS	NNP	O
time	NN	O
after	IN	O
crossover	NN	O
was	VBD	O
14.3	CD	O
months	NNS	O
.	.	O

The	DT	O
most	RBS	O
common	JJ	O
adverse	JJ	O
events	NNS	O
(	(	O
AEs	NNP	O
)	)	O
were	VBD	O
fluid	JJ	O
retention	NN	O
,	,	O
nausea	NN	O
,	,	O
fatigue	NN	O
,	,	O
skin	JJ	O
rash	NN	O
,	,	O
gastrointestinal	JJ	O
complaints	NNS	O
,	,	O
and	CC	O
myalgia	NN	O
.	.	O

The	DT	O
most	RBS	O
common	JJ	O
laboratory	NN	O
abnormality	NN	O
was	VBD	O
anemia	VBN	O
.	.	O

Most	JJS	O
often	RB	O
the	DT	O
AEs	NNP	O
were	VBD	O
of	IN	O
mild-to-moderate	JJ	O
severity	NN	O
.	.	O

Fluid	NNP	O
retention	NN	O
events	NNS	O
and	CC	O
skin	JJ	O
rash	NN	O
were	VBD	O
numerically	RB	O
reported	VBN	O
more	RBR	O
often	RB	O
in	IN	O
the	DT	O
800-mg/day	JJ	O
treatment	NN	O
cohort	NN	O
of	IN	O
patients	NNS	O
.	.	O

Effect	NN	O
of	IN	O
acarbose	NN	O
on	IN	O
additional	JJ	O
insulin	NN	O
therapy	NN	O
in	IN	O
type	NN	C
2	CD	C
diabetic	JJ	C
patients	NNS	O
with	IN	O
late	JJ	C
failure	NN	C
of	IN	O
sulphonylurea	JJ	C
therapy	NN	C
.	.	O

AIM	VB	O
The	DT	O
present	JJ	O
study	NN	O
investigated	VBD	O
the	DT	O
effect	NN	O
of	IN	O
acarbose	NN	O
on	IN	O
insulin	NN	O
requirements	NNS	O
and	CC	O
glycaemic	JJ	O
control	NN	O
in	IN	O
patients	NNS	O
with	IN	O
type	JJ	C
2	CD	C
diabetes	NNS	C
receiving	VBG	O
exogenous	JJ	C
insulin	NN	C
due	JJ	O
to	TO	O
secondary	JJ	O
failure	NN	C
of	IN	O
maximum	NN	O
dose	JJ	O
sulphonylurea	JJ	C
therapy	NN	C
.	.	O

METHODS	VB	O
A	DT	O
single-centre	JJ	O
,	,	O
double-blind	JJ	O
,	,	O
randomized	VBN	O
,	,	O
placebo-controlled	JJ	O
study	NN	O
was	VBD	O
performed	VBN	O
in	IN	O
48	CD	SS
type	NN	C
2	CD	C
diabetic	JJ	C
patients	NNS	O
with	IN	O
late-term	JJ	C
failure	NN	C
following	VBG	O
at	IN	O
least	JJS	O
3	CD	O
years	NNS	O
of	IN	O
sulphonylurea	JJ	C
therapy	NN	C
requiring	VBG	O
additional	JJ	O
insulin	NN	C
therapy	NN	C
to	TO	O
determine	VB	O
the	DT	O
impact	NN	O
of	IN	O
acarbose	NN	O
on	IN	O
glycaemic	JJ	O
control	NN	O
and	CC	O
insulin	NN	O
requirements	NNS	O
.	.	O

The	DT	O
primary	JJ	O
end	NN	O
points	NNS	O
were	VBD	O
glycaemic	JJ	O
response	NN	O
rate	NN	O
(	(	O
responders	NNS	O
being	VBG	O
predefined	VBN	O
as	IN	O
patients	NNS	O
who	WP	O
achieve	VBP	O
a	DT	O
decrease	NN	O
in	IN	O
HbA1c	NNP	O
to	TO	O
less	JJR	O
than	IN	O
8	CD	O
%	NN	O
or	CC	O
a	DT	O
reduction	NN	O
by	IN	O
at	IN	O
least	JJS	O
15	CD	O
%	NN	O
as	IN	O
compared	VBN	O
to	TO	O
the	DT	O
baseline	NN	O
values	NNS	O
)	)	O
and	CC	O
the	DT	O
daily	JJ	O
insulin	NN	O
dose	NN	O
at	IN	O
6	CD	O
months	NNS	O
.	.	O

Secondary	JJ	O
parameters	NNS	O
assessed	VBD	O
included	VBN	O
postprandial	JJ	O
changes	NNS	O
in	IN	O
blood	NN	O
glucose	NN	O
,	,	O
serum	JJ	O
insulin	NN	O
and	CC	O
C-peptide	NNP	O
during	IN	O
the	DT	O
treatment	NN	O
period	NN	O
.	.	O

RESULTS	CC	O
There	EX	O
were	VBD	O
significantly	RB	O
more	JJR	O
responders	NNS	O
in	IN	O
the	DT	O
acarbose-treated	JJ	O
group	NN	O
compared	VBN	O
with	IN	O
the	DT	O
placebo	NN	O
group	NN	O
(	(	O
20/24	CD	O
patients	NNS	O
vs.	FW	O
10/19	CD	O
patients	NNS	O
;	:	O
p	VB	O
<	$	O
0.05	CD	O
)	)	O
.	.	O

The	DT	O
mean	JJ	O
daily	JJ	O
insulin	NN	O
dose	NN	O
after	IN	O
24	CD	O
weeks	NNS	O
of	IN	O
treatment	NN	O
was	VBD	O
16.4	CD	O
+/-	JJ	O
10.1	CD	O
IU	NNP	O
in	IN	O
the	DT	O
acarbose	JJ	O
group	NN	O
and	CC	O
22.4	CD	O
+/-	JJ	O
12.2	CD	O
IU	NNP	O
in	IN	O
the	DT	O
placebo	NN	O
group	NN	O
(	(	O
mean	JJ	O
+/-	JJ	O
s.d	NN	O
.	.	O

;	:	O
p	JJ	O
<	NNP	O
0.07	CD	O
)	)	O
.	.	O

Postprandial	JJ	O
increases	NNS	O
in	IN	O
blood	NN	O
glucose	NN	O
,	,	O
insulin	NN	O
and	CC	O
C-peptide	NNP	O
were	VBD	O
consistently	RB	O
lower	JJR	O
in	IN	O
the	DT	O
acarbose-treated	JJ	O
group	NN	O
than	IN	O
in	IN	O
the	DT	O
placebo	NN	O
group	NN	O
.	.	O

For	IN	O
example	NN	O
,	,	O
the	DT	O
mean	JJ	O
increase	NN	O
in	IN	O
2-h	JJ	O
postprandial	JJ	O
serum	NN	O
insulin	NN	O
remained	VBD	O
almost	RB	O
unchanged	JJ	O
in	IN	O
the	DT	O
acarbose	JJ	O
group	NN	O
at	IN	O
the	DT	O
end	NN	O
of	IN	O
24	CD	O
weeks	NNS	O
of	IN	O
treatment	NN	O
compared	VBN	O
to	TO	O
an	DT	O
increase	NN	O
to	TO	O
43	CD	O
+/-	JJ	O
29	CD	O
microU/ml	NN	O
(	(	O
mean	JJ	O
+/-	JJ	O
s.d	NN	O
.	.	O

)	)	O
at	IN	O
the	DT	O
end	NN	O
of	IN	O
the	DT	O
study	NN	O
period	NN	O
for	IN	O
the	DT	O
placebo	NN	O
group	NN	O
.	.	O

CONCLUSIONS	VB	O
The	DT	O
findings	NNS	O
of	IN	O
this	DT	O
study	NN	O
suggest	VBP	O
that	IN	O
the	DT	O
addition	NN	O
of	IN	O
acarbose	NN	O
to	TO	O
sulphonylurea/insulin	VB	O
combination	NN	O
therapy	NN	O
can	MD	O
improve	VB	O
glycaemic	JJ	O
control	NN	O
in	IN	O
type	NN	C
2	CD	C
diabetic	JJ	C
patients	NNS	O
.	.	O

Acarbose	NNP	O
may	MD	O
also	RB	O
reduce	VB	O
insulin	NN	O
resistance	NN	O
and	CC	O
hyperinsulinaemia	NN	O
.	.	O

Efficacy	NN	O
of	IN	O
intravenous	JJ	O
granisetron	NN	O
to	TO	O
control	VB	O
nausea	NN	O
and	CC	O
vomiting	VBG	O
during	IN	O
multiple	JJ	O
cycles	NNS	O
of	IN	O
cisplatin-based	JJ	O
chemotherapy	NN	O
.	.	O

The	DT	O
safety	NN	O
and	CC	O
efficacy	NN	O
of	IN	O
granisetron	NN	O
(	(	O
10	CD	O
micrograms/kg	NN	O
and	CC	O
40	CD	O
micrograms/kg	NN	O
)	)	O
were	VBD	O
evaluated	VBN	O
during	IN	O
a	DT	O
second	JJ	O
(	(	O
n	JJ	O
=	NNP	O
393	CD	O
)	)	O
and	CC	O
third	JJ	O
(	(	O
n	JJ	O
=	NNP	O
200	CD	O
)	)	O
cycle	NN	O
of	IN	O
chemotherapy	NN	O
in	IN	O
this	DT	O
multicenter	NN	O
,	,	O
double-blind	NN	O
,	,	O
randomized	VBN	O
,	,	O
parallel-group	JJ	O
study	NN	O
.	.	O

Granisetron	NNP	O
was	VBD	O
administered	VBN	O
as	IN	O
a	DT	O
single	JJ	O
intravenous	JJ	O
dose	NN	O
before	IN	O
the	DT	O
start	NN	O
of	IN	O
cisplatin	NN	O
chemotherapy	NN	O
(	(	O
>	CD	O
or	CC	O
=	VB	O
60	CD	O
mg/m2	NN	O
)	)	O
.	.	O

Total	JJ	O
control	NN	O
(	(	O
no	DT	O
vomiting	NN	O
,	,	O
no	DT	O
retching	NN	O
,	,	O
no	DT	O
nausea	NN	O
,	,	O
and	CC	O
no	DT	O
use	NN	O
of	IN	O
antiemetic	JJ	O
rescue	NN	O
medication	NN	O
)	)	O
after	IN	O
the	DT	O
first	JJ	O
24	CD	O
hr	NN	O
following	VBG	O
chemotherapy	NN	O
was	VBD	O
achieved	VBN	O
in	IN	O
40	CD	O
%	NN	O
and	CC	O
49	CD	O
%	NN	O
of	IN	O
patients	NNS	O
in	IN	O
Cycles	NNP	O
2	CD	O
and	CC	O
3	CD	O
,	,	O
respectively	RB	O
,	,	O
for	IN	O
the	DT	O
10	CD	O
micrograms/kg	NN	O
group	NN	O
,	,	O
and	CC	O
in	IN	O
42	CD	O
%	NN	O
and	CC	O
38	CD	O
%	NN	O
of	IN	O
patients	NNS	O
in	IN	O
Cycles	NNP	O
2	CD	O
and	CC	O
3	CD	O
,	,	O
respectively	RB	O
,	,	O
for	IN	O
the	DT	O
40	CD	O
micrograms/kg	NN	O
group	NN	O
.	.	O

Both	DT	O
dose	JJ	O
levels	NNS	O
of	IN	O
granisetron	NN	O
were	VBD	O
well	RB	O
tolerated	VBN	O
.	.	O

The	DT	O
results	NNS	O
demonstrate	VBP	O
comparable	JJ	O
efficacy	NN	O
between	IN	O
the	DT	O
10	CD	O
micrograms/kg	NN	O
and	CC	O
40	CD	O
micrograms/kg	NN	O
doses	NNS	O
of	IN	O
granisetron	NN	O
in	IN	O
preventing	VBG	O
nausea	NN	O
and	CC	O
vomiting	VBG	O
during	IN	O
repeat	NN	O
cycles	NNS	O
of	IN	O
high-dose	JJ	O
cisplatin-based	JJ	O
chemotherapy	NN	O
.	.	O

The	DT	O
results	NNS	O
of	IN	O
this	DT	O
study	NN	O
show	NN	O
that	IN	O
granisetron	VBZ	O
10	CD	O
micrograms/kg	NN	O
is	VBZ	O
safe	JJ	O
and	CC	O
well	RB	O
tolerated	VBN	O
,	,	O
and	CC	O
remains	VBZ	O
effective	JJ	O
with	IN	O
repeat	NN	O
cycle	NN	O
use	NN	O
.	.	O

Psychosocial	JJ	O
nursing	NN	O
therapy	NN	O
following	VBG	O
sudden	JJ	O
cardiac	JJ	C
arrest	NN	C
:	:	O
impact	NN	O
on	IN	O
two-year	JJ	O
survival	NN	O
.	.	O

BACKGROUND	NNP	O
Although	IN	O
psychosocial	JJ	O
therapy	NN	O
has	VBZ	O
been	VBN	O
shown	VBN	O
to	TO	O
reduce	VB	O
mortality	NN	O
after	IN	O
myocardial	JJ	O
infarction	NN	O
,	,	O
it	PRP	O
is	VBZ	O
unknown	JJ	O
whether	IN	O
the	DT	O
benefits	NNS	O
of	IN	O
psychosocial	JJ	O
therapy	NN	O
on	IN	O
mortality	NN	O
reduction	NN	O
extend	VBP	O
to	TO	O
out-of-hospital	JJ	O
sudden	JJ	O
cardiac	NN	O
arrest	NN	O
,	,	O
a	DT	O
main	JJ	O
cause	NN	O
of	IN	O
cardiovascular	JJ	O
mortality	NN	O
.	.	O

OBJECTIVE	NNP	O
Describe	NNP	O
efficacy	NN	O
of	IN	O
psychosocial	JJ	O
therapy	NN	O
on	IN	O
two-year	JJ	O
cardiovascular	JJ	O
mortality	NN	O
in	IN	O
sudden	JJ	O
cardiac	JJ	O
arrest	NN	O
survivors	NNS	O
.	.	O

METHOD	NNP	O
Survivors	NNPS	O
of	IN	O
out-of-hospital	JJ	O
ventricular	JJ	O
fibrillation	NN	O
or	CC	O
asystole	NN	O
(	(	O
N	NNP	O
=	NNP	O
129	CD	SS
)	)	O
,	,	O
documented	VBN	O
by	IN	O
electrocardiograms	NNS	O
from	IN	O
registries	NNS	O
of	IN	O
a	DT	O
citywide	NN	O
Medic	NNP	O
One	NNP	O
unit	NN	O
and	CC	O
two	CD	O
countywide	NN	O
emergency	NN	O
units	NNS	O
,	,	O
were	VBD	O
randomized	VBN	O
into	IN	O
a	DT	O
two	CD	O
group	NN	O
,	,	O
experimental	JJ	O
,	,	O
longitudinal	JJ	O
design	NN	O
.	.	O

The	DT	O
intervention	NN	O
consisted	VBD	O
of	IN	O
11	CD	O
individual	JJ	O
sessions	NNS	O
,	,	O
implementing	VBG	O
three	CD	O
components	NNS	O
:	:	O
physiologic	JJ	O
relaxation	NN	O
with	IN	O
biofeedback	NN	O
training	NN	O
focused	VBD	O
on	IN	O
altering	VBG	O
autonomic	JJ	O
tone	NN	O
;	:	O
cognitive	JJ	O
behavioral	JJ	O
therapy	NN	O
aimed	VBN	O
at	IN	O
self-management	JJ	O
and	CC	O
coping	VBG	O
strategies	NNS	O
for	IN	O
depression	NN	O
,	,	O
anxiety	NN	O
,	,	O
and	CC	O
anger	NN	O
;	:	O
and	CC	O
cardiovascular	JJ	O
health	NN	O
education	NN	O
.	.	O

The	DT	O
primary	JJ	O
outcome	NN	O
measure	NN	O
was	VBD	O
cardiovascular	JJ	O
mortality	NN	O
.	.	O

RESULTS	NNP	O
Risk	NNP	O
of	IN	O
cardiovascular	JJ	O
death	NN	O
was	VBD	O
significantly	RB	O
reduced	VBN	O
86	CD	O
%	NN	O
by	IN	O
psychosocial	JJ	O
therapy	NN	O
,	,	O
p	NN	O
=	NNP	O
.03	NNP	O
.	.	O

Six	NNP	O
of	IN	O
the	DT	O
seven	CD	O
cardiovascular	JJ	O
deaths	NNS	O
in	IN	O
the	DT	O
control	NN	O
group	NN	O
were	VBD	O
caused	VBN	O
by	IN	O
ventricular	JJ	O
arrhythmias	NN	O
.	.	O

The	DT	O
cardiovascular	JJ	O
death	NN	O
in	IN	O
the	DT	O
therapy	NN	O
group	NN	O
was	VBD	O
due	JJ	O
to	TO	O
stroke	VB	O
.	.	O

Controlling	VBG	O
for	IN	O
depression	NN	O
,	,	O
previous	JJ	O
myocardial	JJ	O
infarction	NN	O
,	,	O
low	JJ	O
ejection	NN	O
fraction	NN	O
,	,	O
decreased	JJ	O
heart	NN	O
rate	NN	O
variability	NN	O
,	,	O
and	CC	O
ventricular	JJ	O
ectopic	NN	O
beats	NNS	O
had	VBD	O
little	JJ	O
impact	NN	O
on	IN	O
estimated	VBN	O
treatment	NN	O
effect	NN	O
.	.	O

The	DT	O
risk	NN	O
of	IN	O
all-cause	JJ	O
mortality	NN	O
was	VBD	O
reduced	VBN	O
by	IN	O
62	CD	O
%	NN	O
in	IN	O
the	DT	O
therapy	NN	O
group	NN	O
,	,	O
p	VBP	O
=	JJ	O
.13	NNP	O
.	.	O

There	EX	O
were	VBD	O
a	DT	O
total	NN	O
of	IN	O
three	CD	O
deaths	NNS	O
in	IN	O
the	DT	O
therapy	NN	O
group	NN	O
and	CC	O
eight	CD	O
deaths	NNS	O
in	IN	O
the	DT	O
control	NN	O
group	NN	O
.	.	O

CONCLUSIONS	NNP	O
Psychosocial	NNP	O
therapy	NN	O
significantly	RB	O
reduced	VBD	O
the	DT	O
risk	NN	O
of	IN	O
cardiovascular	JJ	O
death	NN	O
in	IN	O
sudden	JJ	O
cardiac	JJ	O
arrest	NN	O
survivors	NNS	O
.	.	O

Quality	NN	O
of	IN	O
individual	JJ	O
INR	NNP	O
control	NN	O
and	CC	O
the	DT	O
risk	NN	O
of	IN	O
stroke	NN	O
and	CC	O
bleeding	VBG	O
events	NNS	O
in	IN	O
atrial	JJ	C
fibrillation	NN	C
patients	NNS	O
:	:	O
a	DT	O
nested	JJ	O
case	NN	O
control	NN	O
analysis	NN	O
of	IN	O
the	DT	O
ACTIVE	NNP	O
W	NNP	O
study	NN	O
.	.	O

INTRODUCTION	NNP	O
Time	NNP	O
in	IN	O
therapeutic	JJ	O
range	NN	O
(	(	O
TTR	NNP	O
)	)	O
for	IN	O
international	JJ	O
normalized	JJ	O
ratio	NN	O
(	(	O
INR	NNP	O
)	)	O
is	VBZ	O
an	DT	O
accepted	JJ	O
quality	NN	O
measure	NN	O
of	IN	O
anticoagulation	NN	O
control	NN	O
in	IN	O
patient	JJ	O
populations	NNS	O
,	,	O
but	CC	O
its	PRP$	O
usefulness	NN	O
for	IN	O
predicting	VBG	O
stroke	NN	O
and	CC	O
bleeding	NN	O
in	IN	O
individuals	NNS	O
is	VBZ	O
not	RB	O
well	RB	O
understood	RB	O
.	.	O

MATERIALS	NNP	O
AND	CC	O
METHODS	NNP	O
In	IN	O
a	DT	O
nested	JJ	O
case	NN	O
control	NN	O
analysis	NN	O
among	IN	O
ACTIVE	NNP	O
W	NNP	O
study	NN	O
patients	NNS	O
,	,	O
cases	NNS	O
with	IN	O
stroke	NN	C
and	CC	O
cases	NNS	O
with	IN	O
bleeding	NN	C
were	VBD	O
separately	RB	O
matched	VBN	O
with	IN	O
controls	NNS	O
.	.	O

Several	JJ	O
anticoagulation	NN	O
quality	NN	O
measures	NNS	O
were	VBD	O
compared	VBN	O
,	,	O
overall	JJ	O
and	CC	O
in	IN	O
a	DT	O
time-dependent	JJ	O
manner	NN	O
.	.	O

RESULTS	CC	O
32	CD	SS
cases	NNS	O
with	IN	O
ischemic	JJ	C
stroke	NN	C
and	CC	O
234	CD	SS
cases	NNS	O
with	IN	O
bleeding	NN	C
in	IN	O
the	DT	O
analysis	NN	O
were	VBD	O
matched	VBN	O
in	IN	O
a	DT	O
4:1	CD	O
ratio	NN	O
to	TO	O
122	CD	O
and	CC	O
865	CD	O
controls	NNS	O
,	,	O
respectively	RB	O
.	.	O

Follow-up	JJ	O
duration	NN	O
was	VBD	O
257?154days	CD	O
for	IN	O
the	DT	O
stroke	NN	O
analysis	NN	O
and	CC	O
222?146days	CD	O
for	IN	O
the	DT	O
bleeding	NN	O
analysis	NN	O
.	.	O

Compared	VBN	O
with	IN	O
their	PRP$	O
respective	NN	O
controls	NNS	O
,	,	O
the	DT	O
study	NN	O
mean	JJ	O
TTR	NNP	O
of	IN	O
both	DT	O
stroke	NN	O
cases	NNS	O
(	(	O
53.9	CD	O
%	NN	O
?25.1	NNP	O
vs	VBZ	O
63.4	CD	O
%	NN	O
?24.8	NN	O
;	:	O
p=0.055	CC	O
)	)	O
and	CC	O
bleeding	VBG	O
cases	NNS	O
(	(	O
56.2	CD	O
%	NN	O
?25.4	NNP	O
vs	VBZ	O
63.4	CD	O
%	NN	O
?26.8	NN	O
;	:	O
p	CC	O
<	VB	O
0.001	CD	O
)	)	O
was	VBD	O
lower	JJR	O
.	.	O

Time	NNP	O
below	IN	O
range	NN	O
for	IN	O
stroke	NN	O
and	CC	O
time	NN	O
above	IN	O
range	NN	O
for	IN	O
bleeding	VBG	O
were	VBD	O
only	RB	O
greater	JJR	O
in	IN	O
the	DT	O
last	JJ	O
month	NN	O
leading	VBG	O
up	RP	O
to	TO	O
the	DT	O
event	NN	O
,	,	O
not	RB	O
over	IN	O
the	DT	O
entire	JJ	O
study	NN	O
period	NN	O
.	.	O

Rather	CC	O
,	,	O
over	IN	O
the	DT	O
entire	JJ	O
study	NN	O
period	NN	O
bleeding	VBG	O
cases	NNS	O
spent	VBD	O
more	JJR	O
time	NN	O
below	IN	O
range	NN	O
than	IN	O
controls	NNS	O
(	(	O
26.8	CD	O
%	NN	O
?25.9	NNP	O
vs	VBZ	O
20.8	CD	O
%	NN	O
?24.0	NN	O
;	:	O
p=0.001	NN	O
)	)	O
.	.	O

CONCLUSIONS	NNP	O
TTR	NNP	O
was	VBD	O
lower	JJR	O
in	IN	O
individual	JJ	O
AF	NNP	O
patients	NNS	O
with	IN	O
stroke	NN	O
or	CC	O
bleeding	NN	O
compared	VBN	O
with	IN	O
matched	JJ	O
controls	NNS	O
in	IN	O
ACTIVE	NNP	O
W.	NNP	O
Maintaining	VBG	O
a	DT	O
high	JJ	O
TTR	NNP	O
,	,	O
with	IN	O
equal	JJ	O
importance	NN	O
to	TO	O
avoid	VB	O
low	JJ	O
and	CC	O
high	JJ	O
INRs	NNP	O
,	,	O
is	VBZ	O
a	DT	O
relevant	JJ	O
goal	NN	O
of	IN	O
individual	JJ	O
patient	NN	O
treatment	NN	O
to	TO	O
prevent	VB	O
stroke	NN	O
and	CC	O
bleeding	NN	O
.	.	O

[	JJ	O
Clinical	NNP	O
observation	NN	O
on	IN	O
acupuncture	NN	O
combined	VBN	O
with	IN	O
Yizhi	NNP	O
Jiannao	NNP	O
granules	NNS	O
for	IN	O
treatment	NN	O
of	IN	O
Alzheimer	NNP	O
's	POS	O
disease	NN	O
]	NNP	O
.	.	O

OBJECTIVE	NNP	O
To	TO	O
observe	VB	O
clinical	JJ	O
therapeutic	JJ	O
effect	NN	O
of	IN	O
acupuncture	NN	O
combined	VBN	O
with	IN	O
Yizhi	NNP	O
Jiannao	NNP	O
Granules	NNP	O
for	IN	O
treatment	NN	O
of	IN	O
Alzheimer	NNP	O
's	POS	O
disease	NN	O
and	CC	O
its	PRP$	O
effects	NNS	O
on	IN	O
intelligence	NN	O
,	,	O
daily	JJ	O
life	NN	O
and	CC	O
social	JJ	O
activity	NN	O
ability	NN	O
.	.	O

METHODS	NNP	O
Eighty-four	JJ	SS
cases	NNS	O
were	VBD	O
randomly	RB	O
divided	VBN	O
into	IN	O
3	CD	O
groups	NNS	O
,	,	O
28	CD	SS
cases	NNS	O
in	IN	O
each	DT	O
group	NN	O
.	.	O

The	DT	O
combined	JJ	O
acupuncture	NN	O
and	CC	O
medication	NN	O
group	NN	O
was	VBD	O
treated	VBN	O
with	IN	O
acupuncture	NN	O
at	IN	O
Baihui	NNP	O
(	(	O
GV	NNP	O
20	CD	O
)	)	O
,	,	O
Sishencong	NNP	O
(	(	O
EX-HN	NNP	O
1	CD	O
)	)	O
,	,	O
Dazhui	NNP	O
(	(	O
GV	NNP	O
14	CD	O
)	)	O
,	,	O
Guanyuan	NNP	O
(	(	O
CV	NNP	O
4	CD	O
)	)	O
,	,	O
etc	FW	O
.	.	O

and	CC	O
oral	JJ	O
administration	NN	O
of	IN	O
Yizhi	NNP	O
Jiannao	NNP	O
Granules	NNP	O
;	:	O
the	DT	O
Chinese	NNP	O
herb	NN	O
group	NN	O
was	VBD	O
treated	VBN	O
with	IN	O
Yizhi	NNP	O
Jiannao	NNP	O
Granules	NNP	O
,	,	O
and	CC	O
the	DT	O
western	JJ	O
medicine	NN	O
group	NN	O
with	IN	O
oral	JJ	O
administration	NN	O
of	IN	O
Aricept	NNP	O
.	.	O

The	DT	O
scores	NNS	O
for	IN	O
the	DT	O
Mini-Mental	JJ	O
State	NNP	O
Examination	NNP	O
(	(	O
MMSE	NNP	O
)	)	O
,	,	O
Ability	NNP	O
of	IN	O
Daily	NNP	O
Life	NNP	O
(	(	O
ADL	NNP	O
)	)	O
and	CC	O
the	DT	O
therapeutic	JJ	O
effects	NNS	O
were	VBD	O
assessed	VBN	O
and	CC	O
compared	VBN	O
before	IN	O
treatment	NN	O
and	CC	O
after	IN	O
treatment	NN	O
for	IN	O
12	CD	O
weeks	NNS	O
among	IN	O
the	DT	O
groups	NNS	O
.	.	O

RESULTS	NNP	O
After	IN	O
treatment	NN	O
,	,	O
the	DT	O
scores	NNS	O
for	IN	O
MMSE	NNP	O
and	CC	O
ADL	NNP	O
were	VBD	O
improved	VBN	O
in	IN	O
the	DT	O
combined	JJ	O
acupuncture	NN	O
and	CC	O
medication	NN	O
group	NN	O
,	,	O
the	DT	O
Chinese	JJ	O
herb	NN	O
group	NN	O
and	CC	O
the	DT	O
western	JJ	O
medicine	NN	O
group	NN	O
,	,	O
which	WDT	O
were	VBD	O
better	RBR	O
in	IN	O
the	DT	O
combined	JJ	O
acupuncture	NN	O
and	CC	O
medication	NN	O
group	NN	O
(	(	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
.	.	O

The	DT	O
total	JJ	O
effective	JJ	O
rate	NN	O
of	IN	O
85.7	CD	O
%	NN	O
in	IN	O
the	DT	O
combined	JJ	O
acupuncture	NN	O
and	CC	O
medication	NN	O
group	NN	O
was	VBD	O
better	JJR	O
than	IN	O
71.4	CD	O
%	NN	O
in	IN	O
the	DT	O
Chinese	JJ	O
herb	NN	O
group	NN	O
and	CC	O
67.9	CD	O
%	NN	O
in	IN	O
the	DT	O
western	JJ	O
medicine	NN	O
group	NN	O
.	.	O

CONCLUSION	NNP	O
Acupuncture	NNP	O
combined	VBN	O
with	IN	O
Yizhi	NNP	O
Jiannao	NNP	O
Granules	NNP	O
has	VBZ	O
a	DT	O
significant	JJ	O
therapeutic	JJ	O
effect	NN	O
on	IN	O
Alzheimer	NNP	O
's	POS	O
disease	NN	O
,	,	O
which	WDT	O
is	VBZ	O
better	JJR	O
than	IN	O
that	DT	O
of	IN	O
Yizhi	NNP	O
Jiannao	NNP	O
Granules	NNP	O
or	CC	O
Aricept	NNP	O
.	.	O

Comparative	NNP	O
dose	NN	O
efficacy	NN	O
study	NN	O
of	IN	O
atorvastatin	JJ	O
versus	NN	O
simvastatin	NN	O
,	,	O
pravastatin	NN	O
,	,	O
lovastatin	NN	O
,	,	O
and	CC	O
fluvastatin	NN	O
in	IN	O
patients	NNS	C
with	IN	C
hypercholesterolemia	NN	C
(	(	O
the	DT	O
CURVES	NNP	O
study	NN	O
)	)	O
The	DT	O
objective	NN	O
of	IN	O
this	DT	O
multicenter	NN	C
,	,	O
randomized	VBN	O
,	,	O
open-label	JJ	O
,	,	O
parallel-group	JJ	O
,	,	O
8-week	JJ	O
study	NN	O
was	VBD	O
to	TO	O
evaluate	VB	O
the	DT	O
comparative	JJ	O
dose	JJ	O
efficacy	NN	O
of	IN	O
the	DT	O
3-hydroxy-3-methylglutaryl	JJ	O
coenzyme	NN	O
A	NNP	O
(	(	O
HMG-CoA	NNP	O
)	)	O
reductase	NN	O
inhibitor	NN	O
atorvastatin	VBD	O
10	CD	O
,	,	O
20	CD	O
,	,	O
40	CD	O
,	,	O
and	CC	O
80	CD	O
mg	NNS	O
compared	VBN	O
with	IN	O
simvastatin	NN	O
10	CD	O
,	,	O
20	CD	O
,	,	O
and	CC	O
40	CD	O
mg	NN	O
,	,	O
pravastatin	NN	O
10	CD	O
,	,	O
20	CD	O
,	,	O
and	CC	O
40	CD	O
mg	NN	O
,	,	O
lovastatin	VBZ	O
20	CD	O
,	,	O
40	CD	O
,	,	O
and	CC	O
80	CD	O
mg	NN	O
,	,	O
and	CC	O
fluvastatin	$	O
20	CD	O
and	CC	O
40	CD	O
mg.	NN	O
Investigators	NNS	O
enrolled	VBD	O
534	CD	O
hypercholesterolemic	JJ	O
patients	NNS	O
(	(	O
low-density	JJ	O
lipoprotein	NN	O
[	NNP	O
LDL	NNP	O
]	NNP	O
cholesterol	NN	O
>	NN	O
or	CC	O
=	$	O
160	CD	O
mg/dl	NN	O
[	VBD	O
4.2	CD	O
mmol/L	NN	O
]	NN	O
and	CC	O
triglycerides	NNS	O
<	VBP	O
or	CC	O
=	VBP	O
400	CD	O
mg/dl	NN	O
[	VBD	O
4.5	CD	O
mmol/L	NNS	O
]	RB	O
)	)	O
.	.	O

The	DT	O
efficacy	JJ	O
end	NN	O
points	NNS	O
were	VBD	O
mean	JJ	O
percent	NN	O
change	NN	O
in	IN	O
plasma	NN	O
LDL	NNP	O
cholesterol	NN	O
(	(	O
primary	JJ	O
)	)	O
,	,	O
total	JJ	O
cholesterol	NN	O
,	,	O
triglycerides	NNS	O
,	,	O
and	CC	O
high-density	NN	O
lipoprotein	NN	O
cholesterol	NN	O
concentrations	NNS	O
from	IN	O
baseline	NN	O
to	TO	O
the	DT	O
end	NN	O
of	IN	O
treatment	NN	O
(	(	O
week	NN	O
8	CD	O
)	)	O
.	.	O

Atorvastatin	$	O
10	CD	O
,	,	O
20	CD	O
,	,	O
and	CC	O
40	CD	O
mg	NN	O
produced	VBN	O
greater	JJR	O
(	(	O
p	JJ	O
<	NN	O
or	CC	O
=	VB	O
0.01	CD	O
)	)	O
reductions	NNS	O
in	IN	O
LDL	NNP	O
cholesterol	NN	O
,	,	O
-38	CD	O
%	NN	O
,	,	O
-46	CD	O
%	NN	O
,	,	O
and	CC	O
-51	NNP	O
%	NN	O
,	,	O
respectively	RB	O
,	,	O
than	IN	O
the	DT	O
milligram	JJ	O
equivalent	JJ	O
doses	NNS	O
of	IN	O
simvastatin	NN	O
,	,	O
pravastatin	NN	O
,	,	O
lovastatin	NN	O
,	,	O
and	CC	O
fluvastatin	NN	O
.	.	O

Atorvastatin	$	O
10	CD	O
mg	NN	O
produced	VBN	O
LDL	NNP	O
cholesterol	NN	O
reductions	NNS	O
comparable	JJ	O
to	TO	O
or	CC	O
greater	JJR	O
than	IN	O
(	(	O
p	JJ	O
<	NN	O
or	CC	O
=	VB	O
0.02	CD	O
)	)	O
simvastatin	NN	O
10	CD	O
,	,	O
20	CD	O
,	,	O
and	CC	O
40	CD	O
mg	NN	O
,	,	O
pravastatin	NN	O
10	CD	O
,	,	O
20	CD	O
,	,	O
and	CC	O
40	CD	O
mg	NN	O
,	,	O
lovastatin	CC	O
20	CD	O
and	CC	O
40	CD	O
mg	NN	O
,	,	O
and	CC	O
fluvastatin	$	O
20	CD	O
and	CC	O
40	CD	O
mg.	NN	O
Atorvastatin	NNP	O
10	CD	O
,	,	O
20	CD	O
,	,	O
and	CC	O
40	CD	O
mg	NN	O
produced	VBN	O
greater	JJR	O
(	(	O
p	JJ	O
<	NN	O
or	CC	O
=	VB	O
0.01	CD	O
)	)	O
reductions	NNS	O
in	IN	O
total	JJ	O
cholesterol	NN	O
than	IN	O
the	DT	O
milligram	JJ	O
equivalent	JJ	O
doses	NNS	O
of	IN	O
simvastatin	NN	O
,	,	O
pravastatin	NN	O
,	,	O
lovastatin	NN	O
,	,	O
and	CC	O
fluvastatin	NN	O
.	.	O

All	DT	O
reductase	NN	O
inhibitors	NNS	O
studied	VBD	O
had	VBD	O
similar	JJ	O
tolerability	NN	O
.	.	O

There	EX	O
were	VBD	O
no	DT	O
incidences	NNS	O
of	IN	O
persistent	JJ	O
elevations	NNS	O
in	IN	O
serum	NN	O
transaminases	NNS	O
or	CC	O
myositis	NN	O
.	.	O

Combination	NN	O
of	IN	O
sotalol	NN	O
and	CC	O
magnesium	NN	O
prevents	NNS	O
atrial	JJ	O
fibrillation	NN	O
after	IN	O
coronary	JJ	O
artery	NN	O
bypass	NN	O
grafting	NN	O
.	.	O

BACKGROUND	NNP	O
Atrial	NNP	O
fibrillation	NN	O
(	(	O
AF	NNP	O
)	)	O
is	VBZ	O
a	DT	O
common	JJ	O
complication	NN	O
reported	VBD	O
in	IN	O
20	CD	O
%	NN	O
to	TO	O
40	CD	O
%	NN	O
of	IN	O
patients	NNS	O
after	IN	C
coronary	JJ	C
operations	NNS	C
.	.	O

Sotalol	NNP	O
alone	RB	O
and	CC	O
magnesium	VB	O
alone	RB	O
have	VBP	O
been	VBN	O
shown	VBN	O
to	TO	O
partially	RB	O
decrease	VB	O
the	DT	O
incidence	NN	O
of	IN	O
AF	NNP	O
.	.	O

The	DT	O
goal	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
evaluate	VB	O
the	DT	O
efficacy	NN	O
of	IN	O
these	DT	O
two	CD	O
pharmacological	JJ	O
agents	NNS	O
,	,	O
used	VBD	O
alone	RB	O
or	CC	O
in	IN	O
combination	NN	O
,	,	O
to	TO	O
reduce	VB	O
postoperative	JJ	O
AF	NNP	O
.	.	O

METHODS	NNP	O
Two	CD	SS
hundred	VBD	SS
seven	CD	SS
consecutive	JJ	C
coronary	JJ	C
artery	NN	C
bypass	NN	C
patients	NNS	C
(	(	O
mean	JJ	O
age	NN	O
62	CD	O
+/-	JJ	O
11	CD	O
years	NNS	O
)	)	O
were	VBD	O
randomized	VBN	O
to	TO	O
receive	VB	O
sotalol	NN	O
alone	RB	O
(	(	O
80	CD	O
mg	NN	O
twice	RB	O
daily	RB	O
for	IN	O
5	CD	O
days	NNS	O
starting	VBG	O
from	IN	O
the	DT	O
morning	NN	O
of	IN	O
the	DT	O
first	JJ	O
postoperative	JJ	O
day	NN	O
)	)	O
(	(	O
group	NN	O
S	NNP	O
)	)	O
,	,	O
magnesium	NN	O
alone	RB	O
(	(	O
1.5	CD	O
g	NNS	O
daily	RB	O
for	IN	O
6	CD	O
days	NNS	O
starting	VBG	O
in	IN	O
the	DT	O
operating	NN	O
room	NN	O
just	RB	O
before	IN	O
cardiopulmonary	JJ	O
bypass	NN	O
)	)	O
(	(	O
group	NN	O
M	NNP	O
)	)	O
,	,	O
both	DT	O
pharmacologic	JJ	O
agents	NNS	O
at	IN	O
the	DT	O
same	JJ	O
dosages	NNS	O
(	(	O
group	NN	O
S+M	NNP	O
)	)	O
,	,	O
or	CC	O
no	DT	O
antiarrhythmic	JJ	O
agents	NNS	O
(	(	O
group	NN	O
CTR	NNP	O
)	)	O
.	.	O

All	DT	O
patients	NNS	C
with	IN	C
an	DT	C
ejection	NN	C
fraction	NN	C
less	JJR	C
than	IN	C
0.40	CD	C
were	VBD	C
excluded	VBN	C
.	.	O

RESULTS	VB	O
The	DT	O
incidence	NN	O
of	IN	O
postoperative	JJ	O
AF	NNP	O
was	VBD	O
11.8	CD	O
%	NN	O
(	(	O
6/51	CD	O
)	)	O
in	IN	O
the	DT	O
S	NNP	O
group	NN	O
,	,	O
14.8	CD	O
%	NN	O
(	(	O
8/54	CD	O
)	)	O
in	IN	O
the	DT	O
M	NNP	O
group	NN	O
,	,	O
1.9	CD	O
%	NN	O
(	(	O
1/52	CD	O
)	)	O
in	IN	O
the	DT	O
S+M	NNP	O
group	NN	O
,	,	O
and	CC	O
38	CD	O
%	NN	O
(	(	O
19/50	CD	O
)	)	O
in	IN	O
the	DT	O
CTR	NNP	O
group	NN	O
.	.	O

The	DT	O
following	JJ	O
differences	NNS	O
were	VBD	O
significant	JJ	O
:	:	O
group	NN	O
CTR	NNP	O
versus	NN	O
groups	NNS	O
S	NNP	O
,	,	O
M	NNP	O
,	,	O
and	CC	O
S+M	NNP	O
with	IN	O
values	NNS	O
of	IN	O
p	NN	O
=	NN	O
0.002	CD	O
,	,	O
p	NN	O
=	VBD	O
0.007	CD	O
and	CC	O
p	VB	O
<	JJ	O
0.0001	CD	O
,	,	O
respectively	RB	O
;	:	O
and	CC	O
group	NN	O
S+M	NNP	O
versus	NN	O
groups	NNS	O
S	NNP	O
and	CC	O
M	NNP	O
with	IN	O
p	JJ	O
=	$	O
0.04	CD	O
and	CC	O
p	VB	O
=	JJ	O
0.01	CD	O
,	,	O
respectively	RB	O
.	.	O

CONCLUSIONS	NNP	O
Incidence	NNP	O
of	IN	O
AF	NNP	O
after	IN	O
coronary	JJ	O
operation	NN	O
was	VBD	O
significantly	RB	O
reduced	VBN	O
by	IN	O
the	DT	O
administration	NN	O
of	IN	O
sotalol	JJ	O
alone	NN	O
and	CC	O
magnesium	NN	O
alone	RB	O
;	:	O
more	RBR	O
importantly	RB	O
,	,	O
the	DT	O
incidence	NN	O
was	VBD	O
further	RBR	O
reduced	VBN	O
by	IN	O
combining	VBG	O
these	DT	O
agents	NNS	O
.	.	O

Reputation	NNP	O
management	NN	O
:	:	O
evidence	NN	O
for	IN	O
ability	NN	O
but	CC	O
reduced	JJ	O
propensity	NN	O
in	IN	O
autism	NN	O
.	.	O

Previous	JJ	O
research	NN	O
has	VBZ	O
reported	VBN	O
that	IN	O
autistic	JJ	O
adults	NNS	O
do	VBP	O
not	RB	O
manage	VB	O
their	PRP$	O
reputation	NN	O
,	,	O
purportedly	RB	O
due	JJ	O
to	TO	O
problems	NNS	O
with	IN	O
theory	NN	O
of	IN	O
mind	NN	O
[	NNP	O
Izuma	NNP	O
,	,	O
Matsumoto	NNP	O
,	,	O
Camerer	NNP	O
,	,	O
&	CC	O
Adolphs	NNP	O
]	NNP	O
.	.	O

The	DT	O
current	JJ	O
study	NN	O
aimed	VBD	O
to	TO	O
test	VB	O
alternative	JJ	O
explanations	NNS	O
for	IN	O
this	DT	O
apparent	JJ	O
lack	NN	O
of	IN	O
reputation	NN	O
management	NN	O
.	.	O

Twenty	NNP	O
typical	JJ	O
and	CC	O
19	CD	O
autistic	JJ	O
adults	NNS	O
donated	VBD	O
to	TO	O
charity	NN	O
and	CC	O
to	TO	O
a	DT	O
person	NN	O
,	,	O
both	DT	O
when	WRB	O
alone	RB	O
and	CC	O
when	WRB	O
observed	VBN	O
.	.	O

In	IN	O
an	DT	O
additional	JJ	O
manipulation	NN	O
,	,	O
for	IN	O
half	NN	O
of	IN	O
the	DT	O
participants	NNS	O
,	,	O
the	DT	O
observer	NN	O
was	VBD	O
also	RB	O
the	DT	O
recipient	NN	O
of	IN	O
their	PRP$	O
donations	NNS	O
,	,	O
and	CC	O
participants	NNS	O
were	VBD	O
told	VBN	O
that	IN	O
this	DT	O
observer	NN	O
would	MD	O
subsequently	RB	O
have	VB	O
the	DT	O
opportunity	NN	O
to	TO	O
donate	VB	O
to	TO	O
them	PRP	O
(	(	O
motivation	NN	O
condition	NN	O
)	)	O
.	.	O

This	DT	O
manipulation	NN	O
was	VBD	O
designed	VBN	O
to	TO	O
encourage	VB	O
an	DT	O
expectation	NN	O
of	IN	O
a	DT	O
reciprocal	JJ	O
tit-for-tat	NN	O
strategy	NN	O
in	IN	O
the	DT	O
participant	NN	O
,	,	O
which	WDT	O
may	MD	O
motivate	VB	O
participants	NNS	O
to	TO	O
change	VB	O
their	PRP$	O
behavior	NN	O
to	TO	O
receive	VB	O
more	JJR	O
donations	NNS	O
.	.	O

The	DT	O
remaining	VBG	O
participants	NNS	O
were	VBD	O
told	VBN	O
that	IN	O
the	DT	O
person	NN	O
watching	NN	O
was	VBD	O
just	RB	O
observing	VBG	O
the	DT	O
procedure	NN	O
(	(	O
no	DT	O
motivation	NN	O
condition	NN	O
)	)	O
.	.	O

Our	PRP$	O
results	NNS	O
replicated	VBD	O
Izuma	NNP	O
et	CC	O
al	NN	O
.	.	O

's	POS	O
finding	VBG	O
that	IN	O
autistic	JJ	O
adults	NNS	O
did	VBD	O
not	RB	O
donate	VB	O
more	JJR	O
to	TO	O
charity	NN	O
when	WRB	O
observed	VBN	O
.	.	O

Yet	CC	O
,	,	O
in	IN	O
the	DT	O
motivation	NN	O
condition	NN	O
,	,	O
both	DT	O
typical	JJ	O
and	CC	O
autistic	JJ	O
adults	NNS	O
donated	VBD	O
significantly	RB	O
more	RBR	O
to	TO	O
the	DT	O
observer	NN	O
when	WRB	O
watched	VBN	O
,	,	O
although	IN	O
this	DT	O
effect	NN	O
was	VBD	O
significantly	RB	O
attenuated	VBN	O
in	IN	O
autistic	JJ	O
individuals	NNS	O
.	.	O

Results	NNS	O
indicate	VBP	O
that	IN	O
,	,	O
while	IN	O
individuals	NNS	O
with	IN	O
autism	NN	O
may	MD	O
have	VB	O
the	DT	O
ability	NN	O
to	TO	O
think	VB	O
about	IN	O
reputation	NN	O
,	,	O
a	DT	O
reduced	JJ	O
expectation	NN	O
of	IN	O
reciprocal	JJ	O
behavior	NN	O
from	IN	O
others	NNS	O
may	MD	O
reduce	VB	O
the	DT	O
degree	NN	O
to	TO	O
which	WDT	O
they	PRP	O
engage	VBP	O
in	IN	O
reputation	NN	O
management	NN	O
.	.	O

Randomized	VBN	O
trial	NN	O
of	IN	O
recombinant	JJ	O
alpha	JJ	O
2b-interferon	JJ	O
with	IN	O
or	CC	O
without	IN	O
indomethacin	NNS	O
in	IN	O
patients	NNS	O
with	IN	O
metastatic	JJ	C
malignant	JJ	C
melanoma	NN	C
.	.	O

alpha-Interferon	NN	O
has	VBZ	O
antitumor	VBN	O
activity	NN	O
in	IN	O
a	DT	O
variety	NN	O
of	IN	O
malignancies	NNS	O
but	CC	O
is	VBZ	O
frequently	RB	O
associated	VBN	O
with	IN	O
unacceptable	JJ	O
toxic	JJ	O
side-effects	NNS	O
.	.	O

The	DT	O
routine	JJ	O
use	NN	O
of	IN	O
agents	NNS	O
potentially	RB	O
capable	JJ	O
of	IN	O
reducing	VBG	O
these	DT	O
side-effects	NNS	O
has	VBZ	O
not	RB	O
been	VBN	O
recommended	VBN	O
out	IN	O
of	IN	O
concern	NN	O
for	IN	O
possible	JJ	O
reductions	NNS	O
in	IN	O
the	DT	O
therapeutic	JJ	O
activity	NN	O
of	IN	O
interferon	NN	O
.	.	O

We	PRP	O
conducted	VBD	O
a	DT	O
prospective	JJ	O
randomized	VBN	O
trial	NN	O
of	IN	O
alpha-interferon	JJ	O
given	VBN	O
with	IN	O
or	CC	O
without	IN	O
indomethacin	JJ	O
to	TO	O
patients	NNS	O
with	IN	O
malignant	JJ	C
melanoma	NN	C
to	TO	O
determine	VB	O
what	WP	O
effect	NN	O
,	,	O
if	IN	O
any	DT	O
,	,	O
indomethacin	NN	O
might	MD	O
have	VB	O
on	IN	O
the	DT	O
toxic	NN	O
,	,	O
immunomodulatory	NN	O
,	,	O
and	CC	O
therapeutic	JJ	O
properties	NNS	O
of	IN	O
interferon	NN	O
in	IN	O
this	DT	O
disease	NN	O
.	.	O

53	CD	SS
patients	NNS	O
were	VBD	O
stratified	VBN	O
according	VBG	O
to	TO	O
performance	NN	O
status	NN	O
and	CC	O
randomized	VBN	O
to	TO	O
receive	VB	O
alpha	JJ	O
2b-interferon	CD	O
,	,	O
20	CD	O
million	CD	O
units	NNS	O
per	IN	O
m2	NN	O
i.v.	NN	O
,	,	O
5	CD	O
days	NNS	O
per	IN	O
week	NN	O
for	IN	O
4	CD	O
weeks	NNS	O
followed	VBN	O
by	IN	O
10	CD	O
million	CD	O
units	NNS	O
per	IN	O
m2	NN	O
s.c.	NN	O
three	CD	O
times	NNS	O
per	IN	O
week	NN	O
,	,	O
either	RB	O
with	IN	O
or	CC	O
without	IN	O
indomethacin	NN	O
,	,	O
25	CD	O
mg	NN	O
orally	RB	O
three	CD	O
times	NNS	O
a	DT	O
day	NN	O
.	.	O

The	DT	O
overall	JJ	O
major	JJ	O
response	NN	O
rate	NN	O
was	VBD	O
13	CD	O
%	NN	O
(	(	O
three	CD	O
complete	JJ	O
responders	NNS	O
and	CC	O
three	CD	O
partial	JJ	O
responders	NNS	O
among	IN	O
47	CD	O
evaluable	JJ	O
patients	NNS	O
)	)	O
and	CC	O
was	VBD	O
the	DT	O
same	JJ	O
on	IN	O
both	DT	O
arms	NNS	O
.	.	O

The	DT	O
mean	JJ	O
maximal	JJ	O
temperature	NN	O
elevation	NN	O
induced	VBN	O
by	IN	O
interferon	NN	O
was	VBD	O
significantly	RB	O
reduced	VBN	O
(	(	O
from	IN	O
102.1	CD	O
to	TO	O
100.7	CD	O
,	,	O
P	NNP	O
=	NNP	O
0.0002	CD	O
)	)	O
by	IN	O
indomethacin	NN	O
,	,	O
but	CC	O
the	DT	O
incidence	NN	O
and	CC	O
severity	NN	O
of	IN	O
interferon-related	JJ	O
fatigue	NN	O
,	,	O
reduction	NN	O
in	IN	O
performance	NN	O
status	NN	O
,	,	O
headache	NN	O
,	,	O
depression	NN	O
,	,	O
confusion	NN	O
,	,	O
elevations	NNS	O
in	IN	O
liver	JJ	O
function	NN	O
tests	NNS	O
,	,	O
and	CC	O
myelosuppression	NN	O
were	VBD	O
no	DT	O
different	JJ	O
in	IN	O
either	DT	O
arm	NN	O
of	IN	O
the	DT	O
study	NN	O
.	.	O

Indomethacin	NNP	O
did	VBD	O
not	RB	O
reduce	VB	O
the	DT	O
frequency	NN	O
of	IN	O
dose	JJ	O
reductions	NNS	O
for	IN	O
toxic	JJ	O
side-effects	NNS	O
and	CC	O
did	VBD	O
not	RB	O
permit	VB	O
the	DT	O
administration	NN	O
of	IN	O
higher	JJR	O
interferon	NN	O
doses	NNS	O
.	.	O

Peripheral	NNP	O
blood	VBD	O
natural	JJ	O
killer	NN	O
activity	NN	O
was	VBD	O
significantly	RB	O
enhanced	VBN	O
in	IN	O
patients	NNS	O
during	IN	O
maintenance	NN	O
therapy	NN	O
whether	IN	O
or	CC	O
not	RB	O
they	PRP	O
received	VBD	O
indomethacin	NN	O
.	.	O

Indomethacin	NNP	O
appeared	VBD	O
to	TO	O
inhibit	VB	O
augmentation	NN	O
of	IN	O
natural	JJ	O
killer	NN	O
activity	NN	O
during	IN	O
high	JJ	O
dose	JJ	O
induction	NN	O
therapy	NN	O
.	.	O

Immunological	JJ	O
changes	NNS	O
did	VBD	O
not	RB	O
correlate	VB	O
with	IN	O
response	NN	O
status	NN	O
.	.	O

We	PRP	O
conclude	VBP	O
that	IN	O
indomethacin	NN	O
can	MD	O
reduce	VB	O
the	DT	O
fever	NN	O
associated	VBN	O
with	IN	O
interferon	NN	O
therapy	NN	O
in	IN	O
patients	NNS	O
with	IN	O
malignant	JJ	C
melanoma	NN	C
without	IN	O
interfering	VBG	O
with	IN	O
its	PRP$	O
therapeutic	JJ	O
or	CC	O
chronic	JJ	O
immunomodulatory	NN	O
activities	NNS	O
.	.	O

Since	IN	O
fever	NN	O
is	VBZ	O
rarely	RB	O
the	DT	O
dose-limiting	JJ	O
toxicity	NN	O
of	IN	O
interferon	NN	O
,	,	O
indomethacin	NN	O
is	VBZ	O
of	IN	O
marginal	JJ	O
benefit	NN	O
to	TO	O
patients	NNS	O
with	IN	O
malignant	JJ	C
melanoma	NN	C
receiving	VBG	O
interferon	NN	O
at	IN	O
the	DT	O
doses	NNS	O
outlined	VBN	O
in	IN	O
this	DT	O
study	NN	O
.	.	O

LNH-84	JJ	O
regimen	NNS	O
:	:	O
a	DT	O
multicenter	NN	O
study	NN	O
of	IN	O
intensive	JJ	O
chemotherapy	NN	O
in	IN	O
737	CD	O
patients	NNS	O
with	IN	O
aggressive	JJ	O
malignant	JJ	O
lymphoma	NN	O
.	.	O

From	IN	O
July	NNP	O
1984	CD	O
to	TO	O
September	NNP	O
1987	CD	O
,	,	O
737	CD	O
patients	NNS	O
with	IN	O
aggressive	JJ	O
malignant	JJ	O
lymphoma	NN	O
(	(	O
ML	NNP	O
)	)	O
were	VBD	O
treated	VBN	O
by	IN	O
an	DT	O
intensive	JJ	O
regimen	NNS	O
(	(	O
LNH-84	NNP	O
)	)	O
comprising	VBG	O
three	CD	O
or	CC	O
four	CD	O
courses	NNS	O
of	IN	O
doxorubicin	NN	O
,	,	O
75	CD	O
mg/m2	NN	O
;	:	O
cyclophosphamide	NN	O
,	,	O
1,200	CD	O
mg/m2	NN	O
;	:	O
vindesine	NN	O
,	,	O
2	CD	O
mg/m2	NN	O
x	NN	O
2	CD	O
;	:	O
bleomycin	NN	O
,	,	O
10	CD	O
mg	NN	O
x	NN	O
2	CD	O
;	:	O
and	CC	O
prednisolone	NN	O
,	,	O
60	CD	O
mg/m2	NN	O
x	NN	O
5	CD	O
(	(	O
ACVB	NNP	O
)	)	O
,	,	O
consolidation	NN	O
with	IN	O
high-dose	JJ	O
methotrexate	NN	O
,	,	O
ifosfamide	NN	O
,	,	O
etoposide	RB	O
,	,	O
asparaginase	NN	O
,	,	O
and	CC	O
cytarabine	NN	O
,	,	O
and	CC	O
a	DT	O
randomized	VBN	O
late	JJ	O
intensification	NN	O
with	IN	O
two	CD	O
courses	NNS	O
of	IN	O
cytarabine	NN	O
,	,	O
cyclophosphamide	NN	O
,	,	O
teniposide	NN	O
,	,	O
bleomycin	NN	O
,	,	O
and	CC	O
prednisone	NN	O
(	(	O
AraCVmB	NNP	O
)	)	O
.	.	O

Four	CD	O
hundred	VBD	O
forty-two	JJ	O
patients	NNS	O
had	VBD	O
intermediate-grade	JJ	O
ML	NNP	O
,	,	O
221	CD	O
highgrade	NN	O
ML	NNP	O
,	,	O
and	CC	O
74	CD	O
unclassified	JJ	O
ML	NNP	O
.	.	O

Most	JJS	O
of	IN	O
the	DT	O
patients	NNS	O
had	VBD	O
advanced	JJ	O
disease	NN	O
:	:	O
stage	NN	O
IIE	NNP	O
(	(	O
23	CD	O
%	NN	O
)	)	O
,	,	O
III	NNP	O
(	(	O
13	CD	O
%	NN	O
)	)	O
,	,	O
or	CC	O
IV	NNP	O
(	(	O
47	CD	O
%	NN	O
)	)	O
;	:	O
38	CD	O
%	NN	O
disseminated	JJ	O
nodes	NNS	O
;	:	O
38	CD	O
%	NN	O
two	CD	O
or	CC	O
more	JJR	O
extranodal	JJ	O
sites	NNS	O
;	:	O
and	CC	O
41	CD	O
%	NN	O
a	DT	O
tumoral	JJ	O
mass	NN	O
greater	JJR	O
than	IN	O
10	CD	O
cm	NN	O
.	.	O

Five	CD	O
hundred	VBD	O
fifty-three	JJ	O
patients	NNS	O
(	(	O
75	CD	O
%	NN	O
)	)	O
went	VBD	O
into	IN	O
complete	JJ	O
remission	NN	O
(	(	O
CR	NNP	O
)	)	O
,	,	O
63	CD	O
(	(	O
9	CD	O
%	NN	O
)	)	O
into	IN	O
partial	JJ	O
remission	NN	O
,	,	O
62	CD	O
(	(	O
8	CD	O
%	NN	O
)	)	O
failed	VBD	O
to	TO	O
respond	VB	O
,	,	O
and	CC	O
59	CD	O
(	(	O
8	CD	O
%	NN	O
)	)	O
died	VBD	O
during	IN	O
ACVB	NNP	O
courses	NNS	O
,	,	O
17	CD	O
of	IN	O
them	PRP	O
from	IN	O
progression	NN	O
of	IN	O
the	DT	O
disease	NN	O
.	.	O

With	IN	O
a	DT	O
median	JJ	O
follow-up	NN	O
of	IN	O
23	CD	O
months	NNS	O
,	,	O
the	DT	O
estimated	VBN	O
2-year	JJ	O
overall	JJ	O
survival	NN	O
time	NN	O
to	TO	O
failure	NN	O
(	(	O
TTF	NNP	O
)	)	O
,	,	O
and	CC	O
time	NN	O
to	TO	O
relapse	VB	O
(	(	O
TTR	NNP	O
)	)	O
survival	NN	O
are	VBP	O
67	CD	O
%	NN	O
,	,	O
56	CD	O
%	NN	O
,	,	O
and	CC	O
67	CD	O
%	NN	O
,	,	O
respectively	RB	O
.	.	O

Patients	NNS	O
receiving	VBG	O
a	DT	O
late	JJ	O
intensification	NN	O
had	VBD	O
the	DT	O
same	JJ	O
relapse	NN	O
rate	NN	O
as	IN	O
the	DT	O
other	JJ	O
patients	NNS	O
.	.	O

A	DT	O
persistent	JJ	O
fibronecrotic	JJ	O
mass	NN	O
was	VBD	O
found	VBN	O
in	IN	O
150	CD	O
patients	NNS	O
(	(	O
20	CD	O
%	NN	O
)	)	O
and	CC	O
did	VBD	O
not	RB	O
influence	VB	O
the	DT	O
relapse	NN	O
rate	NN	O
.	.	O

Toxicity	NNP	O
was	VBD	O
mainly	RB	O
neutropenia	JJ	O
and	CC	O
infection	NN	O
during	IN	O
the	DT	O
ACVB	NNP	O
courses	NNS	O
,	,	O
with	IN	O
40	CD	O
patients	NNS	O
(	(	O
5	CD	O
%	NN	O
)	)	O
dying	VBG	O
from	IN	O
septic	JJ	O
complications	NNS	O
while	IN	O
responding	VBG	O
to	TO	O
treatment	NN	O
.	.	O

Fifty-three	JJ	O
percent	NN	O
of	IN	O
the	DT	O
patients	NNS	O
had	VBD	O
a	DT	O
neutropenia	NN	O
less	JJR	O
than	IN	O
0.500	CD	O
x	JJ	O
10	CD	O
(	(	O
9	CD	O
)	)	O
/L	NN	O
,	,	O
58	CD	O
%	NN	O
fever	NN	O
(	(	O
6	CD	O
%	NN	O
grade	JJ	O
4	CD	O
)	)	O
,	,	O
and	CC	O
49	CD	O
%	NN	O
a	DT	O
documented	JJ	O
infection	NN	O
(	(	O
8	CD	O
%	NN	O
grade	JJ	O
4	CD	O
)	)	O
.	.	O

These	DT	O
results	NNS	O
obtained	VBD	O
with	IN	O
the	DT	O
LNH-84	JJ	O
regimen	NNS	O
demonstrate	VBP	O
that	IN	O
this	DT	O
therapeutic	JJ	O
scheme	NN	O
is	VBZ	O
an	DT	O
effective	JJ	O
treatment	NN	O
for	IN	O
aggressive	JJ	O
ML	NNP	O
.	.	O

The	DT	O
aging	VBG	O
motor	NN	O
system	NN	O
as	IN	O
a	DT	O
model	NN	O
for	IN	O
plastic	JJ	O
changes	NNS	O
of	IN	O
GABA-mediated	NNP	O
intracortical	JJ	O
inhibition	NN	O
and	CC	O
their	PRP$	O
behavioral	JJ	O
relevance	NN	O
.	.	O

Since	IN	O
GABAA-mediated	JJ	O
intracortical	JJ	O
inhibition	NN	O
has	VBZ	O
been	VBN	O
shown	VBN	O
to	TO	O
underlie	VB	O
plastic	NN	O
changes	NNS	O
throughout	IN	O
the	DT	O
lifespan	NN	O
from	IN	O
development	NN	O
to	TO	O
aging	VBG	O
,	,	O
here	RB	O
,	,	O
the	DT	O
aging	VBG	O
motor	NN	O
system	NN	O
was	VBD	O
used	VBN	O
as	IN	O
a	DT	O
model	NN	O
to	TO	O
analyze	VB	O
the	DT	O
interdependence	NN	O
of	IN	O
plastic	JJ	O
alterations	NNS	O
within	IN	O
the	DT	O
inhibitory	JJ	O
motorcortical	JJ	O
network	NN	O
and	CC	O
level	NN	O
of	IN	O
behavioral	JJ	O
performance	NN	O
.	.	O

Double-pulse	JJ	O
transcranial	JJ	O
magnetic	JJ	O
stimulation	NN	O
(	(	O
dpTMS	NN	O
)	)	O
was	VBD	O
used	VBN	O
to	TO	O
examine	VB	O
inhibition	NN	O
by	IN	O
means	NNS	O
of	IN	O
short-interval	JJ	O
intracortical	JJ	O
inhibition	NN	O
(	(	O
SICI	NNP	O
)	)	O
of	IN	O
the	DT	O
contralateral	JJ	O
primary	JJ	O
motor	NN	O
cortex	NN	O
in	IN	O
a	DT	O
sample	NN	O
of	IN	O
64	CD	O
healthy	JJ	O
right-handed	JJ	O
human	JJ	O
subjects	NNS	O
covering	VBG	O
a	DT	O
wide	JJ	O
range	NN	O
of	IN	O
the	DT	O
adult	NN	O
lifespan	NN	O
(	(	O
age	NN	O
range	NN	O
20-88	CD	O
years	NNS	O
,	,	O
mean	VB	O
47.6	CD	O
?	.	O
20.7	CD	O
,	,	O
34	CD	O
female	NN	O
)	)	O
.	.	O

SICI	NNP	O
was	VBD	O
evaluated	VBN	O
during	IN	O
resting	VBG	O
state	NN	O
and	CC	O
in	IN	O
an	DT	O
event-related	JJ	O
condition	NN	O
during	IN	O
movement	NN	O
preparation	NN	O
in	IN	O
a	DT	O
visually	RB	O
triggered	VBN	O
simple	JJ	O
reaction	NN	O
time	NN	O
task	NN	O
.	.	O

In	IN	O
a	DT	O
subgroup	NN	O
(	(	O
N	NNP	O
=	NNP	O
23	CD	O
)	)	O
,	,	O
manual	JJ	O
motor	NN	O
performance	NN	O
was	VBD	O
tested	VBN	O
with	IN	O
tasks	NNS	O
of	IN	O
graded	VBN	O
dexterous	JJ	O
demand	NN	O
.	.	O

Weak	JJ	O
resting-state	JJ	O
inhibition	NN	O
was	VBD	O
associated	VBN	O
with	IN	O
an	DT	O
overall	JJ	O
lower	JJR	O
manual	JJ	O
motor	NN	O
performance	NN	O
.	.	O

Better	RBR	O
event-related	JJ	O
modulation	NN	O
of	IN	O
inhibition	NN	O
correlated	VBN	O
with	IN	O
better	JJR	O
performance	NN	O
in	IN	O
more	RBR	O
demanding	JJ	O
tasks	NNS	O
,	,	O
in	IN	O
which	WDT	O
fast	RB	O
alternating	VBG	O
activation	NN	O
of	IN	O
cortical	JJ	O
representations	NNS	O
are	VBP	O
necessary	JJ	O
.	.	O

Declining	VBG	O
resting-state	JJ	O
inhibition	NN	O
was	VBD	O
associated	VBN	O
with	IN	O
weakened	JJ	O
event-related	JJ	O
modulation	NN	O
of	IN	O
inhibition	NN	O
.	.	O

Therefore	NN	O
,	,	O
reduced	VBD	O
resting-state	JJ	O
inhibition	NN	O
might	MD	O
lead	VB	O
to	TO	O
a	DT	O
subsequent	JJ	O
loss	NN	O
of	IN	O
modulatory	JJ	O
capacity	NN	O
,	,	O
possibly	RB	O
reflecting	VBG	O
malfunctioning	VBG	O
precision	NN	O
in	IN	O
GABAAergic	NNP	O
neurotransmission	NN	O
;	:	O
the	DT	O
consequence	NN	O
is	VBZ	O
an	DT	O
inevitable	JJ	O
decline	NN	O
in	IN	O
motor	NN	O
function	NN	O
.	.	O

Long	JJ	O
term	NN	O
follow	VBP	O
up	IN	O
of	IN	O
patients	NNS	O
treated	VBN	O
for	IN	O
Helicobacter	NNP	C
pylori	JJ	C
infection	NN	C
.	.	O

BACKGROUND	NNP	O
Helicobacter	NNP	O
pylori	POS	O
infection	NN	O
induces	NNS	O
progressive	JJ	O
inflammatory	JJ	O
changes	NNS	O
in	IN	O
the	DT	O
gastric	JJ	O
mucosa	NN	O
that	WDT	O
may	MD	O
lead	VB	O
to	TO	O
gastric	JJ	O
cancer	NN	O
.	.	O

Understanding	VBG	O
long	JJ	O
term	NN	O
effects	NNS	O
resulting	VBG	O
from	IN	O
the	DT	O
cure	NN	O
of	IN	O
this	DT	O
infection	NN	O
is	VBZ	O
needed	VBN	O
to	TO	O
design	VB	O
cancer	NN	O
prevention	NN	O
strategies	NNS	O
.	.	O

METHODS	NNP	O
A	NNP	O
cohort	NN	O
of	IN	O
795	CD	SS
adults	NNS	A
with	IN	O
preneoplastic	JJ	C
gastric	JJ	C
lesions	NNS	C
was	VBD	O
randomised	VBN	O
to	TO	O
receive	VB	O
anti-H	JJ	O
pylori	NN	O
treatment	NN	O
and/or	JJ	O
antioxidants	NNS	O
.	.	O

At	IN	O
the	DT	O
end	NN	O
of	IN	O
six	CD	O
years	NNS	O
of	IN	O
intervention	NN	O
,	,	O
those	DT	O
who	WP	O
did	VBD	O
not	RB	O
receive	VB	O
anti-H	JJ	O
pylori	NN	O
treatment	NN	O
were	VBD	O
offered	VBN	O
it	PRP	O
.	.	O

Gastric	JJ	O
biopsies	NNS	O
were	VBD	O
obtained	VBN	O
at	IN	O
baseline	NN	O
,	,	O
and	CC	O
at	IN	O
3	CD	O
,	,	O
6	CD	O
,	,	O
and	CC	O
12	CD	O
years	NNS	O
.	.	O

A	DT	O
histopathology	NN	O
score	NN	O
was	VBD	O
utilised	VBN	O
to	TO	O
document	VB	O
changes	NNS	O
in	IN	O
gastric	JJ	O
lesions	NNS	O
.	.	O

Non-linear	JJ	O
mixed	JJ	O
models	NNS	O
were	VBD	O
used	VBN	O
to	TO	O
estimate	VB	O
the	DT	O
cumulative	JJ	O
effect	NN	O
of	IN	O
H	NNP	O
pylori	JJ	O
clearance	NN	O
on	IN	O
histopathology	NN	O
scores	NNS	O
adjusted	VBN	O
for	IN	O
follow	VB	O
up	RP	O
time	NN	O
,	,	O
interventions	NNS	O
,	,	O
and	CC	O
confounders	NNS	O
.	.	O

RESULTS	NNP	O
Ninety	NNP	O
seven	CD	O
per	IN	O
cent	NN	O
of	IN	O
subjects	NNS	O
were	VBD	O
H	NNP	O
pylori	JJ	O
positive	JJ	O
at	IN	O
baseline	NN	O
,	,	O
and	CC	O
53	CD	O
%	NN	O
were	VBD	O
positive	JJ	O
at	IN	O
12	CD	O
years	NNS	O
.	.	O

Subjects	NNS	O
accumulated	JJ	O
1703	CD	O
person	NN	O
years	NNS	O
free	JJ	O
of	IN	O
infection	NN	O
.	.	O

A	DT	O
multivariate	NN	O
model	NN	O
showed	VBD	O
a	DT	O
significant	JJ	O
regression	NN	O
in	IN	O
histopathology	NN	O
score	NN	O
as	IN	O
a	DT	O
function	NN	O
of	IN	O
the	DT	O
square	NN	O
of	IN	O
H	NNP	O
pylori	FW	O
negative	JJ	O
time	NN	O
.	.	O

Subjects	NNS	O
who	WP	O
were	VBD	O
H	NNP	O
pylori	JJ	O
negative	JJ	O
had	VBD	O
14.8	CD	O
%	NN	O
more	JJR	O
regression	NN	O
and	CC	O
13.7	CD	O
%	NN	O
less	JJR	O
progression	NN	O
than	IN	O
patients	NNS	O
who	WP	O
were	VBD	O
positive	JJ	O
at	IN	O
12	CD	O
years	NNS	O
(	(	O
p	JJ	O
=	NNP	O
0.001	CD	O
)	)	O
.	.	O

The	DT	O
rate	NN	O
of	IN	O
healing	NN	O
of	IN	O
gastric	JJ	O
lesions	NNS	O
occurred	VBD	O
more	RBR	O
rapidly	RB	O
as	IN	O
years	NNS	O
free	JJ	O
of	IN	O
infection	NN	O
accumulated	VBN	O
,	,	O
and	CC	O
was	VBD	O
more	RBR	O
pronounced	JJ	O
in	IN	O
less	RBR	O
advanced	JJ	O
lesions	NNS	O
.	.	O

CONCLUSIONS	NNP	O
Preneoplastic	NNP	O
gastric	JJ	O
lesions	NNS	O
regress	NN	O
at	IN	O
a	DT	O
rate	NN	O
equal	JJ	O
to	TO	O
the	DT	O
square	NN	O
of	IN	O
time	NN	O
in	IN	O
patients	NNS	O
rendered	JJ	O
free	JJ	O
of	IN	O
H	NNP	O
pylori	JJ	O
infection	NN	O
.	.	O

Our	PRP$	O
findings	NNS	O
suggest	VBP	O
that	IN	O
patients	NNS	O
with	IN	O
preneoplastic	JJ	C
gastric	JJ	C
lesions	NNS	C
should	MD	O
be	VB	O
treated	VBN	O
and	CC	O
cured	VBN	O
of	IN	O
their	PRP$	O
H	NNP	O
pylori	NN	O
infection	NN	O
.	.	O

Aztreonam	NNP	O
versus	NN	O
gentamicin	NN	O
for	IN	O
short-term	JJ	O
prophylaxis	NN	O
in	IN	O
biliary	JJ	O
and	CC	O
gastric	JJ	O
surgery	NN	O
.	.	O

Short-term	NNP	O
antibiotic	JJ	O
prophylaxis	NN	O
was	VBD	O
studied	VBN	O
in	IN	O
80	CD	SS
patients	NNS	O
undergoing	JJ	O
biliary	JJ	O
or	CC	O
gastric	JJ	O
surgery	NN	O
.	.	O

The	DT	O
patients	NNS	O
were	VBD	O
randomized	VBN	O
to	TO	O
receive	VB	O
1	CD	O
g	NN	O
of	IN	O
aztreonam	NN	O
or	CC	O
80	CD	O
mg	NN	O
of	IN	O
gentamicin	NN	O
intravenously	RB	O
30	CD	O
minutes	NNS	O
before	IN	O
surgery	NN	O
and	CC	O
8	CD	O
and	CC	O
16	CD	O
hours	NNS	O
after	IN	O
surgery	NN	O
.	.	O

Of	IN	O
samples	NNS	O
taken	VBN	O
from	IN	O
the	DT	O
abdominal	JJ	O
cavity	NN	O
for	IN	O
bacteriologic	NN	O
study	NN	O
,	,	O
53	CD	O
%	NN	O
were	VBD	O
culture	NN	O
positive	JJ	O
.	.	O

Wound	IN	O
infections	NNS	O
developed	VBN	O
in	IN	O
two	CD	O
(	(	O
4.5	CD	O
%	NN	O
)	)	O
of	IN	O
44	CD	O
patients	NNS	O
receiving	VBG	O
aztreonam	NN	O
and	CC	O
in	IN	O
seven	CD	O
(	(	O
19.4	CD	O
%	NN	O
)	)	O
of	IN	O
36	CD	O
patients	NNS	O
treated	VBN	O
with	IN	O
gentamicin	NN	O
.	.	O

Staphylococcus	NNP	O
epidermidis	NN	O
and	CC	O
Enterobacter	NNP	O
species	NNS	O
were	VBD	O
isolated	VBN	O
from	IN	O
sites	NNS	O
of	IN	O
wound	JJ	O
infection	NN	O
in	IN	O
the	DT	O
aztreonam	JJ	O
group	NN	O
;	:	O
Escherichia	NNP	O
coli	NNS	O
(	(	O
two	CD	O
isolates	NNS	O
)	)	O
,	,	O
Pseudomonas	NNP	O
aeruginosa	NN	O
(	(	O
two	CD	O
isolates	NNS	O
)	)	O
,	,	O
Enterobacter	NNP	O
species	NNS	O
,	,	O
Klebsiella	NNP	O
species	NNS	O
,	,	O
Enterococcus	NNP	O
faecalis	NN	O
,	,	O
and	CC	O
Aeromonas	NNP	O
hydrophila	NN	O
were	VBD	O
isolated	VBN	O
from	IN	O
the	DT	O
gentamicin	NN	O
group	NN	O
.	.	O

Our	PRP$	O
data	NNS	O
indicate	VBP	O
that	IN	O
aztreonam	NN	O
is	VBZ	O
safe	JJ	O
and	CC	O
effective	JJ	O
for	IN	O
the	DT	O
prevention	NN	O
of	IN	O
infections	NNS	O
following	VBG	O
biliary	JJ	O
and	CC	O
gastric	JJ	O
surgery	NN	O
.	.	O

Improved	VBN	O
fibrinolysis	NN	O
after	IN	O
1-year	JJ	O
treatment	NN	O
with	IN	O
HMG	NNP	O
CoA	NNP	O
reductase	NN	O
inhibitors	NNS	O
in	IN	O
patients	NNS	C
with	IN	C
coronary	JJ	C
heart	NN	C
disease	NN	C
.	.	O

The	DT	O
study	NN	O
was	VBD	O
aimed	VBN	O
to	TO	O
investigate	VB	O
the	DT	O
effect	NN	O
of	IN	O
two	CD	O
different	JJ	O
statins	NNS	O
on	IN	O
the	DT	O
levels	NNS	O
of	IN	O
haemostatic	JJ	O
variables	NNS	O
reflecting	VBG	O
procoagulant	NN	O
and	CC	O
fibrinolytic	JJ	O
activity	NN	O
in	IN	O
patients	NNS	O
with	IN	O
coronary	JJ	O
heart	NN	O
disease	NN	O
(	(	O
CHD	NNP	O
)	)	O
,	,	O
with	IN	O
the	DT	O
hypothesis	NN	O
that	WDT	O
statins	VBZ	O
might	MD	O
beneficially	RB	O
modify	VB	O
these	DT	O
levels	NNS	O
.	.	O

Fifty-eight	JJ	SS
patients	NNS	SS
were	VBD	O
randomized	VBN	O
to	TO	O
treatment	NN	O
with	IN	O
atorvastatin	NN	O
(	(	O
n=28	JJ	O
)	)	O
or	CC	O
simvastatin	NN	O
(	(	O
n=30	JJ	O
)	)	O
for	IN	O
1	CD	O
year	NN	O
.	.	O

The	DT	O
starting	VBG	O
dose	NN	O
in	IN	O
both	DT	O
groups	NNS	O
was	VBD	O
20	CD	O
mg/day	NN	O
.	.	O

Fasting	VBG	O
blood	NN	O
samples	NNS	O
were	VBD	O
collected	VBN	O
before	IN	O
and	CC	O
after	IN	O
12-month	JJ	O
treatment	NN	O
for	IN	O
determinations	NNS	O
of	IN	O
fibrinogen	NN	O
,	,	O
prothrombin	JJ	O
fragment	NN	O
1+2	CD	O
(	(	O
F1+2	NNP	O
)	)	O
,	,	O
plasma	JJ	O
D-dimer	NNP	O
,	,	O
soluble	JJ	O
tissue	NN	O
factor	NN	O
,	,	O
tissue	NN	O
plasminogen	NN	O
activator	NN	O
(	(	O
tPA	NN	O
)	)	O
antigen	NN	O
,	,	O
tPA	NN	O
activity	NN	O
,	,	O
plasminogen	NN	O
activator	NN	O
inhibitor	JJ	O
type-1	JJ	O
activity	NN	O
(	(	O
PAI-1	NNP	O
activity	NN	O
)	)	O
and	CC	O
serum	JJ	O
D-dimer	NNP	O
as	IN	O
a	DT	O
global	JJ	O
test	NN	O
of	IN	O
fibrinolytic	JJ	O
activity	NN	O
.	.	O

In	IN	O
the	DT	O
total	JJ	O
population	NN	O
,	,	O
improved	VBN	O
fibrinolytic	JJ	O
activity	NN	O
was	VBD	O
observed	VBN	O
after	IN	O
1	CD	O
year	NN	O
with	IN	O
increased	JJ	O
levels	NNS	O
of	IN	O
serum	NN	O
D-dimer	NNP	O
(	(	O
P=.001	NNP	O
)	)	O
and	CC	O
tPA	JJ	O
activity	NN	O
(	(	O
P=.024	NNP	O
)	)	O
and	CC	O
a	DT	O
reduction	NN	O
in	IN	O
tPA	NN	O
antigen	NN	O
(	(	O
P=.048	NNP	O
)	)	O
.	.	O

No	DT	O
statistically	RB	O
significant	JJ	O
changes	NNS	O
were	VBD	O
observed	VBN	O
in	IN	O
any	DT	O
of	IN	O
the	DT	O
measured	JJ	O
coagulation	NN	O
variables	NNS	O
.	.	O

Separately	RB	O
examined	VBD	O
,	,	O
an	DT	O
improved	JJ	O
fibrinolytic	JJ	O
profile	NN	O
was	VBD	O
seen	VBN	O
in	IN	O
the	DT	O
atorvastatin	NN	O
group	NN	O
with	IN	O
a	DT	O
significant	JJ	O
increase	NN	O
in	IN	O
serum	JJ	O
D-dimer	NNP	O
(	(	O
P=.005	NNP	O
)	)	O
,	,	O
a	DT	O
borderline	JJ	O
increase	NN	O
in	IN	O
tPA	JJ	O
activity	NN	O
(	(	O
P=.083	NNP	O
)	)	O
and	CC	O
a	DT	O
borderline	NN	O
reduction	NN	O
in	IN	O
tPA	NN	O
antigen	NN	O
(	(	O
P=.069	NNP	O
)	)	O
.	.	O

Within	IN	O
the	DT	O
simvastatin	NN	O
group	NN	O
,	,	O
a	DT	O
reduction	NN	O
in	IN	O
prothrombin	NN	O
F1+2	NNP	O
was	VBD	O
observed	VBN	O
(	(	O
P=.038	NNP	O
)	)	O
.	.	O

The	DT	O
differences	NNS	O
in	IN	O
changes	NNS	O
between	IN	O
the	DT	O
groups	NNS	O
were	VBD	O
statistically	RB	O
significant	JJ	O
only	RB	O
for	IN	O
global	JJ	O
fibrinolysis	NN	O
(	(	O
serum	JJ	O
D-dimer	NNP	O
,	,	O
P=.046	NNP	O
)	)	O
.	.	O

In	IN	O
conclusion	NN	O
,	,	O
an	DT	O
improved	JJ	O
fibrinolytic	JJ	O
profile	NN	O
was	VBD	O
observed	VBN	O
after	IN	O
statin	NN	O
treatment	NN	O
,	,	O
most	RBS	O
pronounced	JJ	O
with	IN	O
atorvastatin	NN	O
.	.	O

The	DT	O
results	NNS	O
indicate	VBP	O
that	IN	O
the	DT	O
drugs	NNS	O
promote	VBP	O
a	DT	O
profibrinolytic	JJ	O
profile	NN	O
,	,	O
and	CC	O
may	MD	O
in	IN	O
part	NN	O
explain	VBP	O
the	DT	O
benefit	NN	O
of	IN	O
statin	NN	O
treatment	NN	O
rendered	VBN	O
in	IN	O
the	DT	O
prevention	NN	O
of	IN	O
CHD	NNP	O
.	.	O

Effects	NNS	O
of	IN	O
weight	JJ	O
reduction	NN	O
interventions	NNS	O
by	IN	O
community	NN	O
pharmacists	NNS	O
.	.	O

OBJECTIVE	NNP	O
To	TO	O
compare	VB	O
a	DT	O
meal	JJ	O
replacement	NN	O
(	(	O
MR	NNP	O
)	)	O
program	NN	O
with	IN	O
a	DT	O
conventional	JJ	O
reduced-calorie	JJ	O
diet	NN	O
(	(	O
RCD	NNP	O
)	)	O
for	IN	O
weight	NN	O
management	NN	O
using	VBG	O
the	DT	O
pharmacy	NN	O
as	IN	O
the	DT	O
setting	NN	O
and	CC	O
the	DT	O
pharmacist	NN	O
as	IN	O
the	DT	O
point	NN	O
of	IN	O
contact	NN	O
for	IN	O
dietary	JJ	O
advice	NN	O
.	.	O

DESIGN	NNP	O
Randomized	NNP	O
,	,	O
controlled	VBD	O
,	,	O
open-label	JJ	O
trial	NN	O
.	.	O

SETTING	NN	O
Travis	NNP	O
Pharmacy	NNP	O
in	IN	O
Shenandoah	NNP	O
,	,	O
Iowa	NNP	O
.	.	O

PATIENTS	NNP	O
Ninety-five	JJ	SS
patients	NNS	O
from	IN	O
southwestern	JJ	O
iowa	NN	O
and	CC	O
southeastern	JJ	O
Nebraska	NNP	O
were	VBD	O
enrolled	VBN	O
,	,	O
of	IN	O
whom	WP	O
88	CD	SS
were	VBD	O
considered	VBN	O
eligible	JJ	O
for	IN	O
comparison	NN	O
(	(	O
by	IN	O
continuing	VBG	O
through	IN	O
week	NN	O
2	CD	O
of	IN	O
the	DT	O
study	NN	O
)	)	O
.	.	O

INTERVENTION	JJ	O
Patients	NNPS	O
were	VBD	O
randomized	VBN	O
to	TO	O
an	DT	O
MR	NNP	O
plan	NN	O
or	CC	O
a	DT	O
traditional	JJ	O
RCD	NNP	O
plan	NN	O
.	.	O

Patients	NNS	O
were	VBD	O
followed	VBN	O
for	IN	O
a	DT	O
3-month	JJ	O
period	NN	O
of	IN	O
active	JJ	O
weight	JJ	O
loss	NN	O
and	CC	O
a	DT	O
10-week	JJ	O
period	NN	O
of	IN	O
weight	JJ	O
maintenance	NN	O
.	.	O

Patients	NNS	O
returned	VBD	O
every	DT	O
3	CD	O
weeks	NNS	O
for	IN	O
follow-up	NN	O
with	IN	O
the	DT	O
pharmacist	NN	O
,	,	O
for	IN	O
a	DT	O
total	NN	O
of	IN	O
13	CD	O
visits	NNS	O
.	.	O

MAIN	NNP	O
OUTCOME	NNP	O
MEASURE	NNP	O
Weight	NNP	O
changes	NNS	O
.	.	O

RESULTS	NNP	O
During	IN	O
the	DT	O
active	JJ	O
weight	NN	O
loss	NN	O
phase	NN	O
,	,	O
the	DT	O
MR	NNP	O
(	(	O
n	JJ	O
=	NNP	O
45	CD	O
)	)	O
and	CC	O
RCD	NNP	O
(	(	O
n	JJ	O
=	NNP	O
43	CD	O
)	)	O
groups	NNS	O
lost	VBD	O
a	DT	O
significant	JJ	O
amount	NN	O
of	IN	O
weight	NN	O
,	,	O
although	IN	O
no	DT	O
significant	JJ	O
difference	NN	O
was	VBD	O
found	VBN	O
between	IN	O
the	DT	O
groups	NNS	O
(	(	O
mean	JJ	O
+/-	JJ	O
standard	NN	O
error	NN	O
=	VBZ	O
4.90	CD	O
+/-	JJ	O
0.30	CD	O
kg	NN	O
MR	NNP	O
versus	NN	O
4.30	CD	O
+/-	JJ	O
0.30	CD	O
kg	NN	O
RCD	NNP	O
;	:	O
P	NNP	O
=	NNP	O
.16	NNP	O
)	)	O
.	.	O

In	IN	O
the	DT	O
weight	NN	O
maintenance	NN	O
phase	NN	O
,	,	O
the	DT	O
MR	NNP	O
group	NN	O
lost	VBD	O
0.70	CD	O
+/-	JJ	O
0.40	CD	O
kg	NN	O
and	CC	O
the	DT	O
RCD	NNP	O
group	NN	O
lost	VBD	O
0.90	CD	O
+/-	JJ	O
0.40	CD	O
kg	NN	O
(	(	O
P	NNP	O
=	NNP	O
.60	NNP	O
)	)	O
.	.	O

Significant	JJ	O
improvements	NNS	O
were	VBD	O
observed	VBN	O
in	IN	O
waist	JJ	O
circumference	NN	O
,	,	O
systolic	JJ	O
and	CC	O
diastolic	JJ	O
blood	NN	O
pressure	NN	O
,	,	O
and	CC	O
triglyceride	NN	O
levels	NNS	O
.	.	O

No	DT	O
significant	JJ	O
changes	NNS	O
were	VBD	O
seen	VBN	O
in	IN	O
high-density	NN	O
lipoprotein	NN	O
cholesterol	NN	O
or	CC	O
low-density	NN	O
lipoprotein	NNS	O
cholesterol	NN	O
levels	NNS	O
in	IN	O
either	DT	O
group	NN	O
.	.	O

CONCLUSION	NNP	O
Successful	NNP	O
weight	VBD	O
management	NN	O
can	MD	O
be	VB	O
achieved	VBN	O
in	IN	O
a	DT	O
pharmacy	NN	O
setting	NN	O
.	.	O

Both	DT	O
MR	NNP	O
and	CC	O
RCD	NNP	O
programs	NNS	O
were	VBD	O
effective	JJ	O
.	.	O

Randomized	VBN	O
trial	NN	O
of	IN	O
daily	JJ	O
versus	FW	O
weekly	JJ	O
administration	NN	O
of	IN	O
2-chlorodeoxyadenosine	JJ	O
in	IN	O
patients	NNS	C
with	IN	C
hairy	JJ	C
cell	NN	C
leukemia	NN	C
:	:	C
a	DT	C
multicenter	NN	C
phase	NN	C
III	NNP	C
trial	NN	C
(	(	C
SAKK	NNP	C
32/98	CD	C
)	)	C
.	.	C

Daily	JJ	O
administration	NN	O
of	IN	O
2-chlorodeoxyadenosine	JJ	O
(	(	O
Cladribine	NNP	O
,	,	O
CDA	NNP	O
)	)	O
is	VBZ	O
a	DT	O
standard	JJ	O
treatment	NN	O
for	IN	O
hairy	NN	O
cell	NN	O
leukemia	NN	O
,	,	O
but	CC	O
may	MD	O
cause	VB	O
severe	JJ	O
neutropenia	NN	O
and	CC	O
neutropenic	JJ	O
fever	NN	O
.	.	O

This	DT	O
trial	NN	O
compared	VBN	O
toxicity	NN	O
and	CC	O
efficacy	NN	O
of	IN	O
weekly	JJ	O
versus	NN	O
daily	RB	O
CDA	NNP	O
administration	NN	O
.	.	O

One	CD	O
hundred	VBD	O
patients	NNS	O
were	VBD	O
randomized	VBN	O
to	TO	O
receive	VB	O
standard	NN	O
(	(	O
CDA	NNP	O
0.14	CD	O
mg/kg/day	JJ	O
day	NN	O
1-5	JJ	O
[	NNP	O
Arm	NNP	O
A	NNP	O
]	NN	O
)	)	O
or	CC	O
experimental	JJ	O
treatment	NN	O
(	(	O
CDA	NNP	O
0.14	CD	O
mg/kg/day	NN	O
once	RB	O
weekly	JJ	O
for	IN	O
5	CD	O
weeks	NNS	O
[	JJ	O
Arm	NNP	O
B	NNP	O
]	NN	O
)	)	O
.	.	O

The	DT	O
primary	JJ	O
endpoint	NN	O
was	VBD	O
average	JJ	O
leukocyte	JJ	O
count	NN	O
within	IN	O
6	CD	O
weeks	NNS	O
from	IN	O
randomization	NN	O
.	.	O

Secondary	JJ	O
endpoints	NNS	O
included	VBD	O
response	NN	O
rates	NNS	O
,	,	O
other	JJ	O
acute	JJ	O
hematotoxicity	NN	O
,	,	O
acute	JJ	O
infection	NN	O
rate	NN	O
,	,	O
hospital	NN	O
admission	NN	O
,	,	O
remission	NN	O
duration	NN	O
,	,	O
event-free	JJ	O
,	,	O
and	CC	O
overall	JJ	O
survival	NN	O
.	.	O

There	EX	O
was	VBD	O
no	DT	O
significant	JJ	O
difference	NN	O
in	IN	O
average	JJ	O
leukocyte	JJ	O
count	NN	O
.	.	O

Response	JJ	O
rate	NN	O
(	(	O
complete	JJ	O
+	NNP	O
partial	JJ	O
remission	NN	O
)	)	O
at	IN	O
week	NN	O
10	CD	O
was	VBD	O
78	CD	O
%	NN	O
(	(	O
95	CD	O
%	NN	O
confidence	NN	O
interval	NN	O
(	(	O
CI	NNP	O
)	)	O
64-88	CD	O
%	NN	O
)	)	O
in	IN	O
Arm	NNP	O
A	NNP	O
and	CC	O
68	CD	O
%	NN	O
(	(	O
95	CD	O
%	NN	O
CI	NNP	O
54-80	CD	O
%	NN	O
)	)	O
in	IN	O
Arm	NNP	O
B	NNP	O
(	(	O
p	JJ	O
=	NNP	O
0.13	CD	O
)	)	O
.	.	O

Best	JJS	O
response	NN	O
rates	NNS	O
during	IN	O
follow-up	JJ	O
were	VBD	O
identical	JJ	O
(	(	O
86	CD	O
%	NN	O
)	)	O
in	IN	O
both	DT	O
arms	NNS	O
.	.	O

No	DT	O
significant	JJ	O
difference	NN	O
was	VBD	O
found	VBN	O
in	IN	O
the	DT	O
rate	NN	O
of	IN	O
grade	NN	O
3+4	CD	O
leukocytopenia	NN	O
(	(	O
94	CD	O
%	NN	O
vs	NN	O
.	.	O

84	CD	O
%	NN	O
)	)	O
,	,	O
grade	VBD	O
3+4	CD	O
neutropenia	NN	O
(	(	O
90	CD	O
%	NN	O
vs	NN	O
.	.	O

80	CD	O
%	NN	O
)	)	O
,	,	O
acute	JJ	O
infection	NN	O
(	(	O
44	CD	O
%	NN	O
vs	NN	O
.	.	O

40	CD	O
%	NN	O
)	)	O
,	,	O
hospitalization	NN	O
(	(	O
38	CD	O
%	NN	O
vs	NN	O
.	.	O

34	CD	O
%	NN	O
)	)	O
,	,	O
and	CC	O
erythrocyte	JJ	O
support	NN	O
(	(	O
22	CD	O
%	NN	O
vs	NN	O
.	.	O

30	CD	O
%	NN	O
)	)	O
within	IN	O
10	CD	O
weeks	NNS	O
.	.	O

Overall	JJ	O
,	,	O
these	DT	O
findings	NNS	O
indicate	VBP	O
that	IN	O
there	EX	O
are	VBP	O
no	DT	O
apparent	JJ	O
advantages	NNS	O
in	IN	O
toxicity	NN	O
and	CC	O
efficacy	NN	O
by	IN	O
giving	VBG	O
CDA	NNP	O
weekly	RB	O
rather	RB	O
than	IN	O
daily	RB	O
.	.	O

Activation	NN	O
and	CC	O
intermuscular	JJ	O
coherence	NN	O
of	IN	O
distal	JJ	O
arm	NN	O
muscles	NNS	O
during	IN	O
proximal	JJ	O
muscle	NN	O
contraction	NN	O
.	.	O

In	IN	O
the	DT	O
human	JJ	O
upper	JJ	O
extremity	NN	O
(	(	O
UE	NNP	O
)	)	O
,	,	O
unintended	JJ	O
effects	NNS	O
of	IN	O
proximal	JJ	O
muscle	NN	O
activation	NN	O
on	IN	O
muscles	NNS	O
controlling	VBG	O
the	DT	O
hand	NN	O
could	MD	O
be	VB	O
an	DT	O
important	JJ	O
aspect	NN	O
of	IN	O
motor	NN	O
control	NN	O
due	JJ	O
to	TO	O
the	DT	O
necessary	JJ	O
coordination	NN	O
of	IN	O
distal	NN	O
and	CC	O
proximal	JJ	O
segments	NNS	O
during	IN	O
functional	JJ	O
activities	NNS	O
.	.	O

This	DT	O
study	NN	O
aimed	VBD	O
to	TO	O
elucidate	VB	O
the	DT	O
effects	NNS	O
of	IN	O
concurrent	JJ	O
activation	NN	O
of	IN	O
elbow	NN	O
muscles	NNS	O
on	IN	O
the	DT	O
coordination	NN	O
between	IN	O
hand	NN	O
muscles	NNS	O
performing	VBG	O
a	DT	O
grip	NN	O
task	NN	O
.	.	O

Eleven	NNP	O
healthy	JJ	O
subjects	NNS	O
performed	VBN	O
precision	NN	O
grip	NN	O
tasks	NNS	O
while	IN	O
a	DT	O
constant	JJ	O
extension	NN	O
or	CC	O
flexion	NN	O
moment	NN	O
was	VBD	O
applied	VBN	O
to	TO	O
their	PRP$	O
elbow	NN	O
joints	NNS	O
,	,	O
inducing	VBG	O
a	DT	O
sustained	VBN	O
submaximal	JJ	O
contraction	NN	O
of	IN	O
elbow	NN	O
muscles	NNS	O
to	TO	O
counter	VB	O
the	DT	O
applied	JJ	O
torque	NN	O
.	.	O

Activation	NNP	O
of	IN	O
four	CD	O
hand	NN	O
muscles	NNS	O
was	VBD	O
measured	VBN	O
during	IN	O
each	DT	O
task	NN	O
condition	NN	O
using	VBG	O
surface	NN	O
electromyography	NN	O
(	(	O
EMG	NNP	O
)	)	O
.	.	O

When	WRB	O
concurrent	JJ	O
activation	NN	O
of	IN	O
elbow	NN	O
muscles	NNS	O
was	VBD	O
induced	VBN	O
,	,	O
significant	JJ	O
changes	NNS	O
in	IN	O
the	DT	O
activation	NN	O
levels	NNS	O
of	IN	O
the	DT	O
hand	NN	O
muscles	NNS	O
were	VBD	O
observed	VBN	O
,	,	O
with	IN	O
greater	JJR	O
effects	NNS	O
on	IN	O
the	DT	O
extrinsic	JJ	O
finger	NN	O
extensor	NN	O
(	(	O
23.2	CD	O
%	NN	O
increase	NN	O
under	IN	O
30	CD	O
%	NN	O
elbow	NN	O
extensor	NN	O
activation	NN	O
;	:	O
p	CC	O
=	VB	O
0.003	CD	O
)	)	O
than	IN	O
extrinsic	JJ	O
finger	NN	O
flexor	NN	O
(	(	O
14.2	CD	O
%	NN	O
increase	NN	O
under	IN	O
30	CD	O
%	NN	O
elbow	NN	O
flexor	JJ	O
activation	NN	O
;	:	O
p	CC	O
=	VB	O
0.130	CD	O
)	)	O
.	.	O

Elbow	NNP	O
muscle	NN	O
activation	NN	O
also	RB	O
induced	VBD	O
involuntary	JJ	O
changes	NNS	O
in	IN	O
the	DT	O
intrinsic	JJ	O
thumb	NN	O
flexor	NN	O
activation	NN	O
(	(	O
44.6	CD	O
%	NN	O
increase	NN	O
under	IN	O
30	CD	O
%	NN	O
elbow	NN	O
extensor	NN	O
activation	NN	O
;	:	O
p	CC	O
=	VB	O
0.005	CD	O
)	)	O
.	.	O

EMG-EMG	JJ	O
coherence	NN	O
analyses	NNS	O
revealed	VBD	O
that	IN	O
elbow	JJ	O
muscle	NN	O
activation	NN	O
significantly	RB	O
reduced	VBD	O
intermuscular	JJ	O
coherence	NN	O
between	IN	O
distal	JJ	O
muscle	NN	O
pairs	NNS	O
,	,	O
with	IN	O
its	PRP$	O
greatest	JJS	O
effects	NNS	O
on	IN	O
coherence	NN	O
in	IN	O
the	DT	O
?-band	NN	O
(	(	O
13-25	JJ	O
Hz	NNP	O
)	)	O
(	(	O
average	NN	O
of	IN	O
17	CD	O
%	NN	O
decrease	NN	O
under	IN	O
30	CD	O
%	NN	O
elbow	NN	O
flexor	JJ	O
activation	NN	O
)	)	O
.	.	O

The	DT	O
results	NNS	O
of	IN	O
this	DT	O
study	NN	O
provide	VBP	O
evidence	NN	O
for	IN	O
involuntary	JJ	O
,	,	O
muscle-specific	JJ	O
interactions	NNS	O
between	IN	O
distal	NN	O
and	CC	O
proximal	JJ	O
UE	NNP	O
muscles	NNS	O
,	,	O
which	WDT	O
may	MD	O
contribute	VB	O
to	TO	O
UE	NNP	O
motor	NN	O
performance	NN	O
in	IN	O
health	NN	O
and	CC	O
disease	NN	O
.	.	O

Effect	NN	O
of	IN	O
antipsychotic	JJ	O
drugs	NNS	O
on	IN	O
cortical	JJ	O
thickness	NN	O
.	.	O

A	DT	O
randomized	JJ	O
controlled	VBN	O
one-year	JJ	O
follow-up	NN	O
study	NN	O
of	IN	O
haloperidol	NN	O
,	,	O
risperidone	NN	O
and	CC	O
olanzapine	NN	O
.	.	O

BACKGROUND	NNP	O
Imaging	NNP	O
evidence	NN	O
indicates	VBZ	O
that	IN	O
brain	NN	O
alterations	NNS	O
are	VBP	O
primary	JJ	O
to	TO	O
the	DT	O
full-blown	JJ	O
onset	NN	O
of	IN	O
schizophrenia	NN	O
and	CC	O
seem	VBP	O
to	TO	O
progress	VB	O
across	IN	O
time	NN	O
.	.	O

The	DT	O
potential	JJ	O
effects	NNS	O
of	IN	O
antipsychotic	JJ	O
medication	NN	O
on	IN	O
brain	NN	O
structure	NN	O
represent	VBP	O
a	DT	O
key	JJ	O
factor	NN	O
in	IN	O
understanding	VBG	O
brain	NN	O
changes	NNS	O
in	IN	O
psychosis	NN	O
.	.	O

We	PRP	O
aimed	VBD	O
to	TO	O
investigate	VB	O
the	DT	O
effects	NNS	O
of	IN	O
low	JJ	O
doses	NNS	O
of	IN	O
haloperidol	NN	O
,	,	O
risperidone	NN	O
and	CC	O
olanzapine	NN	O
on	IN	O
cortical	JJ	O
thickness	NN	O
.	.	O

METHOD	NNP	O
We	PRP	O
investigated	VBD	O
the	DT	O
effects	NNS	O
of	IN	O
risperidone	NN	C
(	(	O
N=16	NNP	C
)	)	O
,	,	O
olanzapine	JJ	C
(	(	O
N=18	NNP	C
)	)	O
and	CC	O
low	JJ	O
doses	NNS	O
of	IN	O
haloperidol	NN	C
(	(	O
N=18	NNP	C
)	)	O
in	IN	O
cortical	JJ	O
thickness	NN	O
changes	NNS	O
during	IN	O
1-year	JJ	O
follow-up	JJ	O
period	NN	O
in	IN	O
a	DT	O
large	JJ	O
and	CC	O
heterogeneous	JJ	O
sample	NN	O
of	IN	O
schizophrenia	NN	C
spectrum	NN	C
patients	NNS	O
.	.	O

The	DT	O
relationship	NN	O
between	IN	O
cortical	JJ	O
thickness	NN	O
changes	NNS	O
and	CC	O
clinical	JJ	O
and	CC	O
cognitive	JJ	O
outcome	NN	O
was	VBD	O
also	RB	O
assessed	VBN	O
.	.	O

A	DT	O
group	NN	O
of	IN	O
45	CD	C
healthy	JJ	C
volunteers	NNS	O
was	VBD	O
also	RB	O
longitudinally	RB	O
evaluated	VBN	O
.	.	O

Magnetic	JJ	O
resonance	NN	O
imaging	VBG	O
brain	NN	O
scans	NNS	O
(	(	O
1.5T	CD	O
)	)	O
were	VBD	O
obtained	VBN	O
and	CC	O
images	NNS	O
were	VBD	O
analyzed	VBN	O
by	IN	O
using	VBG	O
BRAINS2	NNP	O
.	.	O

RESULTS	NNP	O
There	EX	O
were	VBD	O
no	DT	O
significant	JJ	O
effects	NNS	O
of	IN	O
time	NN	O
(	(	O
F	NNP	O
(	(	O
1,47	CD	O
)	)	O
<	NN	O
1.66	CD	O
;	:	O
P	NNP	O
>	NNP	O
0.204	CD	O
)	)	O
,	,	O
treatment	NN	O
group	NN	O
(	(	O
F	NNP	O
(	(	O
2,47	CD	O
)	)	O
<	NN	O
1.47	CD	O
;	:	O
P	NNP	O
>	NNP	O
0.242	CD	O
)	)	O
or	CC	O
group-by-time	JJ	O
interaction	NN	O
(	(	O
F	NNP	O
(	(	O
2,47	CD	O
)	)	O
<	NN	O
1.82	CD	O
;	:	O
P	NNP	O
>	NNP	O
0.174	CD	O
)	)	O
for	IN	O
any	DT	O
of	IN	O
the	DT	O
cortical	JJ	O
thickness	NN	O
variables	NNS	O
.	.	O

When	WRB	O
the	DT	O
group	NN	O
of	IN	O
healthy	JJ	O
controls	NNS	O
was	VBD	O
included	VBN	O
in	IN	O
the	DT	O
analyses	NNS	O
,	,	O
it	PRP	O
is	VBZ	O
of	IN	O
note	NN	O
that	IN	O
group-by-time	JJ	O
interaction	NN	O
showed	VBD	O
a	DT	O
significant	JJ	O
result	NN	O
for	IN	O
the	DT	O
frontal	JJ	O
lobe	NN	O
at	IN	O
trend	NN	O
level	NN	O
(	(	O
F	NNP	O
(	(	O
3,81	CD	O
)	)	O
=2.686	NN	O
;	:	O
P=0.052	NNP	O
)	)	O
.	.	O

After	IN	O
the	DT	O
Bonferroni	NNP	O
adjustment	NN	O
for	IN	O
multiple	JJ	O
comparisons	NNS	O
,	,	O
there	EX	O
were	VBD	O
no	DT	O
significant	JJ	O
associations	NNS	O
between	IN	O
changes	NNS	O
in	IN	O
cortical	JJ	O
thickness	NN	O
and	CC	O
clinical	JJ	O
and	CC	O
cognitive	JJ	O
outcome	NN	O
.	.	O

CONCLUSIONS	NNP	O
Low	NNP	O
doses	NNS	O
of	IN	O
haloperidol	NN	O
,	,	O
risperidone	NN	O
,	,	O
and	CC	O
olanzapine	NN	O
seem	VBP	O
to	TO	O
equally	RB	O
affect	VB	O
gray	JJ	O
matter	NN	O
cortical	JJ	O
thickness	NN	O
,	,	O
overall	JJ	O
and	CC	O
lobes	JJ	O
,	,	O
at	IN	O
the	DT	O
medium-term	NN	O
(	(	O
1	CD	O
year	NN	O
)	)	O
.	.	O

The	DT	O
clinical	JJ	O
effectiveness	NN	O
of	IN	O
treatments	NNS	O
was	VBD	O
not	RB	O
significantly	RB	O
related	VBN	O
to	TO	O
changes	NNS	O
in	IN	O
cortical	JJ	O
thickness	NN	O
.	.	O

A	DT	O
cost-benefit	JJ	O
comparison	NN	O
of	IN	O
intensive	JJ	O
diabetes	NNS	O
management	NN	O
with	IN	O
implantable	JJ	O
pumps	NNS	O
versus	IN	O
multiple	JJ	O
subcutaneous	JJ	O
injections	NNS	O
in	IN	O
patients	NNS	O
with	IN	O
type	NN	C
I	PRP	C
diabetes	VBZ	C
.	.	O

OBJECTIVE	NNP	O
To	TO	O
investigate	VB	O
if	IN	O
intraperitoneal	JJ	O
(	(	O
IP	NNP	O
)	)	O
insulin	NN	O
infusion	NN	O
via	IN	O
programmable	JJ	O
implantable	JJ	O
pumps	NNS	O
is	VBZ	O
a	DT	O
potential	JJ	O
alternative	NN	O
to	TO	O
subcutaneous	JJ	O
(	(	O
SC	NNP	O
)	)	O
insulin	NN	O
via	IN	O
multiple	JJ	O
injections	NNS	O
.	.	O

RESEARCH	NNP	O
DESIGN	NNP	O
AND	NNP	O
METHODS	NNP	O
We	PRP	O
compared	VBN	O
the	DT	O
cost-benefits	NNS	O
of	IN	O
the	DT	O
two	CD	O
methods	NNS	O
using	VBG	O
a	DT	O
randomized	VBN	O
,	,	O
prospective	JJ	O
,	,	O
6-month	JJ	O
,	,	O
crossover	JJ	O
design	NN	O
in	IN	O
10	CD	SS
adult	NN	A
type	NN	C
I	PRP	C
diabetic	JJ	C
patients	NNS	O
.	.	O

RESULTS	NNP	O
When	WRB	O
judged	VBN	O
on	IN	O
the	DT	O
last	JJ	O
month	NN	O
of	IN	O
IP	NNP	O
versus	NN	O
SC	NNP	O
periods	NNS	O
in	IN	O
the	DT	O
nine	CD	O
patients	NNS	O
who	WP	O
completed	VBD	O
the	DT	O
study	NN	O
,	,	O
metabolic	JJ	O
data	NN	O
showed	VBD	O
better	JJR	O
glycemic	JJ	O
control	NN	O
(	(	O
HbA1c	NNP	O
:	:	O
7.2	CD	O
+/-	JJ	O
0.2	CD	O
IP	NNP	O
vs.	FW	O
8.5	CD	O
+/-	JJ	O
0.7	CD	O
%	NN	O
SC	NNP	O
,	,	O
mean	JJ	O
+/-	JJ	O
SE	NNP	O
,	,	O
P	NNP	O
=	NNP	O
0.02	CD	O
)	)	O
,	,	O
reduced	VBN	O
glycemic	JJ	O
fluctuations	NNS	O
(	(	O
SD	NNP	O
of	IN	O
capillary	JJ	O
glucose	JJ	O
values	NNS	O
:	:	O
3.4	CD	O
+/-	JJ	O
0.2	CD	O
IP	NNP	O
vs.	FW	O
4.6	CD	O
+/-	JJ	O
0.2	CD	O
mM	NN	O
SC	NNP	O
,	,	O
P	NNP	O
<	NNP	O
0.01	CD	O
)	)	O
,	,	O
and	CC	O
fewer	JJR	O
mild	JJ	O
hypoglycemic	JJ	O
events	NNS	O
(	(	O
5.7	CD	O
+/-	JJ	O
2.0	CD	O
IP	NNP	O
vs.	FW	O
10.0	CD	O
+/-	JJ	O
3.1	CD	O
events/month	JJ	O
SC	NNP	O
,	,	O
P	NNP	O
=	NNP	O
0.02	CD	O
)	)	O
.	.	O

Quality	NN	O
of	IN	O
life	NN	O
,	,	O
judged	VBN	O
by	IN	O
Diabetes	NNP	O
Control	NNP	O
and	CC	O
Complications	NNP	O
Trial	NNP	O
questionnaires	NNS	O
,	,	O
was	VBD	O
unaffected	VBN	O
by	IN	O
pump	NN	O
therapy	NN	O
.	.	O

Direct	JJ	O
costs	NNS	O
,	,	O
including	VBG	O
pump	JJ	O
acquisition	NN	O
,	,	O
implantation	NN	O
,	,	O
and	CC	O
follow-up	NN	O
,	,	O
were	VBD	O
2.6-fold	JJ	O
higher	JJR	O
with	IN	O
IP	NNP	O
than	IN	O
with	IN	O
SC	NNP	O
delivery	NN	O
.	.	O

CONCLUSIONS	VB	O
The	DT	O
implantable	JJ	O
pump	NN	O
is	VBZ	O
more	RBR	O
effective	JJ	O
in	IN	O
the	DT	O
short	JJ	O
term	NN	O
,	,	O
equally	RB	O
accepted	VBN	O
,	,	O
but	CC	O
more	RBR	O
costly	JJ	O
than	IN	O
multiple	JJ	O
injections	NNS	O
and	CC	O
should	MD	O
be	VB	O
limited	VBN	O
to	TO	O
patients	NNS	O
with	IN	O
unsatisfactory	JJ	O
glycemic	JJ	O
control	NN	O
despite	IN	O
intensive	JJ	O
diabetes	NNS	O
management	NN	O
with	IN	O
SC	NNP	O
insulin	NN	O
.	.	O

In	IN	O
addition	NN	O
,	,	O
longer-term	JJ	O
,	,	O
larger-scale	JJ	O
,	,	O
and	CC	O
comparative	JJ	O
evaluation	NN	O
is	VBZ	O
required	VBN	O
.	.	O

The	DT	O
efficacy	NN	O
of	IN	O
melatonin	NN	O
for	IN	O
sleep	JJ	O
problems	NNS	O
in	IN	O
children	NNS	O
with	IN	O
autism	NN	O
,	,	O
fragile	JJ	O
X	NNP	O
syndrome	NN	O
,	,	O
or	CC	O
autism	NN	O
and	CC	O
fragile	JJ	O
X	NNP	O
syndrome	NN	O
.	.	O

STUDY	NNP	O
OBJECTIVE	NNP	O
To	TO	O
determine	VB	O
the	DT	O
efficacy	NN	O
of	IN	O
melatonin	NN	O
on	IN	O
sleep	NN	C
problems	NNS	C
in	IN	O
children	NNS	O
with	IN	O
autistic	JJ	O
spectrum	NN	O
disorder	NN	O
(	(	O
ASD	NNP	O
)	)	O
and	CC	O
fragile	JJ	O
X	NNP	O
syndrome	NN	O
(	(	O
FXS	NNP	O
)	)	O
.	.	O

METHODS	VB	O
A	DT	O
4-week	JJ	O
,	,	O
randomized	VBN	O
,	,	O
double	JJ	O
blind	NN	O
,	,	O
placebo-controlled	JJ	O
,	,	O
crossover	JJ	O
design	NN	O
was	VBD	O
conducted	VBN	O
following	VBG	O
a	DT	O
1-week	JJ	O
baseline	NN	O
period	NN	O
.	.	O

Either	CC	O
melatonin	NN	O
,	,	O
3	CD	O
mg	NN	O
,	,	O
or	CC	O
placebo	NN	O
was	VBD	O
given	VBN	O
to	TO	O
participants	NNS	O
for	IN	O
2	CD	O
weeks	NNS	O
and	CC	O
then	RB	O
alternated	VBD	O
for	IN	O
another	DT	O
2	CD	O
weeks	NNS	O
.	.	O

Sleep	JJ	O
variables	NNS	O
,	,	O
including	VBG	O
sleep	JJ	O
duration	NN	O
,	,	O
sleep-onset	JJ	O
time	NN	O
,	,	O
sleep-onset	JJ	O
latency	NN	O
time	NN	O
,	,	O
and	CC	O
the	DT	O
number	NN	O
of	IN	O
night	NN	O
awakenings	NNS	O
,	,	O
were	VBD	O
recorded	VBN	O
using	VBG	O
an	DT	O
Actiwatch	NN	O
and	CC	O
from	IN	O
sleep	JJ	O
diaries	NNS	O
completed	VBN	O
by	IN	O
parents	NNS	O
.	.	O

All	DT	O
participants	NNS	O
had	VBD	O
been	VBN	O
thoroughly	RB	O
assessed	VBN	O
for	IN	O
ASD	NNP	O
and	CC	O
also	RB	O
had	VBD	O
DNA	NNP	O
testing	VBG	O
for	IN	O
the	DT	O
diagnosis	NN	O
of	IN	O
FXS	NNP	O
.	.	O

RESULTS	NNP	O
Data	NNP	O
were	VBD	O
successfully	RB	O
obtained	VBN	O
from	IN	O
the	DT	O
12	CD	C
of	IN	O
18	CD	C
subjects	NNS	O
who	WP	O
completed	VBD	O
the	DT	O
study	NN	O
(	(	O
11	CD	C
males	NNS	O
,	,	O
age	NN	O
range	NN	O
2	CD	O
to	TO	O
15.25	CD	O
years	NNS	O
,	,	O
mean	JJ	O
5.47	CD	O
,	,	O
SD	NNP	O
3.6	CD	O
)	)	O
.	.	O

Five	CD	C
participants	NNS	O
met	VBD	O
diagnostic	JJ	O
criteria	NNS	O
for	IN	O
ASD	NNP	O
,	,	O
3	CD	O
for	IN	O
FXS	NNP	O
alone	RB	O
,	,	O
3	CD	O
for	IN	O
FXS	NNP	O
and	CC	O
ASD	NNP	O
,	,	O
and	CC	O
1	CD	O
for	IN	O
fragile	JJ	O
X	NNP	O
premutation	NN	O
.	.	O

Eight	CD	C
out	IN	O
of	IN	O
12	CD	C
had	VBD	O
melatonin	VBN	O
first	RB	O
.	.	O

The	DT	O
conclusions	NNS	O
from	IN	O
a	DT	O
nonparametric	JJ	O
repeated-measures	NNS	O
technique	NN	O
indicate	VBP	O
that	IN	O
mean	JJ	O
night	NN	O
sleep	NN	O
duration	NN	O
was	VBD	O
longer	RBR	O
on	IN	O
melatonin	NN	O
than	IN	O
placebo	NN	O
by	IN	O
21	CD	O
minutes	NNS	O
(	(	O
p	JJ	O
=	NNP	O
.02	NNP	O
)	)	O
,	,	O
mean	JJ	O
sleep-onset	JJ	O
latency	NN	O
was	VBD	O
shorter	JJR	O
by	IN	O
28	CD	O
minutes	NNS	O
(	(	O
p	JJ	O
=	NNP	O
.0001	NNP	O
)	)	O
,	,	O
and	CC	O
mean	VB	O
sleep-onset	JJ	O
time	NN	O
was	VBD	O
earlier	RB	O
by	IN	O
42	CD	O
minutes	NNS	O
(	(	O
p	JJ	O
=	NNP	O
.02	NNP	O
)	)	O
.	.	O

CONCLUSION	VB	O
The	DT	O
results	NNS	O
of	IN	O
this	DT	O
study	NN	O
support	VBD	O
the	DT	O
efficacy	NN	O
and	CC	O
tolerability	NN	O
of	IN	O
melatonin	NN	O
treatment	NN	O
for	IN	O
sleep	JJ	O
problems	NNS	O
in	IN	O
children	NNS	O
with	IN	O
ASD	NNP	O
and	CC	O
FXS	NNP	O
.	.	O

Humoral	NNP	O
immunity	NN	O
after	IN	O
kidney	NN	O
transplantation	NN	O
:	:	O
impact	NN	O
of	IN	O
two	CD	O
randomized	JJ	O
immunosuppressive	JJ	O
protocols	NNS	O
.	.	O

BACKGROUND	NNP	O
Controlling	NNP	O
alloimmune	JJ	O
humoral	JJ	O
response	NN	O
is	VBZ	O
a	DT	O
challenge	NN	O
in	IN	O
transplantation	NN	O
.	.	O

Few	JJ	O
studies	NNS	O
have	VBP	O
evaluated	VBN	O
the	DT	O
impact	NN	O
of	IN	O
maintenance	NN	O
immunosuppression	NN	O
on	IN	O
blood	NN	O
humoral	JJ	O
parameters	NNS	O
.	.	O

MATERIAL/METHODS	NNP	O
We	PRP	O
performed	VBD	O
a	DT	O
post-hoc	JJ	O
analysis	NN	O
on	IN	O
307	CD	O
kidney	NN	O
transplant	NN	O
recipients	NNS	O
included	VBD	O
in	IN	O
a	DT	O
prospective	JJ	O
randomized	VBN	O
trial	NN	O
comparing	VBG	O
tacrolimus/mycophenolate	NN	O
mofetil	NN	O
(	(	O
Tac/MMF	NNP	O
)	)	O
vs.	FW	O
cyclosporine/azathioprine	NN	O
(	(	O
CsA/AZA	NNP	O
)	)	O
,	,	O
both	DT	O
used	VBN	O
with	IN	O
antithymocyte	JJ	O
globulin	NN	O
induction	NN	O
and	CC	O
steroids	NNS	O
.	.	O

Humoral	JJ	O
parameters	NNS	O
were	VBD	O
analyzed	VBN	O
at	IN	O
D0	NNP	O
,	,	O
D15	NNP	O
,	,	O
and	CC	O
M12	NNP	O
.	.	O

RESULTS	NNP	O
IgG	NNP	O
,	,	O
IgA	NNP	O
,	,	O
and	CC	O
IgM	NNP	O
levels	NNS	O
decreased	VBN	O
significantly	RB	O
as	RB	O
soon	RB	O
as	IN	O
D15	NNP	O
in	IN	O
both	DT	O
groups	NNS	O
(	(	O
?35	CD	O
%	NN	O
,	,	O
?26	CD	O
%	NN	O
,	,	O
and	CC	O
?35	CD	O
%	NN	O
respectively	RB	O
,	,	O
vs.	FW	O
D0	NNP	O
)	)	O
.	.	O

At	IN	O
M12	NNP	O
,	,	O
although	IN	O
peripheral	JJ	O
B-cell	NNP	O
counts	NNS	O
did	VBD	O
not	RB	O
differ	VB	O
between	IN	O
the	DT	O
groups	NNS	O
,	,	O
Tac/MMF	NNP	O
regimen	NN	O
was	VBD	O
associated	VBN	O
with	IN	O
lower	JJR	O
IgG	NNP	O
,	,	O
IgA	NNP	O
,	,	O
and	CC	O
IgM	NNP	O
levels	NNS	O
than	IN	O
CsA/AZA	NNP	O
(	(	O
?5.9	CD	O
%	NN	O
,	,	O
?14.6	CD	O
%	NN	O
,	,	O
and	CC	O
?34	NNP	O
%	NN	O
,	,	O
respectively	RB	O
)	)	O
.	.	O

Hypogammaglobulinemia	NNP	O
at	IN	O
D15	NNP	O
was	VBD	O
not	RB	O
associated	VBN	O
with	IN	O
an	DT	O
increased	VBN	O
risk	NN	O
of	IN	O
infections	NNS	O
during	IN	O
the	DT	O
first	JJ	O
year	NN	O
.	.	O

The	DT	O
proportion	NN	O
of	IN	O
HLA-sensitized	JJ	O
patients	NNS	O
decreased	VBN	O
in	IN	O
the	DT	O
Tac/MMF	NNP	O
group	NN	O
(	(	O
15.9	CD	O
%	NN	O
at	IN	O
D0	NNP	O
and	CC	O
6.7	CD	O
%	NN	O
at	IN	O
M12	NNP	O
,	,	O
p=0.02	NN	O
)	)	O
and	CC	O
remained	VBD	O
stable	JJ	O
in	IN	O
the	DT	O
CsA/AZA	NNP	O
group	NN	O
(	(	O
10.3	CD	O
%	NN	O
at	IN	O
D0	NNP	O
and	CC	O
8.9	CD	O
%	NN	O
at	IN	O
M12	NNP	O
,	,	O
p=0.5	NN	O
)	)	O
.	.	O

More	JJR	O
patients	NNS	O
sensitized	VBN	O
at	IN	O
baseline	NN	O
became	VBD	O
non-sensitized	JJ	O
at	IN	O
M12	NNP	O
with	IN	O
Tac/MMF	NNP	O
than	IN	O
with	IN	O
CsA/AZA	NNP	O
.	.	O

CONCLUSIONS	NNP	O
Our	PRP$	O
results	NNS	O
suggest	VBP	O
humoral	JJ	O
immunosuppression	NN	O
is	VBZ	O
better	RBR	O
with	IN	O
Tac/MMF	NNP	O
than	IN	O
with	IN	O
CsA/AZA	NNP	O
during	IN	O
the	DT	O
first	JJ	O
year	NN	O
of	IN	O
kidney	NN	O
transplantation	NN	O
.	.	O

Evidence	NN	O
for	IN	O
poorer	JJR	O
outcome	NN	O
in	IN	O
patients	NNS	O
with	IN	O
severe	JJ	O
negative	JJ	O
trauma-related	JJ	O
cognitions	NNS	O
receiving	VBG	O
prolonged	JJ	O
exposure	NN	O
plus	CC	O
cognitive	JJ	O
restructuring	NN	O
:	:	O
implications	NNS	O
for	IN	O
treatment	NN	O
matching	NN	O
in	IN	O
posttraumatic	JJ	O
stress	NN	O
disorder	NN	O
.	.	O

In	IN	O
the	DT	O
current	JJ	O
article	NN	O
,	,	O
we	PRP	O
address	VBP	O
the	DT	O
existing	VBG	O
assumption	NN	O
in	IN	O
the	DT	O
literature	NN	O
on	IN	O
cognitive	JJ	O
behavioral	JJ	O
treatment	NN	O
of	IN	O
PTSD	NNP	O
that	IN	O
patients	NNS	O
with	IN	O
severe	JJ	O
negative	JJ	O
trauma-related	JJ	O
cognitions	NNS	O
would	MD	O
benefit	VB	O
more	RBR	O
from	IN	O
a	DT	O
treatment	NN	O
package	NN	O
that	WDT	O
includes	VBZ	O
exposure	NN	O
and	CC	O
cognitive	JJ	O
techniques	NNS	O
compared	VBN	O
with	IN	O
a	DT	O
treatment	NN	O
that	WDT	O
includes	VBZ	O
exposure	NN	O
only	RB	O
.	.	O

To	TO	O
test	VB	O
this	DT	O
assumption	NN	O
,	,	O
54	CD	O
PTSD	NN	O
patients	NNS	O
were	VBD	O
randomized	VBN	O
to	TO	O
prolonged	VB	O
exposure	NN	O
therapy	NN	O
or	CC	O
prolonged	JJ	O
exposure	NN	O
therapy	NN	O
plus	CC	O
cognitive	JJ	O
restructuring	NN	O
.	.	O

Contrary	NNP	O
to	TO	O
expectations	NNS	O
,	,	O
findings	NNS	O
revealed	VBD	O
that	IN	O
patients	NNS	O
characterized	VBN	O
by	IN	O
more	JJR	O
severe	JJ	O
pretreatment	NN	O
trauma-related	JJ	O
cognitions	NNS	O
(	(	O
and	CC	O
more	RBR	O
severe	JJ	O
pretreatment	NN	O
PTSD	NNP	O
symptoms	NNS	O
)	)	O
fared	VBD	O
slightly	RB	O
worse	JJR	O
in	IN	O
treatment	NN	O
combining	NN	O
exposure	NN	O
and	CC	O
cognitive	JJ	O
restructuring	NN	O
.	.	O

However	RB	O
,	,	O
there	EX	O
was	VBD	O
no	DT	O
relationship	NN	O
between	IN	O
pre-	NN	O
and	CC	O
post-treatment	JJ	O
measures	NNS	O
of	IN	O
negative	JJ	O
cognitions	NNS	O
and	CC	O
PTSD	NNP	O
symptoms	NNS	O
in	IN	O
the	DT	O
exposure	NN	O
alone	RB	O
group	NN	O
.	.	O

The	DT	O
implications	NNS	O
of	IN	O
these	DT	O
findings	NNS	O
for	IN	O
examining	VBG	O
Person	NNP	O
X	NNP	O
Treatment	NNP	O
interactions	NNS	O
and	CC	O
the	DT	O
efficacy	NN	O
of	IN	O
combining	VBG	O
treatments	NNS	O
for	IN	O
PTSD	NNP	O
are	VBP	O
discussed	VBN	O
.	.	O

Lack	NN	O
of	IN	O
antihistamine	NN	O
properties	NNS	O
of	IN	O
single	JJ	O
dose	JJ	O
cinnarizine	NN	O
in	IN	O
man	NN	C
.	.	C

A	DT	O
simple	JJ	O
way	NN	O
to	TO	O
study	VB	O
a	DT	O
histamine	JJ	O
antagonist	NN	O
in	IN	O
man	NN	O
is	VBZ	O
to	TO	O
observe	VB	O
the	DT	O
effect	NN	O
it	PRP	O
has	VBZ	O
on	IN	O
the	DT	O
magnitude	NN	O
of	IN	O
the	DT	O
skin	JJ	O
reaction	NN	O
to	TO	O
intradermal	JJ	O
histamine	NN	O
.	.	O

The	DT	O
aim	NN	O
of	IN	O
the	DT	O
present	JJ	O
study	NN	O
was	VBD	O
to	TO	O
evaluate	VB	O
the	DT	O
antihistamine	JJ	O
activity	NN	O
of	IN	O
single	JJ	O
oral	JJ	O
doses	NNS	O
of	IN	O
75	CD	O
mg	NNS	O
cinnarizine	VBP	O
using	VBG	O
75	CD	O
mg	JJ	O
diphenhydramine	NN	O
as	IN	O
control	NN	O
,	,	O
both	DT	O
being	VBG	O
compared	VBN	O
to	TO	O
placebo	VB	O
.	.	O

The	DT	O
study	NN	O
was	VBD	O
performed	VBN	O
with	IN	O
two	CD	O
groups	NNS	O
of	IN	O
5	CD	O
healthy	JJ	O
subjects	NNS	O
,	,	O
each	DT	O
group	NN	O
receiving	VBG	O
one	CD	O
of	IN	O
the	DT	O
active	JJ	O
treatments	NNS	O
or	CC	O
placebo	NN	O
randomly	RB	O
under	IN	O
blind	JJ	O
conditions	NNS	O
.	.	O

All	DT	O
subjects	NNS	O
received	VBN	O
intradermal	JJ	O
injections	NNS	O
on	IN	O
the	DT	O
forearm	NN	O
of	IN	O
a	DT	O
0.05	CD	O
ml	NN	O
saline	JJ	O
solution	NN	O
containing	VBG	O
5	CD	O
micrograms	NNS	O
of	IN	O
histamine	NN	O
before	IN	O
and	CC	O
at	IN	O
different	JJ	O
times	NNS	O
after	IN	O
drug	NN	O
intake	NN	O
.	.	O

The	DT	O
histamine-induced	JJ	O
wheal	JJ	O
area	NN	O
was	VBD	O
measured	VBN	O
and	CC	O
,	,	O
after	IN	O
drug	NN	O
administration	NN	O
,	,	O
the	DT	O
percent	NN	O
decrease	NN	O
of	IN	O
the	DT	O
wheal	JJ	O
area	NN	O
was	VBD	O
calculated	VBN	O
.	.	O

Results	NNS	O
showed	VBD	O
that	IN	O
diphenhydramine	NN	O
produced	VBD	O
a	DT	O
significant	JJ	O
inhibition	NN	O
of	IN	O
the	DT	O
histamine-induced	JJ	O
wheal	NN	O
size	NN	O
at	IN	O
1.5	CD	O
h	NN	O
which	WDT	O
lasted	VBD	O
up	RB	O
to	TO	O
4	CD	O
h	NNS	O
after	IN	O
drug	NN	O
administration	NN	O
,	,	O
reaching	VBG	O
maximum	JJ	O
inhibition	NN	O
at	IN	O
2.5	CD	O
h.	NN	O
After	IN	O
cinnarizine	NN	O
treatment	NN	O
no	DT	O
significant	JJ	O
decrease	NN	O
of	IN	O
the	DT	O
histamine-induced	JJ	O
wheal	JJ	O
area	NN	O
was	VBD	O
observed	VBN	O
at	IN	O
any	DT	O
time	NN	O
.	.	O

Dose	NNP	O
dependent	JJ	O
pharmacokinetics	NNS	O
of	IN	O
theophylline	NN	O
:	:	O
Michaelis-Menten	JJ	O
parameters	NNS	O
for	IN	O
its	PRP$	O
major	JJ	O
metabolic	JJ	O
pathways	NNS	O
.	.	O

Dose	NNP	O
Dependency	NNP	O
for	IN	O
pharmacokinetics	NNS	O
of	IN	O
theophylline	NN	O
and	CC	O
the	DT	O
formation	NN	O
of	IN	O
its	PRP$	O
major	JJ	O
metabolites	NNS	O
,	,	O
3-methylxanthine	JJ	O
(	(	O
3-MX	JJ	O
)	)	O
;	:	O
1-methyluric	JJ	O
acid	NN	O
(	(	O
1-MU	JJ	O
)	)	O
;	:	O
1,3-dimethyluric	JJ	O
acid	NN	O
(	(	O
DMU	NNP	O
)	)	O
,	,	O
were	VBD	O
examined	VBN	O
by	IN	O
administering	VBG	O
three	CD	O
single	JJ	O
oral	JJ	O
doses	NNS	O
(	(	O
250	CD	O
,	,	O
375	CD	O
,	,	O
500	CD	O
mg	NN	O
)	)	O
of	IN	O
theophylline	NN	O
to	TO	O
six	CD	SS
healthy	JJ	O
adult	NN	A
volunteers	NNS	O
.	.	O

The	DT	O
serum	NN	O
and	CC	O
urine	JJ	O
concentrations	NNS	O
of	IN	O
theophylline	NN	O
and	CC	O
the	DT	O
metabolites	NNS	O
in	IN	O
serum	NN	O
and	CC	O
urine	NN	O
were	VBD	O
determined	VBN	O
by	IN	O
high-performance	NN	O
liquid	NN	O
chromatography	NN	O
.	.	O

Total	JJ	O
clearance	NN	O
of	IN	O
theophylline	NN	O
decreased	VBN	O
and	CC	O
its	PRP$	O
half	JJ	O
life	NN	O
increased	VBD	O
over	IN	O
the	DT	O
range	NN	O
of	IN	O
doses	NNS	O
administered	VBN	O
(	(	O
p	JJ	O
<	NNP	O
0.01	CD	O
)	)	O
.	.	O

There	EX	O
was	VBD	O
a	DT	O
significant	JJ	O
dose	NN	O
related	JJ	O
decrease	NN	O
in	IN	O
the	DT	O
fractional	JJ	O
recovery	NN	O
of	IN	O
3-MX	JJ	O
and	CC	O
1-MU	JJ	O
(	(	O
p	JJ	O
<	NNP	O
0.001	CD	O
)	)	O
and	CC	O
a	DT	O
dose	NN	O
related	JJ	O
increase	NN	O
in	IN	O
fractional	JJ	O
excretion	NN	O
of	IN	O
DMU	NNP	O
and	CC	O
unchanged	JJ	O
theophylline	NN	O
(	(	O
p	JJ	O
<	NN	O
0.01	CD	O
and	CC	O
p	VB	O
<	JJ	O
0.001	CD	O
respectively	RB	O
)	)	O
.	.	O

No	DT	O
significant	JJ	O
dose	NN	O
related	VBN	O
changes	NNS	O
were	VBD	O
observed	VBN	O
in	IN	O
the	DT	O
renal	JJ	O
clearance	NN	O
of	IN	O
3-MX	JJ	O
,	,	O
1-MU	JJ	O
and	CC	O
DMU	NNP	O
,	,	O
indicating	VBG	O
linear	JJ	O
urinary	JJ	O
excretion	NN	O
kinetics	NNS	O
of	IN	O
the	DT	O
metabolites	NNS	O
.	.	O

Theophylline	NNP	O
metabolic	JJ	O
clearance	NN	O
to	TO	O
3-MX	JJ	O
as	RB	O
well	RB	O
as	IN	O
to	TO	O
1-MU	CD	O
decreased	VBN	O
with	IN	O
increasing	VBG	O
dose	NN	O
but	CC	O
clearance	NN	O
to	TO	O
DMU	NNP	O
remained	VBD	O
unnaffected	JJ	O
by	IN	O
the	DT	O
size	NN	O
of	IN	O
dose	NN	O
.	.	O

The	DT	O
individual	JJ	O
Michaelis-Menten	NNP	O
parameters	NNS	O
Km	NNP	O
and	CC	O
Vmax	NNP	O
were	VBD	O
estimated	VBN	O
for	IN	O
six	CD	O
subjects	NNS	O
receiving	VBG	O
three	CD	O
different	JJ	O
single	JJ	O
doses	NNS	O
.	.	O

The	DT	O
Km	NNP	O
values	NNS	O
for	IN	O
theophylline	JJ	O
metabolism	NN	O
to	TO	O
3-MX	JJ	O
,	,	O
1-MU	JJ	O
and	CC	O
DMU	NNP	O
were	VBD	O
2.4+/-0.6	JJ	O
,	,	O
5.1+/-1.8+/-	JJ	O
and	CC	O
112.3+/-36.8	JJ	O
mg/L	NN	O
respectively	RB	O
and	CC	O
the	DT	O
Vmax	NNP	O
values	NNS	O
were	VBD	O
3.5+/-0.7	JJ	O
,	,	O
7.5+/-2.6	JJ	O
and	CC	O
112.3+/-36.8	JJ	O
mg/hr	NN	O
respectively	RB	O
.	.	O

The	DT	O
Km	NNP	O
values	NNS	O
for	IN	O
the	DT	O
N-demethylation	NNP	O
pathways	NNS	O
(	(	O
3MX	CD	O
and	CC	O
1-MU	JJ	O
)	)	O
were	VBD	O
lower	JJR	O
corresponding	VBG	O
to	TO	O
therapeutic	JJ	O
serum	NN	O
concentrations	NNS	O
of	IN	O
drug	NN	O
.	.	O

These	DT	O
results	NNS	O
suggest	VBP	O
that	IN	O
the	DT	O
elimination	NN	O
kinetics	NNS	O
of	IN	O
theophylline	NN	O
is	VBZ	O
nonlinear	JJ	O
in	IN	O
the	DT	O
human	NN	O
in	IN	O
the	DT	O
therapeutic	JJ	O
range	NN	O
of	IN	O
serum	JJ	O
concenntrations	NNS	O
and	CC	O
can	MD	O
be	VB	O
explained	VBN	O
by	IN	O
saturable	JJ	O
formation	NN	O
kinetics	NNS	O
of	IN	O
3-MX	JJ	O
and	CC	O
1-MU	JJ	O
.	.	O

In	IN	O
contrast	NN	O
to	TO	O
previous	JJ	O
studies	NNS	O
we	PRP	O
did	VBD	O
n't	RB	O
find	VB	O
obvious	JJ	O
indication	NN	O
for	IN	O
nonlinear	JJ	O
formation	NN	O
of	IN	O
DMU	NNP	O
at	IN	O
therapeutic	JJ	O
concentration	NN	O
range	NN	O
.	.	O

Morphological	JJ	O
onset	NN	O
and	CC	O
early	JJ	O
diagnosis	NN	O
in	IN	O
apical	JJ	O
hypertrophic	JJ	O
cardiomyopathy	NN	O
:	:	O
a	DT	O
long	JJ	O
term	NN	O
analysis	NN	O
with	IN	O
nuclear	JJ	O
magnetic	JJ	O
resonance	NN	O
imaging	NN	O
.	.	O

OBJECTIVES	VB	O
A	DT	O
long-term	JJ	O
follow-up	NN	O
study	NN	O
with	IN	O
nuclear	JJ	O
magnetic	JJ	O
resonance	NN	O
(	(	O
NMR	NNP	O
)	)	O
imaging	NN	O
was	VBD	O
undertaken	VBN	O
to	TO	O
detect	VB	O
the	DT	O
morphological	JJ	O
onset	NN	O
and	CC	O
to	TO	O
establish	VB	O
the	DT	O
early	JJ	O
diagnosis	NN	O
in	IN	O
apical	JJ	O
hypertrophic	JJ	O
cardiomyopathy	NN	O
(	(	O
HCM	NNP	O
)	)	O
.	.	O

BACKGROUND	VB	O
A	DT	O
spadelike	JJ	O
configuration	NN	O
on	IN	O
left	JJ	O
ventriculogram	NN	O
(	(	O
LVG	NNP	O
)	)	O
is	VBZ	O
regarded	VBN	O
as	IN	O
a	DT	O
diagnostic	JJ	O
criterion	NN	O
for	IN	O
the	DT	O
classical	JJ	O
apical	JJ	O
HCM	NNP	O
.	.	O

There	EX	O
also	RB	O
exists	VBZ	O
a	DT	O
segmented	JJ	O
hypertrophy	NN	O
at	IN	O
the	DT	O
apical	JJ	O
level	NN	O
without	IN	O
indicating	VBG	O
the	DT	O
spadelike	NN	O
features	NNS	O
(	(	O
a	DT	O
nonspade	NN	O
configuration	NN	O
)	)	O
.	.	O

To	TO	O
detect	VB	O
the	DT	O
hypertrophied	JJ	O
myocardium	NN	O
of	IN	O
the	DT	O
nonspade	JJ	O
configuration	NN	O
,	,	O
circumferential	JJ	O
scrutiny	NN	O
of	IN	O
the	DT	O
apex	NN	O
is	VBZ	O
required	VBN	O
.	.	O

Although	IN	O
both	DT	O
configurations	NNS	O
can	MD	O
be	VB	O
underlying	JJ	O
causes	NNS	O
of	IN	O
giant	JJ	O
negative	JJ	O
T	NNP	O
waves	NNS	O
,	,	O
etiological	JJ	O
relationship	NN	O
between	IN	O
the	DT	O
two	CD	O
is	VBZ	O
not	RB	O
clarified	VBN	O
.	.	O

METHODS	NNP	O
The	DT	O
criteria	NN	O
for	IN	O
the	DT	O
spadelike	NN	O
configuration	NN	O
defined	VBN	O
on	IN	O
left	JJ	O
ventricular	JJ	O
short-axis	JJ	O
NMR	NNP	O
images	NNS	O
were	VBD	O
as	IN	O
follows	VBZ	O
:	:	O
(	(	O
apical	JJ	O
maximal	NN	O
thickness	NN	O
>	NN	O
or	CC	O
=	$	O
15	CD	O
mm	NN	O
)	)	O
,	,	O
(	(	O
apical	JJ	O
anterior	NN	O
thickness	NN	O
over	IN	O
basal	JJ	O
anterior	JJ	O
thickness	NN	O
>	NN	O
or	CC	O
=	VB	O
1.3	CD	O
)	)	O
and	CC	O
(	(	O
apical	JJ	O
posterior	NN	O
thickness	NN	O
over	IN	O
basal	JJ	O
posterior	JJ	O
thickness	NN	O
>	NN	O
or	CC	O
=1.3	NN	O
)	)	O
.	.	O

Thirteen	JJ	O
patients	NNS	O
who	WP	O
had	VBD	O
predominant	JJ	O
hypertrophy	NN	O
(	(	O
>	CD	O
or	CC	O
=	VB	O
15	CD	O
mm	NN	O
)	)	O
at	IN	O
the	DT	O
apical	JJ	O
level	NN	O
without	IN	O
the	DT	O
spadelike	NN	O
configuration	NN	O
underwent	JJ	O
NMR	NNP	O
imaging	VBG	O
twice	RB	O
before	RB	O
and	CC	O
after	IN	O
54+/-10	JJ	O
months	NNS	O
'	POS	O
follow-up	NN	O
.	.	O

RESULTS	NNP	O
Apical	NNP	O
hypertrophy	NN	O
that	WDT	O
had	VBD	O
been	VBN	O
confined	VBN	O
to	TO	O
the	DT	O
lateral	JJ	O
wall	NN	O
in	IN	O
four	CD	O
,	,	O
the	DT	O
anterior-lateral	JJ	O
wall	NN	O
in	IN	O
two	CD	O
,	,	O
and	CC	O
the	DT	O
septal-anterior	JJ	O
wall	NN	O
in	IN	O
one	CD	O
developed	NN	O
to	TO	O
become	VB	O
circumferential	JJ	O
hypertrophy	NN	O
that	WDT	O
fulfilled	VBD	O
the	DT	O
criteria	NNS	O
for	IN	O
the	DT	O
spadelike	NN	O
configuration	NN	O
after	IN	O
the	DT	O
follow-up	JJ	O
period	NN	O
.	.	O

CONCLUSIONS	VB	O
The	DT	O
spadelike	NN	O
configuration	NN	O
can	MD	O
begin	VB	O
with	IN	O
the	DT	O
nonspade	JJ	O
configuration	NN	O
and	CC	O
therefore	NN	O
,	,	O
both	DT	O
can	MD	O
constitute	VB	O
a	DT	O
single	JJ	O
disease	NN	O
entity	NN	O
of	IN	O
apical	JJ	O
HCM	NNP	O
.	.	O

The	DT	O
early	JJ	O
diagnosis	NN	O
of	IN	O
apical	JJ	O
HCM	NNP	O
can	MD	O
be	VB	O
achieved	VBN	O
by	IN	O
identifying	VBG	O
the	DT	O
hypertrophy	NN	O
frequently	RB	O
confined	VBN	O
to	TO	O
the	DT	O
lateral	JJ	O
wall	NN	O
at	IN	O
the	DT	O
apical	JJ	O
level	NN	O
.	.	O

Involvement	NN	O
of	IN	O
cholecystokininA	NN	O
receptors	NNS	O
in	IN	O
transient	NN	O
lower	JJR	O
esophageal	NN	O
sphincter	NN	O
relaxations	NNS	O
triggered	VBN	O
by	IN	O
gastric	JJ	O
distension	NN	O
.	.	O

OBJECTIVE	CC	O
Transient	NNP	O
lower	JJR	O
esophageal	NN	O
sphincter	NN	O
relaxations	NNS	O
(	(	O
TLESRs	NNP	O
)	)	O
are	VBP	O
the	DT	O
main	JJ	O
mechanism	NN	O
underlying	VBG	O
gastroesophageal	JJ	O
reflux	NN	O
.	.	O

In	IN	O
the	DT	O
present	JJ	O
study	NN	O
we	PRP	O
evaluated	VBD	O
the	DT	O
effect	NN	O
of	IN	O
loxiglumide	NN	O
,	,	O
a	DT	O
specific	JJ	O
cholecystokininA	NN	O
(	(	O
CCKA	NNP	O
)	)	O
-receptor	NN	O
antagonist	NN	O
,	,	O
on	IN	O
the	DT	O
occurrence	NN	O
of	IN	O
TLESRs	NNP	O
evoked	VBN	O
by	IN	O
gastric	JJ	O
distension	NN	O
.	.	O

METHODS	NNP	O
Eight	NNP	SS
healthy	JJ	C
subjects	NNS	O
underwent	JJ	O
esophageal	JJ	C
manometry	NN	C
using	VBG	O
a	DT	O
10-lumen	JJ	O
sleeve	NN	O
assembly	NN	O
during	IN	O
placebo	NN	O
or	CC	O
loxiglumide	NN	O
(	(	O
10	CD	O
mg/kg/h	NN	O
)	)	O
in	IN	O
a	DT	O
randomized	JJ	O
double-blind	JJ	O
order	NN	O
.	.	O

Gastric	NNP	O
distension	NN	O
was	VBD	O
induced	VBN	O
by	IN	O
inflation	NN	O
of	IN	O
400	CD	O
ml	NN	O
of	IN	O
air	NN	O
.	.	O

RESULTS	VB	O
Basal	NNP	O
lower	JJR	O
esophageal	NN	O
pressure	NN	O
(	(	O
LESP	NNP	O
)	)	O
and	CC	O
swallow-induced	JJ	O
relaxation	NN	O
were	VBD	O
not	RB	O
affected	VBN	O
by	IN	O
loxiglumide	NN	O
.	.	O

Loxiglumide	NNP	O
significantly	RB	O
reduced	VBD	O
the	DT	O
number	NN	O
of	IN	O
TLESRs	NNP	O
,	,	O
from	IN	O
11.5	CD	O
(	(	O
5.8-18.3	JJ	O
)	)	O
to	TO	O
6.0	CD	O
(	(	O
3.3-14.3	JJ	O
)	)	O
during	IN	O
the	DT	O
total	JJ	O
recording	JJ	O
period	NN	O
of	IN	O
1	CD	O
h	NN	O
,	,	O
and	CC	O
from	IN	O
5.5	CD	O
(	(	O
4.25-7.5	JJ	O
)	)	O
to	TO	O
2.0	CD	O
(	(	O
0.5-6.8	JJ	O
)	)	O
during	IN	O
the	DT	O
first	JJ	O
15	CD	O
min	NN	O
.	.	O

The	DT	O
number	NN	O
of	IN	O
common	JJ	O
cavities	NNS	O
was	VBD	O
significantly	RB	O
decreased	VBN	O
by	IN	O
loxiglumide	NN	O
,	,	O
from	IN	O
8.0	CD	O
(	(	O
4.0-20.0	JJ	O
)	)	O
to	TO	O
5.0	CD	O
(	(	O
2.0-7.8	JJ	O
)	)	O
.	.	O

TLESRs	NNP	O
represented	VBD	O
the	DT	O
main	JJ	O
mechanism	NN	O
(	(	O
60	CD	O
%	NN	O
during	IN	O
placebo	NN	O
,	,	O
74	CD	O
%	NN	O
during	IN	O
loxiglumide	NN	O
)	)	O
underlying	VBG	O
common	JJ	O
cavities	NNS	O
,	,	O
followed	VBN	O
by	IN	O
swallow-induced	JJ	O
relaxation	NN	O
.	.	O

CONCLUSIONS	NNP	O
Loxiglumide	NNP	O
significantly	RB	O
reduces	VBZ	O
the	DT	O
number	NN	O
of	IN	O
TLESRs	NNP	O
triggered	VBN	O
by	IN	O
gastric	JJ	O
distension	NN	O
without	IN	O
interfering	VBG	O
with	IN	O
swallow-related	JJ	O
relaxation	NN	O
of	IN	O
the	DT	O
lower	JJR	O
esophageal	NN	O
sphincter	NN	O
,	,	O
suggesting	VBG	O
the	DT	O
involvement	NN	O
of	IN	O
CCKA	NNP	O
receptors	NNS	O
in	IN	O
the	DT	O
reflex	JJ	O
pathway	NN	O
mediating	VBG	O
TLESRs	NNP	O
.	.	O

Domperidone	NN	O
,	,	O
metoclopramide	NN	O
,	,	O
and	CC	O
placebo	NN	O
.	.	O

All	DT	O
give	JJ	O
symptomatic	JJ	O
improvement	NN	O
in	IN	O
gastroesophageal	JJ	O
reflux	NN	O
.	.	O

A	DT	O
double-blind	JJ	O
crossover	NN	O
study	NN	O
was	VBD	O
conducted	VBN	O
of	IN	O
two	CD	O
gastric	JJ	O
prokinetic	JJ	O
drugs	NNS	O
in	IN	O
23	CD	SS
patients	NNS	SS
with	IN	O
gastroesophageal	JJ	C
reflux	NN	C
.	.	O

Patients	NNS	O
were	VBD	O
divided	VBN	O
into	IN	O
two	CD	O
groups	NNS	O
on	IN	O
the	DT	O
basis	NN	O
of	IN	O
a	DT	O
dual-isotope	JJ	O
mixed-meal	JJ	O
study	NN	O
of	IN	O
their	PRP$	O
gastric	JJ	O
emptying	NN	O
(	(	O
GE	NNP	O
)	)	O
.	.	O

Group	NNP	O
I	PRP	O
had	VBD	O
normal	JJ	O
GE	NNP	O
and	CC	O
group	NN	O
II	NNP	O
delayed	VBD	O
GE	NNP	O
.	.	O

Nine	NNP	O
gastrointestinal	JJ	O
symptoms	NNS	O
were	VBD	O
assessed	VBN	O
for	IN	O
frequency	NN	O
and	CC	O
severity	NN	O
before	IN	O
treatment	NN	O
.	.	O

The	DT	O
trial	NN	O
had	VBD	O
three	CD	O
1-month	JJ	O
treatment	NN	O
periods	NNS	O
using	VBG	O
metoclopramide	RB	O
10	CD	O
mg	NN	O
q.i.d.	NN	O
,	,	O
domperidone	NN	O
20	CD	O
mg	NN	O
q.i.d.	NN	O
,	,	O
or	CC	O
placebo	NN	O
on	IN	O
a	DT	O
random	JJ	O
basis	NN	O
.	.	O

Symptoms	NNS	O
were	VBD	O
reassessed	VBN	O
at	IN	O
the	DT	O
end	NN	O
of	IN	O
each	DT	O
month	NN	O
.	.	O

Taken	NNP	O
as	IN	O
a	DT	O
whole	NN	O
,	,	O
the	DT	O
group	NN	O
showed	VBD	O
a	DT	O
significant	JJ	O
symptomatic	JJ	O
response	NN	O
in	IN	O
all	DT	O
three	CD	O
treatment	NN	O
periods	NNS	O
(	(	O
p	NN	O
less	JJR	O
than	IN	O
0.0001	CD	O
)	)	O
,	,	O
but	CC	O
patients	NNS	O
with	IN	O
delayed	JJ	O
or	CC	O
normal	JJ	O
GE	NNP	O
did	VBD	O
not	RB	O
differ	VB	O
significantly	RB	O
in	IN	O
their	PRP$	O
symptomatic	JJ	O
response	NN	O
.	.	O

Eleven	JJ	O
patients	NNS	O
complained	VBD	O
of	IN	O
side	NN	O
effects	NNS	O
with	IN	O
metoclopramide	NN	O
and	CC	O
three	CD	O
stopped	VBD	O
therapy	NN	O
before	IN	O
the	DT	O
1-month	JJ	O
course	NN	O
was	VBD	O
completed	VBN	O
.	.	O

Two	CD	O
patients	NNS	O
described	JJ	O
side	JJ	O
effects	NNS	O
with	IN	O
domperidone	NN	O
,	,	O
including	VBG	O
one	CD	O
woman	NN	O
with	IN	O
galactorrhea	NN	O
after	IN	O
36	CD	O
h	NN	O
of	IN	O
treatment	NN	O
.	.	O

Three	CD	O
patients	NNS	O
on	IN	O
placebo	NN	O
also	RB	O
complained	VBD	O
of	IN	O
important	JJ	O
side	NN	O
effects	NNS	O
.	.	O

We	PRP	O
conclude	VBP	O
that	IN	O
a	DT	O
significant	JJ	O
placebo	NN	O
effect	NN	O
is	VBZ	O
present	JJ	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
gastroesophageal	JJ	O
reflux	NN	O
.	.	O

No	DT	O
significant	JJ	O
difference	NN	O
was	VBD	O
demonstrated	VBN	O
in	IN	O
symptomatic	JJ	O
improvement	NN	O
between	IN	O
placebo	NN	O
,	,	O
domperidone	NN	O
,	,	O
and	CC	O
metoclopramide	RB	O
in	IN	O
this	DT	O
study	NN	O
.	.	O

Exposure	NN	O
reduced	VBN	O
agoraphobia	NNS	O
but	CC	O
not	RB	O
panic	JJ	O
,	,	O
and	CC	O
cognitive	JJ	O
therapy	NN	O
reduced	VBD	O
panic	JJ	O
but	CC	O
not	RB	O
agoraphobia	RB	O
.	.	O

Earlier	JJR	O
studies	NNS	O
showed	VBD	O
that	IN	O
cognitive	JJ	O
therapy	NN	O
has	VBZ	O
anti-panic	JJ	O
effects	NNS	O
and	CC	O
exposure	NN	O
has	VBZ	O
anti-agoraphobic	JJ	O
effects	NNS	O
while	IN	O
other	JJ	O
studies	NNS	O
suggest	VBP	O
that	IN	O
agoraphobia	NN	O
is	VBZ	O
a	DT	O
secondary	JJ	O
complication	NN	O
of	IN	O
panic	JJ	O
disorder	NN	O
.	.	O

It	PRP	O
was	VBD	O
therefore	RB	O
hypothesized	VBN	O
that	IN	O
cognitive	JJ	O
therapy	NN	O
not	RB	O
only	RB	O
reduces	VBZ	O
panic	NN	O
but	CC	O
also	RB	O
agoraphobia	JJ	O
and	CC	O
that	IN	O
it	PRP	O
potentiates	VBZ	O
the	DT	O
effects	NNS	O
of	IN	O
exposure	NN	O
in	IN	O
vivo	NN	O
.	.	O

Two	CD	O
groups	NNS	O
of	IN	O
12	CD	SS
severe	JJ	O
agoraphobics	NNS	O
were	VBD	O
treated	VBN	O
with	IN	O
4	CD	O
sessions	NNS	O
of	IN	O
cognitive	JJ	O
therapy	NN	O
followed	VBN	O
by	IN	O
8	CD	O
sessions	NNS	O
of	IN	O
cognitive	JJ	O
therapy	NN	O
combined	VBN	O
with	IN	O
in	IN	O
vivo	NN	O
exposure	NN	O
.	.	O

The	DT	O
other	JJ	O
12	CD	SS
received	VBD	O
4	CD	O
sessions	NNS	O
of	IN	O
'associative	JJ	O
therapy	NN	O
'	''	O
,	,	O
a	DT	O
presumably	RB	O
inert	JJ	O
treatment	NN	O
that	WDT	O
controls	VBZ	O
for	IN	O
therapist	NN	O
attention	NN	O
,	,	O
followed	VBN	O
by	IN	O
8	CD	O
sessions	NNS	O
of	IN	O
in	IN	O
vivo	NN	O
exposure	NN	O
that	WDT	O
was	VBD	O
framed	VBN	O
in	IN	O
common	JJ	O
behavioral	JJ	O
terms	NNS	O
.	.	O

The	DT	O
initial	JJ	O
cognitive	JJ	O
therapy	NN	O
produced	VBD	O
a	DT	O
significant	JJ	O
reduction	NN	O
in	IN	O
panic	JJ	O
frequency	NN	O
,	,	O
while	IN	O
associative	JJ	O
therapy	NN	O
did	VBD	O
not	RB	O
affect	VB	O
panic	NN	O
.	.	O

Neither	CC	O
cognitive	JJ	O
therapy	NN	O
alone	RB	O
,	,	O
nor	CC	O
associate	JJ	O
therapy	NN	O
alone	RB	O
significantly	RB	O
reduced	VBN	O
depression	NN	O
,	,	O
state	NN	O
or	CC	O
trait	NN	O
anxiety	NN	O
,	,	O
self-rated	JJ	O
agoraphobia	NN	O
or	CC	O
behavioral	JJ	O
avoidance	NN	O
.	.	O

After	IN	O
adding	VBG	O
exposure	NN	O
however	RB	O
,	,	O
these	DT	O
parameters	NNS	O
were	VBD	O
clearly	RB	O
and	CC	O
significantly	RB	O
reduced	VBN	O
.	.	O

Cognitive	JJ	O
therapy	NN	O
did	VBD	O
not	RB	O
potentiate	VB	O
exposure	NN	O
effects	NNS	O
.	.	O

The	DT	O
results	NNS	O
are	VBP	O
discussed	VBN	O
.	.	O

The	DT	O
effect	NN	O
of	IN	O
phenytoin	NN	O
on	IN	O
the	DT	O
absorption	NN	O
of	IN	O
synthetic	JJ	O
folic	JJ	O
acid	NN	O
polyglutamate	NN	O
.	.	O

The	DT	O
absorption	NN	O
of	IN	O
synthetic	JJ	O
pteroyltriglutamate	NN	O
has	VBZ	O
been	VBN	O
measured	VBN	O
in	IN	O
nine	CD	O
normal	JJ	O
students	NNS	O
with	IN	O
and	CC	O
without	IN	O
the	DT	O
anticonvulsant	JJ	O
drug	NN	O
phenytoin	NN	O
.	.	O

It	PRP	O
has	VBZ	O
been	VBN	O
shown	VBN	O
that	IN	O
phenytoin	NN	O
has	VBZ	O
no	DT	O
effect	NN	O
on	IN	O
the	DT	O
absorption	NN	O
of	IN	O
this	DT	O
folate	JJ	O
polyglutamate	NN	O
.	.	O

The	DT	O
reasons	NNS	O
are	VBP	O
discussed	VBN	O
for	IN	O
the	DT	O
disparity	NN	O
between	IN	O
this	DT	O
result	NN	O
and	CC	O
those	DT	O
reported	VBN	O
in	IN	O
the	DT	O
literature	NN	O
when	WRB	O
folate	NN	O
polyglutamates	NNS	O
derived	VBN	O
from	IN	O
yeast	NN	O
were	VBD	O
used	VBN	O
.	.	O

Phase	NNP	O
III	NNP	O
study	NN	O
of	IN	O
two	CD	O
different	JJ	O
dosing	VBG	O
schedules	NNS	O
of	IN	O
erythropoietin	NN	O
in	IN	O
anemic	JJ	C
patients	NNS	C
with	IN	C
cancer	NN	C
.	.	O

PURPOSE	NNP	O
To	TO	O
compare	VB	O
maintenance	NN	O
epoetin	NN	O
alfa	NN	O
administered	VBD	O
once	RB	O
every	DT	O
3	CD	O
weeks	NNS	O
with	IN	O
continued	JJ	O
weekly	JJ	O
epoetin	NN	O
alfa	NN	O
for	IN	O
patients	NNS	O
with	IN	O
cancer-associated	JJ	C
anemia	NN	C
.	.	O

PATIENTS	NNP	O
AND	CC	O
METHODS	NNP	O
Eligible	JJ	O
patients	NNS	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
at	IN	O
enrollment	NN	O
to	TO	O
receive	VB	O
three	CD	O
weekly	JJ	O
doses	NNS	O
of	IN	O
epoetin	NN	O
alfa	NN	O
40,000	CD	O
U	NNP	O
subcutaneously	RB	O
(	(	O
SC	NNP	O
)	)	O
,	,	O
followed	VBN	O
by	IN	O
either	DT	O
standard	JJ	O
weekly	JJ	O
epoetin	NN	O
alfa	NN	O
(	(	O
40K	CD	O
arm	NN	O
)	)	O
or	CC	O
120,000	CD	O
U	NNP	O
of	IN	O
epoetin	NN	O
alfa	NN	O
(	(	O
120K	CD	O
arm	NN	O
)	)	O
SC	NNP	O
every	DT	O
3	CD	O
weeks	NNS	O
for	IN	O
18	CD	O
additional	JJ	O
weeks	NNS	O
.	.	O

RESULTS	NNP	O
Three	CD	SS
hundred	VBD	SS
sixty-five	JJ	SS
patients	NNS	SS
were	VBD	O
enrolled	VBN	O
.	.	O

One	CD	O
hundred	VBD	O
eighty-three	JJ	O
patients	NNS	O
were	VBD	O
assigned	VBN	O
to	TO	O
the	DT	O
40K	CD	O
arm	NN	O
,	,	O
and	CC	O
182	CD	O
were	VBD	O
assigned	VBN	O
to	TO	O
the	DT	O
120K	CD	O
arm	NN	O
.	.	O

There	EX	O
was	VBD	O
no	DT	O
difference	NN	O
in	IN	O
the	DT	O
proportion	NN	O
of	IN	O
patients	NNS	O
requiring	VBG	O
transfusions	NNS	O
during	IN	O
the	DT	O
study	NN	O
(	(	O
23	CD	O
%	NN	O
in	IN	O
40K	CD	O
arm	NN	O
and	CC	O
18	CD	O
%	NN	O
in	IN	O
120K	CD	O
arm	NN	O
,	,	O
P	NNP	O
=	NNP	O
.22	NNP	O
)	)	O
or	CC	O
specifically	RB	O
during	IN	O
the	DT	O
maintenance	NN	O
phase	NN	O
(	(	O
13	CD	O
%	NN	O
in	IN	O
40K	CD	O
arm	NN	O
v	NN	O
15	CD	O
%	NN	O
in	IN	O
120K	CD	O
arm	NN	O
,	,	O
P	NNP	O
=	NNP	O
.58	NNP	O
)	)	O
.	.	O

Patients	NNS	O
randomly	RB	O
assigned	VBN	O
to	TO	O
the	DT	O
40K	CD	O
arm	NN	O
were	VBD	O
more	RBR	O
likely	JJ	O
to	TO	O
have	VB	O
a	DT	O
>	NN	O
or	CC	O
=	VB	O
2	CD	O
or	CC	O
>	CD	O
or	CC	O
=	VB	O
3	CD	O
g/dL	NN	O
hemoglobin	NN	O
(	(	O
Hb	NNP	O
)	)	O
increment	NN	O
,	,	O
were	VBD	O
more	RBR	O
likely	JJ	O
to	TO	O
have	VB	O
a	DT	O
drug	NN	O
dose	RB	O
held	VBD	O
because	IN	O
of	IN	O
high	JJ	O
Hb	NNP	O
,	,	O
and	CC	O
had	VBD	O
higher	JJR	O
mean	JJ	O
end-of-study	JJ	O
Hb	NNP	O
levels	NNS	O
.	.	O

Toxicities	NNS	O
,	,	O
including	VBG	O
thromboembolism	NN	O
,	,	O
and	CC	O
overall	JJ	O
survival	NN	O
were	VBD	O
similar	JJ	O
.	.	O

Patients	NNS	O
in	IN	O
the	DT	O
40K	CD	O
arm	NN	O
had	VBD	O
a	DT	O
higher	JJR	O
global	JJ	O
quality	NN	O
of	IN	O
life	NN	O
(	(	O
QOL	NNP	O
)	)	O
at	IN	O
baseline	NN	O
for	IN	O
unclear	JJ	O
reasons	NNS	O
,	,	O
whereas	JJ	O
patients	NNS	O
in	IN	O
the	DT	O
120K	CD	O
arm	NN	O
had	VBD	O
a	DT	O
greater	JJR	O
global	JJ	O
QOL	NNP	O
improvement	NN	O
during	IN	O
the	DT	O
study	NN	O
,	,	O
so	IN	O
end-of-study	JJ	O
QOL	NNP	O
was	VBD	O
equivalent	JJ	O
.	.	O

CONCLUSION	NN	O
After	IN	O
three	CD	O
weekly	JJ	O
doses	NNS	O
of	IN	O
epoetin	NN	O
alfa	NN	O
40,000	CD	O
U	NNP	O
,	,	O
a	DT	O
dose	NN	O
of	IN	O
120,000	CD	O
U	NNS	O
can	MD	O
be	VB	O
administered	VBN	O
safely	RB	O
once	RB	O
every	DT	O
3	CD	O
weeks	NNS	O
without	IN	O
increasing	VBG	O
transfusion	NN	O
needs	NNS	O
or	CC	O
sacrificing	VBG	O
QOL	NNP	O
.	.	O

The	DT	O
Hb	NNP	O
increment	NN	O
is	VBZ	O
somewhat	RB	O
greater	JJR	O
with	IN	O
continued	JJ	O
weekly	JJ	O
epoetin	NN	O
alfa	NN	O
.	.	O

Lack	NNP	O
of	IN	O
blinding	VBG	O
as	IN	O
a	DT	O
result	NN	O
of	IN	O
different	JJ	O
treatment	NN	O
schedules	NNS	O
may	MD	O
have	VB	O
confounded	VBN	O
results	NNS	O
.	.	O

Effect	NN	O
of	IN	O
sport-tinted	JJ	O
contact	NN	O
lenses	NNS	O
for	IN	O
contrast	NN	O
enhancement	NN	O
on	IN	O
retinal	JJ	O
straylight	NN	O
measurements	NNS	O
.	.	O

PURPOSE	NNP	O
To	TO	O
investigate	VB	O
the	DT	O
effect	NN	O
of	IN	O
two	CD	O
tinted	JJ	O
contact	NN	O
lenses	NNS	O
(	(	O
CL	NNP	O
)	)	O
designed	VBN	O
for	IN	O
outdoor	JJ	O
sports	NNS	O
activity	NN	O
on	IN	O
the	DT	O
psychometric	JJ	O
determination	NN	O
of	IN	O
retinal	JJ	O
straylight	NN	O
using	VBG	O
the	DT	O
compensation	NN	O
comparison	NN	O
method	NN	O
.	.	O

METHODS	NNP	O
Thirteen	NNP	SS
emmetropic	JJ	C
subjects	NNS	O
were	VBD	O
randomly	RB	O
fitted	VBN	O
with	IN	O
two	CD	O
different	JJ	O
tinted	VBN	O
Nike	NNP	O
Maxsight	NNP	O
(	(	O
Bausch	NNP	O
&	CC	O
Lomb	NNP	O
,	,	O
Rochester	NNP	O
,	,	O
NY	NNP	O
,	,	O
USA	NNP	O
)	)	O
CL	NNP	O
in	IN	O
one	CD	O
eye	NN	O
,	,	O
while	IN	O
the	DT	O
contralateral	JJ	O
eye	NN	O
was	VBD	O
fitted	VBN	O
with	IN	O
a	DT	O
clear	JJ	O
lens	NNS	O
made	VBN	O
of	IN	O
the	DT	O
same	JJ	O
material	NN	O
(	(	O
Optima	NNP	O
38	CD	O
,	,	O
Bausch	NNP	O
&	CC	O
Lomb	NNP	O
)	)	O
.	.	O

Three	CD	O
valid	JJ	O
straylight	NN	O
measurements	NNS	O
were	VBD	O
taken	VBN	O
on	IN	O
each	DT	O
eye	NN	O
before	IN	O
and	CC	O
a	DT	O
few	JJ	O
minutes	NNS	O
after	IN	O
lens	JJ	O
insertion	NN	O
,	,	O
when	WRB	O
lens	VBZ	O
stabilization	NN	O
had	VBD	O
occurred	VBN	O
.	.	O

RESULTS	VB	O
The	DT	O
subjects	NNS	O
'	POS	O
mean	NN	O
straylight	NN	O
values	NNS	O
were	VBD	O
0.90	CD	O
+/-	JJ	O
0.09	CD	O
at	IN	O
baseline	NN	O
and	CC	O
0.95	CD	O
+/-	JJ	O
0.10	CD	O
with	IN	O
the	DT	O
clear	JJ	O
Optima	NNP	O
38	CD	O
CL	NNP	O
.	.	O

Straylight	NNP	O
values	NNS	O
were	VBD	O
0.97	CD	O
+/-	JJ	O
0.10	CD	O
and	CC	O
1.0	CD	O
+/-	JJ	O
0.10	CD	O
log	JJ	O
units	NNS	O
with	IN	O
the	DT	O
amber	NN	O
and	CC	O
grey-green	JJ	O
tinted	JJ	O
CL	NNP	O
,	,	O
respectively	RB	O
.	.	O

Differences	NNS	O
in	IN	O
straylight	NN	O
between	IN	O
baseline	NN	O
(	(	O
without	IN	O
CL	NNP	O
)	)	O
and	CC	O
with	IN	O
the	DT	O
clear	JJ	O
CL	NNP	O
in	IN	O
place	NN	O
were	VBD	O
neither	RB	O
statistically	RB	O
significant	JJ	O
(	(	O
p	JJ	O
=	NNP	O
0.066	CD	O
)	)	O
nor	CC	O
was	VBD	O
there	EX	O
a	DT	O
significant	JJ	O
difference	NN	O
between	IN	O
baseline	NN	O
and	CC	O
the	DT	O
amber	NN	O
CL	NNP	O
(	(	O
p	JJ	O
=	NNP	O
0.052	CD	O
)	)	O
.	.	O

However	RB	O
,	,	O
the	DT	O
grey-green	JJ	O
CL	NNP	O
showed	VBD	O
a	DT	O
statistically	RB	O
significant	JJ	O
difference	NN	O
from	IN	O
baseline	NN	O
(	(	O
p	JJ	O
=	NNP	O
0.006	CD	O
)	)	O
.	.	O

Differences	NNS	O
in	IN	O
straylight	NN	O
with	IN	O
the	DT	O
clear	JJ	O
CL	NNP	O
compared	VBN	O
with	IN	O
the	DT	O
grey-green	JJ	O
CL	NNP	O
were	VBD	O
also	RB	O
statistically	RB	O
different	JJ	O
from	IN	O
zero	NN	O
(	(	O
p	JJ	O
=	NNP	O
0.002	CD	O
)	)	O
showing	VBG	O
an	DT	O
increased	VBN	O
straylight	NN	O
value	NN	O
for	IN	O
the	DT	O
tinted	JJ	O
CL	NNP	O
.	.	O

These	DT	O
differences	NNS	O
were	VBD	O
variable	JJ	O
,	,	O
but	CC	O
consistent	JJ	O
for	IN	O
each	DT	O
subject	NN	O
,	,	O
thus	RB	O
those	DT	O
showing	VBG	O
higher	JJR	O
or	CC	O
lower	JJR	O
changes	NNS	O
with	IN	O
one	CD	O
tinted	JJ	O
lens	VBZ	O
tended	VBN	O
to	TO	O
show	VB	O
the	DT	O
same	JJ	O
trend	NN	O
with	IN	O
the	DT	O
second	JJ	O
lens	NNS	O
(	(	O
r	NN	O
(	(	O
2	CD	O
)	)	O
=	FW	O
0.736	CD	O
)	)	O
.	.	O

CONCLUSIONS	NNP	O
Despite	IN	O
increases	NNS	O
having	VBG	O
been	VBN	O
found	VBN	O
in	IN	O
straylight	JJ	O
values	NNS	O
with	IN	O
tinted	VBN	O
contact	NN	O
lenses	NNS	O
,	,	O
those	DT	O
changes	NNS	O
are	VBP	O
not	RB	O
likely	JJ	O
to	TO	O
induce	VB	O
clinically	RB	O
significant	JJ	O
changes	NNS	O
in	IN	O
visual	JJ	O
function	NN	O
under	IN	O
photopic	NN	O
conditions	NNS	O
,	,	O
even	RB	O
for	IN	O
the	DT	O
grey-green	JJ	O
CL	NNP	O
,	,	O
which	WDT	O
seems	VBZ	O
to	TO	O
increase	VB	O
straylight	JJ	O
values	NNS	O
more	RBR	O
significantly	RB	O
than	IN	O
the	DT	O
amber	JJ	O
CL	NNP	O
.	.	O

This	DT	O
difference	NN	O
between	IN	O
the	DT	O
tinted	JJ	O
CL	NNP	O
could	MD	O
suggest	VB	O
a	DT	O
wavelength	JJ	O
dependence	NN	O
of	IN	O
straylight	NN	O
values	NNS	O
,	,	O
although	IN	O
this	DT	O
should	MD	O
be	VB	O
investigated	VBN	O
further	JJ	O
by	IN	O
controlling	VBG	O
for	IN	O
pupil	NN	O
size	NN	O
and	CC	O
subjects	NNS	O
'	POS	O
pigmentation	NN	O
,	,	O
as	RB	O
well	RB	O
as	IN	O
by	IN	O
using	VBG	O
neutral	JJ	O
density	NN	O
filters	NNS	O
.	.	O

Methotrexate	NNP	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
steroid-dependent	JJ	C
asthma	NN	C
.	.	O

A	DT	O
double-blind	JJ	O
,	,	O
placebo-controlled	JJ	O
,	,	O
crossover	NN	O
study	NN	O
was	VBD	O
designed	VBN	O
to	TO	O
compare	VB	O
steroid	JJ	O
requirements	NNS	O
between	IN	O
placebo	NN	O
and	CC	O
methotrexate	NN	O
(	(	O
MTX	NNP	O
)	)	O
treatment	NN	O
in	IN	O
subjects	NNS	O
with	IN	O
corticosteroid-requiring	JJ	O
asthma	NN	C
.	.	O

Subjects	NNS	O
began	VBD	O
with	IN	O
a	DT	O
steroid	JJ	O
taper	NN	O
and	CC	O
then	RB	O
were	VBD	O
randomized	VBN	O
to	TO	O
a	DT	O
3-month	JJ	O
trial	NN	O
of	IN	O
drug	NN	O
or	CC	O
placebo	NN	O
therapy	NN	O
.	.	O

Subjects	NNS	O
received	VBD	O
15	CD	O
mg	NN	O
of	IN	O
MTX	NNP	O
a	DT	O
week	NN	O
or	CC	O
identical	JJ	O
placebo	NN	O
.	.	O

A	DT	O
1-month	JJ	O
washout	NN	O
period	NN	O
was	VBD	O
completed	VBN	O
before	IN	O
the	DT	O
crossover	NN	O
trial	NN	O
.	.	O

Symptom	NNP	O
scores	NNS	O
,	,	O
peak	NN	O
flow	NN	O
rates	NNS	O
,	,	O
spirometry	NN	O
,	,	O
and	CC	O
beta-agonist	JJ	O
frequency	NN	O
were	VBD	O
closely	RB	O
monitored	VBN	O
.	.	O

Ten	CD	SS
subjects	NNS	SS
completed	VBD	O
the	DT	O
study	NN	O
.	.	O

The	DT	O
average	JJ	O
dose	NN	O
of	IN	O
prednisone	NN	O
during	IN	O
the	DT	O
placebo-treatment	JJ	O
period	NN	O
was	VBD	O
11.97	CD	O
mg/day	NN	O
compared	VBN	O
to	TO	O
8.37	CD	O
mg/day	NNS	O
while	IN	O
subjects	NNS	O
were	VBD	O
taking	VBG	O
MTX	NNP	O
.	.	O

This	DT	O
was	VBD	O
a	DT	O
30	CD	O
%	NN	O
reduction	NN	O
in	IN	O
daily	JJ	O
steroid	JJ	O
requirement	NN	O
(	(	O
p	NN	O
less	JJR	O
than	IN	O
0.01	CD	O
)	)	O
.	.	O

Symptom	JJ	O
scores	NNS	O
and	CC	O
spirometry	NN	O
did	VBD	O
not	RB	O
differ	VB	O
between	IN	O
the	DT	O
crossover	NN	O
trials	NNS	O
,	,	O
and	CC	O
overall	JJ	O
clinical	JJ	O
status	NN	O
was	VBD	O
not	RB	O
altered	VBN	O
.	.	O

Complications	NNS	O
from	IN	O
MTX	NNP	O
were	VBD	O
mild	JJ	O
and	CC	O
included	VBD	O
anorexia	NN	O
,	,	O
alopecia	NN	O
,	,	O
and	CC	O
stomatitis	NN	O
.	.	O

All	DT	O
complications	NNS	O
resolved	VBN	O
with	IN	O
dose	JJ	O
reduction	NN	O
or	CC	O
when	WRB	O
MTX	NNP	O
was	VBD	O
stopped	VBN	O
at	IN	O
the	DT	O
end	NN	O
of	IN	O
the	DT	O
study	NN	O
.	.	O

No	DT	O
subjects	NNS	O
withdrew	VBD	O
from	IN	O
the	DT	O
study	NN	O
because	IN	O
of	IN	O
MTX	NNP	O
complications	NNS	O
.	.	O

Low-dose	JJ	O
MTX	NNP	O
significantly	RB	O
reduced	VBD	O
the	DT	O
steroid	JJ	O
requirement	NN	O
in	IN	O
this	DT	O
group	NN	O
of	IN	O
subjects	NNS	O
with	IN	O
steroid-dependent	JJ	O
asthma	NN	C
.	.	O

This	DT	O
reduction	NN	O
in	IN	O
steroid	JJ	O
requirement	NN	O
was	VBD	O
obtained	VBN	O
without	IN	O
altering	VBG	O
clinical	JJ	O
status	NN	O
and	CC	O
without	IN	O
significant	JJ	O
complication	NN	O
.	.	O

A	DT	O
controlled	VBN	O
study	NN	O
of	IN	O
the	DT	O
effect	NN	O
of	IN	O
indomethacin	NN	O
in	IN	O
uremic	JJ	O
pericarditis	NN	O
.	.	O

To	TO	O
determine	VB	O
the	DT	O
impact	NN	O
of	IN	O
indomethacin	NN	O
on	IN	O
the	DT	O
course	NN	O
of	IN	O
uremic	JJ	O
pericarditis	NN	O
we	PRP	O
performed	VBD	O
a	DT	O
prospective	JJ	O
,	,	O
double	JJ	O
blind	NN	O
study	NN	O
in	IN	O
which	WDT	O
24	CD	O
patients	NNS	O
with	IN	O
endstage	NN	O
chronic	JJ	O
renal	JJ	O
failure	NN	O
and	CC	O
pericarditis	NN	O
randomly	RB	O
received	VBD	O
indomethacin	JJ	O
,	,	O
25	CD	O
mg	NN	O
four	CD	O
times	NNS	O
daily	RB	O
,	,	O
(	(	O
11	CD	O
patients	NNS	O
)	)	O
or	CC	O
a	DT	O
placebo	NN	O
(	(	O
13	CD	O
patients	NNS	O
)	)	O
for	IN	O
a	DT	O
3-week	JJ	O
period	NN	O
.	.	O

All	DT	O
patients	NNS	O
received	VBN	O
peritoneal	JJ	O
or	CC	O
hemodialysis	NN	O
treatment	NN	O
concurrently	RB	O
with	IN	O
the	DT	O
study	NN	O
drug	NN	O
.	.	O

In	IN	O
contrast	NN	O
to	TO	O
the	DT	O
placebo	NN	O
,	,	O
indomethacin	NN	O
produced	VBD	O
an	DT	O
immediate	JJ	O
and	CC	O
sustained	JJ	O
reduction	NN	O
of	IN	O
fever	NN	O
in	IN	O
all	DT	O
but	CC	O
one	CD	O
patient	NN	O
.	.	O

On	IN	O
the	DT	O
other	JJ	O
hand	NN	O
,	,	O
indomethacin	NN	O
had	VBD	O
no	DT	O
effect	NN	O
on	IN	O
the	DT	O
duration	NN	O
of	IN	O
chest	NN	O
pain	NN	O
(	(	O
mean	JJ	O
days	NNS	O
+/-	JJ	O
SE	NNP	O
:	:	O
placebo	NN	O
1.4	CD	O
+/-	JJ	O
0.6	CD	O
,	,	O
indomethacin	JJ	O
5.5	CD	O
+/-	JJ	O
3.3	CD	O
)	)	O
,	,	O
duration	NN	O
of	IN	O
pericardial	JJ	O
friction	NN	O
rub	NN	O
(	(	O
placebo	JJ	O
10.3	CD	O
+/-	JJ	O
1.7	CD	O
,	,	O
indomethacin	JJ	O
16.0	CD	O
+/-	JJ	O
3.8	CD	O
)	)	O
,	,	O
or	CC	O
on	IN	O
the	DT	O
amount	NN	O
of	IN	O
pericardial	JJ	O
effusion	NN	O
.	.	O

Further	NNP	O
,	,	O
indomethacin	NN	O
did	VBD	O
not	RB	O
diminish	VB	O
the	DT	O
need	NN	O
for	IN	O
invasive	JJ	O
surgical	JJ	O
procedures	NNS	O
for	IN	O
relief	NN	O
of	IN	O
tamponade	NN	O
(	(	O
three	CD	O
of	IN	O
13	CD	O
placebo	NN	O
patients	NNS	O
,	,	O
two	CD	O
of	IN	O
11	CD	O
indomethacin	JJ	O
patients	NNS	O
)	)	O
or	CC	O
result	NN	O
in	IN	O
decreased	JJ	O
mortality	NN	O
rate	NN	O
.	.	O

Death	NNP	O
(	(	O
not	RB	O
due	RB	O
to	TO	O
pericarditis	NN	O
)	)	O
occurred	VBD	O
in	IN	O
two	CD	O
patients	NNS	O
treated	VBN	O
with	IN	O
indomethacin	NN	O
and	CC	O
one	CD	O
patient	NN	O
who	WP	O
received	VBD	O
the	DT	O
placebo	NN	O
.	.	O

In	IN	O
our	PRP$	O
patients	NNS	O
pericarditis	VBP	O
encompassed	VBD	O
a	DT	O
wide	JJ	O
spectrum	NN	O
ranging	VBG	O
from	IN	O
a	DT	O
mild	JJ	O
illness	NN	O
of	IN	O
several	JJ	O
days	NNS	O
duration	NN	O
to	TO	O
a	DT	O
painful	JJ	O
and	CC	O
debilitating	JJ	O
disease	NN	O
lasting	JJ	O
weeks	NNS	O
and	CC	O
requiring	VBG	O
surgical	JJ	O
intervention	NN	O
.	.	O

Although	IN	O
the	DT	O
size	NN	O
of	IN	O
our	PRP$	O
population	NN	O
prohibits	VBZ	O
definitive	JJ	O
conclusions	NNS	O
,	,	O
it	PRP	O
would	MD	O
appear	VB	O
that	IN	O
,	,	O
except	IN	O
for	IN	O
fever	NN	O
,	,	O
the	DT	O
manifestations	NNS	O
and	CC	O
natural	JJ	O
history	NN	O
of	IN	O
this	DT	O
illness	NN	O
are	VBP	O
unaffected	VBN	O
by	IN	O
indomethacin	NN	O
.	.	O

Digestive	JJ	O
enzyme	NN	O
supplementation	NN	O
for	IN	O
autism	NN	C
spectrum	NN	C
disorders	NNS	C
:	:	O
a	DT	O
double-blind	JJ	O
randomized	NN	O
controlled	VBD	O
trial	NN	O
.	.	O

To	TO	O
examine	VB	O
the	DT	O
effects	NNS	O
of	IN	O
a	DT	O
digestive	JJ	O
enzyme	NN	O
supplement	NN	O
in	IN	O
improving	VBG	O
expressive	JJ	O
language	NN	O
,	,	O
behaviour	NN	O
and	CC	O
other	JJ	O
symptoms	NNS	O
in	IN	O
children	NNS	O
with	IN	O
Autism	NNP	C
Spectrum	NNP	C
Disorder	NNP	C
.	.	C

Randomized	VBN	O
,	,	O
double-blind	JJ	O
placebo-controlled	JJ	O
trial	NN	O
using	VBG	O
crossover	NN	O
design	NN	O
over	IN	O
6	CD	O
months	NNS	O
for	IN	O
43	CD	SS
children	NNS	O
,	,	O
aged	VBN	O
3-8	CD	O
years	NNS	O
.	.	O

Outcome	NNP	O
measurement	NN	O
tools	NNS	O
included	VBD	O
monthly	JJ	O
Global	NNP	O
Behaviour	NNP	O
Rating	NNP	O
Scales	NNP	O
,	,	O
Additional	NNP	O
Rating	NNP	O
Scales	NNP	O
of	IN	O
other	JJ	O
symptoms	NNS	O
by	IN	O
parents	NNS	O
and	CC	O
therapists	NNS	O
,	,	O
and	CC	O
monthly	JJ	O
completion	NN	O
of	IN	O
the	DT	O
Rescorla	NNP	O
Language	NNP	O
Development	NNP	O
Survey	NNP	O
.	.	O

Compared	VBN	O
with	IN	O
placebo	NN	O
,	,	O
treatment	NN	O
with	IN	O
enzyme	NN	O
was	VBD	O
not	RB	O
associated	VBN	O
with	IN	O
clinically	RB	O
significant	JJ	O
improvement	NN	O
in	IN	O
behaviour	NN	O
,	,	O
food	NN	O
variety	NN	O
,	,	O
gastrointestinal	JJ	O
symptoms	NNS	O
,	,	O
sleep	JJ	O
quality	NN	O
,	,	O
engagement	NN	O
with	IN	O
therapist	NN	O
,	,	O
or	CC	O
the	DT	O
Language	NNP	O
Development	NNP	O
Survey	NNP	O
Vocabulary	NNP	O
or	CC	O
Sentence	NNP	O
Complexity	NNP	O
Scores	NNP	O
.	.	O

A	NNP	O
small	JJ	O
statistically	RB	O
significant	JJ	O
improvement	NN	O
on	IN	O
enzyme	NN	O
therapy	NN	O
was	VBD	O
seen	VBN	O
for	IN	O
the	DT	O
food	NN	O
variety	NN	O
scores	NNS	O
.	.	O

No	DT	O
clinically	RB	O
significant	JJ	O
effect	NN	O
improvement	NN	O
of	IN	O
autism	NN	O
symptoms	NNS	O
with	IN	O
enzyme	NN	O
use	NN	O
was	VBD	O
shown	VBN	O
with	IN	O
this	DT	O
trial	NN	O
,	,	O
however	RB	O
,	,	O
possible	JJ	O
effects	NNS	O
on	IN	O
improvement	NN	O
in	IN	O
food	NN	O
variety	NN	O
warrants	NNS	O
further	RBR	O
detailed	JJ	O
investigation	NN	O
.	.	O

Modest	JJS	O
visceral	JJ	O
fat	NN	O
gain	NN	O
causes	VBZ	O
endothelial	JJ	O
dysfunction	NN	O
in	IN	O
healthy	JJ	O
humans	NNS	O
.	.	O

OBJECTIVES	IN	O
The	DT	O
aim	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
determine	VB	O
the	DT	O
impact	NN	O
of	IN	O
fat	JJ	O
gain	NN	O
and	CC	O
its	PRP$	O
distribution	NN	O
on	IN	O
endothelial	JJ	O
function	NN	O
in	IN	O
lean	JJ	O
healthy	JJ	O
humans	NNS	O
.	.	O

BACKGROUND	NNP	O
Endothelial	NNP	O
dysfunction	NN	O
has	VBZ	O
been	VBN	O
identified	VBN	O
as	IN	O
an	DT	O
independent	JJ	O
predictor	NN	O
of	IN	O
cardiovascular	JJ	O
events	NNS	O
.	.	O

Whether	NNP	O
fat	JJ	O
gain	NN	O
impairs	NNS	O
endothelial	JJ	O
function	NN	O
is	VBZ	O
unknown	JJ	O
.	.	O

METHODS	VB	O
A	DT	O
randomized	NN	O
controlled	VBD	O
study	NN	O
was	VBD	O
conducted	VBN	O
to	TO	O
assess	VB	O
the	DT	O
effects	NNS	O
of	IN	O
fat	JJ	O
gain	NN	O
on	IN	O
endothelial	JJ	O
function	NN	O
.	.	O

Forty-three	JJ	O
normal-weight	JJ	O
healthy	JJ	O
volunteers	NNS	O
were	VBD	O
recruited	VBN	O
(	(	O
mean	JJ	O
age	NN	O
29	CD	O
years	NNS	O
;	:	O
18	CD	O
women	NNS	O
)	)	O
.	.	O

Subjects	NNS	O
were	VBD	O
assigned	VBN	O
to	TO	O
gain	VB	O
weight	NN	O
(	(	O
approximately	RB	O
4	CD	O
kg	NNS	O
)	)	O
(	(	O
n=35	JJ	O
)	)	O
or	CC	O
to	TO	O
maintain	VB	O
weight	NN	O
(	(	O
n=8	JJ	O
)	)	O
.	.	O

Endothelial	JJ	O
function	NN	O
(	(	O
brachial	JJ	O
artery	NN	O
flow-mediated	JJ	O
dilation	NN	O
[	NNP	O
FMD	NNP	O
]	NNP	O
)	)	O
was	VBD	O
measured	VBN	O
at	IN	O
baseline	NN	O
,	,	O
after	IN	O
fat	JJ	O
gain	NN	O
(	(	O
8	CD	O
weeks	NNS	O
)	)	O
,	,	O
and	CC	O
after	IN	O
weight	JJ	O
loss	NN	O
(	(	O
16	CD	O
weeks	NNS	O
)	)	O
for	IN	O
fat	JJ	O
gainers	NNS	O
and	CC	O
at	IN	O
baseline	NN	O
and	CC	O
follow-up	NN	O
(	(	O
8	CD	O
weeks	NNS	O
)	)	O
for	IN	O
weight	NN	O
maintainers	NNS	O
.	.	O

Body	NNP	O
composition	NN	O
was	VBD	O
measured	VBN	O
by	IN	O
dual-energy	JJ	O
X-ray	JJ	O
absorptiometry	NN	O
and	CC	O
abdominal	JJ	O
computed	JJ	O
tomographic	JJ	O
scans	NNS	O
.	.	O

RESULTS	NNP	O
After	IN	O
an	DT	O
average	JJ	O
weight	JJ	O
gain	NN	O
of	IN	O
4.1	CD	O
kg	NN	O
,	,	O
fat	JJ	O
gainers	NNS	O
significantly	RB	O
increased	VBD	O
their	PRP$	O
total	JJ	O
,	,	O
visceral	JJ	O
,	,	O
and	CC	O
subcutaneous	JJ	O
fat	NN	O
.	.	O

Blood	NNP	O
pressure	NN	O
and	CC	O
overnight	JJ	O
polysomnography	NN	O
did	VBD	O
not	RB	O
change	NN	O
after	IN	O
fat	JJ	O
gain	NN	O
or	CC	O
loss	NN	O
.	.	O

FMD	NNP	O
remained	VBD	O
unchanged	JJ	O
in	IN	O
weight	JJ	O
maintainers	NNS	O
.	.	O

FMD	NNP	O
decreased	VBD	O
in	IN	O
fat	JJ	O
gainers	NNS	O
(	(	O
9.1+/-3	CD	O
%	NN	O
vs.	FW	O
7.8+/-3.2	CD	O
%	NN	O
,	,	O
p=0.003	NN	O
)	)	O
but	CC	O
recovered	VBD	O
to	TO	O
baseline	VB	O
when	WRB	O
subjects	NNS	O
shed	VBD	O
the	DT	O
gained	JJ	O
weight	NN	O
.	.	O

There	EX	O
was	VBD	O
a	DT	O
significant	JJ	O
correlation	NN	O
between	IN	O
the	DT	O
decrease	NN	O
in	IN	O
FMD	NNP	O
and	CC	O
the	DT	O
increase	NN	O
in	IN	O
visceral	JJ	O
fat	JJ	O
gain	NN	O
(	(	O
rho=-0.42	JJ	O
,	,	O
p=0.004	NN	O
)	)	O
,	,	O
but	CC	O
not	RB	O
with	IN	O
subcutaneous	JJ	O
fat	JJ	O
gain	NN	O
(	(	O
rho=-0.22	JJ	O
,	,	O
p=0.15	NN	O
)	)	O
.	.	O

CONCLUSIONS	NNP	O
In	IN	O
normal-weight	JJ	O
healthy	JJ	O
young	JJ	O
subjects	NNS	O
,	,	O
modest	JJ	O
fat	JJ	O
gain	NN	O
results	NNS	O
in	IN	O
impaired	JJ	O
endothelial	JJ	O
function	NN	O
,	,	O
even	RB	O
in	IN	O
the	DT	O
absence	NN	O
of	IN	O
changes	NNS	O
in	IN	O
blood	NN	O
pressure	NN	O
.	.	O

Endothelial	JJ	O
function	NN	O
recovers	NNS	O
after	IN	O
weight	JJ	O
loss	NN	O
.	.	O

Increased	VBN	O
visceral	JJ	O
rather	RB	O
than	IN	O
subcutaneous	JJ	O
fat	JJ	O
predicts	NNS	O
endothelial	JJ	O
dysfunction	NN	O
.	.	O

(	(	O
Fat	JJ	O
Gain	NNP	O
and	CC	O
Cardiovascular	NNP	O
Disease	NNP	O
Mechanisms	NNP	O
;	:	O
NCT00589498	NNP	O
)	)	O
.	.	O

Chemoradiation	NN	O
comparing	VBG	O
cisplatin	JJ	O
versus	NN	O
carboplatin	NN	O
in	IN	O
locally	RB	O
advanced	JJ	C
nasopharyngeal	JJ	C
cancer	NN	C
:	:	O
randomised	VBN	O
,	,	O
non-inferiority	NN	O
,	,	O
open	JJ	O
trial	NN	O
.	.	O

PURPOSE	VB	O
This	DT	O
single	JJ	O
centre	NN	O
,	,	O
open	JJ	O
labelled	VBD	O
,	,	O
randomised	VBD	O
non-inferiority	JJ	O
trial	NN	O
compared	VBN	O
concurrent	JJ	O
chemoradiotherapy	NN	O
with	IN	O
carboplatin	JJ	O
versus	JJ	O
standard	NN	O
concurrent	NN	O
chemoradiotherapy	NN	O
with	IN	O
cisplatin	NN	O
in	IN	O
patients	NNS	O
with	IN	O
locoregionally	RB	C
advanced	JJ	C
nasopharyngeal	JJ	C
cancer	NN	C
(	(	O
NPC	NNP	O
)	)	O
.	.	O

PATIENTS	NNP	O
AND	CC	O
METHODS	NNP	O
From	NNP	O
August	NNP	O
1999	CD	O
to	TO	O
December	NNP	O
2004	CD	O
,	,	O
206	CD	SS
patients	NNS	O
with	IN	O
locally	RB	O
advanced	JJ	O
NPC	NNP	O
were	VBD	O
randomised	VBN	O
with	IN	O
101	CD	SS
to	TO	O
cisplatin	VB	O
arm	NN	O
and	CC	O
105	CD	SS
to	TO	O
carboplatin	VB	O
arm	NN	O
.	.	O

Planned	VBD	O
radiotherapy	NN	O
was	VBD	O
the	DT	O
same	JJ	O
in	IN	O
both	DT	O
groups	NNS	O
.	.	O

All	PDT	O
the	DT	O
patients	NNS	O
were	VBD	O
evaluated	VBN	O
for	IN	O
toxicity	NN	O
and	CC	O
survival	NN	O
according	VBG	O
to	TO	O
the	DT	O
as-treated	JJ	O
principle	NN	O
.	.	O

RESULTS	NNP	O
With	IN	O
a	DT	O
median	JJ	O
follow-up	NN	O
of	IN	O
26.3	CD	O
months	NNS	O
(	(	O
range	VB	O
3-74.6	JJ	O
months	NNS	O
)	)	O
,	,	O
59	CD	O
%	NN	O
of	IN	O
patients	NNS	O
in	IN	O
the	DT	O
cisplatin	NN	O
arm	NN	O
completed	VBD	O
the	DT	O
planned	VBN	O
concurrent	NN	O
chemoradiation	NN	O
treatment	NN	O
,	,	O
compared	VBN	O
to	TO	O
73	CD	O
%	NN	O
in	IN	O
the	DT	O
carboplatin	NN	O
arm	NN	O
.	.	O

Forty-two	JJ	O
percent	NN	O
of	IN	O
cisplatin	NN	O
patients	NNS	O
completed	VBD	O
the	DT	O
3	CD	O
cycles	NNS	O
of	IN	O
adjuvant	JJ	O
therapy	NN	O
compared	VBN	O
to	TO	O
70	CD	O
%	NN	O
in	IN	O
the	DT	O
carboplatin	NN	O
group	NN	O
.	.	O

There	EX	O
were	VBD	O
more	JJR	O
renal	JJ	O
toxicity	NN	O
,	,	O
leucopenia	NN	O
,	,	O
and	CC	O
anaemia	NN	O
in	IN	O
the	DT	O
cisplatin	NN	O
group	NN	O
,	,	O
and	CC	O
more	JJR	O
thrombocytopenia	NN	O
in	IN	O
the	DT	O
carboplatin	NN	O
arm	NN	O
.	.	O

The	DT	O
3	CD	O
year	NN	O
disease	NN	O
free	JJ	O
survival	NN	O
rates	NNS	O
were	VBD	O
63.4	CD	O
%	NN	O
for	IN	O
the	DT	O
cisplatin	NN	O
group	NN	O
and	CC	O
60.9	CD	O
%	NN	O
for	IN	O
the	DT	O
carboplatin	NN	O
group	NN	O
(	(	O
p=0.9613	NN	O
)	)	O
(	(	O
HR	$	O
0.70	CD	O
,	,	O
95	CD	O
%	NN	O
confidence	NN	O
interval	NN	O
(	(	O
CI	NNP	O
)	)	O
:	:	O
0.50-0.98	JJ	O
)	)	O
.	.	O

The	DT	O
3	CD	O
year	NN	O
overall	JJ	O
survival	NN	O
rates	NNS	O
were	VBD	O
77.7	CD	O
%	NN	O
and	CC	O
79.2	CD	O
%	NN	O
for	IN	O
cisplatin	NN	O
and	CC	O
carboplatin	NN	O
groups	NNS	O
,	,	O
respectively	RB	O
(	(	O
p=0.9884	NN	O
)	)	O
(	(	O
HR	$	O
0.83	CD	O
,	,	O
95	CD	O
%	NN	O
CI	NNP	O
:	:	O
0.63-1.010	NN	O
)	)	O
.	.	O

CONCLUSION	NNP	O
We	PRP	O
concluded	VBD	O
that	IN	O
the	DT	O
tolerability	NN	O
of	IN	O
carboplatin	NN	O
based	VBN	O
regimen	NNS	O
is	VBZ	O
better	JJR	O
than	IN	O
that	DT	O
of	IN	O
the	DT	O
cisplatin	NN	O
regimen	NN	O
.	.	O

Moreover	RB	O
,	,	O
the	DT	O
treatment	NN	O
efficacy	NN	O
of	IN	O
carboplatin	NN	O
arm	NN	O
is	VBZ	O
not	RB	O
different	JJ	O
from	IN	O
the	DT	O
standard	JJ	O
regimen	NNS	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
locoregional	JJ	C
advanced	JJ	C
stage	NN	C
NPC	NNP	C
.	.	O

Injection	NNP	O
sclerotherapy	NN	O
versus	NN	O
electrocoagulation	NN	O
in	IN	O
the	DT	O
management	NN	O
outcome	NN	O
of	IN	O
early	JJ	O
haemorrhoids	NNS	O
.	.	O

OBJECTIVE	NNP	O
To	TO	O
study	VB	O
the	DT	O
symptomatology	NN	O
of	IN	O
early	JJ	O
hemorrhoids	NNS	O
and	CC	O
to	TO	O
compare	VB	O
injection	NN	O
sclerotherapy	NN	O
(	(	O
IS	NNP	O
)	)	O
with	IN	O
electrocoagulation	NN	O
(	(	O
EC	NNP	O
)	)	O
in	IN	O
the	DT	O
management	NN	O
outcome	NN	O
of	IN	O
early	JJ	O
haemorrhoids	NNS	O
with	IN	O
respect	NN	O
to	TO	O
pain	VB	O
during	IN	O
the	DT	O
procedure	NN	O
,	,	O
reduction	NN	O
in	IN	O
bleeding	VBG	O
per	IN	O
rectum	NN	O
,	,	O
and	CC	O
overall	JJ	O
patient	NN	O
satisfaction	NN	O
score	NN	O
.	.	O

METHODS	NNP	O
A	NNP	O
total	NN	O
of	IN	O
102	CD	SS
patients	NNS	SS
were	VBD	O
included	VBN	O
in	IN	O
this	DT	O
experimental	JJ	O
study	NN	O
at	IN	O
the	DT	O
POF	NNP	O
Hospital	NNP	O
,	,	O
Wah	NNP	O
Cantt	NNP	O
from	IN	O
October	NNP	O
2004	CD	O
to	TO	O
June	NNP	O
2005	CD	O
.	.	O

A	DT	O
detailed	JJ	O
history	NN	O
was	VBD	O
taken	VBN	O
and	CC	O
proctoscopic	JJ	O
examination	NN	O
was	VBD	O
performed	VBN	O
.	.	O

Patients	NNS	O
were	VBD	O
then	RB	O
randomly	RB	O
divided	VBN	O
into	IN	O
two	CD	O
groups	NNS	O
(	(	O
Lottery	NNP	O
method	NN	O
)	)	O
.	.	O

One	CD	O
group	NN	O
was	VBD	O
subjected	VBN	O
to	TO	O
EC	NNP	O
and	CC	O
the	DT	O
other	JJ	O
to	TO	O
IS	NNP	O
.	.	O

In	IN	O
the	DT	O
EC	NNP	O
,	,	O
using	VBG	O
the	DT	O
EC	NNP	O
machine	NN	O
(	(	O
Wieda	NNP	O
,	,	O
China	NNP	O
)	)	O
,	,	O
direct	JJ	O
current	JJ	O
of	IN	O
10-20	JJ	O
mA	NN	O
was	VBD	O
applied	VBN	O
in	IN	O
the	DT	O
submucosal	JJ	O
plane	NN	O
of	IN	O
each	DT	O
pile	NN	O
core	NN	O
for	IN	O
5-7	JJ	O
minutes	NNS	O
.	.	O

In	IN	O
the	DT	O
IS	NNP	O
1-2	JJ	O
ml	NN	O
of	IN	O
5	CD	O
%	NN	O
phenol	NN	O
in	IN	O
almond	NN	O
oil	NN	O
was	VBD	O
injected	VBN	O
in	IN	O
the	DT	O
same	JJ	O
plane	NN	O
in	IN	O
each	DT	O
pile	NN	O
core	NN	O
.	.	O

Pain	NN	O
during	IN	O
the	DT	O
procedure	NN	O
,	,	O
reduction	NN	O
in	IN	O
bleeding	VBG	O
per	IN	O
rectum	NN	O
and	CC	O
overall	JJ	O
patient	NN	O
satisfaction	NN	O
,	,	O
were	VBD	O
studied	VBN	O
as	IN	O
outcome	JJ	O
measures	NNS	O
.	.	O

RESULTS	VB	O
The	DT	A
mean	JJ	A
age	NN	A
of	IN	A
the	DT	A
patients	NNS	A
was	VBD	A
44	CD	A
years	NNS	A
,	,	O
86	CD	O
were	VBD	O
males	NNS	SE
and	CC	O
16	CD	O
were	VBD	O
females	NNS	O
.	.	O

Two	CD	O
thirds	NNS	O
of	IN	O
the	DT	O
patients	NNS	O
were	VBD	O
having	VBG	O
symptoms	NNS	O
for	IN	O
more	JJR	O
than	IN	O
6	CD	O
months	NNS	O
.	.	O

A	DT	O
third	JJ	O
of	IN	O
patients	NNS	O
had	VBD	O
associated	VBN	O
local	JJ	O
pain	NN	O
while	IN	O
another	DT	O
third	JJ	O
had	VBD	O
associated	VBN	O
mucous	JJ	O
discharge	NN	O
.	.	O

Chronic	JJ	O
constipation	NN	O
was	VBD	O
present	JJ	O
in	IN	O
81	CD	O
%	NN	O
patients	NNS	O
.	.	O

Only	RB	O
24.5	CD	O
%	NN	O
of	IN	O
the	DT	O
patients	NNS	O
had	VBD	O
a	DT	O
positive	JJ	C
family	NN	C
history	NN	C
of	IN	C
haemorrhoids	NNS	C
.	.	O

Patients	NNS	O
in	IN	O
the	DT	O
electrocoagulation	NN	O
(	(	O
EC	NNP	O
)	)	O
group	NN	O
experienced	VBD	O
more	JJR	O
pain	NN	O
during	IN	O
the	DT	O
procedure	NN	O
than	IN	O
the	DT	O
injection	NN	O
sclerotherapy	NN	O
(	(	O
IS	NNP	O
)	)	O
group	NN	O
(	(	O
P	NNP	O
<	NNP	O
0.000	CD	O
)	)	O
,	,	O
but	CC	O
EC	NNP	O
was	VBD	O
significantly	RB	O
more	RBR	O
effective	JJ	O
than	IN	O
IS	NNP	O
in	IN	O
terms	NNS	O
of	IN	O
reducing	VBG	O
the	DT	O
bleeding	NN	O
per	IN	O
rectum	NN	O
(	(	O
P	NNP	O
=	NNP	O
0.039	CD	O
)	)	O
,	,	O
and	CC	O
also	RB	O
significantly	RB	O
higher	JJR	O
number	NN	O
of	IN	O
patients	NNS	O
were	VBD	O
fully	RB	O
satisfied	VBN	O
with	IN	O
EC	NNP	O
than	IN	O
with	IN	O
IS	NNP	O
(	(	O
P	NNP	O
<	NNP	O
0.04	CD	O
)	)	O
.	.	O

CONCLUSION	NNP	O
EC	NNP	O
,	,	O
although	IN	O
more	RBR	O
painful	JJ	O
,	,	O
is	VBZ	O
a	DT	O
safe	JJ	O
,	,	O
more	RBR	O
effective	JJ	O
and	CC	O
a	DT	O
highly	RB	O
satisfying	JJ	O
procedure	NN	O
for	IN	O
treating	VBG	O
early	JJ	O
hemorrhoids	NNS	O
.	.	O

Central	JJ	O
5-HT4	JJ	O
receptor	NN	O
binding	NN	O
as	IN	O
biomarker	NN	O
of	IN	O
serotonergic	JJ	O
tonus	NN	O
in	IN	O
humans	NNS	O
:	:	O
a	DT	O
[	$	O
11C	CD	O
]	NNP	O
SB207145	NNP	O
PET	NNP	O
study	NN	O
.	.	O

Identification	NNP	O
of	IN	O
a	DT	O
biomarker	NN	O
that	WDT	O
can	MD	O
inform	VB	O
on	IN	O
extracellular	JJ	O
serotonin	NN	O
(	(	O
5-HT	JJ	O
)	)	O
levels	NNS	O
in	IN	O
the	DT	O
brains	NNS	O
of	IN	O
living	NN	O
humans	NNS	O
would	MD	O
enable	VB	O
greater	JJR	O
understanding	NN	O
of	IN	O
the	DT	O
way	NN	O
brain	NN	O
circuits	NNS	O
are	VBP	O
modulated	VBN	O
by	IN	O
serotonergic	JJ	O
neurotransmission	NN	O
.	.	O

Substantial	JJ	O
evidence	NN	O
from	IN	O
studies	NNS	O
in	IN	O
animals	NNS	O
and	CC	O
humans	NNS	O
indicates	VBZ	O
an	DT	O
inverse	NN	O
relationship	NN	O
between	IN	O
central	JJ	O
5-HT	JJ	O
tonus	NN	O
and	CC	O
5-HT	JJ	O
type	NN	O
4	CD	O
receptor	NN	O
(	(	O
5-HT4R	JJ	O
)	)	O
density	NN	O
,	,	O
suggesting	VBG	O
that	IN	O
5-HT4R	JJ	O
receptor	NN	O
density	NN	O
may	MD	O
be	VB	O
a	DT	O
biomarker	NN	O
marker	NN	O
for	IN	O
5-HT	JJ	O
tonus	NN	O
.	.	O

Here	RB	O
,	,	O
we	PRP	O
investigated	VBD	O
whether	IN	O
a	DT	O
3-week	JJ	O
administration	NN	O
of	IN	O
a	DT	O
selective	JJ	O
serotonin	NN	O
reuptake	NN	O
inhibitor	NN	O
,	,	O
expected	VBN	O
to	TO	O
increase	VB	O
brain	NN	O
5-HT	JJ	O
levels	NNS	O
,	,	O
is	VBZ	O
associated	VBN	O
with	IN	O
a	DT	O
decline	NN	O
in	IN	O
brain	NN	O
5-HT4R	JJ	O
binding	NN	O
.	.	O

A	DT	O
total	NN	O
of	IN	O
35	CD	O
healthy	JJ	O
men	NNS	O
were	VBD	O
studied	VBN	O
in	IN	O
a	DT	O
placebo-controlled	JJ	O
,	,	O
randomized	VBN	O
,	,	O
double-blind	JJ	O
study	NN	O
.	.	O

Participants	NNS	O
were	VBD	O
assigned	VBN	O
to	TO	O
receive	VB	O
3	CD	O
weeks	NNS	O
of	IN	O
oral	JJ	O
dosing	VBG	O
with	IN	O
placebo	NN	O
or	CC	O
fluoxetine	NN	O
,	,	O
40	CD	O
mg	NNS	O
per	IN	O
day	NN	O
.	.	O

Brain	VB	O
5-HT4R	JJ	O
binding	NN	O
was	VBD	O
quantified	VBN	O
at	IN	O
baseline	NN	O
and	CC	O
at	IN	O
follow-up	JJ	O
with	IN	O
[	NNP	O
(	(	O
11	CD	O
)	)	O
C	NNP	O
]	NNP	O
SB207145	NNP	O
positron	NN	O
emission	NN	O
tomography	NN	O
(	(	O
PET	NNP	O
)	)	O
.	.	O

Three	CD	O
weeks	NNS	O
of	IN	O
intervention	NN	O
with	IN	O
fluoxetine	NN	O
was	VBD	O
associated	VBN	O
with	IN	O
a	DT	O
5.2	CD	O
%	NN	O
reduction	NN	O
in	IN	O
brain	NN	O
5-HT4R	JJ	O
binding	NN	O
(	(	O
P=0.017	NNP	O
)	)	O
,	,	O
whereas	JJ	O
placebo	NN	O
intervention	NN	O
did	VBD	O
not	RB	O
change	VB	O
5-HT4R	JJ	O
binding	NN	O
(	(	O
P=0.52	NNP	O
)	)	O
.	.	O

Our	PRP$	O
findings	NNS	O
are	VBP	O
consistent	JJ	O
with	IN	O
a	DT	O
model	NN	O
,	,	O
wherein	VBP	O
the	DT	O
5-HT4R	JJ	O
density	NN	O
adjusts	VBZ	O
to	TO	O
changes	NNS	O
in	IN	O
the	DT	O
extracellular	JJ	O
5-HT	JJ	O
tonus	NN	O
.	.	O

Our	PRP$	O
data	NNS	O
demonstrate	NN	O
for	IN	O
the	DT	O
first	JJ	O
time	NN	O
in	IN	O
humans	NNS	O
that	IN	O
the	DT	O
imaging	NN	O
of	IN	O
central	JJ	O
5-HT4R	JJ	O
binding	NN	O
may	MD	O
be	VB	O
used	VBN	O
as	IN	O
an	DT	O
in	IN	O
vivo	NN	O
biomarker	NN	O
of	IN	O
the	DT	O
central	JJ	O
5-HT	JJ	O
tonus	NN	O
.	.	O

Metformin	NNP	O
does	VBZ	O
not	RB	O
enhance	VB	O
ovulation	NN	O
induction	NN	O
in	IN	O
clomiphene	NN	O
resistant	JJ	O
polycystic	JJ	C
ovary	JJ	C
syndrome	NN	C
in	IN	O
clinical	JJ	O
practice	NN	O
.	.	O

AIMS	NNP	O
To	TO	O
determine	VB	O
whether	IN	O
metformin	NN	O
pretreatment	NN	O
has	VBZ	O
beneficial	JJ	O
effects	NNS	O
in	IN	O
clomiphene	NN	C
resistant	JJ	C
infertile	JJ	C
women	NNS	SE
with	IN	O
polycystic	JJ	C
ovary	JJ	C
syndrome	NN	C
(	(	O
PCOS	NNP	C
)	)	O
in	IN	O
an	DT	O
infertility	NN	O
clinic	NN	O
.	.	O

METHODS	NNP	O
This	DT	O
was	VBD	O
a	DT	O
randomized	JJ	O
placebo	NN	O
controlled	VBD	O
double-blind	NN	O
crossover	NN	O
study	NN	O
of	IN	O
3	CD	O
months	NNS	O
metformin	RB	O
(	(	O
1500	CD	O
mg	IN	O
day-1	NN	O
)	)	O
/placebo	NN	O
,	,	O
followed	VBN	O
by	IN	O
3	CD	O
months	NNS	O
metformin/placebo	VBN	O
together	RB	O
with	IN	O
clomiphene	NN	O
(	(	O
50-100	JJ	O
mg	NN	O
for	IN	O
5	CD	O
days	NNS	O
)	)	O
for	IN	O
three	CD	O
cycles	NNS	O
in	IN	O
clomiphene	NN	C
resistant	JJ	C
women	NNS	SE
with	IN	O
PCOS	NNP	C
.	.	O

The	DT	O
primary	JJ	O
outcomes	NNS	O
were	VBD	O
restoration	NN	O
of	IN	O
spontaneous	JJ	O
menses	NNS	O
,	,	O
ovulation	NN	O
induction	NN	O
(	(	O
spontaneous	JJ	O
or	CC	O
clomiphene	NN	O
induced	VBN	O
)	)	O
and	CC	O
pregnancy	NN	O
.	.	O

Secondary	JJ	O
endpoints	NNS	O
were	VBD	O
changes	NNS	O
in	IN	O
biochemical	JJ	O
parameters	NNS	O
related	VBN	O
to	TO	O
androgens	NNS	O
and	CC	O
insulin	NN	O
.	.	O

RESULTS	NNP	O
Twelve	NNP	SS
women	NNS	SE
completed	VBD	O
the	DT	O
metformin	NN	O
arm	NN	O
and	CC	O
14	CD	SS
the	DT	O
placebo	NN	O
arm	NN	O
.	.	O

Spontaneous	JJ	O
menstruation	NN	O
resumed	VBD	O
in	IN	O
five	CD	O
metformin	NNS	O
treated	VBD	O
patients	NNS	O
and	CC	O
in	IN	O
six	CD	O
placebo	NN	O
treated	VBN	O
women	NNS	O
,	,	O
P=0.63	NNP	O
.	.	O

No	NNP	O
women	NNS	O
given	VBN	O
metformin	NNS	O
spontaneously	RB	O
ovulated	VBD	O
,	,	O
although	IN	O
one	CD	O
patient	NN	O
given	VBN	O
placebo	NN	O
did	VBD	O
,	,	O
P=0.30	NNP	O
.	.	O

There	EX	O
was	VBD	O
no	DT	O
difference	NN	O
in	IN	O
the	DT	O
efficacy	NN	O
of	IN	O
clomiphene	NN	O
between	IN	O
the	DT	O
two	CD	O
groups	NNS	O
with	IN	O
ovulation	NN	O
being	VBG	O
induced	VBN	O
in	IN	O
five	CD	O
(	(	O
out	IN	O
of	IN	O
12	CD	O
)	)	O
metformin	NN	O
treated	VBN	O
women	NNS	O
and	CC	O
four	CD	O
(	(	O
out	IN	O
of	IN	O
14	CD	O
)	)	O
placebo	NN	O
treated	VBN	O
women	NNS	O
,	,	O
P=0.63	NNP	O
.	.	O

Pregnancy	NN	O
occurred	VBD	O
in	IN	O
three	CD	O
(	(	O
out	IN	O
of	IN	O
12	CD	O
)	)	O
women	NNS	O
given	VBN	O
metformin	NNS	O
and	CC	O
two	CD	O
(	(	O
out	IN	O
of	IN	O
14	CD	O
)	)	O
women	NNS	O
given	VBN	O
placebo	NNS	O
,	,	O
P=0.59	NNP	O
.	.	O

CONCLUSIONS	NNP	O
Metformin	NNP	O
is	VBZ	O
not	RB	O
always	RB	O
beneficial	JJ	O
when	WRB	O
given	VBN	O
to	TO	O
clomiphene	VB	C
resistant	JJ	C
infertile	JJ	C
women	NNS	SE
with	IN	O
PCOS	NNP	C
in	IN	O
clinical	JJ	O
practice	NN	O
.	.	O

Allopurinol	NNP	O
use	NN	O
yields	NNS	O
potentially	RB	O
beneficial	JJ	O
effects	NNS	O
on	IN	O
inflammatory	JJ	O
indices	NNS	O
in	IN	O
those	DT	O
with	IN	O
recent	JJ	O
ischemic	JJ	O
stroke	NN	O
:	:	O
a	DT	O
randomized	JJ	O
,	,	O
double-blind	JJ	O
,	,	O
placebo-controlled	JJ	O
trial	NN	O
.	.	O

BACKGROUND	NNP	O
AND	CC	O
PURPOSE	NNP	O
Elevated	NNP	O
serum	NN	O
uric	JJ	O
acid	NN	O
level	NN	O
is	VBZ	O
associated	VBN	O
with	IN	O
poor	JJ	O
outcome	NN	O
and	CC	O
increased	VBD	O
risk	NN	O
of	IN	O
recurrent	NN	O
events	NNS	O
after	IN	O
stroke	NN	O
.	.	O

The	DT	O
xanthine	JJ	O
oxidase	NN	O
inhibitor	NN	O
allopurinol	NN	O
lowers	NNS	O
uric	JJ	O
acid	NN	O
but	CC	O
also	RB	O
attenuates	VBZ	O
expression	NN	O
of	IN	O
inflammatory	JJ	O
adhesion	NN	O
molecules	NNS	O
in	IN	O
murine	NN	O
models	NNS	O
,	,	O
reduces	NNS	O
oxidative	VBP	O
stress	NN	O
in	IN	O
the	DT	O
vasculature	NN	O
,	,	O
and	CC	O
improves	VBZ	O
endothelial	JJ	O
function	NN	O
.	.	O

We	PRP	O
sought	VBD	O
to	TO	O
investigate	VB	O
whether	IN	O
allopurinol	JJ	O
alters	NNS	O
expression	NN	O
of	IN	O
inflammatory	NN	O
markers	NNS	O
after	IN	O
acute	JJ	O
ischemic	JJ	O
stroke	NN	O
.	.	O

METHODS	NNP	O
We	PRP	O
performed	VBD	O
a	DT	O
randomized	VBN	O
,	,	O
double-blind	JJ	O
,	,	O
placebo-controlled	JJ	O
trial	NN	O
to	TO	O
investigate	VB	O
the	DT	O
safety	NN	O
,	,	O
tolerability	NN	O
,	,	O
and	CC	O
effect	NN	O
of	IN	O
6	CD	O
weeks	NNS	O
'	POS	O
treatment	NN	O
with	IN	O
high-	NN	O
(	(	O
300	CD	O
mg	NN	O
once	RB	O
a	DT	O
day	NN	O
)	)	O
or	CC	O
low-	JJ	O
(	(	O
100	CD	O
mg	NN	O
once	RB	O
a	DT	O
day	NN	O
)	)	O
dose	NN	O
allopurinol	NN	O
on	IN	O
levels	NNS	O
of	IN	O
uric	JJ	O
acid	NN	O
and	CC	O
circulating	VBG	O
inflammatory	JJ	O
markers	NNS	O
after	IN	O
ischemic	JJ	O
stroke	NN	O
.	.	O

RESULTS	NNP	O
We	PRP	O
enrolled	VBD	O
50	CD	O
patients	NNS	O
with	IN	O
acute	JJ	O
ischemic	JJ	O
stroke	NN	O
(	(	O
17	CD	O
,	,	O
17	CD	O
,	,	O
and	CC	O
16	CD	O
in	IN	O
the	DT	O
high	JJ	O
,	,	O
low	JJ	O
,	,	O
and	CC	O
placebo	NN	O
groups	NNS	O
,	,	O
respectively	RB	O
)	)	O
.	.	O

Mean	NNP	O
(	(	O
+/-SD	NNP	O
)	)	O
age	NN	O
was	VBD	O
70	CD	O
(	(	O
+/-13	JJ	O
)	)	O
years	NNS	O
.	.	O

Groups	NNP	O
had	VBD	O
similar	JJ	O
characteristics	NNS	O
at	IN	O
baseline	NN	O
.	.	O

There	EX	O
were	VBD	O
no	DT	O
serious	JJ	O
adverse	JJ	O
events	NNS	O
.	.	O

Uric	NNP	O
acid	NN	O
levels	NNS	O
were	VBD	O
significantly	RB	O
reduced	VBN	O
at	IN	O
both	DT	O
7	CD	O
days	NNS	O
and	CC	O
6	CD	O
weeks	NNS	O
in	IN	O
the	DT	O
high-dose	JJ	O
group	NN	O
(	(	O
by	IN	O
0.14	CD	O
mmol/L	NNS	O
at	IN	O
6	CD	O
weeks	NNS	O
,	,	O
P=0.002	NNP	O
)	)	O
.	.	O

Intercellular	JJ	O
adhesion	NN	O
molecule-1	JJ	O
concentration	NN	O
(	(	O
ng/mL	JJ	O
)	)	O
rose	VBD	O
by	IN	O
51.2	CD	O
in	IN	O
the	DT	O
placebo	NN	O
group	NN	O
,	,	O
rose	VBD	O
slightly	RB	O
(	(	O
by	IN	O
10.6	CD	O
)	)	O
in	IN	O
the	DT	O
low-dose	JJ	O
allopurinol	NN	O
group	NN	O
,	,	O
but	CC	O
fell	VBD	O
in	IN	O
the	DT	O
high-dose	JJ	O
group	NN	O
(	(	O
by	IN	O
2.6	CD	O
;	:	O
difference	NN	O
between	IN	O
groups	NNS	O
P=0.012	NNP	O
,	,	O
Kruskal-Wallis	NNP	O
test	NN	O
)	)	O
.	.	O

CONCLUSIONS	NNP	O
Allopurinol	NNP	O
treatment	NN	O
is	VBZ	O
well	RB	O
tolerated	VBN	O
and	CC	O
attenuates	VBZ	O
the	DT	O
rise	NN	O
in	IN	O
intercellular	JJ	O
adhesion	NN	O
molecule-1	NN	O
levels	NNS	O
seen	VBN	O
after	IN	O
stroke	NN	O
.	.	O

Uric	JJ	O
acid	NN	O
levels	NNS	O
were	VBD	O
lowered	VBN	O
with	IN	O
high	JJ	O
doses	NNS	O
.	.	O

These	DT	O
findings	NNS	O
support	NN	O
further	JJ	O
evaluation	NN	O
of	IN	O
allopurinol	NN	O
as	IN	O
a	DT	O
preventive	JJ	O
measure	NN	O
after	IN	O
stroke	NN	O
.	.	O

Evaluation	NN	O
of	IN	O
a	DT	O
new	JJ	O
computer	NN	O
intervention	NN	O
to	TO	O
teach	VB	O
people	NNS	O
with	IN	O
autism	NN	C
or	CC	O
Asperger	NNP	C
syndrome	VBP	C
to	TO	O
recognize	VB	O
and	CC	O
predict	VB	O
emotions	NNS	O
in	IN	O
others	NNS	O
.	.	O

This	DT	O
randomized	VBD	O
controlled	JJ	O
trial	NN	O
looked	VBD	O
at	IN	O
the	DT	O
effect	NN	O
of	IN	O
a	DT	O
new	JJ	O
computer	NN	O
program	NN	O
designed	VBN	O
to	TO	O
teach	VB	O
people	NNS	O
with	IN	O
autistic	JJ	C
spectrum	NN	C
disorders	NNS	C
to	TO	O
better	JJR	O
recognize	VB	O
and	CC	O
predict	VBP	O
emotional	JJ	O
responses	NNS	O
in	IN	O
others	NNS	O
.	.	O

Two	CD	O
groups	NNS	O
of	IN	O
11	CD	SS
children	NNS	A
(	(	O
age	NN	A
12-18	CD	A
)	)	O
with	IN	O
autism	NN	O
or	CC	O
Asperger	NNP	O
syndrome	VBP	O
at	IN	O
two	CD	O
special	JJ	O
schools	NNS	O
participated	VBD	O
:	:	O
one	CD	O
group	NN	O
used	VBD	O
the	DT	O
computer	NN	O
program	NN	O
for	IN	O
10	CD	O
half-hour	JJ	O
sessions	NNS	O
over	IN	O
2	CD	O
weeks	NNS	O
.	.	O

Within-program	NNP	O
data	NN	O
showed	VBD	O
a	DT	O
significant	JJ	O
reduction	NN	O
in	IN	O
errors	NNS	O
made	VBN	O
from	IN	O
first	JJ	O
to	TO	O
last	JJ	O
use	NN	O
.	.	O

Students	NNS	O
were	VBD	O
assessed	VBN	O
pre-	JJ	O
and	CC	O
post-intervention	NN	O
using	VBG	O
facial	JJ	O
expression	NN	O
photographs	NN	O
,	,	O
cartoons	NNS	O
depicting	VBG	O
emotion-laden	JJ	O
situations	NNS	O
,	,	O
and	CC	O
non-literal	JJ	O
stories	NNS	O
.	.	O

Scores	NNS	O
were	VBD	O
not	RB	O
related	VBN	O
to	TO	O
age	NN	O
or	CC	O
verbal	JJ	O
ability	NN	O
.	.	O

The	DT	O
experimental	JJ	O
group	NN	O
made	VBD	O
gains	NNS	O
relative	JJ	O
to	TO	O
the	DT	O
control	NN	O
group	NN	O
on	IN	O
all	DT	O
three	CD	O
measures	NNS	O
.	.	O

Gains	NNP	O
correlated	VBD	O
significantly	RB	O
with	IN	O
the	DT	O
number	NN	O
of	IN	O
times	NNS	O
the	DT	O
computer	NN	O
program	NN	O
was	VBD	O
used	VBN	O
and	CC	O
results	NNS	O
suggest	VBP	O
positive	JJ	O
effects	NNS	O
.	.	O

Further	NNP	O
research	NN	O
could	MD	O
assess	VB	O
whether	IN	O
these	DT	O
gains	NNS	O
generalized	VBD	O
into	IN	O
real	JJ	O
life	NN	O
or	CC	O
improved	VBN	O
performance	NN	O
on	IN	O
theory	NN	O
of	IN	O
mind	NN	O
measures	NNS	O
.	.	O

Combined	VBN	O
therapy	NN	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
primary	JJ	O
mediastinal	JJ	O
B-cell	NNP	O
lymphoma	NN	O
:	:	O
conventional	JJ	O
versus	NN	O
escalated	VBD	O
chemotherapy	NN	O
.	.	O

Treatment	NN	O
of	IN	O
patients	NNS	O
with	IN	O
primary	JJ	O
mediastinal	JJ	O
B-cell	NNP	O
lymphoma	NN	O
(	(	O
PMBCL	NNP	O
)	)	O
remains	VBZ	O
controversial	JJ	O
.	.	O

We	PRP	O
started	VBD	O
a	DT	O
controlled	JJ	O
clinical	JJ	O
trial	NN	O
to	TO	O
evaluate	VB	O
the	DT	O
efficacy	NN	O
and	CC	O
toxicity	NN	O
of	IN	O
a	DT	O
conventional	JJ	O
versus	NN	O
more	RBR	O
intensive	JJ	O
regimen	NNS	O
of	IN	O
combined	JJ	O
chemotherapy	NN	O
followed	VBN	O
by	IN	O
radiotherapy	NN	O
to	TO	O
the	DT	O
mediastinum	NN	O
with	IN	O
the	DT	O
mantle	NN	O
technique	NN	O
.	.	O

From	IN	O
1989	CD	O
to	TO	O
1997	CD	O
,	,	O
68	CD	O
patients	NNS	O
diagnosed	VBN	O
with	IN	O
previously	RB	O
untreated	VBN	O
PMBCL	NNP	O
,	,	O
aged	VBD	O
18-65	CD	O
years	NNS	O
and	CC	O
negative	JJ	O
for	IN	O
immunodeficiency	NN	O
virus	NN	O
test	NN	O
,	,	O
were	VBD	O
considered	VBN	O
candidates	NNS	O
to	TO	O
receive	VB	O
either	DT	O
conventional	JJ	O
chemotherapy	NN	O
with	IN	O
CEOP-Bleo	NNP	O
(	(	O
cyclophosphamide	VB	O
750	CD	O
mg/m	NN	O
(	(	O
2	CD	O
)	)	O
,	,	O
vincristine	JJ	O
1.4	CD	O
mg/m	NN	O
(	(	O
2	CD	O
)	)	O
,	,	O
prednisone	RB	O
40	CD	O
mg/m	NN	O
(	(	O
2	CD	O
)	)	O
,	,	O
epirubicin	$	O
70	CD	O
mg/m	NN	O
(	(	O
2	CD	O
)	)	O
,	,	O
and	CC	O
bleomycin	$	O
10	CD	O
mg/m	NN	O
(	(	O
2	CD	O
)	)	O
)	)	O
or	CC	O
mega	JJ	O
CEOP-Bleo	NNP	O
(	(	O
cyclophosphamide	JJ	O
1000	CD	O
mg/m	NN	O
(	(	O
2	CD	O
)	)	O
,	,	O
epirubicin	$	O
120	CD	O
mg/m	NN	O
(	(	O
2	CD	O
)	)	O
,	,	O
vincristine	NN	O
,	,	O
prednisone	NN	O
,	,	O
and	CC	O
bleomycin	NN	O
at	IN	O
the	DT	O
same	JJ	O
doses	NNS	O
)	)	O
every	DT	O
21	CD	O
days	NNS	O
for	IN	O
six	CD	O
cycles	NNS	O
,	,	O
followed	VBN	O
by	IN	O
radiotherapy	NN	O
to	TO	O
the	DT	O
mediastinum	NN	O
with	IN	O
the	DT	O
mantle	NN	O
technique	NN	O
(	(	O
35-45	JJ	O
Gy	NNP	O
,	,	O
mean	VBP	O
38	CD	O
Gy	NNP	O
)	)	O
.	.	O

Complete	JJ	O
response	NN	O
(	(	O
CR	NNP	O
)	)	O
rates	NNS	O
were	VBD	O
not	RB	O
statistically	RB	O
different	JJ	O
:	:	O
64	CD	O
%	NN	O
[	CC	O
95	CD	O
percent	NN	O
confidence	NN	O
interval	NN	O
(	(	O
CI	NNP	O
)	)	O
:	:	O
58	CD	O
percent	NN	O
to	TO	O
70	CD	O
percent	NN	O
]	NN	O
for	IN	O
conventional	JJ	O
arm	NN	O
vs	NN	O
81	CD	O
percent	NN	O
(	(	O
95	CD	O
CI	NN	O
:	:	O
77-86	JJ	O
percent	NN	O
)	)	O
in	IN	O
the	DT	O
intensive	JJ	O
group	NN	O
(	(	O
p=0.2	NN	O
)	)	O
.	.	O

However	RB	O
,	,	O
failure-free	JJ	O
survival	NN	O
(	(	O
FFS	NNP	O
)	)	O
and	CC	O
overall	JJ	O
survival	NN	O
(	(	O
OS	NNP	O
)	)	O
had	VBD	O
statistical	JJ	O
differences	NNS	O
.	.	O

At	IN	O
5	CD	O
years	NNS	O
,	,	O
actuarial	JJ	O
FFS	NNP	O
for	IN	O
patients	NNS	O
treated	VBN	O
with	IN	O
conventional	JJ	O
chemotherapy	NN	O
was	VBD	O
51	CD	O
percent	NN	O
(	(	O
95	CD	O
percent	NN	O
CI	NN	O
:	:	O
44-59	JJ	O
percent	NN	O
)	)	O
compared	VBN	O
to	TO	O
70	CD	O
percent	NN	O
(	(	O
95	CD	O
percent	NN	O
CI	NN	O
:	:	O
65-76	JJ	O
percent	NN	O
)	)	O
in	IN	O
the	DT	O
intensive	JJ	O
arm	NN	O
(	(	O
p	JJ	O
>	NNP	O
0.01	CD	O
)	)	O
.	.	O

OS	CC	O
rates	NNS	O
were	VBD	O
also	RB	O
different	JJ	O
:	:	O
54	CD	O
percent	NN	O
(	(	O
95	CD	O
percent	NN	O
CI	NN	O
:	:	O
48-57	JJ	O
percent	NN	O
)	)	O
vs	VBZ	O
70	CD	O
percent	NN	O
(	(	O
95	CD	O
percent	NN	O
CI	NN	O
:	:	O
65-76	JJ	O
percent	NN	O
)	)	O
,	,	O
respectively	RB	O
(	(	O
p	JJ	O
<	NNP	O
0.01	CD	O
)	)	O
.	.	O

Toxicity	NN	O
was	VBD	O
mild	JJ	O
and	CC	O
no	DT	O
therapy-related	JJ	O
deaths	NNS	O
were	VBD	O
observed	VBN	O
.	.	O

At	IN	O
a	DT	O
median	JJ	O
follow-up	NN	O
of	IN	O
7.3	CD	O
years	NNS	O
,	,	O
no	DT	O
second	JJ	O
neoplasia	NN	O
or	CC	O
acute	NN	O
leukemia	NN	O
has	VBZ	O
been	VBN	O
observed	VBN	O
.	.	O

The	DT	O
international	JJ	O
prognostic	JJ	O
index	NN	O
was	VBD	O
not	RB	O
useful	JJ	O
to	TO	O
define	VB	O
clinical	JJ	O
risk	NN	O
in	IN	O
this	DT	O
selected	VBN	O
group	NN	O
of	IN	O
patients	NNS	O
.	.	O

Multivariate	NNP	O
analysis	NN	O
identified	VBN	O
pleural	JJ	O
and	CC	O
pericardial	JJ	O
effusion	NN	O
and	CC	O
chemotherapy	NN	O
regimen	NNS	O
as	IN	O
prognostic	JJ	O
factors	NNS	O
influencing	VBG	O
FFS	NNP	O
and	CC	O
OS	NNP	O
.	.	O

We	PRP	O
feel	VBP	O
that	IN	O
patients	NNS	O
with	IN	O
PMBCL	NNP	O
should	MD	O
be	VB	O
treated	VBN	O
with	IN	O
more	RBR	O
intensive	JJ	O
,	,	O
but	CC	O
not	RB	O
myeloablative	JJ	O
chemotherapy	NN	O
,	,	O
followed	VBN	O
by	IN	O
adjuvant	JJ	O
radiotherapy	NN	O
to	TO	O
achieve	VB	O
an	DT	O
improvement	NN	O
in	IN	O
outcome	NN	O
in	IN	O
this	DT	O
setting	NN	O
of	IN	O
patients	NNS	O
.	.	O

Patients	NNS	O
with	IN	O
pleural	JJ	O
or	CC	O
pericardial	JJ	O
effusion	NN	O
are	VBP	O
considered	VBN	O
at	IN	O
high	JJ	O
risk	NN	O
for	IN	O
failure	NN	O
with	IN	O
the	DT	O
actual	JJ	O
programs	NNS	O
of	IN	O
treatment	NN	O
and	CC	O
probably	RB	O
will	MD	O
be	VB	O
considered	VBN	O
for	IN	O
experimental	JJ	O
therapeutic	JJ	O
approaches	NNS	O
.	.	O

Effect	NN	O
of	IN	O
pravastatin	NN	O
on	IN	O
cardiovascular	JJ	O
events	NNS	O
in	IN	O
women	NNS	C
after	IN	C
myocardial	JJ	C
infarction	NN	C
:	:	C
the	DT	O
cholesterol	NN	O
and	CC	O
recurrent	JJ	O
events	NNS	O
(	(	O
CARE	NNP	O
)	)	O
trial	NN	O
.	.	O

OBJECTIVES	IN	O
We	PRP	O
sought	VBD	O
to	TO	O
determine	VB	O
the	DT	O
effect	NN	O
of	IN	O
pravastatin	NN	O
on	IN	O
recurrent	NN	O
cardiovascular	JJ	O
events	NNS	O
in	IN	O
women	NNS	O
with	IN	O
average	JJ	O
cholesterol	NN	O
levels	NNS	O
after	IN	O
myocardial	JJ	O
infarction	NN	O
(	(	O
MI	NNP	O
)	)	O
.	.	O

BACKGROUND	NNP	O
Little	JJ	O
information	NN	O
is	VBZ	O
available	JJ	O
on	IN	O
the	DT	O
effectiveness	NN	O
of	IN	O
lipid	JJ	O
lowering	VBG	O
in	IN	O
secondary	JJ	O
prevention	NN	O
of	IN	O
coronary	JJ	O
heart	NN	O
disease	NN	O
(	(	O
CHD	NNP	O
)	)	O
in	IN	O
women	NNS	O
;	:	O
in	IN	O
particular	JJ	O
,	,	O
those	DT	O
with	IN	O
CHD	NNP	O
and	CC	O
average	JJ	O
cholesterol	NN	O
levels	NNS	O
.	.	O

METHODS	NNP	O
In	IN	O
the	DT	O
Cholesterol	NNP	O
and	CC	O
Recurrent	NNP	O
Events	NNP	O
(	(	O
CARE	NNP	O
)	)	O
trial	NN	O
,	,	O
576	CD	O
postmenopausal	NN	O
women	NNS	O
,	,	O
between	IN	O
3	CD	O
and	CC	O
20	CD	O
months	NNS	O
after	IN	O
MI	NNP	O
,	,	O
with	IN	O
a	DT	O
total	JJ	O
cholesterol	NN	O
level	NN	O
<	VBD	O
240	CD	O
mg/dl	NN	O
and	CC	O
a	DT	O
low	JJ	O
density	NN	O
lipoprotein	NN	O
cholesterol	NN	O
level	NN	O
115	CD	O
to	TO	O
174	CD	O
mg/dl	NNS	O
,	,	O
were	VBD	O
randomized	VBN	O
to	TO	O
receive	VB	O
pravastatin	NN	O
40	CD	O
mg/day	NN	O
or	CC	O
matching	VBG	O
placebo	NN	O
for	IN	O
a	DT	O
median	JJ	O
follow-up	JJ	O
period	NN	O
of	IN	O
5	CD	O
years	NNS	O
.	.	O

The	DT	O
main	JJ	O
outcome	NN	O
measures	NNS	O
were	VBD	O
combined	VBN	O
coronary	JJ	O
events	NNS	O
(	(	O
coronary	JJ	O
death	NN	O
,	,	O
nonfatal	JJ	O
MI	NNP	O
,	,	O
percutaneous	JJ	O
transluminal	JJ	O
coronary	NN	O
angioplasty	NN	O
[	NNP	O
PTCA	NNP	O
]	NNP	O
or	CC	O
coronary	JJ	O
artery	NN	O
bypass	NN	O
graft	NN	O
surgery	NN	O
[	NNP	O
CABG	NNP	O
]	NNP	O
)	)	O
,	,	O
the	DT	O
primary	JJ	O
trial	NN	O
end	NN	O
point	NN	O
(	(	O
coronary	JJ	O
death	NN	O
or	CC	O
nonfatal	JJ	O
MI	NNP	O
)	)	O
and	CC	O
stroke	NN	O
.	.	O

RESULTS	NNP	O
Women	NNP	O
treated	VBD	O
with	IN	O
pravastatin	NN	O
had	VBD	O
a	DT	O
risk	NN	O
reduction	NN	O
of	IN	O
43	CD	O
%	NN	O
for	IN	O
the	DT	O
primary	JJ	O
end	NN	O
point	NN	O
(	(	O
p	JJ	O
=	NNP	O
0.035	CD	O
)	)	O
,	,	O
46	CD	O
%	NN	O
for	IN	O
combined	JJ	O
coronary	JJ	O
events	NNS	O
(	(	O
p	JJ	O
=	NNP	O
0.001	CD	O
)	)	O
,	,	O
48	CD	O
%	NN	O
for	IN	O
PTCA	NNP	O
(	(	O
p	JJ	O
=	NNP	O
0.025	CD	O
)	)	O
,	,	O
40	CD	O
%	NN	O
for	IN	O
CABG	NNP	O
(	(	O
p	JJ	O
=	NNP	O
0.14	CD	O
)	)	O
and	CC	O
56	CD	O
%	NN	O
for	IN	O
stroke	NN	O
(	(	O
p	JJ	O
=	NNP	O
0.07	CD	O
)	)	O
.	.	O

The	DT	O
3,583	CD	O
men	NNS	O
in	IN	O
the	DT	O
CARE	NNP	O
trial	NN	O
also	RB	O
showed	VBD	O
a	DT	O
reduction	NN	O
in	IN	O
risk	NN	O
,	,	O
but	CC	O
the	DT	O
magnitude	NN	O
tended	VBD	O
to	TO	O
be	VB	O
less	JJR	O
.	.	O

Pravastatin	NNP	O
improved	VBD	O
plasma	JJ	O
lipids	NNS	O
similarly	RB	O
in	IN	O
men	NNS	O
and	CC	O
women	NNS	O
.	.	O

There	EX	O
were	VBD	O
no	DT	O
differences	NNS	O
in	IN	O
risk	NN	O
of	IN	O
coronary	JJ	O
events	NNS	O
in	IN	O
the	DT	O
placebo	NN	O
group	NN	O
between	IN	O
men	NNS	O
and	CC	O
women	NNS	O
.	.	O

Minor	JJ	O
differences	NNS	O
between	IN	O
men	NNS	O
and	CC	O
women	NNS	O
were	VBD	O
present	JJ	O
in	IN	O
baseline	NN	O
characteristics	NNS	O
and	CC	O
treatment	NN	O
for	IN	O
MI	NNP	O
,	,	O
in	IN	O
general	JJ	O
,	,	O
conferring	VBG	O
a	DT	O
higher	JJR	O
risk	NN	O
status	NN	O
and	CC	O
a	DT	O
lower	JJR	O
incidence	NN	O
of	IN	O
CABG	NNP	O
in	IN	O
the	DT	O
women	NNS	O
.	.	O

CONCLUSIONS	NNP	O
Pravastatin	NNP	O
led	VBD	O
to	TO	O
significant	JJ	O
early	JJ	O
reduction	NN	O
of	IN	O
a	DT	O
wide	JJ	O
range	NN	O
of	IN	O
cardiovascular	JJ	O
events	NNS	O
in	IN	O
post-MI	JJ	O
women	NNS	O
with	IN	O
average	JJ	O
cholesterol	NN	O
levels	NNS	O
.	.	O

Randomized	VBN	O
trial	NN	O
of	IN	O
fenretinide	NN	O
in	IN	O
superficial	JJ	O
bladder	NN	O
cancer	NN	O
using	VBG	O
DNA	NNP	O
flow	JJ	O
cytometry	NN	O
as	IN	O
an	DT	O
intermediate	JJ	O
end	NN	O
point	NN	O
.	.	O

Retinoids	NNS	O
have	VBP	O
shown	VBN	O
a	DT	O
potential	JJ	O
activity	NN	O
in	IN	O
preventing	VBG	O
tumor	NN	O
recurrence	NN	O
in	IN	O
superficial	JJ	O
bladder	NN	O
cancer	NN	O
.	.	O

We	PRP	O
assessed	VBD	O
the	DT	O
activity	NN	O
of	IN	O
the	DT	O
synthetic	JJ	O
retinoid	NN	O
fenretinide	NN	O
in	IN	O
superficial	JJ	O
bladder	NN	O
cancer	NN	O
using	VBG	O
DNA	NNP	O
flow	JJ	O
cytometry	NN	O
and	CC	O
conventional	JJ	O
cytology	NN	O
as	IN	O
surrogate	JJ	O
biomarkers	NNS	O
.	.	O

A	DT	O
total	NN	O
of	IN	O
99	CD	O
subjects	NNS	O
with	IN	O
resected	JJ	O
superficial	JJ	O
bladder	NN	O
cancer	NN	O
(	(	O
pTa	NN	O
,	,	O
pT1	NN	O
)	)	O
were	VBD	O
randomized	VBN	O
to	TO	O
either	DT	O
fenretinide	NN	O
(	(	O
200	CD	O
mg	NNS	O
day	NN	O
p.o	NN	O
.	.	O

for	IN	O
24	CD	O
months	NNS	O
)	)	O
or	CC	O
no	DT	O
intervention	NN	O
.	.	O

Cystoscopy	NNP	O
and	CC	O
bladder	NN	O
washing	NN	O
for	IN	O
DNA	NNP	O
flow	NN	O
cytometry	NN	O
end	NN	O
points	NNS	O
(	(	O
proportion	NN	O
of	IN	O
DNA	NNP	O
aneuploid	JJ	O
histograms	NN	O
,	,	O
hyperdiploid	JJ	O
fraction	NN	O
,	,	O
and	CC	O
percentage	NN	O
of	IN	O
apoptotic	JJ	O
cells	NNS	O
)	)	O
and	CC	O
proportion	NN	O
of	IN	O
abnormal	JJ	O
cytological	JJ	O
examinations	NNS	O
were	VBD	O
repeated	VBN	O
every	DT	O
4	CD	O
months	NNS	O
for	IN	O
up	IN	O
to	TO	O
36	CD	O
months	NNS	O
.	.	O

The	DT	O
primary	JJ	O
study	NN	O
end	NN	O
point	NN	O
was	VBD	O
the	DT	O
proportion	NN	O
of	IN	O
DNA	NNP	O
aneuploid	JJ	O
histograms	NNS	O
after	IN	O
12	CD	O
months	NNS	O
.	.	O

This	DT	O
figure	NN	O
was	VBD	O
48.9	CD	O
%	NN	O
in	IN	O
the	DT	O
fenretinide	JJ	O
arm	NN	O
and	CC	O
41.9	CD	O
%	NN	O
in	IN	O
the	DT	O
control	NN	O
arm	NN	O
(	(	O
odds	NNS	O
ratio	NN	O
,	,	O
1.16	CD	O
;	:	O
95	CD	O
%	NN	O
confidence	NN	O
interval	NN	O
,	,	O
0.44-3.07	JJ	O
)	)	O
.	.	O

There	EX	O
was	VBD	O
no	DT	O
difference	NN	O
in	IN	O
any	DT	O
other	JJ	O
response	NN	O
biomarker	NN	O
between	IN	O
the	DT	O
two	CD	O
groups	NNS	O
up	RB	O
to	TO	O
36	CD	O
months	NNS	O
,	,	O
nor	CC	O
was	VBD	O
any	DT	O
biomarker	NN	O
able	JJ	O
to	TO	O
predict	VB	O
recurrence	NN	O
risk	NN	O
.	.	O

Recurrence-free	JJ	O
survival	NN	O
was	VBD	O
comparable	JJ	O
between	IN	O
the	DT	O
arms	NNS	O
(	(	O
27	CD	O
events	NNS	O
in	IN	O
the	DT	O
fenretinide	JJ	O
arm	NN	O
versus	NN	O
21	CD	O
in	IN	O
the	DT	O
control	NN	O
arm	NN	O
;	:	O
P	NNP	O
=	NNP	O
0.36	CD	O
)	)	O
.	.	O

Twelve	NNP	O
subjects	VBZ	O
in	IN	O
the	DT	O
fenretinide	JJ	O
arm	NN	O
complained	VBD	O
of	IN	O
diminished	JJ	O
dark	NN	O
adaptability	NN	O
,	,	O
and	CC	O
nine	CD	O
subjects	NNS	O
in	IN	O
the	DT	O
fenretinide	JJ	O
arm	NN	O
versus	IN	O
one	CD	O
control	NN	O
subject	NN	O
had	VBD	O
mild	JJ	O
dermatological	JJ	O
alterations	NNS	O
.	.	O

We	PRP	O
conclude	VBP	O
that	DT	O
fenretinide	NN	O
showed	VBD	O
a	DT	O
lack	NN	O
of	IN	O
effect	NN	O
on	IN	O
the	DT	O
DNA	NNP	O
content	NN	O
distribution	NN	O
and	CC	O
the	DT	O
morphology	NN	O
of	IN	O
urothelial	JJ	O
cells	NNS	O
obtained	VBN	O
in	IN	O
serial	JJ	O
bladder	NN	O
washings	NNS	O
.	.	O

Recurrence-free	JJ	O
survival	NN	O
was	VBD	O
comparable	JJ	O
between	IN	O
groups	NNS	O
.	.	O

Because	IN	O
our	PRP$	O
data	NNS	O
are	VBP	O
hampered	VBN	O
by	IN	O
the	DT	O
lack	NN	O
of	IN	O
predictivity	NN	O
of	IN	O
the	DT	O
selected	VBN	O
biomarkers	NNS	O
,	,	O
additional	JJ	O
studies	NNS	O
are	VBP	O
necessary	JJ	O
to	TO	O
assess	VB	O
the	DT	O
activity	NN	O
of	IN	O
fenretinide	NN	O
in	IN	O
preventing	VBG	O
bladder	NN	O
cancer	NN	O
.	.	O

Recurrence	NN	O
of	IN	O
condylomata	NNS	C
acuminata	NNS	C
following	VBG	C
cryotherapy	NN	C
is	VBZ	O
not	RB	O
prevented	VBN	O
by	IN	O
systemically	RB	O
administered	VBN	O
interferon	NN	O
.	.	O

OBJECTIVE	UH	O
To	TO	O
determine	VB	O
whether	IN	O
interferon	JJ	O
alpha-2a	NN	O
,	,	O
when	WRB	O
utilised	JJ	O
as	IN	O
adjuvant	JJ	O
chemotherapy	NN	O
following	VBG	O
ablation	NN	O
of	IN	O
condylomata	NN	O
acuminata	NNS	O
(	(	O
genital	JJ	O
warts	NNS	O
)	)	O
by	IN	O
cryotherapy	NN	O
,	,	O
is	VBZ	O
effective	JJ	O
in	IN	O
the	DT	O
prevention	NN	O
of	IN	O
recurrences	NNS	O
.	.	O

DESIGN	NNP	O
Randomised	VBD	O
,	,	O
placebo-controlled	JJ	O
,	,	O
double-blind	JJ	O
study	NN	O
.	.	O

Statistical	JJ	O
analysis	NN	O
was	VBD	O
by	IN	O
2-tailed	JJ	O
Fisher	NNP	O
's	POS	O
Exact	NNP	O
Test	NNP	O
.	.	O

PATIENTS	CC	O
97	CD	O
patients	NNS	O
with	IN	O
recurrent	JJ	O
condylomata	NN	O
acuminata	NN	O
.	.	C

INTERVENTION	NNP	O
49	CD	O
patients	NNS	O
were	VBD	O
treated	VBN	O
with	IN	O
cryotherapy	NN	O
plus	CC	O
subcutaneously	RB	O
administered	VBN	O
interferon	NN	O
alpha-2a	NN	O
,	,	O
and	CC	O
48	CD	O
received	VBD	O
cryotherapy	NN	O
plus	CC	O
placebo	NN	O
.	.	O

Of	IN	O
these	DT	O
,	,	O
36	CD	O
and	CC	O
37	CD	O
patients	NNS	O
,	,	O
respectively	RB	O
,	,	O
completed	VBD	O
the	DT	O
study	NN	O
and	CC	O
were	VBD	O
evaluable	JJ	O
.	.	O

MAIN	NNP	O
OUTCOME	NNP	O
MEASURE	NNP	O
Clinical	NNP	O
eradication	NN	O
of	IN	O
condylomata	NN	O
for	IN	O
six	CD	O
months	NNS	O
following	VBG	O
adjuvant	JJ	O
chemotherapy	NN	O
.	.	O

RESULTS	VBN	O
By	IN	O
completion	NN	O
of	IN	O
the	DT	O
adjuvant	JJ	O
chemotherapy	NN	O
,	,	O
10	CD	O
(	(	O
28	CD	O
%	NN	O
)	)	O
interferon	NN	O
recipients	NNS	O
and	CC	O
16	CD	O
(	(	O
43	CD	O
%	NN	O
)	)	O
placebo	NN	O
recipients	NNS	O
experienced	VBD	O
recurrences	NNS	O
.	.	O

At	IN	O
six	CD	O
months	NNS	O
follow-up	RB	O
,	,	O
25	CD	O
(	(	O
69	CD	O
%	NN	O
)	)	O
interferon	NN	O
and	CC	O
27	CD	O
(	(	O
73	CD	O
%	NN	O
)	)	O
placebo	NN	O
recipients	NNS	O
experienced	VBD	O
recurrences	NNS	O
.	.	O

In	IN	O
the	DT	O
six	CD	O
months	NNS	O
following	VBG	O
interferon	NN	O
therapy	NN	O
,	,	O
only	RB	O
31	CD	O
%	NN	O
of	IN	O
interferon	NN	O
and	CC	O
27	CD	O
%	NN	O
of	IN	O
placebo	NN	O
recipients	NNS	O
remained	VBD	O
free	JJ	O
of	IN	O
recurrences	NNS	O
(	(	O
p	JJ	O
=	NNP	O
0.99	CD	O
)	)	O
.	.	O

CONCLUSIONS	NNP	O
Interferon	NNP	O
alpha-2a	NN	O
administered	VBD	O
subcutaneously	RB	O
offers	VBZ	O
no	DT	O
benefit	NN	O
as	IN	O
a	DT	O
chemotherapeutic	JJ	O
adjuvant	NN	O
to	TO	O
cryotherapy	VB	O
when	WRB	O
used	VBN	O
alone	RB	O
in	IN	O
the	DT	O
therapy	NN	O
of	IN	O
genital	JJ	O
warts	NNS	O
in	IN	O
this	DT	O
population	NN	O
of	IN	O
patients	NNS	O
with	IN	O
recurrent	JJ	O
condylomata	NNS	O
.	.	O

Comparison	NNP	O
of	IN	O
the	DT	O
cardiorespiratory	JJ	O
effects	NNS	O
of	IN	O
a	DT	O
combination	NN	O
of	IN	O
ketamine	NN	O
and	CC	O
propofol	NN	O
,	,	O
propofol	VB	O
alone	RB	O
,	,	O
or	CC	O
a	DT	O
combination	NN	O
of	IN	O
ketamine	NN	O
and	CC	O
diazepam	NN	O
before	IN	O
and	CC	O
after	IN	O
induction	NN	O
of	IN	O
anesthesia	NN	O
in	IN	O
dogs	NNS	O
sedated	VBN	O
with	IN	O
acepromazine	NN	O
and	CC	O
oxymorphone	NN	O
.	.	O

OBJECTIVE	UH	O
To	TO	O
evaluate	VB	O
the	DT	O
cardiorespiratory	JJ	O
effects	NNS	O
of	IN	O
IV	NNP	O
administration	NN	O
of	IN	O
propofol	NN	O
(	(	O
4	CD	O
mg/kg	NN	O
)	)	O
,	,	O
ketamine	JJ	O
hydrochloride	NN	O
and	CC	O
propofol	NN	O
(	(	O
2	CD	O
mg/kg	RB	O
each	DT	O
;	:	O
K-P	NNP	O
)	)	O
,	,	O
or	CC	O
ketamine	VB	O
hydrochloride	NN	O
(	(	O
5	CD	O
mg/kg	NN	O
)	)	O
and	CC	O
diazepam	NN	O
(	(	O
0.2	CD	O
mg/kg	NN	O
;	:	O
K-D	NNP	O
)	)	O
before	IN	O
and	CC	O
after	IN	O
induction	NN	O
of	IN	O
anesthesia	NN	O
(	(	O
IoA	NNP	O
)	)	O
in	IN	O
dogs	NNS	O
sedated	VBN	O
with	IN	O
acepromazine	JJ	O
maleate	NN	O
and	CC	O
oxymorphone	NN	O
hydrochloride	NN	O
.	.	O

ANIMALS	$	O
10	CD	SS
healthy	JJ	O
adult	NN	O
Beagles	NNP	O
.	.	O

PROCEDURES	NNP	O
Each	DT	O
dog	NN	O
was	VBD	O
randomly	RB	O
allocated	VBN	O
to	TO	O
receive	VB	O
2	CD	O
of	IN	O
3	CD	O
treatments	NNS	O
(	(	O
1-week	JJ	O
interval	NN	O
)	)	O
.	.	O

For	IN	O
instrumentation	NN	O
prior	RB	O
to	TO	O
each	DT	O
treatment	NN	O
,	,	O
each	DT	O
dog	NN	O
was	VBD	O
anesthetized	VBN	O
with	IN	O
isoflurane	NN	O
.	.	O

After	IN	O
full	JJ	O
recovery	NN	O
,	,	O
acepromazine	NN	O
(	(	O
0.02	CD	O
mg/kg	NN	O
)	)	O
and	CC	O
oxymorphone	NN	O
(	(	O
0.05	CD	O
mg/kg	NN	O
)	)	O
were	VBD	O
administered	VBN	O
IV	NNP	O
.	.	O

Fifteen	NNP	O
minutes	NNS	O
later	RB	O
(	(	O
before	IN	O
IoA	NNP	O
)	)	O
,	,	O
each	DT	O
dog	NN	O
received	VBD	O
treatment	NN	O
IV	NNP	O
with	IN	O
propofol	NN	O
,	,	O
K-P	NNP	O
,	,	O
or	CC	O
K-D.	NNP	O
Cardiorespiratory	NNP	O
and	CC	O
arterial	JJ	O
blood	NN	O
gas	NN	O
variables	NNS	O
were	VBD	O
assessed	VBN	O
before	RB	O
,	,	O
immediately	RB	O
after	IN	O
,	,	O
and	CC	O
5	CD	O
minutes	NNS	O
after	IN	O
IoA	NNP	O
.	.	O

RESULTS	NNP	O
Compared	VBD	O
with	IN	O
findings	NNS	O
before	IN	O
IoA	NNP	O
,	,	O
dogs	NNS	O
receiving	VBG	O
the	DT	O
K-P	NNP	O
or	CC	O
K-D	NNP	O
treatment	NN	O
had	VBD	O
increased	VBN	O
cardiac	JJ	O
output	NN	O
,	,	O
oxygen	NN	O
delivery	NN	O
,	,	O
and	CC	O
heart	NN	O
rate	NN	O
5	CD	O
minutes	NNS	O
after	IN	O
IoA	NNP	O
;	:	O
K-P	NNP	O
administration	NN	O
did	VBD	O
not	RB	O
change	VB	O
mean	JJ	O
arterial	JJ	O
blood	NN	O
pressure	NN	O
or	CC	O
stroke	NN	O
volume	NN	O
and	CC	O
decreased	JJ	O
systemic	JJ	O
vascular	JJ	O
resistance	NN	O
.	.	O

Propofol	NNP	O
decreased	VBD	O
mean	JJ	O
arterial	JJ	O
blood	NN	O
pressure	NN	O
and	CC	O
systemic	JJ	O
vascular	JJ	O
resistance	NN	O
immediately	RB	O
after	IN	O
IoA	NNP	O
but	CC	O
did	VBD	O
not	RB	O
change	VB	O
heart	NN	O
rate	NN	O
,	,	O
cardiac	JJ	O
output	NN	O
,	,	O
or	CC	O
oxygen	NN	O
delivery	NN	O
.	.	O

All	DT	O
treatments	NNS	O
caused	VBD	O
some	DT	O
degree	NN	O
of	IN	O
apnea	NN	O
,	,	O
hypoventilation	NN	O
,	,	O
and	CC	O
hypoxemia	NN	O
(	(	O
Pao2	NNP	O
<	VBZ	O
80	CD	O
mm	NN	O
Hg	NNP	O
)	)	O
.	.	O

CONCLUSIONS	NNP	O
AND	NNP	O
CLINICAL	NNP	O
RELEVANCE	NNP	O
In	IN	O
dogs	NNS	O
,	,	O
K-P	NNP	O
treatment	NN	O
maintained	VBD	O
mean	JJ	O
arterial	JJ	O
blood	NN	O
pressure	NN	O
better	RBR	O
than	IN	O
propofol	VB	O
alone	JJ	O
and	CC	O
increased	JJ	O
heart	NN	O
rate	NN	O
,	,	O
cardiac	JJ	O
output	NN	O
,	,	O
or	CC	O
oxygen	NN	O
delivery	NN	O
,	,	O
as	IN	O
did	VBD	O
the	DT	O
K-D	NNP	O
treatment	NN	O
.	.	O

Supplemental	JJ	O
100	CD	O
%	NN	O
oxygen	NN	O
should	MD	O
be	VB	O
provided	VBN	O
during	IN	O
IoA	NNP	O
with	IN	O
all	DT	O
3	CD	O
treatments	NNS	O
.	.	O

Transitions	NNS	O
during	IN	O
effective	JJ	O
treatment	NN	O
for	IN	O
cocaine-abusing	JJ	C
homeless	JJ	O
persons	NNS	O
:	:	O
establishing	VBG	O
abstinence	NN	O
,	,	O
lapse	NN	O
,	,	O
and	CC	O
relapse	NN	O
,	,	O
and	CC	O
reestablishing	VBG	O
abstinence	NN	O
.	.	O

Data	NNS	O
are	VBP	O
reported	VBN	O
on	IN	O
drug	NN	O
use	NN	O
among	IN	O
cocaine-dependent	JJ	C
homeless	NN	O
persons	NNS	O
who	WP	O
participated	VBD	O
in	IN	O
a	DT	O
clinical	JJ	O
trial	NN	O
that	WDT	O
compared	VBN	O
day	NN	O
treatment	NN	O
only	RB	O
(	(	O
DT	NNP	O
,	,	O
n	JJ	O
=	NNP	O
69	CD	SS
)	)	O
with	IN	O
day	NN	O
treatment	NN	O
plus	CC	O
abstinent-contingent	JJ	O
housing	NN	O
and	CC	O
work	NN	O
(	(	O
DT+	NNP	O
,	,	O
n	JJ	O
=	NNP	O
72	CD	SS
)	)	SS
.	.	O

Drug	NNP	O
use	NN	O
was	VBD	O
measured	VBN	O
with	IN	O
multiple	JJ	O
weekly	JJ	O
urine	NN	O
toxicologies	NNS	O
.	.	O

Compared	VBN	O
with	IN	O
DT	NNP	O
participants	NNS	O
,	,	O
more	JJR	O
DT+	JJ	O
participants	NNS	O
established	VBN	O
abstinence	NN	O
,	,	O
maintained	VBD	O
abstinence	NN	O
for	IN	O
longer	JJR	O
durations	NNS	O
,	,	O
were	VBD	O
marginally	RB	O
significantly	RB	O
more	RBR	O
likely	JJ	O
to	TO	O
lapse	VB	O
,	,	O
and	CC	O
significantly	RB	O
less	RBR	O
likely	JJ	O
to	TO	O
relapse	VB	O
.	.	O

Of	IN	O
all	DT	O
participants	NNS	O
who	WP	O
established	VBD	O
abstinence	NN	O
and	CC	O
then	RB	O
relapsed	VBD	O
,	,	O
DT+	NNP	O
participants	NNS	O
relapsed	VBD	O
later	RB	O
and	CC	O
were	VBD	O
more	RBR	O
likely	JJ	O
to	TO	O
reestablish	VB	O
abstinence	NN	O
.	.	O

These	DT	O
analyses	NNS	O
yield	VBP	O
information	NN	O
on	IN	O
the	DT	O
processes	NNS	O
involved	VBN	O
in	IN	O
the	DT	O
manner	NN	O
in	IN	O
which	WDT	O
drug	NN	O
use	NN	O
changes	NNS	O
as	IN	O
a	DT	O
result	NN	O
of	IN	O
abstinent-contingent	JJ	O
housing	NN	O
and	CC	O
work	NN	O
.	.	O

Low-dose	JJ	O
mifepristone	NN	O
for	IN	O
uterine	JJ	O
leiomyomata	NN	O
.	.	O

OBJECTIVE	UH	O
To	TO	O
compare	VB	O
the	DT	O
effect	NN	O
of	IN	O
5	CD	O
and	CC	O
10	CD	O
mg	NN	O
of	IN	O
mifepristone	NN	O
on	IN	O
uterine	JJ	O
leiomyoma	NN	O
size	NN	O
and	CC	O
symptoms	NNS	O
,	,	O
and	CC	O
to	TO	O
measure	VB	O
side	JJ	O
effects	NNS	O
.	.	O

METHODS	NNP	O
Forty	NNP	O
premenopausal	JJ	O
women	NNS	O
with	IN	O
large	JJ	O
,	,	O
symptomatic	JJ	O
leiomyomata	NNS	O
were	VBD	O
randomized	VBN	O
to	TO	O
receive	VB	O
either	RB	O
5	CD	O
or	CC	O
10	CD	O
mg	NN	O
of	IN	O
mifepristone	JJ	O
daily	JJ	O
for	IN	O
6	CD	O
months	NNS	O
in	IN	O
an	DT	O
open-label	JJ	O
study	NN	O
.	.	O

Uterine	NNP	O
volume	NN	O
was	VBD	O
measured	VBN	O
at	IN	O
bimonthly	JJ	O
intervals	NNS	O
by	IN	O
sonography	NN	O
.	.	O

Serum	NNP	O
concentrations	NNS	O
of	IN	O
hemoglobin	NN	O
levels	NNS	O
,	,	O
follicle-stimulating	JJ	O
hormone	NN	O
,	,	O
and	CC	O
liver	RB	O
enzymes	NNS	O
were	VBD	O
obtained	VBN	O
,	,	O
and	CC	O
endometrial	JJ	O
samples	NNS	O
,	,	O
symptoms	NNS	O
,	,	O
and	CC	O
menstrual	JJ	O
bleeding	NN	O
were	VBD	O
also	RB	O
assessed	VBN	O
.	.	O

RESULTS	NNP	O
Nineteen	NNP	O
of	IN	O
20	CD	O
subjects	NNS	O
taking	VBG	O
5	CD	O
mg	NN	O
and	CC	O
all	DT	O
20	CD	O
subjects	NNS	O
taking	VBG	O
10	CD	O
mg	NN	O
completed	VBD	O
all	DT	O
6	CD	O
months	NNS	O
of	IN	O
the	DT	O
study	NN	O
.	.	O

Mean	NNP	O
uterine	JJ	O
volume	NN	O
shrank	NN	O
by	IN	O
48	CD	O
%	NN	O
(	(	O
P	NNP	O
<	NNP	O
.001	NNP	O
)	)	O
in	IN	O
the	DT	O
5-mg	JJ	O
group	NN	O
and	CC	O
49	CD	O
%	NN	O
(	(	O
P	NNP	O
<	NNP	O
.001	NNP	O
)	)	O
in	IN	O
the	DT	O
10-mg	JJ	O
group	NN	O
,	,	O
a	DT	O
nonsignificant	JJ	O
difference	NN	O
.	.	O

Leiomyoma-related	JJ	O
symptoms	NNS	O
were	VBD	O
comparably	RB	O
reduced	VBN	O
in	IN	O
both	DT	O
groups	NNS	O
.	.	O

Amenorrhea	NNP	O
occurred	VBD	O
in	IN	O
60-65	CD	O
%	NN	O
of	IN	O
both	DT	O
groups	NNS	O
.	.	O

Hemoglobin	NNP	O
levels	NNS	O
increased	VBN	O
by	IN	O
2.5	CD	O
g/dL	NNS	O
in	IN	O
anemic	JJ	O
subjects	NNS	O
.	.	O

The	DT	O
incidence	NN	O
of	IN	O
hot	JJ	O
flashes	NNS	O
increased	VBD	O
significantly	RB	O
over	IN	O
baseline	NN	O
in	IN	O
the	DT	O
10-mg	JJ	O
group	NN	O
but	CC	O
not	RB	O
in	IN	O
the	DT	O
5-mg	JJ	O
group	NN	O
.	.	O

Simple	NNP	O
endometrial	JJ	O
hyperplasia	NN	O
occurred	VBD	O
in	IN	O
28	CD	O
%	NN	O
of	IN	O
all	DT	O
subjects	NNS	O
,	,	O
with	IN	O
no	DT	O
difference	NN	O
between	IN	O
groups	NNS	O
.	.	O

No	DT	O
atypical	JJ	O
hyperplasia	NN	O
was	VBD	O
noted	VBN	O
.	.	O

CONCLUSION	NNP	O
Mifepristone	NNP	O
in	IN	O
doses	NNS	O
of	IN	O
5	CD	O
mg	NNS	O
or	CC	O
10	CD	O
mg	JJ	O
results	NNS	O
in	IN	O
comparable	JJ	O
leiomyoma	NN	O
regression	NN	O
,	,	O
improvement	NN	O
in	IN	O
symptoms	NNS	O
,	,	O
and	CC	O
few	JJ	O
side	NN	O
effects	NNS	O
.	.	O

Further	NNP	O
study	NN	O
is	VBZ	O
needed	VBN	O
to	TO	O
assess	VB	O
the	DT	O
long-term	JJ	O
safety	NN	O
and	CC	O
efficacy	NN	O
of	IN	O
low-dose	JJ	O
mifepristone	NN	O
.	.	O

Combination	NNP	O
hydrocodone	NN	O
and	CC	O
ibuprofen	JJ	O
versus	NN	O
combination	NN	O
codeine	NN	O
and	CC	O
acetaminophen	NN	O
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
chronic	JJ	C
pain	NN	C
.	.	O

OBJECTIVE	CC	O
The	DT	O
objective	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
compare	VB	O
the	DT	O
effectiveness	NN	O
of	IN	O
combination	NN	O
hydrocodone	NN	O
7.5	CD	O
mg	NN	O
and	CC	O
ibuprofen	$	O
200	CD	O
mg	NN	O
with	IN	O
that	DT	O
of	IN	O
combination	NN	O
codeine	NN	O
30	CD	O
mg	NN	O
and	CC	O
acetaminophen	$	O
300	CD	O
mg	NN	O
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
chronic	JJ	O
pain	NN	O
.	.	O

BACKGROUND	NNP	O
Hydrocodone	NNP	O
7.5	CD	O
mg	NN	O
with	IN	O
ibuprofen	JJ	O
200	CD	O
mg	NN	O
is	VBZ	O
the	DT	O
only	JJ	O
approved	VBD	O
fixed-dose	JJ	O
combination	NN	O
analgesic	IN	O
containing	VBG	O
an	DT	O
opioid	NN	O
and	CC	O
ibuprofen	NN	O
.	.	O

METHODS	NNP	O
In	IN	O
this	DT	O
randomized	JJ	O
,	,	O
parallel-group	JJ	O
,	,	O
double-blind	JJ	O
,	,	O
repeated-dose	JJ	O
,	,	O
active-comparator	JJ	O
,	,	O
4-week	JJ	O
,	,	O
multicenter	NN	O
study	NN	O
,	,	O
469	CD	SS
patients	NNS	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
receive	VB	O
a	DT	O
1-tablet	JJ	O
(	(	O
n	JJ	O
=	NNP	O
156	CD	O
)	)	O
or	CC	O
2-tablet	JJ	O
(	(	O
n	JJ	O
=	NNP	O
153	CD	O
)	)	O
dose	NN	O
of	IN	O
combination	NN	O
hydrocodone	NN	O
7.5	CD	O
mg	NN	O
and	CC	O
ibuprofen	$	O
200	CD	O
mg	NN	O
(	(	O
HI1	NNP	O
and	CC	O
HI2	NNP	O
,	,	O
respectively	RB	O
)	)	O
or	CC	O
a	DT	O
2-tablet	JJ	O
dose	NN	O
of	IN	O
combination	NN	O
codeine	NN	O
30	CD	O
mg	NN	O
and	CC	O
acetaminophen	$	O
300	CD	O
mg	NN	O
(	(	O
CA	NNP	O
,	,	O
n	RB	O
=	VBZ	O
160	CD	O
)	)	O
,	,	O
the	DT	O
active	JJ	O
comparator	NN	O
,	,	O
every	DT	O
6	CD	O
to	TO	O
8	CD	O
hours	NNS	O
as	IN	O
needed	VBN	O
for	IN	O
pain	NN	O
.	.	O

Efficacy	NN	O
was	VBD	O
measured	VBN	O
through	IN	O
pain	NN	O
relief	NN	O
scores	NNS	O
,	,	O
number	NN	O
of	IN	O
daily	JJ	O
doses	NNS	O
of	IN	O
study	NN	O
medication	NN	O
,	,	O
number	NN	O
of	IN	O
daily	JJ	O
doses	NNS	O
of	IN	O
supplemental	JJ	O
analgesics	NNS	O
,	,	O
number	NN	O
of	IN	O
patients	NNS	O
who	WP	O
discontinued	VBD	O
therapy	NN	O
due	JJ	O
to	TO	O
an	DT	O
unsatisfactory	JJ	O
analgesic	JJ	O
response	NN	O
,	,	O
and	CC	O
global	JJ	O
assessment	NN	O
scores	NNS	O
.	.	O

RESULTS	NNP	O
Of	IN	O
the	DT	O
469	CD	SS
patients	NNS	O
,	,	O
255	CD	SS
(	(	O
54.4	CD	O
%	NN	O
)	)	O
were	VBD	O
female	JJ	SE
and	CC	O
214	CD	SS
(	(	O
45.6	CD	O
%	NN	O
)	)	O
were	VBD	O
male	JJ	SE
.	.	O

The	DT	O
mean	JJ	O
age	NN	O
was	VBD	O
51.1	CD	A
years	NNS	A
.	.	O

Types	NNS	O
of	IN	O
chronic	NN	C
pain	NN	C
included	VBD	O
back	RB	C
(	(	O
214	CD	O
;	:	O
45.6	CD	O
%	NN	O
)	)	O
,	,	O
arthritic	JJ	C
(	(	O
145	CD	O
;	:	O
30.9	CD	O
%	NN	O
)	)	O
,	,	O
other	JJ	C
musculoskeletal	NN	C
(	(	O
65	CD	O
;	:	O
13.9	CD	O
%	NN	O
)	)	O
,	,	O
cancer	NN	C
(	(	O
6	CD	O
;	:	O
1.3	CD	O
%	NN	O
)	)	O
,	,	O
diabetic	JJ	C
neuropathic	NN	C
(	(	O
3	CD	O
;	:	O
0.6	CD	O
%	NN	O
)	)	O
,	,	O
postherpetic	JJ	C
neuralgic	NN	C
(	(	O
5	CD	O
;	:	O
1.1	CD	O
%	NN	O
)	)	O
,	,	O
other	JJ	C
neurologic	NN	C
(	(	O
21	CD	O
;	:	O
4.5	CD	O
%	NN	O
)	)	O
,	,	O
and	CC	O
other	JJ	O
unclassified	JJ	C
chronic	JJ	C
pain	NN	C
(	(	O
10	CD	O
;	:	O
2.1	CD	O
%	NN	O
)	)	O
.	.	O

During	IN	O
the	DT	O
48	CD	O
hours	NNS	O
prior	RB	O
to	TO	O
the	DT	O
study	NN	O
,	,	O
351	CD	O
(	(	O
74.8	CD	O
%	NN	O
)	)	O
patients	NNS	O
had	VBD	O
been	VBN	O
treated	VBN	O
with	IN	O
opioid	JJ	O
or	CC	O
opioid-nonopioid	JJ	O
combination	NN	O
analgesics	NNS	O
.	.	O

The	DT	O
overall	JJ	O
mean	JJ	O
daily	JJ	O
pain	NN	O
relief	NN	O
score	NN	O
was	VBD	O
significantly	RB	O
greater	JJR	O
in	IN	O
the	DT	O
HI2	NNP	O
group	NN	O
(	(	O
2.25+/-0.89	CD	O
)	)	O
than	IN	O
in	IN	O
the	DT	O
HI1	NNP	O
group	NN	O
(	(	O
1.98+/-0.87	JJ	O
)	)	O
(	(	O
P	NNP	O
=	NNP	O
0.003	CD	O
)	)	O
or	CC	O
the	DT	O
CA	NNP	O
group	NN	O
(	(	O
1.85+/-0.96	JJ	O
)	)	O
(	(	O
P	NNP	O
<	NNP	O
0.001	CD	O
)	)	O
.	.	O

The	DT	O
overall	JJ	O
mean	JJ	O
number	NN	O
of	IN	O
daily	JJ	O
doses	NNS	O
of	IN	O
study	NN	O
medication	NN	O
was	VBD	O
significantly	RB	O
less	RBR	O
in	IN	O
the	DT	O
HI2	NNP	O
group	NN	O
(	(	O
2.94+/-0.99	CD	O
)	)	O
than	IN	O
in	IN	O
the	DT	O
HI1	NNP	O
group	NN	O
(	(	O
3.23+/-0.76	JJ	O
)	)	O
(	(	O
P	NNP	O
=	NNP	O
0.036	CD	O
)	)	O
or	CC	O
the	DT	O
CA	NNP	O
group	NN	O
(	(	O
3.26+/-0.75	JJ	O
)	)	O
(	(	O
P	NNP	O
=	NNP	O
0.014	CD	O
)	)	O
.	.	O

The	DT	O
overall	JJ	O
mean	JJ	O
number	NN	O
of	IN	O
daily	JJ	O
doses	NNS	O
of	IN	O
supplemental	JJ	O
analgesics	NNS	O
was	VBD	O
significantly	RB	O
less	RBR	O
in	IN	O
the	DT	O
HI2	NNP	O
group	NN	O
(	(	O
0.24+/-0.49	CD	O
)	)	O
than	IN	O
in	IN	O
the	DT	O
HI1	NNP	O
group	NN	O
(	(	O
0.34+/-0.58	JJ	O
)	)	O
(	(	O
P	NNP	O
=	NNP	O
0.021	CD	O
)	)	O
or	CC	O
CA	NNP	O
group	NN	O
(	(	O
0.49+/-0.85	JJ	O
)	)	O
(	(	O
P	NNP	O
=	NNP	O
0.010	CD	O
)	)	O
.	.	O

The	DT	O
number	NN	O
of	IN	O
patients	NNS	O
who	WP	O
discontinued	VBD	O
treatment	NN	O
due	JJ	O
to	TO	O
an	DT	O
unsatisfactory	JJ	O
analgesic	JJ	O
response	NN	O
was	VBD	O
significantly	RB	O
less	RBR	O
in	IN	O
the	DT	O
HI2	NNP	O
group	NN	O
(	(	O
2	CD	O
;	:	O
1.3	CD	O
%	NN	O
)	)	O
than	IN	O
in	IN	O
the	DT	O
CA	NNP	O
group	NN	O
(	(	O
12	CD	O
;	:	O
7.5	CD	O
%	NN	O
)	)	O
(	(	O
P	NNP	O
=	NNP	O
0.008	CD	O
)	)	O
.	.	O

HI2	NNP	O
was	VBD	O
more	RBR	O
effective	JJ	O
than	IN	O
HI1	NNP	O
and	CC	O
CA	NNP	O
as	IN	O
measured	VBN	O
by	IN	O
pain	NN	O
relief	NN	O
scores	NNS	O
for	IN	O
week	NN	O
1	CD	O
(	(	O
P	NNP	O
<	VBZ	O
0.001	CD	O
vs	NN	O
HI1	NNP	O
and	CC	O
CA	NNP	O
)	)	O
,	,	O
week	NN	O
2	CD	O
(	(	O
P	NNP	O
<	VBZ	O
0.001	CD	O
vs	NN	O
HI1	NNP	O
and	CC	O
CA	NNP	O
)	)	O
,	,	O
and	CC	O
week	NN	O
3	CD	O
(	(	O
P	NNP	O
=	VBZ	O
0.008	CD	O
vs	NN	O
HI1	NNP	O
and	CC	O
P	NNP	O
<	NNP	O
0.001	CD	O
vs	NN	O
CA	NNP	O
)	)	O
;	:	O
daily	JJ	O
doses	NNS	O
of	IN	O
study	NN	O
medication	NN	O
for	IN	O
week	NN	O
1	CD	O
(	(	O
P	NNP	O
=	VBZ	O
0.019	CD	O
vs	NN	O
HI1	NNP	O
and	CC	O
P	NNP	O
=	NNP	O
0.011	CD	O
vs	NN	O
CA	NNP	O
)	)	O
;	:	O
daily	JJ	O
doses	NNS	O
of	IN	O
supplemental	JJ	O
analgesics	NNS	O
for	IN	O
week	NN	O
1	CD	O
(	(	O
P	NNP	O
=	VBZ	O
0.010	CD	O
vs	NN	O
HI1	NNP	O
and	CC	O
CA	NNP	O
)	)	O
;	:	O
and	CC	O
global	JJ	O
assessment	NN	O
scores	NNS	O
for	IN	O
week	NN	O
1	CD	O
(	(	O
P	NNP	O
=	VBZ	O
0.018	CD	O
vs	NN	O
HI1	NNP	O
and	CC	O
P	NNP	O
<	NNP	O
0.001	CD	O
vs	NN	O
CA	NNP	O
)	)	O
,	,	O
week	NN	O
2	CD	O
(	(	O
P	NNP	O
=	VBZ	O
0.005	CD	O
vs	NN	O
HI1	NNP	O
and	CC	O
P	NNP	O
<	NNP	O
0.001	CD	O
vs	NN	O
CA	NNP	O
)	)	O
,	,	O
and	CC	O
week	NN	O
4	CD	O
(	(	O
P	NNP	O
=	VBZ	O
0.013	CD	O
vs	NN	O
HI1	NNP	O
and	CC	O
P	NNP	O
=	NNP	O
0.023	CD	O
vs	NN	O
CA	NNP	O
)	)	O
.	.	O

There	EX	O
were	VBD	O
no	DT	O
significant	JJ	O
differences	NNS	O
between	IN	O
HI1	NNP	O
and	CC	O
CA	NNP	O
in	IN	O
any	DT	O
efficacy	NN	O
variable	JJ	O
.	.	O

There	EX	O
were	VBD	O
no	DT	O
significant	JJ	O
differences	NNS	O
in	IN	O
the	DT	O
number	NN	O
of	IN	O
patients	NNS	O
experiencing	VBG	O
adverse	JJ	O
events	NNS	O
in	IN	O
the	DT	O
HI2	NNP	O
(	(	O
127	CD	O
;	:	O
83	CD	O
%	NN	O
)	)	O
,	,	O
HI1	NNP	O
(	(	O
124	CD	O
;	:	O
79.5	CD	O
%	NN	O
)	)	O
,	,	O
and	CC	O
CA	NNP	O
(	(	O
129	CD	O
;	:	O
80.6	CD	O
%	NN	O
)	)	O
groups	NNS	O
.	.	O

However	RB	O
,	,	O
the	DT	O
mean	JJ	O
number	NN	O
of	IN	O
patients	NNS	O
who	WP	O
discontinued	VBD	O
treatment	NN	O
due	JJ	O
to	TO	O
adverse	JJ	O
events	NNS	O
was	VBD	O
significantly	RB	O
greater	JJR	O
in	IN	O
the	DT	O
HI2	NNP	O
group	NN	O
(	(	O
40	CD	O
;	:	O
26.1	CD	O
%	NN	O
)	)	O
than	IN	O
in	IN	O
the	DT	O
HI1	NNP	O
group	NN	O
(	(	O
23	CD	O
;	:	O
14.7	CD	O
%	NN	O
)	)	O
(	(	O
P	NNP	O
=	NNP	O
0.013	CD	O
)	)	O
.	.	O

CONCLUSIONS	VB	O
The	DT	O
results	NNS	O
of	IN	O
this	DT	O
study	NN	O
suggest	VBP	O
that	IN	O
2-tablet	JJ	O
doses	NNS	O
of	IN	O
combination	NN	O
hydrocodone	NN	O
7.5	CD	O
mg	NN	O
and	CC	O
ibuprofen	$	O
200	CD	O
mg	NN	O
may	MD	O
be	VB	O
more	RBR	O
effective	JJ	O
than	IN	O
either	DT	O
1-tablet	JJ	O
doses	NNS	O
of	IN	O
this	DT	O
combination	NN	O
or	CC	O
2-tablet	JJ	O
doses	NNS	O
of	IN	O
combination	NN	O
codeine	NN	O
30	CD	O
mg	NN	O
and	CC	O
acetaminophen	$	O
300	CD	O
mg	NN	O
.	.	O

Moreover	RB	O
,	,	O
1-tablet	JJ	O
doses	NNS	O
of	IN	O
combination	NN	O
hydrocodone	NN	O
7.5	CD	O
mg	NN	O
and	CC	O
ibuprofen	$	O
200	CD	O
mg	NN	O
may	MD	O
be	VB	O
as	RB	O
effective	JJ	O
as	IN	O
2-tablet	JJ	O
doses	NNS	O
of	IN	O
combination	NN	O
codeine	NN	O
30	CD	O
mg	NN	O
and	CC	O
acetaminophen	$	O
300	CD	O
mg	NN	O
.	.	O

Partial-area	JJ	O
method	NN	O
in	IN	O
bioequivalence	NN	O
assessment	NN	O
:	:	O
naproxen	NN	O
.	.	O

Regulatory	NNP	O
authorities	NNS	O
require	VBP	O
demonstration	NN	O
of	IN	O
bioequivalence	NN	O
through	IN	O
comparisons	NNS	O
of	IN	O
different	JJ	O
pharmacokinetic	JJ	O
parameters	NNS	O
,	,	O
the	DT	O
area	NN	O
under	IN	O
the	DT	O
plasma	JJ	O
concentration-time	JJ	O
curve	NN	O
(	(	O
AUC	NNP	O
)	)	O
,	,	O
the	DT	O
maximum	JJ	O
plasma	JJ	O
concentration	NN	O
(	(	O
Cmax	NNP	O
)	)	O
,	,	O
and	CC	O
the	DT	O
time	NN	O
to	TO	O
reach	VB	O
peak	JJ	O
concentration	NN	O
(	(	O
Tmax	NNP	O
)	)	O
.	.	O

The	DT	O
applicability	NN	O
and	CC	O
validity	NN	O
of	IN	O
regulatory	JJ	O
requirements	NNS	O
have	VBP	O
been	VBN	O
widely	RB	O
criticized	VBN	O
on	IN	O
statistical	JJ	O
and	CC	O
clinical	JJ	O
relevance	NN	O
grounds	NNS	O
.	.	O

For	IN	O
most	JJS	O
noncomplicated	JJ	O
absorption	NN	O
models	NNS	O
,	,	O
the	DT	O
AUC	NNP	O
correlates	VBZ	O
well	RB	O
with	IN	O
the	DT	O
extent	NN	O
of	IN	O
absorption	NN	O
.	.	O

However	RB	O
,	,	O
in	IN	O
nonlinear	JJ	O
models	NNS	O
of	IN	O
absorption	NN	O
,	,	O
in	IN	O
mechanisms	NN	O
involving	VBG	O
recycling	NN	O
of	IN	O
drugs	NNS	O
,	,	O
and	CC	O
for	IN	O
drugs	NNS	O
with	IN	O
long	JJ	O
half-life	NN	O
,	,	O
the	DT	O
use	NN	O
of	IN	O
total	JJ	O
AUC	NNP	O
(	(	O
from	IN	O
zero	CD	O
to	TO	O
infinity	NN	O
)	)	O
can	MD	O
give	VB	O
erroneous	JJ	O
and	CC	O
clinically	RB	O
irrelevant	JJ	O
results	NNS	O
since	IN	O
the	DT	O
area	NN	O
is	VBZ	O
mostly	RB	O
determined	VBN	O
by	IN	O
elimination	NN	O
phase	NN	O
or	CC	O
by	IN	O
recycling	VBG	O
.	.	O

The	DT	O
calculation	NN	O
of	IN	O
total	JJ	O
AUC	NNP	O
also	RB	O
involves	VBZ	O
prolonged	JJ	O
sampling	NN	O
,	,	O
adding	VBG	O
to	TO	O
the	DT	O
cost	NN	O
and	CC	O
risks	NNS	O
associated	VBN	O
with	IN	O
bioequivalence	NN	O
studies	NNS	O
.	.	O

The	DT	O
use	NN	O
of	IN	O
Cmax	NNP	O
or	CC	O
Tmax	NNP	O
as	IN	O
a	DT	O
measure	NN	O
of	IN	O
rate	NN	O
of	IN	O
absorption	NN	O
,	,	O
to	TO	O
correlate	VB	O
with	IN	O
clinical	JJ	O
relevance	NN	O
,	,	O
is	VBZ	O
widely	RB	O
criticized	VBN	O
on	IN	O
logical	JJ	O
,	,	O
technical	JJ	O
,	,	O
and	CC	O
statistical	JJ	O
grounds	NNS	O
.	.	O

For	IN	O
drugs	NNS	O
used	VBN	O
on	IN	O
a	DT	O
multiple-dose	JJ	O
basis	NN	O
,	,	O
Cmax	NNP	O
and	CC	O
Tmax	NNP	O
evaluations	NNS	O
become	VBP	O
redundant	JJ	O
since	IN	O
the	DT	O
average	JJ	O
plateau	NN	O
concentration	NN	O
is	VBZ	O
not	RB	O
affected	VBN	O
by	IN	O
these	DT	O
parameters	NNS	O
.	.	O

To	TO	O
resolve	VB	O
the	DT	O
drawbacks	NNS	O
in	IN	O
the	DT	O
traditional	JJ	O
methodology	NN	O
of	IN	O
bioequivalence	NN	O
evaluation	NN	O
,	,	O
the	DT	O
use	NN	O
of	IN	O
partial	JJ	O
areas	NNS	O
in	IN	O
lieu	NN	O
of	IN	O
total	JJ	O
AUC	NNP	O
,	,	O
Tmax	NNP	O
,	,	O
and	CC	O
Cmax	NNP	O
is	VBZ	O
suggested	VBN	O
.	.	O

This	DT	O
study	NN	O
investigates	VBZ	O
the	DT	O
logic	NN	O
and	CC	O
robustness	NN	O
of	IN	O
the	DT	O
partial-area	JJ	O
method	NN	O
in	IN	O
establishing	VBG	O
bioequivalence	NN	O
.	.	O

We	PRP	O
conclude	VBP	O
that	IN	O
the	DT	O
5h	CD	O
AUC	NNP	O
is	VBZ	O
a	DT	O
more	RBR	O
relevant	JJ	O
parameter	NN	O
to	TO	O
establish	VB	O
naproxen	NNS	O
bioequivalence	NN	O
than	IN	O
AUCinf	NNP	O
.	.	O

We	PRP	O
recommend	VBP	O
against	IN	O
using	VBG	O
symmetrical	JJ	O
confidence	NN	O
intervals	NNS	O
and	CC	O
report	NN	O
excellent	JJ	O
agreement	NN	O
among	IN	O
several	JJ	O
methods	NNS	O
of	IN	O
calculating	VBG	O
confidence	NN	O
intervals	NNS	O
,	,	O
probability	NN	O
values	NNS	O
,	,	O
and	CC	O
nonparametric	JJ	O
tests	NNS	O
.	.	O

We	PRP	O
suggest	VBP	O
that	IN	O
a	DT	O
single-point	JJ	O
short-term	JJ	O
AUC	NNP	O
is	VBZ	O
a	DT	O
better	JJR	O
indicator	NN	O
of	IN	O
the	DT	O
bioequivalence	NN	O
of	IN	O
generic	JJ	O
products	NNS	O
than	IN	O
the	DT	O
total	JJ	O
AUC	NNP	O
,	,	O
Cmax	NNP	O
,	,	O
and	CC	O
Tmax	NNP	O
as	IN	O
required	VBN	O
currently	RB	O
by	IN	O
the	DT	O
regulatory	JJ	O
authorities	NNS	O
.	.	O

Stress	NNP	O
reduction	NN	O
and	CC	O
analgesia	NN	O
in	IN	O
patients	NNS	O
exposed	VBN	O
to	TO	O
calming	VBG	O
music	NN	O
postoperatively	RB	O
:	:	O
a	DT	O
randomized	NN	O
controlled	VBN	O
trial	NN	O
.	.	O

BACKGROUND	NNP	O
AND	CC	O
OBJECTIVES	NNP	O
This	DT	O
randomized	VBD	O
controlled	JJ	O
trial	NN	O
was	VBD	O
designed	VBN	O
to	TO	O
evaluate	VB	O
,	,	O
first	RB	O
,	,	O
whether	IN	O
intra-	JJ	O
or	CC	O
postoperative	JJ	O
music	NN	O
therapy	NN	O
could	MD	O
influence	VB	O
stress	NN	O
and	CC	O
immune	JJ	O
response	NN	O
during	IN	O
and	CC	O
after	IN	O
general	JJ	O
anaesthesia	NN	O
and	CC	O
second	JJ	O
,	,	O
if	IN	O
there	EX	O
was	VBD	O
a	DT	O
different	JJ	O
response	NN	O
between	IN	O
patients	NNS	O
exposed	VBN	O
to	TO	O
music	NN	O
intra-	NN	O
or	CC	O
postoperatively	RB	O
.	.	O

METHOD	NNP	O
Seventy-five	JJ	O
patients	NNS	O
undergoing	VBG	O
open	JJ	O
hernia	NN	O
repair	NN	O
as	IN	O
day	NN	O
care	NN	O
surgery	NN	O
were	VBD	O
randomly	RB	O
allocated	VBN	O
to	TO	O
three	CD	O
groups	NNS	O
:	:	O
intraoperative	JJ	O
music	NN	O
,	,	O
postoperative	JJ	O
music	NN	O
and	CC	O
silence	NN	O
(	(	O
control	VB	O
group	NN	O
)	)	O
.	.	O

Anaesthesia	NNP	O
and	CC	O
postoperative	JJ	O
analgesia	NN	O
were	VBD	O
standardized	VBN	O
and	CC	O
the	DT	O
same	JJ	O
surgeon	NN	O
performed	VBD	O
all	PDT	O
the	DT	O
operations	NNS	O
.	.	O

Stress	NNP	O
response	NN	O
was	VBD	O
assessed	VBN	O
during	IN	O
and	CC	O
after	IN	O
surgery	NN	O
by	IN	O
determining	VBG	O
the	DT	O
plasma	NN	O
cortisol	NN	O
and	CC	O
blood	NN	O
glucose	NN	O
levels	NNS	O
.	.	O

Immune	NNP	O
function	NN	O
was	VBD	O
evaluated	VBN	O
by	IN	O
studying	VBG	O
immunoglobulin	NN	O
A	NNP	O
(	(	O
IgA	NNP	O
)	)	O
levels	NNS	O
.	.	O

Patients	NNS	O
'	POS	O
postoperative	JJ	O
pain	NN	O
,	,	O
anxiety	NN	O
,	,	O
blood	NN	O
pressure	NN	O
(	(	O
BP	NNP	O
)	)	O
,	,	O
heart	NN	O
rate	NN	O
(	(	O
HR	NNP	O
)	)	O
and	CC	O
oxygen	JJ	O
saturation	NN	O
were	VBD	O
also	RB	O
studied	VBN	O
as	IN	O
stress	NN	O
markers	NNS	O
.	.	O

RESULTS	NNP	O
There	EX	O
was	VBD	O
a	DT	O
significantly	RB	O
greater	JJR	O
decrease	NN	O
in	IN	O
the	DT	O
level	NN	O
of	IN	O
cortisol	NN	O
in	IN	O
the	DT	O
postoperative	JJ	O
music	NN	O
group	NN	O
vs.	IN	O
the	DT	O
control	NN	O
group	NN	O
(	(	O
206	CD	O
and	CC	O
72	CD	O
mmol	NN	O
L	NNP	O
(	(	O
-1	NNP	O
)	)	O
decreases	VBZ	O
,	,	O
respectively	RB	O
)	)	O
after	IN	O
2	CD	O
h	NN	O
in	IN	O
the	DT	O
post	NN	O
anaesthesia	NN	O
care	NN	O
unit	NN	O
.	.	O

The	DT	O
postoperative	JJ	O
music	NN	O
group	NN	O
had	VBD	O
less	JJR	O
anxiety	NN	O
and	CC	O
pain	NN	O
and	CC	O
required	VBD	O
less	JJR	O
morphine	NN	O
after	IN	O
1	CD	O
h	NNS	O
compared	VBN	O
with	IN	O
the	DT	O
control	NN	O
group	NN	O
.	.	O

In	IN	O
the	DT	O
postoperative	JJ	O
music	NN	O
group	NN	O
the	DT	O
total	JJ	O
requirement	NN	O
of	IN	O
morphine	NN	O
was	VBD	O
significantly	RB	O
lower	JJR	O
than	IN	O
in	IN	O
the	DT	O
control	NN	O
group	NN	O
.	.	O

The	DT	O
intraoperative	JJ	O
music	NN	O
group	NN	O
reported	VBD	O
less	JJR	O
pain	NN	O
after	IN	O
1	CD	O
h	NN	O
in	IN	O
the	DT	O
post	NN	O
anaesthesia	NN	O
care	NN	O
unit	NN	O
.	.	O

There	EX	O
was	VBD	O
no	DT	O
difference	NN	O
in	IN	O
IgA	NNP	O
,	,	O
blood	NN	O
glucose	NN	O
,	,	O
BP	NNP	O
,	,	O
HR	NNP	O
and	CC	O
oxygen	NN	O
saturation	NN	O
between	IN	O
the	DT	O
groups	NNS	O
.	.	O

CONCLUSION	NNP	O
This	DT	O
study	NN	O
suggests	VBZ	O
that	IN	O
intraoperative	JJ	O
music	NN	O
may	MD	O
decrease	VB	O
postoperative	JJ	O
pain	NN	O
,	,	O
and	CC	O
that	IN	O
postoperative	JJ	O
music	NN	O
therapy	NN	O
may	MD	O
reduce	VB	O
anxiety	NN	O
,	,	O
pain	NN	O
and	CC	O
morphine	NN	O
consumption	NN	O
.	.	O

Complementary	JJ	O
feeding	NN	O
with	IN	O
fortified	JJ	O
spread	NN	O
and	CC	O
incidence	NN	O
of	IN	O
severe	JJ	O
stunting	VBG	O
in	IN	O
6-	JJ	O
to	TO	O
18-month-old	JJ	O
rural	JJ	O
Malawians	NNPS	O
.	.	O

OBJECTIVE	NNP	O
To	TO	O
compare	VB	O
growth	NN	O
and	CC	O
incidence	NN	O
of	IN	O
malnutrition	NN	O
in	IN	O
infants	NNS	O
receiving	VBG	O
long-term	JJ	O
dietary	JJ	O
supplementation	NN	O
with	IN	O
ready-to-use	NN	O
fortified	VBN	O
spread	NN	O
(	(	O
FS	NNP	O
)	)	O
or	CC	O
micronutrient-fortified	JJ	O
maize-soy	JJ	O
flour	NN	O
(	(	O
likuni	JJ	O
phala	NN	O
[	NNP	O
LP	NNP	O
]	NNP	O
)	)	O
.	.	O

DESIGN	NNP	O
Randomized	NNP	O
,	,	O
controlled	VBD	O
,	,	O
single-blind	JJ	O
trial	NN	O
.	.	O

SETTING	NNP	O
Rural	JJ	O
Malawi	NNP	O
.	.	O

PARTICIPANTS	VB	O
A	DT	O
total	NN	O
of	IN	O
182	CD	O
six-month-old	JJ	O
infants	NNS	O
.	.	O

INTERVENTION	NN	O
Participants	NNS	O
were	VBD	O
randomized	VBN	O
to	TO	O
receive	VB	O
1	CD	O
year	NN	O
of	IN	O
daily	JJ	O
supplementation	NN	O
with	IN	O
71	CD	O
g	NN	O
of	IN	O
LP	NNP	O
(	(	O
282	CD	O
kcal	NN	O
)	)	O
,	,	O
50	CD	O
g	NN	O
of	IN	O
FS	NNP	O
(	(	O
FS50	NNP	O
)	)	O
(	(	O
256	CD	O
kcal	NN	O
)	)	O
,	,	O
or	CC	O
25	CD	O
g	NN	O
of	IN	O
FS	NNP	O
(	(	O
FS25	NNP	O
)	)	O
(	(	O
130	CD	O
[	RB	O
corrected	VBN	O
]	NNP	O
kcal	JJ	O
)	)	O
.	.	O

OUTCOME	NNP	O
MEASURES	NNP	O
Weight	NNP	O
and	CC	O
length	NN	O
gains	NNS	O
and	CC	O
the	DT	O
incidences	NNS	O
of	IN	O
severe	JJ	O
stunting	NN	O
,	,	O
underweight	JJ	O
,	,	O
and	CC	O
wasting	VBG	O
.	.	O

RESULTS	NNP	O
Mean	NNP	O
weight	NN	O
and	CC	O
length	NN	O
gains	NNS	O
in	IN	O
the	DT	O
LP	NNP	O
,	,	O
FS50	NNP	O
,	,	O
and	CC	O
FS25	NNP	O
groups	NNS	O
were	VBD	O
2.37	CD	O
,	,	O
2.47	CD	O
,	,	O
and	CC	O
2.37	CD	O
kg	NN	O
(	(	O
P	NNP	O
=	NNP	O
.66	NNP	O
)	)	O
and	CC	O
12.7	CD	O
,	,	O
13.5	CD	O
,	,	O
and	CC	O
13.2	CD	O
cm	NN	O
(	(	O
P	NNP	O
=	NNP	O
.23	NNP	O
)	)	O
,	,	O
respectively	RB	O
.	.	O

In	IN	O
the	DT	O
same	JJ	O
groups	NNS	O
,	,	O
the	DT	O
cumulative	JJ	O
12-month	JJ	O
incidence	NN	O
of	IN	O
severe	JJ	O
stunting	NN	O
was	VBD	O
13.3	CD	O
%	NN	O
,	,	O
0.0	CD	O
%	NN	O
,	,	O
and	CC	O
3.5	CD	O
%	NN	O
(	(	O
P	NNP	O
=	NNP	O
.01	NNP	O
)	)	O
,	,	O
of	IN	O
severe	JJ	O
underweight	NN	O
was	VBD	O
15.0	CD	O
%	NN	O
,	,	O
22.5	CD	O
%	NN	O
,	,	O
and	CC	O
16.9	CD	O
%	NN	O
(	(	O
P	NNP	O
=	NNP	O
.71	NNP	O
)	)	O
,	,	O
and	CC	O
of	IN	O
severe	JJ	O
wasting	NN	O
was	VBD	O
1.8	CD	O
%	NN	O
,	,	O
1.9	CD	O
%	NN	O
,	,	O
and	CC	O
1.8	CD	O
%	NN	O
(	(	O
P	NNP	O
>	NNP	O
.99	NNP	O
)	)	O
.	.	O

Compared	VBN	O
with	IN	O
LP-supplemented	JJ	O
infants	NNS	O
,	,	O
those	DT	O
given	VBN	O
FS50	NNP	O
gained	VBD	O
a	DT	O
mean	NN	O
of	IN	O
100	CD	O
g	NNS	O
more	JJR	O
weight	NN	O
and	CC	O
0.8	CD	O
cm	NN	O
more	JJR	O
length	NN	O
.	.	O

There	EX	O
was	VBD	O
a	DT	O
significant	JJ	O
interaction	NN	O
between	IN	O
baseline	NN	O
length	NN	O
and	CC	O
intervention	NN	O
(	(	O
P	NNP	O
=	NNP	O
.04	NNP	O
)	)	O
;	:	O
in	IN	O
children	NNS	O
with	IN	O
below-median	JJ	O
length	NN	O
at	IN	O
enrollment	NN	O
,	,	O
those	DT	O
given	VBN	O
FS50	NNP	O
gained	VBD	O
a	DT	O
mean	NN	O
of	IN	O
1.9	CD	O
cm	NNS	O
more	JJR	O
than	IN	O
individuals	NNS	O
receiving	VBG	O
LP	NNP	O
.	.	O

CONCLUSION	NNP	O
One-year-long	JJ	O
complementary	JJ	O
feeding	NN	O
with	IN	O
FS	NNP	O
does	VBZ	O
not	RB	O
have	VB	O
a	DT	O
significantly	RB	O
larger	JJR	O
effect	NN	O
than	IN	O
LP	NNP	O
on	IN	O
mean	JJ	O
weight	NN	O
gain	NN	O
in	IN	O
all	DT	O
infants	NNS	O
,	,	O
but	CC	O
it	PRP	O
is	VBZ	O
likely	JJ	O
to	TO	O
boost	VB	O
linear	JJ	O
growth	NN	O
in	IN	O
the	DT	O
most	RBS	O
disadvantaged	JJ	O
individuals	NNS	O
and	CC	O
,	,	O
hence	RB	O
,	,	O
decrease	VB	O
the	DT	O
incidence	NN	O
of	IN	O
severe	JJ	O
stunting	NN	O
.	.	O

Independent	NNP	O
prognostic	JJ	O
information	NN	O
provided	VBN	O
by	IN	O
sphygmomanometrically	RB	O
determined	VBN	O
pulse	JJ	O
pressure	NN	O
and	CC	O
mean	JJ	O
arterial	JJ	O
pressure	NN	O
in	IN	O
patients	NNS	O
with	IN	O
left	JJ	C
ventricular	JJ	C
dysfunction	NN	C
.	.	O

OBJECTIVES	CC	O
The	DT	O
purpose	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
evaluate	VB	O
the	DT	O
relationship	NN	O
of	IN	O
baseline	NN	O
pulse	JJ	O
pressure	NN	O
and	CC	O
mean	JJ	O
arterial	JJ	O
pressure	NN	O
to	TO	O
mortality	NN	O
in	IN	O
patients	NNS	O
with	IN	O
left	JJ	O
ventricular	JJ	O
dysfunction	NN	O
.	.	O

BACKGROUND	NNP	O
Increased	VBD	O
conduit	NN	O
vessel	NN	O
stiffness	NN	O
increases	VBZ	O
pulse	JJ	O
pressure	NN	O
and	CC	O
pulsatile	NN	O
load	NN	O
,	,	O
potentially	RB	O
contributing	VBG	O
to	TO	O
adverse	VB	O
outcomes	NNS	O
in	IN	O
patients	NNS	O
with	IN	O
left	JJ	O
ventricular	JJ	O
dysfunction	NN	O
.	.	O

METHODS	NNP	O
Pulse	NNP	O
and	CC	O
mean	VB	O
arterial	JJ	O
pressure	NN	O
were	VBD	O
analyzed	VBN	O
for	IN	O
their	PRP$	O
effect	NN	O
on	IN	O
mortality	NN	O
,	,	O
adjusting	VBG	O
for	IN	O
other	JJ	O
modifiers	NNS	O
of	IN	O
risk	NN	O
,	,	O
using	VBG	O
Cox	NNP	O
proportional	JJ	O
hazards	NNS	O
regression	NN	O
analysis	NN	O
of	IN	O
data	NNS	O
collected	VBN	O
from	IN	O
6,781	CD	SS
patients	NNS	O
randomized	VBN	O
into	IN	O
the	DT	O
Studies	NNPS	O
of	IN	O
Left	NNP	O
Ventricular	NNP	O
Dysfunction	NNP	O
trials	NNS	O
.	.	O

RESULTS	NNP	O
Pulse	NNP	O
and	CC	O
mean	VB	O
arterial	JJ	O
pressure	NN	O
were	VBD	O
related	VBN	O
positively	RB	O
to	TO	O
each	DT	O
other	JJ	O
,	,	O
age	NN	O
,	,	O
ejection	NN	O
fraction	NN	O
and	CC	O
prevalence	NN	O
of	IN	O
diabetes	NNS	O
and	CC	O
hypertension	NN	O
and	CC	O
inversely	RB	O
to	TO	O
prior	VB	O
myocardial	JJ	O
infarction	NN	O
and	CC	O
beta-adrenergic	JJ	O
blocking	NN	O
agent	NN	O
use	NN	O
.	.	O

Higher	JJR	O
pulse	JJ	O
pressure	NN	O
was	VBD	O
associated	VBN	O
with	IN	O
increased	JJ	O
prevalence	NN	O
of	IN	O
female	JJ	O
gender	NN	O
,	,	O
greater	JJR	O
calcium	NN	O
channel	NN	O
blocking	VBG	O
agent	NN	O
,	,	O
digoxin	NN	O
and	CC	O
diuretic	JJ	O
use	NN	O
,	,	O
lower	JJR	O
heart	NN	O
rate	NN	O
and	CC	O
a	DT	O
higher	JJR	O
rate	NN	O
of	IN	O
reported	VBN	O
smoking	NN	O
history	NN	O
.	.	O

Higher	JJR	O
mean	JJ	O
arterial	JJ	O
pressure	NN	O
was	VBD	O
associated	VBN	O
with	IN	O
higher	JJR	O
heart	NN	O
rate	NN	O
,	,	O
lower	JJR	O
calcium	NN	O
channel	NN	O
blocker	NN	O
and	CC	O
digoxin	NN	O
use	NN	O
and	CC	O
lower	JJR	O
New	NNP	O
York	NNP	O
Heart	NNP	O
Association	NNP	O
functional	JJ	O
class	NN	O
.	.	O

Over	IN	O
a	DT	O
61-month	JJ	O
follow-up	JJ	O
1,582	CD	O
deaths	NNS	O
(	(	O
1,397	CD	O
cardiovascular	NN	O
)	)	O
occurred	VBD	O
.	.	O

In	IN	O
a	DT	O
multivariate	NN	O
analysis	NN	O
adjusting	VBG	O
for	IN	O
the	DT	O
above	JJ	O
covariates	NNS	O
and	CC	O
treatment	NN	O
assignment	NN	O
,	,	O
higher	JJR	O
pulse	JJ	O
pressure	NN	O
remained	VBD	O
an	DT	O
independent	JJ	O
predictor	NN	O
of	IN	O
total	JJ	O
and	CC	O
cardiovascular	JJ	O
mortality	NN	O
(	(	O
total	JJ	O
mortality	NN	O
relative	NN	O
risk	NN	O
,	,	O
1.05	CD	O
per	IN	O
10	CD	O
mm	NN	O
Hg	NNP	O
increment	NN	O
;	:	O
95	CD	O
%	NN	O
confidence	NN	O
interval	NN	O
,	,	O
1.01	CD	O
to	TO	O
1.10	CD	O
;	:	O
p	NN	O
=	VBZ	O
0.02	CD	O
)	)	O
.	.	O

Mean	JJ	O
arterial	JJ	O
pressure	NN	O
was	VBD	O
inversely	RB	O
related	VBN	O
to	TO	O
total	JJ	O
and	CC	O
cardiovascular	JJ	O
mortality	NN	O
(	(	O
total	JJ	O
mortality	NN	O
relative	NN	O
risk	NN	O
,	,	O
0.89	CD	O
;	:	O
95	CD	O
%	NN	O
confidence	NN	O
interval	NN	O
,	,	O
0.85	CD	O
to	TO	O
0.94	CD	O
;	:	O
p	NN	O
<	VBZ	O
0.0001	CD	O
)	)	O
.	.	O

CONCLUSIONS	NNP	O
One	CD	O
noninvasive	JJ	O
blood	NN	O
pressure	NN	O
measurement	NN	O
provides	VBZ	O
two	CD	O
independent	JJ	O
prognostic	JJ	O
factors	NNS	O
for	IN	O
survival	NN	O
.	.	O

Increased	VBD	O
conduit	NN	O
vessel	NN	O
stiffness	NN	O
,	,	O
as	IN	O
assessed	VBN	O
by	IN	O
pulse	JJ	O
pressure	NN	O
,	,	O
may	MD	O
contribute	VB	O
to	TO	O
increased	VBN	O
mortality	NN	O
in	IN	O
patients	NNS	O
with	IN	O
left	JJ	O
ventricular	JJ	O
dysfunction	NN	O
,	,	O
independent	JJ	O
of	IN	O
mean	JJ	O
arterial	JJ	O
pressure	NN	O
.	.	O

[	JJ	O
Effect	NNP	O
of	IN	O
Selaginella	NNP	O
combined	VBD	O
with	IN	O
radiotherapy	NN	O
on	IN	O
nasopharyngeal	JJ	C
carcinoma	NN	C
]	NNP	O
.	.	O

OBJECTIVE	NNP	O
To	TO	O
observe	VB	O
the	DT	O
Chinese	JJ	O
herbal	JJ	O
medicine	NN	O
Selaginella-induced	NNP	O
radiosensitization	NN	O
of	IN	O
terminal	JJ	C
nasopharyngeal	JJ	C
carcinoma	NN	C
(	(	O
NPC	NNP	C
)	)	O
.	.	O

METHODS	NNP	O
Totally	RB	O
180	CD	SS
patients	NNS	O
with	IN	O
NPC	NNP	C
were	VBD	O
divided	VBN	O
equally	RB	O
into	IN	O
3	CD	O
groups	NNS	O
with	IN	O
the	DT	O
same	JJ	O
radiotherapeutic	JJ	O
protocols	NNS	O
.	.	O

The	DT	O
patients	NNS	O
in	IN	O
group	NN	O
A	NNP	O
received	VBD	O
radiotherapy	NN	O
alone	RB	O
,	,	O
those	DT	O
in	IN	O
group	NN	O
B	NNP	O
were	VBD	O
given	VBN	O
daily	JJ	O
Selaginella	NNP	O
(	(	O
30	CD	O
g	NN	O
)	)	O
prepared	VBD	O
into	IN	O
50	CD	O
ml	JJ	O
decoction	NN	O
during	IN	O
the	DT	O
entire	JJ	O
course	NN	O
of	IN	O
radiotherapy	NN	O
,	,	O
and	CC	O
those	DT	O
in	IN	O
group	NN	O
C	NNP	O
had	VBD	O
Selaginella	NNP	O
30	CD	O
g	JJ	O
daily	RB	O
in	IN	O
the	DT	O
late	JJ	O
course	NN	O
of	IN	O
radiotherapy	NN	O
.	.	O

RESULTS	VB	O
The	DT	O
complete	JJ	O
remission	NN	O
rate	NN	O
of	IN	O
nasopharyngeal	JJ	O
primary	JJ	O
lesions	NNS	O
in	IN	O
groups	NNS	O
B	NNP	O
and	CC	O
C	NNP	O
was	VBD	O
significantly	RB	O
higher	JJR	O
than	IN	O
that	DT	O
in	IN	O
group	NN	O
A	NNP	O
,	,	O
with	IN	O
also	RB	O
significantly	RB	O
higher	JJR	O
complete	JJ	O
remission	NN	O
rates	NNS	O
of	IN	O
the	DT	O
cervical	JJ	O
lymph	NN	O
nodes	NNS	O
.	.	O

The	DT	O
acute	JJ	O
toxicity	NN	O
of	IN	O
the	DT	O
skin	NN	O
and	CC	O
mucous	JJ	O
membrane	NN	O
was	VBD	O
milder	RBR	O
in	IN	O
the	DT	O
latter	JJ	O
two	CD	O
groups	NNS	O
,	,	O
but	CC	O
the	DT	O
differences	NNS	O
were	VBD	O
not	RB	O
significant	JJ	O
.	.	O

CONCLUSION	NNP	O
Selaginella	NNP	O
may	MD	O
induce	VB	O
radiosensitization	NN	O
for	IN	O
terminal	JJ	C
NPC	NNP	C
and	CC	O
does	VBZ	O
not	RB	O
increase	VB	O
the	DT	O
acute	JJ	O
toxicity	NN	O
of	IN	O
radiotherapy	NN	O
.	.	O

Treatment	NN	O
of	IN	O
recurrent	NN	O
chronic	JJ	O
hyperplastic	JJ	O
sinusitis	NN	O
with	IN	O
nasal	JJ	O
polyposis	NN	O
.	.	O

OBJECTIVE	UH	O
To	TO	O
demonstrate	VB	O
the	DT	O
long-term	JJ	O
efficacy	NN	O
of	IN	O
intranasal	JJ	O
furosemide	NN	O
,	,	O
an	DT	O
inhibitor	NN	O
of	IN	O
the	DT	O
sodium	NN	O
chloride	NN	O
cotransporter	NN	O
channel	NN	O
at	IN	O
the	DT	O
basolateral	JJ	O
surface	NN	O
of	IN	O
the	DT	O
respiratory	JJ	O
epithelial	JJ	O
cell	NN	O
,	,	O
vs	VBZ	O
no	DT	O
therapeutic	JJ	O
intervention	NN	O
vs	NN	O
intranasal	NN	O
mometasone	NN	O
furoate	NN	O
,	,	O
a	DT	O
corticosteroid	NN	O
,	,	O
in	IN	O
preventing	VBG	O
relapses	NNS	O
of	IN	O
chronic	JJ	O
hyperplastic	JJ	O
sinusitis	NN	O
with	IN	O
nasal	JJ	O
polyposis	NN	O
.	.	O

DESIGN	NNP	O
Randomized	NNP	O
prospective	NN	O
controlled	VBD	O
study	NN	O
.	.	O

Patients	NNS	O
were	VBD	O
examined	VBN	O
every	DT	O
6	CD	O
months	NNS	O
during	IN	O
follow-up	NN	O
(	(	O
range	NN	O
,	,	O
1-9	JJ	O
years	NNS	O
)	)	O
.	.	O

PATIENTS	VB	O
One	CD	O
hundred	JJ	O
seventy	NN	O
patients	NNS	O
with	IN	O
bilateral	JJ	O
obstructive	CD	O
or	CC	O
minimally	RB	O
obstructive	JJ	O
chronic	JJ	O
hyperplastic	JJ	O
sinusitis	NN	O
with	IN	O
nasal	JJ	O
polyposis	NN	O
.	.	O

INTERVENTION	NNP	O
All	DT	O
patients	NNS	O
were	VBD	O
surgically	RB	O
treated	VBN	O
in	IN	O
the	DT	O
ENT	NNP	O
Department	NNP	O
,	,	O
University	NNP	O
of	IN	O
Siena	NNP	O
Medical	NNP	O
School	NNP	O
.	.	O

One	CD	O
month	NN	O
after	IN	O
surgery	NN	O
,	,	O
group	NN	O
1	CD	O
patients	NNS	O
(	(	O
n	JJ	O
=	NNP	O
97	CD	O
)	)	O
started	VBD	O
treatment	NN	O
with	IN	O
intranasal	JJ	O
furosemide	NN	O
,	,	O
group	NN	O
2	CD	O
(	(	O
n	JJ	O
=	NNP	O
40	CD	O
)	)	O
received	VBD	O
no	DT	O
therapeutic	JJ	O
treatment	NN	O
,	,	O
and	CC	O
group	NN	O
3	CD	O
(	(	O
n	JJ	O
=	NNP	O
33	CD	O
)	)	O
were	VBD	O
treated	VBN	O
with	IN	O
mometasone	NN	O
.	.	O

MAIN	NNP	O
OUTCOME	NNP	O
MEASURES	NNP	O
Clinical	NNP	O
and	CC	O
instrumental	JJ	O
evaluation	NN	O
of	IN	O
postoperative	JJ	O
outcomes	NNS	O
.	.	O

RESULTS	NNP	O
Seventeen	NNP	O
(	(	O
17.5	CD	O
%	NN	O
)	)	O
of	IN	O
97	CD	O
patients	NNS	O
in	IN	O
group	NN	O
1	CD	O
,	,	O
12	CD	O
(	(	O
30.0	CD	O
%	NN	O
)	)	O
of	IN	O
40	CD	O
patients	NNS	O
in	IN	O
group	NN	O
2	CD	O
,	,	O
and	CC	O
8	CD	O
(	(	O
24.2	CD	O
%	NN	O
)	)	O
of	IN	O
33	CD	O
patients	NNS	O
in	IN	O
group	NN	O
3	CD	O
experienced	VBD	O
nasal	JJ	O
polyposis	NN	O
relapses	NNS	O
.	.	O

We	PRP	O
noted	VBD	O
a	DT	O
prevalence	NN	O
of	IN	O
early-stage	JJ	O
relapse	NN	O
in	IN	O
patients	NNS	O
treated	VBN	O
with	IN	O
furosemide	NN	O
or	CC	O
mometasone	NN	O
,	,	O
whereas	JJ	O
patients	NNS	O
who	WP	O
did	VBD	O
not	RB	O
receive	VB	O
any	DT	O
treatment	NN	O
experienced	VBD	O
more	JJR	O
severe	JJ	O
grades	NNS	O
of	IN	O
chronic	JJ	O
hyperplastic	JJ	O
sinusitis	NN	O
with	IN	O
nasal	JJ	O
polyposis	NN	O
(	(	O
P	NNP	O
<	NNP	O
.005	NNP	O
)	)	O
.	.	O

CONCLUSION	NNP	O
Use	NNP	O
of	IN	O
intranasal	NN	O
furosemide	JJ	O
represents	VBZ	O
a	DT	O
valid	JJ	O
therapeutic	JJ	O
treatment	NN	O
in	IN	O
the	DT	O
prevention	NN	O
of	IN	O
chronic	JJ	O
hyperplastic	JJ	O
sinusitis	NN	O
with	IN	O
nasal	JJ	O
polyposis	NN	O
.	.	O

A	DT	O
limited	JJ	O
sampling	NN	O
method	NN	O
for	IN	O
the	DT	O
estimation	NN	O
of	IN	O
flunarizine	JJ	O
area	NN	O
under	IN	O
the	DT	O
curve	NN	O
(	(	O
AUC	NNP	O
)	)	O
and	CC	O
maximum	JJ	O
plasma	JJ	O
concentration	NN	O
(	(	O
Cmax	NNP	O
)	)	O
.	.	O

A	DT	O
limited	JJ	O
sampling	NN	O
model	NN	O
has	VBZ	O
been	VBN	O
developed	VBN	O
for	IN	O
flunarizine	NN	O
following	VBG	O
a	DT	O
30	CD	O
mg	JJ	O
oral	JJ	O
dose	NN	O
in	IN	O
epileptic	JJ	C
patients	NNS	C
who	WP	O
were	VBD	O
receiving	VBG	C
phenytoin	NN	C
or	CC	C
carbamazepine	NN	C
or	CC	C
both	DT	C
,	,	O
to	TO	O
estimate	VB	O
the	DT	O
area	NN	O
under	IN	O
the	DT	O
curve	NN	O
(	(	O
AUC	NNP	O
)	)	O
and	CC	O
maximum	JJ	O
plasma	JJ	O
concentration	NN	O
(	(	O
Cmax	NNP	O
)	)	O
.	.	O

The	DT	O
model	NN	O
was	VBD	O
developed	VBN	O
using	VBG	O
training	VBG	O
data	NNS	O
sets	NNS	O
from	IN	O
30	CD	O
,	,	O
20	CD	O
,	,	O
15	CD	O
,	,	O
or	CC	O
10	CD	O
patients	NNS	O
at	IN	O
one	CD	O
or	CC	O
two	CD	O
time	NN	O
points	NNS	O
.	.	O

The	DT	O
equations	NNS	O
describing	VBG	O
the	DT	O
models	NNS	O
for	IN	O
AUC	NNP	O
using	VBG	O
two	CD	O
time	NN	O
points	NNS	O
(	(	O
3	CD	O
and	CC	O
24h	CD	O
)	)	O
and	CC	O
Cmax	NNP	O
for	IN	O
the	DT	O
training	NN	O
data	NNS	O
set	NN	O
of	IN	O
30	CD	O
subjects	NNS	O
were	VBD	O
AUCpredicted	NNP	O
=	NNP	O
11.1	CD	O
C3h	NNP	O
+	VBD	O
121.4	CD	O
C24h	NNP	O
-	:	O
157	CD	O
(	(	O
r	NN	O
=	RB	O
0.80	CD	O
)	)	O
Cmax	NNP	O
(	(	O
predicted	VBN	O
)	)	O
=	$	O
0.036	CD	O
AUC	NNP	O
+	$	O
42.9	CD	O
(	(	O
r	NN	O
=	RB	O
0.74	CD	O
)	)	O
The	DT	O
model	NN	O
was	VBD	O
validated	VBN	O
on	IN	O
64	CD	SS
patients	NNS	O
who	WP	O
received	VBD	O
flunarizine	JJ	O
orally	RB	O
.	.	O

The	DT	O
model	NN	O
provided	VBD	O
reasonably	RB	O
good	JJ	O
estimates	NNS	O
for	IN	O
both	DT	O
AUC	NNP	O
and	CC	O
Cmax	NNP	O
.	.	O

The	DT	O
mean	NN	O
predicted	VBD	O
AUC	NNP	O
of	IN	O
flunarizine	NN	O
was	VBD	O
1230	CD	O
+/-	JJ	O
717	CD	O
ng	JJ	O
h	NN	O
mL-1	NN	O
,	,	O
whereas	IN	O
the	DT	O
observed	JJ	O
AUC	NNP	O
was	VBD	O
1203	CD	O
+/-	JJ	O
900	CD	O
ng	JJ	O
h	JJ	O
mL-1	NN	O
.	.	O

The	DT	O
bias	NN	O
of	IN	O
the	DT	O
prediction	NN	O
was	VBD	O
2	CD	O
%	NN	O
and	CC	O
precision	NN	O
was	VBD	O
28	CD	O
%	NN	O
.	.	O

The	DT	O
mean	NN	O
predicted	VBD	O
Cmax	NNP	O
of	IN	O
flunarizine	NN	O
was	VBD	O
86	CD	O
+/-	JJ	O
32	CD	O
ng	JJ	O
mL-1	NN	O
as	IN	O
compared	VBN	O
to	TO	O
an	DT	O
observed	JJ	O
mean	NN	O
Cmax	NNP	O
of	IN	O
90	CD	O
+/-	JJ	O
42	CD	O
ng	JJ	O
mL-1	NN	O
.	.	O

The	DT	O
bias	NN	O
and	CC	O
precision	NN	O
of	IN	O
the	DT	O
prediction	NN	O
were	VBD	O
4	CD	O
%	NN	O
and	CC	O
24	CD	O
%	NN	O
,	,	O
respectively	RB	O
.	.	O

The	DT	O
method	NN	O
described	VBD	O
here	RB	O
may	MD	O
be	VB	O
used	VBN	O
to	TO	O
estimate	VB	O
AUC	NNP	O
and	CC	O
Cmax	NNP	O
for	IN	O
flunarizine	NN	O
without	IN	O
detailed	JJ	O
pharmacokinetic	JJ	O
studies	NNS	O
.	.	O

Barriers	NNS	O
to	TO	O
hypertension	NN	O
care	NN	O
and	CC	O
control	NN	O
in	IN	O
young	JJ	O
urban	JJ	O
black	JJ	O
men	NNS	O
.	.	O

Barriers	NNS	O
to	TO	O
high	JJ	O
blood	NN	O
pressure	NN	O
(	(	O
HBP	NNP	O
)	)	O
care	NN	O
and	CC	O
control	NN	O
have	VBP	O
been	VBN	O
reported	VBN	O
in	IN	O
the	DT	O
literature	NN	O
for	IN	O
>	$	O
30	CD	O
years	NNS	O
.	.	O

Few	JJ	O
reports	NNS	O
on	IN	O
barriers	NNS	O
,	,	O
however	RB	O
,	,	O
have	VBP	O
focused	VBN	O
on	IN	O
the	DT	O
young	JJ	O
black	JJ	O
man	NN	O
with	IN	O
HBP	NNP	O
,	,	O
the	DT	O
age/sex/race	NN	O
group	NN	O
with	IN	O
the	DT	O
highest	JJS	O
rates	NNS	O
of	IN	O
early	JJ	O
severe	JJ	O
and	CC	O
complicated	JJ	O
HBP	NNP	O
and	CC	O
the	DT	O
lowest	JJS	O
rates	NNS	O
of	IN	O
awareness	NN	O
,	,	O
treatment	NN	O
,	,	O
and	CC	O
control	NN	O
.	.	O

In	IN	O
a	DT	O
randomized	JJ	O
clinical	JJ	O
trial	NN	O
of	IN	O
comprehensive	JJ	O
care	NN	O
for	IN	O
hypertensive	JJ	O
young	JJ	O
urban	JJ	O
black	JJ	O
men	NNS	O
,	,	O
factors	NNS	O
potentially	RB	O
associated	VBN	O
with	IN	O
care	NN	O
and	CC	O
control	NN	O
were	VBD	O
assessed	VBN	O
at	IN	O
baseline	NN	O
for	IN	O
the	DT	O
309	CD	O
enrolled	VBD	O
men	NNS	O
.	.	O

A	DT	O
majority	NN	O
of	IN	O
the	DT	O
men	NNS	O
encountered	VBD	O
a	DT	O
variety	NN	O
of	IN	O
barriers	NNS	O
including	VBG	O
economic	JJ	O
,	,	O
social	JJ	O
,	,	O
and	CC	O
lifestyle	JJ	O
obstacles	NNS	O
to	TO	O
adequate	VB	O
BP	NNP	O
care	NN	O
and	CC	O
control	NN	O
,	,	O
including	VBG	O
no	DT	O
current	JJ	O
HBP	NNP	O
care	NN	O
(	(	O
49	CD	O
%	NN	O
)	)	O
,	,	O
risk	NN	O
of	IN	O
alcoholism	NN	O
(	(	O
62	CD	O
%	NN	O
)	)	O
,	,	O
use	NN	O
of	IN	O
illicit	NN	O
drugs	NNS	O
(	(	O
45	CD	O
%	NN	O
)	)	O
,	,	O
social	JJ	O
isolation	NN	O
(	(	O
47	CD	O
%	NN	O
)	)	O
,	,	O
unemployment	NN	O
(	(	O
40	CD	O
%	NN	O
)	)	O
,	,	O
and	CC	O
lack	NN	O
of	IN	O
health	NN	O
insurance	NN	O
(	(	O
51	CD	O
%	NN	O
)	)	O
.	.	O

Having	VBG	O
health	NN	O
insurance	NN	O
(	(	O
odds	NNS	O
ratio	VBP	O
=	JJ	O
7.20	CD	O
,	,	O
P	NNP	O
=	NNP	O
.00	NNP	O
)	)	O
and	CC	O
a	DT	O
negative	JJ	O
urine	JJ	O
drug	NN	O
screen	NN	O
(	(	O
odds	NNS	O
ratio	VBP	O
=	JJ	O
.56	NNP	O
,	,	O
P	NNP	O
=	NNP	O
.04	NNP	O
)	)	O
were	VBD	O
significant	JJ	O
predictors	NNS	O
of	IN	O
being	VBG	O
in	IN	O
HBP	NNP	O
care	NN	O
.	.	O

Low	JJ	O
alcoholism	NN	O
risk	NN	O
and	CC	O
employment	NN	O
were	VBD	O
identified	VBN	O
as	IN	O
significant	JJ	O
predictors	NNS	O
of	IN	O
compliance	NN	O
with	IN	O
HBP	NNP	O
medication-taking	JJ	O
behavior	NN	O
.	.	O

Men	NNP	O
currently	RB	O
using	VBG	O
illicit	JJ	O
drugs	NNS	O
were	VBD	O
2.64	CD	O
times	NNS	O
less	RBR	O
likely	JJ	O
to	TO	O
have	VB	O
controlled	VBN	O
BP	NNP	O
compared	VBN	O
with	IN	O
their	PRP$	O
counterparts	NNS	O
who	WP	O
did	VBD	O
not	RB	O
use	VB	O
illicit	JJ	O
drugs	NNS	O
,	,	O
and	CC	O
men	NNS	O
currently	RB	O
taking	VBG	O
HBP	NNP	O
medication	NN	O
were	VBD	O
63	CD	O
times	NNS	O
more	RBR	O
likely	JJ	O
have	VBP	O
controlled	VBN	O
BP	NNP	O
compared	VBN	O
with	IN	O
men	NNS	O
not	RB	O
taking	VBG	O
HBP	NNP	O
medication	NN	O
.	.	O

Comprehensive	JJ	O
interventions	NNS	O
are	VBP	O
needed	VBN	O
to	TO	O
address	VB	O
socioeconomic	JJ	O
and	CC	O
lifestyle	JJ	O
issues	NNS	O
as	RB	O
well	RB	O
as	IN	O
other	JJ	O
barriers	NNS	O
to	TO	O
care	VB	O
and	CC	O
treatment	NN	O
,	,	O
if	IN	O
HBP	NNP	O
care	NN	O
is	VBZ	O
to	TO	O
be	VB	O
salient	JJ	O
and	CC	O
effective	JJ	O
in	IN	O
this	DT	O
high	JJ	O
risk	NN	O
group	NN	O
.	.	O

Topical	JJ	O
treatment	NN	O
of	IN	O
alopecia	NN	O
areata	NN	O
.	.	O

It	PRP	O
has	VBZ	O
been	VBN	O
shown	VBN	O
previously	RB	O
that	IN	O
alopecia	JJ	O
areata	NNS	O
can	MD	O
be	VB	O
treated	VBN	O
with	IN	O
dinitrochlorobenzene	NN	O
(	(	O
DNCB	NNP	O
)	)	O
and	CC	O
other	JJ	O
contact	NN	O
allergens	NNS	O
.	.	O

Whether	IN	O
these	DT	O
agents	NNS	O
work	NN	O
by	IN	O
inducing	VBG	O
immunologic	JJ	O
stimulation	NN	O
or	CC	O
simply	RB	O
a	DT	O
nonspecific	JJ	O
inflammatory	NN	O
reaction	NN	O
has	VBZ	O
not	RB	O
been	VBN	O
definitively	RB	O
demonstrated	VBN	O
.	.	O

To	TO	O
test	VB	O
the	DT	O
relative	JJ	O
importance	NN	O
of	IN	O
these	DT	O
two	CD	O
mechanisms	NNS	O
,	,	O
we	PRP	O
have	VBP	O
randomly	RB	O
studied	VBN	O
22	CD	O
patients	NNS	O
with	IN	O
alopecia	JJ	O
areata	NNS	O
to	TO	O
whom	WP	O
either	DT	O
DNCB	NNP	O
or	CC	O
croton	VB	O
oil	NN	O
was	VBD	O
applied	VBN	O
topically	RB	O
.	.	O

Sixty-three	JJ	O
percent	NN	O
of	IN	O
patients	NNS	O
without	IN	O
spontaneous	JJ	O
regrowth	NN	O
of	IN	O
hair	NN	O
regrew	NNS	O
hair	NN	O
after	IN	O
DNCB	NNP	O
application	NN	O
.	.	O

None	NN	O
of	IN	O
those	DT	O
treated	VBN	O
with	IN	O
croton	NN	O
oil	NN	O
regrew	VBD	O
hair	NN	O
when	WRB	O
treated	VBN	O
later	RB	O
with	IN	O
DNCB	NNP	O
.	.	O

Therefore	NNP	O
,	,	O
a	DT	O
proved	JJ	O
contact	NN	O
allergen	NN	O
was	VBD	O
shown	VBN	O
to	TO	O
be	VB	O
required	VBN	O
for	IN	O
therapeutic	JJ	O
success	NN	O
.	.	O

Patient	JJ	O
acceptance	NN	O
of	IN	O
the	DT	O
induced	JJ	O
contact	NN	O
dermatitis	NN	O
was	VBD	O
excellent	JJ	O
.	.	O

In	IN	O
light	NN	O
of	IN	O
recent	JJ	O
data	NNS	O
on	IN	O
the	DT	O
mutagenicity	NN	O
of	IN	O
DNCB	NNP	O
to	TO	O
bacteria	NNS	O
,	,	O
other	JJ	O
contact	NN	O
allergens	NNS	O
for	IN	O
topical	JJ	O
immunotherapy	NN	O
are	VBP	O
being	VBG	O
sought	VBN	O
.	.	O

Randomized	VBN	O
trial	NN	O
of	IN	O
a	DT	O
stage-of-change	NN	O
oriented	VBN	O
smoking	VBG	O
cessation	NN	O
intervention	NN	O
in	IN	O
infertile	NN	C
and	CC	O
pregnant	JJ	C
women	NNS	SE
.	.	O

OBJECTIVE	NNP	O
To	TO	O
assess	VB	O
a	DT	O
stage-of-change	NN	O
oriented	VBN	O
smoking	VBG	O
cessation	NN	O
intervention	NN	O
for	IN	O
infertile	NN	O
and	CC	O
pregnant	JJ	O
women	NNS	O
,	,	O
compared	VBN	O
with	IN	O
standard	NN	O
of	IN	O
care	NN	O
.	.	O

DESIGN	NNP	O
Randomized	NNP	O
controlled	VBD	O
trial	NN	O
.	.	O

SETTING	NNP	O
Three	CD	O
university	NN	O
teaching	VBG	O
hospitals	NNS	O
in	IN	O
Hamilton	NNP	O
,	,	O
Ontario	NNP	O
,	,	O
Canada	NNP	O
.	.	O

PATIENT	NNP	O
(	(	O
S	NNP	O
)	)	O
Infertile	NNP	O
women	NNS	O
at	IN	O
their	PRP$	O
first	JJ	O
visit	NN	O
to	TO	O
a	DT	O
tertiary	JJ	O
referral	JJ	O
infertility	NN	O
clinic	NN	O
(	(	O
n	JJ	O
=	NNP	O
94	CD	SS
)	)	O
and	CC	O
new	JJ	O
patients	NNS	O
seeking	VBG	O
pre-natal	JJ	O
care	NN	O
(	(	O
n	JJ	O
=	NNP	O
110	CD	SS
)	)	O
who	WP	O
had	VBD	O
smoked	VBN	O
>	NNP	O
/=	$	O
3	CD	O
cigarettes	NNS	O
in	IN	O
the	DT	O
past	JJ	O
six	CD	O
months	NNS	O
.	.	O

INTERVENTION	NNP	O
(	(	O
S	NNP	O
)	)	O
A	NNP	O
three	CD	O
to	TO	O
five	CD	O
minute	NN	O
scripted	VBN	O
intervention	NN	O
and	CC	O
booklet	NN	O
specific	NN	O
to	TO	O
the	DT	O
woman	NN	O
's	POS	O
stage-of-change	NN	O
in	IN	O
the	DT	O
smoking	NN	O
continuum	NN	O
,	,	O
versus	JJ	O
standard	NN	O
of	IN	O
care	NN	O
.	.	O

Exhaled	VBN	O
carbon-monoxide	NN	O
(	(	O
CO	NNP	O
)	)	O
monitoring	NN	O
was	VBD	O
used	VBN	O
to	TO	O
validate	VB	O
exposure	NN	O
in	IN	O
both	DT	O
groups	NNS	O
.	.	O

MAIN	NNP	O
OUTCOME	NNP	O
MEASURE	NNP	O
(	(	O
S	NNP	O
)	)	O
Delta	NNP	O
stage-of-change	NN	O
and	CC	O
rate	NN	O
of	IN	O
maintained	VBN	O
cessation	NN	O
at	IN	O
12	CD	O
months	NNS	O
post	VBN	O
follow-up	JJ	O
.	.	O

RESULT	NNP	O
(	(	O
S	NNP	O
)	)	O
Intervention	NNP	O
and	CC	O
control	NN	O
were	VBD	O
similarly	RB	O
effective	JJ	O
for	IN	O
infertile	JJ	O
women	NNS	O
:	:	O
the	DT	O
rate	NN	O
of	IN	O
maintained	VBN	O
cessation	NN	O
rose	VBD	O
significantly	RB	O
from	IN	O
4	CD	O
%	NN	O
to	TO	O
24	CD	O
%	NN	O
over	IN	O
twelve	JJ	O
months	NNS	O
,	,	O
with	IN	O
a	DT	O
mean	JJ	O
delta	NN	O
stage-of-change	NN	O
0.28	CD	O
.	.	O

In	IN	O
prenatal	JJ	O
women	NNS	O
,	,	O
neither	CC	O
approach	NN	O
was	VBD	O
effective	JJ	O
.	.	O

Maintained	VBN	O
cessation	NN	O
did	VBD	O
not	RB	O
significantly	RB	O
change	VBP	O
from	IN	O
0	CD	O
to	TO	O
12	CD	O
months	NNS	O
(	(	O
19	CD	O
%	NN	O
to	TO	O
18	CD	O
%	NN	O
)	)	O
.	.	O

Mean	JJ	O
delta	JJ	O
stage-of-change	NN	O
declined	VBN	O
by	IN	O
-0.62	NNP	O
.	.	O

CONCLUSION	NNP	O
(	(	O
S	NNP	O
)	)	O
For	IN	O
infertile	JJ	O
women	NNS	O
,	,	O
basic	JJ	O
information	NN	O
describing	VBG	O
the	DT	O
impact	NN	O
of	IN	O
smoking	VBG	O
on	IN	O
fertility	NN	O
,	,	O
along	IN	O
with	IN	O
exhaled	JJ	O
CO	NNP	O
monitoring	NN	O
and	CC	O
a	DT	O
more	RBR	O
intensive	JJ	O
intervention	NN	O
were	VBD	O
both	DT	O
highly	RB	O
effective	JJ	O
.	.	O

In	IN	O
pregnant	JJ	O
women	NNS	O
neither	CC	O
approach	NN	O
was	VBD	O
beneficial	JJ	O
,	,	O
with	IN	O
some	DT	O
evidence	NN	O
of	IN	O
post-partum	JJ	O
relapse	NN	O
.	.	O

A	DT	O
double-blind	JJ	O
,	,	O
placebo-controlled	JJ	O
study	NN	O
of	IN	O
valproate	NN	O
for	IN	O
aggression	NN	O
in	IN	O
youth	NN	O
with	IN	O
pervasive	JJ	O
developmental	NN	O
disorders	NNS	O
.	.	O

OBJECTIVE	IN	O
The	DT	O
aim	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
study	VB	O
valproate	JJ	O
efficacy	NN	O
and	CC	O
safety	NN	O
for	IN	O
aggression	NN	O
in	IN	O
children	NNS	O
and	CC	O
adolescents	NNS	O
with	IN	O
pervasive	JJ	O
developmental	NN	O
disorders	NNS	O
(	(	O
PDD	NNP	O
)	)	O
.	.	O

METHODS	NNP	O
In	IN	O
this	DT	O
prospective	JJ	O
double-blind	NN	O
,	,	O
placebo-controlled	JJ	O
study	NN	O
,	,	O
30	CD	O
subjects	NNS	O
(	(	O
20	CD	O
boys	NNS	O
,	,	O
10	CD	O
girls	NNS	O
)	)	O
6-20	CD	O
years	NNS	O
of	IN	O
age	NN	O
with	IN	O
PDD	NNP	O
and	CC	O
significant	JJ	O
aggression	NN	O
were	VBD	O
randomized	VBN	O
and	CC	O
received	VBN	O
treatment	NN	O
with	IN	O
valproate	NN	O
(	(	O
VPA	NNP	O
)	)	O
or	CC	O
placebo	NN	O
(	(	O
PBO	NNP	O
)	)	O
for	IN	O
8	CD	O
weeks	NNS	O
as	IN	O
outpatients	NNS	O
.	.	O

Mean	NNP	O
VPA	NNP	O
trough	IN	O
blood	NN	O
levels	NNS	O
were	VBD	O
75.5	CD	O
mcg/mL	NNS	O
at	IN	O
week	NN	O
4	CD	O
and	CC	O
77.8	CD	O
mcg/mL	NN	O
at	IN	O
week	NN	O
8	CD	O
.	.	O

RESULTS	VB	O
No	DT	O
treatment	NN	O
difference	NN	O
was	VBD	O
observed	VBN	O
statistically	RB	O
between	IN	O
VPA	NNP	O
and	CC	O
PBO	NNP	O
groups	NNS	O
.	.	O

The	DT	O
Aberrant	NNP	O
Behavior	NNP	O
Checklist	NNP	O
--	:	O
Community	NNP	O
Scale	NNP	O
(	(	O
ABC-C	NNP	O
)	)	O
Irritability	NNP	O
subscale	NN	O
was	VBD	O
the	DT	O
primary	JJ	O
outcome	NN	O
measure	NN	O
(	(	O
p	JJ	O
=	NNP	O
0.65	CD	O
)	)	O
,	,	O
and	CC	O
CGI	NNP	O
--	:	O
Improvement	NNP	O
(	(	O
p	JJ	O
=	NNP	O
0.16	CD	O
)	)	O
and	CC	O
OAS	NNP	O
(	(	O
p	JJ	O
=	NNP	O
0.96	CD	O
)	)	O
were	VBD	O
secondary	JJ	O
outcome	NN	O
measures	NNS	O
.	.	O

Increased	VBN	O
appetite	NN	O
and	CC	O
skin	NN	O
rash	NN	O
were	VBD	O
significant	JJ	O
side	NN	O
effects	NNS	O
.	.	O

Only	RB	O
1	CD	O
subject	NN	O
was	VBD	O
dropped	VBN	O
from	IN	O
the	DT	O
study	NN	O
owing	VBG	O
to	TO	O
side	VB	O
effects	NNS	O
,	,	O
notably	RB	O
a	DT	O
spreading	NN	O
skin	NN	O
rash	NN	O
,	,	O
which	WDT	O
then	RB	O
resolved	VBD	O
spontaneously	RB	O
.	.	O

Two	CD	O
subjects	NNS	O
receiving	VBG	O
VPA	NNP	O
developed	VBD	O
increased	VBN	O
serum	NN	O
ammonia	NN	O
levels	NNS	O
,	,	O
one	CD	O
with	IN	O
an	DT	O
associated	JJ	O
parent	NN	O
report	NN	O
of	IN	O
slurred	JJ	O
speech	NN	O
and	CC	O
mild	JJ	O
cognitive	JJ	O
slowing	NN	O
.	.	O

Poststudy	NNP	O
,	,	O
of	IN	O
16	CD	O
VPA	NNP	O
and	CC	O
PBO	NNP	O
subjects	NNS	O
receiving	VBG	O
VPA	NNP	O
,	,	O
10	CD	O
subjects	NNS	O
demonstrated	VBD	O
sustained	JJ	O
response	NN	O
,	,	O
4	CD	O
of	IN	O
whom	WP	O
later	RB	O
attempted	VBN	O
taper	NN	O
,	,	O
with	IN	O
significant	JJ	O
relapse	NN	O
of	IN	O
aggression	NN	O
.	.	O

CONCLUSION	VB	O
The	DT	O
present	JJ	O
negative	JJ	O
findings	NNS	O
can	MD	O
not	RB	O
be	VB	O
viewed	VBN	O
as	IN	O
conclusive	JJ	O
,	,	O
partly	RB	O
owing	VBG	O
to	TO	O
the	DT	O
large	JJ	O
placebo	NN	O
response	NN	O
,	,	O
subject	JJ	O
heterogeneity	NN	O
,	,	O
and	CC	O
size	NN	O
of	IN	O
the	DT	O
groups	NNS	O
.	.	O

Larger	JJR	O
studies	NNS	O
are	VBP	O
needed	VBN	O
to	TO	O
expand	VB	O
upon	IN	O
these	DT	O
findings	NNS	O
.	.	O

Brief	JJ	O
Report	NNP	O
:	:	O
social	JJ	O
disability	NN	O
in	IN	O
autism	NN	O
spectrum	NN	O
disorder	NN	O
:	:	O
results	NNS	O
from	IN	O
Research	NNP	O
Units	NNP	O
on	IN	O
Pediatric	NNP	O
Psychopharmacology	NNP	O
(	(	O
RUPP	NNP	O
)	)	O
Autism	NNP	O
Network	NNP	O
trials	NNS	O
.	.	O

There	EX	O
is	VBZ	O
growing	VBG	O
interest	NN	O
in	IN	O
measuring	VBG	O
social	JJ	O
disability	NN	O
as	IN	O
a	DT	O
core	NN	O
element	NN	O
of	IN	O
autism	NN	O
spectrum	NN	O
disorders	NNS	O
in	IN	O
medication	NN	O
trials	NNS	O
.	.	O

We	PRP	O
conducted	VBD	O
a	DT	O
secondary	JJ	O
analysis	NN	O
on	IN	O
the	DT	O
Aberrant	NNP	O
Behavior	NNP	O
Checklist	NNP	O
Social	NNP	O
Withdrawal	NNP	O
subscale	JJ	O
using	VBG	O
data	NNS	O
from	IN	O
two	CD	O
federally-funded	JJ	O
,	,	O
multi-site	JJ	O
,	,	O
randomized	JJ	O
trials	NNS	O
with	IN	O
risperidone	NN	O
.	.	O

Study	NNP	O
1	CD	O
included	VBD	O
52	CD	O
subjects	NNS	O
assigned	VBN	O
to	TO	O
placebo	VB	O
and	CC	O
49	CD	O
subjects	NNS	O
to	TO	O
risperidone	VB	O
under	IN	O
double-blind	JJ	O
conditions	NNS	O
.	.	O

Study	NNP	O
2	CD	O
included	VBD	O
49	CD	O
subjects	NNS	O
assigned	VBN	O
to	TO	O
risperidone	VB	O
only	RB	O
and	CC	O
75	CD	O
subjects	NNS	O
assigned	VBN	O
to	TO	O
risperidone	VB	O
plus	JJ	O
parent	NN	O
training	NN	O
.	.	O

After	IN	O
8	CD	O
weeks	NNS	O
of	IN	O
treatment	NN	O
,	,	O
all	DT	O
active	JJ	O
treatments	NNS	O
were	VBD	O
superior	JJ	O
to	TO	O
placebo	VB	O
(	(	O
effect	NN	O
sizes	VBZ	O
ranging	VBG	O
from	IN	O
0.42	CD	O
to	TO	O
0.65	CD	O
)	)	O
.	.	O

The	DT	O
findings	NNS	O
suggest	VBP	O
that	IN	O
the	DT	O
Social	NNP	O
Withdrawal	NNP	O
subscale	NN	O
may	MD	O
be	VB	O
a	DT	O
useful	JJ	O
measure	NN	O
of	IN	O
social	JJ	O
disability	NN	O
in	IN	O
acute	JJ	O
treatment	NN	O
trials	NNS	O
.	.	O

Phonophoresis	NNP	O
versus	NN	O
topical	JJ	O
application	NN	O
of	IN	O
ketoprofen	NN	O
:	:	O
comparison	NN	O
between	IN	O
tissue	NN	O
and	CC	O
plasma	NN	O
levels	NNS	O
.	.	O

BACKGROUND	NNP	O
AND	CC	O
PURPOSE	NNP	O
Over	IN	O
the	DT	O
last	JJ	O
few	JJ	O
decades	NNS	O
,	,	O
application	NN	O
of	IN	O
ultrasound	NN	O
has	VBZ	O
been	VBN	O
attempted	VBN	O
to	TO	O
enhance	VB	O
transdermal	JJ	O
transport	NN	O
of	IN	O
several	JJ	O
drugs	NNS	O
,	,	O
a	DT	O
method	NN	O
referred	VBD	O
to	TO	O
as	IN	O
phonophoresis	NN	O
.	.	O

The	DT	O
purposes	NNS	O
of	IN	O
this	DT	O
study	NN	O
were	VBD	O
to	TO	O
examine	VB	O
the	DT	O
influence	NN	O
of	IN	O
ultrasound	NN	O
on	IN	O
the	DT	O
transdermal	JJ	O
delivery	NN	O
of	IN	O
ketoprofen	NN	O
in	IN	O
humans	NNS	O
and	CC	O
to	TO	O
compare	VB	O
the	DT	O
concentrations	NNS	O
found	VBD	O
after	IN	O
continuous	JJ	O
and	CC	O
pulsed	JJ	O
application	NN	O
.	.	O

SUBJECTS	NNP	O
AND	NNP	O
METHODS	NNP	O
Twenty-six	NNP	SS
patients	NNS	O
with	IN	O
knee	NN	C
disorders	NNS	C
requiring	VBG	C
arthroscopy	NN	C
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
1	CD	O
of	IN	O
3	CD	O
groups	NNS	O
.	.	O

Just	NNP	O
before	IN	O
surgery	NN	O
,	,	O
phonophoresis	NN	O
of	IN	O
a	DT	O
ketoprofen	NN	O
gel	NN	O
(	(	O
Fastum	NNP	O
gel	NN	O
)	)	O
was	VBD	O
given	VBN	O
to	TO	O
group	NN	O
A	NNP	O
using	VBG	O
continuous	JJ	O
ultrasound	NN	O
(	(	O
1	CD	O
MHz	NNP	O
,	,	O
1.5	CD	O
W/cm2	NNP	O
,	,	O
for	IN	O
5	CD	O
minutes	NNS	O
)	)	O
.	.	O

Group	NNP	O
B	NNP	O
received	VBD	O
the	DT	O
same	JJ	O
treatment	NN	O
but	CC	O
with	IN	O
pulsed	JJ	O
ultrasound	NN	O
(	(	O
100	CD	O
Hz	NNP	O
,	,	O
20	CD	O
%	NN	O
duty	NN	O
cycle	NN	O
)	)	O
.	.	O

Group	NNP	O
C	NNP	O
received	VBD	O
5	CD	O
minutes	NNS	O
of	IN	O
sham	NN	O
ultrasound	NN	O
with	IN	O
the	DT	O
ketoprofen	NN	O
gel	NN	O
.	.	O

The	DT	O
ultrasound	JJ	O
head	NN	O
was	VBD	O
moved	VBN	O
over	IN	O
a	DT	O
10-cm2	JJ	O
area	NN	O
using	VBG	O
small	JJ	O
,	,	O
continuous	JJ	O
,	,	O
circular	JJ	O
movements	NNS	O
.	.	O

Biopsies	NNS	O
of	IN	O
adipose	JJ	O
tissue	NN	O
and	CC	O
synovial	JJ	O
tissue	NN	O
were	VBD	O
taken	VBN	O
during	IN	O
surgery	NN	O
to	TO	O
evaluate	VB	O
the	DT	O
local	JJ	O
penetration	NN	O
of	IN	O
the	DT	O
drug	NN	O
.	.	O

Blood	NN	O
samples	NNS	O
also	RB	O
were	VBD	O
collected	VBN	O
to	TO	O
determine	VB	O
whether	IN	O
ketoprofen	NN	O
entered	VBD	O
the	DT	O
systemic	JJ	O
circulation	NN	O
.	.	O

RESULTS	VB	O
The	DT	O
concentration	NN	O
of	IN	O
ketoprofen	NN	O
in	IN	O
plasma	NN	O
was	VBD	O
negligible	JJ	O
in	IN	O
all	DT	O
3	CD	O
groups	NNS	O
.	.	O

The	DT	O
concentration	NN	O
of	IN	O
ketoprofen	NN	O
in	IN	O
synovial	JJ	O
tissue	NN	O
differed	VBD	O
from	IN	O
that	IN	O
in	IN	O
fat	JJ	O
tissue	NN	O
.	.	O

A	DT	O
difference	NN	O
in	IN	O
concentration	NN	O
of	IN	O
ketoprofen	NN	O
in	IN	O
synovial	JJ	O
tissue	NN	O
was	VBD	O
found	VBN	O
between	IN	O
group	NN	O
C	NNP	O
and	CC	O
groups	NNS	O
A	NNP	O
and	CC	O
B	NNP	O
.	.	O

The	DT	O
concentration	NN	O
of	IN	O
ketoprofen	NN	O
in	IN	O
fat	JJ	O
tissue	NN	O
and	CC	O
synovial	JJ	O
tissue	NN	O
was	VBD	O
consistently	RB	O
higher	JJR	O
in	IN	O
group	NN	O
B	NNP	O
than	IN	O
in	IN	O
group	NN	O
A	NNP	O
.	.	O

DISCUSSION	NNP	O
AND	CC	O
CONCLUSION	NNP	O
This	DT	O
study	NN	O
confirms	VBZ	O
that	IN	O
phonophoresis	NN	O
of	IN	O
ketoprofen	NN	O
allows	VBZ	O
the	DT	O
attainment	NN	O
of	IN	O
higher	JJR	O
local	JJ	O
concentrations	NNS	O
,	,	O
whereas	JJ	O
systemic	JJ	O
exposure	NN	O
is	VBZ	O
lower	JJR	O
.	.	O

The	DT	O
results	NNS	O
indicate	VBP	O
that	IN	O
,	,	O
in	IN	O
contrast	NN	O
to	TO	O
sham	VB	O
phonopheresis	NN	O
,	,	O
ultrasound	NN	O
can	MD	O
increase	VB	O
the	DT	O
transdermal	JJ	O
delivery	NN	O
of	IN	O
ketoprofen	NN	O
.	.	O

Comparison	NNP	O
of	IN	O
7-day	JJ	O
and	CC	O
14-day	JJ	O
proton	NN	O
pump	IN	O
inhibitor-containing	JJ	O
triple	JJ	O
therapy	NN	O
for	IN	O
Helicobacter	NNP	C
pylori	JJ	C
eradication	NN	C
:	:	O
neither	CC	O
treatment	NN	O
duration	NN	O
provides	VBZ	O
acceptable	JJ	O
eradication	NN	O
rate	NN	O
in	IN	O
Korea	NNP	O
.	.	O

BACKGROUND	NNP	O
AND	CC	O
AIMS	NNP	O
Although	IN	O
triple	JJ	O
combination	NN	O
therapy	NN	O
containing	VBG	O
a	DT	O
proton	NN	O
pump	NN	O
inhibitor	NN	O
(	(	O
PPI	NNP	O
)	)	O
and	CC	O
two	CD	O
antibiotics	NNS	O
is	VBZ	O
considered	VBN	O
as	IN	O
a	DT	O
standard	JJ	O
regimen	NN	O
for	IN	O
the	DT	O
first-line	JJ	O
anti-Helicobacter	JJ	O
pylori	NN	O
treatment	NN	O
,	,	O
there	EX	O
are	VBP	O
still	RB	O
debates	NNS	O
on	IN	O
the	DT	O
ideal	JJ	O
duration	NN	O
of	IN	O
treatment	NN	O
.	.	O

The	DT	O
aim	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
compare	VB	O
the	DT	O
efficacies	NNS	O
of	IN	O
7-day	JJ	O
and	CC	O
14-day	JJ	O
PPI-containing	JJ	O
triple	NN	O
therapy	NN	O
.	.	O

MATERIALS	NNP	O
AND	CC	O
METHODS	NNP	O
This	DT	O
study	NN	O
was	VBD	O
performed	VBN	O
in	IN	O
a	DT	O
randomized	JJ	O
,	,	O
multicenter	NN	O
,	,	O
prospective	JJ	O
manner	NN	O
.	.	O

After	IN	O
upper	JJ	C
gastrointestinal	JJ	C
endoscopy	NN	C
,	,	O
H.	NNP	O
pylori-infected	JJ	O
patients	NNS	O
with	IN	O
a	DT	O
gastric	JJ	C
ulcer	NN	C
and/or	VBZ	C
a	DT	C
duodenal	JJ	C
ulcer	NN	C
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
a	DT	O
PAC7	NNP	O
group	NN	O
(	(	O
omeprazole	JJ	O
20	CD	O
mg	NN	O
or	CC	O
equivalent	JJ	O
dose	NN	O
of	IN	O
other	JJ	O
PPIs	NNP	O
,	,	O
amoxicillin	NN	O
1000	CD	O
mg	NN	O
,	,	O
and	CC	O
clarithromycin	VBZ	O
500	CD	O
mg	NN	O
twice	RB	O
daily	RB	O
for	IN	O
7	CD	O
days	NNS	O
)	)	O
or	CC	O
to	TO	O
a	DT	O
PAC14	NNP	O
group	NN	O
(	(	O
the	DT	O
same	JJ	O
regimen	NN	O
as	IN	O
the	DT	O
PAC7	NNP	O
group	NN	O
but	CC	O
for	IN	O
14	CD	O
days	NNS	O
)	)	O
.	.	O

H.	NNP	O
pylori	NN	O
status	NN	O
was	VBD	O
evaluated	VBN	O
by	IN	O
(	(	O
13	CD	O
)	)	O
C	NNP	O
urea	JJ	O
breath	NN	O
test	NN	O
5	CD	O
weeks	NNS	O
after	IN	O
anti-ulcer	JJ	O
treatment	NN	O
completion	NN	O
.	.	O

RESULTS	VB	O
A	DT	O
total	NN	O
of	IN	O
598	CD	SS
patients	NNS	O
were	VBD	O
enrolled	VBN	O
;	:	O
337	CD	O
were	VBD	O
randomized	VBN	O
to	TO	O
the	DT	O
PAC7	NNP	O
group	NN	O
and	CC	O
261	CD	O
to	TO	O
the	DT	O
PAC14	NNP	O
group	NN	O
.	.	O

The	DT	O
two	CD	O
groups	NNS	O
were	VBD	O
comparable	JJ	O
in	IN	O
terms	NNS	O
of	IN	O
baseline	NN	O
characteristics	NNS	O
.	.	O

The	DT	O
eradication	NN	O
rates	NNS	O
of	IN	O
the	DT	O
PAC7	NNP	O
group	NN	O
were	VBD	O
not	RB	O
inferior	JJ	O
to	TO	O
those	DT	O
of	IN	O
the	DT	O
PAC14	NNP	O
group	NN	O
in	IN	O
both	DT	O
intention-to-treat	JJ	O
analysis	NN	O
(	(	O
71.2	CD	O
%	NN	O
vs.	FW	O
75.5	CD	O
%	NN	O
)	)	O
and	CC	O
per-protocol	JJ	O
analysis	NN	O
(	(	O
83.6	CD	O
%	NN	O
vs.	FW	O
86.6	CD	O
%	NN	O
)	)	O
.	.	O

Incidences	NNS	O
of	IN	O
adverse	JJ	O
events	NNS	O
were	VBD	O
comparable	JJ	O
.	.	O

CONCLUSIONS	NNP	O
Although	IN	O
the	DT	O
7-day	JJ	O
PPI-containing	JJ	O
triple	JJ	O
anti-H.	JJ	O
pylori	NN	O
therapy	NN	O
is	VBZ	O
not	RB	O
inferior	JJ	O
to	TO	O
the	DT	O
14-day	JJ	O
therapy	NN	O
,	,	O
neither	CC	O
treatment	NN	O
duration	NN	O
provides	VBZ	O
acceptable	JJ	O
eradication	NN	O
rate	NN	O
reaching	VBG	O
90	CD	O
%	NN	O
in	IN	O
per-protocol	JJ	O
analysis	NN	O
.	.	O

New	NNP	O
combination	NN	O
regimen	NNS	O
with	IN	O
higher	JJR	O
efficacy	NN	O
should	MD	O
be	VB	O
developed	VBN	O
as	IN	O
a	DT	O
first-line	JJ	O
eradication	NN	O
therapy	NN	O
for	IN	O
H.	NNP	O
pylori	NN	O
in	IN	O
Korea	NNP	O
.	.	O

Comparison	NNP	O
of	IN	O
menopausal	NN	O
symptoms	NNS	O
during	IN	O
the	DT	O
first	JJ	O
year	NN	O
of	IN	O
adjuvant	JJ	O
therapy	NN	O
with	IN	O
either	DT	O
exemestane	NN	O
or	CC	O
tamoxifen	NN	O
in	IN	O
early	JJ	O
breast	NN	C
cancer	NN	C
:	:	O
report	NN	O
of	IN	O
a	DT	O
Tamoxifen	NNP	O
Exemestane	NNP	O
Adjuvant	NNP	O
Multicenter	NNP	O
trial	NN	O
substudy	NN	O
.	.	O

PURPOSE	NNP	O
Hormonal	NNP	O
breast	NN	O
cancer	NN	O
treatment	NN	O
increases	NNS	O
menopausal	VBP	O
symptoms	NNS	O
in	IN	O
women	NNS	O
.	.	O

This	DT	O
study	NN	O
investigated	VBD	O
differences	NNS	O
between	IN	O
the	DT	O
symptoms	NNS	O
associated	VBN	O
with	IN	O
either	DT	O
adjuvant	JJ	O
tamoxifen	NN	O
or	CC	O
exemestane	NN	O
.	.	O

PATIENTS	NNP	O
AND	CC	O
METHODS	NNP	O
Ten	NNP	O
common	JJ	O
symptoms	NNS	O
were	VBD	O
assessed	VBN	O
by	IN	O
self-report	JJ	O
questionnaire	NN	O
administered	VBD	O
to	TO	O
1,614	CD	SS
consecutive	JJ	O
patients	NNS	O
at	IN	O
baseline	NN	O
and	CC	O
every	DT	O
3	CD	O
months	NNS	O
during	IN	O
the	DT	O
first	JJ	O
year	NN	O
of	IN	O
a	DT	O
double-blind	NN	O
,	,	O
randomized	VBN	O
trial	NN	O
of	IN	O
postmenopausal	JJ	C
women	NNS	SE
with	IN	O
early	JJ	C
hormone	NN	C
receptor-positive	JJ	C
breast	NN	C
cancer	NN	C
.	.	O

Symptoms	NNS	O
were	VBD	O
categorized	VBN	O
as	IN	O
none	NN	O
,	,	O
mild	NN	O
,	,	O
moderate	JJ	O
,	,	O
or	CC	O
severe	RB	O
.	.	O

A	DT	O
hot	JJ	O
flash	NN	O
score	NN	O
was	VBD	O
calculated	VBN	O
at	IN	O
each	DT	O
time	NN	O
point	NN	O
.	.	O

Symptoms	NNS	O
were	VBD	O
analyzed	VBN	O
by	IN	O
repeated-measures	NNS	O
analysis	NN	O
of	IN	O
variance	NN	O
.	.	O

Each	DT	O
time	NN	O
period	NN	O
was	VBD	O
tested	VBN	O
repeatedly	RB	O
against	IN	O
the	DT	O
baseline	NN	O
;	:	O
an	DT	O
overall	JJ	O
P	NNP	O
value	NN	O
was	VBD	O
assigned	VBN	O
for	IN	O
each	DT	O
reported	VBN	O
symptom	NN	O
.	.	O

RESULTS	NNP	O
Compliance	NNP	O
was	VBD	O
excellent	JJ	O
,	,	O
with	IN	O
7,286	CD	O
questionnaires	NNS	O
analyzed	VBN	O
.	.	O

Baseline	NNP	O
symptom	JJ	O
prevalence	NN	O
ranged	VBD	O
from	IN	O
2	CD	O
%	NN	O
(	(	O
vaginal	JJ	O
bleeding	NN	O
)	)	O
to	TO	O
60	CD	O
%	NN	O
to	TO	O
70	CD	O
%	NN	O
(	(	O
bone/muscle	NN	O
aches	NNS	O
and	CC	O
low	JJ	O
energy	NN	O
)	)	O
.	.	O

There	EX	O
were	VBD	O
no	DT	O
significant	JJ	O
differences	NNS	O
in	IN	O
vaginal	JJ	O
bleeding	NN	O
,	,	O
mood	NN	O
alteration	NN	O
,	,	O
or	CC	O
low	JJ	O
energy	NN	O
.	.	O

Patients	NNS	O
receiving	VBG	O
tamoxifen	NN	O
had	VBD	O
significantly	RB	O
more	RBR	O
vaginal	JJ	O
discharge	NN	O
(	(	O
P	NNP	O
<	NNP	O
.0001	NNP	O
)	)	O
.	.	O

Exemestane	NN	O
patients	NNS	O
reported	VBD	O
more	RBR	O
bone/muscle	NN	O
aches	NNS	O
(	(	O
P	NNP	O
<	NNP	O
.0001	NNP	O
)	)	O
,	,	O
vaginal	JJ	O
dryness	NN	O
(	(	O
P	NNP	O
=	NNP	O
.0004	NNP	O
)	)	O
,	,	O
and	CC	O
difficulty	NN	O
sleeping	NN	O
(	(	O
P	NNP	O
=	NNP	O
.03	NNP	O
)	)	O
.	.	O

In	IN	O
both	DT	O
groups	NNS	O
,	,	O
the	DT	O
hot	JJ	O
flash	NN	O
score	NN	O
peaked	VBD	O
at	IN	O
3	CD	O
months	NNS	O
and	CC	O
decreased	JJ	O
thereafter	NN	O
.	.	O

At	IN	O
12	CD	O
months	NNS	O
,	,	O
patients	NNS	O
receiving	VBG	O
tamoxifen	NN	O
had	VBD	O
a	DT	O
significantly	RB	O
higher	JJR	O
mean	JJ	O
hot	JJ	O
flash	NN	O
score	NN	O
(	(	O
P	NNP	O
=	NNP	O
.03	NNP	O
)	)	O
,	,	O
with	IN	O
daily	JJ	O
hot	JJ	O
flashes	NNS	O
increasing	VBG	O
from	IN	O
baseline	NN	O
by	IN	O
33	CD	O
%	NN	O
compared	VBN	O
with	IN	O
a	DT	O
7	CD	O
%	NN	O
increase	NN	O
from	IN	O
baseline	NN	O
with	IN	O
exemestane	NN	O
.	.	O

CONCLUSION	NNP	O
At	IN	O
12	CD	O
months	NNS	O
,	,	O
exemestane	NN	O
was	VBD	O
associated	VBN	O
with	IN	O
fewer	JJR	O
hot	JJ	O
flashes	NNS	O
and	CC	O
less	JJR	O
vaginal	JJ	O
discharge	NN	O
than	IN	O
tamoxifen	NN	O
,	,	O
but	CC	O
with	IN	O
more	JJR	O
vaginal	JJ	O
dryness	NN	O
,	,	O
bone/muscle	NN	O
aches	NNS	O
,	,	O
and	CC	O
difficulty	NN	O
sleeping	NN	O
.	.	O

Symptoms	NNS	O
were	VBD	O
common	JJ	O
in	IN	O
both	DT	O
groups	NNS	O
.	.	O

To	TO	O
compare	VB	O
the	DT	O
efficacy	NN	O
and	CC	O
safety	NN	O
of	IN	O
nifedipine	NN	O
sustained	VBN	O
release	NN	O
with	IN	O
Ginkgo	NNP	O
biloba	NN	O
extract	NN	O
to	TO	O
treat	VB	O
patients	NNS	O
with	IN	O
primary	JJ	C
Raynaud	NNP	C
's	POS	C
phenomenon	NN	C
in	IN	O
South	NNP	O
Korea	NNP	O
;	:	O
Korean	NNP	O
Raynaud	NNP	O
study	NN	O
(	(	O
KOARA	NNP	O
study	NN	O
)	)	O
.	.	O

This	DT	O
study	NN	O
examined	VBD	O
the	DT	O
efficacy	NN	O
and	CC	O
safety	NN	O
of	IN	O
nifedipine	NN	O
sustained	VBN	O
release	NN	O
(	(	O
nifedipine	JJ	O
SR	NNP	O
)	)	O
compared	VBN	O
with	IN	O
Ginkgo	NNP	O
biloba	NN	O
extract	NN	O
as	IN	O
treatment	NN	O
for	IN	O
primary	JJ	O
Raynaud	NNP	O
's	POS	O
phenomenon	NN	O
(	(	O
RP	NNP	O
)	)	O
in	IN	O
Korea	NNP	O
.	.	O

Primary	NNP	O
RP	NNP	O
were	VBD	O
screened	VBN	O
and	CC	O
assigned	VBN	O
to	TO	O
either	CC	O
the	DT	O
nifedipine	JJ	O
SR	NNP	O
group	NN	O
(	(	O
Group	NNP	O
N	NNP	O
)	)	O
or	CC	O
the	DT	O
Ginkgo	NNP	O
biloba	NN	O
extract	NN	O
group	NN	O
(	(	O
Group	NNP	O
G	NNP	O
)	)	O
in	IN	O
the	DT	O
ratio	NN	O
of	IN	O
2:1	CD	O
.	.	O

After	IN	O
a	DT	O
run-in	JJ	O
period	NN	O
of	IN	O
2	CD	O
weeks	NNS	O
,	,	O
patients	NNS	O
received	VBD	O
treatment	NN	O
for	IN	O
8	CD	O
weeks	NNS	O
.	.	O

We	PRP	O
observed	VBD	O
the	DT	O
percent	NN	O
improvement	NN	O
of	IN	O
the	DT	O
RP	NNP	O
attack	NN	O
rate	NN	O
between	IN	O
before	IN	O
and	CC	O
after	IN	O
the	DT	O
8-week	JJ	O
treatment	NN	O
.	.	O

Ninety-three	JJ	SS
subjects	NNS	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
.	.	O

The	DT	O
percent	NN	O
improvement	NN	O
in	IN	O
Group	NNP	O
N	NNP	O
was	VBD	O
50.1	CD	O
%	NN	O
at	IN	O
8	CD	O
weeks	NNS	O
after	IN	O
treatment	NN	O
,	,	O
while	IN	O
it	PRP	O
was	VBD	O
31.0	CD	O
%	NN	O
in	IN	O
Group	NNP	O
G	NNP	O
(	(	O
p	JJ	O
=	NNP	O
0.03	CD	O
)	)	O
.	.	O

No	DT	O
serious	JJ	O
adverse	JJ	O
events	NNS	O
occurred	VBD	O
,	,	O
and	CC	O
almost	RB	O
adverse	JJ	O
events	NNS	O
were	VBD	O
mild	JJ	O
and	CC	O
improved	VBN	O
without	IN	O
specific	JJ	O
treatment	NN	O
.	.	O

nifedipine	JJ	O
SR	NNP	O
was	VBD	O
more	RBR	O
effective	JJ	O
than	IN	O
Ginkgo	NNP	O
biloba	NN	O
extract	NN	O
for	IN	O
treatment	NN	O
of	IN	O
primary	JJ	O
RP	NNP	O
in	IN	O
Korean	JJ	C
patients	NNS	O
.	.	O

Both	DT	O
drugs	NNS	O
were	VBD	O
tolerable	JJ	O
with	IN	O
primary	JJ	O
RP	NNP	O
patients	NNS	O
.	.	O

Automatic	JJ	O
detection	NN	O
of	IN	O
red	JJ	O
lesions	NNS	O
in	IN	O
digital	JJ	O
color	NN	O
fundus	NN	O
photographs	NN	O
.	.	O

The	DT	O
robust	JJ	O
detection	NN	O
of	IN	O
red	JJ	O
lesions	NNS	O
in	IN	O
digital	JJ	O
color	NN	O
fundus	NN	O
photographs	NN	O
is	VBZ	O
a	DT	O
critical	JJ	O
step	NN	O
in	IN	O
the	DT	O
development	NN	O
of	IN	O
automated	JJ	O
screening	VBG	O
systems	NNS	O
for	IN	O
diabetic	JJ	C
retinopathy	NN	O
.	.	O

In	IN	O
this	DT	O
paper	NN	O
,	,	O
a	DT	O
novel	NN	O
red	JJ	O
lesion	NN	O
detection	NN	O
method	NN	O
is	VBZ	O
presented	VBN	O
based	VBN	O
on	IN	O
a	DT	O
hybrid	JJ	O
approach	NN	O
,	,	O
combining	VBG	O
prior	JJ	O
works	NNS	O
by	IN	O
Spencer	NNP	O
et	CC	O
al	NN	O
.	.	O

(	(	O
1996	CD	O
)	)	O
and	CC	O
Frame	NNP	O
et	NNP	O
al	NN	O
.	.	O

(	(	O
1998	CD	O
)	)	O
with	IN	O
two	CD	O
important	JJ	O
new	JJ	O
contributions	NNS	O
.	.	O

The	DT	O
first	JJ	O
contribution	NN	O
is	VBZ	O
a	DT	O
new	JJ	O
red	JJ	O
lesion	NN	O
candidate	NN	O
detection	NN	O
system	NN	O
based	VBN	O
on	IN	O
pixel	JJ	O
classification	NN	O
.	.	O

Using	VBG	O
this	DT	O
technique	NN	O
,	,	O
vasculature	NN	O
and	CC	O
red	JJ	O
lesions	NNS	O
are	VBP	O
separated	VBN	O
from	IN	O
the	DT	O
background	NN	O
of	IN	O
the	DT	O
image	NN	O
.	.	O

After	IN	O
removal	NN	O
of	IN	O
the	DT	O
connected	JJ	O
vasculature	NN	O
the	DT	O
remaining	VBG	O
objects	NNS	O
are	VBP	O
considered	VBN	O
possible	JJ	O
red	JJ	O
lesions	NNS	O
.	.	O

Second	NNP	O
,	,	O
an	DT	O
extensive	JJ	O
number	NN	O
of	IN	O
new	JJ	O
features	NNS	O
are	VBP	O
added	VBN	O
to	TO	O
those	DT	O
proposed	VBN	O
by	IN	O
Spencer-Frame	NNP	O
.	.	O

The	DT	O
detected	JJ	O
candidate	NN	O
objects	NNS	O
are	VBP	O
classified	VBN	O
using	VBG	O
all	DT	O
features	NNS	O
and	CC	O
a	DT	O
k-nearest	JJ	O
neighbor	NN	O
classifier	NN	O
.	.	O

An	DT	O
extensive	JJ	O
evaluation	NN	O
was	VBD	O
performed	VBN	O
on	IN	O
a	DT	O
test	NN	O
set	NN	O
composed	VBN	O
of	IN	O
images	NNS	O
representative	NN	O
of	IN	O
those	DT	O
normally	RB	O
found	VBN	O
in	IN	O
a	DT	O
screening	NN	O
set	NN	O
.	.	O

When	WRB	O
determining	VBG	O
whether	IN	O
an	DT	O
image	NN	O
contains	VBZ	O
red	JJ	O
lesions	NNS	O
the	DT	O
system	NN	O
achieves	VBZ	O
a	DT	O
sensitivity	NN	O
of	IN	O
100	CD	O
%	NN	O
at	IN	O
a	DT	O
specificity	NN	O
of	IN	O
87	CD	O
%	NN	O
.	.	O

The	DT	O
method	NN	O
is	VBZ	O
compared	VBN	O
with	IN	O
several	JJ	O
different	JJ	O
automatic	JJ	O
systems	NNS	O
and	CC	O
is	VBZ	O
shown	VBN	O
to	TO	O
outperform	VB	O
them	PRP	O
all	DT	O
.	.	O

Performance	NNP	O
is	VBZ	O
close	RB	O
to	TO	O
that	DT	O
of	IN	O
a	DT	O
human	JJ	O
expert	NN	O
examining	VBG	O
the	DT	O
images	NNS	O
for	IN	O
the	DT	O
presence	NN	O
of	IN	O
red	JJ	O
lesions	NNS	O
.	.	O

Tailored	NNP	O
,	,	O
iterative	JJ	O
,	,	O
printed	JJ	O
dietary	JJ	O
feedback	NN	O
is	VBZ	O
as	RB	O
effective	JJ	O
as	IN	O
group	NN	O
education	NN	O
in	IN	O
improving	VBG	O
dietary	JJ	O
behaviours	NNS	O
:	:	O
results	NNS	O
from	IN	O
a	DT	O
randomised	VBN	O
control	NN	O
trial	NN	O
in	IN	O
middle-aged	JJ	A
adults	NNS	A
with	IN	O
cardiovascular	JJ	C
risk	NN	C
factors	NNS	C
.	.	O

BACKGROUND	NNP	O
Tailored	NNP	O
nutrition	NN	O
interventions	NNS	O
have	VBP	O
been	VBN	O
shown	VBN	O
to	TO	O
be	VB	O
more	RBR	O
effective	JJ	O
than	IN	O
non-tailored	JJ	O
materials	NNS	O
in	IN	O
changing	VBG	O
dietary	JJ	O
behaviours	NNS	O
,	,	O
particularly	RB	O
fat	JJ	O
intake	NN	O
and	CC	O
fruit	NN	O
and	CC	O
vegetable	JJ	O
intake	NN	O
.	.	O

But	CC	O
further	JJ	O
research	NN	O
examining	VBG	O
efficacy	NN	O
of	IN	O
tailored	JJ	O
nutrition	NN	O
education	NN	O
in	IN	O
comparison	NN	O
to	TO	O
other	JJ	O
nutrition	JJ	O
education	NN	O
methods	NNS	O
and	CC	O
across	IN	O
a	DT	O
wider	NN	O
range	NN	O
of	IN	O
dietary	JJ	O
behaviours	NNS	O
is	VBZ	O
needed	VBN	O
.	.	O

The	DT	O
Stages	NNPS	O
to	TO	O
Healthy	NNP	O
Eating	NNP	O
Patterns	NNP	O
Study	NNP	O
(	(	O
STEPs	NNP	O
)	)	O
was	VBD	O
an	DT	O
intervention	NN	O
study	NN	O
,	,	O
in	IN	O
middle-aged	JJ	A
adults	NNS	A
with	IN	O
cardiovascular	JJ	C
risk	NN	C
factors	NNS	C
,	,	O
to	TO	O
examine	VB	O
the	DT	O
effectiveness	NN	O
of	IN	O
printed	VBN	O
,	,	O
tailored	VBN	O
,	,	O
iterative	JJ	O
dietary	JJ	O
feedback	NN	O
delivered	VBN	O
by	IN	O
mail	NN	O
in	IN	O
improving	VBG	O
short-term	JJ	O
dietary	JJ	O
behaviour	NN	O
in	IN	O
the	DT	O
areas	NNS	O
of	IN	O
saturated	JJ	O
fat	NN	O
,	,	O
fruit	NN	O
,	,	O
vegetable	JJ	O
and	CC	O
grain	NN	O
and	CC	O
cereal	NN	O
intake	NN	O
.	.	O

METHODS	NNP	O
STEPs	NNP	O
was	VBD	O
a	DT	O
3-month	JJ	O
randomised	VBN	O
controlled	VBN	O
trial	NN	O
with	IN	O
a	DT	O
pre	NN	O
and	CC	O
post-test	JJ	O
design	NN	O
.	.	O

There	EX	O
were	VBD	O
three	CD	O
experimental	JJ	O
conditions	NNS	O
:	:	O
1	CD	O
)	)	O
tailored	VBN	O
,	,	O
iterative	JJ	O
,	,	O
printed	JJ	O
dietary	JJ	O
feedback	NN	O
(	(	O
TF	NNP	O
)	)	O
with	IN	O
three	CD	O
instalments	NNS	O
mail-delivered	JJ	O
over	IN	O
a	DT	O
3-month	JJ	O
period	NN	O
that	WDT	O
were	VBD	O
re-tailored	VBN	O
to	TO	O
most	RBS	O
recent	JJ	O
assessment	NN	O
of	IN	O
dietary	JJ	O
intake	NN	O
,	,	O
intention	NN	O
to	TO	O
change	VB	O
and	CC	O
assessment	NN	O
of	IN	O
self-adequacy	NN	O
of	IN	O
dietary	JJ	O
intake	NN	O
.	.	O

Tailoring	VBG	O
for	IN	O
dietary	JJ	O
intake	NN	O
was	VBD	O
performed	VBN	O
on	IN	O
data	NNS	O
from	IN	O
a	DT	O
validated	JJ	O
63-item	JJ	O
combination	NN	O
FFQ	NNP	O
designed	VBN	O
for	IN	O
the	DT	O
purpose	JJ	O
2	CD	O
)	)	O
small	JJ	O
group	NN	O
nutrition	NN	O
education	NN	O
sessions	NNS	O
(	(	O
GE	NNP	O
)	)	O
:	:	O
consisting	NN	O
of	IN	O
two	CD	O
90-minute	JJ	O
dietitian-led	JJ	O
small	JJ	O
group	NN	O
nutrition	NN	O
education	NN	O
sessions	NNS	O
and	CC	O
3	CD	O
)	)	O
and	CC	O
a	DT	O
wait-listed	JJ	O
control	NN	O
(	(	O
C	NNP	O
)	)	O
group	NN	O
who	WP	O
completed	VBD	O
the	DT	O
dietary	JJ	O
measures	NNS	O
and	CC	O
socio-demographic	JJ	O
questionnaires	NNS	O
at	IN	O
baseline	NN	O
and	CC	O
3-months	JJ	O
later	NN	O
.	.	O

Dietary	NNP	O
outcome	NN	O
measures	NNS	O
in	IN	O
the	DT	O
areas	NNS	O
of	IN	O
saturated	JJ	O
fat	JJ	O
intake	NN	O
(	(	O
g	NN	O
)	)	O
,	,	O
and	CC	O
the	DT	O
intake	NN	O
of	IN	O
fruit	NN	O
(	(	O
serves	NNS	O
)	)	O
,	,	O
vegetables	NNS	O
(	(	O
serves	NNS	O
)	)	O
,	,	O
grain	NN	O
and	CC	O
cereals	NNS	O
as	IN	O
total	JJ	O
and	CC	O
wholegrain	NN	O
(	(	O
serves	NNS	O
)	)	O
were	VBD	O
collected	VBN	O
using	VBG	O
7-day	JJ	O
estimated	VBN	O
dietary	JJ	O
records	NNS	O
.	.	O

Descriptive	JJ	O
statistics	NNS	O
,	,	O
paired	VBD	O
t-tests	NNS	O
and	CC	O
general	JJ	O
linear	JJ	O
models	NNS	O
adjusted	VBN	O
for	IN	O
baseline	NN	O
dietary	JJ	O
intake	NN	O
,	,	O
age	NN	O
and	CC	O
gender	NN	O
were	VBD	O
used	VBN	O
to	TO	O
examine	VB	O
the	DT	O
effectiveness	NN	O
of	IN	O
different	JJ	O
nutrition	NN	O
interventions	NNS	O
.	.	O

RESULTS	VB	O
The	DT	O
TF	NNP	O
group	NN	O
reported	VBD	O
a	DT	O
significantly	RB	O
greater	JJR	O
increase	NN	O
in	IN	O
fruit	JJ	O
intake	NN	O
(	(	O
0.3	CD	O
serves/d	NN	O
P	NNP	O
=	NNP	O
0.031	CD	O
)	)	O
in	IN	O
comparison	NN	O
to	TO	O
GE	NNP	O
and	CC	O
the	DT	O
C	NNP	O
group	NN	O
.	.	O

All	DT	O
three	CD	O
intervention	NN	O
groups	NNS	O
showed	VBD	O
a	DT	O
reduction	NN	O
in	IN	O
total	JJ	O
saturated	JJ	O
fat	JJ	O
intake	NN	O
.	.	O

GE	NNP	O
also	RB	O
had	VBD	O
a	DT	O
within-group	JJ	O
increase	NN	O
in	IN	O
mean	JJ	O
vegetable	JJ	O
intake	NN	O
after	IN	O
3	CD	O
months	NNS	O
,	,	O
but	CC	O
this	DT	O
increase	NN	O
was	VBD	O
not	RB	O
different	JJ	O
from	IN	O
changes	NNS	O
in	IN	O
the	DT	O
other	JJ	O
groups	NNS	O
.	.	O

CONCLUSIONS	NNP	O
In	IN	O
this	DT	O
study	NN	O
,	,	O
printed	VBN	O
,	,	O
tailored	VBN	O
,	,	O
iterative	JJ	O
dietary	JJ	O
feedback	NN	O
was	VBD	O
more	RBR	O
effective	JJ	O
than	IN	O
small	JJ	O
group	NN	O
nutrition	NN	O
education	NN	O
in	IN	O
improving	VBG	O
the	DT	O
short-term	JJ	O
fruit	NN	O
intake	VB	O
behaviour	NN	O
,	,	O
and	CC	O
as	IN	O
effective	JJ	O
in	IN	O
improving	VBG	O
saturated	VBN	O
fat	JJ	O
intake	NN	O
of	IN	O
middle-aged	JJ	A
adults	NNS	A
with	IN	O
cardiovascular	JJ	C
risk	NN	C
factors	NNS	C
.	.	O

This	DT	O
showed	VBD	O
that	IN	O
a	DT	O
low-level	JJ	O
dietary	JJ	O
intervention	NN	O
could	MD	O
achieve	VB	O
modest	JJ	O
dietary	JJ	O
behaviour	NN	O
changes	NNS	O
that	WDT	O
are	VBP	O
of	IN	O
public	JJ	O
health	NN	O
significance	NN	O
.	.	O

Sunlight	JJ	O
exposure	NN	O
or	CC	O
vitamin	NN	O
D	NNP	O
supplementation	NN	O
for	IN	O
vitamin	JJ	C
D-deficient	JJ	C
non-western	JJ	O
immigrants	NNS	O
:	:	O
a	DT	O
randomized	JJ	O
clinical	JJ	O
trial	NN	O
.	.	O

UNLABELLED	NNP	O
Vitamin	NNP	O
D	NNP	O
deficiency	NN	O
is	VBZ	O
very	RB	O
common	JJ	O
in	IN	O
non-western	JJ	O
immigrants	NNS	O
.	.	O

In	IN	O
this	DT	O
randomized	JJ	O
clinical	JJ	O
trial	NN	O
,	,	O
vitamin	NN	O
D	NNP	O
800	CD	O
IU/day	NNP	O
or	CC	O
100,000	CD	O
IU/3	JJ	O
months	NNS	O
were	VBD	O
compared	VBN	O
with	IN	O
advised	JJ	O
sunlight	NN	O
exposure	NN	O
.	.	O

Vitamin	NNP	O
D	NNP	O
supplementation	NN	O
was	VBD	O
more	RBR	O
effective	JJ	O
than	IN	O
advised	JJ	O
sunlight	JJ	O
exposure	NN	O
in	IN	O
improving	VBG	O
vitamin	NN	O
D	NNP	O
status	NN	O
and	CC	O
lowering	VBG	O
parathyroid	JJ	O
hormone	NN	O
levels	NNS	O
.	.	O

INTRODUCTION	NNP	O
Vitamin	NNP	O
D	NNP	O
deficiency	NN	O
(	(	O
25-hydroxyvitamin	JJ	O
D	NNP	O
[	NN	O
25	CD	O
(	(	O
OH	NNP	O
)	)	O
D	NNP	O
]	NNP	O
<	VBD	O
25	CD	O
nmol/l	NN	O
)	)	O
is	VBZ	O
common	JJ	O
among	IN	O
non-western	JJ	O
immigrants	NNS	O
.	.	O

It	PRP	O
can	MD	O
be	VB	O
treated	VBN	O
with	IN	O
vitamin	NN	O
D	NNP	O
supplementation	NN	O
or	CC	O
sunlight	JJ	O
exposure	NN	O
.	.	O

METHODS	NNP	O
To	TO	O
determine	VB	O
whether	IN	O
the	DT	O
effect	NN	O
of	IN	O
vitamin	NN	O
D	NNP	O
(	(	O
3	CD	O
)	)	O
supplementation	NN	O
(	(	O
daily	JJ	O
800	CD	O
IU	NNP	O
or	CC	O
100,000	CD	O
IU/3	NNP	O
months	NNS	O
)	)	O
or	CC	O
sunlight	JJ	O
exposure	NN	O
advice	NN	O
is	VBZ	O
similar	JJ	O
with	IN	O
regard	NN	O
to	TO	O
serum	VB	O
25	CD	O
(	(	O
OH	NNP	O
)	)	O
D	NNP	O
and	CC	O
parathyroid	VB	O
hormone	NN	O
(	(	O
PTH	NNP	O
)	)	O
concentrations	NNS	O
.	.	O

Randomized	NNP	O
clinical	JJ	O
trial	NN	O
in	IN	O
11	CD	O
general	JJ	O
practices	NNS	O
in	IN	O
The	DT	O
Netherlands	NNP	O
.	.	O

Non-western	JJ	O
immigrants	NNS	O
,	,	O
aged	VBN	O
18-65	CD	O
years	NNS	O
(	(	O
n	JJ	O
=	NNP	O
232	CD	O
)	)	O
and	CC	O
serum	$	O
25	CD	O
(	(	O
OH	NNP	O
)	)	O
D	NNP	O
<	$	O
25	CD	O
nmol/l	NN	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
supplementation	NN	O
(	(	O
daily	JJ	O
800	CD	O
IU	NNP	O
or	CC	O
100,000	CD	O
IU/3	NNP	O
months	NNS	O
)	)	O
or	CC	O
advice	NN	O
for	IN	O
sunlight	JJ	O
exposure	NN	O
for	IN	O
6	CD	O
months	NNS	O
(	(	O
March-September	NNP	O
)	)	O
.	.	O

Blood	NN	O
samples	NNS	O
were	VBD	O
collected	VBN	O
at	IN	O
baseline	NN	O
,	,	O
during	IN	O
treatment	NN	O
(	(	O
3	CD	O
months	NNS	O
,	,	O
6	CD	O
months	NNS	O
)	)	O
,	,	O
and	CC	O
at	IN	O
follow-up	JJ	O
(	(	O
12	CD	O
months	NNS	O
)	)	O
.	.	O

Statistical	JJ	O
analysis	NN	O
was	VBD	O
performed	VBN	O
with	IN	O
multilevel	JJ	O
regression	NN	O
modelling	NN	O
.	.	O

RESULTS	VB	O
The	DT	O
intention-to-treat	JJ	O
analysis	NN	O
included	VBD	O
211	CD	O
persons	NNS	O
.	.	O

Baseline	NNP	O
serum	NN	O
25	CD	O
(	(	O
OH	NNP	O
)	)	O
D	NNP	O
was	VBD	O
22.5	CD	O
?	.	O
11.1	CD	O
nmol/l	NN	O
.	.	O

After	IN	O
6	CD	O
months	NNS	O
,	,	O
mean	VBP	O
serum	JJ	O
25	CD	O
(	(	O
OH	NNP	O
)	)	O
D	NNP	O
increased	VBD	O
to	TO	O
53	CD	O
nmol/l	NNS	O
with	IN	O
800	CD	O
IU/day	NNP	O
,	,	O
to	TO	O
50.5	CD	O
nmol/l	NNS	O
with	IN	O
100,000	CD	O
IU/3	NNP	O
months	NNS	O
,	,	O
and	CC	O
to	TO	O
29.1	CD	O
nmol/l	NNS	O
with	IN	O
advised	JJ	O
sunlight	NN	O
exposure	NN	O
(	(	O
supplementation	NN	O
vs	FW	O
sunshine	NN	O
p	NN	O
<	NNP	O
0.001	CD	O
)	)	O
.	.	O

Serum	NNP	O
PTH	NNP	O
decreased	VBD	O
significantly	RB	O
in	IN	O
all	DT	O
groups	NNS	O
after	IN	O
3	CD	O
months	NNS	O
,	,	O
more	RBR	O
in	IN	O
the	DT	O
supplementation	NN	O
groups	NNS	O
than	IN	O
in	IN	O
the	DT	O
advised	JJ	O
sunlight	NN	O
group	NN	O
(	(	O
p	JJ	O
<	NNP	O
0.05	CD	O
)	)	O
.	.	O

There	EX	O
was	VBD	O
no	DT	O
significant	JJ	O
effect	NN	O
on	IN	O
physical	JJ	O
performance	NN	O
and	CC	O
functional	JJ	O
limitations	NNS	O
.	.	O

CONCLUSION	NNP	O
Vitamin	NNP	O
D	NNP	O
supplementation	NN	O
is	VBZ	O
more	RBR	O
effective	JJ	O
than	IN	O
advised	JJ	O
sunlight	JJ	O
exposure	NN	O
for	IN	O
treating	VBG	O
vitamin	NN	O
D	NNP	O
deficiency	NN	O
in	IN	O
non-western	JJ	O
immigrants	NNS	O
.	.	O

Eltrombopag	NNP	O
for	IN	O
management	NN	O
of	IN	O
chronic	JJ	O
immune	NN	O
thrombocytopenia	NN	O
(	(	O
RAISE	NNP	O
)	)	O
:	:	O
a	DT	O
6-month	JJ	O
,	,	O
randomised	VBN	O
,	,	O
phase	VB	O
3	CD	O
study	NN	O
.	.	O

BACKGROUND	NNP	O
Eltrombopag	NNP	O
is	VBZ	O
an	DT	O
oral	JJ	O
thrombopoietin	NN	O
receptor	NN	O
agonist	NN	O
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
thrombocytopenia	NN	O
.	.	O

We	PRP	O
aimed	VBD	O
to	TO	O
compare	VB	O
the	DT	O
response	NN	O
to	TO	O
once	RB	O
daily	JJ	O
eltrombopag	NNS	O
versus	VBP	O
placebo	NN	O
in	IN	O
patients	NNS	O
with	IN	O
chronic	JJ	O
immune	JJ	O
thrombocytopenia	NN	O
during	IN	O
a	DT	O
6-month	JJ	O
period	NN	O
.	.	O

METHODS	NNP	O
We	PRP	O
undertook	VBD	O
a	DT	O
phase	NN	O
3	CD	O
,	,	O
double-blind	NN	O
,	,	O
placebo-controlled	JJ	O
study	NN	O
in	IN	O
adults	NNS	O
with	IN	O
previously	RB	O
treated	VBN	O
immune	JJ	O
thrombocytopenia	NN	O
of	IN	O
more	JJR	O
than	IN	O
6	CD	O
months	NNS	O
'	POS	O
duration	NN	O
who	WP	O
had	VBD	O
baseline	NN	O
platelet	NN	O
counts	VBZ	O
lower	JJR	O
than	IN	O
30,000	CD	O
per	IN	O
?L	NN	O
.	.	O

Patients	NNS	O
were	VBD	O
randomly	RB	O
allocated	VBN	O
(	(	O
in	IN	O
a	DT	O
2:1	CD	O
ratio	NN	O
)	)	O
treatment	NN	O
with	IN	O
local	JJ	O
standard	NN	O
of	IN	O
care	NN	O
plus	CC	O
50	CD	O
mg	NN	O
eltrombopag	NN	O
or	CC	O
matching	VBG	O
placebo	JJ	O
once	RB	O
daily	JJ	O
for	IN	O
6	CD	O
months	NNS	O
.	.	O

Randomisation	NN	O
was	VBD	O
done	VBN	O
centrally	RB	O
with	IN	O
a	DT	O
computer-generated	JJ	O
randomisation	NN	O
schedule	NN	O
and	CC	O
was	VBD	O
stratified	VBN	O
by	IN	O
baseline	JJ	O
platelet	NN	O
count	NN	O
(	(	O
?	.	O
15,000	CD	O
per	IN	O
?L	NN	O
)	)	O
,	,	O
use	NN	O
of	IN	O
treatment	NN	O
for	IN	O
immune	JJ	O
thrombocytopenia	NN	O
,	,	O
and	CC	O
splenectomy	JJ	O
status	NN	O
.	.	O

Patients	NNS	O
,	,	O
investigators	NNS	O
,	,	O
and	CC	O
those	DT	O
assessing	VBG	O
data	NNS	O
were	VBD	O
masked	VBN	O
to	TO	O
allocation	NN	O
.	.	O

Dose	JJ	O
modifications	NNS	O
were	VBD	O
made	VBN	O
on	IN	O
the	DT	O
basis	NN	O
of	IN	O
platelet	NN	O
response	NN	O
.	.	O

Patients	NNS	O
were	VBD	O
assessed	VBN	O
for	IN	O
response	NN	O
to	TO	O
treatment	NN	O
(	(	O
defined	VBN	O
as	IN	O
a	DT	O
platelet	NN	O
count	NN	O
of	IN	O
50,000-400,000	CD	O
per	IN	O
?L	NN	O
)	)	O
weekly	NN	O
during	IN	O
the	DT	O
first	JJ	O
6	CD	O
weeks	NNS	O
and	CC	O
at	IN	O
least	JJS	O
once	RB	O
every	DT	O
4	CD	O
weeks	NNS	O
thereafter	RB	O
;	:	O
the	DT	O
primary	JJ	O
endpoint	NN	O
was	VBD	O
the	DT	O
odds	NNS	O
of	IN	O
response	NN	O
to	TO	O
eltrombopag	VB	O
versus	NN	O
placebo	NN	O
.	.	O

Analysis	NN	O
was	VBD	O
by	IN	O
intention	NN	O
to	TO	O
treat	VB	O
.	.	O

This	DT	O
study	NN	O
is	VBZ	O
registered	VBN	O
at	IN	O
ClinicalTrials.gov	NNP	O
,	,	O
number	NN	O
NCT00370331	NNP	O
.	.	O

FINDINGS	NNP	O
Between	NNP	O
Nov	NNP	O
22	CD	O
,	,	O
2006	CD	O
,	,	O
and	CC	O
July	NNP	O
31	CD	O
,	,	O
2007	CD	O
,	,	O
197	CD	O
patients	NNS	O
were	VBD	O
randomly	RB	O
allocated	VBN	O
to	TO	O
treatment	NN	O
groups	NNS	O
and	CC	O
were	VBD	O
included	VBN	O
in	IN	O
the	DT	O
intention-to-treat	JJ	O
analysis	NN	O
(	(	O
135	CD	O
eltrombopag	NN	O
,	,	O
62	CD	O
placebo	NN	O
)	)	O
.	.	O

106	CD	O
(	(	O
79	CD	O
%	NN	O
)	)	O
patients	NNS	O
in	IN	O
the	DT	O
eltrombopag	NN	O
group	NN	O
responded	VBD	O
to	TO	O
treatment	NN	O
at	IN	O
least	JJS	O
once	RB	O
during	IN	O
the	DT	O
study	NN	O
,	,	O
compared	VBN	O
with	IN	O
17	CD	O
(	(	O
28	CD	O
%	NN	O
)	)	O
patients	NNS	O
in	IN	O
the	DT	O
placebo	NN	O
group	NN	O
.	.	O

The	DT	O
odds	NNS	O
of	IN	O
responding	VBG	O
were	VBD	O
greater	JJR	O
in	IN	O
patients	NNS	O
in	IN	O
the	DT	O
eltrombopag	NN	O
group	NN	O
compared	VBN	O
with	IN	O
those	DT	O
in	IN	O
the	DT	O
placebo	NN	O
group	NN	O
throughout	IN	O
the	DT	O
6-month	JJ	O
treatment	NN	O
period	NN	O
(	(	O
odds	NNS	O
ratio	VBP	O
8?2	CD	O
,	,	O
99	CD	O
%	NN	O
CI	NNP	O
3?59-18?73	CD	O
;	:	O
p	CC	O
<	VB	O
0?0001	CD	O
)	)	O
.	.	O

37	CD	O
(	(	O
59	CD	O
%	NN	O
)	)	O
patients	NNS	O
receiving	VBG	O
eltrombopag	NN	O
reduced	VBD	O
concomitant	JJ	O
treatment	NN	O
versus	NN	O
ten	NN	O
(	(	O
32	CD	O
%	NN	O
)	)	O
patients	NNS	O
receiving	VBG	O
placebo	NN	O
(	(	O
p=0?016	NN	O
)	)	O
.	.	O

24	CD	O
(	(	O
18	CD	O
%	NN	O
)	)	O
patients	NNS	O
receiving	VBG	O
eltrombopag	NN	O
needed	VBN	O
rescue	NN	O
treatment	NN	O
compared	VBN	O
with	IN	O
25	CD	O
(	(	O
40	CD	O
%	NN	O
)	)	O
patients	NNS	O
receiving	VBG	O
placebo	NN	O
(	(	O
p=0?001	NN	O
)	)	O
.	.	O

Three	NNP	O
(	(	O
2	CD	O
%	NN	O
)	)	O
patients	NNS	O
receiving	VBG	O
eltrombopag	NN	O
had	VBD	O
thromboembolic	JJ	O
events	NNS	O
compared	VBN	O
with	IN	O
none	NN	O
in	IN	O
patients	NNS	O
on	IN	O
placebo	NN	O
.	.	O

Nine	NNP	O
(	(	O
7	CD	O
%	NN	O
)	)	O
eltrombopag-treated	JJ	O
patients	NNS	O
and	CC	O
two	CD	O
(	(	O
3	CD	O
%	NN	O
)	)	O
in	IN	O
the	DT	O
placebo	NN	O
group	NN	O
had	VBD	O
mild	VBN	O
increases	NNS	O
in	IN	O
alanine	JJ	O
aminotransferase	NN	O
concentration	NN	O
,	,	O
and	CC	O
five	CD	O
(	(	O
4	CD	O
%	NN	O
)	)	O
eltrombopag-treated	JJ	O
patients	NNS	O
(	(	O
vs	IN	O
none	NN	O
allocated	VBN	O
to	TO	O
placebo	VB	O
)	)	O
had	VBD	O
increases	NNS	O
in	IN	O
total	JJ	O
bilirubin	NN	O
.	.	O

Four	CD	O
(	(	O
7	CD	O
%	NN	O
)	)	O
patients	NNS	O
taking	VBG	O
placebo	NN	O
had	VBD	O
serious	JJ	O
bleeding	VBG	O
events	NNS	O
,	,	O
compared	VBN	O
with	IN	O
one	CD	O
(	(	O
<	VB	O
1	CD	O
%	NN	O
)	)	O
patient	NN	O
treated	VBN	O
with	IN	O
eltrombopag	NN	O
.	.	O

INTERPRETATION	NNP	O
Eltrombopag	NNP	O
is	VBZ	O
effective	JJ	O
for	IN	O
management	NN	O
of	IN	O
chronic	JJ	O
immune	NN	O
thrombocytopenia	NN	O
,	,	O
and	CC	O
could	MD	O
be	VB	O
particularly	RB	O
beneficial	JJ	O
for	IN	O
patients	NNS	O
who	WP	O
have	VBP	O
not	RB	O
responded	VBN	O
to	TO	O
splenectomy	VB	O
or	CC	O
previous	JJ	O
treatment	NN	O
.	.	O

These	DT	O
benefits	NNS	O
should	MD	O
be	VB	O
balanced	VBN	O
with	IN	O
the	DT	O
potential	JJ	O
risks	NNS	O
associated	VBN	O
with	IN	O
eltrombopag	JJ	O
treatment	NN	O
.	.	O

FUNDING	NN	O
GlaxoSmithKline	NNP	O
.	.	O

A	DT	O
high	JJ	O
intake	NN	O
of	IN	O
trans	NNS	O
fatty	JJ	O
acids	NNS	O
has	VBZ	O
little	JJ	O
effect	NN	O
on	IN	O
markers	NNS	O
of	IN	O
inflammation	NN	O
and	CC	O
oxidative	JJ	O
stress	NN	O
in	IN	O
humans	NNS	O
.	.	O

Consumption	NN	O
of	IN	O
industrial	JJ	O
trans	NNS	O
fatty	JJ	O
acids	NNS	O
(	(	O
iTFA	NN	O
)	)	O
increases	VBZ	O
LDL	NNP	O
cholesterol	NN	O
,	,	O
decreases	VBZ	O
HDL	NNP	O
cholesterol	NN	O
,	,	O
and	CC	O
is	VBZ	O
strongly	RB	O
associated	VBN	O
with	IN	O
a	DT	O
higher	JJR	O
risk	NN	O
of	IN	O
cardiovascular	JJ	O
disease	NN	O
(	(	O
CVD	NNP	O
)	)	O
.	.	O

However	RB	O
,	,	O
changes	NNS	O
in	IN	O
circulating	VBG	O
cholesterol	NN	O
can	MD	O
not	RB	O
explain	VB	O
the	DT	O
entire	JJ	O
effect	NN	O
.	.	O

Therefore	RB	O
,	,	O
we	PRP	O
studied	VBD	O
whether	IN	O
iTFA	NN	O
and	CC	O
conjugated	VBD	O
linoleic	JJ	O
acid	NN	O
(	(	O
CLA	NNP	O
)	)	O
affect	VBP	O
markers	NNS	O
of	IN	O
inflammation	NN	O
and	CC	O
oxidative	JJ	O
stress	NN	O
.	.	O

Sixty-one	CD	SS
healthy	JJ	O
adults	NNS	A
consumed	VBD	O
each	DT	O
of	IN	O
3	CD	O
diets	NNS	O
for	IN	O
3	CD	O
wk	NN	O
,	,	O
in	IN	O
random	JJ	O
order	NN	O
.	.	O

Diets	NNS	O
were	VBD	O
identical	JJ	O
except	IN	O
for	IN	O
7	CD	O
%	NN	O
of	IN	O
energy	NN	O
provided	VBN	O
by	IN	O
oleic	JJ	O
acid	NN	O
(	(	O
control	VB	O
diet	NN	O
)	)	O
,	,	O
iTFA	JJ	O
,	,	O
or	CC	O
CLA	NNP	O
.	.	O

At	IN	O
the	DT	O
end	NN	O
of	IN	O
the	DT	O
3	CD	O
wk	NN	O
,	,	O
we	PRP	O
measured	VBD	O
plasma	JJ	O
inflammatory	JJ	O
markers	NNS	O
IL-6	NNP	O
,	,	O
C-reactive	NNP	O
protein	NN	O
,	,	O
tumor	NN	O
necrosis	NN	O
factor	NN	O
receptors	NNS	O
I	PRP	O
and	CC	O
II	NNP	O
(	(	O
TNF-RI	NNP	O
and	CC	O
-RII	NNP	O
)	)	O
,	,	O
monocyte	JJ	O
chemotactic	JJ	O
protein-1	NN	O
and	CC	O
E-selectin	NNP	O
,	,	O
and	CC	O
urinary	JJ	O
8-iso-PGF	NN	O
(	(	O
2?	CD	O
)	)	O
,	,	O
a	DT	O
marker	NN	O
of	IN	O
lipid	JJ	O
peroxidation	NN	O
.	.	O

Consumption	NN	O
of	IN	O
iTFA	NN	O
caused	VBD	O
4	CD	O
%	NN	O
lower	JJR	O
TNF-RI	NNP	O
concentrations	NNS	O
and	CC	O
6	CD	O
%	NN	O
higher	JJR	O
E-selectin	JJ	O
concentrations	NNS	O
compared	VBN	O
with	IN	O
oleic	JJ	O
acid	NN	O
(	(	O
control	NN	O
)	)	O
and	CC	O
had	VBD	O
no	DT	O
significant	JJ	O
effect	NN	O
on	IN	O
other	JJ	O
inflammatory	JJ	O
markers	NNS	O
.	.	O

CLA	NNP	O
did	VBD	O
not	RB	O
significantly	RB	O
affect	JJ	O
inflammatory	NN	O
markers	NNS	O
.	.	O

The	DT	O
urine	JJ	O
concentration	NN	O
of	IN	O
8-iso-PGF	JJ	O
(	(	O
2?	CD	O
)	)	O
[	NN	O
geometric	JJ	O
mean	NN	O
(	(	O
95	CD	O
%	NN	O
CI	NNP	O
)	)	O
]	NN	O
was	VBD	O
greater	JJR	O
after	IN	O
the	DT	O
iTFA	NN	O
[	VBZ	O
0.54	CD	O
(	(	O
0.48	CD	O
,	,	O
0.60	CD	O
)	)	O
nmol/mmol	FW	O
creatinine	NN	O
]	NN	O
and	CC	O
the	DT	O
CLA	NNP	O
[	NNP	O
1.2	CD	O
(	(	O
1.1	CD	O
,	,	O
1.3	CD	O
)	)	O
nmol/mmol	FW	O
creatinine	NN	O
]	NNP	O
diet	VBZ	O
periods	NNS	O
than	IN	O
after	IN	O
the	DT	O
control	NN	O
period	NN	O
[	VBD	O
0.45	CD	O
(	(	O
0.41	CD	O
,	,	O
0.50	CD	O
)	)	O
nmol/mmol	FW	O
creatinine	NN	O
;	:	O
P	NNP	O
<	VBD	O
0.05	CD	O
]	NN	O
.	.	O

In	IN	O
conclusion	NN	O
,	,	O
high	JJ	O
intakes	NNS	O
of	IN	O
iTFA	NN	O
and	CC	O
CLA	NNP	O
did	VBD	O
not	RB	O
substantially	RB	O
affect	JJ	O
plasma	NN	O
concentrations	NNS	O
of	IN	O
inflammatory	JJ	O
markers	NNS	O
,	,	O
but	CC	O
they	PRP	O
increased	VBD	O
the	DT	O
urine	JJ	O
8-iso-PGF	JJ	O
(	(	O
2?	CD	O
)	)	O
concentration	NN	O
.	.	O

However	RB	O
,	,	O
it	PRP	O
is	VBZ	O
unlikely	JJ	O
this	DT	O
plays	VBZ	O
a	DT	O
major	JJ	O
role	NN	O
in	IN	O
the	DT	O
mechanism	NN	O
by	IN	O
which	WDT	O
iTFA	JJ	O
increase	NN	O
the	DT	O
risk	NN	O
of	IN	O
CVD	NNP	O
.	.	O

However	RB	O
,	,	O
more	JJR	O
research	NN	O
is	VBZ	O
needed	VBN	O
to	TO	O
fully	RB	O
understand	VB	O
the	DT	O
implications	NNS	O
of	IN	O
these	DT	O
findings	NNS	O
.	.	O

Wheelchair	NNP	O
skills	VBZ	O
training	NN	O
to	TO	O
improve	VB	O
confidence	NN	O
with	IN	O
using	VBG	O
a	DT	O
manual	JJ	O
wheelchair	NN	O
among	IN	O
older	JJR	A
adults	NNS	A
:	:	O
a	DT	O
pilot	NN	O
study	NN	O
.	.	O

OBJECTIVE	NNP	O
To	TO	O
examine	VB	O
the	DT	O
effects	NNS	O
of	IN	O
wheelchair	NN	O
skills	NNS	O
training	VBG	O
on	IN	O
confidence	NN	O
in	IN	O
older	JJR	A
adults	NNS	A
who	WP	O
are	VBP	O
inexperienced	VBN	O
wheelchair	JJ	O
users	NNS	O
.	.	O

DESIGN	NNP	O
Parallel	NNP	O
group	NN	O
,	,	O
single-blind	JJ	O
randomized	VBD	O
controlled	JJ	O
trial	NN	O
.	.	O

SETTING	NNP	O
Research	NNP	O
laboratory	NN	O
in	IN	O
a	DT	O
rehabilitation	NN	O
hospital	NN	O
.	.	O

PARTICIPANTS	JJ	O
Participants	NNS	O
(	(	O
N=20	NNP	SS
)	)	O
who	WP	O
were	VBD	O
community-living	JJ	O
older	JJR	A
adults	NNS	A
at	IN	O
least	JJS	O
65	CD	A
years	NNS	A
old	JJ	A
(	(	O
mean	JJ	O
age	NN	O
,	,	O
70y	CD	A
)	)	O
,	,	O
50	CD	O
%	NN	O
women	NNS	SE
,	,	O
and	CC	O
who	WP	O
had	VBD	O
no	DT	O
experience	NN	O
of	IN	O
using	VBG	O
a	DT	O
wheelchair	NN	O
were	VBD	O
randomly	RB	O
allocated	VBN	O
to	TO	O
an	DT	O
intervention	NN	O
(	(	O
n=10	JJ	O
)	)	O
or	CC	O
control	NN	O
(	(	O
n=10	JJ	O
)	)	O
group	NN	O
.	.	O

INTERVENTIONS	VBZ	O
The	DT	O
intervention	NN	O
group	NN	O
received	VBD	O
two	CD	O
1-hour	JJ	O
training	NN	O
sessions	NNS	O
that	WDT	O
followed	VBD	O
the	DT	O
Wheelchair	NNP	O
Skills	NNP	O
Training	NNP	O
Program	NNP	O
(	(	O
WSTP	NNP	O
)	)	O
protocol	NN	O
.	.	O

The	DT	O
control	NN	O
group	NN	O
received	VBD	O
a	DT	O
single	JJ	O
socialization	NN	O
contact	NN	O
.	.	O

MAIN	NNP	O
OUTCOME	NNP	O
MEASURE	NNP	O
The	DT	O
Wheelchair	NNP	O
Use	NNP	O
Confidence	NNP	O
Scale-Manual	JJ	O
(	(	O
WheelCon-M	NNP	O
)	)	O
was	VBD	O
used	VBN	O
to	TO	O
evaluate	VB	O
confidence	NN	O
with	IN	O
using	VBG	O
a	DT	O
manual	JJ	O
wheelchair	NN	O
.	.	O

The	DT	O
WheelCon-M	NNP	O
is	VBZ	O
a	DT	O
self-report	JJ	O
questionnaire	NN	O
that	WDT	O
comprises	VBZ	O
65	CD	O
items	NNS	O
in	IN	O
6	CD	O
conceptual	JJ	O
areas	NNS	O
.	.	O

RESULTS	VB	O
A	DT	O
1-way	JJ	O
between-groups	JJ	O
analysis	NN	O
of	IN	O
covariance	NN	O
revealed	VBD	O
a	DT	O
significant	JJ	O
difference	NN	O
in	IN	O
postintervention	NN	O
WheelCon-M	JJ	O
scores	NNS	O
between	IN	O
the	DT	O
intervention	NN	O
and	CC	O
control	NN	O
groups	NNS	O
(	(	O
F1,17=10.9	NNP	O
,	,	O
P=.004	NNP	O
)	)	O
after	IN	O
controlling	VBG	O
for	IN	O
baseline	JJ	O
WheelCon-M	JJ	O
scores	NNS	O
.	.	O

A	DT	O
large	JJ	O
effect	NN	O
size	NN	O
was	VBD	O
also	RB	O
observed	VBN	O
(	(	O
partial	JJ	O
?	.	O
(	(	O
2	CD	O
)	)	O
=.39	NN	O
)	)	O
.	.	O

Secondary	JJ	O
analyses	NNS	O
revealed	VBD	O
that	IN	O
the	DT	O
WSTP	NNP	O
had	VBD	O
greater	JJR	O
effects	NNS	O
on	IN	O
confidence	NN	O
in	IN	O
areas	NNS	O
related	VBN	O
to	TO	O
maneuvering	VBG	O
around	IN	O
the	DT	O
physical	JJ	O
environment	NN	O
,	,	O
knowledge	NN	O
and	CC	O
problem	NN	O
solving	NN	O
,	,	O
advocacy	NN	O
,	,	O
and	CC	O
managing	VBG	O
emotions	NNS	O
than	IN	O
in	IN	O
areas	NNS	O
related	VBN	O
to	TO	O
performing	VBG	O
activities	NNS	O
and	CC	O
behaving	VBG	O
in	IN	O
social	JJ	O
situations	NNS	O
.	.	O

CONCLUSION	NNP	O
Two	CD	O
1-hour	JJ	O
WSTP	NNP	O
sessions	NNS	O
improve	VBP	O
confidence	NN	O
with	IN	O
using	VBG	O
a	DT	O
manual	JJ	O
wheelchair	NN	O
among	IN	O
older	JJR	O
adults	NNS	O
who	WP	O
are	VBP	O
inexperienced	VBN	O
wheelchair	JJ	O
users	NNS	O
.	.	O

Training	VBG	O
referential	JJ	O
communicative	JJ	O
skills	NNS	O
to	TO	O
individuals	NNS	O
with	IN	O
autism	NN	O
spectrum	NN	O
disorder	NN	O
:	:	O
a	DT	O
pilot	NN	O
study	NN	O
.	.	O

The	DT	O
present	JJ	O
study	NN	O
reports	VBZ	O
the	DT	O
effects	NNS	O
of	IN	O
referential	JJ	O
communication	NN	O
training	NN	O
in	IN	O
individuals	NNS	O
formally	RB	O
diagnosed	VBN	O
with	IN	O
autism	NN	O
spectrum	NN	O
disorder	NN	O
(	(	O
ASD	NNP	O
)	)	O
.	.	O

Participants	NNS	O
were	VBD	O
20	CD	O
children	NNS	O
with	IN	O
ASD	NNP	O
(	(	O
M	NNP	O
age	NN	O
=	VBD	O
14.3	CD	O
yr.	NN	O
,	,	O
SD	NNP	O
=	NNP	O
4.2	CD	O
;	:	O
6	CD	O
girls	NNS	O
,	,	O
14	CD	O
boys	NNS	O
)	)	O
in	IN	O
the	DT	O
role	NN	O
of	IN	O
speakers	NNS	O
and	CC	O
20	CD	O
control	NN	O
children	NNS	O
,	,	O
who	WP	O
acted	VBD	O
as	IN	O
listeners	NNS	O
.	.	O

They	PRP	O
were	VBD	O
all	DT	O
enrolled	VBN	O
in	IN	O
mainstream	JJ	O
compulsory	NN	O
education	NN	O
.	.	O

Inclusion/exclusion	NNP	O
criteria	NNS	O
were	VBD	O
defined	VBN	O
according	VBG	O
to	TO	O
the	DT	O
clinical	JJ	O
diagnosis	NN	O
of	IN	O
ASD	NNP	O
,	,	O
the	DT	O
presence	NN	O
or	CC	O
absence	NN	O
of	IN	O
additional	JJ	O
or	CC	O
associated	JJ	O
disability	NN	O
,	,	O
previous	JJ	O
training	NN	O
in	IN	O
referential	JJ	O
communication	NN	O
,	,	O
and	CC	O
any	DT	O
drug	NN	O
treatment	NN	O
.	.	O

Speakers	NNS	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
one	CD	O
of	IN	O
two	CD	O
groups	NNS	O
(	(	O
trained	JJ	O
vs	NN	O
untrained	VBD	O
)	)	O
.	.	O

Linguistic	JJ	O
age	NN	O
,	,	O
cognitive	JJ	O
level	NN	O
and	CC	O
autistic	JJ	O
symptoms	NNS	O
were	VBD	O
analyzed	VBN	O
,	,	O
respectively	RB	O
,	,	O
with	IN	O
the	DT	O
Peabody	NNP	O
Picture	NNP	O
Vocabulary	NNP	O
Test	NNP	O
(	(	O
PPVT	NNP	O
)	)	O
,	,	O
the	DT	O
Wechsler	NNP	O
Intelligence	NNP	O
Scale	NNP	O
(	(	O
WISC-R	NNP	O
or	CC	O
WAIS-III	NNP	O
)	)	O
,	,	O
and	CC	O
the	DT	O
Autistic	NNP	O
Behavior	NNP	O
Checklist	NNP	O
(	(	O
ABC	NNP	O
)	)	O
.	.	O

Communicative	JJ	O
abilities	NNS	O
were	VBD	O
analyzed	VBN	O
through	IN	O
two	CD	O
indexes	NNS	O
related	VBN	O
to	TO	O
message	VB	O
complexity	NN	O
and	CC	O
self-regulation	NN	O
.	.	O

The	DT	O
trained	JJ	O
group	NN	O
was	VBD	O
trained	VBN	O
in	IN	O
referential	JJ	O
communication	NN	O
tasks	NNS	O
(	(	O
task	NN	O
analysis	NN	O
,	,	O
role	NN	O
taking	NN	O
,	,	O
and	CC	O
task	JJ	O
evaluation	NN	O
)	)	O
,	,	O
while	IN	O
the	DT	O
untrained	JJ	O
group	NN	O
took	VBD	O
part	NN	O
in	IN	O
a	DT	O
communicative	JJ	O
game	NN	O
but	CC	O
without	IN	O
any	DT	O
specific	JJ	O
communicative	JJ	O
training	NN	O
.	.	O

The	DT	O
results	NNS	O
showed	VBD	O
that	IN	O
the	DT	O
complexity	NN	O
of	IN	O
emitted	JJ	O
messages	NNS	O
had	VBD	O
improved	VBN	O
statistically	RB	O
significantly	RB	O
in	IN	O
the	DT	O
trained	JJ	O
group	NN	O
as	IN	O
an	DT	O
effect	NN	O
of	IN	O
training	NN	O
.	.	O

Ecological	JJ	O
referential	JJ	O
communication	NN	O
is	VBZ	O
shown	VBN	O
to	TO	O
be	VB	O
an	DT	O
appropriate	JJ	O
paradigm	NN	O
for	IN	O
studying	VBG	O
the	DT	O
communicative	JJ	O
process	NN	O
and	CC	O
its	PRP$	O
products	NNS	O
and	CC	O
could	MD	O
be	VB	O
used	VBN	O
to	TO	O
develop	VB	O
and	CC	O
implement	VB	O
a	DT	O
training	NN	O
program	NN	O
focused	VBN	O
on	IN	O
those	DT	O
skills	NNS	O
in	IN	O
which	WDT	O
individuals	NNS	O
with	IN	O
ASD	NNP	O
are	VBP	O
most	RBS	O
deficient	JJ	O
.	.	O

A	DT	O
comparison	NN	O
of	IN	O
single-dose	JJ	O
versus	NN	O
conventional-dose	JJ	O
antibiotic	JJ	O
treatment	NN	O
of	IN	O
bacteriuria	NN	C
in	IN	C
elderly	JJ	C
women	NNS	C
.	.	C

The	DT	O
efficacy	NN	O
of	IN	O
single-dose	JJ	O
antibiotic	JJ	O
therapy	NN	O
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
bacteriuria	NN	O
in	IN	O
a	DT	O
group	NN	O
of	IN	O
non-catheterized	JJ	O
elderly	JJ	O
women	NNS	O
was	VBD	O
compared	VBN	O
with	IN	O
that	DT	O
of	IN	O
conventional	JJ	O
7-10	JJ	O
day	NN	O
courses	NNS	O
of	IN	O
antibiotic	JJ	O
therapy	NN	O
.	.	O

Thirty-one	JJ	O
women	NNS	O
received	VBD	O
single-dose	JJ	O
treatment	NN	O
and	CC	O
22	CD	O
conventional-dose	JJ	O
treatment	NN	O
.	.	O

The	DT	O
cure	NN	O
rates	NNS	O
at	IN	O
1	CD	O
and	CC	O
6	CD	O
weeks	NNS	O
for	IN	O
the	DT	O
single-dose	JJ	O
treatments	NNS	O
were	VBD	O
52	CD	O
%	NN	O
and	CC	O
38	CD	O
%	NN	O
,	,	O
respectively	RB	O
,	,	O
and	CC	O
the	DT	O
cure	NN	O
rates	NNS	O
for	IN	O
the	DT	O
conventional-dose	JJ	O
treatments	NNS	O
at	IN	O
1	CD	O
and	CC	O
6	CD	O
weeks	NNS	O
were	VBD	O
59	CD	O
%	NN	O
and	CC	O
52	CD	O
%	NN	O
,	,	O
respectively	RB	O
.	.	O

It	PRP	O
is	VBZ	O
concluded	VBN	O
that	IN	O
there	EX	O
may	MD	O
be	VB	O
a	DT	O
place	NN	O
for	IN	O
the	DT	O
use	NN	O
of	IN	O
single-dose	JJ	O
antibiotic	JJ	O
therapy	NN	O
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
selected	VBN	O
elderly	JJ	O
women	NNS	O
with	IN	O
bacteriuria	NN	O
,	,	O
but	CC	O
larger	JJR	O
studies	NNS	O
are	VBP	O
needed	VBN	O
.	.	O

Anticholinergic	NNP	O
drugs	NNS	O
:	:	O
effects	NNS	O
on	IN	O
oxygen	NN	O
consumption	NN	O
and	CC	O
energy	NN	O
expenditure	NN	O
.	.	O

Premedication	NN	O
has	VBZ	O
been	VBN	O
shown	VBN	O
to	TO	O
affect	VB	O
both	DT	O
oxygen	NN	O
consumption	NN	O
(	(	O
VO2	NNP	O
)	)	O
and	CC	O
energy	NN	O
expenditure	NN	O
(	(	O
EE	NNP	O
)	)	O
.	.	O

The	DT	O
metabolic	JJ	O
responses	NNS	O
to	TO	O
anticholinergic	VB	O
drugs	NNS	O
have	VBP	O
not	RB	O
been	VBN	O
studied	VBN	O
.	.	O

In	IN	O
this	DT	O
study	NN	O
the	DT	O
effects	NNS	O
of	IN	O
anticholinergic	JJ	O
drugs	NNS	O
on	IN	O
VO2	NNP	O
and	CC	O
EE	NNP	O
(	(	O
calculated	VBN	O
from	IN	O
the	DT	O
measured	VBN	O
rates	NNS	O
of	IN	O
VO2	NNP	O
and	CC	O
carbon	NN	O
dioxide	NN	O
production	NN	O
[	NNP	O
VCO2	NNP	O
]	NN	O
:	:	O
EE	NNP	O
[	NNP	O
kcal/d	NNP	O
]	NNP	O
=	VBD	O
3.581	CD	O
x	NNP	O
VO2	NNP	O
[	NNP	O
L/d	NNP	O
]	NNP	O
+	VBD	O
1.448	CD	O
x	NNP	O
VCO2	NNP	O
[	NNP	O
L/d	NNP	O
]	NNP	O
-	:	O
32.4	CD	O
)	)	O
were	VBD	O
measured	VBN	O
in	IN	O
six	CD	SS
healthy	JJ	O
female	NN	SE
volunteers	NNS	O
.	.	O

They	PRP	O
were	VBD	O
given	VBN	O
intramuscular	JJ	O
atropine	NN	O
(	(	O
15	CD	O
micrograms/kg	NN	O
)	)	O
,	,	O
glycopyrrolate	NN	O
(	(	O
8	CD	O
micrograms/kg	NN	O
)	)	O
,	,	O
scopolamine	NN	O
(	(	O
8	CD	O
micrograms/kg	NN	O
)	)	O
,	,	O
and	CC	O
placebo	NN	O
in	IN	O
a	DT	O
random	JJ	O
double-blind	JJ	O
cross-over	NN	O
design	NN	O
.	.	O

The	DT	O
consecutive	JJ	O
sessions	NNS	O
were	VBD	O
at	IN	O
least	JJS	O
1	CD	O
wk	JJ	O
apart	RB	O
for	IN	O
each	DT	O
subject	NN	O
.	.	O

VO2	NNP	O
and	CC	O
EE	NNP	O
were	VBD	O
measured	VBN	O
using	VBG	O
an	DT	O
indirect	JJ	O
calorimetry	NN	O
(	(	O
Deltatrac	NNP	O
)	)	O
.	.	O

Cardiovascular	JJ	O
responses	NNS	O
were	VBD	O
assessed	VBN	O
using	VBG	O
standard	JJ	O
noninvasive	JJ	O
monitoring	NN	O
.	.	O

Plasma	NNP	O
drug	NN	O
concentrations	NNS	O
were	VBD	O
analyzed	VBN	O
using	VBG	O
a	DT	O
sensitive	JJ	O
modification	NN	O
of	IN	O
radioreceptor	NN	O
assay	NN	O
.	.	O

Subjective	JJ	O
responses	NNS	O
were	VBD	O
measured	VBN	O
with	IN	O
visual	JJ	O
analog	NN	O
scale	NN	O
(	(	O
VAS	NNP	O
)	)	O
.	.	O

Atropine	NNP	O
and	CC	O
glycopyrrolate	NN	O
induced	VBD	O
a	DT	O
significant	JJ	O
increase	NN	O
in	IN	O
heart	NN	O
rate	NN	O
with	IN	O
a	DT	O
simultaneous	JJ	O
decrease	NN	O
in	IN	O
pressure	NN	O
rate	NN	O
quotient	NN	O
(	(	O
PRQ	NNP	O
)	)	O
,	,	O
while	IN	O
scopolamine	NN	O
caused	VBD	O
a	DT	O
significant	JJ	O
decrease	NN	O
in	IN	O
heart	NN	O
rate	NN	O
with	IN	O
a	DT	O
simultaneous	JJ	O
increase	NN	O
in	IN	O
PRQ	NNP	O
.	.	O

Scopolamine	NNP	O
significantly	RB	O
decreased	VBD	O
both	DT	O
VO2	NNP	O
and	CC	O
EE	NNP	O
,	,	O
whereas	JJ	O
glycopyrrolate	NN	O
increased	VBD	O
VO2	NNP	O
.	.	O

Atropine	NNP	O
had	VBD	O
no	DT	O
significant	JJ	O
effect	NN	O
on	IN	O
metabolic	JJ	O
variables	NNS	O
.	.	O

Only	RB	O
scopolamine	NN	O
induced	JJ	O
sedation	NN	O
in	IN	O
this	DT	O
study	NN	O
.	.	O

In	IN	O
conclusion	NN	O
,	,	O
atropine	NN	O
,	,	O
glycopyrrolate	NN	O
,	,	O
and	CC	O
scopolamine	NN	O
differ	NN	O
not	RB	O
only	RB	O
in	IN	O
their	PRP$	O
cardiovascular	NN	O
and	CC	O
central	JJ	O
nervous	JJ	O
system	NN	O
effects	NNS	O
,	,	O
but	CC	O
also	RB	O
in	IN	O
their	PRP$	O
effects	NNS	O
on	IN	O
metabolism	NN	O
.	.	O

Anti-angiogenic	JJ	O
effect	NN	O
of	IN	O
tamoxifen	NN	O
combined	VBN	O
with	IN	O
epirubicin	NN	O
in	IN	O
breast	NN	C
cancer	NN	C
patients	NNS	O
.	.	O

Vascular	JJ	O
endothelial	JJ	O
growth	NN	O
factor	NN	O
A	NNP	O
(	(	O
VEGF-A	NNP	O
)	)	O
and	CC	O
vascular	JJ	O
endothelial	JJ	O
growth	NN	O
factor	NN	O
receptor	NN	O
2	CD	O
(	(	O
VEGFR2	NNP	O
)	)	O
are	VBP	O
the	DT	O
key	JJ	O
factors	NNS	O
mediating	VBG	O
neo-vascularization	NN	O
.	.	O

They	PRP	O
are	VBP	O
often	RB	O
coexpressed	VBN	O
in	IN	O
breast	NN	O
cancer	NN	O
.	.	O

Sex	NNP	O
steroids	NNS	O
may	MD	O
stimulate	VB	O
angiogenesis	NN	O
via	IN	O
the	DT	O
estrogen	NN	O
receptor	NN	O
(	(	O
ER	NNP	O
)	)	O
pathway	RB	O
.	.	O

We	PRP	O
investigated	VBD	O
to	TO	O
compare	VB	O
the	DT	O
effects	NNS	O
of	IN	O
the	DT	O
addition	NN	O
of	IN	O
tamoxifen	NN	O
to	TO	O
epirubicin	VB	O
versus	NN	O
epirubicin	FW	O
alone	RB	O
on	IN	O
VEGF	NNP	O
and	CC	O
VEGFR2	NNP	O
expression	NN	O
in	IN	O
breast	NN	O
cancer	NN	O
patients	NNS	O
.	.	O

The	DT	O
expression	NN	O
of	IN	O
VEGF	NNP	O
and	CC	O
VEGFR2	NNP	O
was	VBD	O
assessed	VBN	O
on	IN	O
tissue	NN	O
microarray	NN	O
by	IN	O
immunohistochemistry	NN	O
at	IN	O
baseline	JJ	O
conditions	NNS	O
and	CC	O
after	IN	O
treatments	NNS	O
in	IN	O
the	DT	O
case	NN	O
of	IN	O
191	CD	SS
patients	NNS	O
with	IN	O
T2-4	NNP	C
N0-1	NNP	C
breast	NN	C
cancer	NN	C
enrolled	VBN	O
in	IN	O
a	DT	O
randomized	JJ	O
trial	NN	O
comparing	VBG	O
four	CD	O
cycles	NNS	O
of	IN	O
single	JJ	O
agent	NN	O
epirubicin	NN	O
versus	NN	O
epirubicin	NN	O
plus	CC	O
tamoxifen	NN	O
as	IN	O
primary	JJ	O
systemic	JJ	O
treatment	NN	O
.	.	O

Epirubicin	NNP	O
alone	RB	O
failed	VBD	O
to	TO	O
induce	VB	O
changes	NNS	O
in	IN	O
VEGF	NNP	O
expression	NN	O
(	(	O
P	NNP	O
=	NNP	O
0.54	CD	O
)	)	O
,	,	O
while	IN	O
the	DT	O
addition	NN	O
of	IN	O
tamoxifen	NN	O
to	TO	O
epirubicin	VB	O
resulted	VBN	O
in	IN	O
a	DT	O
significant	JJ	O
reduction	NN	O
in	IN	O
VEGF	NNP	O
expression	NN	O
(	(	O
P	NNP	O
<	NNP	O
0.001	CD	O
)	)	O
.	.	O

As	IN	O
a	DT	O
consequence	NN	O
,	,	O
baseline	NN	O
VEGF	NNP	O
had	VBD	O
a	DT	O
negative	JJ	O
prognostic	JJ	O
role	NN	O
in	IN	O
patients	NNS	O
who	WP	O
received	VBD	O
epirubicin	JJ	O
alone	RB	O
but	CC	O
not	RB	O
in	IN	O
patients	NNS	O
receiving	VBG	O
epirubicin	JJ	O
plus	CC	O
tamoxifen	JJ	O
(	(	O
interaction	JJ	O
test	NN	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
.	.	O

VEGFR2	NNP	O
expression	NN	O
increased	VBD	O
at	IN	O
residual	JJ	O
tumor	NN	O
histology	NN	O
in	IN	O
both	DT	O
treatment	NN	O
arms	NNS	O
,	,	O
with	IN	O
a	DT	O
lesser	JJR	O
extent	NN	O
in	IN	O
patients	NNS	O
receiving	VBG	O
tamoxifen	JJ	O
plus	CC	O
epirubicin	JJ	O
.	.	O

Decrease	NNP	O
in	IN	O
VEGFR2	NNP	O
expression	NN	O
was	VBD	O
significantly	RB	O
associated	VBN	O
with	IN	O
response	NN	O
rate	NN	O
(	(	O
P	NNP	O
=	NNP	O
0.02	CD	O
)	)	O
.	.	O

The	DT	O
addition	NN	O
of	IN	O
tamoxifen	NN	O
to	TO	O
epirubicin	VB	O
resulted	VBN	O
in	IN	O
a	DT	O
suppression	NN	O
of	IN	O
a	DT	O
key	JJ	O
angiogenic	JJ	O
pathway	NN	O
.	.	O

These	DT	O
data	NNS	O
suggest	VBP	O
a	DT	O
potential	JJ	O
synergism	NN	O
of	IN	O
these	DT	O
two	CD	O
drugs	NNS	O
.	.	O

A	DT	O
controlled	VBN	O
study	NN	O
of	IN	O
early	JJ	O
discharge	NN	O
after	IN	O
uncomplicated	JJ	O
myocardial	JJ	C
infarction	NN	C
.	.	O

Out	IN	O
of	IN	O
383	CD	SS
myocardial	JJ	C
infarction	NN	C
(	(	C
MI	NNP	C
)	)	C
patients	NNS	O
aged	VBN	O
below	IN	O
70	CD	A
years	NNS	O
,	,	O
252	CD	SS
(	(	O
66	CD	O
%	NN	O
)	)	O
were	VBD	O
judged	VBN	O
after	IN	O
the	DT	O
third	JJ	O
day	NN	O
in	IN	O
hospital	NN	O
to	TO	O
have	VB	O
had	VBN	O
uncomplicated	VBN	C
infarctions	NNS	C
.	.	O

These	DT	O
patients	NNS	O
were	VBD	O
allocated	VBN	O
at	IN	O
random	NN	O
to	TO	O
two	CD	O
groups	NNS	O
,	,	O
one	CD	O
of	IN	O
which	WDT	O
was	VBD	O
given	VBN	O
treatment	NN	O
for	IN	O
8	CD	O
days	NNS	O
and	CC	O
the	DT	O
other	JJ	O
for	IN	O
15	CD	O
days	NNS	O
.	.	O

No	DT	O
significant	JJ	O
differences	NNS	O
in	IN	O
mortality	NN	O
,	,	O
morbidity	NN	O
or	CC	O
incapacity	NN	O
for	IN	O
work	NN	O
could	MD	O
be	VB	O
detected	VBN	O
during	IN	O
the	DT	O
three-month	JJ	O
period	NN	O
of	IN	O
follow-up	NN	O
.	.	O

The	DT	O
findings	NNS	O
thus	RB	O
support	VBP	O
previous	JJ	O
conclusions	NNS	O
that	WDT	O
early	RB	O
discharge	VBP	O
from	IN	O
hospital	NN	O
after	IN	O
uncomplicated	JJ	O
MI	NNP	O
is	VBZ	O
not	RB	O
associated	VBN	O
with	IN	O
greater	JJR	O
risk	NN	O
for	IN	O
the	DT	O
patient	NN	O
than	IN	O
later	RB	O
discharge	NN	O
.	.	O

Low	JJ	O
doses	NNS	O
of	IN	O
ketazolam	NN	O
in	IN	O
anxiety	NN	C
:	:	O
a	DT	O
double-blind	NN	O
,	,	O
placebo-controlled	JJ	O
study	NN	O
.	.	O

A	DT	O
multicenter	NN	O
,	,	O
double-blind	JJ	O
,	,	O
between-patient	JJ	O
trial	NN	O
comparing	VBG	O
two	CD	O
doses	NNS	O
of	IN	O
ketazolam	NN	O
(	(	O
15	CD	O
and	CC	O
30	CD	O
mg	NN	O
)	)	O
with	IN	O
placebo	NN	O
,	,	O
each	DT	O
given	VBN	O
once	RB	O
daily	JJ	O
,	,	O
in	IN	O
the	DT	O
evening	NN	O
,	,	O
to	TO	O
92	CD	SS
outpatients	NNS	O
affected	VBN	O
by	IN	O
generalized	JJ	O
anxiety	NN	C
disorders	NNS	C
for	IN	O
at	IN	O
least	JJS	O
1	CD	O
month	NN	O
,	,	O
was	VBD	O
carried	VBN	O
out	RP	O
.	.	O

After	IN	O
1-week	JJ	O
washout	NN	O
period	NN	O
47	CD	SS
patients	NNS	O
were	VBD	O
randomized	VBN	O
to	TO	O
ketazolam	VB	O
15	CD	O
mg	NN	O
,	,	O
and	CC	O
45	CD	O
to	TO	O
placebo	VB	O
for	IN	O
15	CD	O
days	NNS	O
(	(	O
first	JJ	O
period	NN	O
)	)	O
.	.	O

At	IN	O
the	DT	O
end	NN	O
of	IN	O
this	DT	O
period	NN	O
,	,	O
if	IN	O
the	DT	O
patient	NN	O
experienced	VBD	O
a	DT	O
decrease	NN	O
on	IN	O
the	DT	O
total	JJ	O
Hamilton	NNP	O
Anxiety	NNP	O
Rating	NNP	O
Scale	NNP	O
(	(	O
HAM-A	NNP	O
)	)	O
of	IN	O
at	IN	O
least	JJS	O
25	CD	O
%	NN	O
of	IN	O
basal	NN	O
value	NN	O
,	,	O
the	DT	O
treatment	NN	O
was	VBD	O
kept	VBN	O
unchanged	JJ	O
for	IN	O
a	DT	O
further	JJ	O
15	CD	O
days	NNS	O
,	,	O
otherwise	RB	O
15	CD	O
mg	NN	O
of	IN	O
ketazolam	NNS	O
were	VBD	O
added	VBN	O
to	TO	O
the	DT	O
previous	JJ	O
treatment	NN	O
(	(	O
second	JJ	O
period	NN	O
)	)	O
.	.	O

Anxiety	NN	O
was	VBD	O
rated	VBN	O
after	IN	O
2	CD	O
and	CC	O
4	CD	O
weeks	NNS	O
with	IN	O
the	DT	O
Italian	JJ	O
HAM-A	NNP	O
scale	NN	O
and	CC	O
with	IN	O
a	DT	O
4-point	JJ	O
scale	NN	O
(	(	O
patient	NN	O
's	POS	O
assessment	NN	O
)	)	O
.	.	O

Seventy-eight	JJ	SS
patients	NNS	O
completed	VBD	O
the	DT	O
first	JJ	O
period	NN	O
and	CC	O
75	CD	SS
the	DT	O
whole	NN	O
study	NN	O
.	.	O

During	IN	O
the	DT	O
first	JJ	O
period	NN	O
the	DT	O
percentage	NN	O
of	IN	O
responders	NNS	O
was	VBD	O
almost	RB	O
identical	JJ	O
in	IN	O
both	DT	O
treatment	NN	O
groups	NNS	O
,	,	O
but	CC	O
during	IN	O
the	DT	O
second	JJ	O
period	NN	O
a	DT	O
further	JJ	O
slight	NN	O
improvement	NN	O
was	VBD	O
observed	VBN	O
in	IN	O
the	DT	O
early	JJ	O
placebo	NN	O
responders	NNS	O
,	,	O
while	IN	O
the	DT	O
HAM-A	NNP	O
score	NN	O
of	IN	O
patients	NNS	O
on	IN	O
ketazolam	NNS	O
continued	VBN	O
to	TO	O
improve	VB	O
significantly	RB	O
(	(	O
p	NN	O
less	JJR	O
than	IN	O
0.01	CD	O
)	)	O
throughout	IN	O
the	DT	O
study	NN	O
.	.	O

Likewise	VB	O
a	DT	O
significant	JJ	O
(	(	O
p	NN	O
less	JJR	O
than	IN	O
0.001	CD	O
)	)	O
difference	NN	O
between	IN	O
treatments	NNS	O
was	VBD	O
observed	VBN	O
,	,	O
on	IN	O
the	DT	O
4-point	JJ	O
scale	NN	O
,	,	O
in	IN	O
the	DT	O
population	NN	O
as	IN	O
a	DT	O
whole	NN	O
(	(	O
end	NN	O
of	IN	O
first	JJ	O
period	NN	O
)	)	O
as	RB	O
well	RB	O
as	IN	O
in	IN	O
responder	NN	O
patients	NNS	O
(	(	O
end	JJ	O
second	JJ	O
period	NN	O
)	)	O
.	.	O

Tolerability	NN	O
was	VBD	O
good	JJ	O
,	,	O
except	IN	O
in	IN	O
1	CD	O
patient	NN	O
on	IN	O
placebo	NN	O
,	,	O
who	WP	O
was	VBD	O
withdrawn	VBN	O
from	IN	O
the	DT	O
study	NN	O
because	IN	O
of	IN	O
severe	JJ	O
headache	NN	O
.	.	O

Supplementation	NN	O
with	IN	O
n3	JJ	O
fatty	JJ	O
acid	NN	O
ethyl	NN	O
esters	NNS	O
increases	VBZ	O
large	JJ	O
and	CC	O
small	JJ	O
artery	NN	O
elasticity	NN	O
in	IN	O
obese	JJ	O
adults	NNS	O
on	IN	O
a	DT	O
weight	JJ	O
loss	NN	O
diet	NN	O
.	.	O

Increased	VBN	O
arterial	JJ	O
stiffness	NN	O
is	VBZ	O
associated	VBN	O
with	IN	O
enhanced	JJ	O
risk	NN	O
of	IN	O
cardiovascular	JJ	O
disease	NN	O
in	IN	O
obese	JJ	O
individuals	NNS	O
.	.	O

Whether	NNP	O
n3	JJ	O
fatty	RB	O
acid	JJ	O
ethyl	NN	O
ester	NN	O
(	(	O
FAEE	NNP	O
)	)	O
supplementation	NN	O
improves	VBZ	O
arterial	JJ	O
stiffness	NN	O
in	IN	O
obese	JJ	O
participants	NNS	O
on	IN	O
a	DT	O
weight	JJ	O
loss	NN	O
diet	NN	O
has	VBZ	O
not	RB	O
yet	RB	O
been	VBN	O
investigated	VBN	O
.	.	O

The	DT	O
objective	NN	O
of	IN	O
the	DT	O
study	NN	O
was	VBD	O
to	TO	O
carry	VB	O
out	RP	O
a	DT	O
12-wk	JJ	O
randomized	NN	O
,	,	O
single-blind	JJ	O
trial	NN	O
to	TO	O
test	VB	O
the	DT	O
effect	NN	O
of	IN	O
a	DT	O
25	CD	O
%	NN	O
energy	NN	O
deficit	NN	O
weight	VBD	O
loss	NN	O
diet	NN	O
alone	RB	O
(	(	O
WL	NNP	O
)	)	O
(	(	O
n	JJ	O
=	NNP	O
12	CD	O
)	)	O
or	CC	O
WL	NNP	O
plus	CC	O
4	CD	O
g/d	NN	O
Omacor	NNP	O
(	(	O
46	CD	O
%	NN	O
EPA	NNP	O
and	CC	O
38	CD	O
%	NN	O
DHA	NNP	O
)	)	O
supplementation	NN	O
(	(	O
WL+FAEE	NNP	O
)	)	O
(	(	O
n	JJ	O
=	NNP	O
13	CD	O
)	)	O
on	IN	O
arterial	JJ	O
elasticity	NN	O
in	IN	O
obese	JJ	O
adults	NNS	O
.	.	O

Large	NNP	O
(	(	O
C1	NNP	O
)	)	O
and	CC	O
small	JJ	O
artery	NN	O
elasticity	NN	O
(	(	O
C2	NNP	O
)	)	O
were	VBD	O
measured	VBN	O
by	IN	O
pulse	JJ	O
contour	NN	O
analysis	NN	O
of	IN	O
the	DT	O
radial	JJ	O
artery	NN	O
.	.	O

WL	NNP	O
alone	RB	O
reduced	VBD	O
(	(	O
P	NNP	O
<	VBZ	O
0.05	CD	O
in	IN	O
all	DT	O
)	)	O
body	NN	O
weight	NN	O
(	(	O
-3	CD	O
%	NN	O
)	)	O
,	,	O
waist	JJ	O
circumference	NN	O
(	(	O
-4	CD	O
%	NN	O
)	)	O
,	,	O
systolic	JJ	O
(	(	O
-3	CD	O
%	NN	O
)	)	O
and	CC	O
diastolic	JJ	O
(	(	O
-3	CD	O
%	NN	O
)	)	O
blood	NN	O
pressures	NNS	O
,	,	O
cardiac	JJ	O
output	NN	O
(	(	O
-4	CD	O
%	NN	O
)	)	O
,	,	O
plasma	JJ	O
TG	NNP	O
concentration	NN	O
(	(	O
-25	CD	O
%	NN	O
)	)	O
,	,	O
and	CC	O
the	DT	O
homeostasis	NN	O
model	NN	O
assessment	NN	O
(	(	O
HOMA	NNP	O
)	)	O
score	NN	O
(	(	O
-12	CD	O
%	NN	O
)	)	O
and	CC	O
increased	VBD	O
plasma	NN	O
HDL	NNP	O
cholesterol	NN	O
(	(	O
+9	CD	O
%	NN	O
)	)	O
and	CC	O
adiponectin	NN	O
(	(	O
+18	CD	O
%	NN	O
)	)	O
concentrations	NNS	O
.	.	O

However	RB	O
,	,	O
WL	NNP	O
alone	RB	O
did	VBD	O
not	RB	O
alter	VB	O
C1	NNP	O
and	CC	O
C2	NNP	O
.	.	O

The	DT	O
WL+FAEE	NNP	O
intervention	NN	O
significantly	RB	O
reduced	VBN	O
body	NN	O
weight	NN	O
(	(	O
-4	CD	O
%	NN	O
)	)	O
,	,	O
waist	JJ	O
circumference	NN	O
(	(	O
-4	CD	O
%	NN	O
)	)	O
,	,	O
systolic	JJ	O
(	(	O
-8	CD	O
%	NN	O
)	)	O
and	CC	O
diastolic	JJ	O
(	(	O
-5	CD	O
%	NN	O
)	)	O
blood	NN	O
pressures	NNS	O
,	,	O
pulse	JJ	O
pressure	NN	O
(	(	O
-5	CD	O
%	NN	O
)	)	O
,	,	O
heart	NN	O
rate	NN	O
(	(	O
-8	CD	O
%	NN	O
)	)	O
,	,	O
plasma	JJ	O
TG	NNP	O
concentration	NN	O
(	(	O
-36	CD	O
%	NN	O
)	)	O
,	,	O
and	CC	O
HOMA	NNP	O
score	NN	O
(	(	O
-12	CD	O
%	NN	O
)	)	O
and	CC	O
increased	JJ	O
stroke	NN	O
volume	NN	O
(	(	O
+3	CD	O
%	NN	O
)	)	O
,	,	O
plasma	JJ	O
HDL	NNP	O
cholesterol	NN	O
(	(	O
+6	CD	O
%	NN	O
)	)	O
and	CC	O
adiponectin	JJ	O
concentrations	NNS	O
(	(	O
+28	CD	O
%	NN	O
)	)	O
,	,	O
and	CC	O
C1	NNP	O
(	(	O
+20	NNP	O
%	NN	O
)	)	O
and	CC	O
C2	NNP	O
(	(	O
+22	NNP	O
%	NN	O
)	)	O
artery	NN	O
elasticity	NN	O
.	.	O

The	DT	O
changes	NNS	O
in	IN	O
systolic	JJ	O
blood	NN	O
pressure	NN	O
,	,	O
heart	NN	O
rate	NN	O
,	,	O
plasma	NN	O
TGs	NNP	O
,	,	O
C1	NNP	O
,	,	O
and	CC	O
C2	NNP	O
were	VBD	O
significantly	RB	O
greater	JJR	O
in	IN	O
the	DT	O
WL+FAEE	NNP	O
group	NN	O
than	IN	O
in	IN	O
the	DT	O
WL	NNP	O
group	NN	O
.	.	O

Supplementation	NN	O
with	IN	O
n3	JJ	O
FAEEs	NNP	O
improves	VBZ	O
C1	NNP	O
and	CC	O
C2	NNP	O
independently	RB	O
of	IN	O
weight	JJ	O
loss	NN	O
in	IN	O
obese	JJ	O
adults	NNS	O
.	.	O

Blood	NNP	O
purification	NN	O
for	IN	O
critical	JJ	O
care	NN	O
medicine	NN	O
:	:	O
endotoxin	NN	O
adsorption	NN	O
.	.	O

Many	JJ	O
kinds	NNS	O
of	IN	O
blood	NN	O
purifying	VBG	O
technologies	NNS	O
have	VBP	O
been	VBN	O
applied	VBN	O
to	TO	O
the	DT	O
treatment	NN	O
of	IN	O
critically	RB	C
ill	JJ	C
patients	NNS	C
since	IN	O
1979	CD	O
when	WRB	O
plasma	JJ	O
exchange	NN	O
with	IN	O
hollow-fiber	JJ	O
membranes	NNS	O
was	VBD	O
developed	VBN	O
.	.	O

These	DT	O
technologies	NNS	O
have	VBP	O
been	VBN	O
applied	VBN	O
not	RB	O
only	RB	O
to	TO	O
the	DT	O
removal	NN	O
of	IN	O
toxic	JJ	O
substances	NNS	O
,	,	O
but	CC	O
also	RB	O
to	TO	O
the	DT	O
treatment	NN	O
of	IN	O
objective	JJ	O
diseases	NNS	O
and	CC	O
the	DT	O
removal	NN	O
of	IN	O
the	DT	O
factors	NNS	O
relating	VBG	O
to	TO	O
the	DT	O
associated	VBN	O
inflammation	NN	O
.	.	O

This	DT	O
article	NN	O
summarizes	VBZ	O
these	DT	O
methods	NNS	O
and	CC	O
their	PRP$	O
efficacies	NNS	O
for	IN	O
critically	RB	O
ill	JJ	O
patients	NNS	O
,	,	O
especially	RB	O
those	DT	O
with	IN	O
severe	JJ	O
sepsis	NN	O
.	.	O

Attempts	NNS	O
have	VBP	O
been	VBN	O
made	VBN	O
to	TO	O
remove	VB	O
endotoxin	NN	O
,	,	O
the	DT	O
main	JJ	O
cause	NN	O
of	IN	O
sepsis	NN	O
,	,	O
from	IN	O
the	DT	O
circulation	NN	O
using	VBG	O
polymyxin	NN	O
B	NNP	O
immobilized	VBD	O
fiber	NN	O
,	,	O
charcoal	NN	O
hemoperfusion	NN	O
,	,	O
and	CC	O
plasma	NN	O
or	CC	O
whole	JJ	O
blood	NN	O
exchange	NN	O
.	.	O

Attempts	NNS	O
have	VBP	O
also	RB	O
been	VBN	O
made	VBN	O
to	TO	O
remove	VB	O
proinflammatory	NN	O
cytokines	NNS	O
,	,	O
eicosanoides	NNS	O
,	,	O
and	CC	O
coagulative	JJ	O
factors	NNS	O
from	IN	O
the	DT	O
circulation	NN	O
in	IN	O
the	DT	O
human	JJ	O
body	NN	O
.	.	O

Continuous	JJ	O
hemofiltration	NN	O
or	CC	O
hemodiafiltration	NN	O
is	VBZ	O
the	DT	O
representative	JJ	O
technology	NN	O
.	.	O

The	DT	O
efficacy	NN	O
of	IN	O
these	DT	O
methods	NNS	O
has	VBZ	O
been	VBN	O
established	VBN	O
,	,	O
but	CC	O
several	JJ	O
issues	NNS	O
remain	VBP	O
unresolved	JJ	O
.	.	O

All	DT	O
methods	NNS	O
of	IN	O
the	DT	O
treatment	NN	O
of	IN	O
severe	JJ	O
sepsis	NN	O
are	VBP	O
discussed	VBN	O
with	IN	O
reference	NN	O
to	TO	O
treatment	NN	O
indications	NNS	O
,	,	O
efficacy	NN	O
,	,	O
and	CC	O
outcome	JJ	O
parameters	NNS	O
.	.	O

In	IN	O
particular	JJ	O
,	,	O
the	DT	O
clinical	JJ	O
results	NNS	O
of	IN	O
endotoxin	JJ	O
removal	NN	O
with	IN	O
polymyxin	NN	O
B	NNP	O
immobilized	JJ	O
fiber	NN	O
are	VBP	O
summarized	VBN	O
in	IN	O
this	DT	O
article	NN	O
.	.	O

A	DT	O
randomised	JJ	O
open	JJ	O
multicentre	NN	O
comparative	JJ	O
trial	NN	O
of	IN	O
lamotrigine	NN	O
and	CC	O
carbamazepine	NN	O
as	IN	O
monotherapy	NN	O
in	IN	O
patients	NNS	O
with	IN	O
newly	RB	O
diagnosed	VBN	O
or	CC	O
recurrent	JJ	O
epilepsy	NN	O
.	.	O

The	DT	O
efficacy	NN	O
and	CC	O
safety	NN	O
of	IN	O
lamotrigine	NN	O
and	CC	O
carbamazepine	NN	O
as	IN	O
monotherapy	NN	O
in	IN	O
patients	NNS	O
with	IN	O
untreated	JJ	O
,	,	O
newly	RB	O
diagnosed	VBN	O
or	CC	O
recurrent	JJ	O
partial	JJ	O
and/or	NN	O
generalised	VBD	O
tonic-clonic	JJ	O
seizures	NNS	O
,	,	O
were	VBD	O
compared	VBN	O
in	IN	O
a	DT	O
randomised	JJ	O
,	,	O
open	JJ	O
,	,	O
multicentre	JJ	O
study	NN	O
.	.	O

Patients	NNS	O
received	VBD	O
24	CD	O
weeks	NNS	O
'	POS	O
treatment	NN	O
with	IN	O
oral	JJ	O
lamotrigine	NN	O
100	CD	O
mg	NN	O
(	(	O
LTG	NNP	O
100	CD	O
,	,	O
n	RB	O
=	VBZ	O
115	CD	O
)	)	O
or	CC	O
200	CD	O
mg	NN	O
(	(	O
LTG	NNP	O
200	CD	O
,	,	O
n	RB	O
=	VBZ	O
111	CD	O
)	)	O
or	CC	O
carbamazepine	$	O
600	CD	O
mg	NN	O
(	(	O
CBZ	NNP	O
600	CD	O
,	,	O
n	RB	O
=	VBZ	O
117	CD	O
)	)	O
.	.	O

Efficacy	NN	O
measurements	NNS	O
were	VBD	O
comparable	JJ	O
between	IN	O
the	DT	O
three	CD	O
treatment	NN	O
groups	NNS	O
,	,	O
although	IN	O
the	DT	O
higher	JJR	O
lamotrigine	NN	O
dose	NN	O
was	VBD	O
possibly	RB	O
most	RBS	O
effective	JJ	O
,	,	O
with	IN	O
60.4	CD	O
%	NN	O
completing	VBG	O
seizure	NN	O
free	JJ	O
compared	VBN	O
with	IN	O
51.3	CD	O
%	NN	O
(	(	O
LTG	NNP	O
100	CD	O
)	)	O
and	CC	O
54.7	CD	O
%	NN	O
(	(	O
CBZ	NNP	O
600	CD	O
)	)	O
.	.	O

Both	DT	O
dosage	NN	O
regimens	NNS	O
of	IN	O
lamotrigine	NN	O
were	VBD	O
well	RB	O
tolerated	VBN	O
.	.	O

More	JJR	O
patients	NNS	O
on	IN	O
CBZ	NNP	O
600	CD	O
reported	VBD	O
adverse	JJ	O
experiences	NNS	O
,	,	O
66	CD	O
%	NN	O
versus	IN	O
53	CD	O
%	NN	O
(	(	O
LTG	NNP	O
100	CD	O
)	)	O
and	CC	O
58	CD	O
%	NN	O
(	(	O
LTG	NNP	O
200	CD	O
)	)	O
,	,	O
and	CC	O
of	IN	O
these	DT	O
a	DT	O
greater	JJR	O
proportion	NN	O
were	VBD	O
attributed	VBN	O
to	TO	O
CBZ	NNP	O
600	CD	O
treatment	NN	O
,	,	O
53	CD	O
%	NN	O
versus	IN	O
23	CD	O
%	NN	O
(	(	O
LTG	NNP	O
100	CD	O
)	)	O
and	CC	O
28	CD	O
%	NN	O
(	(	O
LTG	NNP	O
200	CD	O
)	)	O
.	.	O

Similarly	RB	O
,	,	O
a	DT	O
greater	JJR	O
proportion	NN	O
of	IN	O
the	DT	O
CBZ	NNP	O
600	CD	O
group	NN	O
required	VBD	O
a	DT	O
change	NN	O
in	IN	O
dose	NN	O
,	,	O
47	CD	O
%	NN	O
versus	IN	O
20	CD	O
%	NN	O
(	(	O
LTG	NNP	O
100	CD	O
)	)	O
and	CC	O
17	CD	O
%	NN	O
(	(	O
LTG	NNP	O
200	CD	O
)	)	O
or	CC	O
withdrew	$	O
completely	RB	O
due	JJ	O
to	TO	O
adverse	JJ	O
experiences	NNS	O
,	,	O
10.3	CD	O
%	NN	O
versus	IN	O
4.3	CD	O
%	NN	O
(	(	O
LTG	NNP	O
100	CD	O
)	)	O
and	CC	O
4.5	CD	O
%	NN	O
(	(	O
LTG	NNP	O
200	CD	O
)	)	O
.	.	O

The	DT	O
most	RBS	O
common	JJ	O
adverse	JJ	O
experience	NN	O
leading	VBG	O
to	TO	O
withdrawal	VB	O
was	VBD	O
rash	NN	O
,	,	O
with	IN	O
approximately	RB	O
double	JJ	O
the	DT	O
proportion	NN	O
of	IN	O
reports	NNS	O
occurring	VBG	O
in	IN	O
patients	NNS	O
on	IN	O
CBZ	NNP	O
600	CD	O
(	(	O
5.1	CD	O
%	NN	O
)	)	O
compared	VBN	O
with	IN	O
lamotrigine	NN	O
(	(	O
1.7	CD	O
%	NN	O
on	IN	O
LTG	NNP	O
100	CD	O
and	CC	O
2.7	CD	O
%	NN	O
on	IN	O
LTG	NNP	O
200	CD	O
)	)	O
.	.	O

Overall	JJ	O
lamotrigine	NN	O
appeared	VBD	O
equally	RB	O
effective	JJ	O
but	CC	O
better	RB	O
tolerated	VBD	O
compared	VBN	O
with	IN	O
carbamazepine	NN	O
.	.	O

Unpacking	VBG	O
attitude	JJ	O
certainty	NN	O
:	:	O
attitude	NN	O
clarity	NN	O
and	CC	O
attitude	NN	O
correctness	NN	O
.	.	O

Attitude	NNP	O
certainty	NN	O
has	VBZ	O
been	VBN	O
the	DT	O
subject	NN	O
of	IN	O
considerable	JJ	O
attention	NN	O
in	IN	O
the	DT	O
attitudes	NNS	O
and	CC	O
persuasion	NN	O
literature	NN	O
.	.	O

The	DT	O
present	JJ	O
research	NN	O
identifies	VBZ	O
2	CD	O
aspects	NNS	O
of	IN	O
attitude	NN	O
certainty	NN	O
and	CC	O
provides	VBZ	O
evidence	NN	O
for	IN	O
the	DT	O
distinctness	NN	O
of	IN	O
the	DT	O
constructs	NNS	O
.	.	O

Specifically	RB	O
,	,	O
it	PRP	O
is	VBZ	O
proposed	VBN	O
that	IN	O
attitude	JJ	O
certainty	NN	O
can	MD	O
be	VB	O
conceptualized	VBN	O
,	,	O
and	CC	O
empirically	RB	O
separated	VBN	O
,	,	O
in	IN	O
terms	NNS	O
of	IN	O
attitude	NN	O
clarity	NN	O
(	(	O
the	DT	O
subjective	NN	O
sense	NN	O
that	WDT	O
one	CD	O
knows	VBZ	O
what	WP	O
one	CD	O
's	POS	O
attitude	NN	O
is	VBZ	O
)	)	O
and	CC	O
attitude	JJ	O
correctness	NN	O
(	(	O
the	DT	O
subjective	NN	O
sense	NN	O
that	IN	O
one	CD	O
's	POS	O
attitude	NN	O
is	VBZ	O
correct	JJ	O
or	CC	O
valid	JJ	O
)	)	O
.	.	O

Experiment	JJ	O
1	CD	O
uses	NNS	O
factor	NN	O
analysis	NN	O
and	CC	O
correlational	JJ	O
data	NNS	O
to	TO	O
provide	VB	O
evidence	NN	O
for	IN	O
viewing	VBG	O
attitude	JJ	O
clarity	NN	O
and	CC	O
attitude	NN	O
correctness	NN	O
as	IN	O
separate	JJ	O
constructs	NNS	O
.	.	O

Experiments	NNS	O
2	CD	O
and	CC	O
3	CD	O
demonstrate	NN	O
that	WDT	O
attitude	VBP	O
clarity	NN	O
and	CC	O
attitude	NN	O
correctness	NN	O
can	MD	O
have	VB	O
distinct	JJ	O
antecedents	NNS	O
(	(	O
repeated	VBN	O
expression	NN	O
and	CC	O
consensus	NN	O
feedback	NN	O
,	,	O
respectively	RB	O
)	)	O
.	.	O

Experiment	JJ	O
4	CD	O
reveals	NNS	O
that	IN	O
these	DT	O
constructs	NNS	O
each	DT	O
play	VBP	O
an	DT	O
independent	JJ	O
role	NN	O
in	IN	O
persuasion	NN	O
and	CC	O
resistance	NN	O
situations	NNS	O
.	.	O

As	IN	O
clarity	NN	O
and	CC	O
correctness	JJ	O
increase	NN	O
,	,	O
attitudes	VBZ	O
become	VBP	O
more	RBR	O
resistant	JJ	O
to	TO	O
counterattitudinal	JJ	O
persuasive	JJ	O
messages	NNS	O
.	.	O

These	DT	O
findings	NNS	O
are	VBP	O
discussed	VBN	O
in	IN	O
relation	NN	O
to	TO	O
the	DT	O
existing	VBG	O
attitude	NN	O
strength	NN	O
literature	NN	O
.	.	O

Benefits	NNS	O
of	IN	O
adding	VBG	O
fluticasone	NN	O
propionate/salmeterol	NN	O
to	TO	O
tiotropium	VB	O
in	IN	O
moderate	JJ	C
to	TO	C
severe	VB	C
COPD	NNP	C
.	.	O

BACKGROUND	NNP	O
Combining	NNP	O
maintenance	NN	O
medications	NNS	O
with	IN	O
different	JJ	O
mechanisms	NNS	O
of	IN	O
action	NN	O
may	MD	O
improve	VB	O
outcomes	NNS	O
in	IN	O
COPD	NNP	O
.	.	O

In	IN	O
this	DT	O
study	NN	O
we	PRP	O
evaluated	VBD	O
the	DT	O
efficacy	NN	O
and	CC	O
safety	NN	O
of	IN	O
fluticasone/salmeterol	NN	O
(	(	O
FSC	NNP	O
)	)	O
(	(	O
250/50	CD	O
mcg	NN	O
twice	RB	O
daily	RB	O
)	)	O
when	WRB	O
added	VBN	O
to	TO	O
tiotropium	VB	O
(	(	O
18	CD	O
mcg	NN	O
once	RB	O
daily	RB	O
)	)	O
(	(	O
TIO	NNP	O
)	)	O
in	IN	O
subjects	NNS	O
with	IN	O
symptomatic	JJ	O
moderate	NN	O
to	TO	O
severe	VB	O
COPD	NNP	O
.	.	O

METHODS	NNP	O
This	DT	O
was	VBD	O
a	DT	O
24-week	JJ	O
,	,	O
randomized	VBN	O
,	,	O
double-blind	JJ	O
,	,	O
parallel	JJ	O
group	NN	O
,	,	O
multi-center	NN	O
study	NN	O
.	.	O

Subjects	VBZ	O
40	CD	O
years	NNS	O
or	CC	O
older	JJR	O
with	IN	O
cigarette	NN	O
smoking	VBG	O
history	NN	O
?10	JJ	O
pack-years	NNS	O
and	CC	O
with	IN	O
the	DT	O
diagnosis	NN	O
of	IN	O
COPD	NNP	O
and	CC	O
post-bronchodilator	NN	O
FEV	NNP	O
(	(	O
1	CD	O
)	)	O
?40	NN	O
to	TO	O
?	.	O
80	CD	O
%	NN	O
of	IN	O
predicted	VBN	O
normal	JJ	O
and	CC	O
FEV	NNP	O
(	(	O
1	CD	O
)	)	O
/FVC	NN	O
of	IN	O
?0.70	NN	O
were	VBD	O
enrolled	VBN	O
.	.	O

Following	VBG	O
a	DT	O
4-week	JJ	O
treatment	NN	O
with	IN	O
open-label	JJ	O
TIO	NNP	O
18	CD	O
mcg	NN	O
once	RB	O
daily	JJ	O
,	,	O
subjects	NNS	O
were	VBD	O
randomized	VBN	O
in	IN	O
a	DT	O
double-blind	JJ	O
fashion	NN	O
to	TO	O
either	VB	O
the	DT	O
addition	NN	O
of	IN	O
FSC	NNP	O
250/50	CD	O
DISKUS	NNP	O
twice	RB	O
daily	RB	O
or	CC	O
matching	VBG	O
placebo	NN	O
.	.	O

The	DT	O
primary	JJ	O
efficacy	NN	O
endpoint	NN	O
was	VBD	O
AM	NNP	O
pre-dose	JJ	O
FEV	NNP	O
(	(	O
1	CD	O
)	)	O
and	CC	O
secondary	JJ	O
endpoints	NNS	O
included	VBD	O
other	JJ	O
measures	NNS	O
of	IN	O
lung	NN	O
function	NN	O
,	,	O
rescue	NN	O
albuterol	NN	O
use	NN	O
,	,	O
health	NN	O
status	NN	O
and	CC	O
exacerbations	NNS	O
.	.	O

RESULTS	VB	O
The	DT	O
addition	NN	O
of	IN	O
FSC	NNP	O
to	TO	O
TIO	NNP	O
significantly	RB	O
improved	VBD	O
lung	JJ	O
function	NN	O
indices	NNS	O
including	VBG	O
AM	NNP	O
pre-dose	JJ	O
FEV	NNP	O
(	(	O
1	CD	O
)	)	O
,	,	O
2	CD	O
h	NN	O
post-dose	JJ	O
FEV	NNP	O
(	(	O
1	CD	O
)	)	O
,	,	O
AM	NNP	O
pre-dose	JJ	O
FVC	NNP	O
,	,	O
2	CD	O
h	NN	O
post-dose	JJ	O
FVC	NNP	O
and	CC	O
AM	NNP	O
pre-dose	JJ	O
IC	NNP	O
compared	VBN	O
with	IN	O
TIO	NNP	O
alone	RB	O
.	.	O

Furthermore	RB	O
,	,	O
this	DT	O
combination	NN	O
was	VBD	O
superior	JJ	O
to	TO	O
TIO	VB	O
alone	RB	O
in	IN	O
reducing	VBG	O
rescue	NN	O
albuterol	NN	O
use	NN	O
.	.	O

However	RB	O
,	,	O
there	EX	O
were	VBD	O
no	DT	O
significant	JJ	O
differences	NNS	O
between	IN	O
the	DT	O
treatment	NN	O
groups	NNS	O
in	IN	O
health	NN	O
status	NN	O
or	CC	O
COPD	NNP	O
exacerbations	NNS	O
.	.	O

The	DT	O
incidence	NN	O
of	IN	O
adverse	JJ	O
events	NNS	O
was	VBD	O
similar	JJ	O
in	IN	O
both	DT	O
groups	NNS	O
.	.	O

CONCLUSIONS	VB	O
The	DT	O
addition	NN	O
of	IN	O
FSC	NNP	O
to	TO	O
subjects	NNS	O
with	IN	O
COPD	NNP	O
treated	VBD	O
with	IN	O
TIO	NNP	O
significantly	RB	O
improves	VBZ	O
lung	JJ	O
function	NN	O
without	IN	O
increasing	VBG	O
the	DT	O
risk	NN	O
of	IN	O
adverse	JJ	O
events	NNS	O
.	.	O

NCT00784550	NNP	O
.	.	O

Bevacizumab	NNP	O
compared	VBN	O
with	IN	O
macular	JJ	O
laser	NN	O
grid	JJ	O
photocoagulation	NN	O
for	IN	O
cystoid	JJ	O
macular	JJ	O
edema	NN	O
in	IN	O
branch	JJ	O
retinal	JJ	O
vein	NN	O
occlusion	NN	O
.	.	O

INTRODUCTION	NNP	O
To	TO	O
evaluate	VB	O
the	DT	O
outcome	NN	O
of	IN	O
cystoid	JJ	O
macular	JJ	O
edema	NN	O
treated	VBN	O
with	IN	O
intravitreal	JJ	O
injections	NNS	O
of	IN	O
bevacizumab	NN	O
and	CC	O
macular	JJ	O
grid	NN	O
laser	NN	O
photocoagulation	NN	O
(	(	O
GLP	NNP	O
)	)	O
,	,	O
in	IN	O
patients	NNS	O
with	IN	O
perfused	JJ	O
branch	NN	O
retinal	JJ	O
vein	NN	O
occlusion	NN	O
.	.	O

METHODS	NNP	O
Thirty	NNP	O
eyes	NNS	O
of	IN	O
30	CD	O
consecutive	JJ	O
patients	NNS	O
with	IN	O
cystoid	JJ	O
macular	JJ	O
edema	NN	O
secondary	JJ	O
to	TO	O
nonischemic	JJ	O
branch	NN	O
retinal	JJ	O
vein	NN	O
occlusion	NN	O
were	VBD	O
assigned	VBN	O
to	TO	O
either	DT	O
GLP	NNP	O
group	NN	O
or	CC	O
to	TO	O
intravitreal	VB	O
bevacizumab	NN	O
(	(	O
IB	NNP	O
)	)	O
group	NN	O
.	.	O

Complete	NNP	O
ophthalmologic	JJ	O
examinations	NNS	O
were	VBD	O
performed	VBN	O
just	RB	O
before	IN	O
GLP	NNP	O
and	CC	O
IB	NNP	O
injection	NN	O
at	IN	O
1	CD	O
,	,	O
3	CD	O
,	,	O
6	CD	O
,	,	O
and	CC	O
12	CD	O
months	NNS	O
after	IN	O
treatment	NN	O
.	.	O

Changes	NNS	O
in	IN	O
logarithm	NN	O
of	IN	O
minimum	JJ	O
angle	NN	O
of	IN	O
resolution	NN	O
(	(	O
logMAR	JJ	O
)	)	O
best-corrected	JJ	O
visual	JJ	O
acuity	NN	O
(	(	O
BCVA	NNP	O
)	)	O
,	,	O
central	JJ	O
macular	JJ	O
thickness	NN	O
(	(	O
CMT	NNP	O
)	)	O
shown	VBN	O
by	IN	O
optical	JJ	O
coherence	NN	O
tomography-3	NN	O
were	VBD	O
evaluated	VBN	O
.	.	O

RESULTS	NNP	O
Baseline	NNP	O
BCVA	NNP	O
(	(	O
logMAR	NN	O
)	)	O
and	CC	O
CMT	NNP	O
were	VBD	O
,	,	O
respectively	RB	O
,	,	O
0.89	CD	O
+/-	JJ	O
0.13	CD	O
and	CC	O
650	CD	O
+/-	JJ	O
140	CD	O
microm	NN	O
for	IN	O
the	DT	O
GLP	NNP	O
group	NN	O
,	,	O
0.87	CD	O
+/-	JJ	O
0.16	CD	O
and	CC	O
690	CD	O
+/-	JJ	O
120	CD	O
microm	NN	O
for	IN	O
the	DT	O
IB	NNP	O
group	NN	O
.	.	O

After	IN	O
the	DT	O
treatment	NN	O
,	,	O
at	IN	O
1	CD	O
,	,	O
3	CD	O
,	,	O
6	CD	O
,	,	O
and	CC	O
12	CD	O
months	NNS	O
in	IN	O
the	DT	O
GLP	NNP	O
group	NN	O
,	,	O
BCVA	NNP	O
had	VBD	O
improved	VBN	O
by	IN	O
0.19	CD	O
,	,	O
0.22	CD	O
,	,	O
0.21	CD	O
,	,	O
and	CC	O
0.20	CD	O
logMAR	NN	O
,	,	O
CMT	NNP	O
had	VBD	O
decreased	VBN	O
by	IN	O
40	CD	O
%	NN	O
,	,	O
41.3	CD	O
%	NN	O
,	,	O
40.5	CD	O
%	NN	O
,	,	O
and	CC	O
42	CD	O
%	NN	O
.	.	O

In	IN	O
the	DT	O
IB	NNP	O
group	NN	O
,	,	O
BCVA	NNP	O
had	VBD	O
improved	VBN	O
by	IN	O
0.31	CD	O
,	,	O
0.32	CD	O
,	,	O
0.30	CD	O
,	,	O
and	CC	O
0.31	CD	O
logMAR	NN	O
and	CC	O
CMT	NNP	O
had	VBD	O
decreased	VBN	O
by	IN	O
59.5	CD	O
%	NN	O
,	,	O
59	CD	O
%	NN	O
,	,	O
60	CD	O
%	NN	O
,	,	O
and	CC	O
60.3	CD	O
%	NN	O
.	.	O

The	DT	O
group	NN	O
receiving	VBG	O
bevacizumab	NN	O
had	VBD	O
better	JJR	O
BCVA	NNP	O
and	CC	O
lower	JJR	O
CMT	NNP	O
values	NNS	O
at	IN	O
all	DT	O
time	NN	O
points	NNS	O
(	(	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
.	.	O

CONCLUSION	NNP	O
Intravitreal	NNP	O
bevacizumab	NN	O
injection	NN	O
improves	VBZ	O
BCVA	NNP	O
and	CC	O
reduces	NNS	O
CMT	NNP	O
more	JJR	O
than	IN	O
GLP	NNP	O
.	.	O

Intravitreal	NNP	O
bevacizumab	JJ	O
injection	NN	O
was	VBD	O
well	RB	O
tolerated	VBN	O
and	CC	O
could	MD	O
be	VB	O
used	VBN	O
as	IN	O
primary	JJ	O
treatment	NN	O
in	IN	O
patients	NNS	O
with	IN	O
cystoid	JJ	O
macular	JJ	O
edema	NN	O
secondary	JJ	O
to	TO	O
perfused	VBN	O
branch	NN	O
retinal	JJ	O
vein	NN	O
occlusion	NN	O
.	.	O

Effect	NN	O
of	IN	O
total	JJ	O
enteral	JJ	O
nutrition	NN	O
on	IN	O
the	DT	O
short-term	JJ	O
outcome	NN	O
of	IN	O
severely	RB	O
malnourished	VBN	C
cirrhotics	NNS	C
.	.	O

A	DT	O
randomized	JJ	O
controlled	JJ	O
trial	NN	O
.	.	O

Thirty-five	JJ	SS
severely	RB	O
malnourished	VBN	C
cirrhotic	JJ	C
patients	NNS	O
were	VBD	O
randomized	VBN	O
to	TO	O
receive	VB	O
either	DT	O
enteral-tube	JJ	O
feeding	NN	O
as	IN	O
the	DT	O
sole	JJ	O
nutritional	JJ	O
support	NN	O
(	(	O
n	JJ	O
=	NNP	O
16	CD	O
)	)	O
or	CC	O
an	DT	O
isocaloric	JJ	O
,	,	O
isonitrogenous	JJ	O
,	,	O
low-sodium	JJ	O
standard	JJ	O
oral	JJ	O
diet	NN	O
(	(	O
n	JJ	O
=	NNP	O
19	CD	O
)	)	O
.	.	O

Both	DT	O
groups	NNS	O
were	VBD	O
homogeneous	JJ	O
regarding	VBG	O
age	NN	O
,	,	O
sex	NN	O
distribution	NN	O
,	,	O
etiology	NN	O
of	IN	O
liver	JJ	O
cirrhosis	NN	O
,	,	O
history	NN	O
of	IN	O
previous	JJ	O
complications	NNS	O
,	,	O
clinical	JJ	O
status	NN	O
,	,	O
liver	RB	O
and	CC	O
renal	JJ	O
function	NN	O
,	,	O
modified	VBD	O
Child	NNP	O
's	POS	O
score	NN	O
,	,	O
and	CC	O
nutritional	JJ	O
status	NN	O
at	IN	O
admission	NN	O
.	.	O

The	DT	O
enteral	JJ	O
formula	NN	O
diet	NN	O
was	VBD	O
energy	NN	O
dense	NN	O
,	,	O
containing	VBG	O
40	CD	O
mmol	NN	O
Na/day	NNP	O
,	,	O
whole	JJ	O
protein	NN	O
plus	CC	O
branched-chain	JJ	O
amino	NN	O
acids	NNS	O
,	,	O
medium-	JJ	O
and	CC	O
long-chain	JJ	O
triglycerides	NNS	O
,	,	O
and	CC	O
maltodextrin	NN	O
.	.	O

It	PRP	O
supplied	VBD	O
2115	CD	O
kcal/day	NN	O
.	.	O

The	DT	O
amount	NN	O
of	IN	O
vitamins	NNS	O
and	CC	O
trace	NN	O
elements	NNS	O
was	VBD	O
at	IN	O
the	DT	O
upper	JJ	O
limit	NN	O
of	IN	O
the	DT	O
recommended	JJ	O
dietary	JJ	O
allowances	NNS	O
.	.	O

The	DT	O
orally	RB	O
fed	JJ	O
patients	NNS	O
were	VBD	O
encouraged	VBN	O
to	TO	O
eat	VB	O
all	DT	O
meals	NNS	O
served	VBD	O
.	.	O

Total	JJ	O
enteral	JJ	O
nutrition	NN	O
was	VBD	O
well	RB	O
tolerated	VBN	O
without	IN	O
major	JJ	O
complications	NNS	O
.	.	O

Serum	NNP	O
albumin	NN	O
and	CC	O
Child	NNP	O
's	POS	O
score	NN	O
improved	VBD	O
in	IN	O
the	DT	O
enterally	RB	O
fed	JJ	O
patients	NNS	O
but	CC	O
not	RB	O
in	IN	O
controls	NNS	O
.	.	O

Mortality	NNP	O
rate	NN	O
while	IN	O
in	IN	O
the	DT	O
hospital	NN	O
was	VBD	O
lower	JJR	O
in	IN	O
patients	NNS	O
on	IN	O
enteral	JJ	O
feeding	NN	O
than	IN	O
in	IN	O
controls	NNS	O
(	(	O
12	CD	O
%	NN	O
vs	JJ	O
47	CD	O
%	NN	O
)	)	O
.	.	O

These	DT	O
results	NNS	O
show	VBP	O
that	IN	O
total	JJ	O
enteral	JJ	O
nutrition	NN	O
is	VBZ	O
safe	JJ	O
and	CC	O
effective	JJ	O
in	IN	O
improving	VBG	O
the	DT	O
short-term	JJ	O
clinical	JJ	O
outcome	NN	O
in	IN	O
severely	RB	O
malnourished	JJ	C
cirrhotics	NNS	C
.	.	O

Emotional	JJ	O
reactivity	NN	O
to	TO	O
social	JJ	O
rejection	NN	O
and	CC	O
negative	JJ	O
evaluation	NN	O
among	IN	O
persons	NNS	O
with	IN	O
borderline	JJ	C
personality	NN	C
features	NNS	O
.	.	O

The	DT	O
present	JJ	O
study	NN	O
examined	VBD	O
the	DT	O
emotional	JJ	O
reactivity	NN	O
of	IN	O
persons	NNS	O
with	IN	O
heightened	JJ	C
borderline	NN	C
personality	NN	C
(	(	C
BP	NNP	C
)	)	C
features	VBZ	O
to	TO	O
social	JJ	O
rejection	NN	O
and	CC	O
negative	JJ	O
evaluation	NN	O
in	IN	O
the	DT	O
laboratory	NN	O
.	.	O

Individuals	NNS	O
with	IN	O
high	JJ	C
levels	NNS	C
of	IN	O
BP	NNP	C
features	NNS	O
(	(	O
n	JJ	O
=	NNP	O
30	CD	SS
)	)	O
and	CC	O
controls	NNS	O
with	IN	O
low	JJ	C
levels	NNS	C
of	IN	O
BP	NNP	C
features	NNS	O
(	(	O
n	JJ	O
=	NNP	O
44	CD	SS
)	)	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
a	DT	O
condition	NN	O
involving	VBG	O
negative	JJ	O
evaluation	NN	O
based	VBN	O
on	IN	O
writing	NN	O
(	(	O
negative	JJ	O
evaluation/academic	NN	O
)	)	O
,	,	O
or	CC	O
a	DT	O
condition	NN	O
involving	VBG	O
negative	JJ	O
evaluation	NN	O
based	VBN	O
on	IN	O
personal	JJ	O
characteristics	NNS	O
as	RB	O
well	RB	O
as	IN	O
social	JJ	O
rejection	NN	O
(	(	O
negative	JJ	O
evaluation/social	JJ	O
rejection	NN	O
)	)	O
.	.	O

Hypothesis	$	O
1	CD	O
was	VBD	O
that	IN	O
high-BP	JJ	C
individuals	NNS	O
,	,	O
but	CC	O
not	RB	O
low-BP	JJ	C
controls	NNS	O
,	,	O
would	MD	O
show	VB	O
greater	JJR	O
emotional	JJ	O
reactivity	NN	O
to	TO	O
the	DT	O
negative	JJ	O
evaluation/social	JJ	O
rejection	NN	O
stressor	NN	O
,	,	O
compared	VBN	O
with	IN	O
the	DT	O
negative	JJ	O
evaluation/academic	JJ	O
(	(	O
writing	VBG	O
)	)	O
stressor	NN	O
.	.	O

Hypothesis	$	O
2	CD	O
was	VBD	O
that	IN	O
high-BP	JJ	C
individuals	NNS	O
would	MD	O
specifically	RB	O
show	VB	O
greater	JJR	O
reactivity	NN	O
of	IN	O
shame-	JJ	O
and	CC	O
anger-related	JJ	O
emotions	NNS	O
to	TO	O
the	DT	O
negative	JJ	O
evaluation/social	JJ	O
rejection	NN	O
stressor	NN	O
compared	VBN	O
with	IN	O
the	DT	O
negative	JJ	O
evaluation/academic	JJ	O
stressor	NN	O
.	.	O

Findings	NNS	O
indicated	VBD	O
that	IN	O
high-BP	JJ	C
individuals	NNS	O
showed	VBD	O
heightened	VBN	O
emotional	JJ	O
reactivity	NN	O
to	TO	O
the	DT	O
social	JJ	O
rejection	NN	O
stressor	NN	O
but	CC	O
not	RB	O
to	TO	O
the	DT	O
negative	JJ	O
evaluation	NN	O
stressor	NN	O
,	,	O
but	CC	O
the	DT	O
opposite	JJ	O
pattern	NN	O
occurred	VBD	O
for	IN	O
controls	NNS	O
.	.	O

In	IN	O
addition	NN	O
,	,	O
there	EX	O
was	VBD	O
evidence	NN	O
for	IN	O
heightened	JJ	O
reactivity	NN	O
of	IN	O
irritability	NN	O
,	,	O
distress	NN	O
,	,	O
and	CC	O
shame	NN	O
for	IN	O
the	DT	O
high-BP	JJ	O
group	NN	O
,	,	O
specifically	RB	O
in	IN	O
the	DT	O
social	JJ	O
rejection	NN	O
condition	NN	O
.	.	O

Nutrient	JJ	O
retention	NN	O
in	IN	O
preterm	JJ	C
infants	NNS	O
fed	VBN	O
standard	JJ	O
infant	NN	O
formulas	NN	O
.	.	O

Our	PRP$	O
purpose	NN	O
was	VBD	O
to	TO	O
compare	VB	O
nitrogen	NN	O
,	,	O
mineral	NN	O
,	,	O
and	CC	O
zinc	NN	O
balance	NN	O
in	IN	O
preterm	JJ	C
infants	NNS	O
fed	VBN	O
standard	JJ	O
infant	NN	O
formulas	NNS	O
,	,	O
Similac	NNP	O
With	IN	O
Iron	NNP	O
and	CC	O
Similac	NNP	O
With	IN	O
Whey	NNP	O
+	NNP	O
Iron	NNP	O
.	.	O

Nitrogen	NNP	O
and	CC	O
magnesium	NN	O
balances	NNS	O
were	VBD	O
similar	JJ	O
during	IN	O
both	DT	O
feeds	NNS	O
,	,	O
and	CC	O
met	VBD	O
estimated	VBN	O
fetal	JJ	O
requirements	NNS	O
.	.	O

Infants	NNS	O
absorbed	VBD	O
and	CC	O
retained	VBD	O
(	(	O
milligrams	FW	O
per	IN	O
kilogram	FW	O
per	IN	O
day	NN	O
)	)	O
more	JJR	O
calcium	NN	O
,	,	O
phosphorus	NN	O
,	,	O
and	CC	O
zinc	NN	O
when	WRB	O
fed	VBN	O
Similac	NNP	O
With	IN	O
Iron	NNP	O
.	.	O

However	RB	O
,	,	O
retention	NN	O
of	IN	O
calcium	NN	O
,	,	O
phosphorus	NN	O
(	(	O
both	DT	O
formulas	NN	O
)	)	O
,	,	O
and	CC	O
zinc	NN	O
(	(	O
Similac	NNP	O
With	IN	O
Whey	NNP	O
+	NNP	O
Iron	NNP	O
)	)	O
was	VBD	O
inadequate	JJ	O
to	TO	O
meet	VB	O
estimated	JJ	O
fetal	JJ	O
requirements	NNS	O
.	.	O

These	DT	O
findings	NNS	O
are	VBP	O
important	JJ	O
in	IN	O
the	DT	O
rapidly	RB	O
growing	VBG	O
preterm	JJ	C
infant	NN	A
,	,	O
who	WP	O
is	VBZ	O
already	RB	O
at	IN	O
risk	NN	O
for	IN	O
the	DT	O
development	NN	O
of	IN	O
rickets	NNS	O
and	CC	O
zinc	NN	O
deficiency	NN	O
and	CC	O
may	MD	O
be	VB	O
fed	VBN	O
either	DT	O
formula	NN	O
on	IN	O
discharge	NN	O
from	IN	O
the	DT	O
newborn	JJ	O
nursery	NN	O
.	.	O

A	DT	O
comparison	NN	O
of	IN	O
sclerotherapy	NN	O
with	IN	O
staple	JJ	O
transection	NN	O
of	IN	O
the	DT	O
esophagus	NN	O
for	IN	O
the	DT	O
emergency	NN	O
control	NN	O
of	IN	O
bleeding	VBG	C
from	IN	C
esophageal	JJ	C
varices	NNS	C
.	.	O

We	PRP	O
compared	VBN	O
two	CD	O
procedures	NNS	O
for	IN	O
the	DT	O
emergency	NN	O
treatment	NN	O
of	IN	O
bleeding	VBG	C
esophageal	JJ	C
varices	NNS	C
in	IN	C
patients	NNS	C
who	WP	C
did	VBD	C
not	RB	C
respond	VB	C
to	TO	C
blood	VB	C
transfusion	NN	C
and	CC	C
vasoactive	JJ	C
drugs	NNS	C
.	.	O

We	PRP	O
randomly	VBP	O
assigned	VBD	O
101	CD	O
patients	NNS	O
with	IN	C
cirrhosis	NN	C
of	IN	C
the	DT	C
liver	NN	C
and	CC	C
bleeding	VBG	C
esophageal	JJ	C
varices	NNS	C
to	TO	O
undergo	VB	O
either	DT	O
emergency	NN	O
sclerotherapy	NN	O
(	(	O
n	JJ	O
=	NNP	O
50	CD	O
)	)	O
or	CC	O
staple	JJ	O
transection	NN	O
of	IN	O
the	DT	O
esophagus	NN	O
(	(	O
n	JJ	O
=	NNP	O
51	CD	O
)	)	O
.	.	O

Four	CD	O
patients	NNS	O
assigned	VBN	O
to	TO	O
sclerotherapy	VB	O
and	CC	O
12	CD	O
assigned	VBN	O
to	TO	O
staple	VB	O
transection	NN	O
did	VBD	O
not	RB	O
actually	RB	O
undergo	VBP	O
those	DT	O
procedures	NNS	O
,	,	O
but	CC	O
all	DT	O
analyses	NNS	O
were	VBD	O
made	VBN	O
on	IN	O
an	DT	O
intention-to-treat	JJ	O
basis	NN	O
.	.	O

Total	JJ	O
mortality	NN	O
did	VBD	O
not	RB	O
differ	VB	O
significantly	RB	O
between	IN	O
the	DT	O
two	CD	O
groups	NNS	O
;	:	O
the	DT	O
relative	JJ	O
risk	NN	O
of	IN	O
death	NN	O
for	IN	O
staple	JJ	O
transection	NN	O
as	IN	O
compared	VBN	O
with	IN	O
sclerotherapy	NN	O
was	VBD	O
0.88	CD	O
(	(	O
95	CD	O
percent	NN	O
confidence	NN	O
interval	NN	O
,	,	O
0.51	CD	O
to	TO	O
1.54	CD	O
)	)	O
.	.	O

Mortality	NN	O
at	IN	O
six	CD	O
weeks	NNS	O
was	VBD	O
44	CD	O
percent	NN	O
among	IN	O
those	DT	O
assigned	VBN	O
to	TO	O
sclerotherapy	VB	O
and	CC	O
35	CD	O
percent	NN	O
among	IN	O
those	DT	O
assigned	VBN	O
to	TO	O
staple	VB	O
transection	NN	O
.	.	O

Complication	NN	O
rates	NNS	O
were	VBD	O
similar	JJ	O
for	IN	O
the	DT	O
two	CD	O
groups	NNS	O
.	.	O

An	DT	O
interval	NN	O
of	IN	O
five	CD	O
days	NNS	O
without	IN	O
bleeding	NN	O
was	VBD	O
achieved	VBN	O
in	IN	O
88	CD	O
percent	NN	O
of	IN	O
those	DT	O
assigned	VBN	O
to	TO	O
staple	VB	O
transection	NN	O
and	CC	O
in	IN	O
62	CD	O
percent	NN	O
of	IN	O
those	DT	O
assigned	VBN	O
to	TO	O
sclerotherapy	VB	O
after	IN	O
a	DT	O
single	JJ	O
injection	NN	O
(	(	O
P	NNP	O
less	JJR	O
than	IN	O
0.01	CD	O
)	)	O
and	CC	O
82	CD	O
percent	NN	O
after	IN	O
three	CD	O
injections	NNS	O
.	.	O

In	IN	O
only	RB	O
2	CD	O
of	IN	O
the	DT	O
11	CD	O
patients	NNS	O
who	WP	O
received	VBD	O
a	DT	O
third	JJ	O
sclerotherapy	NN	O
injection	NN	O
was	VBD	O
bleeding	VBG	O
controlled	VBN	O
for	IN	O
more	JJR	O
than	IN	O
five	CD	O
days	NNS	O
,	,	O
and	CC	O
9	CD	O
died	VBD	O
.	.	O

We	PRP	O
conclude	VBP	O
that	IN	O
staple	JJ	O
transection	NN	O
of	IN	O
the	DT	O
esophagus	NN	O
is	VBZ	O
as	RB	O
safe	JJ	O
as	IN	O
sclerotherapy	NN	O
for	IN	O
the	DT	O
emergency	NN	O
treatment	NN	O
of	IN	O
bleeding	VBG	O
esophageal	JJ	O
varices	NNS	O
and	CC	O
that	IN	O
it	PRP	O
is	VBZ	O
more	RBR	O
effective	JJ	O
than	IN	O
a	DT	O
single	JJ	O
sclerotherapy	NN	O
procedure	NN	O
.	.	O

We	PRP	O
currently	RB	O
recommend	VBP	O
surgery	NN	O
after	IN	O
two	CD	O
injection	NN	O
treatments	NNS	O
have	VBP	O
failed	VBN	O
.	.	O

Effect	NN	O
of	IN	O
recombinant	JJ	O
adenovirus-p53	NN	O
combined	VBN	O
with	IN	O
radiotherapy	NN	O
on	IN	O
long-term	JJ	O
prognosis	NN	O
of	IN	O
advanced	JJ	O
nasopharyngeal	JJ	C
carcinoma	NN	C
.	.	O

PURPOSE	NNP	O
To	TO	O
centrally	RB	O
assess	VB	O
the	DT	O
safety	NN	O
,	,	O
efficacy	NN	O
,	,	O
and	CC	O
6-year	JJ	O
follow-up	NN	O
of	IN	O
recombinant	JJ	O
adenovirus-p53	JJ	O
(	(	O
rAd-p53	NN	O
)	)	O
combined	VBN	O
with	IN	O
radiotherapy	NN	O
(	(	O
RT	NNP	O
)	)	O
for	IN	O
patients	NNS	O
with	IN	O
nasopharyngeal	JJ	O
carcinoma	NN	O
(	(	O
NPC	NNP	C
)	)	O
.	.	O

PATIENTS	NNP	O
AND	CC	O
METHODS	NNP	O
A	NNP	O
randomized	VBD	O
controlled	VBN	O
clinical	JJ	O
study	NN	O
on	IN	O
rAd-p53	NN	O
combined	VBN	O
with	IN	O
RT	NNP	O
in	IN	O
42	CD	SS
patients	NNS	SS
with	IN	O
NPC	NNP	C
was	VBD	O
compared	VBN	O
with	IN	O
a	DT	O
control	NN	O
group	NN	O
of	IN	O
40	CD	SS
patients	NNS	SS
with	IN	O
NPC	NNP	O
treated	VBD	O
with	IN	O
RT	NNP	O
alone	RB	O
.	.	O

In	IN	O
the	DT	O
group	NN	O
receiving	VBG	O
rAd-p53	NN	O
combined	VBN	O
with	IN	O
RT	NNP	O
,	,	O
rAd-p53	NN	O
was	VBD	O
intratumorally	RB	O
injected	VBN	O
once	RB	O
a	DT	O
week	NN	O
for	IN	O
8	CD	O
weeks	NNS	O
.	.	O

Concurrent	NNP	O
RT	NNP	O
(	(	O
70	CD	O
Gy	NNP	O
in	IN	O
35	CD	O
fractions	NNS	O
)	)	O
was	VBD	O
given	VBN	O
to	TO	O
the	DT	O
nasopharyngeal	JJ	O
tumor	NN	O
and	CC	O
neck	NN	O
lymph	NN	O
node	NN	O
.	.	O

Patients	NNS	O
and	CC	O
tumors	NNS	O
were	VBD	O
monitored	VBN	O
for	IN	O
adverse	JJ	O
events	NNS	O
and	CC	O
responses	NNS	O
.	.	O

RESULTS	NNP	O
rAd-p53-specific	JJ	O
p53	NN	O
mRNA	NN	O
was	VBD	O
detected	VBN	O
in	IN	O
postinjection	NN	O
of	IN	O
rAd-p53	JJ	O
biopsies	NNS	O
from	IN	O
16	CD	O
(	(	O
94.1	CD	O
%	NN	O
)	)	O
of	IN	O
17	CD	O
patients	NNS	O
.	.	O

Upregulation	NN	O
of	IN	O
p21/WAF1	NN	O
and	CC	O
Bax	NNP	O
and	CC	O
downregulation	NN	O
of	IN	O
vascular	JJ	O
endothelial	JJ	O
growth	NN	O
factor	NN	O
were	VBD	O
observed	VBN	O
in	IN	O
postinjection	NN	O
tumor	NN	O
biopsy	NN	O
.	.	O

Complete	JJ	O
response	NN	O
rate	NN	O
in	IN	O
the	DT	O
group	NN	O
receiving	VBG	O
rAd-p53	NN	O
combined	VBN	O
with	IN	O
RT	NNP	O
was	VBD	O
observed	VBN	O
at	IN	O
2.73	CD	O
times	NNS	O
that	WDT	O
of	IN	O
the	DT	O
group	NN	O
receiving	VBG	O
RT	NNP	O
alone	RB	O
(	(	O
66.7	CD	O
%	NN	O
v	JJ	O
24.4	CD	O
%	NN	O
)	)	O
.	.	O

Six-year	JJ	O
follow-up	JJ	O
data	NN	O
showed	VBD	O
that	IN	O
rAd-p53	JJ	O
significantly	RB	O
increased	VBD	O
the	DT	O
5-year	JJ	O
locoregional	JJ	O
tumor	NN	O
control	NN	O
rate	NN	O
by	IN	O
25.3	CD	O
%	NN	O
for	IN	O
patients	NNS	O
with	IN	O
NPC	NNP	O
treated	VBD	O
with	IN	O
irradiation	NN	O
(	(	O
P	NNP	O
=	NNP	O
.002	NNP	O
)	)	O
.	.	O

The	DT	O
5-year	JJ	O
overall	JJ	O
survival	NN	O
rate	NN	O
and	CC	O
5-year	JJ	O
disease-free	JJ	O
survival	NN	O
rate	NN	O
of	IN	O
the	DT	O
group	NN	O
receiving	VBG	O
rAd-p53	NN	O
combined	VBN	O
with	IN	O
RT	NNP	O
were	VBD	O
7.5	CD	O
%	NN	O
(	(	O
P	NNP	O
=	NNP	O
.34	NNP	O
)	)	O
and	CC	O
11.7	CD	O
%	NN	O
(	(	O
P	NNP	O
=	NNP	O
.21	NNP	O
)	)	O
higher	JJR	O
than	IN	O
those	DT	O
of	IN	O
the	DT	O
group	NN	O
receiving	VBG	O
RT	NNP	O
alone	RB	O
.	.	O

No	DT	O
dose-limiting	JJ	O
toxicity	NN	O
or	CC	O
adverse	JJ	O
events	NNS	O
appeared	VBD	O
,	,	O
except	IN	O
for	IN	O
transient	NN	O
fever	NN	O
after	IN	O
rAd-p53	JJ	O
administration	NN	O
.	.	O

CONCLUSION	NNP	O
In	IN	O
patients	NNS	O
with	IN	O
NPC	NNP	O
,	,	O
rAd-p53	NN	O
was	VBD	O
safe	JJ	O
and	CC	O
biologically	RB	O
active	JJ	O
.	.	O

Our	PRP$	O
results	NNS	O
indicated	VBD	O
that	IN	O
rAd-p53	JJ	O
improves	NNS	O
radiotherapeutic	JJ	O
tumor	NN	O
control	NN	O
and	CC	O
survival	JJ	O
rate	NN	O
in	IN	O
patients	NNS	O
with	IN	O
NPC	NNP	O
.	.	O

Small	NN	O
but	CC	O
important	JJ	O
errors	NNS	O
in	IN	O
cardiovascular	JJ	O
risk	NN	O
calculation	NN	O
by	IN	O
practice	NN	O
nurses	NNS	O
:	:	O
a	DT	O
cross-sectional	JJ	O
study	NN	O
in	IN	O
randomised	JJ	O
trial	NN	O
setting	NN	O
.	.	O

BACKGROUND	NNP	O
Practice	NNP	O
nurses	NNS	O
play	VBP	O
an	DT	O
increasingly	RB	O
important	JJ	O
role	NN	O
in	IN	O
the	DT	O
prevention	NN	O
of	IN	O
cardiovascular	JJ	O
diseases	NNS	O
but	CC	O
we	PRP	O
do	VBP	O
not	RB	O
have	VB	O
evidence	NN	O
about	IN	O
the	DT	O
accuracy	NN	O
of	IN	O
their	PRP$	O
cardiovascular	JJ	O
risk	NN	O
assessments	NNS	O
during	IN	O
real	JJ	O
practice	NN	O
consultations	NNS	O
.	.	O

OBJECTIVES	NNP	O
To	TO	O
examine	VB	O
how	WRB	O
nurses	NNS	O
perform	VBP	O
with	IN	O
regard	NN	O
to	TO	O
absolute	VB	O
10-year	JJ	O
cardiovascular	JJ	O
risk	NN	O
assessment	NN	O
in	IN	O
actual	JJ	O
practice	NN	O
.	.	O

DESIGN	NNP	O
Cross-sectional	JJ	O
study	NN	O
.	.	O

SETTING	NN	O
This	DT	O
study	NN	O
was	VBD	O
nested	VBN	O
in	IN	O
the	DT	O
IMPALA	NNP	O
study	NN	O
,	,	O
a	DT	O
clustered	VBN	O
randomised	VBN	O
controlled	VBN	O
trial	NN	O
involving	VBG	O
24	CD	O
general	JJ	O
practices	NNS	O
in	IN	O
The	DT	O
Netherlands	NNP	O
.	.	O

PARTICIPANTS	VB	O
24	CD	O
practice	NN	O
nurses	NNS	O
,	,	O
trained	VBN	O
in	IN	O
10-year	JJ	O
cardiovascular	JJ	O
risk	NN	O
assessment	NN	O
,	,	O
calculated	VBD	O
the	DT	O
risk	NN	O
of	IN	O
a	DT	O
total	NN	O
of	IN	O
421	CD	O
patients	NNS	O
without	IN	O
established	VBN	O
cardiovascular	JJ	O
diseases	NNS	O
but	CC	O
eligible	JJ	O
for	IN	O
cardiovascular	JJ	O
risk	NN	O
assessment	NN	O
.	.	O

METHODS	NNP	O
The	DT	O
main	JJ	O
outcome	NN	O
measure	NN	O
was	VBD	O
the	DT	O
accuracy	NN	O
of	IN	O
risk	NN	O
assessments	NNS	O
,	,	O
defined	VBN	O
as	IN	O
(	(	O
1	CD	O
)	)	O
the	DT	O
difference	NN	O
between	IN	O
the	DT	O
10-year	JJ	O
cardiovascular	JJ	O
risk	NN	O
percentage	NN	O
calculated	VBN	O
by	IN	O
nurses	NNS	O
and	CC	O
an	DT	O
independent	JJ	O
assessor	NN	O
,	,	O
and	CC	O
(	(	O
2	CD	O
)	)	O
the	DT	O
agreement	NN	O
between	IN	O
the	DT	O
treatment	NN	O
categories	NNS	O
assigned	VBN	O
by	IN	O
the	DT	O
nurses	NNS	O
(	(	O
low	JJ	O
,	,	O
moderate	JJ	O
or	CC	O
high	JJ	O
risk	NN	O
)	)	O
and	CC	O
those	DT	O
assigned	VBN	O
by	IN	O
the	DT	O
independent	JJ	O
assessor	NN	O
.	.	O

RESULTS	VB	O
Thirty-one	NNP	O
(	(	O
7.4	CD	O
%	NN	O
)	)	O
of	IN	O
the	DT	O
calculated	JJ	O
risk	NN	O
percentages	NNS	O
differed	VBN	O
by	IN	O
more	JJR	O
than	IN	O
our	PRP$	O
preset	NN	O
limits	NNS	O
,	,	O
25	CD	O
(	(	O
81	CD	O
%	NN	O
)	)	O
being	VBG	O
underestimations	NNS	O
.	.	O

Elderly	JJ	O
patients	NNS	O
(	(	O
OR	NNP	O
1.1	CD	O
,	,	O
95	CD	O
%	NN	O
CI	NNP	O
1.0-1.1	CD	O
)	)	O
,	,	O
male	JJ	O
patients	NNS	O
(	(	O
vs.	FW	O
female	NN	O
OR	NNP	O
3.1	CD	O
,	,	O
95	CD	O
%	NN	O
CI	NNP	O
1.2-7.3	CD	O
)	)	O
,	,	O
and	CC	O
smoking	NN	O
patients	NNS	O
(	(	O
vs.	IN	O
non-smoking	NN	O
OR	NNP	O
3.8	CD	O
,	,	O
95	CD	O
%	NN	O
CI	NNP	O
1.7-8.9	CD	O
)	)	O
were	VBD	O
more	RBR	O
likely	JJ	O
to	TO	O
have	VB	O
their	PRP$	O
cardiovascular	JJ	O
risk	NN	O
miscalculated	VBD	O
.	.	O

Ten	NNP	O
(	(	O
28	CD	O
%	NN	O
)	)	O
of	IN	O
the	DT	O
36	CD	O
patients	NNS	O
who	WP	O
should	MD	O
be	VB	O
assigned	VBN	O
to	TO	O
the	DT	O
high-risk	JJ	O
treatment	NN	O
category	NN	O
according	VBG	O
to	TO	O
the	DT	O
independent	JJ	O
calculation	NN	O
,	,	O
were	VBD	O
missed	VBN	O
as	IN	O
high-risk	JJ	O
patients	NNS	O
by	IN	O
the	DT	O
practice	NN	O
nurses	NNS	O
.	.	O

CONCLUSIONS	VB	O
The	DT	O
overall	JJ	O
standard	NN	O
of	IN	O
accuracy	NN	O
of	IN	O
cardiovascular	JJ	O
risk	NN	O
assessment	NN	O
by	IN	O
trained	JJ	O
practice	NN	O
nurses	NNS	O
in	IN	O
actual	JJ	O
practice	NN	O
is	VBZ	O
high	JJ	O
.	.	O

However	RB	O
,	,	O
a	DT	O
significant	JJ	O
number	NN	O
of	IN	O
high-risk	JJ	O
patients	NNS	O
were	VBD	O
misclassified	VBN	O
,	,	O
with	IN	O
the	DT	O
probability	NN	O
that	IN	O
it	PRP	O
led	VBD	O
to	TO	O
missed	VBN	O
opportunities	NNS	O
for	IN	O
risk-reducing	JJ	O
interventions	NNS	O
.	.	O

As	IN	O
cardiovascular	JJ	O
risk	NN	O
assessments	NNS	O
are	VBP	O
frequently	RB	O
done	VBN	O
by	IN	O
nurses	NNS	O
in	IN	O
general	JJ	O
practice	NN	O
,	,	O
further	JJ	O
specific	JJ	O
training	NN	O
should	MD	O
be	VB	O
considered	VBN	O
to	TO	O
prevent	VB	O
undertreatment	NN	O
.	.	O

Development	NNP	O
of	IN	O
an	DT	O
adaptive	JJ	O
low-pass	NN	O
filtered	VBD	O
speech	JJ	O
test	NN	O
for	IN	O
the	DT	O
identification	NN	O
of	IN	O
auditory	NN	O
processing	NN	O
disorders	NNS	O
.	.	O

OBJECTIVE	CC	O
One	CD	O
type	NN	O
of	IN	O
test	NN	O
commonly	RB	O
used	VBD	O
to	TO	O
examine	VB	O
auditory	JJ	O
processing	NN	O
disorders	NNS	O
(	(	O
APD	NNP	O
)	)	O
is	VBZ	O
the	DT	O
low-pass	NN	O
filtered	VBD	O
speech	JJ	O
test	NN	O
(	(	O
LPFST	NNP	O
)	)	O
,	,	O
of	IN	O
which	WDT	O
there	EX	O
are	VBP	O
various	JJ	O
versions	NNS	O
.	.	O

In	IN	O
LPFSTs	NNP	O
,	,	O
a	DT	O
monaural	JJ	O
,	,	O
low-redundancy	JJ	O
speech	NN	O
sample	NN	O
is	VBZ	O
distorted	VBN	O
by	IN	O
using	VBG	O
filtering	VBG	O
to	TO	O
modify	VB	O
its	PRP$	O
frequency	NN	O
content	NN	O
.	.	O

Due	JJ	O
to	TO	O
the	DT	O
richness	NN	O
of	IN	O
the	DT	O
neural	JJ	O
pathways	NNS	O
in	IN	O
the	DT	O
auditory	NN	O
system	NN	O
and	CC	O
the	DT	O
redundancy	NN	O
of	IN	O
acoustic	JJ	O
information	NN	O
in	IN	O
spoken	JJ	O
language	NN	O
,	,	O
a	DT	O
normal	JJ	O
listener	NN	O
is	VBZ	O
able	JJ	O
to	TO	O
recognize	VB	O
speech	NN	O
even	RB	O
when	WRB	O
parts	NNS	O
of	IN	O
the	DT	O
signal	NN	O
are	VBP	O
missing	VBG	O
,	,	O
whereas	IN	O
this	DT	O
ability	NN	O
is	VBZ	O
often	RB	O
impaired	VBN	O
in	IN	O
listeners	NNS	O
with	IN	O
APD	NNP	O
.	.	O

One	CD	O
limitation	NN	O
of	IN	O
the	DT	O
various	JJ	O
versions	NNS	O
of	IN	O
the	DT	O
LPFST	NNP	O
is	VBZ	O
that	IN	O
they	PRP	O
are	VBP	O
carried	VBN	O
out	IN	O
using	VBG	O
a	DT	O
constant	JJ	O
level	NN	O
of	IN	O
low-pass	JJ	O
filtering	NN	O
(	(	O
e.g	NN	O
.	.	O

a	DT	O
fixed	JJ	O
1kHz	CD	O
corner	NN	O
frequency	NN	O
)	)	O
which	WDT	O
makes	VBZ	O
them	PRP	O
prone	VB	O
to	TO	O
ceiling	NN	O
and	CC	O
floor	NN	O
effects	NNS	O
.	.	O

The	DT	O
purpose	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
counter	VB	O
these	DT	O
effects	NNS	O
by	IN	O
modifying	VBG	O
the	DT	O
LPFST	NNP	O
using	VBG	O
a	DT	O
computer-based	JJ	O
adaptive	JJ	O
procedure	NN	O
,	,	O
and	CC	O
to	TO	O
evaluate	VB	O
the	DT	O
performance	NN	O
of	IN	O
normal-hearing	JJ	O
participants	NNS	O
of	IN	O
varying	VBG	O
ages	NNS	O
on	IN	O
the	DT	O
test	NN	O
.	.	O

METHODS	NNP	O
In	IN	O
this	DT	O
preliminary	JJ	O
study	NN	O
,	,	O
33	CD	O
adults	NNS	O
and	CC	O
30	CD	O
children	NNS	O
(	(	O
aged	VBN	O
8-11	CD	O
years	NNS	O
)	)	O
with	IN	O
no	DT	O
known	JJ	O
history	NN	O
of	IN	O
listening	VBG	O
difficulties	NNS	O
were	VBD	O
tested	VBN	O
.	.	O

The	DT	O
University	NNP	O
of	IN	O
Canterbury	NNP	O
Adaptive	NNP	O
Speech	NNP	O
Test	NNP	O
(	(	O
UCAST	NNP	O
)	)	O
platform	NN	O
was	VBD	O
used	VBN	O
to	TO	O
administer	VB	O
a	DT	O
four-alternative	JJ	O
forced-choice	JJ	O
adaptive	JJ	O
test	NN	O
that	WDT	O
altered	VBD	O
a	DT	O
low-pass	JJ	O
filter	NN	O
(	(	O
LPF	NNP	O
)	)	O
to	TO	O
track	VB	O
the	DT	O
corner	NN	O
frequency	NN	O
at	IN	O
which	WDT	O
participants	NNS	O
correctly	RB	O
identified	VBN	O
a	DT	O
certain	JJ	O
percentage	NN	O
of	IN	O
the	DT	O
word	NN	O
stimuli	NN	O
.	.	O

RESULTS	NNP	O
Findings	NNP	O
on	IN	O
the	DT	O
University	NNP	O
of	IN	O
Canterbury	NNP	O
Adaptive	NNP	O
Speech	NNP	O
Test-Filtered	NNP	O
Words	NNP	O
(	(	O
UCAST-FW	NNP	O
)	)	O
indicated	VBD	O
a	DT	O
significant	JJ	O
maturational	JJ	O
effect	NN	O
.	.	O

Adult	NN	O
participants	NNS	O
performed	VBD	O
significantly	RB	O
better	RBR	O
on	IN	O
the	DT	O
UCAST-FW	NNP	O
in	IN	O
comparison	NN	O
to	TO	O
the	DT	O
child	NN	O
participants	NNS	O
.	.	O

The	DT	O
UCAST-FW	JJ	O
test	NN	O
was	VBD	O
reliable	JJ	O
over	IN	O
repeated	JJ	O
administrations	NNS	O
.	.	O

CONCLUSIONS	NNP	O
An	DT	O
adaptive	JJ	O
low-pass	NN	O
filtered	VBD	O
speech	JJ	O
test	NN	O
such	JJ	O
as	IN	O
the	DT	O
UCAST-FW	NNP	O
is	VBZ	O
sensitive	JJ	O
to	TO	O
maturational	JJ	O
changes	NNS	O
in	IN	O
auditory	NN	O
processing	NN	O
ability	NN	O
.	.	O

Wavefront-guided	JJ	O
versus	NN	O
standard	NN	O
LASIK	NNP	O
enhancement	NN	O
for	IN	O
residual	JJ	O
refractive	JJ	O
errors	NNS	O
.	.	O

OBJECTIVE	NNP	O
To	TO	O
assess	VB	O
efficacy	NN	O
,	,	O
safety	NN	O
,	,	O
predictability	NN	O
,	,	O
stability	NN	O
,	,	O
and	CC	O
changes	NNS	O
in	IN	O
higher-order	NN	O
aberrations	NNS	O
(	(	O
HOAs	NNP	O
)	)	O
and	CC	O
contrast	JJ	O
sensitivity	NN	O
(	(	O
CS	NNP	O
)	)	O
after	IN	O
wavefront-guided	JJ	O
and	CC	O
standard	JJ	O
LASIK	NNP	O
enhancement	NN	O
for	IN	O
the	DT	O
correction	NN	O
of	IN	O
residual	JJ	O
refractive	JJ	O
errors	NNS	O
.	.	O

DESIGN	NNP	O
Prospective	NNP	O
,	,	O
randomized	VBD	O
,	,	O
comparative	JJ	O
clinical	JJ	O
study	NN	O
.	.	O

PARTICIPANTS	NNP	O
Twenty	NNP	O
eyes	NNS	O
of	IN	O
20	CD	SS
consecutive	JJ	SS
patients	NNS	SS
(	(	O
spherical	JJ	O
equivalent	NN	O
[	NNP	O
SE	NNP	O
]	NNP	O
,	,	O
-2.01+/-1.36	NNP	O
diopters	NNS	O
[	NNP	O
D	NNP	O
]	NNP	O
)	)	O
treated	VBD	O
with	IN	O
wavefront-guided	JJ	O
Zyoptix	NNP	O
Ablation	NNP	O
Refinement	NNP	O
software	NN	O
(	(	O
ZAR	NNP	O
)	)	O
LASIK	NNP	O
and	CC	O
20	CD	O
eyes	NNS	O
of	IN	O
20	CD	O
consecutive	JJ	O
patients	NNS	O
(	(	O
SE	NNP	O
,	,	O
-1.81+/-1.21	NNP	O
D	NNP	O
)	)	O
treated	VBD	O
with	IN	O
standard	JJ	O
Planoscan	NNP	O
LASIK	NNP	O
,	,	O
both	DT	O
for	IN	O
residual	JJ	C
refractive	JJ	C
error	NN	C
enhancement	NN	O
.	.	O

MAIN	NNP	O
OUTCOME	NNP	O
MEASURES	NNP	O
Efficacy	NNP	O
,	,	O
safety	NN	O
,	,	O
predictability	NN	O
,	,	O
stability	NN	O
,	,	O
HOAs	NNP	O
,	,	O
and	CC	O
CS	NNP	O
were	VBD	O
evaluated	VBN	O
before	IN	O
and	CC	O
after	IN	O
enhancement	NN	O
at	IN	O
6	CD	O
months	NNS	O
'	POS	O
follow-up	NN	O
.	.	O

METHODS	NNP	O
Uncorrected	VBD	O
visual	JJ	O
acuity	NN	O
(	(	O
UCVA	NNP	O
)	)	O
,	,	O
best-corrected	JJ	O
visual	JJ	O
acuity	NN	O
(	(	O
BCVA	NNP	O
)	)	O
,	,	O
manifest	JJS	O
refraction	NN	O
,	,	O
CS	NNP	O
by	IN	O
means	NNS	O
of	IN	O
the	DT	O
Functional	NNP	O
Acuity	NNP	O
Contrast	NNP	O
Test	NNP	O
,	,	O
and	CC	O
HOAs	NNP	O
by	IN	O
means	NNS	O
of	IN	O
Zywave	NNP	O
aberrometry	NN	O
were	VBD	O
evaluated	VBN	O
preoperatively	RB	O
and	CC	O
6	CD	O
months	NNS	O
after	IN	O
retreatment	NN	O
.	.	O

RESULTS	NNP	O
At	IN	O
6	CD	O
months	NNS	O
postoperatively	RB	O
,	,	O
UCVA	NNP	O
was	VBD	O
20/25	CD	O
or	CC	O
better	JJR	O
in	IN	O
100	CD	O
%	NN	O
of	IN	O
the	DT	O
eyes	NNS	O
.	.	O

Efficacy	NN	O
indexes	NNS	O
were	VBD	O
1.09	CD	O
for	IN	O
ZAR	NNP	O
patients	NNS	O
and	CC	O
0.95	CD	O
for	IN	O
Planoscan	JJ	O
patients	NNS	O
.	.	O

No	DT	O
eyes	NNS	O
lost	VBN	O
>	CD	O
or	CC	O
=1	JJ	O
line	NN	O
of	IN	O
BCVA	NNP	O
;	:	O
in	IN	O
the	DT	O
ZAR	NNP	O
group	NN	O
,	,	O
2	CD	O
eyes	NNS	O
gained	VBD	O
1	CD	O
line	NN	O
and	CC	O
6	CD	O
eyes	NNS	O
gained	VBN	O
>	CD	O
or	CC	O
=2	JJ	O
lines	NNS	O
;	:	O
in	IN	O
the	DT	O
Planoscan	NNP	O
group	NN	O
,	,	O
3	CD	O
eyes	NNS	O
gained	VBD	O
1	CD	O
line	NN	O
.	.	O

The	DT	O
ZAR	NNP	O
group	NN	O
showed	VBD	O
a	DT	O
percentage	NN	O
of	IN	O
eyes	NNS	O
(	(	O
94.4	CD	O
%	NN	O
)	)	O
within	IN	O
the	DT	O
0.5-D	JJ	O
range	NN	O
in	IN	O
SE	NNP	O
higher	JJR	O
than	IN	O
that	DT	O
shown	VBN	O
by	IN	O
the	DT	O
Planoscan	NNP	O
group	NN	O
(	(	O
88.8	CD	O
%	NN	O
)	)	O
.	.	O

After	IN	O
6	CD	O
months	NNS	O
,	,	O
the	DT	O
HOA	NNP	O
root	NN	O
mean	NN	O
square	NN	O
(	(	O
RMS	NNP	O
)	)	O
increased	VBD	O
on	IN	O
average	NN	O
by	IN	O
a	DT	O
factor	NN	O
of	IN	O
1.44	CD	O
for	IN	O
the	DT	O
Planoscan	NNP	O
group	NN	O
(	(	O
P	NNP	O
=	NNP	O
0.003	CD	O
)	)	O
.	.	O

No	UH	O
change	NN	O
or	CC	O
reduction	NN	O
in	IN	O
HOA	NNP	O
RMS	NNP	O
was	VBD	O
found	VBN	O
in	IN	O
the	DT	O
ZAR	NNP	O
group	NN	O
(	(	O
factor	NN	O
of	IN	O
0.96	CD	O
;	:	O
P	NNP	O
>	NNP	O
0.01	CD	O
)	)	O
.	.	O

Contrast	NNP	O
sensitivity	NN	O
was	VBD	O
reduced	VBN	O
in	IN	O
the	DT	O
Planoscan	NNP	O
group	NN	O
only	RB	O
at	IN	O
the	DT	O
highest	JJS	O
spatial	JJ	O
frequency	NN	O
(	(	O
18	CD	O
cycles	NNS	O
per	IN	O
degree	NN	O
;	:	O
P	NNP	O
<	NNP	O
0.01	CD	O
)	)	O
.	.	O

There	EX	O
was	VBD	O
a	DT	O
significant	JJ	O
reduction	NN	O
of	IN	O
CS	NNP	O
as	IN	O
a	DT	O
function	NN	O
of	IN	O
HOA	NNP	O
increase	NN	O
for	IN	O
the	DT	O
Planoscan	NNP	O
group	NN	O
(	(	O
P	NNP	O
<	NNP	O
0.0001	CD	O
)	)	O
.	.	O

No	UH	O
changes	NNS	O
were	VBD	O
observed	VBN	O
for	IN	O
the	DT	O
ZAR	NNP	O
group	NN	O
at	IN	O
any	DT	O
spatial	JJ	O
frequency	NN	O
(	(	O
1.5-18	JJ	O
cycles	NNS	O
per	IN	O
degree	NN	O
;	:	O
P	NNP	O
>	NNP	O
0.01	CD	O
)	)	O
.	.	O

CONCLUSIONS	NNP	O
Wavefront-guided	JJ	O
LASIK	NNP	O
using	VBG	O
the	DT	O
ZAR	NNP	O
algorithm	NN	O
is	VBZ	O
an	DT	O
effective	JJ	O
and	CC	O
safe	JJ	O
procedure	NN	O
for	IN	O
treatment	NN	O
of	IN	O
residual	JJ	O
refractive	JJ	O
errors	NNS	O
.	.	O

Wavefront-guided	JJ	O
LASIK	NNP	O
does	VBZ	O
not	RB	O
increase	VB	O
HOAs	NNP	O
and	CC	O
does	VBZ	O
not	RB	O
modify	VB	O
CS	NNP	O
compared	VBN	O
with	IN	O
preoperative	JJ	O
values	NNS	O
.	.	O

Wavefront-guided	JJ	O
LASIK	NNP	O
seems	VBZ	O
to	TO	O
be	VB	O
better	JJR	O
than	IN	O
standard	JJ	O
LASIK	NNP	O
for	IN	O
retreatments	NNS	O
.	.	O

Pilot	NNP	O
comparison	NN	O
between	IN	O
potassium	NN	O
titanyl	NN	O
phosphate	NN	O
laser	NN	O
and	CC	O
bipolar	JJ	O
radiofrequency	NN	O
in	IN	O
paediatric	JJ	C
tonsillectomy	NN	C
.	.	C

OBJECTIVES	NNP	O
To	TO	O
compare	VB	O
the	DT	O
advantages	NNS	O
and	CC	O
disadvantages	NNS	O
of	IN	O
potassium	NN	O
titanyl	NN	O
phosphate	NN	O
laser	NN	O
with	IN	O
those	DT	O
of	IN	O
bipolar	JJ	O
radiofrequency	NN	O
techniques	NNS	O
,	,	O
in	IN	O
paediatric	JJ	O
tonsillectomy	NN	O
.	.	O

STUDY	NNP	O
DESIGN	NNP	O
Prospective	NNP	O
,	,	O
randomised	VBD	O
,	,	O
clinical	JJ	O
study	NN	O
.	.	O

PATIENTS	NNP	O
AND	CC	O
METHODS	NNP	O
From	NNP	O
July	NNP	O
2004	CD	O
to	TO	O
April	NNP	O
2006	CD	O
,	,	O
80	CD	O
patients	NNS	O
aged	VBN	O
between	IN	O
10	CD	O
and	CC	O
15	CD	O
years	NNS	O
,	,	O
with	IN	O
tonsillectomy	NN	O
planned	VBN	O
for	IN	O
chronic	JJ	O
tonsillitis	NN	O
,	,	O
were	VBD	O
included	VBN	O
in	IN	O
the	DT	O
study	NN	O
.	.	O

Children	NNP	O
were	VBD	O
prospectively	RB	O
randomised	VBN	O
into	IN	O
two	CD	O
equal	JJ	O
groups	NNS	O
:	:	O
potassium	NN	O
titanyl	NN	O
phosphate	NN	O
laser	NN	O
tonsillectomy	NN	O
and	CC	O
bipolar	JJ	O
radiofrequency	NN	O
tonsillectomy	NN	O
.	.	O

Operative	JJ	O
time	NN	O
and	CC	O
intra-operative	JJ	O
blood	NN	O
loss	NN	O
were	VBD	O
recorded	VBN	O
.	.	O

Patients	NNS	O
were	VBD	O
scheduled	VBN	O
for	IN	O
follow	VB	O
up	RP	O
during	IN	O
the	DT	O
first	JJ	O
,	,	O
second	JJ	O
and	CC	O
fourth	JJ	O
post-operative	JJ	O
weeks	NNS	O
.	.	O

They	PRP	O
were	VBD	O
asked	VBN	O
to	TO	O
record	VB	O
their	PRP$	O
pain	NN	O
and	CC	O
discomfort	NN	O
on	IN	O
a	DT	O
standardised	JJ	O
visual	JJ	O
analogue	NN	O
scale	NN	O
,	,	O
from	IN	O
zero	CD	O
(	(	O
no	DT	O
pain	NN	O
)	)	O
to	TO	O
10	CD	O
(	(	O
severe	JJ	O
pain	NN	O
)	)	O
.	.	O

Post-operative	JJ	O
complications	NNS	O
were	VBD	O
also	RB	O
recorded	VBN	O
and	CC	O
managed	VBN	O
.	.	O

RESULTS	VB	O
The	DT	O
potassium	NN	O
titanyl	NN	O
phosphate	VBP	O
laser	NN	O
group	NN	O
showed	VBD	O
a	DT	O
slightly	RB	O
longer	RBR	O
operative	JJ	O
time	NN	O
(	(	O
mean	JJ	O
12	CD	O
minutes	NNS	O
)	)	O
than	IN	O
the	DT	O
bipolar	JJ	O
radiofrequency	NN	O
group	NN	O
(	(	O
mean	JJ	O
10	CD	O
minutes	NNS	O
)	)	O
.	.	O

Intra-operative	JJ	O
blood	NN	O
loss	NN	O
was	VBD	O
significantly	RB	O
less	RBR	O
in	IN	O
the	DT	O
potassium	NN	O
titanyl	NN	O
phosphate	VBP	O
laser	NN	O
group	NN	O
(	(	O
mean	JJ	O
21	CD	O
cm3	NN	O
)	)	O
than	IN	O
in	IN	O
the	DT	O
bipolar	JJ	O
radiofrequency	NN	O
group	NN	O
(	(	O
mean	JJ	O
30	CD	O
cm3	NN	O
)	)	O
.	.	O

In	IN	O
the	DT	O
first	JJ	O
week	NN	O
,	,	O
post-operative	JJ	O
pain	NN	O
scores	NNS	O
were	VBD	O
less	RBR	O
in	IN	O
the	DT	O
potassium	NN	O
titanyl	NN	O
phosphate	VBP	O
laser	NN	O
group	NN	O
than	IN	O
in	IN	O
the	DT	O
bipolar	JJ	O
radiofrequency	NN	O
group	NN	O
(	(	O
means	VBZ	O
7.5	CD	O
and	CC	O
8.5	CD	O
,	,	O
respectively	RB	O
)	)	O
.	.	O

However	RB	O
,	,	O
in	IN	O
the	DT	O
second	JJ	O
week	NN	O
pain	NN	O
scores	NNS	O
increased	VBD	O
more	RBR	O
in	IN	O
the	DT	O
potassium	NN	O
titanyl	NN	O
phosphate	VBP	O
laser	NN	O
group	NN	O
than	IN	O
in	IN	O
the	DT	O
bipolar	JJ	O
radiofrequency	NN	O
group	NN	O
(	(	O
means	VBZ	O
8.5	CD	O
and	CC	O
6	CD	O
,	,	O
respectively	RB	O
)	)	O
.	.	O

In	IN	O
the	DT	O
fourth	JJ	O
week	NN	O
,	,	O
both	DT	O
groups	NNS	O
showed	VBD	O
equal	JJ	O
and	CC	O
nearly	RB	O
normal	JJ	O
pain	NN	O
scores	NNS	O
.	.	O

No	DT	O
case	NN	O
of	IN	O
reactionary	JJ	O
post-tonsillectomy	JJ	O
haemorrhage	NN	O
was	VBD	O
recorded	VBN	O
in	IN	O
either	DT	O
group	NN	O
.	.	O

Only	RB	O
one	CD	O
case	NN	O
of	IN	O
secondary	JJ	O
post-tonsillectomy	JJ	O
haemorrhage	NN	O
was	VBD	O
recorded	VBN	O
,	,	O
in	IN	O
the	DT	O
potassium	NN	O
titanyl	NN	O
phosphate	VBP	O
laser	NN	O
group	NN	O
(	(	O
2.5	CD	O
per	IN	O
cent	NN	O
)	)	O
,	,	O
managed	VBD	O
conservatively	RB	O
.	.	O

CONCLUSION	NNP	O
Both	NNP	O
the	DT	O
potassium	NN	O
titanyl	NN	O
phosphate	NN	O
and	CC	O
the	DT	O
bipolar	JJ	O
radiofrequency	NN	O
techniques	NNS	O
were	VBD	O
safe	JJ	O
and	CC	O
easy	JJ	O
to	TO	O
use	VB	O
for	IN	O
tonsillectomy	NN	O
,	,	O
with	IN	O
reduced	VBN	O
operative	JJ	O
time	NN	O
,	,	O
blood	NN	O
loss	NN	O
and	CC	O
complication	NN	O
rates	NNS	O
and	CC	O
better	JJR	O
post-operative	JJ	O
general	JJ	O
patient	NN	O
condition	NN	O
.	.	O

Potassium	NNP	O
titanyl	JJ	O
phosphate	NN	O
laser	NN	O
resulted	VBD	O
in	IN	O
reduced	JJ	O
operative	JJ	O
bleeding	NN	O
and	CC	O
immediate	JJ	O
post-operative	JJ	O
pain	NN	O
,	,	O
compared	VBN	O
with	IN	O
the	DT	O
bipolar	JJ	O
radiofrequency	NN	O
technique	NN	O
.	.	O

However	RB	O
,	,	O
potassium	NN	O
titanyl	NN	O
phosphate	VBP	O
laser	NN	O
required	VBN	O
slightly	RB	O
more	RBR	O
operative	JJ	O
time	NN	O
and	CC	O
caused	VBD	O
more	JJR	O
late	JJ	O
post-operative	JJ	O
pain	NN	O
than	IN	O
the	DT	O
bipolar	JJ	O
radiofrequency	NN	O
technique	NN	O
.	.	O

The	DT	O
low	JJ	O
rate	NN	O
of	IN	O
recorded	VBN	O
complications	NNS	O
showed	VBD	O
that	IN	O
both	DT	O
techniques	NNS	O
cause	VBP	O
little	JJ	O
damage	NN	O
to	TO	O
the	DT	O
tonsillar	JJ	O
bed	NN	O
during	IN	O
dissection	NN	O
,	,	O
thus	RB	O
minimising	VBG	O
complications	NNS	O
.	.	O

Endobronchial	JJ	O
ultrasonography-guided	JJ	O
transbronchial	JJ	O
needle	JJ	O
aspiration	NN	O
increases	VBZ	O
the	DT	O
diagnostic	JJ	O
yield	NN	O
of	IN	O
peripheral	JJ	C
pulmonary	JJ	C
lesions	NNS	C
:	:	C
a	DT	O
randomized	JJ	O
trial	NN	O
.	.	O

BACKGROUND	VB	O
The	DT	O
diagnostic	JJ	O
yield	NN	O
of	IN	O
endobronchial	JJ	O
ultrasonography	NN	O
(	(	O
EBUS	NNP	O
)	)	O
-guided	VBD	O
transbronchial	JJ	O
needle	JJ	O
aspiration	NN	O
(	(	O
TBNA	NNP	O
)	)	O
for	IN	O
peripheral	JJ	O
pulmonary	JJ	O
lesions	NNS	O
(	(	O
PPLs	NNP	O
)	)	O
has	VBZ	O
not	RB	O
been	VBN	O
evaluated	VBN	O
.	.	O

The	DT	O
diagnostic	JJ	O
impact	NN	O
of	IN	O
TBNA	NNP	O
when	WRB	O
the	DT	O
EBUS	NNP	O
probe	NN	O
is	VBZ	O
adjacent	JJ	O
to	TO	O
lesions	NNS	O
remains	VBZ	O
to	TO	O
be	VB	O
determined	VBN	O
.	.	O

DESIGN	VB	O
A	DT	O
prospective	JJ	O
,	,	O
randomized	JJ	O
trial	NN	O
.	.	O

METHODS	NNP	O
Two	CD	O
hundred	VBD	O
two	CD	O
patients	NNS	O
with	IN	O
PPLs	NNP	O
and	CC	O
positive	JJ	O
EBUS	NNP	O
findings	NNS	O
were	VBD	O
enrolled	VBN	O
.	.	O

They	PRP	O
were	VBD	O
randomly	RB	O
classified	VBN	O
into	IN	O
two	CD	O
groups	NNS	O
.	.	O

In	IN	O
the	DT	O
EBUS	NNP	O
conventional	JJ	O
diagnostic	JJ	O
procedures	NNS	O
(	(	O
CDPs	NNP	O
)	)	O
group	NN	O
(	(	O
103	CD	O
patients	NNS	O
)	)	O
,	,	O
both	DT	O
transbronchial	JJ	O
biopsy	NN	O
(	(	O
TBB	NNP	O
)	)	O
and	CC	O
bronchial	JJ	O
washing	NN	O
(	(	O
BW	NNP	O
)	)	O
were	VBD	O
performed	VBN	O
.	.	O

In	IN	O
the	DT	O
EBUS-TBNA	JJ	O
plus	CC	O
CDPs	NNP	O
group	NN	O
(	(	O
99	CD	O
patients	NNS	O
)	)	O
,	,	O
TBNA	NNP	O
,	,	O
TBB	NNP	O
,	,	O
and	CC	O
BW	NNP	O
were	VBD	O
performed	VBN	O
.	.	O

The	DT	O
diagnostic	JJ	O
yield	NN	O
in	IN	O
each	DT	O
group	NN	O
was	VBD	O
compared	VBN	O
.	.	O

RESULTS	VB	O
A	DT	O
total	NN	O
of	IN	O
182	CD	O
patients	NNS	O
(	(	O
94	CD	O
in	IN	O
the	DT	O
EBUS	NNP	O
CDPs	NNP	O
group	NN	O
and	CC	O
88	CD	O
in	IN	O
the	DT	O
EBUS-TBNA	JJ	O
plus	CC	O
CDPs	NNP	O
group	NN	O
)	)	O
were	VBD	O
analyzed	VBN	O
.	.	O

The	DT	O
yield	NN	O
in	IN	O
the	DT	O
EBUS-TBNA	JJ	O
plus	CC	O
CDPs	NNP	O
group	NN	O
(	(	O
78.4	CD	O
%	NN	O
)	)	O
was	VBD	O
significantly	RB	O
higher	JJR	O
than	IN	O
the	DT	O
EBUS	NNP	O
CDPs	NNP	O
group	NN	O
(	(	O
60.6	CD	O
%	NN	O
,	,	O
p	NN	O
=	NNP	O
0.015	CD	O
)	)	O
.	.	O

Cases	NNS	O
in	IN	O
which	WDT	O
the	DT	O
EBUS	NNP	O
probe	NN	O
was	VBD	O
located	VBN	O
within	IN	O
the	DT	O
lesions	NNS	O
had	VBD	O
a	DT	O
significantly	RB	O
higher	RBR	O
diagnostic	JJ	O
yield	NN	O
(	(	O
78.3	CD	O
%	NN	O
)	)	O
than	IN	O
when	WRB	O
the	DT	O
EBUS	NNP	O
probe	NN	O
was	VBD	O
adjacent	JJ	O
to	TO	O
them	PRP	O
(	(	O
47.2	CD	O
%	NN	O
,	,	O
p	NN	O
<	NNP	O
0.001	CD	O
)	)	O
.	.	O

Concerning	VBG	O
the	DT	O
three	CD	O
different	JJ	O
techniques	NNS	O
,	,	O
TBNA	NNP	O
showed	VBD	O
the	DT	O
highest	JJS	O
diagnostic	JJ	O
yield	NN	O
(	(	O
62.5	CD	O
%	NN	O
)	)	O
in	IN	O
comparison	NN	O
to	TO	O
TBB	NNP	O
(	(	O
48.9	CD	O
%	NN	O
)	)	O
and	CC	O
to	TO	O
BW	NNP	O
(	(	O
19.8	CD	O
%	NN	O
)	)	O
.	.	O

The	DT	O
diagnostic	JJ	O
yield	NN	O
of	IN	O
TBNA	NNP	O
remained	VBD	O
unchanged	JJ	O
even	RB	O
when	WRB	O
the	DT	O
EBUS	NNP	O
probe	NN	O
was	VBD	O
adjacent	JJ	O
to	TO	O
the	DT	O
lesions	NNS	O
(	(	O
p	JJ	O
=	NNP	O
0.89	CD	O
)	)	O
.	.	O

No	DT	O
additional	JJ	O
adverse	JJ	O
effects	NNS	O
were	VBD	O
observed	VBN	O
in	IN	O
the	DT	O
EBUS-TBNA	JJ	O
plus	CC	O
CDPs	NNP	O
group	NN	O
.	.	O

CONCLUSIONS	NNP	O
Applying	NNP	O
TBNA	NNP	O
to	TO	O
EBUS-guided	NNP	O
CDPs	NNP	O
further	RBR	O
increased	VBD	O
the	DT	O
diagnostic	JJ	O
yield	NN	O
of	IN	O
PPLs	NNP	O
without	IN	O
additional	JJ	O
risk	NN	O
.	.	O

The	DT	O
diagnostic	JJ	O
advantage	NN	O
of	IN	O
TBNA	NNP	O
became	VBD	O
more	RBR	O
obvious	JJ	O
if	IN	O
the	DT	O
EBUS	NNP	O
probe	NN	O
was	VBD	O
adjacent	JJ	O
to	TO	O
the	DT	O
lesions	NNS	O
.	.	O

TRIAL	NNP	O
REGISTRATION	NNP	O
Clinicaltrials.gov	NNP	O
Identifier	NNP	O
:	:	O
NCT00626587	NN	O
.	.	O

Controlled	VBN	O
trial	NN	O
of	IN	O
induction	NN	O
of	IN	O
labor	NN	O
by	IN	O
vaginal	JJ	O
suppositories	NNS	O
containing	VBG	O
prostaglandin	NN	O
E2	NNP	O
.	.	O

A	NNP	O
group	NN	O
of	IN	O
84	CD	O
women	NNS	O
at	IN	O
39-43	JJ	O
weeks	NNS	O
of	IN	O
pregnancy	NN	O
were	VBD	O
randomly	RB	O
allocated	VBN	O
to	TO	O
a	DT	O
blind	JJ	O
trial	NN	O
of	IN	O
induction	NN	O
of	IN	O
labor	NN	O
with	IN	O
vaginal	JJ	O
suppositories	NNS	O
containing	VBG	O
inert	JJ	O
material	NN	O
or	CC	O
either	CC	O
0.2	CD	O
mg	NN	O
or	CC	O
0.4	CD	O
mg	NN	O
of	IN	O
prostaglandin	NN	O
E2	NNP	O
.	.	O

The	DT	O
suppositories	NNS	O
were	VBD	O
self-administered	JJ	O
every	DT	O
two	CD	O
hours	NNS	O
during	IN	O
waking	VBG	O
hours	NNS	O
on	IN	O
two	CD	O
successive	JJ	O
days	NNS	O
until	IN	O
labor	NN	O
started	VBD	O
or	CC	O
15	CD	O
had	VBD	O
been	VBN	O
used	VBN	O
.	.	O

Side-effects	NNS	O
were	VBD	O
absent	JJ	O
.	.	O

Labor	NN	O
was	VBD	O
established	VBN	O
within	IN	O
48	CD	O
hr	NN	O
of	IN	O
insertion	NN	O
of	IN	O
the	DT	O
first	JJ	O
suppository	NN	O
in	IN	O
9.3	CD	O
%	NN	O
of	IN	O
control	NN	O
patients	NNS	O
,	,	O
65.4	CD	O
%	NN	O
of	IN	O
those	DT	O
treated	VBN	O
with	IN	O
0.2	CD	O
mg	NNS	O
PGE2	NNP	O
and	CC	O
85.7	CD	O
%	NN	O
of	IN	O
those	DT	O
treated	VBN	O
with	IN	O
0.4	CD	O
mg	NNS	O
PGE2	NNP	O
.	.	O

The	DT	O
mean	JJ	O
Apgar	NNP	O
scores	NNS	O
in	IN	O
the	DT	O
three	CD	O
groups	NNS	O
were	VBD	O
the	DT	O
same	JJ	O
.	.	O

The	DT	O
mean	JJ	O
total	NN	O
dose	NN	O
of	IN	O
PGE2	NNP	O
were	VBD	O
2.0	CD	O
mg	NN	O
(	(	O
0.2	CD	O
mg	NNS	O
group	NN	O
)	)	O
and	CC	O
2.3	CD	O
mg	NN	O
(	(	O
0.4	CD	O
mg	NNS	O
group	NN	O
)	)	O
.	.	O

It	PRP	O
is	VBZ	O
concluded	VBN	O
that	IN	O
vaginal	JJ	O
PGE2	NNP	O
is	VBZ	O
an	DT	O
effective	JJ	O
and	CC	O
acceptable	JJ	O
method	NN	O
of	IN	O
inducing	VBG	O
labor	NN	O
at	IN	O
term	NN	O
.	.	O

Epidural	JJ	O
fentanyl-bupivacaine	JJ	O
compared	VBN	O
with	IN	O
clonidine-bupivacaine	NN	O
for	IN	O
analgesia	NN	O
in	IN	O
labour	NN	O
.	.	O

Alpha-adrenergic	JJ	O
agonists	NNS	O
produce	VBP	O
pain	NN	O
relief	NN	O
through	IN	O
an	DT	O
opioid	JJ	O
independent	JJ	O
mechanism	NN	O
and	CC	O
may	MD	O
be	VB	O
alternatives	NNS	O
to	TO	O
opioids	NNS	O
for	IN	O
combination	NN	O
with	IN	O
local	JJ	O
anaesthetics	NNS	O
for	IN	O
analgesia	NN	O
during	IN	O
labour	NN	O
.	.	O

We	PRP	O
studied	VBD	O
41	CD	SS
pregnant	JJ	O
women	NNS	SE
.	.	O

Epidural	JJ	O
block	NN	O
was	VBD	O
performed	VBN	O
with	IN	O
75	CD	O
microg	NNS	O
clonidine	NN	O
(	(	O
n	JJ	O
=	NNP	O
20	CD	O
)	)	O
or	CC	O
50	CD	O
microg	NNS	O
fentanyl	NN	O
(	(	O
n	JJ	O
=	NNP	O
21	CD	O
)	)	O
combined	VBN	O
with	IN	O
0.125	CD	O
%	NN	O
bupivacaine	NN	O
(	(	O
10	CD	O
mL	NN	O
)	)	O
.	.	O

Maternal	JJ	O
vital	JJ	O
parameters	NNS	O
were	VBD	O
measured	VBN	O
.	.	O

Analgesia	NNP	O
was	VBD	O
evaluated	VBN	O
using	VBG	O
a	DT	O
visual	JJ	O
analogue	NN	O
scale	NN	O
(	(	O
VAS	NNP	O
)	)	O
;	:	O
sedation	NN	O
was	VBD	O
scored	VBN	O
using	VBG	O
a	DT	O
five-point	JJ	O
scale	NN	O
.	.	O

There	EX	O
were	VBD	O
no	DT	O
differences	NNS	O
in	IN	O
maternal	JJ	O
vital	JJ	O
parameters	NNS	O
,	,	O
fetal	JJ	O
heart	NN	O
rate	NN	O
(	(	O
FHR	NNP	O
)	)	O
or	CC	O
Apgar	NNP	O
scores	NNS	O
between	IN	O
the	DT	O
groups	NNS	O
.	.	O

Analgesia	NNP	O
lasted	VBD	O
longer	RBR	O
in	IN	O
the	DT	O
bupivacaine-clonidine	JJ	O
group	NN	O
(	(	O
139.4	CD	O
+/-	JJ	O
31	CD	O
min	NN	O
)	)	O
compared	VBN	O
with	IN	O
the	DT	O
bupivacaine-fentanyl	JJ	O
group	NN	O
(	(	O
127.9	CD	O
+/-	JJ	O
48	CD	O
min	NN	O
)	)	O
(	(	O
P	NNP	O
=	NNP	O
0.42	CD	O
)	)	O
.	.	O

Additional	JJ	O
analgesic	JJ	O
requirement	NN	O
was	VBD	O
more	RBR	O
often	RB	O
in	IN	O
the	DT	O
fentanyl-bupivacaine	JJ	O
group	NN	O
and	CC	O
total	JJ	O
bupivacaine	NN	O
requirement	NN	O
was	VBD	O
less	RBR	O
in	IN	O
the	DT	O
clonidine-bupivacaine	JJ	O
group	NN	O
(	(	O
22.5	CD	O
+/-	JJ	O
12.5	CD	O
mg	NN	O
vs.	FW	O
30.9	CD	O
+/-	JJ	O
12.8	CD	O
mg	NN	O
)	)	O
(	(	O
P	NNP	O
=	NNP	O
0.04	CD	O
)	)	O
.	.	O

This	DT	O
small	JJ	O
study	NN	O
confirms	VBZ	O
that	IN	O
this	DT	O
combination	NN	O
of	IN	O
bupivacaine	NN	O
and	CC	O
clonidine	NN	O
provides	VBZ	O
satisfactory	JJ	O
analgesia	NN	O
for	IN	O
first-stage	JJ	O
labour	NN	O
,	,	O
and	CC	O
of	IN	O
longer	JJR	O
duration	NN	O
than	IN	O
bupivacaine-fentanyl	NN	O
.	.	O

Safety	NN	O
and	CC	O
efficacy	NN	O
of	IN	O
oral	JJ	O
DMSA	NNP	O
therapy	NN	O
for	IN	O
children	NNS	A
with	IN	O
autism	NN	C
spectrum	NN	C
disorders	NNS	C
:	:	O
part	NN	O
B	NNP	O
-	:	O
behavioral	JJ	O
results	NNS	O
.	.	O

BACKGROUND	NNP	O
This	DT	O
study	NN	O
investigated	VBD	O
the	DT	O
effects	NNS	O
of	IN	O
oral	JJ	O
dimercapto	NN	O
succinic	JJ	O
acid	NN	O
(	(	O
DMSA	NNP	O
)	)	O
therapy	NN	O
on	IN	O
the	DT	O
behavioural	JJ	O
symptoms	NNS	O
of	IN	O
children	NNS	O
with	IN	O
autism	NN	O
spectrum	NN	O
disorders	NNS	O
(	(	O
ASD	NNP	O
)	)	O
ages	VBZ	O
3-8	JJ	O
years	NNS	O
.	.	O

METHODS	NNP	O
Phase	NNP	O
1	CD	O
involved	VBD	O
65	CD	SS
children	NNS	A
with	IN	O
ASD	NNP	C
who	WP	O
received	VBD	O
one	CD	O
round	NN	O
of	IN	O
DMSA	NNP	O
(	(	O
3	CD	O
days	NNS	O
)	)	O
.	.	O

Participants	NNS	O
who	WP	O
had	VBD	O
high	JJ	C
urinary	JJ	C
excretion	NN	C
of	IN	C
toxic	JJ	C
metals	NNS	C
were	VBD	O
selected	VBN	O
to	TO	O
continue	VB	O
on	IN	O
to	TO	O
phase	VB	O
2	CD	O
.	.	O

In	IN	O
phase	NN	O
2	CD	O
,	,	O
49	CD	SS
participants	NNS	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
in	IN	O
a	DT	O
double-blind	JJ	O
design	NN	O
to	TO	O
receive	VB	O
an	DT	O
additional	JJ	O
6	CD	O
rounds	NNS	O
of	IN	O
either	DT	O
DMSA	NNP	O
or	CC	O
placebo	NN	O
.	.	O

RESULTS	VB	O
The	DT	O
groups	NNS	O
receiving	VBG	O
one	CD	O
round	NN	O
and	CC	O
seven	CD	O
rounds	NNS	O
of	IN	O
DMSA	NNP	O
had	VBD	O
significant	JJ	O
improvements	NNS	O
on	IN	O
all	PDT	O
the	DT	O
assessment	JJ	O
measures	NNS	O
.	.	O

For	IN	O
the	DT	O
seven	CD	O
round	NN	O
group	NN	O
,	,	O
the	DT	O
degree	NN	O
of	IN	O
improvement	NN	O
on	IN	O
the	DT	O
assessment	NN	O
measures	NNS	O
could	MD	O
be	VB	O
partially	RB	O
explained	VBN	O
by	IN	O
a	DT	O
regression	NN	O
analysis	NN	O
based	VBN	O
on	IN	O
excretion	NN	O
of	IN	O
toxic	JJ	O
metals	NNS	O
and	CC	O
changes	NNS	O
in	IN	O
glutathione	NN	O
(	(	O
adjusted	VBN	O
R2	NNP	O
of	IN	O
0.28-0.75	NNP	O
,	,	O
p	NN	O
<	VBD	O
0.02	CD	O
in	IN	O
all	DT	O
cases	NNS	O
)	)	O
.	.	O

One	CD	O
round	NN	O
of	IN	O
DMSA	NNP	O
had	VBD	O
nearly	RB	O
the	DT	O
same	JJ	O
benefit	NN	O
as	IN	O
seven	CD	O
rounds	NNS	O
.	.	O

The	DT	O
assessment	JJ	O
measures	NNS	O
correlated	VBN	O
reasonably	RB	O
with	IN	O
one	CD	O
another	DT	O
at	IN	O
the	DT	O
beginning	NN	O
of	IN	O
the	DT	O
study	NN	O
(	(	O
r	JJ	O
=	NNP	O
0.60-0.87	NN	O
)	)	O
and	CC	O
even	RB	O
better	JJR	O
at	IN	O
the	DT	O
end	NN	O
of	IN	O
the	DT	O
study	NN	O
(	(	O
r	JJ	O
=	NNP	O
0.63-0.94	NN	O
)	)	O
.	.	O

CONCLUSION	NNP	O
Overall	NNP	O
,	,	O
both	DT	O
one	CD	O
and	CC	O
seven	CD	O
rounds	NNS	O
of	IN	O
DMSA	NNP	O
therapy	NN	O
seems	VBZ	O
to	TO	O
be	VB	O
reasonably	RB	O
safe	JJ	O
in	IN	O
children	NNS	A
with	IN	O
ASD	NNP	C
who	WP	O
have	VBP	O
high	JJ	C
urinary	JJ	C
excretion	NN	C
of	IN	C
toxic	JJ	C
metals	NNS	C
,	,	O
and	CC	O
possibly	RB	O
helpful	JJ	O
in	IN	O
reducing	VBG	O
some	DT	O
of	IN	O
the	DT	O
symptoms	NNS	O
of	IN	O
autism	NN	O
in	IN	O
those	DT	O
children	NNS	O
.	.	O

Effect	NN	O
of	IN	O
simvastatin	NN	O
on	IN	O
hemostasis	NN	O
in	IN	O
patients	NNS	C
with	IN	C
isolated	JJ	C
hypertriglyceridemia	NN	C
.	.	C

BACKGROUNDS/AIMS	NNP	O
Elevated	NNP	O
triglyceride	NN	O
levels	NNS	O
seem	VBP	O
to	TO	O
predispose	VB	O
to	TO	O
the	DT	O
earlier	JJR	O
development	NN	O
and	CC	O
accelerated	JJ	O
progression	NN	O
of	IN	O
coronary	JJ	O
artery	NN	O
disease	NN	O
.	.	O

In	IN	O
our	PRP$	O
study	NN	O
,	,	O
we	PRP	O
assessed	VBD	O
for	IN	O
the	DT	O
first	JJ	O
time	NN	O
whether	IN	O
simvastatin	JJ	O
treatment	NN	O
affects	NNS	O
coagulation	NN	O
and	CC	O
fibrinolysis	NN	O
in	IN	O
patients	NNS	C
with	IN	C
isolated	JJ	C
hypertriglyceridemia	NN	C
.	.	C

METHODS	NNP	O
The	DT	O
study	NN	O
included	VBD	O
39	CD	O
patients	NNS	O
with	IN	O
elevated	JJ	O
triglyceride	NN	O
levels	NNS	O
and	CC	O
peripheral	JJ	O
artery	NN	O
sclerosis	NN	O
,	,	O
treated	VBD	O
for	IN	O
90	CD	O
days	NNS	O
with	IN	O
either	DT	O
simvastatin	NN	O
(	(	O
40	CD	O
mg	NNS	O
daily	RB	O
)	)	O
or	CC	O
placebo	NN	O
.	.	O

Plasma	NNP	O
lipids	NNS	O
,	,	O
glucose	JJ	O
homeostasis	NN	O
markers	NNS	O
and	CC	O
hemostasic	JJ	O
variables	NNS	O
were	VBD	O
assessed	VBN	O
at	IN	O
baseline	NN	O
and	CC	O
after	IN	O
treatment	NN	O
.	.	O

RESULTS	NNP	O
Simvastatin	NNP	O
,	,	O
but	CC	O
not	RB	O
placebo	VB	O
,	,	O
administered	VBN	O
to	TO	O
these	DT	O
patients	NNS	O
reduced	VBD	O
plasma	JJ	O
levels/activity	NN	O
of	IN	O
fibrinogen	NN	O
(	(	O
from	IN	O
3.5	CD	O
?	.	O
0.4	CD	O
to	TO	O
2.8	CD	O
?	.	O
0.3	CD	O
g/l	NN	O
,	,	O
p	NN	O
<	NNP	O
0.01	CD	O
)	)	O
,	,	O
factor	NN	O
VII	NNP	O
(	(	O
from	IN	O
144.2	CD	O
?	.	O
16.9	CD	O
to	TO	O
112.5	CD	O
?	.	O
14.0	CD	O
%	NN	O
,	,	O
p	NN	O
<	NNP	O
0.01	CD	O
)	)	O
and	CC	O
plasminogen	JJ	O
activator	NN	O
inhibitor-1	NN	O
(	(	O
from	IN	O
76.9	CD	O
?	.	O
13.5	CD	O
to	TO	O
50.2	CD	O
?	.	O
9.2	CD	O
ng/ml	NN	O
,	,	O
p	NN	O
<	NNP	O
0.001	CD	O
)	)	O
,	,	O
without	IN	O
a	DT	O
significant	JJ	O
reduction	NN	O
in	IN	O
von	NN	O
Willebrand	NNP	O
factor	NN	O
levels	NNS	O
,	,	O
and	CC	O
tended	VBD	O
to	TO	O
prolong	VB	O
the	DT	O
prothrombin	NN	O
and	CC	O
partial	JJ	O
thromboplastin	NN	O
times	NNS	O
.	.	O

CONCLUSION	NNP	O
Our	PRP$	O
results	NNS	O
suggest	VBP	O
that	IN	O
statin	NN	O
treatment	NN	O
produces	VBZ	O
a	DT	O
multidirectional	JJ	O
effect	NN	O
on	IN	O
coagulation	NN	O
and	CC	O
fibrinolysis	NN	O
in	IN	O
patients	NNS	O
with	IN	O
isolated	JJ	O
hypertriglyceridemia	NN	O
and	CC	O
that	IN	O
this	DT	O
treatment	NN	O
may	MD	O
bring	VB	O
some	DT	O
benefits	NNS	O
to	TO	O
patients	NNS	O
with	IN	O
elevated	JJ	O
triglyceride	NN	O
levels	NNS	O
.	.	O

Omega-3	JJ	O
fatty	JJ	O
acids	NNS	O
supplementation	NN	O
in	IN	O
children	NNS	O
with	IN	O
autism	NN	C
:	:	O
a	DT	O
double-blind	JJ	O
randomized	NN	O
,	,	O
placebo-controlled	JJ	O
pilot	NN	O
study	NN	O
.	.	O

BACKGROUND	NNP	O
There	EX	O
is	VBZ	O
increasing	VBG	O
evidence	NN	O
that	IN	O
fatty	JJ	O
acid	JJ	O
deficiencies	NNS	O
or	CC	O
imbalances	NNS	O
may	MD	O
contribute	VB	O
to	TO	O
childhood	VB	O
neurodevelopmental	JJ	C
disorders	NNS	C
.	.	C

METHODS	NNP	O
We	PRP	O
conducted	VBD	O
a	DT	O
randomized	VBN	O
,	,	O
double-blind	JJ	O
,	,	O
placebo-controlled	JJ	O
6-week	JJ	O
pilot	NN	O
trial	NN	O
investigating	VBG	O
the	DT	O
effects	NNS	O
of	IN	O
1.5	CD	O
g/d	NN	O
of	IN	O
omega-3	JJ	O
fatty	JJ	O
acids	NNS	O
(	(	O
.84	JJ	O
g/d	NN	O
eicosapentaenoic	NN	O
acid	NN	O
,	,	O
.7	NNP	O
g/d	NN	O
docosahexaenoic	NN	O
acid	NN	O
)	)	O
supplementation	NN	O
in	IN	O
13	CD	SS
children	NNS	O
(	(	O
aged	VBN	A
5	CD	A
to	TO	A
17	CD	A
years	NNS	A
)	)	O
with	IN	O
autistic	JJ	O
disorders	NNS	O
accompanied	VBN	O
by	IN	O
severe	JJ	C
tantrums	NNS	C
,	,	C
aggression	NN	C
,	,	C
or	CC	C
self-injurious	JJ	C
behavior	NN	C
.	.	O

The	DT	O
outcome	NN	O
measure	NN	O
was	VBD	O
the	DT	O
Aberrant	NNP	O
Behavior	NNP	O
Checklist	NNP	O
(	(	O
ABC	NNP	O
)	)	O
at	IN	O
6	CD	O
weeks	NNS	O
.	.	O

RESULTS	NNP	O
We	PRP	O
observed	VBD	O
an	DT	O
advantage	NN	O
of	IN	O
omega-3	JJ	O
fatty	JJ	O
acids	NNS	O
compared	VBN	O
with	IN	O
placebo	NN	O
for	IN	O
hyperactivity	NN	O
and	CC	O
stereotypy	NN	O
,	,	O
each	DT	O
with	IN	O
a	DT	O
large	JJ	O
effect	NN	O
size	NN	O
.	.	O

Repeated-measures	NNS	O
ANOVA	NNP	O
indicated	VBD	O
a	DT	O
trend	NN	O
toward	IN	O
superiority	NN	O
of	IN	O
omega-3	JJ	O
fatty	JJ	O
acids	NNS	O
over	IN	O
placebo	NN	O
for	IN	O
hyperactivity	NN	O
.	.	O

No	DT	O
clinically	RB	O
relevant	JJ	O
adverse	JJ	O
effects	NNS	O
were	VBD	O
elicited	VBN	O
in	IN	O
either	DT	O
group	NN	O
.	.	O

CONCLUSIONS	VBZ	O
The	DT	O
results	NNS	O
of	IN	O
this	DT	O
study	NN	O
provide	VBP	O
preliminary	JJ	O
evidence	NN	O
that	IN	O
omega-3	JJ	O
fatty	JJ	O
acids	NNS	O
may	MD	O
be	VB	O
an	DT	O
effective	JJ	O
treatment	NN	O
for	IN	O
children	NNS	O
with	IN	O
autism	NN	O
.	.	O

Variations	NNS	O
in	IN	O
EEG	NNP	O
discharges	NNS	O
predict	VBP	O
ADHD	NNP	O
severity	NN	O
within	IN	O
individual	JJ	O
Smith-Lemli-Opitz	JJ	O
patients	NNS	O
.	.	O

OBJECTIVE	IN	O
We	PRP	O
sought	VBD	O
to	TO	O
examine	VB	O
the	DT	O
prevalence	NN	O
of	IN	O
EEG	NNP	O
abnormalities	NNS	O
in	IN	O
Smith-Lemli-Opitz	NNP	C
syndrome	NN	C
(	(	C
SLOS	NNP	C
)	)	C
as	RB	O
well	RB	O
as	IN	O
the	DT	O
relationship	NN	O
between	IN	O
interictal	JJ	O
epileptiform	NN	O
discharges	NNS	O
(	(	O
IEDs	NNP	O
)	)	O
and	CC	O
within-subject	JJ	O
variations	NNS	O
in	IN	O
attentional	JJ	O
symptom	NN	O
severity	NN	O
.	.	O

METHODS	NNP	O
In	IN	O
the	DT	O
context	NN	O
of	IN	O
a	DT	O
clinical	JJ	O
trial	NN	O
for	IN	O
SLOS	NNP	O
,	,	O
we	PRP	O
performed	VBD	O
cross-sectional	JJ	O
and	CC	O
repeated-measure	JJ	O
observational	JJ	O
studies	NNS	O
of	IN	O
the	DT	O
relationship	NN	O
between	IN	O
EEG	NNP	O
findings	NNS	O
and	CC	O
cognitive/behavioral	JJ	O
factors	NNS	O
on	IN	O
23	CD	SS
children	NNS	O
(	(	O
aged	VBN	A
4-17	CD	A
years	NNS	A
)	)	O
.	.	O

EEGs	NNP	O
were	VBD	O
reviewed	VBN	O
for	IN	O
clinical	JJ	O
abnormalities	NNS	O
,	,	O
including	VBG	O
IEDs	NNP	O
,	,	O
by	IN	O
readers	NNS	O
blinded	VBD	O
to	TO	O
participants	NNS	O
'	POS	O
behavioral	NN	O
symptoms	NNS	O
.	.	O

Between-group	JJ	O
differences	NNS	O
in	IN	O
baseline	JJ	O
characteristics	NNS	O
of	IN	O
participants	NNS	O
with	IN	O
and	CC	O
without	IN	O
IEDs	NNP	O
were	VBD	O
analyzed	VBN	O
.	.	O

Within-subject	JJ	O
analyses	NNS	O
examined	VBD	O
the	DT	O
association	NN	O
between	IN	O
the	DT	O
presence	NN	O
of	IN	O
IEDs	NNP	O
and	CC	O
changes	NNS	O
in	IN	O
attention-deficit/hyperactivity	NN	O
disorder	NN	O
(	(	O
ADHD	NNP	O
)	)	O
symptoms	NNS	O
.	.	O

RESULTS	NNP	O
Of	IN	O
85	CD	O
EEGs	NNP	O
,	,	O
43	CD	O
(	(	O
51	CD	O
%	NN	O
)	)	O
were	VBD	O
abnormal	JJ	O
,	,	O
predominantly	RB	O
because	IN	O
of	IN	O
IEDs	NNP	O
.	.	O

Only	RB	O
one	CD	O
subject	NN	O
had	VBD	O
documented	VBN	O
clinical	JJ	O
seizures	NNS	O
.	.	O

IEDs	NNP	O
clustered	VBD	O
in	IN	O
13	CD	O
subjects	NNS	O
(	(	O
57	CD	O
%	NN	O
)	)	O
,	,	O
whereas	$	O
9	CD	O
subjects	NNS	O
(	(	O
39	CD	O
%	NN	O
)	)	O
had	VBD	O
EEGs	NNP	O
consistently	RB	O
free	JJ	O
of	IN	O
IEDs	NNP	O
.	.	O

While	IN	O
there	EX	O
were	VBD	O
no	DT	O
significant	JJ	O
group	NN	O
differences	NNS	O
in	IN	O
sex	NN	O
,	,	O
age	NN	O
,	,	O
intellectual	JJ	O
disability	NN	O
,	,	O
language	NN	O
level	NN	O
,	,	O
or	CC	O
baseline	VB	O
ADHD	NNP	O
symptoms	NNS	O
,	,	O
autistic	JJ	O
symptoms	NNS	O
tended	VBD	O
to	TO	O
be	VB	O
more	RBR	O
prevalent	JJ	O
in	IN	O
the	DT	O
IED	NNP	O
group	NN	O
(	(	O
according	VBG	O
to	TO	O
Autism	NNP	O
Diagnostic	NNP	O
Observation	NNP	O
Schedule-2	NNP	O
criteria	NNS	O
)	)	O
.	.	O

Within	JJ	O
individuals	NNS	O
,	,	O
the	DT	O
presence	NN	O
of	IN	O
IEDs	NNP	O
on	IN	O
a	DT	O
particular	JJ	O
EEG	NNP	O
predicted	VBD	O
,	,	O
on	IN	O
average	NN	O
,	,	O
a	DT	O
27	CD	O
%	NN	O
increase	NN	O
in	IN	O
ADHD	NNP	O
symptom	NN	O
severity	NN	O
.	.	O

CONCLUSIONS	NNP	O
Epileptiform	NNP	O
discharges	NNS	O
are	VBP	O
common	JJ	O
in	IN	O
SLOS	NNP	O
,	,	O
despite	IN	O
a	DT	O
relatively	RB	O
low	JJ	O
prevalence	NN	O
of	IN	O
epilepsy	NN	O
.	.	O

Fluctuations	NNS	O
in	IN	O
the	DT	O
presence	NN	O
of	IN	O
epileptiform	NN	O
discharges	NNS	O
within	IN	O
individual	JJ	O
children	NNS	O
with	IN	O
a	DT	O
developmental	JJ	O
disability	NN	O
syndrome	NN	O
may	MD	O
be	VB	O
associated	VBN	O
with	IN	O
fluctuations	NNS	O
in	IN	O
ADHD	NNP	O
symptomatology	NN	O
,	,	O
even	RB	O
in	IN	O
the	DT	O
absence	NN	O
of	IN	O
clinical	JJ	O
seizures	NNS	O
.	.	O

A	DT	O
placebo-controlled	JJ	O
,	,	O
randomized	JJ	O
clinical	JJ	O
trial	NN	O
using	VBG	O
testosterone	NN	O
undecanoate	NN	O
with	IN	O
injectable	JJ	O
norethisterone	JJ	O
enanthate	NN	O
:	:	O
effect	NN	O
on	IN	O
anthropometric	NN	O
,	,	O
metabolic	JJ	O
and	CC	O
biochemical	JJ	O
parameters	NNS	O
.	.	O

Testosterone	CD	O
administered	VBD	O
alone	RB	O
or	CC	O
in	IN	O
combination	NN	O
with	IN	O
progestogens	NNS	O
in	IN	O
male	JJ	O
contraception	NN	O
induces	NNS	O
reversible	JJ	O
oligo-azoospermia	JJ	O
,	,	O
but	CC	O
its	PRP$	O
effects	NNS	O
on	IN	O
body	NN	O
composition	NN	O
and	CC	O
metabolism	NN	O
are	VBP	O
less	RBR	O
known	JJ	O
.	.	O

We	PRP	O
analysed	VBD	O
anthropometric	JJ	O
and	CC	O
metabolic	JJ	O
parameters	NNS	O
in	IN	O
five	CD	O
groups	NNS	O
of	IN	O
10	CD	O
males	NNS	O
:	:	O
four	CD	O
receiving	VBG	O
testosterone	NN	O
undecanoate	NN	O
(	(	O
TU	NNP	O
:	:	O
1000	CD	O
mg	NN	O
)	)	O
plus	CC	O
norethisterone	JJ	O
enanthate	NN	O
(	(	O
NETE	NNP	O
:	:	O
200	CD	O
mg	NN	O
)	)	O
at	IN	O
different	JJ	O
intervals	NNS	O
(	(	O
every	DT	O
8	CD	O
weeks	NNS	O
:	:	O
NETE-8	JJ	O
;	:	O
every	DT	O
12	CD	O
weeks	NNS	O
:	:	O
NETE-12	NN	O
;	:	O
every	DT	O
6	CD	O
weeks	NNS	O
for	IN	O
12	CD	O
weeks	NNS	O
and	CC	O
then	RB	O
every	DT	O
12	CD	O
weeks	NNS	O
:	:	O
NETE-6/12	JJ	O
;	:	O
every	DT	O
6	CD	O
weeks	NNS	O
for	IN	O
12	CD	O
weeks	NNS	O
and	CC	O
then	RB	O
TU	NNP	O
plus	CC	O
placebo	JJ	O
every	DT	O
12	CD	O
weeks	NNS	O
:	:	O
NETE-6/12/0	NNP	O
)	)	O
and	CC	O
one	CD	O
placebo	NN	O
(	(	O
NETE-0/0	NNP	O
)	)	O
for	IN	O
a	DT	O
total	NN	O
of	IN	O
48	CD	O
weeks	NNS	O
.	.	O

Body	NNP	O
mass	NN	O
index	NN	O
(	(	O
BMI	NNP	O
)	)	O
and	CC	O
waist	JJ	O
circumference	NN	O
did	VBD	O
not	RB	O
change	VB	O
in	IN	O
any	DT	O
groups	NNS	O
except	IN	O
for	IN	O
the	DT	O
NETE-8	NNP	O
in	IN	O
which	WDT	O
BMI	NNP	O
increased	VBD	O
significantly	RB	O
(	(	O
p	JJ	O
=	NNP	O
0.02	CD	O
)	)	O
at	IN	O
the	DT	O
end	NN	O
of	IN	O
the	DT	O
treatment	NN	O
period	NN	O
.	.	O

Lean	JJ	O
body	NN	O
mass	NN	O
(	(	O
MAMC	NNP	O
or	CC	O
AMA	NNP	O
)	)	O
increased	VBD	O
significantly	RB	O
in	IN	O
the	DT	O
highest	JJS	O
hormonal	JJ	O
dose	NN	O
groups	NNS	O
(	(	O
p	JJ	O
=	NN	O
0.04	CD	O
,	,	O
NETE-6/12	NNP	O
;	:	O
p	VBZ	O
=	$	O
0.004	CD	O
,	,	O
NETE-8	NNP	O
)	)	O
.	.	O

No	UH	O
differences	NNS	O
were	VBD	O
observed	VBN	O
in	IN	O
glucose	JJ	O
levels	NNS	O
,	,	O
insulin	NN	O
sensitivity	NN	O
index	NN	O
and	CC	O
lipid	JJ	O
profile	NN	O
as	RB	O
well	RB	O
as	IN	O
in	IN	O
biochemical	JJ	O
and	CC	O
cell	NN	O
count	NN	O
parameters	NNS	O
in	IN	O
any	DT	O
groups	NNS	O
.	.	O

In	IN	O
conclusion	NN	O
,	,	O
NETE	NNP	O
and	CC	O
TU	NNP	O
for	IN	O
48	CD	O
weeks	NNS	O
were	VBD	O
not	RB	O
accompanied	VBN	O
by	IN	O
any	DT	O
metabolic	JJ	O
changes	NNS	O
and	CC	O
any	DT	O
adverse	JJ	O
effects	NNS	O
.	.	O

The	DT	O
weight	JJ	O
gain	NN	O
of	IN	O
the	DT	O
highest	JJS	O
NETE	JJ	O
plus	CC	O
TU	JJ	O
dosage	NN	O
was	VBD	O
mainly	RB	O
because	IN	O
of	IN	O
gain	NN	O
in	IN	O
muscle	NN	O
mass	NN	O
.	.	O

Can	MD	O
acupuncture	VB	O
ease	VB	O
the	DT	O
symptoms	NNS	O
of	IN	O
menopause	NN	C
?	.	O
In	IN	O
a	DT	O
randomized	JJ	O
,	,	O
2-group	JJ	O
clinical	JJ	O
study	NN	O
,	,	O
acupuncture	NN	O
was	VBD	O
used	VBN	O
for	IN	O
the	DT	O
relief	NN	O
of	IN	O
menopausal	NN	C
hot	JJ	C
flushes	NNS	C
,	,	O
sleep	JJ	C
disturbances	NNS	C
,	,	O
and	CC	O
mood	NN	C
changes	NNS	C
.	.	O

The	DT	O
experimental	JJ	O
acupuncture	NN	O
treatment	NN	O
consisted	VBD	O
of	IN	O
specific	JJ	O
acupuncture	NN	O
body	NN	O
points	NNS	O
related	VBN	O
to	TO	O
menopausal	VB	O
symptoms	NNS	O
.	.	O

The	DT	O
comparison	JJ	O
acupuncture	NN	O
treatment	NN	O
consisted	VBN	O
of	IN	O
a	DT	O
treatment	NN	O
designated	VBN	O
as	IN	O
a	DT	O
general	JJ	O
tonic	NN	O
specifically	RB	O
designed	VBN	O
to	TO	O
benefit	VB	O
the	DT	O
flow	NN	O
of	IN	O
Ch'i	NNP	O
(	(	O
energy	NN	O
)	)	O
.	.	O

Results	NNS	O
from	IN	O
the	DT	O
experimental	JJ	O
acupuncture	NN	O
treatment	NN	O
group	NN	O
showed	VBD	O
a	DT	O
decrease	NN	O
in	IN	O
mean	JJ	O
monthly	JJ	O
hot	JJ	O
flush	NN	O
severity	NN	O
for	IN	O
site-specific	JJ	O
acupuncture	NN	O
.	.	O

The	DT	O
comparison	JJ	O
acupuncture	NN	O
treatment	NN	O
group	NN	O
had	VBD	O
no	DT	O
significant	JJ	O
change	NN	O
in	IN	O
severity	NN	O
from	IN	O
baseline	NN	O
over	IN	O
the	DT	O
treatment	NN	O
phase	NN	O
.	.	O

Sleep	JJ	O
disturbances	NNS	O
in	IN	O
the	DT	O
experimental	JJ	O
acupuncture	NN	O
treatment	NN	O
group	NN	O
declined	VBD	O
over	IN	O
the	DT	O
study	NN	O
.	.	O

Mood	NNP	O
changes	NNS	O
in	IN	O
both	DT	O
the	DT	O
experimental	JJ	O
acupuncture	NN	O
treatment	NN	O
group	NN	O
and	CC	O
the	DT	O
comparison	NN	O
acupuncture	NN	O
treatment	NN	O
group	NN	O
showed	VBD	O
a	DT	O
significant	JJ	O
difference	NN	O
between	IN	O
the	DT	O
baseline	NN	O
and	CC	O
the	DT	O
third	JJ	O
month	NN	O
of	IN	O
the	DT	O
study	NN	O
.	.	O

Acupuncture	NNP	O
using	VBG	O
menopausal-specific	JJ	O
sites	NNS	O
holds	VBZ	O
promise	NN	O
for	IN	O
nonhormonal	JJ	O
relief	NN	O
of	IN	O
hot	JJ	O
flushes	NNS	O
and	CC	O
sleep	JJ	O
disturbances	NNS	O
.	.	O

First-line	JJ	O
cisplatin	NN	O
with	IN	O
docetaxel	NN	O
or	CC	O
vinorelbine	NN	O
in	IN	O
patients	NNS	O
with	IN	O
advanced	JJ	O
non-small-cell	JJ	O
lung	NN	O
cancer	NN	O
:	:	O
a	DT	O
quality	NN	O
of	IN	O
life	NN	O
directed	VBN	O
phase	NN	O
II	NNP	O
randomized	VBD	O
trial	NN	O
of	IN	O
Gruppo	NNP	O
Oncologico	NNP	O
Italia	NNP	O
Meridionale	NNP	O
.	.	O

BACKGROUND	NNP	O
Quality	NNP	O
of	IN	O
life	NN	O
(	(	O
QoL	NNP	O
)	)	O
has	VBZ	O
gained	VBN	O
greater	JJR	O
importance	NN	O
in	IN	O
the	DT	O
management	NN	O
of	IN	O
metastatic	JJ	O
non-small-cell	JJ	O
lung	NN	O
cancer	NN	O
due	JJ	O
to	TO	O
the	DT	O
palliative	JJ	O
nature	NN	O
of	IN	O
treatment	NN	O
.	.	O

Docetaxel	NNP	O
(	(	O
DCT	NNP	O
)	)	O
and	CC	O
cisplatin	NN	O
(	(	O
CDDP	NNP	O
)	)	O
doublet	NN	O
has	VBZ	O
been	VBN	O
reported	VBN	O
to	TO	O
be	VB	O
associated	VBN	O
to	TO	O
a	DT	O
better	JJR	O
QoL	NNP	O
than	IN	O
the	DT	O
weekly	JJ	O
vinorelbine	NN	O
(	(	O
VNR	NNP	O
)	)	O
and	CC	O
CDDP	NNP	O
regimen	NNS	O
.	.	O

Recently	RB	O
a	DT	O
newer	NN	O
more	RBR	O
tolerated	JJ	O
schedule	NN	O
of	IN	O
the	DT	O
VNR/CDDP	NNP	O
regimen	NN	O
has	VBZ	O
been	VBN	O
published	VBN	O
and	CC	O
is	VBZ	O
widely	RB	O
employed	VBN	O
in	IN	O
medical	JJ	O
practice	NN	O
.	.	O

The	DT	O
impact	NN	O
of	IN	O
these	DT	O
regimens	NNS	O
on	IN	O
patients	NNS	O
'	POS	O
QoL	NNP	O
as	RB	O
well	RB	O
as	IN	O
symptoms	NNS	O
control	NN	O
and	CC	O
type	NN	O
and	CC	O
grading	VBG	O
chemo-related	JJ	O
side-effects	NNS	O
has	VBZ	O
been	VBN	O
compared	VBN	O
prospectically	RB	O
.	.	O

METHODS	NNP	O
Patients	NNPS	O
received	VBD	O
CDDP	NNP	O
75	CD	O
mg/m	NN	O
(	(	O
2	CD	O
)	)	O
plus	CC	O
DCT	NNP	O
75	CD	O
mg/m	NN	O
(	(	O
2	CD	O
)	)	O
on	IN	O
day	NN	O
1	CD	O
every	DT	O
weeks	NNS	O
(	(	O
arm	IN	O
A	NNP	O
)	)	O
or	CC	O
CDDP	$	O
80	CD	O
mg/m	NN	O
(	(	O
2	CD	O
)	)	O
on	IN	O
day	NN	O
1	CD	O
plus	CC	O
VNR	NNP	O
30	CD	O
mg/m	NN	O
(	(	O
2	CD	O
)	)	O
day	NN	O
1	CD	O
and	CC	O
8	CD	O
every	DT	O
3	CD	O
weeks	NNS	O
(	(	O
arm	NN	O
B	NNP	O
)	)	O
.	.	O

G-CSF	NNP	O
and/or	JJ	O
EPO	NNP	O
were	VBD	O
employed	VBN	O
as	IN	O
needed	VBN	O
.	.	O

Health-related	JJ	O
QoL	NNP	O
was	VBD	O
assessed	VBN	O
at	IN	O
entry	NN	O
and	CC	O
after	IN	O
every	DT	O
cycle	NN	O
by	IN	O
the	DT	O
EORTC-QLQ-C30	NNP	O
and	CC	O
LC13	NNP	O
questionnaires	NNS	O
,	,	O
toxicity	NN	O
by	IN	O
the	DT	O
NCI-NCCN	NNP	O
CTC	NNP	O
vs	NN	O
2	CD	O
,	,	O
and	CC	O
intent-to-treat	JJ	O
objective	JJ	O
response	NN	O
by	IN	O
the	DT	O
Recist	NNP	O
criteria	NNS	O
.	.	O

RESULTS	VB	O
The	DT	O
QoL	NNP	O
questionnaires	NNS	O
were	VBD	O
completed	VBN	O
by	IN	O
37	CD	O
pts	NNS	O
(	(	O
88	CD	O
%	NN	O
)	)	O
in	IN	O
the	DT	O
DCT/CDDP	NNP	O
arm	NN	O
and	CC	O
39	CD	O
pts	NNS	O
(	(	O
87	CD	O
%	NN	O
)	)	O
in	IN	O
the	DT	O
VNR/CDDP	NNP	O
one	NN	O
.	.	O

Baseline	JJ	O
mean	JJ	O
scores	NNS	O
and	CC	O
rates	NNS	O
at	IN	O
which	WDT	O
pts	NNS	O
failed	VBD	O
to	TO	O
complete	VB	O
QoL	NNP	O
assessment	NN	O
were	VBD	O
similar	JJ	O
in	IN	O
the	DT	O
two	CD	O
arms	NNS	O
.	.	O

Global	NNP	O
health	NN	O
status	NN	O
of	IN	O
the	DT	O
EORTC	NNP	O
QLQ-C30	NNP	O
scale	NN	O
and	CC	O
specific	JJ	O
symptoms	NNS	O
control	NN	O
(	(	O
LC13	NNP	O
module	NN	O
)	)	O
improved	VBD	O
during	IN	O
treatment	NN	O
without	IN	O
any	DT	O
statistically	RB	O
significant	JJ	O
difference	NN	O
between	IN	O
the	DT	O
two	CD	O
arms	NNS	O
.	.	O

Emotional	JJ	O
functioning	NN	O
remained	VBD	O
stable	JJ	O
in	IN	O
both	DT	O
groups	NNS	O
during	IN	O
treatment	NN	O
,	,	O
whereas	JJ	O
physical	JJ	O
and	CC	O
role	NN	O
improved	VBN	O
slightly	RB	O
.	.	O

In	IN	O
the	DT	O
DCT/CDDP	NNP	O
arm	NN	O
14	CD	O
pts	NNS	O
(	(	O
33	CD	O
%	NN	O
;	:	O
95	CD	O
%	NN	O
CL	NNP	O
24-40	CD	O
%	NN	O
)	)	O
had	VBD	O
PR	NNP	O
,	,	O
and	CC	O
10	CD	O
(	(	O
24	CD	O
%	NN	O
)	)	O
SD	NNP	O
for	IN	O
a	DT	O
57	CD	O
%	NN	O
TGCR	NNP	O
.	.	O

In	IN	O
the	DT	O
VNR/CDDP	NNP	O
arm	NN	O
12	CD	O
pts	NNS	O
(	(	O
27	CD	O
%	NN	O
)	)	O
achieved	VBD	O
PR	NNP	O
,	,	O
18	CD	O
(	(	O
41	CD	O
%	NN	O
)	)	O
SD	VBZ	O
a	DT	O
68	CD	O
%	NN	O
TGCR	NNP	O
.	.	O

Differences	NNS	O
were	VBD	O
not	RB	O
statistically	RB	O
significant	JJ	O
.	.	O

Median	JJ	O
time-to-progression	NN	O
was	VBD	O
4.2	CD	O
months	NNS	O
in	IN	O
the	DT	O
DCT/CDDP	NNP	O
arm	NN	O
and	CC	O
4.5	CD	O
months	NNS	O
in	IN	O
the	DT	O
VNR/CDDP	NNP	O
one	CD	O
,	,	O
and	CC	O
median	JJ	O
overall	JJ	O
survival	NN	O
was	VBD	O
12.1	CD	O
(	(	O
range	VB	O
1-26+	JJ	O
months	NNS	O
)	)	O
and	CC	O
12.5	CD	O
months	NNS	O
(	(	O
range	VB	O
1-28+	JJ	O
months	NNS	O
)	)	O
for	IN	O
DCT/CDDP	NNP	O
and	CC	O
VNR/CDDP	NNP	O
arms	NNS	O
,	,	O
respectively	RB	O
.	.	O

Febrile	NNP	O
neutropenia	JJ	O
rate	NN	O
was	VBD	O
higher	RBR	O
in	IN	O
the	DT	O
VNR/CDDP	NNP	O
arm	NN	O
(	(	O
p=0.02	NN	O
)	)	O
as	RB	O
well	RB	O
as	IN	O
G3-4	NNP	O
anemia	NN	O
(	(	O
p=0.005	NN	O
)	)	O
and	CC	O
G-CSF/EPO	NNP	O
use	NN	O
(	(	O
p=0.019	NN	O
)	)	O
.	.	O

CONCLUSIONS	NNP	O
Global	NNP	O
and	CC	O
specific	JJ	O
health-related	JJ	O
QoL	NNP	O
data	NNS	O
similar	JJ	O
in	IN	O
both	DT	O
treatment	NN	O
groups	NNS	O
with	IN	O
no	DT	O
statistically	RB	O
significant	JJ	O
difference	NN	O
.	.	O

Efficacy	NN	O
measures	NNS	O
,	,	O
overall	JJ	O
response	NN	O
rate	NN	O
,	,	O
time-to-progression	NN	O
and	CC	O
overall	JJ	O
survival	NN	O
were	VBD	O
equivalent	JJ	O
in	IN	O
both	DT	O
arms	NNS	O
.	.	O

However	RB	O
,	,	O
severe	JJ	O
anemia	NN	O
and	CC	O
febrile	JJ	O
neutropenia	NN	O
are	VBP	O
statistically	RB	O
more	RBR	O
frequent	JJ	O
in	IN	O
the	DT	O
VNR/CDDP	NNP	O
arm	NN	O
than	IN	O
in	IN	O
the	DT	O
DCT/CDDP	NNP	O
one	NN	O
.	.	O

These	DT	O
data	NNS	O
should	MD	O
be	VB	O
considered	VBN	O
in	IN	O
treatment	NN	O
decision-making	NN	O
for	IN	O
pts	NNS	O
with	IN	O
advanced	JJ	O
non-small-cell	JJ	O
lung	NN	O
cancer	NN	O
and	CC	O
for	IN	O
the	DT	O
design	NN	O
of	IN	O
future	JJ	O
trials	NNS	O
with	IN	O
chemotherapy	NN	O
plus	CC	O
biologics	NNS	O
.	.	O

Can	MD	O
incentives	VB	O
undermine	JJ	O
intrinsic	JJ	O
motivation	NN	O
to	TO	O
participate	VB	O
in	IN	O
epidemiologic	JJ	O
surveys	NNS	O
?	.	O
Response	JJ	O
rates	NNS	O
to	TO	O
surveys	NNS	O
are	VBP	O
decreasing	VBG	O
.	.	O

The	DT	O
purpose	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
evaluate	VB	O
the	DT	O
use	NN	O
of	IN	O
lottery	JJ	O
tickets	NNS	O
as	IN	O
incentives	NNS	O
in	IN	O
an	DT	O
epidemiologic	JJ	O
control	NN	O
group	NN	O
.	.	O

A	DT	O
self-administered	JJ	O
questionnaire	NN	O
was	VBD	O
sent	VBN	O
to	TO	O
parents	NNS	O
in	IN	O
the	DT	O
municipality	NN	O
of	IN	O
Stockholm	NNP	O
,	,	O
Sweden	NNP	O
,	,	O
who	WP	O
were	VBD	O
to	TO	O
be	VB	O
used	VBN	O
as	IN	O
a	DT	O
control	NN	O
group	NN	O
in	IN	O
a	DT	O
study	NN	O
addressing	VBG	O
stress	NN	O
in	IN	O
parents	NNS	O
of	IN	O
children	NNS	A
with	IN	O
cancer	NN	C
.	.	O

A	DT	O
stratified	JJ	O
random	JJ	O
sample	NN	O
of	IN	O
450	CD	SS
parents	NNS	O
were	VBD	O
randomized	VBN	O
into	IN	O
three	CD	O
incentive	JJ	O
groups	NNS	O
:	:	O
(	(	O
a	DT	O
)	)	O
no	DT	O
incentive	NN	O
;	:	O
(	(	O
b	NN	O
)	)	O
a	DT	O
promised	JJ	O
incentive	NN	O
of	IN	O
one	CD	O
lottery	NN	O
ticket	NN	O
to	TO	O
be	VB	O
received	VBN	O
upon	IN	O
reply	NN	O
;	:	O
(	(	O
c	NN	O
)	)	O
a	DT	O
promised	JJ	O
incentive	NN	O
of	IN	O
one	CD	O
lottery	NN	O
ticket	NN	O
to	TO	O
be	VB	O
received	VBN	O
upon	IN	O
reply	NN	O
and	CC	O
an	DT	O
additional	JJ	O
lottery	NN	O
ticket	NN	O
upon	IN	O
reply	NN	O
within	IN	O
1	CD	O
week	NN	O
.	.	O

The	DT	O
overall	JJ	O
response	NN	O
rate	NN	O
across	IN	O
the	DT	O
three	CD	O
groups	NNS	O
was	VBD	O
65.3	CD	O
%	NN	O
.	.	O

The	DT	O
response	NN	O
rate	NN	O
was	VBD	O
highest	JJS	O
in	IN	O
the	DT	O
no	DT	O
incentive	NN	O
group	NN	O
(	(	O
69.3	CD	O
%	NN	O
)	)	O
and	CC	O
lowest	JJS	O
in	IN	O
the	DT	O
one	CD	O
plus	CC	O
one	CD	O
lottery	NN	O
ticket	NN	O
group	NN	O
(	(	O
62.0	CD	O
%	NN	O
)	)	O
.	.	O

In	IN	O
a	DT	O
survival	JJ	O
analysis	NN	O
,	,	O
the	DT	O
difference	NN	O
between	IN	O
the	DT	O
two	CD	O
response	NN	O
curves	NNS	O
was	VBD	O
significant	JJ	O
by	IN	O
the	DT	O
log-rank	JJ	O
test	NN	O
(	(	O
P	NNP	O
=	NNP	O
0.04	CD	O
)	)	O
,	,	O
with	IN	O
the	DT	O
no	DT	O
incentive	NN	O
group	NN	O
having	VBG	O
a	DT	O
shorter	JJR	O
time	NN	O
to	TO	O
response	NN	O
than	IN	O
the	DT	O
incentive	NN	O
group	NN	O
.	.	O

Our	PRP$	O
findings	NNS	O
suggest	VBP	O
that	IN	O
the	DT	O
use	NN	O
of	IN	O
lottery	JJ	O
tickets	NNS	O
as	IN	O
incentives	NNS	O
to	TO	O
increase	VB	O
participation	NN	O
in	IN	O
a	DT	O
mail	NN	O
questionnaire	NN	O
among	IN	O
parents	NNS	O
may	MD	O
be	VB	O
less	RBR	O
valuable	JJ	O
or	CC	O
even	RB	O
harmful	JJ	O
.	.	O

Incentives	NNS	O
may	MD	O
undermine	VB	O
motivation	NN	O
in	IN	O
studies	NNS	O
in	IN	O
which	WDT	O
the	DT	O
intrinsic	JJ	O
motivation	NN	O
of	IN	O
the	DT	O
respondents	NNS	O
is	VBZ	O
already	RB	O
high	JJ	O
.	.	O

Augmented	VBN	O
soft	JJ	O
tissue	NN	O
mobilization	NN	O
vs	IN	O
natural	JJ	O
history	NN	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
lateral	JJ	O
epicondylitis	NN	O
:	:	O
a	DT	O
pilot	NN	O
study	NN	O
.	.	O

OBJECTIVE	CC	O
The	DT	O
purpose	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
evaluate	VB	O
the	DT	O
effect	NN	O
of	IN	O
augmented	JJ	O
soft	JJ	O
tissue	NN	O
mobilization	NN	O
(	(	O
ASTM	NNP	O
)	)	O
on	IN	O
the	DT	O
treatment	NN	O
of	IN	O
lateral	JJ	O
epicondylitis	NN	O
.	.	O

METHODS	NNP	O
This	DT	O
randomized	VBD	O
clinical	JJ	O
study	NN	O
assessed	VBD	O
27	CD	SS
subjects	NNS	O
(	(	O
12	CD	SS
men	NNS	SE
and	CC	O
15	CD	SS
women	NNS	SE
)	)	O
with	IN	O
lateral	JJ	C
epicondylitis	NN	C
and	CC	O
were	VBD	O
divided	VBN	O
randomly	RB	O
into	IN	O
2	CD	O
groups	NNS	O
.	.	O

The	DT	O
experimental	JJ	O
group	NN	O
(	(	O
n	JJ	O
=	NNP	O
15	CD	O
)	)	O
received	VBD	O
ASTM	NNP	O
twice	RB	O
a	DT	O
week	NN	O
for	IN	O
5	CD	O
weeks	NNS	O
.	.	O

The	DT	O
subjects	NNS	O
of	IN	O
the	DT	O
control	NN	O
group	NN	O
(	(	O
n	JJ	O
=	NNP	O
12	CD	O
)	)	O
received	VBN	O
advice	NN	O
on	IN	O
the	DT	O
natural	JJ	O
evolution	NN	O
of	IN	O
lateral	JJ	O
epicondylitis	NN	O
,	,	O
computer	NN	O
ergonomics	NNS	O
,	,	O
and	CC	O
stretching	VBG	O
exercises	NNS	O
.	.	O

Patient-rated	JJ	O
outcome	NN	O
was	VBD	O
assessed	VBN	O
at	IN	O
baseline	NN	O
and	CC	O
after	IN	O
6	CD	O
weeks	NNS	O
and	CC	O
3	CD	O
months	NNS	O
using	VBG	O
a	DT	O
visual	JJ	O
analog	NN	O
scale	NN	O
and	CC	O
the	DT	O
Patient-Rated	JJ	O
Tennis	NNP	O
Elbow	NNP	O
Evaluation	NNP	O
.	.	O

The	DT	O
function	NN	O
was	VBD	O
assessed	VBN	O
using	VBG	O
the	DT	O
pain-free	JJ	O
grip	NN	O
strength	NN	O
at	IN	O
baseline	NN	O
and	CC	O
after	IN	O
6	CD	O
weeks	NNS	O
.	.	O

RESULTS	NNP	O
Both	NNP	O
groups	NNS	O
showed	VBD	O
improvements	NNS	O
in	IN	O
pain-free	JJ	O
grip	NN	O
strength	NN	O
,	,	O
visual	JJ	O
analog	NN	O
scale	NN	O
,	,	O
and	CC	O
Patient-Rated	JJ	O
Tennis	NNP	O
Elbow	NNP	O
Evaluation	NNP	O
.	.	O

Sample	NNP	O
size	NN	O
for	IN	O
larger	JJR	O
future	NN	O
randomized	VBD	O
clinical	JJ	O
trial	NN	O
was	VBD	O
116	CD	O
participants	NNS	O
.	.	O

CONCLUSION	VB	O
A	NNP	O
larger	JJR	O
study	NN	O
investigating	VBG	O
the	DT	O
same	JJ	O
hypothesis	NN	O
is	VBZ	O
warranted	VBN	O
to	TO	O
detect	VB	O
difference	NN	O
in	IN	O
the	DT	O
effects	NNS	O
of	IN	O
these	DT	O
treatments	NNS	O
strategies	NNS	O
.	.	O

The	DT	O
study	NN	O
design	NN	O
is	VBZ	O
feasible	JJ	O
,	,	O
and	CC	O
minor	JJ	O
improvements	NNS	O
will	MD	O
help	VB	O
to	TO	O
minimize	VB	O
the	DT	O
potential	JJ	O
bias	NN	O
.	.	O

Impact	NN	O
of	IN	O
a	DT	O
controlled	VBN	O
heated	VBN	O
breathing	VBG	O
tube	NN	O
humidifier	NN	O
on	IN	O
sleep	JJ	O
quality	NN	O
during	IN	O
CPAP	NNP	O
therapy	NN	O
in	IN	O
a	DT	O
cool	JJ	O
sleeping	NN	O
environment	NN	O
.	.	O

There	EX	O
are	VBP	O
conflicting	VBG	O
data	NNS	O
on	IN	O
the	DT	O
effect	NN	O
of	IN	O
adding	VBG	O
a	DT	O
heated	VBN	O
humidifier	NN	O
to	TO	O
nasal	RB	O
continuous	JJ	O
positive	JJ	O
airway	NN	O
pressure	NN	O
(	(	O
CPAP	NNP	O
)	)	O
therapy	NN	O
for	IN	O
patients	NNS	O
with	IN	O
obstructive	JJ	O
sleep	JJ	O
apnoea	NN	O
syndrome	NN	O
(	(	O
OSAS	NNP	O
)	)	O
.	.	O

The	DT	O
effects	NNS	O
of	IN	O
heated	JJ	O
humidification	NN	O
on	IN	O
sleep	JJ	O
quality	NN	O
and	CC	O
treatment	NN	O
side-effects	NNS	O
for	IN	O
patients	NNS	O
who	WP	O
prefer	VBP	O
a	DT	O
cold	JJ	O
bedroom	NN	O
environment	NN	O
have	VBP	O
not	RB	O
been	VBN	O
studied	VBN	O
.	.	O

A	DT	O
randomised	JJ	O
,	,	O
controlled	VBD	O
crossover	RB	O
trial	NN	O
involving	VBG	O
19	CD	O
patients	NNS	O
with	IN	O
a	DT	O
first-ever	JJ	O
diagnosis	NN	O
of	IN	O
OSAS	NNP	O
measured	VBD	O
the	DT	O
effect	NN	O
of	IN	O
conventional	JJ	O
heated	JJ	O
humidification	NN	O
added	VBD	O
to	TO	O
CPAP	NNP	O
compared	VBN	O
with	IN	O
a	DT	O
controlled	VBN	O
heated	VBN	O
breathing	VBG	O
tube	NN	O
humidifier	NN	O
(	(	O
ThermoSmart	NNP	O
(	(	O
R	NNP	O
)	)	O
;	:	O
Fisher	NNP	O
and	CC	O
Paykel	NNP	O
Healthcare	NNP	O
,	,	O
Auckland	NNP	O
,	,	O
New	NNP	O
Zealand	NNP	O
)	)	O
on	IN	O
sleep	JJ	O
quality	NN	O
.	.	O

During	IN	O
the	DT	O
night	NN	O
in	IN	O
the	DT	O
sleep	JJ	O
laboratory	NN	O
at	IN	O
a	DT	O
mean	JJ	O
room	NN	O
temperature	NN	O
of	IN	O
14	CD	O
degrees	NNS	O
C	NNP	O
,	,	O
less	JJR	O
condensation	NN	O
formed	VBN	O
with	IN	O
the	DT	O
controlled	VBN	O
heated	VBD	O
breathing	VBG	O
tube	NN	O
humidifier	NN	O
(	(	O
1.9	CD	O
mL	NN	O
versus	NN	O
35.3	CD	O
mL	NN	O
)	)	O
in	IN	O
the	DT	O
delivery	NN	O
system	NN	O
.	.	O

In	IN	O
addition	NN	O
,	,	O
the	DT	O
total	JJ	O
sleep	JJ	O
time	NN	O
,	,	O
time	NN	O
spent	VBN	O
in	IN	O
sleep	JJ	O
stages	NNS	O
3	CD	O
and	CC	O
4	CD	O
,	,	O
and	CC	O
rapid	JJ	O
eye	NN	O
movement	NN	O
sleep	JJ	O
phases	NNS	O
were	VBD	O
significantly	RB	O
longer	RBR	O
and	CC	O
the	DT	O
overall	JJ	O
side-effect	JJ	O
score	NN	O
was	VBD	O
lower	JJR	O
than	IN	O
with	IN	O
conventional	JJ	O
heated	JJ	O
humidification	NN	O
.	.	O

Patients	NNS	O
on	IN	O
nasal	JJ	O
continuous	JJ	O
positive	JJ	O
airway	NN	O
pressure	NN	O
desiring	VBG	O
a	DT	O
cool	JJ	O
bedroom	NN	O
temperature	NN	O
could	MD	O
benefit	VB	O
from	IN	O
controlled	VBN	O
heated	VBN	O
breathing	VBG	O
tube	JJ	O
humidification	NN	O
technology	NN	O
(	(	O
with	IN	O
inputs	NNS	O
from	IN	O
ambient	JJ	O
temperature	NN	O
,	,	O
set	VBN	O
pressure	NN	O
and	CC	O
flow	NN	O
)	)	O
.	.	O

Use	NNP	O
of	IN	O
the	DT	O
electrothermal	JJ	O
bipolar	JJ	O
vessel	NN	O
system	NN	O
(	(	O
EBVS	NNP	O
)	)	O
in	IN	O
laparoscopic	JJ	O
adrenalectomy	NN	O
:	:	O
a	DT	O
prospective	JJ	O
study	NN	O
.	.	O

BACKGROUND	NNP	O
Since	IN	O
laparoscopic	NN	C
adrenalectomy	NN	C
(	(	C
LA	NNP	C
)	)	C
has	VBZ	O
been	VBN	O
adopted	VBN	O
as	IN	O
the	DT	O
gold	JJ	O
standard	NN	O
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
adrenal	JJ	O
diseases	NNS	O
,	,	O
the	DT	O
development	NN	O
of	IN	O
technology	NN	O
for	IN	O
vascular	JJ	O
control	NN	O
and	CC	O
dissection	NN	O
manoeuvres	NNS	O
,	,	O
amongst	VBZ	O
other	JJ	O
things	NNS	O
,	,	O
may	MD	O
play	VB	O
a	DT	O
pivotal	JJ	O
role	NN	O
in	IN	O
its	PRP$	O
further	JJ	O
improvement	NN	O
.	.	O

We	PRP	O
report	VBP	O
our	PRP$	O
experience	NN	O
with	IN	O
the	DT	O
electrothermal	JJ	O
bipolar	JJ	O
vessel	NN	O
sealing	NN	O
(	(	O
EBVS	NNP	O
)	)	O
device	NN	O
for	IN	O
LA	NNP	O
.	.	O

METHODS	NNP	O
From	IN	O
January	NNP	O
2004	CD	O
to	TO	O
January	NNP	O
2006	CD	O
,	,	O
50	CD	O
patients	NNS	O
(	(	O
pts	NNS	O
)	)	O
undergoing	VBG	O
LA	NNP	O
were	VBD	O
selected	VBN	O
and	CC	O
randomized	VBN	O
for	IN	O
use	NN	O
of	IN	O
the	DT	O
EBVS	NNP	O
(	(	O
25	CD	O
pts	NNS	O
,	,	O
group	NN	O
A	NNP	O
)	)	O
versus	IN	O
the	DT	O
UltraSonic	NNP	O
Shears	NNP	O
(	(	O
USS	NNP	O
)	)	O
device	NN	O
(	(	O
25	CD	O
pts	NNS	O
,	,	O
group	NN	O
B	NNP	O
)	)	O
.	.	O

Age	NNP	O
,	,	O
sex	NN	O
,	,	O
body	NN	O
mass	NN	O
index	NN	O
(	(	O
BMI	NNP	O
)	)	O
,	,	O
previous	JJ	O
surgery	NN	O
and	CC	O
associated	VBN	O
diseases	NNS	O
were	VBD	O
similar	JJ	O
between	IN	O
the	DT	O
two	CD	O
groups	NNS	O
.	.	O

The	DT	O
main	JJ	O
surgical	JJ	O
parameters	NNS	O
collected	VBN	O
for	IN	O
each	DT	O
patient	NN	O
(	(	O
pt	NN	O
)	)	O
concerned	VBD	O
operative	JJ	O
time	NN	O
,	,	O
major	JJ	O
and	CC	O
minor	JJ	O
complications	NNS	O
,	,	O
conversion	NN	O
rate	NN	O
,	,	O
blood	NN	O
loss	NN	O
,	,	O
hospital	JJ	O
stay	NN	O
and	CC	O
histology	NN	O
.	.	O

RESULTS	NNP	O
There	EX	O
was	VBD	O
no	DT	O
mortality	NN	O
in	IN	O
either	DT	O
group	NN	O
.	.	O

The	DT	O
right	JJ	O
adrenalectomy	NN	O
mean	VB	O
operative	JJ	O
time	NN	O
(	(	O
OpT	NNP	O
)	)	O
was	VBD	O
51.8	CD	O
mins	NNS	O
(	(	O
range	VB	O
40-90	JJ	O
mins	NNS	O
)	)	O
and	CC	O
68.6	CD	O
mins	NNS	O
(	(	O
range	VB	O
50-130	NNP	O
mins	NNS	O
)	)	O
in	IN	O
group	NN	O
A	NNP	O
and	CC	O
B	NNP	O
,	,	O
respectively	RB	O
(	(	O
P	NNP	O
not	RB	O
significant	JJ	O
)	)	O
.	.	O

The	DT	O
left	JJ	O
adrenalectomy	JJ	O
mean	JJ	O
OpT	NNP	O
was	VBD	O
72.2	CD	O
mins	NNS	O
(	(	O
range	VB	O
55-100	NNP	O
mins	NNS	O
)	)	O
and	CC	O
94	CD	O
mins	NNS	O
(	(	O
range	VB	O
65-140	NNP	O
mins	NNS	O
)	)	O
for	IN	O
group	NN	O
A	NNP	O
and	CC	O
B	NNP	O
,	,	O
respectively	RB	O
(	(	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
.	.	O

The	DT	O
mean	JJ	O
blood	NN	O
loss	NN	O
was	VBD	O
83	CD	O
ml	NN	O
(	(	O
group	NN	O
A	NNP	O
)	)	O
and	CC	O
210	CD	O
ml	NN	O
(	(	O
group	NN	O
B	NNP	O
)	)	O
(	(	O
p	JJ	O
<	NNP	O
0.05	CD	O
)	)	O
.	.	O

Complications	NNS	O
were	VBD	O
not	RB	O
different	JJ	O
for	IN	O
the	DT	O
two	CD	O
groups	NNS	O
.	.	O

The	DT	O
mean	JJ	O
hospital	NN	O
stay	NN	O
was	VBD	O
2.9	CD	O
and	CC	O
3.1	CD	O
days	NNS	O
in	IN	O
group	NN	O
A	NNP	O
and	CC	O
B	NNP	O
,	,	O
respectively	RB	O
(	(	O
P	NNP	O
not	RB	O
significant	JJ	O
)	)	O
.	.	O

CONCLUSIONS	NNP	O
EBVS	NNP	O
in	IN	O
LA	NNP	O
may	MD	O
provide	VB	O
a	DT	O
significantly	RB	O
short	JJ	O
operating	NN	O
time	NN	O
and	CC	O
blood	NN	O
loss	NN	O
.	.	O

Untoward	NNP	O
effects	NNS	O
of	IN	O
fenfluramine	NN	O
in	IN	O
autistic	JJ	C
children	NNS	A
.	.	O

Several	JJ	O
recent	JJ	O
studies	NNS	O
have	VBP	O
described	VBN	O
the	DT	O
benefits	NNS	O
of	IN	O
fenfluramine	NN	O
for	IN	O
the	DT	O
symptomatic	JJ	O
treatment	NN	O
of	IN	O
infantile	JJ	A
autism	NN	O
.	.	O

No	DT	O
large	JJ	O
surveys	NNS	O
of	IN	O
side	JJ	O
effects	NNS	O
of	IN	O
this	DT	O
drug	NN	O
have	VBP	O
been	VBN	O
reported	VBN	O
in	IN	O
autistic	JJ	O
children	NNS	O
.	.	O

To	TO	O
evaluate	VB	O
the	DT	O
untoward	JJ	O
effects	NNS	O
of	IN	O
fenfluramine	NN	O
in	IN	O
children	NNS	O
with	IN	O
autism	NN	O
,	,	O
12	CD	SS
subjects	NNS	O
were	VBD	O
systematically	RB	O
studied	VBN	O
.	.	O

Medication	NNP	O
was	VBD	O
administered	VBN	O
in	IN	O
a	DT	O
double-blind	JJ	O
,	,	O
placebo-controlled	JJ	O
cross-over	NN	O
study	NN	O
.	.	O

Parents	NNS	O
were	VBD	O
trained	VBN	O
in	IN	O
monitoring	VBG	O
untoward	JJ	O
effects	NNS	O
.	.	O

These	DT	O
observations	NNS	O
were	VBD	O
compiled	VBN	O
in	IN	O
detailed	JJ	O
daily	JJ	O
notes	NNS	O
.	.	O

In	IN	O
addition	NN	O
,	,	O
four	CD	O
cases	NNS	C
describing	VBG	C
unusual	JJ	C
effects	NNS	C
found	VBN	O
in	IN	O
a	DT	O
sample	NN	O
of	IN	O
170	CD	O
patients	NNS	O
treated	VBN	O
with	IN	O
fenfluramine	NN	O
are	VBP	O
also	RB	O
reported	VBN	O
.	.	O

In	IN	O
the	DT	O
initial	JJ	O
2	CD	O
weeks	NNS	O
of	IN	O
active	JJ	O
drug	NN	O
listlessness	NN	O
,	,	O
food	NN	O
refusal	NN	O
,	,	O
and	CC	O
stomach	NN	O
upset	NN	O
were	VBD	O
frequently	RB	O
seen	VBN	O
.	.	O

A	DT	O
different	JJ	O
pattern	NN	O
of	IN	O
untoward	JJ	O
effects	NNS	O
was	VBD	O
seen	VBN	O
in	IN	O
the	DT	O
final	JJ	O
14	CD	O
weeks	NNS	O
of	IN	O
treatment	NN	O
.	.	O

Irritability	NNP	O
,	,	O
agitation	NN	O
,	,	O
and	CC	O
crying	VBG	O
along	RB	O
with	IN	O
continued	VBN	O
food	NN	O
refusal	NN	O
were	VBD	O
noted	VBN	O
.	.	O

The	DT	O
subjects	NNS	O
lost	VBD	O
2.1	CD	O
%	NN	O
of	IN	O
body	NN	O
weight	NN	O
during	IN	O
active	JJ	O
drug	NN	O
phase	NN	O
,	,	O
but	CC	O
there	RB	O
was	VBD	O
a	DT	O
rebound	NN	O
weight	NN	O
gain	NN	O
during	IN	O
the	DT	O
subsequent	JJ	O
placebo	NN	O
phase	NN	O
.	.	O

A	DT	O
thorough	JJ	O
understanding	NN	O
of	IN	O
fenfluramine	NN	O
's	POS	O
side	NN	O
effects	NNS	O
and	CC	O
adverse	JJ	O
reactions	NNS	O
is	VBZ	O
necessary	JJ	O
so	RB	O
as	IN	O
to	TO	O
differentiate	VB	O
them	PRP	O
from	IN	O
the	DT	O
multiple	NN	O
symptoms	NNS	O
inherent	NN	O
in	IN	O
the	DT	O
syndrome	NN	O
of	IN	O
autism	NN	O
.	.	O

Locomoting-to-reach	NN	O
:	:	O
information	NN	O
variables	NNS	O
and	CC	O
control	NN	O
strategies	NNS	O
for	IN	O
nested	JJ	O
actions	NNS	O
.	.	O

Locomoting-to-reach	NNP	O
is	VBZ	O
a	DT	O
basic	JJ	O
perception/action	NN	O
behavior	NN	O
that	WDT	O
requires	VBZ	O
visual	JJ	O
information	NN	O
for	IN	O
the	DT	O
control	NN	O
of	IN	O
both	DT	O
locomotion	NN	O
and	CC	O
reaching	VBG	O
components	NNS	O
.	.	O

We	PRP	O
investigated	VBD	O
the	DT	O
visual	JJ	O
information	NN	O
and	CC	O
the	DT	O
control	NN	O
strategies	NNS	O
used	VBN	O
to	TO	O
guide	VB	O
both	PDT	O
the	DT	O
head	NN	O
and	CC	O
the	DT	O
hand	NN	O
on	IN	O
approach	NN	O
to	TO	O
a	DT	O
target	NN	O
in	IN	O
a	DT	O
locomotion-to-reach	JJ	O
task	NN	O
.	.	O

In	IN	O
this	DT	O
study	NN	O
,	,	O
participants	NNS	C
were	VBD	C
required	VBN	C
to	TO	C
locomote	VB	C
in	IN	C
the	DT	C
dark	NN	C
to	TO	C
a	DT	C
lit	NN	C
target	NN	C
in	IN	C
three	CD	C
different	JJ	C
conditions	NNS	C
:	:	C
monocular	JJ	C
vision/target	NN	C
with	IN	C
image	NN	C
size	NN	C
,	,	C
binocular	JJ	C
vision/target	NN	C
with	IN	C
image	NN	C
size	NN	C
,	,	C
and	CC	C
binocular	JJ	C
vision/point-light	JJ	C
target	NN	C
(	(	C
without	IN	C
image	NN	C
size	NN	C
)	)	C
.	.	C

In	IN	O
task	NN	O
one	CD	O
,	,	O
participants	NNS	O
brought	VBD	O
their	PRP$	O
eyes	NNS	O
to	TO	O
the	DT	O
target	NN	O
.	.	O

In	IN	O
task	NN	O
two	CD	O
,	,	O
participants	NNS	O
brought	VBD	O
their	PRP$	O
outstretched	JJ	O
hand	NN	O
to	TO	O
the	DT	O
target	NN	O
.	.	O

Movement	JJ	O
trajectories	NNS	O
for	IN	O
both	DT	O
tasks	NNS	O
were	VBD	O
analyzed	VBN	O
.	.	O

Results	NNP	O
show	VBP	O
that	IN	O
participants	NNS	O
were	VBD	O
significantly	RB	O
more	RBR	O
accurate	JJ	O
when	WRB	O
binocular	JJ	O
information	NN	O
was	VBD	O
present	JJ	O
.	.	O

In	IN	O
both	DT	O
tasks	NNS	O
,	,	O
participants	NNS	O
were	VBD	O
found	VBN	O
to	TO	O
use	VB	O
a	DT	O
proportional	JJ	O
rate	NN	O
control	NN	O
strategy	NN	O
rather	RB	O
than	IN	O
a	DT	O
constant	JJ	O
?	.	O
strategy	NN	O
.	.	O

In	IN	O
the	DT	O
walk-to-reach	NN	O
task	NN	O
,	,	O
they	PRP	O
used	VBD	O
monocular	JJ	O
and/or	NN	O
binocular	NN	O
?	.	O
information	NN	O
to	TO	O
guide	VB	O
the	DT	O
head	NN	O
and	CC	O
then	RB	O
switched	VBD	O
to	TO	O
using	VBG	O
relative	JJ	O
disparity	NN	O
?	.	O
to	TO	O
guide	VB	O
the	DT	O
hand	NN	O
to	TO	O
final	JJ	O
target	NN	O
acquisition	NN	O
,	,	O
switching	VBG	O
when	WRB	O
the	DT	O
hand	NN	O
centric	NN	O
?	.	O
became	VBD	O
less	JJR	O
than	IN	O
the	DT	O
head	NN	O
centric	JJ	O
?.	NNP	O
Dynamical	NNP	O
models	NNS	O
of	IN	O
the	DT	O
information	NN	O
and	CC	O
control	NN	O
strategies	NNS	O
were	VBD	O
used	VBN	O
to	TO	O
perform	VB	O
simulations	NNS	O
that	WDT	O
were	VBD	O
found	VBN	O
to	TO	O
fit	VB	O
the	DT	O
data	NN	O
well	RB	O
.	.	O

The	DT	O
conclusion	NN	O
is	VBZ	O
that	IN	O
proportional	JJ	O
rate	NN	O
control	NN	O
is	VBZ	O
used	VBN	O
sequentially	RB	O
with	IN	O
head	NN	O
centric	NN	O
,	,	O
then	RB	O
hand-centric	JJ	O
?-based	JJ	O
information	NN	O
,	,	O
using	VBG	O
at	IN	O
each	DT	O
moment	NN	O
the	DT	O
?	.	O
with	IN	O
the	DT	O
smallest	JJS	O
value	NN	O
.	.	O

Implementing	VBG	O
a	DT	O
simplified	JJ	O
neonatal	JJ	C
resuscitation	NN	C
protocol-helping	JJ	C
babies	NNS	C
breathe	VBP	C
at	IN	C
birth	NN	C
(	(	O
HBB	NNP	O
)	)	O
-	:	O
at	IN	O
a	DT	O
tertiary	JJ	O
level	NN	O
hospital	NN	O
in	IN	O
Nepal	NNP	O
for	IN	O
an	DT	O
increased	JJ	O
perinatal	NN	O
survival	NN	O
.	.	O

BACKGROUND	NNP	O
Reducing	NNP	O
neonatal	JJ	O
death	NN	O
has	VBZ	O
been	VBN	O
an	DT	O
emerging	VBG	O
challenge	NN	O
in	IN	O
low	JJ	O
and	CC	O
middle	JJ	O
income	NN	O
countries	NNS	O
in	IN	O
the	DT	O
past	JJ	O
decade	NN	O
.	.	O

The	DT	O
development	NN	O
of	IN	O
the	DT	O
low	JJ	O
cost	NN	O
interventions	NNS	O
and	CC	O
their	PRP$	O
effective	JJ	O
delivery	NN	O
are	VBP	O
needed	VBN	O
to	TO	O
reduce	VB	O
deaths	NNS	O
from	IN	O
birth	NN	O
asphyxia	NN	O
.	.	O

This	DT	O
study	NN	O
will	MD	O
assess	VB	O
the	DT	O
impact	NN	O
of	IN	O
a	DT	O
simplified	JJ	O
neonatal	JJ	O
resuscitation	NN	O
protocol	NN	O
provided	VBN	O
by	IN	O
Helping	VBG	O
Babies	NNS	O
Breathe	NNP	O
(	(	O
HBB	NNP	O
)	)	O
at	IN	O
a	DT	O
tertiary	JJ	O
hospital	NN	O
in	IN	O
Nepal	NNP	O
.	.	O

Perinatal	NNP	O
outcomes	NNS	O
and	CC	O
performance	NN	O
of	IN	O
skilled	JJ	O
birth	NN	O
attendants	NNS	O
on	IN	O
management	NN	O
of	IN	O
intrapartum-related	JJ	O
neonatal	JJ	O
hypoxia	NN	O
will	MD	O
be	VB	O
the	DT	O
main	JJ	O
measurements	NNS	O
.	.	O

METHODS/DESIGN	NNP	O
The	DT	O
study	NN	O
will	MD	O
be	VB	O
carried	VBN	O
out	RP	O
at	IN	O
a	DT	O
tertiary	JJ	O
level	NN	O
maternity	NN	O
hospital	NN	O
in	IN	O
Nepal	NNP	O
.	.	O

A	DT	O
prospective	JJ	O
cohort-study	NN	O
will	MD	O
include	VB	O
a	DT	O
six-month	JJ	O
baseline	NN	O
a	DT	O
six	CD	O
month	NN	O
intervention	NN	O
period	NN	O
and	CC	O
a	DT	O
three-month	JJ	O
post	NN	O
intervention	NN	O
period	NN	O
.	.	O

A	DT	O
quality	NN	O
improvement	NN	O
process	NN	O
cycle	NN	O
will	MD	O
introduce	VB	O
the	DT	O
neonatal	JJ	O
resuscitation	NN	O
protocol	NN	O
.	.	O

A	DT	O
surveillance	NN	O
system	NN	O
,	,	O
including	VBG	O
CCD	NNP	O
cameras	NNS	O
and	CC	O
pulse	JJ	O
oximeters	NNS	O
,	,	O
will	MD	O
be	VB	O
set	VBN	O
up	RP	O
to	TO	O
evaluate	VB	O
the	DT	O
intervention	NN	O
.	.	O

DISCUSSION	NNP	O
Along	IN	O
with	IN	O
a	DT	O
technique	NN	O
to	TO	O
improve	VB	O
health	NN	O
workers	NNS	O
performance	NN	O
on	IN	O
the	DT	O
protocol	NN	O
,	,	O
the	DT	O
study	NN	O
will	MD	O
generate	VB	O
evidence	NN	O
on	IN	O
the	DT	O
research	NN	O
gap	NN	O
on	IN	O
the	DT	O
effectiveness	NN	O
of	IN	O
the	DT	O
simplified	JJ	O
neonatal	JJ	O
resuscitation	NN	O
protocol	NN	O
on	IN	O
intrapartum	NN	O
outcome	NN	O
and	CC	O
early	JJ	O
neonatal	JJ	O
survival	NN	O
.	.	O

This	DT	O
will	MD	O
generate	VB	O
a	DT	O
global	JJ	O
interest	NN	O
and	CC	O
inform	NN	O
policymaking	NN	O
in	IN	O
relation	NN	O
to	TO	O
delivery	NN	O
care	NN	O
in	IN	O
all	DT	O
income	NN	O
settings	NNS	O
.	.	O

TRIAL	NNP	O
REGISTRATION	NNP	O
ISRCTN97846009	NNP	O
.	.	O

Improving	VBG	O
the	DT	O
immunogenicity	NN	O
of	IN	O
pneumococcal	JJ	O
conjugate	NN	O
vaccine	NN	O
in	IN	O
HIV-infected	NNP	O
adults	NNS	O
with	IN	O
a	DT	O
toll-like	JJ	O
receptor	NN	O
9	CD	O
agonist	NN	O
adjuvant	NN	O
:	:	O
a	DT	O
randomized	NN	O
,	,	O
controlled	VBN	O
trial	NN	O
.	.	O

BACKGROUND	NNP	O
Persons	NNP	O
infected	VBD	O
with	IN	O
human	JJ	O
immunodeficiency	NN	O
virus	NN	O
(	(	O
HIV	NNP	O
)	)	O
are	VBP	O
often	RB	O
hyporesponsive	JJ	O
to	TO	O
immunization	NN	O
,	,	O
including	VBG	O
pneumococcal	JJ	O
vaccines	NNS	O
.	.	O

We	PRP	O
hypothesized	VBD	O
that	IN	O
adding	VBG	O
CPG	NNP	O
7909	CD	O
,	,	O
a	DT	O
toll-like	JJ	O
receptor	NN	O
9	CD	O
(	(	O
TLR9	NNP	O
)	)	O
agonist	NN	O
and	CC	O
vaccine	NN	O
adjuvant	NN	O
,	,	O
to	TO	O
7-valent	JJ	O
pneumococcal	JJ	O
conjugate	NN	O
vaccine	NN	O
(	(	O
7vPnC	CD	O
)	)	O
would	MD	O
increase	VB	O
its	PRP$	O
immunogenicity	NN	O
in	IN	O
HIV-infected	NNP	O
adults	NNS	O
.	.	O

METHODS	NNP	O
We	PRP	O
performed	VBD	O
a	DT	O
double-blind	JJ	O
,	,	O
placebo-controlled	JJ	O
,	,	O
phase	VB	O
1b/2a	CD	O
trial	NN	O
randomizing	VBG	O
HIV-positive	JJ	O
patients	NNS	O
to	TO	O
receive	VB	O
double	JJ	O
doses	NNS	O
of	IN	O
7vPnC	CD	O
(	(	O
Prevnar	NNP	O
)	)	O
at	IN	O
0	CD	O
and	CC	O
3	CD	O
months	NNS	O
and	CC	O
1	CD	O
dose	NN	O
of	IN	O
23-valent	JJ	O
pneumococcal	JJ	O
polysaccharide	NN	O
vaccine	NN	O
(	(	O
PPV-23	NNP	O
;	:	O
Pneumo	NNP	O
Novum	NNP	O
)	)	O
at	IN	O
9	CD	O
months	NNS	O
,	,	O
with	IN	O
experimental	JJ	O
patients	NNS	O
receiving	VBG	O
1	CD	O
mg	NN	O
of	IN	O
CPG	NNP	O
7909	CD	O
added	VBD	O
to	TO	O
each	DT	O
of	IN	O
their	PRP$	O
3	CD	O
vaccine	NN	O
doses	NNS	O
;	:	O
control	NN	O
patients	NNS	O
had	VBD	O
phosphate-buffered	JJ	O
saline	NN	O
added	VBN	O
instead	RB	O
.	.	O

Immunogenicity	NNP	O
and	CC	O
safety	NN	O
were	VBD	O
evaluated	VBN	O
for	IN	O
up	RB	O
to	TO	O
10	CD	O
months	NNS	O
.	.	O

The	DT	O
primary	JJ	O
end	NN	O
point	NN	O
was	VBD	O
the	DT	O
proportion	NN	O
of	IN	O
vaccine	NN	O
high	JJ	O
responders	NNS	O
at	IN	O
9	CD	O
months	NNS	O
,	,	O
defined	VBD	O
as	IN	O
a	DT	O
2-fold	JJ	O
increase	NN	O
in	IN	O
IgG	NNP	O
levels	NNS	O
to	TO	O
>	VB	O
or	CC	O
=	VB	O
1	CD	O
microg/mL	NN	O
for	IN	O
at	IN	O
least	JJS	O
5	CD	O
of	IN	O
7	CD	O
of	IN	O
the	DT	O
7vPnC	CD	O
serotypes	NNS	O
.	.	O

RESULTS	NNP	O
Ninety-seven	JJ	O
participants	NNS	O
were	VBD	O
included	VBN	O
in	IN	O
the	DT	O
study	NN	O
.	.	O

The	DT	O
proportion	NN	O
of	IN	O
vaccine	NN	O
high	JJ	O
responders	NNS	O
was	VBD	O
higher	RBR	O
in	IN	O
the	DT	O
experimental	JJ	O
group	NN	O
(	(	O
n	JJ	O
=	NNP	O
48	CD	O
)	)	O
than	IN	O
among	IN	O
controls	NNS	O
(	(	O
n	JJ	O
=	VBZ	O
49	CD	O
;	:	O
48.8	CD	O
%	NN	O
vs	JJ	O
25.0	CD	O
%	NN	O
;	:	O
P	NNP	O
=	NNP	O
.02	NNP	O
)	)	O
at	IN	O
9	CD	O
months	NNS	O
.	.	O

Greater	NNP	O
proportions	NNS	O
of	IN	O
high	JJ	O
responders	NNS	O
were	VBD	O
also	RB	O
observed	VBN	O
at	IN	O
3	CD	O
(	(	O
51.1	CD	O
%	NN	O
vs	JJ	O
39.6	CD	O
%	NN	O
;	:	O
P	NNP	O
=	NNP	O
.26	NNP	O
)	)	O
,	,	O
4	CD	O
(	(	O
77.3	CD	O
%	NN	O
vs	JJ	O
56.3	CD	O
%	NN	O
;	:	O
P	NNP	O
=	NNP	O
.03	NNP	O
)	)	O
,	,	O
and	CC	O
10	CD	O
months	NNS	O
(	(	O
87.8	CD	O
%	NN	O
vs	JJ	O
51.1	CD	O
%	NN	O
;	:	O
P	NNP	O
<	NNP	O
.001	NNP	O
)	)	O
.	.	O

Mild	NNP	O
systemic	JJ	O
and	CC	O
injection	NN	O
site	NN	O
reactions	NNS	O
to	TO	O
7vPnC	CD	O
were	VBD	O
more	JJR	O
common	JJ	O
in	IN	O
the	DT	O
experimental	JJ	O
group	NN	O
than	IN	O
the	DT	O
control	NN	O
group	NN	O
(	(	O
100	CD	O
%	NN	O
vs	JJ	O
81.3	CD	O
%	NN	O
;	:	O
P	NNP	O
=	NNP	O
.002	NNP	O
)	)	O
.	.	O

CPG	JJ	O
7909	CD	O
did	VBD	O
not	RB	O
increase	VB	O
non-7vPnC	JJ	O
IgG	NNP	O
levels	NNS	O
after	IN	O
PPV-23	NNP	O
immunization	NN	O
.	.	O

No	DT	O
adverse	JJ	O
effects	NNS	O
on	IN	O
CD4	NNP	O
(	(	O
+	NNP	O
)	)	O
cell	NN	O
count	NN	O
or	CC	O
organ	JJ	O
functions	NNS	O
occurred	VBD	O
in	IN	O
either	DT	O
group	NN	O
.	.	O

CONCLUSIONS	VB	O
The	DT	O
addition	NN	O
of	IN	O
a	DT	O
TLR9	NNP	O
agonist	NN	O
to	TO	O
7vPnC	CD	O
significantly	RB	O
enhanced	VBD	O
the	DT	O
proportion	NN	O
of	IN	O
vaccine	NN	O
high	JJ	O
responders	NNS	O
.	.	O

TRIAL	NNP	O
REGISTRATION	NNP	O
ClinicalTrials.gov	NNP	O
identifier	NN	O
:	:	O
NCT00562939	NNP	O
.	.	O

Long	JJ	O
term	NN	O
response	NN	O
to	TO	O
therapy	NN	O
of	IN	O
chronic	JJ	C
anti-HBe-positive	JJ	C
hepatitis	NN	C
B	NNP	C
is	VBZ	O
poor	JJ	O
independent	JJ	O
of	IN	O
type	NN	O
and	CC	O
schedule	NN	O
of	IN	O
interferon	NN	O
.	.	O

OBJECTIVE	CC	O
The	DT	O
response	NN	O
rate	NN	O
to	TO	O
alpha	VB	O
interferon	NN	O
(	(	O
IFN	NNP	O
)	)	O
of	IN	O
chronic	JJ	O
anti-HBe-positive	JJ	O
hepatitis	NN	O
B	NNP	O
is	VBZ	O
variable	JJ	O
.	.	O

We	PRP	O
studied	VBD	O
whether	IN	O
type	NN	O
,	,	O
dose	NN	O
,	,	O
and	CC	O
schedule	NN	O
of	IN	O
IFN	NNP	O
,	,	O
and	CC	O
type	NN	O
and	CC	O
frequency	NN	O
of	IN	O
posttreatment	NN	O
monitoring	NN	O
,	,	O
influence	VB	O
the	DT	O
response	NN	O
rate	NN	O
.	.	O

METHODS	NNP	O
Seventy-two	JJ	SS
consecutive	JJ	O
anti-HBe-positive	JJ	O
chronic	NN	O
hepatitis	NN	O
B	NNP	O
patients	NNS	O
(	(	O
59	CD	SS
male	NN	SE
and	CC	O
13	CD	SS
female	NN	SE
,	,	O
median	JJ	O
age	NN	O
41	CD	A
yr	NN	A
)	)	O
stratified	VBN	O
by	IN	O
sex	NN	O
and	CC	O
histology	NN	O
were	VBD	O
randomly	RB	O
allocated	VBN	O
to	TO	O
three	CD	O
treatment	NN	O
arms	NNS	O
.	.	O

Twenty-seven	JJ	O
patients	NNS	O
(	(	O
A	DT	O
)	)	O
received	VBD	O
10	CD	O
million	CD	O
units	NNS	O
alpha-N1	JJ	O
IFN	NNP	O
i.m	NN	O
.	.	O

t.w	NN	O
.	.	O

for	IN	O
24	CD	O
wk	NN	O
(	(	O
total	JJ	O
dose	NN	O
:	:	O
720	CD	O
million	CD	O
units	NNS	O
)	)	O
;	:	O
21	CD	O
(	(	O
B	NNP	O
)	)	O
received	VBD	O
9	CD	O
million	CD	O
units	NNS	O
alpha-2a	JJ	O
IFN	NNP	O
i.m	NN	O
.	.	O

t.w	NN	O
.	.	O

for	IN	O
4	CD	O
wk	NN	O
,	,	O
followed	VBN	O
by	IN	O
18	CD	O
million	CD	O
units	NNS	O
for	IN	O
12	CD	O
wk	NN	O
and	CC	O
9	CD	O
million	CD	O
units	NNS	O
for	IN	O
8	CD	O
wk	NN	O
(	(	O
972	CD	O
million	CD	O
units	NNS	O
)	)	O
;	:	O
24	CD	O
(	(	O
C	NNP	O
)	)	O
received	VBD	O
2	CD	O
alpha-2a	JJ	O
IFN	NNP	O
courses	NNS	O
(	(	O
9	CD	O
million	CD	O
units	NNS	O
i.m	RB	O
.	.	O

t.w	NN	O
.	.	O

for	IN	O
16	CD	O
and	CC	O
12	CD	O
wk	NN	O
separated	VBN	O
by	IN	O
a	DT	O
6-month	JJ	O
interval	NN	O
[	$	O
756	CD	O
million	CD	O
units	NNS	O
]	NNP	O
)	)	O
.	.	O

Primary	JJ	O
response	NN	O
was	VBD	O
defined	VBN	O
by	IN	O
normal	JJ	O
ALT	NNP	O
and	CC	O
serum	VB	O
HBV-DNA	NNP	O
levels	NNS	O
below	IN	O
10	CD	O
pg/ml	NN	O
at	IN	O
the	DT	O
end	NN	O
of	IN	O
therapy	NN	O
and	CC	O
sustained	VBN	O
response	NN	O
by	IN	O
normal	JJ	O
ALT	NNP	O
(	(	O
tested	VBN	O
monthly	RB	O
)	)	O
,	,	O
undetectable	JJ	O
HBV-DNA	NN	O
and	CC	O
IgM	NNP	O
anti-HBc	NN	O
(	(	O
<	JJ	O
7	CD	O
I.U	NNP	O
.	.	O

Paul	NNP	O
Ehrlich	NNP	O
Institute	NNP	O
)	)	O
(	(	O
tested	VBN	O
every	DT	O
3	CD	O
months	NNS	O
)	)	O
during	IN	O
the	DT	O
posttreatment	JJ	O
follow-up	NN	O
.	.	O

RESULTS	NNP	O
At	IN	O
the	DT	O
end	NN	O
of	IN	O
treatment	NN	O
,	,	O
12	CD	O
,	,	O
8	CD	O
,	,	O
and	CC	O
13	CD	O
patients	NNS	O
from	IN	O
groups	NNS	O
A	NNP	O
,	,	O
B	NNP	O
,	,	O
and	CC	O
C	NNP	O
,	,	O
respectively	RB	O
,	,	O
were	VBD	O
responders	NNS	O
.	.	O

At	IN	O
the	DT	O
18-month	JJ	O
follow-up	JJ	O
,	,	O
two	CD	O
patients	NNS	O
in	IN	O
group	NN	O
A	NNP	O
and	CC	O
only	RB	O
one	CD	O
in	IN	O
groups	NNS	O
B	NNP	O
and	CC	O
C	NNP	O
maintained	VBD	O
the	DT	O
response	NN	O
.	.	O

Overall	NNP	O
,	,	O
after	IN	O
34	CD	O
months	NNS	O
(	(	O
median	JJ	O
posttreatment	NN	O
follow-up	NN	O
)	)	O
,	,	O
three	CD	O
patients	NNS	O
were	VBD	O
long	JJ	O
term	NN	O
responders	NNS	O
,	,	O
whereas	NNS	O
three	CD	O
showed	VBD	O
a	DT	O
sustained	VBN	O
remission	NN	O
after	IN	O
relapse	NN	O
.	.	O

CONCLUSIONS	VB	O
The	DT	O
rate	NN	O
of	IN	O
long	JJ	O
term	NN	O
response	NN	O
to	TO	O
interferon	VB	O
of	IN	O
anti-HBe-positive	JJ	O
chronic	JJ	O
hepatitis	NN	O
B	NNP	O
is	VBZ	O
poor	JJ	O
,	,	O
independent	JJ	O
of	IN	O
IFN	NNP	O
type	NN	O
,	,	O
dose	VB	O
,	,	O
or	CC	O
schedule	NN	O
;	:	O
the	DT	O
more	RBR	O
stringent	JJ	O
the	DT	O
monitoring	NN	O
,	,	O
the	DT	O
higher	JJR	O
the	DT	O
relapse	NN	O
rate	NN	O
.	.	O

Ambulatory	NNP	O
phlebectomy	NN	O
versus	NN	O
compression	NN	O
sclerotherapy	NN	O
:	:	O
results	NNS	O
of	IN	O
a	DT	O
randomized	VBN	O
controlled	VBN	O
trial	NN	O
.	.	O

BACKGROUND	NNP	O
Although	IN	O
no	DT	O
randomized	VBN	O
controlled	VBN	O
trial	NN	O
has	VBZ	O
assessed	VBN	O
the	DT	O
effects	NNS	O
of	IN	O
either	DT	O
compression	NN	O
sclerotherapy	NN	O
or	CC	O
ambulatory	JJ	O
phlebectomy	NN	O
,	,	O
both	DT	O
techniques	NNS	O
are	VBP	O
used	VBN	O
to	TO	O
treat	VB	O
varicose	JJ	O
veins	NNS	O
worldwide	RB	O
.	.	O

We	PRP	O
performed	VBD	O
a	DT	O
randomized	VBN	O
controlled	VBN	O
trial	NN	O
to	TO	O
compare	VB	O
recurrence	NN	O
rates	NNS	O
of	IN	O
varicose	JJ	O
veins	NNS	O
and	CC	O
complications	NNS	O
after	IN	O
compression	NN	O
sclerotherapy	NN	O
and	CC	O
ambulatory	JJ	O
phlebectomy	NN	O
.	.	O

METHODS	NNP	O
From	IN	O
September	NNP	O
1996	CD	O
to	TO	O
October	NNP	O
1998	CD	O
,	,	O
we	PRP	O
randomly	RB	O
allocated	VBD	O
49	CD	O
legs	NNS	O
to	TO	O
compression	VB	O
sclerotherapy	NN	O
and	CC	O
49	CD	O
legs	NNS	O
to	TO	O
ambulatory	JJ	O
phlebectomy	NN	O
.	.	O

Our	PRP$	O
primary	JJ	O
outcome	NN	O
parameters	NNS	O
were	VBD	O
as	IN	O
follows	VBZ	O
:	:	O
recurrence	NN	O
rates	NNS	O
at	IN	O
1	CD	O
and	CC	O
2	CD	O
years	NNS	O
and	CC	O
complications	NNS	O
related	VBN	O
to	TO	O
therapy	VB	O
.	.	O

Eighty-two	JJ	O
patients	NNS	O
were	VBD	O
included	VBN	O
,	,	O
of	IN	O
whom	WP	O
16	CD	O
were	VBD	O
included	VBN	O
with	IN	O
both	DT	O
of	IN	O
their	PRP$	O
legs	NNS	O
.	.	O

The	DT	O
number	NN	O
of	IN	O
treated	JJ	O
legs	NN	O
was	VBD	O
therefore	RB	O
98	CD	O
,	,	O
but	CC	O
two	CD	O
patients	NNS	O
were	VBD	O
lost	VBN	O
to	TO	O
follow-up	JJ	O
.	.	O

RESULTS	VB	O
One	CD	O
year	NN	O
recurrence	NN	O
amounted	VBD	O
to	TO	O
1	CD	O
out	IN	O
of	IN	O
48	CD	O
for	IN	O
phlebectomy	NN	O
and	CC	O
12	CD	O
out	IN	O
of	IN	O
48	CD	O
for	IN	O
compression	NN	O
sclerotherapy	NN	O
(	(	O
P	NNP	O
<	NNP	O
0.001	CD	O
)	)	O
;	:	O
at	IN	O
2	CD	O
years	NNS	O
,	,	O
six	CD	O
additional	JJ	O
recurrences	NNS	O
were	VBD	O
found	VBN	O
,	,	O
but	CC	O
then	RB	O
solely	RB	O
for	IN	O
compression	NN	O
sclerotherapy	NN	O
(	(	O
P	NNP	O
<	NNP	O
0.001	CD	O
)	)	O
.	.	O

Significant	JJ	O
differences	NNS	O
in	IN	O
complications	NNS	O
occurring	VBG	O
more	RBR	O
in	IN	O
phlebectomy	NN	O
than	IN	O
in	IN	O
compression	NN	O
sclerotherapy	NN	O
therapy	NN	O
were	VBD	O
blisters	NNS	O
,	,	O
teleangiectatic	JJ	O
matting	NN	O
,	,	O
scar	NN	O
formation	NN	O
,	,	O
and	CC	O
bruising	VBG	O
from	IN	O
bandaging	VBG	O
.	.	O

CONCLUSION	NNP	O
Our	PRP$	O
results	NNS	O
show	VBP	O
that	IN	O
ambulatory	JJ	O
phlebectomy	NN	O
is	VBZ	O
an	DT	O
effective	JJ	O
therapy	NN	O
for	IN	O
varicose	JJ	O
veins	NNS	O
of	IN	O
the	DT	O
leg	NN	O
.	.	O

Recurrence	NN	O
rates	NNS	O
are	VBP	O
significantly	RB	O
lower	JJR	O
than	IN	O
for	IN	O
compression	NN	O
sclerotherapy	NN	O
therapy	NN	O
.	.	O

If	IN	O
varicose	JJ	O
veins	NNS	O
persist	VBP	O
4	CD	O
weeks	NNS	O
after	IN	O
compression	NN	O
sclerotherapy	NN	O
,	,	O
it	PRP	O
can	MD	O
be	VB	O
argued	VBN	O
that	IN	O
to	TO	O
reduce	VB	O
the	DT	O
risk	NN	O
of	IN	O
future	JJ	O
recurrence	NN	O
ambulatory	JJ	O
phlebectomy	NN	O
should	MD	O
be	VB	O
considered	VBN	O
as	IN	O
the	DT	O
better	JJR	O
treatment	NN	O
option	NN	O
.	.	O

Pretreatment	NN	O
and	CC	O
co-administration	NN	O
of	IN	O
oral	JJ	O
anti-diabetic	JJ	O
agent	NN	O
with	IN	O
clomiphene	JJ	O
citrate	NN	O
or	CC	O
rFSH	NN	O
for	IN	O
ovulation	NN	O
induction	NN	O
in	IN	O
clomiphene-citrate-resistant	JJ	O
polycystic	JJ	O
ovary	JJ	O
syndrome	NN	O
.	.	O

AIM	IN	O
The	DT	O
objective	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
explore	VB	O
the	DT	O
result	NN	O
of	IN	O
pretreatment	NN	O
and	CC	O
concomitant	NN	O
use	NN	O
of	IN	O
metformin	NN	O
with	IN	O
clomiphene	JJ	O
citrate	NN	O
(	(	O
CC	NNP	O
)	)	O
and	CC	O
rFSH	NN	O
for	IN	O
ovulation	NN	O
induction	NN	O
in	IN	O
clomiphene-citrate-resistant	JJ	O
polycystic	JJ	O
ovary	JJ	O
syndrome	NN	O
(	(	O
PCOS	NNP	O
)	)	O
.	.	O

MATERIAL	NNP	O
AND	CC	O
METHODS	NNP	O
This	DT	O
randomized	VBD	O
controlled	JJ	O
trial	NN	O
was	VBD	O
done	VBN	O
in	IN	O
the	DT	O
Dhaka	NNP	O
Medical	NNP	O
College	NNP	O
and	CC	O
Hospital	NNP	O
and	CC	O
the	DT	O
Infertility	NNP	O
Care	NNP	O
and	CC	O
Research	NNP	O
Centre	NNP	O
,	,	O
Dhaka	NNP	O
,	,	O
Bangladesh	NNP	O
.	.	O

A	NNP	O
total	NN	O
of	IN	O
165	CD	O
infertile	JJ	O
patients	NNS	O
with	IN	O
CC-resistant	JJ	O
PCOS	NNP	O
who	WP	O
attended	VBD	O
for	IN	O
treatment	NN	O
were	VBD	O
the	DT	O
target	NN	O
population	NN	O
for	IN	O
this	DT	O
study	NN	O
.	.	O

Patients	NNS	O
were	VBD	O
divided	VBN	O
into	IN	O
three	CD	O
groups	NNS	O
:	:	O
groups	NNS	O
A	DT	O
and	CC	O
B	NNP	O
were	VBD	O
given	VBN	O
metformin	NNS	O
and	CC	O
group	NN	O
C	NNP	O
was	VBD	O
the	DT	O
control	NN	O
.	.	O

Along	IN	O
with	IN	O
metformin	NN	O
,	,	O
group	NN	O
A	NNP	O
received	VBD	O
CC	NNP	O
and	CC	O
group	NN	O
B	NNP	O
received	VBD	O
rFSH	NN	O
.	.	O

Group	NNP	O
C	NNP	O
was	VBD	O
treated	VBN	O
with	IN	O
only	RB	O
rFSH	NN	O
.	.	O

Metformin	NNP	O
was	VBD	O
given	VBN	O
1500	CD	O
mg	JJ	O
daily	JJ	O
for	IN	O
4	CD	O
weeks	NNS	O
.	.	O

Afterwards	NNS	O
CC	NNP	O
or	CC	O
rFSH	VB	O
were	VBD	O
added	VBN	O
for	IN	O
induction	NN	O
of	IN	O
ovulation	NN	O
along	IN	O
with	IN	O
metformin	NN	O
.	.	O

Six	NNP	O
ovulatory	JJ	O
cycles	NNS	O
were	VBD	O
assessed	VBN	O
.	.	O

Treatment	NNP	O
was	VBD	O
terminated	VBN	O
when	WRB	O
there	EX	O
was	VBD	O
no	DT	O
response	NN	O
with	IN	O
maximum	JJ	O
dose	NN	O
of	IN	O
CC	NNP	O
and	CC	O
rFSH	NN	O
or	CC	O
after	IN	O
six	CD	O
ovulatory	JJ	O
cycles	NNS	O
without	IN	O
pregnancy	NN	O
or	CC	O
after	IN	O
achieving	VBG	O
pregnancy	NN	O
.	.	O

A	DT	O
P-value	NNP	O
of	IN	O
<	NNP	O
0.5	CD	O
was	VBD	O
considered	VBN	O
as	IN	O
significant	JJ	O
.	.	O

RESULTS	NNP	O
Ovulation	NNP	O
(	(	O
89.09	CD	O
%	NN	O
)	)	O
and	CC	O
pregnancy	NN	O
(	(	O
54.55	CD	O
%	NN	O
)	)	O
rates	NNS	O
were	VBD	O
higher	JJR	O
in	IN	O
group	NN	O
B.	NNP	O
Ovulation	NNP	O
(	(	O
74.55	CD	O
%	NN	O
)	)	O
and	CC	O
pregnancy	NN	O
(	(	O
29.09	CD	O
%	NN	O
)	)	O
rates	NNS	O
were	VBD	O
also	RB	O
satisfactory	JJ	O
in	IN	O
group	NN	O
C	NNP	O
but	CC	O
a	DT	O
dose	NN	O
of	IN	O
rFSH	JJ	O
requirement	NN	O
was	VBD	O
significantly	RB	O
higher	JJR	O
(	(	O
P	NNP	O
=	NNP	O
0.000	CD	O
)	)	O
.	.	O

In	IN	O
group	NN	O
A	NNP	O
,	,	O
both	DT	O
ovulation	NN	O
and	CC	O
pregnancy	NN	O
rate	NN	O
were	VBD	O
much	RB	O
lower	JJR	O
than	IN	O
the	DT	O
other	JJ	O
two	CD	O
groups	NNS	O
(	(	O
27.27	CD	O
%	NN	O
and	CC	O
12.73	CD	O
%	NN	O
,	,	O
respectively	RB	O
)	)	O
.	.	O

CONCLUSIONS	NNP	O
Use	NNP	O
of	IN	O
metformin	NN	O
increases	VBZ	O
the	DT	O
response	NN	O
of	IN	O
ovulation-inducing	JJ	O
agents	NNS	O
and	CC	O
can	MD	O
be	VB	O
used	VBN	O
safely	RB	O
in	IN	O
PCOS	NNP	O
.	.	O

Torasemide	NNP	O
versus	NN	O
furosemide	NN	O
in	IN	O
cirrhosis	NN	O
:	:	O
a	DT	O
long-term	JJ	O
,	,	O
double-blind	JJ	O
,	,	O
randomized	JJ	O
clinical	JJ	O
study	NN	O
.	.	O

The	DT	O
effects	NNS	O
of	IN	O
long-term	JJ	O
therapy	NN	O
(	(	O
70	CD	O
days	NNS	O
)	)	O
with	IN	O
torasemide	NN	O
(	(	O
20	CD	O
mg/day	NN	O
)	)	O
,	,	O
a	DT	O
new	JJ	O
loop	NN	O
diuretic	JJ	O
,	,	O
were	VBD	O
compared	VBN	O
with	IN	O
those	DT	O
of	IN	O
furosemide	NN	O
(	(	O
50	CD	O
mg/day	NN	O
)	)	O
in	IN	O
a	DT	O
randomized	JJ	O
double-blind	JJ	O
trial	NN	O
.	.	O

Both	DT	O
drugs	NNS	O
were	VBD	O
administered	VBN	O
in	IN	O
association	NN	O
with	IN	O
spironolactone	NN	O
(	(	O
200	CD	O
mg/day	NN	O
)	)	O
in	IN	O
28	CD	O
nonazotemic	JJ	O
cirrhotic	JJ	O
patients	NNS	O
with	IN	O
controlled	JJ	O
ascites	NNS	O
.	.	O

The	DT	O
treatments	NNS	O
did	VBD	O
not	RB	O
modify	VB	O
creatinine	JJ	O
clearance	NN	O
and	CC	O
exhibited	VBD	O
a	DT	O
similar	JJ	O
effect	NN	O
on	IN	O
body	NN	O
weight	NN	O
,	,	O
urinary	JJ	O
volume	NN	O
,	,	O
and	CC	O
fractional	JJ	O
excretion	NN	O
of	IN	O
uric	JJ	O
acid	NN	O
,	,	O
sodium	NN	O
,	,	O
and	CC	O
chloride	NN	O
.	.	O

The	DT	O
effect	NN	O
of	IN	O
torasemide	NN	O
on	IN	O
fractional	JJ	O
potassium	NN	O
excretion	NN	O
was	VBD	O
lower	JJR	O
than	IN	O
that	DT	O
of	IN	O
furosemide	NN	O
.	.	O

Torasemide	VB	O
showed	VBD	O
higher	JJR	O
sparing	VBG	O
effect	NN	O
than	IN	O
furosemide	NN	O
on	IN	O
calcium	NN	O
,	,	O
inorganic	JJ	O
phosphate	NN	O
,	,	O
and	CC	O
magnesium	NN	O
excretion	NN	O
and	CC	O
stronger	JJR	O
action	NN	O
on	IN	O
free	JJ	O
water	NN	O
clearance	NN	O
.	.	O

No	DT	O
changes	NNS	O
in	IN	O
serum	NN	O
parameters	NNS	O
were	VBD	O
induced	VBN	O
by	IN	O
either	DT	O
treatment	NN	O
.	.	O

Two	CD	O
episodes	NNS	O
of	IN	O
hepatic	JJ	O
encephalopathy	NN	O
occurred	VBD	O
in	IN	O
the	DT	O
torasemide	NN	O
group	NN	O
.	.	O

In	IN	O
view	NN	O
of	IN	O
its	PRP$	O
effects	NNS	O
on	IN	O
sodium	NN	O
and	CC	O
water	NN	O
excretion	NN	O
and	CC	O
on	IN	O
other	JJ	O
urinary	JJ	O
parameters	NNS	O
,	,	O
torasemide	NN	O
can	MD	O
represent	VB	O
an	DT	O
alternative	JJ	O
tool	NN	O
for	IN	O
the	DT	O
long-term	JJ	O
treatment	NN	O
of	IN	O
ascites	NNS	O
.	.	O

Gemcitabine	NNP	O
and	CC	O
split-dose	JJ	O
paclitaxel	NN	O
or	CC	O
docetaxel	NN	O
in	IN	O
metastatic	JJ	O
breast	NN	O
cancer	NN	O
:	:	O
a	DT	O
randomised	JJ	O
phase	NN	O
II	NNP	O
study	NN	O
.	.	O

PURPOSE	VB	O
The	DT	O
purpose	NN	O
was	VBD	O
to	TO	O
evaluate	VB	O
the	DT	O
activity	NN	O
and	CC	O
toxicity	NN	O
of	IN	O
split-dose	JJ	O
paclitaxel	NN	O
or	CC	O
docetaxel	NN	O
in	IN	O
combination	NN	O
with	IN	O
gemcitabine	NN	O
in	IN	O
patients	NNS	O
with	IN	O
metastatic	JJ	C
breast	NN	C
cancer	NN	C
(	(	O
MBC	NNP	C
)	)	O
who	WP	O
had	VBD	O
previously	RB	C
received	VBN	C
anthracyclines	NNS	C
.	.	O

PATIENTS	NNP	O
AND	CC	O
METHODS	NNP	O
A	NNP	O
total	NN	O
of	IN	O
210	CD	SS
patients	NNS	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
one	CD	O
of	IN	O
three	CD	O
treatment	NN	O
arms	NNS	O
:	:	O
gemcitabine	NN	O
1,250	CD	O
mg/m	NN	O
(	(	O
2	CD	O
)	)	O
Days	VBZ	O
1	CD	O
and	CC	O
8	CD	O
and	CC	O
paclitaxel	VB	O
175	CD	O
mg/m	NN	O
(	(	O
2	CD	O
)	)	O
as	IN	O
a	DT	O
3-h	JJ	O
infusion	NN	O
on	IN	O
Day	NNP	O
1	CD	O
(	(	O
GP1	NNP	O
)	)	O
;	:	O
gemcitabine	$	O
1,000	CD	O
mg/m	NN	O
(	(	O
2	CD	O
)	)	O
Days	VBZ	O
1	CD	O
and	CC	O
8	CD	O
and	CC	O
paclitaxel	VB	O
100	CD	O
mg/m	NN	O
(	(	O
2	CD	O
)	)	O
as	IN	O
a	DT	O
1-h	JJ	O
infusion	NN	O
on	IN	O
Days	NNP	O
1	CD	O
and	CC	O
8	CD	O
(	(	O
GP2	NNP	O
)	)	O
;	:	O
gemcitabine	$	O
1,000	CD	O
mg/m	NN	O
(	(	O
2	CD	O
)	)	O
Days	VBZ	O
1	CD	O
and	CC	O
8	CD	O
and	CC	O
docetaxel	VB	O
40	CD	O
mg/m	NN	O
(	(	O
2	CD	O
)	)	O
as	IN	O
a	DT	O
1-h	JJ	O
infusion	NN	O
on	IN	O
Days	NNP	O
1	CD	O
and	CC	O
8	CD	O
(	(	O
GD	NNP	O
)	)	O
.	.	O

Cycles	NNS	O
were	VBD	O
repeated	VBN	O
every	DT	O
3	CD	O
weeks	NNS	O
.	.	O

RESULTS	NNP	O
For	IN	O
the	DT	O
204	CD	SS
patients	NNS	O
evaluable	JJ	O
for	IN	O
response	NN	O
assessment	NN	O
,	,	O
the	DT	O
response	NN	O
rates	NNS	O
were	VBD	O
48.6	CD	O
%	NN	O
for	IN	O
GP1	NNP	O
,	,	O
52.2	CD	O
%	NN	O
for	IN	O
GP2	NNP	O
,	,	O
and	CC	O
52.3	CD	O
%	NN	O
for	IN	O
GD	NNP	O
.	.	O

Median	JJ	O
response	NN	O
duration	NN	O
,	,	O
time	NN	O
to	TO	O
treatment	NN	O
failure	NN	O
,	,	O
and	CC	O
time	NN	O
to	TO	O
progression	NN	O
(	(	O
TTP	NNP	O
)	)	O
were	VBD	O
similar	JJ	O
in	IN	O
each	DT	O
arm	NN	O
.	.	O

Median	JJ	O
TTP	NNP	O
for	IN	O
GP1	NNP	O
,	,	O
GP2	NNP	O
and	CC	O
GD	NNP	O
was	VBD	O
7.5	CD	O
,	,	O
7.0	CD	O
and	CC	O
7.4	CD	O
months	NNS	O
,	,	O
respectively	RB	O
.	.	O

For	IN	O
the	DT	O
208	CD	SS
patients	NNS	O
evaluable	JJ	O
for	IN	O
safety	NN	O
,	,	O
the	DT	O
most	RBS	O
common	JJ	O
grade	NN	O
3/4	CD	O
toxicity	NN	O
for	IN	O
each	DT	O
regimen	NN	O
was	VBD	O
neutropaenia	RB	O
,	,	O
with	IN	O
64	CD	O
%	NN	O
,	,	O
57	CD	O
%	NN	O
,	,	O
and	CC	O
68	CD	O
%	NN	O
for	IN	O
GP1	NNP	O
,	,	O
GP2	NNP	O
,	,	O
and	CC	O
GD	NNP	O
,	,	O
respectively	RB	O
.	.	O

Grade	VB	O
4	CD	O
neutropaenia	NN	O
,	,	O
grade	VBD	O
3/4	CD	O
anaemia	NN	O
,	,	O
febrile	JJ	O
neutropaenia	NN	O
,	,	O
and	CC	O
diarrhoea	NNS	O
were	VBD	O
more	JJR	O
common	JJ	O
in	IN	O
the	DT	O
docetaxel	NN	O
arm	NN	O
,	,	O
as	IN	O
was	VBD	O
the	DT	O
use	NN	O
of	IN	O
intravenous	JJ	O
antibiotics	NNS	O
and	CC	O
blood	NN	O
transfusions	NNS	O
.	.	O

CONCLUSION	VB	O
The	DT	O
study	NN	O
confirmed	VBD	O
the	DT	O
high	JJ	O
activity	NN	O
of	IN	O
gemcitabine-taxane	JJ	O
combinations	NNS	O
in	IN	O
MBC	NNP	O
.	.	O

Split-dose	JJ	O
paclitaxel	NN	O
had	VBD	O
similar	JJ	O
activity	NN	O
and	CC	O
toxicity	NN	O
to	TO	O
the	DT	O
3-weekly	JJ	O
administration	NN	O
.	.	O

The	DT	O
split-dose	JJ	O
docetaxel	NN	O
regimen	NNS	O
had	VBD	O
similar	JJ	O
activity	NN	O
to	TO	O
the	DT	O
paclitaxel	NN	O
combinations	NNS	O
though	IN	O
associated	VBN	O
with	IN	O
higher	JJR	O
toxicity	NN	O
.	.	O

Virtual	JJ	O
reality	NN	O
for	IN	O
acute	NN	O
pain	NN	O
reduction	NN	O
in	IN	O
adolescents	NNS	A
undergoing	VBG	O
burn	NN	C
wound	NN	C
care	NN	C
:	:	O
a	DT	O
prospective	JJ	O
randomized	NN	O
controlled	VBD	O
trial	NN	O
.	.	O

BACKGROUND	NNP	O
Effective	NNP	O
pain	NN	O
management	NN	O
remains	VBZ	O
a	DT	O
challenge	NN	O
for	IN	O
adolescents	NNS	A
during	IN	O
conscious	JJ	O
burn	NN	O
wound	NN	O
care	NN	O
procedures	NNS	O
.	.	O

Virtual	JJ	O
reality	NN	O
(	(	O
VR	NNP	O
)	)	O
shows	VBZ	O
promise	NN	O
as	IN	O
a	DT	O
non-pharmacological	JJ	O
adjunct	NN	O
in	IN	O
reducing	VBG	O
pain	NN	O
.	.	O

AIMS	VB	O
This	DT	O
study	NN	O
assessed	VBD	O
off-the-shelf	JJ	O
VR	NNP	O
for	IN	O
(	(	O
1	CD	O
)	)	O
its	PRP$	O
effect	NN	O
on	IN	O
reducing	VBG	O
acute	JJ	O
pain	NN	O
intensity	NN	O
during	IN	O
adolescent	JJ	O
burn	NN	O
wound	NN	O
care	NN	O
,	,	O
and	CC	O
(	(	O
2	CD	O
)	)	O
its	PRP$	O
clinical	JJ	O
utility	NN	O
in	IN	O
a	DT	O
busy	JJ	O
hospital	NN	O
setting	NN	O
.	.	O

METHODS	NNP	O
Forty-one	CD	SS
adolescents	NNS	A
(	(	O
11-17	CD	A
years	NNS	A
)	)	O
participated	VBD	O
in	IN	O
this	DT	O
prospective	JJ	O
randomized	NN	O
controlled	VBD	O
trial	NN	O
.	.	O

Acute	NNP	O
pain	NN	O
outcomes	NNS	O
including	VBG	O
adolescent	JJ	O
self-report	NN	O
,	,	O
nursing	VBG	O
staff	NN	O
behavioral	JJ	O
observation	NN	O
,	,	O
caregiver	NN	O
observation	NN	O
and	CC	O
physiological	JJ	O
measures	NNS	O
were	VBD	O
collected	VBN	O
.	.	O

Length	NNP	O
of	IN	O
procedure	NN	O
times	NNS	O
and	CC	O
adolescent	JJ	O
reactions	NNS	O
were	VBD	O
also	RB	O
recorded	VBN	O
to	TO	O
inform	VB	O
clinical	JJ	O
utility	NN	O
.	.	O

RESULTS	NNP	O
Nursing	JJ	O
staff	NN	O
reported	VBD	O
a	DT	O
statistically	RB	O
significant	JJ	O
reduction	NN	O
in	IN	O
pain	NN	O
scores	NNS	O
during	IN	O
dressing	VBG	O
removal	NN	O
,	,	O
and	CC	O
significantly	RB	O
less	JJR	O
rescue	JJ	O
doses	NNS	O
of	IN	O
Entonox	NNP	O
given	VBN	O
to	TO	O
those	DT	O
receiving	VBG	O
VR	NNP	O
,	,	O
compared	VBN	O
to	TO	O
those	DT	O
receiving	VBG	O
standard	JJ	O
distraction	NN	O
.	.	O

For	IN	O
all	DT	O
other	JJ	O
pain	NN	O
outcomes	NNS	O
and	CC	O
length	NN	O
of	IN	O
treatment	NN	O
,	,	O
there	EX	O
was	VBD	O
a	DT	O
trend	NN	O
for	IN	O
lower	JJR	O
pain	NN	O
scores	NNS	O
and	CC	O
treatment	NN	O
times	NNS	O
for	IN	O
those	DT	O
receiving	VBG	O
VR	NNP	O
,	,	O
but	CC	O
these	DT	O
differences	NNS	O
were	VBD	O
not	RB	O
statistically	RB	O
significant	JJ	O
.	.	O

CONCLUSION	NNP	O
Despite	IN	O
only	RB	O
minimal	JJ	O
pain	NN	O
reduction	NN	O
achieved	VBD	O
using	VBG	O
off-the-shelf	JJ	O
VR	NNP	O
,	,	O
other	JJ	O
results	NNS	O
from	IN	O
this	DT	O
trial	NN	O
and	CC	O
previous	JJ	O
research	NN	O
on	IN	O
younger	JJR	O
children	NNS	O
with	IN	O
burns	NNS	O
suggest	VBP	O
a	DT	O
customized	JJ	O
,	,	O
adolescent	JJ	O
and	CC	O
hospital	JJ	O
friendly	JJ	O
device	NN	O
may	MD	O
be	VB	O
more	RBR	O
effective	JJ	O
in	IN	O
pain	NN	O
reduction	NN	O
.	.	O

Parenteral	NNP	O
amino	NN	O
acid	NN	O
and	CC	O
metabolic	JJ	O
acidosis	NN	O
in	IN	O
premature	JJ	O
infants	NNS	O
.	.	O

BACKGROUND	NNP	O
Aggressive	NNP	O
parenteral	JJ	O
nutrition	NN	O
(	(	O
PN	NNP	O
)	)	O
including	VBG	O
amino	JJ	O
acids	NNS	O
is	VBZ	O
recommended	VBN	O
for	IN	O
low-birth-weight	JJ	O
infants	NNS	O
to	TO	O
prevent	VB	O
energy	NN	O
and	CC	O
protein	NN	O
deficit	NN	O
.	.	O

Their	PRP$	O
impact	NN	O
on	IN	O
acid-base	JJ	O
homeostasis	NN	O
has	VBZ	O
not	RB	O
been	VBN	O
examined	VBN	O
.	.	O

METHODS	NNP	O
We	PRP	O
investigated	VBD	O
the	DT	O
impact	NN	O
of	IN	O
dose	NN	O
and	CC	O
duration	NN	O
of	IN	O
parenteral	JJ	O
amino	NN	O
acids	NNS	O
,	,	O
with	IN	O
cysteine	NN	O
,	,	O
on	IN	O
acid-base	JJ	O
parameters	NNS	O
in	IN	O
122	CD	O
low-birth-weight	JJ	O
infants	NNS	O
.	.	O

Premature	NN	O
infants	NNS	O
<	VBP	O
or=32	JJ	O
weeks	NNS	O
,	,	O
<	NNP	O
or=1850	MD	O
g	VB	O
,	,	O
and	CC	O
receiving	VBG	O
parenteral	JJ	O
amino	NN	O
acids	NNS	O
at	IN	O
1.5	CD	O
g/kg/d	NN	O
for	IN	O
an	DT	O
extended	JJ	O
period	NN	O
(	(	O
>	JJ	O
24	CD	O
hours	NNS	O
)	)	O
,	,	O
or	CC	O
3	CD	O
g/kg/d	NN	O
for	IN	O
a	DT	O
short	JJ	O
(	(	O
5	CD	O
hour	NN	O
)	)	O
,	,	O
extended	VBD	O
(	(	O
24	CD	O
hour	NN	O
)	)	O
,	,	O
or	CC	O
prolonged	VBN	O
(	(	O
3-5	JJ	O
days	NNS	O
)	)	O
duration	NN	O
were	VBD	O
included	VBN	O
in	IN	O
the	DT	O
study	NN	O
.	.	O

Data	NNS	O
were	VBD	O
obtained	VBN	O
at	IN	O
age	NN	O
0-3	JJ	O
days	NNS	O
(	(	O
n	JJ	O
=	NNP	O
43	CD	O
)	)	O
or	CC	O
,	,	O
when	WRB	O
clinically	RB	O
stable	JJ	O
,	,	O
age	NN	O
3-5	JJ	O
days	NNS	O
(	(	O
n	JJ	O
=	NNP	O
49	CD	O
)	)	O
.	.	O

Data	NNS	O
from	IN	O
30	CD	C
infants	NNS	C
,	,	C
matched	VBN	C
for	IN	C
birth	NN	C
weight	NN	C
and	CC	C
gestational	JJ	C
age	NN	C
,	,	C
receiving	VBG	C
PN	NNP	C
during	IN	C
the	DT	C
first	JJ	C
5	CD	C
days	NNS	C
after	IN	C
birth	NN	C
were	VBD	O
also	RB	O
obtained	VBN	O
.	.	O

Acidosis	NNP	O
was	VBD	O
defined	VBN	O
as	IN	O
pH	NN	O
<	$	O
7.25	CD	O
.	.	O

RESULTS	JJ	O
Acidosis	NNP	O
was	VBD	O
evident	JJ	O
in	IN	O
all	DT	O
infants	NNS	O
between	IN	O
2	CD	O
and	CC	O
5	CD	O
days	NNS	O
after	IN	O
birth	NN	O
.	.	O

Infants	NNS	O
with	IN	O
large	JJ	O
patent	NN	O
ductus	NN	O
arteriosus	NN	O
(	(	O
PDA	NNP	O
)	)	O
exhibited	VBD	O
significantly	RB	O
(	(	O
p	JJ	O
<	NNP	O
.05	NNP	O
)	)	O
lower	JJR	O
pH	NN	O
early	RB	O
,	,	O
had	VBD	O
higher	JJR	O
blood	NN	O
urea	JJ	O
nitrogen	NN	O
levels	NNS	O
(	(	O
26	CD	O
+/-	JJ	O
9	CD	O
vs	NN	O
18	CD	O
+	NN	O
8	CD	O
mg/dL	NN	O
;	:	O
p	CC	O
<	NNP	O
.05	NNP	O
)	)	O
,	,	O
and	CC	O
had	VBD	O
greater	JJR	O
weight	JJ	O
loss	NN	O
(	(	O
approximately	RB	O
17	CD	O
%	NN	O
of	IN	O
birth	NN	O
weight	NN	O
)	)	O
when	WRB	O
compared	VBN	O
with	IN	O
infants	NNS	O
without	IN	O
PDA	NNP	O
.	.	O

Gestational	NNP	O
age	NN	O
,	,	O
weight	JJ	O
loss	NN	O
,	,	O
and	CC	O
patent	NN	O
ductus	NN	O
arteriosus	NN	O
accounted	VBD	O
for	IN	O
65	CD	O
%	NN	O
of	IN	O
variance	NN	O
in	IN	O
acidosis	NN	O
.	.	O

CONCLUSIONS	NNP	O
Low-birth-weight	JJ	O
infants	NNS	O
develop	VB	O
metabolic	JJ	O
acidosis	NN	O
between	IN	O
2	CD	O
and	CC	O
5	CD	O
days	NNS	O
after	IN	O
birth	NN	O
,	,	O
irrespective	NN	O
of	IN	O
dose	NN	O
and	CC	O
duration	NN	O
of	IN	O
parenteral	JJ	O
amino	NN	O
acid	JJ	O
administration	NN	O
.	.	O

Careful	JJ	O
management	NN	O
of	IN	O
parenteral	JJ	O
fluids	NNS	O
and	CC	O
comorbidities	NNS	O
may	MD	O
lower	VB	O
the	DT	O
incidence	NN	O
of	IN	O
acidosis	NN	O
and	CC	O
promote	NN	O
protein	NN	O
accretion	NN	O
.	.	O

Effect	NN	O
of	IN	O
light-cured	JJ	O
filled	VBN	O
sealant	NN	O
on	IN	O
shear	JJ	O
bond	NN	O
strength	NN	O
of	IN	O
metal	NN	O
and	CC	O
ceramic	JJ	O
brackets	NNS	O
bonded	VBN	O
with	IN	O
a	DT	O
resin-modified	JJ	O
glass	NN	O
ionomer	NN	O
cement	NN	O
.	.	O

INTRODUCTION	NNP	O
Our	PRP$	O
objective	NN	O
was	VBD	O
to	TO	O
evaluate	VB	O
the	DT	O
effects	NNS	O
of	IN	O
a	DT	O
highly	RB	O
filled	VBN	O
light-cured	JJ	O
sealant	NN	O
(	(	O
HFLCS	NNP	O
)	)	O
on	IN	O
the	DT	O
shear	JJ	O
bond	NN	O
strength	NN	O
and	CC	O
bond	NN	O
failure	NN	O
site	NN	O
of	IN	O
metal	NN	O
and	CC	O
ceramic	JJ	O
brackets	NNS	O
bonded	VBN	O
with	IN	O
resin-modified	JJ	O
glass	NN	O
ionomer	NN	O
cement	NN	O
(	(	O
RMGIC	NNP	O
)	)	O
.	.	O

METHODS	NNP	O
Eighty	NNP	SS
freshly	RB	SS
extracted	VBD	SS
maxillary	JJ	SS
premolars	NNS	SS
were	VBD	O
randomly	RB	O
divided	VBN	O
into	IN	O
4	CD	O
groups	NNS	O
(	(	O
20	CD	O
in	IN	O
each	DT	O
group	NN	O
)	)	O
.	.	O

In	IN	O
all	DT	O
groups	NNS	O
,	,	O
the	DT	O
teeth	NNS	O
were	VBD	O
etched	VBN	O
with	IN	O
37	CD	O
%	NN	O
phosphoric	JJ	O
acid	NN	O
for	IN	O
20	CD	O
seconds	NNS	O
,	,	O
and	CC	O
RMGIC	NNP	O
(	(	O
Fuji	NNP	O
Ortho	NNP	O
LC	NNP	O
,	,	O
GC	NNP	O
Europe	NNP	O
,	,	O
Leuven	NNP	O
,	,	O
Belgium	NNP	O
)	)	O
was	VBD	O
used	VBN	O
for	IN	O
bracket	NN	O
bonding	NN	O
.	.	O

In	IN	O
groups	NNS	O
1	CD	O
and	CC	O
3	CD	O
,	,	O
the	DT	O
brackets	NNS	O
were	VBD	O
bonded	VBN	O
directly	RB	O
to	TO	O
etched	VB	O
enamel	JJ	O
surfaces	NNS	O
;	:	O
in	IN	O
groups	NNS	O
2	CD	O
and	CC	O
4	CD	O
,	,	O
the	DT	O
etched	JJ	O
enamel	NN	O
was	VBD	O
covered	VBN	O
with	IN	O
HFLCS	NNP	O
(	(	O
Pro	NNP	O
Seal	NNP	O
,	,	O
Reliance	NNP	O
Orthodontic	NNP	O
Products	NNP	O
,	,	O
Itasca	NNP	O
,	,	O
Ill	NNP	O
)	)	O
.	.	O

Groups	$	O
1	CD	O
and	CC	O
2	CD	O
received	VBD	O
metal	JJ	O
brackets	NNS	O
,	,	O
and	CC	O
groups	NNS	O
3	CD	O
and	CC	O
4	CD	O
had	VBD	O
ceramic	JJ	O
brackets	NNS	O
.	.	O

The	DT	O
specimens	NNS	O
were	VBD	O
stored	VBN	O
in	IN	O
distilled	JJ	O
water	NN	O
at	IN	O
room	NN	O
temperature	NN	O
for	IN	O
24	CD	O
hours	NNS	O
and	CC	O
subsequently	RB	O
tested	VBN	O
in	IN	O
shear	JJ	O
mode	NN	O
with	IN	O
a	DT	O
universal	JJ	O
testing	NN	O
machine	NN	O
.	.	O

After	IN	O
debonding	VBG	O
,	,	O
the	DT	O
teeth	NNS	O
and	CC	O
the	DT	O
brackets	NNS	O
were	VBD	O
examined	VBN	O
under	IN	O
a	DT	O
stereomicroscope	NN	O
(	(	O
model	JJ	O
SMZ-1B	NNP	O
,	,	O
Nikon	NNP	O
,	,	O
Osaka	NNP	O
,	,	O
Japan	NNP	O
)	)	O
at	IN	O
20-times	JJ	O
magnification	NN	O
to	TO	O
assess	VB	O
the	DT	O
residual	JJ	O
adhesive	NN	O
on	IN	O
the	DT	O
tooth	NN	O
surfaces	NNS	O
.	.	O

RESULTS	NNP	O
Interaction	NNP	O
between	IN	O
HFLCS	NNP	O
and	CC	O
bracket	NN	O
type	NN	O
was	VBD	O
not	RB	O
statistically	RB	O
significant	JJ	O
(	(	O
P	NNP	O
=	NNP	O
0.15	CD	O
)	)	O
.	.	O

Pretreatment	NN	O
with	IN	O
HFLCS	NNP	O
did	VBD	O
not	RB	O
cause	VB	O
a	DT	O
statistically	RB	O
significant	JJ	O
change	NN	O
in	IN	O
the	DT	O
shear	JJ	O
bond	NN	O
values	NNS	O
of	IN	O
either	DT	O
metal	NN	O
or	CC	O
ceramic	JJ	O
brackets	NNS	O
(	(	O
P	NNP	O
=	NNP	O
0.38	CD	O
)	)	O
.	.	O

Shear	JJ	O
bond	NN	O
values	NNS	O
of	IN	O
the	DT	O
ceramic	JJ	O
brackets	NNS	O
were	VBD	O
higher	JJR	O
than	IN	O
those	DT	O
of	IN	O
the	DT	O
metal	JJ	O
brackets	NNS	O
independent	JJ	O
of	IN	O
HFLCS	NNP	O
application	NN	O
(	(	O
P	NNP	O
<	NNP	O
0.001	CD	O
)	)	O
.	.	O

No	DT	O
significant	JJ	O
differences	NNS	O
were	VBD	O
found	VBN	O
in	IN	O
bond	NN	O
failure	NN	O
modes	VBZ	O
in	IN	O
the	DT	O
4	CD	O
groups	NNS	O
.	.	O

CONCLUSIONS	NNP	O
HFLCS	NNP	O
application	NN	O
on	IN	O
enamel	NN	O
etched	VBN	O
with	IN	O
37	CD	O
%	NN	O
phosphoric	JJ	O
acid	NN	O
did	VBD	O
not	RB	O
affect	VB	O
the	DT	O
bond	NN	O
strength	NN	O
values	NNS	O
and	CC	O
the	DT	O
bond	NN	O
failure	NN	O
modes	NNS	O
of	IN	O
metal	NN	O
and	CC	O
ceramic	JJ	O
brackets	NNS	O
bonded	VBN	O
with	IN	O
RMGIC	NNP	O
.	.	O

RESULTS	NNP	O
Interaction	NNP	O
between	IN	O
HFLCS	NNP	O
and	CC	O
bracket	NN	O
type	NN	O
was	VBD	O
not	RB	O
statistically	RB	O
significant	JJ	O
(	(	O
P	NNP	O
=	NNP	O
0.15	CD	O
)	)	O
.	.	O

Pretreatment	NN	O
with	IN	O
HFLCS	NNP	O
did	VBD	O
not	RB	O
cause	VB	O
a	DT	O
statistically	RB	O
significant	JJ	O
change	NN	O
in	IN	O
the	DT	O
shear	JJ	O
bond	NN	O
values	NNS	O
of	IN	O
either	DT	O
metal	NN	O
or	CC	O
ceramic	JJ	O
brackets	NNS	O
(	(	O
P	NNP	O
=	NNP	O
0.38	CD	O
)	)	O
.	.	O

Shear	JJ	O
bond	NN	O
values	NNS	O
of	IN	O
the	DT	O
ceramic	JJ	O
brackets	NNS	O
were	VBD	O
higher	JJR	O
than	IN	O
those	DT	O
of	IN	O
the	DT	O
metal	JJ	O
brackets	NNS	O
independent	JJ	O
of	IN	O
HFLCS	NNP	O
application	NN	O
(	(	O
P	NNP	O
<	NNP	O
0.001	CD	O
)	)	O
.	.	O

No	DT	O
significant	JJ	O
differences	NNS	O
were	VBD	O
found	VBN	O
in	IN	O
bond	NN	O
failure	NN	O
modes	VBZ	O
in	IN	O
the	DT	O
4	CD	O
groups	NNS	O
.	.	O

CONCLUSIONS	NNP	O
HFLCS	NNP	O
application	NN	O
on	IN	O
enamel	NN	O
etched	VBN	O
with	IN	O
37	CD	O
%	NN	O
phosphoric	JJ	O
acid	NN	O
did	VBD	O
not	RB	O
affect	VB	O
the	DT	O
bond	NN	O
strength	NN	O
values	NNS	O
and	CC	O
the	DT	O
bond	NN	O
failure	NN	O
modes	NNS	O
of	IN	O
metal	NN	O
and	CC	O
ceramic	JJ	O
brackets	NNS	O
bonded	VBN	O
with	IN	O
RMGIC	NNP	O
.	.	O

Selected	VBN	O
polymorphisms	NNS	O
of	IN	O
GSTP1	NNP	O
and	CC	O
TERT	NNP	O
were	VBD	O
associated	VBN	O
with	IN	O
glioma	NN	C
risk	NN	C
in	IN	O
Han	NNP	O
Chinese	NNP	O
.	.	O

BACKGROUND	NNP	O
Current	NNP	O
evidence	NN	O
suggests	VBZ	O
that	IN	O
a	DT	O
majority	NN	O
of	IN	O
the	DT	O
inherited	JJ	O
risks	NNS	O
play	VBP	O
a	DT	O
major	JJ	O
role	NN	O
in	IN	O
glioma	JJ	O
susceptibility	NN	O
,	,	O
and	CC	O
glioma	NN	O
is	VBZ	O
due	JJ	O
to	TO	O
the	DT	O
co-inheritance	NN	O
of	IN	O
multiple	JJ	O
low-risk	JJ	O
variants	NNS	O
.	.	O

These	DT	O
variants	NNS	O
can	MD	O
be	VB	O
identified	VBN	O
through	IN	O
association	NN	O
studies	NNS	O
including	VBG	O
such	JJ	O
as	IN	O
genome-wide	JJ	O
association	NN	O
studies	NNS	O
(	(	O
GWAS	NNP	O
)	)	O
,	,	O
which	WDT	O
has	VBZ	O
led	VBN	O
the	DT	O
glioma	NN	O
epidemiology	NN	O
researchers	NNS	O
to	TO	O
focus	VB	O
on	IN	O
identifying	VBG	O
potential	JJ	O
disease-causing	JJ	O
factors	NNS	O
.	.	O

METHODS	NNP	O
We	PRP	O
evaluated	VBD	O
and	CC	O
validated	VBD	O
10	CD	O
tag	NN	O
single	JJ	O
nucleotide	JJ	O
polymorphisms	NN	O
(	(	O
tSNPs	NN	O
)	)	O
in	IN	O
seven	CD	O
genes	NNS	O
associated	VBN	O
with	IN	O
glioma	NN	C
susceptibility	NN	O
in	IN	O
a	DT	O
Han	NNP	O
Chinese	NNP	O
population	NN	O
,	,	O
including	VBG	O
301	CD	SS
glioma	NN	O
cases	NNS	O
and	CC	O
302	CD	SS
controls	NNS	O
,	,	O
using	VBG	O
a	DT	O
multiplexed	JJ	O
single	JJ	O
nucleotide	NN	O
polymorphism	NN	O
(	(	O
SNP	NNP	O
)	)	O
MassEXTEND	NNP	O
assay	NN	O
.	.	O

We	PRP	O
ascertained	VBD	O
the	DT	O
genotypic	NN	O
frequencies	NNS	O
for	IN	O
each	DT	O
tSNP	NN	O
in	IN	O
control	NN	O
subjects	NNS	O
were	VBD	O
within	IN	O
Hardy-Weinberg	NNP	O
equilibrium	NN	O
(	(	O
HWE	NNP	O
)	)	O
using	VBG	O
an	DT	O
exact	JJ	O
test	NN	O
,	,	O
and	CC	O
then	RB	O
compared	VBN	O
the	DT	O
genotype	NN	O
and	CC	O
allele	JJ	O
frequencies	NNS	O
of	IN	O
glioma	NN	O
patients	NNS	O
and	CC	O
control	NN	O
subjects	NNS	O
using	VBG	O
the	DT	O
?2	JJ	O
test	NN	O
.	.	O

We	PRP	O
then	RB	O
applied	VBD	O
three	CD	O
genetic	JJ	O
models	NNS	O
(	(	O
dominant	JJ	O
,	,	O
recessive	JJ	O
,	,	O
and	CC	O
additive	JJ	O
)	)	O
using	VBG	O
PLINK	NNP	O
software	NN	O
to	TO	O
assess	VB	O
the	DT	O
association	NN	O
of	IN	O
each	DT	O
tSNP	NN	O
with	IN	O
glioma	NN	O
risk	NN	O
.	.	O

RESULTS	NNP	O
We	PRP	O
identified	VBD	O
two	CD	O
tSNPs	NN	O
to	TO	O
be	VB	O
associated	VBN	O
with	IN	O
glioma	NN	O
susceptibility	NN	O
(	(	O
rs1695	NN	O
,	,	O
GSTP1	NNP	O
,	,	O
P	NNP	O
=	NNP	O
0.019	CD	O
;	:	O
rs2853676	NN	O
,	,	O
TERT	NNP	O
,	,	O
P	NNP	O
=	NNP	O
0.039	CD	O
)	)	O
,	,	O
which	WDT	O
we	PRP	O
confirmed	VBD	O
using	VBG	O
dominant	NN	O
and	CC	O
additive	JJ	O
model	NN	O
analyses	NNS	O
.	.	O

The	DT	O
genotype	NN	O
&	CC	O
ldquo	NN	O
;	:	O
GA	NNP	O
&	CC	O
rdquo	NN	O
;	:	O
for	IN	O
rs1695	NN	O
was	VBD	O
recognized	VBN	O
to	TO	O
be	VB	O
a	DT	O
protective	JJ	O
genotype	NN	O
for	IN	O
glioma	NN	O
(	(	O
OR	NNP	O
,	,	O
0.67	CD	O
;	:	O
95	CD	O
%	NN	O
CI	NNP	O
,	,	O
0.47-0.96	NNP	O
;	:	O
P	NNP	O
=	NNP	O
0.027	CD	O
)	)	O
,	,	O
while	IN	O
the	DT	O
genotype	NN	O
&	CC	O
ldquo	NN	O
;	:	O
AG	NNP	O
&	CC	O
rdquo	NN	O
;	:	O
for	IN	O
rs2853676	NN	O
was	VBD	O
shown	VBN	O
to	TO	O
be	VB	O
a	DT	O
risk	NN	O
genotype	NN	O
for	IN	O
glioma	NN	O
(	(	O
OR	NNP	O
,	,	O
1.50	CD	O
;	:	O
95	CD	O
%	NN	O
CI	NNP	O
,	,	O
1.05-2.15	JJ	O
;	:	O
P	NNP	O
=	NNP	O
0.025	CD	O
)	)	O
.	.	O

CONCLUSION	NNP	O
Our	PRP$	O
results	NNS	O
,	,	O
and	CC	O
those	DT	O
from	IN	O
previous	JJ	O
studies	NNS	O
,	,	O
suggest	VBP	O
potential	JJ	O
genetic	JJ	O
contributes	NNS	O
for	IN	O
GSTP1	NNP	O
and	CC	O
TERT	NNP	O
in	IN	O
glioma	NN	O
development	NN	O
.	.	O

A	DT	O
placebo-controlled	JJ	O
trial	NN	O
of	IN	O
maintenance	NN	O
therapy	NN	O
with	IN	O
fluconazole	JJ	O
after	IN	O
treatment	NN	O
of	IN	O
cryptococcal	JJ	C
meningitis	NN	C
in	IN	O
the	DT	O
acquired	JJ	C
immunodeficiency	NN	C
syndrome	NN	C
.	.	C

California	NNP	O
Collaborative	NNP	O
Treatment	NNP	O
Group	NNP	O
.	.	O

BACKGROUND	NNP	O
AND	NNP	O
METHODS	NNP	O
In	IN	O
patients	NNS	O
with	IN	O
the	DT	O
acquired	JJ	C
immunodeficiency	NN	C
syndrome	NN	C
(	(	C
AIDS	NNP	C
)	)	C
,	,	O
the	DT	O
rate	NN	O
of	IN	O
relapse	NN	O
after	IN	O
primary	JJ	O
treatment	NN	O
for	IN	O
cryptococcal	JJ	O
meningitis	NN	O
remains	VBZ	O
high	JJ	O
.	.	O

We	PRP	O
conducted	VBD	O
a	DT	O
controlled	VBN	O
,	,	O
double-blind	JJ	O
trial	NN	O
to	TO	O
evaluate	VB	O
the	DT	O
efficacy	NN	O
of	IN	O
maintenance	NN	O
therapy	NN	O
with	IN	O
fluconazole	NN	O
.	.	O

At	IN	O
entry	NN	O
into	IN	O
the	DT	O
study	NN	O
,	,	O
all	DT	O
participants	NNS	O
had	VBD	O
sterile	JJ	O
cultures	NNS	O
of	IN	O
cerebrospinal	JJ	O
fluid	NN	O
,	,	O
blood	NN	O
,	,	O
and	CC	O
urine	JJ	O
after	IN	O
following	VBG	O
a	DT	O
standardized	JJ	O
course	NN	O
of	IN	O
therapy	NN	O
for	IN	O
culture-proved	JJ	O
cryptococcal	JJ	C
meningitis	NN	C
.	.	O

The	DT	O
patients	NNS	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
take	VB	O
either	DT	O
fluconazole	NN	O
or	CC	O
placebo	NN	O
as	IN	O
maintenance	NN	O
therapy	NN	O
.	.	O

The	DT	O
dose	NN	O
of	IN	O
fluconazole	NN	O
was	VBD	O
100	CD	O
mg	JJ	O
daily	RB	O
in	IN	O
the	DT	O
first	JJ	O
phase	NN	O
of	IN	O
study	NN	O
and	CC	O
200	CD	O
mg	NNS	O
daily	RB	O
in	IN	O
the	DT	O
second	JJ	O
phase	NN	O
.	.	O

RESULTS	NNP	O
Of	IN	O
84	CD	SS
patients	NNS	O
initially	RB	O
enrolled	VBD	O
,	,	O
16	CD	SS
(	(	O
19	CD	O
percent	NN	O
)	)	O
were	VBD	O
found	VBN	O
to	TO	O
have	VB	O
silent	JJ	O
,	,	O
persistent	JJ	O
infection	NN	C
on	IN	O
the	DT	O
basis	NN	O
of	IN	O
cultures	NNS	O
that	WDT	O
became	VBD	O
positive	JJ	O
after	IN	O
entry	NN	O
into	IN	O
the	DT	O
study	NN	O
;	:	O
7	CD	SS
other	JJ	O
patients	NNS	O
were	VBD	O
lost	VBN	O
to	TO	O
follow-up	NNS	O
shortly	RB	O
after	IN	O
entry	NN	O
.	.	O

Of	IN	O
the	DT	O
remaining	VBG	O
61	CD	SS
patients	NNS	O
,	,	O
10	CD	O
of	IN	O
27	CD	O
assigned	VBN	O
to	TO	O
placebo	VB	O
(	(	O
37	CD	O
percent	NN	O
)	)	O
and	CC	O
1	CD	O
of	IN	O
34	CD	O
assigned	VBN	O
to	TO	O
fluconazole	VB	O
(	(	O
3	CD	O
percent	NN	O
)	)	O
had	VBD	O
a	DT	O
recurrence	NN	O
of	IN	O
cryptococcal	JJ	O
infection	NN	O
at	IN	O
any	DT	O
site	NN	O
(	(	O
difference	NN	O
in	IN	O
risk	NN	O
,	,	O
34	CD	O
percent	NN	O
;	:	O
95	CD	O
percent	NN	O
confidence	NN	O
interval	NN	O
,	,	O
15	CD	O
to	TO	O
53	CD	O
)	)	O
.	.	O

Of	IN	O
the	DT	O
11	CD	O
recurrent	NN	O
infections	NNS	O
,	,	O
7	CD	O
were	VBD	O
detected	VBN	O
in	IN	O
urine	NN	O
obtained	VBN	O
after	IN	O
prostatic	JJ	O
massage	NN	O
.	.	O

There	EX	O
were	VBD	O
four	CD	O
recurrent	NN	O
meningeal	NN	O
infections	NNS	O
in	IN	O
the	DT	O
patients	NNS	O
taking	VBG	O
placebo	NN	O
,	,	O
but	CC	O
none	NN	O
in	IN	O
those	DT	O
taking	VBG	O
fluconazole	JJ	O
(	(	O
mean	JJ	O
duration	NN	O
of	IN	O
follow-up	NN	O
,	,	O
164	CD	O
days	NNS	O
)	)	O
(	(	O
P	NNP	O
=	NNP	O
0.03	CD	O
)	)	O
.	.	O

In	IN	O
multivariate	NN	O
analyses	NNS	O
,	,	O
the	DT	O
best	JJS	O
predictors	NNS	O
of	IN	O
recurrence-free	JJ	O
survival	NN	O
were	VBD	O
fluconazole	JJ	O
treatment	NN	O
(	(	O
P	NNP	O
=	NNP	O
0.02	CD	O
;	:	O
relative	JJ	O
hazard	NN	O
,	,	O
13.2	CD	O
)	)	O
,	,	O
a	DT	O
lower	JJR	O
serum	NN	O
cryptococcal-antigen	NN	O
titer	NN	O
(	(	O
P	NNP	O
=	NNP	O
0.05	CD	O
;	:	O
relative	JJ	O
hazard	NN	O
,	,	O
1.2	CD	O
)	)	O
,	,	O
and	CC	O
more	JJR	O
prolonged	JJ	O
primary	JJ	O
therapy	NN	O
with	IN	O
flucytosine	NN	O
(	(	O
P	NNP	O
=	NNP	O
0.09	CD	O
;	:	O
relative	JJ	O
hazard	NN	O
,	,	O
1.1	CD	O
)	)	O
.	.	O

Survival	NNP	O
and	CC	O
toxicity	NN	O
were	VBD	O
similar	JJ	O
in	IN	O
the	DT	O
two	CD	O
maintenance-treatment	JJ	O
groups	NNS	O
.	.	O

CONCLUSIONS	NNP	O
In	IN	O
patients	NNS	O
with	IN	O
AIDS	NNP	C
,	,	O
silent	JJ	O
persistent	JJ	O
infection	NN	O
is	VBZ	O
common	JJ	O
after	IN	O
clinically	RB	O
successful	JJ	O
treatment	NN	O
for	IN	O
cryptococcal	JJ	O
meningitis	NN	O
.	.	O

Maintenance	NNP	O
therapy	NN	O
with	IN	O
fluconazole	NN	O
is	VBZ	O
highly	RB	O
effective	JJ	O
in	IN	O
preventing	VBG	O
recurrent	JJ	O
cryptococcal	JJ	O
infection	NN	O
.	.	O

Comparison	NNP	O
of	IN	O
the	DT	O
evolutional	JJ	O
process	NN	O
of	IN	O
children	NNS	O
with	IN	O
autism	NN	O
spectrum	NN	O
disorders	NNS	O
in	IN	O
different	JJ	O
language	NN	O
therapeutic	JJ	O
interventions	NNS	O
.	.	O

PURPOSE	NNP	O
To	TO	O
analyze	VB	O
and	CC	O
compare	VB	O
the	DT	O
extension	NN	O
and	CC	O
the	DT	O
speed	NN	O
of	IN	O
the	DT	O
evolutional	JJ	O
process	NN	O
of	IN	O
children	NNS	O
with	IN	O
Autism	NNP	O
Spectrum	NNP	O
Disorders	NNP	O
in	IN	O
direct	JJ	O
and	CC	O
indirect	JJ	O
interventions	NNS	O
as	IN	O
opposed	VBN	O
to	TO	O
only	RB	O
indirect	VB	O
intervention	NN	O
.	.	O

METHODS	NNP	O
The	DT	O
design	NN	O
of	IN	O
this	DT	O
study	NN	O
is	VBZ	O
a	DT	O
clinical	JJ	O
trial	NN	O
.	.	O

The	DT	O
sample	NN	O
was	VBD	O
composed	VBN	O
of	IN	O
11	CD	O
children	NNS	O
diagnosed	VBN	O
with	IN	O
Autism	NNP	O
(	(	O
n=6	NN	O
)	)	O
and	CC	O
Asperger	NNP	O
syndrome	VBP	O
(	(	O
n=5	NN	O
)	)	O
by	IN	O
a	DT	O
multidisciplinary	JJ	O
team	NN	O
,	,	O
that	WDT	O
attended	VBD	O
specialized	JJ	O
speech-language	JJ	O
pathology	NN	O
therapy	NN	O
at	IN	O
the	DT	O
institution	NN	O
were	VBD	O
the	DT	O
study	NN	O
was	VBD	O
carried	VBN	O
out	RP	O
.	.	O

These	DT	O
children	NNS	O
were	VBD	O
randomly	RB	O
divided	VBN	O
into	IN	O
two	CD	O
groups	NNS	O
:	:	O
Therapy	NNP	O
Group	NNP	O
(	(	O
TG	NNP	O
)	)	O
-	:	O
composed	VBN	O
by	IN	O
six	CD	O
subjects	NNS	O
receiving	VBG	O
both	DT	O
direct	JJ	O
and	CC	O
indirect	JJ	O
intervention	NN	O
;	:	O
and	CC	O
Orientation	NNP	O
Group	NNP	O
(	(	O
OG	NNP	O
)	)	O
-	:	O
constituted	VBN	O
by	IN	O
five	CD	O
subjects	NNS	O
receiving	VBG	O
exclusively	RB	O
indirect	JJ	O
intervention	NN	O
.	.	O

It	PRP	O
was	VBD	O
used	VBN	O
the	DT	O
Autism	NNP	O
Behavior	NNP	O
Checklist	NNP	O
(	(	O
ABC	NNP	O
)	)	O
to	TO	O
interview	NN	O
the	DT	O
mothers	NNS	O
,	,	O
and	CC	O
the	DT	O
Sample	NNP	O
of	IN	O
Vocal	NNP	O
Behavior	NNP	O
(	(	O
SVB	NNP	O
)	)	O
,	,	O
in	IN	O
three	CD	O
occasions	NNS	O
:	:	O
at	IN	O
the	DT	O
beginning	NN	O
of	IN	O
the	DT	O
intervention	NN	O
process	NN	O
(	(	O
time	NN	O
0	CD	O
)	)	O
,	,	O
six	CD	O
months	NNS	O
later	RB	O
(	(	O
time	NN	O
1	CD	O
)	)	O
and	CC	O
12	CD	O
months	NNS	O
later	RB	O
(	(	O
time	NN	O
2	CD	O
)	)	O
.	.	O

RESULTS	VB	O
It	PRP	O
was	VBD	O
observed	VBN	O
greater	JJR	O
speed	NN	O
and	CC	O
extension	NN	O
in	IN	O
the	DT	O
evolutional	JJ	O
process	NN	O
of	IN	O
the	DT	O
TG	NNP	O
Group	NNP	O
,	,	O
both	DT	O
in	IN	O
the	DT	O
analysis	NN	O
of	IN	O
the	DT	O
Autism	NNP	O
Behavior	NNP	O
Checklist	NNP	O
(	(	O
total	JJ	O
and	CC	O
partial	JJ	O
scores	NNS	O
)	)	O
and	CC	O
the	DT	O
Sample	NNP	O
of	IN	O
Vocal	NNP	O
Behavior	NNP	O
,	,	O
especially	RB	O
in	IN	O
the	DT	O
item	NN	O
Full	NNP	O
Language	NNP	O
.	.	O

The	DT	O
performance	NN	O
of	IN	O
children	NNS	O
with	IN	O
Asperger	NNP	O
syndrome	NN	O
was	VBD	O
considered	VBN	O
more	RBR	O
positive	JJ	O
when	WRB	O
compared	VBN	O
to	TO	O
that	DT	O
of	IN	O
children	NNS	O
with	IN	O
autism	NN	O
.	.	O

There	EX	O
was	VBD	O
greater	JJR	O
evolution	NN	O
in	IN	O
younger	JJR	O
children	NNS	O
and	CC	O
with	IN	O
normal	JJ	O
,	,	O
mild	JJ	O
,	,	O
and	CC	O
moderate	JJ	O
adaptive	JJ	O
functioning	NN	O
.	.	O

CONCLUSION	VB	O
The	DT	O
tendency	NN	O
towards	NNS	O
better	RBR	O
performance	NN	O
of	IN	O
the	DT	O
children	NNS	O
attending	VBG	O
direct	JJ	O
and	CC	O
indirect	JJ	O
intervention	NN	O
showed	VBD	O
that	IN	O
this	DT	O
association	NN	O
is	VBZ	O
fundamental	JJ	O
in	IN	O
the	DT	O
therapeutic	JJ	O
process	NN	O
of	IN	O
children	NNS	O
with	IN	O
Autism	NNP	O
Spectrum	NNP	O
Disorders	NNP	O
.	.	O

Effects	NNS	O
of	IN	O
vacuum-compression	NN	O
therapy	NN	O
on	IN	O
healing	NN	O
of	IN	O
diabetic	JJ	C
foot	NN	C
ulcers	NNS	C
:	:	O
randomized	VBN	O
controlled	JJ	O
trial	NN	O
.	.	O

A	DT	O
single-blind	JJ	O
,	,	O
randomized	VBN	O
controlled	VBD	O
trial	NN	O
was	VBD	O
conducted	VBN	O
to	TO	O
evaluate	VB	O
vacuum-compression	NN	O
therapy	NN	O
(	(	O
VCT	NNP	O
)	)	O
for	IN	O
the	DT	O
healing	NN	O
of	IN	O
diabetic	JJ	C
foot	NN	C
ulcers	NNS	C
.	.	O

Eighteen	NNP	SS
diabetic	JJ	C
patients	NNS	O
with	IN	O
foot	JJ	C
ulcers	NNS	C
were	VBD	O
recruited	VBN	O
through	IN	O
simple	JJ	O
nonprobability	NN	O
sampling	VBG	O
.	.	O

Subjects	NNS	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
either	DT	O
an	DT	O
experimental	JJ	O
or	CC	O
a	DT	O
control	NN	O
group	NN	O
.	.	O

Before	IN	O
and	CC	O
after	IN	O
intervention	NN	O
,	,	O
the	DT	O
foot	NN	O
ulcer	JJ	O
surface	NN	O
area	NN	O
was	VBD	O
estimated	VBN	O
stereologically	RB	O
,	,	O
based	VBN	O
on	IN	O
Cavalieri	NNP	O
's	POS	O
principle	NN	O
.	.	O

The	DT	O
experimental	JJ	O
group	NN	O
was	VBD	O
treated	VBN	O
with	IN	O
VCT	NNP	O
in	IN	O
addition	NN	O
to	TO	O
conventional	JJ	O
therapy	NN	O
for	IN	O
10	CD	O
sessions	NNS	O
.	.	O

The	DT	O
control	NN	O
group	NN	O
received	VBD	O
only	RB	O
conventional	JJ	O
therapy	NN	O
,	,	O
including	VBG	O
debridement	NN	O
,	,	O
blood	NN	O
glucose	NNS	O
control	NN	O
agents	NNS	O
,	,	O
systemic	JJ	O
antibiotics	NNS	O
,	,	O
wound	IN	O
cleaning	VBG	O
with	IN	O
normal	JJ	O
saline	NN	O
,	,	O
offloading	VBG	O
(	(	O
pressure	NN	O
relief	NN	O
)	)	O
,	,	O
and	CC	O
daily	RB	O
wound	JJ	O
dressings	NNS	O
.	.	O

The	DT	O
mean	JJ	O
foot	NN	O
ulcer	JJ	O
surface	NN	O
area	NN	O
decreased	VBD	O
from	IN	O
46.88	CD	O
+/-	JJ	O
9.28	CD	O
mm	NN	O
(	(	O
2	CD	O
)	)	O
to	TO	O
35.09	CD	O
+/-	JJ	O
4.09	CD	O
mm	NN	O
(	(	O
2	CD	O
)	)	O
in	IN	O
the	DT	O
experimental	JJ	O
group	NN	O
(	(	O
p	JJ	O
=	NNP	O
0.006	CD	O
)	)	O
and	CC	O
from	IN	O
46.62	CD	O
+/-	JJ	O
10.03	CD	O
mm	NN	O
(	(	O
2	CD	O
)	)	O
to	TO	O
42.89	CD	O
+/-	JJ	O
8.1	CD	O
mm	NN	O
(	(	O
2	CD	O
)	)	O
in	IN	O
the	DT	O
control	NN	O
group	NN	O
(	(	O
p	JJ	O
=	NNP	O
0.01	CD	O
)	)	O
.	.	O

After	IN	O
treatment	NN	O
,	,	O
the	DT	O
experimental	JJ	O
group	NN	O
significantly	RB	O
improved	VBN	O
in	IN	O
measures	NNS	O
of	IN	O
foot	NN	O
ulcer	JJ	O
surface	NN	O
area	NN	O
compared	VBN	O
with	IN	O
the	DT	O
control	NN	O
group	NN	O
(	(	O
p	JJ	O
=	NNP	O
0.024	CD	O
)	)	O
.	.	O

VCT	NNP	O
enhances	VBZ	O
diabetic	JJ	O
foot	NN	O
ulcer	NN	O
healing	VBG	O
when	WRB	O
combined	VBN	O
with	IN	O
appropriate	JJ	O
wound	NN	O
care	NN	O
.	.	O

A	DT	O
comparison	NN	O
of	IN	O
live	JJ	O
and	CC	O
videotape	JJ	O
ratings	NNS	O
:	:	O
clomipramine	NN	C
and	CC	O
haloperidol	NN	C
in	IN	C
autism	NN	C
.	.	O

This	DT	O
study	NN	O
compared	VBN	O
live	JJ	O
ratings	NNS	O
with	IN	O
ratings	NNS	O
of	IN	O
videotapes	NNS	O
and	CC	O
compared	VBN	O
response	NN	O
to	TO	O
clomipramine	VB	O
with	IN	O
response	NN	O
to	TO	O
haloperidol	VB	O
in	IN	O
8	CD	SS
subjects	NNS	O
,	,	O
mean	JJ	O
age	NN	O
5.62	CD	A
years	NNS	A
,	,	O
who	WP	O
met	VBD	O
criteria	NNS	O
for	IN	O
autism	NN	O
.	.	O

They	PRP	O
were	VBD	O
consecutive	JJ	O
admissions	NNS	O
to	TO	O
a	DT	O
pilot	NN	O
study	NN	O
of	IN	O
clomipramine	NN	O
(	(	O
n	JJ	O
=	NNP	O
4	CD	O
)	)	O
or	CC	O
a	DT	O
double-blind	JJ	O
,	,	O
placebo	NN	O
controlled	VBD	O
study	NN	O
of	IN	O
haloperidol	NN	O
(	(	O
n	JJ	O
=	NNP	O
4	CD	O
)	)	O
.	.	O

Live	JJ	O
ratings	NNS	O
were	VBD	O
performed	VBN	O
by	IN	O
two	CD	O
raters	NNS	O
at	IN	O
the	DT	O
end	NN	O
of	IN	O
the	DT	O
pre-treatment	JJ	O
placebo	NN	O
baseline	NN	O
period	NN	O
and	CC	O
at	IN	O
the	DT	O
end	NN	O
of	IN	O
the	DT	O
drug	NN	O
treatment	NN	O
period	NN	O
on	IN	O
the	DT	O
CPRS	NNP	O
and	CC	O
the	DT	O
CGI	NNP	O
and	CC	O
were	VBD	O
videotaped	VBN	O
.	.	O

Employing	VBG	O
the	DT	O
same	JJ	O
instruments	NNS	O
,	,	O
these	DT	O
videotapes	NNS	O
were	VBD	O
rated	VBN	O
by	IN	O
two	CD	O
raters	NNS	O
who	WP	O
did	VBD	O
not	RB	O
know	VB	O
the	DT	O
subjects	NNS	O
and	CC	O
were	VBD	O
blind	NNS	O
to	TO	O
study	VB	O
design	NN	O
,	,	O
treatment	NN	O
,	,	O
and	CC	O
study	NN	O
phase	NN	O
.	.	O

Ratings	NNS	O
of	IN	O
videotapes	NNS	O
significantly	RB	O
differed	VBN	O
from	IN	O
live	JJ	O
ratings	NNS	O
.	.	O

A	DT	O
treatment	NN	O
effect	NN	O
for	IN	O
haloperidol	NN	O
was	VBD	O
detected	VBN	O
only	RB	O
on	IN	O
live	JJ	O
ratings	NNS	O
and	CC	O
not	RB	O
on	IN	O
ratings	NNS	O
of	IN	O
videotapes	NNS	O
.	.	O

No	DT	O
treatment	NN	O
effect	NN	O
was	VBD	O
detected	VBN	O
for	IN	O
clomipramine	NN	O
in	IN	O
either	CC	O
live	JJ	O
or	CC	O
videotape	JJ	O
ratings	NNS	O
.	.	O

The	DT	O
effect	NN	O
of	IN	O
topical	JJ	O
nasal	NN	O
fluticasone	NN	O
on	IN	O
objective	JJ	O
sleep	NN	O
testing	NN	O
and	CC	O
the	DT	O
symptoms	NNS	O
of	IN	O
rhinitis	NN	O
,	,	O
sleep	NN	O
,	,	O
and	CC	O
daytime	JJ	O
somnolence	NN	O
in	IN	O
perennial	JJ	C
allergic	JJ	C
rhinitis	NN	C
.	.	O

Recent	NNP	O
data	NN	O
suggested	VBD	O
that	IN	O
daytime	JJ	O
somnolence	NN	O
in	IN	O
patients	NNS	O
with	IN	O
allergic	JJ	C
rhinitis	NN	C
was	VBD	O
secondary	JJ	O
to	TO	O
disrupted	VBN	O
sleep	NN	O
caused	VBN	O
by	IN	O
nasal	JJ	O
congestion	NN	O
.	.	O

Medications	NNS	O
,	,	O
which	WDT	O
decreased	VBD	O
congestion	NN	O
,	,	O
would	MD	O
be	VB	O
expected	VBN	O
to	TO	O
improve	VB	O
sleep	NN	O
and	CC	O
daytime	JJ	O
somnolence	NN	O
.	.	O

Previously	RB	O
,	,	O
we	PRP	O
showed	VBD	O
that	IN	O
nasal	JJ	O
steroids	NNS	O
improved	VBD	O
all	DT	O
three	CD	O
symptoms	NNS	O
.	.	O

Presently	RB	O
,	,	O
we	PRP	O
have	VBP	O
not	RB	O
performed	VBN	O
objective	JJ	O
sleep	NN	O
testing	VBG	O
to	TO	O
determine	VB	O
if	IN	O
there	EX	O
is	VBZ	O
a	DT	O
correlation	NN	O
between	IN	O
subjective	JJ	O
improvement	NN	O
of	IN	O
congestion	NN	O
,	,	O
sleep	NN	O
,	,	O
and	CC	O
daytime	JJ	O
somnolence	NN	O
.	.	O

The	DT	O
objective	NN	O
of	IN	O
this	DT	O
8-week	JJ	O
,	,	O
double-blind	JJ	O
,	,	O
placebo-controlled	JJ	O
study	NN	O
was	VBD	O
to	TO	O
determine	VB	O
if	IN	O
topical	JJ	O
nasal	NN	O
fluticasone	NN	O
is	VBZ	O
effective	JJ	O
at	IN	O
decreasing	VBG	O
subjective	JJ	O
congestion	NN	O
and	CC	O
daytime	JJ	O
somnolence	NN	O
and	CC	O
improving	VBG	O
sleep	NN	O
and	CC	O
if	IN	O
this	DT	O
improvement	NN	O
correlated	VBD	O
with	IN	O
a	DT	O
change	NN	O
in	IN	O
overnight	JJ	O
sleep	NN	O
testing	NN	O
(	(	O
polysomnography	NN	O
)	)	O
.	.	O

We	PRP	O
recruited	VBD	O
32	CD	SS
subjects	NNS	O
with	IN	O
perennial	JJ	C
allergic	JJ	C
rhinitis	NN	C
and	CC	O
randomized	VBD	O
them	PRP	O
in	IN	O
a	DT	O
double-blinded	JJ	O
,	,	O
cross-over	JJ	O
fashion	NN	O
,	,	O
to	TO	O
receive	VB	O
placebo	NN	O
or	CC	O
fluticasone	NN	O
(	(	O
50	CD	O
micrograms	NNS	O
a	DT	O
spray	NN	O
)	)	O
,	,	O
2	CD	O
sprays	NNS	O
each	DT	O
side	NN	O
everyday	RB	O
,	,	O
using	VBG	O
Balaam	NNP	O
's	POS	O
design	NN	O
.	.	O

Questionnaires	NNS	O
,	,	O
quality	NN	O
of	IN	O
life	NN	O
instruments	NNS	O
,	,	O
daily	JJ	O
diary	NN	O
,	,	O
Epworth	NNP	O
Sleepiness	NNP	O
Scale	NNP	O
,	,	O
and	CC	O
an	DT	O
overnight	JJ	O
sleep	JJ	O
test	NN	O
with	IN	O
polysomnograms	NNS	O
were	VBD	O
used	VBN	O
as	IN	O
tools	NNS	O
.	.	O

The	DT	O
last	JJ	O
2	CD	O
weeks	NNS	O
of	IN	O
each	DT	O
4-week	JJ	O
treatment	NN	O
period	NN	O
were	VBD	O
summarized	VBN	O
,	,	O
scored	VBN	O
,	,	O
and	CC	O
compared	VBN	O
by	IN	O
PROC	NNP	O
MIXED	NNP	O
in	IN	O
SAS	NNP	O
.	.	O

Correlations	NNS	O
between	IN	O
arousals	NNS	O
on	IN	O
sleep	NN	O
tests	NNS	O
and	CC	O
subjective	JJ	O
tests	NNS	O
were	VBD	O
performed	VBN	O
.	.	O

Fluticasone	CD	O
improved	JJ	O
subjective	JJ	O
sleep	NN	O
when	WRB	O
compared	VBN	O
with	IN	O
placebo	NN	O
(	(	O
p	JJ	O
=	NNP	O
0.04	CD	O
)	)	O
;	:	O
however	RB	O
,	,	O
there	EX	O
was	VBD	O
no	DT	O
difference	NN	O
in	IN	O
the	DT	O
apnea/hypopnea	NN	O
index	NN	O
in	IN	O
those	DT	O
that	WDT	O
were	VBD	O
treated	VBN	O
.	.	O

Daytime	NNP	O
sleepiness	NN	O
and	CC	O
fatigue	NN	O
were	VBD	O
decreased	VBN	O
by	IN	O
>	JJ	O
10	CD	O
%	NN	O
in	IN	O
the	DT	O
treated	JJ	O
group	NN	O
;	:	O
however	RB	O
,	,	O
this	DT	O
was	VBD	O
not	RB	O
statistically	RB	O
significant	JJ	O
.	.	O

However	RB	O
,	,	O
fluticasone	NN	O
used	VBN	O
at	IN	O
approved	JJ	O
doses	NNS	O
improves	VBZ	O
subjective	JJ	O
sleep	NN	O
in	IN	O
patients	NNS	O
with	IN	O
perennial	JJ	C
allergic	JJ	C
rhinitis	NN	C
without	IN	O
a	DT	O
change	NN	O
in	IN	O
the	DT	O
apnea/hypopnea	NN	O
index	NN	O
.	.	O

Cost-effectiveness	NN	O
of	IN	O
cognitive-behavioral	JJ	O
group	NN	O
therapy	NN	O
for	IN	O
dysfunctional	JJ	O
fear	NN	O
of	IN	O
progression	NN	O
in	IN	O
cancer	NN	O
patients	NNS	O
.	.	O

Anxiety	NNP	O
and	CC	O
fear	NN	O
are	VBP	O
often	RB	O
associated	VBN	O
with	IN	O
chronic	JJ	O
conditions	NNS	O
such	JJ	O
as	IN	O
cancer	NN	O
.	.	O

This	DT	O
paper	NN	O
targets	VBZ	O
the	DT	O
cost-effectiveness	JJ	O
analysis	NN	O
of	IN	O
a	DT	O
cognitive-behavioral	JJ	O
group	NN	O
therapy	NN	O
(	(	O
CBT	NNP	O
)	)	O
in	IN	O
comparison	NN	O
to	TO	O
a	DT	O
client-centered	JJ	O
,	,	O
supportive-experiential	JJ	O
group	NN	O
therapy	NN	O
(	(	O
SET	NNP	O
)	)	O
in	IN	O
cancer	NN	O
patients	NNS	O
with	IN	O
dysfunctional	JJ	O
fear	NN	O
of	IN	O
progression	NN	O
.	.	O

An	DT	O
incremental	JJ	O
cost-effectiveness	JJ	O
analysis	NN	O
was	VBD	O
performed	VBN	O
using	VBG	O
data	NNS	O
from	IN	O
a	DT	O
randomized	VBN	O
controlled	VBN	O
trial	NN	O
among	IN	O
cancer	NN	O
patients	NNS	O
receiving	VBG	O
inpatient	JJ	O
rehabilitation	NN	O
.	.	O

The	DT	O
means	NNPS	O
,	,	O
95	CD	O
%	NN	O
confidence	NN	O
intervals	NNS	O
[	VBP	O
95	CD	O
%	NN	O
CI	NNP	O
]	NNP	O
,	,	O
incremental	JJ	O
cost-effectiveness	JJ	O
graphic	NN	O
and	CC	O
acceptability	NN	O
curve	NN	O
were	VBD	O
obtained	VBN	O
from	IN	O
1,000	CD	O
bootstrap	NN	O
replications	NNS	O
.	.	O

A	DT	O
total	NN	O
of	IN	O
174	CD	O
patients	NNS	O
were	VBD	O
included	VBN	O
in	IN	O
the	DT	O
economic	JJ	O
evaluation	NN	O
.	.	O

The	DT	O
estimated	JJ	O
means	VBZ	O
[	JJ	O
95	CD	O
%	NN	O
CI	NNP	O
]	NNP	O
of	IN	O
direct	JJ	O
costs	NNS	O
and	CC	O
reduction	NN	O
of	IN	O
fear	NN	O
of	IN	O
progression	NN	O
were	VBD	O
<	JJ	O
euro	JJ	O
>	NN	O
9,045.03	CD	O
[	JJ	O
6,359.07	CD	O
;	:	O
12,091.87	CD	O
]	NN	O
and	CC	O
1.41	CD	O
[	JJ	O
0.93	CD	O
;	:	O
1.92	CD	O
]	NN	O
for	IN	O
patients	NNS	O
in	IN	O
the	DT	O
SET	NNP	O
and	CC	O
<	NNP	O
euro	VBP	O
>	$	O
6,682.78	CD	O
[	JJ	O
4,998.09	CD	O
;	:	O
8,440.95	CD	O
]	NN	O
and	CC	O
1.44	CD	O
[	JJ	O
1.02	CD	O
;	:	O
1.09	CD	O
]	NN	O
for	IN	O
patients	NNS	O
in	IN	O
the	DT	O
CBT	NNP	O
.	.	O

The	DT	O
incremental	JJ	O
cost-effectiveness	JJ	O
ratio	NN	O
[	VBD	O
95	CD	O
%	NN	O
CI	NNP	O
]	NNP	O
amounts	NNS	O
to	TO	O
minus	NNS	O
<	NNP	O
euro	VBP	O
>	$	O
78,741.66	CD	O
[	NNP	O
-154,987.20	NNP	O
;	:	O
110,486.32	CD	O
]	NN	O
for	IN	O
an	DT	O
additional	JJ	O
unit	NN	O
of	IN	O
effect	NN	O
.	.	O

Given	VBN	O
the	DT	O
acceptability	NN	O
curve	NN	O
,	,	O
there	EX	O
is	VBZ	O
a	DT	O
92.4	CD	O
%	NN	O
chance	NN	O
that	IN	O
the	DT	O
CBT	NNP	O
,	,	O
compared	VBN	O
with	IN	O
the	DT	O
SET	NNP	O
,	,	O
is	VBZ	O
cost-effective	JJ	O
without	IN	O
the	DT	O
need	NN	O
of	IN	O
additional	JJ	O
costs	NNS	O
to	TO	O
payers	NNS	O
.	.	O

Our	PRP$	O
main	JJ	O
result	NN	O
is	VBZ	O
the	DT	O
superior	JJ	O
cost-effectiveness	NN	O
of	IN	O
the	DT	O
cognitive-behavioral	JJ	O
intervention	NN	O
program	NN	O
in	IN	O
comparison	NN	O
to	TO	O
the	DT	O
non-directive	JJ	O
encounter	NN	O
group	NN	O
for	IN	O
our	PRP$	O
sample	NN	O
of	IN	O
cancer	NN	O
patients	NNS	O
with	IN	O
high	JJ	O
levels	NNS	O
of	IN	O
anxiety	NN	O
.	.	O

Pharmacokinetic	JJ	O
properties	NNS	O
of	IN	O
YM17E	NNP	O
,	,	O
an	DT	O
inhibitor	NN	O
of	IN	O
acyl	NN	O
coenzyme	NN	O
A	DT	O
:	:	O
cholesterol	NN	O
acyl	NN	O
transferase	NN	O
,	,	O
and	CC	O
serum	VB	O
cholesterol	NN	O
levels	NNS	O
in	IN	O
healthy	JJ	C
volunteers	NNS	O
.	.	O

We	PRP	O
conducted	VBD	O
a	DT	O
single	JJ	O
and	CC	O
repeat	JJ	O
oral	JJ	O
dose	NN	O
study	NN	O
of	IN	O
YM17E	NNP	O
,	,	O
a	DT	O
novel	JJ	O
inhibitor	NN	O
of	IN	O
acyl	NN	O
coenzyme	NN	O
A	NNP	O
(	(	O
CoA	NNP	O
)	)	O
:	:	O
cholesterol	NN	O
acyltransferase	NN	O
,	,	O
in	IN	O
healthy	JJ	O
male	NN	SE
volunteers	NNS	O
to	TO	O
evaluate	VB	O
the	DT	O
pharmacokinetic	JJ	O
profile	NN	O
,	,	O
tolerability	NN	O
and	CC	O
effect	NN	O
of	IN	O
the	DT	O
drug	NN	O
on	IN	O
serum	NN	O
cholesterol	NN	O
.	.	O

In	IN	O
the	DT	O
single	JJ	O
administration	NN	O
study	NN	O
,	,	O
YM17E	NNP	O
was	VBD	O
administered	VBN	O
after	IN	O
a	DT	O
meal	NN	O
to	TO	O
two	CD	O
groups	NNS	O
of	IN	O
subjects	NNS	O
(	(	O
each	DT	O
containing	VBG	O
six	CD	SS
subjects	NNS	O
taking	VBG	O
the	DT	O
drug	NN	O
and	CC	O
three	CD	SS
taking	VBG	O
placebo	NN	O
)	)	O
receiving	VBG	O
3	CD	O
,	,	O
60	CD	O
and	CC	O
300	CD	O
mg	NN	O
or	CC	O
15	CD	O
,	,	O
60	CD	O
and	CC	O
450	CD	O
mg	NN	O
YM17E	NNP	O
,	,	O
respectively	RB	O
.	.	O

Plasma	NNP	O
concentrations	NNS	O
of	IN	O
unchanged	JJ	O
drug	NN	O
following	VBG	O
single	JJ	O
oral	JJ	O
administration	NN	O
at	IN	O
3-300	JJ	O
mg	NN	O
after	IN	O
a	DT	O
meal	NN	O
increased	VBN	O
with	IN	O
increasing	VBG	O
dose	NN	O
.	.	O

In	IN	O
contrast	NN	O
,	,	O
plasma	NN	O
concentrations	NNS	O
after	IN	O
administration	NN	O
of	IN	O
450	CD	O
mg	NNS	O
were	VBD	O
almost	RB	O
the	DT	O
same	JJ	O
as	IN	O
after	IN	O
300	CD	O
mg	NN	O
.	.	O

Unchanged	VBD	O
YM17E	NNP	O
was	VBD	O
not	RB	O
detected	VBN	O
in	IN	O
urine	NN	O
after	IN	O
single	JJ	O
administration	NN	O
,	,	O
suggesting	VBG	O
that	IN	O
it	PRP	O
was	VBD	O
excreted	VBN	O
via	IN	O
the	DT	O
bile	NN	O
or	CC	O
urine	NN	O
after	IN	O
metabolism	NN	O
.	.	O

Five	CD	O
active	JJ	O
metabolites	NNS	O
(	(	O
M1	NNP	O
,	,	O
M2-a	NNP	O
,	,	O
M2-b	NNP	O
,	,	O
M3	NNP	O
and	CC	O
M4	NNP	O
)	)	O
were	VBD	O
observed	VBN	O
in	IN	O
plasma	NN	O
at	IN	O
concentrations	NNS	O
comparable	JJ	O
to	TO	O
those	DT	O
of	IN	O
unchanged	JJ	O
YM17E	NNP	O
.	.	O

Their	PRP$	O
plasma	JJ	O
concentrations	NNS	O
increased	VBD	O
in	IN	O
a	DT	O
slightly	RB	O
greater	JJR	O
than	IN	O
dose-dependent	JJ	O
manner	NN	O
from	IN	O
3	CD	O
to	TO	O
300	CD	O
mg	NN	O
.	.	O

The	DT	O
effect	NN	O
of	IN	O
food	NN	O
was	VBD	O
studied	VBN	O
in	IN	O
an	DT	O
open	JJ	O
crossover	NN	O
design	NN	O
with	IN	O
a	DT	O
1-week	JJ	O
washout	NN	O
period	NN	O
.	.	O

Twelve	NNP	O
subjects	VBZ	O
received	VBD	O
150	CD	O
mg	NNS	O
YM17E	VBN	O
in	IN	O
both	DT	O
the	DT	O
fasted	VBN	O
and	CC	O
post-prandial	JJ	O
states	NNS	O
.	.	O

The	DT	O
AUC	NNP	O
and	CC	O
Cmax	NNP	O
after	IN	O
fasting	VBG	O
were	VBD	O
closely	RB	O
similar	JJ	O
to	TO	O
those	DT	O
after	IN	O
a	DT	O
meal	NN	O
,	,	O
showing	VBG	O
that	IN	O
bioavailability	NN	O
was	VBD	O
not	RB	O
affected	VBN	O
by	IN	O
food	NN	O
intake	NN	O
.	.	O

In	IN	O
the	DT	O
repeated	JJ	O
oral	JJ	O
dose	NN	O
study	NN	O
,	,	O
the	DT	O
subjects	NNS	O
received	VBD	O
test	JJ	O
drug	NN	O
at	IN	O
150	CD	O
mg	NN	O
or	CC	O
300	CD	O
mg	NN	O
(	(	O
n	JJ	O
=	RB	O
6	CD	O
each	DT	O
)	)	O
or	CC	O
placebo	NN	O
(	(	O
n	JJ	O
=	NNP	O
3	CD	O
)	)	O
twice	RB	O
a	DT	O
day	NN	O
(	(	O
after	IN	O
breakfast	NN	O
and	CC	O
after	IN	O
dinner	NN	O
)	)	O
for	IN	O
7	CD	O
days	NNS	O
.	.	O

On	IN	O
days	NNS	O
1	CD	O
and	CC	O
7	CD	O
,	,	O
the	DT	O
subjects	NNS	O
received	VBD	O
YM17E	NNP	O
once	RB	O
a	DT	O
day	NN	O
(	(	O
after	IN	O
breakfast	NN	O
)	)	O
for	IN	O
evaluation	NN	O
of	IN	O
pharmacokinetic	JJ	O
properties	NNS	O
.	.	O

After	IN	O
repeated	VBN	O
oral	JJ	O
administration	NN	O
of	IN	O
150	CD	O
mg	NN	O
b.d.	NN	O
,	,	O
plasma	JJ	O
concentrations	NNS	O
reached	VBD	O
steady	JJ	O
state	NN	O
by	IN	O
day	NN	O
5	CD	O
(	(	O
mean	JJ	O
Cmin	NNP	O
48.6	CD	O
ng.ml-1	NN	O
)	)	O
.	.	O

After	IN	O
repeated	JJ	O
administration	NN	O
of	IN	O
300	CD	O
mg	NN	O
b.d.	NN	O
,	,	O
plasma	JJ	O
concentrations	NNS	O
prior	RB	O
to	TO	O
each	DT	O
daily	JJ	O
morning	NN	O
dose	NN	O
increased	VBD	O
up	RB	O
to	TO	O
the	DT	O
5th	JJ	O
day	NN	O
(	(	O
mean	JJ	O
Cmin	NNP	O
166.6	CD	O
ng.ml-1	NN	O
)	)	O
and	CC	O
then	RB	O
tended	VBD	O
to	TO	O
decrease	VB	O
until	IN	O
the	DT	O
7th	JJ	O
day	NN	O
.	.	O

No	DT	O
significant	JJ	O
signs	NNS	O
,	,	O
symptoms	NNS	O
or	CC	O
changes	NNS	O
in	IN	O
serum	NN	O
cholesterol	NN	O
levels	NNS	O
were	VBD	O
observed	VBN	O
during	IN	O
the	DT	O
single	JJ	O
and	CC	O
repeated	JJ	O
oral	JJ	O
dose	NN	O
studies	NNS	O
at	IN	O
150	CD	O
mg	NN	O
b.d	NN	O
.	.	O

Although	IN	O
statistical	JJ	O
analysis	NN	O
was	VBD	O
not	RB	O
conducted	VBN	O
because	IN	O
of	IN	O
the	DT	O
small	JJ	O
number	NN	O
of	IN	O
subjects	NNS	O
,	,	O
all	DT	O
subjects	NNS	O
receiving	VBG	O
repeated	VBD	O
oral	JJ	O
administration	NN	O
of	IN	O
300	CD	O
mg	JJ	O
twice	RB	O
daily	RB	O
showed	VBD	O
a	DT	O
25	CD	O
%	NN	O
decrease	NN	O
in	IN	O
serum	NN	O
cholesterol	NN	O
level	NN	O
on	IN	O
day	NN	O
7	CD	O
,	,	O
but	CC	O
also	RB	O
the	DT	O
simultaneous	JJ	O
occurrence	NN	O
of	IN	O
diarrhoea	NN	O
.	.	O

Laparoscopically	RB	O
assisted	VBN	O
vaginal	JJ	O
hysterectomy	NN	O
versus	IN	O
abdominal	JJ	O
hysterectomy	NN	O
in	IN	O
stage	NN	C
I	PRP	C
endometrial	JJ	C
cancer	NN	C
.	.	O

The	DT	O
purpose	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
evaluate	VB	O
and	CC	O
compare	VB	O
laparoscopic	JJ	O
treatment	NN	O
for	IN	O
stage	NN	C
I	PRP	C
endometrial	JJ	C
cancer	NN	C
with	IN	O
the	DT	O
traditional	JJ	O
transabdominal	JJ	O
approach	NN	O
.	.	O

From	IN	O
July	NNP	O
1996	CD	O
to	TO	O
July	NNP	O
1998	CD	O
,	,	O
61	CD	SS
patients	NNS	O
with	IN	O
clinical	JJ	O
stage	NN	C
I	PRP	C
endometrial	JJ	C
cancer	NN	C
were	VBD	O
treated	VBN	O
at	IN	O
the	DT	O
Gynaecology	NNP	O
Oncology	NNP	O
Unit	NNP	O
at	IN	O
the	DT	O
Royal	NNP	O
North	NNP	O
Shore	NNP	O
of	IN	O
Sydney	NNP	O
,	,	O
Australia	NNP	O
.	.	O

Twenty-nine	JJ	SS
patients	NNS	O
were	VBD	O
treated	VBN	O
with	IN	O
laparoscopic	NN	C
assisted	VBN	C
vaginal	JJ	C
hysterectomy	NN	C
(	(	O
LAVH	NNP	C
)	)	O
and	CC	O
bilateral	JJ	C
salpingo-oophrectomy	NN	C
(	(	O
BSO	NNP	C
)	)	O
plus	CC	O
minus	CC	O
laparoscopic	JJ	C
pelvic	JJ	C
lymphadenectomy	NN	C
(	(	O
LPLA	NNP	C
)	)	O
,	,	O
while	IN	O
32	CD	SS
patients	NNS	O
were	VBD	O
treated	VBN	O
with	IN	O
the	DT	O
traditional	JJ	O
laparotomy	NN	O
and	CC	O
underwent	JJ	O
total	JJ	O
abdominal	JJ	O
hysterectomy	NN	O
(	(	O
TAH	NNP	O
)	)	O
and	CC	O
BSO	NNP	O
plus	CC	O
minus	CC	O
pelvic	JJ	O
lymphadenectomy	NN	O
(	(	O
PLA	NNP	O
)	)	O
.	.	O

The	DT	O
main	JJ	O
outcomes	NNS	O
studied	VBN	O
were	VBD	O
operative	JJ	O
time	NN	O
,	,	O
blood	NN	O
loss	NN	O
,	,	O
blood	NN	O
transfusion	NN	O
,	,	O
intraoperative	JJ	O
complications	NNS	O
,	,	O
postoperative	JJ	O
complications	NNS	O
,	,	O
duration	NN	O
of	IN	O
hospital	NN	O
stay	NN	O
,	,	O
and	CC	O
number	NN	O
of	IN	O
lymph	JJ	O
nodes	NNS	O
obtained	VBN	O
.	.	O

In	IN	O
conclusion	NN	O
,	,	O
laparoscopic	JJ	O
treatment	NN	O
of	IN	O
endometrial	JJ	O
cancer	NN	O
is	VBZ	O
safe	JJ	O
in	IN	O
the	DT	O
hands	NNS	O
of	IN	O
experienced	JJ	O
operators	NNS	O
with	IN	O
minimal	JJ	O
intraoperative	JJ	O
and	CC	O
postoperative	JJ	O
complications	NNS	O
.	.	O

This	DT	O
procedure	NN	O
is	VBZ	O
associated	VBN	O
with	IN	O
significantly	RB	O
less	JJR	O
blood	JJ	O
loss	NN	O
and	CC	O
shorter	JJR	O
hospitalization	NN	O
;	:	O
however	RB	O
,	,	O
it	PRP	O
is	VBZ	O
associated	VBN	O
with	IN	O
significantly	RB	O
longer	RBR	O
operating	VBG	O
time	NN	O
.	.	O

Proper	NNP	O
selection	NN	O
of	IN	O
patients	NNS	O
for	IN	O
the	DT	O
laparoscopic	JJ	O
procedure	NN	O
is	VBZ	O
the	DT	O
vital	JJ	O
step	NN	O
in	IN	O
achieving	VBG	O
the	DT	O
major	JJ	O
goals	NNS	O
of	IN	O
this	DT	O
approach	NN	O
.	.	O

Acute	NNP	O
intravenous	JJ	O
L-arginine	JJ	O
infusion	NN	O
decreases	VBZ	O
endothelin-1	JJ	O
levels	NNS	O
and	CC	O
improves	VBZ	O
endothelial	JJ	O
function	NN	O
in	IN	O
patients	NNS	O
with	IN	O
angina	JJ	C
pectoris	NN	C
and	CC	O
normal	JJ	O
coronary	JJ	O
arteriograms	NNS	C
:	:	O
correlation	NN	O
with	IN	O
asymmetric	JJ	O
dimethylarginine	NN	O
levels	NNS	O
.	.	O

BACKGROUND	NNP	O
We	PRP	O
tested	VBD	O
the	DT	O
hypothesis	NN	O
that	WDT	O
asymmetric	JJ	O
dimethylarginine	NN	O
(	(	O
ADMA	NNP	O
)	)	O
levels	NNS	O
could	MD	O
be	VB	O
elevated	VBN	O
and	CC	O
influence	VB	O
endothelin-1	JJ	O
and	CC	O
nitric	JJ	O
oxide	NN	O
release	NN	O
and	CC	O
action	NN	O
in	IN	O
patients	NNS	O
with	IN	O
cardiac	JJ	C
syndrome	NN	C
X	NNP	C
(	(	O
CSX	NNP	O
)	)	O
.	.	O

In	IN	O
addition	NN	O
,	,	O
we	PRP	O
evaluated	VBD	O
whether	IN	O
an	DT	O
intravenous	JJ	O
infusion	NN	O
of	IN	O
L-arginine	NNP	O
would	MD	O
improve	VB	O
endothelial	JJ	O
function	NN	O
in	IN	O
these	DT	O
subjects	NNS	O
.	.	O

METHODS	NNP	O
AND	CC	O
RESULTS	NNP	O
Nine	NNP	SS
patients	NNS	O
with	IN	O
CSX	NNP	O
and	CC	O
14	CD	O
control	NN	O
subjects	NNS	O
underwent	VBD	O
a	DT	O
continuous	JJ	O
infusion	NN	O
of	IN	O
L-arginine	NNP	O
(	(	O
0.125	CD	O
g/min	NN	O
)	)	O
or	CC	O
saline	NN	O
for	IN	O
120	CD	O
minutes	NNS	O
.	.	O

Sixty	NNP	O
minutes	NNS	O
after	IN	O
L-arginine	NNP	O
or	CC	O
saline	JJ	O
infusions	NNS	O
,	,	O
an	DT	O
intravenous	JJ	O
insulin	NN	O
bolus	NN	O
(	(	O
0.1	CD	O
U/kg	NNP	O
)	)	O
combined	VBD	O
with	IN	O
a	DT	O
euglycemic	JJ	O
clamp	NN	O
was	VBD	O
performed	VBN	O
.	.	O

Basal	NNP	O
ADMA	NNP	O
and	CC	O
endothelin-1	JJ	O
levels	NNS	O
were	VBD	O
higher	JJR	O
in	IN	O
patients	NNS	O
with	IN	O
CSX	NNP	O
than	IN	O
in	IN	O
controls	NNS	O
.	.	O

At	IN	O
the	DT	O
end	NN	O
of	IN	O
the	DT	O
first	JJ	O
hour	NN	O
of	IN	O
infusion	NN	O
,	,	O
compared	VBN	O
with	IN	O
saline	NN	O
,	,	O
L-arginine	JJ	O
infusion	NN	O
increased	VBD	O
basal	JJ	O
forearm	NN	O
blood	NN	O
flow	NN	O
,	,	O
nitrite	JJ	O
and	CC	O
nitrate	JJ	O
(	(	O
NOx	NNP	O
)	)	O
,	,	O
and	CC	O
forearm	NN	O
cGMP	NN	O
release	NN	O
and	CC	O
decreased	VBD	O
endothelin-1	NN	O
.	.	O

After	IN	O
insulin	NN	O
bolus	NN	O
,	,	O
during	IN	O
saline	NN	O
,	,	O
insulin-induced	JJ	O
NOx	NNP	O
,	,	O
endothelin-1	JJ	O
,	,	O
and	CC	O
forearm	NN	O
cGMP	NN	O
release	NN	O
was	VBD	O
almost	RB	O
abolished	VBN	O
.	.	O

Conversely	RB	O
,	,	O
L-arginine	NNP	O
restored	VBD	O
a	DT	O
physiological	JJ	O
profile	NN	O
of	IN	O
all	DT	O
endothelial	JJ	O
variables	NNS	O
compared	VBN	O
with	IN	O
control	NN	O
subjects	NNS	O
.	.	O

In	IN	O
control	NN	O
subjects	NNS	O
,	,	O
compared	VBN	O
with	IN	O
saline	JJ	O
infusion	NN	O
,	,	O
L-arginine	JJ	O
infusion	NN	O
did	VBD	O
not	RB	O
modify	VB	O
any	DT	O
parameter	NN	O
.	.	O

ADMA	NNP	O
levels	NNS	O
were	VBD	O
positively	RB	O
correlated	VBN	O
with	IN	O
basal	JJ	O
endothelin-1	JJ	O
levels	NNS	O
and	CC	O
negatively	RB	O
correlated	VBN	O
with	IN	O
insulin-induced	JJ	O
incremental	JJ	O
levels	NNS	O
of	IN	O
NOx	NNP	O
and	CC	O
forearm	NN	O
cGMP	NN	O
release	NN	O
.	.	O

CONCLUSIONS	NNP	O
Plasma	NNP	O
ADMA	NNP	O
levels	NNS	O
are	VBP	O
increased	VBN	O
in	IN	O
patients	NNS	O
with	IN	O
CSX	NNP	O
,	,	O
and	CC	O
they	PRP	O
are	VBP	O
correlated	VBN	O
with	IN	O
increases	NNS	O
in	IN	O
endothelin-1	JJ	O
and	CC	O
reductions	NNS	O
in	IN	O
insulin-induced	JJ	O
increments	NNS	O
in	IN	O
plasma	NN	O
NOx	NNP	O
and	CC	O
cGMP	NN	O
,	,	O
effects	NNS	O
that	WDT	O
are	VBP	O
reversed	VBN	O
by	IN	O
intravenous	JJ	O
L-arginine	NNP	O
.	.	O

These	DT	O
data	NNS	O
suggest	VBP	O
that	IN	O
increased	VBD	O
ADMA	NNP	O
levels	NNS	O
play	VBP	O
a	DT	O
role	NN	O
in	IN	O
the	DT	O
abnormal	JJ	O
vascular	JJ	O
reactivity	NN	O
that	WDT	O
is	VBZ	O
observed	VBN	O
in	IN	O
patients	NNS	O
with	IN	O
CSX	NNP	O
.	.	O

[	JJ	O
Effect	NNP	O
of	IN	O
ulinastatin	NN	O
on	IN	O
inflammatory	JJ	C
responses	NNS	C
induced	VBN	O
by	IN	O
oesophagectomy	JJ	O
]	NNP	O
.	.	O

OBJECTIVE	NNP	O
To	TO	O
examine	VB	O
the	DT	O
effect	NN	O
of	IN	O
ulinastatin	NN	O
(	(	O
UTI	NNP	O
)	)	O
on	IN	O
the	DT	O
inflammatory	JJ	C
responses	NNS	C
induced	VBN	O
by	IN	O
oesophagectomy	NN	O
.	.	O

METHODS	NNP	O
Forty	NNP	SS
patients	NNS	O
with	IN	O
esophageal	JJ	C
cancer	NN	C
(	(	O
without	IN	O
serious	JJ	C
hypertension	NN	C
,	,	O
heart	NN	C
disease	NN	C
,	,	O
or	CC	O
respiratory	JJ	C
function	NN	C
impairment	NN	C
,	,	O
including	VBG	O
34	CD	SS
men	NNS	SE
and	CC	O
6	CD	SS
women	NNS	SE
aged	VBD	O
46	CD	A
to	TO	A
70	CD	A
years	NNS	A
)	)	O
scheduled	VBD	O
for	IN	O
oesophagectomy	JJ	O
via	IN	O
left	JJ	O
thoracotomy	NN	O
were	VBD	O
randomly	RB	O
divided	VBN	O
into	IN	O
control	NN	O
group	NN	O
(	(	O
n=20	CC	O
)	)	O
and	CC	O
UTI	NNP	O
group	NN	O
(	(	O
n=20	RB	O
)	)	O
.	.	O

Anesthesia	NNP	O
induction	NN	O
and	CC	O
perioperative	JJ	O
management	NN	O
followed	VBD	O
the	DT	O
same	JJ	O
protocols	NNS	O
in	IN	O
the	DT	O
two	CD	O
groups	NNS	O
,	,	O
and	CC	O
in	IN	O
UTI	NNP	O
group	NN	O
,	,	O
patients	NNS	O
received	VBD	O
5000	CD	O
U/kg	NNP	O
UTI	NNP	O
while	IN	O
those	DT	O
in	IN	O
the	DT	O
control	NN	O
group	NN	O
were	VBD	O
given	VBN	O
the	DT	O
same	JJ	O
volume	NN	O
of	IN	O
saline	NN	O
.	.	O

Before	IN	O
operation	NN	O
(	(	O
T	NNP	O
(	(	O
1	CD	O
)	)	O
)	)	O
,	,	O
10	CD	O
min	NN	O
after	IN	O
recovery	NN	O
of	IN	O
two-lung	JJ	O
ventilation	NN	O
(	(	O
T	NNP	O
(	(	O
2	CD	O
)	)	O
)	)	O
,	,	O
and	CC	O
24	CD	O
h	NN	O
(	(	O
T	NNP	O
(	(	O
3	CD	O
)	)	O
)	)	O
and	CC	O
48	CD	O
h	NN	O
(	(	O
T	NNP	O
(	(	O
4	CD	O
)	)	O
)	)	O
after	IN	O
operation	NN	O
,	,	O
the	DT	O
venous	JJ	O
blood	NN	O
sample	NN	O
was	VBD	O
taken	VBN	O
from	IN	O
the	DT	O
internal	JJ	O
jugular	NN	O
vein	NN	O
and	CC	O
the	DT	O
plasma	NN	O
was	VBD	O
separated	VBN	O
and	CC	O
stored	VBN	O
at	IN	O
-70	NNP	O
degrees	NNS	O
C	NNP	O
for	IN	O
later	JJR	O
analysis	NN	O
of	IN	O
IL-6	NNP	O
and	CC	O
IL-8	NNP	O
with	IN	O
enzyme-linked	JJ	O
immunosorbent	NN	O
assay	NN	O
(	(	O
ELISA	NNP	O
)	)	O
.	.	O

The	DT	O
bronchoalveoar	NN	O
lavage	NN	O
fluid	NN	O
(	(	O
BAFL	NNP	O
)	)	O
was	VBD	O
also	RB	O
collected	VBN	O
at	IN	O
T	NNP	O
(	(	O
1	CD	O
)	)	O
and	CC	O
T	NNP	O
(	(	O
2	CD	O
)	)	O
for	IN	O
IL-6	NNP	O
and	CC	O
IL-8	NNP	O
detection	NN	O
.	.	O

RESULTS	NNP	O
IL-6	JJ	O
,	,	O
IL-8	JJ	O
levels	NNS	O
in	IN	O
the	DT	O
plasma	NN	O
and	CC	O
BALF	NNP	O
collected	VBD	O
at	IN	O
T	NNP	O
(	(	O
2	CD	O
)	)	O
-T	NN	O
(	(	O
4	CD	O
)	)	O
increased	VBD	O
significantly	RB	O
as	IN	O
compared	VBN	O
with	IN	O
those	DT	O
in	IN	O
samples	NNS	O
collected	VBN	O
at	IN	O
T	NNP	O
(	(	O
1	CD	O
)	)	O
,	,	O
and	CC	O
their	PRP$	O
peak	JJ	O
concentration	NN	O
inplasma	NN	O
and	CC	O
BALF	NNP	O
samples	NNS	O
were	VBD	O
similar	JJ	O
.	.	O

IL-6	JJ	O
and	CC	O
IL-8	JJ	O
levels	NNS	O
in	IN	O
the	DT	O
UTI	NNP	O
group	NN	O
were	VBD	O
significantly	RB	O
lower	JJR	O
than	IN	O
those	DT	O
in	IN	O
the	DT	O
control	NN	O
group	NN	O
during	IN	O
the	DT	O
time	NN	O
points	NNS	O
of	IN	O
T	NNP	O
(	(	O
2	CD	O
)	)	O
-T	NN	O
(	(	O
4	CD	O
)	)	O
.	.	O

CONCLUSION	NNP	O
Inflammatory	NNP	O
responses	VBZ	O
occur	VBP	O
during	IN	O
and	CC	O
after	IN	O
oesophagectomy	NN	O
,	,	O
which	WDT	O
can	MD	O
be	VB	O
inhibited	VBN	O
with	IN	O
UTI	NNP	O
.	.	O

A	DT	O
psychological	JJ	O
intervention	NN	O
reduces	NNS	O
inflammatory	JJ	O
markers	NNS	O
by	IN	O
alleviating	VBG	O
depressive	JJ	O
symptoms	NNS	O
:	:	O
secondary	JJ	O
analysis	NN	O
of	IN	O
a	DT	O
randomized	VBN	O
controlled	VBN	O
trial	NN	O
.	.	O

OBJECTIVES	UH	O
To	TO	O
test	VB	O
experimentally	RB	O
whether	IN	O
a	DT	O
psychological	JJ	O
intervention	NN	O
reduces	NNS	O
depression-related	JJ	O
symptoms	NNS	O
and	CC	O
markers	NNS	O
of	IN	O
inflammation	NN	O
among	IN	O
cancer	NN	C
patients	NNS	O
and	CC	O
to	TO	O
test	VB	O
one	CD	O
mechanism	NN	O
for	IN	O
the	DT	O
intervention	NN	O
effects	NNS	O
.	.	O

Depression	NNP	O
and	CC	O
inflammation	NN	O
are	VBP	O
common	JJ	O
among	IN	O
cancer	NN	C
patients	NNS	O
.	.	O

Data	NNP	O
suggest	NN	O
that	IN	O
inflammation	NN	O
can	MD	O
contribute	VB	O
to	TO	O
depressive	VB	O
symptoms	NNS	O
,	,	O
although	IN	O
the	DT	O
converse	NN	O
remains	VBZ	O
untested	JJ	O
.	.	O

METHODS	NNP	O
As	IN	O
part	NN	O
of	IN	O
a	DT	O
randomized	JJ	O
clinical	JJ	O
trial	NN	O
,	,	O
newly	RB	O
diagnosed	VBN	O
breast	NN	C
cancer	NN	C
patients	NNS	O
(	(	O
n	JJ	O
=	NNP	O
45	CD	SS
)	)	O
with	IN	O
clinically	RB	C
significant	JJ	C
depressive	JJ	C
symptoms	NNS	C
were	VBD	O
evaluated	VBN	O
and	CC	O
randomized	VBN	O
to	TO	O
psychological	JJ	O
intervention	NN	O
with	IN	O
assessment	NN	O
or	CC	O
assessment	NN	O
only	RB	O
study	VBD	O
arms	NNS	O
.	.	O

The	DT	O
intervention	NN	O
spanned	VBD	O
12	CD	O
months	NNS	O
,	,	O
with	IN	O
assessments	NNS	O
at	IN	O
baseline	NN	O
,	,	O
4	CD	O
,	,	O
8	CD	O
,	,	O
and	CC	O
12	CD	O
months	NNS	O
.	.	O

Mixed-effects	NNS	O
modeling	VBG	O
tested	VBD	O
the	DT	O
hypothesis	NN	O
that	IN	O
the	DT	O
intervention	NN	O
reduced	VBD	O
self-reported	JJ	O
depressive	NN	O
symptoms	NNS	O
(	(	O
Center	NNP	O
for	IN	O
Epidemiological	NNP	O
Studies	NNPS	O
Depression	NNP	O
scale	NN	O
,	,	O
Profile	NNP	O
of	IN	O
Mood	NNP	O
States	NNPS	O
Depression	NNP	O
and	CC	O
Fatigue	NNP	O
subscales	NNS	O
,	,	O
and	CC	O
Medical	NNP	O
Outcomes	NNP	O
Study-Short	NNP	O
Form	NNP	O
36	CD	O
Bodily	NNP	O
Pain	NNP	O
subscale	NN	O
)	)	O
and	CC	O
immune	JJ	O
cell	NN	O
numbers	NNS	O
that	WDT	O
are	VBP	O
elevated	VBN	O
in	IN	O
the	DT	O
presence	NN	O
of	IN	O
inflammation	NN	O
(	(	O
white	JJ	O
blood	NN	O
cell	NN	O
count	NN	O
,	,	O
neutrophil	JJ	O
count	NN	O
,	,	O
and	CC	O
helper/suppressor	VB	O
ratio	NN	O
)	)	O
.	.	O

Mediation	NN	O
analyses	NNS	O
tested	VBD	O
whether	IN	O
change	NN	O
in	IN	O
depressive	JJ	O
symptoms	NNS	O
,	,	O
pain	NN	O
,	,	O
or	CC	O
fatigue	NN	O
predicted	VBN	O
change	NN	O
in	IN	O
white	JJ	O
blood	NN	O
cell	NN	O
count	NN	O
,	,	O
neutrophil	JJ	O
count	NN	O
,	,	O
or	CC	O
the	DT	O
helper/suppressor	NN	O
ratio	NN	O
.	.	O

RESULTS	VB	O
The	DT	O
intervention	NN	O
reduced	VBD	O
significantly	RB	O
depressive	JJ	O
symptoms	NNS	O
,	,	O
pain	NN	O
,	,	O
fatigue	NN	O
,	,	O
and	CC	O
inflammation	NN	O
markers	NNS	O
.	.	O

Moreover	RB	O
,	,	O
the	DT	O
intervention	NN	O
effect	NN	O
on	IN	O
inflammation	NN	O
was	VBD	O
mediated	VBN	O
by	IN	O
its	PRP$	O
effect	NN	O
on	IN	O
depressive	NN	O
symptoms	NNS	O
.	.	O

CONCLUSIONS	VB	O
This	DT	O
is	VBZ	O
the	DT	O
first	JJ	O
experiment	NN	O
to	TO	O
test	VB	O
whether	IN	O
psychological	JJ	O
treatment	NN	O
effective	JJ	O
in	IN	O
reducing	VBG	O
depressive	JJ	O
symptoms	NNS	O
would	MD	O
also	RB	O
reduce	VB	O
indicators	NNS	O
of	IN	O
inflammation	NN	O
.	.	O

Data	NNP	O
show	NN	O
that	IN	O
the	DT	O
intervention	NN	O
reduced	VBD	O
directly	RB	O
depressive	JJ	O
symptoms	NNS	O
and	CC	O
reduced	VBN	O
indirectly	RB	O
inflammation	NN	O
.	.	O

Psychological	JJ	O
treatment	NN	O
may	MD	O
treat	VB	O
effectively	RB	O
depressive	JJ	O
symptoms	NNS	O
,	,	O
pain	NN	O
,	,	O
and	CC	O
fatigue	NN	O
among	IN	O
cancer	NN	C
patients	NNS	O
.	.	O

Therapy	NNP	O
effect	NN	O
of	IN	O
either	CC	O
paclitaxel	NN	O
or	CC	O
cyclophosphamide	JJ	O
combination	NN	O
treatment	NN	O
in	IN	O
patients	NNS	O
with	IN	O
epithelial	JJ	C
ovarian	JJ	C
cancer	NN	C
and	CC	O
relation	NN	O
to	TO	O
TP53	NNP	O
gene	NN	O
status	NN	O
.	.	O

Cell	NNP	O
death	NN	O
after	IN	O
treatment	NN	O
with	IN	O
chemotherapy	NN	O
is	VBZ	O
exerted	VBN	O
by	IN	O
activation	NN	O
of	IN	O
apoptosis	NN	O
,	,	O
and	CC	O
the	DT	O
p53	NN	O
protein	NN	O
has	VBZ	O
been	VBN	O
shown	VBN	O
to	TO	O
actively	RB	O
participate	VB	O
in	IN	O
this	DT	O
process	NN	O
.	.	O

This	DT	O
recent	JJ	O
focus	NN	O
on	IN	O
TP53	NNP	O
status	NN	O
as	IN	O
a	DT	O
possible	JJ	O
determinant	NN	O
of	IN	O
cancer	NN	O
therapy	NN	O
response	NN	O
has	VBZ	O
raised	VBN	O
the	DT	O
question	NN	O
of	IN	O
whether	IN	O
or	CC	O
not	RB	O
mutations	NNS	O
in	IN	O
the	DT	O
TP53	NNP	O
gene	NN	O
have	VBP	O
an	DT	O
influence	NN	O
on	IN	O
paclitaxel	NN	O
therapy	NN	O
.	.	O

The	DT	O
TP53	NNP	O
status	NN	O
has	VBZ	O
been	VBN	O
analysed	VBN	O
at	IN	O
the	DT	O
DNA	NNP	O
level	NN	O
in	IN	O
tumours	NNS	O
from	IN	O
45	CD	SS
ovarian	JJ	C
cancer	NN	C
patients	NNS	O
randomized	VBN	O
to	TO	O
treatment	NN	O
with	IN	O
paclitaxel	NN	O
and	CC	O
cisplatin	NN	O
or	CC	O
cyclophosphamide	NN	O
and	CC	O
cisplatin	NN	O
.	.	O

Therapy	NNP	O
response	NN	O
was	VBD	O
obtained	VBN	O
for	IN	O
38	CD	SS
patients	NNS	O
with	IN	O
clinically	RB	O
evaluable	JJ	O
disease	NN	O
after	IN	O
initial	JJ	O
surgery	NN	O
.	.	O

The	DT	O
positive	JJ	O
response	NN	O
rate	NN	O
to	TO	O
the	DT	O
paclitaxel/cisplatin	NN	O
therapy	NN	O
was	VBD	O
85	CD	O
%	NN	O
vs	JJ	O
61	CD	O
%	NN	O
for	IN	O
the	DT	O
patients	NNS	O
who	WP	O
received	VBD	O
the	DT	O
cyclophosphamide/cisplatin	JJ	O
regimen	NNS	O
.	.	O

A	DT	O
significant	JJ	O
difference	NN	O
in	IN	O
relapse-free	JJ	O
survival	NN	O
in	IN	O
favour	NN	O
of	IN	O
paclitaxel/cisplatin	NN	O
chemotherapy	NN	O
was	VBD	O
found	VBN	O
(	(	O
P	NNP	O
=	NNP	O
0.001	CD	O
)	)	O
.	.	O

A	DT	O
total	NN	O
of	IN	O
33	CD	O
tumour	NN	O
samples	NNS	O
(	(	O
73	CD	O
%	NN	O
)	)	O
had	VBD	O
detectable	JJ	O
sequence	NN	O
alterations	NNS	O
in	IN	O
the	DT	O
TP53	NNP	O
gene	NN	O
.	.	O

When	WRB	O
relapse-free	JJ	O
survival	NN	O
was	VBD	O
estimated	VBN	O
for	IN	O
all	DT	O
patients	NNS	O
with	IN	O
TP53	NNP	O
alterations	NNS	O
in	IN	O
their	PRP$	O
tumours	NNS	O
,	,	O
a	DT	O
significant	JJ	O
better	RBR	O
outcome	NN	O
for	IN	O
the	DT	O
paclitaxel/cisplatin	NN	O
group	NN	O
was	VBD	O
found	VBN	O
compared	VBN	O
with	IN	O
the	DT	O
patient	NN	O
group	NN	O
receiving	VBG	O
cyclophosphamide	NN	O
and	CC	O
cisplatin	NN	O
therapy	NN	O
(	(	O
P	NNP	O
=	NNP	O
0.002	CD	O
)	)	O
.	.	O

We	PRP	O
did	VBD	O
not	RB	O
observe	VB	O
an	DT	O
association	NN	O
between	IN	O
TP53	NNP	O
tumour	NN	O
status	NN	O
and	CC	O
prognosis	NN	O
for	IN	O
patients	NNS	O
who	WP	O
received	VBD	O
paclitaxel/cisplatin	JJ	O
combination	NN	O
treatment	NN	O
,	,	O
indicating	VBG	O
that	IN	O
the	DT	O
effect	NN	O
of	IN	O
this	DT	O
therapy	NN	O
is	VBZ	O
not	RB	O
influenced	VBN	O
by	IN	O
this	DT	O
parameter	NN	O
.	.	O

Prognostic	JJ	O
value	NN	O
of	IN	O
postoperative	JJ	O
CEA	NNP	O
clearance	NN	O
in	IN	O
rectal	JJ	C
cancer	NN	C
patients	NNS	C
with	IN	C
high	JJ	C
preoperative	JJ	C
CEA	NNP	C
levels	NNS	C
.	.	O

PURPOSE	NNP	O
We	PRP	O
determined	VBD	O
the	DT	O
prognostic	JJ	O
value	NN	O
of	IN	O
carcinoembryonic	JJ	O
antigen	NN	O
(	(	O
CEA	NNP	O
)	)	O
clearance	NN	O
after	IN	O
tumor	NN	O
resection	NN	O
with	IN	O
serial	JJ	O
evaluation	NN	O
of	IN	O
postoperative	JJ	O
CEA	NNP	O
levels	NNS	O
in	IN	O
rectal	JJ	O
cancer	NN	O
.	.	O

METHODS	NNP	O
Between	NNP	O
1994	CD	O
and	CC	O
2004	CD	O
,	,	O
we	PRP	O
retrospectively	RB	O
reviewed	VBD	O
122	CD	SS
patients	NNS	O
with	IN	O
rectal	JJ	O
cancer	NN	O
whose	WP$	O
serum	JJ	O
CEA	NNP	O
levels	NNS	O
were	VBD	O
measured	VBN	O
on	IN	O
the	DT	O
preoperative	JJ	O
day	NN	O
and	CC	O
postoperative	JJ	O
days	NNS	O
7	CD	O
and	CC	O
30	CD	O
.	.	O

Patients	NNS	O
with	IN	O
preoperative	JJ	O
CEA	NNP	O
levels	NNS	O
<	VBP	O
5.0	CD	O
ng/ml	NNS	O
were	VBD	O
excluded	VBN	O
.	.	O

An	DT	O
exponential	JJ	O
trend	NN	O
line	NN	O
was	VBD	O
drawn	VBN	O
using	VBG	O
the	DT	O
three	CD	O
CEA	NNP	O
values	NNS	O
.	.	O

Patients	NNS	O
were	VBD	O
categorized	VBN	O
into	IN	O
three	CD	O
groups	NNS	O
based	VBN	O
on	IN	O
R	NNP	O
(	(	O
2	CD	O
)	)	O
values	NNS	O
calculated	VBN	O
through	IN	O
trend	NN	O
line	NN	O
,	,	O
which	WDT	O
indicates	VBZ	O
the	DT	O
correlation	NN	O
coefficient	NN	O
between	IN	O
exponential	JJ	O
graph	NN	O
and	CC	O
measured	VBD	O
CEA	NNP	O
values	NNS	O
:	:	O
exponential	JJ	O
decrease	NN	O
group	NN	O
(	(	O
group	NN	O
1	CD	O
:	:	O
0.9	CD	O
<	NN	O
R	NNP	O
(	(	O
2	CD	O
)	)	O
<	NN	O
or	CC	O
=	VB	O
1.0	CD	O
)	)	O
,	,	O
nearly	RB	O
exponential	JJ	O
decrease	NN	O
group	NN	O
(	(	O
group	NN	O
2	CD	O
:	:	O
0.5	CD	O
<	NN	O
R	NNP	O
(	(	O
2	CD	O
)	)	O
<	NN	O
or	CC	O
=	VB	O
0.9	CD	O
)	)	O
,	,	O
and	CC	O
randomized	JJ	O
clearance	NN	O
group	NN	O
(	(	O
group	NN	O
3	CD	O
:	:	O
0.5	CD	O
<	NN	O
or	CC	O
=	VB	O
R	NNP	O
(	(	O
2	CD	O
)	)	O
)	)	O
.	.	O

We	PRP	O
then	RB	O
analyzed	VBD	O
the	DT	O
CEA	NNP	O
clearance	NN	O
pattern	NN	O
as	IN	O
a	DT	O
prognostic	JJ	O
indicator	NN	O
.	.	O

RESULTS	NNP	O
With	IN	O
a	DT	O
median	JJ	O
follow-up	NN	O
of	IN	O
57	CD	O
months	NNS	O
,	,	O
the	DT	O
5-year	JJ	O
overall	JJ	O
survival	NN	O
was	VBD	O
62.3	CD	O
%	NN	O
vs.	FW	O
48.1	CD	O
%	NN	O
vs.	FW	O
25	CD	O
%	NN	O
and	CC	O
the	DT	O
5-year	JJ	O
disease-free	JJ	O
survival	NN	O
was	VBD	O
58.6	CD	O
%	NN	O
vs.	FW	O
52.7	CD	O
%	NN	O
vs.	FW	O
25	CD	O
%	NN	O
among	IN	O
groups	NNS	O
1	CD	O
,	,	O
2	CD	O
,	,	O
and	CC	O
3	CD	O
(	(	O
P	NNP	O
=	NNP	O
0.014	CD	O
,	,	O
P	NNP	O
=	NNP	O
0.027	CD	O
,	,	O
respectively	RB	O
)	)	O
in	IN	O
patients	NNS	O
with	IN	O
stage	NN	C
III	NNP	C
rectal	JJ	C
cancer	NN	C
.	.	O

For	IN	O
those	DT	O
with	IN	O
stage	NN	O
II	NNP	O
rectal	NN	O
cancer	NN	O
,	,	O
the	DT	O
5-year	JJ	O
overall	JJ	O
survival	NN	O
rate	NN	O
of	IN	O
group	NN	O
1	CD	O
was	VBD	O
significantly	RB	O
better	JJR	O
than	IN	O
groups	NNS	O
2	CD	O
and	CC	O
3	CD	O
(	(	O
88.8	CD	O
%	NN	O
vs.	FW	O
74.1	CD	O
%	NN	O
,	,	O
respectively	RB	O
,	,	O
P	NNP	O
=	NNP	O
0.021	CD	O
)	)	O
.	.	O

CONCLUSIONS	VB	O
The	DT	O
postoperative	JJ	O
pattern	NN	O
of	IN	O
CEA	NNP	O
clearance	NN	O
is	VBZ	O
a	DT	O
useful	JJ	O
prognostic	JJ	O
determinant	NN	O
in	IN	O
patients	NNS	O
with	IN	O
rectal	JJ	O
cancer	NN	O
.	.	O

Patients	NNS	O
with	IN	O
a	DT	O
randomized	JJ	O
pattern	NN	O
of	IN	O
CEA	NNP	O
clearance	NN	O
after	IN	O
tumor	NN	O
resection	NN	O
should	MD	O
be	VB	O
regarded	VBN	O
as	IN	O
having	VBG	O
the	DT	O
possibility	NN	O
of	IN	O
a	DT	O
persistent	JJ	O
CEA	NNP	O
source	NN	O
and	CC	O
may	MD	O
require	VB	O
consideration	NN	O
of	IN	O
intensive	JJ	O
follow-up	NN	O
or	CC	O
adjuvant	JJ	O
therapy	NN	O
.	.	O

Enhanced	NNP	O
pitch	NN	O
sensitivity	NN	O
in	IN	O
individuals	NNS	O
with	IN	O
autism	NN	O
:	:	O
a	DT	O
signal	JJ	O
detection	NN	O
analysis	NN	O
.	.	O

Past	NNP	O
research	NN	O
has	VBZ	O
shown	VBN	O
a	DT	O
superiority	NN	O
of	IN	O
participants	NNS	O
with	IN	O
high-functioning	JJ	C
autism	NN	C
over	IN	O
comparison	NN	O
groups	NNS	O
in	IN	O
memorizing	VBG	O
picture-pitch	JJ	O
associations	NNS	O
and	CC	O
in	IN	O
detecting	VBG	O
pitch	NN	O
changes	NNS	O
in	IN	O
melodies	NNS	O
.	.	O

A	DT	O
subset	NN	O
of	IN	O
individuals	NNS	O
with	IN	O
autism	NN	O
,	,	O
known	VBN	O
as	IN	O
musical	JJ	O
savants	NNS	O
,	,	O
is	VBZ	O
also	RB	O
known	VBN	O
to	TO	O
possess	VB	O
absolute	JJ	O
pitch	NN	O
.	.	O

This	DT	O
superiority	NN	O
might	MD	O
be	VB	O
due	JJ	O
to	TO	O
an	DT	O
abnormally	RB	O
high	JJ	O
sensitivity	NN	O
to	TO	O
fine-grained	JJ	O
pitch	NN	O
differences	NNS	O
in	IN	O
sounds	NNS	O
.	.	O

To	TO	O
test	VB	O
this	DT	O
hypothesis	NN	O
,	,	O
psychoacoustic	JJ	O
tasks	NNS	O
were	VBD	O
devised	VBN	O
so	RB	O
as	IN	O
to	TO	O
use	VB	O
a	DT	O
signal	JJ	O
detection	NN	O
methodology	NN	O
.	.	O

Participants	NNS	O
were	VBD	O
all	DT	O
musically	RB	O
untrained	JJ	O
and	CC	O
were	VBD	O
divided	VBN	O
into	IN	O
a	DT	O
group	NN	SS
of	IN	SS
12	CD	SS
high-functioning	JJ	SS
individuals	NNS	SS
with	IN	SS
autism	NN	SS
and	CC	O
a	DT	O
group	NN	SS
of	IN	SS
12	CD	SS
normally	RB	SS
developing	VBG	SS
individuals	NNS	SS
.	.	O

Their	PRP$	O
task	NN	O
was	VBD	O
to	TO	O
judge	VB	O
the	DT	O
pitch	NN	O
of	IN	O
pure	NN	O
tones	NNS	O
in	IN	O
a	DT	O
same-different	JJ	O
discrimination	NN	O
task	NN	O
and	CC	O
in	IN	O
a	DT	O
high-low	JJ	O
categorization	NN	O
task	NN	O
.	.	O

In	IN	O
both	DT	O
tasks	NNS	O
,	,	O
the	DT	O
obtained	VBN	O
psychometric	JJ	O
functions	NNS	O
revealed	VBD	O
higher	JJR	O
pitch	NN	O
sensitivity	NN	O
for	IN	O
subjects	NNS	O
with	IN	O
autism	NN	O
,	,	O
with	IN	O
a	DT	O
more	RBR	O
pronounced	JJ	O
advantage	NN	O
over	IN	O
control	NN	O
participants	NNS	O
in	IN	O
the	DT	O
categorization	NN	O
task	NN	O
.	.	O

These	DT	O
findings	NNS	O
confirm	VBP	O
that	IN	O
pitch	NN	O
processing	NN	O
is	VBZ	O
enhanced	VBN	O
in	IN	O
high-functioning	JJ	O
autism	NN	O
.	.	O

Superior	JJ	O
performance	NN	O
in	IN	O
pitch	NN	O
discrimination	NN	O
and	CC	O
categorization	NN	O
extends	VBZ	O
previous	JJ	O
findings	NNS	O
of	IN	O
enhanced	JJ	O
visual	JJ	O
performance	NN	O
to	TO	O
the	DT	O
auditory	NN	O
domain	NN	O
.	.	O

Thus	NNP	O
,	,	O
and	CC	O
as	IN	O
predicted	VBN	O
by	IN	O
the	DT	O
enhanced	JJ	O
perceptual	JJ	O
functioning	NN	O
model	NN	O
for	IN	O
peaks	NNS	O
of	IN	O
ability	NN	O
in	IN	O
autism	NN	O
(	(	O
Mottron	NNP	O
&	CC	O
Burack	NNP	O
,	,	O
2001	CD	O
)	)	O
,	,	O
autistic	JJ	O
individuals	NNS	O
outperform	VBP	O
typically	RB	O
developing	VBG	O
population	NN	O
in	IN	O
a	DT	O
variety	NN	O
of	IN	O
low-level	JJ	O
perceptual	JJ	O
tasks	NNS	O
.	.	O

Moclobemide	NNP	O
,	,	O
imipramine	NN	O
and	CC	O
placebo	NN	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
major	JJ	O
depression	NN	C
.	.	O

Moclobemide	NNP	O
was	VBD	O
compared	VBN	O
with	IN	O
imipramine	NN	O
and	CC	O
placebo	NN	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
major	JJ	O
depressive	JJ	O
episodes	NNS	O
in	IN	O
75	CD	SS
outpatients	NNS	O
.	.	O

The	DT	O
dosage	NN	O
of	IN	O
moclobemide	NN	O
(	(	O
25	CD	SS
patients	NNS	O
)	)	O
was	VBD	O
300	CD	O
mg	JJ	O
daily	RB	O
for	IN	O
the	DT	O
first	JJ	O
5	CD	O
days	NNS	O
,	,	O
after	IN	O
which	WDT	O
it	PRP	O
could	MD	O
be	VB	O
increased	VBN	O
to	TO	O
600	CD	O
mg.	NNS	O
Imipramine	NNP	O
(	(	O
25	CD	SS
patients	NNS	O
)	)	O
was	VBD	O
given	VBN	O
in	IN	O
a	DT	O
dosage	NN	O
starting	VBG	O
with	IN	O
33	CD	O
mg	NNS	O
and	CC	O
gradually	RB	O
increased	VBD	O
to	TO	O
100	CD	O
mg/day	NN	O
in	IN	O
the	DT	O
first	JJ	O
5	CD	O
days	NNS	O
,	,	O
after	IN	O
which	WDT	O
it	PRP	O
could	MD	O
be	VB	O
further	RB	O
increased	VBN	O
;	:	O
25	CD	SS
patients	NNS	O
received	VBD	O
placebo	NN	O
.	.	O

Both	DT	O
drugs	NNS	O
were	VBD	O
equally	RB	O
effective	JJ	O
as	IN	O
measured	VBN	O
by	IN	O
the	DT	O
Hamilton	NNP	O
Rating	NNP	O
Scale	NNP	O
for	IN	O
Depression	NNP	O
,	,	O
the	DT	O
overall	JJ	O
assessment	NN	O
of	IN	O
efficacy	NN	O
and	CC	O
the	DT	O
Zung	NNP	O
Self-rating	NNP	O
Scale	NNP	O
,	,	O
and	CC	O
clearly	RB	O
superior	JJ	O
to	TO	O
placebo	VB	O
;	:	O
there	EX	O
were	VBD	O
no	DT	O
significant	JJ	O
differences	NNS	O
between	IN	O
the	DT	O
2	CD	O
active	JJ	O
drugs	NNS	O
.	.	O

Moclobemide	NNP	O
was	VBD	O
better	RBR	O
tolerated	VBN	O
than	IN	O
imipramine	NN	O
,	,	O
and	CC	O
was	VBD	O
almost	RB	O
comparable	JJ	O
to	TO	O
placebo	VB	O
in	IN	O
this	DT	O
respect	NN	O
.	.	O

[	JJ	O
Clinical	NNP	O
application	NN	O
of	IN	O
irradiated	JJ	O
drug-containing	JJ	O
porcine-cornea	NN	O
to	TO	O
patients	NNS	O
with	IN	O
ocular	JJ	C
burns	NNS	C
]	FW	O
.	.	O

OBJECTIVE	UH	O
To	TO	O
explore	VB	O
a	DT	O
new	JJ	O
method	NN	O
for	IN	O
the	DT	O
management	NN	O
of	IN	O
patients	NNS	O
with	IN	O
ocular	JJ	C
burns	NNS	C
.	.	O

METHODS	NNP	O
Fifty-five	JJ	SS
cases	NNS	O
of	IN	O
patients	NNS	O
with	IN	O
ocular	JJ	C
burns	NNS	C
(	(	O
in	IN	O
88	CD	SS
eyes	NNS	O
)	)	O
were	VBD	O
randomly	RB	O
divided	VBN	O
into	IN	O
treatment	NN	O
and	CC	O
control	NN	O
groups	NNS	O
.	.	O

Thirty	NNP	O
cases	NNS	O
in	IN	O
treatment	NN	O
group	NN	O
with	IN	O
49	CD	O
eyes	NNS	O
were	VBD	O
transplanted	VBN	O
with	IN	O
irradiated	JJ	O
drug-containing	NN	O
(	(	O
ofloxacin	UH	O
,	,	O
acetyl	JJ	O
cysteine	NN	O
and	CC	O
reduced	JJ	O
glutathione	NN	O
)	)	O
porcine-cornea	NN	O
.	.	O

25	CD	O
cases	NNS	O
in	IN	O
control	NN	O
group	NN	O
with	IN	O
39	CD	O
eyes	NNS	O
were	VBD	O
treated	VBN	O
with	IN	O
routine	JJ	O
program	NN	O
.	.	O

RESULTS	NNP	O
Thirty-two	JJ	O
eyes	NNS	O
were	VBD	O
rescued	VBN	O
in	IN	O
treatment	NN	O
group	NN	O
with	IN	O
the	DT	O
cure	NN	O
rate	NN	O
of	IN	O
65.3	CD	O
%	NN	O
.	.	O

But	CC	O
only	RB	O
17	CD	O
eyes	NNS	O
were	VBD	O
saved	VBN	O
in	IN	O
control	NN	O
group	NN	O
with	IN	O
the	DT	O
cure	NN	O
rate	NN	O
of	IN	O
43.59	CD	O
%	NN	O
,	,	O
indicating	VBG	O
significant	JJ	O
difference	NN	O
of	IN	O
the	DT	O
cure	NN	O
rate	NN	O
between	IN	O
the	DT	O
two	CD	O
groups	NNS	O
(	(	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
.	.	O

CONCLUSION	NNP	O
Irradiated	VBD	O
drug-containing	JJ	O
porcine-cornea	NN	O
might	MD	O
well	RB	O
be	VB	O
an	DT	O
ideal	JJ	O
therapeutic	JJ	O
material	NN	O
for	IN	O
the	DT	O
management	NN	O
of	IN	O
patients	NNS	O
with	IN	O
ocular	JJ	C
burns	NNS	C
.	.	O

[	RB	O
Dexmedetomidine	NNP	O
use	NN	O
for	IN	O
postoperative	JJ	O
adrenergic	JJ	O
analgesia	NN	O
and	CC	O
sedation	NN	O
in	IN	O
abdominal	JJ	O
surgery	NN	O
]	NN	O
.	.	O

Comparative	NNP	O
study	NN	O
of	IN	O
postoperative	JJ	O
analgesia	NN	O
and	CC	O
sedation	NN	O
with	IN	O
trimeperidine	NN	O
and	CC	O
dexmedetomidine	NN	O
and	CC	O
their	PRP$	O
effects	NNS	O
on	IN	O
haemodynamics	NNS	O
and	CC	O
vegetative	VBP	O
nervous	JJ	O
system	NN	O
was	VBD	O
performed	VBN	O
.	.	O

Assessment	NNP	O
of	IN	O
analgesia	NN	O
and	CC	O
sedation	NN	O
during	IN	O
vagotonia	NN	O
(	(	O
first	JJ	O
part	NN	O
of	IN	O
the	DT	O
study	NN	O
)	)	O
and	CC	O
hypokinetic	JJ	O
type	NN	O
of	IN	O
haemodynamics	NNS	O
(	(	O
second	JJ	O
part	NN	O
of	IN	O
the	DT	O
study	NN	O
)	)	O
was	VBD	O
carried	VBN	O
out	RP	O
with	IN	O
visual	JJ	O
analogue	NN	O
scale	NN	O
(	(	O
VAS	NNP	O
)	)	O
and	CC	O
Richmond	NNP	O
scale	NN	O
.	.	O

Results	NNS	O
of	IN	O
the	DT	O
study	NN	O
showed	VBD	O
that	IN	O
dexmedetomidine	NN	O
is	VBZ	O
more	RBR	O
effective	JJ	O
and	CC	O
safer	JJR	O
than	IN	O
trimeperidine	NN	O
for	IN	O
analgesia	NN	O
and	CC	O
sedation	NN	O
in	IN	O
patients	NNS	O
with	IN	O
spontaneous	JJ	C
breathing	NN	C
after	IN	O
abdominal	JJ	O
surgery	NN	O
.	.	O

Dexmedetomidine	NNP	O
use	NN	O
allows	VBZ	O
keeping	VBG	O
optimal	JJ	O
type	NN	O
of	IN	O
haemodynamics	NNS	O
and	CC	O
vegetative	VBP	O
nervous	JJ	O
system	NN	O
parameters	NNS	O
on	IN	O
first	JJ	O
day	NN	O
of	IN	O
postoperative	JJ	O
period	NN	O
.	.	O

Butorphanol	NNP	O
and	CC	O
meperidine	NN	O
compared	VBN	O
in	IN	O
patients	NNS	O
with	IN	O
acute	JJ	C
ureteral	JJ	C
colic	NN	C
.	.	O

Pain	NNP	O
relief	NN	O
was	VBD	O
evaluated	VBN	O
in	IN	O
81	CD	SS
patients	NNS	O
with	IN	O
acute	JJ	C
ureteral	JJ	C
colic	NN	C
and	CC	O
the	DT	O
confirmed	JJ	O
presence	NN	O
of	IN	O
a	DT	O
calculus	NN	O
.	.	O

A	DT	O
randomized	JJ	O
double-blind	JJ	O
comparison	NN	O
of	IN	O
intramuscular	JJ	O
2	CD	O
and	CC	O
4	CD	O
mg.	NN	O
butorphanol	NN	O
and	CC	O
80	CD	O
mg.	NNS	O
meperidine	NN	O
was	VBD	O
used	VBN	O
.	.	O

Pain	NNP	O
intensity	NN	O
and	CC	O
pain	NN	O
relief	NN	O
were	VBD	O
evaluated	VBN	O
at	IN	O
half	JJ	O
hour	NN	O
and	CC	O
hourly	JJ	O
intervals	NNS	O
for	IN	O
4	CD	O
hours	NNS	O
.	.	O

A	DT	O
2	CD	O
mg.	NN	O
dose	NN	O
of	IN	O
butorphanol	NN	O
was	VBD	O
found	VBN	O
to	TO	O
be	VB	O
analgesically	RB	O
equivalent	JJ	O
to	TO	O
80	CD	O
mg.	NNS	O
meperidine	NN	O
,	,	O
while	IN	O
a	DT	O
4	CD	O
mg.	NN	O
dose	NN	O
of	IN	O
butorphanol	NN	O
was	VBD	O
found	VBN	O
to	TO	O
be	VB	O
more	RBR	O
effective	JJ	O
than	IN	O
80	CD	O
mg.	JJ	O
meperidine	NN	O
and	CC	O
2	CD	O
mg.	NN	O
butorphanol	NN	O
.	.	O

Each	DT	O
patient	NN	O
received	VBD	O
up	RB	O
to	TO	O
2	CD	O
doses	NNS	O
of	IN	O
analgesic	JJ	O
medication	NN	O
when	WRB	O
necessary	JJ	O
.	.	O

There	EX	O
was	VBD	O
no	DT	O
significant	JJ	O
difference	NN	O
in	IN	O
the	DT	O
incidence	NN	O
of	IN	O
side	JJ	O
effects	NNS	O
among	IN	O
treatments	NNS	O
.	.	O

One	CD	O
patient	NN	O
had	VBD	O
visual	JJ	O
hallucinations	NNS	O
after	IN	O
a	DT	O
2	CD	O
mg.	NN	O
dose	NN	O
of	IN	O
butorphanol	NN	O
,	,	O
possibly	RB	O
owing	VBG	O
to	TO	O
its	PRP$	O
antagonistic	JJ	O
activity	NN	O
to	TO	O
significant	JJ	O
narcotic	JJ	O
experience	NN	O
given	VBN	O
previously	RB	O
at	IN	O
another	DT	O
hospital	NN	O
.	.	O

There	EX	O
was	VBD	O
no	DT	O
other	JJ	O
evidence	NN	O
of	IN	O
toxicity	NN	O
with	IN	O
butorphanol	NN	O
.	.	O

It	PRP	O
was	VBD	O
found	VBN	O
to	TO	O
be	VB	O
a	DT	O
safe	JJ	O
,	,	O
effective	JJ	O
and	CC	O
wall	RB	O
tolerated	JJ	O
drug	NN	O
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
ureteral	JJ	O
colic	NN	O
and	CC	O
is	VBZ	O
recommended	VBN	O
in	IN	O
place	NN	O
of	IN	O
narcotics	NNS	O
.	.	O

Long-term	JJ	O
use	NN	O
of	IN	O
Viozan	NNP	O
(	(	O
sibenadet	JJ	O
HCl	NNP	O
)	)	O
in	IN	O
patients	NNS	O
with	IN	O
chronic	JJ	C
obstructive	JJ	C
pulmonary	JJ	C
disease	NN	C
:	:	O
results	NNS	O
of	IN	O
a	DT	O
1-year	JJ	O
study	NN	O
.	.	O

Viozan	NNP	O
(	(	O
sibenadet	JJ	O
HCl	NNP	O
,	,	O
AR-C68397AA	NNP	O
)	)	O
is	VBZ	O
a	DT	O
novel	JJ	O
dual	JJ	O
D2	NNP	O
dopamine	NN	O
receptor	NN	O
,	,	O
beta2-adrenoceptor	JJ	O
agonist	NN	O
that	WDT	O
has	VBZ	O
been	VBN	O
investigated	VBN	O
for	IN	O
efficacy	NN	O
in	IN	O
alleviating	VBG	O
the	DT	O
symptoms	NNS	O
of	IN	O
chronic	JJ	O
obstructive	JJ	O
pulmonary	JJ	O
disease	NN	O
(	(	O
COPD	NNP	O
)	)	O
.	.	O

The	DT	O
slowly	RB	O
progressive	JJ	O
nature	NN	O
of	IN	O
this	DT	O
disease	NN	O
means	VBZ	O
that	IN	O
patients	NNS	O
will	MD	O
require	VB	O
ongoing	JJ	O
therapeutic	JJ	O
management	NN	O
for	IN	O
many	JJ	O
years	NNS	O
,	,	O
or	CC	O
even	RB	O
decades	NNS	O
.	.	O

With	IN	O
such	JJ	O
long-term	JJ	O
treatment	NN	O
,	,	O
the	DT	O
safety	NN	O
profile	NN	O
of	IN	O
new	JJ	O
agents	NNS	O
will	MD	O
be	VB	O
of	IN	O
paramount	JJ	O
importance	NN	O
.	.	O

As	IN	O
part	NN	O
of	IN	O
the	DT	O
large-scale	JJ	O
assessment	NN	O
of	IN	O
sibenadet	NN	O
,	,	O
a	DT	O
12-month	JJ	O
safety	NN	O
study	NN	O
has	VBZ	O
been	VBN	O
conducted	VBN	O
.	.	O

Following	VBG	O
completion	NN	O
of	IN	O
a	DT	O
2-week	JJ	O
baseline	NN	O
period	NN	O
,	,	O
435	CD	SS
adults	NNS	A
with	IN	O
stable	JJ	C
,	,	C
symptomatic	JJ	C
,	,	C
smoking-related	JJ	C
COPD	NNP	C
were	VBD	O
randomized	VBN	O
to	TO	O
receive	VB	O
either	RB	O
500	CD	O
microg	NN	O
sibenadet	NN	O
or	CC	O
placebo	NN	O
delivered	VBN	O
via	IN	O
pressurized	VBN	O
metered	VBD	O
dose	JJ	O
inhaler	NN	O
(	(	O
pMDI	NN	O
)	)	O
,	,	O
three	CD	O
times	NNS	O
daily	RB	O
for	IN	O
52	CD	O
weeks	NNS	O
.	.	O

Sibenadet	NNP	O
therapy	NN	O
was	VBD	O
generally	RB	O
well	RB	O
tolerated	VBN	O
,	,	O
with	IN	O
the	DT	O
only	JJ	O
notable	JJ	O
differences	NNS	O
seen	VBN	O
in	IN	O
the	DT	O
incidence	NN	O
of	IN	O
tremor	NN	O
and	CC	O
taste	NN	O
of	IN	O
treatment	NN	O
(	(	O
16.9	CD	O
%	NN	O
vs.	FW	O
4.1	CD	O
%	NN	O
and	CC	O
14.5	CD	O
%	NN	O
vs.	FW	O
4.1	CD	O
%	NN	O
in	IN	O
the	DT	O
sibenadet	NN	O
and	CC	O
placebo	NN	O
groups	NNS	O
respectively	RB	O
)	)	O
.	.	O

There	EX	O
were	VBD	O
a	DT	O
total	NN	O
of	IN	O
79	CD	SS
patients	NNS	O
with	IN	O
serious	JJ	C
adverse	JJ	C
events	NNS	C
(	(	O
SAEs	NNP	C
)	)	O
,	,	O
43	CD	SS
(	(	O
14.8	CD	O
%	NN	O
)	)	O
in	IN	O
the	DT	O
sibenadet	NN	C
pMDI	NN	C
group	NN	O
and	CC	O
36	CD	SS
(	(	O
24.8	CD	O
%	NN	O
)	)	O
in	IN	O
the	DT	O
placebo	NN	C
group	NN	O
.	.	O

No	DT	O
clinically	RB	O
significant	JJ	O
abnormal	JJ	O
laboratory	NN	O
values	NNS	O
or	CC	O
overall	JJ	O
differences	NNS	O
between	IN	O
treatment	NN	O
groups	NNS	O
were	VBD	O
noted	VBN	O
.	.	O

Similarly	RB	O
,	,	O
there	EX	O
were	VBD	O
no	DT	O
clinically	RB	O
significant	JJ	O
differences	NNS	O
between	IN	O
the	DT	O
two	CD	O
treatment	NN	O
groups	NNS	O
for	IN	O
cardiac	JJ	O
variables	NNS	O
,	,	O
or	CC	O
in	IN	O
vital	JJ	O
signs	NNS	O
.	.	O

The	DT	O
secondary	JJ	O
variables	NNS	O
showed	VBD	O
no	DT	O
notable	JJ	O
differences	NNS	O
with	IN	O
respect	NN	O
to	TO	O
lung	NN	O
function	NN	O
,	,	O
exacerbations	NNS	O
or	CC	O
health-related	JJ	O
quality	NN	O
of	IN	O
life	NN	O
.	.	O

Due	NNP	O
to	TO	O
the	DT	O
effective	JJ	O
beta2-agonist	NN	O
properties	NNS	O
,	,	O
patients	NNS	O
in	IN	O
the	DT	O
sibenadet	NN	O
group	NN	O
did	VBD	O
,	,	O
however	RB	O
,	,	O
report	NN	O
reduced	VBD	O
rescue	JJ	O
medication	NN	O
usage	NN	O
at	IN	O
all	DT	O
timepoints	NNS	O
.	.	O

While	IN	O
the	DT	O
results	NNS	O
of	IN	O
this	DT	O
study	NN	O
show	NN	O
that	IN	O
,	,	O
overall	JJ	O
,	,	O
sibenadet	JJ	O
therapy	NN	O
was	VBD	O
well	RB	O
tolerated	VBN	O
,	,	O
the	DT	O
lack	NN	O
of	IN	O
sustained	JJ	O
benefit	NN	O
reported	VBD	O
in	IN	O
large-scale	JJ	O
clinical	JJ	O
efficacy	NN	O
studies	NNS	O
means	VBZ	O
that	IN	O
sibenadet	NN	O
development	NN	O
will	MD	O
not	RB	O
be	VB	O
continued	VBN	O
.	.	O

The	DT	O
relationship	NN	O
of	IN	O
alexithymia	NN	O
to	TO	O
emotional	JJ	O
dysregulation	NN	O
within	IN	O
an	DT	O
alcohol	NN	O
dependent	JJ	O
treatment	NN	O
sample	NN	O
.	.	O

Difficulties	NNS	O
regulating	VBG	O
emotions	NNS	O
have	VBP	O
implications	NNS	O
for	IN	O
the	DT	O
development	NN	O
,	,	O
maintenance	NN	O
,	,	O
and	CC	O
recovery	NN	O
from	IN	O
alcohol	NN	O
problems	NNS	O
.	.	O

One	CD	O
construct	NN	O
thought	NN	O
to	TO	O
impede	VB	O
the	DT	O
regulation	NN	O
of	IN	O
emotion	NN	O
is	VBZ	O
alexithymia	JJ	O
.	.	O

Alexithymia	NNP	O
is	VBZ	O
characterized	VBN	O
by	IN	O
difficulties	NNS	O
identifying	VBG	O
,	,	O
differentiating	VBG	O
and	CC	O
expressing	VBG	O
feelings	NNS	O
,	,	O
a	DT	O
limited	JJ	O
imagination	NN	O
and	CC	O
fantasy	JJ	O
life	NN	O
,	,	O
and	CC	O
an	DT	O
externally-oriented	JJ	O
thinking	NN	O
style	NN	O
(	(	O
e.g.	UH	O
,	,	O
prefer	VBP	O
talking	VBG	O
about	IN	O
daily	JJ	O
activities	NNS	O
rather	RB	O
than	IN	O
feelings	NNS	O
)	)	O
.	.	O

Given	VBN	O
that	IN	O
poor	JJ	O
emotion	NN	O
regulation	NN	O
skills	NNS	O
have	VBP	O
been	VBN	O
found	VBN	O
to	TO	O
predict	VB	O
posttreatment	NN	O
levels	NNS	O
of	IN	O
alcohol	NN	O
use	NN	O
,	,	O
and	CC	O
that	IN	O
several	JJ	O
defining	VBG	O
characteristics	NNS	O
of	IN	O
alexithymia	JJ	O
bear	JJ	O
similarity	NN	O
to	TO	O
deficits	NNS	O
in	IN	O
emotion	NN	O
regulation	NN	O
skills	NNS	O
,	,	O
it	PRP	O
is	VBZ	O
possible	JJ	O
that	IN	O
alexithymia	NN	O
may	MD	O
predict	VB	O
poorer	JJR	O
alcohol	NN	O
treatment	NN	O
outcomes	NNS	O
.	.	O

Thus	RB	O
,	,	O
the	DT	O
present	JJ	O
study	NN	O
first	RB	O
examined	VBD	O
the	DT	O
relationship	NN	O
of	IN	O
alexithymia	NN	O
to	TO	O
several	JJ	O
other	JJ	O
emotion	NN	O
regulation	NN	O
measures	NNS	O
and	CC	O
then	RB	O
investigated	VBD	O
the	DT	O
impact	NN	O
of	IN	O
alexithymia	NN	O
on	IN	O
attrition	NN	O
and	CC	O
alcohol	NN	O
treatment	NN	O
outcomes	NNS	O
in	IN	O
men	NNS	O
and	CC	O
women	NNS	O
(	(	O
N=77	NNP	O
)	)	O
enrolled	VBD	O
in	IN	O
a	DT	O
12-week	JJ	O
cognitive-behavioral	JJ	O
intervention	NN	O
for	IN	O
alcohol	NN	O
dependence	NN	O
.	.	O

At	IN	O
baseline	NN	O
,	,	O
higher	JJR	O
scores	NNS	O
on	IN	O
alexithymia	NN	O
were	VBD	O
associated	VBN	O
poorer	JJR	O
emotion	NN	O
regulation	NN	O
skills	NNS	O
,	,	O
fewer	JJR	O
percent	NN	O
days	NNS	O
abstinent	NN	O
,	,	O
greater	JJR	O
alcohol	NN	O
dependence	NN	O
severity	NN	O
,	,	O
and	CC	O
several	JJ	O
high-risk	JJ	O
drinking	NN	O
situations	NNS	O
.	.	O

Alexithymia	NNP	O
was	VBD	O
unrelated	JJ	O
to	TO	O
attrition	NN	O
and	CC	O
to	TO	O
level	NN	O
of	IN	O
alcohol	NN	O
consumption	NN	O
at	IN	O
posttreatment	NN	O
.	.	O

Overall	UH	O
,	,	O
the	DT	O
construct	NN	O
of	IN	O
alexithymia	NN	O
is	VBZ	O
shown	VBN	O
to	TO	O
be	VB	O
related	VBN	O
to	TO	O
several	JJ	O
theoretically-related	JJ	O
constructs	NNS	O
(	(	O
e.g.	NN	O
,	,	O
emotion	NN	O
regulation	NN	O
,	,	O
mindfulness	NN	O
)	)	O
but	CC	O
demonstrated	VBD	O
a	DT	O
limited	JJ	O
relationship	NN	O
to	TO	O
drinking	VBG	O
outcomes	NNS	O
in	IN	O
those	DT	O
seeking	VBG	O
treatment	NN	O
for	IN	O
alcohol	NN	O
dependence	NN	O
.	.	O

Short-term	JJ	O
fluoxetine	NN	O
monotherapy	NN	O
for	IN	O
bipolar	JJ	C
type	NN	C
II	NNP	C
or	CC	C
bipolar	JJ	C
NOS	NNP	C
major	JJ	C
depression	NN	C
-	:	C
low	JJ	C
manic	JJ	C
switch	NN	C
rate	NN	C
.	.	O

OBJECTIVES	CC	O
Current	NNP	O
guidelines	NNS	O
for	IN	O
the	DT	O
initial	JJ	O
treatment	NN	O
of	IN	O
bipolar	JJ	C
type	NN	C
II	NNP	C
(	(	O
BP	NNP	C
II	NNP	C
)	)	O
major	JJ	O
depressive	JJ	O
episode	NN	O
(	(	O
MDE	NNP	O
)	)	O
recommend	VBP	O
using	VBG	O
either	CC	O
a	DT	O
mood	NN	O
stabilizer	NN	O
alone	RB	O
or	CC	O
a	DT	O
combination	NN	O
of	IN	O
a	DT	O
mood	NN	O
stabilizer	NN	O
plus	CC	O
a	DT	O
selective	JJ	O
serotonin	NN	O
re-uptake	NN	O
inhibitor	NN	O
(	(	O
SSRI	NNP	O
)	)	O
.	.	O

This	DT	O
recommendation	NN	O
is	VBZ	O
the	DT	O
result	NN	O
of	IN	O
concern	NN	O
over	IN	O
antidepressant-induced	JJ	O
manic	JJ	O
switch	NN	O
episodes	NNS	O
.	.	O

However	RB	O
,	,	O
recent	JJ	O
evidence	NN	O
suggests	VBZ	O
that	IN	O
the	DT	O
manic	JJ	O
switch	NN	O
rate	NN	O
may	MD	O
be	VB	O
low	JJ	O
in	IN	O
BP	NNP	O
II	NNP	O
MDE	NNP	O
during	IN	O
SSRI	NNP	O
therapy	NN	O
.	.	O

METHODS	NNP	O
As	IN	O
part	NN	O
of	IN	O
a	DT	O
randomized	JJ	O
,	,	O
double-blind	JJ	O
,	,	O
placebo-controlled	JJ	O
relapse-prevention	NN	O
study	NN	O
of	IN	O
fluoxetine	JJ	O
monotherapy	NN	O
in	IN	O
BP	NNP	C
II	NNP	C
MDE	NNP	O
,	,	O
37	CD	SS
patients	NNS	O
received	VBD	O
open-label	JJ	O
fluoxetine	NN	O
20	CD	O
mg	NN	O
every	DT	O
day	NN	O
for	IN	O
up	IN	O
to	TO	O
8	CD	O
weeks	NNS	O
.	.	O

Outcome	NNP	O
measures	NNS	O
included	VBD	O
the	DT	O
Hamilton	NNP	O
Depression	NNP	O
Rating	NNP	O
(	(	O
HAM-D	NNP	O
17	CD	O
)	)	O
rating	NN	O
and	CC	O
the	DT	O
Young	NNP	O
Mania	NNP	O
Rating	NNP	O
(	(	O
YMR	NNP	O
)	)	O
scale	NN	O
.	.	O

RESULTS	NNP	O
Eleven	NNP	O
of	IN	O
23	CD	O
patients	NNS	O
(	(	O
48	CD	O
%	NN	O
)	)	O
who	WP	O
completed	VBD	O
8	CD	O
weeks	NNS	O
of	IN	O
fluoxetine	NN	O
treatment	NN	O
showed	VBD	O
a	DT	O
HAM-D	JJ	O
17	CD	O
reduction	NN	O
of	IN	O
>	NN	O
or	CC	O
=50	CD	O
%	NN	O
,	,	O
while	IN	O
14	CD	O
(	(	O
38	CD	O
%	NN	O
)	)	O
of	IN	O
all	DT	O
treated	JJ	O
patients	NNS	O
had	VBD	O
>	VBN	O
or	CC	O
=50	CD	O
%	NN	O
reduction	NN	O
in	IN	O
baseline	JJ	O
HAM-D	JJ	O
17	CD	O
score	NN	O
.	.	O

Using	VBG	O
a	DT	O
conservative	JJ	O
YMR	NNP	O
score	NN	O
of	IN	O
>	NN	O
or	CC	O
=8	VB	O
to	TO	O
identify	VB	O
hypomanic	JJ	O
symptoms	NNS	O
,	,	O
the	DT	O
frequency	NN	O
of	IN	O
patients	NNS	O
with	IN	O
YMR	NNP	O
score	NN	O
>	NN	O
or	CC	O
=8	NN	O
during	IN	O
fluoxetine	NN	O
did	VBD	O
not	RB	O
differ	VB	O
from	IN	O
that	DT	O
seen	VBN	O
during	IN	O
the	DT	O
screen	NN	O
and	CC	O
baseline	JJ	O
period	NN	O
.	.	O

Only	RB	O
three	CD	O
patients	NNS	O
(	(	O
7.3	CD	O
%	NN	O
)	)	O
had	VBD	O
symptoms	NNS	O
suggestive	JJ	O
of	IN	O
hypomania	NN	O
,	,	O
and	CC	O
only	RB	O
one	CD	O
patient	NN	O
stopped	VBD	O
treatment	NN	O
because	IN	O
of	IN	O
a	DT	O
rapid	JJ	O
mood	NN	O
swing	VBG	O
into	IN	O
depression	NN	O
.	.	O

LIMITATIONS	NNP	O
Fluoxetine	NNP	O
was	VBD	O
given	VBN	O
at	IN	O
a	DT	O
fixed	JJ	O
dose	NN	O
of	IN	O
20	CD	O
mg	NNS	O
everyday	JJ	O
.	.	O

Fluoxetine	NNP	O
was	VBD	O
prescribed	VBN	O
in	IN	O
an	DT	O
open-label	JJ	O
manner	NN	O
,	,	O
and	CC	O
the	DT	O
sample	NN	O
size	NN	O
was	VBD	O
limited	VBN	O
.	.	O

CONCLUSIONS	NNP	O
These	DT	O
observations	NNS	O
support	VBP	O
the	DT	O
findings	NNS	O
of	IN	O
a	DT	O
low	JJ	O
manic	JJ	O
switch	NN	O
rate	NN	O
during	IN	O
SSRI	NNP	O
monotherapy	NN	O
of	IN	O
BP	NNP	O
II	NNP	O
MDE	NNP	O
,	,	O
and	CC	O
suggest	VBP	O
that	IN	O
fluoxetine	JJ	O
monotherapy	NN	O
may	MD	O
be	VB	O
a	DT	O
safe	JJ	O
and	CC	O
effective	JJ	O
initial	JJ	O
treatment	NN	O
of	IN	O
BP	NNP	C
II	NNP	C
MDE	NNP	C
.	.	O

Seven-star	NNP	O
needle	JJ	O
stimulation	NN	O
improves	VBZ	O
language	NN	O
and	CC	O
social	JJ	O
interaction	NN	O
of	IN	O
children	NNS	A
with	IN	O
autistic	JJ	C
spectrum	NN	C
disorders	NNS	C
.	.	O

This	DT	O
is	VBZ	O
a	DT	O
randomized	JJ	O
controlled	VBN	O
trial	NN	O
that	WDT	O
aimed	VBD	O
to	TO	O
evaluate	VB	O
the	DT	O
effect	NN	O
of	IN	O
the	DT	O
Seven-star	NNP	O
Needle	NNP	O
Stimulation	NNP	O
treatment	NN	O
on	IN	O
children	NNS	A
with	IN	O
Autistic	NNP	O
Spectrum	NNP	O
Disorders	NNP	O
(	(	O
ASD	NNP	C
)	)	O
.	.	O

Thirty-two	JJ	SS
children	NNS	A
with	IN	O
ASD	NNP	C
were	VBD	O
assigned	VBN	O
randomly	RB	O
into	IN	O
the	DT	O
treatment	NN	O
and	CC	O
control	NN	O
groups	NNS	O
.	.	O

Children	NNP	O
in	IN	O
the	DT	O
treatment	NN	O
group	NN	O
underwent	VBD	O
30	CD	O
sessions	NNS	O
of	IN	O
stimulation	NN	O
over	IN	O
6	CD	O
weeks	NNS	O
,	,	O
while	IN	O
children	NNS	O
in	IN	O
the	DT	O
control	NN	O
group	NN	O
were	VBD	O
on	IN	O
a	DT	O
waiting	VBG	O
list	NN	O
and	CC	O
did	VBD	O
not	RB	O
receive	VB	O
treatment	NN	O
during	IN	O
this	DT	O
period	NN	O
of	IN	O
time	NN	O
.	.	O

Intervention	NNP	O
consisted	VBD	O
of	IN	O
a	DT	O
treatment	NN	O
regime	NN	O
comprising	NN	O
of	IN	O
30	CD	O
sessions	NNS	O
of	IN	O
Seven-star	NNP	O
Needle	NNP	O
Stimulation	NNP	O
,	,	O
delivered	VBD	O
over	IN	O
6	CD	O
weeks	NNS	O
.	.	O

Each	DT	O
session	NN	O
lasted	VBD	O
5	CD	O
to	TO	O
10	CD	O
min	NN	O
,	,	O
children	NNS	O
in	IN	O
the	DT	O
treatment	NN	O
group	NN	O
were	VBD	O
stimulated	VBN	O
at	IN	O
the	DT	O
front	NN	O
and	CC	O
back	RB	O
sides	NNS	O
of	IN	O
their	PRP$	O
body	NN	O
and	CC	O
the	DT	O
head	NN	O
by	IN	O
using	VBG	O
Seven-star	JJ	O
Needles	NNP	O
.	.	O

The	DT	O
change	NN	O
in	IN	O
the	DT	O
children	NNS	O
's	POS	O
behavior	NN	O
was	VBD	O
evaluated	VBN	O
using	VBG	O
parents	NNS	O
'	POS	O
report	NN	O
and	CC	O
neurophysiological	JJ	O
changes	NNS	O
were	VBD	O
measured	VBN	O
by	IN	O
quantitative	JJ	O
EEG	NNP	O
(	(	O
qEEG	NN	O
)	)	O
.	.	O

Results	CC	O
showed	VBD	O
that	IN	O
the	DT	O
treatment	NN	O
group	NN	O
demonstrated	VBD	O
significant	JJ	O
improvement	NN	O
in	IN	O
language	NN	O
and	CC	O
social	JJ	O
interaction	NN	O
,	,	O
but	CC	O
not	RB	O
in	IN	O
stereotyped	JJ	O
behavior	NN	O
or	CC	O
motor	NN	O
function	NN	O
,	,	O
compared	VBN	O
to	TO	O
the	DT	O
control	NN	O
group	NN	O
.	.	O

qEEG	JJ	O
spectral	JJ	O
amplitudes	NNS	O
in	IN	O
the	DT	O
treatment	NN	O
,	,	O
but	CC	O
not	RB	O
in	IN	O
the	DT	O
control	NN	O
group	NN	O
,	,	O
were	VBD	O
also	RB	O
reduced	VBN	O
significantly	RB	O
.	.	O

The	DT	O
results	NNS	O
suggested	VBD	O
that	IN	O
Seven-star	NNP	O
Needle	NNP	O
Stimulation	NNP	O
might	MD	O
be	VB	O
an	DT	O
effective	JJ	O
intervention	NN	O
to	TO	O
improve	VB	O
language	NN	O
and	CC	O
social	JJ	O
functioning	NN	O
of	IN	O
children	NNS	A
with	IN	O
ASD	NNP	C
.	.	O

Feedlot	NNP	O
performance	NN	O
and	CC	O
carcass	NN	O
characteristics	NNS	O
of	IN	O
Holstein	NNP	C
steers	NNS	SE
as	IN	O
affected	VBN	O
by	IN	O
source	NN	O
of	IN	O
dietary	JJ	O
protein	NN	O
and	CC	O
level	NN	O
of	IN	O
ruminally	RB	O
protected	VBN	O
lysine	NN	O
and	CC	O
methionine	NN	O
.	.	O

The	DT	O
objective	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
determine	VB	O
the	DT	O
effects	NNS	O
of	IN	O
source	NN	O
of	IN	O
dietary	JJ	O
CP	NNP	O
and	CC	O
level	NN	O
of	IN	O
ruminally	RB	O
protected	VBN	O
lysine	NN	O
and	CC	O
methionine	NN	O
(	(	O
RPLM	NNP	O
)	)	O
on	IN	O
feedlot	NN	O
performance	NN	O
and	CC	O
carcass	NN	O
characteristics	NNS	O
of	IN	O
Holstein	NNP	C
steers	NNS	C
during	IN	O
a	DT	O
growing-finishing	JJ	O
trial	NN	O
(	(	O
266	CD	O
d	NN	O
)	)	O
.	.	O

A	DT	O
total	NN	O
of	IN	O
168	CD	SS
Holstein	NNP	C
steers	NNS	C
(	(	O
182.7	CD	C
+/-	JJ	C
27.5	CD	C
kg	NN	C
)	)	O
were	VBD	O
used	VBN	O
in	IN	O
a	DT	O
completely	RB	O
randomized	JJ	O
design	NN	O
experiment	NN	O
(	(	O
eight	CD	O
treatments	NNS	O
;	:	O
three	CD	O
pens	NNS	O
of	IN	O
seven	CD	O
steers/treatment	NN	O
)	)	O
.	.	O

Steers	NNPS	O
were	VBD	O
given	VBN	O
ad	NN	O
libitum	NN	O
access	NN	O
to	TO	O
high-concentrate	JJ	O
diets	NNS	O
(	(	O
13	CD	O
%	NN	O
CP	NNP	O
)	)	O
containing	VBG	O
71	CD	O
%	NN	O
whole	JJ	O
shelled	VBN	O
corn	NN	O
,	,	O
10	CD	O
%	NN	O
corn	NN	O
silage	NN	O
,	,	O
4	CD	O
%	NN	O
condensed	JJ	O
distillers	NNS	O
solubles	NNS	O
,	,	O
and	CC	O
15	CD	O
%	NN	O
protein	NN	O
supplements	NNS	O
(	(	O
DM	NNP	O
basis	NN	O
)	)	O
.	.	O

Treatments	NNS	O
were	VBD	O
arranged	VBN	O
as	IN	O
a	DT	O
2	CD	O
x	NN	O
4	CD	O
factorial	JJ	O
.	.	O

The	DT	O
main	JJ	O
factors	NNS	O
were	VBD	O
two	CD	O
sources	NNS	O
of	IN	O
dietary	JJ	O
CP	NNP	O
and	CC	O
four	CD	O
levels	NNS	O
of	IN	O
RPLM	NNP	O
.	.	O

The	DT	O
sources	NNS	O
of	IN	O
dietary	JJ	O
CP	NNP	O
were	VBD	O
soybean	JJ	O
meal	NN	O
(	(	O
SBM	NNP	O
)	)	O
or	CC	O
SBM	NNP	O
and	CC	O
urea	JJ	O
(	(	O
SBM-U	NNP	O
)	)	O
.	.	O

Urea-N	NNP	O
replaced	VBD	O
50	CD	O
%	NN	O
of	IN	O
SBM-N	NNP	O
in	IN	O
the	DT	O
SBM-U	NNP	O
diet	NN	O
.	.	O

The	DT	O
levels	NNS	O
of	IN	O
RPLM	NNP	O
were	VBD	O
0	CD	O
,	,	O
5	CD	O
,	,	O
10	CD	O
,	,	O
and	CC	O
15	CD	O
g	NN	O
per	IN	O
steer	NN	O
daily	RB	O
.	.	O

No	UH	O
interactions	NNS	O
(	(	O
P	NNP	O
>	NNP	O
.10	NNP	O
)	)	O
between	IN	O
source	NN	O
of	IN	O
dietary	JJ	O
CP	NNP	O
and	CC	O
level	NN	O
of	IN	O
RPLM	NNP	O
were	VBD	O
observed	VBN	O
for	IN	O
feedlot	NN	O
performance	NN	O
or	CC	O
carcass	NN	O
characteristics	NNS	O
.	.	O

Feedlot	NNP	O
performance	NN	O
showed	VBD	O
an	DT	O
advantage	NN	O
(	(	O
P	NNP	O
<	NNP	O
.10	NNP	O
)	)	O
to	TO	O
feeding	VBG	O
SMB	NNP	O
during	IN	O
the	DT	O
first	JJ	O
84	CD	O
d	NN	O
of	IN	O
the	DT	O
trial	NN	O
and	CC	O
an	DT	O
advantage	NN	O
to	TO	O
feeding	VBG	O
SBM-U	NNP	O
during	IN	O
the	DT	O
last	JJ	O
98	CD	O
d	NN	O
of	IN	O
the	DT	O
trial	NN	O
.	.	O

However	RB	O
,	,	O
feedlot	JJ	O
performance	NN	O
for	IN	O
the	DT	O
whole	JJ	O
trial	NN	O
and	CC	O
carcass	NN	O
characteristics	NNS	O
(	(	O
except	IN	O
for	IN	O
fat	JJ	O
thickness	NN	O
)	)	O
were	VBD	O
not	RB	O
affected	VBN	O
(	(	O
P	NNP	O
>	NNP	O
.10	NNP	O
)	)	O
by	IN	O
the	DT	O
source	NN	O
of	IN	O
dietary	JJ	O
CP	NNP	O
.	.	O

Steers	NNP	O
fed	VBD	O
diets	NNS	O
containing	VBG	O
SBM-U	NNP	O
had	VBD	O
12	CD	O
%	NN	O
less	JJR	O
(	(	O
P	NNP	O
<	NNP	O
.10	NNP	O
)	)	O
fat	VBZ	O
thickness	JJ	O
than	IN	O
those	DT	O
fed	JJ	O
diets	NNS	O
containing	VBG	O
SBM	NNP	O
.	.	O

Supplementation	NN	O
of	IN	O
diets	NNS	O
with	IN	O
increasing	VBG	O
levels	NNS	O
of	IN	O
RPLM	NNP	O
did	VBD	O
not	RB	O
affect	VB	O
(	(	O
P	NNP	O
>	NNP	O
.10	NNP	O
)	)	O
ADG	NNP	O
or	CC	O
carcass	NN	O
characteristics	NNS	O
.	.	O

However	RB	O
,	,	O
DMI	NNP	O
and	CC	O
gain	NN	O
:	:	O
feed	NN	O
showed	VBD	O
cubic	JJ	O
(	(	O
P	NNP	O
<	NNP	O
.10	NNP	O
)	)	O
responses	VBZ	O
to	TO	O
increasing	VBG	O
dietary	JJ	O
level	NN	O
of	IN	O
RPLM	NNP	O
.	.	O

Supplementation	NN	O
of	IN	O
RPLM	NNP	O
at	IN	O
the	DT	O
10	CD	O
g/d	NNS	O
level	NN	O
improved	VBD	O
gain	NN	O
:	:	O
feed	VBN	O
by	IN	O
12	CD	O
%	NN	O
during	IN	O
the	DT	O
last	JJ	O
98	CD	O
d	NN	O
of	IN	O
the	DT	O
trial	NN	O
,	,	O
and	CC	O
this	DT	O
was	VBD	O
a	DT	O
direct	JJ	O
response	NN	O
to	TO	O
the	DT	O
cubic	JJ	O
effects	NNS	O
of	IN	O
RPLM	NNP	O
on	IN	O
DMI	NNP	O
.	.	O

Results	NNP	O
suggest	VBP	O
a	DT	O
cost	NN	O
advantage	NN	O
for	IN	O
replacing	VBG	O
50	CD	O
%	NN	O
of	IN	O
SBM-N	NNP	O
with	IN	O
that	DT	O
from	IN	O
urea	JJ	O
in	IN	O
high-corn	JJ	O
diets	NNS	O
without	IN	O
negative	JJ	O
effects	NNS	O
on	IN	O
feedlot	NN	O
performance	NN	O
or	CC	O
carcass	NN	O
characteristics	NNS	O
of	IN	O
growing-finishing	JJ	O
Holstein	NNP	C
steers	NNS	C
with	IN	O
extended	JJ	O
feeding	NN	O
periods	NNS	O
(	(	O
266	CD	O
d	NN	O
)	)	O
.	.	O

These	DT	O
types	NNS	O
of	IN	O
diets	NNS	O
seem	VBP	O
to	TO	O
meet	VB	O
the	DT	O
amino	NN	O
acid	NN	O
requirements	NNS	O
and	CC	O
are	VBP	O
not	RB	O
limiting	VBG	O
in	IN	O
lysine	NN	O
and	CC	O
methionine	NN	O
.	.	O

A	DT	O
randomized	VBN	O
,	,	O
controlled	VBN	O
study	NN	O
on	IN	O
the	DT	O
influence	NN	O
of	IN	O
acetaminophen	NN	O
,	,	O
diclofenac	NN	O
,	,	O
or	CC	O
naproxen	RB	O
on	IN	O
aspirin-induced	JJ	O
inhibition	NN	O
of	IN	O
platelet	NN	O
aggregation	NN	O
.	.	O

Nonsteroidal	NNP	O
anti-inflammatory	JJ	O
drugs	NNS	O
(	(	O
NSAID	NNP	O
)	)	O
may	MD	O
interfere	VB	O
with	IN	O
aspirin	NN	O
(	(	O
acetylsalicylic	JJ	O
acid	NN	O
)	)	O
and	CC	O
increase	VB	O
the	DT	O
risk	NN	O
for	IN	O
cardiovascular	JJ	O
events	NNS	O
.	.	O

The	DT	O
clinical	JJ	O
relevance	NN	O
is	VBZ	O
uncertain	JJ	O
.	.	O

The	DT	O
aim	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
analyse	VB	O
the	DT	O
influence	NN	O
of	IN	O
a	DT	O
co-administration	NN	O
of	IN	O
aspirin	NN	O
and	CC	O
NSAID	NNP	O
on	IN	O
platelet	NN	O
aggregation	NN	O
.	.	O

In	IN	O
a	DT	O
randomized	JJ	O
,	,	O
placebo	NN	O
controlled	VBD	O
trial	NN	O
,	,	O
eleven	RB	O
healthy	JJ	O
volunteers	NNS	O
were	VBD	O
studied	VBN	O
during	IN	O
4	CD	O
separate	JJ	O
study	NN	O
periods	NNS	O
of	IN	O
4	CD	O
days	NNS	O
each	DT	O
.	.	O

Individuals	NNS	O
were	VBD	O
treated	VBN	O
on	IN	O
each	DT	O
occasion	NN	O
with	IN	O
100	CD	O
mg	NNS	O
aspirin	JJ	O
daily	RB	O
in	IN	O
combination	NN	O
with	IN	O
either	DT	O
3	CD	O
x	VBD	O
1	CD	O
g	NN	O
acetaminophen	NN	O
,	,	O
3	CD	O
x	NN	O
50	CD	O
mg	NN	O
diclofenac	NN	O
,	,	O
3	CD	O
x	NN	O
250	CD	O
mg	NN	O
naproxen	NN	O
,	,	O
or	CC	O
3	CD	O
x	JJ	O
1	CD	O
placebo	NN	O
.	.	O

Primary	JJ	O
hemostasis	NN	O
was	VBD	O
assessed	VBN	O
with	IN	O
a	DT	O
platelet	NN	O
function	NN	O
analyser	NN	O
(	(	O
PFA-100	NNP	O
)	)	O
,	,	O
which	WDT	O
measures	VBZ	O
the	DT	O
closure	NN	O
time	NN	O
(	(	O
CT	NNP	O
)	)	O
of	IN	O
a	DT	O
collagen-	JJ	O
and	CC	O
epinephrine-coated	JJ	O
pore	NN	O
by	IN	O
aggregating	VBG	O
platelets	NNS	O
in	IN	O
flowing	VBG	O
blood	NN	O
.	.	O

Naproxen	NNP	O
enhanced	VBD	O
the	DT	O
anti-aggregatory	JJ	O
action	NN	O
of	IN	O
aspirin	NN	O
after	IN	O
24	CD	O
h	NN	O
(	(	O
CT	NNP	O
rising	VBG	O
from	IN	O
104+/-16	JJ	O
s	NN	O
at	IN	O
baseline	NN	O
to	TO	O
212+/-69	JJ	O
s	NN	O
at	IN	O
24	CD	O
h	NN	O
,	,	O
P	NNP	O
<	NNP	O
0.001	CD	O
)	)	O
,	,	O
which	WDT	O
was	VBD	O
not	RB	O
seen	VBN	O
with	IN	O
any	DT	O
other	JJ	O
drug	NN	O
combination	NN	O
.	.	O

Diclofenac	NNP	O
reduced	VBD	O
the	DT	O
anti-aggregatory	JJ	O
action	NN	O
of	IN	O
aspirin	NN	O
in	IN	O
the	DT	O
first	JJ	O
two	CD	O
days	NNS	O
,	,	O
since	IN	O
the	DT	O
CT	NNP	O
did	VBD	O
not	RB	O
rise	VB	O
significantly	RB	O
(	(	O
109+/-19	JJ	O
s	NN	O
,	,	O
148+/-56	JJ	O
s	NN	O
,	,	O
and	CC	O
168+/-66	JJ	O
s	NN	O
at	IN	O
0	CD	O
h	NN	O
,	,	O
24	CD	O
h	NN	O
,	,	O
48	CD	O
h	NN	O
,	,	O
respectively	RB	O
,	,	O
P	NNP	O
>	NNP	O
0.05	CD	O
)	)	O
.	.	O

Acetaminophen	NNP	O
had	VBD	O
no	DT	O
effect	NN	O
compared	VBN	O
with	IN	O
placebo	NN	O
.	.	O

After	IN	O
4	CD	O
days	NNS	O
of	IN	O
treatment	NN	O
platelet	NN	O
aggregation	NN	O
was	VBD	O
similarly	RB	O
inhibited	VBN	O
by	IN	O
all	DT	O
combinations	NNS	O
.	.	O

We	PRP	O
conclude	VBP	O
that	IN	O
a	DT	O
co-administration	NN	O
of	IN	O
NSAID	NNP	O
and	CC	O
aspirin	NN	O
may	MD	O
interfere	VB	O
with	IN	O
platelet	NN	O
inhibition	NN	O
at	IN	O
the	DT	O
beginning	NN	O
of	IN	O
a	DT	O
treatment	NN	O
with	IN	O
an	DT	O
increase	NN	O
of	IN	O
naproxen	JJ	O
and	CC	O
a	DT	O
decrease	NN	O
of	IN	O
diclofenac	NN	O
.	.	O

This	DT	O
effect	NN	O
is	VBZ	O
lost	VBN	O
after	IN	O
4	CD	O
days	NNS	O
,	,	O
suggesting	VBG	O
that	IN	O
a	DT	O
regular	JJ	O
daily	JJ	O
co-administration	NN	O
of	IN	O
NSAID	NNP	O
does	VBZ	O
not	RB	O
have	VB	O
an	DT	O
influence	NN	O
on	IN	O
platelet	NN	O
inhibition	NN	O
by	IN	O
aspirin	NN	O
.	.	O

Effect	NN	O
of	IN	O
adhesive	JJ	O
system	NN	O
type	NN	O
and	CC	O
tooth	DT	O
region	NN	O
on	IN	O
the	DT	O
bond	NN	O
strength	NN	O
to	TO	O
dentin	VB	O
.	.	O

PURPOSE	VB	O
This	DT	O
study	NN	O
evaluated	VBD	O
the	DT	O
bond	NN	O
strength	NN	O
of	IN	O
two	CD	O
etch-and-rinse	JJ	O
adhesive	JJ	O
systems	NNS	O
(	(	O
two-	JJ	O
and	CC	O
three-step	NN	O
)	)	O
and	CC	O
a	DT	O
self-etching	JJ	O
system	NN	O
to	TO	O
coronal	VB	O
and	CC	O
root	VB	O
canal	JJ	O
dentin	NN	O
.	.	O

MATERIALS	NNP	O
AND	CC	O
METHODS	NNP	O
The	DT	O
root	NN	O
canals	NNS	O
of	IN	O
30	CD	SS
human	JJ	O
incisors	NNS	O
and	CC	O
canines	NNS	O
were	VBD	O
instrumented	VBN	O
and	CC	O
prepared	VBN	O
with	IN	O
burs	NNS	O
.	.	O

The	DT	O
posts	NNS	O
used	VBD	O
for	IN	O
luting	VBG	O
were	VBD	O
duplicated	VBN	O
with	IN	O
dual	JJ	O
resin	NN	O
cement	NN	O
(	(	O
Duo-link	NNP	O
)	)	O
inside	IN	O
Aestheti	NNP	O
Plus	NNP	O
#	#	O
2	CD	O
molds	NNS	O
.	.	O

Thus	RB	O
,	,	O
three	CD	O
groups	NNS	O
were	VBD	O
formed	VBN	O
(	(	O
n	JJ	O
=	NNP	O
10	CD	O
)	)	O
according	VBG	O
to	TO	O
the	DT	O
adhesive	JJ	O
system	NN	O
employed	VBN	O
:	:	O
All-Bond	JJ	O
2	CD	O
(	(	O
TE3	NNP	O
)	)	O
+	VBP	O
resin	JJ	O
cement	NN	O
post	NN	O
(	(	O
rcp	NN	O
)	)	O
+	VBZ	O
Duo-link	NNP	O
(	(	O
Dl	NNP	O
)	)	O
;	:	O
One-Step	JJ	O
Plus	NNP	O
(	(	O
TE2	NNP	O
)	)	O
+	VBP	O
rcp	JJ	O
+	NNP	O
Dl	NNP	O
;	:	O
Tyrian/One-Step	JJ	O
Plus	NNP	O
(	(	O
SE	NNP	O
)	)	O
+	VBP	O
rcp	JJ	O
+	NNP	O
Dl	NNP	O
.	.	O

Afterwards	NNP	O
,	,	O
8	CD	O
transverse	NN	O
sections	NNS	O
(	(	O
1.5	CD	O
mm	NN	O
)	)	O
were	VBD	O
cut	VBN	O
from	IN	O
4	CD	O
mm	NNS	O
above	IN	O
the	DT	O
CEJ	NNP	O
up	RB	O
to	TO	O
4	CD	O
mm	NNS	O
short	JJ	O
of	IN	O
the	DT	O
root	NN	O
canal	JJ	O
apex	NN	O
,	,	O
comprising	VBG	O
coronal	JJ	O
and	CC	O
root	JJ	O
canal	JJ	O
dentin	NN	O
.	.	O

The	DT	O
sections	NNS	O
were	VBD	O
submitted	VBN	O
to	TO	O
push-out	JJ	O
testing	NN	O
in	IN	O
a	DT	O
universal	JJ	O
testing	VBG	O
machine	NN	O
EMIC	NNP	O
(	(	O
1	CD	O
mm/min	NN	O
)	)	O
.	.	O

Bond	NNP	O
strength	NN	O
data	NNS	O
were	VBD	O
analyzed	VBN	O
with	IN	O
two-way	JJ	O
repeated	JJ	O
measures	NNS	O
ANOVA	NNP	O
and	CC	O
Tukey	NNP	O
's	POS	O
test	NN	O
(	(	O
p	JJ	O
<	NNP	O
0.05	CD	O
)	)	O
.	.	O

RESULTS	VB	O
The	DT	O
relationship	NN	O
between	IN	O
the	DT	O
adhesives	NNS	O
was	VBD	O
not	RB	O
the	DT	O
same	JJ	O
in	IN	O
the	DT	O
different	JJ	O
regions	NNS	O
(	(	O
p	JJ	O
<	NNP	O
0.05	CD	O
)	)	O
.	.	O

Comparison	NNP	O
of	IN	O
the	DT	O
means	NNS	O
achieved	VBN	O
with	IN	O
the	DT	O
adhesives	NNS	O
in	IN	O
each	DT	O
region	NN	O
(	(	O
Tukey	NNP	O
;	:	O
p	VBZ	O
<	$	O
0.05	CD	O
)	)	O
revealed	VBD	O
that	IN	O
TE3	NNP	O
(	(	O
mean	JJ	O
+/-	JJ	O
standard	NN	O
deviation	NN	O
:	:	O
5.22	CD	O
+/-	JJ	O
1.70	CD	O
)	)	O
was	VBD	O
higher	JJR	O
than	IN	O
TE2	NNP	O
(	(	O
2.60	CD	O
+/-	JJ	O
1.74	CD	O
)	)	O
and	CC	O
SE	NNP	O
(	(	O
1.68	CD	O
+/-	JJ	O
1.85	CD	O
)	)	O
.	.	O

CONCLUSION	NNP	O
Under	IN	O
the	DT	O
experimental	JJ	O
conditions	NNS	O
,	,	O
better	JJR	O
bonding	VBG	O
to	TO	O
dentin	VB	O
was	VBD	O
achieved	VBN	O
using	VBG	O
the	DT	O
three-step	JJ	O
etch-and-rinse	JJ	O
system	NN	O
,	,	O
especially	RB	O
in	IN	O
the	DT	O
coronal	JJ	O
region	NN	O
.	.	O

Therefore	RB	O
,	,	O
the	DT	O
traditional	JJ	O
etch-and-rinse	JJ	O
three-step	NN	O
adhesive	JJ	O
system	NN	O
seems	VBZ	O
to	TO	O
be	VB	O
the	DT	O
best	JJS	O
choice	NN	O
for	IN	O
teeth	NN	O
needing	VBG	O
adhesive	JJ	O
endodontic	JJ	O
restorations	NNS	O
.	.	O

Amphotericin	NNP	O
B	NNP	O
in	IN	O
children	NNS	O
with	IN	O
malignant	JJ	C
disease	NN	C
:	:	C
a	DT	O
comparison	NN	O
of	IN	O
the	DT	O
toxicities	NNS	O
and	CC	O
pharmacokinetics	NNS	O
of	IN	O
amphotericin	NN	O
B	NNP	O
administered	VBN	O
in	IN	O
dextrose	JJ	O
versus	NN	O
lipid	JJ	O
emulsion	NN	O
.	.	O

In	IN	O
a	DT	O
prospective	JJ	O
,	,	O
randomized	JJ	O
clinical	JJ	O
trial	NN	O
,	,	O
the	DT	O
toxicity	NN	O
of	IN	O
1	CD	O
mg	NN	O
of	IN	O
amphotericin	NN	O
B	NNP	O
(	(	O
AmB	NNP	O
)	)	O
per	IN	O
kg	NN	O
of	IN	O
body	NN	O
weight	JJ	O
per	IN	O
day	NN	O
infused	VBN	O
in	IN	O
5	CD	O
%	NN	O
dextrose	NN	O
was	VBD	O
compared	VBN	O
with	IN	O
that	DT	O
of	IN	O
AmB	NNP	O
infused	VBD	O
in	IN	O
lipid	JJ	O
emulsion	NN	O
in	IN	O
children	NNS	O
with	IN	O
malignant	JJ	C
disease	NN	C
.	.	C

In	IN	O
an	DT	O
analysis	NN	O
of	IN	O
82	CD	SS
children	NNS	O
who	WP	O
received	VBD	O
a	DT	O
full	JJ	O
course	NN	O
of	IN	O
6	CD	O
days	NNS	O
or	CC	O
more	JJR	O
of	IN	O
AmB	NNP	C
(	(	O
117	CD	O
courses	NNS	O
)	)	O
,	,	O
it	PRP	O
was	VBD	O
shown	VBN	O
that	IN	O
there	EX	O
were	VBD	O
significant	JJ	O
increases	NNS	O
in	IN	O
plasma	JJ	O
urea	JJ	O
and	CC	O
creatinine	JJ	O
concentrations	NNS	O
and	CC	O
in	IN	O
potassium	NN	O
requirement	NN	O
after	IN	O
6	CD	O
days	NNS	O
of	IN	O
therapy	NN	O
with	IN	O
both	DT	O
AmB	NNP	O
infused	VBN	O
in	IN	O
dextrose	NN	O
and	CC	O
AmB	NNP	O
infused	VBD	O
in	IN	O
lipid	JJ	O
emulsion	NN	O
,	,	O
with	IN	O
there	EX	O
being	VBG	O
no	DT	O
difference	NN	O
between	IN	O
the	DT	O
two	CD	O
methods	NNS	O
of	IN	O
AmB	NNP	O
administration	NN	O
.	.	O

An	DT	O
intent-to-treat	JJ	O
comparison	NN	O
of	IN	O
the	DT	O
numbers	NNS	O
of	IN	O
courses	NNS	O
affected	VBN	O
by	IN	O
acute	JJ	O
toxicity	NN	O
(	(	O
fever	NN	O
,	,	O
rigors	NNS	O
)	)	O
and	CC	O
chronic	JJ	O
toxicity	NN	O
(	(	O
nephrotoxicity	NN	O
)	)	O
also	RB	O
indicated	VBD	O
that	IN	O
there	EX	O
was	VBD	O
no	DT	O
significant	JJ	O
difference	NN	O
between	IN	O
AmB	NNP	O
infused	VBD	O
in	IN	O
dextrose	NN	O
(	(	O
78	CD	O
courses	NNS	O
)	)	O
and	CC	O
AmB	NNP	O
infused	VBD	O
in	IN	O
lipid	JJ	O
emulsion	NN	O
(	(	O
84	CD	O
courses	NNS	O
)	)	O
.	.	O

The	DT	O
pharmacokinetics	NNS	O
of	IN	O
AmB	NNP	O
were	VBD	O
investigated	VBN	O
in	IN	O
20	CD	O
children	NNS	O
who	WP	O
received	VBD	O
AmB	NNP	O
in	IN	O
dextrose	NN	O
and	CC	O
15	CD	O
children	NNS	O
who	WP	O
received	VBD	O
AmB	NNP	O
in	IN	O
lipid	JJ	O
emulsion	NN	O
.	.	O

Blood	NN	O
samples	NNS	O
were	VBD	O
collected	VBN	O
up	RB	O
to	TO	O
24	CD	O
h	NN	O
after	IN	O
administration	NN	O
of	IN	O
the	DT	O
first	JJ	O
dose	NN	O
,	,	O
and	CC	O
the	DT	O
concentration	NN	O
of	IN	O
AmB	NNP	O
in	IN	O
plasma	NN	O
was	VBD	O
analyzed	VBN	O
by	IN	O
a	DT	O
high-performance	NN	O
liquid	NN	O
chromatography	NN	O
assay	NN	O
.	.	O

The	DT	O
clearance	NN	O
(	(	O
CL	NNP	O
)	)	O
of	IN	O
AmB	NNP	O
in	IN	O
dextrose	NN	O
(	(	O
0.039	CD	O
+/-	JJ	O
0.016	CD	O
liter	NN	O
.	.	O

h-1	NN	O
.	.	O

kg-1	NN	O
)	)	O
was	VBD	O
significantly	RB	O
lower	JJR	O
(	(	O
P	NNP	O
<	NNP	O
0.005	CD	O
)	)	O
than	IN	O
the	DT	O
CL	NNP	O
of	IN	O
AmB	NNP	O
in	IN	O
lipid	JJ	O
emulsion	NN	O
(	(	O
0.062	CD	O
+/-	JJ	O
0	CD	O
.	.	O

024	CD	O
liter	NN	O
.	.	O

h-1	NN	O
.	.	O

kg-1	NN	O
)	)	O
.	.	O

The	DT	O
steady-state	JJ	O
volume	NN	O
of	IN	O
distribution	NN	O
for	IN	O
AmB	NNP	O
in	IN	O
dextrose	NN	O
(	(	O
0.83	CD	O
+/-	JJ	O
0.33	CD	O
liter	NN	O
.	.	O

kg-1	NN	O
)	)	O
was	VBD	O
also	RB	O
significantly	RB	O
lower	JJR	O
(	(	O
P	NNP	O
<	NNP	O
0.005	CD	O
)	)	O
than	IN	O
that	DT	O
for	IN	O
AmB	NNP	O
in	IN	O
lipid	JJ	O
emulsion	NN	O
(	(	O
1.47	CD	O
+/-	JJ	O
0.77	CD	O
liter	NN	O
.	.	O

kg-1	NN	O
)	)	O
.	.	O

Although	IN	O
AmB	NNP	O
in	IN	O
lipid	JJ	O
emulsion	NN	O
is	VBZ	O
apparently	RB	O
cleared	VBN	O
faster	RBR	O
and	CC	O
distributes	VBZ	O
more	RBR	O
widely	RB	O
than	IN	O
AmB	NNP	O
in	IN	O
dextrose	NN	O
,	,	O
this	DT	O
study	NN	O
did	VBD	O
not	RB	O
reveal	VB	O
any	DT	O
significant	JJ	O
advantage	NN	O
with	IN	O
respect	NN	O
to	TO	O
safety	NN	O
and	CC	O
tolerance	NN	O
in	IN	O
the	DT	O
administration	NN	O
of	IN	O
AmB	NNP	O
in	IN	O
lipid	JJ	O
emulsion	NN	O
compared	VBN	O
to	TO	O
its	PRP$	O
administration	NN	O
in	IN	O
dextrose	NN	O
in	IN	O
children	NNS	A
with	IN	O
malignant	JJ	C
disease	NN	C
.	.	O

Randomized	VBN	O
,	,	O
placebo-controlled	JJ	O
,	,	O
crossover	NN	O
study	NN	O
of	IN	O
methylphenidate	NN	O
for	IN	O
attention-deficit/hyperactivity	NN	O
disorder	NN	O
symptoms	NNS	O
in	IN	O
preschoolers	NNS	O
with	IN	O
developmental	JJ	O
disorders	NNS	O
.	.	O

OBJECTIVE	IN	O
The	DT	O
aim	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
investigate	VB	O
the	DT	O
short-term	JJ	O
efficacy	NN	O
and	CC	O
safety	NN	O
of	IN	O
methylphenidate	NN	O
(	(	O
MPH	NNP	O
)	)	O
to	TO	O
treat	VB	O
attention-deficit/hyperactivity	JJ	O
disorder	NN	O
(	(	O
ADHD	NNP	O
)	)	O
symptoms	NNS	O
in	IN	O
an	DT	O
understudied	JJ	O
population	NN	O
of	IN	O
preschoolers	NNS	O
with	IN	O
pervasive	JJ	O
developmental	JJ	O
disorder	NN	O
(	(	O
PDD	NNP	O
)	)	O
or	CC	O
intellectual	JJ	O
disability	NN	O
(	(	O
ID	NNP	O
)	)	O
.	.	O

METHODS	NNP	O
Fourteen	NNP	O
preschoolers	NNS	O
with	IN	O
developmental	JJ	O
disorders	NNS	O
(	(	O
DD	NNP	O
,	,	O
n	JJ	O
=	VBP	O
14	CD	O
;	:	O
PDD	NNP	O
,	,	O
n	JJ	O
=	VBP	O
12	CD	O
;	:	O
ID	NNP	O
,	,	O
n	JJ	O
=	NNP	O
2	CD	O
)	)	O
underwent	NN	O
MPH	NNP	O
titration	NN	O
in	IN	O
a	DT	O
single-blind	JJ	O
manner	NN	O
followed	VBN	O
by	IN	O
a	DT	O
4-week	JJ	O
double-blind	NN	O
crossover	NN	O
phase	NN	O
.	.	O

Each	DT	O
child	NN	O
was	VBD	O
administered	VBN	O
placebo	NN	O
for	IN	O
2	CD	O
weeks	NNS	O
and	CC	O
optimal	JJ	O
dose	NN	O
for	IN	O
2	CD	O
weeks	NNS	O
.	.	O

The	DT	O
primary	JJ	O
outcome	NN	O
measure	NN	O
was	VBD	O
the	DT	O
Diagnostic	NNP	O
and	CC	O
Statistical	NNP	O
Manual	NNP	O
of	IN	O
Mental	NNP	O
Disorders	NNP	O
,	,	O
4	CD	O
(	(	O
th	NN	O
)	)	O
edition	NN	O
(	(	O
DSM-IV	NNP	O
)	)	O
ADHD	NNP	O
subscale	NN	O
of	IN	O
the	DT	O
Conners	NNP	O
'	POS	O
Parent	NN	O
Rating	VBG	O
Scale-Revised	JJ	O
(	(	O
CPRS-R-DSM-IV-ADHD	NNP	O
)	)	O
.	.	O

RESULTS	NNP	O
MPH	NNP	O
improved	VBD	O
parent-rated	JJ	O
ADHD	NNP	O
symptoms	NNS	O
of	IN	O
the	DT	O
preschoolers	NNS	O
;	:	O
50	CD	O
%	NN	O
were	VBD	O
rated	VBN	O
as	IN	O
responders	NNS	O
.	.	O

The	DT	O
CPRS-R-DSM-IV-ADHD	JJ	O
subscale	NN	O
was	VBD	O
significant	JJ	O
for	IN	O
the	DT	O
PDD	NNP	O
subgroup	NN	O
(	(	O
p	JJ	O
=	NN	O
0.005	CD	O
,	,	O
Cohen	NNP	O
d	VBZ	O
=	NNP	O
0.97	CD	O
)	)	O
and	CC	O
marginally	RB	O
significant	JJ	O
for	IN	O
the	DT	O
entire	JJ	O
DD	NNP	O
sample	NN	O
(	(	O
p	JJ	O
=	NN	O
0.08	CD	O
,	,	O
Cohen	NNP	O
d	VBZ	O
=	NNP	O
0.50	CD	O
)	)	O
.	.	O

Half	NN	O
of	IN	O
the	DT	O
preschoolers	NNS	O
experienced	VBD	O
side	JJ	O
effects	NNS	O
with	IN	O
MPH	NNP	O
,	,	O
including	VBG	O
reports	NNS	O
of	IN	O
increased	VBN	O
stereotypic	NN	O
behavior	NN	O
,	,	O
upset	JJ	O
stomach	NN	O
,	,	O
sleep-related	JJ	O
difficulties	NNS	O
,	,	O
and	CC	O
emotional	JJ	O
lability	NN	O
.	.	O

One	CD	O
child	NN	O
discontinued	VBN	O
during	IN	O
titration	NN	O
due	JJ	O
to	TO	O
side	VB	O
effects	NNS	O
.	.	O

CONCLUSION	VB	O
The	DT	O
predominant	JJ	O
direction	NN	O
of	IN	O
response	NN	O
in	IN	O
these	DT	O
preschoolers	NNS	O
with	IN	O
both	DT	O
ADHD	NNP	O
and	CC	O
PDD/ID	NNP	O
favored	VBD	O
MPH	NNP	O
,	,	O
even	RB	O
though	IN	O
the	DT	O
response	NN	O
was	VBD	O
more	RBR	O
subtle	JJ	O
and	CC	O
variable	JJ	O
than	IN	O
in	IN	O
older	JJR	O
and	CC	O
typically	RB	O
developing	VBG	O
children	NNS	O
.	.	O

Due	NNP	O
to	TO	O
high	JJ	O
rates	NNS	O
of	IN	O
adverse	JJ	O
effects	NNS	O
,	,	O
preschoolers	NNS	O
should	MD	O
be	VB	O
monitored	VBN	O
closely	RB	O
.	.	O

Effect	NN	O
of	IN	O
intravenous	JJ	O
fructose-1,6-diphosphate	NN	O
on	IN	O
myocardial	JJ	O
contractility	NN	O
in	IN	O
patients	NNS	O
with	IN	O
left	JJ	C
ventricular	JJ	C
dysfunction	NN	C
.	.	O

STUDY	NNP	O
OBJECTIVE	NNP	O
To	TO	O
examine	VB	O
the	DT	O
effects	NNS	O
of	IN	O
fructose-1,6-diphosphate	NN	O
on	IN	O
myocardial	JJ	O
performance	NN	O
using	VBG	O
nuclear	JJ	O
scintigraphy	NN	O
.	.	O

DESIGN	NNP	O
Prospective	NNP	O
,	,	O
randomized	VBD	O
,	,	O
single-blind	JJ	O
,	,	O
parallel	JJ	O
study	NN	O
.	.	O

SETTING	NNP	O
Urban	NNP	O
teaching	VBG	O
hospital	JJ	O
clinical	JJ	O
research	NN	O
center	NN	O
.	.	O

PATIENTS	JJ	O
Individuals	NNS	O
with	IN	O
New	NNP	O
York	NNP	O
Heart	NNP	O
Association	NNP	O
functional	JJ	O
class	NN	O
II-III	NNP	O
heart	NN	C
failure	NN	C
(	(	O
mild	JJ	O
to	TO	O
moderate	VB	O
)	)	O
.	.	O

INTERVENTIONS	JJ	O
Subjects	NNPS	O
received	VBD	O
either	DT	O
intravenous	JJ	O
fructose-1,6-diphosphate	JJ	O
125	CD	O
mg/kg	NN	O
or	CC	O
normal	JJ	O
saline	JJ	O
1.3	CD	O
ml/kg	NN	O
every	DT	O
12	CD	O
hours	NNS	O
over	IN	O
10	CD	O
minutes	NNS	O
for	IN	O
four	CD	O
consecutive	JJ	O
doses	NNS	O
.	.	O

Left	NNP	O
ventricular	JJ	O
performance	NN	O
was	VBD	O
assessed	VBN	O
by	IN	O
radionuclide	NN	O
ventriculography	NN	O
at	IN	O
baseline	NN	O
and	CC	O
within	IN	O
60	CD	O
minutes	NNS	O
after	IN	O
the	DT	O
fourth	JJ	O
infusion	NN	O
.	.	O

Vital	JJ	O
signs	NNS	O
were	VBD	O
monitored	VBN	O
throughout	IN	O
the	DT	O
study	NN	O
period	NN	O
.	.	O

MEASUREMENTS	NNP	O
AND	CC	O
MAIN	NNP	O
RESULTS	NNP	O
Fructose-1,6-diphosphate	NNP	O
resulted	VBD	O
in	IN	O
a	DT	O
modest	JJ	O
7	CD	O
%	NN	O
increase	NN	O
in	IN	O
left	JJ	O
ventricular	JJ	O
ejection	NN	O
fraction	NN	O
(	(	O
p	JJ	O
<	NNP	O
0.05	CD	O
)	)	O
.	.	O

Peak	JJ	O
ejection	NN	O
rate	NN	O
and	CC	O
peak	VB	O
diastolic	JJ	O
filling	VBG	O
rate	NN	O
did	VBD	O
not	RB	O
change	VB	O
significantly	RB	O
.	.	O

There	EX	O
were	VBD	O
no	DT	O
changes	NNS	O
in	IN	O
blood	NN	O
pressure	NN	O
or	CC	O
heart	NN	O
rate	NN	O
with	IN	O
either	DT	O
fructose-1,6-diphosphate	JJ	O
or	CC	O
placebo	NN	O
.	.	O

CONCLUSIONS	NNP	O
Fructose-1,6-diphosphate	NNP	O
produces	VBZ	O
a	DT	O
modest	JJ	O
but	CC	O
significant	JJ	O
increase	NN	O
in	IN	O
left	JJ	O
ventricular	JJ	O
ejection	NN	O
fraction	NN	O
in	IN	O
patients	NNS	O
with	IN	O
mild	JJ	O
to	TO	O
moderate	VB	O
heart	NN	C
failure	NN	C
.	.	O

Preschool	NNP	O
based	VBN	O
JASPER	NNP	O
intervention	NN	O
in	IN	O
minimally	RB	O
verbal	JJ	O
children	NNS	O
with	IN	O
autism	NN	O
:	:	O
pilot	NN	O
RCT	NNP	O
.	.	O

In	IN	O
this	DT	O
pilot	NN	O
study	NN	O
,	,	O
we	PRP	O
tested	VBD	O
the	DT	O
effects	NNS	O
of	IN	O
a	DT	O
novel	JJ	O
intervention	NN	O
(	(	O
JASPER	NNP	O
,	,	O
Joint	NNP	O
Attention	NNP	O
Symbolic	NNP	O
Play	NNP	O
Engagement	NNP	O
and	CC	O
Regulation	NNP	O
)	)	O
on	IN	O
3	CD	O
to	TO	O
5	CD	O
year	NN	O
old	JJ	O
,	,	O
minimally	RB	O
verbal	JJ	O
children	NNS	O
with	IN	O
autism	NN	O
who	WP	O
were	VBD	O
attending	VBG	O
a	DT	O
non-public	JJ	O
preschool	NN	O
.	.	O

Participants	NNS	O
were	VBD	O
randomized	VBN	O
to	TO	O
a	DT	O
control	NN	O
group	NN	O
(	(	O
treatment	NN	O
as	IN	O
usual	JJ	O
,	,	O
30	CD	O
h	NN	O
of	IN	O
ABA-based	JJ	O
therapy	NN	O
per	IN	O
week	NN	O
)	)	O
or	CC	O
a	DT	O
treatment	NN	O
group	NN	O
(	(	O
substitution	NN	O
of	IN	O
30	CD	O
min	NN	O
of	IN	O
JASPER	NNP	O
treatment	NN	O
,	,	O
twice	RB	O
weekly	RB	O
during	IN	O
their	PRP$	O
regular	JJ	O
program	NN	O
)	)	O
.	.	O

A	DT	O
baseline	NN	O
of	IN	O
12	CD	O
weeks	NNS	O
in	IN	O
which	WDT	O
no	DT	O
changes	NNS	O
were	VBD	O
noted	VBN	O
in	IN	O
core	NN	O
deficits	NNS	O
was	VBD	O
followed	VBN	O
by	IN	O
12	CD	O
weeks	NNS	O
of	IN	O
intervention	NN	O
for	IN	O
children	NNS	O
randomized	VBN	O
to	TO	O
the	DT	O
JASPER	NNP	O
treatment	NN	O
.	.	O

Participants	NNS	O
in	IN	O
the	DT	O
treatment	NN	O
group	NN	O
demonstrated	VBD	O
greater	JJR	O
play	NN	O
diversity	NN	O
on	IN	O
a	DT	O
standardized	JJ	O
assessment	NN	O
.	.	O

Effects	NNS	O
also	RB	O
generalized	VBD	O
to	TO	O
the	DT	O
classroom	NN	O
,	,	O
where	WRB	O
participants	NNS	O
in	IN	O
the	DT	O
treatment	NN	O
group	NN	O
initiated	VBD	O
more	JJR	O
gestures	NNS	O
and	CC	O
spent	VB	O
less	JJR	O
time	NN	O
unengaged	JJ	O
.	.	O

These	DT	O
results	NNS	O
provide	VBP	O
further	JJ	O
support	NN	O
that	WDT	O
even	RB	O
brief	VBP	O
,	,	O
targeted	JJ	O
interventions	NNS	O
on	IN	O
joint	JJ	O
attention	NN	O
and	CC	O
play	NN	O
can	MD	O
improve	VB	O
core	NN	O
deficits	NNS	O
in	IN	O
minimally	RB	O
verbal	JJ	O
children	NNS	O
with	IN	O
ASD	NNP	O
.	.	O

Serum	NNP	O
selenium	NN	O
concentration	NN	O
and	CC	O
antioxidant	JJ	O
activity	NN	O
in	IN	O
cervical	JJ	C
cancer	NN	C
patients	NNS	O
before	IN	O
and	CC	O
after	IN	O
treatment	NN	O
.	.	O

AIM	NNP	O
In	IN	O
the	DT	O
present	JJ	O
study	NN	O
,	,	O
the	DT	O
effect	NN	O
of	IN	O
chemo	NN	O
and	CC	O
radio	NN	O
therapies	NNS	O
on	IN	O
serum	NN	O
trace	NN	O
elements	NNS	O
content	NN	O
and	CC	O
antioxidant	JJ	O
activity	NN	O
in	IN	O
blood	NN	O
serum	NN	O
of	IN	O
cervical	JJ	C
cancer	NN	C
patients	NNS	O
was	VBD	O
evaluated	VBN	O
.	.	O

METHODS	NNP	O
Among	IN	O
104	CD	SS
cervical	JJ	O
cancer	NN	O
patients	NNS	O
selected	VBN	O
for	IN	O
the	DT	O
present	JJ	O
study	NN	O
,	,	O
54	CD	SS
and	CC	O
50	CD	SS
patients	NNS	O
were	VBD	O
treated	VBN	O
with	IN	O
chemo-	JJ	O
and	CC	O
radiotherapy	NN	O
respectively	RB	O
.	.	O

Plasma	NNP	O
Se	NNP	O
,	,	O
Zn	NNP	O
,	,	O
Cu	NNP	O
and	CC	O
some	DT	O
enzymatic	JJ	O
antioxidants	NNS	O
activities	NNS	O
were	VBD	O
estimated	VBN	O
in	IN	O
serum	NN	O
before	IN	O
and	CC	O
after	IN	O
the	DT	O
treatment	NN	O
.	.	O

RESULTS	VB	O
The	DT	O
decreased	JJ	O
levels	NNS	O
of	IN	O
serum	NN	O
trace	NN	O
elements	NNS	O
,	,	O
glutathione	NN	O
peroxidase	NN	O
activity	NN	O
and	CC	O
total	JJ	O
antioxidant	JJ	O
capacity	NN	O
,	,	O
and	CC	O
increased	VBD	O
malondialdehyde	NN	O
,	,	O
glutathion	NN	O
reductase	NN	O
was	VBD	O
observed	VBN	O
in	IN	O
cervical	JJ	C
cancer	NN	C
patients	NNS	O
when	WRB	O
compared	VBN	O
to	TO	O
healthy	JJ	O
controls	NNS	O
.	.	O

The	DT	O
increased	JJ	O
concentration	NN	O
of	IN	O
serum	NN	O
Se	NNP	O
,	,	O
Zn	NNP	O
was	VBD	O
observed	VBN	O
in	IN	O
patients	NNS	O
treated	VBN	O
with	IN	O
chemotherapy	NN	O
.	.	O

Simultaneously	RB	O
there	EX	O
was	VBD	O
a	DT	O
significant	JJ	O
(	(	O
P	NNP	O
<	NNP	O
0.001	CD	O
)	)	O
increase	NN	O
in	IN	O
glutathione	JJ	O
peroxidase	NN	O
and	CC	O
total	JJ	O
antioxidant	JJ	O
capacity	NN	O
,	,	O
and	CC	O
significant	JJ	O
decrease	NN	O
(	(	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
in	IN	O
malondialdehyde	NN	O
and	CC	O
glutathion	NN	O
reductase	NN	O
levels	NNS	O
in	IN	O
the	DT	O
serum	NN	O
of	IN	O
patients	NNS	O
treated	VBN	O
with	IN	O
chemotherapy	NN	O
compared	VBN	O
to	TO	O
the	DT	O
patients	NNS	O
treated	VBN	O
with	IN	O
radiotherapy	NN	O
.	.	O

CONCLUSION	VB	O
The	DT	O
results	NNS	O
demonstrated	VBD	O
that	IN	O
chemotherapy	NN	O
but	CC	O
not	RB	O
radiotherapy	JJ	O
results	NNS	O
in	IN	O
significant	JJ	O
increase	NN	O
in	IN	O
the	DT	O
trace	NN	O
elements	NNS	O
levels	NNS	O
and	CC	O
antioxidant	JJ	O
activities	NNS	O
in	IN	O
blood	NN	O
serum	NN	O
of	IN	O
cervical	JJ	C
cancer	NN	C
patients	NNS	O
.	.	O

Caudal	NNP	O
analgesia	NN	O
for	IN	O
perianal	JJ	O
surgery	NN	O
.	.	O

A	DT	O
comparison	NN	O
between	IN	O
bupivacaine	NN	O
and	CC	O
diamorphine	NN	O
.	.	O

Seventy-three	JJ	SS
patients	NNS	O
undergoing	VBG	O
elective	JJ	C
perianal	JJ	C
surgery	NN	C
were	VBD	O
randomly	RB	O
divided	VBN	O
into	IN	O
a	DT	O
control	NN	O
group	NN	O
,	,	O
a	DT	O
group	NN	O
who	WP	O
received	VBD	O
a	DT	O
caudal	JJ	O
injection	NN	O
of	IN	O
20	CD	O
ml	NNS	O
bupivacaine	VBP	O
0.5	CD	O
%	NN	O
plain	NN	O
and	CC	O
a	DT	O
group	NN	O
who	WP	O
received	VBD	O
diamorphine	JJ	O
2.5	CD	O
mg	NN	O
in	IN	O
10	CD	O
ml	NNS	O
normal	JJ	O
saline	NN	O
by	IN	O
caudal	JJ	O
injection	NN	O
;	:	O
a	DT	O
comparison	NN	O
was	VBD	O
then	RB	O
made	VBN	O
of	IN	O
postoperative	JJ	O
analgesia	NN	O
requirements	NNS	O
.	.	O

The	DT	O
bupivacaine	NN	O
group	NN	O
had	VBD	O
better	JJR	O
analgesia	NN	O
than	IN	O
the	DT	O
control	NN	O
group	NN	O
for	IN	O
the	DT	O
first	JJ	O
8	CD	O
hours	NNS	O
,	,	O
after	IN	O
which	WDT	O
there	EX	O
was	VBD	O
no	DT	O
difference	NN	O
.	.	O

The	DT	O
diamorphine	NN	O
group	NN	O
had	VBD	O
better	JJR	O
analgesia	NN	O
than	IN	O
the	DT	O
control	NN	O
group	NN	O
for	IN	O
the	DT	O
first	JJ	O
24	CD	O
hours	NNS	O
postoperatively	RB	O
.	.	O

Side	JJ	O
effects	NNS	O
were	VBD	O
less	RBR	O
in	IN	O
the	DT	O
diamorphine	NN	O
group	NN	O
than	IN	O
the	DT	O
control	NN	O
,	,	O
or	CC	O
the	DT	O
bupivacaine	NN	O
group	NN	O
.	.	O

In	IN	O
particular	JJ	O
,	,	O
41	CD	O
%	NN	O
of	IN	O
the	DT	O
bupivacaine	NN	O
group	NN	O
complained	VBD	O
of	IN	O
some	DT	O
degree	NN	O
of	IN	O
urinary	JJ	O
retention	NN	O
and	CC	O
one	CD	O
patient	NN	O
required	VBN	O
temporary	JJ	O
catheterisation	NN	O
.	.	O

It	PRP	O
is	VBZ	O
concluded	VBN	O
that	IN	O
caudal	JJ	O
diamorphine	NN	O
gives	VBZ	O
good	JJ	O
postoperative	JJ	O
analgesia	NN	O
for	IN	O
perianal	JJ	O
operations	NNS	O
,	,	O
particularly	RB	O
when	WRB	O
motor	NN	O
blockade	NN	O
is	VBZ	O
not	RB	O
wanted	VBN	O
by	IN	O
the	DT	O
surgeon	NN	O
.	.	O

Low	JJ	O
body	NN	O
mass	NN	O
index	NN	O
and	CC	O
dyslipidemia	NN	O
in	IN	O
dialysis	NN	C
patients	NNS	C
linked	VBN	O
to	TO	O
elevated	VBN	O
plasma	NN	O
fibroblast	NN	O
growth	NN	O
factor	NN	O
23	CD	O
.	.	O

BACKGROUND	NNP	O
Fibroblast	NNP	O
growth	NN	O
factor	NN	O
23	CD	O
(	(	O
FGF23	NNP	O
)	)	O
has	VBZ	O
been	VBN	O
associated	VBN	O
with	IN	O
death	NN	O
in	IN	O
dialysis	NN	O
patients	NNS	O
.	.	O

Since	IN	O
FGF23	NNP	O
shares	NNS	O
structural	JJ	O
features	NNS	O
with	IN	O
FGF19	NNP	O
subfamily	RB	O
members	NNS	O
that	IN	O
exert	JJ	O
hormonal	JJ	O
control	NN	O
of	IN	O
fat	JJ	O
mass	NN	O
,	,	O
we	PRP	O
hypothesized	VBD	O
that	DT	O
high	JJ	O
circulating	NN	O
FGF23	NNP	O
concentrations	NNS	O
would	MD	O
be	VB	O
associated	VBN	O
with	IN	O
the	DT	O
development	NN	O
of	IN	O
a	DT	O
uremic	JJ	O
lipid	NN	O
profile	NN	O
and	CC	O
lower	JJR	O
body	NN	O
mass	NN	O
index	NN	O
(	(	O
BMI	NNP	O
)	)	O
.	.	O

METHODS	NNP	O
This	DT	O
study	NN	O
was	VBD	O
conducted	VBN	O
among	IN	O
654	CD	O
patients	NNS	O
receiving	VBG	O
chronic	JJ	O
hemodialysis	NN	O
.	.	O

C-terminal	JJ	O
FGF23	NNP	O
concentrations	NNS	O
were	VBD	O
measured	VBN	O
in	IN	O
stored	JJ	O
plasma	NN	O
samples	NNS	O
.	.	O

Linear	JJ	O
regression	NN	O
was	VBD	O
used	VBN	O
to	TO	O
examine	VB	O
the	DT	O
cross-sectional	JJ	O
associations	NNS	O
of	IN	O
plasma	NN	O
FGF23	NNP	O
concentrations	NNS	O
with	IN	O
BMI	NNP	O
,	,	O
total	JJ	O
cholesterol	NN	O
(	(	O
TC	NNP	O
)	)	O
,	,	O
low-density	JJ	O
lipoprotein-cholesterol	NN	O
(	(	O
LDL-C	NNP	O
)	)	O
,	,	O
high-density	JJ	O
lipoprotein-cholesterol	NN	O
(	(	O
HDL-C	NNP	O
)	)	O
and	CC	O
triglycerides	NNS	O
.	.	O

Cox	NNP	O
proportional	JJ	O
hazard	NN	O
models	NNS	O
were	VBD	O
used	VBN	O
to	TO	O
examine	VB	O
the	DT	O
association	NN	O
between	IN	O
FGF23	NNP	O
concentrations	NNS	O
and	CC	O
all-cause	JJ	O
mortality	NN	O
.	.	O

RESULTS	JJ	O
Participants	NNS	O
had	VBD	O
a	DT	O
mean	JJ	O
age	NN	O
of	IN	O
60	CD	O
?	.	O
11	CD	O
years	NNS	O
and	CC	O
a	DT	O
median	JJ	O
(	(	O
IQR	NNP	O
)	)	O
FGF23	NNP	O
concentration	NN	O
of	IN	O
4,212	CD	O
(	(	O
1,411-13,816	JJ	O
)	)	O
RU/ml	NNP	O
.	.	O

An	DT	O
increase	NN	O
per	IN	O
SD	NNP	O
in	IN	O
log10	JJ	O
FGF23	NNP	O
was	VBD	O
associated	VBN	O
with	IN	O
lower	JJR	O
BMI	NNP	O
(	(	O
?	.	O
=	NNP	O
-1.11	NNP	O
;	:	O
p	VBZ	O
=	$	O
0.008	CD	O
)	)	O
,	,	O
TC	NNP	O
(	(	O
?	.	O
=	NNP	O
-6.46	NNP	O
;	:	O
p	VBZ	O
=	$	O
0.02	CD	O
)	)	O
,	,	O
LDL-C	NNP	O
(	(	O
?	.	O
=	NNP	O
-4.73	NNP	O
;	:	O
p	VBZ	O
=	$	O
0.04	CD	O
)	)	O
and	CC	O
HDL-C	NNP	O
(	(	O
?	.	O
=	NNP	O
-2.14	NNP	O
;	:	O
p	VBZ	O
=	$	O
0.03	CD	O
)	)	O
;	:	O
after	IN	O
adjusting	VBG	O
for	IN	O
age	NN	O
,	,	O
gender	NN	O
,	,	O
race	NN	O
,	,	O
cardiovascular	JJ	O
risk	NN	O
factors	NNS	O
,	,	O
serum	NN	O
albumin	NN	O
,	,	O
markers	NNS	O
of	IN	O
mineral	JJ	O
metabolism	NN	O
,	,	O
and	CC	O
use	NN	O
of	IN	O
lipid-lowering	JJ	O
drugs	NNS	O
.	.	O

The	DT	O
association	NN	O
of	IN	O
FGF23	NNP	O
with	IN	O
death	NN	O
was	VBD	O
attenuated	VBN	O
after	IN	O
adjustment	NN	O
for	IN	O
HDL-C	NNP	O
(	(	O
HR	NNP	O
of	IN	O
highest	JJS	O
quartile	NN	O
1.53	CD	O
,	,	O
95	CD	O
%	NN	O
CI	NNP	O
1.06-2.20	CD	O
compared	VBN	O
to	TO	O
lowest	VB	O
quartile	NN	O
)	)	O
.	.	O

CONCLUSION	NNP	O
These	DT	O
results	NNS	O
indicate	VBP	O
that	IN	O
higher	JJR	O
plasma	NN	O
FGF23	NNP	O
levels	NNS	O
are	VBP	O
associated	VBN	O
with	IN	O
lower	JJR	O
BMI	NNP	O
and	CC	O
dyslipidemia	NN	O
in	IN	O
dialysis	NN	O
patients	NNS	O
.	.	O

The	DT	O
association	NN	O
between	IN	O
FGF23	NNP	O
and	CC	O
death	NN	O
may	MD	O
be	VB	O
mediated	VBN	O
through	IN	O
unexplored	JJ	O
metabolic	JJ	O
risk	NN	O
factors	NNS	O
unrelated	VBD	O
to	TO	O
mineral	JJ	O
metabolism	NN	O
.	.	O

Cognitive	JJ	O
behavioral	JJ	O
therapy	NN	O
for	IN	O
anxiety	NN	C
in	IN	C
children	NNS	C
with	IN	C
autism	NN	C
spectrum	NN	C
disorders	NNS	C
:	:	C
a	DT	O
randomized	NN	O
,	,	O
controlled	VBN	O
trial	NN	O
.	.	O

BACKGROUND	NNP	O
Children	NNP	O
with	IN	O
autism	NN	O
spectrum	NN	O
disorders	NNS	O
often	RB	O
present	JJ	O
with	IN	O
comorbid	NN	O
anxiety	NN	O
disorders	NNS	O
that	WDT	O
cause	VBP	O
significant	JJ	O
functional	JJ	O
impairment	NN	O
.	.	O

This	DT	O
study	NN	O
tested	VBD	O
a	DT	O
modular	JJ	O
cognitive	JJ	O
behavioral	JJ	O
therapy	NN	O
(	(	O
CBT	NNP	O
)	)	O
program	NN	O
for	IN	O
children	NNS	O
with	IN	O
this	DT	O
profile	NN	O
.	.	O

A	DT	O
standard	JJ	O
CBT	NNP	O
program	NN	O
was	VBD	O
augmented	VBN	O
with	IN	O
multiple	JJ	O
treatment	NN	O
components	NNS	O
designed	VBN	O
to	TO	O
accommodate	VB	O
or	CC	O
remediate	VB	O
the	DT	O
social	JJ	O
and	CC	O
adaptive	JJ	O
skill	NN	O
deficits	NNS	O
of	IN	O
children	NNS	O
with	IN	O
ASD	NNP	O
that	WDT	O
could	MD	O
pose	VB	O
barriers	NNS	O
to	TO	O
anxiety	VB	O
reduction	NN	O
.	.	O

METHOD	NNP	O
Forty	NNP	O
children	NNS	O
(	(	O
7-11	CD	O
years	NNS	O
old	JJ	O
)	)	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
16	CD	O
sessions	NNS	O
of	IN	O
CBT	NNP	O
or	CC	O
a	DT	O
3-month	JJ	O
waitlist	NN	O
(	(	O
36	CD	O
completed	VBN	O
treatment	NN	O
or	CC	O
waitlist	NN	O
)	)	O
.	.	O

Therapists	NNS	O
worked	VBD	O
with	IN	O
individual	JJ	O
families	NNS	O
.	.	O

The	DT	O
CBT	NNP	O
model	NN	O
emphasized	VBD	O
behavioral	JJ	O
experimentation	NN	O
,	,	O
parent-training	NN	O
,	,	O
and	CC	O
school	NN	O
consultation	NN	O
.	.	O

Independent	JJ	O
evaluators	NNS	O
blind	VBP	O
to	TO	O
treatment	NN	O
condition	NN	O
conducted	VBN	O
structured	JJ	O
diagnostic	JJ	O
interviews	NNS	O
and	CC	O
parents	NNS	O
and	CC	O
children	NNS	O
completed	VBN	O
anxiety	NN	O
symptom	NN	O
checklists	NNS	O
at	IN	O
baseline	NN	O
and	CC	O
posttreatment/postwaitlist	NN	O
.	.	O

RESULTS	NNP	O
In	IN	O
intent-to-treat	JJ	O
analyses	NNS	O
,	,	O
78.5	CD	O
%	NN	O
of	IN	O
the	DT	O
CBT	NNP	O
group	NN	O
met	VBD	O
Clinical	JJ	O
Global	NNP	O
Impressions-Improvement	NNP	O
scale	NN	O
criteria	NNS	O
for	IN	O
positive	JJ	O
treatment	NN	O
response	NN	O
at	IN	O
posttreatment	NN	O
,	,	O
as	IN	O
compared	VBN	O
to	TO	O
only	RB	O
8.7	CD	O
%	NN	O
of	IN	O
the	DT	O
waitlist	NN	O
group	NN	O
.	.	O

CBT	NNP	O
also	RB	O
outperformed	VBD	O
the	DT	O
waitlist	NN	O
on	IN	O
diagnostic	JJ	O
outcomes	NNS	O
and	CC	O
parent	NN	O
reports	NNS	O
of	IN	O
child	NN	O
anxiety	NN	O
,	,	O
but	CC	O
not	RB	O
children	NNS	O
's	POS	O
self-reports	NNS	O
.	.	O

Treatment	NN	O
gains	NNS	O
were	VBD	O
maintained	VBN	O
at	IN	O
3-month	JJ	O
follow-up	NN	O
.	.	O

CONCLUSIONS	VB	O
The	DT	O
CBT	NNP	O
manual	JJ	O
employed	VBN	O
in	IN	O
this	DT	O
study	NN	O
is	VBZ	O
one	CD	O
of	IN	O
the	DT	O
first	JJ	O
adaptations	NNS	O
of	IN	O
an	DT	O
evidence-based	JJ	O
treatment	NN	O
for	IN	O
children	NNS	O
with	IN	O
autism	NN	O
spectrum	NN	O
disorders	NNS	O
.	.	O

Remission	NN	O
of	IN	O
anxiety	NN	O
disorders	NNS	O
appears	VBZ	O
to	TO	O
be	VB	O
an	DT	O
achievable	JJ	O
goal	NN	O
among	IN	O
high-functioning	JJ	O
children	NNS	O
with	IN	O
autism	NN	O
.	.	O

Reversal	NNP	O
of	IN	O
skeletal	JJ	O
effects	NNS	O
of	IN	O
endocrine	NN	O
treatments	NNS	O
in	IN	O
the	DT	O
Intergroup	NNP	O
Exemestane	NNP	O
Study	NNP	O
.	.	O

The	DT	O
adjuvant	JJ	O
use	NN	O
of	IN	O
aromatase	NN	O
inhibitors	NNS	O
in	IN	O
breast	NN	O
cancer	NN	O
is	VBZ	O
associated	VBN	O
with	IN	O
adverse	JJ	O
effects	NNS	O
on	IN	O
bone	NN	O
health	NN	O
.	.	O

We	PRP	O
previously	RB	O
reported	VBD	O
a	DT	O
decline	NN	O
in	IN	O
bone	JJ	O
mineral	JJ	O
density	NN	O
(	(	O
BMD	NNP	O
)	)	O
following	VBG	O
the	DT	O
switch	NN	O
from	IN	O
tamoxifen	NN	O
to	TO	O
exemestane	VB	O
in	IN	O
the	DT	O
Intergroup	NNP	O
Exemestane	NNP	O
Study	NNP	O
(	(	O
IES	NNP	O
)	)	O
.	.	O

Here	RB	O
we	PRP	O
report	VBP	O
effects	NNS	O
of	IN	O
endocrine	JJ	O
treatment	NN	O
withdrawal	NN	O
on	IN	O
BMD	NNP	O
,	,	O
bone	NN	O
turnover	NN	O
markers	NNS	O
(	(	O
BTM	NNP	O
)	)	O
and	CC	O
fracture	JJ	O
rates	NNS	O
.	.	O

4,724	CD	SS
patients	NNS	O
took	VBD	O
part	NN	O
in	IN	O
IES	NNP	O
,	,	O
and	CC	O
206	CD	SS
patients	NNS	O
were	VBD	O
included	VBN	O
in	IN	O
a	DT	O
bone	NN	O
sub-study	NN	O
.	.	O

BMD	NNP	O
and	CC	O
BTM	NNP	O
were	VBD	O
assessed	VBN	O
pre-randomization	NN	O
,	,	O
during	IN	O
and	CC	O
after	IN	O
the	DT	O
end	NN	O
of	IN	O
treatment	NN	O
(	(	O
EOT	NNP	O
)	)	O
.	.	O

To	TO	O
evaluate	VB	O
treatment	NN	O
withdrawal	NN	O
effects	NNS	O
,	,	O
12-	JJ	O
and	CC	O
24-month	JJ	O
post	NN	O
EOT	NNP	O
BMD	NNP	O
results	NNS	O
are	VBP	O
available	JJ	O
for	IN	O
122	CD	O
and	CC	O
126	CD	O
patients	NNS	O
,	,	O
respectively	RB	O
.	.	O

Similar	JJ	O
patient	NN	O
numbers	NNS	O
had	VBD	O
BTM	NNP	O
measured	VBD	O
post	NN	O
EOT	NNP	O
.	.	O

Following	VBG	O
treatment	NN	O
withdrawal	NN	O
,	,	O
the	DT	O
differences	NNS	O
in	IN	O
BMD	NNP	O
observed	VBD	O
between	IN	O
the	DT	O
two	CD	O
endocrine	NN	O
strategies	NNS	O
were	VBD	O
partially	RB	O
reversed	VBN	O
.	.	O

At	IN	O
24	CD	O
months	NNS	O
from	IN	O
EOT	NNP	O
,	,	O
spine	JJ	O
BMD	NNP	O
increased	VBN	O
by	IN	O
1.53	CD	O
%	NN	O
(	(	O
95	CD	O
%	NN	O
CI	NNP	O
0.63-2.43	CD	O
;	:	O
p	CC	O
=	VB	O
0.001	CD	O
)	)	O
after	IN	O
stopping	VBG	O
exemestane	NN	O
and	CC	O
fell	VBD	O
by	IN	O
1.93	CD	O
%	NN	O
(	(	O
95	CD	O
%	NN	O
CI	NNP	O
-2.91	NNP	O
to	TO	O
0.95	CD	O
;	:	O
p	NN	O
=	VBZ	O
0.0002	CD	O
)	)	O
following	VBG	O
tamoxifen	NN	O
withdrawal	NN	O
.	.	O

A	DT	O
similar	JJ	O
pattern	NN	O
of	IN	O
changes	NNS	O
was	VBD	O
observed	VBN	O
at	IN	O
the	DT	O
hip	NN	O
.	.	O

At	IN	O
2	CD	O
years	NNS	O
post	RB	O
EOT	NNP	O
,	,	O
BMD	NNP	O
changes	NNS	O
from	IN	O
baseline	NN	O
were	VBD	O
similar	JJ	O
with	IN	O
both	DT	O
treatment	NN	O
strategies	NNS	O
.	.	O

Corresponding	VBG	O
inverse	JJ	O
changes	NNS	O
in	IN	O
BTM	NNP	O
were	VBD	O
seen	VBN	O
,	,	O
with	IN	O
an	DT	O
increase	NN	O
following	VBG	O
tamoxifen	JJ	O
withdrawal	NN	O
and	CC	O
a	DT	O
reduction	NN	O
after	IN	O
exemestane	NN	O
.	.	O

A	DT	O
higher	JJR	O
number	NN	O
of	IN	O
fractures	NNS	O
occurred	VBD	O
during	IN	O
exemestane	NN	O
treatment	NN	O
,	,	O
but	CC	O
fracture	NN	O
rates	NNS	O
were	VBD	O
similar	JJ	O
after	IN	O
treatment	NN	O
withdrawal	NN	O
.	.	O

With	IN	O
the	DT	O
switch	NN	O
strategy	NN	O
used	VBN	O
in	IN	O
IES	NNP	O
,	,	O
the	DT	O
on	IN	O
treatment	NN	O
adverse	JJ	O
bone	NN	O
effects	NNS	O
of	IN	O
exemestane	NN	O
are	VBP	O
reversed	VBN	O
.	.	O

Ongoing	VBG	O
monitoring	NN	O
of	IN	O
BMD	NNP	O
is	VBZ	O
therefore	RB	O
not	RB	O
routinely	RB	O
required	VBN	O
.	.	O

Pazopanib	NNP	O
in	IN	O
locally	RB	O
advanced	JJ	O
or	CC	O
metastatic	JJ	O
renal	NN	C
cell	NN	C
carcinoma	NN	C
:	:	O
results	NNS	O
of	IN	O
a	DT	O
randomized	JJ	O
phase	NN	O
III	NNP	O
trial	NN	O
.	.	O

PURPOSE	NNP	O
Pazopanib	NNP	O
is	VBZ	O
an	DT	O
oral	JJ	O
angiogenesis	NN	O
inhibitor	NN	O
targeting	VBG	O
vascular	JJ	O
endothelial	JJ	O
growth	NN	O
factor	NN	O
receptor	NN	O
,	,	O
platelet-derived	JJ	O
growth	NN	O
factor	NN	O
receptor	NN	O
,	,	O
and	CC	O
c-Kit	NN	O
.	.	O

This	DT	O
randomized	JJ	O
,	,	O
double-blind	JJ	O
,	,	O
placebo-controlled	JJ	O
phase	NN	O
III	NNP	O
study	NN	O
evaluated	VBD	O
efficacy	NN	O
and	CC	O
safety	NN	O
of	IN	O
pazopanib	JJ	O
monotherapy	NN	O
in	IN	O
treatment-naive	JJ	O
and	CC	O
cytokine-pretreated	JJ	O
patients	NNS	O
with	IN	O
advanced	JJ	O
renal	JJ	O
cell	NN	O
carcinoma	NN	O
(	(	O
RCC	NNP	C
)	)	O
.	.	O

PATIENTS	NNP	O
AND	CC	O
METHODS	NNP	O
Adult	NNP	O
patients	NNS	O
with	IN	O
measurable	JJ	O
,	,	O
locally	RB	O
advanced	JJ	O
,	,	O
and/or	JJ	O
metastatic	JJ	O
RCC	NNP	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
2:1	CD	O
to	TO	O
receive	VB	O
oral	JJ	O
pazopanib	NN	O
or	CC	O
placebo	NN	O
.	.	O

The	DT	O
primary	JJ	O
end	NN	O
point	NN	O
was	VBD	O
progression-free	JJ	O
survival	NN	O
(	(	O
PFS	NNP	O
)	)	O
.	.	O

Secondary	JJ	O
end	NN	O
points	NNS	O
included	VBD	O
overall	JJ	O
survival	NN	O
,	,	O
tumor	NN	O
response	NN	O
rate	NN	O
(	(	O
Response	NNP	O
Evaluation	NNP	O
Criteria	NNP	O
in	IN	O
Solid	NNP	O
Tumors	NNP	O
)	)	O
,	,	O
and	CC	O
safety	NN	O
.	.	O

Radiographic	JJ	O
assessments	NNS	O
of	IN	O
tumors	NNS	O
were	VBD	O
independently	RB	O
reviewed	VBN	O
.	.	O

Results	NNS	O
Of	IN	O
435	CD	SS
patients	NNS	O
enrolled	VBD	O
,	,	O
233	CD	SS
were	VBD	O
treatment	NN	O
naive	JJ	O
(	(	O
54	CD	O
%	NN	O
)	)	O
and	CC	O
202	CD	SS
were	VBD	O
cytokine	NN	O
pretreated	VBN	O
(	(	O
46	CD	O
%	NN	O
)	)	O
.	.	O

PFS	NNP	O
was	VBD	O
significantly	RB	O
prolonged	VBN	O
with	IN	O
pazopanib	NNS	O
compared	VBN	O
with	IN	O
placebo	NN	O
in	IN	O
the	DT	O
overall	JJ	O
study	NN	O
population	NN	O
(	(	O
median	JJ	O
,	,	O
PFS	NNP	O
9.2	CD	O
v	NN	O
4.2	CD	O
months	NNS	O
;	:	O
hazard	PRP$	O
ratio	NN	O
[	NNP	O
HR	NNP	O
]	NNP	O
,	,	O
0.46	CD	O
;	:	O
95	CD	O
%	NN	O
CI	NNP	O
,	,	O
0.34	CD	O
to	TO	O
0.62	CD	O
;	:	O
P	NNP	O
<	NNP	O
.0001	NNP	O
)	)	O
,	,	O
the	DT	O
treatment-naive	JJ	O
subpopulation	NN	O
(	(	O
median	JJ	O
PFS	NNP	O
11.1	CD	O
v	NN	O
2.8	CD	O
months	NNS	O
;	:	O
HR	NNP	O
,	,	O
0.40	CD	O
;	:	O
95	CD	O
%	NN	O
CI	NNP	O
,	,	O
0.27	CD	O
to	TO	O
0.60	CD	O
;	:	O
P	NNP	O
<	NNP	O
.0001	NNP	O
)	)	O
,	,	O
and	CC	O
the	DT	O
cytokine-pretreated	JJ	O
subpopulation	NN	O
(	(	O
median	JJ	O
PFS	NNP	O
,	,	O
7.4	CD	O
v	NN	O
4.2	CD	O
months	NNS	O
;	:	O
HR	NNP	O
,	,	O
0.54	CD	O
;	:	O
95	CD	O
%	NN	O
CI	NNP	O
,	,	O
0.35	CD	O
to	TO	O
0.84	CD	O
;	:	O
P	NNP	O
<	NNP	O
.001	NNP	O
)	)	O
.	.	O

The	DT	O
objective	JJ	O
response	NN	O
rate	NN	O
was	VBD	O
30	CD	O
%	NN	O
with	IN	O
pazopanib	NN	O
compared	VBN	O
with	IN	O
3	CD	O
%	NN	O
with	IN	O
placebo	NN	O
(	(	O
P	NNP	O
<	NNP	O
.001	NNP	O
)	)	O
.	.	O

The	DT	O
median	JJ	O
duration	NN	O
of	IN	O
response	NN	O
was	VBD	O
longer	JJR	O
than	IN	O
1	CD	O
year	NN	O
.	.	O

The	DT	O
most	RBS	O
common	JJ	O
adverse	JJ	O
events	NNS	O
were	VBD	O
diarrhea	RB	O
,	,	O
hypertension	NN	O
,	,	O
hair	NN	O
color	NN	O
changes	NNS	O
,	,	O
nausea	NN	O
,	,	O
anorexia	NN	O
,	,	O
and	CC	O
vomiting	VBG	O
.	.	O

There	EX	O
was	VBD	O
no	DT	O
evidence	NN	O
of	IN	O
clinically	RB	O
important	JJ	O
differences	NNS	O
in	IN	O
quality	NN	O
of	IN	O
life	NN	O
for	IN	O
pazopanib	JJ	O
versus	NN	O
placebo	NN	O
.	.	O

CONCLUSION	NNP	O
Pazopanib	NNP	O
demonstrated	VBD	O
significant	JJ	O
improvement	NN	O
in	IN	O
PFS	NNP	O
and	CC	O
tumor	NN	O
response	NN	O
compared	VBN	O
with	IN	O
placebo	NN	O
in	IN	O
treatment-naive	JJ	O
and	CC	O
cytokine-pretreated	JJ	O
patients	NNS	O
with	IN	O
advanced	JJ	O
and/or	NNS	O
metastatic	JJ	O
RCC	NNP	O
.	.	O

Randomized	VBN	O
controlled	JJ	O
trial	NN	O
:	:	O
Multimodal	NNP	O
Anxiety	NNP	O
and	CC	O
Social	NNP	O
Skill	NNP	O
Intervention	NNP	O
for	IN	O
adolescents	NNS	A
with	IN	O
autism	NN	C
spectrum	NN	C
disorder	NN	C
.	.	O

Anxiety	NN	O
is	VBZ	O
common	JJ	O
among	IN	O
adolescents	NNS	O
with	IN	O
autism	NN	O
spectrum	NN	O
disorders	NNS	O
(	(	O
ASD	NNP	C
)	)	O
and	CC	O
may	MD	O
amplify	VB	O
the	DT	O
core	NN	O
social	JJ	O
disability	NN	O
,	,	O
thus	RB	O
necessitating	VBG	O
combined	VBN	O
treatment	NN	O
approaches	NNS	O
.	.	O

This	DT	O
pilot	NN	O
,	,	O
randomized	VBN	O
controlled	VBN	O
trial	NN	O
evaluated	VBD	O
the	DT	O
feasibility	NN	O
and	CC	O
preliminary	JJ	O
outcomes	NNS	O
of	IN	O
the	DT	O
Multimodal	NNP	O
Anxiety	NNP	O
and	CC	O
Social	NNP	O
Skills	NNP	O
Intervention	NNP	O
(	(	O
MASSI	NNP	O
)	)	O
program	NN	O
in	IN	O
a	DT	O
sample	NN	O
of	IN	O
30	CD	SS
adolescents	NNS	A
with	IN	O
ASD	NNP	C
and	CC	C
anxiety	NN	C
symptoms	NNS	C
of	IN	O
moderate	JJ	O
or	CC	O
greater	JJR	O
severity	NN	O
.	.	O

The	DT	O
treatment	NN	O
was	VBD	O
acceptable	JJ	O
to	TO	O
families	NNS	O
,	,	O
subject	JJ	O
adherence	NN	O
was	VBD	O
high	JJ	O
,	,	O
and	CC	O
therapist	JJ	O
fidelity	NN	O
was	VBD	O
high	JJ	O
.	.	O

A	DT	O
16	CD	O
%	NN	O
improvement	NN	O
in	IN	O
ASD	NNP	O
social	JJ	O
impairment	NN	O
(	(	O
within-group	JJ	O
effect	NN	O
size	NN	O
=	NNP	O
1.18	CD	O
)	)	O
was	VBD	O
observed	VBN	O
on	IN	O
a	DT	O
parent-reported	JJ	O
scale	NN	O
.	.	O

Although	IN	O
anxiety	NN	O
symptoms	NNS	O
declined	VBD	O
by	IN	O
26	CD	O
%	NN	O
,	,	O
the	DT	O
change	NN	O
was	VBD	O
not	RB	O
statistically	RB	O
significant	JJ	O
.	.	O

These	DT	O
findings	NNS	O
suggest	VBP	O
MASSI	NNP	O
is	VBZ	O
a	DT	O
feasible	JJ	O
treatment	NN	O
program	NN	O
and	CC	O
further	JJ	O
evaluation	NN	O
is	VBZ	O
warranted	VBN	O
.	.	O

Evaluation	NN	O
of	IN	O
an	DT	O
intervention	NN	O
to	TO	O
change	VB	O
benzodiazepine-prescribing	JJ	O
behavior	NN	O
in	IN	O
a	DT	O
prepaid	NN	O
group	NN	O
practice	NN	O
setting	VBG	O
.	.	O

To	TO	O
determine	VB	O
the	DT	O
effect	NN	O
of	IN	O
two	CD	O
levels	NNS	O
of	IN	O
educational	JJ	O
intervention	NN	O
on	IN	O
benzodiazepine-prescribing	JJ	O
behavior	NN	O
in	IN	O
an	DT	O
elderly	JJ	O
population	NN	O
in	IN	O
a	DT	O
controlled	JJ	O
prepaid	NN	O
group	NN	O
practice	NN	O
(	(	O
PPGP	NNP	O
)	)	O
setting	NN	O
,	,	O
we	PRP	O
designed	VBD	O
a	DT	O
prospective	JJ	O
controlled	VBN	O
trial	NN	O
,	,	O
with	IN	O
six-month	JJ	O
follow-up	NN	O
.	.	O

Our	PRP$	O
setting	NN	O
was	VBD	O
a	DT	O
270,000	CD	O
member	NN	O
group-model	JJ	O
PPGP	NNP	O
in	IN	O
Colorado	NNP	O
,	,	O
from	IN	O
1990	CD	O
to	TO	O
1991	CD	O
.	.	O

Participants	NNS	O
included	VBD	O
91	CD	O
physicians	NNS	O
,	,	O
62	CD	O
men	NNS	O
and	CC	O
29	CD	O
women	NNS	O
;	:	O
median	JJ	O
age	NN	O
was	VBD	O
38.7	CD	O
years	NNS	O
.	.	O

Group	NNP	O
1	CD	O
received	VBD	O
a	DT	O
one-on-one	JJ	O
educational	JJ	O
presentation	NN	O
by	IN	O
a	DT	O
clinical	JJ	O
pharmacist	NN	O
,	,	O
written	VBN	O
educational	JJ	O
materials	NNS	O
,	,	O
a	DT	O
brief	JJ	O
follow-up	JJ	O
visit	NN	O
,	,	O
and	CC	O
feedback	NN	O
with	IN	O
recommendations	NNS	O
.	.	O

Group	NNP	O
2	CD	O
received	VBD	O
only	RB	O
a	DT	O
face-to-face	JJ	O
presentation	NN	O
,	,	O
given	VBN	O
to	TO	O
departmental	VB	O
groups	NNS	O
,	,	O
as	RB	O
well	RB	O
as	IN	O
the	DT	O
same	JJ	O
written	VBN	O
educational	JJ	O
materials	NNS	O
used	VBN	O
in	IN	O
group	NN	O
1	CD	O
.	.	O

Controls	NNP	O
received	VBD	O
no	DT	O
intervention	NN	O
.	.	O

Our	PRP$	O
primary	JJ	O
outcome	JJ	O
measure	NN	O
was	VBD	O
the	DT	O
benzodiazepine	NN	O
on/off	NN	O
status	NN	O
of	IN	O
the	DT	O
elderly	JJ	O
PPGP	NNP	O
members	NNS	O
.	.	O

The	DT	O
secondary	JJ	O
outcome	NN	O
measure	NN	O
was	VBD	O
the	DT	O
median	JJ	O
change	NN	O
(	(	O
preintervention	NN	O
minus	IN	O
postintervention	NN	O
)	)	O
in	IN	O
a	DT	O
standardized	JJ	O
amount	NN	O
of	IN	O
benzodiazepines	NNS	O
prescribed	VBN	O
per	IN	O
physician	NN	O
.	.	O

Logistic	JJ	O
regression	NN	O
analysis	NN	O
failed	VBD	O
to	TO	O
show	VB	O
a	DT	O
significant	JJ	O
effect	NN	O
on	IN	O
postintervention	NN	O
benzodiazepine	NN	O
on/off	NN	O
status	NN	O
between	IN	O
study	NN	O
groups	NNS	O
,	,	O
when	WRB	O
controlling	VBG	O
for	IN	O
preintervention	NN	O
on/off	NN	O
status	NN	O
,	,	O
PPGP-member	NNP	O
age	NN	O
,	,	O
PPGP-member	NNP	O
gender	NN	O
,	,	O
and	CC	O
all	DT	O
possible	JJ	O
interactions	NNS	O
.	.	O

Analysis	NN	O
of	IN	O
variance	NN	O
failed	VBD	O
to	TO	O
demonstrate	VB	O
an	DT	O
effect	NN	O
of	IN	O
either	DT	O
intervention	NN	O
on	IN	O
the	DT	O
median	JJ	O
change	NN	O
in	IN	O
standardized	JJ	O
amount	NN	O
of	IN	O
benzodiazepines	NNS	O
prescribed	VBN	O
per	IN	O
physician	NN	O
,	,	O
with	IN	O
groups	NNS	O
1	CD	O
,	,	O
2	CD	O
,	,	O
and	CC	O
controls	NNS	O
yielding	VBG	O
values	NNS	O
of	IN	O
-278	NN	O
(	(	O
range	NN	O
:	:	O
-4,137	NN	O
,	,	O
2,844	CD	O
)	)	O
,	,	O
-330	NNP	O
(	(	O
-1,531	NNP	O
,	,	O
1,358	CD	O
)	)	O
,	,	O
and	CC	O
-541	NNP	O
(	(	O
range	NN	O
:	:	O
-3,716	NN	O
,	,	O
2,185	CD	O
)	)	O
,	,	O
respectively	RB	O
.	.	O

We	PRP	O
conclude	VBP	O
that	IN	O
strategies	NNS	O
effective	JJ	O
in	IN	O
changing	VBG	O
physician	JJ	O
prescribing	VBG	O
behavior	NN	O
in	IN	O
other	JJ	O
settings	NNS	O
may	MD	O
not	RB	O
be	VB	O
effective	JJ	O
in	IN	O
a	DT	O
PPGP	NNP	O
setting	VBG	O
with	IN	O
benzodiazepines	NNS	O
in	IN	O
the	DT	O
elderly	JJ	O
as	IN	O
the	DT	O
target	NN	O
for	IN	O
change	NN	O
.	.	O

Efficacy	NN	O
of	IN	O
bepotastine	NN	O
besilate	NN	O
ophthalmic	JJ	O
solution	NN	O
1.5	CD	O
%	NN	O
for	IN	O
seasonal	JJ	C
allergic	JJ	C
conjunctivitis	NN	C
:	:	O
a	DT	O
randomized	JJ	O
,	,	O
placebo-controlled	JJ	O
,	,	O
natural	JJ	O
exposure	NN	O
,	,	O
clinical	JJ	O
trial	NN	O
.	.	O

Allergic	NNP	O
conjunctivitis	NN	O
(	(	O
AC	NNP	O
)	)	O
affects	VBZ	O
an	DT	O
estimated	JJ	O
20	CD	O
%	NN	O
of	IN	O
the	DT	O
population	NN	O
in	IN	O
the	DT	O
Western	JJ	O
world	NN	O
,	,	O
with	IN	O
a	DT	O
large	JJ	O
fraction	NN	O
suffering	VBG	O
due	JJ	O
to	TO	O
seasonal	JJ	O
or	CC	O
perennial	JJ	O
allergen	NN	O
exposures	NNS	O
.	.	O

Bepotastine	NNP	O
besilate	NN	O
ophthalmic	JJ	O
solution	NN	O
(	(	O
BBOS	NNP	O
)	)	O
1.5	CD	O
%	NN	O
,	,	O
a	DT	O
dual-acting	JJ	O
histamine	NN	O
(	(	O
H	NNP	O
(	(	O
1	CD	O
)	)	O
)	)	O
receptor	NN	O
antagonist	NN	O
and	CC	O
mast	NN	O
cell	NN	O
stabilizer	NN	O
,	,	O
is	VBZ	O
indicated	VBN	O
for	IN	O
itching	VBG	O
associated	VBN	O
with	IN	O
AC	NNP	O
.	.	O

This	DT	O
study	NN	O
was	VBD	O
designed	VBN	O
to	TO	O
evaluate	VB	O
the	DT	O
efficacy	NN	O
and	CC	O
safety	NN	O
of	IN	O
BBOS	NNP	O
1.5	CD	O
%	NN	O
for	IN	O
reducing	VBG	O
ocular	JJ	C
itching	NN	C
associated	VBN	O
with	IN	O
AC	NNP	C
in	IN	O
subjects	NNS	O
enrolled	VBN	O
in	IN	O
a	DT	O
natural	JJ	O
exposure	NN	O
trial	NN	O
.	.	O

Eligible	JJ	O
subjects	NNS	O
in	IN	O
a	DT	O
multicenter	NN	O
,	,	O
double-masked	JJ	O
,	,	O
randomized	VBN	O
,	,	O
parallel-group	JJ	O
,	,	O
placebo-controlled	JJ	O
,	,	O
natural	JJ	O
exposure	NN	O
clinical	JJ	O
trial	NN	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
either	DT	O
BBOS	NNP	O
1.5	CD	O
%	NN	O
or	CC	O
placebo	NN	O
eyedrops	NNS	O
on	IN	O
a	DT	O
1:1	CD	O
basis	NN	O
and	CC	O
instilled	VBD	O
1	CD	O
drop	NN	O
of	IN	O
the	DT	O
test	NN	O
agent	NN	O
into	IN	O
both	DT	O
eyes	NNS	O
twice	RB	O
daily	RB	O
for	IN	O
2	CD	O
weeks	NNS	O
.	.	O

The	DT	O
mean	JJ	O
change	NN	O
from	IN	O
baseline	NN	O
in	IN	O
instantaneous	JJ	O
and	CC	O
reflective	JJ	O
ocular	JJ	O
itching	NN	O
scores	NNS	O
at	IN	O
the	DT	O
end	NN	O
of	IN	O
2	CD	O
weeks	NNS	O
of	IN	O
treatment	NN	O
were	VBD	O
evaluated	VBN	O
based	VBN	O
on	IN	O
subject-assessed	JJ	O
severity	NN	O
of	IN	O
instantaneous	JJ	O
and	CC	O
reflective	JJ	O
itching	NN	O
.	.	O

Subject-reported	JJ	O
adverse	JJ	O
events	NNS	O
(	(	O
AEs	NNP	O
)	)	O
were	VBD	O
also	RB	O
recorded	VBN	O
for	IN	O
safety	NN	O
.	.	O

Treatment	NN	O
with	IN	O
BBOS	NNP	O
1.5	CD	O
%	NN	O
significantly	RB	O
reduced	VBN	O
instantaneous	JJ	O
and	CC	O
reflective	JJ	O
ocular	JJ	O
itching	NN	O
scores	NNS	O
from	IN	O
baseline	NN	O
compared	VBN	O
with	IN	O
placebo	NN	O
over	IN	O
the	DT	O
2-week	JJ	O
study	NN	O
period	NN	O
(	(	O
p	JJ	O
=	NN	O
0.007	CD	O
and	CC	O
p	VB	O
=	JJ	O
0.005	CD	O
,	,	O
respectively	RB	O
)	)	O
.	.	O

BBOS	$	O
1.5	CD	O
%	NN	O
was	VBD	O
well	RB	O
tolerated	VBN	O
,	,	O
and	CC	O
AEs	NNP	O
were	VBD	O
generally	RB	O
transient	JJ	O
and	CC	O
mild	JJ	O
.	.	O

This	DT	O
clinical	JJ	O
study	NN	O
indicates	VBZ	O
BBOS	NNP	O
1.5	CD	O
%	NN	O
effectively	RB	O
and	CC	O
safely	RB	O
treated	VBD	O
ocular	JJ	O
itching	NN	O
in	IN	O
a	DT	O
natural	JJ	O
exposure	NN	O
allergy	NN	O
study	NN	O
and	CC	O
is	VBZ	O
a	DT	O
useful	JJ	O
treatment	NN	O
option	NN	O
for	IN	O
the	DT	O
management	NN	O
of	IN	O
ocular	JJ	O
itching	NN	O
associated	VBN	O
with	IN	O
AC	NNP	O
.	.	O

(	(	O
ClinicalTrials.gov	NNP	O
identifier	VBZ	O
number	NN	O
:	:	O
NCT01174823	NNP	O
.	.	O

)	)	O
Poylmerized	VBN	O
whole	JJ	O
ragweed	NN	O
:	:	O
an	DT	O
improved	JJ	O
method	NN	O
of	IN	O
immunotherapy	NN	O
.	.	O

A	DT	O
single-blind	JJ	O
study	NN	O
compared	VBN	O
the	DT	O
effectiveness	NN	O
of	IN	O
glutaraldehyde-treated	JJ	O
polymerized	NNS	O
ragweed	VBP	O
with	IN	O
nonpolymerized	JJ	O
monomeric	JJ	O
ragweed	NN	O
.	.	O

These	DT	O
studies	NNS	O
are	VBP	O
an	DT	O
extension	NN	O
of	IN	O
those	DT	O
previously	RB	O
reported	VBN	O
for	IN	O
polymerized	JJ	O
AgE	NNP	O
using	VBG	O
a	DT	O
readily	RB	O
available	JJ	O
ragweed	NN	O
preparation	NN	O
containing	VBG	O
all	DT	O
ragweed	NN	O
antigens	NNS	O
.	.	O

Nineteen	JJ	SS
ragweed-sensitive	JJ	C
patients	NNS	O
were	VBD	C
randomized	VBN	C
into	IN	C
2	CD	C
groups	NNS	C
;	:	C
10	CD	SS
received	VBD	O
the	DT	O
polymerized	JJ	O
form	NN	O
and	CC	C
9	CD	SS
received	VBD	O
the	DT	O
monomeric	JJ	O
form	NN	O
.	.	C

Four	CD	O
parameters	NNS	O
were	VBD	O
followed	VBN	O
:	:	O
serum-specific	JJ	O
IgE	NNP	O
against	IN	O
antigen	NN	O
E	NNP	O
,	,	O
total	JJ	O
blocking	VBG	O
antibody	NN	O
against	IN	O
antigen	NN	O
E	NNP	O
,	,	O
local	JJ	O
and	CC	O
systemic	JJ	O
reactions	NNS	O
to	TO	O
injection	NN	O
therapy	NN	O
,	,	O
and	CC	O
symptom	NN	O
score	NN	O
indices	NNS	O
.	.	O

Pretreatment	NNP	O
levels	NNS	O
of	IN	O
antigen	NN	O
E	NNP	O
--	:	O
specific	JJ	O
IgE	NNP	O
and	CC	O
blocking	VBG	O
antibody	NN	O
activity	NN	O
were	VBD	O
similar	JJ	O
in	IN	O
both	DT	O
groups	NNS	O
.	.	O

After	IN	O
a	DT	O
total	NN	O
of	IN	O
15,000	CD	O
protein	NNS	O
nitrogen	JJ	O
units	NNS	O
(	(	O
PNU	NNP	O
)	)	O
had	VBD	O
been	VBN	O
given	VBN	O
,	,	O
blocking	VBG	O
antibody	NN	O
activity	NN	O
in	IN	O
the	DT	O
monomer	NN	O
group	NN	O
rose	VBD	O
from	IN	O
a	DT	O
mean	NN	O
of	IN	O
170	CD	O
ng	JJ	O
AgE	NNP	O
bound	NN	O
per	IN	O
ml	NN	O
to	TO	O
a	DT	O
mean	NN	O
of	IN	O
2,813	CD	O
.	.	O

The	DT	O
rise	NN	O
in	IN	O
blocking	VBG	O
antibody	NN	O
activity	NN	O
in	IN	O
the	DT	O
polymer	NN	O
group	NN	O
was	VBD	O
from	IN	O
a	DT	O
mean	NN	O
of	IN	O
181	CD	O
ng	JJ	O
AgE	NNP	O
bound	NN	O
per	IN	O
ml	NN	O
to	TO	O
1,574	CD	O
.	.	O

At	IN	O
15,000	CD	O
PNU	NNP	O
,	,	O
blocking	VBG	O
antibody	NN	O
activity	NN	O
levels	NNS	O
were	VBD	O
not	RB	O
statistically	RB	O
different	JJ	O
in	IN	O
the	DT	O
2	CD	O
groups	NNS	O
.	.	O

After	IN	O
1	CD	O
year	NN	O
of	IN	O
treatment	NN	O
,	,	O
no	DT	O
consistent	JJ	O
decrease	NN	O
in	IN	O
postseasonal	JJ	O
specific	JJ	O
IgE	NNP	O
rise	NN	O
could	MD	O
be	VB	O
shown	VBN	O
in	IN	O
either	DT	O
group	NN	O
.	.	O

Forty	NNP	O
times	NNS	O
less	RBR	O
erythema	JJ	O
and	CC	O
15	CD	O
times	NNS	O
less	JJR	O
induration	NN	O
were	VBD	O
found	VBN	O
with	IN	O
polymerized	JJ	O
ragweed	NN	O
.	.	O

There	EX	O
were	VBD	O
7	CD	O
systemic	JJ	O
reactions	NNS	O
with	IN	O
the	DT	O
monomer	NN	O
and	CC	O
none	NN	O
with	IN	O
the	DT	O
polymer	NN	O
.	.	O

Both	DT	O
groups	NNS	O
experienced	VBD	O
symptomatic	JJ	O
improvement	NN	O
with	IN	O
treatment	NN	O
.	.	O

Treatment	NN	O
with	IN	O
buspirone	NN	O
in	IN	O
a	DT	O
patient	NN	O
with	IN	O
autism	NN	O
.	.	O

This	DT	O
study	NN	O
evaluates	VBZ	O
the	DT	O
safety	NN	O
and	CC	O
efficacy	NN	O
of	IN	O
buspirone	NN	O
hydrochloride	NN	O
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
a	DT	O
patient	NN	O
with	IN	O
autism	NN	O
and	CC	O
hyperactivity	NN	O
disorder	NN	O
and	CC	O
determines	VBZ	O
the	DT	O
effect	NN	O
of	IN	O
buspirone	NN	O
on	IN	O
the	DT	O
number	NN	O
of	IN	O
performance	NN	O
tasks	NNS	O
completed	VBN	O
by	IN	O
the	DT	O
patient	NN	O
at	IN	O
school	NN	O
.	.	O

A	DT	O
3-week	JJ	O
,	,	O
double-blind	JJ	O
,	,	O
placebo-controlled	JJ	O
crossover	NN	O
study	NN	O
was	VBD	O
performed	VBN	O
in	IN	O
a	DT	O
private	JJ	O
physician	NN	O
,	,	O
office-based	JJ	O
practice	NN	O
.	.	O

A	DT	O
child	NN	O
with	IN	O
autism	NN	O
,	,	O
which	WDT	O
was	VBD	O
diagnosed	VBN	O
by	IN	O
Diagnostic	NNP	O
and	CC	O
Statistical	NNP	O
Manual	NNP	O
of	IN	O
Mental	NNP	O
Disorders	NNP	O
,	,	O
Third	NNP	O
Edition	NNP	O
,	,	O
Revised	VBN	O
,	,	O
criteria	NNS	O
,	,	O
was	VBD	O
studied	VBN	O
.	.	O

The	DT	O
child	NN	O
received	VBD	O
placebo	NN	O
for	IN	O
3	CD	O
weeks	NNS	O
and	CC	O
buspirone	NN	O
for	IN	O
3	CD	O
weeks	NNS	O
;	:	O
there	EX	O
was	VBD	O
a	DT	O
1-week	JJ	O
interval	NN	O
between	IN	O
the	DT	O
2	CD	O
treatments	NNS	O
.	.	O

The	DT	O
outcome	NN	O
was	VBD	O
measured	VBN	O
by	IN	O
using	VBG	O
Conners	NNS	O
abbreviated	VBD	O
parent	NN	O
and	CC	O
teacher	NN	O
questionnaires	NNS	O
and	CC	O
by	IN	O
determining	VBG	O
the	DT	O
number	NN	O
of	IN	O
daily	JJ	O
performance	NN	O
tasks	NNS	O
completed	VBN	O
by	IN	O
the	DT	O
child	NN	O
at	IN	O
school	NN	O
.	.	O

Statistical	JJ	O
analysis	NN	O
was	VBD	O
performed	VBN	O
by	IN	O
linear	JJ	O
models	NNS	O
and	CC	O
standard	JJ	O
F	NNP	O
tests	NNS	O
.	.	O

Buspirone	NNP	O
was	VBD	O
found	VBN	O
to	TO	O
be	VB	O
safe	JJ	O
and	CC	O
efficacious	JJ	O
,	,	O
without	IN	O
side	JJ	O
effects	NNS	O
,	,	O
for	IN	O
decreasing	VBG	O
hyperactivity	NN	O
and	CC	O
increasing	VBG	O
completed	VBN	O
performance	NN	O
tasks	NNS	O
.	.	O

The	DT	O
beneficial	JJ	O
effects	NNS	O
of	IN	O
buspirone	NN	O
in	IN	O
helping	VBG	O
this	DT	O
patient	NN	O
with	IN	O
autism	NN	O
in	IN	O
his	PRP$	O
natural	JJ	O
daily	JJ	O
settings	NNS	O
suggest	VBP	O
that	IN	O
buspirone	NN	O
may	MD	O
be	VB	O
an	DT	O
alternative	JJ	O
to	TO	O
neuroleptic	JJ	O
agents	NNS	O
in	IN	O
the	DT	O
medical	JJ	O
therapy	NN	O
of	IN	O
autism	NN	O
;	:	O
further	JJ	O
study	NN	O
in	IN	O
other	JJ	O
patients	NNS	O
is	VBZ	O
needed	VBN	O
.	.	O

Most	RBS	O
effective	JJ	O
regimen	NNS	O
of	IN	O
tranexamic	JJ	O
acid	NN	O
in	IN	O
knee	NN	C
arthroplasty	NN	C
:	:	O
a	DT	O
prospective	JJ	O
randomized	NN	O
controlled	VBD	O
study	NN	O
in	IN	O
240	CD	SS
patients	NNS	SS
.	.	O

BACKGROUND	NNP	O
The	DT	O
antifibrinolytic	JJ	O
tranexamic	JJ	O
acid	NN	O
reduces	NNS	O
surgical	JJ	O
blood	NN	O
loss	NN	O
,	,	O
but	CC	O
studies	NNS	O
have	VBP	O
not	RB	O
identified	VBN	O
an	DT	O
optimal	JJ	O
regimen	NNS	O
.	.	O

QUESTIONS/PURPOSES	NNP	O
We	PRP	O
studied	VBD	O
different	JJ	O
dosages	NNS	O
,	,	O
timings	NNS	O
,	,	O
and	CC	O
modes	NNS	O
of	IN	O
administration	NN	O
to	TO	O
identify	VB	O
the	DT	O
most	RBS	O
effective	JJ	O
regimen	NNS	O
of	IN	O
tranexamic	JJ	O
acid	NN	O
in	IN	O
achieving	VBG	O
maximum	JJ	O
reduction	NN	O
of	IN	O
blood	NN	O
loss	NN	O
in	IN	O
TKA	NNP	O
.	.	O

METHODS	NNP	O
We	PRP	O
prospectively	RB	O
studied	VBD	O
five	CD	O
regimens	NNS	O
(	(	O
four	CD	O
intravenous	NN	O
,	,	O
one	CD	O
local	JJ	O
;	:	O
40	CD	O
patients	NNS	O
each	DT	O
)	)	O
with	IN	O
a	DT	O
control	NN	O
group	NN	O
(	(	O
no	DT	O
tranexamic	JJ	O
acid	NN	O
)	)	O
.	.	O

The	DT	O
four	CD	O
intravenous	JJ	O
(	(	O
10-mg/kg	JJ	O
dose	NN	O
)	)	O
regimens	VBZ	O
included	VBN	O
(	(	O
1	CD	O
)	)	O
intraoperative	NN	O
dose	NN	O
(	(	O
IO	NNP	O
)	)	O
given	VBN	O
before	IN	O
tourniquet	JJ	O
deflation	NN	O
,	,	O
(	(	O
2	CD	O
)	)	O
additional	JJ	O
preoperative	NN	O
dose	NN	O
(	(	O
POIO	NNP	O
)	)	O
,	,	O
(	(	O
3	CD	O
)	)	O
additional	JJ	O
postoperative	NN	O
dose	NN	O
(	(	O
IOPO	NNP	O
)	)	O
,	,	O
and	CC	O
(	(	O
4	CD	O
)	)	O
all	DT	O
three	CD	O
doses	NNS	O
(	(	O
POIOPO	NNP	O
)	)	O
.	.	O

The	DT	O
fifth	JJ	O
regimen	NN	O
was	VBD	O
a	DT	O
single	JJ	O
local	JJ	O
application	NN	O
(	(	O
LA	NNP	O
)	)	O
.	.	O

Two	CD	O
independent	JJ	O
parameters	NNS	O
of	IN	O
drain	NN	O
loss	NN	O
and	CC	O
total	JJ	O
blood	NN	O
loss	NN	O
,	,	O
calculated	VBN	O
by	IN	O
the	DT	O
hemoglobin	NN	O
balance	NN	O
method	NN	O
,	,	O
were	VBD	O
evaluated	VBN	O
statistically	RB	O
.	.	O

RESULTS	NNP	O
Both	NNP	O
parameters	NNS	O
were	VBD	O
reduced	VBN	O
in	IN	O
all	DT	O
five	CD	O
regimens	NNS	O
as	IN	O
against	IN	O
the	DT	O
control	NN	O
.	.	O

A	DT	O
significant	JJ	O
reduction	NN	O
in	IN	O
drain	NN	O
loss	NN	O
was	VBD	O
seen	VBN	O
in	IN	O
the	DT	O
POIO	NNP	O
,	,	O
IOPO	NNP	O
,	,	O
and	CC	O
POIOPO	NNP	O
groups	NNS	O
whereas	VBP	O
total	JJ	O
blood	NN	O
loss	NN	O
was	VBD	O
significantly	RB	O
reduced	VBN	O
in	IN	O
the	DT	O
POIO	NNP	O
,	,	O
POIOPO	NNP	O
,	,	O
and	CC	O
LA	NNP	O
groups	NNS	O
.	.	O

The	DT	O
POIOPO	NNP	O
group	NN	O
had	VBD	O
the	DT	O
least	JJS	O
drain	JJ	O
loss	NN	O
(	(	O
303	CD	O
mL	NN	O
)	)	O
and	CC	O
least	JJS	O
total	JJ	O
blood	NN	O
loss	NN	O
(	(	O
688	CD	O
mL	NN	O
)	)	O
.	.	O

The	DT	O
IO	NNP	O
group	NN	O
had	VBD	O
the	DT	O
greatest	JJS	O
drain	NN	O
loss	NN	O
and	CC	O
the	DT	O
IOPO	NNP	O
group	NN	O
the	DT	O
greatest	JJS	O
total	JJ	O
blood	NN	O
loss	NN	O
.	.	O

CONCLUSIONS	NNP	O
Single-dose	JJ	O
tranexamic	JJ	O
acid	NN	O
did	VBD	O
not	RB	O
give	VB	O
effective	JJ	O
results	NNS	O
.	.	O

The	DT	O
two-dose	JJ	O
regimen	NNS	O
of	IN	O
POIO	NNP	O
was	VBD	O
the	DT	O
least	JJS	O
amount	NN	O
necessary	JJ	O
for	IN	O
effective	JJ	O
results	NNS	O
.	.	O

When	WRB	O
compared	VBN	O
against	IN	O
the	DT	O
control	NN	O
,	,	O
this	DT	O
regimen	NNS	O
produced	VBD	O
reduction	NN	O
of	IN	O
drain	NN	O
loss	NN	O
and	CC	O
total	JJ	O
blood	NN	O
loss	NN	O
,	,	O
whereas	IN	O
the	DT	O
IOPO	NNP	O
regimen	NNS	O
did	VBD	O
not	RB	O
.	.	O

The	DT	O
three-dose	JJ	O
regimen	NNS	O
of	IN	O
POIOPO	NNP	O
produced	VBD	O
maximum	JJ	O
effective	JJ	O
reduction	NN	O
of	IN	O
drain	NN	O
loss	NN	O
and	CC	O
total	JJ	O
blood	NN	O
loss	NN	O
.	.	O

Osteoporosis	NN	O
and	CC	O
gait	NN	O
and	CC	O
balance	NN	O
disturbances	NNS	O
in	IN	O
older	JJR	C
sarcopenic	JJ	C
obese	JJ	C
New	NNP	C
Zealanders	NNP	C
.	.	C

UNLABELLED	NNP	O
Bone	NNP	O
,	,	O
muscle	NN	O
,	,	O
and	CC	O
fat	NN	O
may	MD	O
affect	VB	O
gait	NN	O
and	CC	O
balance	NN	O
in	IN	O
older	JJR	O
adults	NNS	O
.	.	O

Osteoporosis	NN	O
was	VBD	O
prevalent	JJ	O
in	IN	O
low	JJ	O
muscle	NN	O
mass	NN	O
participants	NNS	O
and	CC	O
related	VBN	O
to	TO	O
gait	VB	O
and	CC	O
balance	VB	O
deficits	NNS	O
.	.	O

Low	JJ	O
muscle	NN	O
combined	VBN	O
with	IN	O
high	JJ	O
fat	JJ	O
mass	NN	O
had	VBD	O
more	RBR	O
functional	JJ	O
deficits	NNS	O
and	CC	O
poorer	JJR	O
bone	NN	O
health	NN	O
,	,	O
which	WDT	O
has	VBZ	O
implications	NNS	O
for	IN	O
falls	NNS	O
risk	NN	O
and	CC	O
fractures	NNS	O
.	.	O

INTRODUCTION	NNP	O
Decreasing	VBG	O
bone	NN	O
density	NN	O
and	CC	O
muscle	NN	O
mass	NN	O
and	CC	O
increasing	VBG	O
fat	JJ	O
mass	NN	O
may	MD	O
act	VB	O
synergistically	RB	O
to	TO	O
affect	VB	O
gait	NN	O
and	CC	O
balance	NN	O
in	IN	O
older	JJR	O
adults	NNS	O
.	.	O

METHODS	NNP	O
One	CD	O
hundred	VBD	O
eighty-three	JJ	O
older	NN	O
adults	NNS	O
(	(	O
age	NN	O
72.7	CD	O
+/-	JJ	O
6	CD	O
years	NNS	O
,	,	O
range	VBP	O
56-93	JJ	O
;	:	O
body	NN	O
mass	NN	O
index	NN	O
28.2	CD	O
+/-	JJ	O
4.9	CD	O
,	,	O
range	VBP	O
16.6-46.0	JJ	O
)	)	O
were	VBD	O
recruited	VBN	O
from	IN	O
a	DT	O
New	NNP	O
Zealand	NNP	O
falls	VBZ	O
prevention	NN	O
intervention	NN	O
trial	NN	O
.	.	O

Total	JJ	O
and	CC	O
appendicular	JJ	O
skeletal	JJ	O
muscle	NN	O
mass	NN	O
(	(	O
ASM	NNP	O
)	)	O
,	,	O
percent	JJ	O
fat	NN	O
,	,	O
and	CC	O
bone	NN	O
mineralization	NN	O
were	VBD	O
assessed	VBN	O
by	IN	O
dual	JJ	O
energy	NN	O
X-ray	JJ	O
absorptiometry	NN	O
and	CC	O
used	VBD	O
to	TO	O
characterize	VB	O
normal	JJ	O
lean	JJ	O
(	(	O
NL	NNP	O
,	,	O
n	JJ	O
=	NNP	O
51	CD	O
)	)	O
,	,	O
sarcopenic	JJ	O
(	(	O
SS	NNP	O
,	,	O
n	JJ	O
=	NNP	O
18	CD	O
)	)	O
,	,	O
sarcopenic	JJ	O
obese	NN	O
(	(	O
SO	NNP	O
,	,	O
n	JJ	O
=	NNP	O
29	CD	O
)	)	O
,	,	O
and	CC	O
obese	JJ	O
(	(	O
OO	NNP	O
,	,	O
n	JJ	O
=	NNP	O
85	CD	O
)	)	O
phenotypes	NNS	O
.	.	O

Functional	JJ	O
performance	NN	O
was	VBD	O
assessed	VBN	O
using	VBG	O
timed	VBN	O
up	RP	O
and	CC	O
go	VB	O
,	,	O
chair	NN	O
stand	NN	O
,	,	O
single	JJ	O
leg	NN	O
stand	NN	O
,	,	O
and	CC	O
step	VB	O
test	NN	O
.	.	O

Regression	NN	O
models	NNS	O
were	VBD	O
adjusted	VBN	O
for	IN	O
age	NN	O
,	,	O
sex	NN	O
,	,	O
medications	NNS	O
,	,	O
and	CC	O
physical	JJ	O
activity	NN	O
.	.	O

RESULTS	NNP	O
Femoral	NNP	O
neck	NN	O
osteoporosis	NN	O
was	VBD	O
present	JJ	O
in	IN	O
22	CD	O
%	NN	O
SS	NNP	O
,	,	O
17	CD	O
%	NN	O
SO	NNP	O
,	,	O
12	CD	O
%	NN	O
NL	NNP	O
,	,	O
and	CC	O
7	CD	O
%	NN	O
OO	NNP	O
.	.	O

Femoral	NNP	O
neck	NN	O
osteoporosis	NN	O
with	IN	O
low	JJ	O
ASM	NNP	O
predicted	VBD	O
poor	JJ	O
chair	NN	O
stand	VBP	O
performance	NN	O
(	(	O
beta	JJ	O
-3.3	NNP	O
,	,	O
standard	JJ	O
error	NN	O
1.6	CD	O
,	,	O
p	NN	O
=	NNP	O
0.04	CD	O
)	)	O
.	.	O

SO	RB	O
scored	JJ	O
lowest	NN	O
on	IN	O
the	DT	O
chair	NN	O
stand	NN	O
(	(	O
p	JJ	O
=	NNP	O
0.03	CD	O
)	)	O
and	CC	O
step	JJ	O
test	NN	O
(	(	O
p	JJ	O
=	NNP	O
0.03	CD	O
)	)	O
.	.	O

Higher	JJR	O
ASM	NNP	O
predicted	VBD	O
faster	RBR	O
timed	VBN	O
up	RP	O
and	CC	O
go	VB	O
performance	NN	O
(	(	O
p	JJ	O
=	NNP	O
0.001	CD	O
)	)	O
.	.	O

CONCLUSIONS	NNP	O
Osteoporosis	NNP	O
was	VBD	O
prevalent	VBN	O
in	IN	O
low	JJ	O
ASM	NNP	O
groups	NNS	O
(	(	O
SS	NNP	O
and	CC	O
SO	NNP	O
)	)	O
and	CC	O
related	VBN	O
to	TO	O
gait	VB	O
and	CC	O
balance	VB	O
deficits	NNS	O
,	,	O
particularly	RB	O
in	IN	O
the	DT	O
SO	NNP	O
.	.	O

This	DT	O
has	VBZ	O
implications	NNS	O
for	IN	O
falls	NNS	O
risk	NN	O
,	,	O
fractures	NNS	O
,	,	O
and	CC	O
interventions	NNS	O
.	.	O

[	NN	O
Encephalopathy	NNP	O
therapeutic	JJ	O
tongue	NN	O
acupoint	NN	O
apparatus	NN	O
(	(	O
ETTAA	NNP	O
)	)	O
for	IN	O
42	CD	O
cases	NNS	O
of	IN	O
autism	NN	C
]	NNP	O
.	.	O

OBJECTIVE	NNP	O
To	TO	O
observe	VB	O
the	DT	O
efficacy	NN	O
of	IN	O
encephalopathy	JJ	O
therapeutic	JJ	O
tongue	NN	O
acupoint	NN	O
apparatus	NN	O
(	(	O
ETTAA	NNP	O
)	)	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
autism	NN	C
.	.	O

METHODS	NNP	O
Eighty-four	JJ	SS
children	NNS	A
of	IN	O
autism	NN	C
were	VBD	O
randomly	RB	O
divided	VBN	O
into	IN	O
a	DT	O
tongue	JJ	O
acupuncture	NN	O
group	NN	O
(	(	O
group	NN	O
A	NNP	O
)	)	O
and	CC	O
a	DT	O
conventional	JJ	O
training	NN	O
group	NN	O
(	(	O
group	NN	O
B	NNP	O
)	)	O
,	,	O
42	CD	O
cases	NNS	O
in	IN	O
each	DT	O
group	NN	O
.	.	O

The	DT	O
behavior	JJ	O
training	NN	O
and	CC	O
sensory	JJ	O
integration	NN	O
training	NN	O
were	VBD	O
carried	VBN	O
out	RP	O
in	IN	O
group	NN	O
B	NNP	O
and	CC	O
the	DT	O
ETTAA	NNP	O
was	VBD	O
added	VBN	O
in	IN	O
group	NN	O
A	NNP	O
.	.	O

The	DT	O
apparatus	NN	O
was	VBD	O
switched	VBN	O
on	IN	O
for	IN	O
20	CD	O
min	NN	O
every	DT	O
time	NN	O
and	CC	O
3	CD	O
times	NNS	O
a	DT	O
day	NN	O
.	.	O

Treatment	NN	O
of	IN	O
two	CD	O
months	NNS	O
were	VBD	O
carried	VBN	O
out	RP	O
in	IN	O
both	DT	O
groups	NNS	O
.	.	O

The	DT	O
score	NN	O
of	IN	O
childhood	NN	O
autism	NN	O
rating	NN	O
scale	NN	O
(	(	O
CARS	NNP	O
)	)	O
and	CC	O
clinical	JJ	O
efficacy	NN	O
in	IN	O
both	DT	O
groups	NNS	O
were	VBD	O
observed	VBN	O
before	IN	O
and	CC	O
after	IN	O
treatment	NN	O
.	.	O

RESULTS	NNP	O
After	IN	O
treatment	NN	O
,	,	O
the	DT	O
CARS	NNPS	O
in	IN	O
both	DT	O
groups	NNS	O
were	VBD	O
significantly	RB	O
reduced	VBN	O
(	(	O
42.39	CD	O
+/-	JJ	O
6.86	CD	O
vs	JJ	O
32.15	CD	O
+/-	JJ	O
5.12	CD	O
,	,	O
P	NNP	O
<	NNP	O
0.001	CD	O
;	:	O
44.58	CD	O
+/-	JJ	O
6.76	CD	O
vs	JJ	O
39.72	CD	O
+/-	JJ	O
7.11	CD	O
,	,	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
,	,	O
which	WDT	O
was	VBD	O
more	RBR	O
significant	JJ	O
in	IN	O
group	NN	O
A	NNP	O
(	(	O
P	NNP	O
<	NNP	O
0.01	CD	O
)	)	O
.	.	O

The	DT	O
totally	RB	O
effective	JJ	O
rate	NN	O
in	IN	O
group	NN	O
A	NNP	O
[	RB	O
90.5	CD	O
%	NN	O
(	(	O
38/42	CD	O
)	)	O
]	NN	O
was	VBD	O
superior	JJ	O
to	TO	O
that	DT	O
in	IN	O
group	NN	O
B	NNP	O
[	VBZ	O
66.7	CD	O
%	NN	O
(	(	O
28/42	CD	O
)	)	O
,	,	O
P	NNP	O
<	VBZ	O
0.01	CD	O
]	NN	O
.	.	O

CONCLUSION	VB	O
The	DT	O
clinical	JJ	O
efficacy	NN	O
in	IN	O
tongue	JJ	O
acupuncture	NN	O
group	NN	O
is	VBZ	O
apparently	RB	O
superior	JJ	O
to	TO	O
that	DT	O
in	IN	O
conventional	JJ	O
training	NN	O
group	NN	O
,	,	O
ETTAA	NNP	O
combined	VBD	O
with	IN	O
conventional	JJ	O
training	NN	O
have	VBP	O
a	DT	O
better	JJR	O
curative	JJ	O
effect	NN	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
autism	NN	C
.	.	O

Sialyl	NNP	O
Lewisa	NNP	O
expression	NN	O
as	IN	O
a	DT	O
predictor	NN	O
of	IN	O
the	DT	O
prognosis	NN	O
of	IN	O
colon	NN	C
carcinoma	NN	C
patients	NNS	O
in	IN	O
a	DT	O
prospective	JJ	O
randomized	VBN	O
clinical	JJ	O
trial	NN	O
.	.	O

BACKGROUND	VB	O
The	DT	O
metastatic	JJ	O
potential	NN	O
of	IN	O
tumors	NNS	O
is	VBZ	O
dependent	JJ	O
on	IN	O
the	DT	O
cell	NN	O
to	TO	O
cell	VB	O
adhesion	NN	O
by	IN	O
cell	NN	O
surface	NN	O
carbohydrate	NN	O
antigens	NNS	O
.	.	O

Thus	RB	O
,	,	O
expression	NN	O
of	IN	O
sialyl	NN	O
Lewis	NNP	O
(	(	O
a	DT	O
)	)	O
,	,	O
which	WDT	O
is	VBZ	O
one	CD	O
of	IN	O
the	DT	O
important	JJ	O
molecules	NNS	O
of	IN	O
cell	NN	O
surface	NN	O
carbohydrates	NNS	O
,	,	O
may	MD	O
serve	VB	O
as	IN	O
a	DT	O
prognostic	JJ	O
marker	NN	O
of	IN	O
aggressive	JJ	O
and	CC	O
metastasizing	VBG	O
tumor	NN	O
growth	NN	O
.	.	O

However	RB	O
,	,	O
the	DT	O
prognostic	JJ	O
value	NN	O
of	IN	O
sialyl	JJ	O
Lewis	NNP	O
(	(	O
a	DT	O
)	)	O
expression	NN	O
in	IN	O
colon	NN	O
cancer	NN	O
is	VBZ	O
still	RB	O
controversial	JJ	O
.	.	O

METHODS	NNP	O
In	IN	O
this	DT	O
study	NN	O
,	,	O
we	PRP	O
investigated	VBD	O
the	DT	O
expression	NN	O
of	IN	O
sialyl	NN	O
Lewis	NNP	O
(	(	O
a	DT	O
)	)	O
antigen	NN	O
in	IN	O
233	CD	SS
colon	NN	C
cancer	NN	C
specimens	NNS	O
from	IN	O
patients	NNS	O
who	WP	O
were	VBD	O
registered	VBN	O
in	IN	O
a	DT	O
prospective	JJ	O
adjuvant	NN	O
immunochemotherapy	NN	O
clinical	JJ	O
trial	NN	O
.	.	O

The	DT	O
clinical	JJ	O
course	NN	O
and	CC	O
the	DT	O
prognosis	NN	O
of	IN	O
the	DT	O
patients	NNS	O
were	VBD	O
evaluated	VBN	O
after	IN	O
all	PDT	O
the	DT	O
immunohistochemical	JJ	O
analyses	NNS	O
had	VBD	O
been	VBN	O
performed	VBN	O
.	.	O

RESULTS	NNP	O
Sialyl	NNP	O
Lewis	NNP	O
(	(	O
a	DT	O
)	)	O
expression	NN	O
levels	NNS	O
were	VBD	O
correlated	VBN	O
with	IN	O
both	DT	O
overall	JJ	O
survival	NN	O
(	(	O
P	NNP	O
=	NNP	O
0.0006	CD	O
)	)	O
and	CC	O
disease-free	JJ	O
survival	NN	O
(	(	O
P	NNP	O
=	NNP	O
0.004	CD	O
)	)	O
in	IN	O
all	DT	O
patients	NNS	O
with	IN	O
the	DT	O
log-rank	JJ	O
test	NN	O
.	.	O

This	DT	O
result	NN	O
could	MD	O
be	VB	O
assumed	VBN	O
to	TO	O
have	VB	O
been	VBN	O
influenced	VBN	O
by	IN	O
the	DT	O
difference	NN	O
in	IN	O
the	DT	O
metastatic	JJ	O
preponderance	NN	O
in	IN	O
a	DT	O
high	JJ	O
versus	NN	O
low	JJ	O
sialyl	NN	O
Lewis	NNP	O
(	(	O
a	DT	O
)	)	O
expression	NN	O
in	IN	O
the	DT	O
tumor	NN	O
cells	NNS	O
.	.	O

CONCLUSION	VB	O
This	DT	O
prospective	JJ	O
study	NN	O
in	IN	O
a	DT	O
randomized	NN	O
controlled	VBN	O
trial	NN	O
suggests	VBZ	O
that	IN	O
sialyl	NN	O
Lewis	NNP	O
(	(	O
a	DT	O
)	)	O
expression	NN	O
levels	NNS	O
may	MD	O
serve	VB	O
as	IN	O
an	DT	O
indicator	NN	O
of	IN	O
the	DT	O
metastatic	JJ	O
potential	NN	O
of	IN	O
colon	NN	O
cancer	NN	O
cells	NNS	O
,	,	O
which	WDT	O
would	MD	O
strongly	RB	O
predict	VB	O
the	DT	O
prognosis	NN	O
.	.	O

Effects	NNS	O
of	IN	O
nitric	JJ	O
oxide	JJ	O
synthase	NN	O
inhibition	NN	O
on	IN	O
cutaneous	JJ	O
vasodilation	NN	O
in	IN	O
response	NN	O
to	TO	O
acupuncture	VB	O
stimulation	NN	O
in	IN	O
humans	NNS	O
.	.	O

OBJECTIVES	IN	O
The	DT	O
aim	NN	O
of	IN	O
the	DT	O
present	JJ	O
study	NN	O
was	VBD	O
to	TO	O
elucidate	VB	O
the	DT	O
mechanism	NN	O
of	IN	O
cutaneous	JJ	O
vasodilation	NN	O
following	VBG	O
acupuncture	NN	O
stimulation	NN	O
by	IN	O
investigating	VBG	O
the	DT	O
roles	NNS	O
of	IN	O
nitric	JJ	O
oxide	NN	O
(	(	O
NO	NNP	O
)	)	O
and	CC	O
axon	$	O
reflex	JJ	O
vasodilation	NN	O
.	.	O

METHODS	NNP	O
The	DT	O
subjects	NNS	O
were	VBD	O
17	CD	SS
healthy	JJ	C
male	NN	SE
volunteers	NNS	O
.	.	O

The	DT	O
role	NN	O
of	IN	O
NO	NNP	O
was	VBD	O
investigated	VBN	O
by	IN	O
administering	VBG	O
N	NNP	O
(	(	O
G	NNP	O
)	)	O
-nitro-l-arginine	VBP	O
methyl	JJ	O
ester	NN	O
hydrochloride	NN	O
(	(	O
L-NAME	NNP	O
,	,	O
20	CD	O
mM	NN	O
)	)	O
,	,	O
an	DT	O
NO	NNP	O
synthase	NN	O
inhibitor	NN	O
or	CC	O
Ringer	NNP	O
's	POS	O
solution	NN	O
(	(	O
control	VB	O
site	NN	O
)	)	O
,	,	O
via	IN	O
intradermal	JJ	O
microdialysis	NN	O
(	(	O
protocol	JJ	O
1	CD	O
;	:	O
n=7	NN	O
)	)	O
.	.	O

The	DT	O
role	NN	O
of	IN	O
axon	JJ	O
reflex	JJ	O
vasodilation	NN	O
by	IN	O
local	JJ	O
sensory	NN	O
neurones	NNS	O
was	VBD	O
investigated	VBN	O
by	IN	O
comparing	VBG	O
vasodilation	NN	O
at	IN	O
sites	NNS	O
treated	VBN	O
with	IN	O
'eutectic	JJ	O
mixture	NN	O
of	IN	O
local	JJ	O
anaesthetics	NNS	O
'	POS	O
(	(	O
EMLA	NNP	O
)	)	O
cream	NN	O
(	(	O
2.5	CD	O
%	NN	O
lidocaine	NN	O
and	CC	O
2.5	CD	O
%	NN	O
prilocaine	NN	O
)	)	O
with	IN	O
untreated	JJ	O
sites	NNS	O
(	(	O
control	VB	O
site	NN	O
)	)	O
(	(	O
protocol	JJ	O
2	CD	O
;	:	O
n=10	NN	O
)	)	O
.	.	O

After	IN	O
5	CD	O
min	NN	O
of	IN	O
baseline	NN	O
recording	NN	O
,	,	O
acupuncture	NN	O
was	VBD	O
applied	VBN	O
to	TO	O
PC4	NNP	O
and	CC	O
a	DT	O
control	NN	O
site	NN	O
in	IN	O
proximity	NN	O
to	TO	O
PC4	NNP	O
for	IN	O
10	CD	O
min	NNS	O
and	CC	O
scanning	NN	O
was	VBD	O
performed	VBN	O
for	IN	O
60	CD	O
min	NN	O
after	IN	O
acupuncture	JJ	O
stimulation	NN	O
.	.	O

Skin	NNP	O
blood	NN	O
flow	NN	O
(	(	O
SkBF	NNP	O
)	)	O
was	VBD	O
evaluated	VBN	O
by	IN	O
laser	NN	O
Doppler	NNP	O
perfusion	NN	O
imaging	VBG	O
.	.	O

Cutaneous	JJ	O
vascular	JJ	O
conductance	NN	O
(	(	O
CVC	NNP	O
)	)	O
was	VBD	O
calculated	VBN	O
from	IN	O
the	DT	O
ratio	NN	O
of	IN	O
SkBF	NNP	O
to	TO	O
mean	VB	O
arterial	JJ	O
blood	NN	O
pressure	NN	O
.	.	O

RESULTS	NNP	O
In	IN	O
the	DT	O
first	JJ	O
protocol	NN	O
,	,	O
sites	NNS	O
administered	VBD	O
L-NAME	NNP	O
showed	VBD	O
significant	JJ	O
reductions	NNS	O
in	IN	O
CVC	NNP	O
responses	NNS	O
following	VBG	O
acupuncture	NN	O
stimulation	NN	O
compared	VBN	O
to	TO	O
control	VB	O
sites	NNS	O
(	(	O
administered	VBN	O
Ringer	NNP	O
's	POS	O
solution	NN	O
)	)	O
(	(	O
p	JJ	O
<	NNP	O
0.05	CD	O
)	)	O
.	.	O

In	IN	O
the	DT	O
second	JJ	O
protocol	NN	O
,	,	O
changes	NNS	O
in	IN	O
CVC	NNP	O
responses	NNS	O
after	IN	O
acupuncture	JJ	O
stimulation	NN	O
did	VBD	O
not	RB	O
differ	VB	O
significantly	RB	O
between	IN	O
treated	VBN	O
sites	NNS	O
with	IN	O
EMLA	NNP	O
cream	NN	O
and	CC	O
untreated	JJ	O
sites	NNS	O
(	(	O
p	JJ	O
>	NNP	O
0.05	CD	O
)	)	O
.	.	O

CONCLUSIONS	NNP	O
These	DT	O
data	NNS	O
suggest	VBP	O
that	IN	O
cutaneous	JJ	O
vasodilation	NN	O
in	IN	O
response	NN	O
to	TO	O
acupuncture	VB	O
stimulation	NN	O
may	MD	O
not	RB	O
occur	VB	O
through	IN	O
an	DT	O
axon	JJ	O
reflex	NN	O
as	IN	O
previously	RB	O
reported	VBN	O
.	.	O

Rather	NNP	O
,	,	O
NO	NNP	O
mechanisms	NN	O
appear	VBP	O
to	TO	O
contribute	VB	O
to	TO	O
the	DT	O
vasodilator	NN	O
response	NN	O
.	.	O

Effects	NNS	O
of	IN	O
fenoterol	NN	O
on	IN	O
inspiratory	JJ	O
effort	NN	O
sensation	NN	O
and	CC	O
fatigue	NN	O
during	IN	O
inspiratory	JJ	O
threshold	JJ	O
loading	NN	O
.	.	O

We	PRP	O
studied	VBD	O
the	DT	O
effects	NNS	O
of	IN	O
a	DT	O
single	JJ	O
dose	NN	O
of	IN	O
fenoterol	NN	O
on	IN	O
the	DT	O
relationship	NN	O
between	IN	O
inspiratory	NN	O
effort	NN	O
sensation	NN	O
(	(	O
IES	NNP	O
)	)	O
and	CC	O
inspiratory	JJ	O
muscle	NN	O
fatigue	NN	O
induced	VBN	O
by	IN	O
inspiratory	NN	O
threshold	NN	O
loading	NN	O
in	IN	O
healthy	JJ	O
subjects	NNS	O
.	.	O

The	DT	O
magnitude	NN	O
of	IN	O
the	DT	O
threshold	NN	O
was	VBD	O
60	CD	O
%	NN	O
of	IN	O
maximal	JJ	O
static	JJ	O
inspiratory	NN	O
mouth	NN	O
pressure	NN	O
(	(	O
PI	NNP	O
,	,	O
mmax	NN	O
)	)	O
at	IN	O
functional	JJ	O
residual	JJ	O
capacity	NN	O
,	,	O
and	CC	O
the	DT	O
duty	NN	O
cycle	NN	O
was	VBD	O
0.5	CD	O
.	.	O

Subjects	NNS	O
continued	VBD	O
the	DT	O
threshold	NN	O
loaded	VBD	O
breathing	NN	O
until	IN	O
the	DT	O
target	NN	O
mouth	NN	O
pressure	NN	O
could	MD	O
no	RB	O
longer	RB	O
be	VB	O
maintained	VBN	O
(	(	O
endurance	JJ	O
time	NN	O
)	)	O
.	.	O

The	DT	O
intensity	NN	O
of	IN	O
the	DT	O
IES	NNP	O
was	VBD	O
scored	VBN	O
with	IN	O
a	DT	O
modified	JJ	O
Borg	NNP	O
scale	NN	O
.	.	O

Either	CC	O
fenoterol	NN	O
(	(	O
5	CD	O
mg	NN	O
)	)	O
or	CC	O
a	DT	O
placebo	NN	O
was	VBD	O
given	VBN	O
orally	RB	O
2	CD	O
h	NN	O
before	IN	O
loading	VBG	O
in	IN	O
a	DT	O
randomized	JJ	O
double-blind	NN	O
crossover	NN	O
protocol	NN	O
.	.	O

The	DT	O
endurance	NN	O
time	NN	O
with	IN	O
fenoterol	NN	O
(	(	O
34.4	CD	O
+/-	JJ	O
8.6	CD	O
min	NN	O
)	)	O
was	VBD	O
longer	JJR	O
than	IN	O
that	DT	O
with	IN	O
the	DT	O
placebo	NN	O
(	(	O
22.2	CD	O
+/-	JJ	O
7.1	CD	O
min	NN	O
;	:	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
.	.	O

The	DT	O
ratio	NN	O
of	IN	O
high-	JJ	O
to	TO	O
low-frequency	JJ	O
power	NN	O
of	IN	O
the	DT	O
diaphragmatic	JJ	O
electromyogram	NN	O
(	(	O
EMGdi	NNP	O
)	)	O
decreased	VBD	O
during	IN	O
loading	NN	O
;	:	O
the	DT	O
decrease	NN	O
was	VBD	O
less	RBR	O
with	IN	O
fenoterol	NN	O
(	(	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
.	.	O

The	DT	O
EMGdi	NNP	O
also	RB	O
decreased	VBD	O
with	IN	O
loading	NN	O
;	:	O
the	DT	O
decrease	NN	O
was	VBD	O
greater	JJR	O
on	IN	O
fenoterol	NN	O
treatment	NN	O
(	(	O
P	NNP	O
<	NNP	O
0.01	CD	O
)	)	O
.	.	O

The	DT	O
PI	NNP	O
,	,	O
mmax	NN	O
and	CC	O
maximal	JJ	O
transdiaphragmatic	JJ	O
pressure	NN	O
(	(	O
Pdi	NNP	O
)	)	O
were	VBD	O
similarly	RB	O
decreased	VBN	O
after	IN	O
loading	VBG	O
on	IN	O
either	DT	O
treatment	NN	O
.	.	O

The	DT	O
intensity	NN	O
of	IN	O
the	DT	O
IES	NNP	O
rose	VBD	O
with	IN	O
time	NN	O
during	IN	O
loading	VBG	O
in	IN	O
both	DT	O
groups	NNS	O
but	CC	O
was	VBD	O
lower	JJR	O
with	IN	O
fenoterol	NN	O
than	IN	O
with	IN	O
the	DT	O
placebo	NN	O
(	(	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
.	.	O

The	DT	O
ratio	NN	O
of	IN	O
Pdi	NNP	O
to	TO	O
integrated	JJ	O
activity	NN	O
of	IN	O
the	DT	O
EMGdi	NNP	O
increased	VBD	O
with	IN	O
fenoterol	NN	O
(	(	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
.	.	O

Fenoterol	NNP	O
treatment	NN	O
increased	VBD	O
both	DT	O
superimposed	VBN	O
Pdi	NNP	O
twitch	NN	O
and	CC	O
Pdi	NNP	O
twitch	NN	O
of	IN	O
relaxed	JJ	O
diaphragm	NN	O
and	CC	O
decreased	VBD	O
the	DT	O
value	NN	O
of	IN	O
(	(	O
1-superimposed	JJ	O
Pdi	NNP	O
twitch/Pdi	NN	O
twitch	NN	O
of	IN	O
relaxed	JJ	O
diaphragm	NN	O
)	)	O
.	.	O

Thus	IN	O
we	PRP	O
conclude	VBP	O
that	IN	O
in	IN	O
normal	JJ	O
subjects	NNS	O
fenoterol	JJ	O
reduces	NNS	O
diaphragmatic	JJ	O
fatigue	NN	O
and	CC	O
decreases	VBZ	O
the	DT	O
motor	NN	O
command	NN	O
to	TO	O
the	DT	O
diaphragm	NN	O
,	,	O
resulting	VBG	O
in	IN	O
a	DT	O
decrease	NN	O
in	IN	O
IES	NNP	O
during	IN	O
inspiratory	JJ	O
threshold	JJ	O
loading	NN	O
and	CC	O
a	DT	O
prolongation	NN	O
of	IN	O
endurance	NN	O
.	.	O

A	DT	O
search	NN	O
for	IN	O
serologic	JJ	O
correlates	NNS	O
of	IN	O
immunity	NN	O
to	TO	O
Bordetella	NNP	O
pertussis	NN	O
cough	NN	O
illnesses	NNS	O
.	.	O

In	IN	O
a	DT	O
pertussis	NN	C
vaccine	NN	O
efficacy	NN	O
trial	NN	O
in	IN	O
Germany	NNP	O
we	PRP	O
collected	VBD	O
sera	NN	O
from	IN	O
vaccinees	NNS	O
(	(	O
DTaP	NNP	O
or	CC	O
DTP	NNP	O
)	)	O
after	IN	O
the	DT	O
third	JJ	O
and	CC	O
fourth	JJ	O
doses	NNS	O
of	IN	O
vaccine	NN	O
or	CC	O
at	IN	O
comparable	JJ	O
time	NN	O
periods	NNS	O
in	IN	O
DT	NNP	O
vaccine	NN	O
recipients	NNS	O
.	.	O

In	IN	O
addition	NN	O
,	,	O
sera	NN	O
were	VBD	O
collected	VBN	O
from	IN	O
a	DT	O
randomized	JJ	O
sample	NN	O
of	IN	O
subjects	NNS	O
in	IN	O
each	DT	O
vaccine	NN	O
group	NN	O
at	IN	O
approximately	RB	O
3-month	JJ	O
intervals	NNS	O
from	IN	O
which	WDT	O
antibody	NN	O
kinetic	JJ	O
curves	NNS	O
were	VBD	O
constructed	VBN	O
,	,	O
which	WDT	O
allowed	VBD	O
us	PRP	O
to	TO	O
estimate	VB	O
specific	JJ	O
antibody	NN	O
values	NNS	O
to	TO	O
pertussis	VB	O
toxin	NN	O
(	(	O
PT	NNP	O
)	)	O
,	,	O
filamentous	JJ	O
hemagglutinin	NN	O
(	(	O
FHA	NNP	O
)	)	O
,	,	O
pertactin	JJ	O
and	CC	O
fimbriae-2	JJ	O
at	IN	O
the	DT	O
time	NN	O
of	IN	O
exposure	NN	O
in	IN	O
the	DT	O
household	NN	O
setting	NN	O
.	.	O

The	DT	O
imputed	JJ	O
geometric	JJ	O
mean	NN	O
antibody	NN	O
values	NNS	O
to	TO	O
PT	NNP	O
,	,	O
pertactin	NN	O
and	CC	O
fimbriae-2	NN	O
at	IN	O
the	DT	O
time	NN	O
of	IN	O
household	NN	O
exposure	NN	O
to	TO	O
Bordetella	NNP	O
pertussis	NN	O
infection	NN	O
were	VBD	O
higher	JJR	O
(	(	O
p	JJ	O
<	VBP	O
0.07	CD	O
or	CC	O
lower	JJR	O
)	)	O
in	IN	O
non-cases	NNS	O
compared	VBN	O
with	IN	O
cases	NNS	O
.	.	O

A	DT	O
multivariate	NN	O
(	(	O
classification	NN	O
tree	NN	O
)	)	O
analysis	NN	O
found	VBD	O
that	IN	O
only	RB	O
pertactin	NN	O
and	CC	O
PT	NNP	O
were	VBD	O
significant	JJ	O
in	IN	O
protection	NN	O
.	.	O

Subjects	NNS	O
with	IN	O
an	DT	O
imputed	JJ	O
pertactin	NN	O
value	NN	O
of	IN	O
<	$	O
7	CD	O
EU	NNP	O
ml-1	NN	O
had	VBD	O
a	DT	O
67	CD	O
%	NN	O
(	(	O
18/27	CD	O
)	)	O
chance	NN	O
of	IN	O
infection	NN	O
regardless	NN	O
of	IN	O
the	DT	O
PT	NNP	O
value	NN	O
.	.	O

If	IN	O
the	DT	O
pertactin	NN	O
value	NN	O
was	VBD	O
>	JJ	O
or	CC	O
=	JJ	O
7	CD	O
EU	NNP	O
ml-1	NN	O
and	CC	O
the	DT	O
PT	NNP	O
value	NN	O
>	NN	O
or	CC	O
=	$	O
66	CD	O
EU	NNP	O
ml-1	CD	O
all	DT	O
subjects	NNS	O
were	VBD	O
non-cases	NNS	O
.	.	O

If	IN	O
the	DT	O
pertactin	NN	O
value	NN	O
was	VBD	O
>	JJ	O
or	CC	O
=	JJ	O
7	CD	O
and	CC	O
the	DT	O
PT	NNP	O
value	NN	O
was	VBD	O
<	JJ	O
66	CD	O
EU	NNP	O
ml-1	CD	O
the	DT	O
predicted	JJ	O
probability	NN	O
of	IN	O
being	VBG	O
a	DT	O
case	NN	O
was	VBD	O
31	CD	O
%	NN	O
(	(	O
15/49	CD	O
)	)	O
.	.	O

Logistic	JJ	O
regression	NN	O
analysis	NN	O
also	RB	O
found	VBD	O
that	IN	O
high	JJ	O
versus	NN	O
low	JJ	O
pertactin	NN	O
values	NNS	O
were	VBD	O
associated	VBN	O
with	IN	O
illness	JJ	O
prevention	NN	O
following	VBG	O
household	NN	O
exposure	NN	O
.	.	O

In	IN	O
the	DT	O
presence	NN	O
of	IN	O
antibody	NN	O
to	TO	O
pertactin	VB	O
,	,	O
PT	NNP	O
and	CC	O
fimbriae-2	JJ	O
,	,	O
the	DT	O
additional	JJ	O
presence	NN	O
of	IN	O
antibody	NN	O
to	TO	O
FHA	NNP	O
did	VBD	O
not	RB	O
contribute	VB	O
to	TO	O
protection	NN	O
.	.	O

Our	PRP$	O
data	NNS	O
support	NN	O
historical	JJ	O
data	NNS	O
indicating	VBG	O
that	IN	O
agglutinating	VBG	O
antibodies	NNS	O
are	VBP	O
associated	VBN	O
with	IN	O
protection	NN	O
and	CC	O
also	RB	O
recent	JJ	O
serologic	JJ	O
correlates	NNS	O
data	NNS	O
and	CC	O
clinical	JJ	O
efficacy	NN	O
data	NNS	O
which	WDT	O
indicate	VBP	O
that	IN	O
multicomponent	NN	O
vaccines	NNS	O
containing	VBG	O
pertactin	NN	O
and	CC	O
fimbriae	NN	O
have	VBP	O
better	JJR	O
efficacy	NN	O
than	IN	O
PT	NNP	O
or	CC	O
PT/FHA	NNP	O
vaccines	NNS	O
.	.	O

A	DT	O
randomized	JJ	O
trial	NN	O
of	IN	O
intranasal	NN	O
beclomethasone	NN	O
dipropionate	NN	O
after	IN	O
polypectomy	NN	O
.	.	O

Beneficial	JJ	O
effects	NNS	O
of	IN	O
intranasal	NN	O
beclomethasone	NN	O
dipropionate	NN	O
(	(	O
Bdp	NNP	O
)	)	O
in	IN	O
patients	NNS	O
with	IN	O
nasal	JJ	C
polyposis	NN	C
have	VBP	O
been	VBN	O
reported	VBN	O
earlier	RBR	O
.	.	O

This	DT	O
study	NN	O
was	VBD	O
carried	VBN	O
out	IN	O
to	TO	O
investigate	VB	O
whether	IN	O
long-term	JJ	O
treatment	NN	O
with	IN	O
Bdp	NNP	O
after	IN	O
polypectomy	NN	O
could	MD	O
prevent	VB	O
formation	NN	O
of	IN	O
new	JJ	O
polyps	NNS	O
and	CC	O
reduce	VB	O
the	DT	O
number	NN	O
of	IN	O
surgical	JJ	O
removals	NNS	O
.	.	O

Forty	NNP	SS
consecutive	JJ	O
patients	NNS	O
without	IN	O
laboratory	NN	O
or	CC	O
other	JJ	O
clinical	JJ	O
signs	NNS	O
of	IN	O
allergy	NN	O
but	CC	O
with	IN	O
severe	JJ	C
nasal	JJ	C
polyposis	NN	C
were	VBD	O
included	VBN	O
in	IN	O
the	DT	O
study	NN	O
.	.	O

Twenty	CD	SS
patients	NNS	O
were	VBD	O
treated	VBN	O
with	IN	O
intranasal	JJ	C
Bdp	NNP	C
and	CC	O
twenty	JJ	SS
patients	NNS	O
received	VBD	O
no	DT	O
treatment	NN	O
after	IN	O
polypectomy	NN	C
.	.	O

All	DT	O
patients	NNS	O
were	VBD	O
followed	VBN	O
for	IN	O
at	IN	O
least	JJS	O
2.5	CD	O
years	NNS	O
.	.	O

The	DT	O
size	NN	O
of	IN	O
the	DT	O
polyps	NNS	O
that	WDT	O
recurred	VBD	O
was	VBD	O
estimated	VBN	O
at	IN	O
different	JJ	O
time-intervals	NNS	O
by	IN	O
the	DT	O
examining	VBG	O
doctor	NN	O
.	.	O

After	IN	O
six	CD	O
months	NNS	O
there	RB	O
was	VBD	O
already	RB	O
a	DT	O
significant	JJ	O
difference	NN	O
in	IN	O
favour	NN	O
of	IN	O
the	DT	O
group	NN	O
treated	VBD	O
with	IN	O
intranasal	JJ	O
Bdp	NNP	O
.	.	O

Further	NNP	O
results	NNS	O
of	IN	O
the	DT	O
study	NN	O
and	CC	O
the	DT	O
clinical	JJ	O
implications	NNS	O
are	VBP	O
discussed	VBN	O
.	.	O

Intervention	NN	O
for	IN	O
ineffective	JJ	O
airway	JJ	O
clearance	NN	O
in	IN	O
asthmatic	JJ	O
children	NNS	O
:	:	O
a	DT	O
controlled	VBN	O
and	CC	O
randomized	VBN	O
clinical	JJ	O
trial	NN	O
.	.	O

This	DT	O
study	NN	O
aimed	VBD	O
to	TO	O
analyse	VB	O
the	DT	O
effectiveness	NN	O
of	IN	O
an	DT	O
intervention	NN	O
for	IN	O
the	DT	O
nursing	NN	O
diagnosis	NN	O
of	IN	O
ineffective	JJ	O
airway	JJ	O
clearance	NN	O
in	IN	O
asthmatic	JJ	O
children	NNS	O
.	.	O

A	DT	O
blinded	JJ	O
,	,	O
randomized	VBN	O
and	CC	O
controlled	VBN	O
clinical	JJ	O
trial	NN	O
was	VBD	O
developed	VBN	O
in	IN	O
a	DT	O
paediatric	JJ	O
hospital	NN	O
located	VBN	O
on	IN	O
northeast	NN	O
of	IN	O
Brazil	NNP	O
with	IN	O
42	CD	O
asthmatic	JJ	O
children	NNS	O
aged	VBN	O
?	.	O
36	CD	O
months	NNS	O
.	.	O

The	DT	O
children	NNS	O
were	VBD	O
randomly	RB	O
divided	VBN	O
into	IN	O
two	CD	O
groups	NNS	O
(	(	O
intervention	NN	O
and	CC	O
control	NN	O
)	)	O
by	IN	O
means	NNS	O
of	IN	O
a	DT	O
simple	JJ	O
drawing	NN	O
.	.	O

The	DT	O
applied	JJ	O
intervention	NN	O
included	VBD	O
actions	NNS	O
related	VBN	O
to	TO	O
change	VB	O
of	IN	O
positioning	NN	O
and	CC	O
stimulation	NN	O
of	IN	O
cough	NN	O
.	.	O

The	DT	O
main	JJ	O
findings	NNS	O
of	IN	O
this	DT	O
study	NN	O
show	VBP	O
that	IN	O
before	IN	O
the	DT	O
intervention	NN	O
,	,	O
no	DT	O
significant	JJ	O
difference	NN	O
was	VBD	O
observed	VBN	O
in	IN	O
the	DT	O
health	NN	O
status	NN	O
of	IN	O
the	DT	O
children	NNS	O
.	.	O

After	IN	O
the	DT	O
intervention	NN	O
,	,	O
the	DT	O
indicators	NNS	O
of	IN	O
choking	VBG	O
(	(	O
16.83	CD	O
vs.	FW	O
26.17	CD	O
,	,	O
P	NNP	O
=	NNP	O
0.007	CD	O
)	)	O
and	CC	O
adventitious	JJ	O
breath	NN	O
sounds	NNS	O
(	(	O
16.4	CD	O
vs.	FW	O
26.6	CD	O
,	,	O
P	NNP	O
=	NNP	O
0.005	CD	O
)	)	O
were	VBD	O
higher	JJR	O
,	,	O
on	IN	O
average	NN	O
,	,	O
in	IN	O
the	DT	O
intervention	NN	O
group	NN	O
.	.	O

It	PRP	O
was	VBD	O
observed	VBN	O
an	DT	O
improvement	NN	O
in	IN	O
obstructive	JJ	O
symptoms	NNS	O
in	IN	O
children	NNS	O
who	WP	O
received	VBD	O
the	DT	O
intervention	NN	O
proposed	VBN	O
.	.	O

[	JJ	O
Efficacy	NNP	O
and	CC	O
immune	JJ	O
memory	NN	O
of	IN	O
plasma-derived	JJ	O
hepatitis	NN	O
B	NNP	O
vaccine	NN	O
11	CD	O
years	NNS	O
after	IN	O
primary	JJ	O
immunization	NN	O
]	NN	O
.	.	O

OBJECTIVE	UH	O
To	TO	O
evaluate	VB	O
the	DT	O
long-term	JJ	O
efficacy	NN	O
of	IN	O
hepatitis	NN	C
B	NNP	C
vaccine	NN	O
10	CD	O
years	NNS	O
after	IN	O
primary	JJ	O
immunization	NN	O
to	TO	O
provide	VB	O
scientific	JJ	O
basis	NN	O
for	IN	O
the	DT	O
time	NN	O
of	IN	O
revaccination	NN	O
.	.	O

METHODS	NNP	O
The	DT	O
study	NN	O
was	VBD	O
strictly	RB	O
designed	VBN	O
with	IN	O
randomization	NN	O
,	,	O
double-blinding	NN	O
,	,	O
and	CC	O
placebo-controlled	JJ	O
method	NN	O
to	TO	O
observe	VB	O
the	DT	O
efficacy	NN	O
and	CC	O
immune	JJ	O
memory	NN	O
11	CD	O
years	NNS	O
following	VBG	O
hepatitis	NN	O
B	NNP	O
vaccination	NN	O
.	.	O

RESULTS	NNP	O
Immunogenicity	NNP	O
and	CC	O
protective	JJ	O
rate	NN	O
of	IN	O
vaccine	NN	O
were	VBD	O
still	RB	O
kept	VBN	O
well	RB	O
11	CD	O
years	NNS	O
after	IN	O
immunization	NN	O
with	IN	O
a	DT	O
protective	JJ	O
rate	NN	O
against	IN	O
HBV	NNP	O
infection	NN	O
of	IN	O
73.5	CD	O
%	NN	O
.	.	O

But	CC	O
,	,	O
there	EX	O
was	VBD	O
no	DT	O
significant	JJ	O
difference	NN	O
in	IN	O
HBV	NNP	O
infection	NN	O
rates	NNS	O
between	IN	O
vaccine	NN	O
group	NN	O
and	CC	O
placebo-controlled	JJ	O
group	NN	O
(	(	O
7.89	CD	O
%	NN	O
vs.	FW	O
13.25	CD	O
%	NN	O
,	,	O
P	NNP	O
>	NNP	O
0.1	CD	O
)	)	O
nine	CD	O
to	TO	O
11	CD	O
years	NNS	O
following	VBG	O
immunization	NN	O
.	.	O

There	EX	O
still	RB	O
existed	VBD	O
immune	JJ	O
memory	NN	O
11	CD	O
years	NNS	O
after	IN	O
immunization	NN	O
,	,	O
but	CC	O
it	PRP	O
was	VBD	O
significantly	RB	O
weaker	JJR	O
than	IN	O
that	DT	O
within	IN	O
the	DT	O
first	JJ	O
10	CD	O
years	NNS	O
after	IN	O
immunization	NN	O
.	.	O

CONCLUSION	VB	O
The	DT	O
efficacy	NN	O
of	IN	O
the	DT	O
vaccine	NN	O
had	VBD	O
begun	VBN	O
to	TO	O
drop	VB	O
11	CD	O
years	NNS	O
after	IN	O
immunization	NN	O
,	,	O
which	WDT	O
should	MD	O
be	VB	O
followed	VBN	O
up	RP	O
further	RBR	O
to	TO	O
reach	VB	O
a	DT	O
clear	JJ	O
conclusion	NN	O
.	.	O

Body	NN	O
size	NN	O
indexes	NNS	O
for	IN	O
optimizing	VBG	O
iodine	NN	O
dose	NN	O
for	IN	O
aortic	JJ	O
and	CC	O
hepatic	JJ	O
enhancement	NN	O
at	IN	O
multidetector	NN	O
CT	NNP	O
:	:	O
comparison	NN	O
of	IN	O
total	JJ	O
body	NN	O
weight	NN	O
,	,	O
lean	JJ	O
body	NN	O
weight	NN	O
,	,	O
and	CC	O
blood	NN	O
volume	NN	O
.	.	O

PURPOSE	NNP	O
To	TO	O
evaluate	VB	O
and	CC	O
compare	VB	O
total	JJ	O
body	NN	O
weight	NN	O
(	(	O
TBW	NNP	O
)	)	O
,	,	O
lean	JJ	O
body	NN	O
weight	NN	O
(	(	O
LBW	NNP	O
)	)	O
,	,	O
and	CC	O
estimated	VBD	O
blood	NN	O
volume	NN	O
(	(	O
BV	NNP	O
)	)	O
for	IN	O
the	DT	O
adjustment	NN	O
of	IN	O
the	DT	O
iodine	NN	O
dose	NN	O
required	VBN	O
for	IN	O
contrast	NN	O
material-enhanced	JJ	O
multidetector	NN	O
computed	VBD	O
tomography	NN	O
(	(	O
CT	NNP	O
)	)	O
of	IN	O
the	DT	O
aorta	NN	O
and	CC	O
liver	NN	O
.	.	O

MATERIALS	NNP	O
AND	CC	O
METHODS	NNP	O
Institutional	NNP	O
review	NN	O
committee	NN	O
approval	NN	O
and	CC	O
written	VBN	O
informed	JJ	O
consent	NN	O
were	VBD	O
obtained	VBN	O
.	.	O

One	CD	O
hundred	VBD	O
twenty	NN	O
patients	NNS	O
(	(	O
54	CD	O
men	NNS	O
,	,	O
66	CD	O
women	NNS	O
;	:	O
mean	JJ	O
age	NN	O
,	,	O
64.1	CD	O
years	NNS	O
;	:	O
range	NN	O
,	,	O
19-88	CD	O
years	NNS	O
)	)	O
who	WP	O
underwent	JJ	O
multidetector	NN	O
CT	NNP	O
of	IN	O
the	DT	O
upper	JJ	O
abdomen	NNS	O
were	VBD	O
randomized	VBN	O
into	IN	O
three	CD	O
groups	NNS	O
of	IN	O
40	CD	O
patients	NNS	O
each	DT	O
:	:	O
(	(	O
a	DT	O
)	)	O
TBW	NNP	O
group	NN	O
(	(	O
0.6	CD	O
g	NN	O
of	IN	O
iodine	NN	O
per	IN	O
kilogram	NN	O
of	IN	O
TBW	NNP	O
)	)	O
,	,	O
(	(	O
b	NN	O
)	)	O
LBW	NNP	O
group	NN	O
(	(	O
0.821	CD	O
g	NN	O
of	IN	O
iodine	NN	O
per	IN	O
kilogram	NN	O
of	IN	O
LBW	NNP	O
)	)	O
,	,	O
and	CC	O
(	(	O
c	NN	O
)	)	O
BV	NNP	O
group	NN	O
(	(	O
men	NNS	O
,	,	O
8.6	CD	O
g	NN	O
of	IN	O
iodine	NN	O
per	IN	O
liter	NN	O
of	IN	O
BV	NNP	O
;	:	O
women	NNS	O
,	,	O
9.9	CD	O
g	NN	O
of	IN	O
iodine	NN	O
per	IN	O
liter	NN	O
of	IN	O
BV	NNP	O
)	)	O
.	.	O

Change	NN	O
in	IN	O
CT	NNP	O
number	NN	O
between	IN	O
unenhanced	JJ	O
and	CC	O
contrast-enhanced	JJ	O
images	NNS	O
per	IN	O
gram	NN	O
of	IN	O
iodine	NN	O
and	CC	O
maximum	JJ	O
hepatic	JJ	O
enhancement	NN	O
(	(	O
MHE	NNP	O
)	)	O
adjusted	VBD	O
for	IN	O
iodine	NN	O
dose	NN	O
were	VBD	O
examined	VBN	O
for	IN	O
correlation	NN	O
with	IN	O
TBW	NNP	O
,	,	O
LBW	NNP	O
,	,	O
and	CC	O
BV	NNP	O
by	IN	O
using	VBG	O
linear	JJ	O
regression	NN	O
analysis	NN	O
.	.	O

RESULTS	NNP	O
In	IN	O
the	DT	O
portal	JJ	O
venous	JJ	O
phase	NN	O
,	,	O
correlation	NN	O
coefficients	NNS	O
for	IN	O
the	DT	O
correlation	NN	O
of	IN	O
change	NN	O
in	IN	O
CT	NNP	O
number	NN	O
per	IN	O
gram	NN	O
of	IN	O
iodine	NN	O
with	IN	O
TBW	NNP	O
for	IN	O
the	DT	O
aorta	NN	O
and	CC	O
liver	NN	O
were	VBD	O
-0.71	NNP	O
and	CC	O
-0.79	NNP	O
,	,	O
respectively	RB	O
,	,	O
in	IN	O
the	DT	O
TBW	NNP	O
group	NN	O
;	:	O
-0.80	CC	O
and	CC	O
-0.86	NNP	O
,	,	O
respectively	RB	O
,	,	O
in	IN	O
the	DT	O
LBW	NNP	O
group	NN	O
;	:	O
and	CC	O
-0.68	VB	O
and	CC	O
-0.66	NNP	O
,	,	O
respectively	RB	O
,	,	O
in	IN	O
the	DT	O
BV	NNP	O
group	NN	O
.	.	O

In	IN	O
the	DT	O
liver	NN	O
,	,	O
they	PRP	O
were	VBD	O
marginally	RB	O
higher	JJR	O
in	IN	O
the	DT	O
LBW	NNP	O
group	NN	O
than	IN	O
in	IN	O
the	DT	O
BV	NNP	O
group	NN	O
(	(	O
P	NNP	O
=	NNP	O
.03	NNP	O
)	)	O
.	.	O

Adjusted	VBN	O
MHE	NNP	O
remained	VBD	O
constant	JJ	O
at	IN	O
77.9	CD	O
HU	NNP	O
+/-	JJ	O
10.2	CD	O
(	(	O
standard	JJ	O
deviation	NN	O
)	)	O
in	IN	O
the	DT	O
LBW	NNP	O
group	NN	O
with	IN	O
respect	NN	O
to	TO	O
TBW	NNP	O
,	,	O
but	CC	O
it	PRP	O
increased	VBD	O
in	IN	O
the	DT	O
TBW	NNP	O
(	(	O
r	VB	O
=	RB	O
0.80	CD	O
,	,	O
P	NNP	O
<	NNP	O
.001	NNP	O
)	)	O
and	CC	O
BV	NNP	O
(	(	O
r	VB	O
=	RB	O
0.70	CD	O
,	,	O
P	NNP	O
<	NNP	O
.001	NNP	O
)	)	O
groups	NNS	O
as	IN	O
TBW	NNP	O
increased	VBD	O
.	.	O

CONCLUSION	NN	O
When	WRB	O
LBW	NNP	O
,	,	O
rather	RB	O
than	IN	O
TBW	NNP	O
or	CC	O
BV	NNP	O
,	,	O
is	VBZ	O
used	VBN	O
,	,	O
the	DT	O
iodine	NN	O
dose	NN	O
required	VBN	O
to	TO	O
achieve	VB	O
consistent	JJ	O
hepatic	JJ	O
enhancement	NN	O
may	MD	O
be	VB	O
estimated	VBN	O
more	RBR	O
precisely	RB	O
and	CC	O
with	IN	O
reduced	JJ	O
patient-to-patient	JJ	O
variability	NN	O
.	.	O

[	JJ	O
Supplementary	NNP	O
treatment	NN	O
with	IN	O
Esberitox	NNP	O
of	IN	O
female	JJ	C
patients	NNS	C
undergoing	VBG	C
curative	JJ	C
adjuvant	JJ	C
irradiation	NN	C
following	VBG	C
breast	NN	C
cancer	NN	C
]	NNP	C
.	.	O

1	CD	O
.	.	O

The	DT	O
study	NN	O
was	VBD	O
supposed	VBN	O
to	TO	O
investigate	VB	O
a	DT	O
possible	JJ	O
prevention	NN	O
or	CC	O
reduction	NN	O
of	IN	O
the	DT	O
toxicity	NN	O
of	IN	O
radiotherapy	NN	O
by	IN	O
an	DT	O
additional	JJ	O
treatment	NN	O
with	IN	O
Esberitox	NNP	O
.	.	O

This	DT	O
question	NN	O
arose	VBD	O
when	WRB	O
performing	VBG	O
an	DT	O
investigation	NN	O
about	IN	O
the	DT	O
effect	NN	O
of	IN	O
Esberitox	NNP	O
in	IN	O
a	DT	O
combined	JJ	O
chemo-radiotherapy	NN	O
.	.	O

Whereas	IN	O
the	DT	O
latter	JJ	O
induces	NNS	O
above	IN	O
all	PDT	O
a	DT	O
systemic	JJ	O
damage	NN	O
to	TO	O
the	DT	O
hemopoietic	JJ	O
system	NN	O
,	,	O
radiotherapy	NN	O
is	VBZ	O
a	DT	O
regional	JJ	O
noxa	NN	O
.	.	O

2	CD	O
.	.	O

The	DT	O
present	JJ	O
prospective	JJ	O
,	,	O
randomized	VBD	O
study	NN	O
was	VBD	O
conducted	VBN	O
with	IN	O
50	CD	O
patients	NNS	O
submitted	VBN	O
to	TO	O
curative	VB	O
adjuvant	JJ	O
irradiation	NN	O
following	VBG	O
surgery	NN	O
for	IN	O
mammary	JJ	O
carcinoma	NN	O
.	.	O

The	DT	O
radiotherapy	NN	O
was	VBD	O
performed	VBN	O
in	IN	O
the	DT	O
same	JJ	O
way	NN	O
in	IN	O
all	DT	O
patients	NNS	O
with	IN	O
irradiations	NNS	O
of	IN	O
the	DT	O
thoracic	NN	O
wall	NN	O
and	CC	O
the	DT	O
regional	JJ	O
lymph	NN	O
nodes	NNS	O
.	.	O

Two	CD	O
groups	NNS	O
were	VBD	O
built	VBN	O
by	IN	O
randomization	NN	O
.	.	O

The	DT	O
study	NN	O
group	NN	O
received	VBD	O
an	DT	O
additional	JJ	O
treatment	NN	O
with	IN	O
Esberitox	NNP	O
,	,	O
the	DT	O
control	NN	O
group	NN	O
did	VBD	O
not	RB	O
receive	VB	O
an	DT	O
additional	JJ	O
treatment	NN	O
.	.	O

3	CD	O
.	.	O

As	IN	O
a	DT	O
result	NN	O
,	,	O
no	DT	O
protective	JJ	O
influence	NN	O
of	IN	O
Esberitox	NNP	O
could	MD	O
be	VB	O
demonstrated	VBN	O
.	.	O

The	DT	O
parameters	NNS	O
investigated	VBN	O
were	VBD	O
the	DT	O
peripheral	JJ	O
blood	NN	O
count	NN	O
(	(	O
leucocytes	NNS	O
,	,	O
granulocytes	NNS	O
,	,	O
lymphocytes	NNS	O
,	,	O
monocytes	NNS	O
,	,	O
thrombocytes	NNS	O
,	,	O
hemoglobin	NN	O
,	,	O
hematocrit	NN	O
)	)	O
and	CC	O
the	DT	O
incidence	NN	O
of	IN	O
infections	NNS	O
.	.	O

4	CD	O
.	.	O

This	DT	O
result	NN	O
diverging	VBG	O
from	IN	O
literature	NN	O
is	VBZ	O
discussed	VBN	O
.	.	O

It	PRP	O
is	VBZ	O
probably	RB	O
affected	VBN	O
by	IN	O
volume	NN	O
and	CC	O
extension	NN	O
of	IN	O
the	DT	O
injury	NN	O
induced	VBN	O
by	IN	O
a	DT	O
hematotoxic	NN	O
noxa	NN	O
and	CC	O
furthermore	NN	O
by	IN	O
the	DT	O
ability	NN	O
of	IN	O
regeneration	NN	O
.	.	O

If	IN	O
this	DT	O
ability	NN	O
is	VBZ	O
exhausted	VBN	O
,	,	O
the	DT	O
protective	JJ	O
effect	NN	O
of	IN	O
Esberitox	NNP	O
can	MD	O
act	VB	O
no	DT	O
longer	JJR	O
.	.	O

Therefore	VB	O
the	DT	O
essential	JJ	O
factor	NN	O
seems	VBZ	O
to	TO	O
be	VB	O
the	DT	O
duration	NN	O
of	IN	O
exposure	NN	O
to	TO	O
the	DT	O
noxa	NN	O
.	.	O

Esberitox	NNP	O
was	VBD	O
effective	JJ	O
in	IN	O
case	NN	O
of	IN	O
a	DT	O
short	JJ	O
toxicity	NN	O
,	,	O
it	PRP	O
was	VBD	O
ineffective	JJ	O
in	IN	O
case	NN	O
of	IN	O
prolonged	JJ	O
toxicity	NN	O
,	,	O
if	IN	O
the	DT	O
treatment	NN	O
continuity	NN	O
(	(	O
noxa	JJ	O
)	)	O
was	VBD	O
not	RB	O
broken	VBN	O
up	RP	O
by	IN	O
some	DT	O
regeneration	NN	O
intervals	NNS	O
.	.	O

The	DT	O
radiotherapy	NN	O
studied	VBN	O
in	IN	O
this	DT	O
trial	NN	O
had	VBD	O
a	DT	O
duration	NN	O
of	IN	O
50	CD	O
days	NNS	O
,	,	O
and	CC	O
its	PRP$	O
effect	NN	O
was	VBD	O
that	IN	O
of	IN	O
a	DT	O
longterm	JJ	O
injury	NN	O
.	.	O

Visit-to-visit	NNP	O
blood	NN	O
pressure	NN	O
variability	NN	O
in	IN	O
the	DT	O
European	NNP	O
Lacidipine	NNP	O
Study	NNP	O
on	IN	O
Atherosclerosis	NNP	O
:	:	O
methodological	JJ	O
aspects	NNS	O
and	CC	O
effects	NNS	O
of	IN	O
antihypertensive	JJ	O
treatment	NN	O
.	.	O

BACKGROUND	NNP	O
Recent	NNP	O
studies	NNS	O
have	VBP	O
reported	VBN	O
that	IN	O
in	IN	O
patients	NNS	O
under	IN	O
antihypertensive	JJ	O
treatment	NN	O
visit-to-visit	NN	O
(	(	O
or	CC	O
long-term	JJ	O
)	)	O
variability	NN	O
of	IN	O
clinic	JJ	O
BP	NNP	O
within	IN	O
a	DT	O
given	VBN	O
patient	NN	O
has	VBZ	O
an	DT	O
independent	JJ	O
prognostic	JJ	O
significance	NN	O
.	.	O

Partly	RB	O
based	VBN	O
on	IN	O
between-patient	JJ	O
dispersion	NN	O
of	IN	O
BP	NNP	O
values	NNS	O
during	IN	O
treatment	NN	O
(	(	O
interindividual	JJ	O
variability	NN	O
)	)	O
it	PRP	O
has	VBZ	O
also	RB	O
been	VBN	O
reported	VBN	O
that	IN	O
long-term	JJ	O
clinic	JJ	O
BP	NNP	O
variability	NN	O
is	VBZ	O
greater	JJR	O
for	IN	O
?-blocker	JJR	O
than	IN	O
for	IN	O
calcium	NN	O
antagonist	NN	O
and	CC	O
other	JJ	O
types	NNS	O
of	IN	O
treatment	NN	O
.	.	O

GOALS	NNP	O
To	TO	O
measure	VB	O
visit-to-visit	JJ	O
intraindividual	JJ	O
variations	NNS	O
of	IN	O
both	DT	O
clinic	JJ	O
and	CC	O
24-h	JJ	O
mean	NN	O
BP	NNP	O
in	IN	O
the	DT	O
hypertensive	JJ	O
patients	NNS	O
of	IN	O
the	DT	O
European	NNP	O
Lacidipine	NNP	O
Study	NNP	O
on	IN	O
Atherosclerosis	NNP	O
(	(	O
ELSA	NNP	O
)	)	O
trial	NN	O
treated	VBD	O
for	IN	O
4	CD	O
years	NNS	O
with	IN	O
either	DT	O
atenolol	NN	O
or	CC	O
lacidipine	NN	O
,	,	O
and	CC	O
to	TO	O
check	VB	O
whether	IN	O
interindividual	JJ	O
clinic	NN	O
and	CC	O
24-h	JJ	O
BP	NNP	O
variabilities	NNS	O
during	IN	O
treatment	NN	O
can	MD	O
really	RB	O
be	VB	O
considered	VBN	O
a	DT	O
surrogate	NN	O
of	IN	O
intraindividual	JJ	O
variabilities	NNS	O
in	IN	O
exploring	VBG	O
differences	NNS	O
between	IN	O
?-blocker	NN	O
and	CC	O
calcium	NN	O
antagonist	NN	O
treatments	NNS	O
.	.	O

METHODS	NNP	O
Long-term	JJ	O
intraindividual	JJ	O
BP	NNP	O
variability	NN	O
was	VBD	O
defined	VBN	O
as	IN	O
the	DT	O
coefficient	NN	O
of	IN	O
variation	NN	O
of	IN	O
the	DT	O
average	JJ	O
systolic	JJ	O
or	CC	O
diastolic	JJ	O
values	NNS	O
of	IN	O
clinic	JJ	O
and	CC	O
24-h	JJ	O
BP	NNP	O
measured	VBD	O
at	IN	O
each	DT	O
visit	NN	O
throughout	IN	O
the	DT	O
treatment	NN	O
period	NN	O
.	.	O

Patients	NNS	O
in	IN	O
whom	WP	O
at	IN	O
least	JJS	O
seven	CD	O
clinic	JJ	O
(	(	O
6-month	JJ	O
intervals	NNS	O
)	)	O
or	CC	O
at	IN	O
least	JJS	O
three	CD	O
(	(	O
yearly	JJ	O
intervals	NNS	O
)	)	O
24-h	JJ	O
values	NNS	O
were	VBD	O
available	JJ	O
from	IN	O
the	DT	O
end	NN	O
of	IN	O
the	DT	O
drug	NN	O
titration	NN	O
phase	NN	O
to	TO	O
the	DT	O
end	NN	O
of	IN	O
the	DT	O
study	NN	O
were	VBD	O
considered	VBN	O
.	.	O

RESULTS	JJ	O
Visit-to-visit	JJ	O
24-h	JJ	O
SBP/DBP	NNP	O
variabilities	NNS	O
were	VBD	O
20-25	CD	O
%	NN	O
smaller	JJR	O
than	IN	O
,	,	O
and	CC	O
loosely	RB	O
correlated	VBN	O
with	IN	O
clinic	JJ	O
BP	NNP	O
variability	NN	O
(	(	O
r	NN	O
(	(	O
2	CD	O
)	)	O
<	FW	O
0.022	CD	O
)	)	O
.	.	O

There	EX	O
was	VBD	O
also	RB	O
a	DT	O
very	RB	O
limited	JJ	O
relationship	NN	O
(	(	O
r	NN	O
(	(	O
2	CD	O
)	)	O
<	FW	O
0.026	CD	O
)	)	O
between	IN	O
visit-to-visit	NN	O
and	CC	O
within	IN	O
24-h	JJ	O
ambulatory	NN	O
BP	NNP	O
variabilities	NNS	O
,	,	O
the	DT	O
latter	JJ	O
being	VBG	O
two	CD	O
to	TO	O
three	CD	O
times	NNS	O
greater	JJR	O
than	IN	O
the	DT	O
former	JJ	O
.	.	O

Visit-to-visit	JJ	O
intraindividual	JJ	O
clinic	NN	O
SBP	NNP	O
variability	NN	O
was	VBD	O
only	RB	O
slightly	RB	O
lower	JJR	O
on	IN	O
calcium	NN	O
antagonist	NN	O
than	IN	O
on	IN	O
?-blocker	JJ	O
treatment	NN	O
but	CC	O
little	JJ	O
or	CC	O
no	DT	O
between-treatment	JJ	O
difference	NN	O
was	VBD	O
found	VBN	O
for	IN	O
visit-to-visit	NN	O
clinic	NN	O
DBP	NNP	O
and	CC	O
ambulatory	JJ	O
SBP/DBP	NNP	O
particularly	RB	O
in	IN	O
patients	NNS	O
under	IN	O
monotherapy	NN	O
throughout	IN	O
the	DT	O
study	NN	O
.	.	O

Interindividual	NNP	O
BP	NNP	O
variability	NN	O
was	VBD	O
markedly	RB	O
greater	JJR	O
than	IN	O
the	DT	O
intra-individiual	JJ	O
one	CD	O
of	IN	O
which	WDT	O
it	PRP	O
did	VBD	O
not	RB	O
precisely	RB	O
reflect	VB	O
the	DT	O
treatment-induced	JJ	O
changes	NNS	O
.	.	O

CONCLUSION	NN	O
In	IN	O
mild-to-moderate	JJ	O
hypertensive	JJ	O
patients	NNS	O
,	,	O
visit-to-visit	JJ	O
BP	NNP	O
variability	NN	O
does	VBZ	O
not	RB	O
differ	VB	O
substantially	RB	O
between	IN	O
?-blocker	NN	O
and	CC	O
calcium	NN	O
antagonist	NN	O
treatment	NN	O
.	.	O

Major	JJ	O
discrepancies	NNS	O
exist	VBP	O
between	IN	O
visit-to-visit	NN	O
BP	NNP	O
variability	NN	O
as	IN	O
quantified	VBN	O
by	IN	O
24-h	JJ	O
vs.	FW	O
clinic	JJ	O
BP	NNP	O
,	,	O
making	VBG	O
investigation	NN	O
of	IN	O
which	WDT	O
of	IN	O
these	DT	O
indices	NNS	O
is	VBZ	O
clinically	RB	O
more	RBR	O
relevant	JJ	O
important	JJ	O
.	.	O

Interindividual	JJ	O
BP	NNP	O
variability	NN	O
during	IN	O
treatment	NN	O
shows	NNS	O
marked	VBD	O
quantitative	JJ	O
differences	NNS	O
with	IN	O
intraindividual	JJ	O
BP	NNP	O
variability	NN	O
questioning	VBG	O
whether	IN	O
its	PRP$	O
use	NN	O
can	MD	O
accurately	RB	O
reflect	VB	O
individual	JJ	O
BP	NNP	O
variations	NNS	O
from	IN	O
one	CD	O
visit	NN	O
to	TO	O
another	DT	O
.	.	O

Azelnidipine	NNP	O
and	CC	O
amlodipine	VB	O
anti-coronary	JJ	O
atherosclerosis	NN	O
trial	NN	O
in	IN	O
hypertensive	JJ	O
patients	NNS	O
undergoing	VBG	O
coronary	JJ	O
intervention	NN	O
by	IN	O
serial	JJ	O
volumetric	JJ	O
intravascular	NN	O
ultrasound	NN	O
analysis	NN	O
in	IN	O
Juntendo	NNP	O
university	NN	O
(	(	O
ALPS-J	NNP	O
)	)	O
.	.	O

PURPOSE	NNP	O
Many	JJ	O
trials	NNS	O
have	VBP	O
shown	VBN	O
that	IN	O
calcium	NN	O
channel	NN	O
blockers	NNS	O
(	(	O
CCBs	NNP	O
)	)	O
can	MD	O
reduce	VB	O
the	DT	O
cardiovascular	NN	O
(	(	O
CV	NNP	O
)	)	O
events	NNS	O
in	IN	O
patients	NNS	O
with	IN	O
coronary	JJ	O
artery	NN	O
disease	NN	O
(	(	O
CAD	NNP	O
)	)	O
.	.	O

The	DT	O
mechanisms	NN	O
of	IN	O
this	DT	O
effect	NN	O
could	MD	O
be	VB	O
associated	VBN	O
with	IN	O
plaque	JJ	O
regression	NN	O
due	JJ	O
to	TO	O
the	DT	O
anti-atherosclerotic	JJ	O
properties	NNS	O
of	IN	O
CCBs	NNP	O
.	.	O

The	DT	O
goal	NN	O
of	IN	O
this	DT	O
study	NN	O
is	VBZ	O
to	TO	O
determine	VB	O
the	DT	O
effects	NNS	O
of	IN	O
CCB	NNP	O
on	IN	O
volumetric	JJ	O
quantitative	JJ	O
changes	NNS	O
of	IN	O
coronary	JJ	O
plaques	NNS	O
accessed	VBN	O
by	IN	O
intravascular	JJ	O
ultrasound	NN	O
(	(	O
IVUS	NNP	O
)	)	O
.	.	O

To	TO	O
confirm	VB	O
this	DT	O
hypothesis	NN	O
,	,	O
a	DT	O
multicenter	NN	O
randomized	VBN	O
trial	NN	O
of	IN	O
CCBs	NNP	O
treatment	NN	O
with	IN	O
azelnidipine	NN	O
or	CC	O
amlodipine	NN	O
will	MD	O
be	VB	O
conducted	VBN	O
in	IN	O
hypertensive	JJ	O
CAD	NNP	O
patients	NNS	O
undergoing	VBG	O
elective	JJ	O
percutaneous	JJ	O
coronary	JJ	O
intervention	NN	O
(	(	O
PCI	NNP	O
)	)	O
.	.	O

METHODS	NNP	O
AND	CC	O
RESULTS	NNP	O
Patients	NNPS	O
who	WP	O
have	VBP	O
hypertension	NN	O
and	CC	O
are	VBP	O
scheduled	VBN	O
for	IN	O
PCI	NNP	O
will	MD	O
be	VB	O
enrolled	VBN	O
.	.	O

Subjects	NNS	O
will	MD	O
be	VB	O
randomized	VBN	O
to	TO	O
azelnidipine	VB	O
or	CC	O
amlodipine	VB	O
and	CC	O
observed	VB	O
for	IN	O
48	CD	O
weeks	NNS	O
.	.	O

The	DT	O
primary	JJ	O
endpoint	NN	O
will	MD	O
be	VB	O
the	DT	O
percent	NN	O
change	NN	O
of	IN	O
coronary	JJ	O
plaque	NN	O
volume	NN	O
.	.	O

The	DT	O
secondary	JJ	O
endpoint	NN	O
will	MD	O
include	VB	O
inflammatory	JJ	O
markers	NNS	O
,	,	O
antioxidant	JJ	O
activity	NN	O
,	,	O
and	CC	O
incidence	NN	O
of	IN	O
composite	JJ	O
cardiovascular	JJ	O
events	NNS	O
.	.	O

CONCLUSIONS	NNP	O
In	IN	O
this	DT	O
study	NN	O
,	,	O
we	PRP	O
will	MD	O
investigate	VB	O
the	DT	O
improvement	NN	O
of	IN	O
coronary	JJ	O
plaque	NN	O
with	IN	O
IVUS	NNP	O
by	IN	O
treatment	NN	O
with	IN	O
two	CD	O
dihydropyridine	NN	O
CCBs	NNP	O
in	IN	O
hypertensive	JJ	O
patients	NNS	O
undergoing	VBG	O
elective	JJ	O
PCI	NNP	O
.	.	O

This	DT	O
result	NN	O
will	MD	O
lead	VB	O
to	TO	O
the	DT	O
discovery	NN	O
of	IN	O
more	RBR	O
effective	JJ	O
drug	NN	O
therapy	NN	O
for	IN	O
inhibition	NN	O
of	IN	O
coronary	JJ	O
events	NNS	O
.	.	O

[	NNP	O
Medical	NNP	C
safety	NN	C
and	CC	O
staff	NN	O
mental	JJ	O
health	NN	O
]	NNP	O
.	.	O

Improvement	NNP	O
in	IN	O
patient	JJ	O
safety	NN	O
is	VBZ	O
a	DT	O
high-priority	JJ	O
issue	NN	O
of	IN	O
great	JJ	O
social	JJ	O
import	NN	O
.	.	O

Several	JJ	O
studies	NNS	O
have	VBP	O
reported	VBN	O
that	IN	O
most	JJS	O
adverse	JJ	O
events	NNS	O
are	VBP	O
due	JJ	O
to	TO	O
errors	NNS	O
of	IN	O
hospital	JJ	O
staff	NN	O
,	,	O
and	CC	O
emphasized	VBD	O
the	DT	O
necessity	NN	O
of	IN	O
promoting	VBG	O
countermeasures	NNS	O
against	IN	O
medical	JJ	O
errors	NNS	O
.	.	O

Root	NNP	O
cause	NN	O
analysis	NN	O
(	(	O
RCA	NNP	O
)	)	O
has	VBZ	O
been	VBN	O
implemented	VBN	O
to	TO	O
prevent	VB	O
such	JJ	O
errors	NNS	O
.	.	O

However	RB	O
,	,	O
the	DT	O
retrospective	NN	O
and	CC	O
qualitative	JJ	O
nature	NN	O
of	IN	O
RCA	NNP	O
is	VBZ	O
a	DT	O
limitation	NN	O
in	IN	O
scientific	JJ	O
analyses	NNS	O
examining	VBG	O
causal	JJ	O
relationships	NNS	O
.	.	O

We	PRP	O
showed	VBD	O
that	IN	O
prospective	JJ	O
design	NN	O
path	NN	O
analysis	NN	O
using	VBG	O
structural	JJ	O
equation	NN	O
modeling	NN	O
(	(	O
SEM	NNP	O
)	)	O
model	NN	O
for	IN	O
both	DT	O
direct	JJ	O
and	CC	O
indirect	JJ	O
effects	NNS	O
enabled	VBD	O
statistical	JJ	O
exploration	NN	O
of	IN	O
root	NN	O
causes	NNS	O
and	CC	O
estimation	NN	O
of	IN	O
their	PRP$	O
impact	NN	O
on	IN	O
the	DT	O
outcome	NN	O
.	.	O

Our	PRP$	O
findings	NNS	O
suggested	VBD	O
such	JJ	O
analysis	NN	O
to	TO	O
be	VB	O
useful	JJ	O
in	IN	O
devising	VBG	O
countermeasures	NNS	O
against	IN	O
medical	JJ	O
errors	NNS	O
.	.	O

The	DT	O
SEM	NNP	O
model	NN	O
constructed	VBN	O
in	IN	O
this	DT	O
study	NN	O
suggested	VBD	O
that	IN	O
one	CD	O
of	IN	O
the	DT	O
potential	JJ	O
root	NN	O
causes	NNS	O
was	VBD	O
sleep	JJ	O
disturbance	NN	O
.	.	O

We	PRP	O
conducted	VBD	O
a	DT	O
randomized	VBN	O
crossover	NN	O
study	NN	O
whether	IN	O
or	CC	O
not	RB	O
brief	JJ	O
bright	JJ	O
light	NN	O
(	(	O
BL	NNP	O
)	)	O
exposure	NN	O
on	IN	O
workday	JJ	O
mornings	NNS	O
can	MD	O
improve	VB	O
health	NN	O
,	,	O
performance	NN	O
and	CC	O
safety	NN	O
in	IN	O
nurses	NNS	C
with	IN	C
rapidly	RB	C
rotating	VBG	C
shifts	NNS	C
.	.	O

Significant	JJ	O
improvements	NNS	O
were	VBD	O
noted	VBN	O
in	IN	O
the	DT	O
BL	NNP	O
periods	NNS	O
compared	VBN	O
with	IN	O
the	DT	O
non-BL	JJ	O
periods	NNS	O
for	IN	O
self-assessed	JJ	O
sleepiness	NN	O
at	IN	O
10	CD	O
:	:	O
00	CD	O
on	IN	O
day-shift	JJ	O
days	NNS	O
,	,	O
self-assessment	NN	O
of	IN	O
night	NN	O
sleep	NN	O
for	IN	O
day-shift	JJ	O
days	NNS	O
and	CC	O
for	IN	O
fatigue	NN	O
.	.	O

Mean	NNP	O
response	NN	O
time	NN	O
evaluated	VBN	O
using	VBG	O
the	DT	O
psychomotor	NN	O
vigilance	NN	O
task	NN	O
test	NN	O
(	(	O
PVT	NNP	O
)	)	O
showed	VBD	O
significant	JJ	O
improvement	NN	O
in	IN	O
the	DT	O
BL	NNP	O
periods	NNS	O
compared	VBN	O
with	IN	O
the	DT	O
non-BL	JJ	O
periods	NNS	O
.	.	O

The	DT	O
frequency	NN	O
of	IN	O
perceived	JJ	O
adverse	JJ	O
events	NNS	O
and	CC	O
near	JJ	O
misses	NNS	O
was	VBD	O
also	RB	O
lower	JJR	O
in	IN	O
the	DT	O
BL	NNP	O
than	IN	O
in	IN	O
the	DT	O
non-BL	JJ	O
periods	NNS	O
,	,	O
but	CC	O
not	RB	O
significantly	RB	O
so	RB	O
,	,	O
possibly	RB	O
indicating	VBG	O
that	IN	O
the	DT	O
one-month	JJ	O
observation	NN	O
period	NN	O
was	VBD	O
too	RB	O
short	JJ	O
to	TO	O
achieve	VB	O
any	DT	O
significant	JJ	O
success	NN	O
.	.	O

Despite	IN	O
our	PRP$	O
study	NN	O
's	POS	O
limitations	NNS	O
,	,	O
we	PRP	O
have	VBP	O
effectively	RB	O
demonstrated	VBN	O
the	DT	O
potential	NN	O
for	IN	O
preventing	VBG	O
medical	JJ	O
error	NN	O
risk	NN	O
among	IN	O
night-shift	JJ	O
workers	NNS	O
.	.	O

Factors	NNS	O
that	WDT	O
influence	NN	O
cancer	NN	C
patients	NNS	C
'	POS	C
anxiety	NN	C
following	VBG	O
a	DT	O
medical	JJ	O
consultation	NN	O
:	:	O
impact	NN	O
of	IN	O
a	DT	O
communication	NN	O
skills	VBZ	O
training	VBG	O
programme	NN	O
for	IN	O
physicians	NNS	O
.	.	O

BACKGROUND	NNP	O
No	NNP	O
study	NN	O
has	VBZ	O
yet	RB	O
assessed	VBN	O
the	DT	O
impact	NN	O
of	IN	O
physicians	NNS	O
'	POS	O
skills	NNS	O
acquisition	NN	O
after	IN	O
a	DT	O
communication	NN	O
skills	VBZ	O
training	VBG	O
programme	NN	O
on	IN	O
the	DT	O
evolution	NN	O
of	IN	O
patients	NNS	O
'	POS	O
anxiety	NN	O
following	VBG	O
a	DT	O
medical	JJ	O
consultation	NN	O
.	.	O

This	DT	O
study	NN	O
aimed	VBD	O
to	TO	O
compare	VB	O
the	DT	O
impact	NN	O
,	,	O
on	IN	O
patients	NNS	O
'	POS	O
anxiety	NN	O
,	,	O
of	IN	O
a	DT	O
basic	JJ	O
communication	NN	O
skills	NNS	O
training	VBG	O
programme	NN	O
(	(	O
BT	NNP	O
)	)	O
and	CC	O
the	DT	O
same	JJ	O
programme	NN	O
consolidated	VBN	O
by	IN	O
consolidation	NN	O
workshops	NNS	O
(	(	O
CW	NNP	O
)	)	O
,	,	O
and	CC	O
to	TO	O
investigate	VB	O
physicians	NNS	O
'	POS	O
communication	NN	O
variables	NNS	O
associated	VBN	O
with	IN	O
patients	NNS	O
'	POS	O
anxiety	NN	O
.	.	O

PATIENTS	NNP	O
AND	CC	O
METHODS	NNP	O
Physicians	NNP	C
,	,	O
after	IN	O
attending	VBG	O
the	DT	O
BT	NNP	O
,	,	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
CW	NNP	O
or	CC	O
to	TO	O
a	DT	O
waiting	VBG	O
list	NN	O
.	.	O

The	DT	O
control	NN	O
group	NN	O
was	VBD	O
not	RB	O
a	DT	O
non-intervention	JJ	O
group	NN	O
.	.	O

Consultations	NNS	O
with	IN	O
a	DT	O
cancer	NN	O
patient	NN	O
were	VBD	O
recorded	VBN	O
.	.	O

Patients	NNS	O
'	POS	O
anxiety	NN	O
was	VBD	O
assessed	VBN	O
with	IN	O
the	DT	O
State	NNP	O
Trait	NNP	O
Anxiety	NNP	O
Inventory	NNP	O
before	IN	O
and	CC	O
after	IN	O
a	DT	O
consultation	NN	O
.	.	O

Communication	NNP	O
skills	NNS	O
were	VBD	O
analysed	VBN	O
according	VBG	O
to	TO	O
the	DT	O
Cancer	NNP	O
Research	NNP	O
Campaign	NNP	O
Workshop	NNP	O
Evaluation	NNP	O
Manual	NNP	O
.	.	O

RESULTS	NNP	O
No	NNP	O
statistically	RB	O
significant	JJ	O
change	NN	O
over	IN	O
time	NN	O
and	CC	O
between	IN	O
groups	NNS	O
was	VBD	O
observed	VBN	O
.	.	O

Mixed-effects	NNS	O
modelling	VBG	O
showed	VBD	O
that	IN	O
a	DT	O
decrease	NN	O
in	IN	O
patients	NNS	O
'	POS	O
anxiety	NN	O
was	VBD	O
linked	VBN	O
with	IN	O
screening	JJ	O
questions	NNS	O
(	(	O
P	NNP	O
=	NNP	O
0.045	CD	O
)	)	O
,	,	O
physicians	NNS	O
'	POS	O
satisfaction	NN	O
about	IN	O
support	NN	O
given	VBN	O
(	(	O
P	NNP	O
=	NNP	O
0.004	CD	O
)	)	O
and	CC	O
with	IN	O
patients	NNS	O
'	POS	O
distress	NN	O
(	(	O
P	NNP	O
<	NNP	O
0.001	CD	O
)	)	O
.	.	O

An	DT	O
increase	NN	O
in	IN	O
anxiety	NN	O
was	VBD	O
linked	VBN	O
with	IN	O
breaking	VBG	O
bad	JJ	O
news	NN	O
(	(	O
P	NNP	O
=	NNP	O
0.050	CD	O
)	)	O
and	CC	O
with	IN	O
supportive	JJ	O
skills	NNS	O
(	(	O
P	NNP	O
=	NNP	O
0.013	CD	O
)	)	O
.	.	O

No	DT	O
impact	NN	O
of	IN	O
the	DT	O
training	NN	O
programme	NN	O
was	VBD	O
observed	VBN	O
.	.	O

CONCLUSIONS	VB	O
This	DT	O
study	NN	O
shows	VBZ	O
the	DT	O
influence	NN	O
of	IN	O
some	DT	O
communication	NN	O
skills	NNS	O
on	IN	O
the	DT	O
evolution	NN	O
of	IN	O
patients	NNS	O
'	POS	O
anxiety	NN	O
.	.	O

Physicians	NNS	O
should	MD	O
be	VB	O
aware	JJ	O
of	IN	O
these	DT	O
influences	NNS	O
.	.	O

Heart	NNP	O
rate	NN	O
variability	NN	O
and	CC	O
QT	NNP	O
dispersion	NN	O
in	IN	O
patients	NNS	O
with	IN	O
subclinical	JJ	C
hypothyroidism	NN	C
.	.	O

UNLABELLED	IN	O
The	DT	O
effect	NN	O
of	IN	O
subclinical	JJ	C
hypothyroidism	NN	C
(	(	O
SH	NNP	O
)	)	O
on	IN	O
cardiovascular	JJ	O
autonomic	JJ	O
function	NN	O
and	CC	O
ventricular	JJ	O
repolarization	NN	O
has	VBZ	O
not	RB	O
been	VBN	O
yet	RB	O
elucidated	VBN	O
.	.	O

The	DT	O
aim	NN	O
of	IN	O
the	DT	O
present	JJ	O
study	NN	O
was	VBD	O
to	TO	O
evaluate	VB	O
the	DT	O
dispersion	NN	O
of	IN	O
QT	NNP	O
interval	NN	O
,	,	O
i.e	NN	O
.	.	O

an	DT	O
index	NN	O
of	IN	O
inhomogeneity	NN	O
of	IN	O
repolarization	NN	O
,	,	O
and	CC	O
heart	NN	O
rate	NN	O
variability	NN	O
(	(	O
HRV	NNP	O
)	)	O
,	,	O
i.e	RB	O
.	.	O

a	DT	O
measure	NN	O
of	IN	O
cardiac	JJ	O
autonomic	JJ	O
modulation	NN	O
,	,	O
in	IN	O
SH	NNP	C
patients	NNS	O
.	.	O

METHODS	NNP	O
The	DT	O
study	NN	O
included	VBD	O
42	CD	C
patients	NNS	C
(	(	O
29	CD	C
women	NNS	C
and	CC	O
13	CD	C
men	NNS	C
;	:	O
mean	JJ	O
age	NN	O
53.2+/-14.2	JJ	A
years	NNS	O
;	:	O
body	NN	O
surface	JJ	O
area	NN	O
1.76+/-0.14	JJ	O
m2	NN	O
)	)	O
with	IN	O
SH	NNP	C
,	,	O
as	IN	O
judged	VBN	O
by	IN	O
elevated	JJ	O
serum	NN	O
TSH	NNP	O
levels	NNS	O
(	(	O
>	$	O
3.6	CD	O
mIU/l	NN	O
;	:	O
range	NN	O
,	,	O
3.8-12.0	JJ	O
)	)	O
and	CC	O
normal	JJ	O
free	JJ	O
thyroid	NN	O
hormones	NNS	O
(	(	O
FT4	NNP	O
and	CC	O
FT3	NNP	O
)	)	O
and	CC	O
30	CD	O
euthyroid	JJ	O
volunteer	NN	O
.	.	O

Subjects	NNS	O
with	IN	O
cardiac	JJ	C
,	,	C
metabolic	JJ	C
,	,	C
neurological	JJ	C
disease	NN	C
or	CC	O
any	DT	O
other	JJ	O
systemic	JJ	C
disease	NN	C
that	WDT	O
could	MD	O
affect	VB	O
autonomic	JJ	O
activity	NN	O
were	VBD	O
excluded	VBN	O
from	IN	O
the	DT	O
study	NN	O
.	.	O

Patients	NNS	O
with	IN	O
SH	NNP	C
and	CC	O
control	VB	O
subjects	NNS	O
underwent	VB	O
a	DT	O
full	JJ	O
history	NN	O
,	,	O
physical	JJ	O
examination	NN	O
,	,	O
standard	JJ	O
12-lead	JJ	O
ECG	NNP	O
,	,	O
and	CC	O
24-h	JJ	O
ambulatory	NN	O
ECG	NNP	O
monitoring	NN	O
.	.	O

To	TO	O
evaluate	VB	O
the	DT	O
effect	NN	O
of	IN	O
treatment	NN	O
with	IN	O
L-thyroxine	NNP	O
on	IN	O
QT	NNP	O
dispersion	NN	O
and	CC	O
HRV	NNP	O
,	,	O
15	CD	O
patients	NNS	O
with	IN	O
SH	NNP	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
receive	VB	O
therapy	NN	O
with	IN	O
L-thyroxine	NNP	O
.	.	O

All	PDT	O
the	DT	O
subjects	NNS	O
were	VBD	O
evaluated	VBN	O
at	IN	O
enrolment	NN	O
and	CC	O
after	IN	O
6	CD	O
months	NNS	O
.	.	O

RESULTS	NNP	O
Patients	NNPS	O
with	IN	O
SH	NNP	C
showed	VBD	O
higher	JJR	O
QT	NNP	O
dispersion	NN	O
and	CC	O
lower	JJR	O
HRV	NNP	O
measures	NNS	O
than	IN	O
healthy	JJ	O
controls	NNS	O
(	(	O
P	NNP	O
<	VBZ	O
0.01	CD	O
for	IN	O
all	DT	O
)	)	O
.	.	O

In	IN	O
SH	NNP	O
patients	NNS	O
,	,	O
the	DT	O
standard	JJ	O
deviation	NN	O
of	IN	O
N-Ns	NNP	O
(	(	O
SDNN	NNP	O
)	)	O
was	VBD	O
negatively	RB	O
related	VBN	O
to	TO	O
TSH	NNP	O
(	(	O
r=-0.42	JJ	O
,	,	O
P=0.006	NNP	O
)	)	O
,	,	O
while	IN	O
low	JJ	O
frequency	NN	O
(	(	O
LF	NNP	O
)	)	O
/high	VBP	O
frequency	NN	O
(	(	O
HF	NNP	O
)	)	O
ratio	NN	O
was	VBD	O
positively	RB	O
related	VBN	O
to	TO	O
TSH	NNP	O
(	(	O
r=0.42	NN	O
,	,	O
P=0.006	NNP	O
)	)	O
.	.	O

Moreover	RB	O
,	,	O
in	IN	O
SH	NNP	C
patients	NNS	O
both	DT	O
QT	NNP	O
dispersion	NN	O
and	CC	O
QTc	NNP	O
dispersion	NN	O
were	VBD	O
positively	RB	O
related	VBN	O
to	TO	O
TSH	NNP	O
(	(	O
r=0.64	NN	O
and	CC	O
r=0.63	NN	O
,	,	O
P	NNP	O
<	VBZ	O
0.001	CD	O
for	IN	O
both	DT	O
)	)	O
.	.	O

After	IN	O
6	CD	O
months	NNS	O
,	,	O
the	DT	O
patients	NNS	O
treated	VBN	O
with	IN	O
L-tiroxine	NNP	O
exhibited	VBD	O
a	DT	O
reduction	NN	O
of	IN	O
QT	NNP	O
dispersion	NN	O
and	CC	O
an	DT	O
increase	NN	O
of	IN	O
HRV	NNP	O
parameters	NNS	O
.	.	O

CONCLUSION	VB	O
The	DT	O
results	NNS	O
of	IN	O
the	DT	O
present	JJ	O
study	NN	O
demonstrated	VBD	O
that	IN	O
SH	NNP	O
can	MD	O
alter	VB	O
autonomic	JJ	O
modulation	NN	O
of	IN	O
heart	NN	O
rate	NN	O
and	CC	O
cause	NN	O
increased	VBD	O
inhomogeneity	NN	O
of	IN	O
ventricular	JJ	O
recovery	NN	O
times	NNS	O
.	.	O

Accordingly	RB	O
,	,	O
early	JJ	O
L-thyroxine	JJ	O
treatment	NN	O
may	MD	O
be	VB	O
advised	VBN	O
not	RB	O
only	RB	O
to	TO	O
prevent	VB	O
progression	NN	O
to	TO	O
overt	VB	O
hypothyroidism	NN	O
but	CC	O
also	RB	O
to	TO	O
improve	VB	O
abnormal	JJ	O
cardiac	JJ	O
autonomic	JJ	O
function	NN	O
and	CC	O
ventricular	JJ	O
repolarization	NN	O
inhomogeneity	NN	O
.	.	O

Randomized	VBN	O
controlled	VBD	O
trial	NN	O
to	TO	O
compare	VB	O
the	DT	O
dose	NN	O
of	IN	O
adjuvant	JJ	O
chemotherapy	NN	O
after	IN	O
curative	JJ	O
resection	NN	O
of	IN	O
hepatocellular	JJ	C
carcinoma	NN	C
.	.	O

BACKGROUND	NNP	O
AND	NNP	O
AIM	NNP	O
Adjuvant	NNP	O
locoregional	JJ	O
chemotherapy	NN	O
has	VBZ	O
been	VBN	O
shown	VBN	O
to	TO	O
be	VB	O
useful	JJ	O
to	TO	O
prevent	VB	O
recurrence	NN	O
after	IN	O
curative	JJ	O
resection	NN	O
of	IN	O
hepatocellular	JJ	O
carcinoma	NN	O
(	(	O
HCC	NNP	O
)	)	O
in	IN	O
some	DT	O
retrospective	JJ	O
studies	NNS	O
.	.	O

Our	PRP$	O
aim	NN	O
was	VBD	O
to	TO	O
compare	VB	O
the	DT	O
dose	JJ	O
effect	NN	O
in	IN	O
the	DT	O
prevention	NN	O
of	IN	O
tumor	NN	O
recurrence	NN	O
.	.	O

METHODS	NNP	O
A	NNP	O
prospective	JJ	O
randomized	VBN	O
controlled	JJ	O
trial	NN	O
was	VBD	O
conducted	VBN	O
in	IN	O
patients	NNS	O
with	IN	O
curative	JJ	O
resection	NN	O
of	IN	O
HCC	NNP	C
;	:	O
they	PRP	O
were	VBD	O
given	VBN	O
either	DT	O
one	CD	O
intra-arterial	JJ	O
dose	NN	O
of	IN	O
cisplatin/lipiodol	NN	O
,	,	O
or	CC	O
received	VBD	O
four	CD	O
doses	NNS	O
,	,	O
once	RB	O
every	DT	O
3	CD	O
months	NNS	O
.	.	O

The	DT	O
rates	NNS	O
of	IN	O
recurrence	NN	O
,	,	O
disease-free	JJ	O
and	CC	O
overall	JJ	O
survival	NN	O
were	VBD	O
compared	VBN	O
.	.	O

RESULTS	NNP	O
During	IN	O
a	DT	O
median	JJ	O
follow	NN	O
up	IN	O
of	IN	O
818	CD	O
days	NNS	O
,	,	O
21	CD	SS
patients	NNS	O
received	VBD	O
one	CD	O
dose	NN	O
and	CC	O
19	CD	SS
received	VBD	O
four	CD	O
doses	NNS	O
,	,	O
with	IN	O
10	CD	O
(	(	O
47.6	CD	O
%	NN	O
)	)	O
and	CC	O
eight	CD	O
(	(	O
42.1	CD	O
%	NN	O
)	)	O
recurrences	NNS	O
,	,	O
respectively	RB	O
.	.	O

The	DT	O
1-year	JJ	O
,	,	O
2-year	JJ	O
and	CC	O
3-year	JJ	O
disease-free	JJ	O
survival	NN	O
rates	NNS	O
were	VBD	O
71	CD	O
%	NN	O
,	,	O
54	CD	O
%	NN	O
and	CC	O
44	CD	O
%	NN	O
for	IN	O
the	DT	O
one-dose	JJ	O
group	NN	O
and	CC	O
74	CD	O
%	NN	O
,	,	O
60	CD	O
%	NN	O
and	CC	O
40	CD	O
%	NN	O
for	IN	O
the	DT	O
four-dose	JJ	O
group	NN	O
(	(	O
P	NNP	O
=	NNP	O
0.78	CD	O
)	)	O
.	.	O

The	DT	O
respective	JJ	O
overall	JJ	O
survival	NN	O
rates	NNS	O
were	VBD	O
85	CD	O
%	NN	O
,	,	O
74	CD	O
%	NN	O
,	,	O
55	CD	O
%	NN	O
and	CC	O
84	CD	O
%	NN	O
,	,	O
71	CD	O
%	NN	O
,	,	O
40	CD	O
%	NN	O
(	(	O
P	NNP	O
=	NNP	O
0.64	CD	O
)	)	O
.	.	O

The	DT	O
only	JJ	O
prognostic	JJ	O
factor	NN	O
was	VBD	O
presence	NN	O
of	IN	O
vascular	JJ	O
permeation	NN	O
.	.	O

The	DT	O
side-effects	NNS	O
were	VBD	O
mild	JJ	O
and	CC	O
tolerable	JJ	O
.	.	O

CONCLUSIONS	NNP	O
There	EX	O
is	VBZ	O
no	DT	O
significant	JJ	O
difference	NN	O
in	IN	O
the	DT	O
survival	NN	O
rates	NNS	O
between	IN	O
the	DT	O
two	CD	O
groups	NNS	O
.	.	O

Adjuvant	NNP	O
chemotherapy	NN	O
may	MD	O
not	RB	O
be	VB	O
useful	JJ	O
.	.	O

Pharmacokinetics	NNS	O
and	CC	O
pharmacodynamics	NNS	O
of	IN	O
six	CD	O
epoetin	JJ	O
alfa	NN	O
dosing	VBG	O
regimens	NNS	O
in	IN	O
anemic	JJ	O
critically	RB	O
ill	JJ	O
patients	NNS	O
without	IN	O
acute	JJ	O
blood	NN	O
loss	NN	O
.	.	O

OBJECTIVE	UH	O
To	TO	O
describe	VB	O
the	DT	O
pharmacokinetic	JJ	O
profiles	NNS	O
of	IN	O
six	CD	O
different	JJ	O
dosing	VBG	O
regimens	NNS	O
for	IN	O
epoetin	NN	O
alfa	NN	O
,	,	O
and	CC	O
whether	IN	O
more	JJR	O
rapid	JJ	O
and	CC	O
robust	JJ	O
reticulocytosis	NN	O
can	MD	O
be	VB	O
elicited	VBN	O
with	IN	O
more	RBR	O
frequent	JJ	O
administration	NN	O
of	IN	O
epoetin	JJ	O
alfa	NN	O
in	IN	O
anemic	JJ	O
critically	RB	O
ill	JJ	O
patients	NNS	O
.	.	O

DESIGN	NNP	O
Randomized	NNP	O
,	,	O
open-label	NN	O
,	,	O
multicenter	NN	O
,	,	O
28-day	JJ	O
clinical	JJ	O
trial	NN	O
.	.	O

SETTING	NN	O
Ten	CD	O
centers	NNS	O
in	IN	O
the	DT	O
United	NNP	O
States	NNPS	O
.	.	O

PATIENTS	VB	O
Adult	NNP	O
(	(	O
age	NN	O
>	VBN	O
or=18	CD	O
years	NNS	O
)	)	O
critically	RB	O
ill	JJ	O
patients	NNS	O
with	IN	O
hemoglobin	JJ	O
<	NNP	O
or=12	NN	O
g/dL	NN	O
,	,	O
expected	VBN	O
hospitalization	NN	O
of	IN	O
>	NNP	O
or=7	NNP	O
days	NNS	O
,	,	O
with	IN	O
no	DT	O
ongoing	VBG	O
acute	RB	O
blood	NN	O
loss	NN	O
.	.	O

INTERVENTIONS	NNP	O
One	CD	O
of	IN	O
six	CD	O
dosing	VBG	O
epoetin	NN	O
alfa	NN	O
regimens	VBZ	O
for	IN	O
15	CD	O
days	NNS	O
,	,	O
as	IN	O
follows	VBZ	O
:	:	O
40,000	CD	O
IU	NNP	O
once	RB	O
weekly	RB	O
,	,	O
subcutaneously	RB	O
(	(	O
group	NN	O
A	NNP	O
)	)	O
or	CC	O
intravenously	RB	O
(	(	O
IV	NNP	O
)	)	O
(	(	O
group	NN	O
B	NNP	O
)	)	O
;	:	O
15,000	CD	O
IU	NNP	O
every	DT	O
other	JJ	O
day	NN	O
,	,	O
subcutaneously	RB	O
(	(	O
group	NN	O
C	NNP	O
)	)	O
or	CC	O
IV	NNP	O
(	(	O
group	NN	O
D	NNP	O
)	)	O
;	:	O
or	CC	O
40,000	CD	O
IU	NNP	O
day	NN	O
1	CD	O
and	CC	O
3	CD	O
,	,	O
subcutaneously	RB	O
(	(	O
group	NN	O
E	NNP	O
)	)	O
or	CC	O
IV	NNP	O
(	(	O
group	NN	O
F	NNP	O
)	)	O
,	,	O
followed	VBN	O
by	IN	O
15,000	CD	O
IU	NNP	O
once	RB	O
every	DT	O
other	JJ	O
day	NN	O
on	IN	O
[	NN	O
corrected	VBN	O
]	JJ	O
days	NNS	O
5-15	JJ	O
[	NNP	O
corrected	VBD	O
]	NN	O
MEASUREMENTS	NNP	O
Serum	NNP	O
erythropoietin	NN	O
concentration	NN	O
,	,	O
absolute	JJ	O
reticulocyte	NN	O
count	NN	O
,	,	O
and	CC	O
adverse	JJ	O
events	NNS	O
.	.	O

MAIN	NNP	O
RESULTS	NNP	O
Of	IN	O
the	DT	O
60	CD	O
patients	NNS	O
who	WP	O
were	VBD	O
enrolled	VBN	O
(	(	O
60	CD	O
%	NN	O
men	NNS	O
,	,	O
mean	JJ	O
age	NN	O
53	CD	O
years	NNS	O
,	,	O
mean	VBP	O
Acute	NNP	O
Physiology	NNP	O
and	CC	O
Chronic	NNP	O
Health	NNP	O
Evaluation	NNP	O
II	NNP	O
score	NN	O
,	,	O
19.5	CD	O
)	)	O
,	,	O
30	CD	O
were	VBD	O
evaluable	JJ	O
for	IN	O
both	DT	O
pharmacokinetics	NNS	O
and	CC	O
pharmacodynamics	NNS	O
(	(	O
50	CD	O
%	NN	O
)	)	O
.	.	O

Erythropoietin	NNP	O
exposure	NN	O
was	VBD	O
approximately	RB	O
ten	JJ	O
times	NNS	O
greater	JJR	O
for	IN	O
IV	NNP	O
dosing	VBG	O
than	IN	O
for	IN	O
subcutaneous	JJ	O
dosing	NN	O
.	.	O

Mean	NNP	O
absolute	JJ	O
reticulocyte	NN	O
count	NN	O
peaked	VBD	O
at	IN	O
day	NN	O
11	CD	O
or	CC	O
15	CD	O
in	IN	O
each	DT	O
group	NN	O
and	CC	O
appeared	VBD	O
to	TO	O
be	VB	O
greater	JJR	O
for	IN	O
subcutaneous	JJ	O
dosing	NN	O
(	(	O
mean	JJ	O
peak	NN	O
response	NN	O
149-169	JJ	O
x	NN	O
10	CD	O
(	(	O
9	CD	O
)	)	O
/L	NN	O
)	)	O
compared	VBN	O
with	IN	O
IV	NNP	O
dosing	VBG	O
(	(	O
mean	JJ	O
peak	NN	O
response	NN	O
138-147	JJ	O
x	NN	O
10	CD	O
(	(	O
9	CD	O
)	)	O
/L	NN	O
)	)	O
at	IN	O
most	JJS	O
visits	NNS	O
.	.	O

The	DT	O
most	RBS	O
frequently	RB	O
reported	VBD	O
adverse	JJ	O
events	NNS	O
were	VBD	O
pyrexia	NNS	O
(	(	O
18	CD	O
%	NN	O
)	)	O
,	,	O
hypokalemia	NN	O
(	(	O
15	CD	O
%	NN	O
)	)	O
,	,	O
and	CC	O
hypophosphatemia	NN	O
(	(	O
15	CD	O
%	NN	O
)	)	O
.	.	O

CONCLUSIONS	NNP	O
In	IN	O
this	DT	O
study	NN	O
of	IN	O
anemic	JJ	O
critically	NN	O
ill	JJ	O
patients	NNS	O
treated	VBN	O
with	IN	O
epoetin	JJ	O
alfa	NN	O
,	,	O
all	DT	O
dosing	VBG	O
regimens	NNS	O
were	VBD	O
well	RB	O
tolerated	VBN	O
and	CC	O
appeared	VBN	O
to	TO	O
effect	NN	O
reticulocytosis	NN	O
,	,	O
with	IN	O
a	DT	O
peak	NN	O
at	IN	O
day	NN	O
11	CD	O
or	CC	O
15	CD	O
in	IN	O
most	JJS	O
patients	NNS	O
.	.	O

The	DT	O
pharmacokinetics	NNS	O
of	IN	O
epoetin	JJ	O
alfa	NN	O
did	VBD	O
not	RB	O
predict	VB	O
pharmacodynamic	JJ	O
response	NN	O
in	IN	O
anemic	JJ	O
critically	RB	O
ill	JJ	O
patients	NNS	O
.	.	O

Effectiveness	NN	O
of	IN	O
web-based	JJ	O
tailored	JJ	O
smoking	NN	C
cessation	NN	C
advice	NN	O
reports	NNS	O
(	(	O
iQuit	NN	O
)	)	O
:	:	O
a	DT	O
randomized	JJ	O
trial	NN	O
.	.	O

AIMS	NNP	O
To	TO	O
determine	VB	O
whether	IN	O
web-based	JJ	O
tailored	JJ	O
cessation	NN	O
advice	NN	O
,	,	O
based	VBN	O
on	IN	O
social	JJ	O
cognitive	JJ	O
theory	NN	O
and	CC	O
the	DT	O
perspectives	NNS	O
on	IN	O
change	NN	O
model	NN	O
,	,	O
was	VBD	O
more	RBR	O
effective	JJ	O
in	IN	O
aiding	VBG	O
a	DT	O
quit	NN	O
attempt	NN	O
than	IN	O
broadly	RB	O
similar	JJ	O
web-based	JJ	O
advice	NN	O
that	WDT	O
was	VBD	O
not	RB	O
tailored	VBN	O
.	.	O

DESIGN	JJ	O
Participants	NNS	O
were	VBD	O
allocated	VBN	O
randomly	RB	O
to	TO	O
one	CD	O
of	IN	O
two	CD	O
groups	NNS	O
,	,	O
to	TO	O
receive	VB	O
either	CC	O
a	DT	O
cessation	NN	O
advice	NN	O
report	NN	O
and	CC	O
progress	JJ	O
report	NN	O
that	WDT	O
were	VBD	O
tailored	VBN	O
to	TO	O
individual-level	JJ	O
characteristics	NNS	O
or	CC	O
a	DT	O
cessation	NN	O
advice	NN	O
report	NN	O
that	WDT	O
presented	VBD	O
standardized	JJ	O
(	(	O
non-tailored	JJ	O
)	)	O
content	NN	O
.	.	O

Tailoring	NNP	O
was	VBD	O
based	VBN	O
on	IN	O
smoking-related	JJ	O
beliefs	NN	O
,	,	O
personal	JJ	O
characteristics	NNS	O
and	CC	O
smoking	NN	O
patterns	NNS	O
,	,	O
self-efficacy	NN	O
and	CC	O
outcome	JJ	O
expectations	NNS	O
.	.	O

SETTING	NN	O
Participant	JJ	O
enrolment	NN	O
and	CC	O
baseline	NN	O
assessments	NNS	O
were	VBD	O
conducted	VBN	O
remotely	RB	O
online	JJ	O
via	IN	O
the	DT	O
study	NN	O
website	NN	O
,	,	O
with	IN	O
the	DT	O
advice	NN	O
reports	NNS	O
presented	VBN	O
by	IN	O
the	DT	O
same	JJ	O
website	NN	O
.	.	O

PARTICIPANTS	JJ	O
Participants	NNS	O
(	(	O
n	IN	O
=	NNP	O
1758	CD	O
)	)	O
were	VBD	O
visitors	NNS	O
to	TO	O
the	DT	O
QUIT	NNP	O
website	NN	O
who	WP	O
were	VBD	O
based	VBN	O
in	IN	O
the	DT	O
United	NNP	O
Kingdom	NNP	O
,	,	O
aged	VBD	O
18	CD	A
years	NNS	A
or	CC	A
over	RB	A
and	CC	O
who	WP	O
smoked	VBD	O
cigarettes	NNS	O
or	CC	O
hand-rolled	JJ	O
tobacco	NN	O
.	.	O

MEASUREMENTS	NNP	O
Follow-up	JJ	O
assessments	NNS	O
were	VBD	O
made	VBN	O
at	IN	O
6	CD	O
months	NNS	O
by	IN	O
telephone	NN	O
interview	NN	O
.	.	O

The	DT	O
primary	JJ	O
outcome	NN	O
measure	NN	O
was	VBD	O
self-reported	JJ	O
3	CD	O
months	NNS	O
prolonged	VBN	O
abstinence	NN	O
,	,	O
and	CC	O
secondary	JJ	O
outcomes	NNS	O
were	VBD	O
1	CD	O
month	NN	O
prolonged	VBD	O
abstinence	NN	O
,	,	O
7-day	JJ	O
and	CC	O
24-hour	JJ	O
point	NN	O
prevalence	NN	O
abstinence	NN	O
.	.	O

FINDINGS	IN	O
The	DT	O
intervention	NN	O
group	NN	O
did	VBD	O
not	RB	O
differ	VB	O
from	IN	O
the	DT	O
control	NN	O
group	NN	O
on	IN	O
the	DT	O
primary	JJ	O
outcome	NN	O
(	(	O
9.1	CD	O
%	NN	O
versus	IN	O
9.3	CD	O
%	NN	O
;	:	O
odds	NNS	O
ratio	VBP	O
=	$	O
1.02	CD	O
95	CD	O
%	NN	O
confidence	NN	O
interval	JJ	O
0.73-1.42	NN	O
)	)	O
or	CC	O
on	IN	O
any	DT	O
of	IN	O
the	DT	O
secondary	JJ	O
outcomes	NNS	O
.	.	O

Intervention	NN	O
participants	NNS	O
gave	VBD	O
more	RBR	O
positive	JJ	O
evaluations	NNS	O
of	IN	O
the	DT	O
materials	NNS	O
than	IN	O
control	NN	O
participants	NNS	O
.	.	O

CONCLUSIONS	VB	O
A	DT	O
web-based	JJ	O
intervention	NN	O
that	WDT	O
tailored	VBD	O
content	JJ	O
according	VBG	O
to	TO	O
smoking-related	JJ	O
beliefs	NN	O
,	,	O
personal	JJ	O
characteristics	NNS	O
and	CC	O
smoking	NN	O
patterns	NNS	O
,	,	O
self-efficacy	NN	O
and	CC	O
outcome	NN	O
expectations	NNS	O
,	,	O
was	VBD	O
not	RB	O
more	RBR	O
effective	JJ	O
than	IN	O
web-based	JJ	O
materials	NNS	O
presenting	VBG	O
broadly	RB	O
similar	JJ	O
non-tailored	JJ	O
information	NN	O
.	.	O

Why	WRB	O
are	VBP	O
there	RB	O
sometimes	RB	O
concreteness	JJ	O
effects	NNS	O
in	IN	O
memory	NN	C
for	IN	O
prose	NN	O
?	.	O
Four	CD	SS
experiments	NNS	O
explored	VBD	O
on-line	JJ	O
encoding	NN	O
strategies	NNS	O
and	CC	O
memory	NN	C
for	IN	O
high	JJ	C
imagery	NN	C
and	CC	O
low	JJ	C
imagery	NN	C
texts	NN	O
.	.	O

Results	NNP	O
consistently	RB	O
indicated	VBD	O
that	IN	O
concreteness	NN	O
effects	NNS	O
in	IN	O
memory	NN	O
for	IN	O
text	JJ	O
depend	NN	O
on	IN	O
how	WRB	O
materials	NNS	O
are	VBP	O
presented	VBN	O
in	IN	O
several	JJ	O
different	JJ	O
respects	NNS	O
.	.	O

Most	JJS	O
importantly	RB	O
,	,	O
the	DT	O
experiments	NNS	O
clarified	VBD	O
apparently	RB	O
contradictory	JJ	O
results	NNS	O
of	IN	O
previous	JJ	O
studies	NNS	O
by	IN	O
indicating	VBG	O
that	IN	O
concreteness	NN	O
effects	NNS	O
generally	RB	O
do	VBP	O
not	RB	O
occur	VB	O
in	IN	O
memory	NN	O
for	IN	O
prose	NN	O
when	WRB	O
imageability	NN	O
is	VBZ	O
manipulated	VBN	O
between-subjects	NNS	O
,	,	O
and	CC	O
that	IN	O
their	PRP$	O
occurrence	NN	O
when	WRB	O
imageability	NN	O
is	VBZ	O
manipulated	VBN	O
within-subjects	NNS	O
depends	NNS	O
on	IN	O
the	DT	O
order	NN	O
occurrence	NN	O
when	WRB	O
imageability	NN	O
is	VBZ	O
manipulated	VBN	O
within-subjects	NNS	O
depends	NNS	O
on	IN	O
the	DT	O
order	NN	O
of	IN	O
presentation	NN	O
.	.	O

In	IN	O
addition	NN	O
,	,	O
moving	VBG	O
window	JJ	O
analyses	NNS	O
of	IN	O
text	JJ	O
processing	NN	O
strategies	NNS	O
indicated	VBD	O
that	IN	O
differential	JJ	O
strategies	NNS	O
observed	VBN	O
in	IN	O
previous	JJ	O
studies	NNS	O
when	WRB	O
subjects	NNS	O
listened	VBD	O
to	TO	O
high	JJ	O
vs	NN	O
low	JJ	O
imagery	NN	O
text	NN	O
do	VBP	O
not	RB	O
generalize	VB	O
to	TO	O
reading	NN	O
of	IN	O
the	DT	O
same	JJ	O
materials	NNS	O
.	.	O

Potential	JJ	O
explanations	NNS	O
for	IN	O
the	DT	O
pattern	NN	O
of	IN	O
results	NNS	O
are	VBP	O
evaluated	VBN	O
,	,	O
and	CC	O
implications	NNS	O
for	IN	O
theories	NNS	O
of	IN	O
mental	JJ	O
imagery	NN	O
and	CC	O
memory	NN	O
are	VBP	O
considered	VBN	O
.	.	O

Determinants	NNS	O
of	IN	O
exclusive	JJ	O
breastfeeding	NN	O
in	IN	O
an	DT	O
urban	JJ	O
population	NN	O
of	IN	O
primiparas	NNS	O
in	IN	O
Lebanon	NNP	O
:	:	O
a	DT	O
cross-sectional	JJ	O
study	NN	O
.	.	O

BACKGROUND	NNP	O
The	DT	O
proportion	NN	O
of	IN	O
mothers	NNS	O
who	WP	O
exclusively	RB	O
breastfeed	VBP	O
their	PRP$	O
babies	NNS	O
up	IN	O
to	TO	O
6	CD	O
months	NNS	O
remains	VBZ	O
low	JJ	O
.	.	O

Determinants	NNS	O
of	IN	O
breastfeeding	VBG	O
practices	NNS	O
have	VBP	O
been	VBN	O
largely	RB	O
documented	VBN	O
in	IN	O
high-income	JJ	O
countries	NNS	O
.	.	O

Little	JJ	O
evidence	NN	O
exists	NNS	O
on	IN	O
possible	JJ	O
predictors	NNS	O
of	IN	O
breastfeeding	VBG	O
behaviors	NNS	O
in	IN	O
the	DT	O
Middle	NNP	O
East	NNP	O
.	.	O

Our	PRP$	O
aim	NN	O
was	VBD	O
to	TO	O
assess	VB	O
the	DT	O
prevalence	NN	O
of	IN	O
breastfeeding	VBG	O
in	IN	O
Beirut	NNP	O
and	CC	O
determine	VB	O
the	DT	O
factors	NNS	O
that	WDT	O
impact	VBP	O
breastfeeding	VBG	O
behavior	NN	O
in	IN	O
this	DT	O
population	NN	O
.	.	O

METHODS	NNP	O
Data	NNP	O
for	IN	O
this	DT	O
longitudinal	JJ	O
study	NN	O
is	VBZ	O
nested	VBN	O
within	IN	O
a	DT	O
randomized	VBN	O
controlled	VBN	O
trial	NN	O
(	(	O
RCT	NNP	O
)	)	O
assessing	VBG	O
the	DT	O
impact	NN	O
of	IN	O
a	DT	O
24-hour	JJ	O
hotline	NN	O
and	CC	O
postpartum	NN	O
support	NN	O
film	NN	O
on	IN	O
postpartum	NN	O
stress	NN	O
.	.	O

Healthy	JJ	O
first-time	JJ	O
mothers	NNS	O
delivering	VBG	O
in	IN	O
the	DT	O
capital	NN	O
Beirut	NNP	O
between	IN	O
March	NNP	O
and	CC	O
July	NNP	O
2009	CD	O
,	,	O
were	VBD	O
interviewed	VBN	O
at	IN	O
1-3	JJ	O
days	NNS	O
and	CC	O
8-12	JJ	O
weeks	NNS	O
post	NN	O
delivery	NN	O
.	.	O

A	DT	O
multiple	JJ	O
logistic	JJ	O
regression	NN	O
analysis	NN	O
was	VBD	O
used	VBN	O
to	TO	O
determine	VB	O
the	DT	O
factors	NNS	O
associated	VBN	O
with	IN	O
exclusive	JJ	O
breastfeeding	NN	O
at	IN	O
8-12	JJ	O
weeks	NNS	O
postpartum	NN	O
.	.	O

RESULTS	VB	O
The	DT	O
overall	JJ	O
breastfeeding	NN	O
rate	NN	O
at	IN	O
8-12	JJ	O
weeks	NNS	O
postpartum	NN	O
was	VBD	O
67	CD	O
%	NN	O
.	.	O

The	DT	O
exclusive	JJ	O
breastfeeding	NN	O
rate	NN	O
was	VBD	O
27.4	CD	O
%	NN	O
.	.	O

Factors	NNS	O
associated	VBD	O
with	IN	O
exclusive	JJ	O
breastfeeding	NN	O
included	VBD	O
maternal	JJ	O
work	NN	O
(	(	O
OR=3.92	NNP	O
;	:	O
p-value	JJ	O
<	NNP	O
0.001	CD	O
)	)	O
,	,	O
planned	VBN	O
pregnancy	NN	O
(	(	O
OR=2.42	NNP	O
,	,	O
p-value=0.010	NN	O
)	)	O
,	,	O
intention	NN	O
to	TO	O
breastfeed	VB	O
(	(	O
OR=3.28	NNP	O
;	:	O
p-value=0.043	NN	O
)	)	O
,	,	O
source	NN	O
of	IN	O
maternal	JJ	O
emotional	JJ	O
support	NN	O
(	(	O
OR=1.87	NNP	O
,	,	O
p-value=0.039	NN	O
)	)	O
and	CC	O
the	DT	O
use	NN	O
the	DT	O
postpartum	NN	O
support	NN	O
video	NN	O
,	,	O
the	DT	O
hotline	NN	O
service	NN	O
or	CC	O
both	DT	O
(	(	O
OR=2.55	NNP	O
,	,	O
p-value=0.044	NN	O
;	:	O
OR=3.87	NNP	O
,	,	O
p-value=0.004	NN	O
and	CC	O
OR=4.13	NNP	O
,	,	O
p-value=0.003	NN	O
)	)	O
.	.	O

CONCLUSIONS	VB	O
The	DT	O
proportion	NN	O
of	IN	O
healthy	JJ	O
first-time	JJ	O
mothers	NNS	O
who	WP	O
exclusively	RB	O
breastfeed	VBP	O
in	IN	O
Beirut	NNP	O
is	VBZ	O
extremely	RB	O
low	JJ	O
.	.	O

Factors	NNS	O
associated	VBD	O
with	IN	O
breastfeeding	NN	O
behavior	NN	O
are	VBP	O
diverse	JJ	O
.	.	O

Future	JJ	O
research	NN	O
and	CC	O
interventions	NNS	O
should	MD	O
target	VB	O
different	JJ	O
levels	NNS	O
of	IN	O
the	DT	O
maternal-child	JJ	O
pair	NN	O
's	POS	O
ecosystem	NN	O
.	.	O

TRIAL	NNP	O
REGISTRATION	NNP	O
ClinicalTrials.gov	NNP	O
,	,	O
NCT00857051	NNP	O
.	.	O

Results	NNS	O
of	IN	O
a	DT	O
prospective	JJ	O
randomized	VBN	O
study	NN	O
of	IN	O
hepatic	JJ	O
artery	NN	O
infusion	NN	O
with	IN	O
5-fluorouracil	JJ	O
versus	NN	O
intravenous	JJ	O
5-fluorouracil	JJ	O
in	IN	O
patients	NNS	O
with	IN	O
hepatic	JJ	C
metastases	NNS	C
from	IN	O
colorectal	JJ	O
cancer	NN	C
:	:	O
A	DT	O
Central	NNP	O
Oncology	NNP	O
Group	NNP	O
study	NN	O
.	.	O

In	IN	O
a	DT	O
controlled	VBN	O
,	,	O
prospectively	RB	O
randomized	VBN	O
trial	NN	O
,	,	O
74	CD	SS
patients	NNS	O
with	IN	O
hepatic	JJ	O
metastases	NNS	O
from	IN	O
colorectal	JJ	O
cancer	NN	O
were	VBD	O
randomized	VBN	O
to	TO	O
either	DT	O
intra-arterial	JJ	O
hepatic	JJ	O
artery	NN	O
infusion	NN	O
with	IN	O
5-fluorouracil	JJ	O
(	(	O
5-FU	JJ	O
)	)	O
or	CC	O
systemic	JJ	O
chemotherapy	NN	O
with	IN	O
5-FU	JJ	O
.	.	O

In	IN	O
61	CD	O
acceptable	JJ	O
patients	NNS	O
,	,	O
there	EX	O
was	VBD	O
no	DT	O
significant	JJ	O
difference	NN	O
in	IN	O
terms	NNS	O
of	IN	O
response	NN	O
rate	NN	O
,	,	O
time	NN	O
to	TO	O
progression	NN	O
,	,	O
duration	NN	O
of	IN	O
the	DT	O
response	NN	O
,	,	O
and	CC	O
survival	JJ	O
rate	NN	O
.	.	O

Though	IN	O
the	DT	O
response	NN	O
rate	NN	O
for	IN	O
the	DT	O
intra-arterial	JJ	O
infusion	NN	O
arm	NN	O
was	VBD	O
slightly	RB	O
higher	JJR	O
than	IN	O
for	IN	O
the	DT	O
systemic	JJ	O
arm	NN	O
,	,	O
the	DT	O
difference	NN	O
was	VBD	O
not	RB	O
significant	JJ	O
,	,	O
and	CC	O
the	DT	O
intra-arterial	JJ	O
infusion	NN	O
arm	NN	O
was	VBD	O
associated	VBN	O
with	IN	O
a	DT	O
greater	JJR	O
incidence	NN	O
of	IN	O
nausea	NN	O
,	,	O
vomiting	VBG	O
,	,	O
diarrhea	NN	O
,	,	O
in	IN	O
addition	NN	O
to	TO	O
complications	NNS	O
of	IN	O
femoral-arterial	JJ	O
thrombosis	NN	O
,	,	O
bleeding	NN	O
,	,	O
and	CC	O
infection	NN	O
at	IN	O
the	DT	O
catheter	NN	O
site	NN	O
not	RB	O
seen	VBN	O
in	IN	O
patients	NNS	O
treated	VBN	O
by	IN	O
systemic	JJ	O
chemotherapy	NN	O
.	.	O

Patients	NNS	O
with	IN	O
an	DT	O
objective	JJ	O
response	NN	O
to	TO	O
chemotherapy	VB	O
on	IN	O
either	DT	O
treatment	NN	O
arm	NN	O
survived	VBD	O
twice	RB	O
as	RB	O
long	RB	O
as	IN	O
the	DT	O
nonresponders	NNS	O
.	.	O

Long-term	JJ	O
survival	NN	O
in	IN	O
one	CD	O
patient	NN	O
,	,	O
77	CD	O
months	NNS	O
,	,	O
can	MD	O
occasionally	RB	O
be	VB	O
achieved	VBN	O
in	IN	O
patients	NNS	O
with	IN	O
hepatic	JJ	O
metastases	NNS	O
.	.	O

Immunologic	NNP	O
profiles	NNS	O
of	IN	O
persons	NNS	O
recruited	VBN	O
for	IN	O
a	DT	O
randomized	JJ	O
,	,	O
placebo-controlled	JJ	O
clinical	JJ	O
trial	NN	O
of	IN	O
hookworm	NN	O
infection	NN	O
.	.	O

Data	NNS	O
from	IN	O
epidemiologic	JJ	O
studies	NNS	O
suggest	VBP	O
that	IN	O
hookworm	NN	O
infections	NNS	O
,	,	O
in	IN	O
establishing	VBG	O
an	DT	O
immunologic	JJ	O
phenotype	NN	O
conducive	NN	O
to	TO	O
parasite	VB	O
survival	NN	O
,	,	O
may	MD	O
protect	VB	O
against	IN	O
the	DT	O
development	NN	O
of	IN	O
allergic	JJ	O
disease	NN	O
.	.	O

We	PRP	O
describe	VBP	O
immunologic	JJ	O
findings	NNS	O
from	IN	O
a	DT	O
clinical	JJ	O
study	NN	O
designed	VBN	O
to	TO	O
investigate	VB	O
the	DT	O
safety	NN	O
of	IN	O
iatrogenic	JJ	O
hookworm	NN	O
infection	NN	O
in	IN	O
participants	NNS	O
with	IN	O
allergic	JJ	O
rhinitis	NN	O
.	.	O

The	DT	O
low	JJ	O
,	,	O
relatively	RB	O
safe	JJ	O
level	NN	O
of	IN	O
hookworm	NN	O
infection	NN	O
used	VBN	O
in	IN	O
this	DT	O
study	NN	O
was	VBD	O
immunogenic	JJ	O
,	,	O
inducing	VBG	O
eosinophilia	NNS	O
and	CC	O
a	DT	O
significant	JJ	O
specific	JJ	O
IgG	NNP	O
response	NN	O
.	.	O

Importantly	RB	O
,	,	O
no	DT	O
potentiation	NN	O
of	IN	O
IgE	NNP	O
responses	NNS	O
to	TO	O
the	DT	O
environmental	JJ	O
allergens	NNS	O
to	TO	O
which	WDT	O
the	DT	O
participants	NNS	O
were	VBD	O
sensitized	VBN	O
was	VBD	O
seen	VBN	O
.	.	O

However	RB	O
,	,	O
no	DT	O
evidence	NN	O
of	IN	O
systemic	JJ	O
immune	JJ	O
regulation	NN	O
was	VBD	O
seen	VBN	O
in	IN	O
infected	JJ	O
participants	NNS	O
.	.	O

This	DT	O
finding	NN	O
may	MD	O
indicate	VB	O
that	IN	O
the	DT	O
level	NN	O
of	IN	O
infection	NN	O
or	CC	O
the	DT	O
frequency	NN	O
of	IN	O
infection	NN	O
may	MD	O
have	VB	O
to	TO	O
be	VB	O
altered	VBN	O
in	IN	O
future	JJ	O
trials	NNS	O
to	TO	O
induce	VB	O
a	DT	O
therapeutically	RB	O
conducive	JJ	O
immunologic	NN	O
phenotype	NN	O
.	.	O

The	DT	O
A-V	NNP	O
Impulse	NNP	O
System	NNP	O
reduces	VBZ	O
deep-vein	JJ	C
thrombosis	NN	C
and	CC	O
swelling	NN	O
after	IN	O
hemiarthroplasty	NN	C
for	IN	C
hip	NN	C
fracture	NN	C
.	.	O

We	PRP	O
performed	VBD	O
a	DT	O
prospective	JJ	O
randomised	VBN	O
controlled	JJ	O
trial	NN	O
of	IN	O
the	DT	O
A-V	NNP	O
Impulse	NNP	O
System	NNP	O
in	IN	O
82	CD	SS
patients	NNS	O
treated	VBN	C
by	IN	C
hemiarthroplasty	NN	C
for	IN	C
subcapital	JJ	C
fracture	NN	C
of	IN	C
the	DT	C
femoral	JJ	C
neck	NN	C
.	.	O

The	DT	O
incidence	NN	O
of	IN	O
proximal	JJ	O
deep-vein	JJ	O
thrombosis	NN	O
as	IN	O
assessed	VBN	O
by	IN	O
Doppler	NNP	O
ultrasonography	NN	O
was	VBD	O
23	CD	O
%	NN	O
in	IN	O
the	DT	O
control	NN	O
group	NN	O
and	CC	O
0	CD	O
%	NN	O
in	IN	O
those	DT	O
using	VBG	O
the	DT	O
device	NN	O
(	(	O
p	NN	O
less	JJR	O
than	IN	O
0.01	CD	O
)	)	O
.	.	O

Calf	NNP	O
and	CC	O
thigh	JJ	O
circumferences	NNS	O
were	VBD	O
measured	VBN	O
in	IN	O
both	DT	O
groups	NNS	O
at	IN	O
seven	CD	O
to	TO	O
ten	VB	O
days	NNS	O
after	IN	O
operation	NN	O
.	.	O

In	IN	O
the	DT	O
treatment	NN	O
group	NN	O
there	EX	O
was	VBD	O
a	DT	O
mean	JJ	O
relative	JJ	O
reduction	NN	O
of	IN	O
postoperative	JJ	O
swelling	NN	O
of	IN	O
the	DT	O
thigh	NN	O
by	IN	O
3.27	CD	O
cm	NN	O
(	(	O
p	NN	O
less	JJR	O
than	IN	O
0.001	CD	O
)	)	O
and	CC	O
of	IN	O
the	DT	O
calf	NN	O
by	IN	O
1.55	CD	O
cm	NN	O
(	(	O
p	NN	O
less	JJR	O
than	IN	O
0.001	CD	O
)	)	O
.	.	O

The	DT	O
A-V	NNP	O
Impulse	NNP	O
System	NNP	O
appears	VBZ	O
to	TO	O
be	VB	O
a	DT	O
safe	JJ	O
and	CC	O
effective	JJ	O
method	NN	O
of	IN	O
reducing	VBG	O
the	DT	O
incidence	NN	O
of	IN	O
proximal	JJ	O
deep-vein	JJ	O
thrombosis	NN	O
,	,	O
and	CC	O
of	IN	O
postoperative	JJ	O
swelling	NN	O
.	.	O

Combining	VBG	O
weight-loss	JJ	O
counseling	NN	O
with	IN	O
the	DT	O
weight	NN	O
watchers	NNS	O
plan	VBP	O
for	IN	O
obese	JJ	O
breast	NN	O
cancer	NN	O
survivors	NNS	O
.	.	O

OBJECTIVE	IN	O
The	DT	O
objective	NN	O
was	VBD	O
to	TO	O
develop	VB	O
effective	JJ	O
weight-loss	JJ	O
methods	NNS	O
for	IN	O
women	NNS	O
who	WP	O
have	VBP	O
had	VBN	O
breast	VBN	O
cancer	NN	O
,	,	O
because	IN	O
obesity	NN	O
may	MD	O
result	VB	O
in	IN	O
an	DT	O
adverse	JJ	O
prognosis	NN	O
.	.	O

RESEARCH	NNP	O
METHODS	NNP	O
AND	NNP	O
PROCEDURES	NNP	O
This	DT	O
randomized	VBN	O
pilot	NN	O
study	NN	O
tested	VBD	O
an	DT	O
individualized	JJ	O
approach	NN	O
toward	IN	O
weight	JJ	O
loss	NN	O
in	IN	O
obese	JJ	O
women	NNS	O
who	WP	O
have	VBP	O
had	VBD	O
a	DT	O
diagnosis	NN	O
of	IN	O
breast	NN	O
cancer	NN	O
.	.	O

An	DT	O
individualized	JJ	O
approach	NN	O
was	VBD	O
applied	VBN	O
either	CC	O
alone	RB	O
or	CC	O
combined	VBN	O
with	IN	O
the	DT	O
commercial	JJ	O
Weight	NNP	O
Watchers	NNP	O
program	NN	O
.	.	O

Forty-eight	JJ	O
women	NNS	O
(	(	O
body	NN	O
mass	NN	O
index	NN	O
of	IN	O
30	CD	O
to	TO	O
44	CD	O
kg/m	NNS	O
(	(	O
2	CD	O
)	)	O
)	)	O
were	VBD	O
enrolled	VBN	O
.	.	O

RESULTS	NNP	O
Weight	NNP	O
change	NN	O
after	IN	O
12	CD	O
months	NNS	O
of	IN	O
intervention	NN	O
was	VBD	O
as	IN	O
follows	VBZ	O
(	(	O
mean	JJ	O
+/-	NNP	O
SD	NNP	O
)	)	O
:	:	O
0.85	CD	O
+/-	JJ	O
6.0	CD	O
kg	NN	O
in	IN	O
the	DT	O
control	NN	O
group	NN	O
,	,	O
-2.6	VBZ	O
+/-	JJ	O
5.9	CD	O
kg	NN	O
in	IN	O
the	DT	O
Weight	NNP	O
Watchers	NNP	O
group	NN	O
,	,	O
-8.0	VBZ	O
+/-	JJ	O
5.5	CD	O
kg	NN	O
in	IN	O
the	DT	O
individualized	JJ	O
group	NN	O
,	,	O
and	CC	O
-9.4	VBD	O
+/-	JJ	O
8.6	CD	O
kg	NN	O
in	IN	O
the	DT	O
comprehensive	JJ	O
group	NN	O
that	WDT	O
used	VBD	O
both	DT	O
individualized	JJ	O
counseling	NN	O
and	CC	O
Weight	NNP	O
Watchers	NNP	O
.	.	O

Weight	NNP	O
loss	NN	O
relative	NN	O
to	TO	O
control	VB	O
was	VBD	O
statistically	RB	O
significant	JJ	O
in	IN	O
the	DT	O
comprehensive	JJ	O
group	NN	O
3	CD	O
,	,	O
6	CD	O
,	,	O
and	CC	O
12	CD	O
months	NNS	O
after	IN	O
randomization	NN	O
,	,	O
whereas	JJ	O
weight	NN	O
loss	NN	O
in	IN	O
the	DT	O
individualized	JJ	O
group	NN	O
was	VBD	O
significant	JJ	O
only	RB	O
at	IN	O
12	CD	O
months	NNS	O
.	.	O

Weight	NNP	O
loss	NN	O
of	IN	O
10	CD	O
%	NN	O
or	CC	O
more	JJR	O
of	IN	O
initial	JJ	O
body	NN	O
weight	NN	O
was	VBD	O
observed	VBN	O
in	IN	O
6	CD	O
of	IN	O
10	CD	O
women	NNS	O
in	IN	O
the	DT	O
comprehensive	JJ	O
group	NN	O
at	IN	O
12	CD	O
months	NNS	O
.	.	O

In	IN	O
the	DT	O
comprehensive	JJ	O
and	CC	O
Weight	NNP	O
Watchers-only	NNP	O
groups	NNS	O
,	,	O
weight	JJ	O
loss	NN	O
was	VBD	O
significantly	RB	O
related	VBN	O
to	TO	O
frequency	NN	O
of	IN	O
attendance	NN	O
at	IN	O
Weight	NNP	O
Watchers	NNP	O
meetings	NNS	O
,	,	O
and	CC	O
attendance	NN	O
was	VBD	O
more	RBR	O
frequent	JJ	O
in	IN	O
the	DT	O
comprehensive	JJ	O
group	NN	O
.	.	O

DISCUSSION	NNP	O
These	DT	O
data	NNS	O
indicate	VBP	O
that	IN	O
the	DT	O
most	RBS	O
weight	JJ	O
loss	NN	O
was	VBD	O
achieved	VBN	O
when	WRB	O
the	DT	O
counseling	NN	O
approach	NN	O
combined	VBD	O
both	DT	O
Weight	NNP	O
Watchers	NNPS	O
and	CC	O
individualized	JJ	O
contacts	NNS	O
.	.	O

This	DT	O
was	VBD	O
effective	JJ	O
even	RB	O
though	IN	O
most	JJS	O
of	IN	O
the	DT	O
individualized	JJ	O
contacts	NNS	O
were	VBD	O
by	IN	O
telephone	NN	O
.	.	O

Zinc	NNP	O
and	CC	O
copper	NN	O
balances	NNS	O
in	IN	O
preterm	JJ	C
infants	NNS	A
.	.	O

Preterm	NNP	C
infants	NNS	A
are	VBP	O
at	IN	O
risk	NN	O
for	IN	O
copper	NN	O
and	CC	O
zinc	NN	O
depletion	NN	O
if	IN	O
sufficient	JJ	O
quantities	NNS	O
of	IN	O
these	DT	O
nutrients	NNS	O
are	VBP	O
not	RB	O
provided	VBN	O
in	IN	O
a	DT	O
bioavailable	JJ	O
form	NN	O
in	IN	O
postnatal	JJ	O
life	NN	O
.	.	O

The	DT	O
purpose	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
determine	VB	O
whether	IN	O
the	DT	O
use	NN	O
of	IN	O
a	DT	O
whey-predominant	JJ	O
,	,	O
50	CD	O
%	NN	O
medium	NN	O
chain	NN	O
triglyceride	IN	O
formula	NN	O
with	IN	O
relatively	RB	O
high	JJ	O
concentrations	NNS	O
of	IN	O
zinc	NN	O
and	CC	O
copper	NN	O
would	MD	O
promote	VB	O
the	DT	O
achievement	NN	O
of	IN	O
the	DT	O
in	IN	O
utero	JJ	O
accretion	NN	O
rate	NN	O
for	IN	O
zinc	NN	O
and	CC	O
copper	NN	O
in	IN	O
the	DT	O
preterm	NN	C
infant	NN	A
.	.	O

Two	CD	O
groups	NNS	O
of	IN	O
five	CD	SS
preterm	JJ	C
infants	NNS	A
were	VBD	O
fed	VBN	O
a	DT	O
diet	JJ	O
containing	VBG	O
12.5	CD	O
mg/L	NN	O
of	IN	O
zinc	NN	O
and	CC	O
either	DT	O
0.9	CD	O
mg/L	NN	O
or	CC	O
2.1	CD	O
mg/L	NN	O
of	IN	O
copper	NN	O
.	.	O

Seventy-two-hour	JJ	O
metabolic	JJ	O
balance	NN	O
studies	NNS	O
were	VBD	O
performed	VBN	O
at	IN	O
an	DT	O
average	JJ	O
postconceptual	JJ	O
age	NN	O
of	IN	O
34	CD	O
weeks	NNS	O
and	CC	O
an	DT	O
average	JJ	O
weight	NN	O
of	IN	O
1,549	CD	O
g.	NN	O
All	DT	O
infants	NNS	O
were	VBD	O
in	IN	O
positive	JJ	O
zinc	NN	O
balance	NN	O
and	CC	O
nine	CD	O
of	IN	O
ten	NNS	O
achieved	VBN	O
the	DT	O
in	IN	O
utero	JJ	O
accretion	NN	O
rate	NN	O
for	IN	O
zinc	NN	O
for	IN	O
a	DT	O
34-week	JJ	O
gestation	NN	O
fetus	NN	O
(	(	O
greater	JJR	O
than	IN	O
or	CC	O
equal	JJ	O
to	TO	O
0.432	CD	O
mg/d	NN	O
)	)	O
.	.	O

Three	CD	O
infants	NNS	O
receiving	VBG	O
the	DT	O
high	JJ	O
copper	NN	O
formula	NN	O
and	CC	O
two	CD	O
receiving	VBG	O
the	DT	O
lower	JJR	O
copper	NN	O
formula	NN	O
were	VBD	O
in	IN	O
positive	JJ	O
copper	NN	O
balance	NN	O
.	.	O

Two	CD	O
infants	NNS	O
from	IN	O
each	DT	O
group	NN	O
achieved	VBD	O
the	DT	O
in	IN	O
utero	JJ	O
accretion	NN	O
rate	NN	O
for	IN	O
copper	NN	O
for	IN	O
a	DT	O
34-week	JJ	O
gestation	NN	O
fetus	NN	O
(	(	O
0.088	CD	O
mg/d	NN	O
)	)	O
.	.	O

A	DT	O
formula	NN	O
that	WDT	O
provides	VBZ	O
12.5	CD	O
mg/L	NN	O
of	IN	O
zinc	NN	O
permits	NNS	O
positive	JJ	O
zinc	NN	O
balance	NN	O
and	CC	O
zinc	NN	O
retention	NN	O
similar	JJ	O
to	TO	O
in	IN	O
utero	JJ	O
rates	NNS	O
.	.	O

A	DT	O
formula	NN	O
that	WDT	O
provides	VBZ	O
as	RB	O
much	JJ	O
as	IN	O
2.1	CD	O
mg/L	NN	O
of	IN	O
copper	NN	O
,	,	O
however	RB	O
,	,	O
may	MD	O
not	RB	O
always	RB	O
permit	VBP	O
positive	JJ	O
copper	NN	O
balance	NN	O
.	.	O

Association	NNP	O
of	IN	O
severity	NN	O
of	IN	O
coexisting	VBG	O
patellofemoral	JJ	O
disease	NN	O
with	IN	O
increased	JJ	O
impairments	NNS	O
and	CC	O
functional	JJ	O
limitations	NNS	O
in	IN	O
patients	NNS	O
with	IN	O
knee	JJ	O
osteoarthritis	NN	O
.	.	O

OBJECTIVE	UH	O
To	TO	O
evaluate	VB	O
the	DT	O
association	NN	O
between	IN	O
severity	NN	O
of	IN	O
coexisting	VBG	O
patellofemoral	JJ	O
(	(	O
PF	NNP	O
)	)	O
disease	NN	O
with	IN	O
lower	JJR	O
extremity	NN	O
impairments	NNS	O
and	CC	O
functional	JJ	O
limitations	NNS	O
in	IN	O
patients	NNS	O
with	IN	O
tibiofemoral	JJ	O
(	(	O
TF	NNP	O
)	)	O
osteoarthritis	NN	O
(	(	O
OA	NNP	O
)	)	O
.	.	O

METHODS	NNP	O
Radiographic	NNP	O
views	NNS	O
of	IN	O
the	DT	O
TF	NNP	O
and	CC	O
PF	NNP	O
compartments	NNS	O
,	,	O
knee	VB	O
extension	NN	O
strength	NN	O
,	,	O
and	CC	O
knee	VB	O
range	NN	O
of	IN	O
motion	NN	O
were	VBD	O
obtained	VBN	O
for	IN	O
167	CD	O
patients	NNS	O
with	IN	O
knee	JJ	O
OA	NNP	O
.	.	O

Additionally	RB	O
,	,	O
knee-specific	JJ	O
symptoms	NNS	O
and	CC	O
functional	JJ	O
limitations	NNS	O
were	VBD	O
assessed	VBN	O
using	VBG	O
the	DT	O
Western	NNP	O
Ontario	NNP	O
and	CC	O
McMaster	NNP	O
Universities	NNP	O
Osteoarthritis	NNP	O
Index	NNP	O
(	(	O
WOMAC	NNP	O
)	)	O
and	CC	O
the	DT	O
Activities	NNS	O
of	IN	O
Daily	NNP	O
Living	NNP	O
Scale	NNP	O
(	(	O
ADLS	NNP	O
)	)	O
.	.	O

RESULTS	NNP	O
Moderate/severe	NNP	O
PFOA	NNP	O
was	VBD	O
associated	VBN	O
with	IN	O
lower	JJR	O
knee	NN	O
extension	NN	O
strength	NN	O
(	(	O
mean	VB	O
?	.	O
SD	NNP	O
1.4	CD	O
?	.	O
0.5	CD	O
Nm/body	NN	O
weight	VBD	O
[	NNP	O
BW	NNP	O
]	NNP	O
)	)	O
compared	VBN	O
to	TO	O
no	DT	O
PFOA	NNP	O
(	(	O
mean	VB	O
?	.	O
SD	NNP	O
1.8	CD	O
?	.	O
0.5	CD	O
Nm/BW	NNP	O
)	)	O
.	.	O

Additionally	RB	O
,	,	O
total	JJ	O
knee	NN	O
range	NN	O
of	IN	O
motion	NN	O
was	VBD	O
significantly	RB	O
lower	JJR	O
for	IN	O
patients	NNS	O
with	IN	O
moderate/severe	JJ	O
PFOA	NNP	O
(	(	O
mean	VB	O
?	.	O
SD	NNP	O
120.8?	CD	O
?	.	O
14.4?	CD	O
)	)	O
compared	VBN	O
to	TO	O
no	DT	O
PFOA	NNP	O
(	(	O
mean	VB	O
?	.	O
SD	NNP	O
133.5?	CD	O
?	.	O
10.7?	CD	O
)	)	O
and	CC	O
mild	JJ	O
PFOA	NNP	O
(	(	O
mean	VB	O
?	.	O
SD	NNP	O
125.8?	CD	O
?	.	O
13.0?	CD	O
)	)	O
.	.	O

Moderate/severe	NNP	O
PFOA	NNP	O
and	CC	O
mild	JJ	O
PFOA	NNP	O
were	VBD	O
also	RB	O
associated	VBN	O
with	IN	O
less	JJR	O
pain	NN	O
while	IN	O
standing	VBG	O
(	(	O
odds	NNS	O
ratio	VBP	O
[	CD	O
OR	NNP	O
]	$	O
0.2	CD	O
,	,	O
95	CD	O
%	NN	O
confidence	NN	O
interval	NN	O
[	VBD	O
95	CD	O
%	NN	O
CI	NNP	O
]	NNP	O
0.1-0.7	JJ	O
and	CC	O
OR	NNP	O
0.2	CD	O
,	,	O
95	CD	O
%	NN	O
CI	NNP	O
0.1-0.6	CD	O
,	,	O
respectively	RB	O
)	)	O
on	IN	O
the	DT	O
WOMAC	NNP	O
,	,	O
and	CC	O
moderate/severe	RB	O
PFOA	NNP	O
was	VBD	O
associated	VBN	O
with	IN	O
greater	JJR	O
difficulty	NN	O
with	IN	O
going	VBG	O
downstairs	NNS	O
(	(	O
OR	NNP	O
2.9	CD	O
,	,	O
95	CD	O
%	NN	O
CI	NNP	O
1.0-8.1	CD	O
)	)	O
on	IN	O
the	DT	O
ADLS	NNP	O
.	.	O

CONCLUSION	VB	O
It	PRP	O
appears	VBZ	O
that	IN	O
knees	NNS	O
with	IN	O
more	RBR	O
severe	JJ	O
coexisting	VBG	O
PF	NNP	O
disease	NN	O
demonstrate	NN	O
features	NNS	O
distinct	VBP	O
from	IN	O
those	DT	O
observed	VBN	O
in	IN	O
TFOA	NNP	O
in	IN	O
isolation	NN	O
or	CC	O
in	IN	O
combination	NN	O
with	IN	O
mild	JJ	O
PF	NNP	O
disease	NN	O
.	.	O

Treatment	NNP	O
strategies	VBZ	O
targeting	VBG	O
the	DT	O
PF	NNP	O
joint	NN	O
may	MD	O
be	VB	O
warranted	VBN	O
to	TO	O
mitigate	VB	O
the	DT	O
specific	JJ	O
lower	JJR	O
extremity	NN	O
impairments	NNS	O
and	CC	O
functional	JJ	O
problems	NNS	O
present	JJ	O
in	IN	O
this	DT	O
patient	JJ	O
population	NN	O
.	.	O

Treatment	NN	O
with	IN	O
the	DT	O
dipeptidyl	JJ	O
peptidase-4	JJ	O
inhibitor	NN	O
vildagliptin	NN	O
improves	VBZ	O
fasting	VBG	O
islet-cell	JJ	O
function	NN	O
in	IN	O
subjects	NNS	O
with	IN	O
type	JJ	O
2	CD	O
diabetes	NNS	O
.	.	O

CONTEXT	NNP	O
Dipeptidyl	NNP	O
peptidase	NN	O
4	CD	O
(	(	O
DPP-4	NNP	O
)	)	O
inhibitors	NNS	O
are	VBP	O
proposed	VBN	O
to	TO	O
lower	VB	O
blood	NN	O
glucose	NN	O
in	IN	O
type	NN	O
2	CD	O
diabetes	NNS	O
mellitus	FW	O
(	(	O
T2DM	NNP	O
)	)	O
by	IN	O
prolonging	VBG	O
the	DT	O
activity	NN	O
of	IN	O
the	DT	O
circulating	NN	O
incretins	NNS	O
,	,	O
glucose-dependent	JJ	O
insulinotropic	NN	O
polypeptide	NN	O
(	(	O
GIP	NNP	O
)	)	O
and	CC	O
glucagon-like	JJ	O
peptide	NN	O
1	CD	O
(	(	O
GLP-1	NNP	O
)	)	O
.	.	O

Consistent	JJ	O
with	IN	O
this	DT	O
mechanism	NN	O
of	IN	O
action	NN	O
,	,	O
DPP-4	NNP	O
inhibitors	NNS	O
improve	VBP	O
glucose	JJ	O
tolerance	NN	O
after	IN	O
meals	NNS	O
by	IN	O
increasing	VBG	O
insulin	NN	O
and	CC	O
reducing	VBG	O
glucagon	NN	O
levels	NNS	O
in	IN	O
the	DT	O
plasma	NN	O
.	.	O

However	RB	O
,	,	O
DPP-4	NNP	O
inhibitors	NNS	O
also	RB	O
reduce	VB	O
fasting	VBG	O
blood	NN	O
glucose	NN	O
,	,	O
an	DT	O
unexpected	JJ	O
effect	NN	O
because	IN	O
circulating	VBG	O
levels	NNS	O
of	IN	O
active	JJ	O
GIP	NNP	O
and	CC	O
GLP-1	NNP	O
are	VBP	O
low	JJ	O
in	IN	O
the	DT	O
postabsorptive	JJ	O
state	NN	O
.	.	O

OBJECTIVE	CC	O
The	DT	O
objective	NN	O
of	IN	O
the	DT	O
study	NN	O
was	VBD	O
to	TO	O
examine	VB	O
the	DT	O
effects	NNS	O
of	IN	O
DPP-4	NNP	O
inhibition	NN	O
on	IN	O
fasting	VBG	O
islet	NN	O
function	NN	O
.	.	O

DESIGN	NNP	O
We	PRP	O
conducted	VBD	O
a	DT	O
randomized	VBN	O
,	,	O
double-blind	JJ	O
,	,	O
placebo-controlled	JJ	O
trial	NN	O
.	.	O

SETTING	VB	O
The	DT	O
study	NN	O
was	VBD	O
performed	VBN	O
in	IN	O
General	NNP	O
Clinical	NNP	O
Research	NNP	O
Centers	NNPS	O
at	IN	O
two	CD	O
University	NNP	O
Hospitals	NNP	O
.	.	O

SUBJECTS	NNP	O
Forty-one	JJ	O
subjects	NNS	O
with	IN	O
T2DM	NNP	O
were	VBD	O
treated	VBN	O
with	IN	O
metformin	NN	O
or	CC	O
diet	NN	O
,	,	O
having	VBG	O
good	JJ	O
glycemic	NNS	O
control	NN	O
with	IN	O
glycosylated	JJ	O
hemoglobin	NN	O
values	NNS	O
of	IN	O
6.2-7.5	JJ	O
%	NN	O
.	.	O

INTERVENTION	JJ	O
Subjects	NNPS	O
were	VBD	O
treated	VBN	O
with	IN	O
vildagliptin	NN	O
(	(	O
50	CD	O
mg	NN	O
twice	RB	O
daily	RB	O
)	)	O
or	CC	O
placebo	NN	O
for	IN	O
3	CD	O
months	NNS	O
,	,	O
followed	VBN	O
by	IN	O
a	DT	O
2-wk	JJ	O
washout	NN	O
.	.	O

Major	JJ	O
Outcome	JJ	O
Measure	NN	O
:	:	O
We	PRP	O
measured	VBD	O
insulin	JJ	O
secretion	NN	O
in	IN	O
response	NN	O
to	TO	O
iv	VB	O
glucose	JJ	O
and	CC	O
arginine	JJ	O
before	NN	O
and	CC	O
after	IN	O
treatment	NN	O
and	CC	O
after	IN	O
drug	NN	O
washout	NN	O
.	.	O

RESULTS	CC	O
There	EX	O
were	VBD	O
small	JJ	O
and	CC	O
comparable	JJ	O
reductions	NNS	O
in	IN	O
glycosylated	JJ	O
hemoglobin	NN	O
in	IN	O
both	DT	O
groups	NNS	O
over	IN	O
3	CD	O
months	NNS	O
.	.	O

Vildagliptin	NNP	O
increased	VBD	O
fasting	VBG	O
GLP-1	NNP	O
levels	NNS	O
in	IN	O
subjects	NNS	O
taking	VBG	O
metformin	NN	O
,	,	O
but	CC	O
not	RB	O
those	DT	O
managed	VBN	O
with	IN	O
diet	JJ	O
,	,	O
and	CC	O
raised	VBD	O
active	JJ	O
GIP	NNP	O
levels	NNS	O
slightly	RB	O
.	.	O

DPP-4	JJ	O
inhibitor	NN	O
treatment	NN	O
improved	VBD	O
the	DT	O
acute	JJ	O
insulin	NN	O
and	CC	O
C-peptide	JJ	O
responses	NNS	O
to	TO	O
glucose	VB	O
(	(	O
50	CD	O
and	CC	O
100	CD	O
%	NN	O
respectively	RB	O
;	:	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
and	CC	O
increased	VBD	O
the	DT	O
slope	NN	O
of	IN	O
the	DT	O
C-peptide	NNP	O
response	NN	O
to	TO	O
glucose	VB	O
(	(	O
33	CD	O
%	NN	O
;	:	O
P	NNP	O
=	NNP	O
0.023	CD	O
)	)	O
.	.	O

CONCLUSION	NNP	O
Vildagliptin	NNP	O
improves	VBZ	O
islet	JJ	O
function	NN	O
in	IN	O
T2DM	NNP	O
under	IN	O
fasting	VBG	O
conditions	NNS	O
.	.	O

This	DT	O
suggests	VBZ	O
that	IN	O
DPP-4	NNP	O
inhibition	NN	O
has	VBZ	O
metabolic	JJ	O
benefits	NNS	O
in	IN	O
addition	NN	O
to	TO	O
enhancing	VBG	O
meal-induced	JJ	O
GLP-1	NNP	O
and	CC	O
GIP	NNP	O
activity	NN	O
.	.	O

Safety	NN	O
and	CC	O
acceptability	NN	O
of	IN	O
cellulose	JJ	O
sulfate	NN	O
as	IN	O
a	DT	O
vaginal	JJ	O
microbicide	NN	O
in	IN	O
HIV-infected	JJ	O
women	NNS	O
.	.	O

OBJECTIVES	NNP	O
Few	JJ	O
studies	NNS	O
of	IN	O
topical	JJ	O
microbicides	NNS	O
have	VBP	O
assessed	VBN	O
their	PRP$	O
safety	NN	O
in	IN	O
HIV-infected	JJ	O
women	NNS	O
.	.	O

We	PRP	O
conducted	VBD	O
this	DT	O
study	NN	O
to	TO	O
evaluate	VB	O
the	DT	O
safety	NN	O
and	CC	O
acceptability	NN	O
of	IN	O
6	CD	O
%	NN	O
cellulose	JJ	O
sulfate	NN	O
(	(	O
CS	NNP	O
)	)	O
gel	NN	O
as	IN	O
a	DT	O
vaginal	JJ	O
microbicide	NN	O
in	IN	O
sexually	RB	O
abstinent	JJ	O
and	CC	O
active	JJ	O
HIV-infected	JJ	O
women	NNS	O
.	.	O

METHODS	NNP	O
Fifty-nine	JJ	O
HIV-infected	JJ	O
women	NNS	O
were	VBD	O
enrolled	VBN	O
in	IN	O
a	DT	O
randomized	JJ	O
double-blind	JJ	O
placebo-controlled	JJ	O
study	NN	O
comparing	VBG	O
6	CD	O
%	NN	O
CS	NNP	O
to	TO	O
placebo	VB	O
gel	NNS	O
used	VBN	O
for	IN	O
14	CD	O
days	NNS	O
.	.	O

Sexually	NNP	O
abstinent	JJ	O
women	NNS	O
applied	VBD	O
gel	JJ	O
once	RB	O
or	CC	O
twice	JJ	O
daily	JJ	O
and	CC	O
sexually	RB	O
active	JJ	O
women	NNS	O
used	VBN	O
gel	JJ	O
once	RB	O
daily	JJ	O
.	.	O

RESULTS	NNP	O
CS	NNP	O
gel	NN	O
was	VBD	O
safe	JJ	O
with	IN	O
no	DT	O
reported	VBN	O
severe	RB	O
or	CC	O
life-threatening	JJ	O
adverse	JJ	O
events	NNS	O
(	(	O
AE	NNP	O
)	)	O
.	.	O

Thirty-nine	NNP	O
(	(	O
66	CD	O
%	NN	O
)	)	O
of	IN	O
the	DT	O
participants	NNS	O
experienced	VBD	O
urogenital	JJ	O
AE	NNP	O
judged	VBD	O
as	IN	O
probably	RB	O
or	CC	O
possibly	RB	O
related	VBN	O
to	TO	O
gel	VB	O
.	.	O

The	DT	O
majority	NN	O
(	(	O
51	CD	O
%	NN	O
)	)	O
of	IN	O
these	DT	O
participants	NNS	O
reported	VBD	O
only	RB	O
mild	JJ	O
events	NNS	O
.	.	O

Fewer	JJR	O
women	NNS	O
(	(	O
62	CD	O
%	NN	O
)	)	O
who	WP	O
used	VBD	O
CS	NNP	O
experienced	VBD	O
urogenital	JJ	O
AE	NNP	O
than	IN	O
those	DT	O
assigned	VBN	O
to	TO	O
placebo	VB	O
gel	NN	O
(	(	O
70	CD	O
%	NN	O
)	)	O
(	(	O
P	NNP	O
=	NNP	O
0.59	CD	O
)	)	O
.	.	O

Eleven	NNP	O
(	(	O
19	CD	O
%	NN	O
)	)	O
women	NNS	O
experienced	VBD	O
intermenstrual	JJ	O
bleeding	NN	O
judged	VBD	O
to	TO	O
be	VB	O
probably	RB	O
or	CC	O
possibly	RB	O
related	VBN	O
to	TO	O
gel	VB	O
use	NN	O
(	(	O
four	CD	O
in	IN	O
the	DT	O
CS	NNP	O
and	CC	O
seven	CD	O
in	IN	O
the	DT	O
placebo	NN	O
gel	NN	O
group	NN	O
)	)	O
.	.	O

There	EX	O
was	VBD	O
no	DT	O
increase	NN	O
in	IN	O
AE	NNP	O
by	IN	O
frequency	NN	O
of	IN	O
gel	NN	O
use	NN	O
or	CC	O
sexual	JJ	O
activity	NN	O
with	IN	O
the	DT	O
exception	NN	O
of	IN	O
abdominal/pelvic	NN	O
pain	NN	O
which	WDT	O
was	VBD	O
noted	VBN	O
more	RBR	O
frequently	RB	O
with	IN	O
twice	RB	O
daily	JJ	O
use	NN	O
among	IN	O
sexually	RB	O
abstinent	JJ	O
women	NNS	O
.	.	O

Women	NNS	O
and	CC	O
men	NNS	O
found	VBD	O
the	DT	O
gel	NN	O
highly	RB	O
acceptable	JJ	O
.	.	O

CONCLUSIONS	VB	O
This	DT	O
Phase	NNP	O
I	PRP	O
study	VBP	O
demonstrated	VBD	O
that	IN	O
CS	NNP	O
vaginal	JJ	O
gel	NN	O
was	VBD	O
safe	JJ	O
,	,	O
well	RB	O
tolerated	VBN	O
and	CC	O
acceptable	JJ	O
by	IN	O
HIV-infected	JJ	O
women	NNS	O
and	CC	O
their	PRP$	O
male	JJ	O
partners	NNS	O
.	.	O

Thus	RB	O
,	,	O
further	JJ	O
development	NN	O
of	IN	O
CS	NNP	O
is	VBZ	O
warranted	VBN	O
as	IN	O
a	DT	O
potential	JJ	O
method	NN	O
to	TO	O
prevent	VB	O
HIV	NNP	O
transmission	NN	O
and	CC	O
acquisition	NN	O
.	.	O

Randomized	NNP	O
clinical	JJ	O
trial	NN	O
of	IN	O
cutting	VBG	O
balloon	NN	O
angioplasty	JJ	O
versus	NN	O
high-pressure	NN	O
balloon	NN	O
angioplasty	NN	O
in	IN	O
hemodialysis	NN	C
arteriovenous	JJ	C
fistula	NN	C
stenoses	VBZ	C
resistant	JJ	C
to	TO	C
conventional	JJ	C
balloon	NN	C
angioplasty	NN	C
.	.	C

PURPOSE	NNP	O
To	TO	O
compare	VB	O
the	DT	O
efficacy	NN	O
and	CC	O
safety	NN	O
of	IN	O
cutting	VBG	O
balloon	NN	O
angioplasty	NN	O
(	(	O
CBA	NNP	O
)	)	O
versus	IN	O
high-pressure	NN	O
balloon	NN	O
angioplasty	NN	O
(	(	O
HPBA	NNP	O
)	)	O
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
hemodialysis	NN	C
autogenous	JJ	C
fistula	NN	C
stenoses	VBZ	C
resistant	JJ	C
to	TO	C
conventional	JJ	C
percutaneous	JJ	C
transluminal	JJ	C
angioplasty	NN	C
(	(	C
PTA	NNP	C
)	)	C
.	.	O

MATERIALS	NNP	O
AND	CC	O
METHODS	NNP	O
In	IN	O
a	DT	O
prospective	JJ	O
,	,	O
randomized	JJ	O
clinical	JJ	O
trial	NN	O
involving	VBG	O
patients	NNS	O
with	IN	O
dysfunctional	JJ	C
,	,	C
stenotic	JJ	C
hemodialysis	NN	C
arteriovenous	JJ	C
fistulas	NNS	C
(	(	C
AVFs	NNP	C
)	)	C
,	,	O
patients	NNS	O
were	VBD	O
randomized	VBN	O
to	TO	O
receive	VB	O
CBA	NNP	O
or	CC	O
HPBA	NNP	O
if	IN	O
conventional	JJ	O
PTA	NNP	O
had	VBD	O
suboptimal	JJ	O
results	NNS	O
(	(	O
ie	JJ	O
,	,	O
residual	JJ	O
stenosis	NN	O
>	VBD	O
30	CD	O
%	NN	O
)	)	O
.	.	O

A	DT	O
total	NN	O
of	IN	O
516	CD	SS
patients	NNS	O
consented	VBN	O
to	TO	O
participate	VB	O
in	IN	O
the	DT	O
study	NN	O
from	IN	O
October	NNP	O
2008	CD	O
to	TO	O
September	NNP	O
2011	CD	O
,	,	O
85	CD	O
%	NN	O
of	IN	O
whom	WP	O
(	(	O
n	JJ	O
=	NNP	O
439	CD	SS
)	)	O
had	VBD	O
technically	RB	O
successful	JJ	O
conventional	JJ	O
PTA	NNP	O
.	.	O

The	DT	O
remaining	VBG	O
71	CD	SS
patients	NNS	O
(	(	O
mean	JJ	O
age	NN	O
,	,	O
60	CD	A
y	NN	O
;	:	O
49	CD	SS
men	NNS	O
)	)	O
with	IN	O
suboptimal	JJ	O
PTA	NNP	O
results	NNS	O
were	VBD	O
eventually	RB	O
randomized	VBN	O
:	:	O
36	CD	O
to	TO	O
the	DT	O
CBA	NNP	O
arm	NN	O
and	CC	O
35	CD	O
to	TO	O
the	DT	O
HPBA	NNP	O
arm	NN	O
.	.	O

Primary	JJ	O
and	CC	O
secondary	JJ	O
target	NN	O
lesion	NN	O
patencies	NNS	O
were	VBD	O
determined	VBN	O
by	IN	O
Kaplan-Meier	NNP	O
analysis	NN	O
.	.	O

RESULTS	NNP	O
Clinical	JJ	O
success	NN	O
rates	NNS	O
were	VBD	O
100	CD	O
%	NN	O
in	IN	O
both	DT	O
arms	NNS	O
.	.	O

Primary	JJ	O
target	NN	O
lesion	NN	O
patency	NN	O
rates	NNS	O
at	IN	O
6	CD	O
months	NNS	O
were	VBD	O
66.4	CD	O
%	NN	O
and	CC	O
39.9	CD	O
%	NN	O
for	IN	O
CBA	NNP	O
and	CC	O
HPBA	NNP	O
,	,	O
respectively	RB	O
(	(	O
P	NNP	O
=	NNP	O
.01	NNP	O
)	)	O
.	.	O

Secondary	JJ	O
target	NN	O
lesion	NN	O
patency	NN	O
rates	NNS	O
at	IN	O
6	CD	O
months	NNS	O
were	VBD	O
96.5	CD	O
%	NN	O
for	IN	O
CBA	NNP	O
and	CC	O
80.0	CD	O
%	NN	O
for	IN	O
HPBA	NNP	O
(	(	O
P	NNP	O
=	NNP	O
.03	NNP	O
)	)	O
.	.	O

There	EX	O
was	VBD	O
a	DT	O
single	JJ	O
major	JJ	O
complication	NN	O
of	IN	O
venous	JJ	O
perforation	NN	O
following	VBG	O
CBA	NNP	O
.	.	O

The	DT	O
30-day	JJ	O
mortality	NN	O
rate	NN	O
was	VBD	O
1.4	CD	O
%	NN	O
,	,	O
with	IN	O
one	CD	O
non-procedure-related	JJ	O
death	NN	O
in	IN	O
the	DT	O
HPBA	NNP	O
group	NN	O
.	.	O

CONCLUSIONS	NNP	O
Primary	NNP	O
and	CC	O
secondary	JJ	O
target	NN	O
lesion	NN	O
patency	NN	O
rates	NNS	O
of	IN	O
CBA	NNP	O
were	VBD	O
statistically	RB	O
superior	JJ	O
to	TO	O
those	DT	O
of	IN	O
HPBA	NNP	O
following	VBG	O
suboptimal	JJ	O
conventional	JJ	O
PTA	NNP	O
.	.	O

For	IN	O
AVF	NNP	O
stenoses	VBZ	O
resistant	JJ	O
to	TO	O
conventional	JJ	O
PTA	NNP	O
,	,	O
CBA	NNP	O
may	MD	O
be	VB	O
a	DT	O
better	JJR	O
second-line	JJ	O
treatment	NN	O
given	VBN	O
its	PRP$	O
superior	JJ	O
patency	NN	O
rates	NNS	O
.	.	O

Dexamethasone	NNP	O
therapy	NN	O
and	CC	O
cortisol	JJ	O
excretion	NN	O
in	IN	O
severe	JJ	C
pediatric	JJ	C
head	NN	C
injury	NN	C
.	.	C

Glucocorticoids	NNS	O
are	VBP	O
used	VBN	O
in	IN	O
an	DT	O
attempt	NN	O
to	TO	O
reduce	VB	O
brain	NN	O
edema	NN	O
secondary	JJ	O
to	TO	O
head	VB	O
injury	NN	O
.	.	O

Nevertheless	RB	O
,	,	O
their	PRP$	O
usefulness	JJ	O
remains	NNS	O
uncertain	JJ	O
and	CC	O
contradictory	NN	O
.	.	O

In	IN	O
a	DT	O
randomized	JJ	O
study	NN	O
of	IN	O
24	CD	O
children	NNS	O
with	IN	O
severe	JJ	O
head	NN	O
injury	NN	O
,	,	O
urinary	JJ	O
free	JJ	O
cortisol	NN	O
was	VBD	O
measured	VBN	O
by	IN	O
radioimmunoassay	NN	O
.	.	O

Twelve	CD	O
patients	NNS	O
(	(	O
group	NN	O
1	CD	O
)	)	O
received	VBD	O
dexamethasone	NN	O
and	CC	O
12	CD	O
(	(	O
group	NN	O
2	CD	O
)	)	O
did	VBD	O
not	RB	O
.	.	O

All	DT	O
patients	NNS	O
were	VBD	O
treated	VBN	O
with	IN	O
a	DT	O
standardized	JJ	O
regimen	NN	O
.	.	O

In	IN	O
group	NN	O
1	CD	O
there	EX	O
was	VBD	O
complete	JJ	O
suppression	NN	O
of	IN	O
endogenous	JJ	O
cortisol	NN	O
production	NN	O
.	.	O

In	IN	O
group	NN	O
2	CD	O
free	JJ	O
cortisol	NN	O
was	VBD	O
up	RB	O
to	TO	O
20-fold	CD	O
higher	JJR	O
than	IN	O
under	IN	O
basal	JJ	O
conditions	NNS	O
and	CC	O
reached	VBN	O
maximum	JJ	O
values	NNS	O
on	IN	O
days	NNS	O
1-3	RB	O
.	.	O

Since	IN	O
the	DT	O
excretion	NN	O
of	IN	O
cortisol	NN	O
in	IN	O
urine	JJ	O
reflects	VBZ	O
the	DT	O
production	NN	O
rate	NN	O
closely	RB	O
and	CC	O
is	VBZ	O
not	RB	O
influenced	VBN	O
by	IN	O
liver	NN	O
function	NN	O
and	CC	O
barbiturates	NNS	O
,	,	O
the	DT	O
results	NNS	O
in	IN	O
group	NN	O
2	CD	O
show	NN	O
that	IN	O
the	DT	O
endogenous	JJ	O
production	NN	O
of	IN	O
steroids	NNS	O
is	VBZ	O
an	DT	O
adequate	JJ	O
reaction	NN	O
to	TO	O
severe	VB	O
head	JJ	O
injury	NN	O
.	.	O

Exogenous	JJ	O
glucocorticoids	NNS	O
are	VBP	O
thus	RB	O
unlikely	JJ	O
to	TO	O
have	VB	O
any	DT	O
more	JJR	O
beneficial	JJ	O
effects	NNS	O
than	IN	O
endogenous	JJ	O
cortisol	NN	O
.	.	O

Feasibility	NN	O
of	IN	O
two	CD	O
dose-dense	JJ	O
FEC	NNP	O
regimens	VBZ	O
with	IN	O
growth	NN	O
factor	NN	O
support	NN	O
for	IN	O
adjuvant	JJ	O
therapy	NN	O
in	IN	O
patients	NNS	O
with	IN	O
early	JJ	O
breast	NN	O
cancer	NN	O
:	:	O
results	NNS	O
from	IN	O
a	DT	O
randomised	JJ	O
study	NN	O
of	IN	O
the	DT	O
Central	NNP	O
European	NNP	O
Cooperative	NNP	O
Oncology	NNP	O
Group	NNP	O
(	(	O
CECOG	NNP	O
)	)	O
.	.	O

Addition	NN	O
of	IN	O
epirubicin	NN	O
to	TO	O
adjuvant	VB	O
chemotherapy	NN	O
can	MD	O
provide	VB	O
important	JJ	O
benefits	NNS	O
for	IN	O
patients	NNS	O
with	IN	O
early	JJ	O
breast	NN	O
cancer	NN	O
,	,	O
but	CC	O
the	DT	O
optimal	JJ	O
dose	NN	O
remains	VBZ	O
unclear	JJ	O
.	.	O

Further	JJ	O
improvements	NNS	O
can	MD	O
be	VB	O
achieved	VBN	O
with	IN	O
dose-dense	JJ	O
regimens	NNS	O
,	,	O
but	CC	O
densification	NN	O
of	IN	O
fluorouracil/epirubicin/cyclophosphamide	NN	O
(	(	O
FEC	NNP	O
)	)	O
has	VBZ	O
proved	VBN	O
difficult	JJ	O
,	,	O
with	IN	O
FEC	NNP	O
(	(	O
60	CD	O
)	)	O
providing	VBG	O
little	JJ	O
benefit	NN	O
over	IN	O
standard	JJ	O
chemotherapy	NN	O
and	CC	O
FEC	NNP	O
(	(	O
100	CD	O
)	)	O
associated	VBN	O
with	IN	O
toxicity	NN	O
.	.	O

We	PRP	O
investigated	VBD	O
the	DT	O
feasibility	NN	O
of	IN	O
two	CD	O
intermediate	JJ	O
dose-dense	JJ	O
FEC	NNP	O
regimens	NNS	O
.	.	O

Patients	NNS	O
were	VBD	O
randomised	VBN	O
to	TO	O
six	CD	O
cycles	NNS	O
of	IN	O
FEC	NNP	O
(	(	O
75	CD	O
)	)	O
or	CC	O
FEC	NNP	O
(	(	O
90	CD	O
)	)	O
,	,	O
with	IN	O
all	DT	O
three	CD	O
drugs	NNS	O
given	VBN	O
on	IN	O
day	NN	O
1	CD	O
of	IN	O
each	DT	O
14-day	JJ	O
cycle	NN	O
.	.	O

Patients	NNS	O
also	RB	O
received	VBD	O
pegfilgrastim	JJ	O
6	CD	O
mg	NN	O
as	IN	O
a	DT	O
single	JJ	O
subcutaneous	JJ	O
injection	NN	O
on	IN	O
day	NN	O
2	CD	O
of	IN	O
each	DT	O
cycle	NN	O
.	.	O

The	DT	O
primary	JJ	O
efficacy	NN	O
endpoint	NN	O
was	VBD	O
the	DT	O
proportion	NN	O
of	IN	O
subjects	NNS	O
receiving	VBG	O
>	NN	O
or	CC	O
=85	CD	O
%	NN	O
relative	JJ	O
dose	JJ	O
intensity	NN	O
and	CC	O
was	VBD	O
achieved	VBN	O
by	IN	O
96	CD	O
%	NN	O
and	CC	O
88	CD	O
%	NN	O
of	IN	O
patients	NNS	O
in	IN	O
the	DT	O
FEC	NNP	O
(	(	O
75	CD	O
)	)	O
and	CC	O
FEC	NNP	O
(	(	O
90	CD	O
)	)	O
arms	NNS	O
,	,	O
respectively	RB	O
.	.	O

Of	IN	O
147	CD	O
FEC	NNP	O
(	(	O
75	CD	O
)	)	O
infusions	NNS	O
,	,	O
4.1	CD	O
%	NN	O
were	VBD	O
delayed	VBN	O
,	,	O
while	IN	O
9.8	CD	O
%	NN	O
of	IN	O
143	CD	O
FEC	NNP	O
(	(	O
90	CD	O
)	)	O
infusions	NNS	O
were	VBD	O
delayed	VBN	O
.	.	O

The	DT	O
most	RBS	O
common	JJ	O
reasons	NNS	O
for	IN	O
delay	NN	O
were	VBD	O
adverse	JJ	O
events	NNS	O
and	CC	O
personal/logistical	JJ	O
reasons	NNS	O
.	.	O

One	CD	O
dose	JJ	O
reduction	NN	O
occurred	VBD	O
during	IN	O
the	DT	O
study	NN	O
(	(	O
FEC	NNP	O
(	(	O
90	CD	O
)	)	O
)	)	O
,	,	O
related	VBN	O
to	TO	O
diarrhoea	VB	O
.	.	O

Grade	VB	O
3-4	JJ	O
haematological	JJ	O
toxicities	NNS	O
were	VBD	O
reported	VBN	O
in	IN	O
two	CD	O
patients	NNS	O
in	IN	O
the	DT	O
FEC	NNP	O
(	(	O
90	CD	O
)	)	O
arm	NN	O
.	.	O

There	EX	O
were	VBD	O
no	DT	O
incidences	NNS	O
of	IN	O
febrile	JJ	O
neutropenia	NN	O
during	IN	O
the	DT	O
study	NN	O
.	.	O

The	DT	O
most	RBS	O
common	JJ	O
adverse	JJ	O
events	NNS	O
were	VBD	O
increases	NNS	O
in	IN	O
liver	NN	O
enzymes	NNS	O
and	CC	O
gastrointestinal	JJ	O
events	NNS	O
;	:	O
no	DT	O
event	NN	O
resulted	VBD	O
in	IN	O
discontinuation	NN	O
.	.	O

Only	RB	O
one	CD	O
patient	NN	O
(	(	O
FEC	NNP	O
(	(	O
90	CD	O
)	)	O
)	)	O
experienced	VBD	O
serious	JJ	O
adverse	JJ	O
events	NNS	O
(	(	O
vomiting	VBG	O
and	CC	O
throat	VB	O
oedema	NN	O
)	)	O
.	.	O

In	IN	O
conclusion	NN	O
,	,	O
dose-dense	JJ	O
FEC	NNP	O
(	(	O
75	CD	O
)	)	O
and	CC	O
FEC	NNP	O
(	(	O
90	CD	O
)	)	O
are	VBP	O
feasible	JJ	O
with	IN	O
pegfilgrastim	JJ	O
support	NN	O
.	.	O

These	DT	O
regimens	NNS	O
are	VBP	O
associated	VBN	O
with	IN	O
a	DT	O
very	RB	O
low	JJ	O
risk	NN	O
of	IN	O
Grade	NNP	O
3-4	JJ	O
toxicity	NN	O
.	.	O

Prophylactic	JJ	O
amnioinfusion	NN	O
in	IN	O
pregnancies	NNS	O
complicated	VBN	O
by	IN	O
oligohydramnios	NNS	O
:	:	O
a	DT	O
prospective	JJ	O
study	NN	O
.	.	O

Prophylactic	JJ	O
amnioinfusion	NN	O
was	VBD	O
assessed	VBN	O
in	IN	O
term	NN	O
and	CC	O
post-dates	NNS	O
pregnancies	NNS	O
with	IN	O
decreased	JJ	O
amniotic	JJ	O
fluid	NN	O
volume	NN	O
.	.	O

Subjects	NNS	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
one	CD	O
of	IN	O
three	CD	O
groups	NNS	O
:	:	O
amnioinfusion	NN	O
with	IN	O
warmed	JJ	O
saline	JJ	O
solution	NN	O
,	,	O
room-temperature	JJ	O
saline	NN	O
,	,	O
or	CC	O
control	NN	O
.	.	O

Patients	NNS	O
receiving	VBG	O
prophylactic	JJ	O
amnioinfusion	NN	O
had	VBD	O
a	DT	O
significant	JJ	O
decrease	NN	O
in	IN	O
both	CC	O
the	DT	O
frequency	NN	O
and	CC	O
severity	NN	O
of	IN	O
variable	JJ	O
decelerations	NNS	O
in	IN	O
the	DT	O
first	JJ	O
stage	NN	O
of	IN	O
labor	NN	O
(	(	O
P	NNP	O
=	NNP	O
.006	NNP	O
)	)	O
and	CC	O
in	IN	O
the	DT	O
average	JJ	O
total	JJ	O
number	NN	O
of	IN	O
variable	JJ	O
decelerations	NNS	O
in	IN	O
the	DT	O
first	JJ	O
and	CC	O
second	JJ	O
stages	NNS	O
of	IN	O
labor	NN	O
(	(	O
P	NNP	O
=	NNP	O
.01	NNP	O
)	)	O
compared	VBN	O
with	IN	O
controls	NNS	O
.	.	O

There	EX	O
was	VBD	O
no	DT	O
observed	JJ	O
effect	NN	O
on	IN	O
newborn	JJ	O
serum	NN	O
electrolyte	NN	O
levels	NNS	O
with	IN	O
amnioinfusion	NN	O
,	,	O
nor	CC	O
was	VBD	O
there	EX	O
any	DT	O
apparent	JJ	O
benefit	NN	O
of	IN	O
infusion	NN	O
of	IN	O
warmed	JJ	O
saline	NN	O
compared	VBN	O
with	IN	O
room-temperature	JJ	O
saline	NN	O
.	.	O

In	IN	O
contrast	NN	O
to	TO	O
premature	VB	O
gestations	NNS	O
with	IN	O
oligohydramnios	NNS	O
,	,	O
prophylactic	JJ	O
amnioinfusion	NN	O
was	VBD	O
not	RB	O
associated	VBN	O
with	IN	O
a	DT	O
significant	JJ	O
improvement	NN	O
in	IN	O
mean	JJ	O
umbilical	JJ	O
arterial	NN	O
and	CC	O
venous	JJ	O
pH	NN	O
or	CC	O
a	DT	O
significant	JJ	O
decrease	NN	O
in	IN	O
cesarean	JJ	O
delivery	NN	O
for	IN	O
fetal	JJ	O
distress	NN	O
(	(	O
P	NNP	O
=	NNP	O
.09	NNP	O
)	)	O
.	.	O

This	DT	O
is	VBZ	O
perhaps	RB	O
because	IN	O
the	DT	O
term	NN	O
fetus	NN	O
has	VBZ	O
an	DT	O
enhanced	VBN	O
ability	NN	O
to	TO	O
tolerate	VB	O
recurrent	JJ	O
episodes	NNS	O
of	IN	O
heart	NN	O
rate	NN	O
decelerations	NNS	O
without	IN	O
demonstrating	VBG	O
the	DT	O
rapid	JJ	O
metabolic	JJ	O
changes	NNS	O
seen	VBN	O
in	IN	O
the	DT	O
premature	NN	O
fetus	NN	O
.	.	O

Effects	NNS	O
of	IN	O
individualized	JJ	O
breast	NN	O
cancer	NN	O
risk	NN	O
counseling	NN	O
:	:	O
a	DT	O
randomized	JJ	O
trial	NN	O
.	.	O

BACKGROUND	NNP	O
Studies	NNPS	O
have	VBP	O
shown	VBN	O
that	IN	O
a	DT	O
majority	NN	O
of	IN	O
women	NNS	SE
with	IN	O
a	DT	O
family	NN	O
history	NN	O
of	IN	O
breast	NN	C
cancer	NN	C
have	VBP	O
exaggerated	VBN	O
perceptions	NNS	O
of	IN	O
their	PRP$	O
own	JJ	O
risk	NN	O
of	IN	O
this	DT	O
disease	NN	O
and	CC	O
experience	NN	O
excessive	JJ	O
anxiety	NN	O
.	.	O

In	IN	O
response	NN	O
to	TO	O
the	DT	O
need	NN	O
to	TO	O
communicate	VB	O
more	JJR	O
accurate	JJ	O
risk	NN	O
information	NN	O
to	TO	O
these	DT	O
women	NNS	O
,	,	O
specialized	JJ	O
programs	NNS	O
for	IN	O
breast	NN	O
cancer	NN	O
risk	NN	O
counseling	VBG	O
have	VBP	O
been	VBN	O
initiated	VBN	O
in	IN	O
medical	JJ	O
centers	NNS	O
across	IN	O
the	DT	O
United	NNP	O
States	NNPS	O
.	.	O

PURPOSE	VB	O
Our	PRP$	O
purpose	NN	O
was	VBD	O
1	CD	O
)	)	O
to	TO	O
evaluate	VB	O
the	DT	O
impact	NN	O
of	IN	O
a	DT	O
standardized	JJ	O
protocol	NN	O
for	IN	O
individualized	JJ	O
breast	NN	O
cancer	NN	O
risk	NN	O
counseling	VBG	O
on	IN	O
comprehension	NN	O
of	IN	O
personal	JJ	O
risk	NN	O
among	IN	O
first-degree	JJ	O
relatives	NNS	O
of	IN	O
index	NN	O
breast	NN	O
cancer	NN	O
patients	NNS	O
and	CC	O
2	CD	O
)	)	O
to	TO	O
identify	VB	O
women	NNS	O
most	RBS	O
and	CC	O
least	JJS	O
likely	JJ	O
to	TO	O
benefit	VB	O
from	IN	O
such	JJ	O
counseling	NN	O
.	.	O

METHODS	NNP	O
This	DT	O
study	NN	O
is	VBZ	O
a	DT	O
prospective	JJ	O
randomized	VBN	O
trial	NN	O
comparing	VBG	O
individualized	VBN	O
breast	NN	O
cancer	NN	O
risk	NN	O
counseling	VBG	O
to	TO	O
general	JJ	O
health	NN	O
counseling	NN	O
(	(	O
control	NN	O
)	)	O
.	.	O

We	PRP	O
studied	VBD	O
200	CD	SS
women	NNS	O
aged	VBN	O
35	CD	A
years	NNS	A
and	CC	O
older	JJR	O
who	WP	O
had	VBD	O
a	DT	O
family	NN	O
history	NN	O
of	IN	O
breast	NN	O
cancer	NN	O
in	IN	O
a	DT	O
first-degree	JJ	O
relative	NN	O
.	.	O

Women	NNS	O
with	IN	O
a	DT	O
personal	JJ	O
history	NN	O
of	IN	O
cancer	NN	O
were	VBD	O
excluded	VBN	O
.	.	O

Risk	NNP	O
comprehension	NN	O
was	VBD	O
assessed	VBN	O
as	IN	O
the	DT	O
concordance	NN	O
between	IN	O
perceived	VBN	O
subjective	JJ	O
lifetime	NN	O
breast	NN	O
cancer	NN	O
risk	NN	O
and	CC	O
estimated	VBN	O
objective	JJ	O
lifetime	NN	O
risk	NN	O
.	.	O

RESULTS	VB	O
The	DT	O
results	NNS	O
of	IN	O
logistic	JJ	O
regression	NN	O
analysis	NN	O
showed	VBD	O
that	IN	O
women	NNS	O
who	WP	O
received	VBD	O
risk	NN	O
counseling	NN	O
were	VBD	O
significantly	RB	O
more	RBR	O
likely	JJ	O
to	TO	O
improve	VB	O
their	PRP$	O
risk	NN	O
comprehension	NN	O
,	,	O
compared	VBN	O
with	IN	O
women	NNS	O
in	IN	O
the	DT	O
control	NN	O
condition	NN	O
(	(	O
odds	NNS	O
ratio	VBP	O
[	CD	O
OR	NNP	O
]	NNP	O
=	VBZ	O
3.5	CD	O
;	:	O
95	CD	O
%	NN	O
confidence	NN	O
interval	NN	O
[	NNP	O
CI	NNP	O
]	NNP	O
=	NNP	O
1.3-9.5	CD	O
;	:	O
P	NNP	O
=	NNP	O
.01	NNP	O
)	)	O
.	.	O

However	RB	O
,	,	O
in	IN	O
both	DT	O
groups	NNS	O
,	,	O
about	RB	O
two	CD	O
thirds	NNS	O
of	IN	O
women	NNS	O
continued	VBN	O
to	TO	O
overestimate	VB	O
their	PRP$	O
lifetime	NN	O
risks	NNS	O
substantially	RB	O
following	VBG	O
counseling	VBG	O
.	.	O

Examination	NN	O
of	IN	O
subjects	NNS	O
by	IN	O
treatment	NN	O
interaction	NN	O
effects	NNS	O
indicated	VBD	O
that	IN	O
risk	NN	O
counseling	VBG	O
did	VBD	O
not	RB	O
produce	VB	O
improved	JJ	O
comprehension	NN	O
among	IN	O
the	DT	O
large	JJ	O
proportion	NN	O
of	IN	O
women	NNS	O
who	WP	O
had	VBD	O
high	JJ	O
levels	NNS	O
of	IN	O
anxious	JJ	O
preoccupation	NN	O
with	IN	O
breast	NN	O
cancer	NN	O
at	IN	O
base	NN	O
line	NN	O
(	(	O
P	NNP	O
=	NNP	O
.02	NNP	O
)	)	O
.	.	O

In	IN	O
addition	NN	O
,	,	O
white	JJ	O
women	NNS	O
were	VBD	O
less	RBR	O
likely	JJ	O
to	TO	O
benefit	VB	O
than	IN	O
African-American	JJ	O
women	NNS	O
(	(	O
OR	NNP	O
=	VBZ	O
0.34	CD	O
;	:	O
95	CD	O
%	NN	O
CI	NNP	O
=	NNP	O
0.11-0.99	NN	O
;	:	O
P	NNP	O
=	NNP	O
.05	NNP	O
)	)	O
.	.	O

CONCLUSION	NNP	O
Efforts	NNPS	O
to	TO	O
counsel	NN	O
women	NNS	O
about	IN	O
their	PRP$	O
breast	NN	O
cancer	NN	O
risks	NNS	O
are	VBP	O
not	RB	O
likely	JJ	O
to	TO	O
be	VB	O
effective	JJ	O
unless	IN	O
their	PRP$	O
breast	NN	O
cancer	NN	O
anxieties	NNS	O
are	VBP	O
also	RB	O
addressed	VBN	O
.	.	O

IMPLICATIONS	NNP	O
Attention	NNP	O
to	TO	O
the	DT	O
psychological	JJ	O
aspects	NNS	O
of	IN	O
breast	NN	O
cancer	NN	O
risk	NN	O
will	MD	O
be	VB	O
critical	JJ	O
in	IN	O
the	DT	O
development	NN	O
of	IN	O
risk-counseling	JJ	O
programs	NNS	O
that	WDT	O
incorporate	VBP	O
testing	VBG	O
for	IN	O
the	DT	O
recently	RB	O
cloned	VBN	O
breast	NN	O
cancer	NN	O
susceptibility	NN	O
gene	NN	O
,	,	O
BRCA1	NNP	O
(	(	O
and	CC	O
BRCA2	NNP	O
when	WRB	O
that	DT	O
gene	NN	O
has	VBZ	O
also	RB	O
been	VBN	O
cloned	VBN	O
)	)	O
.	.	O

Financial	JJ	O
and	CC	O
quality-of-life	JJ	O
burden	NN	O
of	IN	O
dysfunctional	JJ	O
uterine	JJ	O
bleeding	NN	O
among	IN	O
women	NNS	O
agreeing	VBG	O
to	TO	O
obtain	VB	O
surgical	JJ	O
treatment	NN	O
.	.	O

PURPOSE	NN	O
In	IN	O
this	DT	O
study	NN	O
,	,	O
we	PRP	O
sought	VBD	O
to	TO	O
1	CD	O
)	)	O
describe	NN	O
elements	NNS	O
of	IN	O
the	DT	O
financial	JJ	O
and	CC	O
quality-of-life	JJ	O
burden	NN	O
of	IN	O
dysfunctional	JJ	O
uterine	JJ	O
bleeding	NN	O
(	(	O
DUB	NNP	O
)	)	O
from	IN	O
the	DT	O
perspective	NN	O
of	IN	O
women	NNS	O
who	WP	O
agreed	VBD	O
to	TO	O
obtain	VB	O
surgical	JJ	O
treatment	NN	O
;	:	O
2	CD	O
)	)	O
explore	NN	O
associations	NNS	O
between	IN	O
DUB	NNP	O
symptom	NN	O
characteristics	NNS	O
and	CC	O
the	DT	O
financial	JJ	O
and	CC	O
quality-of-life	JJ	O
burden	NN	O
;	:	O
3	CD	O
)	)	O
estimate	VBP	O
the	DT	O
annual	JJ	O
dollar	NN	O
value	NN	O
of	IN	O
the	DT	O
financial	JJ	O
burden	NN	O
;	:	O
and	CC	O
4	CD	O
)	)	O
estimate	VBP	O
the	DT	O
most	RBS	O
that	DT	O
could	MD	O
be	VB	O
spent	VBN	O
on	IN	O
surgery	NN	O
to	TO	O
eliminate	VB	O
DUB	NNP	O
symptoms	NNS	O
for	IN	O
which	WDT	O
medical	JJ	O
treatment	NN	O
has	VBZ	O
been	VBN	O
unsuccessful	JJ	O
that	WDT	O
would	MD	O
result	VB	O
in	IN	O
a	DT	O
$	$	O
50,000/quality-adjusted	JJ	O
life-year	JJ	O
incremental	JJ	O
cost-effectiveness	NN	O
ratio	NN	O
.	.	O

METHODS	NNP	O
We	PRP	O
collected	VBD	O
baseline	NN	O
data	NNS	O
on	IN	O
DUB	NNP	O
symptoms	NNS	O
and	CC	O
aspects	NNS	O
of	IN	O
the	DT	O
financial	JJ	O
and	CC	O
quality-of-life	JJ	O
burden	NN	O
for	IN	O
237	CD	O
women	NNS	O
agreeing	VBG	O
to	TO	O
surgery	VB	O
for	IN	O
DUB	NNP	O
in	IN	O
a	DT	O
randomized	JJ	O
trial	NN	O
comparing	VBG	O
hysterectomy	NN	O
with	IN	O
endometrial	JJ	O
ablation	NN	O
.	.	O

Measures	NNS	O
included	VBD	O
out-of-pocket	JJ	O
pharmaceutical	JJ	O
expenditures	NNS	O
,	,	O
excess	JJ	O
expenditures	NNS	O
on	IN	O
pads	NNS	O
or	CC	O
tampons	NNS	O
,	,	O
the	DT	O
value	NN	O
of	IN	O
time	NN	O
missed	VBN	O
from	IN	O
paid	VBN	O
work	NN	O
and	CC	O
home	NN	O
management	NN	O
activities	NNS	O
,	,	O
and	CC	O
health	NN	O
utility	NN	O
.	.	O

We	PRP	O
used	VBD	O
chi2	NN	O
and	CC	O
t	NN	O
tests	NNS	O
to	TO	O
assess	VB	O
the	DT	O
statistical	JJ	O
significance	NN	O
of	IN	O
associations	NNS	O
between	IN	O
DUB	NNP	O
characteristics	NNS	O
and	CC	O
the	DT	O
financial	JJ	O
and	CC	O
quality-of-life	JJ	O
burden	NN	O
.	.	O

The	DT	O
annual	JJ	O
financial	JJ	O
burden	NN	O
was	VBD	O
estimated	VBN	O
.	.	O

RESULTS	NNP	O
Pelvic	NNP	O
pain	NN	O
and	CC	O
cramps	NNS	O
were	VBD	O
associated	VBN	O
with	IN	O
activity	NN	O
limitations	NNS	O
and	CC	O
tiredness	NN	O
was	VBD	O
associated	VBN	O
with	IN	O
a	DT	O
lower	JJR	O
health	NN	O
utility	NN	O
.	.	O

Excess	NNP	O
pharmaceutical	JJ	O
and	CC	O
pad	NN	O
and	CC	O
tampon	NN	O
costs	NNS	O
were	VBD	O
$	$	O
333	CD	O
per	IN	O
patient	NN	O
per	IN	O
year	NN	O
(	(	O
95	CD	O
%	NN	O
confidence	NN	O
interval	NN	O
[	NNP	O
CI	NNP	O
]	NNP	O
,	,	O
$	$	O
263-	JJ	O
$	$	O
403	CD	O
)	)	O
.	.	O

Excess	NNP	O
paid	VBD	O
work	NN	O
and	CC	O
home	NN	O
management	NN	O
loss	NN	O
costs	NNS	O
were	VBD	O
$	$	O
2,291	CD	O
per	IN	O
patient	NN	O
per	IN	O
year	NN	O
(	(	O
95	CD	O
%	NN	O
CI	NNP	O
,	,	O
$	$	O
1847-	JJ	O
$	$	O
2752	CD	O
)	)	O
.	.	O

Effective	JJ	O
surgical	JJ	O
treatment	NN	O
costing	VBG	O
$	$	O
40,000	CD	O
would	MD	O
be	VB	O
cost-effective	JJ	O
compared	VBN	O
with	IN	O
unsuccessful	JJ	O
medical	JJ	O
treatment	NN	O
.	.	O

CONCLUSION	NNP	O
The	DT	O
financial	JJ	O
and	CC	O
quality-of-life	JJ	O
effects	NNS	O
of	IN	O
DUB	NNP	O
represent	VBP	O
a	DT	O
substantial	JJ	O
burden	NN	O
.	.	O

A	DT	O
short-term	JJ	O
cognitive	JJ	O
group	NN	O
treatment	NN	O
program	NN	O
gives	VBZ	O
substantial	JJ	O
weight	NN	O
reduction	NN	O
up	RB	O
to	TO	O
18	CD	O
months	NNS	O
from	IN	O
the	DT	O
end	NN	O
of	IN	O
treatment	NN	O
.	.	O

A	DT	O
randomized	JJ	O
controlled	JJ	O
trial	NN	O
.	.	O

OBJECTIVE	UH	O
To	TO	O
describe	VB	O
and	CC	O
evaluate	VB	O
long-term	JJ	O
efficacy	NN	O
(	(	O
18	CD	O
months	NNS	O
from	IN	O
the	DT	O
end	NN	O
of	IN	O
treatment	NN	O
)	)	O
of	IN	O
a	DT	O
new	JJ	O
cognitive	JJ	O
short-term	JJ	O
weight	NN	O
reducing	VBG	O
treatment	NN	O
program	NN	O
for	IN	O
obese	JJ	O
patients	NNS	O
.	.	O

SUBJECTS	NNP	O
One	CD	O
hundred	CD	O
and	CC	O
five	CD	O
obese	JJ	O
[	NN	O
Body	NNP	O
Mass	NNP	O
Index	NNP	O
(	(	O
BMI	NNP	O
)	)	O
>	VBD	O
or	CC	O
=	$	O
30	CD	O
]	JJ	O
patients	NNS	O
participated	VBN	O
in	IN	O
the	DT	O
study	NN	O
.	.	O

Of	IN	O
these	DT	O
,	,	O
62	CD	O
took	VBD	O
part	NN	O
in	IN	O
the	DT	O
treatment	NN	O
program	NN	O
and	CC	O
43	CD	O
served	VBD	O
as	IN	O
controls	NNS	O
.	.	O

METHOD	NNP	O
From	IN	O
an	DT	O
obesity	NN	O
unit	NN	O
's	POS	O
waiting	VBG	O
list	NN	O
,	,	O
the	DT	O
patients	NNS	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
either	VB	O
a	DT	O
treatment	NN	O
group	NN	O
or	CC	O
remained	VBN	O
in	IN	O
the	DT	O
waiting	VBG	O
list	NN	O
to	TO	O
serve	VB	O
as	IN	O
a	DT	O
control	NN	O
group	NN	O
.	.	O

The	DT	O
treatment	NN	O
group	NN	O
participated	VBD	O
in	IN	O
a	DT	O
10-week	JJ	O
(	(	O
30	CD	O
hours	NNS	O
)	)	O
cognitive	VBP	O
group	NN	O
treatment	NN	O
program	NN	O
.	.	O

All	DT	O
participants	NNS	O
were	VBD	O
weighed	VBN	O
at	IN	O
the	DT	O
outset	NN	O
of	IN	O
the	DT	O
study	NN	O
,	,	O
directly	RB	O
after	IN	O
treatment	NN	O
and	CC	O
at	IN	O
a	DT	O
6-	JJ	O
,	,	O
12-	JJ	O
and	CC	O
18-month	JJ	O
post-treatment	JJ	O
follow-up	NN	O
without	IN	O
any	DT	O
booster	NN	O
treatment	NN	O
after	IN	O
the	DT	O
10-week	JJ	O
program	NN	O
.	.	O

RESULTS	NNP	O
Fifty-seven	NNP	O
(	(	O
92	CD	O
%	NN	O
)	)	O
patients	NNS	O
completed	VBN	O
treatment	NN	O
.	.	O

For	IN	O
the	DT	O
34	CD	O
(	(	O
60	CD	O
%	NN	O
)	)	O
patients	NNS	O
who	WP	O
participated	VBD	O
in	IN	O
the	DT	O
study	NN	O
18	CD	O
months	NNS	O
after	IN	O
treatment	NN	O
was	VBD	O
terminated	VBN	O
,	,	O
the	DT	O
mean	JJ	O
weight	NN	O
loss	NN	O
at	IN	O
treatment	NN	O
's	POS	O
end	NN	O
was	VBD	O
8.5	CD	O
kg	NN	O
(	(	O
SD=16.1	NNP	O
)	)	O
.	.	O

Eighteen	JJ	O
months	NNS	O
later	RB	O
their	PRP$	O
mean	JJ	O
weight	NN	O
loss	NN	O
was	VBD	O
10.4	CD	O
kg	NN	O
(	(	O
SD=10.8	NNP	O
)	)	O
.	.	O

The	DT	O
control	NN	O
patients	NNS	O
(	(	O
n=31.72	JJ	O
%	NN	O
)	)	O
that	WDT	O
participated	VBD	O
in	IN	O
the	DT	O
study	NN	O
during	IN	O
the	DT	O
same	JJ	O
period	NN	O
increased	VBD	O
in	IN	O
weight	NN	O
by	IN	O
2.3	CD	O
kg	NNS	O
(	(	O
SD=7.0	NNP	O
)	)	O
.	.	O

The	DT	O
weight	NN	O
difference	NN	O
between	IN	O
the	DT	O
treatment	NN	O
and	CC	O
control	NN	O
group	NN	O
at	IN	O
the	DT	O
18-month	JJ	O
follow-up	NN	O
was	VBD	O
highly	RB	O
significant	JJ	O
(	(	O
p	JJ	O
<	NNP	O
0.001	CD	O
)	)	O
.	.	O

CONCLUSION	VB	O
The	DT	O
cognitive	JJ	O
group	NN	O
treatment	NN	O
program	NN	O
was	VBD	O
highly	RB	O
acceptable	JJ	O
among	IN	O
the	DT	O
participants	NNS	O
and	CC	O
was	VBD	O
completed	VBN	O
by	IN	O
nearly	RB	O
all	PDT	O
the	DT	O
patients	NNS	O
.	.	O

The	DT	O
10-week	JJ	O
treatment	NN	O
program	NN	O
resulted	VBD	O
in	IN	O
satisfactory	JJ	O
weight	JJ	O
loss	NN	O
.	.	O

The	DT	O
weight	NN	O
difference	NN	O
between	IN	O
the	DT	O
treatment	NN	O
group	NN	O
and	CC	O
controls	NNS	O
was	VBD	O
nearly	RB	O
the	DT	O
same	JJ	O
at	IN	O
18	CD	O
months	NNS	O
after	IN	O
end	NN	O
of	IN	O
treatment	NN	O
as	IN	O
at	IN	O
six	CD	O
months	NNS	O
.	.	O

The	DT	O
study	NN	O
,	,	O
therefore	RB	O
,	,	O
does	VBZ	O
not	RB	O
provide	VB	O
support	NN	O
for	IN	O
the	DT	O
contention	NN	O
that	IN	O
a	DT	O
lengthy	JJ	O
therapy	NN	O
for	IN	O
obesity	NN	O
is	VBZ	O
necessary	JJ	O
if	IN	O
treatment	NN	O
results	NNS	O
are	VBP	O
lasting	VBG	O
.	.	O

Dose-response	JJ	O
effect	NN	O
of	IN	O
flecainide	NN	O
in	IN	O
patients	NNS	O
with	IN	O
symptomatic	JJ	C
paroxysmal	JJ	C
atrial	JJ	C
fibrillation	NN	C
and/or	NN	C
flutter	NN	C
monitored	VBD	O
with	IN	O
trans-telephonic	JJ	O
electrocardiography	NN	O
:	:	O
a	DT	O
multicenter	NN	O
,	,	O
placebo-controlled	JJ	O
,	,	O
double-blind	JJ	O
trial	NN	O
.	.	O

BACKGROUND	VB	O
A	DT	O
double-blind	NN	O
,	,	O
randomized	VBN	O
,	,	O
parallel-group	JJ	O
,	,	O
placebo-controlled	JJ	O
trial	NN	O
was	VBD	O
conducted	VBN	O
in	IN	O
patients	NNS	O
with	IN	O
paroxysmal	JJ	C
atrial	JJ	C
fibrillation	NN	C
or	CC	C
flutter	NN	C
(	(	C
PAF/PAFL	NNP	C
)	)	C
experiencing	VBG	O
2	CD	O
or	CC	O
more	JJR	O
episodes	NNS	O
of	IN	O
symptomatic	JJ	C
PAF/PAFL	NNP	C
during	IN	O
a	DT	O
28-day	JJ	O
observation	NN	O
period	NN	O
to	TO	O
determine	VB	O
the	DT	O
dose-response	JJ	O
effect	NN	O
and	CC	O
safety	NN	O
of	IN	O
flecainide	NN	O
.	.	O

METHODS	NNP	O
AND	NNP	O
RESULTS	NNP	O
A	NNP	O
total	NN	O
of	IN	O
143	CD	SS
patients	NNS	O
at	IN	O
30	CD	O
centers	NNS	O
were	VBD	O
randomized	VBN	O
to	TO	O
receive	VB	O
25	CD	O
,	,	O
50	CD	O
,	,	O
or	CC	O
100	CD	O
mg	NN	O
of	IN	O
flecainide	NN	O
or	CC	O
placebo	VB	O
twice	JJ	O
daily	JJ	O
(	(	O
BID	NNP	O
)	)	O
.	.	O

In	IN	O
123	CD	SS
patients	NNS	O
(	(	O
per	IN	O
protocol	NN	O
set	NN	O
)	)	O
,	,	O
those	DT	O
remaining	VBG	O
free	JJ	O
from	IN	O
PAF/PAFL	NNP	O
after	IN	O
the	DT	O
treatment	NN	O
were	VBD	O
3.1	CD	O
%	NN	O
on	IN	O
placebo	NN	O
,	,	O
7.7	CD	O
%	NN	O
on	IN	O
25	CD	O
mg/BID	NN	O
,	,	O
9.4	CD	O
%	NN	O
on	IN	O
50	CD	O
mg/BID	NN	O
,	,	O
and	CC	O
39.4	CD	O
%	NN	O
on	IN	O
100	CD	O
mg/BID	NN	O
of	IN	O
flecainide	NN	O
.	.	O

As	IN	O
a	DT	O
whole	JJ	O
group	NN	O
,	,	O
a	DT	O
significant	JJ	O
linear	JJ	O
dose-response	NN	O
(	(	O
p	JJ	O
<	NNP	O
0.001	CD	O
)	)	O
was	VBD	O
observed	VBN	O
and	CC	O
a	DT	O
significant	JJ	O
difference	NN	O
between	IN	O
placebo	NN	O
and	CC	O
100	CD	O
mg/BID	NN	O
was	VBD	O
observed	VBN	O
(	(	O
p	JJ	O
<	NNP	O
0.001	CD	O
)	)	O
.	.	O

A	DT	O
similar	JJ	O
dose-response	NN	O
between	IN	O
the	DT	O
present	JJ	O
study	NN	O
and	CC	O
Caucasian	NNP	O
study	NN	O
was	VBD	O
demonstrated	VBN	O
.	.	O

Although	IN	O
there	EX	O
were	VBD	O
5	CD	O
patients	NNS	O
who	WP	O
needed	VBD	O
cardioversion	NN	O
or	CC	O
ablation	NN	O
because	IN	O
of	IN	O
frequent	JJ	O
episodes	NNS	O
of	IN	O
PAF/PAFL	NNP	O
(	(	O
2	CD	O
in	IN	O
25	CD	O
mg/BID	NN	O
,	,	O
1	CD	O
in	IN	O
50	CD	O
mg/BID	NN	O
,	,	O
and	CC	O
2	CD	O
in	IN	O
100	CD	O
mg/BID	NN	O
of	IN	O
flecainide	NN	O
)	)	O
,	,	O
neither	CC	O
death	NN	O
nor	CC	O
ventricular	JJ	O
proarrhythmic	JJ	O
event	NN	O
was	VBD	O
reported	VBN	O
.	.	O

CONCLUSIONS	VB	O
This	DT	O
study	NN	O
indicated	VBD	O
that	IN	O
flecainide	NN	O
exerted	VBD	O
a	DT	O
significant	JJ	O
dose-dependent	JJ	O
effect	NN	O
on	IN	O
the	DT	O
prevention	NN	O
of	IN	O
symptomatic	JJ	O
PAF/PAFL	NNP	O
recurrence	NN	O
and	CC	O
showed	VBD	O
that	IN	O
there	EX	O
was	VBD	O
no	DT	O
inter-ethnic	JJ	O
difference	NN	O
in	IN	O
the	DT	O
clinical	JJ	O
effect	NN	O
of	IN	O
flecainide	NN	O
in	IN	O
patients	NNS	O
with	IN	O
PAF/PAFL	NNP	C
.	.	O

Clofibrate	NNP	O
and	CC	O
diabetes	VBZ	O
control	NN	O
in	IN	O
patients	NNS	C
treated	VBN	C
with	IN	C
oral	JJ	C
hypoglycaemic	JJ	C
agents	NNS	C
.	.	O

1	CD	O
.	.	O

Twenty-two	JJ	SS
maturity-onset	JJ	O
type	NN	O
diabetics	NNS	C
treated	VBD	O
with	IN	O
oral	JJ	O
hypoglycaemic	JJ	O
agents	NNS	O
entered	VBD	O
a	DT	O
single-blind	JJ	O
crossover	NN	O
study	NN	O
using	VBG	O
placebo	NN	O
(	(	O
periods	VB	O
A	DT	O
and	CC	O
C	NNP	O
,	,	O
2	CD	O
months	NNS	O
each	DT	O
)	)	O
and	CC	O
clofibrate	NN	O
(	(	O
2	CD	O
g/day	NN	O
;	:	O
period	NN	O
B	NNP	O
;	:	O
2	CD	O
months	NNS	O
)	)	O
.	.	O

2	CD	O
.	.	O

In	IN	O
thirteen	JJ	SS
patients	NNS	O
,	,	O
under	IN	O
reasonably	RB	O
good	JJ	O
control	NN	O
,	,	O
clofibrate	NN	O
did	VBD	O
not	RB	O
reduce	VB	O
fasting	VBG	O
or	CC	O
post-prandial	JJ	O
blood	NN	O
glucose	NN	O
,	,	O
nor	CC	O
24	CD	O
h	NN	O
glycosuria	NN	O
;	:	O
no	DT	O
improvement	NN	O
was	VBD	O
noted	VBN	O
in	IN	O
the	DT	O
M-value	NNP	O
,	,	O
an	DT	O
index	NN	O
of	IN	O
diabetes	NNS	O
control	NN	O
.	.	O

3	CD	O
.	.	O

In	IN	O
contrast	NN	O
,	,	O
in	IN	O
nine	CD	O
patients	NNS	O
,	,	O
with	IN	O
poor	JJ	O
diabetes	NNS	O
control	NN	O
,	,	O
clofibrate	NN	O
reduced	VBD	O
24	CD	O
h	NN	O
glycosuria	NN	O
and	CC	O
significantly	RB	O
improved	VBD	O
the	DT	O
M-value	NNP	O
.	.	O

4	CD	O
.	.	O

In	IN	O
all	DT	O
patients	NNS	O
,	,	O
clofibrate	JJ	O
therapy	NN	O
was	VBD	O
associated	VBN	O
with	IN	O
a	DT	O
significant	JJ	O
19-23	JJ	O
%	NN	O
reduction	NN	O
in	IN	O
plasma	NN	O
fibrinogen	NN	O
.	.	O

5	CD	O
.	.	O

It	PRP	O
is	VBZ	O
suggested	VBN	O
that	IN	O
addition	NN	O
of	IN	O
clofibrate	NN	O
may	MD	O
be	VB	O
useful	JJ	O
in	IN	O
maturity-onset	JJ	O
diabetics	NNS	O
not	RB	O
adequately	RB	O
controlled	VBN	O
by	IN	O
diet	NN	O
combined	VBN	O
with	IN	O
oral	JJ	O
hypoglycaemic	JJ	O
agents	NNS	O
.	.	O

Resistance	NNP	O
training	NN	O
increases	NNS	O
basal	VBP	O
limb	JJ	O
blood	NN	O
flow	NN	O
and	CC	O
vascular	JJ	O
conductance	NN	O
in	IN	O
aging	VBG	O
humans	NNS	O
.	.	O

Age-related	JJ	O
reductions	NNS	O
in	IN	O
basal	NN	O
limb	NN	O
blood	NN	O
flow	NN	O
and	CC	O
vascular	JJ	O
conductance	NN	O
are	VBP	O
associated	VBN	O
with	IN	O
the	DT	O
metabolic	JJ	O
syndrome	NN	O
,	,	O
functional	JJ	O
impairments	NNS	O
,	,	O
and	CC	O
osteoporosis	NN	O
.	.	O

We	PRP	O
tested	VBD	O
the	DT	O
hypothesis	NN	O
that	IN	O
a	DT	O
strength	NN	O
training	NN	O
program	NN	O
would	MD	O
increase	VB	O
basal	JJ	O
femoral	JJ	O
blood	NN	O
flow	NN	O
in	IN	O
aging	VBG	O
adults	NNS	O
.	.	O

Twenty-six	JJ	O
sedentary	JJ	O
but	CC	O
healthy	JJ	O
middle-aged	JJ	O
and	CC	O
older	JJR	O
subjects	NNS	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
either	CC	O
a	DT	O
whole	JJ	O
body	NN	O
strength	NN	O
training	VBG	O
intervention	NN	O
group	NN	O
(	(	O
52	CD	O
+/-	JJ	O
2	CD	O
yr	NN	O
,	,	O
3	CD	O
men	NNS	O
,	,	O
10	CD	O
women	NNS	O
)	)	O
who	WP	O
underwent	VBD	O
three	CD	O
supervised	VBN	O
resistance	NN	O
training	NN	O
sessions	NNS	O
per	IN	O
week	NN	O
for	IN	O
13	CD	O
wk	NN	O
or	CC	O
a	DT	O
control	NN	O
group	NN	O
(	(	O
53	CD	O
+/-	JJ	O
2	CD	O
yr	NN	O
,	,	O
4	CD	O
men	NNS	O
,	,	O
9	CD	O
women	NNS	O
)	)	O
who	WP	O
participated	VBD	O
in	IN	O
a	DT	O
supervised	JJ	O
stretching	NN	O
program	NN	O
.	.	O

At	IN	O
baseline	NN	O
,	,	O
there	EX	O
were	VBD	O
no	DT	O
significant	JJ	O
differences	NNS	O
in	IN	O
blood	NN	O
pressure	NN	O
,	,	O
cardiac	JJ	O
output	NN	O
,	,	O
basal	JJ	O
femoral	JJ	O
blood	NN	O
flow	NN	O
(	(	O
via	IN	O
Doppler	NNP	O
ultrasound	NN	O
)	)	O
,	,	O
vascular	JJ	O
conductance	NN	O
,	,	O
and	CC	O
vascular	JJ	O
resistance	NN	O
between	IN	O
the	DT	O
two	CD	O
groups	NNS	O
.	.	O

The	DT	O
strength	NN	O
training	VBG	O
group	NN	O
increased	VBD	O
maximal	JJ	O
strength	NN	O
in	IN	O
all	PDT	O
the	DT	O
major	JJ	O
muscle	NN	O
groups	NNS	O
tested	VBD	O
(	(	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
.	.	O

Whole	JJ	O
body	NN	O
lean	JJ	O
body	NN	O
mass	NN	O
increased	VBD	O
(	(	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
with	IN	O
strength	NN	O
training	NN	O
,	,	O
but	CC	O
leg	VBZ	O
fat-free	JJ	O
mass	NN	O
did	VBD	O
not	RB	O
.	.	O

Basal	NNP	O
femoral	JJ	O
blood	NN	O
flow	NN	O
and	CC	O
vascular	JJ	O
conductance	NN	O
increased	VBN	O
by	IN	O
55-60	CD	O
%	NN	O
after	IN	O
strength	NN	O
training	NN	O
(	(	O
both	DT	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
.	.	O

No	DT	O
such	JJ	O
changes	NNS	O
were	VBD	O
observed	VBN	O
in	IN	O
the	DT	O
control	NN	O
group	NN	O
.	.	O

In	IN	O
both	DT	O
groups	NNS	O
,	,	O
there	EX	O
were	VBD	O
no	DT	O
significant	JJ	O
changes	NNS	O
in	IN	O
brachial	JJ	O
blood	NN	O
pressure	NN	O
,	,	O
plasma	JJ	O
endothelin-1	NN	O
and	CC	O
angiotensin	NN	O
II	NNP	O
concentrations	NNS	O
,	,	O
femoral	JJ	O
artery	NN	O
wall	NN	O
thickness	NN	O
,	,	O
cardiac	JJ	O
output	NN	O
,	,	O
and	CC	O
systemic	JJ	O
vascular	JJ	O
resistance	NN	O
.	.	O

Our	PRP$	O
results	NNS	O
indicate	VBP	O
that	IN	O
short-term	JJ	O
strength	NN	O
training	NN	O
increases	NNS	O
basal	VBP	O
femoral	JJ	O
blood	NN	O
flow	NN	O
and	CC	O
vascular	JJ	O
conductance	NN	O
in	IN	O
healthy	JJ	O
middle-aged	JJ	O
and	CC	O
older	JJR	O
adults	NNS	O
.	.	O

Determinants	NNS	O
of	IN	O
serum	JJ	O
creatinine	NN	O
trajectory	NN	O
in	IN	O
acute	JJ	O
contrast	NN	O
nephropathy	NN	C
.	.	O

The	DT	O
aim	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
describe	VB	O
the	DT	O
trajectory	NN	O
of	IN	O
creatinine	NN	O
(	(	O
Cr	NNP	O
)	)	O
rise	NN	O
and	CC	O
its	PRP$	O
determinants	NNS	O
after	IN	O
exposure	NN	O
to	TO	O
radiocontrast	VB	C
media	NNS	O
.	.	O

Included	VBN	O
were	VBD	O
98	CD	SS
subjects	NNS	O
who	WP	O
underwent	VBP	O
cardiac	JJ	C
catheterization	NN	C
and	CC	O
were	VBD	O
randomized	VBN	O
to	TO	O
forced	VBN	O
diuresis	NN	O
with	IN	O
i.v	NN	O
.	.	O

crystalloid	NN	O
,	,	O
furosemide	RB	O
,	,	O
mannitol	NN	O
(	(	O
if	IN	O
pulmonary	JJ	O
capillary	JJ	O
wedge	NN	O
pressure	NN	O
was	VBD	O
<	JJ	O
20	CD	O
mmHg	NN	O
)	)	O
,	,	O
and	CC	O
low	JJ	O
dose	JJ	O
dopamine	NN	O
versus	NN	O
intravenous	JJ	O
crystalloid	NN	O
and	CC	O
matching	VBG	O
placebos	NNS	O
.	.	O

Baseline	NNP	O
and	CC	O
postcatheterization	NN	O
serum	NN	O
Cr	NNP	O
levels	NNS	O
were	VBD	O
analyzed	VBN	O
in	IN	O
a	DT	O
longitudinal	JJ	O
fashion	NN	O
,	,	O
allowing	VBG	O
for	IN	O
differences	NNS	O
in	IN	O
the	DT	O
time	NN	O
between	IN	O
blood	NN	O
draws	NNS	O
,	,	O
to	TO	O
determine	VB	O
the	DT	O
different	JJ	O
critical	JJ	O
trajectories	NNS	O
of	IN	O
serum	NN	O
Cr	NNP	O
.	.	O

The	DT	O
mean	JJ	O
age	NN	O
,	,	O
baseline	NN	O
serum	NN	O
Cr	NNP	O
,	,	O
and	CC	O
Cr	NNP	O
clearance	NN	O
(	(	O
CrCl	NNP	O
)	)	O
were	VBD	O
69.3	CD	A
+/-	JJ	A
10.8	CD	A
years	NNS	A
,	,	O
2.5	CD	O
+/-	JJ	O
0.9	CD	O
mg/dL	NN	O
,	,	O
and	CC	O
31.4	CD	O
+/-	JJ	O
12.1	CD	O
mL/min	NN	O
,	,	O
respectively	RB	O
.	.	O

The	DT	O
clinically	RB	O
driven	JJ	O
postprocedural	JJ	O
observation	NN	O
time	NN	O
was	VBD	O
5.5	CD	O
+/-	JJ	O
5.1	CD	O
days	NNS	O
(	(	O
range	VB	O
19	CD	O
hours	NNS	O
and	CC	O
one	CD	O
Cr	NNP	O
value	NN	O
to	TO	O
25.7	CD	O
days	NNS	O
and	CC	O
18	CD	O
values	NNS	O
)	)	O
.	.	O

The	DT	O
mean	JJ	O
maximum	NN	O
Cr	NNP	O
was	VBD	O
3.3	CD	O
+/-	JJ	O
1.4	CD	O
,	,	O
range	NN	O
1.7-8.7	JJ	O
mg/dL	NN	O
)	)	O
.	.	O

Longitudinal	JJ	O
models	NNS	O
support	VBP	O
baseline	JJ	O
Cr	NNP	O
clearance	NN	O
predictions	NNS	O
for	IN	O
the	DT	O
change	NN	O
in	IN	O
Cr	NNP	O
at	IN	O
24	CD	O
hours	NNS	O
,	,	O
time	NN	O
as	IN	O
the	DT	O
determinant	NN	O
of	IN	O
Cr	NNP	O
trajectory	NN	O
,	,	O
and	CC	O
requisite	JJ	O
monitoring	NN	O
.	.	O

For	IN	O
any	DT	O
given	VBN	O
individual	NN	O
,	,	O
a	DT	O
rise	NN	O
in	IN	O
Cr	NNP	O
of	IN	O
<	NNP	O
or	CC	O
=	$	O
0.5	CD	O
mg/dL	NN	O
in	IN	O
the	DT	O
first	JJ	O
24	CD	O
hours	NNS	O
after	IN	O
contrast	NN	O
exposure	NN	O
predicted	VBD	O
a	DT	O
favorable	JJ	O
outcome	NN	O
.	.	O

Baseline	NNP	O
renal	JJ	O
function	NN	O
is	VBZ	O
the	DT	O
major	JJ	O
determinant	NN	O
of	IN	O
the	DT	O
rate	NN	O
of	IN	O
rise	NN	O
,	,	O
height	NN	O
,	,	O
and	CC	O
duration	NN	O
of	IN	O
Cr	NNP	O
trajectory	NN	O
after	IN	O
contrast	NN	O
exposure	NN	O
.	.	O

Length	NNP	O
of	IN	O
observation	NN	O
and	CC	O
frequency	NN	O
of	IN	O
laboratory	NN	O
measures	NNS	O
can	MD	O
be	VB	O
anticipated	VBN	O
from	IN	O
these	DT	O
models	NNS	O
.	.	O

[	JJ	O
Effect	NNP	O
of	IN	O
dopexamine	NN	O
in	IN	O
splanchnic	JJ	O
perfusion	NN	O
during	IN	O
surgery	NN	O
of	IN	O
the	DT	O
abdominal	JJ	O
aorta	NN	O
]	NNP	O
.	.	O

Abdominal	NNP	O
aortic	JJ	O
surgery	NN	O
has	VBZ	O
significant	JJ	O
effects	NNS	O
on	IN	O
cardiac	NN	O
and	CC	O
splanchnic	JJ	O
perfusion	NN	O
.	.	O

The	DT	O
purpose	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
examine	VB	O
the	DT	O
effects	NNS	O
of	IN	O
dopexamine	NN	O
,	,	O
an	DT	O
inodilator	JJ	O
drug	NN	O
,	,	O
on	IN	O
hemodynamic	JJ	O
and	CC	O
splanchnic	JJ	O
perfusion	NN	O
with	IN	O
measurement	NN	O
of	IN	O
gastric	JJ	O
intramucosal	NN	O
pH	NN	O
,	,	O
by	IN	O
the	DT	O
method	NN	O
of	IN	O
gastric	JJ	O
tonometry	NN	O
,	,	O
during	IN	O
abdominal	JJ	O
aneurysm	JJ	O
resection	NN	O
.	.	O

Twenty-five	JJ	O
patients	NNS	O
undergoing	VBG	O
excision	NN	O
of	IN	O
an	DT	O
aortic	JJ	O
abdominal	JJ	O
aneurysm	NN	O
were	VBD	O
randomly	RB	O
divided	VBN	O
into	IN	O
two	CD	O
groups	NNS	O
.	.	O

During	IN	O
aortic	JJ	O
cross-clamping	JJ	O
Group	NNP	O
II	NNP	O
patients	NNS	O
received	VBD	O
dopexamine	JJ	O
infusion	NN	O
,	,	O
at	IN	O
a	DT	O
dose	NN	O
of	IN	O
1	CD	O
microgram/kg/m	NN	O
,	,	O
and	CC	O
at	IN	O
a	DT	O
dose	NN	O
of	IN	O
0.5	CD	O
micrograms/kg/m	NN	O
from	IN	O
declamping	VBG	O
to	TO	O
the	DT	O
end	NN	O
of	IN	O
the	DT	O
surgery	NN	O
.	.	O

Whereas	NNP	O
Group	NNP	O
I	PRP	O
patients	NNS	O
did	VBD	O
not	RB	O
receive	VB	O
a	DT	O
dopexamine	JJ	O
infusion	NN	O
.	.	O

During	IN	O
aortic	JJ	O
cross-clamping	VBG	O
the	DT	O
intramucosal	NN	O
pH	VBZ	O
value	NN	O
decreased	VBN	O
in	IN	O
Group	NNP	O
I	PRP	O
patients	NNS	O
,	,	O
but	CC	O
did	VBD	O
not	RB	O
change	VB	O
in	IN	O
Group	NNP	O
II	NNP	O
patients	NNS	O
.	.	O

Heart	NNP	O
rate	NN	O
,	,	O
cardiac	JJ	O
index	NN	O
,	,	O
and	CC	O
mixed	JJ	O
venous	JJ	O
oxygen	NN	O
saturation	NN	O
increased	VBD	O
significantly	RB	O
during	IN	O
dopexamine	JJ	O
infusion	NN	O
,	,	O
whereas	JJ	O
systemic	JJ	O
vascular	NN	O
resistance	NN	O
was	VBD	O
reduced	VBN	O
.	.	O

During	IN	O
aortic	JJ	O
cross-clamping	JJ	O
dopexamine	NN	O
was	VBD	O
a	DT	O
useful	JJ	O
agent	NN	O
in	IN	O
improving	VBG	O
splanchnic	JJ	O
blood	NN	O
flow	NN	O
,	,	O
cardiac	JJ	O
index	NN	O
venous	JJ	O
saturation	NN	O
.	.	O

Also	RB	O
,	,	O
since	IN	O
the	DT	O
drug	NN	O
produces	VBZ	O
dose	RB	O
related	JJ	O
hemodynamic	JJ	O
changes	NNS	O
of	IN	O
rapid	JJ	O
onset	NN	O
and	CC	O
reversibility	NN	O
,	,	O
it	PRP	O
is	VBZ	O
possible	JJ	O
to	TO	O
interrupt	VB	O
the	DT	O
infusion	NN	O
before	IN	O
aortic	JJ	O
declamping	NN	O
to	TO	O
avoid	VB	O
the	DT	O
decrease	NN	O
in	IN	O
the	DT	O
intramucosal	NN	O
pH	VBZ	O
value	NN	O
.	.	O

Effect	NN	O
of	IN	O
resistance	NN	O
exercise	NN	O
contraction	NN	O
mode	NN	O
and	CC	O
protein	JJ	O
supplementation	NN	O
on	IN	O
members	NNS	O
of	IN	O
the	DT	O
STARS	NNP	O
signalling	VBG	O
pathway	RB	O
.	.	O

The	DT	O
striated	JJ	O
muscle	NN	O
activator	NN	O
of	IN	O
Rho	NNP	O
signalling	VBG	O
(	(	O
STARS	NNP	O
)	)	O
pathway	NN	O
is	VBZ	O
suggested	VBN	O
to	TO	O
provide	VB	O
a	DT	O
link	NN	O
between	IN	O
external	JJ	O
stress	NN	O
responses	NNS	O
and	CC	O
transcriptional	JJ	O
regulation	NN	O
in	IN	O
muscle	NN	O
.	.	O

However	RB	O
,	,	O
the	DT	O
sensitivity	NN	O
of	IN	O
STARS	NNP	O
signalling	VBG	O
to	TO	O
different	JJ	O
mechanical	JJ	O
stresses	NNS	O
has	VBZ	O
not	RB	O
been	VBN	O
investigated	VBN	O
.	.	O

In	IN	O
a	DT	O
comparative	JJ	O
study	NN	O
,	,	O
we	PRP	O
examined	VBD	O
the	DT	O
regulation	NN	O
of	IN	O
the	DT	O
STARS	NNP	O
signalling	VBG	O
pathway	RB	O
in	IN	O
response	NN	O
to	TO	O
unilateral	JJ	O
resistance	NN	O
exercise	NN	O
performed	VBN	O
as	IN	O
either	DT	O
eccentric	JJ	O
(	(	O
ECC	NNP	O
)	)	O
or	CC	O
concentric	JJ	O
(	(	O
CONC	NNP	O
)	)	O
contractions	NNS	O
as	RB	O
well	RB	O
as	IN	O
prolonged	JJ	O
training	NN	O
;	:	O
with	IN	O
and	CC	O
without	IN	O
whey	JJ	O
protein	NN	O
supplementation	NN	O
.	.	O

Skeletal	JJ	O
muscle	NN	O
STARS	NNP	O
,	,	O
myocardian-related	JJ	O
transcription	NN	O
factor-A	NN	O
(	(	O
MRTF-A	NNP	O
)	)	O
and	CC	O
serum	JJ	O
response	NN	O
factor	NN	O
(	(	O
SRF	NNP	O
)	)	O
mRNA	NN	O
and	CC	O
protein	NN	O
,	,	O
as	RB	O
well	RB	O
as	IN	O
muscle	NN	O
cross-sectional	JJ	O
area	NN	O
and	CC	O
maximal	JJ	O
voluntary	JJ	O
contraction	NN	O
,	,	O
were	VBD	O
measured	VBN	O
.	.	O

A	DT	O
single-bout	NN	O
of	IN	O
exercise	NN	O
produced	VBN	O
increases	NNS	O
in	IN	O
STARS	NNP	O
and	CC	O
SRF	NNP	O
mRNA	NN	O
and	CC	O
decreases	NNS	O
in	IN	O
MRTF-A	NNP	O
mRNA	NN	O
with	IN	O
both	DT	O
ECC	NNP	O
and	CC	O
CONC	NNP	O
exercise	NN	O
,	,	O
but	CC	O
with	IN	O
an	DT	O
enhanced	JJ	O
response	NN	O
occurring	VBG	O
following	VBG	O
ECC	NNP	O
exercise	NN	O
.	.	O

A	DT	O
31	CD	O
%	NN	O
increase	NN	O
in	IN	O
STARS	NNP	O
protein	NN	O
was	VBD	O
observed	VBN	O
exclusively	RB	O
after	IN	O
CONC	NNP	O
exercise	NN	O
(	(	O
P	NNP	O
<	NNP	O
0.001	CD	O
)	)	O
,	,	O
while	IN	O
pSRF	JJ	O
protein	NN	O
levels	NNS	O
increased	VBD	O
similarly	RB	O
by	IN	O
48	CD	O
%	NN	O
with	IN	O
both	DT	O
CONC	NNP	O
and	CC	O
ECC	NNP	O
exercise	NN	O
(	(	O
P	NNP	O
<	NNP	O
0.001	CD	O
)	)	O
.	.	O

Prolonged	VBN	O
ECC	NNP	O
and	CC	O
CONC	NNP	O
training	VBG	O
equally	RB	O
stimulated	VBN	O
muscle	NN	O
hypertrophy	NN	O
and	CC	O
produced	VBD	O
increases	NNS	O
in	IN	O
MRTF-A	NNP	O
protein	NN	O
of	IN	O
125	CD	O
%	NN	O
and	CC	O
99	CD	O
%	NN	O
,	,	O
respectively	RB	O
(	(	O
P	NNP	O
<	NNP	O
0.001	CD	O
)	)	O
.	.	O

No	UH	O
changes	NNS	O
occurred	VBD	O
for	IN	O
total	JJ	O
SRF	NNP	O
protein	NN	O
.	.	O

There	EX	O
was	VBD	O
no	DT	O
effect	NN	O
of	IN	O
whey	NN	O
protein	NN	O
supplementation	NN	O
.	.	O

These	DT	O
results	NNS	O
show	VBP	O
that	IN	O
resistance	NN	O
exercise	NN	O
provides	VBZ	O
an	DT	O
acute	JJ	O
stimulation	NN	O
of	IN	O
the	DT	O
STARS	NNP	O
pathway	NN	O
that	WDT	O
is	VBZ	O
contraction	JJ	O
mode	NN	O
dependent	NN	O
.	.	O

The	DT	O
responses	NNS	O
to	TO	O
acute	VB	O
exercise	NN	O
were	VBD	O
more	RBR	O
pronounced	JJ	O
than	IN	O
responses	NNS	O
to	TO	O
accumulated	JJ	O
training	NN	O
,	,	O
suggesting	VBG	O
that	IN	O
STARS	NNP	O
signalling	VBG	O
is	VBZ	O
primarily	RB	O
involved	VBN	O
in	IN	O
the	DT	O
initial	JJ	O
phase	NN	O
of	IN	O
exercise-induced	JJ	O
muscle	NN	O
adaptations	NNS	O
.	.	O

Remote	NNP	O
ischaemic	JJ	O
conditioning	NN	O
before	IN	O
hospital	JJ	O
admission	NN	O
,	,	O
as	IN	O
a	DT	O
complement	NN	O
to	TO	O
angioplasty	VB	O
,	,	O
and	CC	O
effect	NN	O
on	IN	O
myocardial	JJ	O
salvage	NN	O
in	IN	O
patients	NNS	O
with	IN	O
acute	JJ	C
myocardial	JJ	C
infarction	NN	C
:	:	O
a	DT	O
randomised	JJ	O
trial	NN	O
.	.	O

BACKGROUND	NNP	O
Remote	NNP	O
ischaemic	JJ	O
preconditioning	NN	O
attenuates	NNS	O
cardiac	JJ	O
injury	NN	O
at	IN	O
elective	JJ	O
surgery	NN	O
and	CC	O
angioplasty	NN	O
.	.	O

We	PRP	O
tested	VBD	O
the	DT	O
hypothesis	NN	O
that	WDT	O
remote	VBP	O
ischaemic	JJ	O
conditioning	NN	O
during	IN	O
evolving	VBG	O
ST-elevation	NNP	O
myocardial	JJ	O
infarction	NN	O
,	,	O
and	CC	O
done	VBN	O
before	IN	O
primary	JJ	O
percutaneous	JJ	O
coronary	JJ	O
intervention	NN	O
,	,	O
increases	VBZ	O
myocardial	JJ	O
salvage	NN	O
.	.	O

METHODS	NNP	O
333	CD	SS
consecutive	JJ	O
adult	NN	O
patients	NNS	O
with	IN	O
a	DT	O
suspected	VBN	O
first	JJ	O
acute	JJ	C
myocardial	JJ	C
infarction	NN	C
were	VBD	O
randomly	RB	O
assigned	VBN	O
in	IN	O
a	DT	O
1:1	CD	O
ratio	NN	O
by	IN	O
computerised	JJ	O
block	NN	O
randomisation	NN	O
to	TO	O
receive	VB	O
primary	JJ	O
percutaneous	JJ	O
coronary	JJ	O
intervention	NN	O
with	IN	O
(	(	O
n=166	JJ	O
patients	NNS	O
)	)	O
versus	NN	O
without	IN	O
(	(	O
n=167	NN	O
)	)	O
remote	VBP	O
conditioning	VBG	O
(	(	O
intermittent	JJ	O
arm	NN	O
ischaemia	NN	O
through	IN	O
four	CD	O
cycles	NNS	O
of	IN	O
5-min	JJ	O
inflation	NN	O
and	CC	O
5-min	JJ	O
deflation	NN	O
of	IN	O
a	DT	O
blood-pressure	JJ	O
cuff	NN	O
)	)	O
.	.	O

Allocation	NN	O
was	VBD	O
concealed	VBN	O
with	IN	O
opaque	NN	O
sealed	VBN	O
envelopes	NNS	O
.	.	O

Patients	NNS	O
received	VBD	O
remote	JJ	O
conditioning	NN	O
during	IN	O
transport	NN	O
to	TO	O
hospital	NN	O
,	,	O
and	CC	O
primary	JJ	O
percutaneous	JJ	O
coronary	JJ	O
intervention	NN	O
in	IN	O
hospital	NN	O
.	.	O

The	DT	O
primary	JJ	O
endpoint	NN	O
was	VBD	O
myocardial	JJ	O
salvage	NN	O
index	NN	O
at	IN	O
30	CD	O
days	NNS	O
after	IN	O
primary	JJ	O
percutaneous	JJ	O
coronary	JJ	O
intervention	NN	O
,	,	O
measured	VBN	O
by	IN	O
myocardial	JJ	O
perfusion	NN	O
imaging	NN	O
as	IN	O
the	DT	O
proportion	NN	O
of	IN	O
the	DT	O
area	NN	O
at	IN	O
risk	NN	O
salvaged	VBN	O
by	IN	O
treatment	NN	O
;	:	O
analysis	NN	O
was	VBD	O
per	IN	O
protocol	NN	O
.	.	O

This	DT	O
study	NN	O
is	VBZ	O
registered	VBN	O
with	IN	O
ClinicalTrials.gov	NNP	O
,	,	O
number	NN	O
NCT00435266	NNP	O
.	.	O

FINDINGS	NNP	O
82	CD	O
patients	NNS	O
were	VBD	O
excluded	VBN	O
on	IN	O
arrival	NN	O
at	IN	O
hospital	NN	O
because	IN	O
they	PRP	O
did	VBD	O
not	RB	O
meet	VB	O
inclusion	NN	O
criteria	NNS	O
,	,	O
32	CD	O
were	VBD	O
lost	VBN	O
to	TO	O
follow-up	NN	O
,	,	O
and	CC	O
77	CD	O
did	VBD	O
not	RB	O
complete	VB	O
the	DT	O
follow-up	JJ	O
with	IN	O
data	NNS	O
for	IN	O
salvage	NN	O
index	NN	O
.	.	O

Median	JJ	O
salvage	NN	O
index	NN	O
was	VBD	O
0.75	CD	O
(	(	O
IQR	NNP	O
0.50-0.93	CD	O
,	,	O
n=73	NN	O
)	)	O
in	IN	O
the	DT	O
remote	JJ	O
conditioning	NN	O
group	NN	O
versus	VBD	O
0.55	CD	O
(	(	O
0.35-0.88	CD	O
,	,	O
n=69	NN	O
)	)	O
in	IN	O
the	DT	O
control	NN	O
group	NN	O
,	,	O
with	IN	O
median	JJ	O
difference	NN	O
of	IN	O
0.10	CD	O
(	(	O
95	CD	O
%	NN	O
CI	NNP	O
0.01-0.22	CD	O
;	:	O
p=0.0333	NN	O
)	)	O
;	:	O
mean	JJ	O
salvage	NN	O
index	NN	O
was	VBD	O
0.69	CD	O
(	(	O
SD	NNP	O
0.27	CD	O
)	)	O
versus	NN	O
0.57	CD	O
(	(	O
0.26	CD	O
)	)	O
,	,	O
with	IN	O
mean	JJ	O
difference	NN	O
of	IN	O
0.12	CD	O
(	(	O
95	CD	O
%	NN	O
CI	NNP	O
0.01-0.21	CD	O
;	:	O
p=0.0333	NN	O
)	)	O
.	.	O

Major	JJ	O
adverse	JJ	O
coronary	JJ	O
events	NNS	O
were	VBD	O
death	NN	O
(	(	O
n=3	JJ	O
per	IN	O
group	NN	O
)	)	O
,	,	O
reinfarction	NN	O
(	(	O
n=1	JJ	O
per	IN	O
group	NN	O
)	)	O
,	,	O
and	CC	O
heart	NN	O
failure	NN	O
(	(	O
n=3	JJ	O
per	IN	O
group	NN	O
)	)	O
.	.	O

INTERPRETATION	NNP	O
Remote	NNP	O
ischaemic	JJ	O
conditioning	NN	O
before	IN	O
hospital	JJ	O
admission	NN	O
increases	VBZ	O
myocardial	JJ	O
salvage	NN	O
,	,	O
and	CC	O
has	VBZ	O
a	DT	O
favourable	JJ	O
safety	NN	O
profile	NN	O
.	.	O

Our	PRP$	O
findings	NNS	O
merit	VBP	O
a	DT	O
larger	JJR	O
trial	NN	O
to	TO	O
establish	VB	O
the	DT	O
effect	NN	O
of	IN	O
remote	JJ	O
conditioning	NN	O
on	IN	O
clinical	JJ	O
outcomes	NNS	O
.	.	O

FUNDING	NN	O
Fondation	NNP	O
Leducq	NNP	O
.	.	O

Autism-Spectrum	JJ	O
Quotient-Japanese	JJ	O
version	NN	O
and	CC	O
its	PRP$	O
short	JJ	O
forms	NNS	O
for	IN	O
screening	VBG	O
normally	RB	C
intelligent	JJ	C
persons	NNS	O
with	IN	O
pervasive	JJ	C
developmental	NN	C
disorders	NNS	C
.	.	O

A	DT	O
Japanese	JJ	O
version	NN	O
of	IN	O
the	DT	O
Autism	NNP	O
Spectrum	NNP	O
Quotient	NNP	O
(	(	O
AQ	NNP	O
)	)	O
,	,	O
AQ-J	NNP	O
was	VBD	O
administered	VBN	O
to	TO	O
25	CD	C
normally	RB	C
intelligent	JJ	C
high-functioning	JJ	C
pervasive	JJ	C
developmental	NN	C
disorder	NN	C
(	(	O
HPDD	NNP	C
)	)	O
patients	NNS	O
(	(	O
mean	JJ	O
age	NN	O
,	,	O
24.2	CD	A
years	NNS	A
;	:	O
24	CD	C
male	NN	A
,	,	O
one	CD	C
female	NN	A
)	)	O
and	CC	O
215	CD	C
controls	NNS	O
(	(	O
mean	JJ	O
age	NN	O
,	,	O
30.4	CD	A
years	NNS	A
;	:	O
86	CD	C
male	NN	A
,	,	O
129	CD	C
female	NN	A
)	)	O
randomly	RB	O
selected	VBN	O
from	IN	O
the	DT	O
general	JJ	O
population	NN	O
.	.	O

The	DT	O
AQ-J	NNP	O
had	VBD	O
satisfactory	JJ	O
internal	JJ	O
consistency	NN	O
reliability	NN	O
(	(	O
Cronbach	NNP	O
's	POS	O
alpha	NN	O
>	VBD	O
0.70	CD	O
in	IN	O
the	DT	O
two	CD	O
groups	NNS	O
)	)	O
,	,	O
test-retest	JJ	O
reliability	NN	O
,	,	O
and	CC	O
discriminant	JJ	O
validity	NN	O
[	NNP	O
i.e	NN	O
.	.	O

the	DT	O
AQ-J	NNP	O
score	NN	O
was	VBD	O
significantly	RB	O
higher	JJR	O
in	IN	O
the	DT	O
HPDD	NNP	O
(	(	O
mean	NN	O
,	,	O
29.6	CD	O
)	)	O
than	IN	O
controls	NNS	O
(	(	O
mean	NN	O
,	,	O
22.2	CD	O
)	)	O
]	NN	O
.	.	O

At	IN	O
a	DT	O
cut-off	NN	O
of	IN	O
26	CD	O
,	,	O
the	DT	O
AQ-J	NNP	O
had	VBD	O
satisfactory	JJ	O
sensitivity	NN	O
,	,	O
specificity	NN	O
,	,	O
and	CC	O
negative	JJ	O
predictive	JJ	O
value	NN	O
,	,	O
but	CC	O
it	PRP	O
had	VBD	O
low	JJ	O
positive	JJ	O
predictive	NN	O
value	NN	O
(	(	O
0.24	CD	O
)	)	O
possibly	RB	O
due	JJ	O
to	TO	O
the	DT	O
facts	NNS	O
that	IN	O
the	DT	O
25	CD	O
mild	JJ	O
HPDD	NNP	O
patients	NNS	O
scored	VBD	O
lower	JJR	O
and	CC	O
the	DT	O
controls	NNS	O
scored	VBD	O
higher	JJR	O
on	IN	O
the	DT	O
AQ-J	NNP	O
than	IN	O
British	NNP	O
counterparts	NNS	O
on	IN	O
the	DT	O
AQ	NNP	O
.	.	O

The	DT	O
AQ-J-21	NNP	O
(	(	O
consisting	VBG	O
of	IN	O
21	CD	O
items	NNS	O
significantly	RB	O
associated	VBN	O
with	IN	O
HPDD	NNP	O
diagnosis	NN	O
)	)	O
and	CC	O
the	DT	O
AQ-J-10	NNP	O
(	(	O
consisting	VBG	O
of	IN	O
10	CD	O
of	IN	O
the	DT	O
21	CD	O
items	NNS	O
with	IN	O
an	DT	O
effect	NN	O
size	NN	O
>	NNP	O
0.17	CD	O
)	)	O
had	VBD	O
higher	JJR	O
,	,	O
although	IN	O
not	RB	O
satisfactory	JJ	O
,	,	O
positive	JJ	O
predictive	JJ	O
values	NNS	O
of	IN	O
0.35	CD	O
and	CC	O
0.46	CD	O
at	IN	O
cut-offs	NNS	O
of	IN	O
12	CD	O
and	CC	O
7	CD	O
,	,	O
respectively	RB	O
,	,	O
than	IN	O
the	DT	O
AQ-J	NNP	O
.	.	O

The	DT	O
AQ-J	JJ	O
and	CC	O
two	CD	O
short	JJ	O
forms	NNS	O
are	VBP	O
useful	JJ	O
not	RB	O
to	TO	O
predict	VB	O
but	CC	O
to	TO	O
rule	VB	O
out	RP	O
mild	NN	O
HPDD	NNP	O
,	,	O
the	DT	O
most	RBS	O
difficult	JJ	O
part	NN	O
of	IN	O
HPDD	NNP	O
to	TO	O
be	VB	O
distinguished	VBN	O
from	IN	O
non-PDD	JJ	O
conditions	NNS	O
,	,	O
in	IN	O
persons	NNS	O
scoring	VBG	O
under	IN	O
the	DT	O
cut-offs	NNS	O
and	CC	O
to	TO	O
consider	VB	O
professionals	NNS	O
'	POS	O
examination	NN	O
of	IN	O
HPDD	NNP	O
in	IN	O
persons	NNS	O
scoring	VBG	O
over	IN	O
them	PRP	O
,	,	O
because	IN	O
their	PRP$	O
negative	JJ	O
predictive	JJ	O
values	NNS	O
were	VBD	O
satisfactory	JJ	O
.	.	O

The	DT	O
effects	NNS	O
of	IN	O
a	DT	O
24-h	JJ	O
psychological	JJ	O
training	NN	O
program	NN	O
on	IN	O
attitudes	NNS	O
,	,	O
communication	NN	O
skills	NNS	O
and	CC	O
occupational	JJ	O
stress	NN	O
in	IN	O
oncology	NN	O
:	:	O
a	DT	O
randomised	JJ	O
study	NN	O
.	.	O

The	DT	O
usefulness	NN	O
of	IN	O
psychological	JJ	O
training	NN	O
programs	NNS	O
(	(	O
P.T.P	NNP	O
.	.	O

)	)	O
in	IN	O
health	NN	O
care	NN	O
settings	NNS	O
devoted	VBN	O
to	TO	O
cancer	NN	O
care	NN	O
is	VBZ	O
beginning	VBG	O
to	TO	O
be	VB	O
recognised	VBN	O
but	CC	O
their	PRP$	O
content	NN	O
,	,	O
form	NN	O
and	CC	O
effectiveness	VB	O
need	NN	O
further	JJ	O
investigation	NN	O
.	.	O

Seventy-two	JJ	SS
oncology	NN	C
nurses	NNS	C
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
a	DT	O
24-h	JJ	O
P.T.P	NNP	O
.	.	O

or	CC	O
to	TO	O
a	DT	O
waiting	VBG	O
list	NN	O
period	NN	O
.	.	O

Attitudes	NNS	O
were	VBD	O
assessed	VBN	O
by	IN	O
a	DT	O
semantic	JJ	O
differential	NN	O
questionnaire	NN	O
,	,	O
occupational	JJ	O
stress	NN	O
was	VBD	O
assessed	VBN	O
by	IN	O
the	DT	O
Nursing	NNP	O
Stress	NNP	O
Scale	NNP	O
and	CC	O
communication	NN	O
skills	NNS	O
were	VBD	O
assessed	VBN	O
by	IN	O
standardised	JJ	O
videotaped	VBD	O
role-playing	NN	O
exercises	NNS	O
.	.	O

These	DT	O
were	VBD	O
used	VBN	O
to	TO	O
compare	VB	O
trained	JJ	O
(	(	O
T.S	NNP	O
.	.	O

)	)	O
and	CC	O
control	NN	O
subjects	NNS	O
(	(	O
C.S.	NNP	O
)	)	O
.	.	O

The	DT	O
results	NNS	O
show	VBP	O
a	DT	O
significant	JJ	O
training	NN	O
effect	NN	O
on	IN	O
attitudes	NNS	O
(	(	O
P	NNP	O
=	NNP	O
0.05	CD	O
)	)	O
,	,	O
especially	RB	O
on	IN	O
those	DT	O
related	VBN	O
to	TO	O
self	VB	O
concept	NN	O
(	(	O
P	NNP	O
=	NNP	O
0.004	CD	O
)	)	O
,	,	O
and	CC	O
on	IN	O
the	DT	O
level	NN	O
of	IN	O
occupational	JJ	O
stress	NN	O
related	VBN	O
to	TO	O
inadequate	VB	O
preparation	NN	O
(	(	O
P	NNP	O
=	NNP	O
0.02	CD	O
)	)	O
.	.	O

Limited	VBN	O
changes	NNS	O
were	VBD	O
found	VBN	O
regarding	VBG	O
post-training	JJ	O
communication	NN	O
skills	NNS	O
.	.	O

T.S	NNP	O
.	.	O

were	VBD	O
significantly	RB	O
more	RBR	O
in	IN	O
control	NN	O
of	IN	O
the	DT	O
interview	NN	O
than	IN	O
C.S	NNP	O
.	.	O

(	(	O
P	NNP	O
=	NNP	O
0.02	CD	O
)	)	O
.	.	O

The	DT	O
results	NNS	O
indicate	VBP	O
that	IN	O
24-h	JJ	O
P.T.P	NNP	O
.	.	O

assessed	VBN	O
here	RB	O
are	VBP	O
effective	JJ	O
.	.	O

The	DT	O
data	NN	O
also	RB	O
demonstrate	VBP	O
the	DT	O
need	NN	O
to	TO	O
consolidate	VB	O
the	DT	O
skills	NNS	O
acquired	VBN	O
by	IN	O
regular	JJ	O
post-training	JJ	O
sessions	NNS	O
.	.	O

Effects	NNS	O
of	IN	O
weight	JJ	O
loss	NN	O
and	CC	O
exercise	NN	O
on	IN	O
insulin	NN	O
resistance	NN	O
,	,	O
and	CC	O
intramyocellular	JJ	O
triacylglycerol	NN	O
,	,	O
diacylglycerol	NN	O
and	CC	O
ceramide	NN	O
.	.	O

AIMS/HYPOTHESIS	NNP	O
Intramyocellular	NNP	O
lipids	NNS	O
,	,	O
including	VBG	O
diacylglycerol	NN	O
(	(	O
DAG	NNP	O
)	)	O
and	CC	O
ceramides	NNS	O
,	,	O
have	VBP	O
been	VBN	O
linked	VBN	O
to	TO	O
insulin	VB	O
resistance	NN	O
.	.	O

This	DT	O
randomised	VBD	O
repeated-measures	NNS	O
study	NN	O
examined	VBD	O
the	DT	O
effects	NNS	O
of	IN	O
diet-induced	JJ	O
weight	JJ	O
loss	NN	O
(	(	O
DIWL	NNP	O
)	)	O
and	CC	O
aerobic	JJ	O
exercise	NN	O
(	(	O
EX	NNP	O
)	)	O
on	IN	O
insulin	NN	O
sensitivity	NN	O
and	CC	O
intramyocellular	JJ	O
triacylglycerol	NN	O
(	(	O
IMTG	NNP	O
)	)	O
,	,	O
DAG	NNP	O
and	CC	O
ceramide	NN	O
.	.	O

METHODS	NNP	O
Sixteen	NNP	O
overweight	MD	O
to	TO	O
obese	VB	O
adults	NNS	O
(	(	O
BMI	NNP	O
30.6	CD	O
?	.	O
0.8	CD	O
;	:	O
67.2	CD	O
?	.	O
4.0	CD	O
years	NNS	O
of	IN	O
age	NN	O
)	)	O
with	IN	O
either	DT	O
impaired	JJ	O
fasting	NN	O
glucose	NN	O
,	,	O
or	CC	O
impaired	VBD	O
glucose	JJ	O
tolerance	NN	O
completed	VBD	O
one	CD	O
of	IN	O
two	CD	O
lifestyle	JJ	O
interventions	NNS	O
:	:	O
DIWL	NNP	O
(	(	O
n	JJ	O
=	NNP	O
8	CD	O
)	)	O
or	CC	O
EX	NNP	O
(	(	O
n	JJ	O
=	NNP	O
8	CD	O
)	)	O
.	.	O

Insulin	NNP	O
sensitivity	NN	O
was	VBD	O
determined	VBN	O
using	VBG	O
hyperinsulinaemic-euglycaemic	JJ	O
clamps	NNS	O
.	.	O

Intramyocellular	JJ	O
lipids	NNS	O
were	VBD	O
measured	VBN	O
in	IN	O
muscle	NN	O
biopsies	NNS	O
using	VBG	O
histochemistry	NN	O
and	CC	O
tandem	JJ	O
mass	NN	O
spectrometry	NN	O
.	.	O

RESULTS	NNP	O
Insulin	NNP	O
sensitivity	NN	O
was	VBD	O
improved	VBN	O
with	IN	O
DIWL	NNP	O
(	(	O
20.6	CD	O
?	.	O
4.7	CD	O
%	NN	O
)	)	O
and	CC	O
EX	NNP	O
(	(	O
19.2	CD	O
?	.	O
12.9	CD	O
%	NN	O
)	)	O
.	.	O

Body	NNP	O
weight	VBD	O
and	CC	O
body	NN	O
fat	NNS	O
were	VBD	O
decreased	VBN	O
by	IN	O
both	DT	O
interventions	NNS	O
,	,	O
with	IN	O
greater	JJR	O
decreases	NNS	O
in	IN	O
DIWL	NNP	O
compared	VBN	O
with	IN	O
EX	NNP	O
.	.	O

Muscle	NNP	O
glycogen	NN	O
,	,	O
IMTG	NNP	O
content	NN	O
and	CC	O
oxidative	JJ	O
capacity	NN	O
were	VBD	O
all	DT	O
significantly	RB	O
(	(	O
p	JJ	O
<	NNP	O
0.05	CD	O
)	)	O
decreased	VBN	O
with	IN	O
DIWL	NNP	O
and	CC	O
increased	VBD	O
with	IN	O
EX	NNP	O
.	.	O

There	EX	O
were	VBD	O
decreases	NNS	O
in	IN	O
DAG	NNP	O
with	IN	O
DIWL	NNP	O
(	(	O
-12.4	NNP	O
?	.	O
14.6	CD	O
%	NN	O
)	)	O
and	CC	O
EX	NNP	O
(	(	O
-40.9	NNP	O
?	.	O
12.0	CD	O
%	NN	O
)	)	O
.	.	O

Ceramide	NNP	O
decreased	VBD	O
with	IN	O
EX	NNP	O
(	(	O
-33.7	NNP	O
?	.	O
11.2	CD	O
%	NN	O
)	)	O
,	,	O
but	CC	O
not	RB	O
with	IN	O
DIWL	NNP	O
.	.	O

Dihydroceramide	NNP	O
was	VBD	O
decreased	VBN	O
with	IN	O
both	DT	O
interventions	NNS	O
.	.	O

Sphingosine	NNP	O
was	VBD	O
decreased	VBN	O
only	RB	O
with	IN	O
EX	NNP	O
.	.	O

Changes	NNS	O
in	IN	O
total	JJ	O
DAG	NNP	O
,	,	O
total	JJ	O
ceramides	NNS	O
and	CC	O
other	JJ	O
sphingolipids	NNS	O
did	VBD	O
not	RB	O
correlate	VB	O
with	IN	O
changes	NNS	O
in	IN	O
glucose	NN	O
disposal	NN	O
.	.	O

Stearoyl-coenzyme	VB	O
A	DT	O
desaturase	NN	O
1	CD	O
(	(	O
SCD1	NNP	O
)	)	O
content	NN	O
was	VBD	O
decreased	VBN	O
with	IN	O
DIWL	NNP	O
(	(	O
-19.5	NNP	O
?	.	O
8.5	CD	O
%	NN	O
,	,	O
p	NN	O
<	NNP	O
0.05	CD	O
)	)	O
,	,	O
but	CC	O
increased	VBD	O
with	IN	O
EX	NNP	O
(	(	O
19.6	CD	O
?	.	O
7.4	CD	O
%	NN	O
,	,	O
p	NN	O
<	NNP	O
0.05	CD	O
)	)	O
.	.	O

Diacylglycerol	NNP	O
acyltransferase	VBD	O
1	CD	O
(	(	O
DGAT1	NNP	O
)	)	O
was	VBD	O
unchanged	JJ	O
with	IN	O
the	DT	O
interventions	NNS	O
.	.	O

CONCLUSIONS/INTERPRETATION	NNP	O
Diet-induced	NNP	O
weight	NN	O
loss	NN	O
and	CC	O
exercise	NN	O
training	NN	O
both	DT	O
improved	JJ	O
insulin	NN	O
resistance	NN	O
and	CC	O
decreased	VBD	O
DAG	NNP	O
,	,	O
while	IN	O
only	RB	O
exercise	NN	O
decreased	VBD	O
ceramides	NNS	O
,	,	O
despite	IN	O
the	DT	O
interventions	NNS	O
having	VBG	O
different	JJ	O
effects	NNS	O
on	IN	O
IMTG	NNP	O
.	.	O

These	DT	O
alterations	NNS	O
may	MD	O
be	VB	O
mediated	VBN	O
through	IN	O
differential	JJ	O
changes	NNS	O
in	IN	O
skeletal	JJ	O
muscle	NN	O
capacity	NN	O
for	IN	O
oxidation	NN	O
and	CC	O
triacylglycerol	NN	O
synthesis	NN	O
.	.	O

TRIAL	NNP	O
REGISTRATION	NNP	O
ClinicalTrials.gov	NNP	O
NCT00766298	NNP	O
.	.	O

PROCLAIM	NN	O
:	:	O
pilot	NN	O
study	NN	O
to	TO	O
examine	VB	O
the	DT	O
effects	NNS	O
of	IN	O
clopidogrel	NN	O
on	IN	O
inflammatory	JJ	O
markers	NNS	O
in	IN	O
patients	NNS	O
with	IN	O
metabolic	JJ	O
syndrome	JJ	O
receiving	VBG	O
low-dose	JJ	O
aspirin	NN	O
.	.	O

Metabolic	NNP	O
syndrome	NN	O
is	VBZ	O
associated	VBN	O
with	IN	O
intravascular	JJ	O
inflammation	NN	O
,	,	O
as	IN	O
determined	VBN	O
by	IN	O
increased	JJ	O
levels	NNS	O
of	IN	O
inflammatory	NN	O
biomarkers	NNS	O
and	CC	O
an	DT	O
increased	VBN	O
risk	NN	O
of	IN	O
ischemic	JJ	O
atherothrombotic	JJ	O
events	NNS	O
.	.	O

Evidence	NN	O
suggests	VBZ	O
that	IN	O
atherothrombosis	NN	O
and	CC	O
intravascular	JJ	O
inflammation	NN	O
share	NN	O
predictive	JJ	O
biomarkers	NNS	O
,	,	O
including	VBG	O
high-sensitivity	JJ	O
C-reactive	JJ	O
protein	NN	O
,	,	O
CD40	NNP	O
ligand	NN	O
,	,	O
P-selectin	NNP	O
,	,	O
and	CC	O
N-terminal	JJ	O
pro-brain	JJ	O
natriuretic	JJ	O
peptide	NN	O
.	.	O

Patients	NNS	O
who	WP	O
had	VBD	O
metabolic	JJ	O
syndrome	NN	O
were	VBD	O
randomized	VBN	O
to	TO	O
receive	VB	O
clopidogrel	NN	O
75	CD	O
mg/day	JJ	O
plus	CC	O
aspirin	JJ	O
81	CD	O
mg/day	NN	O
(	(	O
n	JJ	O
=	NNP	O
89	CD	O
)	)	O
or	CC	O
placebo	JJ	O
plus	CC	O
aspirin	JJ	O
81	CD	O
mg/day	NN	O
(	(	O
n	JJ	O
=	NNP	O
92	CD	O
)	)	O
for	IN	O
9	CD	O
weeks	NNS	O
to	TO	O
assess	VB	O
the	DT	O
efficacy	NN	O
of	IN	O
each	DT	O
treatment	NN	O
in	IN	O
suppression	NN	O
of	IN	O
inflammatory	JJ	O
markers	NNS	O
.	.	O

Change	NN	O
from	IN	O
baseline	NN	O
in	IN	O
the	DT	O
levels	NNS	O
of	IN	O
high-sensitivity	NN	O
C-reactive	JJ	O
protein	NN	O
,	,	O
CD40	NNP	O
ligand	NN	O
,	,	O
P-selectin	NNP	O
,	,	O
and	CC	O
N-terminal	JJ	O
pro-brain	JJ	O
natriuretic	JJ	O
peptide	NN	O
at	IN	O
6	CD	O
weeks	NNS	O
was	VBD	O
assessed	VBN	O
to	TO	O
evaluate	VB	O
each	DT	O
treatment	NN	O
.	.	O

There	EX	O
was	VBD	O
a	DT	O
significant	JJ	O
difference	NN	O
at	IN	O
Week	JJ	O
6	CD	O
in	IN	O
model-adjusted	JJ	O
CD40-ligand	NNP	O
levels	NNS	O
in	IN	O
favor	NN	O
of	IN	O
clopidogrel	NN	O
plus	CC	O
aspirin	JJ	O
compared	VBN	O
with	IN	O
placebo	NN	O
plus	CC	O
aspirin	NN	O
in	IN	O
both	DT	O
the	DT	O
intent-to-treat	JJ	O
population	NN	O
(	(	O
difference	NN	O
between	IN	O
least-squares	NNS	O
means	NNS	O
=	VBP	O
-186.5	NNP	O
;	:	O
95	CD	O
%	NN	O
confidence	NN	O
interval	NN	O
,	,	O
-342.3	NN	O
to	TO	O
-30.8	VB	O
;	:	O
P	NNP	O
=	NNP	O
0.02	CD	O
)	)	O
and	CC	O
the	DT	O
per-protocol	JJ	O
population	NN	O
(	(	O
P	NNP	O
=	NNP	O
0.05	CD	O
)	)	O
.	.	O

No	DT	O
significant	JJ	O
differences	NNS	O
were	VBD	O
observed	VBN	O
between	IN	O
the	DT	O
treatment	NN	O
arms	NNS	O
for	IN	O
high-sensitivity	JJ	O
C-reactive	JJ	O
protein	NN	O
,	,	O
P-selectin	NNP	O
,	,	O
and	CC	O
N-terminal	JJ	O
pro-brain	JJ	O
natriuretic	JJ	O
peptide	NN	O
.	.	O

There	EX	O
were	VBD	O
no	DT	O
deaths	NNS	O
or	CC	O
serious	JJ	O
adverse	JJ	O
events	NNS	O
in	IN	O
either	DT	O
treatment	NN	O
arm	NN	O
.	.	O

Data	NNS	O
from	IN	O
this	DT	O
study	NN	O
suggest	VBP	O
that	IN	O
clopidogrel	NN	O
can	MD	O
decrease	VB	O
the	DT	O
expression	NN	O
of	IN	O
the	DT	O
CD40-ligand	NNP	O
biomarker	NN	O
.	.	O

A	DT	O
comparison	NN	O
of	IN	O
seven	CD	O
antiarrhythmic	JJ	O
drugs	NNS	O
in	IN	O
patients	NNS	O
with	IN	O
ventricular	JJ	C
tachyarrhythmias	NNS	C
.	.	O

Electrophysiologic	NNP	O
Study	NNP	O
versus	VBD	O
Electrocardiographic	NNP	O
Monitoring	NNP	O
Investigators	NNP	O
.	.	O

BACKGROUND	NNP	O
The	DT	O
relative	JJ	O
efficacies	NNS	O
of	IN	O
various	JJ	O
antiarrhythmic	JJ	O
drugs	NNS	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
ventricular	JJ	O
tachyarrhythmias	NNS	O
are	VBP	O
not	RB	O
well	RB	O
known	VBN	O
.	.	O

This	DT	O
study	NN	O
examined	VBD	O
the	DT	O
effectiveness	NN	O
of	IN	O
imipramine	NN	O
,	,	O
mexiletine	NN	O
,	,	O
pirmenol	NN	O
,	,	O
procainamide	NN	O
,	,	O
propafenone	NN	O
,	,	O
quinidine	NN	O
,	,	O
and	CC	O
sotalol	NN	O
in	IN	O
patients	NNS	O
with	IN	O
ventricular	JJ	C
tachyarrhythmias	NNS	C
who	WP	O
were	VBD	O
enrolled	VBN	O
in	IN	O
the	DT	O
Electrophysiologic	NNP	O
Study	NNP	O
versus	VBD	O
Electrocardiographic	NNP	O
Monitoring	NNP	O
trial	NN	O
.	.	O

METHODS	JJ	O
Patients	NNPS	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
undergo	VB	O
serial	JJ	O
testing	NN	O
of	IN	O
the	DT	O
efficacy	NN	O
of	IN	O
the	DT	O
seven	CD	O
antiarrhythmic	JJ	O
drugs	NNS	O
by	IN	O
one	CD	O
of	IN	O
two	CD	O
strategies	NNS	O
:	:	O
electrophysiologic	NN	O
study	NN	O
or	CC	O
Holter	NNP	O
monitoring	VBG	O
together	RB	O
with	IN	O
exercise	NN	O
testing	NN	O
.	.	O

The	DT	O
seven	CD	O
drugs	NNS	O
were	VBD	O
then	RB	O
tested	VBN	O
for	IN	O
efficacy	NN	O
in	IN	O
random	JJ	O
order	NN	O
in	IN	O
patients	NNS	O
who	WP	O
were	VBD	O
eligible	JJ	O
to	TO	O
receive	VB	O
them	PRP	O
.	.	O

The	DT	O
frequencies	NNS	O
of	IN	O
predictions	NNS	O
of	IN	O
drug	NN	O
efficacy	NN	O
and	CC	O
of	IN	O
adverse	JJ	O
drug	NN	O
effects	NNS	O
during	IN	O
the	DT	O
initial	JJ	O
drug	NN	O
titration	NN	O
were	VBD	O
tabulated	VBN	O
for	IN	O
all	DT	O
486	CD	SS
randomized	VBN	O
subjects	NNS	O
.	.	O

Patients	NNS	O
received	VBD	O
long-term	JJ	O
treatment	NN	O
with	IN	O
the	DT	O
first	JJ	O
antiarrhythmic	JJ	O
drug	NN	O
that	WDT	O
was	VBD	O
predicted	VBN	O
to	TO	O
be	VB	O
effective	JJ	O
on	IN	O
the	DT	O
basis	NN	O
of	IN	O
drug	NN	O
testing	NN	O
.	.	O

Recurrences	NNS	O
of	IN	O
arrhythmia	NN	O
,	,	O
deaths	NNS	O
,	,	O
and	CC	O
adverse	JJ	O
drug	NN	O
effects	NNS	O
during	IN	O
long-term	JJ	O
follow-up	NNS	O
were	VBD	O
recorded	VBN	O
for	IN	O
the	DT	O
296	CD	SS
patients	NNS	O
in	IN	O
whom	WP	O
an	DT	O
antiarrhythmic	JJ	O
drug	NN	O
was	VBD	O
predicted	VBN	O
to	TO	O
be	VB	O
effective	JJ	O
.	.	O

RESULTS	NNP	O
In	IN	O
the	DT	O
electrophysiologic-study	JJ	O
group	NN	O
,	,	O
the	DT	O
percentage	NN	O
of	IN	O
patients	NNS	O
who	WP	O
had	VBD	O
predictions	NNS	O
of	IN	O
drug	NN	O
efficacy	NN	O
was	VBD	O
higher	JJR	O
with	IN	O
sotalol	NN	O
(	(	O
35	CD	O
percent	NN	O
)	)	O
than	IN	O
with	IN	O
the	DT	O
other	JJ	O
drugs	NNS	O
(	(	O
16	CD	O
percent	NN	O
,	,	O
P	NNP	O
<	NNP	O
0.001	CD	O
)	)	O
.	.	O

There	EX	O
was	VBD	O
no	DT	O
significant	JJ	O
difference	NN	O
among	IN	O
the	DT	O
drugs	NNS	O
in	IN	O
the	DT	O
Holter-monitoring	NNP	O
group	NN	O
.	.	O

The	DT	O
percentage	NN	O
of	IN	O
patients	NNS	O
with	IN	O
adverse	JJ	O
drug	NN	O
effects	NNS	O
was	VBD	O
lowest	JJS	O
among	IN	O
those	DT	O
receiving	VBG	O
sotalol	NN	O
.	.	O

The	DT	O
actuarial	JJ	O
probability	NN	O
of	IN	O
a	DT	O
recurrence	NN	O
of	IN	O
arrhythmia	NN	O
after	IN	O
a	DT	O
prediction	NN	O
of	IN	O
drug	NN	O
efficacy	NN	O
by	IN	O
either	DT	O
strategy	NN	O
was	VBD	O
significantly	RB	O
lower	JJR	O
for	IN	O
patients	NNS	O
treated	VBN	O
with	IN	O
sotalol	NN	O
than	IN	O
for	IN	O
patients	NNS	O
treated	VBN	O
with	IN	O
the	DT	O
other	JJ	O
drugs	NNS	O
(	(	O
risk	NN	O
ratio	NN	O
,	,	O
0.43	CD	O
;	:	O
95	CD	O
percent	NN	O
confidence	NN	O
interval	NN	O
,	,	O
0.29	CD	O
to	TO	O
0.62	CD	O
;	:	O
P	NNP	O
<	NNP	O
0.001	CD	O
)	)	O
.	.	O

With	IN	O
sotalol	NN	O
,	,	O
as	IN	O
compared	VBN	O
with	IN	O
the	DT	O
other	JJ	O
drugs	NNS	O
combined	VBN	O
,	,	O
there	EX	O
were	VBD	O
lower	JJR	O
risks	NNS	O
of	IN	O
death	NN	O
from	IN	O
any	DT	O
cause	NN	O
(	(	O
risk	NN	O
ratio	NN	O
,	,	O
0.50	CD	O
;	:	O
95	CD	O
percent	NN	O
confidence	NN	O
interval	NN	O
,	,	O
0.30	CD	O
to	TO	O
0.80	CD	O
;	:	O
P	NNP	O
=	NNP	O
0.004	CD	O
)	)	O
,	,	O
death	NN	O
from	IN	O
cardiac	JJ	O
causes	NNS	O
,	,	O
(	(	O
0.50	CD	O
;	:	O
P	NNP	O
=	NNP	O
0.02	CD	O
)	)	O
,	,	O
and	CC	O
death	NN	O
from	IN	O
arrhythmia	NN	O
(	(	O
0.50	CD	O
;	:	O
P	NNP	O
=	NNP	O
0.04	CD	O
)	)	O
.	.	O

The	DT	O
cumulative	JJ	O
percentage	NN	O
of	IN	O
patients	NNS	O
in	IN	O
whom	WP	O
a	DT	O
drug	NN	O
was	VBD	O
predicted	VBN	O
to	TO	O
be	VB	O
effective	JJ	O
and	CC	O
in	IN	O
whom	WP	O
it	PRP	O
remained	VBD	O
effective	JJ	O
and	CC	O
tolerated	VBD	O
was	VBD	O
higher	JJR	O
for	IN	O
sotalol	JJR	O
than	IN	O
for	IN	O
the	DT	O
other	JJ	O
drugs	NNS	O
(	(	O
P	NNP	O
<	NNP	O
0.001	CD	O
)	)	O
.	.	O

CONCLUSIONS	NNP	O
Sotalol	NNP	O
was	VBD	O
more	RBR	O
effective	JJ	O
than	IN	O
the	DT	O
other	JJ	O
six	CD	O
antiarrhythmic	JJ	O
drugs	NNS	O
in	IN	O
preventing	VBG	O
death	NN	O
and	CC	O
recurrences	NNS	O
of	IN	O
arrhythmia	NN	O
.	.	O

In	IN	O
patients	NNS	O
similar	JJ	O
to	TO	O
those	DT	O
in	IN	O
this	DT	O
study	NN	O
,	,	O
if	IN	O
antiarrhythmic-drug	JJ	O
therapy	NN	O
is	VBZ	O
to	TO	O
be	VB	O
used	VBN	O
to	TO	O
prevent	VB	O
recurrences	NNS	O
of	IN	O
ventricular	JJ	O
tachyarrhythmias	NNS	O
,	,	O
treatment	NN	O
with	IN	O
sotalol	NN	O
and	CC	O
assessment	NN	O
of	IN	O
its	PRP$	O
potential	JJ	O
efficacy	NN	O
by	IN	O
Holter	NNP	O
monitoring	NN	O
are	VBP	O
a	DT	O
reasonable	JJ	O
initial	JJ	O
strategy	NN	O
.	.	O

Baseline	NNP	O
factors	NNS	O
predicting	VBG	O
placebo	NN	O
response	NN	O
to	TO	O
treatment	NN	O
in	IN	O
children	NNS	O
and	CC	O
adolescents	NNS	O
with	IN	O
autism	NN	O
spectrum	NN	O
disorders	NNS	O
:	:	O
a	DT	O
multisite	JJ	O
randomized	JJ	O
clinical	JJ	O
trial	NN	O
.	.	O

IMPORTANCE	VBZ	O
The	DT	O
finding	NN	O
of	IN	O
factors	NNS	O
that	WDT	O
differentially	RB	O
predict	VBP	O
the	DT	O
likelihood	NN	O
of	IN	O
response	NN	O
to	TO	O
placebo	VB	O
over	IN	O
that	DT	O
of	IN	O
an	DT	O
active	JJ	O
drug	NN	O
could	MD	O
have	VB	O
a	DT	O
significant	JJ	O
impact	NN	O
on	IN	O
study	NN	O
design	NN	O
in	IN	O
this	DT	O
population	NN	O
.	.	O

OBJECTIVE	UH	O
To	TO	O
identify	VB	O
possible	JJ	O
nonspecific	NN	O
,	,	O
baseline	JJ	O
predictors	NNS	O
of	IN	O
response	NN	O
to	TO	O
intervention	NN	O
in	IN	O
a	DT	O
large	JJ	O
randomized	JJ	O
clinical	JJ	O
trial	NN	O
of	IN	O
children	NNS	O
and	CC	O
adolescents	NNS	O
with	IN	O
autism	NN	O
spectrum	NN	O
disorders	NNS	O
.	.	O

DESIGN	NNP	O
,	,	O
SETTING	NNP	O
,	,	O
AND	NNP	O
PARTICIPANTS	NNP	O
Randomized	NNP	O
clinical	JJ	O
trial	NN	O
of	IN	O
citalopram	NN	O
hydrobromide	NN	O
for	IN	O
children	NNS	O
and	CC	O
adolescents	NNS	O
with	IN	O
autism	NN	O
spectrum	NN	O
disorders	NNS	O
and	CC	O
prominent	JJ	O
repetitive	JJ	O
behavior	NN	O
.	.	O

Baseline	NNP	O
data	NN	O
at	IN	O
study	NN	O
entry	NN	O
were	VBD	O
examined	VBN	O
with	IN	O
respect	NN	O
to	TO	O
final	JJ	O
outcome	NN	O
to	TO	O
determine	VB	O
if	IN	O
response	NN	O
predictors	NNS	O
could	MD	O
be	VB	O
identified	VBN	O
.	.	O

A	DT	O
total	NN	O
of	IN	O
149	CD	O
children	NNS	O
and	CC	O
adolescents	NNS	O
5	CD	O
to	TO	O
17	CD	O
years	NNS	O
of	IN	O
age	NN	O
(	(	O
mean	JJ	O
[	NNP	O
SD	NNP	O
]	NNP	O
age	NN	O
,	,	O
9.4	CD	O
[	NN	O
3.1	CD	O
]	CD	O
years	NNS	O
)	)	O
from	IN	O
6	CD	O
academic	JJ	O
centers	NNS	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
citalopram	VB	O
(	(	O
n	JJ	O
=	NNP	O
73	CD	O
)	)	O
or	CC	O
placebo	NN	O
(	(	O
n	JJ	O
=	NNP	O
76	CD	O
)	)	O
.	.	O

Participants	NNS	O
had	VBD	O
autistic	JJ	O
disorder	NN	O
,	,	O
Asperger	NNP	O
syndrome	NN	O
,	,	O
or	CC	O
pervasive	JJ	O
developmental	JJ	O
disorder	NN	O
,	,	O
not	RB	O
otherwise	RB	O
specified	VBN	O
;	:	O
had	VBD	O
illness	JJ	O
severity	NN	O
ratings	NNS	O
that	WDT	O
were	VBD	O
moderate	JJ	O
or	CC	O
more	JJR	O
than	IN	O
moderate	VB	O
on	IN	O
the	DT	O
Clinical	JJ	O
Global	NNP	O
Impression-Severity	NNP	O
scale	NN	O
;	:	O
and	CC	O
scored	VBD	O
moderate	JJ	O
or	CC	O
more	JJR	O
than	IN	O
moderate	VB	O
on	IN	O
compulsive	JJ	O
behaviors	NNS	O
measured	VBN	O
with	IN	O
the	DT	O
modified	JJ	O
Children	NNP	O
's	POS	O
Yale-Brown	JJ	O
Obsessive-Compulsive	JJ	O
Scale	NNP	O
.	.	O

INTERVENTIONS	NNP	O
Twelve	NNP	O
weeks	NNS	O
of	IN	O
treatment	NN	O
with	IN	O
citalopram	NN	O
(	(	O
10	CD	O
mg/5	RB	O
mL	NN	O
)	)	O
or	CC	O
placebo	NN	O
.	.	O

The	DT	O
mean	NN	O
(	(	O
SD	NNP	O
)	)	O
maximum	VBD	O
dose	NN	O
of	IN	O
citalopram	NN	O
was	VBD	O
16.5	CD	O
(	(	O
6.5	CD	O
)	)	O
mg	NN	O
by	IN	O
mouth	JJ	O
daily	JJ	O
(	(	O
maximum	JJ	O
dose	NN	O
,	,	O
20	CD	O
mg/d	NN	O
)	)	O
.	.	O

MAIN	NNP	O
OUTCOMES	NNP	O
AND	NNP	O
MEASURES	NNP	O
A	NNP	O
positive	JJ	O
response	NN	O
was	VBD	O
defined	VBN	O
as	IN	O
having	VBG	O
a	DT	O
score	NN	O
of	IN	O
at	IN	O
least	JJS	O
much	JJ	O
improved	VBN	O
on	IN	O
the	DT	O
Clinical	JJ	O
Global	NNP	O
Impression-Improvement	NNP	O
scale	NN	O
at	IN	O
week	NN	O
12	CD	O
.	.	O

Baseline	NNP	O
measures	VBZ	O
included	VBN	O
demographic	JJ	O
(	(	O
sex	NN	O
,	,	O
age	NN	O
,	,	O
weight	NN	O
,	,	O
and	CC	O
pubertal	JJ	O
status	NN	O
)	)	O
,	,	O
clinical	JJ	O
,	,	O
and	CC	O
family	NN	O
measures	NNS	O
.	.	O

Clinical	JJ	O
variables	NNS	O
included	VBD	O
baseline	NN	O
illness	NN	O
severity	NN	O
ratings	NNS	O
(	(	O
the	DT	O
Aberrant	NNP	O
Behavior	NNP	O
Checklist	NNP	O
,	,	O
the	DT	O
Child	NNP	O
and	CC	O
Adolescent	NNP	O
Symptom	NNP	O
Inventory	NNP	O
,	,	O
the	DT	O
Vineland	NNP	O
Adaptive	NNP	O
Behavior	NNP	O
Scales	NNP	O
,	,	O
the	DT	O
Repetitive	JJ	O
Behavior	NNP	O
Scale-Revised	JJ	O
,	,	O
and	CC	O
the	DT	O
Children	NNP	O
's	POS	O
Yale-Brown	JJ	O
Obsessive-Compulsive	JJ	O
Scale	NNP	O
)	)	O
.	.	O

Family	JJ	O
measures	NNS	O
included	VBD	O
the	DT	O
Caregiver	NNP	O
Strain	NNP	O
Questionnaire	NNP	O
.	.	O

RESULTS	NNP	O
Several	JJ	O
baseline	JJ	O
predictors	NNS	O
of	IN	O
response	NN	O
were	VBD	O
identified	VBN	O
,	,	O
and	CC	O
a	DT	O
principal	JJ	O
component	NN	O
analysis	NN	O
yielded	VBD	O
3	CD	O
composite	JJ	O
measures	NNS	O
(	(	O
disruptive	JJ	O
behavior	NN	O
,	,	O
autism/mood	NN	O
,	,	O
and	CC	O
caregiver	RB	O
strain	NN	O
)	)	O
that	WDT	O
significantly	RB	O
predicted	VBD	O
response	NN	O
at	IN	O
week	NN	O
12	CD	O
.	.	O

Specifically	RB	O
,	,	O
participants	NNS	O
in	IN	O
the	DT	O
placebo	NN	O
group	NN	O
were	VBD	O
significantly	RB	O
less	RBR	O
likely	JJ	O
than	IN	O
participants	NNS	O
in	IN	O
the	DT	O
citalopram	NN	O
group	NN	O
to	TO	O
respond	VB	O
at	IN	O
week	NN	O
12	CD	O
if	IN	O
they	PRP	O
entered	VBD	O
the	DT	O
study	NN	O
more	RBR	O
symptomatic	JJ	O
on	IN	O
each	DT	O
of	IN	O
the	DT	O
3	CD	O
composite	JJ	O
measures	NNS	O
,	,	O
and	CC	O
they	PRP	O
were	VBD	O
at	IN	O
least	JJS	O
2	CD	O
times	NNS	O
less	RBR	O
likely	JJ	O
to	TO	O
be	VB	O
responders	NNS	O
.	.	O

CONCLUSIONS	NNP	O
AND	CC	O
RELEVANCE	NNP	O
This	DT	O
analysis	NN	O
suggests	VBZ	O
strategies	NNS	O
that	WDT	O
may	MD	O
be	VB	O
useful	JJ	O
in	IN	O
anticipating	VBG	O
and	CC	O
potentially	RB	O
mitigating	VBG	O
the	DT	O
nonspecific	JJ	O
response	NN	O
in	IN	O
randomized	JJ	O
clinical	JJ	O
trials	NNS	O
of	IN	O
children	NNS	O
and	CC	O
adolescents	NNS	O
with	IN	O
autism	NN	O
spectrum	NN	O
disorders	NNS	O
.	.	O

TRIAL	NNP	O
REGISTRATION	NNP	O
clinicaltrials.gov	NN	O
Identifier	NNP	O
:	:	O
NCT00086645	NN	O
.	.	O

The	DT	O
influence	NN	O
of	IN	O
sequential	JJ	O
annual	JJ	O
vaccination	NN	O
and	CC	O
of	IN	O
DHEA	NNP	O
administration	NN	O
on	IN	O
the	DT	O
efficacy	NN	O
of	IN	O
the	DT	O
immune	JJ	O
response	NN	O
to	TO	O
influenza	VB	C
vaccine	NN	C
in	IN	O
the	DT	O
elderly	JJ	A
.	.	O

The	DT	O
present	JJ	O
study	NN	O
examined	VBD	O
the	DT	O
effect	NN	O
of	IN	O
repeated	VBN	O
vaccination	NN	O
and	CC	O
of	IN	O
dehydroepiandrosterone	NN	O
(	(	O
DHEA	NNP	O
)	)	O
treatment	NN	O
on	IN	O
the	DT	O
immune	JJ	O
response	NN	O
to	TO	O
influenza	VB	O
vaccine	NN	O
in	IN	O
elderly	JJ	O
subjects	NNS	O
.	.	O

Seventy-one	CD	SS
elderly	JJ	A
volunteers	NNS	O
,	,	O
aged	VBN	O
61-89	CD	A
years	NNS	A
,	,	O
enrolled	VBD	O
in	IN	O
a	DT	O
prospective	JJ	O
randomized	VBN	O
,	,	O
double-blind	JJ	O
study	NN	O
to	TO	O
receive	VB	O
either	DT	O
DHEA	NNP	O
(	(	O
50	CD	O
mg	NN	O
qd	NN	O
p.o	NN	O
.	.	O

for	IN	O
4	CD	O
consecutive	JJ	O
days	NNS	O
starting	VBG	O
2	CD	O
days	NNS	O
before	IN	O
immunization	NN	O
)	)	O
or	CC	O
placebo	NN	O
.	.	O

Antibody	NNP	O
response	NN	O
against	IN	O
the	DT	O
three	CD	O
strains	NNS	O
of	IN	O
vaccine	NN	O
was	VBD	O
measured	VBN	O
before	IN	O
and	CC	O
28	CD	O
days	NNS	O
after	IN	O
vaccination	NN	O
,	,	O
and	CC	O
compared	VBN	O
between	IN	O
previously	RB	O
vaccinated	VBN	O
and	CC	O
non-vaccinated	JJ	O
subjects	NNS	O
.	.	O

DHEA	NNP	O
treatment	NN	O
did	VBD	O
not	RB	O
enhance	VB	O
established	VBN	O
immunity	NN	O
.	.	O

A	DT	O
significant	JJ	O
decrease	NN	O
in	IN	O
attainment	NN	O
of	IN	O
protective	JJ	O
antibody	NN	O
titer	NN	O
(	(	O
titer	NN	O
of	IN	O
1:40	CD	O
or	CC	O
greater	JJR	O
)	)	O
against	IN	O
A/Texas	NNP	O
in	IN	O
subjects	NNS	O
with	IN	O
non-protective	JJ	O
baseline	NN	O
antibody	NN	O
titer	NN	O
was	VBD	O
recorded	VBN	O
following	VBG	O
DHEA	NNP	O
treatment	NN	O
compared	VBN	O
to	TO	O
placebo	VB	O
(	(	O
52	CD	O
vs.	FW	O
84	CD	O
%	NN	O
,	,	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
.	.	O

Post-immunization	NN	O
titers	NNS	O
against	IN	O
influenza	VBP	O
A	DT	O
strains	NNS	O
were	VBD	O
significantly	RB	O
higher	JJR	O
in	IN	O
those	DT	O
subjects	NNS	O
who	WP	O
were	VBD	O
never	RB	O
immunized	VBN	O
before	RB	O
.	.	O

Additionally	RB	O
,	,	O
post-vaccination	JJ	O
protective	JJ	O
titers	NNS	O
against	IN	O
the	DT	O
A/Johannesburg	NNP	O
strain	NN	O
were	VBD	O
more	RBR	O
prevalent	JJ	O
in	IN	O
those	DT	O
subjects	NNS	O
who	WP	O
were	VBD	O
never	RB	O
vaccinated	VBN	O
before	RB	O
.	.	O

The	DT	O
results	NNS	O
were	VBD	O
not	RB	O
the	DT	O
same	JJ	O
for	IN	O
anti-B/Harbin	JJ	O
antibodies-repeated	JJ	O
vaccination	NN	O
caused	VBD	O
a	DT	O
non-significant	JJ	O
increase	NN	O
in	IN	O
HI	NNP	O
titer	NN	O
in	IN	O
previously	RB	O
vaccinated	VBN	O
subjects	NNS	O
.	.	O

[	JJ	C
Metastatic	NNP	C
breast	NN	C
cancer	NN	C
:	:	O
a	DT	O
comparative	JJ	O
study	NN	O
of	IN	O
the	DT	O
efficacy	NN	O
of	IN	O
tamoxifen	NN	O
and	CC	O
the	DT	O
sequential	JJ	O
administration	NN	O
of	IN	O
tamoxifen	NN	O
and	CC	O
medroxyprogesterone	NN	O
acetate	NN	O
]	NNP	O
.	.	O

Seventy-nine	JJ	SS
patients	NNS	O
with	IN	O
an	DT	O
histologically	RB	C
proven	RB	C
disseminated	VBN	C
breast	NN	C
cancer	NN	C
,	,	O
never	RB	C
treated	VBN	C
before	IN	C
with	IN	C
additive	JJ	C
hormonal	JJ	C
therapy	NN	C
,	,	O
entered	VBD	O
into	IN	O
a	DT	O
randomized	JJ	O
trial	NN	O
between	IN	O
june	NN	O
1981	CD	O
and	CC	O
december	VB	O
1982	CD	O
.	.	O

In	IN	O
the	DT	O
first	JJ	O
group	NN	O
44	CD	O
patients	NNS	O
were	VBD	O
given	VBN	O
continually	RB	O
a	DT	O
daily	JJ	O
dose	NN	O
of	IN	O
tamoxifen	NN	O
(	(	O
TAM	NNP	O
)	)	O
of	IN	O
20	CD	O
mg/m2	NN	O
.	.	O

In	IN	O
the	DT	O
2nd	CD	O
group	NN	O
35	CD	O
patients	NNS	O
were	VBD	O
given	VBN	O
a	DT	O
daily	JJ	O
dose	NN	O
of	IN	O
TAM	NNP	O
of	IN	O
20	CD	O
mg/m2	NN	O
for	IN	O
15	CD	O
days	NNS	O
and	CC	O
then	RB	O
an	DT	O
oral	JJ	O
daily	JJ	O
dose	NN	O
of	IN	O
medroxyprogesterone	NN	O
acetate	NN	O
of	IN	O
350	CD	O
mg/m2	NN	O
for	IN	O
the	DT	O
next	JJ	O
15	CD	O
days	NNS	O
.	.	O

In	IN	O
both	DT	O
groups	NNS	O
I	PRP	O
and	CC	O
II	NNP	O
,	,	O
the	DT	O
treatment	NN	O
was	VBD	O
stopped	VBN	O
at	IN	O
the	DT	O
first	JJ	O
manifestation	NN	O
of	IN	O
progression	NN	O
of	IN	O
the	DT	O
disease	NN	O
.	.	O

The	DT	O
hormonal	JJ	O
receptor	NN	O
status	NN	O
was	VBD	O
determined	VBN	O
in	IN	O
30	CD	O
patients	NNS	O
of	IN	O
the	DT	O
group	NN	O
I	PRP	O
and	CC	O
23	CD	O
patients	NNS	O
of	IN	O
the	DT	O
group	NN	O
II	NNP	O
.	.	O

An	DT	O
objective	JJ	O
response	NN	O
to	TO	O
treatment	NN	O
was	VBD	O
observed	VBN	O
in	IN	O
48	CD	O
per	IN	O
cent	NN	O
of	IN	O
the	DT	O
patients	NNS	O
of	IN	O
the	DT	O
group	NN	O
I	PRP	O
and	CC	O
60	CD	O
per	IN	O
cent	NN	O
of	IN	O
the	DT	O
group	NN	O
II	NNP	O
.	.	O

This	DT	O
difference	NN	O
is	VBZ	O
not	RB	O
significant	JJ	O
(	(	O
X2	NNP	O
=	NNP	O
1,05	CD	O
)	)	O
.	.	O

However	RB	O
,	,	O
the	DT	O
mean	JJ	O
duration	NN	O
of	IN	O
therapeutic	JJ	O
response	NN	O
is	VBZ	O
significantly	RB	O
higher	RBR	O
in	IN	O
the	DT	O
group	NN	O
II	NNP	O
(	(	O
p	JJ	O
=	NNP	O
0,01	CD	O
)	)	O
.	.	O

[	RB	O
Comparative	NNP	O
study	NN	O
between	IN	O
5	CD	O
%	NN	O
prilocaine	NN	O
and	CC	O
2	CD	O
%	NN	O
mepivacaine	NN	O
by	IN	O
the	DT	O
subarachnoid	JJ	O
route	NN	O
in	IN	O
transurethral	JJ	O
resections	NNS	O
]	VBP	O
.	.	O

OBJECTIVE	NNP	O
To	TO	O
compare	VB	O
the	DT	O
duration	NN	O
of	IN	O
spinal	JJ	O
block	NN	O
with	IN	O
5	CD	O
%	NN	O
prilocaine	NN	O
and	CC	O
2	CD	O
%	NN	O
mepivacaine	NN	O
in	IN	O
short	JJ	O
procedures	NNS	O
for	IN	O
transurethral	JJ	O
resection	NN	O
and	CC	O
to	TO	O
assess	VB	O
possible	JJ	O
complications	NNS	O
in	IN	O
the	DT	O
immediate	JJ	O
postoperative	JJ	O
period	NN	O
.	.	O

MATERIAL	NNP	O
AND	NNP	O
METHODS	NNP	O
Fifty-seven	NNP	SS
patients	NNS	C
scheduled	VBN	C
for	IN	C
transurethral	JJ	C
resection	NN	C
of	IN	C
the	DT	C
prostate	NN	C
or	CC	C
a	DT	C
vesical	JJ	C
tumor	NN	C
.	.	C

Patients	NNS	O
were	VBD	O
ASA	NNP	C
I-III	NNP	C
,	,	O
over	IN	A
55	CD	A
years	NNS	A
of	IN	A
age	NN	A
and	CC	O
randomly	RB	O
assigned	VBN	O
to	TO	O
two	CD	O
groups	NNS	O
to	TO	O
receive	VB	O
5	CD	O
%	NN	O
prilocaine	NN	O
(	(	O
1	CD	O
mg/kg	NN	O
,	,	O
n	JJ	O
=	NNP	O
27	CD	O
)	)	O
or	CC	O
2	CD	O
%	NN	O
mepivacaine	NN	O
(	(	O
0.8	CD	O
mg/kg	NN	O
,	,	O
n	JJ	O
=	NNP	O
30	CD	O
)	)	O
.	.	O

We	PRP	O
collected	VBD	O
data	NNS	O
on	IN	O
anesthetic	JJ	O
technique	NN	O
,	,	O
levels	NNS	O
of	IN	O
extension	NN	O
of	IN	O
motor	NN	O
and	CC	O
sensory	JJ	O
blockades	NNS	O
,	,	O
duration	NN	O
of	IN	O
blockades	NNS	O
and	CC	O
complications	NNS	O
within	IN	O
the	DT	O
first	JJ	O
24	CD	O
hours	NNS	O
after	IN	O
surgery	NN	O
.	.	O

RESULTS	NNP	O
Demographic	NNP	O
data	NNS	O
,	,	O
ASA	NNP	O
classification	NN	O
and	CC	O
duration	NN	O
of	IN	O
surgery	NN	O
were	VBD	O
similar	JJ	O
in	IN	O
both	DT	O
groups	NNS	O
.	.	O

We	PRP	O
found	VBD	O
statistically	RB	O
significant	JJ	O
differences	NNS	O
(	(	O
p	JJ	O
<	NNP	O
0.05	CD	O
)	)	O
in	IN	O
duration	NN	O
of	IN	O
sensory	JJ	O
blockade	NN	O
(	(	O
120.92	CD	O
+/-	JJ	O
36.21	CD	O
min	NN	O
with	IN	O
prilocaine	NN	O
and	CC	O
145.83	CD	O
+/-	JJ	O
35.81	CD	O
min	NN	O
with	IN	O
mepivacaine	NN	O
)	)	O
and	CC	O
in	IN	O
motor	NN	O
blockade	NN	O
(	(	O
106.29	CD	O
+/-	JJ	O
38.16	CD	O
min	NN	O
with	IN	O
prilocaine	NN	O
and	CC	O
133.16	CD	O
+/-	JJ	O
42.21	CD	O
min	NN	O
with	IN	O
mepivacaine	NN	O
)	)	O
.	.	O

Five	JJ	O
cases	NNS	O
of	IN	O
hypotension	NN	O
and	CC	O
4	CD	O
of	IN	O
bradycardia	NN	O
occurred	VBN	O
in	IN	O
each	DT	O
group	NN	O
and	CC	O
one	CD	O
patient	NN	O
in	IN	O
the	DT	O
mepivacaine	NN	O
group	NN	O
suffered	VBD	O
slight	JJ	O
postoperative	JJ	O
cephalea	NN	O
.	.	O

CONCLUSIONS	NNP	O
Both	NNP	O
local	JJ	O
anesthetics	NNS	O
offer	VBP	O
good	JJ	O
surgical	JJ	O
conditions	NNS	O
with	IN	O
hemodynamic	JJ	O
stability	NN	O
and	CC	O
few	JJ	O
complications	NNS	O
.	.	O

The	DT	O
duration	NN	O
of	IN	O
sensory	NN	O
and	CC	O
motor	NN	O
blockade	NN	O
is	VBZ	O
shorter	JJR	O
with	IN	O
prilocaine	NN	O
than	IN	O
with	IN	O
mepivacaine	NN	O
,	,	O
making	VBG	O
prilocaine	NN	O
more	JJR	O
appropriate	JJ	O
for	IN	O
short	JJ	O
interventions	NNS	O
.	.	O

Granulocyte-macrophage	JJ	O
colony-stimulating	JJ	O
factor	NN	O
as	IN	O
immunomodulating	VBG	O
factor	NN	O
together	RB	O
with	IN	O
influenza	JJ	O
vaccination	NN	O
in	IN	O
stem	NN	C
cell	NN	C
transplant	NN	C
patients	NNS	O
.	.	O

The	DT	O
effect	NN	O
of	IN	O
granulocyte-macrophage	JJ	O
colony-stimulating	JJ	O
factor	NN	O
(	(	O
GM-CSF	NNP	O
)	)	O
on	IN	O
the	DT	O
serological	JJ	O
response	NN	O
at	IN	O
influenza	JJ	O
vaccination	NN	O
was	VBD	O
studied	VBN	O
in	IN	O
117	CD	SS
patients	NNS	O
who	WP	O
had	VBD	O
undergone	JJ	C
stem	NN	C
cell	NN	C
transplantation	NN	C
(	(	O
SCT	NNP	C
)	)	O
.	.	O

The	DT	O
vaccine	NN	O
response	NN	O
was	VBD	O
evaluated	VBN	O
as	IN	O
significant	JJ	O
increases	NNS	O
in	IN	O
levels	NNS	O
of	IN	O
influenza	JJ	O
hemagglutination-inhibition	NN	O
(	(	O
HAI	NNP	O
)	)	O
antibodies	NNS	O
and	CC	O
of	IN	O
IgG	NNP	O
antibodies	NNS	O
measured	VBN	O
by	IN	O
enzyme-linked	JJ	O
immunosorbent	NN	O
assay	NN	O
(	(	O
ELISA	NNP	O
)	)	O
.	.	O

There	EX	O
was	VBD	O
no	DT	O
difference	NN	O
in	IN	O
antibody	NN	O
response	NN	O
to	TO	O
either	DT	O
influenza	VB	O
A	NNP	O
or	CC	O
B	NNP	O
in	IN	O
64	CD	O
patients	NNS	O
who	WP	O
received	VBD	O
GM-CSF	NNP	O
at	IN	O
vaccination	NN	O
,	,	O
compared	VBN	O
with	IN	O
the	DT	O
53	NNS	O
who	WP	O
did	VBD	O
not	RB	O
.	.	O

In	IN	O
the	DT	O
subgroup	NN	O
of	IN	O
allogeneic	JJ	C
SCT	NNP	C
patients	NNS	C
,	,	O
HAI	NNP	O
showed	VBD	O
that	IN	O
the	DT	O
response	NN	O
rate	NN	O
to	TO	O
the	DT	O
influenza	NN	O
B	NNP	O
vaccine	NN	O
was	VBD	O
significantly	RB	O
higher	JJR	O
in	IN	O
the	DT	O
treatment	NN	O
group	NN	O
(	(	O
P	NNP	O
<	NNP	O
.05	NNP	O
)	)	O
.	.	O

ELISA	NN	O
showed	VBD	O
that	IN	O
autologous	JJ	C
SCT	NNP	C
patients	NNS	C
with	IN	C
breast	JJ	C
cancer	NN	C
who	WP	O
received	VBD	O
GM-CSF	NNP	O
had	VBD	O
a	DT	O
better	JJR	O
response	NN	O
to	TO	O
influenza	VB	O
A	NNP	O
(	(	O
P	NNP	O
<	NNP	O
.05	NNP	O
)	)	O
and	CC	O
B	NNP	O
(	(	O
P	NNP	O
<	NNP	O
.01	NNP	O
)	)	O
.	.	O

At	IN	O
early	JJ	O
vaccination	NN	O
,	,	O
4-12	JJ	O
months	NNS	O
after	IN	O
stem	NN	O
cell	NN	O
transplantation	NN	O
,	,	O
these	DT	O
responses	NNS	O
were	VBD	O
more	RBR	O
pronounced	JJ	O
.	.	O

GM-CSF	JJ	O
appears	VBZ	O
to	TO	O
improve	VB	O
the	DT	O
response	NN	O
to	TO	O
influenza	VB	O
vaccination	NN	O
in	IN	O
some	DT	O
groups	NNS	O
of	IN	O
SCT	NNP	C
patients	NNS	C
,	,	O
but	CC	O
only	RB	O
to	TO	O
a	DT	O
limited	JJ	O
extent	NN	O
.	.	O

Engagement	NN	O
with	IN	O
electronic	JJ	O
screen	JJ	O
media	NNS	O
among	IN	O
students	NNS	O
with	IN	O
autism	NN	O
spectrum	NN	O
disorders	NNS	O
.	.	O

This	DT	O
study	NN	O
investigated	VBD	O
the	DT	O
relative	JJ	O
engagement	JJ	O
potential	NN	O
of	IN	O
four	CD	O
types	NNS	O
of	IN	O
electronic	JJ	O
screen	JJ	O
media	NNS	O
(	(	O
ESM	NNP	O
)	)	O
:	:	O
animated	VBN	O
video	NN	O
,	,	O
video	NN	O
of	IN	O
self	NN	O
,	,	O
video	NN	O
of	IN	O
a	DT	O
familiar	JJ	O
person	NN	O
engaged	VBD	O
with	IN	O
an	DT	O
immersive	JJ	O
virtual	JJ	O
reality	NN	O
(	(	O
VR	NNP	O
)	)	O
game	NN	O
,	,	O
and	CC	O
immersion	NN	O
of	IN	O
self	NN	O
in	IN	O
the	DT	O
VR	NNP	O
game	NN	O
.	.	O

Forty-two	JJ	O
students	NNS	O
with	IN	O
autism	NN	O
,	,	O
varying	VBG	O
in	IN	O
age	NN	O
and	CC	O
expressive	JJ	O
communication	NN	O
ability	NN	O
,	,	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
the	DT	O
experimental	JJ	O
conditions	NNS	O
.	.	O

Gaze	NNP	O
duration	NN	O
and	CC	O
vocalization	NN	O
served	VBD	O
as	IN	O
dependent	JJ	O
measures	NNS	O
of	IN	O
engagement	NN	O
.	.	O

The	DT	O
results	NNS	O
reveal	VBP	O
differential	JJ	O
responding	NN	O
across	IN	O
ESM	NNP	O
,	,	O
with	IN	O
some	DT	O
variation	NN	O
related	VBN	O
to	TO	O
the	DT	O
engagement	NN	O
metric	JJ	O
employed	VBN	O
.	.	O

Preferences	NNS	O
for	IN	O
seeing	VBG	O
themselves	PRP	O
on	IN	O
the	DT	O
screen	NN	O
,	,	O
as	RB	O
well	RB	O
as	IN	O
for	IN	O
viewing	VBG	O
the	DT	O
VR	NNP	O
scenarios	NNS	O
,	,	O
emerged	VBD	O
from	IN	O
the	DT	O
data	NNS	O
.	.	O

While	IN	O
the	DT	O
study	NN	O
did	VBD	O
not	RB	O
yield	VB	O
definitive	JJ	O
data	NNS	O
about	IN	O
the	DT	O
relative	JJ	O
engagement	JJ	O
potential	NN	O
of	IN	O
ESM	NNP	O
alternatives	NNS	O
,	,	O
it	PRP	O
does	VBZ	O
provide	VB	O
a	DT	O
foundation	NN	O
for	IN	O
future	JJ	O
research	NN	O
,	,	O
including	VBG	O
guidance	NN	O
related	VBN	O
to	TO	O
participant	JJ	O
profiles	NNS	O
,	,	O
stimulus	NN	O
characteristics	NNS	O
,	,	O
and	CC	O
data	NNS	O
coding	NN	O
challenges	NNS	O
.	.	O

Long-stay	JJ	O
versus	NN	O
short-stay	JJ	O
hospital	NN	O
treatment	NN	O
of	IN	O
children	NNS	A
suffering	VBG	O
from	IN	O
severe	JJ	C
protein-energy	JJ	C
malnutrition	NN	C
.	.	O

OBJECTIVE	UH	O
To	TO	O
contrast	VB	O
early	JJ	O
discharge	NN	O
versus	NN	O
attempted	VBD	O
full	JJ	O
nutritional	JJ	O
rehabilitation	NN	O
in	IN	O
hospital	NN	O
of	IN	O
children	NNS	O
suffering	VBG	O
from	IN	O
severe	JJ	O
protein-energy	JJ	O
malnutrition	NN	O
(	(	O
PEM	NNP	C
)	)	O
.	.	O

DESIGN	NNP	O
Field	NNP	O
experiment	NN	O
,	,	O
two-way	JJ	O
analysis	NN	O
of	IN	O
variance	NN	O
with	IN	O
one	CD	O
between	IN	O
group	NN	O
(	(	O
short-	JJ	O
versus	IN	O
long-stay	NN	O
)	)	O
and	CC	O
one	CD	O
repeated	VBN	O
measures	NNS	O
factor	NN	O
(	(	O
admission	NN	O
,	,	O
then	RB	O
12	CD	O
,	,	O
18	CD	O
,	,	O
24	CD	O
,	,	O
30	CD	O
and	CC	O
36	CD	O
months	NNS	O
post-admission	NN	O
)	)	O
.	.	O

Covariates	NNPS	O
introduced	VBD	O
.	.	O

SETTING	NNP	O
Primary	NNP	O
health	NN	O
care	NN	O
,	,	O
Kingston	NNP	O
,	,	O
Jamaica	NNP	O
.	.	O

SUBJECTS	NNP	O
n	JJ	O
=	NNP	O
81	CD	SS
;	:	O
mean	JJ	O
age	NN	O
11	CD	A
months	NNS	A
;	:	O
79	CD	O
contribute	VBP	O
longitudinal	JJ	O
data	NNS	O
;	:	O
44	CD	O
every	DT	O
measurement	NN	O
.	.	O

INTERVENTIONS	NNP	O
When	WRB	O
concurrent	NN	O
illnesses	NNS	O
had	VBD	O
been	VBN	O
treated	VBN	O
and	CC	O
normal	JJ	O
feeding	VBG	O
re-established	JJ	O
(	(	O
weight	JJ	O
gain	NN	O
5	CD	O
g/kg.day-1	NN	O
)	)	O
,	,	O
subjects	NNS	O
were	VBD	O
randomly	RB	O
allocated	VBN	O
to	TO	O
short-stay	NN	O
(	(	O
SS	NNP	O
)	)	O
or	CC	O
long-stay	JJ	O
(	(	O
LS	NNP	O
)	)	O
group	NN	O
.	.	O

LS	NNP	O
retained	VBD	O
in	IN	O
hospital	NN	O
for	IN	O
full	JJ	O
nutritional	JJ	O
rehabilitation	NN	O
mean	VB	O
40	CD	O
days	NNS	O
)	)	O
.	.	O

SS	NNP	O
discharged	VBD	O
immediately	RB	O
(	(	O
mean	JJ	O
18	CD	O
days	NNS	O
)	)	O
for	IN	O
standard	JJ	O
Health	NNP	O
Service	NNP	O
care	NN	O
at	IN	O
home	NN	O
for	IN	O
6	CD	O
months	NNS	O
plus	CC	O
high-energy	JJ	O
supplement	NN	O
(	(	O
3.31	CD	O
MJ	NNP	O
with	IN	O
20.6	CD	O
g	NNS	O
protein	JJ	O
daily	JJ	O
)	)	O
for	IN	O
first	JJ	O
3	CD	O
months	NNS	O
.	.	O

After	IN	O
discharge	NN	O
LS	NNP	O
received	VBD	O
6	CD	O
months	NNS	O
home	NN	O
care	NN	O
,	,	O
but	CC	O
without	IN	O
supplementation	NN	O
.	.	O

RESULTS	NNP	O
Significant	NNP	O
advantages	VBZ	O
for	IN	O
LS	NNP	O
group	NN	O
on	IN	O
NCHS	NNP	O
weight	NN	O
&	CC	O
length	NN	O
for	IN	O
age	NN	O
at	IN	O
discharge	NN	O
,	,	O
and	CC	O
at	IN	O
12	CD	O
,	,	O
18	CD	O
,	,	O
24	CD	O
and	CC	O
for	IN	O
length	NN	O
also	RB	O
30	CD	O
months	NNS	O
(	(	O
P	NNP	O
<	VBZ	O
0.05	CD	O
to	TO	O
P	NNP	O
<	NNP	O
0.001	CD	O
)	)	O
.	.	O

Weight	NNP	O
advantage	NN	O
peaked	VBD	O
at	IN	O
12	CD	O
and	CC	O
18	CD	O
months	NNS	O
,	,	O
length	NN	O
later	RB	O
at	IN	O
18	CD	O
and	CC	O
24	CD	O
months	NNS	O
.	.	O

CONCLUSIONS	NNP	O
Contrary	NNP	O
to	TO	O
earlier	VB	O
reports	NNS	O
,	,	O
full	JJ	O
nutritional	JJ	O
rehabilitation	NN	O
can	MD	O
be	VB	O
achieved	VBN	O
in	IN	O
hospital	NN	O
for	IN	O
children	NNS	O
suffering	VBG	O
from	IN	O
PEM	NNP	O
.	.	O

Although	IN	O
in	IN	O
the	DT	O
long-term	JJ	O
both	DT	O
groups	NNS	O
move	VBP	O
towards	NNS	O
expected	VBN	O
levels	NNS	O
in	IN	O
their	PRP$	O
home	NN	O
community	NN	O
,	,	O
a	DT	O
significant	JJ	O
advantage	NN	O
maintained	VBD	O
for	IN	O
approximately	RB	O
2	CD	O
years	NNS	O
is	VBZ	O
developmentally	RB	O
advantageous	JJ	O
during	IN	O
the	DT	O
critical	JJ	O
time	NN	O
after	IN	O
weaning	VBG	O
.	.	O

Prevention	NN	O
of	IN	O
postoperative	JJ	O
hypocalcemia	NN	O
with	IN	O
routine	JJ	O
oral	JJ	O
calcium	NN	O
and	CC	O
vitamin	NN	O
D	NNP	O
supplements	NNS	O
in	IN	O
patients	NNS	O
with	IN	O
differentiated	JJ	O
papillary	JJ	O
thyroid	NN	O
carcinoma	NN	O
undergoing	JJ	O
total	JJ	O
thyroidectomy	NN	O
plus	CC	O
central	JJ	O
neck	NN	O
dissection	NN	O
.	.	O

BACKGROUND	NNP	O
Routine	NNP	O
oral	JJ	O
calcium	NN	O
and	CC	O
vitamin	NN	O
D	NNP	O
supplementation	NN	O
may	MD	O
prevent	VB	O
hypocalcemic	JJ	O
crisis	NN	O
,	,	O
but	CC	O
its	PRP$	O
efficacy	NN	O
has	VBZ	O
not	RB	O
been	VBN	O
studied	VBN	O
in	IN	O
patients	NNS	O
undergoing	VBG	O
thyroidectomy	JJ	O
plus	JJ	O
central	JJ	O
neck	NN	O
dissection	NN	O
(	(	O
CND	NNP	O
)	)	O
.	.	O

The	DT	O
authors	NNS	O
therefore	VBP	O
prospectively	RB	O
evaluated	VBN	O
the	DT	O
clinical	JJ	O
usefulness	NN	O
of	IN	O
routine	JJ	O
oral	JJ	O
calcium	NN	O
and	CC	O
vitamin	NN	O
D	NNP	O
supplementation	NN	O
for	IN	O
prevention	NN	O
of	IN	O
hypocalcemia	NN	O
after	IN	O
total	JJ	O
thyroidectomy	NN	O
and	CC	O
CND	NNP	O
.	.	O

METHODS	NNP	O
Of	IN	O
197	CD	O
patients	NNS	O
with	IN	O
differentiated	JJ	O
papillary	JJ	O
thyroid	NN	O
carcinoma	NN	O
,	,	O
49	CD	O
underwent	JJ	O
total	JJ	O
thyroidectomy	NN	O
alone	RB	O
,	,	O
and	CC	O
148	CD	O
underwent	JJ	O
total	JJ	O
thyroidectomy	NN	O
plus	CC	O
CND	NNP	O
.	.	O

The	DT	O
latter	JJ	O
were	VBD	O
randomized	VBN	O
to	TO	O
oral	JJ	O
calcium	NN	O
(	(	O
3	CD	O
g/day	NN	O
)	)	O
plus	CC	O
vitamin	JJ	O
D	NNP	O
(	(	O
1	CD	O
mg/day	NN	O
)	)	O
(	(	O
Group	NNP	O
A	NNP	O
,	,	O
n=49	NN	O
)	)	O
,	,	O
calcium	NN	O
alone	RB	O
(	(	O
Group	NNP	O
B	NNP	O
,	,	O
n=49	NN	O
)	)	O
,	,	O
or	CC	O
no	DT	O
supplements	NNS	O
(	(	O
Group	NNP	O
C	NNP	O
,	,	O
n=50	RB	O
)	)	O
.	.	O

Hypocalcemic	NNP	O
symptoms	NNS	O
,	,	O
serum	JJ	O
calcium	NN	O
,	,	O
and	CC	O
parathyroid	VB	O
hormone	NN	O
(	(	O
PTH	NNP	O
)	)	O
levels	NNS	O
were	VBD	O
compared	VBN	O
among	IN	O
the	DT	O
groups	NNS	O
.	.	O

RESULTS	NNP	O
Group	NNP	O
C	NNP	O
had	VBD	O
significantly	RB	O
higher	JJR	O
incidences	NNS	O
of	IN	O
symptomatic	JJ	O
(	(	O
26.0	CD	O
%	NN	O
vs	JJ	O
6.1	CD	O
%	NN	O
;	:	O
P	NNP	O
<	NNP	O
.015	NNP	O
)	)	O
and	CC	O
laboratory	NN	O
(	(	O
44.0	CD	O
%	NN	O
vs	JJ	O
14.3	CD	O
%	NN	O
;	:	O
P	NNP	O
<	NNP	O
.015	NNP	O
)	)	O
hypocalcemia	NN	O
than	IN	O
the	DT	O
group	NN	O
without	IN	O
CND	NNP	O
.	.	O

The	DT	O
incidences	NNS	O
of	IN	O
symptomatic	JJ	O
and	CC	O
laboratory	JJ	O
hypocalcemia	NN	O
were	VBD	O
significantly	RB	O
decreased	VBN	O
in	IN	O
Groups	NNP	O
A	NNP	O
(	(	O
2.0	CD	O
%	NN	O
and	CC	O
8.2	CD	O
%	NN	O
,	,	O
respectively	RB	O
)	)	O
and	CC	O
B	NNP	O
(	(	O
12.2	CD	O
%	NN	O
and	CC	O
24.5	CD	O
%	NN	O
,	,	O
respectively	RB	O
)	)	O
(	(	O
P	NNP	O
<	NNP	O
.05	NNP	O
)	)	O
.	.	O

Serum	NNP	O
calcium	NN	O
levels	NNS	O
decreased	VBN	O
in	IN	O
most	JJS	O
patients	NNS	O
after	IN	O
surgery	NN	O
,	,	O
but	CC	O
recovered	VBD	O
earliest	JJS	O
in	IN	O
Group	NNP	O
A.	NNP	O
Hypercalcemia	NNP	O
and	CC	O
PTH	NNP	O
inhibition	NN	O
did	VBD	O
not	RB	O
occur	VB	O
in	IN	O
gs	NN	O
A	NNP	O
and	CC	O
B	NNP	O
.	.	O

CONCLUSIONS	NNP	O
Compared	NNP	O
with	IN	O
total	JJ	O
thyroidectomy	NN	O
alone	RB	O
,	,	O
CND	NNP	O
significantly	RB	O
increases	VBZ	O
the	DT	O
rate	NN	O
of	IN	O
postoperative	JJ	O
hypocalcemia	NN	O
,	,	O
which	WDT	O
can	MD	O
be	VB	O
prevented	VBN	O
by	IN	O
routine	JJ	O
postoperative	JJ	O
supplementation	NN	O
with	IN	O
oral	JJ	O
calcium	NN	O
and	CC	O
vitamin	NN	O
D	NNP	O
.	.	O

Comparison	NNP	O
of	IN	O
remifentanil	NN	O
with	IN	O
fentanyl	NN	O
for	IN	O
deep	JJ	O
sedation	NN	O
in	IN	O
oral	JJ	O
surgery	NN	O
.	.	O

PURPOSE	VB	O
The	DT	O
aim	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
compare	VB	O
recovery	NN	O
for	IN	O
oral	JJ	C
surgery	NN	C
patients	NNS	C
given	VBN	O
a	DT	O
deep	JJ	O
sedation	NN	O
regimen	NNS	O
of	IN	O
midazolam	NN	O
,	,	O
propofol	NN	O
,	,	O
and	CC	O
remifentanil	NN	O
with	IN	O
a	DT	O
standard	JJ	O
control	NN	O
of	IN	O
fentanyl	NN	O
in	IN	O
place	NN	O
of	IN	O
remifentanil	NN	O
.	.	O

MATERIALS	NNP	O
AND	CC	O
METHODS	NNP	O
This	DT	O
investigation	NN	O
was	VBD	O
designed	VBN	O
as	IN	O
a	DT	O
randomized	NN	O
,	,	O
prospective	JJ	O
,	,	O
single-blinded	JJ	O
controlled	VBD	O
study	NN	O
.	.	O

Group	NNP	O
1	CD	O
,	,	O
the	DT	O
control	NN	O
,	,	O
received	VBD	O
midazolam	JJ	O
0.03	CD	O
mg/kg	NN	O
,	,	O
fentanyl	VBP	O
1	CD	O
microg/kg	NN	O
,	,	O
and	CC	O
propofol	VB	O
initially	RB	O
at	IN	O
140	CD	O
microg/kg/min	NN	O
.	.	O

Group	NNP	O
2	CD	O
received	VBD	O
midazolam	RB	O
0.03	CD	O
mg/kg	NN	O
,	,	O
remifentanil	NN	O
:	:	O
propofol	NN	O
(	(	O
1:500	CD	O
)	)	O
given	VBN	O
at	IN	O
an	DT	O
initial	JJ	O
propofol	JJ	O
infusion	NN	O
rate	NN	O
of	IN	O
40	CD	O
microg/kg/min	NN	O
.	.	O

Outcome	NNP	O
measures	NNS	O
included	VBD	O
time	NN	O
to	TO	O
response	NN	O
to	TO	O
verbal	JJ	O
command	NN	O
,	,	O
Aldrete	NNP	O
score	VBD	O
=	JJ	O
9	CD	O
,	,	O
Postanesthesia	NNP	O
Discharge	NNP	O
Scoring	NNP	O
System	NNP	O
=	VBD	O
7	CD	O
,	,	O
and	CC	O
assessment	NN	O
by	IN	O
the	DT	O
Digit	NNP	O
Symbol	NNP	O
Substitution	NNP	O
Test	NNP	O
.	.	O

RESULTS	NNP	O
Forty-seven	JJ	O
subjects	NNS	O
were	VBD	O
entered	VBN	O
in	IN	O
the	DT	O
study	NN	O
.	.	O

Baseline	NNP	O
findings	NNS	O
were	VBD	O
homogenous	JJ	O
between	IN	O
the	DT	O
2	CD	O
groups	NNS	O
.	.	O

Subjects	NNS	O
in	IN	O
group	NN	O
2	CD	O
recovered	VBN	O
earlier	JJR	O
(	(	O
P	NNP	O
<	NNP	O
.005	NNP	O
)	)	O
and	CC	O
required	VBN	O
less	JJR	O
propofol	NN	O
for	IN	O
both	DT	O
the	DT	O
induction	NN	O
(	(	O
0.8	CD	O
+/-	JJ	O
0.4	CD	O
versus	NN	O
1.2	CD	O
+/-	JJ	O
0.6	CD	O
mg/kg	NN	O
;	:	O
mean	JJ	O
+/-	JJ	O
SD	NNP	O
,	,	O
P	NNP	O
<	NNP	O
.01	NNP	O
)	)	O
and	CC	O
maintenance	NN	O
of	IN	O
deep	JJ	O
sedation	NN	O
(	(	O
46	CD	O
+/-	JJ	O
9	CD	O
versus	NN	O
131	CD	O
+/-	JJ	O
17	CD	O
microg/kg/min	NN	O
;	:	O
P	NNP	O
<	NNP	O
.005	NNP	O
)	)	O
.	.	O

There	EX	O
were	VBD	O
minor	JJ	O
differences	NNS	O
in	IN	O
vital	JJ	O
signs	NNS	O
.	.	O

CONCLUSIONS	VB	O
This	DT	O
study	NN	O
demonstrated	VBD	O
that	IN	O
this	DT	O
remifentanil	JJ	O
regimen	NNS	O
provided	VBD	O
significantly	RB	O
more	RBR	O
rapid	JJ	O
recovery	NN	O
and	CC	O
used	VBD	O
significantly	RB	O
less	JJR	O
propofol	JJ	O
compared	VBN	O
with	IN	O
the	DT	O
fentanyl	JJ	O
regimen	NNS	O
.	.	O

Group	NNP	O
cognitive	JJ	O
behavior	NN	O
therapy	NN	O
for	IN	O
children	NNS	C
with	IN	C
high-functioning	JJ	C
autism	NN	C
spectrum	NN	C
disorders	NNS	C
and	CC	C
anxiety	NN	C
:	:	C
a	DT	O
randomized	JJ	O
trial	NN	O
.	.	O

BACKGROUND	NNP	O
Children	NNP	O
with	IN	O
high-functioning	JJ	O
autism	NN	O
spectrum	NN	O
disorders	NNS	O
(	(	O
ASD	NNP	O
)	)	O
are	VBP	O
at	IN	O
high	JJ	O
risk	NN	O
for	IN	O
developing	VBG	O
significant	JJ	O
anxiety	NN	O
.	.	O

Anxiety	NN	O
can	MD	O
adversely	RB	O
impact	VB	O
functioning	VBG	O
across	IN	O
school	NN	O
,	,	O
home	NN	O
and	CC	O
community	NN	O
environments	NNS	O
.	.	O

Cognitive	JJ	O
behavioral	JJ	O
therapies	NNS	O
(	(	O
CBT	NNP	O
)	)	O
are	VBP	O
frequently	RB	O
used	VBN	O
with	IN	O
success	NN	O
for	IN	O
children	NNS	O
with	IN	O
anxiety	NN	O
symptoms	NNS	O
.	.	O

Modified	NNP	O
CBT	NNP	O
interventions	NNS	O
for	IN	O
anxiety	NN	O
in	IN	O
children	NNS	O
with	IN	O
ASD	NNP	O
have	VBP	O
also	RB	O
yielded	VBN	O
promising	JJ	O
results	NNS	O
.	.	O

METHODS	NNP	O
Fifty	NNP	O
children	NNS	O
with	IN	O
high-functioning	JJ	O
ASD	NNP	O
and	CC	O
anxiety	NN	O
were	VBD	O
randomizedto	JJ	O
group	NN	O
CBT	NNP	O
or	CC	O
treatment-as-usual	JJ	O
(	(	O
TAU	NNP	O
)	)	O
for	IN	O
12	CD	O
weeks	NNS	O
.	.	O

Independent	NNP	O
clinical	JJ	O
evaluators	NNS	O
,	,	O
blind	NN	O
to	TO	O
condition	NN	O
,	,	O
completed	VBN	O
structured	JJ	O
interviews	NNS	O
(	(	O
Anxiety	NNP	O
Disorders	NNP	O
Interview	NNP	O
Schedule	NNP	O
?	.	O
Parent	NNP	O
Version	NNP	O
;	:	O
ADIS-P	NNP	O
)	)	O
pre-	NN	O
and	CC	O
post-intervention	NN	O
condition	NN	O
.	.	O

RESULTS	NNP	O
Forty-seven	JJ	O
children	NNS	O
completed	VBN	O
either	CC	O
the	DT	O
CBT	NNP	O
or	CC	O
TAU	NNP	O
condition	NN	O
.	.	O

Results	NNS	O
indicated	VBD	O
markedly	RB	O
better	RBR	O
outcomes	NNS	O
for	IN	O
the	DT	O
CBT	NNP	O
group	NN	O
.	.	O

Significant	JJ	O
differences	NNS	O
by	IN	O
group	NN	O
were	VBD	O
noted	VBN	O
in	IN	O
Clinician	JJ	O
Severity	NNP	O
Ratings	NNP	O
,	,	O
diagnostic	JJ	O
status	NN	O
,	,	O
and	CC	O
clinician	JJ	O
ratings	NNS	O
of	IN	O
global	JJ	O
improvement	NN	O
.	.	O

In	IN	O
the	DT	O
intent-to-treat	JJ	O
sample	NN	O
,	,	O
10	CD	O
of	IN	O
20	CD	O
children	NNS	O
(	(	O
50	CD	O
%	NN	O
)	)	O
in	IN	O
the	DT	O
CBT	NNP	O
group	NN	O
had	VBD	O
a	DT	O
clinically	RB	O
meaningful	JJ	O
positive	JJ	O
treatment	NN	O
response	NN	O
,	,	O
compared	VBN	O
to	TO	O
2	CD	O
of	IN	O
23	CD	O
children	NNS	O
(	(	O
8.7	CD	O
%	NN	O
)	)	O
in	IN	O
the	DT	O
TAU	NNP	O
group	NN	O
.	.	O

CONCLUSIONS	NNP	O
Initial	JJ	O
results	NNS	O
from	IN	O
this	DT	O
randomized	VBN	O
,	,	O
designed	VBN	O
treatment	NN	O
study	NN	O
suggest	VBP	O
that	IN	O
agroup	NN	O
CBT	NNP	O
intervention	NN	O
specifically	RB	O
developed	VBD	O
for	IN	O
children	NNS	O
with	IN	O
ASD	NNP	O
may	MD	O
be	VB	O
effective	JJ	O
in	IN	O
decreasing	VBG	O
anxiety	NN	O
.	.	O

Limitations	NNS	O
of	IN	O
this	DT	O
study	NN	O
include	VBP	O
small	JJ	O
sample	JJ	O
size	NN	O
,	,	O
lack	NN	O
of	IN	O
an	DT	O
attention	NN	O
control	NN	O
group	NN	O
,	,	O
and	CC	O
use	NN	O
of	IN	O
outcome	NN	O
measures	NNS	O
normed	VBN	O
with	IN	O
typically	RB	O
developing	VBG	O
children	NNS	O
[	JJ	O
Treatment	NNP	O
of	IN	O
autism	NN	C
children	NNS	C
:	:	C
observation	NN	O
on	IN	O
efficacy	NN	O
of	IN	O
behavior	JJ	O
training	NN	O
with	IN	O
retention	NN	O
of	IN	O
needles	NNS	O
on	IN	O
head	NN	O
]	NN	O
.	.	O

OBJECTIVE	UH	O
To	TO	O
observe	VB	O
the	DT	O
effect	NN	O
difference	NN	O
of	IN	O
behavior	JJ	O
training	NN	O
with	IN	O
head	NN	O
needling	VBG	O
retention	NN	O
and	CC	O
behavior	NN	O
training	NN	O
after	IN	O
acupuncture	NN	O
for	IN	O
autism	NN	O
children	NNS	O
.	.	O

METHODS	NNP	O
Sixty	NNP	O
qualified	VBD	O
autism	NN	O
children	NNS	O
were	VBD	O
divided	VBN	O
randomly	RB	O
into	IN	O
simultaneous	JJ	O
head	NN	O
needling	VBG	O
retention	NN	O
and	CC	O
behavior	JJ	O
training	NN	O
group	NN	O
(	(	O
trial	NN	O
group	NN	O
)	)	O
and	CC	O
behavior	JJ	O
training	NN	O
after	IN	O
acupuncture	NN	O
treatment	NN	O
group	NN	O
(	(	O
control	VB	O
group	NN	O
)	)	O
with	IN	O
30	CD	O
case	NN	O
in	IN	O
each	DT	O
group	NN	O
.	.	O

Retention	NNP	O
needles	NNS	O
on	IN	O
the	DT	O
head	NN	O
with	IN	O
simultaneous	JJ	O
behavior	NN	O
training	NN	O
was	VBD	O
applied	VBN	O
for	IN	O
the	DT	O
trial	NN	O
group	NN	O
.	.	O

The	DT	O
main	JJ	O
acupoints	NNS	O
included	VBD	O
Sishen	NNP	O
Xue	NNP	O
,	,	O
Dingshen	NNP	O
Sanxue	NNP	O
(	(	O
3	CD	O
points	NNS	O
for	IN	O
mental	JJ	O
tranquilization	NN	O
)	)	O
,	,	O
Nao	NNP	O
Sanxue	NNP	O
(	(	O
3	CD	O
points	NNS	O
for	IN	O
the	DT	O
function	NN	O
of	IN	O
brain	NN	O
)	)	O
,	,	O
Shou	NNP	O
Zhisanxue	NNP	O
(	(	O
3	CD	O
points	NNS	O
for	IN	O
mental	JJ	O
activities	NNS	O
on	IN	O
hand	NN	O
)	)	O
and	CC	O
Zozhi	NNP	O
Sonxue	NNP	O
(	(	O
3	CD	O
points	NNS	O
for	IN	O
mental	JJ	O
activities	NNS	O
on	IN	O
foot	NN	O
)	)	O
.	.	O

Other	JJ	O
points	NNS	O
were	VBD	O
combined	VBN	O
according	VBG	O
to	TO	O
conditions	NNS	O
of	IN	O
patients	NNS	O
.	.	O

Needles	NNS	O
on	IN	O
the	DT	O
4	CD	O
extremities	NNS	O
were	VBD	O
withdrawn	VBN	O
first	RB	O
after	IN	O
30	CD	O
minutes	NNS	O
,	,	O
needles	NNS	O
on	IN	O
head	NN	O
were	VBD	O
remained	VBN	O
during	IN	O
behavior	JJ	O
training	NN	O
.	.	O

While	IN	O
behavior	JJ	O
training	NN	O
was	VBD	O
applied	VBN	O
to	TO	O
the	DT	O
control	NN	O
group	NN	O
when	WRB	O
acupuncture	NN	O
treatment	NN	O
was	VBD	O
completely	RB	O
accomplished	VBN	O
.	.	O

Treatments	NNS	O
were	VBD	O
applied	VBN	O
once	RB	O
a	DT	O
day	NN	O
to	TO	O
both	DT	O
groups	NNS	O
.	.	O

And	CC	O
3	CD	O
months	NNS	O
was	VBD	O
taken	VBN	O
as	IN	O
one	CD	O
observation	NN	O
cycle	NN	O
.	.	O

Estimation	NN	O
was	VBD	O
made	VBN	O
on	IN	O
therapeutic	JJ	O
effect	NN	O
and	CC	O
developing	VBG	O
level	NN	O
of	IN	O
autism	NN	O
children	NNS	O
with	IN	O
CARS	NNP	O
and	CC	O
PEP	NNP	O
.	.	O

RESULTS	VB	O
The	DT	O
total	JJ	O
effective	JJ	O
rate	NN	O
of	IN	O
the	DT	O
trial	NN	O
group	NN	O
was	VBD	O
83.3	CD	O
%	NN	O
(	(	O
25/30	CD	O
)	)	O
,	,	O
better	JJR	O
than	IN	O
66.7	CD	O
%	NN	O
(	(	O
20/30	CD	O
)	)	O
of	IN	O
the	DT	O
control	NN	O
group	NN	O
(	(	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
.	.	O

The	DT	O
CARS	NNPS	O
scores	NNS	O
of	IN	O
both	DT	O
groups	NNS	O
declined	VBD	O
after	IN	O
the	DT	O
treatment	NN	O
.	.	O

And	CC	O
the	DT	O
score	NN	O
of	IN	O
trail	NN	O
group	NN	O
was	VBD	O
lower	JJR	O
than	IN	O
the	DT	O
control	NN	O
group	NN	O
(	(	O
all	DT	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
.	.	O

While	IN	O
the	DT	O
PEP	NNP	O
scores	NNS	O
of	IN	O
both	DT	O
groups	NNS	O
increased	VBD	O
,	,	O
and	CC	O
the	DT	O
score	NN	O
of	IN	O
trail	NN	O
group	NN	O
was	VBD	O
higher	JJR	O
than	IN	O
the	DT	O
control	NN	O
group	NN	O
(	(	O
all	DT	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
.	.	O

The	DT	O
increasing	VBG	O
level	NN	O
of	IN	O
scores	NNS	O
of	IN	O
cognitive	JJ	O
understanding	NN	O
and	CC	O
cognitive	JJ	O
expression	NN	O
were	VBD	O
all	DT	O
better	JJR	O
than	IN	O
the	DT	O
control	NN	O
group	NN	O
(	(	O
all	DT	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
.	.	O

CONCLUSION	VB	O
The	DT	O
effect	NN	O
of	IN	O
behavior	JJ	O
training	NN	O
with	IN	O
head	NN	O
needle	JJ	O
retention	NN	O
on	IN	O
autism	NN	O
children	NNS	O
is	VBZ	O
better	JJR	O
than	IN	O
behavior	JJ	O
training	NN	O
after	IN	O
acupuncture	NN	O
treatment	NN	O
,	,	O
especially	RB	O
in	IN	O
enhancing	VBG	O
cognition	NN	O
understanding	NN	O
and	CC	O
cognition	NN	O
expression	NN	O
.	.	O

Noradrenergic	NNP	O
moderation	NN	O
of	IN	O
working	VBG	O
memory	NN	O
impairments	NNS	O
in	IN	O
adults	NNS	A
with	IN	O
autism	NN	C
spectrum	NN	C
disorder	NN	C
.	.	O

In	IN	O
addition	NN	O
to	TO	O
having	VBG	O
difficulties	NNS	O
with	IN	O
social	JJ	O
communications	NNS	O
,	,	O
individuals	NNS	O
with	IN	O
an	DT	O
autism	NN	C
spectrum	NN	C
disorder	NN	C
(	(	C
ASD	NNP	C
)	)	C
often	RB	O
also	RB	O
experience	JJ	O
impairment	NN	O
in	IN	O
higher-order	NN	O
,	,	O
executive	NN	O
skills	NNS	O
.	.	O

The	DT	O
present	JJ	O
study	NN	O
examined	VBD	O
the	DT	O
effects	NNS	O
of	IN	O
pharmacological	JJ	O
modulation	NN	O
of	IN	O
the	DT	O
norepinephrine	NN	O
system	NN	O
on	IN	O
the	DT	O
severity	NN	O
of	IN	O
such	JJ	O
impairments	NNS	O
.	.	O

A	DT	O
sample	NN	O
of	IN	O
14	CD	SS
high-functioning	JJ	O
adults	NNS	A
with	IN	O
ASD	NNP	C
and	CC	O
a	DT	O
demographically-matched	JJ	O
comparison	NN	O
group	NN	O
of	IN	O
13	CD	SS
typically	RB	O
developing	VBG	O
individuals	NNS	O
participated	VBN	O
.	.	O

An	DT	O
AX	NNP	O
continuous	JJ	O
performance	NN	O
test	NN	O
(	(	O
AX-CPT	NNP	O
)	)	O
was	VBD	O
used	VBN	O
to	TO	O
evaluate	VB	O
working	VBG	O
memory	NN	O
and	CC	O
inhibitory	NN	O
control	NN	O
.	.	O

AX-CPT	JJ	O
performance	NN	O
was	VBD	O
assessed	VBN	O
following	VBG	O
administration	NN	O
of	IN	O
a	DT	O
single	JJ	O
dose	NN	O
of	IN	O
propranolol	NN	O
(	(	O
a	DT	O
beta	NN	O
adrenergic	JJ	O
antagonist	NN	O
)	)	O
and	CC	O
following	VBG	O
placebo	NN	O
(	(	O
sugar	NN	O
pill	NN	O
)	)	O
administration	NN	O
.	.	O

Individuals	NNS	O
with	IN	O
ASD	NNP	C
performed	VBD	O
more	RBR	O
poorly	RB	O
than	IN	O
non-ASD	JJ	O
individuals	NNS	O
in	IN	O
the	DT	O
working	JJ	O
memory	NN	O
condition	NN	O
(	(	O
BX	NNP	O
trials	NNS	O
)	)	O
.	.	O

Importantly	RB	O
,	,	O
administration	NN	O
of	IN	O
propranolol	NN	O
attenuated	VBN	O
this	DT	O
impairment	NN	O
,	,	O
with	IN	O
the	DT	O
ASD	NNP	O
group	NN	O
performing	VBG	O
significantly	RB	O
better	RBR	O
in	IN	O
the	DT	O
propranolol	NN	O
condition	NN	O
than	IN	O
the	DT	O
placebo	JJ	O
condition	NN	O
.	.	O

Working	VBG	O
memory	NN	O
performance	NN	O
of	IN	O
the	DT	O
non-ASD	JJ	O
group	NN	O
was	VBD	O
unaffected	VBN	O
by	IN	O
propranolol/placebo	JJ	O
administration	NN	O
.	.	O

No	DT	O
group	NN	O
or	CC	O
medication	NN	O
effects	NNS	O
were	VBD	O
observed	VBN	O
for	IN	O
the	DT	O
inhibition	NN	O
condition	NN	O
(	(	O
AY	NNP	O
trials	NNS	O
)	)	O
.	.	O

The	DT	O
present	JJ	O
findings	NNS	O
suggest	VBP	O
that	IN	O
norepinephrine	NN	O
may	MD	O
play	VB	O
a	DT	O
role	NN	O
in	IN	O
some	DT	O
,	,	O
but	CC	O
not	RB	O
necessarily	RB	O
all	RB	O
,	,	O
cognitive	JJ	O
impairments	NNS	O
associated	VBN	O
with	IN	O
ASD	NNP	O
.	.	O

Additional	NNP	O
research	NN	O
is	VBZ	O
needed	VBN	O
to	TO	O
fully	RB	O
understand	VB	O
whether	IN	O
this	DT	O
role	NN	O
is	VBZ	O
primarily	RB	O
causal	JJ	O
or	CC	O
compensatory	NN	O
in	IN	O
nature	NN	O
.	.	O

Skin	NNP	O
manifestations	NNS	O
of	IN	O
inhaled	JJ	O
corticosteroids	NNS	O
in	IN	O
COPD	NNP	C
patients	NNS	C
:	:	C
results	NNS	O
from	IN	O
Lung	NNP	O
Health	NNP	O
Study	NNP	O
II	NNP	O
.	.	O

OBJECTIVE	NNP	O
To	TO	O
define	VB	O
the	DT	O
relationship	NN	O
between	IN	O
skin	NN	O
bruising	NN	O
(	(	O
as	RB	O
well	RB	O
as	IN	O
other	JJ	O
cutaneous	JJ	O
manifestations	NNS	O
)	)	O
and	CC	O
inhaled	VBN	O
corticosteroid	NN	O
(	(	O
ICS	NNP	O
)	)	O
therapy	NN	O
vs	NN	O
placebo	NN	O
in	IN	O
subjects	NNS	O
with	IN	O
COPD	NNP	O
who	WP	O
were	VBD	O
participating	VBG	O
in	IN	O
a	DT	O
clinical	JJ	O
trial	NN	O
.	.	O

To	TO	O
explore	VB	O
the	DT	O
relationship	NN	O
between	IN	O
easy	JJ	O
skin	NN	O
bruising	NN	O
and	CC	O
other	JJ	O
systemic	JJ	O
effects	NNS	O
of	IN	O
ICS	NNP	O
therapy	NN	O
,	,	O
including	VBG	O
adrenal	JJ	O
suppression	NN	O
and	CC	O
loss	NN	O
of	IN	O
bone	JJ	O
mineral	JJ	O
density	NN	O
(	(	O
BMD	NNP	O
)	)	O
.	.	O

DESIGN	NNP	O
Double-blind	NNP	O
,	,	O
randomized	VBN	O
,	,	O
placebo-controlled	JJ	O
clinical	JJ	O
trial	NN	O
of	IN	O
triamcinolone	NN	O
acetonide	NN	O
(	(	O
1200	CD	O
microg	FW	O
daily	RB	O
)	)	O
vs	NN	O
placebo	NN	O
in	IN	O
participants	NNS	O
with	IN	O
mild-to-moderate	JJ	O
COPD	NNP	O
.	.	O

SETTING	NNP	O
Lung	NNP	O
Health	NNP	O
Study	NNP	O
II	NNP	O
,	,	O
a	DT	O
clinical	JJ	O
trial	NN	O
to	TO	O
assess	VB	O
the	DT	O
effect	NN	O
of	IN	O
ICS	NNP	O
compared	VBN	O
to	TO	O
placebo	VB	O
in	IN	O
1,116	CD	O
participants	NNS	O
in	IN	O
10	CD	O
centers	NNS	O
over	IN	O
>	$	O
3.5	CD	O
to	TO	O
4.5	CD	O
years	NNS	O
.	.	O

PARTICIPANTS	VB	O
A	DT	O
total	NN	O
of	IN	O
1,116	CD	O
smokers	NNS	O
or	CC	O
recent	JJ	O
ex-smokers	NNS	O
with	IN	O
mild-to-moderate	JJ	O
COPD	NNP	O
(	(	O
age	NN	O
range	NN	O
,	,	O
40	CD	O
to	TO	O
69	CD	O
years	NNS	O
;	:	O
mean	JJ	O
age	NN	O
,	,	O
56.3	CD	O
years	NNS	O
;	:	O
37.2	CD	O
%	NN	O
female	NN	O
)	)	O
.	.	O

MEASUREMENTS	NNP	O
AND	CC	O
RESULTS	NNP	O
Every	NNP	O
6	CD	O
months	NNS	O
,	,	O
a	DT	O
structured	JJ	O
questionnaire	NN	O
was	VBD	O
administered	VBN	O
to	TO	O
elicit	VB	O
reports	NNS	O
of	IN	O
any	DT	O
bruising	NN	O
and/or	NN	O
skin	NN	O
rashes	NNS	O
,	,	O
slow	JJ	O
healing	NN	O
of	IN	O
cuts	NNS	O
or	CC	O
sores	NNS	O
,	,	O
or	CC	O
other	JJ	O
skin	JJ	O
changes	NNS	O
.	.	O

Compliance	NN	O
with	IN	O
inhaler	NN	O
use	NN	O
was	VBD	O
assessed	VBN	O
by	IN	O
canister	NN	O
weighing	VBG	O
.	.	O

A	DT	O
significantly	RB	O
higher	JJR	O
proportion	NN	O
of	IN	O
ICS	NNP	O
than	IN	O
placebo	NN	O
participants	NNS	O
who	WP	O
complied	VBD	O
with	IN	O
using	VBG	O
their	PRP$	O
inhaler	NN	O
reported	VBD	O
easy	JJ	O
bruising	NN	O
(	(	O
11.2	CD	O
%	NN	O
vs	JJ	O
3.5	CD	O
%	NN	O
,	,	O
respectively	RB	O
)	)	O
and	CC	O
the	DT	O
slow	JJ	O
healing	NN	O
of	IN	O
skin	NN	O
cuts	NNS	O
or	CC	O
sores	NNS	O
(	(	O
2.4	CD	O
%	NN	O
vs	JJ	O
0.5	CD	O
%	NN	O
,	,	O
respectively	RB	O
)	)	O
.	.	O

Older	JJR	O
men	NNS	O
in	IN	O
the	DT	O
ICS	NNP	O
group	NN	O
with	IN	O
good	JJ	O
inhaler	NN	O
compliance	NN	O
appeared	VBD	O
to	TO	O
be	VB	O
at	IN	O
the	DT	O
greatest	JJS	O
risk	NN	O
of	IN	O
bruising	VBG	O
.	.	O

In	IN	O
those	DT	O
participants	NNS	O
undergoing	VBG	O
serial	JJ	O
measurements	NNS	O
of	IN	O
adrenal	JJ	O
function	NN	O
and	CC	O
BMD	NNP	O
,	,	O
no	DT	O
association	NN	O
was	VBD	O
noted	VBN	O
between	IN	O
skin	JJ	O
bruising	NN	O
and	CC	O
either	CC	O
the	DT	O
suppression	NN	O
of	IN	O
adrenal	JJ	O
function	NN	O
or	CC	O
the	DT	O
loss	NN	O
of	IN	O
BMD	NNP	O
as	IN	O
systemic	JJ	O
complications	NNS	O
of	IN	O
ICS	NNP	O
use	NN	O
.	.	O

CONCLUSION	NNP	O
These	DT	O
findings	NNS	O
indicate	VBP	O
that	IN	O
moderate-to-high	JJ	O
doses	NNS	O
of	IN	O
ICSs	NNP	O
result	NN	O
in	IN	O
an	DT	O
increased	JJ	O
incidence	NN	O
of	IN	O
easy	JJ	O
bruising	NN	O
and	CC	O
impairment	NN	O
in	IN	O
skin	NN	O
healing	NN	O
in	IN	O
middle-aged	JJ	O
to	TO	O
elderly	JJ	O
persons	NNS	O
with	IN	O
COPD	NNP	O
.	.	O

No	DT	O
association	NN	O
was	VBD	O
noted	VBN	O
between	IN	O
skin	JJ	O
bruising	NN	O
and	CC	O
other	JJ	O
markers	NNS	O
of	IN	O
systemic	JJ	O
toxicity	NN	O
from	IN	O
the	DT	O
use	NN	O
of	IN	O
ICSs	NNP	O
.	.	O

Plasmakinetic	JJ	O
prostate	NN	O
resection	NN	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
benign	JJ	O
prostate	JJ	O
hyperplasia	NN	O
:	:	O
results	NNS	O
of	IN	O
1-year	JJ	O
follow	VBP	O
up	RP	O
.	.	O

AIM	NNP	O
In	IN	O
our	PRP$	O
randomized	JJ	O
prospective	JJ	O
study	NN	O
,	,	O
we	PRP	O
aimed	VBD	O
to	TO	O
evaluate	VB	O
the	DT	O
efficiency	NN	O
of	IN	O
plasmakinetic	JJ	O
resection	NN	O
of	IN	O
prostate	NN	O
(	(	O
PKRP	NNP	O
)	)	O
by	IN	O
comparing	VBG	O
the	DT	O
preoperative	NN	O
and	CC	O
postoperative	JJ	O
results	NNS	O
of	IN	O
the	DT	O
transurethral	JJ	O
resection	NN	O
of	IN	O
prostate	NN	O
(	(	O
TURP	NNP	O
)	)	O
and	CC	O
PKRP	NNP	O
techniques	NNS	O
which	WDT	O
we	PRP	O
administered	VBD	O
in	IN	O
patients	NNS	O
with	IN	O
benign	JJ	O
prostate	NN	O
hyperplasia	NN	O
(	(	O
BPH	NNP	O
)	)	O
in	IN	O
our	PRP$	O
clinic	NN	O
.	.	O

METHODS	NNP	O
Of	IN	O
57	CD	O
patients	NNS	O
for	IN	O
whom	WP	O
we	PRP	O
thought	VBD	O
an	DT	O
operative	JJ	O
intervention	NN	O
was	VBD	O
necessary	JJ	O
,	,	O
30	CD	O
cases	NNS	O
in	IN	O
the	DT	O
first	JJ	O
group	NN	O
had	VBD	O
a	DT	O
TURP	NNP	O
and	CC	O
24	CD	O
cases	NNS	O
in	IN	O
the	DT	O
second	JJ	O
group	NN	O
had	VBD	O
a	DT	O
PKRP	NNP	O
.	.	O

International	NNP	O
prostate	JJ	O
symptom	NN	O
scores	NNS	O
(	(	O
I-PSS	NNP	O
)	)	O
,	,	O
uroflowmetry	UH	O
,	,	O
measurement	NN	O
of	IN	O
residual	JJ	O
urine	JJ	O
amount	NN	O
and	CC	O
ultrasonography	NN	O
were	VBD	O
performed	VBN	O
for	IN	O
each	DT	O
patient	NN	O
both	DT	O
preoperatively	RB	O
and	CC	O
postoperatively	RB	O
(	(	O
first	JJ	O
month	NN	O
and	CC	O
first	JJ	O
year	NN	O
)	)	O
.	.	O

Operation	NNP	O
times	NNS	O
,	,	O
urethral	JJ	O
catheterization	NN	O
times	NNS	O
,	,	O
preoperative	JJ	O
and	CC	O
postoperative	JJ	O
Hb	NNP	O
,	,	O
Htc	NNP	O
and	CC	O
serum	VB	O
Na	NNP	O
values	NNS	O
of	IN	O
the	DT	O
patients	NNS	O
were	VBD	O
compared	VBN	O
and	CC	O
the	DT	O
complications	NNS	O
of	IN	O
the	DT	O
groups	NNS	O
were	VBD	O
also	RB	O
compared	VBN	O
.	.	O

RESULTS	VB	O
On	IN	O
first	JJ	O
month	NN	O
and	CC	O
first	JJ	O
year	NN	O
follow	VBP	O
up	RP	O
between	IN	O
the	DT	O
groups	NNS	O
,	,	O
there	EX	O
was	VBD	O
no	DT	O
significant	JJ	O
statistical	JJ	O
difference	NN	O
in	IN	O
I-PSS	NNP	O
,	,	O
maximum	JJ	O
flow	NN	O
rate	NN	O
,	,	O
average	NN	O
flow	NN	O
,	,	O
residual	JJ	O
urine	NN	O
and	CC	O
size	NN	O
of	IN	O
the	DT	O
prostate	NN	O
.	.	O

The	DT	O
decrease	NN	O
in	IN	O
serum	NN	O
Na	NNP	O
level	NN	O
was	VBD	O
found	VBN	O
to	TO	O
be	VB	O
significantly	RB	O
higher	JJR	O
in	IN	O
the	DT	O
TURP	NNP	O
group	NN	O
(	(	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
.	.	O

The	DT	O
operation	NN	O
times	NNS	O
were	VBD	O
not	RB	O
significantly	RB	O
different	JJ	O
between	IN	O
the	DT	O
groups	NNS	O
.	.	O

While	IN	O
the	DT	O
postoperative	JJ	O
catheterization	NN	O
time	NN	O
was	VBD	O
75.7	CD	O
h	NN	O
in	IN	O
TURP	NNP	O
group	NN	O
,	,	O
it	PRP	O
was	VBD	O
found	VBN	O
to	TO	O
be	VB	O
42	CD	O
h	NN	O
in	IN	O
PKRP	NNP	O
group	NN	O
and	CC	O
it	PRP	O
was	VBD	O
clear	JJ	O
that	IN	O
catheterization	NN	O
time	NN	O
was	VBD	O
significantly	RB	O
shorter	JJR	O
(	(	O
P	NNP	O
<	NNP	O
0001	CD	O
)	)	O
.	.	O

CONCLUSION	VB	O
It	PRP	O
is	VBZ	O
obvious	JJ	O
that	IN	O
PKRP	NNP	O
is	VBZ	O
as	RB	O
efficient	JJ	O
as	IN	O
TURP	NNP	O
and	CC	O
it	PRP	O
has	VBZ	O
a	DT	O
similar	JJ	O
morbidity	NN	O
.	.	O

In	IN	O
our	PRP$	O
opinion	NN	O
,	,	O
PKRP	NNP	O
makes	VBZ	O
a	DT	O
promising	JJ	O
treatment	NN	O
for	IN	O
BPH	NNP	O
with	IN	O
its	PRP$	O
advantages	NNS	O
,	,	O
such	JJ	O
as	IN	O
early	JJ	O
removal	NN	O
of	IN	O
postoperative	JJ	O
urethral	JJ	O
catheter	NN	O
,	,	O
a	DT	O
shorter	JJR	O
hospital	NN	O
stay	NN	O
and	CC	O
the	DT	O
absence	NN	O
of	IN	O
TUR	NNP	O
syndrome	NN	O
risk	NN	O
.	.	O

Effects	NNS	O
of	IN	O
supervised	JJ	O
exercise	NN	O
therapy	NN	O
in	IN	O
patients	NNS	O
receiving	VBG	O
radiotherapy	NN	O
for	IN	O
breast	NN	O
cancer	NN	O
.	.	O

PURPOSE	NNP	O
Postoperative	NNP	O
radiotherapy	NN	O
for	IN	O
breast	NN	O
cancer	NN	O
has	VBZ	O
a	DT	O
number	NN	O
of	IN	O
associated	JJ	O
complications	NNS	O
.	.	O

This	DT	O
study	NN	O
examined	VBD	O
whether	IN	O
supervised	VBN	O
moderate-intensity	NN	O
exercise	NN	O
could	MD	O
mitigate	VB	O
the	DT	O
complications	NNS	O
that	WDT	O
occur	VBP	O
during	IN	O
radiotherapy	NN	O
.	.	O

PATIENTS	NNP	O
AND	CC	O
METHODS	NNP	O
Forty	NNP	O
women	NNS	O
were	VBD	O
randomized	VBN	O
before	IN	O
radiotherapy	NN	O
after	IN	O
various	JJ	O
operations	NNS	O
for	IN	O
breast	NN	O
cancer	NN	O
.	.	O

Seventeen	JJ	O
patients	NNS	O
who	WP	O
were	VBD	O
assigned	VBN	O
to	TO	O
the	DT	O
exercise	NN	O
group	NN	O
performed	VBD	O
supervised	VBN	O
moderate-intensity	NN	O
exercise	NN	O
therapy	NN	O
for	IN	O
50	CD	O
min	NN	O
3	CD	O
times	NNS	O
per	IN	O
week	NN	O
for	IN	O
5	CD	O
weeks	NNS	O
.	.	O

Twenty-three	JJ	O
patients	NNS	O
in	IN	O
the	DT	O
control	NN	O
group	NN	O
were	VBD	O
asked	VBN	O
to	TO	O
perform	VB	O
self-shoulder	JJ	O
stretching	VBG	O
exercise	NN	O
.	.	O

The	DT	O
World	NNP	O
Health	NNP	O
Organization	NNP	O
Quality	NNP	O
of	IN	O
Life-BREF	NNP	O
(	(	O
WHOQOL-BREF	NNP	O
)	)	O
,	,	O
brief	JJ	O
fatigue	JJ	O
inventory	NN	O
(	(	O
BFI	NNP	O
)	)	O
,	,	O
range	NN	O
of	IN	O
motion	NN	O
(	(	O
ROM	NNP	O
)	)	O
of	IN	O
the	DT	O
shoulder	NN	O
,	,	O
and	CC	O
pain	NN	O
score	NN	O
were	VBD	O
assessed	VBN	O
before	IN	O
and	CC	O
after	IN	O
radiotherapy	NN	O
.	.	O

RESULTS	CC	O
There	EX	O
were	VBD	O
no	DT	O
significant	JJ	O
differences	NNS	O
noted	VBD	O
at	IN	O
baseline	NN	O
between	IN	O
groups	NNS	O
.	.	O

In	IN	O
the	DT	O
exercise	NN	O
group	NN	O
,	,	O
there	EX	O
was	VBD	O
an	DT	O
increase	NN	O
in	IN	O
the	DT	O
WHOQOL-BREF	NNP	O
and	CC	O
shoulder	NN	O
ROM	NNP	O
and	CC	O
decrease	NN	O
in	IN	O
BFI	NNP	O
and	CC	O
pain	NN	O
score	NN	O
after	IN	O
radiotherapy	NN	O
.	.	O

On	IN	O
the	DT	O
other	JJ	O
hand	NN	O
,	,	O
patients	NNS	O
in	IN	O
the	DT	O
control	NN	O
group	NN	O
showed	VBD	O
decrease	NN	O
in	IN	O
the	DT	O
WHOQOL-BREF	NNP	O
and	CC	O
shoulder	NN	O
ROM	NNP	O
and	CC	O
increase	VB	O
in	IN	O
BFI	NNP	O
and	CC	O
pain	NN	O
score	NN	O
after	IN	O
radiotherapy	NN	O
.	.	O

There	EX	O
were	VBD	O
statistically	RB	O
significant	JJ	O
differences	NNS	O
in	IN	O
the	DT	O
changes	NNS	O
in	IN	O
the	DT	O
WHOQOL	NNP	O
,	,	O
BFI	NNP	O
,	,	O
shoulder	NN	O
ROM	NNP	O
,	,	O
and	CC	O
pain	VB	O
score	NN	O
between	IN	O
the	DT	O
groups	NNS	O
.	.	O

CONCLUSION	NNP	O
Patients	NNPS	O
receiving	VBG	O
radiotherapy	NN	O
for	IN	O
breast	NN	O
cancer	NN	O
may	MD	O
benefit	VB	O
in	IN	O
physical	JJ	O
and	CC	O
psychological	JJ	O
aspects	NNS	O
from	IN	O
supervised	VBN	O
moderate-intensity	NN	O
exercise	NN	O
therapy	NN	O
.	.	O

Effect	NN	O
of	IN	O
systemic	JJ	O
nitric	JJ	O
oxide	IN	O
synthase	JJ	O
inhibition	NN	O
on	IN	O
postexercise	NN	C
hypotension	NN	C
in	IN	O
humans	NNS	O
.	.	O

An	DT	O
acute	JJ	O
bout	NN	O
of	IN	O
aerobic	JJ	O
exercise	NN	O
results	NNS	O
in	IN	O
a	DT	O
reduced	JJ	O
blood	NN	O
pressure	NN	O
that	WDT	O
lasts	VBZ	O
several	JJ	O
hours	NNS	O
.	.	O

Animal	NNP	O
studies	NNS	O
suggest	VBP	O
this	DT	O
response	NN	O
is	VBZ	O
mediated	VBN	O
by	IN	O
increased	JJ	O
production	NN	O
of	IN	O
nitric	JJ	O
oxide	NN	O
.	.	O

We	PRP	O
tested	VBD	O
the	DT	O
extent	NN	O
to	TO	O
which	WDT	O
systemic	JJ	O
nitric	JJ	O
oxide	IN	O
synthase	JJ	O
inhibition	NN	O
[	NNP	O
N	NNP	O
(	(	O
G	NNP	O
)	)	O
-monomethyl-L-arginine	NN	O
(	(	O
L-NMMA	NNP	O
)	)	O
]	NN	O
can	MD	O
reverse	VB	O
the	DT	O
drop	NN	O
in	IN	O
blood	NN	O
pressure	NN	O
that	WDT	O
occurs	VBZ	O
after	IN	O
exercise	NN	O
in	IN	O
humans	NNS	O
.	.	O

Eight	NNP	SS
healthy	JJ	O
subjects	NNS	O
underwent	JJ	O
parallel	JJ	O
experiments	NNS	O
on	IN	O
2	CD	O
separate	JJ	O
days	NNS	O
.	.	O

The	DT	O
order	NN	O
of	IN	O
the	DT	O
experiments	NNS	O
was	VBD	O
randomized	VBN	O
between	IN	O
sham	NN	O
(	(	O
60	CD	O
min	NN	O
of	IN	O
seated	JJ	O
upright	JJ	O
rest	NN	O
)	)	O
and	CC	O
exercise	NN	O
(	(	O
60	CD	O
min	NN	O
of	IN	O
upright	JJ	O
cycling	NN	O
at	IN	O
60	CD	O
%	NN	O
peak	NN	O
aerobic	JJ	O
capacity	NN	O
)	)	O
.	.	O

After	IN	O
both	DT	O
sham	NN	O
and	CC	O
exercise	NN	O
,	,	O
subjects	VBZ	O
received	VBN	O
,	,	O
in	IN	O
sequence	NN	O
,	,	O
systemic	JJ	O
alpha-adrenergic	JJ	O
blockade	NN	O
(	(	O
phentolamine	NN	O
)	)	O
and	CC	O
L-NMMA	NNP	O
.	.	O

Phentolamine	NNP	O
was	VBD	O
given	VBN	O
first	RB	O
to	TO	O
isolate	VB	O
the	DT	O
contribution	NN	O
of	IN	O
nitric	JJ	O
oxide	NN	O
to	TO	O
postexercise	VB	O
hypotension	NN	O
by	IN	O
preventing	VBG	O
reflex	JJ	O
changes	NNS	O
in	IN	O
sympathetic	JJ	O
tone	NN	O
that	WDT	O
result	NN	O
from	IN	O
systemic	JJ	O
nitric	JJ	O
oxide	IN	O
synthase	JJ	O
inhibition	NN	O
and	CC	O
to	TO	O
control	VB	O
for	IN	O
alterations	NNS	O
in	IN	O
resting	VBG	O
sympathetic	JJ	O
activity	NN	O
after	IN	O
exercise	NN	O
.	.	O

During	IN	O
each	DT	O
condition	NN	O
,	,	O
systemic	JJ	O
and	CC	O
regional	JJ	O
hemodynamics	NNS	O
were	VBD	O
measured	VBN	O
.	.	O

Throughout	IN	O
the	DT	O
study	NN	O
,	,	O
arterial	JJ	O
pressure	NN	O
and	CC	O
vascular	JJ	O
resistances	NNS	O
remained	VBD	O
lower	JJR	O
postexercise	NN	O
vs.	FW	O
postsham	NN	O
despite	IN	O
nitric	JJ	O
oxide	JJ	O
synthase	NN	O
inhibition	NN	O
(	(	O
e.g.	JJ	O
,	,	O
mean	JJ	O
arterial	JJ	O
pressure	NN	O
after	IN	O
L-NMMA	NNP	O
was	VBD	O
108.0+/-2.4	JJ	O
mmHg	NN	O
postsham	NN	O
vs.	FW	O
102.1+/-3.3	JJ	O
mmHg	NN	O
postexercise	NN	O
;	:	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
.	.	O

Thus	VB	O
it	PRP	O
does	VBZ	O
not	RB	O
appear	VB	O
that	IN	O
postexercise	NN	O
hypotension	NN	O
is	VBZ	O
dependent	JJ	O
on	IN	O
increased	JJ	O
production	NN	O
of	IN	O
nitric	JJ	O
oxide	NN	O
in	IN	O
humans	NNS	O
.	.	O

[	JJ	O
Effectiveness	NNP	O
of	IN	O
adjuvant	JJ	O
hormone	NN	O
therapy	NN	O
in	IN	O
breast	NN	O
cancer	NN	O
]	NNP	O
.	.	O

A	NNP	O
third	JJ	O
series	NN	O
of	IN	O
randomized	JJ	O
tests	NNS	O
was	VBD	O
undertaken	VBN	O
to	TO	O
evaluate	VB	O
the	DT	O
efficacy	NN	O
of	IN	O
postoperative	JJ	O
adjuvant	JJ	O
hormone	NN	O
therapy	NN	O
(	(	O
tamoxifen	NN	O
,	,	O
diethylstilbestrol	NN	O
,	,	O
orimethen	VBP	O
amino	JJ	O
glutethymide	NN	O
)	)	O
in	IN	O
breast	NN	C
cancer	NN	C
patients	NNS	O
.	.	O

Tamoxifen	NNP	O
was	VBD	O
studied	VBN	O
in	IN	O
176	CD	O
patients	NNS	O
with	IN	O
T1-2N0M0	NNP	C
tumors	NNS	C
.	.	O

Five-year	JJ	O
recurrence-free	JJ	O
survival	NN	O
was	VBD	O
registered	VBN	O
in	IN	O
85.2	CD	O
%	NN	O
of	IN	O
menopausal	NN	O
patients	NNS	O
treated	VBN	O
with	IN	O
tamoxifen	JJ	O
versus	NN	O
71.1	CD	O
%	NN	O
in	IN	O
control	NN	O
(	(	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
.	.	O

Five-year	JJ	O
recurrence-free	JJ	O
survival	NN	O
in	IN	O
menopausal	NN	O
females	NNS	O
with	IN	O
breast	NN	O
tumors	NNS	O
,	,	O
stage	NN	O
IIb	NNP	O
,	,	O
was	VBD	O
71.1	CD	O
%	NN	O
among	IN	O
those	DT	O
treated	VBN	O
with	IN	O
diethylstilbestrol	NN	O
and	CC	O
as	RB	O
low	JJ	O
as	IN	O
57.4	CD	O
%	NN	O
in	IN	O
the	DT	O
tamoxifen	NN	O
group	NN	O
(	(	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
.	.	O

Untoward	NNP	O
side-effect	JJ	O
incidence	NN	O
was	VBD	O
much	JJ	O
higher	JJR	O
in	IN	O
the	DT	O
diethylstilbestrol	NN	O
group	NN	O
(	(	O
30.4	CD	O
%	NN	O
)	)	O
as	IN	O
compared	VBN	O
with	IN	O
tamoxifen	NN	O
(	(	O
3.5	CD	O
%	NN	O
)	)	O
.	.	O

No	DT	O
significant	JJ	O
difference	NN	O
was	VBD	O
found	VBN	O
for	IN	O
the	DT	O
relationship	NN	O
between	IN	O
orimethen	NN	O
and	CC	O
tamoxifen	JJ	O
treatment	NN	O
with	IN	O
respect	NN	O
to	TO	O
5-year	JJ	O
survival	NN	O
and	CC	O
recurrence-free	JJ	O
survival	NN	O
.	.	O

A	DT	O
comparative	JJ	O
study	NN	O
of	IN	O
the	DT	O
pharmacokinetics	NNS	O
of	IN	O
ibuprofen	JJ	O
arginate	NN	O
versus	NN	O
dexibuprofen	NN	O
in	IN	O
healthy	JJ	O
volunteers	NNS	O
.	.	O

OBJECTIVE	NNP	O
Ibuprofen	NNP	O
arginate	NN	O
is	VBZ	O
a	DT	O
salt	JJ	O
formulation	NN	O
of	IN	O
ibuprofen	NN	O
designed	VBN	O
to	TO	O
reach	VB	O
target	NN	O
concentrations	NNS	O
rapidly	RB	O
.	.	O

The	DT	O
primary	JJ	O
objective	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
compare	VB	O
the	DT	O
12-h	JJ	O
pharmacokinetic	JJ	O
profile	NN	O
of	IN	O
S	NNP	O
(	(	O
+	NNP	O
)	)	O
-ibuprofen	VBD	O
following	VBG	O
administration	NN	O
of	IN	O
single	JJ	O
doses	NNS	O
of	IN	O
ibuprofen	JJ	O
arginate	NN	O
(	(	O
600	CD	O
mg	NN	O
)	)	O
and	CC	O
dexibuprofen	NN	O
(	(	O
400	CD	O
mg	NN	O
)	)	O
in	IN	O
healthy	JJ	O
volunteers	NNS	O
.	.	O

METHODS	NNP	O
Twenty-four	JJ	O
volunteers	NNS	O
were	VBD	O
recruited	VBN	O
into	IN	O
an	DT	O
open-label	JJ	O
,	,	O
randomised	JJ	O
,	,	O
two-period	JJ	O
,	,	O
single-centre	JJ	O
study	NN	O
with	IN	O
crossover	NN	O
design	NN	O
.	.	O

RESULTS	NNP	O
Both	DT	O
treatments	NNS	O
were	VBD	O
well	RB	O
tolerated	VBN	O
.	.	O

Ibuprofen	NNP	O
arginate	NN	O
and	CC	O
dexibuprofen	NN	O
showed	VBD	O
similar	JJ	O
bioavailability	NN	O
for	IN	O
S	NNP	O
(	(	O
+	NNP	O
)	)	O
-ibuprofen	NN	O
.	.	O

Compared	VBN	O
with	IN	O
dexibuprofen	NN	O
,	,	O
ibuprofen	JJ	O
arginate	NN	O
demonstrated	VBD	O
a	DT	O
45	CD	O
%	NN	O
higher	JJR	O
maximum	JJ	O
concentration	NN	O
(	(	O
C	NNP	O
(	(	O
max	NN	O
)	)	O
)	)	O
,	,	O
and	CC	O
a	DT	O
time	NN	O
to	TO	O
peak	VB	O
concentration	NN	O
(	(	O
T	NNP	O
(	(	O
max	NN	O
)	)	O
)	)	O
2	CD	O
h	NN	O
sooner	NN	O
.	.	O

CONCLUSION	NNP	O
Ibuprofen	NNP	O
arginate	NN	O
approaches	NNS	O
maximum	JJ	O
concentrations	NNS	O
of	IN	O
S	NNP	O
(	(	O
+	NNP	O
)	)	O
-ibuprofen	VBP	O
faster	RBR	O
and	CC	O
higher	JJR	O
than	IN	O
dexibuprofen	NN	O
.	.	O

Tomato	NNP	O
paste	NN	O
rich	JJ	O
in	IN	O
lycopene	JJ	O
protects	NNS	O
against	IN	O
cutaneous	JJ	O
photodamage	NN	O
in	IN	O
humans	NNS	O
in	IN	O
vivo	NN	O
:	:	O
a	DT	O
randomized	NN	O
controlled	VBN	O
trial	NN	O
.	.	O

BACKGROUND	NNP	O
Previous	NNP	O
epidemiological	JJ	O
,	,	O
animal	JJ	O
and	CC	O
human	JJ	O
data	NNS	O
report	NN	O
that	IN	O
lycopene	NN	O
has	VBZ	O
a	DT	O
protective	JJ	O
effect	NN	O
against	IN	O
ultraviolet	NN	O
radiation	NN	O
(	(	O
UVR	NNP	O
)	)	O
-induced	VBD	O
erythema	NN	O
.	.	O

OBJECTIVES	IN	O
We	PRP	O
examined	VBD	O
whether	IN	O
tomato	NN	O
paste	NN	O
--	:	O
rich	JJ	O
in	IN	O
lycopene	NN	O
,	,	O
a	DT	O
powerful	JJ	O
antioxidant	NN	O
--	:	O
can	MD	O
protect	VB	O
human	JJ	O
skin	NN	O
against	IN	O
UVR-induced	JJ	O
effects	NNS	O
partially	RB	O
mediated	VBN	O
by	IN	O
oxidative	JJ	O
stress	NN	O
,	,	O
i.e	NN	O
.	.	O

erythema	NN	O
,	,	O
matrix	NN	O
changes	NNS	O
and	CC	O
mitochondrial	JJ	O
DNA	NNP	O
(	(	O
mtDNA	NN	O
)	)	O
damage	NN	O
.	.	O

METHODS	NNP	O
In	IN	O
a	DT	O
randomized	NN	O
controlled	VBN	O
study	NN	O
,	,	O
20	CD	SS
healthy	JJ	O
women	NNS	SE
(	(	O
median	JJ	A
age	NN	A
33	CD	A
years	NNS	A
,	,	O
range	VBP	A
21-47	JJ	A
;	:	O
phototype	JJ	O
I/II	NNP	O
)	)	O
ingested	VBD	O
55	CD	O
g	NN	O
tomato	NN	O
paste	NN	O
(	(	O
16	CD	O
mg	RB	O
lycopene	NN	O
)	)	O
in	IN	O
olive	JJ	O
oil	NN	O
,	,	O
or	CC	O
olive	JJ	O
oil	NN	O
alone	RB	O
,	,	O
daily	JJ	O
for	IN	O
12	CD	O
weeks	NNS	O
.	.	O

Pre-	NNP	O
and	CC	O
postsupplementation	NN	O
,	,	O
UVR	NNP	O
erythemal	JJ	O
sensitivity	NN	O
was	VBD	O
assessed	VBN	O
visually	RB	O
as	IN	O
the	DT	O
minimal	JJ	O
erythema	NN	O
dose	NN	O
(	(	O
MED	NNP	O
)	)	O
and	CC	O
quantified	VBN	O
with	IN	O
a	DT	O
reflectance	NN	O
instrument	NN	O
.	.	O

Biopsies	NNS	O
were	VBD	O
taken	VBN	O
from	IN	O
unexposed	JJ	O
and	CC	O
UVR-exposed	JJ	O
(	(	O
3	CD	O
?	.	O
MED	NNP	O
24	CD	O
h	NN	O
earlier	RBR	O
)	)	O
buttock	NN	O
skin	JJ	O
pre-	NN	O
and	CC	O
postsupplementation	NN	O
,	,	O
and	CC	O
analysed	VBD	O
immunohistochemically	RB	O
for	IN	O
procollagen	NN	O
(	(	O
pC	NN	O
)	)	O
I	PRP	O
,	,	O
fibrillin-1	JJ	O
and	CC	O
matrix	JJ	O
metalloproteinase	NN	O
(	(	O
MMP	NNP	O
)	)	O
-1	NN	O
,	,	O
and	CC	O
by	IN	O
quantitative	JJ	O
polymerase	NN	O
chain	NN	O
reaction	NN	O
for	IN	O
mtDNA	JJ	O
3895-bp	JJ	O
deletion	NN	O
.	.	O

RESULTS	VB	O
Mean	NNP	O
?	.	O
SD	NNP	O
erythemal	JJ	O
D	NNP	O
(	(	O
30	CD	O
)	)	O
was	VBD	O
significantly	RB	O
higher	JJR	O
following	VBG	O
tomato	JJ	O
paste	NN	O
vs.	FW	O
control	NN	O
(	(	O
baseline	NN	O
,	,	O
26?5	CD	O
?	.	O
7?5	CD	O
mJ	NN	O
cm	NN	O
(	(	O
-2	NNP	O
)	)	O
;	:	O
control	NN	O
,	,	O
23	CD	O
?	.	O
6?6	CD	O
mJ	NN	O
cm	NN	O
(	(	O
-2	NNP	O
)	)	O
;	:	O
tomato	CC	O
paste	NN	O
,	,	O
36?6	CD	O
?	.	O
14?7	CD	O
mJ	NN	O
cm	NN	O
(	(	O
-2	NNP	O
)	)	O
;	:	O
P	NNP	O
=	NNP	O
0?03	CD	O
)	)	O
,	,	O
while	IN	O
the	DT	O
MED	NNP	O
was	VBD	O
not	RB	O
significantly	RB	O
different	JJ	O
between	IN	O
groups	NNS	O
(	(	O
baseline	NN	O
,	,	O
35?1	CD	O
?	.	O
9?9	CD	O
mJ	NN	O
cm	NN	O
(	(	O
-2	NNP	O
)	)	O
;	:	O
control	NN	O
,	,	O
32?6	CD	O
?	.	O
9?6	CD	O
mJ	NN	O
cm	NN	O
(	(	O
-2	NNP	O
)	)	O
;	:	O
tomato	CC	O
paste	NN	O
,	,	O
42?2	CD	O
?	.	O
11?3	CD	O
mJ	NN	O
cm	NN	O
(	(	O
-2	NNP	O
)	)	O
)	)	O
.	.	O

Presupplementation	NN	O
,	,	O
UVR	NNP	O
induced	VBD	O
an	DT	O
increase	NN	O
in	IN	O
MMP-1	NNP	O
(	(	O
P	NNP	O
=	NNP	O
0?01	CD	O
)	)	O
and	CC	O
a	DT	O
reduction	NN	O
in	IN	O
fibrillin-1	NN	O
(	(	O
P	NNP	O
=	NNP	O
0?03	CD	O
)	)	O
.	.	O

Postsupplementation	NN	O
,	,	O
UVR-induced	JJ	O
MMP-1	NNP	O
was	VBD	O
reduced	VBN	O
in	IN	O
the	DT	O
tomato	NN	O
paste	NN	O
vs.	FW	O
control	NN	O
group	NN	O
(	(	O
P	NNP	O
=	NNP	O
0?04	CD	O
)	)	O
,	,	O
while	IN	O
the	DT	O
UVR-induced	JJ	O
reduction	NN	O
in	IN	O
fibrillin-1	NN	O
was	VBD	O
similarly	RB	O
abrogated	VBN	O
in	IN	O
both	DT	O
groups	NNS	O
,	,	O
and	CC	O
an	DT	O
increase	NN	O
in	IN	O
pCI	JJ	O
deposition	NN	O
was	VBD	O
seen	VBN	O
following	VBG	O
tomato	JJ	O
paste	NN	O
(	(	O
P	NNP	O
=	NNP	O
0?05	CD	O
)	)	O
.	.	O

mtDNA	JJ	O
3895-bp	JJ	O
deletion	NN	O
following	VBG	O
3	CD	O
?	.	O
MED	NNP	O
UVR	NNP	O
was	VBD	O
significantly	RB	O
reduced	VBN	O
postsupplementation	NN	O
with	IN	O
tomato	JJ	O
paste	NN	O
(	(	O
P	NNP	O
=	NNP	O
0?01	CD	O
)	)	O
.	.	O

CONCLUSIONS	NNP	O
Tomato	NNP	O
paste	NN	O
containing	VBG	O
lycopene	NNP	O
provides	VBZ	O
protection	NN	O
against	IN	O
acute	NN	O
and	CC	O
potentially	RB	O
longer-term	JJ	O
aspects	NNS	O
of	IN	O
photodamage	NN	O
.	.	O

Aerobic	NNP	O
exercise	NN	O
improves	VBZ	O
self-reported	JJ	O
sleep	NN	O
and	CC	O
quality	NN	O
of	IN	O
life	NN	O
in	IN	O
older	JJR	A
adults	NNS	A
with	IN	O
insomnia	NN	C
.	.	O

OBJECTIVE	UH	O
To	TO	O
assess	VB	O
the	DT	O
efficacy	NN	O
of	IN	O
moderate	JJ	O
aerobic	JJ	O
physical	JJ	O
activity	NN	O
with	IN	O
sleep	JJ	O
hygiene	NN	O
education	NN	O
to	TO	O
improve	VB	O
sleep	NN	O
,	,	O
mood	NN	O
and	CC	O
quality	NN	O
of	IN	O
life	NN	O
in	IN	O
older	JJR	O
adults	NNS	O
with	IN	O
chronic	JJ	O
insomnia	NN	O
.	.	O

METHODS	NNP	O
Seventeen	NNP	O
sedentary	JJ	O
adults	NNS	O
aged	VBN	O
>	JJ	A
or=55	CD	A
years	NNS	A
with	IN	O
insomnia	NN	O
(	(	O
mean	JJ	O
age	NN	O
61.6	CD	O
[	NN	O
SD?4.3	NNP	O
]	NNP	O
years	NNS	O
;	:	O
16	CD	O
female	NN	O
)	)	O
participated	VBD	O
in	IN	O
a	DT	O
randomized	NN	O
controlled	VBN	O
trial	NN	O
comparing	VBG	O
16	CD	O
weeks	NNS	O
of	IN	O
aerobic	JJ	O
physical	JJ	O
activity	NN	O
plus	CC	O
sleep	JJ	O
hygiene	NN	O
to	TO	O
non-physical	JJ	O
activity	NN	O
plus	CC	O
sleep	JJ	O
hygiene	NN	O
.	.	O

Eligibility	NNP	O
included	VBD	O
primary	JJ	O
insomnia	NN	O
for	IN	O
at	IN	O
least	JJS	O
3	CD	O
months	NNS	O
,	,	O
habitual	JJ	O
sleep	NN	O
duration	NN	O
<	POS	O
6.5h	CD	O
and	CC	O
a	DT	O
Pittsburgh	NNP	O
Sleep	NNP	O
Quality	NNP	O
Index	NNP	O
(	(	O
PSQI	NNP	O
)	)	O
score	VBD	O
>	JJ	O
5	CD	O
.	.	O

Outcomes	NNS	O
included	VBD	O
sleep	JJ	O
quality	NN	O
,	,	O
mood	NN	O
and	CC	O
quality	NN	O
of	IN	O
life	NN	O
questionnaires	NNS	O
(	(	O
PSQI	NNP	O
,	,	O
Epworth	NNP	O
Sleepiness	NNP	O
Scale	NNP	O
[	NNP	O
ESS	NNP	O
]	NNP	O
,	,	O
Short-form	NNP	O
36	CD	O
[	NNP	O
SF-36	NNP	O
]	NNP	O
,	,	O
Center	NNP	O
for	IN	O
Epidemiological	NNP	O
Studies	NNPS	O
Depression	NNP	O
Scale	NNP	O
[	NNP	O
CES-D	NNP	O
]	NNP	O
)	)	O
.	.	O

RESULTS	VB	O
The	DT	O
physical	JJ	O
activity	NN	O
group	NN	O
improved	VBD	O
in	IN	O
sleep	JJ	O
quality	NN	O
on	IN	O
the	DT	O
global	JJ	O
PSQI	NNP	O
(	(	O
p	JJ	O
<	NNP	O
.0001	NNP	O
)	)	O
,	,	O
sleep	JJ	O
latency	NN	O
(	(	O
p=.049	NN	O
)	)	O
,	,	O
sleep	JJ	O
duration	NN	O
(	(	O
p=.04	NN	O
)	)	O
,	,	O
daytime	JJ	O
dysfunction	NN	O
(	(	O
p=.027	NN	O
)	)	O
,	,	O
and	CC	O
sleep	JJ	O
efficiency	NN	O
(	(	O
p=.036	NN	O
)	)	O
PSQI	NNP	O
sub-scores	NNS	O
compared	VBN	O
to	TO	O
the	DT	O
control	NN	O
group	NN	O
.	.	O

The	DT	O
physical	JJ	O
activity	NN	O
group	NN	O
also	RB	O
had	VBD	O
reductions	NNS	O
in	IN	O
depressive	JJ	O
symptoms	NNS	O
(	(	O
p=.044	NN	O
)	)	O
,	,	O
daytime	JJ	O
sleepiness	NN	O
(	(	O
p=.02	NN	O
)	)	O
and	CC	O
improvements	NNS	O
in	IN	O
vitality	NN	O
(	(	O
p=.017	NN	O
)	)	O
compared	VBN	O
to	TO	O
baseline	VB	O
scores	NNS	O
.	.	O

CONCLUSION	NNP	O
Aerobic	NNP	O
physical	JJ	O
activity	NN	O
with	IN	O
sleep	JJ	O
hygiene	NN	O
education	NN	O
is	VBZ	O
an	DT	O
effective	JJ	O
treatment	NN	O
approach	NN	O
to	TO	O
improve	VB	O
sleep	JJ	O
quality	NN	O
,	,	O
mood	NN	O
and	CC	O
quality	NN	O
of	IN	O
life	NN	O
in	IN	O
older	JJR	A
adults	NNS	A
with	IN	O
chronic	JJ	O
insomnia	NN	O
.	.	O

Trace	NNP	O
element	NN	O
supplementation	NN	O
after	IN	O
major	JJ	O
burns	NNS	O
modulates	VBZ	O
antioxidant	JJ	O
status	NN	O
and	CC	O
clinical	JJ	O
course	NN	O
by	IN	O
way	NN	O
of	IN	O
increased	JJ	O
tissue	NN	O
trace	NN	O
element	NN	O
concentrations	NNS	O
.	.	O

BACKGROUND	NNP	O
After	IN	O
major	JJ	O
burns	NNS	O
,	,	O
patients	NNS	O
can	MD	O
develop	VB	O
nutritional	JJ	O
deficiencies	NNS	O
including	VBG	O
trace	NN	O
element	NN	O
(	(	O
TE	NNP	O
)	)	O
deficiencies	NNS	O
.	.	O

Various	JJ	O
complications	NNS	O
,	,	O
such	JJ	O
as	IN	O
infections	NNS	O
and	CC	O
delayed	VBN	O
wound	NN	O
healing	NN	O
,	,	O
influence	VB	O
the	DT	O
clinical	JJ	O
course	NN	O
of	IN	O
such	JJ	O
patients	NNS	O
.	.	O

OBJECTIVES	IN	O
We	PRP	O
aimed	VBD	O
to	TO	O
investigate	VB	O
the	DT	O
effects	NNS	O
of	IN	O
large	JJ	O
,	,	O
intravenous	JJ	O
doses	NNS	O
of	IN	O
TE	NNP	O
supplements	NNS	O
on	IN	O
circulating	NN	O
and	CC	O
cutaneous	JJ	O
TE	NNP	O
tissue	NN	O
concentrations	NNS	O
,	,	O
on	IN	O
antioxidant	JJ	O
status	NN	O
,	,	O
and	CC	O
on	IN	O
clinical	JJ	O
outcome	NN	O
after	IN	O
major	JJ	O
burns	NNS	O
.	.	O

DESIGN	NNP	O
This	DT	O
was	VBD	O
a	DT	O
prospective	JJ	O
,	,	O
randomized	VBN	O
,	,	O
placebo-controlled	JJ	O
trial	NN	O
in	IN	O
21	CD	O
patients	NNS	O
aged	VBD	O
35	CD	O
+/-	JJ	O
11	CD	O
y	NN	O
(	(	O
x	JJ	O
+/-	NNP	O
SD	NNP	O
)	)	O
with	IN	O
burns	NNS	O
on	IN	O
45	CD	O
+/-	JJ	O
21	CD	O
%	NN	O
of	IN	O
their	PRP$	O
body	NN	O
surface	NN	O
area	NN	O
.	.	O

Intravenous	JJ	O
copper	NN	O
,	,	O
selenium	NN	O
,	,	O
and	CC	O
zinc	NN	O
(	(	O
TE	NNP	O
group	NN	O
)	)	O
or	CC	O
vehicle	NN	O
(	(	O
V	NNP	O
group	NN	O
)	)	O
was	VBD	O
given	VBN	O
with	IN	O
a	DT	O
saline	JJ	O
solution	NN	O
for	IN	O
14-21	JJ	O
d.	NN	O
Blood	NNP	O
and	CC	O
urine	JJ	O
samples	NNS	O
were	VBD	O
collected	VBN	O
until	IN	O
day	NN	O
20	CD	O
,	,	O
and	CC	O
skin	FW	O
biopsy	NN	O
specimens	NNS	O
were	VBD	O
collected	VBN	O
on	IN	O
days	NNS	O
3	CD	O
,	,	O
10	CD	O
,	,	O
and	CC	O
20	CD	O
.	.	O

RESULTS	VB	O
The	DT	O
age	NN	O
of	IN	O
the	DT	O
patients	NNS	O
and	CC	O
the	DT	O
severity	NN	O
of	IN	O
their	PRP$	O
burns	NNS	O
did	VBD	O
not	RB	O
differ	VB	O
significantly	RB	O
between	IN	O
the	DT	O
groups	NNS	O
.	.	O

Plasma	NNP	O
TE	NNP	O
concentrations	NNS	O
were	VBD	O
significantly	RB	O
higher	JJR	O
in	IN	O
the	DT	O
TE	NNP	O
group	NN	O
.	.	O

In	IN	O
burned	JJ	O
areas	NNS	O
,	,	O
skin	JJ	O
contents	NNS	O
of	IN	O
both	DT	O
selenium	NN	O
(	(	O
P=0.05	NNP	O
)	)	O
and	CC	O
zinc	NN	O
(	(	O
P=0.04	NNP	O
)	)	O
increased	VBD	O
significantly	RB	O
by	IN	O
day	NN	O
20	CD	O
.	.	O

Plasma	NNP	O
and	CC	O
tissue	NN	O
antioxidant	NN	O
status	NN	O
was	VBD	O
improved	VBN	O
by	IN	O
supplementation	NN	O
.	.	O

The	DT	O
number	NN	O
of	IN	O
infections	NNS	O
in	IN	O
the	DT	O
first	JJ	O
30	CD	O
d	NN	O
was	VBD	O
significantly	RB	O
lower	JJR	O
in	IN	O
the	DT	O
TE	NNP	O
group	NN	O
(	(	O
P=0.015	NNP	O
)	)	O
,	,	O
with	IN	O
a	DT	O
median	JJ	O
number	NN	O
of	IN	O
2	CD	O
versus	NN	O
4	CD	O
infections	NNS	O
per	IN	O
patient	NN	O
in	IN	O
the	DT	O
TE	NNP	O
and	CC	O
V	NNP	O
groups	NNS	O
,	,	O
respectively	RB	O
,	,	O
as	IN	O
a	DT	O
result	NN	O
of	IN	O
a	DT	O
reduction	NN	O
in	IN	O
pulmonary	JJ	O
infections	NNS	O
(	(	O
P=0.03	NNP	O
)	)	O
.	.	O

Wound	IN	O
healing	NN	O
was	VBD	O
improved	VBN	O
in	IN	O
the	DT	O
TE	NNP	O
group	NN	O
,	,	O
with	IN	O
lower	JJR	O
requirements	NNS	O
for	IN	O
regrafting	VBG	O
(	(	O
P=0.02	NNP	O
)	)	O
.	.	O

CONCLUSIONS	NNP	O
TE	NNP	O
supplementation	NN	O
was	VBD	O
associated	VBN	O
with	IN	O
higher	JJR	O
circulating	NN	O
plasma	NN	O
and	CC	O
skin	JJ	O
tissue	NN	O
contents	NNS	O
of	IN	O
selenium	NN	O
and	CC	O
zinc	NN	O
and	CC	O
improved	VBN	O
antioxidant	JJ	O
status	NN	O
.	.	O

These	DT	O
changes	NNS	O
were	VBD	O
associated	VBN	O
with	IN	O
improved	JJ	O
clinical	JJ	O
outcome	NN	O
,	,	O
including	VBG	O
fewer	JJR	O
pulmonary	JJ	O
infections	NNS	O
and	CC	O
better	JJR	O
wound	NN	O
healing	NN	O
.	.	O

A	DT	O
double	JJ	O
blind	NN	O
randomized	VBD	O
study	NN	O
of	IN	O
oral	JJ	O
clodronate	NN	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
bone	NN	C
metastases	NNS	C
from	IN	C
tumors	NNS	C
poorly	RB	C
responsive	VBP	C
to	TO	C
chemotherapy	VB	C
.	.	O

Bisphosphonates	NNS	O
are	VBP	O
used	VBN	O
in	IN	O
oncology	NN	O
as	IN	O
a	DT	O
means	NN	O
of	IN	O
decreasing	VBG	O
complications	NNS	O
due	JJ	O
to	TO	O
bone	VB	O
metastases	NNS	O
,	,	O
in	IN	O
association	NN	O
with	IN	O
anticancer	NN	O
treatment	NN	O
,	,	O
especially	RB	O
in	IN	O
patients	NNS	O
with	IN	O
breast	NN	O
cancer	NN	O
,	,	O
prostate	NN	O
cancer	NN	O
and	CC	O
myeloma	NN	O
.	.	O

Little	JJ	O
is	VBZ	O
known	VBN	O
about	IN	O
the	DT	O
effects	NNS	O
of	IN	O
bisphosphonates	NNS	O
on	IN	O
bone	NN	O
metastases	NNS	O
from	IN	O
other	JJ	O
tumors	NNS	O
and	CC	O
in	IN	O
particular	JJ	O
from	IN	O
tumors	NNS	O
for	IN	O
which	WDT	O
no	DT	O
effective	JJ	O
treatment	NN	O
is	VBZ	O
available	JJ	O
.	.	O

We	PRP	O
conducted	VBD	O
a	DT	O
randomized	VBN	O
,	,	O
double-blind	JJ	O
placebo-controlled	JJ	O
trial	NN	O
of	IN	O
oral	JJ	O
clodronate	NN	O
in	IN	O
patients	NNS	O
with	IN	O
bone	NN	C
metastases	NNS	C
from	IN	C
tumors	NNS	C
poorly	RB	C
responsive	VBP	C
to	TO	C
chemotherapy	VB	C
,	,	O
with	IN	O
the	DT	O
aims	NNS	O
of	IN	O
evaluating	VBG	O
the	DT	O
effects	NNS	O
of	IN	O
this	DT	O
drug	NN	O
on	IN	O
symptoms	NNS	O
control	NN	O
and	CC	O
bone	NN	O
metastases	NNS	O
evolution	NN	O
.	.	O

Sixty-six	JJ	SS
patients	NNS	O
with	IN	O
poorly	JJ	C
responsive	JJ	C
tumors	NNS	C
such	JJ	C
as	IN	C
non-small	JJ	C
cell	NN	C
lung	NN	C
cancer	NN	C
(	(	C
NSCLC	NNP	C
)	)	C
,	,	C
bladder	NN	C
cancer	NN	C
,	,	C
gastrointestinal	JJ	C
cancers	NNS	C
,	,	C
kidney	NN	C
cancer	NN	C
,	,	C
melanoma	NN	C
and	CC	C
metastatic	JJ	C
carcinoma	NN	C
of	IN	C
unknown	JJ	C
origin	NN	C
entered	VBD	O
the	DT	O
study	NN	O
.	.	O

Patients	NNS	O
were	VBD	O
randomized	VBN	O
to	TO	O
receive	VB	O
either	DT	O
clodronate	NN	O
1,600	CD	O
mg/day	NN	O
for	IN	O
one	CD	O
year	NN	O
or	CC	O
identical	JJ	O
placebo-containing	JJ	O
tablets	NNS	O
.	.	O

Various	JJ	O
parameters	NNS	O
such	JJ	O
as	IN	O
Karnofsky	NNP	O
performance	NN	O
status	NN	O
,	,	O
pain	NN	O
score	NN	O
(	(	O
measured	VBN	O
by	IN	O
a	DT	O
visual-analogue	JJ	O
scale	NN	O
)	)	O
and	CC	O
analgesic	JJ	O
requirement	NN	O
were	VBD	O
recorded	VBN	O
at	IN	O
monthly	JJ	O
intervals	NNS	O
.	.	O

Of	IN	O
the	DT	O
66	CD	O
patients	NNS	O
enrolled	VBD	O
,	,	O
9	CD	O
were	VBD	O
observed	VBN	O
for	IN	O
one	CD	O
month	NN	O
or	CC	O
less	JJR	O
;	:	O
7	CD	O
were	VBD	O
followed	VBN	O
for	IN	O
two	CD	O
months	NNS	O
;	:	O
only	RB	O
50	CD	O
patients	NNS	O
were	VBD	O
followed	VBN	O
for	IN	O
more	JJR	O
than	IN	O
2	CD	O
months	NNS	O
and	CC	O
could	MD	O
be	VB	O
adequately	RB	O
evaluated	VBN	O
.	.	O

At	IN	O
3	CD	O
months	NNS	O
both	DT	O
clodronate	NN	O
and	CC	O
placebo-treated	JJ	O
patients	NNS	O
had	VBD	O
a	DT	O
decrease	NN	O
in	IN	O
Karnofsky	NNP	O
performance	NN	O
status	NN	O
,	,	O
with	IN	O
the	DT	O
decrease	NN	O
being	VBG	O
more	RBR	O
evident	JJ	O
in	IN	O
the	DT	O
placebo	NN	O
group	NN	O
.	.	O

Mean	NNP	O
pain	NN	O
scores	NNS	O
showed	VBD	O
an	DT	O
increase	NN	O
of	IN	O
pain	NN	O
in	IN	O
patients	NNS	O
receiving	VBG	O
placebo	NN	O
and	CC	O
a	DT	O
decrease	NN	O
of	IN	O
pain	NN	O
in	IN	O
patients	NNS	O
receiving	VBG	O
clodronate	NN	O
,	,	O
although	IN	O
the	DT	O
difference	NN	O
failed	VBD	O
to	TO	O
be	VB	O
statistically	RB	O
significant	JJ	O
.	.	O

Analgesics	NNPS	O
requirement	NN	O
increased	VBN	O
in	IN	O
both	DT	O
groups	NNS	O
,	,	O
but	CC	O
significantly	RB	O
more	RBR	O
in	IN	O
patients	NNS	O
receiving	VBG	O
placebo	NN	O
(	(	O
p	JJ	O
=	NNP	O
0.042	CD	O
)	)	O
,	,	O
in	IN	O
whom	WP	O
increase	NN	O
in	IN	O
opioid	JJ	O
requirements	NNS	O
was	VBD	O
particularly	RB	O
evident	JJ	O
.	.	O

Toxicity	NNP	O
was	VBD	O
low	JJ	O
,	,	O
with	IN	O
occasional	JJ	O
gastroenteric	JJ	O
discomfort	NN	O
in	IN	O
both	DT	O
groups	NNS	O
.	.	O

The	DT	O
main	JJ	O
problem	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
the	DT	O
difficulty	NN	O
in	IN	O
recruiting	VBG	O
an	DT	O
adequate	JJ	O
number	NN	O
of	IN	O
patients	NNS	O
and	CC	O
following	VBG	O
them	PRP	O
for	IN	O
a	DT	O
sufficient	JJ	O
period	NN	O
of	IN	O
time	NN	O
:	:	O
general	JJ	O
conditions	NNS	O
rapidly	RB	O
deteriorated	VBD	O
in	IN	O
many	JJ	O
patients	NNS	O
,	,	O
and	CC	O
approximately	RB	O
25	CD	O
%	NN	O
of	IN	O
the	DT	O
66	CD	O
enrolled	NNS	O
were	VBD	O
not	RB	O
considered	VBN	O
evaluable	JJ	O
;	:	O
few	JJ	O
patients	NNS	O
survived	VBD	O
for	IN	O
the	DT	O
length	NN	O
of	IN	O
the	DT	O
study	NN	O
,	,	O
one	CD	O
year	NN	O
.	.	O

This	DT	O
might	MD	O
partly	RB	O
account	VB	O
for	IN	O
the	DT	O
lack	NN	O
of	IN	O
significance	NN	O
of	IN	O
some	DT	O
of	IN	O
the	DT	O
parameters	NNS	O
under	IN	O
study	NN	O
.	.	O

With	IN	O
these	DT	O
limits	NNS	O
,	,	O
oral	JJ	O
clodronate	NN	O
demonstrated	VBD	O
some	DT	O
efficacy	NN	O
in	IN	O
symptom	NN	O
control	NN	O
and	CC	O
in	IN	O
reducing	VBG	O
the	DT	O
need	NN	O
for	IN	O
analgesics	NNS	O
.	.	O

Echocardiographic	JJ	O
evaluation	NN	O
of	IN	O
children	NNS	A
with	IN	O
systemic	JJ	C
ventricular	JJ	C
dysfunction	NN	C
treated	VBN	O
with	IN	O
carvedilol	NN	O
.	.	O

Echocardiography	NN	O
is	VBZ	O
used	VBN	O
to	TO	O
measure	VB	O
the	DT	O
therapeutic	JJ	O
effectiveness	NN	O
of	IN	O
heart	NN	O
failure	NN	O
therapy	NN	O
in	IN	O
adults	NNS	A
and	CC	O
children	NNS	A
.	.	O

The	DT	O
purposes	NNS	O
of	IN	O
this	DT	O
study	NN	O
were	VBD	O
(	(	O
1	CD	O
)	)	O
to	TO	O
assess	VB	O
baseline	JJ	O
echocardiographic	JJ	O
predictors	NNS	O
of	IN	O
clinical	JJ	O
outcome	NN	O
,	,	O
(	(	O
2	CD	O
)	)	O
to	TO	O
investigate	VB	O
changes	NNS	O
in	IN	O
echocardiographic	JJ	O
parameters	NNS	O
,	,	O
and	CC	O
(	(	O
3	CD	O
)	)	O
to	TO	O
compare	VB	O
these	DT	O
echocardiographic	JJ	O
changes	NNS	O
with	IN	O
changes	NNS	O
in	IN	O
plasma	NN	O
levels	NNS	O
of	IN	O
b-type	JJ	O
natriuretic	JJ	O
peptide	NN	O
(	(	O
BNP	NNP	O
)	)	O
in	IN	O
a	DT	O
population	NN	O
of	IN	O
children	NNS	A
with	IN	O
systemic	JJ	C
ventricular	JJ	C
dysfunction	NN	C
and	CC	O
symptomatic	JJ	O
heart	NN	O
failure	NN	O
treated	VBN	O
with	IN	O
carvedilol	NN	O
or	CC	O
placebo	NN	O
.	.	O

All	DT	O
available	JJ	O
baseline	NN	O
and	CC	O
6-month	JJ	O
echocardiograms	NNS	O
from	IN	O
Pediatric	NNP	O
Carvedilol	NNP	O
Trial	NNP	O
(	(	O
PCT	NNP	O
)	)	O
participants	NNS	O
(	(	O
carvedilol	JJ	O
n	RB	O
=	JJ	O
161	CD	O
;	:	O
placebo	NN	O
n	IN	O
=	$	O
55	CD	O
)	)	O
were	VBD	O
reviewed	VBN	O
.	.	O

Systolic	NNP	O
and	CC	O
diastolic	JJ	O
sphericity	NN	O
index	NN	O
(	(	O
SI	NNP	O
;	:	O
n	CC	O
=	VB	O
110	CD	O
)	)	O
,	,	O
TEI	NNP	O
index	NN	O
(	(	O
n	JJ	O
=	NNP	O
145	CD	O
)	)	O
,	,	O
and	CC	O
systemic	JJ	O
ventricular	NN	O
dP/dt	NN	O
(	(	O
n	JJ	O
=	NNP	O
70	CD	O
)	)	O
were	VBD	O
measured	VBN	O
.	.	O

The	DT	O
PCT	NNP	O
composite	JJ	O
definition	NN	O
of	IN	O
clinical	JJ	O
outcome	NN	O
(	(	O
i.e.	FW	O
,	,	O
worsened	VBD	O
,	,	O
improved	VBN	O
,	,	O
or	CC	O
unchanged	JJ	O
)	)	O
was	VBD	O
used	VBN	O
.	.	O

For	IN	O
all	DT	O
patients	NNS	O
,	,	O
baseline	VBP	O
TEI	NNP	O
index	NN	O
was	VBD	O
a	DT	O
predictor	NN	O
of	IN	O
worsened	JJ	O
outcome	NN	O
.	.	O

Only	RB	O
children	NNS	O
treated	VBD	O
with	IN	O
carvedilol	NN	O
showed	VBD	O
a	DT	O
significant	JJ	O
decrease	NN	O
in	IN	O
systolic	JJ	O
SI	NNP	O
(	(	O
P	NNP	O
B	NNP	O
0.0001	CD	O
)	)	O
,	,	O
diastolic	JJ	O
SI	NNP	O
(	(	O
P	NNP	O
B	NNP	O
0.0001	CD	O
)	)	O
,	,	O
and	CC	O
TEI	NNP	O
index	NN	O
(	(	O
P	NNP	O
=	NNP	O
0.02	CD	O
)	)	O
.	.	O

An	DT	O
inverse	JJ	O
correlation	NN	O
between	IN	O
changes	NNS	O
in	IN	O
BNP	NNP	O
and	CC	O
changes	NNS	O
in	IN	O
dP/dt	NN	O
(	(	O
r	JJ	O
=	NNP	O
-0.45	NNP	O
,	,	O
P	NNP	O
=	NNP	O
0.04	CD	O
)	)	O
was	VBD	O
found	VBN	O
only	RB	O
in	IN	O
the	DT	O
carvedilol	NN	O
group	NN	O
.	.	O

In	IN	O
conclusion	NN	O
,	,	O
TEI	NNP	O
index	NN	O
predicted	VBD	O
outcome	NN	O
in	IN	O
children	NNS	O
with	IN	O
systemic	JJ	O
ventricular	JJ	O
dysfunction	NN	O
and	CC	O
heart	NN	O
failure	NN	O
.	.	O

Carvedilol	NN	O
may	MD	O
have	VB	O
a	DT	O
beneficial	JJ	O
effect	NN	O
on	IN	O
reversal	NN	O
of	IN	O
left	JJ	O
ventricular	JJ	O
remodeling	NN	O
and	CC	O
global	JJ	O
ventricular	NN	O
function	NN	O
in	IN	O
pediatric	JJ	O
heart	NN	O
failure	NN	O
.	.	O

Effect	NN	O
of	IN	O
diltiazem	NN	O
on	IN	O
symptomatic	JJ	O
and	CC	O
asymptomatic	JJ	O
episodes	NNS	O
of	IN	O
ST	NNP	C
segment	NN	C
depression	NN	C
occurring	VBG	O
during	IN	O
daily	JJ	O
life	NN	O
and	CC	O
during	IN	O
exercise	NN	O
.	.	O

BACKGROUND	NNP	O
Silent	NNP	O
myocardial	JJ	O
ischemia	NN	O
is	VBZ	O
an	DT	O
adverse	JJ	O
prognostic	JJ	O
marker	NN	O
in	IN	O
patients	NNS	O
with	IN	O
coronary	JJ	C
disease	NN	C
;	:	O
however	RB	O
,	,	O
controlled	VBN	O
data	NNS	O
on	IN	O
the	DT	O
effect	NN	O
of	IN	O
treatment	NN	O
are	VBP	O
sparse	JJ	O
and	CC	O
contradictory	NN	O
,	,	O
and	CC	O
the	DT	O
relations	NNS	O
among	IN	O
the	DT	O
occurrence	NN	O
of	IN	O
ST	NNP	O
segment	NN	O
depression	NN	O
,	,	O
drug	NN	O
efficacy	NN	O
,	,	O
and	CC	O
heart	NN	O
rate	NN	O
are	VBP	O
unclear	JJ	O
.	.	O

METHODS	NNP	O
AND	CC	O
RESULTS	NNP	O
Sixty	NNP	SS
patients	NNS	O
with	IN	O
stable	JJ	O
coronary	JJ	O
artery	NN	O
disease	NN	O
,	,	O
a	DT	O
positive	JJ	O
treadmill	NN	O
exercise	NN	O
test	NN	O
and	CC	O
asymptomatic	JJ	O
ST	NNP	C
segment	NN	C
depression	NN	C
on	IN	O
ambulatory	JJ	O
electrocardiographic	JJ	O
recording	VBG	O
were	VBD	O
assessed	VBN	O
in	IN	O
a	DT	O
multicenter	NN	O
,	,	O
double-blind	JJ	O
,	,	O
placebo-controlled	JJ	O
,	,	O
cross-over	JJ	O
trial	NN	O
.	.	O

Treadmill	NNP	O
exercise	NN	O
tests	NNS	O
and	CC	O
72-hour	JJ	O
electrocardiographic	JJ	O
recordings	NNS	O
were	VBD	O
obtained	VBN	O
at	IN	O
the	DT	O
end	NN	O
of	IN	O
two	CD	O
2-week	JJ	O
treatment	NN	O
periods	NNS	O
with	IN	O
sustained-release	JJ	O
diltiazem	NN	O
180	CD	O
mg	NN	O
b.i.d	NN	O
.	.	O

or	CC	O
equivalent	JJ	O
placebo	NN	O
.	.	O

Episodes	NNS	O
of	IN	O
asymptomatic	JJ	O
ST	NNP	O
depression	NN	O
decreased	VBN	O
by	IN	O
50	CD	O
%	NN	O
or	CC	O
more	JJR	O
in	IN	O
70	CD	O
%	NN	O
of	IN	O
the	DT	O
patients	NNS	O
from	IN	O
a	DT	O
median	JJ	O
number	NN	O
of	IN	O
4.5	CD	O
(	(	O
range	NN	O
,	,	O
0-19	NN	O
)	)	O
to	TO	O
1.5	CD	O
(	(	O
range	NN	O
,	,	O
0-13	NN	O
)	)	O
(	(	O
p	JJ	O
=	NNP	O
0.0001	CD	O
)	)	O
;	:	O
their	PRP$	O
cumulative	JJ	O
duration	NN	O
also	RB	O
decreased	VBD	O
from	IN	O
78.5	CD	O
(	(	O
range	NN	O
,	,	O
0-60	NN	O
)	)	O
to	TO	O
24.5	CD	O
(	(	O
range	NN	O
,	,	O
0-411	NN	O
)	)	O
minutes	NNS	O
(	(	O
p	JJ	O
=	NNP	O
0.001	CD	O
)	)	O
.	.	O

No	DT	O
circadian	JJ	O
variation	NN	O
was	VBD	O
found	VBN	O
in	IN	O
the	DT	O
efficacy	NN	O
of	IN	O
diltiazem	NN	O
.	.	O

The	DT	O
occurrence	NN	O
of	IN	O
ischemic	JJ	O
type	NN	O
ST	NNP	O
segment	NN	O
depression	NN	O
was	VBD	O
modulated	VBN	O
by	IN	O
changes	NNS	O
in	IN	O
heart	NN	O
rate	NN	O
rather	RB	O
than	IN	O
by	IN	O
absolute	JJ	O
heart	NN	O
rate	NN	O
.	.	O

Diltiazem	NNP	O
also	RB	O
improved	VBD	O
exercise	NN	O
test	NN	O
end	NN	O
points	NNS	O
but	CC	O
to	TO	O
a	DT	O
lesser	JJR	O
extent	NN	O
.	.	O

Time	NN	O
to	TO	O
ST	NNP	O
segment	NN	O
depression	NN	O
increased	VBD	O
to	TO	O
341	CD	O
+/-	JJ	O
148	CD	O
from	IN	O
296	CD	O
+/-	JJ	O
154	CD	O
seconds	NNS	O
(	(	O
p	JJ	O
=	NNP	O
0.005	CD	O
)	)	O
.	.	O

Although	IN	O
less	JJR	O
frequent	JJ	O
with	IN	O
diltiazem	JJ	O
administration	NN	O
(	(	O
45	CD	O
versus	NN	O
54	CD	O
patients	NNS	O
,	,	O
p	RB	O
less	JJR	O
than	IN	O
0.03	CD	O
)	)	O
,	,	O
exercise-induced	JJ	O
ST	NNP	O
depression	NN	O
was	VBD	O
more	RBR	O
often	RB	O
asymptomatic	JJ	O
(	(	O
98	CD	O
%	NN	O
versus	IN	O
72	CD	O
%	NN	O
of	IN	O
patients	NNS	O
,	,	O
p	RB	O
less	JJR	O
than	IN	O
0.0001	CD	O
)	)	O
.	.	O

CONCLUSIONS	NNP	O
Diltiazem	NNP	O
reduces	VBZ	O
the	DT	O
frequency	NN	O
and	CC	O
severity	NN	O
of	IN	O
ischemic	JJ	O
type	NN	O
ST	NNP	O
depression	NN	O
in	IN	O
patients	NNS	O
with	IN	O
stable	JJ	O
coronary	JJ	O
artery	NN	O
disease	NN	O
.	.	O

Transthoracic	NNP	O
versus	NN	O
transesophageal	NN	O
cardioversion	NN	O
of	IN	O
atrial	JJ	O
fibrillation	NN	O
under	IN	O
light	JJ	O
sedation	NN	O
:	:	O
a	DT	O
prospective	JJ	O
randomized	VBN	O
trial	NN	O
.	.	O

BACKGROUND	NNP	O
Electrical	JJ	O
cardioversion	NN	O
(	(	O
ECV	NNP	O
)	)	O
of	IN	O
atrial	JJ	O
fibrillation	NN	O
(	(	O
AF	NNP	O
)	)	O
is	VBZ	O
limited	VBN	O
by	IN	O
a	DT	O
5-10	JJ	O
%	NN	O
failure	NN	O
rate	NN	O
and	CC	O
by	IN	O
the	DT	O
expense	NN	O
arising	VBG	O
from	IN	O
a	DT	O
perceived	JJ	O
need	NN	O
for	IN	O
general	JJ	O
anesthesia	NN	O
.	.	O

A	DT	O
transesophageal	JJ	O
approach	NN	O
using	VBG	O
light	JJ	O
sedation	NN	O
has	VBZ	O
been	VBN	O
proposed	VBN	O
as	IN	O
a	DT	O
means	NN	O
of	IN	O
augmenting	VBG	O
the	DT	O
success	NN	O
rate	NN	O
and	CC	O
avoiding	VBG	O
the	DT	O
need	NN	O
for	IN	O
general	JJ	O
anesthesia	NN	O
.	.	O

We	PRP	O
hypothesized	VBD	O
that	IN	O
the	DT	O
high	JJ	O
rate	NN	O
of	IN	O
success	NN	O
and	CC	O
the	DT	O
lower	JJR	O
energy	NN	O
requirement	NN	O
associated	VBN	O
with	IN	O
biphasic	JJ	O
cardioversion	NN	O
might	MD	O
eliminate	VB	O
any	DT	O
advantage	NN	O
of	IN	O
the	DT	O
transesophageal	JJ	O
approach	NN	O
.	.	O

METHODS	NNP	O
We	PRP	O
randomly	VBP	O
assigned	VBD	O
60	CD	O
patients	NNS	O
attending	VBG	O
for	IN	O
ECV	NNP	O
of	IN	O
persistent	JJ	O
AF	NNP	O
to	TO	O
a	DT	O
transesophageal	NN	O
or	CC	O
a	DT	O
transthoracic	JJ	O
approach	NN	O
.	.	O

Sedation	NN	O
of	IN	O
moderate	JJ	O
depth	NN	O
was	VBD	O
achieved	VBN	O
with	IN	O
intravenous	JJ	O
midazolam	NNS	O
.	.	O

The	DT	O
dose	NN	O
of	IN	O
midazolam	NN	O
was	VBD	O
titrated	VBN	O
in	IN	O
the	DT	O
same	JJ	O
manner	NN	O
in	IN	O
both	DT	O
groups	NNS	O
.	.	O

RESULTS	NNP	O
Sinus	NNP	O
rhythm	NN	O
was	VBD	O
restored	VBN	O
in	IN	O
29/30	CD	O
patients	NNS	O
(	(	O
97	CD	O
%	NN	O
)	)	O
in	IN	O
each	DT	O
group	NN	O
using	VBG	O
a	DT	O
similar	JJ	O
number	NN	O
of	IN	O
shocks	NNS	O
for	IN	O
both	DT	O
groups	NNS	O
(	(	O
1.3	CD	O
+/-	JJ	O
0.6	CD	O
transesophageal	NN	O
vs	NN	O
1.4	CD	O
+/-	JJ	O
0.7	CD	O
transthoracic	NN	O
,	,	O
P	NNP	O
=	NNP	O
NS	NNP	O
)	)	O
with	IN	O
a	DT	O
similar	JJ	O
procedure	NN	O
duration	NN	O
(	(	O
14.1	CD	O
+/-	JJ	O
8.2	CD	O
minutes	NNS	O
vs	JJ	O
13.8	CD	O
+/-	JJ	O
7.5	CD	O
minutes	NNS	O
,	,	O
P	NNP	O
=	NNP	O
NS	NNP	O
)	)	O
.	.	O

Both	DT	O
groups	NNS	O
received	VBD	O
similar	JJ	O
doses	NNS	O
of	IN	O
midazolam	NN	O
(	(	O
4.2	CD	O
+/-	JJ	O
2.7	CD	O
mg	NN	O
vs	NN	O
4.4	CD	O
+/-	JJ	O
2.8	CD	O
mg	NN	O
,	,	O
P	NNP	O
=	NNP	O
NS	NNP	O
)	)	O
and	CC	O
both	DT	O
reported	VBD	O
a	DT	O
similar	JJ	O
discomfort	NN	O
score	NN	O
in	IN	O
(	(	O
0.9	CD	O
+/-	JJ	O
1.3	CD	O
vs	JJ	O
1.1	CD	O
+/-	JJ	O
1.8	CD	O
,	,	O
P	NNP	O
=	NNP	O
NS	NNP	O
)	)	O
.	.	O

No	DT	O
complication	NN	O
occurred	VBD	O
in	IN	O
either	DT	O
group	NN	O
.	.	O

CONCLUSION	NNP	O
AF	NNP	O
may	MD	O
be	VB	O
cardioverted	VBN	O
safely	RB	O
and	CC	O
effectively	RB	O
by	IN	O
either	CC	O
a	DT	O
transthoracic	NN	O
or	CC	O
a	DT	O
transesophageal	JJ	O
approach	NN	O
.	.	O

The	DT	O
use	NN	O
of	IN	O
sedation	NN	O
of	IN	O
moderate	JJ	O
depth	NN	O
renders	NNS	O
cardioversion	NN	O
by	IN	O
either	DT	O
approach	NN	O
acceptable	JJ	O
.	.	O

As	IN	O
transesophageal	NN	O
ECV	NNP	O
shows	VBZ	O
no	DT	O
clear	JJ	O
advantage	NN	O
,	,	O
transthoracic	JJ	O
cardioversion	NN	O
should	MD	O
remain	VB	O
the	DT	O
approach	NN	O
of	IN	O
first	JJ	O
choice	NN	O
.	.	O

Five-year	JJ	O
outcome	NN	O
of	IN	O
surgical	JJ	O
treatment	NN	O
of	IN	O
migraine	NN	O
headaches	NNS	O
.	.	O

BACKGROUND	NNP	O
This	DT	O
study	NN	O
was	VBD	O
designed	VBN	O
to	TO	O
assess	VB	O
the	DT	O
long-term	JJ	O
efficacy	NN	O
of	IN	O
surgical	JJ	O
deactivation	NN	O
of	IN	O
migraine	NN	O
headache	NN	O
trigger	NN	O
sites	NNS	O
.	.	O

METHODS	NNP	O
One	CD	SS
hundred	VBD	SS
twenty-five	JJ	SS
volunteers	NNS	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
the	DT	O
treatment	NN	SS
(	(	SS
n	JJ	SS
=	NNP	SS
100	CD	SS
)	)	SS
or	CC	O
control	VB	SS
group	NN	SS
(	(	SS
n	JJ	SS
=	NNP	SS
25	CD	SS
)	)	SS
after	IN	O
examination	NN	O
by	IN	O
the	DT	O
team	NN	O
neurologist	NN	O
to	TO	O
ensure	VB	O
a	DT	O
diagnosis	NN	O
of	IN	O
migraine	NN	C
headache	NN	C
.	.	O

Patients	NNS	O
were	VBD	O
asked	VBN	O
to	TO	O
complete	VB	O
the	DT	O
Medical	NNP	O
Outcomes	NNP	O
Study	NNP	O
36-Item	JJ	O
Short	NNP	O
Form	NNP	O
Health	NNP	O
Survey	NNP	O
,	,	O
Migraine-Specific	NNP	O
Quality	NNP	O
of	IN	O
Life	NNP	O
,	,	O
and	CC	O
Migraine	NNP	O
Disability	NNP	O
Assessment	NNP	O
questionnaires	VBZ	O
before	IN	O
treatment	NN	O
and	CC	O
at	IN	O
12-	JJ	O
and	CC	O
60-month	JJ	O
postoperative	JJ	O
follow-up	NN	O
.	.	O

The	DT	O
treatment	NN	O
group	NN	O
received	VBD	O
botulinum	RB	O
toxin	NN	O
to	TO	O
confirm	VB	O
the	DT	O
trigger	NN	O
sites	VBZ	O
;	:	O
controls	NNS	O
received	VBD	O
saline	JJ	O
injections	NNS	O
.	.	O

Treated	VBN	O
patients	NNS	O
underwent	JJ	O
surgical	JJ	O
deactivation	NN	O
of	IN	O
trigger	NN	O
site	NN	O
(	(	O
s	JJ	O
)	)	O
.	.	O

Results	NNS	O
were	VBD	O
analyzed	VBN	O
at	IN	O
1	CD	O
year	NN	O
(	(	O
previously	RB	O
published	VBN	O
)	)	O
and	CC	O
5	CD	O
years	NNS	O
postoperatively	RB	O
(	(	O
the	DT	O
subject	NN	O
of	IN	O
this	DT	O
report	NN	O
)	)	O
.	.	O

RESULTS	JJ	O
Eighty-nine	NNP	O
of	IN	O
100	CD	SS
patients	NNS	O
in	IN	O
the	DT	O
treatment	NN	O
group	NN	O
underwent	JJ	O
surgery	NN	O
,	,	O
and	CC	O
79	CD	O
were	VBD	O
followed	VBN	O
for	IN	O
5	CD	O
years	NNS	O
.	.	O

Ten	CD	O
patients	NNS	O
underwent	JJ	O
deactivation	NN	O
of	IN	O
additional	JJ	O
(	(	O
different	JJ	O
)	)	O
trigger	NN	O
sites	NNS	O
during	IN	O
the	DT	O
follow-up	JJ	O
period	NN	O
and	CC	O
were	VBD	O
not	RB	O
included	VBN	O
in	IN	O
the	DT	O
data	NN	O
analysis	NN	O
.	.	O

The	DT	O
final	JJ	O
outcome	NN	O
with	IN	O
or	CC	O
without	IN	O
inclusion	NN	O
of	IN	O
these	DT	O
10	CD	O
patients	NNS	O
was	VBD	O
not	RB	O
statistically	RB	O
different	JJ	O
.	.	O

Sixty-one	NN	O
(	(	O
88	CD	O
percent	NN	O
)	)	O
of	IN	O
69	CD	O
patients	NNS	O
have	VBP	O
experienced	VBN	O
a	DT	O
positive	JJ	O
response	NN	O
to	TO	O
the	DT	O
surgery	NN	O
after	IN	O
5	CD	O
years	NNS	O
.	.	O

Twenty	NNP	O
(	(	O
29	CD	O
percent	NN	O
)	)	O
reported	VBD	O
complete	JJ	O
elimination	NN	O
of	IN	O
migraine	NN	O
headache	NN	O
,	,	O
41	CD	O
(	(	O
59	CD	O
percent	NN	O
)	)	O
noticed	VBD	O
a	DT	O
significant	JJ	O
decrease	NN	O
,	,	O
and	CC	O
eight	CD	O
(	(	O
12	CD	O
percent	NN	O
)	)	O
experienced	VBD	O
no	DT	O
significant	JJ	O
change	NN	O
.	.	O

When	WRB	O
compared	VBN	O
with	IN	O
the	DT	O
baseline	NN	O
values	NNS	O
,	,	O
all	DT	O
measured	VBD	O
variables	NNS	O
at	IN	O
60	CD	O
months	NNS	O
improved	VBN	O
significantly	RB	O
(	(	O
p	JJ	O
<	NNP	O
0.0001	CD	O
)	)	O
.	.	O

CONCLUSION	NNP	O
Based	VBD	O
on	IN	O
the	DT	O
5-year	JJ	O
follow-up	JJ	O
data	NNS	O
,	,	O
there	EX	O
is	VBZ	O
strong	JJ	O
evidence	NN	O
that	IN	O
surgical	JJ	O
manipulation	NN	O
of	IN	O
one	CD	O
or	CC	O
more	JJR	O
migraine	JJ	O
trigger	NN	O
sites	NNS	O
can	MD	O
successfully	RB	O
eliminate	VB	O
or	CC	O
reduce	VB	O
the	DT	O
frequency	NN	O
,	,	O
duration	NN	O
,	,	O
and	CC	O
intensity	NN	O
of	IN	O
migraine	NN	O
headache	NN	O
in	IN	O
a	DT	O
lasting	JJ	O
manner	NN	O
.	.	O

Teaching	VBG	O
picture-to-object	JJ	O
relations	NNS	O
in	IN	O
picture-based	JJ	O
requesting	NN	O
by	IN	O
children	NNS	A
with	IN	O
autism	NN	C
:	:	O
a	DT	O
comparison	NN	O
between	IN	O
error	NN	O
prevention	NN	O
and	CC	O
error	NN	O
correction	NN	O
teaching	NN	O
procedures	NNS	O
.	.	O

BACKGROUND	NNP	O
Children	NNP	A
who	WP	O
have	VBP	O
a	DT	O
combination	NN	O
of	IN	O
language	NN	C
and	CC	C
developmental	JJ	C
disabilities	NNS	C
with	IN	O
autism	NN	C
often	RB	O
experience	JJ	O
major	JJ	O
difficulties	NNS	O
in	IN	O
learning	VBG	O
relations	NNS	O
between	IN	O
objects	NNS	O
and	CC	O
their	PRP$	O
graphic	JJ	O
representations	NNS	O
.	.	O

Therefore	RB	O
,	,	O
they	PRP	O
would	MD	O
benefit	VB	O
from	IN	O
teaching	VBG	O
procedures	NNS	O
that	WDT	O
minimize	VBP	O
their	PRP$	O
difficulties	NNS	O
in	IN	O
acquiring	VBG	O
these	DT	O
relations	NNS	O
.	.	O

This	DT	O
study	NN	O
compared	VBN	O
two	CD	O
teaching	NN	O
procedures	NNS	O
,	,	O
an	DT	O
error	NN	O
prevention	NN	O
procedure	NN	O
and	CC	O
an	DT	O
error	NN	O
correction	NN	O
procedure	NN	O
,	,	O
for	IN	O
teaching	VBG	O
relations	NNS	O
between	IN	O
objects	NNS	O
and	CC	O
pictures	NNS	O
.	.	O

METHOD	JJ	O
Participants	NNS	O
were	VBD	O
two	CD	O
groups	NNS	O
of	IN	O
children	NNS	A
with	IN	O
autism	NN	C
,	,	O
aged	VBD	O
between	IN	O
3	CD	A
and	CC	O
7	CD	A
years	NNS	O
.	.	O

In	IN	O
the	DT	O
context	NN	O
of	IN	O
picture-to-object	JJ	O
requesting	NN	O
,	,	O
one	CD	O
group	NN	O
was	VBD	O
taught	VBN	O
using	VBG	O
an	DT	O
error	NN	O
correction	NN	O
method	NN	O
and	CC	O
the	DT	O
other	JJ	O
group	NN	O
with	IN	O
an	DT	O
error	NN	O
prevention	NN	O
method	NN	O
.	.	O

The	DT	O
measures	NNS	O
for	IN	O
each	DT	O
child	NN	O
were	VBD	O
accuracy	NN	O
of	IN	O
correspondences	NNS	O
between	IN	O
taught	JJ	O
picture	NN	O
and	CC	O
object	JJ	O
pairs	NNS	O
and	CC	O
accuracy	NN	O
of	IN	O
delayed	JJ	O
correspondences	NNS	O
in	IN	O
learning	VBG	O
outcome	JJ	O
tests	NNS	O
with	IN	O
all	DT	O
combinations	NNS	O
of	IN	O
object	NN	O
and	CC	O
picture	NN	O
pairs	NNS	O
presented	VBN	O
to	TO	O
them	PRP	O
throughout	IN	O
the	DT	O
study	NN	O
.	.	O

RESULTS	NNP	O
The	DT	O
group	NN	O
receiving	VBG	O
the	DT	O
error	NN	O
prevention-based	JJ	O
teaching	NN	O
made	VBN	O
significantly	RB	O
fewer	JJR	O
errors	NNS	O
during	IN	O
the	DT	O
teaching	NN	O
phases	NNS	O
and	CC	O
in	IN	O
their	PRP$	O
learning	NN	O
outcome	NN	O
test	NN	O
for	IN	O
correspondences	NNS	O
between	IN	O
all	DT	O
combinations	NNS	O
of	IN	O
pictures	NNS	O
and	CC	O
objects	NNS	O
.	.	O

CONCLUSIONS	VB	O
The	DT	O
error	NN	O
prevention	NN	O
teaching	NN	O
procedure	NN	O
would	MD	O
seem	VB	O
to	TO	O
provide	VB	O
a	DT	O
more	RBR	O
efficient	JJ	O
and	CC	O
ecologically	RB	O
valid	JJ	O
method	NN	O
than	IN	O
the	DT	O
error	NN	O
correction	NN	O
procedure	NN	O
for	IN	O
teaching	VBG	O
relations	NNS	O
between	IN	O
objects	NNS	O
and	CC	O
their	PRP$	O
graphic-based	JJ	O
referents	NNS	O
.	.	O

Improvements	NNS	O
in	IN	O
the	DT	O
methodology	NN	O
were	VBD	O
suggested	VBN	O
for	IN	O
providing	VBG	O
a	DT	O
stronger	JJR	O
basis	NN	O
for	IN	O
comparison	NN	O
between	IN	O
error	NN	O
correction	NN	O
and	CC	O
error	NN	O
prevention	NN	O
teaching	VBG	O
methods	NNS	O
.	.	O

Laparoscopic	NNP	O
vs	NN	O
open	JJ	O
appendectomy	NN	O
in	IN	O
overweight	JJ	C
patients	NNS	O
.	.	O

BACKGROUND	NNP	O
Laparoscopic	NNP	O
appendectomy	NN	O
(	(	O
LA	NNP	O
)	)	O
has	VBZ	O
been	VBN	O
associated	VBN	O
with	IN	O
a	DT	O
faster	JJ	O
recovery	NN	O
and	CC	O
less	RBR	O
postoperative	JJ	O
pain	NN	O
than	IN	O
the	DT	O
open	JJ	O
technique	NN	O
.	.	O

However	RB	O
,	,	O
few	JJ	O
data	NNS	O
are	VBP	O
available	JJ	O
on	IN	O
the	DT	O
clinical	JJ	O
outcome	NN	O
of	IN	O
LA	NNP	O
in	IN	O
overweight	JJ	O
patients	NNS	O
.	.	O

METHODS	NNP	O
A	NNP	O
group	NN	O
of	IN	O
106	CD	SS
patients	NNS	O
with	IN	O
a	DT	O
body	NN	O
mass	NN	O
index	NN	O
(	(	O
BMI	NNP	O
)	)	O
>	VBD	O
26.4	CD	O
,	,	O
representing	VBG	O
the	DT	O
upper	JJ	O
quintile	NN	O
of	IN	O
500	CD	O
prospectively	RB	O
randomized	JJ	O
patients	NNS	O
,	,	O
were	VBD	O
included	VBN	O
in	IN	O
the	DT	O
study	NN	O
.	.	O

They	PRP	O
were	VBD	O
randomized	VBN	O
to	TO	O
undergo	VB	O
either	DT	O
laparoscopic	NN	O
or	CC	O
open	JJ	O
appendectomy	NN	O
(	(	O
OA	NNP	O
)	)	O
.	.	O

Operating	NN	O
and	CC	O
anesthesia	NN	O
times	NNS	O
,	,	O
postoperative	JJ	O
pain	NN	O
,	,	O
complications	NNS	O
,	,	O
hospital	NN	O
stay	NN	O
,	,	O
functional	JJ	O
index	NN	O
(	(	O
1	CD	O
week	NN	O
postoperatively	RB	O
)	)	O
,	,	O
sick	JJ	O
leave	VBP	O
,	,	O
and	CC	O
time	NN	O
to	TO	O
full	JJ	O
recovery	NN	O
were	VBD	O
documented	VBN	O
.	.	O

RESULTS	NNP	O
In	IN	O
OA	NNP	O
,	,	O
the	DT	O
operating	NN	O
time	NN	O
for	IN	O
overweight	JJ	O
patients	NNS	O
was	VBD	O
significantly	RB	O
longer	JJR	O
than	IN	O
that	DT	O
for	IN	O
patients	NNS	O
in	IN	O
the	DT	O
normal	JJ	O
weight	NN	O
range	NN	O
(	(	O
40	CD	O
vs	RB	O
35	CD	O
min	NN	O
,	,	O
p	NN	O
<	NNP	O
0.05	CD	O
)	)	O
.	.	O

In	IN	O
LA	NNP	O
,	,	O
there	EX	O
was	VBD	O
no	DT	O
difference	NN	O
in	IN	O
operating	NN	O
time	NN	O
between	IN	O
the	DT	O
normal	JJ	O
and	CC	O
overweight	JJ	O
patients	NNS	O
.	.	O

Overweight	JJ	O
patients	NNS	O
who	WP	O
underwent	JJ	O
LA	NNP	O
had	VBD	O
longer	RBR	O
operating	NN	O
and	CC	O
anesthesia	NN	O
times	NNS	O
than	IN	O
their	PRP$	O
OA	NNP	O
counterparts	NNS	O
(	(	O
55	CD	O
vs	RB	O
40	CD	O
min	NN	O
,	,	O
p	NN	O
<	VBD	O
0.001	CD	O
;	:	O
and	CC	O
125	CD	O
vs	NN	O
100	CD	O
min	NN	O
,	,	O
p	NN	O
<	VBD	O
0.001	CD	O
,	,	O
respectively	RB	O
)	)	O
.	.	O

Postoperative	JJ	O
pain	NN	O
was	VBD	O
significantly	RB	O
greater	JJR	O
in	IN	O
overweight	JJ	O
patients	NNS	O
who	WP	O
underwent	VBP	O
OA	NNP	O
than	IN	O
in	IN	O
those	DT	O
treated	VBN	O
with	IN	O
the	DT	O
laparoscopic	NN	O
technique	NN	O
.	.	O

Postoperative	JJ	O
pain	NN	O
was	VBD	O
also	RB	O
significantly	RB	O
greater	JJR	O
in	IN	O
overweight	JJ	O
patients	NNS	O
subjected	VBN	O
to	TO	O
OA	NNP	O
than	IN	O
in	IN	O
patients	NNS	O
of	IN	O
normal	JJ	O
weight	NN	O
after	IN	O
4	CD	O
weeks	NNS	O
;	:	O
the	DT	O
clinical	JJ	O
significance	NN	O
may	MD	O
,	,	O
however	RB	O
,	,	O
be	VB	O
of	IN	O
less	JJR	O
importance	NN	O
since	IN	O
the	DT	O
values	NNS	O
are	VBP	O
low	JJ	O
(	(	O
0.26	CD	O
vs	NN	O
0.09	CD	O
,	,	O
p	NN	O
<	NNP	O
0.05	CD	O
)	)	O
.	.	O

There	EX	O
were	VBD	O
no	DT	O
significant	JJ	O
differences	NNS	O
between	IN	O
the	DT	O
two	CD	O
operating	VBG	O
techniques	NNS	O
in	IN	O
terms	NNS	O
of	IN	O
complications	NNS	O
.	.	O

Hospital	NNP	O
stay	NN	O
was	VBD	O
longer	JJR	O
for	IN	O
overweight	NN	O
patients	NNS	O
than	IN	O
for	IN	O
normal-weight	JJ	O
patients	NNS	O
undergoing	VBG	O
OA	NNP	O
(	(	O
3.0	CD	O
vs	NN	O
2.0	CD	O
,	,	O
p	NN	O
<	NNP	O
0.01	CD	O
)	)	O
.	.	O

The	DT	O
functional	JJ	O
index	NN	O
did	VBD	O
not	RB	O
differ	VB	O
between	IN	O
any	DT	O
group	NN	O
of	IN	O
patients	NNS	O
.	.	O

Sick	NNP	O
leave	NN	O
was	VBD	O
longer	JJR	O
for	IN	O
overweight	JJ	O
patients	NNS	O
who	WP	O
underwent	VBP	O
OA	NNP	O
than	IN	O
for	IN	O
normal-weight	JJ	O
patients	NNS	O
treated	VBN	O
with	IN	O
the	DT	O
same	JJ	O
technique	NN	O
(	(	O
17	CD	O
vs	RB	O
13	CD	O
days	NNS	O
,	,	O
p	VBP	O
<	RB	O
0.01	CD	O
)	)	O
.	.	O

In	IN	O
the	DT	O
laparoscopic	NN	O
group	NN	O
,	,	O
however	RB	O
,	,	O
there	EX	O
were	VBD	O
no	DT	O
differences	NNS	O
between	IN	O
the	DT	O
overweight	NN	O
and	CC	O
normal-weight	JJ	O
patients	NNS	O
.	.	O

Time	NN	O
to	TO	O
full	JJ	O
recovery	NN	O
was	VBD	O
greater	JJR	O
in	IN	O
overweight	JJ	O
patients	NNS	O
subjected	VBN	O
to	TO	O
OA	NNP	O
than	IN	O
in	IN	O
the	DT	O
overweight	JJ	O
patients	NNS	O
in	IN	O
the	DT	O
LA	NNP	O
group	NN	O
(	(	O
22	CD	O
vs	RB	O
15	CD	O
days	NNS	O
,	,	O
p	VBP	O
<	RB	O
0.001	CD	O
)	)	O
.	.	O

CONCLUSION	NN	O
In	IN	O
this	DT	O
study	NN	O
,	,	O
overweight	JJ	O
patients	NNS	O
who	WP	O
were	VBD	O
submitted	VBN	O
to	TO	O
LA	NNP	O
had	VBD	O
less	RBR	O
postoperative	JJ	O
pain	NN	O
and	CC	O
a	DT	O
faster	RBR	O
postoperative	JJ	O
recovery	NN	O
than	IN	O
overweight	JJ	O
patients	NNS	O
who	WP	O
had	VBD	O
OA	NNP	O
.	.	O

LA	NNP	O
also	RB	O
abolished	VBD	O
some	DT	O
of	IN	O
the	DT	O
negative	JJ	O
effects	NNS	O
that	WDT	O
overweight	VBD	O
had	VBD	O
on	IN	O
operating	NN	O
time	NN	O
,	,	O
hospital	NN	O
stay	NN	O
,	,	O
and	CC	O
sick	JJ	O
leave	NN	O
with	IN	O
the	DT	O
open	JJ	O
technique	NN	O
.	.	O

However	RB	O
,	,	O
anesthesia	NN	O
and	CC	O
operating	NN	O
times	NNS	O
were	VBD	O
significantly	RB	O
longer	RBR	O
in	IN	O
LA	NNP	O
for	IN	O
both	DT	O
overweight	JJ	O
patients	NNS	O
and	CC	O
those	DT	O
with	IN	O
a	DT	O
normal	JJ	O
BMI	NNP	O
.	.	O

Two	CD	O
large	JJ	O
preoperative	JJ	O
doses	NNS	O
of	IN	O
erythropoietin	NN	O
do	VBP	O
not	RB	O
reduce	VB	O
the	DT	O
systemic	JJ	C
inflammatory	NN	C
response	NN	C
to	TO	C
cardiac	VB	C
surgery	NN	C
.	.	C

OBJECTIVES	NNP	O
Cardiac	NNP	O
surgery	NN	O
and	CC	O
cardiopulmonary	JJ	O
bypass	NN	O
(	(	O
CPB	NNP	O
)	)	O
induce	VBP	O
an	DT	O
inflammatory	JJ	O
reaction	NN	O
that	WDT	O
may	MD	O
lead	VB	O
to	TO	O
tissue	VB	O
injury	NN	O
.	.	O

Experimental	JJ	O
studies	NNS	O
suggest	VBP	O
that	IN	O
recombinant	JJ	O
human	JJ	O
erythropoietin	NN	O
(	(	O
EPO	NNP	O
)	)	O
independent	JJ	O
of	IN	O
its	PRP$	O
erythropoietic	JJ	O
effect	NN	O
may	MD	O
be	VB	O
used	VBN	O
clinically	RB	O
as	IN	O
an	DT	O
anti-inflammatory	JJ	O
drug	NN	O
.	.	O

This	DT	O
study	NN	O
tested	VBD	O
the	DT	O
hypothesis	NN	O
that	IN	O
2	CD	O
large	JJ	O
doses	NNS	O
of	IN	O
EPO	NNP	O
administered	VBD	O
shortly	RB	O
before	IN	O
CPB	NNP	O
ameliorate	VBP	O
the	DT	O
systemic	JJ	O
inflammatory	NN	O
response	NN	O
to	TO	O
CPB	NNP	O
.	.	O

DESIGN	NNP	O
AND	NNP	O
SETTING	NNP	O
A	NNP	O
prospective	JJ	O
,	,	O
double-blind	JJ	O
,	,	O
placebo-controlled	JJ	O
and	CC	O
randomized	JJ	O
study	NN	O
at	IN	O
a	DT	O
single	JJ	O
tertiary	NN	O
care	NN	O
hospital	NN	O
.	.	O

PARTICIPANTS	CC	O
Patients	NNS	O
scheduled	VBN	O
for	IN	O
coronary	JJ	O
artery	NN	O
bypass	NN	O
graft	NN	O
surgery	NN	O
with	IN	O
CPB	NNP	O
.	.	O

INTERVENTIONS	NNP	O
EPO	NNP	O
(	(	O
epoetin	JJ	O
alfa	NN	O
,	,	O
500	CD	O
IU/kg	NNP	O
intravenously	RB	O
,	,	O
n	JJ	O
=	NNP	O
22	CD	O
)	)	O
or	CC	O
placebo	NN	O
(	(	O
n	JJ	O
=	NNP	O
21	CD	O
)	)	O
was	VBD	O
administered	VBN	O
12	CD	O
to	TO	O
18	CD	O
hours	NNS	O
preoperatively	RB	O
and	CC	O
again	RB	O
at	IN	O
the	DT	O
induction	NN	O
of	IN	O
anesthesia	NN	O
.	.	O

MEASUREMENTS	NNP	O
AND	CC	O
MAIN	NNP	O
RESULTS	NNP	O
CPB	NNP	O
in	IN	O
both	DT	O
groups	NNS	O
greatly	RB	O
increased	VBD	O
plasma	JJ	O
concentrations	NNS	O
of	IN	O
tumor	NN	O
necrosis	NN	O
factor	NN	O
alpha	NN	O
(	(	O
TNF-alpha	NNP	O
)	)	O
,	,	O
interleukin	FW	O
(	(	O
IL	NNP	O
)	)	O
-1beta	NN	O
,	,	O
IL-1beta	NNP	O
receptor	NN	O
antagonist	NN	O
,	,	O
IL-6	NNP	O
,	,	O
IL-10	NNP	O
,	,	O
and	CC	O
N-terminal	JJ	O
probrain	NN	O
natriuretic	JJ	O
peptide	NN	O
(	(	O
NT-proBNP	NNP	O
)	)	O
.	.	O

Compared	VBN	O
with	IN	O
placebo	NN	O
,	,	O
EPO	NNP	O
at	IN	O
day	NN	O
3	CD	O
after	IN	O
CPB	NNP	O
augmented	VBD	O
the	DT	O
TNF-alpha	JJ	O
response	NN	O
(	(	O
p	JJ	O
<	NNP	O
0.05	CD	O
)	)	O
and	CC	O
at	IN	O
2	CD	O
hours	NNS	O
after	IN	O
CPB	NNP	O
increased	VBD	O
NT-proBNP	NNP	O
(	(	O
p	JJ	O
<	NNP	O
0.05	CD	O
)	)	O
.	.	O

Also	RB	O
,	,	O
EPO	NNP	O
tended	VBD	O
to	TO	O
enhance	VB	O
the	DT	O
CPB-induced	JJ	O
increase	NN	O
in	IN	O
IL-1beta	NNP	O
receptor	NN	O
antagonist	NN	O
(	(	O
p	JJ	O
=	NNP	O
0.057	CD	O
)	)	O
.	.	O

Otherwise	UH	O
,	,	O
EPO	NNP	O
had	VBD	O
no	DT	O
effect	NN	O
on	IN	O
pro-	NN	O
and	CC	O
antiinflammatory	NN	O
mediators	NNS	O
compared	VBN	O
with	IN	O
placebo	NN	O
.	.	O

CONCLUSIONS	NNP	O
Two	CD	O
large	JJ	O
doses	NNS	O
of	IN	O
EPO	NNP	O
given	VBN	O
shortly	RB	O
before	IN	O
CPB	NNP	O
do	VBP	O
not	RB	O
reduce	VB	O
perioperative	JJ	O
release	NN	O
of	IN	O
inflammatory	JJ	O
cytokines	NNS	O
.	.	O

In	IN	O
contrast	NN	O
,	,	O
EPO	NNP	O
may	MD	O
augment	VB	O
the	DT	O
TNF-alpha	NNP	O
and	CC	O
NT-proBNP	NNP	O
response	NN	O
.	.	O

Although	IN	O
the	DT	O
long-term	JJ	O
clinical	JJ	O
impact	NN	O
remains	VBZ	O
unknown	JJ	O
,	,	O
the	DT	O
findings	NNS	O
do	VBP	O
not	RB	O
support	VB	O
use	NN	O
of	IN	O
EPO	NNP	O
as	IN	O
an	DT	O
anti-inflammatory	JJ	O
drug	NN	O
in	IN	O
patients	NNS	O
undergoing	JJ	O
cardiac	JJ	O
surgery	NN	O
.	.	O

Music	NNP	O
or	CC	O
guided	VBN	O
imagery	NN	O
for	IN	O
women	NNS	O
undergoing	VBG	O
colposcopy	NN	O
:	:	O
a	DT	O
randomized	NN	O
controlled	VBN	O
study	NN	O
of	IN	O
effects	NNS	O
on	IN	O
anxiety	NN	O
,	,	O
perceived	VBD	O
pain	NN	O
,	,	O
and	CC	O
patient	JJ	O
satisfaction	NN	O
.	.	O

OBJECTIVE	IN	O
It	PRP	O
was	VBD	O
hypothesized	VBN	O
that	IN	O
music	NN	O
or	CC	O
guided	VBN	O
imagery	NN	O
versus	NN	O
usual	JJ	O
care	NN	O
would	MD	O
result	VB	O
in	IN	O
less	JJR	O
anxiety	NN	O
and	CC	O
perceived	VBD	O
pain	NN	O
for	IN	O
colposcopy	NN	O
patients	NNS	O
.	.	O

MATERIALS	NNP	O
AND	CC	O
METHODS	NNP	O
Patients	NNPS	O
were	VBD	O
randomized	VBN	O
to	TO	O
music	NN	O
,	,	O
guided	VBD	O
imagery	NN	O
,	,	O
or	CC	O
usual	JJ	O
care	NN	O
after	IN	O
completing	VBG	O
a	DT	O
baseline	NN	O
questionnaire	NN	O
.	.	O

All	DT	O
patients	NNS	O
completed	VBD	O
a	DT	O
postprocedure	NN	O
questionnaire	NN	O
.	.	O

RESULTS	NNP	O
Study	NNP	O
participants	NNS	O
(	(	O
N=170	NNP	O
)	)	O
had	VBD	O
a	DT	O
mean	JJ	O
age	NN	O
of	IN	O
28.4	CD	O
years	NNS	O
(	(	O
SD=9.6	NNP	O
;	:	O
range	VB	O
18-60	JJ	O
)	)	O
and	CC	O
formed	VBD	O
a	DT	O
racially	RB	O
diverse	JJ	O
group	NN	O
.	.	O

Education/income	NNP	O
levels	NNS	O
were	VBD	O
low	JJ	O
.	.	O

No	DT	O
between-group	JJ	O
differences	NNS	O
were	VBD	O
found	VBN	O
for	IN	O
postprocedure	NN	O
anxiety	NN	O
or	CC	O
pain	NN	O
rating	NN	O
.	.	O

CONCLUSIONS	NNP	O
Mind-body	JJ	O
interventions	NNS	O
had	VBD	O
no	DT	O
statistically	RB	O
significant	JJ	O
impact	NN	O
on	IN	O
reported	VBN	O
anxiety	NN	O
,	,	O
perceived	VBD	O
pain	NN	O
,	,	O
or	CC	O
satisfaction	NN	O
with	IN	O
care	NN	O
,	,	O
even	RB	O
for	IN	O
those	DT	O
who	WP	O
anticipated	VBD	O
the	DT	O
most	RBS	O
pain	NN	O
or	CC	O
started	VBN	O
with	IN	O
high	JJ	O
anxiety	NN	O
.	.	O

Interventions	NNS	O
in	IN	O
the	DT	O
initial	JJ	O
prodromal	JJ	C
states	NNS	C
of	IN	C
psychosis	NN	C
in	IN	O
Germany	NNP	O
:	:	O
concept	NN	O
and	CC	O
recruitment	NN	O
.	.	O

BACKGROUND	VB	O
The	DT	O
Early	JJ	O
Detection	NN	O
and	CC	O
Intervention	NNP	O
Programme	NNP	O
of	IN	O
the	DT	O
German	JJ	O
Research	NNP	O
Network	NNP	O
on	IN	O
Schizophrenia	NNP	O
(	(	O
GRNS	NNP	O
)	)	O
investigates	VBZ	O
the	DT	O
initial	JJ	O
prodromal	JJ	C
phase	NN	C
of	IN	C
psychosis	NN	C
in	IN	O
a	DT	O
multidimensional	JJ	O
approach	NN	O
.	.	O

Two	CD	O
intervention	NN	O
strategies	NNS	O
are	VBP	O
being	VBG	O
studied	VBN	O
by	IN	O
two	CD	O
large-scale	JJ	O
multicentre	JJ	O
projects	NNS	O
.	.	O

AIMS	NNP	O
To	TO	O
present	VB	O
the	DT	O
concept	NN	O
of	IN	O
the	DT	O
intervention	NN	O
studies	NNS	O
,	,	O
and	CC	O
to	TO	O
provide	VB	O
an	DT	O
interim	JJ	O
report	NN	O
of	IN	O
the	DT	O
recruitment	JJ	O
procedure	NN	O
.	.	O

METHOD	NNP	O
Comprehensive	NNP	O
cognitive-behavioural	JJ	O
therapy	NN	O
has	VBZ	O
been	VBN	O
developed	VBN	O
for	IN	O
patients	NNS	O
in	IN	O
the	DT	O
early	JJ	O
initial	JJ	O
prodromal	JJ	O
state	NN	O
.	.	O

For	IN	O
patients	NNS	O
in	IN	O
the	DT	O
late	JJ	O
initial	JJ	O
prodromal	JJ	O
state	NN	O
the	DT	O
atypical	JJ	O
neuroleptic	JJ	O
amisulpride	NN	O
is	VBZ	O
explored	VBN	O
.	.	O

Both	DT	O
interventions	NNS	O
are	VBP	O
evaluated	VBN	O
in	IN	O
randomised	JJ	O
controlled	VBN	O
trials	NNS	O
using	VBG	O
clinical	JJ	O
management	NN	O
as	IN	O
the	DT	O
control	NN	O
condition	NN	O
.	.	O

RESULTS	NNP	O
Between	NNP	O
January	NNP	O
2001	CD	O
and	CC	O
March	NNP	O
2003	CD	O
,	,	O
1212	CD	SS
individuals	NNS	O
seeking	VBG	O
help	NN	O
for	IN	O
mental	JJ	O
health	NN	O
problems	NNS	O
were	VBD	O
screened	VBN	O
for	IN	O
putative	JJ	O
prodromal	NN	O
symptoms	NNS	O
at	IN	O
four	CD	O
university	NN	O
centres	NNS	O
.	.	O

More	JJR	O
than	IN	O
388	CD	SS
individuals	NNS	O
fulfilled	VBD	O
criteria	NNS	O
for	IN	O
both	DT	O
interventions	NNS	O
and	CC	O
188	CD	SS
(	(	O
48.5	CD	O
%	NN	O
)	)	O
gave	VBD	O
informed	VBN	O
consent	NN	O
to	TO	O
participate	VB	O
in	IN	O
the	DT	O
trials	NNS	O
.	.	O

CONCLUSIONS	VB	O
The	DT	O
screening	NN	O
procedure	NN	O
appears	VBZ	O
to	TO	O
be	VB	O
feasible	JJ	O
and	CC	O
trial	NN	O
participation	NN	O
seems	VBZ	O
to	TO	O
be	VB	O
acceptable	JJ	O
to	TO	O
a	DT	O
relevant	JJ	O
proportion	NN	O
of	IN	O
people	NNS	O
at	IN	O
increased	VBN	O
risk	NN	O
of	IN	O
developing	VBG	O
psychosis	NN	O
.	.	O

Blood	NNP	O
pressure	NN	O
biofeedback	NN	O
treatment	NN	O
of	IN	O
white-coat	JJ	O
hypertension	NN	O
.	.	O

OBJECTIVE	CC	O
The	DT	O
objective	NN	O
of	IN	O
the	DT	O
study	NN	O
was	VBD	O
to	TO	O
compare	VB	O
blood	NN	O
pressure	NN	O
(	(	O
BP	NNP	O
)	)	O
biofeedback	NN	O
treatment	NN	O
(	(	O
BF	NNP	O
)	)	O
effects	NNS	O
between	IN	O
white-coat	JJ	O
hypertension	NN	O
and	CC	O
essential	JJ	O
hypertension	NN	O
.	.	O

METHODS	NNP	O
Fifteen	NNP	SS
white-coat	JJ	C
hypertensive	JJ	C
out-patients	NNS	O
and	CC	O
23	CD	SS
essential	JJ	C
hypertensive	JJ	C
out-patients	NNS	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
groups	NNS	O
A	NNP	O
or	CC	O
B	NNP	O
.	.	O

Subjects	NNS	O
in	IN	O
group	NN	O
A	NNP	O
underwent	NN	O
BF	NNP	O
once	RB	O
a	DT	O
week	NN	O
for	IN	O
a	DT	O
total	NN	O
of	IN	O
four	CD	O
sessions	NNS	O
.	.	O

Those	DT	O
in	IN	O
group	NN	O
B	NNP	O
visited	VBD	O
the	DT	O
clinic	NN	O
only	RB	O
to	TO	O
measure	VB	O
BP	NNP	O
and	CC	O
later	RB	O
underwent	VBD	O
the	DT	O
same	JJ	O
BF	NNP	O
.	.	O

RESULTS	NNP	O
In	IN	O
group	NN	O
A	NNP	O
,	,	O
BPs	NNP	O
of	IN	O
white-coat	JJ	O
hypertensives	NNS	O
and	CC	O
essential	JJ	O
hypertensives	NNS	O
were	VBD	O
significantly	RB	O
reduced	VBN	O
by	IN	O
22/11	CD	O
and	CC	O
14/8	CD	O
mmHg	NN	O
,	,	O
respectively	RB	O
.	.	O

In	IN	O
group	NN	O
B	NNP	O
,	,	O
they	PRP	O
were	VBD	O
unchanged	JJ	O
during	IN	O
the	DT	O
same	JJ	O
period	NN	O
but	CC	O
later	RB	O
suppressed	VBN	O
by	IN	O
BF	NNP	O
.	.	O

Under	IN	O
BF	NNP	O
,	,	O
pulse	NN	O
and	CC	O
respiratory	NN	O
rates	NNS	O
were	VBD	O
significantly	RB	O
higher	JJR	O
,	,	O
and	CC	O
elevation	NN	O
of	IN	O
diastolic	JJ	O
BP	NNP	O
due	JJ	O
to	TO	O
mental	JJ	O
stress	NN	O
testing	NN	O
was	VBD	O
better	RBR	O
suppressed	VBN	O
in	IN	O
white-coat	NN	O
hypertensives	NNS	O
than	IN	O
in	IN	O
essential	JJ	O
hypertensives	NNS	O
.	.	O

CONCLUSION	VB	O
This	DT	O
treatment	NN	O
was	VBD	O
effective	JJ	O
in	IN	O
both	DT	O
types	NNS	O
of	IN	O
hypertension	NN	O
,	,	O
and	CC	O
pressor	NN	O
response	NN	O
to	TO	O
stress	VB	O
seems	VBZ	O
to	TO	O
be	VB	O
important	JJ	O
in	IN	O
the	DT	O
differentiated	JJ	O
BF	NNP	O
effect	NN	O
.	.	O

Measurement	NN	O
of	IN	O
health-related	JJ	O
quality	NN	O
of	IN	O
life	NN	O
in	IN	O
multiple	JJ	C
myeloma	NN	C
.	.	O

Nordic	NNP	O
Myeloma	NNP	O
Study	NNP	O
Group	NNP	O
.	.	O

When	WRB	O
a	DT	O
randomized	VBN	O
trial	NN	O
(	(	O
NMSG	NNP	O
4/90	CD	O
)	)	O
comparing	VBG	O
treatment	NN	O
with	IN	O
melphalan/prednisone	NN	O
to	TO	O
melphalan/	VB	O
prednisone	NN	O
+	NNP	O
interferon	VBZ	O
alpha-2b	NN	O
in	IN	O
newly	RB	O
diagnosed	VBN	O
multiple	JJ	C
myeloma	NN	C
was	VBD	O
initiated	VBN	O
in	IN	O
1990	CD	O
,	,	O
a	DT	O
quality-of-life	JJ	O
assessment	NN	O
was	VBD	O
integrated	VBN	O
into	IN	O
the	DT	O
study	NN	O
.	.	O

We	PRP	O
used	VBD	O
the	DT	O
questionnaire	NN	O
(	(	O
QLQ-C30	NNP	O
)	)	O
developed	VBN	O
by	IN	O
the	DT	O
European	JJ	O
Organization	NNP	O
of	IN	O
Research	NNP	O
and	CC	O
Treatment	NNP	O
of	IN	O
Cancer	NNP	O
(	(	O
EORTC	NNP	O
)	)	O
Study	NNP	O
Group	NNP	O
on	IN	O
Quality	NNP	O
of	IN	O
Life	NNP	O
.	.	O

The	DT	O
QLQ-C30	JJ	O
incorporates	NNS	O
five	CD	O
functional	JJ	O
scales	NNS	O
,	,	O
three	CD	O
symptom	NN	O
scales	NNS	O
,	,	O
a	DT	O
global	JJ	O
health	NN	O
and	CC	O
quality-of	JJ	O
life	NN	O
scale	NN	O
and	CC	O
some	DT	O
single	JJ	O
symptom	NN	O
measures	NNS	O
.	.	O

The	DT	O
questionnaire	NN	O
was	VBD	O
completed	VBN	O
prior	JJ	O
to	TO	O
treatment	NN	O
and	CC	O
after	IN	O
1	CD	O
,	,	O
6	CD	O
,	,	O
12	CD	O
,	,	O
24	CD	O
,	,	O
36	CD	O
and	CC	O
48	CD	O
months	NNS	O
.	.	O

524	CD	SS
(	(	O
90.2	CD	O
%	NN	O
)	)	O
of	IN	O
581	CD	SS
patients	NNS	O
enrolled	VBN	O
in	IN	O
the	DT	O
NMSG	NNP	O
4/90	CD	O
completed	VBD	O
the	DT	O
first	JJ	O
questionnaire	NN	O
,	,	O
and	CC	O
484	CD	SS
(	(	O
83.3	CD	O
%	NN	O
)	)	O
completed	VBD	O
all	DT	O
questionnaires	NNS	O
given	VBN	O
to	TO	O
them	PRP	O
.	.	O

All	DT	O
but	CC	O
one	CD	O
of	IN	O
the	DT	O
scales	NNS	O
met	VBD	O
the	DT	O
minimum	JJ	O
criteria	NNS	O
of	IN	O
reliability	NN	O
(	(	O
Cronbach	NNP	O
's	POS	O
alpha	NN	O
>	NNP	O
/	NNP	O
0.70	CD	O
)	)	O
.	.	O

Validity	NNP	O
was	VBD	O
shown	VBN	O
by	IN	O
(	(	O
1	CD	O
)	)	O
the	DT	O
ability	NN	O
of	IN	O
the	DT	O
scales	NNS	O
to	TO	O
discriminate	VB	O
clearly	RB	O
between	IN	O
patients	NNS	O
differing	VBG	O
in	IN	O
clinical	JJ	O
status	NN	O
as	IN	O
defined	VBN	O
by	IN	O
pretreatment	NN	O
W.H.O	NNP	O
.	.	O

performance	NN	O
index	NN	O
and	CC	O
Durie	NNP	O
&	CC	O
Salmon	NNP	O
stage	NN	O
,	,	O
and	CC	O
(	(	O
2	CD	O
)	)	O
the	DT	O
sensitivity	NN	O
to	TO	O
changes	NNS	O
in	IN	O
objective	JJ	O
disease	NN	O
status	NN	O
(	(	O
response	NN	O
and	CC	O
relapse	NN	O
)	)	O
.	.	O

This	DT	O
is	VBZ	O
the	DT	O
first	JJ	O
report	NN	O
of	IN	O
the	DT	O
measurement	NN	O
of	IN	O
health-related	JJ	O
quality	NN	O
of	IN	O
life	NN	O
in	IN	O
a	DT	O
prospective	JJ	O
clinical	JJ	O
trial	NN	O
in	IN	O
multiple	JJ	O
myeloma	NN	O
.	.	O

The	DT	O
results	NNS	O
demonstrate	VBP	O
that	IN	O
the	DT	O
QLQ-C30	NNP	O
is	VBZ	O
a	DT	O
reliable	JJ	O
and	CC	O
valid	JJ	O
instrument	NN	O
for	IN	O
the	DT	O
measurement	NN	O
of	IN	O
quality	NN	O
of	IN	O
life	NN	O
in	IN	O
these	DT	O
patients	NNS	O
.	.	O

The	DT	O
data	NN	O
will	MD	O
be	VB	O
used	VBN	O
for	IN	O
a	DT	O
cost-utility	JJ	O
analysis	NN	O
of	IN	O
the	DT	O
results	NNS	O
of	IN	O
the	DT	O
NMSG	NNP	O
4/90	CD	O
trial	NN	O
.	.	O

Local	JJ	O
delivery	NN	O
of	IN	O
a	DT	O
recombinant	NN	O
adenoassociated	VBN	O
vector	NN	O
containing	VBG	O
a	DT	O
tumour	JJ	O
necrosis	NN	O
factor	NN	O
alpha	IN	O
antagonist	JJ	O
gene	NN	O
in	IN	O
inflammatory	JJ	O
arthritis	NN	O
:	:	O
a	DT	O
phase	NN	O
1	CD	O
dose-escalation	NN	O
safety	NN	O
and	CC	O
tolerability	NN	O
study	NN	O
.	.	O

OBJECTIVE	NNP	O
To	TO	O
examine	VB	O
the	DT	O
safety	NN	O
and	CC	O
tolerability	NN	O
of	IN	O
a	DT	O
single	JJ	O
intra-articular	JJ	O
injection	NN	O
of	IN	O
rAAV2-TNFR	NN	O
:	:	O
Fc	NNP	O
,	,	O
an	DT	O
adenoassociated	JJ	O
virus	NN	O
serotype	NN	O
2	CD	O
vector	NN	O
containing	VBG	O
the	DT	O
cDNA	NN	O
for	IN	O
the	DT	O
human	JJ	O
tumour	JJ	O
necrosis	NN	O
factor-immunoglobulin	JJ	O
Fc	NNP	O
fusion	NN	O
gene	NN	O
(	(	O
tgAAC94	NN	O
)	)	O
,	,	O
in	IN	O
subjects	NNS	O
with	IN	O
inflammatory	JJ	O
arthritis	NN	O
.	.	O

METHODS	NNP	O
In	IN	O
a	DT	O
double-blind	JJ	O
,	,	O
placebo-controlled	JJ	O
,	,	O
phase	JJ	O
1	CD	O
,	,	O
dose-escalation	NN	O
study	NN	O
,	,	O
15	CD	C
subjects	NNS	C
with	IN	C
inflammatory	JJ	C
arthritis	NN	C
(	(	C
14	CD	C
with	IN	C
rheumatoid	JJ	C
arthritis	NN	C
and	CC	C
1	CD	C
with	IN	C
ankylosing	VBG	C
spondylitis	NN	C
)	)	C
not	RB	C
receiving	VBG	C
tumour	JJ	C
necrosis	NN	C
factor	NN	C
alpha	NN	C
(	(	C
TNFalpha	NNP	C
)	)	C
inhibitors	NNS	C
with	IN	C
persistent	JJ	C
moderate	NN	C
(	(	C
grade	JJ	C
2	CD	C
)	)	C
or	CC	C
severe	JJ	C
(	(	C
grade	JJ	C
3	CD	C
)	)	C
swelling	NN	C
in	IN	C
a	DT	C
target	NN	C
joint	NN	C
due	JJ	C
to	TO	C
inflammatory	JJ	C
arthritis	NN	C
received	VBD	O
a	DT	O
single	JJ	O
intra-articular	JJ	O
injection	NN	O
of	IN	O
rAAV2-TNFR	NN	O
:	:	O
Fc	NN	O
at	IN	O
1	CD	O
x	JJ	O
10	CD	O
(	(	O
10	CD	O
)	)	O
(	(	O
n	JJ	O
=	NNP	O
5	CD	O
)	)	O
or	CC	O
1	CD	O
x	JJ	O
10	CD	O
(	(	O
11	CD	O
)	)	O
(	(	O
n	JJ	O
=	NNP	O
6	CD	O
)	)	O
DNase	NNP	O
resistant	JJ	O
particles	NNS	O
per	IN	O
ml	NN	O
joint	NN	O
volume	NN	O
or	CC	O
placebo	NN	O
(	(	O
n	JJ	O
=	NNP	O
4	CD	O
)	)	O
into	IN	O
a	DT	O
knee	NN	O
(	(	O
n	JJ	O
=	NNP	O
14	CD	O
)	)	O
or	CC	O
ankle	NN	O
(	(	O
n	JJ	O
=	NNP	O
1	CD	O
)	)	O
.	.	O

Safety	NN	O
was	VBD	O
assessed	VBN	O
through	IN	O
adverse	JJ	O
event	NN	O
monitoring	NN	O
.	.	O

As	IN	O
a	DT	O
secondary	JJ	O
objective	NN	O
,	,	O
changes	NNS	O
in	IN	O
injected	JJ	O
joint	NN	O
tenderness	NN	O
and	CC	O
swelling	VBG	O
scores	NNS	O
,	,	O
each	DT	O
measured	VBN	O
on	IN	O
a	DT	O
four-point	JJ	O
scale	NN	O
,	,	O
were	VBD	O
evaluated	VBN	O
.	.	O

RESULTS	NNP	O
Intra-articular	JJ	O
injections	NNS	O
of	IN	O
rAAV2-TNFR	NN	O
:	:	O
Fc	NN	O
were	VBD	O
well	RB	O
tolerated	VBN	O
with	IN	O
no	DT	O
major	JJ	O
safety	NN	O
issues	NNS	O
.	.	O

One	CD	O
event	NN	O
,	,	O
mild	JJ	O
knee	NN	O
pruritus	NN	O
,	,	O
was	VBD	O
considered	VBN	O
probably	RB	O
related	VBN	O
.	.	O

Synovial	JJ	O
fluid	NN	O
TNFR	NNP	O
:	:	O
Fc	NNP	O
protein	NN	O
was	VBD	O
not	RB	O
detected	VBN	O
(	(	O
nor	CC	O
expected	VBN	O
)	)	O
at	IN	O
the	DT	O
doses	NNS	O
used	VBN	O
.	.	O

At	IN	O
12	CD	O
weeks	NNS	O
after	IN	O
injection	NN	O
,	,	O
a	DT	O
two-point	JJ	O
decrease	NN	O
in	IN	O
swelling	VBG	O
was	VBD	O
noted	VBN	O
in	IN	O
2/11	CD	O
and	CC	O
2/4	CD	O
subjects	NNS	O
injected	VBN	O
with	IN	O
rAAV2-TNFR	NN	O
:	:	O
Fc	NNP	O
and	CC	O
placebo	NN	O
,	,	O
respectively	RB	O
.	.	O

CONCLUSION	VB	O
A	DT	O
single	JJ	O
dose	NN	O
of	IN	O
intra-articular	JJ	O
rAAV2-TNFR	NN	O
:	:	O
Fc	CD	O
appears	VBZ	O
to	TO	O
be	VB	O
safe	JJ	O
and	CC	O
well	RB	O
tolerated	VBN	O
in	IN	O
subjects	NNS	O
without	IN	O
concurrent	JJ	O
systemic	JJ	O
TNFalpha	NNP	O
antagonist	NN	O
use	NN	O
.	.	O

It	PRP	O
is	VBZ	O
thus	RB	O
feasible	JJ	O
to	TO	O
proceed	VB	O
with	IN	O
larger	JJR	O
trials	NNS	O
to	TO	O
further	JJ	O
test	NN	O
the	DT	O
safety	NN	O
and	CC	O
efficacy	NN	O
of	IN	O
local	JJ	O
TNFR	NNP	O
:	:	O
Fc	NNP	O
gene	NN	O
transfer	NN	O
as	IN	O
a	DT	O
therapeutic	JJ	O
modality	NN	O
for	IN	O
patients	NNS	O
with	IN	O
inflammatory	JJ	O
arthritis	NN	O
.	.	O

Oral	JJ	O
bioavailability	NN	O
of	IN	O
moxifloxacin	NN	O
after	IN	C
Roux-en-Y	NNP	C
gastric	JJ	C
bypass	NN	C
surgery	NN	C
.	.	C

OBJECTIVES	CC	O
Roux-en-Y	JJ	O
gastric	JJ	O
bypass	NN	O
surgery	NN	O
is	VBZ	O
the	DT	O
most	RBS	O
commonly	RB	O
performed	JJ	O
procedure	NN	O
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
morbid	NN	O
obesity	NN	O
.	.	O

This	DT	O
anatomical	JJ	O
alteration	NN	O
may	MD	O
affect	VB	O
the	DT	O
absorption	NN	O
and	CC	O
consequently	RB	O
the	DT	O
bioavailability	NN	O
of	IN	O
oral	JJ	O
drugs	NNS	O
.	.	O

This	DT	O
study	NN	O
aims	VBZ	O
to	TO	O
investigate	VB	O
the	DT	O
oral	JJ	O
bioavailability	NN	O
of	IN	O
moxifloxacin	NN	O
in	IN	O
12	CD	C
healthy	JJ	C
volunteers	NNS	C
who	WP	C
underwent	VBP	C
gastric	JJ	C
bypass	NN	C
surgery	NN	C
.	.	C

PATIENTS	NNP	O
AND	CC	O
METHODS	NNP	O
In	IN	O
this	DT	O
randomized	VBN	O
crossover	NN	O
study	NN	O
,	,	O
each	DT	O
subject	NN	O
received	VBD	O
two	CD	O
single	JJ	O
standard	NN	O
doses	NNS	O
of	IN	O
400	CD	O
mg	NN	O
of	IN	O
moxifloxacin	NN	O
orally	RB	O
or	CC	O
intravenously	RB	O
administered	VBN	O
on	IN	O
two	CD	O
occasions	NNS	O
separated	VBN	O
by	IN	O
a	DT	O
washout	JJ	O
period	NN	O
of	IN	O
1	CD	O
week	NN	O
.	.	O

Serial	JJ	O
venous	JJ	O
blood	NN	O
samples	NNS	O
were	VBD	O
drawn	VBN	O
up	RB	O
to	TO	O
72	CD	O
h	NN	O
after	IN	O
dosing	VBG	O
and	CC	O
moxifloxacin	JJ	O
plasma	NN	O
levels	NNS	O
were	VBD	O
measured	VBN	O
by	IN	O
a	DT	O
validated	JJ	O
HPLC	NNP	O
method	NN	O
with	IN	O
fluorescence	NN	O
detection	NN	O
.	.	O

[	CC	O
clinicaltrials.gov	JJ	O
database	NN	O
(	(	O
identifier	NN	O
:	:	O
NCT01130922	NNP	O
)	)	O
.	.	O

]	JJ	O
RESULTS	NNP	O
After	IN	O
oral	JJ	O
dosing	NN	O
,	,	O
moxifloxacin	FW	O
plasma	NN	O
concentrations	NNS	O
reached	VBD	O
a	DT	O
maximum	JJ	O
(	(	O
C	NNP	O
(	(	O
max	NN	O
)	)	O
)	)	O
of	IN	O
3.38	CD	O
?	.	O
1.41	CD	O
mg/L	NN	O
after	IN	O
1.75	CD	O
h	NN	O
(	(	O
0.75-4.00	JJ	O
)	)	O
.	.	O

After	IN	O
intravenous	JJ	O
dosing	NN	O
,	,	O
C	NNP	O
(	(	O
max	NN	O
)	)	O
and	CC	O
T	NNP	O
(	(	O
max	NN	O
)	)	O
were	VBD	O
4.53	CD	O
?	.	O
1.43	CD	O
mg/L	NN	O
and	CC	O
1.03	CD	O
h	NN	O
(	(	O
0.75-2.50	JJ	O
)	)	O
,	,	O
respectively	RB	O
.	.	O

The	DT	O
mean	JJ	O
areas	NNS	O
under	IN	O
the	DT	O
plasma	JJ	O
concentration	NN	O
time	NN	O
curve	NN	O
extrapolated	VBD	O
to	TO	O
infinity	NN	O
(	(	O
AUC	NNP	O
(	(	O
?	.	O
)	)	O
)	)	O
were	VBD	O
46.2	CD	O
?	.	O
1.4	CD	O
mg	NN	O
?	.	O
h/L	NN	O
after	IN	O
oral	JJ	O
dosing	NN	O
and	CC	O
52.3	CD	O
?	.	O
1.3	CD	O
mg	NN	O
?	.	O
h/L	NN	O
after	IN	O
intravenous	JJ	O
dosing	NN	O
,	,	O
resulting	VBG	O
in	IN	O
a	DT	O
mean	JJ	O
oral	JJ	O
bioavailability	NN	O
of	IN	O
88.32	CD	O
%	NN	O
[	JJ	O
90	CD	O
%	NN	O
confidence	NN	O
interval	NN	O
(	(	O
CI	NNP	O
)	)	O
85.64	CD	O
%	NN	O
-91.08	CD	O
%	NN	O
]	NN	O
.	.	O

CONCLUSIONS	VB	O
This	DT	O
study	NN	O
confirms	VBZ	O
that	IN	O
exposure	NN	O
to	TO	O
moxifloxacin	VB	O
is	VBZ	O
equivalent	JJ	O
for	IN	O
oral	JJ	O
and	CC	O
intravenous	JJ	O
administration	NN	O
of	IN	O
400	CD	O
mg	NN	O
dosages	NNS	O
in	IN	O
healthy	JJ	O
volunteers	NNS	O
who	WP	O
underwent	VBP	O
gastric	JJ	O
bypass	NN	O
surgery	NN	O
.	.	O

But	CC	O
these	DT	O
exposures	NNS	O
were	VBD	O
more	JJR	O
than	IN	O
50	CD	O
%	NN	O
higher	JJR	O
than	IN	O
those	DT	O
described	VBN	O
for	IN	O
subjects	NNS	O
without	IN	O
gastric	JJ	O
bypass	NN	O
.	.	O

This	DT	O
may	MD	O
suggest	VB	O
a	DT	O
higher	JJR	O
enterohepatic	JJ	O
recirculation	NN	O
of	IN	O
moxifloxacin	NN	O
after	IN	O
gastric	JJ	O
bypass	NN	O
.	.	O

Effect	NN	O
of	IN	O
home-based	JJ	O
nursing	NN	O
pulmonary	JJ	O
rehabilitation	NN	O
on	IN	O
patients	NNS	O
with	IN	O
chronic	JJ	O
obstructive	JJ	O
pulmonary	JJ	O
disease	NN	O
:	:	O
a	DT	O
randomised	JJ	O
clinical	JJ	O
trial	NN	O
.	.	O

Fatigue	NNP	O
is	VBZ	O
a	DT	O
common	JJ	O
symptom	NN	O
of	IN	O
patients	NNS	O
with	IN	O
chronic	JJ	O
obstructive	JJ	O
pulmonary	JJ	O
disease	NN	O
(	(	O
COPD	NNP	O
)	)	O
,	,	O
and	CC	O
results	NNS	O
in	IN	O
a	DT	O
reduction	NN	O
of	IN	O
daily	JJ	O
activity	NN	O
and	CC	O
quality	NN	O
of	IN	O
life	NN	O
in	IN	O
patients	NNS	O
with	IN	O
the	DT	O
disease	NN	O
.	.	O

The	DT	O
authors	NNS	O
aimed	VBN	O
to	TO	O
identify	VB	O
the	DT	O
effect	NN	O
of	IN	O
home-based	JJ	O
nursing	NN	O
pulmonary	JJ	O
rehabilitation	NN	O
on	IN	O
fatigue	NN	O
,	,	O
activities	NNS	O
of	IN	O
daily	JJ	O
living	NN	O
(	(	O
ADL	NNP	O
)	)	O
and	CC	O
quality	NN	O
of	IN	O
life	NN	O
(	(	O
QOL	NNP	O
)	)	O
in	IN	O
patients	NNS	O
with	IN	O
COPD	NNP	O
.	.	O

A	NNP	O
block	NN	O
randomisation	NN	O
method	NN	O
was	VBD	O
used	VBN	O
to	TO	O
randomise	VB	O
participants	NNS	O
into	IN	O
case	NN	O
and	CC	O
control	NN	O
groups	NNS	O
.	.	O

Fatigue	NNP	O
,	,	O
ADL	NNP	O
and	CC	O
QOL	NNP	O
were	VBD	O
assessed	VBN	O
before	IN	O
and	CC	O
after	IN	O
the	DT	O
intervention	NN	O
in	IN	O
both	DT	O
groups	NNS	O
.	.	O

Independent	NNP	O
and	CC	O
paired	VBD	O
t-tests	NNS	O
,	,	O
chi-squared	JJ	O
tests	NNS	O
and	CC	O
covariance	NN	O
analysis	NN	O
were	VBD	O
used	VBN	O
to	TO	O
analysing	VBG	O
data	NNS	O
.	.	O

Findings	NNS	O
showed	VBD	O
the	DT	O
significant	JJ	O
decrease	NN	O
in	IN	O
the	DT	O
mean	JJ	O
scores	NNS	O
of	IN	O
fatigue	NN	O
(	(	O
p	JJ	O
<	NNP	O
0.001	CD	O
)	)	O
and	CC	O
significant	JJ	O
improvement	NN	O
in	IN	O
mean	JJ	O
scores	NNS	O
of	IN	O
ADL	NNP	O
(	(	O
p	JJ	O
<	NNP	O
0.001	CD	O
)	)	O
and	CC	O
QOL	NNP	O
(	(	O
p	JJ	O
<	NNP	O
0.001	CD	O
)	)	O
after	IN	O
home-based	JJ	O
nursing	NN	O
pulmonary	JJ	O
rehabilitation	NN	O
in	IN	O
the	DT	O
case	NN	O
group	NN	O
.	.	O

Home-based	JJ	O
nursing	NN	O
pulmonary	JJ	O
rehabilitation	NN	O
can	MD	O
be	VB	O
an	DT	O
effective	JJ	O
,	,	O
inexpensive	JJ	O
and	CC	O
accessible	JJ	O
programme	NN	O
for	IN	O
decreasing	VBG	O
fatigue	NN	O
and	CC	O
improving	VBG	O
ADL	NNP	O
and	CC	O
QOL	NNP	O
for	IN	O
patients	NNS	O
with	IN	O
COPD	NNP	O
.	.	O

Arterial	NNP	O
cardiovascular	JJ	O
risk	NN	O
factors	NNS	O
and	CC	O
venous	JJ	O
thrombosis	NN	O
:	:	O
results	NNS	O
from	IN	O
a	DT	O
population-based	JJ	O
,	,	O
prospective	JJ	O
study	NN	O
(	(	O
the	DT	O
HUNT	NNP	O
2	CD	O
)	)	O
.	.	O

BACKGROUND	NNP	O
An	DT	O
explanation	NN	O
for	IN	O
the	DT	O
increased	VBN	O
risk	NN	O
of	IN	O
myocardial	JJ	O
infarction	NN	O
and	CC	O
stroke	NN	O
in	IN	O
patients	NNS	O
with	IN	O
venous	JJ	O
thrombosis	NN	O
is	VBZ	O
lacking	VBG	O
.	.	O

The	DT	O
objective	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
investigate	VB	O
whether	IN	O
risk	NN	O
factors	NNS	O
for	IN	O
arterial	JJ	O
cardiovascular	JJ	O
disease	NN	O
also	RB	O
increase	VBZ	O
the	DT	O
risk	NN	O
of	IN	O
venous	JJ	O
thrombosis	NN	O
.	.	O

DESIGN	NNP	O
AND	CC	O
METHODS	NNP	O
Cases	NNP	O
who	WP	O
had	VBD	O
a	DT	O
first	JJ	O
venous	JJ	O
thrombosis	NN	O
(	(	O
n=515	JJ	O
)	)	O
and	CC	O
matched	VBN	O
controls	NNS	O
(	(	O
n=1,505	NN	O
)	)	O
were	VBD	O
identified	VBN	O
from	IN	O
a	DT	O
population-based	JJ	O
,	,	O
nested	JJ	O
,	,	O
case-cohort	JJ	O
study	NN	O
(	(	O
the	DT	O
HUNT	NNP	O
2	CD	O
study	NN	O
)	)	O
comprising	VBG	O
71	CD	O
%	NN	O
(	(	O
n=66,140	JJ	O
)	)	O
of	IN	O
the	DT	O
adult	NN	O
residents	NNS	O
of	IN	O
Nord-Tr?ndelag	NNP	O
County	NNP	O
in	IN	O
Norway	NNP	O
.	.	O

RESULTS	VB	O
The	DT	O
age-	JJ	O
and	CC	O
sex-adjusted	JJ	O
odds	NNS	O
ratio	NN	O
of	IN	O
venous	JJ	O
thrombosis	NN	O
for	IN	O
subjects	NNS	O
with	IN	O
concentrations	NNS	O
of	IN	O
C-reactive	JJ	O
protein	NN	O
in	IN	O
the	DT	O
highest	JJS	O
quintile	NN	O
was	VBD	O
1.6	CD	O
(	(	O
95	CD	O
%	NN	O
confidence	NN	O
interval	NN	O
:	:	O
1.2-2.2	JJ	O
)	)	O
compared	VBN	O
to	TO	O
subjects	NNS	O
with	IN	O
C-reactive	JJ	O
protein	NN	O
in	IN	O
the	DT	O
lowest	JJS	O
quintile	NN	O
.	.	O

This	DT	O
association	NN	O
was	VBD	O
strongest	VBN	O
in	IN	O
subjects	NNS	O
who	WP	O
experienced	VBD	O
venous	JJ	O
thrombosis	NN	O
within	IN	O
a	DT	O
year	NN	O
after	IN	O
blood	NN	O
sampling	VBG	O
with	IN	O
a	DT	O
three-fold	JJ	O
increased	JJ	O
risk	NN	O
of	IN	O
participants	NNS	O
in	IN	O
the	DT	O
highest	JJS	O
versus	NN	O
the	DT	O
lowest	JJS	O
quintile	NN	O
.	.	O

Having	VBG	O
first	JJ	O
degree	JJ	O
relatives	NNS	O
who	WP	O
had	VBD	O
a	DT	O
myocardial	JJ	O
infarction	NN	O
before	IN	O
the	DT	O
age	NN	O
of	IN	O
60	CD	O
years	NNS	O
was	VBD	O
positively	RB	O
associated	VBN	O
with	IN	O
venous	JJ	O
thrombosis	NN	O
compared	VBN	O
to	TO	O
not	RB	O
having	VBG	O
a	DT	O
positive	JJ	O
family	NN	O
history	NN	O
[	NNP	O
odds	VBZ	O
ratio	NN	O
1.3	CD	O
(	(	O
95	CD	O
%	NN	O
confidence	NN	O
interval	NN	O
:	:	O
1.1-1.6	JJ	O
)	)	O
]	NN	O
.	.	O

Subjects	NNS	O
with	IN	O
blood	NN	O
pressure	NN	O
in	IN	O
the	DT	O
highest	JJS	O
quintile	NN	O
had	VBD	O
half	PDT	O
the	DT	O
risk	NN	O
of	IN	O
developing	VBG	O
venous	JJ	O
thrombosis	NN	O
compared	VBN	O
to	TO	O
subjects	NNS	O
whose	WP$	O
blood	NN	O
pressure	NN	O
was	VBD	O
in	IN	O
the	DT	O
lowest	JJS	O
quintile	NN	O
.	.	O

There	EX	O
were	VBD	O
no	DT	O
associations	NNS	O
between	IN	O
the	DT	O
risk	NN	O
of	IN	O
venous	JJ	O
thrombosis	NN	O
and	CC	O
total	JJ	O
cholesterol	NN	O
,	,	O
low	JJ	O
density	NN	O
lipoprotein-cholesterol	NN	O
,	,	O
high	JJ	O
density	NN	O
lipoprotein-cholesterol	NN	O
,	,	O
triglycerides	NNS	O
,	,	O
glucose	NN	O
or	CC	O
smoking	NN	O
.	.	O

We	PRP	O
confirmed	VBD	O
the	DT	O
positive	JJ	O
association	NN	O
between	IN	O
obesity	NN	O
and	CC	O
venous	JJ	O
thrombosis	NN	O
.	.	O

CONCLUSIONS	NNP	O
C-reactive	JJ	O
protein	NN	O
and	CC	O
a	DT	O
family	NN	O
history	NN	O
of	IN	O
myocardial	JJ	O
infarction	NN	O
were	VBD	O
positively	RB	O
associated	VBN	O
with	IN	O
subsequent	JJ	O
venous	JJ	O
thrombosis	NN	O
.	.	O

Blood	NNP	O
pressure	NN	O
was	VBD	O
inversely	RB	O
correlated	VBN	O
to	TO	O
venous	JJ	O
thrombosis	NN	O
.	.	O

These	DT	O
findings	NNS	O
should	MD	O
be	VB	O
confirmed	VBN	O
by	IN	O
further	JJ	O
investigations	NNS	O
.	.	O

A	DT	O
phase	NN	O
II	NNP	O
randomized	VBD	O
trial	NN	O
comparing	VBG	O
radiotherapy	NN	O
with	IN	O
concurrent	JJ	O
weekly	JJ	O
cisplatin	NN	O
or	CC	O
weekly	JJ	O
paclitaxel	NN	O
in	IN	O
patients	NNS	O
with	IN	O
advanced	JJ	C
cervical	JJ	C
cancer	NN	C
.	.	O

PURPOSE/OBJECTIVE	VB	O
This	DT	O
is	VBZ	O
a	DT	O
prospective	JJ	O
comparison	NN	O
of	IN	O
weekly	JJ	O
cisplatin	NN	O
to	TO	O
weekly	VB	O
paclitaxel	NN	O
as	IN	O
concurrent	JJ	O
chemotherapy	NN	O
with	IN	O
standard	JJ	O
radiotherapy	NN	O
for	IN	O
locally	RB	O
advanced	JJ	C
cervical	JJ	C
carcinoma	NN	C
.	.	O

MATERIALS/METHODS	NNP	O
Between	NNP	O
May	NNP	O
2000	CD	O
and	CC	O
May	NNP	O
2004	CD	O
,	,	O
31	CD	SS
women	NNS	O
with	IN	O
FIGO	NNP	C
stage	NN	C
IB2-IVA	NNP	C
cervical	JJ	C
cancer	NN	C
or	CC	C
with	IN	C
postsurgical	JJ	C
pelvic	JJ	C
recurrence	NN	C
were	VBD	O
enrolled	VBN	O
into	IN	O
this	DT	O
phase	NN	O
II	NNP	O
study	NN	O
and	CC	O
randomized	VBN	O
to	TO	O
receive	VB	O
on	IN	O
a	DT	O
weekly	JJ	O
basis	NN	O
either	CC	O
40	CD	O
mg/m?	NN	O
Cisplatin	NNP	O
(	(	O
group	NN	O
I	PRP	O
;	:	O
16	CD	O
patients	NNS	O
)	)	O
or	CC	O
50	CD	O
mg/m?	NNS	O
paclitaxel	NN	O
(	(	O
group	NN	O
II	NNP	O
;	:	O
15	CD	O
patients	NNS	O
)	)	O
concurrently	RB	O
with	IN	O
radiotherapy	NN	O
.	.	O

Median	JJ	O
total	NN	O
dose	NN	O
to	TO	O
point	VB	O
A	NNP	O
was	VBD	O
74	CD	O
Gy	NNP	O
(	(	O
range	NN	O
:	:	O
66-92	JJ	O
Gy	NNP	O
)	)	O
for	IN	O
group	NN	O
I	PRP	O
and	CC	O
66	CD	O
Gy	NNP	O
(	(	O
range	NN	O
:	:	O
40-98	JJ	O
Gy	NNP	O
)	)	O
for	IN	O
group	NN	O
II	NNP	O
.	.	O

Median	JJ	O
follow-up	JJ	O
time	NN	O
was	VBD	O
46	CD	O
months	NNS	O
.	.	O

RESULTS	NNP	O
Patient	NNP	O
and	CC	O
tumor	NN	O
characteristics	NNS	O
were	VBD	O
similar	JJ	O
in	IN	O
both	DT	O
groups	NNS	O
.	.	O

The	DT	O
mean	JJ	O
number	NN	O
of	IN	O
chemotherapy	NN	O
cycles	NNS	O
was	VBD	O
also	RB	O
comparable	JJ	O
with	IN	O
87	CD	O
%	NN	O
and	CC	O
80	CD	O
%	NN	O
of	IN	O
patients	NNS	O
receiving	VBG	O
at	IN	O
least	JJS	O
4	CD	O
doses	NNS	O
in	IN	O
groups	NNS	O
I	PRP	O
and	CC	O
II	NNP	O
,	,	O
respectively	RB	O
.	.	O

Seven	JJ	O
patients	NNS	O
(	(	O
44	CD	O
%	NN	O
)	)	O
of	IN	O
group	NN	O
I	PRP	O
and	CC	O
8	CD	O
patients	NNS	O
(	(	O
53	CD	O
%	NN	O
)	)	O
of	IN	O
group	NN	O
II	NNP	O
developed	VBD	O
tumor	NN	O
recurrence	NN	O
.	.	O

The	DT	O
Median	JJ	O
Survival	NNP	O
time	NN	O
was	VBD	O
not	RB	O
reached	VBN	O
for	IN	O
Group	NNP	O
I	PRP	O
and	CC	O
53	CD	O
months	NNS	O
for	IN	O
group	NN	O
II	NNP	O
.	.	O

The	DT	O
proportion	NN	O
of	IN	O
patients	NNS	O
surviving	VBG	O
at	IN	O
2	CD	O
and	CC	O
5	CD	O
years	NNS	O
was	VBD	O
78	CD	O
%	NN	O
and	CC	O
54	CD	O
%	NN	O
for	IN	O
group	NN	O
I	PRP	O
and	CC	O
73	CD	O
%	NN	O
and	CC	O
43	CD	O
%	NN	O
for	IN	O
group	NN	O
II	NNP	O
respectively	RB	O
.	.	O

CONCLUSIONS	VB	O
This	DT	O
small	JJ	O
prospective	JJ	O
study	NN	O
shows	NNS	O
that	WDT	O
weekly	VBP	O
paclitaxel	NN	O
does	VBZ	O
not	RB	O
provide	VB	O
any	DT	O
clinical	JJ	O
advantage	NN	O
over	IN	O
weekly	JJ	O
cisplatin	NN	O
for	IN	O
concurrent	JJ	O
chemoradiation	NN	O
for	IN	O
advanced	JJ	O
carcinoma	NN	O
of	IN	O
the	DT	O
cervix	NN	O
.	.	O

Hysteroscopic	NNP	O
transcervical	JJ	O
endometrial	JJ	O
resection	NN	O
versus	IN	O
thermal	JJ	O
destruction	NN	O
for	IN	O
menorrhagia	NN	O
:	:	O
a	DT	O
prospective	JJ	O
randomized	VBN	O
trial	NN	O
on	IN	O
satisfaction	NN	O
rate	NN	O
.	.	O

OBJECTIVE	IN	O
The	DT	O
purpose	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
compare	VB	O
the	DT	O
satisfaction	NN	O
rate	NN	O
and	CC	O
the	DT	O
effectiveness	NN	O
of	IN	O
transcervical	JJ	O
hysteroscopic	NN	O
endometrial	JJ	O
resection	NN	O
and	CC	O
thermal	JJ	O
destruction	NN	O
of	IN	O
the	DT	O
endometrium	NN	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
menorrhagia	NN	C
.	.	O

STUDY	NNP	O
DESIGN	NNP	O
A	NNP	O
prospective	JJ	O
randomized	VBN	O
trial	NN	O
with	IN	O
2	CD	O
years	NNS	O
of	IN	O
follow-up	NN	O
was	VBD	O
carried	VBN	O
out	RP	O
in	IN	O
the	DT	O
Department	NNP	O
of	IN	O
Gynecology	NNP	O
of	IN	O
the	DT	O
University	NNP	O
of	IN	O
Naples	NNP	O
.	.	O

Eighty-two	JJ	SS
patients	NNS	O
who	WP	O
were	VBD	O
affected	VBN	O
by	IN	O
menorrhagia	NN	O
that	WDT	O
was	VBD	O
unresponsive	JJ	C
to	TO	C
medical	JJ	C
treatment	NN	C
were	VBD	O
respectively	RB	O
randomized	VBN	O
to	TO	O
transcervical	JJ	O
hysteroscopic	NN	O
endometrial	JJ	O
resection	NN	O
or	CC	O
to	TO	O
thermal	JJ	O
destruction	NN	O
of	IN	O
the	DT	O
endometrium	NN	O
.	.	O

Satisfaction	NN	O
rate	NN	O
,	,	O
operative	JJ	O
time	NN	O
,	,	O
discharge	NN	O
time	NN	O
,	,	O
complication	NN	O
rate	NN	O
,	,	O
reintervention	NN	O
rate	NN	O
,	,	O
and	CC	O
resumption	NN	O
of	IN	O
normal	JJ	O
activity	NN	O
were	VBD	O
evaluated	VBN	O
in	IN	O
each	DT	O
group	NN	O
.	.	O

RESULTS	VB	O
The	DT	O
satisfaction	NN	O
rate	NN	O
was	VBD	O
significantly	RB	O
higher	JJR	O
in	IN	O
the	DT	O
thermal	JJ	O
destruction	NN	O
group	NN	O
.	.	O

Operative	JJ	O
time	NN	O
was	VBD	O
significantly	RB	O
shorter	JJR	O
in	IN	O
the	DT	O
thermal	JJ	O
destruction	NN	O
group	NN	O
(	(	O
24	CD	O
+/-	JJ	O
4	CD	O
minutes	NNS	O
vs	JJ	O
37	CD	O
+/-	JJ	O
6	CD	O
minutes	NNS	O
)	)	O
.	.	O

Intraoperative	JJ	O
blood	NN	O
loss	NN	O
was	VBD	O
significantly	RB	O
lower	JJR	O
in	IN	O
the	DT	O
thermal	JJ	O
destruction	NN	O
group	NN	O
(	(	O
7.2	CD	O
+/-	JJ	O
2.8	CD	O
mL	NN	O
vs	NN	O
89	CD	O
+/-	JJ	O
38	CD	O
mL	NN	O
)	)	O
.	.	O

Reintervention	NN	O
rates	NNS	O
were	VBD	O
higher	JJR	O
in	IN	O
the	DT	O
transcervical	JJ	O
hysteroscopic	NN	O
endometrial	JJ	O
resection	NN	O
group	NN	O
,	,	O
although	IN	O
postoperative	JJ	O
pain	NN	O
was	VBD	O
not	RB	O
significantly	RB	O
different	JJ	O
between	IN	O
the	DT	O
two	CD	O
groups	NNS	O
.	.	O

Discharge	NNP	O
time	NN	O
,	,	O
complication	NN	O
rate	NN	O
,	,	O
and	CC	O
resumption	NN	O
of	IN	O
normal	JJ	O
activity	NN	O
were	VBD	O
not	RB	O
significantly	RB	O
different	JJ	O
between	IN	O
the	DT	O
two	CD	O
groups	NNS	O
.	.	O

CONCLUSION	NNP	O
Thermal	NNP	O
destruction	NN	O
of	IN	O
the	DT	O
endometrium	NN	O
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
menorrhagia	NN	O
should	MD	O
be	VB	O
considered	VBN	O
an	DT	O
effective	JJ	O
therapeutic	JJ	O
option	NN	O
because	IN	O
of	IN	O
its	PRP$	O
acceptability	NN	O
among	IN	O
patients	NNS	O
,	,	O
shorter	RB	O
operative	JJ	O
time	NN	O
,	,	O
and	CC	O
lower	JJR	O
blood	NN	O
loss	NN	O
.	.	O

Validation	NN	O
of	IN	O
a	DT	O
novel	JJ	O
satisfaction	NN	O
questionnaire	NN	O
for	IN	O
patients	NNS	O
with	IN	O
rheumatoid	JJ	O
arthritis	NN	O
receiving	VBG	O
outpatient	JJ	O
clinical	JJ	O
nurse	NN	O
specialist	NN	O
care	NN	O
,	,	O
inpatient	NN	O
care	NN	O
,	,	O
or	CC	O
day	NN	O
patient	JJ	O
team	NN	O
care	NN	O
.	.	O

OBJECTIVES	NNP	O
To	TO	O
develop	VB	O
and	CC	O
validate	VB	O
a	DT	O
questionnaire	NN	O
for	IN	O
measuring	VBG	O
satisfaction	NN	O
with	IN	O
different	JJ	O
forms	NNS	O
of	IN	O
complex	JJ	O
multidisciplinary	JJ	O
care	NN	O
in	IN	O
patients	NNS	O
with	IN	O
rheumatoid	JJ	O
arthritis	NN	O
(	(	O
RA	NNP	O
)	)	O
.	.	O

METHODS	PDT	O
The	DT	O
satisfaction	NN	O
questionnaire	NN	O
(	(	O
score	JJ	O
range	NN	O
0-100	NN	O
)	)	O
comprised	VBD	O
28	CD	O
items	NNS	O
covering	VBG	O
11	CD	O
domains	NNS	O
.	.	O

Together	RB	O
with	IN	O
a	DT	O
visual	JJ	O
analog	NN	O
scale	NN	O
(	(	O
VAS	NNP	O
,	,	O
range	VB	O
0-100	NNP	O
)	)	O
on	IN	O
overall	JJ	O
satisfaction	NN	O
,	,	O
the	DT	O
questionnaire	NN	O
was	VBD	O
applied	VBN	O
in	IN	O
210	CD	SS
RA	NNP	O
patients	NNS	O
who	WP	O
participated	VBD	O
in	IN	O
a	DT	O
randomized	JJ	O
trial	NN	O
comparing	VBG	O
3	CD	O
types	NNS	O
of	IN	O
multidisciplinary	JJ	O
care	NN	O
.	.	O

RESULTS	VB	O
The	DT	O
questionnaire	NN	O
was	VBD	O
returned	VBN	O
by	IN	O
174	CD	SS
patients	NNS	SS
(	(	SS
83	CD	SS
%	NN	SS
)	)	SS
.	.	O

The	DT	O
questionnaire	NN	O
and	CC	O
VAS	NNP	O
scores	NNS	O
in	IN	O
the	DT	O
total	JJ	O
group	NN	O
were	VBD	O
75	CD	O
(	(	O
SD	NNP	O
12	CD	O
)	)	O
and	CC	O
83	CD	O
(	(	O
SD	NNP	O
20	CD	O
)	)	O
,	,	O
respectively	RB	O
.	.	O

Reliability	NNP	O
analysis	NN	O
showed	VBD	O
Cronbach	NNP	O
's	POS	O
alpha	NN	O
of	IN	O
the	DT	O
questionnaire	NN	O
was	VBD	O
0.91	CD	O
.	.	O

Spearman	NNP	O
's	POS	O
correlation	NN	O
coefficient	NN	O
between	IN	O
the	DT	O
satisfaction	NN	O
questionnaire	NN	O
score	NN	O
and	CC	O
VAS	NNP	O
score	NN	O
was	VBD	O
0.58	CD	O
(	(	O
P	NNP	O
<	NNP	O
0.01	CD	O
)	)	O
.	.	O

Mean	JJ	O
total	JJ	O
satisfaction	NN	O
questionnaire	NN	O
scores	NNS	O
were	VBD	O
72	CD	O
(	(	O
SD	NNP	O
9	CD	O
)	)	O
,	,	O
76	CD	O
(	(	O
SD	NNP	O
14	CD	O
)	)	O
,	,	O
and	CC	O
78	CD	O
(	(	O
SD	NNP	O
11	CD	O
)	)	O
,	,	O
in	IN	O
the	DT	O
nurse	JJ	O
specialist	NN	O
,	,	O
inpatient	JJ	O
and	CC	O
day	NN	O
patient	NN	O
groups	NNS	O
,	,	O
respectively	RB	O
(	(	O
nurse	JJ	O
specialist	NN	O
versus	IN	O
day	NN	O
patient	NN	O
,	,	O
P	NNP	O
=	NNP	O
0.004	CD	O
)	)	O
.	.	O

Significant	JJ	O
differences	NNS	O
between	IN	O
nurse	JJ	O
specialist	NN	O
and	CC	O
day	NN	O
patients	NNS	O
were	VBD	O
seen	VBN	O
in	IN	O
the	DT	O
following	JJ	O
domains	NNS	O
:	:	O
waiting	VBG	O
time	NN	O
during	IN	O
the	DT	O
treatment	NN	O
,	,	O
autonomy	NN	O
,	,	O
coordination	NN	O
,	,	O
non-financial	JJ	O
access	NN	O
,	,	O
and	CC	O
quality	NN	O
of	IN	O
general	JJ	O
information	NN	O
(	(	O
all	DT	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
.	.	O

CONCLUSION	NNP	O
Overall	NNP	O
,	,	O
patients	NNS	O
were	VBD	O
highly	RB	O
satisfied	VBN	O
with	IN	O
the	DT	O
multidisciplinary	JJ	O
care	NN	O
they	PRP	O
received	VBD	O
.	.	O

Major	JJ	O
differences	NNS	O
regarding	VBG	O
the	DT	O
organization	NN	O
of	IN	O
care	NN	O
were	VBD	O
reflected	VBN	O
in	IN	O
the	DT	O
results	NNS	O
of	IN	O
the	DT	O
questionnaire	NN	O
scores	NNS	O
.	.	O

The	DT	O
satisfaction	NN	O
questionnaire	NN	O
appears	VBZ	O
to	TO	O
be	VB	O
a	DT	O
useful	JJ	O
instrument	NN	O
for	IN	O
measuring	VBG	O
satisfaction	NN	O
with	IN	O
complex	JJ	O
multidisciplinary	NN	O
care	NN	O
in	IN	O
RA	NNP	O
patients	NNS	O
.	.	O

Randomized	VBN	O
trial	NN	O
of	IN	O
intensive	JJ	O
early	JJ	O
intervention	NN	O
for	IN	O
children	NNS	A
with	IN	O
pervasive	JJ	C
developmental	JJ	C
disorder	NN	C
.	.	O

Young	NNP	A
children	NNS	A
with	IN	O
pervasive	JJ	C
developmental	JJ	C
disorder	NN	C
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
intensive	VB	O
treatment	NN	O
or	CC	O
parent	NN	O
training	NN	O
.	.	O

The	DT	O
intensive	JJ	O
treatment	NN	O
group	NN	O
(	(	O
7	CD	SS
with	IN	O
autism	NN	C
,	,	O
8	CD	SS
with	IN	O
pervasive	JJ	O
developmental	JJ	O
disorder	NN	O
not	RB	O
otherwise	RB	O
specified	VBN	O
--	:	O
NOS	NNP	O
)	)	O
averaged	VBD	O
24.52	CD	O
hours	NNS	O
per	IN	O
week	NN	O
of	IN	O
individual	JJ	O
treatment	NN	O
for	IN	O
one	CD	O
year	NN	O
,	,	O
gradually	RB	O
reducing	VBG	O
hours	NNS	O
over	IN	O
the	DT	O
next	JJ	O
1	CD	O
to	TO	O
2	CD	O
years	NNS	O
.	.	O

The	DT	O
parent	NN	A
training	NN	O
group	NN	O
(	(	O
7	CD	SS
with	IN	O
autism	NN	O
,	,	O
6	CD	SS
with	IN	O
pervasive	JJ	C
developmental	JJ	C
disorder	NN	C
NOS	NNP	O
)	)	O
received	VBD	O
3	CD	O
to	TO	O
9	CD	O
months	NNS	O
of	IN	O
parent	NN	O
training	NN	O
.	.	O

The	DT	O
groups	NNS	O
appeared	VBD	O
similar	JJ	O
at	IN	O
intake	NN	O
on	IN	O
all	DT	O
measures	NNS	O
;	:	O
however	RB	O
,	,	O
at	IN	O
follow-up	JJ	O
the	DT	O
intensive	JJ	O
treatment	NN	O
group	NN	O
outperformed	VBD	O
the	DT	O
parent	NN	O
training	VBG	O
group	NN	O
on	IN	O
measures	NNS	O
of	IN	O
intelligence	NN	O
,	,	O
visual-spatial	JJ	O
skills	NNS	O
,	,	O
language	NN	O
,	,	O
and	CC	O
academics	NNS	O
,	,	O
though	IN	O
not	RB	O
adaptive	JJ	O
functioning	NN	O
or	CC	O
behavior	NN	O
problems	NNS	O
.	.	O

Children	NNP	A
with	IN	O
pervasive	JJ	C
developmental	JJ	C
disorder	NN	C
NOS	NNP	O
may	MD	O
have	VB	O
gained	VBN	O
more	JJR	O
than	IN	O
those	DT	O
with	IN	O
autism	NN	O
.	.	O

Mediterranean	NNP	O
diet	NN	O
and	CC	O
high	JJ	O
dietary	JJ	O
acid	NN	O
load	NN	O
associated	VBN	O
with	IN	O
mixed	JJ	O
nuts	NNS	O
:	:	O
effect	NN	O
on	IN	O
bone	NN	O
metabolism	NN	O
in	IN	O
elderly	JJ	A
subjects	NNS	O
.	.	O

OBJECTIVES	NNP	O
To	TO	O
analyze	VB	O
the	DT	O
effect	NN	O
of	IN	O
differing	VBG	O
diet	NN	O
on	IN	O
the	DT	O
acid	JJ	O
load	NN	O
content	NN	O
on	IN	O
bone	NN	O
metabolism	NN	O
.	.	O

DESIGN	NNP	O
Multicentric	NNP	O
,	,	O
randomized	VBD	O
,	,	O
single-blind	JJ	O
,	,	O
parallel-group	JJ	O
clinical	JJ	O
trial	NN	O
.	.	O

SETTING	NN	O
Outpatient	JJ	O
clinics	NNS	O
.	.	O

PARTICIPANTS	VB	O
Two	CD	SS
hundred	CD	SS
thirty-eight	JJ	SS
elderly	JJ	A
men	NNS	C
and	CC	O
women	NNS	C
aged	VBD	O
60	CD	A
to	TO	A
80	CD	A
at	IN	O
high	JJ	O
risk	NN	O
for	IN	O
cardiovascular	JJ	C
disease	NN	C
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
three	CD	O
interventional	JJ	O
groups	NNS	O
:	:	O
a	DT	O
recommended	JJ	O
low-fat	JJ	O
diet	NN	O
(	(	O
control	VB	O
diet	JJ	O
group	NN	O
)	)	O
,	,	O
a	DT	O
Mediterranean	NNP	O
diet	NN	O
supplemented	VBD	O
with	IN	O
virgin	JJ	O
olive	JJ	O
oil	NN	O
,	,	O
or	CC	O
a	DT	O
Mediterranean	NNP	O
diet	NN	O
supplemented	VBD	O
with	IN	O
mixed	JJ	O
nuts	NNS	O
.	.	O

MEASUREMENTS	NNP	O
Main	NNP	O
outcomes	NNS	O
were	VBD	O
12-month	JJ	O
changes	NNS	O
from	IN	O
baseline	NN	O
in	IN	O
bone	NN	O
formation	NN	O
and	CC	O
resorption	NN	O
markers	NNS	O
and	CC	O
bone	NN	O
mass	NN	O
measured	VBD	O
according	VBG	O
to	TO	O
quantitative	JJ	O
ultrasound	JJ	O
scanning	NN	O
.	.	O

RESULTS	VB	O
The	DT	O
baseline	NN	O
data	NNS	O
on	IN	O
the	DT	O
anthropometric	NN	O
,	,	O
bone	NN	O
densitometry	NN	O
,	,	O
and	CC	O
biochemical	JJ	O
variables	NNS	O
did	VBD	O
not	RB	O
differ	VB	O
between	IN	O
the	DT	O
three	CD	O
groups	NNS	O
.	.	O

Dietary	NNP	O
potential	JJ	O
renal	JJ	O
acid	NN	O
load	NN	O
(	(	O
PRAL	NNP	O
)	)	O
and	CC	O
daily	JJ	O
net	NN	O
endogenous	JJ	O
acid	NN	O
production	NN	O
(	(	O
NEAP	NNP	O
)	)	O
at	IN	O
baseline	NN	O
did	VBD	O
not	RB	O
differ	VB	O
between	IN	O
groups	NNS	O
.	.	O

After	IN	O
intervention	NN	O
,	,	O
subjects	NNS	O
allocated	VBD	O
to	TO	O
the	DT	O
Mediterranean	NNP	O
diet	NN	O
with	IN	O
mixed	JJ	O
nuts	NNS	O
had	VBD	O
a	DT	O
significant	JJ	O
increase	NN	O
of	IN	O
PRAL	NNP	O
and	CC	O
NEAP	NNP	O
.	.	O

In	IN	O
comparison	NN	O
,	,	O
subjects	NNS	O
in	IN	O
the	DT	O
Mediterranean	NNP	O
diet	NN	O
with	IN	O
nuts	NNS	O
group	NN	O
had	VBD	O
higher	JJR	O
parathyroid	NN	O
hormone	NN	O
(	(	O
PTH	NNP	O
)	)	O
levels	NNS	O
(	(	O
2.63	CD	O
,	,	O
95	CD	O
%	NN	O
confidence	NN	O
interval	NN	O
(	(	O
CI	NNP	O
)	)	O
=-1.01-6.35	NN	O
,	,	O
P=.02	NNP	O
)	)	O
and	CC	O
a	DT	O
nonsignificantly	RB	O
higher	JJR	O
(	(	O
0.31	CD	O
,	,	O
95	CD	O
%	NN	O
CI=-0.13-0.74	NNP	O
,	,	O
P=.14	NNP	O
)	)	O
urine	VBP	O
free	JJ	O
deoxypyridoxine	NN	O
:	:	O
creatinine	NN	O
ratio	NN	O
,	,	O
a	DT	O
marker	NN	O
of	IN	O
bone	NN	O
resorption	NN	O
,	,	O
than	IN	O
the	DT	O
control	NN	O
group	NN	O
and	CC	O
the	DT	O
Mediterranean	NNP	O
diet	NN	O
with	IN	O
virgin	JJ	O
olive	JJ	O
oil	NN	O
group	NN	O
.	.	O

CONCLUSION	VB	O
A	DT	O
Mediterranean	NNP	O
dietary	JJ	O
pattern	NN	O
associated	VBN	O
with	IN	O
a	DT	O
high	JJ	O
dietary	JJ	O
acid	NN	O
load	NN	O
derived	VBN	O
from	IN	O
consumption	NN	O
of	IN	O
mixed	JJ	O
nuts	NNS	O
does	VBZ	O
not	RB	O
seem	VB	O
to	TO	O
have	VB	O
a	DT	O
much	RB	O
greater	JJR	O
effect	NN	O
on	IN	O
bone	NN	O
metabolism	NN	O
biomarkers	NNS	O
,	,	O
with	IN	O
the	DT	O
exception	NN	O
of	IN	O
PTH	NNP	O
levels	NNS	O
,	,	O
than	IN	O
a	DT	O
Mediterranean	NNP	O
diet	NN	O
without	IN	O
mixed	JJ	O
nuts	NNS	O
or	CC	O
a	DT	O
control	NN	O
diet	NN	O
in	IN	O
elderly	JJ	A
subjects	NNS	O
.	.	O

Pentoxifylline	NNP	O
therapy	NN	O
in	IN	O
HIV	NNP	C
seropositive	JJ	C
subjects	NNS	O
with	IN	O
elevated	JJ	O
TNF	NNP	O
.	.	O

Tumor	NNP	O
necrosis	IN	O
factor-alpha	JJ	O
(	(	O
TNF-alpha	NNP	O
)	)	O
is	VBZ	O
thought	VBN	O
to	TO	O
induce	VB	O
cachexia	NN	O
in	IN	O
subjects	NNS	O
infected	VBN	O
with	IN	O
human	JJ	O
immunodeficiency	NN	O
virus	NN	O
(	(	O
HIV	NNP	O
)	)	O
,	,	O
and	CC	O
it	PRP	O
has	VBZ	O
been	VBN	O
suggested	VBN	O
that	IN	O
HIV-seropositive	JJ	C
patients	NNS	O
would	MD	O
benefit	VB	O
from	IN	O
treatment	NN	O
with	IN	O
pentoxifylline	NN	O
,	,	O
a	DT	O
known	VBN	O
suppressor	NN	O
of	IN	O
TNF-alpha	NNP	O
production	NN	O
.	.	O

The	DT	O
purpose	NN	O
of	IN	O
the	DT	O
present	JJ	O
study	NN	O
was	VBD	O
to	TO	O
examine	VB	O
how	WRB	O
pentoxifylline	NN	O
at	IN	O
a	DT	O
dose	NN	O
of	IN	O
800	CD	O
mg	JJ	O
thrice	JJ	O
daily	RB	O
would	MD	O
influence	VB	O
the	DT	O
cellular	JJ	O
immune	NN	O
system	NN	O
in	IN	O
HIV-seropositive	JJ	O
persons	NNS	O
with	IN	O
elevated	JJ	O
TNF-alpha	NNP	O
.	.	O

Six	NNP	SS
HIV-seropositive	JJ	C
subjects	NNS	O
with	IN	O
elevated	JJ	O
amounts	NNS	O
of	IN	O
TNF-alpha	NNP	O
in	IN	O
plasma	NN	O
at	IN	O
least	JJS	O
at	IN	O
two	CD	O
occasions	NNS	O
were	VBD	O
included	VBN	O
in	IN	O
an	DT	O
open	JJ	O
,	,	O
controlled	VBN	O
,	,	O
randomized	VBN	O
,	,	O
cross-over	JJ	O
study	NN	O
consisting	VBG	O
of	IN	O
a	DT	O
6	CD	O
week	NN	O
treatment	NN	O
period	NN	O
and	CC	O
a	DT	O
6	CD	O
week	NN	O
control	NN	O
period	NN	O
.	.	O

Blood	NN	O
samples	NNS	O
were	VBD	O
collected	VBN	O
before	RB	O
and	CC	O
at	IN	O
the	DT	O
end	NN	O
of	IN	O
each	DT	O
period	NN	O
.	.	O

Pentoxifylline	NNP	O
treatment	NN	O
did	VBD	O
not	RB	O
influence	VB	O
the	DT	O
concentration	NN	O
of	IN	O
plasma-TNF-alpha	NN	O
,	,	O
subpopulations	NNS	O
of	IN	O
blood	NN	O
mononuclear	NN	O
cells	NNS	O
,	,	O
the	DT	O
proliferative	JJ	O
responses	NNS	O
nor	CC	O
the	DT	O
natural	JJ	O
killer	NN	O
(	(	O
NK	NNP	O
)	)	O
,	,	O
and	CC	O
lymphokine	NN	O
activated	VBN	O
killer	NN	O
(	(	O
LAK	NNP	O
)	)	O
cell	NN	O
activities	NNS	O
.	.	O

Furthermore	RB	O
,	,	O
pentoxifylline	JJ	O
treatment	NN	O
did	VBD	O
not	RB	O
influence	VB	O
the	DT	O
weight	NN	O
,	,	O
temperature	NN	O
,	,	O
well	RB	O
being	VBG	O
,	,	O
or	CC	O
tiredness	NN	O
of	IN	O
the	DT	O
subjects	NNS	O
.	.	O

However	RB	O
,	,	O
the	DT	O
patients	NNS	O
frequently	RB	O
reported	VBD	O
gastrointestinal	JJ	O
side	NN	O
effects	NNS	O
.	.	O

In	IN	O
vitro	NN	O
,	,	O
however	RB	O
,	,	O
pentoxifylline	NN	O
at	IN	O
suprapharmacological	JJ	O
concentrations	NNS	O
inhibited	VBD	O
the	DT	O
blood	NN	O
mononuclear	NN	O
cell	NN	O
(	(	O
BMNC	NNP	O
)	)	O
proliferative	NN	O
responses	NNS	O
,	,	O
NK	NNP	O
,	,	O
and	CC	O
LAK	NNP	O
cell	NN	O
activities	NNS	O
.	.	O

Improving	VBG	O
emotion	NN	O
regulation	NN	O
with	IN	O
CBT	NNP	O
in	IN	O
young	JJ	O
children	NNS	O
with	IN	O
high	JJ	O
functioning	VBG	O
autism	NN	O
spectrum	NN	O
disorders	NNS	O
:	:	O
a	DT	O
pilot	NN	O
study	NN	O
.	.	O

BACKGROUND	NNP	O
AND	CC	O
AIMS	NNP	O
This	DT	O
pilot	NN	O
study	NN	O
tested	VBD	O
the	DT	O
efficacy	NN	O
of	IN	O
a	DT	O
developmentally	RB	O
modified	VBN	O
CBT	NNP	O
for	IN	O
young	JJ	O
children	NNS	O
with	IN	O
Autism	NNP	O
Spectrum	NNP	O
Disorders	NNP	O
(	(	O
ASD	NNP	O
)	)	O
to	TO	O
teach	VB	O
emotion	NN	O
regulation	NN	O
strategies	NNS	O
for	IN	O
reducing	VBG	O
anger	NN	O
and	CC	O
anxiety	NN	O
,	,	O
commonly	RB	O
noted	VBD	O
problems	NNS	O
in	IN	O
this	DT	O
population	NN	O
.	.	O

METHOD	NNP	O
Eleven	NNP	O
5-7	JJ	O
year-old	JJ	O
children	NNS	O
participated	VBN	O
in	IN	O
a	DT	O
CBT-group	NNP	O
while	IN	O
parents	NNS	O
participated	VBN	O
in	IN	O
psychoeducation	NN	O
.	.	O

Children	NNP	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
an	DT	O
experimental	JJ	O
or	CC	O
delayed-treatment	JJ	O
control	NN	O
group	NN	O
.	.	O

RESULTS	CC	O
From	IN	O
pre-	JJ	O
to	TO	O
post-treatment	JJ	O
,	,	O
all	DT	O
children	NNS	O
had	VBD	O
less	RBR	O
parent	NN	O
reported	VBD	O
negativity/lability	NN	O
,	,	O
better	JJR	O
parent	NN	O
reported	VBD	O
emotion	NN	O
regulation	NN	O
,	,	O
and	CC	O
shorter	JJR	O
outbursts	NNS	O
,	,	O
and	CC	O
also	RB	O
generated	VBD	O
more	RBR	O
coping	JJ	O
strategies	NNS	O
in	IN	O
response	NN	O
to	TO	O
vignettes	NNS	O
.	.	O

Parents	NNS	O
also	RB	O
reported	VBD	O
increases	NNS	O
in	IN	O
their	PRP$	O
own	JJ	O
confidence	NN	O
and	CC	O
their	PRP$	O
child	NN	O
's	POS	O
ability	NN	O
to	TO	O
deal	VB	O
with	IN	O
anger	NN	O
and	CC	O
anxiety	NN	O
.	.	O

CONCLUSIONS	VB	O
This	DT	O
study	NN	O
suggests	VBZ	O
that	IN	O
young	JJ	O
children	NNS	O
with	IN	O
high	JJ	O
functioning	VBG	O
ASD	NNP	O
may	MD	O
benefit	VB	O
from	IN	O
CBT	NNP	O
to	TO	O
improve	VB	O
regulation	NN	O
of	IN	O
anger	NN	O
and	CC	O
anxiety	NN	O
,	,	O
and	CC	O
parent	NN	O
training	NN	O
may	MD	O
improve	VB	O
parental	JJ	O
self-efficacy	NN	O
.	.	O

Future	JJ	O
studies	NNS	O
are	VBP	O
needed	VBN	O
to	TO	O
make	VB	O
conclusions	NNS	O
about	IN	O
its	PRP$	O
efficacy	NN	O
.	.	O

Sleep	NNP	O
patterns	NNS	O
in	IN	O
autistic	JJ	O
children	NNS	O
.	.	O

Sleep	JJ	O
disturbances	NNS	O
are	VBP	O
regarded	VBN	O
as	IN	O
a	DT	O
common	JJ	O
clinical	JJ	O
feature	NN	O
in	IN	O
autistic	JJ	O
children	NNS	O
.	.	O

This	DT	O
concept	NN	O
is	VBZ	O
based	VBN	O
primarily	RB	O
on	IN	O
informal	JJ	O
observations	NNS	O
or	CC	O
studies	NNS	O
conducted	VBN	O
with	IN	O
questionnaires	NNS	O
.	.	O

In	IN	O
this	DT	O
study	NN	O
we	PRP	O
compared	VBN	O
data	NNS	O
obtained	VBN	O
by	IN	O
questionnaires	NNS	O
to	TO	O
that	DT	O
obtained	VBN	O
with	IN	O
actigraphy	NN	O
.	.	O

Among	IN	O
22	CD	O
autistic	JJ	O
children	NNS	O
,	,	O
12	CD	O
were	VBD	O
reported	VBN	O
as	IN	O
having	VBG	O
sleep	JJ	O
problems	NNS	O
and	CC	O
8	CD	O
patients	NNS	O
completed	VBD	O
72	CD	O
hours	NNS	O
actigraphy	RB	O
.	.	O

While	IN	O
the	DT	O
employment	NN	O
of	IN	O
questionnaires	NNS	O
disclosed	VBN	O
that	IN	O
autistic	JJ	O
children	NNS	O
had	VBD	O
an	DT	O
earlier	JJR	O
morning	NN	O
awakening	NN	O
time	NN	O
and	CC	O
multiple	NN	O
and	CC	O
early	JJ	O
night	NN	O
arousals	NNS	O
,	,	O
actigraphic	JJ	O
monitoring	NN	O
showed	VBD	O
that	IN	O
with	IN	O
the	DT	O
exception	NN	O
of	IN	O
an	DT	O
earlier	JJR	O
morning	NN	O
arousal	NN	O
time	NN	O
(	(	O
p	JJ	O
=	NNP	O
.045	NNP	O
)	)	O
,	,	O
sleep	JJ	O
patterns	NNS	O
of	IN	O
autistic	JJ	O
children	NNS	O
were	VBD	O
similar	JJ	O
to	TO	O
that	DT	O
of	IN	O
normal	JJ	O
children	NNS	O
.	.	O

Parental	JJ	O
oversensitivity	NN	O
to	TO	O
sleep	VB	O
disturbances	NNS	O
of	IN	O
the	DT	O
autistic	JJ	O
children	NNS	O
may	MD	O
explain	VB	O
this	DT	O
phenomenon	NN	O
.	.	O

The	DT	O
injured	JJ	C
colon	NN	C
:	:	O
therapeutic	JJ	O
considerations	NNS	O
.	.	O

A	DT	O
prospective	JJ	O
randomized	NN	O
study	NN	O
was	VBD	O
carried	VBN	O
out	RP	O
at	IN	O
the	DT	O
Detroit	NNP	O
General	NNP	O
Hospital	NNP	O
over	IN	O
a	DT	O
two	CD	O
year	NN	O
period	NN	O
to	TO	O
evaluate	VB	O
methods	NNS	O
of	IN	O
management	NN	O
in	IN	O
165	CD	SS
patients	NNS	O
with	IN	O
colonic	JJ	C
injuries	NNS	C
.	.	O

Results	NNS	O
of	IN	O
the	DT	O
study	NN	O
show	NN	O
that	IN	O
primary	JJ	O
closure	NN	O
is	VBZ	O
a	DT	O
safe	JJ	O
and	CC	O
reiable	JJ	O
method	NN	O
of	IN	O
management	NN	O
when	WRB	O
rigid	JJ	O
criteria	NNS	O
are	VBP	O
incorporated	VBN	O
in	IN	O
an	DT	O
ongoing	JJ	O
protocol	NN	O
.	.	O

Moreover	RB	O
,	,	O
the	DT	O
technic	NN	O
of	IN	O
exteriorization	NN	O
is	VBZ	O
a	DT	O
safe	JJ	O
adjunct	NN	O
to	TO	O
management	NN	O
and	CC	O
is	VBZ	O
recommended	VBN	O
in	IN	O
any	DT	C
patient	NN	C
with	IN	C
a	DT	C
colonic	JJ	C
injury	NN	C
above	IN	C
18	CD	C
cm	NN	C
in	IN	O
which	WDT	O
one	CD	O
suture	NN	O
line	NN	O
is	VBZ	O
required	VBN	O
and	CC	O
in	IN	O
which	WDT	O
the	DT	O
additional	JJ	O
operating	NN	O
time	NN	O
of	IN	O
twenty	NN	O
minutes	NNS	O
will	MD	O
not	RB	O
compromise	VB	O
the	DT	O
management	NN	O
of	IN	O
secondary	JJ	O
injuries	NNS	O
.	.	O

Patients	NNS	O
not	RB	O
fulfilling	VBG	O
these	DT	O
criteria	NNS	O
should	MD	O
have	VB	O
primary	JJ	O
colostomy	NN	O
.	.	O

These	DT	O
principles	NNS	O
make	VBP	O
it	PRP	O
possible	JJ	O
to	TO	O
reduce	VB	O
the	DT	O
need	NN	O
for	IN	O
primary	JJ	O
colostomy	NN	O
to	TO	O
approximately	RB	O
50	CD	O
per	IN	O
cent	NN	O
in	IN	O
a	DT	O
large	JJ	O
ongoing	VBG	O
group	NN	O
of	IN	O
patients	NNS	C
with	IN	C
colonic	JJ	C
injury	NN	C
.	.	O

A	DT	O
randomized	JJ	O
prospective	NN	O
controlled	VBN	O
trial	NN	O
of	IN	O
oral	JJ	O
ganciclovir	NN	O
versus	IN	O
oral	JJ	O
valacyclovir	NN	O
for	IN	O
prophylaxis	NN	O
of	IN	O
cytomegalovirus	NN	O
disease	NN	O
after	IN	O
renal	JJ	C
transplantation	NN	C
.	.	C

Oral	NNP	O
ganciclovir	NN	O
and	CC	O
valacyclovir	NN	O
reduce	VB	O
the	DT	O
incidence	NN	O
of	IN	O
cytomegalovirus	NN	O
(	(	O
CMV	NNP	O
)	)	O
disease	NN	O
after	IN	O
renal	JJ	O
transplantation	NN	O
(	(	O
RTx	NNP	O
)	)	O
.	.	O

Our	PRP$	O
study	NN	O
was	VBD	O
designed	VBN	O
to	TO	O
compare	VB	O
the	DT	O
efficacy	NN	O
,	,	O
costs	NNS	O
,	,	O
and	CC	O
safety	NN	O
of	IN	O
oral	JJ	O
ganciclovir	NN	O
and	CC	O
valacyclovir	NN	O
in	IN	O
the	DT	O
prophylaxis	NN	O
of	IN	O
CMV	NNP	O
disease	NN	O
over	IN	O
the	DT	O
first	JJ	O
6	CD	O
months	NNS	O
after	IN	O
RTx	NNP	O
.	.	O

A	NNP	O
total	NN	O
of	IN	O
38	CD	O
patients	NNS	O
was	VBD	O
randomized	VBN	O
to	TO	O
3-month	JJ	O
treatment	NN	O
with	IN	O
either	DT	O
oral	JJ	O
ganciclovir	NN	O
(	(	O
1	CD	O
g	NN	O
t.i.d.	NN	O
,	,	O
n=14	RB	O
,	,	O
GAN	NNP	O
group	NN	O
)	)	O
or	CC	O
oral	JJ	O
valacyclovir	NN	O
(	(	O
2	CD	O
g	NN	O
q.i.d.	NN	O
,	,	O
n=12	RB	O
,	,	O
VAL	NNP	O
group	NN	O
)	)	O
.	.	O

A	DT	O
third	JJ	O
group	NN	O
(	(	O
C	NNP	O
,	,	O
n=12	NN	O
)	)	O
received	VBD	O
no	DT	O
prophylaxis	NN	O
.	.	O

The	DT	O
patients	NNS	O
were	VBD	O
monitored	VBN	O
by	IN	O
CMV-nested	JJ	O
PCR	NNP	O
in	IN	O
whole	JJ	O
blood	NN	O
.	.	O

No	DT	O
differences	NNS	O
were	VBD	O
found	VBN	O
between	IN	O
the	DT	O
groups	NNS	O
in	IN	O
their	PRP$	O
demographic	JJ	O
characteristics	NNS	O
,	,	O
immunosuppressive	JJ	O
protocols	NNS	O
,	,	O
or	CC	O
donor	NN	O
and	CC	O
recipient	NN	O
CMV	NNP	O
serology	NN	O
.	.	O

Thirty-six	CD	O
out	IN	O
of	IN	O
38	CD	O
(	(	O
94.7	CD	O
%	NN	O
)	)	O
recipients	NNS	O
were	VBD	O
CMV-seropositive	JJ	O
.	.	O

Over	IN	O
the	DT	O
6-month	JJ	O
post-RTx	JJ	O
period	NN	O
,	,	O
there	EX	O
were	VBD	O
13	CD	O
episodes	NNS	O
of	IN	O
CMV	NNP	O
disease	NN	O
in	IN	O
eight	CD	O
(	(	O
66.7	CD	O
%	NN	O
)	)	O
patients	NNS	O
of	IN	O
the	DT	O
C	NNP	O
group	NN	O
compared	VBN	O
with	IN	O
none	NN	O
in	IN	O
the	DT	O
GAN	NNP	O
and	CC	O
VAL	NNP	O
groups	NNS	O
(	(	O
P=0.0005	NNP	O
,	,	O
GAN	NNP	O
vs	NNP	O
C	NNP	O
;	:	O
P=0.001	NNP	O
,	,	O
VAL	NNP	O
vs	NNP	O
C	NNP	O
)	)	O
.	.	O

The	DT	O
incidence	NN	O
of	IN	O
CMV	NNP	O
viremia	NN	O
was	VBD	O
30.8	CD	O
%	NN	O
,	,	O
50.0	CD	O
%	NN	O
,	,	O
and	CC	O
91.7	CD	O
%	NN	O
in	IN	O
the	DT	O
GAN	NNP	O
,	,	O
VAL	NNP	O
,	,	O
and	CC	O
C	NNP	O
groups	NNS	O
,	,	O
respectively	RB	O
(	(	O
P=0.004	NNP	O
,	,	O
GAN	NNP	O
vs	NNP	O
C	NNP	O
;	:	O
P=0.07	NNP	O
,	,	O
VAL	NNP	O
vs	NNP	O
C	NNP	O
;	:	O
P=NS	NNP	O
,	,	O
GAN	NNP	O
vs	NNP	O
VAL	NNP	O
)	)	O
.	.	O

Treatment	JJ	O
failure	NN	O
(	(	O
death	NN	O
,	,	O
graft	NN	O
loss	NN	O
,	,	O
CMV	NNP	O
disease	NN	O
,	,	O
or	CC	O
withdrawal	NN	O
from	IN	O
study	NN	O
)	)	O
occurred	VBD	O
in	IN	O
14.3	CD	O
%	NN	O
,	,	O
0	CD	O
%	NN	O
and	CC	O
66.7	CD	O
%	NN	O
in	IN	O
the	DT	O
GAN	NNP	O
,	,	O
VAL	NNP	O
,	,	O
and	CC	O
C	NNP	O
groups	NNS	O
,	,	O
respectively	RB	O
(	(	O
P=0.014	NNP	O
,	,	O
GAN	NNP	O
vs	NNP	O
C	NNP	O
;	:	O
P=0.001	NNP	O
,	,	O
VAL	NNP	O
vs	NNP	O
C	NNP	O
;	:	O
P=NS	NNP	O
,	,	O
GAN	NNP	O
vs	NNP	O
VAL	NNP	O
)	)	O
.	.	O

The	DT	O
average	JJ	O
CMV-associated	JJ	O
costs	NNS	O
per	IN	O
patient	NN	O
(	(	O
in	IN	O
2001	CD	O
euros	NN	O
)	)	O
were	VBD	O
2,449+/-1,178	JJ	O
,	,	O
2,485+/-581	JJ	O
,	,	O
and	CC	O
4,259+/-4,616	JJ	O
in	IN	O
the	DT	O
GAN	NNP	O
,	,	O
VAL	NNP	O
,	,	O
and	CC	O
C	NNP	O
groups	NNS	O
,	,	O
respectively	RB	O
.	.	O

Ganciclovir	NNP	O
and	CC	O
valacyclovir	NN	O
were	VBD	O
well	RB	O
tolerated	VBN	O
,	,	O
with	IN	O
ganciclovir	JJ	O
having	VBG	O
had	VBD	O
to	TO	O
be	VB	O
withdrawn	VBN	O
shortly	RB	O
in	IN	O
one	CD	O
patient	NN	O
only	RB	O
because	IN	O
of	IN	O
thrombocytopenia	NN	O
.	.	O

In	IN	O
conclusion	NN	O
,	,	O
oral	JJ	O
ganciclovir	NN	O
and	CC	O
valacyclovir	NN	O
are	VBP	O
equally	RB	O
safe	JJ	O
and	CC	O
effective	JJ	O
in	IN	O
the	DT	O
prophylaxis	NN	O
of	IN	O
CMV	NNP	O
disease	NN	O
after	IN	O
RTx	NNP	O
.	.	O

Both	DT	O
are	VBP	O
cost-effective	JJ	O
and	CC	O
help	VB	O
reduce	VB	O
CMV-associated	JJ	O
costs	NNS	O
by	IN	O
some	DT	O
40	CD	O
%	NN	O
compared	VBN	O
with	IN	O
patients	NNS	O
without	IN	O
prophylaxis	NN	O
.	.	O

Report	NN	O
on	IN	O
the	DT	O
second	JJ	O
myelomatosis	NN	O
trial	NN	O
after	IN	O
five	CD	O
years	NNS	O
of	IN	O
follow-up	NN	O
.	.	O

Medical	NNP	O
Research	NNP	O
Council	NNP	O
's	POS	O
Working	NNP	O
Party	NNP	O
on	IN	O
Leukaemia	NNP	C
in	IN	O
Adults	NNP	A
.	.	O

Three	CD	SS
hundred	VBD	SS
and	CC	SS
seventy-two	JJ	SS
patients	NNS	O
were	VBD	O
randomized	VBN	O
between	IN	O
3	CD	O
regimens	NNS	O
of	IN	O
chemotherapy	NN	O
:	:	O
cyclophosphamide	NN	O
,	,	O
intermittent	NN	O
melphalan	NN	O
,	,	O
and	CC	O
melphalan	NN	O
with	IN	O
prednisone	NN	O
,	,	O
and	CC	O
were	VBD	O
followed	VBN	O
up	RP	O
to	TO	O
death	NN	O
or	CC	O
for	IN	O
at	IN	O
least	JJS	O
5	CD	O
years	NNS	O
.	.	O

There	EX	O
was	VBD	O
no	DT	O
difference	NN	O
in	IN	O
survival	NN	O
between	IN	O
the	DT	O
treatments	NNS	O
,	,	O
either	RB	O
overall	JJ	O
or	CC	O
in	IN	O
any	DT	O
subgroup	NN	O
of	IN	O
patients	NNS	O
.	.	O

Therefore	RB	O
,	,	O
the	DT	O
choice	NN	O
among	IN	O
these	DT	O
3	CD	O
treatments	NNS	O
should	MD	O
be	VB	O
guided	VBN	O
by	IN	O
the	DT	O
patient	NN	O
's	POS	O
comfort	NN	O
and	CC	O
convenience	NN	O
.	.	O

The	DT	O
most	RBS	O
important	JJ	O
prognostic	JJ	O
feature	NN	O
at	IN	O
presentation	NN	O
was	VBD	O
the	DT	O
quality	NN	O
of	IN	O
renal	JJ	O
function	NN	O
.	.	O

It	PRP	O
was	VBD	O
possible	JJ	O
to	TO	O
define	VB	O
good	JJ	C
,	,	C
intermediate	JJ	C
and	CC	C
poor	JJ	C
renal-function	NN	C
groups	NNS	O
which	WDT	O
were	VBD	O
highly	RB	O
correlated	VBN	O
with	IN	O
prognosis	NN	O
(	(	O
X2	NNP	O
for	IN	O
trend	NN	O
=	NNP	O
62.6	CD	O
)	)	O
.	.	O

The	DT	O
haemoglobin	JJ	O
level	NN	O
at	IN	O
presentation	NN	O
was	VBD	O
strongly	RB	O
correlated	VBN	O
with	IN	O
prognosis	NN	O
among	IN	O
patients	NNS	O
in	IN	O
the	DT	O
good	JJ	C
renal-function	NN	C
group	NN	O
.	.	O

Among	IN	O
107	CD	SS
patients	NNS	O
who	WP	O
presented	VBD	O
with	IN	O
good	JJ	C
renal	JJ	C
function	NN	C
and	CC	O
with	IN	O
haemoglobin	NNS	O
above	IN	O
100	CD	O
g/l	NN	O
,	,	O
the	DT	O
5-year	JJ	O
survival	NN	O
was	VBD	O
43	CD	O
%	NN	O
.	.	O

Other	JJ	O
prognostic	JJ	O
features	NNS	O
were	VBD	O
much	RB	O
less	RBR	O
important	JJ	O
when	WRB	O
account	NN	O
was	VBD	O
taken	VBN	O
of	IN	O
renal	JJ	O
function	NN	O
and	CC	O
haemoglobin	JJ	O
level	NN	O
.	.	O

A	DT	O
controlled	VBN	O
comparison	NN	O
between	IN	O
single	JJ	O
doses	NNS	O
of	IN	O
intravenous	JJ	O
and	CC	O
intramuscular	JJ	O
morphine	NN	O
with	IN	O
respect	NN	O
to	TO	O
analgesic	JJ	O
effects	NNS	O
and	CC	O
patient	JJ	O
safety	NN	O
.	.	O

UNLABELLED	VBN	O
BACKGROUND	NNP	O
AND	NNP	O
AIM	NNP	O
OF	NNP	O
INVESTIGATION	NNP	O
:	:	O
Intramuscular	NNP	O
(	(	O
IM	NNP	O
)	)	O
administration	NN	O
has	VBZ	O
been	VBN	O
considered	VBN	O
to	TO	O
be	VB	O
safer	JJR	O
than	IN	O
intravenous	JJ	O
(	(	O
IV	NNP	O
)	)	O
for	IN	O
opioids	NNS	O
on	IN	O
wards	NNS	O
,	,	O
but	CC	O
a	DT	O
comparative	JJ	O
knowledge	NN	O
of	IN	O
patient	JJ	O
safety	NN	O
and	CC	O
analgesic	JJ	O
potency	NN	O
following	VBG	O
a	DT	O
single	JJ	O
dose	NN	O
of	IN	O
IV	NNP	O
and	CC	O
IM	NNP	O
administration	NN	O
is	VBZ	O
lacking	VBG	O
.	.	O

This	DT	O
study	NN	O
was	VBD	O
carried	VBN	O
out	IN	O
to	TO	O
compare	VB	O
patient	JJ	O
safety	NN	O
and	CC	O
analgesic	JJ	O
efficacy	NN	O
of	IN	O
a	DT	O
single	JJ	O
and	CC	O
high	JJ	O
dose	NN	O
of	IN	O
morphine	NN	O
given	VBN	O
IM	NNP	O
or	CC	O
IV	NNP	O
for	IN	O
post-operative	JJ	O
pain	NN	O
management	NN	O
.	.	O

MATERIALS	NNP	O
AND	CC	O
METHODS	NNP	O
Thirty-eight	NNP	O
patients	NNS	O
with	IN	O
post-operative	JJ	O
pain	NN	O
following	VBG	O
hip	NN	O
replacement	NN	O
surgery	NN	O
were	VBD	O
given	VBN	O
IM	NNP	O
or	CC	O
IV	NNP	O
morphine	VBP	O
10	CD	O
mg	NN	O
at	IN	O
a	DT	O
specified	JJ	O
pain	NN	O
level	NN	O
.	.	O

The	DT	O
study	NN	O
was	VBD	O
randomized	VBN	O
and	CC	O
double	JJ	O
blinded	VBN	O
.	.	O

Time	NN	O
to	TO	O
onset	VB	O
of	IN	O
analgesic	JJ	O
effect	NN	O
(	(	O
11-point	JJ	O
numeric	NN	O
rating	NN	O
scale	NN	O
)	)	O
,	,	O
respiratory	JJ	O
function	NN	O
(	(	O
p	NN	O
(	(	O
a	DT	O
)	)	O
CO2	NNP	O
,	,	O
p	NN	O
(	(	O
a	DT	O
)	)	O
O2	NNP	O
,	,	O
and	CC	O
respiratory	JJ	O
rate	NN	O
)	)	O
,	,	O
level	NN	O
of	IN	O
sedation	NN	O
(	(	O
5-point	JJ	O
verbal	NN	O
rating	NN	O
scale	NN	O
)	)	O
,	,	O
and	CC	O
hemodynamic	JJ	O
function	NN	O
were	VBD	O
recorded	VBN	O
.	.	O

RESULTS	NNP	O
In	IN	O
the	DT	O
IV	NNP	O
group	NN	O
there	EX	O
was	VBD	O
a	DT	O
slight	JJ	O
but	CC	O
significant	JJ	O
increase	NN	O
in	IN	O
p	NN	O
(	(	O
a	DT	O
)	)	O
CO2	NNP	O
after	IN	O
5	CD	O
,	,	O
10	CD	O
,	,	O
and	CC	O
15	CD	O
min	NNS	O
compared	VBN	O
with	IN	O
the	DT	O
IM	NNP	O
group	NN	O
(	(	O
5.2	CD	O
vs.	FW	O
4.8	CD	O
,	,	O
5.4	CD	O
,	,	O
vs.	FW	O
5.0	CD	O
and	CC	O
5.5	CD	O
vs.	FW	O
5.1	CD	O
kPa	NN	O
,	,	O
respectively	RB	O
)	)	O
.	.	O

The	DT	O
IV	NNP	O
group	NN	O
had	VBD	O
a	DT	O
significantly	RB	O
faster	RBR	O
onset	NN	O
of	IN	O
analgesic	JJ	O
effect	NN	O
than	IN	O
the	DT	O
IM	NNP	O
group	NN	O
(	(	O
5	CD	O
vs.	FW	O
20	CD	O
min	NN	O
)	)	O
.	.	O

Between	$	O
5	CD	O
and	CC	O
25	CD	O
min	NN	O
after	IN	O
morphine	JJ	O
administration	NN	O
,	,	O
pain	NN	O
status	NN	O
in	IN	O
the	DT	O
IV	NNP	O
group	NN	O
was	VBD	O
significantly	RB	O
improved	VBN	O
compared	VBN	O
with	IN	O
the	DT	O
IM	NNP	O
group	NN	O
.	.	O

Patients	NNS	O
in	IN	O
the	DT	O
IV	NNP	O
group	NN	O
were	VBD	O
slightly	RB	O
more	RBR	O
sedated	JJ	O
than	IN	O
the	DT	O
IM	NNP	O
group	NN	O
5	CD	O
and	CC	O
10	CD	O
min	NN	O
after	IN	O
morphine	NN	O
.	.	O

CONCLUSION	VB	O
A	DT	O
10	CD	O
mg	NN	O
bolus	NN	O
dose	NN	O
of	IN	O
IV	NNP	O
morphine	NN	O
given	VBN	O
to	TO	O
patients	NNS	O
with	IN	O
moderate	JJ	O
pain	NN	O
after	IN	O
surgery	NN	O
does	VBZ	O
not	RB	O
cause	VB	O
severe	JJ	O
respiratory	NN	O
depression	NN	O
,	,	O
but	CC	O
provides	VBZ	O
more	RBR	O
rapid	JJ	O
and	CC	O
better	RBR	O
initial	JJ	O
analgesia	NN	O
than	IN	O
10	CD	O
mg	NNS	O
given	VBN	O
IM	NNP	O
.	.	O

IV	NNP	O
morphine	VBD	O
even	RB	O
at	IN	O
a	DT	O
dose	NN	O
as	RB	O
high	JJ	O
as	IN	O
10	CD	O
mg	NN	O
IV	NNP	O
is	VBZ	O
well	RB	O
tolerated	VBN	O
if	IN	O
there	EX	O
is	VBZ	O
a	DT	O
certain	JJ	O
level	NN	O
of	IN	O
pain	NN	O
at	IN	O
its	PRP$	O
administration	NN	O
.	.	O

The	DT	O
safety	NN	O
of	IN	O
IV	NNP	O
morphine	NN	O
on	IN	O
the	DT	O
general	JJ	O
ward	NN	O
needs	VBZ	O
to	TO	O
be	VB	O
further	RB	O
explored	VBN	O
in	IN	O
adequately	RB	O
controlled	JJ	O
studies	NNS	O
.	.	O

Postoperative	JJ	O
pain	NN	O
control	NN	O
for	IN	O
outpatient	JJ	O
oral	JJ	C
surgery	NN	C
.	.	O

16	CD	SS
healthy	JJ	C
patients	NNS	O
requiring	VBG	C
removal	NN	C
of	IN	C
bilateral	JJ	C
symmetrically-impacted	JJ	C
mandibular	JJ	C
third	JJ	C
molars	NNS	C
participated	VBD	O
in	IN	O
a	DT	O
double-blind	NN	O
randomised	VBN	O
crossover	RB	O
trial	NN	O
to	TO	O
test	VB	O
the	DT	O
effectiveness	NN	O
of	IN	O
postoperative	JJ	O
pain	NN	O
control	NN	O
using	VBG	O
a	DT	O
long-acting	JJ	O
anti-inflammatory	JJ	O
agent	NN	O
(	(	O
diflunisal	NN	O
)	)	O
in	IN	O
combination	NN	O
with	IN	O
a	DT	O
long-acting	JJ	O
local	JJ	O
anaesthetic	JJ	O
agent	NN	O
(	(	O
bupivacaine	NN	O
)	)	O
.	.	O

Results	NNS	O
were	VBD	O
compared	VBN	O
to	TO	O
the	DT	O
more	RBR	O
traditional	JJ	O
method	NN	O
of	IN	O
using	VBG	O
an	DT	O
oral	JJ	O
analgesic	NN	O
with	IN	O
shorter	JJR	O
duration	NN	O
of	IN	O
action	NN	O
(	(	O
paracetamol	NN	O
with	IN	O
codeine	NN	O
)	)	O
with	IN	O
lignocaine	NN	O
as	IN	O
the	DT	O
local	JJ	O
anaesthetic	NN	O
.	.	O

Using	VBG	O
a	DT	O
visual	JJ	O
analogue	NN	O
pain	NN	O
scale	NN	O
,	,	O
patients	NNS	O
reported	VBD	O
that	IN	O
significantly	RB	O
reduced	VBN	O
pain	NN	O
was	VBD	O
experienced	VBN	O
over	IN	O
the	DT	O
first	JJ	O
4	CD	O
days	NNS	O
postoperatively	RB	O
with	IN	O
the	DT	O
diflunisal/bupivacaine	NN	O
treatment	NN	O
and	CC	O
patient	JJ	O
preference	NN	O
for	IN	O
this	DT	O
treatment	NN	O
was	VBD	O
highly	RB	O
significant	JJ	O
.	.	O

This	DT	O
report	NN	O
represents	VBZ	O
the	DT	O
first	JJ	O
such	JJ	O
study	NN	O
of	IN	O
diflunisal	NN	O
used	VBN	O
for	IN	O
an	DT	O
extended	JJ	O
course	NN	O
in	IN	O
oral	JJ	O
surgery	NN	O
with	IN	O
pain	NN	O
assessment	NN	O
over	IN	O
the	DT	O
same	JJ	O
period	NN	O
.	.	O

No	DT	O
significant	JJ	O
side-effects	NNS	O
or	CC	O
adverse	JJ	O
reactions	NNS	O
were	VBD	O
encountered	VBN	O
.	.	O

Comparative	JJ	O
efficacy	NN	O
and	CC	O
safety	NN	O
of	IN	O
calcium	NN	O
carbasalate	NN	O
plus	CC	O
metoclopramide	JJ	O
versus	NN	O
ergotamine	NN	O
tartrate	NN	O
plus	CC	O
caffeine	NN	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
acute	JJ	C
migraine	NN	C
attacks	NNS	C
.	.	O

This	DT	O
randomized	JJ	O
,	,	O
double-blind	JJ	O
,	,	O
double-dummy	JJ	O
,	,	O
multicenter	NN	O
,	,	O
parallel-group	JJ	O
study	NN	O
aimed	VBN	O
at	IN	O
comparing	VBG	O
the	DT	O
efficacy	NN	O
and	CC	O
safety	NN	O
of	IN	O
calcium	NN	O
carbasalate	NN	O
(	(	O
equivalent	JJ	O
to	TO	O
900	CD	O
mg	NNS	O
aspirin	RB	O
)	)	O
plus	CC	O
metoclopramide	$	O
10	CD	O
mg	NN	O
(	(	O
CM	NNP	O
)	)	O
with	IN	O
ergotamine	JJ	O
tartrate	NN	O
1	CD	O
mg	NN	O
plus	CC	O
caffeine	JJ	O
100	CD	O
mg	NN	O
(	(	O
EC	NNP	O
)	)	O
administered	VBN	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
2	CD	O
acute	JJ	O
migraine	NN	O
attacks	NNS	O
.	.	O

A	DT	O
total	NN	O
of	IN	O
296	CD	SS
patients	NNS	O
fulfilling	VBG	O
the	DT	O
International	NNP	O
Headache	NNP	O
Society	NNP	O
diagnostic	JJ	O
criteria	NNS	O
for	IN	O
migraine	NN	C
were	VBD	O
enrolled	VBN	O
.	.	O

In	IN	O
total	JJ	O
,	,	O
one	CD	O
or	CC	O
two	CD	O
migraine	NN	O
attacks	NNS	O
were	VBD	O
treated	VBN	O
in	IN	O
268	CD	O
and	CC	O
235	CD	O
patients	NNS	O
,	,	O
respectively	RB	O
.	.	O

The	DT	O
primary	JJ	O
endpoint	NN	O
for	IN	O
the	DT	O
first	JJ	O
treated	VBD	O
attack	NN	O
was	VBD	O
headache	NN	O
relief	NN	O
,	,	O
with	IN	O
intensity	NN	O
decreasing	VBG	O
from	IN	O
moderate	JJ	O
or	CC	O
severe	JJ	O
to	TO	O
mild	VB	O
or	CC	O
absent	VB	O
2	CD	O
h	NN	O
after	IN	O
drug	NN	O
intake	NN	O
.	.	O

Usual	JJ	O
secondary	JJ	O
efficacy	NN	O
endpoints	NNS	O
were	VBD	O
assessed	VBN	O
.	.	O

A	DT	O
superiority	NN	O
of	IN	O
CM	NNP	O
over	IN	O
EC	NNP	O
was	VBD	O
observed	VBN	O
for	IN	O
both	DT	O
treated	JJ	O
attacks	NNS	O
for	IN	O
the	DT	O
main	JJ	O
endpoint	NN	O
:	:	O
success	NN	O
in	IN	O
54	CD	O
versus	NN	O
36	CD	O
%	NN	O
,	,	O
p	NN	O
=	VBD	O
0.003	CD	O
for	IN	O
the	DT	O
first	JJ	O
attack	NN	O
and	CC	O
60	CD	O
versus	NN	O
44	CD	O
%	NN	O
,	,	O
p	NN	O
=	VBD	O
0.02	CD	O
for	IN	O
the	DT	O
second	JJ	O
attack	NN	O
.	.	O

CM	NNP	O
was	VBD	O
also	RB	O
significantly	RB	O
superior	JJ	O
to	TO	O
EC	NNP	O
during	IN	O
the	DT	O
first	JJ	O
attack	NN	O
for	IN	O
complete	JJ	O
headache	NN	O
relief	NN	O
(	(	O
20	CD	O
vs.	FW	O
8	CD	O
%	NN	O
,	,	O
p	NN	O
=	NNP	O
0.006	CD	O
)	)	O
,	,	O
nausea	NN	O
(	(	O
42	CD	O
vs.	FW	O
63	CD	O
%	NN	O
,	,	O
p	NN	O
=	VBD	O
0	CD	O
.	.	O

007	CD	O
)	)	O
and	CC	O
willingness	NN	O
to	TO	O
take	VB	O
the	DT	O
drug	NN	O
again	RB	O
(	(	O
90	CD	O
vs.	FW	O
80	CD	O
%	NN	O
,	,	O
p	NN	O
=	NNP	O
0.043	CD	O
)	)	O
.	.	O

The	DT	O
global	JJ	O
efficacy	NN	O
evaluation	NN	O
,	,	O
rated	VBN	O
by	IN	O
the	DT	O
investigators	NNS	O
,	,	O
was	VBD	O
significantly	RB	O
more	RBR	O
favorable	JJ	O
to	TO	O
CM	NNP	O
for	IN	O
both	DT	O
attacks	NNS	O
(	(	O
p	VB	O
=	$	O
0.001	CD	O
for	IN	O
the	DT	O
first	JJ	O
attack	NN	O
and	CC	O
p	NN	O
=	VBP	O
0.02	CD	O
for	IN	O
the	DT	O
second	JJ	O
)	)	O
.	.	O

The	DT	O
patients	NNS	O
'	POS	O
evaluation	NN	O
was	VBD	O
significant	JJ	O
for	IN	O
the	DT	O
first	JJ	O
attack	NN	O
(	(	O
p	JJ	O
=	NNP	O
0.002	CD	O
)	)	O
.	.	O

The	DT	O
global	JJ	O
incidence	NN	O
of	IN	O
adverse	JJ	O
events	NNS	O
was	VBD	O
45	CD	O
%	NN	O
higher	JJR	O
with	IN	O
EC	NNP	O
,	,	O
though	IN	O
not	RB	O
significant	JJ	O
(	(	O
32	CD	O
vs.	FW	O
22	CD	O
%	NN	O
,	,	O
p	NN	O
=	NNP	O
0.075	CD	O
)	)	O
.	.	O

They	PRP	O
were	VBD	O
most	RBS	O
often	RB	O
unspecific	JJ	O
and	CC	O
mild	JJ	O
to	TO	O
moderate	VB	O
in	IN	O
intensity	NN	O
.	.	O

Gastrointestinal	JJ	O
side	NN	O
effects	NNS	O
were	VBD	O
significantly	RB	O
less	RBR	O
frequent	JJ	O
with	IN	O
CM	NNP	O
than	IN	O
EC	NNP	O
(	(	O
7	CD	O
vs.	FW	O
21	CD	O
%	NN	O
,	,	O
p	NN	O
=	NNP	O
0.001	CD	O
)	)	O
.	.	O

Thus	RB	O
,	,	O
CM	NNP	O
is	VBZ	O
more	RBR	O
effective	JJ	O
and	CC	O
has	VBZ	O
a	DT	O
better	JJR	O
gastrointestinal	JJ	O
safety	NN	O
than	IN	O
EC	NNP	O
in	IN	O
the	DT	O
acute	JJ	O
treatment	NN	O
of	IN	O
migraine	NN	O
attacks	NNS	O
.	.	O

Peripheral	JJ	O
arterial	JJ	O
disease	NN	O
:	:	O
therapeutic	JJ	O
confidence	NN	O
of	IN	O
CT	NNP	O
versus	NNP	O
digital	JJ	O
subtraction	NN	O
angiography	NN	O
and	CC	O
effects	NNS	O
on	IN	O
additional	JJ	O
imaging	NN	O
recommendations	NNS	O
.	.	O

PURPOSE	NNP	O
To	TO	O
compare	VB	O
multi-detector	JJ	O
row	NN	O
computed	VBN	O
tomographic	JJ	O
(	(	O
CT	NNP	O
)	)	O
angiography	NN	O
and	CC	O
digital	JJ	O
subtraction	NN	O
angiography	NN	O
(	(	O
DSA	NNP	O
)	)	O
prior	RB	O
to	TO	O
revascularization	NN	O
in	IN	O
patients	NNS	O
with	IN	O
symptomatic	JJ	O
peripheral	JJ	O
arterial	JJ	O
disease	NN	O
for	IN	O
the	DT	O
purpose	NN	O
of	IN	O
assessing	VBG	O
recommendations	NNS	O
for	IN	O
additional	JJ	O
imaging	NN	O
and	CC	O
physician	JJ	O
confidence	NN	O
ratings	NNS	O
for	IN	O
chosen	NN	O
therapy	NN	O
.	.	O

MATERIALS	NNP	O
AND	CC	O
METHODS	NNP	O
In	IN	O
a	DT	O
randomized	NN	O
controlled	VBN	O
trial	NN	O
,	,	O
73	CD	O
patients	NNS	O
were	VBD	O
assigned	VBN	O
to	TO	O
CT	NNP	O
angiography	NN	O
,	,	O
and	CC	O
72	CD	O
were	VBD	O
assigned	VBN	O
to	TO	O
DSA	NNP	O
.	.	O

Physician	JJ	O
confidence	NN	O
in	IN	O
the	DT	O
treatment	NN	O
decision	NN	O
was	VBD	O
measured	VBN	O
as	IN	O
a	DT	O
continuous	JJ	O
outcome	NN	O
on	IN	O
a	DT	O
scale	NN	O
of	IN	O
0-10	NNP	O
(	(	O
uncertain	JJ	O
to	TO	O
certain	JJ	O
)	)	O
and	CC	O
as	IN	O
a	DT	O
dichotomous	JJ	O
outcome	NN	O
(	(	O
further	JJ	O
imaging	NN	O
recommended	VBD	O
,	,	O
yes	UH	O
or	CC	O
no	DT	O
)	)	O
.	.	O

Mean	JJ	O
confidence	NN	O
scores	NNS	O
and	CC	O
additional	JJ	O
imaging	NN	O
recommendations	NNS	O
were	VBD	O
compared	VBN	O
between	IN	O
CT	NNP	O
and	CC	O
DSA	NNP	O
groups	NNS	O
in	IN	O
an	DT	O
intention-to-diagnose-and-treat	JJ	O
analysis	NN	O
.	.	O

To	TO	O
detect	VB	O
trends	NNS	O
in	IN	O
confidence	NN	O
,	,	O
confidence	NN	O
scores	NNS	O
were	VBD	O
plotted	VBN	O
over	IN	O
time	NN	O
,	,	O
and	CC	O
multiple	JJ	O
linear	JJ	O
regression	NN	O
analysis	NN	O
was	VBD	O
performed	VBN	O
.	.	O

To	TO	O
detect	VB	O
trends	NNS	O
in	IN	O
additional	JJ	O
imaging	NN	O
recommendations	NNS	O
,	,	O
logistic	JJ	O
regression	NN	O
analysis	NN	O
was	VBD	O
used	VBN	O
.	.	O

Data	NNS	O
from	IN	O
eligible	JJ	O
nonrandomized	JJ	O
patients	NNS	O
were	VBD	O
analyzed	VBN	O
separately	RB	O
.	.	O

RESULTS	NNP	O
No	NNP	O
statistically	RB	O
significant	JJ	O
difference	NN	O
in	IN	O
baseline	NN	O
characteristics	NNS	O
between	IN	O
randomized	VBN	O
groups	NNS	O
was	VBD	O
found	VBN	O
.	.	O

CT	NNP	O
had	VBD	O
a	DT	O
lower	JJR	O
confidence	NN	O
score	JJR	O
than	IN	O
did	VBD	O
DSA	NNP	O
(	(	O
7.2	CD	O
vs	NN	O
8.2	CD	O
,	,	O
P	NNP	O
<	NNP	O
.001	NNP	O
)	)	O
.	.	O

Further	JJ	O
imaging	NN	O
was	VBD	O
recommended	VBN	O
more	RBR	O
often	RB	O
after	IN	O
CT	NNP	O
(	(	O
25	CD	O
of	IN	O
71	CD	O
patients	NNS	O
,	,	O
35	CD	O
%	NN	O
)	)	O
than	IN	O
after	IN	O
DSA	NNP	O
(	(	O
nine	CD	O
of	IN	O
66	CD	O
patients	NNS	O
,	,	O
14	CD	O
%	NN	O
;	:	O
P	NNP	O
=	NNP	O
.003	NNP	O
)	)	O
.	.	O

Analysis	NN	O
of	IN	O
trends	NNS	O
demonstrated	VBN	O
increasing	VBG	O
(	(	O
but	CC	O
not	RB	O
statistically	RB	O
significant	JJ	O
)	)	O
confidence	NN	O
in	IN	O
CT	NNP	O
and	CC	O
stable	JJ	O
confidence	NN	O
in	IN	O
DSA	NNP	O
.	.	O

No	NNP	O
significant	JJ	O
difference	NN	O
was	VBD	O
found	VBN	O
in	IN	O
baseline	NN	O
characteristics	NNS	O
between	IN	O
randomized	VBN	O
and	CC	O
nonrandomized	JJ	O
patients	NNS	O
.	.	O

Among	IN	O
nonrandomized	JJ	O
patients	NNS	O
,	,	O
no	DT	O
significant	JJ	O
difference	NN	O
in	IN	O
mean	JJ	O
confidence	NN	O
score	NN	O
(	(	O
8.2	CD	O
vs	NN	O
8.3	CD	O
,	,	O
P	NNP	O
=	NNP	O
.26	NNP	O
)	)	O
was	VBD	O
found	VBN	O
between	IN	O
CT	NNP	O
(	(	O
n	JJ	O
=	NNP	O
24	CD	O
)	)	O
and	CC	O
DSA	NNP	O
(	(	O
n	JJ	O
=	NNP	O
26	CD	O
)	)	O
.	.	O

CONCLUSION	NN	O
With	IN	O
CT	NNP	O
angiography	NN	O
,	,	O
physician	JJ	O
confidence	NN	O
decreases	NNS	O
with	IN	O
an	DT	O
associated	JJ	O
increase	NN	O
in	IN	O
additional	JJ	O
imaging	NN	O
prior	RB	O
to	TO	O
revascularization	NN	O
in	IN	O
patients	NNS	O
with	IN	O
symptomatic	JJ	O
peripheral	JJ	O
arterial	JJ	O
disease	NN	O
.	.	O

Given	VBN	O
that	IN	O
CT	NNP	O
is	VBZ	O
less	RBR	O
invasive	JJ	O
than	IN	O
DSA	NNP	O
,	,	O
results	NNS	O
suggest	VBP	O
that	IN	O
CT	NNP	O
may	MD	O
replace	VB	O
DSA	NNP	O
in	IN	O
selected	VBN	O
cases	NNS	O
.	.	O

Chronology	NN	O
of	IN	O
panic	NN	O
and	CC	O
avoidance	NN	O
,	,	O
age	NN	O
of	IN	O
onset	NN	O
in	IN	O
panic	JJ	C
disorder	NN	C
,	,	O
and	CC	O
prediction	NN	O
of	IN	O
treatment	NN	O
response	NN	O
.	.	O

A	DT	O
report	NN	O
from	IN	O
the	DT	O
Cross-National	JJ	O
Collaborative	NNP	O
Panic	NNP	O
Study	NNP	O
.	.	O

The	DT	O
relevance	NN	O
of	IN	O
the	DT	O
chronology	NN	O
between	IN	O
panic	JJ	O
disorder	NN	O
and	CC	O
avoidance	NN	O
behavior	NN	O
and	CC	O
of	IN	O
an	DT	O
early	JJ	O
,	,	O
medium	NN	O
or	CC	O
late	JJ	O
onset	NN	O
of	IN	O
panic	JJ	O
disorder	NN	O
was	VBD	O
tested	VBN	O
.	.	O

Groups	NNP	O
from	IN	O
the	DT	O
sample	NN	O
of	IN	O
the	DT	O
cross-national	JJ	O
collaborative	NN	O
panic	NN	O
study	NN	O
(	(	O
CNCPS	NNP	O
)	)	O
were	VBD	O
compared	VBN	O
for	IN	O
differences	NNS	O
in	IN	O
basic	JJ	O
characteristics	NNS	O
and	CC	O
for	IN	O
the	DT	O
ability	NN	O
to	TO	O
predict	VB	O
treatment	NN	O
response	NN	O
.	.	O

Patients	NNS	O
who	WP	O
developed	VBD	O
avoidance	NN	O
behavior	NN	O
before	IN	O
the	DT	O
full	JJ	C
syndrome	NN	C
of	IN	O
panic	JJ	C
disorder	NN	C
had	VBD	O
less	RBR	O
often	RB	O
a	DT	O
full	JJ	O
agoraphobia	NN	O
but	CC	O
were	VBD	O
not	RB	O
different	JJ	O
in	IN	O
their	PRP$	O
response	NN	O
to	TO	O
treatment	NN	O
.	.	O

Patients	NNS	O
with	IN	O
an	DT	O
early	JJ	O
onset	NN	O
of	IN	O
panic	JJ	O
disorder	NN	O
suffered	VBD	O
more	RBR	O
often	RB	O
from	IN	O
agoraphobia	NNS	O
.	.	O

The	DT	O
treatment	NN	O
response	NN	O
was	VBD	O
similar	JJ	O
in	IN	O
the	DT	O
groups	NNS	O
with	IN	O
early	JJ	O
,	,	O
medium	NN	O
or	CC	O
late	JJ	O
onset	NN	O
of	IN	O
panic	JJ	O
disorder	NN	O
.	.	O

Neither	CC	O
the	DT	O
chronology	NN	O
between	IN	O
panic	JJ	O
disorder	NN	O
and	CC	O
avoidance	NN	O
behavior	NN	O
nor	CC	O
the	DT	O
age	NN	O
of	IN	O
onset	NN	O
of	IN	O
panic	JJ	O
disorder	NN	O
predicted	VBD	O
outcome	NN	O
in	IN	O
short-term	JJ	O
treatment	NN	O
with	IN	O
alprazolam	NN	O
or	CC	O
imipramine	NN	O
.	.	O

Adult	NNP	A
height	NN	O
in	IN	O
short	JJ	O
children	NNS	A
born	VBN	O
SGA	NNP	C
treated	VBD	O
with	IN	O
growth	NN	O
hormone	NN	O
and	CC	O
gonadotropin	NN	O
releasing	VBG	O
hormone	NN	O
analog	NN	O
:	:	O
results	NNS	O
of	IN	O
a	DT	O
randomized	JJ	O
,	,	O
dose-response	JJ	O
GH	NNP	O
trial	NN	O
.	.	O

CONTEXT	NNP	O
GH	NNP	O
treatment	NN	O
is	VBZ	O
effective	JJ	O
in	IN	O
improving	VBG	O
height	NN	O
in	IN	O
short	JJ	C
children	NNS	C
born	VBP	C
small	JJ	C
for	IN	C
gestational	JJ	C
age	NN	C
(	(	C
SGA	NNP	C
)	)	C
.	.	O

GH	NNP	O
is	VBZ	O
thought	VBN	O
to	TO	O
have	VB	O
limited	VBN	O
effect	NN	O
when	WRB	O
started	VBD	O
during	IN	O
adolescence	NN	O
.	.	O

OBJECTIVE	CC	O
The	DT	O
aim	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
investigate	VB	O
GH	NNP	O
treatment	NN	O
efficacy	NN	O
in	IN	O
short	JJ	O
SGA	NNP	O
children	NNS	O
when	WRB	O
treatment	NN	O
was	VBD	O
started	VBN	O
during	IN	O
adolescence	NN	O
;	:	O
to	TO	O
assess	VB	O
whether	IN	O
GH	NNP	O
2	CD	O
mg/m	NN	O
(	(	O
2	CD	O
)	)	O
?	.	O
d	NN	O
during	IN	O
puberty	JJ	O
improves	NNS	O
adult	VBP	O
height	NN	O
(	(	O
AH	NNP	O
)	)	O
compared	VBN	O
with	IN	O
1	CD	O
mg/m	NNS	O
(	(	O
2	CD	O
)	)	O
?	.	O
d	NN	O
;	:	O
and	CC	O
to	TO	O
assess	VB	O
whether	IN	O
an	DT	O
additional	JJ	O
2-yr	JJ	O
postponement	NN	O
of	IN	O
puberty	NN	O
by	IN	O
GnRH	NNP	O
analog	NN	O
(	(	O
GnRHa	NNP	O
)	)	O
improves	VBZ	O
AH	NNP	O
in	IN	O
children	NNS	O
who	WP	O
are	VBP	O
short	JJ	O
at	IN	O
the	DT	O
start	NN	O
of	IN	O
puberty	NN	O
(	(	O
<	JJ	O
140	CD	O
cm	NN	O
)	)	O
,	,	O
with	IN	O
a	DT	O
poor	JJ	O
AH	NNP	O
expectation	NN	O
.	.	O

PATIENTS	NNP	O
AND	CC	O
DESIGN	NNP	O
In	IN	O
this	DT	O
longitudinal	JJ	O
,	,	O
randomized	VBN	O
,	,	O
dose-response	JJ	O
GH	NNP	O
trial	NN	O
,	,	O
we	PRP	O
included	VBD	O
121	CD	O
short	JJ	O
SGA	NNP	O
children	NNS	O
(	(	O
60	CD	O
boys	NNS	O
)	)	O
at	IN	O
least	JJS	O
8	CD	O
yr	NN	O
of	IN	O
age	NN	O
.	.	O

We	PRP	O
performed	VBD	O
intention-to-treat	JJ	O
analyses	NNS	O
on	IN	O
all	DT	O
children	NNS	O
and	CC	O
uncensored	JJ	O
case	NN	O
analyses	VBZ	O
on	IN	O
84	CD	O
children	NNS	O
who	WP	O
reached	VBD	O
AH	NNP	O
.	.	O

Besides	NNP	O
,	,	O
we	PRP	O
evaluated	VBD	O
growth	NN	O
during	IN	O
2	CD	O
yr	NNS	O
of	IN	O
combined	JJ	O
GH/GnRHa	NNP	O
and	CC	O
subsequent	JJ	O
GH	NNP	O
treatment	NN	O
until	IN	O
AH	NNP	O
in	IN	O
a	DT	O
subgroup	NN	O
of	IN	O
40	CD	O
pubertal	JJ	O
children	NNS	O
with	IN	O
a	DT	O
height	NN	O
of	IN	O
less	JJR	O
than	IN	O
140	CD	O
cm	NN	O
at	IN	O
the	DT	O
start	NN	O
.	.	O

RESULTS	NNP	O
Short	NNP	O
SGA	NNP	O
children	NNS	O
started	VBD	O
treatment	NN	O
at	IN	O
a	DT	O
median	JJ	O
age	NN	O
of	IN	O
11.2	CD	O
yr	NNS	O
,	,	O
when	WRB	O
46	CD	O
%	NN	O
had	VBD	O
already	RB	O
started	VBN	O
puberty	NN	O
.	.	O

Median	JJ	O
height	NN	O
increased	VBD	O
from	IN	O
-2.9	NN	O
at	IN	O
start	NN	O
to	TO	O
-1.7	VB	O
sd	NN	O
score	NN	O
(	(	O
SDS	NNP	O
)	)	O
at	IN	O
AH	NNP	O
(	(	O
P	NNP	O
<	NNP	O
0.001	CD	O
)	)	O
.	.	O

Treatment	NN	O
with	IN	O
GH	NNP	O
2	CD	O
vs.	FW	O
1	CD	O
mg/m	NN	O
(	(	O
2	CD	O
)	)	O
?	.	O
d	NN	O
during	IN	O
puberty	NN	O
resulted	VBD	O
in	IN	O
significantly	RB	O
better	JJR	O
AH	NNP	O
(	(	O
P	NNP	O
=	NNP	O
0.001	CD	O
)	)	O
,	,	O
also	RB	O
after	IN	O
correction	NN	O
for	IN	O
gender	NN	O
,	,	O
age	NN	O
at	IN	O
start	NN	O
,	,	O
height	VBD	O
SDS	NNP	O
at	IN	O
start	NN	O
,	,	O
treatment	NN	O
years	NNS	O
before	IN	O
puberty	NN	O
,	,	O
and	CC	O
target	VB	O
height	JJ	O
SDS	NNP	O
.	.	O

AH	NNP	O
was	VBD	O
similar	JJ	O
in	IN	O
children	NNS	O
who	WP	O
started	VBD	O
puberty	NN	O
at	IN	O
less	JJR	O
than	IN	O
140	CD	O
cm	NN	O
and	CC	O
received	VBD	O
GH/GnRHa	NNP	O
,	,	O
compared	VBN	O
with	IN	O
children	NNS	O
who	WP	O
started	VBD	O
puberty	NN	O
greater	JJR	O
than	IN	O
140	CD	O
cm	NN	O
and	CC	O
received	VBD	O
GH	NNP	O
only	RB	O
(	(	O
P	NNP	O
=	NNP	O
0.795	CD	O
)	)	O
.	.	O

CONCLUSION	NN	O
When	WRB	O
started	VBN	O
in	IN	O
adolescence	NN	O
,	,	O
GH	NNP	O
treatment	NN	O
significantly	RB	O
improves	VBZ	O
AH	NNP	O
in	IN	O
short	JJ	O
SGA	NNP	O
children	NNS	O
,	,	O
particularly	RB	O
with	IN	O
GH	NNP	O
2	CD	O
mg/m	NN	O
(	(	O
2	CD	O
)	)	O
?	.	O
d	NN	O
during	IN	O
puberty	NN	O
.	.	O

When	WRB	O
SGA	NNP	O
children	NNS	O
are	VBP	O
short	JJ	O
at	IN	O
the	DT	O
start	NN	O
of	IN	O
puberty	NN	O
,	,	O
they	PRP	O
can	MD	O
benefit	VB	O
from	IN	O
combined	JJ	O
GH/GnRHa	NNP	O
treatment	NN	O
.	.	O

The	DT	O
11-beta-hydroxysteroid	JJ	O
dehydrogenase	NN	O
type	NN	O
1	CD	O
inhibitor	NN	O
INCB13739	NNP	O
improves	VBZ	O
hyperglycemia	NN	O
in	IN	O
patients	NNS	O
with	IN	O
type	JJ	O
2	CD	O
diabetes	NNS	O
inadequately	RB	O
controlled	VBN	O
by	IN	O
metformin	NN	O
monotherapy	NN	O
.	.	O

OBJECTIVE	CC	O
11-Beta-hydroxysteroid	JJ	O
dehydrogenase	NN	O
type	NN	O
1	CD	O
(	(	O
11betaHSD1	CD	O
)	)	O
converts	NNS	O
inactive	JJ	O
cortisone	NN	O
into	IN	O
active	JJ	O
cortisol	NN	O
,	,	O
thereby	RB	O
amplifying	VBG	O
intracellular	JJ	O
glucocorticoid	JJ	O
action	NN	O
.	.	O

The	DT	O
efficacy	NN	O
and	CC	O
safety	NN	O
of	IN	O
the	DT	O
11betaHSD1	CD	O
inhibitor	NN	O
INCB13739	NNP	O
were	VBD	O
assessed	VBN	O
when	WRB	O
added	VBN	O
to	TO	O
ongoing	VBG	O
metformin	NN	O
monotherapy	NN	O
in	IN	O
patients	NNS	O
with	IN	O
type	JJ	O
2	CD	O
diabetes	NNS	O
exhibiting	VBG	O
inadequate	JJ	O
glycemic	NNS	O
control	NN	O
(	(	O
A1C	NNP	O
7-11	CD	O
%	NN	O
)	)	O
.	.	O

RESEARCH	NNP	O
DESIGN	NNP	O
AND	NNP	O
METHODS	NNP	O
This	DT	O
double-blind	JJ	O
placebo-controlled	JJ	O
paralleled	VBN	O
study	NN	O
randomized	VBD	O
302	CD	O
patients	NNS	O
with	IN	O
type	JJ	O
2	CD	O
diabetes	NNS	O
(	(	O
mean	JJ	O
A1C	NNP	O
8.3	CD	O
%	NN	O
)	)	O
on	IN	O
metformin	NN	O
monotherapy	NN	O
(	(	O
mean	JJ	O
1.5	CD	O
g/day	NN	O
)	)	O
to	TO	O
receive	VB	O
one	CD	O
of	IN	O
five	CD	O
INCB13739	NNP	O
doses	NNS	O
or	CC	O
placebo	NN	O
once	RB	O
daily	JJ	O
for	IN	O
12	CD	O
weeks	NNS	O
.	.	O

The	DT	O
primary	JJ	O
end	NN	O
point	NN	O
was	VBD	O
the	DT	O
change	NN	O
in	IN	O
A1C	NNP	O
at	IN	O
study	JJ	O
end	NN	O
.	.	O

Other	JJ	O
end	NN	O
points	NNS	O
included	VBD	O
changes	NNS	O
in	IN	O
fasting	VBG	O
glucose	NN	O
,	,	O
lipids	NNS	O
,	,	O
weight	NN	O
,	,	O
adverse	JJ	O
events	NNS	O
,	,	O
and	CC	O
safety	NN	O
.	.	O

RESULTS	NNP	O
After	IN	O
12	CD	O
weeks	NNS	O
,	,	O
200	CD	O
mg	NN	O
of	IN	O
INCB13739	NNP	O
resulted	VBD	O
in	IN	O
significant	JJ	O
reductions	NNS	O
in	IN	O
A1C	NNP	O
(	(	O
-0.6	NNP	O
%	NN	O
)	)	O
,	,	O
fasting	VBG	O
plasma	NN	O
glucose	NN	O
(	(	O
-24	NNP	O
mg/dl	NN	O
)	)	O
,	,	O
and	CC	O
homeostasis	NN	O
model	NN	O
assessment-insulin	JJ	O
resistance	NN	O
(	(	O
HOMA-IR	NNP	O
)	)	O
(	(	O
-24	CD	O
%	NN	O
)	)	O
compared	VBN	O
with	IN	O
placebo	NN	O
.	.	O

Total	JJ	O
cholesterol	NN	O
,	,	O
LDL	NNP	O
cholesterol	NN	O
,	,	O
and	CC	O
triglycerides	NNS	O
were	VBD	O
all	DT	O
significantly	RB	O
decreased	VBN	O
in	IN	O
hyperlipidemic	JJ	O
patients	NNS	O
.	.	O

Body	NNP	O
weight	VBD	O
decreased	JJ	O
relative	NN	O
to	TO	O
placebo	VB	O
after	IN	O
INCB13739	NNP	O
therapy	NN	O
.	.	O

A	DT	O
reversible	JJ	O
dose-dependent	JJ	O
elevation	NN	O
in	IN	O
adrenocorticotrophic	JJ	O
hormone	NN	O
,	,	O
generally	RB	O
within	IN	O
the	DT	O
normal	JJ	O
reference	NN	O
range	NN	O
,	,	O
was	VBD	O
observed	VBN	O
.	.	O

Basal	NNP	O
cortisol	JJ	O
homeostasis	NN	O
,	,	O
testosterone	NN	O
in	IN	O
men	NNS	O
,	,	O
and	CC	O
free	JJ	O
androgen	NN	O
index	NN	O
in	IN	O
women	NNS	O
were	VBD	O
unchanged	JJ	O
by	IN	O
INCB13739	NNP	O
.	.	O

Adverse	JJ	O
events	NNS	O
were	VBD	O
similar	JJ	O
across	IN	O
all	DT	O
treatment	NN	O
groups	NNS	O
.	.	O

CONCLUSIONS	NNP	O
INCB13739	NNP	O
added	VBD	O
to	TO	O
ongoing	VBG	O
metformin	NN	O
therapy	NN	O
was	VBD	O
efficacious	JJ	O
and	CC	O
well	RB	O
tolerated	VBN	O
in	IN	O
patients	NNS	O
with	IN	O
type	JJ	O
2	CD	O
diabetes	NNS	O
who	WP	O
had	VBD	O
inadequate	JJ	O
glycemic	NNS	O
control	NN	O
with	IN	O
metformin	NN	O
alone	RB	O
.	.	O

11BetaHSD1	CD	O
inhibition	NN	O
offers	NNS	O
a	DT	O
new	JJ	O
potential	JJ	O
approach	NN	O
to	TO	O
control	VB	O
glucose	JJ	O
and	CC	O
cardiovascular	JJ	O
risk	NN	O
factors	NNS	O
in	IN	O
type	NN	O
2	CD	O
diabetes	NNS	O
.	.	O

Effect	NN	O
of	IN	O
allopurinol	NN	O
on	IN	O
myocardial	JJ	O
oxygen	NN	O
free	JJ	O
radical	JJ	O
production	NN	O
in	IN	O
coronary	JJ	O
bypass	NN	O
surgery	NN	O
.	.	O

OBJECTIVES	NNP	O
Allopurinol	NNP	O
protects	VBZ	O
the	DT	O
heart	NN	O
from	IN	O
reperfusion	NN	O
injury	NN	O
.	.	O

The	DT	O
aim	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
investigate	VB	O
myocardial	JJ	O
free	JJ	O
radical	JJ	O
production	NN	O
during	IN	O
reperfusion	NN	O
with	IN	O
and	CC	O
without	IN	O
allopurinol	JJ	O
treatment	NN	O
in	IN	O
coronary	JJ	C
artery	NN	C
bypass	NN	C
grafting	VBG	C
patients	NNS	O
randomized	VBN	O
into	IN	O
allopurinol	NN	O
(	(	O
n	JJ	O
=	NNP	O
14	CD	SS
)	)	O
or	CC	O
placebo	NN	O
(	(	O
n	JJ	O
=	NNP	O
13	CD	SS
)	)	O
groups	NNS	O
.	.	O

DESIGN	NNP	O
Allopurinol	NNP	O
(	(	O
1	CD	O
g	NN	O
)	)	O
was	VBD	O
given	VBN	O
blind	RB	O
prior	JJ	O
to	TO	O
cardiopulmonary	JJ	O
bypass	NN	O
and	CC	O
prior	JJ	O
to	TO	O
opening	VBG	O
the	DT	O
aorta	NN	O
.	.	O

Oxygen	NNP	O
free	JJ	O
radicals	NNS	O
were	VBD	O
measured	VBN	O
before	IN	O
anesthesia	NN	O
in	IN	O
arterial	JJ	O
blood	NN	O
,	,	O
before	IN	O
cross-clamping	JJ	O
and	CC	O
1	CD	O
and	CC	O
10	CD	O
min	NN	O
after	IN	O
reperfusion	NN	O
in	IN	O
arterial	JJ	O
and	CC	O
coronary	JJ	O
sinus	NN	O
blood	NN	O
.	.	O

Levels	NNS	O
were	VBD	O
measured	VBN	O
as	IN	O
relative	JJ	O
concentrations	NNS	O
by	IN	O
the	DT	O
electron	NN	O
spin	NN	O
resonance	NN	O
method	NN	O
.	.	O

RESULTS	NNP	O
One	CD	O
minute	NN	O
after	IN	O
reperfusion	NN	O
the	DT	O
level	NN	O
of	IN	O
spin-trapped	JJ	O
radicals	NNS	O
in	IN	O
arterial	JJ	O
blood	NN	O
was	VBD	O
elevated	VBN	O
significantly	RB	O
(	(	O
p	JJ	O
=	NNP	O
0.016	CD	O
)	)	O
in	IN	O
the	DT	O
allopurinol	NN	O
group	NN	O
,	,	O
from	IN	O
7.7	CD	O
(	(	O
SE	NNP	O
:	:	O
0.8	CD	O
)	)	O
to	TO	O
8.6	CD	O
(	(	O
1.4	CD	O
)	)	O
and	CC	O
non-significantly	RB	O
(	(	O
p	JJ	O
=	NNP	O
0.074	CD	O
)	)	O
in	IN	O
the	DT	O
placebo	NN	O
group	NN	O
,	,	O
from	IN	O
7.3	CD	O
(	(	O
0.7	CD	O
)	)	O
to	TO	O
8.3	CD	O
(	(	O
0.8	CD	O
)	)	O
.	.	O

Ten	CD	O
minutes	NNS	O
after	IN	O
reperfusion	NN	O
the	DT	O
arterial	JJ	O
values	NNS	O
were	VBD	O
8.6	CD	O
(	(	O
1.5	CD	O
)	)	O
in	IN	O
the	DT	O
allopurinol	NN	O
and	CC	O
7.6	CD	O
(	(	O
0.7	CD	O
)	)	O
in	IN	O
the	DT	O
placebo	NN	O
group	NN	O
,	,	O
the	DT	O
sinus	NN	O
values	NNS	O
being	VBG	O
7.6	CD	O
(	(	O
1.3	CD	O
)	)	O
and	CC	O
8.3	CD	O
(	(	O
0.8	CD	O
)	)	O
,	,	O
respectively	RB	O
.	.	O

Myocardial	NNP	O
free	JJ	O
radical	JJ	O
production	NN	O
was	VBD	O
-0.94	NNP	O
(	(	O
1.21	CD	O
)	)	O
in	IN	O
the	DT	O
allopurinol	NN	O
and	CC	O
+0.79	NNP	O
(	(	O
0.96	CD	O
)	)	O
in	IN	O
the	DT	O
placebo	NN	O
group	NN	O
after	IN	O
10	CD	O
min	JJ	O
reperfusion	NN	O
,	,	O
the	DT	O
difference	NN	O
being	VBG	O
significant	JJ	O
(	(	O
p	JJ	O
=	NNP	O
0.043	CD	O
)	)	O
.	.	O

CONCLUSIONS	NNP	O
All	DT	O
patients	NNS	O
in	IN	O
both	DT	O
groups	NNS	O
had	VBD	O
an	DT	O
increasing	VBG	O
tendency	NN	O
to	TO	O
free	JJ	O
radical	JJ	O
production	NN	O
during	IN	O
early	JJ	O
reperfusion	NN	O
.	.	O

Patients	NNS	O
treated	VBD	O
with	IN	O
allopurinol	NN	O
showed	VBD	O
less	RBR	O
myocardial	JJ	O
production	NN	O
of	IN	O
free	JJ	O
radicals	NNS	O
,	,	O
indicating	VBG	O
that	IN	O
its	PRP$	O
protective	JJ	O
effect	NN	O
may	MD	O
be	VB	O
due	JJ	O
to	TO	O
its	PRP$	O
antioxidative	JJ	O
properties	NNS	O
.	.	O

Early	RB	O
versus	NN	O
late	JJ	O
hCG	NN	O
administration	NN	O
to	TO	O
trigger	VB	O
ovulation	NN	O
in	IN	O
mild	NN	O
stimulated	VBN	O
IUI	NNP	O
cycles	NNS	O
:	:	O
a	DT	O
randomized	JJ	O
clinical	JJ	O
trial	NN	O
.	.	O

OBJECTIVES	UH	O
To	TO	O
verify	VB	O
non-inferiority	NN	O
of	IN	O
the	DT	O
clinical	JJ	O
pregnancy	NN	O
rate	NN	O
of	IN	O
Early	NNP	O
hCG	NN	O
administration	NN	O
(	(	O
leading	VBG	O
follicle	NN	O
sizes	NNS	O
within	IN	O
16.0-16.9	JJ	O
mm	NN	O
in	IN	O
diameter	NN	O
)	)	O
compared	VBN	O
to	TO	O
Late	NNP	O
hCG	NN	O
administration	NN	O
(	(	O
leading	VBG	O
follicle	NN	O
sizes	NNS	O
within	IN	O
18.0-18.9	JJ	O
mm	NN	O
in	IN	O
diameter	NN	O
)	)	O
.	.	O

STUDY	NNP	O
DESIGN	NNP	O
Prospective	NNP	O
randomized	VBD	O
trial	NN	O
.	.	O

Six	CD	O
hundred	CD	O
and	CC	O
twelve	VB	O
infertile	JJ	O
women	NNS	O
candidates	NNS	O
for	IN	O
intrauterine	JJ	O
insemination	NN	O
(	(	O
IUI	NNP	O
)	)	O
received	VBD	O
HP-hMG	JJ	O
75	CD	O
IU/day	NNP	O
SC	NNP	O
from	IN	O
cycle	NN	O
days	NNS	O
4	CD	O
to	TO	O
8	CD	O
and	CC	O
then	RB	O
as	IN	O
per	IN	O
ovarian	JJ	O
response	NN	O
.	.	O

Ovulation	NN	O
was	VBD	O
randomly	RB	O
triggered	VBN	O
(	(	O
hCG	JJ	O
5000	CD	O
IU	NNP	O
,	,	O
IM	NNP	O
)	)	O
when	WRB	O
the	DT	O
leading	VBG	O
follicle	NN	O
diameter	NN	O
ranged	VBD	O
between	IN	O
either	CC	O
16.0	CD	O
and	CC	O
16.9	CD	O
mm	NN	O
(	(	O
Early	JJ	O
hCG	NN	O
group	NN	O
,	,	O
n=227	RB	O
)	)	O
or	CC	O
18.0	CD	O
and	CC	O
18.9	CD	O
mm	NNS	O
(	(	O
Late	JJ	O
hCG	NN	O
group	NN	O
,	,	O
n=207	NN	O
)	)	O
and	CC	O
IUI	NNP	O
was	VBD	O
performed	VBN	O
approximately	RB	O
36	CD	O
h	NN	O
later	RB	O
.	.	O

RESULTS	NNP	O
Whereas	NNP	O
population	NN	O
and	CC	O
sperm	JJ	O
characteristics	NNS	O
were	VBD	O
comparable	JJ	O
in	IN	O
both	DT	O
groups	NNS	O
,	,	O
the	DT	O
number	NN	O
of	IN	O
follicles	NNS	O
?	.	O
14	CD	O
mm	NN	O
in	IN	O
diameter	NN	O
(	(	O
P	NNP	O
<	NNP	O
0.007	CD	O
)	)	O
and	CC	O
serum	JJ	O
estradiol	NN	O
levels	NNS	O
(	(	O
P	NNP	O
<	NNP	O
0.001	CD	O
)	)	O
on	IN	O
the	DT	O
day	NN	O
of	IN	O
hCG	NN	O
were	VBD	O
lower	JJR	O
in	IN	O
the	DT	O
Early	JJ	O
versus	NN	O
the	DT	O
Late	NNP	O
hCG	NN	O
groups	NNS	O
.	.	O

Clinical	NNP	O
(	(	O
11.9	CD	O
%	NN	O
versus	IN	O
12.1	CD	O
%	NN	O
)	)	O
and	CC	O
ongoing	VBG	O
(	(	O
11.0	CD	O
%	NN	O
versus	IN	O
8.6	CD	O
%	NN	O
)	)	O
pregnancy	NN	O
rates	NNS	O
per	IN	O
randomized	VBN	O
women	NNS	O
were	VBD	O
similar	JJ	O
in	IN	O
the	DT	O
two	CD	O
groups	NNS	O
and	CC	O
statistical	JJ	O
non-inferiority	NN	O
of	IN	O
clinical	JJ	O
and	CC	O
ongoing	JJ	O
pregnancy	NN	O
rates	NNS	O
was	VBD	O
demonstrated	VBN	O
.	.	O

CONCLUSION	NNP	O
These	DT	O
results	NNS	O
suggest	VBP	O
that	IN	O
hCG	NN	O
administered	VBD	O
when	WRB	O
the	DT	O
largest	JJS	O
follicle	NN	O
size	NN	O
reaches	VBZ	O
16.0-16.9	JJ	O
mm	NN	O
leads	VBZ	O
to	TO	O
similar	JJ	O
clinical	JJ	O
and	CC	O
ongoing	JJ	O
pregnancy	NN	O
rates	NNS	O
as	IN	O
when	WRB	O
it	PRP	O
reaches	VBZ	O
18.0-18.9	JJ	O
mm	NN	O
in	IN	O
IUI	NNP	O
cycles	NNS	O
.	.	O

Avatar	NNP	O
assistant	NN	O
:	:	O
improving	VBG	O
social	JJ	O
skills	NNS	O
in	IN	O
students	NNS	C
with	IN	C
an	DT	C
ASD	NNP	C
through	IN	O
a	DT	O
computer-based	JJ	O
intervention	NN	O
.	.	O

This	DT	O
study	NN	O
assessed	VBD	O
the	DT	O
efficacy	NN	O
of	IN	O
FaceSay	NNP	O
,	,	O
a	DT	O
computer-based	JJ	O
social	JJ	O
skills	NNS	O
training	VBG	O
program	NN	O
for	IN	O
children	NNS	O
with	IN	O
Autism	NNP	O
Spectrum	NNP	O
Disorders	NNP	O
(	(	O
ASD	NNP	O
)	)	O
.	.	O

This	DT	O
randomized	VBD	O
controlled	VBN	O
study	NN	O
(	(	O
N	NNP	O
=	NNP	O
49	CD	O
)	)	O
indicates	VBZ	O
that	IN	O
providing	VBG	O
children	NNS	O
with	IN	O
low-functioning	JJ	O
autism	NN	O
(	(	O
LFA	NNP	O
)	)	O
and	CC	O
high	JJ	O
functioning	NN	O
autism	NN	O
(	(	O
HFA	NNP	O
)	)	O
opportunities	VBZ	O
to	TO	O
practice	NN	O
attending	VBG	O
to	TO	O
eye	NN	O
gaze	NN	O
,	,	O
discriminating	VBG	O
facial	JJ	O
expressions	NNS	O
and	CC	O
recognizing	VBG	O
faces	VBZ	O
and	CC	O
emotions	NNS	O
in	IN	O
FaceSay	NNP	O
's	POS	O
structured	JJ	O
environment	NN	O
with	IN	O
interactive	JJ	O
,	,	O
realistic	JJ	O
avatar	NN	O
assistants	NNS	O
improved	VBD	O
their	PRP$	O
social	JJ	O
skills	NNS	O
abilities	NNS	O
.	.	O

The	DT	O
children	NNS	O
with	IN	O
LFA	NNP	O
demonstrated	VBD	O
improvements	NNS	O
in	IN	O
two	CD	O
areas	NNS	O
of	IN	O
the	DT	O
intervention	NN	O
:	:	O
emotion	NN	O
recognition	NN	O
and	CC	O
social	JJ	O
interactions	NNS	O
.	.	O

The	DT	O
children	NNS	O
with	IN	O
HFA	NNP	O
demonstrated	VBD	O
improvements	NNS	O
in	IN	O
all	DT	O
three	CD	O
areas	NNS	O
:	:	O
facial	JJ	O
recognition	NN	O
,	,	O
emotion	NN	O
recognition	NN	O
,	,	O
and	CC	O
social	JJ	O
interactions	NNS	O
.	.	O

These	DT	O
findings	NNS	O
,	,	O
particularly	RB	O
the	DT	O
measured	JJ	O
improvements	NNS	O
to	TO	O
social	JJ	O
interactions	NNS	O
in	IN	O
a	DT	O
natural	JJ	O
environment	NN	O
,	,	O
are	VBP	O
encouraging	VBG	O
.	.	O

Effects	NNS	O
of	IN	O
creatine	JJ	O
supplementation	NN	O
on	IN	O
repetitive	JJ	O
sprint	NN	O
performance	NN	O
and	CC	O
body	NN	O
composition	NN	O
in	IN	O
competitive	JJ	O
swimmers	NNS	O
.	.	O

In	IN	O
a	DT	O
double-blind	NN	O
and	CC	O
randomized	JJ	O
manner	NN	O
,	,	O
18	CD	O
male	NN	O
and	CC	O
female	JJ	O
junior	JJ	O
competitive	JJ	O
swimmers	NNS	O
supplemented	VBD	O
their	PRP$	O
diets	NNS	O
with	IN	O
21	CD	O
g.day-1	NN	O
of	IN	O
creatine	NN	O
monohydrate	NN	O
(	(	O
Cr	NNP	O
)	)	O
or	CC	O
a	DT	O
maltodextrin	JJ	O
placebo	NN	O
(	(	O
P	NNP	O
)	)	O
for	IN	O
9	CD	O
days	NNS	O
during	IN	O
training	NN	O
.	.	O

Prior	NNP	O
to	TO	O
and	CC	O
following	VBG	O
supplementation	NN	O
,	,	O
subjects	NNS	O
performed	VBD	O
three	CD	O
100-m	JJ	O
freestyle	JJ	O
sprint	NN	O
swims	NNS	O
(	(	O
long	JJ	O
course	NN	O
)	)	O
with	IN	O
60	CD	O
s	JJ	O
rest/recovery	NN	O
between	IN	O
heats	NNS	O
.	.	O

In	IN	O
addition	NN	O
,	,	O
subjects	NNS	O
performed	VBD	O
three	CD	O
20-s	JJ	O
arm	NN	O
ergometer	NN	O
maximal-effort	JJ	O
sprint	NN	O
tests	NNS	O
in	IN	O
the	DT	O
prone	NN	O
position	NN	O
with	IN	O
60	CD	O
s	JJ	O
rest/recovery	NN	O
between	IN	O
sprint	NN	O
tests	NNS	O
.	.	O

Significant	JJ	O
differences	NNS	O
were	VBD	O
observed	VBN	O
among	IN	O
swim	JJ	O
times	NNS	O
,	,	O
with	IN	O
Cr	NNP	O
subjects	NNS	O
swimming	VBG	O
significantly	RB	O
faster	RBR	O
than	IN	O
P	NNP	O
subjects	NNS	O
following	VBG	O
supplementation	NN	O
in	IN	O
Heat	NNP	O
1	CD	O
and	CC	O
significantly	RB	O
decreasing	VBG	O
swim	JJ	O
time	NN	O
in	IN	O
the	DT	O
second	JJ	O
100-m	JJ	O
sprint	NN	O
.	.	O

There	EX	O
was	VBD	O
also	RB	O
some	DT	O
evidence	NN	O
that	IN	O
cumulative	JJ	O
time	NN	O
to	TO	O
perform	VB	O
the	DT	O
three	CD	O
100-m	JJ	O
swims	NNS	O
was	VBD	O
decreased	VBN	O
in	IN	O
the	DT	O
Cr	NNP	O
group	NN	O
.	.	O

Results	NNP	O
indicate	VBP	O
that	IN	O
9	CD	O
days	NNS	O
of	IN	O
Cr	NNP	O
supplementation	NN	O
during	IN	O
swim	JJ	O
training	NN	O
may	MD	O
provide	VB	O
some	DT	O
ergogenic	JJ	O
value	NN	O
to	TO	O
competitive	JJ	O
junior	JJ	O
swimmers	NNS	O
during	IN	O
repetitive	JJ	O
sprint	NN	O
performance	NN	O
.	.	O

[	JJ	O
Myocardial	NNP	O
ischemia	NN	O
with	IN	O
stable	JJ	O
angina	JJ	O
pectoris	NN	O
:	:	O
clinico-ergometric	JJ	O
evaluation	NN	O
after	IN	O
the	DT	O
use	NN	O
of	IN	O
diltiazem	NN	O
]	NN	O
.	.	O

PURPOSE	NNP	O
To	TO	O
evaluate	VB	O
the	DT	O
efficacy	NN	O
of	IN	O
diltiazem	JJ	O
versus	NN	O
placebo	NN	O
in	IN	O
patients	NNS	O
with	IN	O
stable	JJ	C
angina	NN	C
.	.	O

METHODS	NNP	O
Eight-seven	JJ	SS
angina	NNS	O
pectoris	JJ	O
patients	NNS	O
,	,	O
mean	JJ	A
age	NN	A
of	IN	A
57	CD	A
+/-	JJ	A
9	CD	A
,	,	O
82	CD	O
white	JJ	O
and	CC	O
79	CD	SE
male	NN	SE
were	VBD	O
evaluated	VBN	O
in	IN	O
a	DT	O
randomized	JJ	O
,	,	O
double-blind	JJ	O
trial	NN	O
of	IN	O
two	CD	O
groups	NNS	O
of	IN	O
patients	NNS	O
diltiazem	JJ	O
and	CC	O
placebo	NN	O
,	,	O
3	CD	O
to	TO	O
4	CD	O
tablets	NNS	O
a	DT	O
day	NN	O
(	(	O
diltiazem	JJ	O
180	CD	O
to	TO	O
240	CD	O
mg	NNS	O
daily	RB	O
)	)	O
.	.	O

The	DT	O
patients	NNS	O
were	VBD	O
evaluated	VBN	O
after	IN	O
laboratory	NN	O
tests	NNS	O
and	CC	O
clinical-ergometric	JJ	O
examinations	NNS	O
.	.	O

A	DT	O
coronary	JJ	O
arteriography	NN	O
was	VBD	O
performed	VBN	O
on	IN	O
study	NN	O
entry	NN	O
.	.	O

RESULTS	VB	O
The	DT	O
average	NN	O
of	IN	O
anginal	JJ	O
attacks	NNS	O
,	,	O
number	NN	O
of	IN	O
weekly	JJ	O
sublingual	JJ	O
nitrate	NN	O
,	,	O
heart	NN	O
rate	NN	O
,	,	O
systolic	JJ	O
and	CC	O
diastolic	JJ	O
pressure	NN	O
at	IN	O
rest	NN	O
and	CC	O
at	IN	O
the	DT	O
end	NN	O
of	IN	O
diltiazem	JJ	O
period	NN	O
were	VBD	O
significantly	RB	O
lower	JJR	O
(	(	O
p	JJ	O
<	NNP	O
0.05	CD	O
)	)	O
regarding	VBG	O
same	JJ	O
periods	NNS	O
on	IN	O
placebo	NN	O
.	.	O

The	DT	O
percentage	NN	O
of	IN	O
depression	NN	O
for	IN	O
ST-segment	NNP	O
was	VBD	O
lower	JJR	O
for	IN	O
diltiazem	NN	O
when	WRB	O
compared	VBN	O
with	IN	O
placebo	NN	O
(	(	O
p	JJ	O
<	NNP	O
0.05	CD	O
)	)	O
and	CC	O
the	DT	O
percentage	NN	O
of	IN	O
patients	NNS	O
that	WDT	O
reach	VBP	O
higher	JJR	O
stages	NNS	O
in	IN	O
the	DT	O
ergometric	JJ	O
test	NN	O
was	VBD	O
significantly	RB	O
better	JJR	O
for	IN	O
diltiazem	NN	O
.	.	O

Heart	NNP	O
rate	NN	O
and	CC	O
systolic	JJ	O
plus	CC	O
diastolic	JJ	O
pressures	NNS	O
after	IN	O
exercise	NN	O
did	VBD	O
not	RB	O
differ	VB	O
in	IN	O
both	DT	O
groups	NNS	O
.	.	O

CONCLUSION	NNP	O
Diltiazem	NNP	O
reduced	VBD	O
the	DT	O
clinical	JJ	O
and	CC	O
electrocardiographical	JJ	O
aspects	NNS	O
and	CC	O
raises	VBZ	O
the	DT	O
effort	NN	O
tolerance	NN	O
during	IN	O
the	DT	O
ergometric	JJ	O
test	NN	O
in	IN	O
patients	NNS	O
with	IN	O
stable	JJ	O
angina	NN	O
.	.	O

Application	NN	O
of	IN	O
ambulatory	JJ	O
blood	NN	O
pressure	NN	O
monitoring	NN	O
to	TO	O
clinical	JJ	O
therapeutic	JJ	O
decisions	NNS	O
in	IN	O
hypertension	NN	O
.	.	O

The	DT	O
antihypertensive	JJ	O
efficacies	NNS	O
of	IN	O
lisinopril	NN	O
and	CC	O
captopril	NN	O
were	VBD	O
compared	VBN	O
using	VBG	O
office	NN	O
sphygmomanometry	NN	O
and	CC	O
24-h	JJ	O
ambulatory	NN	O
blood	NN	O
pressure	NN	O
monitoring	NN	O
.	.	O

In	IN	O
a	DT	O
double-blind	NN	O
,	,	O
prospective	JJ	O
,	,	O
randomly	RB	O
allocated	VBN	O
trial	NN	O
,	,	O
the	DT	O
patients	NNS	O
were	VBD	O
given	VBN	O
increasing	VBG	O
doses	NNS	O
of	IN	O
captopril	NN	O
at	IN	O
25-100	JJ	O
mg	NN	O
twice	RB	O
a	DT	O
day	NN	O
or	CC	O
lisinopril	NN	O
at	IN	O
10-40	JJ	O
mg	NN	O
once	IN	O
a	DT	O
day	NN	O
until	IN	O
a	DT	O
clinical	JJ	O
response	NN	O
was	VBD	O
achieved	VBN	O
or	CC	O
the	DT	O
highest	JJS	O
dose	NN	O
was	VBD	O
reached	VBN	O
.	.	O

A	DT	O
response	NN	O
was	VBD	O
defined	VBN	O
as	IN	O
a	DT	O
reduction	NN	O
in	IN	O
diastolic	JJ	O
pressure	NN	O
below	IN	O
90	CD	O
mmHg	NN	O
or	CC	O
a	DT	O
fall	NN	O
of	IN	O
at	IN	O
least	JJS	O
10	CD	O
mmHg	NN	O
from	IN	O
baseline	NN	O
.	.	O

The	DT	O
ambulatory	NN	O
monitoring	NN	O
showed	VBD	O
that	IN	O
lisinopril	NN	O
reduced	VBD	O
blood	NN	O
pressure	NN	O
from	IN	O
baseline	NN	O
to	TO	O
the	DT	O
final	JJ	O
value	NN	O
and	CC	O
maintained	VBD	O
the	DT	O
reduction	NN	O
to	TO	O
a	DT	O
greater	JJR	O
degree	NN	O
than	IN	O
captopril	NN	O
throughout	IN	O
24-h	JJ	O
periods	NNS	O
of	IN	O
observation	NN	O
.	.	O

The	DT	O
office	NN	O
measurements	NNS	O
showed	VBD	O
a	DT	O
similar	JJ	O
trend	NN	O
,	,	O
but	CC	O
the	DT	O
intertreatment	JJ	O
differences	NNS	O
did	VBD	O
not	RB	O
reach	VB	O
statistical	JJ	O
significance	NN	O
.	.	O

No	DT	O
first-dose	JJ	O
side	NN	O
effects	NNS	O
were	VBD	O
observed	VBN	O
with	IN	O
either	DT	O
drug	NN	O
.	.	O

Once	IN	O
a	DT	O
day	NN	O
lisinopril	NN	O
appeared	VBD	O
to	TO	O
be	VB	O
a	DT	O
more	RBR	O
effective	JJ	O
antihypertensive	JJ	O
regimen	NNS	O
than	IN	O
twice	RB	O
a	DT	O
day	NN	O
captopril	NN	O
.	.	O

Comparison	NNP	O
of	IN	O
nitinol	JJ	O
tipless	NN	O
stone	NN	O
baskets	NNS	O
in	IN	O
an	DT	O
in	IN	O
vitro	JJ	O
caliceal	NN	O
model	NN	O
.	.	O

PURPOSE	NNP	O
Tipless	NNP	O
stone	NN	O
baskets	NNS	O
facilitate	VBP	O
caliceal	JJ	O
calculi	JJ	O
extraction	NN	O
during	IN	O
flexible	JJ	O
ureteroscopy	NN	O
.	.	O

We	PRP	O
evaluated	VBD	O
the	DT	O
stone	NN	O
capture	NN	O
rate	NN	O
of	IN	O
9	CD	O
commercially	RB	O
available	JJ	O
tipless	NN	O
stone	NN	O
baskets	NNS	O
in	IN	O
an	DT	O
in	IN	O
vitro	NN	O
model	NN	O
using	VBG	O
novice	NN	O
and	CC	O
expert	NN	O
operators	NNS	O
.	.	O

MATERIALS	NNP	O
AND	CC	O
METHODS	NNP	O
The	DT	O
Microvasive	NNP	O
Zerotip	NNP	O
(	(	O
2.4Fr	CD	O
,	,	O
3.0Fr	CD	O
)	)	O
,	,	O
Cook	NNP	O
N-Circle	NNP	O
(	(	O
2.2Fr	CD	O
,	,	O
3.0Fr	CD	O
,	,	O
3.2Fr	CD	O
)	)	O
,	,	O
Bard	NNP	O
Dimension	NNP	O
(	(	O
3.0Fr	CD	O
,	,	O
Sacred	NNP	O
Heart	NNP	O
Medical	NNP	O
Halo	NNP	O
(	(	O
1.9Fr	CD	O
)	)	O
,	,	O
Vantage	NNP	O
(	(	O
1.9Fr	CD	O
)	)	O
and	CC	O
Circon-ACMI	JJ	O
Sur-Catch-NT	NNP	O
(	(	O
3.0Fr	CD	O
)	)	O
were	VBD	O
tested	VBN	O
by	IN	O
3	CD	O
novice	NNS	O
and	CC	O
3	CD	O
experienced	VBD	O
basket	NN	O
operators	NNS	O
.	.	O

Each	DT	O
operator	NN	O
performed	VBD	O
stone	JJ	O
extraction	NN	O
of	IN	O
2	CD	O
,	,	O
5	CD	O
and	CC	O
8	CD	O
mm	NN	O
calculi	NN	O
(	(	O
size	NN	O
determined	VBN	O
by	IN	O
digital	JJ	O
caliper	NN	O
with	IN	O
3	CD	O
repetitions	NNS	O
of	IN	O
each	DT	O
basket	NN	O
.	.	O

The	DT	O
time	NN	O
to	TO	O
extraction	NN	O
of	IN	O
the	DT	O
calculus	NN	O
from	IN	O
a	DT	O
convex	NN	O
based	VBN	O
test	NN	O
tube	NN	O
caliceal	NN	O
model	NN	O
was	VBD	O
recorded	VBN	O
.	.	O

Statistical	JJ	O
analysis	NN	O
was	VBD	O
performed	VBN	O
using	VBG	O
repeated	JJ	O
measures	NNS	O
ANOVA	NNP	O
and	CC	O
Fisher	NNP	O
's	POS	O
pairwise	NN	O
comparisons	NNS	O
.	.	O

RESULTS	NNP	O
After	IN	O
a	DT	O
learning	JJ	O
curve	NN	O
of	IN	O
27	CD	O
basket	NN	O
retrievals	NNS	O
,	,	O
there	EX	O
was	VBD	O
no	DT	O
significant	JJ	O
difference	NN	O
in	IN	O
stone	NN	O
capture	NN	O
times	NNS	O
between	IN	O
novice	NN	O
(	(	O
38	CD	O
+/-	JJ	O
54	CD	O
seconds	NNS	O
)	)	O
and	CC	O
expert	JJ	O
operators	NNS	O
(	(	O
32	CD	O
+/-	JJ	O
49	CD	O
seconds	NNS	O
,	,	O
p	NN	O
=	NNP	O
0.174	CD	O
)	)	O
.	.	O

For	IN	O
total	JJ	O
stone	NN	O
capture	NN	O
(	(	O
all	DT	O
sizes	NNS	O
)	)	O
the	DT	O
Sacred	NNP	O
Heart	NNP	O
Halo	NNP	O
resulted	VBD	O
in	IN	O
the	DT	O
most	RBS	O
rapid	JJ	O
stone	NN	O
extraction	NN	O
(	(	O
17	CD	O
+/-	JJ	O
14	CD	O
seconds	NNS	O
)	)	O
by	IN	O
novices	NNS	O
and	CC	O
experts	NNS	O
,	,	O
while	IN	O
the	DT	O
Sur-Catch	NNP	O
NT	NNP	O
resulted	VBD	O
in	IN	O
the	DT	O
slowest	JJS	O
stone	NN	O
extraction	NN	O
(	(	O
78	CD	O
+/-	JJ	O
90	CD	O
,	,	O
seconds	NNS	O
,	,	O
p	NN	O
=	NNP	O
0.001	CD	O
)	)	O
.	.	O

The	DT	O
Halo	NNP	O
(	(	O
14	CD	O
+/-	JJ	O
9	CD	O
seconds	NNS	O
)	)	O
and	CC	O
Vantage	NNP	O
(	(	O
19	CD	O
+/-	JJ	O
12	CD	O
seconds	NNS	O
)	)	O
baskets	NNS	O
were	VBD	O
significantly	RB	O
faster	JJR	O
for	IN	O
2	CD	O
mm	NNS	O
calculi	NN	O
than	IN	O
the	DT	O
N-Circle	NNP	O
(	(	O
73	CD	O
+/-	JJ	O
60	CD	O
seconds	NNS	O
,	,	O
p	NN	O
=	NNP	O
0.006	CD	O
)	)	O
,	,	O
Sur-Catch	NNP	O
(	(	O
169	CD	O
+/-	JJ	O
85	CD	O
seconds	NNS	O
,	,	O
p	NN	O
=	NNP	O
0.0005	CD	O
)	)	O
and	CC	O
Dimension	NNP	O
(	(	O
73	CD	O
+/-	JJ	O
70	CD	O
seconds	NNS	O
,	,	O
p	NN	O
=	NNP	O
0.017	CD	O
)	)	O
.	.	O

The	DT	O
Zerotip	NNP	O
functioned	VBD	O
well	RB	O
for	IN	O
2	CD	O
mm	NNS	O
calculi	NN	O
in	IN	O
the	DT	O
hands	NNS	O
of	IN	O
expert	NN	O
operators	NNS	O
(	(	O
15	CD	O
+/-	JJ	O
9	CD	O
seconds	NNS	O
)	)	O
but	CC	O
not	RB	O
novice	JJ	O
operators	NNS	O
(	(	O
94	CD	O
+/-	JJ	O
95	CD	O
seconds	NNS	O
)	)	O
.	.	O

The	DT	O
Sur-Catch	JJ	O
NT	NNP	O
was	VBD	O
significantly	RB	O
slower	JJR	O
for	IN	O
2	CD	O
mm	NNS	O
calculi	NN	O
than	IN	O
the	DT	O
N-Circle	NNP	O
(	(	O
p	JJ	O
=	NNP	O
0.01	CD	O
)	)	O
,	,	O
Dimension	NNP	O
(	(	O
p	JJ	O
=.03	NN	O
)	)	O
,	,	O
Halo	NNP	O
(	(	O
p	JJ	O
=.0005	NN	O
)	)	O
,	,	O
Vantage	NNP	O
(	(	O
p	JJ	O
=.001	NN	O
)	)	O
and	CC	O
Zerotip	NNP	O
(	(	O
p	JJ	O
=.002	NN	O
)	)	O
.	.	O

For	IN	O
5	CD	O
mm	NNS	O
calculi	VBP	O
the	DT	O
Halo	NNP	O
was	VBD	O
superior	JJ	O
(	(	O
12	CD	O
+/-	JJ	O
8	CD	O
seconds	NNS	O
)	)	O
,	,	O
while	IN	O
the	DT	O
Zerotip	NNP	O
were	VBD	O
superior	JJ	O
for	IN	O
8	CD	O
mm	NNS	O
calculi	NN	O
(	(	O
8	CD	O
+/-	JJ	O
3	CD	O
seconds	NNS	O
)	)	O
compared	VBN	O
to	TO	O
the	DT	O
N-Circle	NNP	O
(	(	O
23	CD	O
+/-	JJ	O
28	CD	O
seconds	NNS	O
,	,	O
p	NN	O
=	NNP	O
0.026	CD	O
)	)	O
,	,	O
Halo	NNP	O
(	(	O
26	CD	O
+/-	JJ	O
18	CD	O
seconds	NNS	O
,	,	O
p	NN	O
=	NNP	O
0.021	CD	O
)	)	O
and	CC	O
Vantage	NNP	O
(	(	O
23	CD	O
+/-	JJ	O
15	CD	O
seconds	NNS	O
,	,	O
p	NN	O
=	NNP	O
0.006	CD	O
)	)	O
.	.	O

CONCLUSIONS	VB	O
The	DT	O
Sacred	NNP	O
Heart	NNP	O
Halo	NNP	O
and	CC	O
Vantage	NNP	O
baskets	NNS	O
resulted	VBD	O
in	IN	O
the	DT	O
most	RBS	O
expeditious	JJ	O
stone	NN	O
extraction	NN	O
,	,	O
especially	RB	O
for	IN	O
2	CD	O
to	TO	O
5	CD	O
mm	NNS	O
calculi	VBP	O
while	IN	O
the	DT	O
Microvasive	NNP	O
Zerotip	NNP	O
was	VBD	O
optimal	JJ	O
for	IN	O
8	CD	O
mm	NN	O
calculi	NN	O
.	.	O

The	DT	O
Sur-Catch	JJ	O
NT	NNP	O
had	VBD	O
the	DT	O
slowest	JJS	O
stone	JJ	O
capture	NN	O
rate	NN	O
for	IN	O
all	DT	O
stone	NN	O
sizes	VBZ	O
.	.	O

Caliceal	NNP	O
models	NNS	O
of	IN	O
stone	NN	O
basketing	NN	O
may	MD	O
be	VB	O
useful	JJ	O
to	TO	O
train	VB	O
novice	JJ	O
urology	NN	O
residents	NNS	O
and	CC	O
nursing	NN	O
assistants	NNS	O
.	.	O

Randomized	VBN	O
trial	NN	O
of	IN	O
liberal	JJ	O
versus	NN	O
restrictive	JJ	O
guidelines	NNS	O
for	IN	O
red	JJ	O
blood	NN	O
cell	NN	O
transfusion	NN	O
in	IN	O
preterm	JJ	O
infants	NNS	O
.	.	O

OBJECTIVE	NNP	O
Although	IN	O
many	JJ	O
centers	NNS	O
have	VBP	O
introduced	VBN	O
more	RBR	O
restrictive	JJ	O
transfusion	NN	O
policies	NNS	O
for	IN	O
preterm	JJ	O
infants	NNS	O
in	IN	O
recent	JJ	O
years	NNS	O
,	,	O
the	DT	O
benefits	NNS	O
and	CC	O
adverse	JJ	O
consequences	NNS	O
of	IN	O
allowing	VBG	O
lower	JJR	O
hematocrit	NN	O
levels	NNS	O
have	VBP	O
not	RB	O
been	VBN	O
systematically	RB	O
evaluated	VBN	O
.	.	O

The	DT	O
objective	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
determine	VB	O
if	IN	O
restrictive	JJ	O
guidelines	NNS	O
for	IN	O
red	JJ	O
blood	NN	O
cell	NN	O
(	(	O
RBC	NNP	O
)	)	O
transfusions	NNS	O
for	IN	O
preterm	JJ	O
infants	NNS	O
can	MD	O
reduce	VB	O
the	DT	O
number	NN	O
of	IN	O
transfusions	NNS	O
without	IN	O
adverse	JJ	O
consequences	NNS	O
.	.	O

DESIGN	NNP	O
,	,	O
SETTING	NNP	O
,	,	O
AND	NNP	O
PATIENTS	NNP	O
We	PRP	O
enrolled	VBD	O
100	CD	O
hospitalized	JJ	O
preterm	NN	O
infants	NNS	O
with	IN	O
birth	JJ	O
weights	NNS	O
of	IN	O
500	CD	O
to	TO	O
1300	CD	O
g	NN	O
into	IN	O
a	DT	O
randomized	JJ	O
clinical	JJ	O
trial	NN	O
comparing	VBG	O
2	CD	O
levels	NNS	O
of	IN	O
hematocrit	NN	O
threshold	NN	O
for	IN	O
RBC	NNP	O
transfusion	NN	O
.	.	O

INTERVENTION	NNP	O
The	DT	O
infants	NNS	O
were	VBD	O
assigned	VBN	O
randomly	RB	O
to	TO	O
either	VB	O
the	DT	O
liberal-	NN	O
or	CC	O
the	DT	O
restrictive-transfusion	NN	O
group	NN	O
.	.	O

For	IN	O
each	DT	O
group	NN	O
,	,	O
transfusions	NNS	O
were	VBD	O
given	VBN	O
only	RB	O
when	WRB	O
the	DT	O
hematocrit	NN	O
level	NN	O
fell	VBD	O
below	IN	O
the	DT	O
assigned	JJ	O
value	NN	O
.	.	O

In	IN	O
each	DT	O
group	NN	O
,	,	O
the	DT	O
transfusion	NN	O
threshold	NN	O
levels	NNS	O
decreased	VBN	O
with	IN	O
improving	VBG	O
clinical	JJ	O
status	NN	O
.	.	O

MAIN	NNP	O
OUTCOME	NNP	O
MEASURES	NNP	O
We	PRP	O
recorded	VBD	O
the	DT	O
number	NN	O
of	IN	O
transfusions	NNS	O
,	,	O
the	DT	O
number	NN	O
of	IN	O
donor	JJ	O
exposures	NNS	O
,	,	O
and	CC	O
various	JJ	O
clinical	JJ	O
and	CC	O
physiologic	JJ	O
outcomes	NNS	O
.	.	O

RESULTS	JJ	O
Infants	NNS	O
in	IN	O
the	DT	O
liberal-transfusion	NN	O
group	NN	O
received	VBD	O
more	JJR	O
RBC	JJ	O
transfusions	NNS	O
(	(	O
5.2	CD	O
+/-	JJ	O
4.5	CD	O
[	JJ	O
mean	JJ	O
+/-	JJ	O
SD	NNP	O
]	NNP	O
vs	VBD	O
3.3	CD	O
+/-	JJ	O
2.9	CD	O
in	IN	O
the	DT	O
restrictive-transfusion	NN	O
group	NN	O
)	)	O
.	.	O

However	RB	O
,	,	O
the	DT	O
number	NN	O
of	IN	O
donors	NNS	O
to	TO	O
whom	WP	O
the	DT	O
infants	NNS	O
were	VBD	O
exposed	VBN	O
was	VBD	O
not	RB	O
significantly	RB	O
different	JJ	O
(	(	O
2.8	CD	O
+/-	JJ	O
2.5	CD	O
vs	JJ	O
2.2	CD	O
+/-	JJ	O
2.0	CD	O
)	)	O
.	.	O

There	EX	O
was	VBD	O
no	DT	O
difference	NN	O
between	IN	O
the	DT	O
groups	NNS	O
in	IN	O
the	DT	O
percentage	NN	O
of	IN	O
infants	NNS	O
who	WP	O
avoided	VBD	O
transfusions	NNS	O
altogether	RB	O
(	(	O
12	CD	O
%	NN	O
in	IN	O
the	DT	O
liberal-transfusion	NN	O
group	NN	O
versus	VBD	O
10	CD	O
%	NN	O
in	IN	O
the	DT	O
restrictive-transfusion	NN	O
group	NN	O
)	)	O
.	.	O

Infants	NNS	O
in	IN	O
the	DT	O
restrictive-transfusion	NN	O
group	NN	O
were	VBD	O
more	RBR	O
likely	JJ	O
to	TO	O
have	VB	O
intraparenchymal	JJ	O
brain	NN	O
hemorrhage	NN	O
or	CC	O
periventricular	JJ	O
leukomalacia	NN	O
,	,	O
and	CC	O
they	PRP	O
had	VBD	O
more	RBR	O
frequent	JJ	O
episodes	NNS	O
of	IN	O
apnea	NN	O
,	,	O
including	VBG	O
both	DT	O
mild	JJ	O
and	CC	O
severe	JJ	O
episodes	NNS	O
.	.	O

CONCLUSIONS	NNP	O
Although	IN	O
both	DT	O
transfusion	NN	O
programs	NNS	O
were	VBD	O
well	RB	O
tolerated	VBN	O
,	,	O
our	PRP$	O
finding	NN	O
of	IN	O
more	RBR	O
frequent	JJ	O
major	JJ	O
adverse	JJ	O
neurologic	NN	O
events	NNS	O
in	IN	O
the	DT	O
restrictive	JJ	O
RBC-transfusion	NNP	O
group	NN	O
suggests	VBZ	O
that	IN	O
the	DT	O
practice	NN	O
of	IN	O
restrictive	JJ	O
transfusions	NNS	O
may	MD	O
be	VB	O
harmful	JJ	O
to	TO	O
preterm	VB	O
infants	NNS	O
.	.	O

Heparin-coated	JJ	O
cardiopulmonary	JJ	O
bypass	NN	O
circuits	NNS	O
reduce	VB	O
circulating	VBG	O
complement	JJ	O
factors	NNS	O
and	CC	O
interleukin-6	NN	O
in	IN	O
paediatric	JJ	O
heart	NN	O
surgery	NN	O
.	.	O

Children	NNP	O
are	VBP	O
sensitive	JJ	O
to	TO	O
the	DT	O
inflammatory	JJ	O
side	NN	O
effects	NNS	O
of	IN	O
cardiopulmonary	JJ	O
bypass	NN	O
(	(	O
CPB	NNP	O
)	)	O
.	.	O

Our	PRP$	O
intention	NN	O
was	VBD	O
to	TO	O
investigate	VB	O
if	IN	O
the	DT	O
biocompatibility	NN	O
benefits	NNS	O
of	IN	O
heparin-coated	JJ	O
CPB	NNP	O
circuits	NNS	O
apply	VBP	O
to	TO	O
children	NNS	O
.	.	O

In	IN	O
20	CD	O
operations	NNS	O
,	,	O
19	CD	O
children	NNS	O
were	VBD	O
randomized	VBN	O
to	TO	O
heparin-coated	JJ	O
(	(	O
group	NN	O
HC	NNP	O
,	,	O
n	JJ	O
=	NNP	O
10	CD	O
)	)	O
or	CC	O
standard	JJ	O
(	(	O
group	NN	O
C	NNP	O
,	,	O
n	JJ	O
=	NNP	O
10	CD	O
)	)	O
bypass	NN	O
circuits	NNS	O
.	.	O

Plasma	NNP	O
levels	NNS	O
of	IN	O
acute	JJ	O
phase	NN	O
reactants	NNS	O
,	,	O
interleukins	NNS	O
,	,	O
granulocytic	JJ	O
proteins	NNS	O
and	CC	O
complement	JJ	O
factors	NNS	O
were	VBD	O
measured	VBN	O
.	.	O

All	DT	O
were	VBD	O
significantly	RB	O
elevated	VBN	O
after	IN	O
CPB	NNP	O
.	.	O

Levels	NNP	O
of	IN	O
complement	NN	O
factor	NN	O
C3a	NNP	O
(	(	O
851	CD	O
(	(	O
791-959	CD	O
)	)	O
ng/ml	FW	O
[	JJ	O
median	NN	O
with	IN	O
quartiles	NNS	O
]	VBP	O
in	IN	O
group	NN	O
C	NNP	O
,	,	O
497	CD	O
(	(	O
476-573	JJ	O
)	)	O
ng/ml	NN	O
in	IN	O
group	NN	O
HC	NNP	O
,	,	O
p	NN	O
<	NNP	O
0.001	CD	O
)	)	O
,	,	O
Terminal	NNP	O
Complement	NNP	O
Complex	NNP	O
(	(	O
114	CD	O
(	(	O
71-130	CD	O
)	)	O
AU/ml	NNP	O
in	IN	O
group	NN	O
C	NNP	O
,	,	O
35.5	CD	O
(	(	O
28.9-51.4	JJ	O
)	)	O
AU/ml	NNP	O
in	IN	O
group	NN	O
HC	NNP	O
,	,	O
p	NN	O
<	NNP	O
0.001	CD	O
)	)	O
,	,	O
and	CC	O
interleukin-6	NN	O
(	(	O
570	CD	O
(	(	O
203-743	JJ	O
)	)	O
pg/ml	NN	O
in	IN	O
group	NN	O
C	NNP	O
,	,	O
168	CD	O
(	(	O
111-206	CD	O
)	)	O
pg/ml	NN	O
in	IN	O
group	NN	O
HC	NNP	O
,	,	O
p	NN	O
=	NNP	O
0.005	CD	O
)	)	O
,	,	O
were	VBD	O
significantly	RB	O
reduced	VBN	O
in	IN	O
group	NN	O
HC	NNP	O
.	.	O

Heparin-coated	JJ	O
CPB	NNP	O
circuits	NNS	O
improve	VBP	O
the	DT	O
biocompatibility	NN	O
of	IN	O
CPB	NNP	O
during	IN	O
heart	NN	O
surgery	NN	O
in	IN	O
the	DT	O
paediatric	JJ	O
patient	NN	O
population	NN	O
,	,	O
as	IN	O
reflected	VBN	O
by	IN	O
significantly	RB	O
reduced	VBN	O
levels	NNS	O
of	IN	O
circulating	VBG	O
complement	JJ	O
factors	NNS	O
and	CC	O
interleukin-6	NN	O
.	.	O

A	DT	O
randomized	JJ	O
phase	NN	O
II	NNP	O
trial	NN	O
of	IN	O
5-fluorouracil	JJ	O
,	,	O
with	IN	O
or	CC	O
without	IN	O
human	JJ	O
interferon-beta	NN	O
,	,	O
for	IN	O
advanced	JJ	C
colorectal	JJ	C
cancer	NN	C
.	.	O

This	DT	O
study	NN	O
compared	VBN	O
the	DT	O
efficacy	NN	O
and	CC	O
safety	NN	O
of	IN	O
5-fluorouracil	JJ	O
(	(	O
5-FU	JJ	O
)	)	O
monotherapy	NN	O
to	TO	O
that	DT	O
of	IN	O
5-FU	JJ	O
combined	VBN	O
with	IN	O
natural	JJ	O
human	JJ	O
interferon-beta	NN	O
(	(	O
IFN-beta	NNP	O
)	)	O
in	IN	O
patients	NNS	O
with	IN	O
unresectable	JJ	O
,	,	O
advanced	JJ	C
colorectal	JJ	C
carcinoma	NN	C
.	.	O

Forty-nine	JJ	SS
chemotherapy-naive	JJ	C
patients	NNS	O
were	VBD	O
randomized	VBN	O
to	TO	O
5-FU	JJ	O
alone	RB	O
or	CC	O
to	TO	O
the	DT	O
combination	NN	O
.	.	O

All	DT	O
patients	NNS	O
received	VBD	O
750	CD	O
mg	NNS	O
m	NN	O
(	(	O
-2	JJ	O
)	)	O
day	NN	O
(	(	O
-1	JJ	O
)	)	O
5-FU	NN	O
for	IN	O
5	CD	O
days	NNS	O
by	IN	O
continuous	JJ	O
intravenous	JJ	O
(	(	O
i.v	JJ	O
.	.	O

)	)	O
infusion	NN	O
,	,	O
followed	VBD	O
after	IN	O
day	NN	O
15	CD	O
by	IN	O
a	DT	O
weekly	JJ	O
i.v	NN	O
.	.	O

bolus	NN	O
of	IN	O
750	CD	O
mg	NNS	O
m	NN	O
(	(	O
-2	NNP	O
)	)	O
.	.	O

IFN-beta	NNP	O
was	VBD	O
injected	VBN	O
intramuscularly	RB	O
three	CD	O
times	NNS	O
weekly	RB	O
at	IN	O
9	CD	O
M	NNP	O
IU	NNP	O
.	.	O

Treatment	NNP	O
continued	VBD	O
for	IN	O
52	CD	O
weeks	NNS	O
,	,	O
or	CC	O
until	IN	O
disease	JJ	O
progression	NN	O
or	CC	O
intolerable	JJ	O
toxicity	NN	O
.	.	O

Clinical	JJ	O
endpoints	NNS	O
were	VBD	O
tumor	JJ	O
response	NN	O
,	,	O
time	NN	O
to	TO	O
progression	NN	O
,	,	O
survival	NN	O
and	CC	O
toxicity	NN	O
.	.	O

The	DT	O
addition	NN	O
of	IN	O
IFN-3	NNP	O
to	TO	O
5-FU	CD	O
significantly	RB	O
improved	VBN	O
response	NN	O
rate	NN	O
(	(	O
33.3	CD	O
%	NN	O
vs	JJ	O
4.5	CD	O
%	NN	O
for	IN	O
evaluable	JJ	O
patients	NNS	O
;	:	O
P	NNP	O
=	NNP	O
0.021	CD	O
)	)	O
,	,	O
time	NN	O
to	TO	O
progression	NN	O
(	(	O
median	JJ	O
7.2	CD	O
vs	JJ	O
4.2	CD	O
months	NNS	O
;	:	O
P	NNP	O
=	NNP	O
0.0435	CD	O
)	)	O
,	,	O
and	CC	O
survival	JJ	O
time	NN	O
(	(	O
median	JJ	O
15.9	CD	O
vs	JJ	O
7.2	CD	O
months	NNS	O
;	:	O
P	NNP	O
=	NNP	O
0.038	CD	O
)	)	O
without	IN	O
significantly	RB	O
increasing	VBG	O
toxicity	NN	O
compared	VBN	O
to	TO	O
5-FU	JJ	O
alone	RB	O
.	.	O

Cumulative	JJ	O
5-FU	JJ	O
dose	NN	O
was	VBD	O
higher	JJR	O
with	IN	O
combined	JJ	O
therapy	NN	O
(	(	O
P	NNP	O
<	NNP	O
0.001	CD	O
)	)	O
:	:	O
more	JJR	O
patients	NNS	O
receiving	VBG	O
monotherapy	JJ	O
discontinued	VBN	O
treatment	NN	O
because	IN	O
of	IN	O
disease	NN	O
progression	NN	O
.	.	O

Fever	NNP	O
was	VBD	O
more	RBR	O
frequent	JJ	O
with	IN	O
combined	JJ	O
therapy	NN	O
(	(	O
P	NNP	O
=	NNP	O
0.008	CD	O
)	)	O
;	:	O
there	EX	O
were	VBD	O
no	DT	O
other	JJ	O
differences	NNS	O
in	IN	O
toxicity	NN	O
.	.	O

The	DT	O
only	JJ	O
grade	NN	O
IV	NNP	O
toxicity	NN	O
observed	VBD	O
was	VBD	O
neutropenia	JJ	O
(	(	O
two	CD	O
patients	NNS	O
per	IN	O
group	NN	O
)	)	O
.	.	O

A	DT	O
randomized	JJ	O
phase	NN	O
III	NNP	O
trial	NN	O
has	VBZ	O
been	VBN	O
initiated	VBN	O
to	TO	O
confirm	VB	O
the	DT	O
synergy	NN	O
between	IN	O
5-FU	JJ	O
and	CC	O
IFN-beta	NNP	O
.	.	O

Cryotherapy	NN	O
does	VBZ	O
not	RB	O
affect	VB	O
peroneal	JJ	O
reaction	NN	O
following	VBG	O
sudden	JJ	O
inversion	NN	O
.	.	O

CONTEXT	NNP	O
If	IN	O
ankle	JJ	O
joint	NN	O
cryotherapy	NN	O
impairs	VBZ	O
the	DT	O
ability	NN	O
of	IN	O
the	DT	O
ankle	JJ	O
musculature	NN	O
to	TO	O
counteract	VB	O
potentially	RB	O
injurious	JJ	O
forces	NNS	O
,	,	O
the	DT	O
ankle	NN	O
is	VBZ	O
left	VBN	O
vulnerable	JJ	O
to	TO	O
injury	VB	O
.	.	O

OBJECTIVE	NNP	O
To	TO	O
compare	VB	O
peroneal	JJ	O
reaction	NN	O
to	TO	O
sudden	JJ	O
inversion	NN	O
following	VBG	O
ankle	JJ	O
joint	JJ	O
cryotherapy	NN	O
.	.	O

DESIGN	NNP	O
Repeated	VBD	O
measures	NNS	O
design	NN	O
with	IN	O
independent	JJ	O
variables	NNS	O
,	,	O
treatment	NN	O
(	(	O
cryotherapy	NN	O
and	CC	O
control	NN	O
)	)	O
,	,	O
and	CC	O
time	NN	O
(	(	O
baseline	NN	O
,	,	O
immediately	RB	O
post	NN	O
treatment	NN	O
,	,	O
15	CD	O
minutes	NNS	O
post	RB	O
treatment	NN	O
,	,	O
and	CC	O
30	CD	O
minutes	NNS	O
post	RB	O
treatment	NN	O
)	)	O
.	.	O

SETTING	NNP	O
University	NNP	O
research	NN	O
laboratory	NN	O
.	.	O

PATIENTS	CC	O
OR	CC	O
OTHER	NNP	O
PARTICIPANTS	NNP	O
Twenty-seven	NNP	SS
healthy	JJ	C
volunteers	NNS	O
.	.	O

INTERVENTION	NNP	O
(	(	O
S	NNP	O
)	)	O
An	DT	O
ice	NN	O
bag	NN	O
was	VBD	O
secured	VBN	O
to	TO	O
the	DT	O
lateral	JJ	O
ankle	NN	O
joint	NN	O
for	IN	O
20	CD	O
minutes	NNS	O
.	.	O

MAIN	NNP	O
OUTCOME	NNP	O
MEASURES	NNP	O
The	DT	O
onset	NN	O
and	CC	O
average	JJ	O
root	NN	O
mean	JJ	O
square	JJ	O
amplitude	NN	O
of	IN	O
EMG	NNP	O
activity	NN	O
in	IN	O
the	DT	O
peroneal	NN	O
muscles	NNS	O
was	VBD	O
calculated	VBN	O
following	VBG	O
the	DT	O
release	NN	O
of	IN	O
a	DT	O
trap	NN	O
door	NN	O
mechanism	NN	O
causing	VBG	O
inversion	NN	O
.	.	O

RESULTS	NNP	O
There	EX	O
was	VBD	O
no	DT	O
statistically	RB	O
significant	JJ	O
change	NN	O
from	IN	O
baseline	NN	O
for	IN	O
peroneal	JJ	O
reaction	NN	O
time	NN	O
or	CC	O
average	JJ	O
peroneal	JJ	O
muscle	NN	O
activity	NN	O
at	IN	O
any	DT	O
post	NN	O
treatment	NN	O
time	NN	O
.	.	O

CONCLUSIONS	NNP	O
Cryotherapy	NNP	O
does	VBZ	O
not	RB	O
affect	VB	O
peroneal	JJ	O
muscle	NN	O
reaction	NN	O
following	VBG	O
sudden	JJ	O
inversion	NN	O
perturbation	NN	O
.	.	O

RESPECT-PTSD	JJ	O
:	:	O
re-engineering	JJ	O
systems	NNS	O
for	IN	O
the	DT	O
primary	JJ	O
care	NN	O
treatment	NN	O
of	IN	O
PTSD	NNP	C
,	,	O
a	DT	O
randomized	VBN	O
controlled	VBN	O
trial	NN	O
.	.	O

BACKGROUND	NNP	O
Although	IN	O
collaborative	JJ	O
care	NN	O
is	VBZ	O
effective	JJ	O
for	IN	O
treating	VBG	O
depression	NN	O
and	CC	O
other	JJ	O
mental	JJ	O
disorders	NNS	O
in	IN	O
primary	JJ	O
care	NN	O
,	,	O
there	EX	O
have	VBP	O
been	VBN	O
no	DT	O
randomized	JJ	O
trials	NNS	O
of	IN	O
collaborative	JJ	O
care	NN	O
specifically	RB	O
for	IN	O
patients	NNS	C
with	IN	C
Posttraumatic	NNP	C
stress	NN	C
disorder	NN	C
(	(	C
PTSD	NNP	C
)	)	C
.	.	O

OBJECTIVE	UH	O
To	TO	O
compare	VB	O
a	DT	O
collaborative	JJ	O
approach	NN	O
,	,	O
the	DT	O
Three	NNP	O
Component	NNP	O
Model	NNP	O
(	(	O
3CM	CD	O
)	)	O
,	,	O
with	IN	O
usual	JJ	O
care	NN	O
for	IN	O
treating	VBG	O
PTSD	NNP	O
in	IN	O
primary	JJ	O
care	NN	O
.	.	O

DESIGN	VB	O
The	DT	O
study	NN	O
was	VBD	O
a	DT	O
two-arm	JJ	O
,	,	O
parallel	JJ	O
randomized	VBD	O
clinical	JJ	O
trial	NN	O
.	.	O

PTSD	JJ	O
patients	NNS	O
were	VBD	O
recruited	VBN	O
from	IN	O
five	CD	O
primary	JJ	O
care	NN	O
clinics	NNS	O
at	IN	O
four	CD	O
Veterans	NNS	O
Affairs	NNP	O
healthcare	NN	O
facilities	NNS	O
and	CC	O
randomized	VBN	O
to	TO	O
receive	VB	O
usual	JJ	O
care	NN	O
or	CC	O
usual	JJ	O
care	NN	O
plus	CC	O
3CM	CD	O
.	.	O

Blinded	VBN	O
assessors	NNS	O
collected	VBD	O
data	NNS	O
at	IN	O
baseline	NN	O
and	CC	O
3-month	JJ	O
and	CC	O
6-month	JJ	O
follow-up	NN	O
.	.	O

PARTICIPANTS	JJ	O
Participants	NNS	O
were	VBD	O
195	CD	SS
Veterans	NNPS	O
.	.	O

Their	PRP$	O
average	JJ	O
age	NN	O
was	VBD	O
45	CD	A
years	NNS	A
,	,	O
91	CD	O
%	NN	O
were	VBD	O
male	JJ	O
,	,	O
58	CD	O
%	NN	O
were	VBD	O
white	JJ	O
,	,	O
40	CD	O
%	NN	O
served	VBN	O
in	IN	O
Iraq	NNP	O
or	CC	O
Afghanistan	NNP	O
,	,	O
and	CC	O
42	CD	O
%	NN	O
served	VBD	O
in	IN	O
Vietnam	NNP	O
.	.	O

INTERVENTION	NNP	O
All	NNP	O
participants	NNS	O
received	VBD	O
usual	JJ	O
care	NN	O
.	.	O

Participants	NNS	O
assigned	VBD	O
to	TO	O
3CM	CD	O
also	RB	O
received	VBD	O
telephone	NN	O
care	NN	O
management	NN	O
.	.	O

Care	NN	O
managers	NNS	O
received	VBD	O
supervision	NN	O
from	IN	O
a	DT	O
psychiatrist	NN	O
.	.	O

MAIN	NNP	O
MEASURES	NNP	O
PTSD	NNP	O
symptom	NN	O
severity	NN	O
was	VBD	O
the	DT	O
primary	JJ	O
outcome	NN	O
.	.	O

Depression	NNP	O
,	,	O
functioning	NN	O
,	,	O
perceived	VBD	O
quality	NN	O
of	IN	O
care	NN	O
,	,	O
utilization	NN	O
,	,	O
and	CC	O
costs	NNS	O
were	VBD	O
secondary	JJ	O
outcomes	NNS	O
.	.	O

KEY	JJ	O
RESULTS	NNP	O
There	EX	O
were	VBD	O
no	DT	O
differences	NNS	O
between	IN	O
3CM	CD	O
and	CC	O
usual	JJ	O
care	NN	O
in	IN	O
symptoms	NNS	O
or	CC	O
functioning	VBG	O
.	.	O

Participants	NNS	O
assigned	VBD	O
to	TO	O
3CM	CD	O
were	VBD	O
more	RBR	O
likely	JJ	O
to	TO	O
have	VB	O
a	DT	O
mental	JJ	O
health	NN	O
visit	NN	O
,	,	O
fill	VB	O
an	DT	O
antidepressant	JJ	O
prescription	NN	O
,	,	O
and	CC	O
have	VBP	O
adequate	VBN	O
antidepressant	JJ	O
refills	NNS	O
.	.	O

3CM	CD	O
participants	NNS	O
also	RB	O
had	VBD	O
more	RBR	O
mental	JJ	O
health	NN	O
visits	NNS	O
and	CC	O
higher	JJR	O
outpatient	NN	O
pharmacy	NN	O
costs	NNS	O
.	.	O

CONCLUSIONS	NNP	O
Results	NNP	O
suggest	VBP	O
the	DT	O
need	NN	O
for	IN	O
careful	JJ	O
examination	NN	O
of	IN	O
the	DT	O
way	NN	O
that	IN	O
collaborative	JJ	O
care	NN	O
models	NNS	O
are	VBP	O
implemented	VBN	O
for	IN	O
treating	VBG	O
PTSD	NNP	O
,	,	O
and	CC	O
for	IN	O
additional	JJ	O
supports	NNS	O
to	TO	O
encourage	VB	O
primary	JJ	O
care	NN	O
providers	NNS	O
to	TO	O
manage	VB	O
PTSD	NNP	O
.	.	O

A	DT	O
controlled	JJ	O
trial	NN	O
of	IN	O
extended	JJ	O
radical	JJ	O
versus	NN	O
radical	JJ	O
mastectomy	NN	O
.	.	O

Ten-year	JJ	O
results	NNS	O
.	.	O

In	IN	O
view	NN	O
of	IN	O
increasing	VBG	O
debate	NN	O
over	IN	O
possible	JJ	O
benefit	NN	O
of	IN	O
more	JJR	O
complete	JJ	O
surgery	NN	O
compared	VBN	O
to	TO	O
conservative	JJ	O
procedures	NNS	O
,	,	O
a	DT	O
randomized	VBN	O
controlled	VBN	O
trial	NN	O
contrasting	VBG	O
the	DT	O
then	RB	O
standard	NN	O
Halsted	NNP	O
radical	NN	O
(	(	O
RDL	NNP	O
)	)	O
operation	NN	O
with	IN	O
the	DT	O
more	RBR	O
complete	JJ	O
extended	JJ	O
radical	NN	O
(	(	O
EXT	NNP	O
)	)	O
mastectomy	NN	O
was	VBD	O
initiated	VBN	O
in	IN	O
1973	CD	O
.	.	O

Between	IN	O
November	NNP	O
1973	CD	O
and	CC	O
July	NNP	O
1982	CD	O
,	,	O
123	CD	SS
women	NNS	SE
younger	JJR	A
than	IN	A
70	CD	A
years	NNS	A
of	IN	A
age	NN	A
and	CC	O
at	IN	O
clinical	JJ	C
Stages	NNP	C
I	PRP	C
and	CC	C
II	NNP	C
were	VBD	O
enrolled	VBN	O
.	.	O

Of	IN	O
the	DT	O
total	JJ	O
series	NN	O
,	,	O
112	CD	SS
were	VBD	O
treated	VBN	O
by	IN	O
the	DT	O
same	JJ	O
surgeon	NN	O
and	CC	O
confirmed	VBD	O
pathologically	RB	O
as	IN	O
having	VBG	O
invasive	JJ	C
mammary	JJ	C
carcinoma	NN	C
.	.	O

In	IN	O
this	DT	O
more	RBR	O
homogeneous	JJ	O
subgroup	NN	O
,	,	O
the	DT	O
10-year	JJ	O
survival	NN	O
rates	NNS	O
(	(	O
and	CC	O
standard	JJ	O
errors	NNS	O
)	)	O
were	VBD	O
for	IN	O
RDL	NNP	O
,	,	O
60	CD	O
%	NN	O
(	(	O
+/-	JJ	O
7	CD	O
%	NN	O
)	)	O
and	CC	O
for	IN	O
EXT	NNP	O
,	,	O
74	CD	O
%	NN	O
(	(	O
+/-	JJ	O
6	CD	O
%	NN	O
)	)	O
(	(	O
P	NNP	O
value	NN	O
for	IN	O
comparison	NN	O
of	IN	O
survival	JJ	O
curves	NNS	O
=	VBP	O
0.13	CD	O
)	)	O
.	.	O

In	IN	O
patients	NNS	O
from	IN	O
this	DT	O
subgroup	NN	O
with	IN	O
central-medial	JJ	O
tumors	NNS	O
,	,	O
comprising	VBG	O
62	CD	O
%	NN	O
of	IN	O
the	DT	O
total	NN	O
,	,	O
survival	NN	O
after	IN	O
RDL	NNP	O
at	IN	O
10	CD	O
years	NNS	O
was	VBD	O
60	CD	O
%	NN	O
(	(	O
+/-	JJ	O
8	CD	O
%	NN	O
)	)	O
,	,	O
and	CC	O
after	IN	O
EXT	NNP	O
86	CD	O
%	NN	O
(	(	O
+/-	JJ	O
6	CD	O
%	NN	O
)	)	O
(	(	O
P	NNP	O
=	NNP	O
0.025	CD	O
)	)	O
.	.	O

In	IN	O
the	DT	O
remaining	VBG	O
patients	NNS	O
with	IN	O
lateral	JJ	C
tumors	NNS	C
,	,	O
survival	JJ	O
rates	NNS	O
were	VBD	O
unaffected	VBN	O
by	IN	O
treatment	NN	O
:	:	O
58	CD	O
%	NN	O
(	(	O
+/-	JJ	O
13	CD	O
%	NN	O
)	)	O
and	CC	O
56	CD	O
%	NN	O
(	(	O
+/-	JJ	O
11	CD	O
%	NN	O
)	)	O
,	,	O
respectively	RB	O
(	(	O
P	NNP	O
=	NNP	O
0.62	CD	O
)	)	O
.	.	O

Comparison	NNP	O
of	IN	O
a	DT	O
nonrandomized	JJ	O
series	NN	O
of	IN	O
266	CD	O
RDL	NNP	O
and	CC	O
124	CD	O
EXT	NNP	O
patients	NNS	O
treated	VBD	O
between	IN	O
1960	CD	O
and	CC	O
1978	CD	O
found	VBD	O
differences	NNS	O
consistent	JJ	O
with	IN	O
those	DT	O
of	IN	O
the	DT	O
randomized	VBN	O
study	NN	O
,	,	O
although	IN	O
not	RB	O
statistically	RB	O
significant	JJ	O
.	.	O

A	DT	O
sensory	JJ	O
integration	NN	O
therapy	NN	O
program	NN	O
on	IN	O
sensory	JJ	C
problems	NNS	C
for	IN	O
children	NNS	O
with	IN	O
autism	NN	C
.	.	O

The	DT	O
study	NN	O
was	VBD	O
planned	VBN	O
to	TO	O
investigate	VB	O
the	DT	O
effect	NN	O
of	IN	O
a	DT	O
sensory	JJ	O
integration	NN	O
therapy	NN	O
program	NN	O
on	IN	O
sensory	JJ	O
problems	NNS	O
of	IN	O
children	NNS	O
with	IN	O
autism	NN	C
.	.	O

This	DT	O
study	NN	O
was	VBD	O
conducted	VBN	O
at	IN	O
the	DT	O
Trakya	NNP	O
University	NNP	O
Training	NNP	O
and	CC	O
Research	NNP	O
Center	NNP	O
for	IN	O
Mentally	NNP	O
and	CC	O
Physically	NNP	O
Handicapped	NNP	O
Children	NNP	O
in	IN	O
Turkey	NNP	O
.	.	O

The	DT	O
children	NNS	O
were	VBD	O
separated	VBN	O
into	IN	O
two	CD	O
groups	NNS	O
,	,	O
each	DT	O
comprising	VBG	O
15	CD	SS
children	NNS	O
between	IN	O
7	CD	O
and	CC	O
11	CD	O
years	NNS	O
of	IN	O
age	NN	O
with	IN	O
autism	NN	C
,	,	O
according	VBG	O
to	TO	O
DSM-IV	NNP	O
criteria	NNS	O
.	.	O

The	DT	O
children	NNS	O
in	IN	O
each	DT	O
group	NN	O
were	VBD	O
assessed	VBN	O
initially	RB	O
on	IN	O
a	DT	O
checklist	NN	O
,	,	O
Sensory	NNP	O
Evaluation	NNP	O
Form	NNP	O
for	IN	O
Children	NNP	O
with	IN	O
Autism	NNP	O
,	,	O
developed	VBD	O
to	TO	O
evaluate	VB	O
sensory	JJ	O
characteristics	NNS	O
of	IN	O
children	NNS	O
with	IN	O
autism	NN	O
,	,	O
and	CC	O
at	IN	O
the	DT	O
end	NN	O
of	IN	O
the	DT	O
study	NN	O
,	,	O
participants	NNS	O
were	VBD	O
assessed	VBN	O
again	RB	O
on	IN	O
the	DT	O
checklist	NN	O
.	.	O

Statistically	NNP	O
significant	JJ	O
differences	NNS	O
between	IN	O
groups	NNS	O
indicated	VBD	O
that	IN	O
the	DT	O
sensory	JJ	O
integration	NN	O
therapy	NN	O
program	NN	O
positively	RB	O
affected	VBD	O
treated	JJ	O
children	NNS	O
.	.	O

The	DT	O
therapeutic	JJ	O
efficacy	NN	O
and	CC	O
cost-effectiveness	NN	O
of	IN	O
aggressive	JJ	O
tocolysis	NN	O
for	IN	O
premature	JJ	C
labor	NN	C
associated	VBN	C
with	IN	C
premature	JJ	C
rupture	NN	C
of	IN	C
the	DT	C
membranes	NNS	C
.	.	O

We	PRP	O
conducted	VBD	O
a	DT	O
randomized	JJ	O
trial	NN	O
comparing	VBG	O
bed	VBD	O
rest	NN	O
with	IN	O
tocolysis	NN	O
to	TO	O
determine	VB	O
the	DT	O
therapeutic	JJ	O
efficacy	NN	O
,	,	O
safety	NN	O
,	,	O
and	CC	O
cost-effectiveness	NN	O
of	IN	O
tocolysis	NN	O
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
preterm	JJ	C
labor	NN	C
after	IN	C
membrane	JJ	C
rupture	NN	C
.	.	O

One	CD	SS
hundred	VBD	SS
nine	CD	SS
women	NNS	SS
participated	VBD	O
over	IN	O
a	DT	O
26-month	JJ	O
interval	NN	O
.	.	O

Treatment	NNP	O
groups	NNS	O
did	VBD	O
not	RB	O
differ	VB	O
significantly	RB	O
in	IN	O
terms	NNS	O
of	IN	O
gestational	JJ	O
age	NN	O
at	IN	O
membrane	NN	O
rupture	NN	O
,	,	O
gestational	JJ	O
age	NN	O
at	IN	O
delivery	NN	O
,	,	O
birth	NN	O
weight	NN	O
,	,	O
maternal	JJ	O
or	CC	O
fetal	JJ	O
infectious	JJ	O
morbidity	NN	O
,	,	O
respiratory	JJ	O
distress	NN	O
syndrome	NN	O
,	,	O
necrotizing	VBG	O
enterocolitis	NN	O
,	,	O
or	CC	O
perinatal	JJ	O
mortality	NN	O
.	.	O

Prolongation	NN	O
of	IN	O
intrauterine	JJ	O
time	NN	O
after	IN	O
the	DT	O
onset	NN	O
of	IN	O
uterine	JJ	O
contractions	NNS	O
was	VBD	O
seen	VBN	O
in	IN	O
women	NNS	O
receiving	VBG	O
tocolysis	NN	O
(	(	O
105.2	CD	O
+/-	JJ	O
157	CD	O
hours	NNS	O
versus	JJ	O
62.1	CD	O
+/-	JJ	O
77	CD	O
hours	NNS	O
,	,	O
p	VBP	O
=	RB	O
0.06	CD	O
)	)	O
.	.	O

This	DT	O
prolongation	NN	O
was	VBD	O
not	RB	O
associated	VBN	O
with	IN	O
a	DT	O
significant	JJ	O
reduction	NN	O
in	IN	O
the	DT	O
total	JJ	O
cost	NN	O
per	IN	O
surviving	VBG	O
infant	NN	O
(	(	O
tocolysis	NN	O
,	,	O
$	$	O
38,593	CD	O
+/-	JJ	O
$	$	O
40,887	CD	O
versus	NN	O
bed	NN	O
rest	NN	O
,	,	O
$	$	O
43,158	CD	O
+/-	JJ	O
$	$	O
37,116	CD	O
;	:	O
p	NN	O
=	VBZ	O
0.445	CD	O
)	)	O
.	.	O

The	DT	O
cost	NN	O
difference	NN	O
was	VBD	O
artifactual	JJ	O
.	.	O

The	DT	O
number	NN	O
of	IN	O
very	RB	O
premature	JJ	O
infants	NNS	O
born	VBN	O
(	(	O
less	JJR	O
than	IN	O
28	CD	O
weeks	NNS	O
'	POS	O
gestation	NN	O
)	)	O
was	VBD	O
unequal	JJ	O
in	IN	O
the	DT	O
two	CD	O
groups	NNS	O
(	(	O
12	CD	O
in	IN	O
the	DT	O
bed	NN	O
rest	NN	O
group	NN	O
and	CC	O
5	CD	O
in	IN	O
the	DT	O
tocolysis	NN	O
group	NN	O
)	)	O
and	CC	O
skewed	VBD	O
the	DT	O
results	NNS	O
.	.	O

Before	IN	O
28	CD	O
weeks	NNS	O
'	POS	O
gestation	NN	O
tocolysis	NN	O
was	VBD	O
associated	VBN	O
with	IN	O
a	DT	O
significant	JJ	O
increase	NN	O
in	IN	O
intrauterine	JJ	O
time	NN	O
after	IN	O
the	DT	O
onset	NN	O
of	IN	O
regular	JJ	O
contractions	NNS	O
(	(	O
p	JJ	O
=	NNP	O
0.05	CD	O
)	)	O
.	.	O

However	RB	O
,	,	O
there	EX	O
was	VBD	O
no	DT	O
identifiable	JJ	O
perinatal	JJ	O
benefit	NN	O
garnered	VBD	O
from	IN	O
the	DT	O
additional	JJ	O
5	CD	O
days	NNS	O
.	.	O

After	IN	O
28	CD	O
weeks	NNS	O
there	EX	O
were	VBD	O
no	DT	O
significant	JJ	O
differences	NNS	O
between	IN	O
treatment	NN	O
groups	NNS	O
in	IN	O
terms	NNS	O
of	IN	O
intrauterine	NN	O
time	NN	O
after	IN	O
the	DT	O
onset	NN	O
of	IN	O
regular	JJ	O
contractions	NNS	O
and	CC	O
total	JJ	O
cost	NN	O
per	IN	O
surviving	VBG	O
infant	NN	O
.	.	O

Because	IN	O
tocolysis	NN	O
does	VBZ	O
not	RB	O
improve	VB	O
perinatal	JJ	O
outcome	NN	O
and	CC	O
can	MD	O
itself	PRP	O
be	VB	O
associated	VBN	O
with	IN	O
major	JJ	O
maternal	JJ	O
morbidity	NN	O
,	,	O
it	PRP	O
should	MD	O
be	VB	O
avoided	VBN	O
after	IN	O
28	CD	O
weeks	NNS	O
'	POS	O
gestation	NN	O
.	.	O

Before	IN	O
28	CD	O
weeks	NNS	O
'	POS	O
gestation	NN	O
tocolysis	NN	O
may	MD	O
greatly	RB	O
increase	VB	O
intrauterine	JJ	O
time	NN	O
,	,	O
but	CC	O
the	DT	O
benefit	NN	O
of	IN	O
this	DT	O
prolongation	NN	O
is	VBZ	O
not	RB	O
clear	JJ	O
.	.	O

Comparison	NNP	O
between	IN	O
intermittent	JJ	O
mandatory	JJ	O
ventilation	NN	O
and	CC	O
synchronized	JJ	O
intermittent	NN	O
mandatory	JJ	O
ventilation	NN	O
with	IN	O
pressure	NN	O
support	NN	O
in	IN	O
children	NNS	A
.	.	O

OBJECTIVE	NN	O
To	TO	O
compare	VB	O
intermittent	JJ	O
mandatory	JJ	O
ventilation	NN	O
(	(	O
IMV	NNP	O
)	)	O
with	IN	O
synchronized	JJ	O
intermittent	JJ	O
mandatory	NN	O
ventilation	NN	O
plus	CC	O
pressure	NN	O
support	NN	O
(	(	O
SIMV+PS	NNP	O
)	)	O
in	IN	O
terms	NNS	O
of	IN	O
time	NN	O
on	IN	O
mechanical	JJ	O
ventilation	NN	O
,	,	O
duration	NN	O
of	IN	O
weaning	VBG	O
and	CC	O
length	NN	O
of	IN	O
stay	NN	O
in	IN	O
a	DT	O
pediatric	JJ	O
intensive	JJ	O
care	NN	O
unit	NN	O
(	(	O
PICU	NNP	O
)	)	O
.	.	O

METHODS	NNP	O
This	DT	O
was	VBD	O
a	DT	O
randomized	JJ	O
clinical	JJ	O
trial	NN	O
that	WDT	O
enrolled	VBD	O
children	NNS	A
aged	VBN	O
28	CD	A
days	NNS	A
to	TO	A
4	CD	A
years	NNS	A
who	WP	O
were	VBD	O
admitted	VBN	O
to	TO	O
a	DT	O
PICU	NNP	O
between	IN	O
October	NNP	O
of	IN	O
2005	CD	O
and	CC	O
June	NNP	O
of	IN	O
2007	CD	O
and	CC	O
put	VB	O
on	IN	O
mechanical	JJ	O
ventilation	NN	O
(	(	O
MV	NNP	O
)	)	O
for	IN	O
more	JJR	O
than	IN	O
48	CD	O
hours	NNS	O
.	.	O

These	DT	O
patients	NNS	O
were	VBD	O
allocated	VBN	O
to	TO	O
one	CD	O
of	IN	O
two	CD	O
groups	NNS	O
by	IN	O
drawing	VBG	O
lots	NNS	O
:	:	O
IMV	NNP	O
group	NN	O
(	(	O
IMVG	NNP	O
;	:	O
n	CC	O
=	VB	O
35	CD	O
)	)	O
and	CC	O
SIMV+PS	NNP	O
group	NN	O
(	(	O
SIMVG	NNP	O
;	:	O
n	CC	O
=	VB	O
35	CD	O
)	)	O
.	.	O

Children	NNP	A
were	VBD	O
excluded	VBN	O
if	IN	O
they	PRP	O
had	VBD	O
undergone	JJ	O
tracheotomy	NN	O
or	CC	O
had	VBD	O
chronic	JJ	C
respiratory	NN	C
diseases	NNS	C
.	.	C

Data	NNS	O
on	IN	O
oxygenation	NN	O
and	CC	O
ventilation	NN	O
were	VBD	O
recorded	VBN	O
at	IN	O
admission	NN	O
and	CC	O
at	IN	O
the	DT	O
start	NN	O
of	IN	O
weaning	VBG	O
.	.	O

RESULTS	CC	O
There	EX	O
were	VBD	O
no	DT	O
statistical	JJ	O
differences	NNS	O
between	IN	O
the	DT	O
groups	NNS	O
in	IN	O
terms	NNS	O
of	IN	O
age	NN	O
,	,	O
sex	NN	O
,	,	O
indication	NN	O
for	IN	O
MV	NNP	O
,	,	O
PRISM	NNP	O
score	NN	O
,	,	O
Comfort	NNP	O
scale	NN	O
,	,	O
use	NN	O
of	IN	O
sedatives	NNS	O
or	CC	O
ventilation	NN	O
and	CC	O
oxygenation	NN	O
parameters	NNS	O
.	.	O

The	DT	O
median	JJ	O
time	NN	O
on	IN	O
MV	NNP	O
was	VBD	O
5	CD	O
days	NNS	O
for	IN	O
both	DT	O
groups	NNS	O
(	(	O
p	JJ	O
=	NNP	O
0.120	CD	O
)	)	O
.	.	O

There	EX	O
were	VBD	O
also	RB	O
no	DT	O
statistical	JJ	O
differences	NNS	O
between	IN	O
the	DT	O
two	CD	O
groups	NNS	O
for	IN	O
duration	NN	O
of	IN	O
weaning	VBG	O
[	JJ	O
IMVG	NNP	O
:	:	O
1	CD	O
day	NN	O
(	(	O
1-6	JJ	O
)	)	O
vs.	FW	O
SIMVG	NNP	O
:	:	O
1	CD	O
day	NN	O
(	(	O
1-6	JJ	O
)	)	O
;	:	O
p	CC	O
=	$	O
0.262	CD	O
]	NN	O
or	CC	O
length	NN	O
of	IN	O
hospital	NN	O
stay	NN	O
[	JJ	O
IMVG	NNP	O
:	:	O
8	CD	O
days	NNS	O
(	(	O
2-22	JJ	O
)	)	O
vs.	FW	O
SIMVG	NNP	O
:	:	O
6	CD	O
days	NNS	O
(	(	O
3-20	JJ	O
)	)	O
;	:	O
p	CC	O
=	$	O
0.113	CD	O
]	NNP	O
.	.	O

CONCLUSION	NNP	O
Among	IN	O
the	DT	O
children	NNS	A
studied	VBN	O
here	RB	O
,	,	O
there	EX	O
was	VBD	O
no	DT	O
statistically	RB	O
significant	JJ	O
difference	NN	O
between	IN	O
IMV	NNP	O
and	CC	O
SIMV+PS	NNP	O
in	IN	O
terms	NNS	O
of	IN	O
time	NN	O
on	IN	O
MV	NNP	O
,	,	O
duration	NN	O
of	IN	O
weaning	VBG	O
or	CC	O
time	NN	O
spent	VBN	O
in	IN	O
the	DT	O
PICU	NNP	O
.	.	O

ClinicalTrials.govID	NN	O
:	:	O
NCT00549809	NNP	O
.	.	O

Predictive	JJ	O
validity	NN	O
of	IN	O
a	DT	O
medication	NN	O
adherence	NN	O
measure	NN	O
in	IN	O
an	DT	O
outpatient	JJ	O
setting	NN	O
.	.	O

This	DT	O
study	NN	O
examines	VBZ	O
the	DT	O
psychometric	JJ	O
properties	NNS	O
and	CC	O
tests	VBZ	O
the	DT	O
concurrent	NN	O
and	CC	O
predictive	JJ	O
validity	NN	O
of	IN	O
a	DT	O
structured	JJ	O
,	,	O
self-reported	JJ	O
medication	NN	O
adherence	NN	O
measure	NN	O
in	IN	O
patients	NNS	O
with	IN	O
hypertension	NN	C
.	.	O

The	DT	O
authors	NNS	O
also	RB	O
assessed	VBD	O
various	JJ	O
psychosocial	JJ	O
determinants	NNS	O
of	IN	O
adherence	NN	O
,	,	O
such	JJ	O
as	IN	O
knowledge	NN	O
,	,	O
social	JJ	O
support	NN	O
,	,	O
satisfaction	NN	O
with	IN	O
care	NN	O
,	,	O
and	CC	O
complexity	NN	O
of	IN	O
the	DT	O
medical	JJ	O
regimen	NNS	O
.	.	O

A	DT	O
total	NN	O
of	IN	O
1367	CD	SS
patients	NNS	O
participated	VBN	O
in	IN	O
the	DT	O
study	NN	O
;	:	O
mean	JJ	O
age	NN	O
was	VBD	O
52.5	CD	A
years	NNS	A
,	,	O
40.8	CD	O
%	NN	O
were	VBD	O
male	JJ	SE
,	,	O
76.5	CD	O
%	NN	O
were	VBD	O
black	JJ	O
,	,	O
50.8	CD	O
%	NN	O
graduated	VBN	O
from	IN	O
high	JJ	O
school	NN	O
,	,	O
26	CD	O
%	NN	O
were	VBD	O
married	VBN	O
,	,	O
and	CC	O
54.1	CD	O
%	NN	O
had	VBD	O
income	NN	O
<	NNP	O
$	$	O
5,000	CD	O
.	.	O

The	DT	O
8-item	JJ	O
medication	NN	O
adherence	NN	O
scale	NN	O
was	VBD	O
reliable	JJ	O
(	(	O
alpha=.83	NN	O
)	)	O
and	CC	O
significantly	RB	O
associated	VBN	O
with	IN	O
blood	NN	O
pressure	NN	O
control	NN	O
(	(	O
P	NNP	O
<	NNP	O
.05	NNP	O
)	)	O
.	.	O

Using	VBG	O
a	DT	O
cutpoint	NN	O
of	IN	O
<	$	O
6	CD	O
,	,	O
the	DT	O
sensitivity	NN	O
of	IN	O
the	DT	O
measure	NN	O
to	TO	O
identify	VB	O
patients	NNS	O
with	IN	O
poor	JJ	O
blood	NN	O
pressure	NN	O
control	NN	O
was	VBD	O
estimated	VBN	O
to	TO	O
be	VB	O
93	CD	O
%	NN	O
,	,	O
and	CC	O
the	DT	O
specificity	NN	O
was	VBD	O
53	CD	O
%	NN	O
.	.	O

The	DT	O
medication	NN	O
adherence	NN	O
measure	NN	O
proved	VBD	O
to	TO	O
be	VB	O
reliable	JJ	O
,	,	O
with	IN	O
good	JJ	O
concurrent	NN	O
and	CC	O
predictive	JJ	O
validity	NN	O
in	IN	O
primarily	RB	O
low-income	JJ	O
,	,	O
minority	NN	O
patients	NNS	O
with	IN	O
hypertension	NN	O
and	CC	O
might	MD	O
function	VB	O
as	IN	O
a	DT	O
screening	VBG	O
tool	NN	O
in	IN	O
outpatient	JJ	O
settings	NNS	O
with	IN	O
other	JJ	O
patient	NN	O
groups	NNS	O
.	.	O

Double-blind	NNP	O
,	,	O
placebo-controlled	JJ	O
trial	NN	O
of	IN	O
risperidone	NN	O
plus	CC	O
topiramate	NN	O
in	IN	O
children	NNS	A
with	IN	O
autistic	JJ	C
disorder	NN	C
.	.	O

BACKGROUND	NNP	O
Autism	NNP	O
is	VBZ	O
a	DT	O
complex	JJ	O
neurodevelopmental	JJ	O
disorder	NN	O
that	WDT	O
forms	VBZ	O
part	NN	O
of	IN	O
a	DT	O
spectrum	NN	O
of	IN	O
related	JJ	O
disorders	NNS	O
referred	VBD	O
to	TO	O
as	IN	O
Autism	NNP	O
Spectrum	NNP	O
Disorders	NNP	O
.	.	O

The	DT	O
present	JJ	O
study	NN	O
assessed	VBD	O
the	DT	O
effects	NNS	O
of	IN	O
topiramate	NN	O
plus	CC	O
risperidone	NN	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
autistic	JJ	C
disorder	NN	C
.	.	O

METHOD	NNP	O
Forty	NNP	SS
children	NNS	O
between	IN	O
the	DT	O
ages	NNS	A
of	IN	A
4	CD	A
and	CC	A
12	CD	A
years	NNS	A
with	IN	O
a	DT	O
DSM	NNP	C
IV	NNP	C
clinical	JJ	C
diagnosis	NN	C
of	IN	C
autism	NN	C
who	WP	O
were	VBD	O
outpatients	NNS	O
from	IN	O
a	DT	O
specialty	NN	O
clinic	NN	O
for	IN	O
children	NNS	O
were	VBD	O
recruited	VBN	O
.	.	O

The	DT	O
children	NNS	O
presented	VBN	O
with	IN	O
a	DT	O
chief	JJ	O
complaint	NN	O
of	IN	O
severely	RB	C
disruptive	JJ	C
symptoms	NNS	C
related	VBN	O
to	TO	O
autistic	JJ	C
disorder	NN	C
.	.	O

Patients	NNS	O
were	VBD	O
randomly	RB	O
allocated	VBN	O
to	TO	O
topiramate+risperidone	VB	O
(	(	O
Group	NNP	O
A	NNP	O
)	)	O
or	CC	O
placebo+risperidone	NN	O
(	(	O
Group	NNP	O
B	NNP	O
)	)	O
for	IN	O
an	DT	O
8-week	JJ	O
,	,	O
double-blind	JJ	O
,	,	O
placebo-controlled	JJ	O
study	NN	O
.	.	O

The	DT	O
dose	NN	O
of	IN	O
risperidone	NN	O
was	VBD	O
titrated	VBN	O
up	RB	O
to	TO	O
2	CD	O
mg/day	NN	O
for	IN	O
children	NNS	O
between	IN	O
10	CD	O
and	CC	O
40	CD	O
kg	NN	O
and	CC	O
3	CD	O
mg/day	NN	O
for	IN	O
children	NNS	O
weighting	VBG	O
above	IN	O
40	CD	O
kg	NN	O
.	.	O

The	DT	O
dose	NN	O
of	IN	O
topiramate	NN	O
was	VBD	O
titrated	VBN	O
up	RB	O
to	TO	O
200	CD	O
mg/day	NN	O
depending	VBG	O
on	IN	O
weight	NN	O
(	(	O
100	CD	O
mg/day	NN	O
for	IN	O
<	$	O
30	CD	O
kg	NN	O
and	CC	O
200	CD	O
mg/day	NN	O
for	IN	O
>	$	O
30	CD	O
kg	NN	O
)	)	O
.	.	O

Patients	NNS	O
were	VBD	O
assessed	VBN	O
at	IN	O
baseline	NN	O
and	CC	O
after	IN	O
2	CD	O
,	,	O
4	CD	O
,	,	O
6	CD	O
and	CC	O
8	CD	O
weeks	NNS	O
after	IN	O
starting	VBG	O
medication	NN	O
.	.	O

Measure	NN	O
of	IN	O
outcome	NN	O
was	VBD	O
the	DT	O
Aberrant	NNP	O
Behavior	NNP	O
Checklist-Community	NNP	O
(	(	O
ABC-C	NNP	O
)	)	O
Rating	VBG	O
Scale	NNP	O
.	.	O

RESULTS	NNP	O
Difference	NNP	O
between	IN	O
the	DT	O
two	CD	O
protocols	NNS	O
was	VBD	O
significant	JJ	O
as	IN	O
the	DT	O
group	NN	O
that	WDT	O
received	VBD	O
topiramate	NN	O
had	VBD	O
a	DT	O
greater	JJR	O
reduction	NN	O
in	IN	O
ABC-C	NNP	O
subscale	NN	O
scores	NNS	O
for	IN	O
irritability	NN	O
,	,	O
stereotypic	JJ	O
behavior	NN	O
and	CC	O
hyperactivity/noncompliance	NN	O
.	.	O

CONCLUSION	VB	O
The	DT	O
results	NNS	O
suggest	VBP	O
that	IN	O
the	DT	O
combination	NN	O
of	IN	O
topiramate	NN	O
with	IN	O
risperidone	NN	O
may	MD	O
be	VB	O
superior	JJ	O
to	TO	O
risperidone	VB	O
monotherapy	NN	O
for	IN	O
children	NNS	A
with	IN	O
autistic	JJ	C
disorder	NN	C
.	.	O

However	RB	O
the	DT	O
results	NNS	O
need	VBP	O
to	TO	O
be	VB	O
further	RB	O
confirmed	VBN	O
by	IN	O
a	DT	O
larger	JJR	O
randomized	VBN	O
controlled	VBN	O
trial	NN	O
.	.	O

In-season	JJ	O
effect	NN	O
of	IN	O
short-term	JJ	O
sprint	NN	O
and	CC	O
power	NN	O
training	NN	O
programs	NNS	O
on	IN	O
elite	JJ	O
junior	JJ	O
soccer	NN	O
players	NNS	O
.	.	O

The	DT	O
aim	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
examine	VB	O
the	DT	O
effects	NNS	O
of	IN	O
2	CD	O
in-season	JJ	O
short-term	JJ	O
sprint	NN	O
and	CC	O
power	NN	O
training	NN	O
protocols	NNS	O
on	IN	O
vertical	JJ	O
countermovement	NN	O
jump	NN	O
height	NN	O
(	(	O
with	IN	O
or	CC	O
without	IN	O
arms	NNS	O
)	)	O
,	,	O
sprint	NN	O
(	(	O
Sprint-15m	NNP	O
)	)	O
speed	NN	O
,	,	O
and	CC	O
agility	NN	O
(	(	O
Agility-15m	NNP	O
)	)	O
speed	NN	O
in	IN	O
male	JJ	SE
elite	JJ	O
junior	JJ	O
soccer	NN	O
players	NNS	O
.	.	O

Twenty	NNP	O
highly	RB	O
trained	VBD	O
soccer	NN	O
players	NNS	O
(	(	O
age	NN	O
18.3	CD	A
+/-	JJ	A
0.6	CD	A
years	NNS	A
,	,	O
height	VBD	O
177	CD	O
+/-	JJ	O
4	CD	O
cm	NN	O
,	,	O
body	NN	O
mass	VBD	O
71.4	CD	O
+/-	JJ	O
6.9	CD	O
kg	NN	O
,	,	O
sum	NN	O
skinfolds	NNS	O
48.1	CD	O
+/-	JJ	O
11.4	CD	O
mm	NN	O
)	)	O
,	,	O
members	NNS	O
of	IN	O
a	DT	O
professional	JJ	O
soccer	NN	O
academy	NN	O
,	,	O
were	VBD	O
randomly	RB	O
allocated	VBN	O
to	TO	O
either	VB	O
a	DT	O
CONTRAST	NNP	O
(	(	O
n	JJ	O
=	NNP	O
10	CD	O
)	)	O
or	CC	O
SPRINT	NNP	O
(	(	O
n	JJ	O
=	NNP	O
10	CD	O
)	)	O
group	NN	O
.	.	O

The	DT	O
training	NN	O
intervention	NN	O
consisted	VBD	O
of	IN	O
6	CD	O
supervised	JJ	O
training	NN	O
sessions	NNS	O
over	IN	O
7	CD	O
weeks	NNS	O
,	,	O
targeting	VBG	O
the	DT	O
improvement	NN	O
of	IN	O
the	DT	O
players	NNS	O
'	POS	O
speed	NN	O
and	CC	O
power	NN	O
.	.	O

CONTRAST	NNP	O
protocol	NN	O
consisted	VBD	O
of	IN	O
alternating	VBG	O
heavy-light	JJ	O
resistance	NN	O
(	(	O
15-50	CD	O
%	NN	O
body	NN	O
mass	NN	O
)	)	O
with	IN	O
soccer-specific	JJ	O
drills	NNS	O
(	(	O
small-sided	JJ	O
games	NNS	O
or	CC	O
technical	JJ	O
skills	NNS	O
)	)	O
.	.	O

SPRINT	NNP	O
training	NN	O
protocol	NN	O
used	VBN	O
line	NN	O
30-m	JJ	O
sprints	NNS	O
(	(	O
2-4	JJ	O
sets	NNS	O
of	IN	O
4	CD	O
x	JJ	O
30	CD	O
m	NN	O
with	IN	O
180	CD	O
and	CC	O
90	CD	O
seconds	NNS	O
of	IN	O
recovery	NN	O
,	,	O
respectively	RB	O
)	)	O
.	.	O

At	IN	O
baseline	JJ	O
no	DT	O
difference	NN	O
between	IN	O
physical	JJ	O
test	NN	O
performance	NN	O
was	VBD	O
evident	JJ	O
between	IN	O
the	DT	O
2	CD	O
groups	NNS	O
(	(	O
p	JJ	O
>	NNP	O
0.05	CD	O
)	)	O
.	.	O

No	DT	O
time	NN	O
x	VBZ	O
training	VBG	O
group	NN	O
effect	NN	O
was	VBD	O
found	VBN	O
for	IN	O
any	DT	O
of	IN	O
the	DT	O
vertical	JJ	O
jump	NN	O
and	CC	O
Agility-15m	JJ	O
variables	NNS	O
(	(	O
p	JJ	O
>	NNP	O
0.05	CD	O
)	)	O
.	.	O

A	DT	O
time	NN	O
x	JJ	O
training	VBG	O
group	NN	O
effect	NN	O
was	VBD	O
found	VBN	O
for	IN	O
Sprint-15m	JJ	O
performance	NN	O
with	IN	O
the	DT	O
CONTRAST	NNP	O
group	NN	O
showing	VBG	O
significantly	RB	O
better	JJR	O
scores	NNS	O
than	IN	O
the	DT	O
SPRINT	NNP	O
group	NN	O
(	(	O
7.23	CD	O
+/-	JJ	O
0.18	CD	O
vs.	FW	O
7.09	CD	O
+/-	JJ	O
0.20	CD	O
m.s	NN	O
,	,	O
p	NN	O
<	NNP	O
0.01	CD	O
)	)	O
.	.	O

In	IN	O
light	NN	O
of	IN	O
these	DT	O
findings	NNS	O
CONTRAST	NNP	O
training	NN	O
should	MD	O
be	VB	O
preferred	VBN	O
to	TO	O
line	NN	O
sprint	NN	O
training	NN	O
in	IN	O
the	DT	O
short	JJ	O
term	NN	O
in	IN	O
young	JJ	O
elite	JJ	O
soccer	NN	O
players	NNS	O
when	WRB	O
the	DT	O
aim	NN	O
is	VBZ	O
to	TO	O
improve	VB	O
soccer-specific	JJ	O
sprint	NN	O
performance	NN	O
(	(	O
15	CD	O
m	NN	O
)	)	O
during	IN	O
the	DT	O
competitive	JJ	O
season	NN	O
.	.	O

A	DT	O
program	NN	O
of	IN	O
screening	VBG	O
and	CC	O
prompting	VBG	O
improves	NNS	O
short-term	JJ	O
physician	JJ	O
counseling	NN	O
of	IN	O
dependent	NN	O
and	CC	O
nondependent	JJ	O
harmful	JJ	O
drinkers	NNS	O
.	.	O

BACKGROUND	NNP	O
Physicians	NNPS	O
in	IN	O
the	DT	O
general	JJ	O
medical	JJ	O
setting	VBG	O
commonly	RB	O
encounter	RB	O
but	CC	O
rarely	RB	O
counsel	NN	O
patients	NNS	O
with	IN	O
dependent	JJ	O
or	CC	O
harmful	JJ	O
drinking	NN	O
behaviors	NNS	O
.	.	O

We	PRP	O
tested	VBD	O
whether	IN	O
providing	VBG	O
physicians	NNS	O
with	IN	O
their	PRP$	O
patients	NNS	O
'	POS	O
results	NNS	O
on	IN	O
the	DT	O
alcohol	NN	O
module	NN	O
of	IN	O
the	DT	O
Diagnostic	NNP	O
Interview	NNP	O
Schedule	NNP	O
and	CC	O
counseling	VBG	O
directives	NNS	O
would	MD	O
prompt	VB	O
them	PRP	O
to	TO	O
counsel	NN	O
these	DT	O
patients	NNS	O
.	.	O

METHODS	NNP	O
We	PRP	O
randomly	VBP	O
assigned	VBN	O
83	CD	O
first-	JJ	O
,	,	O
second-	JJ	O
,	,	O
and	CC	O
third-year	JJ	O
medical	JJ	O
residents	NNS	O
to	TO	O
receive	VB	O
or	CC	O
not	RB	O
to	TO	O
receive	VB	O
diagnostic	JJ	O
information	NN	O
and	CC	O
counseling	VBG	O
directives	NNS	O
on	IN	O
214	CD	O
patients	NNS	O
who	WP	O
reported	VBD	O
at	IN	O
least	JJS	O
one	CD	O
symptom	NN	O
of	IN	O
alcohol	NN	O
impairment	NN	O
as	IN	O
defined	VBN	O
in	IN	O
the	DT	O
Diagnostic	NNP	O
and	CC	O
Statistical	NNP	O
Manual	NNP	O
of	IN	O
Mental	NNP	O
Disorders	NNP	O
,	,	O
Third	NNP	O
Edition	NNP	O
.	.	O

Using	VBG	O
binary	JJ	O
logistic	JJ	O
regression	NN	O
,	,	O
we	PRP	O
examined	VBD	O
the	DT	O
effect	NN	O
of	IN	O
specific	JJ	O
covariables	NNS	O
on	IN	O
rates	NNS	O
of	IN	O
physician	JJ	O
counseling	NN	O
.	.	O

These	DT	O
variables	NNS	O
included	VBD	O
physician	JJ	O
information	NN	O
status	NN	O
,	,	O
patient	JJ	O
gender	NN	O
,	,	O
and	CC	O
drinking	VBG	O
disorder	NN	O
severity	NN	O
and	CC	O
recency	NN	O
.	.	O

We	PRP	O
also	RB	O
examined	VBD	O
the	DT	O
effect	NN	O
of	IN	O
physician	JJ	O
prompting	VBG	O
on	IN	O
counseling	NN	O
of	IN	O
female	JJ	O
patients	NNS	O
,	,	O
patients	NNS	O
with	IN	O
inactive	JJ	O
disorders	NNS	O
,	,	O
and	CC	O
nondependent	NN	O
but	CC	O
harmful	JJ	O
drinkers	NNS	O
.	.	O

We	PRP	O
determined	VBD	O
counseling	VBG	O
by	IN	O
post-visit	JJ	O
patient	JJ	O
interviews	NNS	O
.	.	O

RESULTS	NNP	O
Physician	JJ	O
prompting	NN	O
,	,	O
dependent	JJ	O
drinking	NN	O
,	,	O
and	CC	O
recent	JJ	O
disorder	NN	O
activity	NN	O
were	VBD	O
significant	JJ	O
correlates	NNS	O
of	IN	O
physician	JJ	O
counseling	NN	O
(	(	O
P	NNP	O
<	NNP	O
.05	NNP	O
)	)	O
,	,	O
while	IN	O
male	JJ	O
gender	NN	O
was	VBD	O
a	DT	O
marginally	RB	O
significant	JJ	O
correlate	NN	O
(	(	O
P	NNP	O
=	NNP	O
.08	NNP	O
)	)	O
.	.	O

Informed	VBN	O
physicians	NNS	O
counseled	VBD	O
female	JJ	O
patients	NNS	O
,	,	O
harmful	JJ	O
but	CC	O
nondependent	JJ	O
drinkers	NNS	O
,	,	O
and	CC	O
patients	NNS	O
with	IN	O
inactive	JJ	O
disorders	NNS	O
more	RBR	O
often	RB	O
than	IN	O
their	PRP$	O
uninformed	JJ	O
colleagues	NNS	O
,	,	O
although	IN	O
only	RB	O
the	DT	O
last	JJ	O
variable	JJ	O
achieved	VBD	O
statistical	JJ	O
significance	NN	O
.	.	O

CONCLUSIONS	NNP	O
Providing	VBG	O
physicians	NNS	O
with	IN	O
the	DT	O
results	NNS	O
of	IN	O
the	DT	O
Diagnostic	NNP	O
Interview	NNP	O
Schedule	NNP	O
and	CC	O
counseling	VBG	O
directives	NNS	O
resulted	VBD	O
in	IN	O
short-term	JJ	O
improvement	NN	O
in	IN	O
their	PRP$	O
rates	NNS	O
of	IN	O
counseling	VBG	O
patients	NNS	O
with	IN	O
a	DT	O
history	NN	O
of	IN	O
dependent	NN	O
or	CC	O
nondependent	NN	O
but	CC	O
harmful	JJ	O
drinking	NN	O
.	.	O

Further	NNP	O
research	NN	O
is	VBZ	O
necessary	JJ	O
to	TO	O
determine	VB	O
long-term	JJ	O
gains	NNS	O
in	IN	O
rates	NNS	O
of	IN	O
physician	JJ	O
counseling	NN	O
and	CC	O
improvements	NNS	O
in	IN	O
the	DT	O
course	NN	O
of	IN	O
these	DT	O
patients	NNS	O
.	.	O

Antihistamines	NNS	O
do	VBP	O
not	RB	O
inhibit	VB	O
the	DT	O
wheal	NN	O
induced	VBN	O
by	IN	O
the	DT	O
intradermal	JJ	O
injection	NN	O
of	IN	O
autologous	JJ	O
serum	NN	O
in	IN	O
resistant	JJ	O
chronic	JJ	O
idiopathic	JJ	O
urticaria	NN	O
.	.	O

Some	DT	O
patients	NNS	O
with	IN	O
chronic	JJ	O
idiopathic	JJ	O
urticaria	NN	O
(	(	O
CIU	NNP	O
)	)	O
are	VBP	O
resistant	JJ	O
to	TO	O
conventional	JJ	O
doses	NNS	O
of	IN	O
antihistamines	NNS	O
(	(	O
AHs	NNP	O
)	)	O
.	.	O

This	DT	O
study	NN	O
was	VBD	O
designed	VBN	O
to	TO	O
check	VB	O
whether	IN	O
the	DT	O
skin	JJ	O
wheal	NN	O
and	CC	O
flare	JJ	O
reaction	NN	O
produced	VBN	O
by	IN	O
the	DT	O
intradermal	JJ	O
injection	NN	O
of	IN	O
autologous	JJ	O
serum	NN	O
(	(	O
AS	IN	O
)	)	O
and	CC	O
by	IN	O
histamine	NN	O
differs	NNS	O
in	IN	O
AH-resistant	NNP	O
and	CC	O
AH	NNP	O
responder	VBP	O
CIU	NNP	O
patients	NNS	O
.	.	O

CIU	NNP	O
patients	NNS	O
with	IN	O
treatment	NN	O
failure	NN	O
under	IN	O
fexofenadine	NN	O
at	IN	O
180	CD	O
mg	NN	O
q.d	NN	O
.	.	O

increased	VBD	O
their	PRP$	O
daily	JJ	O
dose	NN	O
of	IN	O
AH	NNP	O
to	TO	O
4	CD	O
tablets	NNS	O
daily	RB	O
.	.	O

Those	DT	O
with	IN	O
significant	JJ	O
improvement	NN	O
of	IN	O
urticaria	JJ	O
activity	NN	O
score	NN	O
under	IN	O
fexofenadine	NN	O
at	IN	O
180	CD	O
mg	NNS	O
were	VBD	O
included	VBN	O
in	IN	O
the	DT	O
CIU	NNP	O
group	NN	O
.	.	O

Subjects	VBZ	O
with	IN	O
treatment	NN	O
failure	NN	O
despite	IN	O
a	DT	O
full	JJ	O
8-week	JJ	O
fourfold	JJ	O
fexofenadine	NN	O
treatment	NN	O
were	VBD	O
included	VBN	O
in	IN	O
the	DT	O
resistant	JJ	O
CIU	NNP	O
(	(	O
R-CIU	NNP	O
group	NN	O
)	)	O
.	.	O

The	DT	O
control	NN	O
group	NN	O
consisted	VBD	O
of	IN	O
sex-	JJ	O
and	CC	O
age-matched	JJ	O
patents	NNS	O
with	IN	O
allergic	JJ	O
rhinitis	NN	O
.	.	O

The	DT	O
AS	NNP	O
skin	JJ	O
test	NN	O
and	CC	O
intradermal	JJ	O
histamine-induced	JJ	O
wheal	NN	O
and	CC	O
flare	JJ	O
reaction	NN	O
were	VBD	O
performed	VBN	O
at	IN	O
baseline	NN	O
(	(	O
without	IN	O
AH	NNP	O
)	)	O
,	,	O
after	IN	O
8	CD	O
and	CC	O
16	CD	O
weeks	NNS	O
(	(	O
under	IN	O
AH	NNP	O
treatment	NN	O
)	)	O
.	.	O

Forty-six	JJ	O
subjects	NNS	O
were	VBD	O
included	VBN	O
in	IN	O
the	DT	O
CIU	NNP	O
group	NN	O
,	,	O
21	CD	O
were	VBD	O
in	IN	O
the	DT	O
R-CIU	NNP	O
group	NN	O
,	,	O
and	CC	O
44	CD	O
were	VBD	O
in	IN	O
the	DT	O
control	NN	O
group	NN	O
.	.	O

Under	IN	O
AH	NNP	O
therapy	NN	O
,	,	O
the	DT	O
skin	JJ	O
reaction	NN	O
to	TO	O
intradermal	VB	O
histamine	JJ	O
injection	NN	O
was	VBD	O
significantly	RB	O
diminished	VBN	O
in	IN	O
all	DT	O
study	NN	O
groups	NNS	O
.	.	O

In	IN	O
the	DT	O
R-CIU	NNP	O
group	NN	O
,	,	O
fexofenadine	NN	O
at	IN	O
180	CD	O
mg	NNS	O
did	VBD	O
not	RB	O
suppress	VB	O
AS-induced	NNP	O
wheal	JJ	O
reaction	NN	O
(	(	O
5.96	CD	O
?	.	O
2.25	CD	O
mm	NN	O
;	:	O
p	CC	O
=	VB	O
0.85	CD	O
)	)	O
,	,	O
and	CC	O
with	IN	O
a	DT	O
fourfold	JJ	O
AH	NNP	O
dose	VB	O
some	DT	O
reduction	NN	O
of	IN	O
AS-induced	NNP	O
wheal	NN	O
(	(	O
3.79	CD	O
?	.	O
1.74	CD	O
mm	NN	O
;	:	O
p	CC	O
=	VB	O
0.008	CD	O
)	)	O
was	VBD	O
observed	VBN	O
but	CC	O
remained	VBD	O
larger	JJR	O
than	IN	O
in	IN	O
the	DT	O
CIU	NNP	O
(	(	O
2.31	CD	O
?	.	O
1.12	CD	O
;	:	O
p	NN	O
=	VBZ	O
0.006	CD	O
)	)	O
and	CC	O
control	NN	O
groups	NNS	O
(	(	O
2.52	CD	O
?	.	O
1.36	CD	O
;	:	O
p	NN	O
=	VBZ	O
0.037	CD	O
)	)	O
.	.	O

AHs	NNP	O
do	VBP	O
not	RB	O
inhibit	VB	O
the	DT	O
wheal	NN	O
induced	VBN	O
by	IN	O
the	DT	O
intradermal	JJ	O
injection	NN	O
of	IN	O
AS	NNP	O
in	IN	O
R-CIU	NNP	O
.	.	O

Plasma	NNP	O
pH	NN	O
does	VBZ	O
not	RB	O
influence	VB	O
the	DT	O
cerebral	JJ	O
metabolic	JJ	O
ratio	NN	O
during	IN	O
maximal	JJ	O
whole	JJ	O
body	NN	O
exercise	NN	O
.	.	O

Exercise	NN	O
lowers	VBZ	O
the	DT	O
cerebral	JJ	O
metabolic	JJ	O
ratio	NN	O
of	IN	O
O2	NNP	O
to	TO	O
carbohydrate	VB	O
(	(	O
glucose+1/2	JJ	O
lactate	NN	O
)	)	O
and	CC	O
metabolic	JJ	O
acidosis	NN	O
appears	VBZ	O
to	TO	O
promote	VB	O
cerebral	JJ	O
lactate	JJ	O
uptake	NN	O
.	.	O

However	RB	O
,	,	O
the	DT	O
influence	NN	O
of	IN	O
pH	NN	O
on	IN	O
cerebral	JJ	O
lactate	JJ	O
uptake	NN	O
and	CC	O
,	,	O
in	IN	O
turn	NN	O
,	,	O
on	IN	O
the	DT	O
cerebral	JJ	O
metabolic	JJ	O
ratio	NN	O
during	IN	O
exercise	NN	O
is	VBZ	O
not	RB	O
known	VBN	O
.	.	O

Sodium	NN	O
bicarbonate	NN	O
(	(	O
Bicarb	NNP	O
,	,	O
1	CD	O
M	NNP	O
;	:	O
350-500	CD	O
ml	NN	O
)	)	O
or	CC	O
an	DT	O
equal	JJ	O
volume	NN	O
of	IN	O
normal	JJ	O
saline	NN	O
(	(	O
Sal	NNP	O
)	)	O
was	VBD	O
infused	VBN	O
intravenously	RB	O
at	IN	O
a	DT	O
constant	JJ	O
rate	NN	O
during	IN	O
a	DT	O
'2000	CD	O
m	NN	O
'	''	O
maximal	JJ	O
ergometer	NN	O
row	NN	O
in	IN	O
six	CD	O
male	JJ	O
oarsmen	NNS	O
(	(	O
23?2	CD	O
years	NNS	O
;	:	O
mean?S.D.	NN	O
)	)	O
.	.	O

During	IN	O
the	DT	O
Sal	NNP	O
trial	NN	O
,	,	O
pH	NN	O
decreased	VBD	O
from	IN	O
7.41?0.01	CD	O
at	IN	O
rest	NN	O
to	TO	O
7.02?0.02	CD	O
but	CC	O
only	RB	O
to	TO	O
7.36?0.02	CD	O
(	(	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
during	IN	O
the	DT	O
Bicarb	NNP	O
trial	NN	O
.	.	O

Arterial	JJ	O
lactate	NN	O
increased	VBD	O
to	TO	O
21.4?0.8	CD	O
and	CC	O
32.7?2.3	CD	O
mM	NN	O
during	IN	O
the	DT	O
Sal	NNP	O
and	CC	O
Bicarb	NNP	O
trials	NNS	O
,	,	O
respectively	RB	O
(	(	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
.	.	O

Also	RB	O
,	,	O
the	DT	O
arterial-jugular	JJ	O
venous	JJ	O
lactate	NN	O
difference	NN	O
increased	VBD	O
from-0.03?0.01	JJ	O
mM	NN	O
at	IN	O
rest	NN	O
to	TO	O
3.2?0.9	CD	O
mM	NN	O
(	(	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
and	CC	O
3.4?1.4	CD	O
mM	NN	O
(	(	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
following	VBG	O
the	DT	O
Sal	NNP	O
and	CC	O
Bicarb	NNP	O
trials	NNS	O
,	,	O
respectively	RB	O
.	.	O

Accordingly	RB	O
,	,	O
the	DT	O
cerebral	JJ	O
metabolic	NN	O
ratio	NN	O
decreased	VBD	O
equally	RB	O
during	IN	O
the	DT	O
Sal	NNP	O
and	CC	O
Bicarb	NNP	O
trials	NNS	O
:	:	O
from	IN	O
5.8?0.6	CD	O
at	IN	O
rest	NN	O
to	TO	O
1.7?0.1	CD	O
and	CC	O
1.8?0.2	CD	O
,	,	O
respectively	RB	O
.	.	O

The	DT	O
enlarged	JJ	O
blood-buffering	NN	O
capacity	NN	O
after	IN	O
infusion	NN	O
of	IN	O
Bicarb	NNP	O
eliminated	VBD	O
metabolic	JJ	O
acidosis	NN	O
during	IN	O
maximal	JJ	O
exercise	NN	O
but	CC	O
that	DT	O
did	VBD	O
not	RB	O
affect	VB	O
the	DT	O
cerebral	JJ	O
lactate	NN	O
uptake	NN	O
and	CC	O
,	,	O
therefore	RB	O
,	,	O
the	DT	O
decrease	NN	O
in	IN	O
the	DT	O
cerebral	JJ	O
metabolic	NN	O
ratio	NN	O
.	.	O

Incidence	NN	O
and	CC	O
clinical	JJ	O
significance	NN	O
of	IN	O
false-negative	JJ	C
sextant	JJ	C
prostate	NN	C
biopsies	NNS	C
.	.	C

PURPOSE	NNP	O
Since	IN	O
most	JJS	O
patients	NNS	O
do	VBP	O
not	RB	O
undergo	VB	O
repeat	NN	O
sextant	JJ	O
prostate	NN	O
biopsies	NNS	O
after	IN	O
a	DT	O
biopsy	NN	O
is	VBZ	O
positive	JJ	O
for	IN	O
prostate	NN	O
cancer	NN	O
,	,	O
the	DT	O
true	JJ	O
incidence	NN	O
of	IN	O
false-negative	JJ	O
biopsies	NNS	O
is	VBZ	O
not	RB	O
well	RB	O
defined	VBN	O
.	.	O

We	PRP	O
assess	VBP	O
the	DT	O
incidence	NN	O
and	CC	O
clinical	JJ	O
significance	NN	O
of	IN	O
false-negative	JJ	O
sextant	JJ	O
prostate	NN	O
biopsies	NNS	O
in	IN	O
patients	NNS	O
undergoing	VBG	O
radical	JJ	O
prostatectomy	NN	O
.	.	O

MATERIALS	NNP	O
AND	NNP	O
METHODS	NNP	O
A	NNP	O
total	NN	O
of	IN	O
118	CD	O
patients	NNS	O
with	IN	O
biopsy	NN	O
proved	VBN	O
prostate	JJ	O
cancer	NN	O
underwent	JJ	O
repeat	NN	O
sextant	JJ	O
prostate	NN	O
biopsy	NN	O
before	IN	O
enrollment	NN	O
in	IN	O
a	DT	O
prospective	JJ	O
randomized	VBN	O
trial	NN	O
of	IN	O
radical	JJ	O
prostatectomy	NN	O
with	IN	O
or	CC	O
without	IN	O
neoadjuvant	JJ	O
hormonal	JJ	O
therapy	NN	O
.	.	O

Clinical	JJ	O
parameters	NNS	O
were	VBD	O
assessed	VBN	O
to	TO	O
determine	VB	O
potential	JJ	O
sources	NNS	O
of	IN	O
bias	NN	O
.	.	O

Pathological	JJ	O
parameters	NNS	O
and	CC	O
prostate	NN	O
specific	JJ	O
antigen	NN	O
relapse-free	JJ	O
survival	NN	O
rates	NNS	O
were	VBD	O
compared	VBN	O
to	TO	O
determine	VB	O
the	DT	O
clinical	JJ	O
significance	NN	O
of	IN	O
false-negative	JJ	O
biopsies	NNS	O
.	.	O

RESULTS	NNP	O
Of	IN	O
the	DT	O
118	CD	O
patients	NNS	O
27	CD	O
(	(	O
23	CD	O
%	NN	O
)	)	O
had	VBD	O
a	DT	O
negative	JJ	O
repeat	NN	O
sextant	JJ	O
biopsy	NN	O
.	.	O

Except	IN	O
for	IN	O
initial	JJ	O
clinical	JJ	O
stage	NN	O
,	,	O
no	DT	O
differences	NNS	O
were	VBD	O
noted	VBN	O
in	IN	O
the	DT	O
clinical	JJ	O
or	CC	O
pathological	JJ	O
parameters	NNS	O
,	,	O
or	CC	O
prostate	VB	O
specific	JJ	O
antigen	NN	O
relapse	NN	O
rates	NNS	O
in	IN	O
patients	NNS	O
with	IN	O
negative	JJ	O
versus	NN	O
positive	JJ	O
repeat	NN	O
biopsies	NNS	O
.	.	O

CONCLUSIONS	NNP	O
Our	PRP$	O
findings	NNS	O
suggest	VBP	O
that	IN	O
this	DT	O
23	CD	O
%	NN	O
incidence	NN	O
of	IN	O
false-negative	JJ	O
biopsies	NNS	O
represents	VBZ	O
significant	JJ	O
cancer	NN	O
.	.	O

This	DT	O
relatively	RB	O
high	JJ	O
incidence	NN	O
is	VBZ	O
important	JJ	O
to	TO	O
consider	VB	O
in	IN	O
treatment	NN	O
modalities	NNS	O
in	IN	O
which	WDT	O
prostate	VBP	O
biopsy	NN	O
may	MD	O
be	VB	O
performed	VBN	O
to	TO	O
determine	VB	O
response	NN	O
to	TO	O
therapy	NN	O
.	.	O

Comparison	NNP	O
of	IN	O
an	DT	O
allograft	NN	O
in	IN	O
an	DT	O
experimental	JJ	O
putty	NN	O
carrier	NN	O
and	CC	O
a	DT	O
bovine-derived	JJ	O
xenograft	NN	O
used	VBN	O
in	IN	O
ridge	JJ	O
preservation	NN	O
:	:	O
a	DT	O
clinical	JJ	O
and	CC	O
histologic	JJ	O
study	NN	O
in	IN	O
humans	NNS	C
.	.	O

PURPOSE	VB	O
The	DT	O
aim	NN	O
of	IN	O
this	DT	O
randomized	VBN	O
,	,	O
controlled	VBN	O
,	,	O
blinded	VBD	O
clinical	JJ	O
study	NN	O
was	VBD	O
to	TO	O
compare	VB	O
ridge	JJ	O
dimensions	NNS	O
and	CC	O
histologic	JJ	O
characteristics	NNS	O
of	IN	O
ridges	NNS	O
preserved	VBN	O
with	IN	O
2	CD	O
different	JJ	O
graft	NN	O
materials	NNS	O
.	.	O

MATERIALS	NNP	O
AND	CC	O
METHODS	NNP	O
Twenty-four	NNP	SS
subjects	NNS	O
,	,	O
each	DT	O
requiring	VBG	O
a	DT	O
nonmolar	JJ	C
extraction	NN	C
and	CC	O
delayed	JJ	C
implant	NN	C
placement	NN	C
,	,	O
were	VBD	O
randomly	RB	O
selected	VBN	O
to	TO	O
receive	VB	O
ridge	NN	O
preservation	NN	O
treatment	NN	O
with	IN	O
either	DT	O
an	DT	O
allograft	NN	O
in	IN	O
an	DT	O
experimental	JJ	O
putty	NN	O
carrier	NN	O
plus	CC	O
a	DT	O
calcium	NN	O
sulfate	NN	O
barrier	NN	O
(	(	O
PUT	NNP	O
)	)	O
or	CC	O
a	DT	O
bovine-derived	JJ	O
xenograft	NN	O
(	(	O
BDX	NNP	O
)	)	O
plus	CC	O
a	DT	O
collagen	NN	O
membrane	NN	O
.	.	O

Horizontal	NNP	O
and	CC	O
vertical	JJ	O
ridge	NN	O
dimensions	NNS	O
were	VBD	O
determined	VBN	O
using	VBG	O
a	DT	O
digital	JJ	O
caliper	NN	O
and	CC	O
a	DT	O
template	NN	O
.	.	O

At	IN	O
4	CD	O
months	NNS	O
postextraction	NN	O
,	,	O
a	DT	O
trephine	NN	O
core	NN	O
was	VBD	O
obtained	VBN	O
for	IN	O
histologic	JJ	O
analysis	NN	O
.	.	O

RESULTS	VB	O
The	DT	O
average	JJ	O
ridge	NN	O
width	NN	O
decreased	VBN	O
by	IN	O
0.50	CD	O
mm	NN	O
for	IN	O
both	DT	O
groups	NNS	O
(	(	O
P	NNP	O
<	NNP	O
.05	NNP	O
)	)	O
.	.	O

The	DT	O
midbuccal	JJ	O
vertical	JJ	O
change	NN	O
for	IN	O
the	DT	O
PUT	NNP	O
group	NN	O
was	VBD	O
a	DT	O
loss	NN	O
of	IN	O
0.3+/-0.7	JJ	O
mm	NN	O
versus	IN	O
a	DT	O
gain	NN	O
of	IN	O
0.7+/-1.2	JJ	O
mm	NN	O
for	IN	O
the	DT	O
BDX	NNP	O
group	NN	O
,	,	O
a	DT	O
difference	NN	O
of	IN	O
1.0	CD	O
mm	NN	O
(	(	O
P	NNP	O
>	NNP	O
.05	NNP	O
)	)	O
.	.	O

Histologic	NNP	O
analysis	NN	O
revealed	VBD	O
vital	JJ	O
bone	NN	O
in	IN	O
the	DT	O
PUT	NNP	O
group	NN	O
of	IN	O
about	RB	O
61	CD	O
%	NN	O
+/-9	JJ	O
%	NN	O
versus	IN	O
26	CD	O
%	NN	O
+/-20	JJ	O
%	NN	O
for	IN	O
the	DT	O
BDX	NNP	O
group	NN	O
(	(	O
P	NNP	O
<	NNP	O
.05	NNP	O
)	)	O
.	.	O

DISCUSSION	NNP	O
Greater	NNP	O
vital	JJ	O
bone	NN	O
fill	NN	O
in	IN	O
the	DT	O
PUT	NNP	O
group	NN	O
may	MD	O
be	VB	O
attributable	JJ	O
to	TO	O
earlier	RBR	O
and	CC	O
greater	JJR	O
vascular	JJ	O
invasion	NN	O
of	IN	O
the	DT	O
carrier	NN	O
material	NN	O
.	.	O

The	DT	O
putty	JJ	O
material	NN	O
was	VBD	O
characterized	VBN	O
by	IN	O
ease	NN	O
of	IN	O
handling	VBG	O
,	,	O
simple	JJ	O
placement	NN	O
,	,	O
and	CC	O
enhanced	VBD	O
graft	NN	O
particle	NN	O
containment	NN	O
.	.	O

CONCLUSIONS	NNP	O
Allograft	NNP	O
mixed	VBD	O
with	IN	O
an	DT	O
experimental	JJ	O
putty	NN	O
carrier	NN	O
produced	VBD	O
significantly	RB	O
more	RBR	O
vital	JJ	O
bone	NN	O
fill	NN	O
than	IN	O
did	VBD	O
the	DT	O
use	NN	O
of	IN	O
a	DT	O
xenograft	NN	O
with	IN	O
no	DT	O
carrier	NN	O
material	NN	O
.	.	O

Ridge	NNP	O
width	NN	O
and	CC	O
height	JJ	O
dimensions	NNS	O
were	VBD	O
similarly	RB	O
preserved	VBN	O
with	IN	O
both	DT	O
graft	NN	O
materials	NNS	O
.	.	O

Lamivudine	NNP	O
300	CD	O
mg	NN	O
QD	NNP	O
versus	NN	O
continued	VBD	O
lamivudine	JJ	O
150	CD	O
mg	NNS	O
BID	NNP	O
with	IN	O
stavudine	NN	O
and	CC	O
a	DT	O
protease	NN	O
inhibitor	NN	O
in	IN	O
suppressed	JJ	O
patients	NNS	O
.	.	O

PURPOSE	NNP	O
To	TO	O
compare	VB	O
the	DT	O
efficacy	NN	O
(	(	O
sustained	VBN	O
virologic	IN	O
suppression	NN	O
)	)	O
and	CC	O
safety/tolerability	NN	O
of	IN	O
a	DT	O
switch	NN	O
to	TO	O
lamivudine	VB	O
300	CD	O
mg	NNS	O
once	RB	O
daily	JJ	O
(	(	O
QD	NNP	O
)	)	O
versus	NN	O
continued	VBD	O
lamivudine	JJ	O
150	CD	O
mg	JJ	O
twice	RB	O
daily	RB	O
(	(	O
BID	NNP	O
)	)	O
in	IN	O
virologically	RB	O
suppressed	VBN	O
patients	NNS	O
(	(	O
HIV-1	NNP	O
RNA	NNP	O
<	NNP	O
400	CD	O
copies/mL	NN	O
for	IN	O
>	NN	O
or	CC	O
=3	JJ	O
months	NNS	O
)	)	O
on	IN	O
stable	JJ	O
(	(	O
>	JJ	O
or	CC	O
=6	JJ	O
months	NNS	O
)	)	O
therapy	NN	O
with	IN	O
lamivudine	JJ	O
150	CD	O
mg	NN	O
BID	NNP	O
plus	CC	O
stavudine	NN	O
and	CC	O
either	DT	O
indinavir	NN	O
or	CC	O
nelfinavir	NN	O
.	.	O

METHOD	NNP	O
Eighty-nine	NNP	O
suppressed	VBD	O
patients	NNS	O
>	CD	O
or	CC	O
=18	CD	O
years	NNS	O
old	JJ	O
with	IN	O
CD4	NNP	O
counts	VBZ	O
>	JJ	O
50	CD	O
cells/mm	NN	O
(	(	O
3	CD	O
)	)	O
were	VBD	O
enrolled	VBN	O
in	IN	O
this	DT	O
phase	NN	O
II	NNP	O
,	,	O
open-label	NN	O
,	,	O
multicenter	NN	O
,	,	O
randomized	VBN	O
,	,	O
stratified	VBN	O
(	(	O
by	IN	O
pretrial	JJ	O
protease	NN	O
inhibitor	NN	O
[	NNP	O
PI	NNP	O
]	NNP	O
)	)	O
,	,	O
parallel-group	JJ	O
clinical	JJ	O
trial	NN	O
.	.	O

Eighty-one	JJ	O
patients	NNS	O
received	VBD	O
either	RB	O
lamivudine	JJ	O
300	CD	O
mg	NN	O
QD	NNP	O
(	(	O
n	JJ	O
=	NNP	O
39	CD	O
)	)	O
or	CC	O
150	CD	O
mg	NNS	O
BID	NNP	O
(	(	O
n	JJ	O
=	NNP	O
42	CD	O
)	)	O
with	IN	O
their	PRP$	O
pretrial	JJ	O
stavudine/PI	NN	O
regimens	NNS	O
for	IN	O
24	CD	O
weeks	NNS	O
.	.	O

RESULTS	VB	O
A	DT	O
high	JJ	O
rate	NN	O
of	IN	O
virologic	JJ	O
suppression	NN	O
was	VBD	O
sustained	VBN	O
with	IN	O
both	DT	O
regimens	NNS	O
throughout	IN	O
the	DT	O
trial	NN	O
.	.	O

At	IN	O
week	NN	O
24	CD	O
,	,	O
intent-to-treat	NN	O
:	:	O
exposed	VBN	O
(	(	O
missing	VBG	O
=	NNP	O
failure	NN	O
)	)	O
analyses	VBZ	O
showed	VBD	O
no	DT	O
statistically	RB	O
significant	JJ	O
differences	NNS	O
in	IN	O
the	DT	O
percentage	NN	O
of	IN	O
patients	NNS	O
with	IN	O
HIV-1	NNP	O
RNA	NNP	O
<	NNP	O
400	CD	O
copies/mL	NN	O
(	(	O
95	CD	O
%	NN	O
[	JJ	O
QD	NNP	O
]	NNP	O
vs.	IN	O
90	CD	O
%	NN	O
[	JJ	O
BID	NNP	O
]	NNP	O
)	)	O
or	CC	O
<	$	O
50	CD	O
copies/mL	NN	O
(	(	O
82	CD	O
%	NN	O
[	JJ	O
QD	NNP	O
]	NNP	O
vs.	IN	O
81	CD	O
%	NN	O
[	JJ	O
BID	NNP	O
]	NNP	O
)	)	O
or	CC	O
in	IN	O
the	DT	O
median	JJ	O
change	NN	O
from	IN	O
baseline	NN	O
in	IN	O
CD4	NNP	O
counts	NNS	O
(	(	O
+42	JJ	O
cells/mm	NN	O
(	(	O
3	CD	O
)	)	O
[	NN	O
QD	NNP	O
]	NNP	O
vs.	FW	O
+22	NNP	O
cells/mm	NN	O
(	(	O
3	CD	O
)	)	O
[	FW	O
BID	NNP	O
]	NNP	O
)	)	O
.	.	O

Both	DT	O
regimens	NNS	O
were	VBD	O
well	RB	O
tolerated	VBN	O
.	.	O

No	DT	O
patient	NN	O
experienced	VBD	O
virologic	JJ	O
failure	NN	O
,	,	O
clinical	JJ	O
disease	NN	O
progression	NN	O
,	,	O
or	CC	O
a	DT	O
drug-related	JJ	O
serious	JJ	O
adverse	JJ	O
event	NN	O
during	IN	O
the	DT	O
trial	NN	O
.	.	O

Self-reported	JJ	O
medication	NN	O
adherence	NN	O
was	VBD	O
high	JJ	O
in	IN	O
both	DT	O
groups	NNS	O
.	.	O

CONCLUSION	NNP	O
Patients	NNPS	O
who	WP	O
experience	VBP	O
virologic	JJ	O
suppression	NN	O
with	IN	O
a	DT	O
regimen	NNS	O
of	IN	O
lamivudine	JJ	O
150	CD	O
mg	NN	O
BID	NNP	O
in	IN	O
combination	NN	O
with	IN	O
stavudine/PI	NN	O
can	MD	O
maintain	VB	O
that	DT	O
suppression	NN	O
by	IN	O
continuing	VBG	O
their	PRP$	O
regimen	NNS	O
or	CC	O
switching	VBG	O
to	TO	O
lamivudine	VB	O
300	CD	O
mg	NN	O
QD	NNP	O
and	CC	O
continuing	VBG	O
the	DT	O
other	JJ	O
components	NNS	O
.	.	O

Adverse	JJ	O
event	NN	O
profiles	NNS	O
were	VBD	O
comparable	JJ	O
among	IN	O
treatment	NN	O
regimens	NNS	O
,	,	O
and	CC	O
no	DT	O
new	JJ	O
safety	NN	O
concerns	NNS	O
were	VBD	O
raised	VBN	O
.	.	O

Efficacy	NN	O
of	IN	O
chlorhexidine	NN	O
gluconate	NN	O
use	NN	O
in	IN	O
the	DT	O
prevention	NN	O
of	IN	O
perirectal	JJ	O
infections	NNS	O
in	IN	O
patients	NNS	O
with	IN	O
acute	JJ	C
leukemia	NN	C
.	.	O

The	DT	O
frequency	NN	O
of	IN	O
rectal	JJ	C
infections	NNS	C
is	VBZ	O
increased	VBN	O
in	IN	O
patients	NNS	O
with	IN	O
acute	JJ	C
leukemia	NN	C
.	.	O

Complications	NNS	O
associated	VBN	O
with	IN	O
rectal	JJ	O
lesions	NNS	O
may	MD	O
be	VB	O
severe	JJ	O
enough	RB	O
to	TO	O
cause	VB	O
life-threatening	JJ	O
septicemia	NN	O
.	.	O

Clinical	JJ	O
research	NN	O
evaluating	VBG	O
the	DT	O
effects	NNS	O
of	IN	O
preventive	JJ	O
perirectal	NN	O
skin	NN	O
care	NN	O
is	VBZ	O
scarce	JJ	O
.	.	O

This	DT	O
study	NN	O
's	POS	O
purpose	NN	O
was	VBD	O
to	TO	O
determine	VB	O
whether	IN	O
using	VBG	O
chlorhexidine	JJ	O
gluconate	NN	O
(	(	O
CHG	NNP	O
)	)	O
in	IN	O
a	DT	O
prophylactic	JJ	O
perirectal	JJ	O
skin-care	JJ	O
regimen	NNS	O
decreases	VBZ	O
perirectal	JJ	O
infections	NNS	O
and	CC	O
whether	IN	O
it	PRP	O
produces	VBZ	O
more	JJR	O
skin	JJ	O
irritation	NN	O
than	IN	O
a	DT	O
nonmedicated	JJ	O
skin	NN	O
cleanser	NN	O
.	.	O

The	DT	O
sample	NN	O
consisted	VBD	O
of	IN	O
40	CD	SS
patients	NNS	O
,	,	O
16	CD	O
of	IN	O
whom	WP	O
were	VBD	O
randomized	VBN	O
to	TO	O
use	VB	O
chlorhexidine	NN	O
and	CC	O
24	CD	O
of	IN	O
whom	WP	O
were	VBD	O
randomized	VBN	O
to	TO	O
use	VB	O
nonmedicated	JJ	O
skin	NN	O
cleanser	NN	O
.	.	O

Chi-square	JJ	O
and	CC	O
t-tests	NNS	O
were	VBD	O
used	VBN	O
to	TO	O
analyze	VB	O
the	DT	O
incidence	NN	O
of	IN	O
skin	JJ	O
breakdown	NN	O
and	CC	O
rectal	JJ	O
infections	NNS	O
;	:	O
the	DT	O
correlation	NN	O
between	IN	O
the	DT	O
two	CD	O
factors	NNS	O
;	:	O
a	DT	O
positive	JJ	O
history	NN	O
of	IN	O
rectal	JJ	O
infections	NNS	O
,	,	O
fissures	NNS	O
,	,	O
or	CC	O
hemorrhoids	NNS	O
;	:	O
presence	NN	O
of	IN	O
hemorrhoids	NNS	O
;	:	O
severity	NN	O
of	IN	O
diarrhea	NN	O
;	:	O
and	CC	O
duration	NN	O
and	CC	O
severity	NN	O
of	IN	O
granulocytopenia	NN	O
.	.	O

A	DT	O
positive	JJ	O
relationship	NN	O
was	VBD	O
found	VBN	O
between	IN	O
the	DT	O
severity	NN	O
of	IN	O
granulocytopenia	NN	O
and	CC	O
the	DT	O
incidence	NN	O
of	IN	O
rectal	JJ	O
infections	NNS	O
(	(	O
p	JJ	O
=	NNP	O
0.02	CD	O
)	)	O
.	.	O

No	DT	O
significant	JJ	O
difference	NN	O
was	VBD	O
seen	VBN	O
in	IN	O
the	DT	O
occurrence	NN	O
of	IN	O
perirectal	JJ	O
infections	NNS	O
(	(	O
p	JJ	O
=	NNP	O
0.35	CD	O
)	)	O
or	CC	O
skin	JJ	O
breakdown	NN	O
(	(	O
p	JJ	O
=	NNP	O
0.18	CD	O
)	)	O
between	IN	O
the	DT	O
two	CD	O
groups	NNS	O
.	.	O

The	DT	O
data	NN	O
suggest	NN	O
that	IN	O
CHG	NNP	O
does	VBZ	O
not	RB	O
offer	VB	O
increased	JJ	O
protection	NN	O
against	IN	O
perirectal	JJ	O
infections	NNS	O
in	IN	O
patients	NNS	O
undergoing	VBG	O
intensive	JJ	O
chemotherapy	NN	O
,	,	O
nor	CC	O
is	VBZ	O
it	PRP	O
more	RBR	O
irritating	JJ	O
than	IN	O
a	DT	O
nonmedicated	JJ	O
skin	NN	O
cleanser	NN	O
.	.	O

Further	JJ	O
studies	NNS	O
are	VBP	O
needed	VBN	O
to	TO	O
examine	VB	O
the	DT	O
efficacy	NN	O
of	IN	O
hygienic	JJ	O
measures	NNS	O
such	JJ	O
as	IN	O
using	VBG	O
skin	JJ	O
disinfectants	NNS	O
to	TO	O
prevent	VB	O
infections	NNS	O
in	IN	O
patients	NNS	O
who	WP	O
are	VBP	O
immunocompromised	VBN	O
.	.	O

A	DT	O
randomized	JJ	O
trial	NN	O
comparing	VBG	O
intravesical	JJ	O
instillations	NNS	O
of	IN	O
mitoxantrone	NN	O
and	CC	O
doxorubicin	NN	O
in	IN	O
patients	NNS	O
with	IN	O
superficial	JJ	O
bladder	NN	O
cancer	NN	O
.	.	O

BACKGROUND	NNP	O
This	DT	O
randomized	JJ	O
trial	NN	O
was	VBD	O
conducted	VBN	O
to	TO	O
compare	VB	O
the	DT	O
efficacy	NN	O
and	CC	O
side	JJ	O
effects	NNS	O
of	IN	O
intravesical	JJ	O
mitoxantrone	NN	O
instillation	NN	O
with	IN	O
those	DT	O
of	IN	O
doxorubicin	NN	O
in	IN	O
superficial	JJ	O
bladder	NN	O
cancer	NN	O
following	VBG	O
transurethral	JJ	O
resection	NN	O
.	.	O

METHODS	NNP	O
Sixty-three	JJ	O
patients	NNS	O
were	VBD	O
randomized	VBN	O
into	IN	O
mitoxantrone	NN	O
and	CC	O
doxorubicin	NN	O
groups	NNS	O
.	.	O

Most	JJS	O
of	IN	O
the	DT	O
patients	NNS	O
enrolled	VBN	O
were	VBD	O
elderly	JJ	O
people	NNS	O
(	(	O
mean	JJ	O
age	NN	O
,	,	O
71	CD	O
years	NNS	O
)	)	O
.	.	O

The	DT	O
instilled	JJ	O
doses	NNS	O
of	IN	O
doxorubicin	NN	O
and	CC	O
mitoxantrone	NN	O
were	VBD	O
30	CD	O
and	CC	O
14	CD	O
mg	NN	O
,	,	O
respectively	RB	O
.	.	O

Disease	NNP	O
recurrence	NN	O
and	CC	O
side	NN	O
effects	NNS	O
were	VBD	O
compared	VBN	O
using	VBG	O
Fisher	NNP	O
's	POS	O
exact	JJ	O
test	NN	O
.	.	O

The	DT	O
interval	NN	O
to	TO	O
recurrence	NN	O
was	VBD	O
shown	VBN	O
by	IN	O
Kaplan-Meier	NNP	O
survivorship	NN	O
curves	NNS	O
,	,	O
and	CC	O
the	DT	O
log-rank	JJ	O
test	NN	O
was	VBD	O
used	VBN	O
to	TO	O
compare	VB	O
the	DT	O
time	NN	O
to	TO	O
recurrence	VB	O
.	.	O

RESULTS	VB	O
The	DT	O
median	JJ	O
follow-up	JJ	O
period	NN	O
was	VBD	O
36	CD	O
months	NNS	O
.	.	O

Thirty-three	JJ	O
patients	NNS	O
received	VBD	O
mitoxantrone	NN	O
,	,	O
whereas	JJ	O
30	CD	O
patients	NNS	O
used	VBN	O
doxorubicin	NN	O
.	.	O

The	DT	O
recurrence	NN	O
rate	NN	O
in	IN	O
the	DT	O
doxorubicin	NN	O
group	NN	O
was	VBD	O
30	CD	O
%	NN	O
(	(	O
95	CD	O
%	NN	O
CI	NNP	O
:	:	O
19.8	CD	O
%	NN	O
-38.8	NNP	O
%	NN	O
)	)	O
,	,	O
while	IN	O
it	PRP	O
was	VBD	O
27.3	CD	O
%	NN	O
(	(	O
95	CD	O
%	NN	O
CI	NNP	O
:	:	O
17.5	CD	O
%	NN	O
-36.8	NNP	O
%	NN	O
)	)	O
in	IN	O
the	DT	O
mitoxantrone	NN	O
group	NN	O
.	.	O

The	DT	O
median	JJ	O
recurrence-free	JJ	O
survival	NN	O
in	IN	O
the	DT	O
mitoxantrone	NN	O
group	NN	O
and	CC	O
in	IN	O
the	DT	O
doxorubicin	NN	O
group	NN	O
was	VBD	O
22	CD	O
and	CC	O
20	CD	O
months	NNS	O
,	,	O
respectively	RB	O
(	(	O
p=0.580	NN	O
)	)	O
.	.	O

Higher	JJR	O
recurrence	NN	O
rates	NNS	O
were	VBD	O
found	VBN	O
for	IN	O
Grade	NNP	O
III	NNP	O
and	CC	O
multiple	JJ	O
primary	JJ	O
tumors	NNS	O
.	.	O

There	EX	O
was	VBD	O
no	DT	O
significant	JJ	O
difference	NN	O
in	IN	O
response	NN	O
rates	NNS	O
(	(	O
p=0.784	NN	O
)	)	O
.	.	O

The	DT	O
incidence	NN	O
of	IN	O
side	NN	O
effects	NNS	O
was	VBD	O
20	CD	O
%	NN	O
in	IN	O
the	DT	O
doxorubicin	NN	O
group	NN	O
and	CC	O
21.2	CD	O
%	NN	O
in	IN	O
the	DT	O
mitoxantrone	NN	O
group	NN	O
.	.	O

However	RB	O
,	,	O
the	DT	O
difference	NN	O
was	VBD	O
not	RB	O
significant	JJ	O
(	(	O
p	JJ	O
>	NNP	O
0.99	CD	O
)	)	O
.	.	O

CONCLUSIONS	VB	O
The	DT	O
results	NNS	O
revealed	VBD	O
that	IN	O
the	DT	O
efficacy	NN	O
and	CC	O
side	JJ	O
effects	NNS	O
of	IN	O
mitoxantrone	NN	O
were	VBD	O
similar	JJ	O
to	TO	O
those	DT	O
of	IN	O
doxorubicin	NN	O
.	.	O

Especially	RB	O
for	IN	O
patients	NNS	O
with	IN	O
pulmonary	JJ	O
tuberculosis	NN	O
or	CC	O
aged	VBN	O
patients	NNS	O
with	IN	O
primary	JJ	O
bladder	NN	O
tumors	NNS	O
,	,	O
mitoxantrone	NN	O
and	CC	O
doxorubicin	NN	O
may	MD	O
be	VB	O
the	DT	O
tolerable	JJ	O
and	CC	O
effective	JJ	O
intravesical	JJ	O
agents	NNS	O
.	.	O

Different	NNP	O
therapeutic	JJ	O
modalities	NNS	O
for	IN	O
treatment	NN	O
of	IN	O
melasma	NN	O
.	.	O

BACKGROUND	NNP	O
Chemical	NNP	O
peels	NNS	O
and	CC	O
topical	JJ	O
depigmenting	NN	O
agents	NNS	O
have	VBP	O
become	VBN	O
a	DT	O
popular	JJ	O
modality	NN	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
melasma	NN	O
.	.	O

AIMS	NNP	O
To	TO	O
compare	VB	O
the	DT	O
clinical	JJ	O
efficacy	NN	O
of	IN	O
trichloroacetic	JJ	O
acid	NN	O
peel	VB	O
20	CD	O
%	NN	O
vs	NN	O
.	.	O

Jessner	NNP	O
's	POS	O
solution	NN	O
peel	NN	O
vs.	IN	O
the	DT	O
topical	JJ	O
mixture	NN	O
of	IN	O
hydroquinone	NN	O
2	CD	O
%	NN	O
and	CC	O
kojic	NN	O
acid	NN	O
.	.	O

PATIENTS	NNP	O
AND	CC	O
METHODS	NNP	O
Forty	NNP	SS
five	CD	SS
patients	NNS	O
with	IN	O
melasma	NNS	C
were	VBD	O
randomly	RB	O
assigned	VBN	O
into	IN	O
three	CD	O
groups	NNS	O
of	IN	O
fifteen	JJ	O
patients	NNS	O
each	DT	O
.	.	O

Group	NNP	O
A	NNP	O
received	VBD	O
Jessner	NNP	O
's	POS	O
solution	NN	O
peel	NN	O
,	,	O
group	NN	O
B	NNP	O
received	VBD	O
trichloroacetic	JJ	O
acid	NN	O
peel	VB	O
20	CD	O
%	NN	O
,	,	O
and	CC	O
group	NN	O
C	NNP	O
received	VBD	O
topical	JJ	O
hydroquinone	NN	O
2	CD	O
%	NN	O
and	CC	O
kojic	NN	O
acid	NN	O
.	.	O

All	DT	O
patients	NNS	O
were	VBD	O
seen	VBN	O
in	IN	O
follow-up	JJ	O
period	NN	O
after	IN	O
16	CD	O
weeks	NNS	O
;	:	O
clinical	JJ	O
evaluation	NN	O
using	VBG	O
Melasma	NNP	O
Area	NNP	O
and	CC	O
Severity	NNP	O
Index	NNP	O
(	(	O
MASI	NNP	O
)	)	O
score	NN	O
and	CC	O
photography	NN	O
were	VBD	O
recorded	VBN	O
before	IN	O
and	CC	O
after	IN	O
treatment	NN	O
and	CC	O
after	IN	O
16	CD	O
weeks	NNS	O
.	.	O

RESULTS	NNP	O
There	EX	O
was	VBD	O
a	DT	O
decrease	NN	O
in	IN	O
MASI	NNP	O
score	NN	O
in	IN	O
all	DT	O
three	CD	O
groups	NNS	O
after	IN	O
treatment	NN	O
and	CC	O
after	IN	O
follow-up	JJ	O
period	NN	O
but	CC	O
after	IN	O
treatment	NN	O
MASI	NNP	O
score	NN	O
was	VBD	O
statistically	RB	O
significantly	RB	O
lower	JJR	O
in	IN	O
group	NN	O
A	NNP	O
than	IN	O
group	NN	O
C	NNP	O
(	(	O
P	NNP	O
=	NNP	O
0.01	CD	O
)	)	O
,	,	O
and	CC	O
it	PRP	O
was	VBD	O
also	RB	O
statistically	RB	O
significantly	RB	O
lower	JJR	O
in	IN	O
group	NN	O
B	NNP	O
than	IN	O
group	NN	O
C	NNP	O
(	(	O
P	NNP	O
<	NNP	O
0.001	CD	O
)	)	O
but	CC	O
there	EX	O
was	VBD	O
no	DT	O
statistically	RB	O
significant	JJ	O
difference	NN	O
between	IN	O
groups	NNS	O
A	NNP	O
and	CC	O
B	NNP	O
.	.	O

After	IN	O
the	DT	O
follow-up	JJ	O
period	NN	O
,	,	O
MASI	NNP	O
score	NN	O
was	VBD	O
statistically	RB	O
significantly	RB	O
lower	JJR	O
in	IN	O
group	NN	O
A	NNP	O
than	IN	O
group	NN	O
C	NNP	O
(	(	O
P	NNP	O
<	NNP	O
0.001	CD	O
)	)	O
,	,	O
statistically	RB	O
significantly	RB	O
lower	JJR	O
in	IN	O
group	NN	O
B	NNP	O
than	IN	O
group	NN	O
C	NNP	O
(	(	O
P	NNP	O
<	NNP	O
0.001	CD	O
)	)	O
,	,	O
and	CC	O
statistically	RB	O
significantly	RB	O
lower	JJR	O
in	IN	O
group	NN	O
B	NNP	O
than	IN	O
group	NN	O
A	NNP	O
(	(	O
P	NNP	O
=	NNP	O
0.035	CD	O
)	)	O
.	.	O

The	DT	O
statistical	JJ	O
analysis	NN	O
was	VBD	O
done	VBN	O
through	IN	O
one-way	JJ	O
anova	NN	O
followed	VBN	O
by	IN	O
least	JJS	O
significant	JJ	O
difference	NN	O
(	(	O
LSD	NNP	O
)	)	O
.	.	O

CONCLUSION	NNP	O
Trichloroacetic	NNP	O
acid	VBD	O
20	CD	O
%	NN	O
showed	VBD	O
better	JJR	O
results	NNS	O
than	IN	O
Jessner	NNP	O
's	POS	O
solution	NN	O
as	IN	O
peeling	NN	O
agent	NN	O
and	CC	O
hydroquinone	VB	O
2	CD	O
%	NN	O
with	IN	O
kojic	JJ	O
acid	NN	O
as	IN	O
a	DT	O
topical	JJ	O
agent	NN	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
melasma	NN	O
.	.	O

Pharmacokinetics	NNS	O
and	CC	O
follicular	JJ	O
dynamics	NNS	O
of	IN	O
corifollitropin	NN	O
alfa	NN	O
versus	NN	O
recombinant	JJ	O
FSH	NNP	O
during	IN	O
ovarian	JJ	O
stimulation	NN	O
for	IN	O
IVF	NNP	O
.	.	O

A	NNP	O
single	JJ	O
injection	NN	O
of	IN	O
corifollitropin	NN	O
alfa	NN	O
can	MD	O
replace	VB	O
seven	CD	O
daily	JJ	O
injections	NNS	O
of	IN	O
recombinant	JJ	O
FSH	NNP	O
(	(	O
rFSH	NN	O
)	)	O
using	VBG	O
a	DT	O
gonadotrophin-releasing	JJ	O
hormone	NN	O
antagonist	NN	O
protocol	NN	O
in	IN	O
ovarian	JJ	O
stimulation	NN	O
prior	RB	O
to	TO	O
IVF	NNP	O
or	CC	O
intracytoplasmic	JJ	O
sperm	JJ	O
injection	NN	O
.	.	O

This	DT	O
double-blind	JJ	O
randomized	NN	O
controlled	VBD	O
trial	NN	O
assessed	VBD	O
the	DT	O
pharmacokinetics	NNS	O
and	CC	O
pharmacodynamics	NNS	O
of	IN	O
150?g	CD	O
corifollitropin	NN	O
alfa	NN	O
versus	IN	O
daily	JJ	O
200IU	CD	O
rFSH	NN	O
in	IN	O
1509	CD	O
patients	NNS	O
.	.	O

Comparative	JJ	O
analyses	NNS	O
were	VBD	O
performed	VBN	O
on	IN	O
serum	JJ	O
concentrations	NNS	O
of	IN	O
FSH	NNP	O
immunoreactivity	NN	O
(	(	O
pharmacokinetics	NNS	O
)	)	O
,	,	O
and	CC	O
the	DT	O
number	NN	O
and	CC	O
size	NN	O
of	IN	O
growing	VBG	O
follicles	NNS	O
,	,	O
and	CC	O
inhibin	NN	O
B	NNP	O
and	CC	O
oestradiol	JJ	O
concentrations	NNS	O
as	IN	O
biomarkers	NNS	O
of	IN	O
ovarian	JJ	O
response	NN	O
(	(	O
pharmacodynamics	NNS	O
)	)	O
.	.	O

The	DT	O
rate	NN	O
of	IN	O
follicular	JJ	O
development	NN	O
was	VBD	O
similar	JJ	O
in	IN	O
both	DT	O
treatment	NN	O
groups	NNS	O
.	.	O

By	IN	O
stimulation	NN	O
day	NN	O
8	CD	O
,	,	O
33	CD	O
%	NN	O
of	IN	O
patients	NNS	O
treated	VBN	O
with	IN	O
corifollitropin	NN	O
alfa	NN	O
reached	VBD	O
the	DT	O
criterion	NN	O
for	IN	O
human	JJ	O
chorionic	NN	O
gonadotrophin	NN	O
(	(	O
HCG	NNP	O
)	)	O
injection	NN	O
.	.	O

The	DT	O
number	NN	O
of	IN	O
follicles	NNS	O
?11mm	NNP	O
was	VBD	O
slightly	RB	O
higher	JJR	O
after	IN	O
corifollitropin	NN	O
alfa	NN	O
compared	VBN	O
with	IN	O
daily	JJ	O
rFSH	NN	O
at	IN	O
stimulation	NN	O
day	NN	O
8	CD	O
(	(	O
difference	NN	O
,	,	O
1.2	CD	O
;	:	O
95	CD	O
%	NN	O
confidence	NN	O
interval	NN	O
(	(	O
CI	NNP	O
)	)	O
0.5-1.8	NN	O
;	:	O
P	NNP	O
<	NNP	O
0.01	CD	O
)	)	O
and	CC	O
on	IN	O
the	DT	O
day	NN	O
of	IN	O
HCG	NNP	O
injection	NN	O
(	(	O
difference	NN	O
,	,	O
2.1	CD	O
;	:	O
95	CD	O
%	NN	O
CI	NNP	O
1.4-2.8	CD	O
;	:	O
P	NNP	O
<	NNP	O
0.01	CD	O
)	)	O
.	.	O

The	DT	O
rise	NN	O
of	IN	O
inhibin	NN	O
B	NNP	O
and	CC	O
oestradiol	JJ	O
concentrations	NNS	O
was	VBD	O
similar	JJ	O
in	IN	O
both	DT	O
treatment	NN	O
groups	NNS	O
.	.	O

Although	IN	O
the	DT	O
pharmacokinetics	NNS	O
of	IN	O
corifollitropin	NN	O
alfa	NN	O
and	CC	O
rFSH	NN	O
are	VBP	O
quite	RB	O
different	JJ	O
their	PRP$	O
pharmacodynamic	JJ	O
profiles	NNS	O
at	IN	O
the	DT	O
dosages	NNS	O
used	VBN	O
are	VBP	O
similar	JJ	O
.	.	O

A	DT	O
single	JJ	O
injection	NN	O
of	IN	O
corifollitropin	NN	O
alfa	NN	O
can	MD	O
replace	VB	O
seven	CD	O
daily	JJ	O
injections	NNS	O
of	IN	O
recombinant	JJ	O
FSH	NNP	O
(	(	O
rFSH	NN	O
)	)	O
using	VBG	O
a	DT	O
gonadotrophin-releasing	JJ	O
hormone	NN	O
antagonist	NN	O
protocol	NN	O
in	IN	O
ovarian	JJ	O
stimulation	NN	O
prior	RB	O
to	TO	O
IVF	NNP	O
or	CC	O
intracytoplasmic	JJ	O
sperm	JJ	O
injection	NN	O
.	.	O

The	DT	O
objective	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
compare	VB	O
the	DT	O
pharmacokinetics	NNS	O
and	CC	O
pharmacodynamics	NNS	O
of	IN	O
corifollitropin	NN	O
alfa	JJ	O
versus	JJ	O
daily	JJ	O
rFSH	NN	O
.	.	O

A	DT	O
total	NN	O
of	IN	O
1509	CD	O
patients	NNS	O
were	VBD	O
randomized	VBN	O
in	IN	O
a	DT	O
double-blind	NN	O
,	,	O
controlled	VBN	O
trial	NN	O
to	TO	O
either	VB	O
a	DT	O
single	JJ	O
injection	NN	O
of	IN	O
150?g	CD	O
corifollitropin	NN	O
alfa	NN	O
or	CC	O
to	TO	O
daily	JJ	O
injections	NNS	O
of	IN	O
200IU	CD	O
rFSH	NN	O
for	IN	O
the	DT	O
first	JJ	O
7	CD	O
days	NNS	O
of	IN	O
ovarian	JJ	O
stimulation	NN	O
.	.	O

Serum	NNP	O
levels	NNS	O
of	IN	O
FSH	NNP	O
immunoreactivity	NN	O
were	VBD	O
analysed	VBN	O
(	(	O
pharmacokinetic	JJ	O
analysis	NN	O
)	)	O
,	,	O
together	RB	O
with	IN	O
the	DT	O
number	NN	O
and	CC	O
size	NN	O
of	IN	O
growing	VBG	O
follicles	NNS	O
and	CC	O
serum	NN	O
inhibin	NN	O
B	NNP	O
and	CC	O
oestradiol	JJ	O
concentrations	NNS	O
as	IN	O
biomarkers	NNS	O
of	IN	O
the	DT	O
ovarian	JJ	O
response	NN	O
(	(	O
pharmacodynamic	JJ	O
analysis	NN	O
)	)	O
.	.	O

Serum	NNP	O
FSH	NNP	O
immunoreactivity	NN	O
levels	NNS	O
were	VBD	O
higher	JJR	O
up	RB	O
to	TO	O
stimulation	VB	O
day	NN	O
5	CD	O
for	IN	O
corifollitropin	NN	O
alfa	NN	O
compared	VBN	O
with	IN	O
the	DT	O
daily	JJ	O
rFSH	NN	O
regimen	NNS	O
but	CC	O
were	VBD	O
similar	JJ	O
from	IN	O
day	NN	O
8	CD	O
onwards	NNS	O
,	,	O
when	WRB	O
patients	NNS	O
started	VBD	O
rFSH	RB	O
if	IN	O
the	DT	O
criteria	NN	O
for	IN	O
human	JJ	O
chorionic	NN	O
gonadotrophin	NN	O
were	VBD	O
not	RB	O
yet	RB	O
reached	VBN	O
.	.	O

Corifollitropin	NNP	O
alfa	JJ	O
treatment	NN	O
resulted	VBD	O
in	IN	O
a	DT	O
similar	JJ	O
growth	NN	O
rate	NN	O
of	IN	O
follicles	NNS	O
though	IN	O
a	DT	O
slightly	RB	O
higher	JJR	O
number	NN	O
of	IN	O
follicles	NNS	O
were	VBD	O
recruited	VBN	O
compared	VBN	O
with	IN	O
daily	JJ	O
rFSH	NN	O
.	.	O

It	PRP	O
is	VBZ	O
concluded	VBN	O
that	IN	O
the	DT	O
pharmacokinetics	NNS	O
of	IN	O
corifollitropin	NN	O
alfa	NN	O
and	CC	O
rFSH	NN	O
are	VBP	O
quite	RB	O
different	JJ	O
but	CC	O
their	PRP$	O
induced	JJ	O
pharmacodynamic	JJ	O
effects	NNS	O
at	IN	O
the	DT	O
dosages	NNS	O
used	VBN	O
are	VBP	O
similar	JJ	O
.	.	O

14	CD	O
day	NN	O
endoscopy	NN	O
study	NN	O
comparing	VBG	O
risedronate	NN	O
and	CC	O
alendronate	NN	O
in	IN	O
postmenopausal	JJ	C
women	NNS	SE
stratified	VBN	O
by	IN	O
Helicobacter	NNP	C
pylori	NN	C
status	NN	O
.	.	O

OBJECTIVE	NNP	O
Bisphosphonates	NNPS	O
are	VBP	O
effective	JJ	O
treatment	NN	O
for	IN	O
osteoporosis	NN	O
but	CC	O
have	VBP	O
been	VBN	O
associated	VBN	O
with	IN	O
gastrointestinal	JJ	O
(	(	O
GI	NNP	O
)	)	O
mucosal	NN	O
injury	NN	O
.	.	O

This	DT	O
study	NN	O
compared	VBN	O
the	DT	O
incidence	NN	O
of	IN	O
gastric	JJ	O
ulcers	NNS	O
after	IN	O
treatment	NN	O
with	IN	O
risedronate	NN	O
,	,	O
a	DT	O
pyridinyl	NN	O
bisphosphonate	NN	O
,	,	O
or	CC	O
alendronate	NN	O
,	,	O
a	DT	O
primary	JJ	O
amino	NN	O
bisphosphonate	NN	O
,	,	O
in	IN	O
healthy	JJ	C
postmenopausal	NN	C
women	NNS	SE
stratified	VBN	O
by	IN	O
Helicobacter	NNP	C
pylori	NN	C
status	NN	O
.	.	O

METHODS	NNP	O
Subjects	NNPS	O
were	VBD	O
randomized	VBN	O
to	TO	O
receive	VB	O
risedronate	NN	O
5	CD	O
mg	NN	O
(	(	O
n	JJ	O
=	NNP	O
318	CD	O
)	)	O
or	CC	O
alendronate	$	O
10	CD	O
mg	NN	O
(	(	O
n	JJ	O
=	NNP	O
317	CD	O
)	)	O
daily	RB	O
for	IN	O
14	CD	O
days	NNS	O
.	.	O

Endoscopy	NNP	O
and	CC	O
evaluator-blind	JJ	O
assessments	NNS	O
of	IN	O
the	DT	O
esophageal	NN	O
,	,	O
gastric	NN	O
,	,	O
and	CC	O
duodenal	JJ	O
mucosa	NN	O
were	VBD	O
performed	VBN	O
at	IN	O
baseline	NN	O
and	CC	O
on	IN	O
Days	NNP	O
8	CD	O
and	CC	O
15	CD	O
.	.	O

RESULTS	NNP	O
Overall	NNP	O
,	,	O
gastric	JJ	O
ulcers	NNS	O
>	VBP	O
or	CC	O
=	VBP	O
3	CD	O
mm	NNS	O
were	VBD	O
observed	VBN	O
in	IN	O
18	CD	O
(	(	O
6.0	CD	O
%	NN	O
)	)	O
of	IN	O
300	CD	O
evaluable	JJ	O
subjects	NNS	O
in	IN	O
the	DT	O
risedronate	NN	O
group	NN	O
and	CC	O
36	CD	O
(	(	O
12.1	CD	O
%	NN	O
)	)	O
of	IN	O
297	CD	O
in	IN	O
the	DT	O
alendronate	NN	O
group	NN	O
during	IN	O
treatment	NN	O
(	(	O
p	JJ	O
=	NNP	O
0.013	CD	O
)	)	O
.	.	O

On	IN	O
Day	NNP	O
8	CD	O
,	,	O
the	DT	O
incidences	NNS	O
of	IN	O
gastric	JJ	O
ulcers	NNS	O
in	IN	O
the	DT	O
risedronate	NN	O
and	CC	O
alendronate	NN	O
groups	NNS	O
were	VBD	O
3.6	CD	O
%	NN	O
and	CC	O
6.6	CD	O
%	NN	O
,	,	O
respectively	RB	O
(	(	O
p	JJ	O
=	NNP	O
0.133	CD	O
)	)	O
,	,	O
and	CC	O
on	IN	O
Day	NNP	O
15	CD	O
,	,	O
they	PRP	O
were	VBD	O
3.3	CD	O
%	NN	O
and	CC	O
8.7	CD	O
%	NN	O
(	(	O
p	JJ	O
=	NNP	O
0.008	CD	O
)	)	O
.	.	O

The	DT	O
incidence	NN	O
of	IN	O
gastric	JJ	O
ulcers	NNS	O
was	VBD	O
not	RB	O
affected	VBN	O
by	IN	O
H.	NNP	O
pylori	NN	O
status	NN	O
.	.	O

Mean	NNP	O
gastric	JJ	O
endoscopy	NN	O
scores	NNS	O
at	IN	O
Days	NNP	O
8	CD	O
and	CC	O
15	CD	O
were	VBD	O
significantly	RB	O
lower	JJR	O
in	IN	O
the	DT	O
risedronate	NN	O
group	NN	O
than	IN	O
in	IN	O
the	DT	O
alendronate	NN	O
group	NN	O
(	(	O
p	JJ	O
<	NNP	O
0.001	CD	O
)	)	O
.	.	O

Mean	JJ	O
esophageal	NN	O
and	CC	O
duodenal	JJ	O
endoscopy	NN	O
scores	NNS	O
were	VBD	O
similar	JJ	O
in	IN	O
the	DT	O
2	CD	O
groups	NNS	O
at	IN	O
Days	NNP	O
8	CD	O
and	CC	O
15	CD	O
.	.	O

When	WRB	O
the	DT	O
treatment	NN	O
groups	NNS	O
were	VBD	O
combined	VBN	O
,	,	O
gastric	JJ	O
endoscopy	NN	O
scores	NNS	O
were	VBD	O
significantly	RB	O
higher	JJR	O
among	IN	O
H.	NNP	O
pylori	FW	O
negative	JJ	O
than	IN	O
H.	NNP	O
pylori	FW	O
positive	JJ	O
subjects	NNS	O
at	IN	O
Days	NNP	O
8	CD	O
and	CC	O
15	CD	O
(	(	O
p	NN	O
<	RB	O
0.05	CD	O
)	)	O
.	.	O

Upper	NNP	O
GI	NNP	O
adverse	JJ	O
events	NNS	O
were	VBD	O
reported	VBN	O
by	IN	O
18	CD	O
(	(	O
5.7	CD	O
%	NN	O
)	)	O
subjects	VBZ	O
in	IN	O
the	DT	O
risedronate	NN	O
group	NN	O
(	(	O
19	CD	O
events	NNS	O
)	)	O
and	CC	O
28	CD	O
(	(	O
8.8	CD	O
%	NN	O
)	)	O
subjects	VBZ	O
in	IN	O
the	DT	O
alendronate	NN	O
group	NN	O
(	(	O
32	CD	O
events	NNS	O
)	)	O
.	.	O

Symptoms	NNS	O
did	VBD	O
not	RB	O
predict	VB	O
the	DT	O
presence	NN	O
of	IN	O
mucosal	JJ	O
damage	NN	O
.	.	O

CONCLUSION	NNP	O
Risedronate	NNP	O
was	VBD	O
associated	VBN	O
with	IN	O
a	DT	O
significantly	RB	O
lower	JJR	O
incidence	NN	O
of	IN	O
gastric	JJ	O
ulcers	NNS	O
than	IN	O
alendronate	NN	O
.	.	O

H.	NNP	O
pylori	JJ	O
infection	NN	O
did	VBD	O
not	RB	O
increase	VB	O
the	DT	O
incidence	NN	O
of	IN	O
bisphosphonate	NN	O
related	VBN	O
gastric	JJ	O
ulcers	NNS	O
.	.	O

The	DT	O
findings	NNS	O
from	IN	O
this	DT	O
14	CD	O
day	NN	O
study	NN	O
in	IN	O
healthy	JJ	O
volunteers	NNS	O
support	VBP	O
the	DT	O
hypothesis	NN	O
that	WDT	O
bisphosphonates	VBZ	O
may	MD	O
differ	VB	O
from	IN	O
one	CD	O
another	DT	O
in	IN	O
their	PRP$	O
potential	JJ	O
to	TO	O
produce	VB	O
upper	JJ	O
GI	NNP	O
mucosal	NN	O
damage	NN	O
.	.	O

Prophylactic	JJ	O
lidocaine	NN	O
in	IN	O
the	DT	O
early	JJ	O
phase	NN	O
of	IN	O
suspected	JJ	O
myocardial	JJ	O
infarction	NN	O
.	.	O

Four	CD	SS
hundred	VBD	SS
two	CD	SS
patients	NNS	O
with	IN	O
suspected	JJ	C
myocardial	JJ	C
infarction	NN	C
seen	VBN	O
within	IN	O
6	CD	O
hours	NNS	O
of	IN	O
the	DT	O
onset	NN	O
of	IN	O
symptoms	NNS	O
entered	VBD	O
a	DT	O
double-blind	JJ	O
randomized	JJ	O
trial	NN	O
of	IN	O
lidocaine	NN	O
vs	NN	O
placebo	NN	O
.	.	O

During	IN	O
the	DT	O
1	CD	O
hour	NN	O
after	IN	O
administration	NN	O
of	IN	O
the	DT	O
drug	NN	O
the	DT	O
incidence	NN	O
of	IN	O
ventricular	JJ	O
fibrillation	NN	O
or	CC	O
sustained	VBN	O
ventricular	JJ	O
tachycardia	NN	O
among	IN	O
the	DT	O
204	CD	SS
patients	NNS	O
with	IN	O
acute	JJ	C
myocardial	JJ	C
infarction	NN	C
was	VBD	O
low	JJ	O
,	,	O
1.5	CD	O
%	NN	O
.	.	O

Lidocaine	NNP	O
,	,	O
given	VBN	O
in	IN	O
a	DT	O
300	CD	O
mg	NN	O
dose	VBD	O
intramuscularly	RB	O
followed	VBN	O
by	IN	O
100	CD	O
mg	NN	O
intravenously	RB	O
,	,	O
did	VBD	O
not	RB	O
prevent	VB	O
sustained	JJ	O
ventricular	JJ	O
tachycardia	NN	O
,	,	O
although	IN	O
there	EX	O
was	VBD	O
a	DT	O
significant	JJ	O
reduction	NN	O
in	IN	O
the	DT	O
number	NN	O
of	IN	O
patients	NNS	O
with	IN	O
warning	VBG	O
arrhythmias	NNS	O
between	IN	O
15	CD	O
and	CC	O
45	CD	O
minutes	NNS	O
after	IN	O
the	DT	O
administration	NN	O
of	IN	O
lidocaine	NN	O
(	(	O
p	NN	O
less	JJR	O
than	IN	O
0.05	CD	O
)	)	O
.	.	O

The	DT	O
average	JJ	O
plasma	JJ	O
lidocaine	JJ	O
level	NN	O
10	CD	O
minutes	NNS	O
after	IN	O
administration	NN	O
for	IN	O
patients	NNS	O
without	IN	O
a	DT	O
myocardial	JJ	O
infarction	NN	O
was	VBD	O
significantly	RB	O
higher	JJR	O
than	IN	O
that	DT	O
for	IN	O
patients	NNS	O
with	IN	O
an	DT	O
acute	JJ	O
infarction	NN	O
.	.	O

The	DT	O
mean	JJ	O
plasma	NN	O
lidocaine	JJ	O
level	NN	O
of	IN	O
patients	NNS	O
on	IN	O
beta-blocking	JJ	O
agents	NNS	O
was	VBD	O
no	DT	O
different	JJ	O
from	IN	O
that	DT	O
in	IN	O
patients	NNS	O
not	RB	O
on	IN	O
beta	NN	O
blocking	VBG	O
agents	NNS	O
.	.	O

During	IN	O
the	DT	O
1-hour	JJ	O
study	NN	O
period	NN	O
,	,	O
the	DT	O
incidence	NN	O
of	IN	O
central	JJ	O
nervous	JJ	O
system	NN	O
side	NN	O
effects	NNS	O
was	VBD	O
significantly	RB	O
greater	JJR	O
in	IN	O
the	DT	O
lidocaine	NN	O
group	NN	O
,	,	O
hypotension	NN	O
occurred	VBD	O
in	IN	O
11	CD	O
patients	NNS	O
,	,	O
nine	CD	O
of	IN	O
whom	WP	O
had	VBD	O
received	VBN	O
lidocaine	NN	O
,	,	O
and	CC	O
four	CD	O
patients	NNS	O
died	VBD	O
from	IN	O
asystole	NN	O
,	,	O
three	CD	O
of	IN	O
whom	WP	O
had	VBD	O
had	VBN	O
lidocaine	NN	O
.	.	O

We	PRP	O
can	MD	O
not	RB	O
advocate	VB	O
the	DT	O
administration	NN	O
of	IN	O
lidocaine	JJ	O
prophylactically	RB	O
in	IN	O
the	DT	O
early	JJ	O
hours	NNS	O
of	IN	O
suspected	JJ	O
myocardial	JJ	O
infarction	NN	O
.	.	O

Intravenous	JJ	O
platelet	NN	O
blockade	NN	O
with	IN	O
cangrelor	NN	O
during	IN	O
PCI	NNP	O
.	.	O

BACKGROUND	NNP	O
Intravenous	NNP	O
cangrelor	NN	O
,	,	O
a	DT	O
rapid-acting	NN	O
,	,	O
reversible	JJ	O
adenosine	NN	O
diphosphate	NN	O
(	(	O
ADP	NNP	O
)	)	O
receptor	NN	O
antagonist	NN	O
,	,	O
might	MD	O
reduce	VB	O
ischemic	JJ	O
events	NNS	O
during	IN	O
percutaneous	JJ	O
coronary	JJ	O
intervention	NN	O
(	(	O
PCI	NNP	O
)	)	O
.	.	O

METHODS	NNP	O
In	IN	O
this	DT	O
double-blind	NN	O
,	,	O
placebo-controlled	JJ	O
study	NN	O
,	,	O
we	PRP	O
randomly	VBP	O
assigned	JJ	O
5362	CD	SS
patients	NNS	O
who	WP	O
had	VBD	O
not	RB	O
been	VBN	O
treated	VBN	O
with	IN	O
clopidogrel	NN	O
to	TO	O
receive	VB	O
either	DT	O
cangrelor	NN	O
or	CC	O
placebo	NN	O
at	IN	O
the	DT	O
time	NN	O
of	IN	O
PCI	NNP	O
,	,	O
followed	VBN	O
by	IN	O
600	CD	O
mg	NNS	O
of	IN	O
clopidogrel	NN	O
.	.	O

The	DT	O
primary	JJ	O
end	NN	O
point	NN	O
was	VBD	O
a	DT	O
composite	JJ	O
of	IN	O
death	NN	O
,	,	O
myocardial	JJ	O
infarction	NN	O
,	,	O
or	CC	O
ischemia-driven	JJ	O
revascularization	NN	O
at	IN	O
48	CD	O
hours	NNS	O
.	.	O

Enrollment	NN	O
was	VBD	O
stopped	VBN	O
when	WRB	O
an	DT	O
interim	JJ	O
analysis	NN	O
concluded	VBD	O
that	IN	O
the	DT	O
trial	NN	O
would	MD	O
be	VB	O
unlikely	JJ	O
to	TO	O
show	VB	O
superiority	NN	O
for	IN	O
the	DT	O
primary	JJ	O
end	NN	O
point	NN	O
.	.	O

RESULTS	VB	O
The	DT	O
primary	JJ	O
end	NN	O
point	NN	O
occurred	VBD	O
in	IN	O
185	CD	O
of	IN	O
2654	CD	SS
patients	NNS	O
receiving	VBG	O
cangrelor	NN	O
(	(	O
7.0	CD	O
%	NN	O
)	)	O
and	CC	O
in	IN	O
210	CD	O
of	IN	O
2641	CD	SS
patients	NNS	O
receiving	VBG	O
placebo	NN	O
(	(	O
8.0	CD	O
%	NN	O
)	)	O
(	(	O
odds	NNS	O
ratio	NN	O
in	IN	O
the	DT	O
cangrelor	NN	O
group	NN	O
,	,	O
0.87	CD	O
;	:	O
95	CD	O
%	NN	O
confidence	NN	O
interval	NN	O
[	NNP	O
CI	NNP	O
]	NNP	O
,	,	O
0.71	CD	O
to	TO	O
1.07	CD	O
;	:	O
P=0.17	NNP	O
)	)	O
(	(	O
modified	VBN	O
intention-to-treat	NN	O
population	NN	O
adjusted	VBN	O
for	IN	O
missing	VBG	O
data	NNS	O
)	)	O
.	.	O

In	IN	O
the	DT	O
cangrelor	NN	O
group	NN	O
,	,	O
as	IN	O
compared	VBN	O
with	IN	O
the	DT	O
placebo	NN	O
group	NN	O
,	,	O
two	CD	O
prespecified	VBD	O
secondary	JJ	O
end	NN	O
points	NNS	O
were	VBD	O
significantly	RB	O
reduced	VBN	O
at	IN	O
48	CD	O
hours	NNS	O
:	:	O
the	DT	O
rate	NN	O
of	IN	O
stent	JJ	O
thrombosis	NN	O
,	,	O
from	IN	O
0.6	CD	O
%	NN	O
to	TO	O
0.2	CD	O
%	NN	O
(	(	O
odds	JJ	O
ratio	NN	O
,	,	O
0.31	CD	O
;	:	O
95	CD	O
%	NN	O
CI	NNP	O
,	,	O
0.11	CD	O
to	TO	O
0.85	CD	O
;	:	O
P=0.02	NNP	O
)	)	O
,	,	O
and	CC	O
the	DT	O
rate	NN	O
of	IN	O
death	NN	O
from	IN	O
any	DT	O
cause	NN	O
,	,	O
from	IN	O
0.7	CD	O
%	NN	O
to	TO	O
0.2	CD	O
%	NN	O
(	(	O
odds	JJ	O
ratio	NN	O
,	,	O
0.33	CD	O
;	:	O
95	CD	O
%	NN	O
CI	NNP	O
,	,	O
0.13	CD	O
to	TO	O
0.83	CD	O
;	:	O
P=0.02	NNP	O
)	)	O
.	.	O

There	EX	O
was	VBD	O
no	DT	O
significant	JJ	O
difference	NN	O
in	IN	O
the	DT	O
rate	NN	O
of	IN	O
blood	NN	O
transfusion	NN	O
(	(	O
1.0	CD	O
%	NN	O
in	IN	O
the	DT	O
cangrelor	NN	O
group	NN	O
and	CC	O
0.6	CD	O
%	NN	O
in	IN	O
the	DT	O
placebo	NN	O
group	NN	O
,	,	O
P=0.13	NNP	O
)	)	O
,	,	O
though	IN	O
major	JJ	O
bleeding	VBG	O
on	IN	O
one	CD	O
scale	NN	O
was	VBD	O
increased	VBN	O
in	IN	O
the	DT	O
cangrelor	NN	O
group	NN	O
,	,	O
from	IN	O
3.5	CD	O
%	NN	O
to	TO	O
5.5	CD	O
%	NN	O
(	(	O
P	NNP	O
<	NNP	O
0.001	CD	O
)	)	O
,	,	O
because	IN	O
of	IN	O
more	JJR	O
groin	JJ	O
hematomas	NN	O
.	.	O

CONCLUSIONS	VB	O
The	DT	O
use	NN	O
of	IN	O
periprocedural	JJ	O
cangrelor	NN	O
during	IN	O
PCI	NNP	O
was	VBD	O
not	RB	O
superior	JJ	O
to	TO	O
placebo	VB	O
in	IN	O
reducing	VBG	O
the	DT	O
primary	JJ	O
end	NN	O
point	NN	O
.	.	O

The	DT	O
prespecified	JJ	O
secondary	JJ	O
end	NN	O
points	NNS	O
of	IN	O
stent	JJ	O
thrombosis	NN	O
and	CC	O
death	NN	O
were	VBD	O
lower	JJR	O
in	IN	O
the	DT	O
cangrelor	NN	O
group	NN	O
,	,	O
with	IN	O
no	DT	O
significant	JJ	O
increase	NN	O
in	IN	O
the	DT	O
rate	NN	O
of	IN	O
transfusion	NN	O
.	.	O

Further	NNP	O
study	NN	O
of	IN	O
intravenous	JJ	O
ADP	NNP	O
blockade	NN	O
with	IN	O
cangrelor	NN	O
may	MD	O
be	VB	O
warranted	VBN	O
.	.	O

(	(	O
ClinicalTrials.gov	NNP	O
number	NN	O
,	,	O
NCT00385138	NNP	O
.	.	O

)	)	O
Randomized	NNP	O
comparison	NN	O
of	IN	O
two	CD	O
communication	NN	O
interventions	NNS	O
for	IN	O
preschoolers	NNS	A
with	IN	O
autism	NN	C
spectrum	NN	C
disorders	NNS	C
.	.	O

This	DT	O
randomized	JJ	O
group	NN	O
experiment	NN	O
compared	VBN	O
the	DT	O
efficacy	NN	O
of	IN	O
2	CD	O
communication	NN	O
interventions	NNS	O
(	(	O
Responsive	JJ	O
Education	NN	O
and	CC	O
Prelinguistic	NNP	O
Milieu	NNP	O
Teaching	NNP	O
[	NNP	O
RPMT	NNP	O
]	NNP	O
and	CC	O
the	DT	O
Picture	NNP	O
Exchange	NNP	O
Communication	NNP	O
System	NNP	O
[	NNP	O
PECS	NNP	O
]	NNP	O
)	)	O
in	IN	O
36	CD	SS
preschoolers	NNS	O
with	IN	O
autism	NN	C
spectrum	NN	C
disorders	NNS	C
.	.	C

Each	DT	O
treatment	NN	O
was	VBD	O
delivered	VBN	O
3	CD	O
times	NNS	O
per	IN	O
week	NN	O
,	,	O
in	IN	O
20-min	JJ	O
sessions	NNS	O
,	,	O
for	IN	O
6	CD	O
months	NNS	O
.	.	O

The	DT	O
results	NNS	O
revealed	VBD	O
that	IN	O
the	DT	O
RPMT	NNP	O
facilitated	VBD	O
the	DT	O
frequency	NN	O
of	IN	O
generalized	JJ	O
turn	NN	O
taking	VBG	O
and	CC	O
generalized	VBN	O
initiating	NN	O
joint	JJ	O
attention	NN	O
more	RBR	O
than	IN	O
did	VBD	O
the	DT	O
PECS	NNP	O
.	.	O

The	DT	O
latter	JJ	O
effect	NN	O
occurred	VBD	O
only	RB	O
for	IN	O
children	NNS	O
who	WP	O
began	VBD	O
treatment	NN	O
with	IN	O
at	IN	O
least	JJS	O
some	DT	O
initiating	VBG	O
joint	JJ	O
attention	NN	O
.	.	O

In	IN	O
contrast	NN	O
,	,	O
the	DT	O
PECS	NNP	O
facilitated	VBD	O
generalized	JJ	O
requests	NNS	O
more	RBR	O
than	IN	O
the	DT	O
RPMT	NNP	O
in	IN	O
children	NNS	O
with	IN	O
very	RB	O
little	JJ	O
initiating	VBG	O
joint	JJ	O
attention	NN	O
prior	RB	O
to	TO	O
treatment	NN	O
.	.	O

These	DT	O
effect	NN	O
sizes	NNS	O
were	VBD	O
large	JJ	O
.	.	O

Remifentanil	NNP	O
with	IN	O
morphine	JJ	O
transitional	JJ	O
analgesia	NN	O
shortens	VBZ	O
neurological	JJ	O
recovery	NN	O
compared	VBN	O
to	TO	O
fentanyl	VB	O
for	IN	O
supratentorial	JJ	O
craniotomy	NN	O
.	.	O

PURPOSE	NNP	O
To	TO	O
compare	VB	O
the	DT	O
recovery	NN	O
profiles	NNS	O
,	,	O
efficacy	NN	O
and	CC	O
safety	NN	O
of	IN	O
remifentanil	NN	O
and	CC	O
morphine	NN	O
for	IN	O
transitional	JJ	O
analgesia	NN	O
with	IN	O
fentanyl	NN	O
in	IN	O
patients	NNS	O
undergoing	VBG	O
elective	JJ	C
craniotomy	NN	C
for	IN	O
supratentorial	JJ	C
mass	NN	C
lesions	NNS	C
.	.	O

METHODS	NNP	O
Ninety-one	JJ	SS
patients	NNS	O
were	VBD	O
enrolled	VBN	O
in	IN	O
this	DT	O
prospective	JJ	O
,	,	O
randomized	VBN	O
,	,	O
multicentre	FW	O
study	NN	O
.	.	O

Anesthesia	NNP	O
was	VBD	O
induced	VBN	O
with	IN	O
thiopental	JJ	O
and	CC	O
remifentanil	NN	O
(	(	O
1.0	CD	O
micro	NN	O
g	NN	O
x	NNP	O
kg	NN	O
(	(	O
-1	NNP	O
)	)	O
bolus	NN	O
and	CC	O
a	DT	O
1	CD	O
micro	NN	O
g	NN	O
x	NNP	O
kg	NN	O
(	(	O
-1	NNP	O
)	)	O
x	VBP	O
min	NN	O
(	(	O
-1	NNP	O
)	)	O
infusion	NN	O
)	)	O
or	CC	O
fentanyl	NN	O
(	(	O
1	CD	O
micro	NN	O
g	NN	O
x	NNP	O
kg	NN	O
(	(	O
-1	NNP	O
)	)	O
bolus	NN	O
and	CC	O
a	DT	O
1.0	CD	O
micro	NN	O
g	NN	O
x	NNP	O
kg	NN	O
(	(	O
-1	NNP	O
)	)	O
x	VBP	O
min	NN	O
(	(	O
-1	NNP	O
)	)	O
infusion	NN	O
)	)	O
.	.	O

The	DT	O
opioid	JJ	O
infusion	NN	O
continued	VBD	O
until	IN	O
the	DT	O
level	NN	O
of	IN	O
anesthesia	NN	O
was	VBD	O
deemed	VBN	O
appropriate	JJ	O
for	IN	O
intubation	NN	O
.	.	O

Anesthesia	NNP	O
was	VBD	O
maintained	VBN	O
with	IN	O
N	NNP	O
(	(	O
2	CD	O
)	)	O
O/O	NNP	O
(	(	O
2	CD	O
)	)	O
,	,	O
isoflurane	$	O
0.5	CD	O
MAC	NNP	O
and	CC	O
remifentanil	VB	O
0.2	CD	O
micro	NN	O
g	NN	O
x	NNP	O
kg	NN	O
(	(	O
-1	NNP	O
)	)	O
x	VBP	O
min	NN	O
(	(	O
-1	JJ	O
)	)	O
or	CC	O
fentanyl	$	O
0.04	CD	O
micro	NN	O
g	NN	O
x	NNP	O
kg	NN	O
(	(	O
-1	NNP	O
)	)	O
x	VBP	O
min	NN	O
(	(	O
-1	NNP	O
)	)	O
.	.	O

At	IN	O
bone	NN	O
flap	NN	O
replacement	NN	O
,	,	O
either	DT	O
morphine	NN	O
0.08	CD	O
mg	NN	O
x	NN	O
kg	NN	O
(	(	O
-1	NN	O
)	)	O
(	(	O
remifentanil	JJ	O
group	NN	O
)	)	O
or	CC	O
saline	NN	O
(	(	O
fentanyl	JJ	O
group	NN	O
)	)	O
was	VBD	O
given	VBN	O
.	.	O

RESULTS	NNP	O
Systolic	NNP	O
blood	NN	O
pressure	NN	O
was	VBD	O
greater	JJR	O
in	IN	O
those	DT	O
receiving	VBG	O
fentanyl	NN	O
during	IN	O
induction	NN	O
(	(	O
145.6	CD	O
+/-17.5	JJ	O
mmHg	NN	O
vs	NN	O
128.8	CD	O
+/-18.3	JJ	O
mmHg	NN	O
;	:	O
P	NNP	O
=	NNP	O
0.006	CD	O
)	)	O
and	CC	O
intubation	NN	O
(	(	O
126.9	CD	O
+/-17.1	JJ	O
vs	NN	O
110.9	CD	O
+/-16.5	JJ	O
mmHg	NN	O
;	:	O
P	NNP	O
<	NNP	O
0.001	CD	O
)	)	O
.	.	O

Median	JJ	O
time	NN	O
to	TO	O
tracheal	VB	O
extubation	NN	O
was	VBD	O
similar	JJ	O
but	CC	O
less	RBR	O
variable	JJ	O
in	IN	O
the	DT	O
remifentanil	NN	O
group	NN	O
(	(	O
remifentanil	JJ	O
=	$	O
8	CD	O
min	NN	O
:	:	O
range	NN	O
=	VBZ	O
2-44	JJ	O
min	NN	O
;	:	O
fentanyl	CC	O
=	$	O
8	CD	O
min	NN	O
:	:	O
range	NN	O
=	VBZ	O
1-732	JJ	O
min	NN	O
)	)	O
.	.	O

The	DT	O
fentanyl	JJ	O
patients	NNS	O
required	VBD	O
a	DT	O
longer	JJR	O
time	NN	O
to	TO	O
achieve	VB	O
the	DT	O
first	JJ	O
normal	JJ	O
neurological	JJ	O
score	NN	O
(	(	O
fentanyl	JJ	O
=	$	O
38.0	CD	O
min	NN	O
;	:	O
remifentanil	CC	O
=	$	O
26.0	CD	O
min	NN	O
;	:	O
P	NNP	O
=	NNP	O
0.035	CD	O
)	)	O
.	.	O

Both	CC	O
the	DT	O
anesthesiologists	NNS	O
and	CC	O
the	DT	O
recovery	NN	O
room	NN	O
nurses	NNS	O
rated	VBD	O
remifentanil	JJ	O
better	RBR	O
with	IN	O
respect	NN	O
to	TO	O
level	NN	O
of	IN	O
consciousness	NN	O
.	.	O

Analgesics	NNS	O
were	VBD	O
required	VBN	O
earlier	RBR	O
in	IN	O
patients	NNS	O
receiving	VBG	O
remifentanil	NN	O
;	:	O
median	JJ	O
time	NN	O
0.5	CD	O
vs	NN	O
1.08	CD	O
hr	NN	O
,	,	O
P	NNP	O
<	VBZ	O
0.001	CD	O
.	.	O

CONCLUSIONS	NNP	O
Remifentanil	NNP	O
is	VBZ	O
a	DT	O
suitable	JJ	O
alternative	NN	O
to	TO	O
fentanyl	VB	O
in	IN	O
supratentorial	JJ	O
craniotomy	NN	O
.	.	O

Time	NN	O
to	TO	O
preoperative	VB	O
neurological	JJ	O
recovery	NN	O
is	VBZ	O
faster	RBR	O
and	CC	O
morphine	VB	O
provides	VBZ	O
some	DT	O
transitional	JJ	O
analgesia	NN	O
without	IN	O
compromising	VBG	O
the	DT	O
quality	NN	O
of	IN	O
recovery	NN	O
.	.	O

Effect	NN	O
of	IN	O
delayed	JJ	O
cord	NN	O
clamping	VBG	O
on	IN	O
iron	NN	O
stores	NNS	O
in	IN	O
infants	NNS	A
born	VBN	O
to	TO	O
anemic	JJ	C
mothers	NNS	O
:	:	O
a	DT	O
randomized	NN	O
controlled	VBN	O
trial	NN	O
.	.	O

OBJECTIVE	UH	O
To	TO	O
study	VB	O
the	DT	O
effects	NNS	O
of	IN	O
cord	NN	O
clamping	VBG	O
on	IN	O
iron	NN	O
stores	NNS	O
of	IN	O
infants	NNS	O
born	VBN	O
to	TO	O
anemic	VB	O
mothers	NNS	O
at	IN	O
3	CD	O
months	NNS	O
of	IN	O
age	NN	O
.	.	O

DESIGN	NNP	O
Randomized	NNP	O
controlled	VBD	O
trial	NN	O
.	.	O

SETTING	NN	O
Teaching	NNP	O
hospital	NN	O
.	.	O

METHODS	NNP	O
Infants	NNPS	O
born	VBN	O
to	TO	O
mothers	NNS	O
with	IN	O
hemoglobin	NN	O
(	(	O
Hb	NNP	O
)	)	O
<	VBD	O
100	CD	O
g/L	NNS	O
were	VBD	O
randomized	VBN	O
at	IN	O
delivery	NN	O
to	TO	O
either	DT	O
immediate	JJ	O
cord	NN	O
clamping	NN	O
(	(	O
early	JJ	O
group	NN	O
)	)	O
or	CC	O
cord	NN	O
clamping	VBG	O
delayed	VBN	O
till	JJ	O
descent	NN	O
of	IN	O
placenta	NN	O
into	IN	O
vagina	NN	O
(	(	O
delayed	VBN	O
group	NN	O
)	)	O
.	.	O

The	DT	O
outcome	NN	O
measures	NNS	O
were	VBD	O
infant	NN	O
's	POS	O
hemoglobin	NN	O
and	CC	O
serum	NN	O
ferritin	VBP	O
3	CD	O
months	NNS	O
after	IN	O
delivery	NN	O
.	.	O

RESULTS	CC	O
There	EX	O
were	VBD	O
102	CD	O
neonates	NNS	O
randomized	VBN	O
to	TO	O
early	JJ	O
(	(	O
n	JJ	O
=	NNP	O
43	CD	O
)	)	O
or	CC	O
delayed	VBN	O
cord	NN	O
clamping	NN	O
(	(	O
n	JJ	O
=	NNP	O
59	CD	O
)	)	O
.	.	O

The	DT	O
groups	NNS	O
were	VBD	O
comparable	JJ	O
for	IN	O
maternal	JJ	O
age	NN	O
,	,	O
parity	NN	O
,	,	O
weight	NN	O
and	CC	O
supplemental	JJ	O
iron	NN	O
intake	NN	O
,	,	O
infant	JJ	O
s	NN	O
birth	NN	O
weight	NN	O
,	,	O
gestation	NN	O
and	CC	O
sex	NN	O
.	.	O

The	DT	O
mean	JJ	O
infant	NN	O
ferritin	NN	O
and	CC	O
Hb	NNP	O
at	IN	O
3	CD	O
months	NNS	O
were	VBD	O
significantly	RB	O
higher	JJR	O
in	IN	O
the	DT	O
delayed	JJ	O
clamping	NN	O
group	NN	O
(	(	O
118.4	CD	O
microg/L	NN	O
and	CC	O
99	CD	O
g/L	NN	O
)	)	O
than	IN	O
in	IN	O
the	DT	O
early	JJ	O
clamping	NN	O
group	NN	O
(	(	O
73	CD	O
microg/L	NN	O
and	CC	O
88	CD	O
g/L	NN	O
)	)	O
.	.	O

The	DT	O
mean	JJ	O
decrease	NN	O
in	IN	O
Hb	NNP	O
(	(	O
g/L	NN	O
)	)	O
at	IN	O
3	CD	O
months	NNS	O
adjusted	VBN	O
for	IN	O
co-variates	NNS	O
was	VBD	O
significantly	RB	O
less	RBR	O
in	IN	O
the	DT	O
delayed	JJ	O
clamping	NN	O
group	NN	O
compared	VBN	O
to	TO	O
the	DT	O
early	JJ	O
clamping	NN	O
group	NN	O
(	(	O
-1.09	NNP	O
,	,	O
95	CD	O
%	NN	O
CI-1.58	NNP	O
to	TO	O
-0.62	VB	O
,	,	O
p	VB	O
>	NNP	O
0.001	CD	O
)	)	O
.	.	O

The	DT	O
odds	NNS	O
for	IN	O
anemia	NN	O
(	(	O
<	JJ	O
100	CD	O
g/L	NN	O
)	)	O
at	IN	O
3	CD	O
months	NNS	O
was	VBD	O
7.7	CD	O
(	(	O
95	CD	O
%	NN	O
CI	NNP	O
1.84-34.9	CD	O
)	)	O
times	NNS	O
higher	RBR	O
in	IN	O
the	DT	O
early	JJ	O
compared	VBN	O
to	TO	O
the	DT	O
delayed	JJ	O
clamping	NN	O
group	NN	O
.	.	O

CONCLUSION	NNP	O
Iron	NNP	O
stores	NNS	O
and	CC	O
Hb	NNP	O
in	IN	O
infancy	NN	O
can	MD	O
be	VB	O
improved	VBN	O
in	IN	O
neonates	NNS	O
born	VBN	O
to	TO	O
anemic	VB	O
mothers	NNS	O
by	IN	O
delaying	VBG	O
cord	NN	O
clamping	NN	O
at	IN	O
birth	NN	O
.	.	O

Teaching	VBG	O
emotion	NN	O
recognition	NN	O
skills	NNS	O
to	TO	O
young	JJ	C
children	NNS	A
with	IN	C
autism	NN	C
:	:	C
a	DT	O
randomised	JJ	O
controlled	JJ	O
trial	NN	O
of	IN	O
an	DT	O
emotion	NN	O
training	NN	O
programme	NN	O
.	.	O

BACKGROUND	NNP	O
Children	NNP	O
with	IN	O
autism	NN	O
have	VBP	O
difficulties	NNS	O
in	IN	O
emotion	NN	O
recognition	NN	O
and	CC	O
a	DT	O
number	NN	O
of	IN	O
interventions	NNS	O
have	VBP	O
been	VBN	O
designed	VBN	O
to	TO	O
target	VB	O
these	DT	O
problems	NNS	O
.	.	O

However	RB	O
,	,	O
few	JJ	O
emotion	NN	O
training	NN	O
interventions	NNS	O
have	VBP	O
been	VBN	O
trialled	VBN	O
with	IN	O
young	JJ	O
children	NNS	O
with	IN	O
autism	NN	O
and	CC	O
co-morbid	JJ	O
ID	NNP	O
.	.	O

This	DT	O
study	NN	O
aimed	VBD	O
to	TO	O
evaluate	VB	O
the	DT	O
efficacy	NN	O
of	IN	O
an	DT	O
emotion	NN	O
training	NN	O
programme	NN	O
for	IN	O
a	DT	O
group	NN	O
of	IN	O
young	JJ	O
children	NNS	O
with	IN	O
autism	NN	O
with	IN	O
a	DT	O
range	NN	O
of	IN	O
intellectual	JJ	O
ability	NN	O
.	.	O

METHODS	NNP	O
Participants	NNPS	O
were	VBD	O
55	CD	SS
children	NNS	O
with	IN	O
autistic	JJ	O
disorder	NN	O
,	,	O
aged	VBN	O
4-7	CD	O
years	NNS	O
(	(	O
FSIQ	NNP	O
42-107	CD	O
)	)	O
.	.	O

Children	NNP	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
an	DT	O
intervention	NN	O
(	(	O
n	JJ	O
=	NNP	O
28	CD	O
)	)	O
or	CC	O
control	VB	O
group	NN	O
(	(	O
n	JJ	O
=	NNP	O
27	CD	O
)	)	O
.	.	O

Participants	NNS	O
in	IN	O
the	DT	O
intervention	NN	O
group	NN	O
watched	VBD	O
a	DT	O
DVD	NNP	O
designed	VBN	O
to	TO	O
teach	VB	O
emotion	NN	O
recognition	NN	O
skills	NNS	O
to	TO	O
children	NNS	O
with	IN	O
autism	NN	O
(	(	O
the	DT	O
Transporters	NNPS	O
)	)	O
,	,	O
whereas	IN	O
the	DT	O
control	NN	O
group	NN	O
watched	VBD	O
a	DT	O
DVD	NNP	O
of	IN	O
Thomas	NNP	O
the	DT	O
Tank	NNP	O
Engine	NNP	O
.	.	O

Participants	NNS	O
were	VBD	O
assessed	VBN	O
on	IN	O
their	PRP$	O
ability	NN	O
to	TO	O
complete	VB	O
basic	JJ	O
emotion	NN	O
recognition	NN	O
tasks	NNS	O
,	,	O
mindreading	VBG	O
and	CC	O
theory	NN	O
of	IN	O
mind	NN	O
(	(	O
TOM	NNP	O
)	)	O
tasks	NNS	O
before	IN	O
and	CC	O
after	IN	O
the	DT	O
4-week	JJ	O
intervention	NN	O
period	NN	O
,	,	O
and	CC	O
at	IN	O
3-month	JJ	O
follow-up	NN	O
.	.	O

RESULTS	NNP	O
Analyses	NNP	O
controlled	VBD	O
for	IN	O
the	DT	O
effect	NN	O
of	IN	O
chronological	JJ	O
age	NN	O
,	,	O
verbal	JJ	O
intelligence	NN	O
,	,	O
gender	NN	O
and	CC	O
DVD	NNP	O
viewing	VBG	O
time	NN	O
on	IN	O
outcomes	NNS	O
.	.	O

Children	NNP	O
in	IN	O
the	DT	O
intervention	NN	O
group	NN	O
showed	VBD	O
improved	JJ	O
performance	NN	O
in	IN	O
the	DT	O
recognition	NN	O
of	IN	O
anger	NN	O
compared	VBN	O
with	IN	O
the	DT	O
control	NN	O
group	NN	O
,	,	O
with	IN	O
few	JJ	O
improvements	NNS	O
maintained	VBD	O
at	IN	O
3-month	JJ	O
follow-up	NN	O
.	.	O

There	EX	O
was	VBD	O
no	DT	O
generalisation	NN	O
of	IN	O
skills	NNS	O
to	TO	O
TOM	NNP	O
or	CC	O
social	JJ	O
skills	NNS	O
.	.	O

CONCLUSIONS	VB	O
The	DT	O
Transporters	NNP	O
programme	NN	O
showed	VBD	O
limited	JJ	O
efficacy	NN	O
in	IN	O
teaching	VBG	O
basic	JJ	O
emotion	NN	O
recognition	NN	O
skills	NNS	O
to	TO	O
young	JJ	O
children	NNS	O
with	IN	O
autism	NN	O
with	IN	O
a	DT	O
lower	JJR	O
range	NN	O
of	IN	O
cognitive	JJ	O
ability	NN	O
.	.	O

Improvements	NNS	O
were	VBD	O
limited	VBN	O
to	TO	O
the	DT	O
recognition	NN	O
of	IN	O
expressions	NNS	O
of	IN	O
anger	NN	O
,	,	O
with	IN	O
poor	JJ	O
maintenance	NN	O
of	IN	O
these	DT	O
skills	NNS	O
at	IN	O
follow-up	NN	O
.	.	O

These	DT	O
findings	NNS	O
provide	VBP	O
limited	JJ	O
support	NN	O
for	IN	O
the	DT	O
efficacy	NN	O
of	IN	O
the	DT	O
Transporters	NNP	O
programme	NN	O
for	IN	O
young	JJ	O
children	NNS	O
with	IN	O
autism	NN	O
of	IN	O
a	DT	O
lower	JJR	O
cognitive	JJ	O
range	NN	O
.	.	O

Comparison	NNP	O
of	IN	O
yoga	NNP	O
versus	NN	O
stretching	VBG	O
for	IN	O
chronic	JJ	C
low	JJ	C
back	RB	C
pain	NN	C
:	:	O
protocol	NN	O
for	IN	O
the	DT	O
Yoga	NNP	O
Exercise	NNP	O
Self-care	NNP	O
(	(	O
YES	NNP	O
)	)	O
trial	NN	O
.	.	O

BACKGROUND	NNP	O
Back	NNP	O
pain	NN	O
,	,	O
one	CD	O
of	IN	O
the	DT	O
most	RBS	O
prevalent	JJ	O
conditions	NNS	O
afflicting	VBG	O
American	JJ	O
adults	NNS	O
,	,	O
is	VBZ	O
the	DT	O
leading	VBG	O
reason	NN	O
for	IN	O
using	VBG	O
complementary	JJ	O
and	CC	O
alternative	JJ	O
medicine	NN	O
(	(	O
CAM	NNP	O
)	)	O
therapies	NNS	O
.	.	O

Yoga	NNP	O
is	VBZ	O
an	DT	O
increasingly	RB	O
popular	JJ	O
mind-body	NN	O
CAM	NNP	O
therapy	NN	O
often	RB	O
used	VBN	O
for	IN	O
relieving	VBG	O
back	RB	O
pain	NN	O
and	CC	O
several	JJ	O
small	JJ	O
studies	NNS	O
have	VBP	O
found	VBN	O
yoga	RB	O
effective	JJ	O
for	IN	O
this	DT	O
condition	NN	O
.	.	O

This	DT	O
study	NN	O
will	MD	O
assess	VB	O
whether	IN	O
yoga	NN	O
is	VBZ	O
effective	JJ	O
for	IN	O
treating	VBG	O
chronic	JJ	O
low	JJ	O
back	RB	O
pain	NN	O
compared	VBN	O
with	IN	O
self	PRP	O
care	NN	O
and	CC	O
exercise	NN	O
and	CC	O
will	MD	O
explore	VB	O
the	DT	O
mechanisms	NNS	O
responsible	JJ	O
for	IN	O
any	DT	O
observed	JJ	O
benefits	NNS	O
.	.	O

METHODS/DESIGN	NNP	O
A	NNP	O
total	NN	O
of	IN	O
210	CD	C
participants	NNS	O
with	IN	O
low	JJ	C
back	RB	C
pain	NN	C
lasting	NN	O
at	IN	O
least	JJS	O
3	CD	O
months	NNS	O
will	MD	O
be	VB	O
recruited	VBN	O
from	IN	O
primary	JJ	O
care	NN	O
clinics	NNS	O
of	IN	O
a	DT	O
large	JJ	O
healthcare	NN	O
system	NN	O
based	VBN	O
in	IN	O
Seattle	NNP	O
.	.	O

They	PRP	O
will	MD	O
be	VB	O
randomized	VBN	O
in	IN	O
a	DT	O
2:2:1	CD	O
ratio	NN	O
to	TO	O
receive	VB	O
12	CD	O
weekly	JJ	O
yoga	NN	O
classes	NNS	O
,	,	O
12	CD	O
weekly	JJ	O
conventional	JJ	O
therapeutic	JJ	O
exercise	NN	O
classes	NNS	O
of	IN	O
comparable	JJ	O
physical	JJ	O
exertion	NN	O
,	,	O
or	CC	O
a	DT	O
self-care	JJ	O
book	NN	O
.	.	O

Interviewers	NNS	O
masked	VBD	O
to	TO	O
participants	NNS	O
'	POS	O
treatment	NN	O
group	NN	O
will	MD	O
assess	VB	O
outcomes	NNS	O
at	IN	O
baseline	NN	O
and	CC	O
6	CD	O
,	,	O
12	CD	O
and	CC	O
26	CD	O
weeks	NNS	O
after	IN	O
randomization	NN	O
.	.	O

Primary	JJ	O
outcomes	NNS	O
will	MD	O
be	VB	O
back-related	JJ	O
dysfunction	NN	O
and	CC	O
symptom	NN	O
bothersomeness	NN	O
.	.	O

In	IN	O
addition	NN	O
,	,	O
data	NNS	O
will	MD	O
be	VB	O
collected	VBN	O
on	IN	O
physical	JJ	O
measurements	NNS	O
(	(	O
e.g.	NN	O
,	,	O
flexion	NN	O
)	)	O
at	IN	O
baseline	NN	O
and	CC	O
12	CD	O
weeks	NNS	O
and	CC	O
saliva	NN	O
samples	NNS	O
will	MD	O
be	VB	O
obtained	VBN	O
at	IN	O
baseline	NN	O
,	,	O
6	CD	O
and	CC	O
12	CD	O
weeks	NNS	O
.	.	O

Information	NN	O
will	MD	O
be	VB	O
collected	VBN	O
on	IN	O
specific	JJ	O
physical	JJ	O
,	,	O
psychological	JJ	O
,	,	O
and	CC	O
physiological	JJ	O
factors	NNS	O
to	TO	O
allow	VB	O
exploration	NN	O
of	IN	O
possible	JJ	O
mechanisms	NNS	O
of	IN	O
action	NN	O
through	IN	O
which	WDT	O
yoga	NN	O
could	MD	O
relieve	VB	O
back	RB	O
pain	NN	O
and	CC	O
dysfunction	NN	O
.	.	O

The	DT	O
effectiveness	NN	O
of	IN	O
yoga	NN	O
will	MD	O
be	VB	O
assessed	VBN	O
using	VBG	O
analysis	NN	O
of	IN	O
covariance	NN	O
(	(	O
using	VBG	O
general	JJ	O
estimating	VBG	O
equations	NNS	O
-	:	O
GEE	NNP	O
)	)	O
within	IN	O
an	DT	O
intention-to-treat	JJ	O
context	NN	O
.	.	O

If	IN	O
yoga	NN	O
is	VBZ	O
found	VBN	O
effective	JJ	O
,	,	O
further	JJ	O
analyses	NNS	O
will	MD	O
explore	VB	O
whether	IN	O
yoga	NN	O
's	POS	O
benefits	NNS	O
are	VBP	O
attributable	JJ	O
to	TO	O
physical	JJ	O
,	,	O
psychological	JJ	O
and/or	NN	O
physiological	JJ	O
factors	NNS	O
.	.	O

CONCLUSIONS	VB	O
This	DT	O
study	NN	O
will	MD	O
provide	VB	O
the	DT	O
clearest	JJS	O
evidence	NN	O
to	TO	O
date	NN	O
about	IN	O
the	DT	O
value	NN	O
of	IN	O
yoga	NN	O
as	IN	O
a	DT	O
therapeutic	JJ	O
option	NN	O
for	IN	O
treating	VBG	O
chronic	JJ	C
back	RB	C
pain	NN	C
,	,	O
and	CC	O
if	IN	O
the	DT	O
results	NNS	O
are	VBP	O
positive	JJ	O
,	,	O
will	MD	O
help	VB	O
focus	VB	O
future	JJ	O
,	,	O
more	RBR	O
in-depth	JJ	O
,	,	O
research	NN	O
on	IN	O
the	DT	O
most	RBS	O
promising	JJ	O
potential	JJ	O
mechanisms	NN	O
of	IN	O
action	NN	O
identified	VBN	O
by	IN	O
this	DT	O
study	NN	O
.	.	O

Clinical	JJ	O
pathway	NN	O
for	IN	O
fractured	JJ	C
neck	NN	C
of	IN	C
femur	NN	C
:	:	C
a	DT	O
prospective	JJ	O
,	,	O
controlled	VBD	O
study	NN	O
.	.	O

OBJECTIVE	NNP	O
To	TO	O
assess	VB	O
outcomes	NNS	O
of	IN	O
using	VBG	O
a	DT	O
clinical	JJ	O
pathway	NN	O
for	IN	O
managing	VBG	O
patients	NNS	O
with	IN	O
fractured	JJ	C
neck	NN	C
of	IN	C
femur	NN	C
.	.	O

DESIGN	NNP	O
Prospective	NNP	O
,	,	O
pseudorandomised	VBD	O
,	,	O
controlled	VBD	O
trial	NN	O
.	.	O

SETTING	NN	O
St	NNP	O
Vincent	NNP	O
's	POS	O
Hospital	NNP	O
,	,	O
Melbourne	NNP	O
,	,	O
Victoria	NNP	O
(	(	O
a	DT	O
tertiary	JJ	O
referral	NN	O
,	,	O
university	NN	O
teaching	VBG	O
hospital	NN	O
)	)	O
,	,	O
1	CD	O
October	NNP	O
1997	CD	O
to	TO	O
30	CD	O
November	NNP	O
1998	CD	O
.	.	O

PARTICIPANTS	VB	O
111	CD	SS
patients	NNS	SS
(	(	O
80	CD	SS
women	NNS	O
and	CC	O
31	CD	SS
men	NNS	O
;	:	O
mean	JJ	O
age	NN	O
,	,	O
81	CD	O
years	NNS	O
)	)	O
admitted	VBD	O
via	IN	O
the	DT	O
emergency	NN	O
department	NN	O
with	IN	O
a	DT	O
primary	JJ	O
diagnosis	NN	O
of	IN	O
fractured	JJ	C
neck	NN	C
of	IN	C
femur	NN	C
.	.	O

INTERVENTIONS	NNP	O
Management	NNP	O
guided	VBN	O
by	IN	O
a	DT	O
clinical	JJ	O
pathway	NN	O
(	(	O
55	CD	O
patients	NNS	O
)	)	O
or	CC	O
established	VBN	O
standard	NN	O
of	IN	O
care	NN	O
(	(	O
control	NN	O
group	NN	O
,	,	O
56	CD	O
patients	NNS	O
)	)	O
.	.	O

MAIN	NNP	O
OUTCOME	NNP	O
MEASURES	NNP	O
Timing	NNP	O
of	IN	O
referrals	NNS	O
and	CC	O
discharge	NN	O
planning	NN	O
;	:	O
total	JJ	O
length	NN	O
of	IN	O
stay	NN	O
;	:	O
and	CC	O
complication	NN	O
and	CC	O
readmission	NN	O
rates	NNS	O
within	IN	O
28	CD	O
days	NNS	O
of	IN	O
discharge	NN	O
.	.	O

RESULTS	JJ	O
Patients	NNS	O
managed	VBD	O
according	VBG	O
to	TO	O
the	DT	O
clinical	JJ	O
pathway	NN	O
had	VBD	O
a	DT	O
shorter	NN	O
total	JJ	O
stay	NN	O
(	(	O
6.6	CD	O
versus	NN	O
8.0	CD	O
days	NNS	O
;	:	O
P	NNP	O
=	NNP	O
0.03	CD	O
)	)	O
,	,	O
even	RB	O
if	IN	O
assessment	NN	O
for	IN	O
placement	NN	O
by	IN	O
the	DT	O
Aged	NNP	O
Care	NNP	O
Assessment	NNP	O
Service	NNP	O
was	VBD	O
required	VBN	O
(	(	O
9.5	CD	O
versus	NN	O
13.6	CD	O
days	NNS	O
;	:	O
P	NNP	O
=	NNP	O
0.03	CD	O
)	)	O
.	.	O

There	EX	O
were	VBD	O
no	DT	O
significant	JJ	O
differences	NNS	O
in	IN	O
complication	NN	O
and	CC	O
readmission	NN	O
rates	NNS	O
between	IN	O
pathway	NN	O
and	CC	O
control	NN	O
patients	NNS	O
(	(	O
complication	NN	O
rates	NNS	O
,	,	O
24	CD	O
%	NN	O
versus	IN	O
36	CD	O
%	NN	O
;	:	O
P	NNP	O
=	VBZ	O
0.40	CD	O
;	:	O
readmission	NN	O
rates	NNS	O
,	,	O
4	CD	O
%	NN	O
versus	IN	O
11	CD	O
%	NN	O
;	:	O
P	NNP	O
=	NNP	O
0.28	CD	O
)	)	O
.	.	O

CONCLUSION	NNP	O
Coordinated	VBD	O
multidisciplinary	JJ	O
care	NN	O
of	IN	O
patients	NNS	O
with	IN	O
fractured	JJ	C
neck	NN	C
of	IN	C
femur	NN	C
reduces	NNS	O
length	NN	O
of	IN	O
stay	NN	O
without	IN	O
increasing	VBG	O
complications	NNS	O
.	.	O

Effect	NN	O
of	IN	O
treatment	NN	O
with	IN	O
paromomycin	NN	O
on	IN	O
endotoxemia	NN	O
in	IN	O
patients	NNS	O
with	IN	O
alcoholic	JJ	C
liver	NN	SS
disease	NN	SS
--	:	O
a	DT	O
double-blind	JJ	O
,	,	O
placebo-controlled	JJ	O
trial	NN	O
.	.	O

The	DT	O
results	NNS	O
of	IN	O
experimental	JJ	O
and	CC	O
clinical	JJ	O
studies	NNS	O
support	VBP	O
the	DT	O
hypothesis	NN	O
that	IN	O
gut-derived	JJ	O
endotoxins	NNS	O
might	MD	O
be	VB	O
of	IN	O
relevance	NN	O
for	IN	O
the	DT	O
development	NN	O
and	CC	O
course	NN	O
of	IN	O
alcoholic	JJ	O
liver	NN	O
disease	NN	O
.	.	O

The	DT	O
aim	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
test	VB	O
the	DT	O
effect	NN	O
of	IN	O
a	DT	O
nonabsorbable	JJ	O
,	,	O
broad-spectrum	JJ	O
antibiotic	NN	O
on	IN	O
endotoxemia	NN	O
in	IN	O
patients	NNS	O
with	IN	O
alcoholic	JJ	C
liver	NN	C
disease	NN	C
.	.	O

Fifty	JJ	SS
patients	NNS	O
with	IN	O
alcoholic	JJ	C
liver	NN	C
disease	NN	C
(	(	O
27	CD	SS
with	IN	O
cirrhosis	NN	C
,	,	O
23	CD	SS
without	IN	O
cirrhosis	NN	C
)	)	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
receive	VB	O
either	DT	O
paromomycin	NN	O
sulfate	NN	O
(	(	O
3	CD	O
x	RB	O
1	CD	O
g/day	NN	O
)	)	O
or	CC	O
placebo	NN	O
in	IN	O
a	DT	O
double-blind	JJ	O
fashion	NN	O
for	IN	O
at	IN	O
least	JJS	O
3	CD	O
weeks	NNS	O
,	,	O
and	CC	O
if	IN	O
possible	JJ	O
4	CD	O
weeks	NNS	O
.	.	O

Endotoxin	NNP	O
concentration	NN	O
,	,	O
liver	JJ	O
function	NN	O
tests	NNS	O
,	,	O
and	CC	O
other	JJ	O
laboratory	NN	O
parameters	NNS	O
were	VBD	O
determined	VBN	O
in	IN	O
weekly	JJ	O
intervals	NNS	O
.	.	O

Endotoxin	NNP	O
concentration	NN	O
was	VBD	O
also	RB	O
determined	VBN	O
in	IN	O
15	CD	SS
healthy	JJ	C
controls	NNS	O
.	.	O

Groups	NNP	O
receiving	VBG	O
paromomycin	NN	O
or	CC	O
placebo	NN	O
were	VBD	O
similar	JJ	O
for	IN	O
clinical	JJ	O
and	CC	O
biological	JJ	O
items	NNS	O
collected	VBN	O
initially	RB	O
.	.	O

Mean	JJ	O
initial	JJ	O
endotoxin	NN	O
concentrations	NNS	O
were	VBD	O
significantly	RB	O
elevated	VBN	O
in	IN	O
both	DT	O
groups	NNS	O
(	(	O
mean	JJ	O
+/-	JJ	O
SEM	NNP	O
;	:	O
paromomycin	NN	O
,	,	O
16.7	CD	O
+/-	JJ	O
5.3	CD	O
pg/ml	NN	O
;	:	O
placebo	NN	O
,	,	O
17.5	CD	O
+/-	JJ	O
6.9	CD	O
pg/ml	NN	O
;	:	O
healthy	JJ	O
controls	NNS	O
,	,	O
2.3	CD	O
+/-	JJ	O
0.4	CD	O
pg/ml	NN	O
)	)	O
.	.	O

Although	IN	O
the	DT	O
mean	JJ	O
endotoxin	NN	O
concentration	NN	O
was	VBD	O
lower	JJR	O
in	IN	O
the	DT	O
verum	NN	O
group	NN	O
after	IN	O
1	CD	O
week	NN	O
(	(	O
paromomycin	NN	O
,	,	O
8.0	CD	O
+/-	JJ	O
1.9	CD	O
pg/ml	NN	O
;	:	O
placebo	NN	O
,	,	O
14.6	CD	O
+/-	JJ	O
3.5	CD	O
pg/ml	NN	O
;	:	O
p	CC	O
>	VB	O
0.05	CD	O
)	)	O
,	,	O
paromomycin	JJ	O
treatment	NN	O
had	VBD	O
no	DT	O
significant	JJ	O
effect	NN	O
on	IN	O
endotoxin	NN	O
concentration	NN	O
or	CC	O
liver	JJ	O
function	NN	O
tests	NNS	O
during	IN	O
the	DT	O
4-week	JJ	O
period	NN	O
.	.	O

The	DT	O
beneficial	JJ	O
effect	NN	O
of	IN	O
paromomycin	NN	O
treatment	NN	O
on	IN	O
endotoxemia	NN	O
in	IN	O
cirrhotics	NNS	O
reported	VBN	O
in	IN	O
earlier	JJR	O
studies	NNS	O
could	MD	O
not	RB	O
be	VB	O
reproduced	VBN	O
under	IN	O
the	DT	O
conditions	NNS	O
of	IN	O
this	DT	O
trial	NN	O
in	IN	O
patients	NNS	O
with	IN	O
alcoholic	JJ	C
liver	NN	C
disease	NN	C
.	.	O

Efficacy	NN	O
of	IN	O
dose-intensified	JJ	O
MEC	NNP	O
(	(	O
methotrexate	NN	O
,	,	O
epirubicin	NN	O
and	CC	O
cisplatin	NN	O
)	)	O
chemotherapy	NN	O
for	IN	O
advanced	JJ	C
urothelial	JJ	C
carcinoma	NN	C
:	:	O
a	DT	O
prospective	JJ	O
randomized	VBN	O
trial	NN	O
comparing	VBG	O
MEC	NNP	O
and	CC	O
M-VAC	NNP	O
(	(	O
methotrexate	NN	O
,	,	O
vinblastine	NN	O
,	,	O
doxorubicin	NN	O
and	CC	O
cisplatin	NN	O
)	)	O
.	.	O

Japanese	JJ	O
Urothelial	JJ	C
Cancer	NNP	C
Research	NNP	O
Group	NNP	O
.	.	O

BACKGROUND	NNP	O
To	TO	O
evaluate	VB	O
the	DT	O
antitumor	NN	O
activity	NN	O
in	IN	O
patients	NNS	O
with	IN	O
T3b	NNP	C
,	,	C
T4	NNP	C
or	CC	C
metastatic	JJ	C
urothelial	JJ	C
carcinoma	NN	C
treated	VBN	O
with	IN	O
MEC	NNP	O
or	CC	O
M-VAC	NNP	O
chemotherapy	NN	O
,	,	O
by	IN	O
performing	VBG	O
a	DT	O
multi-center	JJ	O
randomized	JJ	O
prospective	JJ	O
study	NN	O
.	.	O

METHODS	NNP	O
From	IN	O
1991	CD	O
to	TO	O
1995	CD	O
,	,	O
89	CD	SS
patients	NNS	O
with	IN	O
T3b	NNP	C
,	,	C
T4	NNP	C
or	CC	C
metastatic	JJ	C
urothelial	JJ	C
carcinoma	NN	C
were	VBD	O
randomly	RB	O
allocated	VBN	O
to	TO	O
a	DT	O
methotrexate	NN	O
,	,	O
epirubicin	NN	O
and	CC	O
cisplatin	NN	O
chemotherapy	NN	O
group	NN	O
(	(	O
arm	JJ	O
1	CD	O
:	:	O
S-MEC	JJ	O
therapy	NN	O
;	:	O
n	CC	O
=	VB	O
29	CD	O
)	)	O
,	,	O
a	DT	O
dose-intensified	JJ	O
MEC	NNP	O
therapy	NN	O
combined	VBN	O
with	IN	O
G-CSF	NNP	O
group	NN	O
(	(	O
arm	JJ	O
2	CD	O
:	:	O
I-MEC	JJ	O
therapy	NN	O
;	:	O
n	CC	O
=	VB	O
30	CD	O
)	)	O
or	CC	O
a	DT	O
methotrexate	NN	O
,	,	O
vinblastine	NN	O
,	,	O
doxorubicin	NN	O
and	CC	O
cisplatin	NN	O
chemotherapy	NN	O
(	(	O
arm	JJ	O
3	CD	O
:	:	O
M-VAC	JJ	O
therapy	NN	O
;	:	O
n	CC	O
=	VB	O
30	CD	O
)	)	O
.	.	O

At	IN	O
the	DT	O
registration	NN	O
center	NN	O
,	,	O
the	DT	O
patients	NNS	O
were	VBD	O
stratified	VBN	O
into	IN	O
previously	RB	O
untreated	JJ	O
patients	NNS	O
and	CC	O
patients	NNS	O
with	IN	O
recurrence	NN	O
after	IN	O
radical	JJ	O
operation	NN	O
and	CC	O
then	RB	O
randomly	RB	O
allocated	VBN	O
to	TO	O
the	DT	O
treatment	NN	O
groups	NNS	O
.	.	O

In	IN	O
each	DT	O
arm	NN	O
,	,	O
two	CD	O
or	CC	O
more	JJR	O
courses	NNS	O
of	IN	O
chemotherapy	NN	O
(	(	O
4-week	JJ	O
cycles	NNS	O
)	)	O
were	VBD	O
performed	VBN	O
.	.	O

RESULTS	NNP	O
Of	IN	O
the	DT	O
88	CD	O
eligible	JJ	O
patients	NNS	O
,	,	O
four	CD	O
treated	VBN	O
with	IN	O
S-MEC	NNP	O
therapy	NN	O
and	CC	O
two	CD	O
treated	VBN	O
with	IN	O
I-MEC	NNP	O
therapy	NN	O
showed	VBD	O
CR	NNP	O
.	.	O

The	DT	O
response	NN	O
rates	NNS	O
(	(	O
CR	NNP	O
+	NNP	O
PR	NNP	O
)	)	O
were	VBD	O
52	CD	O
%	NN	O
(	(	O
15/29	CD	O
)	)	O
with	IN	O
S-MEC	NNP	O
therapy	NN	O
,	,	O
76	CD	O
%	NN	O
(	(	O
22/29	CD	O
)	)	O
with	IN	O
I-MEC	NNP	O
therapy	NN	O
and	CC	O
47	CD	O
%	NN	O
(	(	O
14/30	CD	O
)	)	O
with	IN	O
M-VAC	NNP	O
therapy	NN	O
.	.	O

The	DT	O
response	NN	O
rate	NN	O
with	IN	O
I-MEC	NNP	O
therapy	NN	O
was	VBD	O
significantly	RB	O
higher	JJR	O
than	IN	O
that	DT	O
with	IN	O
M-VAC	NNP	O
therapy	NN	O
(	(	O
P	NNP	O
=	NNP	O
0.02	CD	O
)	)	O
.	.	O

Although	IN	O
the	DT	O
incidence	NN	O
of	IN	O
leukopenia	NN	O
was	VBD	O
low	JJ	O
with	IN	O
I-MEC	NNP	O
therapy	NN	O
,	,	O
the	DT	O
incidence	NN	O
of	IN	O
thrombocytopenia	NN	O
was	VBD	O
high	JJ	O
with	IN	O
this	DT	O
therapy	NN	O
.	.	O

CONCLUSION	NNP	O
MEC	NNP	O
therapy	NN	O
used	VBN	O
in	IN	O
this	DT	O
study	NN	O
is	VBZ	O
promising	VBG	O
in	IN	O
terms	NNS	O
of	IN	O
the	DT	O
antitumor	NN	O
effects	NNS	O
.	.	O

Milk	NNP	O
protein	NN	O
quantity	NN	O
and	CC	O
quality	NN	O
in	IN	O
low-birth-weight	JJ	C
infants	NNS	A
.	.	O

IV	NNP	O
.	.	O

Effects	NNS	O
on	IN	O
tyrosine	NN	O
and	CC	O
phenylalanine	NN	O
in	IN	O
plasma	NN	O
and	CC	O
urine	NN	O
.	.	O

Well	UH	O
,	,	O
appropriate-for-gestational	JJ	A
age	NN	A
,	,	O
low-birth-weight	JJ	C
infants	NNS	A
were	VBD	O
divided	VBN	O
into	IN	O
three	CD	O
gestational	JJ	O
age	NN	O
groups	NNS	O
and	CC	O
assigned	VBD	O
randomly	RB	O
within	IN	O
each	DT	O
age	NN	O
group	NN	O
to	TO	O
one	CD	O
of	IN	O
five	CD	O
feeding	VBG	O
regimens	NNS	O
:	:	O
pooled	VBN	O
human	JJ	O
milk	NN	O
(	(	O
BM	NNP	O
)	)	O
;	:	O
formula	$	O
1	CD	O
(	(	O
F1	NNP	O
)	)	O
=	VBD	O
1.5	CD	O
gm/dl	NN	O
protein	NN	O
,	,	O
60	CD	O
parts	NNS	O
bovine	NN	O
whey	NN	O
proteins	NNS	O
:	:	O
40	CD	O
parts	NNS	O
bovine	NN	O
caseins	NNS	O
;	:	O
F2	NNP	O
=	VBD	O
3.0	CD	O
gm/dl	NN	O
,	,	O
60:40	CD	O
;	:	O
F3	NNP	O
=	VBD	O
1.5	CD	O
gm/dl	NN	O
,	,	O
18:82	CD	O
;	:	O
F4	NNP	O
=	VBD	O
3.0	CD	O
gm/dl	NN	O
,	,	O
18:82	CD	O
.	.	O

Plasma	NNP	O
and	CC	O
urine	JJ	O
concentrations	NNS	O
of	IN	O
tyrosine	NN	O
and	CC	O
phenylalanine	NN	O
were	VBD	O
far	RB	O
higher	JJR	O
in	IN	O
the	DT	O
infants	NNS	O
fed	VBP	O
F1	NNP	O
to	TO	O
F4	NNP	O
,	,	O
especially	RB	O
F2	NNP	O
and	CC	O
F4	NNP	O
,	,	O
than	IN	O
in	IN	O
the	DT	O
infants	NNS	O
fed	VBN	O
BM	NNP	O
.	.	O

These	DT	O
findings	NNS	O
offer	VBP	O
further	JJ	O
evidence	NN	O
for	IN	O
the	DT	O
limited	JJ	O
capacity	NN	O
of	IN	O
the	DT	O
low-birth-weight	JJ	O
infant	NN	O
to	TO	O
catabolize	VB	O
tyrosine	NN	O
.	.	O

Infants	NNS	O
fed	VBD	O
F3	NNP	O
had	VBD	O
significantly	RB	O
higher	JJR	O
plasma	JJ	O
tyrosine	NN	O
concentrations	NNS	O
than	IN	O
infants	NNS	O
fed	VBN	O
F1	NNP	O
,	,	O
and	CC	O
those	DT	O
fed	VBN	O
F4	NNP	O
had	VBD	O
higher	JJR	O
concentrations	NNS	O
than	IN	O
those	DT	O
fed	JJ	O
F2	NNP	O
.	.	O

Thus	NNP	O
,	,	O
increased	VBD	O
plasma	JJ	O
tyrosine	NN	O
concentrations	NNS	O
in	IN	O
low-birth-weight	JJ	O
infants	NNS	O
are	VBP	O
related	VBN	O
directly	RB	O
both	DT	O
to	TO	O
the	DT	O
quantity	NN	O
and	CC	O
to	TO	O
the	DT	O
quality	NN	O
of	IN	O
the	DT	O
protein	NN	O
in	IN	O
their	PRP$	O
diets	NNS	O
.	.	O

High-pressure	NN	O
,	,	O
rapid-inflation	NN	O
pneumatic	JJ	O
compression	NN	O
improves	VBZ	O
venous	JJ	O
hemodynamics	NNS	O
in	IN	O
healthy	JJ	O
volunteers	NNS	O
and	CC	O
patients	NNS	O
who	WP	O
are	VBP	O
post-thrombotic	JJ	O
.	.	O

PURPOSE	NNP	O
Deep	NNP	O
vein	NN	O
thrombosis	NN	O
(	(	O
DVT	NNP	O
)	)	O
is	VBZ	O
a	DT	O
preventable	JJ	O
cause	NN	O
of	IN	O
morbidity	NN	O
and	CC	O
mortality	NN	O
in	IN	O
patients	NNS	O
who	WP	O
are	VBP	O
hospitalized	VBN	O
.	.	O

An	DT	O
important	JJ	O
part	NN	O
of	IN	O
the	DT	O
mechanism	NN	O
of	IN	O
DVT	NNP	O
prophylaxis	NN	O
with	IN	O
intermittent	JJ	O
pneumatic	JJ	O
compression	NN	O
(	(	O
IPC	NNP	O
)	)	O
is	VBZ	O
reduced	VBN	O
venous	JJ	O
stasis	NN	O
with	IN	O
increased	JJ	O
velocity	NN	O
of	IN	O
venous	JJ	O
return	NN	O
.	.	O

The	DT	O
conventional	JJ	O
methods	NNS	O
of	IN	O
IPC	NNP	O
use	NN	O
low	JJ	O
pressure	NN	O
and	CC	O
slow	JJ	O
inflation	NN	O
of	IN	O
the	DT	O
air	NN	O
bladder	NN	O
on	IN	O
the	DT	O
leg	NN	O
to	TO	O
augment	VB	O
venous	JJ	O
return	NN	O
.	.	O

Recently	RB	O
,	,	O
compression	NN	O
devices	NNS	O
have	VBP	O
been	VBN	O
designed	VBN	O
that	IN	O
produce	VBP	O
high	JJ	O
pressure	NN	O
and	CC	O
rapid	JJ	O
inflation	NN	O
of	IN	O
air	NN	O
cuffs	NNS	O
on	IN	O
the	DT	O
plantar	NN	O
plexus	NN	O
of	IN	O
the	DT	O
foot	NN	O
and	CC	O
the	DT	O
calf	NN	O
.	.	O

The	DT	O
purpose	NN	O
of	IN	O
this	DT	O
study	NN	O
is	VBZ	O
to	TO	O
evaluate	VB	O
the	DT	O
venous	JJ	O
velocity	NN	O
response	NN	O
to	TO	O
high-pressure	NN	O
,	,	O
rapid-inflation	NN	O
compression	NN	O
devices	NNS	O
versus	VBP	O
standard	JJ	O
,	,	O
low-pressure	JJ	O
,	,	O
slow-inflation	JJ	O
compression	NN	O
devices	NNS	O
in	IN	O
healthy	JJ	O
volunteers	NNS	O
and	CC	O
patients	NNS	O
with	IN	O
severe	JJ	O
post-thrombotic	JJ	O
venous	JJ	O
disease	NN	O
.	.	O

METHOD	NNP	O
Twenty-two	NNP	O
lower	JJR	O
extremities	NNS	O
from	IN	O
healthy	JJ	O
volunteers	NNS	O
and	CC	O
11	CD	O
lower	JJR	O
extremities	NNS	O
from	IN	O
patients	NNS	O
with	IN	O
class	NN	O
4	CD	O
to	TO	O
class	NN	O
6	CD	O
post-thrombotic	JJ	O
chronic	JJ	O
venous	JJ	O
insufficiency	NN	O
were	VBD	O
studied	VBN	O
.	.	O

With	IN	O
duplex	JJ	O
ultrasound	NN	O
scanning	NN	O
(	(	O
ATL-Ultramark	NNP	O
9	CD	O
,	,	O
Advanced	NNP	O
Tech	NNP	O
Laboratory	NNP	O
,	,	O
Bothell	NNP	O
,	,	O
Wash	NNP	O
)	)	O
,	,	O
acute	JJ	O
DVT	NNP	O
was	VBD	O
excluded	VBN	O
before	IN	O
subject	JJ	O
evaluation	NN	O
.	.	O

Venous	JJ	O
velocities	NNS	O
were	VBD	O
monitored	VBN	O
after	IN	O
the	DT	O
application	NN	O
of	IN	O
each	DT	O
of	IN	O
five	CD	O
IPC	NNP	O
devices	NNS	O
,	,	O
with	IN	O
all	PDT	O
the	DT	O
patients	NNS	O
in	IN	O
the	DT	O
supine	JJ	O
position	NN	O
.	.	O

Three	CD	O
high-pressure	NN	O
,	,	O
rapid-compression	NN	O
devices	NNS	O
and	CC	O
two	CD	O
standard	NN	O
,	,	O
low-pressure	JJ	O
,	,	O
slow-inflation	JJ	O
compression	NN	O
devices	NNS	O
were	VBD	O
applied	VBN	O
in	IN	O
a	DT	O
random	JJ	O
sequence	NN	O
.	.	O

Maximal	NNP	O
venous	JJ	O
velocities	NNS	O
were	VBD	O
obtained	VBN	O
at	IN	O
the	DT	O
common	JJ	O
femoral	JJ	O
vein	NN	O
and	CC	O
the	DT	O
popliteal	NN	O
vein	NN	O
for	IN	O
all	PDT	O
the	DT	O
devices	NNS	O
and	CC	O
were	VBD	O
recorded	VBN	O
as	IN	O
the	DT	O
mean	JJ	O
peak	JJ	O
velocity	NN	O
of	IN	O
three	CD	O
compression	NN	O
cycles	NNS	O
and	CC	O
compared	VBN	O
with	IN	O
baseline	NN	O
velocities	NNS	O
.	.	O

RESULTS	VB	O
The	DT	O
baseline	NN	O
venous	JJ	O
velocities	NNS	O
were	VBD	O
higher	JJR	O
in	IN	O
the	DT	O
femoral	JJ	O
veins	NNS	O
than	IN	O
in	IN	O
the	DT	O
popliteal	NN	O
veins	NNS	O
in	IN	O
both	DT	O
the	DT	O
volunteers	NNS	O
and	CC	O
the	DT	O
post-thrombotic	JJ	O
subjects	NNS	O
.	.	O

Standard	NNP	O
and	CC	O
high-pressure	NN	O
,	,	O
rapid-inflation	NN	O
compression	NN	O
significantly	RB	O
increased	VBD	O
the	DT	O
popliteal	NN	O
and	CC	O
femoral	JJ	O
vein	NN	O
velocities	NNS	O
in	IN	O
healthy	JJ	O
and	CC	O
post-thrombotic	JJ	O
subjects	NNS	O
.	.	O

High-pressure	NN	O
,	,	O
rapid-inflation	NN	O
compression	NN	O
produced	VBD	O
significantly	RB	O
higher	JJR	O
maximal	JJ	O
venous	JJ	O
velocities	NNS	O
in	IN	O
the	DT	O
popliteal	NN	O
and	CC	O
femoral	JJ	O
veins	NNS	O
in	IN	O
both	DT	O
healthy	JJ	O
volunteers	NNS	O
and	CC	O
patients	NNS	O
who	WP	O
were	VBD	O
post-thrombotic	JJ	O
as	IN	O
compared	VBN	O
with	IN	O
standard	JJ	O
compression	NN	O
.	.	O

Compared	VBN	O
with	IN	O
the	DT	O
healthy	JJ	O
volunteers	NNS	O
,	,	O
the	DT	O
patients	NNS	O
who	WP	O
were	VBD	O
post-thrombotic	JJ	O
had	VBD	O
a	DT	O
significantly	RB	O
attenuated	VBN	O
velocity	NN	O
response	NN	O
at	IN	O
both	DT	O
the	DT	O
popliteal	NN	O
and	CC	O
the	DT	O
femoral	JJ	O
vein	NN	O
levels	NNS	O
.	.	O

CONCLUSION	NNP	O
High-pressure	NNP	O
,	,	O
rapid-inflation	NN	O
pneumatic	JJ	O
compression	NN	O
increases	NNS	O
popliteal	NN	O
and	CC	O
femoral	JJ	O
vein	NN	O
velocity	NN	O
as	IN	O
compared	VBN	O
with	IN	O
standard	JJ	O
,	,	O
low-pressure	JJ	O
,	,	O
slow-inflation	JJ	O
pneumatic	JJ	O
compression	NN	O
.	.	O

Patients	NNS	O
with	IN	O
post-thrombotic	JJ	O
venous	JJ	O
disease	NN	O
have	VBP	O
a	DT	O
compromised	JJ	O
hemodynamic	JJ	O
response	NN	O
to	TO	O
all	DT	O
IPC	NNP	O
devices	NNS	O
.	.	O

However	RB	O
,	,	O
an	DT	O
increased	VBN	O
velocity	NN	O
response	NN	O
to	TO	O
the	DT	O
high-pressure	NN	O
,	,	O
rapid-inflation	NN	O
compression	NN	O
device	NN	O
is	VBZ	O
preserved	VBN	O
.	.	O

High-pressure	NN	O
,	,	O
rapid-inflation	NN	O
pneumatic	JJ	O
compression	NN	O
may	MD	O
offer	VB	O
additional	JJ	O
protection	NN	O
from	IN	O
thrombotic	JJ	O
complications	NNS	O
on	IN	O
the	DT	O
basis	NN	O
of	IN	O
an	DT	O
improved	JJ	O
hemodynamic	JJ	O
response	NN	O
,	,	O
both	DT	O
in	IN	O
healthy	JJ	O
volunteers	NNS	O
and	CC	O
in	IN	O
patients	NNS	O
who	WP	O
were	VBD	O
post-thrombotic	JJ	O
.	.	O

Acute	JJ	O
effects	NNS	O
of	IN	O
caffeine	JJ	O
ingestion	NN	O
on	IN	O
signal-averaged	JJ	O
electrocardiograms	NNS	O
.	.	O

BACKGROUND	NNP	O
Although	IN	O
moderate	JJ	O
caffeine	NN	O
ingestion	NN	O
has	VBZ	O
not	RB	O
been	VBN	O
shown	VBN	O
to	TO	O
be	VB	O
arrhythmogenic	JJ	O
,	,	O
caffeine	JJ	O
toxicity	NN	O
can	MD	O
cause	VB	O
severe	JJ	O
cardiac	JJ	O
arrhythmias	NN	O
,	,	O
including	VBG	O
atrial	JJ	O
fibrillation	NN	O
and	CC	O
ventricular	JJ	O
tachycardia	NN	O
.	.	O

Atrial	JJ	O
fibrillation	NN	O
and	CC	O
ventricular	JJ	O
tachycardia	NN	O
have	VBP	O
been	VBN	O
associated	VBN	O
with	IN	O
prolongation	NN	O
of	IN	O
P-wave	NNP	O
and	CC	O
QRS	NNP	O
complex	JJ	O
durations	NNS	O
on	IN	O
signal-averaged	JJ	O
electrocardiograms	NNS	O
.	.	O

This	DT	O
study	NN	O
investigated	VBD	O
acute	JJ	O
effects	NNS	O
of	IN	O
caffeine	JJ	O
ingestion	NN	O
on	IN	O
signal-averaged	JJ	O
P-wave	NNP	O
and	CC	O
QRS	NNP	O
complexes	NNS	O
.	.	O

METHODS	NNP	O
AND	CC	O
RESULTS	NNP	O
Signal-averaged	JJ	O
electrocardiograms	NNS	O
were	VBD	O
obtained	VBN	O
from	IN	O
12	CD	O
normal	JJ	O
subjects	NNS	O
(	(	O
6	CD	O
men	NNS	O
,	,	O
6	CD	O
women	NNS	O
;	:	O
ages	VBZ	O
21	CD	O
to	TO	O
26	CD	O
years	NNS	O
)	)	O
before	IN	O
and	CC	O
after	IN	O
ingestion	NN	O
of	IN	O
caffeine	NN	O
(	(	O
5	CD	O
mg/kg	NN	O
body	NN	O
weight	NN	O
)	)	O
or	CC	O
placebo	NN	O
in	IN	O
a	DT	O
randomized	JJ	O
,	,	O
double-blind	JJ	O
,	,	O
crossover	JJ	O
fashion	NN	O
.	.	O

Electrocardiograms	NNP	O
for	IN	O
signal	JJ	O
averaging	NN	O
were	VBD	O
recorded	VBN	O
from	IN	O
electrodes	NNS	O
left	VBN	O
in	IN	O
a	DT	O
constant	JJ	O
location	NN	O
.	.	O

After	IN	O
bandpass	NN	O
filtering	NN	O
(	(	O
30	CD	O
to	TO	O
300	CD	O
Hz	NNP	O
)	)	O
and	CC	O
amplification	NN	O
,	,	O
signals	NNS	O
were	VBD	O
sampled	VBN	O
over	IN	O
7.2	CD	O
minutes	NNS	O
at	IN	O
2000	CD	O
Hz	NNP	O
.	.	O

Signal-averaged	JJ	O
P-wave	NNP	O
and	CC	O
QRS	NNP	O
complex	JJ	O
durations	NNS	O
did	VBD	O
not	RB	O
significantly	RB	O
change	VBP	O
after	IN	O
placebo	NN	O
ingestion	NN	O
.	.	O

After	IN	O
caffeine	JJ	O
ingestion	NN	O
QRS	NNP	O
duration	NN	O
prolonged	VBD	O
in	IN	O
9	CD	O
of	IN	O
11	CD	O
subjects	NNS	O
at	IN	O
90	CD	O
minutes	NNS	O
(	(	O
mean	JJ	O
+/-	JJ	O
SEM	NNP	O
=	NNP	O
0.8+/-0.3	JJ	O
ms	NN	O
,	,	O
P	NNP	O
<	NNP	O
.02	NNP	O
)	)	O
and	CC	O
in	IN	O
8	CD	O
of	IN	O
9	CD	O
after	IN	O
3	CD	O
hours	NNS	O
(	(	O
1.1+/-0.2	JJ	O
ms	NN	O
,	,	O
P	NNP	O
<	NNP	O
.001	NNP	O
)	)	O
.	.	O

No	DT	O
significant	JJ	O
change	NN	O
in	IN	O
P-wave	NNP	O
duration	NN	O
or	CC	O
heart	NN	O
rate	NN	O
was	VBD	O
found	VBN	O
after	IN	O
caffeine	JJ	O
ingestion	NN	O
at	IN	O
any	DT	O
test	NN	O
interval	NN	O
.	.	O

Average	JJ	O
caffeine	JJ	O
level	NN	O
in	IN	O
saliva	JJ	O
90	CD	O
minutes	NNS	O
after	IN	O
ingestion	NN	O
was	VBD	O
6.6+/-1.6	JJ	O
(	(	O
SD	NNP	O
)	)	O
microg/dL	NN	O
.	.	O

CONCLUSIONS	NNP	O
Although	IN	O
probably	RB	O
not	RB	O
arrhythmogenic	JJ	O
in	IN	O
normal	JJ	O
subjects	NNS	O
,	,	O
moderate	JJ	O
caffeine	NN	O
ingestion	NN	O
does	VBZ	O
produce	VB	O
a	DT	O
small	JJ	O
but	CC	O
statistically	RB	O
significant	JJ	O
prolongation	NN	O
of	IN	O
signal-averaged	JJ	O
QRS	NNP	O
complexes	NNS	O
.	.	O

Further	JJ	O
prolongation	NN	O
caused	VBN	O
by	IN	O
excessive	JJ	O
caffeine	NNS	O
intake	VBP	O
may	MD	O
be	VB	O
a	DT	O
factor	NN	O
in	IN	O
the	DT	O
genesis	NN	O
of	IN	O
arrhythmias	NNS	O
associated	VBN	O
with	IN	O
caffeine	JJ	O
toxicity	NN	O
.	.	O

Working	VBG	O
well	RB	O
with	IN	O
a	DT	O
disability	NN	O
:	:	O
health	NN	O
promotion	NN	O
as	IN	O
a	DT	O
means	NN	O
to	TO	O
employment	NN	O
.	.	O

PURPOSE/OBJECTIVE	VB	O
The	DT	O
purpose	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
test	VB	O
the	DT	O
utility	NN	O
of	IN	O
the	DT	O
Working	NNP	O
Well	NNP	O
with	IN	O
a	DT	O
Disability	NNP	O
health-promotion	NN	O
program	NN	O
with	IN	O
vocational	JJ	O
rehabilitation	NN	O
(	(	O
VR	NNP	O
)	)	O
clients	NNS	O
.	.	O

Health-promotion	NN	O
interventions	NNS	O
have	VBP	O
been	VBN	O
shown	VBN	O
to	TO	O
reduce	VB	O
limitation	NN	O
from	IN	O
secondary	JJ	O
conditions	NNS	O
,	,	O
which	WDT	O
can	MD	O
be	VB	O
a	DT	O
significant	JJ	O
barrier	NN	O
to	TO	O
labor	NN	O
force	NN	O
participation	NN	O
among	IN	O
people	NNS	O
with	IN	O
disabilities	NNS	O
.	.	O

The	DT	O
state	NN	O
and	CC	O
federal	JJ	O
VR	NNP	O
system	NN	O
represents	VBZ	O
a	DT	O
potential	JJ	O
access	NN	O
point	NN	O
for	IN	O
delivery	NN	O
of	IN	O
health-promotion	NN	O
activities	NNS	O
.	.	O

RESEARCH	NNP	O
METHOD/DESIGN	NNP	O
A	NNP	O
total	NN	O
of	IN	O
297	CD	O
VR	NNP	O
clients	NNS	O
participated	VBD	O
in	IN	O
a	DT	O
randomized	JJ	O
trial	NN	O
of	IN	O
the	DT	O
Working	NNP	O
Well	NNP	O
health	NN	O
promotion	NN	O
program	NN	O
.	.	O

Control	NNP	O
and	CC	O
intervention	NN	O
participants	NNS	O
provided	VBD	O
baseline	NN	O
and	CC	O
four	CD	O
waves	NNS	O
of	IN	O
quarterly	JJ	O
follow-up	JJ	O
data	NNS	O
.	.	O

Data	NNS	O
were	VBD	O
analyzed	VBN	O
with	IN	O
repeated-measures	NNS	O
ANOVA	NNP	O
.	.	O

RESULTS	NNP	O
Intervention-group	JJ	O
participants	NNS	O
who	WP	O
attended	VBD	O
over	IN	O
half	NN	O
of	IN	O
the	DT	O
Working	NNP	O
Well	NNP	O
sessions	NNS	O
reported	VBD	O
significantly	RB	O
lower	JJR	O
rates	NNS	O
of	IN	O
limitation	NN	O
from	IN	O
secondary	JJ	O
conditions	NNS	O
over	IN	O
the	DT	O
1-year	JJ	O
study	NN	O
span	NN	O
,	,	O
F	NNP	O
(	(	O
1	CD	O
,	,	O
124	CD	O
)	)	O
=	NN	O
4.11	CD	O
,	,	O
p	NN	O
=	NNP	O
.004	NNP	O
.	.	O

Control-group	NN	O
participants	NNS	O
also	RB	O
experienced	VBD	O
significantly	RB	O
lower	JJR	O
rates	NNS	O
of	IN	O
limitation	NN	O
,	,	O
but	CC	O
pre-	JJ	O
to	TO	O
postdifferences	NNS	O
were	VBD	O
less	RBR	O
dramatic	JJ	O
,	,	O
F	NNP	O
(	(	O
1	CD	O
,	,	O
308	CD	O
)	)	O
=	NN	O
4.19	CD	O
,	,	O
p	NN	O
=	NNP	O
.006	NNP	O
.	.	O

CONCLUSIONS/IMPLICATIONS	NNP	O
Overall	NNP	O
,	,	O
health	NN	O
data	NNS	O
indicated	VBD	O
that	IN	O
the	DT	O
Working	NNP	O
Well	NNP	O
program	NN	O
may	MD	O
be	VB	O
particularly	RB	O
helpful	JJ	O
to	TO	O
VR	NNP	O
clients	NNS	O
with	IN	O
higher	JJR	O
rates	NNS	O
of	IN	O
secondary	JJ	O
health	NN	O
conditions	NNS	O
and	CC	O
may	MD	O
represent	VB	O
one	CD	O
strategy	NN	O
for	IN	O
overcoming	VBG	O
barriers	NNS	O
to	TO	O
employment	NN	O
.	.	O

The	DT	O
effect	NN	O
of	IN	O
metronidazole	NN	O
on	IN	O
the	DT	O
incidence	NN	O
of	IN	O
postoperative	JJ	C
wound	NN	C
infection	NN	C
in	IN	O
elective	JJ	O
colon	NN	O
surgery	NN	O
.	.	O

A	DT	O
prospective	JJ	O
randomized	VBN	O
clinical	JJ	O
trial	NN	O
assessing	VBG	O
the	DT	O
relative	JJ	O
effectiveness	NN	O
of	IN	O
erythromycin-neomycin	JJ	O
and	CC	O
metronidazole-neomycin	JJ	O
as	IN	O
a	DT	O
preoperative	JJ	O
bowel	NN	O
preparation	NN	O
was	VBD	O
carried	VBN	O
out	RP	O
.	.	O

Bacteriologic	NNP	O
studies	NNS	O
of	IN	O
feces	NNS	O
and	CC	O
colon	NN	O
content	NN	O
revealed	VBD	O
no	DT	O
significant	JJ	O
difference	NN	O
in	IN	O
the	DT	O
reduction	NN	O
of	IN	O
aerobic	JJ	O
bacteria	NNS	O
between	IN	O
the	DT	O
two	CD	O
groups	NNS	O
.	.	O

There	EX	O
was	VBD	O
,	,	O
however	RB	O
,	,	O
a	DT	O
significantly	RB	O
greater	JJR	O
reduction	NN	O
in	IN	O
anaerobic	JJ	O
bacteria	NNS	O
in	IN	O
the	DT	O
feces	NNS	O
and	CC	O
colon	NN	O
contents	NNS	O
of	IN	O
patients	NNS	O
receiving	VBG	O
metronidazole	NN	O
.	.	O

Wound	IN	O
infection	NN	O
rate	NN	O
was	VBD	O
25	CD	O
%	NN	O
in	IN	O
the	DT	O
erythromycin	NN	O
group	NN	O
,	,	O
and	CC	O
organisms	NNS	O
recovered	VBN	O
from	IN	O
the	DT	O
wound	NN	O
in	IN	O
all	DT	O
cases	NNS	O
were	VBD	O
fecal	JJ	O
in	IN	O
nature	NN	O
.	.	O

Two	CD	O
wound	IN	O
infections	NNS	O
occurred	VBD	O
in	IN	O
the	DT	O
metronidazole	NN	O
group	NN	O
(	(	O
5	CD	O
%	NN	O
)	)	O
and	CC	O
in	IN	O
both	DT	O
cases	NNS	O
the	DT	O
organisms	NNS	O
recovered	VBN	O
were	VBD	O
staphylococci	NNS	O
of	IN	O
presumed	JJ	O
skin	JJ	O
origin	NN	O
.	.	O

These	DT	O
studies	NNS	O
suggest	VBP	O
that	IN	O
anaerobic	JJ	O
bacteria	NNS	O
are	VBP	O
the	DT	O
major	JJ	O
contributors	NNS	O
to	TO	O
wound	VB	O
infection	NN	O
after	IN	O
colon	NN	O
surgery	NN	O
and	CC	O
that	IN	O
their	PRP$	O
specific	JJ	O
reduction	NN	O
is	VBZ	O
associated	VBN	O
with	IN	O
a	DT	O
lower	JJR	O
incidence	NN	O
of	IN	O
wound	JJ	O
infection	NN	O
.	.	O

Effect	NN	O
of	IN	O
chelation	NN	O
therapy	NN	O
on	IN	O
progressive	JJ	O
diabetic	JJ	O
nephropathy	NN	O
in	IN	O
patients	NNS	O
with	IN	O
type	JJ	C
2	CD	C
diabetes	NNS	C
and	CC	O
high-normal	JJ	C
body	NN	C
lead	JJ	C
burdens	NNS	C
.	.	O

BACKGROUND	VB	O
A	DT	O
previous	JJ	O
study	NN	O
in	IN	O
type	NN	C
2	CD	C
diabetic	JJ	C
patients	NNS	O
with	IN	O
high-normal	JJ	O
body	NN	O
lead	NN	O
burdens	VBZ	O
showed	VBD	O
that	IN	O
EDTA	NNP	O
chelation	NN	O
therapy	NN	O
for	IN	O
3	CD	O
months	NNS	O
slows	VBZ	O
progressive	JJ	O
diabetic	JJ	O
nephropathy	NN	O
during	IN	O
a	DT	O
12-month	JJ	O
follow-up	NN	O
.	.	O

The	DT	O
effect	NN	O
of	IN	O
a	DT	O
longer	JJR	O
course	NN	O
of	IN	O
therapy	NN	O
on	IN	O
kidney	NN	O
function	NN	O
decrease	NN	O
over	IN	O
a	DT	O
longer	JJR	O
follow-up	NN	O
is	VBZ	O
not	RB	O
known	VBN	O
.	.	O

STUDY	NNP	O
DESIGN	NNP	O
A	NNP	O
12-month	JJ	O
run-in	JJ	O
phase	NN	O
,	,	O
then	RB	O
a	DT	O
randomized	VBN	O
single-blind	NN	O
study	NN	O
with	IN	O
a	DT	O
27-month	JJ	O
intervention	NN	O
.	.	O

SETTING	NNP	O
&	CC	O
PARTICIPANTS	NNP	O
University	NNP	O
medical	JJ	O
center	NN	O
;	:	O
50	CD	O
patients	NNS	O
(	(	O
serum	JJ	O
creatinine	NN	O
,	,	O
1.5-3.9	JJ	O
mg/dL	NN	O
)	)	O
with	IN	O
high-normal	JJ	O
body	NN	O
lead	JJ	O
burden	NN	O
(	(	O
?80-	JJ	O
<	NN	O
600	CD	O
?g	NN	O
)	)	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
the	DT	O
treatment	NN	O
and	CC	O
control	NN	O
groups	NNS	O
.	.	O

INTERVENTION	NNP	O
The	DT	O
treatment	NN	O
group	NN	O
received	VBD	O
weekly	JJ	O
chelation	NN	O
therapy	NN	O
for	IN	O
3	CD	O
months	NNS	O
to	TO	O
reduce	VB	O
their	PRP$	O
body	NN	O
lead	JJ	O
burden	NN	O
to	TO	O
<	VB	O
60	CD	O
?g	NNS	O
and	CC	O
then	RB	O
as	IN	O
needed	VBN	O
for	IN	O
24	CD	O
months	NNS	O
to	TO	O
maintain	VB	O
this	DT	O
level	NN	O
.	.	O

The	DT	O
control	NN	O
group	NN	O
received	VBD	O
placebo	NN	O
for	IN	O
3	CD	O
months	NNS	O
and	CC	O
then	RB	O
weekly	VB	O
for	IN	O
5	CD	O
weeks	NNS	O
at	IN	O
6-month	JJ	O
intervals	NNS	O
for	IN	O
24	CD	O
months	NNS	O
.	.	O

OUTCOMES	IN	O
The	DT	O
primary	JJ	O
end	NN	O
point	NN	O
was	VBD	O
change	NN	O
in	IN	O
estimated	VBN	O
glomerular	JJ	O
filtration	NN	O
rate	NN	O
(	(	O
eGFR	NN	O
)	)	O
over	IN	O
time	NN	O
.	.	O

A	DT	O
secondary	JJ	O
end	NN	O
point	NN	O
was	VBD	O
a	DT	O
2-fold	JJ	O
increase	NN	O
in	IN	O
baseline	JJ	O
serum	NN	O
creatinine	NN	O
level	NN	O
or	CC	O
the	DT	O
requirement	NN	O
for	IN	O
renal	JJ	O
replacement	NN	O
therapy	NN	O
.	.	O

MEASUREMENTS	NNP	O
Body	NNP	O
lead	JJ	O
burdens	NNS	O
were	VBD	O
assessed	VBN	O
by	IN	O
EDTA	NNP	O
mobilization	NN	O
tests	NNS	O
and	CC	O
eGFR	NN	O
was	VBD	O
calculated	VBN	O
using	VBG	O
the	DT	O
equation	NN	O
for	IN	O
Chinese	JJ	O
patients	NNS	O
with	IN	O
type	JJ	O
2	CD	O
diabetes	NNS	O
.	.	O

RESULTS	NNP	O
Mean	NNP	O
baseline	NN	O
eGFRs	NN	O
in	IN	O
the	DT	O
treatment	NN	O
and	CC	O
control	NN	O
groups	NNS	O
were	VBD	O
similar	JJ	O
.	.	O

After	IN	O
3	CD	O
months	NNS	O
of	IN	O
chelation	NN	O
therapy	NN	O
,	,	O
the	DT	O
change	NN	O
in	IN	O
eGFR	NN	O
in	IN	O
the	DT	O
treatment	NN	O
group	NN	O
(	(	O
+1.0	NNP	O
?	.	O
4.8	CD	O
mL/min/1.73	NN	O
m	NN	O
(	(	O
2	CD	O
)	)	O
)	)	O
differed	VBN	O
significantly	RB	O
from	IN	O
that	DT	O
in	IN	O
the	DT	O
control	NN	O
group	NN	O
(	(	O
-1.5	NNP	O
?	.	O
4.8	CD	O
mL/min/1.73	NN	O
m	NN	O
(	(	O
2	CD	O
)	)	O
;	:	O
P	NNP	O
=	NNP	O
0.04	CD	O
)	)	O
.	.	O

In	IN	O
the	DT	O
subsequent	JJ	O
24-month	JJ	O
intervention	NN	O
,	,	O
the	DT	O
yearly	JJ	O
rate	NN	O
of	IN	O
decrease	NN	O
in	IN	O
eGFR	NN	O
(	(	O
5.6	CD	O
?	.	O
5.0	CD	O
mL/min/1.73	NN	O
m	NN	O
(	(	O
2	CD	O
)	)	O
per	IN	O
year	NN	O
)	)	O
in	IN	O
the	DT	O
treatment	NN	O
group	NN	O
was	VBD	O
slower	JJR	O
than	IN	O
that	DT	O
(	(	O
9.2	CD	O
?	.	O
3.6	CD	O
mL/min/1.73	NN	O
m	NN	O
(	(	O
2	CD	O
)	)	O
per	IN	O
year	NN	O
;	:	O
P	NNP	O
=	NNP	O
0.04	CD	O
)	)	O
in	IN	O
the	DT	O
control	NN	O
group	NN	O
.	.	O

17	CD	O
(	(	O
68	CD	O
%	NN	O
)	)	O
control-group	NN	O
patients	NNS	O
and	CC	O
9	CD	O
(	(	O
36	CD	O
%	NN	O
)	)	O
treatment-group	NN	O
patients	NNS	O
achieved	VBD	O
the	DT	O
secondary	JJ	O
end	NN	O
point	NN	O
.	.	O

LIMITATIONS	NNP	O
Small	NNP	O
sample	NN	O
size	NN	O
,	,	O
not	RB	O
double	JJ	O
blind	NN	O
.	.	O

CONCLUSIONS	VB	O
A	DT	O
27-month	JJ	O
course	NN	O
of	IN	O
EDTA	NNP	O
chelation	NN	O
therapy	NN	O
retards	VBZ	O
the	DT	O
progression	NN	O
of	IN	O
diabetic	JJ	O
nephropathy	NN	O
in	IN	O
type	NN	O
2	CD	O
diabetic	JJ	O
patients	NNS	O
with	IN	O
high-normal	JJ	O
body	NN	O
lead	JJ	O
burdens	NNS	O
.	.	O

Prognostic	JJ	O
factor	NN	O
analysis	NN	O
in	IN	O
patients	NNS	O
with	IN	O
advanced	JJ	C
prostate	NN	C
cancer	NN	C
treated	VBN	O
by	IN	O
castration	NN	O
plus	CC	O
anandron	NN	O
or	CC	O
placebo	NN	O
:	:	O
a	DT	O
final	JJ	O
update	NN	O
.	.	O

PURPOSE	NNP	O
Different	NNP	O
outcome	NN	O
results	NNS	O
have	VBP	O
been	VBN	O
published	VBN	O
in	IN	O
trials	NNS	O
comparing	VBG	O
maximal	JJ	O
androgen	NN	O
blockade	NN	O
(	(	O
MAB	NNP	O
)	)	O
with	IN	O
chemical	NN	O
or	CC	O
surgical	JJ	O
castration	NN	O
alone	RB	O
.	.	O

The	DT	O
conflicting	NN	O
results	NNS	O
could	MD	O
be	VB	O
explained	VBN	O
by	IN	O
the	DT	O
fact	NN	O
that	IN	O
patients	NNS	O
were	VBD	O
included	VBN	O
with	IN	O
different	JJ	O
prognostic	JJ	O
factors	NNS	O
.	.	O

In	IN	O
this	DT	O
new	JJ	O
analysis	NN	O
of	IN	O
the	DT	O
Anandron	NNP	O
European	NNP	O
Study	NNP	O
,	,	O
independent	JJ	O
prognostic	JJ	O
factors	NNS	O
have	VBP	O
been	VBN	O
evaluated	VBN	O
in	IN	O
order	NN	O
to	TO	O
identify	VB	O
those	DT	O
which	WDT	O
could	MD	O
influence	VB	O
the	DT	O
study	NN	O
outcome	NN	O
and	CC	O
the	DT	O
impact	NN	O
of	IN	O
the	DT	O
treatment	NN	O
.	.	O

MATERIAL	NNP	O
AND	NNP	O
METHODS	NNP	O
399	CD	SS
out	IN	O
of	IN	O
457	CD	SS
patients	NNS	O
recruited	VBN	O
in	IN	O
this	DT	O
study	NN	O
were	VBD	O
divided	VBN	O
in	IN	O
a	DT	O
good	JJ	O
or	CC	O
poor	JJ	O
prognostic	JJ	O
group	NN	O
depending	VBG	O
on	IN	O
the	DT	O
presence	NN	O
of	IN	O
two	CD	O
or	CC	O
more	JJR	O
poor	JJ	O
prognostic	JJ	O
factors	NNS	O
,	,	O
these	DT	O
were	VBD	O
pain	NN	O
requiring	VBG	O
treatment	NN	O
,	,	O
>	VBZ	O
5	CD	O
bone	NN	O
metastases	NNS	O
,	,	O
hydronephrosis	NN	O
,	,	O
and	CC	O
alkaline	JJ	O
phosphatase	NN	O
>	VBD	O
2	CD	O
ULN	NNP	O
.	.	O

RESULTS	NNP	O
When	WRB	O
expressed	VBN	O
as	IN	O
a	DT	O
percentage	NN	O
,	,	O
the	DT	O
improvement	NN	O
in	IN	O
time	NN	O
to	TO	O
progression	NN	O
,	,	O
overall	JJ	O
and	CC	O
cancer	NN	O
specific	JJ	O
survival	NN	O
in	IN	O
the	DT	O
Anandron	NNP	O
treated	VBD	O
patients	NNS	O
was	VBD	O
identical	JJ	O
in	IN	O
both	DT	O
groups	NNS	O
.	.	O

In	IN	O
absolute	JJ	O
terms	NNS	O
this	DT	O
improvement	NN	O
,	,	O
however	RB	O
,	,	O
was	VBD	O
greater	JJR	O
in	IN	O
the	DT	O
good	JJ	O
prognostic	JJ	O
group	NN	O
.	.	O

CONCLUSION	NNP	O
In	IN	O
comparison	NN	O
with	IN	O
surgical	JJ	O
castration	NN	O
MAB	NNP	O
using	VBG	O
Anandron	NNP	O
,	,	O
in	IN	O
patients	NNS	O
with	IN	O
metastatic	JJ	C
prostate	NN	C
cancer	NN	C
improves	VBZ	O
the	DT	O
time	NN	O
to	TO	O
objective	VB	O
progression	NN	O
,	,	O
overall	JJ	O
and	CC	O
cancer	NN	O
specific	JJ	O
survival	NN	O
,	,	O
irrespective	NN	O
of	IN	O
certain	JJ	O
poor	JJ	O
prognostic	JJ	O
factors	NNS	O
.	.	O

Tetrahydrobiopterin	NN	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
children	NNS	O
with	IN	O
autistic	JJ	O
disorder	NN	O
:	:	O
a	DT	O
double-blind	JJ	O
placebo-controlled	JJ	O
crossover	NN	O
study	NN	O
.	.	O

Twelve	NNP	O
children	NNS	O
,	,	O
all	DT	O
boys	NNS	O
,	,	O
aged	VBD	O
4	CD	O
to	TO	O
7	CD	O
years	NNS	O
,	,	O
with	IN	O
a	DT	O
diagnosis	NN	O
of	IN	O
autistic	JJ	O
disorder	NN	O
and	CC	O
low	JJ	O
concentrations	NNS	O
of	IN	O
spinal	JJ	O
6R-l-erythro-5,6,7,8-tetrahydrobiopterin	JJ	O
(	(	O
tetrahydrobiopterin	NN	O
)	)	O
were	VBD	O
selected	VBN	O
to	TO	O
participate	VB	O
in	IN	O
a	DT	O
double-blind	NN	O
,	,	O
randomized	VBN	O
,	,	O
placebo-controlled	JJ	O
,	,	O
crossover	NN	O
study	NN	O
.	.	O

The	DT	O
children	NNS	O
received	VBD	O
a	DT	O
daily	JJ	O
dose	NN	O
of	IN	O
3	CD	O
mg	NNS	O
tetrahydrobiopterin	JJ	O
per	IN	O
kilogram	NN	O
during	IN	O
6	CD	O
months	NNS	O
alternating	VBG	O
with	IN	O
placebo	NN	O
.	.	O

Treatment-induced	JJ	O
effects	NNS	O
were	VBD	O
assessed	VBN	O
with	IN	O
the	DT	O
Childhood	NNP	O
Autism	NNP	O
Rating	NNP	O
Scale	NNP	O
every	DT	O
third	JJ	O
month	NN	O
.	.	O

The	DT	O
results	NNS	O
showed	VBD	O
small	JJ	O
nonsignificant	JJ	O
changes	NNS	O
in	IN	O
the	DT	O
total	JJ	O
scores	NNS	O
of	IN	O
Childhood	NNP	O
Autism	NNP	O
Rating	NNP	O
Scale	NNP	O
after	IN	O
3-	JJ	O
and	CC	O
6-month	JJ	O
treatment	NN	O
.	.	O

Post	NNP	O
hoc	NN	O
analysis	NN	O
looking	VBG	O
at	IN	O
the	DT	O
3	CD	O
core	NN	O
symptoms	NNS	O
of	IN	O
autism	NN	O
,	,	O
that	WDT	O
is	VBZ	O
,	,	O
social	JJ	O
interaction	NN	O
,	,	O
communication	NN	O
,	,	O
and	CC	O
stereotyped	VBD	O
behaviors	NNS	O
,	,	O
revealed	VBD	O
a	DT	O
significant	JJ	O
improvement	NN	O
of	IN	O
the	DT	O
social	JJ	O
interaction	NN	O
score	NN	O
after	IN	O
6	CD	O
months	NNS	O
of	IN	O
active	JJ	O
treatment	NN	O
.	.	O

In	IN	O
addition	NN	O
,	,	O
a	DT	O
high	JJ	O
positive	JJ	O
correlation	NN	O
was	VBD	O
found	VBN	O
between	IN	O
response	NN	O
of	IN	O
the	DT	O
social	JJ	O
interaction	NN	O
score	NN	O
and	CC	O
IQ	NNP	O
.	.	O

The	DT	O
results	NNS	O
indicate	VBP	O
a	DT	O
possible	JJ	O
effect	NN	O
of	IN	O
tetrahydrobiopterin	NN	O
treatment	NN	O
.	.	O

The	DT	O
Finnish	JJ	O
Diabetes	NNP	C
Prevention	NNP	O
Study	NNP	O
.	.	O

The	DT	O
aim	NN	O
of	IN	O
the	DT	O
Finnish	NNP	O
Diabetes	NNP	C
Prevention	NNP	O
Study	NNP	O
is	VBZ	O
to	TO	O
assess	VB	O
the	DT	O
efficacy	NN	O
of	IN	O
an	DT	O
intensive	JJ	O
diet-exercise	NN	O
programme	NN	O
in	IN	O
preventing	VBG	O
or	CC	O
delaying	VBG	O
type	JJ	C
2	CD	C
diabetes	NNS	C
in	IN	O
individuals	NNS	O
with	IN	O
impaired	JJ	C
glucose	JJ	C
tolerance	NN	C
(	(	C
IGT	NNP	C
)	)	C
and	CC	O
to	TO	O
evaluate	VB	O
the	DT	O
effect	NN	O
of	IN	O
the	DT	O
programme	NN	O
on	IN	O
the	DT	O
risk	NN	O
factors	NNS	O
of	IN	O
atherosclerotic	JJ	O
vascular	NN	O
diseases	NNS	O
and	CC	O
the	DT	O
incidence	NN	O
of	IN	O
cardiovascular	JJ	O
events	NNS	O
.	.	O

In	IN	O
this	DT	O
ongoing	JJ	O
study	NN	O
,	,	O
a	DT	O
total	NN	O
of	IN	O
523	CD	SS
overweight	JJ	O
subjects	NNS	O
with	IN	O
IGT	NNP	C
based	VBN	O
on	IN	O
two	CD	O
oral	JJ	O
glucose	JJ	O
tolerance	NN	O
tests	NNS	O
were	VBD	O
randomized	VBN	O
to	TO	O
either	DT	O
an	DT	O
intervention	NN	O
group	NN	O
or	CC	O
a	DT	O
control	NN	O
group	NN	O
.	.	O

The	DT	O
main	JJ	O
measure	NN	O
in	IN	O
the	DT	O
intervention	NN	O
group	NN	O
is	VBZ	O
individual	JJ	O
dietary	JJ	O
advice	NN	O
aimed	VBN	O
at	IN	O
reducing	VBG	O
weight	NN	O
and	CC	O
intake	NN	O
of	IN	O
saturated	JJ	O
fat	NN	O
and	CC	O
increasing	VBG	O
intake	NN	O
of	IN	O
dietary	JJ	O
fibre	NN	O
.	.	O

The	DT	O
intervention	NN	O
subjects	NNS	O
are	VBP	O
individually	RB	O
guided	VBN	O
to	TO	O
increase	VB	O
their	PRP$	O
level	NN	O
of	IN	O
physical	JJ	O
activity	NN	O
.	.	O

The	DT	O
control	NN	O
group	NN	O
receives	VBZ	O
general	JJ	O
information	NN	O
about	IN	O
the	DT	O
benefits	NNS	O
of	IN	O
weight	NN	O
reduction	NN	O
,	,	O
physical	JJ	O
activity	NN	O
and	CC	O
healthy	JJ	O
diet	NN	O
in	IN	O
the	DT	O
prevention	NN	O
of	IN	O
diabetes	NNS	O
.	.	O

A	DT	O
pilot	NN	O
study	NN	O
began	VBD	O
in	IN	O
1993	CD	O
,	,	O
and	CC	O
recruitment	NN	O
ended	VBN	O
in	IN	O
1998	CD	O
.	.	O

By	IN	O
the	DT	O
end	NN	O
of	IN	O
April	NNP	O
1999	CD	O
there	EX	O
were	VBD	O
65	CD	O
new	JJ	O
cases	NNS	O
of	IN	O
diabetes	NNS	O
,	,	O
34	CD	O
drop-outs	NNS	O
and	CC	O
one	CD	O
death	NN	O
.	.	O

The	DT	O
weight	NN	O
reduction	NN	O
was	VBD	O
greater	JJR	O
(	(	O
-4.6	NNP	O
kg	NN	O
)	)	O
at	IN	O
1	CD	O
year	NN	O
in	IN	O
the	DT	O
intervention	NN	O
group	NN	O
(	(	O
n	JJ	O
=	NNP	O
152	CD	O
)	)	O
than	IN	O
in	IN	O
the	DT	O
control	NN	O
group	NN	O
(	(	O
n	JJ	O
=	NN	O
143	CD	O
,	,	O
-0.9	NNP	O
kg	NNP	O
,	,	O
P	NNP	O
<	NNP	O
0.0001	CD	O
)	)	O
,	,	O
and	CC	O
this	DT	O
difference	NN	O
was	VBD	O
sustained	VBN	O
in	IN	O
the	DT	O
second	JJ	O
year	NN	O
of	IN	O
follow-up	NN	O
.	.	O

At	IN	O
1	CD	O
year	NN	O
43.4	CD	O
%	NN	O
and	CC	O
at	IN	O
2	CD	O
years	NNS	O
41.8	CD	O
%	NN	O
of	IN	O
the	DT	O
intervention	NN	O
subjects	NNS	O
had	VBD	O
achieved	VBN	O
a	DT	O
weight	JJ	O
reduction	NN	O
of	IN	O
at	IN	O
least	JJS	O
5	CD	O
kg	NNS	O
,	,	O
while	IN	O
the	DT	O
corresponding	JJ	O
figures	NNS	O
for	IN	O
the	DT	O
control	NN	O
subjects	VBZ	O
were	VBD	O
14.0	CD	O
and	CC	O
12.0	CD	O
%	NN	O
(	(	O
P	NNP	O
<	VBZ	O
0.001	CD	O
between	IN	O
the	DT	O
groups	NNS	O
)	)	O
.	.	O

At	IN	O
1	CD	O
year	NN	O
the	DT	O
intervention	NN	O
group	NN	O
showed	VBD	O
significantly	RB	O
greater	JJR	O
reductions	NNS	O
in	IN	O
2	CD	O
h	NN	O
glucose	NN	O
,	,	O
fasting	VBG	O
and	CC	O
2	CD	O
h	NN	O
insulin	NN	O
,	,	O
systolic	JJ	O
and	CC	O
diastolic	JJ	O
blood	NN	O
pressure	NN	O
,	,	O
and	CC	O
serum	NN	O
triglycerides	NNS	O
.	.	O

Most	JJS	O
of	IN	O
the	DT	O
beneficial	JJ	O
changes	NNS	O
in	IN	O
cardiovascular	JJ	O
risk	NN	O
factors	NNS	O
were	VBD	O
sustained	VBN	O
for	IN	O
2	CD	O
years	NNS	O
.	.	O

These	DT	O
interim	JJ	O
results	NNS	O
of	IN	O
the	DT	O
ongoing	JJ	O
Finnish	JJ	O
Diabetes	NNP	O
Prevention	NNP	O
Study	NNP	O
demonstrate	VB	O
the	DT	O
efficacy	NN	O
and	CC	O
feasibility	NN	O
of	IN	O
the	DT	O
lifestyle	JJ	O
intervention	NN	O
programme	NN	O
.	.	O

Instant	JJ	O
Recess?	NNP	O
:	:	O
a	DT	O
practical	JJ	O
tool	NN	O
for	IN	O
increasing	VBG	O
physical	JJ	O
activity	NN	O
during	IN	O
the	DT	O
school	NN	O
day	NN	O
.	.	O

BACKGROUND	NNP	O
An	DT	O
increased	JJ	O
prevalence	NN	O
of	IN	O
overweight/obesity	NN	O
among	IN	O
children	NNS	O
has	VBZ	O
led	VBN	O
to	TO	O
school	NN	O
district	NN	O
level	NN	O
policies	NNS	O
to	TO	O
increase	VB	O
physical	JJ	O
activity	NN	O
(	(	O
PA	NNP	O
)	)	O
among	IN	O
elementary	JJ	O
school	NN	O
students	NNS	O
.	.	O

Interventions	NNS	O
are	VBP	O
needed	VBN	O
that	IN	O
increase	NN	O
activity	NN	O
levels	NNS	O
without	IN	O
sacrificing	VBG	O
time	NN	O
spent	VBN	O
in	IN	O
academics	NNS	O
.	.	O

OBJECTIVES	IN	O
We	PRP	O
evaluated	VBD	O
a	DT	O
policy	NN	O
implementation	NN	O
intervention	NN	O
for	IN	O
to	TO	O
increase	VB	O
in-school	JJ	O
PA	NNP	O
in	IN	O
elementary	JJ	O
schools	NNS	O
in	IN	O
Forsyth	NNP	O
County	NNP	O
,	,	O
North	NNP	O
Carolina	NNP	O
,	,	O
in	IN	O
a	DT	O
randomized	JJ	O
study	NN	O
with	IN	O
a	DT	O
delayed	JJ	O
intervention	NN	O
control	NN	O
group	NN	O
.	.	O

METHODS	NNP	O
The	DT	O
study	NN	O
included	VBD	O
third-	JJ	O
through	IN	O
fifth-grade	JJ	O
classrooms	NNS	O
in	IN	O
eight	CD	O
elementary	JJ	O
schools	NNS	O
.	.	O

Instant	NNP	O
Recess?	NNP	O
was	VBD	O
used	VBN	O
to	TO	O
introduce	VB	O
10-minute	JJ	O
PA	NNP	O
breaks	NNS	O
in	IN	O
classrooms	NNS	O
on	IN	O
schedules	NNS	O
determined	VBN	O
by	IN	O
teachers	NNS	O
.	.	O

Direct	JJ	O
observation	NN	O
was	VBD	O
used	VBN	O
to	TO	O
measure	VB	O
activity	NN	O
levels	NNS	O
,	,	O
other	JJ	O
student	NN	O
behaviors	NNS	O
,	,	O
and	CC	O
teacher	NN	O
behaviors	NNS	O
related	VBN	O
to	TO	O
PA	NNP	O
in	IN	O
the	DT	O
classrooms	NNS	O
.	.	O

RESULTS	NNP	O
Twenty-eight	JJ	O
visits	NNS	O
to	TO	O
schools	NNS	O
were	VBD	O
made	VBN	O
during	IN	O
the	DT	O
spring	NN	O
and	CC	O
fall	NN	O
semesters	NNS	O
of	IN	O
2009	CD	O
.	.	O

At	IN	O
baseline	JJ	O
11	CD	O
%	NN	O
to	TO	O
44	CD	O
%	NN	O
of	IN	O
intervention	NN	O
and	CC	O
control	NN	O
schools	NNS	O
were	VBD	O
engaged	VBN	O
in	IN	O
classroom-based	JJ	O
PA.	NNP	O
PA	NNP	O
increased	VBD	O
from	IN	O
baseline	NN	O
to	TO	O
spring	VB	O
follow-up	NN	O
in	IN	O
intervention	NN	O
schools	NNS	O
and	CC	O
was	VBD	O
maintained	VBN	O
the	DT	O
following	VBG	O
fall	NN	O
.	.	O

Control	NNP	O
schools	NNS	O
decreased	VBD	O
PA	NNP	O
from	IN	O
baseline	NN	O
to	TO	O
spring	NN	O
and	CC	O
increased	VBD	O
PA	NNP	O
once	RB	O
they	PRP	O
began	VBD	O
the	DT	O
intervention	NN	O
.	.	O

Students	NNS	O
in	IN	O
classrooms	NNS	O
engaged	VBN	O
in	IN	O
Instant	NNP	O
Recess	NNP	O
exhibited	VBD	O
statistically	RB	O
significant	JJ	O
increases	NNS	O
in	IN	O
light	NN	O
(	(	O
51	CD	O
%	NN	O
)	)	O
and	CC	O
moderate-intensity	NN	O
(	(	O
16	CD	O
%	NN	O
)	)	O
PA	NNP	O
and	CC	O
increases	NNS	O
in	IN	O
time	NN	O
spent	VBN	O
in	IN	O
on-task	JJ	O
behavior	NN	O
(	(	O
11	CD	O
%	NN	O
)	)	O
.	.	O

Control	NNP	O
schools	NNS	O
experienced	VBD	O
similar	JJ	O
benefits	NNS	O
after	IN	O
they	PRP	O
began	VBD	O
implementing	VBG	O
Instant	NNP	O
Recess	NNP	O
.	.	O

CONCLUSIONS	NNP	O
Instant	NNP	O
Recess	NNP	O
is	VBZ	O
useful	JJ	O
for	IN	O
increasing	VBG	O
PA	NNP	O
and	CC	O
improving	VBG	O
behavior	NN	O
among	IN	O
elementary	JJ	O
school	NN	O
children	NNS	O
.	.	O

Additional	NNP	O
research	NN	O
may	MD	O
be	VB	O
needed	VBN	O
to	TO	O
understand	VB	O
how	WRB	O
to	TO	O
create	VB	O
policies	NNS	O
supporting	VBG	O
classroom	NN	O
activity	NN	O
breaks	NNS	O
and	CC	O
how	WRB	O
to	TO	O
assess	VB	O
policy	NN	O
adherence	NN	O
.	.	O

Beta	NNP	O
radiation	NN	O
as	IN	O
an	DT	O
adjunct	JJ	O
to	TO	O
low-risk	JJ	O
trabeculectomy	NN	C
.	.	O

PURPOSE	NNP	O
To	TO	O
assess	VB	O
a	DT	O
single	JJ	O
dose	NN	O
of	IN	O
intraoperative	JJ	O
beta	NN	O
radiation	NN	O
used	VBN	O
to	TO	O
enhance	VB	O
the	DT	O
success	NN	O
rate	NN	O
of	IN	O
trabeculectomy	NN	O
in	IN	O
a	DT	O
population	NN	O
of	IN	O
low-risk	JJ	O
glaucoma	NN	C
patients	NNS	O
in	IN	O
whom	WP	O
antimetabolites	NNS	O
might	MD	O
not	RB	O
be	VB	O
indicated	VBN	O
.	.	O

METHODS	VB	O
A	DT	O
prospective	JJ	O
randomized	VBN	O
trial	NN	O
of	IN	O
65	CD	SS
eyes	NNS	O
was	VBD	O
designed	VBN	O
,	,	O
with	IN	O
31	CD	SS
eyes	NNS	O
receiving	VBG	O
750	CD	O
rads	NNS	O
of	IN	O
intraoperative	JJ	O
beta	NN	O
radiation	NN	O
(	(	O
group	NN	O
1	CD	O
)	)	O
,	,	O
and	CC	O
34	CD	SS
eyes	NNS	O
receiving	VBG	O
no	DT	O
supplementation	NN	O
(	(	O
group	NN	O
2	CD	O
)	)	O
.	.	O

RESULTS	JJ	O
Mean	JJ	O
follow-up	JJ	O
time	NN	O
was	VBD	O
24	CD	O
months	NNS	O
.	.	O

Mean	NNP	O
postoperative	JJ	O
intraocular	JJ	O
pressure	NN	O
was	VBD	O
12.2	CD	O
mmHg	NN	O
in	IN	O
group	NN	O
1	CD	O
,	,	O
and	CC	O
13.7	CD	O
mmHg	NN	O
in	IN	O
group	NN	O
2	CD	O
(	(	O
P	NNP	O
=	NNP	O
0.16	CD	O
)	)	O
.	.	O

Mean	JJ	O
decrease	NN	O
in	IN	O
intraocular	JJ	O
pressure	NN	O
was	VBD	O
10.3	CD	O
mmHg	NN	O
in	IN	O
group	NN	O
1	CD	O
,	,	O
and	CC	O
9.3	CD	O
mmHg	NN	O
in	IN	O
group	NN	O
2	CD	O
(	(	O
P	NNP	O
=	NNP	O
0.49	CD	O
)	)	O
.	.	O

The	DT	O
two	CD	O
groups	NNS	O
were	VBD	O
not	RB	O
significantly	RB	O
different	JJ	O
in	IN	O
terms	NNS	O
of	IN	O
surgical	JJ	O
complications	NNS	O
.	.	O

CONCLUSION	NN	O
For	IN	O
this	DT	O
population	NN	O
of	IN	O
low-risk	JJ	C
patients	NNS	C
,	,	O
there	EX	O
was	VBD	O
no	DT	O
significant	JJ	O
difference	NN	O
in	IN	O
outcome	NN	O
after	IN	O
applications	NNS	O
of	IN	O
a	DT	O
single	JJ	O
intraoperative	JJ	O
dose	NN	O
of	IN	O
beta	NN	O
radiation	NN	O
.	.	O

The	DT	O
effects	NNS	O
of	IN	O
haloperidol	NN	O
on	IN	O
discrimination	NN	O
learning	NN	O
and	CC	O
behavioral	JJ	O
symptoms	NNS	O
in	IN	O
autistic	JJ	C
children	NNS	O
.	.	O

This	DT	O
double-blind	JJ	O
and	CC	O
placebo-controlled	JJ	O
clinical	JJ	O
trial	NN	O
in	IN	O
autistic	JJ	O
children	NNS	O
had	VBD	O
three	CD	O
objectives	NNS	O
:	:	O
(	(	O
a	DT	O
)	)	O
to	TO	O
replicate	VB	O
earlier	JJR	O
findings	NNS	O
that	IN	O
haloperidol	JJ	O
administration	NN	O
is	VBZ	O
associated	VBN	O
with	IN	O
a	DT	O
significant	JJ	O
reduction	NN	O
of	IN	O
behavioral	JJ	O
symptoms	NNS	O
;	:	O
(	(	O
b	NN	O
)	)	O
to	TO	O
further	JJ	O
assess	NN	O
its	PRP$	O
safety	NN	O
when	WRB	O
given	VBN	O
on	IN	O
a	DT	O
short-term	JJ	O
basis	NN	O
;	:	O
and	CC	O
(	(	O
c	NN	O
)	)	O
to	TO	O
assess	VB	O
whether	IN	O
it	PRP	O
has	VBZ	O
an	DT	O
effect	NN	O
on	IN	O
discrimination	NN	O
learning	NN	O
.	.	O

Forty-five	JJ	SS
children	NNS	O
,	,	O
2.02	CD	A
to	TO	A
7.58	CD	A
years	NNS	O
old	JJ	O
(	(	O
M	NNP	A
=	NNP	A
4.49	CD	A
)	)	O
,	,	O
completed	VBD	O
this	DT	O
crossover	NN	O
design	NN	O
,	,	O
with	IN	O
random	JJ	O
assignment	NN	O
to	TO	O
treatment	NN	O
sequences	NNS	O
.	.	O

Haloperidol	NNP	O
was	VBD	O
shown	VBN	O
to	TO	O
be	VB	O
a	DT	O
powerful	JJ	O
therapeutic	JJ	O
agent	NN	O
when	WRB	O
administered	VBN	O
for	IN	O
4	CD	O
weeks	NNS	O
and	CC	O
free	JJ	O
of	IN	O
side	JJ	O
effects	NNS	O
;	:	O
at	IN	O
doses	NNS	O
ranging	VBG	O
from	IN	O
0.25	CD	O
to	TO	O
4.0	CD	O
mg/day	NN	O
(	(	O
M	NNP	O
=	NNP	O
0.844	CD	O
)	)	O
,	,	O
there	EX	O
was	VBD	O
a	DT	O
clinically	RB	O
and	CC	O
statistically	RB	O
significant	JJ	O
reduction	NN	O
of	IN	O
a	DT	O
variety	NN	O
of	IN	O
symptoms	NNS	O
.	.	O

Under	IN	O
the	DT	O
given	VBN	O
conditions	NNS	O
,	,	O
the	DT	O
children	NNS	O
failed	VBD	O
to	TO	O
learn	VB	O
on	IN	O
either	DT	O
haloperidol	NN	O
or	CC	O
placebo	NN	O
.	.	O

A	DT	O
controlled	JJ	O
trial	NN	O
of	IN	O
trimethoprim-sulfamethoxazole	JJ	O
or	CC	O
aerosolized	JJ	O
pentamidine	NN	O
for	IN	O
secondary	JJ	O
prophylaxis	NN	O
of	IN	O
Pneumocystis	NNP	O
carinii	NN	O
pneumonia	NN	O
in	IN	O
patients	NNS	O
with	IN	O
the	DT	O
acquired	JJ	C
immunodeficiency	NN	C
syndrome	NN	C
.	.	O

AIDS	NNP	O
Clinical	JJ	O
Trials	NNP	O
Group	NNP	O
Protocol	NNP	O
021	CD	O
.	.	O

BACKGROUND	NNP	O
Pneumocystis	NNP	O
carinii	NN	O
pneumonia	NN	O
(	(	O
PCP	NNP	O
)	)	O
continues	VBZ	O
to	TO	O
be	VB	O
the	DT	O
most	RBS	O
common	JJ	O
index	NN	O
diagnosis	NN	O
in	IN	O
the	DT	O
acquired	JJ	O
immunodeficiency	NN	O
syndrome	NN	O
(	(	O
AIDS	NNP	O
)	)	O
,	,	O
but	CC	O
it	PRP	O
is	VBZ	O
not	RB	O
clear	JJ	O
which	WDT	O
of	IN	O
several	JJ	O
available	JJ	O
agents	NNS	O
is	VBZ	O
the	DT	O
most	RBS	O
effective	JJ	O
in	IN	O
preventing	VBG	O
a	DT	O
recurrence	NN	O
of	IN	O
PCP	NNP	O
.	.	O

METHODS	NNP	O
We	PRP	O
conducted	VBD	O
a	DT	O
comparative	JJ	O
,	,	O
open-label	JJ	O
trial	NN	O
in	IN	O
310	CD	SS
adults	NNS	A
with	IN	O
AIDS	NNP	C
who	WP	O
had	VBD	O
recently	RB	O
recovered	VBN	O
from	IN	O
an	DT	O
initial	JJ	O
episode	NN	O
of	IN	O
PCP	NNP	C
and	CC	O
had	VBD	O
no	DT	O
treatment-limiting	JJ	O
toxic	NN	O
effects	NNS	O
of	IN	O
trimethoprim-sulfamethoxazole	JJ	O
or	CC	O
pentamidine	NN	O
.	.	O

All	PDT	O
the	DT	O
patients	NNS	O
were	VBD	O
treated	VBN	O
with	IN	O
zidovudine	NN	O
and	CC	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
receive	VB	O
either	RB	O
800	CD	O
mg	NN	O
of	IN	O
sulfamethoxazole	NN	O
and	CC	O
160	CD	O
mg	NN	O
of	IN	O
trimethoprim	JJ	O
once	JJ	O
daily	JJ	O
or	CC	O
300	CD	O
mg	NN	O
of	IN	O
aerosolized	JJ	O
pentamidine	NN	O
administered	VBN	O
every	DT	O
four	CD	O
weeks	NNS	O
by	IN	O
jet	NN	O
nebulizer	NN	O
.	.	O

The	DT	O
participants	NNS	O
were	VBD	O
followed	VBN	O
for	IN	O
a	DT	O
median	NN	O
of	IN	O
17.4	CD	O
months	NNS	O
.	.	O

RESULTS	NNP	O
In	IN	O
the	DT	O
trimethoprim-sulfamethoxazole	JJ	O
group	NN	O
(	(	O
n	JJ	O
=	NNP	O
154	CD	O
)	)	O
there	EX	O
were	VBD	O
14	CD	O
recurrences	NNS	O
of	IN	O
PCP	NNP	O
,	,	O
as	IN	O
compared	VBN	O
with	IN	O
36	CD	O
recurrences	NNS	O
(	(	O
including	VBG	O
1	CD	O
extrapulmonary	JJ	O
recurrence	NN	O
)	)	O
in	IN	O
the	DT	O
aerosolized-pentamidine	JJ	O
group	NN	O
(	(	O
n	JJ	O
=	NNP	O
156	CD	O
)	)	O
.	.	O

The	DT	O
estimated	JJ	O
recurrence	NN	O
rates	NNS	O
at	IN	O
18	CD	O
months	NNS	O
were	VBD	O
11.4	CD	O
percent	NN	O
with	IN	O
trimethoprim-sulfamethoxazole	JJ	O
and	CC	O
27.6	CD	O
percent	NN	O
with	IN	O
pentamidine	NN	O
(	(	O
P	NNP	O
<	NNP	O
0.001	CD	O
)	)	O
.	.	O

The	DT	O
risk	NN	O
of	IN	O
a	DT	O
recurrence	NN	O
(	(	O
adjusted	VBN	O
for	IN	O
initial	JJ	O
CD4	NNP	O
cell	NN	O
count	NN	O
)	)	O
was	VBD	O
3.25	CD	O
times	NNS	O
higher	RBR	O
in	IN	O
the	DT	O
pentamidine	NN	O
group	NN	O
(	(	O
P	NNP	O
<	NNP	O
0.001	CD	O
,	,	O
95	CD	O
percent	NN	O
confidence	NN	O
interval	NN	O
,	,	O
1.72	CD	O
to	TO	O
6.16	CD	O
)	)	O
.	.	O

There	EX	O
were	VBD	O
no	DT	O
significant	JJ	O
differences	NNS	O
between	IN	O
the	DT	O
groups	NNS	O
in	IN	O
survival	NN	O
or	CC	O
in	IN	O
hematologic	JJ	O
or	CC	O
hepatic	JJ	O
toxicity	NN	O
.	.	O

Crossovers	NNS	O
from	IN	O
trimethoprim-sulfamethoxazole	JJ	O
to	TO	O
aerosolized	JJ	O
pentamidine	NN	O
were	VBD	O
more	JJR	O
common	JJ	O
than	IN	O
the	DT	O
reverse	NN	O
(	(	O
27	CD	O
vs.	FW	O
4	CD	O
percent	NN	O
)	)	O
,	,	O
partly	RB	O
because	IN	O
of	IN	O
the	DT	O
study	NN	O
protocols	NNS	O
for	IN	O
the	DT	O
management	NN	O
of	IN	O
leukopenia	NN	O
.	.	O

There	EX	O
were	VBD	O
19	CD	O
serious	JJ	O
bacterial	JJ	O
infections	NNS	O
in	IN	O
the	DT	O
trimethoprim-sulfamethoxazole	JJ	O
group	NN	O
and	CC	O
38	CD	O
in	IN	O
the	DT	O
pentamidine	NN	O
group	NN	O
.	.	O

The	DT	O
time	NN	O
to	TO	O
a	DT	O
first	JJ	O
bacterial	JJ	O
infection	NN	O
was	VBD	O
significantly	RB	O
greater	JJR	O
for	IN	O
those	DT	O
assigned	VBN	O
to	TO	O
trimethoprim-sulfamethoxazole	JJ	O
(	(	O
P	NNP	O
=	NNP	O
0.017	CD	O
)	)	O
.	.	O

CONCLUSIONS	NNP	O
In	IN	O
patients	NNS	O
with	IN	O
AIDS	NNP	C
who	WP	O
are	VBP	O
receiving	VBG	O
zidovudine	NN	O
,	,	O
trimethoprim-sulfamethoxazole	JJ	O
is	VBZ	O
more	RBR	O
effective	JJ	O
than	IN	O
aerosolized	JJ	O
pentamidine	NN	O
in	IN	O
conventional	JJ	O
doses	NNS	O
for	IN	O
the	DT	O
prevention	NN	O
of	IN	O
recurrent	NN	O
pneumocystis	NN	O
infection	NN	O
.	.	O

Effects	NNS	O
of	IN	O
large	JJ	O
doses	NNS	O
of	IN	O
arachidonic	JJ	O
acid	NN	O
added	VBD	O
to	TO	O
docosahexaenoic	VB	O
acid	NN	O
on	IN	O
social	JJ	C
impairment	NN	C
in	IN	C
individuals	NNS	C
with	IN	C
autism	NN	C
spectrum	NN	C
disorders	NNS	C
:	:	C
a	DT	O
double-blind	NN	O
,	,	O
placebo-controlled	JJ	O
,	,	O
randomized	JJ	O
trial	NN	O
.	.	O

Autism	NNP	O
spectrum	NN	O
disorders	NNS	O
are	VBP	O
a	DT	O
neurodevelopmental	JJ	O
disorders	NNS	O
with	IN	O
reduced	JJ	O
cortical	JJ	O
functional	JJ	O
connectivity	NN	O
relating	VBG	O
to	TO	O
social	JJ	O
cognition	NN	O
.	.	O

Polyunsaturated	VBN	O
fatty	JJ	O
acids	NNS	O
arachidonic	JJ	O
acid	NN	O
(	(	O
ARA	NNP	O
)	)	O
and	CC	O
docosahexaenoic	JJ	O
acid	NN	O
(	(	O
DHA	NNP	O
)	)	O
may	MD	O
have	VB	O
key	JJ	O
role	NN	O
in	IN	O
brain	NN	O
network	NN	O
maturation	NN	O
.	.	O

In	IN	O
particularly	RB	O
,	,	O
ARA	NNP	O
is	VBZ	O
important	JJ	O
in	IN	O
signal	JJ	O
transduction	NN	O
related	VBN	O
to	TO	O
neuronal	JJ	O
maturation	NN	O
.	.	O

Supplementation	NN	O
with	IN	O
larger	JJR	O
ARA	NNP	O
doses	VBZ	O
added	VBN	O
to	TO	O
DHA	NNP	O
may	MD	O
therefore	VB	O
mitigate	VB	O
social	JJ	O
impairment	NN	O
.	.	O

In	IN	O
a	DT	O
16-week	JJ	O
,	,	O
double-blind	JJ	O
,	,	O
randomized	VBN	O
,	,	O
placebo-controlled	JJ	O
trial	NN	O
,	,	O
we	PRP	O
evaluated	VBD	O
the	DT	O
efficacy	NN	O
of	IN	O
supplementation	NN	O
with	IN	O
large	JJ	O
doses	NNS	O
of	IN	O
ARA	NNP	O
added	VBD	O
to	TO	O
DHA	NNP	O
(	(	O
n	JJ	O
=	NNP	O
7	CD	O
)	)	O
or	CC	O
placebo	NN	O
(	(	O
n	JJ	O
=	NNP	O
6	CD	O
)	)	O
in	IN	O
13	CD	O
participants	NNS	O
(	(	O
mean	JJ	O
age	NN	O
,	,	O
14.6	CD	O
[	NN	O
SD	NNP	O
,	,	O
5.9	CD	O
]	CD	O
years	NNS	O
)	)	O
.	.	O

To	TO	O
examine	VB	O
underlying	JJ	O
mechanisms	NNS	O
underlying	VBG	O
the	DT	O
effect	NN	O
of	IN	O
our	PRP$	O
supplementation	NN	O
regimen	NNS	O
,	,	O
we	PRP	O
examined	VBD	O
plasma	JJ	O
levels	NNS	O
of	IN	O
antioxidants	NNS	O
transferrin	JJ	O
and	CC	O
superoxide	JJ	O
dismutase	NN	O
,	,	O
which	WDT	O
are	VBP	O
useful	JJ	O
markers	NNS	O
of	IN	O
signal	JJ	O
transduction	NN	O
.	.	O

The	DT	O
outcome	NN	O
measures	NNS	O
were	VBD	O
the	DT	O
Social	NNP	O
Responsiveness	NNP	O
Scale	NNP	O
and	CC	O
the	DT	O
Aberrant	NNP	O
Behavior	NNP	O
Checklist-Community	NNP	O
.	.	O

Repeated-measures	JJ	O
analysis	NN	O
of	IN	O
variance	NN	O
revealed	VBD	O
that	IN	O
our	PRP$	O
supplementation	NN	O
regimen	NNS	O
significantly	RB	O
improved	VBN	O
Aberrant	NNP	O
Behavior	NNP	O
Checklist-Community-measured	NNP	O
social	JJ	O
withdrawal	NN	O
and	CC	O
Social	NNP	O
Responsiveness	NNP	O
Scale-measured	JJ	O
communication	NN	O
.	.	O

Treatment	NNP	O
effect	NN	O
sizes	NNS	O
were	VBD	O
more	RBR	O
favorable	JJ	O
for	IN	O
the	DT	O
treatment	NN	O
group	NN	O
compared	VBN	O
with	IN	O
the	DT	O
placebo	NN	O
group	NN	O
(	(	O
communication	NN	O
:	:	O
treatment	NN	O
groups	NNS	O
,	,	O
0.87	CD	O
vs	NN	O
,	,	O
placebo	NN	O
,	,	O
0.44	CD	O
;	:	O
social	JJ	O
withdrawal	NN	O
:	:	O
treatment	NN	O
groups	NNS	O
,	,	O
0.88	CD	O
,	,	O
vs	NN	O
placebo	NN	O
,	,	O
0.54	CD	O
)	)	O
.	.	O

There	EX	O
was	VBD	O
a	DT	O
significant	JJ	O
difference	NN	O
in	IN	O
the	DT	O
change	NN	O
in	IN	O
plasma	NN	O
transferrin	NN	O
levels	NNS	O
and	CC	O
a	DT	O
trend	NN	O
toward	IN	O
a	DT	O
significant	JJ	O
difference	NN	O
in	IN	O
the	DT	O
change	NN	O
in	IN	O
plasma	JJ	O
superoxide	JJ	O
dismutase	NN	O
levels	NNS	O
between	IN	O
the	DT	O
2	CD	O
groups	NNS	O
.	.	O

This	DT	O
preliminary	JJ	O
study	NN	O
suggests	VBZ	O
that	IN	O
supplementation	NN	O
with	IN	O
larger	JJR	O
ARA	NNP	O
doses	VBZ	O
added	VBN	O
to	TO	O
DHA	NNP	O
improves	NNS	O
impaired	VBD	O
social	JJ	O
interaction	NN	O
in	IN	O
individuals	NNS	O
with	IN	O
autism	NN	O
spectrum	NN	O
disorder	NN	O
by	IN	O
up-regulating	JJ	O
signal	JJ	O
transduction	NN	O
.	.	O

Effect	NN	O
of	IN	O
clinical	JJ	O
pharmacy	NN	O
services	NNS	O
on	IN	O
the	DT	O
blood	NN	O
pressure	NN	O
of	IN	O
African-American	JJ	O
renal	JJ	C
transplant	NN	C
patients	NNS	O
.	.	O

OBJECTIVE	IN	O
The	DT	O
objective	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
determine	VB	O
if	IN	O
African-American	JJ	O
renal	JJ	O
transplant	NN	O
patients	NNS	O
who	WP	O
received	VBD	O
direct	JJ	O
patient	NN	O
care	NN	O
from	IN	O
a	DT	O
clinical	JJ	O
pharmacist	NN	O
had	VBD	O
better	RBR	O
blood	NN	O
pressure	NN	O
control	NN	O
compared	VBN	O
to	TO	O
African-American	JJ	O
renal	JJ	O
transplant	NN	O
patients	NNS	O
who	WP	O
did	VBD	O
not	RB	O
have	VB	O
clinical	JJ	O
pharmacy	NN	O
services	NNS	O
.	.	O

METHODS	NNP	O
Renal	NNP	SS
transplant	NN	SS
patients	NNS	SS
were	VBD	O
prospectively	RB	O
randomized	VBN	O
into	IN	O
an	DT	O
intervention	NN	O
group	NN	O
or	CC	O
a	DT	O
control	NN	O
group	NN	O
.	.	O

Patients	NNS	O
in	IN	O
the	DT	O
intervention	NN	O
group	NN	O
received	VBD	O
clinical	JJ	O
pharmacy	NN	O
services	NNS	O
that	WDT	O
included	VBD	O
a	DT	O
clinical	JJ	O
pharmacist	NN	O
performing	VBG	O
patient	JJ	O
medication	NN	O
reviews	NNS	O
,	,	O
with	IN	O
emphasis	NN	O
on	IN	O
preventing	VBG	O
or	CC	O
resolving	VBG	O
medication-related	JJ	O
problems	NNS	O
and	CC	O
providing	VBG	O
medication	NN	O
recommendations	NNS	O
.	.	O

Patients	NNS	O
in	IN	O
the	DT	O
control	NN	O
group	NN	O
received	VBD	O
routine	JJ	O
clinic	NN	O
services	NNS	O
,	,	O
but	CC	O
had	VBD	O
no	DT	O
clinical	JJ	O
pharmacist	NN	O
interaction	NN	O
.	.	O

Analysis	NN	O
was	VBD	O
performed	VBN	O
to	TO	O
detect	VB	O
differences	NNS	O
between	IN	O
the	DT	O
intervention	NN	O
and	CC	O
control	NN	O
groups	NNS	O
in	IN	O
baseline	NN	O
and	CC	O
quarterly	JJ	O
systolic	JJ	O
blood	NN	O
pressure	NN	O
(	(	O
SBP	NNP	O
)	)	O
and	CC	O
diastolic	JJ	O
blood	NN	O
pressure	NN	O
(	(	O
DBP	NNP	O
)	)	O
for	IN	O
one	CD	O
year	NN	O
post-study	NN	O
enrollment	NN	O
.	.	O

RESULTS	CC	O
There	EX	O
were	VBD	O
no	DT	O
differences	NNS	O
between	IN	O
the	DT	O
intervention	NN	O
(	(	O
N	NNP	O
=	NNP	O
13	CD	SS
)	)	O
and	CC	O
control	NN	O
(	(	O
N	NNP	O
=	NNP	O
10	CD	SS
)	)	O
groups	NNS	O
in	IN	O
baseline	NN	O
blood	NN	O
pressures	NNS	O
or	CC	O
in	IN	O
the	DT	O
percentage	NN	O
of	IN	O
hypertensive	JJ	O
patients	NNS	O
.	.	O

Significant	JJ	O
differences	NNS	O
in	IN	O
the	DT	O
change	NN	O
in	IN	O
SBP	NNP	O
and	CC	O
DBP	NNP	O
from	IN	O
baseline	NN	O
between	IN	O
the	DT	O
intervention	NN	O
and	CC	O
control	NN	O
groups	NNS	O
were	VBD	O
observed	VBN	O
at	IN	O
the	DT	O
second	JJ	O
,	,	O
third	JJ	O
,	,	O
and	CC	O
fourth	JJ	O
quarters	NNS	O
of	IN	O
the	DT	O
study	NN	O
,	,	O
favoring	VBG	O
the	DT	O
intervention	NN	O
group	NN	O
(	(	O
P	NNP	O
<	NNP	O
.01	NNP	O
)	)	O
.	.	O

Mean	NNP	O
SBP	NNP	O
was	VBD	O
significantly	RB	O
lower	JJR	O
in	IN	O
the	DT	O
intervention	NN	O
group	NN	O
at	IN	O
the	DT	O
second	JJ	O
(	(	O
137.8	CD	O
+/-	JJ	O
15.0	CD	O
vs	JJ	O
168.9	CD	O
+/-	JJ	O
15.3	CD	O
)	)	O
,	,	O
third	JJ	O
(	(	O
135.9	CD	O
+/-	JJ	O
11.7	CD	O
vs	JJ	O
164.6	CD	O
+/-	JJ	O
20.1	CD	O
)	)	O
,	,	O
and	CC	O
fourth	JJ	O
(	(	O
145.3	CD	O
+/-	JJ	O
16.8	CD	O
vs	JJ	O
175.8	CD	O
+/-	JJ	O
33.9	CD	O
)	)	O
quarters	NNS	O
of	IN	O
the	DT	O
study	NN	O
(	(	O
P	NNP	O
<	NNP	O
.05	NNP	O
)	)	O
.	.	O

Mean	NNP	O
DBP	NNP	O
was	VBD	O
significantly	RB	O
lower	JJR	O
in	IN	O
the	DT	O
intervention	NN	O
group	NN	O
at	IN	O
the	DT	O
second	JJ	O
(	(	O
76.0	CD	O
+/-	JJ	O
11.8	CD	O
vs	JJ	O
84.9	CD	O
+/-	JJ	O
6.1	CD	O
)	)	O
and	CC	O
fourth	JJ	O
(	(	O
77.0	CD	O
+/-	JJ	O
10.2	CD	O
vs	JJ	O
91.8	CD	O
+/-	JJ	O
12.0	CD	O
)	)	O
quarters	NNS	O
(	(	O
P	NNP	O
<	NNP	O
.05	NNP	O
)	)	O
.	.	O

CONCLUSION	NNP	O
Direct	NNP	O
patient	NN	O
care	NN	O
services	NNS	O
provided	VBN	O
by	IN	O
a	DT	O
clinical	JJ	O
pharmacist	NN	O
,	,	O
in	IN	O
addition	NN	O
to	TO	O
routine	VB	O
clinical	JJ	O
services	NNS	O
,	,	O
have	VBP	O
a	DT	O
positive	JJ	O
effect	NN	O
on	IN	O
the	DT	O
blood	NN	O
pressure	NN	O
of	IN	O
African-American	JJ	O
renal	JJ	O
transplant	NN	O
patients	NNS	O
.	.	O

A	DT	O
multidisciplinary	JJ	O
team	NN	O
that	WDT	O
includes	VBZ	O
a	DT	O
clinical	JJ	O
pharmacist	NN	O
is	VBZ	O
beneficial	JJ	O
to	TO	O
patient	VB	O
care	NN	O
.	.	O

Granulocyte-colony	JJ	O
stimulating	NN	O
factor	NN	O
for	IN	O
mobilizing	VBG	O
bone	NN	O
marrow	NN	O
stem	NN	O
cells	NNS	O
in	IN	O
subacute	JJ	O
stroke	NN	O
:	:	O
the	DT	O
stem	NN	O
cell	VBP	O
trial	NN	O
of	IN	O
recovery	NN	O
enhancement	NN	O
after	IN	O
stroke	VBD	C
2	CD	O
randomized	VBN	O
controlled	VBN	O
trial	NN	O
.	.	O

BACKGROUND	NNP	O
AND	CC	O
PURPOSE	NNP	O
Granulocyte-colony	NNP	O
stimulating	VBG	O
factor	NN	O
(	(	O
G-CSF	NNP	O
)	)	O
is	VBZ	O
neuroprotective	JJ	O
in	IN	O
experimental	JJ	O
stroke	NN	O
and	CC	O
mobilizes	VBZ	O
CD34	NNP	O
(	(	O
+	NNP	O
)	)	O
peripheral	JJ	O
blood	NN	O
stem	NN	O
cells	NNS	O
into	IN	O
the	DT	O
circulation	NN	O
.	.	O

We	PRP	O
assessed	VBD	O
the	DT	O
safety	NN	O
of	IN	O
G-CSF	NNP	O
in	IN	O
recent	JJ	O
stroke	NN	O
in	IN	O
a	DT	O
phase	NN	O
IIb	NNP	O
single-center	NN	O
randomized	NN	O
,	,	O
controlled	VBN	O
trial	NN	O
.	.	O

METHODS	NNP	O
G-CSF	NNP	O
(	(	O
10	CD	O
?g/kg	NN	O
)	)	O
or	CC	O
placebo	NN	O
(	(	O
ratio	VB	O
2:1	CD	O
)	)	O
was	VBD	O
given	VBN	O
SC	NNP	O
for	IN	O
5	CD	O
days	NNS	O
to	TO	O
60	CD	O
patients	NNS	O
3	CD	O
to	TO	O
30	CD	O
days	NNS	O
after	IN	O
ischemic	JJ	O
or	CC	O
hemorrhagic	JJ	O
stroke	NN	O
.	.	O

The	DT	O
primary	JJ	O
outcome	NN	O
was	VBD	O
the	DT	O
frequency	NN	O
of	IN	O
serious	JJ	O
adverse	JJ	O
events	NNS	O
.	.	O

Peripheral	NNP	O
blood	NN	O
counts	NNS	O
,	,	O
CD34	NNP	O
(	(	O
+	NNP	O
)	)	O
count	NN	O
,	,	O
and	CC	O
functional	JJ	O
outcome	NN	O
were	VBD	O
measured	VBN	O
.	.	O

MRI	NNP	O
assessed	VBD	O
lesion	NN	O
volume	NN	O
,	,	O
atrophy	NN	O
,	,	O
and	CC	O
the	DT	O
presence	NN	O
of	IN	O
iron-labeled	JJ	O
CD34	NNP	O
(	(	O
+	NNP	O
)	)	O
cells	NNS	O
reinjected	VBN	O
on	IN	O
day	NN	O
6	CD	O
.	.	O

RESULTS	NNP	O
Sixty	NNP	O
patients	NNS	O
were	VBD	O
recruited	VBN	O
at	IN	O
mean	NN	O
of	IN	O
8	CD	O
days	NNS	O
(	(	O
SD	NNP	O
?	.	O
5	CD	O
)	)	O
post	NN	O
ictus	NN	O
,	,	O
with	IN	O
mean	JJ	O
age	NN	O
71	CD	O
years	NNS	O
(	(	O
?	.	O
12	CD	O
years	NNS	O
)	)	O
and	CC	O
53	CD	O
%	NN	O
men	NNS	O
.	.	O

The	DT	O
groups	NNS	O
were	VBD	O
well	RB	O
matched	VBN	O
for	IN	O
baseline	JJ	O
minimization/prognostic	JJ	O
factors	NNS	O
.	.	O

There	EX	O
were	VBD	O
no	DT	O
significant	JJ	O
differences	NNS	O
between	IN	O
groups	NNS	O
in	IN	O
the	DT	O
number	NN	O
of	IN	O
participants	NNS	O
with	IN	O
serious	JJ	O
adverse	JJ	O
events	NNS	O
:	:	O
G-CSF	JJ	O
15	CD	O
(	(	O
37.5	CD	O
%	NN	O
)	)	O
of	IN	O
40	CD	O
versus	NN	O
placebo	NN	O
7	CD	O
(	(	O
35	CD	O
%	NN	O
)	)	O
of	IN	O
20	CD	O
,	,	O
death	NN	O
or	CC	O
dependency	NN	O
(	(	O
modified	JJ	O
Rankin	NNP	O
Score	NN	O
:	:	O
G-CSF	JJ	O
3.3	CD	O
?	.	O
1.3	CD	O
,	,	O
placebo	NN	O
3.0	CD	O
?	.	O
1.3	CD	O
)	)	O
at	IN	O
90	CD	O
days	NNS	O
,	,	O
or	CC	O
the	DT	O
number	NN	O
of	IN	O
injections	NNS	O
received	VBN	O
.	.	O

G-CSF	NNP	O
increased	VBD	O
CD34	NNP	O
(	(	O
+	NNP	O
)	)	O
and	CC	O
total	JJ	O
white	JJ	O
cell	NN	O
counts	NNS	O
of	IN	O
9.5-	CD	O
and	CC	O
4.2-fold	JJ	O
,	,	O
respectively	RB	O
.	.	O

There	EX	O
was	VBD	O
a	DT	O
trend	NN	O
toward	IN	O
reduction	NN	O
in	IN	O
MRI	NNP	O
ischemic	JJ	O
lesion	NN	O
volume	NN	O
with	IN	O
respect	NN	O
to	TO	O
change	VB	O
from	IN	O
baseline	NN	O
in	IN	O
G-CSF-treated	JJ	O
patients	NNS	O
(	(	O
P=0.06	NNP	O
)	)	O
.	.	O

In	IN	O
1	CD	O
participant	NN	O
,	,	O
there	EX	O
was	VBD	O
suggestion	NN	O
that	IN	O
labeled	VBD	O
CD34	NNP	O
(	(	O
+	NNP	O
)	)	O
cells	NNS	O
had	VBD	O
migrated	VBN	O
to	TO	O
the	DT	O
ischemic	JJ	O
lesion	NN	O
.	.	O

CONCLUSIONS	VB	O
This	DT	O
randomized	VBN	O
,	,	O
double-blind	JJ	O
,	,	O
placebo-controlled	JJ	O
trial	NN	O
suggests	VBZ	O
that	IN	O
G-CSF	NNP	O
is	VBZ	O
safe	JJ	O
when	WRB	O
administered	VBN	O
subacutely	RB	O
.	.	O

It	PRP	O
is	VBZ	O
feasible	JJ	O
to	TO	O
label	VB	O
and	CC	O
readminister	VB	O
iron-labeled	JJ	O
CD34	NNP	O
(	(	O
+	NNP	O
)	)	O
cells	NNS	O
in	IN	O
patients	NNS	O
with	IN	O
ischemic	JJ	O
stroke	NN	O
.	.	O

CLINICAL	NNP	O
TRIAL	NNP	O
REGISTRATION	NNP	O
URL	NNP	O
:	:	O
www.controlled-trials.com	NN	O
.	.	O

Unique	NNP	O
identifier	NN	O
:	:	O
ISRCTN63336619	NNP	O
.	.	O

Effect	NN	O
of	IN	O
device-guided	JJ	O
breathing	NN	O
exercises	NNS	O
on	IN	O
blood	NN	O
pressure	NN	O
in	IN	O
patients	NNS	O
with	IN	O
hypertension	NN	C
:	:	O
a	DT	O
randomized	NN	O
controlled	VBN	O
trial	NN	O
.	.	O

OBJECTIVE	NNP	O
Hypertension	NNP	O
is	VBZ	O
a	DT	O
chronic	JJ	O
disorder	NN	O
with	IN	O
a	DT	O
high	JJ	O
prevalence	NN	O
worldwide	NN	O
.	.	O

Despite	IN	O
considerable	JJ	O
efforts	NNS	O
,	,	O
it	PRP	O
is	VBZ	O
sometimes	RB	O
hard	JJ	O
to	TO	O
reach	VB	O
treatment	NN	O
goals	NNS	O
for	IN	O
blood	NN	O
pressure	NN	O
(	(	O
BP	NNP	O
)	)	O
with	IN	O
classical	JJ	O
treatment	NN	O
options	NNS	O
.	.	O

Reducing	VBG	O
breathing	VBG	O
frequency	NN	O
has	VBZ	O
been	VBN	O
advocated	VBN	O
as	IN	O
a	DT	O
method	NN	O
to	TO	O
reduce	VB	O
BP	NNP	O
.	.	O

METHODS	NNP	O
A	NNP	O
randomized	JJ	O
,	,	O
single-blind	JJ	O
,	,	O
controlled	VBD	O
trial	NN	O
was	VBD	O
conducted	VBN	O
in	IN	O
30	CD	SS
non-diabetic	JJ	C
patients	NNS	C
with	IN	C
hypertension	NN	C
over	IN	O
a	DT	O
period	NN	O
of	IN	O
9	CD	O
weeks	NNS	O
to	TO	O
evaluate	VB	O
the	DT	O
effect	NN	O
of	IN	O
a	DT	O
device	NN	O
that	WDT	O
helps	VBZ	O
to	TO	O
slow	VB	O
breathing	NN	O
(	(	O
Resperate	NNP	O
)	)	O
on	IN	O
BP	NNP	O
and	CC	O
quality	NN	O
of	IN	O
life	NN	O
(	(	O
QoL	NNP	O
)	)	O
.	.	O

The	DT	O
control	NN	O
group	NN	O
listened	VBD	O
to	TO	O
music	NN	O
and	CC	O
used	VBN	O
no	DT	O
other	JJ	O
therapeutic	JJ	O
device	NN	O
.	.	O

RESULTS	NNP	O
There	EX	O
was	VBD	O
no	DT	O
significant	JJ	O
difference	NN	O
in	IN	O
change	NN	O
in	IN	O
BP	NNP	O
between	IN	O
intervention	NN	O
and	CC	O
control	NN	O
;	:	O
BP	NNP	O
-4.2	NNP	O
mmHg	NN	O
(	(	O
95	CD	O
%	NN	O
CI	NNP	O
-12.4	NNP	O
to	TO	O
3.9	CD	O
)	)	O
/-2.6	NN	O
mmHg	NN	O
(	(	O
95	CD	O
%	NN	O
CI	NNP	O
-8.4	NNP	O
to	TO	O
3.3	CD	O
)	)	O
.	.	O

This	DT	O
result	NN	O
did	VBD	O
not	RB	O
alter	VB	O
in	IN	O
post	NN	O
hoc	NN	O
analyses	NNS	O
,	,	O
when	WRB	O
patients	NNS	O
not	RB	O
achieving	VBG	O
target	NN	O
breathing	NN	O
frequency	NN	O
(	(	O
<	JJ	O
10	CD	O
breaths/min	NN	O
)	)	O
or	CC	O
non-compliant	JJ	O
patients	NNS	O
were	VBD	O
excluded	VBN	O
.	.	O

QoL	NNP	O
did	VBD	O
not	RB	O
change	VB	O
over	IN	O
time	NN	O
.	.	O

CONCLUSIONS	NNP	O
We	PRP	O
found	VBD	O
no	DT	O
effect	NN	O
of	IN	O
the	DT	O
Resperate	NNP	O
on	IN	O
BP	NNP	O
or	CC	O
QoL	NNP	O
compared	VBN	O
with	IN	O
the	DT	O
control	NN	O
group	NN	O
.	.	O

We	PRP	O
conclude	VBP	O
that	IN	O
,	,	O
at	IN	O
this	DT	O
moment	NN	O
,	,	O
this	DT	O
device	NN	O
has	VBZ	O
no	DT	O
added	VBN	O
value	NN	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
hypertension	NN	O
.	.	O

Sivelestat	NNP	O
sodium	NN	O
hydrate	NN	O
improves	VBZ	O
septic	JJ	O
acute	NN	O
lung	NN	O
injury	NN	O
by	IN	O
reducing	VBG	O
alveolar	JJ	O
dysfunction	NN	O
.	.	O

Sivelestat	NNP	O
sodium	NN	O
hydrate	NN	O
(	(	O
sivelestat	NN	O
)	)	O
is	VBZ	O
a	DT	O
selective	JJ	O
inhibitor	NN	O
of	IN	O
polymorphonuclear	JJ	O
leukocyte	JJ	O
elastase	NN	O
(	(	O
PMN-E	NNP	O
)	)	O
.	.	O

We	PRP	O
administered	VBD	O
sivelestat	NNS	O
to	TO	O
patients	NNS	O
with	IN	O
septic	JJ	C
acute	NN	C
lung	NN	C
injury	NN	C
(	(	C
ALI	NNP	C
)	)	C
to	TO	O
examine	VB	O
its	PRP$	O
usefulness	NN	O
.	.	O

The	DT	O
primary	JJ	O
endpoints	NNS	O
in	IN	O
the	DT	O
study	NN	O
were	VBD	O
the	DT	O
duration	NN	O
of	IN	O
artificial	JJ	O
ventilation	NN	O
and	CC	O
pulmonary	JJ	O
oxygenation	NN	O
ability	NN	O
,	,	O
and	CC	O
the	DT	O
secondary	JJ	O
endpoints	NNS	O
were	VBD	O
mortality	NN	O
and	CC	O
the	DT	O
concentrations	NNS	O
of	IN	O
PMN-E	NNP	O
,	,	O
SP-D	NNP	O
,	,	O
TNF-alpha	NNP	O
and	CC	O
IL-8	NNP	O
in	IN	O
blood	NN	O
.	.	O

In	IN	O
the	DT	O
sivelestat	NN	O
group	NN	O
,	,	O
the	DT	O
duration	NN	O
of	IN	O
artificial	JJ	O
ventilation	NN	O
,	,	O
pulmonary	JJ	O
oxygenation	NN	O
ability	NN	O
,	,	O
and	CC	O
the	DT	O
blood	NN	O
PMN-E	NNP	O
,	,	O
SP-D	NNP	O
,	,	O
TNF-alpha	NNP	O
and	CC	O
IL-8	NNP	O
concentrations	NNS	O
decreased	VBD	O
significantly	RB	O
.	.	O

Administration	NNP	O
of	IN	O
sivelestat	NN	O
was	VBD	O
found	VBN	O
to	TO	O
reduce	VB	O
alveolar	JJ	O
dysfunction	NN	O
and	CC	O
improve	VB	O
respiratory	NN	O
function	NN	O
,	,	O
and	CC	O
it	PRP	O
was	VBD	O
suggested	VBN	O
that	IN	O
early	JJ	O
administration	NN	O
might	MD	O
be	VB	O
useful	JJ	O
.	.	O

Rate-modulated	JJ	O
cardiac	NN	O
pacing	NN	O
based	VBN	O
on	IN	O
transthoracic	JJ	O
impedance	NN	O
measurements	NNS	O
of	IN	O
minute	JJ	O
ventilation	NN	O
:	:	O
correlation	NN	O
with	IN	O
exercise	NN	O
gas	NN	O
exchange	NN	O
.	.	O

The	DT	O
relation	NN	O
of	IN	O
pacing	VBG	O
rate	NN	O
to	TO	O
physiologic	VB	O
variables	NNS	O
of	IN	O
metabolic	JJ	O
demand	NN	O
was	VBD	O
examined	VBN	O
in	IN	O
10	CD	SS
consecutive	JJ	O
patients	NNS	O
with	IN	O
a	DT	O
minute	NN	O
ventilation-sensing	NN	O
,	,	O
rate-modulating	JJ	O
ventricular	JJ	O
pacemaker	NN	O
implanted	VBN	O
for	IN	O
complete	JJ	O
heart	NN	O
block	NN	O
.	.	O

All	DT	O
patients	NNS	O
had	VBD	O
paroxysmal	JJ	C
(	(	O
seven	CD	SS
patients	NNS	O
)	)	O
or	CC	O
chronic	JJ	O
(	(	O
three	CD	SS
patients	NNS	O
)	)	O
atrial	JJ	C
fibrillation	NN	C
and	CC	O
were	VBD	O
referred	VBN	O
for	IN	O
catheter	JJR	O
ablation	NN	O
of	IN	O
the	DT	O
atrioventricular	JJ	O
junction	NN	O
.	.	O

Treadmill	NNP	O
exercise	NN	O
testing	VBG	O
with	IN	O
measurement	NN	O
of	IN	O
expired	NNP	O
gas	NN	O
exchange	NN	O
and	CC	O
respiratory	NN	O
flow	NN	O
was	VBD	O
performed	VBN	O
before	IN	O
ablation	NN	O
and	CC	O
4	CD	O
weeks	NNS	O
after	IN	O
pacemaker	NN	O
implantation	NN	O
,	,	O
with	IN	O
the	DT	O
pacemaker	NN	O
programmed	VBD	O
to	TO	O
both	DT	O
the	DT	O
fixed-rate	JJ	O
VVI	NNP	O
and	CC	O
rate-modulating	JJ	O
minute	NN	O
ventilation	NN	O
VVIR	NNP	O
pacing	VBG	O
modes	NNS	O
in	IN	O
random	JJ	O
sequence	NN	O
.	.	O

The	DT	O
relation	NN	O
of	IN	O
pacing	VBG	O
rate	NN	O
to	TO	O
oxygen	VB	O
consumption	NN	O
(	(	O
VO2	NNP	O
)	)	O
,	,	O
expired	VBD	O
carbon	NN	O
dioxide	NN	O
concentration	NN	O
(	(	O
VCO2	NNP	O
)	)	O
,	,	O
respiratory	JJ	O
quotient	NN	O
,	,	O
tidal	JJ	O
volume	NN	O
,	,	O
respiratory	NN	O
rate	NN	O
and	CC	O
minute	NN	O
ventilation	NN	O
was	VBD	O
determined	VBN	O
during	IN	O
exercise	NN	O
in	IN	O
the	DT	O
rate-modulating	JJ	O
minute	NN	O
ventilation	NN	O
pacing	VBG	O
mode	NN	O
.	.	O

Pacing	VBG	O
rate	NN	O
was	VBD	O
highly	RB	O
correlated	VBN	O
with	IN	O
minute	JJ	O
ventilation	NN	O
(	(	O
r	JJ	O
=	NNP	O
0.89	CD	O
)	)	O
,	,	O
respiratory	JJ	O
quotient	NN	O
(	(	O
r	JJ	O
=	NNP	O
0.89	CD	O
)	)	O
,	,	O
VCO2	NNP	O
(	(	O
r	VB	O
=	RB	O
0.87	CD	O
)	)	O
,	,	O
tidal	JJ	O
volume	NN	O
(	(	O
r	JJ	O
=	NNP	O
0.87	CD	O
)	)	O
,	,	O
VO2	NNP	O
(	(	O
r	VB	O
=	RB	O
0.84	CD	O
)	)	O
and	CC	O
respiratory	JJ	O
rate	NN	O
(	(	O
r	NN	O
=	RB	O
0.84	CD	O
)	)	O
.	.	O

The	DT	O
mean	JJ	O
exercise	NN	O
duration	NN	O
increased	VBD	O
from	IN	O
8.3	CD	O
+/-	JJ	O
2.8	CD	O
min	NN	O
in	IN	O
the	DT	O
fixed	JJ	O
rate	NN	O
pacing	VBG	O
mode	NN	O
to	TO	O
10.2	CD	O
+/-	JJ	O
3.4	CD	O
min	NN	O
in	IN	O
the	DT	O
rate-modulating	NN	O
,	,	O
minute	NN	O
ventilation	NN	O
mode	NN	O
(	(	O
p	JJ	O
=	NNP	O
0.0001	CD	O
)	)	O
.	.	O

The	DT	O
maximal	JJ	O
VO2	NNP	O
increased	VBD	O
from	IN	O
13.4	CD	O
+/-	JJ	O
3.4	CD	O
to	TO	O
16.3	CD	O
+/-	JJ	O
4.1	CD	O
cc/kg	NN	O
per	IN	O
min	NN	O
(	(	O
p	JJ	O
=	NNP	O
0.0004	CD	O
)	)	O
.	.	O

The	DT	O
maximal	JJ	O
heart	NN	O
rate	NN	O
achieved	VBN	O
in	IN	O
the	DT	O
minute	NN	O
ventilation	NN	O
pacing	VBG	O
mode	NN	O
was	VBD	O
136	CD	O
+/-	JJ	O
9.7	CD	O
beats/min	NN	O
,	,	O
similar	JJ	O
to	TO	O
that	DT	O
observed	VBN	O
in	IN	O
the	DT	O
patient	NN	O
's	POS	O
intrinsic	JJ	O
cardiac	JJ	O
rhythm	NN	O
before	IN	O
ablation	NN	O
(	(	O
134.9	CD	O
+/-	JJ	O
30.1	CD	O
beats/min	NN	O
,	,	O
p	NN	O
=	NNP	O
NS	NNP	O
)	)	O
.	.	O

(	(	O
ABSTRACT	NNP	O
TRUNCATED	NNP	O
AT	NNP	O
250	CD	O
WORDS	NNP	O
)	)	O
Supporting	VBG	O
families	NNS	O
in	IN	O
challenging	VBG	O
contexts	NN	O
:	:	O
the	DT	O
CAPEDP	NNP	O
project	NN	O
.	.	O

Although	IN	O
France	NNP	O
has	VBZ	O
one	CD	O
of	IN	O
the	DT	O
most	RBS	O
generous	JJ	O
health	NN	O
and	CC	O
social	JJ	O
care	NN	O
systems	NNS	O
for	IN	O
infant	NN	O
and	CC	O
maternal	JJ	O
well-being	NN	O
in	IN	O
the	DT	O
Western	JJ	O
world	NN	O
,	,	O
professionals	NNS	O
have	VBP	O
been	VBN	O
increasingly	RB	O
concerned	VBN	O
by	IN	O
the	DT	O
rising	VBG	O
number	NN	O
of	IN	O
children	NNS	O
being	VBG	O
referred	VBN	O
for	IN	O
mental	JJ	O
health	NN	O
problems	NNS	O
.	.	O

The	DT	O
present	JJ	O
article	NN	O
describes	VBZ	O
the	DT	O
first	JJ	O
home-visiting	JJ	O
program	NN	O
in	IN	O
France	NNP	O
to	TO	O
specifically	RB	O
target	VB	O
mental	JJ	O
health	NN	O
questions	NNS	O
in	IN	O
families	NNS	O
living	VBG	O
in	IN	O
vulnerable	JJ	O
contexts	NN	O
.	.	O

The	DT	O
CAPEDP	NNP	O
project	NN	O
,	,	O
involving	VBG	O
440	CD	O
women	NNS	O
and	CC	O
their	PRP$	O
families	NNS	O
,	,	O
took	VBD	O
place	NN	O
in	IN	O
Paris	NNP	O
and	CC	O
its	PRP$	O
inner	JJ	O
suburbs	NNS	O
from	IN	O
2006	CD	O
to	TO	O
2011	CD	O
.	.	O

To	TO	O
be	VB	O
eligible	JJ	O
for	IN	O
inclusion	NN	O
,	,	O
women	NNS	O
had	VBD	O
to	TO	O
be	VB	O
(	(	O
i	NN	O
)	)	O
under	IN	O
26	CD	O
years	NNS	O
old	JJ	O
,	,	O
(	(	O
ii	NN	O
)	)	O
less	JJR	O
that	IN	O
27	CD	O
weeks	NNS	O
pregnant	JJ	O
,	,	O
(	(	O
iii	NN	O
)	)	O
sufficiently	RB	O
fluent	VBN	O
in	IN	O
French	JJ	O
to	TO	O
give	VB	O
truly	NN	O
informed	JJ	O
consent	NN	O
to	TO	O
participate	VB	O
in	IN	O
the	DT	O
study	NN	O
and	CC	O
benefit	NN	O
from	IN	O
the	DT	O
intervention	NN	O
and	CC	O
(	(	O
iv	NN	O
)	)	O
presenting	VBG	O
with	IN	O
one	CD	O
or	CC	O
more	JJR	O
of	IN	O
the	DT	O
following	JJ	O
social	JJ	O
vulnerability	NN	O
factors	NNS	O
:	:	O
low	JJ	O
income	NN	O
,	,	O
low	JJ	O
educational	JJ	O
level	NN	O
,	,	O
and/or	RB	O
intending	VBG	O
to	TO	O
bring	VB	O
up	RP	O
the	DT	O
child	NN	O
without	IN	O
the	DT	O
child	NN	O
's	POS	O
father	NN	O
.	.	O

The	DT	O
intervention	NN	O
consisted	VBD	O
of	IN	O
44	CD	O
home	NN	O
visits	NNS	O
from	IN	O
the	DT	O
third	JJ	O
trimester	NN	O
of	IN	O
pregnancy	NN	O
through	IN	O
to	TO	O
the	DT	O
child	NN	O
's	POS	O
second	JJ	O
birthday	NN	O
.	.	O

The	DT	O
aim	NN	O
of	IN	O
the	DT	O
intervention	NN	O
was	VBD	O
to	TO	O
promote	VB	O
infant	JJ	O
mental	JJ	O
health	NN	O
and	CC	O
reduce	VB	O
the	DT	O
incidence	NN	O
of	IN	O
infant	JJ	O
mental	JJ	O
health	NN	O
problems	NNS	O
at	IN	O
the	DT	O
age	NN	O
of	IN	O
two	CD	O
years	NNS	O
.	.	O

The	DT	O
intervention	NN	O
paid	VBD	O
particular	JJ	O
attention	NN	O
to	TO	O
postnatal	JJ	O
maternal	JJ	O
depression	NN	O
and	CC	O
promoting	VBG	O
parenting	VBG	O
skills	NNS	O
and	CC	O
attachment	JJ	O
security	NN	O
,	,	O
particularly	RB	O
through	IN	O
the	DT	O
use	NN	O
of	IN	O
video	NN	O
during	IN	O
home-visits	NNS	O
.	.	O

A	DT	O
major	JJ	O
issue	NN	O
was	VBD	O
that	IN	O
of	IN	O
adapting	VBG	O
international	JJ	O
best	JJS	O
practice	NN	O
recommendations	NNS	O
with	IN	O
regard	NN	O
to	TO	O
home-visiting	JJ	O
programs	NNS	O
to	TO	O
the	DT	O
particularities	NNS	O
of	IN	O
the	DT	O
existing	VBG	O
French	JJ	O
social	JJ	O
and	CC	O
health	NN	O
care	NN	O
system	NN	O
.	.	O

An	DT	O
original	JJ	O
aspect	NN	O
of	IN	O
the	DT	O
intervention	NN	O
was	VBD	O
to	TO	O
use	VB	O
trained	JJ	O
clinical	JJ	O
psychologists	NNS	O
to	TO	O
conduct	VB	O
all	DT	O
home	NN	O
visits	NNS	O
.	.	O

The	DT	O
Social	NNP	O
Communication	NNP	O
Assessment	NNP	O
for	IN	O
Toddlers	NNP	O
with	IN	O
Autism	NNP	O
(	(	O
SCATA	NNP	O
)	)	O
:	:	O
an	DT	O
instrument	NN	O
to	TO	O
measure	VB	O
the	DT	O
frequency	NN	O
,	,	O
form	NN	O
and	CC	O
function	NN	O
of	IN	O
communication	NN	O
in	IN	O
toddlers	NNS	O
with	IN	O
autism	NN	O
spectrum	NN	O
disorder	NN	O
.	.	O

The	DT	O
Social	NNP	O
Communication	NNP	O
Assessment	NNP	O
for	IN	O
Toddlers	NNP	O
with	IN	O
Autism	NNP	O
(	(	O
SCATA	NNP	O
)	)	O
was	VBD	O
designed	VBN	O
to	TO	O
measure	VB	O
non-verbal	JJ	O
communication	NN	O
,	,	O
including	VBG	O
early	JJ	O
and	CC	O
atypical	JJ	O
communication	NN	O
,	,	O
in	IN	O
young	JJ	O
children	NNS	O
with	IN	O
autism	NN	O
spectrum	NN	O
disorder	NN	O
.	.	O

Each	DT	O
communicative	JJ	O
act	NN	O
is	VBZ	O
scored	VBN	O
according	VBG	O
to	TO	O
its	PRP$	O
form	NN	O
,	,	O
function	NN	O
,	,	O
role	NN	O
and	CC	O
complexity	NN	O
.	.	O

The	DT	O
SCATA	NNP	O
was	VBD	O
used	VBN	O
to	TO	O
measure	VB	O
communicative	JJ	O
ability	NN	O
longitudinally	RB	O
in	IN	O
two	CD	O
samples	NNS	O
of	IN	O
toddlers	NNS	O
with	IN	O
autism	NN	O
spectrum	NN	O
disorder	NN	O
.	.	O

Overall	JJ	O
frequency	NN	O
of	IN	O
non-verbal	JJ	O
communicative	JJ	O
acts	NNS	O
did	VBD	O
not	RB	O
change	NN	O
between	IN	O
the	DT	O
two	CD	O
assessments	NNS	O
.	.	O

However	RB	O
,	,	O
the	DT	O
form	NN	O
and	CC	O
complexity	NN	O
,	,	O
the	DT	O
function	NN	O
and	CC	O
the	DT	O
role	NN	O
the	DT	O
child	NN	O
took	VBD	O
in	IN	O
the	DT	O
interaction	NN	O
did	VBD	O
change	VB	O
with	IN	O
time	NN	O
.	.	O

Both	DT	O
frequency	NN	O
and	CC	O
function	NN	O
of	IN	O
communicative	JJ	O
acts	NNS	O
in	IN	O
toddlerhood	NN	O
were	VBD	O
positively	RB	O
associated	VBN	O
with	IN	O
later	JJ	O
language	NN	O
ability	NN	O
:	:	O
social	JJ	O
acts	NNS	O
,	,	O
comments	NNS	O
and	CC	O
initiations	NNS	O
showed	VBD	O
greater	JJR	O
predictive	JJ	O
association	NN	O
than	IN	O
requests	NNS	O
and	CC	O
responses	NNS	O
.	.	O

[	JJ	O
Comparative	NNP	O
effects	NNS	O
of	IN	O
nebivolol	NN	O
and	CC	O
valsartan	NN	O
on	IN	O
atrial	JJ	O
electromechanical	JJ	O
coupling	NN	O
in	IN	O
newly	RB	C
diagnosed	VBN	C
stage	NN	C
1	CD	C
hypertensive	JJ	C
patients	NNS	C
]	VBP	C
.	.	O

OBJECTIVES	NNP	O
Hypertension	NNP	O
is	VBZ	O
an	DT	O
important	JJ	O
cardiovascular	NN	O
risk	NN	O
factor	NN	O
for	IN	O
the	DT	O
development	NN	O
of	IN	O
atrial	JJ	O
fibrillation	NN	O
(	(	O
AF	NNP	O
)	)	O
.	.	O

Increased	VBN	O
atrial	JJ	O
electromechanical	JJ	O
coupling	NN	O
time	NN	O
interval	NN	O
measured	VBN	O
by	IN	O
tissue	NN	O
Doppler	NNP	O
is	VBZ	O
accepted	VBN	O
as	IN	O
an	DT	O
important	JJ	O
factor	NN	O
for	IN	O
prediction	NN	O
of	IN	O
AF	NNP	O
development	NN	O
in	IN	O
hypertensive	JJ	C
patients	NNS	C
.	.	C

The	DT	O
aim	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
compare	VB	O
the	DT	O
effects	NNS	O
of	IN	O
valsartan	NN	O
,	,	O
an	DT	O
angiotensin	NN	O
receptor	NN	O
blocker	NN	O
,	,	O
and	CC	O
nebivolol	RB	O
,	,	O
a	DT	O
beta-blocker	NN	O
,	,	O
on	IN	O
atrial	JJ	O
electromechanical	JJ	O
coupling	NN	O
in	IN	O
newly	RB	C
diagnosed	VBN	C
stage	NN	C
1	CD	C
hypertensive	JJ	C
patients	NNS	C
.	.	C

STUDY	NNP	O
DESIGN	NNP	O
The	DT	O
study	NN	O
included	VBD	O
60	CD	C
newly	RB	C
diagnosed	VBN	C
stage	NN	C
1	CD	C
hypertensive	JJ	C
patients	NNS	C
with	IN	C
no	DT	C
other	JJ	C
systemic	JJ	C
disease	NN	C
.	.	C

The	DT	O
patients	NNS	O
were	VBD	O
randomized	VBN	O
to	TO	O
receive	VB	O
nebivolol	JJ	O
5	CD	O
mg	NN	O
(	(	O
30	CD	O
patients	NNS	O
;	:	O
21	CD	O
women	NNS	O
,	,	O
9	CD	O
men	NNS	O
;	:	O
mean	JJ	O
age	NN	O
48.4	CD	O
?	.	O
11.4	CD	O
years	NNS	O
)	)	O
and	CC	O
valsartan	$	O
160	CD	O
mg	NN	O
(	(	O
30	CD	O
patients	NNS	O
;	:	O
21	CD	O
women	NNS	O
,	,	O
9	CD	O
men	NNS	O
;	:	O
mean	JJ	O
age	NN	O
49.8	CD	O
?	.	O
11.3	CD	O
years	NNS	O
)	)	O
.	.	O

All	PDT	O
the	DT	O
patients	NNS	O
underwent	JJ	O
tissue	NN	O
Doppler	NNP	O
echocardiographic	JJ	O
examination	NN	O
before	IN	O
and	CC	O
three	CD	O
months	NNS	O
after	IN	O
treatment	NN	O
to	TO	O
compare	VB	O
the	DT	O
effects	NNS	O
of	IN	O
the	DT	O
two	CD	O
drugs	NNS	O
on	IN	O
atrial	JJ	O
electromechanical	JJ	O
coupling	NN	O
.	.	O

RESULTS	NNP	O
Baseline	NNP	O
blood	NN	O
pressures	NNS	O
,	,	O
electrocardiographic	JJ	O
and	CC	O
echocardiographic	JJ	O
findings	NNS	O
,	,	O
and	CC	O
atrial	JJ	O
electromechanical	JJ	O
coupling	NN	O
were	VBD	O
similar	JJ	O
in	IN	O
both	DT	O
groups	NNS	O
(	(	O
p	JJ	O
>	NNP	O
0.05	CD	O
)	)	O
.	.	O

Both	DT	O
drugs	NNS	O
significantly	RB	O
reduced	VBD	O
blood	NN	O
pressure	NN	O
after	IN	O
treatment	NN	O
,	,	O
with	IN	O
similar	JJ	O
efficacy	NN	O
(	(	O
p	JJ	O
>	NNP	O
0.05	CD	O
)	)	O
.	.	O

Atrial	JJ	O
electromechanical	JJ	O
coupling	NN	O
time	NN	O
intervals	NNS	O
showed	VBD	O
significant	JJ	O
decreases	NNS	O
in	IN	O
both	DT	O
groups	NNS	O
.	.	O

CONCLUSION	NNP	O
Prolonged	VBD	O
interatrial	JJ	O
electromechanical	JJ	O
time	NN	O
intervals	NNS	O
in	IN	O
hypertensives	NNS	O
are	VBP	O
improved	VBN	O
with	IN	O
antihypertensive	JJ	O
treatment	NN	O
.	.	O

Beta-carotene	NNP	O
in	IN	O
HIV	NNP	C
infection	NN	C
.	.	C

beta-Carotene	NN	O
has	VBZ	O
been	VBN	O
reported	VBN	O
to	TO	O
have	VB	O
an	DT	O
immunostimulatory	JJ	O
effect	NN	O
.	.	O

Recent	JJ	O
studies	NNS	O
suggest	VBP	O
that	IN	O
beta-carotene	JJ	O
supplementation	NN	O
can	MD	O
increase	VB	O
CD4	NNP	O
counts	NNS	O
in	IN	O
HIV-infected	JJ	C
patients	NNS	O
.	.	O

Our	PRP$	O
double-blind	JJ	O
,	,	O
placebo-controlled	JJ	O
clinical	JJ	O
trial	NN	O
was	VBD	O
designed	VBN	O
to	TO	O
test	VB	O
the	DT	O
efficacy	NN	O
of	IN	O
beta-carotene	NN	O
in	IN	O
raising	VBG	O
CD4	NNP	O
counts	NNS	O
in	IN	O
HIV-infected	JJ	C
patients	NNS	O
.	.	O

Twenty-one	CD	SS
HIV-seropositive	JJ	C
patients	NNS	O
were	VBD	O
randomized	VBN	O
to	TO	O
receive	VB	O
either	DT	O
beta-carotene	NN	O
,	,	O
180	CD	O
mg/day	NN	O
or	CC	O
placebo	NN	O
for	IN	O
4	CD	O
weeks	NNS	O
,	,	O
and	CC	O
then	RB	O
crossed	VBD	O
over	IN	O
to	TO	O
receive	VB	O
the	DT	O
alternative	JJ	O
treatment	NN	O
for	IN	O
the	DT	O
following	JJ	O
4	CD	O
weeks	NNS	O
.	.	O

beta-Carotene	NN	O
resulted	VBD	O
in	IN	O
a	DT	O
statistically	RB	O
significant	JJ	O
increase	NN	O
in	IN	O
total	JJ	O
WBC	NNP	O
count	NN	O
(	(	O
p	JJ	O
=	NNP	O
0.01	CD	O
)	)	O
,	,	O
%	NN	O
change	NN	O
in	IN	O
CD4	NNP	O
count	NN	O
(	(	O
p	JJ	O
=	NNP	O
0.02	CD	O
)	)	O
,	,	O
and	CC	O
%	NN	O
change	NN	O
in	IN	O
CD4/CD8	NNP	O
ratios	NNS	O
(	(	O
p	JJ	O
=	NNP	O
0.02	CD	O
)	)	O
compared	VBN	O
to	TO	O
placebo	VB	O
.	.	O

The	DT	O
absolute	JJ	O
CD4	NNP	O
count	NN	O
,	,	O
absolute	JJ	O
CD4/CD8	NNP	O
ratio	NN	O
,	,	O
and	CC	O
total	JJ	O
and	CC	O
B-lymphocytes	NNP	O
all	DT	O
increased	VBN	O
on	IN	O
carotene	NN	O
and	CC	O
fell	VBD	O
during	IN	O
placebo	NN	O
,	,	O
but	CC	O
these	DT	O
differences	NNS	O
did	VBD	O
not	RB	O
reach	VB	O
statistical	JJ	O
significance	NN	O
.	.	O

No	DT	O
toxicity	NN	O
was	VBD	O
observed	VBN	O
on	IN	O
either	DT	O
treatment	NN	O
.	.	O

beta-Carotene	JJ	O
appears	VBZ	O
to	TO	O
have	VB	O
an	DT	O
immunostimulatory	JJ	O
effect	NN	O
in	IN	O
HIV-infected	JJ	C
patients	NNS	O
.	.	O

Further	JJ	O
studies	NNS	O
are	VBP	O
needed	VBN	O
to	TO	O
demonstrate	VB	O
whether	IN	O
beta-carotene	NN	O
has	VBZ	O
a	DT	O
role	NN	O
as	IN	O
adjunct	JJ	O
therapy	NN	O
in	IN	O
treatment	NN	O
of	IN	O
HIV-infected	JJ	C
patients	NNS	O
.	.	O

Abstinence	NN	O
or	CC	O
controlled	VBN	O
drinking	NN	O
in	IN	O
clinical	JJ	O
practice	NN	O
:	:	O
indications	NNS	O
at	IN	O
initial	JJ	O
assessment	NN	O
.	.	O

Previous	JJ	O
research	NN	O
has	VBZ	O
suggested	VBN	O
two	CD	O
leading	JJ	O
hypotheses	NNS	O
concerning	VBG	O
which	WDT	O
excessive	JJ	O
drinkers	NNS	O
can	MD	O
re-establish	VB	O
control	NN	O
:	:	O
one	CD	O
based	VBN	O
upon	IN	O
level	NN	O
of	IN	O
dependence	NN	O
,	,	O
the	DT	O
other	JJ	O
upon	IN	O
the	DT	O
client	NN	O
's	POS	O
personal	JJ	O
persuasion	NN	O
.	.	O

Using	VBG	O
initial	JJ	O
assessment	NN	O
data	NNS	O
from	IN	O
46	CD	SS
clients	NNS	O
of	IN	O
a	DT	O
clinical	JJ	O
psychology	NN	O
alcohol	NN	O
problems	NNS	O
service	NN	O
(	(	O
30	CD	SS
men	NNS	SS
,	,	O
16	CD	SS
women	NNS	SS
)	)	O
,	,	O
an	DT	O
attempt	NN	O
was	VBD	O
made	VBN	O
to	TO	O
operationalize	VB	O
the	DT	O
concepts	NNS	O
of	IN	O
dependence	NN	O
and	CC	O
personal	JJ	O
persuasion	NN	O
using	VBG	O
a	DT	O
variety	NN	O
of	IN	O
indicators	NNS	O
of	IN	O
each	DT	O
.	.	O

Although	IN	O
SADQ	NNP	O
scores	NNS	O
and	CC	O
Rand	NNP	O
definite	VBP	O
alcoholism	NN	O
were	VBD	O
in	IN	O
general	JJ	O
agreement	NN	O
,	,	O
there	EX	O
were	VBD	O
a	DT	O
number	NN	O
of	IN	O
borderline	JJ	O
instances	NNS	O
and	CC	O
cases	NNS	O
of	IN	O
disagreement	NN	O
,	,	O
and	CC	O
neither	DT	O
was	VBD	O
in	IN	O
good	JJ	O
agreement	NN	O
with	IN	O
estimates	NNS	O
of	IN	O
problem	NN	O
duration	NN	O
,	,	O
nor	CC	O
with	IN	O
reports	NNS	O
of	IN	O
recent	JJ	O
or	CC	O
earlier	RBR	O
attainment	NN	O
of	IN	O
abstinence	NN	O
or	CC	O
control	NN	O
.	.	O

Indicators	NNS	O
of	IN	O
personal	JJ	O
persuasion	NN	O
were	VBD	O
more	RBR	O
consistent	JJ	O
.	.	O

Those	DT	O
with	IN	O
dependence	NN	O
indicators	NNS	O
for	IN	O
abstinence	NN	O
tended	VBD	O
to	TO	O
prefer	VB	O
abstinence	NN	O
as	IN	O
a	DT	O
goal	NN	O
,	,	O
but	CC	O
there	EX	O
were	VBD	O
many	JJ	O
departures	NNS	O
from	IN	O
this	DT	O
pattern	NN	O
particularly	RB	O
for	IN	O
women	NNS	O
.	.	O

It	PRP	O
is	VBZ	O
concluded	VBN	O
that	IN	O
in	IN	O
clinical	JJ	O
practice	NN	O
it	PRP	O
will	MD	O
be	VB	O
very	RB	O
difficult	JJ	O
to	TO	O
make	VB	O
a	DT	O
clear	JJ	O
cut	NN	O
recommendation	NN	O
about	IN	O
treatment	NN	O
goal	NN	O
at	IN	O
initial	JJ	O
assessment	NN	O
except	IN	O
in	IN	O
a	DT	O
few	JJ	O
cases	NNS	O
.	.	O

Predictors	NNS	O
of	IN	O
recruited	JJ	O
melanoma	NN	C
families	NNS	O
into	IN	O
a	DT	O
behavioral	JJ	O
intervention	NN	O
project	NN	O
.	.	O

BACKGROUND	NNP	O
Examination	NNP	O
of	IN	O
families	NNS	O
represents	VBZ	O
an	DT	O
important	JJ	O
priority	NN	O
in	IN	O
health	NN	O
research	NN	O
.	.	O

In	IN	O
this	DT	O
paper	NN	O
we	PRP	O
report	VBP	O
on	IN	O
individual	JJ	O
and	CC	O
family-level	JJ	O
factors	NNS	O
associated	VBN	O
with	IN	O
enrollment	NN	O
in	IN	O
a	DT	O
cancer	NN	O
prevention	NN	O
research	NN	O
project	NN	O
.	.	O

We	PRP	O
approached	VBD	O
families	NNS	O
affected	VBN	O
by	IN	O
melanoma	NN	C
for	IN	O
possible	JJ	O
participation	NN	O
in	IN	O
a	DT	O
randomized	NN	O
controlled	VBN	O
trial	NN	O
of	IN	O
a	DT	O
web-based	JJ	O
communication	NN	O
and	CC	O
support	NN	O
intervention	NN	O
.	.	O

METHODS	NNP	O
We	PRP	O
recruited	VBD	O
three	CD	SS
family	NN	SS
members	NNS	SS
per	IN	SS
family	NN	SS
for	IN	O
assessment	NN	O
-	:	O
the	DT	O
melanoma	NN	O
case	NN	O
,	,	O
a	DT	O
first-degree	JJ	O
relative	NN	O
(	(	O
FDR	NNP	O
)	)	O
,	,	O
and	CC	O
a	DT	O
relative	NN	O
who	WP	O
is	VBZ	O
a	DT	O
parent	NN	O
of	IN	O
a	DT	O
child	JJ	O
age	NN	O
18	CD	A
or	CC	A
younger	JJR	A
.	.	O

Recruitment	NNP	O
involved	VBD	O
three	CD	O
steps	NNS	O
:	:	O
requesting	VBG	O
the	DT	O
physician	NN	O
's	POS	O
consent	NN	O
to	TO	O
approach	VB	O
the	DT	O
melanoma	NN	O
case	NN	O
,	,	O
approaching	VBG	O
the	DT	O
case	NN	O
to	TO	O
request	VB	O
their	PRP$	O
participation	NN	O
and	CC	O
family	NN	O
contact	NN	O
information	NN	O
,	,	O
and	CC	O
they	PRP	O
approaching	VBG	O
the	DT	O
FDRs	NNP	O
and	CC	O
parents	NNS	O
.	.	O

RESULTS	NNP	O
Of	IN	O
the	DT	O
1380	CD	SS
families	NNS	O
approached	VBD	O
,	,	O
313	CD	SS
were	VBD	O
enrolled	VBN	O
,	,	O
263	CD	O
were	VBD	O
excluded	VBN	O
because	IN	O
we	PRP	O
could	MD	O
not	RB	O
find	VB	O
or	CC	O
contact	VB	O
a	DT	O
family	NN	O
member	NN	O
(	(	O
FDR	CD	O
or	CC	O
parent	NN	O
)	)	O
,	,	O
331	CD	O
did	VBD	O
not	RB	O
have	VB	O
eligible	JJ	O
family	NN	O
members	NNS	O
,	,	O
and	CC	O
473	CD	O
refused	VBD	O
.	.	O

The	DT	O
most	RBS	O
frequently	RB	O
noted	VBD	O
reason	NN	O
for	IN	O
refusal	NN	O
was	VBD	O
being	VBG	O
too	RB	O
busy	JJ	O
or	CC	O
having	VBG	O
no	DT	O
time	NN	O
.	.	O

The	DT	O
primary	JJ	O
predictors	NNS	O
of	IN	O
participation	NN	O
for	IN	O
cases	NNS	O
(	(	O
OR=1.6	NNP	O
;	:	O
CI=1.01-2.51	NNP	O
)	)	O
and	CC	O
FDRs	NNP	O
(	(	O
OR=2.15	NNP	O
;	:	O
CI=1.11-4.13	NNP	O
)	)	O
included	VBD	O
higher	JJR	O
educational	JJ	O
attainment	NN	O
.	.	O

FDRs	NNP	O
were	VBD	O
more	RBR	O
likely	JJ	O
to	TO	O
enroll	VB	O
if	IN	O
they	PRP	O
were	VBD	O
female	JJ	O
(	(	O
OR=1.77	NNP	O
;	:	O
CI=1.1-.85	NNP	O
)	)	O
and	CC	O
parents	NNS	O
were	VBD	O
more	RBR	O
likely	JJ	O
to	TO	O
enroll	VB	O
if	IN	O
the	DT	O
case	NN	O
had	VBD	O
been	VBN	O
diagnosed	VBN	O
more	RBR	O
recently	RB	O
(	(	O
OR=3.3	NNP	O
;	:	O
CI=1.9-5.93	NNP	O
)	)	O
,	,	O
if	IN	O
the	DT	O
parent	NN	O
was	VBD	O
partnered	VBN	O
(	(	O
OR=4.37	NNP	O
;	:	O
CI=1.86-10.26	NNP	O
)	)	O
,	,	O
and	CC	O
if	IN	O
the	DT	O
parent	NN	O
lived	VBD	O
in	IN	O
the	DT	O
same	JJ	O
city	NN	O
as	IN	O
the	DT	O
case	NN	O
(	(	O
OR=2.88	NNP	O
;	:	O
CI=1.08-7.68	NNP	O
)	)	O
.	.	O

CONCLUSIONS	VB	O
The	DT	O
results	NNS	O
can	MD	O
provide	VB	O
information	NN	O
on	IN	O
potential	JJ	O
directions	NNS	O
for	IN	O
future	JJ	O
family	NN	O
recruitment	NN	O
.	.	O

The	DT	O
effects	NNS	O
of	IN	O
a	DT	O
multi-component	JJ	O
higher-functioning	JJ	C
autism	NN	C
anti-stigma	JJ	O
program	NN	O
on	IN	O
adolescent	JJ	C
boys	NNS	C
.	.	C

A	DT	O
six-session	JJ	O
higher-functioning	JJ	C
autism	NN	C
anti-stigma	JJ	O
program	NN	O
incorporating	NN	O
descriptive	NN	O
,	,	O
explanatory	NN	O
and	CC	O
directive	JJ	O
information	NN	O
was	VBD	O
delivered	VBN	O
to	TO	O
adolescent	VB	C
boys	NNS	C
and	CC	O
the	DT	O
impact	NN	O
upon	IN	O
knowledge	NN	O
,	,	O
attitudes	NNS	O
and	CC	O
behavioural	JJ	O
intentions	NNS	O
towards	NNS	O
peers	NNS	O
with	IN	O
autism	NN	O
was	VBD	O
evaluated	VBN	O
.	.	O

Participants	NNS	O
were	VBD	O
seventh-	JJ	O
,	,	O
eighth-	JJ	O
and	CC	O
ninth-grade	JJ	O
students	NNS	O
(	(	O
N	NNP	O
=	NNP	O
395	CD	O
)	)	O
from	IN	O
regular	JJ	O
classes	NNS	O
in	IN	O
a	DT	O
mainstream	JJ	O
school	NN	O
.	.	O

Two-eighth-grade	JJ	O
classes	NNS	O
were	VBD	O
randomly	RB	O
allocated	VBN	O
to	TO	O
the	DT	O
intervention	NN	O
condition	NN	O
and	CC	O
all	DT	O
remaining	VBG	O
students	NNS	O
were	VBD	O
either	RB	O
allocated	VBN	O
to	TO	O
the	DT	O
no-intervention	JJ	O
peer	NN	O
or	CC	O
no-intervention	JJ	O
non-peer	JJ	O
condition	NN	O
.	.	O

The	DT	O
anti-stigma	JJ	O
program	NN	O
improved	VBD	O
the	DT	O
knowledge	NN	O
and	CC	O
attitudes	NNS	O
,	,	O
but	CC	O
not	RB	O
the	DT	O
behavioural	JJ	O
intentions	NNS	O
of	IN	O
participants	NNS	O
towards	VBP	O
their	PRP$	O
peers	NNS	O
with	IN	O
autism	NN	O
.	.	O

Knowledge	NNP	O
and	CC	O
attitudinal	JJ	O
changes	NNS	O
were	VBD	O
maintained	VBN	O
at	IN	O
follow-up	NN	O
.	.	O

There	EX	O
were	VBD	O
no	DT	O
spill-over	JJ	O
effects	NNS	O
of	IN	O
the	DT	O
program	NN	O
to	TO	O
non-targeted	JJ	O
students	NNS	O
.	.	O

These	DT	O
results	NNS	O
provide	VBP	O
some	DT	O
preliminary	JJ	O
evidence	NN	O
for	IN	O
the	DT	O
effectiveness	NN	O
of	IN	O
multi-session	NN	O
anti-stigma	JJ	O
programs	NNS	O
incorporating	VBG	O
combined	VBN	O
information	NN	O
for	IN	O
adolescent	NN	O
students	NNS	O
in	IN	O
inclusive	JJ	O
educational	JJ	O
environments	NNS	O
.	.	O

Predicting	VBG	O
completion	NN	O
of	IN	O
treatment	NN	O
among	IN	O
foreign-born	JJ	C
adolescents	NNS	A
treated	VBN	O
for	IN	O
latent	JJ	C
tuberculosis	NN	C
infection	NN	C
in	IN	O
Los	NNP	O
Angeles	NNP	O
.	.	O

SETTING	NNP	O
Two	CD	O
health	NN	O
clinics	NNS	O
in	IN	O
Los	NNP	O
Angeles	NNP	O
County	NNP	O
,	,	O
California	NNP	O
.	.	O

OBJECTIVE	NNP	O
To	TO	O
identify	VB	O
factors	NNS	O
associated	VBN	O
with	IN	O
completion	NN	O
of	IN	O
care	NN	O
among	IN	O
foreign-born	JJ	C
adolescents	NNS	A
treated	VBN	O
for	IN	O
latent	JJ	C
tuberculosis	NN	C
infection	NN	C
(	(	C
LTBI	NNP	C
)	)	C
.	.	O

DESIGN	VB	O
A	DT	O
total	NN	O
of	IN	O
766	CD	SS
low-income	JJ	C
adolescents	NNS	A
(	(	O
79	CD	O
%	NN	O
participation	NN	O
rate	NN	O
)	)	O
,	,	O
including	VBG	O
610	CD	SS
foreign-born	JJ	C
,	,	O
were	VBD	O
recruited	VBN	O
.	.	O

In	IN	O
prospective	JJ	O
face-to-face	NN	O
interviews	NNS	O
,	,	O
data	NNS	O
were	VBD	O
obtained	VBN	O
on	IN	O
socio-demographic	JJ	O
and	CC	O
lifestyle	JJ	O
characteristics	NNS	O
,	,	O
psychosocial	JJ	O
factors	NNS	O
and	CC	O
clinic-related	JJ	O
variables	NNS	O
.	.	O

Medical	JJ	O
chart	NN	O
data	NNS	O
were	VBD	O
abstracted	VBN	O
regarding	VBG	O
clinic	JJ	O
appointment	NN	O
keeping	VBG	O
and	CC	O
completion	NN	O
of	IN	O
treatment	NN	O
.	.	O

Univariate	NNP	O
and	CC	O
multivariate	VB	O
logistic	JJ	O
regression	NN	O
analyses	NNS	O
were	VBD	O
performed	VBN	O
to	TO	O
identify	VB	O
factors	NNS	O
associated	VBN	O
with	IN	O
completion	NN	O
of	IN	O
care	NN	O
.	.	O

RESULTS	NNP	O
Foreign-born	JJ	C
adolescents	NNS	A
were	VBD	O
more	RBR	O
likely	JJ	O
to	TO	O
complete	VB	O
care	NN	O
than	IN	O
US-born	JJ	O
adolescents	NNS	O
,	,	O
with	IN	O
82	CD	O
%	NN	O
completion	NN	O
of	IN	O
care	NN	O
rate	NN	O
.	.	O

In	IN	O
logistic	JJ	O
regression	NN	O
analyses	NNS	O
after	IN	O
controlling	VBG	O
for	IN	O
age	NN	O
,	,	O
medication	NN	O
taking	VBG	O
behavior	NN	O
(	(	O
OR	CC	O
1.26	CD	O
,	,	O
95	CD	O
%	NN	O
CI	NNP	O
1.15-1.39	CD	O
)	)	O
,	,	O
living	VBG	O
with	IN	O
both	DT	O
parents	NNS	O
(	(	O
OR	NNP	O
1.74	CD	O
,	,	O
95	CD	O
%	NN	O
CI	NNP	O
1.02-2.97	CD	O
)	)	O
,	,	O
sexual	JJ	O
intercourse	NN	O
(	(	O
OR	CC	O
0.66	CD	O
,	,	O
95	CD	O
%	NN	O
CI	NNP	O
0.36-1.19	NN	O
)	)	O
and	CC	O
speaking	VBG	O
mostly	RB	O
or	CC	O
only	RB	O
English	JJ	O
with	IN	O
parents	NNS	O
(	(	O
OR	NNP	O
0.39	CD	O
,	,	O
95	CD	O
%	NN	O
CI	NNP	O
0.15-1.03	NN	O
)	)	O
were	VBD	O
independently	RB	O
associated	VBN	O
with	IN	O
completion	NN	O
of	IN	O
care	NN	O
.	.	O

CONCLUSION	NNP	O
These	DT	O
findings	NNS	O
contribute	VBP	O
to	TO	O
our	PRP$	O
understanding	NN	O
of	IN	O
the	DT	O
factors	NNS	O
that	WDT	O
may	MD	O
explain	VB	O
why	WRB	O
some	DT	O
adolescents	NNS	O
complete	JJ	O
care	NN	O
whereas	IN	O
others	NNS	O
do	VBP	O
not	RB	O
.	.	O

They	PRP	O
provide	VBP	O
supportive	JJ	O
evidence	NN	O
that	WDT	O
tailored	VBD	O
intervention	NN	O
programs	NNS	O
should	MD	O
be	VB	O
developed	VBN	O
to	TO	O
support	VB	O
the	DT	O
screening	NN	O
and	CC	O
completion	NN	O
of	IN	O
treatment	NN	O
of	IN	O
foreign-born	JJ	C
adolescents	NNS	A
.	.	O

Accumulated	VBN	O
brisk	JJ	O
walking	NN	O
reduces	NNS	O
arterial	JJ	O
stiffness	NN	O
in	IN	O
overweight	JJ	O
adults	NNS	O
:	:	O
evidence	NN	O
from	IN	O
a	DT	O
randomized	VBN	O
control	NN	O
trial	NN	O
.	.	O

Arterial	JJ	O
stiffness	NN	O
is	VBZ	O
a	DT	O
major	JJ	O
contributor	NN	O
to	TO	O
the	DT	O
development	NN	O
of	IN	O
atherosclerosis	NN	O
and	CC	O
consequently	RB	O
cardiovascular	JJ	O
disease	NN	O
.	.	O

This	DT	O
study	NN	O
aimed	VBD	O
to	TO	O
examine	VB	O
whether	IN	O
6	CD	O
months	NNS	O
of	IN	O
accumulated	VBN	O
(	(	O
3	CD	O
?	.	O
10	CD	O
minutes	NNS	O
,	,	O
5	CD	O
days/week	NN	O
)	)	O
brisk	NN	O
walking	NN	O
was	VBD	O
sufficient	JJ	O
to	TO	O
reduce	VB	O
arterial	JJ	O
stiffness	NN	O
in	IN	O
sedentary	JJ	O
,	,	O
overweight	JJ	O
individuals	NNS	O
.	.	O

Seventy-seven	JJ	O
individuals	NNS	O
(	(	O
19	CD	O
men	NNS	O
,	,	O
58	CD	O
women	NNS	O
;	:	O
age	NN	O
,	,	O
30-55	CD	O
years	NNS	O
)	)	O
were	VBD	O
randomly	RB	O
allocated	VBN	O
to	TO	O
one	CD	O
of	IN	O
three	CD	O
groups	NNS	O
;	:	O
two	CD	O
groups	NNS	O
completed	VBD	O
30	CD	O
minutes	NNS	O
of	IN	O
accumulated	JJ	O
walking	VBG	O
with	IN	O
either	DT	O
monthly	JJ	O
or	CC	O
weekly	JJ	O
telephone	NN	O
support	NN	O
;	:	O
the	DT	O
third	JJ	O
group	NN	O
(	(	O
control	NN	O
)	)	O
performed	VBD	O
stretching	VBG	O
exercises	NNS	O
.	.	O

The	DT	O
walking	VBG	O
groups	NNS	O
were	VBD	O
combined	VBN	O
and	CC	O
telephone	NN	O
support	NN	O
included	VBD	O
as	IN	O
a	DT	O
covariate	NN	O
.	.	O

Anthropometry	NNP	O
,	,	O
blood	NN	O
pressure	NN	O
(	(	O
BP	NNP	O
)	)	O
,	,	O
blood	NN	O
lipids	NNS	O
,	,	O
pulse	RB	O
wave	VBP	O
velocity	NN	O
(	(	O
PWV	NNP	O
)	)	O
,	,	O
and	CC	O
NOx	NNP	O
(	(	O
surrogate	JJ	O
marker	NN	O
for	IN	O
nitric	JJ	O
oxide	NN	O
)	)	O
were	VBD	O
measured	VBN	O
at	IN	O
baseline	NN	O
,	,	O
post-intervention	NN	O
and	CC	O
4	CD	O
months	NNS	O
post-intervention	NN	O
.	.	O

No	CC	O
changes	NNS	O
were	VBD	O
observed	VBN	O
for	IN	O
anthropometry	NN	O
,	,	O
BP	NNP	O
,	,	O
or	CC	O
lipids	NNS	O
.	.	O

However	RB	O
,	,	O
at	IN	O
the	DT	O
end	NN	O
of	IN	O
the	DT	O
intervention	NN	O
,	,	O
there	EX	O
was	VBD	O
a	DT	O
decrease	NN	O
in	IN	O
PWV	NNP	O
(	(	O
P	NNP	O
<	NNP	O
.001	NNP	O
)	)	O
accompanied	VBN	O
by	IN	O
an	DT	O
increase	NN	O
in	IN	O
NOx	NNP	O
(	(	O
P	NNP	O
<	NNP	O
.001	NNP	O
)	)	O
,	,	O
with	IN	O
changes	NNS	O
maintained	VBD	O
4	CD	O
months	NNS	O
post-intervention	NN	O
.	.	O

A	NNP	O
strong	JJ	O
negative	JJ	O
correlation	NN	O
between	IN	O
PWV	NNP	O
and	CC	O
NOx	NNP	O
was	VBD	O
also	RB	O
observed	VBN	O
(	(	O
P	NNP	O
<	NNP	O
.001	NNP	O
;	:	O
r	NN	O
=	NNP	O
-0.65	NNP	O
)	)	O
.	.	O

A	DT	O
lifestyle	JJ	O
approach	NN	O
to	TO	O
meeting	VBG	O
current	JJ	O
physical	JJ	O
activity	NN	O
guidelines	NNS	O
results	NNS	O
in	IN	O
favorable	JJ	O
alterations	NNS	O
in	IN	O
arterial	JJ	O
function	NN	O
in	IN	O
overweight	JJ	O
individuals	NNS	O
.	.	O

Households	NNS	O
with	IN	O
young	JJ	A
children	NNS	A
and	CC	O
use	NN	O
of	IN	O
freely	RB	O
distributed	VBN	O
bednets	NNS	O
in	IN	O
rural	JJ	O
Madagascar	NNP	O
.	.	O

BACKGROUND	NNP	O
Malaria	NNP	O
infections	NNS	O
are	VBP	O
the	DT	O
leading	VBG	O
cause	NN	O
of	IN	O
death	NN	O
for	IN	O
children	NNS	A
in	IN	O
Madagascar	NNP	O
.	.	O

Insecticide-treated	JJ	O
bednets	NNS	O
offer	VBP	O
effective	JJ	O
prevention	NN	O
,	,	O
but	CC	O
it	PRP	O
is	VBZ	O
unclear	JJ	O
how	WRB	O
well	RB	O
free	JJ	O
bednet	NN	O
distribution	NN	O
programs	NNS	O
reach	VBP	O
young	JJ	A
children	NNS	A
.	.	O

METHODS	NNP	O
We	PRP	O
conducted	VBD	O
a	DT	O
secondary	JJ	O
analysis	NN	O
of	IN	O
a	DT	O
free	JJ	O
bednet	NN	O
distribution	NN	O
program	NN	O
in	IN	O
Madagascar	NNP	O
from	IN	O
2007-2008	JJ	O
.	.	O

Interviews	NNS	O
were	VBD	O
performed	VBN	O
at	IN	O
baseline	NN	O
and	CC	O
6	CD	O
months	NNS	O
.	.	O

Principal	JJ	O
components	NNS	O
analysis	NN	O
was	VBD	O
used	VBN	O
to	TO	O
construct	VB	O
a	DT	O
wealth	NN	O
and	CC	O
malaria	NNS	O
knowledge	VBP	O
index	NN	O
.	.	O

Coverage	NNP	O
efficiency	NN	O
was	VBD	O
calculated	VBN	O
as	IN	O
coverage	NN	O
of	IN	O
children	NNS	O
per	IN	O
bednet	NN	O
owned	VBN	O
.	.	O

Univariable	JJ	O
and	CC	O
multivariable	JJ	O
regressions	NNS	O
were	VBD	O
used	VBN	O
to	TO	O
determine	VB	O
predictors	NNS	O
of	IN	O
bednet	NN	O
use	NN	O
.	.	O

RESULTS	NNP	O
Bednet	NNP	O
use	NN	O
,	,	O
among	IN	O
the	DT	O
560	CD	SS
households	NNS	O
in	IN	O
the	DT	O
study	NN	O
,	,	O
increased	VBD	O
from	IN	O
6	CD	O
to	TO	O
91	CD	O
%	NN	O
after	IN	O
6	CD	O
months	NNS	O
.	.	O

Coverage	NNP	O
efficiency	NN	O
increased	VBD	O
from	IN	O
1.29	CD	O
to	TO	O
1.56	CD	O
children	NNS	O
covered	VBN	O
per	IN	O
bednet	NN	O
owned	VBN	O
.	.	O

In	IN	O
multivariable	JJ	O
analysis	NN	O
,	,	O
having	VBG	O
a	DT	O
child	NN	O
under	IN	A
5	CD	A
years	NNS	A
of	IN	O
age	NN	O
was	VBD	O
the	DT	O
only	JJ	O
variable	NN	O
associated	VBN	O
with	IN	O
bednet	NN	O
use	NN	O
(	(	O
OR	CC	O
9.10	CD	O
;	:	O
p=0.001	NN	O
)	)	O
,	,	O
yielding	VBG	O
a	DT	O
99	CD	O
%	NN	O
likelihood	NN	O
of	IN	O
using	VBG	O
a	DT	O
bednet	NN	O
(	(	O
95	CD	O
%	NN	O
CI	NNP	O
96.4	CD	O
to	TO	O
99.9	CD	O
%	NN	O
)	)	O
versus	VBZ	O
82	CD	O
%	NN	O
(	(	O
95	CD	O
%	NN	O
CI	NNP	O
72.2	CD	O
to	TO	O
88.4	CD	O
%	NN	O
)	)	O
in	IN	O
households	NNS	O
without	IN	O
young	JJ	O
children	NNS	O
.	.	O

CONCLUSION	VB	O
This	DT	O
free	JJ	O
bednet	NN	O
distribution	NN	O
program	NN	O
achieved	VBN	O
high	JJ	O
levels	NNS	O
of	IN	O
adherence	NN	O
after	IN	O
6	CD	O
months	NNS	O
.	.	O

Household	NNP	O
presence	NN	O
of	IN	O
children	NNS	O
was	VBD	O
associated	VBN	O
with	IN	O
bednet	NN	O
use	NN	O
,	,	O
but	CC	O
not	RB	O
household	JJ	O
income	NN	O
or	CC	O
education	NN	O
,	,	O
suggesting	VBG	O
that	IN	O
distribution	NN	O
to	TO	O
priority	NN	O
groups	NNS	O
may	MD	O
help	VB	O
overcome	VB	O
traditional	JJ	O
barriers	NNS	O
to	TO	O
adoption	NN	O
in	IN	O
some	DT	O
settings	NNS	O
.	.	O

Safety	NN	O
and	CC	O
efficacy	NN	O
of	IN	O
a	DT	O
low	JJ	O
molecular	JJ	O
weight	NN	O
heparin	NN	O
(	(	O
Logiparin	NNP	O
)	)	O
versus	NN	O
dextran	NN	O
as	IN	O
prophylaxis	NN	O
against	IN	O
thrombosis	NN	O
after	IN	O
total	JJ	C
hip	NN	C
replacement	NN	C
.	.	O

In	IN	O
order	NN	O
to	TO	O
study	VB	O
the	DT	O
plasma	NN	O
levels	NNS	O
of	IN	O
factor	NN	O
XaI	NNP	O
and	CC	O
IIaI	NNP	O
activity	NN	O
an	DT	O
enzymatically	RB	O
depolymerized	VBN	O
low	JJ	O
molecular	JJ	O
weight	NN	O
heparin	NN	O
(	(	O
LMW-heparin	NNP	O
;	:	O
Logiparin	NNP	O
)	)	O
was	VBD	O
given	VBN	O
s.c.	NN	O
in	IN	O
a	DT	O
dose	NN	O
of	IN	O
35	CD	O
XaI	NNP	O
mu/kg	NN	O
b.w	NN	O
.	.	O

once	RB	O
daily	JJ	O
for	IN	O
7	CD	O
days	NNS	O
to	TO	O
10	CD	SS
patients	NNS	O
undergoing	JJ	O
total	JJ	O
hip	NN	O
replacement	NN	O
(	(	O
THR	NNP	C
)	)	O
in	IN	O
a	DT	O
pilot	NN	O
study	NN	O
.	.	O

The	DT	O
XaI	NN	O
activity	NN	O
was	VBD	O
less	JJR	O
than	IN	O
or	CC	O
equal	JJ	O
to	TO	O
0.24	CD	O
XaI	NNP	O
units/ml	NN	O
and	CC	O
the	DT	O
IIaI	NNP	O
activity	NN	O
less	JJR	O
than	IN	O
or	CC	O
equal	JJ	O
to	TO	O
0.043	CD	O
IIaI	NNP	O
mu/ml	NN	O
.	.	O

No	DT	O
accumulation	NN	O
of	IN	O
the	DT	O
activities	NNS	O
were	VBD	O
seen	VBN	O
.	.	O

No	DT	O
phlebographically	RB	O
verified	VBN	O
thrombi	NN	O
or	CC	O
any	DT	O
bleeding	JJ	O
complications	NNS	O
were	VBD	O
registered	VBN	O
.	.	O

From	IN	O
this	DT	O
study	NN	O
it	PRP	O
was	VBD	O
concluded	VBN	O
that	IN	O
the	DT	O
given	VBN	O
dose	NN	O
of	IN	O
Logiparin	NNP	O
was	VBD	O
safe	JJ	O
with	IN	O
regard	NN	O
to	TO	O
bleeding	VBG	O
complications	NNS	O
.	.	O

Based	VBN	O
on	IN	O
these	DT	O
data	NNS	O
,	,	O
an	DT	O
open	JJ	O
,	,	O
randomized	VBD	O
controlled	VBN	O
trial	NN	O
was	VBD	O
started	VBN	O
.	.	O

In	IN	O
this	DT	O
main	JJ	O
study	NN	O
the	DT	O
thromboprophylactic	JJ	O
effect	NN	O
of	IN	O
the	DT	O
LMW-heparin	NNP	O
(	(	O
Logiparin	NNP	O
)	)	O
in	IN	O
a	DT	O
dose	NN	O
of	IN	O
35	CD	O
XaI	NNP	O
mu/kg	NN	O
b.w	NN	O
.	.	O

once	RB	O
daily	JJ	O
was	VBD	O
compared	VBN	O
with	IN	O
that	DT	O
of	IN	O
dextran	NN	O
70	CD	O
in	IN	O
patients	NNS	O
undergoing	JJ	C
THR	NNP	C
.	.	O

100	CD	SS
patients	NNS	O
were	VBD	O
randomized	VBN	O
.	.	O

The	DT	O
over-all	JJ	O
thrombosis	NN	O
rate	NN	O
was	VBD	O
28	CD	O
%	NN	O
in	IN	O
patients	NNS	O
treated	VBN	O
with	IN	O
LMW-heparin	NNP	O
and	CC	O
39	CD	O
%	NN	O
in	IN	O
those	DT	O
given	VBN	O
dextran	NN	O
,	,	O
a	DT	O
non-significant	JJ	O
difference	NN	O
.	.	O

No	UH	O
bleeding	VBG	O
complications	NNS	O
,	,	O
deaths	NNS	O
or	CC	O
pulmonary	JJ	O
embolism	NN	O
were	VBD	O
recorded	VBN	O
in	IN	O
either	DT	O
group	NN	O
.	.	O

Peroperative	JJ	O
blood	NN	O
loss	NN	O
and	CC	O
transfusion	NN	O
requirements	NNS	O
were	VBD	O
similar	JJ	O
in	IN	O
the	DT	O
two	CD	O
groups	NNS	O
.	.	O

In	IN	O
conclusion	NN	O
,	,	O
the	DT	O
investigated	JJ	O
LMW-heparin	NNP	O
(	(	O
Logiparin	NNP	O
)	)	O
is	VBZ	O
safe	JJ	O
and	CC	O
effective	JJ	O
in	IN	O
preventing	VBG	O
postoperative	JJ	O
thromboembolism	NN	O
in	IN	O
patients	NNS	O
undergoing	JJ	O
total	JJ	O
hip	NN	O
replacement	NN	O
,	,	O
but	CC	O
the	DT	O
dosage	NN	O
can	MD	O
probably	RB	O
be	VB	O
optimized	VBN	O
.	.	O

Efficacy	NN	O
and	CC	O
safety	NN	O
of	IN	O
sildenafil	NN	O
in	IN	O
Asian	JJ	O
males	NNS	O
with	IN	O
erectile	JJ	C
dysfunction	NN	C
and	CC	O
cardiovascular	JJ	C
risk	NN	C
.	.	O

OBJECTIVE	NNP	O
Assess	NNP	O
the	DT	O
effectiveness	NN	O
of	IN	O
sildenafil	NN	O
in	IN	O
Asian	JJ	O
males	NNS	O
with	IN	O
erectile	JJ	C
dysfunction	NN	C
(	(	O
ED	NNP	C
)	)	O
and	CC	O
one	CD	O
or	CC	O
more	JJR	O
of	IN	O
the	DT	O
co-morbidities	NNS	O
,	,	O
mild-to-moderate	JJ	O
hypertension	NN	C
,	,	O
dyslipidemia	NN	C
,	,	O
and	CC	O
diabetes	NNS	C
.	.	O

MATERIAL	NNP	O
AND	NNP	O
METHOD	NNP	O
A	NNP	O
six-week	JJ	O
,	,	O
double-blind	JJ	O
,	,	O
randomized	VBN	O
,	,	O
placebo-controlled	JJ	O
,	,	O
multicenter	NN	O
study	NN	O
was	VBD	O
carried	VBN	O
out	RP	O
in	IN	O
Thailand	NNP	O
,	,	O
Malaysia	NNP	O
and	CC	O
Singapore	NNP	O
.	.	O

One	CD	SS
hundred	CD	SS
and	CC	SS
fifty	VB	SS
five	CD	SS
male	JJ	SS
subjects	NNS	O
were	VBD	O
randomized	VBN	O
(	(	O
2:1	CD	O
)	)	O
to	TO	O
sildenafil	VB	O
(	(	O
n	JJ	O
=	NNP	O
104	CD	O
)	)	O
or	CC	O
placebo	NN	O
(	(	O
n	JJ	O
=	NNP	O
51	CD	O
)	)	O
.	.	O

Sildenafil	NNP	O
was	VBD	O
started	VBN	O
at	IN	O
50	CD	O
mg	NN	O
and	CC	O
increased	VBD	O
(	(	O
100	CD	O
mg	NN	O
)	)	O
or	CC	O
decreased	VBN	O
(	(	O
25	CD	O
mg	NN	O
)	)	O
at	IN	O
week	NN	O
2	CD	O
if	IN	O
necessary	JJ	O
.	.	O

RESULTS	VB	O
On	IN	O
the	DT	O
primary	JJ	O
efficacy	NN	O
endpoint	NN	O
,	,	O
sildenafil-treated	JJ	O
subjects	NNS	O
had	VBD	O
significantly	RB	O
better	JJR	O
scores	NNS	O
on	IN	O
the	DT	O
International	NNP	O
Index	NNP	O
of	IN	O
Erectile	NNP	O
Function	NNP	O
(	(	O
IIEF	NNP	O
)	)	O
questions	NNS	O
3	CD	O
and	CC	O
4	CD	O
than	IN	O
placebo	NN	O
(	(	O
p	JJ	O
<	NN	O
0.001	CD	O
,	,	O
both	DT	O
questions	NNS	O
)	)	O
.	.	O

When	WRB	O
accumulated	VBN	O
into	IN	O
IIEF	NNP	O
domains	NNS	O
,	,	O
all	DT	O
five	CD	O
domains	NNS	O
were	VBD	O
significant	JJ	O
in	IN	O
favor	NN	O
of	IN	O
sildenafil	NN	O
.	.	O

In	IN	O
addition	NN	O
,	,	O
sildenafil-treated	JJ	O
subjects	NNS	O
were	VBD	O
more	RBR	O
satisfied	JJ	O
with	IN	O
treatment	NN	O
and	CC	O
had	VBD	O
a	DT	O
higher	JJR	O
intercourse	JJ	O
success	NN	O
rate	NN	O
.	.	O

The	DT	O
majority	NN	O
of	IN	O
adverse	JJ	O
events	NNS	O
were	VBD	O
mild	VBN	O
in	IN	O
severity	NN	O
;	:	O
the	DT	O
most	RBS	O
commonly	RB	O
reported	VBD	O
treatment-related	JJ	O
events	NNS	O
were	VBD	O
dizziness	NN	O
(	(	O
7.7	CD	O
%	NN	O
)	)	O
and	CC	O
tinnitus	NN	O
(	(	O
2.9	CD	O
%	NN	O
)	)	O
.	.	O

CONCLUSION	NNP	O
Sildenafil	NNP	O
(	(	O
25	CD	O
,	,	O
50	CD	O
,	,	O
and	CC	O
100	CD	O
mg	NN	O
)	)	O
was	VBD	O
found	VBN	O
to	TO	O
be	VB	O
an	DT	O
effective	JJ	O
,	,	O
safe	JJ	O
,	,	O
and	CC	O
well-tolerated	JJ	O
treatment	NN	O
for	IN	O
ED	NNP	O
in	IN	O
the	DT	O
present	JJ	O
study	NN	O
population	NN	O
of	IN	O
Thai	NNP	O
,	,	O
Malaysian	NNP	O
,	,	O
and	CC	O
Singaporean	NNP	O
males	NNS	O
who	WP	O
also	RB	O
had	VBD	O
increased	VBN	O
cardiovascular	JJ	O
risk	NN	O
T	NNP	O
lymphocyte	JJ	O
subsets	NNS	O
and	CC	O
NK	NNP	O
cell	VBP	O
cytotoxicity	NN	O
in	IN	O
chronic	JJ	O
hemodialysis	NN	C
patients	NNS	O
.	.	O

The	DT	O
effect	NN	O
of	IN	O
recombinant	JJ	O
human	JJ	O
erythropoietin	NN	O
(	(	O
rHu-EPO	JJ	O
)	)	O
treatment	NN	O
.	.	O

We	PRP	O
investigated	VBD	O
subpopulations	NNS	O
of	IN	O
T	NNP	O
lymphocytes	NNS	O
,	,	O
NK	NNP	O
cell	NN	O
number	NN	O
and	CC	O
cytotoxic	JJ	O
activity	NN	O
in	IN	O
14	CD	SS
chronic	JJ	C
uremic	JJ	C
patients	NNS	C
on	IN	C
regular	JJ	C
hemodialysis	NN	C
treatment	NN	O
.	.	O

We	PRP	O
observed	VBD	O
a	DT	O
significantly	RB	O
decreased	VBN	O
absolute	NN	O
lymphocyte	NN	O
number	NN	O
and	CC	O
percentage	NN	O
of	IN	O
CD3	NNP	O
cells	NNS	O
.	.	O

Relative	JJ	O
numbers	NNS	O
of	IN	O
CD16	NNP	O
cells	NNS	O
were	VBD	O
significantly	RB	O
elevated	VBN	O
,	,	O
but	CC	O
NK	NNP	O
cell	VBP	O
cytotoxic	JJ	O
activity	NN	O
was	VBD	O
within	IN	O
a	DT	O
normal	JJ	O
range	NN	O
.	.	O

Nine	JJ	SS
patients	NNS	O
with	IN	O
chronic	JJ	C
renal	JJ	C
anemia	NN	C
on	IN	C
maintenance	NN	C
hemodialysis	NN	C
were	VBD	O
enrolled	VBN	O
in	IN	O
rHu-EPO	JJ	O
treatment	NN	O
trial	NN	O
.	.	O

The	DT	O
treatment	NN	O
was	VBD	O
continued	VBN	O
till	IN	O
the	DT	O
hematocrit	NN	O
level	NN	O
reached	VBD	O
30	CD	O
%	NN	O
.	.	O

Each	DT	O
of	IN	O
the	DT	O
patients	NNS	O
had	VBD	O
corrected	VBN	O
anemia	NN	O
and	CC	O
well-being	NN	O
.	.	O

After	IN	O
12	CD	O
weeks	NNS	O
of	IN	O
the	DT	O
treatment	NN	O
we	PRP	O
observed	VBD	O
in	IN	O
these	DT	O
patients	NNS	O
decreases	NNS	O
in	IN	O
CD3	NNP	O
,	,	O
CD4	NNP	O
,	,	O
CD8	NNP	O
and	CC	O
CD16	NNP	O
cell	NN	O
numbers	NNS	O
and	CC	O
elevation	NN	O
of	IN	O
CD4/CD8	NNP	O
ratio	NN	O
.	.	O

Cytotoxic	NNP	O
activity	NN	O
of	IN	O
NK	NNP	O
cells	NNS	O
did	VBD	O
not	RB	O
change	VB	O
significantly	RB	O
.	.	O

Presented	VBN	O
results	NNS	O
indicate	VBP	O
that	IN	O
chronic	JJ	O
hemodialysis	NN	O
patients	NNS	O
have	VBP	O
significantly	RB	O
diminished	VBN	O
lymphocyte	JJ	O
number	NN	O
.	.	O

rHu	JJ	O
EPO	NNP	O
treatment	NN	O
affects	VBZ	O
the	DT	O
T	NNP	O
lymphocyte	NN	O
subsets	NNS	O
inducing	VBG	O
a	DT	O
deep	JJ	O
decrease	NN	O
of	IN	O
CD8	NNP	O
and	CC	O
CD16	NNP	O
cell	NN	O
percentage	NN	O
leading	VBG	O
to	TO	O
normalisation	NN	O
of	IN	O
the	DT	O
CD4/CD8	NNP	O
ratio	NN	O
.	.	O

Superior	JJ	O
fixation	NN	O
of	IN	O
pegged	JJ	O
trabecular	JJ	O
metal	NN	O
over	IN	O
screw-fixed	JJ	O
pegged	JJ	O
porous	JJ	O
titanium	NN	O
fiber	NN	O
mesh	NN	O
:	:	O
a	DT	O
randomized	JJ	O
clinical	JJ	O
RSA	NNP	O
study	NN	O
on	IN	O
cementless	JJ	O
tibial	JJ	O
components	NNS	O
.	.	O

BACKGROUND	NNP	O
AND	CC	O
PURPOSE	NNP	O
Lasting	NNP	O
stability	NN	O
of	IN	O
cementless	NN	O
implants	NNS	O
depends	VBZ	O
on	IN	O
osseointegration	NN	O
into	IN	O
the	DT	O
implant	JJ	O
surface	NN	O
,	,	O
and	CC	O
long-term	JJ	O
implant	JJ	O
fixation	NN	O
can	MD	O
be	VB	O
predicted	VBN	O
using	VBG	O
radiostereometric	JJ	O
analysis	NN	O
(	(	O
RSA	NNP	O
)	)	O
with	IN	O
short-term	JJ	O
follow-up	JJ	O
.	.	O

We	PRP	O
hypothesized	VBD	O
that	IN	O
there	EX	O
would	MD	O
be	VB	O
improved	VBN	O
fixation	NN	O
of	IN	O
high-porosity	NN	O
trabecular	JJ	O
metal	NN	O
(	(	O
TM	NNP	O
)	)	O
tibial	JJ	O
components	NNS	O
compared	VBN	O
to	TO	O
low-porosity	JJ	O
titanium	NN	O
pegged	VBD	O
porous	JJ	O
fiber-metal	JJ	O
(	(	O
Ti	NNP	O
)	)	O
polyethylene	NN	O
metal	JJ	O
backings	NNS	O
.	.	O

METHODS	NNP	O
In	IN	O
a	DT	O
prospective	JJ	O
,	,	O
parallel-group	JJ	O
,	,	O
randomized	VBN	O
unblinded	JJ	O
clinical	JJ	O
trial	NN	O
,	,	O
we	PRP	O
compared	VBN	O
cementless	JJ	O
tibial	JJ	O
components	NNS	O
in	IN	O
patients	NNS	O
aged	VBN	O
70	CD	O
years	NNS	O
and	CC	O
younger	JJR	O
with	IN	O
osteoarthritis	NN	O
.	.	O

The	DT	O
pre-study	JJ	O
sample	NN	O
size	NN	O
calculation	NN	O
was	VBD	O
22	CD	O
patients	NNS	O
per	IN	O
group	NN	O
.	.	O

25	CD	O
TM	NNP	O
tibial	JJ	O
components	NNS	O
were	VBD	O
fixed	VBN	O
press-fit	JJ	O
by	IN	O
2	CD	O
hexagonal	JJ	O
pegs	NN	O
(	(	O
TM	NNP	O
group	NN	O
)	)	O
and	CC	O
25	CD	O
Ti	NNP	O
tibial	JJ	O
components	NNS	O
were	VBD	O
fixed	VBN	O
press-fit	JJ	O
and	CC	O
by	IN	O
4	CD	O
supplemental	JJ	O
screws	NNS	O
(	(	O
Ti	NNP	O
group	NN	O
)	)	O
.	.	O

Stereo	NNP	O
radiographs	NN	O
for	IN	O
evaluation	NN	O
of	IN	O
absolute	JJ	O
component	NN	O
migration	NN	O
(	(	O
primary	JJ	O
effect	NN	O
size	NN	O
)	)	O
and	CC	O
single-direction	JJ	O
absolute	NN	O
component	NN	O
migration	NN	O
(	(	O
secondary	JJ	O
effect	NN	O
size	NN	O
)	)	O
were	VBD	O
obtained	VBN	O
within	IN	O
the	DT	O
first	JJ	O
postoperative	JJ	O
week	NN	O
and	CC	O
at	IN	O
6	CD	O
weeks	NNS	O
,	,	O
6	CD	O
months	NNS	O
,	,	O
1	CD	O
year	NN	O
,	,	O
and	CC	O
2	CD	O
years	NNS	O
.	.	O

American	JJ	O
Knee	NNP	O
Society	NNP	O
score	NN	O
was	VBD	O
used	VBN	O
for	IN	O
clinical	JJ	O
assessment	NN	O
preoperatively	RB	O
,	,	O
and	CC	O
at	IN	O
1	CD	O
and	CC	O
2	CD	O
years	NNS	O
.	.	O

RESULTS	VB	O
There	EX	O
were	VBD	O
no	DT	O
intraoperative	JJ	O
complications	NNS	O
,	,	O
and	CC	O
no	DT	O
postoperative	JJ	O
infections	NNS	O
or	CC	O
revisions	NNS	O
.	.	O

All	DT	O
patients	NNS	O
had	VBD	O
improved	VBN	O
function	NN	O
and	CC	O
regained	VBD	O
full	JJ	O
extension	NN	O
.	.	O

All	DT	O
tibial	JJ	O
components	NNS	O
migrated	VBN	O
initially	RB	O
.	.	O

Most	JJS	O
migration	NN	O
of	IN	O
the	DT	O
TM	NNP	O
components	NNS	O
(	(	O
n	JJ	O
=	NNP	O
24	CD	O
)	)	O
occurred	VBD	O
within	IN	O
the	DT	O
first	JJ	O
3	CD	O
months	NNS	O
after	IN	O
surgery	NN	O
whereas	JJ	O
migration	NN	O
of	IN	O
the	DT	O
Ti	NNP	O
components	NNS	O
(	(	O
n	JJ	O
=	NNP	O
22	CD	O
)	)	O
appeared	VBD	O
to	TO	O
stabilize	VB	O
first	RB	O
after	IN	O
1	CD	O
year	NN	O
.	.	O

The	DT	O
TM	NNP	O
components	NNS	O
migrated	VBD	O
less	JJR	O
than	IN	O
the	DT	O
Ti	NNP	O
components	NNS	O
at	IN	O
1	CD	O
year	NN	O
(	(	O
p	JJ	O
=	NNP	O
0.01	CD	O
)	)	O
and	CC	O
2	CD	O
years	NNS	O
(	(	O
p	JJ	O
=	NNP	O
0.004	CD	O
)	)	O
.	.	O

INTERPRETATION	NNP	O
We	PRP	O
conclude	VBP	O
that	IN	O
the	DT	O
mechanical	JJ	O
fixation	NN	O
of	IN	O
TM	NNP	O
tibial	JJ	O
components	NNS	O
is	VBZ	O
superior	JJ	O
to	TO	O
that	DT	O
of	IN	O
screw-fixed	JJ	O
Ti	NNP	O
tibial	JJ	O
components	NNS	O
.	.	O

We	PRP	O
expect	VBP	O
long-term	JJ	O
implant	JJ	O
survival	NN	O
to	TO	O
be	VB	O
better	RB	O
with	IN	O
the	DT	O
TM	NNP	O
tibial	JJ	O
component	NN	O
.	.	O

Immunologic	NNP	O
and	CC	O
hemodynamic	JJ	O
effects	NNS	O
of	IN	O
low-dose	JJ	O
hydrocortisone	NN	O
in	IN	O
septic	JJ	C
shock	NN	C
:	:	C
a	DT	O
double-blind	NN	O
,	,	O
randomized	VBN	O
,	,	O
placebo-controlled	JJ	O
,	,	O
crossover	NN	O
study	NN	O
.	.	O

Within	IN	O
the	DT	O
last	JJ	O
few	JJ	O
years	NNS	O
,	,	O
increasing	VBG	O
evidence	NN	O
of	IN	O
relative	JJ	O
adrenal	JJ	C
insufficiency	NN	C
in	IN	O
septic	JJ	C
shock	NN	C
evoked	VBD	O
a	DT	O
reassessment	NN	O
of	IN	O
hydrocortisone	NN	O
therapy	NN	O
.	.	O

To	TO	O
evaluate	VB	O
the	DT	O
effects	NNS	O
of	IN	O
hydrocortisone	NN	O
on	IN	O
the	DT	O
balance	NN	O
between	IN	O
proinflammatory	NN	O
and	CC	O
antiinflammation	NN	O
,	,	O
40	CD	SS
patients	NNS	O
with	IN	O
septic	JJ	C
shock	NN	C
were	VBD	O
randomized	VBN	O
in	IN	O
a	DT	O
double-blind	JJ	O
crossover	NN	O
study	NN	O
to	TO	O
receive	VB	O
either	CC	O
the	DT	O
first	JJ	O
100	CD	O
mg	NN	O
of	IN	O
hydrocortisone	NN	O
as	IN	O
a	DT	O
loading	NN	O
dose	NN	O
and	CC	O
10	CD	O
mg	NNS	O
per	IN	O
hour	NN	O
until	IN	O
Day	NNP	O
3	CD	O
(	(	O
n	JJ	O
=	NNP	O
20	CD	O
)	)	O
or	CC	O
placebo	NN	O
(	(	O
n	JJ	O
=	NNP	O
20	CD	O
)	)	O
,	,	O
followed	VBN	O
by	IN	O
the	DT	O
opposite	JJ	O
medication	NN	O
until	IN	O
Day	NNP	O
6	CD	O
.	.	O

Hydrocortisone	CD	O
infusion	NN	O
induced	VBD	O
an	DT	O
increase	NN	O
of	IN	O
mean	JJ	O
arterial	JJ	O
pressure	NN	O
,	,	O
systemic	JJ	O
vascular	NN	O
resistance	NN	O
,	,	O
and	CC	O
a	DT	O
decline	NN	O
of	IN	O
heart	NN	O
rate	NN	O
,	,	O
cardiac	JJ	O
index	NN	O
,	,	O
and	CC	O
norepinephrine	JJ	O
requirement	NN	O
.	.	O

A	DT	O
reduction	NN	O
of	IN	O
plasma	NN	O
nitrite/nitrate	NN	O
indicated	VBD	O
inhibition	NN	O
of	IN	O
nitric	JJ	O
oxide	JJ	O
formation	NN	O
and	CC	O
correlated	VBN	O
with	IN	O
a	DT	O
reduction	NN	O
of	IN	O
vasopressor	NN	O
support	NN	O
.	.	O

The	DT	O
inflammatory	JJ	O
response	NN	O
(	(	O
interleukin-6	JJ	O
and	CC	O
interleukin-8	JJ	O
)	)	O
,	,	O
endothelial	JJ	O
(	(	O
soluble	JJ	O
E-selectin	NN	O
)	)	O
and	CC	O
neutrophil	JJ	O
activation	NN	O
(	(	O
expression	NN	O
of	IN	O
CD11b	NNP	O
,	,	O
CD64	NNP	O
)	)	O
,	,	O
and	CC	O
antiinflammatory	JJ	O
response	NN	O
(	(	O
soluble	JJ	O
tumor	NN	O
necrosis	NN	O
factor	NN	O
receptors	NNS	O
I	PRP	O
and	CC	O
II	NNP	O
and	CC	O
interleukin-10	JJ	O
)	)	O
were	VBD	O
attenuated	VBN	O
.	.	O

In	IN	O
peripheral	JJ	O
blood	NN	O
monocytes	NNS	O
,	,	O
human	JJ	O
leukocyte	VBD	O
antigen-DR	JJ	O
expression	NN	O
was	VBD	O
only	RB	O
slightly	RB	O
depressed	VBN	O
,	,	O
whereas	NNS	O
in	IN	O
vitro	JJ	O
phagocytosis	NN	O
and	CC	O
the	DT	O
monocyte-activating	JJ	O
cytokine	JJ	O
interleukin-12	NN	O
increased	VBD	O
.	.	O

Hydrocortisone	NNP	O
withdrawal	NN	O
induced	VBD	O
hemodynamic	JJ	O
and	CC	O
immunologic	JJ	O
rebound	NN	O
effects	NNS	O
.	.	O

In	IN	O
conclusion	NN	O
,	,	O
hydrocortisone	NN	O
therapy	NN	O
restored	VBD	O
hemodynamic	JJ	O
stability	NN	O
and	CC	O
differentially	RB	O
modulated	VBD	O
the	DT	O
immunologic	JJ	O
response	NN	O
to	TO	O
stress	VB	O
in	IN	O
a	DT	O
way	NN	O
of	IN	O
antiinflammation	NN	O
rather	RB	O
than	IN	O
immunosuppression	NN	O
.	.	O

The	DT	O
lunar	JJ	C
stent	NN	C
characteristics	NNS	O
and	CC	O
clinical	JJ	O
results	NNS	O
.	.	O

One	CD	O
of	IN	O
the	DT	O
frequent	JJ	O
long-term	JJ	O
complications	NNS	O
after	IN	O
stent	JJ	O
implantation	NN	O
is	VBZ	O
restenosis	JJ	O
due	JJ	O
to	TO	O
the	DT	O
building	NN	O
up	IN	O
of	IN	O
a	DT	O
neointima	NN	O
within	IN	O
the	DT	O
artery	NN	O
,	,	O
as	RB	O
well	RB	O
as	IN	O
endovascular	JJ	O
hyperplasia	NN	O
(	(	O
tissue	VB	O
growth	NN	O
)	)	O
.	.	O

The	DT	O
interesting	JJ	O
feature	NN	O
of	IN	O
the	DT	O
Lunar	NNP	O
stent	NN	O
from	IN	O
Inflow	NNP	O
Dynamics	NNP	O
is	VBZ	O
that	IN	O
it	PRP	O
is	VBZ	O
coated	VBN	O
with	IN	O
a	DT	O
layer	NN	O
of	IN	O
iridium	NN	O
oxide	NN	O
.	.	O

The	DT	O
iridium	NN	O
oxide	IN	O
coating	NN	O
is	VBZ	O
believed	VBN	O
to	TO	O
reduce	VB	O
restenosis	NN	O
by	IN	O
decreasing	VBG	O
the	DT	O
inflammatory	JJ	O
response	NN	O
to	TO	O
the	DT	O
stent	NN	O
via	IN	O
its	PRP$	O
antioxidant	JJ	O
action	NN	O
.	.	O

The	DT	O
MOONLIGHT	NNP	O
(	(	O
Multicenter	NNP	O
Objective	NNP	O
ObservatioNal	NNP	O
Lunar	NNP	O
Iridiumoxide	NNP	O
intimal	JJ	O
GrowtH	NNP	O
Trial	NNP	O
)	)	O
study	NN	O
was	VBD	O
carried	VBN	O
out	IN	O
to	TO	O
evaluate	VB	O
the	DT	O
immediate	JJ	O
outcome	NN	O
and	CC	O
long-term	JJ	O
angiographic	JJ	O
success	NN	O
after	IN	O
implantation	NN	O
of	IN	O
Lunar	NNP	O
stents	NNS	O
.	.	O

Between	IN	O
March	NNP	O
2001	CD	O
and	CC	O
November	NNP	O
2001	CD	O
,	,	O
87	CD	SS
patients	NNS	O
with	IN	O
99	CD	O
lesions	NNS	C
were	VBD	O
enrolled	VBN	O
in	IN	O
this	DT	O
study	NN	O
and	CC	O
were	VBD	O
treated	VBN	O
with	IN	O
12	CD	O
and	CC	O
16	CD	O
mm	NNS	O
long	JJ	O
iridium-oxide	JJ	O
coated	VBN	O
Lunar	NNP	O
stents	NNS	O
.	.	O

Delivery	NN	O
of	IN	O
the	DT	O
Lunar	NNP	O
stent	NN	O
was	VBD	O
successful	JJ	O
in	IN	O
most	JJS	O
lesions	NNS	O
and	CC	O
the	DT	O
optimal	JJ	O
radiopacity	NN	O
facilitated	VBN	O
optimal	JJ	O
stent	NN	O
positioning	VBG	O
with	IN	O
optimal	JJ	O
immediate	JJ	O
clinical	JJ	O
and	CC	O
angiographic	JJ	O
results	NNS	O
is	VBZ	O
an	DT	O
unselected	JJ	O
patient	NN	O
and	CC	O
lesion	NN	O
population	NN	O
.	.	O

Preliminary	JJ	O
clinical	JJ	O
and	CC	O
angiographic	JJ	O
follow-up	JJ	O
show	NN	O
a	DT	O
low	JJ	O
rate	NN	O
of	IN	O
cardiac	JJ	O
events	NNS	O
at	IN	O
6	CD	O
months	NNS	O
(	(	O
16.1	CD	O
%	NN	O
MACE	NNP	O
)	)	O
and	CC	O
a	DT	O
moderate	JJ	O
hyperplastic	JJ	O
response	NN	O
.	.	O

Effects	NNS	O
of	IN	O
irrigation	NN	O
fluid	NN	O
temperature	NN	O
on	IN	O
core	NN	O
body	NN	O
temperature	NN	O
during	IN	O
transurethral	JJ	O
resection	NN	O
of	IN	O
the	DT	O
prostate	NN	O
.	.	O

OBJECTIVES	UH	O
To	TO	O
determine	VB	O
the	DT	O
effect	NN	O
irrigation	NN	O
fluid	NN	O
temperature	NN	O
has	VBZ	O
on	IN	O
core	NN	O
body	NN	O
temperature	NN	O
changes	NNS	O
in	IN	O
patients	NNS	O
undergoing	JJ	O
transurethral	JJ	C
resection	NN	C
of	IN	C
the	DT	C
prostate	NN	C
(	(	O
TURP	NNP	O
)	)	O
.	.	O

METHODS	NNP	O
Fifty-six	NNP	SS
male	NN	SE
patients	NNS	O
(	(	O
mean	JJ	O
age	NN	O
71.2	CD	A
+/-	JJ	O
8.2	CD	O
years	NNS	O
)	)	O
scheduled	VBD	O
for	IN	O
TURP	NNP	C
were	VBD	O
enrolled	VBN	O
in	IN	O
the	DT	O
study	NN	O
.	.	O

Patients	NNS	O
were	VBD	O
randomized	VBN	O
to	TO	O
one	CD	O
of	IN	O
two	CD	O
groups	NNS	O
.	.	O

Group	NNP	O
1	CD	O
consisted	VBD	O
of	IN	O
27	CD	SS
patients	NNS	O
who	WP	O
received	VBD	O
room	NN	O
temperature	NN	O
irrigation	NN	O
fluid	NN	O
(	(	O
70	CD	O
degrees	NNS	O
F	NNP	O
)	)	O
throughout	IN	O
TURP	NNP	O
;	:	O
group	NN	O
2	CD	O
consisted	VBD	O
of	IN	O
29	CD	SS
patients	NNS	O
whose	WP$	O
procedure	NN	O
was	VBD	O
performed	VBN	O
with	IN	O
warmed	JJ	O
irrigation	NN	O
fluid	NN	O
(	(	O
91.5	CD	O
degrees	NNS	O
F	NNP	O
)	)	O
.	.	O

The	DT	O
irrigation	NN	O
fluid	NN	O
used	VBN	O
for	IN	O
both	DT	O
groups	NNS	O
was	VBD	O
glycine	NN	O
.	.	O

The	DT	O
baseline	NN	O
temperature	NN	O
,	,	O
final	JJ	O
temperature	NN	O
,	,	O
total	JJ	O
time	NN	O
in	IN	O
the	DT	O
operating	NN	O
room	NN	O
,	,	O
and	CC	O
amount	NN	O
of	IN	O
irrigation	NN	O
fluid	NN	O
used	VBN	O
during	IN	O
the	DT	O
procedure	NN	O
were	VBD	O
recorded	VBN	O
for	IN	O
each	DT	O
patient	NN	O
.	.	O

RESULTS	NNP	O
No	NNP	O
significant	JJ	O
difference	NN	O
in	IN	O
the	DT	O
average	JJ	O
time	NN	O
spent	VBN	O
in	IN	O
the	DT	O
operating	NN	O
room	NN	O
or	CC	O
in	IN	O
the	DT	O
total	JJ	O
irrigation	NN	O
fluid	NN	O
used	VBN	O
between	IN	O
the	DT	O
two	CD	O
groups	NNS	O
was	VBD	O
observed	VBN	O
.	.	O

Of	IN	O
the	DT	O
27	CD	O
patients	NNS	O
who	WP	O
received	VBD	O
room	NN	O
temperature	NN	O
irrigation	NN	O
fluid	NN	O
,	,	O
15	CD	O
(	(	O
55.6	CD	O
%	NN	O
)	)	O
had	VBD	O
a	DT	O
decrease	NN	O
in	IN	O
body	NN	O
temperature	NN	O
.	.	O

A	DT	O
decrease	NN	O
in	IN	O
temperature	NN	O
was	VBD	O
observed	VBN	O
in	IN	O
21	CD	O
(	(	O
72.4	CD	O
%	NN	O
)	)	O
of	IN	O
the	DT	O
29	CD	O
patients	NNS	O
who	WP	O
received	VBD	O
warm	JJ	O
irrigation	NN	O
fluid	NN	O
.	.	O

Groups	NNP	O
1	CD	O
and	CC	O
2	CD	O
had	VBD	O
12	CD	O
(	(	O
44.4	CD	O
%	NN	O
)	)	O
of	IN	O
27	CD	O
and	CC	O
8	CD	O
(	(	O
27.6	CD	O
%	NN	O
)	)	O
of	IN	O
29	CD	O
patients	NNS	O
,	,	O
respectively	RB	O
,	,	O
who	WP	O
demonstrated	VBD	O
an	DT	O
elevation	NN	O
in	IN	O
their	PRP$	O
core	NN	O
body	NN	O
temperature	NN	O
.	.	O

CONCLUSIONS	VB	O
The	DT	O
results	NNS	O
of	IN	O
our	PRP$	O
study	NN	O
suggest	VBP	O
that	IN	O
irrigation	NN	O
fluid	NN	O
temperature	NN	O
is	VBZ	O
not	RB	O
a	DT	O
factor	NN	O
responsible	JJ	O
for	IN	O
altering	VBG	O
the	DT	O
core	NN	O
body	NN	O
temperature	NN	O
in	IN	O
patients	NNS	O
undergoing	JJ	O
TURP	NNP	O
.	.	O

Enhancing	VBG	O
the	DT	O
self-esteem	NN	O
of	IN	O
inpatient	JJ	C
alcoholics	NNS	C
.	.	O

This	DT	O
study	NN	O
examined	VBD	O
the	DT	O
effect	NN	O
of	IN	O
pairing	VBG	O
inpatient	JJ	O
alcoholics	NNS	O
with	IN	O
nursing	NN	O
home	NN	O
residents	NNS	O
(	(	O
NHRs	NNP	O
)	)	O
on	IN	O
the	DT	O
alcoholics	NNS	O
'	POS	O
self-esteem	NN	O
.	.	O

In	IN	O
this	DT	O
PALS	NNP	O
program	NN	O
,	,	O
the	DT	O
alcoholic	JJ	O
inpatients	NNS	O
assumed	VBD	O
a	DT	O
helping-companion	NN	O
relationship	NN	O
with	IN	O
the	DT	O
NHRs	NNP	O
for	IN	O
2	CD	O
hr	NNS	O
per	IN	O
day	NN	O
during	IN	O
their	PRP$	O
last	JJ	O
2	CD	O
weeks	NNS	O
of	IN	O
treatment	NN	O
.	.	O

Fifty	NNP	O
alcoholic	JJ	O
inpatients	NNS	C
were	VBD	C
randomly	RB	C
assigned	VBN	C
to	TO	C
the	DT	C
PALS	NNP	C
program	NN	C
(	(	C
n	JJ	C
=	NNP	C
25	CD	C
)	)	C
or	CC	C
to	TO	C
the	DT	C
library	NN	C
for	IN	C
free	JJ	C
reading	NN	C
time	NN	C
(	(	C
n	JJ	C
=	NNP	C
25	CD	C
)	)	C
.	.	O

The	DT	O
Tennessee	NNP	O
Self-Concept	NNP	O
Scale	NNP	O
(	(	O
TSCS	NNP	O
)	)	O
was	VBD	O
administered	VBN	O
to	TO	O
all	DT	O
subjects	NNS	O
in	IN	O
both	DT	O
groups	NNS	O
before	IN	O
and	CC	O
after	IN	O
the	DT	O
interventions	NNS	O
.	.	O

Of	IN	O
the	DT	O
nine	CD	O
TSCS	NNP	O
scales	NNS	O
,	,	O
the	DT	O
improvement	NN	O
on	IN	O
the	DT	O
Moral-Ethical	JJ	O
scale	NN	O
was	VBD	O
significantly	RB	O
greater	JJR	O
in	IN	O
the	DT	O
PALS	NNP	O
group	NN	O
.	.	O

Because	IN	O
the	DT	O
alcoholic	JJ	O
inpatients	NNS	O
in	IN	O
the	DT	O
PALS	NNP	O
group	NN	O
engaged	VBD	O
in	IN	O
altruistic	JJ	O
(	(	O
moral	JJ	O
)	)	O
behavior	NN	O
,	,	O
this	DT	O
study	NN	O
provides	VBZ	O
a	DT	O
logical	JJ	O
link	NN	O
between	IN	O
the	DT	O
intervention	NN	O
and	CC	O
the	DT	O
outcome	NN	O
,	,	O
which	WDT	O
has	VBZ	O
been	VBN	O
a	DT	O
prevalent	JJ	O
weakness	NN	O
in	IN	O
previous	JJ	O
studies	NNS	O
of	IN	O
self-esteem	NN	O
in	IN	O
alcoholics	NNS	O
.	.	O

Is	VBZ	O
periprostatic	JJ	O
local	JJ	O
anesthesia	NN	O
for	IN	O
transrectal	JJ	C
ultrasound	NN	C
guided	VBD	C
prostate	NN	C
biopsy	NN	C
associated	VBN	O
with	IN	O
increased	JJ	O
infectious	JJ	O
or	CC	O
hemorrhagic	JJ	O
complications	NNS	O
?	.	O
A	DT	O
prospective	JJ	O
randomized	VBN	O
trial	NN	O
.	.	O

PURPOSE	NNP	O
Periprostatic	NNP	O
local	JJ	O
anesthesia	NN	O
for	IN	O
prostate	NN	O
biopsy	NN	O
requires	VBZ	O
2	CD	O
or	CC	O
more	JJR	O
extra	JJ	O
needle	JJ	O
punctures	NNS	O
and	CC	O
injection	NN	O
of	IN	O
the	DT	O
local	JJ	O
anesthetic	NN	O
through	IN	O
the	DT	O
highly	RB	O
colonized	JJ	O
rectum	NN	O
.	.	O

To	TO	O
our	PRP$	O
knowledge	NN	O
we	PRP	O
report	VBP	O
the	DT	O
first	JJ	O
prospective	JJ	O
randomized	VBN	O
trial	NN	O
to	TO	O
assess	VB	O
the	DT	O
infectious	JJ	O
or	CC	O
hemorrhagic	JJ	O
complications	NNS	O
associated	VBN	O
with	IN	O
this	DT	O
method	NN	O
.	.	O

MATERIALS	NNP	O
AND	NNP	O
METHODS	NNP	O
A	NNP	O
total	NN	O
of	IN	O
100	CD	SS
consecutive	JJ	O
patients	NNS	O
with	IN	O
sterile	JJ	C
urine	JJ	C
cultures	NNS	C
underwent	JJ	O
transrectal	JJ	C
ultrasound	NN	C
guided	VBD	C
prostate	NN	C
biopsy	NN	C
.	.	O

They	PRP	O
were	VBD	O
randomized	VBN	O
to	TO	O
receive	VB	O
a	DT	O
periprostatic	JJ	O
nerve	NN	O
block	NN	O
or	CC	O
no	DT	O
anesthesia	NN	O
.	.	O

Patients	NNS	O
were	VBD	O
evaluated	VBN	O
for	IN	O
the	DT	O
amount	NN	O
of	IN	O
rectal	NN	O
and	CC	O
urethral	JJ	O
bleeding	NN	O
,	,	O
and	CC	O
symptoms	NNS	O
and	CC	O
signs	NNS	O
of	IN	O
infection	NN	O
after	IN	O
biopsy	NN	O
.	.	O

RESULTS	VB	O
The	DT	O
amount	NN	O
of	IN	O
urethral	JJ	O
bleeding	NN	O
was	VBD	O
slight	JJ	O
and	CC	O
similar	JJ	O
in	IN	O
the	DT	O
2	CD	O
groups	NNS	O
.	.	O

Rectal	JJ	O
bleeding	NN	O
was	VBD	O
significantly	RB	O
less	RBR	O
in	IN	O
the	DT	O
patients	NNS	O
who	WP	O
received	VBD	O
anesthesia	NN	O
.	.	O

High	JJ	O
fever	NN	O
(	(	O
greater	JJR	O
than	IN	O
37.8C	CD	O
)	)	O
was	VBD	O
more	RBR	O
frequent	JJ	O
in	IN	O
the	DT	O
nerve	NN	O
block	NN	O
group	NN	O
and	CC	O
2	CD	O
patients	NNS	O
in	IN	O
this	DT	O
group	NN	O
required	VBD	O
rehospitalization	NN	O
.	.	O

Bacteriuria	NNP	O
in	IN	O
post-biopsy	JJ	O
urine	JJ	O
cultures	NNS	O
was	VBD	O
significantly	RB	O
more	JJR	O
common	JJ	O
in	IN	O
the	DT	O
anesthesia	NN	O
group	NN	O
.	.	O

CONCLUSIONS	NNP	O
Our	PRP$	O
results	NNS	O
suggest	VBP	O
that	IN	O
periprostatic	JJ	O
local	JJ	O
anesthesia	NN	O
for	IN	O
prostate	JJ	O
biopsy	NN	O
does	VBZ	O
not	RB	O
increase	VB	O
the	DT	O
risk	NN	O
of	IN	O
urethral	JJ	O
bleeding	NN	O
.	.	O

It	PRP	O
is	VBZ	O
associated	VBN	O
with	IN	O
a	DT	O
decreased	JJ	O
incidence	NN	O
of	IN	O
rectal	JJ	O
bleeding	NN	O
,	,	O
presumably	RB	O
due	JJ	O
to	TO	O
decreased	JJ	O
patient	NN	O
discomfort	NN	O
.	.	O

The	DT	O
incidence	NN	O
of	IN	O
bacteriuria	NN	O
was	VBD	O
significantly	RB	O
higher	JJR	O
in	IN	O
the	DT	O
anesthesia	NN	O
group	NN	O
.	.	O

High	NNP	O
fever	NN	O
and	CC	O
hospitalization	NN	O
due	JJ	O
to	TO	O
infectious	JJ	O
complications	NNS	O
were	VBD	O
also	RB	O
more	RBR	O
common	JJ	O
in	IN	O
the	DT	O
local	JJ	O
anesthesia	NN	O
group	NN	O
,	,	O
although	IN	O
not	RB	O
statistically	RB	O
significant	JJ	O
.	.	O

Prospective	JJ	O
randomized	JJ	O
trials	NNS	O
seem	VBP	O
warranted	VBN	O
to	TO	O
determine	VB	O
the	DT	O
optimum	JJ	O
antibiotic	JJ	O
prophylaxis	NN	O
regimen	NNS	O
in	IN	O
patients	NNS	O
undergoing	VBG	O
biopsy	NN	O
with	IN	O
a	DT	O
periprostatic	JJ	O
nerve	NN	O
block	NN	O
.	.	O

Effects	NNS	O
of	IN	O
short-term	JJ	O
isotonic	JJ	O
&	CC	O
isometric	JJ	O
training	NN	O
on	IN	O
cardiovascular	JJ	O
&	CC	O
pulmonary	JJ	O
function	NN	O
.	.	O

A	DT	O
randomised	JJ	O
control	NN	O
trial	NN	O
of	IN	O
short-term	JJ	O
exercises	NNS	O
on	IN	O
specific	JJ	O
cardiovascular	JJ	O
and	CC	O
respiratory	JJ	O
parameters	NNS	O
was	VBD	O
undertaken	VBN	O
in	IN	O
normal	JJ	O
male	JJ	O
college	NN	O
students	NNS	O
.	.	O

The	DT	O
effects	NNS	O
of	IN	O
isotonic	JJ	O
training	NN	O
(	(	O
5BX	CD	O
programme	NN	O
)	)	O
and	CC	O
isometric	JJ	O
training	NN	O
(	(	O
a	DT	O
programme	NN	O
of	IN	O
isometric	JJ	O
exercises	NNS	O
working	VBG	O
all	DT	O
major	JJ	O
groups	NNS	O
of	IN	O
muscles	NNS	O
)	)	O
were	VBD	O
compared	VBN	O
with	IN	O
a	DT	O
control	NN	O
group	NN	O
with	IN	O
no	DT	O
specific	JJ	O
workout	NN	O
.	.	O

Both	DT	O
isotonic	JJ	O
and	CC	O
isometric	JJ	O
training	NN	O
resulted	VBD	O
in	IN	O
significant	JJ	O
cardiovascular	JJ	O
improvement	NN	O
but	CC	O
seemed	VBD	O
inadequate	JJ	O
to	TO	O
improve	VB	O
vital	JJ	O
capacity	NN	O
and	CC	O
flow	NN	O
rates	NNS	O
.	.	O

Isotonic	JJ	O
training	NN	O
in	IN	O
addition	NN	O
,	,	O
improved	JJ	O
ventilatory	NN	O
efficiency	NN	O
.	.	O

It	PRP	O
is	VBZ	O
concluded	VBN	O
that	IN	O
such	JJ	O
isotonic	JJ	O
or	CC	O
isometric	JJ	O
training	NN	O
of	IN	O
thrice	NN	O
a	DT	O
week	NN	O
for	IN	O
ten	JJ	O
weeks	NNS	O
,	,	O
requiring	VBG	O
no	DT	O
equipment	NN	O
,	,	O
less	JJR	O
time	NN	O
and	CC	O
space	NN	O
can	MD	O
be	VB	O
promoted	VBN	O
to	TO	O
improve	VB	O
physical	JJ	O
fitness	NN	O
.	.	O

[	JJ	O
Effects	NNS	O
of	IN	O
transcutaneous	JJ	O
electrical	JJ	O
stimulation	NN	O
of	IN	O
auricular	JJ	O
Shenmen	NNP	O
point	NN	O
on	IN	O
postoperative	JJ	O
nausea	NN	O
and	CC	O
vomiting	NN	O
and	CC	O
patient-controlled	JJ	O
epidural	JJ	O
analgesia	NN	O
in	IN	O
cesarean	JJ	O
section	NN	O
]	NNP	O
.	.	O

OBJECTIVE	NNP	O
To	TO	O
investigate	VB	O
the	DT	O
effects	NNS	O
of	IN	O
transcutaneous	JJ	O
electrical	JJ	O
stimulation	NN	O
of	IN	O
auricular	JJ	O
Shenmen	NNP	O
point	NN	O
on	IN	O
postoperative	JJ	O
nausea	NN	O
and	CC	O
vomiting	NN	O
and	CC	O
patient-controlled	JJ	O
epidural	JJ	O
analgesia	NN	O
in	IN	O
cesarean	JJ	O
section	NN	O
.	.	O

METHODS	NNP	O
After	IN	O
IRB	NNP	O
approval	NN	O
and	CC	O
informed	JJ	O
consent	NN	O
,	,	O
one	CD	O
hundred	CD	O
and	CC	O
eighty	VB	O
singleton	NN	O
primiparas	IN	O
undergoing	VBG	O
elective	JJ	O
cesarean	JJ	O
section	NN	O
,	,	O
in	IN	O
Qingdao	NNP	O
Municipal	NNP	O
Hospital	NNP	O
,	,	O
and	CC	O
Qingdao	NNP	O
Hiser	NNP	O
Medical	NNP	O
Center	NNP	O
,	,	O
from	IN	O
November	NNP	O
2011	CD	O
to	TO	O
March	NNP	O
2012	CD	O
,	,	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
three	CD	O
groups	NNS	O
:	:	O
transcutaneous	JJ	O
electrical	JJ	O
stimulation	NN	O
of	IN	O
auricular	JJ	O
Shenmen	NNP	O
point	NN	O
group	NN	O
(	(	O
group	NN	O
A	NNP	O
,	,	O
n	JJ	O
=	NNP	O
60	CD	O
)	)	O
,	,	O
transcutaneous	JJ	O
electrical	JJ	O
stimulation	NN	O
of	IN	O
auricular	JJ	O
Eye	NNP	O
point	NN	O
group	NN	O
(	(	O
group	NN	O
B	NNP	O
,	,	O
n	JJ	O
=	NNP	O
60	CD	O
)	)	O
and	CC	O
control	NN	O
group	NN	O
(	(	O
group	NN	O
C	NNP	O
,	,	O
n	JJ	O
=	NNP	O
60	CD	O
)	)	O
.	.	O

Women	NNP	O
of	IN	O
group	NN	O
A	NNP	O
received	VBD	O
transcutaneous	JJ	O
electrical	JJ	O
stimulation	NN	O
of	IN	O
auricular	JJ	O
Shenmen	NNP	O
point	NN	O
(	(	O
frequency	NN	O
1.5	CD	O
HZ	NNP	O
)	)	O
at	IN	O
the	DT	O
time	NN	O
of	IN	O
preoperation	NN	O
,	,	O
4	CD	O
,	,	O
10	CD	O
and	CC	O
22	CD	O
hours	NNS	O
of	IN	O
postoperation	NN	O
for	IN	O
30	CD	O
minutes	NNS	O
.	.	O

The	DT	O
strength	NN	O
was	VBD	O
controlled	VBN	O
by	IN	O
themselves	PRP	O
.	.	O

Women	NNP	O
of	IN	O
group	NN	O
B	NNP	O
received	VBD	O
stimulation	NN	O
of	IN	O
auricular	JJ	O
Eye	NNP	O
point	NN	O
as	IN	O
group	NN	O
A	NNP	O
.	.	O

Women	NNP	O
of	IN	O
group	NN	O
C	NNP	O
received	VBD	O
pressurization	NN	O
and	CC	O
connected	VBN	O
line	NN	O
were	VBD	O
the	DT	O
same	JJ	O
with	IN	O
group	NN	O
A	NNP	O
,	,	O
but	CC	O
without	IN	O
electrical	JJ	O
stimulation	NN	O
.	.	O

The	DT	O
following	JJ	O
indexes	NNS	O
was	VBD	O
observed	VBN	O
:	:	O
the	DT	O
incidence	NN	O
of	IN	O
postoperative	JJ	O
nausea	NN	O
and	CC	O
vomiting	NN	O
(	(	O
PONV	NNP	O
)	)	O
for	IN	O
48	CD	O
hours	NNS	O
;	:	O
the	DT	O
rate	NN	O
of	IN	O
metoclopramide	NN	O
;	:	O
the	DT	O
visual	JJ	O
analogue	NN	O
scale	NN	O
(	(	O
VAS	NNP	O
)	)	O
score	NN	O
of	IN	O
rest	NN	O
pain	NN	O
,	,	O
uterine	JJ	O
contration	NN	O
pain	NN	O
and	CC	O
dynamic	JJ	O
pain	NN	O
at	IN	O
the	DT	O
time	NN	O
of	IN	O
postoperation	NN	O
for	IN	O
6	CD	O
,	,	O
12	CD	O
,	,	O
24	CD	O
and	CC	O
48	CD	O
hours	NNS	O
(	(	O
T	NNP	O
(	(	O
1	CD	O
)	)	O
-T	NN	O
(	(	O
4	CD	O
)	)	O
)	)	O
;	:	O
the	DT	O
total	JJ	O
number	NN	O
and	CC	O
effective	JJ	O
compressions	NNS	O
number	NN	O
of	IN	O
patient-controlled	JJ	O
epidural	JJ	O
analgesia	NN	O
(	(	O
PCEA	NNP	O
)	)	O
;	:	O
the	DT	O
dose	NN	O
of	IN	O
analgesia	JJ	O
mixture	NN	O
;	:	O
the	DT	O
anal	JJ	O
exhaust	JJ	O
time	NN	O
;	:	O
the	DT	O
volume	NN	O
of	IN	O
postoperative	JJ	O
bleeding	NN	O
for	IN	O
6	CD	O
hours	NNS	O
of	IN	O
postoperation	NN	O
and	CC	O
the	DT	O
other	JJ	O
side	NN	O
effects	NNS	O
.	.	O

RESULTS	NNP	O
Compared	NNP	O
with	IN	O
group	NN	O
B	NNP	O
and	CC	O
group	NN	O
C	NNP	O
,	,	O
the	DT	O
incidence	NN	O
of	IN	O
PONV	NNP	O
,	,	O
the	DT	O
rate	NN	O
of	IN	O
metoclopramide	NN	O
,	,	O
the	DT	O
VAS	NNP	O
score	NN	O
at	IN	O
the	DT	O
time	NN	O
T	NNP	O
(	(	O
1	CD	O
)	)	O
-T	NN	O
(	(	O
4	CD	O
)	)	O
,	,	O
the	DT	O
total	JJ	O
number	NN	O
and	CC	O
effective	JJ	O
compressions	NNS	O
number	NN	O
of	IN	O
PCEA	NNP	O
,	,	O
the	DT	O
ratio	NN	O
of	IN	O
the	DT	O
total	JJ	O
number	NN	O
with	IN	O
effective	JJ	O
compressions	NNS	O
number	NN	O
and	CC	O
the	DT	O
dose	NN	O
of	IN	O
analgesia	JJ	O
mixture	NN	O
were	VBD	O
decreased	VBN	O
in	IN	O
group	NN	O
A	NNP	O
(	(	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
,	,	O
but	CC	O
no	DT	O
difference	NN	O
compared	VBN	O
group	NN	O
B	NNP	O
with	IN	O
group	NN	O
C	NNP	O
(	(	O
P	NNP	O
>	NNP	O
0.05	CD	O
)	)	O
.	.	O

The	DT	O
anal	JJ	O
exhaust	NN	O
time	NN	O
and	CC	O
the	DT	O
volume	NN	O
of	IN	O
postoperative	JJ	O
bleeding	NN	O
for	IN	O
6	CD	O
hours	NNS	O
of	IN	O
postoperation	NN	O
were	VBD	O
no	DT	O
difference	NN	O
in	IN	O
the	DT	O
three	CD	O
groups	NNS	O
(	(	O
P	NNP	O
>	NNP	O
0.05	CD	O
)	)	O
.	.	O

No	UH	O
other	JJ	O
side	NN	O
effects	NNS	O
were	VBD	O
observed	VBN	O
.	.	O

CONCLUSION	NNP	O
Transcutaneous	NNP	O
electrical	JJ	O
stimulation	NN	O
of	IN	O
auricular	JJ	O
Shenmen	NNS	O
point	NN	O
can	MD	O
reduce	VB	O
the	DT	O
incidence	NN	O
of	IN	O
PONV	NNP	O
and	CC	O
improves	VBZ	O
analgesia	JJ	O
effect	NN	O
of	IN	O
PCEA	NNP	O
in	IN	O
postoperation	NN	O
of	IN	O
cesarean	JJ	O
section	NN	O
.	.	O

Long-term	JJ	O
survival	NN	O
in	IN	O
a	DT	O
phase	NN	O
III	NNP	O
,	,	O
randomised	VBD	O
study	NN	O
of	IN	O
topotecan	JJ	O
versus	NN	O
paclitaxel	NN	O
in	IN	O
advanced	JJ	O
epithelial	JJ	O
ovarian	JJ	O
carcinoma	NN	O
.	.	O

BACKGROUND	IN	O
We	PRP	O
have	VBP	O
continued	VBN	O
to	TO	O
monitor	VB	O
the	DT	O
survival	NN	O
of	IN	O
patients	NNS	O
randomised	VBN	O
in	IN	O
a	DT	O
previously	RB	O
reported	VBN	O
multicentre	JJ	O
phase	NN	O
III	NNP	O
study	NN	O
of	IN	O
topotecan	JJ	O
versus	NN	O
paclitaxel	NN	O
in	IN	O
patients	NNS	O
with	IN	O
advanced	JJ	O
epithelial	JJ	O
ovarian	JJ	O
cancer	NN	O
who	WP	O
had	VBD	O
failed	VBN	O
one	CD	O
prior	JJ	O
platinum-based	JJ	O
regimen	NNS	O
.	.	O

PATIENTS	NNP	O
AND	CC	O
METHODS	NNP	O
Patients	NNPS	O
with	IN	O
bidimensionally	RB	O
measurable	JJ	O
disease	NN	O
were	VBD	O
randomised	VBN	O
to	TO	O
topotecan	VB	O
(	(	O
1.5	CD	O
mg/m	NN	O
(	(	O
2	CD	O
)	)	O
/day	NN	O
for	IN	O
5	CD	O
days	NNS	O
)	)	O
or	CC	O
paclitaxel	NN	O
(	(	O
175	CD	O
mg/m	NN	O
(	(	O
2	CD	O
)	)	O
/day	NN	O
as	IN	O
a	DT	O
3-h	JJ	O
infusion	NN	O
)	)	O
every	DT	O
21	CD	O
days	NNS	O
.	.	O

Patients	NNS	O
were	VBD	O
eligible	JJ	O
for	IN	O
treatment	NN	O
with	IN	O
the	DT	O
alternate	NN	O
therapy	NN	O
at	IN	O
third	JJ	O
line	NN	O
.	.	O

The	DT	O
European	JJ	O
Organisation	NNP	O
for	IN	O
Research	NNP	O
and	CC	O
Treatment	NNP	O
of	IN	O
Cancer	NNP	O
Quality	NNP	O
of	IN	O
Life	NNP	O
(	(	O
EORTC	NNP	O
QOL	NNP	O
)	)	O
-C30	VBP	O
questionnaire	NN	O
was	VBD	O
also	RB	O
used	VBN	O
to	TO	O
measure	VB	O
eight	CD	O
symptoms	NNS	O
at	IN	O
baseline	NN	O
and	CC	O
during	IN	O
each	DT	O
course	NN	O
(	(	O
pain	NN	O
,	,	O
anorexia	NN	O
,	,	O
diarrhoea	NN	O
,	,	O
fatigue	NN	O
,	,	O
nausea	NN	O
and	CC	O
vomiting	NN	O
,	,	O
dyspnea	NN	O
,	,	O
constipation	NN	O
and	CC	O
insomnia	NN	O
)	)	O
.	.	O

RESULTS	VB	O
A	DT	O
total	NN	O
of	IN	O
226	CD	O
patients	NNS	O
were	VBD	O
evaluable	JJ	O
for	IN	O
response	NN	O
.	.	O

Demographic	JJ	O
characteristics	NNS	O
were	VBD	O
similar	JJ	O
in	IN	O
both	DT	O
treatment	NN	O
groups	NNS	O
,	,	O
as	IN	O
were	VBD	O
results	NNS	O
of	IN	O
the	DT	O
EORTC	NNP	O
QOL-30	NNP	O
questionnaire	NN	O
.	.	O

For	IN	O
the	DT	O
topotecan	JJ	O
group	NN	O
,	,	O
median	JJ	O
time	NN	O
to	TO	O
progression	NN	O
was	VBD	O
18.9	CD	O
weeks	NNS	O
(	(	O
range	NN	O
<	RB	O
1	CD	O
to	TO	O
92.6+	CD	O
weeks	NNS	O
;	:	O
25	CD	O
%	NN	O
censored	VBN	O
)	)	O
,	,	O
and	CC	O
,	,	O
for	IN	O
paclitaxel	NN	O
,	,	O
14.7	CD	O
weeks	NNS	O
(	(	O
range	NN	O
<	RB	O
1	CD	O
to	TO	O
137.3+	CD	O
weeks	NNS	O
;	:	O
12.3	CD	O
%	NN	O
censored	VBN	O
)	)	O
;	:	O
P	NNP	O
=	VBD	O
0.076	CD	O
.	.	O

At	IN	O
4	CD	O
years	NNS	O
post-randomisation	NN	O
,	,	O
median	JJ	O
survival	NN	O
in	IN	O
the	DT	O
topotecan	JJ	O
group	NN	O
was	VBD	O
63.0	CD	O
weeks	NNS	O
(	(	O
range	NN	O
<	RB	O
1	CD	O
to	TO	O
238.4+	CD	O
weeks	NNS	O
;	:	O
20.5	CD	O
%	NN	O
censored	VBN	O
)	)	O
and	CC	O
,	,	O
for	IN	O
paclitaxel	NN	O
,	,	O
53.0	CD	O
weeks	NNS	O
(	(	O
range	NN	O
<	RB	O
1	CD	O
to	TO	O
226.3+	CD	O
weeks	NNS	O
;	:	O
12.3	CD	O
%	NN	O
censored	VBN	O
)	)	O
;	:	O
P	NNP	O
=	VBD	O
0.44	CD	O
.	.	O

CONCLUSION	NNP	O
Topotecan	NNP	O
continues	VBZ	O
to	TO	O
demonstrate	VB	O
comparable	JJ	O
efficacy	NN	O
and	CC	O
survival	NN	O
to	TO	O
paclitaxel	VB	O
with	IN	O
manageable	JJ	O
and	CC	O
non-cumulative	JJ	O
haematological	JJ	O
toxicity	NN	O
.	.	O

Non-haematological	JJ	O
toxicity	NN	O
was	VBD	O
generally	RB	O
mild	VBN	O
for	IN	O
both	DT	O
groups	NNS	O
.	.	O

The	DT	O
long-term	JJ	O
survival	NN	O
rate	NN	O
indicates	VBZ	O
substantial	JJ	O
therapeutic	JJ	O
benefit	NN	O
for	IN	O
this	DT	O
group	NN	O
of	IN	O
patients	NNS	O
receiving	VBG	O
topotecan	JJ	O
at	IN	O
relapse	NN	O
of	IN	O
ovarian	JJ	O
cancer	NN	O
.	.	O

The	DT	O
efficacy	NN	O
of	IN	O
audiotapes	NNS	O
in	IN	O
promoting	VBG	O
psychological	JJ	O
well-being	NN	O
in	IN	O
cancer	NN	O
patients	NNS	O
:	:	O
a	DT	O
randomised	JJ	O
,	,	O
controlled	JJ	O
trial	NN	O
.	.	O

Open	VB	O
or	CC	O
uncontrolled	JJ	O
studies	NNS	O
have	VBP	O
suggested	VBN	O
that	IN	O
providing	VBG	O
cancer	NN	O
patients	NNS	O
with	IN	O
audiotapes	NNS	O
of	IN	O
their	PRP$	O
clinical	JJ	O
interviews	NNS	O
can	MD	O
improve	VB	O
information	NN	O
recall	NN	O
and	CC	O
reduce	VB	O
psychological	JJ	O
distress	NN	O
.	.	O

We	PRP	O
tested	VBD	O
these	DT	O
hypotheses	NNS	O
in	IN	O
a	DT	O
'clinician-blind	JJ	O
'	''	O
,	,	O
prospective	JJ	O
,	,	O
randomised	VBD	O
controlled	VBN	O
trial	NN	O
.	.	O

A	DT	O
total	NN	O
of	IN	O
117	CD	O
patients	NNS	O
newly	RB	O
referred	VBN	O
to	TO	O
a	DT	O
medical	JJ	O
oncology	NN	O
clinic	NN	O
who	WP	O
were	VBD	O
to	TO	O
be	VB	O
given	VBN	O
'bad	CD	O
news	NN	O
'	POS	O
had	VBD	O
their	PRP$	O
consultations	NNS	O
audiotaped	VBN	O
.	.	O

Blind	NNP	O
to	TO	O
the	DT	O
clinician	JJ	O
,	,	O
patients	NNS	O
were	VBD	O
randomly	RB	O
allocated	VBN	O
to	TO	O
receive	VB	O
a	DT	O
copy	NN	O
of	IN	O
the	DT	O
tape	NN	O
to	TO	O
play	VB	O
at	IN	O
home	NN	O
or	CC	O
not	RB	O
(	(	O
control	VB	O
group	NN	O
)	)	O
.	.	O

At	IN	O
6	CD	O
months	NNS	O
follow-up	JJ	O
,	,	O
tape	NN	O
group	NN	O
patients	NNS	O
reported	VBD	O
positive	JJ	O
attitudes	NNS	O
to	TO	O
the	DT	O
audiotape	NN	O
and	CC	O
were	VBD	O
shown	VBN	O
to	TO	O
recall	VB	O
significantly	RB	O
more	JJR	O
information	NN	O
about	IN	O
their	PRP$	O
illness	NN	O
than	IN	O
did	VBD	O
controls	NNS	O
.	.	O

Overall	JJ	O
improvement	NN	O
in	IN	O
psychological	JJ	O
distress	NN	O
at	IN	O
1	CD	O
and	CC	O
6	CD	O
months	NNS	O
follow-up	RB	O
,	,	O
as	IN	O
measured	VBN	O
with	IN	O
the	DT	O
30-item	JJ	O
General	NNP	O
Health	NNP	O
Questionnaire	NNP	O
and	CC	O
the	DT	O
Hospital	NNP	O
Anxiety	NNP	O
and	CC	O
Depression	NNP	O
Scale	NNP	O
was	VBD	O
no	DT	O
different	JJ	O
in	IN	O
the	DT	O
two	CD	O
groups	NNS	O
.	.	O

However	RB	O
,	,	O
a	DT	O
second-order	JJ	O
interaction	NN	O
suggested	VBD	O
that	IN	O
poor-prognosis	NN	O
patients	NNS	O
were	VBD	O
disadvantaged	VBN	O
specifically	RB	O
by	IN	O
access	NN	O
to	TO	O
the	DT	O
audiotape	NN	O
,	,	O
with	IN	O
less	JJR	O
improvement	NN	O
in	IN	O
psychological	JJ	O
distress	NN	O
at	IN	O
6	CD	O
months	NNS	O
follow-up	JJ	O
than	IN	O
non-tape	JJ	O
controls	NNS	O
.	.	O

Patient	JJ	O
access	NN	O
to	TO	O
audiotapes	NNS	O
of	IN	O
clinical	JJ	O
interviews	NNS	O
promotes	VBZ	O
factual	JJ	O
retention	NN	O
but	CC	O
does	VBZ	O
not	RB	O
reliably	RB	O
reduce	VB	O
psychological	JJ	O
distress	NN	O
and	CC	O
may	MD	O
be	VB	O
actively	RB	O
unhelpful	JJ	O
in	IN	O
some	DT	O
subgroups	NNS	O
of	IN	O
patients	NNS	O
.	.	O

A	DT	O
randomised	JJ	O
comparison	NN	O
of	IN	O
three	CD	O
drainage	NN	O
systems	NNS	O
following	VBG	O
cholecystectomy	NN	O
.	.	O

The	DT	O
efficacy	NN	O
of	IN	O
low	JJ	O
pressure	NN	O
,	,	O
high	JJ	O
pressure	NN	O
and	CC	O
passive	JJ	O
drainage	NN	O
systems	NNS	O
have	VBP	O
been	VBN	O
compared	VBN	O
after	IN	O
cholecystectomy	NN	O
.	.	O

Symptoms	NNS	O
of	IN	O
pain	NN	O
,	,	O
discomfort	NN	O
and	CC	O
nausea	NN	O
were	VBD	O
compared	VBN	O
using	VBG	O
linear	JJ	O
analogue	NN	O
scales	NNS	O
and	CC	O
spirometry	NN	O
was	VBD	O
used	VBN	O
to	TO	O
examine	VB	O
pre-operative	JJ	O
and	CC	O
postoperative	JJ	O
respiratory	NN	O
function	NN	O
.	.	O

The	DT	O
low	JJ	O
pressure	NN	O
suction	NN	O
drain	NN	O
removed	VBD	O
an	DT	O
intraperitoneal	NN	O
marker	NN	O
,	,	O
gentamicin	NN	O
,	,	O
more	RBR	O
effectively	RB	O
than	IN	O
the	DT	O
high	JJ	O
pressure	NN	O
suction	NN	O
drain	NN	O
,	,	O
but	CC	O
not	RB	O
more	RBR	O
effectively	RB	O
than	IN	O
the	DT	O
passive	JJ	O
drain	NN	O
.	.	O

There	EX	O
were	VBD	O
no	DT	O
differences	NNS	O
in	IN	O
postoperative	JJ	O
respiratory	NN	O
function	NN	O
nor	CC	O
in	IN	O
the	DT	O
amount	NN	O
of	IN	O
pain	NN	O
or	CC	O
discomfort	NN	O
between	IN	O
the	DT	O
groups	NNS	O
.	.	O

The	DT	O
passive	JJ	O
drain	NN	O
group	NN	O
reported	VBD	O
less	JJR	O
nausea	NN	O
than	IN	O
the	DT	O
suction	NN	O
drain	NN	O
groups	NNS	O
.	.	O

If	IN	O
a	DT	O
negative	JJ	O
pressure	NN	O
drainage	NN	O
system	NN	O
is	VBZ	O
to	TO	O
be	VB	O
used	VBN	O
,	,	O
a	DT	O
low	JJ	O
pressure	NN	O
suction	NN	O
drain	NN	O
should	MD	O
be	VB	O
used	VBN	O
in	IN	O
preference	NN	O
to	TO	O
a	DT	O
high	JJ	O
pressure	NN	O
system	NN	O
.	.	O

The	DT	O
cost-effectiveness	NN	O
of	IN	O
parasitologic	JJ	O
diagnosis	NN	O
for	IN	O
malaria-suspected	JJ	O
patients	NNS	O
in	IN	O
an	DT	O
era	NN	O
of	IN	O
combination	NN	O
therapy	NN	O
.	.	O

The	DT	O
introduction	NN	O
of	IN	O
artemisinin-based	JJ	O
combination	NN	O
therapy	NN	O
in	IN	O
sub-Saharan	NN	O
Africa	NNP	O
has	VBZ	O
prompted	VBN	O
calls	NNS	O
for	IN	O
increased	VBN	O
use	NN	O
of	IN	O
parasitologic	JJ	O
diagnosis	NN	O
for	IN	O
malaria	NN	O
.	.	O

We	PRP	O
evaluated	VBD	O
the	DT	O
cost-effectiveness	NN	O
of	IN	O
rapid	JJ	O
diagnostic	JJ	O
tests	NNS	O
(	(	O
RDTs	NNP	O
)	)	O
in	IN	O
comparison	NN	O
to	TO	O
microscopy	VB	O
in	IN	O
guiding	VBG	O
treatment	NN	O
of	IN	O
non-severe	JJ	O
febrile	JJ	O
illness	NN	O
at	IN	O
varying	VBG	O
levels	NNS	O
of	IN	O
malaria	NN	O
endemicity	NN	O
using	VBG	O
data	NNS	O
on	IN	O
test	NN	O
accuracy	NN	O
and	CC	O
costs	NNS	O
collected	VBN	O
as	IN	O
part	NN	O
of	IN	O
a	DT	O
Tanzanian	JJ	O
trial	NN	O
.	.	O

If	IN	O
prescribers	NNS	O
complied	VBD	O
with	IN	O
current	JJ	O
guidelines	NNS	O
,	,	O
microscopy	NN	O
would	MD	O
give	VB	O
rise	NN	O
to	TO	O
lower	JJR	O
average	NN	O
costs	NNS	O
per	IN	O
patient	NN	O
correctly	RB	O
treated	VBD	O
than	IN	O
RDTs	NNP	O
in	IN	O
areas	NNS	O
of	IN	O
both	DT	O
high	JJ	O
and	CC	O
low	JJ	O
transmission	NN	O
.	.	O

RDT	NNP	O
introduction	NN	O
would	MD	O
result	VB	O
in	IN	O
an	DT	O
additional	JJ	O
2.3	CD	O
%	NN	O
and	CC	O
9.4	CD	O
%	NN	O
of	IN	O
patients	NNS	O
correctly	RB	O
treated	VBN	O
,	,	O
at	IN	O
an	DT	O
incremental	JJ	O
cost	NN	O
of	IN	O
$	$	O
25	CD	O
and	CC	O
$	$	O
7	CD	O
in	IN	O
the	DT	O
low	JJ	O
and	CC	O
high	JJ	O
transmission	NN	O
settings	NNS	O
,	,	O
respectively	RB	O
.	.	O

Cost-effectiveness	NNP	O
would	MD	O
be	VB	O
worse	JJR	O
if	IN	O
prescribers	NNS	O
do	VBP	O
not	RB	O
comply	VB	O
with	IN	O
test	NN	O
results	NNS	O
.	.	O

The	DT	O
cost	NN	O
of	IN	O
this	DT	O
additional	JJ	O
benefit	NN	O
may	MD	O
be	VB	O
higher	JJR	O
than	IN	O
many	JJ	O
countries	NNS	O
can	MD	O
afford	VB	O
without	IN	O
external	JJ	O
assistance	NN	O
or	CC	O
lower	JJR	O
RDT	NNP	O
prices	NNS	O
.	.	O

Effects	NNS	O
of	IN	O
hydraulic	JJ	O
circuit	NN	O
training	NN	O
on	IN	O
cardiovascular	JJ	C
function	NN	C
.	.	O

The	DT	O
effect	NN	O
of	IN	O
hydraulic	JJ	O
circuit	NN	O
training	NN	O
(	(	O
HCT	NNP	O
)	)	O
on	IN	O
cardiovascular	NN	O
(	(	O
CV	NNP	O
)	)	O
function	NN	O
was	VBD	O
assessed	VBN	O
in	IN	O
32	CD	SS
healthy	JJ	O
middle-aged	JJ	O
males	NNS	SE
(	(	O
X	JJ	O
age	NN	O
=	VBD	O
42.2	CD	A
+/-	JJ	A
2.1	CD	A
yr	NN	A
)	)	O
.	.	O

Maximal	NNP	O
aerobic	JJ	O
power	NN	O
(	(	O
VO2max	NNP	O
)	)	O
,	,	O
with	IN	O
simultaneous	JJ	O
measurement	NN	O
of	IN	O
stroke	NN	O
volume	NN	O
(	(	O
SV	NNP	O
)	)	O
and	CC	O
cardiac	JJ	O
output	NN	O
(	(	O
CO	NNP	O
)	)	O
,	,	O
by	IN	O
impedance	NN	O
cardiography	NN	O
,	,	O
was	VBD	O
assessed	VBN	O
pre-	JJ	O
and	CC	O
post-training	JJ	O
.	.	O

Subjects	NNS	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
a	DT	O
nonexercising	JJ	O
control	NN	O
group	NN	O
,	,	O
a	DT	O
cycle	NN	O
training	NN	O
group	NN	O
(	(	O
cycle	NN	O
)	)	O
,	,	O
or	CC	O
one	CD	O
of	IN	O
the	DT	O
two	CD	O
HCT	NNP	O
groups	NNS	O
.	.	O

Training	VBG	O
groups	NNS	O
participated	VBN	O
in	IN	O
a	DT	O
9	CD	O
wk	NN	O
program	NN	O
,	,	O
3	CD	O
d.wk-1	NN	O
.	.	O

Subjects	NNS	O
assigned	VBD	O
to	TO	O
HCT	NNP	O
exercised	VBN	O
on	IN	O
a	DT	O
9	CD	O
station	NN	O
circuit	NN	O
,	,	O
completing	VBG	O
3	CD	O
circuits.d-1	JJ	O
.	.	O

Each	DT	O
circuit	NN	O
consisted	VBD	O
of	IN	O
three	CD	O
20	CD	O
s	JJ	O
work	NN	O
intervals	NNS	O
at	IN	O
each	DT	O
station	NN	O
with	IN	O
a	DT	O
1:1	CD	O
work	NN	O
:	:	O
rest	NN	O
ratio	NN	O
.	.	O

One	CD	O
HCT	NNP	O
group	NN	O
(	(	O
HCTmax	NNP	O
)	)	O
completed	VBD	O
the	DT	O
maximal	JJ	O
repetitions	NNS	O
possible	JJ	O
(	(	O
RM	NNP	O
)	)	O
during	IN	O
each	DT	O
work	NN	O
interval	NN	O
.	.	O

The	DT	O
other	JJ	O
HCT	NNP	O
group	NN	O
(	(	O
HCTsub	NNP	O
)	)	O
exercised	VBD	O
at	IN	O
70-85	CD	O
%	NN	O
of	IN	O
RM	NNP	O
.	.	O

Following	VBG	O
training	NN	O
VO2max	NNP	O
(	(	O
ml.kg-1	JJ	O
min-1	NN	O
)	)	O
was	VBD	O
significantly	RB	O
increased	VBN	O
in	IN	O
all	DT	O
training	NN	O
groups	NNS	O
(	(	O
18.0	CD	O
,	,	O
12.5	CD	O
,	,	O
and	CC	O
11.3	CD	O
%	NN	O
for	IN	O
cycle	NN	O
,	,	O
HCTsub	NNP	O
,	,	O
and	CC	O
HCTmax	NNP	O
groups	NNS	O
,	,	O
respectively	RB	O
;	:	O
P	NNP	O
less	JJR	O
than	IN	O
0.05	CD	O
)	)	O
.	.	O

The	DT	O
increase	NN	O
in	IN	O
VO2max	NNP	O
observed	VBD	O
in	IN	O
the	DT	O
cycle	NN	O
group	NN	O
was	VBD	O
significantly	RB	O
greater	JJR	O
than	IN	O
that	DT	O
recorded	VBN	O
by	IN	O
the	DT	O
two	CD	O
HCT	NNP	O
groups	NNS	O
(	(	O
P	NNP	O
less	JJR	O
than	IN	O
0.05	CD	O
)	)	O
.	.	O

For	IN	O
all	DT	O
three	CD	O
training	VBG	O
groups	NNS	O
,	,	O
the	DT	O
increase	NN	O
in	IN	O
VO2max	NNP	O
was	VBD	O
associated	VBN	O
with	IN	O
increases	NNS	O
in	IN	O
SVmax	NNP	O
and	CC	O
COmax	NNP	O
(	(	O
P	NNP	O
less	JJR	O
than	IN	O
0.05	CD	O
for	IN	O
both	DT	O
)	)	O
.	.	O

These	DT	O
findings	NNS	O
suggest	VBP	O
that	IN	O
both	DT	O
maximal	JJ	O
and	CC	O
submaximal	JJ	O
HCT	NNP	O
programs	NNS	O
can	MD	O
elicit	VB	O
improvements	NNS	O
in	IN	O
cardiovascular	JJ	O
fitness	NN	O
.	.	O

Randomized	VBN	O
,	,	O
controlled	VBD	O
study	NN	O
of	IN	O
various	JJ	O
agents	NNS	O
for	IN	O
endoscopic	NN	O
injection	NN	O
sclerotherapy	NN	O
of	IN	O
bleeding	VBG	O
canine	NN	O
gastric	JJ	O
varices	NNS	O
.	.	O

The	DT	O
purpose	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
compare	VB	O
the	DT	O
relative	JJ	O
efficacy	NN	O
and	CC	O
technical	JJ	O
ease	NN	O
of	IN	O
use	NN	O
of	IN	O
eight	CD	O
different	JJ	O
agents	NNS	O
for	IN	O
endoscopic	JJ	O
hemostasis	NN	O
and	CC	O
obliteration	NN	O
of	IN	O
bleeding	VBG	O
gastric	JJ	O
varices	NNS	O
in	IN	O
a	DT	O
canine	NN	O
model	NN	O
,	,	O
as	IN	O
no	DT	O
comparative	JJ	O
data	NNS	O
are	VBP	O
available	JJ	O
on	IN	O
gastric	JJ	O
variceal	NN	O
sclerotherapy	NN	O
.	.	O

Large	JJ	O
bleeding	VBG	O
gastric	JJ	O
varices	NNS	O
in	IN	O
20	CD	SS
heparinized	JJ	C
dogs	NNS	O
were	VBD	O
randomized	VBN	O
to	TO	O
endoscopic	VB	O
injection	NN	O
treatment	NN	O
with	IN	O
one	CD	O
of	IN	O
the	DT	O
following	JJ	O
agents	NNS	O
:	:	O
cyanoacrylate	NN	O
;	:	O
a	DT	O
1:1:1	CD	O
mixture	NN	O
of	IN	O
sodium	NN	O
tetradecyl	NN	O
sulfate	VBP	O
3	CD	O
%	NN	O
,	,	O
ethanol	RB	O
98	CD	O
%	NN	O
,	,	O
and	CC	O
normal	JJ	O
saline	JJ	O
solution	NN	O
;	:	O
ethanolamine	VB	O
oleate	VBP	O
5	CD	O
%	NN	O
;	:	O
sodium	NN	O
morrhuate	VBP	O
5	CD	O
%	NN	O
;	:	O
sodium	NN	O
tetradecyl	NN	O
sulfate	VBP	O
1.5	CD	O
%	NN	O
;	:	O
polidocanol	CC	O
1	CD	O
%	NN	O
;	:	O
normal	JJ	O
saline	JJ	O
solution	NN	O
with	IN	O
epinephrine	JJ	O
1:10,000	CD	O
;	:	O
or	CC	O
normal	JJ	O
saline	JJ	O
solution	NN	O
(	(	O
control	NN	O
)	)	O
.	.	O

The	DT	O
number	NN	O
and	CC	O
volume	NN	O
of	IN	O
injections	NNS	O
and	CC	O
the	DT	O
time	NN	O
required	VBN	O
to	TO	O
achieve	VB	O
complete	JJ	O
hemostasis	NN	O
were	VBD	O
evaluated	VBN	O
;	:	O
follow-up	JJ	O
endoscopy	NN	O
was	VBD	O
performed	VBN	O
at	IN	O
1	CD	O
month	NN	O
to	TO	O
assess	VB	O
gastric	JJ	O
variceal	NN	O
obliteration	NN	O
.	.	O

Cyanoacrylate	NNP	O
was	VBD	O
the	DT	O
best	JJS	O
agent	NN	O
overall	JJ	O
in	IN	O
terms	NNS	O
of	IN	O
immediate	JJ	O
efficacy	NN	O
,	,	O
low	JJ	O
volume	NN	O
requirement	NN	O
,	,	O
time	NN	O
required	VBN	O
for	IN	O
initial	JJ	O
hemostasis	NN	O
,	,	O
and	CC	O
reduction	NN	O
of	IN	O
gastric	JJ	O
variceal	NN	O
size	NN	O
.	.	O

Cyanoacrylate	NNP	O
,	,	O
tetradecyl	NN	O
sulfate	NN	O
,	,	O
and	CC	O
polidocanol	NN	O
were	VBD	O
the	DT	O
most	RBS	O
effective	JJ	O
agents	NNS	O
for	IN	O
reducing	VBG	O
gastric	JJ	O
variceal	NN	O
size	NN	O
.	.	O

Epinephrine	NNP	O
was	VBD	O
effective	JJ	O
for	IN	O
controlling	VBG	O
induced	JJ	O
or	CC	O
secondary	JJ	O
bleeding	NN	O
caused	VBN	O
by	IN	O
puncture	NN	O
of	IN	O
the	DT	O
gastric	JJ	O
varices	NNS	O
with	IN	O
the	DT	O
sclerotherapy	NN	O
needle	NN	O
during	IN	O
intravariceal	JJ	O
injections	NNS	O
.	.	O

Ongoing	VBG	O
studies	NNS	O
are	VBP	O
evaluating	VBG	O
combinations	NNS	O
of	IN	O
agents	NNS	O
with	IN	O
different	JJ	O
mechanisms	NNS	O
of	IN	O
action	NN	O
,	,	O
such	JJ	O
as	IN	O
epinephrine	NN	O
(	(	O
for	IN	O
vasoconstriction	NN	O
to	TO	O
minimize	VB	O
secondary	JJ	O
bleeding	NN	O
)	)	O
plus	CC	O
alcohol	NN	O
,	,	O
and/or	JJ	O
tetradecyl	NN	O
sulfate	NN	O
(	(	O
for	IN	O
variceal	NN	O
thrombosis	NN	O
and	CC	O
sclerosis	NN	O
)	)	O
.	.	O

(	(	O
ABSTRACT	NNP	O
TRUNCATED	NNP	O
AT	NNP	O
250	CD	O
WORDS	NNP	O
)	)	O
Midazolam	NNP	O
as	IN	O
a	DT	O
main	JJ	O
anesthesia	NN	O
induction	NN	O
agent	NN	O
--	:	O
a	DT	O
comparison	NN	O
with	IN	O
thiopental	JJ	O
and	CC	O
diazepam	NN	O
.	.	O

A	DT	O
clinical	JJ	O
randomized	JJ	O
investigation	NN	O
was	VBD	O
undertaken	VBN	O
to	TO	O
determine	VB	O
the	DT	O
value	NN	O
of	IN	O
midazolam	NN	O
as	IN	O
a	DT	O
narcotic	JJ	O
adjuvant	NN	O
for	IN	O
anesthetic	JJ	O
induction	NN	O
.	.	O

Thirty	NNP	SS
ASA	NNP	C
I-II	NNP	C
adult	NN	O
patients	NNS	O
undergoing	VBG	O
selective	JJ	O
surgery	NN	O
were	VBD	O
allocated	VBN	O
randomly	RB	O
into	IN	O
two	CD	O
groups	NNS	O
to	TO	O
receive	VB	O
one	CD	O
of	IN	O
the	DT	O
following	JJ	O
agents	NNS	O
:	:	O
midazolam	NN	O
0.3	CD	O
mg/kg	NN	O
,	,	O
thiopental	JJ	O
5	CD	O
mg/kg	NN	O
,	,	O
or	CC	O
diazepam	VB	O
0.4	CD	O
mg/kg	NN	O
.	.	O

The	DT	O
induction	NN	O
time	NN	O
as	IN	O
measured	VBN	O
from	IN	O
the	DT	O
onset	NN	O
of	IN	O
injection	NN	O
to	TO	O
loss	NN	O
of	IN	O
the	DT	O
eyelash	NN	O
reflex	NN	O
was	VBD	O
shortest	VBN	O
in	IN	O
the	DT	O
case	NN	O
of	IN	O
thiopental	NN	O
;	:	O
while	IN	O
a	DT	O
lower	JJR	O
frequency	NN	O
of	IN	O
apnea	NN	O
,	,	O
lesser	JJR	O
suppression	NN	O
of	IN	O
circulation	NN	O
,	,	O
and	CC	O
lack	NN	O
of	IN	O
venous	JJ	O
irritation	NN	O
were	VBD	O
points	NNS	O
favoring	VBG	O
midazolam	NN	O
.	.	O

However	RB	O
,	,	O
further	JJ	O
study	NN	O
is	VBZ	O
needed	VBN	O
to	TO	O
clarify	VB	O
the	DT	O
moderate	JJ	O
cardiovascular	JJ	O
response	NN	O
seen	VBN	O
during	IN	O
intubation	NN	O
in	IN	O
some	DT	O
cases	NNS	O
as	RB	O
well	RB	O
as	IN	O
to	TO	O
elucidate	VB	O
any	DT	O
patient	JJ	O
population	NN	O
differences	NNS	O
.	.	O

Sodium	NN	O
bicarbonate	NN	O
,	,	O
N-acetylcysteine	NNP	O
,	,	O
and	CC	O
saline	NN	O
for	IN	O
prevention	NN	O
of	IN	O
radiocontrast-induced	JJ	O
nephropathy	NN	O
.	.	O

A	DT	O
comparison	NN	O
of	IN	O
3	CD	O
regimens	NNS	O
for	IN	O
protecting	VBG	O
contrast-induced	JJ	O
nephropathy	JJ	O
in	IN	O
patients	NNS	O
undergoing	VBG	O
coronary	JJ	O
procedures	NNS	O
.	.	O

A	DT	O
single-center	JJ	O
prospective	NN	O
controlled	VBN	O
trial	NN	O
.	.	O

BACKGROUND	NNP	O
Several	NNP	O
protective	JJ	O
therapies	NNS	O
have	VBP	O
been	VBN	O
developed	VBN	O
to	TO	O
prevent	VB	O
contrast-induced	JJ	O
nephropathy	JJ	O
(	(	O
CIN	NNP	O
)	)	O
.	.	O

We	PRP	O
aimed	VBD	O
to	TO	O
investigate	VB	O
the	DT	O
efficacy	NN	O
of	IN	O
sodium	NN	O
bicarbonate	NN	O
by	IN	O
comparing	VBG	O
2	CD	O
other	JJ	O
regimens	NNS	O
,	,	O
including	VBG	O
combination	NN	O
of	IN	O
N-acetylcysteine	NNP	O
(	(	O
NAC	NNP	O
)	)	O
plus	CC	O
sodium	JJ	O
chloride	NN	O
and	CC	O
sodium	NN	O
chloride	NN	O
alone	RB	O
,	,	O
to	TO	O
prevent	VB	O
CIN	NNP	O
in	IN	O
patients	NNS	C
undergoing	VBG	C
cardiovascular	JJ	C
procedures	NNS	C
.	.	C

METHODS	NNP	O
We	PRP	O
prospectively	RB	O
enrolled	VBD	O
264	CD	O
patients	NNS	O
who	WP	O
were	VBD	O
scheduled	VBN	O
for	IN	O
cardiovascular	JJ	O
procedures	NNS	O
and	CC	O
had	VBD	O
a	DT	O
baseline	JJ	O
creatinine	NN	O
level	NN	O
>	VBD	O
1.2	CD	O
mg/dL	NN	O
.	.	O

The	DT	O
patients	NNS	O
were	VBD	O
assigned	VBN	O
1	CD	O
of	IN	O
3	CD	O
prophylactic	JJ	O
regimens	NNS	O
:	:	O
infusion	NN	O
of	IN	O
sodium	NN	O
bicarbonate	NN	O
,	,	O
sodium	NN	O
chloride	NN	O
,	,	O
sodium	NN	O
chloride	NN	O
plus	CC	O
oral	JJ	O
NAC	NNP	O
(	(	O
600	CD	O
mg	RB	O
bid	NN	O
)	)	O
.	.	O

Contrast-induced	JJ	O
nephropathy	NN	O
was	VBD	O
defined	VBN	O
as	IN	O
an	DT	O
increase	NN	O
in	IN	O
serum	JJ	O
creatinine	NN	O
level	NN	O
>	VBD	O
25	CD	O
%	NN	O
or	CC	O
0.5	CD	O
mg/dL	NNS	O
after	IN	O
48	CD	O
hours	NNS	O
.	.	O

RESULTS	VB	O
There	EX	O
were	VBD	O
no	DT	O
significant	JJ	O
differences	NNS	O
among	IN	O
groups	NNS	O
regarding	VBG	O
baseline	NN	O
demographic	JJ	O
properties	NNS	O
and	CC	O
nephropathy	JJ	O
risk	NN	O
factors	NNS	O
.	.	O

The	DT	O
change	NN	O
in	IN	O
creatinine	JJ	O
clearance	NN	O
was	VBD	O
significantly	RB	O
better	RBR	O
in	IN	O
the	DT	O
sodium	NN	O
bicarbonate	NN	O
group	NN	O
than	IN	O
other	JJ	O
2	CD	O
groups	NNS	O
(	(	O
P	NNP	O
=	NNP	O
.007	NNP	O
)	)	O
.	.	O

The	DT	O
incidence	NN	O
of	IN	O
CIN	NNP	O
was	VBD	O
significantly	RB	O
lower	JJR	O
in	IN	O
the	DT	O
sodium	NN	O
bicarbonate	NN	O
group	NN	O
(	(	O
4.5	CD	O
%	NN	O
)	)	O
compared	VBN	O
with	IN	O
sodium	JJ	O
chloride	NN	O
alone	RB	O
(	(	O
13.6	CD	O
%	NN	O
,	,	O
P	NNP	O
=	NNP	O
.036	NNP	O
)	)	O
and	CC	O
tended	VBD	O
to	TO	O
be	VB	O
lower	JJR	O
than	IN	O
in	IN	O
the	DT	O
combination	NN	O
group	NN	O
(	(	O
12.5	CD	O
%	NN	O
,	,	O
P	NNP	O
=	NNP	O
.059	NNP	O
)	)	O
.	.	O

After	IN	O
adjusting	VBG	O
the	DT	O
Mehran	NNP	O
nephropathy	NN	O
risk	NN	O
score	NN	O
,	,	O
the	DT	O
risk	NN	O
of	IN	O
CIN	NNP	O
significantly	RB	O
reduced	VBD	O
with	IN	O
sodium	NN	O
bicarbonate	NN	O
compared	VBN	O
with	IN	O
sodium	JJ	O
chloride	NN	O
alone	RB	O
(	(	O
adjusted	VBN	O
risk	NN	O
ratio	NN	O
0.29	CD	O
,	,	O
P	NNP	O
=	NNP	O
.043	NNP	O
)	)	O
.	.	O

CONCLUSIONS	NNP	O
Hydration	NNP	O
with	IN	O
sodium	JJ	O
bicarbonate	NN	O
provides	VBZ	O
better	JJR	O
protection	NN	O
against	IN	O
CIN	NNP	O
than	IN	O
the	DT	O
sodium	NN	O
chloride	JJ	O
infusion	NN	O
does	VBZ	O
alone	RB	O
.	.	O

Combination	NNP	O
therapy	NN	O
of	IN	O
NAC	NNP	O
plus	CC	O
sodium	JJ	O
chloride	NN	O
did	VBD	O
not	RB	O
offer	VB	O
additional	JJ	O
benefit	NN	O
over	IN	O
hydration	NN	O
with	IN	O
sodium	JJ	O
chloride	NN	O
alone	RB	O
.	.	O

Histamine	NNP	C
intolerance-like	NN	C
symptoms	NNS	C
in	IN	O
healthy	JJ	C
volunteers	NNS	O
after	IN	O
oral	JJ	O
provocation	NN	O
with	IN	O
liquid	JJ	O
histamine	NN	O
.	.	O

Histamine	NNP	O
in	IN	O
food	NN	O
at	IN	O
non-toxic	JJ	O
doses	NNS	O
has	VBZ	O
been	VBN	O
proposed	VBN	O
to	TO	O
be	VB	O
a	DT	O
major	JJ	O
cause	NN	O
of	IN	O
food	NN	O
intolerance	NN	O
causing	NN	O
symptoms	NNS	O
like	IN	O
diarrhea	NN	O
,	,	O
hypotension	NN	O
,	,	O
headache	NN	O
,	,	O
pruritus	NN	O
and	CC	O
flush	NN	O
(	(	O
histamine	JJ	O
intolerance	NN	O
)	)	O
.	.	O

Histamine-rich	JJ	O
foods	NNS	O
such	JJ	O
as	IN	O
cheese	NN	O
,	,	O
sausages	NNS	O
,	,	O
sauerkraut	NN	O
,	,	O
tuna	NN	O
,	,	O
tomatoes	NNS	O
,	,	O
and	CC	O
alcoholic	JJ	O
beverages	NNS	O
may	MD	O
contain	VB	O
histamine	VB	O
up	IN	O
to	TO	O
500	CD	O
mg/kg	NNS	O
.	.	O

We	PRP	O
conducted	VBD	O
a	DT	O
randomized	VBN	O
,	,	O
double-blind	JJ	O
,	,	O
placebo-controlled	JJ	O
cross-over	NN	O
study	NN	O
in	IN	O
10	CD	SS
healthy	JJ	O
females	NNS	SE
(	(	O
age	NN	O
range	NN	O
22-36	CD	A
years	NNS	A
,	,	O
mean	JJ	O
29.1	CD	O
+/-	JJ	O
5.4	CD	O
)	)	O
who	WP	O
were	VBD	O
hospitalized	VBN	O
and	CC	O
challenged	VBN	O
on	IN	O
two	CD	O
consecutive	JJ	O
days	NNS	O
with	IN	O
placebo	NN	O
(	(	O
peppermint	JJ	O
tea	NN	O
)	)	O
or	CC	O
75	CD	O
mg	NN	O
of	IN	O
pure	JJ	O
histamine	NN	O
(	(	O
equaling	VBG	O
124	CD	O
mg	JJ	O
histamine	NN	O
dihydrochloride	NN	O
,	,	O
dissolved	VBN	O
in	IN	O
peppermint	NN	O
tea	NN	O
)	)	O
.	.	O

Objective	JJ	O
parameters	NNS	O
(	(	O
heart	NN	O
rate	NN	O
,	,	O
blood	NN	O
pressure	NN	O
,	,	O
skin	JJ	O
temperature	NN	O
,	,	O
peak	VB	O
flow	NN	O
)	)	O
as	RB	O
well	RB	O
as	IN	O
a	DT	O
total	JJ	O
clinical	JJ	O
symptom	NN	O
score	NN	O
using	VBG	O
a	DT	O
standardized	VBN	O
protocol	NN	O
were	VBD	O
recorded	VBN	O
at	IN	O
baseline	NN	O
,	,	O
10	CD	O
,	,	O
20	CD	O
,	,	O
40	CD	O
,	,	O
80	CD	O
minutes	NNS	O
,	,	O
and	CC	O
24	CD	O
hours	NNS	O
.	.	O

The	DT	O
subjects	NNS	O
received	VBD	O
a	DT	O
histamine-free	JJ	O
diet	NN	O
also	RB	O
low	JJ	O
in	IN	O
allergen	NN	O
24	CD	O
hours	NNS	O
before	IN	O
hospitalization	NN	O
and	CC	O
over	IN	O
the	DT	O
whole	JJ	O
observation	NN	O
period	NN	O
.	.	O

Blood	NN	O
samples	NNS	O
were	VBD	O
drawn	VBN	O
at	IN	O
baseline	NN	O
,	,	O
10	CD	O
,	,	O
20	CD	O
,	,	O
40	CD	O
,	,	O
and	CC	O
80	CD	O
minutes	NNS	O
,	,	O
and	CC	O
histamine	NN	O
and	CC	O
the	DT	O
histamine-degrading	JJ	O
enzyme	NN	O
diamine	NN	O
oxidase	NN	O
(	(	O
DAO	NNP	O
)	)	O
were	VBD	O
determined	VBN	O
.	.	O

After	IN	O
histamine	JJ	O
challenge	NN	O
,	,	O
5	CD	O
of	IN	O
10	CD	O
subjects	NNS	O
showed	VBD	O
no	DT	O
reaction	NN	O
.	.	O

One	CD	O
individual	NN	O
experienced	VBD	O
tachycardia	NN	O
,	,	O
mild	JJ	O
hypotension	NN	O
after	IN	O
20	CD	O
minutes	NNS	O
,	,	O
sneezing	VBG	O
,	,	O
itching	NN	O
of	IN	O
the	DT	O
nose	NN	O
,	,	O
and	CC	O
rhinorrhea	NN	O
after	IN	O
60	CD	O
minutes	NNS	O
.	.	O

Four	CD	O
subjects	NNS	O
experienced	VBD	O
delayed	JJ	O
symptoms	NNS	O
like	IN	O
diarrhea	NN	O
(	(	O
4x	CD	O
)	)	O
,	,	O
flatulence	NN	O
(	(	O
3x	CD	O
)	)	O
,	,	O
headache	NN	O
(	(	O
3x	CD	O
)	)	O
,	,	O
pruritus	NN	O
(	(	O
2x	CD	O
)	)	O
and	CC	O
ocular	JJ	O
symptoms	NNS	O
(	(	O
1x	CD	O
)	)	O
starting	VBG	O
3	CD	O
to	TO	O
24	CD	O
hours	NNS	O
after	IN	O
provocation	NN	O
.	.	O

No	DT	O
subject	NN	O
reacted	VBD	O
to	TO	O
placebo	VB	O
.	.	O

No	DT	O
changes	NNS	O
were	VBD	O
observed	VBN	O
in	IN	O
histamine	NN	O
and	CC	O
DAO	NNP	O
levels	NNS	O
within	IN	O
the	DT	O
first	JJ	O
80	CD	O
minutes	NNS	O
in	IN	O
non-reactors	NNS	O
as	RB	O
well	RB	O
as	IN	O
reactors	NNS	O
.	.	O

There	EX	O
was	VBD	O
no	DT	O
difference	NN	O
in	IN	O
challenge	NN	O
with	IN	O
histamine	JJ	O
versus	NN	O
challenge	NN	O
with	IN	O
placebo	NN	O
.	.	O

We	PRP	O
conclude	VBP	O
that	IN	O
75	CD	O
mg	NN	O
of	IN	O
pure	NN	O
liquid	JJ	O
oral	JJ	O
histamine	NN	O
--	:	O
a	DT	O
dose	JJ	O
found	VBN	O
in	IN	O
normal	JJ	O
meals	NNS	O
--	:	O
can	MD	O
provoke	VB	O
immediate	JJ	O
as	RB	O
well	RB	O
as	IN	O
delayed	VBN	O
symptoms	NNS	O
in	IN	O
50	CD	O
%	NN	O
of	IN	O
healthy	JJ	O
females	NNS	SE
without	IN	O
a	DT	O
history	NN	O
of	IN	O
food	NN	O
intolerance	NN	O
.	.	O

The	DT	O
NORwegian	JJ	O
study	NN	O
on	IN	O
DIstrict	NNP	O
treatment	NN	O
of	IN	O
ST-elevation	NNP	O
myocardial	JJ	O
infarction	NN	O
(	(	O
NORDISTEMI	NNP	O
)	)	O
.	.	O

OBJECTIVES	NNP	O
Thrombolysis	NNP	O
is	VBZ	O
the	DT	O
treatment	NN	O
of	IN	O
choice	NN	O
for	IN	O
patients	NNS	O
with	IN	O
ST-elevation	NNP	O
myocardial	JJ	O
infarction	NN	O
(	(	O
STEMI	NNP	O
)	)	O
living	NN	O
in	IN	O
rural	JJ	O
areas	NNS	O
with	IN	O
long	JJ	O
transfer	NN	O
delays	NNS	O
to	TO	O
percutaneous	JJ	O
coronary	JJ	O
intervention	NN	O
(	(	O
PCI	NNP	O
)	)	O
.	.	O

This	DT	O
trial	NN	O
compares	VBZ	O
two	CD	O
different	JJ	O
strategies	NNS	O
following	VBG	O
thrombolysis	NN	O
:	:	O
to	TO	O
transfer	VB	O
all	DT	O
patients	NNS	O
for	IN	O
immediate	JJ	O
coronary	JJ	O
angiography	NN	O
and	CC	O
intervention	NN	O
,	,	O
or	CC	O
to	TO	O
manage	VB	O
the	DT	O
patients	NNS	O
more	RBR	O
conservatively	RB	O
.	.	O

DESIGN	VB	O
The	DT	O
NORwegian	JJ	O
study	NN	O
on	IN	O
DIstrict	NNP	O
treatment	NN	O
of	IN	O
STEMI	NNP	O
(	(	O
NORDISTEMI	NNP	O
)	)	O
is	VBZ	O
an	DT	O
open	JJ	O
,	,	O
prospective	JJ	O
,	,	O
randomized	VBD	O
controlled	VBN	O
trial	NN	O
in	IN	O
patients	NNS	O
with	IN	O
STEMI	NNP	O
of	IN	O
less	JJR	O
than	IN	O
6	CD	O
hours	NNS	O
of	IN	O
duration	NN	O
and	CC	O
more	JJR	O
than	IN	O
90	CD	O
minutes	NNS	O
expected	VBD	O
time	NN	O
delay	NN	O
to	TO	O
PCI	NNP	O
.	.	O

A	NNP	O
total	NN	O
of	IN	O
266	CD	O
patients	NNS	O
will	MD	O
receive	VB	O
full-dose	JJ	O
thrombolysis	NN	O
,	,	O
preferably	RB	O
pre-hospital	JJ	O
,	,	O
and	CC	O
then	RB	O
be	VB	O
randomized	VBN	O
to	TO	O
either	DT	O
strategy	NN	O
.	.	O

Our	PRP$	O
primary	JJ	O
endpoint	NN	O
is	VBZ	O
the	DT	O
one	CD	O
year	NN	O
combined	VBN	O
incidence	NN	O
of	IN	O
death	NN	O
,	,	O
reinfarction	NN	O
,	,	O
stroke	VBD	O
or	CC	O
new	JJ	O
myocardial	JJ	O
ischaemia	NN	O
.	.	O

The	DT	O
study	NN	O
is	VBZ	O
registered	VBN	O
with	IN	O
ClinicalTrials.gov	NNP	O
,	,	O
number	NN	O
NCT00161005	NNP	O
.	.	O

RESULTS	VBN	O
By	IN	O
April	NNP	O
2006	CD	O
,	,	O
109	CD	O
patients	NNS	O
have	VBP	O
been	VBN	O
randomized	VBN	O
.	.	O

Thrombolysis	NN	O
has	VBZ	O
been	VBN	O
given	VBN	O
pre-hospital	JJ	O
to	TO	O
52	CD	O
%	NN	O
of	IN	O
patients	NNS	O
.	.	O

The	DT	O
median	JJ	O
transport	NN	O
distance	NN	O
from	IN	O
first	JJ	O
medical	JJ	O
contact	NN	O
to	TO	O
catheterization	NN	O
laboratory	NN	O
was	VBD	O
155	CD	O
km	NN	O
(	(	O
range	JJ	O
90-396	CD	O
km	NN	O
)	)	O
.	.	O

Results	NNS	O
of	IN	O
the	DT	O
study	NN	O
are	VBP	O
expected	VBN	O
in	IN	O
2008	CD	O
.	.	O

Bradykinin-induced	JJ	O
cough	NN	O
reflex	NN	O
markedly	RB	O
increases	VBZ	O
in	IN	O
patients	NNS	O
with	IN	O
cough	NN	C
associated	VBN	O
with	IN	O
captopril	NN	O
and	CC	O
enalapril	NN	O
.	.	O

We	PRP	O
studied	VBD	O
the	DT	O
effects	NNS	O
of	IN	O
angiotensin	NN	O
converting	VBG	O
enzyme	NN	O
(	(	O
ACE	NNP	O
)	)	O
inhibitors	NNS	O
on	IN	O
cough	NN	O
responses	NNS	O
to	TO	O
bradykinin	VB	O
(	(	O
BK	NNP	O
)	)	O
,	,	O
substance	NN	O
P	NNP	O
(	(	O
SP	NNP	O
)	)	O
and	CC	O
citric	JJ	O
acid	NN	O
in	IN	O
a	DT	O
double	JJ	O
blind	NN	O
,	,	O
random	NN	O
study	NN	O
on	IN	O
10	CD	SS
hypertensive	JJ	C
patients	NNS	O
receiving	VBG	O
ACE	NNP	O
inhibitors	NNS	O
.	.	O

Of	IN	O
these	DT	O
patients	NNS	O
,	,	O
five	CD	SS
had	VBD	O
reported	VBN	O
cough	NN	C
with	IN	O
ACE	NNP	O
inhibitors	NNS	O
.	.	O

Cough	NNP	O
responses	VBZ	O
to	TO	O
citric	VB	O
acid	NN	O
were	VBD	O
similar	JJ	O
between	IN	O
patients	NNS	O
with	IN	O
and	CC	O
without	IN	O
cough	NN	O
,	,	O
and	CC	O
SP	NNP	O
up	RB	O
to	TO	O
10	CD	O
(	(	O
-5	NN	O
)	)	O
M	NNP	O
did	VBD	O
not	RB	O
cause	VB	O
cough	NN	O
in	IN	O
any	DT	O
of	IN	O
the	DT	O
subjects	NNS	O
.	.	O

BK	NNP	O
caused	VBD	O
cough	NN	O
at	IN	O
13.4	CD	O
+/-	JJ	O
1.2	CD	O
(	(	O
-log	NNP	O
M	NNP	O
)	)	O
in	IN	O
5	CD	SS
patients	NNS	O
with	IN	O
cough	NN	O
associated	VBN	O
with	IN	O
ACE	NNP	O
inhibitors	NNS	O
,	,	O
but	CC	O
it	PRP	O
did	VBD	O
not	RB	O
cause	VB	O
cough	NN	O
at	IN	O
concentrations	NNS	O
up	RB	O
to	TO	O
10	CD	O
(	(	O
-5	NN	O
)	)	O
M	NNP	O
in	IN	O
other	JJ	O
5	CD	SS
patients	NNS	O
.	.	O

One	CD	O
month	NN	O
after	IN	O
the	DT	O
withdrawal	NN	O
of	IN	O
ACE	NNP	O
inhibitors	NNS	O
,	,	O
5	CD	SS
patients	NNS	O
were	VBD	O
free	JJ	O
from	IN	O
cough	NN	O
symptoms	NNS	O
,	,	O
and	CC	O
BK	NNP	O
did	VBD	O
not	RB	O
cause	VB	O
cough	NN	O
up	RB	O
to	TO	O
10	CD	O
(	(	O
-5	NN	O
)	)	O
M	NNP	O
in	IN	O
these	DT	O
patients	NNS	O
,	,	O
except	IN	O
for	IN	O
one	CD	O
who	WP	O
coughed	VBD	O
at	IN	O
10	CD	O
(	(	O
-9	NN	O
)	)	O
M	NNP	O
,	,	O
without	IN	O
changes	NNS	O
in	IN	O
responses	NNS	O
to	TO	O
citric	VB	O
acid	NN	O
.	.	O

BK	NNP	O
caused	VBD	O
cough	NN	O
at	IN	O
14.3	CD	O
+/-	JJ	O
0.7	CD	O
(	(	O
-log	NNP	O
M	NNP	O
)	)	O
although	IN	O
BK1-7	NNP	O
,	,	O
a	DT	O
major	JJ	O
metabolite	NN	O
of	IN	O
BK	NNP	O
by	IN	O
ACE	NNP	O
,	,	O
caused	VBD	O
cough	NN	O
at	IN	O
5.7	CD	O
+/-	JJ	O
0.7	CD	O
(	(	O
-log	NNP	O
M	NNP	O
)	)	O
in	IN	O
another	DT	O
3	CD	O
patients	NNS	O
with	IN	O
cough	NN	O
associated	VBN	O
with	IN	O
ACE	NNP	O
inhibitor	NN	O
.	.	O

These	DT	O
results	NNS	O
suggest	VBP	O
that	IN	O
impaired	JJ	O
metabolism	NN	O
of	IN	O
BK	NNP	O
induced	VBN	O
by	IN	O
ACE	NNP	O
inhibitors	NNS	O
may	MD	O
relate	VB	O
to	TO	O
the	DT	O
manifestation	NN	O
of	IN	O
cough	NN	O
in	IN	O
hypertensive	JJ	O
patients	NNS	O
receiving	VBG	O
ACE	NNP	O
inhibitors	NNS	O
.	.	O

Open	JJ	C
flap	NN	C
debridement	NN	C
with	IN	O
or	CC	O
without	IN	O
intentional	JJ	O
cementum	NN	O
removal	NN	O
:	:	O
a	DT	O
4-month	JJ	O
follow-up	NN	O
.	.	O

OBJECTIVES	IN	O
The	DT	O
aim	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
investigate	VB	O
the	DT	O
influence	NN	O
of	IN	O
cementum	NN	O
removal	NN	O
on	IN	O
periodontal	JJ	O
repair	NN	O
.	.	O

MATERIAL	NNP	O
AND	NNP	O
METHODS	NNP	O
Forty	NNP	SS
subjects	NNS	O
with	IN	O
chronic	JJ	C
periodontitis	NN	C
and	CC	O
presenting	NN	C
,	,	C
at	IN	C
least	JJS	C
,	,	C
two	CD	C
proximal	JJ	C
sites	NNS	C
in	IN	C
anterior	JJ	C
teeth	NNS	C
(	(	C
upper	JJ	C
or	CC	C
lower	JJR	C
)	)	C
with	IN	C
probing	VBG	C
depth	JJ	C
>	NN	C
or	CC	C
=5	JJ	C
mm	NNS	C
were	VBD	O
selected	VBN	O
.	.	O

After	IN	O
oral	JJ	O
hygiene	NN	O
instructions	NNS	O
and	CC	O
ultrasonic	JJ	O
supragingival	NN	O
instrumentation	NN	O
,	,	O
the	DT	O
subjects	NNS	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
for	IN	O
one	CD	O
of	IN	O
the	DT	O
following	JJ	O
groups	NNS	O
:	:	O
CIC	NNP	O
,	,	O
scaled	VBD	O
with	IN	O
Gracey	NNP	O
curettes	NNS	O
;	:	O
CIUS	NNP	O
,	,	O
scaled	VBD	O
with	IN	O
ultrasonic	JJ	O
device	NN	O
;	:	O
CDC	NNP	O
,	,	O
calculus	JJ	O
deattachment	NN	O
with	IN	O
Gracey	NNP	O
curettes	NNS	O
and	CC	O
brushing	VBG	O
with	IN	O
saline	JJ	O
solution	NN	O
;	:	O
and	CC	O
CDUS	NNP	O
,	,	O
calculus	JJ	O
deattachment	NN	O
with	IN	O
ultrasonic	JJ	O
device	NN	O
and	CC	O
brushing	VBG	O
with	IN	O
saline	JJ	O
solution	NN	O
.	.	O

Full-thickness	JJ	O
flaps	NNS	O
were	VBD	O
reflected	VBN	O
and	CC	O
the	DT	O
instrumentation	NN	O
was	VBD	O
performed	VBN	O
with	IN	O
a	DT	O
clinical	JJ	O
microscope	NN	O
.	.	O

Probing	VBG	O
depth	NN	O
(	(	O
PD	NNP	O
)	)	O
,	,	O
relative	JJ	O
gingival	NN	O
margin	NN	O
level	NN	O
(	(	O
RGML	NNP	O
)	)	O
and	CC	O
relative	JJ	O
attachment	NN	O
level	NN	O
(	(	O
RAL	NNP	O
)	)	O
were	VBD	O
registered	VBN	O
at	IN	O
five	CD	O
experimental	JJ	O
periods	NNS	O
:	:	O
baseline	NN	O
and	CC	O
30	CD	O
,	,	O
60	CD	O
,	,	O
90	CD	O
and	CC	O
120	CD	O
days	NNS	O
postoperative	JJ	O
.	.	O

RESULTS	VB	O
All	PDT	O
the	DT	O
approaches	NNS	O
were	VBD	O
able	JJ	O
to	TO	O
markedly	RB	O
reduce	VB	O
the	DT	O
PD	NNP	O
values	NNS	O
from	IN	O
the	DT	O
baseline	NN	O
to	TO	O
the	DT	O
other	JJ	O
evaluation	NN	O
periods	NNS	O
(	(	O
p	JJ	O
<	NNP	O
0.0001	CD	O
)	)	O
.	.	O

The	DT	O
increase	NN	O
in	IN	O
RGML	NNP	O
values	NNS	O
was	VBD	O
statistically	RB	O
significant	JJ	O
only	RB	O
for	IN	O
the	DT	O
CDUS	NNP	O
group	NN	O
.	.	O

There	EX	O
were	VBD	O
no	DT	O
statistically	RB	O
significant	JJ	O
differences	NNS	O
between	IN	O
the	DT	O
baseline	NN	O
and	CC	O
postoperative	JJ	O
values	NNS	O
in	IN	O
all	DT	O
groups	NNS	O
for	IN	O
the	DT	O
RAL	NNP	O
changes	NNS	O
.	.	O

The	DT	O
changes	NNS	O
in	IN	O
RAL	NNP	O
were	VBD	O
statistically	RB	O
significant	JJ	O
only	RB	O
among	IN	O
the	DT	O
groups	NNS	O
CDC	NNP	O
and	CC	O
CDUS	NNP	O
(	(	O
p	JJ	O
<	NNP	O
0.0001	CD	O
)	)	O
.	.	O

CONCLUSION	VB	O
The	DT	O
conventional	JJ	O
scaling	NN	O
and	CC	O
root	NN	O
planing	NN	O
and	CC	O
the	DT	O
calculus	JJ	O
deattachment	NN	O
were	VBD	O
effective	JJ	O
in	IN	O
reducing	VBG	O
the	DT	O
probing	VBG	O
depth	NN	O
values	NNS	O
,	,	O
regardless	RB	O
of	IN	O
the	DT	O
instrumentation	NN	O
method	NN	O
.	.	O

Impacts	NNS	O
of	IN	O
a	DT	O
disease	JJ	O
management	NN	O
program	NN	O
for	IN	O
dually	RB	O
eligible	JJ	O
beneficiaries	NNS	O
.	.	O

The	DT	O
LifeMasters	NNPS	O
Supported	NNP	O
SelfCare	NNP	O
demonstration	NN	O
program	NN	O
provides	VBZ	O
disease	JJ	O
management	NN	O
(	(	O
DM	NNP	O
)	)	O
services	NNS	O
to	TO	O
Florida	NNP	O
Medicare	NNP	O
beneficiaries	NNS	O
who	WP	O
are	VBP	O
also	RB	O
enrolled	VBN	O
in	IN	O
Medicaid	NNP	O
and	CC	O
have	VBP	O
congestive	JJ	O
heart	NN	O
failure	NN	O
(	(	O
CHF	NNP	O
)	)	O
,	,	O
diabetes	VBZ	O
,	,	O
or	CC	O
coronary	JJ	O
artery	NN	O
disease	NN	O
(	(	O
CAD	NNP	O
)	)	O
.	.	O

The	DT	O
population-based	JJ	O
program	NN	O
provides	VBZ	O
primarily	RB	O
telephonic	JJ	O
patient	JJ	O
education	NN	O
and	CC	O
monitoring	NN	O
services	NNS	O
.	.	O

Findings	NNS	O
from	IN	O
the	DT	O
randomized	VBN	O
,	,	O
intent-to-treat	JJ	O
design	NN	O
over	IN	O
the	DT	O
first	JJ	O
18	CD	O
months	NNS	O
of	IN	O
operations	NNS	O
show	VBP	O
virtually	RB	O
no	DT	O
overall	JJ	O
impacts	NNS	O
on	IN	O
hospital	NN	O
or	CC	O
emergency	NN	O
room	NN	O
(	(	O
ER	NNP	O
)	)	O
use	NN	O
,	,	O
Medicare	NNP	O
expenditures	VBZ	O
,	,	O
quality	NN	O
of	IN	O
care	NN	O
,	,	O
or	CC	O
prescription	NN	O
drug	NN	O
use	NN	O
for	IN	O
the	DT	O
33,000	CD	O
enrollees	NNS	O
.	.	O

However	RB	O
,	,	O
for	IN	O
beneficiaries	NNS	O
with	IN	O
CHF	NNP	O
who	WP	O
resided	VBD	O
in	IN	O
high-cost	NN	O
South	NNP	O
Florida	NNP	O
counties	NNS	O
,	,	O
the	DT	O
program	NN	O
reduced	VBN	O
Medicare	NNP	O
expenditures	NNS	O
by	IN	O
9.6	CD	O
percent	NN	O
.	.	O

Improved	VBN	O
intraoperative	JJ	O
management	NN	O
of	IN	O
anastomotic	JJ	C
bleeding	NN	C
during	IN	O
aortic	JJ	O
reconstruction	NN	O
:	:	O
results	NNS	O
of	IN	O
a	DT	O
randomized	VBN	O
controlled	VBN	O
trial	NN	O
.	.	O

In	IN	O
a	DT	O
randomized	NN	O
controlled	VBN	O
trial	NN	O
,	,	O
the	DT	O
effectiveness	NN	O
of	IN	O
a	DT	O
polymeric	JJ	O
surgical	JJ	O
sealant	NN	O
(	(	O
CoSeal	NNP	O
)	)	O
was	VBD	O
compared	VBN	O
to	TO	O
Gelfoam/thrombin	NNP	O
for	IN	O
managing	VBG	O
anastomotic	JJ	C
bleeding	NN	C
after	IN	O
implantation	NN	O
of	IN	O
Dacron	NNP	O
grafts	NNS	O
during	IN	O
aortic	JJ	O
reconstruction	NN	O
for	IN	O
nonruptured	JJ	C
aneurysms	NNS	C
.	.	O

Each	DT	O
treatment	NN	O
was	VBD	O
directly	RB	O
applied	VBN	O
to	TO	O
the	DT	O
suture	NN	O
line	NN	O
after	IN	O
confirmation	NN	O
of	IN	O
anastomotic	JJ	O
bleeding	NN	O
.	.	O

The	DT	O
proportion	NN	O
of	IN	O
suture	NN	O
line	NN	O
sites	VBZ	O
that	IN	O
achieved	VBD	O
immediate	JJ	O
sealing	NN	O
and	CC	O
the	DT	O
proportion	NN	O
sealed	VBD	O
within	IN	O
5	CD	O
minutes	NNS	O
were	VBD	O
determined	VBN	O
among	IN	O
37	CD	SS
experimental	JJ	O
(	(	O
59	CD	O
sites	NNS	O
)	)	O
and	CC	O
17	CD	SS
control	NN	O
subjects	NNS	O
(	(	O
27	CD	O
sites	NNS	O
)	)	O
.	.	O

A	DT	O
significantly	RB	O
greater	JJR	O
proportion	NN	O
of	IN	O
bleeding	VBG	O
suture	NN	O
line	NN	O
sites	NNS	O
treated	VBD	O
with	IN	O
the	DT	O
polymeric	JJ	O
sealant	NN	O
achieved	VBN	O
immediate	JJ	O
sealing	NN	O
following	VBG	O
reestablishment	NN	O
of	IN	O
blood	NN	O
flow	NN	O
compared	VBN	O
with	IN	O
control-treated	JJ	O
sites	NNS	O
[	VBP	O
48	CD	O
of	IN	O
59	CD	O
(	(	O
81	CD	O
%	NN	O
)	)	O
vs	VBZ	O
10	CD	O
of	IN	O
27	CD	O
(	(	O
37	CD	O
%	NN	O
)	)	O
;	:	O
P	NNP	O
=	VBD	O
0.002	CD	O
]	NN	O
.	.	O

The	DT	O
difference	NN	O
between	IN	O
treatment	NN	O
groups	NNS	O
was	VBD	O
maintained	VBN	O
after	IN	O
5	CD	O
minutes	NNS	O
with	IN	O
approximately	RB	O
85	CD	O
per	IN	O
cent	NN	O
(	(	O
50	CD	O
of	IN	O
59	CD	O
)	)	O
of	IN	O
CoSeal	NNP	O
sites	NNS	O
compared	VBN	O
to	TO	O
just	RB	O
over	IN	O
one-half	JJ	O
(	(	O
14	CD	O
of	IN	O
27	CD	O
)	)	O
of	IN	O
control	NN	O
sites	VBZ	O
demonstrating	VBG	O
ultimate	JJ	O
sealing	NN	O
(	(	O
P	NNP	O
=	NNP	O
0.01	CD	O
)	)	O
.	.	O

There	EX	O
were	VBD	O
no	DT	O
adverse	JJ	O
events	NNS	O
related	VBN	O
to	TO	O
the	DT	O
use	NN	O
of	IN	O
the	DT	O
polymeric	JJ	O
sealant	NN	O
in	IN	O
this	DT	O
study	NN	O
.	.	O

These	DT	O
results	NNS	O
support	VBP	O
the	DT	O
use	NN	O
of	IN	O
this	DT	O
novel	JJ	O
sealant	NN	O
for	IN	O
the	DT	O
intraoperative	JJ	O
management	NN	O
of	IN	O
anastomotic	JJ	C
bleeding	NN	C
during	IN	O
aortic	JJ	O
reconstruction	NN	O
procedures	NNS	O
.	.	O

Exposure	NN	O
to	TO	O
the	DT	O
self-face	NN	O
facilitates	VBZ	O
identification	NN	O
of	IN	O
dynamic	JJ	O
facial	JJ	O
expressions	NNS	O
:	:	O
influences	NNS	O
on	IN	O
individual	JJ	O
differences	NNS	O
.	.	O

A	DT	O
growing	VBG	O
literature	NN	O
suggests	VBZ	O
that	IN	O
the	DT	O
self-face	NN	O
is	VBZ	O
involved	VBN	O
in	IN	O
processing	VBG	O
the	DT	O
facial	JJ	O
expressions	NNS	O
of	IN	O
others	NNS	O
.	.	O

The	DT	O
authors	NNS	O
experimentally	RB	O
activated	VBD	O
self-face	JJ	O
representations	NNS	O
to	TO	O
assess	VB	O
its	PRP$	O
effects	NNS	O
on	IN	O
the	DT	O
recognition	NN	O
of	IN	O
dynamically	RB	O
emerging	VBG	O
facial	JJ	O
expressions	NNS	O
of	IN	O
others	NNS	O
.	.	O

They	PRP	O
exposed	VBD	O
participants	NNS	O
to	TO	O
videos	NNS	O
of	IN	O
either	DT	O
their	PRP$	O
own	JJ	O
faces	VBZ	O
(	(	O
self-face	JJ	O
prime	NN	O
)	)	O
or	CC	O
faces	VBZ	O
of	IN	O
others	NNS	O
(	(	O
nonself-face	JJ	O
prime	NN	O
)	)	O
prior	RB	O
to	TO	O
a	DT	O
facial	JJ	O
expression	NN	O
judgment	NN	O
task	NN	O
.	.	O

Their	PRP$	O
results	NNS	O
show	VBP	O
that	IN	O
experimentally	RB	O
activating	VBG	O
self-face	JJ	O
representations	NNS	O
results	NNS	O
in	IN	O
earlier	JJR	O
recognition	NN	O
of	IN	O
dynamically	RB	O
emerging	VBG	O
facial	JJ	O
expression	NN	O
.	.	O

As	IN	O
a	DT	O
group	NN	O
,	,	O
participants	NNS	O
in	IN	O
the	DT	O
self-face	JJ	O
prime	JJ	O
condition	NN	O
recognized	VBD	O
expressions	NNS	O
earlier	RBR	O
(	(	O
when	WRB	O
less	RBR	O
affective	JJ	O
perceptual	JJ	O
information	NN	O
was	VBD	O
available	JJ	O
)	)	O
compared	VBN	O
to	TO	O
participants	NNS	O
in	IN	O
the	DT	O
nonself-face	JJ	O
prime	JJ	O
condition	NN	O
.	.	O

There	EX	O
were	VBD	O
individual	JJ	O
differences	NNS	O
in	IN	O
performance	NN	O
,	,	O
such	JJ	O
that	IN	O
poorer	JJR	O
expression	NN	O
identification	NN	O
was	VBD	O
associated	VBN	O
with	IN	O
higher	JJR	O
autism	NN	C
traits	NNS	O
(	(	O
in	IN	O
this	DT	O
neurocognitively	RB	C
healthy	JJ	C
sample	NN	C
)	)	O
.	.	O

However	RB	O
,	,	O
when	WRB	O
randomized	VBN	O
into	IN	O
the	DT	O
self-face	JJ	O
prime	JJ	O
condition	NN	O
,	,	O
participants	NNS	O
with	IN	O
high	JJ	C
autism	NN	C
traits	NNS	C
performed	VBN	O
as	RB	O
well	RB	O
as	IN	O
those	DT	O
with	IN	O
low	JJ	C
autism	NN	C
traits	NNS	C
.	.	O

Taken	VB	O
together	RB	O
,	,	O
these	DT	O
data	NNS	O
suggest	VBP	O
that	IN	O
the	DT	O
ability	NN	O
to	TO	O
recognize	VB	O
facial	JJ	O
expressions	NNS	O
in	IN	O
others	NNS	O
is	VBZ	O
linked	VBN	O
with	IN	O
the	DT	O
internal	JJ	O
representations	NNS	O
of	IN	O
our	PRP$	O
own	JJ	O
faces	VBZ	O
.	.	O

Successful	JJ	O
treatment	NN	O
of	IN	O
blepharitis	NN	C
with	IN	O
bibrocathol	NN	O
(	(	O
Posiformin?	NNP	O
2	CD	O
%	NN	O
)	)	O
.	.	O

BACKGROUND	NNP	O
Bibrocathol	NNP	O
is	VBZ	O
a	DT	O
well-established	JJ	O
antiseptic	JJ	O
drug	NN	O
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
acute	NN	O
eyelid	JJ	O
diseases	NNS	O
like	IN	O
blepharitis	NN	O
.	.	O

Despite	IN	O
its	PRP$	O
frequent	JJ	O
use	NN	O
in	IN	O
clinical	JJ	O
practice	NN	O
,	,	O
no	DT	O
controlled	JJ	O
clinical	JJ	O
trial	NN	O
on	IN	O
the	DT	O
efficacy	NN	O
of	IN	O
bibrocathol	$	O
2	CD	O
%	NN	O
eye	NN	O
ointment	NN	O
has	VBZ	O
been	VBN	O
performed	VBN	O
until	IN	O
now	RB	O
.	.	O

The	DT	O
aim	NN	O
of	IN	O
the	DT	O
study	NN	O
was	VBD	O
to	TO	O
investigate	VB	O
efficacy	NN	O
,	,	O
safety	NN	O
and	CC	O
tolerability	NN	O
of	IN	O
bibrocathol	NN	O
(	(	O
Posiformin?	NNP	O
2	CD	O
%	NN	O
)	)	O
eye	NN	O
ointment	NN	O
in	IN	O
patients	NNS	O
diagnosed	VBN	O
with	IN	O
blepharitis	NN	O
.	.	O

METHODS	NNP	O
In	IN	O
this	DT	O
multi-center	NN	O
,	,	O
randomized	VBN	O
,	,	O
double-masked	JJ	O
,	,	O
placebo-controlled	JJ	O
parallel-group	NN	O
comparison	NN	O
,	,	O
the	DT	O
change	NN	O
of	IN	O
signs	NNS	O
and	CC	O
symptoms	NNS	O
(	(	O
sum	VB	O
score	NN	O
)	)	O
of	IN	O
blepharitis	NN	O
in	IN	O
197	CD	O
patients	NNS	O
(	(	O
ITT	NNP	O
(	(	O
intention-to-treat-group	JJ	O
)	)	O
;	:	O
mean	JJ	O
age	NN	O
56	CD	O
?	.	O
18	CD	O
years	NNS	O
,	,	O
56	CD	O
%	NN	O
female	NN	O
,	,	O
active	JJ	O
drug	NN	O
:	:	O
vehicle	NN	O
=	IN	O
97:100	CD	O
)	)	O
over	IN	O
2	CD	O
weeks	NNS	O
treatment	NN	O
with	IN	O
bibrocathol	JJ	O
2	CD	O
%	NN	O
eye	NN	O
ointment	NN	O
was	VBD	O
evaluated	VBN	O
.	.	O

RESULTS	JJ	O
Patients	NNPS	O
receiving	VBG	O
bibrocathol	RB	O
2	CD	O
%	NN	O
showed	VBD	O
greater	JJR	O
improvement	NN	O
in	IN	O
the	DT	O
sum	NN	O
score	NN	O
than	IN	O
the	DT	O
placebo	NN	O
patients	NNS	O
(	(	O
p	JJ	O
<	NN	O
0.0001	CD	O
,	,	O
Cohen	NNP	O
's	POS	O
effect	NN	O
size	NN	O
d	NN	O
=	NNP	O
0.73	CD	O
)	)	O
.	.	O

Also	RB	O
,	,	O
the	DT	O
results	NNS	O
from	IN	O
further	JJ	O
efficacy	NN	O
assessments	NNS	O
improvement	NN	O
of	IN	O
single	JJ	O
symptoms	NNS	O
and	CC	O
ocular	JJ	O
discomfort	NN	O
measured	VBN	O
by	IN	O
a	DT	O
VAS	NNP	O
(	(	O
visual	JJ	O
analogue	NN	O
scale	NN	O
)	)	O
supported	VBD	O
treatment	NN	O
with	IN	O
bibrocathol	NN	O
.	.	O

Patients	NNS	O
and	CC	O
investigators	NNS	O
provided	VBD	O
favorable	JJ	O
tolerability	NN	O
ratings	NNS	O
preferring	VBG	O
bibrocathol	NN	O
over	IN	O
placebo	NN	O
.	.	O

No	DT	O
safety	NN	O
issues	NNS	O
were	VBD	O
observed	VBN	O
with	IN	O
regard	NN	O
to	TO	O
intraocular	JJ	O
pressure	NN	O
,	,	O
visual	JJ	O
acuity	NN	O
,	,	O
or	CC	O
occurrence	NN	O
of	IN	O
adverse	JJ	O
events	NNS	O
.	.	O

CONCLUSIONS	NNP	O
Blepharitis	NNP	O
therapy	NN	O
with	IN	O
the	DT	O
antiseptic	JJ	O
bibrocathol	NN	O
2	CD	O
%	NN	O
in	IN	O
this	DT	O
trial	NN	O
was	VBD	O
highly	RB	O
efficacious	JJ	O
and	CC	O
safe	JJ	O
.	.	O

Long-term	JJ	O
anticoagulant	NN	O
treatment	NN	O
after	IN	O
acute	JJ	O
myocardial	JJ	O
infarction	NN	O
.	.	O

The	DT	O
Warfarin	NNP	O
Re-Infarction	NNP	O
Study	NNP	O
.	.	O

High	NNP	O
levels	NNS	O
of	IN	O
fibrinogen	NN	O
and	CC	O
clotting	VBG	O
factor	NN	O
VII	NNP	O
are	VBP	O
associated	VBN	O
with	IN	O
an	DT	O
increased	VBN	O
risk	NN	O
for	IN	O
subsequent	JJ	O
death	NN	O
and	CC	O
cardiovascular	JJ	O
disease	NN	O
in	IN	O
apparently	RB	O
healthy	JJ	O
individuals	NNS	O
.	.	O

Furthermore	RB	O
,	,	O
pathoanatomic	JJ	O
studies	NNS	O
and	CC	O
coronary	JJ	O
angiography	NN	O
have	VBP	O
confirmed	VBN	O
a	DT	O
relationship	NN	O
between	IN	O
coronary	JJ	O
thrombus	NN	O
formation	NN	O
and	CC	O
acute	JJ	O
Q-wave	NNP	O
infarction	NN	O
.	.	O

Effective	JJ	O
antithrombotic	JJ	O
agents	NNS	O
may	MD	O
prevent	VB	O
or	CC	O
limit	VB	O
thrombus	JJ	O
formation	NN	O
and	CC	O
events	NNS	O
related	VBN	O
to	TO	O
thrombosis	NN	O
.	.	O

The	DT	O
Warfarin	NNP	O
Re-Infarction	NNP	O
Study	NNP	O
(	(	O
WARIS	NNP	O
)	)	O
studied	VBD	O
the	DT	O
effect	NN	O
of	IN	O
warfarin	NN	O
in	IN	O
survivors	NNS	O
of	IN	O
acute	JJ	O
myocardial	JJ	O
infarction	NN	O
.	.	O

Patients	NNS	O
aged	VBD	O
75	CD	O
years	NNS	O
or	CC	O
less	JJR	O
were	VBD	O
randomized	VBN	O
in	IN	O
a	DT	O
double-blind	JJ	O
,	,	O
placebo-controlled	JJ	O
study	NN	O
to	TO	O
test	VB	O
whether	IN	O
long-term	JJ	O
treatment	NN	O
with	IN	O
warfarin	JJ	O
reduces	NNS	O
the	DT	O
risk	NN	O
of	IN	O
death	NN	O
,	,	O
reinfarction	NN	O
,	,	O
and	CC	O
thromboembolic	JJ	O
morbidity	NN	O
.	.	O

A	DT	O
total	NN	O
of	IN	O
1918	CD	SS
patients	NNS	O
were	VBD	O
screened	VBN	O
for	IN	O
participation	NN	O
;	:	O
1214	CD	SS
were	VBD	O
recruited	VBN	O
.	.	O

The	DT	O
mean	JJ	O
follow-up	NN	O
was	VBD	O
37	CD	O
months	NNS	O
.	.	O

Analyzed	VBN	O
on	IN	O
an	DT	O
intention-to-treat	JJ	O
basis	NN	O
,	,	O
123	CD	O
(	(	O
20	CD	O
%	NN	O
)	)	O
in	IN	O
the	DT	O
placebo	NN	O
group	NN	O
died	VBD	O
,	,	O
versus	FW	O
94	CD	O
(	(	O
15	CD	O
%	NN	O
)	)	O
in	IN	O
the	DT	O
warfarin	NN	O
group	NN	O
,	,	O
a	DT	O
risk	NN	O
reduction	NN	O
of	IN	O
24	CD	O
%	NN	O
(	(	O
P	NNP	O
=	NNP	O
0.026	CD	O
)	)	O
.	.	O

Considering	VBG	O
patients	NNS	O
on	IN	O
treatment	NN	O
or	CC	O
within	IN	O
28	CD	O
days	NNS	O
after	IN	O
discontinuing	VBG	O
the	DT	O
test	NN	O
medication	NN	O
,	,	O
92	CD	O
in	IN	O
the	DT	O
placebo	NN	O
group	NN	O
died	VBD	O
,	,	O
as	IN	O
compared	VBN	O
with	IN	O
60	CD	O
of	IN	O
the	DT	O
warfarin-treated	JJ	O
patients	NNS	O
,	,	O
a	DT	O
risk	NN	O
reduction	NN	O
of	IN	O
35	CD	O
%	NN	O
(	(	O
P	NNP	O
=	NNP	O
0.005	CD	O
)	)	O
.	.	O

Relapsing	VBG	O
myocardial	JJ	O
infarction	NN	O
(	(	O
fatal	JJ	O
and	CC	O
nonfatal	JJ	O
)	)	O
was	VBD	O
reduced	VBN	O
by	IN	O
43	CD	O
%	NN	O
(	(	O
P	NNP	O
=	NNP	O
0.0001	CD	O
)	)	O
.	.	O

The	DT	O
incidence	NN	O
of	IN	O
cerebrovascular	JJ	O
attacks	NNS	O
was	VBD	O
lower	RBR	O
in	IN	O
the	DT	O
warfarin	NN	O
group	NN	O
(	(	O
16	CD	O
patients	NNS	O
)	)	O
than	IN	O
the	DT	O
placebo	NN	O
group	NN	O
(	(	O
41	CD	O
patients	NNS	O
)	)	O
,	,	O
a	DT	O
highly	RB	O
significant	JJ	O
reduction	NN	O
of	IN	O
61	CD	O
%	NN	O
(	(	O
P	NNP	O
=	NNP	O
0.0003	CD	O
)	)	O
.	.	O

Serious	JJ	O
bleeding	NN	O
occurred	VBD	O
in	IN	O
11	CD	O
patients	NNS	O
taking	VBG	O
warfarin	NN	O
,	,	O
an	DT	O
incidence	NN	O
of	IN	O
0.6	CD	O
%	NN	O
per	IN	O
year	NN	O
.	.	O

In	IN	O
conclusion	NN	O
,	,	O
long-term	JJ	O
anticoagulant	JJ	O
therapy	NN	O
may	MD	O
be	VB	O
recommended	VBN	O
after	IN	O
acute	JJ	O
myocardial	JJ	O
infarction	NN	O
.	.	O

Acute	NNP	O
cardiac	JJ	O
effects	NNS	O
of	IN	O
nicotine	NN	O
in	IN	O
healthy	JJ	O
young	JJ	O
adults	NNS	O
.	.	O

BACKGROUND	NNP	O
Nicotine	NNP	O
is	VBZ	O
known	VBN	O
to	TO	O
have	VB	O
many	JJ	O
physiologic	JJ	O
effects	NNS	O
.	.	O

The	DT	O
influence	NN	O
of	IN	O
nicotine	NN	O
delivered	VBN	O
in	IN	O
chewing	VBG	O
gum	NN	O
upon	IN	O
cardiac	JJ	O
hemodynamics	NNS	O
and	CC	O
conduction	NN	O
has	VBZ	O
not	RB	O
been	VBN	O
well-characterized	JJ	O
.	.	O

METHODS	NNP	O
We	PRP	O
studied	VBD	O
the	DT	O
effects	NNS	O
of	IN	O
nicotine	NN	O
in	IN	O
nonsmoking	VBG	O
adults	NNS	O
(	(	O
6	CD	O
male	NN	O
,	,	O
5	CD	O
female	NN	O
;	:	O
ages	VBZ	O
23-36	CD	O
years	NNS	O
)	)	O
using	VBG	O
a	DT	O
double-blind	NN	O
,	,	O
randomized	VBN	O
,	,	O
cross-over	JJ	O
study	NN	O
.	.	O

Subjects	NNS	O
chewed	VBD	O
nicotine	JJ	O
gum	NN	O
(	(	O
4	CD	O
mg	NN	O
)	)	O
or	CC	O
placebo	NN	O
.	.	O

After	IN	O
20	CD	O
minutes	NNS	O
(	(	O
approximate	JJ	O
time	NN	O
to	TO	O
peak	VB	O
nicotine	JJ	O
levels	NNS	O
)	)	O
,	,	O
echocardiograms	JJ	O
and	CC	O
signal-averaged	JJ	O
electrocardiograms	NNS	O
(	(	O
SAECG	NNP	O
)	)	O
were	VBD	O
obtained	VBN	O
.	.	O

After	IN	O
40	CD	O
minutes	NNS	O
,	,	O
subjects	NNS	O
were	VBD	O
again	RB	O
given	VBN	O
nicotine	JJ	O
gum	NN	O
or	CC	O
placebo	NN	O
in	IN	O
cross-over	JJ	O
fashion	NN	O
.	.	O

Standard	NNP	O
echocardiographic	JJ	O
measurements	NNS	O
were	VBD	O
made	VBN	O
from	IN	O
two-dimensional	JJ	O
images	NNS	O
.	.	O

We	PRP	O
then	RB	O
calculated	VBD	O
end-systolic	JJ	O
wall	NN	O
stress	NN	O
(	(	O
ESWS	NNP	O
)	)	O
,	,	O
shortening	VBG	O
fraction	NN	O
(	(	O
SF	NNP	O
)	)	O
,	,	O
systemic	JJ	O
vascular	NN	O
resistance	NN	O
(	(	O
SVR	NNP	O
)	)	O
,	,	O
velocity	NN	O
for	IN	O
circumferential	JJ	O
fiber	NN	O
shortening	NN	O
corrected	VBN	O
for	IN	O
heart	NN	O
rate	NN	O
(	(	O
Vcfc	NNP	O
)	)	O
,	,	O
stroke	VBD	O
volume	NN	O
,	,	O
and	CC	O
cardiac	JJ	O
output	NN	O
.	.	O

P	NNP	O
wave	NN	O
and	CC	O
QRS	NNP	O
duration	NN	O
were	VBD	O
measured	VBN	O
from	IN	O
SAECG	NNP	O
.	.	O

RESULTS	NNP	O
Significant	JJ	O
differences	NNS	O
(	(	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
from	IN	O
control	NN	O
or	CC	O
placebo	NN	O
were	VBD	O
found	VBN	O
for	IN	O
ESWS	NNP	O
,	,	O
mean	JJ	O
blood	NN	O
pressure	NN	O
,	,	O
cardiac	JJ	O
output	NN	O
,	,	O
SVR	NNP	O
,	,	O
heart	NN	O
rate	NN	O
,	,	O
and	CC	O
P	NNP	O
wave	VBP	O
duration	NN	O
.	.	O

No	DT	O
significant	JJ	O
changes	NNS	O
were	VBD	O
seen	VBN	O
in	IN	O
left	JJ	O
ventricular	JJ	O
ejection	NN	O
time	NN	O
(	(	O
LVET	NNP	O
)	)	O
,	,	O
LV	NNP	O
dimensions	NNS	O
,	,	O
SF	NNP	O
,	,	O
contractility	NN	O
(	(	O
Vcfc	NNP	O
)	)	O
,	,	O
or	CC	O
QRS	NNP	O
duration	NN	O
.	.	O

CONCLUSIONS	NNP	O
These	DT	O
results	NNS	O
suggest	VBP	O
that	IN	O
nicotine	JJ	O
chewing	VBG	O
gum	NN	O
increases	NNS	O
afterload	NN	O
and	CC	O
cardiac	JJ	O
output	NN	O
.	.	O

Cardiac	JJ	O
contractility	NN	O
does	VBZ	O
not	RB	O
change	VB	O
acutely	RB	O
in	IN	O
response	NN	O
to	TO	O
nicotine	VB	O
gum	NN	O
.	.	O

Heart	NNP	O
rate	NN	O
and	CC	O
P	NNP	O
wave	VBP	O
duration	NN	O
are	VBP	O
increased	VBN	O
by	IN	O
chewing	VBG	O
nicotine	JJ	O
gum	NN	O
.	.	O

Combined	VBN	O
use	NN	O
of	IN	O
vasopressin	NN	O
and	CC	O
synthetic	JJ	O
hypothalamic	JJ	O
releasing	NN	O
factors	NNS	O
as	IN	O
a	DT	O
new	JJ	O
test	NN	O
of	IN	O
anterior	JJ	O
pituitary	JJ	O
function	NN	O
.	.	O

Nine	NNP	O
normal	JJ	O
volunteers	NNS	O
and	CC	O
15	CD	O
patients	NNS	O
with	IN	O
pituitary	JJ	O
disorders	NNS	O
were	VBD	O
given	VBN	O
a	DT	O
combined	JJ	O
test	NN	O
of	IN	O
anterior	JJ	O
pituitary	JJ	O
function	NN	O
using	VBG	O
four	CD	O
hypothalamic	JJ	O
releasing	VBG	O
factors	NNS	O
and	CC	O
arginine	JJ	O
vasopressin	NN	O
.	.	O

Rapid	JJ	O
sequential	JJ	O
intravenous	JJ	O
infusions	NNS	O
of	IN	O
human	JJ	O
corticotrophin	NN	O
releasing	VBG	O
factor	NN	O
100	CD	O
micrograms	NNS	O
,	,	O
growth	NN	O
hormone	NN	O
releasing	VBG	O
factor	NN	O
100	CD	O
micrograms	NNS	O
,	,	O
luteinising	VBG	O
hormone	NN	O
releasing	VBG	O
hormone	NN	O
100	CD	O
micrograms	NNS	O
,	,	O
and	CC	O
thyrotrophin	IN	O
releasing	VBG	O
hormone	NN	O
200	CD	O
micrograms	NNS	O
were	VBD	O
administered	VBN	O
.	.	O

Arginine	NNP	O
vasopressin	NN	O
(	(	O
10	CD	O
pressor	NN	O
units	NNS	O
)	)	O
was	VBD	O
given	VBN	O
intramuscularly	RB	O
at	IN	O
the	DT	O
same	JJ	O
time	NN	O
.	.	O

Plasma	NNP	O
or	CC	O
serum	NN	O
samples	NNS	O
were	VBD	O
assayed	VBN	O
for	IN	O
concentrations	NNS	O
of	IN	O
cortisol	NN	O
,	,	O
growth	NN	O
hormone	NN	O
,	,	O
luteinising	VBG	O
hormone	NN	O
,	,	O
follicle	NN	O
stimulating	VBG	O
hormone	NN	O
,	,	O
prolactin	NN	O
,	,	O
and	CC	O
thyroid	JJ	O
stimulating	VBG	O
hormone	NN	O
at	IN	O
multiple	JJ	O
times	NNS	O
for	IN	O
120	CD	O
minutes	NNS	O
.	.	O

No	DT	O
troublesome	JJ	O
side	NN	O
effects	NNS	O
occurred	VBD	O
.	.	O

The	DT	O
results	NNS	O
of	IN	O
the	DT	O
releasing	VBG	O
factor	NN	O
combined	VBD	O
test	NN	O
with	IN	O
arginine	JJ	O
vasopressin	NN	O
were	VBD	O
compared	VBN	O
in	IN	O
the	DT	O
same	JJ	O
subjects	NNS	O
with	IN	O
a	DT	O
conventional	JJ	O
combined	JJ	O
test	NN	O
using	VBG	O
insulin	NN	O
together	RB	O
with	IN	O
thyrotrophin	JJ	O
releasing	VBG	O
hormone	NN	O
and	CC	O
luteinising	VBG	O
hormone	NN	O
releasing	VBG	O
hormone	NN	O
.	.	O

No	DT	O
difference	NN	O
was	VBD	O
observed	VBN	O
in	IN	O
the	DT	O
basal	NN	O
and	CC	O
peak	JJ	O
concentrations	NNS	O
of	IN	O
luteinising	VBG	O
hormone	NN	O
,	,	O
follicle	NN	O
stimulating	VBG	O
hormone	NN	O
,	,	O
thyroid	JJ	O
stimulating	VBG	O
hormone	NN	O
,	,	O
and	CC	O
prolactin	NN	O
.	.	O

Both	DT	O
cortisol	NN	O
and	CC	O
growth	NN	O
hormone	NN	O
responses	VBZ	O
to	TO	O
the	DT	O
releasing	VBG	O
factors	NNS	O
with	IN	O
arginine	JJ	O
vasopressin	NN	O
were	VBD	O
much	RB	O
greater	JJR	O
than	IN	O
those	DT	O
seen	VBN	O
with	IN	O
insulin	NN	O
induced	VBN	O
hypoglycaemia	NN	O
or	CC	O
the	DT	O
combined	JJ	O
releasing	NN	O
factors	NNS	O
without	IN	O
arginine	JJ	O
vasopressin	NN	O
.	.	O

Patients	NNS	O
with	IN	O
pituitary	JJ	O
hypo-function	NN	O
were	VBD	O
similarly	RB	O
recognised	VBN	O
in	IN	O
both	DT	O
studies	NNS	O
.	.	O

There	EX	O
was	VBD	O
a	DT	O
rapid	JJ	O
increase	NN	O
in	IN	O
all	DT	O
hormone	NN	O
values	NNS	O
with	IN	O
a	DT	O
peak	NN	O
usually	RB	O
by	IN	O
60	CD	O
minutes	NNS	O
.	.	O

In	IN	O
most	JJS	O
people	NNS	O
adequate	VBP	O
assessment	NN	O
of	IN	O
individual	JJ	O
hormone	NN	O
reserves	NNS	O
may	MD	O
be	VB	O
achieved	VBN	O
using	VBG	O
basal	NN	O
,	,	O
30	CD	O
minute	NN	O
,	,	O
and	CC	O
60	CD	O
minute	NN	O
samples	NNS	O
.	.	O

This	DT	O
new	JJ	O
combined	JJ	O
releasing	NN	O
factor	NN	O
test	NN	O
appears	VBZ	O
to	TO	O
be	VB	O
a	DT	O
safe	JJ	O
,	,	O
rapid	JJ	O
,	,	O
and	CC	O
useful	JJ	O
test	NN	O
of	IN	O
anterior	JJ	O
pituitary	JJ	O
function	NN	O
.	.	O

A	DT	O
randomized	JJ	O
,	,	O
double-blind	JJ	O
,	,	O
vehicle-controlled	JJ	O
study	NN	O
to	TO	O
assess	VB	O
5	CD	O
%	NN	O
imiquimod	JJ	O
cream	NN	O
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
multiple	JJ	C
actinic	JJ	C
keratoses	NNS	C
.	.	O

BACKGROUND	NNP	O
Actinic	NNP	O
keratoses	NNS	O
(	(	O
AKs	NNP	O
)	)	O
are	VBP	O
precancerous	JJ	O
epidermal	JJ	O
lesions	NNS	O
found	VBD	O
most	JJS	O
frequently	RB	O
on	IN	O
areas	NNS	O
of	IN	O
the	DT	O
skin	NN	O
exposed	VBD	O
to	TO	O
the	DT	O
sun	NN	O
.	.	O

Several	JJ	O
case	NN	O
studies	NNS	O
published	VBN	O
recently	RB	O
have	VBP	O
indicated	VBN	O
that	IN	O
5	CD	O
%	NN	O
imiquimod	JJ	O
cream	NN	O
,	,	O
currently	RB	O
licensed	VBN	O
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
genital	JJ	O
warts	NNS	O
,	,	O
may	MD	O
be	VB	O
an	DT	O
effective	JJ	O
treatment	NN	O
for	IN	O
AK	NNP	O
.	.	O

OBJECTIVE	NNP	O
To	TO	O
assess	VB	O
the	DT	O
efficacy	NN	O
and	CC	O
safety	NN	O
of	IN	O
imiquimod	NN	O
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
AK	NNP	O
.	.	O

DESIGN	NNP	O
Patients	NNPS	O
in	IN	O
this	DT	O
randomized	JJ	O
,	,	O
double-blind	JJ	O
,	,	O
vehicle-controlled	JJ	O
study	NN	O
applied	VBD	O
5	CD	O
%	NN	O
imiquimod	JJ	O
cream	NN	O
or	CC	O
vehicle	NN	O
to	TO	O
AK	NNP	O
lesions	NNS	O
3	CD	O
times	NNS	O
per	IN	O
week	NN	O
for	IN	O
a	DT	O
maximum	NN	O
of	IN	O
12	CD	O
weeks	NNS	O
or	CC	O
until	IN	O
lesions	NNS	O
had	VBD	O
resolved	VBN	O
.	.	O

In	IN	O
the	DT	O
event	NN	O
of	IN	O
an	DT	O
adverse	JJ	O
reaction	NN	O
,	,	O
application	NN	O
of	IN	O
imiquimod	NN	O
was	VBD	O
reduced	VBN	O
to	TO	O
1	CD	O
or	CC	O
2	CD	O
times	NNS	O
per	IN	O
week	NN	O
.	.	O

Rest	JJS	O
periods	NNS	O
were	VBD	O
also	RB	O
allowed	VBN	O
if	IN	O
necessary	JJ	O
.	.	O

SETTING	VB	O
A	DT	O
specialized	JJ	O
outpatient	NN	O
dermatology	NN	O
clinic	NN	O
within	IN	O
a	DT	O
state-funded	JJ	O
hospital	NN	O
in	IN	O
Germany	NNP	O
.	.	O

PATIENTS	VB	O
The	DT	O
study	NN	O
population	NN	O
was	VBD	O
aged	VBN	O
45	CD	A
to	TO	A
85	CD	A
years	NNS	O
.	.	O

Of	IN	O
52	CD	SS
patients	NNS	O
screened	VBD	O
,	,	O
36	CD	O
men	NNS	SE
and	CC	SE
women	NNS	SE
with	IN	O
AK	NNP	O
confirmed	VBN	O
by	IN	O
histological	JJ	O
diagnosis	NN	O
were	VBD	O
enrolled	VBN	O
.	.	O

Patients	NNS	O
were	VBD	O
excluded	VBN	O
from	IN	O
the	DT	O
study	NN	O
if	IN	O
they	PRP	O
did	VBD	O
not	RB	O
have	VB	O
a	DT	O
histological	JJ	O
diagnosis	NN	O
for	IN	O
AK	NNP	O
,	,	O
if	IN	O
they	PRP	O
were	VBD	O
older	JJR	O
than	IN	O
85	CD	O
years	NNS	O
,	,	O
or	CC	O
if	IN	O
they	PRP	O
did	VBD	O
not	RB	O
comply	VB	O
with	IN	O
the	DT	O
protocol	NN	O
.	.	O

All	DT	O
patients	NNS	O
had	VBD	O
responded	VBN	O
to	TO	O
a	DT	O
notice	NN	O
asking	VBG	O
for	IN	O
volunteers	NNS	O
.	.	O

MAIN	NNP	O
OUTCOME	NNP	O
MEASURES	NNP	O
The	DT	O
number	NN	O
and	CC	O
appearance	NN	O
of	IN	O
lesions	NNS	O
were	VBD	O
evaluated	VBN	O
before	RB	O
,	,	O
during	IN	O
,	,	O
and	CC	O
after	IN	O
treatment	NN	O
.	.	O

All	DT	O
adverse	JJ	O
effects	NNS	O
were	VBD	O
recorded	VBN	O
.	.	O

RESULTS	NNP	O
Lesions	NNP	O
treated	VBD	O
with	IN	O
5	CD	O
%	NN	O
imiquimod	JJ	O
cream	NN	O
were	VBD	O
clinically	RB	O
cleared	VBN	O
in	IN	O
21	CD	O
(	(	O
84	CD	O
%	NN	O
)	)	O
of	IN	O
25	CD	O
patients	NNS	O
and	CC	O
partially	RB	O
cleared	VBN	O
in	IN	O
2	CD	O
(	(	O
8	CD	O
%	NN	O
)	)	O
.	.	O

Clearance	NN	O
was	VBD	O
histologically	RB	O
confirmed	VBN	O
2	CD	O
weeks	NNS	O
after	IN	O
the	DT	O
last	JJ	O
application	NN	O
of	IN	O
imiquimod	NN	O
in	IN	O
all	DT	O
patients	NNS	O
clinically	RB	O
diagnosed	VBN	O
as	IN	O
lesion	NN	O
free	NN	O
.	.	O

Only	RB	O
10	CD	O
%	NN	O
of	IN	O
patients	NNS	O
treated	VBN	O
with	IN	O
imiquimod	NN	O
were	VBD	O
clinically	RB	O
diagnosed	VBN	O
with	IN	O
recurrence	NN	O
1	CD	O
year	NN	O
after	IN	O
treatment	NN	O
.	.	O

No	DT	O
reduction	NN	O
in	IN	O
the	DT	O
size	NN	O
or	CC	O
number	NN	O
of	IN	O
AK	NNP	O
lesions	NNS	O
was	VBD	O
observed	VBN	O
in	IN	O
vehicle-treated	JJ	O
patients	NNS	O
.	.	O

Adverse	JJ	O
effects	NNS	O
reported	VBN	O
by	IN	O
patients	NNS	O
treated	VBN	O
with	IN	O
imiquimod	NN	O
included	VBD	O
erythema	NN	O
,	,	O
edema	NN	O
,	,	O
induration	NN	O
,	,	O
vesicles	NNS	O
,	,	O
erosion	NN	O
,	,	O
ulceration	NN	O
,	,	O
excoriation	NN	O
,	,	O
and	CC	O
scabbing	VBG	O
.	.	O

However	RB	O
,	,	O
imiquimod	NN	O
was	VBD	O
well	RB	O
tolerated	VBN	O
since	IN	O
all	DT	O
patients	NNS	O
completed	VBD	O
the	DT	O
12-week	JJ	O
treatment	NN	O
.	.	O

Only	RB	O
a	DT	O
few	JJ	O
,	,	O
mild	JJ	O
adverse	JJ	O
reactions	NNS	O
to	TO	O
the	DT	O
vehicle	NN	O
cream	NN	O
were	VBD	O
reported	VBN	O
.	.	O

CONCLUSION	NNP	O
Application	NNP	O
of	IN	O
5	CD	O
%	NN	O
imiquimod	JJ	O
cream	NN	O
for	IN	O
12	CD	O
weeks	NNS	O
is	VBZ	O
an	DT	O
effective	JJ	O
and	CC	O
well-tolerated	JJ	O
treatment	NN	O
for	IN	O
AK	NNP	O
.	.	O

Analysis	NN	O
of	IN	O
face	NN	O
gaze	NN	O
in	IN	O
autism	NN	O
using	VBG	O
Bubbles	NNP	O
.	.	O

One	CD	O
of	IN	O
the	DT	O
components	NNS	O
of	IN	O
abnormal	JJ	O
social	JJ	O
functioning	NN	O
in	IN	O
autism	NN	O
is	VBZ	O
an	DT	O
impaired	JJ	O
ability	NN	O
to	TO	O
direct	VB	O
eye	NN	O
gaze	NN	O
onto	IN	O
other	JJ	O
people	NNS	O
's	POS	O
faces	VBZ	O
in	IN	O
social	JJ	O
situations	NNS	O
.	.	O

Here	RB	O
,	,	O
we	PRP	O
investigated	VBD	O
the	DT	O
relationship	NN	O
between	IN	O
gaze	NN	O
onto	IN	O
the	DT	O
eye	NN	O
and	CC	O
mouth	JJ	O
regions	NNS	O
of	IN	O
faces	VBZ	O
,	,	O
and	CC	O
the	DT	O
visual	JJ	O
information	NN	O
that	WDT	O
was	VBD	O
present	JJ	O
within	IN	O
those	DT	O
regions	NNS	O
.	.	O

We	PRP	O
used	VBD	O
the	DT	O
Bubbles	NNP	O
method	NN	O
to	TO	O
vary	VB	O
the	DT	O
facial	JJ	O
information	NN	O
available	JJ	O
on	IN	O
any	DT	O
given	VBN	O
trial	NN	O
by	IN	O
revealing	VBG	O
only	RB	O
small	JJ	O
parts	NNS	O
of	IN	O
the	DT	O
face	NN	O
,	,	O
and	CC	O
measured	VBD	O
the	DT	O
eye	NN	O
movements	NNS	O
made	VBN	O
as	IN	O
participants	NNS	O
viewed	IN	O
these	DT	O
stimuli	NNS	O
.	.	O

Compared	VBN	O
to	TO	O
ten	VB	O
IQ-	NNP	O
and	CC	O
age-matched	JJ	O
healthy	JJ	O
controls	NNS	O
,	,	O
eight	CD	O
participants	NNS	O
with	IN	O
autism	NN	O
showed	VBD	O
less	JJR	O
fixation	JJ	O
specificity	NN	O
to	TO	O
the	DT	O
eyes	NNS	O
and	CC	O
mouth	NN	O
,	,	O
a	DT	O
greater	JJR	O
tendency	NN	O
to	TO	O
saccade	VB	O
away	RB	O
from	IN	O
the	DT	O
eyes	NNS	O
when	WRB	O
information	NN	O
was	VBD	O
present	JJ	O
in	IN	O
those	DT	O
regions	NNS	O
,	,	O
and	CC	O
abnormal	JJ	O
directionality	NN	O
of	IN	O
saccades	NNS	O
.	.	O

The	DT	O
findings	NNS	O
provide	VBP	O
novel	JJ	O
detail	NN	O
to	TO	O
the	DT	O
abnormal	JJ	O
way	NN	O
in	IN	O
which	WDT	O
people	NNS	O
with	IN	O
autism	NN	O
look	NN	O
at	IN	O
faces	VBZ	O
,	,	O
an	DT	O
impairment	NN	O
that	WDT	O
likely	JJ	O
influences	VBZ	O
all	DT	O
subsequent	JJ	O
face	NN	O
processing	NN	O
.	.	O

Capsaicin	NNP	O
jelly	RB	O
against	IN	O
migraine	NN	C
pain	NN	O
.	.	O

OBJECTIVE	NNP	O
Recent	NNP	O
studies	NNS	O
support	VBP	O
the	DT	O
role	NN	O
of	IN	O
extracranial	JJ	O
perivascular	JJ	O
afferents	NNS	O
in	IN	O
a	DT	O
substantial	JJ	O
percentage	NN	O
of	IN	O
migraineurs	NNS	O
.	.	O

Perivascular	JJ	O
afferent	JJ	O
fibres	NNS	O
of	IN	O
the	DT	O
superficial	JJ	O
temporal	JJ	O
artery	NN	O
contain	NN	O
peptides	NNS	O
,	,	O
like	IN	O
calcitonin	JJ	O
gene-related	JJ	O
peptide	NN	O
(	(	O
CGRP	NNP	O
)	)	O
and	CC	O
substance	NN	O
P	NNP	O
(	(	O
SP	NNP	O
)	)	O
.	.	O

CGRP	NNP	O
and	CC	O
SP	NNP	O
are	VBP	O
considered	VBN	O
relevant	JJ	O
in	IN	O
the	DT	O
genesis	NN	O
of	IN	O
migraine	NN	O
pain	NN	O
.	.	O

Capsaicin	NNP	O
is	VBZ	O
an	DT	O
agonist	NN	O
of	IN	O
the	DT	O
transient	NN	O
receptor	NN	O
potential	JJ	O
vanilloid	NN	O
type	NN	O
1	CD	O
.	.	O

It	PRP	O
causes	VBZ	O
membrane	JJ	O
depolarisation	NN	O
of	IN	O
sensory	JJ	O
neurons	NNS	O
,	,	O
which	WDT	O
release	VBP	O
CGRP	NNP	O
,	,	O
SP	NNP	O
and	CC	O
other	JJ	O
pain	NN	O
peptides	NNS	O
;	:	O
excitation	NN	O
is	VBZ	O
followed	VBN	O
by	IN	O
a	DT	O
refractory	NN	O
state	NN	O
,	,	O
causing	VBG	O
inactivation	NN	O
.	.	O

Topical	JJ	O
capsaicin	NN	O
has	VBZ	O
been	VBN	O
found	VBN	O
to	TO	O
be	VB	O
efficacious	JJ	O
in	IN	O
several	JJ	O
types	NNS	O
of	IN	O
neuropathic	JJ	O
pain	NN	O
.	.	O

We	PRP	O
attempted	VBD	O
to	TO	O
verify	VB	O
whether	IN	O
topical	JJ	O
periarterial	JJ	O
capsaicin	NN	O
could	MD	O
ameliorate	VB	O
pain	NN	O
in	IN	O
absence	NN	O
of	IN	O
and	CC	O
during	IN	O
a	DT	O
migraine	JJ	O
attack	NN	O
.	.	O

METHODS	NNP	O
On	IN	O
23	CD	C
migraineurs	NNS	O
showing	VBG	O
pain	NN	O
at	IN	O
pressure	NN	O
on	IN	O
scalp	NN	O
arteries	NNS	O
,	,	O
we	PRP	O
administered	VBD	O
topical	JJ	O
capsaicin	NN	O
0.1	CD	O
%	NN	O
or	CC	O
vaseline	NN	O
jelly	RB	O
on	IN	O
painful	JJ	O
arteries	NNS	O
in	IN	O
absence	NN	O
of	IN	O
migraine	JJ	O
attack	NN	O
.	.	O

In	IN	O
those	DT	O
having	VBG	O
pain	NN	O
reduction	NN	O
>	VBD	O
50	CD	O
%	NN	O
,	,	O
we	PRP	O
made	VBD	O
the	DT	O
same	JJ	O
comparison	NN	O
during	IN	O
a	DT	O
migraine	JJ	O
attack	NN	O
.	.	O

RESULTS	NNP	O
Topical	NNP	O
capsaicin	NN	O
caused	VBD	O
>	JJ	O
50	CD	O
%	NN	O
reduction	NN	O
of	IN	O
arterial	JJ	O
pain	NN	O
in	IN	O
absence	NN	O
of	IN	O
attack	NN	O
in	IN	O
17/23	CD	O
patients	NNS	O
,	,	O
as	IN	O
opposed	VBN	O
to	TO	O
two	CD	O
with	IN	O
vaseline	NN	O
.	.	O

During	IN	O
attacks	NNS	O
of	IN	O
mild-	NN	O
to	TO	O
moderate-intensity	NN	O
,	,	O
>	VB	O
50	CD	O
%	NN	O
improvement	NN	O
was	VBD	O
obtained	VBN	O
in	IN	O
11/17	CD	O
with	IN	O
capsaicin	NN	O
and	CC	O
in	IN	O
one	CD	O
with	IN	O
vaseline	NN	O
.	.	O

CONCLUSIONS	NNP	O
Although	IN	O
referring	VBG	O
to	TO	O
a	DT	O
small	JJ	O
number	NN	O
of	IN	O
patients	NNS	O
,	,	O
our	PRP$	O
data	NNS	O
show	VBP	O
that	IN	O
topical	JJ	O
capsaicin	NN	O
may	MD	O
relieve	VB	O
arterial	JJ	O
pain	NN	O
in	IN	O
absence	NN	O
of	IN	O
and	CC	O
during	IN	O
a	DT	O
migraine	JJ	O
attack	NN	O
in	IN	O
a	DT	O
substantial	JJ	O
number	NN	O
of	IN	O
patients	NNS	O
experiencing	VBG	O
scalp	JJ	O
arterial	JJ	O
tenderness	NN	O
.	.	O

More	RBR	O
active	JJ	O
capsacinoids	NNS	O
might	MD	O
be	VB	O
tried	VBN	O
in	IN	O
the	DT	O
future	NN	O
and	CC	O
could	MD	O
provide	VB	O
a	DT	O
new	JJ	O
method	NN	O
for	IN	O
treating	VBG	O
migraine	NN	O
attacks	NNS	O
.	.	O

Bioequivalence	NNP	O
evaluation	NN	O
of	IN	O
a	DT	O
fixed	VBN	O
dose	JJ	O
combination	NN	O
lamivudine	NN	O
+	NNP	O
stavudine	NN	O
tablet	NN	O
with	IN	O
concurrent	JJ	O
administration	NN	O
of	IN	O
lamivudine	JJ	O
tablet	NN	O
and	CC	O
stavudine	NN	O
capsule	NN	O
in	IN	O
healthy	JJ	O
volunteers	NNS	O
.	.	O

The	DT	O
study	NN	O
was	VBD	O
designed	VBN	O
to	TO	O
compare	VB	O
the	DT	O
rate	NN	O
and	CC	O
extent	NN	O
of	IN	O
absorption	NN	O
of	IN	O
a	DT	O
fixed	VBN	O
dose	JJ	O
combination	NN	O
tablet	NN	O
of	IN	O
lamivudine	NN	O
(	(	O
CAS	NNP	O
134678-17-4	CD	O
)	)	O
and	CC	O
stavudine	NN	O
(	(	O
CAS	NNP	O
3056-17-5	CD	O
)	)	O
with	IN	O
the	DT	O
concurrent	JJ	O
administration	NN	O
of	IN	O
lamivudine	JJ	O
tablet	NN	O
and	CC	O
stavudine	NN	O
capsule	NN	O
in	IN	O
24	CD	SS
healthy	JJ	O
volunteers	NNS	O
under	IN	C
fasting	VBG	C
conditions	NNS	O
.	.	O

The	DT	O
volunteers	NNS	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
the	DT	O
test	NN	O
or	CC	O
reference	NN	O
treatment	NN	O
,	,	O
with	IN	O
the	DT	O
two	CD	O
treatment	NN	O
periods	NNS	O
separated	VBN	O
by	IN	O
a	DT	O
washout	JJ	O
period	NN	O
of	IN	O
at	IN	O
least	JJS	O
7	CD	O
days	NNS	O
.	.	O

Plasma	NNP	O
samples	NNS	O
were	VBD	O
analyzed	VBN	O
for	IN	O
both	DT	O
analytes	NNS	O
lamivudine	VBP	O
and	CC	O
stavudine	VBP	O
by	IN	O
a	DT	O
validated	JJ	O
analytical	JJ	O
method	NN	O
.	.	O

Since	IN	O
the	DT	O
90	CD	O
%	NN	O
confidence	NN	O
intervals	NNS	O
for	IN	O
the	DT	O
test/reference	NN	O
mean	JJ	O
ratio	NN	O
of	IN	O
the	DT	O
In-transformed	NNP	O
pharmacokinetic	JJ	O
variables	NNS	O
C	NNP	O
(	(	O
max	NN	O
)	)	O
AUC	NNP	O
(	(	O
0-t	JJ	O
)	)	O
and	CC	O
AUC	NNP	O
(	(	O
0-infinity	NN	O
)	)	O
were	VBD	O
clearly	RB	O
within	IN	O
the	DT	O
conventional	JJ	O
bioequivalence	NN	O
range	NN	O
of	IN	O
80	CD	O
%	NN	O
to	TO	O
125	CD	O
%	NN	O
,	,	O
the	DT	O
two	CD	O
treatments	NNS	O
were	VBD	O
considered	VBN	O
bioequivalent	NN	O
.	.	O

The	DT	O
safety	NN	O
profiles	NNS	O
of	IN	O
both	DT	O
the	DT	O
test	NN	O
and	CC	O
reference	NN	O
formulations	NNS	O
were	VBD	O
comparable	JJ	O
.	.	O

Multimodal	NNP	O
therapy	NN	O
for	IN	O
the	DT	O
management	NN	O
of	IN	O
primary	JJ	O
,	,	O
nonmetastatic	JJ	O
Ewing	NNP	O
's	POS	O
sarcoma	NN	O
of	IN	O
bone	NN	O
:	:	O
an	DT	O
Intergroup	NNP	O
Study	NNP	O
.	.	O

A	NNP	O
randomized	JJ	O
study	NN	O
of	IN	O
264	CD	O
children	NNS	O
and	CC	O
adults	NNS	O
with	IN	O
previously	RB	O
untreated	VBN	O
localized	JJ	O
Ewing	NNP	O
's	POS	O
sarcoma	NN	O
of	IN	O
bone	NN	O
was	VBD	O
undertaken	VBN	O
between	IN	O
1973	CD	O
and	CC	O
1978	CD	O
by	IN	O
83	CD	O
institutions	NNS	O
of	IN	O
three	CD	O
national	JJ	O
study	NN	O
groups	NNS	O
:	:	O
Children	NNP	O
's	POS	O
Cancer	NNP	O
Study	NNP	O
Group	NNP	O
,	,	O
Southwest	NNP	O
Oncology	NNP	O
Group	NNP	O
,	,	O
and	CC	O
Cancer	NNP	O
and	CC	O
Leukemia	NNP	O
Group	NNP	O
B	NNP	O
.	.	O

The	DT	O
Intergroup	NNP	O
Study	NNP	O
was	VBD	O
designed	VBN	O
to	TO	O
determine	VB	O
if	IN	O
the	DT	O
addition	NN	O
of	IN	O
adriamycin	NN	O
(	(	O
ADR	NNP	O
)	)	O
or	CC	O
bilateral	JJ	O
pulmonary	JJ	O
radiotherapy	NN	O
(	(	O
RT	NNP	O
)	)	O
to	TO	O
vincristine	VB	O
,	,	O
dactinomycin	NN	O
,	,	O
and	CC	O
cyclophosphamide	NN	O
(	(	O
VAC	NNP	O
therapy	NN	O
)	)	O
would	MD	O
improve	VB	O
survival	NN	O
and	CC	O
reduce	VB	O
local	JJ	O
recurrences	NNS	O
and	CC	O
metastases	NNS	O
.	.	O

All	DT	O
patients	NNS	O
received	VBD	O
RT	NNP	O
to	TO	O
the	DT	O
primary	JJ	O
lesion	NN	O
,	,	O
and	CC	O
the	DT	O
survival	NN	O
rate	NN	O
after	IN	O
3	CD	O
years	NNS	O
was	VBD	O
65	CD	O
%	NN	O
.	.	O

The	DT	O
most	RBS	O
effective	JJ	O
treatment	NN	O
regimen	NNS	O
was	VBD	O
VAC	NNP	O
plus	CC	O
ADR	NNP	O
;	:	O
74	CD	O
%	NN	O
of	IN	O
the	DT	O
patients	NNS	O
were	VBD	O
free	JJ	O
of	IN	O
disease	NN	O
at	IN	O
2	CD	O
years	NNS	O
.	.	O

The	DT	O
lengths	NNS	O
of	IN	O
disease-free	JJ	O
status	NN	O
and	CC	O
survival	NN	O
of	IN	O
patients	NNS	O
treated	VBN	O
with	IN	O
VAC	NNP	O
plus	CC	O
ADR	NNP	O
or	CC	O
VAC	NNP	O
plus	CC	O
RT	NNP	O
did	VBD	O
not	RB	O
differ	VB	O
.	.	O

However	RB	O
,	,	O
both	DT	O
regimens	NNS	O
were	VBD	O
significantly	RB	O
superior	JJ	O
to	TO	O
treatment	NN	O
with	IN	O
VAC	NNP	O
alone	RB	O
.	.	O

The	DT	O
addition	NN	O
of	IN	O
ADR	NNP	O
or	CC	O
bilateral	JJ	O
pulmonary	JJ	O
RT	NNP	O
to	TO	O
VAC	NNP	O
was	VBD	O
highly	RB	O
advantageous	JJ	O
to	TO	O
patients	NNS	O
with	IN	O
nonpelvic	JJ	O
primaries	NNS	O
.	.	O

Bone	NN	O
and	CC	O
lung	NN	O
were	VBD	O
the	DT	O
major	JJ	O
sites	NNS	O
of	IN	O
distant	JJ	O
relapse	NN	O
,	,	O
but	CC	O
the	DT	O
addition	NN	O
of	IN	O
bilateral	JJ	O
pulmonary	JJ	O
RT	NNP	O
showed	VBD	O
no	DT	O
advantage	NN	O
over	IN	O
that	DT	O
of	IN	O
ADR	NNP	O
in	IN	O
reducing	VBG	O
the	DT	O
occurrence	NN	O
of	IN	O
lung	NN	O
metastases	NNS	O
.	.	O

These	DT	O
recent	JJ	O
results	NNS	O
should	MD	O
eliminate	VB	O
some	DT	O
of	IN	O
the	DT	O
pessimism	NN	O
that	WDT	O
has	VBZ	O
accompanied	VBN	O
a	DT	O
diagnosis	NN	O
of	IN	O
Ewing	NNP	O
's	POS	O
sarcoma	NN	O
,	,	O
although	IN	O
distant	JJ	O
metastases	NNS	O
continued	VBD	O
to	TO	O
be	VB	O
a	DT	O
major	JJ	O
reason	NN	O
for	IN	O
failure	NN	O
in	IN	O
the	DT	O
control	NN	O
of	IN	O
this	DT	O
tumor	NN	O
.	.	O

Survival	NN	O
of	IN	O
these	DT	O
patients	NNS	O
can	MD	O
be	VB	O
improved	VBN	O
through	IN	O
well-controlled	JJ	O
clinical	JJ	O
trials	NNS	O
designed	VBN	O
to	TO	O
determine	VB	O
optimal	JJ	O
adjuvant	JJ	O
chemotherapy	NN	O
and	CC	O
treatment	NN	O
of	IN	O
the	DT	O
primary	JJ	O
lesion	NN	O
.	.	O

Effectiveness	NN	O
of	IN	O
initiating	VBG	O
treatment	NN	O
with	IN	O
valsartan/hydrochlorothiazide	NN	O
in	IN	O
patients	NNS	O
with	IN	O
stage-1	JJ	O
or	CC	O
stage-2	JJ	O
hypertension	NN	C
.	.	O

This	DT	O
prospective	JJ	O
,	,	O
6-week	JJ	O
,	,	O
multicenter	NN	O
,	,	O
double-blind	NN	O
study	NN	O
examined	VBD	O
the	DT	O
benefits	NNS	O
of	IN	O
initiating	VBG	O
treatment	NN	O
with	IN	O
combination	NN	O
valsartan/hydrochlorothiazide	NN	O
(	(	O
HCTZ	NNP	O
)	)	O
compared	VBN	O
with	IN	O
initial	JJ	O
valsartan	NNS	O
monotherapy	NN	O
for	IN	O
648	CD	C
patients	NNS	O
with	IN	O
stage-1	JJ	O
or	CC	O
stage-2	JJ	O
hypertension	NN	O
(	(	O
age=52.6+/-10	JJ	A
years	NNS	A
;	:	O
54	CD	O
%	NN	O
male	NN	A
;	:	O
baseline	VB	O
blood	NN	O
pressure	NN	O
(	(	O
BP	NNP	O
)	)	O
=161/98	VBP	O
mm	JJ	O
Hg	NNP	O
,	,	O
32	CD	O
%	NN	O
stage	NN	O
1	CD	O
)	)	O
.	.	O

Patients	NNS	O
were	VBD	O
randomized	VBN	O
to	TO	O
valsartan	VB	O
80	CD	O
mg	NN	O
(	(	O
V-low	NNP	O
)	)	O
,	,	O
valsartan	$	O
160	CD	O
mg	NN	O
(	(	O
V-high	NNP	O
)	)	O
or	CC	O
valsartan/HCTZ	$	O
160/12.5	CD	O
mg	NN	O
(	(	O
V/HCTZ	NNP	O
)	)	O
,	,	O
and	CC	O
electively	RB	O
titrated	VBN	O
after	IN	O
weeks	NNS	O
2	CD	O
and	CC	O
4	CD	O
to	TO	O
the	DT	O
next	JJ	O
dosage	NN	O
level	NN	O
(	(	O
maximum	JJ	O
dose	NN	O
valsartan/HCTZ	NN	O
160/25	CD	O
mg	NN	O
)	)	O
if	IN	O
BP	NNP	O
remained	VBD	O
>	JJ	O
140/90	CD	O
mm	NN	O
Hg	NNP	O
.	.	O

At	IN	O
end	NN	O
of	IN	O
the	DT	O
study	NN	O
,	,	O
patients	NNS	O
initiated	VBN	O
with	IN	O
V/HCTZ	NNP	O
required	VBD	O
less	JJR	O
titration	JJ	O
steps	NNS	O
compared	VBN	O
with	IN	O
the	DT	O
initial	JJ	O
valsartan	NN	O
monotherapy	NN	O
groups	NNS	O
(	(	O
63	CD	O
vs	RB	O
86	CD	O
%	NN	O
required	VBN	O
titration	NN	O
by	IN	O
study	JJ	O
end	NN	O
,	,	O
respectively	RB	O
)	)	O
and	CC	O
reached	VBD	O
the	DT	O
target	NN	O
BP	NNP	O
goal	NN	O
of	IN	O
<	$	O
140/90	CD	O
mm	NN	O
Hg	NNP	O
in	IN	O
a	DT	O
shorter	JJ	O
period	NN	O
of	IN	O
time	NN	O
(	(	O
2.8	CD	O
weeks	NNS	O
)	)	O
(	(	O
P	NNP	O
<	NNP	O
0.0001	CD	O
)	)	O
vs	NN	O
V-low	NNP	O
(	(	O
4.3	CD	O
weeks	NNS	O
)	)	O
and	CC	O
V-high	NNP	O
(	(	O
3.9	CD	O
weeks	NNS	O
)	)	O
.	.	O

Initial	JJ	O
combination	NN	O
therapy	NN	O
was	VBD	O
also	RB	O
associated	VBN	O
with	IN	O
higher	JJR	O
BP	NNP	O
control	NN	O
rates	NNS	O
and	CC	O
greater	JJR	O
reductions	NNS	O
in	IN	O
both	DT	O
systolic	JJ	O
and	CC	O
diastolic	JJ	O
BP	NNP	O
from	IN	O
baseline	NN	O
(	(	O
63	CD	O
%	NN	O
,	,	O
-27.7+/-13/-15.1+/-8	NNP	O
mm	NNP	O
Hg	NNP	O
)	)	O
compared	VBN	O
with	IN	O
V-low	NNP	O
(	(	O
46	CD	O
%	NN	O
,	,	O
-21.2+/-13/-11.4+/-8	NNP	O
mm	NNP	O
Hg	NNP	O
,	,	O
P	NNP	O
<	NNP	O
0.0001	CD	O
)	)	O
or	CC	O
V-high	NNP	O
(	(	O
51	CD	O
%	NN	O
,	,	O
-24.0+/-13/-12.0+/-10	NNP	O
mm	NNP	O
Hg	NNP	O
,	,	O
P	NNP	O
<	NNP	O
0.01	CD	O
)	)	O
.	.	O

Overall	JJ	O
and	CC	O
drug-related	JJ	O
AEs	NNP	O
were	VBD	O
mild	JJ	O
to	TO	O
moderate	VB	O
and	CC	O
were	VBD	O
similar	JJ	O
between	IN	O
V/HCTZ	NNP	O
(	(	O
53.1	CD	O
and	CC	O
14.1	CD	O
%	NN	O
,	,	O
respectively	RB	O
)	)	O
and	CC	O
the	DT	O
two	CD	O
monotherapy	NN	O
groups	NNS	O
,	,	O
V-low	NNP	O
(	(	O
50.5	CD	O
and	CC	O
13.8	CD	O
%	NN	O
)	)	O
and	CC	O
V-high	NNP	O
(	(	O
50.7	CD	O
and	CC	O
11.8	CD	O
%	NN	O
)	)	O
.	.	O

In	IN	O
conclusion	NN	O
,	,	O
initiating	VBG	O
therapy	NN	O
with	IN	O
a	DT	O
combination	NN	O
of	IN	O
valsartan	NN	O
and	CC	O
low-dose	JJ	O
HCTZ	NNP	O
results	NNS	O
in	IN	O
early	JJ	O
,	,	O
improved	JJ	O
BP	NNP	O
efficacy	NN	O
with	IN	O
similar	JJ	O
tolerability	NN	O
as	IN	O
compared	VBN	O
with	IN	O
starting	VBG	O
treatment	NN	O
with	IN	O
a	DT	O
low	JJ	O
or	CC	O
higher	JJR	O
dose	NN	O
of	IN	O
valsartan	NN	O
for	IN	O
patients	NNS	O
with	IN	O
stage-1	JJ	O
and	CC	O
stage-2	JJ	O
hypertension	NN	O
.	.	O

Impact	NN	O
of	IN	O
vitamin	NN	O
D	NNP	O
supplementation	NN	O
on	IN	O
inflammatory	JJ	O
markers	NNS	O
in	IN	O
African	JJ	O
Americans	NNPS	O
:	:	O
results	NNS	O
of	IN	O
a	DT	O
four-arm	JJ	O
,	,	O
randomized	VBN	O
,	,	O
placebo-controlled	JJ	O
trial	NN	O
.	.	O

African	JJ	O
Americans	NNPS	O
have	VBP	O
a	DT	O
disproportionate	JJ	O
burden	NN	O
of	IN	O
inflammation-associated	JJ	O
chronic	JJ	O
diseases	NNS	O
such	JJ	O
as	IN	O
cancer	NN	O
and	CC	O
lower	JJR	O
circulating	NN	O
levels	NNS	O
of	IN	O
25-hydroxyvitamin	JJ	O
D	NNP	O
[	NN	O
25	CD	O
(	(	O
OH	NNP	O
)	)	O
D	NNP	O
]	NNP	O
.	.	O

The	DT	O
effect	NN	O
of	IN	O
vitamin	NN	O
D3	NNP	O
(	(	O
cholecalciferol	NN	O
)	)	O
supplementation	NN	O
on	IN	O
inflammatory	JJ	O
markers	NNS	O
is	VBZ	O
uncertain	JJ	O
.	.	O

We	PRP	O
conducted	VBD	O
a	DT	O
randomized	VBN	O
,	,	O
double-blind	JJ	O
,	,	O
placebo-controlled	JJ	O
trial	NN	O
of	IN	O
supplemental	JJ	O
oral	JJ	O
vitamin	NN	O
D	NNP	O
(	(	O
placebo	NN	O
,	,	O
1,000	CD	O
,	,	O
2,000	CD	O
,	,	O
or	CC	O
4,000	CD	O
IU/day	NN	O
of	IN	O
vitamin	NN	O
D3	NNP	O
orally	RB	O
for	IN	O
3	CD	O
months	NNS	O
)	)	O
in	IN	O
328	CD	O
African	JJ	O
Americans	NNPS	O
(	(	O
median	JJ	O
age	NN	O
,	,	O
51	CD	O
years	NNS	O
)	)	O
of	IN	O
public	JJ	O
housing	NN	O
communities	NNS	O
in	IN	O
Boston	NNP	O
,	,	O
MA	NNP	O
,	,	O
who	WP	O
were	VBD	O
enrolled	VBN	O
over	RP	O
three	CD	O
consecutive	JJ	O
winter	NN	O
periods	NNS	O
(	(	O
2007-2010	JJ	O
)	)	O
.	.	O

Change	NN	O
from	IN	O
0	CD	O
to	TO	O
3	CD	O
months	NNS	O
of	IN	O
plasma	NN	O
levels	NNS	O
of	IN	O
25	CD	O
(	(	O
OH	NNP	O
)	)	O
D	NNP	O
,	,	O
high-sensitivity	JJ	O
C-reactive	JJ	O
protein	NN	O
(	(	O
CRP	NNP	O
)	)	O
,	,	O
interleukin	FW	O
(	(	O
IL	NNP	O
)	)	O
-6	NN	O
,	,	O
IL-10	NNP	O
,	,	O
and	CC	O
soluble	JJ	O
TNF-?	NNP	O
receptor	NN	O
type	NN	O
2	CD	O
(	(	O
sTNF-R2	NN	O
)	)	O
in	IN	O
292	CD	O
(	(	O
89	CD	O
%	NN	O
)	)	O
participants	NNS	O
were	VBD	O
measured	VBN	O
.	.	O

Overall	NNP	O
,	,	O
no	DT	O
statistically	RB	O
significant	JJ	O
changes	NNS	O
in	IN	O
CRP	NNP	O
,	,	O
IL-6	NNP	O
,	,	O
IL-10	NNP	O
,	,	O
and	CC	O
sTNF-R2	NNS	O
were	VBD	O
observed	VBN	O
after	IN	O
the	DT	O
vitamin	NN	O
D	NNP	O
supplementation	NN	O
period	NN	O
.	.	O

Baseline	NNP	O
CRP	NNP	O
was	VBD	O
significantly	RB	O
inversely	RB	O
associated	VBN	O
with	IN	O
the	DT	O
baseline	NN	O
25	CD	O
(	(	O
OH	NNP	O
)	)	O
D	NNP	O
level	NN	O
(	(	O
P	NNP	O
<	NNP	O
0.001	CD	O
)	)	O
in	IN	O
unadjusted	JJ	O
and	CC	O
adjusted	JJ	O
models	NNS	O
.	.	O

An	DT	O
interaction	NN	O
between	IN	O
baseline	NN	O
25	CD	O
(	(	O
OH	NNP	O
)	)	O
D	NNP	O
and	CC	O
vitamin	NNP	O
D	NNP	O
supplementation	NN	O
was	VBD	O
observed	VBN	O
for	IN	O
outcome	JJ	O
change	NN	O
in	IN	O
log	NN	O
CRP	NNP	O
(	(	O
month	NN	O
3-month	RB	O
0	CD	O
;	:	O
P	NNP	O
for	IN	O
interaction	NN	O
=	NNP	O
0.04	CD	O
)	)	O
.	.	O

Within	IN	O
an	DT	O
unselected	JJ	O
population	NN	O
of	IN	O
African	JJ	O
Americans	NNPS	O
,	,	O
short-term	JJ	O
exposure	NN	O
to	TO	O
vitamin	VB	O
D	NNP	O
supplementation	NN	O
produced	VBD	O
no	DT	O
change	NN	O
in	IN	O
circulating	VBG	O
inflammatory	JJ	O
markers	NNS	O
.	.	O

This	DT	O
study	NN	O
confirms	VBZ	O
the	DT	O
strong	JJ	O
independent	JJ	O
association	NN	O
of	IN	O
CRP	NNP	O
with	IN	O
25	CD	O
(	(	O
OH	NNP	O
)	)	O
D	NNP	O
status	NN	O
even	RB	O
after	IN	O
adjusting	VBG	O
for	IN	O
body	NN	O
mass	NN	O
index	NN	O
.	.	O

Future	JJ	O
studies	NNS	O
of	IN	O
longer	JJR	O
supplemental	JJ	O
vitamin	NN	O
D3	NNP	O
duration	NN	O
are	VBP	O
necessary	JJ	O
to	TO	O
examine	VB	O
the	DT	O
complex	JJ	O
influence	NN	O
of	IN	O
vitamin	NN	O
D3	NNP	O
on	IN	O
CRP	NNP	O
and	CC	O
other	JJ	O
chronic	JJ	O
inflammatory	NN	O
cytokines	NNS	O
for	IN	O
possible	JJ	O
reduction	NN	O
of	IN	O
cancer	NN	O
health	NN	O
disparities	NNS	O
in	IN	O
African	JJ	O
Americans	NNPS	O
.	.	O

[	JJ	O
Local	NNP	O
therapy	NN	O
of	IN	O
grade	NN	O
1	CD	O
and	CC	O
2	CD	O
hemorrhoids	NNS	C
.	.	O

Effectiveness	NN	O
of	IN	O
a	DT	O
combination	NN	O
preparation	NN	O
with	IN	O
standardized	JJ	O
blood	NN	O
leech	NN	O
extract	NN	O
]	NNP	O
.	.	O

AIMS	NNP	O
Testing	VBG	O
the	DT	O
effectiveness	NN	O
of	IN	O
a	DT	O
topical	JJ	O
combination	NN	O
preparation	NN	O
containing	VBG	O
standardized	VBN	O
leech	JJ	O
extract	NN	O
,	,	O
polidocanol	NN	O
and	CC	O
allantoin	NN	O
.	.	O

STUDY	NNP	O
DESIGN	NNP	O
Placebo-controlled	NNP	O
,	,	O
double-blind	NN	O
study	NN	O
in	IN	O
80	CD	SS
patients	NNS	O
with	IN	O
first	JJ	O
and	CC	O
second	JJ	O
degree	NN	O
hemorrhoids	NNS	O
;	:	O
duration	NN	O
of	IN	O
treatment	NN	O
one	CD	O
week	NN	O
;	:	O
examinations	NNS	O
performed	VBD	O
on	IN	O
admission	NN	O
and	CC	O
on	IN	O
days	NNS	O
3	CD	O
,	,	O
4	CD	O
,	,	O
5	CD	O
and	CC	O
8	CD	O
.	.	O

RESULTS	VB	O
Both	DT	O
the	DT	O
subjective	NN	O
and	CC	O
objective	JJ	O
symptoms	NNS	O
and	CC	O
signs	NNS	O
improved	VBN	O
during	IN	O
the	DT	O
one	CD	O
week	NN	O
of	IN	O
treatment	NN	O
statistically	RB	O
significantly	RB	O
more	RBR	O
rapidly	RB	O
under	IN	O
the	DT	O
test	NN	O
preparation	NN	O
as	IN	O
compared	VBN	O
with	IN	O
placebo	NN	O
.	.	O

Histologically	NNP	O
demonstrable	JJ	O
signs	NNS	O
of	IN	O
inflammation	NN	O
were	VBD	O
more	JJR	O
clearly	RB	O
improved	VBN	O
in	IN	O
the	DT	O
preparation	NN	O
group	NN	O
than	IN	O
in	IN	O
the	DT	O
placebo	NN	O
group	NN	O
.	.	O

No	DT	O
side	NN	O
effects	NNS	O
were	VBD	O
observed	VBN	O
.	.	O

CONCLUSIONS	VB	O
The	DT	O
good	JJ	O
efficacy	NN	O
and	CC	O
tolerability	NN	O
of	IN	O
a	DT	O
topical	JJ	O
therapeutic	JJ	O
preparation	NN	O
in	IN	O
first	JJ	O
and	CC	O
second	JJ	O
degree	NN	O
hemorrhoids	NNS	O
have	VBP	O
been	VBN	O
convincingly	RB	O
demonstrated	VBN	O
.	.	O

Different	NNP	O
aprotinin	NN	O
applications	NNS	O
influencing	VBG	O
hemostatic	JJ	O
changes	NNS	O
in	IN	O
orthotopic	NN	O
liver	NN	O
transplantation	NN	O
.	.	O

The	DT	O
effect	NN	O
of	IN	O
different	JJ	O
aprotinin	NN	O
applications	NNS	O
on	IN	O
hemostatic	JJ	O
changes	NNS	O
and	CC	O
blood	NN	O
product	NN	O
requirements	NNS	O
in	IN	O
orthotopic	JJ	O
liver	NN	O
transplantation	NN	O
was	VBD	O
investigated	VBN	O
in	IN	O
a	DT	O
prospective	JJ	O
,	,	O
open	JJ	O
,	,	O
and	CC	O
randomized	VBD	O
study	NN	O
.	.	O

From	IN	O
November	NNP	O
1989	CD	O
to	TO	O
June	NNP	O
1990	CD	O
,	,	O
13	CD	C
patients	NNS	O
received	VBD	O
aprotinin	RB	O
as	IN	O
a	DT	O
bolus	NN	O
of	IN	O
0.5	CD	O
Mill	NNP	O
.	.	O

Kallikrein	NNP	O
inactivator	JJ	O
units	NNS	O
(	(	O
KIU	NNP	O
)	)	O
on	IN	O
three	CD	O
occasions	NNS	O
in	IN	O
the	DT	O
course	NN	O
of	IN	O
an	DT	O
OLT	NNP	O
,	,	O
whereas	RB	O
10	CD	O
other	JJ	O
patients	NNS	O
were	VBD	O
treated	VBN	O
with	IN	O
continuous	JJ	O
aprotinin	JJ	O
infusion	NN	O
of	IN	O
0.1-0.4	JJ	O
Mill	NNP	O
.	.	O

KIU/hr	NNP	O
.	.	O

Before	IN	O
and	CC	O
after	IN	O
reperfusion	NN	O
of	IN	O
the	DT	O
graft	NN	O
liver	NN	O
,	,	O
signs	NNS	O
of	IN	O
hyperfibrinolysis	NN	O
,	,	O
measured	VBN	O
by	IN	O
thrombelastography	NN	O
,	,	O
were	VBD	O
significantly	RB	O
lower	JJR	O
in	IN	O
the	DT	O
infusion	NN	O
group	NN	O
.	.	O

Tissue-type	JJ	O
plasminogen	NN	O
activator	NN	O
(	(	O
t-PA	JJ	O
)	)	O
activity	NN	O
increased	VBD	O
during	IN	O
the	DT	O
anhepatic	JJ	O
phase	NN	O
but	CC	O
to	TO	O
a	DT	O
significantly	RB	O
lesser	JJR	O
extent	NN	O
in	IN	O
the	DT	O
infusion	NN	O
group	NN	O
.	.	O

Blood	NNP	O
product	NN	O
requirements	NNS	O
during	IN	O
OLT	NNP	O
were	VBD	O
tendentiously	RB	O
higher	JJR	O
in	IN	O
the	DT	O
bolus	NN	O
group	NN	O
but	CC	O
not	RB	O
significantly	RB	O
so	RB	O
.	.	O

However	RB	O
,	,	O
the	DT	O
use	NN	O
of	IN	O
packed	JJ	O
red	JJ	O
blood	NN	O
cells	NNS	O
was	VBD	O
significantly	RB	O
lower	JJR	O
in	IN	O
the	DT	O
postoperative	JJ	O
period	NN	O
,	,	O
whereas	IN	O
there	EX	O
was	VBD	O
no	DT	O
significant	JJ	O
difference	NN	O
in	IN	O
fresh	JJ	O
frozen	NN	O
plasma	NN	O
requirements	NNS	O
between	IN	O
the	DT	O
two	CD	O
groups	NNS	O
.	.	O

All	DT	O
23	CD	SS
patients	NNS	O
have	VBP	O
survived	VBN	O
,	,	O
and	CC	O
only	RB	O
one	CD	O
woman	NN	O
of	IN	O
each	DT	O
group	NN	O
required	VBN	O
retransplantation	NN	O
due	JJ	O
to	TO	O
severe	VB	O
host-versus-graft	JJ	O
reactions	NNS	O
.	.	O

Furthermore	RB	O
,	,	O
we	PRP	O
investigated	VBD	O
the	DT	O
perfusate	NN	O
of	IN	O
the	DT	O
graft	NN	O
liver	NN	O
in	IN	O
both	DT	O
groups	NNS	O
and	CC	O
detected	JJ	O
signs	NNS	O
of	IN	O
a	DT	O
decreased	JJ	O
t-PA	JJ	O
release	NN	O
in	IN	O
the	DT	O
infusion	NN	O
group	NN	O
.	.	O

Our	PRP$	O
results	NNS	O
demonstrate	VBP	O
an	DT	O
advantage	NN	O
of	IN	O
aprotinin	NN	O
given	VBN	O
as	IN	O
continuous	JJ	O
infusion	NN	O
over	IN	O
bolus	JJ	O
application	NN	O
in	IN	O
OLT	NNP	O
.	.	O

Making	VBG	O
the	DT	O
connection	NN	O
:	:	O
randomized	VBN	O
controlled	VBD	O
trial	NN	O
of	IN	O
social	JJ	O
skills	NNS	O
at	IN	O
school	NN	O
for	IN	O
children	NNS	A
with	IN	O
autism	NN	C
spectrum	NN	C
disorders	NNS	C
.	.	O

BACKGROUND	NNP	O
This	DT	O
study	NN	O
compared	VBN	O
two	CD	O
interventions	NNS	O
for	IN	O
improving	VBG	O
the	DT	O
social	JJ	O
skills	NNS	O
of	IN	O
high	JJ	O
functioning	VBG	O
children	NNS	C
with	IN	O
autism	NN	C
spectrum	NN	C
disorders	NNS	C
in	IN	O
general	JJ	O
education	NN	O
classrooms	NNS	O
.	.	O

One	CD	O
intervention	NN	O
involved	VBN	O
a	DT	O
peer-mediated	JJ	O
approach	NN	O
(	(	O
PEER	NNP	O
)	)	O
and	CC	O
the	DT	O
other	JJ	O
involved	VBD	O
a	DT	O
child-assisted	JJ	O
approach	NN	O
(	(	O
CHILD	NNP	O
)	)	O
.	.	O

METHOD	PDT	O
The	DT	O
two	CD	O
interventions	NNS	O
were	VBD	O
crossed	VBN	O
in	IN	O
a	DT	O
2	CD	O
?	.	O
2	CD	O
factorial	JJ	O
design	NN	O
yielding	VBG	O
control	NN	O
,	,	O
PEER	NNP	O
,	,	O
CHILD	NNP	O
,	,	O
and	CC	O
both	DT	O
PEER	NNP	O
and	CC	O
CHILD	NNP	O
conditions	NNS	O
.	.	O

Sixty	NNP	O
children	NNS	O
participated	VBD	O
from	IN	O
56	CD	O
classrooms	NNS	O
in	IN	O
30	CD	O
schools	NNS	O
.	.	O

Interventions	NNS	O
involved	VBD	O
12	CD	O
sessions	NNS	O
over	IN	O
6	CD	O
weeks	NNS	O
,	,	O
with	IN	O
a	DT	O
3-month	JJ	O
follow-up	NN	O
.	.	O

Outcome	NNP	O
measures	NNS	O
included	VBD	O
self	NN	O
,	,	O
peer	NN	O
and	CC	O
teacher	JJR	O
reports	NNS	O
of	IN	O
social	JJ	O
skills	NNS	O
and	CC	O
independent	JJ	O
weekly	JJ	O
observations	NNS	O
of	IN	O
children	NNS	O
on	IN	O
their	PRP$	O
school	NN	O
playground	NN	O
over	IN	O
the	DT	O
course	NN	O
of	IN	O
the	DT	O
intervention	NN	O
.	.	O

RESULTS	NNP	O
Significant	JJ	O
improvements	NNS	O
were	VBD	O
found	VBN	O
in	IN	O
social	JJ	O
network	NN	O
salience	NN	O
,	,	O
number	NN	O
of	IN	O
friendship	JJ	O
nominations	NNS	O
,	,	O
teacher	JJ	O
report	NN	O
of	IN	O
social	JJ	O
skills	NNS	O
in	IN	O
the	DT	O
classroom	NN	O
,	,	O
and	CC	O
decreased	JJ	O
isolation	NN	O
on	IN	O
the	DT	O
playground	NN	O
for	IN	O
children	NNS	O
who	WP	O
received	VBD	O
PEER	NNP	O
interventions	NNS	O
.	.	O

Changes	NNS	O
obtained	VBN	O
at	IN	O
the	DT	O
end	NN	O
of	IN	O
the	DT	O
treatment	NN	O
persisted	VBD	O
to	TO	O
the	DT	O
3-month	JJ	O
follow-up	NN	O
.	.	O

CONCLUSIONS	NNP	O
These	DT	O
data	NNS	O
suggest	VBP	O
that	IN	O
significant	JJ	O
improvements	NNS	O
can	MD	O
be	VB	O
made	VBN	O
in	IN	O
peer	JJ	O
social	JJ	O
connections	NNS	O
for	IN	O
children	NNS	O
with	IN	O
autism	NN	O
spectrum	NN	O
disorders	NNS	O
in	IN	O
general	JJ	O
education	NN	O
classrooms	NNS	O
with	IN	O
a	DT	O
brief	JJ	O
intervention	NN	O
,	,	O
and	CC	O
that	IN	O
these	DT	O
gains	NNS	O
persist	VBP	O
over	IN	O
time	NN	O
.	.	O

Why	WRB	O
were	VBD	O
the	DT	O
results	NNS	O
of	IN	O
the	DT	O
Heart	NNP	O
Outcomes	NNP	O
Prevention	NNP	O
Evaluation	NNP	O
(	(	O
HOPE	NNP	O
)	)	O
trial	NN	O
so	IN	O
astounding	VBG	O
?	.	O
The	DT	O
Heart	NNP	O
Outcomes	NNP	O
Prevention	NNP	O
Evaluation	NNP	O
(	(	O
HOPE	NNP	O
)	)	O
study	NN	O
was	VBD	O
important	JJ	O
because	IN	O
it	PRP	O
showed	VBD	O
the	DT	O
benefits	NNS	O
of	IN	O
ramipril	NN	O
-	:	O
an	DT	O
angiotensin-converting	JJ	O
enzyme	NN	O
(	(	O
ACE	NNP	O
)	)	O
inhibitor	NN	O
-	:	O
in	IN	O
patients	NNS	O
at	IN	O
high	JJ	C
risk	NN	C
for	IN	C
cardiovascular	JJ	C
events	NNS	C
.	.	O

Treatment	NN	O
with	IN	O
ramipril	NN	O
significantly	RB	O
reduced	VBD	O
the	DT	O
rates	NNS	O
of	IN	O
death	NN	O
,	,	O
myocardial	JJ	O
infarction	NN	O
,	,	O
stroke	NN	O
,	,	O
coronary	JJ	O
revascularization	NN	O
,	,	O
cardiac	JJ	O
arrest	NN	O
and	CC	O
heart	NN	O
failure	NN	O
,	,	O
as	RB	O
well	RB	O
as	IN	O
the	DT	O
risk	NN	O
of	IN	O
diabetes-related	JJ	O
complications	NNS	O
and	CC	O
of	IN	O
diabetes	NNS	O
itself	PRP	O
.	.	O

The	DT	O
effects	NNS	O
of	IN	O
therapy	NN	O
with	IN	O
vitamin	JJ	O
E	NN	O
were	VBD	O
also	RB	O
evaluated	VBN	O
,	,	O
but	CC	O
no	DT	O
statistical	JJ	O
benefits	NNS	O
were	VBD	O
shown	VBN	O
.	.	O

The	DT	O
benefits	NNS	O
of	IN	O
ACE	NNP	O
inhibitor	NN	O
therapy	NN	O
that	WDT	O
were	VBD	O
observed	VBN	O
were	VBD	O
likely	JJ	O
due	JJ	O
to	TO	O
a	DT	O
variety	NN	O
of	IN	O
mechanisms	NNS	O
,	,	O
not	RB	O
just	RB	O
a	DT	O
reduction	NN	O
in	IN	O
blood	NN	O
pressure	NN	O
.	.	O

The	DT	O
peroxisome	JJ	O
proliferator-activated	JJ	O
receptor-gamma	JJ	O
agonist	NN	O
pioglitazone	NN	O
increases	VBZ	O
number	NN	O
and	CC	O
function	NN	O
of	IN	O
endothelial	JJ	O
progenitor	NN	O
cells	NNS	O
in	IN	O
patients	NNS	O
with	IN	O
coronary	JJ	O
artery	NN	O
disease	NN	O
and	CC	O
normal	JJ	O
glucose	JJ	O
tolerance	NN	O
.	.	O

OBJECTIVE	CC	O
Peroxisome	JJ	O
proliferator-activated	JJ	O
receptor-gamma	NN	O
(	(	O
PPAR	NNP	O
gamma	NN	O
)	)	O
agonists	VBZ	O
(	(	O
thiazolidinediones	NNS	O
[	NNP	O
TZDs	NNP	O
]	NNP	O
)	)	O
are	VBP	O
used	VBN	O
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
diabetes	NNS	O
.	.	O

Bone	CD	O
marrow-derived	JJ	O
endothelial	JJ	O
progenitor	NN	O
cells	NNS	O
(	(	O
EPCs	NNP	O
)	)	O
improve	VB	O
vascular	JJ	O
function	NN	O
and	CC	O
predict	NN	O
cardiovascular	NN	O
risk	NN	O
.	.	O

The	DT	O
effect	NN	O
of	IN	O
pioglitazone	NN	O
therapy	NN	O
on	IN	O
EPCs	NNP	O
was	VBD	O
examined	VBN	O
.	.	O

RESEARCH	NNP	O
DESIGN	NNP	O
AND	NNP	O
METHODS	NNP	O
AND	NNP	O
RESULTS	NNP	O
We	PRP	O
performed	VBD	O
a	DT	O
prospective	JJ	O
,	,	O
randomized	VBN	O
,	,	O
double-blind	JJ	O
study	NN	O
on	IN	O
patients	NNS	O
with	IN	O
documented	JJ	O
stable	JJ	O
coronary	JJ	O
artery	NN	O
disease	NN	O
and	CC	O
normal	JJ	O
glucose	JJ	O
tolerance	NN	O
.	.	O

Of	IN	O
54	CD	O
patients	NNS	O
with	IN	O
normal	JJ	O
fasting	VBG	O
glucose	JJ	O
levels	NNS	O
,	,	O
18	CD	O
showed	VBD	O
impaired	JJ	O
glucose	JJ	O
tolerance	NN	O
and	CC	O
36	CD	O
patients	NNS	O
with	IN	O
normal	JJ	O
glucose	JJ	O
tolerance	NN	O
were	VBD	O
randomized	VBN	O
to	TO	O
30-day	JJ	O
treatment	NN	O
with	IN	O
pioglitazone	NN	O
(	(	O
45	CD	O
mg	NN	O
)	)	O
or	CC	O
placebo	NN	O
in	IN	O
addition	NN	O
to	TO	O
optimal	VB	O
medical	JJ	O
therapy	NN	O
.	.	O

All	DT	O
patients	NNS	O
in	IN	O
the	DT	O
TZD	NNP	O
group	NN	O
showed	VBD	O
an	DT	O
increase	NN	O
of	IN	O
adiponectin	JJ	O
levels	NNS	O
as	IN	O
an	DT	O
indicator	NN	O
of	IN	O
compliance	NN	O
(	(	O
11.4	CD	O
+/-	JJ	O
1.1	CD	O
to	TO	O
36.8	CD	O
+/-	JJ	O
2.1	CD	O
microg/ml	NN	O
;	:	O
P	NNP	O
<	NNP	O
0.001	CD	O
)	)	O
.	.	O

TZD	NNP	O
,	,	O
but	CC	O
not	RB	O
placebo	VB	O
,	,	O
decreased	VBN	O
mean	JJ	O
high-sensitivity	NN	O
C-reactive	JJ	O
protein	NN	O
to	TO	O
43	CD	O
+/-	JJ	O
19	CD	O
%	NN	O
(	(	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
.	.	O

Pioglitazone	NN	O
increased	VBD	O
CD34	NNP	O
(	(	O
+	NNP	O
)	)	O
/kinase	NN	O
insert	JJ	O
domain	NN	O
receptor	NN	O
(	(	O
+	NNP	O
)	)	O
EPCs	NNP	O
to	TO	O
142	CD	O
+/-	JJ	O
9	CD	O
%	NN	O
and	CC	O
cultured	VBD	O
1,1'-dioctadecyl-3,3,3',3'-tetramethylindocarbocyanine-labeled	JJ	O
acetylated	JJ	O
LDL	NNP	O
(	(	O
+	NNP	O
)	)	O
/lectin	NN	O
(	(	O
+	NNP	O
)	)	O
EPCs	NNP	O
to	TO	O
180	CD	O
+/-	JJ	O
3	CD	O
%	NN	O
(	(	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
.	.	O

EPC	JJ	O
numbers	NNS	O
were	VBD	O
not	RB	O
changed	VBN	O
in	IN	O
the	DT	O
placebo	NN	O
group	NN	O
.	.	O

TZD	NNP	O
increased	VBD	O
the	DT	O
SDF-1-induced	NNP	O
migratory	NN	O
capacity	NN	O
to	TO	O
146	CD	O
+/-	JJ	O
9	CD	O
%	NN	O
per	IN	O
EPC	NNP	O
number	NN	O
(	(	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
and	CC	O
upregulated	VBD	O
the	DT	O
clonogenic	JJ	O
potential	NN	O
of	IN	O
EPCs	NNP	O
,	,	O
increasing	VBG	O
the	DT	O
colony-forming	JJ	O
units	NNS	O
to	TO	O
172	CD	O
+/-	JJ	O
12	CD	O
%	NN	O
(	(	O
P	NNP	O
<	NNP	O
0.001	CD	O
)	)	O
.	.	O

In	IN	O
cultured	JJ	O
human	JJ	O
EPCs	NNP	O
,	,	O
TZD	NNP	O
increased	VBD	O
EPC	NNP	O
numbers	NNS	O
and	CC	O
migration	NN	O
and	CC	O
reduced	JJ	O
NADPH-oxidase	NNP	O
activity	NN	O
.	.	O

The	DT	O
TZD	NNP	O
effect	NN	O
was	VBD	O
reversed	VBN	O
by	IN	O
the	DT	O
PPAR	NNP	O
gamma	NN	O
antagonist	NN	O
GW9662	NNP	O
and	CC	O
mimicked	VBN	O
by	IN	O
treatment	NN	O
with	IN	O
adiponectin	NN	O
.	.	O

CONCLUSIONS	VB	O
The	DT	O
PPAR	NNP	O
gamma	NN	O
agonist	NN	O
pioglitazone	NN	O
increases	VBZ	O
the	DT	O
number	NN	O
and	CC	O
function	NN	O
of	IN	O
EPCs	NNP	O
in	IN	O
patients	NNS	O
with	IN	O
coronary	JJ	O
artery	NN	O
disease	NN	O
.	.	O

The	DT	O
effect	NN	O
represents	VBZ	O
a	DT	O
potential	JJ	O
regenerative	NN	O
mechanism	NN	O
in	IN	O
atherosclerosis	NN	O
and	CC	O
is	VBZ	O
observed	VBN	O
in	IN	O
normoglycemic	JJ	O
individuals	NNS	O
with	IN	O
stable	JJ	O
coronary	JJ	O
artery	NN	O
disease	NN	O
.	.	O

The	DT	O
effect	NN	O
of	IN	O
Naftidrofuryl	NNP	O
on	IN	O
ethanol-induced	JJ	O
liver	NN	O
damage	NN	O
in	IN	O
chronic	JJ	C
alcoholic	JJ	C
patients	NNS	O
.	.	O

A	DT	O
prospective	JJ	O
double-blind	JJ	O
placebo-controlled	JJ	O
trial	NN	O
of	IN	O
intramuscular	JJ	O
Naftidrofuryl	NNP	O
was	VBD	O
carried	VBN	O
out	RP	O
on	IN	O
32	CD	SS
randomly	RB	O
selected	VBN	O
hospitalized	VBN	O
male	JJ	SE
alcoholic	JJ	C
patients	NNS	O
with	IN	O
clinical	JJ	O
,	,	O
biochemical	JJ	O
and	CC	O
histological	JJ	O
evidence	NN	O
of	IN	O
hepatic	JJ	C
damage	NN	C
.	.	O

Seventeen	JJ	O
patients	NNS	O
received	VBD	O
the	DT	O
drug	NN	O
(	(	O
40	CD	O
mg	NN	O
in	IN	O
5	CD	O
ml	NN	O
i.m	NN	O
.	.	O

three	CD	O
times	NNS	O
daily	RB	O
for	IN	O
6	CD	O
days	NNS	O
)	)	O
and	CC	O
15	CD	O
patients	NNS	O
received	VBD	O
a	DT	O
placebo	NN	O
(	(	O
5	CD	O
ml	NN	O
in	IN	O
normal	JJ	O
saline	JJ	O
i.m	NN	O
.	.	O

three	CD	O
times	NNS	O
daily	RB	O
for	IN	O
6	CD	O
days	NNS	O
)	)	O
.	.	O

The	DT	O
drug	NN	O
was	VBD	O
well	RB	O
tolerated	VBN	O
and	CC	O
there	EX	O
were	VBD	O
no	DT	O
adverse	JJ	O
side-effects	NNS	O
.	.	O

Naftidrofuryl	NNP	O
significantly	RB	O
improved	VBD	O
the	DT	O
physiological	JJ	O
function	NN	O
of	IN	O
the	DT	O
liver	NN	O
cells	NNS	O
as	IN	O
reflected	VBN	O
by	IN	O
indocyanine	NN	O
green	NN	O
(	(	O
ICG	NNP	O
)	)	O
clearance	NN	O
by	IN	O
the	DT	O
liver	NN	O
(	(	O
t	JJ	O
=	VBZ	O
2.61	CD	O
;	:	O
p	NN	O
less	JJR	O
than	IN	O
or	CC	O
equal	JJ	O
to	TO	O
0.02	CD	O
)	)	O
and	CC	O
also	RB	O
caused	VBD	O
a	DT	O
larger	JJR	O
fall	NN	O
in	IN	O
raised	VBN	O
serum	NN	O
levels	NNS	O
of	IN	O
gamma	NN	O
glutamyl	NN	O
transpeptidase	NN	O
(	(	O
GGT	NNP	O
)	)	O
than	IN	O
did	VBD	O
the	DT	O
placebo	NN	O
injections	NNS	O
.	.	O

Overall	JJ	O
clinical	JJ	O
improvement	NN	O
(	(	O
e.g	NN	O
.	.	O

appetite	NN	O
,	,	O
body	NN	O
weight	NN	O
,	,	O
reduced	VBD	O
liver	JJ	O
size	NN	O
,	,	O
general	JJ	O
sense	NN	O
of	IN	O
well-being	NN	O
)	)	O
was	VBD	O
more	RBR	O
clearly	RB	O
evident	JJ	O
in	IN	O
patients	NNS	O
of	IN	O
the	DT	O
treated	VBN	O
group	NN	O
than	IN	O
in	IN	O
those	DT	O
of	IN	O
the	DT	O
placebo	NN	O
group	NN	O
.	.	O

Naftidrofuryl	NNP	O
,	,	O
therefore	RB	O
,	,	O
appears	VBZ	O
to	TO	O
be	VB	O
of	IN	O
benefit	NN	O
in	IN	O
ethanol-induced	JJ	C
liver	NN	C
damage	NN	C
and	CC	O
more	RBR	O
extensive	JJ	O
long-term	JJ	O
trials	NNS	O
are	VBP	O
suggested	VBN	O
in	IN	O
patients	NNS	O
with	IN	O
alcoholic	JJ	C
liver	NN	C
disease	NN	C
(	(	C
ALD	NNP	C
)	)	C
.	.	O

?-Blockers	NNS	O
in	IN	O
patients	NNS	O
with	IN	O
intermittent	JJ	O
claudication	NN	O
and	CC	O
arterial	JJ	O
hypertension	NN	O
:	:	O
results	NNS	O
from	IN	O
the	DT	O
nebivolol	NN	O
or	CC	O
metoprolol	NN	O
in	IN	O
arterial	JJ	O
occlusive	JJ	O
disease	NN	O
trial	NN	O
.	.	O

The	DT	O
use	NN	O
of	IN	O
?-receptor	NN	O
blockers	NNS	O
in	IN	O
peripheral	JJ	O
arterial	JJ	O
disease	NN	O
is	VBZ	O
controversial	JJ	O
for	IN	O
their	PRP$	O
impact	NN	O
on	IN	O
vasomotor	NN	O
tone	NN	O
.	.	O

The	DT	O
?-blocker	NN	O
nebivolol	NN	O
possesses	VBZ	O
vasodilating	VBG	O
,	,	O
endothelium-dependent	JJ	O
,	,	O
NO-releasing	JJ	O
properties	NNS	O
that	WDT	O
might	MD	O
be	VB	O
beneficial	JJ	O
in	IN	O
peripheral	JJ	O
arterial	JJ	O
disease	NN	O
.	.	O

The	DT	O
aim	NN	O
of	IN	O
the	DT	O
study	NN	O
was	VBD	O
to	TO	O
evaluate	VB	O
the	DT	O
effects	NNS	O
and	CC	O
tolerability	NN	O
of	IN	O
nebivolol	NN	O
in	IN	O
comparison	NN	O
with	IN	O
metoprolol	NN	O
in	IN	O
these	DT	O
patients	NNS	O
.	.	O

A	DT	O
total	NN	O
of	IN	O
128	CD	O
patients	NNS	O
with	IN	O
intermittent	JJ	O
claudication	NN	O
and	CC	O
essential	JJ	O
hypertension	NN	O
were	VBD	O
included	VBN	O
and	CC	O
double-blind	JJ	O
randomized	VBN	O
to	TO	O
receive	VB	O
5	CD	O
mg	NN	O
of	IN	O
nebivolol	NN	O
(	(	O
N=65	NNP	O
)	)	O
or	CC	O
95	CD	O
mg	NN	O
of	IN	O
metoprolol	NN	O
(	(	O
N=63	NNP	O
)	)	O
once	RB	O
daily	JJ	O
.	.	O

End	NN	O
points	NNS	O
were	VBD	O
changes	NNS	O
in	IN	O
ankle-brachial	JJ	O
index	NN	O
,	,	O
initial	JJ	O
and	CC	O
absolute	JJ	O
claudication	NN	O
distance	NN	O
,	,	O
endothelial	JJ	O
function	NN	O
assessed	VBN	O
by	IN	O
flow-mediated	JJ	O
dilatation	NN	O
of	IN	O
the	DT	O
brachial	JJ	O
artery	NN	O
,	,	O
blood	NN	O
pressure	NN	O
,	,	O
and	CC	O
quality	NN	O
of	IN	O
life	NN	O
using	VBG	O
the	DT	O
claudication	NN	O
scale	NN	O
questionnaire	NN	O
.	.	O

End	NN	O
point	NN	O
analysis	NN	O
was	VBD	O
possible	JJ	O
in	IN	O
109	CD	O
patients	NNS	O
(	(	O
85.2	CD	O
%	NN	O
)	)	O
.	.	O

After	IN	O
the	DT	O
48-week	JJ	O
treatment	NN	O
period	NN	O
,	,	O
ankle-brachial	JJ	O
index	NN	O
and	CC	O
absolute	JJ	O
claudication	NN	O
distance	NN	O
improved	VBD	O
significantly	RB	O
in	IN	O
both	DT	O
patient	JJ	O
groups	NNS	O
(	(	O
P	NNP	O
<	VBZ	O
0.05	CD	O
for	IN	O
both	DT	O
)	)	O
,	,	O
with	IN	O
no	DT	O
difference	NN	O
across	IN	O
treatments	NNS	O
.	.	O

A	DT	O
significant	JJ	O
increase	NN	O
of	IN	O
initial	JJ	O
claudication	NN	O
distance	NN	O
was	VBD	O
found	VBN	O
in	IN	O
the	DT	O
nebivolol	JJ	O
group	NN	O
.	.	O

Adjusted	VBN	O
mean	JJ	O
change	NN	O
of	IN	O
initial	JJ	O
claudication	NN	O
distance	NN	O
was	VBD	O
33.9	CD	O
%	NN	O
after	IN	O
nebivolol	NN	O
(	(	O
P=0.003	NNP	O
)	)	O
and	CC	O
16.6	CD	O
%	NN	O
after	IN	O
metoprolol	NN	O
(	(	O
P=0.12	NNP	O
)	)	O
treatment	NN	O
.	.	O

Quality	NN	O
of	IN	O
life	NN	O
was	VBD	O
not	RB	O
influenced	VBN	O
by	IN	O
either	DT	O
treatment	NN	O
,	,	O
and	CC	O
there	EX	O
was	VBD	O
no	DT	O
relevant	JJ	O
change	NN	O
in	IN	O
flow-mediated	JJ	O
dilatation	NN	O
in	IN	O
patients	NNS	O
treated	VBN	O
with	IN	O
nebivolol	NN	O
or	CC	O
metoprolol	NN	O
(	(	O
P=0.16	NNP	O
)	)	O
.	.	O

Both	DT	O
drugs	NNS	O
were	VBD	O
equally	RB	O
effective	JJ	O
in	IN	O
lowering	VBG	O
blood	NN	O
pressure	NN	O
.	.	O

In	IN	O
conclusion	NN	O
,	,	O
?-blocker	JJ	O
therapy	NN	O
was	VBD	O
well	RB	O
tolerated	VBN	O
in	IN	O
patients	NNS	O
with	IN	O
intermittent	JJ	O
claudication	NN	O
and	CC	O
arterial	JJ	O
hypertension	NN	O
during	IN	O
a	DT	O
treatment	NN	O
period	NN	O
of	IN	O
?1	JJ	O
year	NN	O
.	.	O

In	IN	O
the	DT	O
direct	JJ	O
comparison	NN	O
,	,	O
there	EX	O
was	VBD	O
no	DT	O
significant	JJ	O
difference	NN	O
between	IN	O
nebivolol	NNS	O
and	CC	O
metoprolol	NN	O
.	.	O

Rationale	NNP	O
and	CC	O
study	VB	O
design	NN	O
of	IN	O
the	DT	O
increase	NN	O
of	IN	O
vagal	JJ	O
tone	NN	O
in	IN	O
heart	NN	O
failure	NN	O
study	NN	O
:	:	O
INOVATE-HF	NNP	O
.	.	O

BACKGROUND	NNP	O
Imbalance	NNP	O
between	IN	O
the	DT	O
parasympathetic	JJ	O
and	CC	O
sympathetic	JJ	O
nervous	JJ	O
systems	NNS	O
is	VBZ	O
a	DT	O
recognized	VBN	O
contributor	NN	O
to	TO	O
progression	NN	O
of	IN	O
chronic	JJ	O
heart	NN	O
failure	NN	O
.	.	O

Current	JJ	O
therapy	NN	O
with	IN	O
beta	NN	O
adrenergic	JJ	O
antagonists	NNS	O
is	VBZ	O
designed	VBN	O
to	TO	O
moderate	VB	O
the	DT	O
up-regulation	NN	O
of	IN	O
norepinephrine	NN	O
and	CC	O
sympathetic	JJ	O
effects	NNS	O
;	:	O
however	RB	O
,	,	O
to	TO	O
date	NN	O
,	,	O
there	EX	O
are	VBP	O
no	DT	O
therapies	NNS	O
that	WDT	O
specifically	RB	O
address	VBP	O
the	DT	O
withdrawal	NN	O
of	IN	O
parasympathetic	JJ	O
influences	NNS	O
on	IN	O
cardiac	JJ	O
function	NN	O
and	CC	O
structure	NN	O
.	.	O

METHODS/RESULTS	NNP	O
In	IN	O
order	NN	O
to	TO	O
evaluate	VB	O
the	DT	O
impact	NN	O
of	IN	O
vagus	NN	O
nerve	NN	O
stimulation	NN	O
,	,	O
an	DT	O
international	JJ	O
multi-center	NN	O
randomized	VBD	O
clinical	JJ	O
trial	NN	O
(	(	O
INOVATE-HF	NNP	O
)	)	O
has	VBZ	O
been	VBN	O
designed	VBN	O
to	TO	O
assess	VB	O
safety	NN	O
and	CC	O
efficacy	NN	O
of	IN	O
vagus	NN	O
nerve	NN	O
stimulation	NN	O
in	IN	O
symptomatic	JJ	O
patients	NNS	O
with	IN	O
heart	NN	O
failure	NN	O
on	IN	O
optimal	JJ	O
medical	JJ	O
therapy	NN	O
using	VBG	O
the	DT	O
CardioFit	NNP	O
System	NNP	O
(	(	O
BioControl	NNP	O
Medical	NNP	O
,	,	O
Yehud	NNP	O
,	,	O
Israel	NNP	O
)	)	O
.	.	O

Up	UH	O
to	TO	O
650	CD	O
patients	NNS	O
from	IN	O
80	CD	O
sites	NNS	O
will	MD	O
be	VB	O
recruited	VBN	O
and	CC	O
randomized	VBN	O
in	IN	O
a	DT	O
3:2	CD	O
ratio	NN	O
to	TO	O
receive	VB	O
active	JJ	O
treatment	NN	O
or	CC	O
standard	NN	O
optimal	JJ	O
medical	JJ	O
therapy	NN	O
.	.	O

Inclusion	NNP	O
criteria	NNS	O
include	VBP	O
left	JJ	O
ventricular	JJ	O
systolic	JJ	O
dysfunction	NN	O
,	,	O
the	DT	O
presence	NN	O
of	IN	O
New	NNP	O
York	NNP	O
Heart	NNP	O
Association	NNP	O
Class	NNP	O
III	NNP	O
symptoms	NNS	O
,	,	O
sinus	NN	O
rhythm	NN	O
,	,	O
and	CC	O
QRS	NNP	O
width	VBD	O
less	JJR	O
than	IN	O
120	CD	O
milliseconds	NNS	O
.	.	O

The	DT	O
study	NN	O
is	VBZ	O
powered	VBN	O
to	TO	O
detect	VB	O
differences	NNS	O
in	IN	O
the	DT	O
primary	JJ	O
efficacy	JJ	O
end	NN	O
point	NN	O
of	IN	O
all-cause	JJ	O
mortality	NN	O
and	CC	O
heart	NN	O
failure	NN	O
hospitalization	NN	O
and	CC	O
2	CD	O
safety	NN	O
end	NN	O
points	NNS	O
.	.	O

CONCLUSION	NNP	O
Vagal	NNP	O
nerve	NN	O
stimulation	NN	O
with	IN	O
CardioFit	NNP	O
as	IN	O
a	DT	O
treatment	NN	O
for	IN	O
symptomatic	JJ	O
heart	NN	O
failure	NN	O
is	VBZ	O
under	IN	O
active	JJ	O
investigation	NN	O
as	IN	O
a	DT	O
novel	JJ	O
approach	NN	O
to	TO	O
restore	VB	O
balance	NN	O
between	IN	O
the	DT	O
sympathetic	JJ	O
and	CC	O
parasympathetic	JJ	O
nervous	JJ	O
systems	NNS	O
.	.	O

If	IN	O
shown	VBN	O
to	TO	O
be	VB	O
safe	JJ	O
and	CC	O
effective	JJ	O
in	IN	O
decreasing	VBG	O
heart	NN	O
failure	NN	O
events	NNS	O
and	CC	O
mortality	NN	O
,	,	O
this	DT	O
novel	JJ	O
approach	NN	O
will	MD	O
impact	VB	O
the	DT	O
treatment	NN	O
paradigm	NN	O
for	IN	O
heart	NN	O
failure	NN	O
.	.	O

Preliminary	JJ	O
findings	NNS	O
of	IN	O
the	DT	O
minimally-invasive	JJ	O
surgery	NN	O
plus	CC	O
rtPA	NN	O
for	IN	O
intracerebral	JJ	C
hemorrhage	NN	C
evacuation	NN	O
(	(	O
MISTIE	NNP	O
)	)	O
clinical	JJ	O
trial	NN	O
.	.	O

INTRODUCTION	NNP	O
Compared	VBD	O
to	TO	O
ischemic	VB	O
stroke	NN	O
,	,	O
intracerebral	JJ	O
hemorrhage	NN	O
(	(	O
ICH	NNP	O
)	)	O
is	VBZ	O
easily	RB	O
and	CC	O
rapidly	RB	O
identified	VBN	O
,	,	O
occurs	VBZ	O
in	IN	O
younger	JJR	A
patients	NNS	O
,	,	O
and	CC	O
produces	VBZ	O
relatively	RB	O
small	JJ	O
initial	JJ	O
injury	NN	O
to	TO	O
cerebral	JJ	O
tissues	NNS	O
--	:	O
all	DT	O
factors	NNS	O
suggesting	VBG	O
that	IN	O
interventional	JJ	O
amelioration	NN	O
is	VBZ	O
possible	JJ	O
.	.	O

Investigations	NNS	O
from	IN	O
the	DT	O
last	JJ	O
decade	NN	O
established	VBD	O
that	IN	O
extent	NN	O
of	IN	O
ICH-mediated	NNP	O
brain	NN	O
injury	NN	O
relates	VBZ	O
directly	RB	O
to	TO	O
blood	VB	O
clot	NN	O
volume	NN	O
and	CC	O
duration	NN	O
of	IN	O
blood	NN	O
exposure	NN	O
to	TO	O
brain	NN	O
tissue	NN	O
.	.	O

Using	VBG	O
minimally-invasive	JJ	O
surgery	NN	O
plus	CC	O
recombinant	JJ	O
tissue	NN	O
plasminogen	NN	O
activator	NN	O
(	(	O
rtPA	NN	O
)	)	O
,	,	O
MISTIE	NNP	O
investigators	NNS	O
explored	VBD	O
aggressive	JJ	O
avenues	NNS	O
to	TO	O
treat	VB	O
ICH	NNP	O
.	.	O

METHODS	NNP	O
We	PRP	O
investigated	VBD	O
the	DT	O
difference	NN	O
between	IN	O
surgical	JJ	O
intervention	NN	O
plus	CC	O
rtPA	NN	O
and	CC	O
standard	JJ	O
medical	JJ	O
management	NN	O
for	IN	O
ICH	NNP	O
.	.	O

Subjects	NNS	O
in	IN	O
both	DT	O
groups	NNS	O
were	VBD	O
medically	RB	O
managed	VBN	O
according	VBG	O
to	TO	O
standard	JJ	O
ICU	NNP	O
protocols	NNS	O
.	.	O

Subjects	NNS	O
randomized	VBD	O
to	TO	O
surgery	VB	O
underwent	JJ	O
stereotactic	JJ	O
catheter	NN	O
placement	NN	O
and	CC	O
clot	NN	O
aspiration	NN	O
.	.	O

Injections	NNS	O
of	IN	O
rtPA	NN	O
were	VBD	O
then	RB	O
given	VBN	O
through	IN	O
hematoma	NN	O
catheter	NN	O
every	DT	O
8	CD	O
h	NN	O
,	,	O
up	RB	O
to	TO	O
9	CD	O
doses	NNS	O
,	,	O
or	CC	O
until	IN	O
a	DT	O
clot-reduction	JJ	O
endpoint	NN	O
.	.	O

After	IN	O
each	DT	O
injection	NN	O
the	DT	O
system	NN	O
was	VBD	O
flushed	VBN	O
with	IN	O
sterile	JJ	O
saline	NN	O
and	CC	O
closed	VBD	O
for	IN	O
60	CD	O
min	NN	O
before	IN	O
opening	VBG	O
to	TO	O
spontaneous	JJ	O
drainage	NN	O
.	.	O

RESULTS	JJ	O
Average	JJ	O
aspiration	NN	O
of	IN	O
clots	NNS	O
for	IN	O
all	DT	O
patients	NNS	O
randomized	VBN	O
to	TO	O
surgery	VB	O
plus	CC	O
rtPA	VB	O
was	VBD	O
20	CD	O
%	NN	O
of	IN	O
mean	JJ	O
initial	JJ	O
clot	NN	O
size	NN	O
.	.	O

After	IN	O
acute	JJ	O
treatment	NN	O
phase	NN	O
(	(	O
aspiration	NN	O
plus	CC	O
rtPA	NN	O
)	)	O
,	,	O
clot	NN	O
was	VBD	O
reduced	VBN	O
an	DT	O
average	NN	O
of	IN	O
46	CD	O
%	NN	O
.	.	O

Recorded	VBN	O
adverse	JJ	O
events	NNS	O
were	VBD	O
within	IN	O
safety	NN	O
limits	NNS	O
,	,	O
including	VBG	O
30-day	JJ	O
mortality	NN	O
,	,	O
8	CD	O
%	NN	O
;	:	O
symptomatic	JJ	O
re-bleeding	NN	O
,	,	O
8	CD	O
%	NN	O
;	:	O
and	CC	O
bacterial	JJ	O
ventriculitis	NN	O
,	,	O
0	CD	O
%	NN	O
.	.	O

Patients	NNS	O
randomized	VBD	O
to	TO	O
medical	JJ	O
management	NN	O
showed	VBD	O
4	CD	O
%	NN	O
clot	NN	O
resolution	NN	O
in	IN	O
a	DT	O
similar	JJ	O
time	NN	O
window	NN	O
.	.	O

Preliminary	JJ	O
analysis	NN	O
indicates	VBZ	O
that	IN	O
clot	NN	O
resolution	NN	O
rates	NNS	O
are	VBP	O
greatly	RB	O
dependent	JJ	O
on	IN	O
catheter	NN	O
placement	NN	O
.	.	O

Location	NN	O
of	IN	O
ICH	NNP	O
also	RB	O
affects	VBZ	O
efficacy	NN	O
of	IN	O
aggressive	JJ	O
treatment	NN	O
of	IN	O
ICH	NNP	O
.	.	O

CONCLUSION	NNP	O
There	EX	O
is	VBZ	O
tentative	JJ	O
indication	NN	O
that	IN	O
minimally-invasive	JJ	O
surgery	NN	O
plus	CC	O
rtPA	NN	O
shows	NNS	O
greater	JJR	O
clot	NN	O
resolution	NN	O
than	IN	O
traditional	JJ	O
medical	JJ	O
management	NN	O
.	.	O

Efficacy	NN	O
and	CC	O
safety	NN	O
of	IN	O
bexarotene	NN	O
combined	VBN	O
with	IN	O
psoralen-ultraviolet	NN	O
A	NNP	O
(	(	O
PUVA	NNP	O
)	)	O
compared	VBN	O
with	IN	O
PUVA	NNP	O
treatment	NN	O
alone	RB	O
in	IN	O
stage	JJ	O
IB-IIA	JJ	O
mycosis	NN	O
fungoides	NNS	O
:	:	O
final	JJ	O
results	NNS	O
from	IN	O
the	DT	O
EORTC	NNP	O
Cutaneous	NNP	C
Lymphoma	NNP	C
Task	NNP	O
Force	NNP	O
phase	NN	O
III	NNP	O
randomized	VBD	O
clinical	JJ	O
trial	NN	O
(	(	O
NCT00056056	NNP	O
)	)	O
.	.	O

BACKGROUND	NNP	O
Psoralen	NNP	O
plus	CC	O
ultraviolet	VB	O
A	NNP	O
(	(	O
PUVA	NNP	O
)	)	O
is	VBZ	O
the	DT	O
standard	JJ	O
treatment	NN	O
for	IN	O
early	JJ	O
stages	NNS	O
of	IN	O
mycosis	NN	C
fungoides	NNS	C
.	.	O

There	EX	O
have	VBP	O
been	VBN	O
no	DT	O
adequate	JJ	O
randomized	VBN	O
controlled	JJ	O
trials	NNS	O
with	IN	O
sufficient	JJ	O
power	NN	O
comparing	VBG	O
this	DT	O
modality	NN	O
with	IN	O
other	JJ	O
therapies	NNS	O
.	.	O

OBJECTIVE	NNP	O
To	TO	O
assess	VB	O
disease	NN	O
response	NN	O
and	CC	O
to	TO	O
compare	VB	O
the	DT	O
response	NN	O
rates	NNS	O
of	IN	O
patients	NNS	O
treated	VBN	O
with	IN	O
PUVA	NNP	O
alone	RB	O
or	CC	O
PUVA	NNP	O
and	CC	O
bexarotene	NN	O
.	.	O

METHODS	NNP	O
EORTC	NNP	O
21011	CD	O
(	(	O
NCT	NNP	O
00056056	CD	O
)	)	O
was	VBD	O
a	DT	O
randomized	JJ	O
phase	NN	O
III	NNP	O
study	NN	O
comparing	VBG	O
combined	VBN	O
bexarotene	NN	O
(	(	O
Targretin	NNP	O
(	(	O
?	.	O
)	)	O
)	)	O
and	CC	O
PUVA	NNP	O
vs.	FW	O
PUVA	NNP	O
alone	RB	O
in	IN	O
patients	NNS	O
with	IN	O
stage	NN	O
IB	NNP	O
and	CC	O
IIA	NNP	O
mycosis	NN	O
fungoides	NNS	O
(	(	O
MF	NNP	O
)	)	O
.	.	O

The	DT	O
primary	JJ	O
endpoint	NN	O
was	VBD	O
the	DT	O
overall	JJ	O
response	NN	O
rate	NN	O
[	NNP	O
complete	JJ	O
clinical	JJ	O
response	NN	O
(	(	O
CCR	NNP	O
)	)	O
plus	CC	O
partial	JJ	O
response	NN	O
(	(	O
PR	NNP	O
)	)	O
]	NN	O
.	.	O

RESULTS	VB	O
The	DT	O
study	NN	O
was	VBD	O
prematurely	RB	O
closed	VBN	O
due	JJ	O
to	TO	O
low	JJ	O
accrual	JJ	O
after	IN	O
93	CD	O
of	IN	O
145	CD	O
required	JJ	O
patients	NNS	O
(	(	O
65	CD	O
%	NN	O
)	)	O
were	VBD	O
randomized	VBN	O
.	.	O

Of	IN	O
the	DT	O
93	CD	O
randomized	JJ	O
patients	NNS	O
,	,	O
87	CD	O
started	VBD	O
treatment	NN	O
,	,	O
41	CD	O
received	VBD	O
PUVA	NNP	O
and	CC	O
46	CD	O
received	VBD	O
PUVA	NNP	O
+	NNP	O
bexarotene	NN	O
.	.	O

Total	JJ	O
UVA	NNP	O
doses	NNS	O
received	VBD	O
were	VBD	O
107	CD	O
J	NNP	O
cm	NN	O
(	(	O
-2	NN	O
)	)	O
(	(	O
range	VB	O
1?4-489?9	CD	O
)	)	O
in	IN	O
the	DT	O
PUVA	NNP	O
arm	NN	O
vs.	FW	O
101?7	CD	O
J	NNP	O
cm	NN	O
(	(	O
-2	NN	O
)	)	O
(	(	O
0?2-529?9	JJ	O
)	)	O
in	IN	O
the	DT	O
combination	NN	O
arm	NN	O
.	.	O

The	DT	O
safety	NN	O
profile	NN	O
was	VBD	O
acceptable	JJ	O
with	IN	O
few	JJ	O
grade	JJ	O
3-4	JJ	O
toxicities	NNS	O
observed	VBN	O
in	IN	O
either	DT	O
arm	NN	O
.	.	O

More	JJR	O
drop-outs	NNS	O
due	JJ	O
to	TO	O
toxicity	NN	O
were	VBD	O
observed	VBN	O
in	IN	O
the	DT	O
combination	NN	O
arm	NN	O
compared	VBN	O
with	IN	O
the	DT	O
PUVA-alone	JJ	O
arm	NN	O
.	.	O

The	DT	O
best	JJS	O
overall	JJ	O
response	NN	O
(	(	O
CCR	NNP	O
+	NNP	O
PR	NNP	O
)	)	O
rate	NN	O
was	VBD	O
71	CD	O
%	NN	O
for	IN	O
PUVA	NNP	O
alone	RB	O
and	CC	O
77	CD	O
%	NN	O
for	IN	O
the	DT	O
combination	NN	O
arm	NN	O
(	(	O
P	NNP	O
=	NNP	O
0?57	CD	O
)	)	O
.	.	O

The	DT	O
median	JJ	O
duration	NN	O
of	IN	O
response	NN	O
was	VBD	O
9?7	CD	O
months	NNS	O
for	IN	O
PUVA	NNP	O
vs.	FW	O
5?8	CD	O
months	NNS	O
for	IN	O
the	DT	O
combination	NN	O
arm	NN	O
(	(	O
P	NNP	O
=	NNP	O
0?33	CD	O
)	)	O
.	.	O

CCR	NNP	O
was	VBD	O
seen	VBN	O
in	IN	O
25	CD	O
patients	NNS	O
of	IN	O
whom	WP	O
10	CD	O
received	VBD	O
PUVA	NNP	O
alone	RB	O
(	(	O
CCR	NNP	O
22	CD	O
%	NN	O
)	)	O
and	CC	O
15	CD	O
received	VBN	O
combination	NN	O
therapy	NN	O
(	(	O
CCR	NNP	O
31	CD	O
%	NN	O
)	)	O
(	(	O
P	NNP	O
=	NNP	O
0?45	CD	O
)	)	O
.	.	O

CCR	NNP	O
was	VBD	O
sustained	VBN	O
in	IN	O
25	CD	O
%	NN	O
of	IN	O
patients	NNS	O
regardless	RB	O
of	IN	O
therapy	NN	O
.	.	O

There	EX	O
was	VBD	O
a	DT	O
trend	NN	O
towards	VBZ	O
fewer	JJR	O
PUVA	NNP	O
sessions	NNS	O
needed	VBD	O
to	TO	O
achieve	VB	O
CCR	NNP	O
in	IN	O
the	DT	O
combination	NN	O
arm	NN	O
(	(	O
median	JJ	O
22	CD	O
)	)	O
compared	VBN	O
with	IN	O
the	DT	O
PUVA	NNP	O
arm	NN	O
(	(	O
median	JJ	O
27?5	CD	O
)	)	O
(	(	O
P	NNP	O
=	NNP	O
0?11	CD	O
)	)	O
.	.	O

Similarly	RB	O
,	,	O
a	DT	O
trend	NN	O
towards	NNS	O
lower	JJR	O
UVA	NNP	O
dose	NN	O
required	VBN	O
to	TO	O
achieve	VB	O
CCR	NNP	O
in	IN	O
the	DT	O
combination	NN	O
arm	NN	O
(	(	O
median	JJ	O
55?8	CD	O
J	NNP	O
cm	NN	O
(	(	O
-2	NNP	O
)	)	O
)	)	O
compared	VBN	O
with	IN	O
the	DT	O
PUVA	NNP	O
arm	NN	O
alone	RB	O
(	(	O
median	JJ	O
117?5	CD	O
J	NNP	O
cm	NN	O
(	(	O
-2	NNP	O
)	)	O
)	)	O
(	(	O
P	NNP	O
=	NNP	O
0?5	CD	O
)	)	O
was	VBD	O
observed	VBN	O
.	.	O

CONCLUSIONS	NNP	O
No	NNP	O
significant	JJ	O
difference	NN	O
in	IN	O
response	NN	O
rate	NN	O
or	CC	O
response	NN	O
duration	NN	O
was	VBD	O
observed	VBN	O
in	IN	O
this	DT	O
study	NN	O
.	.	O

However	RB	O
,	,	O
there	EX	O
was	VBD	O
a	DT	O
trend	NN	O
towards	VBZ	O
fewer	JJR	O
PUVA	NNP	O
sessions	NNS	O
and	CC	O
lower	JJR	O
UVA	NNP	O
dose	NN	O
required	VBN	O
to	TO	O
achieve	VB	O
CCR	NNP	O
in	IN	O
the	DT	O
combination	NN	O
arm	NN	O
(	(	O
PUVA	NNP	O
+	NNP	O
bexarotene	NN	O
)	)	O
but	CC	O
this	DT	O
did	VBD	O
not	RB	O
achieve	VB	O
statistical	JJ	O
significance	NN	O
due	JJ	O
to	TO	O
insufficient	JJ	O
power	NN	O
.	.	O

The	DT	O
effect	NN	O
of	IN	O
random	JJ	O
modulation	NN	O
of	IN	O
functional	JJ	O
electrical	JJ	O
stimulation	NN	O
parameters	NNS	O
on	IN	O
muscle	NN	C
fatigue	NN	C
.	.	O

Muscle	NNP	O
contractions	NNS	O
induced	VBN	O
by	IN	O
functional	JJ	O
electrical	JJ	O
stimulation	NN	O
(	(	O
FES	NNP	O
)	)	O
tend	VBP	O
to	TO	O
result	VB	O
in	IN	O
rapid	JJ	O
muscle	NN	O
fatigue	NN	O
,	,	O
which	WDT	O
greatly	RB	O
limits	VBZ	O
activities	NNS	O
such	JJ	O
as	IN	O
FES-assisted	JJ	O
standing	NN	O
and	CC	O
walking	NN	O
.	.	O

It	PRP	O
was	VBD	O
hypothesized	VBN	O
that	IN	O
muscle	NN	O
fatigue	NN	O
caused	VBN	O
by	IN	O
FES	NNP	O
could	MD	O
be	VB	O
reduced	VBN	O
by	IN	O
randomly	RB	O
modulating	VBG	O
parameters	NNS	O
of	IN	O
the	DT	O
electrical	JJ	O
stimulus	NN	O
.	.	O

Seven	NNP	SS
paraplegic	JJ	O
subjects	NNS	O
participated	VBN	O
in	IN	O
this	DT	O
study	NN	O
.	.	O

While	IN	O
subjects	NNS	O
were	VBD	O
seated	VBN	O
,	,	O
FES	NNP	O
was	VBD	O
applied	VBN	O
to	TO	O
quadriceps	NNS	O
and	CC	O
tibialis	JJ	O
anterior	JJ	O
muscles	NNS	O
bilaterally	RB	O
using	VBG	O
surface	NN	O
electrodes	NNS	O
.	.	O

The	DT	O
isometric	JJ	O
force	NN	O
was	VBD	O
measured	VBN	O
,	,	O
and	CC	O
the	DT	O
time	NN	O
for	IN	O
the	DT	O
force	NN	O
to	TO	O
drop	VB	O
by	IN	O
3	CD	O
dB	NN	O
(	(	O
fatigue	JJ	O
time	NN	O
)	)	O
and	CC	O
the	DT	O
normalized	JJ	O
force-time	JJ	O
integral	JJ	O
(	(	O
FTI	NNP	O
)	)	O
were	VBD	O
determined	VBN	O
.	.	O

Four	CD	O
different	JJ	O
modes	NNS	O
of	IN	O
FES	NNP	O
were	VBD	O
applied	VBN	O
in	IN	O
random	JJ	O
order	NN	O
:	:	O
constant	JJ	O
stimulation	NN	O
,	,	O
randomized	VBN	O
frequency	NN	O
(	(	O
mean	JJ	O
40	CD	O
Hz	NNP	O
)	)	O
,	,	O
randomized	VBN	O
current	JJ	O
amplitude	NN	O
,	,	O
and	CC	O
randomized	VBD	O
pulsewidth	NN	O
(	(	O
mean	JJ	O
250	CD	O
micros	NN	O
)	)	O
.	.	O

In	IN	O
randomized	JJ	O
trials	NNS	O
,	,	O
stimulation	NN	O
parameters	NNS	O
were	VBD	O
stochastically	RB	O
modulated	VBN	O
every	DT	O
100	CD	O
ms	NN	O
in	IN	O
a	DT	O
range	NN	O
of	IN	O
+/-15	NNP	O
%	NN	O
using	VBG	O
a	DT	O
uniform	JJ	O
probability	NN	O
distribution	NN	O
.	.	O

There	EX	O
was	VBD	O
no	DT	O
significant	JJ	O
difference	NN	O
between	IN	O
the	DT	O
fatigue	NN	O
time	NN	O
measurements	NNS	O
for	IN	O
the	DT	O
four	CD	O
modes	NNS	O
of	IN	O
stimulation	NN	O
.	.	O

There	EX	O
was	VBD	O
also	RB	O
no	DT	O
significant	JJ	O
difference	NN	O
in	IN	O
the	DT	O
FTI	NNP	O
measurements	NNS	O
.	.	O

Therefore	RB	O
,	,	O
our	PRP$	O
particular	JJ	O
method	NN	O
of	IN	O
stochastic	JJ	O
modulation	NN	O
of	IN	O
the	DT	O
stimulation	NN	O
parameters	NNS	O
,	,	O
which	WDT	O
involved	VBD	O
moderate	JJ	O
(	(	O
15	CD	O
%	NN	O
)	)	O
variations	NNS	O
updated	VBN	O
every	DT	O
100	CD	O
ms	NN	O
and	CC	O
centered	VBD	O
around	IN	O
40	CD	O
Hz	NNP	O
,	,	O
appeared	VBD	O
to	TO	O
have	VB	O
no	DT	O
effect	NN	O
on	IN	O
muscle	NN	O
fatigue	NN	O
.	.	O

There	EX	O
was	VBD	O
a	DT	O
strong	JJ	O
correlation	NN	O
between	IN	O
maximum	JJ	O
force	NN	O
measurements	NNS	O
and	CC	O
stimulation	NN	O
order	NN	O
,	,	O
which	WDT	O
was	VBD	O
not	RB	O
apparent	JJ	O
in	IN	O
the	DT	O
fatigue	JJ	O
time	NN	O
or	CC	O
FTI	NNP	O
measurements	NNS	O
.	.	O

It	PRP	O
was	VBD	O
concluded	VBN	O
that	IN	O
a	DT	O
10-min	JJ	O
rest	NN	O
period	NN	O
between	IN	O
stimulation	NN	O
trials	NNS	O
was	VBD	O
insufficient	JJ	O
to	TO	O
allow	VB	O
full	JJ	O
recovery	NN	O
of	IN	O
muscle	NN	O
strength	NN	O
.	.	O

Covariation	NN	O
of	IN	O
adolescent	JJ	A
physical	JJ	O
activity	NN	O
and	CC	O
dietary	JJ	O
behaviors	NNS	O
over	IN	O
12	CD	O
months	NNS	O
.	.	O

PURPOSE	VB	O
This	DT	O
study	NN	O
examined	VBD	O
covariation	NN	O
among	IN	O
changes	NNS	O
in	IN	O
dietary	JJ	O
,	,	O
physical	JJ	O
activity	NN	O
,	,	O
and	CC	O
sedentary	JJ	O
behaviors	NNS	O
over	IN	O
12	CD	O
months	NNS	O
among	IN	O
adolescents	NNS	O
participating	VBG	O
in	IN	O
a	DT	O
health	NN	C
behavior	NN	C
intervention	NN	C
.	.	O

Evidence	NN	O
of	IN	O
covariation	NN	O
among	IN	O
behaviors	NNS	O
would	MD	O
suggest	VB	O
multi-behavior	JJ	O
interventions	NNS	O
could	MD	O
have	VB	O
synergistic	JJ	O
effects	NNS	O
.	.	O

METHODS	NNP	O
Prospective	JJ	O
analyses	NNS	O
were	VBD	O
conducted	VBN	O
with	IN	O
baseline	NN	O
and	CC	O
12-month	JJ	O
assessments	NNS	O
from	IN	O
a	DT	O
randomized	VBN	O
controlled	VBN	O
trial	NN	O
to	TO	O
promote	VB	O
improved	JJ	O
diet	JJ	O
,	,	O
physical	JJ	O
activity	NN	O
,	,	O
and	CC	O
sedentary	JJ	O
behaviors	NNS	O
(	(	O
experimental	JJ	O
condition	NN	O
)	)	O
or	CC	O
SUN	NNP	O
protection	NN	O
behaviors	NNS	O
(	(	O
comparison	JJ	O
condition	NN	O
)	)	O
.	.	O

Participants	NNS	O
were	VBD	O
adolescent	JJ	O
girls	NNS	SE
and	CC	O
boys	NNS	SE
(	(	O
N	NNP	O
=	NNP	O
878	CD	SS
)	)	O
aged	VBN	O
11-15	CD	A
years	NNS	O
on	IN	O
entry	NN	O
.	.	O

The	DT	O
main	JJ	O
outcomes	NNS	O
were	VBD	O
:	:	O
diet	NN	O
,	,	O
based	VBN	O
on	IN	O
multiple	JJ	O
24-hour	JJ	O
recalls	NNS	O
(	(	O
total	JJ	O
fat	NN	O
,	,	O
grams	NNS	O
of	IN	O
fiber	NN	O
,	,	O
servings	NNS	O
of	IN	O
fruit	NN	O
and	CC	O
vegetables	NNS	O
,	,	O
total	JJ	O
calories	NNS	O
)	)	O
;	:	O
average	JJ	O
daily	JJ	O
energy	NN	O
expenditure	NN	O
(	(	O
kcals/kg	NN	O
)	)	O
based	VBN	O
on	IN	O
7-day	JJ	O
physical	JJ	O
activity	NN	O
recall	VBP	O
interviews	NNS	O
;	:	O
daily	JJ	O
minutes	NNS	O
of	IN	O
moderate-vigorous	JJ	O
physical	JJ	O
activity	NN	O
minutes	NNS	O
from	IN	O
accelerometery	NN	O
;	:	O
and	CC	O
self-reported	JJ	O
daily	JJ	O
hours	NNS	O
of	IN	O
sedentary	JJ	O
behavior	NN	O
.	.	O

RESULTS	NNP	O
Covariation	NNP	O
was	VBD	O
found	VBN	O
between	IN	O
fat	NN	O
and	CC	O
calories	NNS	O
(	(	O
r	NN	O
=	NNP	O
.16	NNP	O
)	)	O
,	,	O
fiber	NN	O
and	CC	O
calories	NNS	O
(	(	O
r	NN	O
=	NNP	O
.53	NNP	O
)	)	O
,	,	O
fiber	NN	O
and	CC	O
fruit/vegetables	NNS	O
(	(	O
r	NN	O
=	NNP	O
.53	NNP	O
)	)	O
,	,	O
calories	NNS	O
and	CC	O
fruit/vegetables	NNS	O
(	(	O
r	NN	O
=	NNP	O
.34	NNP	O
)	)	O
,	,	O
and	CC	O
fruit	NN	O
and	CC	O
vegetables	NNS	O
and	CC	O
sedentary	JJ	O
behavior	NN	O
(	(	O
r	JJ	O
=	NNP	O
-.12	NNP	O
)	)	O
for	IN	O
the	DT	O
total	JJ	O
sample	NN	O
(	(	O
all	DT	O
p	NN	O
values	NNS	O
<	NNP	O
.01	NNP	O
)	)	O
.	.	O

The	DT	O
pattern	NN	O
of	IN	O
findings	NNS	O
was	VBD	O
similar	JJ	O
for	IN	O
most	JJS	O
subgroups	NNS	O
defined	VBN	O
by	IN	O
gender	NN	O
and	CC	O
study	NN	O
condition	NN	O
.	.	O

CONCLUSIONS	VB	O
The	DT	O
strongest	JJS	O
covariation	NN	O
was	VBD	O
observed	VBN	O
for	IN	O
diet	JJ	O
variables	NNS	O
that	WDT	O
are	VBP	O
inherently	RB	O
related	VBN	O
(	(	O
calories	NNS	O
and	CC	O
fat	NN	O
,	,	O
fiber	NN	O
,	,	O
and	CC	O
fruit/vegetables	NNS	O
)	)	O
.	.	O

Little	JJ	O
covariation	NN	O
was	VBD	O
detected	VBN	O
within	IN	O
or	CC	O
between	IN	O
other	JJ	O
diet	JJ	O
,	,	O
physical	JJ	O
activity	NN	O
and	CC	O
sedentary	JJ	O
behavior	NN	O
domains	NNS	O
suggesting	VBG	O
that	IN	O
interventions	NNS	O
to	TO	O
improve	VB	O
these	DT	O
behaviors	NNS	O
in	IN	O
adolescents	NNS	O
need	VBP	O
to	TO	O
include	VB	O
specific	JJ	O
program	NN	O
components	NNS	O
for	IN	O
each	DT	O
target	NN	O
behavior	NN	O
of	IN	O
interest	NN	O
.	.	O

Prospective	JJ	O
study	NN	O
of	IN	O
Clostridium	NNP	O
difficile	JJ	O
intestinal	JJ	O
colonization	NN	O
and	CC	O
disease	NN	O
following	VBG	O
single-dose	JJ	O
antibiotic	JJ	O
prophylaxis	NN	O
in	IN	O
surgery	NN	O
.	.	O

A	DT	O
total	NN	O
of	IN	O
108	CD	SS
volunteers	NNS	O
undergoing	VBG	O
an	DT	O
elective	JJ	C
surgical	JJ	C
procedure	NN	C
were	VBD	O
randomly	RB	O
given	VBN	O
a	DT	O
single	JJ	O
2-g	JJ	O
intravenous	JJ	O
prophylactic	JJ	O
dose	NN	O
of	IN	O
either	CC	O
a	DT	O
cephalosporin	NN	O
or	CC	O
mezlocillin	NN	O
.	.	O

Stool	NNP	O
samples	NNS	O
were	VBD	O
cultured	VBN	O
for	IN	O
Clostridium	NNP	O
difficile	VBP	O
the	DT	O
day	NN	O
before	IN	O
the	DT	O
operation	NN	O
and	CC	O
later	RB	O
on	IN	O
postoperative	JJ	O
days	NNS	O
4	CD	O
,	,	O
7	CD	O
,	,	O
and	CC	O
14	CD	O
.	.	O

C.	NNP	O
difficile	NN	O
was	VBD	O
detected	VBN	O
in	IN	O
23.0	CD	O
%	NN	O
of	IN	O
patients	NNS	O
who	WP	O
received	VBD	O
a	DT	O
cephalosporin	NN	O
(	(	O
cefoxitin	NN	O
,	,	O
8.3	CD	O
%	NN	O
;	:	O
cefazolin	NN	O
,	,	O
14.3	CD	O
%	NN	O
;	:	O
cefotetan	NN	O
,	,	O
20.0	CD	O
%	NN	O
;	:	O
ceftriaxone	NN	O
,	,	O
25.0	CD	O
%	NN	O
;	:	O
cefoperazone	NN	O
,	,	O
43.7	CD	O
%	NN	O
)	)	O
,	,	O
in	IN	O
3.3	CD	O
%	NN	O
of	IN	O
patients	NNS	O
given	VBN	O
mezlocillin	NNS	O
,	,	O
and	CC	O
in	IN	O
none	NN	O
of	IN	O
15	CD	SS
control	NN	O
volunteers	NNS	O
given	VBN	O
no	DT	O
antimicrobial	JJ	O
agent	NN	O
.	.	O

No	DT	O
patient	NN	O
experienced	VBD	O
diarrhea	NN	O
.	.	O

Treatment	NN	O
of	IN	O
vasculogenic	JJ	C
sexual	JJ	C
dysfunction	NN	C
with	IN	O
pentoxifylline	NN	O
.	.	O

OBJECTIVE	UH	O
To	TO	O
evaluate	VB	O
the	DT	O
use	NN	O
of	IN	O
pentoxifylline	NN	O
to	TO	O
treat	VB	O
impotence	NN	O
in	IN	O
men	NNS	O
with	IN	O
mild	NN	O
to	TO	O
moderate	VB	O
penile	IN	O
vascular	JJ	O
insufficiency	NN	O
.	.	O

DESIGN	NNP	O
Double-blind	NNP	O
randomized	VBD	O
clinical	JJ	O
trial	NN	O
.	.	O

SETTING	NN	O
Sexual	JJ	O
Dysfunction	NNP	O
Clinic	NNP	O
at	IN	O
VA	NNP	O
Medical	NNP	O
Center	NNP	O
,	,	O
Sepulveda	NNP	O
,	,	O
CA	NNP	O
.	.	O

PARTICIPANTS	NNP	O
Convenience	NNP	O
sample	NN	O
of	IN	O
couples	NNS	O
.	.	O

INTERVENTION	NNP	O
Twelve	NNP	O
weeks	NNS	O
of	IN	O
treatment	NN	O
with	IN	O
placebo	NN	O
or	CC	O
400	CD	O
mg	JJ	O
tid	NN	O
of	IN	O
pentoxifylline	NN	O
.	.	O

MEASUREMENTS	NNP	O
(	(	O
1	CD	O
)	)	O
Report	NN	O
of	IN	O
patient	JJ	O
verified	VBN	O
by	IN	O
partner	NN	O
as	IN	O
to	TO	O
number	NN	O
of	IN	O
coital	JJ	O
episodes	NNS	O
per	IN	O
month	NN	O
;	:	O
(	(	O
2	CD	O
)	)	O
penile-brachial	JJ	O
pressure	NN	O
index	NN	O
determinations	NNS	O
.	.	O

RESULTS	NNP	O
Pentoxifylline	NNP	O
therapy	VBZ	O
regularly	RB	O
increased	VBN	O
the	DT	O
PBPI	NNP	O
in	IN	O
impotent	JJ	O
men	NNS	O
in	IN	O
comparison	NN	O
with	IN	O
the	DT	O
placebo	NN	O
,	,	O
frequently	RB	O
into	IN	O
the	DT	O
normal	JJ	O
range	NN	O
.	.	O

Pentoxifylline	NNP	O
therapy	NN	O
was	VBD	O
particularly	RB	O
useful	JJ	O
in	IN	O
restoring	VBG	O
the	DT	O
PBPI	NNP	O
in	IN	O
men	NNS	O
with	IN	O
the	DT	O
pelvic	JJ	O
steal	JJ	O
syndrome	NN	O
;	:	O
six	CD	O
of	IN	O
seven	CD	O
such	JJ	O
subjects	NNS	O
improved	VBN	O
into	IN	O
the	DT	O
normal	JJ	O
range	NN	O
.	.	O

During	IN	O
the	DT	O
pentoxifylline	JJ	O
treatment	NN	O
period	NN	O
,	,	O
in	IN	O
contrast	NN	O
with	IN	O
the	DT	O
control	NN	O
period	NN	O
,	,	O
nine	CD	O
men	NNS	O
were	VBD	O
able	JJ	O
to	TO	O
reestablish	VB	O
coital	JJ	O
function	NN	O
and	CC	O
three	CD	O
had	VBD	O
no	DT	O
improvement	NN	O
.	.	O

Six	NNP	O
couples	NNS	O
did	VBD	O
not	RB	O
attempt	VB	O
intercourse	JJ	O
despite	IN	O
a	DT	O
professed	JJ	O
interest	NN	O
in	IN	O
sexual	JJ	O
activity	NN	O
;	:	O
however	RB	O
five	CD	O
out	IN	O
of	IN	O
the	DT	O
six	CD	O
men	NNS	O
experienced	VBD	O
erections	NNS	O
during	IN	O
episodes	NNS	O
of	IN	O
fantasy	NN	O
or	CC	O
attempts	NNS	O
at	IN	O
masturbation	NN	O
during	IN	O
treatment	NN	O
.	.	O

There	EX	O
were	VBD	O
no	DT	O
complications	NNS	O
of	IN	O
therapy	NN	O
.	.	O

CONCLUSIONS	NNP	O
These	DT	O
promising	VBG	O
preliminary	JJ	O
results	NNS	O
suggest	VBP	O
a	DT	O
well	RB	O
tolerated	JJ	O
alternative	JJ	O
therapy	NN	O
for	IN	O
erectile	JJ	O
dysfunction	NN	O
in	IN	O
patients	NNS	O
with	IN	O
mild	JJ	O
to	TO	O
moderate	VB	O
penile	IN	O
vascular	JJ	O
disease	NN	O
.	.	O

Removal	NN	O
of	IN	O
inflammatory	JJ	O
cytokines	NNS	O
and	CC	O
endotoxin	NN	O
by	IN	O
veno-venous	JJ	O
continuous	JJ	O
renal	JJ	O
replacement	NN	O
therapy	NN	O
for	IN	O
burned	JJ	C
patients	NNS	C
with	IN	O
sepsis	NN	C
.	.	O

OBJECTIVE	UH	O
To	TO	O
evaluate	VB	O
the	DT	O
effect	NN	O
of	IN	O
veno-venous	JJ	O
continuous	JJ	O
renal	JJ	O
replacement	NN	O
therapy	NN	O
(	(	O
CRRT	NNP	O
)	)	O
on	IN	O
the	DT	O
plasma	NN	O
levels	NNS	O
of	IN	O
endotoxin	NN	O
and	CC	O
cytokines	NNS	O
in	IN	O
severely	RB	C
burned	VBN	C
patients	NNS	C
with	IN	O
sepsis	NN	C
.	.	O

METHODS	NNP	O
Twenty	NNP	SS
adult	NN	O
severely	RB	C
burned	VBD	C
patients	NNS	C
with	IN	C
sepsis	NN	C
were	VBD	O
studied	VBN	O
.	.	O

For	IN	O
the	DT	O
diagnosis	NN	O
of	IN	O
sepsis	NN	O
,	,	O
patients	NNS	O
were	VBD	O
randomly	RB	O
divided	VBN	O
into	IN	O
CRRT	NNP	O
(	(	O
n=10	NN	O
)	)	O
and	CC	O
Control	NNP	O
(	(	O
n=10	RB	O
)	)	O
.	.	O

Both	DT	O
groups	NNS	O
received	VBD	O
conventional	JJ	O
therapy	NN	O
after	IN	O
admission	NN	O
.	.	O

Veno-venous	JJ	O
CRRT	NNP	O
was	VBD	O
administered	VBN	O
to	TO	O
10	CD	O
patients	NNS	O
in	IN	O
the	DT	O
CRRT	NNP	O
group	NN	O
whenever	WDT	O
patients	NNS	O
were	VBD	O
determined	VBN	O
to	TO	O
be	VB	O
septic	JJ	O
.	.	O

The	DT	O
plasma	JJ	O
level	NN	O
of	IN	O
endotoxin	NN	O
,	,	O
TNF-alpha	NNP	O
,	,	O
IL-1	NNP	O
beta	NN	O
,	,	O
IL-6	NNP	O
and	CC	O
IL-8	NNP	O
were	VBD	O
measured	VBN	O
at	IN	O
0	CD	O
,	,	O
1	CD	O
,	,	O
2	CD	O
,	,	O
6	CD	O
,	,	O
12	CD	O
,	,	O
36	CD	O
and	CC	O
60	CD	O
h	NN	O
after	IN	O
CRRT	NNP	O
initiation	NN	O
,	,	O
and	CC	O
at	IN	O
0	CD	O
,	,	O
12	CD	O
,	,	O
36	CD	O
and	CC	O
60	CD	O
h	NN	O
after	IN	O
the	DT	O
patients	NNS	O
were	VBD	O
diagnosed	VBN	O
as	IN	O
having	VBG	O
sepsis	NN	O
in	IN	O
the	DT	O
Control	NNP	O
group	NN	O
.	.	O

MAIN	NNP	O
RESULTS	NNP	O
Plasma	NNP	O
level	NN	O
of	IN	O
endotoxin	NN	O
and	CC	O
all	PDT	O
the	DT	O
cytokines	NNS	O
after	IN	O
CRRT	NNP	O
initiation	NN	O
were	VBD	O
significantly	RB	O
lower	JJR	O
than	IN	O
those	DT	O
before	IN	O
the	DT	O
treatment	NN	O
(	(	O
P	NNP	O
<	NNP	O
0.01	CD	O
)	)	O
.	.	O

The	DT	O
serial	JJ	O
change	NN	O
of	IN	O
endotoxin	NN	O
,	,	O
IL-1	NNP	O
beta	NN	O
,	,	O
IL-6	NNP	O
and	CC	O
IL-8	NNP	O
was	VBD	O
significantly	RB	O
lower	JJR	O
at	IN	O
12	CD	O
,	,	O
36	CD	O
and	CC	O
60	CD	O
h	NN	O
after	IN	O
treatment	NN	O
compared	VBN	O
with	IN	O
Control	NNP	O
groups	NNS	O
(	(	O
P	NNP	O
<	NNP	O
0.01	CD	O
)	)	O
.	.	O

A	DT	O
significant	JJ	O
decrease	NN	O
in	IN	O
plasma	JJ	O
TNF-alpha	JJ	O
levels	NNS	O
was	VBD	O
seen	VBN	O
at	IN	O
36	CD	O
and	CC	O
60	CD	O
h	NN	O
after	IN	O
treatment	NN	O
compared	VBN	O
with	IN	O
Control	NNP	O
groups	NNS	O
(	(	O
P	NNP	O
<	NNP	O
0.01	CD	O
)	)	O
.	.	O

CONCLUSION	NNP	O
Plasma	NNP	O
endotoxin	NN	O
and	CC	O
cytokines	NNS	O
(	(	O
TNF-alpha	NNP	O
,	,	O
IL-1	NNP	O
beta	NN	O
,	,	O
IL-6	NNP	O
and	CC	O
IL-8	NNP	O
)	)	O
can	MD	O
be	VB	O
removed	VBN	O
effectively	RB	O
with	IN	O
CRRT	NNP	O
in	IN	O
severely	RB	O
burned	VBN	O
patients	NNS	O
with	IN	O
sepsis	NN	O
.	.	O

Predictors	NNS	O
of	IN	O
survival	NN	O
and	CC	O
eradication	NN	O
of	IN	O
Mycobacterium	NNP	O
avium	NN	O
complex	NN	O
bacteremia	NN	O
(	(	O
MAC	NNP	O
)	)	O
in	IN	O
AIDS	NNP	C
patients	NNS	O
in	IN	O
the	DT	O
Canadian	NNP	O
randomized	VBD	O
MAC	NNP	O
treatment	NN	O
trial	NN	O
.	.	O

Canadian	JJ	O
HIV	NNP	O
Trials	NNP	O
Network	NNP	O
Protocol	NNP	O
010	CD	O
Study	NNP	O
Group	NNP	O
.	.	O

OBJECTIVE	NNP	O
To	TO	O
assess	VB	O
the	DT	O
importance	NN	O
of	IN	O
baseline	NN	O
characteristics	NNS	O
including	VBG	O
medical	JJ	O
history	NN	O
,	,	O
indicators	NNS	O
of	IN	O
current	JJ	O
disease	NN	O
status	NN	O
,	,	O
therapeutic	JJ	O
drug	NN	O
use	NN	O
,	,	O
in	IN	O
vitro	JJ	O
drug	NN	O
susceptibility	NN	O
,	,	O
immune	JJ	O
status	NN	O
and	CC	O
mycobacterial	JJ	O
load	NN	O
on	IN	O
bacteriologic	JJ	O
response	NN	O
and	CC	O
survival	NN	O
in	IN	O
HIV-positive	JJ	C
patients	NNS	O
with	IN	O
Mycobacterium	NNP	C
avium	NN	C
complex	NN	C
(	(	C
MAC	NNP	C
)	)	C
bacteremia	NN	C
.	.	O

DESIGN	NNP	O
An	DT	O
observational	JJ	O
substudy	NN	O
of	IN	O
an	DT	O
open-label	JJ	O
randomized	NN	O
controlled	VBD	O
trial	NN	O
of	IN	O
two	CD	O
alternative	JJ	O
therapeutic	JJ	O
regimens	NNS	O
for	IN	O
MAC	NNP	O
.	.	O

SETTING	NNP	O
Twenty-four	JJ	SS
hospital-based	JJ	O
HIV	NNP	O
clinics	NNS	O
in	IN	O
16	CD	O
Canadian	JJ	O
cities	NNS	O
.	.	O

MAIN	NNP	O
OUTCOME	NNP	O
MEASURES	NNP	O
The	DT	O
main	JJ	O
outcome	NN	O
measures	NNS	O
were	VBD	O
survival	JJ	O
and	CC	O
bacteriologic	JJ	O
response	NN	O
,	,	O
defined	VBN	O
by	IN	O
consecutive	JJ	O
negative	JJ	O
blood	NN	O
cultures	NNS	O
for	IN	O
MAC	NNP	O
at	IN	O
least	JJS	O
2	CD	O
weeks	NNS	O
apart	RB	O
within	IN	O
16	CD	O
weeks	NNS	O
of	IN	O
study	NN	O
entry	NN	O
.	.	O

RESULTS	NNP	O
Prior	NNP	O
AIDS	NNP	O
diagnosis	NN	O
,	,	O
low	JJ	O
Karnofsky	NNP	O
score	NN	O
,	,	O
active	JJ	O
unstable	JJ	O
AIDS-related	JJ	O
conditions	NNS	O
,	,	O
absence	NN	O
of	IN	O
antiretroviral	JJ	O
therapy	NN	O
and	CC	O
absence	NN	O
of	IN	O
Pneumocystis	NNP	O
carinii	NN	O
pneumonia	NN	O
prophylaxis	NN	O
were	VBD	O
associated	VBN	O
with	IN	O
shorter	JJR	O
survival	NN	O
by	IN	O
univariate	JJ	O
regression	NN	O
using	VBG	O
the	DT	O
proportional	JJ	O
hazards	NNS	O
model	NN	O
.	.	O

On	IN	O
multivariate	NN	O
analysis	NN	O
,	,	O
antiretroviral	JJ	O
therapy	NN	O
was	VBD	O
not	RB	O
an	DT	O
independent	JJ	O
predictor	NN	O
of	IN	O
mortality	NN	O
,	,	O
and	CC	O
previous	JJ	O
rifabutin	NN	O
prophylaxis	NN	O
was	VBD	O
independently	RB	O
associated	VBN	O
with	IN	O
poor	JJ	O
survival	NN	O
outcomes	NNS	O
,	,	O
a	DT	O
result	NN	O
consistent	JJ	O
across	IN	O
study	NN	O
treatment	NN	O
.	.	O

Using	VBG	O
a	DT	O
logistic	JJ	O
regression	NN	O
model	NN	O
,	,	O
baseline	JJ	O
quantitative	JJ	O
mycobacterial	JJ	O
load	NN	O
[	NNP	O
relative	JJ	O
odds	NNS	O
of	IN	O
clearing	NN	O
,	,	O
1.97	CD	O
for	IN	O
a	DT	O
decrease	NN	O
of	IN	O
1	CD	O
log10	JJ	O
colony	NN	O
forming	VBG	O
count	NN	O
;	:	O
95	CD	O
%	NN	O
confidence	NN	O
interval	NN	O
(	(	O
CI	NNP	O
)	)	O
,	,	O
1.36-2.87	JJ	O
;	:	O
P	NNP	O
<	VBD	O
0.001	CD	O
]	NN	O
and	CC	O
Karnofsky	NNP	O
score	NN	O
were	VBD	O
the	DT	O
only	JJ	O
statistically	RB	O
significant	JJ	O
univariate	JJ	O
predictors	NNS	O
of	IN	O
clearance	NN	O
,	,	O
although	IN	O
previous	JJ	O
prophylaxis	NN	O
with	IN	O
rifabutin	NN	O
was	VBD	O
also	RB	O
a	DT	O
significant	JJ	O
predictor	NN	O
in	IN	O
a	DT	O
multivariate	NN	O
model	NN	O
(	(	O
relative	JJ	O
odds	NNS	O
of	IN	O
clearing	NN	O
,	,	O
0.39	CD	O
;	:	O
95	CD	O
%	NN	O
CI	NNP	O
,	,	O
0.17-0.88	NNP	O
;	:	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
.	.	O

CONCLUSIONS	VB	O
This	DT	O
study	NN	O
indicates	VBZ	O
that	IN	O
although	IN	O
the	DT	O
level	NN	O
of	IN	O
MAC	NNP	O
bacteremia	NN	O
is	VBZ	O
an	DT	O
important	JJ	O
predictor	NN	O
of	IN	O
clearance	NN	O
,	,	O
it	PRP	O
is	VBZ	O
not	RB	O
associated	VBN	O
with	IN	O
survival	NN	O
.	.	O

The	DT	O
effect	NN	O
of	IN	O
the	DT	O
PostureJac	NNP	O
on	IN	O
deep	JJ	O
cervical	JJ	O
flexor	NN	O
endurance	NN	O
:	:	O
implications	NNS	O
in	IN	O
the	DT	O
management	NN	O
of	IN	O
cervicogenic	JJ	O
headache	NN	O
and	CC	O
mechanical	JJ	O
neck	NN	O
pain	NN	O
.	.	O

The	DT	O
convergence	NN	O
of	IN	O
cervical	JJ	O
and	CC	O
trigeminal	JJ	O
afferents	NNS	O
on	IN	O
second-order	JJ	O
neurons	NNS	O
in	IN	O
the	DT	O
trigeminocervical	JJ	O
nucleus	NN	O
may	MD	O
refer	VB	O
pain	NN	O
from	IN	O
the	DT	O
upper	JJ	O
cervical	JJ	O
spine	NN	O
into	IN	O
the	DT	O
head	NN	O
and	CC	O
face	NN	O
.	.	O

Furthermore	RB	O
,	,	O
bi-directional	JJ	O
interactions	NNS	O
between	IN	O
trigeminal	JJ	O
and	CC	O
upper	JJ	O
cervical	JJ	O
afferents	NNS	O
may	MD	O
also	RB	O
explain	VB	O
neck	NN	O
symptoms	NNS	O
of	IN	O
trigeminal	JJ	O
origin	NN	O
(	(	O
e.g.	JJ	O
,	,	O
migraine	NN	O
)	)	O
.	.	O

It	PRP	O
is	VBZ	O
known	VBN	O
that	IN	O
cervicogenic	JJ	O
headache	NN	O
sufferers	NNS	O
present	JJ	O
with	IN	O
several	JJ	O
musculoskeletal	JJ	O
changes	NNS	O
including	VBG	O
poor	JJ	O
endurance	NN	O
of	IN	O
the	DT	O
deep	JJ	O
cervical	JJ	O
flexor	NN	O
muscles	NNS	O
.	.	O

These	DT	O
intrinsic	JJ	O
muscles	NNS	O
of	IN	O
the	DT	O
neck	NN	O
contribute	NN	O
to	TO	O
stabilization	NN	O
and	CC	O
protection	NN	O
of	IN	O
the	DT	O
cervical	JJ	O
spine	NN	O
and	CC	O
are	VBP	O
critical	JJ	O
for	IN	O
the	DT	O
control	NN	O
of	IN	O
both	DT	O
intervertebral	JJ	O
motion	NN	O
and	CC	O
the	DT	O
cervical	JJ	O
lordosis	NN	O
.	.	O

The	DT	O
purpose	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
determine	VB	O
whether	IN	O
the	DT	O
use	NN	O
of	IN	O
the	DT	O
PostureJac	NNP	O
(	(	O
SomatoCentric	NNP	O
Systems	NNP	O
,	,	O
Inc.	NNP	O
,	,	O
Toronto	NNP	O
,	,	O
Ontario	NNP	O
,	,	O
Canada	NNP	O
)	)	O
,	,	O
a	DT	O
posture	NN	O
support	NN	O
and	CC	O
exercise	NN	O
jacket	NN	O
,	,	O
was	VBD	O
effective	JJ	O
in	IN	O
enhancing	VBG	O
deep	JJ	O
cervical	JJ	O
muscle	NN	O
endurance	NN	O
.	.	O

Forty-five	JJ	SS
(	(	O
45	CD	SS
)	)	O
female	NN	SE
subjects	NNS	O
,	,	O
between	IN	O
the	DT	O
ages	NNS	O
of	IN	O
18	CD	A
and	CC	A
40	CD	A
years	NNS	A
,	,	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
three	CD	O
groups	NNS	O
consisting	VBG	O
of	IN	O
the	DT	O
no-treatment	JJ	O
control	NN	O
,	,	O
the	DT	O
treatment-control	NN	O
(	(	O
table	JJ	O
stabilization	NN	O
)	)	O
,	,	O
and	CC	O
the	DT	O
experimental	JJ	O
(	(	O
PostureJac	NNP	O
)	)	O
group	NN	O
.	.	O

The	DT	O
outcome	JJ	O
measure	NN	O
of	IN	O
deep	JJ	O
cervical	JJ	O
flexor	NN	O
muscle	NN	O
endurance	NN	O
was	VBD	O
based	VBN	O
on	IN	O
the	DT	O
Flexor	NNP	O
Endurance	NNP	O
Test	NNP	O
and	CC	O
was	VBD	O
recorded	VBN	O
in	IN	O
seconds	NNS	O
.	.	O

The	DT	O
results	NNS	O
indicated	VBD	O
that	IN	O
the	DT	O
PostureJac	NNP	O
group	NN	O
was	VBD	O
superior	JJ	O
to	TO	O
the	DT	O
no-treatment	JJ	O
control	NN	O
(	(	O
p=.001	NN	O
)	)	O
and	CC	O
the	DT	O
treatment-control	NN	O
(	(	O
p=.004	NN	O
)	)	O
groups	NNS	O
in	IN	O
terms	NNS	O
of	IN	O
increasing	VBG	O
endurance	NN	O
of	IN	O
the	DT	O
deep	JJ	O
cervical	JJ	O
flexors	NNS	O
.	.	O

Consequently	RB	O
,	,	O
the	DT	O
PostureJac	NNP	O
may	MD	O
be	VB	O
a	DT	O
useful	JJ	O
therapeutic	JJ	O
tool	NN	O
in	IN	O
the	DT	O
management	NN	O
of	IN	O
cervicogenic	JJ	O
headache	NN	O
and	CC	O
mechanical	JJ	O
neck	NN	O
pain	NN	O
.	.	O

The	DT	O
effect	NN	O
of	IN	O
quality	NN	O
and	CC	O
amount	NN	O
of	IN	O
dietary	JJ	O
fat	NN	O
on	IN	O
the	DT	O
susceptibility	NN	O
of	IN	O
low	JJ	O
density	NN	O
lipoprotein	NN	O
to	TO	O
oxidation	NN	O
in	IN	O
subjects	NNS	O
with	IN	O
impaired	JJ	C
glucose	JJ	C
tolerance	NN	C
.	.	O

OBJECTIVES	IN	O
We	PRP	O
examined	VBD	O
the	DT	O
effects	NNS	O
of	IN	O
a	DT	O
high	JJ	O
fat	NN	O
diet	JJ	O
rich	JJ	O
in	IN	O
monounsaturated	JJ	O
fat	NN	O
(	(	O
MUFA-diet	NNP	O
)	)	O
and	CC	O
a	DT	O
moderate	JJ	O
fat	NN	O
diet	JJ	O
rich	JJ	O
in	IN	O
polyunsaturated	JJ	O
fat	NN	O
(	(	O
PUFA-diet	NNP	O
)	)	O
on	IN	O
the	DT	O
susceptibility	NN	O
of	IN	O
LDL	NNP	O
to	TO	O
oxidation	NN	O
.	.	O

SUBJECTS	NNP	O
29	CD	SS
subjects	NNS	O
with	IN	O
impaired	JJ	O
glucose	JJ	O
tolerance	NN	O
.	.	O

METHODS	NNP	O
After	IN	O
consuming	VBG	O
a	DT	O
run-in	JJ	O
diet	JJ	O
[	FW	O
37	CD	O
%	NN	O
of	IN	O
energy	NN	O
(	(	O
E	NNP	O
%	NN	O
)	)	O
fat	NN	O
,	,	O
18	CD	O
E	NNP	O
%	NN	O
saturated	VBD	O
fat	JJ	O
]	NN	O
for	IN	O
three	CD	O
weeks	NNS	O
,	,	O
subjects	NNS	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
either	RB	O
to	TO	O
a	DT	O
MUFA-diet	JJ	O
(	(	O
40	CD	O
E	NNP	O
%	NN	O
fat	NN	O
,	,	O
19	CD	O
E	NNP	O
%	NN	O
monounsaturated	VBD	O
fatty	JJ	O
acids	NNS	O
)	)	O
or	CC	O
a	DT	O
PUFA-diet	JJ	O
(	(	O
34	CD	O
E	NNP	O
%	NN	O
fat	NN	O
,	,	O
10	CD	O
E	NNP	O
%	NN	O
polyunsaturated	VBD	O
fat	NN	O
)	)	O
for	IN	O
eight	CD	O
weeks	NNS	O
.	.	O

The	DT	O
susceptibility	NN	O
of	IN	O
LDL	NNP	O
to	TO	O
oxidation	NN	O
was	VBD	O
measured	VBN	O
by	IN	O
challenging	VBG	O
LDL	NNP	O
with	IN	O
hemin	NN	O
and	CC	O
H2O2	NNP	O
and	CC	O
measuring	VBG	O
the	DT	O
time	NN	O
for	IN	O
the	DT	O
reaction	NN	O
to	TO	O
reach	VB	O
maximum	JJ	O
velocity	NN	O
.	.	O

Results	NNS	O
are	VBP	O
expressed	VBN	O
as	IN	O
lag	NN	O
time	NN	O
to	TO	O
oxidation	NN	O
in	IN	O
minutes	NNS	O
.	.	O

RESULTS	NNP	O
In	IN	O
the	DT	O
PUFA-diet	JJ	O
group	NN	O
(	(	O
n	JJ	O
=	NNP	O
15	CD	O
)	)	O
lag	NN	O
time	NN	O
tended	VBD	O
to	TO	O
decrease	VB	O
during	IN	O
the	DT	O
experimental	JJ	O
diet	NN	O
(	(	O
97	CD	O
+/-	JJ	O
28	CD	O
vs	JJ	O
90	CD	O
+/-	JJ	O
25	CD	O
min	NN	O
,	,	O
mean	JJ	O
+/-	JJ	O
s.d.	NN	O
,	,	O
P	NNP	O
=	NNP	O
0.073	CD	O
)	)	O
,	,	O
whereas	RB	O
in	IN	O
the	DT	O
MUFA-diet	JJ	O
group	NN	O
(	(	O
n	JJ	O
=	NNP	O
14	CD	O
)	)	O
there	EX	O
was	VBD	O
no	DT	O
significant	JJ	O
change	NN	O
(	(	O
lag	JJ	O
time	NN	O
96	CD	O
+/-	JJ	O
24	CD	O
vs	JJ	O
100	CD	O
+/-	JJ	O
16	CD	O
min	NN	O
,	,	O
P	NNP	O
=	NNP	O
0.408	CD	O
)	)	O
.	.	O

The	DT	O
mean	JJ	O
change	NN	O
in	IN	O
lag	NN	O
time	NN	O
was	VBD	O
-7	JJ	O
+/-	JJ	O
14	CD	O
min	NN	O
(	(	O
-7.2	CD	O
%	NN	O
)	)	O
in	IN	O
the	DT	O
PUFA-diet	JJ	O
group	NN	O
and	CC	O
+4	VBZ	O
+/-	JJ	O
16	CD	O
min	NN	O
(	(	O
+4.0	CD	O
%	NN	O
)	)	O
in	IN	O
the	DT	O
MUFA-diet	JJ	O
group	NN	O
(	(	O
P	NNP	O
=	NNP	O
0.029	CD	O
,	,	O
PUFA-diet	JJ	O
group	NN	O
vs	VBD	O
MUFA-diet	NNP	O
group	NN	O
)	)	O
.	.	O

The	DT	O
alpha-tocopherol	JJ	O
concentration	NN	O
in	IN	O
LDL	NNP	O
increased	VBD	O
significantly	RB	O
(	(	O
P	NNP	O
<	NNP	O
0.01	CD	O
)	)	O
in	IN	O
both	DT	O
diet	JJ	O
groups	NNS	O
relative	VBP	O
to	TO	O
the	DT	O
run-in	JJ	O
diet	JJ	O
period	NN	O
,	,	O
but	CC	O
LDL	NNP	O
particle	VBD	O
score	RB	O
did	VBD	O
not	RB	O
change	VB	O
in	IN	O
either	DT	O
of	IN	O
the	DT	O
diet	JJ	O
groups	NNS	O
during	IN	O
the	DT	O
dietary	JJ	O
intervention	NN	O
.	.	O

In	IN	O
subjects	NNS	O
with	IN	O
impaired	JJ	O
glucose	JJ	O
tolerance	NN	O
a	DT	O
PUFA-rich	JJ	O
diet	NN	O
with	IN	O
a	DT	O
moderate	JJ	O
amount	NN	O
of	IN	O
fat	NN	O
tended	VBN	O
to	TO	O
increase	VB	O
the	DT	O
susceptibility	NN	O
of	IN	O
LDL	NNP	O
to	TO	O
oxidation	NN	O
as	IN	O
compared	VBN	O
to	TO	O
a	DT	O
higher	JJR	O
fat	JJ	O
diet	JJ	O
rich	NN	O
in	IN	O
MUFA	NNP	O
.	.	O

Furthermore	NNP	O
,	,	O
the	DT	O
negative	JJ	O
mean	NN	O
change	NN	O
in	IN	O
lag	NN	O
time	NN	O
to	TO	O
oxidation	NN	O
found	VBN	O
in	IN	O
the	DT	O
PUFA-diet	JJ	O
group	NN	O
differed	VBD	O
significantly	RB	O
from	IN	O
the	DT	O
slightly	RB	O
positive	JJ	O
mean	NN	O
change	NN	O
found	VBD	O
in	IN	O
the	DT	O
MUFA-diet	JJ	O
group	NN	O
.	.	O

Nordic	NNP	O
walking	NN	O
and	CC	O
chronic	JJ	O
low	JJ	O
back	RB	O
pain	NN	O
:	:	O
design	NN	O
of	IN	O
a	DT	O
randomized	JJ	O
clinical	JJ	O
trial	NN	O
.	.	O

BACKGROUND	NNP	O
Low	NNP	O
Back	NNP	O
Pain	NNP	O
is	VBZ	O
a	DT	O
major	JJ	O
public	JJ	O
health	NN	O
problem	NN	O
all	DT	O
over	IN	O
the	DT	O
western	JJ	O
world	NN	O
.	.	O

Active	JJ	O
approaches	NNS	O
including	VBG	O
exercise	NN	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
low	JJ	O
back	RB	O
pain	NN	O
results	NNS	O
in	IN	O
better	JJR	O
outcomes	NNS	O
for	IN	O
patients	NNS	O
,	,	O
but	CC	O
it	PRP	O
is	VBZ	O
not	RB	O
known	VBN	O
exactly	RB	O
which	WDT	O
types	NNS	O
of	IN	O
back	NN	O
exercises	NNS	O
are	VBP	O
most	RBS	O
beneficial	JJ	O
or	CC	O
whether	IN	O
general	JJ	O
physical	JJ	O
activity	NN	O
provide	VBP	O
similar	JJ	O
benefits	NNS	O
.	.	O

Nordic	NNP	O
Walking	NNP	O
is	VBZ	O
a	DT	O
popular	JJ	O
and	CC	O
fast	JJ	O
growing	VBG	O
type	NN	O
of	IN	O
exercise	NN	O
in	IN	O
Northern	NNP	O
Europe	NNP	O
.	.	O

Initial	NNP	O
studies	NNS	O
have	VBP	O
demonstrated	VBN	O
that	IN	O
persons	NNS	O
performing	VBG	O
Nordic	NNP	O
Walking	NNP	O
are	VBP	O
able	JJ	O
to	TO	O
exercise	VB	O
longer	JJR	O
and	CC	O
harder	RBR	O
compared	VBN	O
to	TO	O
normal	JJ	O
walking	VBG	O
thereby	RB	O
increasing	VBG	O
their	PRP$	O
cardiovascular	JJ	O
metabolism	NN	O
.	.	O

Until	IN	O
now	RB	O
no	DT	O
studies	NNS	O
have	VBP	O
been	VBN	O
performed	VBN	O
to	TO	O
investigate	VB	O
whether	IN	O
Nordic	NNP	O
Walking	NNP	O
has	VBZ	O
beneficial	JJ	O
effects	NNS	O
in	IN	O
relation	NN	O
to	TO	O
low	VB	O
back	RB	O
pain	NN	O
.	.	O

The	DT	O
primary	JJ	O
aim	NN	O
of	IN	O
this	DT	O
study	NN	O
is	VBZ	O
to	TO	O
investigate	VB	O
whether	IN	O
supervised	JJ	O
Nordic	NNP	O
Walking	NNP	O
can	MD	O
reduce	VB	O
pain	NN	O
and	CC	O
improve	VB	O
function	NN	O
in	IN	C
a	DT	C
population	NN	C
of	IN	C
chronic	JJ	C
low	JJ	C
back	RB	C
pain	NN	C
patients	NNS	C
when	WRB	O
compared	VBN	O
to	TO	O
unsupervised	JJ	O
Nordic	NNP	O
Walking	NNP	O
and	CC	O
advice	NN	O
to	TO	O
stay	VB	O
active	JJ	O
.	.	O

In	IN	O
addition	NN	O
we	PRP	O
investigate	VBP	O
whether	IN	O
there	EX	O
is	VBZ	O
an	DT	O
increase	NN	O
in	IN	O
the	DT	O
cardiovascular	JJ	O
metabolism	NN	O
in	IN	O
persons	NNS	O
performing	VBG	O
supervised	VBD	O
Nordic	NNP	O
Walking	NNP	O
compared	VBN	O
to	TO	O
persons	NNS	O
who	WP	O
are	VBP	O
advised	VBN	O
to	TO	O
stay	VB	O
active	JJ	O
.	.	O

Finally	RB	O
,	,	O
we	PRP	O
investigate	VBP	O
whether	IN	O
there	EX	O
is	VBZ	O
a	DT	O
difference	NN	O
in	IN	O
compliance	NN	O
between	IN	O
persons	NNS	O
receiving	VBG	O
supervised	VBD	O
Nordic	NNP	O
Walking	NNP	O
and	CC	O
persons	NNS	O
doing	VBG	O
unsupervised	JJ	O
Nordic	NNP	O
Walking	NNP	O
.	.	O

METHODS	NNP	O
One	CD	C
hundred	CD	C
and	CC	C
fifty	JJ	C
patients	NNS	C
with	IN	C
low	JJ	C
back	RB	C
pain	NN	C
for	IN	C
at	IN	C
least	JJS	C
eight	CD	C
weeks	NNS	C
and	CC	C
referred	VBD	C
to	TO	C
a	DT	C
specialized	JJ	C
secondary	JJ	C
sector	NN	C
outpatient	NN	C
back	RB	C
pain	NN	C
clinic	NN	C
are	VBP	C
included	VBN	C
in	IN	C
the	DT	C
study	NN	C
.	.	C

After	IN	O
completion	NN	O
of	IN	O
the	DT	O
standard	NN	O
back	RB	O
centre	JJ	O
treatment	NN	O
patients	NNS	O
are	VBP	O
randomized	VBN	O
into	IN	O
one	CD	O
of	IN	O
three	CD	O
groups	NNS	O
:	:	O
A	DT	O
)	)	O
Nordic	NNP	O
Walking	NNP	O
twice	RB	O
a	DT	O
week	NN	O
for	IN	O
eight	CD	O
weeks	NNS	O
under	IN	O
supervision	NN	O
of	IN	O
a	DT	O
specially	RB	O
trained	JJ	O
instructor	NN	O
;	:	O
B	NNP	O
)	)	O
Unsupervised	VBD	O
Nordic	NNP	O
Walking	NNP	O
for	IN	O
eight	CD	O
weeks	NNS	O
after	IN	O
one	CD	O
training	NN	O
session	NN	O
with	IN	O
an	DT	O
instructor	NN	O
;	:	O
C	NNP	O
)	)	O
A	DT	O
one	CD	O
hour	NN	O
motivational	JJ	O
talk	NN	O
including	VBG	O
advice	NN	O
to	TO	O
stay	VB	O
active	JJ	O
.	.	O

Outcome	NN	O
measures	NNS	O
are	VBP	O
pain	NN	O
,	,	O
function	NN	O
,	,	O
overall	JJ	O
health	NN	O
,	,	O
cardiovascular	JJ	O
ability	NN	O
and	CC	O
activity	NN	O
level	NN	O
.	.	O

RESULTS	NNP	O
No	NNP	O
results	NNS	O
available	JJ	O
at	IN	O
this	DT	O
point	NN	O
.	.	O

DISCUSSION	NNP	O
This	DT	O
study	NN	O
will	MD	O
investigate	VB	O
the	DT	O
effect	NN	O
of	IN	O
Nordic	NNP	O
Walking	VBG	O
on	IN	O
pain	NN	O
and	CC	O
function	NN	O
in	IN	O
a	DT	O
population	NN	O
of	IN	O
people	NNS	O
with	IN	O
chronic	JJ	O
LBP	NNP	O
.	.	O

Calcium	NNP	O
channel	NN	O
blocker	NN	O
inhibition	NN	O
of	IN	O
AGE	NNP	O
and	CC	O
RAGE	NNP	O
axis	VBP	O
limits	NNS	O
renal	JJ	O
injury	NN	O
in	IN	O
nondiabetic	JJ	C
patients	NNS	O
with	IN	O
stage	NN	C
I	PRP	C
or	CC	C
II	NNP	C
chronic	JJ	C
kidney	NN	C
disease	NN	C
.	.	O

BACKGROUND	NNP	O
There	EX	O
is	VBZ	O
a	DT	O
growing	VBG	O
body	NN	O
of	IN	O
evidence	NN	O
that	IN	O
advanced	VBD	O
glycation	JJ	O
end	NN	O
products	NNS	O
(	(	O
AGE	NNP	O
)	)	O
and	CC	O
their	PRP$	O
receptor	NN	O
(	(	O
RAGE	NNP	O
)	)	O
system	NN	O
are	VBP	O
implicated	VBN	O
in	IN	O
chronic	JJ	O
kidney	NN	O
disease	NN	O
(	(	O
CKD	NNP	O
)	)	O
.	.	O

We	PRP	O
have	VBP	O
previously	RB	O
found	VBN	O
that	IN	O
a	DT	O
long-acting	JJ	O
calcium	NN	O
channel	NN	O
blocker	NN	O
,	,	O
azelnidipine	NN	O
,	,	O
but	CC	O
not	RB	O
amlodipine	VB	O
,	,	O
improves	VBZ	O
renal	JJ	O
injury	NN	O
in	IN	O
CKD	NNP	O
patients	NNS	O
.	.	O

However	RB	O
,	,	O
little	JJ	O
is	VBZ	O
known	VBN	O
about	IN	O
the	DT	O
effect	NN	O
of	IN	O
azelnidipine	NN	O
on	IN	O
the	DT	O
AGE-RAGE	NNP	O
axis	NN	O
in	IN	O
humans	NNS	O
.	.	O

In	IN	O
this	DT	O
study	NN	O
,	,	O
we	PRP	O
examined	VBD	O
whether	IN	O
azelnidipine	JJ	O
addition	NN	O
could	MD	O
have	VB	O
renoprotective	JJ	O
properties	NNS	O
in	IN	O
hypertensive	JJ	O
CKD	NNP	O
patients	NNS	O
by	IN	O
reducing	VBG	O
serum	NN	O
levels	NNS	O
of	IN	O
AGE	NNP	O
and	CC	O
soluble	JJ	O
form	NN	O
of	IN	O
RAGE	NNP	O
(	(	O
sRAGE	NN	O
)	)	O
.	.	O

Thirty	NNP	SS
nondiabetic	JJ	C
stage	NN	C
I	PRP	C
or	CC	C
II	NNP	C
CKD	NNP	C
patients	NNS	O
who	WP	O
had	VBD	O
already	RB	O
been	VBN	O
treated	VBN	O
with	IN	O
angiotensin	NN	O
II	NNP	O
receptor	NN	O
blockers	NNS	O
were	VBD	O
enrolled	VBN	O
in	IN	O
this	DT	O
study	NN	O
.	.	O

HYPOTHESIS	NNP	O
We	PRP	O
hypothesized	VBD	O
that	IN	O
azelnidipine	NN	O
treatment	NN	O
could	MD	O
limit	VB	O
renal	JJ	O
injury	NN	O
partly	RB	O
by	IN	O
blocking	VBG	O
the	DT	O
AGE-RAGE	NNP	O
axis	NN	O
.	.	O

METHODS	JJ	O
Patients	NNPS	O
were	VBD	O
randomly	RB	O
divided	VBN	O
into	IN	O
2	CD	O
groups	NNS	O
;	:	O
one	CD	O
group	NN	O
was	VBD	O
treated	VBN	O
with	IN	O
16	CD	O
mg	NNS	O
azelnidipine	NN	O
and	CC	O
the	DT	O
other	JJ	O
with	IN	O
5	CD	O
mg	NNS	O
amlodipine	JJ	O
once	RB	O
daily	JJ	O
.	.	O

They	PRP	O
were	VBD	O
followed	VBN	O
up	RP	O
for	IN	O
6	CD	O
months	NNS	O
.	.	O

RESULTS	NNP	O
Proteinuria	NNP	O
was	VBD	O
positively	RB	O
correlated	VBN	O
with	IN	O
circulating	VBG	O
AGE	NNP	O
and	CC	O
sRAGE	NN	O
levels	NNS	O
in	IN	O
our	PRP$	O
subjects	NNS	O
.	.	O

Both	DT	O
drugs	NNS	O
exhibited	VBN	O
comparable	JJ	O
and	CC	O
significant	JJ	O
blood	NN	O
pressure	NN	O
(	(	O
BP	NNP	O
)	)	O
-lowering	VBG	O
effects	NNS	O
.	.	O

Although	IN	O
neither	DT	O
of	IN	O
them	PRP	O
affected	VBD	O
glucose	NN	O
,	,	O
glycated	VBD	O
hemoglobin	NN	O
,	,	O
lipid	JJ	O
levels	NNS	O
,	,	O
and	CC	O
estimated	VBD	O
glomerular	JJ	O
filtration	NN	O
rate	NN	O
,	,	O
treatment	NN	O
with	IN	O
azelnidipine	NN	O
,	,	O
but	CC	O
not	RB	O
amlodipine	VB	O
,	,	O
decreased	VBN	O
circulating	NN	O
AGE	NNP	O
,	,	O
sRAGE	NN	O
,	,	O
proteinuria	NN	O
,	,	O
and	CC	O
urinary	JJ	O
levels	NNS	O
of	IN	O
liver-type	JJ	O
fatty	JJ	O
acid	NN	O
binding	VBG	O
protein	NN	O
,	,	O
a	DT	O
marker	NN	O
of	IN	O
tubular	JJ	O
injury	NN	O
,	,	O
in	IN	O
a	DT	O
BP-lowering-independent	JJ	O
manner	NN	O
.	.	O

CONCLUSIONS	NNP	O
Our	PRP$	O
present	JJ	O
results	NNS	O
suggest	VBP	O
that	IN	O
azelnidipine	NN	O
may	MD	O
exert	VB	O
renoprotective	JJ	O
properties	NNS	O
in	IN	O
nondiabetic	JJ	C
hypertensive	JJ	C
CKD	NNP	C
patients	NNS	O
via	IN	O
its	PRP$	O
unique	JJ	O
inhibitory	JJ	O
effects	NNS	O
on	IN	O
the	DT	O
AGE-RAGE	NNP	O
axis	NN	O
.	.	O

Quantification	NN	O
of	IN	O
cyproheptadine	NN	O
in	IN	C
human	JJ	C
plasma	NN	C
by	IN	O
high-performance	NN	O
liquid	NN	O
chromatography	NN	O
coupled	VBD	O
to	TO	O
electrospray	VB	O
tandem	JJ	O
mass	NN	O
spectrometry	NN	O
in	IN	O
a	DT	O
bioequivalence	NN	O
study	NN	O
.	.	O

A	DT	O
rapid	JJ	O
,	,	O
sensitive	JJ	O
and	CC	O
specific	JJ	O
method	NN	O
to	TO	O
quantify	VB	O
cyproheptadine	NN	O
in	IN	O
human	JJ	O
plasma	NN	O
using	VBG	O
amitriptyline	NN	O
as	IN	O
the	DT	O
internal	JJ	O
standard	NN	O
(	(	O
IS	NNP	O
)	)	O
is	VBZ	O
described	VBN	O
.	.	O

The	DT	O
analyte	NN	O
and	CC	O
the	DT	O
IS	NNP	O
were	VBD	O
extracted	VBN	O
from	IN	O
plasma	NN	O
by	IN	O
liquid-liquid	JJ	O
extraction	NN	O
using	VBG	O
a	DT	O
diethyl-ether/dichloromethane	NN	O
(	(	O
70/30	CD	O
;	:	O
v/v	NN	O
)	)	O
solvent	NN	O
.	.	O

After	IN	O
removing	VBG	O
and	CC	O
drying	VBG	O
the	DT	O
organic	JJ	O
phase	NN	O
,	,	O
the	DT	O
extracts	NNS	O
were	VBD	O
reconstituted	VBN	O
with	IN	O
a	DT	O
fixed	JJ	O
volume	NN	O
of	IN	O
acetonitrile/water	NN	O
(	(	O
50/50	CD	O
v/v	NN	O
)	)	O
+0.1	CD	O
%	NN	O
of	IN	O
acetic	JJ	O
acid	NN	O
.	.	O

The	DT	O
extracts	NNS	O
were	VBD	O
analyzed	VBN	O
by	IN	O
high	JJ	O
performance	NN	O
liquid	NN	O
chromatography	NN	O
coupled	VBD	O
to	TO	O
electrospray	VB	O
tandem	JJ	O
mass	NN	O
spectrometry	NN	O
(	(	O
LC-MS/MS	NNP	O
)	)	O
.	.	O

Chromatography	NNP	O
was	VBD	O
performed	VBN	O
isocratically	RB	O
using	VBG	O
an	DT	O
Alltech	NNP	O
Prevail	NNP	O
C18	NNP	O
5	CD	O
?m	NNP	O
analytical	JJ	O
column	NN	O
,	,	O
(	(	O
150	CD	O
mm	NN	O
x	VBD	O
4.6	CD	O
mm	NNS	O
I.D.	NNP	O
)	)	O
.	.	O

The	DT	O
method	NN	O
had	VBD	O
a	DT	O
chromatographic	JJ	O
run	NN	O
time	NN	O
of	IN	O
4	CD	O
min	NNS	O
and	CC	O
a	DT	O
linear	JJ	O
calibration	NN	O
curve	NN	O
ranging	VBG	O
from	IN	O
0.05	CD	O
to	TO	O
10	CD	O
ng/mL	NNS	O
(	(	O
r2	VB	O
>	RB	O
0.99	CD	O
)	)	O
.	.	O

The	DT	O
limit	NN	O
of	IN	O
quantification	NN	O
was	VBD	O
0.05	CD	O
ng/mL	RB	O
.	.	O

This	DT	O
HPLC/MS/MS	NNP	O
procedure	NN	O
was	VBD	O
used	VBN	O
to	TO	O
assess	VB	O
the	DT	O
bioequivalence	NN	O
of	IN	O
cyproheptadine	NN	O
in	IN	O
two	CD	O
cyproheptadine	NN	O
+	NNS	O
cobamamide	VBP	O
(	(	O
4	CD	O
mg	NN	O
+	VBD	O
1	CD	O
mg	NN	O
)	)	O
tablet	NN	O
formulations	NNS	O
(	(	O
Cobactin?	NNP	O
[	NNP	O
cyproheptadine	NN	O
+	NNP	O
cobamamide	NN	O
]	NNP	O
test	NN	O
formulation	NN	O
supplied	VBN	O
from	IN	O
Zambon	NNP	O
Laborat?rios	NNP	O
Farmac?uticos	NNP	O
Ltda	NNP	O
.	.	O

and	CC	O
Cobavital?	NNP	O
from	IN	O
Solvay	NNP	O
Farma	NNP	O
(	(	O
standard	JJ	O
reference	NN	O
formulation	NN	O
)	)	O
)	)	O
.	.	O

A	DT	O
single	JJ	O
4	CD	O
mg	NN	O
+	VBD	O
1	CD	O
mg	NN	O
[	NNP	O
cyproheptadine	NN	O
+	NNP	O
cobamamide	NN	O
]	NNP	O
dose	NN	O
of	IN	O
each	DT	O
formulation	NN	O
was	VBD	O
administered	VBN	O
to	TO	O
healthy	JJ	O
volunteers	NNS	O
.	.	O

The	DT	O
study	NN	O
was	VBD	O
conducted	VBN	O
using	VBG	O
an	DT	O
open	JJ	O
,	,	O
randomized	VBN	O
,	,	O
two-period	JJ	O
crossover	NN	O
design	NN	O
with	IN	O
a	DT	O
1-week	JJ	O
washout	NN	O
interval	NN	O
.	.	O

Since	IN	O
the	DT	O
90	CD	O
%	NN	O
CI	NNP	O
for	IN	O
Cmax	NNP	O
and	CC	O
AUCs	NNP	O
ratios	NNS	O
were	VBD	O
all	DT	O
within	IN	O
the	DT	O
80-125	JJ	O
%	NN	O
bioequivalence	NN	O
limit	NN	O
proposed	VBN	O
by	IN	O
the	DT	O
US	NNP	O
Food	NNP	O
and	CC	O
Drug	NNP	O
Administration	NNP	O
,	,	O
it	PRP	O
was	VBD	O
concluded	VBN	O
that	IN	O
the	DT	O
cyproheptadine	JJ	O
test	NN	O
formulation	NN	O
(	(	O
Cobactin?	NNP	O
)	)	O
is	VBZ	O
bioequivalent	JJ	O
to	TO	O
the	DT	O
Cobavital?	NNP	O
formulation	NN	O
for	IN	O
both	DT	O
the	DT	O
rate	NN	O
and	CC	O
the	DT	O
extent	NN	O
of	IN	O
absorption	NN	O
of	IN	O
cyproheptadine	NN	O
.	.	O

A	DT	O
clinical	JJ	O
evaluation	NN	O
of	IN	O
a	DT	O
blood	NN	O
conservation	NN	O
device	NN	O
in	IN	O
medical	JJ	C
intensive	JJ	C
care	NN	C
unit	NN	C
patients	NNS	C
.	.	C

OBJECTIVES	NNP	O
This	DT	O
study	NN	O
was	VBD	O
designed	VBN	O
to	TO	O
a	DT	O
)	)	O
document	NN	O
the	DT	O
efficacy	NN	O
of	IN	O
a	DT	O
device	NN	O
intended	VBN	O
to	TO	O
conserve	VB	O
blood	NN	O
in	IN	O
critically	RB	O
ill	JJ	O
patients	NNS	O
;	:	O
b	NN	O
)	)	O
determine	VBZ	O
the	DT	O
effect	NN	O
of	IN	O
this	DT	O
blood	NN	O
conservation	NN	O
on	IN	O
hemoglobin	JJ	O
concentration	NN	O
and	CC	O
the	DT	O
need	NN	O
for	IN	O
blood	NN	O
transfusions	NNS	O
;	:	O
c	NNS	O
)	)	O
determine	VBP	O
if	IN	O
the	DT	O
blood	NN	O
conservation	NN	O
device	NN	O
resulted	VBD	O
in	IN	O
interference	NN	O
with	IN	O
arterial	JJ	O
pressure	NN	O
waveforms	NNS	O
;	:	O
d	NN	O
)	)	O
determine	NN	O
if	IN	O
use	NN	O
of	IN	O
the	DT	O
blood	NN	O
conservation	NN	O
device	NN	O
resulted	VBD	O
in	IN	O
a	DT	O
difference	NN	O
in	IN	O
the	DT	O
number	NN	O
of	IN	O
accidental	JJ	O
needle	JJ	O
punctures	NNS	O
suffered	VBN	O
by	IN	O
healthcare	JJ	O
workers	NNS	O
.	.	O

DESIGN	NNP	O
Prospective	NNP	O
,	,	O
randomized	VBD	O
,	,	O
controlled	VBD	O
trial	NN	O
.	.	O

A	DT	O
clinical	JJ	O
trial	NN	O
using	VBG	O
prospective	JJ	O
,	,	O
random	JJ	O
allocation	NN	O
of	IN	O
consecutive	JJ	O
eligible	JJ	O
patients	NNS	O
.	.	O

SETTING	VBG	O
The	DT	O
medical	JJ	O
intensive	JJ	O
care	NN	O
unit	NN	O
(	(	O
ICU	NNP	O
)	)	O
of	IN	O
a	DT	O
university	NN	O
hospital	NN	O
located	VBN	O
in	IN	O
a	DT	O
large	JJ	O
metropolitan	JJ	O
area	NN	O
.	.	O

PATIENTS	VB	O
A	DT	O
total	NN	O
of	IN	O
100	CD	O
patients	NNS	O
who	WP	O
were	VBD	O
admitted	VBN	O
to	TO	O
the	DT	O
medical	JJ	O
ICU	NNP	O
,	,	O
required	VBD	O
arterial	JJ	O
line	NN	O
monitoring	NN	O
for	IN	O
clinical	JJ	O
purposes	NNS	O
,	,	O
and	CC	O
were	VBD	O
managed	VBN	O
by	IN	O
the	DT	O
ICU	NNP	O
medical	JJ	O
service	NN	O
.	.	O

Exclusion	NNP	O
criteria	NNS	O
included	VBD	O
active	JJ	O
bleeding	NN	O
or	CC	O
chronic	JJ	O
renal	JJ	O
failure	NN	O
at	IN	O
the	DT	O
time	NN	O
of	IN	O
ICU	NNP	O
admission	NN	O
.	.	O

INTERVENTIONS	JJ	O
Patients	NNPS	O
in	IN	O
the	DT	O
experimental	JJ	O
group	NN	O
had	VBD	O
a	DT	O
blood	NN	O
conservation	NN	O
device	NN	O
incorporated	VBN	O
into	IN	O
the	DT	O
arterial	JJ	O
pressure	NN	O
monitoring	NN	O
system	NN	O
,	,	O
while	IN	O
patients	NNS	O
in	IN	O
the	DT	O
control	NN	O
group	NN	O
received	VBD	O
a	DT	O
conventional	JJ	O
arterial	JJ	O
pressure	NN	O
monitoring	NN	O
system	NN	O
.	.	O

MEASUREMENTS	NNP	O
AND	CC	O
MAIN	NNP	O
RESULTS	NNP	O
Data	NNP	O
gathered	VBD	O
included	VBN	O
:	:	O
age	NN	O
;	:	O
gender	NN	O
;	:	O
ICU	NNP	O
discharge	NN	O
status	NN	O
;	:	O
the	DT	O
duration	NN	O
of	IN	O
ICU	NNP	O
stay	NN	O
;	:	O
time	NN	O
in	IN	O
the	DT	O
study	NN	O
;	:	O
volume	NN	O
of	IN	O
all	DT	O
blood	NN	O
drawn	NN	O
,	,	O
discarded	VBD	O
,	,	O
or	CC	O
lost	VBN	O
due	JJ	O
to	TO	O
leakage	VB	O
;	:	O
hemoglobin	JJ	O
concentrations	NNS	O
;	:	O
blood	NN	O
transfusions	NNS	O
;	:	O
and	CC	O
accidental	JJ	O
needle	JJ	O
injuries	NNS	O
.	.	O

Arterial	JJ	O
pressure	NN	O
waveforms	NNS	O
were	VBD	O
recorded	VBN	O
and	CC	O
inspected	VBN	O
for	IN	O
dampening	VBG	O
or	CC	O
other	JJ	O
deformation	NN	O
.	.	O

Mean	NNP	O
hemoglobin	JJ	O
concentrations	NNS	O
were	VBD	O
compared	VBN	O
on	IN	O
ICU	NNP	O
admission	NN	O
and	CC	O
at	IN	O
12-hr	JJ	O
intervals	NNS	O
.	.	O

Demographic	NNP	O
and	CC	O
clinical	JJ	O
characteristics	NNS	O
of	IN	O
the	DT	O
two	CD	O
groups	NNS	O
were	VBD	O
not	RB	O
significantly	RB	O
different	JJ	O
.	.	O

The	DT	O
volume	NN	O
of	IN	O
blood	NN	O
drawn	NN	O
and	CC	O
discarded	VBD	O
from	IN	O
arterial	JJ	O
catheters	NNS	O
was	VBD	O
significantly	RB	O
lower	JJR	O
in	IN	O
the	DT	O
blood	NN	O
conservation	NN	O
group	NN	O
(	(	O
blood	NN	O
conservation	NN	O
device	NN	O
:	:	O
5.7	CD	O
+/-	JJ	O
7.5	CD	O
mL	NN	O
;	:	O
control	NN	O
:	:	O
96.4	CD	O
+/-	JJ	O
88.5	CD	O
mL	NN	O
;	:	O
p	CC	O
<	NNP	O
.0001	NNP	O
)	)	O
,	,	O
as	IN	O
was	VBD	O
the	DT	O
total	JJ	O
volume	NN	O
of	IN	O
blood	NN	O
discarded	VBN	O
(	(	O
blood	NN	O
conservation	NN	O
device	NN	O
:	:	O
19.4	CD	O
+/-	JJ	O
47.4	CD	O
mL	NN	O
;	:	O
control	NN	O
:	:	O
103.5	CD	O
+/-	JJ	O
99.9	CD	O
mL	NN	O
;	:	O
p	CC	O
<	NNP	O
.0001	NNP	O
)	)	O
.	.	O

Mean	NNP	O
hemoglobin	JJ	O
concentration	NN	O
on	IN	O
admission	NN	O
was	VBD	O
similar	JJ	O
in	IN	O
the	DT	O
two	CD	O
groups	NNS	O
(	(	O
blood	NN	O
conservation	NN	O
device	NN	O
group	NN	O
:	:	O
11.8	CD	O
+/-	JJ	O
2.5	CD	O
g/dL	NN	O
;	:	O
control	NN	O
group	NN	O
:	:	O
12.6	CD	O
+/-	JJ	O
2.3	CD	O
g/dL	NN	O
)	)	O
.	.	O

In	IN	O
both	DT	O
groups	NNS	O
,	,	O
the	DT	O
mean	JJ	O
hemoglobin	NN	O
concentration	NN	O
declined	VBD	O
most	JJS	O
rapidly	RB	O
in	IN	O
the	DT	O
first	JJ	O
24	CD	O
hrs	NN	O
of	IN	O
ICU	NNP	O
care	NN	O
and	CC	O
,	,	O
thereafter	RB	O
,	,	O
declined	VBD	O
more	RBR	O
slowly	RB	O
.	.	O

Although	IN	O
the	DT	O
mean	JJ	O
hemoglobin	NN	O
concentration	NN	O
was	VBD	O
higher	RBR	O
in	IN	O
the	DT	O
blood	NN	O
conservation	NN	O
group	NN	O
after	IN	O
6	CD	O
days	NNS	O
,	,	O
statistical	JJ	O
significance	NN	O
was	VBD	O
not	RB	O
reached	VBN	O
until	IN	O
9.5	CD	O
days	NNS	O
of	IN	O
ICU	NNP	O
care	NN	O
.	.	O

The	DT	O
mean	JJ	O
change	NN	O
in	IN	O
hemoglobin	JJ	O
concentration	NN	O
(	(	O
overall	JJ	O
:	:	O
1.2	CD	O
+/-	JJ	O
2.2	CD	O
g/dL	NN	O
)	)	O
during	IN	O
the	DT	O
study	NN	O
represents	VBZ	O
a	DT	O
statistically	RB	O
significant	JJ	O
(	(	O
p	JJ	O
<	NNP	O
.0001	NNP	O
)	)	O
decrease	NN	O
of	IN	O
9.7	CD	O
%	NN	O
.	.	O

Hemoglobin	NNP	O
concentration	NN	O
during	IN	O
the	DT	O
study	NN	O
decreased	VBN	O
by	IN	O
1.4	CD	O
+/-	JJ	O
2.2	CD	O
g/dL	NN	O
in	IN	O
the	DT	O
control	NN	O
group	NN	O
and	CC	O
1.0	CD	O
+/-	JJ	O
2.3	CD	O
g/dL	NN	O
in	IN	O
the	DT	O
blood	NN	O
conservation	NN	O
group	NN	O
(	(	O
p	JJ	O
=	NNP	O
nonsignificant	NN	O
)	)	O
.	.	O

Univariate	NNP	O
and	CC	O
multiple	JJ	O
regression	NN	O
analysis	NN	O
demonstrated	VBD	O
discarded	JJ	O
blood	NN	O
volume	NN	O
to	TO	O
be	VB	O
a	DT	O
significant	JJ	O
and	CC	O
independent	JJ	O
predictor	NN	O
of	IN	O
the	DT	O
decline	NN	O
in	IN	O
hemoglobin	JJ	O
concentration	NN	O
.	.	O

Transfusion	NN	O
requirements	NNS	O
were	VBD	O
similar	JJ	O
in	IN	O
both	DT	O
groups	NNS	O
.	.	O

The	DT	O
blood	NN	O
conservation	NN	O
system	NN	O
did	VBD	O
not	RB	O
alter	VB	O
or	CC	O
interfere	VB	O
with	IN	O
pressure	NN	O
waveforms	NNS	O
.	.	O

There	EX	O
were	VBD	O
no	DT	O
accidental	JJ	O
needle	JJ	O
injuries	NNS	O
noted	VBD	O
.	.	O

CONCLUSIONS	VB	O
The	DT	O
conservation	NN	O
of	IN	O
blood	NN	O
in	IN	O
critically	RB	O
ill	JJ	O
patients	NNS	O
must	MD	O
be	VB	O
a	DT	O
high-priority	JJ	O
concern	NN	O
of	IN	O
all	DT	O
healthcare	JJ	O
workers	NNS	O
.	.	O

Our	PRP$	O
data	NNS	O
indicate	VBP	O
that	IN	O
the	DT	O
blood	NN	O
conservation	NN	O
system	NN	O
eliminates	VBZ	O
a	DT	O
significant	JJ	O
factor	NN	O
in	IN	O
the	DT	O
decline	NN	O
in	IN	O
hemoglobin	JJ	O
concentration	NN	O
.	.	O

With	IN	O
devices	NNS	O
as	IN	O
described	NN	O
here	RB	O
,	,	O
there	EX	O
is	VBZ	O
no	DT	O
reason	NN	O
to	TO	O
continue	VB	O
the	DT	O
practice	NN	O
of	IN	O
wasting	VBG	O
the	DT	O
blood	NN	O
of	IN	O
critically	RB	O
ill	JJ	O
patients	NNS	O
in	IN	O
order	NN	O
to	TO	O
prevent	VB	O
preanalytic	JJ	O
error	NN	O
.	.	O

Mandibular	JJ	O
advancement	NN	O
splint	NN	O
improves	VBZ	O
indices	NNS	O
of	IN	O
obstructive	JJ	C
sleep	NN	C
apnoea	NN	C
and	CC	C
snoring	VBG	C
but	CC	O
side	JJ	O
effects	NNS	O
are	VBP	O
common	JJ	O
.	.	O

AIM	NNP	O
To	TO	O
assess	VB	O
the	DT	O
efficacy	NN	O
of	IN	O
a	DT	O
mandibular	JJ	O
advancement	NN	O
splint	NN	O
(	(	O
MAS	NNP	O
)	)	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
obstructive	JJ	O
sleep	JJ	O
apnoea	NN	O
syndrome	NN	O
(	(	O
OSAS	NNP	O
)	)	O
.	.	O

METHODS	NNP	O
Nineteen	NNP	SS
patients	NNS	O
using	VBG	O
a	DT	O
MAS	NNP	O
for	IN	O
symptomatic	JJ	O
OSAS	NNP	O
underwent	NN	O
polysomnography	NN	O
,	,	O
with	IN	O
MAS	NNP	O
use	NN	O
randomised	VBD	O
to	TO	O
one	CD	O
half	NN	O
of	IN	O
the	DT	O
night	NN	O
.	.	O

Indices	NNS	O
of	IN	O
snoring	VBG	O
and	CC	O
OSAS	NNP	O
were	VBD	O
compared	VBN	O
.	.	O

Side	NNP	O
effects	NNS	O
,	,	O
compliance	NN	O
and	CC	O
treatment	NN	O
response	NN	O
were	VBD	O
evaluated	VBN	O
by	IN	O
questionnaire	NN	O
.	.	O

RESULTS	NNP	O
Use	NNP	O
of	IN	O
the	DT	O
MAS	NNP	O
improved	VBD	O
total	JJ	O
respiratory	NN	O
disturbance	NN	O
index	NN	O
(	(	O
RDI	NNP	O
)	)	O
from	IN	O
22.2	CD	O
+/-	JJ	O
19.8	CD	O
(	(	O
SD	NNP	O
)	)	O
events	NNS	O
per	IN	O
hour	NN	O
to	TO	O
16.5	CD	O
+/-	JJ	O
21.4/hr	CD	O
(	(	O
p	NN	O
=	RB	O
0.03	CD	O
)	)	O
,	,	O
supine	JJ	O
RDI	NNP	O
(	(	O
30.8	CD	O
+/-	JJ	O
23.8/hr	CD	O
to	TO	O
18.8	CD	O
+/-	JJ	O
22.1/hr	CD	O
,	,	O
p	NN	O
=	NNP	O
0.01	CD	O
)	)	O
,	,	O
arousal	JJ	O
index	NN	O
(	(	O
25.2	CD	O
+/-	JJ	O
18.9/hr	CD	O
to	TO	O
19.3	CD	O
+/-	JJ	O
14.2/hr	CD	O
,	,	O
p	NN	O
=	NNP	O
0.01	CD	O
)	)	O
and	CC	O
snoring	VBG	O
intensity	NN	O
(	(	O
52.7	CD	O
+/-	JJ	O
4.1	CD	O
to	TO	O
50.7	CD	O
+/-	JJ	O
2.7	CD	O
dB	NN	O
,	,	O
p	NN	O
=	NNP	O
0.02	CD	O
)	)	O
but	CC	O
not	RB	O
total	JJ	O
snore	NN	O
frequency	NN	O
(	(	O
p	JJ	O
>	NNP	O
0.05	CD	O
)	)	O
.	.	O

Using	VBG	O
polysomnographic	JJ	O
criteria	NNS	O
,	,	O
MAS	NNP	O
treatment	NN	O
was	VBD	O
completely	RB	O
successful	JJ	O
in	IN	O
four	CD	O
(	(	O
21	CD	O
%	NN	O
)	)	O
patients	NNS	O
,	,	O
partially	RB	O
successful	JJ	O
in	IN	O
ten	NN	O
(	(	O
52.6	CD	O
%	NN	O
)	)	O
and	CC	O
a	DT	O
failure	NN	O
in	IN	O
five	CD	O
(	(	O
26.3	CD	O
%	NN	O
)	)	O
.	.	O

Treatment	NN	O
over	IN	O
a	DT	O
median	NN	O
of	IN	O
6.5	CD	O
weeks	NNS	O
(	(	O
range	VB	O
2-48	CD	O
)	)	O
was	VBD	O
perceived	VBN	O
as	IN	O
beneficial	JJ	O
by	IN	O
ten	NN	O
of	IN	O
eleven	JJ	O
partners	NNS	O
.	.	O

Fifteen	JJ	O
patients	NNS	O
(	(	O
79	CD	O
%	NN	O
)	)	O
reported	VBD	O
side	JJ	O
effects	NNS	O
,	,	O
9	CD	O
(	(	O
46	CD	O
%	NN	O
)	)	O
did	VBD	O
not	RB	O
use	VB	O
the	DT	O
device	NN	O
every	DT	O
night	NN	O
and	CC	O
four	CD	O
(	(	O
21	CD	O
%	NN	O
)	)	O
used	VBD	O
the	DT	O
device	NN	O
less	JJR	O
than	IN	O
three	CD	O
nights	NNS	O
per	IN	O
week	NN	O
.	.	O

CONCLUSION	NNP	O
The	DT	O
use	NN	O
of	IN	O
the	DT	O
MAS	NNP	O
resulted	VBD	O
in	IN	O
significant	JJ	O
reductions	NNS	O
in	IN	O
indices	NNS	O
of	IN	O
OSAS	NNP	O
and	CC	O
snoring	VBG	O
.	.	O

However	RB	O
,	,	O
a	DT	O
significant	JJ	O
number	NN	O
of	IN	O
patients	NNS	O
had	VBD	O
difficulty	NN	O
tolerating	NN	O
and	CC	O
regularly	RB	O
using	VBG	O
the	DT	O
device	NN	O
.	.	O

Metabolic	JJ	O
responses	NNS	O
to	TO	O
oral	JJ	O
surgery	NN	O
under	IN	O
local	JJ	O
anesthesia	NN	O
and	CC	O
sedation	NN	O
with	IN	O
intravenous	JJ	O
midazolam	NNS	O
:	:	O
the	DT	O
effects	NNS	O
of	IN	O
two	CD	O
different	JJ	O
local	JJ	O
anesthetics	NNS	O
.	.	O

The	DT	O
effects	NNS	O
of	IN	O
epinephrine-free	JJ	O
and	CC	O
epinephrine-containing	JJ	O
local	JJ	O
anesthetic	JJ	O
solutions	NNS	O
on	IN	O
plasma	NN	O
potassium	NN	O
and	CC	O
blood	NN	O
glucose	JJ	O
concentrations	NNS	O
were	VBD	O
investigated	VBN	O
in	IN	O
20	CD	SS
patients	NNS	O
undergoing	JJ	O
oral	JJ	C
surgery	NN	C
with	IN	O
intravenous	JJ	O
midazolam	NNS	O
sedation	NN	C
.	.	O

Ten	CD	O
patients	NNS	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
receive	VB	O
4.4	CD	O
mL	NN	O
of	IN	O
2	CD	O
%	NN	O
lidocaine	NN	O
with	IN	O
1:80,000	CD	O
epinephrine	NN	O
as	IN	O
a	DT	O
local	JJ	O
anesthetic	NN	O
and	CC	O
10	CD	O
were	VBD	O
given	VBN	O
4.4	CD	O
mL	NN	O
of	IN	O
3	CD	O
%	NN	O
prilocaine	NN	O
with	IN	O
0.03	CD	O
IU/mL	NNP	O
felypressin	NN	O
.	.	O

There	EX	O
were	VBD	O
significant	JJ	O
changes	NNS	O
from	IN	O
baseline	NN	O
potassium	NN	O
and	CC	O
glucose	JJ	O
concentrations	NNS	O
both	DT	O
within	IN	O
and	CC	O
between	IN	O
treatments	NNS	O
in	IN	O
the	DT	O
early	JJ	O
postinjection	NN	O
period	NN	O
.	.	O

The	DT	O
epinephrine-containing	JJ	O
local	JJ	O
anesthetic	NN	O
significantly	RB	O
reduced	VBD	O
the	DT	O
plasma	NN	O
potassium	NN	O
concentration	NN	O
10	CD	O
min	NN	O
after	IN	O
injection	NN	O
,	,	O
by	IN	O
0.16	CD	O
+/-	JJ	O
0.20	CD	O
mmol/L	NN	O
(	(	O
mean	JJ	O
+/-	NNP	O
SD	NNP	O
)	)	O
,	,	O
and	CC	O
increased	VBD	O
the	DT	O
blood	NN	O
glucose	JJ	O
concentration	NN	O
at	IN	O
10	CD	O
,	,	O
20	CD	O
,	,	O
and	CC	O
30	CD	O
min	NN	O
(	(	O
by	IN	O
0.46	CD	O
+/-	JJ	O
0.37	CD	O
,	,	O
0.63	CD	O
+/-	JJ	O
0.45	CD	O
,	,	O
and	CC	O
0.56	CD	O
+/-	JJ	O
0.28	CD	O
mmol/L	NN	O
,	,	O
respectively	RB	O
)	)	O
.	.	O

Conversely	RB	O
,	,	O
plasma	JJ	O
potassium	NN	O
increased	VBD	O
and	CC	O
blood	NN	O
glucose	NN	O
decreased	VBD	O
10	CD	O
,	,	O
20	CD	O
,	,	O
and	CC	O
30	CD	O
min	NN	O
following	VBG	O
the	DT	O
administration	NN	O
of	IN	O
the	DT	O
epinephrine-free	JJ	O
solution	NN	O
.	.	O

At	IN	O
30	CD	O
min	NN	O
potassium	NN	O
was	VBD	O
increased	VBN	O
by	IN	O
0.24	CD	O
+/-	JJ	O
0.16	CD	O
mmol/L	NN	O
,	,	O
and	CC	O
glucose	NN	O
was	VBD	O
decreased	VBN	O
by	IN	O
0.23	CD	O
+/-	JJ	O
0.16	CD	O
mmol/L	NN	O
.	.	O

It	PRP	O
is	VBZ	O
concluded	VBN	O
that	IN	O
epinephrine-free	JJ	O
and	CC	O
epinephrine-containing	JJ	O
local	JJ	O
anesthetics	NNS	O
differ	VBP	O
in	IN	O
their	PRP$	O
metabolic	JJ	O
effects	NNS	O
during	IN	O
oral	JJ	O
surgery	NN	O
with	IN	O
midazolam	JJ	O
sedation	NN	O
.	.	O

Active	JJ	O
warming	NN	O
,	,	O
not	RB	O
passive	JJ	O
heat	NN	O
retention	NN	O
,	,	O
maintains	VBZ	O
normothermia	JJ	O
during	IN	O
combined	JJ	O
epidural-general	JJ	O
anesthesia	NN	O
for	IN	O
hip	NN	O
and	CC	O
knee	NN	O
arthroplasty	NN	C
.	.	O

STUDY	NNP	O
OBJECTIVE	NNP	O
to	TO	O
compare	VB	O
passive	JJ	O
heat	NN	O
retention	NN	O
by	IN	O
low-flow	JJ	O
anesthesia	NN	O
,	,	O
alone	RB	O
and	CC	O
with	IN	O
additional	JJ	O
thermal	JJ	O
insulation	NN	O
by	IN	O
reflective	JJ	O
blankets	NNS	O
,	,	O
with	IN	O
forced-air	JJ	O
warming	VBG	O
preventing	VBG	O
intraoperative	JJ	O
hypothermia	NN	O
during	IN	O
combined	JJ	O
epidural-general	JJ	O
anesthesia	NN	O
.	.	O

DESIGN	NNP	O
Randomized	NNP	O
,	,	O
controlled	VBD	O
study	NN	O
.	.	O

SETTING	NNP	O
Inpatient	NNP	O
anesthesia	NN	O
at	IN	O
a	DT	O
university	NN	O
department	NN	O
of	IN	O
orthopedic	JJ	O
surgery	NN	O
.	.	O

PATIENTS	CC	O
30	CD	SS
ASA	NNP	O
physical	JJ	O
status	NN	O
I	PRP	SS
and	CC	O
II	NNP	SS
patients	NNS	O
,	,	O
who	WP	O
were	VBD	O
scheduled	VBN	O
for	IN	O
elective	JJ	O
hip	NN	O
or	CC	O
knee	VB	O
arthroplasty	JJ	O
and	CC	O
were	VBD	O
free	JJ	O
from	IN	O
systemic	JJ	C
disease	NN	C
.	.	C

INTERVENTIONS	JJ	O
Patients	NNPS	O
received	VBD	O
epidural	JJ	O
block	NN	O
up	RB	O
to	TO	O
T10	NNP	O
by	IN	O
alkalinized	JJ	O
lidocaine	JJ	O
2	CD	O
%	NN	O
,	,	O
and	CC	O
then	RB	O
were	VBD	O
administered	VBN	O
standard	JJ	O
general	JJ	O
anesthesia	NN	O
by	IN	O
means	NNS	O
of	IN	O
low-flow	JJ	O
rebreathing	NN	O
system	NN	O
(	(	O
fresh	JJ	O
gas	NN	O
flow	NN	O
=	VBD	O
1	CD	O
L/min	NNP	O
)	)	O
.	.	O

All	DT	O
procedures	NNS	O
started	VBD	O
between	IN	O
8	CD	O
and	CC	O
10	CD	O
AM	NNP	O
,	,	O
and	CC	O
operating	NN	O
room	NN	O
(	(	O
OR	NNP	O
)	)	O
temperature	NN	O
was	VBD	O
maintained	VBN	O
between	IN	O
21	CD	O
degrees	NNS	O
and	CC	O
23	CD	O
degrees	NNS	O
C	NNP	O
,	,	O
with	IN	O
relative	JJ	O
humidity	NN	O
ranging	VBG	O
between	IN	O
40	CD	O
%	NN	O
and	CC	O
45	CD	O
%	NN	O
.	.	O

For	IN	O
heat	NN	O
retention	NN	O
or	CC	O
warming	VBG	O
therapy	NN	O
,	,	O
patients	NNS	O
received	VBD	O
either	RB	O
low-flow	JJ	O
anesthesia	NN	O
only	RB	O
(	(	O
control	NN	O
,	,	O
n	JJ	O
=	NNP	O
10	CD	O
)	)	O
,	,	O
low-flow	JJ	O
anesthesia	NN	O
with	IN	O
additional	JJ	O
reflective	JJ	O
blankets	NNS	O
(	(	O
blanket	NN	O
,	,	O
n	JJ	O
=	NNP	O
10	CD	O
)	)	O
,	,	O
or	CC	O
low-flow	JJ	O
anesthesia	NN	O
with	IN	O
active	JJ	O
forced-air	JJ	O
warming	NN	O
(	(	O
forced-air	JJ	O
,	,	O
n	JJ	O
=	NNP	O
10	CD	O
)	)	O
.	.	O

Tympanic	JJ	O
temperature	NN	O
was	VBD	O
measured	VBN	O
at	IN	O
OR	NNP	O
arrival	NN	O
(	(	O
baseline	NN	O
)	)	O
;	:	O
immediately	RB	O
following	VBG	O
general	JJ	O
anesthesia	JJ	O
induction	NN	O
;	:	O
30	CD	O
,	,	O
60	CD	O
,	,	O
90	CD	O
,	,	O
and	CC	O
120	CD	O
minutes	NNS	O
from	IN	O
general	JJ	O
anesthesia	NN	O
induction	NN	O
;	:	O
and	CC	O
at	IN	O
the	DT	O
end	NN	O
of	IN	O
surgery	NN	O
.	.	O

MEASUREMENTS	NNP	O
AND	CC	O
MAIN	NNP	O
RESULTS	NNP	O
Duration	NNP	O
of	IN	O
anesthesia	NN	O
,	,	O
invasiveness	NN	O
of	IN	O
surgery	NN	O
,	,	O
and	CC	O
baseline	NN	O
core	NN	O
temperature	NN	O
were	VBD	O
similar	JJ	O
in	IN	O
the	DT	O
three	CD	O
groups	NNS	O
.	.	O

Core	NNP	O
temperature	NN	O
decreased	VBN	O
in	IN	O
all	PDT	O
the	DT	O
three	CD	O
groups	NNS	O
30	CD	O
minutes	NNS	O
after	IN	O
general	JJ	O
anesthesia	NN	O
induction	NN	O
compared	VBN	O
with	IN	O
baseline	NN	O
(	(	O
p	JJ	O
<	NNP	O
0.01	CD	O
)	)	O
;	:	O
afterwards	NNS	O
,	,	O
it	PRP	O
progressively	RB	O
decreased	VBD	O
in	IN	O
the	DT	O
control	NN	O
and	CC	O
blankets	NNS	O
groups	NNS	O
(	(	O
p	JJ	O
=	NNP	O
0.004	CD	O
)	)	O
,	,	O
with	IN	O
a	DT	O
reduction	NN	O
from	IN	O
baseline	NN	O
values	NNS	O
measured	VBN	O
at	IN	O
the	DT	O
end	NN	O
of	IN	O
surgery	NN	O
of	IN	O
2.0	CD	O
degrees	NNS	O
C	NNP	O
and	CC	O
1.6	CD	O
degrees	NNS	O
C	NNP	O
,	,	O
respectively	RB	O
.	.	O

In	IN	O
the	DT	O
forced-air	JJ	O
group	NN	O
,	,	O
after	IN	O
the	DT	O
initial	JJ	O
significant	JJ	O
decrease	NN	O
(	(	O
p	JJ	O
=	$	O
0.01	CD	O
vs.	FW	O
baseline	NN	O
)	)	O
,	,	O
core	JJ	O
temperature	NN	O
progressively	RB	O
increased	VBD	O
to	TO	O
35.8	CD	O
+/-	JJ	O
0.6	CD	O
degrees	NNS	O
C	NNP	O
,	,	O
which	WDT	O
was	VBD	O
similar	JJ	O
to	TO	O
preoperative	VB	O
values	NNS	O
and	CC	O
significantly	RB	O
higher	JJR	O
than	IN	O
either	CC	O
the	DT	O
control	NN	O
or	CC	O
blankets	NNS	O
groups	NNS	O
(	(	O
p	JJ	O
=	NNP	O
0.004	CD	O
)	)	O
.	.	O

CONCLUSIONS	NNP	O
During	IN	O
combined	VBN	O
epidural-general	JJ	O
anesthesia	NN	O
for	IN	O
elective	JJ	O
hip	NN	O
and	CC	O
knee	NN	O
arthroplasty	NN	O
,	,	O
passive	JJ	O
heat	NN	O
retention	NN	O
by	IN	O
means	NNS	O
of	IN	O
low-flow	JJ	O
anesthesia	NN	O
alone	RB	O
and	CC	O
in	IN	O
combination	NN	O
with	IN	O
reflective	JJ	O
blankets	NNS	O
is	VBZ	O
ineffective	JJ	O
in	IN	O
maintaining	VBG	O
intraoperative	JJ	O
normothermia	NN	O
and	CC	O
definitely	RB	O
inferior	JJ	O
to	TO	O
active	JJ	O
forced-air	JJ	O
warning	NN	O
.	.	O

[	JJ	O
Acute	NNP	O
cardiovascular	NN	O
and	CC	O
metabolic	JJ	O
changes	NNS	O
in	IN	O
interval	NN	O
and	CC	O
endurance	NN	O
training	NN	O
in	IN	O
selected	VBN	C
patients	NNS	C
following	VBG	C
aortocoronary	JJ	C
bypass	NN	C
operation	NN	C
]	NNP	O
.	.	O

UNLABELLED	VB	O
This	DT	O
study	NN	O
compared	VBN	O
the	DT	O
acute	NN	O
changes	NNS	O
of	IN	O
cardiovascular	NN	O
and	CC	O
metabolic	JJ	O
reactions	NNS	O
during	IN	O
interval	NN	O
and	CC	O
continuous	JJ	O
training	NN	O
after	IN	O
coronary	JJ	O
bypass	NN	O
surgery	NN	O
.	.	O

Two	CD	O
groups	NNS	O
of	IN	O
9	CD	SS
male	JJ	SE
patients	NNS	O
(	(	O
age	NN	A
:	:	A
59	CD	A
+/-	JJ	A
4	CD	A
and	CC	A
56	CD	A
+/-	JJ	A
6	CD	A
years	NNS	A
,	,	A
resp	NN	A
.	.	O

)	)	O
each	DT	O
trained	VBN	O
on	IN	O
bicycle	NN	O
ergometer	JJ	O
start	NN	O
on	IN	O
post-operative	JJ	O
days	NNS	O
24	CD	O
and	CC	O
26	CD	O
,	,	O
resp	NN	O
.	.	O

In	IN	O
both	DT	O
training	NN	O
groups	NNS	O
training	VBG	O
heart	NN	O
rate	NN	O
was	VBD	O
set	VBN	O
at	IN	O
86	CD	O
%	NN	O
of	IN	O
individual	JJ	O
maximum	JJ	O
heart	NN	O
rate	NN	O
.	.	O

In	IN	O
the	DT	O
last	JJ	O
week	NN	O
of	IN	O
training	VBG	O
the	DT	O
exercise	NN	O
intensity	NN	O
in	IN	O
the	DT	O
group	NN	O
of	IN	O
patients	NNS	O
who	WP	O
were	VBD	O
trained	VBN	O
by	IN	O
the	DT	O
continuous	JJ	O
method	NN	O
was	VBD	O
at	IN	O
83	CD	O
watts	NN	O
,	,	O
and	CC	O
at	IN	O
20:121	CD	O
watts	NN	O
in	IN	O
the	DT	O
group	NN	O
of	IN	O
patients	NNS	O
who	WP	O
were	VBD	O
trained	VBN	O
by	IN	O
interval	JJ	O
method	NN	O
(	(	O
rest	NN	O
:	:	O
work	NN	O
each	DT	O
1:1	CD	O
min	NN	O
)	)	O
.	.	O

At	IN	O
this	DT	O
exercise	NN	O
training	NN	O
that	WDT	O
lasted	VBD	O
for	IN	O
20	CD	O
min	PDT	O
the	DT	O
acute	JJ	O
response	NN	O
of	IN	O
heart	NN	O
rate	NN	O
,	,	O
blood	NN	O
pressure	NN	O
,	,	O
rate-pressure	JJ	O
product	NN	O
,	,	O
glucose	JJ	O
,	,	O
lactate	JJ	O
and	CC	O
catecholamines	NNS	O
was	VBD	O
measured	VBN	O
.	.	O

RESULTS	NNP	O
In	IN	O
both	DT	O
methods	NNS	O
there	EX	O
were	VBD	O
no	DT	O
significant	JJ	O
differences	NNS	O
in	IN	O
systolic	JJ	O
and	CC	O
diastolic	JJ	O
pressure	NN	O
,	,	O
rate-pressure	JJ	O
product	NN	O
,	,	O
in	IN	O
glucose	NN	O
or	CC	O
catecholamine	NN	O
levels	NNS	O
.	.	O

However	RB	O
,	,	O
there	EX	O
was	VBD	O
a	DT	O
significantly	RB	O
higher	JJR	O
rate	NN	O
of	IN	O
lactate	NN	O
in	IN	O
the	DT	O
second	JJ	O
10	CD	O
min	NN	O
of	IN	O
the	DT	O
interval	JJ	O
training	NN	O
.	.	O

And	CC	O
,	,	O
in	IN	O
spite	NN	O
of	IN	O
higher	JJR	O
peripheral	JJ	O
exercise	NN	O
intensity	NN	O
by	IN	O
interval	JJ	O
training	NN	O
,	,	O
there	EX	O
was	VBD	O
no	DT	O
higher	JJR	O
cardiac	NN	O
work	NN	O
than	IN	O
by	IN	O
the	DT	O
continuous	JJ	O
training	NN	O
.	.	O

These	DT	O
findings	NNS	O
suggest	VBP	O
that	IN	O
interval	JJ	O
training	NN	O
strains	VBZ	O
the	DT	O
oxidative	JJ	O
capacity	NN	O
of	IN	O
the	DT	O
trained	JJ	O
muscles	NNS	O
in	IN	O
a	DT	O
more	RBR	O
intensive	JJ	O
and	CC	O
direct	JJ	O
way	NN	O
than	IN	O
does	VBZ	O
continuous	JJ	O
training	NN	O
.	.	O

Children	NNP	O
's	POS	O
Yale-Brown	JJ	O
Obsessive	NNP	O
Compulsive	NNP	O
Scale	NNP	O
modified	VBD	O
for	IN	O
pervasive	JJ	O
developmental	NN	O
disorders	NNS	O
.	.	O

OBJECTIVE	NNP	O
To	TO	O
examine	VB	O
the	DT	O
psychometric	JJ	O
properties	NNS	O
of	IN	O
the	DT	O
Children	NNP	O
's	POS	O
Yale-Brown	JJ	O
Obsessive	NNP	O
Compulsive	NNP	O
Scales	NNP	O
(	(	O
CYBOCS	NNP	O
)	)	O
modified	VBD	O
for	IN	O
pervasive	JJ	O
developmental	NN	O
disorders	NNS	O
(	(	O
PDDs	NNP	O
)	)	O
.	.	O

METHOD	NNP	O
Raters	NNPS	O
from	IN	O
five	CD	O
Research	NNP	O
Units	NNS	O
on	IN	O
Pediatric	NNP	O
Psychopharmacology	NNP	O
(	(	O
RUPP	NNP	O
)	)	O
Autism	NNP	O
Network	NNP	O
were	VBD	O
trained	VBN	O
to	TO	O
reliability	NN	O
.	.	O

The	DT	O
modified	JJ	O
scale	NN	O
(	(	O
CYBOCS-PDD	NNP	O
)	)	O
,	,	O
which	WDT	O
contains	VBZ	O
only	RB	O
the	DT	O
five	CD	O
Compulsion	NNP	O
severity	NN	O
items	NNS	O
(	(	O
range	VB	O
0-20	NN	O
)	)	O
,	,	O
was	VBD	O
administered	VBN	O
to	TO	O
172	CD	O
medication-free	JJ	O
children	NNS	O
(	(	O
mean	JJ	O
8.2	CD	O
+/-	JJ	O
2.6	CD	O
years	NNS	O
)	)	O
with	IN	O
PDD	NNP	O
(	(	O
autistic	JJ	O
disorder	NN	O
,	,	O
n	JJ	O
=	VBP	O
152	CD	O
;	:	O
Asperger	NNP	O
's	POS	O
disorder	NN	O
,	,	O
n	JJ	O
=	VBP	O
6	CD	O
;	:	O
PDD	NNP	O
not	RB	O
otherwise	RB	O
specified	VBN	O
,	,	O
n	JJ	O
=	NNP	O
14	CD	O
)	)	O
participating	NN	O
in	IN	O
RUPP	NNP	O
clinical	JJ	O
trials	NNS	O
.	.	O

Reliability	NNP	O
was	VBD	O
assessed	VBN	O
by	IN	O
intraclass	NN	O
correlation	NN	O
coefficient	NN	O
(	(	O
ICC	NNP	O
)	)	O
and	CC	O
internal	JJ	O
consistency	NN	O
by	IN	O
Cronbach	NNP	O
's	POS	O
alpha	JJ	O
coefficient	NN	O
.	.	O

Correlations	NNS	O
with	IN	O
ratings	NNS	O
of	IN	O
repetitive	JJ	O
behavior	NN	O
and	CC	O
disruptive	JJ	O
behavior	NN	O
were	VBD	O
examined	VBN	O
for	IN	O
validity	NN	O
.	.	O

RESULTS	NNP	O
Eleven	NNP	O
raters	NNS	O
showed	VBD	O
excellent	JJ	O
reliability	NN	O
(	(	O
ICC	NNP	O
=	NNP	O
0.97	CD	O
)	)	O
.	.	O

The	DT	O
mean	JJ	O
CYBOCS	NNP	O
score	NN	O
was	VBD	O
14.4	CD	O
(	(	O
+/-	JJ	O
3.86	CD	O
)	)	O
with	IN	O
excellent	JJ	O
internal	JJ	O
consistency	NN	O
(	(	O
alpha	JJ	O
=	NNP	O
.85	NNP	O
)	)	O
.	.	O

Correlations	NNS	O
with	IN	O
other	JJ	O
measures	NNS	O
of	IN	O
repetitive	JJ	O
behavior	NN	O
ranged	VBD	O
from	IN	O
r	NN	O
=	$	O
0.11	CD	O
to	TO	O
r	VB	O
=	JJ	O
0.28	CD	O
and	CC	O
were	VBD	O
similar	JJ	O
to	TO	O
correlations	NNS	O
with	IN	O
measures	NNS	O
of	IN	O
irritability	NN	O
(	(	O
r	JJ	O
=	NNP	O
0.24	CD	O
)	)	O
and	CC	O
hyperactivity	NN	O
(	(	O
r	JJ	O
=	NNP	O
0.25	CD	O
)	)	O
.	.	O

Children	NNP	O
with	IN	O
higher	JJR	O
scores	NNS	O
on	IN	O
the	DT	O
CYBOCS-PDD	NNP	O
had	VBD	O
higher	JJR	O
levels	NNS	O
of	IN	O
maladaptive	JJ	O
behaviors	NNS	O
and	CC	O
lower	JJR	O
adaptive	JJ	O
functioning	NN	O
.	.	O

CONCLUSIONS	VB	O
The	DT	O
five-item	JJ	O
CYBOCS-PDD	NNP	O
is	VBZ	O
reliable	JJ	O
,	,	O
distinct	JJ	O
from	IN	O
other	JJ	O
measures	NNS	O
of	IN	O
repetitive	JJ	O
behavior	NN	O
,	,	O
and	CC	O
sensitive	JJ	O
to	TO	O
change	VB	O
.	.	O

Response	NN	O
of	IN	O
pre-core	NN	O
mutant	NN	O
chronic	JJ	O
hepatitis	NN	O
B	NNP	O
infection	NN	O
to	TO	O
lamivudine	VB	O
.	.	O

The	DT	O
proportion	NN	O
of	IN	O
chronic	JJ	O
liver	NN	O
disease	NN	O
associated	VBN	O
with	IN	O
the	DT	O
pre-core	JJ	O
mutant	NN	O
of	IN	O
hepatitis	NN	O
B	NNP	O
virus	NN	O
(	(	O
HBV	NNP	O
)	)	O
infection	NN	O
is	VBZ	O
increasing	VBG	O
,	,	O
particularly	RB	O
in	IN	O
Mediterranean	NNP	O
Europe	NNP	O
and	CC	O
in	IN	O
Asia	NNP	O
.	.	O

The	DT	O
pre-core	JJ	O
mutant	NN	O
HBV	NNP	O
is	VBZ	O
unable	JJ	O
to	TO	O
produce	VB	O
hepatitis	NN	O
B	NNP	O
e	NN	O
antigen	NN	O
(	(	O
HBeAg	NNP	O
)	)	O
,	,	O
so	RB	O
that	IN	O
patients	NNS	O
with	IN	O
this	DT	O
variant	NN	O
do	VBP	O
not	RB	O
present	VB	O
with	IN	O
HBV	NNP	O
characterised	VBN	O
by	IN	O
HBeAg	NNP	O
in	IN	O
the	DT	O
serum	NN	O
.	.	O

Pre-core	NN	O
mutant	JJ	O
chronic	JJ	O
hepatitis	NN	O
B	NNP	O
infection	NN	O
usually	RB	O
proceeds	VBZ	O
to	TO	O
serious	JJ	O
liver	JJ	O
disease	NN	O
.	.	O

Wild-type	JJ	O
HBV	NNP	O
infection	NN	O
may	MD	O
be	VB	O
mild	JJ	O
and	CC	O
respond	NN	O
relatively	RB	O
well	RB	O
to	TO	O
interferon	VB	O
(	(	O
IFN	NNP	O
)	)	O
alpha	NN	O
therapy	NN	O
,	,	O
but	CC	O
IFN	NNP	O
alpha	NN	O
is	VBZ	O
not	RB	O
an	DT	O
effective	JJ	O
therapeutic	JJ	O
option	NN	O
in	IN	O
pre-core	NN	O
mutant	NN	O
hepatitis	NN	O
B	NNP	O
infection	NN	O
and	CC	O
new	JJ	O
therapeutic	JJ	O
options	NNS	O
are	VBP	O
needed	VBN	O
.	.	O

Clinical	JJ	O
data	NNS	O
show	VBP	O
that	IN	O
lamivudine	NN	O
is	VBZ	O
an	DT	O
effective	JJ	O
treatment	NN	O
for	IN	O
patients	NNS	C
with	IN	C
pre-core	JJ	C
mutant	NN	C
hepatitis	NN	C
B	NNP	C
.	.	O

There	EX	O
is	VBZ	O
profound	JJ	O
suppression	NN	O
of	IN	O
HBV	NNP	O
replication	NN	O
and	CC	O
improvement	NN	O
in	IN	O
indicators	NNS	O
of	IN	O
liver	JJ	O
disease	NN	O
in	IN	O
most	JJS	O
patients	NNS	O
.	.	O

In	IN	O
conclusion	NN	O
,	,	O
lamivudine	NN	O
is	VBZ	O
suitable	JJ	O
for	IN	O
treatment	NN	O
of	IN	O
a	DT	O
wide	JJ	O
range	NN	O
of	IN	O
patients	NNS	C
with	IN	C
chronic	JJ	C
hepatitis	NN	C
B	NNP	C
,	,	C
including	VBG	C
those	DT	C
with	IN	C
pre-core	JJ	C
mutant	JJ	C
HBV	NNP	C
infection	NN	C
.	.	O

Evolution	NN	O
of	IN	O
coronary	JJ	O
stenoses	NNS	O
is	VBZ	O
related	VBN	O
to	TO	O
baseline	VB	O
severity	NN	O
--	:	O
a	DT	O
prospective	JJ	O
quantitative	JJ	O
angiographic	JJ	O
analysis	NN	O
in	IN	O
patients	NNS	O
with	IN	O
moderate	JJ	C
coronary	JJ	C
disease	NN	C
.	.	O

INTACT	JJ	O
Investigators	NNPS	O
.	.	O

International	NNP	O
Nifedipine	NNP	O
Trial	NNP	O
on	IN	O
Antiatherosclerotic	NNP	O
Therapy	NNP	O
.	.	O

A	DT	O
correlation	NN	O
of	IN	O
the	DT	O
angiographic	JJ	O
evolution	NN	O
of	IN	O
coronary	JJ	O
stenoses	NNS	O
(	(	O
stenosis	NN	O
diameter	NN	O
>	NN	O
or	CC	O
=	VB	O
20	CD	O
%	NN	O
)	)	O
with	IN	O
morphological	JJ	O
stenosis	NN	O
parameters	NNS	O
at	IN	O
baseline	NN	O
could	MD	O
help	VB	O
to	TO	O
identify	VB	O
the	DT	O
risk	NN	O
of	IN	O
progressive	JJ	O
stenoses	NNS	O
.	.	O

Therefore	RB	O
,	,	O
the	DT	O
data	NN	O
of	IN	O
the	DT	O
prospective	JJ	O
INTACT	NNP	O
study	NN	O
(	(	O
International	NNP	O
Nifedipine	NNP	O
Trial	NNP	O
on	IN	O
Antiatherosclerotic	NNP	O
Therapy	NNP	O
)	)	O
were	VBD	O
reviewed	VBN	O
.	.	O

In	IN	O
348	CD	SS
patients	NNS	O
with	IN	O
moderate	JJ	C
coronary	JJ	C
artery	NN	C
disease	NN	C
,	,	O
standardized	VBD	O
coronary	JJ	O
angiograms	NNS	O
were	VBD	O
taken	VBN	O
3	CD	O
years	NNS	O
apart	RB	O
and	CC	O
were	VBD	O
quantitatively	RB	O
analysed	VBN	O
.	.	O

Changes	NNS	O
in	IN	O
the	DT	O
minimal	JJ	O
diameter	NN	O
of	IN	O
the	DT	O
1063	CD	O
preexisting	VBG	O
coronary	JJ	O
stenoses	NNS	O
compared	VBN	O
between	IN	O
both	DT	O
angiograms	NNS	O
were	VBD	O
set	VBN	O
in	IN	O
relation	NN	O
to	TO	O
a	DT	O
number	NN	O
of	IN	O
conventional	JJ	O
stenosis	NN	O
parameters	NNS	O
at	IN	O
baseline	NN	O
.	.	O

Regression	NNP	O
analysis	NN	O
demonstrated	VBD	O
a	DT	O
significant	JJ	O
correlation	NN	O
of	IN	O
the	DT	O
changes	NNS	O
in	IN	O
minimal	JJ	O
diameter	NN	O
with	IN	O
baseline	NN	O
%	NN	O
diameter	NN	O
stenosis	NN	O
(	(	O
r	JJ	O
=	VBZ	O
0.30	CD	O
;	:	O
P	NNP	O
<	NNP	O
0.001	CD	O
)	)	O
,	,	O
minimal	JJ	O
diameter	NN	O
(	(	O
r	JJ	O
=	NNP	O
-0.28	NNP	O
;	:	O
P	NNP	O
<	NNP	O
0.001	CD	O
)	)	O
and	CC	O
reference	NN	O
diameter	NN	O
of	IN	O
stenoses	NNS	O
(	(	O
r	NN	O
=	NNP	O
-0.14	NNP	O
;	:	O
P	NNP	O
<	NNP	O
0.001	CD	O
)	)	O
.	.	O

The	DT	O
changes	NNS	O
were	VBD	O
not	RB	O
correlated	VBN	O
with	IN	O
stenosis	NN	O
length	NN	O
and	CC	O
plaque	JJ	O
area	NN	O
.	.	O

The	DT	O
baseline	NN	O
parameters	NNS	O
of	IN	O
22	CD	O
preexisting	VBG	O
stenoses	NNS	O
progressing	VBG	O
to	TO	O
occlusions	NNS	O
differed	VBN	O
from	IN	O
those	DT	O
remaining	VBG	O
patent	NN	O
only	RB	O
with	IN	O
regard	NN	O
to	TO	O
the	DT	O
%	NN	O
diameter	NN	O
stenosis	NN	O
(	(	O
43	CD	O
+/-	JJ	O
9	CD	O
%	NN	O
vs	JJ	O
39	CD	O
+/-	JJ	O
11	CD	O
%	NN	O
;	:	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
.	.	O

Additional	JJ	O
progression	NN	O
of	IN	O
coronary	JJ	O
disease	NN	O
became	VBD	O
manifest	JJS	O
through	IN	O
development	NN	O
of	IN	O
228	CD	O
stenoses	NNS	O
and	CC	O
19	CD	O
occlusions	NNS	O
at	IN	O
arterial	JJ	O
sites	NNS	O
free	VBP	O
from	IN	O
definitive	JJ	O
stenoses	NNS	O
in	IN	O
the	DT	O
baseline	NN	O
angiograms	NN	O
.	.	O

Thus	RB	O
,	,	O
progression	NN	O
of	IN	O
atherosclerosis	NN	O
predominantly	RB	O
occurred	VBD	O
in	IN	O
mild	NN	O
preexisting	VBG	O
coronary	JJ	O
stenoses	NNS	O
and	CC	O
developed	VBN	O
at	IN	O
previously	RB	O
angiographically	RB	O
normal	JJ	O
sites	NNS	O
.	.	O

Since	IN	O
the	DT	O
conventional	JJ	O
angiographic	JJ	O
parameters	NNS	O
analysed	VBN	O
in	IN	O
this	DT	O
study	NN	O
failed	VBD	O
to	TO	O
identify	VB	O
individual	JJ	O
arterial	JJ	O
sites	NNS	O
with	IN	O
an	DT	O
increased	VBN	O
risk	NN	O
for	IN	O
progression	NN	O
,	,	O
definition	NN	O
of	IN	O
new	JJ	O
angiographic	JJ	O
parameters	NNS	O
or	CC	O
application	NN	O
of	IN	O
new	JJ	O
techniques	NNS	O
seem	VBP	O
mandatory	JJ	O
to	TO	O
this	DT	O
end	NN	O
.	.	O

Efficacy	NN	O
of	IN	O
a	DT	O
family	NN	O
practice-based	JJ	O
lifestyle	JJ	O
intervention	NN	O
program	NN	O
to	TO	O
increase	VB	O
physical	JJ	O
activity	NN	O
and	CC	O
reduce	VB	O
clinical	JJ	O
and	CC	O
physiological	JJ	O
markers	NNS	O
of	IN	O
vascular	JJ	O
health	NN	O
in	IN	O
patients	NNS	O
with	IN	O
high	JJ	C
normal	JJ	C
blood	NN	C
pressure	NN	C
and/or	RB	O
high	JJ	C
normal	JJ	C
blood	NN	C
glucose	NN	C
(	(	C
SNAC	NNP	C
)	)	C
:	:	O
study	NN	O
protocol	NN	O
for	IN	O
a	DT	O
randomized	VBN	O
controlled	VBN	O
trial	NN	O
.	.	O

BACKGROUND	NNP	O
Previous	JJ	O
interventions	NNS	O
to	TO	O
increase	VB	O
physical	JJ	O
activity	NN	O
and	CC	O
reduce	VB	O
cardiovascular	JJ	O
risk	NN	O
factors	NNS	O
have	VBP	O
been	VBN	O
targeted	VBN	O
at	IN	O
individuals	NNS	O
with	IN	O
established	VBN	O
disease	NN	O
;	:	O
less	CC	O
attention	NN	O
has	VBZ	O
been	VBN	O
given	VBN	O
to	TO	O
intervention	VB	O
among	IN	O
individuals	NNS	O
with	IN	O
high	JJ	C
risk	NN	C
for	IN	C
disease	NN	C
nor	CC	O
has	VBZ	O
there	RB	O
been	VBN	O
determination	NN	O
of	IN	O
the	DT	O
influence	NN	O
of	IN	O
setting	VBG	O
in	IN	O
which	WDT	O
the	DT	O
intervention	NN	O
is	VBZ	O
provided	VBN	O
.	.	O

In	IN	O
particular	JJ	O
,	,	O
family	NN	O
practice	NN	O
represents	VBZ	O
an	DT	O
ideal	JJ	O
setting	NN	O
for	IN	O
the	DT	O
provision	NN	O
and	CC	O
long-term	JJ	O
maintenance	NN	O
of	IN	O
lifestyle	JJ	O
interventions	NNS	O
for	IN	O
patients	NNS	O
at	IN	O
risk	NN	O
(	(	O
ie	JJ	O
high-normal	JJ	C
blood	NN	C
pressure	NN	C
or	CC	C
impaired	JJ	C
glucose	JJ	C
tolerance	NN	C
)	)	O
.	.	O

METHODS/DESIGN	PDT	O
The	DT	O
Staged	NNP	O
Nutrition	NNP	O
and	CC	O
Activity	NNP	O
Counseling	NNP	O
(	(	O
SNAC	NNP	O
)	)	O
study	NN	O
is	VBZ	O
a	DT	O
randomized	JJ	O
clustered	JJ	O
design	NN	O
clinical	JJ	O
trial	NN	O
that	WDT	O
will	MD	O
investigate	VB	O
the	DT	O
effectiveness	NN	O
and	CC	O
efficacy	NN	O
of	IN	O
a	DT	O
multi-component	JJ	O
lifestyle	JJ	O
intervention	NN	O
on	IN	O
cardiovascular	JJ	O
disease	NN	O
risk	NN	O
factors	NNS	O
and	CC	O
vascular	JJ	O
function	NN	O
in	IN	O
patients	NNS	O
at	IN	O
risk	NN	O
in	IN	O
primary	JJ	O
care	NN	O
.	.	O

Patients	NNS	O
will	MD	O
be	VB	O
randomized	VBN	O
by	IN	O
practice	NN	O
to	TO	O
either	VB	O
a	DT	O
standard	NN	O
of	IN	O
care	NN	O
lifestyle	JJ	O
intervention	NN	O
or	CC	O
a	DT	O
behaviourally-based	JJ	O
,	,	O
matched	VBD	O
prescriptive	JJ	O
physical	JJ	O
activity	NN	O
and	CC	O
diet	JJ	O
change	NN	O
program	NN	O
.	.	O

The	DT	O
primary	JJ	O
goal	NN	O
is	VBZ	O
to	TO	O
increase	VB	O
physical	JJ	O
activity	NN	O
and	CC	O
improve	VB	O
dietary	JJ	O
intake	NN	O
according	VBG	O
to	TO	O
Canada	NNP	O
's	POS	O
Guides	NNP	O
to	TO	O
Physical	NNP	O
Activity	NNP	O
Healthy	NNP	O
Eating	NNP	O
over	IN	O
24	CD	O
months	NNS	O
.	.	O

The	DT	O
primary	JJ	O
intention	NN	O
to	TO	O
treat	VB	O
analysis	NN	O
will	MD	O
compare	VB	O
behavioral	JJ	O
,	,	O
physiological	JJ	O
and	CC	O
metabolic	JJ	O
outcomes	NNS	O
at	IN	O
6	CD	O
,	,	O
12	CD	O
and	CC	O
24	CD	O
months	NNS	O
post-randomization	JJ	O
including	VBG	O
estimation	NN	O
of	IN	O
incident	JJ	O
hypertension	NN	O
and/or	NN	O
diabetes	VBZ	O
.	.	O

DISCUSSION	VB	O
The	DT	O
design	NN	O
features	NNS	O
of	IN	O
our	PRP$	O
trial	NN	O
,	,	O
and	CC	O
the	DT	O
practical	JJ	O
problems	NNS	O
(	(	O
and	CC	O
solutions	NNS	O
)	)	O
associated	VBN	O
with	IN	O
implementing	VBG	O
these	DT	O
design	NN	O
features	NNS	O
,	,	O
particularly	RB	O
those	DT	O
that	IN	O
result	NN	O
in	IN	O
potential	JJ	O
delay	NN	O
between	IN	O
recruitment	NN	O
,	,	O
baseline	NN	O
data	NNS	O
collection	NN	O
,	,	O
randomization	NN	O
,	,	O
intervention	NN	O
,	,	O
and	CC	O
assessment	NN	O
will	MD	O
be	VB	O
discussed	VBN	O
.	.	O

Results	NNS	O
of	IN	O
the	DT	O
SNAC	NNP	O
trial	NN	O
will	MD	O
provide	VB	O
scientific	JJ	O
rationale	NN	O
for	IN	O
the	DT	O
implementation	NN	O
of	IN	O
this	DT	O
lifestyle	JJ	O
intervention	NN	O
in	IN	O
primary	JJ	O
care	NN	O
.	.	O

TRIAL	NNP	O
REGISTRATION	NNP	O
ISRCTN	NNP	O
:	:	O
ISRCTN:42921300	NNP	O
.	.	O

Twice-a-day	JJ	O
versus	NN	O
four-times-a-day	JJ	O
ofloxacin	JJ	O
treatment	NN	O
of	IN	O
external	JJ	O
ocular	JJ	O
infection	NN	O
.	.	O

PURPOSE	VB	O
The	DT	O
purpose	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
compare	VB	O
the	DT	O
efficacies	NNS	O
of	IN	O
0.3	CD	O
%	NN	O
ofloxacin	JJ	O
eyedrops	NNS	O
,	,	O
when	WRB	O
given	VBN	O
twice-a-day	JJ	O
(	(	O
BID	NNP	O
)	)	O
versus	IN	O
four-times-a-day	JJ	O
(	(	O
QID	NNP	O
)	)	O
,	,	O
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
external	JJ	O
ocular	JJ	O
disease	NN	O
.	.	O

METHOD	NNP	O
Fifty	NNP	SS
patients	NNS	O
with	IN	O
blepharitis	NN	C
,	,	O
conjuctivitis	NN	C
,	,	O
or	CC	O
blepharoconjunctivitis	NN	C
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
treatment	NN	O
with	IN	O
0.3	CD	O
%	NN	O
ofloxacin	JJ	O
eyedrops	NNS	O
,	,	O
BID	NNP	O
or	CC	O
QID	NNP	O
,	,	O
for	IN	O
10	CD	O
days	NNS	O
.	.	O

Signs	NNP	O
,	,	O
symptoms	NNS	O
,	,	O
and	CC	O
cultures	NNS	O
were	VBD	O
evaluated	VBN	O
at	IN	O
the	DT	O
beginning	NN	O
and	CC	O
at	IN	O
the	DT	O
end	NN	O
of	IN	O
the	DT	O
study	NN	O
.	.	O

RESULTS	VB	O
The	DT	O
clinical	JJ	O
outcome	NN	O
was	VBD	O
virtually	RB	O
identical	JJ	O
in	IN	O
the	DT	O
two	CD	O
groups	NNS	O
.	.	O

There	EX	O
was	VBD	O
a	DT	O
significant	JJ	O
decrease	NN	O
in	IN	O
clinical	JJ	O
scores	NNS	O
in	IN	O
the	DT	O
BID	NNP	O
and	CC	O
QID	NNP	O
groups	NNS	O
by	IN	O
days	NNS	O
3	CD	O
to	TO	O
5	CD	O
(	(	O
2.6-3.0	JJ	O
points	NNS	O
)	)	O
and	CC	O
a	DT	O
further	JJ	O
decrease	NN	O
by	IN	O
day	NN	O
11	CD	O
(	(	O
4.3-5.0	JJ	O
points	NNS	O
)	)	O
.	.	O

There	EX	O
was	VBD	O
no	DT	O
significant	JJ	O
difference	NN	O
between	IN	O
the	DT	O
two	CD	O
groups	NNS	O
at	IN	O
any	DT	O
time	NN	O
interval	NN	O
.	.	O

Microbiologic	NNP	O
studies	NNS	O
showed	VBD	O
a	DT	O
reduction	NN	O
in	IN	O
colony-forming	JJ	O
units	NNS	O
in	IN	O
87	CD	O
%	NN	O
of	IN	O
the	DT	O
BID	NNP	O
group	NN	O
and	CC	O
in	IN	O
80	CD	O
%	NN	O
of	IN	O
the	DT	O
QID	NNP	O
group	NN	O
.	.	O

CONCLUSION	NNP	O
The	DT	O
treatment	NN	O
of	IN	O
external	JJ	O
ocular	JJ	O
disease	NN	O
with	IN	O
0.3	CD	O
%	NN	O
ofloxacin	JJ	O
eyedrops	NN	O
was	VBD	O
equally	RB	O
effective	JJ	O
when	WRB	O
given	VBN	O
BID	NNP	O
or	CC	O
QID	NNP	O
.	.	O

An	DT	O
open	JJ	O
multicenter	NN	O
efficacy	NN	O
and	CC	O
safety	NN	O
evaluation	NN	O
of	IN	O
amlodipine	NN	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
symptomatic	JJ	O
myocardial	JJ	O
ischemia	NN	O
.	.	O

The	DT	O
efficacy	NN	O
and	CC	O
safety	NN	O
of	IN	O
amlodipine	NN	O
(	(	O
5-10	JJ	O
mg	NN	O
)	)	O
once	RB	O
daily	JJ	O
were	VBD	O
studied	VBN	O
in	IN	O
an	DT	O
open	JJ	O
study	NN	O
in	IN	O
patients	NNS	O
with	IN	O
symptomatic	JJ	O
myocardial	JJ	O
ischemia	NN	O
.	.	O

The	DT	O
study	NN	O
is	VBZ	O
ongoing	VBG	O
and	CC	O
this	DT	O
report	NN	O
is	VBZ	O
based	VBN	O
on	IN	O
an	DT	O
interim	JJ	O
analysis	NN	O
of	IN	O
data	NNS	O
from	IN	O
78	CD	O
patients	NNS	O
.	.	O

A	DT	O
2-week	JJ	O
baseline	NN	O
period	NN	O
in	IN	O
which	WDT	O
patients	NNS	O
maintained	VBD	O
their	PRP$	O
current	JJ	O
antianginal	JJ	O
therapy	NN	O
was	VBD	O
followed	VBN	O
by	IN	O
a	DT	O
10-week	JJ	O
treatment	NN	O
period	NN	O
with	IN	O
5-10	JJ	O
mg	NN	O
of	IN	O
amlodipine/day	NN	O
.	.	O

Both	CC	O
the	DT	O
median	JJ	O
number	NN	O
of	IN	O
angina	JJ	O
attacks	NNS	O
per	IN	O
week	NN	O
and	CC	O
the	DT	O
median	JJ	O
number	NN	O
of	IN	O
nitroglycerin	NN	O
(	(	O
NTG	NNP	O
)	)	O
tablets	NNS	O
consumed/week	VBP	O
were	VBD	O
significantly	RB	O
reduced	VBN	O
after	IN	O
amlodipine	NN	O
(	(	O
mean	JJ	O
daily	RB	O
dose	NN	O
of	IN	O
8.6	CD	O
mg	NNS	O
)	)	O
when	WRB	O
compared	VBN	O
with	IN	O
baseline	NN	O
(	(	O
p	JJ	O
<	NNP	O
0.05	CD	O
)	)	O
.	.	O

A	DT	O
total	NN	O
of	IN	O
98.4	CD	O
%	NN	O
of	IN	O
patients	NNS	O
(	(	O
63/64	CD	O
)	)	O
experienced	VBD	O
a	DT	O
reduction	NN	O
in	IN	O
the	DT	O
frequency	NN	O
of	IN	O
angina	JJ	O
attacks/week	NN	O
and	CC	O
91	CD	O
%	NN	O
of	IN	O
patients	NNS	O
(	(	O
58/64	CD	O
)	)	O
had	VBD	O
angina	VBN	O
attacks	NNS	O
reduced	VBD	O
to	TO	O
<	VB	O
or	CC	O
=	VB	O
2/week	CD	O
.	.	O

In	IN	O
self-assessments	NNS	O
,	,	O
95	CD	O
%	NN	O
of	IN	O
patients	NNS	O
(	(	O
55/58	CD	O
)	)	O
reported	VBD	O
improved	JJ	O
angina	NNS	O
control	NN	O
and	CC	O
91	CD	O
%	NN	O
(	(	O
53/58	CD	O
)	)	O
felt	VBD	O
their	PRP$	O
ability	NN	O
to	TO	O
perform	VB	O
usual	JJ	O
activities	NNS	O
had	VBD	O
improved	VBN	O
.	.	O

Twenty-seven	JJ	O
patients	NNS	O
experienced	JJ	O
adverse	JJ	O
events	NNS	O
reported	VBN	O
as	IN	O
drug	NN	O
related	VBN	O
.	.	O

The	DT	O
most	RBS	O
common	JJ	O
adverse	JJ	O
event	NN	O
noted	VBD	O
was	VBD	O
edema	RB	O
.	.	O

Amlodipine	NNP	O
once	RB	O
daily	RB	O
significantly	RB	O
reduced	VBN	O
the	DT	O
incidence	NN	O
of	IN	O
angina	NN	O
attacks	NNS	O
and	CC	O
the	DT	O
concomitant	JJ	O
need	NN	O
of	IN	O
nitroglycerin	NN	O
for	IN	O
relief	NN	O
of	IN	O
symptoms	NNS	O
and	CC	O
thus	RB	O
improved	VBN	O
the	DT	O
patients	NNS	O
'	POS	O
ability	NN	O
to	TO	O
perform	VB	O
daily	JJ	O
activities	NNS	O
.	.	O

Most	JJS	O
adverse	JJ	O
events	NNS	O
reported	VBN	O
were	VBD	O
mild	JJ	O
or	CC	O
moderate	JJ	O
and	CC	O
the	DT	O
incidence	NN	O
is	VBZ	O
as	RB	O
would	MD	O
be	VB	O
expected	VBN	O
in	IN	O
this	DT	O
patient	JJ	O
population	NN	O
.	.	O

The	DT	O
effects	NNS	O
of	IN	O
the	DT	O
angiotensin-converting	JJ	O
enzyme	NN	O
inhibitor	NN	O
imidapril	NN	O
on	IN	O
plasma	NN	O
plasminogen	NN	O
activator	NN	O
inhibitor	NN	O
activity	NN	O
in	IN	O
patients	NNS	O
with	IN	O
acute	JJ	C
myocardial	JJ	C
infarction	NN	C
.	.	O

This	DT	O
study	NN	O
sought	VBD	O
to	TO	O
determine	VB	O
whether	IN	O
early	JJ	O
treatment	NN	O
with	IN	O
angiotensin-converting	JJ	O
enzyme	NN	O
(	(	O
ACE	NNP	O
)	)	O
inhibitors	NNS	O
in	IN	O
patients	NNS	O
with	IN	O
acute	JJ	O
myocardial	JJ	O
infarction	NN	O
(	(	O
AMI	NNP	O
)	)	O
is	VBZ	O
useful	JJ	O
for	IN	O
the	DT	O
improvement	NN	O
of	IN	O
fibrinolytic	JJ	O
function	NN	O
,	,	O
as	RB	O
well	RB	O
as	IN	O
left	VBN	O
ventricular	JJ	O
function	NN	O
.	.	O

This	DT	O
study	NN	O
was	VBD	O
designed	VBN	O
to	TO	O
examine	VB	O
the	DT	O
levels	NNS	O
of	IN	O
plasma	NN	O
plasminogen	NN	O
activator	NN	O
inhibitor	NN	O
(	(	O
PAI	NNP	O
)	)	O
activity	NN	O
and	CC	O
serum	JJ	O
ACE	NNP	O
activity	NN	O
during	IN	O
the	DT	O
course	NN	O
of	IN	O
2	CD	O
weeks	NNS	O
in	IN	O
40	CD	SS
patients	NNS	O
with	IN	O
AMI	NNP	C
within	IN	O
12	CD	O
hours	NNS	O
after	IN	O
the	DT	O
onset	NN	O
of	IN	O
the	DT	O
symptom	NN	O
and	CC	O
who	WP	O
randomly	VBP	O
received	VBN	O
early	JJ	O
treatment	NN	O
with	IN	O
either	CC	O
the	DT	O
ACE	NNP	O
inhibitor	NN	O
imidapril	NN	O
or	CC	O
a	DT	O
placebo	NN	O
(	(	O
20	CD	SS
patients	NNS	O
in	IN	O
the	DT	O
imidapril	NN	O
group	NN	O
and	CC	O
20	CD	SS
in	IN	O
the	DT	O
placebo	NN	O
group	NN	O
)	)	O
.	.	O

The	DT	O
levels	NNS	O
of	IN	O
serum	JJ	O
ACE	NNP	O
activity	NN	O
in	IN	O
the	DT	O
imidapril	NN	O
group	NN	O
decreased	VBD	O
significantly	RB	O
(	(	O
p	JJ	O
<	NNP	O
0.01	CD	O
)	)	O
8	CD	O
hours	NNS	O
after	IN	O
the	DT	O
administration	NN	O
of	IN	O
imidapril	NN	O
,	,	O
and	CC	O
the	DT	O
levels	NNS	O
24	CD	O
hours	NNS	O
after	IN	O
administration	NN	O
were	VBD	O
significantly	RB	O
lower	JJR	O
than	IN	O
those	DT	O
in	IN	O
the	DT	O
placebo	NN	O
group	NN	O
(	(	O
3.6	CD	O
+/-	JJ	O
0.6	CD	O
IU/L	NNP	O
vs	VBD	O
7.4	CD	O
+/-	JJ	O
0.8	CD	O
IU/L	NNP	O
;	:	O
p	VBZ	O
<	$	O
0.001	CD	O
)	)	O
.	.	O

The	DT	O
plasma	JJ	O
PAI	NNP	O
activity	NN	O
increased	VBD	O
gradually	RB	O
to	TO	O
peak	VB	O
levels	NNS	O
16	CD	O
hours	NNS	O
after	IN	O
the	DT	O
administration	NN	O
of	IN	O
imidapril	NN	O
and	CC	O
placebo	NN	O
.	.	O

The	DT	O
levels	NNS	O
in	IN	O
the	DT	O
placebo	NN	O
group	NN	O
decreased	VBD	O
gradually	RB	O
but	CC	O
remained	VBD	O
high	JJ	O
during	IN	O
the	DT	O
study	NN	O
period	NN	O
.	.	O

On	IN	O
the	DT	O
other	JJ	O
hand	NN	O
,	,	O
the	DT	O
levels	NNS	O
of	IN	O
PAI	NNP	O
activity	NN	O
in	IN	O
the	DT	O
imidapril	NN	O
group	NN	O
decreased	VBD	O
rapidly	RB	O
and	CC	O
those	DT	O
48	CD	O
hours	NNS	O
after	IN	O
administration	NN	O
were	VBD	O
significantly	RB	O
lower	JJR	O
than	IN	O
those	DT	O
in	IN	O
the	DT	O
placebo	NN	O
group	NN	O
(	(	O
7.9	CD	O
+/-	JJ	O
1.9	CD	O
IU/ml	NNP	O
vs	VBD	O
18.4	CD	O
+/-	JJ	O
3.5	CD	O
IU/ml	NNP	O
;	:	O
p	VBZ	O
<	$	O
0.01	CD	O
)	)	O
.	.	O

The	DT	O
levels	NNS	O
of	IN	O
left	JJ	O
ventricular	JJ	O
ejection	NN	O
fraction	NN	O
about	IN	O
2	CD	O
weeks	NNS	O
after	IN	O
admission	NN	O
were	VBD	O
significantly	RB	O
higher	JJR	O
in	IN	O
the	DT	O
imidapril	NN	O
group	NN	O
than	IN	O
in	IN	O
the	DT	O
placebo	NN	O
group	NN	O
(	(	O
65.9	CD	O
%	NN	O
+/-	JJ	O
2.5	CD	O
%	NN	O
vs	JJ	O
49.1	CD	O
%	NN	O
+/-	JJ	O
4.4	CD	O
%	NN	O
;	:	O
p	CC	O
<	VB	O
0.01	CD	O
)	)	O
.	.	O

This	DT	O
study	NN	O
showed	VBD	O
that	IN	O
imidapril	NN	O
,	,	O
an	DT	O
ACE	NNP	O
inhibitor	NN	O
,	,	O
might	MD	O
be	VB	O
useful	JJ	O
for	IN	O
the	DT	O
improvement	NN	O
of	IN	O
fibrinolytic	JJ	O
function	NN	O
and	CC	O
left	VBD	O
ventricular	JJ	O
function	NN	O
in	IN	O
the	DT	O
acute	JJ	O
phase	NN	O
of	IN	O
myocardial	JJ	O
infarction	NN	O
.	.	O

Gonadotropin-releasing	VBG	O
hormone	NN	O
agonist	NN	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
premenstrual	JJ	O
symptoms	NNS	O
with	IN	O
and	CC	O
without	IN	O
ongoing	VBG	O
dysphoria	NN	O
:	:	O
a	DT	O
controlled	VBN	O
study	NN	O
.	.	O

Gonadotropin-releasing	VBG	O
hormone	NN	O
(	(	O
GnRH	NNP	O
)	)	O
agonists	NNS	O
have	VBP	O
been	VBN	O
shown	VBN	O
to	TO	O
reduce	VB	O
symptoms	NNS	O
of	IN	O
premenstrual	JJ	O
syndrome	NN	O
(	(	O
PMS	NNP	O
)	)	O
.	.	O

This	DT	O
randomized	JJ	O
,	,	O
placebo-controlled	JJ	O
study	NN	O
examined	VBD	O
the	DT	O
efficacy	NN	O
of	IN	O
the	DT	O
GnRH	NNP	O
agonist	NN	O
,	,	O
leuprolide	JJ	O
acetate	NN	O
depot	NN	O
,	,	O
in	IN	O
a	DT	O
clearly	RB	O
defined	VBN	O
PMS	NNP	C
sample	JJ	O
versus	NNS	O
women	NNS	C
with	IN	O
premenstrual	JJ	C
symptoms	NNS	O
in	IN	O
combination	NN	O
with	IN	O
dysphoric	NN	C
symptoms	NNS	O
throughout	IN	O
the	DT	O
cycle	NN	O
,	,	O
termed	VBD	O
the	DT	O
premenstrual	JJ	O
exacerbation	NN	O
(	(	O
PME	NNP	O
)	)	O
group	NN	O
.	.	O

Evaluation	NN	O
included	VBD	O
the	DT	O
Structured	NNP	O
Clinical	NNP	O
Interview	NNP	O
for	IN	O
DSM-III-R	NNP	O
,	,	O
administered	VBN	O
in	IN	O
the	DT	O
follicular	JJ	O
phase	NN	O
,	,	O
and	CC	O
the	DT	O
subject	NN	O
Penn	NNP	O
Dally	NNP	O
Symptoms	NNP	O
Report	NNP	O
(	(	O
DSR	NNP	O
)	)	O
maintained	VBD	O
throughout	IN	O
the	DT	O
study	NN	O
.	.	O

Thirty-three	NNP	SS
eligible	JJ	O
women	NNS	SE
were	VBD	O
randomized	VBN	O
to	TO	O
double-blind	VB	O
treatment	NN	O
and	CC	O
administered	VBD	O
3.75	CD	O
mg	NN	O
of	IN	O
depot	NN	O
leuprolide	NN	O
or	CC	O
a	DT	O
placebo	NN	O
once	RB	O
a	DT	O
month	NN	O
for	IN	O
3	CD	O
months	NNS	O
.	.	O

The	DT	O
subjects	NNS	O
were	VBD	O
seen	VBN	O
for	IN	O
efficacy	NN	O
evaluations	NNS	O
at	IN	O
the	DT	O
end	NN	O
of	IN	O
each	DT	O
cycle	NN	O
.	.	O

Outcome	CC	O
measures	NNS	O
were	VBD	O
the	DT	O
DSRs	NNP	O
and	CC	O
the	DT	O
17-item	JJ	O
Hamilton	NNP	O
Depression	NNP	O
Rating	NNP	O
Scale	NNP	O
(	(	O
HAM-D17	NNP	O
)	)	O
.	.	O

The	DT	O
PMS	NNP	O
leuprolide	JJ	O
subjects	NNS	O
improved	VBN	O
significantly	RB	O
compared	VBN	O
with	IN	O
the	DT	O
PMS	NNP	O
placebo	NN	O
and	CC	O
PME	NNP	O
leuprolide	RB	O
groups	NNS	O
.	.	O

The	DT	O
PME	NNP	O
leuprolide	NN	O
group	NN	O
,	,	O
who	WP	O
had	VBD	O
dysphoric	NN	O
symptoms	NNS	O
throughout	IN	O
the	DT	O
cycle	NN	O
,	,	O
did	VBD	O
not	RB	O
improve	VB	O
.	.	O

Depression	NNP	O
symptoms	NNS	O
were	VBD	O
at	IN	O
clinical	JJ	O
levels	NNS	O
premenstrually	RB	O
in	IN	O
the	DT	O
PMS	NNP	O
and	CC	O
PME	NNP	O
groups	NNS	O
;	:	O
following	VBG	O
treatment	NN	O
they	PRP	O
remitted	VBD	O
in	IN	O
the	DT	O
PMS	NNP	O
group	NN	O
but	CC	O
not	RB	O
in	IN	O
the	DT	O
PME	NNP	O
leuprolide	JJ	O
subjects	NNS	O
.	.	O

Efficacy	NN	O
did	VBD	O
not	RB	O
occur	VB	O
until	IN	O
after	IN	O
several	JJ	O
months	NNS	O
of	IN	O
leuprolide	JJ	O
treatment	NN	O
,	,	O
but	CC	O
there	EX	O
was	VBD	O
no	DT	O
evidence	NN	O
that	IN	O
PMS	NNP	O
symptoms	NNS	O
worsened	VBD	O
with	IN	O
the	DT	O
onset	NN	O
of	IN	O
treatment	NN	O
.	.	O

These	DT	O
results	NNS	O
replicate	VBP	O
the	DT	O
findings	NNS	O
in	IN	O
our	PRP$	O
preliminary	JJ	O
open-label	NN	O
study	NN	O
.	.	O

Leuprolide	NNP	O
reduced	VBD	O
PMS	NNP	O
symptoms	NNS	O
to	TO	O
minimal	JJ	O
levels	NNS	O
where	WRB	O
symptoms	NNS	O
were	VBD	O
limited	VBN	O
to	TO	O
the	DT	O
luteal	JJ	O
phase	NN	O
.	.	O

Leuprolide	NNP	O
was	VBD	O
not	RB	O
effective	JJ	O
for	IN	O
women	NNS	O
with	IN	O
ongoing	VBG	O
dysphoric	NN	O
symptoms	NNS	O
,	,	O
suggesting	VBG	O
that	IN	O
premenstrual	JJ	O
depression	NN	O
may	MD	O
have	VB	O
mechanisms	NNS	O
different	JJ	O
from	IN	O
those	DT	O
of	IN	O
other	JJ	O
dysphoric	JJ	O
mood	NN	O
disorders	NNS	O
.	.	O

Influence	NN	O
of	IN	O
special-effect	JJ	O
contact	NN	O
lenses	NNS	O
(	(	O
Crazy	NNP	O
Lenses	NNP	O
)	)	O
on	IN	O
visual	JJ	O
function	NN	O
.	.	O

PURPOSE	NNP	O
Special-effect	JJ	O
contact	NN	O
lenses	NNS	O
(	(	O
opaque	NN	O
,	,	O
tinted	VBD	O
soft	JJ	O
contact	NN	O
lenses	VBZ	O
that	IN	O
incorporate	JJ	O
decorative	JJ	O
images	NNS	O
such	JJ	O
as	IN	O
cateyes	NNS	O
,	,	O
stars	NNS	O
,	,	O
or	CC	O
hearts	NNS	O
to	TO	O
alter	VB	O
eye	NN	O
color	NN	O
and	CC	O
structure	NN	O
)	)	O
have	VBP	O
become	VBN	O
increasingly	RB	O
popular	JJ	O
.	.	O

The	DT	O
purpose	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
investigate	VB	O
whether	IN	O
such	JJ	O
lenses	NNS	O
impair	VBP	O
visual	JJ	O
function	NN	O
.	.	O

METHODS	NNP	O
A	DT	O
clear	JJ	O
soft	JJ	O
contact	NN	O
lens	NNS	O
and	CC	O
a	DT	O
special-effect	JJ	O
soft	JJ	O
contact	NN	O
lens	NNS	O
(	(	O
Crazy	NNP	O
lens	VBZ	O
,	,	O
)	)	O
were	VBD	O
fit	JJ	O
in	IN	O
changing	VBG	O
sequence	NN	O
in	IN	O
nine	CD	SS
healthy	JJ	C
subjects	NNS	O
.	.	O

The	DT	O
parameters	NNS	O
studied	VBD	O
included	VBN	O
:	:	O
visual	JJ	O
acuity	NN	O
,	,	O
contrast	NN	O
sensitivity	NN	O
(	(	O
with	IN	O
and	CC	O
without	IN	O
glare	NN	O
)	)	O
,	,	O
visual	JJ	O
field	NN	O
,	,	O
and	CC	O
mesopic	NN	O
vision	NN	O
(	(	O
with	IN	O
and	CC	O
without	IN	O
glare	NN	O
)	)	O
.	.	O

RESULTS	VB	O
The	DT	O
following	JJ	O
parameters	NNS	O
displayed	VBD	O
a	DT	O
statistically	RB	O
significant	JJ	O
difference	NN	O
(	(	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
.	.	O

Visual	JJ	O
acuity	NN	O
was	VBD	O
decreased	VBN	O
to	TO	O
0.9	CD	O
+/-	JJ	O
0.23	CD	O
in	IN	O
the	DT	O
Crazy	NNP	O
lens	VBZ	O
group	NN	O
as	IN	O
compared	VBN	O
with	IN	O
1.2	CD	O
+/-	JJ	O
0.13	CD	O
in	IN	O
the	DT	O
clear	JJ	O
lens	NNS	O
group	NN	O
.	.	O

Goldmann	NNP	O
visual	JJ	O
field	NN	O
displayed	VBD	O
a	DT	O
significant	JJ	O
constriction	NN	O
of	IN	O
the	DT	O
isopters	NNS	O
:	:	O
III/4	NNP	O
,	,	O
I/4	NNP	O
,	,	O
and	CC	O
I/3	NNP	O
.	.	O

Mesopic	NNP	O
vision	NN	O
without	IN	O
glare	NN	O
was	VBD	O
reduced	VBN	O
from	IN	O
1:2.5	CD	O
to	TO	O
1:7.4	CD	O
.	.	O

Contrast	NNP	O
sensitivity	NN	O
was	VBD	O
significantly	RB	O
reduced	VBN	O
in	IN	O
a	DT	O
photopic	JJ	O
condition	NN	O
with	IN	O
and	CC	O
without	IN	O
glare	NN	O
and	CC	O
in	IN	O
a	DT	O
scotopic	JJ	O
condition	NN	O
without	IN	O
glare	NN	O
.	.	O

Furthermore	RB	O
,	,	O
the	DT	O
special-effect	JJ	O
lenses	NNS	O
were	VBD	O
associated	VBN	O
with	IN	O
a	DT	O
decrease	NN	O
in	IN	O
lens	NNS	O
wearing	VBG	O
comfort	NN	O
.	.	O

CONCLUSIONS	NNP	O
Special-effect	JJ	O
contact	NN	O
lenses	NNS	O
were	VBD	O
associated	VBN	O
with	IN	O
a	DT	O
reduction	NN	O
of	IN	O
many	JJ	O
visual	JJ	O
functions	NNS	O
,	,	O
including	VBG	O
visual	JJ	O
acuity	NN	O
and	CC	O
contrast	NN	O
sensitivity	NN	O
.	.	O

For	IN	O
some	DT	O
wearers	NNS	O
this	DT	O
may	MD	O
interfere	VB	O
with	IN	O
activities	NNS	O
where	WRB	O
excellent	JJ	O
vision	NN	O
is	VBZ	O
crucial	JJ	O
,	,	O
such	JJ	O
as	IN	O
driving	VBG	O
a	DT	O
car	NN	O
.	.	O

Response	NNP	O
prediction	NN	O
in	IN	O
metastasised	JJ	O
colorectal	NN	O
cancer	NN	O
using	VBG	O
intratumoural	JJ	O
thymidylate	JJ	O
synthase	NN	O
:	:	O
results	NNS	O
of	IN	O
a	DT	O
randomised	JJ	O
multicentre	NN	O
trial	NN	O
.	.	O

BACKGROUND	NNP	O
Molecular	NNP	O
markers	NNS	O
to	TO	O
predict	VB	O
response	NN	O
to	TO	O
5-fluorouracil	JJ	O
(	(	O
FU	NNP	O
)	)	O
-based	VBD	O
treatment	NN	O
of	IN	O
recurrent	NN	O
or	CC	O
metastasised	VBN	O
colorectal	JJ	O
cancer	NN	O
(	(	O
mCRC	NN	O
)	)	O
are	VBP	O
not	RB	O
established	VBN	O
.	.	O

The	DT	O
aim	NN	O
of	IN	O
this	DT	O
trial	NN	O
was	VBD	O
to	TO	O
determine	VB	O
the	DT	O
value	NN	O
of	IN	O
thymidylate	JJ	O
synthase	NN	O
(	(	O
TS	NNP	O
)	)	O
,	,	O
a	DT	O
key	JJ	O
enzyme	NN	O
of	IN	O
DNA	NNP	O
synthesis	NN	O
and	CC	O
target	NN	O
of	IN	O
5-FU	JJ	O
,	,	O
to	TO	O
predict	VB	O
response	NN	O
to	TO	O
chemotherapy	NN	O
of	IN	O
mCRC	NN	O
.	.	O

METHODS	NNP	O
Tumour	NNP	O
tissue	NN	O
was	VBD	O
obtained	VBN	O
from	IN	O
168	CD	O
patients	NNS	O
with	IN	O
mCRC	NN	O
for	IN	O
relative	JJ	O
thymidylate	NN	O
synthase	NN	O
(	(	O
TS	NNP	O
)	)	O
mRNA	NN	O
quantitation	NN	O
.	.	O

Patients	NNS	O
were	VBD	O
randomised	VBN	O
to	TO	O
receive	VB	O
either	DT	O
5-FU/folinic	JJ	O
acid	NN	O
(	(	O
FA	NNP	O
,	,	O
FUFA	NNP	O
)	)	O
alone	RB	O
or	CC	O
in	IN	O
combination	NN	O
with	IN	O
irinotecan	JJ	O
5-fluorouracil/folinic	JJ	O
acid	NN	O
and	CC	O
irinotecan	JJ	O
(	(	O
FOLFIRI	NNP	O
)	)	O
stratified	VBN	O
by	IN	O
TS	NNP	O
(	(	O
low	JJ	O
versus	RB	O
high	JJ	O
)	)	O
.	.	O

Primary	JJ	O
end-point	NN	O
was	VBD	O
overall	JJ	O
response	NN	O
to	TO	O
first-line	JJ	O
treatment	NN	O
among	IN	O
TS	NNP	O
high	JJ	O
patients	NNS	O
.	.	O

All	DT	O
parties	NNS	O
,	,	O
except	IN	O
for	IN	O
the	DT	O
randomisation	NN	O
centre	NN	O
,	,	O
were	VBD	O
blinded	VBN	O
for	IN	O
TS	NNP	O
status	NN	O
.	.	O

RESULTS	NNP	O
Biopsies	NNP	O
(	(	O
n=168	RB	O
)	)	O
were	VBD	O
taken	VBN	O
without	IN	O
complications	NNS	O
.	.	O

TS	NN	O
levels	NNS	O
were	VBD	O
available	JJ	O
for	IN	O
147	CD	O
patients	NNS	O
(	(	O
87.5	CD	O
%	NN	O
)	)	O
.	.	O

Analysing	VBG	O
response	NN	O
to	TO	O
FUFA	NNP	O
and	CC	O
FOLFIRI	NNP	O
in	IN	O
the	DT	O
per	NN	O
protocol	NN	O
set	VBN	O
(	(	O
n=119	NN	O
)	)	O
after	IN	O
un-blinding	JJ	O
TS	NNP	O
in	IN	O
the	DT	O
data	NN	O
base	NN	O
revealed	VBD	O
a	DT	O
trend	NN	O
to	TO	O
better	JJR	O
overall	JJ	O
response	NN	O
to	TO	O
FOLFIRI	NNP	O
(	(	O
9/19	CD	O
,	,	O
47	CD	O
%	NN	O
)	)	O
in	IN	O
TS	NNP	O
high	JJ	O
compared	VBN	O
to	TO	O
FUFA	NNP	O
(	(	O
5/23	CD	O
,	,	O
22	CD	O
%	NN	O
,	,	O
p=0.077	NN	O
)	)	O
.	.	O

In	IN	O
patients	NNS	O
with	IN	O
biopsies	NNS	O
taken	VBN	O
from	IN	O
liver	JJ	O
lesions	NNS	O
(	(	O
n=91	NN	O
)	)	O
overall	JJ	O
response	NN	O
to	TO	O
FOLFIRI	NNP	O
and	CC	O
FUFA	NNP	O
in	IN	O
TS	NNP	O
high	NN	O
was	VBD	O
53	CD	O
%	NN	O
(	(	O
9/17	CD	O
)	)	O
and	CC	O
18	CD	O
%	NN	O
(	(	O
3/17	CD	O
)	)	O
,	,	O
respectively	RB	O
(	(	O
p=0.035	NN	O
)	)	O
.	.	O

In	IN	O
patients	NNS	O
with	IN	O
low	JJ	O
TS	NNP	O
,	,	O
no	DT	O
remarkable	JJ	O
difference	NN	O
in	IN	O
overall	JJ	O
response	NN	O
to	TO	O
FOLFIRI	NNP	O
and	CC	O
FUFA	NNP	O
was	VBD	O
observed	VBN	O
.	.	O

CONCLUSIONS	NNP	O
Taking	VBG	O
a	DT	O
pre-treatment	JJ	O
biopsy	NN	O
is	VBZ	O
a	DT	O
safe	JJ	O
and	CC	O
feasible	JJ	O
procedure	NN	O
in	IN	O
mCRC	NN	O
.	.	O

After	IN	O
validation	NN	O
of	IN	O
our	PRP$	O
data	NNS	O
in	IN	O
a	DT	O
larger	JJR	O
group	NN	O
TS	NNP	O
determination	NN	O
may	MD	O
have	VB	O
the	DT	O
potential	NN	O
to	TO	O
better	JJR	O
help	NN	O
direct	VB	O
systemic	JJ	O
treatment	NN	O
in	IN	O
patients	NNS	O
with	IN	O
primarily	RB	O
non-resectable	JJ	O
mCRC	NN	O
.	.	O

Eberconazole	JJ	O
1	CD	O
%	NN	O
cream	NN	O
is	VBZ	O
an	DT	O
effective	JJ	O
and	CC	O
safe	JJ	O
alternative	NN	O
for	IN	O
dermatophytosis	NN	O
treatment	NN	O
:	:	O
multicenter	NN	O
,	,	O
randomized	VBN	O
,	,	O
double-blind	JJ	O
,	,	O
comparative	JJ	O
trial	NN	O
with	IN	O
miconazole	JJ	O
2	CD	O
%	NN	O
cream	NN	O
.	.	O

BACKGROUND	NNP	O
Eberconazole	NNP	O
is	VBZ	O
a	DT	O
topical	JJ	O
,	,	O
broad-spectrum	JJ	O
imidazole	NN	O
derivative	NN	O
,	,	O
effective	JJ	O
in	IN	O
dermatophytoses	NNS	O
,	,	O
candidiasis	NN	O
,	,	O
and	CC	O
pityriasis	NN	O
treatment	NN	O
.	.	O

In	IN	O
previous	JJ	O
trials	NNS	O
,	,	O
it	PRP	O
showed	VBD	O
a	DT	O
higher	JJR	O
efficacy	NN	O
than	IN	O
clotrimazole	NN	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
dermatophytoses	NNS	O
.	.	O

The	DT	O
purpose	NN	O
of	IN	O
this	DT	O
trial	NN	O
was	VBD	O
to	TO	O
evaluate	VB	O
the	DT	O
efficacy	NN	O
of	IN	O
eberconazole	JJ	O
1	CD	O
%	NN	O
cream	NN	O
compared	VBN	O
with	IN	O
miconazole	JJ	O
2	CD	O
%	NN	O
cream	NN	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
dermatophytoses	NNS	O
.	.	O

METHODS	NNP	O
A	NNP	O
multicenter	NN	O
,	,	O
double-blind	NN	O
,	,	O
randomized	VBN	O
trial	NN	O
was	VBD	O
performed	VBN	O
in	IN	O
653	CD	O
patients	NNS	O
with	IN	O
dermatophytoses	NNS	O
,	,	O
randomized	VBN	O
to	TO	O
eberconazole	VB	O
1	CD	O
%	NN	O
cream	NN	O
every	DT	O
12	CD	O
h	NN	O
or	CC	O
miconazole	VB	O
2	CD	O
%	NN	O
cream	NN	O
every	DT	O
12	CD	O
h	NN	O
for	IN	O
4	CD	O
weeks	NNS	O
.	.	O

Treatment	NNP	O
efficacy	NN	O
was	VBD	O
assessed	VBN	O
on	IN	O
the	DT	O
basis	NN	O
of	IN	O
the	DT	O
percentage	NN	O
of	IN	O
effective	JJ	O
response	NN	O
after	IN	O
4	CD	O
weeks	NNS	O
through	IN	O
mycologic	NN	O
and	CC	O
clinical	JJ	O
assessment	NN	O
.	.	O

RESULTS	NNP	O
Of	IN	O
the	DT	O
653	CD	O
patients	NNS	O
included	VBN	O
in	IN	O
the	DT	O
trial	NN	O
,	,	O
360	CD	O
produced	VBD	O
positive	JJ	O
baseline	NN	O
mycologic	NN	O
cultures	NNS	O
and	CC	O
were	VBD	O
included	VBN	O
in	IN	O
the	DT	O
efficacy	NN	O
assessment	NN	O
.	.	O

Clinical	JJ	O
efficacy	NN	O
was	VBD	O
shown	VBN	O
in	IN	O
76.1	CD	O
%	NN	O
of	IN	O
patients	NNS	O
receiving	VBG	O
eberconazole	JJ	O
and	CC	O
in	IN	O
75.0	CD	O
%	NN	O
of	IN	O
patients	NNS	O
receiving	VBG	O
miconazole	NN	O
.	.	O

The	DT	O
incidence	NN	O
of	IN	O
adverse	JJ	O
events	NNS	O
related	VBN	O
to	TO	O
treatment	NN	O
was	VBD	O
0.91	CD	O
%	NN	O
for	IN	O
eberconazole	NN	O
and	CC	O
0.92	CD	O
%	NN	O
for	IN	O
miconazole	NN	O
,	,	O
none	NN	O
being	VBG	O
serious	JJ	O
,	,	O
and	CC	O
all	DT	O
being	VBG	O
local	JJ	O
and	CC	O
transient	NN	O
.	.	O

CONCLUSIONS	NNP	O
Eberconazole	NNP	O
1	CD	O
%	NN	O
cream	NN	O
is	VBZ	O
an	DT	O
effective	JJ	O
treatment	NN	O
for	IN	O
fungal	JJ	O
infections	NNS	O
produced	VBN	O
by	IN	O
dermatophytes	NNS	O
,	,	O
with	IN	O
a	DT	O
good	JJ	O
safety	NN	O
and	CC	O
tolerability	NN	O
profile	NN	O
,	,	O
and	CC	O
can	MD	O
be	VB	O
considered	VBN	O
a	DT	O
good	JJ	O
alternative	NN	O
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
dermatophytoses	NNS	O
.	.	O

Effects	NNS	O
of	IN	O
Thai	NNP	O
traditional	JJ	O
massage	NN	O
on	IN	O
autistic	JJ	C
children	NNS	A
's	POS	A
behavior	NN	O
.	.	O

OBJECTIVES	CC	O
The	DT	O
objective	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
access	NN	O
whether	IN	O
there	EX	O
were	VBD	O
any	DT	O
therapeutic	JJ	O
effects	NNS	O
of	IN	O
Thai	NNP	O
Traditional	NNP	O
Massage	NNP	O
(	(	O
TTM	NNP	O
)	)	O
on	IN	O
major	JJ	O
behavioral	JJ	O
and	CC	O
emotional	JJ	O
disturbances	NNS	O
in	IN	O
Thai	NNP	O
autistic	JJ	O
children	NNS	O
.	.	O

DESIGN	NN	O
This	DT	O
was	VBD	O
a	DT	O
randomized	VBN	O
controlled	VBN	O
trial	NN	O
study	NN	O
.	.	O

SETTINGS/LOCATION	NNP	O
The	DT	O
study	NN	O
was	VBD	O
conducted	VBN	O
at	IN	O
the	DT	O
Rehabilitation	NNP	O
Centre	NNP	O
of	IN	O
the	DT	O
Thai	NNP	O
Red	NNP	O
Cross	NNP	O
Society	NNP	O
.	.	O

SUBJECTS	NNP	O
A	NNP	O
total	NN	O
of	IN	O
60	CD	SS
autistic	JJ	C
children	NNS	O
between	IN	O
the	DT	O
ages	NNS	O
of	IN	O
3	CD	A
and	CC	A
10	CD	A
completed	VBD	O
this	DT	O
study	NN	O
.	.	O

INTERVENTIONS	NNP	O
Standard	NNP	O
sensory	JJ	O
integration	NN	O
therapy	NN	O
(	(	O
SI	NNP	O
)	)	O
was	VBD	O
compared	VBN	O
to	TO	O
the	DT	O
SI	NNP	O
with	IN	O
TTM	NNP	O
treatments	NNS	O
.	.	O

OUTCOME	NNP	O
MEASURES	NNP	O
Parents	NNP	O
and	CC	O
teachers	NNS	O
assessed	VBD	O
major	JJ	O
behavior	NN	O
disturbances	NNS	O
using	VBG	O
the	DT	O
Conners	NNPS	O
'	POS	O
Rating	VBG	O
Scales	NNS	O
at	IN	O
0	CD	O
and	CC	O
8	CD	O
weeks	NNS	O
.	.	O

Sleep	JJ	O
Diary	NNP	O
(	(	O
SD	NNP	O
)	)	O
,	,	O
recorded	VBN	O
by	IN	O
the	DT	O
parents	NNS	O
,	,	O
assessed	VBD	O
the	DT	O
patient	NN	O
's	POS	O
sleeping	NN	O
patterns	NNS	O
every	DT	O
week	NN	O
.	.	O

RESULTS	NNP	O
Sixty	NNP	SS
(	(	SS
60	CD	SS
)	)	SS
autistic	JJ	O
children	NNS	O
,	,	O
mean	JJ	O
age	NN	O
4.67	CD	A
+/-	JJ	A
1.82	CD	A
,	,	O
were	VBD	O
recruited	VBN	O
.	.	O

No	DT	O
statistical	JJ	O
differences	NNS	O
were	VBD	O
seen	VBN	O
in	IN	O
the	DT	O
demographic	JJ	O
and	CC	O
baseline	JJ	O
data	NN	O
among	IN	O
both	DT	O
groups	NNS	O
.	.	O

From	IN	O
both	CC	O
the	DT	O
Conners	NNPS	O
'	POS	O
Teacher	NNP	O
Questionnaire	NNP	O
and	CC	O
SD	NNP	O
,	,	O
statistical	JJ	O
improvement	NN	O
was	VBD	O
detected	VBN	O
for	IN	O
conduct	NN	O
problem	NN	O
,	,	O
hyperactivity	NN	O
,	,	O
inattention-passivity	NN	O
,	,	O
hyperactivity	NN	O
index	NN	O
,	,	O
and	CC	O
sleeping	VBG	O
behavior	NN	O
.	.	O

However	RB	O
,	,	O
results	NNS	O
from	IN	O
the	DT	O
Conners	NNP	O
'	POS	O
Parent	NNP	O
Questionnaire	NNP	O
revealed	VBD	O
an	DT	O
improvement	NN	O
only	RB	O
for	IN	O
anxiety	NN	O
(	(	O
p	JJ	O
=	NNP	O
0.04	CD	O
)	)	O
in	IN	O
the	DT	O
massage	NN	O
group	NN	O
,	,	O
whereas	IN	O
when	WRB	O
both	DT	O
groups	NNS	O
were	VBD	O
compared	VBN	O
,	,	O
a	DT	O
significant	JJ	O
improvement	NN	O
in	IN	O
conduct	NN	O
problem	NN	O
(	(	O
p	JJ	O
=	NNP	O
0.03	CD	O
)	)	O
and	CC	O
anxiety	NN	O
(	(	O
p	JJ	O
=	NNP	O
0.01	CD	O
)	)	O
was	VBD	O
found	VBN	O
.	.	O

Results	NNS	O
indicated	VBD	O
that	IN	O
TTM	NNP	O
may	MD	O
have	VB	O
a	DT	O
positive	JJ	O
effect	NN	O
in	IN	O
improving	VBG	O
stereotypical	JJ	O
behaviors	NNS	O
in	IN	O
autistic	JJ	O
children	NNS	O
.	.	O

CONCLUSIONS	NNP	O
Over	IN	O
a	DT	O
period	NN	O
of	IN	O
8	CD	O
weeks	NNS	O
,	,	O
our	PRP$	O
findings	NNS	O
suggested	VBD	O
that	IN	O
TTM	NNP	O
could	MD	O
be	VB	O
used	VBN	O
as	IN	O
a	DT	O
complementary	JJ	O
therapy	NN	O
for	IN	O
autistic	JJ	O
children	NNS	O
in	IN	O
Thailand	NNP	O
.	.	O

Effects	NNS	O
of	IN	O
exposure	NN	O
to	TO	O
thin-ideal	JJ	O
media	NNS	O
images	NNS	O
on	IN	O
body	NN	O
dissatisfaction	NN	O
:	:	O
testing	VBG	O
the	DT	O
inclusion	NN	O
of	IN	O
a	DT	O
disclaimer	NN	O
versus	NN	O
warning	VBG	O
label	NN	O
.	.	O

The	DT	O
current	JJ	O
study	NN	O
was	VBD	O
designed	VBN	O
to	TO	O
determine	VB	O
whether	IN	O
the	DT	O
inclusion	NN	O
of	IN	O
a	DT	O
disclaimer	NN	O
(	(	O
i.e.	FW	O
,	,	O
Retouched	NNP	O
photograph	NN	O
aimed	VBN	O
at	IN	O
changing	VBG	O
a	DT	O
person	NN	O
's	POS	O
physical	JJ	O
appearance	NN	O
.	.	O

)	)	O
or	CC	O
warning	VBG	O
(	(	O
i.e.	FW	O
,	,	O
Warning	VBG	O
:	:	O
Trying	NN	O
to	TO	O
look	VB	O
as	RB	O
thin	JJ	O
as	IN	O
this	DT	O
model	NN	O
may	MD	O
be	VB	O
dangerous	JJ	O
to	TO	O
your	PRP$	O
health	NN	O
.	.	O

)	)	O
added	VBD	O
to	TO	O
images	NNS	O
of	IN	O
thin/attractive	JJ	O
models	NNS	O
would	MD	O
affect	VB	O
body	NN	O
dissatisfaction	NN	O
and	CC	O
intent	NN	O
to	TO	O
diet	VB	O
in	IN	O
female	JJ	SE
undergraduate	JJ	SE
students	NNS	SE
(	(	SE
n=342	NN	SE
)	)	SE
.	.	SE

Participants	NNS	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
one	CD	O
of	IN	O
four	CD	O
groups	NNS	O
:	:	O
(	(	O
a	DT	O
)	)	O
disclaimer	NN	O
,	,	O
(	(	O
b	NN	O
)	)	O
warning	NN	O
,	,	O
(	(	O
c	NN	O
)	)	O
model	NN	O
control	NN	O
,	,	O
or	CC	O
(	(	O
d	NN	O
)	)	O
car	NN	O
control	NN	O
.	.	O

Results	NNP	O
revealed	VBD	O
a	DT	O
significant	JJ	O
interaction	NN	O
between	IN	O
group	NN	O
and	CC	O
time	NN	O
,	,	O
whereby	WRB	O
only	RB	O
the	DT	O
car	NN	O
control	NN	O
group	NN	O
reported	VBD	O
a	DT	O
significant	JJ	O
change	NN	O
(	(	O
i.e.	FW	O
,	,	O
decrease	NN	O
)	)	O
in	IN	O
body	NN	O
dissatisfaction	NN	O
over	IN	O
time	NN	O
.	.	O

Groups	NNP	O
did	VBD	O
not	RB	O
differ	VB	O
on	IN	O
intent	NN	O
to	TO	O
diet	VB	O
measured	VBN	O
at	IN	O
post-exposure	NN	O
.	.	O

The	DT	O
results	NNS	O
largely	RB	O
replicate	VBP	O
other	JJ	O
findings	NNS	O
in	IN	O
this	DT	O
area	NN	O
and	CC	O
call	VB	O
into	IN	O
question	NN	O
advocacy	NN	O
efforts	NNS	O
to	TO	O
label	VB	O
media	NNS	O
images	NNS	O
as	IN	O
a	DT	O
strategy	NN	O
to	TO	O
decrease	VB	O
women	NNS	SE
's	POS	SE
identification	NN	O
with	IN	O
the	DT	O
stimuli	NNS	O
.	.	O

[	JJ	O
Effects	NNS	O
of	IN	O
an	DT	O
intensive	JJ	O
therapy	NN	O
program	NN	O
for	IN	O
behaviorally	RB	C
disordered	VBN	C
mentally	RB	C
handicapped	JJ	C
patients	NNS	O
on	IN	O
staff	NN	O
personnel	NNS	O
in	IN	O
residential	JJ	O
care	NN	O
]	NNP	O
.	.	O

This	DT	O
study	NN	O
evaluates	VBZ	O
the	DT	O
effects	NNS	O
of	IN	O
an	DT	O
intensive	JJ	O
therapy	NN	O
program	NN	O
designed	VBN	O
for	IN	O
mentally	RB	C
handicapped	JJ	C
persons	NNS	O
with	IN	O
severely	RB	O
disturbed	VBN	O
or	CC	O
autistic	JJ	C
behavior	NN	C
on	IN	O
their	PRP$	O
staff	NN	O
personal	JJ	O
which	WDT	O
had	VBD	O
an	DT	O
active	JJ	O
role	NN	O
in	IN	O
the	DT	O
program	NN	O
.	.	O

The	DT	O
staff	NN	O
members	NNS	O
rated	VBD	O
their	PRP$	O
professional	JJ	O
competence	NN	O
,	,	O
quality	NN	O
of	IN	O
interaction	NN	O
with	IN	O
the	DT	O
client	NN	O
,	,	O
team	JJ	O
culture	NN	O
and	CC	O
work	NN	O
satisfaction	NN	O
before	IN	O
and	CC	O
after	IN	O
being	VBG	O
engaged	VBN	O
in	IN	O
the	DT	O
program	NN	O
,	,	O
with	IN	O
additional	JJ	O
ratings	NNS	O
of	IN	O
their	PRP$	O
personal	JJ	O
aims	NNS	O
at	IN	O
the	DT	O
beginning	NN	O
of	IN	O
the	DT	O
program	NN	O
.	.	O

Three	NNP	O
sets	NNS	O
of	IN	O
data	NNS	O
were	VBD	O
obtained	VBN	O
with	IN	O
the	DT	O
program	NN	O
being	VBG	O
conducted	VBN	O
three	CD	O
times	NNS	O
in	IN	O
a	DT	O
row	NN	O
.	.	O

The	DT	O
testings	NNS	O
of	IN	O
the	DT	O
related	VBN	O
as	RB	O
well	RB	O
as	IN	O
the	DT	O
independent	JJ	O
samples	NNS	O
show	VBP	O
differentiated	JJ	O
program	NN	O
effects	NNS	O
.	.	O

The	DT	O
main	JJ	O
effect	NN	O
is	VBZ	O
an	DT	O
increase	NN	O
of	IN	O
the	DT	O
professional	JJ	O
competence	NN	O
and	CC	O
quality	NN	O
of	IN	O
interaction	NN	O
,	,	O
especially	RB	O
by	IN	O
the	DT	O
qualified	JJ	O
staff	NN	O
members	NNS	O
.	.	O

Trainees	NNP	O
put	VBD	O
emphasis	NN	O
on	IN	O
the	DT	O
development	NN	O
of	IN	O
their	PRP$	O
personal	JJ	O
relationship	NN	O
with	IN	O
the	DT	O
client	NN	O
.	.	O

The	DT	O
results	NNS	O
are	VBP	O
discussed	VBN	O
in	IN	O
terms	NNS	O
of	IN	O
the	DT	O
impact	NN	O
of	IN	O
learning	VBG	O
processes	NNS	O
specific	JJ	O
to	TO	O
the	DT	O
roles	NNS	O
of	IN	O
the	DT	O
staff	NN	O
members	NNS	O
and	CC	O
motivational	JJ	O
factors	NNS	O
on	IN	O
learning	NN	O
and	CC	O
therapy	NN	O
outcome	NN	O
,	,	O
along	IN	O
with	IN	O
institutional	JJ	O
conditions	NNS	O
influencing	VBG	O
successful	JJ	O
learning	NN	O
.	.	O

Thus	VB	O
the	DT	O
program	NN	O
facilitates	VBZ	O
the	DT	O
professional	JJ	O
and	CC	O
interpersonal	JJ	O
learning	NN	O
process	NN	O
of	IN	O
staff	NN	O
members	NNS	O
in	IN	O
a	DT	O
specific	JJ	O
way	NN	O
with	IN	O
success	NN	O
as	RB	O
well	RB	O
as	IN	O
with	IN	O
limitations	NNS	O
.	.	O

Phase	NNP	O
III	NNP	O
comparative	JJ	O
study	NN	O
of	IN	O
high-dose	JJ	O
cisplatin	NN	O
versus	IN	O
a	DT	O
combination	NN	O
of	IN	O
paclitaxel	NN	O
and	CC	O
cisplatin	NN	O
in	IN	O
patients	NNS	O
with	IN	O
advanced	JJ	O
non-small-cell	JJ	O
lung	NN	O
cancer	NN	O
.	.	O

PURPOSE	NNP	O
New	NNP	O
effective	JJ	O
chemotherapy	NN	O
is	VBZ	O
needed	VBN	O
to	TO	O
improve	VB	O
the	DT	O
outcome	NN	O
of	IN	O
patients	NNS	O
with	IN	O
advanced	JJ	O
non-small-cell	JJ	O
lung	NN	O
cancer	NN	O
(	(	O
NSCLC	NNP	O
)	)	O
.	.	O

Paclitaxel	NNP	O
administered	VBD	O
as	IN	O
a	DT	O
single	JJ	O
agent	NN	O
or	CC	O
in	IN	O
combination	NN	O
with	IN	O
cisplatin	NN	O
has	VBZ	O
been	VBN	O
shown	VBN	O
to	TO	O
be	VB	O
a	DT	O
potentially	RB	O
new	JJ	O
useful	JJ	O
agent	NN	O
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
NSCLC	NNP	O
.	.	O

PATIENTS	NNP	O
AND	CC	O
METHODS	NNP	O
Between	NNP	O
January	NNP	O
1995	CD	O
and	CC	O
April	NNP	O
1996	CD	O
,	,	O
414	CD	O
patients	NNS	O
with	IN	O
stage	NN	O
IIIB	NNP	O
or	CC	O
IV	NNP	O
NSCLC	NNP	O
were	VBD	O
randomized	VBN	O
to	TO	O
received	VB	O
either	RB	O
a	DT	O
control	NN	O
arm	NN	O
of	IN	O
high-dose	JJ	O
cisplatin	NN	O
(	(	O
100	CD	O
mg/m	NN	O
(	(	O
2	CD	O
)	)	O
)	)	O
or	CC	O
a	DT	O
combination	NN	O
of	IN	O
paclitaxel	NN	O
(	(	O
175	CD	O
mg/m	NN	O
(	(	O
2	CD	O
)	)	O
,	,	O
3-hour	JJ	O
infusion	NN	O
)	)	O
and	CC	O
cisplatin	NN	O
(	(	O
80	CD	O
mg/m	NN	O
(	(	O
2	CD	O
)	)	O
)	)	O
every	DT	O
21	CD	O
days	NNS	O
.	.	O

RESULTS	NNP	O
Compared	VBD	O
with	IN	O
the	DT	O
cisplatin-only	JJ	O
arm	NN	O
,	,	O
there	EX	O
was	VBD	O
a	DT	O
9	CD	O
%	NN	O
improvement	NN	O
(	(	O
95	CD	O
%	NN	O
confidence	NN	O
interval	NN	O
,	,	O
0	CD	O
%	NN	O
to	TO	O
19	CD	O
%	NN	O
)	)	O
in	IN	O
overall	JJ	O
response	NN	O
rate	NN	O
for	IN	O
the	DT	O
paclitaxel/cisplatin	NN	O
arm	NN	O
(	(	O
17	CD	O
%	NN	O
v	JJ	O
26	CD	O
%	NN	O
,	,	O
respectively	RB	O
;	:	O
P=.028	NNP	O
)	)	O
.	.	O

Median	JJ	O
time	NN	O
to	TO	O
progression	NN	O
was	VBD	O
2.7	CD	O
and	CC	O
4.1	CD	O
months	NNS	O
in	IN	O
the	DT	O
control	NN	O
and	CC	O
paclitaxel/cisplatin	NN	O
arm	NN	O
,	,	O
respectively	RB	O
(	(	O
P=.026	NNP	O
)	)	O
.	.	O

The	DT	O
study	NN	O
,	,	O
however	RB	O
,	,	O
failed	VBD	O
to	TO	O
show	VB	O
a	DT	O
significant	JJ	O
improvement	NN	O
in	IN	O
median	JJ	O
survival	NN	O
for	IN	O
the	DT	O
paclitaxel/cisplatin	NN	O
arm	NN	O
(	(	O
8.6	CD	O
months	NNS	O
in	IN	O
the	DT	O
control	NN	O
arm	NN	O
v	NN	O
8.1	CD	O
months	NNS	O
in	IN	O
the	DT	O
paclitaxel/cisplatin	NN	O
arm	NN	O
,	,	O
P=.862	NNP	O
)	)	O
.	.	O

There	EX	O
was	VBD	O
more	JJR	O
hematotoxicity	NN	O
,	,	O
peripheral	JJ	O
neuropathy	NN	O
,	,	O
and	CC	O
arthralgia/myalgia	NN	O
on	IN	O
the	DT	O
paclitaxel/cisplatin	NN	O
arm	NN	O
,	,	O
whereas	IN	O
the	DT	O
high-dose	JJ	O
cisplatin	NN	O
arm	NN	O
produced	VBD	O
more	JJR	O
ototoxicity	NN	O
,	,	O
nausea	NN	O
,	,	O
vomiting	NN	O
,	,	O
and	CC	O
nephrotoxicity	NN	O
.	.	O

Quality	NN	O
of	IN	O
life	NN	O
(	(	O
QOL	NNP	O
)	)	O
was	VBD	O
similar	JJ	O
overall	JJ	O
between	IN	O
the	DT	O
two	CD	O
arms	NNS	O
.	.	O

CONCLUSION	NN	O
This	DT	O
large	JJ	O
randomized	JJ	O
phase	NN	O
III	NNP	O
trial	NN	O
failed	VBD	O
to	TO	O
show	VB	O
a	DT	O
significant	JJ	O
improvement	NN	O
in	IN	O
survival	NN	O
for	IN	O
the	DT	O
paclitaxel/cisplatin	NN	O
combination	NN	O
compared	VBN	O
with	IN	O
high-dose	JJ	O
cisplatin	NN	O
in	IN	O
patients	NNS	O
with	IN	O
advanced	JJ	O
NSCLC	NNP	O
.	.	O

However	RB	O
,	,	O
the	DT	O
paclitaxel/cisplatin	NN	O
combination	NN	O
did	VBD	O
produce	VB	O
a	DT	O
better	JJR	O
clinical	JJ	O
response	NN	O
,	,	O
resulting	VBG	O
in	IN	O
an	DT	O
increased	JJ	O
time	NN	O
to	TO	O
progression	NN	O
while	IN	O
providing	VBG	O
a	DT	O
similar	JJ	O
QOL	NNP	O
.	.	O

Cost-effectiveness	NN	O
of	IN	O
combined	JJ	O
manipulation	NN	O
,	,	O
stabilizing	VBG	O
exercises	NNS	O
,	,	O
and	CC	O
physician	JJ	O
consultation	NN	O
compared	VBN	O
to	TO	O
physician	JJ	O
consultation	NN	O
alone	RB	O
for	IN	O
chronic	JJ	C
low	JJ	C
back	RB	C
pain	NN	C
:	:	C
a	DT	O
prospective	JJ	O
randomized	VBN	O
trial	NN	O
with	IN	O
2-year	JJ	O
follow-up	NN	O
.	.	O

STUDY	NNP	O
DESIGN	NNP	O
A	NNP	O
prospective	JJ	O
,	,	O
randomized	VBD	O
controlled	VBN	O
trial	NN	O
.	.	O

OBJECTIVE	UH	O
To	TO	O
examine	VB	O
long-term	JJ	O
effects	NNS	O
and	CC	O
costs	NNS	O
of	IN	O
combined	JJ	O
manipulative	JJ	O
treatment	NN	O
,	,	O
stabilizing	VBG	O
exercises	NNS	O
,	,	O
and	CC	O
physician	JJ	O
consultation	NN	O
compared	VBN	O
with	IN	O
physician	JJ	O
consultation	NN	O
alone	RB	O
for	IN	O
chronic	JJ	C
low	JJ	C
back	RB	C
pain	NN	C
(	(	C
cLBP	NN	C
)	)	O
.	.	O

SUMMARY	NNP	O
OF	IN	O
BACKGROUND	NNP	O
DATA	NNP	O
An	DT	O
obvious	JJ	O
gap	NN	O
exists	NNS	O
in	IN	O
knowledge	NN	O
concerning	VBG	O
long-term	JJ	O
efficacy	NN	O
and	CC	O
cost-effectiveness	NN	O
of	IN	O
manipulative	JJ	O
treatment	NN	O
methods	NNS	O
.	.	O

METHODS	NNP	O
Of	IN	O
204	CD	SS
patients	NNS	O
with	IN	O
cLBP	NNS	O
whose	WP$	O
Oswestry	NNP	O
Disability	NNP	O
Index	NNP	O
(	(	O
ODI	NNP	O
)	)	O
was	VBD	O
at	IN	O
least	JJS	O
16	CD	O
%	NN	O
,	,	O
102	CD	O
were	VBD	O
randomized	VBN	O
into	IN	O
a	DT	O
combined	JJ	O
manipulative	JJ	O
treatment	NN	O
,	,	O
exercise	NN	O
,	,	O
and	CC	O
physician	JJ	O
consultation	NN	O
group	NN	O
(	(	O
i.e.	FW	O
,	,	O
a	DT	O
combination	NN	O
group	NN	O
)	)	O
,	,	O
and	CC	O
102	CD	O
to	TO	O
a	DT	O
consultation	NN	O
alone	RB	O
group	NN	O
.	.	O

All	DT	O
patients	NNS	O
were	VBD	O
clinically	RB	O
examined	VBN	O
,	,	O
informed	VBN	O
about	IN	O
their	PRP$	O
back	NN	O
pain	NN	O
,	,	O
and	CC	O
encouraged	VBD	O
to	TO	O
stay	VB	O
active	JJ	O
and	CC	O
exercise	NN	O
according	VBG	O
to	TO	O
specific	JJ	O
instructions	NNS	O
based	VBN	O
on	IN	O
clinical	JJ	O
evaluation	NN	O
.	.	O

Treatment	NNP	O
included	VBD	O
4	CD	O
sessions	NNS	O
of	IN	O
manual	JJ	O
therapy	NN	O
and	CC	O
stabilizing	NN	O
exercises	NNS	O
aimed	VBN	O
at	IN	O
correcting	VBG	O
the	DT	O
lumbopelvic	JJ	O
rhythm	NN	O
.	.	O

Questionnaires	VBZ	O
inquired	VBN	O
about	IN	O
pain	NN	O
(	(	O
visual	JJ	O
analog	NN	O
scale	NN	O
(	(	O
VAS	NNP	O
)	)	O
)	)	O
,	,	O
disability	NN	O
(	(	O
ODI	NNP	O
)	)	O
,	,	O
health-related	JJ	O
quality	NN	O
of	IN	O
life	NN	O
(	(	O
15D	CD	O
Quality	NN	O
of	IN	O
Life	NNP	O
Instrument	NNP	O
)	)	O
,	,	O
satisfaction	NN	O
with	IN	O
care	NN	O
,	,	O
and	CC	O
costs	NNS	O
.	.	O

RESULTS	NNP	O
Significant	NNP	O
improvement	NN	O
occurred	VBD	O
in	IN	O
both	DT	O
groups	NNS	O
on	IN	O
every	DT	O
self-rated	JJ	O
outcome	NN	O
measurement	NN	O
.	.	O

Within	IN	O
2	CD	O
years	NNS	O
,	,	O
the	DT	O
combination	NN	O
group	NN	O
showed	VBD	O
only	RB	O
a	DT	O
slightly	RB	O
more	RBR	O
significant	JJ	O
reduction	NN	O
in	IN	O
VAS	NNP	O
(	(	O
P	NNP	O
=	NNP	O
0.01	CD	O
,	,	O
analysis	NN	O
of	IN	O
variance	NN	O
)	)	O
but	CC	O
clearly	RB	O
higher	JJR	O
patient	JJ	O
satisfaction	NN	O
(	(	O
P	NNP	O
=	NNP	O
0.001	CD	O
,	,	O
Pearson	NNP	O
chi2	NN	O
)	)	O
as	IN	O
compared	VBN	O
to	TO	O
the	DT	O
consultation	NN	O
group	NN	O
.	.	O

Incremental	JJ	O
analysis	NN	O
showed	VBD	O
that	IN	O
for	IN	O
combined	JJ	O
group	NN	O
compared	VBN	O
to	TO	O
consultation	NN	O
group	NN	O
,	,	O
a	DT	O
one-point	JJ	O
change	NN	O
in	IN	O
VAS	NNP	O
scale	NN	O
cost	NN	O
$	$	O
512	CD	O
.	.	O

CONCLUSIONS	NNP	O
Physician	JJ	O
consultation	NN	O
alone	RB	O
was	VBD	O
more	RBR	O
cost-effective	JJ	O
for	IN	O
both	DT	O
health	NN	O
care	NN	O
use	NN	O
and	CC	O
work	NN	O
absenteeism	NN	O
,	,	O
and	CC	O
led	VBD	O
to	TO	O
equal	JJ	O
improvement	NN	O
in	IN	O
disability	NN	O
and	CC	O
health-related	JJ	O
quality	NN	O
of	IN	O
life	NN	O
.	.	O

It	PRP	O
seems	VBZ	O
obvious	JJ	O
that	IN	O
encouraging	VBG	O
information	NN	O
and	CC	O
advice	NN	O
are	VBP	O
major	JJ	O
elements	NNS	O
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
patients	NNS	O
with	IN	O
cLBP	NN	C
.	.	O

The	DT	O
reliability	NN	O
of	IN	O
catheter-tip	JJ	O
transducers	NNS	O
for	IN	O
the	DT	O
measurement	NN	O
of	IN	O
intrauterine	JJ	O
pressure	NN	O
in	IN	O
the	DT	O
third	JJ	O
stage	NN	O
of	IN	O
labour	NN	O
.	.	O

In	IN	O
order	NN	O
to	TO	O
assess	VB	O
the	DT	O
reliability	NN	O
of	IN	O
intrauterine	JJ	O
pressure	NN	O
measurements	NNS	O
in	IN	O
the	DT	O
third	JJ	O
stage	NN	O
of	IN	O
labour	NN	O
,	,	O
catheter-tip	JJ	O
transducers	NNS	O
were	VBD	O
used	VBN	O
in	IN	O
20	CD	O
women	NNS	O
randomly	RB	O
allocated	VBN	O
into	IN	O
two	CD	O
groups	NNS	O
of	IN	O
10	CD	O
.	.	O

In	IN	O
each	DT	O
case	NN	O
in	IN	O
the	DT	O
first	JJ	O
group	NN	O
two	CD	O
catheters	NNS	O
were	VBD	O
tied	VBN	O
together	RB	O
and	CC	O
introduced	VBN	O
transcervically	RB	O
into	IN	O
the	DT	O
uterine	JJ	O
cavity	NN	O
after	IN	O
delivery	NN	O
of	IN	O
the	DT	O
placenta	NN	O
.	.	O

In	IN	O
each	DT	O
case	NN	O
in	IN	O
the	DT	O
second	JJ	O
group	NN	O
two	CD	O
catheters	NNS	O
were	VBD	O
inserted	VBN	O
independently	RB	O
into	IN	O
the	DT	O
same	JJ	O
uterine	JJ	O
cavity	NN	O
.	.	O

The	DT	O
active	JJ	O
and	CC	O
cumulative	JJ	O
active	JJ	O
pressures	NNS	O
recorded	VBN	O
from	IN	O
the	DT	O
pairs	NNS	O
of	IN	O
catheters	NNS	O
within	IN	O
each	DT	O
uterine	JJ	O
cavity	NN	O
were	VBD	O
compared	VBN	O
.	.	O

Comparison	NNP	O
of	IN	O
individual	JJ	O
active	JJ	O
pressure	NN	O
readings	NNS	O
from	IN	O
separate	JJ	O
transducers	NNS	O
revealed	VBD	O
good	JJ	O
agreement	NN	O
whether	IN	O
the	DT	O
catheters	NNS	O
were	VBD	O
tied	VBN	O
together	RB	O
or	CC	O
were	VBD	O
separate	JJ	O
.	.	O

Cumulative	JJ	O
active	JJ	O
pressure	NN	O
was	VBD	O
very	RB	O
similar	JJ	O
when	WRB	O
assessed	VBN	O
by	IN	O
each	DT	O
catheter	NN	O
in	IN	O
the	DT	O
same	JJ	O
uterus	NN	O
.	.	O

Intrauterine	NNP	O
catheter-tip	JJ	O
transducers	NNS	O
can	MD	O
be	VB	O
used	VBN	O
reliably	RB	O
to	TO	O
measure	VB	O
uterine	JJ	O
activity	NN	O
in	IN	O
the	DT	O
third	JJ	O
stage	NN	O
of	IN	O
labour	JJ	O
although	IN	O
there	EX	O
may	MD	O
be	VB	O
minor	JJ	O
contraction	NN	O
by	IN	O
contraction	NN	O
differences	NNS	O
in	IN	O
recordings	NNS	O
of	IN	O
individual	JJ	O
active	JJ	O
pressures	NNS	O
.	.	O

Relaxation	NN	O
and	CC	O
imagery	NN	O
and	CC	O
cognitive-behavioral	JJ	O
training	NN	O
reduce	VB	O
pain	NN	O
during	IN	O
cancer	NN	O
treatment	NN	O
:	:	O
a	DT	O
controlled	JJ	O
clinical	JJ	O
trial	NN	O
.	.	O

Few	NNP	O
controlled	VBD	O
clinical	JJ	O
trials	NNS	O
of	IN	O
psychological	JJ	O
interventions	NNS	O
for	IN	O
cancer	NN	O
pain	NN	O
relief	NN	O
exist	NN	O
in	IN	O
spite	NN	O
of	IN	O
frequent	JJ	O
support	NN	O
for	IN	O
their	PRP$	O
importance	NN	O
as	IN	O
adjuncts	NNS	O
to	TO	O
medical	JJ	O
treatment	NN	O
.	.	O

This	DT	O
study	NN	O
compared	VBN	O
oral	JJ	O
mucositis	NN	O
pain	NN	O
levels	NNS	O
in	IN	O
4	CD	O
groups	NNS	O
of	IN	O
cancer	NN	O
patients	NNS	O
receiving	VBG	O
bone	NN	O
marrow	NN	O
transplants	NNS	O
(	(	O
BMT	NNP	O
)	)	O
:	:	O
(	(	O
1	CD	O
)	)	O
treatment	NN	O
as	IN	O
usual	JJ	O
control	NN	O
,	,	O
(	(	O
2	CD	O
)	)	O
therapist	NN	O
support	NN	O
,	,	O
(	(	O
3	CD	O
)	)	O
relaxation	NN	O
and	CC	O
imagery	NN	O
training	NN	O
,	,	O
and	CC	O
(	(	O
4	CD	O
)	)	O
training	NN	O
in	IN	O
a	DT	O
package	NN	O
of	IN	O
cognitive-behavioral	JJ	O
coping	NN	O
skills	NNS	O
which	WDT	O
included	VBD	O
relaxation	NN	O
and	CC	O
imagery	NN	O
.	.	O

A	DT	O
total	NN	O
of	IN	O
94	CD	O
patients	NNS	O
completed	VBD	O
the	DT	O
study	NN	O
which	WDT	O
involved	VBD	O
two	CD	O
training	NN	O
sessions	NNS	O
prior	RB	O
to	TO	O
treatment	NN	O
and	CC	O
twice	RB	O
a	DT	O
week	NN	O
'booster	POS	O
'	POS	O
sessions	NNS	O
during	IN	O
the	DT	O
first	JJ	O
5	CD	O
weeks	NNS	O
of	IN	O
treatment	NN	O
.	.	O

Results	NNS	O
confirmed	VBD	O
our	PRP$	O
hypothesis	NN	O
that	IN	O
patients	NNS	O
who	WP	O
received	VBD	O
either	DT	O
relaxation	NN	O
and	CC	O
imagery	VB	O
alone	RB	O
or	CC	O
patients	NNS	O
who	WP	O
received	VBD	O
the	DT	O
package	NN	O
of	IN	O
cognitive-behavioral	JJ	O
coping	NN	O
skills	NNS	O
would	MD	O
report	VB	O
less	JJR	O
pain	NN	O
than	IN	O
patients	NNS	O
in	IN	O
the	DT	O
other	JJ	O
2	CD	O
groups	NNS	O
.	.	O

The	DT	O
hypothesis	NN	O
that	IN	O
the	DT	O
cognitive-behavioral	JJ	O
skills	NNS	O
package	NN	O
would	MD	O
have	VB	O
an	DT	O
additive	JJ	O
effect	NN	O
beyond	IN	O
relaxation	NN	O
and	CC	O
imagery	NN	O
alone	RB	O
was	VBD	O
not	RB	O
confirmed	VBN	O
.	.	O

Average	JJ	O
visual	JJ	O
analogue	NN	O
scale	NN	O
(	(	O
VAS	NNP	O
)	)	O
report	NN	O
of	IN	O
pain	NN	O
within	IN	O
the	DT	O
therapist	JJ	O
support	NN	O
group	NN	O
was	VBD	O
not	RB	O
significantly	RB	O
lower	JJR	O
than	IN	O
the	DT	O
control	NN	O
group	NN	O
(	(	O
P	NNP	O
=	NNP	O
0.103	CD	O
)	)	O
nor	CC	O
significantly	RB	O
higher	JJR	O
than	IN	O
the	DT	O
training	NN	O
groups	NNS	O
.	.	O

Patient	JJ	O
reports	NNS	O
of	IN	O
relative	JJ	O
helpfulness	NN	O
of	IN	O
the	DT	O
interventions	NNS	O
for	IN	O
managing	VBG	O
pain	NN	O
and	CC	O
nausea	NN	O
matched	VBD	O
the	DT	O
results	NNS	O
of	IN	O
VAS	NNP	O
reports	NNS	O
.	.	O

From	IN	O
these	DT	O
results	NNS	O
,	,	O
we	PRP	O
conclude	VBP	O
that	DT	O
relaxation	NN	O
and	CC	O
imagery	NN	O
training	NN	O
reduces	NNS	O
cancer	NN	O
treatment-related	JJ	O
pain	NN	O
;	:	O
adding	VBG	O
cognitive-behavioral	JJ	O
skills	NNS	O
to	TO	O
the	DT	O
relaxation	NN	O
with	IN	O
imagery	NN	O
does	VBZ	O
not	RB	O
,	,	O
on	IN	O
average	NN	O
,	,	O
further	JJ	O
improve	VB	O
pain	NN	O
relief	NN	O
.	.	O

Comparison	NNP	O
of	IN	O
chemotherapy	NN	O
with	IN	O
chemohormonal	JJ	O
therapy	NN	O
as	IN	O
first-line	JJ	O
therapy	NN	O
for	IN	O
metastatic	JJ	C
,	,	C
hormone-sensitive	JJ	C
breast	NN	C
cancer	NN	C
:	:	O
An	DT	O
Eastern	JJ	O
Cooperative	NNP	O
Oncology	NNP	O
Group	NNP	O
study	NN	O
.	.	O

PURPOSE	NNP	O
Although	IN	O
hormonal	JJ	O
therapy	NN	O
represents	VBZ	O
standard	JJ	O
therapy	NN	O
for	IN	O
metastatic	JJ	O
hormone-sensitive	JJ	O
disease	NN	O
,	,	O
many	JJ	O
patients	NNS	O
receive	VBP	O
initial	JJ	O
chemotherapy	NN	O
because	IN	O
of	IN	O
the	DT	O
location	NN	O
,	,	O
bulk	NN	O
,	,	O
or	CC	O
aggressiveness	NN	O
of	IN	O
their	PRP$	O
disease	NN	O
.	.	O

It	PRP	O
is	VBZ	O
uncertain	JJ	O
whether	IN	O
simultaneous	JJ	O
hormonal	JJ	O
therapy	NN	O
provides	VBZ	O
additional	JJ	O
benefit	NN	O
compared	VBN	O
with	IN	O
chemotherapy	NN	O
alone	RB	O
.	.	O

Eastern	JJ	O
Cooperative	NNP	O
Oncology	NNP	O
Group	NNP	O
trial	NN	O
E3186	NNP	O
was	VBD	O
initiated	VBN	O
to	TO	O
explore	VB	O
this	DT	O
question	NN	O
.	.	O

PATIENTS	NN	O
AND	CC	O
METHODS	NNP	O
Between	NNP	O
January	NNP	O
1988	CD	O
and	CC	O
December	NNP	O
1992	CD	O
,	,	O
231	CD	SS
patients	NNS	O
with	IN	O
estrogen	JJ	O
receptor	NN	O
(	(	O
ER	NNP	O
)	)	O
-positive	CD	O
or	CC	O
ER-unknown	JJ	O
metastatic	JJ	O
breast	NN	O
cancer	NN	O
were	VBD	O
randomized	VBN	O
to	TO	O
receive	VB	O
either	DT	O
chemotherapy	NN	O
(	(	O
cyclophosphamide	NN	O
,	,	O
doxorubicin	NN	O
,	,	O
and	CC	O
fluorouracil	RB	O
?CAF	NNP	O
)	)	O
or	CC	O
chemohormonal	JJ	O
therapy	NN	O
(	(	O
CAF	NNP	O
plus	CC	O
tamoxifen	NN	O
and	CC	O
Halotestin	NNP	O
?fluoxymesterone	NN	O
;	:	O
Pharmacia-Upjohn	NNP	O
,	,	O
Kalamazoo	NNP	O
,	,	O
MI	NNP	O
?CAFTH	NNP	O
)	)	O
as	IN	O
front-line	JJ	O
therapy	NN	O
for	IN	O
metastatic	JJ	O
breast	NN	O
cancer	NN	O
.	.	O

Patients	NNS	O
who	WP	O
experienced	VBD	O
a	DT	O
complete	JJ	O
response	NN	O
to	TO	O
induction	NN	O
therapy	NN	O
either	CC	O
received	VBD	O
or	CC	O
did	VBD	O
not	RB	O
receive	JJ	O
maintenance	NN	O
cyclophosphamide	NN	O
,	,	O
methotrexate	NN	O
,	,	O
fluorouracil	NN	O
,	,	O
prednisone	NN	O
,	,	O
and	CC	O
TH	NNP	O
as	IN	O
a	DT	O
secondary	JJ	O
randomization	NN	O
.	.	O

RESULTS	VB	O
The	DT	O
response	NN	O
rates	NNS	O
(	(	O
complete	JJ	O
response	NN	O
and	CC	O
partial	JJ	O
response	NN	O
)	)	O
of	IN	O
patients	NNS	O
who	WP	O
received	VBD	O
CAF	NNP	O
and	CC	O
CAFTH	NNP	O
were	VBD	O
similar	JJ	O
(	(	O
69.2	CD	O
%	NN	O
v	JJ	O
68.9	CD	O
%	NN	O
,	,	O
respectively	RB	O
;	:	O
P	NNP	O
=.99	NNP	O
)	)	O
.	.	O

Time	NN	O
to	TO	O
treatment	NN	O
failure	NN	O
(	(	O
TTF	NNP	O
)	)	O
was	VBD	O
slightly	RB	O
longer	JJR	O
for	IN	O
patients	NNS	O
who	WP	O
received	VBD	O
chemohormonal	JJ	O
therapy	NN	O
compared	VBN	O
with	IN	O
chemotherapy	NN	O
alone	RB	O
patients	NNS	O
(	(	O
13.4	CD	O
months	NNS	O
v	RB	O
10.3	CD	O
months	NNS	O
,	,	O
respectively	RB	O
;	:	O
P	NNP	O
=.087	NNP	O
)	)	O
,	,	O
and	CC	O
TTF	NNP	O
was	VBD	O
significantly	RB	O
longer	RBR	O
in	IN	O
ER-positive	JJ	O
compared	VBN	O
with	IN	O
ER-negative	JJ	O
patients	NNS	O
(	(	O
17.4	CD	O
months	NNS	O
v	RB	O
10.3	CD	O
months	NNS	O
,	,	O
respectively	RB	O
;	:	O
P	NNP	O
=.048	NNP	O
)	)	O
.	.	O

However	RB	O
,	,	O
ER	NNP	O
status	NN	O
had	VBD	O
no	DT	O
effect	NN	O
on	IN	O
overall	JJ	O
survival	NN	O
(	(	O
30.0	CD	O
months	NNS	O
for	IN	O
CAF	NNP	O
v	FW	O
29.3	CD	O
months	NNS	O
for	IN	O
CAFTH	NNP	O
)	)	O
.	.	O

CONCLUSION	NNP	O
In	IN	O
patients	NNS	O
with	IN	O
potentially	RB	O
hormone-sensitive	JJ	O
metastatic	JJ	O
breast	NN	O
cancer	NN	O
,	,	O
chemohormonal	JJ	O
therapy	NN	O
prolongs	NNS	O
TTF	NNP	O
for	IN	O
ER-positive	JJ	O
patients	NNS	O
without	IN	O
improving	VBG	O
overall	JJ	O
survival	NN	O
.	.	O

Stepping	VBG	O
Stones	NNP	O
Triple	NNP	O
P	NNP	O
:	:	O
an	DT	O
RCT	NNP	O
of	IN	O
a	DT	O
parenting	VBG	O
program	NN	O
with	IN	O
parents	NNS	C
of	IN	C
a	DT	C
child	NN	C
diagnosed	VBN	C
with	IN	C
an	DT	C
autism	NN	C
spectrum	NN	C
disorder	NN	C
.	.	C

Whilst	IN	O
the	DT	O
Triple	NNP	O
P	NNP	O
Positive	NNP	O
Parenting	NNP	O
Program	NNP	O
has	VBZ	O
a	DT	O
large	JJ	O
evidence	NN	O
base	NN	O
(	(	O
Sanders	NNP	O
,	,	O
Clinical	NNP	O
Child	NNP	O
and	CC	O
Family	NNP	O
Psychology	NNP	O
Review	NNP	O
2:71-90	CD	O
,	,	O
1999	CD	O
;	:	O
Sanders	NNP	O
,	,	O
Journal	NNP	O
of	IN	O
Consulting	NNP	O
and	CC	O
Clinical	NNP	O
Psychology	NNP	O
68:624-640	CD	O
,	,	O
2000	CD	O
)	)	O
and	CC	O
preliminary	JJ	O
evidence	NN	O
indicates	VBZ	O
that	IN	O
Stepping	VBG	O
Stones	NNP	O
Triple	NNP	O
P	NNP	O
is	VBZ	O
also	RB	O
efficacious	JJ	O
(	(	O
Roberts	NNP	O
,	,	O
Journal	NNP	O
of	IN	O
Clinical	NNP	O
Child	NNP	O
and	CC	O
Adolescent	NNP	O
Psychology	NNP	O
,	,	O
35	CD	O
(	(	O
2	CD	O
)	)	O
:180-193	NN	O
,	,	O
2006	CD	O
)	)	O
,	,	O
to	TO	O
date	NN	O
Stepping	NNP	O
Stones	NNP	O
has	VBZ	O
not	RB	O
been	VBN	O
evaluated	VBN	O
with	IN	O
the	DT	O
ASD	NNP	O
population	NN	O
.	.	O

Fifty-nine	JJ	O
families	NNS	O
with	IN	O
a	DT	O
child	NN	O
with	IN	O
ASD	NNP	O
aged	VBD	O
between	IN	O
2	CD	O
and	CC	O
9	CD	O
participated	VBN	O
in	IN	O
this	DT	O
randomized	VBN	O
controlled	VBD	O
trial	NN	O
.	.	O

The	DT	O
results	NNS	O
demonstrate	VBP	O
significant	JJ	O
improvements	NNS	O
in	IN	O
parental	JJ	O
reports	NNS	O
of	IN	O
child	JJ	O
behaviour	NN	O
and	CC	O
parenting	NN	O
styles	NNS	O
with	IN	O
the	DT	O
treatment	NN	O
effects	NNS	O
for	IN	O
child	NN	O
behaviour	NN	O
,	,	O
parental	NN	O
over	IN	O
reactivity	NN	O
and	CC	O
parental	JJ	O
verbosity	NN	O
being	VBG	O
maintained	VBN	O
at	IN	O
follow-up	JJ	O
6	CD	O
months	NNS	O
later	RB	O
.	.	O

Further	RBR	O
,	,	O
the	DT	O
results	NNS	O
suggest	VBP	O
significant	JJ	O
improvements	NNS	O
in	IN	O
parental	JJ	O
satisfaction	NN	O
and	CC	O
conflict	NN	O
about	RB	O
parenting	VBG	O
as	RB	O
well	RB	O
as	IN	O
a	DT	O
sleeper	JJ	O
effect	NN	O
for	IN	O
parental	JJ	O
efficacy	NN	O
.	.	O

The	DT	O
results	NNS	O
indicate	VBP	O
that	IN	O
Stepping	VBG	O
Stones	NNP	O
Triple	NNP	O
P	NNP	O
is	VBZ	O
a	DT	O
promising	JJ	O
intervention	NN	O
for	IN	O
parents	NNS	O
of	IN	O
children	NNS	O
with	IN	O
ASD	NNP	O
.	.	O

Limitations	NNS	O
and	CC	O
future	JJ	O
research	NN	O
are	VBP	O
also	RB	O
addressed	VBN	O
.	.	O

The	DT	O
adrenocorticotrophic	JJ	O
hormone	NN	O
(	(	O
4-9	JJ	O
)	)	O
analog	NN	O
ORG	IN	O
2766	CD	O
benefits	NNS	O
autistic	JJ	O
children	NNS	O
:	:	O
report	NN	O
on	IN	O
a	DT	O
second	JJ	O
controlled	JJ	O
clinical	JJ	O
trial	NN	O
.	.	O

In	IN	O
a	DT	O
second	JJ	O
controlled	VBN	O
crossover	NN	O
trial	NN	O
,	,	O
20	CD	O
autistic	JJ	O
children	NNS	O
received	VBD	O
40	CD	O
mg/day	NN	O
of	IN	O
the	DT	O
neuropeptide	NN	O
ORG	NNP	O
2766	CD	O
,	,	O
a	DT	O
synthetic	JJ	O
analog	NN	O
of	IN	O
ACTH	NNP	O
(	(	O
4-9	JJ	O
)	)	O
,	,	O
for	IN	O
8	CD	O
weeks	NNS	O
.	.	O

Parents	NNS	O
'	POS	O
checklist	NN	O
ratings	NNS	O
(	(	O
ABC	NNP	O
)	)	O
as	RB	O
well	RB	O
as	IN	O
clinicians	NNS	O
'	POS	O
ratings	NNS	O
(	(	O
CGI	NNP	O
)	)	O
pointed	VBD	O
to	TO	O
significant	JJ	O
improvements	NNS	O
after	IN	O
the	DT	O
course	NN	O
of	IN	O
treatment	NN	O
;	:	O
improvements	NNS	O
were	VBD	O
clearest	VBN	O
on	IN	O
the	DT	O
ABC	NNP	O
social	JJ	O
withdrawal	NN	O
subscale	NN	O
.	.	O

The	DT	O
analysis	NN	O
of	IN	O
individual	JJ	O
target	NN	O
symptoms	NNS	O
and	CC	O
the	DT	O
parents	NNS	O
'	POS	O
treatment	NN	O
preferences	NNS	O
substantiated	VBD	O
the	DT	O
beneficial	JJ	O
effects	NNS	O
of	IN	O
ORG	NNP	O
2766	CD	O
.	.	O

In	IN	O
an	DT	O
ethologically	RB	O
analyzed	JJ	O
playroom	NN	O
session	NN	O
,	,	O
ORG	NNP	O
2766	CD	O
treatment	NN	O
was	VBD	O
associated	VBN	O
with	IN	O
an	DT	O
improvement	NN	O
in	IN	O
the	DT	O
children	NNS	O
's	POS	O
play	NN	O
behavior	NN	O
and	CC	O
a	DT	O
significant	JJ	O
increase	NN	O
in	IN	O
the	DT	O
social	JJ	O
interaction	NN	O
between	IN	O
child	NN	O
and	CC	O
experimenter	NN	O
.	.	O

Gaze	NNP	O
coordination	NN	O
between	IN	O
child	NN	O
and	CC	O
experimenter	NN	O
also	RB	O
was	VBD	O
improved	VBN	O
.	.	O

Disopyramide-pyridostigmine	JJ	O
interaction	NN	O
:	:	O
selective	JJ	O
reversal	NN	O
of	IN	O
anticholinergic	NN	O
symptoms	NNS	O
with	IN	O
preservation	NN	O
of	IN	O
antiarrhythmic	JJ	O
effect	NN	O
.	.	O

This	DT	O
double-blind	NN	O
,	,	O
randomized	VBN	O
,	,	O
placebo	FW	O
crossover	NN	O
study	NN	O
was	VBD	O
used	VBN	O
to	TO	O
evaluate	VB	O
the	DT	O
effects	NNS	O
of	IN	O
a	DT	O
cholinesterase	NN	O
inhibitor	NN	O
--	:	O
slow-release	JJ	O
pyridostigmine	NN	O
(	(	O
180	CD	O
mg	NNS	O
orally	RB	O
every	DT	O
12	CD	O
hours	NNS	O
)	)	O
--	:	O
on	IN	O
the	DT	O
anticholinergic	NN	O
and	CC	O
antiarrhythmic	JJ	O
properties	NNS	O
of	IN	O
disopyramide	NN	O
.	.	O

Quantitative	JJ	O
side	NN	O
effects	NNS	O
questionnaire	VBP	O
scores	NNS	O
were	VBD	O
used	VBN	O
to	TO	O
guide	VB	O
disopyramide	JJ	O
administration	NN	O
in	IN	O
20	CD	SS
men	NNS	SE
with	IN	O
ventricular	JJ	C
tachycardia	NN	C
.	.	O

Disopyramide	NNP	O
was	VBD	O
given	VBN	O
to	TO	O
each	DT	O
patient	NN	O
both	DT	O
with	IN	O
placebo	NN	C
and	CC	O
with	IN	O
active	JJ	C
pyridostigmine	NN	C
.	.	C

The	DT	O
maximal	JJ	O
administered	VBD	O
dose	NN	O
for	IN	O
each	DT	O
regimen	NN	O
was	VBD	O
used	VBN	O
in	IN	O
conjunction	NN	O
with	IN	O
corresponding	JJ	O
questionnaire	NN	O
scores	NNS	O
to	TO	O
calculate	VB	O
an	DT	O
index	NN	O
or	CC	O
estimate	NN	O
of	IN	O
the	DT	O
maximal	JJ	O
tolerable	JJ	O
dose	NN	O
of	IN	O
disopyramide	NN	O
.	.	O

Additional	JJ	O
evaluations	NNS	O
performed	VBN	O
at	IN	O
baseline	NN	O
and	CC	O
at	IN	O
each	DT	O
maximal	NN	O
administered	VBD	O
dose	JJ	O
regimen	NNS	O
included	VBD	O
tear	JJ	O
and	CC	O
saliva	JJ	O
quantitation	NN	O
,	,	O
24	CD	O
hour	NN	O
electrocardiogram	NN	O
(	(	O
ECG	NNP	O
)	)	O
,	,	O
exercise	VBP	O
testing	VBG	O
and	CC	O
programmed	VBD	O
ventricular	JJ	O
stimulation	NN	O
.	.	O

Results	NNS	O
showed	VBD	O
that	IN	O
the	DT	O
maximal	NN	O
administered	VBD	O
dose	NN	O
of	IN	O
disopyramide	NN	O
was	VBD	O
greater	JJR	O
with	IN	O
active	JJ	O
pyridostigmine	NN	O
than	IN	O
with	IN	O
placebo	NN	O
:	:	O
295	CD	O
+/-	JJ	O
75	CD	O
versus	NN	O
245	CD	O
+/-	JJ	O
100	CD	O
mg	NN	O
every	DT	O
6	CD	O
hours	NNS	O
(	(	O
p	NN	O
less	JJR	O
than	IN	O
0.05	CD	O
)	)	O
.	.	O

The	DT	O
calculated	JJ	O
maximal	NN	O
tolerable	JJ	O
dose	NN	O
was	VBD	O
substantially	RB	O
greater	JJR	O
in	IN	O
the	DT	O
presence	NN	O
of	IN	O
pyridostigmine	NN	O
:	:	O
355	CD	O
+/-	JJ	O
90	CD	O
versus	NN	O
260	CD	O
+/-	JJ	O
115	CD	O
mg	NN	O
every	DT	O
6	CD	O
hours	NNS	O
(	(	O
p	NN	O
less	JJR	O
than	IN	O
0.001	CD	O
)	)	O
.	.	O

Maximal	JJ	O
side	NN	O
effects	NNS	O
questionnaire	NN	O
scores	NNS	O
also	RB	O
reflected	VBD	O
decreased	JJ	O
anticholinergic	JJ	O
activity	NN	O
in	IN	O
the	DT	O
presence	NN	O
of	IN	O
pyridostigmine	NN	O
compared	VBN	O
with	IN	O
placebo	NN	O
:	:	O
101.9	CD	O
+/-	JJ	O
2.2	CD	O
versus	NN	O
104.6	CD	O
+/-	JJ	O
2.8	CD	O
,	,	O
respectively	RB	O
(	(	O
p	NN	O
less	JJR	O
than	IN	O
0.005	CD	O
)	)	O
.	.	O

Baseline	NNP	O
tear	NN	O
and	CC	O
saliva	JJ	O
production	NN	O
was	VBD	O
significantly	RB	O
reduced	VBN	O
during	IN	O
disopyramide	JJ	O
therapy	NN	O
,	,	O
but	CC	O
was	VBD	O
restored	VBN	O
toward	IN	O
normal	JJ	O
by	IN	O
the	DT	O
addition	NN	O
of	IN	O
pyridostigmine	NN	O
.	.	O

(	(	O
ABSTRACT	NNP	O
TRUNCATED	NNP	O
AT	NNP	O
250	CD	O
WORDS	NNP	O
)	)	O
MF101	NNP	O
,	,	O
a	DT	O
selective	JJ	O
estrogen	NN	O
receptor	NN	O
beta	NN	O
modulator	NN	O
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
menopausal	NN	O
hot	JJ	O
flushes	NNS	O
:	:	O
a	DT	O
phase	NN	O
II	NNP	O
clinical	JJ	O
trial	NN	O
.	.	O

OBJECTIVE	NN	O
To	TO	O
determine	VB	O
the	DT	O
optimal	JJ	O
dose	NN	O
,	,	O
safety	NN	O
,	,	O
and	CC	O
efficacy	NN	O
of	IN	O
an	DT	O
estrogen	NN	O
receptor	NN	O
beta	NN	O
selective	JJ	O
Chinese	NNP	O
herbal	NN	O
extract	NN	O
,	,	O
menopausal	JJ	O
formula	NN	O
101	CD	O
(	(	O
MF101	NNP	O
)	)	O
,	,	O
for	IN	O
treating	VBG	O
hot	JJ	O
flushes	NNS	O
.	.	O

METHODS	NNP	O
A	NNP	O
randomized	NN	O
,	,	O
blinded	VBD	O
trial	NN	O
in	IN	O
217	CD	SS
postmenopausal	JJ	C
women	NNS	SE
with	IN	O
hot	JJ	C
flushes	NNS	C
randomized	VBD	O
to	TO	O
5	CD	O
or	CC	O
10	CD	O
g/day	NN	O
of	IN	O
MF101	NNP	O
or	CC	O
placebo	NN	O
for	IN	O
12	CD	O
weeks	NNS	O
.	.	O

RESULTS	VB	O
The	DT	O
effects	NNS	O
of	IN	O
5	CD	O
g/day	NN	O
of	IN	O
MF101	NNP	O
did	VBD	O
not	RB	O
differ	VB	O
from	IN	O
those	DT	O
of	IN	O
placebo	NN	O
.	.	O

After	IN	O
12	CD	O
weeks	NNS	O
,	,	O
the	DT	O
mean	JJ	O
percent	NN	O
decrease	NN	O
in	IN	O
frequency	NN	O
of	IN	O
hot	JJ	O
flushes	NNS	O
in	IN	O
the	DT	O
10	CD	O
g/day	NN	O
group	NN	O
was	VBD	O
12.9	CD	O
%	NN	O
greater	JJR	O
than	IN	O
that	DT	O
in	IN	O
the	DT	O
placebo	NN	O
group	NN	O
(	(	O
P	NNP	O
=	NNP	O
0.15	CD	O
)	)	O
,	,	O
the	DT	O
median	JJ	O
percent	NN	O
decrease	NN	O
was	VBD	O
11.7	CD	O
%	NN	O
greater	JJR	O
than	IN	O
that	DT	O
in	IN	O
the	DT	O
placebo	NN	O
group	NN	O
(	(	O
P	NNP	O
=	NNP	O
0.05	CD	O
)	)	O
,	,	O
and	CC	O
the	DT	O
proportion	NN	O
of	IN	O
women	NNS	O
with	IN	O
at	IN	O
least	JJS	O
a	DT	O
50	CD	O
%	NN	O
reduction	NN	O
in	IN	O
hot	JJ	O
flushes	NNS	O
was	VBD	O
16.2	CD	O
%	NN	O
greater	JJR	O
than	IN	O
that	DT	O
in	IN	O
the	DT	O
placebo	NN	O
group	NN	O
(	(	O
P	NNP	O
=	NNP	O
0.03	CD	O
)	)	O
.	.	O

CONCLUSIONS	NNP	O
Treatment	NNP	O
with	IN	O
10	CD	O
g/day	NN	O
of	IN	O
MF101	NNP	O
reduces	VBZ	O
the	DT	O
frequency	NN	O
of	IN	O
hot	JJ	O
flushes	NNS	O
.	.	O

Trials	NNS	O
with	IN	O
higher	JJR	O
doses	NNS	O
are	VBP	O
planned	VBN	O
.	.	O

Maintenance	NN	O
of	IN	O
response	NN	O
following	VBG	O
stabilization	NN	O
of	IN	O
mixed	JJ	O
index	NN	O
episodes	NNS	O
with	IN	O
olanzapine	JJ	O
monotherapy	NN	O
in	IN	O
a	DT	O
randomized	JJ	O
,	,	O
double-blind	JJ	O
,	,	O
placebo-controlled	JJ	O
study	NN	O
of	IN	O
bipolar	JJ	C
1	CD	C
disorder	NN	C
.	.	O

BACKGROUND	NNP	O
In	IN	O
a	DT	O
population	NN	O
of	IN	O
patients	NNS	O
with	IN	O
manic	JJ	O
and	CC	O
mixed	JJ	O
mood	NN	C
episodes	NNS	C
,	,	O
olanzapine	NN	O
has	VBZ	O
proven	VBN	O
effective	JJ	O
in	IN	O
maintaining	VBG	O
response	NN	O
,	,	O
as	IN	O
compared	VBN	O
to	TO	O
placebo	VB	O
.	.	O

Whether	IN	O
this	DT	O
is	VBZ	O
true	JJ	O
for	IN	O
the	DT	O
subpopulation	NN	O
of	IN	O
patients	NNS	O
with	IN	O
a	DT	O
mixed	JJ	O
index	NN	O
episode	NN	O
is	VBZ	O
not	RB	O
known	VBN	O
.	.	O

METHODS	NNP	O
Post-hoc	JJ	O
analyses	NNS	O
were	VBD	O
conducted	VBN	O
on	IN	O
data	NNS	O
from	IN	O
patients	NNS	O
presenting	VBG	O
with	IN	O
a	DT	O
mixed	JJ	O
index	NN	O
episode	NN	O
who	WP	O
were	VBD	O
enrolled	VBN	O
in	IN	O
a	DT	O
larger	JJR	O
double-blind	NN	O
,	,	O
placebo-controlled	JJ	O
trial	NN	O
.	.	O

Patients	NNS	O
who	WP	O
met	VBD	O
remission	NN	O
criteria	NNS	O
at	IN	O
2	CD	O
consecutive	JJ	O
weekly	JJ	O
visits	NNS	O
during	IN	O
6	CD	O
to	TO	O
12	CD	O
weeks	NNS	O
of	IN	O
open-label	JJ	O
olanzapine	JJ	O
treatment	NN	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
olanzapine	VB	O
or	CC	O
placebo	VB	O
treatment	NN	O
for	IN	O
48	CD	O
weeks	NNS	O
.	.	O

The	DT	O
incidence	NN	O
of	IN	O
and	CC	O
time	NN	O
to	TO	O
symptomatic	JJ	O
relapse	NN	O
were	VBD	O
calculated	VBN	O
for	IN	O
any	DT	O
mood	NN	O
episode	NN	O
,	,	O
and	CC	O
for	IN	O
depressive	JJ	O
,	,	O
manic	JJ	O
,	,	O
hypo-manic	JJ	O
,	,	O
and	CC	O
mixed	JJ	O
mood	NN	O
episodes	NNS	O
.	.	O

RESULTS	VB	O
A	DT	O
total	NN	O
of	IN	O
121	CD	SS
of	IN	O
304	CD	SS
patients	NNS	O
(	(	O
39.8	CD	O
%	NN	O
)	)	O
met	VBD	O
criteria	NNS	O
for	IN	O
symptomatic	JJ	O
remission	NN	O
in	IN	O
the	DT	O
open-label	JJ	O
treatment	NN	O
phase	NN	O
and	CC	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
olanzapine	VB	O
(	(	O
n=76	NN	O
)	)	O
or	CC	O
placebo	NN	O
(	(	O
n=45	JJ	O
)	)	O
.	.	O

Compared	VBN	O
to	TO	O
the	DT	O
placebo	NN	O
group	NN	O
,	,	O
the	DT	O
olanzapine	NN	O
group	NN	O
had	VBD	O
a	DT	O
lower	JJR	O
incidence	NN	O
of	IN	O
(	(	O
59.2	CD	O
%	NN	O
versus	IN	O
91.1	CD	O
%	NN	O
,	,	O
p	NN	O
<	NNP	O
0.001	CD	O
)	)	O
and	CC	O
a	DT	O
longer	JJR	O
time	NN	O
to	TO	O
(	(	O
46	CD	O
versus	NN	O
15	CD	O
days	NNS	O
,	,	O
p	VBP	O
<	RB	O
0.001	CD	O
)	)	O
symptomatic	JJ	O
relapse	NN	O
of	IN	O
any	DT	O
kind	NN	O
.	.	O

Olanzapine-treated	JJ	O
patients	NNS	O
also	RB	O
experienced	VBD	O
longer	JJR	O
time	NN	O
to	TO	O
depressive	VB	O
symptomatic	JJ	O
relapse	NN	O
(	(	O
85	CD	O
versus	NN	O
22	CD	O
days	NNS	O
,	,	O
p=0.001	NN	O
)	)	O
and	CC	O
manic	JJ	O
symptomatic	JJ	O
relapse	NN	O
(	(	O
too	RB	O
few	JJ	O
relapses	NNS	O
to	TO	O
calculate	VB	O
versus	NN	O
42	CD	O
days	NNS	O
,	,	O
p	VBP	O
<	RB	O
0.001	CD	O
)	)	O
than	IN	O
did	VBD	O
placebo-treated	JJ	O
patients	NNS	O
.	.	O

CONCLUSIONS	NNP	O
Compared	NNP	O
with	IN	O
placebo	NN	O
,	,	O
olanzapine	JJ	O
treatment	NN	O
was	VBD	O
associated	VBN	O
with	IN	O
longer	JJR	O
maintenance	NN	O
of	IN	O
response	NN	O
in	IN	O
patients	NNS	O
presenting	VBG	O
with	IN	O
a	DT	O
mixed	JJ	C
index	NN	C
episode	NN	C
of	IN	O
bipolar	NN	C
I	PRP	C
disorder	VBP	C
.	.	O

Sustained	VBN	O
oral	JJ	C
health	NN	C
improvement	NN	C
and	CC	O
use	NN	O
of	IN	O
toothbrushes	NNS	O
and	CC	O
dentifrice	NN	O
by	IN	O
previous	JJ	O
users	NNS	O
of	IN	O
traditional	JJ	O
materials	NNS	O
in	IN	O
a	DT	O
rural	JJ	O
population	NN	O
in	IN	O
Andhra	NNP	O
Pradesh	NNP	O
,	,	O
India	NNP	O
.	.	O

AIM	NNP	O
To	TO	O
follow-up	NN	O
,	,	O
one	CD	O
year	NN	O
later	RB	O
,	,	O
a	DT	O
double-blind	NN	O
,	,	O
randomised	VBN	O
study	NN	O
,	,	O
which	WDT	O
investigated	VBD	O
the	DT	O
effect	NN	O
of	IN	O
regular	JJ	O
brushing	NN	O
with	IN	O
dentifrices	NNS	O
on	IN	O
the	DT	O
oral	JJ	C
health	NN	C
of	IN	O
an	DT	O
economically	RB	O
disadvantaged	JJ	O
rural	JJ	O
population	NN	O
in	IN	O
Andhra	NNP	O
Pradesh	NNP	O
,	,	O
India	NNP	O
who	WP	O
were	VBD	O
primarily	RB	O
users	NNS	O
of	IN	O
traditional	JJ	O
materials	NNS	O
.	.	O

SUBJECTS	NNP	O
150	CD	SS
of	IN	O
the	DT	O
original	JJ	O
study	NN	O
population	NN	O
.	.	O

METHOD	NNP	O
Examination	NNP	O
to	TO	O
determine	VB	O
whether	IN	O
the	DT	O
improvements	NNS	O
in	IN	O
oral	JJ	O
health	NN	O
status	NN	O
and	CC	O
oral	JJ	O
health	NN	O
behaviour	NN	O
(	(	O
use	NN	O
of	IN	O
toothbrush	NN	O
and	CC	O
dentifrice	NN	O
)	)	O
,	,	O
being	VBG	O
unsupported	JJ	O
,	,	O
had	VBD	O
been	VBN	O
sustained	VBN	O
since	IN	O
completion	NN	O
of	IN	O
the	DT	O
original	JJ	O
study	NN	O
.	.	O

RESULTS	NNP	O
Data	NNP	O
analysis	NN	O
showed	VBD	O
sustained	VBN	O
,	,	O
statistically	RB	O
significant	JJ	O
improvements	NNS	O
in	IN	O
gingival	JJ	O
health	NN	O
as	IN	O
measured	VBN	O
by	IN	O
gingival	NN	O
bleeding	NN	O
and	CC	O
plaque	NN	O
indices	NNS	O
(	(	O
GBI	NNP	O
and	CC	O
PI	NNP	O
)	)	O
comparing	VBG	O
users	NNS	O
and	CC	O
non-users	NNS	O
of	IN	O
toothbrushes	NNS	O
and	CC	O
dentifrice	NN	O
in	IN	O
the	DT	O
original	JJ	O
study	NN	O
(	(	O
PI	NNP	O
:	:	O
p	NN	O
=	VBZ	O
0.04	CD	O
;	:	O
GBI	NNP	O
:	:	O
p	NN	O
=	VBZ	O
0.03	CD	O
)	)	O
and	CC	O
sustained	VBN	O
use	NN	O
of	IN	O
toothbrushes	NNS	O
and	CC	O
dentifrice	NN	O
by	IN	O
60	CD	O
%	NN	O
of	IN	O
the	DT	O
subjects	NNS	O
at	IN	O
follow-up	JJ	O
one	CD	O
year	NN	O
later	RB	O
.	.	O

CONCLUSIONS	VB	O
This	DT	O
study	NN	O
shows	VBZ	O
a	DT	O
beneficial	JJ	O
effect	NN	O
on	IN	O
oral	JJ	O
hygiene	NN	O
indices	NNS	O
following	VBG	O
the	DT	O
introduction	NN	O
of	IN	O
toothbrushes	NNS	O
and	CC	O
dentifrices	NNS	O
to	TO	O
a	DT	O
community	NN	O
using	VBG	O
traditional	JJ	O
oral	JJ	O
hygiene	NN	O
materials	NNS	O
and	CC	O
sustainability	NN	O
of	IN	O
use	NN	O
of	IN	O
these	DT	O
materials	NNS	O
with	IN	O
motivation	NN	O
and	CC	O
support	NN	O
.	.	O

It	PRP	O
may	MD	O
therefore	RB	O
be	VB	O
concluded	VBN	O
that	IN	O
it	PRP	O
is	VBZ	O
feasible	JJ	O
to	TO	O
achieve	VB	O
significant	JJ	O
use	NN	O
of	IN	O
conventional	JJ	O
toothbrushes	NNS	O
and	CC	O
toothpastes	NNS	O
,	,	O
with	IN	O
consequent	JJ	O
major	JJ	O
and	CC	O
sustained	JJ	O
improvements	NNS	O
in	IN	O
plaque	NN	O
control	NN	O
and	CC	O
gingival	JJ	O
health	NN	O
in	IN	O
a	DT	O
disadvantaged	JJ	O
population	NN	O
hitherto	NN	O
often	RB	O
considered	VBN	O
as	IN	O
not	RB	O
amenable	JJ	O
to	TO	O
conventional	JJ	O
oral	JJ	O
hygiene	NN	O
for	IN	O
cultural	JJ	O
or	CC	O
economic	JJ	O
reasons	NNS	O
.	.	O

Rapid	JJ	O
tightening	NN	O
of	IN	O
blood	NN	O
glucose	NN	O
control	NN	O
leads	VBZ	O
to	TO	O
transient	VB	O
deterioration	NN	O
of	IN	O
retinopathy	NN	O
in	IN	O
insulin	NN	O
dependent	NN	O
diabetes	VBZ	C
mellitus	NNS	C
:	:	O
the	DT	O
Oslo	NNP	O
study	NN	O
.	.	O

In	IN	O
a	DT	O
study	NN	O
of	IN	O
retinopathy	NN	O
during	IN	O
one	CD	O
year	NN	O
of	IN	O
tight	JJ	O
blood	NN	O
glucose	VB	O
control	NN	O
45	CD	O
type	NN	O
I	PRP	O
(	(	O
insulin	JJ	O
dependent	NN	O
)	)	O
diabetics	NNS	C
without	IN	O
proliferative	JJ	O
retinopathy	NN	O
were	VBD	O
randomised	VBN	O
to	TO	O
receive	VB	O
either	RB	O
continuous	JJ	O
subcutaneous	JJ	O
insulin	NN	O
infusion	NN	O
,	,	O
multiple	JJ	O
insulin	NN	O
injections	NNS	O
,	,	O
or	CC	O
conventional	JJ	O
insulin	NN	O
treatment	NN	O
(	(	O
controls	NNS	O
)	)	O
.	.	O

Near	IN	O
normoglycaemia	NN	O
was	VBD	O
achieved	VBN	O
with	IN	O
continuous	JJ	O
infusion	NN	O
and	CC	O
multiple	JJ	O
injections	NNS	O
but	CC	O
not	RB	O
with	IN	O
conventional	JJ	O
treatment	NN	O
.	.	O

Blind	NNP	O
evaluation	NN	O
of	IN	O
fluorescein	JJ	O
angiograms	NNS	O
performed	VBD	O
three	CD	O
monthly	JJ	O
showed	VBD	O
progression	NN	O
of	IN	O
retinopathy	NN	O
in	IN	O
the	DT	O
control	NN	O
group	NN	O
,	,	O
transient	JJ	O
deterioration	NN	O
in	IN	O
the	DT	O
continuous	JJ	O
infusion	NN	O
group	NN	O
,	,	O
and	CC	O
no	DT	O
change	NN	O
in	IN	O
the	DT	O
multiple	JJ	O
injection	NN	O
group	NN	O
.	.	O

Half	PDT	O
the	DT	O
patients	NNS	O
receiving	VBG	O
continuous	JJ	O
infusion	NN	O
and	CC	O
multiple	JJ	O
injections	NNS	O
developed	VBD	O
retinal	JJ	O
cotton	NN	O
wool	NN	O
spots	NNS	O
after	IN	O
three	CD	O
to	TO	O
six	CD	O
months	NNS	O
.	.	O

These	DT	O
changes	NNS	O
regressed	VBD	O
in	IN	O
all	DT	O
but	CC	O
four	CD	O
patients	NNS	O
after	IN	O
12	CD	O
months	NNS	O
.	.	O

Control	NNP	O
patients	NNS	O
did	VBD	O
not	RB	O
develop	VB	O
cotton	NN	O
wool	NN	O
spots	NNS	O
.	.	O

Patients	NNS	O
who	WP	O
developed	VBD	O
cotton	NN	O
wool	NN	O
spots	NNS	O
are	VBP	O
characterised	VBN	O
by	IN	O
a	DT	O
larger	JJR	O
decrement	NN	O
in	IN	O
glycosylated	JJ	O
haemoglobin	NN	O
and	CC	O
blood	NN	O
glucose	NN	O
values	NNS	O
,	,	O
more	RBR	O
frequent	JJ	O
episodes	NNS	O
of	IN	O
hypoglycaemia	NN	O
,	,	O
a	DT	O
longer	JJR	O
duration	NN	O
of	IN	O
diabetes	NNS	O
,	,	O
and	CC	O
more	RBR	O
severe	JJ	O
retinopathy	NN	O
at	IN	O
onset	NN	O
.	.	O

A	DT	O
large	JJ	O
and	CC	O
rapid	JJ	O
fall	NN	O
in	IN	O
blood	NN	O
glucose	JJ	O
concentration	NN	O
may	MD	O
promote	VB	O
transient	JJ	O
deterioration	NN	O
of	IN	O
diabetic	JJ	O
retinopathy	NN	O
.	.	O

A	DT	O
trial	NN	O
with	IN	O
3'-azido-2',3'-dideoxythymidine	JJ	O
and	CC	O
human	JJ	O
interferon-?	NN	O
in	IN	O
cats	NNS	O
naturally	RB	O
infected	VBN	O
with	IN	O
feline	JJ	O
leukaemia	NN	O
virus	NN	O
.	.	O

Feline	NNP	O
leukaemia	NN	O
virus	NN	O
(	(	O
FeLV	NNP	O
)	)	O
infection	NN	O
is	VBZ	O
still	RB	O
one	CD	O
of	IN	O
the	DT	O
leading	JJ	O
causes	NNS	O
of	IN	O
infection-related	JJ	O
deaths	NNS	O
in	IN	O
domestic	JJ	O
cats	NNS	O
.	.	O

Treatment	NN	O
with	IN	O
various	JJ	O
drugs	NNS	O
has	VBZ	O
been	VBN	O
attempted	VBN	O
,	,	O
but	CC	O
none	NN	O
has	VBZ	O
resulted	VBN	O
in	IN	O
cure	NN	O
or	CC	O
complete	JJ	O
virus	NN	O
elimination	NN	O
.	.	O

Human	JJ	O
interferon-?2a	JJ	O
(	(	O
huIFN-?2a	JJ	O
)	)	O
and	CC	O
3'-azido-2',3'-dideoxythymidine	JJ	O
(	(	O
AZT	NNP	O
)	)	O
have	VBP	O
been	VBN	O
proven	VBN	O
to	TO	O
decrease	VB	O
antigenaemia	NN	O
in	IN	O
cats	NNS	O
infected	VBN	O
experimentally	RB	O
with	IN	O
FeLV	NNP	O
.	.	O

The	DT	O
purpose	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
assess	VB	O
the	DT	O
efficacy	NN	O
of	IN	O
huIFN-?2a	NN	O
,	,	O
AZT	NNP	O
and	CC	O
a	DT	O
combination	NN	O
of	IN	O
both	DT	O
drugs	NNS	O
in	IN	O
cats	NNS	O
infected	VBN	O
naturally	RB	O
with	IN	O
FeLV	NNP	O
in	IN	O
a	DT	O
placebo-controlled	JJ	O
double-blinded	JJ	O
trial	NN	O
.	.	O

Fourty-four	CD	O
FeLV-infected	JJ	O
cats	NNS	O
in	IN	O
which	WDT	O
free	JJ	O
FeLV	NNP	O
p27	NN	O
antigen	NN	O
was	VBD	O
detected	VBN	O
in	IN	O
serum	NN	O
by	IN	O
enzyme-linked	JJ	O
immunosorbent	JJ	O
assay	NN	O
were	VBD	O
included	VBN	O
in	IN	O
the	DT	O
study	NN	O
.	.	O

Cats	NNS	O
were	VBD	O
assigned	VBN	O
to	TO	O
one	CD	O
of	IN	O
four	CD	O
treatment	NN	O
groups	NNS	O
that	WDT	O
received	VBD	O
either	RB	O
high	JJ	O
dose	JJ	O
huIFN-?2a	NN	O
(	(	O
10	CD	O
(	(	O
5	CD	O
)	)	O
IU/kg	NNP	O
q24h	NN	O
;	:	O
12	CD	O
cats	NNS	O
)	)	O
,	,	O
AZT	NNP	O
(	(	O
5	CD	O
mg/kg	NN	O
q12h	NN	O
;	:	O
10	CD	O
cats	NNS	O
,	,	O
both	DT	O
of	IN	O
these	DT	O
treatments	NNS	O
(	(	O
12	CD	O
cats	NNS	O
)	)	O
or	CC	O
placebo	NN	O
(	(	O
10	CD	O
cats	NNS	O
)	)	O
.	.	O

All	DT	O
cats	NNS	O
were	VBD	O
treated	VBN	O
for	IN	O
6	CD	O
weeks	NNS	O
.	.	O

Clinical	JJ	O
variables	NNS	O
,	,	O
including	VBG	O
stomatitis	NN	O
,	,	O
and	CC	O
laboratory	NN	O
parameters	NNS	O
,	,	O
such	JJ	O
as	IN	O
CD4	NNP	O
(	(	O
+	NNP	O
)	)	O
and	CC	O
CD8	NNP	O
(	(	O
+	NNP	O
)	)	O
counts	NNS	O
and	CC	O
serum	NN	O
FeLV	NNP	O
p	VBZ	O
27	CD	O
antigen	NN	O
concentration	NN	O
,	,	O
were	VBD	O
recorded	VBN	O
throughout	IN	O
the	DT	O
treatment	NN	O
period	NN	O
.	.	O

No	DT	O
significant	JJ	O
difference	NN	O
among	IN	O
the	DT	O
groups	NNS	O
was	VBD	O
observed	VBN	O
during	IN	O
the	DT	O
treatment	NN	O
period	NN	O
for	IN	O
any	DT	O
of	IN	O
the	DT	O
parameters	NNS	O
.	.	O

Aside	RB	O
from	IN	O
anaemia	NN	O
in	IN	O
one	CD	O
cat	NN	O
treated	VBN	O
with	IN	O
AZT	NNP	O
,	,	O
no	DT	O
adverse	JJ	O
effects	NNS	O
were	VBD	O
observed	VBN	O
.	.	O

It	PRP	O
was	VBD	O
not	RB	O
possible	JJ	O
to	TO	O
demonstrate	VB	O
efficacy	NN	O
of	IN	O
huIFN-?2a	NN	O
or	CC	O
AZT	NNP	O
alone	RB	O
or	CC	O
together	RB	O
in	IN	O
cats	NNS	O
infected	VBN	O
naturally	RB	O
with	IN	O
FeLV	NNP	O
when	WRB	O
given	VBN	O
according	VBG	O
to	TO	O
this	DT	O
regimen	NNS	O
for	IN	O
6	CD	O
weeks	NNS	O
;	:	O
however	RB	O
,	,	O
no	DT	O
notable	JJ	O
side	NN	O
effects	NNS	O
were	VBD	O
detected	VBN	O
.	.	O

[	RB	O
Clinical	NNP	O
study	NN	O
on	IN	O
dan	NN	O
shao	NN	O
tang	NN	O
in	IN	O
treating	VBG	O
IgA	NNP	O
nephropathy	NN	O
of	IN	O
deficiency	NN	O
of	IN	O
yin	NN	O
with	IN	O
damp-heat	JJ	O
symptom	NN	O
]	NNP	O
.	.	O

OBJECTIVE	NNP	O
To	TO	O
explore	VB	O
the	DT	O
effect	NN	O
of	IN	O
Dan	NNP	O
Shao	NNP	O
Tang	NNP	O
(	(	O
DST	NNP	O
)	)	O
in	IN	O
treating	VBG	O
IgA	NNP	O
nephropathy	NN	O
(	(	O
IgAN	NNP	O
)	)	O
of	IN	O
deficiency	NN	O
of	IN	O
Yin	NNP	O
with	IN	O
damp-heat	JJ	O
symptom	NN	O
.	.	O

METHODS	NNP	O
90	CD	SS
patients	NNS	O
with	IN	O
IgAN	NNP	C
of	IN	C
deficiency	NN	C
of	IN	C
Yin	NNP	C
with	IN	O
damp-heat	JJ	C
symptom	NN	C
were	VBD	O
randomly	RB	O
divided	VBN	O
into	IN	O
two	CD	O
groups	NNS	O
.	.	O

50	CD	O
patients	NNS	O
in	IN	O
treatment	NN	O
group	NN	O
were	VBD	O
treated	VBN	O
with	IN	O
DST	NNP	O
and	CC	O
western	JJ	O
medicine	NN	O
and	CC	O
40	CD	O
patients	NNS	O
in	IN	O
control	NN	O
group	NN	O
were	VBD	O
treated	VBN	O
only	RB	O
with	IN	O
western	JJ	O
medicine	NN	O
.	.	O

The	DT	O
effects	NNS	O
and	CC	O
changes	NNS	O
of	IN	O
the	DT	O
indexes	NNS	O
including	VBG	O
renal	JJ	O
function	NN	O
,	,	O
hematuria	NN	O
,	,	O
proteinuria	NN	O
,	,	O
blood	NN	O
IgA	NNP	O
before	IN	O
and	CC	O
after	IN	O
treatment	NN	O
were	VBD	O
observed	VBN	O
.	.	O

RESULTS	NNP	O
After	IN	O
six	CD	O
months	NNS	O
treatment	NN	O
,	,	O
the	DT	O
general	JJ	O
effective	JJ	O
rate	NN	O
in	IN	O
treatment	NN	O
group	NN	O
was	VBD	O
70.00	CD	O
%	NN	O
,	,	O
which	WDT	O
was	VBD	O
markedly	RB	O
higher	JJR	O
than	IN	O
that	DT	O
in	IN	O
control	NN	O
group	NN	O
(	(	O
37.50	CD	O
%	NN	O
,	,	O
P	NNP	O
<	NNP	O
0.01	CD	O
)	)	O
.	.	O

Treatment	NNP	O
group	NN	O
is	VBZ	O
obviously	RB	O
better	JJR	O
than	IN	O
control	NN	O
group	NN	O
on	IN	O
decreasing	VBG	O
hematuria	NN	O
,	,	O
proteinuria	NN	O
,	,	O
blood	NN	O
IgA	NNP	O
and	CC	O
improving	VBG	O
renal	JJ	O
function	NN	O
(	(	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
.	.	O

CONCLUSION	NNP	O
DST	NNP	O
is	VBZ	O
effective	JJ	O
on	IN	O
IgAN	NNP	O
of	IN	O
deficiency	NN	O
of	IN	O
Yin	NNP	O
with	IN	O
damp-heat	JJ	O
symptom	NN	O
.	.	O

Anti-emetic	JJ	O
efficacy	NN	O
of	IN	O
prophylactic	JJ	O
granisetron	NNS	O
compared	VBN	O
with	IN	O
perphenazine	NN	O
for	IN	O
the	DT	O
prevention	NN	O
of	IN	O
post-operative	JJ	C
vomiting	NN	C
in	IN	O
children	NNS	A
.	.	O

We	PRP	O
have	VBP	O
compared	VBN	O
the	DT	O
efficacy	NN	O
of	IN	O
granisetron	NN	O
with	IN	O
perphenazine	NN	O
in	IN	O
the	DT	O
prevention	NN	O
of	IN	O
vomiting	VBG	O
after	IN	O
tonsillectomy	NN	O
with	IN	O
or	CC	O
without	IN	O
adenoidectomy	NN	O
in	IN	O
children	NNS	O
.	.	O

In	IN	O
a	DT	O
prospective	JJ	O
,	,	O
randomized	VBN	O
,	,	O
double-blind	JJ	O
study	NN	O
,	,	O
90	CD	SS
paediatric	JJ	O
patients	NNS	O
,	,	O
ASA	NNP	O
I	PRP	O
,	,	O
aged	VBN	O
4-10	CD	A
years	NNS	A
,	,	O
received	VBD	O
granisetron	NN	O
40	CD	O
mg	JJ	O
kg-1	NN	O
or	CC	O
perphenazine	VB	O
70	CD	O
mg	JJ	O
kg-1	NN	O
(	(	O
n	JJ	O
=	RB	O
45	CD	O
each	DT	O
)	)	O
intravenously	RB	O
immediately	RB	O
after	IN	O
an	DT	O
inhalation	NN	O
induction	NN	O
of	IN	O
anaesthesia	NN	O
.	.	O

A	DT	O
standard	JJ	O
general	JJ	O
anaesthetic	JJ	O
technique	NN	O
was	VBD	O
employed	VBN	O
throughout	IN	O
.	.	O

A	DT	O
complete	JJ	O
response	NN	O
,	,	O
defined	VBD	O
as	IN	O
no	DT	O
emesis	NN	O
with	IN	O
no	DT	O
need	NN	O
for	IN	O
another	DT	O
rescue	NN	O
antiemetic	JJ	O
,	,	O
during	IN	O
the	DT	O
first	JJ	O
3	CD	O
h	NN	O
(	(	O
0-3	JJ	O
h	NN	O
)	)	O
after	IN	O
anesthesia	NN	O
was	VBD	O
87	CD	O
%	NN	O
with	IN	O
granisetron	NN	O
and	CC	O
78	CD	O
%	NN	O
with	IN	O
perphenazine	NN	O
(	(	O
P	NNP	O
=	NNP	O
0.204	CD	O
)	)	O
.	.	O

The	DT	O
corresponding	JJ	O
incidence	NN	O
during	IN	O
the	DT	O
next	JJ	O
21	CD	O
h	NN	O
(	(	O
3-24	JJ	O
h	NN	O
)	)	O
after	IN	O
anaesthesia	NN	O
was	VBD	O
87	CD	O
%	NN	O
and	CC	O
62	CD	O
%	NN	O
(	(	O
P	NNP	O
=	NNP	O
0.007	CD	O
)	)	O
.	.	O

No	UH	O
clinically	RB	O
serious	JJ	O
adverse	JJ	O
events	NNS	O
were	VBD	O
observed	VBN	O
in	IN	O
any	DT	O
of	IN	O
the	DT	O
groups	NNS	O
.	.	O

We	PRP	O
conclude	VBP	O
that	DT	O
granisetron	NN	O
is	VBZ	O
a	DT	O
better	JJR	O
anti-emetic	JJ	O
than	IN	O
perphenazine	NN	O
for	IN	O
the	DT	O
long-term	JJ	O
prevention	NN	O
of	IN	O
post-operative	JJ	O
vomiting	NN	O
in	IN	O
children	NNS	O
undergoing	VBG	O
general	JJ	O
anaesthesia	NN	O
for	IN	O
tonsillectomy	NN	C
.	.	O

A	DT	O
comparative	JJ	O
study	NN	O
of	IN	O
ofloxacin	NN	O
and	CC	O
cefixime	NN	O
for	IN	O
treatment	NN	O
of	IN	O
typhoid	JJ	C
fever	NN	C
in	IN	O
children	NNS	A
.	.	O

The	DT	O
Dong	NNP	O
Nai	NNP	O
Pediatric	NNP	O
Center	NNP	O
Typhoid	NNP	O
Study	NNP	O
Group	NNP	O
.	.	O

BACKGROUND	NNP	O
Despite	IN	O
concerns	NNS	O
about	IN	O
safety	NN	O
in	IN	O
children	NNS	O
,	,	O
fluoroquinolone	NN	O
antibiotics	NNS	O
have	VBP	O
become	VBN	O
the	DT	O
treatment	NN	O
of	IN	O
choice	NN	O
in	IN	O
patients	NNS	O
with	IN	O
multidrug-resistant	JJ	C
typhoid	NN	C
fever	NN	C
in	IN	O
Vietnam	NNP	O
.	.	O

However	RB	O
,	,	O
quinolone-resistant	JJ	O
strains	NNS	O
of	IN	O
Salmonella	NNP	O
typhi	NN	O
have	VBP	O
recently	RB	O
been	VBN	O
reported	VBN	O
from	IN	O
Vietnam	NNP	O
;	:	O
and	CC	O
if	IN	O
quinolone	JJ	O
resistance	NN	O
becomes	NNS	O
established	VBN	O
,	,	O
alternative	JJ	O
oral	JJ	O
treatment	NN	O
options	NNS	O
will	MD	O
be	VB	O
needed	VBN	O
.	.	O

OBJECTIVE	NNP	O
Cefixime	NNP	O
,	,	O
an	DT	O
orally	RB	O
administered	VBN	O
third	JJ	O
generation	NN	O
cephalosporin	NN	O
,	,	O
was	VBD	O
compared	VBN	O
with	IN	O
ofloxacin	NN	O
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
uncomplicated	JJ	O
typhoid	NN	O
fever	NN	O
in	IN	O
children	NNS	O
.	.	O

METHODS	NNP	O
In	IN	O
an	DT	O
open	JJ	O
trial	NN	O
children	NNS	A
with	IN	O
suspected	JJ	O
typhoid	NN	C
fever	NN	C
were	VBD	O
randomized	VBN	O
to	TO	O
receive	VB	O
either	DT	O
ofloxacin	NN	O
(	(	O
10	CD	O
mg/kg/day	NN	O
in	IN	O
two	CD	O
divided	JJ	O
doses	NNS	O
)	)	O
for	IN	O
5	CD	O
days	NNS	O
or	CC	O
cefixime	NN	O
(	(	O
20	CD	O
mg/kg/day	NN	O
in	IN	O
two	CD	O
divided	JJ	O
doses	NNS	O
)	)	O
for	IN	O
7	CD	O
days	NNS	O
.	.	O

RESULTS	NNP	O
S.	NNP	O
typhi	NN	O
was	VBD	O
isolated	VBN	O
from	IN	O
82	CD	SS
patients	NNS	O
(	(	O
44	CD	O
in	IN	O
the	DT	O
cefixime	NN	O
group	NN	O
,	,	O
38	CD	O
in	IN	O
the	DT	O
ofloxacin	JJ	O
group	NN	O
)	)	O
and	CC	O
70	CD	SS
(	(	O
85	CD	O
%	NN	O
)	)	O
of	IN	O
the	DT	O
isolates	NNS	O
were	VBD	O
multidrug-resistant	JJ	O
.	.	O

Median	JJ	O
(	(	O
95	CD	O
%	NN	O
confidence	NN	O
interval	NN	O
,	,	O
range	NN	O
)	)	O
fever	NN	O
clearance	NN	O
times	NNS	O
were	VBD	O
4.4	CD	O
(	(	O
4	CD	O
to	TO	O
5.2	CD	O
,	,	O
0.2	CD	O
to	TO	O
9.9	CD	O
)	)	O
days	NNS	O
for	IN	O
ofloxacin	JJ	O
recipients	NNS	O
and	CC	O
8.5	CD	O
(	(	O
4.2	CD	O
to	TO	O
9	CD	O
,	,	O
1.8	CD	O
to	TO	O
15.2	CD	O
)	)	O
days	NNS	O
for	IN	O
cefixime-treated	JJ	O
patients	NNS	O
(	(	O
P	NNP	O
<	NNP	O
0.0001	CD	O
)	)	O
.	.	O

There	EX	O
were	VBD	O
11	CD	O
treatment	NN	O
failures	NNS	O
(	(	O
10	CD	O
acute	NN	O
and	CC	O
one	CD	O
relapse	NN	O
)	)	O
in	IN	O
the	DT	O
cefixime	NN	O
group	NN	O
and	CC	O
1	CD	O
acute	NN	O
treatment	NN	O
failure	NN	O
in	IN	O
the	DT	O
ofloxacin	NN	O
group	NN	O
(	(	O
mean	JJ	O
difference	NN	O
,	,	O
22	CD	O
%	NN	O
;	:	O
95	CD	O
%	NN	O
confidence	NN	O
interval	NN	O
,	,	O
9	CD	O
to	TO	O
36	CD	O
%	NN	O
)	)	O
.	.	O

CONCLUSION	NNP	O
Short	NNP	O
course	NN	O
treatment	NN	O
with	IN	O
cefixime	NN	O
may	MD	O
provide	VB	O
a	DT	O
useful	JJ	O
alternative	JJ	O
treatment	NN	O
in	IN	O
cases	NNS	O
of	IN	O
uncomplicated	JJ	C
typhoid	NN	C
fever	NN	C
in	IN	O
children	NNS	A
,	,	O
but	CC	O
it	PRP	O
is	VBZ	O
less	RBR	O
effective	JJ	O
than	IN	O
short	JJ	O
course	NN	O
treatment	NN	O
with	IN	O
ofloxacin	NN	O
.	.	O

Quantitative	JJ	O
angiographic	JJ	O
methods	NNS	O
for	IN	O
appropriate	JJ	O
end-point	JJ	O
analysis	NN	O
,	,	O
edge-effect	JJ	O
evaluation	NN	O
,	,	O
and	CC	O
prediction	NN	O
of	IN	O
recurrent	NN	O
restenosis	NN	O
after	IN	O
coronary	JJ	O
brachytherapy	NN	O
with	IN	O
gamma	JJ	O
irradiation	NN	O
.	.	O

OBJECTIVES	CC	O
The	DT	O
study	NN	O
was	VBD	O
done	VBN	O
to	TO	O
investigate	VB	O
the	DT	O
relationship	NN	O
between	IN	O
clinical	JJ	O
restenosis	NN	O
and	CC	O
the	DT	O
relative	JJ	O
angiographic	JJ	O
location	NN	O
of	IN	O
the	DT	O
recurrent	NN	O
restenotic	JJ	O
lesion	NN	O
,	,	O
after	IN	O
treatment	NN	O
of	IN	O
in-stent	JJ	O
restenosis	NN	O
with	IN	O
vascular	JJ	O
brachytherapy	NN	O
in	IN	O
the	DT	O
Washington	NNP	O
Radiation	NNP	O
for	IN	O
In-Stent	NNP	O
Restenosis	NNP	O
Trial	NNP	O
(	(	O
WRIST	NNP	O
)	)	O
.	.	O

BACKGROUND	NNP	O
Intracoronary	NNP	O
radiation	NN	O
therapy	NN	O
reduces	VBZ	O
recurrence	NN	O
of	IN	O
in-stent	JJ	O
restenosis	NN	O
.	.	O

We	PRP	O
investigated	VBD	O
the	DT	O
above	JJ	O
objective	NN	O
in	IN	O
patients	NNS	O
enrolled	VBN	O
in	IN	O
WRIST	NNP	O
.	.	O

METHODS	NNP	O
The	DT	O
WRIST	NNP	O
study	NN	O
randomized	VBD	O
130	CD	O
patients	NNS	O
to	TO	O
double-blinded	JJ	O
therapy	NN	O
with	IN	O
gamma	JJ	O
irradiation	NN	O
(	(	O
iridium-192	JJ	O
[	NNP	O
(	(	O
192	CD	O
)	)	O
Ir	NNP	O
]	NNP	O
)	)	O
versus	NN	O
placebo	NN	O
after	IN	O
interventional	JJ	O
treatment	NN	O
of	IN	O
diffuse	NN	O
in-stent	JJ	O
restenosis	NN	O
.	.	O

After	IN	O
the	DT	O
intervention	NN	O
and	CC	O
at	IN	O
follow-up	NN	O
,	,	O
three	CD	O
vessel	NN	O
segments	NNS	O
were	VBD	O
individually	RB	O
analyzed	VBN	O
with	IN	O
quantitative	JJ	O
coronary	JJ	O
angiography	NN	O
:	:	O
1	CD	O
)	)	O
the	DT	O
stent	NN	O
,	,	O
2	CD	O
)	)	O
the	DT	O
radiation	NN	O
ribbon	NN	O
,	,	O
and	CC	O
3	CD	O
)	)	O
the	DT	O
ribbon+margin	NN	O
segment	NN	O
(	(	O
including	VBG	O
5	CD	O
mm	NN	O
on	IN	O
either	DT	O
end	NN	O
of	IN	O
the	DT	O
injured	JJ	O
or	CC	O
radiation-ribbon	JJ	O
segment	NN	O
)	)	O
.	.	O

Receiver	NNP	O
operator	NN	O
curves	NNS	O
(	(	O
ROC	NNP	O
)	)	O
were	VBD	O
used	VBN	O
to	TO	O
assess	VB	O
the	DT	O
value	NN	O
of	IN	O
the	DT	O
follow-up	JJ	O
percent	NN	O
diameter	NN	O
stenosis	NN	O
(	(	O
DS	NNP	O
)	)	O
for	IN	O
each	DT	O
of	IN	O
the	DT	O
three	CD	O
analyzed	VBD	O
segments	NNS	O
in	IN	O
predicting	VBG	O
target	NN	O
vessel	NN	O
revascularization	NN	O
(	(	O
TVR	NNP	O
)	)	O
.	.	O

RESULTS	NNP	O
(	(	O
192	CD	O
)	)	O
Ir	NNP	O
reduced	VBD	O
recurrent	JJ	O
restenosis	NN	O
(	(	O
23.7	CD	O
%	NN	O
vs.	FW	O
60.7	CD	O
%	NN	O
,	,	O
p	NN	O
<	NNP	O
0.001	CD	O
)	)	O
and	CC	O
the	DT	O
length	NN	O
of	IN	O
recurrent	JJ	O
restenosis	NN	O
(	(	O
8.99	CD	O
+/-	JJ	O
4.34	CD	O
mm	NN	O
vs.	FW	O
17.54	CD	O
+/-	JJ	O
10.48	CD	O
mm	NN	O
,	,	O
p	NN	O
<	NNP	O
0.001	CD	O
)	)	O
at	IN	O
follow-up	JJ	O
compared	VBN	O
to	TO	O
placebo	VB	O
.	.	O

Isolated	NNP	O
stent	NN	O
edge	NN	O
(	(	O
3.4	CD	O
%	NN	O
)	)	O
and	CC	O
ribbon	NN	O
edge	NN	O
(	(	O
1.7	CD	O
%	NN	O
)	)	O
restenoses	VBZ	O
were	VBD	O
infrequent	NN	O
in	IN	O
both	DT	O
groups	NNS	O
.	.	O

The	DT	O
best	JJS	O
angiographic	JJ	O
surrogate	NN	O
of	IN	O
TVR	NNP	O
was	VBD	O
the	DT	O
50	CD	O
%	NN	O
follow-up	JJ	O
DS	NNP	O
obtained	VBD	O
from	IN	O
the	DT	O
ribbon+margin	NN	O
analysis	NN	O
(	(	O
ROC	NNP	O
area	NN	O
0.806	CD	O
)	)	O
.	.	O

CONCLUSIONS	NNP	O
In	IN	O
WRIST	NNP	O
,	,	O
not	RB	O
only	RB	O
was	VBD	O
(	(	O
192	CD	O
)	)	O
Ir	NNP	O
therapy	NN	O
effective	JJ	O
in	IN	O
reducing	VBG	O
restenosis	NN	O
,	,	O
but	CC	O
it	PRP	O
also	RB	O
reduced	VBD	O
the	DT	O
lesion	NN	O
length	NN	O
of	IN	O
treatment	NN	O
failures	NNS	O
by	IN	O
50	CD	O
%	NN	O
,	,	O
and	CC	O
it	PRP	O
was	VBD	O
not	RB	O
associated	VBN	O
with	IN	O
edge	NN	O
proliferation	NN	O
.	.	O

The	DT	O
restenosis	NN	O
rate	NN	O
obtained	VBN	O
from	IN	O
the	DT	O
vessel	NN	O
segment	NN	O
inclusive	NN	O
of	IN	O
the	DT	O
dose	JJ	O
fall-off	JJ	O
zones	NNS	O
was	VBD	O
the	DT	O
best	JJS	O
correlate	NN	O
of	IN	O
TVR	NNP	O
and	CC	O
should	MD	O
become	VB	O
a	DT	O
standard	JJ	O
analysis	NN	O
site	NN	O
in	IN	O
all	DT	O
vascular	JJ	O
brachytherapy	NN	O
trials	NNS	O
.	.	O

[	JJ	O
Carbohydrate	NNP	O
substitutes	NNS	O
:	:	O
comparative	JJ	O
study	NN	O
of	IN	O
intestinal	JJ	O
absorption	NN	O
of	IN	O
fructose	NN	O
,	,	O
sorbitol	NN	O
and	CC	O
xylitol	NNP	O
]	NNP	O
.	.	O

BACKGROUND	NNP	O
The	DT	O
carbohydrate	NN	O
substitutes	NNS	O
fructose	VBP	O
,	,	O
sorbitol	JJ	O
and	CC	O
xylitol	NNS	O
are	VBP	O
gaining	VBG	O
more	JJR	O
and	CC	O
more	JJR	O
importance	NN	O
in	IN	O
the	DT	O
production	NN	O
of	IN	O
dietary	JJ	O
food	NN	O
.	.	O

But	CC	O
they	PRP	O
can	MD	O
provoke	VB	O
gastrointestinal	JJ	O
side-effects	NNS	O
.	.	O

In	IN	O
a	DT	O
randomized	JJ	O
double	JJ	O
blind	NN	O
study	VBD	O
the	DT	O
rate	NN	O
of	IN	O
malabsorption	NN	O
of	IN	O
these	DT	O
sugars	NNS	O
was	VBD	O
compared	VBN	O
and	CC	O
the	DT	O
concomitant	NN	O
symptoms	NNS	O
were	VBD	O
recorded	VBN	O
.	.	O

SUBJECTS	NNP	O
AND	NNP	O
METHODS	NNP	O
25	CD	SS
healthy	JJ	O
controls	NNS	O
received	VBD	O
25	CD	O
g	NN	O
of	IN	O
each	DT	O
sugar	NN	O
within	IN	O
3	CD	O
consecutive	JJ	O
days	NNS	O
.	.	O

The	DT	O
intestinal	JJ	O
absorption	NN	O
was	VBD	O
determined	VBN	O
by	IN	O
H2-exhalation	NNP	O
tests	NNS	O
and	CC	O
the	DT	O
clinical	JJ	O
symptoms	NNS	O
were	VBD	O
recorded	VBN	O
.	.	O

RESULTS	VB	O
The	DT	O
rate	NN	O
of	IN	O
malabsorption	NN	O
was	VBD	O
84	CD	O
%	NN	O
for	IN	O
sorbitol	NN	O
,	,	O
36	CD	O
%	NN	O
for	IN	O
fructose	JJ	O
and	CC	O
12	CD	O
%	NN	O
for	IN	O
xylitol	NNP	O
(	(	O
p	JJ	O
<	VBP	O
0.01	CD	O
for	IN	O
sorbitol	NN	O
versus	NN	O
fructose	NN	O
and	CC	O
xylitol	NN	O
)	)	O
.	.	O

57	CD	O
%	NN	O
of	IN	O
the	DT	O
participants	NNS	O
with	IN	O
pathological	JJ	O
H2-test	NNP	O
after	IN	O
sorbitol	NN	O
and	CC	O
56	CD	O
%	NN	O
after	IN	O
fructose	JJ	O
reported	VBD	O
symptoms	NNS	O
,	,	O
while	IN	O
all	DT	O
of	IN	O
the	DT	O
3	CD	O
malabsorbers	NNS	O
of	IN	O
xylitol	NN	O
were	VBD	O
symptomatic	JJ	O
.	.	O

CONCLUSIONS	NNP	O
There	EX	O
is	VBZ	O
an	DT	O
advantage	NN	O
to	TO	O
administering	VBG	O
xylitol	NN	O
and	CC	O
fructose	JJ	O
with	IN	O
regard	NN	O
to	TO	O
the	DT	O
intestinal	JJ	O
absorption	NN	O
and	CC	O
concomitant	NN	O
symptoms	NNS	O
as	IN	O
compared	VBN	O
with	IN	O
sorbitol	NN	O
.	.	O

H2-exhalation	NN	O
tests	NNS	O
appear	VBP	O
to	TO	O
be	VB	O
a	DT	O
reliable	JJ	O
diagnostic	JJ	O
tool	NN	O
to	TO	O
detect	VB	O
carbohydrate	JJ	O
malabsorption	NN	O
and	CC	O
should	MD	O
find	VB	O
broader	JJR	O
application	NN	O
in	IN	O
patients	NNS	O
suffering	VBG	O
from	IN	O
non-specific	JJ	O
abdominal	JJ	O
complaints	NNS	O
.	.	O

Dietary	NNP	O
patterns	NNS	O
differ	VBP	O
between	IN	O
urban	JJ	O
and	CC	O
rural	JJ	O
older	JJR	O
,	,	O
long-term	JJ	C
survivors	NNS	C
of	IN	C
breast	NN	C
,	,	C
prostate	NN	C
,	,	C
and	CC	C
colorectal	JJ	C
cancer	NN	C
and	CC	O
are	VBP	O
associated	VBN	O
with	IN	O
body	NN	O
mass	NN	O
index	NN	O
.	.	O

BACKGROUND	NNP	O
Older	NNP	O
adult	NN	O
cancer	NN	O
survivors	NNS	O
are	VBP	O
at	IN	O
greater	JJR	O
risk	NN	O
of	IN	O
cancer	NN	O
recurrence	NN	O
and	CC	O
other	JJ	O
comorbidities	NNS	O
that	WDT	O
can	MD	O
be	VB	O
prevented	VBN	O
through	IN	O
improved	VBN	O
diet	JJ	O
and	CC	O
weight	JJ	O
management	NN	O
.	.	O

The	DT	O
tertiary	JJ	O
prevention	NN	O
needs	NNS	O
of	IN	O
rural-dwelling	JJ	O
survivors	NNS	O
can	MD	O
be	VB	O
even	RB	O
greater	JJR	O
,	,	O
yet	RB	O
little	JJ	O
is	VBZ	O
known	VBN	O
about	IN	O
rural	JJ	O
and	CC	O
urban	JJ	O
differences	NNS	O
in	IN	O
lifestyle	JJ	O
factors	NNS	O
among	IN	O
this	DT	O
high-risk	JJ	O
population	NN	O
.	.	O

OBJECTIVES	NNP	O
To	TO	O
compare	VB	O
dietary	JJ	O
patterns	NNS	O
of	IN	O
urban	JJ	O
and	CC	O
rural	JJ	O
cancer	NN	O
survivors	NNS	O
and	CC	O
to	TO	O
examine	VB	O
associations	NNS	O
of	IN	O
dietary	JJ	O
patterns	NNS	O
with	IN	O
body	NN	O
mass	NN	O
index	NN	O
(	(	O
BMI	NNP	O
)	)	O
.	.	O

DESIGN	VB	O
A	DT	O
secondary	JJ	O
analysis	NN	O
was	VBD	O
performed	VBN	O
of	IN	O
baseline	NN	O
data	NNS	O
from	IN	O
the	DT	O
Reach	NNP	O
Out	NNP	O
to	TO	O
Enhance	VB	O
Wellness	NNP	O
(	(	O
RENEW	NNP	O
)	)	O
trial	NN	O
,	,	O
a	DT	O
diet	JJ	O
and	CC	O
exercise	JJ	O
intervention	NN	O
among	IN	O
overweight	JJ	O
,	,	O
long-term	JJ	O
(	(	O
?5	CD	O
years	NNS	O
)	)	O
,	,	O
older	JJR	O
survivors	NNS	O
of	IN	O
colorectal	NN	O
,	,	O
breast	NN	O
,	,	O
and	CC	O
prostate	NN	O
cancer	NN	O
.	.	O

Survivors	NNS	O
in	IN	O
the	DT	O
present	JJ	O
analysis	NN	O
(	(	O
n=729	JJ	O
)	)	O
underwent	JJ	O
two	CD	O
45-	JJ	O
to	TO	O
60-minute	JJ	O
telephone	NN	O
surveys	NNS	O
,	,	O
which	WDT	O
included	VBD	O
two	CD	O
24-hour	JJ	O
dietary	JJ	O
recalls	NNS	O
.	.	O

Principal	JJ	O
components	NNS	O
analysis	NN	O
and	CC	O
multivariable	JJ	O
general	JJ	O
linear	JJ	O
models	NNS	O
were	VBD	O
used	VBN	O
to	TO	O
derive	VB	O
dietary	JJ	O
patterns	NNS	O
and	CC	O
to	TO	O
evaluate	VB	O
associations	NNS	O
between	IN	O
dietary	JJ	O
patterns	NNS	O
and	CC	O
BMI	NNP	O
,	,	O
respectively	RB	O
.	.	O

RESULTS	VB	O
Principal	JJ	O
components	NNS	O
analysis	NN	O
identified	VBD	O
three	CD	O
primary	JJ	O
dietary	JJ	O
patterns	NNS	O
among	IN	O
rural	JJ	O
dwellers	NNS	O
(	(	O
high	JJ	O
sweets	NNS	O
and	CC	O
starches	NNS	O
,	,	O
high	JJ	O
reduced-fat	NN	O
dairy	NN	O
,	,	O
cereal	NN	O
,	,	O
nuts	NNS	O
,	,	O
and	CC	O
fruits	NNS	O
,	,	O
and	CC	O
mixed	JJ	O
)	)	O
and	CC	O
three	CD	O
among	IN	O
urban	JJ	O
dwellers	NNS	O
(	(	O
high	JJ	O
fruits	NNS	O
and	CC	O
vegetables	NNS	O
,	,	O
high	JJ	O
meat	NN	O
and	CC	O
refined	VBD	O
grains	NNS	O
,	,	O
and	CC	O
high	JJ	O
sugar-sweetened	JJ	O
beverages	NNS	O
)	)	O
.	.	O

Among	IN	O
rural	JJ	O
survivors	NNS	O
,	,	O
greater	JJR	O
adherence	NN	O
to	TO	O
the	DT	O
high	JJ	O
reduced-fat	NN	O
dairy	NN	O
,	,	O
cereal	NN	O
,	,	O
nuts	NNS	O
,	,	O
and	CC	O
fruits	NNS	O
pattern	NN	O
was	VBD	O
positively	RB	O
associated	VBN	O
with	IN	O
lower	JJR	O
BMI	NNP	O
(	(	O
P	NNP	O
trend	NN	O
<	NNP	O
0.05	CD	O
)	)	O
,	,	O
whereas	IN	O
higher	JJR	O
scores	NNS	O
on	IN	O
the	DT	O
mixed	JJ	O
pattern	NN	O
was	VBD	O
associated	VBN	O
with	IN	O
greater	JJR	O
BMI	NNP	O
(	(	O
P	NNP	O
trend	NN	O
<	NNP	O
0.05	CD	O
)	)	O
.	.	O

Greater	NNP	O
adherence	NN	O
to	TO	O
the	DT	O
high	JJ	O
fruits	NNS	O
and	CC	O
vegetables	NNS	O
pattern	VBP	O
among	IN	O
urban	JJ	O
survivors	NNS	O
was	VBD	O
inversely	RB	O
associated	VBN	O
with	IN	O
BMI	NNP	O
(	(	O
P	NNP	O
trend	NN	O
<	NNP	O
0.05	CD	O
)	)	O
.	.	O

CONCLUSIONS	NNP	O
Urban	NNP	O
and	CC	O
rural	JJ	O
differences	NNS	O
in	IN	O
dietary	JJ	O
intake	NN	O
behavior	NN	O
should	MD	O
be	VB	O
considered	VBN	O
in	IN	O
designing	VBG	O
public	JJ	O
health	NN	O
interventions	NNS	O
among	IN	O
the	DT	O
increasing	VBG	O
population	NN	O
of	IN	O
older	JJR	O
cancer	NN	O
survivors	NNS	O
.	.	O

In	IN	O
addition	NN	O
,	,	O
targeting	VBG	O
overall	JJ	O
dietary	JJ	O
patterns	NNS	O
might	MD	O
be	VB	O
one	CD	O
approach	NN	O
to	TO	O
help	VB	O
reduce	VB	O
the	DT	O
burden	NN	O
of	IN	O
obesity	NN	O
among	IN	O
this	DT	O
population	NN	O
.	.	O

Cardiovascular	JJ	O
effects	NNS	O
of	IN	O
tamoxifen	NN	O
in	IN	O
women	NNS	O
with	IN	O
and	CC	O
without	IN	O
heart	NN	O
disease	NN	O
:	:	O
breast	NN	O
cancer	NN	O
prevention	NN	O
trial	NN	O
.	.	O

National	NNP	O
Surgical	NNP	O
Adjuvant	NNP	O
Breast	NNP	O
and	CC	O
Bowel	NNP	O
Project	NNP	O
Breast	NNP	O
Cancer	NNP	O
Prevention	NNP	O
Trial	NNP	O
Investigators	NNP	O
.	.	O

BACKGROUND	NNP	O
The	DT	O
overall	JJ	O
effect	NN	O
of	IN	O
prophylactic	JJ	O
tamoxifen	NN	O
in	IN	O
women	NNS	O
depends	NNS	O
on	IN	O
the	DT	O
balance	NN	O
between	IN	O
the	DT	O
effects	NNS	O
of	IN	O
the	DT	O
drug	NN	O
,	,	O
which	WDT	O
include	VBP	O
preventing	VBG	O
breast	NN	O
cancer	NN	O
and	CC	O
altering	VBG	O
cardiovascular	JJ	O
risk	NN	O
.	.	O

In	IN	O
a	DT	O
recent	JJ	O
clinical	JJ	O
trial	NN	O
,	,	O
postmenopausal	JJ	O
estrogen-progestin	JJ	O
therapy	NN	O
was	VBD	O
shown	VBN	O
to	TO	O
increase	VB	O
the	DT	O
risk	NN	O
of	IN	O
early	JJ	O
cardiovascular	JJ	O
events	NNS	O
among	IN	O
women	NNS	O
with	IN	O
a	DT	O
history	NN	O
of	IN	O
coronary	JJ	O
heart	NN	O
disease	NN	O
(	(	O
CHD	NNP	O
)	)	O
.	.	O

The	DT	O
cardiovascular	JJ	O
effects	NNS	O
of	IN	O
tamoxifen	NN	O
in	IN	O
women	NNS	O
with	IN	O
and	CC	O
without	IN	O
CHD	NNP	O
are	VBP	O
not	RB	O
known	VBN	O
.	.	O

The	DT	O
National	NNP	O
Surgical	NNP	O
Adjuvant	NNP	O
Breast	NNP	O
and	CC	O
Bowel	NNP	O
Project	NNP	O
Breast	NNP	O
Cancer	NNP	O
Prevention	NNP	O
Trial	NNP	O
(	(	O
BCPT	NNP	O
)	)	O
is	VBZ	O
the	DT	O
only	JJ	O
clinical	JJ	O
trial	NN	O
that	WDT	O
provides	VBZ	O
data	NNS	O
to	TO	O
assess	VB	O
the	DT	O
cardiovascular	JJ	O
effects	NNS	O
of	IN	O
tamoxifen	NN	O
in	IN	O
women	NNS	O
with	IN	O
and	CC	O
without	IN	O
CHD	NNP	O
.	.	O

METHODS	NNP	O
A	NNP	O
total	NN	O
of	IN	O
13	CD	O
388	CD	O
women	NNS	O
at	IN	O
increased	VBN	O
risk	NN	O
for	IN	O
breast	NN	O
cancer	NN	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
in	IN	O
the	DT	O
BCPT	NNP	O
to	TO	O
receive	VB	O
either	DT	O
tamoxifen	NN	O
(	(	O
20	CD	O
mg/day	NN	O
)	)	O
or	CC	O
placebo	NN	O
.	.	O

Cardiovascular	JJ	O
follow-up	NN	O
was	VBD	O
available	JJ	O
for	IN	O
13	CD	O
194	CD	O
women	NNS	O
,	,	O
1048	CD	O
of	IN	O
whom	WP	O
had	VBD	O
prior	RB	O
clinical	JJ	O
CHD	NNP	O
.	.	O

Fatal	NNP	O
and	CC	O
nonfatal	JJ	O
myocardial	JJ	O
infarction	NN	O
,	,	O
unstable	JJ	O
angina	NN	O
,	,	O
and	CC	O
severe	JJ	O
angina	NN	O
were	VBD	O
tabulated	VBN	O
(	(	O
mean	JJ	O
follow-up	NN	O
:	:	O
49	CD	O
months	NNS	O
)	)	O
.	.	O

All	DT	O
statistical	JJ	O
tests	NNS	O
were	VBD	O
two-sided	JJ	O
.	.	O

RESULTS	NNP	O
Cardiovascular	JJ	O
event	NN	O
rates	NNS	O
were	VBD	O
not	RB	O
statistically	RB	O
significantly	RB	O
different	JJ	O
between	IN	O
women	NNS	O
assigned	VBN	O
to	TO	O
receive	VB	O
tamoxifen	NN	O
and	CC	O
those	DT	O
assigned	VBN	O
to	TO	O
receive	VB	O
placebo	NN	O
,	,	O
independent	JJ	O
of	IN	O
pre-existing	JJ	O
CHD	NNP	O
.	.	O

Among	IN	O
women	NNS	O
without	IN	O
CHD	NNP	O
(	(	O
6074	CD	O
on	IN	O
tamoxifen	NN	O
versus	NN	O
6072	CD	O
on	IN	O
placebo	NN	O
)	)	O
,	,	O
risk	JJ	O
ratios	NNS	O
(	(	O
95	CD	O
%	NN	O
confidence	NN	O
intervals	NNS	O
[	VBP	O
CIs	NNP	O
]	NNP	O
)	)	O
for	IN	O
tamoxifen	NN	O
users	NNS	O
were	VBD	O
1.75	CD	O
(	(	O
0.44	CD	O
to	TO	O
8.13	CD	O
)	)	O
for	IN	O
fatal	JJ	O
myocardial	JJ	O
infarction	NN	O
,	,	O
1.11	CD	O
(	(	O
0.55	CD	O
to	TO	O
2.28	CD	O
)	)	O
for	IN	O
nonfatal	JJ	O
myocardial	JJ	O
infarction	NN	O
,	,	O
0.69	CD	O
(	(	O
0.29	CD	O
to	TO	O
1.57	CD	O
)	)	O
for	IN	O
unstable	JJ	O
angina	NN	O
,	,	O
and	CC	O
0.83	CD	O
(	(	O
0.32	CD	O
to	TO	O
2.10	CD	O
)	)	O
for	IN	O
severe	JJ	O
angina	NN	O
.	.	O

In	IN	O
women	NNS	O
with	IN	O
CHD	NNP	O
(	(	O
516	CD	O
on	IN	O
tamoxifen	NNS	O
versus	$	O
532	CD	O
on	IN	O
placebo	NN	O
)	)	O
,	,	O
risk	JJ	O
ratios	NNS	O
(	(	O
95	CD	O
%	NN	O
CIs	NNP	O
)	)	O
for	IN	O
tamoxifen	NN	O
users	NNS	O
were	VBD	O
0.00	CD	O
(	(	O
0	CD	O
to	TO	O
1.58	CD	O
)	)	O
for	IN	O
fatal	JJ	O
myocardial	JJ	O
infarction	NN	O
,	,	O
1.25	CD	O
(	(	O
0.32	CD	O
to	TO	O
5.18	CD	O
)	)	O
for	IN	O
nonfatal	JJ	O
myocardial	JJ	O
infarction	NN	O
,	,	O
2.26	CD	O
(	(	O
0.87	CD	O
to	TO	O
6.55	CD	O
)	)	O
for	IN	O
unstable	JJ	O
angina	NN	O
,	,	O
and	CC	O
1.39	CD	O
(	(	O
0.23	CD	O
to	TO	O
9.47	CD	O
)	)	O
for	IN	O
severe	JJ	O
angina	NN	O
.	.	O

There	EX	O
was	VBD	O
no	DT	O
evidence	NN	O
that	IN	O
the	DT	O
lack	NN	O
of	IN	O
association	NN	O
between	IN	O
tamoxifen	NN	O
and	CC	O
cardiovascular	JJ	O
events	NNS	O
was	VBD	O
related	VBN	O
to	TO	O
an	DT	O
early	JJ	O
increase	NN	O
in	IN	O
risk	NN	O
that	WDT	O
may	MD	O
have	VB	O
been	VBN	O
offset	VBN	O
by	IN	O
a	DT	O
late	JJ	O
decrease	NN	O
in	IN	O
risk	NN	O
.	.	O

CONCLUSION	NN	O
When	WRB	O
used	VBN	O
for	IN	O
breast	NN	O
cancer	NN	O
prevention	NN	O
in	IN	O
women	NNS	O
with	IN	O
or	CC	O
without	IN	O
heart	NN	O
disease	NN	O
,	,	O
tamoxifen	NN	O
is	VBZ	O
not	RB	O
associated	VBN	O
with	IN	O
beneficial	JJ	O
or	CC	O
adverse	JJ	O
cardiovascular	JJ	O
effects	NNS	O
.	.	O

Low-dose	JJ	O
,	,	O
vaginally	RB	O
administered	VBN	O
estrogens	NNS	O
may	MD	O
enhance	VB	O
local	JJ	O
benefits	NNS	O
of	IN	O
systemic	JJ	O
therapy	NN	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
urogenital	JJ	C
atrophy	NN	C
in	IN	O
postmenopausal	JJ	C
women	NNS	SS
on	IN	C
hormone	NN	C
therapy	NN	C
.	.	O

BACKGROUND	NNP	O
When	WRB	O
genital	JJ	O
atrophy	NN	O
exists	NNS	O
,	,	O
systemic	JJ	O
hormone	NN	O
therapy	NN	O
(	(	O
HT	NNP	O
)	)	O
has	VBZ	O
a	DT	O
timing	NN	O
until	IN	O
to	TO	O
induce	VB	O
vaginal	JJ	O
proliferation	NN	O
and	CC	O
symptomatic	JJ	O
relieve	NN	O
.	.	O

Thus	RB	O
,	,	O
in	IN	O
order	NN	O
to	TO	O
obtain	VB	O
a	DT	O
prompt	JJ	O
improvement	NN	O
,	,	O
the	DT	O
association	NN	O
of	IN	O
local	JJ	O
therapy	NN	O
acting	VBG	O
on	IN	O
the	DT	O
genital	JJ	O
epithelium	NN	O
to	TO	O
the	DT	O
systemic	JJ	O
treatment	NN	O
should	MD	O
be	VB	O
considered	VBN	O
.	.	O

OBJECTIVE	UH	O
To	TO	O
evaluate	VB	O
the	DT	O
effects	NNS	O
of	IN	O
a	DT	O
combined	JJ	O
therapy	NN	O
consisting	NN	O
of	IN	O
vaginal	JJ	O
estriol	NN	O
with	IN	O
transdermal	JJ	O
17-beta-estradiol	JJ	O
(	(	O
50	CD	O
microg/day	NN	O
)	)	O
plus	CC	O
medroxyprogesterone	JJ	O
acetate	NN	O
(	(	O
5	CD	O
mg/day	NN	O
)	)	O
per	IN	O
os	NN	O
in	IN	O
shortening	VBG	O
the	DT	O
period	NN	O
of	IN	O
uro-genital	JJ	O
symptoms	NNS	O
.	.	O

SUBJECTS	NNP	O
AND	NNP	O
METHODS	NNP	O
In	IN	O
a	DT	O
randomized	JJ	O
,	,	O
double	JJ	O
blind	NN	O
,	,	O
controlled	VBN	O
with	IN	O
placebo	NN	O
study	NN	O
,	,	O
27	CD	SS
women	NNS	SS
with	IN	O
climacteric	JJ	C
symptoms	NNS	C
and	CC	O
atrophic	JJ	C
vaginitis	NN	C
were	VBD	O
treated	VBN	O
for	IN	O
4	CD	O
months	NNS	O
with	IN	O
HT	NNP	O
plus	CC	O
vaginal	JJ	O
estriol	NN	O
0.5	CD	O
mg/day	NN	O
(	(	O
group	NN	O
E	NNP	O
)	)	O
or	CC	O
placebo	NN	O
(	(	O
group	NN	O
P	NNP	O
)	)	O
.	.	O

Patients	NNS	O
use	VBP	O
the	DT	O
local	JJ	O
medication	NN	O
daily	RB	O
for	IN	O
the	DT	O
first	JJ	O
3	CD	O
weeks	NNS	O
and	CC	O
twice-weekly	JJ	O
thereafter	NN	O
.	.	O

Before	IN	O
entering	VBG	O
in	IN	O
the	DT	O
study	NN	O
,	,	O
patients	NNS	O
were	VBD	O
asked	VBN	O
about	IN	O
HT	NNP	O
and	CC	O
selected	VBN	O
for	IN	O
inclusion	NN	O
.	.	O

In	IN	O
the	DT	O
first	JJ	O
visit	NN	O
,	,	O
electible	JJ	O
patients	NNS	O
after	IN	O
written	VBN	O
informed	JJ	O
consent	NN	O
were	VBD	O
randomized	VBN	O
to	TO	O
receive	VB	O
HT	NNP	O
plus	CC	O
local	JJ	O
estriol	NN	O
or	CC	O
placebo	NN	O
.	.	O

All	PDT	O
the	DT	O
subjects	NNS	O
had	VBD	O
baseline	NN	O
studies	NNS	O
,	,	O
including	VBG	O
medical	JJ	O
history	NN	O
,	,	O
physical	JJ	O
examination	NN	O
,	,	O
blood	NN	O
and	CC	O
urine	JJ	O
analysis	NN	O
.	.	O

In	IN	O
order	NN	O
to	TO	O
evaluate	VB	O
the	DT	O
effect	NN	O
of	IN	O
local	JJ	O
treatment	NN	O
on	IN	O
urinary	JJ	O
and	CC	O
genital	JJ	O
symptoms	NNS	O
,	,	O
a	DT	O
score	NN	O
for	IN	O
genital	NN	O
,	,	O
urinary	JJ	O
and	CC	O
colposcopic	JJ	O
complaints	NNS	O
(	(	O
0	CD	O
minimum-100	JJ	O
maximum	NN	O
)	)	O
was	VBD	O
developed	VBN	O
.	.	O

This	DT	O
score	NN	O
and	CC	O
Blatt-Kuperman	NNP	O
were	VBD	O
recorded	VBN	O
and	CC	O
performed	VBN	O
in	IN	O
every	DT	O
control	NN	O
.	.	O

RESULTS	CC	O
There	EX	O
were	VBD	O
no	DT	O
differences	NNS	O
on	IN	O
climacteric	NN	O
symptoms	NNS	O
relief	NN	O
between	IN	O
the	DT	O
two	CD	O
groups	NNS	O
.	.	O

Additionally	RB	O
,	,	O
the	DT	O
improvement	NN	O
in	IN	O
urinary	JJ	O
symptoms	NNS	O
at	IN	O
the	DT	O
end	NN	O
of	IN	O
the	DT	O
study	NN	O
was	VBD	O
similar	JJ	O
for	IN	O
both	DT	O
groups	NNS	O
(	(	O
from	IN	O
16.5	CD	O
+/-	JJ	O
6.1	CD	O
to	TO	O
8.5	CD	O
+/-	JJ	O
2.4	CD	O
for	IN	O
E	NNP	O
group	NN	O
and	CC	O
from	IN	O
15.8	CD	O
+/-	JJ	O
7.8	CD	O
to	TO	O
8.8	CD	O
+/-	JJ	O
2.7	CD	O
for	IN	O
P	NNP	O
group	NN	O
;	:	O
P	NNP	O
<	VBD	O
0.01	CD	O
versus	NN	O
basal	NN	O
)	)	O
;	:	O
however	RB	O
,	,	O
those	DT	O
women	NNS	O
in	IN	O
group	NN	O
E	NNP	O
reached	VBD	O
significant	JJ	O
improvement	NN	O
on	IN	O
urinary	JJ	O
complaints	NNS	O
since	IN	O
the	DT	O
first	JJ	O
month	NN	O
of	IN	O
treatment	NN	O
.	.	O

Additionally	RB	O
,	,	O
a	DT	O
significant	JJ	O
difference	NN	O
between	IN	O
E	NNP	O
and	CC	O
P	NNP	O
was	VBD	O
observed	VBN	O
at	IN	O
months	NNS	O
2	CD	O
and	CC	O
3	CD	O
,	,	O
although	IN	O
no	DT	O
differences	NNS	O
were	VBD	O
detected	VBN	O
at	IN	O
the	DT	O
end	NN	O
of	IN	O
the	DT	O
study	NN	O
.	.	O

Papanicolaou	NNP	O
smear	JJ	O
showed	VBD	O
reactive	JJ	O
or	CC	O
reparative	JJ	O
changes	NNS	O
and	CC	O
karyopyknotic	JJ	O
index	NN	O
exhibited	VBD	O
a	DT	O
significant	JJ	O
increase	NN	O
in	IN	O
superficial	JJ	O
cells	NNS	O
in	IN	O
both	DT	O
groups	NNS	O
and	CC	O
at	IN	O
the	DT	O
end	NN	O
of	IN	O
the	DT	O
study	NN	O
.	.	O

CONCLUSIONS	NNP	O
Adding	NNP	O
vaginal	JJ	O
estriol	NN	O
to	TO	O
HRT	NNP	O
may	MD	O
shorten	VB	O
the	DT	O
latency	NN	O
period	NN	O
for	IN	O
urinary	JJ	O
symptoms	NNS	O
.	.	O

Blind	NNP	O
versus	NN	O
open	JJ	O
approach	NN	O
to	TO	O
laparoscopic	VB	O
cholecystectomy	NN	O
:	:	O
a	DT	O
randomized	JJ	O
study	NN	O
.	.	O

Intraabdominal	NNP	O
structures	NNS	O
may	MD	O
be	VB	O
damaged	VBN	O
during	IN	O
blind	JJ	O
introduction	NN	O
of	IN	O
the	DT	O
first	JJ	O
trocar	NN	O
for	IN	O
laparoscopic	JJ	O
operations	NNS	O
.	.	O

In	IN	O
this	DT	O
study	NN	O
,	,	O
150	CD	SS
patients	NNS	O
with	IN	O
gallbladder	JJ	C
lithiasis	NN	C
who	WP	O
underwent	JJ	O
laparoscopy	NN	C
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
two	CD	O
groups	NNS	O
,	,	O
a	DT	O
blind	NN	O
(	(	O
V	NNP	O
group	NN	O
)	)	O
or	CC	O
an	DT	O
open	JJ	O
(	(	O
H	NNP	O
group	NN	O
)	)	O
,	,	O
in	IN	O
order	NN	O
to	TO	O
compare	VB	O
the	DT	O
results	NNS	O
and	CC	O
the	DT	O
rate	NN	O
of	IN	O
complications	NNS	O
.	.	O

No	DT	O
mortality	NN	O
was	VBD	O
observed	VBN	O
.	.	O

Major	JJ	O
complications	NNS	O
occurred	VBD	O
in	IN	O
3/75	CD	O
(	(	O
4	CD	O
%	NN	O
)	)	O
patients	NNS	O
of	IN	O
the	DT	O
V	NNP	O
group	NN	O
and	CC	O
in	IN	O
1/75	CD	O
(	(	O
1.3	CD	O
%	NN	O
)	)	O
patient	NN	O
of	IN	O
the	DT	O
H	NNP	O
group	NN	O
(	(	O
p	JJ	O
<	NNP	O
0.05	CD	O
)	)	O
.	.	O

Minor	JJ	O
complications	NNS	O
occurred	VBD	O
in	IN	O
5/75	CD	O
(	(	O
6.7	CD	O
%	NN	O
)	)	O
patients	NNS	O
of	IN	O
either	DT	O
group	NN	O
.	.	O

The	DT	O
achievement	NN	O
of	IN	O
pneumoperitoneum	NN	O
required	VBN	O
4.5+/-0.4	JJ	O
min	NN	O
in	IN	O
the	DT	O
V	NNP	O
group	NN	O
and	CC	O
3.2+/-0.2	JJ	O
min	NN	O
in	IN	O
the	DT	O
H	NNP	O
group	NN	O
(	(	O
p	JJ	O
<	NNP	O
0.05	CD	O
)	)	O
.	.	O

The	DT	O
open	JJ	O
laparoscopic	NN	O
technique	NN	O
is	VBZ	O
safer	JJR	O
and	CC	O
faster	RBR	O
than	IN	O
the	DT	O
blind	JJ	O
approach	NN	O
;	:	O
therefore	RB	O
,	,	O
it	PRP	O
is	VBZ	O
proposed	VBN	O
that	IN	O
this	DT	O
approach	NN	O
be	VB	O
routinely	RB	O
used	VBN	O
in	IN	O
all	DT	O
laparoscopic	NN	O
procedures	NNS	O
.	.	O

Control	NN	O
of	IN	O
perioperative	JJ	O
hypertension	NN	O
during	IN	O
coronary	JJ	O
artery	NN	O
surgery	NN	O
.	.	O

A	DT	O
randomised	JJ	O
double-blind	NN	O
study	NN	O
comparing	VBG	O
isosorbide	JJ	O
dinitrate	NN	O
and	CC	O
nitroglycerin	NN	O
.	.	O

A	DT	O
reduction	NN	O
in	IN	O
the	DT	O
causes	NNS	O
of	IN	O
myocardial	JJ	O
ischaemia	NN	O
remains	VBZ	O
of	IN	O
prime	JJ	O
importance	NN	O
during	IN	O
coronary	JJ	O
artery	NN	O
surgery	NN	O
.	.	O

Hypertension	NN	O
with	IN	O
the	DT	O
ensuing	VBG	O
increase	NN	O
in	IN	O
myocardial	JJ	O
oxygen	NN	O
demand	NN	O
is	VBZ	O
a	DT	O
major	JJ	O
factor	NN	O
in	IN	O
the	DT	O
aetiology	NN	O
of	IN	O
perioperative	JJ	O
myocardial	JJ	O
ischaemia	NN	O
.	.	O

Nitroglycerin	NNP	O
(	(	O
NTG	NNP	O
)	)	O
has	VBZ	O
long	RB	O
been	VBN	O
used	VBN	O
beneficially	RB	O
to	TO	O
reduce	VB	O
myocardial	JJ	O
oxygen	NN	O
demand	NN	O
by	IN	O
its	PRP$	O
effects	NNS	O
on	IN	O
the	DT	O
systemic	JJ	O
and	CC	O
peripheral	JJ	O
vascular	JJ	O
resistances	NNS	O
.	.	O

An	DT	O
alternative	JJ	O
nitrate	NN	O
,	,	O
isosorbide	JJ	O
dinitrate	NN	O
(	(	O
ISDN	NNP	O
)	)	O
is	VBZ	O
now	RB	O
available	JJ	O
as	IN	O
an	DT	O
intravenous	JJ	O
preparation	NN	O
,	,	O
and	CC	O
may	MD	O
offer	VB	O
technical	JJ	O
advantages	NNS	O
,	,	O
both	DT	O
due	JJ	O
to	TO	O
its	PRP$	O
stability	NN	O
in	IN	O
solution	NN	O
and	CC	O
also	RB	O
its	PRP$	O
longer	NN	O
in	IN	O
vivo	JJ	O
half-life	NN	O
.	.	O

We	PRP	O
designed	VBD	O
and	CC	O
carried	VBD	O
out	RP	O
a	DT	O
multi-centre	JJ	O
study	NN	O
to	TO	O
compare	VB	O
and	CC	O
evaluate	VB	O
the	DT	O
efficacy	NN	O
of	IN	O
ISDN	NNP	O
and	CC	O
NTG	NNP	O
in	IN	O
the	DT	O
management	NN	O
of	IN	O
perioperative	JJ	O
hypertension	NN	O
in	IN	O
85	CD	O
patients	NNS	O
undergoing	JJ	O
elective	JJ	O
coronary	JJ	O
artery	NN	O
surgery	NN	O
.	.	O

A	DT	O
total	NN	O
of	IN	O
288	CD	O
events	NNS	O
in	IN	O
which	WDT	O
the	DT	O
systolic	NN	O
blood	NN	O
pressure	NN	O
(	(	O
SBP	NNP	O
)	)	O
exceeded	VBD	O
a	DT	O
predetermined	JJ	O
trigger	NN	O
value	NN	O
were	VBD	O
observed	VBN	O
.	.	O

ISDN	NNP	O
was	VBD	O
successful	JJ	O
in	IN	O
treating	VBG	O
hypertension	NN	O
in	IN	O
63	CD	O
%	NN	O
of	IN	O
the	DT	O
events	NNS	O
,	,	O
whereas	NNS	O
NTG	NNP	O
had	VBD	O
an	DT	O
83	CD	O
%	NN	O
success	NN	O
.	.	O

The	DT	O
SBP	NNP	O
was	VBD	O
significantly	RB	O
lowered	VBN	O
after	IN	O
treatment	NN	O
with	IN	O
either	DT	O
ISDN	NNP	O
,	,	O
155	CD	O
mmHg	NN	O
to	TO	O
138	CD	O
mmHg	NN	O
,	,	O
or	CC	O
NTG	NNP	O
,	,	O
160	CD	O
mmHg	NN	O
to	TO	O
130	CD	O
mmHg	NN	O
.	.	O

The	DT	O
mean	JJ	O
successful	JJ	O
dose	NN	O
rate	NN	O
for	IN	O
ISDN	NNP	O
was	VBD	O
6.5	CD	O
micrograms	JJ	O
kg-1	JJ	O
min-1	NN	O
,	,	O
whereas	NNS	O
for	IN	O
NTG	NNP	O
this	DT	O
was	VBD	O
3.8	CD	O
micrograms	JJ	O
kg-1	JJ	O
min-1	NN	O
.	.	O

In	IN	O
the	DT	O
ISDN	NNP	O
group	NN	O
less	JJR	O
events	NNS	O
took	VBD	O
place	NN	O
possibly	RB	O
due	JJ	O
to	TO	O
the	DT	O
longer	JJR	O
duration	NN	O
of	IN	O
this	DT	O
drug	NN	O
.	.	O

In	IN	O
many	JJ	O
previous	JJ	O
studies	NNS	O
NTG	NNP	O
has	VBZ	O
been	VBN	O
found	VBN	O
to	TO	O
be	VB	O
effective	JJ	O
in	IN	O
controlling	VBG	O
hypertension	NN	O
;	:	O
ISDN	NNP	O
offers	NNS	O
and	CC	O
alternative	JJ	O
approach	NN	O
in	IN	O
reducing	VBG	O
hypertension	NN	O
.	.	O

Use	NNP	O
of	IN	O
an	DT	O
inspiratory	JJ	O
impedance	NN	O
threshold	JJ	O
device	NN	O
on	IN	O
a	DT	O
facemask	NN	O
and	CC	O
endotracheal	VB	O
tube	NN	O
to	TO	O
reduce	VB	O
intrathoracic	JJ	O
pressures	NNS	O
during	IN	O
the	DT	O
decompression	NN	O
phase	NN	O
of	IN	O
active	JJ	O
compression-decompression	NN	O
cardiopulmonary	JJ	O
resuscitation	NN	O
.	.	O

INTRODUCTION	NNP	O
Use	NNP	O
of	IN	O
an	DT	O
inspiratory	JJ	O
impedance	NN	O
threshold	NN	O
device	NN	O
(	(	O
ITD	NNP	O
)	)	O
significantly	RB	O
increases	VBZ	O
coronary	JJ	O
perfusion	NN	O
pressures	NNS	O
and	CC	O
survival	NN	O
in	IN	O
patients	NNS	O
ventilated	VBN	O
with	IN	O
an	DT	O
endotracheal	JJ	O
tube	NN	O
(	(	O
ETT	NNP	O
)	)	O
during	IN	O
active	JJ	O
compression-decompression	NN	O
cardiopulmonary	JJ	O
resuscitation	NN	O
.	.	O

We	PRP	O
tested	VBD	O
the	DT	O
hypothesis	NN	O
that	IN	O
the	DT	O
ITD	NNP	O
could	MD	O
lower	VB	O
intratracheal	NN	O
pressures	NNS	O
when	WRB	O
attached	VBN	O
to	TO	O
either	VB	O
a	DT	O
facemask	NN	O
or	CC	O
ETT	NNP	O
.	.	O

METHODS	NNP	O
An	DT	O
active	JJ	O
and	CC	O
sham	JJ	O
ITD	NNP	O
were	VBD	O
randomly	RB	O
applied	VBN	O
first	RB	O
to	TO	O
a	DT	O
facemask	NN	O
and	CC	O
then	RB	O
to	TO	O
an	DT	O
ETT	NNP	O
during	IN	O
active	JJ	O
compression-decompression	NN	O
cardiopulmonary	JJ	O
resuscitation	NN	O
in	IN	O
13	CD	O
out-of-hospital	JJ	O
cardiac	JJ	O
arrest	NN	O
patients	NNS	O
in	IN	O
a	DT	O
randomized	JJ	O
,	,	O
double-blinded	JJ	O
,	,	O
prospective	JJ	O
clinical	JJ	O
trial	NN	O
.	.	O

The	DT	O
compression-to-bag-valve	JJ	O
ventilation	NN	O
ratio	NN	O
was	VBD	O
15:2	CD	O
.	.	O

Airway	NN	O
pressures	NNS	O
(	(	O
surrogate	NN	O
for	IN	O
intrathoracic	JJ	O
pressure	NN	O
)	)	O
were	VBD	O
measured	VBN	O
with	IN	O
a	DT	O
pressure	NN	O
transducer	NN	O
.	.	O

A	DT	O
sham	NN	O
and	CC	O
an	DT	O
active	JJ	O
ITD	NNP	O
were	VBD	O
used	VBN	O
for	IN	O
1	CD	O
min	NNS	O
each	DT	O
in	IN	O
a	DT	O
randomized	JJ	O
order	NN	O
,	,	O
first	RB	O
on	IN	O
a	DT	O
facemask	NN	O
and	CC	O
then	RB	O
on	IN	O
an	DT	O
ETT	NNP	O
.	.	O

Statistical	JJ	O
analyses	NNS	O
were	VBD	O
made	VBN	O
using	VBG	O
Friedman	NNP	O
's	POS	O
and	CC	O
Wilcoxon	NNP	O
's	POS	O
rank-sum	JJ	O
tests	NNS	O
.	.	O

RESULTS	NNP	O
For	IN	O
the	DT	O
primary	JJ	O
end	NN	O
point	NN	O
,	,	O
mean	JJ	O
+/-	JJ	O
sd	NN	O
maximum	JJ	O
negative	JJ	O
intrathoracic	NN	O
pressures	NNS	O
(	(	O
mm	VB	O
Hg	NNP	O
)	)	O
during	IN	O
the	DT	O
decompression	NN	O
phase	NN	O
of	IN	O
cardiopulmonary	JJ	O
resuscitation	NN	O
were	VBD	O
-1.0	JJ	O
+/-	JJ	O
0.73	CD	O
mm	NN	O
Hg	NNP	O
with	IN	O
a	DT	O
sham	NN	O
vs.	FW	O
-4.6	NNP	O
+/-	JJ	O
3.7	CD	O
mm	NN	O
Hg	NNP	O
with	IN	O
an	DT	O
active	JJ	O
ITD	NN	O
on	IN	O
the	DT	O
facemask	NN	O
(	(	O
p	JJ	O
=	NNP	O
.003	NNP	O
)	)	O
and	CC	O
-1.3	JJ	O
+/-	JJ	O
1.3	CD	O
mm	NN	O
Hg	NNP	O
with	IN	O
a	DT	O
sham	NN	O
ITD	NNP	O
vs.	IN	O
-7.3	NNP	O
+/-	JJ	O
4.5	CD	O
mm	NN	O
Hg	NNP	O
with	IN	O
an	DT	O
active	JJ	O
ITD	NNP	O
on	IN	O
an	DT	O
ETT	NNP	O
(	(	O
p	JJ	O
=	NNP	O
.0009	NNP	O
)	)	O
.	.	O

Decompression	NNP	O
phase	NN	O
airway	NN	O
pressures	NNS	O
with	IN	O
the	DT	O
facemask	NN	O
and	CC	O
ETT	NNP	O
were	VBD	O
not	RB	O
statistically	RB	O
different	JJ	O
.	.	O

CONCLUSIONS	NNP	O
Use	NNP	O
of	IN	O
an	DT	O
active	JJ	O
ITD	NNP	O
attached	VBD	O
to	TO	O
a	DT	O
facemask	NN	O
or	CC	O
an	DT	O
ETT	NNP	O
resulted	VBD	O
in	IN	O
a	DT	O
significantly	RB	O
lower	JJR	O
negative	JJ	O
intratracheal	JJ	O
pressure	NN	O
during	IN	O
the	DT	O
decompression	NN	O
phase	NN	O
of	IN	O
active	JJ	O
compression-decompression	NN	O
cardiopulmonary	JJ	O
resuscitation	NN	O
when	WRB	O
compared	VBN	O
with	IN	O
controls	NNS	O
.	.	O

Airway	NNP	O
pressures	VBZ	O
with	IN	O
an	DT	O
ITD	NNP	O
on	IN	O
either	CC	O
a	DT	O
facemask	NN	O
or	CC	O
ETT	NNP	O
were	VBD	O
similar	JJ	O
.	.	O

The	DT	O
ITD-facemask	JJ	O
combination	NN	O
was	VBD	O
practical	JJ	O
and	CC	O
enables	VBZ	O
rapid	JJ	O
deployment	NN	O
of	IN	O
this	DT	O
life-saving	JJ	O
technology	NN	O
.	.	O

Effect	NN	O
of	IN	O
m-chlorophenylpiperazine	NN	O
on	IN	O
plasma	NN	O
homovanillic	JJ	O
acid	NN	O
concentrations	NNS	O
in	IN	O
healthy	JJ	C
subjects	NNS	C
.	.	O

In	IN	O
view	NN	O
of	IN	O
the	DT	O
abundant	JJ	O
anatomical	JJ	O
and	CC	O
functional	JJ	O
interactions	NNS	O
between	IN	O
serotonin	NN	O
and	CC	O
dopamine	NN	O
systems	NNS	O
,	,	O
this	DT	O
study	NN	O
examined	VBD	O
the	DT	O
effect	NN	O
of	IN	O
the	DT	O
serotonin	JJ	O
agonist	NN	O
,	,	O
m-chlorophenylpiperazine	NN	O
(	(	O
mCPP	NN	O
)	)	O
on	IN	O
plasma	NN	O
concentrations	NNS	O
of	IN	O
the	DT	O
dopamine	NN	O
metabolite	NN	O
,	,	O
homovanillic	JJ	O
acid	NN	O
.	.	O

Plasma	NNP	O
prolactin	NN	O
levels	NNS	O
,	,	O
body	NN	O
temperature	NN	O
,	,	O
and	CC	O
mCPP	RB	O
blood	NN	O
level	NN	O
were	VBD	O
also	RB	O
measured	VBN	O
.	.	O

mCPP	NN	O
(	(	O
0.35	CD	O
mg/kg	NN	O
)	)	O
and	CC	O
placebo	$	O
were	VBD	O
administered	VBN	O
orally	RB	O
to	TO	O
10	CD	O
healthy	JJ	O
men	NNS	O
in	IN	O
a	DT	O
randomized	JJ	O
double-blind	NN	O
design	NN	O
.	.	O

Variables	NNS	O
were	VBD	O
measured	VBN	O
for	IN	O
210	CD	O
min	NNS	O
after	IN	O
administration	NN	O
of	IN	O
capsules	NNS	O
.	.	O

mCPP	NNS	O
raised	VBD	O
prolactin	NN	O
and	CC	O
temperature	NN	O
as	IN	O
compared	VBN	O
to	TO	O
placebo	VB	O
,	,	O
but	CC	O
did	VBD	O
not	RB	O
affect	VB	O
plasma	NN	O
homovanillic	JJ	O
acid	JJ	O
concentrations	NNS	O
.	.	O

Results	VB	O
suggest	JJS	O
that	IN	O
mCPP	NN	O
does	VBZ	O
not	RB	O
alter	VB	O
dopamine	NN	O
function	NN	O
.	.	O

A	DT	O
double-blind	JJ	O
placebo	NN	O
controlled	VBD	O
trial	NN	O
of	IN	O
piracetam	NN	O
added	VBN	O
to	TO	O
risperidone	VB	O
in	IN	O
patients	NNS	O
with	IN	O
autistic	JJ	C
disorder	NN	C
.	.	O

It	PRP	O
has	VBZ	O
been	VBN	O
reported	VBN	O
that	IN	O
autism	NN	O
is	VBZ	O
a	DT	O
hypoglutamatergic	JJ	O
disorder	NN	O
.	.	O

Therefore	RB	O
,	,	O
it	PRP	O
was	VBD	O
of	IN	O
interest	NN	O
to	TO	O
assess	VB	O
the	DT	O
efficacy	NN	O
of	IN	O
piracetam	NN	O
,	,	O
a	DT	O
positive	JJ	O
modulator	NN	O
of	IN	O
AMPA-sensitive	JJ	O
glutamate	NN	O
receptors	NNS	O
in	IN	O
autistic	JJ	O
disorder	NN	O
.	.	O

About	IN	O
40	CD	SS
children	NNS	A
between	IN	O
the	DT	O
ages	NNS	O
three	CD	A
and	CC	A
11	CD	A
years	NNS	A
(	(	O
inclusive	JJ	O
)	)	O
with	IN	O
a	DT	O
DSM	NNP	O
IV	NNP	O
clinical	JJ	O
diagnosis	NN	O
of	IN	O
autism	NN	C
and	CC	O
who	WP	O
were	VBD	O
outpatients	NNS	O
from	IN	O
a	DT	O
specialty	NN	O
clinic	NN	O
for	IN	O
children	NNS	O
were	VBD	O
recruited	VBN	O
.	.	O

The	DT	O
children	NNS	A
presented	VBN	O
with	IN	O
a	DT	O
chief	JJ	O
complaint	NN	O
of	IN	O
severely	RB	O
disruptive	JJ	O
symptoms	NNS	O
related	VBN	O
to	TO	O
autistic	JJ	C
disorder	NN	C
.	.	O

Patients	NNS	O
were	VBD	O
randomly	RB	O
allocated	VBN	O
to	TO	O
piracetam	VB	O
+	NNP	O
risperidone	NN	O
(	(	O
Group	NNP	O
A	NNP	O
)	)	O
or	CC	O
placebo	JJ	O
+	NN	O
risperidone	NN	O
(	(	O
Group	NNP	O
B	NNP	O
)	)	O
for	IN	O
a	DT	O
10-week	JJ	O
,	,	O
double-blind	JJ	O
,	,	O
placebo-controlled	JJ	O
study	NN	O
.	.	O

The	DT	O
dose	NN	O
of	IN	O
risperidone	NN	O
was	VBD	O
titrated	VBN	O
up	RB	O
to	TO	O
2	CD	O
mg/day	NN	O
for	IN	O
children	NNS	O
between	IN	O
10	CD	O
and	CC	O
40	CD	O
kg	NN	O
and	CC	O
3	CD	O
mg/day	NN	O
for	IN	O
children	NNS	O
weighting	VBG	O
above	IN	O
40	CD	O
kg	NN	O
.	.	O

The	DT	O
dose	NN	O
of	IN	O
piracetam	NN	O
was	VBD	O
titrated	VBN	O
up	RB	O
to	TO	O
800	CD	O
mg/day	NN	O
.	.	O

Patients	NNS	O
were	VBD	O
assessed	VBN	O
at	IN	O
baseline	NN	O
and	CC	O
after	IN	O
2	CD	O
,	,	O
4	CD	O
,	,	O
6	CD	O
,	,	O
8	CD	O
and	CC	O
10	CD	O
weeks	NNS	O
of	IN	O
starting	VBG	O
medication	NN	O
.	.	O

The	DT	O
measure	NN	O
of	IN	O
the	DT	O
outcome	NN	O
was	VBD	O
the	DT	O
Aberrant	NNP	O
Behavior	NNP	O
Checklist-Community	NNP	O
(	(	O
ABC-C	NNP	O
)	)	O
Rating	VBG	O
Scale	NNP	O
(	(	O
total	JJ	O
score	NN	O
)	)	O
.	.	O

The	DT	O
ABC-C	JJ	O
Rating	NNP	O
Scale	NNP	O
scores	VBZ	O
improved	VBN	O
with	IN	O
piracetam	NN	O
.	.	O

The	DT	O
difference	NN	O
between	IN	O
the	DT	O
two	CD	O
protocols	NNS	O
was	VBD	O
significant	JJ	O
as	IN	O
indicated	VBN	O
by	IN	O
the	DT	O
effect	NN	O
of	IN	O
group	NN	O
,	,	O
the	DT	O
between	IN	O
subjects	NNS	O
factor	NN	O
(	(	O
F	NNP	O
=	NNP	O
5.85	CD	O
,	,	O
d.f	NN	O
.	.	O

=	CC	O
1	CD	O
,	,	O
P	NNP	O
=	NNP	O
0.02	CD	O
)	)	O
.	.	O

The	DT	O
changes	NNS	O
at	IN	O
the	DT	O
endpoint	NN	O
compared	VBN	O
with	IN	O
baseline	NN	O
were	VBD	O
:	:	O
-11.90	JJ	O
+/-	JJ	O
3.79	CD	O
(	(	O
mean	JJ	O
+/-	NNP	O
SD	NNP	O
)	)	O
and	CC	O
-5.15	JJ	O
+/-	JJ	O
3.04	CD	O
for	IN	O
group	NN	O
A	NNP	O
and	CC	O
B	NNP	O
respectively	RB	O
.	.	O

A	DT	O
significant	JJ	O
difference	NN	O
was	VBD	O
observed	VBN	O
on	IN	O
the	DT	O
change	NN	O
in	IN	O
scores	NNS	O
in	IN	O
the	DT	O
ABC-C	NNP	O
Rating	NNP	O
Scale	NNP	O
in	IN	O
week	NN	O
10	CD	O
compared	VBN	O
with	IN	O
baseline	NN	O
in	IN	O
the	DT	O
two	CD	O
groups	NNS	O
(	(	O
t	JJ	O
=	NN	O
6.017	CD	O
,	,	O
d.f	NN	O
.	.	O

=	CC	O
38	CD	O
,	,	O
P	NNP	O
<	NNP	O
0.0001	CD	O
)	)	O
.	.	O

The	DT	O
results	NNS	O
suggest	VBP	O
that	IN	O
a	DT	O
combination	NN	O
of	IN	O
atypical	JJ	O
antipsychotic	JJ	O
medications	NNS	O
and	CC	O
a	DT	O
glutamate	JJ	O
agent	NN	O
such	JJ	O
as	IN	O
piracetam	NNS	O
,	,	O
might	MD	O
have	VB	O
increase	VBN	O
synergistic	JJ	O
effects	NNS	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
autism	NN	O
.	.	O

Iobitridol	NNP	O
300	CD	O
compared	VBN	O
to	TO	O
iopromide	VB	O
300	CD	O
--	:	O
a	DT	O
double-blind	JJ	O
randomized	JJ	O
phase-III	NN	O
study	NN	O
of	IN	O
clinical	JJ	O
tolerance	NN	O
in	IN	O
total	JJ	O
body	NN	O
CT.	NNP	O
UNLABELLED	NNP	O
PURPOSE	NNP	O
,	,	O
MATERIAL	NNP	O
AND	NNP	O
METHODS	NNP	O
:	:	O
The	DT	O
clinical	JJ	O
safety	NN	O
of	IN	O
iobitriodol	JJ	O
300	CD	O
mg	NN	O
I/ml	NNP	O
and	CC	O
iopromide	RB	O
300	CD	O
mg	NNS	O
I/ml	NNP	O
were	VBD	O
compared	VBN	O
in	IN	O
a	DT	O
randomized	JJ	O
double	JJ	O
blind	IN	O
phase-III	JJ	O
study	NN	O
conducted	VBD	O
on	IN	O
60	CD	O
patients	NNS	O
undergoing	JJ	O
abdominal	JJ	O
CT	NNP	O
for	IN	O
a	DT	O
variety	NN	O
of	IN	O
indications	NNS	O
.	.	O

Each	DT	O
examination	NN	O
was	VBD	O
rated	VBN	O
as	IN	O
diagnostic	JJ	O
or	CC	O
nondiagnostic	JJ	O
and	CC	O
the	DT	O
image	NN	O
quality	NN	O
was	VBD	O
noted	VBN	O
.	.	O

Nature	NN	O
,	,	O
onset	NN	O
,	,	O
intensity	NN	O
as	RB	O
well	RB	O
as	IN	O
outcome	NN	O
of	IN	O
each	DT	O
adverse	JJ	O
reaction	NN	O
were	VBD	O
recorded	VBN	O
.	.	O

RESULTS	NNP	O
There	EX	O
was	VBD	O
no	DT	O
significant	JJ	O
difference	NN	O
in	IN	O
imaging	VBG	O
quality	NN	O
and	CC	O
side	NN	O
effects	NNS	O
between	IN	O
the	DT	O
contrast	NN	O
media	NNS	O
.	.	O

In	IN	O
this	DT	O
study	NN	O
,	,	O
both	DT	O
iobitridol	NNS	O
and	CC	O
iopromide	NN	O
provided	VBD	O
excellent	JJ	O
image	NN	O
quality	NN	O
and	CC	O
a	DT	O
low	JJ	O
rate	NN	O
of	IN	O
side	NN	O
effects	NNS	O
.	.	O

CONCLUSION	NNP	O
Iobitridol	NNP	O
is	VBZ	O
a	DT	O
safe	JJ	O
and	CC	O
effective	JJ	O
nonionic	JJ	O
contrast	NN	O
agent	NN	O
for	IN	O
contrast-enhanced	JJ	O
body	NN	O
CT	NNP	O
.	.	O

The	DT	O
double-blind	JJ	O
sham-controlled	JJ	O
study	NN	O
of	IN	O
high-frequency	NN	O
rTMS	NN	O
(	(	O
20	CD	O
Hz	NNP	O
)	)	O
for	IN	O
negative	JJ	O
symptoms	NNS	O
in	IN	O
schizophrenia	NN	C
:	:	O
negative	JJ	O
results	NNS	O
.	.	O

The	DT	O
high-frequency	NN	O
repetitive	JJ	O
transcranial	JJ	O
magnetic	JJ	O
stimulation	NN	O
(	(	O
HF-rTMS	NNP	O
)	)	O
over	IN	O
the	DT	O
prefrontal	JJ	O
cortex	NN	O
is	VBZ	O
a	DT	O
promising	JJ	O
method	NN	O
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
negative	JJ	O
symptoms	NNS	O
of	IN	O
schizophrenia	NN	C
.	.	O

Using	VBG	O
double-blind	JJ	O
sham-controlled	JJ	O
parallel	NN	O
design	NN	O
,	,	O
we	PRP	O
evaluated	VBD	O
the	DT	O
effect	NN	O
of	IN	O
HF-rTMS	NNP	O
over	IN	O
the	DT	O
left	JJ	O
dorsolateral	JJ	O
prefrontal	NN	O
cortex	NN	O
(	(	O
DLPFC	NNP	O
)	)	O
on	IN	O
negative	JJ	O
symptoms	NNS	O
in	IN	O
patients	NNS	O
with	IN	O
schizophrenia	NN	C
.	.	O

Sixteen	NNP	SS
schizophrenia	NN	C
patients	NNS	O
with	IN	O
predominantly	RB	O
negative	JJ	O
symptoms	NNS	O
on	IN	O
stable	JJ	O
antipsychotic	JJ	O
medication	NN	O
were	VBD	O
treated	VBN	O
with	IN	O
20	CD	O
Hz	NNP	O
rTMS	NN	O
(	(	O
90	CD	O
%	NN	O
of	IN	O
motor	NN	O
threshold	NN	O
,	,	O
2000	CD	O
stimuli	NN	O
per	IN	O
session	NN	O
)	)	O
over	IN	O
ten	JJ	O
days	NNS	O
within	IN	O
2	CD	O
weeks	NNS	O
with	IN	O
six	CD	O
weeks	NNS	O
follow-up	RB	O
.	.	O

The	DT	O
effect	NN	O
was	VBD	O
assessed	VBN	O
using	VBG	O
PANSS	NNP	O
,	,	O
CGI	NNP	O
,	,	O
MADRS	NNP	O
and	CC	O
neuropsychological	JJ	O
tests	NNS	O
.	.	O

We	PRP	O
failed	VBD	O
to	TO	O
find	VB	O
any	DT	O
significant	JJ	O
effect	NN	O
of	IN	O
active	JJ	O
rTMS	NN	O
.	.	O

Sham	NNP	O
rTMS	NN	O
showed	VBD	O
a	DT	O
trend	NN	O
for	IN	O
improvement	NN	O
over	IN	O
time	NN	O
on	IN	O
positive	JJ	O
and	CC	O
negative	JJ	O
subscales	NNS	O
of	IN	O
PANSS	NNP	O
and	CC	O
MADRS	NNP	O
.	.	O

Between-group	NNP	O
comparisons	NNS	O
failed	VBD	O
to	TO	O
reveal	VB	O
any	DT	O
significant	JJ	O
differences	NNS	O
on	IN	O
any	DT	O
rating	NN	O
scales	NNS	O
except	IN	O
a	DT	O
positive	JJ	O
subscale	NN	O
of	IN	O
PANSS	NNP	O
after	IN	O
8	CD	O
weeks	NNS	O
.	.	O

Results	NNS	O
from	IN	O
our	PRP$	O
study	NN	O
did	VBD	O
not	RB	O
confirm	VB	O
that	IN	O
HF-rTMS	NNP	O
over	IN	O
the	DT	O
left	JJ	O
DLPCF	NNP	O
affects	VBZ	O
the	DT	O
negative	JJ	O
symptoms	NNS	O
of	IN	O
schizophrenia	NN	O
and	CC	O
alternative	JJ	O
rTMS	NN	O
approaches	NNS	O
are	VBP	O
discussed	VBN	O
.	.	O

The	DT	O
clinical	JJ	O
and	CC	O
biochemical	JJ	O
effects	NNS	O
of	IN	O
propofol	JJ	O
infusion	NN	O
with	IN	O
and	CC	O
without	IN	O
EDTA	NNP	O
for	IN	O
maintenance	NN	O
anesthesia	NN	O
in	IN	O
healthy	JJ	O
children	NNS	O
undergoing	VBG	O
ambulatory	NN	C
surgery	NN	C
.	.	O

UNLABELLED	IN	O
We	PRP	O
conducted	VBD	O
this	DT	O
randomized	VBN	O
,	,	O
double-blinded	JJ	O
,	,	O
comparative	JJ	O
,	,	O
parallel-group	JJ	O
study	NN	O
to	TO	O
determine	VB	O
whether	IN	O
adding	VBG	O
EDTA	NNP	O
to	TO	O
propofol	VB	O
would	MD	O
affect	VB	O
the	DT	O
clinical	JJ	O
profile	NN	O
,	,	O
calcium	NN	O
and	CC	O
magnesium	NN	O
homeostasis	NN	O
,	,	O
or	CC	O
renal	JJ	O
function	NN	O
in	IN	O
healthy	JJ	O
children	NNS	O
.	.	O

After	IN	O
the	DT	O
induction	NN	O
of	IN	O
anesthesia	NN	O
with	IN	O
halothane	NN	O
,	,	O
69	CD	SS
ambulatory	JJ	C
surgical	JJ	C
patients	NNS	O
(	(	O
1	CD	A
mo	NN	A
to	TO	A
<	VB	A
17	CD	A
yr	NNP	A
old	JJ	A
)	)	O
,	,	O
received	VBD	O
propofol	NN	O
without	IN	O
EDTA	NNP	O
(	(	O
n	JJ	O
=	NNP	O
33	CD	O
)	)	O
or	CC	O
propofol	NN	O
with	IN	O
EDTA	NNP	O
(	(	O
n	JJ	O
=	NNP	O
36	CD	O
)	)	O
.	.	O

Blood	NN	O
samples	NNS	O
were	VBD	O
obtained	VBN	O
for	IN	O
the	DT	O
measurement	NN	O
of	IN	O
ionized	JJ	O
calcium	NN	O
,	,	O
ionized	JJ	O
magnesium	NN	O
,	,	O
and	CC	O
laboratory	JJ	O
indicators	NNS	O
of	IN	O
renal	JJ	O
function	NN	O
.	.	O

Hemodynamic	NNP	O
measurements	NNS	O
,	,	O
recovery	NN	O
,	,	O
and	CC	O
adverse	JJ	O
events	NNS	O
were	VBD	O
recorded	VBN	O
.	.	O

Propofol	NNP	O
with	IN	O
EDTA	NNP	O
produced	VBD	O
no	DT	O
significant	JJ	O
effects	NNS	O
on	IN	O
clinical	JJ	O
efficacy	NN	O
or	CC	O
renal	JJ	O
function	NN	O
.	.	O

Propofol	NNP	O
and	CC	O
propofol	JJ	O
EDTA	NNP	O
produced	VBD	O
a	DT	O
statistically	RB	O
significant	JJ	O
decrease	NN	O
from	IN	O
baseline	NN	O
in	IN	O
serum	JJ	O
concentrations	NNS	O
of	IN	O
ionized	JJ	O
calcium	NN	O
and	CC	O
magnesium	NN	O
during	IN	O
infusion	NN	O
(	(	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
,	,	O
but	CC	O
with	IN	O
no	DT	O
apparent	JJ	O
clinical	JJ	O
effect	NN	O
.	.	O

Hemodynamic	NNP	O
measurements	NNS	O
generally	RB	O
remained	VBD	O
stable	JJ	O
and	CC	O
were	VBD	O
similar	JJ	O
for	IN	O
both	DT	O
groups	NNS	O
.	.	O

Statistically	NNP	O
significant	JJ	O
changes	NNS	O
in	IN	O
systolic	JJ	O
blood	NN	O
pressure	NN	O
,	,	O
mean	JJ	O
arterial	JJ	O
pressure	NN	O
,	,	O
and	CC	O
heart	NN	O
rate	NN	O
were	VBD	O
not	RB	O
considered	VBN	O
clinically	RB	O
significant	JJ	O
.	.	O

Adverse	JJ	O
events	NNS	O
were	VBD	O
mild	JJ	O
or	CC	O
moderate	JJ	O
.	.	O

The	DT	O
addition	NN	O
of	IN	O
EDTA	NNP	O
does	VBZ	O
not	RB	O
alter	VB	O
the	DT	O
clinical	JJ	O
profile	NN	O
of	IN	O
propofol	NN	O
in	IN	O
pediatric	JJ	O
ambulatory	JJ	C
surgical	JJ	C
patients	NNS	O
.	.	O

With	IN	O
or	CC	O
without	IN	O
EDTA	NNP	O
,	,	O
propofol	NN	O
is	VBZ	O
associated	VBN	O
with	IN	O
a	DT	O
decrease	NN	O
in	IN	O
ionized	JJ	O
calcium	NN	O
with	IN	O
no	DT	O
apparent	JJ	O
clinical	JJ	O
effect	NN	O
.	.	O

IMPLICATIONS	VBZ	O
The	DT	O
addition	NN	O
of	IN	O
EDTA	NNP	O
does	VBZ	O
not	RB	O
alter	VB	O
the	DT	O
clinical	JJ	O
profile	NN	O
of	IN	O
propofol	NN	O
in	IN	O
pediatric	JJ	O
ambulatory	JJ	C
surgical	JJ	C
patients	NNS	O
.	.	O

With	IN	O
or	CC	O
without	IN	O
EDTA	NNP	O
,	,	O
propofol	NN	O
is	VBZ	O
associated	VBN	O
with	IN	O
a	DT	O
decrease	NN	O
in	IN	O
ionized	JJ	O
calcium	NN	O
with	IN	O
no	DT	O
apparent	JJ	O
clinical	JJ	O
effect	NN	O
.	.	O

Simulating	VBG	O
a	DT	O
memory	NN	O
impairment	NN	O
:	:	O
can	MD	O
amnesics	VB	C
implicitly	RB	O
outperform	JJ	O
simulators	NNS	O
?	.	O
OBJECTIVES	IN	O
The	DT	O
purpose	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
examine	VB	O
the	DT	O
effectiveness	NN	O
of	IN	O
a	DT	O
variety	NN	O
of	IN	O
tests	NNS	O
in	IN	O
differentiating	VBG	O
simulating	VBG	O
test	NN	O
performances	NNS	O
from	IN	O
genuine	JJ	O
memory-impaired	JJ	C
and	CC	O
normal	JJ	O
(	(	O
control	NN	O
)	)	O
test	NN	O
performances	NNS	O
.	.	O

DESIGN	VB	O
A	DT	O
simulation	NN	O
design	NN	O
was	VBD	O
implemented	VBN	O
,	,	O
based	VBN	O
on	IN	O
an	DT	O
analogue	NN	O
design	NN	O
in	IN	O
which	WDT	O
normal	JJ	O
participants	NNS	O
were	VBD	O
given	VBN	O
experimental	JJ	O
instructions	NNS	O
to	TO	O
feign	VB	O
a	DT	O
mental	JJ	O
impairment	NN	O
and	CC	O
are	VBP	O
compared	VBN	O
to	TO	O
(	(	O
a	DT	O
)	)	O
other	JJ	O
normal	JJ	O
participants	NNS	O
with	IN	O
instructions	NNS	O
to	TO	O
perform	VB	O
honestly	RB	O
,	,	O
and	CC	O
(	(	O
b	NN	O
)	)	O
a	DT	O
comparison	NN	O
group	NN	O
,	,	O
for	IN	O
example	NN	O
,	,	O
acquired	VBD	C
brain-injured	JJ	C
persons	NNS	O
,	,	O
with	IN	O
similar	JJ	O
instructions	NNS	O
.	.	O

METHOD	NNP	O
Forty	NNP	SS
individuals	NNS	O
comprised	VBD	O
the	DT	O
simulating	NN	O
and	CC	O
control	NN	O
group	NN	O
and	CC	O
all	DT	O
participants	NNS	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
the	DT	O
simulating	NN	O
and	CC	O
control	NN	O
groups	NNS	O
.	.	O

Twenty	CD	SS
memory-impaired	JJ	C
patients	NNS	O
,	,	O
all	DT	O
of	IN	O
whom	WP	O
had	VBD	O
been	VBN	O
diagnosed	VBN	O
as	IN	O
suffering	VBG	O
from	IN	O
a	DT	O
memory	NN	C
impairment	NN	C
following	VBG	O
acquired	VBD	C
brain	NN	C
damage	NN	C
,	,	C
participated	VBD	O
as	IN	O
the	DT	O
memory-impaired	JJ	O
control	NN	O
group	NN	O
.	.	O

The	DT	O
simulation	NN	O
group	NN	O
was	VBD	O
directed	VBN	O
to	TO	O
imitate	VB	O
a	DT	O
person	NN	O
with	IN	O
a	DT	O
memory	NN	O
impairment	NN	O
.	.	O

The	DT	O
primary	JJ	O
outcome	JJ	O
measure	NN	O
involved	VBN	O
identifying	VBG	O
those	DT	O
tests	NNS	O
,	,	O
if	IN	O
any	DT	O
,	,	O
where	WRB	O
simulators	NNS	O
were	VBD	O
significantly	RB	O
different	JJ	O
from	IN	O
normal	JJ	O
and	CC	O
memory-impaired	JJ	O
participants	NNS	O
.	.	O

RESULTS	VB	O
On	IN	O
5	CD	O
of	IN	O
the	DT	O
15	CD	O
tasks	NNS	O
administered	VBN	O
,	,	O
simulators	NNS	O
performed	VBD	O
significantly	RB	O
differently	RB	O
from	IN	O
normal	JJ	O
and	CC	O
memory-impaired	JJ	O
participants	NNS	O
.	.	O

Of	IN	O
these	DT	O
5	CD	O
tasks	NNS	O
,	,	O
the	DT	O
coin-in-the-hand	NN	O
,	,	O
when	WRB	O
administered	VBN	O
in	IN	O
conjunction	NN	O
with	IN	O
the	DT	O
autobiographical	JJ	O
interview	NN	O
,	,	O
identified	VBD	O
95	CD	O
per	IN	O
cent	NN	O
of	IN	O
the	DT	O
simulators	NNS	O
without	IN	O
misclassifying	VBG	O
any	DT	O
of	IN	O
the	DT	O
memory-impaired	JJ	O
or	CC	O
normal	JJ	O
participants	NNS	O
.	.	O

CONCLUSION	VB	O
It	PRP	O
is	VBZ	O
suggested	VBN	O
that	IN	O
these	DT	O
two	CD	O
tests	NNS	O
,	,	O
when	WRB	O
administered	VBN	O
jointly	RB	O
,	,	O
might	MD	O
be	VB	O
of	IN	O
use	NN	O
in	IN	O
clinical	JJ	O
settings	NNS	O
to	TO	O
assist	VB	O
in	IN	O
the	DT	O
detection	NN	O
of	IN	O
malingerers	NNS	O
.	.	O

Levamisole	NNP	O
versus	NN	O
placebo	NN	O
as	IN	O
an	DT	O
adjunct	NN	O
to	TO	O
primary	JJ	O
therapy	NN	O
of	IN	O
laryngopharyngeal	JJ	C
epidermoid	JJ	C
carcinoma	NN	C
.	.	C

Evaluation	NN	O
of	IN	O
the	DT	O
immune	JJ	O
status	NN	O
.	.	O

Twenty-four	CD	O
patients	NNS	O
,	,	O
with	IN	O
a	DT	O
biopsy-proven	JJ	O
laryngeal	NN	O
or	CC	O
hypopharyngeal	NN	O
carcinoma	NN	O
,	,	O
received	VBD	O
as	IN	O
an	DT	O
adjunct	NN	O
to	TO	O
their	PRP$	O
primary	JJ	O
treatment	NN	O
(	(	O
surgery	JJ	O
and/or	RB	O
radiotherapy	NN	O
)	)	O
,	,	O
levamisole	JJ	O
(	(	O
150	CD	O
mg	NNS	O
daily	RB	O
during	IN	O
three	CD	O
consecutive	JJ	O
days	NNS	O
,	,	O
every	DT	O
fortnight	NN	O
)	)	O
or	CC	O
placebo	NN	O
,	,	O
following	VBG	O
a	DT	O
single-blind	JJ	O
,	,	O
but	CC	O
randomized	VBD	O
method	NN	O
.	.	O

At	IN	O
the	DT	O
end	NN	O
of	IN	O
the	DT	O
follow-up	NN	O
,	,	O
an	DT	O
investigation	NN	O
of	IN	O
the	DT	O
immune	NN	O
status	NN	O
was	VBD	O
done	VBN	O
,	,	O
and	CC	O
compared	VBN	O
with	IN	O
that	DT	O
of	IN	O
a	DT	O
healthy	JJ	O
control-group	NN	O
.	.	O

It	PRP	O
is	VBZ	O
concluded	VBN	O
that	IN	O
the	DT	O
immunity	NN	O
is	VBZ	O
disturbed	VBN	O
in	IN	O
patients	NNS	O
with	IN	O
laryngo-pharyngeal	JJ	O
cancer	NN	O
,	,	O
but	CC	O
that	IN	O
this	DT	O
disturbance	NN	O
does	VBZ	O
not	RB	O
clearly	RB	O
correlate	NN	O
with	IN	O
the	DT	O
clinical	JJ	O
state	NN	O
of	IN	O
the	DT	O
disease	NN	O
.	.	O

Also	RB	O
,	,	O
the	DT	O
immunological	JJ	O
measures	NNS	O
did	VBD	O
not	RB	O
appear	VB	O
relevant	JJ	O
to	TO	O
the	DT	O
significantly	RB	O
favourable	JJ	O
effect	NN	O
of	IN	O
levamisole	NN	O
on	IN	O
the	DT	O
prognosis	NN	O
.	.	O

[	NNS	C
Localised	VBN	C
prostate	JJ	C
cancer	NN	C
:	:	C
the	DT	O
PREFERE	NNP	O
trial	NN	O
]	NNP	O
.	.	O

Prostate	NNP	O
cancer	NN	O
is	VBZ	O
the	DT	O
most	RBS	O
common	JJ	O
carcinoma	NN	C
of	IN	O
the	DT	O
elderly	JJ	O
man	NN	O
and	CC	O
holds	VBZ	O
the	DT	O
third	JJ	O
place	NN	O
in	IN	O
the	DT	O
ranking	NN	O
of	IN	O
cancer-specific	JJ	O
mortality	NN	O
.	.	O

However	RB	O
,	,	O
mortality	NN	O
rates	NNS	O
of	IN	O
3	CD	O
%	NN	O
are	VBP	O
low	JJ	O
,	,	O
and	CC	O
half	NN	O
of	IN	O
the	DT	O
patients	NNS	O
will	MD	O
die	VB	O
from	IN	O
intercurrent	JJ	O
disease	NN	O
.	.	O

Due	NNP	O
to	TO	O
the	DT	O
significantly	RB	O
improved	VBN	O
diagnostic	JJ	O
methods	NNS	O
and	CC	O
the	DT	O
increasing	VBG	O
use	NN	O
of	IN	O
PSA	NNP	O
screening	NN	O
,	,	O
there	EX	O
has	VBZ	O
been	VBN	O
a	DT	O
stage	NN	O
migration	NN	O
towards	NNS	O
early	RB	O
tumour	VBP	O
stages	NNS	O
that	WDT	O
are	VBP	O
prognostically	RB	O
heterogeneous	JJ	O
and	CC	O
require	NN	O
differentiated	VBN	O
treatment	NN	O
.	.	O

Based	VBN	O
on	IN	O
the	DT	O
discussions	NNS	O
of	IN	O
the	DT	O
Joint	NNP	O
Federal	NNP	O
Committee	NNP	O
(	(	O
G-BA	NNP	O
)	)	O
and	CC	O
the	DT	O
conceptual	JJ	O
work	NN	O
of	IN	O
the	DT	O
MDS	NNP	O
,	,	O
the	DT	O
Competence	NNP	O
Centre	NNP	O
Oncology	NNP	O
of	IN	O
the	DT	O
MDK	NNP	O
,	,	O
the	DT	O
IQWIG	NNP	O
and	CC	O
the	DT	O
National	NNP	O
Association	NNP	O
of	IN	O
Statutory	NNP	O
Health	NNP	O
Insurance	NNP	O
Funds	NNP	O
(	(	O
GKV-Spitzenverband	NNP	O
)	)	O
,	,	O
a	DT	O
prospective	JJ	O
randomised	VBN	O
multicentre	JJ	O
trial	NN	O
was	VBD	O
developed	VBN	O
comparing	VBG	O
the	DT	O
four	CD	O
treatments	NNS	O
actually	RB	O
recommended	VBN	O
by	IN	O
the	DT	O
German	JJ	O
and	CC	O
European	JJ	O
guidelines	NNS	O
for	IN	O
localised	JJ	O
prostate	NN	O
cancer	NN	O
(	(	O
radical	JJ	O
prostatectomy	NN	O
,	,	O
percutaneous	JJ	O
radiotherapy	NN	O
and	CC	O
permanent	JJ	O
seed	NN	O
implantation	NN	O
and	CC	O
active	JJ	O
surveillance	NN	O
)	)	O
allowing	VBG	O
a	DT	O
rejection	NN	O
of	IN	O
one	CD	O
or	CC	O
two	CD	O
treatment	NN	O
options	NNS	O
.	.	O

The	DT	O
trial	NN	O
is	VBZ	O
expected	VBN	O
to	TO	O
start	VB	O
at	IN	O
the	DT	O
beginning	NN	O
of	IN	O
next	JJ	O
year	NN	O
.	.	O

Biochemical	NNP	O
and	CC	O
functional	JJ	O
effects	NNS	O
of	IN	O
creatine	NN	O
phosphate	NN	O
in	IN	O
cardioplegic	JJ	O
solution	NN	O
during	IN	O
aortic	JJ	O
valve	NN	O
surgery	NN	O
--	:	O
a	DT	O
clinical	JJ	O
study	NN	O
.	.	O

During	IN	O
myocardial	JJ	O
ischemia	NN	O
there	EX	O
is	VBZ	O
a	DT	O
drop	NN	O
in	IN	O
high-energy	JJ	O
phosphates	NNS	O
in	IN	O
the	DT	O
myocardium	NN	O
.	.	O

Cold	NNP	O
potassium	NN	O
cardioplegia	NN	O
decreases	NNS	O
but	CC	O
does	VBZ	O
not	RB	O
altogether	RB	O
prevent	VB	O
this	DT	O
reduction	NN	O
.	.	O

Supplementation	NN	O
of	IN	O
cardioplegic	JJ	O
solutions	NNS	O
with	IN	O
the	DT	O
high-energy	JJ	O
compound	NN	O
creatine	NN	O
phosphate	NN	O
(	(	O
10	CD	O
mmol/L	NN	O
)	)	O
compared	VBN	O
to	TO	O
plain	VB	O
cardioplegic	JJ	O
solutions	NNS	O
was	VBD	O
investigated	VBN	O
in	IN	O
this	DT	O
study	NN	O
.	.	O

Thirty	NNP	O
patients	NNS	O
scheduled	VBN	O
for	IN	O
aortic	JJ	O
valve	NNS	O
replacement	NN	O
were	VBD	O
included	VBN	O
.	.	O

The	DT	O
patients	NNS	O
were	VBD	O
randomized	VBN	O
to	TO	O
group	NN	O
I	PRP	O
(	(	O
creatine	VB	O
phosphate	NN	O
)	)	O
or	CC	O
group	NN	O
II	NNP	O
(	(	O
control	NN	O
)	)	O
.	.	O

Postoperative	JJ	O
hemodynamic	JJ	O
evaluation	NN	O
revealed	VBD	O
no	DT	O
significant	JJ	O
differences	NNS	O
between	IN	O
the	DT	O
groups	NNS	O
.	.	O

However	RB	O
,	,	O
group	NN	O
I	PRP	O
exhibited	VBD	O
a	DT	O
tendency	NN	O
toward	IN	O
a	DT	O
better	JJR	O
stroke-work	NN	O
index	NN	O
(	(	O
135	CD	O
+/-	JJ	O
18	CD	O
%	NN	O
vs.	FW	O
102	CD	O
+/-	JJ	O
5	CD	O
%	NN	O
recovery	NN	O
15	CD	O
minutes	NNS	O
after	IN	O
bypass	NN	O
and	CC	O
145	CD	O
+/-	JJ	O
16	CD	O
%	NN	O
vs.	FW	O
119	CD	O
+/-	JJ	O
11	CD	O
%	NN	O
recovery	NN	O
105	CD	O
min	NN	O
after	IN	O
bypass	NN	O
)	)	O
.	.	O

There	EX	O
were	VBD	O
fewer	JJR	O
patients	NNS	O
in	IN	O
group	NN	O
I	PRP	O
(	(	O
5/15	CD	O
)	)	O
needing	VBG	O
inotropic	JJ	O
support	NN	O
compared	VBN	O
to	TO	O
group	NN	O
II	NNP	O
(	(	O
9/14	CD	O
)	)	O
.	.	O

The	DT	O
myocardial	JJ	O
content	NN	O
of	IN	O
ATP	NNP	O
and	CC	O
creatine	NN	O
phosphate	NN	O
showed	VBD	O
no	DT	O
significant	JJ	O
differences	NNS	O
during	IN	O
ischemia	NN	O
and	CC	O
reperfusion	NN	O
.	.	O

It	PRP	O
is	VBZ	O
concluded	VBN	O
that	IN	O
the	DT	O
myocardial	JJ	O
protection	NN	O
during	IN	O
ischemia	NN	O
was	VBD	O
sufficient	JJ	O
to	TO	O
prevent	VB	O
significant	JJ	O
reductions	NNS	O
of	IN	O
myocardial	JJ	O
ATP	NNP	O
and	CC	O
creatine	VB	O
phosphate	JJ	O
irrespective	NN	O
of	IN	O
supplementation	NN	O
with	IN	O
CP	NNP	O
.	.	O

Improved	VBN	O
frontoparietal	JJ	O
white	JJ	O
matter	NN	O
integrity	NN	O
in	IN	O
overweight	JJ	C
children	NNS	O
is	VBZ	O
associated	VBN	O
with	IN	O
attendance	NN	O
at	IN	O
an	DT	O
after-school	JJ	O
exercise	NN	O
program	NN	O
.	.	O

Aerobic	NNP	O
fitness	NN	O
is	VBZ	O
associated	VBN	O
with	IN	O
white	JJ	O
matter	NN	O
integrity	NN	O
(	(	O
WMI	NNP	O
)	)	O
in	IN	O
adults	NNS	O
as	IN	O
measured	VBN	O
by	IN	O
diffusion	NN	O
tensor	NN	O
imaging	NN	O
(	(	O
DTI	NNP	O
)	)	O
.	.	O

This	DT	O
study	NN	O
examined	VBD	O
the	DT	O
effect	NN	O
of	IN	O
an	DT	O
8-month	JJ	O
exercise	NN	O
intervention	NN	O
on	IN	O
WMI	NNP	O
in	IN	O
children	NNS	A
.	.	O

Participants	NNS	O
were	VBD	O
18	CD	O
sedentary	JJ	O
,	,	O
overweight	JJ	O
(	(	O
BMI?85th	NNP	O
percentile	NN	O
)	)	O
8-	CD	O
to	TO	O
11-year-old	JJ	O
children	NNS	O
(	(	O
94	CD	O
%	NN	O
Black	NNP	O
)	)	O
,	,	O
randomly	RB	O
assigned	VBN	O
to	TO	O
either	DT	O
an	DT	O
aerobic	JJ	O
exercise	NN	O
(	(	O
n=10	JJ	O
)	)	O
or	CC	O
sedentary	JJ	O
attention	NN	O
control	NN	O
group	NN	O
(	(	O
n=8	RB	O
)	)	O
.	.	O

Each	DT	O
group	NN	O
was	VBD	O
offered	VBN	O
an	DT	O
instructor-led	JJ	O
after-school	JJ	O
program	NN	O
every	DT	O
school	NN	O
day	NN	O
for	IN	O
approximately	RB	O
8	CD	O
months	NNS	O
.	.	O

Before	IN	O
and	CC	O
after	IN	O
the	DT	O
program	NN	O
,	,	O
all	DT	O
subjects	NNS	O
participated	VBN	O
in	IN	O
DTI	NNP	O
scans	NNS	O
.	.	O

Tractography	NN	O
was	VBD	O
conducted	VBN	O
to	TO	O
isolate	VB	O
the	DT	O
superior	JJ	O
longitudinal	JJ	O
fasciculus	NN	O
and	CC	O
investigate	VB	O
whether	IN	O
the	DT	O
exercise	NN	O
intervention	NN	O
affected	VBD	O
WMI	NNP	O
in	IN	O
this	DT	O
region	NN	O
.	.	O

There	EX	O
was	VBD	O
no	DT	O
group	NN	O
by	IN	O
time	NN	O
interaction	NN	O
for	IN	O
WMI	NNP	O
in	IN	O
the	DT	O
superior	JJ	O
longitudinal	JJ	O
fasciculus	NN	O
.	.	O

There	EX	O
was	VBD	O
a	DT	O
group	NN	O
by	IN	O
time	NN	O
by	IN	O
attendance	NN	O
interaction	NN	O
,	,	O
however	RB	O
,	,	O
such	JJ	O
that	IN	O
higher	JJR	O
attendance	NN	O
at	IN	O
the	DT	O
exercise	NN	O
intervention	NN	O
,	,	O
but	CC	O
not	RB	O
the	DT	O
control	NN	O
intervention	NN	O
,	,	O
was	VBD	O
associated	VBN	O
with	IN	O
increased	JJ	O
WMI	NNP	O
.	.	O

Heart	NNP	O
rate	NN	O
and	CC	O
the	DT	O
total	JJ	O
dose	NN	O
of	IN	O
exercise	NN	O
correlated	VBN	O
with	IN	O
WMI	NNP	O
changes	NNS	O
in	IN	O
the	DT	O
exercise	NN	O
group	NN	O
.	.	O

In	IN	O
the	DT	O
overall	JJ	O
sample	NN	O
,	,	O
increased	VBD	O
WMI	NNP	O
was	VBD	O
associated	VBN	O
with	IN	O
improved	JJ	O
scores	NNS	O
on	IN	O
a	DT	O
measure	NN	O
of	IN	O
attention	NN	O
and	CC	O
improved	VBN	O
teacher	JJ	O
ratings	NNS	O
of	IN	O
executive	NN	O
function	NN	O
.	.	O

This	DT	O
study	NN	O
indicates	VBZ	O
that	IN	O
participating	VBG	O
in	IN	O
an	DT	O
exercise	NN	O
intervention	NN	O
improves	VBZ	O
WMI	NNP	O
in	IN	O
children	NNS	O
as	IN	O
compared	VBN	O
to	TO	O
a	DT	O
sedentary	JJ	O
after-school	JJ	O
program	NN	O
.	.	O

Assessment	NN	O
of	IN	O
therapeutic	JJ	O
response	NN	O
of	IN	O
Plasmodium	NNP	O
falciparum	NN	O
to	TO	O
chloroquine	VB	O
and	CC	O
sulfadoxine-pyrimethamine	VB	O
in	IN	O
an	DT	O
area	NN	O
of	IN	O
low	JJ	C
malaria	NNS	C
transmission	NN	O
in	IN	O
Colombia	NNP	O
.	.	O

Although	IN	O
chloroquine	NN	O
(	(	O
CQ	NNP	O
)	)	O
resistance	NN	O
was	VBD	O
first	RB	O
reported	VBN	O
in	IN	O
Colombia	NNP	O
in	IN	O
1961	CD	O
and	CC	O
sulfadoxine-pyrimethamine	JJ	O
(	(	O
SP	NNP	O
)	)	O
resistance	NN	O
in	IN	O
1981	CD	O
,	,	O
the	DT	O
frequency	NN	O
of	IN	O
treatment	NN	O
failures	NNS	O
to	TO	O
these	DT	O
drugs	NNS	O
in	IN	O
Colombia	NNP	O
is	VBZ	O
unclear	JJ	O
.	.	O

A	DT	O
modified	JJ	O
World	NNP	O
Health	NNP	O
Organization	NNP	O
14-day	JJ	O
in	IN	O
vivo	JJ	O
drug	NN	O
efficacy	NN	O
test	NN	O
for	IN	O
uncomplicated	JJ	O
Plasmodium	NNP	O
falciparum	NN	O
malaria	NN	O
in	IN	O
areas	NNS	O
with	IN	O
intense	JJ	O
malaria	NNS	O
transmission	NN	O
was	VBD	O
adapted	VBN	O
to	TO	O
reflect	VB	O
the	DT	O
clinical	JJ	O
and	CC	O
epidemiologic	JJ	O
features	NNS	O
of	IN	O
a	DT	O
low-intensity	JJ	O
malaria	NN	O
transmission	NN	O
area	NN	O
in	IN	O
the	DT	O
Pacific	NNP	O
Coast	NNP	O
Region	NNP	O
of	IN	O
Colombia	NNP	O
.	.	O

Patients	NNPS	O
>	JJ	A
or	CC	A
=1	JJ	A
year	NN	A
of	IN	A
age	NN	A
with	IN	O
a	DT	O
parasite	JJ	O
density	NN	O
>	NN	O
or	CC	O
=1,000	CD	O
asexual	JJ	O
parasites	NNS	O
per	IN	O
microliter	NN	O
were	VBD	O
enrolled	VBN	O
in	IN	O
this	DT	O
study	NN	O
.	.	O

Forty-four	CD	SS
percent	NN	O
(	(	O
24	CD	O
of	IN	O
54	CD	O
)	)	O
of	IN	O
the	DT	O
CQ-treated	JJ	O
patients	NNS	O
were	VBD	O
therapeutic	JJ	O
failures	NNS	O
,	,	O
including	VBG	O
7	CD	O
early	JJ	O
treatment	NN	O
failures	NNS	O
(	(	O
ETFs	NNP	O
)	)	O
and	CC	O
17	CD	O
late	JJ	O
treatment	NN	O
failures	NNS	O
(	(	O
LTFs	NNP	O
)	)	O
.	.	O

Four	CD	O
(	(	O
6	CD	O
%	NN	O
)	)	O
of	IN	O
67	CD	O
SP-treated	JJ	O
patients	NNS	O
were	VBD	O
therapeutic	JJ	O
failures	NNS	O
(	(	O
2	CD	O
ETFs	NNP	O
and	CC	O
2	CD	O
LTFs	NNP	O
)	)	O
.	.	O

Therapeutic	JJ	O
failure	NN	O
in	IN	O
the	DT	O
CQ-treated	JJ	O
group	NN	O
was	VBD	O
associated	VBN	O
with	IN	O
an	DT	O
age	NN	O
<	VBD	O
15	CD	O
years	NNS	O
old	JJ	O
(	(	O
P	NNP	O
<	NNP	O
0.01	CD	O
)	)	O
,	,	O
but	CC	O
was	VBD	O
not	RB	O
associated	VBN	O
with	IN	O
initial	JJ	O
parasite	JJ	O
density	NN	O
,	,	O
the	DT	O
presence	NN	O
of	IN	O
CQ	NNP	O
or	CC	O
sulfa-containing	JJ	O
drugs	NNS	O
in	IN	O
urine	NN	O
,	,	O
or	CC	O
a	DT	O
history	NN	O
of	IN	O
malaria	NN	O
.	.	O

The	DT	O
high	JJ	O
level	NN	O
of	IN	O
therapeutic	JJ	O
failures	NNS	O
to	TO	O
CQ	NNP	O
detected	VBN	O
in	IN	O
this	DT	O
study	NN	O
underscores	VBZ	O
the	DT	O
need	NN	O
and	CC	O
importance	NN	O
of	IN	O
drug	NN	O
efficacy	NN	O
evaluation	NN	O
in	IN	O
the	DT	O
development	NN	O
of	IN	O
a	DT	O
rational	JJ	O
national	JJ	O
antimalarial	JJ	O
drug	NN	O
policy	NN	O
.	.	O

The	DT	O
relatively	RB	O
low	JJ	O
level	NN	O
of	IN	O
therapeutic	JJ	O
failures	NNS	O
to	TO	O
SP	NNP	O
compared	VBN	O
with	IN	O
other	JJ	O
South	JJ	O
American	JJ	O
countries	NNS	O
raises	VBZ	O
further	JJ	O
questions	NNS	O
regarding	VBG	O
factors	NNS	O
that	WDT	O
might	MD	O
have	VB	O
prevented	VBN	O
the	DT	O
rapid	JJ	O
development	NN	O
of	IN	O
in	IN	O
vivo	NN	O
resistance	NN	O
to	TO	O
this	DT	O
drug	NN	O
combination	NN	O
.	.	O

18F-FDG	JJ	O
PET/CT	NNP	O
for	IN	O
early	JJ	O
prediction	NN	O
of	IN	O
response	NN	O
to	TO	O
neoadjuvant	JJ	O
lapatinib	NN	O
,	,	O
trastuzumab	NN	O
,	,	O
and	CC	O
their	PRP$	O
combination	NN	O
in	IN	O
HER2-positive	JJ	C
breast	NN	C
cancer	NN	C
:	:	C
results	NNS	O
from	IN	O
Neo-ALTTO	NNP	O
.	.	O

UNLABELLED	NNP	O
Molecular	NNP	O
imaging	VBG	O
receives	NNS	O
increased	VBD	O
attention	NN	O
for	IN	O
selecting	VBG	O
patients	NNS	O
who	WP	O
will	MD	O
benefit	VB	O
from	IN	O
targeted	JJ	O
anticancer	NN	O
therapies	NNS	O
.	.	O

Neo-ALTTO	NNP	O
(	(	O
Neoadjuvant	NNP	O
Lapatinib	NNP	O
and/or	VBZ	O
Trastuzumab	NNP	O
Treatment	NNP	O
Optimisation	NNP	O
)	)	O
enrolled	VBD	O
455	CD	O
women	NNS	O
with	IN	O
invasive	JJ	O
human	JJ	O
epidermal	JJ	O
growth	NN	O
factor	NN	O
receptor	NN	O
2	CD	O
(	(	O
HER2	NNP	O
)	)	O
-positive	VBP	O
breast	NN	O
cancer	NN	O
and	CC	O
compared	VBN	O
rates	NNS	O
of	IN	O
pathologic	JJ	O
complete	JJ	O
response	NN	O
(	(	O
pCR	NN	O
)	)	O
to	TO	O
neoadjuvant	JJ	O
lapatinib	NN	O
,	,	O
trastuzumab	NN	O
,	,	O
and	CC	O
their	PRP$	O
combination	NN	O
.	.	O

Each	DT	O
anti-HER2	JJ	O
therapy	NN	O
was	VBD	O
given	VBN	O
alone	RB	O
for	IN	O
6	CD	O
wk	NN	O
,	,	O
followed	VBN	O
by	IN	O
12	CD	O
wk	NN	O
of	IN	O
the	DT	O
same	JJ	O
therapy	NN	O
plus	CC	O
weekly	JJ	O
paclitaxel	NN	O
.	.	O

The	DT	O
early	JJ	O
metabolic	JJ	O
effects	NNS	O
of	IN	O
the	DT	O
anti-HER2	JJ	O
therapies	NNS	O
on	IN	O
the	DT	O
primary	JJ	O
tumors	NNS	O
and	CC	O
their	PRP$	O
predictive	JJ	O
values	NNS	O
for	IN	O
pCR	NN	O
were	VBD	O
assessed	VBN	O
in	IN	O
a	DT	O
subset	NN	O
of	IN	O
patients	NNS	O
.	.	O

METHODS	NNP	O
Eighty-six	JJ	SS
patients	NNS	SS
underwent	JJ	SS
(	(	SS
18	CD	SS
)	)	SS
F-FDG	CD	SS
PET/CT	NNP	SS
at	IN	O
baseline	NN	O
and	CC	O
weeks	NNS	O
2	CD	O
and	CC	O
6	CD	O
of	IN	O
anti-HER2	JJ	O
treatment	NN	O
.	.	O

An	DT	O
imaging	VBG	O
core	NN	O
laboratory	NN	O
provided	VBD	O
central	JJ	O
validation	NN	O
,	,	O
and	CC	O
2	CD	O
independent	JJ	O
reviewers	NNS	O
,	,	O
masked	VBD	O
to	TO	O
assigned	VB	O
treatment	NN	O
arm	NN	O
and	CC	O
clinical	JJ	O
outcomes	NNS	O
,	,	O
performed	VBN	O
consensus	NN	O
(	(	O
18	CD	O
)	)	O
F-FDG	NNP	O
PET/CT	NNP	O
readings	NNS	O
.	.	O

Maximum	NNP	O
standardized	VBD	O
uptake	JJ	O
value	NN	O
(	(	O
SUVmax	NNP	O
)	)	O
reductions	NNS	O
from	IN	O
baseline	NN	O
were	VBD	O
used	VBN	O
to	TO	O
measure	VB	O
metabolic	JJ	O
response	NN	O
.	.	O

RESULTS	NNP	O
Seventy-seven	NNP	O
of	IN	O
the	DT	O
86	CD	O
enrolled	VBD	O
patients	NNS	O
presented	VBD	O
an	DT	O
evaluable	JJ	O
baseline	NN	O
(	(	O
18	CD	O
)	)	O
F-FDG	NNP	O
PET/CT	NNP	O
scan	JJ	O
;	:	O
of	IN	O
these	DT	O
,	,	O
68	CD	O
and	CC	O
66	CD	O
were	VBD	O
evaluable	JJ	O
at	IN	O
weeks	NNS	O
2	CD	O
and	CC	O
6	CD	O
,	,	O
respectively	RB	O
.	.	O

Metabolic	JJ	O
responses	NNS	O
in	IN	O
the	DT	O
primary	JJ	O
tumors	NNS	O
were	VBD	O
evident	JJ	O
after	IN	O
2	CD	O
wk	NN	O
of	IN	O
targeted	JJ	O
therapy	NN	O
and	CC	O
correlated	VBN	O
highly	RB	O
with	IN	O
metabolic	JJ	O
responses	NNS	O
at	IN	O
week	NN	O
6	CD	O
(	(	O
R	NNP	O
(	(	O
2	CD	O
)	)	O
=	FW	O
0.81	CD	O
)	)	O
.	.	O

pCRs	NN	O
were	VBD	O
associated	VBN	O
with	IN	O
greater	JJR	O
SUVmax	NNP	O
reductions	NNS	O
at	IN	O
both	DT	O
time	NN	O
points	NNS	O
.	.	O

Mean	NNP	O
SUVmax	NNP	O
reductions	NNS	O
for	IN	O
pCR	NN	O
and	CC	O
non-pCR	JJ	O
,	,	O
respectively	RB	O
,	,	O
were	VBD	O
54.3	CD	O
%	NN	O
versus	IN	O
32.8	CD	O
%	NN	O
at	IN	O
week	NN	O
2	CD	O
(	(	O
P	NNP	O
=	NNP	O
0.02	CD	O
)	)	O
and	CC	O
61.5	CD	O
%	NN	O
versus	IN	O
34.1	CD	O
%	NN	O
at	IN	O
week	NN	O
6	CD	O
(	(	O
P	NNP	O
=	NNP	O
0.02	CD	O
)	)	O
.	.	O

(	(	O
18	CD	O
)	)	O
F-FDG	NNP	O
PET/CT	NNP	O
metabolic	JJ	O
response	NN	O
rates	NNS	O
at	IN	O
weeks	NNS	O
2	CD	O
and	CC	O
6	CD	O
were	VBD	O
71.6	CD	O
%	NN	O
and	CC	O
60	CD	O
%	NN	O
,	,	O
respectively	RB	O
using	VBG	O
European	JJ	O
Organization	NNP	O
for	IN	O
Research	NNP	O
and	CC	O
Treatment	NNP	O
of	IN	O
Cancer	NNP	O
criteria	NNS	O
;	:	O
pCR	VBN	O
rates	NNS	O
were	VBD	O
twice	RB	O
as	RB	O
high	JJ	O
for	IN	O
(	(	O
18	CD	O
)	)	O
F-FDG	NNP	O
PET/CT	NNP	O
responders	NNS	O
than	IN	O
nonresponders	NNS	O
(	(	O
week	NN	O
2	CD	O
:	:	O
42	CD	O
%	NN	O
vs.	FW	O
21	CD	O
%	NN	O
,	,	O
P	NNP	O
=	NNP	O
0.12	CD	O
;	:	O
week	NN	O
6	CD	O
:	:	O
44	CD	O
%	NN	O
vs.	FW	O
19	CD	O
%	NN	O
,	,	O
P	NNP	O
=	NNP	O
0.05	CD	O
)	)	O
.	.	O

CONCLUSION	NNP	O
Early	NNP	O
metabolic	JJ	O
assessment	NN	O
using	VBG	O
(	(	O
18	CD	O
)	)	O
F-FDG	CD	O
PET/CT	NNP	O
can	MD	O
identify	VB	O
patients	NNS	O
with	IN	O
an	DT	O
increased	VBN	O
likelihood	NN	O
of	IN	O
pCR	NN	O
after	IN	O
neoadjuvant	JJ	O
trastuzumab	NN	O
,	,	O
lapatinib	NN	O
,	,	O
or	CC	O
their	PRP$	O
combination	NN	O
when	WRB	O
given	VBN	O
with	IN	O
chemotherapy	NN	O
.	.	O

Prospective	JJ	O
randomised	VBD	O
trial	NN	O
of	IN	O
amifostine	JJ	O
cytoprotection	NN	O
in	IN	O
myeloma	NN	C
patients	NNS	O
undergoing	VBG	O
high-dose	JJ	O
melphalan	NN	O
conditioned	VBN	O
autologous	JJ	O
stem	NN	O
cell	NN	O
transplantation	NN	O
.	.	O

In	IN	O
this	DT	O
prospective	JJ	O
multicentre	NN	O
trial	NN	O
,	,	O
90	CD	SS
patients	NNS	O
undergoing	VBG	O
autologous	JJ	C
stem	NN	C
cell	NN	C
transplantation	NN	C
(	(	C
ASCT	NNP	C
)	)	O
were	VBD	O
randomised	VBN	O
to	TO	O
receive	VB	O
(	(	O
n=43	NN	O
)	)	O
or	CC	O
not	RB	O
receive	JJ	O
(	(	O
n=47	JJ	O
)	)	O
amifostine	VBP	O
910	CD	O
mg/m	NN	O
(	(	O
2	CD	O
)	)	O
prior	RB	O
to	TO	O
melphalan	VB	O
200	CD	O
mg/m	NN	O
(	(	O
2	CD	O
)	)	O
.	.	O

Patients	NNS	O
were	VBD	O
monitored	VBN	O
for	IN	O
regimen-related	JJ	O
toxicity	NN	O
,	,	O
engraftment	NN	O
,	,	O
supportive	JJ	O
care	NN	O
,	,	O
response	NN	O
and	CC	O
survival	NN	O
.	.	O

Both	DT	O
groups	NNS	O
underwent	VBD	O
ASCT	NNP	O
at	IN	O
a	DT	O
median	NN	O
of	IN	O
8	CD	O
months	NNS	O
from	IN	O
diagnosis	NN	O
and	CC	O
were	VBD	O
matched	VBN	O
for	IN	O
disease	NN	O
characteristics	NNS	O
,	,	O
prior	JJ	O
therapy	NN	O
and	CC	O
pre-ASCT	JJ	O
disease	NN	O
responsiveness	NN	O
.	.	O

Amifostine	NNP	O
infusional	JJ	O
side-effects	NNS	O
were	VBD	O
frequent	JJ	O
,	,	O
occurring	VBG	O
in	IN	O
65	CD	O
%	NN	O
of	IN	O
patients	NNS	O
,	,	O
but	CC	O
of	IN	O
mild	JJ	O
severity	NN	O
.	.	O

Amifostine	NNP	O
use	NN	O
was	VBD	O
associated	VBN	O
with	IN	O
a	DT	O
reduction	NN	O
in	IN	O
the	DT	O
median	JJ	O
grade	NN	O
of	IN	O
oral	JJ	O
mucositis	NN	O
(	(	O
1	CD	O
vs	NN	O
2	CD	O
,	,	O
P=0.01	NNP	O
)	)	O
and	CC	O
the	DT	O
frequency	NN	O
of	IN	O
severe	JJ	O
(	(	O
WHO	NNP	O
grades	VBZ	O
3	CD	O
or	CC	O
4	CD	O
)	)	O
mucositis	NN	O
(	(	O
12	CD	O
vs	RB	O
33	CD	O
%	NN	O
,	,	O
P=0.02	NNP	O
)	)	O
,	,	O
but	CC	O
no	DT	O
reduction	NN	O
in	IN	O
the	DT	O
requirement	NN	O
for	IN	O
parenteral	JJ	O
nutrition	NN	O
or	CC	O
analgesic	JJ	O
use	NN	O
.	.	O

Conversion	NN	O
to	TO	O
complete	VB	O
remission	NN	O
post-ASCT	NN	O
occurred	VBD	O
in	IN	O
30	CD	O
and	CC	O
14	CD	O
%	NN	O
of	IN	O
the	DT	O
amifostine	NN	O
and	CC	O
control	NN	O
groups	NNS	O
,	,	O
respectively	RB	O
(	(	O
P=0.09	NNP	O
)	)	O
.	.	O

With	IN	O
a	DT	O
median	JJ	O
follow-up	NN	O
of	IN	O
35	CD	O
months	NNS	O
,	,	O
there	EX	O
was	VBD	O
no	DT	O
statistically	RB	O
significant	JJ	O
difference	NN	O
between	IN	O
the	DT	O
median	JJ	O
progression-free	NN	O
or	CC	O
overall	JJ	O
survival	NN	O
times	NNS	O
for	IN	O
the	DT	O
two	CD	O
groups	NNS	O
.	.	O

We	PRP	O
conclude	VBP	O
that	IN	O
amifostine	NN	O
can	MD	O
be	VB	O
safely	RB	O
administered	VBN	O
prior	RB	O
to	TO	O
high-dose	JJ	O
melphalan	NN	O
and	CC	O
significantly	RB	O
reduces	VBZ	O
the	DT	O
frequency	NN	O
and	CC	O
severity	NN	O
of	IN	O
therapy-induced	JJ	O
oral	JJ	O
mucositis	NN	O
.	.	O

Treatment	NN	O
of	IN	O
acute	JJ	O
asthma	NN	O
.	.	O

Lack	NNP	O
of	IN	O
therapeutic	JJ	O
benefit	NN	O
and	CC	O
increase	NN	O
of	IN	O
the	DT	O
toxicity	NN	O
from	IN	O
aminophylline	JJ	O
given	VBN	O
in	IN	O
addition	NN	O
to	TO	O
high	JJ	O
doses	NNS	O
of	IN	O
salbutamol	NN	O
delivered	VBN	O
by	IN	O
metered-dose	JJ	O
inhaler	NN	O
with	IN	O
a	DT	O
spacer	NN	O
.	.	O

We	PRP	O
conducted	VBD	O
a	DT	O
randomized	VBN	O
,	,	O
double-blind	JJ	O
,	,	O
placebo-controlled	JJ	O
study	NN	O
to	TO	O
determine	VB	O
if	IN	O
intravenous	JJ	O
aminophylline	NN	O
adds	VBZ	O
any	DT	O
benefit	NN	O
to	TO	O
high	JJ	O
doses	NNS	O
of	IN	O
inhaled	JJ	O
salbutamol	NN	O
in	IN	O
patients	NNS	O
who	WP	O
presented	VBD	O
for	IN	O
treatment	NN	O
of	IN	O
acute	JJ	C
asthma	NN	C
.	.	O

We	PRP	O
studied	VBD	O
94	CD	SS
patients	NNS	O
(	(	O
mean	JJ	O
age	NN	O
,	,	O
35.6	CD	O
+/-	JJ	O
11.2	CD	O
years	NNS	O
)	)	O
with	IN	O
moderate	JJ	C
to	TO	C
severe	VB	C
acute	JJ	C
asthma	NN	C
.	.	O

All	DT	O
patients	NNS	O
received	VBD	O
therapy	NN	O
with	IN	O
salbutamol	NN	O
delivered	VBN	O
with	IN	O
metered-dose	JJ	O
inhaler	NN	O
(	(	O
MDI	NNP	O
)	)	O
into	IN	O
a	DT	O
spacer	NN	O
device	NN	O
(	(	O
Volumatic	NNP	O
)	)	O
in	IN	O
four	CD	O
puffs	NNS	O
(	(	O
400	CD	O
micrograms	NNS	O
)	)	O
at	IN	O
10-min	JJ	O
interval	NN	O
,	,	O
and	CC	O
intravenous	JJ	O
hydrocortisone	NN	O
(	(	O
500	CD	O
mg	NN	O
)	)	O
.	.	O

Patients	NNS	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
receive	VB	O
either	CC	O
a	DT	O
loading	NN	O
dose	NN	O
of	IN	O
intravenous	JJ	O
aminophylline	NN	O
followed	VBN	O
by	IN	O
a	DT	O
routine	JJ	O
infusion	NN	O
(	(	O
n	JJ	O
=	NNP	O
45	CD	O
)	)	O
or	CC	O
an	DT	O
equal	JJ	O
volume	NN	O
of	IN	O
placebo	NN	O
as	IN	O
a	DT	O
loading	NN	O
dose	NN	O
and	CC	O
infusion	NN	O
(	(	O
n	JJ	O
=	NNP	O
49	CD	O
)	)	O
.	.	O

The	DT	O
two	CD	O
groups	NNS	O
showed	VBD	O
no	DT	O
differences	NNS	O
in	IN	O
measurements	NNS	O
of	IN	O
peak	JJ	O
expiratory	NN	O
flow	NN	O
,	,	O
FEV1	NNP	O
,	,	O
and	CC	O
FVC	NNP	O
at	IN	O
baseline	NN	O
and	CC	O
at	IN	O
the	DT	O
end	NN	O
of	IN	O
treatment	NN	O
.	.	O

However	RB	O
,	,	O
the	DT	O
patients	NNS	O
treated	VBN	O
with	IN	O
aminophylline	NN	O
had	VBD	O
significantly	RB	O
more	RBR	O
adverse	JJ	O
effects	NNS	O
(	(	O
p	JJ	O
<	NNP	O
0.05	CD	O
)	)	O
.	.	O

There	EX	O
were	VBD	O
no	DT	O
differences	NNS	O
in	IN	O
the	DT	O
final	JJ	O
mean	NN	O
dose	NN	O
of	IN	O
salbutamol	NN	O
(	(	O
6.3	CD	O
+/-	JJ	O
44.5	CD	O
mg	NN	O
for	IN	O
the	DT	O
placebo	NN	O
group	NN	O
and	CC	O
5.8	CD	O
+/-	JJ	O
4.2	CD	O
mg	NN	O
for	IN	O
the	DT	O
aminophylline	NN	O
group	NN	O
)	)	O
,	,	O
hospital	JJ	O
admission	NN	O
rate	NN	O
(	(	O
10.2	CD	O
percent	NN	O
for	IN	O
the	DT	O
placebo	NN	O
group	NN	O
and	CC	O
9.0	CD	O
percent	NN	O
for	IN	O
the	DT	O
aminophylline	NN	O
group	NN	O
)	)	O
,	,	O
and	CC	O
mean	JJ	O
duration	NN	O
of	IN	O
Emergency	NNP	O
Department	NNP	O
treatment	NN	O
(	(	O
2.5	CD	O
+/-	JJ	O
1.83	CD	O
h	NN	O
for	IN	O
the	DT	O
placebo	NN	O
group	NN	O
and	CC	O
2.37	CD	O
+/-	JJ	O
1.75	CD	O
h	NN	O
for	IN	O
the	DT	O
aminophylline	NN	O
group	NN	O
)	)	O
.	.	O

The	DT	O
results	NNS	O
were	VBD	O
similar	JJ	O
when	WRB	O
the	DT	O
patients	NNS	O
were	VBD	O
divided	VBN	O
in	IN	O
accord	NN	O
with	IN	O
the	DT	O
degree	NN	O
of	IN	O
respiratory	NN	O
obstruction	NN	O
(	(	O
baseline	JJ	O
FEV1	NNP	O
<	NNP	O
30	CD	O
percent	NN	O
of	IN	O
predicted	VBN	O
)	)	O
and	CC	O
theophylline	JJ	O
level	NN	O
at	IN	O
30	CD	O
min	NN	O
of	IN	O
treatment	NN	O
(	(	O
placebo	JJ	O
group	NN	O
patients	NNS	O
with	IN	O
theophylline	JJ	O
level	NN	O
<	VBD	O
10	CD	O
mg/L	NN	O
vs	NN	O
aminophylline	NN	O
group	NN	O
patients	NNS	O
with	IN	O
theophylline	JJ	O
level	NN	O
>	NN	O
or	CC	O
=	$	O
10	CD	O
mg/L	NN	O
)	)	O
.	.	O

We	PRP	O
conclude	VBP	O
that	DT	O
intravenous	JJ	O
aminophylline	NN	O
adds	VBZ	O
to	TO	O
the	DT	O
toxicity	NN	O
but	CC	O
not	RB	O
the	DT	O
efficacy	NN	O
of	IN	O
inhaled	JJ	O
salbutamol	NN	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
acute	JJ	O
exacerbations	NNS	O
of	IN	O
asthma	NN	O
.	.	O

Effects	NNS	O
of	IN	O
extended	JJ	O
release	NN	O
methylphenidate	NN	O
treatment	NN	O
on	IN	O
ratings	NNS	O
of	IN	O
attention-deficit/hyperactivity	NN	O
disorder	NN	O
(	(	O
ADHD	NNP	O
)	)	O
and	CC	O
associated	VBN	O
behavior	NN	O
in	IN	O
children	NNS	A
with	IN	O
autism	NN	C
spectrum	NN	C
disorders	NNS	C
and	CC	C
ADHD	NNP	C
symptoms	NNS	C
.	.	O

OBJECTIVE	IN	O
The	DT	O
purpose	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
examine	VB	O
the	DT	O
behavioral	JJ	O
effects	NNS	O
of	IN	O
four	CD	O
doses	NNS	O
of	IN	O
psychostimulant	JJ	O
medication	NN	O
,	,	O
combining	VBG	O
extended-release	JJ	O
methylphenidate	NN	O
(	(	O
MPH	NNP	O
)	)	O
in	IN	O
the	DT	O
morning	NN	O
with	IN	O
immediate-release	JJ	O
MPH	NNP	O
in	IN	O
the	DT	O
afternoon	NN	O
.	.	O

METHOD	NNP	O
The	DT	O
sample	NN	O
comprised	VBD	O
24	CD	SS
children	NNS	A
(	(	O
19	CD	SS
boys	NNS	SE
;	:	O
5	CD	SS
girls	NNS	SE
)	)	O
who	WP	O
met	VBD	O
American	NNP	O
Psychiatric	NNP	O
Association	NNP	O
,	,	O
Diagnostic	NNP	O
and	CC	O
Statistical	NNP	O
Manual	NNP	O
of	IN	O
Mental	NNP	O
Disorders	NNP	O
,	,	O
4th	CD	O
ed	NN	O
.	.	O

(	(	O
DSM-IV-TR	NNP	O
)	)	O
criteria	NN	O
for	IN	O
an	DT	O
autism	NN	O
spectrum	NN	O
disorder	NN	O
(	(	O
ASD	NNP	O
)	)	O
on	IN	O
the	DT	O
Autism	NNP	O
Diagnostic	NNP	O
Interview-Revised	JJ	O
(	(	O
ADI-R	NNP	O
)	)	O
and	CC	O
the	DT	O
Autism	NNP	O
Diagnostic	NNP	O
Observation	NNP	O
Schedule	NNP	O
(	(	O
ADOS	NNP	O
)	)	O
,	,	O
and	CC	O
had	VBD	O
significant	JJ	O
symptoms	NNS	O
of	IN	O
attention-deficit/hyperactivity	NN	O
disorder	NN	O
(	(	O
ADHD	NNP	O
)	)	O
.	.	O

This	DT	O
sample	NN	O
consisted	VBD	O
of	IN	O
elementary	JJ	A
school-age	NN	A
,	,	A
community-based	JJ	A
children	NNS	A
(	(	O
mean	JJ	O
chronological	JJ	O
age=8.8	NN	A
years	NNS	A
,	,	O
SD=1.7	NNP	O
;	:	O
mean	JJ	O
intelligence	NN	O
quotient	NN	O
[	NNP	O
IQ	NNP	O
]	NNP	O
=85	NNP	O
;	:	O
SD=16.8	NNP	O
)	)	O
.	.	O

Effects	NNS	O
of	IN	O
four	CD	O
dose	NN	O
levels	NNS	O
of	IN	O
MPH	NNP	O
on	IN	O
parent	NN	O
and	CC	O
teacher	RB	O
behavioral	JJ	O
ratings	NNS	O
were	VBD	O
investigated	VBN	O
using	VBG	O
a	DT	O
within-subject	JJ	O
,	,	O
crossover	NN	O
,	,	O
placebo-controlled	JJ	O
design	NN	O
.	.	O

RESULTS	NNP	O
MPH	NNP	O
treatment	NN	O
was	VBD	O
associated	VBN	O
with	IN	O
significant	JJ	O
declines	NNS	O
in	IN	O
hyperactive	JJ	O
and	CC	O
impulsive	JJ	O
behavior	NN	O
at	IN	O
both	DT	O
home	NN	O
and	CC	O
school	NN	O
.	.	O

Parents	NNS	O
noted	VBD	O
significant	JJ	O
declines	NNS	O
in	IN	O
inattentive	JJ	O
and	CC	O
oppositional	JJ	O
behavior	NN	O
,	,	O
and	CC	O
improvements	NNS	O
in	IN	O
social	JJ	O
skills	NNS	O
.	.	O

No	DT	O
exacerbation	NN	O
of	IN	O
stereotypies	NNS	O
was	VBD	O
noted	VBN	O
,	,	O
and	CC	O
side	JJ	O
effects	NNS	O
were	VBD	O
similar	JJ	O
to	TO	O
those	DT	O
seen	VBN	O
in	IN	O
typically	RB	O
developing	VBG	O
children	NNS	O
with	IN	O
ADHD	NNP	O
.	.	O

Dose	NNP	O
response	NN	O
was	VBD	O
primarily	RB	O
linear	JJ	O
in	IN	O
the	DT	O
dose	JJ	O
range	NN	O
studied	VBN	O
.	.	O

CONCLUSIONS	VB	O
The	DT	O
results	NNS	O
of	IN	O
this	DT	O
study	NN	O
suggest	VBP	O
that	IN	O
MPH	NNP	O
formulations	NNS	O
are	VBP	O
efficacious	JJ	O
and	CC	O
well-tolerated	JJ	O
for	IN	O
children	NNS	A
with	IN	O
ASD	NNP	C
and	CC	O
significant	JJ	C
ADHD	NNP	C
symptoms	NNS	C
.	.	O

The	DT	O
SPEM	NNP	O
(	(	O
Studio	NNP	O
Policentrico	NNP	O
Elettrocateteri	NNP	O
Membrane	NNP	O
)	)	O
:	:	O
a	DT	O
multicenter	NN	O
study	NN	O
on	IN	O
membrane	NN	C
leads	NNS	C
.	.	O

SPEM	NNP	O
is	VBZ	O
a	DT	O
multicenter	NN	O
randomized	VBN	O
double-blind	NN	O
study	NN	O
performed	VBD	O
to	TO	O
test	VB	O
the	DT	O
acute	NN	O
and	CC	O
chronic	JJ	O
electrophysiological	JJ	O
behavior	NN	O
of	IN	O
three	CD	O
different	JJ	O
ventricular	JJ	C
leads	NNS	C
:	:	O
(	(	O
1	CD	O
)	)	O
an	DT	O
ion	NN	O
exchange	NN	O
membrane	NN	O
with	IN	O
30-microgram	JJ	O
dexamethasone	NN	O
elution	NN	O
in	IN	O
a	DT	O
contoured	JJ	O
activated	JJ	O
carbon	NN	O
tip	NN	O
lead	NN	O
(	(	O
Membrane	NNP	O
1400T	CD	O
,	,	O
30	CD	O
patients	NNS	O
)	)	O
;	:	O
(	(	O
2	CD	O
)	)	O
the	DT	O
same	JJ	O
lead	NN	O
design	NN	O
without	IN	O
steroid	NN	O
(	(	O
Membrane	NNP	O
1401T	CD	O
,	,	O
24	CD	O
patients	NNS	O
)	)	O
;	:	O
and	CC	O
(	(	O
3	CD	O
)	)	O
the	DT	O
same	JJ	O
lead	NN	O
design	NN	O
without	IN	O
steroid	NN	O
or	CC	O
membrane	NN	O
(	(	O
control	NN	O
group	NN	O
,	,	O
27	CD	O
patients	NNS	O
)	)	O
.	.	O

Twenty-three	CD	SS
of	IN	O
the	DT	O
81	CD	SS
patients	NNS	O
were	VBD	O
women	NNS	SE
;	:	O
the	DT	O
mean	JJ	O
age	NN	O
for	IN	O
all	DT	O
patients	NNS	O
was	VBD	O
74	CD	A
+/-	JJ	A
10	CD	A
years	NNS	A
.	.	O

Parameters	NNS	O
are	VBP	O
calculated	VBN	O
both	DT	O
in	IN	O
uni-	JJ	O
and	CC	O
bipolar	JJ	O
configuration	NN	O
at	IN	O
implant	JJ	O
and	CC	O
at	IN	O
follow-up	JJ	O
after	IN	O
1	CD	O
,	,	O
5	CD	O
,	,	O
15	CD	O
,	,	O
30	CD	O
,	,	O
90	CD	O
,	,	O
180	CD	O
,	,	O
and	CC	O
360	CD	O
days	NNS	O
.	.	O

Implant	JJ	O
threshold	NN	O
(	(	O
chronaxie	JJ	O
=	$	O
0.413	CD	O
+/-	JJ	O
0.280	CD	O
ms	NN	O
,	,	O
rheobase	VB	O
=	JJ	O
0.264	CD	O
+/-	JJ	O
0.099	CD	O
V	NNP	O
)	)	O
,	,	O
signal	JJ	O
amplitude	NN	O
(	(	O
13.45	CD	O
+/-	JJ	O
5.87	CD	O
mV	NN	O
)	)	O
,	,	O
and	CC	O
slew	JJ	O
rate	NN	O
(	(	O
2.05	CD	O
+/-	JJ	O
1.38	CD	O
V/s	NNP	O
)	)	O
reveal	VBP	O
no	DT	O
significant	JJ	O
differences	NNS	O
.	.	O

Pacing	VBG	O
impedance	NN	O
values	NNS	O
both	DT	O
at	IN	O
implant	NN	O
(	(	O
unipolar	JJ	O
571	CD	O
+/-	JJ	O
165	CD	O
omega	NN	O
;	:	O
bipolar	JJ	O
605	CD	O
+/-	JJ	O
123	CD	O
omega	NN	O
)	)	O
and	CC	O
at	IN	O
follow-ups	NNS	O
(	(	O
unipolar	JJ	O
480	CD	O
+/-	JJ	O
72	CD	O
omega	NN	O
;	:	O
bipolar	JJ	O
518	CD	O
+/-	JJ	O
75	CD	O
omega	NN	O
)	)	O
are	VBP	O
slightly	RB	O
lower	JJR	O
in	IN	O
the	DT	O
unipolar	JJ	O
configuration	NN	O
.	.	O

At	IN	O
15	CD	O
and	CC	O
30-day	JJ	O
follow-ups	NNS	O
,	,	O
control	NN	O
group	NN	O
and	CC	O
nonsteroid	JJ	O
leads	VBZ	O
show	VB	O
a	DT	O
higher	JJR	O
threshold	JJ	O
value	NN	O
growth	NN	O
(	(	O
in	IN	O
unipolar	NN	O
from	IN	O
0.16	CD	O
+/-	JJ	O
0.11	CD	O
to	TO	O
1.19	CD	O
+/-	JJ	O
0.85	CD	O
microJ	NN	O
;	:	O
in	IN	O
bipolar	NN	O
from	IN	O
0.18	CD	O
+/-	JJ	O
0.13	CD	O
to	TO	O
1.24	CD	O
+/-	JJ	O
0.88	CD	O
microJ	NN	O
)	)	O
than	IN	O
the	DT	O
membrane	NN	O
steroid	NN	O
leads	VBZ	O
(	(	O
in	IN	O
unipolar	NN	O
from	IN	O
0.13	CD	O
+/-	JJ	O
0.11	CD	O
to	TO	O
0.70	CD	O
+/-	JJ	O
0.39	CD	O
microJ	NN	O
;	:	O
in	IN	O
bipolar	NN	O
from	IN	O
0.23	CD	O
+/-	JJ	O
0.32	CD	O
to	TO	O
0.76	CD	O
+/-	JJ	O
0.36	CD	O
microJ	NN	O
)	)	O
;	:	O
the	DT	O
threshold	NN	O
of	IN	O
nonsteroid	JJ	O
leads	NNS	O
decreases	NNS	O
after	IN	O
1-3	JJ	O
months	NNS	O
and	CC	O
it	PRP	O
settles	VBZ	O
at	IN	O
the	DT	O
same	JJ	O
threshold	JJ	O
level	NN	O
of	IN	O
the	DT	O
leads	NNS	O
with	IN	O
membrane	NN	O
and	CC	O
steroid	NN	O
(	(	O
in	IN	O
unipolar	JJ	O
0.60	CD	O
+/-	JJ	O
0.33	CD	O
microJ	NN	O
;	:	O
in	IN	O
bipolar	JJ	O
0.55	CD	O
+/-	JJ	O
0.26	CD	O
microJ	NN	O
)	)	O
,	,	O
which	WDT	O
has	VBZ	O
been	VBN	O
stable	JJ	O
since	IN	O
the	DT	O
first	JJ	O
month	NN	O
.	.	O

The	DT	O
ion	NN	O
exchange	NN	O
membrane	NN	O
is	VBZ	O
effective	JJ	O
in	IN	O
reducing	VBG	O
the	DT	O
chronic	JJ	O
pacing	NN	O
threshold	NN	O
like	IN	O
acute	JJ	O
steroid	JJ	O
elution	NN	O
at	IN	O
low	JJ	O
doses	NNS	O
,	,	O
but	CC	O
membrane	FW	O
alone	RB	O
does	VBZ	O
not	RB	O
prevent	VB	O
an	DT	O
acute	JJ	O
pacing	NN	O
threshold	JJ	O
increase	NN	O
through	IN	O
the	DT	O
first	JJ	O
month	NN	O
postimplant	NN	O
.	.	O

Hemostatic	JJ	O
function	NN	O
of	IN	O
aspirin-treated	JJ	O
platelets	NNS	O
vulnerable	JJ	O
to	TO	O
cardiopulmonary	JJ	O
bypass	NN	O
.	.	O

Altered	NNP	O
shear-induced	JJ	O
pathway	NN	O
.	.	O

The	DT	O
impaired	JJ	O
hemostasis	NN	O
of	IN	O
aspirin-treated	JJ	C
patients	NNS	C
is	VBZ	O
an	DT	O
annoying	VBG	O
problem	NN	O
during	IN	O
and	CC	O
after	IN	O
cardiopulmonary	JJ	C
bypass	NN	C
.	.	O

The	DT	O
hemostatic	JJ	O
function	NN	O
of	IN	O
platelets	NNS	O
comprises	NNS	O
two	CD	O
mechanisms	NNS	O
:	:	O
the	DT	O
shear-induced	JJ	O
and	CC	O
the	DT	O
cyclooxygenase	NN	O
pathways	NNS	O
.	.	O

Because	IN	O
the	DT	O
latter	NN	O
is	VBZ	O
inhibited	VBN	O
in	IN	O
aspirin-treated	JJ	C
patients	NNS	C
,	,	O
the	DT	O
hemostatic	JJ	O
function	NN	O
depends	VBZ	O
mainly	RB	O
on	IN	O
the	DT	O
former	JJ	O
pathway	NN	O
.	.	O

To	TO	O
investigate	VB	O
the	DT	O
effect	NN	O
of	IN	O
cardiopulmonary	JJ	O
bypass	NN	O
on	IN	O
the	DT	O
shear-induced	JJ	O
pathway	NN	O
,	,	O
a	DT	O
double-blind	JJ	O
study	NN	O
of	IN	O
preoperative	JJ	O
aspirin	NN	O
treatment	NN	O
(	(	O
325	CD	O
mg	NN	O
)	)	O
and	CC	O
placebo	NN	O
was	VBD	O
conducted	VBN	O
in	IN	O
40	CD	O
patients	NNS	O
undergoing	JJ	C
coronary	JJ	C
artery	NN	C
bypass	NN	C
grafting	NN	C
.	.	O

Postoperative	JJ	O
blood	NN	O
loss	NN	O
was	VBD	O
higher	RBR	O
in	IN	O
the	DT	O
aspirin-treated	JJ	O
patients	NNS	O
than	IN	O
in	IN	O
the	DT	O
placebo-treated	JJ	O
patients	NNS	O
(	(	O
p	JJ	O
<	NNP	O
0.05	CD	O
)	)	O
.	.	O

The	DT	O
shear-induced	JJ	O
hemostasis	NN	O
was	VBD	O
monitored	VBN	O
by	IN	O
the	DT	O
in	IN	O
vitro	NN	O
bleeding	VBG	O
test	NN	O
(	(	O
Thrombostat	NNP	O
)	)	O
,	,	O
which	WDT	O
mimics	VBD	O
bleeding	VBG	O
through	IN	O
an	DT	O
injured	JJ	O
arteriole	NN	O
.	.	O

The	DT	O
shear-induced	JJ	O
pathway	NN	O
of	IN	O
aspirin-treated	JJ	O
platelets	NNS	O
was	VBD	O
not	RB	O
affected	VBN	O
before	IN	O
cardiopulmonary	JJ	O
bypass	NN	O
,	,	O
but	CC	O
it	PRP	O
was	VBD	O
impaired	VBN	O
more	RBR	O
during	IN	O
the	DT	O
operation	NN	O
(	(	O
p	JJ	O
<	NNP	O
0.01	CD	O
)	)	O
and	CC	O
remained	VBD	O
worse	JJR	O
afterward	NN	O
(	(	O
p	JJ	O
<	NNP	O
0.05	CD	O
)	)	O
,	,	O
compared	VBN	O
with	IN	O
that	DT	O
of	IN	O
placebo-treated	JJ	O
platelets	NNS	O
.	.	O

The	DT	O
inhibitory	JJ	O
effects	NNS	O
of	IN	O
aspirin	NN	O
on	IN	O
thromboxane	NN	O
production	NN	O
and	CC	O
on	IN	O
collagen-induced	JJ	O
platelet	NN	O
aggregation	NN	O
remained	VBD	O
throughout	IN	O
the	DT	O
operation	NN	O
.	.	O

In	IN	O
aspirin-treated	JJ	O
platelets	NNS	O
,	,	O
the	DT	O
aggregation	NN	O
capacity	NN	O
induced	VBN	O
by	IN	O
adenosine	JJ	O
diphosphate	NN	O
was	VBD	O
inhibited	VBN	O
before	IN	O
the	DT	O
operation	NN	O
(	(	O
p	JJ	O
<	NNP	O
0.05	CD	O
)	)	O
and	CC	O
showed	VBD	O
substantial	JJ	O
recovery	NN	O
during	IN	O
the	DT	O
operation	NN	O
(	(	O
p	JJ	O
<	NNP	O
0.05	CD	O
)	)	O
.	.	O

These	DT	O
results	NNS	O
suggest	VBP	O
that	IN	O
the	DT	O
shear-induced	JJ	O
pathway	NN	O
of	IN	O
aspirin-treated	JJ	O
platelets	NNS	O
is	VBZ	O
more	RBR	O
vulnerable	JJ	O
to	TO	O
cardiopulmonary	JJ	O
bypass	NN	O
than	IN	O
the	DT	O
pathway	NN	O
in	IN	O
normal	JJ	O
platelets	NNS	O
and	CC	O
causes	NNS	O
severe	JJ	O
impairment	NN	O
of	IN	O
hemostasis	NN	O
afterward	NN	O
.	.	O

Effect	NN	O
of	IN	O
total	JJ	O
androgen	NN	O
ablation	NN	O
on	IN	O
pathologic	JJ	O
stage	NN	O
and	CC	O
resection	NN	O
limit	NN	O
status	NN	O
of	IN	O
prostate	NN	C
cancer	NN	C
.	.	O

Initial	JJ	O
results	NNS	O
of	IN	O
the	DT	O
Italian	JJ	O
PROSIT	NNP	O
study	NN	O
.	.	O

The	DT	O
likelihood	NN	O
of	IN	O
finding	VBG	O
organ-confined	JJ	O
untreated	JJ	O
prostate	NN	O
cancer	NN	O
(	(	O
PCa	NNP	O
)	)	O
by	IN	O
pathological	JJ	O
examination	NN	O
at	IN	O
the	DT	O
time	NN	O
of	IN	O
radical	JJ	O
prostatectomy	NN	O
(	(	O
RP	NNP	O
)	)	O
is	VBZ	O
only	RB	O
50	CD	O
%	NN	O
in	IN	O
patients	NNS	O
with	IN	O
clinically	RB	O
organ-confined	JJ	O
disease	NN	O
.	.	O

In	IN	O
addition	NN	O
,	,	O
tumour	NN	O
is	VBZ	O
present	JJ	O
at	IN	O
the	DT	O
resection	NN	O
margin	NN	O
in	IN	O
approximately	RB	O
30	CD	O
%	NN	O
of	IN	O
clinical	JJ	O
T2	NNP	O
(	(	O
clinical	JJ	O
stage	NN	O
B	NNP	O
)	)	O
cases	NNS	O
.	.	O

The	DT	O
issue	NN	O
of	IN	O
clinical	JJ	O
understaging	NN	O
and	CC	O
of	IN	O
resection	NN	O
limit	NN	O
positivity	NN	O
have	VBP	O
led	VBN	O
to	TO	O
the	DT	O
development	NN	O
of	IN	O
novel	JJ	O
management	NN	O
practices	NNS	O
,	,	O
including	VBG	O
neoadjuvant	JJ	O
hormonal	JJ	O
therapy	NN	O
(	(	O
NHT	NNP	O
)	)	O
.	.	O

The	DT	O
optimal	JJ	O
duration	NN	O
of	IN	O
NHT	NNP	O
is	VBZ	O
unknown	JJ	O
.	.	O

We	PRP	O
undertook	VBD	O
the	DT	O
present	JJ	O
analysis	NN	O
to	TO	O
evaluate	VB	O
the	DT	O
effect	NN	O
of	IN	O
NHT	NNP	O
on	IN	O
pathologic	JJ	O
stage	NN	O
of	IN	O
PCa	NNP	O
and	CC	O
resection	NN	O
limit	NN	O
status	NN	O
in	IN	O
patients	NNS	O
with	IN	O
prostate	JJ	O
cancer	NN	O
and	CC	O
treated	VBN	O
with	IN	O
total	JJ	O
androgen	NN	O
ablation	NN	O
either	DT	O
for	IN	O
three	CD	O
or	CC	O
six	CD	O
months	NNS	O
before	IN	O
RP	NNP	O
.	.	O

Between	NNP	O
January	NNP	O
1996	CD	O
and	CC	O
February	NNP	O
1998	CD	O
,	,	O
259	CD	O
men	NNS	SE
with	IN	O
prostate	NN	C
cancer	NN	C
underwent	JJ	O
radical	JJ	O
retropubic	NN	O
prostatectomy	NN	O
and	CC	O
bilateral	JJ	O
pelvic	JJ	O
node	NN	O
dissection	NN	O
in	IN	O
the	DT	O
26	CD	O
centres	NNS	O
participating	VBG	O
in	IN	O
the	DT	O
Italian	JJ	O
randomised	VBD	O
prospective	JJ	O
PROSIT	NNP	O
study	NN	O
.	.	O

Whole	NNP	O
mount	NN	O
sectioning	NN	O
of	IN	O
the	DT	O
complete	JJ	O
RP	NNP	O
specimens	NNS	O
was	VBD	O
adopted	VBN	O
in	IN	O
each	DT	O
centre	NN	O
for	IN	O
accurately	RB	O
evaluating	VBG	O
the	DT	O
pathologic	JJ	O
stage	NN	O
and	CC	O
resection	NN	O
limit	NN	O
status	NN	O
.	.	O

By	IN	O
February	NNP	O
1998	CD	O
,	,	O
haematoxylin	NN	O
and	CC	O
eosin	NN	O
stained	VBD	O
sections	NNS	O
from	IN	O
155	CD	O
RP	NNP	O
specimens	NNS	O
had	VBD	O
been	VBN	O
received	VBN	O
and	CC	O
evaluated	VBN	O
by	IN	O
the	DT	O
reviewing	VBG	O
pathologist	NN	O
(	(	O
RM	NNP	O
)	)	O
.	.	O

64	CD	O
cases	NNS	O
had	VBD	O
not	RB	O
been	VBN	O
treated	VBN	O
with	IN	O
total	JJ	O
androgen	NN	O
ablation	NN	O
(	(	O
e.g	JJ	O
.	.	O

NHT	NNP	O
)	)	O
before	IN	O
RP	NNP	O
was	VBD	O
performed	VBN	O
,	,	O
whereas	JJ	O
58	CD	O
and	CC	O
33	CD	O
had	VBD	O
been	VBN	O
treated	VBN	O
for	IN	O
three	CD	O
and	CC	O
six	CD	O
months	NNS	O
,	,	O
respectively	RB	O
.	.	O

114	CD	O
patients	NNS	O
were	VBD	O
clinical	JJ	O
stage	NN	O
B	NNP	O
whereas	IN	O
41	CD	O
were	VBD	O
clinical	JJ	O
stage	NN	O
C.	NNP	O
After	IN	O
three	CD	O
months	NNS	O
of	IN	O
total	JJ	O
androgen	NN	O
ablation	NN	O
,	,	O
pathological	JJ	O
stage	NN	O
B	NNP	O
was	VBD	O
more	RBR	O
prevalent	JJ	O
among	IN	O
patients	NNS	O
with	IN	O
clinical	JJ	O
B	NNP	O
tumours	NN	O
,	,	O
compared	VBN	O
with	IN	O
untreated	JJ	O
patients	NNS	O
(	(	O
57	CD	O
%	NN	O
in	IN	O
treated	JJ	O
patients	NNS	O
vs.	FW	O
36	CD	O
%	NN	O
in	IN	O
untreated	JJ	O
)	)	O
.	.	O

The	DT	O
percentage	NN	O
of	IN	O
cancers	NNS	O
with	IN	O
negative	JJ	O
margins	NNS	O
was	VBD	O
statistically	RB	O
significantly	RB	O
greater	JJR	O
in	IN	O
patients	NNS	O
treated	VBN	O
with	IN	O
neoadjuvant	JJ	O
therapy	NN	O
than	IN	O
those	DT	O
treated	VBN	O
with	IN	O
immediate	JJ	O
surgery	NN	O
alone	RB	O
(	(	O
69	CD	O
%	NN	O
vs.	FW	O
42	CD	O
%	NN	O
,	,	O
respectively	RB	O
)	)	O
.	.	O

After	IN	O
six	CD	O
months	NNS	O
of	IN	O
NHT	NNP	O
therapy	VBP	O
the	DT	O
proportion	NN	O
of	IN	O
patients	NNS	O
with	IN	O
pathological	JJ	O
stage	NN	O
B	NNP	O
(	(	O
67	CD	O
%	NN	O
vs.	FW	O
36	CD	O
%	NN	O
,	,	O
respectively	RB	O
)	)	O
and	CC	O
negative	JJ	O
margins	NNS	O
was	VBD	O
greater	JJR	O
than	IN	O
after	IN	O
3	CD	O
months	NNS	O
(	(	O
92	CD	O
%	NN	O
vs.	FW	O
42	CD	O
%	NN	O
,	,	O
respectively	RB	O
)	)	O
.	.	O

For	IN	O
clinical	JJ	O
C	NNP	O
tumours	NN	O
,	,	O
the	DT	O
prevalence	NN	O
of	IN	O
pathological	JJ	O
stage	NN	O
B	NNP	O
and	CC	O
negative	JJ	O
margins	NNS	O
in	IN	O
the	DT	O
patients	NNS	O
treated	VBD	O
for	IN	O
either	DT	O
3	CD	O
or	CC	O
6	CD	O
months	NNS	O
was	VBD	O
not	RB	O
as	RB	O
high	JJ	O
as	IN	O
in	IN	O
the	DT	O
clinical	JJ	O
B	NNP	O
tumours	NN	O
,	,	O
when	WRB	O
compared	VBN	O
with	IN	O
the	DT	O
untreated	JJ	O
group	NN	O
(	(	O
pathological	JJ	O
stage	NN	O
B	NNP	O
:	:	O
31	CD	O
%	NN	O
and	CC	O
33	CD	O
%	NN	O
vs.	FW	O
6	CD	O
%	NN	O
in	IN	O
the	DT	O
clinical	JJ	O
C	NNP	O
cases	NNS	O
,	,	O
respectively	RB	O
.	.	O

Negative	JJ	O
margins	NNS	O
:	:	O
56	CD	O
%	NN	O
and	CC	O
67	CD	O
%	NN	O
vs.	FW	O
31	CD	O
%	NN	O
,	,	O
respectively	RB	O
)	)	O
.	.	O

The	DT	O
initial	JJ	O
results	NNS	O
of	IN	O
this	DT	O
study	NN	O
suggest	VBP	O
that	IN	O
total	JJ	O
androgen	NN	O
ablation	NN	O
before	IN	O
RP	NNP	O
is	VBZ	O
beneficial	JJ	O
in	IN	O
men	NNS	O
with	IN	O
clinical	JJ	O
stage	NN	O
B	NNP	O
because	IN	O
of	IN	O
the	DT	O
significant	JJ	O
pathological	JJ	O
downstaging	NN	O
and	CC	O
decrease	NN	O
in	IN	O
the	DT	O
number	NN	O
of	IN	O
positive	JJ	O
margins	NNS	O
in	IN	O
the	DT	O
RP	NNP	O
specimens	NNS	O
.	.	O

These	DT	O
two	CD	O
effects	NNS	O
are	VBP	O
more	RBR	O
pronounced	JJ	O
after	IN	O
six	CD	O
months	NNS	O
of	IN	O
NHT	NNP	O
than	IN	O
after	IN	O
three	CD	O
months	NNS	O
of	IN	O
therapy	NN	O
.	.	O

The	DT	O
same	JJ	O
degree	NN	O
of	IN	O
beneficial	JJ	O
effects	NNS	O
are	VBP	O
not	RB	O
observed	VBN	O
in	IN	O
clinical	JJ	O
C	NNP	O
tumours	NN	O
.	.	O

Serum	NNP	O
bactericidal	NN	O
activities	NNS	O
and	CC	O
comparative	JJ	O
pharmacokinetics	NNS	O
of	IN	O
meropenem	NN	O
and	CC	O
imipenem-cilastatin	NN	O
.	.	O

The	DT	O
pharmacokinetics	NNS	O
and	CC	O
serum	NN	O
bactericidal	NN	O
activities	NNS	O
(	(	O
SBAs	NNP	O
)	)	O
of	IN	O
imipenem	NN	O
and	CC	O
meropenem	NN	O
were	VBD	O
investigated	VBN	O
in	IN	O
a	DT	O
randomized	VBN	O
crossover	NN	O
study	NN	O
.	.	O

Twelve	NNP	O
healthy	JJ	O
male	NN	O
volunteers	NNS	O
received	VBD	O
a	DT	O
constant	JJ	O
30-min	JJ	O
infusion	NN	O
of	IN	O
either	CC	O
1	CD	O
g	NN	O
of	IN	O
imipenem	JJ	O
plus	CC	O
1	CD	O
g	NN	O
of	IN	O
cilastatin	NN	O
or	CC	O
1	CD	O
g	NN	O
of	IN	O
meropenem	NN	O
.	.	O

The	DT	O
concentrations	NNS	O
of	IN	O
the	DT	O
drugs	NNS	O
in	IN	O
serum	NN	O
and	CC	O
urine	NN	O
were	VBD	O
determined	VBN	O
by	IN	O
bioassay	NN	O
and	CC	O
high-pressure	NN	O
liquid	NN	O
chromatography	NN	O
.	.	O

Pharmacokinetic	JJ	O
parameters	NNS	O
were	VBD	O
based	VBN	O
on	IN	O
an	DT	O
open	JJ	O
two-compartment	JJ	O
model	NN	O
and	CC	O
a	DT	O
noncompartmental	JJ	O
technique	NN	O
.	.	O

At	IN	O
the	DT	O
end	NN	O
of	IN	O
infusion	NN	O
,	,	O
the	DT	O
mean	JJ	O
concentrations	NNS	O
of	IN	O
imipenem	NN	O
and	CC	O
meropenem	NN	O
measured	VBN	O
in	IN	O
serum	NN	O
were	VBD	O
61.2	CD	O
+/-	JJ	O
9.8	CD	O
and	CC	O
51.6	CD	O
+/-	JJ	O
6.5	CD	O
mg/liter	NN	O
,	,	O
respectively	RB	O
;	:	O
urinary	JJ	O
recoveries	NNS	O
were	VBD	O
48.6	CD	O
%	NN	O
+/-	JJ	O
8.2	CD	O
%	NN	O
and	CC	O
60.0	CD	O
%	NN	O
+/-	JJ	O
6.5	CD	O
%	NN	O
of	IN	O
the	DT	O
dose	NN	O
in	IN	O
12	CD	O
h	NN	O
,	,	O
respectively	RB	O
;	:	O
and	CC	O
the	DT	O
areas	NNS	O
under	IN	O
the	DT	O
concentration-time	JJ	O
curve	NN	O
from	IN	O
time	NN	O
zero	CD	O
to	TO	O
infinity	NN	O
were	VBD	O
96.1	CD	O
+/-	JJ	O
14.4	CD	O
and	CC	O
70.5	CD	O
+/-	JJ	O
10.3	CD	O
mg.h/liter	NN	O
,	,	O
respectively	RB	O
(	(	O
P	NNP	O
<	NNP	O
or	CC	O
=	VB	O
0.02	CD	O
)	)	O
.	.	O

Imipenem	NNP	O
had	VBD	O
a	DT	O
mean	JJ	O
half-life	NN	O
of	IN	O
66.7	CD	O
+/-	JJ	O
10.4	CD	O
min	NN	O
;	:	O
that	IN	O
of	IN	O
meropenem	NN	O
was	VBD	O
64.4	CD	O
+/-	JJ	O
6.9	CD	O
min	NN	O
.	.	O

The	DT	O
volumes	NNS	O
of	IN	O
distribution	NN	O
at	IN	O
steady	JJ	O
state	NN	O
of	IN	O
imipenem	NN	O
and	CC	O
meropenem	NN	O
were	VBD	O
15.3	CD	O
+/-	JJ	O
3.3	CD	O
and	CC	O
18.6	CD	O
+/-	JJ	O
3.0	CD	O
liters/70	NN	O
kg	NN	O
,	,	O
respectively	RB	O
,	,	O
and	CC	O
the	DT	O
mean	JJ	O
renal	JJ	O
clearances	NNS	O
per	IN	O
1.73	CD	O
m2	NNS	O
were	VBD	O
85.6	CD	O
+/-	JJ	O
17.6	CD	O
and	CC	O
144.6	CD	O
+/-	JJ	O
26.0	CD	O
ml/min	NN	O
,	,	O
respectively	RB	O
.	.	O

Both	DT	O
antibiotics	NNS	O
were	VBD	O
well	RB	O
tolerated	VBN	O
in	IN	O
this	DT	O
single-dose	JJ	O
administration	NN	O
study	NN	O
.	.	O

The	DT	O
SBAs	NNP	O
were	VBD	O
measured	VBN	O
by	IN	O
the	DT	O
microdilution	NN	O
method	NN	O
of	IN	O
Reller	NNP	O
and	CC	O
Stratton	NNP	O
(	(	O
L.	NNP	O
B.	NNP	O
Reller	NNP	O
and	CC	O
C.	NNP	O
W.	NNP	O
Stratton	NNP	O
,	,	O
J.	NNP	O
Infect	NNP	O
.	.	O

Dis	NNP	O
.	.	O

136:196-204	CD	O
,	,	O
1977	CD	O
)	)	O
against	IN	O
40	CD	O
clinically	RB	O
isolated	JJ	O
strains	NNS	O
.	.	O

Mean	NNP	O
reciprocal	JJ	O
bactericidal	NN	O
titers	NNS	O
were	VBD	O
measured	VBN	O
1	CD	O
and	CC	O
6	CD	O
h	NN	O
after	IN	O
administration	NN	O
.	.	O

After	IN	O
1	CD	O
and	CC	O
6	CD	O
h	NN	O
the	DT	O
median	JJ	O
SBAs	NNP	O
for	IN	O
imipenem	NN	O
and	CC	O
meropenem	NN	O
,	,	O
were	VBD	O
409	CD	O
and	CC	O
34.9	CD	O
and	CC	O
97.9	CD	O
and	CC	O
5.8	CD	O
,	,	O
respectively	RB	O
,	,	O
against	IN	O
Staphylococcus	NNP	O
aureus	NN	O
,	,	O
19.9	CD	O
and	CC	O
4.4	CD	O
and	CC	O
19.4	CD	O
and	CC	O
4.8	CD	O
,	,	O
respectively	RB	O
,	,	O
against	IN	O
Pseudomonas	NNP	O
aeruginosa	NN	O
,	,	O
34.3	CD	O
and	CC	O
2.2	CD	O
and	CC	O
232	CD	O
and	CC	O
15.5	CD	O
,	,	O
respectively	RB	O
,	,	O
against	IN	O
Enterobacter	NNP	O
cloacae	NN	O
,	,	O
and	CC	O
13.4	CD	O
and	CC	O
2.25	CD	O
and	CC	O
90.7	CD	O
and	CC	O
7.9	CD	O
,	,	O
respectively	RB	O
,	,	O
against	IN	O
Proteus	NNP	O
mirabilis	NN	O
.	.	O

Both	DT	O
drugs	NNS	O
had	VBD	O
rather	RB	O
short	JJ	O
biological	JJ	O
elimination	NN	O
half-lives	NNS	O
and	CC	O
a	DT	O
predominantly	RB	O
renal	JJ	O
route	NN	O
of	IN	O
elimination	NN	O
.	.	O

Both	DT	O
carbapenems	NNS	O
revealed	VBD	O
high	JJ	O
SBAs	NNP	O
against	IN	O
clinically	RB	O
important	JJ	O
pathogens	NNS	O
at	IN	O
1	CD	O
h	NN	O
;	:	O
meropenem	NN	O
had	VBD	O
a	DT	O
higher	JJR	O
SBA	NNP	O
against	IN	O
E.	NNP	O
cloacae	NN	O
and	CC	O
P.	NNP	O
mirabilis	NN	O
,	,	O
and	CC	O
the	DT	O
SBA	NNP	O
of	IN	O
imipenem	NN	O
against	IN	O
S.	NNP	O
aureus	NN	O
was	VBD	O
greater	JJR	O
than	IN	O
the	DT	O
SBA	NNP	O
of	IN	O
meropenem	NN	O
.	.	O

Carotid	NNP	O
sinus	CC	O
syndrome	NN	O
:	:	O
a	DT	O
modifiable	JJ	O
risk	NN	O
factor	NN	O
for	IN	O
nonaccidental	JJ	O
falls	NNS	O
in	IN	O
older	JJR	O
adults	NNS	O
(	(	O
SAFE	NNP	O
PACE	NNP	O
)	)	O
.	.	O

OBJECTIVES	CC	O
The	DT	O
aim	NN	O
of	IN	O
the	DT	O
study	NN	O
was	VBD	O
to	TO	O
determine	VB	O
whether	IN	O
cardiac	JJ	O
pacing	NN	O
reduces	NNS	O
falls	VBZ	O
in	IN	O
older	JJR	O
adults	NNS	O
with	IN	O
cardioinhibitory	JJ	O
carotid	NNS	O
sinus	VBP	O
hypersensitivity	NN	O
(	(	O
CSH	NNP	O
)	)	O
.	.	O

BACKGROUND	NNP	O
Cardioinhibitory	NNP	O
carotid	NN	O
sinus	NN	O
syndrome	JJ	O
causes	NNS	O
syncope	NN	O
,	,	O
and	CC	O
symptoms	NNS	O
respond	NN	O
to	TO	O
cardiac	VB	O
pacing	NN	O
.	.	O

There	EX	O
is	VBZ	O
circumstantial	JJ	O
evidence	NN	O
for	IN	O
an	DT	O
association	NN	O
between	IN	O
falls	NNS	O
and	CC	O
the	DT	O
syndrome	NN	O
.	.	O

METHODS	NNP	O
A	NNP	O
randomized	VBD	O
controlled	JJ	O
trial	NN	O
was	VBD	O
done	VBN	O
of	IN	O
consecutive	JJ	O
older	JJR	O
patients	NNS	O
(	(	O
>	JJ	O
50	CD	O
years	NNS	O
)	)	O
attending	VBG	O
an	DT	O
accident	NN	O
and	CC	O
emergency	NN	O
facility	NN	O
because	IN	O
of	IN	O
a	DT	O
non-accidental	JJ	O
fall	NN	O
.	.	O

Patients	NNS	O
were	VBD	O
randomized	VBN	O
to	TO	O
dual-chamber	VB	O
pacemaker	NN	O
implant	NN	O
(	(	O
paced	JJ	O
patients	NNS	O
)	)	O
or	CC	O
standard	JJ	O
treatment	NN	O
(	(	O
controls	NNS	O
)	)	O
.	.	O

The	DT	O
primary	JJ	O
outcome	NN	O
was	VBD	O
the	DT	O
number	NN	O
of	IN	O
falls	NNS	O
during	IN	O
one	CD	O
year	NN	O
of	IN	O
follow-up	NN	O
.	.	O

RESULTS	NNP	O
One	CD	O
hundred	VBD	O
seventy-five	JJ	O
eligible	JJ	O
patients	NNS	O
(	(	O
mean	JJ	O
age	NN	O
73	CD	O
+/-	JJ	O
10	CD	O
years	NNS	O
;	:	O
60	CD	O
%	NN	O
women	NNS	O
)	)	O
were	VBD	O
randomized	VBN	O
to	TO	O
the	DT	O
trial	NN	O
:	:	O
pacemaker	NN	O
87	CD	O
;	:	O
controls	NNS	O
88	CD	O
.	.	O

Falls	NNP	O
(	(	O
without	IN	O
loss	NN	O
of	IN	O
consciousness	NN	O
)	)	O
were	VBD	O
reduced	VBN	O
by	IN	O
two-thirds	NNS	O
:	:	O
controls	NNS	O
reported	VBD	O
669	CD	O
falls	NNS	O
(	(	O
mean	JJ	O
9.3	CD	O
;	:	O
range	NN	O
0	CD	O
to	TO	O
89	CD	O
)	)	O
,	,	O
and	CC	O
paced	VBD	O
patients	NNS	O
216	CD	O
falls	NNS	O
(	(	O
mean	JJ	O
4.1	CD	O
;	:	O
range	NN	O
0	CD	O
to	TO	O
29	CD	O
)	)	O
.	.	O

Thus	RB	O
,	,	O
paced	VBD	O
patients	NNS	O
were	VBD	O
significantly	RB	O
less	RBR	O
likely	JJ	O
to	TO	O
fall	VB	O
(	(	O
odds	NNS	O
ratio	VBP	O
0.42	CD	O
;	:	O
95	CD	O
%	NN	O
confidence	NN	O
interval	NN	O
:	:	O
0.23	CD	O
,	,	O
0.75	CD	O
)	)	O
than	IN	O
were	VBD	O
controls	NNS	O
.	.	O

Syncopal	JJ	O
events	NNS	O
were	VBD	O
also	RB	O
reduced	VBN	O
during	IN	O
the	DT	O
follow-up	JJ	O
period	NN	O
,	,	O
but	CC	O
there	EX	O
were	VBD	O
much	RB	O
fewer	JJR	O
syncopal	JJ	O
events	NNS	O
than	IN	O
falls-28	JJ	O
episodes	NNS	O
in	IN	O
paced	JJ	O
patients	NNS	O
and	CC	O
47	CD	O
in	IN	O
controls	NNS	O
.	.	O

Injurious	JJ	O
events	NNS	O
were	VBD	O
reduced	VBN	O
by	IN	O
70	CD	O
%	NN	O
(	(	O
202	CD	O
in	IN	O
controls	NNS	O
compared	VBN	O
to	TO	O
61	CD	O
in	IN	O
paced	JJ	O
patients	NNS	O
)	)	O
.	.	O

CONCLUSIONS	NNP	O
There	EX	O
is	VBZ	O
a	DT	O
strong	JJ	O
association	NN	O
between	IN	O
non-accidental	JJ	O
falls	NNS	O
and	CC	O
cardioinhibitory	NN	O
CSH	NNP	O
.	.	O

These	DT	O
patients	NNS	O
would	MD	O
not	RB	O
usually	RB	O
be	VB	O
referred	VBN	O
for	IN	O
cardiovascular	JJ	O
assessment	NN	O
.	.	O

Carotid	NNP	O
sinus	JJ	O
hypersensitivity	NN	O
should	MD	O
be	VB	O
considered	VBN	O
in	IN	O
all	DT	O
older	JJR	O
adults	NNS	O
who	WP	O
have	VBP	O
non-accidental	JJ	O
falls	NNS	O
.	.	O

Additive	JJ	O
IOP-reducing	JJ	O
effect	NN	O
of	IN	O
latanoprost	NN	O
in	IN	O
patients	NNS	O
insufficiently	RB	C
controlled	VBN	C
on	IN	O
timolol	NN	O
.	.	O

PURPOSE	NNP	O
To	TO	O
evaluate	VB	O
the	DT	O
effect	NN	O
on	IN	O
intraocular	JJ	O
pressure	NN	O
(	(	O
IOP	NNP	O
)	)	O
of	IN	O
switching	VBG	O
from	IN	O
timolol	NN	O
to	TO	O
latanoprost	VB	O
or	CC	O
adding	VBG	O
latanoprost	NN	O
to	TO	O
timolol	VB	O
in	IN	O
patients	NNS	O
with	IN	O
open	JJ	O
angle	NN	C
glaucoma	NN	C
or	CC	C
ocular	JJ	C
hypertension	NN	C
where	WRB	O
IOP	NNP	O
is	VBZ	O
not	RB	O
adequately	RB	O
controlled	VBN	O
with	IN	O
timolol	NN	O
.	.	O

METHODS	NNP	O
This	DT	O
was	VBD	O
a	DT	O
6-week	JJ	O
,	,	O
double-masked	JJ	O
,	,	O
randomised	VBD	O
multi-centre	NN	O
study	NN	O
.	.	O

53	CD	SS
patients	NNS	O
with	IN	O
primary	JJ	C
open	JJ	C
angle	NN	C
glaucoma	NN	C
,	,	O
capsular	JJ	C
glaucoma	NN	C
,	,	O
or	CC	O
ocular	JJ	C
hypertension	NN	C
with	IN	O
an	DT	O
IOP	NNP	O
of	IN	O
at	IN	O
least	JJS	O
21	CD	O
mmHg	NN	O
on	IN	O
current	JJ	O
therapy	NN	O
were	VBD	O
recruited	VBN	O
.	.	O

After	IN	O
a	DT	O
run-in	JJ	O
period	NN	O
of	IN	O
at	IN	O
least	JJS	O
2	CD	O
weeks	NNS	O
on	IN	O
timolol	NN	O
,	,	O
5	CD	O
mg/ml	NN	O
twice	RB	O
daily	RB	O
,	,	O
patients	NNS	O
were	VBD	O
randomised	VBN	O
to	TO	O
one	CD	O
of	IN	O
three	CD	O
groups	NNS	O
.	.	O

One	CD	O
group	NN	O
continued	VBD	O
on	IN	O
timolol	NN	O
,	,	O
one	CD	O
switched	VBN	O
from	IN	O
timolol	NN	O
to	TO	O
latanoprost	VB	O
,	,	O
50	CD	O
microg/ml	NN	O
once	RB	O
daily	JJ	O
,	,	O
and	CC	O
a	DT	O
third	JJ	O
group	NN	O
received	VBD	O
latanoprost	RB	O
in	IN	O
addition	NN	O
to	TO	O
timolol	VB	O
.	.	O

The	DT	O
efficacy	NN	O
was	VBD	O
evaluated	VBN	O
by	IN	O
comparing	VBG	O
IOP	NNP	O
at	IN	O
9	CD	O
AM	NNP	O
at	IN	O
baseline	NN	O
and	CC	O
after	IN	O
6	CD	O
weeks	NNS	O
of	IN	O
treatment	NN	O
.	.	O

RESULTS	NNP	O
IOP	NNP	O
at	IN	O
baseline	NN	O
and	CC	O
after	IN	O
6	CD	O
weeks	NNS	O
of	IN	O
treatment	NN	O
(	(	O
mean	JJ	O
+/-	NNP	O
SEM	NNP	O
)	)	O
were	VBD	O
24.2	CD	O
+/-	JJ	O
0.9	CD	O
and	CC	O
23.8	CD	O
+/-	JJ	O
1.0	CD	O
mmHg	NN	O
(	(	O
n	JJ	O
=	NNP	O
16	CD	O
)	)	O
for	IN	O
patients	NNS	O
continuing	VBG	O
on	IN	O
timolol	NN	O
,	,	O
26.3	CD	O
+/-	JJ	O
1.2	CD	O
and	CC	O
19.6	CD	O
+/-	JJ	O
1.1	CD	O
mmHg	NN	O
(	(	O
n	JJ	O
=	NNP	O
17	CD	O
)	)	O
for	IN	O
patients	NNS	O
switching	VBG	O
to	TO	O
latanoprost	VB	O
,	,	O
and	CC	O
23.2	CD	O
+/-	JJ	O
1.0	CD	O
and	CC	O
17.5	CD	O
+/-	JJ	O
0.8	CD	O
mmHg	NN	O
(	(	O
n	JJ	O
=	NNP	O
17	CD	O
)	)	O
for	IN	O
patients	NNS	O
with	IN	O
combined	JJ	O
treatment	NN	O
.	.	O

Adding	VBG	O
latanoprost	NN	O
to	TO	O
timolol	VB	O
reduced	VBN	O
IOP	NNP	O
with	IN	O
5.9	CD	O
+/-	JJ	O
0.9	CD	O
mmHg	NN	O
(	(	O
p	JJ	O
<	NNP	O
0.001	CD	O
)	)	O
and	CC	O
switching	VBG	O
from	IN	O
timolol	NN	O
to	TO	O
latanoprost	VB	O
reduced	VBN	O
IOP	NNP	O
with	IN	O
5.0	CD	O
+/-	JJ	O
0.9	CD	O
mmHg	NN	O
(	(	O
p	JJ	O
<	NNP	O
0.001	CD	O
)	)	O
,	,	O
which	WDT	O
caused	VBD	O
in	IN	O
each	DT	O
group	NN	O
a	DT	O
significant	JJ	O
IOP	NNP	O
reduction	NN	O
of	IN	O
about	RB	O
25	CD	O
%	NN	O
.	.	O

CONCLUSIONS	VB	O
The	DT	O
effect	NN	O
of	IN	O
latanoprost	NN	O
was	VBD	O
additive	JJ	O
to	TO	O
that	DT	O
of	IN	O
timolol	NN	O
,	,	O
and	CC	O
a	DT	O
good	JJ	O
effect	NN	O
on	IN	O
IOP	NNP	O
reduction	NN	O
was	VBD	O
also	RB	O
achieved	VBN	O
by	IN	O
switching	VBG	O
from	IN	O
timolol	NN	O
to	TO	O
latanoprost	VB	O
,	,	O
suggesting	VBG	O
that	IN	O
a	DT	O
switch	NN	O
in	IN	O
many	JJ	O
patients	NNS	O
is	VBZ	O
an	DT	O
effective	JJ	O
alternative	NN	O
to	TO	O
combination	NN	O
treatment	NN	O
.	.	O

[	NN	O
Study	NNP	O
on	IN	O
safety	NN	O
and	CC	O
immunogenicity	NN	O
of	IN	O
oral	JJ	O
poliomyelitis	NN	O
attenuated	VBD	O
live	JJ	O
vaccine	NN	O
(	(	O
human	JJ	O
diploid	NN	O
cell	NN	O
)	)	O
]	NN	O
.	.	O

OBJECTIVE	UH	O
To	TO	O
evaluate	VB	O
the	DT	O
safety	NN	O
and	CC	O
Immunogenicity	NNP	O
of	IN	O
the	DT	O
Poliomyelitis	NNP	O
vaccine	NN	O
(	(	O
Human	NNP	O
Diploid	NNP	O
Cell	NNP	O
)	)	O
in	IN	O
>	NN	O
or	CC	O
=2	VB	O
month-old	JJ	O
children	NNS	O
.	.	O

METHODS	NNP	O
A	NNP	O
random	NN	O
,	,	O
blind	NN	O
and	CC	O
control	NN	O
trial	NN	O
,	,	O
1200	CD	SS
healthy	JJ	O
children	NNS	A
of	IN	O
2-5	JJ	A
months	NNS	A
old	JJ	A
in	IN	O
Jiangsu	NNP	O
province	NN	O
were	VBD	O
administered	VBN	O
OPV	NNP	C
(	(	C
HDC	NNP	C
)	)	C
vaccine	NN	C
and	CC	O
control	NN	O
vaccines	NNS	O
.	.	O

The	DT	O
antibody	NN	O
was	VBD	O
tested	VBN	O
by	IN	O
neutralization	NN	O
test	NN	O
.	.	O

RESULTS	NNP	O
After	IN	O
3	CD	O
doses	NNS	O
of	IN	O
the	DT	O
OPV	NNP	O
(	(	O
HDC	NNP	O
)	)	O
vaccine	NN	O
,	,	O
the	DT	O
systemic	JJ	O
reactions	NNS	O
were	VBD	O
mild	JJ	O
.	.	O

After	IN	O
1	CD	O
month	NN	O
of	IN	O
vaccination	NN	O
with	IN	O
3	CD	O
doses	NNS	O
of	IN	O
the	DT	O
OPV	NNP	O
(	(	O
HDC	NNP	O
)	)	O
vaccine	NN	O
,	,	O
the	DT	O
immune	JJ	O
success	NN	O
rates	NNS	O
of	IN	O
I	PRP	O
,	,	O
II	NNP	O
,	,	O
III	NNP	O
type	NN	O
were	VBD	O
98.28	CD	O
%	NN	O
,	,	O
99.45	CD	O
%	NN	O
,	,	O
and	CC	O
95.71	CD	O
%	NN	O
respectively	RB	O
,	,	O
the	DT	O
GMTs	NNP	O
of	IN	O
I	PRP	O
,	,	O
II	NNP	O
,	,	O
III	NNP	O
type	NN	O
in	IN	O
susceptible	JJ	O
children	NNS	O
were	VBD	O
1:1243.72	CD	O
,	,	O
1:234.38	CD	O
and	CC	O
1:273.10	CD	O
respectively	RB	O
.	.	O

CONCLUSIONS	VB	O
The	DT	O
OPV	NNP	O
(	(	O
HDC	NNP	O
)	)	O
vaccine	NN	O
was	VBD	O
safe	JJ	O
and	CC	O
immunogenicity	NN	O
for	IN	O
the	DT	O
children	NNS	O
>	VBP	O
or	CC	O
=2	JJ	O
months	NNS	O
old	JJ	O
.	.	O

Inflammatory	JJ	O
response	NN	O
in	IN	O
humans	NNS	O
exposed	VBN	C
to	TO	C
2.0	CD	C
ppm	NNS	C
nitrogen	JJ	C
dioxide	NN	C
.	.	O

Nitrogen	NNP	O
dioxide	NN	O
(	(	O
NO2	NNP	O
)	)	O
is	VBZ	O
a	DT	O
common	JJ	O
indoor	NN	O
air	NN	O
pollutant	NN	O
,	,	O
especially	RB	O
in	IN	O
homes	NNS	O
with	IN	O
unvented	JJ	O
combustion	NN	O
appliances	NNS	O
.	.	O

Epidemiological	JJ	O
studies	NNS	O
suggest	VBP	O
that	IN	O
children	NNS	O
living	VBG	O
in	IN	O
homes	NNS	O
with	IN	O
unvented	JJ	O
heating	NN	O
sources	NNS	O
are	VBP	O
more	JJR	O
prone	NN	O
to	TO	O
respiratory	NN	O
infections	NNS	O
than	IN	O
children	NNS	O
living	VBG	O
in	IN	O
homes	NNS	O
with	IN	O
lower	JJR	O
levels	NNS	O
of	IN	O
NO2	NNP	O
.	.	O

However	RB	O
,	,	O
experimental	JJ	O
studies	NNS	O
in	IN	O
which	WDT	O
human	JJ	O
volunteers	NNS	O
were	VBD	O
exposed	VBN	O
acutely	RB	O
to	TO	O
moderate	JJ	O
levels	NNS	O
of	IN	O
NO2	NNP	O
(	(	O
0.5-2.0	JJ	O
ppm	NN	O
)	)	O
have	VBP	O
shown	VBN	O
little	JJ	O
evidence	NN	O
of	IN	O
lung	NN	O
inflammation	NN	O
or	CC	O
decreased	VBN	O
host	NN	O
resistance	NN	O
capacity	NN	O
.	.	O

In	IN	O
the	DT	O
study	NN	O
reported	VBD	O
here	RB	O
,	,	O
8	CD	SS
healthy	JJ	O
volunteers	NNS	O
were	VBD	O
exposed	VBN	C
to	TO	C
2.0	CD	C
ppm	NN	C
NO2	NNP	C
and	CC	C
to	TO	C
filtered	VB	C
air	NN	C
for	IN	C
4	CD	C
h	NNS	C
while	IN	O
undergoing	VBG	O
intermittent	JJ	C
moderate	JJ	C
exercise	NN	C
.	.	O

Bronchoalveolar	JJ	O
lavage	NN	O
was	VBD	O
performed	VBN	O
the	DT	O
following	JJ	O
morning	NN	O
.	.	O

The	DT	O
lavage	NN	O
was	VBD	O
divided	VBN	O
into	IN	O
a	DT	O
predominantly	RB	O
bronchial	JJ	O
washing	NN	O
(	(	O
first	JJ	O
20	CD	O
ml	NN	O
of	IN	O
lavage	NN	O
;	:	O
BL	NNP	O
)	)	O
and	CC	O
a	DT	O
predominantly	RB	O
alveolar	JJ	O
washing	NN	O
(	(	O
BAL	NNP	O
)	)	O
.	.	O

In	IN	O
the	DT	O
BL	NNP	O
,	,	O
NO2	NNP	O
exposure	NN	O
caused	VBD	O
increases	NNS	O
in	IN	O
polymorphonuclear	JJ	O
neutrophils	NNS	O
(	(	O
PMNs	NNP	O
)	)	O
,	,	O
interleukin	JJ	O
6	CD	O
(	(	O
IL-6	NNP	O
)	)	O
,	,	O
IL-8	NNP	O
,	,	O
alpha1-antitrypsin	NN	O
,	,	O
and	CC	O
tissue	NN	O
plasminogen	NN	O
activator	NN	O
,	,	O
and	CC	O
decreases	NNS	O
in	IN	O
epithelial	JJ	O
cells	NNS	O
.	.	O

In	IN	O
the	DT	O
BAL	NNP	O
,	,	O
there	EX	O
were	VBD	O
no	DT	O
NO2-induced	JJ	O
changes	NNS	O
in	IN	O
either	DT	O
cell	NN	O
numbers	NNS	O
or	CC	O
soluble	JJ	O
mediators	NNS	O
.	.	O

On	IN	O
the	DT	O
other	JJ	O
hand	NN	O
,	,	O
alveolar	JJ	O
macrophages	NNS	O
from	IN	O
BAL	NNP	O
showed	VBD	O
a	DT	O
decrease	NN	O
in	IN	O
the	DT	O
ability	NN	O
to	TO	O
phagocytose	VB	O
unopsonized	JJ	O
Candida	NNP	O
albicans	NNS	O
and	CC	O
a	DT	O
decrease	NN	O
in	IN	O
superoxide	JJ	O
production	NN	O
.	.	O

No	DT	O
difference	NN	O
in	IN	O
susceptibility	NN	O
to	TO	O
virus	VB	O
infection	NN	O
was	VBD	O
found	VBN	O
between	IN	O
the	DT	O
NO2-	NNP	O
and	CC	O
air-exposed	JJ	O
macrophages	NNS	O
.	.	O

No	DT	O
changes	NNS	O
in	IN	O
lung	NN	O
function	NN	O
were	VBD	O
observed	VBN	O
,	,	O
but	CC	O
the	DT	O
aerosol	JJ	O
bolus	JJ	O
recovery	NN	O
technique	NN	O
revealed	VBD	O
a	DT	O
statistically	RB	O
significant	JJ	O
(	(	O
p	JJ	O
<	NNP	O
.05	NNP	O
)	)	O
decrease	NN	O
in	IN	O
the	DT	O
fraction	NN	O
of	IN	O
aerosol	NN	O
recovered	VBD	O
following	VBG	O
nitrogen	NN	O
dioxide	NN	O
exposure	NN	O
,	,	O
which	WDT	O
is	VBZ	O
suggestive	JJ	O
of	IN	O
small	JJ	O
obstructive	JJ	O
changes	NNS	O
induced	VBN	O
by	IN	O
NO2	NNP	O
.	.	O

Use	NNP	O
of	IN	O
an	DT	O
Internet	NNP	O
portal	NN	O
to	TO	O
improve	VB	O
community-based	JJ	O
pediatric	JJ	A
ADHD	NNP	C
care	NN	O
:	:	O
a	DT	O
cluster	NN	O
randomized	VBN	O
trial	NN	O
.	.	O

OBJECTIVE	NN	O
To	TO	O
determine	VB	O
the	DT	O
effectiveness	NN	O
of	IN	O
a	DT	O
quality	NN	O
improvement	NN	O
program	NN	O
to	TO	O
improve	VB	O
pediatricians	NNS	O
'	POS	O
adherence	NN	O
to	TO	O
existing	VBG	O
,	,	O
evidence-based	JJ	O
,	,	O
attention-deficit/hyperactivity	JJ	O
disorder	NN	O
(	(	O
ADHD	NNP	O
)	)	O
practice	NN	O
guidelines	NNS	O
.	.	O

METHODS	NNP	O
Forty-nine	JJ	SS
community-based	JJ	O
pediatricians	NNS	O
at	IN	O
8	CD	O
practices	NNS	O
participated	VBN	O
in	IN	O
a	DT	O
cluster-randomized	JJ	O
trial	NN	O
.	.	O

Practices	NNS	O
were	VBD	O
matched	VBN	O
according	VBG	O
to	TO	O
the	DT	O
numbers	NNS	O
of	IN	O
pediatricians	NNS	O
and	CC	O
the	DT	O
proportions	NNS	O
of	IN	O
patients	NNS	O
receiving	VBG	O
Medicaid	NNP	O
.	.	O

The	DT	O
medical	JJ	O
charts	NNS	O
for	IN	O
a	DT	O
random	JJ	O
sample	NN	O
of	IN	O
patients	NNS	O
with	IN	O
ADHD	NNP	O
for	IN	O
each	DT	O
of	IN	O
the	DT	O
participating	VBG	O
pediatricians	NNS	O
were	VBD	O
examined	VBN	O
at	IN	O
baseline	NN	O
and	CC	O
6	CD	O
months	NNS	O
.	.	O

All	DT	O
practices	NNS	O
participated	VBN	O
in	IN	O
4	CD	O
sessions	NNS	O
of	IN	O
training	NN	O
,	,	O
including	VBG	O
didactic	JJ	O
lectures	NNS	O
and	CC	O
office	NN	O
flow	NN	O
modification	NN	O
workshops	NNS	O
.	.	O

Practices	NNS	O
were	VBD	O
then	RB	O
given	VBN	O
access	NN	O
to	TO	O
an	DT	O
ADHD	NNP	O
Internet	NNP	O
portal	NN	O
that	WDT	O
allowed	VBD	O
parents	NNS	O
,	,	O
teachers	NNS	O
,	,	O
and	CC	O
pediatricians	NNS	O
to	TO	O
input	VB	O
information	NN	O
(	(	O
eg	NN	O
,	,	O
rating	NN	O
scales	NNS	O
)	)	O
about	IN	O
patients	NNS	O
,	,	O
after	IN	O
which	WDT	O
information	NN	O
was	VBD	O
scored	VBN	O
,	,	O
interpreted	VBN	O
,	,	O
and	CC	O
formatted	VBN	O
in	IN	O
a	DT	O
report	NN	O
style	NN	O
that	WDT	O
was	VBD	O
helpful	JJ	O
for	IN	O
assessment	NN	O
and	CC	O
treatment	NN	O
of	IN	O
patients	NNS	O
with	IN	O
ADHD	NNP	O
.	.	O

Physicians	NNPS	O
evaluated	VBD	O
their	PRP$	O
practice	NN	O
behaviors	NNS	O
quarterly	RB	O
and	CC	O
addressed	VBD	O
underperforming	JJ	O
areas	NNS	O
.	.	O

RESULTS	NNP	O
Pediatricians	NNPS	O
in	IN	O
the	DT	O
intervention	NN	O
group	NN	O
,	,	O
compared	VBN	O
with	IN	O
those	DT	O
in	IN	O
the	DT	O
control	NN	O
group	NN	O
,	,	O
demonstrated	VBD	O
significantly	RB	O
higher	JJR	O
rates	NNS	O
of	IN	O
many	JJ	O
American	JJ	O
Academy	NNP	O
of	IN	O
Pediatrics-recommended	NNP	O
ADHD	NNP	O
care	NN	O
practices	NNS	O
,	,	O
including	VBG	O
collection	NN	O
of	IN	O
parent	NN	O
(	(	O
Cohen	NNP	O
's	POS	O
d	NN	O
=	VBZ	O
0.69	CD	O
)	)	O
and	CC	O
teacher	$	O
(	(	O
d	JJ	O
=	NNP	O
0.68	CD	O
)	)	O
rating	NN	O
scales	NNS	O
for	IN	O
assessment	NN	O
of	IN	O
children	NNS	O
with	IN	O
ADHD	NNP	O
,	,	O
use	NN	O
of	IN	O
Diagnostic	NNP	O
and	CC	O
Statistical	NNP	O
Manual	NNP	O
of	IN	O
Mental	NNP	O
Disorders	NNP	O
,	,	O
Fourth	NNP	O
Edition	NNP	O
,	,	O
criteria	NNS	O
(	(	O
d	VB	O
=	RB	O
0.85	CD	O
)	)	O
,	,	O
and	CC	O
use	NN	O
of	IN	O
teacher	NN	O
rating	NN	O
scales	NNS	O
to	TO	O
monitor	VB	O
treatment	NN	O
responses	NNS	O
(	(	O
d	VB	O
=	RB	O
1.01	CD	O
)	)	O
.	.	O

CONCLUSION	VB	O
A	DT	O
quality	NN	O
improvement	NN	O
intervention	NN	O
that	WDT	O
can	MD	O
be	VB	O
widely	RB	O
disseminated	VBN	O
by	IN	O
using	VBG	O
Internet-based	JJ	O
information	NN	O
technology	NN	O
significantly	RB	O
improved	VBD	O
the	DT	O
quality	NN	O
of	IN	O
ADHD	NNP	O
care	NN	O
in	IN	O
community-based	JJ	O
pediatric	JJ	O
settings	NNS	O
.	.	O

Lack	NN	O
of	IN	O
effect	NN	O
of	IN	O
warfarin	NN	O
on	IN	O
the	DT	O
restenosis	NN	O
rate	NN	O
or	CC	O
on	IN	O
clinical	JJ	O
outcome	NN	O
after	IN	O
balloon	NN	O
coronary	JJ	O
angioplasty	NN	O
.	.	O

Between	NNP	O
September	NNP	O
1985	CD	O
and	CC	O
April	NNP	O
1987	CD	O
,	,	O
110	CD	O
consecutive	JJ	O
patients	NNS	O
who	WP	O
had	VBD	O
successful	JJ	O
coronary	JJ	O
angioplasty	NN	O
were	VBD	O
included	VBN	O
in	IN	O
a	DT	O
randomised	JJ	O
prospective	NN	O
controlled	VBN	O
evaluation	NN	O
of	IN	O
the	DT	O
effects	NNS	O
of	IN	O
warfarin	NN	O
on	IN	O
restenosis	NN	O
.	.	O

The	DT	O
warfarin	NN	O
(	(	O
n	JJ	O
=	NNP	O
56	CD	O
)	)	O
and	CC	O
the	DT	O
control	NN	O
(	(	O
n	JJ	O
=	NNP	O
54	CD	O
)	)	O
groups	NNS	O
were	VBD	O
not	RB	O
different	JJ	O
in	IN	O
terms	NNS	O
of	IN	O
age	NN	O
,	,	O
sex	NN	O
,	,	O
previous	JJ	O
coronary	JJ	O
bypass	NN	O
surgery	NN	O
or	CC	O
coronary	JJ	O
balloon	NN	O
angioplasty	NN	O
,	,	O
severity	NN	O
of	IN	O
symptoms	NNS	O
,	,	O
and	CC	O
frequency	NN	O
of	IN	O
multivessel	JJ	O
disease	NN	O
or	CC	O
of	IN	O
total	JJ	O
coronary	JJ	O
occlusions	NNS	O
.	.	O

Warfarin	NNP	O
was	VBD	O
started	VBN	O
on	IN	O
the	DT	O
day	NN	O
of	IN	O
the	DT	O
procedure	NN	O
and	CC	O
the	DT	O
dosage	NN	O
was	VBD	O
adjusted	VBN	O
to	TO	O
maintain	VB	O
the	DT	O
thromboplastin	JJ	O
international	JJ	O
normalised	VBN	O
ratio	NN	O
greater	JJR	O
than	IN	O
or	CC	O
equal	JJ	O
to	TO	O
2.5	CD	O
.	.	O

One	CD	O
hundred	CD	O
and	CC	O
five	CD	O
(	(	O
96	CD	O
%	NN	O
)	)	O
of	IN	O
the	DT	O
patients	NNS	O
were	VBD	O
given	VBN	O
verapamil	NNS	O
and	CC	O
other	JJ	O
antianginal	JJ	O
drugs	NNS	O
were	VBD	O
prescribed	VBN	O
as	IN	O
needed	VBN	O
.	.	O

Low	JJ	O
molecular	JJ	O
weight	NN	O
dextran	NN	O
and	CC	O
heparin	NN	O
were	VBD	O
given	VBN	O
during	IN	O
the	DT	O
procedure	NN	O
and	CC	O
heparin	NN	O
was	VBD	O
continued	VBN	O
for	IN	O
24	CD	O
hours	NNS	O
in	IN	O
all	DT	O
patients	NNS	O
.	.	O

One	CD	O
hundred	CD	O
and	CC	O
eight	CD	O
(	(	O
98	CD	O
%	NN	O
)	)	O
of	IN	O
patients	NNS	O
were	VBD	O
followed	VBN	O
up	RP	O
clinically	RB	O
after	IN	O
a	DT	O
median	NN	O
of	IN	O
five	CD	O
months	NNS	O
(	(	O
range	VB	O
1-20	CD	O
)	)	O
.	.	O

Eighty	NNP	O
five	CD	O
(	(	O
77	CD	O
%	NN	O
)	)	O
had	VBD	O
follow	VBN	O
up	RP	O
angiography	NN	O
at	IN	O
five	CD	O
months	NNS	O
.	.	O

In	IN	O
the	DT	O
warfarin	NN	O
group	NN	O
symptoms	NNS	O
improved	VBN	O
in	IN	O
46	CD	O
(	(	O
85	CD	O
%	NN	O
)	)	O
patients	NNS	O
by	IN	O
at	IN	O
least	JJS	O
1	CD	O
angina	JJ	O
class	NN	O
and	CC	O
31	CD	O
(	(	O
57	CD	O
%	NN	O
)	)	O
were	VBD	O
symptom	JJ	O
free	JJ	O
;	:	O
the	DT	O
exercise	NN	O
test	NN	O
remained	VBD	O
positive	JJ	O
in	IN	O
20	CD	O
(	(	O
36	CD	O
%	NN	O
)	)	O
patients	NNS	O
and	CC	O
the	DT	O
angiographic	JJ	O
restenosis	NN	O
rate	NN	O
was	VBD	O
25	CD	O
%	NN	O
per	IN	O
lesion	NN	O
and	CC	O
29	CD	O
%	NN	O
per	IN	O
patient	NN	O
.	.	O

There	EX	O
were	VBD	O
no	DT	O
major	JJ	O
bleeding	NN	O
complications	NNS	O
.	.	O

In	IN	O
the	DT	O
control	NN	O
group	NN	O
46	CD	O
(	(	O
85	CD	O
%	NN	O
)	)	O
patients	NNS	O
were	VBD	O
improved	VBN	O
by	IN	O
at	IN	O
least	JJS	O
1	CD	O
angina	JJ	O
class	NN	O
and	CC	O
31	CD	O
(	(	O
57	CD	O
%	NN	O
)	)	O
were	VBD	O
symptom	JJ	O
free	JJ	O
;	:	O
the	DT	O
exercise	NN	O
test	NN	O
was	VBD	O
positive	JJ	O
in	IN	O
11	CD	O
(	(	O
21	CD	O
%	NN	O
)	)	O
patients	NNS	O
and	CC	O
the	DT	O
angiographic	JJ	O
restenosis	NN	O
rate	NN	O
was	VBD	O
33	CD	O
%	NN	O
per	IN	O
lesion	NN	O
and	CC	O
37	CD	O
%	NN	O
per	IN	O
patient	NN	O
.	.	O

Although	IN	O
the	DT	O
incidence	NN	O
of	IN	O
angiographic	JJ	O
restenosis	NN	O
tended	VBD	O
to	TO	O
be	VB	O
lower	JJR	O
with	IN	O
warfarin	NN	O
,	,	O
none	NN	O
of	IN	O
these	DT	O
differences	NNS	O
was	VBD	O
significant	JJ	O
.	.	O

These	DT	O
data	NNS	O
suggest	VBP	O
that	IN	O
the	DT	O
combination	NN	O
of	IN	O
verapamil	NN	O
and	CC	O
warfarin	NN	O
,	,	O
in	IN	O
the	DT	O
absence	NN	O
of	IN	O
aspirin	NN	O
,	,	O
is	VBZ	O
not	RB	O
significantly	RB	O
better	JJR	O
than	IN	O
verapamil	NN	O
alone	RB	O
in	IN	O
preventing	VBG	O
symptom	JJ	O
recurrence	NN	O
or	CC	O
angiographic	JJ	O
restenosis	NN	O
after	IN	O
coronary	JJ	O
angioplasty	NN	O
.	.	O

Evaluation	NN	O
of	IN	O
AMSA	NNP	O
in	IN	O
children	NNS	A
with	IN	O
acute	JJ	C
leukemia	NN	C
.	.	O

A	DT	O
Pediatric	NNP	O
Oncology	NNP	O
Group	NNP	O
study	NN	O
.	.	O

One	CD	SS
hundred	VBD	SS
four	CD	SS
children	NNS	A
with	IN	O
advanced	JJ	C
leukemia	NN	C
in	IN	O
relapse	NN	O
(	(	O
74	CD	SS
with	IN	O
acute	JJ	C
lymphocytic	JJ	C
leukemia	NN	C
[	NNP	C
ALL	NNP	C
]	NNP	C
and	CC	O
30	CD	SS
with	IN	O
acute	JJ	C
nonlymphocytic	JJ	C
leukemia	NN	C
[	NNP	C
ANLL	NNP	C
]	NNP	C
)	)	C
received	VBD	O
AMSA	NNP	O
(	(	O
4'-	JJ	O
(	(	O
9-Acridinylamino	CD	O
)	)	O
methanesulfon	FW	O
-m-anisidide	NN	O
)	)	O
at	IN	O
a	DT	O
dose	NN	O
of	IN	O
120	CD	O
mg/m2/day	NN	O
for	IN	O
5	CD	O
days	NNS	O
(	(	O
Regimen	NNP	O
I	PRP	O
)	)	O
or	CC	O
60	CD	O
mg/m2/day	NN	O
for	IN	O
10	CD	O
days	NNS	O
(	(	O
Regimen	NNP	O
II	NNP	O
)	)	O
.	.	O

Children	NNP	A
with	IN	O
ALL	NNP	C
were	VBD	O
randomized	VBN	O
between	IN	O
Regimens	NNP	O
I	PRP	O
and	CC	O
II	NNP	O
(	(	O
31	CD	O
and	CC	O
36	CD	O
evaluable	JJ	O
patients	NNS	O
,	,	O
respectively	RB	O
)	)	O
.	.	O

All	DT	O
29	CD	O
evaluable	JJ	O
patients	NNS	O
with	IN	O
ANLL	NNP	C
were	VBD	O
treated	VBN	O
on	IN	O
Regimen	NNP	O
I.	NNP	O
Eighty-eight	NNP	O
percent	NN	O
of	IN	O
evaluable	JJ	O
patients	NNS	O
experienced	VBD	O
severe	JJ	O
or	CC	O
life-threatening	JJ	O
toxicity	NN	O
,	,	O
with	IN	O
no	DT	O
statistical	JJ	O
differences	NNS	O
between	IN	O
Regimens	NNP	O
I	PRP	O
and	CC	O
II	NNP	O
.	.	O

Bacterial	NNP	O
or	CC	O
fungal	JJ	O
infections	NNS	O
(	(	O
considered	VBN	O
life-threatening	NN	O
or	CC	O
fatal	NN	O
)	)	O
occurred	VBD	O
in	IN	O
17	CD	O
children	NNS	O
with	IN	O
ALL	DT	O
and	CC	O
in	IN	O
7	CD	O
with	IN	O
ANLL	NNP	O
.	.	O

Fatal	NNP	C
cardiac	JJ	C
toxicity	NN	C
occurred	VBD	O
in	IN	O
one	CD	O
patient	NN	O
.	.	O

Complete	NNP	O
or	CC	O
partial	JJ	O
response	NN	O
occurred	VBD	O
in	IN	O
25.0	CD	O
%	NN	O
(	(	O
SE	NNP	O
=	RB	O
8.8	CD	O
%	NN	O
)	)	O
,	,	O
28.1	CD	O
%	NN	O
(	(	O
SE	NNP	O
=	RB	O
8.0	CD	O
%	NN	O
)	)	O
,	,	O
and	CC	O
25.9	CD	O
%	NN	O
(	(	O
SE	NNP	O
=	RB	O
8.4	CD	O
%	NN	O
)	)	O
of	IN	O
evaluable	JJ	O
patients	NNS	O
on	IN	O
ALL	NNP	O
Regimen	NNP	O
I	PRP	O
,	,	O
ALL	DT	O
Regimen	NNP	O
II	NNP	O
,	,	O
and	CC	O
ANLL	NNP	O
,	,	O
respectively	RB	O
.	.	O

However	RB	O
,	,	O
responses	NNS	O
were	VBD	O
of	IN	O
short	JJ	O
duration	NN	O
(	(	O
16-91	JJ	O
days	NNS	O
)	)	O
.	.	O

There	EX	O
was	VBD	O
no	DT	O
significant	JJ	O
difference	NN	O
in	IN	O
the	DT	O
duration	NN	O
of	IN	O
survival	NN	O
from	IN	O
treatment	NN	O
start	NN	O
for	IN	O
the	DT	O
two	CD	O
ALL	DT	O
regimens	NNS	O
(	(	O
P	NNP	O
=	NNP	O
0.46	CD	O
)	)	O
.	.	O

The	DT	O
median	JJ	O
duration	NN	O
of	IN	O
survival	NN	O
for	IN	O
ANLL	NNP	O
patients	NNS	O
was	VBD	O
significantly	RB	O
longer	JJR	O
(	(	O
P	NNP	O
=	NNP	O
0.004	CD	O
)	)	O
than	IN	O
that	DT	O
of	IN	O
ALL	NNP	O
patients	NNS	O
treated	VBD	O
on	IN	O
Regimens	NNP	O
I	PRP	O
and	CC	O
II	NNP	O
combined	VBD	O
.	.	O

Eighty-two	JJ	O
percent	NN	O
of	IN	O
the	DT	O
complete	JJ	O
or	CC	O
partial	JJ	O
responses	NNS	O
(	(	O
18	CD	O
of	IN	O
22	CD	O
)	)	O
occurred	VBD	O
after	IN	O
the	DT	O
first	JJ	O
course	NN	O
of	IN	O
AMSA	NNP	O
.	.	O

At	IN	O
the	DT	O
dose	JJ	O
schedules	NNS	O
investigated	VBN	O
,	,	O
and	CC	O
in	IN	O
a	DT	O
heavily	RB	O
pretreated	VBN	O
patient	JJ	O
population	NN	O
,	,	O
AMSA	NNP	O
had	VBD	O
activity	NN	O
in	IN	O
childhood	NN	O
leukemia	NN	O
.	.	O

However	RB	O
,	,	O
the	DT	O
high	JJ	O
incidence	NN	O
of	IN	O
severe	JJ	O
,	,	O
life-threatening	JJ	O
,	,	O
or	CC	O
fatal	JJ	O
infections	NNS	O
meant	VBP	O
that	IN	O
the	DT	O
quality	NN	O
and	CC	O
quantity	NN	O
of	IN	O
responses	NNS	O
and	CC	O
survival	NN	O
was	VBD	O
not	RB	O
commensurate	JJ	O
with	IN	O
the	DT	O
toxicity	NN	O
,	,	O
and	CC	O
that	IN	O
it	PRP	O
would	MD	O
be	VB	O
difficult	JJ	O
to	TO	O
incorporate	VB	O
this	DT	O
drug	NN	O
into	IN	O
combination	NN	O
chemotherapy	NN	O
with	IN	O
other	JJ	O
myelosuppressive	JJ	O
agents	NNS	O
.	.	O

Vaginal	NNP	O
pH	NN	O
and	CC	O
microflora	NN	O
related	VBN	O
to	TO	O
yeast	VB	O
infections	NNS	O
and	CC	O
treatment	NN	O
.	.	O

The	DT	O
relationship	NN	O
between	IN	O
vaginal	JJ	O
pH	NN	O
,	,	O
microflora	NN	O
,	,	O
and	CC	O
yeast	JJS	O
infection	NN	O
was	VBD	O
investigated	VBN	O
in	IN	O
93	CD	SS
women	NNS	SE
randomly	RB	O
treated	VBN	O
with	IN	O
either	DT	O
nystatin	NN	O
or	CC	O
miconazole	JJ	O
pessaries	NNS	O
and	CC	O
cream	NN	O
for	IN	O
two	CD	O
weeks	NNS	O
.	.	O

The	DT	O
vaginal	JJ	O
pH	NN	O
was	VBD	O
measured	VBN	O
in	IN	O
a	DT	O
control	NN	O
group	NN	O
of	IN	O
48	CD	SS
women	NNS	SE
.	.	SE

In	IN	O
the	DT	O
study	NN	O
group	NN	O
,	,	O
37	CD	O
patients	NNS	O
defaulted	VBD	O
,	,	O
39	CD	O
were	VBD	O
cured	VBN	O
,	,	O
and	CC	O
17	CD	O
required	JJ	O
treatment	NN	O
during	IN	O
the	DT	O
six-month	JJ	O
follow-up	JJ	O
period	NN	O
.	.	O

In	IN	O
both	DT	O
study	NN	O
and	CC	O
control	NN	O
groups	NNS	O
before	IN	O
and	CC	O
after	IN	O
treatment	NN	O
the	DT	O
mean	JJ	O
vaginal	JJ	O
pH	NN	O
was	VBD	O
in	IN	O
the	DT	O
range	NN	O
of	IN	O
4.3-4.6	JJ	O
.	.	O

Lactobacilli	NNP	O
were	VBD	O
plentiful	JJ	O
in	IN	O
78	CD	O
(	(	O
91	CD	O
%	NN	O
)	)	O
out	IN	O
of	IN	O
86	CD	O
patients	NNS	O
and	CC	O
shows	VBZ	O
that	IN	O
lactobacilli	NN	O
and	CC	O
yeasts	NNS	O
commonly	RB	O
coexist	VBP	O
.	.	O

The	DT	O
influence	NN	O
of	IN	O
other	JJ	O
organisms	NNS	O
appeared	VBD	O
to	TO	O
be	VB	O
negligible	JJ	O
.	.	O

The	DT	O
trial	NN	O
showed	VBD	O
that	IN	O
nystatin	NN	O
and	CC	O
micromazole	NN	O
were	VBD	O
equallly	RB	O
effective	JJ	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
vaginal	JJ	O
yeast	NN	O
infection	NN	O
and	CC	O
that	IN	O
the	DT	O
broad-spectrum	JJ	O
activity	NN	O
of	IN	O
micronazole	NN	O
offered	VBN	O
no	DT	O
advantage	NN	O
in	IN	O
this	DT	O
condition	NN	O
.	.	O

Prospectively	RB	O
randomized	VBN	O
toxicity	NN	O
study	NN	O
of	IN	O
high-dose	JJ	O
versus	NN	O
low-dose	JJ	O
treatment	NN	O
strategies	NNS	O
for	IN	O
lymphoblastoid	JJ	O
interferon	NN	O
.	.	O

It	PRP	O
is	VBZ	O
unclear	JJ	O
from	IN	O
preliminary	JJ	O
laboratory	NN	O
studies	NNS	O
whether	IN	O
a	DT	O
high-	NN	O
or	CC	O
a	DT	O
low-dose	JJ	O
interferon	NN	O
treatment	NN	O
strategy	NN	O
is	VBZ	O
optimal	JJ	O
.	.	O

As	IN	O
part	NN	O
of	IN	O
an	DT	O
ongoing	JJ	O
study	NN	O
of	IN	O
mechanisms	NNS	O
of	IN	O
interferon	NN	O
action	NN	O
,	,	O
we	PRP	O
have	VBP	O
evaluated	VBN	O
toxicity	NN	O
in	IN	O
a	DT	O
two-arm	JJ	O
protocol	NN	O
in	IN	O
which	WDT	O
patients	NNS	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
receive	VB	O
lymphoblastoid	JJ	O
interferon	NN	O
by	IN	O
either	CC	O
a	DT	O
low-dose	JJ	O
treatment	NN	O
strategy	NN	O
(	(	O
2	CD	O
X	RB	O
10	CD	O
(	(	O
6	CD	O
)	)	O
units/m2	JJ	O
daily	JJ	O
X	$	O
28	CD	O
days	NNS	O
then	RB	O
daily	JJ	O
X	NNP	O
5	CD	O
days	NNS	O
every	DT	O
other	JJ	O
week	NN	O
by	IN	O
im	JJ	O
injection	NN	O
)	)	O
or	CC	O
a	DT	O
high-dose	JJ	O
treatment	NN	O
strategy	NN	O
(	(	O
5	CD	O
X	RB	O
10	CD	O
(	(	O
6	CD	O
)	)	O
units/m2	NN	O
by	IN	O
continuous	JJ	O
iv	JJ	O
infusion	NN	O
over	IN	O
24	CD	O
hours	NNS	O
,	,	O
escalating	VBG	O
by	IN	O
5	CD	O
X	NNS	O
10	CD	O
(	(	O
6	CD	O
)	)	O
units/m2/day	NN	O
as	IN	O
tolerated	VBN	O
over	IN	O
10	CD	O
days	NNS	O
,	,	O
repeated	VBD	O
every	DT	O
28	CD	O
days	NNS	O
)	)	O
.	.	O

The	DT	O
main	JJ	O
toxic	NN	O
effects	NNS	O
in	IN	O
both	DT	O
arms	NNS	O
were	VBD	O
fever	RB	O
,	,	O
fatigue	NN	O
,	,	O
and	CC	O
anorexia	RB	O
.	.	O

Marked	JJ	O
interpatient	NN	O
differences	NNS	O
within	IN	O
each	DT	O
dose	JJ	O
arm	NN	O
were	VBD	O
greater	JJR	O
than	IN	O
differences	NNS	O
between	IN	O
arms	NNS	O
.	.	O

Additional	JJ	O
significant	JJ	O
toxic	NN	O
effects	NNS	O
included	VBD	O
nausea	NN	O
and	CC	O
vomiting	NN	O
,	,	O
hypotension	NN	O
,	,	O
leukopenia	NN	O
,	,	O
thrombocytopenia	NN	O
,	,	O
and	CC	O
evidence	NN	O
of	IN	O
hepatic	JJ	O
toxicity	NN	O
.	.	O

Minor	JJ	O
changes	NNS	O
in	IN	O
serum	NN	O
electrolytes	NNS	O
were	VBD	O
noted	VBN	O
.	.	O

Coagulation	NNP	O
studies	NNS	O
were	VBD	O
normal	JJ	O
.	.	O

The	DT	O
dose-limiting	JJ	O
toxic	NN	O
effect	NN	O
for	IN	O
the	DT	O
high-dose	JJ	O
arm	NN	O
was	VBD	O
myelosuppression	NN	O
.	.	O

Median	JJ	O
maximum	NN	O
tolerated	VBD	O
dose	JJ	O
among	IN	O
high-dose	JJ	O
strategy	NN	O
patients	NNS	O
was	VBD	O
18	CD	O
X	JJ	O
10	CD	O
(	(	O
6	CD	O
)	)	O
units/m2	NN	O
,	,	O
but	CC	O
there	RB	O
was	VBD	O
marked	VBN	O
interpatient	JJ	O
variation	NN	O
.	.	O

We	PRP	O
conclude	VBP	O
that	IN	O
both	DT	O
dose	JJ	O
schedules	NNS	O
were	VBD	O
relatively	RB	O
well-tolerated	JJ	O
.	.	O

Because	IN	O
of	IN	O
individual	JJ	O
variation	NN	O
in	IN	O
tolerance	NN	O
,	,	O
high-dose	JJ	O
treatment	NN	O
should	MD	O
include	VB	O
a	DT	O
dose	JJ	O
escalation	NN	O
strategy	NN	O
.	.	O

Risperidone	NN	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
negative	JJ	O
symptoms	NNS	O
of	IN	O
schizophrenia	NN	O
:	:	O
a	DT	O
meta-analysis	NN	O
.	.	O

Risperidone	NN	O
has	VBZ	O
antiserotonergic	VBN	O
and	CC	O
antidopaminergic	JJ	O
properties	NNS	O
that	WDT	O
may	MD	O
make	VB	O
it	PRP	O
more	RBR	O
effective	JJ	O
than	IN	O
conventional	JJ	O
antipsychotic	JJ	O
agents	NNS	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
the	DT	O
negative	JJ	O
symptoms	NNS	O
of	IN	O
schizophrenia	NN	O
.	.	O

Clinical	JJ	O
trials	NNS	O
in	IN	O
chronic	JJ	O
schizophrenic	JJ	O
patients	NNS	O
have	VBP	O
shown	VBN	O
trends	NNS	O
in	IN	O
favor	NN	O
of	IN	O
risperidone	NN	O
in	IN	O
the	DT	O
control	NN	O
of	IN	O
negative	JJ	O
symptoms	NNS	O
compared	VBN	O
with	IN	O
haloperidol	NN	O
,	,	O
perphenazine	NN	O
or	CC	O
zuclopenthixol	NN	O
,	,	O
but	CC	O
the	DT	O
differences	NNS	O
were	VBD	O
not	RB	O
consistently	RB	O
statistically	RB	O
significant	JJ	O
.	.	O

A	DT	O
meta-analysis	NN	O
of	IN	O
the	DT	O
pooled	JJ	O
results	NNS	O
from	IN	O
six	CD	O
double-blind	JJ	O
trials	NNS	O
showed	VBD	O
that	IN	O
risperidone	NN	O
at	IN	O
doses	NNS	O
ranging	VBG	O
from	IN	O
4	CD	O
to	TO	O
8	CD	O
mg/day	NN	O
had	VBD	O
a	DT	O
significantly	RB	O
(	(	O
p	JJ	O
<	NNP	O
0.004	CD	O
)	)	O
higher	JJR	O
negative	JJ	O
symptom	JJ	O
response	NN	O
rate	NN	O
,	,	O
defined	VBN	O
as	IN	O
the	DT	O
percentage	NN	O
of	IN	O
patients	NNS	O
with	IN	O
a	DT	O
20	CD	O
%	NN	O
or	CC	O
more	JJR	O
reduction	NN	O
in	IN	O
scores	NNS	O
on	IN	O
the	DT	O
negative	JJ	O
subscale	NN	O
of	IN	O
the	DT	O
Positive	NNP	O
and	CC	O
Negative	NNP	O
Syndrome	NNP	O
Scale	NNP	O
,	,	O
than	IN	O
patients	NNS	O
receiving	VBG	O
active	JJ	O
controls	NNS	O
.	.	O

The	DT	O
combined	JJ	O
patient	JJ	O
population	NN	O
treated	VBN	O
with	IN	O
4-8	JJ	O
mg/day	NN	O
of	IN	O
risperidone	NN	O
was	VBD	O
1.43	CD	O
times	NNS	O
more	RBR	O
likely	JJ	O
to	TO	O
have	VB	O
had	VBN	O
a	DT	O
clinical	JJ	O
response	NN	O
on	IN	O
the	DT	O
negative	JJ	O
symptom	NN	O
subscale	NN	O
than	IN	O
the	DT	O
combined	JJ	O
population	NN	O
treated	VBN	O
with	IN	O
haloperidol	NN	O
,	,	O
perphenazine	NN	O
or	CC	O
zuclopenthixol	NN	O
.	.	O

Temozolomide	NNP	O
and	CC	O
cisplatin	VB	O
versus	NN	O
temozolomide	NN	O
in	IN	O
patients	NNS	O
with	IN	O
advanced	JJ	C
melanoma	NN	C
:	:	O
a	DT	O
randomized	JJ	O
phase	NN	O
II	NNP	O
study	NN	O
of	IN	O
the	DT	O
Hellenic	NNP	O
Cooperative	NNP	O
Oncology	NNP	O
Group	NNP	O
.	.	O

PURPOSE	NNP	O
Temozolomide	NNP	O
(	(	O
TMZ	NNP	O
)	)	O
is	VBZ	O
an	DT	O
oral	JJ	O
alkylating	NN	O
agent	NN	O
that	WDT	O
produces	VBZ	O
methyl	JJ	O
adducts	NNS	O
at	IN	O
the	DT	O
0.6	CD	O
position	NN	O
of	IN	O
guanine	NN	O
.	.	O

The	DT	O
methyl	NN	O
adducts	NNS	O
are	VBP	O
removed	VBN	O
by	IN	O
the	DT	O
DNA	NNP	O
repair	NN	O
enzyme	JJ	O
AGAT	NNP	O
.	.	O

As	IN	O
demonstrated	VBN	O
by	IN	O
in	IN	O
vitro	NN	O
studies	NNS	O
,	,	O
cisplatin	NN	O
(	(	O
CDDP	NNP	O
)	)	O
is	VBZ	O
able	JJ	O
to	TO	O
down-regulate	VB	O
the	DT	O
AGAT	NNP	O
activity	NN	O
,	,	O
suggesting	VBG	O
that	IN	O
CDDP	NNP	O
could	MD	O
enhance	VB	O
the	DT	O
antitumor	NN	O
activity	NN	O
of	IN	O
TMZ	NNP	O
.	.	O

We	PRP	O
designed	VBD	O
a	DT	O
randomized	JJ	O
phase	NN	O
II	NNP	O
study	NN	O
to	TO	O
evaluate	VB	O
and	CC	O
compare	VB	O
the	DT	O
activity	NN	O
and	CC	O
safety	NN	O
profile	NN	O
of	IN	O
the	DT	O
combination	NN	O
versus	IN	O
single-agent	JJ	O
TMZ	NNP	O
in	IN	O
patients	NNS	O
with	IN	O
advanced	JJ	C
melanoma	NN	C
.	.	O

PATIENTS	NNP	O
AND	CC	O
METHODS	NNP	O
From	NNP	O
January	NNP	O
2000	CD	O
to	TO	O
April	NNP	O
2002	CD	O
,	,	O
132	CD	SS
patients	NNS	O
were	VBD	O
enrolled	VBN	O
on	IN	O
the	DT	O
study	NN	O
.	.	O

Patient	NNP	O
and	CC	O
tumor	NN	O
characteristics	NNS	O
were	VBD	O
well	RB	O
balanced	VBN	O
between	IN	O
the	DT	O
two	CD	O
arms	NNS	O
.	.	O

Patients	NNS	O
with	IN	O
cerebral	JJ	C
metastases	NNS	C
were	VBD	O
included	VBN	O
.	.	O

Patients	NNS	O
received	VBD	O
TMZ	NNP	O
200	CD	O
mg/m	NN	O
(	(	O
2	CD	O
)	)	O
/day	NN	O
orally	RB	O
for	IN	O
five	CD	O
consecutive	JJ	O
days	NNS	O
every	DT	O
4	CD	O
weeks	NNS	O
or	CC	O
TMZ	NNP	O
+	NNP	O
CDDP	NNP	O
200	CD	O
mg/m	NN	O
(	(	O
2	CD	O
)	)	O
daily	RB	O
on	IN	O
days	NNS	O
1-5	CD	O
and	CC	O
75	CD	O
mg/m	NN	O
(	(	O
2	CD	O
)	)	O
of	IN	O
CDDP	NNP	O
on	IN	O
day	NN	O
1	CD	O
.	.	O

RESULTS	NNP	O
Tumor	NNP	O
responses	VBZ	O
(	(	O
complete	JJ	O
and	CC	O
partial	JJ	O
responses	NNS	O
)	)	O
were	VBD	O
seen	VBN	O
in	IN	O
16	CD	O
patients	NNS	O
(	(	O
26	CD	O
%	NN	O
)	)	O
in	IN	O
arm	NN	O
A	NN	O
and	CC	O
19	CD	O
patients	NNS	O
(	(	O
29	CD	O
%	NN	O
)	)	O
in	IN	O
arm	NN	O
B	NNP	O
.	.	O

The	DT	O
median	JJ	O
time	NN	O
to	TO	O
progression	NN	O
(	(	O
TTP	NNP	O
)	)	O
was	VBD	O
3.8	CD	O
months	NNS	O
in	IN	O
arm	NN	O
A	NN	O
and	CC	O
5.8	CD	O
months	NNS	O
in	IN	O
arm	NN	O
B	NNP	O
.	.	O

The	DT	O
median	JJ	O
overall	JJ	O
survival	NN	O
(	(	O
OS	NNP	O
)	)	O
was	VBD	O
11.5	CD	O
months	NNS	O
in	IN	O
arm	NN	O
A	NN	O
and	CC	O
12	CD	O
months	NNS	O
in	IN	O
arm	NN	O
B	NNP	O
.	.	O

The	DT	O
difference	NN	O
between	IN	O
treatment	NN	O
arms	NNS	O
regarding	VBG	O
objective	JJ	O
response	NN	O
rates	NNS	O
,	,	O
TTP	NNP	O
and	CC	O
OS	NNP	O
were	VBD	O
not	RB	O
statistically	RB	O
significant	JJ	O
.	.	O

Toxicity	NN	O
was	VBD	O
comparable	JJ	O
between	IN	O
the	DT	O
two	CD	O
arms	NNS	O
for	IN	O
anemia	NN	O
,	,	O
leukopenia	NN	O
,	,	O
neutropenia	NN	O
,	,	O
thrombocytopenia	NN	O
,	,	O
fatigue	NN	O
,	,	O
constipation	NN	O
and	CC	O
arthralgias/myalgias	NN	O
.	.	O

There	EX	O
was	VBD	O
significantly	RB	O
more	JJR	O
grade	JJ	O
3	CD	O
and	CC	O
4	CD	O
emesis	NN	O
in	IN	O
the	DT	O
combination	NN	O
arm	NN	O
.	.	O

CONCLUSIONS	NNP	O
No	NNP	O
clear	JJ	O
benefit	NN	O
in	IN	O
terms	NNS	O
of	IN	O
response	NN	O
rates	NNS	O
,	,	O
median	JJ	O
TTP	NNP	O
or	CC	O
OS	NNP	O
was	VBD	O
shown	VBN	O
with	IN	O
the	DT	O
combination	NN	O
of	IN	O
TMZ	NNP	O
+	NNP	O
CDDP	NNP	O
.	.	O

Additionally	RB	O
,	,	O
the	DT	O
combination	NN	O
was	VBD	O
associated	VBN	O
with	IN	O
higher	JJR	O
incidence	NN	O
of	IN	O
grade	NN	O
3	CD	O
and	CC	O
4	CD	O
emesis	NN	O
.	.	O

Lidocaine	NNP	O
and	CC	O
bupivacaine	NN	O
mixtures	NNS	O
for	IN	O
epidural	JJ	O
blockade	NN	O
.	.	O

In	IN	O
a	DT	O
prospective	JJ	O
double-blind	NN	O
clinical	JJ	O
study	NN	O
,	,	O
single-dose	JJ	O
lumbar	NN	O
epidural	JJ	O
blockade	NN	O
was	VBD	O
instituted	VBN	O
in	IN	O
60	CD	SS
healthy	JJ	C
patients	NNS	C
undergoing	VBG	C
lower	JJR	C
abdominal	JJ	C
surgery	NN	C
.	.	O

Patients	NNS	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
one	CD	O
of	IN	O
five	CD	O
groups	NNS	O
.	.	O

Each	DT	O
group	NN	O
received	VBD	O
treatment	NN	O
with	IN	O
a	DT	O
different	JJ	O
local	JJ	O
anesthetic	JJ	O
solution	NN	O
containing	VBG	O
1:200,000	CD	O
epinephrine	NN	O
.	.	O

Local	JJ	O
anesthetic	JJ	O
solutions	NNS	O
used	VBN	O
were	VBD	O
0.5	CD	O
per	IN	O
cent	NN	O
bupivacaine	NN	O
HCl	NNP	O
,	,	O
2	CD	O
per	IN	O
cent	NN	O
lidocaine	NN	O
HCl	NNP	O
,	,	O
and	CC	O
lidocaine-bupivacaine	JJ	O
mixtures	NNS	O
in	IN	O
the	DT	O
ratios	NNS	O
of	IN	O
1:3	CD	O
,	,	O
1:1	CD	O
or	CC	O
3:1	CD	O
by	IN	O
volume	NN	O
.	.	O

Onset	NNP	O
and	CC	O
complete	JJ	O
spread	NN	O
of	IN	O
sensory	JJ	O
blockade	NN	O
were	VBD	O
similar	JJ	O
in	IN	O
all	DT	O
five	CD	O
groups	NNS	O
.	.	O

Time	NNP	O
to	TO	O
regression	VB	O
to	TO	O
two	CD	O
segments	NNS	O
of	IN	O
partial	JJ	O
and	CC	O
complete	JJ	O
sensory	NN	O
blockade	NN	O
was	VBD	O
positively	RB	O
correlated	VBN	O
(	(	O
P	NNP	O
less	JJR	O
than	IN	O
0.05	CD	O
)	)	O
with	IN	O
increasing	VBG	O
dose	NN	O
of	IN	O
bupivacaine	NN	O
in	IN	O
the	DT	O
solutions	NNS	O
and	CC	O
ranged	VBD	O
from	IN	O
84	CD	O
min	NN	O
(	(	O
partial	JJ	O
)	)	O
and	CC	O
70	CD	O
min	NN	O
(	(	O
complete	JJ	O
)	)	O
for	IN	O
lidocaine	NN	O
,	,	O
to	TO	O
128	CD	O
min	NN	O
(	(	O
partial	JJ	O
)	)	O
and	CC	O
101	CD	O
min	NN	O
(	(	O
complete	JJ	O
)	)	O
for	IN	O
bupivacaine	NN	O
.	.	O

Using	VBG	O
skin	JJ	O
temperature	NN	O
as	IN	O
a	DT	O
criterion	NN	O
of	IN	O
sympathetic	JJ	O
blockade	NN	O
,	,	O
all	DT	O
three	CD	O
mixtures	NNS	O
demonstrated	VBD	O
a	DT	O
duration	NN	O
of	IN	O
action	NN	O
intermediate	NN	O
between	IN	O
the	DT	O
two	CD	O
single	JJ	O
drugs	NNS	O
,	,	O
lidocaine	NN	O
(	(	O
124	CD	O
+/-	JJ	O
13	CD	O
min	NN	O
)	)	O
and	CC	O
bupivacaine	NN	O
(	(	O
286	CD	O
+/-	JJ	O
32	CD	O
min	NN	O
)	)	O
.	.	O

Onset	NNP	O
of	IN	O
complete	JJ	O
motor	NN	O
blockade	NN	O
was	VBD	O
fastest	JJS	O
and	CC	O
the	DT	O
degree	NN	O
of	IN	O
motor	NN	O
blockade	NN	O
was	VBD	O
most	RBS	O
profound	JJ	O
with	IN	O
the	DT	O
mixture	NN	O
containing	VBG	O
equal	JJ	O
proportions	NNS	O
of	IN	O
lidocaine	NN	O
and	CC	O
bupivacaine	NN	O
.	.	O

Pharmacokinetics	NNS	O
of	IN	O
individual	JJ	O
drugs	NNS	O
were	VBD	O
unaltered	VBN	O
in	IN	O
any	DT	O
of	IN	O
the	DT	O
mixtures	NNS	O
.	.	O

A	DT	O
randomized	JJ	O
trial	NN	O
of	IN	O
a	DT	O
brief	JJ	O
alcohol	NN	O
intervention	NN	O
for	IN	O
needle	JJ	O
exchangers	NNS	O
(	(	O
BRAINE	NNP	O
)	)	O
.	.	O

AIMS	UH	O
To	TO	O
test	VB	O
motivational	JJ	O
interviewing	NN	O
(	(	O
MI	NNP	O
)	)	O
as	IN	O
a	DT	O
brief	JJ	O
intervention	NN	O
for	IN	O
reducing	VBG	O
alcohol	NN	O
use	NN	O
among	IN	O
needle	JJ	O
exchange	NN	O
clients	NNS	O
.	.	O

DESIGN	NNP	O
Randomized	NNP	O
clinical	JJ	O
trial	NN	O
.	.	O

SETTING	NNP	O
Needle	NNP	O
exchange	NN	O
program-Providence	NN	O
,	,	O
Rhode	NNP	O
Island	NNP	O
,	,	O
USA	NNP	O
.	.	O

PARTICIPANTS	NNP	O
Between	NNP	O
2/98	CD	O
and	CC	O
10/99	CD	O
,	,	O
we	PRP	O
recruited	VBD	O
187	CD	SS
AUDIT-positive	JJ	C
(	(	C
>	JJ	C
8	CD	C
)	)	C
active	JJ	C
injection	NN	C
drug	NN	C
users	NNS	C
.	.	O

INTERVENTION	NNP	O
Those	DT	O
assigned	VBN	O
to	TO	O
a	DT	O
brief	JJ	O
motivational	JJ	O
intervention	NN	O
(	(	O
MI	NNP	O
)	)	O
condition	NN	O
received	VBD	O
two	CD	O
1-hour	JJ	O
therapist	JJ	O
sessions	NNS	O
following	VBG	O
assessment	NN	O
visits	NNS	O
,	,	O
1	CD	O
month	NN	O
apart	RB	O
,	,	O
focusing	VBG	O
on	IN	O
alcohol	NN	O
use	NN	O
and	CC	O
HIV	NNP	O
risk-taking	NN	O
.	.	O

MEASUREMENTS	NNP	O
Control	NNP	O
and	CC	O
MI	NNP	O
subjects	NNS	O
received	VBD	O
identical	JJ	O
research	NN	O
assessments	NNS	O
at	IN	O
baseline	NN	O
,	,	O
1	CD	O
and	CC	O
6	CD	O
months	NNS	O
following	VBG	O
study	NN	O
enrollment	NN	O
.	.	O

At	IN	O
6	CD	O
months	NNS	O
,	,	O
study	NN	O
outcomes	NNS	O
included	VBD	O
days	NNS	O
of	IN	O
alcohol	NN	O
use	NN	O
measured	VBD	O
using	VBG	O
the	DT	O
time-line	JJ	O
follow-back	JJ	O
method	NN	O
.	.	O

FINDINGS	NNP	O
Study	NNP	O
retention	NN	O
was	VBD	O
96.8	CD	O
%	NN	O
at	IN	O
6	CD	O
months	NNS	O
.	.	O

Participants	NNS	O
reported	VBD	O
an	DT	O
average	NN	O
of	IN	O
12.0	CD	O
drinking	NN	O
days	NNS	O
at	IN	O
baseline	NN	O
and	CC	O
8.3	CD	O
at	IN	O
6	CD	O
months	NNS	O
.	.	O

Significant	JJ	O
reductions	NNS	O
in	IN	O
drinking	NN	O
days	NNS	O
were	VBD	O
observed	VBN	O
in	IN	O
both	DT	O
treatment	NN	O
conditions	NNS	O
.	.	O

We	PRP	O
found	VBD	O
significant	JJ	O
treatment	NN	O
x	NNP	O
baseline	NN	O
drinking	VBG	O
day	NN	O
interaction	NN	O
effects	NNS	O
.	.	O

Tests	NNS	O
for	IN	O
simple	JJ	O
main	JJ	O
effects	NNS	O
were	VBD	O
significant	JJ	O
for	IN	O
subjects	NNS	O
with	IN	O
above	JJ	O
median	NN	O
(	(	O
>	JJ	O
9	CD	O
)	)	O
baseline	NN	O
drinking	VBG	O
day	NN	O
frequency	NN	O
,	,	O
but	CC	O
not	RB	O
for	IN	O
those	DT	O
with	IN	O
below	JJ	O
median	JJ	O
baseline	NN	O
drinking	NN	O
frequency	NN	O
.	.	O

Comparisons	NNS	O
on	IN	O
dichotomous	JJ	O
outcomes	NNS	O
provided	VBD	O
supporting	VBG	O
evidence	NN	O
of	IN	O
treatment	NN	O
efficacy	NN	O
;	:	O
those	DT	O
in	IN	O
MI	NNP	O
were	VBD	O
over	RB	O
two	CD	O
times	NNS	O
more	RBR	O
likely	JJ	O
than	IN	O
controls	NNS	O
to	TO	O
report	VB	O
reductions	NNS	O
of	IN	O
7	CD	O
days	NNS	O
or	CC	O
more	JJR	O
(	(	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
.	.	O

CONCLUSIONS	VB	O
This	DT	O
study	NN	O
provides	VBZ	O
the	DT	O
first	JJ	O
direct	JJ	O
evidence	NN	O
that	IN	O
brief	JJ	O
MI	NNP	O
can	MD	O
decrease	VB	O
alcohol	NN	O
use	NN	O
among	IN	O
active	JJ	O
injection	NN	O
drug	NN	O
users	NNS	O
with	IN	O
drinking	NN	O
problems	NNS	O
.	.	O

Heavier	JJR	O
drinkers	NNS	O
seem	VBP	O
best	RB	O
suited	VBN	O
for	IN	O
this	DT	O
intervention	NN	O
,	,	O
but	CC	O
the	DT	O
optimal	JJ	O
intensity	NN	O
of	IN	O
treatments	NNS	O
and	CC	O
which	WDT	O
components	NNS	O
of	IN	O
brief	JJ	O
intervention	NN	O
are	VBP	O
most	RBS	O
effective	JJ	O
deserve	NN	O
further	RB	O
study	NN	O
.	.	O

Comparison	NNP	O
of	IN	O
short-term	JJ	O
efficacy	NN	O
of	IN	O
diltiazem	NN	O
and	CC	O
propranolol	NN	O
in	IN	O
unstable	JJ	O
angina	NN	O
at	IN	O
rest	NN	O
--	:	O
a	DT	O
randomized	JJ	O
trial	NN	O
in	IN	O
70	CD	SS
patients	NNS	O
.	.	O

The	DT	O
short-term	JJ	O
efficacy	NN	O
of	IN	O
diltiazem	NN	O
(	(	O
D	NNP	O
)	)	O
has	VBZ	O
been	VBN	O
compared	VBN	O
to	TO	O
that	DT	O
of	IN	O
propranolol	NN	O
(	(	O
P	NNP	O
)	)	O
,	,	O
in	IN	O
a	DT	O
group	NN	O
of	IN	O
70	CD	SS
patients	NNS	O
hospitalized	VBN	O
in	IN	O
the	DT	O
Coronary	NNP	O
Care	NNP	O
Unit	NNP	O
for	IN	O
unstable	JJ	C
angina	NN	C
,	,	O
defined	VBN	O
as	IN	O
recent	JJ	O
(	(	O
less	JJR	O
than	IN	O
one	CD	O
month	NN	O
)	)	O
appearance	NN	O
or	CC	O
aggravation	NN	O
of	IN	O
spontaneous	JJ	O
chest	NN	C
pains	NNS	C
.	.	C

Among	IN	O
the	DT	O
70	CD	SS
patients	NNS	O
,	,	O
24	CD	SS
had	VBD	O
angina	VBN	C
only	RB	O
at	IN	O
rest	NN	O
.	.	O

The	DT	O
patients	NNS	O
have	VBP	O
been	VBN	O
divided	VBN	O
into	IN	O
two	CD	O
groups	NNS	O
according	VBG	O
to	TO	O
ST-T	JJ	O
changes	NNS	O
during	IN	O
chest	NN	C
pain	NN	C
:	:	O
29	CD	SS
with	IN	O
ST	NNP	O
elevation	NN	O
(	(	O
group	NN	O
A	NNP	O
)	)	O
and	CC	O
41	CD	SS
with	IN	O
other	JJ	O
repolarization	NN	C
abnormalities	NNS	C
(	(	C
group	NN	C
B	NNP	C
)	)	C
.	.	O

Treatment	NN	O
was	VBD	O
then	RB	O
randomized	VBN	O
in	IN	O
each	DT	O
group	NN	O
.	.	O

Treatment	NNP	O
Treatment	NNP	O
was	VBD	O
considered	VBN	O
successful	JJ	O
only	RB	O
if	IN	O
spontaneous	JJ	O
chest	NN	O
pains	NNS	O
disappeared	VBD	O
completely	RB	O
.	.	O

Thirty-four	JJ	O
patients	NNS	O
were	VBD	O
treated	VBN	O
with	IN	O
D	NNP	O
(	(	O
282	CD	O
+/-	JJ	O
102	CD	O
mg/day	NN	O
)	)	O
and	CC	O
36	CD	O
with	IN	O
P	NNP	O
(	(	O
158	CD	O
+/-	JJ	O
81	CD	O
mg/day	NN	O
)	)	O
.	.	O

In	IN	O
the	DT	O
whole	JJ	O
group	NN	O
and	CC	O
in	IN	O
groups	NNS	O
A	NNP	O
and	CC	O
B	NNP	O
considered	VBD	O
individually	RB	O
,	,	O
responses	NNS	O
to	TO	O
D	NNP	O
and	CC	O
P	NNP	O
did	VBD	O
not	RB	O
differ	VB	O
.	.	O

Among	IN	O
the	DT	O
24	CD	SS
patients	NNS	O
with	IN	O
angina	JJ	C
exclusively	RB	O
at	IN	O
rest	NN	O
,	,	O
nine	CD	O
successes	NNS	O
and	CC	O
four	CD	O
failures	NNS	O
were	VBD	O
observed	VBN	O
with	IN	O
D.	NNP	O
There	EX	O
was	VBD	O
no	DT	O
symptomatic	JJ	O
relief	NN	O
among	IN	O
the	DT	O
11	CD	O
patients	NNS	O
treated	VBN	O
by	IN	O
P	NNP	O
(	(	O
P	NNP	O
=	NNP	O
0.001	CD	O
)	)	O
.	.	O

Moreover	RB	O
,	,	O
the	DT	O
number	NN	O
of	IN	O
episodes	NNS	O
of	IN	O
angina	NN	O
was	VBD	O
decreased	VBN	O
by	IN	O
D	NNP	O
and	CC	O
unchanged	JJ	O
by	IN	O
P	NNP	O
,	,	O
while	IN	O
eight	CD	O
out	IN	O
of	IN	O
the	DT	O
11	CD	O
failures	NNS	O
with	IN	O
P	NNP	O
were	VBD	O
immediate	JJ	O
successes	NNS	O
when	WRB	O
treatment	NN	O
was	VBD	O
replaced	VBN	O
with	IN	O
D.	NNP	O
These	DT	O
results	NNS	O
suggest	VBP	O
that	IN	O
D	NNP	O
is	VBZ	O
preferable	JJ	O
to	TO	O
P	VB	O
for	IN	O
management	NN	O
of	IN	O
unstable	JJ	O
angina	NNS	C
in	IN	O
patients	NNS	O
with	IN	O
angina	NN	C
which	WDT	O
is	VBZ	O
exclusively	RB	O
spontaneous	JJ	O
.	.	O

[	JJ	O
Comparison	NNP	O
between	IN	O
anterior	JJ	O
rhinomanometry	NN	O
and	CC	O
impulse-oscillometric	JJ	O
rhinometry	NN	O
found	VBD	O
within	IN	O
nasal	JJ	C
allergen	JJ	C
provocation	NN	O
]	NNP	O
.	.	O

UNLABELLED	NNP	O
Besides	IN	O
the	DT	O
standard	JJ	O
method	NN	O
of	IN	O
anterior	JJ	O
rhinomanometry	NN	O
(	(	O
aR	NN	O
)	)	O
,	,	O
the	DT	O
impulse-oscillometric	JJ	O
rhinometry	NN	O
(	(	O
IOS	NNP	O
)	)	O
is	VBZ	O
available	JJ	O
for	IN	O
measurements	NNS	O
of	IN	O
the	DT	O
nasal	JJ	O
resistance	NN	O
.	.	O

The	DT	O
aR	NN	O
is	VBZ	O
a	DT	O
procedure	NN	O
dependent	NN	O
on	IN	O
the	DT	O
cooperation	NN	O
of	IN	O
the	DT	O
patient	NN	O
,	,	O
whereas	JJ	O
IOS	NNP	O
is	VBZ	O
measured	VBN	O
regardless	RB	O
from	IN	O
the	DT	O
breathing	NN	O
activities	NNS	O
of	IN	O
the	DT	O
patient	NN	O
.	.	O

We	PRP	O
examined	VBD	O
weather	RP	O
the	DT	O
resistance-measurement	NN	O
by	IN	O
means	NNS	O
of	IN	O
IOS	NNP	O
in	IN	O
comparison	NN	O
to	TO	O
the	DT	O
aR	NN	O
is	VBZ	O
a	DT	O
more	RBR	O
suitable	JJ	O
method	NN	O
for	IN	O
nasal	JJ	O
allergic	JJ	O
provocation	NN	O
.	.	O

METHOD	NNP	O
17	CD	SS
patients	NNS	O
with	IN	O
anamnestic	JJ	O
known	VBN	O
rhinokonjunktivitis	NN	C
(	(	O
6	CD	O
f	NN	O
,	,	O
11	CD	O
m	NN	O
)	)	O
had	VBD	O
a	DT	O
pricktest	NN	O
and	CC	O
then	RB	O
a	DT	O
nasal	JJ	O
provocation	NN	O
testing	VBG	O
with	IN	O
an	DT	O
allergen	NN	O
which	WDT	O
provoked	VBD	O
a	DT	O
reaction	NN	O
on	IN	O
the	DT	O
skin	NN	O
.	.	O

The	DT	O
complete	JJ	O
resistance	NN	O
of	IN	O
the	DT	O
nose	NN	O
was	VBD	O
measured	VBN	O
in	IN	O
a	DT	O
randomized	JJ	O
order	NN	O
by	IN	O
means	NNS	O
of	IN	O
aR	NN	O
and	CC	O
IOS	NNP	O
.	.	O

RESULTS	VB	O
The	DT	O
complete	JJ	O
resistance	NN	O
showed	VBD	O
neither	CC	O
in	IN	O
the	DT	O
basic	JJ	O
measurement	NN	O
(	(	O
aR	JJ	O
0,38	CD	O
+/-	JJ	O
0,14	CD	O
kPa/l/s	NN	O
;	:	O
IOS	NNP	O
0,38	CD	O
+/-	JJ	O
0,11	CD	O
kPa/l/s	NN	O
)	)	O
nor	CC	O
in	IN	O
the	DT	O
control	NN	O
solution	NN	O
(	(	O
aR	JJ	O
0,38	CD	O
+/-	JJ	O
0,14	CD	O
;	:	O
IOS	NNP	O
0,39	CD	O
+/-	JJ	O
0,14	CD	O
)	)	O
nor	CC	O
after	IN	O
application	NN	O
of	IN	O
the	DT	O
allergenic	JJ	O
solution	NN	O
(	(	O
15	CD	O
min	NN	O
:	:	O
aR	JJ	O
0,69	CD	O
+/-	JJ	O
0,27	CD	O
;	:	O
IOS	NNP	O
0,77	CD	O
+/-	JJ	O
0,42	CD	O
;	:	O
30	CD	O
min	NN	O
:	:	O
aR	JJ	O
0,65	CD	O
+/-	JJ	O
0,29	CD	O
;	:	O
IOS	NNP	O
0,6	CD	O
+/-	JJ	O
0,38	CD	O
)	)	O
a	DT	O
significant	JJ	O
difference	NN	O
between	IN	O
the	DT	O
two	CD	O
methods	NNS	O
.	.	O

The	DT	O
results	NNS	O
of	IN	O
the	DT	O
measurement	NN	O
of	IN	O
aR	NN	O
and	CC	O
IOS	NNP	O
after	IN	O
the	DT	O
allergenic	JJ	O
solution	NN	O
showed	VBD	O
a	DT	O
positive	JJ	O
correlation	NN	O
(	(	O
15	CD	O
min	NN	O
:	:	O
r	NN	O
=	VBZ	O
0,63	CD	O
,	,	O
p	NN	O
<	VBD	O
0,01	CD	O
;	:	O
30	CD	O
min	NN	O
:	:	O
r	NN	O
=	VBZ	O
0,67	CD	O
,	,	O
p	NN	O
<	NNP	O
0,01	CD	O
)	)	O
.	.	O

We	PRP	O
found	VBD	O
by	IN	O
means	NNS	O
of	IN	O
clinic	NN	O
and	CC	O
measurement	NN	O
methods	NNS	O
in	IN	O
the	DT	O
aR	NN	O
of	IN	O
7	CD	SS
patients	NNS	O
a	DT	O
positive	JJ	O
reaction	NN	O
,	,	O
within	IN	O
7	CD	O
patient	NN	O
a	DT	O
negative	JJ	O
reaction	NN	O
,	,	O
3	CD	O
patients	NNS	O
had	VBD	O
a	DT	O
unspecific	JJ	O
nasal	NN	O
hyperreactivity	NN	O
.	.	O

There	EX	O
was	VBD	O
a	DT	O
correspondence	NN	O
in	IN	O
6	CD	O
of	IN	O
the	DT	O
7	CD	O
patients	NNS	O
with	IN	O
positive	JJ	O
reaction	NN	O
in	IN	O
aR	NN	O
between	IN	O
both	DT	O
methods	NNS	O
.	.	O

4	CD	O
of	IN	O
the	DT	O
7	CD	O
results	NNS	O
with	IN	O
negative	JJ	O
reaction	NN	O
in	IN	O
the	DT	O
aR	NN	O
would	MD	O
have	VB	O
been	VBN	O
positive	JJ	O
then	RB	O
underlying	VBG	O
the	DT	O
same	JJ	O
criteria	NNS	O
in	IN	O
the	DT	O
IOS	NNP	O
without	IN	O
announcing	VBG	O
the	DT	O
symptomscore	NN	O
a	DT	O
relevant	JJ	O
clinical	JJ	O
symptomatic	NN	O
while	IN	O
testing	VBG	O
.	.	O

CONCLUSION	NNP	O
IOS	NNP	O
is	VBZ	O
a	DT	O
suitable	JJ	O
procedure	NN	O
for	IN	O
nasal	JJ	O
provocation	NN	O
testing	VBG	O
and	CC	O
provides	VBZ	O
results	NNS	O
similar	JJ	O
to	TO	O
the	DT	O
aR	NN	O
.	.	O

In	IN	O
comparison	NN	O
to	TO	O
aR	VB	O
IOS	NNP	O
is	VBZ	O
not	RB	O
dependent	JJ	O
on	IN	O
the	DT	O
patients	NNS	O
cooperation	NN	O
.	.	O

Due	NNP	O
to	TO	O
its	PRP$	O
higher	JJR	O
sensitivity	NN	O
the	DT	O
valid	JJ	O
limits	NNS	O
of	IN	O
the	DT	O
aR	NN	O
at	IN	O
provocation	NN	O
testings	NNS	O
can	MD	O
not	RB	O
be	VB	O
transferred	VBN	O
to	TO	O
IOS	NNP	O
to	TO	O
avoid	VB	O
a	DT	O
false	JJ	O
positive	JJ	O
reaction	NN	O
.	.	O

Results	NNS	O
of	IN	O
a	DT	O
phase	NN	O
I/II	NNP	O
trial	NN	O
of	IN	O
recombinant	JJ	O
human	JJ	O
granulocyte-macrophage	NN	O
colony-stimulating	NN	O
factor	NN	O
in	IN	O
very	RB	O
low	JJ	O
birthweight	NN	O
neonates	NNS	O
:	:	O
significant	JJ	O
induction	NN	O
of	IN	O
circulatory	NN	O
neutrophils	NNS	O
,	,	O
monocytes	NNS	O
,	,	O
platelets	NNS	O
,	,	O
and	CC	O
bone	NN	O
marrow	NN	O
neutrophils	NNS	O
.	.	O

Neonates	NNS	O
,	,	O
especially	RB	O
those	DT	O
of	IN	O
very	RB	O
low	JJ	O
birthweight	NN	O
(	(	O
VLBW	NNP	O
)	)	O
,	,	O
have	VBP	O
an	DT	O
increased	VBN	O
risk	NN	O
of	IN	O
nosocomial	JJ	O
infections	NNS	O
secondary	JJ	O
to	TO	O
deficiencies	NNS	O
in	IN	O
development	NN	O
.	.	O

We	PRP	O
previously	RB	O
demonstrated	VBD	O
that	IN	O
granulocyte-macrophage	JJ	O
colony-stimulating	JJ	O
factor	NN	O
(	(	O
GM-CSF	NNP	O
)	)	O
production	NN	O
and	CC	O
mRNA	JJ	O
expression	NN	O
from	IN	O
stimulated	VBN	O
neonatal	JJ	O
mononuclear	JJ	O
cells	NNS	O
are	VBP	O
significantly	RB	O
less	JJR	O
than	IN	O
that	DT	O
from	IN	O
adult	NN	O
cells	NNS	O
.	.	O

Recombinant	JJ	O
murine	JJ	O
GM-CSF	NNP	O
administration	NN	O
to	TO	O
neonatal	JJ	O
rats	NNS	O
has	VBZ	O
resulted	VBN	O
in	IN	O
neutrophilia	JJ	O
,	,	O
increased	JJ	O
neutrophil	NN	O
production	NN	O
,	,	O
and	CC	O
increased	VBD	O
survival	NN	O
of	IN	O
pups	NNS	O
during	IN	O
experimental	JJ	O
Staphylococcus	NNP	O
aureus	NN	O
sepsis	NN	O
.	.	O

In	IN	O
the	DT	O
present	JJ	O
study	NN	O
,	,	O
we	PRP	O
sought	VBD	O
to	TO	O
determine	VB	O
the	DT	O
safety	NN	O
and	CC	O
biologic	JJ	O
response	NN	O
of	IN	O
recombinant	JJ	O
human	JJ	O
(	(	O
rhu	NN	O
)	)	O
GM-CSF	NNP	O
in	IN	O
VLBW	NNP	O
neonates	NNS	O
.	.	O

Twenty	NNP	O
VLBW	NNP	O
neonates	NNS	O
(	(	O
500	CD	O
to	TO	O
1,500	CD	O
g	NN	O
)	)	O
,	,	O
aged	VBD	O
<	JJ	O
72	CD	O
hours	NNS	O
,	,	O
were	VBD	O
randomized	VBN	O
to	TO	O
receive	VB	O
either	DT	O
placebo	NN	O
(	(	O
n	JJ	O
=	NNP	O
5	CD	O
)	)	O
or	CC	O
rhuGM-CSF	NN	O
at	IN	O
5.0	CD	O
micrograms/kg	NN	O
once	RB	O
per	IN	O
day	NN	O
(	(	O
n	JJ	O
=	NNP	O
5	CD	O
)	)	O
,	,	O
5.0	CD	O
micrograms/kg	NN	O
twice	RB	O
per	IN	O
day	NN	O
(	(	O
n	JJ	O
=	NNP	O
5	CD	O
)	)	O
,	,	O
or	CC	O
10	CD	O
micrograms/kg	NN	O
once	RB	O
per	IN	O
day	NN	O
(	(	O
n	JJ	O
=	NNP	O
5	CD	O
)	)	O
given	VBN	O
via	IN	O
2-hour	JJ	O
intravenous	JJ	O
infusion	NN	O
for	IN	O
7	CD	O
days	NNS	O
.	.	O

Complete	JJ	O
blood	NN	O
counts	NNS	O
,	,	O
differential	NN	O
,	,	O
and	CC	O
platelet	NN	O
counts	NNS	O
were	VBD	O
obtained	VBN	O
,	,	O
and	CC	O
tibial	JJ	O
bone	NN	O
marrow	NN	O
aspirate	NN	O
was	VBD	O
performed	VBN	O
on	IN	O
day	NN	O
8	CD	O
.	.	O

Neutrophil	NNP	O
C3bi	NNP	O
receptor	NN	O
expression	NN	O
was	VBD	O
measured	VBN	O
at	IN	O
0	CD	O
and	CC	O
24	CD	O
hours	NNS	O
.	.	O

GM-CSF	JJ	O
levels	NNS	O
were	VBD	O
measured	VBN	O
by	IN	O
a	DT	O
sandwich	JJ	O
enzyme-linked	JJ	O
immunosorbent	NN	O
assay	NN	O
at	IN	O
2	CD	O
,	,	O
4	CD	O
,	,	O
6	CD	O
,	,	O
12	CD	O
,	,	O
and	CC	O
24	CD	O
hours	NNS	O
after	IN	O
the	DT	O
first	JJ	O
dose	NN	O
of	IN	O
rhuGM-CSF	NN	O
.	.	O

At	IN	O
all	DT	O
doses	NNS	O
,	,	O
rhuGM-CSF	NN	O
was	VBD	O
well	RB	O
tolerated	VBN	O
,	,	O
and	CC	O
there	EX	O
was	VBD	O
no	DT	O
evidence	NN	O
of	IN	O
grade	NN	O
III	NNP	O
or	CC	O
IV	NNP	O
toxicity	NN	O
.	.	O

Within	IN	O
48	CD	O
hours	NNS	O
of	IN	O
administration	NN	O
,	,	O
there	EX	O
was	VBD	O
a	DT	O
significant	JJ	O
increase	NN	O
in	IN	O
the	DT	O
circulating	VBG	O
absolute	JJ	O
neutrophil	NN	O
count	NN	O
(	(	O
ANC	NNP	O
)	)	O
at	IN	O
5.0	CD	O
micrograms/kg	NN	O
twice	RB	O
per	IN	O
day	NN	O
and	CC	O
10.0	CD	O
micrograms/kg	NN	O
once	RB	O
per	IN	O
day	NN	O
,	,	O
which	WDT	O
continued	VBD	O
for	IN	O
at	IN	O
least	JJS	O
24	CD	O
hours	NNS	O
after	IN	O
discontinuation	NN	O
of	IN	O
rhuGM-CSF	NN	O
.	.	O

When	WRB	O
the	DT	O
ANC	NNP	O
was	VBD	O
normalized	VBN	O
for	IN	O
each	DT	O
patient	NN	O
's	POS	O
first	JJ	O
ANC	NNP	O
,	,	O
there	EX	O
was	VBD	O
a	DT	O
significant	JJ	O
increase	NN	O
in	IN	O
the	DT	O
ANC	NNP	O
on	IN	O
days	NNS	O
6	CD	O
and	CC	O
7	CD	O
at	IN	O
each	DT	O
dose	JJ	O
level	NN	O
.	.	O

By	IN	O
day	NN	O
7	CD	O
,	,	O
all	DT	O
tested	JJ	O
doses	NNS	O
of	IN	O
rhuGM-CSF	NN	O
resulted	VBD	O
in	IN	O
an	DT	O
increase	NN	O
in	IN	O
the	DT	O
absolute	NN	O
monocyte	NN	O
count	NN	O
(	(	O
AMC	NNP	O
)	)	O
compared	VBN	O
with	IN	O
placebo-treated	JJ	O
neonates	NNS	O
.	.	O

In	IN	O
those	DT	O
receiving	VBG	O
rhuGM-CSF	JJ	O
5.0	CD	O
micrograms/kg	NN	O
twice	RB	O
per	IN	O
day	NN	O
,	,	O
there	EX	O
was	VBD	O
additionally	RB	O
a	DT	O
significant	JJ	O
increase	NN	O
in	IN	O
the	DT	O
day	NN	O
7	CD	O
and	CC	O
8	CD	O
platelet	NN	O
count	NN	O
.	.	O

Tibial	NNP	O
bone	NN	O
marrow	NN	O
aspirates	VBZ	O
demonstrated	VBD	O
a	DT	O
significant	JJ	O
increase	NN	O
in	IN	O
the	DT	O
bone	NN	O
marrow	NN	O
neutrophil	JJ	O
storage	NN	O
pool	NN	O
(	(	O
BM	NNP	O
NSP	NNP	O
)	)	O
at	IN	O
5.0	CD	O
micrograms/kg	NN	O
twice	RB	O
per	IN	O
day	NN	O
and	CC	O
10.0	CD	O
micrograms/kg	NN	O
once	RB	O
per	IN	O
day	NN	O
.	.	O

Neutrophil	NNP	O
C3bi	NNP	O
receptor	NN	O
expression	NN	O
was	VBD	O
significantly	RB	O
increased	VBN	O
24	CD	O
hours	NNS	O
after	IN	O
the	DT	O
first	JJ	O
dose	NN	O
of	IN	O
rhuGM-CSF	NN	O
at	IN	O
5.0	CD	O
micrograms/kg	NN	O
once	RB	O
per	IN	O
day	NN	O
.	.	O

The	DT	O
elimination	NN	O
half-life	NN	O
(	(	O
T1/2	NNP	O
)	)	O
of	IN	O
rhuGM-CSF	NN	O
was	VBD	O
1.4	CD	O
+/-	JJ	O
0.8	CD	O
to	TO	O
3.9	CD	O
+/-	JJ	O
2.8	CD	O
hours	NNS	O
.	.	O

(	(	O
ABSTRACT	NNP	O
TRUNCATED	NNP	O
AT	NNP	O
400	CD	O
WORDS	NNP	O
)	)	O
Immunogenicity	NN	O
and	CC	O
reactogenicity	NN	O
of	IN	O
a	DT	O
group	NN	O
C	NNP	O
meningococcal	JJ	O
conjugate	NN	O
vaccine	NN	O
compared	VBN	O
with	IN	O
a	DT	O
group	NN	O
A+C	NNP	O
meningococcal	JJ	O
polysaccharide	NN	O
vaccine	NN	O
in	IN	O
adolescents	NNS	C
in	IN	O
a	DT	O
randomised	JJ	O
observer-blind	NN	O
controlled	VBN	O
trial	NN	O
.	.	O

This	DT	O
study	NN	O
evaluated	VBD	O
the	DT	O
immunogenicity	NN	O
and	CC	O
reactogenicity	NN	O
of	IN	O
a	DT	O
group	NN	O
C	NNP	O
meningococcal	JJ	O
conjugate	NN	O
vaccine	NN	O
(	(	O
MenC	NNP	O
)	)	O
compared	VBN	O
with	IN	O
a	DT	O
group	NN	O
A+C	NNP	O
meningococcal	JJ	O
polysaccharide	NN	O
vaccine	NN	O
(	(	O
MenPS	NNP	O
)	)	O
in	IN	O
healthy	JJ	O
adolescents	NNS	O
.	.	O

Subjects	NNS	O
were	VBD	O
randomised	VBN	O
to	TO	O
receive	VB	O
one	CD	O
dose	NN	O
of	IN	O
either	DT	O
MenC	NNP	O
(	(	O
n=92	NN	O
)	)	O
or	CC	O
MenPS	NNP	O
(	(	O
n=90	NN	O
)	)	O
.	.	O

Group	NNP	O
C	NNP	O
meningococcal	JJ	O
IgG	NNP	O
antibody	NN	O
concentrations	NNS	O
and	CC	O
bactericidal	JJ	O
titres	NNS	O
were	VBD	O
higher	JJR	O
in	IN	O
the	DT	O
MenC	NNP	O
group	NN	O
than	IN	O
the	DT	O
MenPS	NNP	O
group	NN	O
at	IN	O
1	CD	O
month	NN	O
(	(	O
22.8	CD	O
U/ml	NNP	O
vs	NN	O
4.0	CD	O
U/ml	NNP	O
,	,	O
p	NN	O
<	VBD	O
0.001	CD	O
,	,	O
and	CC	O
87	CD	O
vs	NN	O
20	CD	O
,	,	O
p	NN	O
<	VBD	O
0.001	CD	O
,	,	O
respectively	RB	O
)	)	O
and	CC	O
12	CD	O
months	NNS	O
(	(	O
6.1	CD	O
U/ml	NNP	O
vs	NN	O
3.0	CD	O
U/ml	NNP	O
,	,	O
p	NN	O
<	VBD	O
0.001	CD	O
,	,	O
and	CC	O
81.3	CD	O
vs	NN	O
20.2	CD	O
,	,	O
p	NN	O
<	VBD	O
0.001	CD	O
,	,	O
respectively	RB	O
)	)	O
.	.	O

No	DT	O
differences	NNS	O
in	IN	O
post	NN	O
immunisation	NN	O
reaction	NN	O
rates	NNS	O
were	VBD	O
noted	VBN	O
between	IN	O
the	DT	O
two	CD	O
vaccinated	VBD	O
groups	NNS	O
.	.	O

This	DT	O
study	NN	O
demonstrated	VBD	O
the	DT	O
safety	NN	O
and	CC	O
enhanced	JJ	O
immunogenicity	NN	O
of	IN	O
the	DT	O
candidate	NN	O
meningococcal	JJ	O
conjugate	NN	O
vaccine	NN	O
as	IN	O
compared	VBN	O
with	IN	O
the	DT	O
licensed	JJ	O
polysaccharide	NN	O
vaccine	NN	O
in	IN	O
adolescents	NNS	O
.	.	O

New	NNP	O
hope	NN	O
for	IN	O
children	NNS	A
with	IN	O
Kawasaki	NNP	C
disease	NN	O
.	.	O

Kawasaki	NNP	O
disease	NN	O
is	VBZ	O
now	RB	O
the	DT	O
most	RBS	O
common	JJ	O
cause	NN	O
of	IN	O
acquired	VBN	O
heart	NN	C
disease	NN	O
in	IN	O
America	NNP	O
's	POS	O
children	NNS	O
.	.	O

It	PRP	O
is	VBZ	O
an	DT	O
acute	JJ	O
febrile	NN	O
illness	NN	O
that	WDT	O
may	MD	O
cause	VB	O
coronary	JJ	O
artery	NN	O
aneurysm	NN	O
formation	NN	O
in	IN	O
infected	JJ	O
children	NNS	O
.	.	O

The	DT	O
results	NNS	O
of	IN	O
a	DT	O
multicenter	NN	O
,	,	O
randomized	VBN	O
trial	NN	O
on	IN	O
the	DT	O
effect	NN	O
of	IN	O
intravenous	JJ	O
administration	NN	O
of	IN	O
gamma	JJ	O
globulin	NN	O
(	(	O
IVGG	NNP	O
)	)	O
plus	CC	O
aspirin	JJ	O
versus	NN	O
aspirin	NN	O
alone	RB	O
upon	IN	O
coronary	JJ	O
aneurysm	NN	O
formation	NN	O
show	VBP	O
a	DT	O
decrease	NN	O
in	IN	O
coronary	JJ	O
aneurysm	NN	O
formation	NN	O
from	IN	O
the	DT	O
usual	JJ	O
20	CD	O
%	NN	O
-30	NN	O
%	NN	O
to	TO	O
3	CD	O
%	NN	O
.	.	O

Administration	NNP	O
of	IN	O
IVGG	NNP	O
presents	VBZ	O
some	DT	O
unique	JJ	O
challenges	NNS	O
for	IN	O
nurses	NNS	O
.	.	O

Also	RB	O
,	,	O
the	DT	O
pediatric	JJ	O
nurse	NN	O
must	MD	O
educate	VB	O
parents	NNS	O
and	CC	O
children	NNS	O
about	IN	O
this	DT	O
disease	NN	O
to	TO	O
prepare	VB	O
them	PRP	O
for	IN	O
discharge	NN	O
and	CC	O
long-term	JJ	O
follow-up	JJ	O
care	NN	O
.	.	O

Cardiovascular	JJ	O
effects	NNS	O
of	IN	O
non-depolarizing	JJ	O
neuromuscular	JJ	O
blockers	NNS	O
in	IN	O
patients	NNS	O
with	IN	O
aortic	JJ	O
valve	NN	O
disease	NN	O
.	.	O

To	TO	O
compare	VB	O
haemodynamic	JJ	O
responses	NNS	O
associated	VBN	O
with	IN	O
equipotent	JJ	O
doses	NNS	O
of	IN	O
neuromuscular	JJ	O
blockers	NNS	O
and	CC	O
high-dose	JJ	O
fentanyl	NN	O
(	(	O
50	CD	O
micrograms.kg-1	NN	O
)	)	O
,	,	O
40	CD	O
patients	NNS	O
with	IN	O
aortic	JJ	O
valve	NNS	O
stenosis	NN	O
(	(	O
AS	IN	O
)	)	O
and	CC	O
20	CD	O
patients	NNS	O
with	IN	O
aortic	JJ	O
insufficiency	NN	O
(	(	O
AI	NNP	O
)	)	O
were	VBD	O
randomized	VBN	O
to	TO	O
four	CD	O
study	NN	O
groups	NNS	O
to	TO	O
receive	VB	O
the	DT	O
following	NN	O
:	:	O
(	(	O
1	CD	O
)	)	O
pancuronium	NN	O
0.12	CD	O
mg.kg-1	NN	O
,	,	O
(	(	O
2	CD	O
)	)	O
vecuronium	NN	O
0.12	CD	O
mg.kg-1	NN	O
,	,	O
(	(	O
3	CD	O
)	)	O
atracurium	NN	O
0.4	CD	O
mg.kg-1	NN	O
,	,	O
or	CC	O
(	(	O
4	CD	O
)	)	O
pancuronium-metocurine	NN	O
mixture	NN	O
(	(	O
0.4	CD	O
mg	NN	O
+	VBD	O
1.6	CD	O
mg/ml	NN	O
)	)	O
:	:	O
1	CD	O
ml/10	NNS	O
kg	NN	O
)	)	O
.	.	O

Neuromuscular	JJ	O
blockers	NNS	O
were	VBD	O
injected	VBN	O
at	IN	O
the	DT	O
same	JJ	O
time	NN	O
with	IN	O
the	DT	O
fentanyl	NN	O
;	:	O
haemodynamics	NNS	O
were	VBD	O
recorded	VBN	O
with	IN	O
the	DT	O
patients	NNS	O
awake	VBP	O
(	(	O
baseline	NN	O
)	)	O
,	,	O
at	IN	O
two	CD	O
minutes	NNS	O
post-induction	NN	O
,	,	O
and	CC	O
at	IN	O
two	CD	O
and	CC	O
five	CD	O
minutes	NNS	O
after	IN	O
intubation	NN	O
.	.	O

In	IN	O
patients	NNS	O
with	IN	O
AS	NNP	O
,	,	O
pancuronium	NN	O
increased	VBD	O
heart	NN	O
rate	NN	O
more	JJR	O
than	IN	O
vecuronium	NN	O
or	CC	O
atracurium	NN	O
;	:	O
heart	NN	O
rates	NNS	O
were	VBD	O
also	RB	O
higher	JJR	O
with	IN	O
the	DT	O
pancuronium-metocurine	JJ	O
mixture	NN	O
than	IN	O
with	IN	O
vecuronium	NN	O
.	.	O

Although	IN	O
there	EX	O
were	VBD	O
no	DT	O
ECG	NNP	O
signs	NNS	O
of	IN	O
ischaemia	NN	O
,	,	O
one	CD	O
patient	NN	O
given	VBN	O
pancuronium	NN	O
developed	VBD	O
severe	JJ	O
hypotension	NN	O
associated	VBN	O
with	IN	O
tachycardia	NN	O
.	.	O

Reductions	NNS	O
in	IN	O
SVR	NNP	O
after	IN	O
atracurium	NN	O
allowed	VBD	O
small	JJ	O
but	CC	O
significant	JJ	O
(	(	O
p	NN	O
less	JJR	O
than	IN	O
0.01	CD	O
)	)	O
decreases	NNS	O
in	IN	O
MAP	NNP	O
which	WDT	O
were	VBD	O
well	RB	O
tolerated	VBN	O
;	:	O
one	CD	O
patient	NN	O
,	,	O
however	RB	O
,	,	O
did	VBD	O
develop	VB	O
severe	JJ	O
hypotension	NN	O
.	.	O

Intubation	NNP	O
resulted	VBD	O
in	IN	O
significant	JJ	O
(	(	O
p	NN	O
less	JJR	O
than	IN	O
0.01	CD	O
)	)	O
increases	NNS	O
in	IN	O
MAP	NNP	O
in	IN	O
the	DT	O
pancuronium-metocurine	JJ	O
mixture	NN	O
group	NN	O
.	.	O

Vecuronium	NNP	O
permitted	VBD	O
the	DT	O
most	RBS	O
stable	JJ	O
overall	JJ	O
haemodynamic	JJ	O
course	NN	O
at	IN	O
all	DT	O
measurement	JJ	O
times	NNS	O
.	.	O

In	IN	O
contrast	NN	O
,	,	O
patients	NNS	O
with	IN	O
AI	NNP	O
showed	VBD	O
stable	JJ	O
haemodynamics	NNS	O
after	IN	O
vecuronium	NN	O
,	,	O
pancuronium	NN	O
and	CC	O
the	DT	O
pancuronium-metocurine	JJ	O
mixture	NN	O
;	:	O
one	CD	O
patient	NN	O
became	VBD	O
tachycardic	JJ	O
following	VBG	O
vecuronium	NN	O
.	.	O

Atracurium	NNP	O
caused	VBD	O
unexplained	JJ	O
elevations	NNS	O
in	IN	O
diastolic	JJ	O
and	CC	O
mean	JJ	O
arterial	NN	O
pressures	NNS	O
which	WDT	O
were	VBD	O
significant	JJ	O
when	WRB	O
compared	VBN	O
to	TO	O
vecuronium	VB	O
(	(	O
p	NN	O
less	JJR	O
than	IN	O
0.01	CD	O
)	)	O
.	.	O

These	DT	O
results	NNS	O
in	IN	O
increases	NNS	O
in	IN	O
PCWP	NNP	O
;	:	O
mean	JJ	O
PA	NNP	O
pressures	NNS	O
and	CC	O
CVP	NNP	O
were	VBD	O
also	RB	O
increased	VBN	O
.	.	O

These	DT	O
effects	NNS	O
of	IN	O
atracurium	NN	O
inpatients	NNS	O
with	IN	O
Al	NNP	O
need	VBP	O
further	JJ	O
evaluation	NN	O
.	.	O

Monotherapy	NNP	O
of	IN	O
mild	JJ	C
hypertension	NN	C
with	IN	O
nifedipine	NN	O
.	.	O

The	DT	O
effectiveness	NN	O
of	IN	O
nifedipine	JJ	O
as	IN	O
first-line	JJ	O
monotherapy	NN	O
for	IN	O
mild	JJ	C
diastolic	JJ	C
hypertension	NN	C
(	(	O
range	NN	O
:	:	O
95	CD	O
to	TO	O
105	CD	O
mm	NNS	O
Hg	NNP	O
)	)	O
was	VBD	O
tested	VBN	O
in	IN	O
this	DT	O
placebo-controlled	JJ	O
,	,	O
double-blind	JJ	O
,	,	O
randomized	JJ	O
trial	NN	O
.	.	O

Fifty-six	JJ	SS
patients	NNS	O
were	VBD	O
enrolled	VBN	O
and	CC	O
,	,	O
after	IN	O
titration	NN	O
of	IN	O
the	DT	O
placebo	NN	O
or	CC	O
active	JJ	O
drug	NN	O
,	,	O
they	PRP	O
were	VBD	O
followed	VBN	O
for	IN	O
12	CD	O
weeks	NNS	O
.	.	O

Significant	JJ	O
declines	NNS	O
in	IN	O
the	DT	O
sitting	VBG	O
systolic	JJ	O
and	CC	O
diastolic	JJ	O
pressures	NNS	O
of	IN	O
-19	JJ	O
+/-	JJ	O
4	CD	O
mm	NN	O
Hg	NNP	O
(	(	O
standard	JJ	O
error	NN	O
)	)	O
and	CC	O
-13	$	O
+/-	JJ	O
2	CD	O
mm	NN	O
Hg	NNP	O
,	,	O
respectively	RB	O
,	,	O
were	VBD	O
observed	VBN	O
during	IN	O
this	DT	O
follow-up	JJ	O
period	NN	O
.	.	O

Overall	JJ	O
,	,	O
75	CD	O
percent	NN	O
of	IN	O
patients	NNS	O
receiving	VBG	O
active	JJ	O
drug	NN	O
had	VBD	O
diastolic	JJ	O
pressures	NNS	O
less	RBR	O
than	IN	O
or	CC	O
equal	JJ	O
to	TO	O
90	CD	O
mm	NNS	O
Hg	NNP	O
at	IN	O
the	DT	O
last	JJ	O
treatment	NN	O
visit	NN	O
.	.	O

Heart	NNP	O
rate	NN	O
was	VBD	O
not	RB	O
significantly	RB	O
changed	VBN	O
in	IN	O
the	DT	O
sitting	VBG	O
position	NN	O
during	IN	O
the	DT	O
treatment	NN	O
period	NN	O
,	,	O
and	CC	O
the	DT	O
majority	NN	O
of	IN	O
patients	NNS	O
(	(	O
75	CD	O
percent	NN	O
)	)	O
showed	VBD	O
a	DT	O
response	NN	O
to	TO	O
nifedipine	JJ	O
doses	NNS	O
of	IN	O
10	CD	O
or	CC	O
20	CD	O
mg	NNS	O
orally	RB	O
three	CD	O
times	NNS	O
daily	RB	O
in	IN	O
the	DT	O
capsule	NN	O
form	NN	O
.	.	O

The	DT	O
levels	NNS	O
of	IN	O
the	DT	O
systolic	NN	O
and	CC	O
diastolic	JJ	O
pressures	NNS	O
at	IN	O
entry	NN	O
were	VBD	O
not	RB	O
predictive	JJ	O
of	IN	O
the	DT	O
dose	NN	O
of	IN	O
nifedipine	NN	O
required	VBN	O
for	IN	O
effective	JJ	O
blood	NN	O
pressure	NN	O
control	NN	O
.	.	O

Inhaled	VBN	O
fluticasone	NN	O
reduces	NNS	O
sputum	VBP	O
inflammatory	JJ	O
indices	NNS	O
in	IN	O
severe	JJ	C
bronchiectasis	NN	C
.	.	O

Although	IN	O
corticosteroid	JJ	O
therapy	NN	O
might	MD	O
be	VB	O
clinically	RB	O
beneficial	JJ	O
for	IN	O
bronchiectasis	NN	C
,	,	O
very	RB	O
little	JJ	O
is	VBZ	O
known	VBN	O
of	IN	O
its	PRP$	O
effects	NNS	O
on	IN	O
the	DT	O
inflammatory	NN	O
and	CC	O
infective	JJ	O
markers	NNS	O
in	IN	O
bronchiectasis	NN	O
.	.	O

We	PRP	O
have	VBP	O
therefore	RB	O
performed	VBN	O
a	DT	O
double-blind	JJ	O
,	,	O
placebo-controlled	JJ	O
study	NN	O
to	TO	O
evaluate	VB	O
the	DT	O
effects	NNS	O
of	IN	O
a	DT	O
4-wk	JJ	O
administration	NN	O
of	IN	O
inhaled	JJ	O
fluticasone	NN	O
in	IN	O
bronchiectasis	NN	O
.	.	O

Twenty-four	CD	SS
patients	NNS	SS
(	(	O
12	CD	SE
female	NN	SE
;	:	O
mean	JJ	A
age	NN	A
51	CD	A
yr	NN	A
)	)	O
were	VBD	O
randomized	VBN	O
into	IN	O
receiving	VBG	O
either	CC	O
inhaled	JJ	O
fluticasone	NN	O
(	(	O
500	CD	O
microgram	NN	O
twice	RB	O
daily	RB	O
)	)	O
via	IN	O
the	DT	O
Accuhaler	NNP	O
device	NN	O
(	(	O
n	JJ	O
=	NNP	O
12	CD	O
)	)	O
or	CC	O
placebo	NN	O
.	.	O

At	IN	O
each	DT	O
visit	NN	O
,	,	O
spirometry	NN	O
,	,	O
24-h	JJ	O
sputum	NN	O
volume	NN	O
,	,	O
sputum	NN	O
leukocyte	NN	O
density	NN	O
,	,	O
bacterial	JJ	O
densities	NNS	O
,	,	O
and	CC	O
concentrations	NNS	O
of	IN	O
interleukin	NN	O
(	(	O
IL	NNP	O
)	)	O
-1beta	NN	O
,	,	O
IL-8	NNP	O
,	,	O
tumor	NN	O
necrosis	NN	O
factor-alpha	JJ	O
(	(	O
TNF-alpha	NNP	O
)	)	O
,	,	O
and	CC	O
leukotriene	JJ	O
B4	NNP	O
(	(	O
LTB4	NNP	O
)	)	O
were	VBD	O
determined	VBN	O
.	.	O

There	EX	O
was	VBD	O
a	DT	O
significant	JJ	O
(	(	O
p	JJ	O
<	NNP	O
0.05	CD	O
)	)	O
decrease	NN	O
in	IN	O
sputum	NN	O
leukocyte	NN	O
density	NN	O
and	CC	O
IL-1beta	NNP	O
,	,	O
IL-8	NNP	O
,	,	O
and	CC	O
LTB4	NNP	O
after	IN	O
fluticasone	NN	O
treatment	NN	O
.	.	O

The	DT	O
fluticasone	NN	O
group	NN	O
had	VBD	O
one	CD	O
and	CC	O
the	DT	O
placebo	NN	O
group	NN	O
three	CD	O
episodes	NNS	O
of	IN	O
exacerbation	NN	O
.	.	O

There	EX	O
were	VBD	O
no	DT	O
significant	JJ	O
changes	NNS	O
in	IN	O
spirometry	NN	O
(	(	O
p	JJ	O
>	NNP	O
0.05	CD	O
)	)	O
or	CC	O
any	DT	O
reported	JJ	O
adverse	JJ	O
reactions	NNS	O
in	IN	O
either	DT	O
group	NN	O
.	.	O

The	DT	O
results	NNS	O
of	IN	O
this	DT	O
study	NN	O
show	VB	O
that	IN	O
high-dose	JJ	O
fluticasone	NN	O
is	VBZ	O
effective	JJ	O
in	IN	O
reducing	VBG	O
the	DT	O
sputum	NN	O
inflammatory	NN	O
indices	NNS	O
in	IN	O
bronchiectasis	NN	O
.	.	O

Large-scale	JJ	O
and	CC	O
long-term	JJ	O
studies	NNS	O
are	VBP	O
indicated	VBN	O
to	TO	O
evaluate	VB	O
the	DT	O
effects	NNS	O
of	IN	O
inhaled	JJ	O
steroid	JJ	O
therapy	NN	O
on	IN	O
the	DT	O
inflammatory	JJ	O
components	NNS	O
in	IN	O
bronchiectasis	NN	C
.	.	O

Couple-responsible	JJ	O
therapy	NN	O
process	NN	O
:	:	O
positive	JJ	O
proximal	JJ	O
outcomes	NNS	O
.	.	O

Therapist-couple	JJ	O
struggle	NN	O
vs.	FW	O
cooperation	NN	O
is	VBZ	O
linked	VBN	O
to	TO	O
clinical	JJ	O
outcome	NN	O
.	.	O

This	DT	O
research	NN	O
conceptualizes	NN	O
and	CC	O
investigates	VBZ	O
treatment	NN	O
process	NN	O
as	IN	O
it	PRP	O
relates	VBZ	O
to	TO	O
the	DT	O
occurrence	NN	O
of	IN	O
struggle	NN	O
versus	NN	O
cooperation	NN	O
.	.	O

Models	NNS	O
of	IN	O
couple-responsible	JJ	O
and	CC	O
therapist-responsible	JJ	O
process	NN	O
in	IN	O
couple	NN	O
therapy	NN	O
were	VBD	O
developed	VBN	O
.	.	O

Couple-responsible	JJ	O
process	NN	O
consists	VBZ	O
of	IN	O
enactments	NNS	O
,	,	O
accommodation	NN	O
,	,	O
and	CC	O
inductive	JJ	O
process	NN	O
.	.	O

Therapist-responsible	JJ	O
process	NN	O
consists	VBZ	O
of	IN	O
primary	JJ	O
therapist-couple	JJ	O
interaction	NN	O
,	,	O
therapist	JJ	O
interpretation	NN	O
,	,	O
and	CC	O
direct	JJ	O
instruction	NN	O
.	.	O

In	IN	O
counterbalanced	JJ	O
order	NN	O
,	,	O
25	CD	O
couples	NNS	C
were	VBD	O
exposed	VBN	O
to	TO	O
couple-responsible	JJ	O
and	CC	O
therapist-responsible	JJ	O
episodes	NNS	O
during	IN	O
one	CD	O
therapy	NN	O
session	NN	O
.	.	O

Couples	NNP	O
reviewed	VBD	O
videotapes	NNS	O
of	IN	O
the	DT	O
episodes	NNS	O
and	CC	O
completed	VBD	O
measures	NNS	O
of	IN	O
responsibility	NN	O
,	,	O
struggle	NN	O
,	,	O
and	CC	O
cooperation	NN	O
.	.	O

Perceived	NNP	O
responsibility	NN	O
was	VBD	O
higher	JJR	O
and	CC	O
struggle	NN	O
was	VBD	O
lower	JJR	O
during	IN	O
couple-responsible	JJ	O
episodes	NNS	O
.	.	O

No	DT	O
difference	NN	O
in	IN	O
cooperation	NN	O
was	VBD	O
found	VBN	O
.	.	O

Presence	NN	O
or	CC	O
absence	NN	O
of	IN	O
a	DT	O
contrast	NN	O
condition	NN	O
,	,	O
where	WRB	O
couples	NNS	O
reported	VBD	O
on	IN	O
one	CD	O
therapist	NN	O
process	NN	O
after	IN	O
already	RB	O
experiencing	VBG	O
its	PRP$	O
opposite	NN	O
,	,	O
led	VBN	O
to	TO	O
main	JJ	O
effects	NNS	O
for	IN	O
responsibility	NN	O
and	CC	O
struggle	NN	O
,	,	O
and	CC	O
mediated	VBD	O
effects	NNS	O
of	IN	O
struggle	NN	O
and	CC	O
cooperation	NN	O
.	.	O

Generally	NNP	O
speaking	NN	O
,	,	O
responsibility	NN	O
was	VBD	O
even	RB	O
higher	JJR	O
during	IN	O
couple-responsible	JJ	O
episodes	NNS	O
and	CC	O
even	RB	O
lower	JJR	O
during	IN	O
therapist-responsible	JJ	O
episodes	NNS	O
when	WRB	O
contrast	NN	O
was	VBD	O
present	JJ	O
.	.	O

Similarly	RB	O
,	,	O
struggle	NN	O
was	VBD	O
even	RB	O
lower	JJR	O
during	IN	O
couple-responsible	JJ	O
episodes	NNS	O
and	CC	O
even	RB	O
higher	JJR	O
during	IN	O
therapist-responsible	JJ	O
episodes	NNS	O
when	WRB	O
contrast	NN	O
was	VBD	O
present	JJ	O
.	.	O

For	IN	O
both	DT	O
couple-responsible	JJ	O
and	CC	O
therapist-responsible	JJ	O
episodes	NNS	O
,	,	O
cooperation	NN	O
was	VBD	O
negatively	RB	O
affected	VBN	O
by	IN	O
a	DT	O
shift	NN	O
from	IN	O
the	DT	O
prior	JJ	O
,	,	O
opposite	JJ	O
therapist	NN	O
process	NN	O
.	.	O

Significant	JJ	O
proportions	NNS	O
of	IN	O
the	DT	O
variance	NN	O
in	IN	O
responsibility	NN	O
,	,	O
struggle	NN	O
,	,	O
and	CC	O
cooperation	NN	O
,	,	O
however	RB	O
,	,	O
were	VBD	O
not	RB	O
accounted	VBN	O
for	IN	O
by	IN	O
therapist	JJ	O
process	NN	O
alone	RB	O
.	.	O

Denosumab	NNP	O
compared	VBN	O
with	IN	O
zoledronic	JJ	O
acid	NN	O
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
bone	NN	O
metastases	NNS	O
in	IN	O
patients	NNS	O
with	IN	O
advanced	JJ	C
breast	NN	C
cancer	NN	C
:	:	O
a	DT	O
randomized	JJ	O
,	,	O
double-blind	JJ	O
study	NN	O
.	.	O

PURPOSE	VB	O
This	DT	O
randomized	VBN	O
study	NN	O
compared	VBN	O
denosumab	NN	O
,	,	O
a	DT	O
fully	RB	O
human	JJ	O
monoclonal	JJ	O
antibody	NN	O
against	IN	O
receptor	NN	O
activator	NN	O
of	IN	O
nuclear	JJ	O
factor	NN	O
?	.	O
B	NNP	O
(	(	O
RANK	NNP	O
)	)	O
ligand	NN	O
,	,	O
with	IN	O
zoledronic	JJ	O
acid	NN	O
in	IN	O
delaying	VBG	O
or	CC	O
preventing	VBG	O
skeletal-related	JJ	O
events	NNS	O
(	(	O
SREs	NNP	O
)	)	O
in	IN	O
patients	NNS	O
with	IN	O
breast	JJ	C
cancer	NN	C
with	IN	C
bone	NN	C
metastases	NNS	C
.	.	O

PATIENTS	NNP	O
AND	CC	O
METHODS	NNP	O
Patients	NNPS	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
receive	VB	O
either	RB	O
subcutaneous	JJ	O
denosumab	NN	O
120	CD	O
mg	NN	O
and	CC	O
intravenous	JJ	O
placebo	NN	O
(	(	O
n	JJ	O
=	NNP	O
1,026	CD	O
)	)	O
or	CC	O
intravenous	JJ	O
zoledronic	JJ	O
acid	NN	O
4	CD	O
mg	NN	O
adjusted	VBN	O
for	IN	O
creatinine	JJ	O
clearance	NN	O
and	CC	O
subcutaneous	JJ	O
placebo	NN	O
(	(	O
n	JJ	O
=	NNP	O
1,020	CD	O
)	)	O
every	DT	O
4	CD	O
weeks	NNS	O
.	.	O

All	DT	O
patients	NNS	O
were	VBD	O
strongly	RB	O
recommended	VBN	O
to	TO	O
take	VB	O
daily	JJ	O
calcium	NN	O
and	CC	O
vitamin	NN	O
D	NNP	O
supplements	NNS	O
.	.	O

The	DT	O
primary	JJ	O
end	NN	O
point	NN	O
was	VBD	O
time	NN	O
to	TO	O
first	VB	O
on-study	JJ	O
SRE	NNP	O
(	(	O
defined	VBN	O
as	IN	O
pathologic	JJ	O
fracture	NN	O
,	,	O
radiation	NN	O
or	CC	O
surgery	NN	O
to	TO	O
bone	VB	O
,	,	O
or	CC	O
spinal	JJ	O
cord	NN	O
compression	NN	O
)	)	O
.	.	O

RESULTS	NNP	O
Denosumab	NNP	O
was	VBD	O
superior	JJ	O
to	TO	O
zoledronic	JJ	O
acid	NN	O
in	IN	O
delaying	VBG	O
time	NN	O
to	TO	O
first	VB	O
on-study	JJ	O
SRE	NNP	O
(	(	O
hazard	NN	O
ratio	NN	O
,	,	O
0.82	CD	O
;	:	O
95	CD	O
%	NN	O
CI	NNP	O
,	,	O
0.71	CD	O
to	TO	O
0.95	CD	O
;	:	O
P	NNP	O
=	NNP	O
.01	NNP	O
superiority	NN	O
)	)	O
and	CC	O
time	NN	O
to	TO	O
first	RB	O
and	CC	O
subsequent	JJ	O
(	(	O
multiple	JJ	O
)	)	O
on-study	NN	O
SREs	NNP	O
(	(	O
rate	NN	O
ratio	NN	O
,	,	O
0.77	CD	O
;	:	O
95	CD	O
%	NN	O
CI	NNP	O
,	,	O
0.66	CD	O
to	TO	O
0.89	CD	O
;	:	O
P	NNP	O
=	NNP	O
.001	NNP	O
)	)	O
.	.	O

Reduction	NN	O
in	IN	O
bone	NN	O
turnover	NN	O
markers	NNS	O
was	VBD	O
greater	JJR	O
with	IN	O
denosumab	NN	O
.	.	O

Overall	JJ	O
survival	NN	O
,	,	O
disease	NN	O
progression	NN	O
,	,	O
and	CC	O
rates	NNS	O
of	IN	O
adverse	JJ	O
events	NNS	O
(	(	O
AEs	NNP	O
)	)	O
and	CC	O
serious	JJ	O
AEs	NNP	O
were	VBD	O
similar	JJ	O
between	IN	O
groups	NNS	O
.	.	O

An	DT	O
excess	NN	O
of	IN	O
renal	JJ	O
AEs	NNP	O
and	CC	O
acute-phase	JJ	O
reactions	NNS	O
occurred	VBD	O
with	IN	O
zoledronic	JJ	O
acid	NN	O
;	:	O
hypocalcemia	NN	O
occurred	VBD	O
more	RBR	O
frequently	RB	O
with	IN	O
denosumab	NN	O
.	.	O

Osteonecrosis	NN	O
of	IN	O
the	DT	O
jaw	NN	O
occurred	VBD	O
infrequently	RB	O
(	(	O
2.0	CD	O
%	NN	O
,	,	O
denosumab	NN	O
;	:	O
1.4	CD	O
%	NN	O
,	,	O
zoledronic	JJ	O
acid	NN	O
;	:	O
P	NNP	O
=	NNP	O
.39	NNP	O
)	)	O
.	.	O

CONCLUSION	NNP	O
Denosumab	NNP	O
was	VBD	O
superior	JJ	O
to	TO	O
zoledronic	JJ	O
acid	NN	O
in	IN	O
delaying	VBG	O
or	CC	O
preventing	VBG	O
SREs	NNP	O
in	IN	O
patients	NNS	O
with	IN	O
breast	JJ	O
cancer	NN	O
metastatic	NN	O
to	TO	O
bone	NN	O
and	CC	O
was	VBD	O
generally	RB	O
well	RB	O
tolerated	VBN	O
.	.	O

With	IN	O
the	DT	O
convenience	NN	O
of	IN	O
a	DT	O
subcutaneous	JJ	O
injection	NN	O
and	CC	O
no	DT	O
requirement	NN	O
for	IN	O
renal	JJ	O
monitoring	NN	O
,	,	O
denosumab	JJ	O
represents	VBZ	O
a	DT	O
potential	JJ	O
treatment	NN	O
option	NN	O
for	IN	O
patients	NNS	O
with	IN	O
bone	NN	O
metastases	NNS	O
.	.	O

Fusidic	NNP	O
acid	VBZ	O
prophylaxis	NN	O
before	IN	O
cataract	JJ	O
surgery	NN	O
:	:	O
patient	JJ	O
self-administration	NN	O
.	.	O

In	IN	O
a	DT	O
placebo-controlled	JJ	O
,	,	O
randomised	JJ	O
,	,	O
double-blind	JJ	O
clinical	JJ	O
trial	NN	O
,	,	O
the	DT	O
authors	NNS	O
evaluated	VBD	O
the	DT	O
efficacy	NN	O
of	IN	O
patient-administered	JJ	O
1	CD	O
%	NN	O
fusidic	JJ	O
acid	RB	O
viscous	JJ	O
eye	NN	O
drops	NNS	O
in	IN	O
clearing	VBG	O
the	DT	O
commonest	JJS	O
organisms	JJ	O
causing	VBG	O
pseudophakic	NN	O
endophthalmitis	NN	O
(	(	O
Staphylococcus	NNP	O
epidermidis	RB	O
and	CC	O
aureus	RB	O
)	)	O
from	IN	O
the	DT	O
lids	NNS	O
and	CC	O
conjunctivae	NN	O
of	IN	O
79	CD	SS
patients	NNS	SS
before	IN	O
cataract	JJ	O
surgery	NN	O
.	.	O

The	DT	O
treatment	NN	O
group	NN	O
self-administered	JJ	O
fusidic	JJ	O
acid	NN	O
viscous	JJ	O
eye	NN	O
drops	VBZ	O
four	CD	O
times	NNS	O
daily	RB	O
for	IN	O
seven	CD	O
days	NNS	O
before	IN	O
surgery	NN	O
;	:	O
the	DT	O
placebo	NN	O
group	NN	O
received	VBD	O
inert	JJ	O
ophthalmic	JJ	O
drops	NNS	O
.	.	O

Fellow	NNP	O
eyes	NNS	O
of	IN	O
both	DT	O
groups	NNS	O
remained	VBD	O
untreated	JJ	O
as	IN	O
a	DT	O
natural	JJ	O
control	NN	O
.	.	O

Lower	JJR	O
fornix	NN	O
and	CC	O
lid	JJ	O
margin	NN	O
cultures	NNS	O
were	VBD	O
taken	VBN	O
from	IN	O
both	DT	O
eyes	NNS	O
before	IN	O
and	CC	O
after	IN	O
treatment	NN	O
.	.	O

Before	IN	O
treatment	NN	O
,	,	O
there	EX	O
was	VBD	O
no	DT	O
statistical	JJ	O
difference	NN	O
in	IN	O
organism	NN	O
counts	NNS	O
between	IN	O
the	DT	O
groups	NNS	O
.	.	O

After	IN	O
treatment	NN	O
,	,	O
eyes	NNS	O
receiving	VBG	O
fusidic	JJ	O
acid	NNS	O
were	VBD	O
more	RBR	O
likely	JJ	O
to	TO	O
be	VB	O
free	JJ	O
of	IN	O
clinically	RB	O
relevant	JJ	O
Staphylococcus	NNP	O
spp	NN	O
.	.	O

than	IN	O
all	DT	O
pre-treatment	JJ	O
eyes	NNS	O
(	(	O
for	IN	O
lids	NNS	O
,	,	O
P	NNP	O
<	NNP	O
0.001	CD	O
;	:	O
conjunctivae	NN	O
,	,	O
P	NNP	O
=	NNP	O
0.02	CD	O
)	)	O
.	.	O

A	DT	O
highly	RB	O
significant	JJ	O
(	(	O
P	NNP	O
<	NNP	O
0.001	CD	O
)	)	O
number	NN	O
of	IN	O
lid	JJ	O
margins	NNS	O
were	VBD	O
rendered	VBN	O
'clinically	RB	O
clean	JJ	O
'	''	O
(	(	O
i.e.	FW	O
,	,	O
0-49	JJ	O
organisms/swab	NN	O
)	)	O
by	IN	O
fusidic	JJ	O
acid	NN	O
when	WRB	O
compared	VBN	O
with	IN	O
untreated	JJ	O
eyes	NNS	O
.	.	O

Treatment	NNP	O
also	RB	O
effectively	RB	O
(	(	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
reduced	VBD	O
the	DT	O
numbers	NNS	O
of	IN	O
bacteria	NNS	O
isolated	VBN	O
from	IN	O
conjunctivae	NN	O
.	.	O

This	DT	O
study	NN	O
indicates	VBZ	O
that	IN	O
there	EX	O
is	VBZ	O
a	DT	O
highly	RB	O
significant	JJ	O
reduction	NN	O
of	IN	O
Staphylococcus	NNP	O
spp	NN	O
.	.	O

(	(	O
P	NNP	O
<	NNP	O
0.001	CD	O
)	)	O
,	,	O
non-Staphylococcus	JJ	O
spp	NN	O
.	.	O

(	(	O
P	NNP	O
<	NNP	O
0.001	CD	O
)	)	O
and	CC	O
attainment	NN	O
of	IN	O
sterile	JJ	O
eyes	NNS	O
(	(	O
P	NNP	O
<	NNP	O
0.001	CD	O
)	)	O
at	IN	O
operation	NN	O
gained	VBN	O
by	IN	O
patient	JJ	O
self-administration	NN	O
of	IN	O
1	CD	O
%	NN	O
fusidic	JJ	O
acid	RB	O
four	CD	O
times	NNS	O
daily	RB	O
for	IN	O
seven	CD	O
days	NNS	O
before	IN	O
surgery	NN	O
.	.	O

Treatment	NN	O
of	IN	O
whiplash	NN	O
associated	VBN	O
neck	RB	O
pain	VBP	O
[	RB	O
corrected	VBN	O
]	NN	O
with	IN	O
botulinum	JJ	O
toxin-A	NN	O
:	:	O
a	DT	O
pilot	NN	O
study	NN	O
.	.	O

OBJECTIVE	NNP	O
Up	NNP	O
to	TO	O
87	CD	O
%	NN	O
of	IN	O
patients	NNS	O
with	IN	O
whiplash	NN	O
associated	VBN	O
disorder	NN	O
(	(	O
WAD	NNP	O
)	)	O
have	VBP	O
some	DT	O
degree	NN	O
of	IN	O
muscle	NN	O
spasm	NN	O
that	WDT	O
is	VBZ	O
contributory	JJ	O
to	TO	O
both	DT	O
pain	NN	O
and	CC	O
dysfunction	NN	O
.	.	O

Botulinum	NNP	O
toxin	NN	O
A	NNP	O
(	(	O
BTX-A	NNP	O
)	)	O
produces	VBZ	O
prolonged	JJ	O
muscle	NN	O
relaxation	NN	O
that	WDT	O
is	VBZ	O
dose-dependent	JJ	O
and	CC	O
can	MD	O
be	VB	O
easily	RB	O
targeted	VBN	O
to	TO	O
affected	JJ	O
muscles	NNS	O
.	.	O

BTX-A	NNP	O
therapy	NN	O
may	MD	O
be	VB	O
an	DT	O
effective	JJ	O
form	NN	O
of	IN	O
therapy	NN	O
offering	VBG	O
an	DT	O
alternative	NN	O
or	CC	O
adjunct	NN	O
to	TO	O
conventional	JJ	O
modalities	NNS	O
.	.	O

We	PRP	O
investigated	VBD	O
BTX-A	NNP	O
as	IN	O
therapy	NN	O
in	IN	O
patients	NNS	O
with	IN	O
WAD	NNP	C
.	.	O

METHODS	NNP	O
This	DT	O
randomized	VBN	O
,	,	O
double	JJ	O
blind	NN	O
,	,	O
placebo	NN	O
controlled	VBD	O
study	NN	O
compares	VBZ	O
outcome	JJ	O
measures	NNS	O
in	IN	O
26	CD	SS
patients	NNS	O
with	IN	O
chronic	JJ	C
neck	NN	C
pain	NN	C
(	(	O
WAD-II	NNP	O
chronic	NN	O
)	)	O
subsequent	NN	O
to	TO	O
a	DT	O
motor	NN	O
vehicle	NN	O
accident	NN	O
.	.	O

One-half	NN	O
of	IN	O
the	DT	O
patients	NNS	O
received	VBD	O
100	CD	O
units	NNS	O
BTX-A	NNP	O
,	,	O
diluted	VBD	O
in	IN	O
1	CD	O
ml	NNS	O
saline	NN	O
,	,	O
while	IN	O
the	DT	O
other	JJ	O
half	NN	O
received	VBD	O
just	RB	O
saline	NN	O
(	(	O
1	CD	O
ml	NN	O
)	)	O
.	.	O

Five	CD	O
trigger	NN	O
points	NNS	O
received	VBD	O
0.2	CD	O
ml	NNS	O
each	DT	O
of	IN	O
injectant	JJ	O
via	IN	O
a	DT	O
30	CD	O
gauge	NN	O
needle	NN	O
.	.	O

Outcome	NNP	O
measures	NNS	O
included	VBD	O
total	JJ	O
subjective	JJ	O
neck	NN	O
,	,	O
shoulder	NN	O
,	,	O
and	CC	O
head	NN	O
pain	NN	O
based	VBN	O
on	IN	O
visual	JJ	O
analog	NN	O
scales	NNS	O
;	:	O
objective	JJ	O
total	JJ	O
range	NN	O
of	IN	O
neck	NN	O
motion	NN	O
(	(	O
ROM	NNP	O
)	)	O
,	,	O
and	CC	O
the	DT	O
Vernon-Mior	NNP	O
subjective	JJ	O
function	NN	O
index	NN	O
.	.	O

Followup	CD	O
assessments	NNS	O
were	VBD	O
carried	VBN	O
out	RP	O
at	IN	O
2	CD	O
and	CC	O
4	CD	O
weeks	NNS	O
post-treatment	JJ	O
.	.	O

RESULTS	NNP	O
Fourteen	NNP	SS
subjects	VBZ	O
receiving	VBG	O
BTX-A	NNP	O
and	CC	O
12	CD	O
receiving	NN	O
saline	NN	O
completed	VBD	O
the	DT	O
study	NN	O
.	.	O

The	DT	O
treatment	NN	O
group	NN	O
showed	VBD	O
a	DT	O
trend	NN	O
toward	IN	O
improvement	NN	O
in	IN	O
ROM	NNP	O
and	CC	O
reduction	NN	O
in	IN	O
pain	NN	O
at	IN	O
2	CD	O
weeks	NNS	O
post-injection	NN	O
.	.	O

At	IN	O
4	CD	O
weeks	NNS	O
post-injection	NN	O
the	DT	O
treatment	NN	O
group	NN	O
was	VBD	O
significantly	RB	O
improved	VBN	O
from	IN	O
preinjection	NN	O
levels	NNS	O
(	(	O
p	VB	O
<	RB	O
0.01	CD	O
)	)	O
.	.	O

The	DT	O
placebo	NN	O
group	NN	O
showed	VBD	O
no	DT	O
statistically	RB	O
significant	JJ	O
changes	NNS	O
at	IN	O
any	DT	O
post-treatment	JJ	O
time	NN	O
.	.	O

The	DT	O
Vernon-Mior	JJ	O
scale	NN	O
revealed	VBD	O
a	DT	O
trend	NN	O
to	TO	O
improvement	NN	O
for	IN	O
both	DT	O
groups	NNS	O
.	.	O

CONCLUSION	NNP	O
BTX-A	NNP	O
treatment	NN	O
of	IN	O
subjects	NNS	O
with	IN	O
chronic	JJ	O
WAD	NNP	O
II	NNP	O
neck	NN	O
pain	NN	O
resulted	VBD	O
in	IN	O
a	DT	O
significant	JJ	O
(	(	O
p	JJ	O
<	NNP	O
0.01	CD	O
)	)	O
improvement	NN	O
in	IN	O
ROM	NNP	O
and	CC	O
subjective	JJ	O
pain	NN	O
compared	VBN	O
to	TO	O
a	DT	O
placebo	NN	O
group	NN	O
,	,	O
but	CC	O
only	RB	O
a	DT	O
trend	NN	O
to	TO	O
improvement	NN	O
in	IN	O
subjective	JJ	O
functioning	NN	O
.	.	O

Comparison	NNP	O
of	IN	O
0.25	CD	O
%	NN	O
S	NNP	O
(	(	O
-	:	O
)	)	O
-bupivacaine	VBP	O
with	IN	O
0.25	CD	O
%	NN	O
RS-bupivacaine	NNP	O
for	IN	O
epidural	JJ	O
analgesia	NN	O
in	IN	O
labour	NN	C
.	.	O

We	PRP	O
have	VBP	O
compared	VBN	O
the	DT	O
efficacy	NN	O
of	IN	O
0.25	CD	O
%	NN	O
S	NNP	O
(	(	O
-	:	O
)	)	O
-bupivacaine	VBP	O
with	IN	O
0.25	CD	O
%	NN	O
RS-bupivacaine	NNP	O
in	IN	O
providing	VBG	O
epidural	JJ	O
analgesia	NN	O
for	IN	O
labour	NN	O
in	IN	O
a	DT	O
randomized	JJ	O
,	,	O
multicentre	JJ	O
,	,	O
double-blind	JJ	O
study	NN	O
.	.	O

Analgesia	NNP	O
was	VBD	O
initiated	VBN	O
with	IN	O
10	CD	O
ml	NN	O
of	IN	O
the	DT	O
study	NN	O
solution	NN	O
and	CC	O
maintained	VBN	O
with	IN	O
10-ml	JJ	O
top-ups	NNS	O
.	.	O

We	PRP	O
studied	VBD	O
137	CD	SS
women	NNS	SE
and	CC	O
treatments	NNS	O
were	VBD	O
found	VBN	O
to	TO	O
be	VB	O
equivalent	JJ	O
for	IN	O
onset	NN	O
,	,	O
duration	NN	O
and	CC	O
quality	NN	O
of	IN	O
block	NN	O
.	.	O

Median	JJ	O
onset	NN	O
of	IN	O
pain	NN	O
relief	NN	O
was	VBD	O
12	CD	O
min	NN	O
for	IN	O
both	DT	O
drugs	NNS	O
and	CC	O
median	JJ	O
duration	NN	O
was	VBD	O
49	CD	O
(	(	O
range	VB	O
3-129	NNP	O
)	)	O
min	NN	O
and	CC	O
51	CD	O
(	(	O
7-157	CD	O
)	)	O
min	NN	O
for	IN	O
S	NNP	O
(	(	O
-	:	O
)	)	O
-bupivacaine	NN	O
and	CC	O
RS	NNP	O
bupivacaine	NN	O
,	,	O
respectively	RB	O
.	.	O

The	DT	O
estimated	JJ	O
treatment	NN	O
difference	NN	O
for	IN	O
duration	NN	O
of	IN	O
pain	NN	O
relief	NN	O
was	VBD	O
-4	NNP	O
(	(	O
90	CD	O
%	NN	O
CI	NNP	O
-13	NNP	O
,	,	O
6	CD	O
)	)	O
min	NN	O
.	.	O

Thirty	NNP	O
patients	NNS	O
failed	VBD	O
to	TO	O
achieve	VB	O
pain	NN	O
relief	NN	O
after	IN	O
the	DT	O
first	JJ	O
injection	NN	O
(	(	O
20	CD	O
patients	NNS	O
after	IN	O
S	NNP	O
(	(	O
-	:	O
)	)	O
-bupivacaine	NN	O
and	CC	O
10	CD	O
after	IN	O
RS-bupivacaine	NNP	O
;	:	O
P	NNP	O
=	NNP	O
0.039	CD	O
)	)	O
.	.	O

However	RB	O
,	,	O
median	JJ	O
duration	NN	O
of	IN	O
pain	NN	O
relief	NN	O
from	IN	O
the	DT	O
first	JJ	O
top-up	NN	O
was	VBD	O
82	CD	O
(	(	O
range	VB	O
3-164	NNP	O
)	)	O
min	NN	O
for	IN	O
S	NNP	O
(	(	O
-	:	O
)	)	O
-bupivacaine	NN	O
and	CC	O
76	CD	O
(	(	O
22-221	JJ	O
)	)	O
min	NN	O
for	IN	O
RS-bupivacaine	NNP	O
.	.	O

There	EX	O
were	VBD	O
no	DT	O
significant	JJ	O
differences	NNS	O
in	IN	O
the	DT	O
quality	NN	O
of	IN	O
analgesia	NN	O
,	,	O
as	IN	O
assessed	VBN	O
by	IN	O
the	DT	O
investigators	NNS	O
.	.	O

There	EX	O
were	VBD	O
no	DT	O
significant	JJ	O
differences	NNS	O
in	IN	O
the	DT	O
extent	NN	O
of	IN	O
sensory	JJ	O
block	NN	O
,	,	O
percentage	NN	O
of	IN	O
patients	NNS	O
with	IN	O
motor	NN	O
block	NN	O
or	CC	O
incidence	NN	O
of	IN	O
adverse	JJ	O
events	NNS	O
.	.	O

Single	NNP	O
negative	JJ	O
colposcopy	NN	O
:	:	O
is	VBZ	O
it	PRP	O
enough	RB	O
to	TO	O
rule	VB	O
out	IN	O
high-grade	JJ	O
disease	NN	O
?	.	O
It	PRP	O
has	VBZ	O
been	VBN	O
proposed	VBN	O
that	IN	O
women	NNS	SE
who	WP	O
have	VBP	O
a	DT	O
negative	JJ	C
colposcopic	NN	C
examination	NN	C
or	CC	C
who	WP	C
have	VBP	C
no	DT	C
cervical	JJ	C
intraepithelial	JJ	C
neoplasia	NN	C
(	(	C
CIN	NNP	C
)	)	C
on	IN	C
colposcopic	NN	C
biopsy	NN	C
can	MD	O
be	VB	O
safely	RB	O
returned	VBN	O
to	TO	O
routine	VB	O
screening	VBG	O
with	IN	O
the	DT	O
next	JJ	O
visit	NN	O
being	VBG	O
three	CD	O
or	CC	O
five	CD	O
years	NNS	O
later	RB	O
.	.	O

We	PRP	O
present	JJ	O
data	NNS	O
regarding	VBG	O
551	CD	SS
women	NNS	SE
who	WP	O
had	VBD	O
colposcopy	NN	O
in	IN	O
Wales	NNP	O
for	IN	O
a	DT	O
low-grade	JJ	C
cytological	JJ	C
abnormality	NN	C
and	CC	O
who	WP	O
were	VBD	O
followed	VBN	O
through	IN	O
Cervical	NNP	O
Screening	NNP	O
Wales	NNP	O
for	IN	O
subsequent	JJ	O
CIN	NNP	O
.	.	O

Of	IN	O
436	CD	O
women	NNS	O
declared	VBD	O
CIN	NNP	O
free	JJ	O
initially	RB	O
,	,	O
26	CD	O
(	(	O
6.0	CD	O
%	NN	O
)	)	O
had	VBD	O
high-grade	JJ	O
CIN	NNP	O
diagnosed	VBD	O
on	IN	O
follow-up	NN	O
.	.	O

We	PRP	O
suggest	VBP	O
that	IN	O
additional	JJ	O
screening	NN	O
at	IN	O
an	DT	O
interval	NN	O
of	IN	O
less	JJR	O
than	IN	O
three	CD	O
years	NNS	O
should	MD	O
be	VB	O
offered	VBN	O
to	TO	O
women	NNS	SE
with	IN	O
a	DT	O
negative	JJ	C
colposcopy	NN	C
or	CC	C
a	DT	C
biopsy	NN	C
without	IN	C
CIN	NNP	C
.	.	O

Bronchodilator	NNP	O
response	NN	O
to	TO	O
salbutamol	VB	O
after	IN	O
spontaneous	JJ	O
recovery	NN	O
from	IN	O
nonspecific	JJ	O
bronchial	JJ	O
provocation	NN	O
tests	NNS	O
in	IN	O
asthma	NN	C
.	.	O

Assessment	NN	O
of	IN	O
airway	NN	O
responsiveness	NN	O
by	IN	O
bronchoprovocation	NN	O
and	CC	O
bronchodilatation	NN	O
tests	NNS	O
is	VBZ	O
important	JJ	O
in	IN	O
the	DT	O
diagnostic	JJ	O
work-up	JJ	O
protocol	NN	O
of	IN	O
bronchial	JJ	C
asthma	NN	C
and	CC	O
it	PRP	O
would	MD	O
be	VB	O
convenient	JJ	O
to	TO	O
undertake	VB	O
both	DT	O
tests	NNS	O
on	IN	O
the	DT	O
same	JJ	O
occasion	NN	O
.	.	O

However	RB	O
,	,	O
it	PRP	O
is	VBZ	O
not	RB	O
known	VBN	O
whether	IN	O
this	DT	O
can	MD	O
be	VB	O
done	VBN	O
accurately	RB	O
.	.	O

Therefore	RB	O
,	,	O
this	DT	O
study	NN	O
evaluated	VBD	O
the	DT	O
effect	NN	O
of	IN	O
a	DT	O
prior	JJ	O
bronchial	JJ	O
provocation	NN	O
test	NN	O
on	IN	O
the	DT	O
bronchodilator	NN	O
response	NN	O
to	TO	O
salbutamol	VB	O
after	IN	O
spontaneous	JJ	O
recovery	NN	O
of	IN	O
the	DT	O
forced	JJ	O
expiratory	NN	O
volume	NN	O
in	IN	O
one	CD	O
second	NN	O
(	(	O
FEV1	NNP	O
)	)	O
in	IN	O
a	DT	O
group	NN	O
of	IN	O
asthmatic	JJ	C
subjects	NNS	O
.	.	O

On	IN	O
two	CD	O
separate	JJ	O
occasions	NNS	O
at	IN	O
the	DT	O
same	JJ	O
time	NN	O
of	IN	O
day	NN	O
,	,	O
concentration-response	JJ	O
studies	NNS	O
with	IN	O
inhaled	JJ	O
histamine	NN	O
or	CC	O
methacholine	NN	O
,	,	O
or	CC	O
a	DT	O
sham	JJ	O
challenge	NN	O
with	IN	O
normal	JJ	O
saline	NN	O
were	VBD	O
carried	VBN	O
out	RP	O
in	IN	O
a	DT	O
blinded	JJ	O
,	,	O
randomized	JJ	O
manner	NN	O
.	.	O

Changes	NNS	O
in	IN	O
airway	NN	O
calibre	NN	O
were	VBD	O
followed	VBN	O
as	IN	O
FEV1	NNP	O
and	CC	O
agonist	JJ	O
responsiveness	NN	O
expressed	VBN	O
as	IN	O
the	DT	O
provocative	JJ	O
concentration	NN	O
causing	VBG	O
a	DT	O
20	CD	O
%	NN	O
fall	NN	O
in	IN	O
FEV1	NNP	O
(	(	O
PC20	NNP	O
)	)	O
.	.	O

After	IN	O
either	DT	O
spontaneous	JJ	O
recovery	NN	O
or	CC	O
a	DT	O
fixed-duration	JJ	O
wait	NN	O
of	IN	O
45	CD	O
min	NNS	O
(	(	O
when	WRB	O
appropriate	NN	O
)	)	O
,	,	O
the	DT	O
subjects	NNS	O
received	VBD	O
2x100	CD	O
microg	NN	O
of	IN	O
salbutamol	NN	O
from	IN	O
a	DT	O
metered	VBN	O
dose	NN	O
inhaler	NN	O
with	IN	O
a	DT	O
spacer	NN	O
.	.	O

The	DT	O
bronchodilator	NN	O
response	NN	O
to	TO	O
salbutamol	VB	O
was	VBD	O
expressed	VBN	O
as	IN	O
a	DT	O
percentage	NN	O
of	IN	O
initial	JJ	O
FEV1	NNP	O
(	(	O
deltaFEV1	CD	O
%	NN	O
init	NN	O
)	)	O
.	.	O

Bronchial	JJ	O
challenge	NN	O
with	IN	O
both	DT	O
agonists	NNS	O
failed	VBD	O
to	TO	O
alter	VB	O
significantly	RB	O
the	DT	O
airway	NN	O
response	NN	O
to	TO	O
salbutamol	VB	O
,	,	O
with	IN	O
the	DT	O
deltaFEV1	NN	O
%	NN	O
init	JJ	O
mean	JJ	O
value	NN	O
(	(	O
range	NN	O
)	)	O
being	VBG	O
16.9	CD	O
%	NN	O
(	(	O
9.0-31.9	CD	O
)	)	O
and	CC	O
17.5	CD	O
%	NN	O
(	(	O
11.6-31.2	JJ	O
)	)	O
on	IN	O
the	DT	O
sham	NN	O
and	CC	O
histamine/methacholine	JJ	O
challenge	NN	O
day	NN	O
respectively	RB	O
.	.	O

It	PRP	O
was	VBD	O
shown	VBN	O
that	IN	O
the	DT	O
degree	NN	O
of	IN	O
bronchodilatation	NN	O
achieved	VBN	O
after	IN	O
salbutamol	JJ	O
200	CD	O
microg	NN	O
is	VBZ	O
not	RB	O
affected	VBN	O
by	IN	O
prior	JJ	O
bronchoprovocation	NN	O
testing	VBG	O
when	WRB	O
enough	JJ	O
time	NN	O
is	VBZ	O
allowed	VBN	O
for	IN	O
the	DT	O
airways	NNS	O
to	TO	O
recover	VB	O
spontaneously	RB	O
to	TO	O
baseline	VB	O
forced	JJ	O
expiratory	NN	O
volume	NN	O
in	IN	O
one	CD	O
second	NN	O
.	.	O

Thus	NNP	O
evaluation	NN	O
of	IN	O
airway	NN	O
responsiveness	NN	O
by	IN	O
both	DT	O
bronchial	JJ	O
provocation	NN	O
tests	NNS	O
and	CC	O
bronchodilator	NN	O
testing	NN	O
can	MD	O
be	VB	O
assessed	VBN	O
reliably	RB	O
within	IN	O
a	DT	O
few	JJ	O
hours	NNS	O
in	IN	O
asthmatic	JJ	C
patients	NNS	O
.	.	O

Are	NNP	O
oral	JJ	O
cathartics	NNS	O
of	IN	O
value	NN	O
in	IN	O
optimizing	VBG	O
the	DT	O
gallium	NN	O
scan	JJ	O
?	.	O
Concise	NNP	O
communication	NN	O
.	.	O

The	DT	O
normal	JJ	O
intestinal	JJ	O
secretion	NN	O
of	IN	O
9-15	CD	O
%	NN	O
of	IN	O
an	DT	O
administered	VBN	O
dose	NN	O
of	IN	O
gallium-67	NN	O
may	MD	O
prevent	VB	O
early	JJ	O
detection	NN	O
of	IN	O
intra-abdominal	JJ	O
disease	NN	O
.	.	O

We	PRP	O
randomized	VBD	C
50	CD	SS
patients	NNS	O
to	TO	O
receive	VB	O
either	DT	O
no	DT	O
bowel	NN	O
preparation	NN	O
or	CC	O
30	CD	O
cc	NN	O
of	IN	O
milk	NN	O
of	IN	O
magnesia	JJ	O
plus	CC	O
5	CD	O
cc	NN	O
of	IN	O
cascara	NN	O
.	.	O

No	DT	O
significant	JJ	O
difference	NN	O
was	VBD	O
found	VBN	O
between	IN	O
the	DT	O
two	CD	O
groups	NNS	O
in	IN	O
frequency	NN	O
with	IN	O
which	WDT	O
gallium	NN	O
interfered	VBD	O
with	IN	O
readings	NNS	O
or	CC	O
time	NN	O
to	TO	O
complete	VB	O
the	DT	O
study	NN	O
.	.	O

Isoflurane	NNP	O
and	CC	O
propofol	NN	O
for	IN	O
long-term	JJ	O
sedation	NN	O
in	IN	O
the	DT	O
intensive	JJ	O
care	NN	O
unit	NN	O
.	.	O

A	DT	O
crossover	NN	O
study	NN	O
.	.	O

Propofol	NNP	O
and	CC	O
isoflurane	NN	O
have	VBP	O
been	VBN	O
reported	VBN	O
recently	RB	O
to	TO	O
offer	VB	O
better	JJR	O
sedation	NN	O
than	IN	O
alternative	JJ	O
agents	NNS	O
in	IN	O
patients	NNS	O
who	WP	C
require	VBP	C
long-term	JJ	C
ventilation	NN	C
in	IN	C
the	DT	C
Intensive	NNP	C
Care	NNP	C
Unit	NNP	C
.	.	O

This	DT	O
is	VBZ	O
the	DT	O
first	JJ	O
report	NN	O
of	IN	O
a	DT	O
direct	JJ	O
comparison	NN	O
between	IN	O
propofol	NN	O
and	CC	O
isoflurane	NN	O
.	.	O

Twenty-four	CD	O
patients	NNS	O
predicted	VBN	O
to	TO	O
require	VB	C
artificial	JJ	C
ventilation	NN	C
for	IN	C
at	IN	C
least	JJS	C
48	CD	C
h	NNS	C
were	VBD	O
entered	VBN	O
into	IN	O
a	DT	O
randomised	VBN	O
crossover	NN	O
study	NN	O
to	TO	O
monitor	VB	O
sedation	NN	O
quality	NN	O
and	CC	O
time	NN	O
to	TO	O
recovery	NN	O
from	IN	O
sedation	NN	O
.	.	O

There	EX	O
were	VBD	O
no	DT	O
significant	JJ	O
differences	NNS	O
between	IN	O
the	DT	O
two	CD	O
agents	NNS	O
in	IN	O
either	DT	O
end-point	NN	O
,	,	O
with	IN	O
over	IN	O
95	CD	O
%	NN	O
optimal	JJ	O
sedation	NN	O
achieved	VBN	O
by	IN	O
the	DT	O
use	NN	O
of	IN	O
each	DT	O
drug	NN	O
.	.	O

Few	JJ	O
adverse	JJ	O
events	NNS	O
were	VBD	O
noted	VBN	O
.	.	O

Technological	JJ	O
advances	NNS	O
in	IN	O
the	DT	O
administration	NN	O
of	IN	O
volatile	JJ	O
agents	NNS	O
as	IN	O
long-term	JJ	O
sedatives	NNS	O
in	IN	O
the	DT	O
Intensive	NNP	O
Care	NNP	O
Unit	NNP	O
may	MD	O
facilitate	VB	O
their	PRP$	O
more	JJR	O
widespread	JJ	O
use	NN	O
.	.	O

Expectancies	NNS	O
,	,	O
not	RB	O
aroma	RB	O
,	,	O
explain	JJ	O
impact	NN	O
of	IN	O
lavender	NN	O
aromatherapy	NN	O
on	IN	O
psychophysiological	JJ	O
indices	NNS	O
of	IN	O
relaxation	NN	O
in	IN	O
young	JJ	A
healthy	JJ	C
women	NNS	SE
.	.	O

OBJECTIVES	NNP	O
In	IN	O
aromatherapy	NN	O
,	,	O
lavender	JJR	O
aroma	NN	O
is	VBZ	O
reputed	VBN	O
to	TO	O
assist	VB	O
with	IN	O
relaxation	NN	O
.	.	O

However	RB	O
,	,	O
while	IN	O
there	EX	O
is	VBZ	O
much	JJ	O
anecdotal	JJ	O
evidence	NN	O
to	TO	O
that	DT	O
effect	NN	O
,	,	O
the	DT	O
empirical	JJ	O
literature	NN	O
is	VBZ	O
very	RB	O
inconsistent	JJ	O
.	.	O

Failure	NN	O
to	TO	O
employ	VB	O
adequate	JJ	O
placebos	NNS	O
,	,	O
proper	JJ	O
blinding	NN	O
,	,	O
objective	JJ	O
measures	NNS	O
,	,	O
or	CC	O
screening	NN	O
of	IN	O
prior	JJ	O
beliefs	NNS	O
about	IN	O
aromatherapy	NN	O
means	NNS	O
that	IN	O
many	JJ	O
previous	JJ	O
findings	NNS	O
could	MD	O
have	VB	O
been	VBN	O
influenced	VBN	O
by	IN	O
expectancy	NN	O
biases	NNS	O
.	.	O

The	DT	O
present	JJ	O
study	NN	O
sought	VBD	O
to	TO	O
establish	VB	O
whether	IN	O
lavender	NN	O
aroma	NN	O
and/or	JJ	O
expectancies	NNS	O
affect	VBP	O
post-stress	JJ	O
relaxation	NN	O
.	.	O

DESIGN	VB	O
A	DT	O
double-blind	NN	O
,	,	O
3	CD	O
(	(	O
aroma	NN	O
)	)	O
x	VBZ	O
3	CD	O
(	(	O
instruction	NN	O
)	)	O
x	VBZ	O
10	CD	O
(	(	O
time	NN	O
in	IN	O
minutes	NNS	O
)	)	O
mixed-factorial	JJ	O
placebo-controlled	JJ	O
trial	NN	O
.	.	O

METHOD	NNP	O
In	IN	O
a	DT	O
laboratory	NN	O
,	,	O
96	CD	SS
healthy	JJ	C
undergraduate	JJ	O
women	NNS	SE
were	VBD	O
exposed	VBN	O
to	TO	O
lavender	VB	O
,	,	O
placebo	NN	O
,	,	O
or	CC	O
no	DT	O
aroma	NN	O
during	IN	O
physiologically	RB	O
assessed	VBN	O
relaxation	NN	O
after	IN	O
an	DT	O
arousing	VBG	O
cognitive	JJ	O
task	NN	O
.	.	O

Where	WRB	O
an	DT	O
aroma	NN	O
was	VBD	O
presented	VBN	O
,	,	O
an	DT	O
instructional	JJ	O
priming	NN	O
procedure	NN	O
was	VBD	O
used	VBN	O
to	TO	O
manipulate	VB	O
participants	NNS	O
'	POS	O
expectancies	NNS	O
about	IN	O
the	DT	O
aroma	NN	O
's	POS	O
likely	JJ	O
impact	NN	O
on	IN	O
their	PRP$	O
ability	NN	O
to	TO	O
relax	VB	O
.	.	O

RESULTS	NNP	O
Results	NNP	O
showed	VBD	O
no	DT	O
effect	NN	O
of	IN	O
aroma	NN	O
on	IN	O
galvanic	JJ	O
skin	NN	O
response	NN	O
during	IN	O
relaxation	NN	O
.	.	O

However	RB	O
,	,	O
the	DT	O
nature	NN	O
of	IN	O
instructional	JJ	O
prime	NN	O
was	VBD	O
associated	VBN	O
with	IN	O
relaxation	NN	O
patterns	NNS	O
:	:	O
when	WRB	O
expecting	VBG	O
the	DT	O
aroma	NN	O
to	TO	O
inhibit	VB	O
them	PRP	O
,	,	O
participants	NNS	O
relaxed	VBD	O
more	RBR	O
;	:	O
when	WRB	O
expecting	VBG	O
facilitation	NN	O
,	,	O
participants	NNS	O
relaxed	VBD	O
less	RBR	O
.	.	O

The	DT	O
effect	NN	O
was	VBD	O
not	RB	O
seen	VBN	O
with	IN	O
regard	NN	O
to	TO	O
self-reported	JJ	O
relaxation	NN	O
(	(	O
as	IN	O
represented	VBN	O
by	IN	O
changes	NNS	O
in	IN	O
state	NN	O
anxiety	NN	O
)	)	O
and	CC	O
was	VBD	O
independent	JJ	O
of	IN	O
ratings	NNS	O
of	IN	O
attitudes	NNS	O
towards	NNS	O
aromatherapy	NN	O
.	.	O

CONCLUSIONS	VB	O
The	DT	O
findings	NNS	O
imply	VBP	O
that	IN	O
the	DT	O
previous	JJ	O
associations	NNS	O
of	IN	O
lavender	NN	O
aroma	NN	O
with	IN	O
assisted	JJ	O
relaxation	NN	O
may	MD	O
have	VB	O
been	VBN	O
influenced	VBN	O
by	IN	O
expectancy	NN	O
biases	NNS	O
,	,	O
and	CC	O
that	IN	O
the	DT	O
relevant	JJ	O
expectancies	NNS	O
are	VBP	O
easily	RB	O
manipulable	JJ	O
.	.	O

Primary	JJ	O
stenting	NN	O
of	IN	O
occluded	JJ	O
native	JJ	O
coronary	JJ	O
arteries	NNS	O
:	:	O
final	JJ	O
results	NNS	O
of	IN	O
the	DT	O
Primary	NNP	O
Stenting	NNP	O
of	IN	O
Occluded	NNP	O
Native	NNP	O
Coronary	NNP	O
Arteries	NNP	O
(	(	O
PRISON	NNP	O
)	)	O
study	NN	O
.	.	O

BACKGROUND	NNP	O
Primary	NNP	O
intracoronary	JJ	O
stent	NN	O
placement	NN	O
after	IN	O
successfully	RB	O
crossing	VBG	O
chronic	JJ	O
total	JJ	O
coronary	JJ	O
occlusions	NNS	O
may	MD	O
decrease	VB	O
the	DT	O
high	JJ	O
restenosis	NN	O
rate	NN	O
at	IN	O
long-term	JJ	O
follow-up	JJ	O
compared	VBN	O
with	IN	O
conventional	JJ	O
balloon	NN	O
angioplasty	NN	O
.	.	O

METHODS	NNP	O
In	IN	O
a	DT	O
prospective	JJ	O
,	,	O
randomized	JJ	O
trial	NN	O
,	,	O
balloon	NN	O
angioplasty	NN	O
was	VBD	O
compared	VBN	O
with	IN	O
stent	JJ	O
implantation	NN	O
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
chronic	JJ	C
total	JJ	C
occlusions	NNS	C
.	.	O

Patients	NNS	O
were	VBD	O
followed	VBN	O
for	IN	O
12	CD	O
months	NNS	O
with	IN	O
angiographic	JJ	O
follow-up	NN	O
at	IN	O
6	CD	O
months	NNS	O
.	.	O

Quantitative	JJ	O
coronary	JJ	O
analysis	NN	O
was	VBD	O
performed	VBN	O
by	IN	O
an	DT	O
independent	JJ	O
core	NN	O
lab	NN	O
.	.	O

RESULTS	VB	O
A	DT	O
total	NN	O
of	IN	O
200	CD	O
patients	NNS	O
were	VBD	O
enrolled	VBN	O
.	.	O

Baseline	JJ	O
characteristics	NNS	O
were	VBD	O
evenly	RB	O
distributed	VBN	O
.	.	O

After	IN	O
the	DT	O
procedure	NN	O
the	DT	O
mean	NN	O
minimal	JJ	O
luminal	JJ	O
diameter	NN	O
in	IN	O
the	DT	O
conventional	JJ	O
group	NN	O
was	VBD	O
2.34	CD	O
+/-	JJ	O
0.46	CD	O
mm	NN	O
versus	NN	O
2.90	CD	O
+/-	JJ	O
0.41	CD	O
mm	NN	O
in	IN	O
the	DT	O
stented	VBN	O
group	NN	O
(	(	O
P	NNP	O
<	NNP	O
.0001	NNP	O
)	)	O
.	.	O

The	DT	O
6-month	JJ	O
angiographic	JJ	O
follow-up	NN	O
showed	VBD	O
a	DT	O
mean	JJ	O
minimal	JJ	O
luminal	JJ	O
diameter	NN	O
of	IN	O
1.57	CD	O
+/-	JJ	O
0.74	CD	O
mm	NN	O
in	IN	O
the	DT	O
conventional	JJ	O
group	NN	O
versus	VBD	O
1.93	CD	O
+/-	JJ	O
0.85	CD	O
mm	NN	O
in	IN	O
the	DT	O
stented	VBN	O
group	NN	O
(	(	O
P	NNP	O
=.009	NNP	O
)	)	O
and	CC	O
a	DT	O
mean	JJ	O
diameter	NN	O
stenosis	NN	O
of	IN	O
44.7	CD	O
%	NN	O
+/-	JJ	O
25.0	CD	O
%	NN	O
versus	IN	O
35.5	CD	O
%	NN	O
+/-	JJ	O
26.5	CD	O
%	NN	O
(	(	O
P	NNP	O
=.036	NNP	O
)	)	O
.	.	O

Binary	JJ	O
angiographic	JJ	O
restenosis	NN	O
(	(	O
>	JJ	O
50	CD	O
%	NN	O
diameter	JJ	O
stenosis	NN	O
)	)	O
was	VBD	O
seen	VBN	O
in	IN	O
33	CD	O
%	NN	O
in	IN	O
the	DT	O
conventional	JJ	O
group	NN	O
versus	VBD	O
22	CD	O
%	NN	O
in	IN	O
the	DT	O
stented	VBN	O
group	NN	O
(	(	O
P	NNP	O
=.137	NNP	O
)	)	O
.	.	O

The	DT	O
reocclusion	NN	O
rates	NNS	O
were	VBD	O
7.3	CD	O
%	NN	O
and	CC	O
8.2	CD	O
%	NN	O
,	,	O
respectively	RB	O
(	(	O
P	NNP	O
=	NNP	O
1.00	CD	O
)	)	O
.	.	O

At	IN	O
12	CD	O
month	NN	O
follow-up	NN	O
,	,	O
the	DT	O
rate	NN	O
of	IN	O
target	NN	O
lesion	NN	O
revascularization	NN	O
was	VBD	O
significantly	RB	O
higher	JJR	O
in	IN	O
the	DT	O
conventional	JJ	O
group	NN	O
(	(	O
29	CD	O
%	NN	O
versus	IN	O
13	CD	O
%	NN	O
,	,	O
P	NNP	O
<	NNP	O
.0001	NNP	O
)	)	O
.	.	O

CONCLUSION	NNP	O
These	DT	O
data	NNS	O
demonstrate	NN	O
that	IN	O
stenting	VBG	O
of	IN	O
chronic	JJ	O
total	JJ	O
occlusions	NNS	O
is	VBZ	O
superior	JJ	O
to	TO	O
balloon	VB	O
angioplasty	JJ	O
alone	RB	O
with	IN	O
a	DT	O
statistically	RB	O
significant	JJ	O
reduction	NN	O
in	IN	O
the	DT	O
need	NN	O
for	IN	O
target	NN	O
lesion	NN	O
revascularization	NN	O
and	CC	O
a	DT	O
lower	JJR	O
,	,	O
but	CC	O
not	RB	O
significant	JJ	O
,	,	O
restenosis	NN	O
rate	NN	O
.	.	O

Quick	JJ	O
change	NN	O
versus	NN	O
double	JJ	O
pump	NN	O
while	IN	O
changing	VBG	O
the	DT	O
infusion	NN	O
of	IN	O
inotropes	NNS	O
:	:	O
an	DT	O
experimental	JJ	O
study	NN	O
.	.	O

BACKGROUND	NNP	O
Quick	NNP	O
change	NN	O
(	(	O
QC	NNP	O
)	)	O
and	CC	O
double	JJ	O
pumping	NN	O
(	(	O
DP	NNP	O
)	)	O
are	VBP	O
common	JJ	O
methods	NNS	O
of	IN	O
substituting	VBG	O
the	DT	O
infusion	NN	O
of	IN	O
inotropes	NNS	O
given	VBN	O
through	IN	O
intravenous	JJ	O
pump	NN	O
.	.	O

AIMS	IN	O
The	DT	O
aim	NN	O
of	IN	O
the	DT	O
study	NN	O
was	VBD	O
to	TO	O
compare	VB	O
two	CD	O
methods	NNS	O
in	IN	O
respect	NN	O
with	IN	O
the	DT	O
variation	NN	O
in	IN	O
mean	JJ	O
arterial	JJ	O
pressure	NN	O
(	(	O
MAP	NNP	O
)	)	O
.	.	O

The	DT	O
hypothesis	NN	O
was	VBD	O
that	IN	O
the	DT	O
DP	NNP	O
method	NN	O
could	MD	O
be	VB	O
the	DT	O
most	RBS	O
effective	JJ	O
in	IN	O
achieving	VBG	O
haemodynamic	JJ	O
stability	NN	O
.	.	O

DESIGN	VB	O
The	DT	O
study	NN	O
is	VBZ	O
a	DT	O
randomized	JJ	O
research	NN	O
in	IN	O
an	DT	O
open	JJ	O
randomized	JJ	O
clinical	JJ	O
trial	NN	O
.	.	O

METHODS	NNP	O
The	DT	O
study	NN	O
took	VBD	O
place	NN	O
at	IN	O
the	DT	O
Paediatric	NNP	O
Intensive	NNP	O
Care	NNP	O
Unit	NNP	O
of	IN	O
Padua	NNP	O
Hospital	NNP	O
.	.	O

It	PRP	C
considered	VBD	C
patients	NNS	C
of	IN	C
0-36	JJ	C
months	NNS	C
,	,	C
not	RB	C
premature	NN	C
,	,	C
treated	VBN	C
with	IN	C
inotropic	JJ	C
infusion	NN	C
with	IN	C
monitoring	NN	C
of	IN	C
blood	NN	C
pressure	NN	C
.	.	C

The	DT	O
research	NN	O
obtained	VBD	O
the	DT	O
approval	NN	O
of	IN	O
the	DT	O
Hospital	NNP	O
Research	NNP	O
Ethics	NNP	O
committee	NN	O
and	CC	O
parents	NNS	O
signed	VBD	O
informed	JJ	O
consent	NN	O
.	.	O

Comparison	NNP	O
of	IN	O
the	DT	O
two	CD	O
groups	NNS	O
made	VBN	O
use	NN	O
of	IN	O
the	DT	O
Wilcoxon	NNP	O
test	NN	O
for	IN	O
the	DT	O
continuous	JJ	O
variables	NNS	O
and	CC	O
the	DT	O
Fisher	NNP	O
's	POS	O
exact	JJ	O
test	NN	O
for	IN	O
the	DT	O
comparison	NN	O
of	IN	O
frequencies	NNS	O
,	,	O
at	IN	O
significance	NN	O
value	NN	O
of	IN	O
5	CD	O
%	NN	O
.	.	O

The	DT	O
data	NNS	O
were	VBD	O
registered	VBN	O
in	IN	O
an	DT	O
Excel	NNP	O
spreadsheet	NN	O
and	CC	O
analysed	VBN	O
with	IN	O
SAS	NNP	O
.	.	O

RESULTS	VB	O
The	DT	O
sample	NN	O
comprised	VBD	O
30	CD	O
patients	NNS	O
of	IN	O
age	NN	O
between	IN	O
1	CD	O
and	CC	O
27	CD	O
months	NNS	O
,	,	O
of	IN	O
whom	WP	O
13	CD	O
(	(	O
43	CD	O
%	NN	O
)	)	O
were	VBD	O
male	JJ	O
.	.	O

They	PRP	O
were	VBD	O
all	DT	O
affected	VBN	O
by	IN	O
cardiac	NN	O
,	,	O
respiratory	NN	O
or	CC	O
infective	JJ	O
pathology	NN	O
,	,	O
all	DT	O
of	IN	O
them	PRP	O
intubated	VBN	O
and	CC	O
on	IN	O
artificial	JJ	O
respiratory	NN	O
support	NN	O
,	,	O
sedated	VBN	O
and	CC	O
infused	VBN	O
with	IN	O
dopamine	NN	O
.	.	O

The	DT	O
characteristics	NNS	O
of	IN	O
the	DT	O
patients	NNS	O
of	IN	O
the	DT	O
two	CD	O
groups	NNS	O
did	VBD	O
not	RB	O
differ	VB	O
significantly	RB	O
.	.	O

The	DT	O
percentage	NN	O
variation	NN	O
of	IN	O
the	DT	O
baseline	NN	O
value	NN	O
of	IN	O
MAP	NNP	O
after	IN	O
30	CD	O
min	NN	O
from	IN	O
starting	VBG	O
the	DT	O
treatment	NN	O
between	IN	O
the	DT	O
two	CD	O
methods	NNS	O
was	VBD	O
not	RB	O
statistically	RB	O
significant	JJ	O
(	(	O
p	JJ	O
=	NNP	O
0.85	CD	O
)	)	O
.	.	O

The	DT	O
95	CD	O
%	NN	O
confidence	NN	O
interval	NN	O
for	IN	O
the	DT	O
difference	NN	O
in	IN	O
the	DT	O
percentage	NN	O
variation	NN	O
of	IN	O
MAP	NNP	O
between	IN	O
the	DT	O
two	CD	O
groups	NNS	O
was	VBD	O
(	(	O
-3.1	JJ	O
,	,	O
+3.7	NNP	O
)	)	O
.	.	O

From	IN	O
a	DT	O
clinical	JJ	O
perspective	NN	O
,	,	O
the	DT	O
methods	NNS	O
are	VBP	O
to	TO	O
be	VB	O
considered	VBN	O
equivalent	JJ	O
.	.	O

CONCLUSIONS	VB	O
The	DT	C
study	NN	C
was	VBD	C
conducted	VBN	C
on	IN	C
a	DT	C
limited	JJ	C
sample	NN	C
;	:	C
no	DT	O
statistically	RB	O
significant	JJ	O
differences	NNS	O
were	VBD	O
detected	VBN	O
;	:	O
QC	NNP	O
is	VBZ	O
the	DT	O
quickest	JJS	O
and	CC	O
more	JJR	O
cost-effective	JJ	O
method	NN	O
.	.	O

The	DT	O
role	NN	O
of	IN	O
the	DT	O
MA-sensitive	JJ	O
leukocyte	NN	O
chemotaxis	NN	O
in	IN	O
rheumatoid	JJ	C
arthritis	NN	C
.	.	O

A	DT	O
randomized	JJ	O
double-blind	JJ	O
clinical	JJ	O
trial	NN	O
of	IN	O
griseofulvin	NN	O
treatment	NN	O
.	.	O

Polymorphonuclear	JJ	O
leukocyte	NN	O
(	(	O
PMN	NNP	O
)	)	O
chemotaxis	NN	O
is	VBZ	O
thought	VBN	O
to	TO	O
play	VB	O
an	DT	O
essential	JJ	O
role	NN	O
in	IN	O
the	DT	O
pathogenesis	NN	O
of	IN	O
rheumatoid	JJ	O
arthritis	NN	O
.	.	O

PMN	NNP	O
chemotaxis	NN	O
is	VBZ	O
in	IN	O
part	NN	O
sensitive	NN	O
to	TO	O
microtubule	VB	O
antagonists	NNS	O
(	(	O
MAs	NNP	O
)	)	O
,	,	O
e.g	RB	O
.	.	O

colchicine	NN	O
.	.	O

The	DT	O
antimycotic	JJ	O
antibiotic	JJ	O
griseofulvin	NN	O
inhibits	VBZ	O
the	DT	O
MA-sensitive	JJ	O
PMN	NNP	O
chemotaxis	NN	O
in	IN	O
vitro	NN	O
in	IN	O
concentrations	NNS	O
far	RB	O
below	IN	O
those	DT	O
obtained	VBN	O
in	IN	O
serum	NN	O
during	IN	O
antimycotic	JJ	O
therapy	NN	O
.	.	O

The	DT	O
role	NN	O
of	IN	O
the	DT	O
MA-sensitive	JJ	O
chemotaxis	NN	O
in	IN	O
rheumatoid	JJ	O
arthritis	NN	O
could	MD	O
thus	RB	O
be	VB	O
elucidated	VBN	O
by	IN	O
a	DT	O
clinical	JJ	O
trial	NN	O
of	IN	O
griseofulvin	NN	O
treatment	NN	O
.	.	O

Griseofulvin	NNP	O
(	(	O
n	JJ	O
=	NNP	O
20	CD	SS
)	)	O
was	VBD	O
tested	VBN	O
in	IN	O
a	DT	O
randomized	JJ	O
double-blind	NN	O
study	NN	O
versus	IN	O
placebo	NN	O
(	(	O
m	JJ	O
=	NNP	O
19	CD	SS
)	)	O
during	IN	O
one	CD	O
year	NN	O
in	IN	O
patients	NNS	O
with	IN	O
rheumatoid	JJ	O
arthritis	NN	O
of	IN	O
mild-moderate	JJ	O
activity	NN	O
.	.	O

No	DT	O
beneficial	JJ	O
effect	NN	O
of	IN	O
griseofulvin	NN	O
treatment	NN	O
was	VBD	O
noted	VBN	O
on	IN	O
clinical	JJ	O
symptoms	NNS	O
or	CC	O
laboratory	JJ	O
parameters	NNS	O
of	IN	O
rheumatoid	JJ	O
arthritis	NN	O
.	.	O

Moreover	RB	O
,	,	O
the	DT	O
placebo-treated	JJ	O
patients	NNS	O
showed	VBD	O
more	RBR	O
improvement	NN	O
than	IN	O
the	DT	O
griseofulvin-treated	JJ	O
patients	NNS	O
.	.	O

It	PRP	O
is	VBZ	O
therefore	RB	O
suggested	VBN	O
that	IN	O
the	DT	O
MA-sensitive	JJ	O
chemotaxis	NN	O
plays	VBZ	O
a	DT	O
reparative	JJ	O
role	NN	O
in	IN	O
the	DT	O
inflammatory	JJ	O
lesions	NNS	O
of	IN	O
rheumatoid	JJ	O
arthritis	NN	O
.	.	O

Antioxidant	JJ	O
supplementation	NN	O
and	CC	O
exercise-induced	JJ	O
oxidative	JJ	C
stress	NN	C
in	IN	O
the	DT	O
60-year-old	JJ	A
as	IN	O
measured	VBN	O
by	IN	O
antipyrine	NN	O
hydroxylates	NNS	O
.	.	O

The	DT	O
effects	NNS	O
of	IN	O
12	CD	O
weeks	NNS	O
of	IN	O
antioxidant	JJ	O
supplementation	NN	O
on	IN	O
exercise-induced	JJ	O
oxidative	JJ	O
stress	NN	O
were	VBD	O
investigated	VBN	O
in	IN	O
older	JJR	O
adults	NNS	O
(	(	O
60	CD	O
(	(	O
SE	NNP	O
1	CD	O
)	)	O
years	NNS	O
;	:	O
BMI	NNP	O
26	CD	O
(	(	O
SE	NNP	O
1	CD	O
)	)	O
kg/m	NN	O
(	(	O
2	CD	O
)	)	O
)	)	O
.	.	O

Subjects	NNS	O
were	VBD	O
randomly	RB	O
divided	VBN	O
in	IN	O
two	CD	O
groups	NNS	O
:	:	O
supplementation	NN	O
(	(	O
n	JJ	O
11	CD	O
)	)	O
with	IN	O
100	CD	O
mg	NNS	O
dl-alpha-tocopheryl	JJ	O
acetate	NN	O
,	,	O
200	CD	O
mg	NN	O
ascorbic	JJ	O
acid	NN	O
,	,	O
and	CC	O
2	CD	O
mg	NN	O
beta-carotene	NN	O
,	,	O
and	CC	O
placebo	NN	O
(	(	O
n	JJ	O
9	CD	O
)	)	O
.	.	O

Before	IN	O
and	CC	O
after	IN	O
the	DT	O
12	CD	O
week	NN	O
supplementation	NN	O
period	NN	O
,	,	O
subjects	NNS	O
cycled	VBD	O
for	IN	O
45	CD	O
min	NN	O
at	IN	O
submaximal	JJ	O
intensity	NN	O
(	(	O
50	CD	O
%	NN	O
maximal	JJ	O
workload	NN	O
capacity	NN	O
)	)	O
.	.	O

Antipyrine	NNP	O
was	VBD	O
used	VBN	O
as	IN	O
marker	NN	O
for	IN	O
oxidative	JJ	O
stress	NN	O
.	.	O

Antipyrine	NNP	O
reacts	VBZ	O
quickly	RB	O
with	IN	O
hydroxyl	JJ	O
radicals	NNS	O
to	TO	O
form	VB	O
para-	JJ	O
and	CC	O
ortho-hydroxyantipyrine	JJ	O
.	.	O

The	DT	O
latter	JJ	O
metabolite	NN	O
is	VBZ	O
not	RB	O
formed	VBN	O
in	IN	O
man	NN	O
through	IN	O
the	DT	O
mono-oxygenase	JJ	O
pathway	NN	O
of	IN	O
cytochrome	JJ	O
P450	NNP	O
.	.	O

Daily	NNP	O
supplementation	NN	O
significantly	RB	O
increased	VBD	O
plasma	JJ	O
concentrations	NNS	O
of	IN	O
alpha-tocopherol	NN	O
and	CC	O
beta-carotene	NN	O
in	IN	O
the	DT	O
supplemented	VBN	O
group	NN	O
(	(	O
Delta	NNP	O
14.4	CD	O
(	(	O
SE	NNP	O
3.2	CD	O
)	)	O
and	CC	O
0.4	CD	O
(	(	O
se	VB	O
0.1	CD	O
)	)	O
micromol/l	NN	O
;	:	O
P	NNP	O
<	VBZ	O
0.001	CD	O
and	CC	O
P	NNP	O
<	NNP	O
0.01	CD	O
)	)	O
.	.	O

No	DT	O
significant	JJ	O
differences	NNS	O
,	,	O
within	IN	O
and	CC	O
between	IN	O
groups	NNS	O
,	,	O
were	VBD	O
observed	VBN	O
in	IN	O
the	DT	O
exercise-induced	JJ	O
increase	NN	O
in	IN	O
the	DT	O
ratios	NNS	O
para-	JJ	O
and	CC	O
ortho-hydroxyantipyrine	JJ	O
to	TO	O
antipyrine	VB	O
.	.	O

In	IN	O
addition	NN	O
,	,	O
supplementation	NN	O
did	VBD	O
not	RB	O
affect	VB	O
the	DT	O
exercise-induced	JJ	O
increase	NN	O
in	IN	O
thiobarbituric	JJ	O
acid	NN	O
reactive	JJ	O
substances	NNS	O
in	IN	O
plasma	NN	O
.	.	O

In	IN	O
conclusion	NN	O
,	,	O
in	IN	O
60-year-old	JJ	O
subjects	NNS	O
antioxidant	JJ	O
supplementation	NN	O
had	VBD	O
no	DT	O
effect	NN	O
on	IN	O
the	DT	O
exercise-induced	JJ	O
increase	NN	O
in	IN	O
oxidative	JJ	O
stress	NN	O
as	IN	O
measured	VBN	O
by	IN	O
free	JJ	O
radical	JJ	O
products	NNS	O
of	IN	O
antipyrine	NN	O
.	.	O

An	DT	O
empirical	JJ	O
comparison	NN	O
of	IN	O
the	DT	O
St	NNP	O
George	NNP	O
's	POS	O
Respiratory	NNP	O
Questionnaire	NNP	O
(	(	O
SGRQ	NNP	O
)	)	O
and	CC	O
the	DT	O
Chronic	NNP	O
Respiratory	NNP	O
Disease	NNP	O
Questionnaire	NNP	O
(	(	O
CRQ	NNP	O
)	)	O
in	IN	O
a	DT	O
clinical	JJ	O
trial	NN	O
setting	NN	O
.	.	O

BACKGROUND	IN	O
The	DT	O
Chronic	NNP	O
Respiratory	NNP	O
Questionnaire	NNP	O
(	(	O
CRQ	NNP	O
)	)	O
and	CC	O
the	DT	O
St	NNP	O
George	NNP	O
's	POS	O
Respiratory	NNP	O
Questionnaire	NNP	O
(	(	O
SGRQ	NNP	O
)	)	O
are	VBP	O
the	DT	O
two	CD	O
most	JJS	O
widely	RB	O
used	VBN	O
quality	NN	O
of	IN	O
life	NN	O
questionnaires	NNS	O
in	IN	O
chronic	JJ	O
obstructive	JJ	O
pulmonary	JJ	O
disease	NN	O
(	(	O
COPD	NNP	O
)	)	O
.	.	O

A	DT	O
study	NN	O
was	VBD	O
undertaken	VBN	O
to	TO	O
compare	VB	O
directly	RB	O
the	DT	O
self-administered	JJ	O
version	NN	O
of	IN	O
the	DT	O
CRQ	NNP	O
and	CC	O
the	DT	O
SGRQ	NNP	O
with	IN	O
respect	NN	O
to	TO	O
feasibility	NN	O
,	,	O
internal	JJ	O
consistency	NN	O
,	,	O
validity	NN	O
,	,	O
and	CC	O
sensitivity	NN	O
to	TO	O
changes	NNS	O
resulting	VBG	O
from	IN	O
bronchodilator	NN	O
therapy	NN	O
.	.	O

METHODS	NNP	O
One	CD	O
hundred	CD	O
and	CC	O
forty	VB	O
four	CD	O
patients	NNS	O
with	IN	O
moderate	JJ	O
or	CC	O
severe	JJ	O
COPD	NNP	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
receive	VB	O
three	CD	O
months	NNS	O
of	IN	O
treatment	NN	O
with	IN	O
either	DT	O
salmeterol	NN	O
,	,	O
salmeterol	NN	O
+	NNP	O
ipratropium	NN	O
bromide	NN	O
,	,	O
or	CC	O
placebo	NN	O
.	.	O

Quality	NN	O
of	IN	O
life	NN	O
was	VBD	O
measured	VBN	O
at	IN	O
baseline	NN	O
and	CC	O
after	IN	O
12	CD	O
weeks	NNS	O
of	IN	O
treatment	NN	O
.	.	O

RESULTS	VB	O
The	DT	O
proportions	NNS	O
of	IN	O
missing	VBG	O
values	NNS	O
per	IN	O
patient	NN	O
were	VBD	O
low	JJ	O
for	IN	O
both	DT	O
questionnaires	NNS	O
(	(	O
0.54	CD	O
%	NN	O
for	IN	O
the	DT	O
CRQ	NNP	O
and	CC	O
2	CD	O
%	NN	O
for	IN	O
the	DT	O
SGRQ	NNP	O
)	)	O
.	.	O

The	DT	O
internal	JJ	O
consistency	NN	O
was	VBD	O
good	JJ	O
for	IN	O
both	DT	O
questionnaires	NNS	O
(	(	O
Cronbach	NNP	O
's	POS	O
alpha	NN	O
coefficients	NNS	O
>	VBP	O
/=	$	O
0.84	CD	O
for	IN	O
the	DT	O
CRQ	NNP	O
and	CC	O
>	NNP	O
/=	NNP	O
0.76	CD	O
for	IN	O
the	DT	O
SGRQ	NNP	O
)	)	O
.	.	O

Factor	NNP	O
analysis	NN	O
confirmed	VBD	O
the	DT	O
original	JJ	O
domain	NN	O
structure	NN	O
of	IN	O
the	DT	O
CRQ	NNP	O
but	CC	O
not	RB	O
of	IN	O
the	DT	O
SGRQ	NNP	O
.	.	O

Correlations	NNS	O
with	IN	O
forced	JJ	O
expiratory	NN	O
volume	NN	O
in	IN	O
one	CD	O
second	NN	O
(	(	O
FEV	NNP	O
(	(	O
1	CD	O
)	)	O
)	)	O
%	NN	O
predicted	VBN	O
and	CC	O
peak	JJ	O
expiratory	NN	O
flow	NN	O
rate	NN	O
(	(	O
PEFR	NNP	O
)	)	O
were	VBD	O
low	JJ	O
for	IN	O
both	DT	O
questionnaires	NNS	O
but	CC	O
better	JJR	O
for	IN	O
the	DT	O
SGRQ	NNP	O
than	IN	O
for	IN	O
the	DT	O
CRQ	NNP	O
.	.	O

The	DT	O
ability	NN	O
to	TO	O
discriminate	VB	O
between	IN	O
subjects	NNS	O
with	IN	O
different	JJ	O
levels	NNS	O
of	IN	O
FEV	NNP	O
(	(	O
1	CD	O
)	)	O
was	VBD	O
somewhat	RB	O
better	JJR	O
for	IN	O
the	DT	O
SGRQ	NNP	O
.	.	O

The	DT	O
correlations	NNS	O
with	IN	O
symptom	JJ	O
scores	NNS	O
were	VBD	O
comparable	JJ	O
for	IN	O
both	DT	O
questionnaires	NNS	O
.	.	O

Cross	NNP	O
sectionally	RB	O
,	,	O
the	DT	O
scores	NNS	O
of	IN	O
the	DT	O
two	CD	O
questionnaires	NNS	O
were	VBD	O
moderately	RB	O
to	TO	O
highly	RB	O
correlated	VBN	O
(	(	O
coefficients	NNS	O
ranged	VBD	O
from	IN	O
0.35	CD	O
to	TO	O
0.72	CD	O
)	)	O
.	.	O

Longitudinally	RB	O
,	,	O
these	DT	O
correlations	NNS	O
were	VBD	O
lower	JJR	O
(	(	O
coefficients	NNS	O
ranged	VBD	O
from	IN	O
0.17	CD	O
to	TO	O
0.54	CD	O
)	)	O
but	CC	O
were	VBD	O
still	RB	O
significant	JJ	O
.	.	O

The	DT	O
CRQ	NNP	O
total	NN	O
and	CC	O
emotions	NNS	O
score	NN	O
and	CC	O
the	DT	O
SGRQ	NNP	O
symptoms	NNS	O
score	NN	O
were	VBD	O
the	DT	O
most	RBS	O
responsive	JJ	O
to	TO	O
change	VB	O
.	.	O

The	DT	O
SGRQ	NNP	O
symptoms	NNS	O
domain	NN	O
was	VBD	O
the	DT	O
only	JJ	O
domain	NN	O
where	WRB	O
the	DT	O
improvement	NN	O
in	IN	O
patients	NNS	O
receiving	VBG	O
combination	NN	O
treatment	NN	O
crossed	VBD	O
the	DT	O
threshold	NN	O
for	IN	O
clinical	JJ	O
relevance	NN	O
.	.	O

CONCLUSIONS	NNP	O
Since	IN	O
this	DT	O
analysis	NN	O
of	IN	O
reliability	NN	O
,	,	O
validity	NN	O
,	,	O
and	CC	O
responsiveness	NN	O
to	TO	O
change	VB	O
did	VBD	O
not	RB	O
clearly	RB	O
favour	VBP	O
one	CD	O
instrument	NN	O
above	IN	O
the	DT	O
other	JJ	O
,	,	O
the	DT	O
choice	NN	O
between	IN	O
the	DT	O
CRQ	NNP	O
and	CC	O
the	DT	O
SGRQ	NNP	O
can	MD	O
be	VB	O
based	VBN	O
on	IN	O
other	JJ	O
considerations	NNS	O
such	JJ	O
as	IN	O
the	DT	O
required	JJ	O
sample	NN	O
size	NN	O
or	CC	O
the	DT	O
availability	NN	O
of	IN	O
reference	NN	O
values	NNS	O
.	.	O

Levels	NNS	O
of	IN	O
recombinant	JJ	O
human	JJ	O
granulocyte	NN	O
colony-stimulating	NN	O
factor	NN	O
in	IN	O
serum	NN	O
are	VBP	O
inversely	RB	O
correlated	VBN	O
with	IN	O
circulating	VBG	O
neutrophil	JJ	O
counts	NNS	O
.	.	O

Recombinant	NNP	O
human	JJ	O
granulocyte	NN	O
colony-stimulating	NN	O
factor	NN	O
(	(	O
rhG-CSF	NN	O
)	)	O
is	VBZ	O
effective	JJ	O
in	IN	O
countering	VBG	O
chemotherapy-induced	JJ	O
neutropenia	NN	O
.	.	O

However	RB	O
,	,	O
serum	JJ	O
rhG-CSF	NN	O
levels	NNS	O
can	MD	O
not	RB	O
be	VB	O
maintained	VBN	O
throughout	IN	O
the	DT	O
course	NN	O
of	IN	O
rhG-CSF	JJ	O
therapy	NN	O
.	.	O

The	DT	O
drop	NN	O
in	IN	O
serum	JJ	O
rhG-CSF	JJ	O
levels	NNS	O
may	MD	O
vary	VB	O
with	IN	O
the	DT	O
duration	NN	O
of	IN	O
rhG-CSF	JJ	O
administration	NN	O
or	CC	O
with	IN	O
the	DT	O
circulating	VBG	O
neutrophil	JJ	O
counts	NNS	O
.	.	O

We	PRP	O
investigated	VBD	O
the	DT	O
relationship	NN	O
between	IN	O
serum	JJ	O
G-CSF	NNP	O
levels	NNS	O
and	CC	O
circulating	VBG	O
neutrophil	JJ	O
counts	NNS	O
and	CC	O
the	DT	O
pharmacokinetics	NNS	O
of	IN	O
rhG-CSF	NN	O
for	IN	O
patients	NNS	O
with	IN	O
lung	NN	C
cancer	NN	C
who	WP	O
had	VBD	O
been	VBN	O
treated	VBN	C
with	IN	C
myelosuppressive	JJ	C
chemotherapy	NN	C
and	CC	C
then	RB	C
with	IN	C
subcutaneous	JJ	C
rhG-CSF	NN	C
(	(	C
lenograstim	NN	C
,	,	C
2	CD	C
micrograms	NNS	C
per	IN	C
kg	NN	C
of	IN	C
body	NN	C
weight	JJ	C
per	IN	C
day	NN	C
)	)	C
.	.	O

Twelve	CD	SS
patients	NNS	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
four	CD	O
groups	NNS	O
with	IN	O
different	JJ	O
rhG-CSF	JJ	O
therapy	NN	O
schedules	NNS	O
.	.	O

Serum	NNP	O
G-CSF	JJ	O
levels	NNS	O
were	VBD	O
measured	VBN	O
by	IN	O
an	DT	O
enzyme	JJ	O
immunoassay	NN	O
method	NN	O
.	.	O

Serum	NNP	O
G-CSF	NNP	O
levels	NNS	O
during	IN	O
the	DT	O
rhG-CSF	JJ	O
therapy	NN	O
greatly	RB	O
exceeded	VBD	O
endogenous	JJ	O
G-CSF	NNP	O
levels	NNS	O
and	CC	O
were	VBD	O
mainly	RB	O
due	JJ	O
to	TO	O
the	DT	O
presence	NN	O
of	IN	O
exogenous	JJ	O
rhG-CSF	NN	O
rather	RB	O
than	IN	O
increased	VBN	O
levels	NNS	O
of	IN	O
endogenous	JJ	O
G-CSF	NNP	O
.	.	O

Despite	IN	O
the	DT	O
duration	NN	O
of	IN	O
rhG-CSF	JJ	O
administration	NN	O
,	,	O
serum	JJ	O
G-CSF	NNP	O
levels	NNS	O
during	IN	O
rhG-CSF	JJ	O
therapy	NN	O
were	VBD	O
inversely	RB	O
correlated	VBN	O
with	IN	O
circulating	VBG	O
neutrophil	JJ	O
counts	NNS	O
(	(	O
r2	VB	O
=	RB	O
0.73	CD	O
,	,	O
P	NNP	O
<	NNP	O
0.0001	CD	O
)	)	O
.	.	O

The	DT	O
value	NN	O
for	IN	O
the	DT	O
area	NN	O
under	IN	O
the	DT	O
concentration-time	JJ	O
curve	NN	O
of	IN	O
rhG-CSF	NN	O
on	IN	O
the	DT	O
day	NN	O
of	IN	O
neutrophilia	NN	O
was	VBD	O
lower	JJR	O
than	IN	O
that	DT	O
on	IN	O
the	DT	O
day	NN	O
of	IN	O
neutropenia	NN	O
(	(	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
.	.	O

Our	PRP$	O
results	NNS	O
suggest	VBP	O
that	IN	O
the	DT	O
fall	NN	O
in	IN	O
serum	JJ	O
G-CSF	NNP	O
levels	NNS	O
during	IN	O
rhG-CSF	JJ	O
therapy	NN	O
may	MD	O
result	VB	O
from	IN	O
increased	VBN	O
clearance	NN	O
and/or	NN	O
decreased	VBD	O
absorption	NN	O
of	IN	O
rhG-CSF	NN	O
,	,	O
two	CD	O
processes	NNS	O
related	VBN	O
to	TO	O
circulating	VBG	O
neutrophil	JJ	O
counts	NNS	O
.	.	O

Measuring	VBG	O
the	DT	O
impact	NN	O
of	IN	O
patient	JJ	O
counseling	NN	O
in	IN	O
the	DT	O
outpatient	JJ	O
pharmacy	NN	O
setting	NN	O
:	:	O
the	DT	O
research	NN	O
design	NN	O
of	IN	O
the	DT	O
Kaiser	NNP	O
Permanente/USC	NNP	O
patient	NN	O
consultation	NN	O
study	NN	O
.	.	O

This	DT	O
article	NN	O
describes	VBZ	O
the	DT	O
research	NN	O
method	NN	O
used	VBN	O
to	TO	O
measure	VB	O
the	DT	O
impact	NN	O
of	IN	O
three	CD	O
alternative	JJ	O
models	NNS	O
of	IN	O
patient	JJ	O
counseling	NN	O
in	IN	O
the	DT	O
outpatient	JJ	O
pharmacy	NN	O
setting	VBG	O
.	.	O

The	DT	O
study	NN	O
was	VBD	O
conducted	VBN	O
in	IN	O
pharmacies	NNS	O
operated	VBN	O
by	IN	O
the	DT	O
Southern	NNP	O
California	NNP	O
region	NN	O
Kaiser	NNP	O
Permanente	NNP	O
Medical	NNP	O
Care	NNP	O
Program	NNP	O
.	.	O

Both	DT	O
random	JJ	O
assignment	NN	O
and	CC	O
large-scale	JJ	O
geographic	JJ	O
area	NN	O
research	NN	O
designs	NNS	O
were	VBD	O
used	VBN	O
.	.	O

The	DT	O
presentation	NN	O
of	IN	O
the	DT	O
research	NN	O
design	NN	O
includes	VBZ	O
discussions	NNS	O
of	IN	O
data	NNS	O
collection	NN	O
and	CC	O
patient	JJ	O
sampling	VBG	O
methods	NNS	O
;	:	O
the	DT	O
measurement	NN	O
of	IN	O
patient	JJ	O
outcomes	NNS	O
,	,	O
including	VBG	O
measures	NNS	O
of	IN	O
health	NN	O
care	NN	O
costs	NNS	O
and	CC	O
utilization	NN	O
,	,	O
patient	JJ	O
functional	JJ	O
status	NN	O
,	,	O
and	CC	O
quality	NN	O
of	IN	O
life	NN	O
.	.	O

Demographic	NNP	O
data	NNS	O
are	VBP	O
presented	VBN	O
for	IN	O
the	DT	O
study	NN	O
population	NN	O
,	,	O
including	VBG	O
an	DT	O
analysis	NN	O
of	IN	O
potential	JJ	O
biased	JJ	O
selection	NN	O
of	IN	O
patients	NNS	O
electing	VBG	O
to	TO	O
participate	VB	O
in	IN	O
random	JJ	O
assignment	NN	O
.	.	O

Data	NNS	O
are	VBP	O
also	RB	O
presented	VBN	O
documenting	VBG	O
potential	JJ	O
selection	NN	O
bias	NN	O
across	IN	O
geographically	RB	O
determined	VBN	O
treatment	NN	O
groups	NNS	O
in	IN	O
the	DT	O
geographic	JJ	O
area	NN	O
design	NN	O
arm	NN	O
.	.	O

Finally	RB	O
,	,	O
the	DT	O
article	NN	O
presents	VBZ	O
the	DT	O
analysis	NN	O
plan	NN	O
for	IN	O
the	DT	O
study	NN	O
and	CC	O
discusses	NNS	O
study	VBP	O
limitations	NNS	O
.	.	O

Randomised	VBN	O
trial	NN	O
of	IN	O
efficacy	NN	O
and	CC	O
safety	NN	O
of	IN	O
oral	JJ	O
ganciclovir	NN	O
in	IN	O
the	DT	O
prevention	NN	O
of	IN	O
cytomegalovirus	NN	O
disease	NN	O
in	IN	O
liver-transplant	JJ	C
recipients	NNS	O
.	.	O

The	DT	O
Oral	NNP	O
Ganciclovir	NNP	O
International	NNP	O
Transplantation	NNP	O
Study	NNP	O
Group	NNP	O
[	NNP	O
corrected	VBD	O
]	NNP	O
.	.	O

BACKGROUND	NNP	O
Cytomegalovirus	NNP	O
(	(	O
CMV	NNP	O
)	)	O
disease	NN	O
is	VBZ	O
a	DT	O
frequent	JJ	O
cause	NN	O
of	IN	O
serious	JJ	O
morbidity	NN	O
after	IN	O
solid-organ	JJ	O
transplantation	NN	O
.	.	O

The	DT	O
prophylactic	JJ	O
regimens	NNS	O
used	VBN	O
to	TO	O
prevent	VB	O
CMV	NNP	O
infection	NN	O
and	CC	O
disease	NN	O
have	VBP	O
shown	VBN	O
limited	JJ	O
benefit	NN	O
in	IN	O
seronegative	JJ	O
recipients	NNS	O
.	.	O

We	PRP	O
studied	VBD	O
the	DT	O
safety	NN	O
and	CC	O
efficacy	NN	O
of	IN	O
oral	JJ	O
ganciclovir	NN	O
in	IN	O
the	DT	O
prevention	NN	O
of	IN	O
CMV	NNP	O
disease	NN	O
following	VBG	O
orthotopic	NN	O
liver	JJ	O
transplantation	NN	O
.	.	O

METHODS	NNP	O
Between	NNP	O
December	NNP	O
,	,	O
1993	CD	O
,	,	O
and	CC	O
April	NNP	O
,	,	O
1995	CD	O
,	,	O
304	CD	SS
liver-transplant	JJ	O
recipients	NNS	O
were	VBD	O
randomised	VBN	O
to	TO	O
receive	VB	O
oral	JJ	O
ganciclovir	NN	O
1000	CD	O
mg	NN	O
or	CC	O
matching	VBG	O
placebo	NN	O
three	CD	O
times	NNS	O
a	DT	O
day	NN	O
.	.	O

Seronegative	JJ	O
recipients	NNS	O
of	IN	O
seronegative	JJ	C
livers	NNS	C
were	VBD	O
excluded	VBN	O
.	.	O

Study	NNP	O
drug	NN	O
was	VBD	O
administered	VBN	O
as	RB	O
soon	RB	O
as	IN	O
the	DT	O
patient	NN	O
was	VBD	O
able	JJ	O
to	TO	O
take	VB	O
medication	NN	O
by	IN	O
mouth	NN	O
(	(	O
no	DT	O
later	RB	O
than	IN	O
day	NN	O
10	CD	O
)	)	O
until	IN	O
the	DT	O
98th	CD	O
day	NN	O
after	IN	O
transplantation	NN	O
.	.	O

Patients	NNS	O
were	VBD	O
assessed	VBN	O
at	IN	O
specified	VBN	O
times	NNS	O
throughout	IN	O
the	DT	O
first	JJ	O
6	CD	O
months	NNS	O
after	IN	O
surgery	NN	O
for	IN	O
evidence	NN	O
of	IN	O
CMV	NNP	O
infection	NN	O
,	,	O
CMV	NNP	O
disease	NN	O
,	,	O
rejection	NN	O
,	,	O
opportunistic	JJ	O
infections	NNS	O
,	,	O
and	CC	O
possible	JJ	O
drug	NN	O
toxicity	NN	O
.	.	O

FINDINGS	IN	O
The	DT	O
Kaplan-Meier	NNP	O
estimate	NN	O
of	IN	O
the	DT	O
6-month	JJ	O
incidence	NN	O
of	IN	O
CMV	NNP	O
disease	NN	O
was	VBD	O
29	CD	O
(	(	O
18.9	CD	O
%	NN	O
)	)	O
of	IN	O
154	CD	O
in	IN	O
the	DT	O
placebo	NN	O
group	NN	O
,	,	O
compared	VBN	O
with	IN	O
seven	CD	O
(	(	O
4.8	CD	O
%	NN	O
)	)	O
of	IN	O
150	CD	O
in	IN	O
the	DT	O
ganciclovir	NN	O
group	NN	O
(	(	O
p	JJ	O
<	NNP	O
0.001	CD	O
)	)	O
.	.	O

In	IN	O
the	DT	O
high-risk	JJ	O
group	NN	O
of	IN	O
seronegative	JJ	O
recipients	NNS	O
(	(	O
R-	NNP	O
)	)	O
of	IN	O
seropositive	JJ	O
livers	NNS	O
(	(	O
D+	NNP	O
)	)	O
,	,	O
incidence	NN	O
of	IN	O
CMV	NNP	O
disease	NN	O
was	VBD	O
11	CD	O
(	(	O
44.0	CD	O
%	NN	O
)	)	O
of	IN	O
25	CD	O
in	IN	O
the	DT	O
placebo	NN	O
group	NN	O
,	,	O
three	CD	O
(	(	O
14.8	CD	O
%	NN	O
)	)	O
of	IN	O
21	CD	O
in	IN	O
the	DT	O
ganciclovir	NN	O
group	NN	O
(	(	O
p	JJ	O
=	NNP	O
0.02	CD	O
)	)	O
.	.	O

Significant	JJ	O
benefit	NN	O
was	VBD	O
also	RB	O
observed	VBN	O
in	IN	O
those	DT	O
receiving	VBG	O
antibodies	NNS	O
to	TO	O
lymphocytes	NNS	O
,	,	O
where	WRB	O
the	DT	O
incidence	NN	O
of	IN	O
CMV	NNP	O
disease	NN	O
was	VBD	O
12	CD	O
(	(	O
32.9	CD	O
%	NN	O
)	)	O
of	IN	O
37	CD	O
in	IN	O
the	DT	O
placebo	NN	O
group	NN	O
and	CC	O
two	CD	O
(	(	O
4.6	CD	O
%	NN	O
)	)	O
of	IN	O
44	CD	O
in	IN	O
the	DT	O
ganciclovir	NN	O
group	NN	O
(	(	O
p	JJ	O
=	NNP	O
0.002	CD	O
)	)	O
.	.	O

Oral	JJ	O
ganciclovir	NN	O
reduced	VBD	O
the	DT	O
incidence	NN	O
of	IN	O
CMV	NNP	O
infection	NN	O
(	(	O
placebo	JJ	O
79	CD	O
[	JJ	O
51.5	CD	O
%	NN	O
]	NN	O
of	IN	O
154	CD	O
;	:	O
ganciclovir	CC	O
37	CD	O
[	JJ	O
24.5	CD	O
%	NN	O
]	NN	O
of	IN	O
150	CD	O
;	:	O
p	NN	O
<	VBZ	O
0.001	CD	O
)	)	O
and	CC	O
also	RB	O
reduced	VBN	O
symptomatic	JJ	O
herpes-simplex	JJ	O
infections	NNS	O
(	(	O
Kaplan-Meier	NNP	O
estimates	NNS	O
:	:	O
placebo	NN	O
36	CD	O
[	JJ	O
23.5	CD	O
%	NN	O
]	NN	O
of	IN	O
154	CD	O
;	:	O
ganciclovir	JJ	O
five	CD	O
[	JJ	O
3.5	CD	O
%	NN	O
]	NN	O
of	IN	O
150	CD	O
;	:	O
p	NN	O
<	VBZ	O
0.001	CD	O
)	)	O
.	.	O

INTERPRETATION	NNP	O
Oral	NNP	O
ganciclovir	NN	O
is	VBZ	O
a	DT	O
safe	JJ	O
and	CC	O
effective	JJ	O
method	NN	O
for	IN	O
the	DT	O
prevention	NN	O
of	IN	O
CMV	NNP	O
disease	NN	O
after	IN	O
orthotopic	NN	O
liver	NN	C
transplantation	NN	C
.	.	O

Scales	NNS	O
for	IN	O
the	DT	O
assessment	NN	O
of	IN	O
neuroleptic	JJ	O
response	NN	O
in	IN	O
schizophrenic	JJ	C
children	NNS	A
:	:	O
specific	JJ	O
measures	NNS	O
derived	VBN	O
from	IN	O
the	DT	O
CPRS	NNP	O
.	.	O

This	DT	O
article	NN	O
reports	VBZ	O
the	DT	O
psychometric	JJ	O
properties	NNS	O
of	IN	O
two	CD	O
scales	NNS	O
for	IN	O
rating	NN	O
positive	JJ	O
and	CC	O
negative	JJ	O
schizophrenic	JJ	O
signs	NNS	O
and	CC	O
symptoms	NNS	O
.	.	O

These	DT	O
Positive	NNP	O
and	CC	O
Negative	NNP	O
Syndrome	NNP	O
Scales	NNP	O
consist	NN	O
of	IN	O
items	NNS	O
selected	VBN	O
from	IN	O
the	DT	O
Children	NNP	O
's	POS	O
Psychiatric	NNP	O
Rating	NNP	O
Scale	NNP	O
(	(	O
CPRS	NNP	O
)	)	O
,	,	O
which	WDT	O
contains	VBZ	O
items	NNS	O
covering	VBG	O
a	DT	O
wide	JJ	O
range	NN	O
of	IN	O
childhood	NN	O
psychopathology	NN	O
.	.	O

CPRS	NNP	O
rating	NN	O
data	NNS	O
were	VBD	O
analyzed	VBN	O
for	IN	O
19	CD	SS
schizophrenic	JJ	C
children	NNS	A
,	,	O
16	CD	SS
males	NNS	SE
and	CC	O
3	CD	SS
females	NNS	SE
,	,	O
mean	JJ	A
age	NN	A
8.9	CD	A
years	NNS	A
(	(	O
range	VB	O
5.5-11.7	NNP	A
)	)	O
,	,	O
evaluated	VBN	O
in	IN	O
a	DT	O
double-blind	JJ	O
,	,	O
placebo-controlled	JJ	O
crossover	NN	O
study	NN	O
of	IN	O
haloperidol	NN	O
.	.	O

We	PRP	O
describe	VBP	O
the	DT	O
item	NN	O
composition	NN	O
and	CC	O
coherence	NN	O
of	IN	O
each	DT	O
scale	NN	O
,	,	O
the	DT	O
interrater	NN	O
reliabilities	NNS	O
of	IN	O
clinicians	NNS	O
using	VBG	O
the	DT	O
scales	NNS	O
,	,	O
and	CC	O
the	DT	O
sensitivity	NN	O
of	IN	O
the	DT	O
scales	NNS	O
for	IN	O
resolving	VBG	O
treatment	NN	O
response	NN	O
.	.	O

Schizophrenic	JJ	C
children	NNS	A
showed	VBD	O
both	DT	O
positive	JJ	O
and	CC	O
negative	JJ	O
signs	NNS	O
and	CC	O
symptoms	NNS	O
,	,	O
and	CC	O
both	DT	O
improved	VBN	O
with	IN	O
neuroleptic	JJ	O
treatment	NN	O
.	.	O

Suppression	NN	O
of	IN	O
immediate	JJ	O
and	CC	O
late	JJ	O
anti-IgE-induced	JJ	O
skin	NN	O
reactions	NNS	O
by	IN	O
topically	RB	O
applied	VBN	O
alcohol/onion	NN	O
extract	NN	O
.	.	O

In	IN	O
a	DT	O
double	JJ	O
blind	NN	O
study	NN	O
,	,	O
alcohol/onion	NN	O
extract	NN	O
(	(	O
5	CD	O
%	NN	O
ethanol	NN	O
)	)	O
was	VBD	O
injected	VBN	O
simultaneously	RB	O
with	IN	O
20	CD	O
IU	NNP	O
and	CC	O
200	CD	O
IU	NNP	O
rabbit	NN	O
anti-human-IgE	JJ	O
intradermally	RB	O
in	IN	O
12	CD	O
adult	NN	O
volunteers	NNS	O
(	(	O
6	CD	O
atopics	NNS	O
,	,	O
6	CD	O
non-atopics	NNS	O
)	)	O
.	.	O

Diameters	NNS	O
of	IN	O
wheals	NNS	O
and	CC	O
flares	NNS	O
were	VBD	O
measured	VBN	O
10	CD	O
min	NN	O
after	IN	O
and	CC	O
compared	VBN	O
with	IN	O
control	NN	O
sites	NNS	O
challenged	VBD	O
with	IN	O
20	CD	O
IU	NNP	O
and	CC	O
200	CD	O
IU	NNP	O
anti-IgE	NN	O
in	IN	O
a	DT	O
5	CD	O
%	NN	O
ethanol	JJ	O
solution	NN	O
.	.	O

The	DT	O
skin	NN	O
sites	NNS	O
were	VBD	O
then	RB	O
treated	VBN	O
epidermally	RB	O
with	IN	O
45	CD	O
%	NN	O
alcohol/onion	NN	O
extract	NN	O
and	CC	O
45	CD	O
%	NN	O
ethanol	NN	O
under	IN	O
occlusion	NN	O
.	.	O

Diameters	NNS	O
of	IN	O
late	JJ	O
cutaneous	JJ	O
reactions	NNS	O
were	VBD	O
measured	VBN	O
hourly	RB	O
.	.	O

Oedema	NNP	O
formation	NN	O
was	VBD	O
clinically	RB	O
estimated	VBN	O
according	VBG	O
to	TO	O
an	DT	O
arbitrary	JJ	O
scale	NN	O
and	CC	O
skin	NN	O
thickness	NN	O
measured	VBN	O
with	IN	O
a	DT	O
calliper	NN	O
.	.	O

In	IN	O
the	DT	O
onion-treated	JJ	O
skin	NN	O
sites	VBZ	O
the	DT	O
wheal	JJ	O
areas	NNS	O
were	VBD	O
significantly	RB	O
reduced	VBN	O
(	(	O
20	CD	O
IU	NNP	O
:	:	O
control	NN	O
:	:	O
108	CD	O
+/-	JJ	O
53	CD	O
mm2	NN	O
;	:	O
onion	NN	O
69	CD	O
+/-	JJ	O
42	CD	O
mm2	NN	O
,	,	O
P	NNP	O
less	JJR	O
than	IN	O
0.05	CD	O
;	:	O
200	CD	O
IU	NNP	O
anti-IgE	JJ	O
:	:	O
control	NN	O
:	:	O
152	CD	O
+/-	JJ	O
25	CD	O
mm2	NN	O
,	,	O
onion	NN	O
:	:	O
138	CD	O
+/-	JJ	O
26	CD	O
mm2	NN	O
,	,	O
P	NNP	O
less	JJR	O
than	IN	O
0.02	CD	O
)	)	O
.	.	O

The	DT	O
oedema	JJ	O
formation	NN	O
during	IN	O
the	DT	O
late	JJ	O
phase	NN	O
skin	JJ	O
reaction	NN	O
was	VBD	O
markedly	RB	O
depressed	JJ	O
(	(	O
P	NNP	O
less	JJR	O
than	IN	O
0.005	CD	O
at	IN	O
2	CD	O
h	NN	O
,	,	O
P	NNP	O
less	JJR	O
than	IN	O
0.01	CD	O
at	IN	O
4	CD	O
and	CC	O
6	CD	O
h	NN	O
,	,	O
P	NNP	O
less	JJR	O
than	IN	O
0.02	CD	O
at	IN	O
8	CD	O
h	NN	O
)	)	O
.	.	O

The	DT	O
extent	NN	O
of	IN	O
late	JJ	O
skin	NN	O
reactions	NNS	O
was	VBD	O
slightly	RB	O
,	,	O
but	CC	O
not	RB	O
significantly	RB	O
reduced	VBN	O
.	.	O

Obviously	RB	O
,	,	O
onions	NNS	O
contain	VBP	O
pharmacologically	RB	O
active	JJ	O
substances	NNS	O
with	IN	O
anti-inflammatory	JJ	O
and/or	NN	O
allergic	NN	O
properties	NNS	O
.	.	O

Supplementation	NN	O
with	IN	O
iron	NN	O
and	CC	O
riboflavin	NN	O
enhances	NNS	O
dark	JJ	O
adaptation	NN	O
response	NN	O
to	TO	O
vitamin	VB	O
A-fortified	NNP	O
rice	NN	O
in	IN	O
iron-deficient	JJ	C
,	,	C
pregnant	JJ	C
,	,	C
nightblind	JJ	C
Nepali	NNP	O
women	NNS	SE
.	.	O

BACKGROUND	NNP	O
Nightblindness	NNP	O
affects	VBZ	O
16-52	CD	O
%	NN	O
of	IN	O
pregnant	JJ	O
women	NNS	O
in	IN	O
areas	NNS	O
of	IN	O
Nepal	NNP	O
and	CC	O
in	IN	O
some	DT	O
cases	NNS	O
persists	NNS	O
after	IN	O
vitamin	VBG	O
A	DT	O
treatment	NN	O
.	.	O

Iron	NNP	O
and	CC	O
riboflavin	VB	O
affect	JJ	O
vitamin	NN	O
A	DT	O
utilization	NN	O
and	CC	O
photoreceptor	NN	O
function	NN	O
,	,	O
respectively	RB	O
,	,	O
and	CC	O
pilot	NN	O
data	NNS	O
in	IN	O
the	DT	O
study	NN	O
population	NN	O
showed	VBD	O
a	DT	O
high	JJ	O
prevalence	NN	O
of	IN	O
iron	NN	O
and	CC	O
riboflavin	NN	O
deficiencies	NNS	O
.	.	O

OBJECTIVE	IN	O
The	DT	O
objective	NN	O
was	VBD	O
to	TO	O
assess	VB	O
the	DT	O
effect	NN	O
of	IN	O
supplemental	JJ	O
iron	NN	O
and	CC	O
riboflavin	NN	O
on	IN	O
pupillary	JJ	O
threshold	NN	O
(	(	O
PT	NNP	O
)	)	O
and	CC	O
plasma	JJ	O
retinol	NN	O
in	IN	O
nightblind	NN	O
,	,	O
pregnant	JJ	C
Nepali	NNP	O
women	NNS	SE
given	VBN	O
vitamin	JJ	O
A-fortified	JJ	O
rice	NN	O
.	.	O

DESIGN	NNP	O
Nightblind	NNP	C
pregnant	JJ	O
women	NNS	SE
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
receive	VB	O
,	,	O
6	CD	O
d/wk	NN	O
under	IN	O
supervision	NN	O
for	IN	O
6	CD	O
wk	NN	O
,	,	O
a	DT	O
vitamin	JJ	O
A-fortified	JJ	O
rice	NN	O
curry	NN	O
dish	JJ	O
providing	VBG	O
850	CD	O
microg	JJ	O
retinal	JJ	O
activity	NN	O
equivalents/d	NN	O
with	IN	O
either	DT	O
a	DT	O
30-mg	JJ	O
Fe	NNP	O
and	CC	O
6-mg	JJ	O
riboflavin	NN	O
(	(	O
FeR	NNP	O
+	NNP	O
VA	NNP	O
)	)	O
capsule	NN	O
or	CC	O
a	DT	O
placebo	NN	O
control	NN	O
(	(	O
VA	NNP	O
only	RB	O
)	)	O
capsule	NN	O
.	.	O

Hemoglobin	NNP	O
,	,	O
erythrocyte	NN	O
riboflavin	NN	O
,	,	O
and	CC	O
plasma	NN	O
ferritin	NN	O
and	CC	O
retinol	NN	O
were	VBD	O
measured	VBN	O
before	IN	O
and	CC	O
after	IN	O
the	DT	O
intervention	NN	O
.	.	O

Dark	NNP	O
adaptation	NN	O
was	VBD	O
assessed	VBN	O
by	IN	O
PT	NNP	O
score	NN	O
.	.	O

RESULTS	NNP	O
Women	NNP	O
who	WP	O
were	VBD	O
iron	JJ	O
deficient	NN	O
at	IN	O
baseline	NN	O
(	(	O
n=38	JJ	O
)	)	O
had	VBD	O
significantly	RB	O
greater	JJR	O
improvement	NN	O
in	IN	O
PT	NNP	O
score	NN	O
with	IN	O
iron	NN	O
and	CC	O
riboflavin	NN	O
supplementation	NN	O
than	IN	O
without	IN	O
(	(	O
P=0.05	NNP	O
)	)	O
.	.	O

Iron	NNP	O
and	CC	O
riboflavin	JJ	O
supplements	NNS	O
significantly	RB	O
reduced	VBD	O
the	DT	O
prevalences	NNS	O
of	IN	O
riboflavin	JJ	O
deficiency	NN	O
(	(	O
from	IN	O
60	CD	O
%	NN	O
to	TO	O
6	CD	O
%	NN	O
;	:	O
P	NNP	O
<	NNP	O
0.0001	CD	O
)	)	O
,	,	O
iron	JJ	O
deficiency	NN	O
anemia	NN	O
(	(	O
from	IN	O
35	CD	O
%	NN	O
to	TO	O
15	CD	O
%	NN	O
;	:	O
P	NNP	O
<	NNP	O
0.007	CD	O
)	)	O
,	,	O
and	CC	O
abnormal	JJ	O
PT	NNP	O
(	(	O
from	IN	O
87	CD	O
%	NN	O
to	TO	O
30	CD	O
%	NN	O
;	:	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
from	IN	O
baseline	NN	O
.	.	O

Mean	JJ	O
increases	NNS	O
in	IN	O
erythrocyte	JJ	O
riboflavin	NN	O
(	(	O
P	NNP	O
<	NNP	O
0.0001	CD	O
)	)	O
and	CC	O
plasma	JJ	O
ferritin	NN	O
(	(	O
P=0.01	NNP	O
)	)	O
were	VBD	O
greater	JJR	O
in	IN	O
the	DT	O
FeR	NNP	O
+	NNP	O
VA	NNP	O
group	NN	O
than	IN	O
in	IN	O
the	DT	O
VA	NNP	O
only	RB	O
group	NN	O
.	.	O

CONCLUSIONS	NNP	O
Iron	NNP	O
deficiency	NN	O
may	MD	O
limit	VB	O
the	DT	O
efficacy	NN	O
of	IN	O
vitamin	NN	O
A	DT	O
to	TO	O
normalize	VB	O
dark	JJ	O
adaptation	NN	O
in	IN	O
pregnant	JJ	O
Nepali	NNP	O
women	NNS	O
.	.	O

Further	JJ	O
studies	NNS	O
are	VBP	O
needed	VBN	O
to	TO	O
assess	VB	O
the	DT	O
effect	NN	O
of	IN	O
simultaneous	JJ	O
delivery	NN	O
of	IN	O
iron	NN	O
and	CC	O
vitamin	VB	O
A	NNP	O
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
nightblindness	NN	O
.	.	O

Failure	NN	O
of	IN	O
lithium	NN	O
to	TO	O
reduce	VB	O
period	NN	O
of	IN	O
neutropenia	NN	O
during	IN	O
induction	NN	O
therapy	NN	O
of	IN	O
acute	JJ	C
myeloid	NN	C
leukemia	NN	C
.	.	O

Fifty-four	CD	SS
patients	NNS	O
treated	VBN	O
with	IN	O
daunorubicin	NN	C
,	,	O
cytosine	JJ	C
arabinoside	NN	C
and	CC	O
thioquanine	NN	C
for	IN	O
acute	JJ	C
myeloid	NN	C
leukemia	NN	C
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
receive	VB	O
oral	JJ	O
lithium	NN	O
carbonate	NN	O
1200	CD	O
mg	JJ	O
daily	JJ	O
or	CC	O
no	DT	O
lithium	NN	O
.	.	O

The	DT	O
duration	NN	O
of	IN	O
neutropenia	NN	O
(	(	O
less	JJR	O
than	IN	O
0.5	CD	O
x	JJ	O
10	CD	O
(	(	O
9	CD	O
)	)	O
/L	NN	O
)	)	O
was	VBD	O
similar	JJ	O
between	IN	O
controls	NNS	O
(	(	O
median	JJ	O
22.5	CD	O
days	NNS	O
)	)	O
and	CC	O
patients	NNS	O
treated	VBN	O
with	IN	O
lithium	NN	O
(	(	O
median	JJ	O
24	CD	O
days	NNS	O
)	)	O
.	.	O

The	DT	O
number	NN	O
of	IN	O
remissions	NNS	O
,	,	O
relapse-free	JJ	O
survival	NN	O
and	CC	O
survival	NN	O
were	VBD	O
similar	JJ	O
for	IN	O
the	DT	O
lithium	NN	O
treated	VBD	O
and	CC	O
control	VB	O
groups	NNS	O
of	IN	O
patients	NNS	O
.	.	O

There	EX	O
was	VBD	O
no	DT	O
apparent	JJ	O
clinical	JJ	O
efficacy	NN	O
in	IN	O
the	DT	O
use	NN	O
of	IN	O
lithium	NN	O
to	TO	O
reduce	VB	O
the	DT	O
period	NN	O
of	IN	O
neutropenia	NN	O
in	IN	O
patients	NNS	O
undergoing	JJ	O
remission	NN	C
induction	NN	C
therapy	NN	C
for	IN	O
acute	JJ	C
myeloid	NN	C
leukemia	NN	C
.	.	O

Deliberate	NNP	O
hypotension	NN	O
in	IN	O
patients	NNS	O
with	IN	O
intracranial	JJ	C
arteriovenous	JJ	C
malformations	NNS	C
:	:	O
esmolol	NN	O
compared	VBN	O
with	IN	O
isoflurane	NN	O
and	CC	O
sodium	NN	O
nitroprusside	RB	O
.	.	O

Thirty	JJ	SS
patients	NNS	O
undergoing	VBG	O
resection	NN	O
of	IN	O
arteriovenous	JJ	C
malformations	NNS	C
with	IN	O
deliberate	JJ	O
hypotension	NN	O
were	VBD	O
randomized	VBN	O
to	TO	O
receive	VB	O
1	CD	O
of	IN	O
3	CD	O
hypotensive	JJ	O
agents	NNS	O
.	.	O

Anesthesia	NNP	O
was	VBD	O
maintained	VBN	O
with	IN	O
isoflurane	NN	O
and	CC	O
nitrous	JJ	O
oxide	NN	O
in	IN	O
all	DT	O
patients	NNS	O
.	.	O

Mean	NNP	O
arterial	JJ	O
pressure	NN	O
was	VBD	O
reduced	VBN	O
20	CD	O
%	NN	O
to	TO	O
60-65	JJ	O
mm	NN	O
Hg	NNP	O
with	IN	O
use	NN	O
of	IN	O
either	DT	O
isoflurane	NN	O
(	(	O
less	JJR	O
than	IN	O
or	CC	O
equal	JJ	O
to	TO	O
4	CD	O
%	NN	O
)	)	O
,	,	O
sodium	JJ	O
nitroprusside	NN	O
(	(	O
less	JJR	O
than	IN	O
or	CC	O
equal	JJ	O
to	TO	O
8	CD	O
micrograms.kg-1.min-1	NN	O
)	)	O
,	,	O
or	CC	O
esmolol	NN	O
(	(	O
less	JJR	O
than	IN	O
or	CC	O
equal	JJ	O
to	TO	O
24	CD	O
mg/min	NN	O
)	)	O
.	.	O

Esmolol	NNP	O
was	VBD	O
associated	VBN	O
with	IN	O
a	DT	O
decrease	NN	O
in	IN	O
cardiac	JJ	O
output	NN	O
from	IN	O
6.2	CD	O
+/-	JJ	O
1.3	CD	O
to	TO	O
3.8	CD	O
+/-	JJ	O
0.8	CD	O
L/min	NNP	O
,	,	O
which	WDT	O
,	,	O
because	IN	O
of	IN	O
a	DT	O
22	CD	O
%	NN	O
increase	NN	O
in	IN	O
systemic	JJ	O
vascular	JJ	O
resistance	NN	O
,	,	O
far	RB	O
exceeded	VBD	O
the	DT	O
reduction	NN	O
in	IN	O
mean	JJ	O
arterial	JJ	O
pressure	NN	O
.	.	O

Systemic	NNP	O
vascular	JJ	O
resistance	NN	O
increased	VBD	O
despite	IN	O
a	DT	O
32	CD	O
%	NN	O
decrease	NN	O
in	IN	O
plasma	JJ	O
renin	NN	O
activity	NN	O
.	.	O

In	IN	O
contrast	NN	O
,	,	O
with	IN	O
sodium	JJ	O
nitroprusside	NN	O
or	CC	O
isoflurane	NN	O
,	,	O
the	DT	O
decrease	NN	O
in	IN	O
mean	JJ	O
arterial	JJ	O
pressure	NN	O
was	VBD	O
associated	VBN	O
with	IN	O
decreases	NNS	O
in	IN	O
systemic	JJ	O
vascular	JJ	O
resistance	NN	O
of	IN	O
similar	JJ	O
magnitude	NN	O
,	,	O
with	IN	O
no	DT	O
change	NN	O
in	IN	O
cardiac	JJ	O
output	NN	O
.	.	O

Plasma	NNP	O
renin	NN	O
activity	NN	O
levels	NNS	O
increased	VBD	O
48	CD	O
%	NN	O
with	IN	O
sodium	NN	O
nitroprusside	NN	O
and	CC	O
126	CD	O
%	NN	O
with	IN	O
isoflurane	NN	O
.	.	O

Heart	NNP	O
rate	NN	O
increased	VBD	O
13	CD	O
%	NN	O
with	IN	O
sodium	NN	O
nitroprusside	NN	O
,	,	O
remained	VBD	O
unchanged	JJ	O
with	IN	O
isoflurane	NN	O
,	,	O
and	CC	O
decreased	VBD	O
23	CD	O
%	NN	O
with	IN	O
esmolol	NN	O
.	.	O

Although	IN	O
esmolol	NN	O
may	MD	O
be	VB	O
used	VBN	O
as	IN	O
a	DT	O
primary	JJ	O
hypotensive	JJ	O
agent	NN	O
,	,	O
the	DT	O
potential	NN	O
for	IN	O
marked	JJ	O
myocardial	JJ	O
depression	NN	O
must	MD	O
be	VB	O
recognized	VBN	O
.	.	O

The	DT	O
differences	NNS	O
in	IN	O
pharmacologic	NN	O
properties	NNS	O
for	IN	O
the	DT	O
different	JJ	O
hypotensive	JJ	O
agents	NNS	O
suggest	VBP	O
that	IN	O
combinations	NNS	O
of	IN	O
these	DT	O
agents	NNS	O
may	MD	O
provide	VB	O
a	DT	O
pharmacologic	NN	O
profile	NN	O
superior	JJ	O
to	TO	O
either	DT	O
agent	NN	O
alone	RB	O
.	.	O

Single	NNP	O
and	CC	O
short-term	JJ	O
dosing	NN	O
effects	NNS	O
of	IN	O
levocetirizine	NN	O
on	IN	O
adenosine	JJ	O
monophosphate	NN	O
bronchoprovocation	NN	O
in	IN	O
atopic	NN	O
asthma	NN	O
.	.	O

AIMS	NNP	O
Adenosine	NNP	O
monophosphate	NN	O
(	(	O
AMP	NNP	O
)	)	O
acts	VBZ	O
indirectly	RB	O
via	IN	O
primed	VBN	O
airway	RB	O
mast	JJ	O
cells	NNS	O
to	TO	O
induce	VB	O
bronchial	JJ	O
hyper-responsiveness	NN	O
,	,	O
which	WDT	O
in	IN	O
turn	NN	O
correlates	NNS	O
with	IN	O
eosinophilic	JJ	O
asthmatic	JJ	O
inflammation	NN	O
and	CC	O
atopic	JJ	O
disease	NN	O
expression	NN	O
.	.	O

We	PRP	O
evaluated	VBD	O
single	JJ	O
and	CC	O
short-term	JJ	O
dosing	NN	O
effects	NNS	O
of	IN	O
a	DT	O
modern	JJ	O
histamine	NN	O
H1-receptor	NNP	O
antagonist	NN	O
,	,	O
levocetirizine	NN	O
,	,	O
given	VBN	O
at	IN	O
the	DT	O
usual	JJ	O
clinically	RB	O
recommended	VBD	O
dose	NN	O
,	,	O
on	IN	O
the	DT	O
primary	JJ	O
outcome	NN	O
of	IN	O
AMP	NNP	O
bronchoprovocation	NN	O
.	.	O

METHODS	NNP	O
Fifteen	NNP	SS
atopic	NN	C
asthmatics	NNS	C
were	VBD	O
randomized	VBN	O
in	IN	O
double-blind	NN	O
,	,	O
cross-over	JJ	O
fashion	NN	O
to	TO	O
receive	VB	O
for	IN	O
1	CD	O
week	NN	O
either	CC	O
levocetirizine	JJ	O
5	CD	O
mg	NN	O
or	CC	O
placebo	NN	O
.	.	O

There	EX	O
was	VBD	O
a	DT	O
1-week	JJ	O
washout	NN	O
period	NN	O
prior	RB	O
to	TO	O
each	DT	O
randomized	VBN	O
treatment	NN	O
.	.	O

The	DT	O
provocative	JJ	O
concentration	NN	O
of	IN	O
AMP	NNP	O
producing	VBG	O
a	DT	O
20	CD	O
%	NN	O
fall	NN	O
in	IN	O
FEV1	NNP	O
(	(	O
PC20	NNP	O
)	)	O
was	VBD	O
measured	VBN	O
after	IN	O
each	DT	O
washout	NN	O
at	IN	O
baseline	NN	O
and	CC	O
at	IN	O
4-6	JJ	O
h	NN	O
following	VBG	O
the	DT	O
first	JJ	O
and	CC	O
last	JJ	O
doses	NNS	O
of	IN	O
each	DT	O
randomized	VBN	O
treatment	NN	O
.	.	O

RESULTS	NNP	O
Baseline	NNP	O
mean	JJ	O
+/-	JJ	O
SEM	NNP	O
values	NNS	O
after	IN	O
washout	NN	O
prior	RB	O
to	TO	O
each	DT	O
randomized	VBN	O
treatment	NN	O
comparing	VBG	O
levocetirizine	JJ	O
vs	NN	O
placebo	NN	O
were	VBD	O
not	RB	O
significantly	RB	O
different	JJ	O
for	IN	O
prechallenge	NN	O
FEV1	NNP	O
(	(	O
%	NN	O
predicted	VBN	O
)	)	O
83	CD	O
+/-	JJ	O
4	CD	O
vs	JJ	O
82	CD	O
+/-	JJ	O
4	CD	O
,	,	O
or	CC	O
AMP	NNP	O
PC20	NNP	O
(	(	O
mg	JJ	O
ml	NN	O
(	(	O
-1	NNP	O
)	)	O
)	)	O
45	CD	O
+/-	JJ	O
24	CD	O
vs	JJ	O
45	CD	O
+/-	JJ	O
22	CD	O
,	,	O
respectively	RB	O
.	.	O

Airway	NNP	O
calibre	NN	O
as	IN	O
prechallenge	NN	O
FEV1	NNP	O
for	IN	O
levocetirizine	JJ	O
vs	NN	O
placebo	NN	O
was	VBD	O
not	RB	O
significantly	RB	O
different	JJ	O
following	VBG	O
the	DT	O
first	JJ	O
dose	JJ	O
86	CD	O
+/-	JJ	O
4	CD	O
vs	JJ	O
82	CD	O
+/-	JJ	O
4	CD	O
,	,	O
or	CC	O
the	DT	O
last	JJ	O
dose	JJ	O
85	CD	O
+/-	JJ	O
4	CD	O
vs	JJ	O
83	CD	O
+/-	JJ	O
4	CD	O
,	,	O
respectively	RB	O
.	.	O

There	EX	O
were	VBD	O
significant	JJ	O
improvements	NNS	O
(	(	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
in	IN	O
AMP	NNP	O
PC20	NNP	O
comparing	VBG	O
levocetirizine	JJ	O
vs	NN	O
placebo	NN	O
following	VBG	O
the	DT	O
first	JJ	O
dose	JJ	O
123	CD	O
+/-	JJ	O
73	CD	O
vs	JJ	O
48	CD	O
+/-	JJ	O
24	CD	O
,	,	O
a	DT	O
1.4	CD	O
doubling	VBG	O
dilution	NN	O
difference	NN	O
(	(	O
95	CD	O
%	NN	O
CI	NNP	O
0.8	CD	O
,	,	O
1.9	CD	O
)	)	O
,	,	O
and	CC	O
the	DT	O
last	JJ	O
dose	JJ	O
127	CD	O
+/-	JJ	O
74	CD	O
vs	JJ	O
53	CD	O
+/-	JJ	O
29	CD	O
,	,	O
a	DT	O
1.2	CD	O
doubling	VBG	O
dilution	NN	O
difference	NN	O
(	(	O
95	CD	O
%	NN	O
CI	NNP	O
0.5	CD	O
,	,	O
2.0	CD	O
)	)	O
.	.	O

AMP	NNP	O
PC20	NNP	O
was	VBD	O
also	RB	O
improved	VBN	O
(	(	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
by	IN	O
the	DT	O
first	JJ	O
and	CC	O
last	JJ	O
doses	NNS	O
of	IN	O
levocetirizine	NN	O
but	CC	O
not	RB	O
placebo	VB	O
,	,	O
vs	FW	O
respective	JJ	O
baseline	NN	O
values	NNS	O
,	,	O
with	IN	O
there	EX	O
being	VBG	O
no	DT	O
difference	NN	O
in	IN	O
the	DT	O
degree	NN	O
of	IN	O
protection	NN	O
between	IN	O
first	JJ	O
and	CC	O
last	JJ	O
doses	NNS	O
.	.	O

CONCLUSIONS	NNP	O
Single	NNP	O
and	CC	O
short-term	JJ	O
dosing	NN	O
with	IN	O
levocetirizine	NN	O
conferred	VBN	O
similar	JJ	O
improvements	NNS	O
in	IN	O
bronchial	JJ	O
hyper-responsiveness	NN	O
to	TO	O
AMP	NNP	O
challenge	NN	O
,	,	O
which	WDT	O
was	VBD	O
unrelated	JJ	O
to	TO	O
prechallenge	VB	O
airway	RB	O
calibre	NN	O
.	.	O

Further	JJ	O
studies	NNS	O
are	VBP	O
indicated	VBN	O
to	TO	O
evaluate	VB	O
the	DT	O
longer-term	JJ	O
effects	NNS	O
of	IN	O
levocetirizine	NN	O
on	IN	O
asthma	JJ	O
exacerbations	NNS	O
.	.	O

Playing	VBG	O
on	IN	O
the	DT	O
typewriter	NN	O
,	,	O
typing	VBG	O
on	IN	O
the	DT	O
piano	NN	O
:	:	O
manipulation	NN	O
knowledge	NN	O
of	IN	O
objects	NNS	O
.	.	O

Two	CD	O
experiments	NNS	O
investigated	VBD	O
sensory/motor-based	JJ	O
functional	JJ	O
knowledge	NN	O
of	IN	O
man-made	JJ	O
objects	NNS	O
:	:	O
manipulation	NN	O
features	NNS	O
associated	VBN	O
with	IN	O
the	DT	O
actual	JJ	O
usage	NN	O
of	IN	O
objects	NNS	O
.	.	O

In	IN	O
Experiment	JJ	O
1	CD	O
,	,	O
a	DT	O
series	NN	O
of	IN	O
prime-target	JJ	O
pairs	NNS	O
was	VBD	O
presented	VBN	O
auditorily	RB	O
,	,	O
and	CC	O
participants	NNS	O
were	VBD	O
asked	VBN	O
to	TO	O
make	VB	O
a	DT	O
lexical	JJ	O
decision	NN	O
on	IN	O
the	DT	O
target	NN	O
word	NN	O
.	.	O

Participants	NNS	O
made	VBD	O
a	DT	O
significantly	RB	O
faster	JJR	O
decision	NN	O
about	IN	O
the	DT	O
target	NN	O
word	NN	O
(	(	O
e.g	NN	O
.	.	O

'typewriter	CC	O
'	POS	O
)	)	O
following	VBG	O
a	DT	O
related	JJ	O
prime	NN	O
that	WDT	O
shared	VBD	O
manipulation	NN	O
features	NNS	O
with	IN	O
the	DT	O
target	NN	O
(	(	O
e.g	JJ	O
.	.	O

'piano	CC	O
'	POS	O
)	)	O
than	IN	O
an	DT	O
unrelated	JJ	O
prime	NN	O
(	(	O
e.g	NN	O
.	.	O

'blanket	CC	O
'	POS	O
)	)	O
.	.	O

In	IN	O
Experiment	JJ	O
2	CD	O
,	,	O
participants	NNS	O
'	POS	O
eye	NN	O
movements	NNS	O
were	VBD	O
monitored	VBN	O
when	WRB	O
they	PRP	O
viewed	VBD	O
a	DT	O
visual	JJ	O
display	NN	O
on	IN	O
a	DT	O
computer	NN	O
screen	NN	O
while	IN	O
listening	VBG	O
to	TO	O
a	DT	O
concurrent	JJ	O
auditory	NN	O
input	NN	O
.	.	O

Participants	NNS	O
were	VBD	O
instructed	VBN	O
to	TO	O
simply	RB	O
identify	VB	O
the	DT	O
auditory	NN	O
input	NN	O
and	CC	O
touch	VB	O
the	DT	O
corresponding	JJ	O
object	NN	O
on	IN	O
the	DT	O
computer	NN	O
display	NN	O
.	.	O

Participants	NNS	O
fixated	VBD	O
an	DT	O
object	JJ	O
picture	NN	O
(	(	O
e.g	JJ	O
.	.	O

typewriter	NN	O
)	)	O
related	VBN	O
to	TO	O
a	DT	O
target	NN	O
word	NN	O
(	(	O
e.g	NN	O
.	.	O

'piano	CC	O
'	POS	O
)	)	O
significantly	RB	O
more	RBR	O
often	RB	O
than	IN	O
an	DT	O
unrelated	JJ	O
object	JJ	O
picture	NN	O
(	(	O
e.g	JJ	O
.	.	O

bucket	NN	O
)	)	O
as	RB	O
well	RB	O
as	IN	O
a	DT	O
visually	RB	O
matched	VBN	O
control	NN	O
(	(	O
e.g	JJ	O
.	.	O

couch	NN	O
)	)	O
.	.	O

Results	NNS	O
of	IN	O
the	DT	O
two	CD	O
experiments	NNS	O
suggest	VBP	O
that	IN	O
manipulation	NN	O
knowledge	NN	O
of	IN	O
words	NNS	O
is	VBZ	O
retrieved	VBN	O
without	IN	O
conscious	JJ	O
effort	NN	O
and	CC	O
that	DT	O
manipulation	NN	O
knowledge	NN	O
constitutes	VBZ	O
a	DT	O
part	NN	O
of	IN	O
the	DT	O
lexical-semantic	JJ	O
representation	NN	O
of	IN	O
objects	NNS	O
.	.	O

Effect	NN	O
of	IN	O
laquinimod	NN	O
on	IN	O
MRI-monitored	JJ	O
disease	NN	O
activity	NN	O
in	IN	O
patients	NNS	C
with	IN	C
relapsing-remitting	JJ	C
multiple	JJ	C
sclerosis	NN	C
:	:	C
a	DT	C
multicentre	NN	C
,	,	O
randomised	VBN	O
,	,	O
double-blind	JJ	O
,	,	O
placebo-controlled	JJ	O
phase	NN	O
IIb	NNP	O
study	NN	O
.	.	O

BACKGROUND	VB	O
A	DT	O
24-week	JJ	O
phase	NN	O
II	NNP	O
trial	NN	O
has	VBZ	O
shown	VBN	O
that	IN	O
0.3	CD	O
mg	NN	O
of	IN	O
laquinimod	JJ	O
given	VBN	O
daily	JJ	O
to	TO	O
patients	NNS	O
with	IN	O
relapsing-remitting	JJ	O
multiple	JJ	O
sclerosis	NN	O
was	VBD	O
well	RB	O
tolerated	VBN	O
and	CC	O
reduced	VBN	O
the	DT	O
formation	NN	O
of	IN	O
active	JJ	O
lesions	NNS	O
.	.	O

We	PRP	O
assessed	VBD	O
the	DT	O
effect	NN	O
of	IN	O
oral	JJ	O
daily	JJ	O
0.3	CD	O
and	CC	O
0.6	CD	O
mg	NN	O
laquinimod	NN	O
on	IN	O
MRI-monitored	JJ	O
disease	NN	O
activity	NN	O
in	IN	O
a	DT	O
36-week	JJ	O
double-blind	NN	O
,	,	O
placebo-controlled	JJ	O
phase	NN	O
IIb	NNP	O
study	NN	O
.	.	O

METHODS	NNP	O
The	DT	O
study	NN	O
was	VBD	O
done	VBN	O
in	IN	O
51	CD	O
centres	NNS	O
in	IN	O
nine	CD	O
countries	NNS	O
.	.	O

Inclusion	NN	O
criteria	NNS	O
were	VBD	O
one	CD	O
or	CC	O
more	JJR	O
relapses	NNS	O
in	IN	O
the	DT	O
year	NN	O
before	IN	O
entry	NN	O
and	CC	O
at	IN	O
least	JJS	O
one	CD	O
gadolinium	NN	O
enhancing	NN	O
(	(	O
GdE	NNP	O
)	)	O
lesion	NN	O
on	IN	O
screening	VBG	O
MRI	NNP	O
.	.	O

Of	IN	O
720	CD	O
patients	NNS	O
screened	VBD	O
,	,	O
306	CD	SS
eligible	JJ	O
patients	NNS	O
were	VBD	O
enrolled	VBN	O
.	.	O

Patients	NNS	O
,	,	O
aged	VBN	O
18-50	CD	A
years	NNS	O
,	,	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
placebo	VB	O
(	(	O
n=102	NN	O
)	)	O
,	,	O
laquinimod	$	O
0.3	CD	O
mg	NN	O
a	DT	O
day	NN	O
(	(	O
n=98	NN	O
)	)	O
,	,	O
or	CC	O
0.6	CD	O
mg	NNS	O
a	DT	O
day	NN	O
(	(	O
n=106	JJ	O
)	)	O
.	.	O

Brain	NNP	O
MRI	NNP	O
scans	NNS	O
and	CC	O
clinical	JJ	O
assessments	NNS	O
were	VBD	O
done	VBN	O
at	IN	O
week	NN	O
-4	NN	O
,	,	O
baseline	NN	O
,	,	O
and	CC	O
monthly	RB	O
from	IN	O
week	NN	O
12	CD	O
to	TO	O
week	NN	O
36	CD	O
.	.	O

The	DT	O
primary	JJ	O
outcome	NN	O
was	VBD	O
the	DT	O
cumulative	JJ	O
number	NN	O
of	IN	O
GdE	NNP	O
lesions	NNS	O
at	IN	O
weeks	NNS	O
24	CD	O
,	,	O
28	CD	O
,	,	O
32	CD	O
,	,	O
and	CC	O
36	CD	O
.	.	O

The	DT	O
principal	JJ	O
analysis	NN	O
of	IN	O
the	DT	O
primary	JJ	O
endpoint	NN	O
was	VBD	O
done	VBN	O
on	IN	O
the	DT	O
intention-to-treat	JJ	O
cohort	NN	O
.	.	O

This	DT	O
study	NN	O
is	VBZ	O
registered	VBN	O
with	IN	O
ClinicalTrials.gov	NNP	O
,	,	O
number	NN	O
NCT00349193	NNP	O
.	.	O

FINDINGS	NNP	O
Compared	NNP	O
with	IN	O
placebo	NN	O
,	,	O
treatment	NN	O
with	IN	O
laquinimod	JJ	O
0.6	CD	O
mg	JJ	O
per	IN	O
day	NN	O
showed	VBD	O
a	DT	O
40.4	CD	O
%	NN	O
reduction	NN	O
of	IN	O
the	DT	O
baseline	NN	O
adjusted	VBN	O
mean	JJ	O
cumulative	JJ	O
number	NN	O
of	IN	O
GdE	NNP	O
lesions	NNS	O
per	IN	O
scan	NN	O
on	IN	O
the	DT	O
last	JJ	O
four	CD	O
scans	NNS	O
(	(	O
simple	JJ	O
means	VBZ	O
4.2	CD	O
[	NN	O
SD	NNP	O
9.2	CD	O
]	NNP	O
vs	NN	O
2.6	CD	O
[	NN	O
5.3	CD	O
]	NN	O
,	,	O
p=0.0048	NN	O
)	)	O
;	:	O
treatment	NN	O
with	IN	O
0.3	CD	O
mg	NNS	O
per	IN	O
day	NN	O
showed	VBD	O
no	DT	O
significant	JJ	O
effects	NNS	O
(	(	O
3.9	CD	O
[	RB	O
5.5	CD	O
]	JJ	O
vs	NN	O
placebo	NN	O
,	,	O
p=0.6740	NN	O
)	)	O
.	.	O

Both	DT	O
doses	NNS	O
of	IN	O
laquinimod	NN	O
were	VBD	O
well	RB	O
tolerated	VBN	O
,	,	O
with	IN	O
some	DT	O
transient	NN	O
and	CC	O
dose-dependent	JJ	O
increases	NNS	O
in	IN	O
liver	NN	O
enzymes	NNS	O
.	.	O

A	DT	O
case	NN	O
of	IN	O
Budd-Chiari	NNP	O
syndrome-ie	NN	O
,	,	O
a	DT	O
thrombotic	JJ	O
venous	JJ	O
outflow	JJ	O
obstruction	NN	O
of	IN	O
the	DT	O
liver-occurred	JJ	O
after	IN	O
1	CD	O
month	NN	O
of	IN	O
exposure	NN	O
in	IN	O
a	DT	O
patient	NN	O
with	IN	O
underlying	JJ	O
hypercoagulability	NN	O
who	WP	O
received	VBD	O
0.6	CD	O
mg	NN	O
laquinimod	NN	O
.	.	O

Anticoagulant	NNP	O
treatment	NN	O
resulted	VBD	O
in	IN	O
a	DT	O
decline	NN	O
of	IN	O
liver	NN	O
enzymes	NNS	O
to	TO	O
normal	JJ	O
without	IN	O
any	DT	O
clinical	JJ	O
signs	NNS	O
of	IN	O
hepatic	JJ	O
decompensation	NN	O
.	.	O

INTERPRETATION	NNP	O
In	IN	O
patients	NNS	O
with	IN	O
relapsing-remitting	JJ	O
multiple	JJ	O
sclerosis	NN	O
,	,	O
0.6	CD	O
mg	NNS	O
per	IN	O
day	NN	O
laquinimod	NN	O
significantly	RB	O
reduced	VBN	O
MRI-measured	JJ	O
disease	NN	O
activity	NN	O
and	CC	O
was	VBD	O
well	RB	O
tolerated	VBN	O
.	.	O

Abacavir	NNP	O
once	RB	O
or	CC	O
twice	RB	O
daily	RB	O
combined	VBN	O
with	IN	O
once-daily	JJ	O
lamivudine	NN	O
and	CC	O
efavirenz	NN	O
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
antiretroviral-naive	JJ	C
HIV-infected	JJ	C
adults	NNS	A
:	:	O
results	NNS	O
of	IN	O
the	DT	O
Ziagen	NNP	O
Once	NNP	O
Daily	NNP	O
in	IN	O
Antiretroviral	NNP	O
Combination	NNP	O
Study	NNP	O
.	.	O

The	DT	O
long	JJ	O
intracellular	JJ	O
half-life	NN	O
of	IN	O
abacavir	NN	O
(	(	O
ABC	NNP	O
)	)	O
supports	VBZ	O
its	PRP$	O
once-daily	JJ	O
use	NN	O
,	,	O
and	CC	O
this	DT	O
would	MD	O
be	VB	O
expected	VBN	O
to	TO	O
simplify	VB	O
treatment	NN	O
if	IN	O
ABC	NNP	O
could	MD	O
be	VB	O
given	VBN	O
as	IN	O
part	NN	O
of	IN	O
a	DT	O
complete	JJ	O
once-daily	JJ	O
regimen	NNS	O
.	.	O

A	DT	O
randomized	JJ	O
double-blind	JJ	O
clinical	JJ	O
trial	NN	O
compared	VBN	O
the	DT	O
efficacy	NN	O
and	CC	O
safety	NN	O
of	IN	O
600	CD	O
mg	NN	O
of	IN	O
ABC	NNP	O
administered	VBD	O
once	RB	O
daily	JJ	O
(	(	O
n	JJ	O
=	NNP	O
384	CD	O
)	)	O
versus	NN	O
300	CD	O
mg	NN	O
of	IN	O
ABC	NNP	O
administered	VBD	O
twice	RB	O
daily	JJ	O
(	(	O
n	JJ	O
=	NNP	O
386	CD	O
)	)	O
in	IN	O
combination	NN	O
with	IN	O
300	CD	O
mg	NNS	O
of	IN	O
lamivudine	NN	O
(	(	O
3TC	CD	O
)	)	O
and	CC	O
600	CD	O
mg	NN	O
of	IN	O
efavirenz	NN	O
(	(	O
EFV	NNP	O
)	)	O
administered	VBD	O
once	RB	O
daily	JJ	O
in	IN	O
antiretroviral-naive	JJ	C
patients	NNS	O
over	IN	O
48	CD	O
weeks	NNS	O
.	.	O

The	DT	O
baseline	NN	O
median	JJ	O
plasma	NN	O
HIV-1	NNP	O
RNA	NNP	O
level	NN	O
was	VBD	O
4.89	CD	O
log10	JJ	O
copies/mL	NN	O
(	(	O
44	CD	O
%	NN	O
with	IN	O
viral	JJ	O
load	NN	O
>	VBD	O
100,000	CD	O
copies/mL	NN	O
)	)	O
,	,	O
and	CC	O
the	DT	O
median	JJ	O
CD4	NNP	O
cell	NN	O
count	NN	O
was	VBD	O
262	CD	O
cells/mm	NN	O
.	.	O

ABC	NNP	O
administered	VBD	O
once	RB	O
daily	JJ	O
was	VBD	O
non-inferior	JJ	O
to	TO	O
the	DT	O
twice-daily	JJ	O
regimen	NNS	O
,	,	O
with	IN	O
66	CD	O
%	NN	O
and	CC	O
68	CD	O
%	NN	O
of	IN	O
patients	NNS	O
in	IN	O
these	DT	O
respective	JJ	O
treatment	NN	O
arms	NNS	O
achieving	VBG	O
a	DT	O
confirmed	JJ	O
plasma	NN	O
HIV-1	NNP	O
RNA	NNP	O
level	NN	O
<	VBD	O
50	CD	O
copies/mL	NN	O
(	(	O
95	CD	O
%	NN	O
confidence	NN	O
interval	NN	O
:	:	O
-8.4	CD	O
%	NN	O
,	,	O
4.9	CD	O
%	NN	O
)	)	O
.	.	O

The	DT	O
ABC	NNP	O
once-daily	JJ	O
and	CC	O
twice-daily	JJ	O
regimens	NNS	O
were	VBD	O
similar	JJ	O
with	IN	O
respect	NN	O
to	TO	O
infrequency	NN	O
of	IN	O
virologic	JJ	O
failure	NN	O
(	(	O
10	CD	O
%	NN	O
vs.	FW	O
8	CD	O
%	NN	O
)	)	O
,	,	O
emergence	NN	O
of	IN	O
resistance	NN	O
mutations	NNS	O
,	,	O
CD4	NNP	O
cell	NN	O
increases	NNS	O
from	IN	O
baseline	NN	O
(	(	O
median	JJ	O
,	,	O
188	CD	O
vs.	FW	O
200	CD	O
cells/mm	NN	O
)	)	O
,	,	O
safety	NN	O
profile	NN	O
,	,	O
and	CC	O
incidence	NN	O
of	IN	O
ABC-related	NNP	O
hypersensitivity	NN	O
reactions	NNS	O
(	(	O
9	CD	O
%	NN	O
vs.	FW	O
7	CD	O
%	NN	O
)	)	O
.	.	O

ABC	NNP	O
administered	VBD	O
once	RB	O
daily	JJ	O
in	IN	O
combination	NN	O
with	IN	O
3TC	CD	O
and	CC	O
EFV	NNP	O
administered	VBD	O
once	RB	O
daily	JJ	O
was	VBD	O
non-inferior	JJ	O
to	TO	O
the	DT	O
ABC	NNP	O
twice-daily	JJ	O
dosing	NN	O
schedule	NN	O
when	WRB	O
combined	VBN	O
with	IN	O
3TC	CD	O
and	CC	O
EFV	NNP	O
over	IN	O
48	CD	O
weeks	NNS	O
.	.	O

Delayed	VBN	O
alloimmunization	NN	O
using	VBG	O
random	JJ	O
single	JJ	O
donor	NN	O
platelet	NN	O
transfusions	NNS	O
:	:	O
a	DT	O
prospective	JJ	O
study	NN	O
in	IN	O
thrombocytopenic	JJ	C
patients	NNS	O
with	IN	O
acute	JJ	C
leukemia	NN	C
.	.	O

A	DT	O
randomized	JJ	O
study	NN	O
was	VBD	O
performed	VBN	O
in	IN	O
54	CD	SS
thrombocytopenic	JJ	C
patients	NNS	O
with	IN	O
acute	JJ	C
leukemia	NN	C
.	.	O

Alloimmunization	NN	O
of	IN	O
recipients	NNS	O
of	IN	O
random	JJ	O
multiple-donor	JJ	O
platelet	NN	O
concentrates	NNS	O
(	(	O
MD	NNP	O
group	NN	O
)	)	O
was	VBD	O
compared	VBN	O
to	TO	O
that	DT	O
of	IN	O
patients	NNS	O
receiving	VBG	O
random	JJ	O
single-donor	JJ	O
platelets	NNS	O
(	(	O
SD	NNP	O
group	NN	O
)	)	O
.	.	O

In	IN	O
the	DT	O
SD	NNP	O
patients	NNS	O
,	,	O
formation	NN	O
of	IN	O
alloantibodies	NNS	O
(	(	O
mostly	RB	O
anti-HLA	RB	O
)	)	O
occurred	VBD	O
less	RBR	O
frequently	RB	O
(	(	O
p	NN	O
less	JJR	O
than	IN	O
0.002	CD	O
)	)	O
,	,	O
after	IN	O
a	DT	O
longer	JJR	O
time	NN	O
period	NN	O
(	(	O
p	NN	O
less	JJR	O
than	IN	O
0.002	CD	O
)	)	O
,	,	O
and	CC	O
after	IN	O
a	DT	O
higher	JJR	O
number	NN	O
of	IN	O
transfusions	NNS	O
(	(	O
p	NN	O
less	JJR	O
than	IN	O
0.005	CD	O
)	)	O
as	IN	O
compared	VBN	O
to	TO	O
MD	NNP	O
patients	NNS	O
.	.	O

SD	NNP	O
patients	NNS	O
also	RB	O
became	VBD	O
refractory	JJ	O
to	TO	O
random	VB	O
platelets	NNS	O
less	RBR	O
frequently	RB	O
(	(	O
p	NN	O
less	JJR	O
than	IN	O
0.005	CD	O
)	)	O
,	,	O
after	IN	O
a	DT	O
longer	JJR	O
time	NN	O
period	NN	O
,	,	O
and	CC	O
after	IN	O
a	DT	O
higher	JJR	O
number	NN	O
of	IN	O
transfusions	NNS	O
(	(	O
p	NN	O
less	JJR	O
than	IN	O
0.02	CD	O
)	)	O
.	.	O

In	IN	O
SD	NNP	O
patients	NNS	O
,	,	O
the	DT	O
increments	NNS	O
after	IN	O
the	DT	O
first	JJ	O
and	CC	O
the	DT	O
last	JJ	O
transfusion	NN	O
were	VBD	O
in	IN	O
the	DT	O
same	JJ	O
range	NN	O
,	,	O
whereas	NNS	O
in	IN	O
MD	NNP	O
patients	NNS	O
,	,	O
the	DT	O
1-hr	JJ	O
(	(	O
p	NN	O
less	JJR	O
than	IN	O
0.001	CD	O
)	)	O
and	CC	O
the	DT	O
24-hr	JJ	O
(	(	O
p	NN	O
less	JJR	O
than	IN	O
0.025	CD	O
)	)	O
increments	NNS	O
decreased	VBN	O
from	IN	O
the	DT	O
first	JJ	O
to	TO	O
the	DT	O
last	JJ	O
transfusion	NN	O
.	.	O

Thus	RB	O
,	,	O
the	DT	O
use	NN	O
of	IN	O
random	NN	O
SD	NNP	O
platelet	NN	O
transfusions	NNS	O
postponed	VBD	O
alloimmunization	NN	O
.	.	O

Randomized	VBN	O
,	,	O
controlled	VBD	O
trial	NN	O
of	IN	O
an	DT	O
intervention	NN	O
for	IN	O
toddlers	NNS	A
with	IN	O
autism	NN	C
:	:	O
the	DT	O
Early	JJ	O
Start	NNP	O
Denver	NNP	O
Model	NNP	O
.	.	O

OBJECTIVE	NNP	O
To	TO	O
conduct	VB	O
a	DT	O
randomized	NN	O
,	,	O
controlled	VBD	O
trial	NN	O
to	TO	O
evaluate	VB	O
the	DT	O
efficacy	NN	O
of	IN	O
the	DT	O
Early	JJ	O
Start	NNP	O
Denver	NNP	O
Model	NNP	O
(	(	O
ESDM	NNP	O
)	)	O
,	,	O
a	DT	O
comprehensive	JJ	O
developmental	JJ	O
behavioral	JJ	O
intervention	NN	O
,	,	O
for	IN	O
improving	VBG	O
outcomes	NNS	O
of	IN	O
toddlers	NNS	A
diagnosed	VBN	O
with	IN	O
autism	NN	C
spectrum	NN	C
disorder	NN	C
(	(	C
ASD	NNP	C
)	)	C
.	.	O

METHODS	NNP	O
Forty-eight	JJ	SS
children	NNS	A
diagnosed	VBN	O
with	IN	O
ASD	NNP	C
between	IN	O
18	CD	A
and	CC	A
30	CD	A
months	NNS	A
of	IN	A
age	NN	A
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
1	CD	O
of	IN	O
2	CD	O
groups	NNS	O
:	:	O
(	(	O
1	CD	O
)	)	O
ESDM	NNP	O
intervention	NN	O
,	,	O
which	WDT	O
is	VBZ	O
based	VBN	O
on	IN	O
developmental	JJ	O
and	CC	O
applied	JJ	O
behavioral	JJ	O
analytic	JJ	O
principles	NNS	O
and	CC	O
delivered	VBN	O
by	IN	O
trained	JJ	O
therapists	NNS	O
and	CC	O
parents	NNS	O
for	IN	O
2	CD	O
years	NNS	O
;	:	O
or	CC	O
(	(	O
2	CD	O
)	)	O
referral	NN	O
to	TO	O
community	NN	O
providers	NNS	O
for	IN	O
intervention	NN	O
commonly	RB	O
available	JJ	O
in	IN	O
the	DT	O
community	NN	O
.	.	O

RESULTS	NNP	O
Compared	VBD	O
with	IN	O
children	NNS	O
who	WP	O
received	VBD	O
community-intervention	NN	O
,	,	O
children	NNS	O
who	WP	O
received	VBD	O
ESDM	NNP	O
showed	VBD	O
significant	JJ	O
improvements	NNS	O
in	IN	O
IQ	NNP	O
,	,	O
adaptive	JJ	O
behavior	NN	O
,	,	O
and	CC	O
autism	NN	O
diagnosis	NN	O
.	.	O

Two	CD	O
years	NNS	O
after	IN	O
entering	VBG	O
intervention	NN	O
,	,	O
the	DT	O
ESDM	NNP	O
group	NN	O
on	IN	O
average	NN	O
improved	VBD	O
17.6	CD	O
standard	NN	O
score	NN	O
points	NNS	O
(	(	O
1	CD	O
SD	NNP	O
:	:	O
15	CD	O
points	NNS	O
)	)	O
compared	VBN	O
with	IN	O
7.0	CD	O
points	NNS	O
in	IN	O
the	DT	O
comparison	NN	O
group	NN	O
relative	VBP	O
to	TO	O
baseline	VB	O
scores	NNS	O
.	.	O

The	DT	O
ESDM	NNP	O
group	NN	O
maintained	VBD	O
its	PRP$	O
rate	NN	O
of	IN	O
growth	NN	O
in	IN	O
adaptive	JJ	O
behavior	NN	O
compared	VBN	O
with	IN	O
a	DT	O
normative	JJ	O
sample	NN	O
of	IN	O
typically	RB	O
developing	VBG	O
children	NNS	O
.	.	O

In	IN	O
contrast	NN	O
,	,	O
over	IN	O
the	DT	O
2-year	JJ	O
span	NN	O
,	,	O
the	DT	O
comparison	NN	O
group	NN	O
showed	VBD	O
greater	JJR	O
delays	NNS	O
in	IN	O
adaptive	JJ	O
behavior	NN	O
.	.	O

Children	NNP	O
who	WP	O
received	VBD	O
ESDM	NNP	O
also	RB	O
were	VBD	O
more	RBR	O
likely	JJ	O
to	TO	O
experience	VB	O
a	DT	O
change	NN	O
in	IN	O
diagnosis	NN	O
from	IN	O
autism	NN	O
to	TO	O
pervasive	VB	O
developmental	JJ	O
disorder	NN	O
,	,	O
not	RB	O
otherwise	RB	O
specified	VBN	O
,	,	O
than	IN	O
the	DT	O
comparison	NN	O
group	NN	O
.	.	O

CONCLUSIONS	NNP	O
This	DT	O
is	VBZ	O
the	DT	O
first	JJ	O
randomized	VBN	O
,	,	O
controlled	VBN	O
trial	NN	O
to	TO	O
demonstrate	VB	O
the	DT	O
efficacy	NN	O
of	IN	O
a	DT	O
comprehensive	JJ	O
developmental	JJ	O
behavioral	JJ	O
intervention	NN	O
for	IN	O
toddlers	NNS	A
with	IN	O
ASD	NNP	C
for	IN	O
improving	VBG	O
cognitive	JJ	O
and	CC	O
adaptive	JJ	O
behavior	NN	O
and	CC	O
reducing	VBG	O
severity	NN	O
of	IN	O
ASD	NNP	O
diagnosis	NN	O
.	.	O

Results	NNS	O
of	IN	O
this	DT	O
study	NN	O
underscore	VBD	O
the	DT	O
importance	NN	O
of	IN	O
early	JJ	O
detection	NN	O
of	IN	O
and	CC	O
intervention	NN	O
in	IN	O
autism	NN	O
.	.	O

Effect	NN	O
of	IN	O
L-carnitine	NNP	O
on	IN	O
myocardial	JJ	O
metabolism	NN	O
:	:	O
results	NNS	O
of	IN	O
a	DT	O
balanced	JJ	O
,	,	O
placebo-controlled	JJ	O
,	,	O
double-blind	JJ	O
study	NN	O
in	IN	O
patients	NNS	O
undergoing	VBG	O
open	JJ	O
heart	NN	O
surgery	NN	O
.	.	O

The	DT	O
effects	NNS	O
of	IN	O
L-carnitine	NNP	O
on	IN	O
cardiac	JJ	O
performance	NN	O
after	IN	O
open	JJ	O
heart	NN	O
surgery	NN	O
were	VBD	O
evaluated	VBN	O
in	IN	O
a	DT	O
balanced	JJ	O
,	,	O
placebo-controlled	JJ	O
,	,	O
double-blind	JJ	O
study	NN	O
in	IN	O
38	CD	SS
patients	NNS	O
.	.	O

Preoperative	JJ	O
haemodynamic	JJ	O
status	NN	O
was	VBD	O
good	JJ	O
in	IN	O
all	DT	O
of	IN	O
them	PRP	O
.	.	O

Seventeen	JJ	O
subjects	NNS	O
underwent	JJ	O
mitral	JJ	O
valve	NN	O
replacement	NN	O
and	CC	O
19	CD	SS
patients	NNS	O
coronary	JJ	C
artery	JJ	C
bypass	NN	O
grafting	NN	O
.	.	O

Five	CD	O
grams	NNS	O
L-carnitine	JJ	O
were	VBD	O
given	VBN	O
intravenously	RB	O
over	IN	O
2	CD	O
h	NNS	O
,	,	O
twice	RB	O
daily	RB	O
for	IN	O
5	CD	O
consecutive	JJ	O
days	NNS	O
;	:	O
moreover	RB	O
,	,	O
10	CD	O
g	JJ	O
L-carnitine	NNP	O
in	IN	O
1500	CD	O
ml	NN	O
cardioplegia	NN	O
were	VBD	O
administered	VBN	O
through	IN	O
the	DT	O
aortic	JJ	O
root	NN	O
after	IN	O
aortic	JJ	O
cross-clamping	NN	O
.	.	O

Surgery	NN	O
was	VBD	O
always	RB	O
planned	VBN	O
on	IN	O
treatment	NN	O
day	NN	O
3	CD	O
.	.	O

The	DT	O
post-ischaemic	JJ	O
functional	JJ	O
recovery	NN	O
of	IN	O
the	DT	O
heart	NN	O
was	VBD	O
assessed	VBN	O
by	IN	O
clinical	JJ	O
parameters	NNS	O
,	,	O
as	RB	O
well	RB	O
as	IN	O
by	IN	O
biochemical	JJ	O
and	CC	O
ultrastructure	JJ	O
evaluations	NNS	O
on	IN	O
biopsy	NN	O
specimens	NNS	O
.	.	O

No	DT	O
differences	NNS	O
were	VBD	O
found	VBN	O
between	IN	O
the	DT	O
control	NN	O
and	CC	O
the	DT	O
treatment	NN	O
group	NN	O
with	IN	O
respect	NN	O
to	TO	O
all	DT	O
clinical	JJ	O
parameters	NNS	O
of	IN	O
cardiac	JJ	O
performance	NN	O
after	IN	O
cardiopulmonary	JJ	O
bypass	NN	O
.	.	O

At	IN	O
anaesthesia	JJ	O
induction	NN	O
,	,	O
serum	JJ	O
carnitine	NN	O
was	VBD	O
significantly	RB	O
increased	VBN	O
in	IN	O
treated	JJ	O
patients	NNS	O
,	,	O
but	CC	O
carnitine	JJ	O
concentrations	NNS	O
in	IN	O
the	DT	O
right	JJ	O
atrial	JJ	O
biopsy	NN	O
obtained	VBN	O
just	RB	O
before	RB	O
aortic	JJ	O
declamping	NN	O
were	VBD	O
similar	JJ	O
in	IN	O
the	DT	O
two	CD	O
groups	NNS	O
.	.	O

In	IN	O
patients	NNS	O
with	IN	O
mitral	JJ	O
valve	FW	O
replacement	NN	O
,	,	O
L-carnitine	JJ	O
therapy	NN	O
was	VBD	O
associated	VBN	O
with	IN	O
significantly	RB	O
higher	JJR	O
concentrations	NNS	O
of	IN	O
pyruvate	NN	O
,	,	O
ATP	NNP	O
and	CC	O
creatine	JJ	O
phosphate	NN	O
in	IN	O
papillary	JJ	O
muscle	NN	O
.	.	O

Glycogen	NN	O
levels	NNS	O
were	VBD	O
also	RB	O
higher	JJR	O
in	IN	O
the	DT	O
treated	JJ	O
group	NN	O
,	,	O
but	CC	O
the	DT	O
difference	NN	O
was	VBD	O
not	RB	O
statistically	RB	O
significant	JJ	O
.	.	O

Myocardial	JJ	O
ultrastructure	NN	O
on	IN	O
septal	JJ	O
biopsies	NNS	O
,	,	O
obtained	VBD	O
within	IN	O
5	CD	O
min	NN	O
from	IN	O
weaning	VBG	O
from	IN	O
extracorporeal	JJ	O
circulation	NN	O
,	,	O
showed	VBD	O
better	JJR	O
preservation	NN	O
scores	NNS	O
for	IN	O
all	DT	O
considered	VBN	O
parameters	NNS	O
(	(	O
nucleus	NN	O
,	,	O
sarcoplasmic	JJ	O
reticulum	NN	O
,	,	O
mitochondria	NN	O
and	CC	O
cellular	JJ	O
oedema	NN	O
)	)	O
in	IN	O
the	DT	O
treated	JJ	O
subjects	NNS	O
,	,	O
although	IN	O
the	DT	O
difference	NN	O
reached	VBD	O
statistical	JJ	O
significance	NN	O
only	RB	O
for	IN	O
nuclei	NN	O
.	.	O

When	WRB	O
biochemical	JJ	O
and	CC	O
ultrastructural	JJ	O
data	NNS	O
are	VBP	O
considered	VBN	O
,	,	O
these	DT	O
findings	NNS	O
suggest	VBP	O
that	IN	O
L-carnitine	NNP	O
improves	VBZ	O
myocardial	JJ	O
metabolism	NN	O
.	.	O

However	RB	O
,	,	O
it	PRP	O
can	MD	O
not	RB	O
be	VB	O
concluded	VBN	O
that	IN	O
L-carnitine	NNP	O
provides	VBZ	O
an	DT	O
advantageous	JJ	O
support	NN	O
therapy	NN	O
for	IN	O
well-compensated	JJ	O
patients	NNS	O
requiring	VBG	O
cardiac	JJ	O
surgery	NN	O
.	.	O

In	IN	O
contrast	NN	O
,	,	O
the	DT	O
positive	JJ	O
effects	NNS	O
of	IN	O
L-carnitine	NNP	O
on	IN	O
cardiac	JJ	O
recovery	NN	O
after	IN	O
bypass	NN	O
might	MD	O
become	VB	O
clinically	RB	O
relevant	JJ	O
in	IN	O
the	DT	O
surgical	JJ	O
setting	NN	O
for	IN	O
haemodynamically	RB	O
compromised	JJ	O
patients	NNS	O
,	,	O
in	IN	O
which	WDT	O
further	JJ	O
investigations	NNS	O
are	VBP	O
required	VBN	O
.	.	O

Effects	NNS	O
of	IN	O
a	DT	O
standardized	JJ	O
pamphlet	NN	O
on	IN	O
insomnia	NN	C
in	IN	O
children	NNS	A
with	IN	O
autism	NN	C
spectrum	NN	C
disorders	NNS	C
.	.	O

OBJECTIVE	NNP	O
Sleep	NNP	O
difficulties	NNS	O
are	VBP	O
common	JJ	O
reasons	NNS	O
why	WRB	O
parents	NNS	O
seek	VBP	O
medical	JJ	O
intervention	NN	O
in	IN	O
children	NNS	O
with	IN	O
autism	NN	C
spectrum	NN	C
disorders	NNS	C
(	(	C
ASDs	NNP	C
)	)	O
.	.	O

We	PRP	O
determined	VBD	O
whether	IN	O
a	DT	O
pamphlet	NN	O
alone	RB	O
could	MD	O
be	VB	O
used	VBN	O
by	IN	O
parents	NNS	O
to	TO	O
help	VB	O
their	PRP$	O
child	NN	O
's	POS	O
insomnia	NN	O
.	.	O

METHODS	NNP	O
Thirty-six	JJ	SS
children	NNS	A
with	IN	O
ASD	NNP	C
,	,	O
ages	VBZ	A
2	CD	A
to	TO	A
10	CD	A
years	NNS	A
,	,	O
were	VBD	O
enrolled	VBN	O
.	.	O

All	DT	O
had	VBD	O
prolonged	VBN	C
sleep	JJ	C
latency	NN	C
confirmed	VBN	O
by	IN	O
actigraphy	NN	O
showing	VBG	O
a	DT	O
mean	JJ	O
sleep	JJ	O
latency	NN	O
of	IN	O
30	CD	O
minutes	NNS	O
or	CC	O
more	JJR	O
.	.	O

Parents	NNS	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
receive	VB	O
the	DT	O
sleep	JJ	O
education	NN	O
pamphlet	NN	O
or	CC	O
no	DT	O
intervention	NN	O
.	.	O

Children	NNP	O
wore	VBD	O
an	DT	O
actigraphy	NN	O
device	NN	O
to	TO	O
record	VB	O
baseline	NN	O
sleep	JJ	O
parameters	NNS	O
,	,	O
with	IN	O
the	DT	O
primary	JJ	O
outcome	NN	O
variable	JJ	O
being	VBG	O
change	NN	O
in	IN	O
sleep	JJ	O
latency	NN	O
.	.	O

Actigraphy	NNP	O
data	NNS	O
were	VBD	O
collected	VBN	O
a	DT	O
second	JJ	O
time	NN	O
2	CD	O
weeks	NNS	O
after	IN	O
the	DT	O
parent	NN	O
received	VBD	O
the	DT	O
randomization	NN	O
assignment	NN	O
and	CC	O
analyzed	VBN	O
by	IN	O
using	VBG	O
Student	NNP	O
's	POS	O
t	JJ	O
test	NN	O
.	.	O

Parents	NNS	O
were	VBD	O
also	RB	O
asked	VBN	O
a	DT	O
series	NN	O
of	IN	O
questions	NNS	O
to	TO	O
gather	VB	O
information	NN	O
about	IN	O
the	DT	O
pamphlet	NN	O
and	CC	O
its	PRP$	O
usefulness	NN	O
.	.	O

RESULTS	NNP	O
Although	IN	O
participants	NNS	O
randomized	VBN	O
to	TO	O
the	DT	O
2	CD	O
arms	NNS	O
did	VBD	O
not	RB	O
differ	VB	O
statistically	RB	O
in	IN	O
age	NN	O
,	,	O
gender	NN	O
,	,	O
socioeconomic	JJ	O
status	NN	O
,	,	O
total	JJ	O
Children	NNP	O
's	POS	O
Sleep	NNP	O
Habits	NNP	O
Questionnaire	NNP	O
score	NN	O
,	,	O
or	CC	O
actigraphy	NN	O
parameters	NNS	O
,	,	O
some	DT	O
differences	NNS	O
may	MD	O
be	VB	O
large	JJ	O
enough	RB	O
to	TO	O
affect	VB	O
results	NNS	O
.	.	O

Mean	JJ	O
change	NN	O
in	IN	O
sleep-onset	JJ	O
latency	NN	O
did	VBD	O
not	RB	O
differ	VB	O
between	IN	O
the	DT	O
randomized	VBN	O
groups	NNS	O
(	(	O
pamphlet	VB	O
versus	NN	O
no	DT	O
pamphlet	NN	O
)	)	O
.	.	O

Parents	NNS	O
commented	VBD	O
that	IN	O
the	DT	O
pamphlet	NN	O
contained	VBD	O
good	JJ	O
information	NN	O
,	,	O
but	CC	O
indicated	VBD	O
that	IN	O
it	PRP	O
would	MD	O
have	VB	O
been	VBN	O
more	RBR	O
useful	JJ	O
to	TO	O
be	VB	O
given	VBN	O
specific	JJ	O
examples	NNS	O
of	IN	O
how	WRB	O
to	TO	O
take	VB	O
the	DT	O
information	NN	O
and	CC	O
put	VB	O
it	PRP	O
into	IN	O
practice	NN	O
.	.	O

CONCLUSIONS	VB	O
A	DT	O
sleep	JJ	O
education	NN	O
pamphlet	NN	O
did	VBD	O
not	RB	O
appear	VB	O
to	TO	O
improve	VB	O
sleep	JJ	C
latency	NN	C
in	IN	O
children	NNS	O
with	IN	O
ASDs	NNP	C
.	.	O

Safety	NN	O
and	CC	O
efficacy	NN	O
of	IN	O
dalcetrapib	NN	O
on	IN	O
atherosclerotic	JJ	O
disease	NN	O
using	VBG	O
novel	JJ	O
non-invasive	JJ	O
multimodality	NN	O
imaging	NN	O
(	(	O
dal-PLAQUE	JJ	O
)	)	O
:	:	O
a	DT	O
randomised	JJ	O
clinical	JJ	O
trial	NN	O
.	.	O

BACKGROUND	NNP	O
Dalcetrapib	NNP	O
modulates	VBZ	O
cholesteryl	VBP	O
ester	NN	O
transfer	NN	O
protein	NN	O
(	(	O
CETP	NNP	O
)	)	O
activity	NN	O
to	TO	O
raise	VB	O
high-density	NN	O
lipoprotein	NN	O
cholesterol	NN	O
(	(	O
HDL-C	NNP	O
)	)	O
.	.	O

After	IN	O
the	DT	O
failure	NN	O
of	IN	O
torcetrapib	NN	O
it	PRP	O
was	VBD	O
unknown	JJ	O
if	IN	O
HDL	NNP	O
produced	VBN	O
by	IN	O
interaction	NN	O
with	IN	O
CETP	NNP	O
had	VBD	O
pro-atherogenic	JJ	O
or	CC	O
pro-inflammatory	JJ	O
properties	NNS	O
.	.	O

dal-PLAQUE	NN	O
is	VBZ	O
the	DT	O
first	JJ	O
multicentre	NN	O
study	NN	O
using	VBG	O
novel	JJ	O
non-invasive	JJ	O
multimodality	NN	O
imaging	VBG	O
to	TO	O
assess	VB	O
structural	JJ	O
and	CC	O
inflammatory	JJ	O
indices	NNS	O
of	IN	O
atherosclerosis	NN	O
as	IN	O
primary	JJ	O
endpoints	NNS	O
.	.	O

METHODS	NNP	O
In	IN	O
this	DT	O
phase	NN	O
2b	CD	O
,	,	O
double-blind	NN	O
,	,	O
multicentre	JJ	O
trial	NN	O
,	,	O
patients	NNS	O
(	(	A
aged	VBN	A
18-75	CD	A
years	NNS	A
)	)	A
with	IN	C
,	,	C
or	CC	C
with	IN	C
high	JJ	C
risk	NN	C
of	IN	C
,	,	C
coronary	JJ	C
heart	NN	C
disease	NN	C
were	VBD	O
randomly	RB	O
assigned	VBN	O
(	(	O
1:1	CD	O
)	)	O
to	TO	O
dalcetrapib	VB	O
600	CD	O
mg/day	NN	O
or	CC	O
placebo	NN	O
for	IN	O
24	CD	O
months	NNS	O
.	.	O

Randomisation	NN	O
was	VBD	O
done	VBN	O
with	IN	O
a	DT	O
computer-generated	JJ	O
randomisation	NN	O
code	NN	O
and	CC	O
was	VBD	O
stratified	VBN	O
by	IN	O
centre	NN	O
.	.	O

Patients	NNS	O
and	CC	O
investigators	NNS	O
were	VBD	O
masked	VBN	O
to	TO	O
treatment	NN	O
.	.	O

Coprimary	JJ	O
endpoints	NNS	O
were	VBD	O
MRI-assessed	JJ	O
indices	NNS	O
(	(	O
total	JJ	O
vessel	NN	O
area	NN	O
,	,	O
wall	JJ	O
area	NN	O
,	,	O
wall	NN	O
thickness	NN	O
,	,	O
and	CC	O
normalised	VBD	O
wall	NN	O
index	NN	O
[	JJ	O
average	JJ	O
carotid	NN	O
]	NN	O
)	)	O
after	IN	O
24	CD	O
months	NNS	O
and	CC	O
(	(	O
18	CD	O
)	)	O
F-fluorodeoxyglucose	NNP	O
(	(	O
(	(	O
18	CD	O
)	)	O
F-FDG	NN	O
)	)	O
PET/CT	NNP	O
assessment	NN	O
of	IN	O
arterial	JJ	O
inflammation	NN	O
within	IN	O
an	DT	O
index	NN	O
vessel	NN	O
(	(	O
right	JJ	O
carotid	NN	O
,	,	O
left	VBD	O
carotid	NN	O
,	,	O
or	CC	O
ascending	VBG	O
thoracic	JJ	O
aorta	NN	O
)	)	O
after	IN	O
6	CD	O
months	NNS	O
,	,	O
with	IN	O
no-harm	JJ	O
boundaries	NNS	O
established	VBN	O
before	IN	O
unblinding	NN	O
of	IN	O
the	DT	O
trial	NN	O
.	.	O

Analysis	NN	O
was	VBD	O
by	IN	O
intention	NN	O
to	TO	O
treat	VB	O
.	.	O

This	DT	O
trial	NN	O
is	VBZ	O
registered	VBN	O
at	IN	O
ClinicalTrials.gov	NNP	O
,	,	O
NCT00655473	NNP	O
.	.	O

FINDINGS	NNP	O
189	CD	SS
patients	NNS	O
were	VBD	O
screened	VBN	O
and	CC	O
130	CD	SS
randomly	RB	O
assigned	VBN	SS
to	TO	O
placebo	VB	O
(	(	O
66	CD	SS
patients	NNS	O
)	)	O
or	CC	O
dalcetrapib	NN	O
(	(	O
64	CD	SS
patients	NNS	O
)	)	O
.	.	O

For	IN	O
the	DT	O
coprimary	JJ	O
MRI	NNP	O
and	CC	O
PET/CT	NNP	O
endpoints	NNS	O
,	,	O
CIs	NNP	O
were	VBD	O
below	IN	O
the	DT	O
no-harm	JJ	O
boundary	NN	O
or	CC	O
the	DT	O
adverse	JJ	O
change	NN	O
was	VBD	O
numerically	RB	O
lower	JJR	O
in	IN	O
the	DT	O
dalcetrapib	NN	O
group	NN	O
than	IN	O
in	IN	O
the	DT	O
placebo	NN	O
group	NN	O
.	.	O

MRI-derived	JJ	O
change	NN	O
in	IN	O
total	JJ	O
vessel	JJ	O
area	NN	O
was	VBD	O
reduced	VBN	O
in	IN	O
patients	NNS	O
given	VBN	O
dalcetrapib	NNS	O
compared	VBN	O
with	IN	O
those	DT	O
given	VBN	O
placebo	NNS	O
after	IN	O
24	CD	O
months	NNS	O
;	:	O
absolute	JJ	O
change	NN	O
from	IN	O
baseline	NN	O
relative	NN	O
to	TO	O
placebo	VB	O
was	VBD	O
-4?01	JJ	O
mm	NN	O
(	(	O
2	CD	O
)	)	O
(	(	O
90	CD	O
%	NN	O
CI	NNP	O
-7?23	NNP	O
to	TO	O
-0?80	VB	O
;	:	O
nominal	JJ	O
p=0?04	NN	O
)	)	O
.	.	O

The	DT	O
PET/CT	NNP	O
measure	NN	O
of	IN	O
index	NN	O
vessel	JJ	O
most-diseased-segment	JJ	O
target-to-background	NN	O
ratio	NN	O
(	(	O
TBR	NNP	O
)	)	O
was	VBD	O
not	RB	O
different	JJ	O
between	IN	O
groups	NNS	O
,	,	O
but	CC	O
carotid	JJ	O
artery	NN	O
analysis	NN	O
showed	VBD	O
a	DT	O
7	CD	O
%	NN	O
reduction	NN	O
in	IN	O
most-diseased-segment	JJ	O
TBR	NNP	O
in	IN	O
the	DT	O
dalcetrapib	NN	O
group	NN	O
compared	VBN	O
with	IN	O
the	DT	O
placebo	NN	O
group	NN	O
(	(	O
-7?3	NNP	O
[	RB	O
90	CD	O
%	NN	O
CI	NNP	O
-13?5	NNP	O
to	TO	O
-0?8	VB	O
]	NNP	O
;	:	O
nominal	JJ	O
p=0?07	NN	O
)	)	O
.	.	O

Dalcetrapib	NNP	O
did	VBD	O
not	RB	O
increase	VB	O
office	NN	O
blood	NN	O
pressure	NN	O
and	CC	O
the	DT	O
frequency	NN	O
of	IN	O
adverse	JJ	O
events	NNS	O
was	VBD	O
similar	JJ	O
between	IN	O
groups	NNS	O
.	.	O

INTERPRETATION	NNP	O
Dalcetrapib	NNP	O
showed	VBD	O
no	DT	O
evidence	NN	O
of	IN	O
a	DT	O
pathological	JJ	O
effect	NN	O
related	VBN	O
to	TO	O
the	DT	O
arterial	JJ	O
wall	NN	O
over	IN	O
24	CD	O
months	NNS	O
.	.	O

Moreover	RB	O
,	,	O
this	DT	O
trial	NN	O
suggests	VBZ	O
possible	JJ	O
beneficial	JJ	O
vascular	JJ	O
effects	NNS	O
of	IN	O
dalcetrapib	NN	O
,	,	O
including	VBG	O
the	DT	O
reduction	NN	O
in	IN	O
total	JJ	O
vessel	JJ	O
enlargement	NN	O
over	IN	O
24	CD	O
months	NNS	O
,	,	O
but	CC	O
long-term	JJ	O
safety	NN	O
and	CC	O
clinical	JJ	O
outcomes	NNS	O
efficacy	NN	O
of	IN	O
dalcetrapib	NNS	O
need	VBP	O
to	TO	O
be	VB	O
analysed	VBN	O
.	.	O

FUNDING	NN	O
F	NNP	O
Hoffmann-La	NNP	O
Roche	NNP	O
Ltd	NNP	O
.	.	O

Effectiveness	NN	O
of	IN	O
norgestimate	NN	O
and	CC	O
ethinyl	NN	O
estradiol	NN	O
in	IN	O
treating	VBG	O
moderate	JJ	C
acne	NN	C
vulgaris	NN	C
.	.	O

BACKGROUND	NNP	O
An	DT	O
excess	NN	O
of	IN	O
androgen	NN	O
is	VBZ	O
believed	VBN	O
to	TO	O
contribute	VB	O
to	TO	O
development	NN	O
of	IN	O
acne	NN	O
in	IN	O
some	DT	O
patients	NNS	O
.	.	O

Because	IN	O
oral	JJ	O
contraceptives	NNS	O
(	(	O
OCs	NNP	O
)	)	O
may	MD	O
reduce	VB	O
the	DT	O
active	JJ	O
androgen	NN	O
level	NN	O
,	,	O
hormonal	JJ	O
therapy	NN	O
with	IN	O
OCs	NNP	O
has	VBZ	O
been	VBN	O
used	VBN	O
successfully	RB	O
to	TO	O
treat	VB	O
patients	NNS	O
with	IN	O
acne	NN	C
,	,	O
although	IN	O
this	DT	O
treatment	NN	O
has	VBZ	O
previously	RB	O
not	RB	O
been	VBN	O
studied	VBN	O
in	IN	O
placebo-controlled	JJ	O
trials	NNS	O
.	.	O

OBJECTIVE	CC	O
Our	PRP$	O
purpose	NN	O
was	VBD	O
to	TO	O
evaluate	VB	O
the	DT	O
efficacy	NN	O
of	IN	O
a	DT	O
triphasic	JJ	O
,	,	O
combination	NN	O
OC	NNP	O
(	(	O
ORTHO	NNP	O
TRI-CYCLEN	NNP	O
[	NNP	O
Ortho-McNeil	NNP	O
Pharmaceutical	NNP	O
,	,	O
Raritan	NNP	O
,	,	O
N.J.	NNP	O
]	NNP	O
,	,	O
norgestimate/ethinyl	RB	O
estradiol	NN	O
)	)	O
compared	VBN	O
with	IN	O
placebo	NN	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
moderate	JJ	O
acne	NN	O
vulgaris	NN	O
.	.	O

METHODS	NNP	O
Two	CD	SS
hundred	VBD	SS
fifty-seven	RB	SS
healthy	JJ	C
female	NN	SE
subjects	NNS	O
,	,	O
15	CD	A
to	TO	A
49	CD	A
years	NNS	A
of	IN	O
age	NN	O
with	IN	O
moderate	JJ	C
acne	NNS	C
vulgaris	NN	C
,	,	O
were	VBD	O
enrolled	VBN	O
in	IN	O
a	DT	O
multicenter	NN	O
,	,	O
randomized	VBN	O
,	,	O
double-blind	JJ	O
,	,	O
placebo-controlled	JJ	O
clinical	JJ	O
trial	NN	O
.	.	O

Each	DT	O
month	NN	O
for	IN	O
6	CD	O
months	NNS	O
,	,	O
subjects	VBZ	O
received	VBN	O
either	RB	O
3	CD	O
consecutive	JJ	O
weeks	NNS	O
of	IN	O
the	DT	O
OC	NNP	O
(	(	O
i.e.	FW	O
,	,	O
tablets	NNS	O
containing	VBG	O
a	DT	O
fixed	VBN	O
dose	NN	O
of	IN	O
ethinyl	JJ	O
estradiol	NN	O
[	VBD	O
0.035	CD	O
mg	NN	O
]	NN	O
and	CC	O
increasing	VBG	O
doses	NNS	O
of	IN	O
norgestimate	JJ	O
[	NNS	O
0.180	CD	O
mg	NNS	O
,	,	O
0.215	CD	O
mg	NN	O
,	,	O
0.250	CD	O
mg	NN	O
]	NN	O
)	)	O
followed	VBN	O
by	IN	O
7	CD	O
days	NNS	O
of	IN	O
inactive	JJ	O
drug	NN	O
or	CC	O
placebo	NN	O
(	(	O
color-matched	JJ	O
tablets	NNS	O
)	)	O
.	.	O

Efficacy	NN	O
was	VBD	O
assessed	VBN	O
by	IN	O
facial	JJ	O
acne	JJ	O
lesion	NN	O
counts	NNS	O
,	,	O
an	DT	O
investigator	NN	O
's	POS	O
global	JJ	O
assessment	NN	O
,	,	O
a	DT	O
subject	NN	O
's	POS	O
self-assessment	NN	O
,	,	O
and	CC	O
an	DT	O
analysis	NN	O
of	IN	O
within-cycle	JJ	O
variation	NN	O
(	(	O
cycle	NN	O
6	CD	O
)	)	O
in	IN	O
lesion	NN	O
counts	NNS	O
.	.	O

RESULTS	NNP	O
Of	IN	O
the	DT	O
160	CD	SS
subjects	NNS	O
in	IN	O
whom	WP	O
efficacy	NN	O
could	MD	O
be	VB	O
evaluated	VBN	O
,	,	O
the	DT	O
OC	NNP	O
group	NN	O
showed	VBD	O
a	DT	O
statistically	RB	O
significantly	RB	O
greater	JJR	O
improvement	NN	O
than	IN	O
the	DT	O
placebo	NN	O
group	NN	O
for	IN	O
all	DT	O
primary	JJ	O
efficacy	NN	O
measures	NNS	O
.	.	O

The	DT	O
mean	JJ	O
decrease	NN	O
in	IN	O
inflammatory	JJ	O
lesion	NN	O
count	NN	O
from	IN	O
baseline	NN	O
to	TO	O
cycle	NN	O
6	CD	O
was	VBD	O
11.8	CD	O
(	(	O
62.0	CD	O
%	NN	O
)	)	O
versus	NN	O
7.6	CD	O
(	(	O
38.6	CD	O
%	NN	O
)	)	O
(	(	O
p	JJ	O
=	NNP	O
0.0001	CD	O
)	)	O
,	,	O
and	CC	O
the	DT	O
mean	JJ	O
decrease	NN	O
in	IN	O
total	JJ	O
lesion	NN	O
count	NN	O
was	VBD	O
29.1	CD	O
(	(	O
53.1	CD	O
%	NN	O
)	)	O
versus	NN	O
14.1	CD	O
(	(	O
26.8	CD	O
%	NN	O
)	)	O
(	(	O
p	JJ	O
=	NNP	O
0.0001	CD	O
)	)	O
in	IN	O
the	DT	O
OC	NNP	O
and	CC	O
placebo	NN	O
groups	NNS	O
,	,	O
respectively	RB	O
.	.	O

In	IN	O
the	DT	O
investigator	NN	O
's	POS	O
global	JJ	O
assessment	NN	O
,	,	O
93.7	CD	O
%	NN	O
of	IN	O
the	DT	O
active	JJ	O
treatment	NN	O
group	NN	O
versus	VBD	O
65.4	CD	O
%	NN	O
of	IN	O
the	DT	O
placebo	NN	O
group	NN	O
were	VBD	O
rated	VBN	O
as	IN	O
improved	VBN	O
at	IN	O
the	DT	O
end	NN	O
of	IN	O
the	DT	O
study	NN	O
(	(	O
p	JJ	O
<	NNP	O
0.001	CD	O
)	)	O
.	.	O

Six	CD	O
of	IN	O
the	DT	O
seven	CD	O
secondary	JJ	O
efficacy	NN	O
measures	NNS	O
(	(	O
total	JJ	O
comedones	NNS	O
,	,	O
open	JJ	O
comedones	NNS	O
,	,	O
closed	VBD	O
comedones	NNS	O
,	,	O
papules	NNS	O
,	,	O
pustules	NNS	O
,	,	O
and	CC	O
the	DT	O
subject	NN	O
's	POS	O
self-assessment	NN	O
of	IN	O
study	NN	O
treatment	NN	O
)	)	O
were	VBD	O
also	RB	O
significantly	RB	O
more	RBR	O
favorable	JJ	O
in	IN	O
the	DT	O
OC	NNP	O
group	NN	O
compared	VBN	O
with	IN	O
the	DT	O
placebo	NN	O
group	NN	O
.	.	O

CONCLUSION	NNP	O
An	DT	O
OC	NNP	O
containing	VBG	O
0.035	CD	O
mg	NN	O
of	IN	O
ethinyl	JJ	O
estradiol	NN	O
combined	VBN	O
with	IN	O
the	DT	O
triphasic	JJ	O
regimen	NNS	O
of	IN	O
norgestimate	NN	O
is	VBZ	O
a	DT	O
safe	JJ	O
and	CC	O
effective	JJ	O
treatment	NN	O
of	IN	O
moderate	JJ	O
acne	NNS	O
vulgaris	VBP	O
in	IN	O
women	NNS	SE
with	IN	O
no	DT	O
known	VBN	O
contraindication	NN	O
to	TO	O
OC	NNP	O
therapy	NN	O
.	.	O

Rehabilitation	NNP	O
outcomes	VBZ	O
following	VBG	O
percutaneous	JJ	O
coronary	JJ	O
interventions	NNS	O
(	(	O
PCI	NNP	O
)	)	O
.	.	O

This	DT	O
prospective	JJ	O
study	NN	O
evaluated	VBD	O
the	DT	O
effect	NN	O
of	IN	O
an	DT	O
individualized	JJ	O
,	,	O
comprehensive	JJ	O
,	,	O
home-based	JJ	O
cardiac	JJ	O
rehabilitation	NN	O
program	NN	O
combining	NN	O
exercise	NN	O
training	NN	O
with	IN	O
risk	NN	O
factor	NN	O
modification	NN	O
and	CC	O
psychosocial	JJ	O
counseling	NN	O
on	IN	O
risk	NN	O
factors	NNS	O
,	,	O
psychological	JJ	O
well-being	NN	O
,	,	O
functional	JJ	O
capacity	NN	O
,	,	O
and	CC	O
work	NN	O
resumption	NN	O
in	IN	O
99	CD	O
post-percutaneous	JJ	O
coronary	JJ	O
interventions	NNS	O
(	(	O
PCI	NNP	O
)	)	O
patients	NNS	O
randomized	VBN	O
to	TO	O
control	VB	O
(	(	O
standard	JJ	O
care	NN	O
plus	CC	O
telephone	NN	O
follow-up	NN	O
,	,	O
n=49	NN	O
)	)	O
or	CC	O
intervention	NN	O
(	(	O
individualized	VBN	O
,	,	O
comprehensive	JJ	O
,	,	O
home-based	JJ	O
cardiac	JJ	O
rehabilitation	NN	O
,	,	O
n=50	NN	O
)	)	O
groups	NNS	O
.	.	O

Data	NNS	O
were	VBD	O
collected	VBN	O
at	IN	O
time	NN	O
1	CD	O
(	(	O
T	NNP	O
(	(	O
1	CD	O
)	)	O
)	)	O
during	IN	O
hospital	JJ	O
admission	NN	O
,	,	O
time	NN	O
2	CD	O
(	(	O
T	NNP	O
(	(	O
2	CD	O
)	)	O
)	)	O
approximately	RB	O
2	CD	O
months	NNS	O
post-PCI	JJ	O
,	,	O
and	CC	O
time	NN	O
3	CD	O
(	(	O
T	NNP	O
(	(	O
3	CD	O
)	)	O
)	)	O
approximately	RB	O
12	CD	O
months	NNS	O
post-PCI	JJ	O
.	.	O

Results	VB	O
suggest	JJS	O
that	IN	O
the	DT	O
allocation	NN	O
to	TO	O
an	DT	O
individualized	VBN	O
,	,	O
comprehensive	JJ	O
,	,	O
home-based	JJ	O
cardiac	JJ	O
rehabilitation	NN	O
program	NN	O
provided	VBD	O
more	RBR	O
advantageous	JJ	O
outcomes	NNS	O
.	.	O

At	IN	O
both	DT	O
follow-ups	NNS	O
,	,	O
the	DT	O
intervention	NN	O
group	NN	O
showed	VBD	O
within-group	JJ	O
improvement	NN	O
in	IN	O
serum	NN	O
cholesterol	NN	O
levels	NNS	O
(	(	O
P	NNP	O
<	NNP	O
0.02	CD	O
;	:	O
P	NNP	O
<	NNP	O
0.01	CD	O
)	)	O
and	CC	O
exercise	JJ	O
participation	NN	O
(	(	O
P	NNP	O
<	NNP	O
0.001	CD	O
;	:	O
P	NNP	O
<	NNP	O
0.001	CD	O
)	)	O
with	IN	O
differences	NNS	O
in	IN	O
exercise	NN	O
participation	NN	O
favoring	VBG	O
the	DT	O
intervention	NN	O
group	NN	O
(	(	O
P	NNP	O
<	NNP	O
0.01	CD	O
)	)	O
at	IN	O
T	NNP	O
(	(	O
2	CD	O
)	)	O
.	.	O

Repeated	VBN	O
measures	NNS	O
ANOVA	NNP	O
showed	VBD	O
significant	JJ	O
improvements	NNS	O
over	IN	O
time	NN	O
in	IN	O
body	NN	O
mass	NN	O
index	NN	O
(	(	O
BMI	NNP	O
)	)	O
(	(	O
P	NNP	O
<	NNP	O
0.01	CD	O
)	)	O
,	,	O
psychological	JJ	O
well-being	NN	O
(	(	O
P	NNP	O
<	NNP	O
0.001	CD	O
)	)	O
,	,	O
and	CC	O
functional	JJ	O
capacity	NN	O
(	(	O
P	NNP	O
<	NNP	O
0.001	CD	O
)	)	O
for	IN	O
both	DT	O
groups	NNS	O
.	.	O

More	JJR	O
patients	NNS	O
in	IN	O
the	DT	O
intervention	NN	O
group	NN	O
had	VBD	O
returned	VBN	O
to	TO	O
work	VB	O
at	IN	O
T	NNP	O
(	(	O
2	CD	O
)	)	O
(	(	O
P	NNP	O
<	NNP	O
0.001	CD	O
)	)	O
and	CC	O
did	VBD	O
so	RB	O
more	RBR	O
quickly	RB	O
(	(	O
P	NNP	O
<	NNP	O
0.01	CD	O
)	)	O
.	.	O

These	DT	O
findings	NNS	O
suggest	VBP	O
that	IN	O
an	DT	O
individualized	JJ	O
,	,	O
comprehensive	JJ	O
,	,	O
home-based	JJ	O
cardiac	JJ	O
rehabilitation	NN	O
program	NN	O
improves	VBZ	O
risk	NN	O
factor	NN	O
profiles	NNS	O
and	CC	O
work	NN	O
resumption	NN	O
patterns	NNS	O
for	IN	O
patients	NNS	O
following	VBG	O
PCI	NNP	O
.	.	O

Modulation	NN	O
of	IN	O
oxidant	JJ	O
stress	NN	O
in	IN	O
vivo	NN	O
in	IN	O
chronic	JJ	O
cigarette	NN	O
smokers	NNS	O
.	.	O

BACKGROUND	NNP	O
Free	JJ	O
radical-induced	JJ	O
oxidative	JJ	O
damage	NN	O
is	VBZ	O
thought	VBN	O
to	TO	O
be	VB	O
involved	VBN	O
in	IN	O
the	DT	O
pathogenesis	NN	O
of	IN	O
diseases	NNS	O
associated	VBN	O
with	IN	O
cigarette	NN	O
smoking	NN	O
.	.	O

We	PRP	O
examined	VBD	O
the	DT	O
production	NN	O
of	IN	O
8-epi-prostaglandin	JJ	O
(	(	O
PG	NNP	O
)	)	O
F2	NNP	O
alpha	NN	O
,	,	O
a	DT	O
stable	JJ	O
product	NN	O
of	IN	O
lipid	JJ	O
peroxidation	NN	O
in	IN	O
vivo	NN	O
,	,	O
and	CC	O
its	PRP$	O
modulation	NN	O
by	IN	O
aspirin	NN	O
and	CC	O
antioxidant	JJ	O
vitamins	NNS	O
in	IN	O
chronic	JJ	O
cigarette	NN	O
smokers	NNS	O
.	.	O

METHODS	NNP	O
AND	CC	O
RESULTS	NNP	O
We	PRP	O
performed	VBD	O
the	DT	O
following	JJ	O
studies	NNS	O
:	:	O
(	(	O
1	CD	O
)	)	O
a	DT	O
cross-sectional	JJ	O
comparison	NN	O
of	IN	O
smokers	NNS	O
and	CC	O
control	NN	O
subjects	NNS	O
,	,	O
(	(	O
2	CD	O
)	)	O
an	DT	O
examination	NN	O
of	IN	O
the	DT	O
dose-response	JJ	O
relationship	NN	O
,	,	O
(	(	O
3	CD	O
)	)	O
an	DT	O
exploration	NN	O
of	IN	O
the	DT	O
effect	NN	O
of	IN	O
smoking	VBG	O
cessation	NN	O
(	(	O
3	CD	O
weeks	NNS	O
)	)	O
and	CC	O
nicotine	JJ	O
patch	NN	O
supplementation	NN	O
,	,	O
(	(	O
4	CD	O
)	)	O
the	DT	O
effect	NN	O
of	IN	O
aspirin	NN	O
consumption	NN	O
,	,	O
and	CC	O
(	(	O
5	CD	O
)	)	O
the	DT	O
effects	NNS	O
of	IN	O
5	CD	O
days	NNS	O
'	POS	O
dosing	VBG	O
with	IN	O
vitamin	NN	O
E	NNP	O
(	(	O
100	CD	O
and	CC	O
800	CD	O
U	NNP	O
)	)	O
,	,	O
vitamin	FW	O
C	NNP	O
(	(	O
2	CD	O
g	NN	O
)	)	O
,	,	O
and	CC	O
their	PRP$	O
combination	NN	O
.	.	O

8-epi-PGF2	JJ	O
alpha	JJ	O
excretion	NN	O
(	(	O
in	IN	O
pmol/mmol	NN	O
,	,	O
mean	JJ	O
+/-	JJ	O
SEM	NNP	O
)	)	O
was	VBD	O
176.5+/-30.6	JJ	O
in	IN	O
heavy	JJ	O
smokers	NNS	O
,	,	O
92.7+/-4.8	CD	O
(	(	O
P	NNP	O
<	NNP	O
.05	NNP	O
)	)	O
in	IN	O
moderate	JJ	C
smokers	NNS	C
,	,	O
and	CC	O
54.1+/-2.7	JJ	O
(	(	O
P	NNP	O
<	NNP	O
.005	NNP	O
)	)	O
in	IN	O
nonsmokers	NNS	C
.	.	O

Urinary	JJ	O
levels	NNS	O
fell	VBD	O
from	IN	O
145.5+/-24.9	CD	O
to	TO	O
114.6+/-27.1	CD	O
(	(	O
week	NN	O
2	CD	O
,	,	O
P	NNP	O
<	NNP	O
.05	NNP	O
)	)	O
and	CC	O
112.6+/-24.9	JJ	O
(	(	O
week	NN	O
3	CD	O
,	,	O
P	NNP	O
<	NNP	O
.05	NNP	O
)	)	O
on	IN	O
cessation	NN	O
of	IN	O
smoking	NN	O
.	.	O

Aspirin	NNP	O
treatment	NN	O
failed	VBD	O
to	TO	O
suppress	VB	O
urinary	JJ	O
levels	NNS	O
of	IN	O
8-epi-PGF2	JJ	O
alpha	NN	O
despite	IN	O
a	DT	O
significant	JJ	O
reduction	NN	O
in	IN	O
urinary	JJ	O
11-dehydro-TxB2	JJ	O
production	NN	O
and	CC	O
suppression	NN	O
of	IN	O
8-epi-PGF2	JJ	O
alpha	NN	O
and	CC	O
TxB2	NNP	O
in	IN	O
serum	NN	O
.	.	O

Vitamin	NNP	O
C	NNP	O
(	(	O
pre	NN	O
,	,	O
194.6+/-40.9	JJ	O
;	:	O
post	NN	O
,	,	O
137.2+/-34.1	JJ	O
;	:	O
P	NNP	O
<	NNP	O
.05	NNP	O
)	)	O
and	CC	O
a	DT	O
combination	NN	O
of	IN	O
vitamin	JJ	O
C	NNP	O
and	CC	O
E	NNP	O
(	(	O
pre	NN	O
,	,	O
171.0+/-39.8	JJ	O
;	:	O
post	NN	O
,	,	O
133.5+/-29.6	JJ	O
P	NNP	O
<	NNP	O
.05	NNP	O
)	)	O
suppressed	VBD	O
urinary	JJ	O
8-epi-PGF2	JJ	O
alpha	NN	O
,	,	O
whereas	IN	O
vitamin	JJ	O
E	NNP	O
alone	RB	O
had	VBD	O
no	DT	O
effect	NN	O
.	.	O

CONCLUSIONS	NNP	O
Urinary	NNP	O
8-epi-PGF2	JJ	O
alpha	NN	O
may	MD	O
represent	VB	O
a	DT	O
noninvasive	JJ	O
,	,	O
quantitative	JJ	O
index	NN	O
of	IN	O
oxidant	JJ	O
stress	NN	O
in	IN	O
vivo	NN	O
.	.	O

Elevated	JJ	O
levels	NNS	O
of	IN	O
8-epi-PGF2	JJ	O
alpha	NN	O
in	IN	O
smokers	NNS	O
may	MD	O
be	VB	O
modulated	VBN	O
by	IN	O
quitting	VBG	O
cigarettes	NNS	O
and	CC	O
switching	VBG	O
to	TO	O
nicotine	VB	O
patches	NNS	O
or	CC	O
by	IN	O
antioxidant	JJ	O
vitamin	NN	O
therapy	NN	O
.	.	O

Risperidone	NN	O
in	IN	O
children	NNS	A
with	IN	O
autism	NN	C
and	CC	O
serious	JJ	O
behavioral	JJ	C
problems	NNS	C
.	.	O

BACKGROUND	NNP	O
Atypical	NNP	O
antipsychotic	JJ	O
agents	NNS	O
,	,	O
which	WDT	O
block	VBP	O
postsynaptic	JJ	O
dopamine	NN	O
and	CC	O
serotonin	NN	O
receptors	NNS	O
,	,	O
have	VBP	O
advantages	NNS	O
over	IN	O
traditional	JJ	O
antipsychotic	JJ	O
medications	NNS	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
adults	NNS	O
with	IN	O
schizophrenia	NN	O
and	CC	O
may	MD	O
be	VB	O
beneficial	JJ	O
in	IN	O
children	NNS	O
with	IN	O
autistic	JJ	O
disorder	NN	O
who	WP	O
have	VBP	O
serious	JJ	O
behavioral	JJ	O
disturbances	NNS	O
.	.	O

However	RB	O
,	,	O
data	NNS	O
on	IN	O
the	DT	O
safety	NN	O
and	CC	O
efficacy	NN	O
of	IN	O
atypical	JJ	O
antipsychotic	JJ	O
agents	NNS	O
in	IN	O
children	NNS	O
are	VBP	O
limited	VBN	O
.	.	O

METHODS	NNP	O
We	PRP	O
conducted	VBD	O
a	DT	O
multisite	NN	O
,	,	O
randomized	VBN	O
,	,	O
double-blind	JJ	O
trial	NN	O
of	IN	O
risperidone	NN	O
as	IN	O
compared	VBN	O
with	IN	O
placebo	NN	O
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
autistic	JJ	C
disorder	NN	C
accompanied	VBN	O
by	IN	O
severe	JJ	O
tantrums	NNS	O
,	,	O
aggression	NN	O
,	,	O
or	CC	O
self-injurious	JJ	O
behavior	NN	O
in	IN	O
children	NNS	O
5	CD	O
to	TO	O
17	CD	O
years	NNS	O
old	JJ	O
.	.	O

The	DT	O
primary	JJ	O
outcome	NN	O
measures	NNS	O
were	VBD	O
the	DT	O
score	NN	O
on	IN	O
the	DT	O
Irritability	NNP	O
subscale	NN	O
of	IN	O
the	DT	O
Aberrant	NNP	O
Behavior	NNP	O
Checklist	NNP	O
and	CC	O
the	DT	O
rating	NN	O
on	IN	O
the	DT	O
Clinical	NNP	O
Global	NNP	O
Impressions	NNP	O
-	:	O
Improvement	NN	O
(	(	O
CGI-I	NNP	O
)	)	O
scale	NN	O
at	IN	O
eight	CD	O
weeks	NNS	O
.	.	O

RESULTS	VB	O
A	DT	O
total	NN	O
of	IN	O
101	CD	SS
children	NNS	O
(	(	O
82	CD	SS
boys	NNS	SE
and	CC	O
19	CD	SS
girls	NNS	SE
;	:	O
mean	VB	O
[	IN	O
+/-SD	JJ	O
]	NNP	O
age	NN	O
,	,	O
8.8+/-2.7	CD	O
years	NNS	O
)	)	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
receive	VB	O
risperidone	NN	O
(	(	O
49	CD	SS
children	NNS	O
)	)	O
or	CC	O
placebo	NN	O
(	(	O
52	CD	O
)	)	O
.	.	O

Treatment	NN	O
with	IN	O
risperidone	NN	O
for	IN	O
eight	CD	O
weeks	NNS	O
(	(	O
dose	JJ	O
range	NN	O
,	,	O
0.5	CD	O
to	TO	O
3.5	CD	O
mg	NNS	O
per	IN	O
day	NN	O
)	)	O
resulted	VBD	O
in	IN	O
a	DT	O
56.9	CD	O
percent	NN	O
reduction	NN	O
in	IN	O
the	DT	O
Irritability	NNP	O
score	NN	O
,	,	O
as	IN	O
compared	VBN	O
with	IN	O
a	DT	O
14.1	CD	O
percent	NN	O
decrease	NN	O
in	IN	O
the	DT	O
placebo	NN	O
group	NN	O
(	(	O
P	NNP	O
<	NNP	O
0.001	CD	O
)	)	O
.	.	O

The	DT	O
rate	NN	O
of	IN	O
a	DT	O
positive	JJ	O
response	NN	O
,	,	O
defined	VBD	O
as	IN	O
at	IN	O
least	JJS	O
a	DT	O
25	CD	O
percent	NN	O
decrease	NN	O
in	IN	O
the	DT	O
Irritability	NNP	O
score	NN	O
and	CC	O
a	DT	O
rating	NN	O
of	IN	O
much	JJ	O
improved	VBN	O
or	CC	O
very	RB	O
much	JJ	O
improved	VBN	O
on	IN	O
the	DT	O
CGI-I	NNP	O
scale	NN	O
,	,	O
was	VBD	O
69	CD	O
percent	NN	O
in	IN	O
the	DT	O
risperidone	NN	O
group	NN	O
(	(	O
34	CD	O
of	IN	O
49	CD	O
children	NNS	O
had	VBD	O
a	DT	O
positive	JJ	O
response	NN	O
)	)	O
and	CC	O
12	CD	O
percent	NN	O
in	IN	O
the	DT	O
placebo	NN	O
group	NN	O
(	(	O
6	CD	O
of	IN	O
52	CD	O
,	,	O
P	NNP	O
<	NNP	O
0.001	CD	O
)	)	O
.	.	O

Risperidone	NNP	O
therapy	NN	O
was	VBD	O
associated	VBN	O
with	IN	O
an	DT	O
average	JJ	O
weight	JJ	O
gain	NN	O
of	IN	O
2.7+/-2.9	JJ	O
kg	NN	O
,	,	O
as	IN	O
compared	VBN	O
with	IN	O
0.8+/-2.2	JJ	O
kg	NN	O
with	IN	O
placebo	NN	O
(	(	O
P	NNP	O
<	NNP	O
0.001	CD	O
)	)	O
.	.	O

Increased	VBN	O
appetite	RB	O
,	,	O
fatigue	NN	O
,	,	O
drowsiness	NN	O
,	,	O
dizziness	NN	O
,	,	O
and	CC	O
drooling	VBG	O
were	VBD	O
more	JJR	O
common	JJ	O
in	IN	O
the	DT	O
risperidone	NN	O
group	NN	O
than	IN	O
in	IN	O
the	DT	O
placebo	NN	O
group	NN	O
(	(	O
P	NNP	O
<	VBZ	O
0.05	CD	O
for	IN	O
each	DT	O
comparison	NN	O
)	)	O
.	.	O

In	IN	O
two	CD	O
thirds	NNS	O
of	IN	O
the	DT	O
children	NNS	O
with	IN	O
a	DT	O
positive	JJ	O
response	NN	O
to	TO	O
risperidone	VB	O
at	IN	O
eight	CD	O
weeks	NNS	O
(	(	O
23	CD	O
of	IN	O
34	CD	O
)	)	O
,	,	O
the	DT	O
benefit	NN	O
was	VBD	O
maintained	VBN	O
at	IN	O
six	CD	O
months	NNS	O
.	.	O

CONCLUSIONS	NNP	O
Risperidone	NNP	O
was	VBD	O
effective	JJ	O
and	CC	O
well	RB	O
tolerated	VBN	O
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
tantrums	NNS	O
,	,	O
aggression	NN	O
,	,	O
or	CC	O
self-injurious	JJ	O
behavior	NN	O
in	IN	O
children	NNS	A
with	IN	O
autistic	JJ	C
disorder	NN	C
.	.	O

The	DT	O
short	JJ	O
period	NN	O
of	IN	O
this	DT	O
trial	NN	O
limits	VBZ	O
inferences	NNS	O
about	IN	O
adverse	JJ	O
effects	NNS	O
such	JJ	O
as	IN	O
tardive	JJ	O
dyskinesia	NN	O
.	.	O

Gastrointestinal	NNP	O
safety	NN	O
of	IN	O
NO-aspirin	NNP	O
(	(	O
NCX-4016	NNP	O
)	)	O
in	IN	O
healthy	JJ	C
human	JJ	C
volunteers	NNS	O
:	:	O
a	DT	O
proof	NN	O
of	IN	O
concept	NN	O
endoscopic	NN	O
study	NN	O
.	.	O

BACKGROUND	NNP	O
AND	CC	O
AIMS	NNP	O
NCX-4016	NNP	O
is	VBZ	O
a	DT	O
nitric	JJ	O
oxide-releasing	JJ	O
derivative	NN	O
of	IN	O
aspirin	NN	O
with	IN	O
antiplatelet	NN	O
activity	NN	O
.	.	O

The	DT	O
aim	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
investigate	VB	O
the	DT	O
effect	NN	O
of	IN	O
NCX-4016	NNP	O
on	IN	O
gastrointestinal	JJ	O
mucosa	NN	O
and	CC	O
platelet	NN	O
functions	NNS	O
in	IN	O
healthy	JJ	C
human	JJ	C
volunteers	NNS	O
.	.	O

METHODS	NNP	O
This	DT	O
was	VBD	O
a	DT	O
parallel-group	JJ	O
,	,	O
double-blind	JJ	O
,	,	O
placebo-controlled	JJ	O
study	NN	O
.	.	O

Forty	NNP	SS
healthy	JJ	O
subjects	NNS	O
were	VBD	O
randomly	RB	O
allocated	VBN	O
to	TO	O
receive	VB	O
7	CD	O
days	NNS	O
of	IN	O
treatment	NN	O
with	IN	O
NCX-4016	NNP	O
(	(	O
400	CD	O
and	CC	O
800	CD	O
mg	NN	O
twice	RB	O
daily	RB	O
)	)	O
,	,	O
equimolar	JJ	O
doses	NNS	O
of	IN	O
aspirin	NN	O
(	(	O
200	CD	O
and	CC	O
420	CD	O
mg	NN	O
twice	RB	O
daily	RB	O
)	)	O
,	,	O
or	CC	O
placebo	NN	O
.	.	O

Upper	IN	O
endoscopies	NNS	O
were	VBD	O
performed	VBN	O
before	RB	O
and	CC	O
at	IN	O
the	DT	O
end	NN	O
of	IN	O
the	DT	O
treatment	NN	O
period	NN	O
,	,	O
and	CC	O
gastroduodenal	JJ	O
lesions	NNS	O
were	VBD	O
graded	VBN	O
using	VBG	O
a	DT	O
predefined	VBN	O
scoring	NN	O
system	NN	O
.	.	O

Basal	NNP	O
and	CC	O
posttreatment	JJ	O
platelet	NN	O
aggregation	NN	O
in	IN	O
response	NN	O
to	TO	O
arachidonic	JJ	O
acid	NN	O
(	(	O
AA	NNP	O
)	)	O
and	CC	O
serum	JJ	O
thromboxane	NN	O
(	(	O
TX	NNP	O
)	)	O
B	NNP	O
(	(	O
2	CD	O
)	)	O
and	CC	O
AA-stimulated	JJ	O
platelet	NN	O
TXB	NNP	O
(	(	O
2	CD	O
)	)	O
production	NN	O
were	VBD	O
investigated	VBN	O
.	.	O

RESULTS	NNP	O
Mucosal	NNP	O
endoscopic	JJ	O
injury	NN	O
score	NN	O
on	IN	O
day	NN	O
7	CD	O
was	VBD	O
0.63	CD	O
+/-	JJ	O
0.16	CD	O
in	IN	O
the	DT	O
placebo	NN	O
group	NN	O
and	CC	O
11.0	CD	O
+/-	JJ	O
3.0	CD	O
and	CC	O
16.1	CD	O
+/-	JJ	O
1.6	CD	O
in	IN	O
healthy	JJ	C
volunteers	NNS	O
treated	VBD	O
with	IN	O
200	CD	O
and	CC	O
420	CD	O
mg	NN	O
aspirin	JJ	O
twice	RB	O
daily	RB	O
(	(	O
P	NNP	O
<	VBZ	O
0.0001	CD	O
vs.	FW	O
placebo	NN	O
)	)	O
.	.	O

NCX-4016	NN	O
was	VBD	O
virtually	RB	O
devoid	JJ	O
of	IN	O
gastric	JJ	O
and	CC	O
duodenal	JJ	O
toxicity	NN	O
,	,	O
resulting	VBG	O
in	IN	O
a	DT	O
total	JJ	O
gastric	NN	O
and	CC	O
duodenal	JJ	O
endoscopic	NN	O
score	NN	O
of	IN	O
1.38	CD	O
+/-	JJ	O
0.3	CD	O
and	CC	O
1.25	CD	O
+/-	JJ	O
0.5	CD	O
(	(	O
P	NNP	O
<	VBZ	O
0.0001	CD	O
vs.	NN	O
aspirin	NN	O
,	,	O
not	RB	O
significant	JJ	O
vs.	FW	O
placebo	NN	O
)	)	O
.	.	O

NCX-4016	JJ	O
inhibited	JJ	O
AA-induced	JJ	O
platelet	NN	O
aggregation	NN	O
as	RB	O
well	RB	O
as	IN	O
serum	NN	O
TXB	NNP	O
(	(	O
2	CD	O
)	)	O
and	CC	O
platelet	NN	O
TXB	NNP	O
(	(	O
2	CD	O
)	)	O
generation	NN	O
induced	VBN	O
by	IN	O
AA	NNP	O
to	TO	O
the	DT	O
same	JJ	O
extent	NN	O
as	IN	O
aspirin	NN	O
(	(	O
not	RB	O
significant	JJ	O
vs.	FW	O
aspirin	NN	O
)	)	O
.	.	O

CONCLUSIONS	NNP	O
In	IN	O
this	DT	O
study	NN	O
,	,	O
we	PRP	O
have	VBP	O
proven	VBN	O
the	DT	O
concept	NN	O
that	IN	O
addition	NN	O
of	IN	O
an	DT	O
NO-donating	JJ	O
moiety	NN	O
to	TO	O
aspirin	VB	O
results	NNS	O
in	IN	O
a	DT	O
new	JJ	O
chemical	NN	O
entity	NN	O
that	WDT	O
maintains	VBZ	O
cyclooxygenase-1	NN	O
and	CC	O
platelet	VB	O
inhibitory	JJ	O
activity	NN	O
while	IN	O
nearly	RB	O
avoiding	VBG	O
gastrointestinal	JJ	O
damage	NN	O
.	.	O

Sucralfate	NNP	O
overcomes	VBZ	O
adverse	JJ	O
effect	NN	O
of	IN	O
cigarette	NN	O
smoking	NN	O
on	IN	O
duodenal	JJ	C
ulcer	NN	C
healing	NN	O
and	CC	O
prolongs	NNS	O
subsequent	JJ	O
remission	NN	O
.	.	O

A	DT	O
unicenter	JJ	O
,	,	O
single-blind	JJ	O
,	,	O
randomized	VBD	O
study	NN	O
was	VBD	O
conducted	VBN	O
on	IN	O
283	CD	SS
patients	NNS	O
with	IN	O
active	JJ	O
duodenal	JJ	C
ulcer	NN	C
to	TO	O
compare	VB	O
possible	JJ	O
factors	NNS	O
that	WDT	O
may	MD	O
affect	VB	O
healing	NN	O
and	CC	O
relapse	NN	O
in	IN	O
patients	NNS	O
treated	VBN	O
with	IN	O
a	DT	O
potent	JJ	O
antisecretory	NN	O
agent	NN	O
,	,	O
cimetidine	NN	O
,	,	O
or	CC	O
a	DT	O
site-protective	JJ	O
and	CC	O
cytoprotective	JJ	O
agent	NN	O
,	,	O
sucralfate	NN	O
.	.	O

The	DT	O
endoscopic	NN	O
healing	VBG	O
rates	NNS	O
at	IN	O
4	CD	O
wk	NNS	O
were	VBD	O
76	CD	O
%	NN	O
and	CC	O
79	CD	O
%	NN	O
,	,	O
respectively	RB	O
,	,	O
and	CC	O
cross-over	JJ	O
treatment	NN	O
of	IN	O
the	DT	O
failures	NNS	O
for	IN	O
a	DT	O
further	JJ	O
4	CD	O
wk	NN	O
resulted	VBD	O
in	IN	O
68	CD	O
%	NN	O
healing	VBG	O
with	IN	O
cimetidine	NN	O
and	CC	O
69	CD	O
%	NN	O
healing	VBG	O
with	IN	O
sucralfate	NN	O
,	,	O
both	DT	O
differences	NNS	O
being	VBG	O
not	RB	O
statistically	RB	O
different	JJ	O
.	.	O

Unlike	IN	O
cimetidine	NN	O
,	,	O
healing	VBG	O
by	IN	O
sucralfate	NN	O
was	VBD	O
unaffected	VBN	O
by	IN	O
cigarette	NN	O
smoking	NN	O
,	,	O
reluctance	NN	O
to	TO	O
give	VB	O
up	RP	O
smoking	NN	O
,	,	O
habitual	JJ	O
use	NN	O
of	IN	O
alcohol	NN	O
,	,	O
high	JJ	O
maximal	JJ	O
acid	NN	O
output	NN	O
,	,	O
and	CC	O
large	JJ	O
ulcer	JJ	O
diameter	NN	O
.	.	O

In	IN	O
particular	JJ	O
,	,	O
the	DT	O
healing	VBG	O
rate	NN	O
of	IN	O
smokers	NNS	O
treated	VBN	O
with	IN	O
sucralfate	NN	O
(	(	O
82	CD	O
%	NN	O
)	)	O
was	VBD	O
significantly	RB	O
greater	JJR	O
than	IN	O
that	DT	O
of	IN	O
smokers	NNS	O
treated	VBN	O
with	IN	O
cimetidine	NN	O
(	(	O
63	CD	O
%	NN	O
)	)	O
.	.	O

Duodenal	NNP	O
bulb	NN	O
deformity	NN	O
significantly	RB	O
affected	VBD	O
healing	NN	O
in	IN	O
both	DT	O
groups	NNS	O
,	,	O
and	CC	O
was	VBD	O
the	DT	O
only	JJ	O
offsetting	VBG	O
factor	NN	O
identifiable	JJ	O
for	IN	O
sucralfate	NN	O
out	IN	O
of	IN	O
46	CD	O
factors	NNS	O
examined	VBD	O
.	.	O

Of	IN	O
the	DT	O
patients	NNS	O
with	IN	O
healed	JJ	O
ulcers	NNS	C
,	,	O
238	CD	SS
participated	VBN	O
in	IN	O
a	DT	O
24-mo	JJ	O
follow-up	NN	O
study	NN	O
consisting	VBG	O
of	IN	O
interviews	NNS	O
at	IN	O
2-mo	JJ	O
intervals	NNS	O
and	CC	O
endoscopy	NN	O
at	IN	O
4-mo	JJ	O
intervals	NNS	O
or	CC	O
whenever	WRB	O
symptoms	NNS	O
recurred	VBD	O
.	.	O

The	DT	O
cumulative	JJ	O
relapse	NN	O
rate	NN	O
was	VBD	O
significantly	RB	O
(	(	O
p	NN	O
less	JJR	O
than	IN	O
0.007	CD	O
)	)	O
greater	JJR	O
in	IN	O
patients	NNS	O
healed	VBN	O
with	IN	O
cimetidine	NN	O
than	IN	O
with	IN	O
sucralfate	NN	O
,	,	O
50	CD	O
%	NN	O
relapse	NN	O
occurring	VBG	O
at	IN	O
6	CD	O
and	CC	O
12	CD	O
mo	NN	O
,	,	O
respectively	RB	O
.	.	O

In	IN	O
both	DT	O
,	,	O
the	DT	O
cumulative	JJ	O
relapse	NN	O
rate	NN	O
was	VBD	O
significantly	RB	O
greater	JJR	O
in	IN	O
cigarette	NN	O
smokers	NNS	O
than	IN	O
in	IN	O
nonsmokers	NNS	O
,	,	O
but	CC	O
smokers	NNS	O
and	CC	O
nonsmokers	NNS	O
treated	VBN	O
with	IN	O
cimetidine	NN	O
relapsed	VBN	O
(	(	O
50	CD	O
%	NN	O
at	IN	O
4	CD	O
and	CC	O
8	CD	O
mo	NN	O
,	,	O
respectively	RB	O
)	)	O
faster	RBR	O
than	IN	O
the	DT	O
corresponding	JJ	O
smokers	NNS	O
and	CC	O
nonsmokers	NNS	O
treated	VBN	O
with	IN	O
sucralfate	NN	O
(	(	O
50	CD	O
%	NN	O
at	IN	O
8	CD	O
and	CC	O
18	CD	O
mo	NN	O
,	,	O
respectively	RB	O
)	)	O
.	.	O

Furthermore	UH	O
,	,	O
in	IN	O
cimetidine-	NN	O
but	CC	O
not	RB	O
sucralfate-healed	JJ	O
patients	NNS	O
,	,	O
early	JJ	O
ulcer	NN	O
relapse	NN	O
(	(	O
within	IN	O
6	CD	O
mo	NN	O
)	)	O
was	VBD	O
associated	VBN	O
with	IN	O
short	JJ	O
duration	NN	O
of	IN	O
illness	NN	O
,	,	O
short	JJ	O
remission	NN	O
period	NN	O
,	,	O
long	JJ	O
symptomatic	JJ	O
spell	NN	O
,	,	O
and	CC	O
reluctance	NN	O
to	TO	O
give	VB	O
up	RP	O
smoking	VBG	O
.	.	O

We	PRP	O
conclude	VBP	O
that	IN	O
smoking	VBG	O
adversely	RB	O
affects	VBZ	O
duodenal	JJ	O
ulcer	NN	O
healing	NN	O
by	IN	O
cimetidine	NN	O
and	CC	O
hastens	VBZ	O
subsequent	JJ	O
relapse	NN	O
,	,	O
and	CC	O
that	IN	O
sucralfate	NN	O
overcomes	VBZ	O
the	DT	O
adverse	JJ	O
effect	NN	O
of	IN	O
smoking	VBG	O
on	IN	O
healing	NN	O
as	IN	O
encountered	VBN	O
with	IN	O
cimetidine	NN	O
,	,	O
and	CC	O
results	NNS	O
in	IN	O
a	DT	O
subsequent	JJ	O
remission	NN	O
period	NN	O
double	JJ	O
that	IN	O
of	IN	O
cimetidine	NN	O
.	.	O

Comparison	NNP	O
of	IN	O
the	DT	O
acute	JJ	O
effects	NNS	O
of	IN	O
salbutamol	NN	O
and	CC	O
terbutaline	NN	O
on	IN	O
heart	NN	O
rate	NN	O
variability	NN	O
in	IN	O
adult	JJ	A
asthmatic	JJ	O
patients	NNS	O
.	.	O

This	DT	O
study	NN	O
investigated	VBD	O
the	DT	O
effects	NNS	O
of	IN	O
beta2-adrenergic	JJ	O
agonist	JJ	O
therapy	NN	O
on	IN	O
heart	NN	O
rate	NN	O
variability	NN	O
(	(	O
HRV	NNP	O
)	)	O
in	IN	O
adult	NN	O
asthmatic	JJ	O
patients	NNS	O
by	IN	O
using	VBG	O
frequency	NN	O
domain	NN	O
measures	NNS	O
of	IN	O
HRV	NNP	O
.	.	O

A	NNP	O
randomized	JJ	O
crossover	NN	O
design	NN	O
was	VBD	O
used	VBN	O
.	.	O

Twenty	NNP	SS
adult	NN	O
patients	NNS	O
with	IN	O
asthma	NNS	O
were	VBD	O
studied	VBN	O
.	.	O

All	DT	O
patients	NNS	O
showed	VBD	O
a	DT	O
mild-to-moderate	JJ	O
decrease	NN	O
in	IN	O
baseline	NN	O
forced	VBN	O
expiratory	JJ	O
volume	NN	O
in	IN	O
one	CD	O
second	NN	O
.	.	O

Any	CC	O
diseases	NNS	O
that	WDT	O
might	MD	O
have	VB	O
influenced	VBN	O
the	DT	O
autonomic	JJ	O
function	NN	O
were	VBD	O
excluded	VBN	O
.	.	O

All	DT	O
patients	NNS	O
had	VBD	O
a	DT	O
complete	JJ	O
physical	JJ	O
examination	NN	O
and	CC	O
medical	JJ	O
history	NN	O
that	WDT	O
revealed	VBD	O
no	DT	O
cardiovascular	JJ	O
disease	NN	O
or	CC	O
medication	NN	O
.	.	O

The	DT	O
study	NN	O
used	VBD	O
200	CD	O
microg	NN	O
inhaled	VBN	O
salbutamol	NN	O
and	CC	O
500	CD	O
microg	NN	O
inhaled	VBN	O
terbutaline	NN	O
.	.	O

HRV	NNP	O
analysis	NN	O
was	VBD	O
performed	VBN	O
for	IN	O
each	DT	O
5-min	CD	O
segment	NN	O
,	,	O
5	CD	O
min	NN	O
before	IN	O
inhalation	NN	O
of	IN	O
the	DT	O
study	NN	O
drug	NN	O
and	CC	O
5	CD	O
,	,	O
10	CD	O
,	,	O
15	CD	O
,	,	O
20	CD	O
,	,	O
25	CD	O
and	CC	O
30	CD	O
min	NN	O
after	IN	O
inhalation	NN	O
.	.	O

Total	JJ	O
power	NN	O
(	(	O
TP	NNP	O
:	:	O
<	NN	O
0.40	CD	O
Hz	NNP	O
)	)	O
,	,	O
high-frequency	JJ	O
power	NN	O
(	(	O
HF	NNP	O
:	:	O
0.15-0.40	JJ	O
Hz	NNP	O
)	)	O
,	,	O
low-frequency	JJ	O
power	NN	O
(	(	O
LF	JJ	O
:	:	O
0.04-0.15	JJ	O
Hz	NNP	O
)	)	O
and	CC	O
LF/HF	NNP	O
ratio	NN	O
were	VBD	O
calculated	VBN	O
.	.	O

The	DT	O
LF	NNP	O
and	CC	O
LF/HF	NNP	O
ratio	NN	O
increased	VBD	O
and	CC	O
TP	NNP	O
decreased	VBD	O
at	IN	O
5	CD	O
,	,	O
10	CD	O
,	,	O
15	CD	O
and	CC	O
20	CD	O
min	NN	O
after	IN	O
the	DT	O
salbutamol	NN	O
and	CC	O
the	DT	O
terbutaline	NN	O
inhalation	NN	O
,	,	O
HF	NNP	O
did	VBD	O
not	RB	O
change	VB	O
significantly	RB	O
after	IN	O
the	DT	O
salbutamol	NN	O
and	CC	O
terbutaline	JJ	O
inhalation	NN	O
.	.	O

Acute	NNP	O
salbutamol	NN	O
and	CC	O
terbutaline	JJ	O
inhalation	NN	O
produce	VBP	O
similar	JJ	O
effects	NNS	O
on	IN	O
heart	NN	O
rate	NN	O
variability	NN	O
and	CC	O
increase	VB	O
sympathetic	JJ	O
modulation	NN	O
in	IN	O
the	DT	O
cardiac	JJ	O
autonomic	JJ	O
activity	NN	O
.	.	O

Naltrexone	NN	O
in	IN	O
autistic	JJ	C
children	NNS	A
:	:	O
a	DT	O
double-blind	JJ	O
and	CC	O
placebo-controlled	JJ	O
study	NN	O
.	.	O

A	DT	O
double-blind	JJ	O
,	,	O
placebo-controlled	JJ	O
study	NN	O
was	VBD	O
designed	VBN	O
to	TO	O
assess	VB	O
critically	RB	O
the	DT	O
effects	NNS	O
of	IN	O
naltrexone	NN	O
on	IN	O
behavioral	JJ	O
symptoms	NNS	O
and	CC	O
learning	VBG	O
in	IN	O
autistic	JJ	C
children	NNS	O
,	,	O
and	CC	O
its	PRP$	O
safety	NN	O
.	.	O

This	DT	O
is	VBZ	O
a	DT	O
preliminary	JJ	O
report	NN	O
on	IN	O
18	CD	SS
children	NNS	A
,	,	O
ages	VBZ	O
3.08	CD	A
to	TO	O
7.99	CD	A
years	NNS	O
,	,	O
who	WP	O
completed	VBD	O
this	DT	O
ongoing	JJ	O
study	NN	O
.	.	O

Subjects	NNS	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
naltrexone	CD	O
or	CC	O
placebo	NN	O
and	CC	O
received	VBD	O
daily	JJ	O
doses	NNS	O
over	IN	O
a	DT	O
period	NN	O
of	IN	O
21	CD	O
days	NNS	O
.	.	O

Naltrexone	NN	O
was	VBD	O
superior	JJ	O
to	TO	O
placebo	VB	O
according	VBG	O
to	TO	O
blind	VB	O
Clinical	JJ	O
Global	NNP	O
Consensus	NNP	O
Ratings	NNP	O
(	(	O
unpublished	JJ	O
scale	NN	O
)	)	O
.	.	O

However	RB	O
,	,	O
other	JJ	O
behavioral	JJ	O
rating	NN	O
measures	NNS	O
did	VBD	O
not	RB	O
confirm	VB	O
this	DT	O
result	NN	O
.	.	O

There	EX	O
was	VBD	O
only	RB	O
a	DT	O
suggestion	NN	O
that	IN	O
naltrexone	NN	O
reduced	VBD	O
fidgety	NN	O
and	CC	O
hyperactive	JJ	O
behavior	NN	O
and	CC	O
tended	VBD	O
to	TO	O
alleviate	VB	O
overall	JJ	O
symptomatology	NN	O
in	IN	O
older	JJR	O
children	NNS	O
.	.	O

Naltrexone	NN	O
did	VBD	O
not	RB	O
appear	VB	O
to	TO	O
affect	VB	O
discrimination	NN	O
learning	VBG	O
.	.	O

Results	NNS	O
are	VBP	O
preliminary	JJ	O
and	CC	O
,	,	O
owing	VBG	O
to	TO	O
the	DT	O
small	JJ	O
sample	NN	O
size	NN	O
,	,	O
can	MD	O
be	VB	O
considered	VBN	O
only	RB	O
suggestive	JJ	O
until	IN	O
this	DT	O
study	NN	O
is	VBZ	O
completed	VBN	O
or	CC	O
replication	NN	O
is	VBZ	O
obtained	VBN	O
from	IN	O
independent	JJ	O
research	NN	O
.	.	O

Intra-operative	JJ	O
antibiotic	JJ	O
prophylaxis	NN	O
in	IN	O
neurosurgery	NN	O
.	.	O

A	DT	O
prospective	JJ	O
,	,	O
randomized	VBN	O
,	,	O
controlled	VBN	O
study	NN	O
on	IN	O
cefotiam	NN	O
.	.	O

In	IN	O
this	DT	O
prospective	JJ	O
,	,	O
randomized	VBN	O
and	CC	O
controlled	VBN	O
study	VB	O
the	DT	O
effect	NN	O
of	IN	O
cefotiam	NN	O
for	IN	O
the	DT	O
prevention	NN	O
of	IN	O
wound	JJ	O
infections	NNS	O
following	VBG	O
trepanations	NNS	O
was	VBD	O
investigated	VBN	O
.	.	O

The	DT	O
main	JJ	O
interest	NN	O
was	VBD	O
centered	VBN	O
on	IN	O
the	DT	O
rate	NN	O
of	IN	O
post-operative	JJ	O
bone	NN	O
flap	NN	O
infections	NNS	O
requiring	VBG	O
operative	JJ	O
revision	NN	O
.	.	O

Administration	NNP	O
of	IN	O
cefotiam	NN	O
was	VBD	O
randomized	VBN	O
for	IN	O
patients	NNS	O
undergoing	VBG	O
major	JJ	O
craniotomies	NNS	O
.	.	O

The	DT	O
antibiotic	NN	O
was	VBD	O
administered	VBN	O
intravenously	RB	O
in	IN	O
a	DT	O
single	JJ	O
dose	NN	O
of	IN	O
2	CD	O
g	NN	O
with	IN	O
induction	NN	O
of	IN	O
anaesthesia	NN	O
.	.	O

Only	JJ	O
clean	JJ	O
or	CC	O
clean	JJ	O
contaminated	VBN	O
cases	NNS	O
were	VBD	O
included	VBN	O
.	.	O

Excluded	VBN	O
were	VBD	O
contaminated	VBN	O
cases	NNS	O
,	,	O
operations	NNS	O
with	IN	O
a	DT	O
transnasal-transsphenoidal	JJ	O
approach	NN	O
,	,	O
shunt-operations	NNS	O
and	CC	O
patients	NNS	O
with	IN	O
any	DT	O
other	JJ	O
preoperative	JJ	O
infection	NN	O
or	CC	O
antibiotic	JJ	O
therapy	NN	O
.	.	O

Outpatients	NNS	O
were	VBD	O
excluded	VBN	O
due	JJ	O
to	TO	O
difficulties	NNS	O
in	IN	O
obtaining	VBG	O
sufficient	JJ	O
clinical	JJ	O
information	NN	O
.	.	O

From	NNP	O
originally	RB	O
918	CD	SS
consecutive	JJ	O
patients	NNS	O
operated	VBN	O
on	IN	O
711	CD	SS
fulfilled	VBD	O
the	DT	O
entry	NN	O
criteria	NNS	O
.	.	O

With	IN	O
regard	NN	O
to	TO	O
age	NN	O
,	,	O
sex	NN	O
,	,	O
diagnosis	NN	O
and	CC	O
the	DT	O
site	NN	O
of	IN	O
te	JJ	O
trepanation	NN	O
,	,	O
control	NN	O
patients	NNS	O
(	(	O
n	JJ	O
=	NNP	O
355	CD	SS
)	)	O
and	CC	O
cefotiam	$	O
treated	VBN	O
patients	NNS	O
(	(	O
n	JJ	O
=	NNP	O
356	CD	SS
)	)	O
were	VBD	O
shown	VBN	O
to	TO	O
be	VB	O
comparable	JJ	O
.	.	O

In	IN	O
the	DT	O
various	JJ	O
subgroups	NNS	O
formed	VBN	O
for	IN	O
different	JJ	O
primary	JJ	O
diagnoses	NNS	O
,	,	O
concomitant	JJ	O
steroidal	NN	O
therapy	NN	O
and	CC	O
concomitant	NN	O
severe	JJ	O
internal	JJ	O
medical	JJ	O
diseases	NNS	O
cefotiam	VBP	O
treated	VBN	O
patients	NNS	O
and	CC	O
controls	NNS	O
were	VBD	O
comparable	JJ	O
as	RB	O
well	RB	O
.	.	O

A	DT	O
highly	RB	O
significant	JJ	O
difference	NN	O
for	IN	O
bone	NN	O
flap	NN	O
infection	NN	O
could	MD	O
be	VB	O
shown	VBN	O
with	IN	O
0.3	CD	O
%	NN	O
in	IN	O
the	DT	O
cefotiam	NN	O
group	NN	O
versus	VBD	O
5.1	CD	O
%	NN	O
in	IN	O
the	DT	O
control	NN	O
group	NN	O
(	(	O
p	VBZ	O
less	JJR	O
than	IN	O
0.001	CD	O
)	)	O
.	.	O

The	DT	O
overall	JJ	O
rate	NN	O
of	IN	O
post-operative	JJ	O
deep	JJ	O
wound	NN	O
infections	NNS	O
including	VBG	O
meningitis	NN	O
and	CC	O
abscesses	NNS	O
was	VBD	O
also	RB	O
significantly	RB	O
(	(	O
p	NN	O
less	JJR	O
than	IN	O
0.005	CD	O
)	)	O
different	JJ	O
with	IN	O
3.1	CD	O
%	NN	O
in	IN	O
the	DT	O
cefotiam	NN	O
versus	IN	O
9.0	CD	O
%	NN	O
in	IN	O
the	DT	O
control	NN	O
group	NN	O
.	.	O

Thus	VB	O
it	PRP	O
was	VBD	O
concluded	VBN	O
that	IN	O
a	DT	O
single	JJ	O
dose	NN	O
of	IN	O
cefotiam	NN	O
significantly	RB	O
reduces	VBZ	O
post-operative	JJ	O
deep	JJ	O
wound	NN	O
infection	NN	O
.	.	O

Predictors	NNS	O
of	IN	O
smoking	VBG	C
cessation	NN	C
among	IN	O
cancer	NN	C
patients	NNS	O
enrolled	VBN	O
in	IN	O
a	DT	O
smoking	NN	O
cessation	NN	O
program	NN	O
.	.	O

UNLABELLED	NNP	O
Many	JJ	O
cancer	NN	O
patients	NNS	O
continue	VBP	O
to	TO	O
smoke	VB	O
postdiagnosis	NN	O
,	,	O
which	WDT	O
is	VBZ	O
associated	VBN	O
with	IN	O
poorer	JJR	O
clinical	JJ	O
outcomes	NNS	O
.	.	O

Identifying	VBG	O
prospective	JJ	O
predictors	NNS	O
of	IN	O
smoking	VBG	O
cessation	NN	O
among	IN	O
patients	NNS	O
currently	RB	O
receiving	VBG	O
smoking	VBG	O
cessation	NN	O
treatment	NN	O
can	MD	O
help	VB	O
guide	VB	O
the	DT	O
development	NN	O
and	CC	O
implementation	NN	O
of	IN	O
smoking	VBG	O
cessation	NN	O
programs	NNS	O
with	IN	O
this	DT	O
population	NN	O
.	.	O

MATERIAL	NNP	O
AND	CC	O
METHODS	NNP	O
Data	NNP	O
from	IN	O
246	CD	SS
cancer	NN	C
patients	NNS	O
participating	VBG	O
in	IN	O
a	DT	O
randomized	JJ	O
placebo-controlled	JJ	O
smoking	NN	O
cessation	NN	O
clinical	JJ	O
trial	NN	O
were	VBD	O
used	VBN	O
to	TO	O
examine	VB	O
baseline	JJ	O
predictors	NNS	O
of	IN	O
end-of-treatment	JJ	O
and	CC	O
six-month	JJ	O
postbaseline	NN	O
smoking	NN	O
cessation	NN	O
outcomes	RB	O
.	.	O

Baseline	NNP	O
demographic	JJ	O
,	,	O
smoking-related	JJ	O
,	,	O
disease-related	JJ	O
,	,	O
and	CC	O
psychological	JJ	O
variables	NNS	O
were	VBD	O
examined	VBN	O
as	IN	O
predictors	NNS	O
of	IN	O
biochemically-confirmed	JJ	O
point-prevalence	NN	O
abstinence	NN	O
.	.	O

RESULTS	NNP	O
Multivariate	NNP	O
analysis	NN	O
indicated	VBD	O
that	IN	O
,	,	O
for	IN	O
end-of-treatment	JJ	O
abstinence	NN	O
,	,	O
patients	NNS	O
were	VBD	O
significantly	RB	O
more	RBR	O
likely	JJ	O
to	TO	O
have	VB	O
quit	NN	O
smoking	VBG	O
if	IN	O
they	PRP	O
were	VBD	O
older	JJR	O
(	(	O
OR	NNP	O
=	VBZ	O
1.06	CD	O
,	,	O
95	CD	O
%	NN	O
CI	NNP	O
:	:	O
1.03-1.10	JJ	O
,	,	O
p	JJ	O
<	NNP	O
0.05	CD	O
)	)	O
and	CC	O
were	VBD	O
diagnosed	VBN	O
with	IN	O
a	DT	O
non-tobacco	JJ	O
related	JJ	O
cancer	NN	O
(	(	O
OR	NNP	O
=	VBZ	O
2.54	CD	O
,	,	O
95	CD	O
%	NN	O
CI	NNP	O
:	:	O
1.24-5.20	JJ	O
,	,	O
p	JJ	O
<	NNP	O
0.05	CD	O
)	)	O
.	.	O

Likewise	NNP	O
,	,	O
for	IN	O
six-month	JJ	O
abstinence	NN	O
,	,	O
patients	NNS	O
were	VBD	O
significantly	RB	O
more	RBR	O
likely	JJ	O
to	TO	O
have	VB	O
quit	NN	O
smoking	VBG	O
if	IN	O
they	PRP	O
were	VBD	O
older	JJR	O
(	(	O
OR	NNP	O
=	VBZ	O
1.04	CD	O
,	,	O
95	CD	O
%	NN	O
CI	NNP	O
:	:	O
1.01-1.08	JJ	O
,	,	O
p	JJ	O
<	NNP	O
0.05	CD	O
)	)	O
and	CC	O
were	VBD	O
significantly	RB	O
less	RBR	O
likely	JJ	O
to	TO	O
have	VB	O
quit	NN	O
smoking	VBG	O
if	IN	O
they	PRP	O
were	VBD	O
female	JJ	O
(	(	O
OR	NNP	O
=	VBZ	O
0.47	CD	O
,	,	O
95	CD	O
%	NN	O
CI	NNP	O
:	:	O
0.22-0.97	JJ	O
,	,	O
p	JJ	O
<	NNP	O
0.05	CD	O
)	)	O
.	.	O

Patients	NNS	O
with	IN	O
tobacco-related	JJ	O
cancers	NNS	O
and	CC	O
female	JJ	SE
patients	NNS	O
reported	VBD	O
significantly	RB	O
higher	JJR	O
levels	NNS	O
of	IN	O
depression	NN	O
symptoms	NNS	O
(	(	O
p	JJ	O
<	NNP	O
0.05	CD	O
)	)	O
,	,	O
which	WDT	O
proved	VBD	O
predictive	NN	O
of	IN	O
smoking	VBG	O
relapse	NN	O
.	.	O

CONCLUSIONS	NNP	O
Patient	NNP	O
age	NN	O
,	,	O
gender	NN	O
,	,	O
and	CC	O
cancer-type	NN	O
may	MD	O
be	VB	O
important	JJ	O
factors	NNS	O
to	TO	O
consider	VB	O
when	WRB	O
developing	VBG	O
and	CC	O
implementing	VBG	O
smoking	VBG	O
cessation	NN	O
interventions	NNS	O
for	IN	O
cancer	NN	O
patients	NNS	O
.	.	O

Fentanyl	NNP	O
supplementation	NN	O
to	TO	O
inhalation	NN	C
anaesthesia	NN	C
.	.	O

In	IN	O
eight	CD	SS
out	IN	O
of	IN	O
15	CD	SS
healthy	JJ	C
patients	NNS	O
undergoing	VBG	O
body	NN	O
surface	NN	O
surgery	NN	O
,	,	O
the	DT	O
effect	NN	O
of	IN	O
a	DT	O
fentanyl	JJ	O
infusion	NN	O
on	IN	O
a	DT	O
conventional	JJ	O
thiopentone	NN	O
,	,	O
nitrous	JJ	O
oxide	NN	O
,	,	O
oxygen	NN	O
and	CC	O
halothane	NN	O
anaesthetic	NN	O
was	VBD	O
studied	VBN	O
.	.	O

The	DT	O
fentanyl	JJ	O
infusion	NN	O
(	(	O
2	CD	O
micrograms/kg/hour	NN	O
)	)	O
reduced	VBD	O
the	DT	O
induction	NN	O
dose	NN	O
of	IN	O
thiopentone	NN	O
and	CC	O
caused	VBD	O
marked	JJ	O
respiratory	JJ	O
depression	NN	O
with	IN	O
a	DT	O
reduction	NN	O
in	IN	O
the	DT	O
patients	NNS	O
'	POS	O
response	NN	O
to	TO	O
surgery	NN	O
.	.	O

The	DT	O
mean	JJ	O
arterial	JJ	O
pressures	NNS	O
and	CC	O
pulse	JJ	O
rates	NNS	O
were	VBD	O
not	RB	O
significantly	RB	O
different	JJ	O
in	IN	O
each	DT	O
group	NN	O
throughout	IN	O
the	DT	O
course	NN	O
of	IN	O
the	DT	O
operation	NN	O
.	.	O

The	DT	O
fentanyl	NN	O
made	VBD	O
no	DT	O
difference	NN	O
to	TO	O
the	DT	O
patients	NNS	O
'	POS	O
postoperative	JJ	O
analgesic	JJ	O
requirements	NNS	O
or	CC	O
to	TO	O
their	PRP$	O
recovery	NN	O
in	IN	O
the	DT	O
first	JJ	O
24	CD	O
hours	NNS	O
.	.	O

Yohimbine	NN	O
in	IN	O
neurally	RB	C
mediated	VBN	C
syncope	NN	C
.	.	O

Pathophysiological	JJ	O
implications	NNS	O
.	.	O

In	IN	O
this	DT	O
study	NN	O
,	,	O
we	PRP	O
evaluated	VBD	O
if	IN	O
increased	VBN	O
sympathetic	JJ	O
stimulation	NN	O
is	VBZ	O
an	DT	O
essential	JJ	O
requirement	NN	O
for	IN	O
the	DT	O
development	NN	O
of	IN	O
neurally	RB	O
mediated	VBN	O
syncope	NN	O
(	(	O
NMS	NNP	O
)	)	O
by	IN	O
manipulating	VBG	O
overall	JJ	O
sympathetic	JJ	O
outflow	NN	O
in	IN	O
subjects	NNS	C
susceptible	JJ	C
to	TO	C
tilt-induced	JJ	C
syncope	NN	C
.	.	O

Eight	NNP	SS
previously	RB	O
characterized	VBD	O
patients	NNS	O
with	IN	O
recurrent	JJ	O
NMS	NNP	O
(	(	O
five	CD	SS
females	NNS	SE
and	CC	O
three	CD	SS
males	NNS	SE
;	:	O
34+/-2	JJ	A
yr	NN	A
)	)	O
were	VBD	O
recruited	VBN	O
from	IN	O
the	DT	O
Vanderbilt	NNP	O
Syncope	NNP	O
Unit	NNP	O
and	CC	O
eight	CD	SS
age-matched	JJ	A
controls	NNS	C
underwent	JJ	O
initial	JJ	O
administration	NN	O
of	IN	O
clonidine	NN	O
(	(	O
CLO	NNP	O
)	)	O
or	CC	O
yohimbine	NN	O
(	(	O
YHO	NNP	O
)	)	O
.	.	O

This	DT	O
was	VBD	O
done	VBN	O
,	,	O
prospectively	RB	O
,	,	O
to	TO	O
determine	VB	O
doses	NNS	O
of	IN	O
these	DT	O
agents	NNS	O
that	WDT	O
would	MD	O
increase	VB	O
or	CC	O
decrease	VB	O
plasma	JJ	O
norepinephrine	NN	O
levels	NNS	O
by	IN	O
>	NNP	O
/=	NNP	O
30	CD	O
%	NN	O
.	.	O

On	IN	O
a	DT	O
different	JJ	O
day	NN	O
,	,	O
in	IN	O
all	DT	O
subjects	NNS	O
we	PRP	O
determined	VBD	O
intraarterial	JJ	O
blood	NN	O
pressure	NN	O
,	,	O
EKG	NNP	O
and	CC	O
muscle	NN	O
sympathetic	JJ	O
nerve	NN	O
activity	NN	O
(	(	O
MSNA	NNP	O
)	)	O
both	DT	O
supine	JJ	O
and	CC	O
during	IN	O
upright	JJ	O
tilt	NN	O
.	.	O

After	IN	O
this	DT	O
,	,	O
subjects	VBZ	O
randomly	RB	O
received	VBN	O
either	CC	O
CLO	NNP	O
or	CC	O
YHO	NNP	O
,	,	O
and	CC	O
3	CD	O
h	NN	O
later	RB	O
another	DT	O
tilt	NN	O
was	VBD	O
performed	VBN	O
.	.	O

After	IN	O
1	CD	O
wk	NN	O
,	,	O
a	DT	O
similar	JJ	O
procedure	NN	O
with	IN	O
the	DT	O
other	JJ	O
drug	NN	O
was	VBD	O
performed	VBN	O
.	.	O

During	IN	O
the	DT	O
two	CD	O
basal	NN	O
tilts	NNS	O
,	,	O
all	PDT	O
the	DT	O
control	NN	O
subjects	VBZ	O
completed	VBN	O
the	DT	O
study	NN	O
,	,	O
whereas	IN	O
all	PDT	O
the	DT	O
NMS	NNP	O
patients	NNS	O
developed	VBD	O
syncope	NN	O
.	.	O

Reduction	NN	O
in	IN	O
sympathetic	JJ	O
tone	NN	O
by	IN	O
CLO	NNP	O
resulted	VBD	O
in	IN	O
a	DT	O
decreased	JJ	O
tolerance	NN	O
to	TO	O
tilt	VB	O
in	IN	O
three	CD	O
out	IN	O
of	IN	O
eight	CD	O
controls	NNS	O
and	CC	O
in	IN	O
all	PDT	O
the	DT	O
NMS	NNP	O
patients	NNS	O
.	.	O

In	IN	O
contrast	NN	O
,	,	O
YHO	NNP	O
not	RB	O
only	RB	O
increased	VBD	O
basal	NN	O
plasma	NN	O
NorEpi	NNP	O
levels	NNS	O
and	CC	O
MSNA	NNP	O
,	,	O
but	CC	O
also	RB	O
prevented	VBD	O
syncope	NN	O
in	IN	O
seven	CD	O
out	IN	O
of	IN	O
eight	CD	O
patients	NNS	O
.	.	O

In	IN	O
a	DT	O
selected	JJ	O
population	NN	O
of	IN	O
patients	NNS	O
,	,	O
increased	VBD	O
sympathetic	JJ	O
activity	NN	O
is	VBZ	O
not	RB	O
a	DT	O
prerequisite	NN	O
for	IN	O
the	DT	O
development	NN	O
of	IN	O
syncope	NN	O
.	.	O

Yohimbine-induced	JJ	O
enhancement	NN	O
of	IN	O
sympathetic	JJ	O
tone	NN	O
in	IN	O
patients	NNS	O
with	IN	O
NMS	NNP	O
improves	VBZ	O
orthostatic	JJ	O
tolerance	NN	O
and	CC	O
raises	VBZ	O
the	DT	O
possibility	NN	O
that	IN	O
this	DT	O
drug	NN	O
may	MD	O
be	VB	O
a	DT	O
useful	JJ	O
agent	NN	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
NMS	NNP	O
.	.	O

Reduced	VBN	O
albuminuria	NNS	O
with	IN	O
sarpogrelate	NN	O
is	VBZ	O
accompanied	VBN	O
by	IN	O
a	DT	O
decrease	NN	O
in	IN	O
monocyte	JJ	O
chemoattractant	JJ	O
protein-1	NN	O
levels	NNS	O
in	IN	O
type	NN	C
2	CD	C
diabetes	NNS	C
.	.	O

BACKGROUND	NNP	O
AND	NNP	O
OBJECTIVES	NNP	O
Sarpogrelate	NNP	O
has	VBZ	O
been	VBN	O
shown	VBN	O
to	TO	O
reduce	VB	O
albuminuria	NNS	O
in	IN	O
diabetic	JJ	O
nephropathy	NN	O
.	.	O

For	IN	O
examination	NN	O
of	IN	O
whether	IN	O
this	DT	O
is	VBZ	O
based	VBN	O
on	IN	O
the	DT	O
same	JJ	O
mechanisms	NN	O
as	IN	O
angiotensin	NN	O
II	NNP	O
receptor	NN	O
blockers	NNS	O
or	CC	O
thiazolidinedione	NN	O
,	,	O
effects	NNS	O
of	IN	O
sarpogrelate	NN	O
on	IN	O
atherosclerotic	JJ	O
inflammatory	NN	O
molecules	NNS	O
and	CC	O
their	PRP$	O
relations	NNS	O
to	TO	O
albuminuria	NNS	O
in	IN	O
patients	NNS	O
who	WP	O
had	VBD	O
diabetes	NNS	C
and	CC	O
had	VBD	O
already	RB	O
been	VBN	O
treated	VBN	O
with	IN	O
angiotensin	NN	O
II	NNP	O
receptor	NN	O
blockers	NNS	O
and	CC	O
with	IN	O
or	CC	O
without	IN	O
thiazolidinedione	NN	O
were	VBD	O
examined	VBN	O
.	.	O

DESIGN	NNP	O
,	,	O
SETTING	NNP	O
,	,	O
PARTICIPANTS	NNP	O
,	,	O
&	CC	O
MEASUREMENTS	NNP	O
Forty	NNP	SS
patients	NNS	O
who	WP	O
had	VBD	O
diabetes	NNS	C
with	IN	O
nephropathy	JJ	C
and	CC	O
arteriosclerosis	NN	C
obliterans	NNS	C
and	CC	O
had	VBD	O
already	RB	O
been	VBN	O
treated	VBN	O
with	IN	O
angiotensin	NN	O
II	NNP	O
receptor	NN	O
blocker	NN	O
(	(	O
n	JJ	O
=	NNP	O
40	CD	O
)	)	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
sarpogrelate	VB	O
(	(	O
300	CD	O
mg/d	NN	O
;	:	O
n	CC	O
=	VB	O
20	CD	O
)	)	O
or	CC	O
aspirin	JJ	O
group	NN	O
(	(	O
100	CD	O
mg/d	NN	O
;	:	O
n	CC	O
=	VB	O
20	CD	O
)	)	O
.	.	O

Plasma	NNP	O
monocyte	JJ	O
chemoattractant	JJ	O
protein-1	NN	O
and	CC	O
urinary	JJ	O
albumin-to-creatinine	JJ	O
ratio	NN	O
and	CC	O
monocyte	NN	O
chemoattractant	JJ	O
protein-1	NN	O
were	VBD	O
measured	VBN	O
at	IN	O
baseline	NN	O
and	CC	O
16	CD	O
wk	NN	O
after	IN	O
administration	NN	O
.	.	O

RESULTS	NNP	O
Only	RB	O
the	DT	O
sarpogrelate	NN	O
group	NN	O
showed	VBD	O
increases	NNS	O
in	IN	O
plasma	NN	O
adiponectin	NN	O
and	CC	O
decreases	NNS	O
in	IN	O
both	DT	O
plasma	NN	O
and	CC	O
urinary	JJ	O
monocyte	NN	O
chemoattractant	JJ	O
protein-1	JJ	O
and	CC	O
albumin-to-creatinine	JJ	O
ratio	NN	O
levels	NNS	O
.	.	O

Moreover	RB	O
,	,	O
percentage	NN	O
change	NN	O
of	IN	O
monocyte	NN	O
chemoattractant	JJ	O
protein-1	JJ	O
level	NN	O
correlated	VBD	O
positively	RB	O
to	TO	O
that	DT	O
of	IN	O
albumin-to-creatinine	JJ	O
ratio	NN	O
.	.	O

Even	RB	O
when	WRB	O
the	DT	O
sarpogrelate	NN	O
group	NN	O
was	VBD	O
further	RB	O
divided	VBN	O
into	IN	O
two	CD	O
groups	NNS	O
with	IN	O
(	(	O
n	JJ	O
=	NNP	O
9	CD	O
)	)	O
or	CC	O
without	IN	O
thiazolidinedione	NN	O
(	(	O
n	JJ	O
=	NNP	O
11	CD	O
)	)	O
,	,	O
changes	NNS	O
in	IN	O
monocyte	NN	O
chemoattractant	JJ	O
protein-1	JJ	O
or	CC	O
albumin-to-creatinine	JJ	O
ratio	NN	O
did	VBD	O
not	RB	O
differ	VB	O
.	.	O

CONCLUSIONS	NNP	O
Sarpogrelate	NNP	O
can	MD	O
reduce	VB	O
albuminuria	NNS	O
and	CC	O
plasma	NN	O
and	CC	O
urinary	JJ	O
monocyte	NN	O
chemoattractant	JJ	O
protein-1	JJ	O
levels	NNS	O
while	IN	O
increasing	VBG	O
plasma	NN	O
adiponectin	NN	O
in	IN	O
diabetic	JJ	O
nephropathy	NN	O
.	.	O

These	DT	O
effects	NNS	O
seem	VBP	O
to	TO	O
be	VB	O
mediated	VBN	O
via	IN	O
mechanisms	NNS	O
that	WDT	O
are	VBP	O
different	JJ	O
from	IN	O
those	DT	O
of	IN	O
angiotensin	JJ	O
II	NNP	O
receptor	NN	O
blocker	NN	O
or	CC	O
thiazolidinedione	NN	O
.	.	O

Comparison	NNP	O
of	IN	O
endocrine	NN	O
and	CC	O
radiation	NN	O
therapy	NN	O
in	IN	O
locally	RB	O
advanced	JJ	O
prostatic	JJ	O
cancer	NN	O
.	.	O

151	CD	SS
patients	NNS	O
with	IN	O
locally	RB	O
advanced	JJ	O
prostatic	JJ	O
cancer	NN	O
(	(	O
T3-4	NNP	O
M0	NNP	O
)	)	O
,	,	O
representing	VBG	O
38	CD	O
%	NN	O
of	IN	O
the	DT	O
404	CD	O
cancer	NN	O
patients	NNS	O
in	IN	O
a	DT	O
Finnish	JJ	O
multicenter	NN	O
study	NN	O
,	,	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
one	CD	O
of	IN	O
three	CD	O
treatment	NN	O
arms	NNS	O
:	:	O
orchiectomy	NN	O
,	,	O
estrogens	VBZ	O
or	CC	O
radiotherapy	NN	O
.	.	O

During	IN	O
the	DT	O
4-year	JJ	O
follow-up	JJ	O
period	NN	O
there	EX	O
were	VBD	O
no	DT	O
significant	JJ	O
differences	NNS	O
in	IN	O
the	DT	O
progression	NN	O
rates	NNS	O
(	(	O
appearance	NN	O
of	IN	O
metastases	NNS	O
in	IN	O
bone	NN	O
scan	NN	O
)	)	O
between	IN	O
the	DT	O
therapy	NN	O
groups	NNS	O
.	.	O

The	DT	O
frequency	NN	O
of	IN	O
thromboembolic	JJ	O
and	CC	O
other	JJ	O
cardiovascular	JJ	O
complications	NNS	O
was	VBD	O
highest	JJS	O
in	IN	O
the	DT	O
estrogen	NN	O
group	NN	O
(	(	O
13/50	CD	O
patients	NNS	O
)	)	O
.	.	O

In	IN	O
the	DT	O
radiotherapy	NN	O
group	NN	O
,	,	O
19	CD	O
of	IN	O
45	CD	O
patients	NNS	O
had	VBD	O
bowel	NN	O
or	CC	O
bladder	NN	O
complications	NNS	O
.	.	O

On	IN	O
the	DT	O
other	JJ	O
hand	NN	O
,	,	O
orchiectomy	NN	O
has	VBZ	O
few	JJ	O
,	,	O
if	IN	O
any	DT	O
,	,	O
complications	NNS	O
.	.	O

The	DT	O
high	JJ	O
risk	NN	O
of	IN	O
complications	NNS	O
associated	VBN	O
with	IN	O
estrogens	NNS	O
and	CC	O
radiotherapy	NN	O
has	VBZ	O
to	TO	O
be	VB	O
taken	VBN	O
into	IN	O
consideration	NN	O
in	IN	O
the	DT	O
selection	NN	O
of	IN	O
treatment	NN	O
.	.	O

Activator	NNP	O
protein-1	NN	O
(	(	O
AP-1	NNP	O
)	)	O
signalling	VBG	O
in	IN	O
human	JJ	O
atherosclerosis	NN	C
:	:	O
results	NNS	O
of	IN	O
a	DT	O
systematic	JJ	O
evaluation	NN	O
and	CC	O
intervention	NN	O
study	NN	O
.	.	O

Animal	NNP	O
studies	NNS	O
implicate	VBP	O
the	DT	O
AP-1	NNP	O
(	(	O
activator	IN	O
protein-1	NN	O
)	)	O
pro-inflammatory	NN	O
pathway	NN	O
as	IN	O
a	DT	O
promising	NN	O
target	NN	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
atherosclerotic	JJ	C
disease	NN	C
.	.	O

It	PRP	O
is	VBZ	O
,	,	O
however	RB	O
,	,	O
unclear	JJ	O
whether	IN	O
these	DT	O
observations	NNS	O
apply	VBP	O
to	TO	O
human	JJ	O
atherosclerosis	NN	C
.	.	O

Therefore	IN	O
we	PRP	O
evaluated	VBD	O
the	DT	O
profile	NN	O
of	IN	O
AP-1	NNP	O
activation	NN	O
through	IN	O
histological	JJ	O
analysis	NN	O
and	CC	O
tested	VBD	O
the	DT	O
potential	JJ	O
benefit	NN	O
of	IN	O
AP-1	NNP	O
inhibition	NN	O
in	IN	O
a	DT	O
clinical	JJ	O
trial	NN	O
.	.	O

AP-1	JJ	O
activation	NN	O
was	VBD	O
quantified	VBN	O
by	IN	O
phospho-c-Jun	JJ	O
nuclear	JJ	O
translocation	NN	O
(	(	O
immunohistochemistry	NN	O
)	)	O
on	IN	O
a	DT	O
biobank	NN	O
of	IN	O
aortic	JJ	C
wall	NN	C
samples	NNS	O
from	IN	O
organ	JJ	O
donors	NNS	O
.	.	O

The	DT	O
effect	NN	O
of	IN	O
AP-1	NNP	O
inhibition	NN	O
on	IN	O
vascular	JJ	O
parameters	NNS	O
was	VBD	O
tested	VBN	O
through	IN	O
a	DT	O
double	JJ	O
blind	JJ	O
placebo-controlled	JJ	O
cross-over	NN	O
study	NN	O
of	IN	O
28	CD	O
days	NNS	O
doxycycline	NN	O
or	CC	O
placebo	NN	O
in	IN	O
patients	NNS	O
with	IN	O
symptomatic	JJ	O
peripheral	JJ	O
artery	NN	O
disease	NN	O
.	.	O

Vascular	JJ	O
function	NN	O
was	VBD	O
assessed	VBN	O
by	IN	O
brachial	JJ	O
dilation	NN	O
as	RB	O
well	RB	O
as	IN	O
by	IN	O
plasma	NN	O
samples	NNS	O
analysed	VBN	O
for	IN	O
hs-CRP	NN	O
(	(	O
high-sensitivity	JJ	O
C-reactive	NNP	O
protein	NN	O
)	)	O
,	,	O
IL-6	NNP	O
(	(	O
interleukin-6	NN	O
)	)	O
,	,	O
IL-8	NNP	O
,	,	O
ICAM-1	NNP	O
(	(	O
intercellular	JJ	O
adhesion	NN	O
molecule-1	NN	O
)	)	O
,	,	O
vWF	FW	O
(	(	O
von	FW	O
Willebrand	NNP	O
factor	NN	O
)	)	O
,	,	O
MCP-1	NNP	O
(	(	O
monocyte	JJ	O
chemoattractant	NN	O
protein-1	NN	O
)	)	O
,	,	O
PAI-1	NNP	O
(	(	O
plasminogen	JJ	O
activator	NN	O
inhibitor-1	NN	O
)	)	O
and	CC	O
fibrinogen	NN	O
.	.	O

Histological	JJ	O
evaluation	NN	O
of	IN	O
human	JJ	O
atherosclerosis	NN	O
showed	VBD	O
minimal	JJ	O
AP-1	NNP	O
activation	NN	O
in	IN	O
non-diseased	JJ	O
arterial	JJ	O
wall	NN	O
(	(	O
i.e	JJ	O
.	.	O

vessel	NN	O
wall	NN	O
without	IN	O
any	DT	O
signs	NNS	O
of	IN	O
atherosclerotic	JJ	O
disease	NN	O
)	)	O
.	.	O

A	DT	O
gradual	JJ	O
increase	NN	O
of	IN	O
AP-1	NNP	O
activation	NN	O
was	VBD	O
found	VBN	O
in	IN	O
non-progressive	JJ	O
and	CC	O
progressive	JJ	O
phases	NNS	O
of	IN	O
atherosclerosis	NN	O
respectively	RB	O
(	(	O
P	NNP	O
<	NNP	O
0.044	CD	O
)	)	O
.	.	O

No	DT	O
significant	JJ	O
difference	NN	O
was	VBD	O
found	VBN	O
between	IN	O
progressive	JJ	O
and	CC	O
vulnerable	JJ	O
lesions	NNS	O
.	.	O

The	DT	O
expression	NN	O
of	IN	O
phospho-c-Jun	JJ	O
diminished	VBN	O
as	IN	O
the	DT	O
lesion	NN	O
stabilized	VBN	O
(	(	O
P	NNP	O
<	NNP	O
0.016	CD	O
)	)	O
and	CC	O
does	VBZ	O
not	RB	O
significantly	RB	O
differ	VBP	O
from	IN	O
the	DT	O
normal	JJ	O
aortic	JJ	O
wall	NN	O
(	(	O
P	NNP	O
<	NNP	O
0.33	CD	O
)	)	O
.	.	O

Evaluation	NN	O
of	IN	O
the	DT	O
doxycycline	NN	O
intervention	NN	O
only	RB	O
revealed	VBD	O
a	DT	O
borderline-significant	JJ	O
reduction	NN	O
of	IN	O
circulating	VBG	O
hs-CRP	JJ	O
levels	NNS	O
(	(	O
-0.51	NNP	O
?g/ml	NNP	O
,	,	O
P=0.05	NNP	O
)	)	O
and	CC	O
did	VBD	O
not	RB	O
affect	VB	O
any	DT	O
of	IN	O
the	DT	O
other	JJ	O
markers	NNS	O
of	IN	O
systemic	JJ	O
inflammation	NN	O
and	CC	O
vascular	JJ	O
function	NN	O
.	.	O

Our	PRP$	O
studies	NNS	O
do	VBP	O
not	RB	O
characterize	VB	O
AP-1	NNP	O
as	IN	O
a	DT	O
therapeutic	JJ	O
target	NN	O
for	IN	O
progressive	JJ	O
human	JJ	O
atherosclerotic	JJ	O
disease	NN	O
.	.	O

The	DT	O
additive	JJ	O
analgesic	JJ	O
efficacy	NN	O
of	IN	O
acetaminophen	NN	O
,	,	O
1000	CD	O
mg	NN	O
,	,	O
and	CC	O
codeine	NN	O
,	,	O
60	CD	O
mg	NN	O
,	,	O
in	IN	O
dental	JJ	C
pain	NN	C
.	.	O

In	IN	O
a	DT	O
double-blind	NN	O
,	,	O
randomized	VBN	O
,	,	O
single-dose	JJ	O
trial	NN	O
the	DT	O
analgesic	JJ	O
contribution	NN	O
of	IN	O
acetaminophen	NN	O
,	,	O
1000	CD	O
mg	NN	O
,	,	O
and	CC	O
codeine	NN	O
,	,	O
60	CD	O
mg	NN	O
,	,	O
was	VBD	O
determined	VBN	O
.	.	O

The	DT	O
study	NN	O
was	VBD	O
a	DT	O
2	CD	O
X	NN	O
2	CD	O
factorial	JJ	O
experiment	NN	O
in	IN	O
which	WDT	O
120	CD	SS
patients	NNS	O
suffering	VBG	O
from	IN	O
pain	NN	O
as	IN	O
a	DT	O
result	NN	O
of	IN	O
oral	JJ	O
surgery	NN	O
rated	VBD	O
their	PRP$	O
pain	NN	O
intensity	NN	O
and	CC	O
pain	NN	O
relief	NN	O
for	IN	O
up	IN	O
to	TO	O
5	CD	O
hours	NNS	O
after	IN	O
a	DT	O
single	JJ	O
dose	NN	O
of	IN	O
one	CD	O
of	IN	O
:	:	O
1000	CD	O
mg	NN	O
acetaminophen	NN	O
,	,	O
60	CD	O
mg	NN	O
codeine	NN	O
,	,	O
1000	CD	O
mg	NN	O
acetaminophen	NN	O
plus	CC	O
60	CD	O
mg	NN	O
codeine	NN	O
,	,	O
or	CC	O
placebo	NN	O
.	.	O

The	DT	O
factorial	JJ	O
analysis	NN	O
showed	VBD	O
that	IN	O
both	DT	O
1000	CD	O
mg	NN	O
acetaminophen	NN	O
and	CC	O
60	CD	O
mg	NN	O
codeine	NN	O
made	VBD	O
a	DT	O
statistically	RB	O
significant	JJ	O
(	(	O
P	NNP	O
less	JJR	O
than	IN	O
0.05	CD	O
)	)	O
contribution	NN	O
to	TO	O
the	DT	O
analgesic	JJ	O
effectiveness	NN	O
of	IN	O
the	DT	O
combination	NN	O
on	IN	O
all	DT	O
measures	NNS	O
of	IN	O
efficacy	NN	O
(	(	O
sum	NN	O
of	IN	O
pain	NN	O
intensity	NN	O
differences	NNS	O
,	,	O
largest	JJS	O
pain	NN	O
intensity	NN	O
difference	NN	O
,	,	O
total	JJ	O
pain	NN	O
relief	NN	O
,	,	O
largest	JJS	O
pain	NN	O
relief	NN	O
,	,	O
and	CC	O
time	NN	O
to	TO	O
remedication	NN	O
)	)	O
.	.	O

The	DT	O
incidence	NN	O
of	IN	O
adverse	JJ	O
effects	NNS	O
did	VBD	O
not	RB	O
appear	VB	O
to	TO	O
differ	VB	O
among	IN	O
the	DT	O
treatments	NNS	O
,	,	O
including	VBG	O
placebo	NN	O
.	.	O

MSLT	NNP	O
in	IN	O
primary	JJ	O
insomnia	NN	O
:	:	O
stability	NN	O
and	CC	O
relation	NN	O
to	TO	O
nocturnal	JJ	O
sleep	NN	O
.	.	O

STUDY	NNP	O
OBJECTIVES	NNP	O
To	TO	O
assess	VB	O
the	DT	O
stability	NN	O
of	IN	O
the	DT	O
multiple	JJ	O
sleep	JJ	O
latency	NN	O
test	NN	O
(	(	O
MSLT	NNP	O
)	)	O
in	IN	O
primary	JJ	O
insomnia	NN	O
and	CC	O
its	PRP$	O
relation	NN	O
to	TO	O
total	JJ	O
sleep	JJ	O
time	NN	O
.	.	O

DESIGN	NNP	O
Randomized	NNP	O
,	,	O
double-blind	NN	O
,	,	O
placebo	NN	O
controlled	VBD	O
,	,	O
clinical	JJ	O
trial	NN	O
.	.	O

SETTING	NN	O
Outpatient	NN	O
with	IN	O
sleep	JJ	O
laboratory	NN	O
assessments	NNS	O
in	IN	O
months	NNS	O
1	CD	O
and	CC	O
8	CD	O
of	IN	O
treatment	NN	O
.	.	O

PARTICIPANTS	VB	O
Ninety-five	JJ	SS
primary	JJ	O
insomniacs	NN	C
,	,	O
32-64	CD	A
years	NNS	A
old	JJ	A
and	CC	A
55	CD	A
age-	JJ	A
and	CC	O
sex-matched	JJ	O
general	JJ	O
population-based	JJ	O
,	,	O
representative	JJ	O
controls	NNS	O
.	.	O

INTERVENTIONS	NNP	O
After	IN	O
a	DT	O
screening	JJ	O
nocturnal	JJ	O
polysomnograms	NNS	O
(	(	O
NPSG	NNP	O
)	)	O
and	CC	O
MSLT	NNP	O
the	DT	O
following	JJ	O
day	NN	O
,	,	O
participants	NNS	O
with	IN	O
primary	JJ	C
insomnia	NNS	C
were	VBD	O
randomized	VBN	O
to	TO	O
take	VB	O
zolpidem	NN	O
10	CD	O
mg	NN	O
(	(	O
n	JJ	O
=	NNP	O
50	CD	O
)	)	O
or	CC	O
placebo	NN	O
(	(	O
n	JJ	O
=	NNP	O
45	CD	O
)	)	O
nightly	RB	O
for	IN	O
12	CD	O
months	NNS	O
.	.	O

During	IN	O
months	NNS	O
1	CD	O
and	CC	O
8	CD	O
,	,	O
while	IN	O
taking	VBG	O
their	PRP$	O
prescribed	JJ	O
treatments	NNS	O
,	,	O
NPSGs	NNP	O
and	CC	O
MSLTs	NNP	O
the	DT	O
following	JJ	O
day	NN	O
were	VBD	O
conducted	VBN	O
.	.	O

A	DT	O
population-based	JJ	O
sample	NN	O
served	VBD	O
as	IN	O
controls	NNS	O
and	CC	O
received	VBD	O
a	DT	O
single	JJ	O
NPSG	NNP	O
followed	VBN	O
by	IN	O
MSLT	NNP	O
.	.	O

RESULTS	NNP	O
Mean	NNP	O
daily	JJ	O
sleep	NN	O
latency	NN	O
on	IN	O
the	DT	O
screening	VBG	O
MSLT	NNP	O
of	IN	O
insomniacs	NN	O
was	VBD	O
normally	RB	O
distributed	VBN	O
across	IN	O
the	DT	O
full	JJ	O
range	NN	O
of	IN	O
MSLT	NNP	O
scores	NNS	O
and	CC	O
significantly	RB	O
higher	JJR	O
than	IN	O
those	DT	O
of	IN	O
a	DT	O
population-based	JJ	O
representative	NN	O
control	NN	O
sample	NN	O
(	(	O
P	NNP	O
<	NNP	O
0.006	CD	O
)	)	O
.	.	O

The	DT	O
insomniacs	NN	O
with	IN	O
the	DT	O
highest	JJS	O
screening	NN	O
MSLTs	NNP	O
had	VBD	O
the	DT	O
shortest	JJS	O
screening	NN	O
total	JJ	O
sleep	JJ	O
times	NNS	O
(	(	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
.	.	O

The	DT	O
MSLTs	NNP	O
of	IN	O
insomniacs	NN	O
during	IN	O
treatment	NN	O
in	IN	O
study	JJ	O
month	NN	O
1	CD	O
were	VBD	O
correlated	VBN	O
(	(	O
r	VB	O
=	RB	O
0.44	CD	O
,	,	O
P	NNP	O
<	NNP	O
0.001	CD	O
)	)	O
with	IN	O
their	PRP$	O
month	NN	O
8	CD	O
MSLT	NNP	O
.	.	O

The	DT	O
mean	JJ	O
MSLT	NNP	O
score	NN	O
of	IN	O
the	DT	O
zolpidem	NNP	O
group	NN	O
did	VBD	O
not	RB	O
differ	VB	O
from	IN	O
that	DT	O
of	IN	O
the	DT	O
placebo	NN	O
group	NN	O
,	,	O
and	CC	O
the	DT	O
stability	NN	O
within	IN	O
treatment	NN	O
groups	NNS	O
also	RB	O
did	VBD	O
not	RB	O
differ	VB	O
.	.	O

CONCLUSIONS	NNP	O
These	DT	O
data	NNS	O
support	NN	O
the	DT	O
hypothesis	NN	O
that	IN	O
some	DT	O
insomniacs	NN	O
show	VBP	O
a	DT	O
reliable	JJ	O
disorder	NN	O
of	IN	O
hyperarousal	NN	O
with	IN	O
increased	JJ	O
wake	NN	O
drive	NN	O
both	DT	O
at	IN	O
night	NN	O
and	CC	O
during	IN	O
the	DT	O
day	NN	O
.	.	O

Can	MD	O
simvastatin	VB	O
improve	VB	O
erectile	JJ	O
function	NN	O
and	CC	O
health-related	JJ	O
quality	NN	O
of	IN	O
life	NN	O
in	IN	O
men	NNS	O
aged	VBN	O
?40	CD	O
years	NNS	O
with	IN	O
erectile	JJ	O
dysfunction	NN	O
?	.	O
Results	NNS	O
of	IN	O
the	DT	O
Erectile	NNP	O
Dysfunction	NNP	O
and	CC	O
Statins	NNP	O
Trial	NNP	O
[	NNP	O
ISRCTN66772971	NNP	O
]	NNP	O
.	.	O

OBJECTIVE	NNP	O
To	TO	O
evaluate	VB	O
the	DT	O
effectiveness	NN	O
and	CC	O
cost-effectiveness	NN	O
of	IN	O
simvastatin	NN	O
on	IN	O
erectile	JJ	O
function	NN	O
and	CC	O
health-related	JJ	O
quality	NN	O
of	IN	O
life	NN	O
in	IN	O
men	NNS	O
aged	VBN	O
?40	CD	O
years	NNS	O
with	IN	O
erectile	JJ	O
dysfunction	NN	O
(	(	O
ED	NNP	O
)	)	O
.	.	O

PATIENTS	NNP	O
AND	CC	O
METHODS	NNP	O
ED	NNP	O
is	VBZ	O
common	JJ	O
in	IN	O
men	NNS	O
aged	VBN	O
?40	CD	O
years	NNS	O
and	CC	O
impacts	NNS	O
upon	VBP	O
their	PRP$	O
overall	JJ	O
health-related	JJ	O
quality	NN	O
of	IN	O
life	NN	O
and	CC	O
that	IN	O
of	IN	O
their	PRP$	O
partners	NNS	O
.	.	O

Men	NNP	SE
aged	VBD	O
?40	CD	O
years	NNS	O
who	WP	O
were	VBD	O
not	RB	O
receiving	VBG	O
lipid	JJ	O
lowering	NN	O
or	CC	O
anti-hypertensive	JJ	C
medication	NN	O
and	CC	O
not	RB	O
at	IN	O
high	JJ	O
cardiovascular	JJ	O
risk	NN	O
were	VBD	O
recruited	VBN	O
from	IN	O
10	CD	O
general	JJ	O
practices	NNS	O
in	IN	O
the	DT	O
East	NNP	O
of	IN	O
England	NNP	O
.	.	O

In	IN	O
total	JJ	O
,	,	O
173	CD	SS
eligible	JJ	O
men	NNS	SE
with	IN	O
untreated	JJ	C
ED	NNP	C
were	VBD	O
randomized	VBN	O
to	TO	O
double-blind	VB	O
treatment	NN	O
with	IN	O
40	CD	O
mg	NNS	O
of	IN	O
simvastatin	NN	O
or	CC	O
placebo	NN	O
once	RB	O
daily	JJ	O
for	IN	O
6	CD	O
months	NNS	O
.	.	O

Data	NNS	O
were	VBD	O
collected	VBN	O
at	IN	O
three	CD	O
points	NNS	O
over	IN	O
30	CD	O
weeks	NNS	O
.	.	O

The	DT	O
main	JJ	O
outcome	NN	O
was	VBD	O
erectile	JJ	O
function	NN	O
(	(	O
International	NNP	O
Index	NNP	O
of	IN	O
Erectile	NNP	O
Function-5	NNP	O
score	NN	O
)	)	O
.	.	O

Secondary	JJ	O
outcomes	NNS	O
included	VBD	O
male	JJ	O
ED-specific	JJ	O
quality	NN	O
of	IN	O
life	NN	O
(	(	O
MED-QoL	NNP	O
)	)	O
,	,	O
quality-adjusted	JJ	O
life	NN	O
years	NNS	O
(	(	O
QALYs	NNP	O
)	)	O
using	VBG	O
the	DT	O
generic	JJ	O
Euroqol	NNP	O
measure	NN	O
(	(	O
EQ-5D	NNP	O
)	)	O
,	,	O
endothelial	JJ	O
function	NN	O
,	,	O
cardiovascular	JJ	O
risk	NN	O
,	,	O
cholesterol	NN	O
and	CC	O
health	NN	O
service	NN	O
costs	NNS	O
.	.	O

RESULTS	NNP	O
There	EX	O
was	VBD	O
no	DT	O
significant	JJ	O
difference	NN	O
in	IN	O
erectile	JJ	O
function	NN	O
between	IN	O
the	DT	O
simvastatin	NN	O
and	CC	O
placebo	NN	O
groups	NNS	O
(	(	O
mean	JJ	O
change	NN	O
,	,	O
1.28	CD	O
vs	NN	O
0.07	CD	O
,	,	O
z	NN	O
=	VBD	O
1.1	CD	O
,	,	O
p	NN	O
=	NNP	O
0.27	CD	O
)	)	O
,	,	O
although	IN	O
a	DT	O
significant	JJ	O
improvement	NN	O
in	IN	O
MED-QoL	NNP	O
was	VBD	O
observed	VBN	O
(	(	O
5	CD	O
%	NN	O
vs	JJ	O
2	CD	O
%	NN	O
,	,	O
z	NN	O
=	VBD	O
2.09	CD	O
,	,	O
p	NN	O
=	NNP	O
0.04	CD	O
)	)	O
.	.	O

Both	DT	O
10-year	JJ	O
cardiovascular	NN	O
risk	NN	O
and	CC	O
low-density	NN	O
lipoprotein	NN	O
were	VBD	O
reduced	VBN	O
(	(	O
cardiovascular	JJ	O
risk	NN	O
,	,	O
z	NN	O
=	NNP	O
-3.67	NNP	O
,	,	O
p	NN	O
<	VBD	O
0.001	CD	O
;	:	O
low-density	JJ	O
lipoprotein	NN	O
,	,	O
z	NN	O
=	NNP	O
-5.46	NNP	O
,	,	O
p	NN	O
<	NNP	O
0.001	CD	O
)	)	O
,	,	O
with	IN	O
no	DT	O
consistent	JJ	O
change	NN	O
in	IN	O
endothelial	JJ	O
function	NN	O
.	.	O

The	DT	O
frequency	NN	O
of	IN	O
sexual	JJ	O
encounters	NNS	O
is	VBZ	O
correlated	VBN	O
with	IN	O
improved	JJ	O
erectile	JJ	O
function	NN	O
.	.	O

The	DT	O
joint	JJ	O
distribution	NN	O
of	IN	O
costs	NNS	O
and	CC	O
QALY	NNP	O
benefits	NNS	O
indicates	VBZ	O
that	IN	O
the	DT	O
probability	NN	O
of	IN	O
simvastatin	NN	O
being	VBG	O
cost-effective	JJ	O
for	IN	O
willingness-to-pay	JJ	O
thresholds	NNS	O
of	IN	O
?20,000	NN	O
and	CC	O
?30,000	NN	O
is	VBZ	O
86	CD	O
%	NN	O
and	CC	O
83	CD	O
%	NN	O
,	,	O
respectively	RB	O
.	.	O

CONCLUSIONS	NNP	O
Identifying	VBG	O
men	NNS	O
with	IN	O
ED	NNP	O
provides	VBZ	O
an	DT	O
opportunity	NN	O
to	TO	O
modify	VB	O
future	JJ	O
cardiovascular	JJ	O
risk	NN	O
and	CC	O
to	TO	O
improve	VB	O
MED-QoL	NNP	O
by	IN	O
treating	VBG	O
them	PRP	O
with	IN	O
40	CD	O
mg	NNS	O
of	IN	O
simvastatin	NN	O
.	.	O

The	DT	O
joint	JJ	O
analysis	NN	O
of	IN	O
costs	NNS	O
and	CC	O
QALY	NNP	O
benefits	NNS	O
suggests	VBZ	O
that	IN	O
there	EX	O
is	VBZ	O
high	JJ	O
probability	NN	O
that	IN	O
simvastatin	NN	O
is	VBZ	O
a	DT	O
cost-effective	JJ	O
strategy	NN	O
in	IN	O
men	NNS	O
with	IN	O
ED	NNP	O
.	.	O

The	DT	O
findings	NNS	O
could	MD	O
influence	VB	O
urological	JJ	O
and	CC	O
primary	JJ	O
care	NN	O
practice	NN	O
by	IN	O
including	VBG	O
questions	NNS	O
on	IN	O
ED	NNP	O
during	IN	O
routine	JJ	O
consultations	NNS	O
and	CC	O
relevant	JJ	O
clinical	JJ	O
protocols	NNS	O
.	.	O

This	DT	O
provides	VBZ	O
an	DT	O
opportunity	NN	O
to	TO	O
impart	VB	O
lifestyle	JJ	O
advice	NN	O
.	.	O

Antibiotic	JJ	O
strategy	NN	O
after	IN	O
the	DT	O
empiric	JJ	O
phase	NN	O
in	IN	O
patients	NNS	O
treated	VBN	O
for	IN	O
a	DT	O
hematological	JJ	C
malignancy	NN	C
.	.	O

Empiric	JJ	O
broad-spectrum	JJ	O
antibiotic	JJ	O
therapy	NN	O
has	VBZ	O
become	VBN	O
a	DT	O
generally	RB	O
accepted	VBN	O
strategy	NN	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
febrile	JJ	C
neutropenic	JJ	C
patients	NNS	O
.	.	O

Particularly	NNP	O
in	IN	O
patients	NNS	O
with	IN	O
prolonged	JJ	C
neutropenia	NN	C
,	,	O
subsequent	JJ	O
adaptation	NN	O
of	IN	O
such	JJ	O
a	DT	O
regimen	NNS	O
will	MD	O
be	VB	O
the	DT	O
rule	NN	O
rather	RB	O
than	IN	O
exception	NN	O
.	.	O

Since	IN	O
there	EX	O
are	VBP	O
no	DT	O
uniformly	RB	O
accepted	VBN	O
guidelines	NNS	O
for	IN	O
the	DT	O
modification	NN	O
of	IN	O
antibiotic	JJ	O
therapy	NN	O
during	IN	O
the	DT	O
post-empiric	JJ	O
phase	NN	O
,	,	O
we	PRP	O
assessed	VBD	O
the	DT	O
impact	NN	O
of	IN	O
a	DT	O
set	NN	O
of	IN	O
rules	NNS	O
that	WDT	O
evolved	VBD	O
during	IN	O
the	DT	O
first	JJ	O
randomized	JJ	O
trials	NNS	O
.	.	O

Evaluation	NN	O
of	IN	O
the	DT	O
clinician	NN	O
's	POS	O
compliance	NN	O
with	IN	O
these	DT	O
rules	NNS	O
in	IN	O
1951	CD	O
febrile	NN	O
neutropenic	JJ	O
episodes	NNS	O
was	VBD	O
the	DT	O
subject	NN	O
of	IN	O
the	DT	O
present	JJ	O
analysis	NN	O
.	.	O

Treatment	NNP	O
was	VBD	O
modified	VBN	O
in	IN	O
761	CD	O
(	(	O
39	CD	O
%	NN	O
)	)	O
cases	NNS	O
,	,	O
and	CC	O
these	DT	O
changes	NNS	O
were	VBD	O
made	VBN	O
according	VBG	O
to	TO	O
the	DT	O
rules	NNS	O
in	IN	O
76	CD	O
%	NN	O
.	.	O

For	IN	O
75	CD	O
%	NN	O
of	IN	O
the	DT	O
alterations	NNS	O
in	IN	O
treatment	NN	O
during	IN	O
the	DT	O
evening	NN	O
and	CC	O
night	NN	O
shifts	NNS	O
,	,	O
no	DT	O
reasonable	JJ	O
explanation	NN	O
was	VBD	O
established	VBN	O
,	,	O
while	IN	O
93	CD	O
%	NN	O
of	IN	O
the	DT	O
modifications	NNS	O
during	IN	O
the	DT	O
normal	JJ	O
working	JJ	O
hours	NNS	O
were	VBD	O
made	VBN	O
for	IN	O
objective	JJ	O
reasons	NNS	O
.	.	O

The	DT	O
empiric	JJ	O
regimen	NN	O
was	VBD	O
more	RBR	O
frequently	RB	O
changed	VBN	O
in	IN	O
patients	NNS	O
with	IN	O
a	DT	O
clinical	JJ	O
focus	NN	O
of	IN	O
infection	NN	O
at	IN	O
the	DT	O
onset	NN	O
of	IN	O
fever	NN	O
than	IN	O
in	IN	O
patients	NNS	O
who	WP	O
showed	VBD	O
fever	RB	O
as	IN	O
the	DT	O
only	JJ	O
symptom	NN	O
of	IN	O
a	DT	O
possible	JJ	O
infection	NN	O
.	.	O

The	DT	O
perceived	JJ	O
need	NN	O
for	IN	O
modification	NN	O
amounted	VBD	O
to	TO	O
69	CD	O
%	NN	O
in	IN	O
pulmonary	JJ	O
infections	NNS	O
,	,	O
to	TO	O
51	CD	O
%	NN	O
in	IN	O
skin	NN	O
and	CC	O
soft-tissue	NN	O
infections	NNS	O
,	,	O
to	TO	O
44	CD	O
%	NN	O
in	IN	O
patients	NNS	O
with	IN	O
abdominal	JJ	O
complaints	NNS	O
,	,	O
and	CC	O
to	TO	O
37	CD	O
%	NN	O
in	IN	O
upper	JJ	O
respiratory	NN	O
tract	NN	O
infections	NNS	O
.	.	O

Glycopeptides	NNP	O
constituted	VBD	O
22	CD	O
%	NN	O
of	IN	O
modifications	NNS	O
,	,	O
particularly	RB	O
in	IN	O
patients	NNS	O
with	IN	O
a	DT	O
central	JJ	O
venous	JJ	O
catheter	NN	O
,	,	O
and	CC	O
systemically	RB	O
active	JJ	O
antifungals	NNS	O
were	VBD	O
administered	VBN	O
in	IN	O
16	CD	O
%	NN	O
of	IN	O
cases	NNS	O
.	.	O

Especially	RB	O
inexperienced	JJ	O
clinicians	NNS	O
tend	VBP	O
to	TO	O
adjust	VB	O
antibiotic	JJ	O
therapy	NN	O
,	,	O
in	IN	O
spite	NN	O
of	IN	O
the	DT	O
fact	NN	O
that	IN	O
persistence	NN	O
of	IN	O
fever	NN	O
alone	RB	O
seldom	JJ	O
reflects	VBZ	O
inadequate	JJ	O
treatment	NN	O
when	WRB	O
the	DT	O
clinical	JJ	O
condition	NN	O
of	IN	O
the	DT	O
patient	NN	O
is	VBZ	O
stable	JJ	O
or	CC	O
improving	VBG	O
.	.	O

On	IN	O
the	DT	O
other	JJ	O
hand	NN	O
,	,	O
the	DT	O
development	NN	O
of	IN	O
subsequent	JJ	O
infectious	JJ	O
events	NNS	O
emphasizes	VBZ	O
that	IN	O
a	DT	O
genuine	JJ	O
need	NN	O
for	IN	O
modification	NN	O
does	VBZ	O
frequently	RB	O
exist	VB	O
.	.	O

Effect	NN	O
of	IN	O
two	CD	O
monophasic	JJ	O
oral	JJ	O
contraceptives	NNS	O
containing	VBG	O
gestodene	NN	O
or	CC	O
desogestrel	NN	O
on	IN	O
serum	NN	O
lipoprotein	NN	O
lipid	JJ	O
levels	NNS	O
.	.	O

Forty-nine	NNP	SS
healthy	JJ	O
women	NNS	SE
aged	VBN	O
20-35	JJ	A
years	NNS	O
who	WP	O
had	VBD	O
not	RB	O
been	VBN	O
pregnant	JJ	O
or	CC	O
using	VBG	O
an	DT	O
oral	JJ	O
contraceptive	NN	O
(	(	O
OC	NNP	O
)	)	O
for	IN	O
the	DT	O
previous	JJ	O
3	CD	O
months	NNS	O
were	VBD	O
randomized	VBN	O
into	IN	O
two	CD	O
groups	NNS	O
,	,	O
one	CD	O
group	NN	O
taking	VBG	O
an	DT	O
OC	NNP	O
containing	VBG	O
75	CD	O
micrograms	NNS	O
gestodene	NN	O
(	(	O
GTD	NNP	O
)	)	O
and	CC	O
30	CD	O
micrograms	NNS	O
ethinyl	VBP	O
estradiol	NN	O
(	(	O
EE	NNP	O
)	)	O
,	,	O
and	CC	O
the	DT	O
other	JJ	O
group	NN	O
using	VBG	O
an	DT	O
OC	NNP	O
with	IN	O
150	CD	O
micrograms	NNS	O
desogestrel	NN	O
(	(	O
DSG	NNP	O
)	)	O
and	CC	O
30	CD	O
micrograms	NNS	O
EE	NNP	O
.	.	O

Fasting	VBG	O
blood	NN	O
samples	NNS	O
were	VBD	O
taken	VBN	O
before	RB	O
treatment	NN	O
,	,	O
and	CC	O
after	IN	O
cycles	NNS	O
3	CD	O
and	CC	O
6	CD	O
,	,	O
between	IN	O
the	DT	O
18th	CD	O
and	CC	O
the	DT	O
22nd	CD	O
day	NN	O
of	IN	O
the	DT	O
cycle	NN	O
.	.	O

Blood	NNP	O
lipoprotein	JJ	O
lipid	JJ	O
levels	NNS	O
were	VBD	O
measured	VBN	O
.	.	O

Serum	NNP	O
total	JJ	O
cholesterol	NN	O
did	VBD	O
not	RB	O
change	VB	O
significantly	RB	O
in	IN	O
both	DT	O
groups	NNS	O
.	.	O

However	RB	O
,	,	O
in	IN	O
the	DT	O
first	JJ	O
three	CD	O
cycles	NNS	O
,	,	O
serum	JJ	O
triglyceride	NN	O
increased	VBN	O
by	IN	O
46	CD	O
%	NN	O
and	CC	O
40	CD	O
%	NN	O
and	CC	O
HDL-cholesterol	NNP	O
by	IN	O
14	CD	O
%	NN	O
and	CC	O
8	CD	O
%	NN	O
in	IN	O
the	DT	O
GTD	NNP	O
and	CC	O
DSG	NNP	O
groups	NNS	O
,	,	O
respectively	RB	O
.	.	O

The	DT	O
serum	NN	O
LDL	NNP	O
level	NN	O
decreased	VBN	O
by	IN	O
6.2	CD	O
%	NN	O
and	CC	O
11.8	CD	O
%	NN	O
,	,	O
respectively	RB	O
.	.	O

Between	VB	O
the	DT	O
third	JJ	O
and	CC	O
sixth	JJ	O
cycle	NN	O
,	,	O
no	DT	O
further	JJ	O
significant	JJ	O
changes	NNS	O
were	VBD	O
observed	VBN	O
,	,	O
nor	CC	O
did	VBD	O
these	DT	O
changes	NNS	O
differ	VBP	O
significantly	RB	O
between	IN	O
the	DT	O
two	CD	O
groups	NNS	O
.	.	O

In	IN	O
conclusion	NN	O
,	,	O
both	DT	O
OC	NNP	O
preparations	NNS	O
exerted	VBD	O
small	JJ	O
and	CC	O
probably	RB	O
favorable	JJ	O
effects	NNS	O
on	IN	O
serum	NN	O
lipoprotein	NN	O
lipid	JJ	O
levels	NNS	O
.	.	O

Clozapine	NNP	O
versus	NN	O
placebo	NN	O
in	IN	O
Huntington	NNP	C
's	POS	C
disease	NN	C
:	:	O
a	DT	O
double	JJ	O
blind	NN	O
randomised	VBD	O
comparative	JJ	O
study	NN	O
.	.	O

OBJECTIVES	NNP	O
To	TO	O
establish	VB	O
the	DT	O
effect	NN	O
of	IN	O
the	DT	O
atypical	JJ	O
neuroleptic	JJ	O
clozapine	NN	O
on	IN	O
chorea	NN	O
,	,	O
voluntary	JJ	O
motor	NN	O
performance	NN	O
,	,	O
and	CC	O
functional	JJ	O
disability	NN	O
in	IN	O
patients	NNS	O
with	IN	O
Huntington	NNP	O
's	POS	O
disease	NN	O
.	.	O

METHODS	NNP	O
Thirty	NNP	SS
three	CD	SS
patients	NNS	O
with	IN	O
Huntington	NNP	O
's	POS	O
disease	NN	O
participated	VBD	O
in	IN	O
a	DT	O
double	JJ	O
blind	NN	O
randomised	VBD	O
trial	NN	O
.	.	O

A	DT	O
maximum	NN	O
of	IN	O
150	CD	O
mg/day	JJ	O
clozapine	NN	O
or	CC	O
placebo	NN	O
equivalent	NN	O
was	VBD	O
given	VBN	O
for	IN	O
a	DT	O
period	NN	O
of	IN	O
31	CD	O
days	NNS	O
.	.	O

Assessments	NNS	O
were	VBD	O
performed	VBN	O
in	IN	O
the	DT	O
week	NN	O
before	IN	O
and	CC	O
at	IN	O
the	DT	O
last	JJ	O
day	NN	O
of	IN	O
the	DT	O
trial	NN	O
.	.	O

Chorea	NNP	O
was	VBD	O
scored	VBN	O
using	VBG	O
the	DT	O
abnormal	JJ	O
involuntary	JJ	O
movement	NN	O
scale	NN	O
(	(	O
AIMS	NNP	O
)	)	O
,	,	O
the	DT	O
chorea	NN	O
score	NN	O
of	IN	O
the	DT	O
unified	JJ	O
Huntington	NNP	O
's	POS	O
disease	NN	O
rating	NN	O
scale	NN	O
(	(	O
UHDRS	NNP	O
)	)	O
,	,	O
and	CC	O
judgement	NN	O
of	IN	O
video	JJ	O
recordings	NNS	O
.	.	O

Voluntary	JJ	O
motor	NN	O
performance	NN	O
was	VBD	O
assessed	VBN	O
using	VBG	O
the	DT	O
UHDRS	NNP	O
motor	NN	O
scale	NN	O
.	.	O

Patients	NNS	O
and	CC	O
their	PRP$	O
partners	NNS	O
completed	VBD	O
a	DT	O
questionnaire	NN	O
regarding	VBG	O
functional	JJ	O
disability	NN	O
.	.	O

Twelve	CD	O
patients	NNS	O
already	RB	O
used	VBD	O
other	JJ	O
neuroleptic	JJ	O
medication	NN	O
,	,	O
which	WDT	O
was	VBD	O
kept	FW	O
unchanged	JJ	O
during	IN	O
the	DT	O
trial	NN	O
period	NN	O
.	.	O

Results	NNS	O
of	IN	O
neuroleptic	JJ	O
naive	JJ	O
and	CC	O
neuroleptic	JJ	O
treated	JJ	O
patients	NNS	O
were	VBD	O
analysed	VBN	O
separately	RB	O
.	.	O

RESULTS	NNP	O
Clozapine	NNP	O
tended	VBD	O
to	TO	O
reduce	VB	O
chorea	NN	O
in	IN	O
neuroleptic	JJ	O
naive	JJ	O
patients	NNS	O
only	RB	O
(	(	O
AIMS	NNP	O
)	)	O
;	:	O
improvement	NN	O
seemed	VBD	O
more	RBR	O
pronounced	JJ	O
in	IN	O
patients	NNS	O
receiving	VBG	O
higher	JJR	O
doses	NNS	O
of	IN	O
clozapine	NN	O
.	.	O

Other	JJ	O
measures	NNS	O
of	IN	O
chorea	NN	O
(	(	O
UHDRS	NNP	O
chorea	NN	O
score	NN	O
,	,	O
video	JJ	O
ratings	NNS	O
)	)	O
showed	VBD	O
no	DT	O
improvement	NN	O
.	.	O

Clozapine	NNP	O
had	VBD	O
no	DT	O
beneficial	JJ	O
effect	NN	O
on	IN	O
chorea	NN	O
in	IN	O
patients	NNS	O
already	RB	O
receiving	VBG	O
neuroleptic	JJ	O
medication	NN	O
.	.	O

Voluntary	JJ	O
motor	NN	O
performance	NN	O
did	VBD	O
not	RB	O
improve	VB	O
with	IN	O
clozapine	NN	O
.	.	O

Neuroleptic	JJ	O
naive	JJ	O
patients	NNS	O
reported	VBN	O
aggravation	NN	O
of	IN	O
functional	JJ	O
disability	NN	O
,	,	O
possibly	RB	O
reflecting	VBG	O
the	DT	O
frequent	JJ	O
occurrence	NN	O
of	IN	O
side	NN	O
effects	NNS	O
.	.	O

Adverse	JJ	O
reactions	NNS	O
forced	VBD	O
trial	NN	O
termination	NN	O
in	IN	O
six	CD	O
patients	NNS	O
and	CC	O
dose	JJ	O
reduction	NN	O
in	IN	O
another	DT	O
eight	CD	O
,	,	O
and	CC	O
consisted	VBD	O
mainly	RB	O
of	IN	O
drowsiness	NN	O
,	,	O
fatigue	NN	O
,	,	O
anticholinergic	NN	O
symptoms	NNS	O
,	,	O
and	CC	O
walking	VBG	O
difficulties	NNS	O
.	.	O

CONCLUSIONS	NNP	O
Clozapine	NNP	O
has	VBZ	O
little	JJ	O
beneficial	JJ	O
effect	NN	O
in	IN	O
patients	NNS	O
with	IN	O
Huntington	NNP	O
's	POS	O
disease	NN	O
,	,	O
although	IN	O
individual	JJ	O
patients	NNS	O
may	MD	O
tolerate	VB	O
doses	NNS	O
high	JJ	O
enough	RB	O
to	TO	O
reduce	VB	O
chorea	NN	O
.	.	O

Because	IN	O
adverse	JJ	O
reactions	NNS	O
are	VBP	O
often	RB	O
encountered	VBN	O
,	,	O
clozapine	NN	O
should	MD	O
be	VB	O
used	VBN	O
with	IN	O
restraint	NN	O
in	IN	O
this	DT	O
patient	NN	O
group	NN	O
.	.	O

Comparison	NNP	O
of	IN	O
the	DT	O
effects	NNS	O
of	IN	O
terazosin	NN	O
and	CC	O
enalapril	NN	O
on	IN	O
laboratory	NN	O
stress	NN	O
testing	VBG	O
blood	NN	O
pressure	NN	O
in	IN	O
patients	NNS	O
with	IN	O
essential	JJ	C
hypertension	NN	C
.	.	O

It	PRP	O
is	VBZ	O
the	DT	O
current	JJ	O
opinion	NN	O
that	IN	O
an	DT	O
ideal	JJ	O
antihypertensive	JJ	O
drug	NN	O
should	MD	O
reduce	VB	O
blood	NN	O
pressure	NN	O
(	(	O
BP	NNP	O
)	)	O
not	RB	O
only	RB	O
at	IN	O
rest	NN	O
but	CC	O
also	RB	O
during	IN	O
stressful	JJ	O
situations	NNS	O
.	.	O

The	DT	O
current	JJ	O
study	NN	O
was	VBD	O
aimed	VBN	O
to	TO	O
compare	VB	O
the	DT	O
effects	NNS	O
of	IN	O
the	DT	O
selective	JJ	O
alpha	NN	O
1-adrenergic	JJ	O
blocker	NN	O
terazosin	NN	O
(	(	O
5	CD	O
mg	NN	O
once	RB	O
daily	JJ	O
)	)	O
and	CC	O
of	IN	O
the	DT	O
angiotensin-converting	JJ	O
enzyme	NN	O
inhibitor	NN	O
enalapril	NN	O
(	(	O
20	CD	O
mg	NN	O
once	RB	O
daily	RB	O
)	)	O
on	IN	O
cardiovascular	JJ	O
response	NN	O
to	TO	O
a	DT	O
set	NN	O
of	IN	O
standardized	JJ	O
laboratory	NN	O
stressors	NNS	O
,	,	O
such	JJ	O
as	IN	O
mental	JJ	O
arithmetic	JJ	O
,	,	O
handgrip	JJ	O
test	NN	O
and	CC	O
cycle	NN	O
ergometry	NN	O
,	,	O
in	IN	O
a	DT	O
group	NN	O
of	IN	O
16	CD	SS
essential	JJ	O
hypertensive	JJ	O
patients	NNS	O
.	.	O

The	DT	O
study	NN	O
was	VBD	O
a	DT	O
randomized	JJ	O
,	,	O
double-blind	JJ	O
,	,	O
cross-over	JJ	O
trial	NN	O
preceded	VBN	O
by	IN	O
a	DT	O
placebo	JJ	O
run-in	JJ	O
period	NN	O
.	.	O

Terazosin	NNP	O
and	CC	O
enalapril	VB	O
had	VBD	O
a	DT	O
comparable	JJ	O
effect	NN	O
on	IN	O
resting	VBG	O
BP	NNP	O
,	,	O
reducing	VBG	O
systolic	JJ	O
(	(	O
SBP	NNP	O
)	)	O
and	CC	O
diastolic	JJ	O
(	(	O
DBP	NNP	O
)	)	O
blood	NN	O
pressure	NN	O
from	IN	O
159.5	CD	O
+/-	JJ	O
13.9/101.6	CD	O
+/-	JJ	O
8.8	CD	O
mm	NN	O
Hg	NNP	O
during	IN	O
placebo	NN	O
by	IN	O
7.8	CD	O
%	NN	O
/6.7	CC	O
%	NN	O
and	CC	O
by	IN	O
11.3	CD	O
%	NN	O
/10.2	CD	O
%	NN	O
,	,	O
respectively	RB	O
.	.	O

The	DT	O
response	NN	O
rate	NN	O
to	TO	O
the	DT	O
two	CD	O
treatments	NNS	O
was	VBD	O
approximately	RB	O
the	DT	O
same	JJ	O
,	,	O
being	VBG	O
69	CD	O
%	NN	O
and	CC	O
75	CD	O
%	NN	O
after	IN	O
terazosin	NN	O
and	CC	O
enalapril	NN	O
,	,	O
respectively	RB	O
.	.	O

During	IN	O
mental	JJ	O
arithmetic	JJ	O
,	,	O
from	IN	O
an	DT	O
average	NN	O
of	IN	O
181.6	CD	O
+/-	JJ	O
17.8/118.6	CD	O
+/-	JJ	O
11.5	CD	O
mm	NN	O
Hg	NNP	O
during	IN	O
placebo	NN	O
,	,	O
BP	NNP	O
was	VBD	O
reduced	VBN	O
by	IN	O
11.5	CD	O
%	NN	O
/7.9	CD	O
%	NN	O
after	IN	O
terazosin	NN	O
and	CC	O
by	IN	O
13.6	CD	O
%	NN	O
/8.5	CD	O
%	NN	O
after	IN	O
enalapril	NN	O
;	:	O
during	IN	O
handgrip	NN	O
test	NN	O
,	,	O
BP	NNP	O
decreased	VBD	O
from	IN	O
207.2	CD	O
+/-	JJ	O
22.2/142.2	CD	O
+/-	JJ	O
13.6	CD	O
mm	NN	O
Hg	NNP	O
by	IN	O
7.3	CD	O
%	NN	O
/8.4	CD	O
%	NN	O
after	IN	O
terazosin	NN	O
and	CC	O
by	IN	O
7.7	CD	O
%	NN	O
/7.1	CD	O
%	NN	O
after	IN	O
enalapril	NN	O
;	:	O
finally	RB	O
,	,	O
during	IN	O
cycle	NN	O
ergometry	NN	O
,	,	O
terazosin	NN	O
and	CC	O
enalapril	NN	O
lowered	VBN	O
BP	NNP	O
by	IN	O
5.4	CD	O
%	NN	O
/6.7	CC	O
%	NN	O
and	CC	O
7	CD	O
%	NN	O
/3.1	CD	O
%	NN	O
,	,	O
respectively	RB	O
,	,	O
from	IN	O
a	DT	O
placebo	NN	O
value	NN	O
of	IN	O
215.5	CD	O
+/-	JJ	O
17.3/127.6	CD	O
+/-	JJ	O
11.2	CD	O
.	.	O

No	DT	O
significant	JJ	O
difference	NN	O
in	IN	O
antihypertensive	JJ	O
efficacy	NN	O
was	VBD	O
observed	VBN	O
between	IN	O
the	DT	O
two	CD	O
drugs	NNS	O
,	,	O
either	RB	O
at	IN	O
rest	NN	O
and	CC	O
during	IN	O
stress	JJ	O
testing	VBG	O
.	.	O

(	(	O
ABSTRACT	NNP	O
TRUNCATED	NNP	O
AT	NNP	O
250	CD	O
WORDS	NNP	O
)	)	O
Ciprofloxacin	NNP	O
,	,	O
lomefloxacin	NN	O
,	,	O
or	CC	O
levofloxacin	CC	O
as	IN	O
treatment	NN	O
for	IN	O
chronic	JJ	C
osteomyelitis	NN	C
.	.	O

The	DT	O
efficacy	NN	O
and	CC	O
safety	NN	O
of	IN	O
three	CD	O
oral	JJ	O
fluoroquinolones	NNS	O
(	(	O
lomefloxacin	NN	O
,	,	O
levofloxacin	NN	O
,	,	O
and	CC	O
ciprofloxacin	NN	O
)	)	O
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
chronic	JJ	O
osteomyelitis	NN	O
were	VBD	O
analyzed	VBN	O
.	.	O

Twenty-seven	JJ	SS
patients	NNS	O
had	VBD	O
documented	VBN	O
infections	NNS	C
with	IN	C
quinolone-sensitive	JJ	C
organisms	NNS	C
and	CC	O
received	VBD	O
either	DT	O
lomefloxacin	NN	O
,	,	O
levofloxacin	NN	O
,	,	O
or	CC	O
ciprofloxacin	NN	O
.	.	O

Levofloxacin	NNP	O
was	VBD	O
effective	JJ	O
therapy	NN	O
for	IN	O
9	CD	O
of	IN	O
15	CD	O
(	(	O
60	CD	O
%	NN	O
)	)	O
patients	NNS	O
.	.	O

Lomefloxacin	NNP	O
was	VBD	O
effective	JJ	O
therapy	NN	O
for	IN	O
five	CD	O
of	IN	O
seven	CD	O
(	(	O
71	CD	O
%	NN	O
)	)	O
patients	NNS	O
,	,	O
and	CC	O
ciprofloxacin	NN	O
was	VBD	O
effective	JJ	O
therapy	NN	O
for	IN	O
two	CD	O
of	IN	O
five	CD	O
patients	NNS	O
(	(	O
40	CD	O
%	NN	O
)	)	O
.	.	O

Average	JJ	O
follow-up	NN	O
was	VBD	O
11.8	CD	O
months	NNS	O
for	IN	O
patients	NNS	O
who	WP	O
completed	VBD	O
the	DT	O
course	NN	O
of	IN	O
therapy	NN	O
,	,	O
and	CC	O
the	DT	O
average	JJ	O
duration	NN	O
of	IN	O
therapy	NN	O
was	VBD	O
60.6	CD	O
days	NNS	O
.	.	O

Gram-positive	JJ	O
bacteria	NNS	O
were	VBD	O
isolated	VBN	O
from	IN	O
18	CD	O
patients	NNS	O
,	,	O
and	CC	O
11	CD	O
patients	NNS	O
were	VBD	O
cured	VBN	O
.	.	O

Oral	JJ	O
fluoroquinolones	NNS	O
can	MD	O
be	VB	O
safe	JJ	O
,	,	O
effective	JJ	O
therapy	NN	O
if	IN	O
they	PRP	O
are	VBP	O
given	VBN	O
for	IN	O
a	DT	O
prolonged	JJ	O
course	NN	O
as	IN	O
treatment	NN	O
for	IN	O
infections	NNS	O
caused	VBN	O
by	IN	O
susceptible	JJ	O
gram-positive	JJ	O
as	RB	O
well	RB	O
as	IN	O
gram-negative	JJ	O
organisms	NNS	O
and	CC	O
in	IN	O
combination	NN	O
with	IN	O
adequate	JJ	O
surgical	JJ	O
debridement	NN	O
.	.	O

Analysis	NN	O
of	IN	O
treatment	NN	O
in	IN	O
childhood	NN	O
leukaemia	NN	O
.	.	O

I.	NNP	O
Predisposition	NNP	O
to	TO	O
methotrexate-induced	JJ	O
neutropenia	NN	O
after	IN	O
craniospinal	JJ	O
irradiation	NN	O
.	.	O

Report	NNP	O
to	TO	O
the	DT	O
Medical	NNP	O
Research	NNP	O
Council	NNP	O
of	IN	O
the	DT	O
Working	NNP	O
Party	NNP	O
on	IN	O
Leukaemia	NNP	O
in	IN	O
Childhood	NNP	O
.	.	O

The	DT	O
degree	NN	O
of	IN	O
drug-induced	JJ	O
neutropenia	NNS	O
resulting	VBG	O
from	IN	O
a	DT	O
controlled	VBN	O
trial	NN	O
(	(	O
UKALL	NNP	O
I	PRP	O
)	)	O
of	IN	O
treatment	NN	O
in	IN	O
acute	JJ	O
lymphoblastic	JJ	O
leukaemia	NN	O
was	VBD	O
analysed	VBN	O
.	.	O

The	DT	O
main	JJ	O
agent	NN	O
associated	VBN	O
with	IN	O
severe	JJ	O
neutropenia	NN	O
was	VBD	O
methotrexate	NN	O
,	,	O
and	CC	O
methotrexate-induced	JJ	O
neutropenia	NN	O
was	VBD	O
significantly	RB	O
greater	JJR	O
in	IN	O
patients	NNS	O
who	WP	O
had	VBD	O
received	VBN	O
craniospinal	JJ	C
irradiation	NN	C
.	.	O

The	DT	O
synergistic	JJ	O
toxic	NN	O
effect	NN	O
of	IN	O
irradiation	NN	O
followed	VBN	O
by	IN	O
methotrexate	NN	O
treatment	NN	O
seems	VBZ	O
to	TO	O
have	VB	O
contributed	VBN	O
to	TO	O
three	CD	O
of	IN	O
the	DT	O
five	CD	O
deaths	NNS	O
which	WDT	O
occurred	VBD	O
in	IN	O
complete	JJ	O
remission	NN	O
in	IN	O
this	DT	O
trial	NN	O
;	:	O
all	DT	O
deaths	NNS	O
in	IN	O
remission	NN	O
occurred	VBD	O
in	IN	O
patients	NNS	O
who	WP	O
had	VBD	O
received	VBN	O
central	JJ	O
nervous	JJ	O
system	NN	O
prophylaxis	NN	O
.	.	O

Analysis	NN	O
of	IN	O
patients	NNS	O
who	WP	O
subsequently	RB	O
relapsed	VBD	O
compared	VBN	O
with	IN	O
those	DT	O
still	RB	O
in	IN	O
remission	NN	O
after	IN	O
18	CD	O
months	NNS	O
of	IN	O
treatment	NN	O
indicated	VBD	O
that	IN	O
the	DT	O
former	JJ	O
,	,	O
on	IN	O
average	NN	O
,	,	O
had	VBD	O
slightly	RB	O
lower	JJR	O
neutrophil	NN	O
counts	NNS	O
.	.	O

This	DT	O
suggests	VBZ	O
that	IN	O
the	DT	O
children	NNS	O
who	WP	O
relapsed	VBD	O
did	VBD	O
not	RB	O
receive	VB	O
any	DT	O
less	RBR	O
aggressive	JJ	O
treatment	NN	O
than	IN	O
those	DT	O
who	WP	O
remained	VBD	O
in	IN	O
remission	NN	O
.	.	O

Comparison	NNP	O
of	IN	O
succinylcholine	NN	O
with	IN	O
two	CD	O
doses	NNS	O
of	IN	O
rocuronium	NN	O
using	VBG	O
a	DT	O
new	JJ	O
method	NN	O
of	IN	O
monitoring	VBG	O
neuromuscular	JJ	C
block	NN	C
at	IN	O
the	DT	O
laryngeal	NN	O
muscles	NNS	O
by	IN	O
surface	NN	O
laryngeal	NN	O
electromyography	NN	O
.	.	O

We	PRP	O
compared	VBN	O
the	DT	O
onset	NN	O
of	IN	O
neuromuscular	JJ	O
block	NN	O
with	IN	O
succinylcholine	NN	O
(	(	O
1	CD	O
mg	RB	O
kg-1	NN	O
)	)	O
and	CC	O
two	CD	O
doses	NNS	O
of	IN	O
rocuronium	NN	O
(	(	O
0.6	CD	O
and	CC	O
0.9	CD	O
mg	JJ	O
kg-1	NN	O
)	)	O
at	IN	O
the	DT	O
adductor	NN	O
pollicis	NN	O
muscle	NN	O
using	VBG	O
electromyography	NN	O
(	(	O
EMG	NNP	O
)	)	O
and	CC	O
acceleromyography	NN	O
(	(	O
AMG	NNP	O
)	)	O
,	,	O
and	CC	O
at	IN	O
the	DT	O
adductor	NN	O
laryngeal	NN	O
muscles	NNS	O
with	IN	O
a	DT	O
new	JJ	O
electromyographic	JJ	O
method	NN	O
using	VBG	O
a	DT	O
disposable	JJ	O
surface	NN	O
electrode	NN	O
attached	VBN	O
to	TO	O
the	DT	O
cuff	NN	O
of	IN	O
a	DT	O
tracheal	JJ	O
tube	NN	O
.	.	O

At	IN	O
the	DT	O
larynx	NN	O
,	,	O
the	DT	O
mean	NN	O
(	(	O
+/-	JJ	O
SD	NNP	O
)	)	O
time	NN	O
to	TO	O
90	CD	O
%	NN	O
block	NN	O
and	CC	O
the	DT	O
onset	JJ	O
time	NN	O
of	IN	O
succinylcholine	NN	O
(	(	O
38	CD	O
+/-	JJ	O
15	CD	O
and	CC	O
47	CD	O
+/-	JJ	O
19	CD	O
s	NN	O
,	,	O
respectively	RB	O
)	)	O
were	VBD	O
significantly	RB	O
shorter	JJR	O
(	(	O
P	NNP	O
<	NNP	O
0.01	CD	O
)	)	O
than	IN	O
for	IN	O
rocuronium	NN	O
0.6	CD	O
mg	NN	O
kg-1	NN	O
(	(	O
92	CD	O
+/-	JJ	O
42	CD	O
and	CC	O
106	CD	O
+/-	JJ	O
38	CD	O
s	NN	O
)	)	O
and	CC	O
rocuronium	$	O
0.9	CD	O
mg	JJ	O
kg-1	NN	O
(	(	O
52	CD	O
+/-	JJ	O
31	CD	O
and	CC	O
64	CD	O
+/-	JJ	O
30	CD	O
s	NN	O
)	)	O
.	.	O

We	PRP	O
found	VBD	O
that	IN	O
,	,	O
with	IN	O
comparable	JJ	O
degrees	NNS	O
of	IN	O
neuromuscular	JJ	O
block	NN	O
,	,	O
the	DT	O
onset	JJ	O
time	NN	O
of	IN	O
succinylcholine	NN	O
at	IN	O
the	DT	O
adductor	NN	O
pollicis	NN	O
was	VBD	O
significantly	RB	O
shorter	JJR	O
(	(	O
P	NNP	O
<	NNP	O
0.01	CD	O
)	)	O
than	IN	O
for	IN	O
rocuronium	NN	O
0.6	CD	O
mg	NN	O
kg-1	NN	O
and	CC	O
0.9	CD	O
mg	NNS	O
kg-1	JJ	O
(	(	O
EMG	NNP	O
,	,	O
80	CD	O
+/-	JJ	O
39	CD	O
vs	JJ	O
145	CD	O
+/-	JJ	O
48	CD	O
s	NN	O
and	CC	O
99	CD	O
+/-	JJ	O
31	CD	O
s	NN	O
;	:	O
AMG	NNP	O
,	,	O
90	CD	O
+/-	JJ	O
39	CD	O
vs	JJ	O
124	CD	O
+/-	JJ	O
53	CD	O
s	NN	O
and	CC	O
106	CD	O
+/-	JJ	O
38	CD	O
s	NN	O
)	)	O
.	.	O

Clinical	JJ	O
duration	NN	O
at	IN	O
the	DT	O
adductor	NN	O
pollicis	NN	O
(	(	O
AMG	NNP	O
)	)	O
was	VBD	O
significantly	RB	O
longer	JJR	O
(	(	O
P	NNP	O
<	NNP	O
0.01	CD	O
)	)	O
for	IN	O
both	DT	O
rocuronium	NN	O
groups	NNS	O
than	IN	O
for	IN	O
succinylcholine	NN	O
(	(	O
T4	NNP	O
:	:	O
T1	NNP	O
=	VBZ	O
0.7	CD	O
,	,	O
54	CD	O
+/-	JJ	O
18	CD	O
and	CC	O
77	CD	O
+/-	JJ	O
21	CD	O
vs	JJ	O
8	CD	O
+/-	JJ	O
6	CD	O
min	NN	O
)	)	O
.	.	O

The	DT	O
surface	NN	O
laryngeal	JJ	O
electrode	NN	O
proved	VBD	O
non-invasive	JJ	O
,	,	O
easy	JJ	O
to	TO	O
use	VB	O
and	CC	O
reliable	VB	O
in	IN	O
measuring	VBG	O
onset	NN	O
of	IN	O
the	DT	O
neuromuscular	JJ	O
block	NN	O
at	IN	O
the	DT	O
larynx	NN	O
.	.	O

Preoperative	JJ	O
irradiation	NN	O
versus	IN	O
the	DT	O
use	NN	O
of	IN	O
nonsteroidal	JJ	O
anti-inflammatory	JJ	O
drugs	NNS	O
for	IN	O
prevention	NN	O
of	IN	O
heterotopic	JJ	O
ossification	NN	O
following	VBG	O
total	JJ	C
hip	JJ	C
replacement	NN	C
:	:	O
the	DT	O
results	NNS	O
of	IN	O
a	DT	O
randomized	JJ	O
trial	NN	O
.	.	O

PURPOSE	NNP	O
Previous	JJ	O
studies	NNS	O
showed	VBD	O
the	DT	O
effectiveness	NN	O
of	IN	O
early	JJ	O
preoperative	NN	O
(	(	O
4	CD	O
h	NN	O
before	IN	O
operation	NN	O
)	)	O
irradiation	NN	O
for	IN	O
prevention	NN	O
of	IN	O
heterotopic	NN	O
ossification	NN	O
(	(	O
HO	NNP	O
)	)	O
after	IN	O
total	JJ	O
hip	NN	O
replacement	NN	O
.	.	O

This	DT	O
procedure	NN	O
can	MD	O
result	VB	O
in	IN	O
logistic	JJ	O
problems	NNS	O
,	,	O
if	IN	O
there	EX	O
is	VBZ	O
a	DT	O
great	JJ	O
distance	NN	O
between	IN	O
the	DT	O
department	NN	O
of	IN	O
radiotherapy	NN	O
and	CC	O
the	DT	O
orthopedic	JJ	O
clinic	NN	O
.	.	O

To	TO	O
avoid	VB	O
these	DT	O
organizational	JJ	O
problems	NNS	O
a	DT	O
prospective	JJ	O
study	NN	O
was	VBD	O
undertaken	VBN	O
to	TO	O
analyze	VB	O
the	DT	O
effectiveness	NN	O
of	IN	O
preoperative	JJ	O
irradiation	NN	O
on	IN	O
the	DT	O
day	NN	O
preceding	VBG	O
surgery	NN	O
(	(	O
16-20	JJ	O
h	NN	O
before	IN	O
operation	NN	O
)	)	O
.	.	O

METHODS	NNP	O
AND	CC	O
MATERIALS	NNP	O
Between	NNP	O
1995	CD	O
and	CC	O
1996	CD	O
,	,	O
100	CD	SS
patients	NNS	SS
were	VBD	O
randomized	VBN	O
to	TO	O
receive	VB	O
a	DT	O
prophylactic	JJ	O
therapy	NN	O
for	IN	O
prevention	NN	O
of	IN	O
heterotopic	NN	C
ossification	NN	C
.	.	O

Forty-six	JJ	O
patients	NNS	O
were	VBD	O
irradiated	VBN	O
with	IN	O
7	CD	O
Gy	NNP	O
single	JJ	O
dose	NN	O
within	IN	O
16-20	JJ	O
h	NN	O
before	IN	O
operation	NN	O
.	.	O

Fifty-four	CD	O
patients	NNS	O
were	VBD	O
treated	VBN	O
with	IN	O
nonsteroidal	JJ	O
anti-inflammatory	JJ	O
drugs	NNS	O
(	(	O
NSAID	NNP	O
)	)	O
(	(	O
Voltaren	NNP	O
resinat	VBZ	O
2	CD	O
x	NN	O
75	CD	O
mg/day	NN	O
for	IN	O
2	CD	O
weeks	NNS	O
)	)	O
.	.	O

Heterotopic	NNP	O
ossification	NN	O
was	VBD	O
scored	VBN	O
according	VBG	O
to	TO	O
the	DT	O
Brooker	NNP	O
Grading	NNP	O
system	NN	O
.	.	O

One	CD	SS
hundred	VBD	SS
patients	NNS	SS
receiving	VBG	O
no	DT	O
prophylactic	JJ	O
therapy	NN	O
after	IN	O
total	JJ	O
hip	NN	O
arthroplasty	NN	O
between	IN	O
1988	CD	O
and	CC	O
1992	CD	O
were	VBD	O
analyzed	VBN	O
and	CC	O
defined	VBN	O
as	IN	O
the	DT	O
historical	JJ	O
control	NN	O
group	NN	O
.	.	O

RESULTS	NNP	O
Incidence	NNP	O
of	IN	O
heterotopic	NN	O
ossification	NN	O
was	VBD	O
47.8	CD	O
%	NN	O
in	IN	O
the	DT	O
7	CD	O
Gy	NNP	O
preoperative	JJ	O
group	NN	O
(	(	O
Brooker	NNP	O
Score	NNP	O
I	PRP	O
:	:	O
36.9	CD	O
%	NN	O
;	:	O
II	NNP	O
:	:	O
8.7	CD	O
%	NN	O
;	:	O
III	NNP	O
:	:	O
2.2	CD	O
%	NN	O
;	:	O
IV	NNP	O
:	:	O
0	CD	O
%	NN	O
)	)	O
and	CC	O
11.1	CD	O
%	NN	O
in	IN	O
the	DT	O
NSAID	NNP	O
group	NN	O
(	(	O
Brooker	NNP	O
Score	NNP	O
I	PRP	O
:	:	O
9.3	CD	O
%	NN	O
;	:	O
II	NNP	O
:	:	O
1.8	CD	O
%	NN	O
;	:	O
III	NNP	O
:	:	O
0	CD	O
%	NN	O
;	:	O
IV	NNP	O
:	:	O
0	CD	O
%	NN	O
)	)	O
.	.	O

Regarding	VBG	O
overall	JJ	O
heterotopic	NN	O
ossification	NN	O
there	EX	O
was	VBD	O
a	DT	O
significant	JJ	O
difference	NN	O
between	IN	O
the	DT	O
NSAID	NNP	O
group	NN	O
and	CC	O
the	DT	O
7	CD	O
Gy	NNP	O
group	NN	O
(	(	O
p	JJ	O
<	NNP	O
0.01	CD	O
)	)	O
.	.	O

Analyzing	VBG	O
the	DT	O
clinically	RB	O
significant	JJ	O
heterotopic	NN	O
ossification	NN	O
(	(	O
Brooker	NNP	O
Score	NNP	O
III	NNP	O
and	CC	O
IV	NNP	O
)	)	O
there	EX	O
was	VBD	O
no	DT	O
significant	JJ	O
difference	NN	O
between	IN	O
the	DT	O
two	CD	O
treatment	NN	O
arms	NNS	O
(	(	O
p	JJ	O
>	NNP	O
0.05	CD	O
)	)	O
.	.	O

In	IN	O
the	DT	O
untreated	JJ	O
historical	JJ	O
control	NN	O
group	NN	O
the	DT	O
incidence	NN	O
of	IN	O
heterotopic	NN	O
ossification	NN	O
was	VBD	O
65	CD	O
%	NN	O
(	(	O
Brooker	NNP	O
Score	NNP	O
I	PRP	O
:	:	O
26	CD	O
%	NN	O
;	:	O
II	NNP	O
:	:	O
15	CD	O
%	NN	O
;	:	O
III	NNP	O
:	:	O
19	CD	O
%	NN	O
;	:	O
IV	NNP	O
:	:	O
5	CD	O
%	NN	O
)	)	O
.	.	O

Referring	VBG	O
to	TO	O
overall	JJ	O
and	CC	O
to	TO	O
clinically	RB	O
relevant	JJ	O
heterotopic	NN	O
ossification	NN	O
the	DT	O
incidence	NN	O
of	IN	O
HO	NNP	O
was	VBD	O
greater	JJR	O
in	IN	O
the	DT	O
control	NN	O
group	NN	O
than	IN	O
in	IN	O
the	DT	O
prophylactically	RB	O
treated	VBN	O
groups	NNS	O
(	(	O
p	JJ	O
<	NNP	O
0.05	CD	O
)	)	O
.	.	O

CONCLUSION	NNP	O
Irradiation	NNP	O
within	IN	O
16-20	JJ	O
h	NN	O
before	IN	O
operation	NN	O
and	CC	O
use	NN	O
of	IN	O
NSAID	NNP	O
(	(	O
Voltaren	NNP	O
resinat	NN	O
)	)	O
can	MD	O
reduce	VB	O
the	DT	O
incidence	NN	O
of	IN	O
clinically	RB	O
relevant	JJ	O
heterotopic	NN	O
ossification	NN	O
after	IN	O
total	JJ	O
hip	NN	O
replacement	NN	O
.	.	O

Onset/offset	NNP	O
characteristics	NNS	O
and	CC	O
intubating	VBG	O
conditions	NNS	O
of	IN	O
rapacuronium	NN	O
:	:	O
a	DT	O
comparison	NN	O
with	IN	O
rocuronium	NN	O
.	.	O

We	PRP	O
compared	VBN	O
onset	PRP	O
and	CC	O
offset	VB	O
of	IN	O
action	NN	O
and	CC	O
tracheal	JJ	O
intubating	NN	O
conditions	NNS	O
after	IN	O
rapacuronium	NN	O
and	CC	O
rocuronium	NN	O
in	IN	O
60	CD	SS
patients	NNS	O
in	IN	O
a	DT	O
randomized	JJ	O
,	,	O
assessor-blinded	JJ	O
study	NN	O
.	.	O

Following	VBG	O
induction	NN	O
of	IN	O
anaesthesia	NN	O
with	IN	O
propofol	JJ	O
2.5	CD	O
mg	JJ	O
kg-1	NN	O
,	,	O
either	CC	O
rapacuronium	NN	O
1.5	CD	O
mg	NN	O
kg-1	NN	O
(	(	O
n	JJ	O
=	NNP	O
30	CD	O
)	)	O
or	CC	O
rocuronium	$	O
0.6	CD	O
mg	JJ	O
kg-1	NN	O
(	(	O
n	JJ	O
=	NNP	O
30	CD	O
)	)	O
was	VBD	O
administered	VBN	O
to	TO	O
facilitate	VB	O
tracheal	JJ	O
intubation	NN	O
.	.	O

Anaesthesia	NNP	O
was	VBD	O
maintained	VBN	O
with	IN	O
either	CC	O
a	DT	O
propofol	JJ	O
infusion	NN	O
(	(	O
100	CD	O
micrograms	NNS	O
kg-1	JJ	O
min-1	JJ	O
)	)	O
or	CC	O
sevoflurane	NN	O
(	(	O
1	CD	O
%	NN	O
end-tidal	JJ	O
)	)	O
with	IN	O
66	CD	O
%	NN	O
nitrous	JJ	O
oxide	NN	O
(	(	O
N2O	NNP	O
)	)	O
,	,	O
n	JJ	O
=	VBP	O
15	CD	O
in	IN	O
each	DT	O
subgroup	NN	O
.	.	O

Neuromuscular	JJ	O
monitoring	NN	O
was	VBD	O
performed	VBN	O
using	VBG	O
an	DT	O
electromyographic	JJ	O
(	(	O
EMG	NNP	O
)	)	O
device	NN	O
(	(	O
Datex	NNP	O
Relaxograph	NNP	O
)	)	O
.	.	O

The	DT	O
lag	NN	O
times	NNS	O
(	(	O
mean	JJ	O
42	CD	O
(	(	O
SD	NNP	O
11	CD	O
)	)	O
s	NN	O
and	CC	O
44	CD	O
(	(	O
16	CD	O
)	)	O
s	NN	O
)	)	O
,	,	O
maximum	JJ	O
block	NN	O
(	(	O
99	CD	O
(	(	O
2	CD	O
)	)	O
%	NN	O
and	CC	O
98	CD	O
(	(	O
3	CD	O
)	)	O
%	NN	O
)	)	O
and	CC	O
intubating	JJ	O
conditions	NNS	O
at	IN	O
60	CD	O
s	NN	O
(	(	O
good-to-excellent	JJ	O
in	IN	O
86	CD	O
%	NN	O
and	CC	O
84	CD	O
%	NN	O
of	IN	O
patients	NNS	O
)	)	O
were	VBD	O
similar	JJ	O
for	IN	O
rapacuronium	NN	O
and	CC	O
rocuronium	NN	O
,	,	O
respectively	RB	O
.	.	O

The	DT	O
onset	JJ	O
time	NN	O
of	IN	O
rapacuronium	NN	O
was	VBD	O
shorter	JJR	O
than	IN	O
rocuronium	NN	O
(	(	O
87	CD	O
(	(	O
20	CD	O
)	)	O
vs	NN	O
141	CD	O
(	(	O
65	CD	O
)	)	O
s	NN	O
,	,	O
P	NNP	O
<	NNP	O
0.001	CD	O
)	)	O
,	,	O
and	CC	O
the	DT	O
degree	NN	O
of	IN	O
block	NN	O
at	IN	O
60	CD	O
s	NN	O
was	VBD	O
greater	JJR	O
(	(	O
69	CD	O
(	(	O
26	CD	O
)	)	O
vs	NN	O
50	CD	O
(	(	O
27	CD	O
)	)	O
%	NN	O
,	,	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
.	.	O

Twenty-five	JJ	O
per	IN	O
cent	NN	O
recovery	NN	O
was	VBD	O
shorter	JJR	O
with	IN	O
rapacuronium	NN	O
than	IN	O
rocuronium	NN	O
during	IN	O
propofol	NN	O
(	(	O
15.0	CD	O
(	(	O
3.2	CD	O
)	)	O
vs	NN	O
39.1	CD	O
(	(	O
14.2	CD	O
)	)	O
min	NN	O
,	,	O
P	NNP	O
<	NNP	O
0.001	CD	O
)	)	O
and	CC	O
sevoflurane	NN	O
(	(	O
15.1	CD	O
(	(	O
4.2	CD	O
)	)	O
vs	NN	O
47.8	CD	O
(	(	O
19.0	CD	O
)	)	O
min	NN	O
,	,	O
P	NNP	O
<	NNP	O
0.001	CD	O
)	)	O
anaesthesia	NN	O
.	.	O

We	PRP	O
conclude	VBP	O
that	IN	O
rapacuronium	NN	O
1.5	CD	O
mg	NN	O
kg-1	NN	O
had	VBD	O
a	DT	O
more	RBR	O
rapid	JJ	O
onset	NN	O
,	,	O
similar	JJ	O
intubating	NN	O
conditions	NNS	O
,	,	O
and	CC	O
shorter	JJR	O
recovery	NN	O
times	NNS	O
than	IN	O
rocuronium	NN	O
0.6	CD	O
mg	JJ	O
kg-1	NN	O
.	.	O

Single-needle	JJ	O
acupuncture	NN	O
alleviates	VBZ	O
gag	JJ	O
reflex	NN	O
during	IN	O
transesophageal	JJ	C
echocardiography	NN	C
:	:	O
a	DT	O
blinded	VBN	O
,	,	O
randomized	VBN	O
,	,	O
controlled	VBD	O
pilot	NN	O
trial	NN	O
.	.	O

OBJECTIVES	UH	O
To	TO	O
study	VB	O
the	DT	O
effect	NN	O
of	IN	O
single-needle	JJ	O
acupuncture	NN	O
in	IN	O
suppressing	VBG	O
gag-reflex	JJ	O
in	IN	O
transesophageal	JJ	O
echocardiography	NN	O
(	(	O
TEE	NNP	O
)	)	O
.	.	O

DESIGN	NNP	O
Prospective	NNP	O
,	,	O
blinded	VBD	O
trial	NN	O
.	.	O

Settings/locations	NNS	O
:	:	O
Patients	NNS	O
with	IN	O
ischemic	JJ	C
stroke	NN	C
or	CC	C
transient	JJ	C
ischemic	JJ	C
attack	NN	C
undergoing	JJ	O
TEE	NNP	O
because	IN	O
of	IN	O
presumed	JJ	O
cardioembolic	JJ	O
origin	NN	O
in	IN	O
a	DT	O
specialized	JJ	O
stroke	NN	O
unit	NN	O
of	IN	O
the	DT	O
Johann	NNP	O
Wolfgang	NNP	O
Goethe-University	NNP	O
,	,	O
Frankfurt/Main	NNP	O
,	,	O
Germany	NNP	O
.	.	O

Subjects/Study	NNP	O
interventions	NNS	O
:	:	O
Forty-one	CD	SS
(	(	SS
41	CD	SS
)	)	SS
patients	NNS	O
were	VBD	O
studied	VBN	O
.	.	O

Patients	NNS	O
received	VBD	O
single-needle	JJ	O
acupuncture	NN	O
with	IN	O
a	DT	O
0.2	CD	O
x	NN	O
13	CD	O
mm	NN	O
disposable	JJ	O
acupuncture	NN	O
needle	NN	O
(	(	O
Suzhou	NNP	O
Medical	NNP	O
Appliances	NNP	O
,	,	O
China	NNP	O
)	)	O
,	,	O
10-mm	JJ	O
deep	NN	O
either	NN	O
at	IN	O
Chengjiang	NNP	O
(	(	O
midline	NN	O
between	IN	O
lower	JJR	O
lip	NN	O
and	CC	O
chin	NN	O
)	)	O
or	CC	O
superficially	RB	O
at	IN	O
a	DT	O
sham	NN	O
point	NN	O
(	(	O
tip	NN	O
of	IN	O
the	DT	O
chin	NN	O
)	)	O
during	IN	O
TEE	NNP	O
or	CC	O
no	DT	O
acupuncture	NN	O
for	IN	O
alleviating	VBG	O
gag	NN	O
reflex	NN	O
.	.	O

OUTCOME	NNP	O
MEASURES	NNP	O
Severity	NNP	O
of	IN	O
gagging	NN	O
was	VBD	O
rated	VBN	O
on	IN	O
a	DT	O
visual-analogue	JJ	O
scale	NN	O
.	.	O

RESULTS	VB	O
The	DT	O
acupuncture	NN	O
group	NN	O
experienced	VBD	O
significantly	RB	O
less	RBR	O
gagging	VBG	O
than	IN	O
the	DT	O
sham	NN	O
group	NN	O
(	(	O
p	JJ	O
=	NNP	O
0.037	CD	O
)	)	O
or	CC	O
the	DT	O
nonacupuncture	NN	O
group	NN	O
(	(	O
p	JJ	O
=	NNP	O
0.013	CD	O
)	)	O
.	.	O

CONCLUSIONS	NNP	O
Acupuncture	NNP	O
of	IN	O
CV24	NNP	O
is	VBZ	O
an	DT	O
easy	JJ	O
to	TO	O
apply	VB	O
and	CC	O
effective	JJ	O
method	NN	O
to	TO	O
reduce	VB	O
gag	NN	O
reflex	NN	O
during	IN	O
TEE	NNP	O
.	.	O

Rett	NNP	O
syndrome	NN	O
:	:	O
randomized	VBN	O
controlled	VBD	O
trial	NN	O
of	IN	O
L-carnitine	NNP	O
.	.	O

Rett	NNP	O
syndrome	NN	O
is	VBZ	O
a	DT	O
severe	JJ	O
neurodevelopmental	JJ	O
disorder	NN	O
of	IN	O
unknown	JJ	O
etiology	NN	O
,	,	O
occurring	VBG	O
almost	RB	O
exclusively	RB	O
in	IN	O
female	JJ	O
patients	NNS	O
.	.	O

The	DT	O
etiology	NN	O
and	CC	O
functional	JJ	O
significance	NN	O
of	IN	O
plasma	JJ	O
carnitine	NN	O
deficiency	NN	O
seen	VBN	O
in	IN	O
some	DT	O
patients	NNS	O
with	IN	O
Rett	NNP	O
syndrome	NN	O
is	VBZ	O
unknown	JJ	O
.	.	O

To	TO	O
investigate	VB	O
whether	IN	O
L-carnitine	JJ	O
might	MD	O
be	VB	O
of	IN	O
benefit	NN	O
in	IN	O
Rett	NNP	O
syndrome	NN	O
,	,	O
a	DT	O
randomized	VBN	O
,	,	O
placebo-controlled	JJ	O
,	,	O
double-blind	JJ	O
crossover	NN	O
trial	NN	O
of	IN	O
L-carnitine	NNP	O
has	VBZ	O
been	VBN	O
completed	VBN	O
in	IN	O
35	CD	O
subjects	NNS	O
.	.	O

Eight-week	JJ	O
treatment	NN	O
phases	NNS	O
were	VBD	O
completed	VBN	O
for	IN	O
both	DT	O
a	DT	O
placebo	NN	O
and	CC	O
L-carnitine	NNP	O
.	.	O

Outcome	NNP	O
was	VBD	O
measured	VBN	O
by	IN	O
parents/caregivers	NNS	O
and	CC	O
at	IN	O
medical	JJ	O
follow-up	NN	O
using	VBG	O
three	CD	O
established	VBN	O
tools	NNS	O
:	:	O
the	DT	O
Rett	NNP	O
Syndrome	NNP	O
Motor	NNP	O
Behavioral	NNP	O
Assessment	NNP	O
,	,	O
the	DT	O
Hand	NNP	O
Apraxia	NNP	O
Scale	NNP	O
,	,	O
and	CC	O
the	DT	O
Patient	NNP	O
Well-Being	NNP	O
Index	NNP	O
.	.	O

Analysis	NNP	O
comparing	VBG	O
change	NN	O
between	IN	O
baseline	NN	O
and	CC	O
week	NN	O
8	CD	O
of	IN	O
treatment	NN	O
for	IN	O
L-carnitine	NNP	O
and	CC	O
the	DT	O
placebo	NN	O
showed	VBD	O
that	IN	O
both	DT	O
parents/caregivers	NNS	O
and	CC	O
medical	JJ	O
follow-up	NN	O
detected	JJ	O
improvements	NNS	O
in	IN	O
the	DT	O
subjects	NNS	O
'	POS	O
well-being	NN	O
.	.	O

In	IN	O
addition	NN	O
,	,	O
medical	JJ	O
review	NN	O
showed	VBD	O
an	DT	O
improvement	NN	O
on	IN	O
the	DT	O
Hand	NNP	O
Apraxia	NNP	O
Scale	NNP	O
for	IN	O
a	DT	O
higher	JJR	O
proportion	NN	O
of	IN	O
girls	NNS	O
on	IN	O
L-carnitine	NNP	O
.	.	O

Identification	NN	O
of	IN	O
predictors	NNS	O
of	IN	O
clinical	JJ	O
improvement	NN	O
has	VBZ	O
been	VBN	O
limited	VBN	O
by	IN	O
the	DT	O
power	NN	O
of	IN	O
the	DT	O
study	NN	O
.	.	O

These	DT	O
findings	NNS	O
suggest	VBP	O
that	IN	O
L-carnitine	NNP	O
is	VBZ	O
of	IN	O
benefit	NN	O
in	IN	O
some	DT	O
patients	NNS	O
with	IN	O
Rett	NNP	O
syndrome	NN	O
.	.	O

While	IN	O
L-carnitine	NNP	O
did	VBD	O
not	RB	O
lead	VB	O
to	TO	O
major	JJ	O
functional	JJ	O
changes	NNS	O
in	IN	O
ability	NN	O
,	,	O
the	DT	O
type	NN	O
of	IN	O
changes	NNS	O
reported	VBN	O
could	MD	O
still	RB	O
have	VB	O
a	DT	O
substantial	JJ	O
impact	NN	O
on	IN	O
the	DT	O
girls	NNS	O
and	CC	O
their	PRP$	O
families	NNS	O
.	.	O

Information	NN	O
is	VBZ	O
still	RB	O
needed	VBN	O
,	,	O
however	RB	O
,	,	O
to	TO	O
determine	VB	O
if	IN	O
only	RB	O
subgroups	NNS	O
of	IN	O
girls	NNS	O
with	IN	O
the	DT	O
disorder	NN	O
are	VBP	O
responsive	JJ	O
to	TO	O
L-carnitine	NNP	O
and	CC	O
the	DT	O
appropriate	JJ	O
duration	NN	O
of	IN	O
therapy	NN	O
.	.	O

Memory	NN	O
monitoring	NN	O
by	IN	O
animals	NNS	C
and	CC	C
humans	NNS	C
.	.	C

The	DT	O
authors	NNS	O
asked	VBD	O
whether	IN	O
animals	NNS	O
and	CC	O
humans	NNS	O
would	MD	O
use	VB	O
similarly	RB	O
an	DT	O
uncertain	JJ	O
response	NN	O
to	TO	O
escape	VB	O
indeterminate	JJ	O
memories	NNS	O
.	.	O

Monkeys	NNS	O
and	CC	O
humans	NNS	O
performed	VBD	O
serial	JJ	O
probe	NN	O
recognition	NN	O
tasks	NNS	O
that	WDT	O
produced	VBD	O
differential	JJ	O
memory	NN	O
difficulty	NN	O
across	IN	O
serial	JJ	O
positions	NNS	O
(	(	O
e.g.	NN	O
,	,	O
primacy	NN	O
and	CC	O
recency	NN	O
effects	NNS	O
)	)	O
.	.	O

Participants	NNS	O
were	VBD	O
given	VBN	O
an	DT	O
escape	NN	O
option	NN	O
that	WDT	O
let	VBD	O
them	PRP	O
avoid	VB	O
any	DT	O
trials	NNS	O
they	PRP	O
wished	VBD	O
and	CC	O
receive	VB	O
a	DT	O
hint	NN	O
to	TO	O
the	DT	O
trial	NN	O
's	POS	O
answer	NN	O
.	.	O

Across	IN	O
species	NNS	O
,	,	O
across	IN	O
tasks	NNS	O
,	,	O
and	CC	O
even	RB	O
across	IN	O
conspecifics	NNS	O
with	IN	O
sharper	NN	O
or	CC	O
duller	NN	O
memories	NNS	O
,	,	O
monkeys	NNS	O
and	CC	O
humans	NNS	O
used	VBD	O
the	DT	O
escape	NN	O
option	NN	O
selectively	RB	O
when	WRB	O
more	RBR	O
indeterminate	JJ	O
memory	NN	O
traces	NNS	O
were	VBD	O
probed	VBN	O
.	.	O

Their	PRP$	O
pattern	NN	O
of	IN	O
escaping	VBG	O
always	RB	O
mirrored	VBN	O
the	DT	O
pattern	NN	O
of	IN	O
their	PRP$	O
primary	JJ	O
memory	NN	O
performance	NN	O
across	IN	O
serial	JJ	O
positions	NNS	O
.	.	O

Signal-detection	NN	O
analyses	NNS	O
confirm	VBP	O
the	DT	O
similarity	NN	O
of	IN	O
the	DT	O
animals	NNS	O
'	POS	O
and	CC	O
humans	NNS	O
'	POS	O
performances	NNS	O
.	.	O

Optimality	NNP	O
analyses	VBZ	O
assess	VB	O
their	PRP$	O
efficiency	NN	O
.	.	O

Several	JJ	O
aspects	NNS	O
of	IN	O
monkeys	NNS	O
'	POS	O
performance	NN	O
suggest	VBP	O
the	DT	O
cognitive	JJ	O
sophistication	NN	O
of	IN	O
their	PRP$	O
decisions	NNS	O
to	TO	O
escape	VB	O
.	.	O

FDA	NNP	O
review	NN	O
of	IN	O
a	DT	O
panitumumab	NN	O
(	(	O
Vectibix	NNP	O
)	)	O
clinical	JJ	O
trial	NN	O
for	IN	O
first-line	JJ	O
treatment	NN	O
of	IN	O
metastatic	JJ	C
colorectal	JJ	C
cancer	NN	C
.	.	O

On	IN	O
September	NNP	O
27	CD	O
,	,	O
2006	CD	O
,	,	O
the	DT	O
U.S.	NNP	O
Food	NNP	O
and	CC	O
Drug	NNP	O
Administration	NNP	O
granted	VBD	O
accelerated	VBD	O
approval	NN	O
to	TO	O
panitumumab	VB	O
(	(	O
Vectibix	NNP	O
;	:	O
Amgen	NNP	O
,	,	O
Inc.	NNP	O
,	,	O
Thousand	NNP	O
Oaks	NNP	O
,	,	O
CA	NNP	O
)	)	O
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
patients	NNS	O
with	IN	O
epidermal	JJ	C
growth	NN	C
factor	NN	C
receptor-expressing	NN	C
,	,	O
metastatic	JJ	C
colorectal	NN	C
carcinoma	NN	C
with	IN	O
disease	JJ	O
progression	NN	O
on	IN	O
or	CC	O
following	VBG	O
fluoropyrimidine-	JJ	O
,	,	O
oxaliplatin-	JJ	O
,	,	O
and	CC	O
irinotecan-containing	JJ	O
chemotherapy	NN	O
regimens	NNS	O
.	.	O

Accelerated	NNP	O
approval	NN	O
was	VBD	O
based	VBN	O
on	IN	O
demonstration	NN	O
of	IN	O
a	DT	O
beneficial	JJ	O
effect	NN	O
on	IN	O
progression-free	JJ	O
survival	NN	O
(	(	O
PFS	NNP	O
)	)	O
.	.	O

The	DT	O
present	JJ	O
submission	NN	O
summarizes	VBZ	O
a	DT	O
second	JJ	O
clinical	JJ	O
trial	NN	O
,	,	O
to	TO	O
be	VB	O
included	VBN	O
in	IN	O
the	DT	O
panitumumab	JJ	O
package	NN	O
insert	NN	O
in	IN	O
June	NNP	O
2008	CD	O
,	,	O
of	IN	O
chemotherapy	NN	O
and	CC	O
bevacizumab	NN	O
with	IN	O
and	CC	O
without	IN	O
panitumumab	NN	O
in	IN	O
the	DT	O
first-line	JJ	O
treatment	NN	O
of	IN	O
patients	NNS	O
with	IN	O
metastatic	JJ	C
colorectal	JJ	C
cancer	NN	C
.	.	O

The	DT	O
study	NN	O
was	VBD	O
closed	VBN	O
when	WRB	O
inferior	JJ	O
PFS	NNP	O
and	CC	O
greater	JJR	O
toxicity	NN	O
were	VBD	O
demonstrated	VBN	O
at	IN	O
the	DT	O
time	NN	O
of	IN	O
the	DT	O
planned	VBN	O
interim	NN	O
efficacy	NN	O
analysis	NN	O
.	.	O

Patients	NNS	O
receiving	VBG	O
panitumumab	NN	O
in	IN	O
combination	NN	O
with	IN	O
bevacizumab	NN	O
and	CC	O
chemotherapy	NN	O
experienced	VBD	O
a	DT	O
higher	JJR	O
incidence	NN	O
of	IN	O
death	NN	O
(	(	O
9	CD	O
%	NN	O
versus	IN	O
4	CD	O
%	NN	O
)	)	O
and	CC	O
a	DT	O
higher	JJR	O
risk	NN	O
for	IN	O
grade	NN	O
3	CD	O
and	CC	O
4	CD	O
toxicities	NNS	O
than	IN	O
patients	NNS	O
receiving	VBG	O
bevacizumab	NN	O
and	CC	O
chemotherapy	NN	O
alone	RB	O
.	.	O

The	DT	O
incidences	NNS	O
of	IN	O
any	DT	O
Common	NNP	O
Terminology	NNP	O
Criteria	NNP	O
for	IN	O
Adverse	NNP	O
Events	NNP	O
grade	VBD	O
3	CD	O
and	CC	O
4	CD	O
adverse	JJ	O
events	NNS	O
(	(	O
AEs	NNP	O
)	)	O
were	VBD	O
87	CD	O
%	NN	O
and	CC	O
72	CD	O
%	NN	O
in	IN	O
the	DT	O
panitumumab	NN	O
and	CC	O
control	NN	O
groups	NNS	O
,	,	O
respectively	RB	O
.	.	O

Grade	VB	O
3	CD	O
and	CC	O
4	CD	O
AEs	NNP	O
occurring	VBG	O
more	JJR	O
commonly	RB	O
in	IN	O
panitumumab-treated	JJ	O
patients	NNS	O
included	VBD	O
rash/acneiform	NN	O
dermatitis	NN	O
,	,	O
diarrhea	NN	O
,	,	O
dehydration	NN	O
,	,	O
primarily	RB	O
resulting	VBG	O
from	IN	O
diarrhea	NN	O
,	,	O
hypokalemia	NN	O
,	,	O
stomatitis/mucositis	NN	O
,	,	O
and	CC	O
pulmonary	JJ	O
embolism	NN	O
.	.	O

The	DT	O
addition	NN	O
of	IN	O
panitumumab	NN	O
to	TO	O
bevacizumab	VB	O
and	CC	O
chemotherapy	VB	O
for	IN	O
the	DT	O
first-line	JJ	O
treatment	NN	O
of	IN	O
metastatic	JJ	O
colorectal	NN	C
cancer	NN	C
was	VBD	O
harmful	JJ	O
when	WRB	O
compared	VBN	O
with	IN	O
bevacizumab	NN	O
and	CC	O
chemotherapy	NN	O
alone	RB	O
.	.	O

The	DT	O
use	NN	O
of	IN	O
panitumumab	NN	O
in	IN	O
this	DT	O
setting	NN	O
can	MD	O
not	RB	O
be	VB	O
recommended	VBN	O
.	.	O

Falls	NNS	O
and	CC	O
mobility	NN	O
in	IN	O
Parkinson	NNP	C
's	POS	C
disease	NN	C
:	:	O
protocol	NN	O
for	IN	O
a	DT	O
randomised	VBN	O
controlled	JJ	O
clinical	JJ	O
trial	NN	O
.	.	O

BACKGROUND	NNP	O
Although	IN	O
physical	JJ	O
therapy	NN	O
and	CC	O
falls	VBZ	O
prevention	NN	O
education	NN	O
are	VBP	O
argued	VBN	O
to	TO	O
reduce	VB	O
falls	NNS	O
and	CC	O
disability	NN	O
in	IN	O
people	NNS	O
with	IN	O
idiopathic	JJ	O
Parkinson	NNP	C
's	POS	C
disease	NN	C
,	,	O
this	DT	O
has	VBZ	O
not	RB	O
yet	RB	O
been	VBN	O
confirmed	VBN	O
with	IN	O
a	DT	O
large	JJ	O
scale	NN	O
randomised	VBD	O
controlled	JJ	O
clinical	JJ	O
trial	NN	O
.	.	O

The	DT	O
study	NN	O
will	MD	O
investigate	VB	O
the	DT	O
effects	NNS	O
on	IN	O
falls	NNS	O
,	,	O
mobility	NN	O
and	CC	O
quality	NN	O
of	IN	O
life	NN	O
of	IN	O
(	(	O
i	NN	O
)	)	O
movement	NN	O
strategy	NN	O
training	NN	O
combined	VBN	O
with	IN	O
falls	NNS	O
prevention	JJ	O
education	NN	O
,	,	O
(	(	O
ii	NN	O
)	)	O
progressive	NN	O
resistance	NN	O
strength	NN	O
training	NN	O
combined	VBN	O
with	IN	O
falls	NNS	O
prevention	JJ	O
education	NN	O
,	,	O
(	(	O
iii	NN	O
)	)	O
a	DT	O
generic	JJ	O
life-skills	JJ	O
social	JJ	O
program	NN	O
(	(	O
control	VB	O
group	NN	O
)	)	O
.	.	O

METHODS/DESIGN	JJ	O
People	NNS	O
with	IN	O
idiopathic	JJ	C
Parkinson	NNP	C
's	POS	C
disease	NN	C
who	WP	O
live	VBP	O
at	IN	O
home	NN	O
will	MD	O
be	VB	O
recruited	VBN	O
and	CC	O
randomly	RB	O
allocated	VBD	O
to	TO	O
one	CD	O
of	IN	O
three	CD	O
groups	NNS	O
.	.	O

Each	DT	O
person	NN	O
shall	MD	O
receive	VB	O
therapy	NN	O
in	IN	O
an	DT	O
out-patient	JJ	O
setting	NN	O
in	IN	O
groups	NNS	O
of	IN	O
3-4	JJ	O
.	.	O

Each	DT	O
group	NN	O
shall	MD	O
be	VB	O
scheduled	VBN	O
to	TO	O
meet	VB	O
once	RB	O
per	IN	O
week	NN	O
for	IN	O
2	CD	O
hours	NNS	O
for	IN	O
8	CD	O
consecutive	JJ	O
weeks	NNS	O
.	.	O

All	DT	O
participants	NNS	O
will	MD	O
also	RB	O
have	VB	O
a	DT	O
structured	JJ	O
2	CD	O
hour	NN	O
home	NN	O
practice	NN	O
program	NN	O
for	IN	O
each	DT	O
week	NN	O
during	IN	O
the	DT	O
8	CD	O
week	NN	O
intervention	NN	O
phase	NN	O
.	.	O

Assessments	NNS	O
will	MD	O
occur	VB	O
before	IN	O
therapy	NN	O
,	,	O
after	IN	O
the	DT	O
8	CD	O
week	NN	O
therapy	NN	O
program	NN	O
,	,	O
and	CC	O
at	IN	O
3	CD	O
and	CC	O
12	CD	O
months	NNS	O
after	IN	O
the	DT	O
intervention	NN	O
.	.	O

A	DT	O
falls	JJ	O
calendar	NN	O
will	MD	O
be	VB	O
kept	VBN	O
by	IN	O
each	DT	O
participant	NN	O
for	IN	O
12	CD	O
months	NNS	O
after	IN	O
outpatient	JJ	O
therapy.Consistent	NN	O
with	IN	O
the	DT	O
recommendations	NNS	O
of	IN	O
the	DT	O
Prevention	NNP	O
of	IN	O
Falls	NNP	O
Network	NNP	O
Europe	NNP	O
group	NN	O
,	,	O
three	CD	O
falls	NNS	O
variables	NNS	O
will	MD	O
be	VB	O
used	VBN	O
as	IN	O
the	DT	O
primary	JJ	O
outcome	NN	O
measures	NNS	O
:	:	O
the	DT	O
number	NN	O
of	IN	O
fallers	NNS	O
,	,	O
the	DT	O
number	NN	O
of	IN	O
multiple	JJ	O
fallers	NNS	O
and	CC	O
the	DT	O
falls	JJ	O
rate	NN	O
.	.	O

In	IN	O
addition	NN	O
to	TO	O
quantifying	VBG	O
falls	NNS	O
,	,	O
we	PRP	O
shall	MD	O
measure	VB	O
mobility	NN	O
,	,	O
activity	NN	O
limitations	NNS	O
and	CC	O
quality	NN	O
of	IN	O
life	NN	O
as	IN	O
secondary	JJ	O
outcomes	NNS	O
.	.	O

DISCUSSION	NNP	O
This	DT	O
study	NN	O
has	VBZ	O
the	DT	O
potential	NN	O
to	TO	O
determine	VB	O
whether	IN	O
outpatient	JJ	O
movement	NN	O
strategy	NN	O
training	NN	O
combined	VBN	O
with	IN	O
falls	NNS	O
prevention	JJ	O
education	NN	O
or	CC	O
progressive	JJ	O
resistance	NN	O
strength	NN	O
training	NN	O
combined	VBN	O
with	IN	O
falls	NNS	O
prevention	JJ	O
education	NN	O
are	VBP	O
effective	JJ	O
for	IN	O
reducing	VBG	O
falls	NNS	O
and	CC	O
improving	VBG	O
mobility	NN	O
and	CC	O
life	NN	O
quality	NN	O
in	IN	O
people	NNS	O
with	IN	O
Parkinson	NNP	C
's	POS	C
disease	NN	C
who	WP	O
live	VBP	O
at	IN	O
home	NN	O
.	.	O

TRIAL	NNP	O
REGISTRATION	NNP	O
Australia	NNP	O
and	CC	O
New	NNP	O
Zealand	NNP	O
Clinical	NNP	O
Trials	NNP	O
Register	NNP	O
(	(	O
ANZCTR	NNP	O
)	)	O
:	:	O
ACTRN12606000344594	NN	O
.	.	O

The	DT	O
impact	NN	O
of	IN	O
schizophrenic	JJ	C
patient	NN	O
functionality	NN	O
on	IN	O
service	NN	O
utilization	NN	O
and	CC	O
cost	NN	O
.	.	O

Based	VBN	O
on	IN	O
a	DT	O
presentation	NN	O
by	IN	O
Sandra	NNP	O
L.	NNP	O
Tunis	NNP	O
,	,	O
PhD	NNP	O
.	.	O

With	IN	O
the	DT	O
advent	NN	O
of	IN	O
atypical	JJ	O
agents	NNS	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
schizophrenia	NN	O
,	,	O
physicians	NNS	O
and	CC	O
policy	NN	O
makers	NNS	O
must	MD	O
consider	VB	O
the	DT	O
costs	NNS	O
that	WDT	O
may	MD	O
accompany	VB	O
greater	JJR	O
clinical	JJ	O
efficacy	NN	O
.	.	O

Analyses	VBZ	O
reveal	NN	O
that	WDT	O
olanzapine	NN	O
shows	VBZ	O
a	DT	O
greater	JJR	O
clinical	JJ	O
cost	NN	O
effectiveness	NN	O
,	,	O
as	RB	O
well	RB	O
as	IN	O
a	DT	O
greater	JJR	O
functional	JJ	O
cost	NN	O
effectiveness	NN	O
,	,	O
than	IN	O
haloperidol	NN	O
,	,	O
and	CC	O
that	IN	O
functional	JJ	O
outcomes	NNS	O
,	,	O
in	IN	O
particular	JJ	O
,	,	O
show	VBP	O
promise	NN	O
as	IN	O
important	JJ	O
measures	NNS	O
of	IN	O
effectiveness	NN	O
.	.	O

Functional	JJ	O
outcomes	NNS	O
can	MD	O
help	VB	O
differentiate	VB	O
medications	NNS	O
and	CC	O
can	MD	O
be	VB	O
used	VBN	O
to	TO	O
help	VB	O
demonstrate	VB	O
the	DT	O
cost	NN	O
effectiveness	NN	O
of	IN	O
atypical	JJ	O
agents	NNS	O
.	.	O

Mental	NNP	O
health	NN	O
and	CC	O
physical	JJ	O
health	NN	O
functioning	NN	O
,	,	O
as	RB	O
well	RB	O
as	IN	O
work	NN	O
status	NN	O
,	,	O
are	VBP	O
all	DT	O
measures	NNS	O
of	IN	O
functioning	VBG	O
that	WDT	O
have	VBP	O
been	VBN	O
used	VBN	O
to	TO	O
evaluate	VB	O
treatment	NN	O
strategies	NNS	O
.	.	O

When	WRB	O
comparing	VBG	O
olanzapine	NN	O
with	IN	O
haloperidol	NN	O
,	,	O
cost	NN	O
savings	NNS	O
are	VBP	O
seen	VBN	O
throughout	IN	O
the	DT	O
treatment	NN	O
period	NN	O
(	(	O
1	CD	O
year	NN	O
)	)	O
,	,	O
with	IN	O
physical	JJ	O
functioning	VBG	O
most	JJS	O
highly	RB	O
affected	VBN	O
over	IN	O
time	NN	O
.	.	O

Functional	JJ	O
outcomes	NNS	O
can	MD	O
therefore	VB	O
serve	VB	O
2	CD	O
purposes	NNS	O
:	:	O
to	TO	O
enhance	VB	O
compliance	NN	O
by	IN	O
improving	VBG	O
health-related	JJ	O
quality	NN	O
of	IN	O
life	NN	O
and	CC	O
to	TO	O
assist	VB	O
in	IN	O
making	VBG	O
both	DT	O
treatment	NN	O
and	CC	O
formulary	JJ	O
decisions	NNS	O
.	.	O

Prevention	NN	O
of	IN	O
venous	JJ	O
thromboembolism	NN	O
after	IN	O
knee	NN	C
arthroplasty	NN	C
.	.	O

A	DT	O
randomized	JJ	O
,	,	O
double-blind	JJ	O
trial	NN	O
comparing	VBG	O
enoxaparin	NN	O
with	IN	O
warfarin	NN	O
.	.	O

OBJECTIVE	UH	O
To	TO	O
compare	VB	O
the	DT	O
effectiveness	NN	O
and	CC	O
safety	NN	O
of	IN	O
fixed-dose	JJ	O
enoxaparin	NN	O
and	CC	O
adjusted	VBD	O
dose	JJ	O
warfarin	NN	O
in	IN	O
preventing	VBG	O
venous	JJ	O
thromboembolism	NN	O
after	IN	C
knee	NN	C
arthroplasty	NN	C
.	.	O

DESIGN	VB	O
A	DT	O
randomized	JJ	O
,	,	O
double-blind	JJ	O
controlled	VBN	O
trial	NN	O
.	.	O

SETTING	NN	O
8	CD	O
university	NN	O
hospitals	NNS	O
.	.	O

PATIENTS	VB	O
670	CD	SS
consecutive	JJ	O
patients	NNS	O
who	WP	O
had	VBD	O
knee	VBN	C
arthroplasty	RB	C
.	.	O

INTERVENTION	NN	O
Patients	NNPS	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
receive	VB	O
enoxaparin	NN	O
(	(	O
30	CD	O
mg	NN	O
subcutaneously	RB	O
every	DT	O
12	CD	O
hours	NNS	O
)	)	O
or	CC	O
adjusted-dose	JJ	O
warfarin	NN	O
(	(	O
international	JJ	O
normalized	VBN	O
ratio	NN	O
,	,	O
2.0	CD	O
to	TO	O
3.0	CD	O
)	)	O
.	.	O

Both	DT	O
regimens	NNS	O
were	VBD	O
started	VBN	O
after	IN	O
surgery	NN	O
.	.	O

MEASUREMENTS	PDT	O
The	DT	O
primary	JJ	O
end	NN	O
point	NN	O
was	VBD	O
the	DT	O
incidence	NN	O
of	IN	O
deep	JJ	O
venous	JJ	O
thrombosis	NN	O
in	IN	O
patients	NNS	O
with	IN	O
adequate	JJ	C
bilateral	JJ	C
venograms	NNS	C
;	:	O
the	DT	O
secondary	JJ	O
end	NN	O
point	NN	O
was	VBD	O
hemorrhage	NN	O
.	.	O

RESULTS	NNP	O
Among	IN	O
the	DT	O
417	CD	SS
patients	NNS	O
with	IN	O
adequate	JJ	C
venograms	NNS	C
,	,	O
109	CD	O
of	IN	O
211	CD	O
warfarin	NN	O
recipients	NNS	O
(	(	O
51.7	CD	O
%	NN	O
)	)	O
had	VBD	O
deep	JJ	O
venous	JJ	O
thrombosis	NN	O
compared	VBN	O
with	IN	O
76	CD	O
of	IN	O
206	CD	O
enoxaparin	NN	O
recipients	NNS	O
(	(	O
36.9	CD	O
%	NN	O
)	)	O
(	(	O
P	NNP	O
=	NNP	O
0.003	CD	O
)	)	O
.	.	O

The	DT	O
absolute	NN	O
risk	NN	O
difference	NN	O
was	VBD	O
14.8	CD	O
%	NN	O
in	IN	O
favor	NN	O
of	IN	O
enoxaparin	NN	O
(	(	O
95	CD	O
%	NN	O
Cl	NNP	O
,	,	O
5.3	CD	O
%	NN	O
to	TO	O
24.1	CD	O
%	NN	O
)	)	O
Twenty-two	NNP	O
warfarin	NN	O
recipients	NNS	O
(	(	O
10.4	CD	O
%	NN	O
)	)	O
and	CC	O
24	CD	O
enoxaparin	NN	O
recipients	NNS	O
(	(	O
11.7	CD	O
%	NN	O
)	)	O
had	VBD	O
proximal	JJ	O
venous	JJ	O
thrombosis	NN	O
(	(	O
P	NNP	O
>	NNP	O
0.2	CD	O
)	)	O
.	.	O

The	DT	O
absolute	NN	O
risk	NN	O
difference	NN	O
was	VBD	O
1.2	CD	O
%	NN	O
in	IN	O
favor	NN	O
of	IN	O
warfarin	NN	O
(	(	O
Cl	NNP	O
,	,	O
-7.2	NNP	O
%	NN	O
to	TO	O
4.8	CD	O
%	NN	O
)	)	O
.	.	O

The	DT	O
incidence	NN	O
of	IN	O
major	JJ	O
bleeding	NN	O
was	VBD	O
1.8	CD	O
%	NN	O
(	(	O
6	CD	O
of	IN	O
334	CD	O
patients	NNS	O
)	)	O
in	IN	O
the	DT	O
warfarin	NN	O
group	NN	O
and	CC	O
2.1	CD	O
%	NN	O
(	(	O
7	CD	O
of	IN	O
336	CD	O
patients	NNS	O
)	)	O
in	IN	O
the	DT	O
enoxaparin	NN	O
group	NN	O
(	(	O
P	NNP	O
>	NNP	O
0.2	CD	O
)	)	O
.	.	O

The	DT	O
absolute	NN	O
risk	NN	O
difference	NN	O
was	VBD	O
0.3	CD	O
%	NN	O
in	IN	O
favor	NN	O
of	IN	O
warfarin	NN	O
(	(	O
Cl	NNP	O
,	,	O
-2.4	NNP	O
%	NN	O
to	TO	O
1.8	CD	O
%	NN	O
)	)	O
.	.	O

CONCLUSIONS	VB	O
A	DT	O
postoperative	JJ	O
,	,	O
fixed-dose	JJ	O
enoxaparin	NN	O
regimen	NNS	O
is	VBZ	O
more	RBR	O
effective	JJ	O
than	IN	O
adjusted-dose	JJ	O
warfarin	NN	O
in	IN	O
preventing	VBG	O
deep	JJ	O
venous	JJ	O
thrombosis	NN	O
after	IN	C
knee	NN	C
arthroplasty	NN	C
.	.	O

No	DT	O
differences	NNS	O
were	VBD	O
seen	VBN	O
in	IN	O
the	DT	O
incidence	NN	O
of	IN	O
proximal	JJ	O
venous	JJ	O
thrombosis	NN	O
or	CC	O
clinically	RB	O
overt	JJ	O
hemorrhage	NN	O
.	.	O

A	DT	O
pilot	NN	O
study	NN	O
of	IN	O
the	DT	O
safety	NN	O
and	CC	O
efficacy	NN	O
of	IN	O
supplemental	JJ	O
arginine	NN	O
to	TO	O
enhance	VB	O
immune	JJ	O
function	NN	O
in	IN	O
persons	NNS	O
with	IN	O
HIV/AIDS	NNP	O
.	.	O

OBJECTIVE	NNP	O
We	PRP	O
collected	VBD	O
preliminary	JJ	O
data	NNS	O
on	IN	O
the	DT	O
safety	NN	O
and	CC	O
efficacy	NN	O
of	IN	O
supplemental	JJ	O
arginine	NN	O
to	TO	O
improve	VB	O
natural	JJ	O
killer	NN	O
cell	NN	O
cytotoxicity	NN	O
in	IN	O
a	DT	O
sample	NN	O
of	IN	O
persons	NNS	O
with	IN	O
human	JJ	O
immunodeficiency	NN	O
virus	NN	O
(	(	O
HIV	NNP	O
)	)	O
and	CC	O
acquired	VBD	O
immunodeficiency	NN	O
syndrome	NN	O
(	(	O
AIDS	NNP	O
)	)	O
.	.	O

METHODS	NNP	O
In	IN	O
a	DT	O
randomized	JJ	O
,	,	O
double-blind	JJ	O
,	,	O
placebo-controlled	JJ	O
pilot	NN	O
study	NN	O
in	IN	O
an	DT	O
academic	JJ	O
medical	JJ	O
center-based	JJ	O
infectious	JJ	O
disease	NN	O
clinic	NN	O
,	,	O
11	CD	SS
clinically	RB	O
stable	JJ	O
,	,	O
HIV-infected	JJ	O
adults	NNS	A
had	VBD	O
been	VBN	O
treated	VBN	O
with	IN	O
highly	RB	O
active	JJ	O
,	,	O
antiretroviral	JJ	O
therapy	NN	O
and	CC	O
had	VBD	O
HIV	NNP	O
plasma	NN	O
RNA	NNP	O
levels	NNS	O
of	IN	O
less	JJR	O
than	IN	O
10	CD	O
000	CD	O
copies/mL	NN	O
.	.	O

Participants	NNS	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
receive	VB	O
19.6	CD	O
g	NN	O
of	IN	O
arginine/d	NN	O
(	(	O
n	JJ	O
=	NNP	O
6	CD	O
)	)	O
or	CC	O
placebo	NN	O
(	(	O
n	JJ	O
=	NNP	O
5	CD	O
)	)	O
for	IN	O
14	CD	O
d.	NN	O
Plasma	NNP	O
HIV	NNP	O
RNA	NNP	O
levels	NNS	O
,	,	O
neuropsychologic	RB	O
functioning	NN	O
,	,	O
and	CC	O
self-reported	JJ	O
adverse	JJ	O
events	NNS	O
were	VBD	O
analyzed	VBN	O
for	IN	O
safety	NN	O
of	IN	O
treatment	NN	O
.	.	O

Efficacy	NN	O
was	VBD	O
measured	VBN	O
by	IN	O
natural	JJ	O
killer	NN	O
cell	NN	O
cytotoxicity	NN	O
.	.	O

RESULTS	NNP	O
None	NN	O
of	IN	O
the	DT	O
participants	NNS	O
experienced	VBD	O
any	DT	O
adverse	JJ	O
clinical	NN	O
,	,	O
virologic	NN	O
,	,	O
or	CC	O
neuropsychologic	JJ	O
events	NNS	O
that	WDT	O
necessitated	VBD	O
withdrawal	NN	O
from	IN	O
the	DT	O
study	NN	O
.	.	O

The	DT	O
arginine-supplemented	JJ	O
group	NN	O
showed	VBD	O
a	DT	O
mean	JJ	O
natural	JJ	O
killer	NN	O
cell	NN	O
cytotoxicity	NN	O
increase	NN	O
of	IN	O
18.9	CD	O
lytic	JJ	O
units	NNS	O
,	,	O
whereas	IN	O
the	DT	O
placebo	NN	O
group	NN	O
showed	VBD	O
an	DT	O
increase	NN	O
of	IN	O
0.3	CD	O
lytic	JJ	O
units	NNS	O
.	.	O

This	DT	O
difference	NN	O
was	VBD	O
not	RB	O
statistically	RB	O
significant	JJ	O
(	(	O
P	NNP	O
=	NNP	O
0.79	CD	O
)	)	O
.	.	O

CONCLUSIONS	NNP	O
Short-term	JJ	O
arginine	NN	O
supplementation	NN	O
is	VBZ	O
safe	JJ	O
for	IN	O
persons	NNS	O
with	IN	O
HIV/AIDS	NNP	O
.	.	O

Additional	NNP	O
studies	NNS	O
with	IN	O
larger	JJR	O
samples	NNS	O
and	CC	O
longer	JJR	O
periods	NNS	O
are	VBP	O
warranted	VBN	O
to	TO	O
determine	VB	O
the	DT	O
effects	NNS	O
of	IN	O
arginine	JJ	O
supplementation	NN	O
on	IN	O
other	JJ	O
indices	NNS	O
of	IN	O
immune	JJ	O
function	NN	O
and	CC	O
on	IN	O
clinical	JJ	O
outcomes	NNS	O
such	JJ	O
as	IN	O
intercurrent	JJ	O
illnesses	NNS	O
.	.	O

Satisfactory	JJ	O
sampling	NN	O
in	IN	O
cytological	JJ	C
cervical	JJ	C
diagnosis	NN	C
:	:	O
comparison	NN	O
between	IN	O
a	DT	O
conventional	JJ	O
and	CC	O
a	DT	O
new	JJ	O
sampling	NN	O
device	NN	O
.	.	O

AIM	NNP	O
Inadequate	NNP	O
cervical	JJ	O
sampling	NN	O
is	VBZ	O
the	DT	O
most	RBS	O
frequent	JJ	O
cause	NN	O
of	IN	O
misdiagnosis	NN	O
in	IN	O
cervical	JJ	C
cancer	NN	C
screening	NN	O
.	.	O

The	DT	O
aim	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
test	VB	O
the	DT	O
ability	NN	O
of	IN	O
PapCone?	NNP	O
versus	IN	O
the	DT	O
conventional	JJ	O
sampling	NN	O
method	NN	O
(	(	O
Ayre	NNP	O
's	POS	O
spatula	NN	O
plus	CC	O
cytobrush	NN	O
)	)	O
to	TO	O
collect	VB	O
ectocervical	JJ	O
and	CC	O
glandular	JJ	O
cells	NNS	O
.	.	O

MATERIALS	NNP	O
AND	CC	O
METHODS	NNP	O
In	IN	O
18	CD	SS
healthy	JJ	C
women	NNS	SE
,	,	O
two	CD	O
ecto-endocervical	JJ	O
samples	NNS	O
,	,	O
obtained	VBN	O
by	IN	O
two	CD	O
different	JJ	O
methods	NNS	O
,	,	O
were	VBD	O
obtained	VBN	O
at	IN	O
a	DT	O
three-month	JJ	O
interval	NN	O
.	.	O

Qualitative	JJ	O
and	CC	O
quantitative	JJ	O
parameters	NNS	O
were	VBD	O
evaluated	VBN	O
.	.	O

Ultrastructure	NN	O
features	NNS	O
of	IN	O
sampling	VBG	O
devices	NNS	O
were	VBD	O
analyzed	VBN	O
by	IN	O
scanning	VBG	O
electron	NN	O
microscopy	NN	O
(	(	O
SEM	NNP	O
)	)	O
before	IN	O
and	CC	O
after	IN	O
sampling	VBG	O
.	.	O

RESULTS	VB	O
The	DT	O
?	.	O
(	(	O
2	CD	O
)	)	O
test	NN	O
revealed	VBD	O
a	DT	O
statistically	RB	O
significant	JJ	O
difference	NN	O
between	IN	O
the	DT	O
two	CD	O
methods	NNS	O
:	:	O
PapCone?	NNP	O
caused	VBD	O
less	JJR	O
cell	NN	O
overlap	NN	O
and	CC	O
sampled	VBD	O
less	JJR	O
white	JJ	O
blood	NN	O
cells	NNS	O
(	(	O
p	JJ	O
<	NNP	O
0.05	CD	O
)	)	O
and	CC	O
more	RBR	O
metaplastic	JJ	O
cells	NNS	O
(	(	O
p	JJ	O
<	NNP	O
0.01	CD	O
)	)	O
.	.	O

SEM	NNP	O
evaluation	NN	O
highlighted	VBD	O
the	DT	O
porous	JJ	O
and	CC	O
spongy	JJ	O
structure	NN	O
of	IN	O
PapCone?	NNP	O
that	WDT	O
was	VBD	O
responsible	JJ	O
for	IN	O
the	DT	O
large	JJ	O
number	NN	O
of	IN	O
glandular	JJ	O
cells	NNS	O
on	IN	O
its	PRP$	O
surface	NN	O
.	.	O

CONCLUSION	NNP	O
Cervical	NNP	O
smears	NNS	O
performed	VBN	O
by	IN	O
PapCone?	NNP	O
were	VBD	O
adequate	JJ	O
and	CC	O
generally	RB	O
easier	JJR	O
to	TO	O
screen	VB	O
than	IN	O
conventionally	RB	O
performed	VBN	O
ones	NNS	O
.	.	O

Treatment	NN	O
of	IN	O
posterior	JJ	C
uveitis	NN	C
with	IN	O
a	DT	O
fluocinolone	NN	O
acetonide	NN	O
implant	NN	O
:	:	O
three-year	JJ	O
clinical	JJ	O
trial	NN	O
results	NNS	O
.	.	O

OBJECTIVES	NNP	O
To	TO	O
evaluate	VB	O
the	DT	O
safety	NN	O
and	CC	O
efficacy	NN	O
of	IN	O
0.59-mg	JJ	O
and	CC	O
2.1-mg	JJ	O
fluocinolone	NN	O
acetonide	NN	O
(	(	O
FA	NNP	O
)	)	O
intravitreous	JJ	O
implants	NNS	O
in	IN	O
noninfectious	JJ	C
posterior	JJ	C
uveitis	NN	C
.	.	O

DESIGN	VB	O
A	DT	O
3-year	JJ	O
,	,	O
multicenter	NN	O
,	,	O
randomized	VBN	O
,	,	O
historically	RB	O
controlled	VBN	O
trial	NN	O
of	IN	O
the	DT	O
0.59-mg	JJ	O
FA	NNP	O
intravitreous	JJ	O
implant	NN	O
in	IN	O
110	CD	SS
patients	NNS	O
and	CC	O
the	DT	O
2.1-mg	JJ	O
FA	NNP	O
intravitreous	JJ	O
implant	NN	O
in	IN	O
168	CD	SS
patients	NNS	O
.	.	O

MAIN	NNP	O
OUTCOME	NNP	O
MEASURES	NNP	O
Recurrence	NNP	O
rate	NN	O
,	,	O
vision	NN	O
,	,	O
and	CC	O
complications	NNS	O
.	.	O

RESULTS	NNP	O
Uveitis	NNP	O
recurrence	NN	O
was	VBD	O
reduced	VBN	O
in	IN	O
implanted	JJ	O
eyes	NNS	O
from	IN	O
62	CD	O
%	NN	O
(	(	O
during	IN	O
the	DT	O
1-year	JJ	O
preimplantation	NN	O
period	NN	O
)	)	O
to	TO	O
4	CD	O
%	NN	O
,	,	O
10	CD	O
%	NN	O
,	,	O
and	CC	O
20	CD	O
%	NN	O
during	IN	O
the	DT	O
1-	JJ	O
,	,	O
2-	JJ	O
,	,	O
and	CC	O
3-year	JJ	O
postimplantation	NN	O
periods	NNS	O
,	,	O
respectively	RB	O
,	,	O
for	IN	O
the	DT	O
0.59-mg	JJ	O
dose	NN	O
group	NN	O
(	(	O
P	NNP	O
<	NNP	O
.01	NNP	O
)	)	O
and	CC	O
from	IN	O
58	CD	O
%	NN	O
to	TO	O
7	CD	O
%	NN	O
,	,	O
17	CD	O
%	NN	O
,	,	O
and	CC	O
41	CD	O
%	NN	O
,	,	O
respectively	RB	O
,	,	O
for	IN	O
the	DT	O
2.1-mg	JJ	O
dose	NN	O
group	NN	O
(	(	O
P	NNP	O
<	NNP	O
.01	NNP	O
)	)	O
.	.	O

More	RBR	O
implanted	JJ	O
eyes	NNS	O
than	IN	O
nonimplanted	JJ	O
eyes	NNS	O
had	VBD	O
improved	VBN	O
visual	JJ	O
acuity	NN	O
(	(	O
P	NNP	O
<	NNP	O
.01	NNP	O
)	)	O
.	.	O

Implanted	VBN	O
eyes	NNS	O
had	VBD	O
higher	JJR	O
incidences	NNS	O
of	IN	O
intraocular	JJ	O
pressure	NN	O
elevation	NN	O
(	(	O
>	CD	O
or	CC	O
=	VB	O
10	CD	O
mm	NNS	O
Hg	NNP	O
)	)	O
than	IN	O
nonimplanted	VBN	O
eyes	NNS	O
(	(	O
P	NNP	O
<	NNP	O
.01	NNP	O
)	)	O
,	,	O
and	CC	O
glaucoma	NN	O
surgery	NN	O
was	VBD	O
required	VBN	O
in	IN	O
40	CD	O
%	NN	O
of	IN	O
implanted	JJ	O
eyes	NNS	O
vs	VBP	O
2	CD	O
%	NN	O
of	IN	O
nonimplanted	JJ	O
eyes	NNS	O
(	(	O
P	NNP	O
<	NNP	O
.01	NNP	O
)	)	O
.	.	O

Cataracts	NNPS	O
were	VBD	O
extracted	VBN	O
in	IN	O
93	CD	O
%	NN	O
of	IN	O
phakic	NN	O
implanted	VBN	O
eyes	NNS	O
vs	VBP	O
20	CD	O
%	NN	O
of	IN	O
phakic	NN	O
nonimplanted	VBN	O
eyes	NNS	O
(	(	O
P	NNP	O
<	NNP	O
.01	NNP	O
)	)	O
.	.	O

CONCLUSIONS	VB	O
The	DT	O
FA	NNP	O
implant	NN	O
significantly	RB	O
reduced	VBN	O
uveitis	JJ	O
recurrence	NN	O
and	CC	O
improved	VBD	O
or	CC	O
stabilized	VBN	O
visual	JJ	O
acuity	NN	O
in	IN	O
subjects	NNS	O
with	IN	O
noninfectious	JJ	C
posterior	JJ	C
uveitis	NN	C
.	.	O

Most	JJS	O
subjects	NNS	O
required	VBN	O
cataract	JJ	O
extraction	NN	O
,	,	O
and	CC	O
a	DT	O
significant	JJ	O
proportion	NN	O
required	VBN	O
intraocular	JJ	O
pressure-lowering	JJ	O
surgery	NN	O
.	.	O

APPLICATION	NNP	O
TO	NNP	O
CLINICAL	NNP	O
PRACTICE	NNP	O
The	DT	O
FA	NNP	O
implant	NN	O
provides	VBZ	O
an	DT	O
alternative	JJ	O
therapy	NN	O
for	IN	O
prolonged	JJ	O
control	NN	O
of	IN	O
inflammation	NN	O
in	IN	O
noninfectious	JJ	O
posterior	JJ	O
uveitis	NN	O
.	.	O

TRIAL	NNP	O
REGISTRATION	NNP	O
clinicaltrials.gov	NN	O
Identifier	NNP	O
:	:	O
NCT00407082	NN	O
.	.	O

Chemotherapy	NN	O
with	IN	O
cyclophosphamide	NN	O
,	,	O
doxorubicin	NN	O
,	,	O
vincristine	NN	O
,	,	O
and	CC	O
prednisone	VB	O
alone	RB	O
or	CC	O
with	IN	O
levamisole	JJ	O
or	CC	O
with	IN	O
levamisole	JJ	O
plus	CC	O
BCG	NNP	O
for	IN	O
malignant	JJ	O
lymphoma	NN	O
:	:	O
a	DT	O
Southwest	NNP	O
Oncology	NNP	O
Group	NNP	O
Study	NNP	O
.	.	O

Between	NNP	O
1977	CD	O
and	CC	O
1983	CD	O
the	DT	O
Southwest	NNP	O
Oncology	NNP	O
Group	NNP	O
(	(	O
SWOG	NNP	O
)	)	O
evaluated	VBD	O
chemotherapy	NN	O
alone	RB	O
(	(	O
cyclophosphamide	JJ	O
,	,	O
doxorubicin	NN	O
,	,	O
vincristine	NN	O
,	,	O
prednisone	NN	O
;	:	O
CHOP	NNP	O
)	)	O
or	CC	O
chemoimmunotherapy	NN	O
(	(	O
CHOP-levamisole	JJ	O
or	CC	O
CHOP-levamisole-BCG	JJ	O
)	)	O
in	IN	O
a	DT	O
randomized	JJ	O
prospective	JJ	O
clinical	JJ	O
trial	NN	O
involving	VBG	O
715	CD	SS
eligible	JJ	O
patients	NNS	O
with	IN	O
all	DT	O
types	NNS	O
of	IN	O
malignant	JJ	C
lymphoma	NN	C
(	(	O
ML	NNP	O
)	)	O
.	.	O

Of	IN	O
281	CD	SS
evaluable	JJ	O
patients	NNS	O
with	IN	O
favorable	JJ	O
histologic	JJ	O
types	NNS	O
of	IN	O
ML	NNP	C
,	,	O
171	CD	O
(	(	O
61	CD	O
%	NN	O
)	)	O
achieved	VBD	O
complete	JJ	O
remission	NN	O
(	(	O
CR	NNP	O
)	)	O
and	CC	O
there	EX	O
was	VBD	O
no	DT	O
difference	NN	O
in	IN	O
CR	NNP	O
rate	NN	O
,	,	O
CR	NNP	O
duration	NN	O
,	,	O
or	CC	O
survival	NN	O
according	VBG	O
to	TO	O
the	DT	O
type	NN	O
of	IN	O
initial	JJ	O
treatment	NN	O
.	.	O

Of	IN	O
388	CD	SS
evaluable	JJ	O
patients	NNS	O
with	IN	O
unfavorable	JJ	O
histologic	JJ	O
types	NNS	O
of	IN	O
ML	NNP	O
,	,	O
194	CD	O
(	(	O
50	CD	O
%	NN	O
)	)	O
achieved	VBD	O
CR	NNP	O
.	.	O

Levamisole	NNP	O
appeared	VBD	O
to	TO	O
adversely	RB	O
affect	VB	O
CR	NNP	O
rates	NNS	O
in	IN	O
nodular	JJ	O
mixed	JJ	O
and	CC	O
nodular	JJ	O
large-cell	NN	O
lymphoma	NN	O
and	CC	O
CR	NNP	O
duration	NN	O
in	IN	O
patients	NNS	O
with	IN	O
unfavorable	JJ	O
histology	NN	O
ML	NNP	O
.	.	O

Chemoimmunotherapy	NNP	O
with	IN	O
levamisole	JJ	O
or	CC	O
levamisole-BCG	JJ	O
offers	NNS	O
no	DT	O
advantage	NN	O
in	IN	O
terms	NNS	O
of	IN	O
CR	NNP	O
rates	NNS	O
,	,	O
CR	NNP	O
duration	NN	O
,	,	O
or	CC	O
survival	NN	O
compared	VBN	O
to	TO	O
CHOP	NNP	O
chemotherapy	NN	O
alone	RB	O
,	,	O
and	CC	O
levamisole	NN	O
may	MD	O
have	VB	O
had	VBD	O
an	DT	O
adverse	JJ	O
impact	NN	O
on	IN	O
outcome	NN	O
in	IN	O
certain	JJ	O
subtypes	NNS	O
of	IN	O
ML	NNP	O
.	.	O

Randomized	VBN	O
Phase	NNP	O
II	NNP	O
trial	NN	O
assessing	VBG	O
estramustine	NN	O
and	CC	O
vinblastine	JJ	O
combination	NN	O
chemotherapy	NN	O
vs	JJ	O
estramustine	NN	O
alone	RB	O
in	IN	O
patients	NNS	O
with	IN	O
progressive	JJ	C
hormone-escaped	JJ	C
metastatic	JJ	C
prostate	NN	C
cancer	NN	C
.	.	O

Based	VBN	O
on	IN	O
the	DT	O
results	NNS	O
of	IN	O
combined	JJ	O
data	NNS	O
from	IN	O
three	CD	O
North	JJ	O
American	JJ	O
Phase	NNP	O
II	NNP	O
studies	NNS	O
,	,	O
a	DT	O
randomised	JJ	O
Phase	NNP	O
II	NNP	O
study	NN	O
in	IN	O
the	DT	O
same	JJ	O
patient	JJ	O
population	NN	O
was	VBD	O
performed	VBN	O
,	,	O
using	VBG	O
combination	NN	O
chemotherapy	NN	O
with	IN	O
estramustine	JJ	O
phosphate	NN	O
(	(	O
EMP	NNP	O
)	)	O
and	CC	O
vinblastine	NN	O
(	(	O
VBL	NNP	O
)	)	O
in	IN	O
hormone	NN	O
refractory	NN	O
prostate	NN	O
cancer	NN	O
patients	NNS	O
.	.	O

In	IN	O
all	DT	O
,	,	O
92	CD	SS
patients	NNS	O
were	VBD	O
randomised	VBN	O
into	IN	O
a	DT	O
Phase	NNP	O
II	NNP	O
study	NN	O
of	IN	O
oral	JJ	O
EMP	NNP	O
(	(	O
10	CD	O
mg	NNS	O
kg	JJ	O
day	NN	O
continuously	RB	O
)	)	O
or	CC	O
oral	JJ	O
EMP	NNP	O
in	IN	O
combination	NN	O
with	IN	O
intravenous	JJ	O
VBL	NNP	O
(	(	O
4	CD	O
mg	NN	O
m	NN	O
(	(	O
2	CD	O
)	)	O
week	NN	O
for	IN	O
6	CD	O
weeks	NNS	O
,	,	O
followed	VBN	O
by	IN	O
2	CD	O
weeks	NNS	O
rest	NN	O
)	)	O
.	.	O

The	DT	O
end	NN	O
points	NNS	O
were	VBD	O
toxicity	NN	O
and	CC	O
PSA	NNP	O
response	NN	O
in	IN	O
both	DT	O
groups	NNS	O
,	,	O
with	IN	O
the	DT	O
option	NN	O
to	TO	O
continue	VB	O
the	DT	O
trial	NN	O
as	IN	O
a	DT	O
Phase	NNP	O
III	NNP	O
study	NN	O
with	IN	O
time	NN	O
to	TO	O
progression	NN	O
and	CC	O
survival	NN	O
as	IN	O
end	NN	O
points	NNS	O
,	,	O
if	IN	O
sufficient	JJ	O
responses	NNS	O
were	VBD	O
observed	VBN	O
.	.	O

Toxicity	NNP	O
was	VBD	O
unexpectedly	RB	O
high	JJ	O
in	IN	O
both	DT	O
treatment	NN	O
arms	NNS	O
and	CC	O
led	VBD	O
to	TO	O
treatment	NN	O
withdrawal	NN	O
or	CC	O
refusal	NN	O
in	IN	O
49	CD	O
%	NN	O
of	IN	O
all	DT	O
patients	NNS	O
,	,	O
predominantly	RB	O
already	RB	O
during	IN	O
the	DT	O
first	JJ	O
treatment	NN	O
cycle	NN	O
.	.	O

The	DT	O
mean	JJ	O
treatment	NN	O
duration	NN	O
was	VBD	O
10	CD	O
and	CC	O
14	CD	O
weeks	NNS	O
,	,	O
median	JJ	O
time	NN	O
to	TO	O
PSA	NNP	O
progression	NN	O
was	VBD	O
27.2	CD	O
and	CC	O
30.8	CD	O
weeks	NNS	O
,	,	O
median	JJ	O
survival	NN	O
time	NN	O
was	VBD	O
44	CD	O
and	CC	O
50.9	CD	O
weeks	NNS	O
,	,	O
and	CC	O
PSA	NNP	O
response	NN	O
rate	NN	O
was	VBD	O
only	RB	O
24.6	CD	O
and	CC	O
28.9	CD	O
%	NN	O
in	IN	O
the	DT	O
EMP/VBL	NNP	O
and	CC	O
EMP	NNP	O
arms	NNS	O
,	,	O
respectively	RB	O
.	.	O

There	EX	O
was	VBD	O
no	DT	O
correlation	NN	O
between	IN	O
PSA	NNP	O
response	NN	O
and	CC	O
survival	NN	O
.	.	O

While	IN	O
the	DT	O
PSA	NNP	O
response	NN	O
in	IN	O
the	DT	O
patients	NNS	O
tested	VBD	O
was	VBD	O
less	JJR	O
than	IN	O
half	NN	O
that	WDT	O
recorded	VBD	O
in	IN	O
the	DT	O
North	JJ	O
American	JJ	O
studies	NNS	O
,	,	O
the	DT	O
toxicity	NN	O
of	IN	O
EMP	NNP	O
monotherapy	NN	O
or	CC	O
in	IN	O
combination	NN	O
with	IN	O
VBL	NNP	O
was	VBD	O
much	RB	O
higher	JJR	O
than	IN	O
expected	VBN	O
.	.	O

Further	NNP	O
research	NN	O
on	IN	O
more	RBR	O
effective	JJ	O
and	CC	O
less	RBR	O
toxic	JJ	O
treatment	NN	O
strategies	NNS	O
for	IN	O
hormone	NN	O
refractory	NN	O
prostate	NN	O
cancer	NN	O
is	VBZ	O
mandatory	JJ	O
.	.	O

Does	NNP	O
temporary	JJ	O
clamping	NN	O
of	IN	O
drains	NNS	O
following	VBG	O
knee	NN	O
arthroplasty	JJ	O
reduce	VB	O
blood	NN	O
loss	NN	O
?	.	O
A	DT	O
randomised	JJ	O
controlled	VBN	O
trial	NN	O
.	.	O

In	IN	O
a	DT	O
randomised	JJ	O
,	,	O
blinded	VBD	O
study	NN	O
76	CD	SS
patients	NNS	O
undergoing	JJ	O
primary	JJ	C
total	JJ	C
knee	NN	C
arthroplasty	NN	C
were	VBD	O
assigned	VBN	O
to	TO	O
either	DT	O
immediate	JJ	O
drain	NN	O
opening	NN	O
(	(	O
n	JJ	O
=	NNP	O
45	CD	O
)	)	O
or	CC	O
drains	NNS	O
opened	VBN	O
at	IN	O
2	CD	O
h	NN	O
(	(	O
n	JJ	O
=	NNP	O
31	CD	O
)	)	O
.	.	O

No	DT	O
significant	JJ	O
differences	NNS	O
were	VBD	O
found	VBN	O
between	IN	O
the	DT	O
groups	NNS	O
for	IN	O
the	DT	O
volume	NN	O
of	IN	O
drained	JJ	O
blood	NN	O
,	,	O
transfusion	NN	O
requirements	NNS	O
,	,	O
knee	JJ	O
motion	NN	O
or	CC	O
wound	NN	O
status	NN	O
.	.	O

The	DT	O
authors	NNS	O
conclude	VBP	O
that	IN	O
the	DT	O
practice	NN	O
of	IN	O
clamping	VBG	O
drains	NNS	O
has	VBZ	O
no	DT	O
benefit	NN	O
in	IN	O
routine	JJ	O
knee	NN	O
arthroplasty	NN	O
.	.	O

However	RB	O
,	,	O
when	WRB	O
faced	VBN	O
with	IN	O
immediate	JJ	O
brisk	JJ	O
blood	NN	O
loss	NN	O
,	,	O
the	DT	O
results	NNS	O
suggest	VBP	O
that	IN	O
drains	NNS	O
can	MD	O
be	VB	O
clamped	VBN	O
without	IN	O
any	DT	O
excess	JJ	O
morbidity	NN	O
.	.	O

Efficiency	NN	O
of	IN	O
adjuvant	JJ	O
immunochemotherapy	NN	O
following	VBG	O
curative	JJ	O
resection	NN	O
in	IN	O
patients	NNS	O
with	IN	O
locally	RB	O
advanced	JJ	O
gastric	JJ	C
cancer	NN	C
.	.	C

BACKGROUND	NNP	O
Despite	IN	O
curative	JJ	O
resection	NN	O
,	,	O
50	CD	O
%	NN	O
-90	CD	O
%	NN	O
of	IN	O
gastric	JJ	C
cancer	NN	C
patients	NNS	O
die	VBP	O
of	IN	O
disease	NN	O
relapse	NN	O
.	.	O

Although	IN	O
some	DT	O
clinical	JJ	O
trials	NNS	O
have	VBP	O
indicated	VBN	O
that	IN	O
chemotherapy	NN	O
and	CC	O
immunochemotherapy	NN	O
may	MD	O
be	VB	O
effective	JJ	O
modalities	NNS	O
,	,	O
more	RBR	O
recent	JJ	O
studies	NNS	O
have	VBP	O
not	RB	O
been	VBN	O
able	JJ	O
to	TO	O
define	VB	O
the	DT	O
standard	JJ	O
treatment	NN	O
for	IN	O
advanced	JJ	O
gastric	JJ	C
cancer	NN	C
.	.	C

The	DT	O
present	JJ	O
study	NN	O
evaluated	VBD	O
the	DT	O
effect	NN	O
of	IN	O
adjuvant	JJ	O
immunochemotherapy	NN	O
with	IN	O
the	DT	O
use	NN	O
of	IN	O
BCG	NNP	O
(	(	O
bacille	IN	O
Calmette-Guerin	NNP	O
)	)	O
and	CC	O
FAM	NNP	O
(	(	O
5-fluorouracil	JJ	O
,	,	O
adriamycin	JJ	O
,	,	O
mitomycin	JJ	O
C	NNP	O
)	)	O
chemotherapy	NN	O
on	IN	O
the	DT	O
survival	NN	O
of	IN	O
patients	NNS	O
with	IN	O
locally	RB	O
advanced	VBN	O
resectable	JJ	C
gastric	JJ	C
cancer	NN	C
.	.	C

METHODS	NNP	O
A	NNP	O
total	NN	O
of	IN	O
156	CD	SS
patients	NNS	O
with	IN	O
stage	NN	C
III	NNP	C
or	CC	C
IV	NNP	C
gastric	JJ	C
cancer	NN	C
who	WP	O
had	VBD	O
undergone	JJ	O
curative	JJ	C
resection	NN	C
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
three	CD	O
treatment	NN	O
groups	NNS	O
:	:	O
BCG	NNP	O
+	NNP	O
FAM	NNP	O
(	(	O
immunochemotherapy	NN	O
)	)	O
,	,	O
FAM	NNP	O
(	(	O
chemotherapy	NN	O
)	)	O
,	,	O
and	CC	O
control	NN	O
(	(	O
surgery	NN	O
only	RB	O
)	)	O
.	.	O

Treatment	NN	O
was	VBD	O
continued	VBN	O
for	IN	O
2	CD	O
years	NNS	O
or	CC	O
until	IN	O
death	NN	O
.	.	O

Further	NNP	O
postsurgical	JJ	O
follow	VBP	O
up	RP	O
was	VBD	O
carried	VBN	O
on	IN	O
for	IN	O
up	IN	O
to	TO	O
10	CD	O
years	NNS	O
.	.	O

RESULTS	VB	O
Overall	JJ	O
10-year	JJ	O
survival	NN	O
was	VBD	O
47.1	CD	O
%	NN	O
for	IN	O
the	DT	O
immunochemotherapy	NN	O
group	NN	O
(	(	O
P	NNP	O
<	VBZ	O
0.037	CD	O
vs	NN	O
FAM	NNP	O
and	CC	O
P	NNP	O
<	NNP	O
0.0006	CD	O
vs	NNS	O
control	NN	O
)	)	O
,	,	O
30	CD	O
%	NN	O
for	IN	O
the	DT	O
chemotherapy	NN	O
group	NN	O
(	(	O
vs	FW	O
control	NN	O
,	,	O
NS	NNP	O
)	)	O
,	,	O
and	CC	O
15.2	CD	O
%	NN	O
for	IN	O
the	DT	O
control	NN	O
group	NN	O
.	.	O

In	IN	O
patients	NNS	O
with	IN	O
pT2/T3	JJ	C
primary	JJ	C
tumors	NNS	C
,	,	O
10-year	JJ	O
survival	NN	O
was	VBD	O
55.3	CD	O
%	NN	O
for	IN	O
BCG	NNP	O
+	NNP	O
FAM	NNP	O
vs	VBD	O
28.2	CD	O
%	NN	O
for	IN	O
FAM	NNP	O
(	(	O
P	NNP	O
<	NNP	O
0.01	CD	O
)	)	O
and	CC	O
14.6	CD	O
%	NN	O
for	IN	O
the	DT	O
control	NN	O
group	NN	O
(	(	O
P	NNP	O
<	NNP	O
0.00018	CD	O
)	)	O
.	.	O

BCG	NNP	O
+	NNP	O
FAM	NNP	O
significantly	RB	O
improved	VBD	O
the	DT	O
survival	NN	O
of	IN	O
patients	NNS	O
with	IN	O
intestinal-type	JJ	C
but	CC	C
not	RB	C
diffuse-type	JJ	C
cancer	NN	C
.	.	C

Immunochemotherapy	NNP	O
was	VBD	O
well	RB	O
tolerated	VBN	O
.	.	O

CONCLUSION	VB	O
This	DT	O
study	NN	O
,	,	O
based	VBN	O
on	IN	O
a	DT	O
limited	JJ	O
number	NN	O
of	IN	O
patients	NNS	O
,	,	O
indicates	VBZ	O
that	IN	O
adjuvant	JJ	O
immunochemotherapy	NN	O
(	(	O
BCG	NNP	O
+	NNP	O
FAM	NNP	O
)	)	O
may	MD	O
prolong	VB	O
the	DT	O
survival	NN	O
of	IN	O
gastric	JJ	C
cancer	NN	C
patients	NNS	O
after	IN	O
curative	JJ	C
gastrectomy	NN	C
;	:	O
in	IN	O
particular	JJ	O
,	,	O
in	IN	O
patients	NNS	O
with	IN	O
pT2/T3	JJ	C
tumors	NNS	C
and	CC	C
intestinal-type	JJ	C
primary	JJ	C
tumors	NNS	C
.	.	C

There	EX	O
was	VBD	O
no	DT	O
survival	JJ	O
benefit	NN	O
from	IN	O
FAM	NNP	O
adjuvant	JJ	O
chemotherapy	NN	O
.	.	O

[	JJ	O
Effect	NNP	O
of	IN	O
liu	NN	O
wei	NN	O
di	NN	O
huang	NN	O
or	CC	O
jin	NN	O
gui	NN	O
shen	NN	O
qi	JJ	O
decoction	NN	O
as	IN	O
on	IN	O
adjuvant	JJ	O
treatment	NN	O
in	IN	O
small	JJ	C
cell	NN	C
lung	NN	C
cancer	NN	C
]	NNP	O
.	.	O

Eighty-three	JJ	O
patients	NNS	O
with	IN	O
small	JJ	O
cell	NN	O
lung	NN	O
cancer	NN	O
were	VBD	O
randomized	VBN	O
with	IN	O
or	CC	O
without	IN	O
using	VBG	O
a	DT	O
traditional	JJ	O
Chinese	JJ	O
Kidney-tonifying	NNP	O
decoction	NN	O
(	(	O
Liu	NNP	O
Wei	NNP	O
Di	NNP	O
Huang	NNP	O
or	CC	O
Jin	NNP	O
Gui	NNP	O
Shen	NNP	O
Qi	NNP	O
medicinal	JJ	O
decoction	NN	O
)	)	O
in	IN	O
chemotherapy	NN	O
or	CC	O
radiotherapy	NN	O
courses	NNS	O
.	.	O

74	CD	O
patients	NNS	O
were	VBD	O
availble	JJ	O
to	TO	O
be	VB	O
analysis	NN	O
.	.	O

The	DT	O
two	CD	O
treatment	NN	O
groups	NNS	O
were	VBD	O
well-matched	JJ	O
in	IN	O
age	NN	O
,	,	O
sex	NN	O
,	,	O
stage	NN	O
and	CC	O
performance	NN	O
status	NN	O
.	.	O

There	EX	O
was	VBD	O
a	DT	O
statistically	RB	O
significant	JJ	O
difference	NN	O
in	IN	O
response	NN	O
rate	NN	O
and	CC	O
the	DT	O
median	JJ	O
survival	NN	O
between	IN	O
two	CD	O
groups	NNS	O
.	.	O

The	DT	O
overall	JJ	O
response	NN	O
rate	NN	O
(	(	O
CR+PR	NNP	O
)	)	O
was	VBD	O
91.5	CD	O
%	NN	O
for	IN	O
Chinese	JJ	O
herb	NN	O
group	NN	O
and	CC	O
46.9	CD	O
%	NN	O
for	IN	O
control	NN	O
group	NN	O
(	(	O
P	NNP	O
less	JJR	O
than	IN	O
0.001	CD	O
)	)	O
.	.	O

The	DT	O
median	JJ	O
survival	NN	O
was	VBD	O
16	CD	O
months	NNS	O
for	IN	O
the	DT	O
traditional	JJ	O
Chinese	JJ	O
Kidney-tonifying	NNP	O
decoction	NN	O
group	NN	O
,	,	O
and	CC	O
10	CD	O
months	NNS	O
for	IN	O
the	DT	O
control	NN	O
group	NN	O
(	(	O
P	NNP	O
less	JJR	O
than	IN	O
0.05	CD	O
)	)	O
.	.	O

Survival	JJ	O
curve	NN	O
(	(	O
Kaplan-meire	NNP	O
's	POS	O
)	)	O
of	IN	O
the	DT	O
Chinese	NNP	O
herb	NN	O
group	NN	O
was	VBD	O
better	JJR	O
than	IN	O
that	DT	O
of	IN	O
the	DT	O
control	NN	O
group	NN	O
.	.	O

10	CD	O
patients	NNS	O
of	IN	O
Chinese	JJ	O
herb	NN	O
group	NN	O
was	VBD	O
alive	JJ	O
beyond	IN	O
more	JJR	O
than	IN	O
2	CD	O
years	NNS	O
.	.	O

Until	IN	O
now	RB	O
,	,	O
4	CD	O
patients	NNS	O
in	IN	O
the	DT	O
Chinese	JJ	O
herb	NN	O
group	NN	O
,	,	O
one	CD	O
in	IN	O
the	DT	O
control	NN	O
group	NN	O
are	VBP	O
still	RB	O
enjoying	VBG	O
their	PRP$	O
disease-free	JJ	O
life	NN	O
for	IN	O
more	JJR	O
than	IN	O
7	CD	O
years	NNS	O
.	.	O

Hematologic	NNP	O
toxicities	NNS	O
were	VBD	O
observed	VBN	O
much	RB	O
frequently	RB	O
in	IN	O
the	DT	O
patients	NNS	O
of	IN	O
the	DT	O
control	NN	O
group	NN	O
(	(	O
P	NNP	O
less	JJR	O
than	IN	O
0.005	CD	O
and	CC	O
0.01/WBC	CD	O
and	CC	O
BPC	NNP	O
)	)	O
.	.	O

Results	NNS	O
of	IN	O
animal	JJ	O
experiments	NNS	O
with	IN	O
the	DT	O
same	JJ	O
traditional	JJ	O
medicinal	JJ	O
decoctions	NNS	O
as	IN	O
used	VBN	O
in	IN	O
clinic	NN	O
have	VBP	O
showed	VBN	O
immuno-enhancement	JJ	O
activities	NNS	O
.	.	O

These	DT	O
results	NNS	O
have	VBP	O
showed	VBN	O
that	IN	O
the	DT	O
traditional	JJ	O
Chinese	JJ	O
Kidney-tonifying	NNP	O
decoction	NN	O
may	MD	O
enhance	VB	O
non-specific	JJ	O
immunology	NN	O
activities	NNS	O
and	CC	O
may	MD	O
be	VB	O
much	JJ	O
useful	JJ	O
for	IN	O
solid	JJ	O
cancer	NN	O
patients	NNS	O
as	IN	O
an	DT	O
adjuvant	JJ	O
treatment	NN	O
.	.	O

Beneficial	JJ	O
effect	NN	O
of	IN	O
etidronate	NN	O
therapy	NN	O
in	IN	O
chronically	RB	C
hospitalized	VBN	C
,	,	O
disabled	JJ	C
patients	NNS	O
with	IN	O
stroke	NN	C
.	.	O

Incidence	NN	O
of	IN	O
hip	NN	O
fractures	NNS	O
is	VBZ	O
high	JJ	O
in	IN	O
chronically	RB	O
hospitalized	VBN	O
,	,	O
disabled	VBD	O
,	,	O
elderly	JJ	A
patients	NNS	O
after	IN	O
stroke	NN	O
.	.	O

Duration	NN	O
of	IN	O
hospitalization	NN	O
was	VBD	O
more	JJR	O
than	IN	O
1	CD	O
year	NN	O
because	IN	O
of	IN	O
insufficiency	NN	O
of	IN	O
nursing	NN	O
homes	NNS	O
.	.	O

Our	PRP$	O
study	NN	O
showed	VBD	O
that	IN	O
immobilization-induced	JJ	O
hypercalcemia	NN	O
and	CC	O
25-hydroxyvitamin	JJ	O
D	NNP	O
deficiency	NN	O
contribute	NN	O
to	TO	O
reduced	VB	O
bone	JJ	O
mineral	JJ	O
density	NN	O
(	(	O
BMD	NNP	O
)	)	O
.	.	O

This	DT	O
study	NN	O
was	VBD	O
designed	VBN	O
to	TO	O
address	VB	O
the	DT	O
possibility	NN	O
that	WDT	O
treatment	NN	O
with	IN	O
etidronate	NN	O
may	MD	O
reduce	VB	O
the	DT	O
bone	NN	O
resorption	NN	O
and	CC	O
lower	JJR	O
the	DT	O
incidence	NN	O
of	IN	O
fractures	NNS	O
in	IN	O
elderly	JJ	O
patients	NNS	O
who	WP	O
are	VBP	O
chronically	RB	O
hospitalized	VBN	O
and	CC	O
disabled	VBN	O
as	IN	O
a	DT	O
result	NN	O
of	IN	O
hemiparesis	NN	C
after	IN	O
stroke	NN	O
.	.	O

Patients	NNS	O
with	IN	O
stroke	NN	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
daily	VB	O
treatment	NN	O
with	IN	O
400	CD	O
mg	NNS	O
of	IN	O
etidronate	NN	O
(	(	O
n	JJ	O
=	NNP	O
40	CD	O
)	)	O
or	CC	O
a	DT	O
placebo	NN	O
(	(	O
n	JJ	O
=	NNP	O
40	CD	O
)	)	O
,	,	O
and	CC	O
followed	VBD	O
up	RB	O
for	IN	O
2	CD	O
years	NNS	O
.	.	O

At	IN	O
baseline	NN	O
,	,	O
both	DT	O
groups	NNS	O
had	VBD	O
low	JJ	O
BMD	NNP	O
with	IN	O
high	JJ	O
levels	NNS	O
of	IN	O
serum	NN	O
ionized	VBN	O
calcium	NN	O
and	CC	O
urinary	JJ	O
deoxypyridinoline	NN	O
.	.	O

In	IN	O
the	DT	O
etidronate	NN	O
group	NN	O
,	,	O
serum	NN	O
calcium	NN	O
and	CC	O
urinary	JJ	O
deoxypyridinoline	NN	O
levels	NNS	O
decreased	VBN	O
significantly	RB	O
during	IN	O
the	DT	O
study	NN	O
period	NN	O
,	,	O
whereas	IN	O
the	DT	O
levels	NNS	O
in	IN	O
the	DT	O
placebo	NN	O
group	NN	O
were	VBD	O
increased	VBN	O
.	.	O

BMD	NNP	O
on	IN	O
the	DT	O
hemiplegic	JJ	O
side	NN	O
increased	VBN	O
by	IN	O
1.4	CD	O
%	NN	O
in	IN	O
the	DT	O
etidronate	NN	O
group	NN	O
and	CC	O
decreased	VBN	O
by	IN	O
2.2	CD	O
%	NN	O
in	IN	O
the	DT	O
placebo	NN	O
group	NN	O
(	(	O
P	NNP	O
<	NNP	O
.001	NNP	O
)	)	O
.	.	O

Two	CD	O
patients	NNS	O
sustained	VBD	O
hip	JJ	O
fractures	NNS	O
in	IN	O
the	DT	O
placebo	NN	O
group	NN	O
,	,	O
and	CC	O
no	DT	O
hip	NN	O
fracture	NN	O
occurred	VBD	O
in	IN	O
the	DT	O
etidronate	NN	O
group	NN	O
.	.	O

Treatment	NN	O
with	IN	O
etidronate	NN	O
increases	NNS	O
BMD	NNP	O
in	IN	O
chronically	RB	O
hospitalized	VBN	O
patients	NNS	O
poststroke	VBD	O
,	,	O
and	CC	O
may	MD	O
prevent	VB	O
hip	NN	O
fracture	NN	O
.	.	O

An	DT	O
evaluation	NN	O
of	IN	O
an	DT	O
adaptive	JJ	O
automation	NN	O
system	NN	O
using	VBG	O
a	DT	O
cognitive	JJ	O
vigilance	NN	O
task	NN	O
.	.	O

The	DT	O
performance	NN	O
of	IN	O
an	DT	O
adaptive	JJ	O
automation	NN	O
system	NN	O
was	VBD	O
evaluated	VBN	O
using	VBG	O
a	DT	O
cognitive	JJ	O
vigilance	NN	O
task	NN	O
.	.	O

Participants	NNS	O
responded	VBD	O
to	TO	O
the	DT	O
presence	NN	O
of	IN	O
a	DT	O
green	JJ	O
K	NNP	O
in	IN	O
an	DT	O
array	NN	O
of	IN	O
two	CD	O
,	,	O
five	CD	O
,	,	O
or	CC	O
nine	CD	O
distractor	NN	O
stimuli	NNS	O
during	IN	O
a	DT	O
40-min	JJ	O
vigil	NN	O
.	.	O

The	DT	O
array	NN	O
with	IN	O
the	DT	O
target	NN	O
stimulus	NN	O
was	VBD	O
presented	VBN	O
once	RB	O
each	DT	O
minute	NN	O
.	.	O

Participants	NNS	O
EEG	NNP	O
was	VBD	O
recorded	VBN	O
and	CC	O
an	DT	O
engagement	JJ	O
index	NN	O
(	(	O
EI	NNP	O
=	VBZ	O
20	CD	O
x	NN	O
beta/	NN	O
(	(	O
alpha	JJ	O
+	NNP	O
theta	NN	O
)	)	O
)	)	O
was	VBD	O
derived	VBN	O
.	.	O

In	IN	O
the	DT	O
negative	JJ	O
feedback	NN	O
condition	NN	O
,	,	O
increases	VBZ	O
in	IN	O
the	DT	O
EI	NNP	O
caused	VBD	O
the	DT	O
number	NN	O
of	IN	O
stimuli	NNS	O
in	IN	O
the	DT	O
array	NN	O
to	TO	O
decrease	VB	O
while	IN	O
decreases	NNS	O
in	IN	O
the	DT	O
EI	NNP	O
caused	VBD	O
the	DT	O
number	NN	O
of	IN	O
stimuli	NNS	O
to	TO	O
increase	VB	O
.	.	O

For	IN	O
the	DT	O
positive	JJ	O
feedback	NN	O
condition	NN	O
,	,	O
increases	VBZ	O
in	IN	O
the	DT	O
index	NN	O
caused	VBD	O
an	DT	O
increase	NN	O
in	IN	O
the	DT	O
array	NN	O
size	NN	O
(	(	O
AS	IN	O
)	)	O
while	IN	O
decreases	NNS	O
caused	VBD	O
a	DT	O
decrease	NN	O
in	IN	O
the	DT	O
array	NN	O
size	NN	O
.	.	O

Each	DT	O
experimental	JJ	O
participant	NN	O
had	VBD	O
a	DT	O
yoked	VBN	O
control	NN	O
partner	NN	O
who	WP	O
received	VBD	O
the	DT	O
same	JJ	O
pattern	NN	O
of	IN	O
changes	NNS	O
in	IN	O
array	JJ	O
irrespective	NN	O
of	IN	O
their	PRP$	O
engagement	JJ	O
index	NN	O
.	.	O

A	DT	O
vigilance	NN	O
decrement	NN	O
was	VBD	O
seen	VBN	O
only	RB	O
for	IN	O
the	DT	O
positive	JJ	O
feedback	NN	O
,	,	O
experimental	JJ	O
group	NN	O
.	.	O

Processing	VBG	O
familiar	JJ	O
and	CC	O
unfamiliar	JJ	O
auditory	NN	O
stimuli	NN	O
during	IN	O
general	JJ	C
anesthesia	NN	C
.	.	O

We	PRP	O
tested	VBD	O
memory	NN	O
priming	NN	O
for	IN	O
auditory	JJ	O
stimuli	NNS	O
presented	VBN	O
during	IN	O
general	JJ	C
propofol-sufentanil	JJ	C
anesthesia	NN	C
in	IN	O
58	CD	SS
patients	NNS	O
undergoing	JJ	O
day-case	JJ	C
arthroscopic	NN	C
surgery	NN	C
.	.	O

Stimuli	NNP	O
were	VBD	O
presented	VBN	O
via	IN	O
headphones	NNS	O
and	CC	O
consisted	VBN	O
of	IN	O
common	JJ	O
facts	NNS	O
(	(	O
Group	NNP	SS
A	NNP	SS
,	,	SS
29	CD	SS
patients	NNS	O
)	)	O
,	,	O
or	CC	O
familiar	JJ	O
or	CC	O
unfamiliar	JJ	O
full	JJ	O
names	NNS	O
of	IN	O
fictitious	JJ	O
people	NNS	O
(	(	O
GRoup	NNP	SS
B	NNP	SS
,	,	SS
29	CD	SS
patients	NNS	O
)	)	O
.	.	O

Group	NNP	O
A	NNP	O
was	VBD	O
expected	VBN	O
to	TO	O
give	VB	O
more	JJR	O
correct	JJ	O
answers	NNS	O
to	TO	O
questions	NNS	O
about	IN	O
the	DT	O
common	JJ	O
facts	NNS	O
than	IN	O
Group	NNP	O
B	NNP	O
,	,	O
when	WRB	O
tested	VBN	O
postoperatively	RB	O
,	,	O
and	CC	O
Group	NNP	O
B	NNP	O
to	TO	O
attribute	VB	O
more	JJR	O
fame	NN	O
to	TO	O
presented	VBN	O
names	NNS	O
than	IN	O
Group	NNP	O
A	NNP	O
(	(	O
famous	JJ	O
names	RB	O
test	NN	O
)	)	O
.	.	O

Because	IN	O
the	DT	O
process	NN	O
for	IN	O
learning	VBG	O
new	JJ	O
or	CC	O
unfamiliar	JJ	O
stimuli	NNS	O
(	(	O
elaboration	NN	O
)	)	O
in	IN	O
particular	JJ	O
may	MD	O
be	VB	O
impaired	VBN	O
under	IN	O
general	JJ	C
anesthesia	NN	C
,	,	O
more	JJR	O
memory	NN	O
priming	NN	O
was	VBD	O
expected	VBN	O
for	IN	O
familiar	JJ	O
than	IN	O
for	IN	O
unfamiliar	JJ	O
material	NN	O
.	.	O

No	DT	O
significant	JJ	O
differences	NNS	O
were	VBD	O
demonstrated	VBN	O
between	IN	O
the	DT	O
two	CD	O
groups	NNS	O
in	IN	O
performance	NN	O
on	IN	O
common	JJ	O
facts	NNS	O
or	CC	O
in	IN	O
fame	NN	O
attributed	VBN	O
to	TO	O
the	DT	O
names	NNS	O
.	.	O

The	DT	O
amount	NN	O
of	IN	O
memory	NN	O
priming	NN	O
,	,	O
however	RB	O
,	,	O
was	VBD	O
positively	RB	O
related	VBN	O
to	TO	O
one	CD	O
of	IN	O
two	CD	O
measures	NNS	O
of	IN	O
preoperative	JJ	O
anxiety	NN	O
.	.	O

Double-blind	JJ	O
placebo-controlled	JJ	O
trial	NN	O
of	IN	O
secretin	NN	O
:	:	O
effects	NNS	O
on	IN	O
aberrant	JJ	O
behavior	NN	O
in	IN	O
children	NNS	O
with	IN	O
autism	NN	O
.	.	O

Secretin	NNP	O
has	VBZ	O
been	VBN	O
proposed	VBN	O
as	IN	O
a	DT	O
treatment	NN	O
alternative	NN	O
for	IN	O
autistic	JJ	O
spectrum	NN	O
disorders	NNS	O
,	,	O
but	CC	O
empirical	JJ	O
support	NN	O
is	VBZ	O
lacking	VBG	O
.	.	O

A	DT	O
double-blind	JJ	O
placebo-controlled	JJ	O
study	NN	O
examined	VBD	O
the	DT	O
effect	NN	O
of	IN	O
a	DT	O
single	JJ	O
dose	NN	O
of	IN	O
synthetic	JJ	O
human	JJ	O
secretin	NN	O
on	IN	O
aberrant	JJ	O
behavior	NN	O
.	.	O

Parent	NN	O
and	CC	O
teacher	NN	O
data	NNS	O
from	IN	O
the	DT	O
Aberrant	NNP	O
Behavior	NNP	O
Checklist	NNP	O
for	IN	O
eight	CD	O
male	JJ	O
children	NNS	O
were	VBD	O
analyzed	VBN	O
for	IN	O
reliable	JJ	O
change	NN	O
in	IN	O
a	DT	O
clinical	JJ	O
replication	NN	O
series	NN	O
.	.	O

By	IN	O
parent	NN	O
and	CC	O
teacher	NN	O
report	NN	O
,	,	O
the	DT	O
majority	NN	O
of	IN	O
change	NN	O
occurred	VBD	O
either	CC	O
on	IN	O
the	DT	O
placebo	NN	O
trial	NN	O
or	CC	O
reflected	VBN	O
deterioration	NN	O
subsequent	NN	O
to	TO	O
secretin	VB	O
infusion	NN	O
.	.	O

Repeated-measures	JJ	O
multivariate	JJ	O
analysis	NN	O
of	IN	O
variance	NN	O
results	NNS	O
were	VBD	O
similar	JJ	O
.	.	O

Results	NNS	O
are	VBP	O
consistent	JJ	O
with	IN	O
other	JJ	O
studies	NNS	O
,	,	O
suggesting	VBG	O
that	IN	O
secretin	NN	O
may	MD	O
not	RB	O
be	VB	O
an	DT	O
effective	JJ	O
treatment	NN	O
option	NN	O
.	.	O

Efficacy	NN	O
of	IN	O
porcine	NN	O
secretin	NN	O
in	IN	O
children	NNS	O
with	IN	O
autism	NN	O
and	CC	O
pervasive	JJ	O
developmental	JJ	O
disorder	NN	O
.	.	O

Secretin	NNP	O
,	,	O
a	DT	O
gastrointestinal	JJ	O
(	(	O
GI	NNP	O
)	)	O
hormone	NN	O
,	,	O
was	VBD	O
reported	VBN	O
in	IN	O
a	DT	O
preliminary	JJ	O
study	NN	O
to	TO	O
improve	VB	O
language	NN	O
and	CC	O
behavior	NN	O
in	IN	O
children	NNS	O
with	IN	O
autism/pervasive	JJ	O
developmental	JJ	O
disorder	NN	O
(	(	O
PDD	NNP	O
)	)	O
and	CC	O
chronic	JJ	O
diarrhea	NN	O
.	.	O

To	TO	O
determine	VB	O
the	DT	O
efficacy	NN	O
of	IN	O
secretin	NN	O
,	,	O
we	PRP	O
completed	VBD	O
a	DT	O
double-blind	JJ	O
,	,	O
placebo-controlled	JJ	O
,	,	O
crossover	NN	O
(	(	O
3	CD	O
weeks	NNS	O
)	)	O
study	NN	O
in	IN	O
children	NNS	O
with	IN	O
autism/PDD	NN	O
and	CC	O
various	JJ	O
GI	NNP	O
conditions	NNS	O
using	VBG	O
a	DT	O
single	JJ	O
dose	NN	O
of	IN	O
intravenous	JJ	O
porcine	NN	O
secretin	NN	O
.	.	O

Children	NNP	O
with	IN	O
chronic	NN	O
,	,	O
active	JJ	O
diarrhea	NN	O
showed	VBD	O
a	DT	O
reduction	NN	O
in	IN	O
aberrant	JJ	O
behaviors	NNS	O
when	WRB	O
treated	VBN	O
with	IN	O
the	DT	O
secretin	NN	O
but	CC	O
not	RB	O
when	WRB	O
treated	VBN	O
with	IN	O
the	DT	O
placebo	NN	O
.	.	O

Children	NNP	O
with	IN	O
no	DT	O
GI	NNP	O
problems	NNS	O
are	VBP	O
unaffected	VBN	O
by	IN	O
either	DT	O
secretin	NN	O
or	CC	O
placebo	NN	O
.	.	O

The	DT	O
improvement	NN	O
seen	VBN	O
with	IN	O
secretin	NN	O
in	IN	O
children	NNS	O
with	IN	O
autism/PDD	NN	O
and	CC	O
chronic	JJ	O
diarrhea	NN	O
suggests	VBZ	O
that	IN	O
there	EX	O
may	MD	O
be	VB	O
a	DT	O
subtype	NN	O
of	IN	O
children	NNS	O
with	IN	O
autism/PDD	NN	O
who	WP	O
respond	VBZ	O
to	TO	O
secretin	VB	O
.	.	O

Amphotericin	NNP	O
versus	NN	O
pentamidine	NN	O
in	IN	O
antimony-unresponsive	JJ	C
kala-azar	NN	C
.	.	O

We	PRP	O
compared	VBN	O
the	DT	O
efficacy	NN	O
of	IN	O
amphotericin	NN	O
B	NNP	O
and	CC	O
pentamidine	JJ	O
isethionate	NN	O
in	IN	O
a	DT	O
prospective	JJ	O
randomised	VBN	O
trial	NN	O
in	IN	O
120	CD	SS
uncomplicated	JJ	O
and	CC	O
parasitologically	RB	O
confirmed	VBN	O
cases	NNS	O
of	IN	O
antimony-unresponsive	JJ	C
kala-azar	NN	C
.	.	O

Doses	NNS	O
were	VBD	O
twenty	JJ	O
intramuscular	JJ	O
injections	NNS	O
of	IN	O
pentamidine	NN	O
4	CD	O
mg/kg	NN	O
on	IN	O
alternate	JJ	O
days	NNS	O
or	CC	O
fourteen	JJ	O
definitive	JJ	O
doses	NNS	O
of	IN	O
amphotericin	JJ	O
0.5	CD	O
mg/kg	NN	O
infused	VBN	O
in	IN	O
5	CD	O
%	NN	O
dextrose	NN	O
on	IN	O
alternate	JJ	O
days	NNS	O
.	.	O

48	CD	O
(	(	O
80	CD	O
%	NN	O
)	)	O
patients	NNS	O
given	VBN	O
pentamidine	VBP	O
showed	VBN	O
initial	JJ	O
cure	NN	O
and	CC	O
46	CD	O
(	(	O
77	CD	O
%	NN	O
)	)	O
showed	VBD	O
definitive	JJ	O
cure	NN	O
compared	VBN	O
with	IN	O
60	CD	O
(	(	O
100	CD	O
%	NN	O
)	)	O
and	CC	O
59	CD	O
(	(	O
98	CD	O
%	NN	O
)	)	O
cases	NNS	O
,	,	O
respectively	RB	O
,	,	O
on	IN	O
amphotericin	NN	O
(	(	O
p	JJ	O
<	NNP	O
0.001	CD	O
)	)	O
.	.	O

Amphotericin	NNP	O
also	RB	O
brought	VBD	O
about	RB	O
quicker	JJR	O
abatement	NN	O
of	IN	O
fever	NN	O
and	CC	O
more	JJR	O
complete	JJ	O
spleen	JJ	O
regression	NN	O
.	.	O

Effects	NNS	O
of	IN	O
a	DT	O
combination	NN	O
of	IN	O
evening	VBG	O
primrose	JJ	O
oil	NN	O
(	(	O
gamma	NN	O
linolenic	RB	O
acid	NN	O
)	)	O
and	CC	O
fish	JJ	O
oil	NN	O
(	(	O
eicosapentaenoic	JJ	O
+	NNP	O
docahexaenoic	NN	O
acid	NN	O
)	)	O
versus	NN	O
magnesium	NN	O
,	,	O
and	CC	O
versus	NN	O
placebo	NN	O
in	IN	O
preventing	VBG	O
pre-eclampsia	NN	C
.	.	C

In	IN	O
a	DT	O
placebo	NN	O
controlled	VBN	O
,	,	O
partially	RB	O
double-blinded	JJ	O
,	,	O
clinical	JJ	O
trial	NN	O
,	,	O
a	DT	O
combination	NN	O
of	IN	O
evening	VBG	O
primrose	JJ	O
oil	NN	O
and	CC	O
fish	JJ	O
oil	NN	O
was	VBD	O
compared	VBN	O
to	TO	O
Magnesium	NNP	O
Oxide	NNP	O
,	,	O
and	CC	O
to	TO	O
a	DT	O
Placebo	NNP	O
in	IN	O
preventing	VBG	O
Pre-Eclampsia	NNP	O
of	IN	O
Pregnancy	NNP	O
.	.	O

All	DT	O
were	VBD	O
given	VBN	O
as	IN	O
nutritional	JJ	O
supplements	NNS	O
for	IN	O
six	CD	O
months	NNS	O
to	TO	O
a	DT	O
group	NN	O
of	IN	O
primiparous	JJ	O
and	CC	O
multiparous	JJ	O
pregnant	JJ	O
women	NNS	O
.	.	O

Some	DT	C
of	IN	C
these	DT	C
women	NNS	C
had	VBD	C
personal	JJ	C
or	CC	C
family	NN	C
histories	NNS	C
of	IN	C
hypertension	NN	C
(	(	C
21	CD	C
%	NN	C
)	)	C
.	.	C

Only	RB	O
those	DT	O
patients	NNS	O
who	WP	O
received	VBD	O
prenatal	JJ	O
care	NN	O
at	IN	O
the	DT	O
Central	NNP	O
Maternity	NNP	O
Hospital	NNP	O
for	IN	O
Luanda	NNP	O
were	VBD	O
included	VBN	O
in	IN	O
the	DT	O
study	NN	O
.	.	O

Compared	VBN	O
to	TO	O
the	DT	O
Placebo	NNP	O
group	NN	O
(	(	O
29	CD	O
%	NN	O
)	)	O
,	,	O
the	DT	O
group	NN	O
receiving	VBG	O
the	DT	O
mixture	NN	O
of	IN	O
evening	VBG	O
primrose	JJ	O
oil	NN	O
and	CC	O
fish	JJ	O
oil	NN	O
containing	VBG	O
Gamma-linolenic	JJ	O
acid	NN	O
(	(	O
GLA	NNP	O
)	)	O
,	,	O
Eicosapentaenoic	NNP	O
acid	NN	O
(	(	O
EPA	NNP	O
)	)	O
,	,	O
and	CC	O
Docosahexaenoic	NNP	O
acid	NN	O
(	(	O
DHA	NNP	O
)	)	O
had	VBD	O
a	DT	O
significantly	RB	O
lower	JJR	O
incidence	NN	O
of	IN	O
edema	NN	O
(	(	O
13	CD	O
%	NN	O
,	,	O
p	NN	O
=	NNP	O
0.004	CD	O
)	)	O
.	.	O

The	DT	O
group	NN	O
receiving	VBG	O
Magnesium	NNP	O
Oxide	NNP	O
had	VBD	O
statistically	RB	O
significant	JJ	O
fewer	JJR	O
subjects	NNS	O
who	WP	O
developed	VBD	O
hypertension	NN	O
of	IN	O
pregnancy	NN	O
.	.	O

There	EX	O
were	VBD	O
3	CD	O
cases	NNS	O
of	IN	O
eclampsia	NN	O
,	,	O
all	DT	O
in	IN	O
the	DT	O
Placebo	NNP	O
group	NN	O
.	.	O

Sustained	JJ	O
effect	NN	O
of	IN	O
SQ-standardized	NNP	O
grass	NN	O
allergy	NN	O
immunotherapy	NN	O
tablet	NN	O
on	IN	O
rhinoconjunctivitis	NN	O
quality	NN	O
of	IN	O
life	NN	O
.	.	O

BACKGROUND	IN	O
The	DT	O
prevalence	NN	O
of	IN	O
allergic	JJ	O
rhinoconjunctivitis	NN	O
has	VBZ	O
increased	VBN	O
significantly	RB	O
over	IN	O
the	DT	O
past	JJ	O
decades	NNS	O
with	IN	O
grass	NN	O
pollen	NN	O
being	VBG	O
a	DT	O
common	JJ	O
trigger	NN	O
.	.	O

The	DT	O
impact	NN	O
of	IN	O
allergy	NN	O
on	IN	O
patient	NN	O
's	POS	O
quality	NN	O
of	IN	O
life	NN	O
is	VBZ	O
substantial	JJ	O
.	.	O

AIM	NNP	O
To	TO	O
investigate	VB	O
the	DT	O
sustained	JJ	O
effect	NN	O
on	IN	O
quality	NN	O
of	IN	O
life	NN	O
during	IN	O
the	DT	O
grass	NN	O
pollen	NN	O
season	NN	O
1	CD	O
year	NN	O
after	IN	O
3	CD	O
years	NNS	O
of	IN	O
treatment	NN	O
with	IN	O
the	DT	O
SQ-standardized	JJ	O
grass	NN	O
allergy	NN	O
immunotherapy	NN	O
tablet	NN	O
(	(	O
AIT	NNP	O
)	)	O
,	,	O
Graza	NNP	O
(	(	O
Phleum	NNP	O
pratense	VBZ	O
75,000	CD	O
SQ-T/2800	JJ	O
BAU	NNP	O
;	:	O
ALK	NNP	O
,	,	O
Denmark	NNP	O
)	)	O
.	.	O

METHODS	PDT	O
The	DT	O
trial	NN	O
was	VBD	O
a	DT	O
randomized	JJ	O
,	,	O
parallel-group	JJ	O
,	,	O
double-blind	JJ	O
,	,	O
placebo-controlled	JJ	O
trial	NN	O
in	IN	O
adult	NN	A
subjects	NNS	O
with	IN	O
a	DT	O
history	NN	O
of	IN	O
moderate-severe	JJ	C
grass	NN	C
pollen	NN	C
induced	VBD	C
rhinoconjunctivitis	NN	C
inadequately	RB	C
controlled	VBN	O
by	IN	O
symptomatic	JJ	O
medications	NNS	O
.	.	O

Subjects	NNS	O
received	VBD	O
3	CD	O
years	NNS	O
of	IN	O
grass	NN	O
AIT	NNP	O
(	(	O
n	JJ	O
=	NNP	O
157	CD	O
)	)	O
or	CC	O
placebo	NN	O
(	(	O
n	JJ	O
=	NNP	O
126	CD	O
)	)	O
,	,	O
followed	VBN	O
by	IN	O
1	CD	O
year	NN	O
of	IN	O
follow-up	NN	O
.	.	O

Quality	NN	O
of	IN	O
life	NN	O
assessments	NNS	O
were	VBD	O
based	VBN	O
on	IN	O
the	DT	O
standardized	JJ	O
rhinoconjunctivitis	NN	O
quality	NN	O
of	IN	O
life	NN	O
questionnaire	NN	O
(	(	O
RQLQ	NNP	O
(	(	O
S	NNP	O
)	)	O
)	)	O
;	:	O
completed	VBN	O
weekly	JJ	O
during	IN	O
the	DT	O
entire	JJ	O
grass	NN	O
pollen	NN	O
season	NN	O
.	.	O

RESULTS	NNP	O
During	IN	O
follow-up	JJ	O
,	,	O
the	DT	O
overall	JJ	O
RQLQ	NNP	O
(	(	O
S	NNP	O
)	)	O
score	NN	O
for	IN	O
the	DT	O
entire	JJ	O
grass	NN	O
pollen	NN	O
season	NN	O
was	VBD	O
significantly	RB	O
improved	VBN	O
in	IN	O
the	DT	O
active	JJ	O
group	NN	O
(	(	O
relative	JJ	O
difference	NN	O
to	TO	O
placebo	VB	O
:	:	O
23	CD	O
%	NN	O
,	,	O
P	NNP	O
=	NNP	O
0.004	CD	O
)	)	O
.	.	O

The	DT	O
improvement	NN	O
was	VBD	O
higher	JJR	O
during	IN	O
the	DT	O
peak	NN	O
pollen	NN	O
season	NN	O
(	(	O
28	CD	O
%	NN	O
,	,	O
P	NNP	O
=	NNP	O
0.001	CD	O
)	)	O
.	.	O

The	DT	O
treatment	NN	O
effect	NN	O
of	IN	O
grass	NN	O
AIT	NNP	O
during	IN	O
the	DT	O
follow-up	JJ	O
year	NN	O
and	CC	O
the	DT	O
previous	JJ	O
three	CD	O
treatment	NN	O
years	NNS	O
was	VBD	O
similar	JJ	O
.	.	O

Improvements	NNS	O
were	VBD	O
found	VBN	O
in	IN	O
all	DT	O
seven	CD	O
RQLQ	NNP	O
(	(	O
S	NNP	O
)	)	O
domains	VBZ	O
.	.	O

The	DT	O
RQLQ	NNP	O
(	(	O
S	NNP	O
)	)	O
as	IN	O
a	DT	O
function	NN	O
of	IN	O
the	DT	O
weekly	JJ	O
average	NN	O
pollen	NN	O
counts	VBZ	O
showed	VBD	O
a	DT	O
clear	JJ	O
separation	NN	O
between	IN	O
the	DT	O
treatment	NN	O
groups	NNS	O
(	(	O
P	NNP	O
<	NNP	O
0.001	CD	O
)	)	O
.	.	O

CONCLUSION	NNP	O
In	IN	O
subjects	NNS	O
inadequately	RB	O
controlled	VBN	O
by	IN	O
symptomatic	JJ	O
medications	NNS	O
,	,	O
grass	NN	O
AIT	NNP	O
provided	VBD	O
sustained	VBN	O
and	CC	O
clinically	RB	O
relevant	JJ	O
improvements	NNS	O
in	IN	O
rhinoconjunctivitis	NN	O
quality	NN	O
of	IN	O
life	NN	O
compared	VBN	O
to	TO	O
placebo	VB	O
.	.	O

The	DT	O
effect	NN	O
increased	VBD	O
with	IN	O
increasing	VBG	O
grass	NN	O
pollen	NN	O
exposure	NN	O
.	.	O

The	DT	O
influence	NN	O
of	IN	O
ventricular	JJ	O
fibrillation	NN	O
duration	NN	O
on	IN	O
defibrillation	NN	O
efficacy	NN	O
using	VBG	O
biphasic	JJ	O
waveforms	NNS	O
in	IN	O
humans	NNS	O
.	.	O

OBJECTIVES	IN	O
The	DT	O
purpose	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
prospectively	RB	O
investigate	VB	O
the	DT	O
influence	NN	O
of	IN	O
ventricular	JJ	O
fibrillation	NN	O
(	(	O
VF	NNP	O
)	)	O
durations	NNS	O
of	IN	O
5	CD	O
,	,	O
10	CD	O
and	CC	O
20	CD	O
s	NN	O
on	IN	O
the	DT	O
defibrillation	NN	O
threshold	NN	O
(	(	O
DFT	NNP	O
)	)	O
during	IN	O
implantable	JJ	O
cardioverter-defibrillator	NN	O
(	(	O
ICD	NNP	O
)	)	O
implantation	NN	O
.	.	O

BACKGROUND	NNP	O
Although	IN	O
the	DT	O
DFT	NNP	O
using	VBG	O
monophasic	JJ	O
waveforms	NNS	O
has	VBZ	O
been	VBN	O
shown	VBN	O
to	TO	O
increase	VB	O
with	IN	O
VF	NNP	O
duration	NN	O
in	IN	O
humans	NNS	O
,	,	O
the	DT	O
effect	NN	O
of	IN	O
VF	NNP	O
duration	NN	O
on	IN	O
defibrillation	NN	O
efficacy	NN	O
using	VBG	O
biphasic	JJ	O
waveforms	NNS	O
in	IN	O
humans	NNS	O
is	VBZ	O
not	RB	O
known	VBN	O
.	.	O

METHODS	NNP	O
Thirty	NNP	SS
patients	NNS	C
undergoing	VBG	C
primary	JJ	C
ICD	NNP	C
implantation	NN	C
or	CC	C
pulse	JJ	C
generator	NN	C
replacement	NN	C
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
have	VB	O
the	DT	O
DFT	NNP	O
determined	VBD	O
using	VBG	O
biphasic	JJ	O
shocks	NNS	O
at	IN	O
two	CD	O
durations	NNS	O
of	IN	O
VF	NNP	O
each	DT	O
(	(	O
5	CD	O
and	CC	O
10	CD	O
s	NN	O
,	,	O
10	CD	O
and	CC	O
20	CD	O
s	NN	O
or	CC	O
5	CD	O
and	CC	O
20	CD	O
s	NN	O
)	)	O
.	.	O

RESULTS	NNP	O
There	EX	O
was	VBD	O
no	DT	O
statistically	RB	O
significant	JJ	O
difference	NN	O
in	IN	O
the	DT	O
mean	JJ	O
DFT	NNP	O
comparing	VBG	O
VF	NNP	O
durations	NNS	O
of	IN	O
5	CD	O
s	NNS	O
(	(	O
9.5+/-6.0	CD	O
J	NNP	O
)	)	O
and	CC	O
10	CD	O
s	NN	O
(	(	O
10.8+/-7.0	JJ	O
J	NNP	O
)	)	O
(	(	O
p=0.4	NN	O
)	)	O
.	.	O

The	DT	O
mean	JJ	O
DFT	NNP	O
significantly	RB	O
increased	VBD	O
from	IN	O
10.9+/-6.1	JJ	O
J	NNP	O
at	IN	O
10	CD	O
s	NN	O
of	IN	O
VF	NNP	O
to	TO	O
12.6+/-5.6	JJ	O
J	NNP	O
(	(	O
p=0.03	NN	O
)	)	O
at	IN	O
20	CD	O
s	NN	O
of	IN	O
VF	NNP	O
,	,	O
and	CC	O
from	IN	O
7.0+/-3.5	JJ	O
J	NNP	O
at	IN	O
5	CD	O
s	NN	O
of	IN	O
VF	NNP	O
to	TO	O
10.5+/-6.3	JJ	O
J	NNP	O
(	(	O
p=0.04	NN	O
)	)	O
at	IN	O
20	CD	O
s	NN	O
of	IN	O
VF	NNP	O
.	.	O

An	DT	O
increase	NN	O
in	IN	O
the	DT	O
DFT	NNP	O
was	VBD	O
observed	VBN	O
in	IN	O
14	CD	SS
patients	NNS	O
as	IN	O
VF	NNP	O
duration	NN	O
increased	VBD	O
.	.	O

There	EX	O
were	VBD	O
no	DT	O
clinical	JJ	O
characteristics	NNS	O
that	WDT	O
differentiated	VBD	O
patients	NNS	O
with	IN	O
and	CC	O
without	IN	O
an	DT	O
increase	NN	O
in	IN	O
the	DT	O
DFT	NNP	O
.	.	O

CONCLUSIONS	NNP	O
Defibrillation	NNP	O
efficacy	NN	O
decreases	VBZ	O
with	IN	O
increasing	VBG	O
VF	NNP	O
duration	NN	O
using	VBG	O
biphasic	JJ	O
waveforms	NNS	O
in	IN	O
humans	NNS	O
.	.	O

Ventricular	JJ	O
fibrillation	NN	O
durations	NNS	O
greater	JJR	O
than	IN	O
10	CD	O
s	NN	O
may	MD	O
negatively	RB	O
affect	VB	O
the	DT	O
effectiveness	NN	O
of	IN	O
ICD	NNP	O
therapy	NN	O
.	.	O

Impact	NN	O
of	IN	O
prior	JJ	O
pharmacotherapy	NN	O
on	IN	O
remission	NN	O
of	IN	O
psychotic	JJ	C
depression	NN	C
in	IN	O
a	DT	O
randomized	NN	O
controlled	VBN	O
trial	NN	O
.	.	O

Having	VBG	O
failed	VBN	O
to	TO	O
respond	VB	O
to	TO	O
an	DT	O
adequate	JJ	O
antidepressant	JJ	O
treatment	NN	O
course	NN	O
predicts	VBZ	O
poorer	JJR	O
treatment	NN	O
outcomes	NNS	O
in	IN	O
patients	NNS	O
with	IN	O
major	JJ	C
depression	NN	C
.	.	O

However	RB	O
,	,	O
little	JJ	O
is	VBZ	O
known	VBN	O
about	IN	O
the	DT	O
impact	NN	O
of	IN	O
prior	JJ	O
treatment	NN	O
on	IN	O
the	DT	O
outcome	NN	O
of	IN	O
major	JJ	C
depression	NN	C
with	IN	O
psychotic	JJ	C
features	NNS	C
(	(	C
MDpsy	NNP	C
)	)	C
.	.	O

We	PRP	O
examined	VBD	O
the	DT	O
effect	NN	O
of	IN	O
prior	JJ	O
treatment	NN	O
history	NN	O
on	IN	O
the	DT	O
outcome	NN	O
of	IN	O
pharmacotherapy	NN	O
of	IN	O
MDpsy	NNP	C
in	IN	O
patients	NNS	O
who	WP	O
participated	VBD	O
in	IN	O
the	DT	O
STOPD-PD	NNP	O
study	NN	O
,	,	O
a	DT	O
randomized	VBN	O
,	,	O
double-blind	JJ	O
,	,	O
clinical	JJ	O
trial	NN	O
comparing	VBG	O
a	DT	O
combination	NN	O
of	IN	O
olanzapine	JJ	O
plus	CC	O
sertraline	JJ	O
vs.	FW	O
olanzapine	JJ	O
plus	CC	O
placebo	NN	O
.	.	O

The	DT	O
strength	NN	O
of	IN	O
treatment	NN	O
courses	NNS	O
received	VBD	O
prior	RB	O
to	TO	O
randomization	NN	O
was	VBD	O
classified	VBN	O
using	VBG	O
a	DT	O
validated	JJ	O
method	NN	O
.	.	O

A	DT	O
hierarchy	NN	O
of	IN	O
outcomes	NNS	O
was	VBD	O
hypothesized	VBN	O
based	VBN	O
on	IN	O
treatments	NNS	O
received	VBN	O
prior	RB	O
to	TO	O
randomization	NN	O
and	CC	O
randomized	JJ	O
treatment	NN	O
.	.	O

A	DT	O
high	JJ	O
remission	NN	O
rate	NN	O
was	VBD	O
observed	VBN	O
in	IN	O
subjects	NNS	O
with	IN	O
a	DT	O
history	NN	O
of	IN	O
no	DT	O
prior	JJ	O
treatment	NN	O
or	CC	O
inadequate	JJ	O
treatment	NN	O
who	WP	O
were	VBD	O
treated	VBN	O
with	IN	O
a	DT	O
combination	NN	O
of	IN	O
olanzapine	NN	O
and	CC	O
sertraline	NN	O
.	.	O

A	DT	O
low	JJ	O
remission	NN	O
rate	NN	O
was	VBD	O
observed	VBN	O
in	IN	O
subjects	NNS	O
who	WP	O
had	VBD	O
previously	RB	O
failed	VBN	O
to	TO	O
respond	VB	O
to	TO	O
an	DT	O
antidepressant	JJ	O
alone	NN	O
and	CC	O
who	WP	O
were	VBD	O
treated	VBN	O
with	IN	O
olanzapine	JJ	O
monotherapy	NN	O
.	.	O

A	DT	O
low	JJ	O
remission	NN	O
rate	NN	O
was	VBD	O
also	RB	O
observed	VBN	O
in	IN	O
subjects	NNS	O
who	WP	O
had	VBD	O
previously	RB	O
failed	VBN	O
to	TO	O
respond	VB	O
to	TO	O
a	DT	O
combination	NN	O
of	IN	O
an	DT	O
antipsychotic	JJ	O
and	CC	O
an	DT	O
antidepressant	NN	O
.	.	O

Similar	JJ	O
to	TO	O
patients	NNS	O
with	IN	O
major	JJ	O
depression	NN	O
,	,	O
these	DT	O
results	NNS	O
emphasize	VBP	O
the	DT	O
impact	NN	O
of	IN	O
prior	JJ	O
pharmacotherapy	NN	O
on	IN	O
treatment	NN	O
outcomes	NNS	O
in	IN	O
patients	NNS	O
with	IN	O
MDpsy	NNP	C
.	.	O

The	DT	O
role	NN	O
of	IN	O
adjunctive	JJ	O
exenatide	NN	O
therapy	NN	O
in	IN	O
pediatric	JJ	A
type	NN	C
1	CD	C
diabetes	NNS	C
.	.	O

OBJECTIVE	NNP	O
Exenatide	NNP	O
improves	VBZ	O
postprandial	JJ	O
glycemic	JJ	O
excursions	NNS	O
in	IN	O
type	NN	O
2	CD	O
diabetes	NNS	O
.	.	O

Exenatide	NNP	O
could	MD	O
benefit	VB	O
type	JJ	O
1	CD	O
diabetes	NNS	O
as	RB	O
well	RB	O
.	.	O

We	PRP	O
aimed	VBD	O
to	TO	O
determine	VB	O
an	DT	O
effective	JJ	O
and	CC	O
safe	JJ	O
glucose-lowering	NN	O
adjuvant	JJ	O
exenatide	NN	O
dose	NN	O
in	IN	O
adolescents	NNS	A
with	IN	O
type	JJ	C
1	CD	C
diabetes	NNS	C
.	.	O

RESEARCH	NNP	O
DESIGN	NNP	O
AND	NNP	O
METHODS	NNP	O
Eight	NNP	SS
subjects	NNS	O
completed	VBD	O
a	DT	O
three-part	JJ	O
double-blinded	JJ	O
randomized	VBN	O
controlled	VBN	O
study	NN	O
of	IN	O
premeal	JJ	O
exenatide	NN	O
.	.	O

Two	CD	O
doses	NNS	O
of	IN	O
exenatide	NN	O
(	(	O
1.25	CD	O
and	CC	O
2.5	CD	O
microg	NN	O
)	)	O
were	VBD	O
compared	VBN	O
with	IN	O
insulin	NN	O
monotherapy	NN	O
.	.	O

Prandial	JJ	O
insulin	NN	O
dose	NN	O
was	VBD	O
reduced	VBN	O
by	IN	O
20	CD	O
%	NN	O
.	.	O

Gastric	NNP	O
emptying	VBG	O
and	CC	O
hormones	NNS	O
were	VBD	O
analyzed	VBN	O
for	IN	O
300	CD	O
min	JJ	O
postmeal	NN	O
.	.	O

RESULTS	NNP	O
Treatment	NNP	O
with	IN	O
both	DT	O
doses	NNS	O
of	IN	O
exenatide	JJ	O
versus	NN	O
insulin	NN	O
monotherapy	NN	O
significantly	RB	O
reduced	VBD	O
glucose	JJ	O
excursions	NNS	O
over	IN	O
300	CD	O
min	NNS	O
(	(	O
P	NNP	O
<	NNP	O
0.0001	CD	O
)	)	O
.	.	O

Exenatide	NNP	O
administration	NN	O
failed	VBD	O
to	TO	O
suppress	VB	O
glucagon	NN	O
but	CC	O
delayed	VBD	O
gastric	JJ	O
emptying	NN	O
(	(	O
P	NNP	O
<	NNP	O
0.004	CD	O
)	)	O
.	.	O

CONCLUSIONS	NNP	O
Adjunctive	NNP	O
exenatide	NN	O
therapy	NN	O
reduces	VBZ	O
postprandial	JJ	O
hyperglycemia	NN	O
in	IN	O
adolescents	NNS	A
with	IN	O
type	JJ	C
1	CD	C
diabetes	NNS	C
.	.	O

This	DT	O
reduction	NN	O
in	IN	O
glucose	JJ	O
excursion	NN	O
occurs	VBZ	O
despite	IN	O
reduction	NN	O
in	IN	O
insulin	NN	O
dose	NN	O
.	.	O

We	PRP	O
suggest	VBP	O
that	DT	O
exenatide	NN	O
has	VBZ	O
therapeutic	JJ	O
potential	NN	O
as	IN	O
adjunctive	JJ	O
therapy	NN	O
in	IN	O
type	NN	O
1	CD	O
diabetes	NNS	O
.	.	O

A	DT	O
randomized	JJ	O
parallel	NN	O
study	NN	O
to	TO	O
assess	VB	O
the	DT	O
safety	NN	O
and	CC	O
efficacy	NN	O
of	IN	O
two	CD	O
different	JJ	O
dosing	VBG	O
regimens	NNS	O
of	IN	O
5	CD	O
%	NN	O
imiquimod	NN	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
superficial	JJ	O
basal	NN	O
cell	NN	O
carcinoma	NN	O
.	.	O

OBJECTIVES	CC	O
This	DT	O
study	NN	O
was	VBD	O
designed	VBN	O
to	TO	O
compare	VB	O
the	DT	O
safety	NN	O
and	CC	O
efficacy	NN	O
of	IN	O
two	CD	O
cycled	VBD	O
dosing	VBG	O
regimens	NNS	O
of	IN	O
imiquimod	JJ	O
5	CD	O
%	NN	O
cream	NN	O
for	IN	O
treatment	NN	O
of	IN	O
superficial	JJ	O
basal	NN	O
cell	NN	O
carcinoma	NN	O
(	(	O
sBCC	NN	O
)	)	O
.	.	O

METHODS	JJ	O
Patients	NNPS	O
(	(	O
n	JJ	O
=	NNP	O
32	CD	O
)	)	O
were	VBD	O
randomized	VBN	O
to	TO	O
receive	VB	O
one	CD	O
of	IN	O
two	CD	O
treatment	NN	O
regimens	NNS	O
:	:	O
8	CD	O
weeks	NNS	O
of	IN	O
treatment	NN	O
with	IN	O
once-daily	JJ	O
dosing	VBG	O
for	IN	O
alternate	JJ	O
weeks	NNS	O
(	(	O
R1	NNP	O
)	)	O
and	CC	O
5	CD	O
weeks	NNS	O
of	IN	O
once-daily	JJ	O
dosing	NN	O
with	IN	O
a	DT	O
1-week	JJ	O
interval	NN	O
in	IN	O
the	DT	O
middle	NN	O
of	IN	O
the	DT	O
course	NN	O
(	(	O
R2	NNP	O
)	)	O
.	.	O

Efficacy	NN	O
measures	NNS	O
were	VBD	O
tumour	JJ	O
clearance	NN	O
at	IN	O
weeks	NNS	O
19	CD	O
and	CC	O
52	CD	O
and	CC	O
measures	NNS	O
of	IN	O
patients	NNS	O
'	POS	O
acceptability	NN	O
.	.	O

RESULTS	NNP	O
Data	NNP	O
from	IN	O
30	CD	O
patients	NNS	O
(	(	O
13	CD	O
females	NNS	O
)	)	O
,	,	O
14	CD	O
on	IN	O
R1	NNP	O
and	CC	O
16	CD	O
on	IN	O
R2	NNP	O
,	,	O
were	VBD	O
analysed	VBN	O
.	.	O

The	DT	O
results	NNS	O
revealed	VBD	O
an	DT	O
initial	JJ	O
clearance	NN	O
rate	NN	O
of	IN	O
64	CD	O
%	NN	O
at	IN	O
week	NN	O
19	CD	O
for	IN	O
R1	NNP	O
and	CC	O
81	CD	O
%	NN	O
for	IN	O
R2	NNP	O
(	(	O
95	CD	O
%	NN	O
CI	NNP	O
for	IN	O
difference	NN	O
:	:	O
-14	NN	O
%	NN	O
to	TO	O
45	CD	O
%	NN	O
,	,	O
p	NN	O
=	NNP	O
0.21	CD	O
)	)	O
.	.	O

However	RB	O
,	,	O
clearance	NN	O
rates	NNS	O
at	IN	O
week	NN	O
52	CD	O
were	VBD	O
significantly	RB	O
different	JJ	O
:	:	O
43	CD	O
%	NN	O
for	IN	O
R1	NNP	O
and	CC	O
88	CD	O
%	NN	O
for	IN	O
R2	NNP	O
(	(	O
95	CD	O
%	NN	O
CI	NNP	O
for	IN	O
difference	NN	O
:	:	O
11	CD	O
%	NN	O
to	TO	O
68	CD	O
%	NN	O
,	,	O
p	NN	O
=	NNP	O
0.02	CD	O
)	)	O
.	.	O

There	EX	O
was	VBD	O
no	DT	O
difference	NN	O
in	IN	O
acceptability	NN	O
of	IN	O
treatment	NN	O
as	IN	O
measured	VBN	O
by	IN	O
composite	JJ	O
median	JJ	O
visual	JJ	O
analogue	NN	O
scores	NNS	O
at	IN	O
week	NN	O
8	CD	O
.	.	O

CONCLUSION	NNP	O
Five	NNP	O
weeks	NNS	O
of	IN	O
5	CD	O
%	NN	O
imiquimod	JJ	O
cream	NN	O
once	RB	O
daily	JJ	O
with	IN	O
a	DT	O
1-week	JJ	O
interval	NN	O
was	VBD	O
more	RBR	O
effective	JJ	O
but	CC	O
as	RB	O
well	RB	O
tolerated	VBN	O
as	IN	O
the	DT	O
8-week	JJ	O
alternate	NN	O
week	NN	O
regimen	NNS	O
for	IN	O
sBCC	NN	O
.	.	O

Utilization	NN	O
patterns	NNS	O
of	IN	O
conventional	JJ	O
and	CC	O
complementary/alternative	JJ	O
treatments	NNS	O
in	IN	O
children	NNS	A
with	IN	O
autism	NN	C
spectrum	NN	O
disorders	NNS	O
and	CC	O
developmental	JJ	O
disabilities	NNS	O
in	IN	O
a	DT	O
population-based	JJ	O
study	NN	O
.	.	O

OBJECTIVE	NNP	O
To	TO	O
compare	VB	O
the	DT	O
utilization	NN	O
of	IN	O
conventional	JJ	O
treatments	NNS	O
and	CC	O
utilization	NN	O
of	IN	O
complementary	JJ	O
and	CC	O
alternative	JJ	O
medicine	NN	O
in	IN	O
preschoolers	NNS	A
with	IN	O
autism	NN	O
spectrum	NN	O
disorders	NNS	O
(	(	O
ASD	NNP	O
)	)	O
and	CC	O
other	JJ	O
developmental	JJ	O
disabilities	NNS	O
(	(	O
DD	NNP	O
)	)	O
.	.	O

METHODS	JJ	O
Participants	NNS	O
were	VBD	O
578	CD	SS
children	NNS	A
who	WP	O
were	VBD	O
part	NN	O
of	IN	O
an	DT	O
ongoing	JJ	O
population-based	JJ	O
,	,	O
case-control	JJ	O
study	NN	O
of	IN	O
2-	JJ	A
to	TO	A
5-year	JJ	A
olds	NNS	A
with	IN	O
ASD	NNP	O
,	,	O
DD	NNP	O
,	,	O
and	CC	O
the	DT	O
general	JJ	O
population	NN	O
.	.	O

Parents	NNS	O
completed	VBD	O
an	DT	O
interview	NN	O
on	IN	O
past	JJ	O
and	CC	O
current	JJ	O
services	NNS	O
.	.	O

RESULTS	NNP	O
Four	CD	SS
hundred	VBD	SS
fifty-three	JJ	SS
children	NNS	O
with	IN	O
ASD	NNP	O
and	CC	O
125	CD	SS
DD	NNP	O
children	NNS	A
were	VBD	O
included	VBN	O
.	.	O

ASD	NNP	O
families	NNS	O
received	VBD	O
more	RBR	O
hours	NNS	O
of	IN	O
conventional	JJ	O
services	NNS	O
compared	VBN	O
with	IN	O
DD	NNP	O
families	NNS	O
(	(	O
17.8	CD	O
vs	RB	O
11	CD	O
;	:	O
p	NN	O
<	NNP	O
.001	NNP	O
)	)	O
.	.	O

The	DT	O
use	NN	O
of	IN	O
psychotropic	NN	O
medications	NNS	O
was	VBD	O
low	JJ	O
in	IN	O
both	DT	O
groups	NNS	O
(	(	O
approximately	RB	O
3	CD	O
%	NN	O
)	)	O
.	.	O

Overall	JJ	O
,	,	O
complementary	JJ	O
and	CC	O
alternative	JJ	O
medicine	NN	O
(	(	O
CAM	NNP	O
)	)	O
use	NN	O
was	VBD	O
not	RB	O
significantly	RB	O
different	JJ	O
in	IN	O
ASD	NNP	O
(	(	O
39	CD	O
%	NN	O
)	)	O
versus	NN	O
DD	NNP	O
(	(	O
30	CD	O
%	NN	O
)	)	O
.	.	O

Hispanic	JJ	O
families	NNS	O
in	IN	O
both	DT	O
groups	NNS	O
used	VBD	O
CAM	NNP	O
less	RBR	O
often	RB	O
than	IN	O
non-Hispanic	JJ	O
families	NNS	O
.	.	O

Variables	NNS	O
such	JJ	O
as	IN	O
level	NN	O
of	IN	O
function	NN	O
,	,	O
immunization	NN	O
status	NN	O
,	,	O
and	CC	O
the	DT	O
presence	NN	O
of	IN	O
an	DT	O
identified	VBN	O
neurogenetic	JJ	O
disorder	NN	O
were	VBD	O
not	RB	O
predictive	JJ	O
of	IN	O
CAM	NNP	O
use	NN	O
.	.	O

A	DT	O
higher	JJR	O
level	NN	O
of	IN	O
parental	JJ	O
education	NN	O
was	VBD	O
associated	VBN	O
with	IN	O
an	DT	O
increased	VBN	O
CAM	NNP	O
use	NN	O
in	IN	O
ASD	NNP	O
and	CC	O
DD	NNP	O
.	.	O

Families	NNS	O
who	WP	O
used	VBD	O
>	$	O
20	CD	O
hours	NNS	O
per	IN	O
week	NN	O
of	IN	O
conventional	JJ	O
services	NNS	O
were	VBD	O
more	RBR	O
likely	JJ	O
to	TO	O
use	VB	O
CAM	NNP	O
,	,	O
including	VBG	O
potentially	RB	O
unsafe	JJ	O
or	CC	O
disproven	JJ	O
CAM	NNP	O
.	.	O

Underimmunized	VBN	O
children	NNS	A
were	VBD	O
marginally	RB	O
more	RBR	O
likely	JJ	O
to	TO	O
use	VB	O
CAM	NNP	O
but	CC	O
not	RB	O
more	RBR	O
likely	JJ	O
to	TO	O
have	VB	O
received	VBN	O
potentially	RB	O
unsafe	JJ	O
or	CC	O
disproven	JJ	O
CAM	NNP	O
.	.	O

CONCLUSION	NNP	O
Use	NNP	O
of	IN	O
CAM	NNP	O
is	VBZ	O
common	JJ	O
in	IN	O
families	NNS	O
of	IN	O
young	JJ	A
children	NNS	A
with	IN	O
neurodevelopmental	JJ	O
disorders	NNS	O
,	,	O
and	CC	O
it	PRP	O
is	VBZ	O
predicted	VBN	O
by	IN	O
higher	JJR	O
parental	JJ	O
education	NN	O
and	CC	O
non-Hispanic	JJ	O
ethnicity	NN	O
but	CC	O
not	RB	O
developmental	JJ	O
characteristics	NNS	O
.	.	O

Further	NNP	O
research	NN	O
should	MD	O
address	VB	O
how	WRB	O
health	NN	O
care	NN	O
providers	NNS	O
can	MD	O
support	VB	O
families	NNS	O
in	IN	O
making	VBG	O
decisions	NNS	O
about	IN	O
CAM	NNP	O
use	NN	O
.	.	O

Long-term	JJ	O
outcome	NN	O
of	IN	O
migraine	JJ	C
therapy	NN	O
:	:	O
predictive	JJ	O
value	NN	O
of	IN	O
the	DT	O
frontotemporal	JJ	O
nitroglycerin	JJ	O
test	NN	O
.	.	O

We	PRP	O
evaluated	VBD	O
whether	IN	O
type	NN	O
of	IN	O
response	NN	O
to	TO	O
the	DT	O
migraine-induction	JJ	O
test	NN	O
with	IN	O
a	DT	O
nitroglycerin	JJ	O
ointment	NN	O
applied	VBN	O
to	TO	O
the	DT	O
frontotemporal	JJ	O
head	NN	O
region	NN	O
could	MD	O
predict	VB	O
the	DT	O
efficacy	NN	O
of	IN	O
antimigraine	JJ	O
therapy	NN	O
.	.	O

Forty-two	JJ	SS
patients	NNS	O
with	IN	O
migraine	NN	O
without	IN	O
aura	JJ	O
underwent	NN	O
the	DT	O
test	NN	O
before	IN	O
and	CC	O
2	CD	O
months	NNS	O
after	IN	O
antimigraine	JJ	O
therapy	NN	O
.	.	O

Two	CD	O
and	CC	O
4	CD	O
months	NNS	O
after	IN	O
treatment	NN	O
withdrawal	NN	O
,	,	O
most	RBS	O
subjects	NNS	O
with	IN	O
a	DT	O
negative	JJ	O
response	NN	O
to	TO	O
the	DT	O
post-treatment	JJ	O
test	NN	O
maintained	VBD	O
treatment	NN	O
benefit	NN	O
,	,	O
whereas	JJ	O
benefit	NN	O
was	VBD	O
lost	VBN	O
in	IN	O
patients	NNS	O
with	IN	O
an	DT	O
early	JJ	O
onset	NN	O
migraine	NN	O
response	NN	O
.	.	O

Preliminary	JJ	O
findings	NNS	O
from	IN	O
a	DT	O
prospective	JJ	O
,	,	O
randomized	JJ	O
trial	NN	O
of	IN	O
two	CD	O
palatal	JJ	O
operations	NNS	O
for	IN	O
sleep-disordered	JJ	O
breathing	NN	O
.	.	O

OBJECTIVES	IN	O
We	PRP	O
compared	VBN	O
the	DT	O
efficacy	NN	O
of	IN	O
2	CD	O
palatal	JJ	O
surgical	JJ	O
procedures	NNS	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
patients	NNS	O
with	IN	O
mild	JJ	C
sleep-disordered	JJ	C
breathing	NN	C
(	(	C
SDB	NNP	C
)	)	C
.	.	O

STUDY	NNP	O
DESIGN	NNP	O
AND	NNP	O
SETTING	NNP	O
We	PRP	O
conducted	VBD	O
a	DT	O
prospective	JJ	O
,	,	O
randomized	VBN	O
,	,	O
crossover	RB	O
surgical	JJ	O
trial	NN	O
at	IN	O
a	DT	O
university	NN	O
hospital	NN	O
.	.	O

METHODS	NNP	O
Twenty	NNP	SS
patients	NNS	O
with	IN	O
mild	JJ	O
SDB	NNP	O
for	IN	O
whom	WP	O
conservative	JJ	O
treatment	NN	O
failed	VBD	O
were	VBD	O
identified	VBN	O
and	CC	O
consecutively	RB	O
enrolled	VBD	O
into	IN	O
an	DT	O
institutional	JJ	O
review	NN	O
board-approved	JJ	O
surgical	JJ	O
protocol	NN	O
.	.	O

They	PRP	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
undergo	VB	O
either	DT	O
radiofrequency	NN	O
ablation	NN	O
of	IN	O
the	DT	O
palate	NN	O
(	(	O
RFAP	NNP	O
)	)	O
for	IN	O
a	DT	O
planned	JJ	O
3-stage	JJ	O
treatment	NN	O
or	CC	O
laser-assisted	JJ	O
uvulopalatoplasty	JJ	O
(	(	O
LAUP	NNP	O
)	)	O
,	,	O
also	RB	O
for	IN	O
3	CD	O
stages	NNS	O
of	IN	O
treatment	NN	O
,	,	O
using	VBG	O
a	DT	O
CO	NNP	O
(	(	O
2	CD	O
)	)	O
laser	NN	O
.	.	O

Parameters	NNS	O
assessed	VBD	O
included	JJ	O
severity	NN	O
of	IN	O
SDB	NNP	O
(	(	O
polysomnography	NN	O
)	)	O
,	,	O
subjective	JJ	O
and	CC	O
objective	JJ	O
loudness	NN	O
of	IN	O
snoring	VBG	O
(	(	O
visual	JJ	O
analog	NN	O
scale	NN	O
and	CC	O
SNAP	NNP	O
recording	NN	O
)	)	O
,	,	O
sleepiness	NN	O
(	(	O
Epworth	NNP	O
Sleepiness	NNP	O
Scale	NNP	O
)	)	O
,	,	O
and	CC	O
anatomic	JJ	O
changes	NNS	O
(	(	O
upper	JJ	O
airway	RB	O
endoscopy	NN	O
)	)	O
,	,	O
as	RB	O
well	RB	O
as	IN	O
demographic	JJ	O
factors	NNS	O
.	.	O

Patients	NNS	O
not	RB	O
achieving	VBG	O
satisfactory	JJ	O
improvement	NN	O
in	IN	O
their	PRP$	O
condition	NN	O
were	VBD	O
crossed	VBN	O
over	IN	O
to	TO	O
the	DT	O
alternative	JJ	O
surgical	JJ	O
therapy	NN	O
for	IN	O
attempted	JJ	O
salvage	NN	O
.	.	O

RESULTS	NNP	O
Seventeen	NNP	O
of	IN	O
the	DT	O
enrolled	JJ	O
patients	NNS	O
have	VBP	O
completed	VBN	O
the	DT	O
protocol	NN	O
.	.	O

Ten	CD	O
of	IN	O
these	DT	O
were	VBD	O
randomized	VBN	O
to	TO	O
the	DT	O
RFAP	NNP	O
group	NN	O
,	,	O
and	CC	O
7	CD	O
to	TO	O
the	DT	O
LAUP	NNP	O
group	NN	O
.	.	O

Six	CD	O
of	IN	O
the	DT	O
RFAP	NNP	O
patients	NNS	O
(	(	O
60	CD	O
%	NN	O
)	)	O
achieved	VBD	O
a	DT	O
satisfactory	JJ	O
resolution	NN	O
of	IN	O
their	PRP$	O
snoring	NN	O
,	,	O
and	CC	O
4	CD	O
failed	VBD	O
and	CC	O
were	VBD	O
salvaged	VBN	O
with	IN	O
LAUP	NNP	O
.	.	O

Six	NNP	O
of	IN	O
the	DT	O
LAUP	NNP	O
patients	NNS	O
(	(	O
86	CD	O
%	NN	O
)	)	O
achieved	VBD	O
a	DT	O
satisfactory	JJ	O
resolution	NN	O
of	IN	O
their	PRP$	O
snoring	NN	O
,	,	O
and	CC	O
1	CD	O
patient	NN	O
failed	VBD	O
and	CC	O
was	VBD	O
salvaged	VBN	O
with	IN	O
nasal	JJ	O
surgery	NN	O
.	.	O

One	CD	O
patient	NN	O
who	WP	O
was	VBD	O
initially	RB	O
cured	VBN	O
had	VBD	O
a	DT	O
relapse	NN	O
after	IN	O
9	CD	O
months	NNS	O
and	CC	O
was	VBD	O
successfully	RB	O
salvaged	VBN	O
with	IN	O
RFA	NNP	O
.	.	O

CONCLUSION	NNP	O
Prospective	NNP	O
,	,	O
randomized	VBD	O
trials	NNS	O
of	IN	O
surgery	NN	O
for	IN	O
SDB	NNP	O
are	VBP	O
possible	JJ	O
.	.	O

Preliminary	JJ	O
findings	NNS	O
from	IN	O
the	DT	O
current	JJ	O
protocol	NN	O
reveal	NN	O
a	DT	O
slight	JJ	O
advantage	NN	O
of	IN	O
LAUP	NNP	O
over	IN	O
RFAP	NNP	O
but	CC	O
with	IN	O
a	DT	O
greater	JJR	O
degree	NN	O
of	IN	O
discomfort	NN	O
postoperatively	RB	O
.	.	O

Monitoring	VBG	O
tumour	NN	O
cells	NNS	O
in	IN	O
the	DT	O
peripheral	JJ	O
blood	NN	O
of	IN	O
small	JJ	O
cell	NN	O
lung	NN	O
cancer	NN	O
patients	NNS	O
.	.	O

BACKGROUND	NNP	O
Flow	NNP	O
cytometry	NN	O
was	VBD	O
used	VBN	O
to	TO	O
enumerate	VB	O
tumour	JJ	O
cells	NNS	O
in	IN	O
longitudinal	JJ	O
studies	NNS	O
of	IN	O
peripheral	JJ	O
blood	NN	O
from	IN	O
small	JJ	O
cell	NN	O
lung	NN	O
cancer	NN	O
(	(	O
SCLC	NNP	O
)	)	O
patients	NNS	O
,	,	O
together	RB	O
with	IN	O
magnetic	JJ	O
bead	NN	O
selection	NN	O
to	TO	O
isolate	VB	O
and	CC	O
identify	VB	O
these	DT	O
cells	NNS	O
.	.	O

As	IN	O
part	NN	O
of	IN	O
a	DT	O
trial	NN	O
,	,	O
11	CD	O
patients	NNS	O
received	VBD	O
either	RB	O
standard	JJ	O
(	(	O
four	CD	O
weekly	RB	O
)	)	O
chemotherapy	NN	O
with	IN	O
ifosfamide	NN	O
,	,	O
carboplatin	NN	O
,	,	O
and	CC	O
etoposide	RB	O
(	(	O
ICE	NNP	O
)	)	O
or	CC	O
accelerated	VBN	O
(	(	O
two	CD	O
weekly	RB	O
)	)	O
ICE	NNP	O
with	IN	O
filgrastim	NN	O
(	(	O
granulocyte	JJ	O
colony-stimulating	NN	O
factor	NN	O
[	IN	O
G-CSF	NNP	O
]	NNP	O
)	)	O
and	CC	O
autologous	JJ	O
stem	NN	O
cell	NN	O
support	NN	O
.	.	O

METHODS	NNP	O
Fresh	NNP	O
venous	JJ	O
blood	NN	O
was	VBD	O
taken	VBN	O
throughout	IN	O
treatment	NN	O
and	CC	O
follow-up	NN	O
.	.	O

Aliquots	NNS	O
were	VBD	O
stained	VBN	O
with	IN	O
a	DT	O
tumour-specific	JJ	O
antibody	NN	O
against	IN	O
epithelial	JJ	O
tissue	NN	O
(	(	O
Ber	NNP	O
EP4	NNP	O
)	)	O
,	,	O
verified	VBD	O
as	IN	O
a	DT	O
good	JJ	O
marker	NN	O
of	IN	O
SCLC	NNP	O
cells	NNS	O
by	IN	O
immunohistochemistry	NN	O
.	.	O

Matched	NNP	O
samples	NNS	O
labelled	VBD	O
with	IN	O
Ber	NNP	O
EP4	NNP	O
were	VBD	O
separated	VBN	O
magnetically	RB	O
by	IN	O
adding	VBG	O
a	DT	O
secondary	JJ	O
bead-antibody	NN	O
conjugate	NN	O
for	IN	O
confirmation	NN	O
of	IN	O
tumour	NN	O
cell	NN	O
identity	NN	O
.	.	O

RESULTS	NNP	O
Circulating	NNP	O
tumour	JJ	O
cells	NNS	O
were	VBD	O
detected	VBN	O
and	CC	O
monitored	VBN	O
throughout	IN	O
treatment	NN	O
periods	NNS	O
.	.	O

An	DT	O
initial	JJ	O
rise	NN	O
in	IN	O
circulating	VBG	O
cells	NNS	O
after	IN	O
the	DT	O
first	JJ	O
cycle	NN	O
was	VBD	O
followed	VBN	O
by	IN	O
a	DT	O
fall	NN	O
in	IN	O
both	DT	O
treatment	NN	O
arms	NNS	O
to	TO	O
baseline	NN	O
levels	NNS	O
set	VBN	O
by	IN	O
normal	JJ	O
controls	NNS	O
.	.	O

This	DT	O
was	VBD	O
achieved	VBN	O
by	IN	O
week	NN	O
12	CD	O
in	IN	O
the	DT	O
accelerated	JJ	O
treatment	NN	O
arm	NN	O
and	CC	O
by	IN	O
week	NN	O
24	CD	O
in	IN	O
the	DT	O
standard	JJ	O
arm	NN	O
.	.	O

CONCLUSIONS	NNP	O
Flow	NNP	O
cytometry	NN	O
and	CC	O
magnetic	JJ	O
bead	NN	O
isolation	NN	O
can	MD	O
be	VB	O
used	VBN	O
to	TO	O
identify	VB	O
changes	NNS	O
in	IN	O
numbers	NNS	O
of	IN	O
circulating	VBG	O
tumour	JJ	O
cells	NNS	O
in	IN	O
patients	NNS	O
undergoing	JJ	O
chemotherapy	NN	O
for	IN	O
SCLC	NNP	O
and	CC	O
thereafter	RB	O
during	IN	O
follow-up	JJ	O
periods	NNS	O
.	.	O

Absence	NN	O
of	IN	O
tumour	JJ	O
cells	NNS	O
may	MD	O
indicate	VB	O
a	DT	O
more	RBR	O
favourable	JJ	O
patient	NN	O
group	NN	O
who	WP	O
would	MD	O
benefit	VB	O
from	IN	O
a	DT	O
more	RBR	O
intense	JJ	O
course	NN	O
of	IN	O
treatment	NN	O
.	.	O

A	DT	O
comparison	NN	O
of	IN	O
a	DT	O
spiritually	RB	O
based	VBN	O
and	CC	O
non-spiritually	RB	O
based	VBN	O
educational	JJ	O
intervention	NN	O
for	IN	O
informed	JJ	O
decision	NN	O
making	NN	O
for	IN	O
prostate	NN	O
cancer	NN	O
screening	VBG	O
among	IN	O
church-attending	JJ	O
African-American	JJ	O
men	NNS	SE
.	.	O

INTRODUCTION	NNP	O
Health	NNP	O
communication	NN	O
interventions	NNS	O
have	VBP	O
been	VBN	O
modestly	RB	O
effective	JJ	O
for	IN	O
increasing	VBG	O
informed	JJ	O
decision	NN	O
making	NN	O
for	IN	O
prostate	NN	O
cancer	NN	O
screening	VBG	O
among	IN	O
African-American	JJ	O
men	NNS	SE
;	:	O
however	RB	O
,	,	O
knowledge	NN	O
and	CC	O
informed	JJ	O
decision	NN	O
making	NN	O
is	VBZ	O
still	RB	O
questionable	JJ	O
even	RB	O
with	IN	O
screening	VBG	O
.	.	O

Church-based	JJ	O
programs	NNS	O
may	MD	O
be	VB	O
more	RBR	O
effective	JJ	O
if	IN	O
they	PRP	O
are	VBP	O
spiritually	RB	O
based	VBN	O
in	IN	O
nature	NN	O
.	.	O

OBJECTIVE	CC	O
The	DT	O
aims	NNS	O
of	IN	O
the	DT	O
present	JJ	O
study	NN	O
were	VBD	O
to	TO	O
implement	VB	O
and	CC	O
provide	VB	O
an	DT	O
initial	JJ	O
evaluation	NN	O
of	IN	O
a	DT	O
spiritually	RB	O
based	VBN	O
prostate	NN	O
cancer	NN	O
screening	VBG	O
informed	JJ	O
decision	NN	O
making	VBG	O
intervention	NN	O
for	IN	O
African-American	JJ	O
men	NNS	SE
who	WP	O
attend	VBP	O
church	NN	O
,	,	O
and	CC	O
determine	VB	O
its	PRP$	O
efficacy	NN	O
for	IN	O
increasing	VBG	O
informed	JJ	O
decision	NN	O
making	NN	O
.	.	O

DESIGN	NNP	O
AND	CC	O
METHOD	NNP	O
Churches	NNP	O
were	VBD	O
randomized	VBN	O
to	TO	O
receive	VB	O
either	CC	O
the	DT	O
spiritually	RB	O
based	VBN	O
or	CC	O
the	DT	O
non-spiritual	JJ	O
intervention	NN	O
.	.	O

Trained	NNP	O
community	NN	O
health	NN	O
advisors	NNS	O
,	,	O
who	WP	O
were	VBD	O
African-American	JJ	O
male	JJ	O
church	NN	O
members	NNS	O
,	,	O
led	VBD	O
an	DT	O
educational	JJ	O
session	NN	O
and	CC	O
distributed	VBD	O
educational	JJ	O
print	NN	O
materials	NNS	O
.	.	O

Participants	NNS	O
completed	VBD	O
baseline	NN	O
and	CC	O
immediate	JJ	O
follow-up	JJ	O
surveys	NNS	O
to	TO	O
assess	VB	O
the	DT	O
intervention	NN	O
impact	NN	O
on	IN	O
study	NN	O
outcomes	NNS	O
.	.	O

RESULTS	VB	O
The	DT	O
spiritually	RB	O
based	VBN	O
intervention	NN	O
appeared	VBD	O
to	TO	O
be	VB	O
more	RBR	O
effective	JJ	O
in	IN	O
areas	NNS	O
such	JJ	O
as	IN	O
knowledge	NN	O
,	,	O
and	CC	O
men	NNS	O
read	VBP	O
more	JJR	O
of	IN	O
their	PRP$	O
materials	NNS	O
in	IN	O
the	DT	O
spiritually	RB	O
based	VBN	O
group	NN	O
than	IN	O
in	IN	O
the	DT	O
non-spiritual	JJ	O
group	NN	O
.	.	O

CONCLUSIONS	NNP	O
Further	NNP	O
examination	NN	O
of	IN	O
the	DT	O
efficacy	NN	O
of	IN	O
the	DT	O
spiritually	RB	O
based	VBN	O
approach	NN	O
to	TO	O
health	NN	O
communication	NN	O
is	VBZ	O
warranted	VBN	O
.	.	O

Effects	NNS	O
of	IN	O
mild	JJ	O
physical	JJ	O
exercise	NN	O
on	IN	O
serum	NN	O
lipoproteins	NNS	O
and	CC	O
metabolites	NNS	O
of	IN	O
arachidonic	JJ	O
acid	NN	O
:	:	O
a	DT	O
controlled	VBN	O
randomised	JJ	O
trial	NN	O
in	IN	O
middle	JJ	A
aged	VBN	A
men	NNS	SE
.	.	O

To	TO	O
study	VB	O
the	DT	O
effects	NNS	O
of	IN	O
physical	JJ	O
exercise	NN	O
on	IN	O
biochemical	JJ	O
risk	NN	O
factors	NNS	O
for	IN	O
ischaemic	JJ	O
heart	NN	O
disease	NN	O
31	CD	SS
healthy	JJ	C
middle	NNS	O
aged	VBN	O
men	NNS	O
undertook	IN	O
regular	JJ	O
physical	JJ	O
exercise	NN	O
for	IN	O
two	CD	O
months	NNS	O
and	CC	O
29	CD	O
served	VBD	O
as	IN	O
controls	NNS	O
in	IN	O
a	DT	O
randomised	JJ	O
trial	NN	O
.	.	O

In	IN	O
the	DT	O
men	NNS	O
taking	VBG	O
regular	JJ	O
exercise	NN	O
serum	NN	O
cholesterol	NN	O
concentrations	NNS	O
increased	VBD	O
26	CD	O
%	NN	O
more	JJR	O
in	IN	O
the	DT	O
high	JJ	O
density	NN	O
lipoprotein	VBP	O
subfraction	NN	O
two	CD	O
(	(	O
HDL2	NNP	O
)	)	O
and	CC	O
decreased	VBD	O
31	CD	O
%	NN	O
more	JJR	O
in	IN	O
the	DT	O
subfraction	NN	O
three	CD	O
(	(	O
HDL3	NNP	O
)	)	O
and	CC	O
9	CD	O
%	NN	O
more	JJR	O
in	IN	O
the	DT	O
low	JJ	O
density	NN	O
lipoprotein	NN	O
fraction	NN	O
than	IN	O
in	IN	O
the	DT	O
control	NN	O
group	NN	O
.	.	O

A	DT	O
tendency	NN	O
towards	NNS	O
increased	VBD	O
plasma	JJ	O
6-keto-prostaglandin	JJ	O
F1	NNP	O
alpha	NN	O
concentration	NN	O
and	CC	O
decreased	VBD	O
serum	NN	O
thromboxane	NN	O
B2	NNP	O
concentration	NN	O
was	VBD	O
found	VBN	O
during	IN	O
the	DT	O
period	NN	O
of	IN	O
regular	JJ	O
exercise	NN	O
,	,	O
but	CC	O
prostaglandin	VBP	O
E2	NNP	O
concentrations	NNS	O
remained	VBD	O
unchanged	JJ	O
.	.	O

The	DT	O
increase	NN	O
in	IN	O
plasma	JJ	O
6-keto-prostaglandin	JJ	O
F1	NNP	O
alpha	NN	O
concentration	NN	O
was	VBD	O
associated	VBN	O
with	IN	O
an	DT	O
increase	NN	O
in	IN	O
serum	JJ	O
HDL2	NNP	O
cholesterol	NN	O
concentration	NN	O
in	IN	O
the	DT	O
group	NN	O
taking	VBG	O
regular	JJ	O
exercise	NN	O
.	.	O

Our	PRP$	O
data	NNS	O
suggest	VBP	O
that	IN	O
mild	JJ	O
regular	JJ	O
physical	JJ	O
exercise	NN	O
favourably	RB	O
influences	VBZ	O
cholesterol	NN	O
distribution	NN	O
in	IN	O
serum	NN	O
lipoproteins	NNS	O
in	IN	O
healthy	JJ	O
middle	NN	O
aged	VBN	O
men	NNS	O
and	CC	O
may	MD	O
have	VB	O
beneficial	JJ	O
effects	NNS	O
on	IN	O
circulating	VBG	O
metabolites	NNS	O
of	IN	O
arachidonic	JJ	O
acid	NN	O
.	.	O

Differences	NNS	O
in	IN	O
reach	NN	O
and	CC	O
attrition	NN	O
between	IN	O
Web-based	JJ	O
and	CC	O
print-delivered	JJ	O
tailored	JJ	O
interventions	NNS	O
among	IN	O
adults	NNS	A
over	IN	A
50	CD	A
years	NNS	A
of	IN	A
age	NN	A
:	:	O
clustered	VBN	O
randomized	JJ	O
trial	NN	O
.	.	O

BACKGROUND	VB	O
The	DT	O
Internet	NNP	O
has	VBZ	O
the	DT	O
potential	JJ	O
to	TO	O
provide	VB	O
large	JJ	O
populations	NNS	O
with	IN	O
individual	JJ	O
health	NN	O
promotion	NN	O
advice	NN	O
at	IN	O
a	DT	O
relatively	RB	O
low	JJ	O
cost	NN	O
.	.	O

Despite	IN	O
the	DT	O
high	JJ	O
rates	NNS	O
of	IN	O
Internet	NNP	O
access	NN	O
,	,	O
actual	JJ	O
reach	NN	O
by	IN	O
Web-based	JJ	O
interventions	NNS	O
is	VBZ	O
often	RB	O
disappointingly	RB	O
low	JJ	O
,	,	O
and	CC	O
differences	NNS	O
in	IN	O
use	NN	O
between	IN	O
demographic	JJ	O
subgroups	NNS	O
are	VBP	O
present	JJ	O
.	.	O

Furthermore	RB	O
,	,	O
Web-based	JJ	O
interventions	NNS	O
often	RB	O
have	VBP	O
to	TO	O
deal	VB	O
with	IN	O
high	JJ	O
rates	NNS	O
of	IN	O
attrition	NN	O
.	.	O

OBJECTIVE	CC	O
This	DT	O
study	NN	O
aims	VBZ	O
to	TO	O
assess	VB	O
user	JJ	O
characteristics	NNS	O
related	VBN	O
to	TO	O
participation	NN	O
and	CC	O
attrition	NN	O
when	WRB	O
comparing	VBG	O
Web-based	JJ	O
and	CC	O
print-delivered	JJ	O
tailored	JJ	O
interventions	NNS	O
containing	VBG	O
similar	JJ	O
content	NN	O
and	CC	O
thereby	RB	O
to	TO	O
provide	VB	O
recommendations	NNS	O
in	IN	O
choosing	VBG	O
the	DT	O
appropriate	JJ	O
delivery	NN	O
mode	NN	O
for	IN	O
a	DT	O
particular	JJ	O
target	NN	O
audience	NN	O
.	.	O

METHODS	NNP	O
We	PRP	O
studied	VBD	O
the	DT	O
distribution	NN	O
of	IN	O
a	DT	O
Web-based	JJ	O
and	CC	O
a	DT	O
print-delivered	JJ	O
version	NN	O
of	IN	O
the	DT	O
Active	NNP	O
Plus	NNP	O
intervention	NN	O
in	IN	O
a	DT	O
clustered	JJ	O
randomized	NN	O
controlled	VBN	O
trial	NN	O
(	(	O
RCT	NNP	O
)	)	O
.	.	O

Participants	NNS	O
were	VBD	O
recruited	VBN	O
via	IN	O
direct	JJ	O
mailing	NN	O
within	IN	O
the	DT	O
participating	VBG	O
Municipal	NNP	O
Health	NNP	O
Council	NNP	O
regions	NNS	O
and	CC	O
randomized	VBN	O
to	TO	O
the	DT	O
printed	VBN	O
or	CC	O
Web-based	VBN	O
intervention	NN	O
by	IN	O
their	PRP$	O
region	NN	O
.	.	O

Based	VBN	O
on	IN	O
the	DT	O
answers	NNS	O
given	VBN	O
in	IN	O
a	DT	O
prior	JJ	O
assessment	NN	O
,	,	O
participants	NNS	O
received	VBD	O
tailored	JJ	O
advice	NN	O
on	IN	O
3	CD	O
occasions	NNS	O
:	:	O
(	(	O
1	CD	O
)	)	O
within	IN	O
2	CD	O
weeks	NNS	O
after	IN	O
the	DT	O
baseline	NN	O
,	,	O
(	(	O
2	CD	O
)	)	O
2	CD	O
months	NNS	O
after	IN	O
the	DT	O
baseline	NN	O
,	,	O
and	CC	O
(	(	O
3	CD	O
)	)	O
within	IN	O
4	CD	O
months	NNS	O
after	IN	O
the	DT	O
baseline	NN	O
(	(	O
based	VBN	O
on	IN	O
a	DT	O
second	JJ	O
assessment	NN	O
at	IN	O
3	CD	O
months	NNS	O
)	)	O
.	.	O

The	DT	O
baseline	NN	O
(	(	O
printed	VBN	O
or	CC	O
Web-based	VBN	O
)	)	O
results	NNS	O
were	VBD	O
analyzed	JJ	O
using	VBG	O
ANOVA	NNP	O
and	CC	O
chi-square	JJ	O
tests	NNS	O
to	TO	O
establish	VB	O
the	DT	O
differences	NNS	O
in	IN	O
user	JJ	O
characteristics	NNS	O
between	IN	O
both	DT	O
intervention	NN	O
groups	NNS	O
.	.	O

We	PRP	O
used	VBD	O
logistic	JJ	O
regression	NN	O
analyses	NNS	O
to	TO	O
study	VB	O
the	DT	O
interaction	NN	O
between	IN	O
the	DT	O
user	NN	O
characteristics	NNS	O
and	CC	O
the	DT	O
delivery	NN	O
mode	NN	O
in	IN	O
the	DT	O
prediction	NN	O
of	IN	O
dropout	NN	O
rate	NN	O
within	IN	O
the	DT	O
intervention	NN	O
period	NN	O
.	.	O

RESULTS	VB	O
The	DT	O
printed	JJ	O
intervention	NN	O
resulted	VBD	O
in	IN	O
a	DT	O
higher	JJR	O
participation	NN	O
rate	NN	O
(	(	O
19	CD	O
%	NN	O
)	)	O
than	IN	O
the	DT	O
Web-based	JJ	O
intervention	NN	O
(	(	O
12	CD	O
%	NN	O
)	)	O
.	.	O

Participants	NNS	O
of	IN	O
the	DT	O
Web-based	JJ	O
intervention	NN	O
were	VBD	O
significantly	RB	O
younger	JJR	O
(	(	O
P	NNP	O
<	NNP	O
.001	NNP	O
)	)	O
,	,	O
more	RBR	O
often	RB	O
men	NNS	O
(	(	O
P=.01	NNP	O
)	)	O
,	,	O
had	VBD	O
a	DT	O
higher	JJR	O
body	NN	O
mass	NN	O
index	NN	O
(	(	O
BMI	NNP	O
)	)	O
(	(	O
P=.001	NNP	O
)	)	O
and	CC	O
a	DT	O
lower	JJR	O
intention	NN	O
to	TO	O
be	VB	O
physically	RB	O
active	JJ	O
(	(	O
P=.03	NNP	O
)	)	O
than	IN	O
participants	NNS	O
of	IN	O
the	DT	O
printed	VBN	O
intervention	NN	O
.	.	O

The	DT	O
dropout	NN	O
rate	NN	O
was	VBD	O
significantly	RB	O
higher	JJR	O
in	IN	O
the	DT	O
Web-based	JJ	O
intervention	NN	O
group	NN	O
(	(	O
53	CD	O
%	NN	O
)	)	O
compared	VBN	O
to	TO	O
the	DT	O
print-delivered	JJ	O
intervention	NN	O
(	(	O
39	CD	O
%	NN	O
,	,	O
P	NNP	O
<	NNP	O
.001	NNP	O
)	)	O
.	.	O

A	DT	O
low	JJ	O
intention	NN	O
to	TO	O
be	VB	O
physically	RB	O
active	JJ	O
was	VBD	O
a	DT	O
strong	JJ	O
predictor	NN	O
for	IN	O
dropout	NN	O
within	IN	O
both	DT	O
delivery	NN	O
modes	FW	O
(	(	O
P	NNP	O
<	NNP	O
.001	NNP	O
)	)	O
.	.	O

The	DT	O
difference	NN	O
in	IN	O
dropout	NN	O
rate	NN	O
between	IN	O
the	DT	O
Web-based	JJ	O
and	CC	O
the	DT	O
printed	JJ	O
intervention	NN	O
was	VBD	O
not	RB	O
explained	VBN	O
by	IN	O
user	JJ	O
characteristics	NNS	O
.	.	O

CONCLUSIONS	VB	O
The	DT	O
reach	NN	O
of	IN	O
the	DT	O
same	JJ	O
tailored	JJ	O
physical	JJ	O
activity	NN	O
(	(	O
PA	NNP	O
)	)	O
intervention	NN	O
in	IN	O
a	DT	O
printed	JJ	O
or	CC	O
Web-based	JJ	O
delivery	NN	O
mode	NN	O
differed	VBD	O
between	IN	O
sociodemographic	JJ	O
subgroups	NNS	O
of	IN	O
participants	NNS	O
over	IN	O
50	CD	O
years	NNS	O
of	IN	O
age	NN	O
.	.	O

Although	IN	O
the	DT	O
reach	NN	O
of	IN	O
the	DT	O
Web-based	JJ	O
intervention	NN	O
is	VBZ	O
lower	JJR	O
,	,	O
Web-based	JJ	O
interventions	NNS	O
can	MD	O
be	VB	O
a	DT	O
good	JJ	O
channel	NN	O
to	TO	O
reach	VB	O
high-risk	JJ	O
populations	NNS	O
(	(	O
lower	JJR	O
PA	NNP	O
intention	NN	O
and	CC	O
higher	JJR	O
BMI	NNP	O
)	)	O
.	.	O

While	IN	O
the	DT	O
dropout	NN	O
rate	NN	O
was	VBD	O
significantly	RB	O
higher	JJR	O
in	IN	O
the	DT	O
Web-based	JJ	O
intervention	NN	O
group	NN	O
,	,	O
no	DT	O
specific	JJ	O
user	NN	O
characteristics	NNS	O
explained	VBD	O
the	DT	O
difference	NN	O
in	IN	O
dropout	NN	O
rates	NNS	O
between	IN	O
the	DT	O
delivery	NN	O
modes	NN	O
.	.	O

More	JJR	O
research	NN	O
is	VBZ	O
needed	VBN	O
to	TO	O
determine	VB	O
what	WP	O
caused	VBD	O
the	DT	O
high	JJ	O
rate	NN	O
of	IN	O
dropout	NN	O
in	IN	O
the	DT	O
Web-based	JJ	O
intervention	NN	O
.	.	O

TRIAL	NNP	O
REGISTRATION	NNP	O
Dutch	NNP	O
Trial	NNP	O
Register	NNP	O
(	(	O
NTR	NNP	O
)	)	O
:	:	O
2297	CD	O
:	:	O
http	NN	O
:	:	O
//www.trialregister.nl/trialreg/admin/rctview.asp	NN	O
?	.	O
TC=2297	NNP	O
(	(	O
Archived	VBN	O
by	IN	O
WebCite	NNP	O
at	IN	O
http	NN	O
:	:	O
//www.webcitation.org/65TkwoESp	NN	O
)	)	O
.	.	O

Effect	NN	O
of	IN	O
ranolazine	NN	O
on	IN	O
A1C	NNP	O
and	CC	O
glucose	JJ	O
levels	NNS	O
in	IN	O
hyperglycemic	JJ	C
patients	NNS	C
with	IN	O
non-ST	JJ	O
elevation	NN	O
acute	NN	C
coronary	JJ	C
syndrome	NN	C
.	.	O

OBJECTIVE	IN	O
We	PRP	O
determined	VBD	O
the	DT	O
relationships	NNS	O
between	IN	O
glycemia	NN	O
at	IN	O
randomization	NN	O
,	,	O
concurrent	JJ	O
antidiabetic	JJ	O
therapy	NN	O
,	,	O
and	CC	O
change	NN	O
in	IN	O
A1C	NNP	O
and	CC	O
fasting	VBG	O
plasma	NN	O
glucose	NN	O
(	(	O
FPG	NNP	O
)	)	O
in	IN	O
patients	NNS	O
with	IN	O
diabetes	NNS	O
receiving	VBG	O
standard	JJ	O
treatment	NN	O
for	IN	O
diabetes	NNS	O
and	CC	O
randomized	VBN	O
to	TO	O
ranolazine	VB	O
or	CC	O
placebo	VB	O
within	IN	O
the	DT	O
MERLIN-TIMI-36	NNP	O
(	(	O
MERLIN	NNP	O
)	)	O
study	NN	O
.	.	O

Ranolazine	NNP	O
is	VBZ	O
a	DT	O
novel	JJ	O
first-in-class	JJ	O
drug	NN	O
approved	VBD	O
for	IN	O
treating	VBG	O
angina	JJ	O
pectoris	NN	O
.	.	O

RESEARCH	NNP	O
DESIGN	NNP	O
AND	NNP	O
METHODS	NNP	O
Randomization	NNP	O
and	CC	O
4-month	JJ	O
glycemic	NN	O
and	CC	O
antidiabetes	VBZ	O
drug	NN	O
usage	NN	O
data	NNS	O
from	IN	O
MERLIN	NNP	O
were	VBD	O
analyzed	VBN	O
using	VBG	O
Spotfire	NNP	O
and	CC	O
SAS	NNP	O
version	NN	O
9.1	CD	O
software	NN	O
.	.	O

RESULTS	NNP	O
In	IN	O
patients	NNS	O
with	IN	O
diabetes	NNS	O
and	CC	O
A1C	NNP	O
of	IN	O
>	NNP	O
or=8-10	JJ	O
%	NN	O
at	IN	O
randomization	NN	O
(	(	O
n	JJ	O
=	NNP	O
171	CD	O
)	)	O
,	,	O
there	EX	O
was	VBD	O
an	DT	O
absolute	JJ	O
A1C	NNP	O
reduction	NN	O
in	IN	O
the	DT	O
ranolazine	NN	O
group	NN	O
of	IN	O
1.2	CD	O
%	NN	O
(	(	O
95	CD	O
%	NN	O
CI	NNP	O
-1.4	NNP	O
to	TO	O
-1.0	VB	O
)	)	O
,	,	O
and	CC	O
the	DT	O
placebo-adjusted	JJ	O
(	(	O
n	JJ	O
=	NNP	O
182	CD	O
)	)	O
decrease	NN	O
in	IN	O
A1C	NNP	O
by	IN	O
ranolazine	NN	O
was	VBD	O
0.59	CD	O
%	NN	O
(	(	O
95	CD	O
%	NN	O
CI	NNP	O
-0.99	NNP	O
to	TO	O
-0.20	VB	O
,	,	O
P	NNP	O
<	NNP	O
0.001	CD	O
)	)	O
.	.	O

In	IN	O
patients	NNS	O
with	IN	O
FPG	NNP	O
of	IN	O
150-400	JJ	O
mg/dl	NN	O
at	IN	O
randomization	NN	O
,	,	O
ranolazine	NN	O
(	(	O
n	JJ	O
=	NNP	O
131	CD	O
)	)	O
compared	VBN	O
with	IN	O
placebo	NN	O
(	(	O
n	JJ	O
=	NNP	O
147	CD	O
)	)	O
reduced	VBN	O
FPG	NNP	O
by	IN	O
25.7	CD	O
mg/dl	NNS	O
(	(	O
95	CD	O
%	NN	O
CI	NNP	O
-43.3	NNP	O
to	TO	O
-8.1	VB	O
,	,	O
P	NNP	O
=	NNP	O
0.001	CD	O
)	)	O
.	.	O

When	WRB	O
changes	NNS	O
in	IN	O
either	DT	O
A1C	NNP	O
or	CC	O
FPG	NNP	O
were	VBD	O
correlated	VBN	O
to	TO	O
A1C	NNP	O
or	CC	O
FPG	NNP	O
at	IN	O
randomization	NN	O
,	,	O
the	DT	O
slopes	NNS	O
were	VBD	O
significantly	RB	O
steeper	JJR	O
for	IN	O
ranolazine	NN	O
than	IN	O
placebo	NN	O
(	(	O
A1C	NNP	O
,	,	O
P	NNP	O
=	NNP	O
0.046	CD	O
;	:	O
FPG	NNP	O
,	,	O
P	NNP	O
<	NNP	O
0.001	CD	O
)	)	O
,	,	O
indicating	VBG	O
that	IN	O
lowering	VBG	O
of	IN	O
A1C	NNP	O
and	CC	O
FPG	NNP	O
by	IN	O
ranolazine	NN	O
is	VBZ	O
related	VBN	O
to	TO	O
hyperglycemia	VB	O
at	IN	O
randomization	NN	O
.	.	O

Ranolazine	NNP	O
,	,	O
compared	VBN	O
with	IN	O
placebo	NN	O
,	,	O
was	VBD	O
not	RB	O
associated	VBN	O
with	IN	O
serious	JJ	O
hypoglycemic	JJ	O
events	NNS	O
,	,	O
associated	VBN	O
with	IN	O
significant	JJ	O
changes	NNS	O
in	IN	O
concurrent	JJ	O
antidiabetic	JJ	O
therapy	NN	O
,	,	O
or	CC	O
dependent	NN	O
on	IN	O
a	DT	O
history	NN	O
of	IN	O
angina	NN	O
.	.	O

CONCLUSIONS	NNP	O
Ranolazine	NNP	O
,	,	O
when	WRB	O
added	VBN	O
to	TO	O
concurrent	VB	O
antidiabetes	NNS	O
treatment	NN	O
,	,	O
lowers	NNS	O
FPG	NNP	O
and	CC	O
A1C	NNP	O
in	IN	O
patients	NNS	O
with	IN	O
cardiovascular	JJ	O
disease	NN	O
and	CC	O
poorly	RB	O
controlled	VBN	O
diabetes	NNS	O
.	.	O

Treating	VBG	O
the	DT	O
substance-abusing	JJ	C
suicidal	JJ	C
patient	NN	O
.	.	O

Studies	NNPS	O
concerning	VBG	O
the	DT	O
treatment	NN	O
of	IN	O
substance-abusing	JJ	C
suicidal	NN	C
patients	NNS	O
are	VBP	O
scarce	JJ	O
despite	IN	O
the	DT	O
frequent	JJ	O
presence	NN	O
of	IN	O
suicidal	JJ	O
behavior	NN	O
among	IN	O
this	DT	O
population	NN	O
.	.	O

Indeed	RB	O
,	,	O
suicidality	NN	O
(	(	O
ideation	NN	O
or	CC	O
behavior	NN	O
)	)	O
is	VBZ	O
generally	RB	O
an	DT	O
exclusion	NN	O
criterion	NN	O
for	IN	O
participation	NN	O
in	IN	O
treatment	NN	O
studies	NNS	O
of	IN	O
subjects	NNS	O
with	IN	O
alcohol	NN	C
or	CC	C
drug	NN	C
abuse	NN	C
.	.	O

Consequently	RB	O
,	,	O
to	TO	O
date	NN	O
,	,	O
little	JJ	O
is	VBZ	O
known	VBN	O
about	IN	O
the	DT	O
optimal	JJ	O
treatment	NN	O
of	IN	O
this	DT	O
population	NN	O
.	.	O

The	DT	O
first	JJ	O
study	NN	O
involving	VBG	O
substance-abusing	JJ	C
suicidal	JJ	C
patients	NNS	O
was	VBD	O
an	DT	O
open-label	JJ	O
trial	NN	O
conducted	VBN	O
in	IN	O
the	DT	O
early	JJ	O
1990s	CD	O
.	.	O

This	DT	O
study	NN	O
involved	VBD	O
12	CD	SS
patients	NNS	O
,	,	O
all	DT	O
of	IN	O
whom	WP	O
demonstrated	VBD	O
recent	JJ	C
suicidal	JJ	C
ideations	NNS	C
and	CC	O
had	VBD	C
made	VBN	C
a	DT	C
lifetime	NN	C
suicide	NN	C
attempt	NN	C
.	.	O

The	DT	O
results	NNS	O
of	IN	O
that	DT	O
open-label	JJ	O
study	NN	O
demonstrated	VBD	O
significant	JJ	O
within-group	JJ	O
improvement	NN	O
in	IN	O
both	DT	O
depressive	JJ	O
symptoms	NNS	O
(	(	O
including	VBG	O
suicidal	JJ	O
ideations	NNS	O
)	)	O
and	CC	O
level	NN	O
of	IN	O
drinking	NN	O
.	.	O

However	RB	O
,	,	O
substantial	JJ	O
residual	JJ	O
depressive	NN	O
symptoms	NNS	O
and	CC	O
drinking	NN	O
persisted	VBN	O
at	IN	O
the	DT	O
end	NN	O
of	IN	O
the	DT	O
trial	NN	O
.	.	O

Also	RB	O
,	,	O
because	IN	O
no	DT	O
placebo	NN	O
control	NN	O
group	NN	O
was	VBD	O
utilized	VBN	O
,	,	O
the	DT	O
authors	NNS	O
of	IN	O
that	DT	O
study	NN	O
could	MD	O
not	RB	O
rule	VB	O
out	IN	O
the	DT	O
possibility	NN	O
that	IN	O
the	DT	O
apparent	JJ	O
therapeutic	JJ	O
effect	NN	O
from	IN	O
fluoxetine	NN	O
was	VBD	O
the	DT	O
result	NN	O
of	IN	O
the	DT	O
placebo	NN	O
effect	NN	O
.	.	O

To	TO	O
date	NN	O
,	,	O
only	RB	O
one	CD	O
double-blind	NN	O
,	,	O
placebo-controlled	JJ	O
study	NN	O
of	IN	O
subjects	NNS	O
with	IN	O
alcohol	NN	C
or	CC	C
substance	NN	C
abuse	NN	C
has	VBZ	O
included	VBN	O
substantial	JJ	O
numbers	NNS	O
of	IN	O
suicidal	JJ	O
patients	NNS	O
.	.	O

The	DT	O
study	NN	O
involved	VBD	O
51	CD	SS
subjects	NNS	O
,	,	O
of	IN	O
whom	WP	O
20	CD	SS
(	(	O
39	CD	O
%	NN	O
)	)	O
had	VBD	O
made	VBN	O
a	DT	O
suicide	JJ	C
attempt	NN	C
in	IN	C
the	DT	C
current	JJ	C
depressive	JJ	C
episode	NN	C
,	,	O
31	CD	SS
(	(	O
61	CD	O
%	NN	O
)	)	O
had	VBD	O
made	VBN	O
a	DT	O
suicide	JJ	C
attempt	NN	C
in	IN	C
their	PRP$	C
lifetime	NN	C
,	,	O
and	CC	O
46	CD	SS
(	(	O
90	CD	O
%	NN	O
)	)	O
had	VBD	O
reported	VBN	O
suicidal	JJ	C
ideations	NNS	C
in	IN	O
the	DT	O
week	NN	O
before	IN	O
hospitalization	NN	O
.	.	O

The	DT	O
results	NNS	O
of	IN	O
that	DT	O
double-blind	NN	O
,	,	O
placebo-controlled	JJ	O
study	NN	O
suggest	VBP	O
that	IN	O
fluoxetine	NN	O
was	VBD	O
effective	JJ	O
in	IN	O
decreasing	VBG	O
but	CC	O
not	RB	O
eliminating	VBG	O
both	CC	O
the	DT	O
depressive	NN	O
symptoms	NNS	O
(	(	O
including	VBG	O
suicidal	JJ	O
ideations	NNS	O
)	)	O
and	CC	O
the	DT	O
level	NN	O
of	IN	O
alcohol	JJ	O
consumption	NN	O
among	IN	O
a	DT	O
study	NN	O
group	NN	O
of	IN	O
subjects	NNS	O
with	IN	O
comorbid	NN	O
major	JJ	O
depressive	JJ	O
disorder	NN	O
and	CC	O
alcohol	NN	O
dependence	NN	O
,	,	O
many	JJ	O
of	IN	O
whom	WP	O
displayed	VBD	O
suicidal	JJ	O
ideations	NNS	O
.	.	O

A	DT	O
secondary	JJ	O
data	NN	O
analysis	NN	O
from	IN	O
that	DT	O
study	NN	O
suggested	VBD	O
that	IN	O
cigarette	NN	O
smoking	NN	O
is	VBZ	O
also	RB	O
significantly	RB	O
decreased	VBN	O
by	IN	O
fluoxetine	NN	O
,	,	O
but	CC	O
the	DT	O
magnitude	NN	O
of	IN	O
the	DT	O
decrease	NN	O
is	VBZ	O
limited	JJ	O
and	CC	O
few	JJ	O
of	IN	O
these	DT	O
patients	NNS	O
totally	RB	O
quit	VBP	O
smoking	VBG	O
with	IN	O
fluoxetine	JJ	O
treatment	NN	O
alone	RB	O
.	.	O

Another	DT	O
secondary	JJ	O
data	NN	O
analysis	NN	O
from	IN	O
that	DT	O
study	NN	O
suggested	VBD	O
that	IN	O
marijuana	NN	O
smoking	NN	O
was	VBD	O
also	RB	O
significantly	RB	O
decreased	VBN	O
in	IN	O
a	DT	O
subgroup	NN	O
of	IN	O
subjects	NNS	O
who	WP	O
demonstrated	VBD	O
cannabis	NN	O
abuse	NN	O
and	CC	O
that	IN	O
the	DT	O
magnitude	NN	O
of	IN	O
this	DT	O
improvement	NN	O
was	VBD	O
robust	JJ	O
.	.	O

A	DT	O
third	JJ	O
secondary	JJ	O
data	NNS	O
analysis	NN	O
from	IN	O
that	DT	O
study	NN	O
suggested	VBD	O
that	IN	O
cocaine	NN	O
abuse	NN	O
acts	VBZ	O
as	IN	O
a	DT	O
predictor	NN	O
of	IN	O
poor	JJ	O
outcome	NN	O
for	IN	O
both	DT	O
depressive	JJ	O
symptoms	NNS	O
(	(	O
including	VBG	O
suicidality	NN	O
)	)	O
and	CC	O
level	NN	O
of	IN	O
alcohol	NN	O
use	NN	O
in	IN	O
this	DT	O
population	NN	O
.	.	O

The	DT	O
results	NNS	O
of	IN	O
a	DT	O
1-year	JJ	O
naturalistic	JJ	O
follow-up	NN	O
study	NN	O
involving	VBG	O
the	DT	O
patients	NNS	O
from	IN	O
that	DT	O
study	NN	O
suggest	VBP	O
that	IN	O
the	DT	O
benefits	NNS	O
of	IN	O
fluoxetine	NN	O
in	IN	O
decreasing	VBG	O
depressive	JJ	O
symptoms	NNS	O
and	CC	O
level	NN	O
of	IN	O
drinking	VBG	O
persist	NN	O
1	CD	O
year	NN	O
after	IN	O
entering	VBG	O
the	DT	O
treatment	NN	O
program	NN	O
.	.	O

To	TO	O
date	NN	O
,	,	O
no	DT	O
other	JJ	O
double-blind	NN	O
,	,	O
placebo-controlled	JJ	O
studies	NNS	O
involving	VBG	O
substantial	JJ	O
numbers	NNS	O
of	IN	O
substance-abusing	JJ	C
suicidal	NN	C
patients	NNS	O
have	VBP	O
been	VBN	O
reported	VBN	O
to	TO	O
either	DT	O
confirm	NN	O
or	CC	O
refute	VB	O
these	DT	O
findings	NNS	O
.	.	O

Further	JJ	O
studies	NNS	O
are	VBP	O
clearly	RB	O
warranted	VBN	O
to	TO	O
evaluate	VB	O
the	DT	O
efficacy	NN	O
of	IN	O
various	JJ	O
pharmacotherapeutic	JJ	O
agents	NNS	O
and	CC	O
various	JJ	O
psychotherapies	NNS	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
substance-abusing	JJ	C
suicidal	JJ	C
patients	NNS	O
.	.	O

The	DT	O
effects	NNS	O
of	IN	O
peer	NN	O
counseling	VBG	O
on	IN	O
smoking	VBG	O
cessation	NN	O
and	CC	O
reduction	NN	O
.	.	O

OBJECTIVE	UH	O
To	TO	O
evaluate	VB	O
a	DT	O
peer	NN	O
counseling	VBG	O
intervention	NN	O
for	IN	O
pregnant	JJ	C
smokers	NNS	C
.	.	O

METHODS	NNP	O
One	CD	SS
hundred	VBD	SS
forty-two	NN	SS
pregnant	NN	O
,	,	O
predominantly	RB	O
Hispanic	JJ	O
women	NNS	SE
were	VBD	O
assigned	VBN	O
to	TO	O
a	DT	O
peer-led	JJ	O
smoking	NN	O
cessation	NN	O
program	NN	O
or	CC	O
to	TO	O
usual	JJ	O
care	NN	O
.	.	O

RESULTS	NNP	O
Compared	VBD	O
with	IN	O
usual	JJ	O
care	NN	O
,	,	O
peer	NN	O
counseling	NN	O
reduced	VBN	O
smoking	NN	O
(	(	O
-9.1	JJ	O
versus	NN	O
-4.5	NNP	O
cigarettes	VBZ	O
daily	RB	O
,	,	O
P	NNP	O
=.03	NNP	O
)	)	O
,	,	O
but	CC	O
did	VBD	O
not	RB	O
affect	VB	O
absolute	JJ	O
quit	NN	O
rates	NNS	O
(	(	O
24	CD	O
%	NN	O
versus	IN	O
21	CD	O
%	NN	O
)	)	O
at	IN	O
36	CD	O
weeks	NNS	O
'	POS	O
gestation	NN	O
.	.	O

Infant	NNP	O
birth	NN	O
weight	VBD	O
negatively	RB	O
correlated	VBN	O
with	IN	O
cigarettes	NNS	O
smoked	VBN	O
per	IN	O
day	NN	O
(	(	O
r	VB	O
=	NNP	O
-0.29	NNP	O
,	,	O
P	NNP	O
<	NNP	O
.01	NNP	O
)	)	O
and	CC	O
expired	JJ	O
carbon	NN	O
monoxide	NN	O
(	(	O
r	JJ	O
=	NNP	O
-0.39	NN	O
,	,	O
(	(	O
P	NNP	O
<	NNP	O
.001	NNP	O
)	)	O
at	IN	O
delivery	NN	O
.	.	O

Birth	NNP	O
weight	VBD	O
for	IN	O
infants	NNS	O
born	VBN	O
to	TO	O
women	NNS	O
who	WP	O
quit	VBP	O
smoking	VBG	O
averaged	VBD	O
7.2	CD	O
lb	JJ	O
versus	NN	O
6.8	CD	O
and	CC	O
6.3	CD	O
lb	NN	O
for	IN	O
mothers	NNS	O
smoking	VBG	O
one	CD	O
to	TO	O
six	CD	O
and	CC	O
more	JJR	O
than	IN	O
six	CD	O
cigarettes	NNS	O
per	IN	O
day	NN	O
at	IN	O
delivery	NN	O
(	(	O
P	NNP	O
<	NNP	O
.01	NNP	O
)	)	O
.	.	O

CONCLUSION	NNP	O
Peer	NNP	O
counseling	NN	O
reduced	VBD	O
the	DT	O
number	NN	O
of	IN	O
cigarettes	NNS	O
smoked	VBN	O
daily	RB	O
but	CC	O
did	VBD	O
not	RB	O
increase	VB	O
cigarette	NN	O
abstinence	NN	O
rates	NNS	O
.	.	O

Infant	NNP	O
birth	NN	O
weight	NN	O
increases	NNS	O
with	IN	O
both	DT	O
smoking	VBG	O
cessation	NN	O
and	CC	O
smoking	NN	O
reduction	NN	O
,	,	O
suggesting	VBG	O
that	IN	O
peer	NN	O
counseling	VBG	O
intervention	NN	O
programs	NNS	O
may	MD	O
improve	VB	O
newborn	JJR	O
health	NN	O
despite	IN	O
their	PRP$	O
failure	NN	O
to	TO	O
affect	VB	O
smoking	VBG	O
cessation	NN	O
.	.	O

Roles	NNS	O
of	IN	O
adapalene	NN	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
pityriasis	NN	C
versicolor	NN	C
.	.	O

BACKGROUND	NNP	O
Ketoconazole	NNP	O
is	VBZ	O
a	DT	O
typical	JJ	O
treatment	NN	O
available	JJ	O
for	IN	O
pityriasis	NN	C
versicolor	NN	C
;	:	O
tretinoin	CC	O
cream	NN	O
is	VBZ	O
effective	JJ	O
,	,	O
too	RB	O
.	.	O

Adapalene	NNP	O
gel	NN	O
is	VBZ	O
a	DT	O
tretinoin	JJ	O
derivative	NN	O
and	CC	O
has	VBZ	O
a	DT	O
lower	JJR	O
incidence	NN	O
of	IN	O
irritation	NN	O
compared	VBN	O
with	IN	O
other	JJ	O
topical	JJ	O
retinoid	NN	O
products	NNS	O
.	.	O

However	RB	O
,	,	O
there	EX	O
are	VBP	O
no	DT	O
reports	NNS	O
on	IN	O
adapalene	NN	O
gel	NN	O
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
pityriasis	NN	C
versicolor	NN	C
.	.	O

OBJECTIVE	UH	O
To	TO	O
study	VB	O
the	DT	O
effect	NN	O
of	IN	O
adapalene	NN	O
gel	NN	O
comparing	VBG	O
the	DT	O
treatment	NN	O
with	IN	O
adapalene	JJ	O
gel	NNS	O
and	CC	O
2	CD	O
%	NN	O
ketoconazole	JJ	O
cream	NN	O
in	IN	O
pityriasis	NN	C
versicolor	NN	C
.	.	O

METHODS	NNP	O
Eighty	NNP	SS
patients	NNS	O
suffering	VBG	O
from	IN	O
pityriasis	NN	C
versicolor	NN	C
were	VBD	O
randomly	RB	O
divided	VBN	O
into	IN	O
two	CD	O
groups	NNS	O
;	:	O
one	CD	O
group	NN	O
were	VBD	O
treated	VBN	O
with	IN	O
2	CD	O
%	NN	O
ketoconazole	JJ	O
cream	NN	O
topically	RB	O
twice	JJ	O
daily	RB	O
for	IN	O
2	CD	O
weeks	NNS	O
,	,	O
adapalene	JJ	O
gel	NN	O
was	VBD	O
used	VBN	O
for	IN	O
the	DT	O
other	JJ	O
group	NN	O
in	IN	O
a	DT	O
similar	JJ	O
fashion	NN	O
.	.	O

RESULTS	CC	O
There	EX	O
were	VBD	O
no	DT	O
significant	JJ	O
differences	NNS	O
in	IN	O
efficacy	NN	O
between	IN	O
the	DT	O
two	CD	O
groups	NNS	O
.	.	O

No	DT	O
major	JJ	O
side	NN	O
effects	NNS	O
were	VBD	O
noted	VBN	O
in	IN	O
any	DT	O
of	IN	O
the	DT	O
groups	NNS	O
either	CC	O
.	.	O

CONCLUSION	NNP	O
Adapalene	NNP	O
was	VBD	O
the	DT	O
favorable	JJ	O
option	NN	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
pityriasis	NN	C
versicolor	NN	C
.	.	O

The	DT	O
probable	JJ	O
therapeutic	JJ	O
mechanism	NN	O
of	IN	O
adapalene	NN	O
is	VBZ	O
also	RB	O
discussed	VBN	O
.	.	O

Beneficial	JJ	O
effects	NNS	O
of	IN	O
a	DT	O
soy-based	JJ	O
dietary	JJ	O
supplement	NN	O
on	IN	O
lipid	JJ	O
levels	NNS	O
and	CC	O
cardiovascular	JJ	O
risk	NN	O
markers	NNS	O
in	IN	O
type	NN	O
2	CD	O
diabetic	JJ	O
subjects	NNS	O
.	.	O

OBJECTIVE	NNP	O
Consumption	NNP	O
of	IN	O
soy	NN	O
protein	NN	O
has	VBZ	O
recently	RB	O
been	VBN	O
shown	VBN	O
to	TO	O
improve	VB	O
the	DT	O
blood	NN	O
lipid	JJ	O
levels	NNS	O
in	IN	O
nondiabetic	JJ	O
subjects	NNS	O
.	.	O

The	DT	O
purpose	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
evaluate	VB	O
if	IN	O
a	DT	O
dietary	JJ	O
supplement	NN	O
of	IN	O
soy	NN	O
protein	NN	O
,	,	O
isoflavones	NNS	O
,	,	O
and	CC	O
cotyledon	VB	O
fiber	NN	O
(	(	O
Abalon	NNP	O
)	)	O
affects	VBZ	O
cardiovascular	JJ	O
risk	NN	O
markers	NNS	O
,	,	O
blood	NN	O
glucose	NN	O
,	,	O
and	CC	O
insulin	NN	O
levels	NNS	O
in	IN	O
type	NN	O
2	CD	O
diabetic	JJ	O
subjects	NNS	O
.	.	O

RESEARCH	NNP	O
DESIGN	NNP	O
AND	NNP	O
METHODS	NNP	O
Twenty	NNP	SS
type	NN	C
2	CD	C
diabetic	JJ	C
subjects	NNS	O
participated	VBN	O
in	IN	O
a	DT	O
crossover	NN	O
trial	NN	O
.	.	O

They	PRP	O
were	VBD	O
randomized	VBN	O
to	TO	O
double-blind	JJ	O
supplementation	NN	O
for	IN	O
6	CD	O
weeks	NNS	O
with	IN	O
Abalon	NNP	O
(	(	O
soy	JJ	O
protein	NN	O
[	VBD	O
50	CD	O
g/day	JJ	O
]	NNP	O
with	IN	O
high	JJ	O
levels	NNS	O
of	IN	O
isoflavones	NNS	O
[	NNP	O
minimum	VBD	O
165	CD	O
mg/day	NN	O
]	NNP	O
and	CC	O
cotyledon	VB	O
fiber	NN	O
[	$	O
20	CD	O
g/day	JJ	O
]	NNPS	O
)	)	O
or	CC	O
placebo	NN	O
(	(	O
casein	JJ	O
[	VBZ	O
50	CD	O
g/day	NN	O
]	NNP	O
and	CC	O
cellulose	VB	O
[	JJ	O
20	CD	O
g/day	JJ	O
]	NNP	O
)	)	O
,	,	O
separated	VBN	O
by	IN	O
a	DT	O
3-week	JJ	O
wash-out	JJ	O
period	NN	O
.	.	O

RESULTS	VB	O
The	DT	O
results	NNS	O
are	VBP	O
expressed	VBN	O
as	IN	O
means	NNS	O
+/-	JJ	O
SD	NNP	O
.	.	O

The	DT	O
percentage	NN	O
mean	JJ	O
treatment	NN	O
difference	NN	O
between	IN	O
Abalon	NNP	O
and	CC	O
placebo	NN	O
demonstrated	VBD	O
significantly	RB	O
lower	JJR	O
mean	NN	O
values	NNS	O
after	IN	O
Abalon	NNP	O
for	IN	O
LDL	NNP	O
cholesterol	NN	O
(	(	O
10	CD	O
+/-	JJ	O
15	CD	O
%	NN	O
,	,	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
,	,	O
LDL/UHDL	NNP	O
ratio	NN	O
(	(	O
12	CD	O
+/-	JJ	O
18	CD	O
%	NN	O
,	,	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
,	,	O
apolipoprotein	RB	O
(	(	O
apo	NN	O
)	)	O
B100	NNP	O
(	(	O
30	CD	O
+/-	JJ	O
38	CD	O
%	NN	O
,	,	O
P	NNP	O
<	NNP	O
0.01	CD	O
)	)	O
,	,	O
triglycerides	NNS	O
(	(	O
22	CD	O
+/-	JJ	O
10	CD	O
%	NN	O
,	,	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
,	,	O
and	CC	O
homocysteine	NN	O
(	(	O
14	CD	O
+/-	JJ	O
21	CD	O
%	NN	O
,	,	O
P	NNP	O
<	NNP	O
0.01	CD	O
)	)	O
,	,	O
whereas	VBD	O
the	DT	O
total	JJ	O
cholesterol	NN	O
value	NN	O
tended	VBD	O
to	TO	O
be	VB	O
less	RBR	O
significant	JJ	O
but	CC	O
still	RB	O
lower	JJR	O
(	(	O
8	CD	O
+/-	JJ	O
15	CD	O
%	NN	O
,	,	O
P	NNP	O
<	NNP	O
0.08	CD	O
)	)	O
.	.	O

No	UH	O
change	NN	O
occurred	VBD	O
in	IN	O
HDL	NNP	O
cholesterol	NN	O
,	,	O
apo	JJ	O
B100/apo	NNP	O
A1	NNP	O
ratio	NN	O
,	,	O
plasminogen	NN	O
activator	NN	O
inhibitor	NN	O
1	CD	O
,	,	O
factor	NN	O
VIIc	NNP	O
,	,	O
von	NNP	O
Willebrand	NNP	O
factor	NN	O
,	,	O
fibrinogen	NN	O
,	,	O
lipoprotein	NN	O
(	(	O
a	DT	O
)	)	O
,	,	O
glucose	JJ	O
,	,	O
HbA1c	NNP	O
,	,	O
or	CC	O
24-h	JJ	O
blood	NN	O
pressure	NN	O
.	.	O

CONCLUSIONS	NNP	O
These	DT	O
results	NNS	O
indicate	VBP	O
beneficial	JJ	O
effects	NNS	O
of	IN	O
dietary	JJ	O
supplementation	NN	O
with	IN	O
Abalon	NNP	O
on	IN	O
cardiovascular	JJ	O
risk	NN	O
markers	NNS	O
in	IN	O
type	NN	O
2	CD	O
diabetic	JJ	O
subjects	NNS	O
.	.	O

This	DT	O
improvement	NN	O
is	VBZ	O
seen	VBN	O
even	RB	O
in	IN	O
individuals	NNS	O
with	IN	O
near-normal	JJ	O
lipid	JJ	O
values	NNS	O
.	.	O

Nasal	NNP	O
oxytocin	MD	O
for	IN	O
social	JJ	O
deficits	NNS	O
in	IN	O
childhood	NN	O
autism	NN	C
:	:	C
a	DT	O
randomized	NN	O
controlled	VBN	O
trial	NN	O
.	.	O

The	DT	O
last	JJ	O
two	CD	O
decades	NNS	O
have	VBP	O
witnessed	VBN	O
a	DT	O
surge	NN	O
in	IN	O
research	NN	O
investigating	VBG	O
the	DT	O
application	NN	O
of	IN	O
oxytocin	NN	O
as	IN	O
a	DT	O
method	NN	O
of	IN	O
enhancing	VBG	O
social	JJ	O
behaviour	NN	O
in	IN	O
humans	NNS	O
.	.	O

Preliminary	JJ	O
evidence	NN	O
suggests	VBZ	O
oxytocin	NN	O
may	MD	O
have	VB	O
potential	NN	O
as	IN	O
an	DT	O
intervention	NN	O
for	IN	O
autism	NN	O
.	.	O

We	PRP	O
evaluated	VBD	O
a	DT	O
5-day	JJ	O
'live-in	NN	O
'	POS	O
intervention	NN	O
using	VBG	O
a	DT	O
double-blind	JJ	O
randomized	VBN	O
control	NN	O
trial	NN	O
.	.	O

38	CD	O
male	JJ	A
youths	NNS	A
(	(	A
7-16	CD	A
years	NNS	A
old	JJ	A
)	)	A
with	IN	O
autism	NN	C
spectrum	NN	C
disorders	NNS	C
were	VBD	O
administered	VBN	O
24	CD	O
or	CC	O
12	CD	O
international	JJ	O
units	NNS	O
(	(	O
depending	VBG	O
on	IN	O
weight	NN	O
)	)	O
intranasal	NN	O
placebo	NN	O
or	CC	O
oxytocin	JJ	O
once	RB	O
daily	RB	O
over	IN	O
four	CD	O
consecutive	JJ	O
days	NNS	O
.	.	O

The	DT	O
oxytocin	NN	O
or	CC	O
placebo	NN	O
was	VBD	O
administered	VBN	O
during	IN	O
parent-child	JJ	O
interaction	NN	O
training	NN	O
sessions	NNS	O
.	.	O

Parent	NN	O
and	CC	O
child	NN	O
behaviours	NNS	O
were	VBD	O
assessed	VBN	O
using	VBG	O
parent	NN	O
reports	NNS	O
,	,	O
clinician	JJ	O
ratings	NNS	O
,	,	O
and	CC	O
independent	JJ	O
observations	NNS	O
,	,	O
at	IN	O
multiple	JJ	O
time	NN	O
points	NNS	O
to	TO	O
measure	VB	O
side-effects	NNS	O
;	:	O
social	JJ	O
interaction	NN	O
skills	NNS	O
;	:	O
repetitive	JJ	O
behaviours	NNS	O
;	:	O
emotion	NN	O
recognition	NN	O
and	CC	O
diagnostic	JJ	O
status	NN	O
.	.	O

Compared	VBN	O
to	TO	O
placebo	VB	O
,	,	O
intranasal	VB	O
oxytocin	RB	O
did	VBD	O
not	RB	O
significantly	RB	O
improve	VB	O
emotion	NN	O
recognition	NN	O
,	,	O
social	JJ	O
interaction	NN	O
skills	NNS	O
,	,	O
or	CC	O
general	JJ	O
behavioral	JJ	O
adjustment	NN	O
in	IN	O
male	JJ	O
youths	NNS	O
with	IN	O
autism	NN	O
spectrum	NN	O
disorders	NNS	O
.	.	O

The	DT	O
results	NNS	O
show	VBP	O
that	IN	O
the	DT	O
benefits	NNS	O
of	IN	O
nasal	JJ	O
oxytocin	NN	O
for	IN	O
young	JJ	O
individuals	NNS	O
with	IN	O
autism	NN	C
spectrum	NN	C
disorders	NNS	C
may	MD	O
be	VB	O
more	JJR	O
circumscribed	JJ	O
than	IN	O
suggested	VBN	O
by	IN	O
previous	JJ	O
studies	NNS	O
,	,	O
and	CC	O
suggest	JJS	O
caution	NN	O
in	IN	O
recommending	VBG	O
it	PRP	O
as	IN	O
an	DT	O
intervention	NN	O
that	WDT	O
is	VBZ	O
broadly	RB	O
effective	JJ	O
.	.	O

Weight	NNP	O
and	CC	O
leptin	JJ	O
changes	NNS	O
among	IN	O
risperidone-treated	JJ	O
youths	NNS	O
with	IN	O
autism	NN	O
:	:	O
6-month	JJ	O
prospective	JJ	O
data	NNS	O
.	.	O

OBJECTIVE	IN	O
The	DT	O
authors	NNS	O
examined	VBD	O
the	DT	O
developmental	JJ	O
impact	NN	O
and	CC	O
temporal	JJ	O
characteristics	NNS	O
of	IN	O
risperidone-associated	JJ	O
weight	NN	O
change	NN	O
.	.	O

METHOD	NNP	O
Weight	NNP	O
change	NN	O
was	VBD	O
measured	VBN	O
for	IN	O
63	CD	O
children	NNS	O
and	CC	O
adolescents	NNS	O
with	IN	O
autism	NN	O
treated	VBN	O
with	IN	O
risperidone	NN	O
for	IN	O
6	CD	O
months	NNS	O
.	.	O

Change	NNP	O
in	IN	O
serum	NN	O
leptin	NN	O
levels	NNS	O
after	IN	O
2	CD	O
months	NNS	O
was	VBD	O
examined	VBN	O
as	IN	O
a	DT	O
predictor	NN	O
of	IN	O
final	JJ	O
weight	NN	O
gain	NN	O
in	IN	O
mixed	JJ	O
regression	NN	O
models	NNS	O
that	WDT	O
controlled	VBD	O
for	IN	O
site	NN	O
,	,	O
gender	NN	O
,	,	O
age	NN	O
,	,	O
and	CC	O
risperidone	NN	O
dose	NN	O
.	.	O

RESULTS	NNP	O
Age-	JJ	O
and	CC	O
gender-standardized	JJ	O
weight	NN	O
increased	VBD	O
after	IN	O
6	CD	O
months	NNS	O
of	IN	O
treatment	NN	O
(	(	O
gross	JJ	O
:	:	O
mean=5.6	NN	O
kg	NN	O
[	NNP	O
SD=3.9	NNP	O
]	NNP	O
;	:	O
standardized	VBN	O
:	:	O
mean=0.6	NN	O
z	NN	O
[	NNP	O
SD=0.5	NNP	O
]	NNP	O
)	)	O
and	CC	O
was	VBD	O
positively	RB	O
correlated	VBN	O
with	IN	O
weight	NN	O
gained	VBN	O
after	IN	O
1	CD	O
month	NN	O
.	.	O

Change	NN	O
in	IN	O
leptin	NN	O
levels	NNS	O
after	IN	O
2	CD	O
months	NNS	O
of	IN	O
treatment	NN	O
(	(	O
mean=-0.3	JJ	O
ng/ml	NN	O
,	,	O
SD=6.2	NNP	O
)	)	O
(	(	O
N=48	NNP	O
)	)	O
did	VBD	O
not	RB	O
predict	JJ	O
final	JJ	O
weight	NN	O
gain	NN	O
.	.	O

CONCLUSIONS	NNP	O
Chronic	NNP	O
risperidone	NN	O
exposure	NN	O
in	IN	O
children	NNS	O
with	IN	O
autism	NN	O
causes	NNS	O
weight	VBD	O
gain	NN	O
in	IN	O
excess	NN	O
of	IN	O
developmentally	RB	O
expected	VBN	O
norms	NNS	O
that	WDT	O
follows	VBZ	O
a	DT	O
curvilinear	JJ	O
trajectory	NN	O
and	CC	O
decelerates	VBZ	O
over	IN	O
time	NN	O
.	.	O

Serum	NNP	O
leptin	JJ	O
change	NN	O
does	VBZ	O
not	RB	O
reliably	VB	O
predict	JJ	O
risperidone-associated	JJ	O
weight	NN	O
gain	NN	O
.	.	O

Effect	NN	O
of	IN	O
phenylephrine	NN	O
on	IN	O
the	DT	O
haemodynamic	JJ	O
state	NN	O
and	CC	O
cerebral	JJ	O
oxygen	NN	O
saturation	NN	O
during	IN	O
anaesthesia	NN	O
in	IN	O
the	DT	O
upright	JJ	O
position	NN	O
.	.	O

BACKGROUND	IN	O
The	DT	O
upright	JJ	O
sitting	NN	O
or	CC	O
beachchair	NN	O
position	NN	O
is	VBZ	O
associated	VBN	O
with	IN	O
hypotension	NN	O
,	,	O
risk	NN	O
of	IN	O
cerebral	JJ	O
hypoperfusion	NN	O
,	,	O
and	CC	O
cerebral	JJ	O
injury	NN	O
.	.	O

We	PRP	O
hypothesized	VBD	O
that	IN	O
by	IN	O
increasing	VBG	O
arterial	JJ	O
pressure	NN	O
with	IN	O
phenylephrine	JJ	O
administration	NN	O
,	,	O
cerebral	JJ	O
perfusion	NN	O
,	,	O
and	CC	O
postoperative	JJ	O
recovery	NN	O
would	MD	O
be	VB	O
improved	VBN	O
.	.	O

METHODS	NNP	O
Thirty-four	JJ	SS
patients	NNS	O
undergoing	VBG	O
elective	JJ	C
shoulder	NN	C
surgery	NN	C
were	VBD	O
randomized	VBN	O
to	TO	O
receive	VB	O
either	DT	O
saline	NN	O
or	CC	O
phenylephrine	NN	O
infusion	NN	O
(	(	O
PE	NNP	O
)	)	O
5	CD	O
min	NN	O
before	IN	O
being	VBG	O
placed	VBN	O
in	IN	O
the	DT	O
upright	JJ	O
position	NN	O
.	.	O

Simultaneous	JJ	O
measurements	NNS	O
of	IN	O
mean	JJ	O
arterial	JJ	O
pressure	NN	O
,	,	O
cerebral	JJ	O
oxygen	NN	O
saturation	NN	O
,	,	O
middle	JJ	O
cerebral	JJ	O
artery	NN	O
velocity	NN	O
,	,	O
and	CC	O
cardiac	JJ	O
function	NN	O
using	VBG	O
transthoracic	JJ	O
echocardiography	NN	O
were	VBD	O
made	VBN	O
.	.	O

Postoperative	JJ	O
neurocognitive	JJ	O
function	NN	O
was	VBD	O
assessed	VBN	O
.	.	O

RESULTS	NNP	O
At	IN	O
the	DT	O
commencement	NN	O
of	IN	O
PE	NNP	O
,	,	O
mean	NN	O
(	(	O
SD	NNP	O
)	)	O
cerebral	JJ	O
oxygen	NN	O
saturation	NN	O
significantly	RB	O
decreased	VBN	O
from	IN	O
77	CD	O
(	(	O
10	CD	O
)	)	O
to	TO	O
67	CD	O
(	(	O
13	CD	O
)	)	O
%	NN	O
(	(	O
P=0.02	NNP	O
)	)	O
,	,	O
and	CC	O
further	RB	O
to	TO	O
59	CD	O
(	(	O
11	CD	O
)	)	O
%	NN	O
on	IN	O
upright	JJ	O
positioning	NN	O
.	.	O

The	DT	O
level	NN	O
of	IN	O
cerebral	JJ	O
saturation	NN	O
upright	NN	O
was	VBD	O
not	RB	O
significantly	RB	O
different	JJ	O
to	TO	O
patients	NNS	O
receiving	VBG	O
saline	NN	O
(	(	O
P=0.07	NNP	O
)	)	O
,	,	O
with	IN	O
values	NNS	O
remaining	VBG	O
at	IN	O
room-air	JJ	O
levels	NNS	O
.	.	O

Middle	NNP	O
cerebral	JJ	O
artery	RB	O
blood	NN	O
velocity	NN	O
increased	VBN	O
by	IN	O
20	CD	O
%	NN	O
(	(	O
P=0.04	NNP	O
)	)	O
.	.	O

Phenylephrine	NNP	O
prevented	VBD	O
hypotension	NN	O
in	IN	O
the	DT	O
upright	JJ	O
position	NN	O
primarily	RB	O
by	IN	O
maintaining	VBG	O
preload	NN	O
and	CC	O
increasing	VBG	O
systemic	JJ	O
vascular	NN	O
resistance	NN	O
(	(	O
P=0.01	NNP	O
)	)	O
,	,	O
and	CC	O
was	VBD	O
associated	VBN	O
with	IN	O
a	DT	O
decrease	NN	O
in	IN	O
cardiac	JJ	O
output	NN	O
.	.	O

No	DT	O
postoperative	JJ	O
neurocognitive	JJ	O
dysfunction	NN	O
was	VBD	O
identified	VBN	O
.	.	O

CONCLUSIONS	NNP	O
Despite	IN	O
maintaining	VBG	O
arterial	JJ	O
pressure	NN	O
with	IN	O
phenylephrine	NN	O
,	,	O
cerebral	JJ	O
desaturation	NN	O
occurred	VBD	O
with	IN	O
upright	JJ	O
positioning	VBG	O
.	.	O

Cerebral	NNP	O
oxygen	IN	O
saturation	NN	O
can	MD	O
provide	VB	O
a	DT	O
valuable	JJ	O
endpoint	NN	O
when	WRB	O
evaluating	VBG	O
the	DT	O
effect	NN	O
of	IN	O
vasopressor	NN	O
therapy	NN	O
on	IN	O
cerebral	JJ	O
perfusion	NN	O
.	.	O

[	IN	O
The	DT	O
application	NN	O
of	IN	O
naphcon	JJ	O
eye	NN	O
drops	NNS	O
during	IN	O
Lasik	NNP	O
surgery	NN	O
]	NN	O
.	.	O

PURPOSE	NNP	O
To	TO	O
evaluate	VB	O
the	DT	O
effects	NNS	O
of	IN	O
Naphcon	NNP	O
eye	NN	O
drops	NNS	O
for	IN	O
preventing	VBG	O
conjunctival	JJ	C
bleeding	NN	C
during	IN	O
Lasik	NNP	O
surgery	NN	O
.	.	O

METHODS	NNP	O
One	CD	SS
hundred	VBN	SS
cases	NNS	O
(	(	O
200	CD	O
eyes	NNS	O
)	)	O
were	VBD	O
divided	VBN	O
into	IN	O
treating	VBG	O
group	NN	O
and	CC	O
control	NN	O
group	NN	O
randomly	RB	O
according	VBG	O
to	TO	O
using	VBG	O
and	CC	O
not	RB	O
using	VBG	O
Naphcon	NNP	O
eye	NN	O
drops	NNS	O
before	IN	O
Lasik	NNP	O
surgery	NN	O
.	.	O

Treating	VBG	O
group	NN	O
patients	NNS	O
received	VBD	O
three	CD	O
times	NNS	O
Naphcon	NNP	O
eye	NN	O
drops	NNS	O
during	IN	O
15	CD	O
minutes	NNS	O
before	IN	O
surgery	NN	O
.	.	O

RESULTS	VB	O
The	DT	O
incidence	NN	O
of	IN	O
conjunctival	JJ	O
bleeding	VBG	O
from	IN	O
treating	VBG	O
and	CC	O
control	VB	O
group	NN	O
were	VBD	O
8	CD	O
%	NN	O
and	CC	O
15	CD	O
%	NN	O
respectively	RB	O
.	.	O

There	EX	O
was	VBD	O
significant	JJ	O
statistical	JJ	O
difference	NN	O
between	IN	O
them	PRP	O
.	.	O

CONCLUSION	NNP	O
Naphcon	NNP	O
eye	NN	O
drop	NN	O
is	VBZ	O
an	DT	O
effective	JJ	O
agent	NN	O
to	TO	O
prevent	VB	O
conjunctival	JJ	C
bleeding	NN	C
.	.	O

Determination	NN	O
of	IN	O
vital	JJ	O
status	NN	O
at	IN	O
the	DT	O
end	NN	O
of	IN	O
the	DT	O
DIG	NNP	O
trial	NN	O
.	.	O

The	DT	O
Digitalis	NNP	O
Investigation	NNP	O
Group	NNP	O
(	(	O
DIG	NNP	O
)	)	O
trial	NN	O
was	VBD	O
a	DT	O
randomized	JJ	O
,	,	O
double-blind	JJ	O
placebo-controlled	JJ	O
trial	NN	O
whose	WP$	O
primary	JJ	O
objective	NN	O
was	VBD	O
to	TO	O
determine	VB	O
whether	IN	O
digoxin	NN	O
had	VBD	O
beneficial	JJ	O
,	,	O
harmful	JJ	O
,	,	O
or	CC	O
no	DT	O
effect	NN	O
on	IN	O
total	JJ	O
mortality	NN	O
in	IN	O
patients	NNS	O
with	IN	O
heart	NN	O
failure	NN	O
who	WP	O
were	VBD	O
in	IN	O
sinus	NN	O
rhythm	NN	O
and	CC	O
whose	WP$	O
ejection	NN	O
fraction	NN	O
was	VBD	O
<	JJ	O
/=0.45	NNP	O
.	.	O

The	DT	O
study	NN	O
was	VBD	O
designed	VBN	O
as	IN	O
a	DT	O
large	JJ	O
simple	JJ	O
trial	NN	O
with	IN	O
a	DT	O
large	JJ	O
number	NN	O
of	IN	O
centers	NNS	O
(	(	O
302	CD	O
)	)	O
in	IN	O
the	DT	O
United	NNP	O
States	NNPS	O
and	CC	O
Canada	NNP	O
,	,	O
many	JJ	O
of	IN	O
which	WDT	O
were	VBD	O
inexperienced	VBN	O
in	IN	O
research	NN	O
.	.	O

To	TO	O
ensure	VB	O
that	IN	O
the	DT	O
results	NNS	O
of	IN	O
the	DT	O
trial	NN	O
would	MD	O
be	VB	O
reported	VBN	O
accurately	RB	O
without	IN	O
possible	JJ	O
bias	NN	O
due	JJ	O
to	TO	O
missing	VBG	O
data	NNS	O
,	,	O
the	DT	O
study	NN	O
leadership	NN	O
decided	VBD	O
that	IN	O
no	DT	O
outcome	NN	O
results	NNS	O
would	MD	O
be	VB	O
reported	VBN	O
until	IN	O
the	DT	O
vital	JJ	O
status	NN	O
at	IN	O
the	DT	O
end	NN	O
of	IN	O
the	DT	O
study	NN	O
was	VBD	O
known	VBN	O
for	IN	O
at	IN	O
least	JJS	O
97	CD	O
%	NN	O
of	IN	O
the	DT	O
study	NN	O
participants	NNS	O
.	.	O

Planning	VBG	O
for	IN	O
closeout	NN	O
of	IN	O
the	DT	O
study	NN	O
began	VBD	O
a	DT	O
year	NN	O
prior	RB	O
to	TO	O
the	DT	O
common	JJ	O
end	NN	O
date	NN	O
of	IN	O
December	NNP	O
31	CD	O
,	,	O
1995	CD	O
and	CC	O
included	VBD	O
plans	NNS	O
for	IN	O
obtaining	VBG	O
vital	JJ	O
status	NN	O
on	IN	O
December	NNP	O
31	CD	O
,	,	O
1995	CD	O
.	.	O

Participants	NNS	O
were	VBD	O
given	VBN	O
postcards	NNS	O
at	IN	O
their	PRP$	O
final	JJ	O
study	NN	O
visit	NN	O
to	TO	O
be	VB	O
completed	VBN	O
and	CC	O
mailed	VBN	O
on	IN	O
or	CC	O
after	IN	O
January	NNP	O
1	CD	O
,	,	O
1996	CD	O
.	.	O

Of	IN	O
5602	CD	O
postcards	NNS	O
distributed	VBN	O
,	,	O
5070	CD	O
(	(	O
90.5	CD	O
%	NN	O
)	)	O
were	VBD	O
completed	VBN	O
and	CC	O
returned	VBN	O
.	.	O

A	DT	O
contract	NN	O
search	NN	O
agency	NN	O
was	VBD	O
hired	VBN	O
to	TO	O
locate	VB	O
the	DT	O
remaining	VBG	O
participants	NNS	O
.	.	O

Of	IN	O
the	DT	O
total	JJ	O
7788	CD	O
participants	NNS	O
entered	VBD	O
into	IN	O
the	DT	O
DIG	NNP	O
trial	NN	O
,	,	O
only	RB	O
97	CD	O
participants	NNS	O
(	(	O
1.2	CD	O
%	NN	O
)	)	O
could	MD	O
not	RB	O
have	VB	O
their	PRP$	O
vital	JJ	O
status	NN	O
as	IN	O
of	IN	O
December	NNP	O
31	CD	O
,	,	O
1995	CD	O
determined	VBD	O
.	.	O

It	PRP	O
is	VBZ	O
recommended	VBN	O
that	IN	O
investigators	NNS	O
having	VBG	O
an	DT	O
outcome	NN	O
measure	NN	O
with	IN	O
a	DT	O
common	JJ	O
end	NN	O
date	NN	O
include	VBP	O
plans	NNS	O
in	IN	O
their	PRP$	O
protocols	NNS	O
for	IN	O
obtaining	VBG	O
their	PRP$	O
measures	NNS	O
and	CC	O
activate	VBP	O
those	DT	O
plans	NNS	O
as	RB	O
early	RB	O
as	IN	O
possible	JJ	O
during	IN	O
the	DT	O
course	NN	O
of	IN	O
the	DT	O
study	NN	O
.	.	O

Double	JJ	O
contrast	NN	O
arthrography	NN	C
of	IN	O
the	DT	O
knee	NN	O
.	.	O

Comparison	NNP	O
between	IN	O
three	CD	O
contrast	NN	O
media	NNS	O
.	.	O

Meglumine	NNP	O
iothalamate	NN	O
(	(	O
Conray	NNP	O
Meglumin	NNP	O
)	)	O
,	,	O
sodium-calcium-meglumine	JJ	O
metrizoate	NN	O
(	(	O
Isopaque	NNP	O
Cerebral	NNP	O
)	)	O
and	CC	O
dimeglumine	JJ	O
iocarmate	NN	O
(	(	O
Dimerex	NNP	O
)	)	O
,	,	O
each	DT	O
containing	VBG	O
about	IN	O
280	CD	O
mg	NNS	O
I/ml	NNP	O
,	,	O
were	VBD	O
compared	VBN	O
in	IN	O
two	CD	O
series	NN	O
of	IN	O
double	JJ	O
contrast	NN	O
knee	NN	O
arthrography	NN	C
,	,	O
190	CD	SS
and	CC	O
184	CD	SS
patients	NNS	O
each	DT	O
.	.	O

With	IN	O
Dimerex	NNP	O
the	DT	O
mixing	NN	O
of	IN	O
the	DT	O
contrast	NN	O
medium	NN	O
with	IN	O
the	DT	O
synovial	JJ	O
fluid	NN	O
was	VBD	O
slower	JJR	O
than	IN	O
with	IN	O
Conray	NNP	O
Meglumin	NNP	O
,	,	O
and	CC	O
a	DT	O
good	JJ	O
or	CC	O
fair	JJ	O
image	NN	O
quality	NN	O
,	,	O
as	IN	O
evaluated	VBN	O
subjectively	RB	O
,	,	O
lasted	VBD	O
longer	RBR	O
.	.	O

No	DT	O
difference	NN	O
was	VBD	O
observed	VBN	O
between	IN	O
Isopaque	NNP	O
Cerebral	NNP	O
and	CC	O
Conray	NNP	O
Meglumin	NNP	O
,	,	O
regardless	RB	O
of	IN	O
dosage	NN	O
.	.	O

A	DT	O
comparison	NN	O
of	IN	O
the	DT	O
effect	NN	O
of	IN	O
short-term	JJ	O
aromatase	NN	O
inhibitor	NN	O
(	(	O
letrozole	JJ	O
)	)	O
and	CC	O
GnRH	NNP	O
agonist	NN	O
(	(	O
triptorelin	NN	O
)	)	O
versus	NN	O
case	NN	O
control	NN	O
on	IN	O
pregnancy	NN	O
rate	NN	O
and	CC	O
symptom	NN	O
and	CC	O
sign	NN	O
recurrence	NN	O
after	IN	O
laparoscopic	JJ	O
treatment	NN	O
of	IN	O
endometriosis	NN	O
.	.	O

PURPOSE	NNP	O
To	TO	O
compare	VB	O
the	DT	O
role	NN	O
of	IN	O
an	DT	O
aromatase	NN	O
inhibitor	NN	O
(	(	O
letrozole	JJ	O
)	)	O
with	IN	O
a	DT	O
GnRH	NNP	O
agonist	NN	O
(	(	O
triptorelin	NN	O
)	)	O
versus	NN	O
case	NN	O
control	NN	O
on	IN	O
the	DT	O
pregnancy	NN	O
rate	NN	O
and	CC	O
recurrence	NN	O
of	IN	O
symptoms	NNS	O
and	CC	O
signs	NNS	O
in	IN	O
patients	NNS	O
with	IN	O
endometriosis	NN	C
.	.	O

METHODS	NNP	O
In	IN	O
a	DT	O
prospective	JJ	O
randomized	VBN	O
clinical	JJ	O
trial	NN	O
,	,	O
after	IN	O
treatment	NN	O
of	IN	O
144	CD	SS
infertile	JJ	C
women	NNS	SE
in	IN	O
their	PRP$	O
reproductive	JJ	O
age	NN	O
by	IN	O
laparoscopy	NN	O
(	(	O
whose	WP$	O
endometriosis	NN	O
was	VBD	O
confirmed	VBN	O
by	IN	O
prior	JJ	O
laparoscopy	NN	O
)	)	O
,	,	O
they	PRP	O
were	VBD	O
divided	VBN	O
into	IN	O
3	CD	O
groups	NNS	O
:	:	O
group	NN	O
1	CD	O
(	(	O
47	CD	SS
cases	NNS	O
)	)	O
who	WP	O
received	VBD	O
letrozole	NN	O
for	IN	O
2	CD	O
months	NNS	O
,	,	O
group	NN	O
2	CD	O
(	(	O
40	CD	O
patients	NNS	O
)	)	O
who	WP	O
were	VBD	O
prescribed	VBN	O
triptorelin	NN	O
for	IN	O
2	CD	O
months	NNS	O
and	CC	O
group	NN	O
3	CD	O
who	WP	O
were	VBD	O
57	CD	O
patients	NNS	O
in	IN	O
the	DT	O
control	NN	O
group	NN	O
and	CC	O
did	VBD	O
not	RB	O
receive	VB	O
any	DT	O
medication	NN	O
.	.	O

We	PRP	O
followed	VBD	O
up	RP	O
each	DT	O
group	NN	O
at	IN	O
least	JJS	O
for	IN	O
12	CD	O
months	NNS	O
after	IN	O
their	PRP$	O
restoration	NN	O
of	IN	O
regular	JJ	O
cycle	NN	O
.	.	O

RESULTS	JJ	O
Pregnancy	NNP	O
rate	NN	O
was	VBD	O
23.4	CD	O
%	NN	O
in	IN	O
group	NN	O
1	CD	O
,	,	O
27.5	CD	O
%	NN	O
in	IN	O
group	NN	O
2	CD	O
,	,	O
and	CC	O
28.1	CD	O
%	NN	O
in	IN	O
group	NN	O
3	CD	O
.	.	O

The	DT	O
results	NNS	O
did	VBD	O
not	RB	O
show	VB	O
significant	JJ	O
differences	NNS	O
among	IN	O
the	DT	O
3	CD	O
groups	NNS	O
.	.	O

Recurrence	NNP	O
rate	NN	O
of	IN	O
endometriosis	NN	O
was	VBD	O
6.4	CD	O
%	NN	O
in	IN	O
group	NN	O
1	CD	O
,	,	O
5	CD	O
%	NN	O
group	NN	O
2	CD	O
and	CC	O
5.3	CD	O
%	NN	O
in	IN	O
group	NN	O
3	CD	O
,	,	O
which	WDT	O
was	VBD	O
not	RB	O
statistically	RB	O
significantly	RB	O
different	JJ	O
as	RB	O
well	RB	O
.	.	O

CONCLUSION	NNP	O
Pregnancy	NNP	O
rate	NN	O
and	CC	O
endometriosis	NN	O
recurrence	NN	O
rate	NN	O
are	VBP	O
comparable	JJ	O
among	IN	O
the	DT	O
3	CD	O
groups	NNS	O
.	.	O

Changes	NNS	O
in	IN	O
motor	NN	O
cortex	NN	O
excitability	NN	O
associated	VBN	O
with	IN	O
temporal	JJ	O
repetitive	JJ	O
transcranial	JJ	O
magnetic	JJ	O
stimulation	NN	O
in	IN	O
tinnitus	NN	C
:	:	O
hints	NNS	O
for	IN	O
cross-modal	JJ	O
plasticity	NN	O
?	.	O
BACKGROUND	NNP	O
Motor	NNP	O
cortex	VBP	O
excitability	NN	O
was	VBD	O
found	VBN	O
to	TO	O
be	VB	O
changed	VBN	O
after	IN	O
repetitive	JJ	O
transcranial	JJ	O
magnetic	JJ	O
stimulation	NN	O
(	(	O
rTMS	NN	O
)	)	O
of	IN	O
the	DT	O
temporal	JJ	O
cortex	NN	O
highlighting	VBG	O
the	DT	O
occurrence	NN	O
of	IN	O
cross-modal	JJ	O
plasticity	NN	O
in	IN	O
non-invasive	JJ	O
brain	NN	O
stimulation	NN	O
.	.	O

Here	RB	O
,	,	O
we	PRP	O
investigated	VBD	O
the	DT	O
effects	NNS	O
of	IN	O
temporal	JJ	O
low-frequency	NN	O
rTMS	NN	O
on	IN	O
motor	NN	O
cortex	NN	O
plasticity	NN	O
in	IN	O
a	DT	O
large	JJ	O
sample	NN	O
of	IN	O
tinnitus	NN	C
patients	NNS	O
.	.	O

In	IN	O
116	CD	SS
patients	NNS	O
with	IN	O
chronic	JJ	O
tinnitus	NN	C
different	JJ	O
parameters	NNS	O
of	IN	O
cortical	JJ	O
excitability	NN	O
were	VBD	O
assessed	VBN	O
before	IN	O
and	CC	O
after	IN	O
ten	JJ	O
rTMS	JJ	O
treatment	NN	O
sessions	NNS	O
.	.	O

Patients	NNS	O
received	VBD	O
one	CD	O
of	IN	O
three	CD	O
different	JJ	O
protocols	NNS	O
all	DT	O
including	VBG	O
1	CD	O
Hz	NNP	O
rTMS	NN	O
over	IN	O
the	DT	O
left	JJ	O
temporal	JJ	O
cortex	NN	O
.	.	O

Treatment	NNP	O
response	NN	O
was	VBD	O
defined	VBN	O
as	IN	O
improvement	NN	O
by	IN	O
at	IN	O
least	JJS	O
five	CD	O
points	NNS	O
in	IN	O
the	DT	O
tinnitus	NN	O
questionnaire	NN	O
(	(	O
TQ	NNP	O
)	)	O
.	.	O

Variables	NNS	O
of	IN	O
interest	NN	O
were	VBD	O
resting	VBG	O
motor	NN	O
threshold	NN	O
(	(	O
RMT	NNP	O
)	)	O
,	,	O
short-interval	JJ	O
intra-cortical	JJ	O
inhibition	NN	O
(	(	O
SICI	NNP	O
)	)	O
,	,	O
intracortical	JJ	O
facilitation	NN	O
(	(	O
ICF	NNP	O
)	)	O
,	,	O
and	CC	O
cortical	JJ	O
silent	JJ	O
period	NN	O
(	(	O
CSP	NNP	O
)	)	O
.	.	O

RESULTS	NNP	O
After	IN	O
rTMS	JJ	O
treatment	NN	O
RMT	NNP	O
was	VBD	O
decreased	VBN	O
by	IN	O
about	IN	O
1	CD	O
%	NN	O
of	IN	O
stimulator	NN	O
output	NN	O
near-significantly	RB	O
in	IN	O
the	DT	O
whole	JJ	O
group	NN	O
of	IN	O
patients	NNS	O
.	.	O

SICI	NNP	O
was	VBD	O
associated	VBN	O
with	IN	O
significant	JJ	O
changes	NNS	O
with	IN	O
respect	NN	O
to	TO	O
treatment	NN	O
response	NN	O
.	.	O

The	DT	O
group	NN	O
of	IN	O
treatment	NN	O
responders	NNS	O
showed	VBD	O
a	DT	O
decrease	NN	O
of	IN	O
SICI	NNP	O
over	IN	O
the	DT	O
course	NN	O
of	IN	O
treatment	NN	O
,	,	O
the	DT	O
group	NN	O
of	IN	O
non-responders	NNS	O
the	DT	O
reverse	NN	O
pattern	NN	O
.	.	O

CONCLUSIONS	NNP	O
Minor	NNP	O
RMT	NNP	O
changes	NNS	O
during	IN	O
rTMS	NN	O
treatment	NN	O
do	VBP	O
not	RB	O
necessarily	RB	O
suggest	VB	O
the	DT	O
need	NN	O
for	IN	O
systematic	JJ	O
re-examination	NN	O
of	IN	O
the	DT	O
RMT	NNP	O
for	IN	O
safety	NN	O
and	CC	O
efficacy	NN	O
issues	NNS	O
.	.	O

Treatment	NNP	O
response	NN	O
to	TO	O
rTMS	VB	O
was	VBD	O
shown	VBN	O
to	TO	O
be	VB	O
related	VBN	O
to	TO	O
changes	NNS	O
in	IN	O
SICI	NNP	O
that	WDT	O
might	MD	O
reflect	VB	O
modulation	NN	O
of	IN	O
GABAergic	NNP	O
mechanisms	FW	O
directly	RB	O
or	CC	O
indirectly	RB	O
related	VBN	O
to	TO	O
rTMS	VB	O
treatment	NN	O
effects	NNS	O
.	.	O

Benzodiazepine	NNP	O
and	CC	O
opioid	JJ	O
sedation	NN	O
attenuate	IN	O
the	DT	O
sympathetic	JJ	O
response	NN	O
to	TO	O
fiberoptic	JJ	C
bronchoscopy	NN	C
.	.	O

Prophylactic	JJ	O
labetalol	NN	O
gave	VBD	O
no	DT	O
additional	JJ	O
benefit	NN	O
.	.	O

Results	NNS	O
of	IN	O
a	DT	O
randomized	JJ	O
double-blind	JJ	O
placebo-controlled	JJ	O
study	NN	O
.	.	O

BACKGROUND	NNP	O
Hypertension	NNP	O
and	CC	O
tachycardia	NN	O
are	VBP	O
common	JJ	O
during	IN	O
fiber-optic	JJ	C
bronchoscopy	NN	C
(	(	C
FOB	NNP	C
)	)	C
,	,	O
and	CC	O
this	DT	O
may	MD	O
lead	VB	O
to	TO	O
cardiac	JJ	O
ischemia	NN	O
.	.	O

The	DT	O
prophylactic	JJ	O
addition	NN	O
of	IN	O
a	DT	O
beta-adrenergic	JJ	O
anatagonist	NN	O
might	MD	O
mask	VB	O
this	DT	O
response	NN	O
and	CC	O
prevent	VB	O
the	DT	O
deleterious	JJ	O
cardiovascular	JJ	O
effects	NNS	O
of	IN	O
FOB	NNP	O
.	.	O

METHODS	NNP	O
We	PRP	O
performed	VBD	O
a	DT	O
randomized	JJ	O
double-blind	JJ	O
placebo-controlled	JJ	O
trial	NN	O
of	IN	O
labetalol	$	O
10mg	CD	O
iv	NN	O
given	VBN	O
with	IN	O
midazolam-alfentanil	JJ	O
sedation	NN	O
.	.	O

We	PRP	O
monitored	VBD	O
heart	NN	O
rate	NN	O
(	(	O
HR	NNP	O
)	)	O
and	CC	O
systolic/diastolic	JJ	O
blood	NN	O
pressure	NN	O
(	(	O
SBP/DBP	NNP	O
)	)	O
throughout	IN	O
the	DT	O
bronchoscopy	NN	O
and	CC	O
calculated	VBD	O
the	DT	O
rate-pressure	JJ	O
product	NN	O
(	(	O
RPP=	NNP	O
(	(	O
HRxSBP	NNP	O
)	)	O
/100	NN	O
)	)	O
.	.	O

One-hundred	JJ	SS
twenty	NN	SS
patients	NNS	O
were	VBD	O
enrolled	VBN	O
.	.	O

RESULTS	NNP	O
In	IN	O
the	DT	O
placebo	NN	O
group	NN	O
,	,	O
there	EX	O
was	VBD	O
no	DT	O
rise	NN	O
in	IN	O
HR	NNP	O
,	,	O
SBP	NNP	O
,	,	O
DBP	NNP	O
or	CC	O
RPP	NNP	O
,	,	O
and	CC	O
there	EX	O
was	VBD	O
no	DT	O
difference	NN	O
between	IN	O
the	DT	O
placebo	NN	O
and	CC	O
labetalol	NN	O
groups	NNS	O
.	.	O

Adverse	JJ	O
events	NNS	O
during	IN	O
bronchoscopy	NN	O
were	VBD	O
similar	JJ	O
in	IN	O
both	DT	O
groups	NNS	O
.	.	O

In	IN	O
a	DT	O
subgroup	NN	O
of	IN	O
patients	NNS	O
undergoing	VBG	O
interventional	JJ	O
bronchoscopy	NN	O
,	,	O
there	EX	O
was	VBD	O
a	DT	O
trend	NN	O
towards	NNS	O
lower	JJR	O
SBP	NNP	O
(	(	O
p=0.06	NN	O
)	)	O
.	.	O

CONCLUSIONS	JJ	O
Patients	NNPS	O
undergoing	VBG	O
FOB	NNP	C
under	IN	O
adequate	JJ	O
midazolam-alfentanil	JJ	O
sedation	NN	O
do	VBP	O
not	RB	O
develop	VB	O
excessive	JJ	O
sympathetic	JJ	O
drive	NN	O
that	WDT	O
may	MD	O
lead	VB	O
to	TO	O
cardiac	JJ	O
stress	NN	O
.	.	O

The	DT	O
addition	NN	O
of	IN	O
labetalol	NN	O
did	VBD	O
not	RB	O
confer	VB	O
additional	JJ	O
benefit	NN	O
or	CC	O
risk	NN	O
to	TO	O
the	DT	O
patients	NNS	O
.	.	O

(	(	O
ClinicalTrials.gov	NNP	O
number	NN	O
,	,	O
NCT00394537	NNP	O
)	)	O
.	.	O

Accuracy	NN	O
and	CC	O
feasibility	NN	O
of	IN	O
contrast	NN	O
echocardiography	NN	O
for	IN	O
detection	NN	O
of	IN	O
perfusion	NN	O
defects	NNS	O
in	IN	O
routine	JJ	O
practice	NN	O
:	:	O
comparison	NN	O
with	IN	O
wall	JJ	O
motion	NN	O
and	CC	O
technetium-99m	JJ	O
sestamibi	NN	O
single-photon	JJ	O
emission	NN	O
computed	VBD	O
tomography	NN	O
.	.	O

The	DT	O
Nycomed	NNP	O
NC100100	NNP	O
Investigators	NNP	O
.	.	O

OBJECTIVES	NNP	O
We	PRP	O
sought	VBD	O
to	TO	O
assess	VB	O
the	DT	O
feasibility	NN	O
and	CC	O
accuracy	NN	O
of	IN	O
myocardial	JJ	O
contrast	NN	O
echocardiography	NN	O
(	(	O
MCE	NNP	O
)	)	O
using	VBG	O
standard	JJ	O
imaging	NN	O
approaches	NNS	O
for	IN	O
the	DT	O
detection	NN	O
of	IN	O
perfusion	NN	O
defects	NNS	O
in	IN	O
patients	NNS	O
who	WP	O
had	VBD	O
a	DT	O
myocardial	JJ	O
infarction	NN	O
(	(	O
MI	NNP	O
)	)	O
.	.	O

BACKGROUND	NNP	O
Myocardial	NNP	O
contrast	NN	O
echocardiography	NN	O
may	MD	O
be	VB	O
more	JJR	O
versatile	JJ	O
than	IN	O
perfusion	NN	O
scintigraphy	NN	O
for	IN	O
identifying	VBG	O
the	DT	O
presence	NN	O
and	CC	O
extent	NN	O
of	IN	O
perfusion	NN	O
defects	NNS	O
after	IN	O
MI	NNP	O
.	.	O

However	RB	O
,	,	O
its	PRP$	O
reliability	NN	O
in	IN	O
routine	JJ	O
practice	NN	O
is	VBZ	O
unclear	JJ	O
.	.	O

METHODS	NNP	O
Fundamental	NNP	O
or	CC	O
harmonic	JJ	O
MCE	NNP	O
was	VBD	O
performed	VBN	O
with	IN	O
continuous	JJ	O
or	CC	O
triggered	JJ	O
imaging	NN	O
in	IN	O
203	CD	O
patients	NNS	O
with	IN	O
a	DT	O
previous	JJ	O
MI	NNP	O
using	VBG	O
bolus	JJ	O
doses	NNS	O
of	IN	O
a	DT	O
perfluorocarbon-filled	JJ	O
contrast	NN	O
agent	NN	O
(	(	O
NC100100	NNP	O
)	)	O
.	.	O

All	DT	O
patients	NNS	O
underwent	JJ	O
single-photon	JJ	O
emission	NN	O
computed	VBN	O
tomography	NN	O
(	(	O
SPECT	NNP	O
)	)	O
after	IN	O
the	DT	O
injection	NN	O
of	IN	O
technetium-99m	JJ	O
(	(	O
Tc-99m	NNP	O
)	)	O
sestamibi	NN	O
at	IN	O
rest	NN	O
.	.	O

Quantitative	NNP	O
and	CC	O
semiquantitative	JJ	O
SPECT	NNP	O
,	,	O
wall	NN	O
motion	NN	O
and	CC	O
digitized	JJ	O
echocardiographic	JJ	O
data	NNS	O
were	VBD	O
interpreted	VBN	O
independently	RB	O
.	.	O

The	DT	O
accuracy	NN	O
of	IN	O
MCE	NNP	O
was	VBD	O
assessed	VBN	O
for	IN	O
detection	NN	O
of	IN	O
segments	NNS	O
and	CC	O
patients	NNS	O
with	IN	O
moderate	JJ	O
and	CC	O
severe	JJ	O
sestamibi-SPECT	JJ	O
defects	NNS	O
,	,	O
as	RB	O
well	RB	O
as	IN	O
for	IN	O
detection	NN	O
of	IN	O
patients	NNS	O
with	IN	O
extensive	JJ	O
perfusion	NN	O
defects	NNS	O
(	(	O
>	VB	O
12	CD	O
%	NN	O
of	IN	O
left	JJ	O
ventricle	NN	O
)	)	O
.	.	O

RESULTS	NNP	O
In	IN	O
segments	NNS	O
with	IN	O
diagnostic	JJ	O
MCE	NNP	O
,	,	O
the	DT	O
segmental	JJ	O
sensitivity	NN	O
ranged	VBD	O
from	IN	O
14	CD	O
%	NN	O
to	TO	O
65	CD	O
%	NN	O
,	,	O
and	CC	O
the	DT	O
specificity	NN	O
varied	VBD	O
from	IN	O
78	CD	O
%	NN	O
to	TO	O
95	CD	O
%	NN	O
,	,	O
depending	VBG	O
on	IN	O
the	DT	O
dose	NN	O
of	IN	O
contrast	NN	O
agent	NN	O
.	.	O

Using	VBG	O
both	DT	O
segment-	JJ	O
and	CC	O
patient-based	JJ	O
analysis	NN	O
,	,	O
the	DT	O
greatest	JJS	O
accuracy	NN	O
and	CC	O
proportion	NN	O
of	IN	O
interpretable	JJ	O
images	NNS	O
were	VBD	O
obtained	VBN	O
using	VBG	O
harmonic	JJ	O
imaging	NN	O
in	IN	O
the	DT	O
triggered	JJ	O
mode	NN	O
.	.	O

For	IN	O
the	DT	O
detection	NN	O
of	IN	O
extensive	JJ	O
defects	NNS	O
,	,	O
the	DT	O
sensitivity	NN	O
varied	VBD	O
from	IN	O
13	CD	O
%	NN	O
to	TO	O
48	CD	O
%	NN	O
,	,	O
with	IN	O
specificity	NN	O
from	IN	O
63	CD	O
%	NN	O
to	TO	O
100	CD	O
%	NN	O
.	.	O

Harmonic	NNP	O
imaging	NN	O
remained	VBD	O
the	DT	O
most	RBS	O
accurate	JJ	O
approach	NN	O
.	.	O

Time	NNP	O
since	IN	O
MI	NNP	O
and	CC	O
SPECT	NNP	O
defect	VBP	O
location	NN	O
and	CC	O
intensity	NN	O
were	VBD	O
all	DT	O
determinants	NNS	O
of	IN	O
the	DT	O
MCE	NNP	O
response	NN	O
.	.	O

The	DT	O
extent	NN	O
of	IN	O
defects	NNS	O
on	IN	O
MCE	NNP	O
was	VBD	O
less	JJR	O
than	IN	O
the	DT	O
extent	NN	O
of	IN	O
either	DT	O
abnormal	JJ	O
wall	NN	O
motion	NN	O
or	CC	O
SPECT	NNP	O
abnormalities	NNS	O
.	.	O

The	DT	O
combination	NN	O
of	IN	O
wall	JJ	O
motion	NN	O
and	CC	O
MCE	NNP	O
assessment	NN	O
gave	VBD	O
the	DT	O
best	JJS	O
balance	NN	O
of	IN	O
sensitivity	NN	O
(	(	O
46	CD	O
%	NN	O
to	TO	O
55	CD	O
%	NN	O
)	)	O
and	CC	O
specificity	NN	O
(	(	O
82	CD	O
%	NN	O
to	TO	O
83	CD	O
%	NN	O
)	)	O
.	.	O

CONCLUSIONS	NNP	O
Although	IN	O
MCE	NNP	O
is	VBZ	O
specific	JJ	O
,	,	O
it	PRP	O
has	VBZ	O
limited	VBN	O
sensitivity	NN	O
for	IN	O
detection	NN	O
of	IN	O
moderate	JJ	O
or	CC	O
severe	JJ	O
perfusion	NN	O
defects	NNS	O
,	,	O
and	CC	O
it	PRP	O
underestimates	VBZ	O
the	DT	O
extent	NN	O
of	IN	O
SPECT	NNP	O
defects	NNS	O
.	.	O

The	DT	O
best	JJS	O
results	NNS	O
are	VBP	O
obtained	VBN	O
by	IN	O
integration	NN	O
with	IN	O
wall	DT	O
motion	NN	O
.	.	O

More	RBR	O
sophisticated	JJ	O
methods	NNS	O
of	IN	O
acquisition	NN	O
and	CC	O
interpretation	NN	O
are	VBP	O
needed	VBN	O
to	TO	O
enhance	VB	O
the	DT	O
feasibility	NN	O
of	IN	O
this	DT	O
technique	NN	O
in	IN	O
routine	JJ	O
practice	NN	O
.	.	O

Validation	NN	O
of	IN	O
an	DT	O
FFQ	NNP	O
for	IN	O
evaluation	NN	O
of	IN	O
EPA	NNP	O
and	CC	O
DHA	NNP	O
intake	VBP	O
.	.	O

OBJECTIVE	NNP	O
To	TO	O
validate	VB	O
an	DT	O
FFQ	NNP	O
for	IN	O
the	DT	O
assessment	NN	O
of	IN	O
dietary	JJ	O
EPA	NNP	O
and	CC	O
DHA	NNP	O
against	IN	O
their	PRP$	O
relative	JJ	O
concentrations	NNS	O
in	IN	O
red	JJ	O
blood	NN	O
cells	NNS	O
(	(	O
RBC	NNP	O
)	)	O
.	.	O

DESIGN	NNP	O
Cross-sectional	JJ	O
analysis	NN	O
of	IN	O
baseline	NN	O
data	NNS	O
.	.	O

Intakes	NNS	O
of	IN	O
marine	NN	O
food	NN	O
products	NNS	O
and	CC	O
EPA	NNP	O
and	CC	O
DHA	NNP	O
were	VBD	O
estimated	VBN	O
by	IN	O
FFQ	NNP	O
on	IN	O
the	DT	O
basis	NN	O
of	IN	O
consumption	NN	O
of	IN	O
marine	NN	O
food	NN	O
products	NNS	O
in	IN	O
the	DT	O
last	JJ	O
month	NN	O
.	.	O

Fatty	NNP	O
acid	JJ	O
composition	NN	O
of	IN	O
RBC	NNP	O
membranes	NNS	O
was	VBD	O
quantified	VBN	O
by	IN	O
GC	NNP	O
.	.	O

SETTING	NNP	O
Saint-Fran?ois	JJ	O
d'Assise	NN	O
Hospital	NNP	O
,	,	O
Qu?bec	NNP	O
,	,	O
Canada	NNP	O
.	.	O

SUBJECTS	NNP	O
A	NNP	O
total	NN	O
of	IN	O
sixty-five	JJ	O
middle-aged	JJ	O
women	NNS	O
who	WP	O
participated	VBD	O
in	IN	O
a	DT	O
randomized	JJ	O
clinical	JJ	O
trial	NN	O
.	.	O

RESULTS	NNP	O
Spearman	NNP	O
's	POS	O
correlation	NN	O
coefficient	NN	O
between	IN	O
intake	NN	O
of	IN	O
EPA	NNP	O
,	,	O
DHA	NNP	O
and	CC	O
EPA	NNP	O
+	NNP	O
DHA	NNP	O
and	CC	O
their	PRP$	O
corresponding	JJ	O
concentration	NN	O
in	IN	O
RBC	NNP	O
was	VBD	O
0.46	CD	O
,	,	O
0.40	CD	O
and	CC	O
0.42	CD	O
,	,	O
respectively	RB	O
(	(	O
all	DT	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
.	.	O

Multiple	JJ	O
regression	NN	O
analysis	NN	O
of	IN	O
EPA+DHA	NNP	O
intake	NN	O
and	CC	O
RBC	NNP	O
EPA	NNP	O
+	NNP	O
DHA	NNP	O
concentration	NN	O
indicated	VBD	O
positive	JJ	O
and	CC	O
significant	JJ	O
correlations	NNS	O
for	IN	O
oily	RB	O
fish	JJ	O
(	(	O
beta	JJ	O
=	NN	O
0.44	CD	O
,	,	O
95	CD	O
%	NN	O
CI	NNP	O
0.16	CD	O
,	,	O
0.72	CD	O
,	,	O
P	NNP	O
=	NNP	O
0.0027	CD	O
)	)	O
,	,	O
total	JJ	O
fish	NN	O
(	(	O
beta	JJ	O
=	NN	O
0.42	CD	O
,	,	O
95	CD	O
%	NN	O
CI	NNP	O
0.19	CD	O
,	,	O
0.64	CD	O
,	,	O
P	NNP	O
=	NNP	O
0.0005	CD	O
)	)	O
and	CC	O
marine	VB	O
food	NN	O
products	NNS	O
(	(	O
beta	NN	O
=	RB	O
0.42	CD	O
,	,	O
95	CD	O
%	NN	O
CI	NNP	O
0.20	CD	O
,	,	O
0.64	CD	O
,	,	O
P	NNP	O
=	NNP	O
0.0003	CD	O
)	)	O
.	.	O

No	UH	O
other	JJ	O
marine	VB	O
food	NN	O
products	NNS	O
significantly	RB	O
predicted	VBD	O
RBC	NNP	O
EPA	NNP	O
+	NNP	O
DHA	NNP	O
concentration	NN	O
.	.	O

CONCLUSIONS	NNP	O
Although	IN	O
the	DT	O
present	JJ	O
validation	NN	O
study	NN	O
was	VBD	O
undertaken	VBN	O
among	IN	O
middle-aged	JJ	O
women	NNS	O
with	IN	O
low	JJ	O
consumption	NN	O
of	IN	O
marine	NN	O
food	NN	O
products	NNS	O
(	(	O
<	$	O
3	CD	O
servings/week	NN	O
)	)	O
,	,	O
our	PRP$	O
FFQ	NNP	O
provided	VBD	O
estimates	NNS	O
of	IN	O
EPA	NNP	O
and	CC	O
DHA	NNP	O
intakes	NNS	O
that	WDT	O
correlated	VBD	O
fairly	RB	O
well	RB	O
with	IN	O
their	PRP$	O
RBC	NNP	O
concentrations	NNS	O
.	.	O

However	RB	O
,	,	O
the	DT	O
absence	NN	O
of	IN	O
correlations	NNS	O
between	IN	O
EPA	NNP	O
+	NNP	O
DHA	NNP	O
intakes	NNS	O
from	IN	O
different	JJ	O
marine	NN	O
species	NNS	O
suggests	VBZ	O
that	IN	O
a	DT	O
minimum	JJ	O
EPA	NNP	O
+	NNP	O
DHA	NNP	O
intake	NN	O
is	VBZ	O
necessary	JJ	O
to	TO	O
observe	VB	O
a	DT	O
relationship	NN	O
with	IN	O
RBC	NNP	O
EPA	NNP	O
+	NNP	O
DHA	NNP	O
concentrations	NNS	O
.	.	O

A	DT	O
placebo-controlled	JJ	O
,	,	O
fixed-dose	JJ	O
study	NN	O
of	IN	O
aripiprazole	NN	O
in	IN	O
children	NNS	O
and	CC	O
adolescents	NNS	O
with	IN	O
irritability	NN	C
associated	VBN	O
with	IN	O
autistic	JJ	C
disorder	NN	C
.	.	O

OBJECTIVE	UH	O
To	TO	O
evaluate	VB	O
the	DT	O
short-term	JJ	O
efficacy	NN	O
and	CC	O
safety	NN	O
of	IN	O
aripiprazole	NN	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
irritability	NN	O
in	IN	O
children	NNS	O
and	CC	O
adolescents	NNS	O
with	IN	O
autistic	JJ	C
disorder	NN	C
.	.	O

METHOD	NNP	O
Two	CD	SS
hundred	VBD	SS
eighteen	JJ	SS
children	NNS	O
and	CC	O
adolescents	NNS	O
(	(	O
aged	VBN	O
6-17	CD	O
years	NNS	O
)	)	O
with	IN	O
a	DT	O
diagnosis	NN	O
of	IN	O
autistic	JJ	C
disorder	NN	C
,	,	O
and	CC	O
with	IN	O
behaviors	NNS	O
such	JJ	O
as	IN	O
tantrums	NNS	C
,	,	O
aggression	NN	C
,	,	C
self-injurious	JJ	C
behavior	NN	C
,	,	C
or	CC	O
a	DT	O
combination	NN	O
of	IN	O
these	DT	O
symptoms	NNS	O
,	,	O
were	VBD	O
randomized	VBN	O
1:1:1:1	CD	O
to	TO	O
aripiprazole	VB	O
(	(	O
5	CD	O
,	,	O
10	CD	O
,	,	O
or	CC	O
15	CD	O
mg/day	NN	O
)	)	O
or	CC	O
placebo	NN	O
in	IN	O
this	DT	O
8-week	JJ	O
double-blind	NN	O
,	,	O
randomized	VBN	O
,	,	O
placebo-controlled	JJ	O
,	,	O
parallel-group	JJ	O
study	NN	O
.	.	O

Efficacy	NNP	O
was	VBD	O
evaluated	VBN	O
using	VBG	O
the	DT	O
caregiver-rated	JJ	O
Aberrant	NNP	O
Behavior	NNP	O
Checklist	NNP	O
Irritability	NNP	O
subscale	NN	O
(	(	O
primary	JJ	O
efficacy	NN	O
measure	NN	O
)	)	O
and	CC	O
the	DT	O
clinician-rated	JJ	O
Clinical	JJ	O
Global	NNP	O
Impressions-Improvement	NNP	O
score	NN	O
.	.	O

Safety	NNP	O
and	CC	O
tolerability	NN	O
were	VBD	O
also	RB	O
assessed	VBN	O
.	.	O

RESULTS	NNP	O
At	IN	O
week	NN	O
8	CD	O
,	,	O
all	DT	O
aripiprazole	JJ	O
doses	NNS	O
produced	VBN	O
significantly	RB	O
greater	JJR	O
improvement	NN	O
than	IN	O
placebo	NN	O
in	IN	O
mean	JJ	O
Aberrant	NNP	O
Behavior	NNP	O
Checklist	NNP	O
Irritability	NNP	O
subscale	NN	O
scores	NNS	O
(	(	O
5	CD	O
mg/day	NN	O
,	,	O
-12.4	NNP	O
;	:	O
10	CD	O
mg/day	NN	O
,	,	O
-13.2	NNP	O
;	:	O
15	CD	O
mg/day	NN	O
,	,	O
-14.4	NNP	O
;	:	O
versus	NN	O
placebo	NN	O
,	,	O
-8.4	NNP	O
;	:	O
all	DT	O
p	VBP	O
<	NNP	O
.05	NNP	O
)	)	O
.	.	O

All	DT	O
aripiprazole	JJ	O
doses	NNS	O
demonstrated	VBN	O
significantly	RB	O
greater	JJR	O
improvements	NNS	O
in	IN	O
mean	JJ	O
Clinical	JJ	O
Global	NNP	O
Impressions-Improvement	NNP	O
score	NN	O
than	IN	O
placebo	NN	O
at	IN	O
week	NN	O
8	CD	O
.	.	O

Discontinuation	NN	O
rates	NNS	O
due	JJ	O
to	TO	O
adverse	JJ	O
events	NNS	O
were	VBD	O
as	IN	O
follows	VBZ	O
:	:	O
placebo	VB	O
7.7	CD	O
%	NN	O
,	,	O
aripiprazole	JJ	O
5	CD	O
mg/day	JJ	O
9.4	CD	O
%	NN	O
,	,	O
10	CD	O
mg/day	JJ	O
13.6	CD	O
%	NN	O
,	,	O
and	CC	O
15	CD	O
mg/day	JJ	O
7.4	CD	O
%	NN	O
.	.	O

The	DT	O
most	RBS	O
common	JJ	O
adverse	JJ	O
event	NN	O
leading	VBG	O
to	TO	O
discontinuation	NN	O
was	VBD	O
sedation	NN	O
.	.	O

There	EX	O
were	VBD	O
two	CD	O
serious	JJ	O
adverse	JJ	O
events	NNS	O
:	:	O
presyncope	NN	O
(	(	O
5	CD	O
mg/day	NN	O
)	)	O
and	CC	O
aggression	NN	O
(	(	O
10	CD	O
mg/day	NN	O
)	)	O
.	.	O

At	IN	O
week	NN	O
8	CD	O
,	,	O
mean	JJ	O
weight	NN	O
change	NN	O
(	(	O
last	JJ	O
observation	NN	O
carried	VBD	O
forward	RB	O
)	)	O
was	VBD	O
as	IN	O
follows	VBZ	O
:	:	O
placebo	NN	O
+0.3	NNP	O
kg	NN	O
,	,	O
aripiprazole	JJ	O
5	CD	O
mg/day	JJ	O
+1.3	NNP	O
kg	NN	O
,	,	O
10	CD	O
mg/day	NN	O
+1.3	NNP	O
kg	NN	O
,	,	O
and	CC	O
15	CD	O
mg/day	NN	O
+1.5	NNP	O
kg	NN	O
;	:	O
all	DT	O
p	VBP	O
<	JJ	O
.05	NNP	O
versus	NN	O
placebo	NN	O
.	.	O

CONCLUSIONS	NNP	O
Aripiprazole	NNP	O
was	VBD	O
efficacious	JJ	O
and	CC	O
generally	RB	O
safe	JJ	O
and	CC	O
well	RB	O
tolerated	VBN	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
children	NNS	O
and	CC	O
adolescents	NNS	O
with	IN	O
irritability	NN	C
associated	VBN	O
with	IN	O
autistic	JJ	C
disorder	NN	C
.	.	C

Low-intensity	NNP	O
exercise	NN	O
and	CC	O
reduction	NN	O
of	IN	O
the	DT	O
risk	NN	O
for	IN	O
falls	NNS	O
among	IN	O
at-risk	JJ	O
elders	NNS	O
.	.	O

BACKGROUND	NNP	O
Among	IN	O
elderly	JJ	O
persons	NNS	O
,	,	O
falls	VBZ	O
account	NN	O
for	IN	O
87	CD	O
%	NN	O
of	IN	O
all	DT	O
fractures	NNS	O
and	CC	O
are	VBP	O
contributing	VBG	O
factors	NNS	O
in	IN	O
many	JJ	O
nursing	NN	O
home	NN	O
admissions	NNS	O
.	.	O

This	DT	O
study	NN	O
evaluated	VBD	O
the	DT	O
effect	NN	O
of	IN	O
an	DT	O
easily	RB	O
implemented	VBN	O
,	,	O
low-intensity	JJ	O
exercise	NN	O
program	NN	O
on	IN	O
the	DT	O
incidence	NN	O
of	IN	O
falls	NNS	O
and	CC	O
the	DT	O
time	NN	O
to	TO	O
first	VB	O
fall	NN	O
among	IN	O
a	DT	O
clinically	RB	O
defined	JJ	O
population	NN	O
of	IN	O
elderly	JJ	O
men	NNS	O
and	CC	O
women	NNS	O
.	.	O

METHODS	VB	O
This	DT	O
community-based	JJ	O
,	,	O
randomized	JJ	O
trial	NN	O
compared	VBN	O
the	DT	O
exercise	NN	O
intervention	NN	O
with	IN	O
a	DT	O
no-intervention	JJ	O
control	NN	O
.	.	O

The	DT	O
participants	NNS	O
were	VBD	O
294	CD	O
men	NNS	O
and	CC	O
women	NNS	O
,	,	O
aged	VBD	O
60	CD	O
years	NNS	O
or	CC	O
older	JJR	O
,	,	O
who	WP	O
had	VBD	O
either	CC	O
a	DT	O
hospital	JJ	O
admission	NN	O
or	CC	O
bed	NN	O
rest	NN	O
for	IN	O
2	CD	O
days	NNS	O
or	CC	O
more	JJR	O
within	IN	O
the	DT	O
previous	JJ	O
month	NN	O
.	.	O

Exercise	NN	O
participants	NNS	O
were	VBD	O
scheduled	VBN	O
to	TO	O
attend	VB	O
exercise	NN	O
sessions	NNS	O
lasting	VBG	O
45	CD	O
minutes	NNS	O
,	,	O
including	VBG	O
warm-up	JJ	O
and	CC	O
cool-down	JJ	O
,	,	O
3	CD	O
times	NNS	O
a	DT	O
week	NN	O
for	IN	O
8	CD	O
weeks	NNS	O
(	(	O
24	CD	O
sessions	NNS	O
)	)	O
.	.	O

Assessments	NNS	O
included	VBD	O
gait	NN	O
and	CC	O
balance	NN	O
measures	NNS	O
,	,	O
self-reported	JJ	O
physical	JJ	O
function	NN	O
,	,	O
the	DT	O
number	NN	O
of	IN	O
medications	NNS	O
being	VBG	O
taking	VBG	O
at	IN	O
baseline	NN	O
,	,	O
participant	JJ	O
age	NN	O
,	,	O
sex	NN	O
,	,	O
and	CC	O
history	NN	O
of	IN	O
falling	VBG	O
.	.	O

Falls	NNS	O
were	VBD	O
tracked	VBN	O
for	IN	O
1	CD	O
year	NN	O
after	IN	O
each	DT	O
participant	NN	O
's	POS	O
baseline	JJ	O
assessment	NN	O
.	.	O

RESULTS	VB	O
29	CD	O
%	NN	O
of	IN	O
the	DT	O
study	NN	O
participants	NNS	O
reported	VBD	O
a	DT	O
fall	NN	O
during	IN	O
the	DT	O
study	NN	O
period	NN	O
.	.	O

The	DT	O
effect	NN	O
of	IN	O
exercise	NN	O
in	IN	O
preventing	VBG	O
falls	NNS	O
varied	VBN	O
significantly	RB	O
by	IN	O
baseline	JJ	O
physical	JJ	O
function	NN	O
level	NN	O
(	(	O
p	JJ	O
<	NN	O
or	CC	O
=.002	NN	O
)	)	O
.	.	O

The	DT	O
risk	NN	O
for	IN	O
falls	NNS	O
decreased	VBN	O
for	IN	O
exercise	NN	O
participants	NNS	O
with	IN	O
low	JJ	O
baseline	NN	O
physical	JJ	O
functioning	NN	O
(	(	O
hazard	JJ	O
ratio	NN	O
,	,	O
.51	NN	O
)	)	O
but	CC	O
increased	VBD	O
for	IN	O
exercise	NN	O
participants	NNS	O
with	IN	O
high	JJ	O
baseline	NN	O
physical	JJ	O
functioning	NN	O
(	(	O
hazard	JJ	O
ratio	NN	O
,	,	O
3.51	CD	O
)	)	O
.	.	O

CONCLUSIONS	VB	O
This	DT	O
easily	RB	O
implemented	VBN	O
,	,	O
low-intensity	JJ	O
exercise	NN	O
program	NN	O
appears	VBZ	O
to	TO	O
reduce	VB	O
the	DT	O
risk	NN	O
for	IN	O
falls	NNS	O
among	IN	O
elderly	JJ	O
men	NNS	O
and	CC	O
women	NNS	O
recovering	VBG	O
from	IN	O
recent	JJ	O
hospitalizations	NNS	O
,	,	O
bed	VBD	O
rest	NN	O
,	,	O
or	CC	O
both	DT	O
who	WP	O
have	VBP	O
low	JJ	O
levels	NNS	O
of	IN	O
physical	JJ	O
functioning	NN	O
.	.	O

[	NN	O
Mitoxantrone	NNP	O
(	(	O
MTX	NNP	O
)	)	O
versus	NN	O
mitomycin	NN	O
C	NNP	O
(	(	O
MMC	NNP	O
)	)	O
in	IN	O
the	DT	O
ablative	JJ	O
treatment	NN	O
of	IN	O
Ta	NNP	C
,	,	C
T1	NNP	C
superficial	JJ	C
bladder	NN	C
tumors	NNS	C
.	.	O

Phase	NNP	O
III	NNP	O
,	,	O
randomized	VBD	O
prospective	JJ	O
study	NN	O
]	NNP	O
.	.	O

A	NNP	O
prospective	JJ	O
randomized	NN	O
study	NN	O
was	VBD	O
conducted	VBN	O
to	TO	O
determine	VB	O
the	DT	O
ablation	NN	O
capacity	NN	O
of	IN	O
mitoxantrone	NN	O
in	IN	O
Ta-T1	NNP	O
superficial	JJ	O
bladder	NN	O
tumors	NNS	O
versus	VBP	O
mitomycin	JJ	O
C	NNP	O
,	,	O
a	DT	O
drug	NN	O
whose	WP$	O
intravesical	JJ	O
ablation	NN	O
properties	NNS	O
are	VBP	O
well-known	JJ	O
.	.	O

Fifty-seven	JJ	O
patients	NNS	O
comprised	VBD	O
the	DT	O
study	NN	O
.	.	O

The	DT	O
tumor	NN	O
was	VBD	O
not	RB	O
completely	RB	O
resected	VBN	O
when	WRB	O
the	DT	O
patient	NN	O
underwent	JJ	O
TUR	NNP	O
.	.	O

This	DT	O
residual	JJ	O
tumor	NN	O
was	VBD	O
used	VBN	O
as	IN	O
control	NN	O
.	.	O

The	DT	O
patients	NNS	O
were	VBD	O
treated	VBN	O
with	IN	O
either	DT	O
20	CD	O
mg	NN	O
Mitoxantrone	NNP	O
or	CC	O
40	CD	O
mg	NNS	O
mitomycin	JJ	O
C	NNP	O
weekly	NN	O
for	IN	O
8	CD	O
weeks	NNS	O
and	CC	O
two	CD	O
other	JJ	O
instillations	NNS	O
every	DT	O
15	CD	O
days	NNS	O
in	IN	O
50	CD	O
ml	NNS	O
saline	JJ	O
solution	NN	O
.	.	O

Response	NNP	O
to	TO	O
therapy	NN	O
was	VBD	O
evaluated	VBN	O
between	IN	O
the	DT	O
4th	CD	O
and	CC	O
8th	CD	O
week	NN	O
and	CC	O
classified	VBD	O
as	IN	O
complete	JJ	O
response	NN	O
(	(	O
CR	NNP	O
)	)	O
,	,	O
defined	VBD	O
as	IN	O
no	DT	O
gross	JJ	O
and	CC	O
microscopic	JJ	O
evidence	NN	O
of	IN	O
residual	JJ	O
tumor	NN	O
,	,	O
or	CC	O
no	DT	O
response	NN	O
(	(	O
NR	NNP	O
)	)	O
or	CC	O
therapeutic	JJ	O
failure	NN	O
.	.	O

CR	NNP	O
was	VBD	O
observed	VBN	O
in	IN	O
77.7	CD	O
%	NN	O
of	IN	O
the	DT	O
patients	NNS	O
treated	VBN	O
with	IN	O
mitomycin	JJ	O
C	NNP	O
and	CC	O
in	IN	O
50	CD	O
%	NN	O
in	IN	O
those	DT	O
that	WDT	O
had	VBD	O
been	VBN	O
treated	VBN	O
with	IN	O
Mitoxantrone	NNP	O
.	.	O

Treatment	NNP	O
was	VBD	O
discontinued	VBN	O
because	IN	O
of	IN	O
side	NN	O
effects	NNS	O
in	IN	O
15	CD	O
%	NN	O
of	IN	O
the	DT	O
patients	NNS	O
treated	VBN	O
with	IN	O
mitomycin	JJ	O
C	NNP	O
and	CC	O
in	IN	O
63.4	CD	O
%	NN	O
of	IN	O
those	DT	O
who	WP	O
received	VBD	O
Mitoxantrone	NNP	O
.	.	O

We	PRP	O
can	MD	O
conclude	VB	O
from	IN	O
the	DT	O
results	NNS	O
of	IN	O
the	DT	O
present	JJ	O
study	NN	O
that	IN	O
Mitoxantrone	NNP	O
is	VBZ	O
a	DT	O
useful	JJ	O
agent	NN	O
for	IN	O
ablation	NN	O
therapy	NN	O
of	IN	O
superficial	JJ	O
bladder	NN	O
tumors	NNS	O
,	,	O
although	IN	O
the	DT	O
high	JJ	O
incidence	NN	O
of	IN	O
severe	JJ	O
side	NN	O
effects	NNS	O
warrants	NNS	O
its	PRP$	O
limited	JJ	O
use	NN	O
and	CC	O
at	IN	O
high	JJ	O
dilutions	NNS	O
.	.	O

Insular	JJ	O
and	CC	O
anterior	JJ	O
cingulate	NN	O
circuits	NNS	O
in	IN	O
smokers	NNS	O
with	IN	O
schizophrenia	NN	C
.	.	O

Schizophrenia	NNP	C
(	(	O
SZ	NNP	C
)	)	O
is	VBZ	O
associated	VBN	O
with	IN	O
high	JJ	O
rates	NNS	O
of	IN	O
smoking	NN	O
.	.	O

We	PRP	O
previously	RB	O
found	VBD	O
that	IN	O
resting	VBG	O
state	NN	O
functional	JJ	O
connectivity	NN	O
(	(	O
rsFC	NN	O
)	)	O
between	IN	O
the	DT	O
dorsal	NN	O
anterior	JJ	O
cingulate	NN	O
(	(	O
dACC	NN	O
)	)	O
and	CC	O
striatum	NN	O
is	VBZ	O
independently	RB	O
associated	VBN	O
with	IN	O
nicotine	JJ	O
addiction	NN	O
and	CC	O
psychiatric	JJ	O
illness	NN	O
.	.	O

Since	IN	O
the	DT	O
insula	NN	O
is	VBZ	O
implicated	VBN	O
in	IN	O
nicotine	JJ	O
dependence	NN	O
,	,	O
we	PRP	O
hypothesized	VBD	O
that	IN	O
SZ	NNP	O
smokers	NNS	O
will	MD	O
have	VB	O
greater	JJR	O
dysfunction	NN	O
in	IN	O
smoking-related	JJ	O
insular	NN	O
and	CC	O
dACC	NN	O
circuits	NNS	O
than	IN	O
normal	JJ	C
control	NN	C
smokers	NNS	C
(	(	O
NC	NNP	O
)	)	O
independent	JJ	O
of	IN	O
smoking	VBG	O
severity	NN	O
,	,	O
consistent	NN	O
with	IN	O
an	DT	O
inherent	JJ	O
disease-related	JJ	O
weakening	NN	O
of	IN	O
smoking-related	JJ	O
circuits	NNS	O
.	.	O

Nicotine	NNP	O
challenge	NN	O
was	VBD	O
used	VBN	O
to	TO	O
demonstrate	VB	O
that	DT	O
decreased	VBD	O
rsFC	NN	O
in	IN	O
identified	JJ	O
circuits	NNS	O
reflects	VBZ	O
addiction	JJ	O
trait	NN	O
and	CC	O
is	VBZ	O
not	RB	O
affected	VBN	O
by	IN	O
pharmacological	JJ	O
state	NN	O
.	.	O

Twenty-four	CD	SS
NC	NNP	C
smokers	NNS	O
and	CC	O
20	CD	SS
smokers	NNS	O
with	IN	O
SZ	NNP	C
matched	VBD	O
on	IN	O
nicotine	JJ	O
addiction	NN	O
severity	NN	O
participated	VBN	O
in	IN	O
a	DT	O
resting	NN	O
state	NN	O
fMRI	NN	O
study	NN	O
and	CC	O
were	VBD	O
scanned	VBN	O
during	IN	O
two	CD	O
separate	JJ	O
sessions	NNS	O
while	IN	O
receiving	VBG	O
a	DT	O
placebo	NN	O
or	CC	O
nicotine	JJ	O
patch	NN	O
,	,	O
in	IN	O
a	DT	O
randomized	JJ	O
,	,	O
cross-over	JJ	O
design	NN	O
.	.	O

Using	VBG	O
individualized	JJ	O
,	,	O
anatomically	RB	O
defined	VBN	O
anterior	JJ	O
and	CC	O
posterior	JJ	O
insula	NN	O
and	CC	O
dACC	NN	O
as	IN	O
regions	NNS	O
of	IN	O
interest	NN	O
(	(	O
ROI	NNP	O
)	)	O
,	,	O
whole	JJ	O
brain	NN	O
rsFC	NN	O
was	VBD	O
performed	VBN	O
using	VBG	O
each	DT	O
ROI	NNP	O
as	IN	O
a	DT	O
seed	NN	O
.	.	O

Significant	NNP	O
negative	JJ	O
correlations	NNS	O
between	IN	O
smoking	VBG	O
severity	NN	O
and	CC	O
rsFC	NN	O
between	IN	O
insula	NN	O
,	,	O
dACC	NN	O
and	CC	O
striatum	NN	O
were	VBD	O
found	VBN	O
for	IN	O
both	DT	O
groups	NNS	O
.	.	O

Furthermore	RB	O
,	,	O
smokers	NNS	O
with	IN	O
SZ	NNP	C
demonstrated	VBD	O
additive	JJ	O
reductions	NNS	O
in	IN	O
circuit	NN	O
strength	NN	O
between	IN	O
the	DT	O
dACC	NN	O
and	CC	O
insula	NN	O
compared	VBN	O
to	TO	O
NC	NNP	O
smokers	NNS	O
independent	JJ	O
of	IN	O
smoking	VBG	O
severity	NN	O
.	.	O

Nicotine	NNP	O
challenge	NN	O
did	VBD	O
not	RB	O
significantly	RB	O
alter	VB	O
rsFC	NN	O
in	IN	O
insula-dACC-striatal	JJ	O
circuits	NNS	O
.	.	O

Reduced	VBN	O
rsFC	JJ	O
strength	NN	O
between	IN	O
the	DT	O
insula	NN	O
,	,	O
dACC	NN	O
and	CC	O
striatum	NN	O
is	VBZ	O
associated	VBN	O
with	IN	O
nicotine	JJ	O
addiction	NN	O
severity	NN	O
in	IN	O
both	DT	O
non-psychiatrically	RB	O
ill	NN	O
and	CC	O
in	IN	O
SZ	NNP	O
smokers	NNS	O
.	.	O

Decreased	VBN	O
insula-dACC	JJ	O
rsFC	NN	O
may	MD	O
index	NN	O
overlapping	VBG	O
circuitry	NN	O
associated	VBN	O
with	IN	O
smoking	NN	O
and	CC	O
SZ	NNP	O
.	.	O

Relationship	NN	O
between	IN	O
endogenous	JJ	O
estrogen	NN	O
concentrations	NNS	O
and	CC	O
serum	NN	O
cholesteryl	NN	O
ester	NN	O
transfer	NN	O
protein	NN	O
concentrations	NNS	O
in	IN	O
Chinese	JJ	O
women	NNS	SE
.	.	O

BACKGROUND	NNP	O
CETP	NNP	O
plays	VBZ	O
an	DT	O
important	JJ	O
role	NN	O
in	IN	O
HDL	NNP	O
metabolism	NN	O
and	CC	O
in	IN	O
the	DT	O
reverse	NN	O
cholesterol	NN	O
transport	NN	O
pathway	NN	O
.	.	O

METHODS	NNP	O
The	DT	O
relationship	NN	O
between	IN	O
the	DT	O
changes	NNS	O
of	IN	O
endogenous	JJ	O
estrogen	NN	O
and	CC	O
the	DT	O
concentration	NN	O
of	IN	O
cholesteryl	NN	O
ester	NN	O
transfer	NN	O
protein	NN	O
(	(	O
CETP	NNP	O
)	)	O
in	IN	O
the	DT	O
serum	NN	O
of	IN	O
Chinese	JJ	O
women	NNS	O
was	VBD	O
investigated	VBN	O
.	.	O

Serum	NNP	O
concentrations	NNS	O
of	IN	O
estradiol	NN	O
(	(	O
E	NNP	O
(	(	O
2	CD	O
)	)	O
)	)	O
,	,	O
follicle-stimulating	JJ	O
hormone	NN	O
(	(	O
FSH	NNP	O
)	)	O
,	,	O
CETP	NNP	O
and	CC	O
lipid	JJ	O
profile	NN	O
were	VBD	O
determined	VBN	O
in	IN	O
196	CD	SS
Chinese	JJ	C
women	NNS	SE
(	(	O
52	CD	SS
premenopausal	NN	C
with	IN	O
ages	NNS	A
ranging	VBG	A
from	IN	A
18	CD	A
to	TO	A
40	CD	A
years	NNS	A
,	,	O
57	CD	SS
perimenopausal	NN	C
from	IN	O
41	CD	A
to	TO	A
60	CD	A
years	NNS	A
,	,	O
and	CC	O
87	CD	SS
postmenopausal	NN	C
from	IN	O
61	CD	A
to	TO	A
81	CD	A
years	NNS	A
)	)	O
.	.	O

RESULTS	NNP	O
Serum	NNP	O
CETP	NNP	O
concentration	NN	O
was	VBD	O
significantly	RB	O
lower	JJR	O
in	IN	O
postmenopausal	JJ	O
women	NNS	O
compared	VBN	O
with	IN	O
those	DT	O
in	IN	O
perimenopausal	NN	O
and	CC	O
premenopausal	JJ	O
women	NNS	O
(	(	O
1.39+/-1.06	JJ	O
,	,	O
2.36+/-1.50	JJ	O
and	CC	O
2.31+/-1.25	JJ	O
mg/l	NN	O
,	,	O
respectively	RB	O
,	,	O
P	NNP	O
<	NNP	O
0.0001	CD	O
)	)	O
.	.	O

Even	RB	O
in	IN	O
the	DT	O
women	NNS	O
around	IN	O
the	DT	O
menopausal	NN	O
,	,	O
CETP	NNP	O
concentration	NN	O
in	IN	O
postmenopause	NN	O
was	VBD	O
significantly	RB	O
lower	JJR	O
than	IN	O
that	DT	O
in	IN	O
premenopause	NN	O
(	(	O
1.93+/-1.33	JJ	O
vs.	IN	O
3.42+/-1.35	JJ	O
mg/l	NN	O
,	,	O
P	NNP	O
<	NNP	O
0.01	CD	O
)	)	O
.	.	O

In	IN	O
addition	NN	O
,	,	O
CETP	NNP	O
concentration	NN	O
had	VBD	O
a	DT	O
highly	RB	O
positive	JJ	O
correlation	NN	O
with	IN	O
serum	JJ	O
concentration	NN	O
of	IN	O
E	NNP	O
(	(	O
2	CD	O
)	)	O
(	(	O
r=0.243	NN	O
,	,	O
P	NNP	O
<	NNP	O
0.001	CD	O
)	)	O
,	,	O
while	IN	O
negative	JJ	O
correlation	NN	O
of	IN	O
CETP	NNP	O
concentration	NN	O
with	IN	O
serum	JJ	O
concentration	NN	O
of	IN	O
FSH	NNP	O
was	VBD	O
found	VBN	O
(	(	O
r=-0.273	JJ	O
,	,	O
P	NNP	O
<	NNP	O
0.001	CD	O
)	)	O
.	.	O

CONCLUSIONS	NNP	O
Estrogen	NNP	O
may	MD	O
affect	VB	O
the	DT	O
concentration	NN	O
of	IN	O
CETP	NNP	O
.	.	O

Line-item	JJ	O
analysis	NN	O
of	IN	O
the	DT	O
Aberrant	NNP	O
Behavior	NNP	O
Checklist	NNP	O
:	:	O
results	NNS	O
from	IN	O
two	CD	O
studies	NNS	O
of	IN	O
aripiprazole	NN	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
irritability	NN	C
associated	VBN	O
with	IN	O
autistic	JJ	C
disorder	NN	C
.	.	O

OBJECTIVES	CC	O
The	DT	O
aim	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
evaluate	VB	O
the	DT	O
efficacy	NN	O
of	IN	O
aripiprazole	NN	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
discrete	JJ	O
symptoms	NNS	O
of	IN	O
irritability	NN	O
associated	VBN	O
with	IN	O
autistic	JJ	O
disorder	NN	O
,	,	O
as	RB	O
well	RB	O
as	IN	O
other	JJ	O
symptoms	NNS	O
captured	VBN	O
on	IN	O
the	DT	O
Aberrant	NNP	O
Behavior	NNP	O
Checklist	NNP	O
(	(	O
ABC	NNP	O
)	)	O
.	.	O

METHODS	NNP	O
This	DT	O
was	VBD	O
a	DT	O
post	NN	O
hoc	NN	O
analysis	NN	O
of	IN	O
data	NNS	O
from	IN	O
two	CD	O
8-week	JJ	O
,	,	O
randomized	VBN	O
,	,	O
double-blind	JJ	O
,	,	O
multicenter	JJ	O
trials	NNS	O
to	TO	O
evaluate	VB	O
the	DT	O
efficacy	NN	O
of	IN	O
aripiprazole	NN	O
dosed	VBN	O
flexibly	RB	O
(	(	O
2-15	JJ	O
mg/day	NN	O
,	,	O
n=47	NN	O
)	)	O
or	CC	O
fixed	VBN	O
(	(	O
5	CD	O
,	,	O
10	CD	O
,	,	O
or	CC	O
15	CD	O
mg/day	NN	O
,	,	O
n	JJ	O
=	NNP	O
166	CD	O
)	)	O
versus	NN	O
placebo	NN	O
(	(	O
flexibly	RB	O
dosed	VBN	O
,	,	O
n	JJ	O
=	VBP	O
51	CD	O
;	:	O
fixed	VBN	O
dose	NN	O
,	,	O
n	JJ	O
=	NNP	O
52	CD	O
)	)	O
.	.	O

The	DT	O
effects	NNS	O
of	IN	O
treatment	NN	O
on	IN	O
the	DT	O
58	CD	O
ABC	NNP	O
items	NNS	O
were	VBD	O
evaluated	VBN	O
.	.	O

RESULTS	NNP	O
Statistically	NNP	O
significantly	RB	O
greater	JJR	O
improvement	NN	O
was	VBD	O
seen	VBN	O
with	IN	O
aripiprazole	JJ	O
versus	NN	O
placebo	NN	O
(	(	O
p	JJ	O
<	NNP	O
0.05	CD	O
)	)	O
for	IN	O
all	DT	O
arms	NNS	O
in	IN	O
both	DT	O
trials	NNS	O
on	IN	O
the	DT	O
ABC-Irritability	NNP	O
total	JJ	O
subscale	NN	O
score	NN	O
and	CC	O
on	IN	O
the	DT	O
following	JJ	O
individual	JJ	O
ABC-Irritability	NNP	O
items	NNS	O
:	:	O
Mood	NNP	O
changes	NNS	O
quickly	RB	O
,	,	O
cries/screams	NNS	O
inappropriately	RB	O
,	,	O
and	CC	O
stamps	JJ	O
feet/bangs	NNS	O
objects	NNS	O
.	.	O

Several	JJ	O
additional	JJ	O
items	NNS	O
measuring	VBG	O
tantrum-like	JJ	O
behaviors	NNS	O
improved	VBN	O
in	IN	O
the	DT	O
flexibly	RB	O
dosed	VBN	O
trial	NN	O
and	CC	O
at	IN	O
least	JJS	O
one	CD	O
arm	NN	O
of	IN	O
the	DT	O
fixed-dose	JJ	O
trial	NN	O
(	(	O
p	JJ	O
<	NNP	O
0.05	CD	O
)	)	O
.	.	O

Measures	NNS	O
of	IN	O
self-injurious	JJ	O
behavior	NN	O
,	,	O
which	WDT	O
had	VBD	O
low	JJ	O
baseline	NN	O
values	NNS	O
,	,	O
demonstrated	VBD	O
numerical	JJ	O
,	,	O
but	CC	O
not	RB	O
statistically	RB	O
significant	JJ	O
,	,	O
improvement	NN	O
in	IN	O
both	DT	O
trials	NNS	O
.	.	O

Statistically	RB	O
significantly	RB	O
greater	JJR	O
improvement	NN	O
in	IN	O
ABC	NNP	O
Stereotypic	NNP	O
Behavior	NNP	O
and	CC	O
Hyperactivity	NNP	O
total	JJ	O
subscale	NN	O
scores	NNS	O
was	VBD	O
also	RB	O
consistent	JJ	O
across	IN	O
all	DT	O
arms	NNS	O
in	IN	O
both	DT	O
trials	NNS	O
.	.	O

In	IN	O
particular	JJ	O
,	,	O
there	EX	O
was	VBD	O
a	DT	O
cluster	NN	O
of	IN	O
items	NNS	O
related	VBN	O
to	TO	O
hyperkinesis	VB	O
that	WDT	O
were	VBD	O
consistently	RB	O
sensitive	JJ	O
to	TO	O
treatment	NN	O
.	.	O

CONCLUSIONS	NNP	O
Aripiprazole	NNP	O
is	VBZ	O
efficacious	JJ	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
irritability	NN	O
in	IN	O
children	NNS	O
and	CC	O
adolescents	NNS	O
with	IN	O
autistic	JJ	C
disorder	NN	C
,	,	O
particularly	RB	O
with	IN	O
respect	NN	O
to	TO	O
symptoms	NNS	O
associated	VBN	O
with	IN	O
tantrum	JJ	O
behavior	NN	O
.	.	O

A	DT	O
randomized	JJ	O
comparison	NN	O
of	IN	O
tamoxifen	NN	O
with	IN	O
surgical	JJ	O
oophorectomy	NN	O
in	IN	O
premenopausal	NN	C
patients	NNS	O
with	IN	O
advanced	JJ	C
breast	NN	C
cancer	NN	C
.	.	O

We	PRP	O
randomized	VBD	O
122	CD	SS
premenopausal	JJ	C
women	NNS	SE
to	TO	O
receive	VB	O
tamoxifen	NN	O
or	CC	O
to	TO	O
undergo	VB	O
a	DT	O
surgical	JJ	O
oophorectomy	NN	O
.	.	O

Of	IN	O
54	CD	SS
evaluable	JJ	O
women	NNS	SE
treated	VBN	O
with	IN	O
tamoxifen	NN	O
,	,	O
24	CD	O
%	NN	O
had	VBD	O
an	DT	O
objective	JJ	O
response	NN	O
,	,	O
as	IN	O
compared	VBN	O
with	IN	O
21	CD	O
%	NN	O
of	IN	O
53	CD	SS
women	NNS	SE
having	VBG	O
an	DT	O
oophorectomy	NN	O
.	.	O

The	DT	O
median	JJ	O
duration	NN	O
of	IN	O
response	NN	O
for	IN	O
tamoxifen	NN	O
(	(	O
20	CD	O
months	NNS	O
)	)	O
was	VBD	O
longer	JJR	O
than	IN	O
that	DT	O
for	IN	O
surgical	JJ	O
oophorectomy	NN	O
(	(	O
7	CD	O
months	NNS	O
)	)	O
,	,	O
but	CC	O
this	DT	O
did	VBD	O
not	RB	O
achieve	VB	O
statistical	JJ	O
significance	NN	O
(	(	O
P	NNP	O
=	NNP	O
.056	NNP	O
)	)	O
.	.	O

Overall	JJ	O
median	JJ	O
survival	NN	O
was	VBD	O
15	CD	O
months	NNS	O
for	IN	O
58	CD	SS
patients	NNS	O
receiving	VBG	O
tamoxifen	NN	O
and	CC	O
25	CD	O
months	NNS	O
for	IN	O
53	CD	O
patients	NNS	O
undergoing	JJ	O
oophorectomy	JJ	O
(	(	O
P	NNP	O
=	NNP	O
.18	NNP	O
)	)	O
.	.	O

Toxicity	NN	O
was	VBD	O
greater	JJR	O
in	IN	O
those	DT	O
undergoing	JJ	O
oophorectomy	NN	O
,	,	O
though	IN	O
both	DT	O
treatments	NNS	O
were	VBD	O
well	RB	O
tolerated	VBN	O
.	.	O

In	IN	O
those	DT	O
premenopausal	JJ	C
women	NNS	SE
for	IN	O
whom	WP	O
hormonal	JJ	O
therapy	NN	O
is	VBZ	O
indicated	VBN	O
,	,	O
tamoxifen	EX	O
is	VBZ	O
a	DT	O
suitable	JJ	O
alternative	NN	O
to	TO	O
surgical	JJ	O
oophorectomy	NN	O
.	.	O

Efficacy	NN	O
and	CC	O
safety	NN	O
of	IN	O
mizolastine	JJ	O
10	CD	O
mg	NN	O
in	IN	O
a	DT	O
placebo-controlled	JJ	O
comparison	NN	O
with	IN	O
loratadine	NN	O
in	IN	O
chronic	JJ	C
idiopathic	JJ	C
urticaria	NNS	C
:	:	O
results	NNS	O
of	IN	O
the	DT	O
MILOR	NNP	O
Study	NNP	O
.	.	O

BACKGROUND	NNP	O
Mizolastine	NNP	O
is	VBZ	O
a	DT	O
novel	JJ	O
histamine	NN	O
H1-antagonist	NN	O
registered	VBD	O
in	IN	O
Europe	NNP	O
for	IN	O
the	DT	O
management	NN	O
of	IN	O
allergic	JJ	O
rhinitis	NN	O
and	CC	O
urticaria	NN	O
.	.	O

OBJECTIVES	NNP	O
To	TO	O
compare	VB	O
the	DT	O
clinical	JJ	O
efficacy	NN	O
and	CC	O
safety	NN	O
of	IN	O
mizolastine	NN	O
with	IN	O
loratadine	NN	O
and	CC	O
placebo	NN	O
in	IN	O
patients	NNS	O
with	IN	O
chronic	JJ	C
idiopathic	JJ	C
urticaria	NN	C
(	(	C
CIU	NNP	C
)	)	C
.	.	O

METHODS	CC	O
A	DT	O
multicentre	NN	O
,	,	O
double-blind	NN	O
,	,	O
parallel	JJ	O
group	NN	O
study	NN	O
was	VBD	O
designed	VBN	O
in	IN	O
which	WDT	O
247	CD	SS
patients	NNS	O
with	IN	O
CIU	NNP	C
were	VBD	O
randomised	VBN	O
after	IN	O
a	DT	O
1-week	JJ	O
placebo	NN	O
run-in	JJ	O
period	NN	O
to	TO	O
10	CD	O
mg	NNS	O
daily	JJ	O
mizolastine	NN	O
(	(	O
n	JJ	O
=	NNP	O
88	CD	O
)	)	O
,	,	O
10	CD	O
mg	JJ	O
daily	JJ	O
loratadine	NN	O
(	(	O
n	JJ	O
=	NNP	O
79	CD	O
)	)	O
,	,	O
or	CC	O
placebo	NN	O
(	(	O
n	JJ	O
=	NNP	O
80	CD	O
)	)	O
for	IN	O
a	DT	O
4-week	JJ	O
treatment	NN	O
period	NN	O
.	.	O

RESULTS	NNP	O
Mizolastine	NNP	O
and	CC	O
loratadine	VB	O
both	DT	O
relieved	JJ	O
symptoms	NNS	O
of	IN	O
CIU	NNP	O
.	.	O

After	IN	O
2	CD	O
weeks	NNS	O
'	POS	O
treatment	NN	O
,	,	O
the	DT	O
severity	NN	O
of	IN	O
pruritus	NN	O
(	(	O
visual	JJ	O
analogue	NN	O
score	NN	O
(	(	O
VAS	NNP	O
)	)	O
assessed	VBN	O
by	IN	O
patients	NNS	O
)	)	O
decreased	VBD	O
significantly	RB	O
in	IN	O
both	CC	O
the	DT	O
mizolastine	NN	O
and	CC	O
loratadine	NN	O
groups	NNS	O
compared	VBN	O
with	IN	O
placebo	NN	O
(	(	O
mizolastine	NN	O
:	:	O
-36.7	NN	O
mm	NN	O
,	,	O
P	NNP	O
=	NNP	O
0.0001	CD	O
;	:	O
loratadine	NN	O
:	:	O
-29.8	NN	O
,	,	O
P	NNP	O
=	NNP	O
0.0071	CD	O
;	:	O
placebo	NN	O
:	:	O
-16.3	NN	O
)	)	O
;	:	O
this	DT	O
improvement	NN	O
with	IN	O
both	DT	O
active	JJ	O
treatments	NNS	O
was	VBD	O
maintained	VBN	O
throughout	IN	O
the	DT	O
treatment	NN	O
period	NN	O
,	,	O
the	DT	O
difference	NN	O
being	VBG	O
significant	JJ	O
only	RB	O
for	IN	O
the	DT	O
mizolastine	NN	O
group	NN	O
(	(	O
P	NNP	O
=	NNP	O
0.0090	CD	O
)	)	O
.	.	O

Both	DT	O
active	JJ	O
treatments	NNS	O
were	VBD	O
also	RB	O
associated	VBN	O
with	IN	O
reduced	JJ	O
weekly	JJ	O
episodes	NNS	O
of	IN	O
urticaria	NNS	O
compared	VBN	O
with	IN	O
placebo	NN	O
,	,	O
which	WDT	O
was	VBD	O
significant	JJ	O
after	IN	O
2	CD	O
weeks	NNS	O
'	POS	O
treatment	NN	O
(	(	O
mizolastine	NN	O
:	:	O
7.9	CD	O
episodes	NNS	O
,	,	O
P	NNP	O
=	NNP	O
0.0061	CD	O
;	:	O
loratadine	NN	O
:	:	O
8.3	CD	O
,	,	O
P	NNP	O
=	NNP	O
0.0221	CD	O
;	:	O
placebo	NN	O
:	:	O
13.3	CD	O
)	)	O
.	.	O

Angioedema	NNP	O
was	VBD	O
improved	VBN	O
to	TO	O
a	DT	O
clinically	RB	O
significant	JJ	O
extent	NN	O
with	IN	O
mizolastine	NN	O
,	,	O
and	CC	O
loratadine	NN	O
compared	VBN	O
with	IN	O
placebo	NN	O
in	IN	O
those	DT	O
patients	NNS	O
who	WP	O
had	VBD	O
this	DT	O
symptom	NN	O
before	IN	O
treatment	NN	O
.	.	O

Overall	JJ	O
tolerability	NN	O
of	IN	O
both	DT	O
treatments	NNS	O
was	VBD	O
similar	JJ	O
to	TO	O
placebo	VB	O
,	,	O
and	CC	O
there	EX	O
were	VBD	O
no	DT	O
clinically	RB	O
relevant	JJ	O
effects	NNS	O
on	IN	O
cardiac	JJ	O
repolarisation	NN	O
with	IN	O
either	DT	O
mizolastine	NN	O
or	CC	O
loratadine	NN	O
.	.	O

CONCLUSION	NNP	O
Mizolastine	NNP	O
(	(	O
10	CD	O
mg	NNS	O
daily	RB	O
)	)	O
is	VBZ	O
confirmed	VBN	O
as	IN	O
an	DT	O
effective	JJ	O
and	CC	O
well	RB	O
tolerated	JJ	O
agent	NN	O
,	,	O
comparable	JJ	O
to	TO	O
loratadine	VB	O
and	CC	O
superior	VB	O
to	TO	O
placebo	VB	O
,	,	O
for	IN	O
the	DT	O
management	NN	O
of	IN	O
CIU	NNP	O
.	.	O

Mizolastine	NNP	O
acted	VBD	O
as	RB	O
rapidly	RB	O
as	IN	O
loratadine	NN	O
in	IN	O
improving	VBG	O
urticarial	JJ	O
symptoms	NNS	O
from	IN	O
the	DT	O
first	JJ	O
day	NN	O
of	IN	O
treatment	NN	O
.	.	O

Antibiotic	JJ	O
therapy	NN	O
of	IN	O
acute	JJ	O
exacerbations	NNS	O
of	IN	O
chronic	JJ	O
bronchitis	NN	O
.	.	O

A	DT	O
controlled	VBN	O
study	NN	O
using	VBG	O
tetracycline	NN	O
.	.	O

We	PRP	O
conducted	VBD	O
a	DT	O
double-blind	NN	O
,	,	O
randomized	VBN	O
,	,	O
placebo-controlled	JJ	O
trial	NN	O
in	IN	O
40	CD	O
patients	NNS	O
to	TO	O
evaluate	VB	O
the	DT	O
need	NN	O
for	IN	O
antibiotics	NNS	O
in	IN	O
acute	JJ	O
exacerbations	NNS	O
of	IN	O
chronic	JJ	O
bronchitis	NN	O
.	.	O

All	DT	O
patients	NNS	O
were	VBD	O
sufficiently	RB	O
ill	VBN	O
to	TO	O
require	VB	O
hospitalization	NN	O
although	IN	O
none	NN	O
needed	VBD	O
ventilatory	JJ	O
support	NN	O
;	:	O
the	DT	O
presence	NN	O
of	IN	O
pneumonia	NN	O
was	VBD	O
excluded	VBN	O
.	.	O

Treatment	NNP	O
consisted	VBD	O
of	IN	O
bronchodilators	NNS	O
,	,	O
corticosteroids	NNS	O
,	,	O
and	CC	O
either	DT	O
tetracycline	NN	O
,	,	O
500	CD	O
mg	NN	O
,	,	O
or	CC	O
placebo	NN	O
by	IN	O
mouth	NN	O
every	DT	O
6	CD	O
hours	NNS	O
for	IN	O
1	CD	O
week	NN	O
.	.	O

Arterial	JJ	O
blood	NN	O
gases	NNS	O
,	,	O
spirometric	JJ	O
tests	NNS	O
,	,	O
bacteriologic	JJ	O
evaluation	NN	O
of	IN	O
sputum	NN	O
,	,	O
and	CC	O
patient	NN	O
and	CC	O
physician	JJ	O
evaluation	NN	O
of	IN	O
the	DT	O
severity	NN	O
of	IN	O
illness	NN	O
were	VBD	O
assessed	VBN	O
at	IN	O
the	DT	O
beginning	NN	O
and	CC	O
end	NN	O
of	IN	O
the	DT	O
study	NN	O
.	.	O

All	DT	O
patients	NNS	O
improved	VBN	O
both	DT	O
symptomatically	RB	O
and	CC	O
by	IN	O
objective	JJ	O
measures	NNS	O
of	IN	O
lung	NN	O
function	NN	O
.	.	O

At	IN	O
the	DT	O
end	NN	O
of	IN	O
the	DT	O
study	NN	O
period	NN	O
there	EX	O
were	VBD	O
no	DT	O
differences	NNS	O
between	IN	O
those	DT	O
patients	NNS	O
receiving	VBG	O
tetracycline	NN	O
and	CC	O
those	DT	O
receiving	VBG	O
placebo	NN	O
.	.	O

We	PRP	O
conclude	VBP	O
that	IN	O
antibiotic	JJ	O
therapy	NN	O
is	VBZ	O
not	RB	O
needed	VBN	O
in	IN	O
moderately	RB	O
ill	JJ	O
patients	NNS	O
with	IN	O
exacerbations	NNS	O
of	IN	O
chronic	JJ	O
bronchitis	NN	O
.	.	O

An	DT	O
interactive	JJ	O
computer	NN	O
program	NN	O
can	MD	O
effectively	RB	O
educate	VB	O
potential	JJ	O
users	NNS	O
of	IN	O
cystic	JJ	C
fibrosis	NN	C
carrier	NN	C
tests	NNS	O
.	.	O

The	DT	O
demand	NN	O
for	IN	O
cystic	JJ	O
fibrosis	NN	O
(	(	O
CF	NNP	O
)	)	O
carrier	NN	O
testing	VBG	O
is	VBZ	O
steadily	RB	O
growing	VBG	O
,	,	O
not	RB	O
only	RB	O
from	IN	O
individuals	NNS	O
with	IN	O
raised	VBN	C
a	DT	C
priori	FW	C
carrier	NN	C
risk	NN	C
,	,	O
but	CC	O
also	RB	O
from	IN	O
the	DT	O
general	JJ	O
population	NN	O
.	.	O

This	DT	O
trend	NN	O
will	MD	O
likely	RB	O
exceed	VB	O
the	DT	O
availability	NN	O
of	IN	O
genetic	JJ	O
counselors	NNS	O
,	,	O
making	VBG	O
it	PRP	O
impossible	JJ	O
to	TO	O
provide	VB	O
standard	JJ	O
face-to-face	JJ	O
genetic	JJ	O
counseling	NN	O
to	TO	O
all	PDT	O
those	DT	O
asking	VBG	O
for	IN	O
the	DT	O
test	NN	O
.	.	O

In	IN	O
order	NN	O
to	TO	O
reduce	VB	O
the	DT	O
time	NN	O
needed	VBN	O
to	TO	O
educate	VB	O
individuals	NNS	O
on	IN	O
the	DT	O
basics	NNS	O
of	IN	O
the	DT	O
disease	NN	O
,	,	O
its	PRP$	O
genetic	JJ	O
transmission	NN	O
,	,	O
and	CC	O
carrier	NN	O
testing	VBG	O
peculiarities	NNS	O
,	,	O
we	PRP	O
developed	VBD	O
an	DT	O
educational	JJ	O
method	NN	O
based	VBN	O
on	IN	O
an	DT	O
interactive	JJ	O
computer	NN	O
program	NN	O
(	(	O
IC	NNP	O
)	)	O
.	.	O

To	TO	O
assess	VB	O
the	DT	O
effectiveness	NN	O
of	IN	O
this	DT	O
program	NN	O
and	CC	O
to	TO	O
compare	VB	O
it	PRP	O
to	TO	O
a	DT	O
classical	JJ	O
genetic	JJ	O
counseling	NN	O
session	NN	O
,	,	O
we	PRP	O
conducted	VBD	O
a	DT	O
comparative	JJ	O
trial	NN	O
.	.	O

In	IN	O
a	DT	O
population	NN	O
setting	NN	O
of	IN	O
people	NNS	O
undergoing	VBG	O
assisted	JJ	O
reproduction	NN	O
,	,	O
44	CD	SS
individuals	NNS	SS
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
either	DT	O
receiving	VBG	O
standard	JJ	O
one-on-one	JJ	O
genetic	JJ	O
counseling	NN	O
or	CC	O
education	NN	O
by	IN	O
the	DT	O
IC	NNP	O
program	NN	O
.	.	O

We	PRP	O
measured	VBD	O
pre-	JJ	O
and	CC	O
post-intervention	NN	O
knowledge	NN	O
about	IN	O
CF	NNP	O
genetic	JJ	O
transmission	NN	O
and	CC	O
carrier	NN	O
testing	NN	O
.	.	O

Starting	VBG	O
from	IN	O
an	DT	O
equivalent	JJ	O
baseline	NN	O
of	IN	O
correct	JJ	O
answers	NNS	O
to	TO	O
a	DT	O
specially	RB	O
designed	VBN	O
multiple-choice	NN	O
questionnaire	NN	O
(	(	O
47	CD	O
%	NN	O
in	IN	O
the	DT	O
counselor	NN	O
group	NN	O
and	CC	O
45	CD	O
%	NN	O
in	IN	O
the	DT	O
computer	NN	O
group	NN	O
)	)	O
both	DT	O
groups	NNS	O
showed	VBD	O
a	DT	O
highly	RB	O
significant	JJ	O
and	CC	O
similar	JJ	O
increase	NN	O
(	(	O
reaching	VBG	O
84	CD	O
%	NN	O
in	IN	O
the	DT	O
counselor	NN	O
group	NN	O
and	CC	O
85	CD	O
%	NN	O
in	IN	O
the	DT	O
computer	NN	O
group	NN	O
)	)	O
.	.	O

The	DT	O
computer	NN	O
program	NN	O
under	IN	O
evaluation	NN	O
can	MD	O
successfully	RB	O
educate	VB	O
individuals	NNS	O
considering	VBG	O
genetic	JJ	O
testing	NN	O
for	IN	O
CF	NNP	O
.	.	O

Dentists	NNS	O
United	NNP	O
to	TO	O
Extinguish	VB	O
Tobacco	NNP	O
(	(	O
DUET	NNP	O
)	)	O
:	:	O
a	DT	O
study	NN	O
protocol	NN	O
for	IN	O
a	DT	O
cluster	NN	O
randomized	VBN	O
,	,	O
controlled	VBN	O
trial	NN	O
for	IN	O
enhancing	VBG	O
implementation	NN	O
of	IN	O
clinical	JJ	O
practice	NN	O
guidelines	NNS	O
for	IN	O
treating	VBG	O
tobacco	NN	C
dependence	NN	C
in	IN	O
dental	JJ	O
care	NN	O
settings	NNS	O
.	.	O

BACKGROUND	NNP	O
Although	IN	O
dental	JJ	O
care	NN	O
settings	NNS	O
provide	VBP	O
an	DT	O
exceptional	JJ	O
opportunity	NN	O
to	TO	O
reach	VB	O
smokers	NNS	C
and	CC	O
provide	VB	O
brief	JJ	O
cessation	NN	O
advice	NN	O
and	CC	O
treatment	NN	O
to	TO	O
reduce	VB	O
oral	JJ	O
and	CC	O
other	JJ	O
tobacco-related	JJ	O
health	NN	O
conditions	NNS	O
,	,	O
dental	JJ	O
care	NN	O
providers	NNS	O
demonstrate	VBP	O
limited	JJ	O
adherence	NN	O
to	TO	O
evidence-based	JJ	O
guidelines	NNS	O
for	IN	O
treatment	NN	O
of	IN	O
tobacco	NN	C
use	NN	C
and	CC	C
dependence	NN	C
.	.	O

METHODS/DESIGN	NNP	O
Guided	VBN	O
by	IN	O
a	DT	O
multi-level	NN	O
,	,	O
conceptual	JJ	O
framework	NN	O
that	WDT	O
emphasizes	VBZ	O
changes	NNS	O
in	IN	O
provider	NN	O
beliefs	NNS	O
and	CC	O
organizational	JJ	O
characteristics	NNS	O
as	IN	O
drivers	NNS	O
of	IN	O
improvement	NN	O
in	IN	O
tobacco	NN	O
treatment	NN	O
delivery	NN	O
,	,	O
the	DT	O
current	JJ	O
protocol	NN	O
will	MD	O
use	VB	O
a	DT	O
cluster	NN	O
,	,	O
randomized	VBN	O
design	NN	O
and	CC	O
multiple	JJ	O
data	NNS	O
sources	NNS	O
(	(	O
patient	JJ	O
exit	NN	O
interviews	NNS	O
,	,	O
provider	NN	O
surveys	NNS	O
,	,	O
site	NN	O
observations	NNS	O
,	,	O
chart	JJ	O
audits	NN	O
,	,	O
and	CC	O
semi-structured	JJ	O
provider	NN	O
interviews	NNS	O
)	)	O
to	TO	O
study	VB	O
the	DT	O
process	NN	O
of	IN	O
implementing	VBG	O
clinical	JJ	O
practice	NN	O
guidelines	NNS	O
for	IN	O
treating	VBG	O
tobacco	NN	O
dependence	NN	O
in	IN	O
18	CD	O
public	JJ	O
dental	NN	O
care	NN	O
clinics	NNS	O
in	IN	O
New	NNP	O
York	NNP	O
City	NNP	O
.	.	O

The	DT	O
specific	JJ	O
aims	NNS	O
of	IN	O
this	DT	O
comparative-effectiveness	JJ	O
research	NN	O
trial	NN	O
are	VBP	O
to	TO	O
:	:	O
compare	VB	O
the	DT	O
effectiveness	NN	O
of	IN	O
three	CD	O
promising	VBG	O
strategies	NNS	O
for	IN	O
implementation	NN	O
of	IN	O
tobacco	NN	O
use	NN	O
treatment	NN	O
guidelines-staff	JJ	O
training	NN	O
and	CC	O
current	JJ	O
best	JJS	O
practices	NNS	O
(	(	O
CBP	NNP	O
)	)	O
,	,	O
CBP	NNP	O
+	NNP	O
provider	NN	O
performance	NN	O
feedback	NN	O
(	(	O
PF	NNP	O
)	)	O
,	,	O
and	CC	O
CBP	NNP	O
+	NNP	O
PF	NNP	O
+	NNP	O
provider	NN	O
reimbursement	NN	O
for	IN	O
delivery	NN	O
of	IN	O
tobacco	NN	O
cessation	NN	O
treatment	NN	O
(	(	O
pay-for-performance	NN	O
,	,	O
or	CC	O
P4P	NNP	O
)	)	O
;	:	O
examine	JJ	O
potential	JJ	O
theory-driven	JJ	O
mechanisms	NNS	O
hypothesized	VBN	O
to	TO	O
explain	VB	O
the	DT	O
comparative	JJ	O
effectiveness	NN	O
of	IN	O
three	CD	O
strategies	NNS	O
for	IN	O
implementation	NN	O
;	:	O
and	CC	O
identify	VB	O
baseline	JJ	O
organizational	JJ	O
factors	NNS	O
that	WDT	O
influence	VBP	O
the	DT	O
implementation	NN	O
of	IN	O
evidence-based	JJ	O
tobacco	NN	O
use	NN	O
treatment	NN	O
practices	NNS	O
in	IN	O
dental	JJ	O
clinics	NNS	O
.	.	O

The	DT	O
primary	JJ	O
outcome	NN	O
is	VBZ	O
change	VBN	O
in	IN	O
providers	NNS	O
'	POS	O
tobacco	NN	O
treatment	NN	O
practices	NNS	O
and	CC	O
the	DT	O
secondary	JJ	O
outcomes	NNS	O
are	VBP	O
cost	VBN	O
per	IN	O
quit	NN	O
,	,	O
use	NN	O
of	IN	O
tobacco	NN	O
cessation	NN	O
treatments	NNS	O
,	,	O
quit	NN	O
attempts	NNS	O
,	,	O
and	CC	O
smoking	VBG	O
abstinence	NN	O
.	.	O

DISCUSSION	NNP	O
We	PRP	O
hypothesize	VBP	O
that	IN	O
the	DT	O
value	NN	O
of	IN	O
these	DT	O
promising	JJ	O
implementation	NN	O
strategies	NNS	O
is	VBZ	O
additive	JJ	O
and	CC	O
that	IN	O
incorporating	VBG	O
all	DT	O
three	CD	O
strategies	NNS	O
(	(	O
CBP	NNP	O
,	,	O
PF	NNP	O
,	,	O
and	CC	O
P4P	NNP	O
)	)	O
will	MD	O
be	VB	O
superior	JJ	O
to	TO	O
CBP	VB	O
alone	RB	O
and	CC	O
CBP	NNP	O
+	NNP	O
PF	NNP	O
in	IN	O
improving	VBG	O
delivery	NN	O
of	IN	O
cessation	NN	O
assistance	NN	O
to	TO	O
smokers	NNS	O
.	.	O

The	DT	O
findings	NNS	O
will	MD	O
improve	VB	O
knowledge	NN	O
pertinent	NN	O
to	TO	O
the	DT	O
implementation	NN	O
,	,	O
dissemination	NN	O
,	,	O
and	CC	O
sustained	VBD	O
utilization	NN	O
of	IN	O
evidence-based	JJ	O
tobacco	NN	O
use	NN	O
treatment	NN	O
in	IN	O
dental	JJ	O
practices	NNS	O
.	.	O

TRIAL	NNP	O
REGISTRATION	NNP	O
NCT01615237	NNP	O
.	.	O

Treatment	NN	O
of	IN	O
duodenal	JJ	C
ulcer	NN	C
with	IN	O
low-dose	JJ	O
antacids	NNS	O
.	.	O

The	DT	O
aim	NN	O
of	IN	O
the	DT	O
present	JJ	O
investigation	NN	O
was	VBD	O
to	TO	O
compare	VB	O
the	DT	O
efficacy	NN	O
of	IN	O
a	DT	O
low-dose	JJ	O
antacid	NN	O
(	(	O
Maalox	NNP	O
70	CD	O
,	,	O
280	CD	O
mmol/day	NN	O
)	)	O
with	IN	O
that	DT	O
of	IN	O
the	DT	O
H2-receptor	NNP	O
antagonist	NN	O
cimetidine	NN	O
(	(	O
Tagamet	NNP	O
,	,	O
200	CD	O
mg	NN	O
three	CD	O
times	NNS	O
daily	RB	O
and	CC	O
400	CD	O
mg/day	NN	O
)	)	O
after	IN	O
14	CD	O
and	CC	O
28	CD	O
days	NNS	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
duodenal	JJ	C
ulcer	NN	C
.	.	O

The	DT	O
prospective	JJ	O
multicentre	NN	O
study	NN	O
included	VBD	O
171	CD	SS
patients	NNS	O
with	IN	O
endoscopically	RB	O
confirmed	VBN	O
duodenal	JJ	C
ulcers	NNS	C
.	.	O

The	DT	O
patients	NNS	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
the	DT	O
treatment	NN	O
groups	NNS	O
with	IN	O
antacid	JJ	O
containing	VBG	O
Mg	NNP	O
and	CC	O
Al	NNP	O
hydroxide	NN	O
(	(	O
M	NNP	O
)	)	O
(	(	O
4	CD	O
X	RB	O
70	CD	O
mmol/day	NN	O
;	:	O
n	CC	O
=	VB	O
86	CD	O
)	)	O
or	CC	O
to	TO	O
the	DT	O
group	NN	O
receiving	VBG	O
cimetidine	NN	O
(	(	O
T	NNP	O
)	)	O
(	(	O
1000	CD	O
mg/day	NN	O
;	:	O
n	CC	O
=	VB	O
85	CD	O
)	)	O
.	.	O

The	DT	O
two	CD	O
treatment	NN	O
groups	NNS	O
were	VBD	O
matched	VBN	O
for	IN	O
age	NN	O
,	,	O
sex	NN	O
,	,	O
drinking	NN	O
and	CC	O
smoking	NN	O
habits	NNS	O
,	,	O
and	CC	O
drug	NN	O
use	NN	O
.	.	O

Endoscopic	JJ	O
examinations	NNS	O
were	VBD	O
carried	VBN	O
out	RP	O
before	IN	O
the	DT	O
start	NN	O
of	IN	O
treatment	NN	O
and	CC	O
14	CD	O
days	NNS	O
later	RB	O
.	.	O

If	IN	O
the	DT	O
ulcer	NN	O
was	VBD	O
still	RB	O
present	JJ	O
at	IN	O
this	DT	O
time	NN	O
,	,	O
the	DT	O
second	JJ	O
endoscopic	NN	O
examination	NN	O
was	VBD	O
done	VBN	O
after	IN	O
a	DT	O
further	JJ	O
14	CD	O
days	NNS	O
.	.	O

Endoscopically	RB	O
,	,	O
the	DT	O
ulcer	NN	O
had	VBD	O
healed	VBN	O
at	IN	O
14	CD	O
days	NNS	O
in	IN	O
38.8	CD	O
%	NN	O
(	(	O
M	NNP	O
)	)	O
and	CC	O
in	IN	O
34.9	CD	O
%	NN	O
(	(	O
T	NNP	O
)	)	O
and	CC	O
at	IN	O
28	CD	O
days	NNS	O
in	IN	O
80.0	CD	O
%	NN	O
(	(	O
M	NNP	O
)	)	O
and	CC	O
74.7	CD	O
%	NN	O
(	(	O
T	NNP	O
)	)	O
,	,	O
respectively	RB	O
.	.	O

The	DT	O
healing	VBG	O
rate	NN	O
did	VBD	O
not	RB	O
differ	VB	O
significantly	RB	O
between	IN	O
the	DT	O
two	CD	O
treatment	NN	O
groups	NNS	O
.	.	O

Complaints	NNS	O
,	,	O
measured	VBN	O
as	IN	O
percentage	NN	O
of	IN	O
days	NNS	O
per	IN	O
week	NN	O
with	IN	O
upper	JJ	O
abdominal	JJ	O
pain	NN	O
,	,	O
were	VBD	O
significantly	RB	O
reduced	VBN	O
in	IN	O
both	DT	O
groups	NNS	O
.	.	O

No	DT	O
significant	JJ	O
differences	NNS	O
were	VBD	O
found	VBN	O
between	IN	O
the	DT	O
two	CD	O
treatment	NN	O
groups	NNS	O
with	IN	O
regard	NN	O
to	TO	O
pain	VB	O
relief	NN	O
or	CC	O
side	NN	O
effects	NNS	O
.	.	O

Treatment	NN	O
had	VBD	O
to	TO	O
be	VB	O
abandoned	VBN	O
in	IN	O
one	CD	O
patient	NN	O
receiving	VBG	O
antacid	NN	O
because	IN	O
of	IN	O
diarrhoea	NN	O
and	CC	O
in	IN	O
one	CD	O
patient	NN	O
receiving	VBG	O
cimetidine	NN	O
because	IN	O
of	IN	O
the	DT	O
absence	NN	O
of	IN	O
any	DT	O
response	NN	O
.	.	O

(	(	O
ABSTRACT	NNP	O
TRUNCATED	NNP	O
AT	NNP	O
250	CD	O
WORDS	NNP	O
)	)	O
Effect	NN	O
of	IN	O
ischemic	JJ	O
postconditioning	NN	O
in	IN	O
correction	NN	O
of	IN	O
tetralogy	NN	O
of	IN	O
Fallot	NNP	O
.	.	O

Inappropriate	NNP	O
myocardial	JJ	O
protection	NN	O
is	VBZ	O
considered	VBN	O
one	CD	O
of	IN	O
the	DT	O
main	JJ	O
causes	NNS	O
of	IN	O
mortality	NN	O
and	CC	O
morbidity	NN	O
in	IN	O
the	DT	O
correction	NN	O
of	IN	O
tetralogy	NN	O
of	IN	O
Fallot	NNP	O
(	(	O
TOF	NNP	O
)	)	O
.	.	O

Results	NNS	O
of	IN	O
previous	JJ	O
reports	NNS	O
about	IN	O
the	DT	O
effects	NNS	O
of	IN	O
ischemic	JJ	O
postconditioning	NN	O
on	IN	O
myocardial	JJ	O
protection	NN	O
in	IN	O
animals	NNS	O
and	CC	O
humans	NNS	O
are	VBP	O
very	RB	O
encouraging	JJ	O
.	.	O

This	DT	O
randomized	JJ	O
and	CC	O
controlled	JJ	O
trial	NN	O
aimed	VBN	O
to	TO	O
assess	VB	O
the	DT	O
effect	NN	O
of	IN	O
ischemic	JJ	O
postconditioning	VBG	O
on	IN	O
protection	NN	O
against	IN	O
myocardial	JJ	O
ischemia	NN	O
reperfusion	NN	O
injury	NN	O
in	IN	O
TOF	NNP	O
patients	NNS	O
receiving	VBG	O
cardioplegia	NN	O
.	.	O

From	IN	O
January	NNP	O
2008	CD	O
to	TO	O
June	NNP	O
2010	CD	O
,	,	O
80	CD	O
consecutive	JJ	O
children	NNS	O
undergoing	VBG	O
correction	NN	O
of	IN	O
TOF	NNP	O
were	VBD	O
enrolled	VBN	O
and	CC	O
randomly	RB	O
assigned	VBN	O
to	TO	O
either	VB	O
a	DT	O
postconditioning	NN	O
group	NN	O
(	(	O
three	CD	O
cycles	NNS	O
of	IN	O
30	CD	O
seconds	NNS	O
of	IN	O
ischemia	NN	O
and	CC	O
30	CD	O
seconds	NNS	O
of	IN	O
reperfusion	NN	O
using	VBG	O
re-clamping	JJ	O
and	CC	O
de-clamping	JJ	O
starting	VBG	O
30	CD	O
seconds	NNS	O
after	IN	O
the	DT	O
initial	JJ	O
de-clamping	NN	O
of	IN	O
the	DT	O
aorta	NN	O
,	,	O
n	JJ	O
=	NNP	O
41	CD	O
)	)	O
or	CC	O
a	DT	O
control	NN	O
group	NN	O
(	(	O
n	JJ	O
=	NNP	O
39	CD	O
)	)	O
.	.	O

Cardiac	NNP	O
troponin	NN	O
I	PRP	O
(	(	O
cTnI	NN	O
)	)	O
was	VBD	O
assayed	VBN	O
preoperatively	RB	O
,	,	O
and	CC	O
then	RB	O
4	CD	O
hours	NNS	O
,	,	O
8	CD	O
hours	NNS	O
,	,	O
12	CD	O
hours	NNS	O
,	,	O
20	CD	O
hours	NNS	O
,	,	O
and	CC	O
48	CD	O
hours	NNS	O
after	IN	O
persistent	JJ	O
reperfusion	NN	O
.	.	O

The	DT	O
pre-	JJ	O
,	,	O
intra-	JJ	O
and	CC	O
postoperative	JJ	O
relevant	JJ	O
data	NNS	O
of	IN	O
all	DT	O
selected	VBN	O
patients	NNS	O
were	VBD	O
analyzed	VBN	O
.	.	O

As	IN	O
a	DT	O
result	NN	O
,	,	O
ischemic	JJ	O
postconditioning	NN	O
reduced	VBD	O
postoperative	JJ	O
peak	NN	O
release	NN	O
by	IN	O
45	CD	O
%	NN	O
for	IN	O
cTnI	NN	O
compared	VBN	O
with	IN	O
the	DT	O
control	NN	O
group	NN	O
(	(	O
0.43	CD	O
?	.	O
0.18	CD	O
ng/mL	JJ	O
versus	NN	O
0.78	CD	O
?	.	O
0.15	CD	O
ng/mL	NN	O
,	,	O
P	NNP	O
<	NNP	O
0.0001	CD	O
)	)	O
.	.	O

Ischemic	NNP	O
postconditioned	VBD	O
patients	NNS	O
had	VBD	O
a	DT	O
lower	JJR	O
peak	NN	O
inotropic	NN	O
score	NN	O
during	IN	O
the	DT	O
first	JJ	O
postoperative	JJ	O
24	CD	O
hours	NNS	O
(	(	O
5.6	CD	O
?	.	O
2.2	CD	O
?g/kg/minute	JJ	O
versus	NN	O
8.6	CD	O
?	.	O
3.6	CD	O
?g/kg/minute	NN	O
,	,	O
P	NNP	O
<	NNP	O
0.0001	CD	O
)	)	O
,	,	O
extubation	JJ	O
time	NN	O
(	(	O
21.5	CD	O
?	.	O
7.3	CD	O
hours	NNS	O
versus	IN	O
30.2	CD	O
?	.	O
12.4	CD	O
hours	NNS	O
,	,	O
P	NNP	O
=	NNP	O
0.0002	CD	O
)	)	O
and	CC	O
length	NN	O
of	IN	O
ICU	NNP	O
stay	NN	O
(	(	O
43.4	CD	O
?	.	O
12.6	CD	O
hours	NNS	O
versus	IN	O
56.3	CD	O
?	.	O
17.8	CD	O
hours	NNS	O
,	,	O
P	NNP	O
=	NNP	O
0.0003	CD	O
)	)	O
,	,	O
while	IN	O
they	PRP	O
had	VBD	O
a	DT	O
higher	JJR	O
cardiac	JJ	O
output	NN	O
on	IN	O
the	DT	O
first	JJ	O
postoperative	JJ	O
day	NN	O
(	(	O
1.41	CD	O
?	.	O
0.26	CD	O
L/minute	NNP	O
versus	NN	O
1.28	CD	O
?	.	O
0.25	CD	O
L/minute	NNP	O
,	,	O
P	NNP	O
=	NNP	O
0.0255	CD	O
)	)	O
as	IN	O
compared	VBN	O
to	TO	O
the	DT	O
control	NN	O
group	NN	O
.	.	O

In	IN	O
conclusion	NN	O
,	,	O
ischemic	JJ	O
postconditioning	NN	O
may	MD	O
to	TO	O
some	DT	O
extent	NN	O
provide	VBP	O
myocardial	JJ	O
protection	NN	O
in	IN	O
children	NNS	O
undergoing	VBG	O
correction	NN	O
of	IN	O
tetralogy	NN	O
of	IN	O
Fallot	NNP	O
.	.	O

The	DT	O
Randomised	JJ	O
Intervention	NNP	O
Treatment	NNP	O
of	IN	O
Angina	NNP	O
(	(	O
RITA	NNP	O
)	)	O
Trial	NNP	O
protocol	NN	O
:	:	O
a	DT	O
long	JJ	O
term	NN	O
study	NN	O
of	IN	O
coronary	JJ	O
angioplasty	NN	O
and	CC	O
coronary	JJ	O
artery	NN	O
bypass	NN	O
surgery	NN	O
in	IN	O
patients	NNS	O
with	IN	O
angina	NN	C
.	.	O

The	DT	O
Randomised	JJ	O
Intervention	NNP	O
Treatment	NNP	O
of	IN	O
Angina	NNP	O
(	(	O
RITA	NNP	O
)	)	O
Trial	NNP	O
is	VBZ	O
a	DT	O
prospective	JJ	O
,	,	O
randomised	VBD	O
study	NN	O
to	TO	O
compare	VB	O
the	DT	O
short	JJ	O
term	NN	O
and	CC	O
long	JJ	O
term	NN	O
effects	NNS	O
of	IN	O
percutaneous	JJ	O
transluminal	JJ	O
coronary	NN	O
angioplasty	NN	O
and	CC	O
coronary	JJ	O
artery	NN	O
bypass	NN	O
surgery	NN	O
.	.	O

During	IN	O
the	DT	O
study	NN	O
a	DT	O
register	NN	O
of	IN	O
patients	NNS	O
undergoing	VBG	O
coronary	JJ	C
arteriography	NN	C
at	IN	O
the	DT	O
fourteen	JJ	O
participating	VBG	O
centres	NNS	O
is	VBZ	O
being	VBG	O
maintained	VBN	O
to	TO	O
assess	VB	O
the	DT	O
overall	JJ	O
context	NN	O
of	IN	O
patient	JJ	O
recruitment	NN	O
.	.	O

Patients	NNS	O
with	IN	O
arteriographically	RB	C
proven	JJ	C
coronary	JJ	C
artery	NN	C
disease	NN	C
are	VBP	O
considered	VBN	O
for	IN	O
the	DT	O
trial	NN	O
if	IN	O
the	DT	O
participating	VBG	O
cardiologist	NN	O
and	CC	O
surgeon	NN	O
agree	VBP	O
that	IN	O
equivalent	JJ	O
revascularisation	NN	O
could	MD	O
be	VB	O
achieved	VBN	O
by	IN	O
either	DT	O
treatment	NN	O
method	NN	O
.	.	O

Patients	NNS	O
who	WP	O
satisfy	VBP	O
the	DT	O
trial	NN	O
entry	NN	O
criteria	NNS	O
are	VBP	O
randomised	VBN	O
to	TO	O
treatment	NN	O
by	IN	O
coronary	JJ	O
angioplasty	NN	O
or	CC	O
coronary	JJ	O
artery	NN	O
bypass	NN	O
surgery	NN	O
,	,	O
with	IN	O
prospective	JJ	O
stratification	NN	O
into	IN	O
groups	NNS	O
with	IN	O
one	CD	O
,	,	O
two	CD	O
,	,	O
or	CC	O
three	CD	O
treatment	NN	O
vessels	NNS	O
.	.	O

Randomisation	NNP	O
implies	VBZ	O
an	DT	O
intention	NN	O
to	TO	O
treat	VB	O
the	DT	O
patient	NN	O
by	IN	O
the	DT	O
assigned	JJ	O
procedure	NN	O
and	CC	O
the	DT	O
analysis	NN	O
of	IN	O
long	JJ	O
term	NN	O
results	NNS	O
will	MD	O
include	VB	O
all	DT	O
randomised	JJ	O
cases	NNS	O
.	.	O

The	DT	O
trial	NN	O
will	MD	O
recruit	VB	O
at	IN	O
least	JJS	O
1000	CD	SS
patients	NNS	O
who	WP	O
will	MD	O
be	VB	O
followed	VBN	O
for	IN	O
five	CD	O
years	NNS	O
.	.	O

The	DT	O
major	JJ	O
trial	NN	O
end	NN	O
points	NNS	O
include	VBP	O
death	NN	O
,	,	O
new	JJ	O
myocardial	JJ	O
infarction	NN	O
,	,	O
and	CC	O
new	JJ	O
coronary	JJ	O
angioplasty	NN	O
or	CC	O
coronary	JJ	O
artery	NN	O
bypass	NN	O
procedures	NNS	O
.	.	O

Other	JJ	O
outcome	JJ	O
measures	NNS	O
include	VBP	O
symptom	NN	O
and	CC	O
employment	NN	O
status	NN	O
,	,	O
quality	NN	O
of	IN	O
life	NN	O
,	,	O
exercise	NN	O
tolerance	NN	O
,	,	O
and	CC	O
left	VBD	O
ventricular	JJ	O
function	NN	O
.	.	O

Antibiotic	JJ	O
elimination	NN	O
of	IN	O
group-B	JJ	O
streptococci	NN	O
in	IN	O
urine	NN	O
in	IN	O
prevention	NN	O
of	IN	O
preterm	JJ	C
labour	NN	C
.	.	O

The	DT	O
presence	NN	O
of	IN	O
group-B	JJ	O
streptococci	NN	O
in	IN	O
the	DT	O
urine	NN	O
of	IN	O
pregnant	JJ	C
women	NNS	SE
seems	VBZ	O
to	TO	O
be	VB	O
associated	VBN	O
with	IN	O
preterm	JJ	O
labour	NN	O
.	.	O

Urine	JJ	O
samples	NNS	O
from	IN	O
4122	CD	SS
women	NNS	O
at	IN	O
27-31	JJ	O
weeks	NNS	O
'	POS	O
gestation	NN	O
were	VBD	O
examined	VBN	O
for	IN	O
bacteria	NNS	O
.	.	O

Group-B	JJ	O
streptococci	NN	O
were	VBD	O
found	VBN	O
in	IN	O
the	DT	O
urine	NN	O
of	IN	O
69	CD	O
women	NNS	O
.	.	O

In	IN	O
a	DT	O
double-blind	NN	O
,	,	O
controlled	VBD	O
study	NN	O
these	DT	O
patients	NNS	O
were	VBD	O
given	VBN	O
either	CC	O
penicillin	NN	O
(	(	O
10	CD	O
(	(	O
6	CD	O
)	)	O
IU	NNP	O
three	CD	O
times	NNS	O
daily	RB	O
for	IN	O
6	CD	O
days	NNS	O
;	:	O
37	CD	O
patients	NNS	O
)	)	O
or	CC	O
placebo	NN	O
(	(	O
32	CD	O
patients	NNS	O
)	)	O
.	.	O

The	DT	O
rates	NNS	O
of	IN	O
primary	JJ	O
rupture	NN	O
of	IN	O
the	DT	O
membranes	NNS	O
(	(	O
11	CD	O
%	NN	O
v	JJ	O
53	CD	O
%	NN	O
;	:	O
p	CC	O
less	JJR	O
than	IN	O
0.001	CD	O
)	)	O
and	CC	O
preterm	VB	O
labour	NN	O
(	(	O
5.4	CD	O
%	NN	O
v	JJ	O
38	CD	O
%	NN	O
;	:	O
p	CC	O
less	JJR	O
than	IN	O
0.002	CD	O
)	)	O
were	VBD	O
significantly	RB	O
lower	JJR	O
in	IN	O
the	DT	O
penicillin	NN	O
group	NN	O
than	IN	O
in	IN	O
the	DT	O
placebo	NN	O
group	NN	O
.	.	O

These	DT	O
results	NNS	O
suggest	VBP	O
that	IN	O
treatment	NN	O
and	CC	O
follow-up	NN	O
to	TO	O
prevent	VB	O
recolonisation	NN	O
in	IN	O
pregnant	JJ	C
women	NNS	O
with	IN	O
group-B	JJ	C
streptococci	NN	C
in	IN	O
the	DT	O
urine	NN	O
may	MD	O
reduce	VB	O
the	DT	O
frequency	NN	O
of	IN	O
preterm	JJ	O
labour	NN	O
in	IN	O
these	DT	O
patients	NNS	O
.	.	O

Pharmacokinetic	NNP	O
study	NN	O
of	IN	O
RU	NNP	O
486	CD	O
and	CC	O
its	PRP$	O
metabolites	NNS	O
after	IN	O
oral	JJ	O
administration	NN	O
of	IN	O
single	JJ	O
doses	NNS	O
to	TO	O
pregnant	VB	C
and	CC	O
non-pregnant	JJ	C
women	NNS	SE
.	.	O

RU	NNP	O
486	CD	O
and	CC	O
three	CD	O
of	IN	O
its	PRP$	O
metabolites	NNS	O
(	(	O
RU	NNP	O
42633-monodemethyl	CD	O
,	,	O
RU	NNP	O
42848-didemethyl	CD	O
,	,	O
and	CC	O
RU	NNP	O
42698-hydroxymetabolite	JJ	O
)	)	O
were	VBD	O
determined	VBN	O
by	IN	O
HPLC	NNP	O
in	IN	O
plasma	NN	O
from	IN	O
nine	CD	SS
non-pregnant	JJ	C
and	CC	O
36	CD	SS
pregnant	JJ	C
women	NNS	SE
.	.	O

Each	DT	O
non-pregnant	JJ	O
subject	NN	O
took	VBD	O
an	DT	O
oral	JJ	O
dose	NN	O
of	IN	O
RU	NNP	O
486	CD	O
(	(	O
25	CD	O
,	,	O
100	CD	O
,	,	O
400	CD	O
and	CC	O
600	CD	O
mg	NNS	O
consecutively	RB	O
)	)	O
once	RB	O
per	IN	O
menstrual	JJ	O
cycle	NN	O
.	.	O

Six	CD	O
of	IN	O
the	DT	O
nine	CD	O
women	NNS	O
also	RB	O
received	VBD	O
a	DT	O
dose	NN	O
of	IN	O
200	CD	O
mg	NN	O
.	.	O

The	DT	O
36	CD	SS
pregnant	JJ	C
women	NNS	SE
were	VBD	O
randomized	VBN	O
into	IN	O
four	CD	O
groups	NNS	O
which	WDT	O
were	VBD	O
given	VBN	O
a	DT	O
single	JJ	O
dose	NN	O
of	IN	O
25	CD	O
,	,	O
100	CD	O
,	,	O
400	CD	O
or	CC	O
600	CD	O
mg	NNS	O
RU	NNP	O
486	CD	O
.	.	O

Blood	NN	O
samples	NNS	O
were	VBD	O
taken	VBN	O
up	RB	O
to	TO	O
120	CD	O
h	NN	O
after	IN	O
dosing	VBG	O
.	.	O

Peak	NNP	O
concentrations	NNS	O
of	IN	O
RU	NNP	O
486	CD	O
occurred	VBD	O
on	IN	O
most	JJS	O
occasions	NNS	O
within	IN	O
2	CD	O
h.	NN	O
Plasma	NNP	O
concentrations	NNS	O
at	IN	O
1	CD	O
h	NN	O
and	CC	O
at	IN	O
24	CD	O
h	NN	O
increased	VBN	O
in	IN	O
proportion	NN	O
to	TO	O
log	VB	O
dose	RB	O
.	.	O

There	EX	O
was	VBD	O
a	DT	O
wide	JJ	O
variability	NN	O
(	(	O
up	IN	O
to	TO	O
ten-fold	JJ	O
)	)	O
in	IN	O
the	DT	O
pharmacokinetic	JJ	O
parameters	NNS	O
within	IN	O
each	DT	O
dose	NN	O
group	NN	O
.	.	O

Plasma	NNP	O
concentrations	NNS	O
of	IN	O
RU	NNP	O
42633	CD	O
were	VBD	O
similar	JJ	O
to	TO	O
those	DT	O
of	IN	O
RU	NNP	O
486	CD	O
but	CC	O
concentrations	NNS	O
of	IN	O
RU	NNP	O
42848	CD	O
and	CC	O
RU	NNP	O
42698	CD	O
were	VBD	O
much	JJ	O
lower	JJR	O
.	.	O

As	IN	O
with	IN	O
RU	NNP	O
486	CD	O
,	,	O
the	DT	O
plasma	JJ	O
concentrations	NNS	O
of	IN	O
the	DT	O
metabolites	NNS	O
were	VBD	O
maintained	VBN	O
at	IN	O
high	JJ	O
levels	NNS	O
for	IN	O
up	IN	O
to	TO	O
48-72	JJ	O
h	NN	O
after	IN	O
dosing	VBG	O
.	.	O

The	DT	O
findings	NNS	O
were	VBD	O
consistent	JJ	O
with	IN	O
a	DT	O
rapid	JJ	O
metabolism	NN	O
of	IN	O
RU	NNP	O
486	CD	O
to	TO	O
RU	NNP	O
42633	CD	O
;	:	O
removal	NN	O
of	IN	O
the	DT	O
second	JJ	O
methyl	NN	O
group	NN	O
leading	VBG	O
to	TO	O
RU	NNP	O
42698	CD	O
occurred	VBD	O
much	RB	O
more	RBR	O
slowly	RB	O
and	CC	O
to	TO	O
a	DT	O
much	RB	O
less	RBR	O
extent	JJ	O
than	IN	O
removal	NN	O
of	IN	O
the	DT	O
first	JJ	O
.	.	O

There	EX	O
appeared	VBD	O
to	TO	O
be	VB	O
no	DT	O
significant	JJ	O
differences	NNS	O
between	IN	O
the	DT	O
non-pregnant	JJ	C
and	CC	O
pregnant	JJ	C
women	NNS	SE
in	IN	O
either	CC	O
the	DT	O
plasma	JJ	O
concentrations	NNS	O
or	CC	O
pharmacokinetic	JJ	O
parameters	NNS	O
of	IN	O
RU	NNP	O
486	CD	O
and	CC	O
its	PRP$	O
metabolites	NNS	O
.	.	O

Double-blind	NNP	O
comparison	NN	O
of	IN	O
doxepin	NN	O
versus	NN	O
bupropion	NN	O
in	IN	O
outpatients	NNS	O
with	IN	O
a	DT	O
major	JJ	O
depressive	JJ	C
disorder	NN	C
.	.	O

A	DT	O
double-blind	NN	O
controlled	VBN	O
study	NN	O
comparing	VBG	O
the	DT	O
effects	NNS	O
of	IN	O
bupropion	NN	O
to	TO	O
doxepin	VB	O
in	IN	O
outpatients	NNS	O
with	IN	O
primary	JJ	C
depression	NN	C
was	VBD	O
conducted	VBN	O
to	TO	O
evaluate	VB	O
efficacy	NN	O
and	CC	O
safety	NN	O
differences	NNS	O
between	IN	O
the	DT	O
two	CD	O
drugs	NNS	O
.	.	O

Following	VBG	O
a	DT	O
7-day	JJ	O
placebo	NN	O
washout	NN	O
period	NN	O
,	,	O
patients	NNS	O
could	MD	O
be	VB	O
treated	VBN	O
for	IN	O
up	RB	O
to	TO	O
13	CD	O
weeks	NNS	O
on	IN	O
either	DT	O
treatment	NN	O
.	.	O

Antidepressant	JJ	O
response	NN	O
was	VBD	O
assessed	VBN	O
by	IN	O
the	DT	O
Hamilton	NNP	O
Depression	NNP	O
and	CC	O
Anxiety	NNP	O
Scales	NNP	O
,	,	O
Clinical	NNP	O
Global	NNP	O
Severity	NNP	O
and	CC	O
Improvement	NNP	O
Ratings	NNP	O
,	,	O
and	CC	O
the	DT	O
Zung	NNP	O
Self-Rating	NNP	O
Depression	NNP	O
Scale	NNP	O
.	.	O

Comparable	JJ	O
efficacy	NN	O
between	IN	O
the	DT	O
compounds	NNS	O
was	VBD	O
found	VBN	O
across	IN	O
the	DT	O
13-week	JJ	O
study	NN	O
.	.	O

Doxepin	NNP	O
differed	VBD	O
from	IN	O
bupropion	NN	O
mainly	RB	O
on	IN	O
the	DT	O
sleep	JJ	O
factor	NN	O
of	IN	O
the	DT	O
Hamilton	NNP	O
Depression	NNP	O
Scale	NNP	O
,	,	O
with	IN	O
doxepin	NN	O
improving	VBG	O
sleep	NN	O
to	TO	O
a	DT	O
greater	JJR	O
extent	NN	O
than	IN	O
bupropion	NN	O
.	.	O

Doxepin	NNP	O
produced	VBD	O
a	DT	O
greater	JJR	O
incidence	NN	O
of	IN	O
anticholinergic	JJ	O
side	NN	O
effects	NNS	O
,	,	O
including	VBG	O
dry	JJ	O
mouth	NN	O
,	,	O
constipation	NN	O
,	,	O
sleepiness	NN	O
,	,	O
and	CC	O
tiredness	NN	O
,	,	O
in	IN	O
comparison	NN	O
to	TO	O
bupropion	NN	O
.	.	O

Also	RB	O
,	,	O
increased	VBD	O
appetite	NN	O
and	CC	O
weight	JJ	O
gain	NN	O
were	VBD	O
consistent	JJ	O
side	NN	O
effects	NNS	O
of	IN	O
doxepin	NN	O
relative	NN	O
to	TO	O
bupropion	NN	O
.	.	O

Fluoroscopic	NNP	O
functional	JJ	O
evaluation	NN	O
of	IN	O
bileaflet	NN	O
prostheses	NNS	O
:	:	O
effect	NN	O
of	IN	O
different	JJ	O
intraoperative	JJ	O
valve	NN	O
orientation	NN	O
.	.	O

Fluoroscopy	NNP	O
is	VBZ	O
a	DT	O
reliable	JJ	O
,	,	O
easy	JJ	O
,	,	O
and	CC	O
readily	RB	O
available	JJ	O
technique	NN	O
to	TO	O
follow-up	JJ	O
prosthesis	NN	O
functioning	NN	O
after	IN	O
heart	NN	O
valve	NN	O
surgery	NN	O
.	.	O

The	DT	O
different	JJ	O
orientation	NN	O
given	VBN	O
to	TO	O
the	DT	O
prosthesis	NN	O
may	MD	O
represent	VB	O
a	DT	O
limitation	NN	O
of	IN	O
the	DT	O
technique	NN	O
accounting	NN	O
for	IN	O
unsatisfactory	JJ	O
results	NNS	O
in	IN	O
10	CD	O
%	NN	O
to	TO	O
40	CD	O
%	NN	O
of	IN	O
the	DT	O
cases	NNS	O
.	.	O

The	DT	O
aim	NN	O
of	IN	O
the	DT	O
study	NN	O
was	VBD	O
to	TO	O
evaluate	VB	O
whether	IN	O
and	CC	O
to	TO	O
what	WP	O
extent	VB	O
different	JJ	O
intraoperative	JJ	O
valve	NN	O
orientation	NN	O
influence	NN	O
feasibility	NN	O
and	CC	O
accuracy	NN	O
of	IN	O
postoperative	JJ	O
fluoroscopic	JJ	O
evaluation	NN	O
of	IN	O
bileaflet	NN	O
prostheses	NNS	O
.	.	O

We	PRP	O
prospectively	RB	O
evaluated	VBD	O
90	CD	O
patients	NNS	O
who	WP	O
had	VBD	O
aortic	JJ	O
,	,	O
mitral	JJ	O
,	,	O
and/or	JJ	O
tricuspid	JJ	O
valve	FW	O
replacement	NN	O
with	IN	O
Sorin	NNP	O
Bicarbon	NNP	O
or	CC	O
CarboMedics	NNPS	O
bileaflet	NN	O
prostheses	NNS	O
.	.	O

Fifty	NNP	O
percent	NN	O
of	IN	O
the	DT	O
patients	NNS	O
in	IN	O
each	DT	O
group	NN	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
receive	VB	O
prostheses	NNS	O
oriented	VBN	O
in	IN	O
a	DT	O
perpendicular	NN	O
or	CC	O
a	DT	O
parallel	JJ	O
position	NN	O
with	IN	O
respect	NN	O
to	TO	O
the	DT	O
ventricular	JJ	O
septum	NN	O
.	.	O

Fluoroscopic	NNP	O
evaluation	NN	O
was	VBD	O
considered	VBN	O
appropriate	JJ	O
when	WRB	O
the	DT	O
prosthesis	NN	O
'	POS	O
tilting	VBG	O
disk	NN	O
projection	NN	O
was	VBD	O
obtained	VBN	O
.	.	O

The	DT	O
valve	NN	O
's	POS	O
hemodynamic	JJ	O
performance	NN	O
was	VBD	O
investigated	VBN	O
through	IN	O
Doppler	NNP	O
study	NN	O
.	.	O

A	DT	O
proper	JJ	O
fluoroscopic	NN	O
evaluation	NN	O
was	VBD	O
rapidly	RB	O
(	(	O
15	CD	O
+/-	JJ	O
5	CD	O
seconds	NNS	O
)	)	O
achieved	VBN	O
in	IN	O
all	DT	O
patients	NNS	O
with	IN	O
the	DT	O
former	JJ	O
orientation	NN	O
,	,	O
whereas	IN	O
it	PRP	O
was	VBD	O
impossible	JJ	O
to	TO	O
obtain	VB	O
it	PRP	O
in	IN	O
8	CD	O
of	IN	O
20	CD	O
(	(	O
40	CD	O
%	NN	O
)	)	O
,	,	O
19	CD	O
of	IN	O
20	CD	O
(	(	O
95	CD	O
%	NN	O
)	)	O
,	,	O
and	CC	O
4	CD	O
of	IN	O
5	CD	O
(	(	O
80	CD	O
%	NN	O
)	)	O
of	IN	O
patients	NNS	O
with	IN	O
the	DT	O
latter	JJ	O
orientation	NN	O
.	.	O

In	IN	O
the	DT	O
remaining	VBG	O
patients	NNS	O
extremely	RB	O
angulated	VBN	O
,	,	O
uneasy	JJ	O
projection	NN	O
was	VBD	O
often	RB	O
required	VBN	O
to	TO	O
get	VB	O
a	DT	O
correct	JJ	O
fluoroscopic	NN	O
image	NN	O
.	.	O

The	DT	O
Doppler	NNP	O
study	NN	O
showed	VBD	O
a	DT	O
similarly	RB	O
favorable	JJ	O
hemodynamic	JJ	O
performance	NN	O
regardless	NN	O
of	IN	O
valve	JJ	O
orientation	NN	O
.	.	O

Prosthesis	NNP	O
orientation	NN	O
crucially	RB	O
affects	VBZ	O
the	DT	O
rate	NN	O
of	IN	O
success	NN	O
of	IN	O
the	DT	O
fluoroscopic	JJ	O
evaluation	NN	O
.	.	O

The	DT	O
orientation	NN	O
perpendicular	NN	O
to	TO	O
the	DT	O
ventricular	JJ	O
septum	NN	O
greatly	RB	O
facilitates	VBZ	O
the	DT	O
postoperative	JJ	O
feasibility	NN	O
and	CC	O
accuracy	NN	O
of	IN	O
fluoroscopy	NN	O
,	,	O
and	CC	O
it	PRP	O
is	VBZ	O
not	RB	O
detrimental	JJ	O
to	TO	O
the	DT	O
valve	NN	O
's	POS	O
hemodynamic	JJ	O
performance	NN	O
.	.	O

This	DT	O
valve	JJ	O
orientation	NN	O
may	MD	O
provide	VB	O
a	DT	O
better	JJR	O
fluoroscopic	NN	O
window	NN	O
whenever	WRB	O
a	DT	O
valve	NN	O
dysfunction	NN	O
is	VBZ	O
suspected	VBN	O
.	.	O

Microbiologic	JJ	O
yields	NNS	O
and	CC	O
complication	NN	O
rates	NNS	O
of	IN	O
vitreous	JJ	O
needle	JJ	O
aspiration	NN	O
versus	IN	O
mechanized	VBN	O
vitreous	JJ	O
biopsy	NN	O
in	IN	O
the	DT	O
Endophthalmitis	NNP	O
Vitrectomy	NNP	O
Study	NNP	O
.	.	O

PURPOSE	NNP	O
To	TO	O
compare	VB	O
the	DT	O
microbiologic	JJ	O
yields	NNS	O
and	CC	O
complication	NN	O
rates	NNS	O
associated	VBN	O
with	IN	O
vitreous	JJ	O
needle	JJ	O
tap	NN	O
and	CC	O
vitreous	JJ	O
biopsy	NN	O
in	IN	O
the	DT	O
Endophthalmitis	NNP	C
Vitrectomy	NNP	C
Study	NNP	O
(	(	O
EVS	NNP	O
)	)	O
.	.	O

METHODS	NNP	O
Of	IN	O
420	CD	SS
EVS	NNP	C
patients	NNS	O
with	IN	O
postoperative	JJ	C
endophthalmitis	NN	C
,	,	O
201	CD	SS
received	VBD	O
immediate	JJ	O
vitreous	JJ	O
tap	NN	O
or	CC	O
biopsy	NN	C
(	(	O
without	IN	O
pars	NNS	O
plana	VBP	O
vitrectomy	NN	O
)	)	O
by	IN	O
random	JJ	O
assignment	NN	O
and	CC	O
193	CD	SS
completed	VBN	O
9-12	CD	O
months	NNS	O
of	IN	O
follow-up	NN	O
.	.	O

Vitreous	JJ	O
specimens	NNS	O
were	VBD	O
obtained	VBN	O
by	IN	O
biopsy	NN	O
with	IN	O
a	DT	O
20-gauge	JJ	O
vitrectomy	NN	O
cutting	VBG	O
instrument	NN	O
or	CC	O
by	IN	O
needle	JJ	O
tap	NN	O
with	IN	O
a	DT	O
22-27-gauge	JJ	O
needle	NN	O
.	.	O

If	IN	O
resistance	NN	O
to	TO	O
aspiration	NN	O
by	IN	O
needle	JJ	O
tap	NN	O
was	VBD	O
noted	VBN	O
,	,	O
a	DT	O
vitreous	JJ	O
biopsy	NN	O
was	VBD	O
performed	VBN	O
.	.	O

RESULTS	NNP	O
Of	IN	O
201	CD	SS
patients	NNS	O
undergoing	JJ	O
tap	NN	O
or	CC	O
biopsy	NN	C
,	,	O
70	CD	SS
(	(	O
35	CD	O
%	NN	O
)	)	O
had	VBD	O
needle	JJ	C
tap	NN	C
,	,	O
127	CD	SS
(	(	O
63	CD	O
%	NN	O
)	)	O
had	VBD	O
mechanized	VBN	C
biopsy	NN	C
,	,	O
and	CC	O
4	CD	SS
(	(	O
2	CD	O
%	NN	O
)	)	O
had	VBD	O
initial	JJ	O
needle	JJ	C
tap	NN	C
that	WDT	O
was	VBD	O
aborted	VBN	O
to	TO	O
mechanized	VBN	O
biopsy	NN	O
(	(	O
abort	JJ	O
eyes	NNS	O
)	)	O
.	.	O

Intraoperative	JJ	O
hyphema	NN	O
occurred	VBD	O
in	IN	O
2	CD	O
tap	JJ	O
eyes	NNS	O
(	(	O
3	CD	O
%	NN	O
)	)	O
,	,	O
3	CD	O
biopsy	NN	O
eyes	NNS	O
(	(	O
2	CD	O
%	NN	O
)	)	O
,	,	O
and	CC	O
0	CD	O
(	(	O
0	CD	O
%	NN	O
)	)	O
abort	NN	O
eyes	NNS	O
.	.	O

Postoperative	JJ	O
retinal	JJ	O
detachment	NN	O
developed	VBD	O
in	IN	O
8	CD	O
(	(	O
11	CD	O
%	NN	O
)	)	O
tap	NN	O
eyes	NNS	O
,	,	O
10	CD	O
(	(	O
8	CD	O
%	NN	O
)	)	O
biopsy	NN	O
eyes	NNS	O
,	,	O
and	CC	O
0	CD	O
(	(	O
0	CD	O
%	NN	O
)	)	O
abort	NN	O
eyes	NNS	O
(	(	O
not	RB	O
significant	JJ	O
)	)	O
.	.	O

Respective	JJ	O
rates	NNS	O
of	IN	O
culture	NN	O
and	CC	O
gram	NN	O
stain	VBP	O
positivity	NN	O
were	VBD	O
69	CD	O
%	NN	O
and	CC	O
42	CD	O
%	NN	O
in	IN	O
tap	JJ	O
eyes	NNS	O
and	CC	O
66	CD	O
%	NN	O
and	CC	O
41	CD	O
%	NN	O
in	IN	O
biopsy	JJ	O
eyes	NNS	O
(	(	O
not	RB	O
significant	JJ	O
)	)	O
.	.	O

The	DT	O
rate	NN	O
of	IN	O
severe	JJ	O
visual	JJ	O
loss	NN	O
(	(	O
final	JJ	O
acuity	NN	O
<	NNP	O
5/200	CD	O
)	)	O
was	VBD	O
significantly	RB	O
higher	JJR	O
in	IN	O
tap	JJ	O
eyes	NNS	O
(	(	O
16	CD	O
eyes	NNS	O
,	,	O
24	CD	O
%	NN	O
)	)	O
compared	VBN	O
with	IN	O
biopsy	JJ	O
eyes	NNS	O
(	(	O
13	CD	O
eyes	NNS	O
,	,	O
11	CD	O
%	NN	O
)	)	O
and	CC	O
abort	JJ	O
eyes	NNS	O
(	(	O
0	CD	O
eyes	NNS	O
,	,	O
0	CD	O
%	NN	O
;	:	O
P	NNP	O
=	NNP	O
0.043	CD	O
)	)	O
.	.	O

The	DT	O
difference	NN	O
was	VBD	O
largely	RB	O
explained	VBN	O
by	IN	O
the	DT	O
greater	JJR	O
proportion	NN	O
of	IN	O
virulent	JJ	O
organisms	NNS	O
in	IN	O
the	DT	O
tap	JJ	O
eyes	NNS	O
compared	VBN	O
with	IN	O
biopsy	JJ	O
eyes	NNS	O
.	.	O

When	WRB	O
visual	JJ	O
acuity	NN	O
outcome	NN	O
was	VBD	O
defined	VBN	O
by	IN	O
other	JJ	O
thresholds	NNS	O
(	(	O
20/40	CD	O
and	CC	O
20/100	CD	O
)	)	O
,	,	O
the	DT	O
difference	NN	O
was	VBD	O
not	RB	O
significant	JJ	O
.	.	O

CONCLUSIONS	VB	O
This	DT	O
study	NN	O
showed	VBD	O
no	DT	O
significant	JJ	O
differences	NNS	O
between	IN	O
mechanized	VBN	O
vitreous	JJ	O
biopsy	NN	O
and	CC	O
needle	JJ	O
tap	NN	O
with	IN	O
respect	NN	O
to	TO	O
microbiologic	JJ	O
yield	NN	O
,	,	O
operative	JJ	O
complications	NNS	O
,	,	O
short-term	JJ	O
(	(	O
9-12	JJ	O
months	NNS	O
)	)	O
retinal	JJ	O
detachment	NN	O
risk	NN	O
,	,	O
or	CC	O
visual	JJ	O
outcome	NN	O
.	.	O

Choice	NNP	O
of	IN	O
vitreous	JJ	O
sampling	VBG	O
procedure	NN	O
must	MD	O
depend	VB	O
on	IN	O
the	DT	O
clinical	JJ	O
judgment	NN	O
of	IN	O
the	DT	O
surgeon	NN	O
.	.	O

Walking	VBG	O
trials	NNS	O
in	IN	O
postmenopausal	JJ	C
women	NNS	SE
:	:	O
effect	NN	O
of	IN	O
one	CD	O
vs	NN	O
two	CD	O
daily	JJ	O
bouts	NNS	O
on	IN	O
aerobic	JJ	O
fitness	NN	O
.	.	O

We	PRP	O
compared	VBN	O
the	DT	O
effects	NNS	O
of	IN	O
one	CD	O
vs	NN	O
two	CD	O
daily	JJ	O
bouts	NNS	O
of	IN	O
walking	VBG	O
on	IN	O
aerobic	JJ	O
fitness	NN	O
and	CC	O
body	NN	O
composition	NN	O
in	IN	O
postmenopausal	JJ	C
women	NNS	SE
.	.	O

One	CD	SS
hundred	CD	SS
and	CC	SS
thirty-four	JJ	SS
subjects	NNS	O
were	VBD	O
randomized	VBN	O
into	IN	O
exercise	NN	O
groups	NNS	O
or	CC	O
a	DT	O
control	NN	O
group	NN	O
and	CC	O
130	CD	SS
completed	VBD	O
the	DT	O
study	NN	O
.	.	O

The	DT	O
subjects	NNS	O
walked	VBD	O
5	CD	O
d/week	NN	O
for	IN	O
15	CD	O
weeks	NNS	O
at	IN	O
65	CD	O
%	NN	O
of	IN	O
their	PRP$	O
maximal	NN	O
aerobic	JJ	O
power	NN	O
expending	VBG	O
300	CD	O
kcal	JJ	O
(	(	O
1255	CD	O
kJ	NN	O
)	)	O
in	IN	O
exercise	NN	O
in	IN	O
one	CD	O
(	(	O
Group	NNP	O
S1	NNP	O
)	)	O
or	CC	O
two	CD	O
daily	JJ	O
sessions	NNS	O
(	(	O
Group	NNP	O
S2	NNP	O
)	)	O
.	.	O

VO	NNP	O
(	(	O
2max	CD	O
)	)	O
was	VBD	O
measured	VBN	O
in	IN	O
a	DT	O
direct	JJ	O
maximal	NN	O
treadmill	NN	O
test	NN	O
.	.	O

Body	NNP	O
mass	NN	O
index	NN	O
(	(	O
BMI	NNP	O
)	)	O
was	VBD	O
calculated	VBN	O
and	CC	O
the	DT	O
percentage	NN	O
of	IN	O
body	NN	O
fat	NN	O
(	(	O
fat	JJ	O
%	NN	O
)	)	O
estimated	VBN	O
using	VBG	O
skinfold	JJ	O
measurements	NNS	O
.	.	O

The	DT	O
net	JJ	O
change	NN	O
in	IN	O
the	DT	O
VO	NNP	O
(	(	O
2max	CD	O
)	)	O
was	VBD	O
2.5	CD	O
mL	NN	O
min/kg	NN	O
(	(	O
95	CD	O
%	NN	O
CI	NNP	O
1.5	CD	O
,	,	O
3.5	CD	O
)	)	O
(	(	O
8.7	CD	O
%	NN	O
)	)	O
in	IN	O
Group	NNP	O
S1	NNP	O
and	CC	O
2.5	CD	O
mL	NN	O
min/kg	NN	O
(	(	O
95	CD	O
%	NN	O
CI	NNP	O
1.5	CD	O
,	,	O
3.5	CD	O
)	)	O
(	(	O
8.8	CD	O
%	NN	O
)	)	O
in	IN	O
Group	NNP	O
S2	NNP	O
.	.	O

The	DT	O
net	JJ	O
change	NN	O
in	IN	O
body	NN	O
mass	NN	O
was	VBD	O
-1.2	JJ	O
kg	NN	O
(	(	O
95	CD	O
%	NN	O
CI-1.9	NNP	O
,	,	O
-0.5	NNP	O
)	)	O
in	IN	O
Group	NNP	O
S1	NNP	O
and	CC	O
-1.1	NNP	O
kg	NNP	O
(	(	O
95	CD	O
%	NN	O
CI	NNP	O
-1.8	NNP	O
,	,	O
-0.4	NNP	O
)	)	O
in	IN	O
Group	NNP	O
S2	NNP	O
.	.	O

The	DT	O
net	JJ	O
fat	NN	O
%	NN	O
change	NN	O
was	VBD	O
-2.1	JJ	O
%	NN	O
(	(	O
95	CD	O
%	NN	O
CI-2.7	NNP	O
,	,	O
-1.4	NNP	O
)	)	O
in	IN	O
Group	NNP	O
S1	NNP	O
and	CC	O
-1.7	NNP	O
%	NN	O
(	(	O
95	CD	O
%	NN	O
CI-2.3	NNP	O
,	,	O
-1.0	NNP	O
)	)	O
in	IN	O
Group	NNP	O
S2	NNP	O
.	.	O

Exercise	NN	O
improved	VBD	O
the	DT	O
maximal	NN	O
aerobic	JJ	O
power	NN	O
and	CC	O
body	NN	O
composition	NN	O
equally	RB	O
when	WRB	O
walking	NN	O
was	VBD	O
performed	VBN	O
in	IN	O
one	CD	O
or	CC	O
two	CD	O
daily	JJ	O
bouts	NNS	O
.	.	O

Comparison	NNP	O
between	IN	O
the	DT	O
central	JJ	O
effects	NNS	O
of	IN	O
camazepam	NN	O
and	CC	O
temazepam	NN	O
.	.	O

Computerized	JJ	O
analysis	NN	O
of	IN	O
sleep	JJ	O
recordings	NNS	O
.	.	O

The	DT	O
effects	NNS	O
of	IN	O
acute	JJ	O
administration	NN	O
per	IN	O
os	NN	O
of	IN	O
30	CD	O
mg	NNS	O
camazepam	NN	O
and	CC	O
the	DT	O
same	JJ	O
dose	NN	O
of	IN	O
temazepam	NN	O
,	,	O
were	VBD	O
compared	VBN	O
with	IN	O
placebo	NN	O
in	IN	O
8	CD	C
young	JJ	C
male	NN	C
volunteers	NNS	C
,	,	C
fully	RB	C
adapted	VBN	C
to	TO	C
the	DT	C
laboratory	NN	C
environment	NN	C
by	IN	C
6	CD	C
nights	NNS	C
of	IN	C
adaptation	NN	C
.	.	C

The	DT	O
study	NN	O
was	VBD	O
double-blind	JJ	O
,	,	O
in	IN	O
a	DT	O
random	NN	O
order	NN	O
,	,	O
10	CD	O
days	NNS	O
separating	VBG	O
each	DT	O
session	NN	O
.	.	O

Spectral	JJ	O
analysis	NN	O
was	VBD	O
performed	VBN	O
on	IN	O
the	DT	O
all-night	JJ	O
records	NNS	O
(	(	O
1-min	JJ	O
epochs	NN	O
)	)	O
,	,	O
and	CC	O
the	DT	O
relative	JJ	O
power	NN	O
of	IN	O
six	CD	O
frequency	NN	O
bands	NNS	O
calculated	VBN	O
.	.	O

Concerning	VBG	O
sleep	JJ	O
parameters	NNS	O
,	,	O
temazepam	NN	O
induces	NNS	O
a	DT	O
statistically	RB	O
significant	JJ	O
reduction	NN	O
of	IN	O
:	:	O
phase	NN	O
shifts	NNS	O
;	:	O
number	NN	O
of	IN	O
awakenings	NNS	O
;	:	O
percent	JJ	O
duration	NN	O
of	IN	O
sleep	JJ	O
stages	NNS	O
I	PRP	O
and	CC	O
IV	NNP	O
.	.	O

A	NNP	O
significant	JJ	O
increase	NN	O
of	IN	O
the	DT	O
percent	NN	O
duration	NN	O
of	IN	O
stage	NN	O
II	NNP	O
and	CC	O
sleep	JJ	O
efficiency	NN	O
was	VBD	O
also	RB	O
found	VBN	O
.	.	O

Camazepam	NNP	O
shows	VBZ	O
modification	NN	O
,	,	O
with	IN	O
the	DT	O
same	JJ	O
trend	NN	O
,	,	O
but	CC	O
not	RB	O
reaching	VBG	O
statistical	JJ	O
significance	NN	O
.	.	O

Concerning	VBG	O
spectral	JJ	O
analysis	NN	O
,	,	O
temazepam	NN	O
induces	NNS	O
a	DT	O
light	JJ	O
increase	NN	O
of	IN	O
the	DT	O
relative	JJ	O
power	NN	O
of	IN	O
the	DT	O
slowest	JJS	O
frequencies	NNS	O
,	,	O
paralleled	VBN	O
by	IN	O
an	DT	O
increase	NN	O
of	IN	O
the	DT	O
fast	JJ	O
bands	NNS	O
,	,	O
while	IN	O
major	JJ	O
effects	NNS	O
are	VBP	O
found	VBN	O
on	IN	O
the	DT	O
characteristic	JJ	O
periodicity	NN	O
of	IN	O
delta	NN	O
activities	NNS	O
,	,	O
which	WDT	O
appear	VBP	O
disrupted	VBN	O
by	IN	O
the	DT	O
drug	NN	O
.	.	O

These	DT	O
effects	NNS	O
are	VBP	O
not	RB	O
evident	JJ	O
with	IN	O
camazepam	NN	O
,	,	O
which	WDT	O
does	VBZ	O
not	RB	O
seem	VB	O
to	TO	O
distort	VB	O
the	DT	O
normal	JJ	O
sleep	JJ	O
pattern	NN	O
.	.	O

Infrared	NNP	O
LED	NNP	O
irradiation	NN	O
applied	VBD	O
during	IN	O
high-intensity	NN	O
treadmill	NN	O
training	VBG	O
improves	NNS	O
maximal	JJ	O
exercise	NN	O
tolerance	NN	O
in	IN	O
postmenopausal	JJ	O
women	NNS	O
:	:	O
a	DT	O
6-month	JJ	O
longitudinal	JJ	O
study	NN	O
.	.	O

Reduced	NNP	O
aerobic	JJ	O
fitness	NN	O
is	VBZ	O
associated	VBN	O
with	IN	O
an	DT	O
increased	VBN	O
risk	NN	O
of	IN	O
cardiovascular	JJ	O
diseases	NNS	O
among	IN	O
the	DT	O
older	JJR	O
population	NN	O
.	.	O

The	DT	O
aim	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
investigate	VB	O
the	DT	O
effects	NNS	O
of	IN	O
LED	NNP	O
irradiation	NN	O
(	(	O
850	CD	O
nm	RB	O
)	)	O
applied	VBD	O
during	IN	O
treadmill	JJ	O
training	VBG	O
on	IN	O
the	DT	O
maximal	JJ	O
exercise	NN	O
tolerance	NN	O
in	IN	O
postmenopausal	JJ	O
women	NNS	O
.	.	O

At	IN	O
the	DT	O
beginning	NN	O
of	IN	O
the	DT	O
study	NN	O
,	,	O
45	CD	O
postmenopausal	JJ	O
women	NNS	O
were	VBD	O
assigned	VBN	O
randomly	RB	O
to	TO	O
three	CD	O
groups	NNS	O
,	,	O
and	CC	O
30	CD	O
women	NNS	O
completed	VBD	O
the	DT	O
entire	JJ	O
6	CD	O
months	NNS	O
of	IN	O
the	DT	O
study	NN	O
.	.	O

The	DT	O
groups	NNS	O
were	VBD	O
:	:	O
(	(	O
1	CD	O
)	)	O
the	DT	O
LED	NNP	O
group	NN	O
(	(	O
treadmill	IN	O
training	VBG	O
associated	VBN	O
with	IN	O
phototherapy	NN	O
,	,	O
n	JJ	O
=	NNP	O
10	CD	O
)	)	O
,	,	O
(	(	O
2	CD	O
)	)	O
the	DT	O
exercise	NN	O
group	NN	O
(	(	O
treadmill	IN	O
training	NN	O
,	,	O
n	JJ	O
=	NNP	O
10	CD	O
)	)	O
,	,	O
and	CC	O
(	(	O
3	CD	O
)	)	O
the	DT	O
sedentary	JJ	O
group	NN	O
(	(	O
neither	DT	O
physical	JJ	O
training	NN	O
nor	CC	O
phototherapy	NN	O
,	,	O
n	JJ	O
=	NNP	O
10	CD	O
)	)	O
.	.	O

The	DT	O
training	NN	O
was	VBD	O
performed	VBN	O
for	IN	O
45	CD	O
min	NN	O
twice	RB	O
a	DT	O
week	NN	O
for	IN	O
6	CD	O
months	NNS	O
at	IN	O
intensities	NNS	O
between	IN	O
85	CD	O
%	NN	O
and	CC	O
90	CD	O
%	NN	O
maximal	JJ	O
heart	NN	O
rate	NN	O
(	(	O
HRmax	NNP	O
)	)	O
.	.	O

The	DT	O
irradiation	NN	O
parameters	NNS	O
were	VBD	O
39	CD	O
mW/cm	NN	O
(	(	O
2	CD	O
)	)	O
,	,	O
45	CD	O
min	NN	O
and	CC	O
108	CD	O
J/cm	NNP	O
(	(	O
2	CD	O
)	)	O
.	.	O

The	DT	O
cardiovascular	JJ	O
parameters	NNS	O
were	VBD	O
measured	VBN	O
at	IN	O
baseline	NN	O
and	CC	O
after	IN	O
6	CD	O
months	NNS	O
.	.	O

As	IN	O
expected	VBN	O
,	,	O
no	DT	O
significant	JJ	O
differences	NNS	O
were	VBD	O
found	VBN	O
in	IN	O
the	DT	O
sedentary	JJ	O
group	NN	O
(	(	O
p	VB	O
?	.	O
0.05	CD	O
)	)	O
.	.	O

The	DT	O
maximal	JJ	O
time	NN	O
of	IN	O
tolerance	NN	O
(	(	O
Tlim	NNP	O
)	)	O
,	,	O
metabolic	JJ	O
equivalents	NNS	O
(	(	O
METs	NNP	O
)	)	O
and	CC	O
Bruce	NNP	O
stage	NN	O
reached	VBD	O
significantly	RB	O
higher	JJR	O
values	NNS	O
in	IN	O
the	DT	O
LED	NNP	O
group	NN	O
and	CC	O
the	DT	O
exercise	NN	O
group	NN	O
(	(	O
p	JJ	O
<	NNP	O
0.01	CD	O
)	)	O
.	.	O

Furthermore	UH	O
,	,	O
the	DT	O
HR	NNP	O
,	,	O
double	JJ	O
product	NN	O
and	CC	O
Borg	NNP	O
score	NN	O
at	IN	O
isotime	NN	O
were	VBD	O
significantly	RB	O
lower	JJR	O
in	IN	O
the	DT	O
LED	NNP	O
group	NN	O
and	CC	O
in	IN	O
the	DT	O
exercise	NN	O
group	NN	O
(	(	O
p	JJ	O
<	NNP	O
0.05	CD	O
)	)	O
.	.	O

However	RB	O
,	,	O
the	DT	O
time	NN	O
of	IN	O
recovery	NN	O
showed	VBD	O
a	DT	O
significant	JJ	O
decrease	NN	O
only	RB	O
in	IN	O
the	DT	O
LED	NNP	O
group	NN	O
(	(	O
p	JJ	O
=	NNP	O
0.003	CD	O
)	)	O
.	.	O

Moreover	RB	O
,	,	O
the	DT	O
differences	NNS	O
between	IN	O
before	IN	O
and	CC	O
after	IN	O
training	NN	O
(	(	O
delta	JJ	O
values	NNS	O
)	)	O
for	IN	O
the	DT	O
Tlim	NNP	O
,	,	O
METs	NNP	O
and	CC	O
HR	NNP	O
at	IN	O
isotime	NN	O
were	VBD	O
greater	JJR	O
in	IN	O
the	DT	O
LED	NNP	O
group	NN	O
than	IN	O
in	IN	O
the	DT	O
exercise	NN	O
group	NN	O
with	IN	O
a	DT	O
significant	JJ	O
intergroup	NN	O
difference	NN	O
(	(	O
p	JJ	O
<	NNP	O
0.05	CD	O
)	)	O
.	.	O

Therefore	RB	O
,	,	O
the	DT	O
infrared	JJ	O
LED	NNP	O
irradiation	NN	O
during	IN	O
treadmill	JJ	O
training	NN	O
can	MD	O
improve	VB	O
maximal	JJ	O
performance	NN	O
and	CC	O
post-exercise	JJ	O
recovery	NN	O
in	IN	O
postmenopausal	JJ	O
women	NNS	O
.	.	O

Boosting	VBG	O
uptake	NN	O
of	IN	O
influenza	JJ	O
immunisation	NN	O
:	:	O
a	DT	O
randomised	JJ	O
controlled	JJ	O
trial	NN	O
of	IN	O
telephone	NN	O
appointing	VBG	O
in	IN	O
general	JJ	O
practice	NN	O
.	.	O

BACKGROUND	NNP	O
Immunisation	NNP	O
against	IN	O
influenza	NN	O
is	VBZ	O
an	DT	O
effective	JJ	O
intervention	NN	O
that	WDT	O
reduces	VBZ	O
serologically	RB	O
confirmed	VBN	O
cases	NNS	O
by	IN	O
between	IN	O
60	CD	O
%	NN	O
and	CC	O
70	CD	O
%	NN	O
.	.	O

Almost	NNP	O
all	DT	O
influenza	JJ	O
immunisation	NN	O
in	IN	O
the	DT	O
UK	NNP	O
is	VBZ	O
done	VBN	O
within	IN	O
general	JJ	O
practice	NN	O
.	.	O

Current	JJ	O
evidence	NN	O
on	IN	O
the	DT	O
effectiveness	NN	O
of	IN	O
patient	JJ	O
reminders	NNS	O
for	IN	O
all	DT	O
types	NNS	O
of	IN	O
immunisation	NN	O
programmes	NNS	O
is	VBZ	O
largely	RB	O
based	VBN	O
on	IN	O
North	JJ	O
American	JJ	O
studies	NNS	O
.	.	O

AIM	NNP	O
To	TO	O
determine	VB	O
whether	IN	O
telephone	NN	O
appointments	NNS	O
offered	VBD	O
bygeneral	JJ	O
practice	NN	O
receptionists	NNS	O
increase	VBP	O
the	DT	O
uptake	NN	O
of	IN	O
irfluenza	JJ	O
immunisation	NN	O
among	IN	O
the	DT	O
registered	JJ	O
population	NN	O
aged	VBD	O
over	IN	A
65	CD	A
years	NNS	A
in	IN	O
east	JJ	O
London	NNP	O
practices	NNS	O
.	.	O

DESIGN	NNP	O
OF	NNP	O
STUDY	NNP	O
Randomised	VBD	O
controlled	VBN	O
trial	NN	O
.	.	O

SETTING	NNP	O
Three	NNP	O
research	NN	O
general	JJ	O
practices	NNS	O
within	IN	O
the	DT	O
East	NNP	O
London	NNP	O
and	CC	O
Essex	NNP	O
network	NN	O
of	IN	O
researchers	NNS	O
(	(	O
ELENoR	NNP	O
)	)	O
.	.	O

METHOD	JJ	O
Participants	NNS	O
were	VBD	O
1,820	CD	SS
low-risk	JJ	O
patients	NNS	O
aged	VBD	O
65	CD	A
to	TO	A
74	CD	A
years	NNS	O
who	WP	O
had	VBD	O
not	RB	O
previously	RB	O
been	VBN	O
in	IN	O
a	DT	O
recall	NN	O
system	NN	O
for	IN	O
influenza	JJ	O
immunisation	NN	O
at	IN	O
their	PRP$	O
general	JJ	O
practice	NN	O
.	.	O

The	DT	O
intervention	NN	O
,	,	O
during	IN	O
October	NNP	O
2000	CD	O
,	,	O
was	VBD	O
a	DT	O
telephone	NN	O
call	NN	O
from	IN	O
the	DT	O
practice	NN	O
receptionist	NN	O
to	TO	O
intervention	NN	O
group	NN	O
households	NNS	O
,	,	O
offering	VBG	O
an	DT	O
appointment	NN	O
for	IN	O
influenza	JJ	O
immunisation	NN	O
at	IN	O
a	DT	O
nurse-run	JJ	O
.	.	O

clinic	JJ	O
Main	NNP	O
outcome	NN	O
measures	NNS	O
were	VBD	O
the	DT	O
numbers	NNS	O
of	IN	O
individuals	NNS	O
in	IN	O
each	DT	O
group	NN	O
receiving	VBG	O
immunisation	NN	O
,	,	O
and	CC	O
practice	NN	O
costs	NNS	O
of	IN	O
a	DT	O
telephone-appointing	JJ	O
programme	NN	O
.	.	O

RESULTS	NNP	O
intention	NN	O
to	TO	O
treat	VB	O
analysis	NN	O
showed	VBD	O
an	DT	O
immunisation	NN	O
rate	NN	O
in	IN	O
the	DT	O
control	NN	O
group	NN	O
of	IN	O
44	CD	O
%	NN	O
,	,	O
compared	VBN	O
with	IN	O
50	CD	O
%	NN	O
in	IN	O
the	DT	O
intervention	NN	O
group	NN	O
(	(	O
odds	NNS	O
ratio	VBP	O
=	JJ	O
1.29	CD	O
,	,	O
95	CD	O
%	NN	O
confidence	NN	O
interval	NN	O
=	VBD	O
1.03	CD	O
to	TO	O
1.63	CD	O
)	)	O
.	.	O

Of	IN	O
the	DT	O
patients	NNS	O
making	VBG	O
a	DT	O
telephone	NN	O
appointment	NN	O
,	,	O
88	CD	O
%	NN	O
recieved	JJ	O
immunisation	NN	O
,	,	O
while	IN	O
22	CD	O
%	NN	O
of	IN	O
those	DT	O
not	RB	O
wanting	VBG	O
an	DT	O
appointment	NN	O
went	VBD	O
on	IN	O
to	TO	O
be	VB	O
immunised	VBN	O
.	.	O

In	IN	O
the	DT	O
controlgroup	NN	O
,	,	O
income	NN	O
generated	VBD	O
was	VBD	O
11.35	CD	O
pounds	NNS	O
per	IN	O
immunisation	NN	O
,	,	O
for	IN	O
each	DT	O
additional	JJ	O
immunisation	NN	O
in	IN	O
the	DT	O
intervention	NN	O
group	NN	O
the	DT	O
income	NN	O
was	VBD	O
5.20	CD	O
pounds	NNS	O
.	.	O

The	DT	O
'number	NNP	O
needed	VBD	O
to	TO	O
telephone	NN	O
'	''	O
was	VBD	O
17	CD	O
.	.	O

CONCLUSION	NNP	O
Uptake	NNP	O
of	IN	O
influenza	JJ	O
immunisation	NN	O
among	IN	O
the	DT	O
low-risk	JJ	O
older	JJR	O
population	NN	O
in	IN	O
inner-city	JJ	O
areas	NNS	O
can	MD	O
be	VB	O
boosted	VBN	O
by	IN	O
around	IN	O
6	CD	O
%	NN	O
using	VBG	O
a	DT	O
simple	JJ	O
intervention	NN	O
by	IN	O
receptionists	NNS	O
.	.	O

Immunisation	NN	O
rates	NNS	O
in	IN	O
this	DT	O
low-risk	JJ	O
group	NN	O
fell	VBD	O
well	RB	O
short	RB	O
of	IN	O
the	DT	O
60	CD	O
%	NN	O
government	NN	O
target	NN	O
.	.	O

Improving	VBG	O
immunisation	NN	O
rates	NNS	O
will	MD	O
require	VB	O
a	DT	O
sustained	JJ	O
public	JJ	O
health	NN	O
campaign	NN	O
.	.	O

Retaining	VBG	O
the	DT	O
item-of-service	JJ	O
payments	NNS	O
to	TO	O
practices	NNS	O
should	MD	O
support	VB	O
costs	NNS	O
of	IN	O
practice-based	JJ	O
interventions	NNS	O
.	.	O

Losartan	NNP	O
vs.	FW	O
amlodipine	NN	O
treatment	NN	O
in	IN	O
elderly	JJ	O
oncologic	JJ	C
hypertensive	JJ	C
patients	NNS	O
:	:	O
a	DT	O
randomized	JJ	O
clinical	JJ	O
trial	NN	O
.	.	O

Elderly	JJ	O
neoplastic	JJ	C
patients	NNS	O
frequently	RB	O
may	MD	O
show	VB	O
hypertension	NN	C
and	CC	O
hyperuricemia	NN	C
,	,	O
before	IN	O
and	CC	O
after	IN	O
chemotherapeutic	JJ	O
treatments	NNS	O
.	.	O

The	DT	O
purpose	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
evaluate	VB	O
the	DT	O
efficacy	NN	O
of	IN	O
losartan	NN	O
which	WDT	O
is	VBZ	O
an	DT	O
antihypertensive	JJ	O
drug	NN	O
with	IN	O
uricosuric	JJ	O
properties	NNS	O
vs.	FW	O
amlodipine	NN	O
in	IN	O
hypertensive	JJ	O
neoplastic	JJ	O
elderly	JJ	O
patients	NNS	O
.	.	O

This	DT	O
was	VBD	O
an	DT	O
open-labeled	JJ	O
,	,	O
randomized	VBN	O
,	,	O
comparative	JJ	O
trial	NN	O
.	.	O

The	DT	O
study	NN	O
was	VBD	O
performed	VBN	O
as	IN	O
a	DT	O
30-day	JJ	O
study	NN	O
.	.	O

Seventy	NNP	SS
patients	NNS	O
with	IN	O
cancer	NN	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
receive	VB	O
losartan	NN	O
or	CC	O
amlodipine	NN	O
.	.	O

Blood	NNP	O
pressure	NN	O
(	(	O
BP	NNP	O
)	)	O
,	,	O
blood	VBD	O
urea	JJ	O
nitrogen	NN	O
(	(	O
BUN	NNP	O
)	)	O
levels	NNS	O
,	,	O
creatinine	NN	O
,	,	O
serum	NN	O
and	CC	O
urinary	JJ	O
uric	JJ	O
acid	NN	O
,	,	O
creatinine	NN	O
and	CC	O
uric	JJ	O
acid	JJ	O
clearance	NN	O
were	VBD	O
determined	VBN	O
before	IN	O
and	CC	O
after	IN	O
chemotherapy	NN	O
.	.	O

One	CD	O
day	NN	O
after	IN	O
chemotherapy	NN	O
in	IN	O
losartan	JJ	O
group	NN	O
vs.	FW	O
amlodipine	NN	O
group	NN	O
we	PRP	O
observed	VBD	O
a	DT	O
significant	JJ	O
difference	NN	O
in	IN	O
urinary	JJ	O
uric	JJ	O
acid	NN	O
(	(	O
p	JJ	O
<	NNP	O
0.001	CD	O
)	)	O
of	IN	O
18	CD	O
mg/24	NNS	O
h	VBD	O
vs.	FW	O
40	CD	O
mg/24	NN	O
h.	NN	O
Thirty	NNP	O
days	NNS	O
after	IN	O
chemotherapy	NN	O
we	PRP	O
observed	VBD	O
a	DT	O
significant	JJ	O
difference	NN	O
in	IN	O
azotemia	NN	O
of	IN	O
0.0	CD	O
mg/dl	NNS	O
vs.	FW	O
3.8	CD	O
mg/dl	NN	O
(	(	O
p	JJ	O
<	NNP	O
0.001	CD	O
)	)	O
,	,	O
serum	JJ	O
uric	JJ	O
acid	NN	O
of	IN	O
0.05	CD	O
mg/dl	NNS	O
vs.	FW	O
0.49	CD	O
mg/dl	NN	O
(	(	O
p	JJ	O
<	NNP	O
0.001	CD	O
)	)	O
,	,	O
urinary	JJ	O
uric	JJ	O
acid	NN	O
(	(	O
p	JJ	O
<	NNP	O
0.001	CD	O
)	)	O
of	IN	O
23	CD	O
mg/24	NNS	O
h	VBD	O
vs.	FW	O
0.0	CD	O
mg/24	NN	O
h	NN	O
,	,	O
GFR	NNP	O
of	IN	O
2	CD	O
ml/min/1.73	NNS	O
m	NN	O
(	(	O
2	CD	O
)	)	O
vs.	FW	O
-8	FW	O
ml/min/1.73	FW	O
m	NN	O
(	(	O
2	CD	O
)	)	O
(	(	O
p	JJ	O
<	NNP	O
0.05	CD	O
)	)	O
and	CC	O
systolic	JJ	O
BP	NNP	O
(	(	O
SBP	NNP	O
)	)	O
of	IN	O
3.6	CD	O
mmHg	NNS	O
vs.	FW	O
0.8	CD	O
mmHg	NN	O
(	(	O
p	JJ	O
<	NNP	O
0.05	CD	O
)	)	O
.	.	O

The	DT	O
findings	NNS	O
of	IN	O
the	DT	O
present	JJ	O
study	NN	O
support	VBD	O
the	DT	O
effective	JJ	O
role	NN	O
of	IN	O
losartan	JJ	O
compared	VBN	O
to	TO	O
amlodipine	VB	O
in	IN	O
treating	VBG	O
hypertension	NN	C
and	CC	O
hyperuricemia	NN	C
in	IN	O
elderly	JJ	O
patients	NNS	O
under	IN	O
chemotherapeutic	JJ	C
treatment	NN	C
.	.	O

Effectiveness	NN	O
of	IN	O
the	DT	O
school	NN	O
dental	JJ	O
screening	VBG	O
programme	NN	O
in	IN	O
stimulating	VBG	O
dental	JJ	O
attendance	NN	O
for	IN	O
children	NNS	A
in	IN	O
need	NN	O
of	IN	O
treatment	NN	O
in	IN	O
Northern	NNP	O
Ireland	NNP	O
.	.	O

UNLABELLED	IN	O
The	DT	O
school	NN	O
dental	JJ	O
screening	NN	O
programme	NN	O
has	VBZ	O
been	VBN	O
in	IN	O
existence	NN	O
from	IN	O
the	DT	O
beginning	NN	O
of	IN	O
the	DT	O
20th	JJ	O
century	NN	O
yet	RB	O
its	PRP$	O
value	NN	O
in	IN	O
encouraging	JJ	O
attendance	NN	O
among	IN	O
children	NNS	O
with	IN	O
a	DT	O
dental	JJ	C
health	NN	C
need	NN	O
is	VBZ	O
not	RB	O
fully	RB	O
established	VBN	O
.	.	O

OBJECTIVE	NNP	O
To	TO	O
evaluate	VB	O
the	DT	O
effectiveness	NN	O
of	IN	O
school	NN	O
dental	JJ	O
screening	NN	O
in	IN	O
promoting	VBG	O
dental	JJ	O
attendance	NN	O
among	IN	O
children	NNS	A
with	IN	O
a	DT	O
treatment	NN	O
need	NN	O
and	CC	O
to	TO	O
examine	VB	O
the	DT	O
relative	JJ	O
importance	NN	O
of	IN	O
screening	NN	O
,	,	O
social	JJ	O
class	NN	O
and	CC	O
other	JJ	O
factors	NNS	O
in	IN	O
dental	JJ	O
attendance	NN	O
.	.	O

METHODS	NNP	O
Sixty-four	JJ	SS
participating	NN	O
schools	NNS	O
were	VBD	O
assigned	VBN	O
to	TO	O
study	VB	O
and	CC	O
control	VB	O
groups	NNS	O
using	VBG	O
a	DT	O
stratified	JJ	O
,	,	O
blocked	JJ	O
randomisation	NN	O
technique	NN	O
.	.	O

The	DT	O
study	NN	O
group	NN	O
children	NNS	O
received	VBD	O
the	DT	O
standard	JJ	O
school	NN	O
dental	JJ	O
screening	NN	O
and	CC	O
the	DT	O
dental	JJ	O
attendance	NN	O
of	IN	O
those	DT	O
with	IN	O
a	DT	O
positive	JJ	O
screening	NN	O
result	NN	O
was	VBD	O
assessed	VBN	O
after	IN	O
2	CD	O
months	NNS	O
by	IN	O
means	NNS	O
of	IN	O
a	DT	O
questionnaire	NN	O
issued	VBN	O
to	TO	O
the	DT	O
children	NNS	O
's	POS	O
parents	NNS	O
.	.	O

The	DT	O
control	NN	O
group	NN	O
children	NNS	O
were	VBD	O
not	RB	O
,	,	O
at	IN	O
this	DT	O
stage	NN	O
,	,	O
screened	VBD	O
,	,	O
yet	CC	O
their	PRP$	O
parents	NNS	O
received	VBD	O
the	DT	O
same	JJ	O
questionnaire	NN	O
assessing	VBG	O
dental	JJ	O
attendance	NN	O
over	IN	O
the	DT	O
2-month	JJ	O
period	NN	O
.	.	O

However	RB	O
,	,	O
only	RB	O
questionnaires	VBZ	O
from	IN	O
control	NN	O
group	NN	O
children	NNS	O
who	WP	O
had	VBD	O
a	DT	O
positive	JJ	O
result	NN	O
at	IN	O
a	DT	O
subsequent	JJ	O
screening	NN	O
were	VBD	O
retained	VBN	O
for	IN	O
analysis	NN	O
.	.	O

RESULTS	VB	O
A	DT	O
total	NN	O
of	IN	O
2,321	CD	SS
children	NNS	SS
were	VBD	O
screened	VBN	O
,	,	O
with	IN	O
980	CD	SS
having	VBG	O
a	DT	O
positive	JJ	O
result	NN	O
.	.	O

The	DT	O
mean	JJ	O
dmft	NN	O
of	IN	O
those	DT	O
screening	VBG	O
positive	JJ	O
was	VBD	O
4.85	CD	O
.	.	O

In	IN	O
all	DT	O
,	,	O
664	CD	SS
completed	VBN	O
questionnaires	NNS	O
were	VBD	O
returned	VBN	O
,	,	O
giving	VBG	O
a	DT	O
response	NN	O
rate	NN	O
of	IN	O
67.8	CD	O
%	NN	O
.	.	O

Dental	JJ	O
attendance	NN	O
was	VBD	O
reported	VBN	O
among	IN	O
45.5	CD	O
%	NN	O
of	IN	O
the	DT	O
study	NN	O
group	NN	O
(	(	O
n=352	NN	O
)	)	O
in	IN	O
the	DT	O
2	CD	O
months	NNS	O
following	VBG	O
screening	NN	O
.	.	O

In	IN	O
the	DT	O
same	JJ	O
period	NN	O
,	,	O
27.6	CD	O
%	NN	O
of	IN	O
the	DT	O
control	NN	O
group	NN	O
(	(	O
n=312	RB	O
)	)	O
claimed	VBD	O
attendance	NN	O
.	.	O

The	DT	O
effect	NN	O
was	VBD	O
found	VBN	O
to	TO	O
be	VB	O
significant	JJ	O
among	IN	O
the	DT	O
high	JJ	O
employed	VBN	O
group	NN	O
(	(	O
P	NNP	O
<	NNP	O
0.01	CD	O
)	)	O
and	CC	O
the	DT	O
unemployed	JJ	O
group	NN	O
(	(	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
.	.	O

CONCLUSION	NNP	O
School	NNP	O
dental	JJ	O
screening	NN	O
was	VBD	O
capable	JJ	O
of	IN	O
stimulating	VBG	O
dental	JJ	O
attendance	NN	O
.	.	O

The	DT	O
strong	JJ	O
effect	NN	O
among	IN	O
the	DT	O
lowest	JJS	O
socio-economic	JJ	O
group	NN	O
shows	VBZ	O
that	IN	O
school	NN	O
dental	JJ	O
screening	NN	O
may	MD	O
be	VB	O
used	VBN	O
to	TO	O
decrease	VB	O
dental	JJ	O
health	NN	O
inequalities	NNS	O
.	.	O

Effect	NN	O
of	IN	O
spinal	JJ	O
versus	NN	O
general	JJ	O
anesthesia	NN	O
on	IN	O
bladder	NN	O
compliance	NN	O
and	CC	O
intraabdominal	JJ	O
pressure	NN	O
during	IN	O
transurethral	JJ	O
procedures	NNS	O
.	.	O

STUDY	NNP	O
OBJECTIVE	NNP	O
To	TO	O
evaluate	VB	O
the	DT	O
influence	NN	O
of	IN	O
spinal	JJ	O
versus	NN	O
general	JJ	O
anesthesia	NN	O
on	IN	O
bladder	NN	O
compliance	NN	O
and	CC	O
intraabdominal	JJ	O
pressure	NN	O
in	IN	O
elderly	JJ	A
males	NNS	A
undergoing	VBG	O
elective	JJ	C
transurethral	JJ	C
resection	NN	C
of	IN	C
the	DT	C
prostate	NN	C
.	.	O

DESIGN	NNP	O
Prospective	NNP	O
,	,	O
randomized	VBD	O
,	,	O
open-label	JJ	O
study	NN	O
.	.	O

SETTING	NN	O
Teaching	NNP	O
hospital	NN	O
.	.	O

PATIENTS	CC	O
21	CD	SS
ASA	NNP	O
physical	JJ	O
status	NN	O
I	PRP	O
,	,	O
II	NNP	O
,	,	O
and	CC	O
III	NNP	O
patients	NNS	O
at	IN	A
least	JJS	A
18	CD	A
years	NNS	O
of	IN	O
age	NN	O
,	,	O
undergoing	VBG	O
transurethral	JJ	O
surgery	NN	O
.	.	O

INTERVENTIONS	NNP	O
According	VBG	O
to	TO	O
a	DT	O
computer-generated	JJ	O
randomization	NN	O
schedule	NN	O
,	,	O
patients	NNS	O
were	VBD	O
allocated	VBN	O
to	TO	O
one	CD	O
of	IN	O
two	CD	O
groups	NNS	O
.	.	O

In	IN	O
Group	NNP	O
Spinal	NNP	O
(	(	O
S	NNP	O
)	)	O
,	,	O
10	CD	O
mg	NN	O
of	IN	O
hyperbaric	JJ	O
tetracaine	NN	O
was	VBD	O
administered	VBN	O
intrathecally	RB	O
.	.	O

In	IN	O
Group	NNP	O
General	NNP	O
Anesthesia	NNP	O
(	(	O
GA	NNP	O
)	)	O
,	,	O
patients	NNS	O
received	VBD	O
,	,	O
fentanyl	RB	O
intravenous	JJ	O
(	(	O
i.v	JJ	O
.	.	O

1	CD	O
to	TO	O
2	CD	O
micrograms/kg	NNS	O
and	CC	O
propofol	NN	O
i.v	NN	O
.	.	O

1.0	CD	O
to	TO	O
2.0	CD	O
mg/kg	NN	O
for	IN	O
induction	NN	O
of	IN	O
anesthesia	NN	O
.	.	O

Thereafter	NNP	O
,	,	O
a	DT	O
laryngeal	JJ	O
mask	NN	O
airway	NN	O
was	VBD	O
inserted	VBN	O
and	CC	O
,	,	O
with	IN	O
spontaneous	JJ	O
ventilation	NN	O
,	,	O
anesthesia	NN	O
was	VBD	O
maintained	VBN	O
by	IN	O
administering	VBG	O
isoflurane	NN	O
(	(	O
end-tidal	JJ	O
0.7	CD	O
%	NN	O
to	TO	O
1.2	CD	O
%	NN	O
)	)	O
and	CC	O
70	CD	O
%	NN	O
nitrous	JJ	O
oxide	NN	O
(	(	O
N2O	NNP	O
)	)	O
in	IN	O
oxygen	NN	O
.	.	O

Intraabdominal	JJ	O
pressure	NN	O
and	CC	O
bladder	NN	O
compliance	NN	O
were	VBD	O
recorded	VBN	O
prior	RB	O
to	TO	O
the	DT	O
induction	NN	O
of	IN	O
anesthesia	NN	O
and	CC	O
immediately	RB	O
before	IN	O
the	DT	O
onset	NN	O
of	IN	O
the	DT	O
surgical	JJ	O
procedure	NN	O
.	.	O

MEASUREMENTS	NNP	O
AND	CC	O
MAIN	NNP	O
RESULTS	NNP	O
The	DT	O
two	CD	O
groups	NNS	O
were	VBD	O
demographically	RB	O
comparable	JJ	O
.	.	O

In	IN	O
Group	NNP	O
S	NNP	O
,	,	O
mean	JJ	O
bladder	NN	O
compliance	NN	O
was	VBD	O
significantly	RB	O
(	(	O
p	JJ	O
=	NNP	O
0.003	CD	O
)	)	O
higher	JJR	O
and	CC	O
mean	JJ	O
intraabdominal	JJ	O
pressure	NN	O
significantly	RB	O
lower	JJR	O
(	(	O
p	JJ	O
=	NNP	O
0.007	CD	O
)	)	O
when	WRB	O
compared	VBN	O
to	TO	O
baseline	VB	O
preanesthetic	JJ	O
values	NNS	O
.	.	O

In	IN	O
Group	NNP	O
GA	NNP	O
,	,	O
mean	JJ	O
intraabdominal	JJ	O
pressure	NN	O
significantly	RB	O
(	(	O
p	JJ	O
=	NNP	O
0.006	CD	O
)	)	O
decreased	VBD	O
when	WRB	O
compared	VBN	O
to	TO	O
baseline	VB	O
preanesthetic	JJ	O
recordings	NNS	O
.	.	O

Following	VBG	O
the	DT	O
induction	NN	O
of	IN	O
general	JJ	O
anesthesia	NN	O
,	,	O
a	DT	O
small	JJ	O
change	NN	O
in	IN	O
bladder	NN	O
compliance	NN	O
was	VBD	O
noted	VBN	O
.	.	O

However	RB	O
,	,	O
statistical	JJ	O
significance	NN	O
was	VBD	O
not	RB	O
reached	VBN	O
.	.	O

Data	NNS	O
were	VBD	O
analyzed	VBN	O
and	CC	O
compared	VBN	O
using	VBG	O
Student	NNP	O
's	POS	O
t-test	NN	O
(	(	O
p	JJ	O
<	NN	O
0.05	CD	O
was	VBD	O
considered	VBN	O
statistically	RB	O
significant	JJ	O
)	)	O
.	.	O

CONCLUSION	NNP	O
Both	NNP	O
spinal	JJ	O
and	CC	O
general	JJ	O
anesthesia	NN	O
induced	VBD	O
a	DT	O
significant	JJ	O
decrease	NN	O
in	IN	O
intraabdominal	JJ	O
pressure	NN	O
.	.	O

While	IN	O
both	DT	O
techniques	NNS	O
were	VBD	O
associated	VBN	O
with	IN	O
an	DT	O
increase	NN	O
in	IN	O
bladder	NN	O
compliance	NN	O
,	,	O
statistical	JJ	O
significance	NN	O
was	VBD	O
demonstrated	VBN	O
only	RB	O
in	IN	O
the	DT	O
spinal	JJ	O
anesthesia	NN	O
treatment	NN	O
group	NN	O
.	.	O

The	DT	O
effectiveness	NN	O
of	IN	O
single-dose	JJ	O
metronidazole	JJ	O
therapy	NN	O
for	IN	O
patients	NNS	O
and	CC	O
their	PRP$	O
partners	NNS	O
with	IN	O
bacterial	JJ	O
vaginosis	NN	O
.	.	O

A	DT	O
randomized	JJ	O
,	,	O
placebo-controlled	JJ	O
,	,	O
double-blind	JJ	O
clinical	JJ	O
trial	NN	O
was	VBD	O
performed	VBN	O
to	TO	O
test	VB	O
the	DT	O
hypothesis	NN	O
that	IN	O
a	DT	O
2-g	JJ	O
single	JJ	O
dose	NN	O
of	IN	O
metronidazole	NN	O
for	IN	O
male	JJ	O
partners	NNS	O
of	IN	O
women	NNS	O
with	IN	O
bacterial	JJ	O
vaginosis	NN	O
was	VBD	O
more	RBR	O
effective	JJ	O
than	IN	O
placebo	NN	O
in	IN	O
improving	VBG	O
cure	NN	O
rate	NN	O
and	CC	O
decreasing	VBG	O
recurrence	NN	O
rate	NN	O
.	.	O

In	IN	O
addition	NN	O
,	,	O
the	DT	O
effectiveness	NN	O
of	IN	O
a	DT	O
2-g	JJ	O
single	JJ	O
dose	NN	O
of	IN	O
metronidazole	NN	O
was	VBD	O
compared	VBN	O
with	IN	O
a	DT	O
seven-day	JJ	O
course	NN	O
of	IN	O
500	CD	O
mg	NN	O
of	IN	O
metronidazole	JJ	O
twice	NN	O
a	DT	O
day	NN	O
in	IN	O
patients	NNS	O
with	IN	O
bacterial	JJ	O
vaginosis	NN	O
.	.	O

Statistically	NNP	O
significant	JJ	O
benefits	NNS	O
of	IN	O
partner	NN	O
treatment	NN	O
were	VBD	O
noted	VBN	O
in	IN	O
the	DT	O
initial	JJ	O
cure	NN	O
rate	NN	O
by	IN	O
Gram-stained	JJ	O
smear	JJ	O
criteria	NNS	O
(	(	O
P	NNP	O
less	JJR	O
than	IN	O
.01	NN	O
)	)	O
and	CC	O
in	IN	O
percentage	NN	O
of	IN	O
women	NNS	O
with	IN	O
symptoms	NNS	O
eight	CD	O
weeks	NNS	O
after	IN	O
initiating	VBG	O
therapy	NN	O
(	(	O
P	NNP	O
less	JJR	O
than	IN	O
.05	NN	O
)	)	O
.	.	O

The	DT	O
seven-day	JJ	O
course	NN	O
of	IN	O
metronidazole	NN	O
was	VBD	O
superior	JJ	O
to	TO	O
the	DT	O
single-dose	JJ	O
regimen	NNS	O
in	IN	O
the	DT	O
percentage	NN	O
of	IN	O
patients	NNS	O
with	IN	O
clue	JJ	O
cells	NNS	O
and	CC	O
the	DT	O
percentage	NN	O
of	IN	O
patients	NNS	O
with	IN	O
a	DT	O
positive	JJ	O
sniff	NN	O
test	NN	O
at	IN	O
the	DT	O
first	JJ	O
follow-up	JJ	O
visit	NN	O
;	:	O
however	RB	O
,	,	O
differences	NNS	O
in	IN	O
the	DT	O
initial	JJ	O
cure	NN	O
rate	NN	O
assessed	VBN	O
by	IN	O
clinical	JJ	O
criteria	NNS	O
and	CC	O
Gram-stained	JJ	O
smear	JJ	O
criteria	NNS	O
were	VBD	O
not	RB	O
statistically	RB	O
significant	JJ	O
between	IN	O
the	DT	O
two	CD	O
patient	NN	O
treatment	NN	O
regimens	NNS	O
.	.	O

Recurrence	NN	O
rates	NNS	O
by	IN	O
Gram-stained	JJ	O
smear	JJ	O
criteria	NNS	O
between	IN	O
patient	NN	O
and	CC	O
partner	NN	O
treatment	NN	O
groups	NNS	O
at	IN	O
five	CD	O
and	CC	O
eight	CD	O
weeks	NNS	O
after	IN	O
initiation	NN	O
of	IN	O
treatment	NN	O
were	VBD	O
also	RB	O
not	RB	O
significantly	RB	O
different	JJ	O
between	IN	O
the	DT	O
two	CD	O
patient	NN	O
regimens	NNS	O
.	.	O

Single-dose	JJ	O
metronidazole	JJ	O
treatment	NN	O
of	IN	O
the	DT	O
sexual	JJ	O
partner	NN	O
of	IN	O
women	NNS	O
with	IN	O
bacterial	JJ	O
vaginosis	NN	O
improves	VBZ	O
initial	JJ	O
bacterial	JJ	O
vaginosis	NN	O
cure	NN	O
rates	NNS	O
.	.	O

The	DT	O
seven-day	JJ	O
course	NN	O
of	IN	O
metronidazole	NN	O
was	VBD	O
not	RB	O
found	VBN	O
by	IN	O
statistical	JJ	O
analysis	NN	O
to	TO	O
be	VB	O
significantly	RB	O
superior	JJ	O
to	TO	O
single-dose	JJ	O
therapy	NN	O
when	WRB	O
considering	VBG	O
initial	JJ	O
cure	NN	O
rates	NNS	O
by	IN	O
clinical	JJ	O
or	CC	O
Gram-stained	JJ	O
smear	JJ	O
criteria	NNS	O
or	CC	O
recurrence	NN	O
rates	NNS	O
.	.	O

(	(	O
ABSTRACT	NNP	O
TRUNCATED	NNP	O
AT	NNP	O
250	CD	O
WORDS	NNP	O
)	)	O
Improved	NNP	O
responsiveness	NN	O
of	IN	O
PCOS	NNP	O
patients	NNS	O
to	TO	O
clomiphene	VB	O
after	IN	O
CYP17a	NNP	O
inhibitor	NN	O
.	.	O

PURPOSE	NNP	O
To	TO	O
study	VB	O
the	DT	O
effect	NN	O
of	IN	O
CYP17a	NNP	O
inhibitor	NN	O
,	,	O
ketoconazole	NN	O
,	,	O
on	IN	O
clomiphene	NN	O
responsiveness	NN	O
in	IN	O
PCOS	NNP	O
patients	NNS	O
.	.	O

METHODS	NNP	O
Prospective	JJ	O
analysis	NN	O
was	VBD	O
employed	VBN	O
with	IN	O
the	DT	O
setup	NN	O
at	IN	O
Alexandria	NNP	O
IVF/ICSI	NNP	O
center	NN	O
.	.	O

Ninety-seven	JJ	O
insulin-resistant	JJ	O
PCOS	NNP	O
patients	NNS	O
undergoing	VBG	O
ovulation	NN	O
induction	NN	O
using	VBG	O
clomiphene	JJ	O
citrate	NN	O
were	VBD	O
randomly	RB	O
divided	VBN	O
,	,	O
by	IN	O
random	JJ	O
number	NN	O
table	NN	O
,	,	O
into	IN	O
two	CD	O
groups	NNS	O
.	.	O

The	DT	O
first	JJ	O
group	NN	O
(	(	O
n	JJ	O
=	NNP	O
49	CD	O
)	)	O
received	VBN	O
ketoconazole	NN	O
(	(	O
400	CD	O
mg	NNS	O
daily	RB	O
)	)	O
till	NN	O
correction	NN	O
of	IN	O
metabolic	JJ	O
syndrome	NN	O
followed	VBN	O
by	IN	O
clomiphene	NN	O
(	(	O
100	CD	O
mg/day	NN	O
)	)	O
;	:	O
the	DT	O
second	JJ	O
group	NN	O
(	(	O
n	JJ	O
=	NNP	O
48	CD	O
)	)	O
receiving	VBG	O
clomiphene	NN	O
without	IN	O
ketoconazole	JJ	O
pretreatment	NN	O
.	.	O

Main	NNP	O
outcome	JJ	O
measures	NNS	O
were	VBD	O
incidence	NN	O
of	IN	O
clomiphene	NN	O
resistance	NN	O
,	,	O
monofollicular	JJ	O
response	NN	O
,	,	O
fasting	VBG	O
insulin/glucose	JJ	O
ratio	NN	O
,	,	O
serum	NN	O
testosterone	NN	O
,	,	O
and	CC	O
pregnancy	NN	O
rates	NNS	O
.	.	O

RESULTS	VB	O
The	DT	O
ketoconazole	NN	O
group	NN	O
showed	VBD	O
significantly	RB	O
(	(	O
p	JJ	O
<	NNP	O
0.05	CD	O
)	)	O
higher	JJR	O
incidence	NN	O
of	IN	O
monofollicular	JJ	O
response	NN	O
(	(	O
38	CD	O
%	NN	O
)	)	O
,	,	O
higher	JJR	O
pregnancy	NN	O
rates	NNS	O
,	,	O
and	CC	O
significantly	RB	O
less	JJR	O
marked	JJ	O
antiestrogenic	NN	O
manifestations	NNS	O
than	IN	O
did	VBD	O
the	DT	O
control	NN	O
group	NN	O
.	.	O

They	PRP	O
also	RB	O
had	VBD	O
significantly	RB	O
lower	JJR	O
incidence	NN	O
of	IN	O
clomiphene	NN	O
resistance	NN	O
(	(	O
11.6	CD	O
%	NN	O
)	)	O
,	,	O
lower	JJR	O
serum	NN	O
testosterone	NN	O
levels	NNS	O
,	,	O
less	JJR	O
hyperinsulinaemia	NN	O
,	,	O
than	IN	O
did	VBD	O
the	DT	O
control	NN	O
group	NN	O
.	.	O

CONCLUSION	NNP	O
Ketoconazole	NNP	O
improved	VBD	O
clomiphene	JJ	O
responsivenss	NN	O
in	IN	O
PCOS	NNP	O
patients	NNS	O
and	CC	O
attenuated	VBD	O
its	PRP$	O
untoward	JJ	O
biological	JJ	O
effects	NNS	O
.	.	O

Laser-aided	JJ	O
external	JJ	O
drainage	NN	O
of	IN	O
subretinal	JJ	C
fluid	NN	C
:	:	O
prospective	JJ	O
randomized	VBN	O
comparison	NN	O
with	IN	O
needle	JJ	O
drainage	NN	O
.	.	O

In	IN	O
a	DT	O
prospective	JJ	O
randomized	VBN	O
study	NN	O
of	IN	O
50	CD	SS
consecutive	JJ	O
eyes	NNS	O
,	,	O
we	PRP	O
compared	VBN	O
the	DT	O
safety	NN	O
and	CC	O
efficacy	NN	O
of	IN	O
draining	VBG	O
subretinal	JJ	O
fluid	NN	O
transchoroidally	RB	O
in	IN	O
primary	JJ	O
scleral	JJ	O
buckling	NN	O
for	IN	O
rhegmatogenous	JJ	O
retinal	JJ	O
detachment	NN	O
using	VBG	O
a	DT	O
needle	JJ	O
,	,	O
with	IN	O
the	DT	O
safety	NN	O
and	CC	O
efficacy	NN	O
of	IN	O
the	DT	O
same	JJ	O
procedure	NN	O
using	VBG	O
an	DT	O
angulated	VBN	O
endolaser	NN	O
probe	NN	O
set	VBN	O
at	IN	O
1	CD	O
W	NNP	O
for	IN	O
0.2	CD	O
seconds	NNS	O
,	,	O
using	VBG	O
an	DT	O
average	NN	O
of	IN	O
2.4	CD	O
laser	NN	O
burns	NNS	O
.	.	O

There	EX	O
were	VBD	O
no	DT	O
significant	JJ	O
complications	NNS	O
associated	VBN	O
with	IN	O
the	DT	O
laser-aided	JJ	O
drainage	NN	O
procedures	NNS	O
(	(	O
25	CD	O
eyes	NNS	O
)	)	O
.	.	O

In	IN	O
the	DT	O
transchoroidal	NN	O
needle	JJ	O
drainage	NN	O
procedures	NNS	O
(	(	O
25	CD	O
eyes	NNS	O
)	)	O
,	,	O
subretinal	JJ	O
hemorrhage	NN	O
occurred	VBD	O
in	IN	O
three	CD	O
eyes	NNS	O
and	CC	O
retinal	JJ	O
incarceration	NN	O
in	IN	O
one	CD	O
.	.	O

Thus	VB	O
,	,	O
though	IN	O
our	PRP$	O
numbers	NNS	O
are	VBP	O
small	JJ	O
,	,	O
there	EX	O
appears	VBZ	O
to	TO	O
be	VB	O
some	DT	O
advantage	NN	O
of	IN	O
laser-assisted	JJ	O
drainage	NN	O
in	IN	O
terms	NNS	O
of	IN	O
a	DT	O
lower	JJR	O
incidence	NN	O
of	IN	O
complications	NNS	O
.	.	O

Prevention	NN	O
of	IN	O
coronary	JJ	O
spasm	NN	O
by	IN	O
nicorandil	NNS	O
:	:	O
comparison	NN	O
with	IN	O
nifedipine	NN	O
.	.	O

The	DT	O
efficacy	NN	O
of	IN	O
nicorandil	NN	O
was	VBD	O
compared	VBN	O
with	IN	O
that	DT	O
of	IN	O
nifedipine	NN	O
in	IN	O
13	CD	O
patients	NNS	O
with	IN	O
vasospastic	JJ	O
angina	NNS	O
enrolled	VBN	O
in	IN	O
a	DT	O
randomized	JJ	O
,	,	O
placebo-controlled	JJ	O
,	,	O
crossover	NN	O
study	NN	O
.	.	O

All	DT	O
patients	NNS	O
had	VBD	O
a	DT	O
coronary	JJ	O
spasm	NN	O
during	IN	O
coronary	JJ	O
arteriography	NN	O
,	,	O
either	CC	O
spontaneously	RB	O
or	CC	O
ergometrine-induced	JJ	O
.	.	O

During	IN	O
two	CD	O
consecutive	JJ	O
periods	NNS	O
of	IN	O
2	CD	O
days	NNS	O
,	,	O
patients	NNS	O
received	VBD	O
active	JJ	O
drugs	NNS	O
or	CC	O
placebo	NN	O
in	IN	O
a	DT	O
randomized	JJ	O
order	NN	O
.	.	O

Each	DT	O
patient	NN	O
received	VBD	O
single	JJ	O
oral	JJ	O
doses	NNS	O
of	IN	O
30	CD	O
mg	NN	O
nicorandil	NN	O
,	,	O
10	CD	O
mg	NN	O
nifedipine	NN	O
,	,	O
and	CC	O
,	,	O
on	IN	O
2	CD	O
days	NNS	O
,	,	O
a	DT	O
placebo	NN	O
.	.	O

One	CD	O
hour	NN	O
after	IN	O
drug	NN	O
intake	NN	O
,	,	O
patients	NNS	O
underwent	VBD	O
an	DT	O
ergometrine	JJ	O
test	NN	O
with	IN	O
increasing	VBG	O
doses	NNS	O
of	IN	O
Methergin	NNP	O
(	(	O
ergometrine	NN	O
)	)	O
(	(	O
0.05	CD	O
,	,	O
0.10	CD	O
,	,	O
0.20	CD	O
,	,	O
and	CC	O
0.40	CD	O
mg	NN	O
every	DT	O
5	CD	O
min	NN	O
)	)	O
.	.	O

After	IN	O
placebo	NN	O
,	,	O
the	DT	O
tests	NNS	O
always	RB	O
were	VBD	O
positive	JJ	O
,	,	O
and	CC	O
the	DT	O
ECG	NNP	O
changes	NNS	O
occurred	VBD	O
at	IN	O
the	DT	O
same	JJ	O
+/-	JJ	O
1	CD	O
dose	NN	O
of	IN	O
ergometrine	NN	O
in	IN	O
10	CD	O
cases	NNS	O
,	,	O
showing	VBG	O
good	JJ	O
reproducibility	NN	O
.	.	O

After	IN	O
nicorandil	NN	O
,	,	O
the	DT	O
tests	NNS	O
were	VBD	O
negative	JJ	O
in	IN	O
nine	CD	O
patients	NNS	O
and	CC	O
positive	JJ	O
for	IN	O
a	DT	O
higher	JJR	O
or	CC	O
lower	JJR	O
dose	NN	O
of	IN	O
ergometrine	NN	O
in	IN	O
three	CD	O
and	CC	O
one	CD	O
patient	NN	O
,	,	O
respectively	RB	O
(	(	O
p	JJ	O
=	$	O
0.0034	CD	O
vs.	FW	O
placebo	NN	O
)	)	O
.	.	O

After	IN	O
nifedipine	NN	O
,	,	O
the	DT	O
tests	NNS	O
were	VBD	O
negative	JJ	O
in	IN	O
five	CD	O
patients	NNS	O
and	CC	O
positive	JJ	O
for	IN	O
a	DT	O
higher	JJR	O
or	CC	O
the	DT	O
same	JJ	O
dose	NN	O
of	IN	O
ergometrine	NN	O
in	IN	O
four	CD	O
and	CC	O
four	CD	O
patients	NNS	O
,	,	O
respectively	RB	O
(	(	O
p	JJ	O
=	$	O
0.0039	CD	O
vs.	FW	O
placebo	NN	O
)	)	O
.	.	O

Nifedipine	NNP	O
(	(	O
10	CD	O
mg	NN	O
)	)	O
and	CC	O
nicorandil	$	O
(	(	O
30	CD	O
mg	NN	O
)	)	O
were	VBD	O
equally	RB	O
effective	JJ	O
in	IN	O
eight	CD	O
patients	NNS	O
;	:	O
in	IN	O
the	DT	O
remaining	VBG	O
five	CD	O
patients	NNS	O
,	,	O
nicorandil	NNS	O
had	VBD	O
better	JJR	O
results	NNS	O
(	(	O
p	JJ	O
=	NNP	O
0.06	CD	O
)	)	O
.	.	O

Nicorandil	NNP	O
(	(	O
30	CD	O
mg	NN	O
)	)	O
prevents	VBZ	O
ergometrine-induced	JJ	O
coronary	JJ	O
spasm	NN	O
.	.	O

This	DT	O
compound	NN	O
may	MD	O
be	VB	O
beneficial	JJ	O
in	IN	O
patients	NNS	O
with	IN	O
vasospastic	JJ	O
angina	NN	O
.	.	O

Human	NNP	O
papillomavirus	NN	O
and	CC	O
Papanicolaou	NNP	O
tests	NNS	O
to	TO	O
screen	VB	O
for	IN	O
cervical	JJ	O
cancer	NN	O
.	.	O

BACKGROUND	NNP	O
Screening	NNP	O
for	IN	O
cervical	JJ	O
cancer	NN	O
based	VBN	O
on	IN	O
testing	VBG	O
for	IN	O
human	JJ	O
papillomavirus	NN	O
(	(	O
HPV	NNP	O
)	)	O
increases	VBZ	O
the	DT	O
sensitivity	NN	O
of	IN	O
detection	NN	O
of	IN	O
high-grade	NN	O
(	(	O
grade	JJ	O
2	CD	O
or	CC	O
3	CD	O
)	)	O
cervical	JJ	O
intraepithelial	JJ	O
neoplasia	NN	O
,	,	O
but	CC	O
whether	IN	O
this	DT	O
gain	NN	O
represents	VBZ	O
overdiagnosis	NN	O
or	CC	O
protection	NN	O
against	IN	O
future	JJ	O
high-grade	JJ	O
cervical	JJ	O
epithelial	JJ	O
neoplasia	NN	O
or	CC	O
cervical	JJ	O
cancer	NN	O
is	VBZ	O
unknown	JJ	O
.	.	O

METHODS	NNP	O
In	IN	O
a	DT	O
population-based	JJ	O
screening	NN	O
program	NN	O
in	IN	O
Sweden	NNP	O
,	,	O
12,527	CD	SS
women	NNS	SE
32	CD	A
to	TO	A
38	CD	A
years	NNS	A
of	IN	A
age	NN	A
were	VBD	O
randomly	RB	O
assigned	VBN	O
at	IN	O
a	DT	O
1:1	CD	O
ratio	NN	O
to	TO	O
have	VB	O
an	DT	O
HPV	NNP	O
test	NN	O
plus	CC	O
a	DT	O
Papanicolaou	NNP	O
(	(	O
Pap	NNP	O
)	)	O
test	NN	O
(	(	O
intervention	NN	O
group	NN	O
)	)	O
or	CC	O
a	DT	O
Pap	JJ	O
test	NN	O
alone	RB	O
(	(	O
control	VB	O
group	NN	O
)	)	O
.	.	O

Women	NNS	O
with	IN	O
a	DT	O
positive	JJ	O
HPV	NNP	O
test	NN	O
and	CC	O
a	DT	O
normal	JJ	O
Pap	NNP	O
test	NN	O
result	NN	O
were	VBD	O
offered	VBN	O
a	DT	O
second	JJ	O
HPV	NNP	O
test	NN	O
at	IN	O
least	JJS	O
1	CD	O
year	NN	O
later	RB	O
,	,	O
and	CC	O
those	DT	O
who	WP	O
were	VBD	O
found	VBN	O
to	TO	O
be	VB	O
persistently	RB	O
infected	VBN	O
with	IN	O
the	DT	O
same	JJ	O
high-risk	JJ	O
type	NN	O
of	IN	O
HPV	NNP	O
were	VBD	O
then	RB	O
offered	VBN	O
colposcopy	NN	O
with	IN	O
cervical	JJ	O
biopsy	NN	O
.	.	O

A	DT	O
similar	JJ	O
number	NN	O
of	IN	O
double-blinded	JJ	O
Pap	NNP	O
smears	NNS	O
and	CC	O
colposcopies	NNS	O
with	IN	O
biopsy	NN	O
were	VBD	O
performed	VBN	O
in	IN	O
randomly	RB	O
selected	VBN	O
women	NNS	O
in	IN	O
the	DT	O
control	NN	O
group	NN	O
.	.	O

Comprehensive	JJ	O
registry	NN	O
data	NNS	O
were	VBD	O
used	VBN	O
to	TO	O
follow	VB	O
the	DT	O
women	NNS	O
for	IN	O
a	DT	O
mean	NN	O
of	IN	O
4.1	CD	O
years	NNS	O
.	.	O

The	DT	O
relative	JJ	O
rates	NNS	O
of	IN	O
grade	JJ	O
2	CD	O
or	CC	O
3	CD	O
cervical	JJ	O
intraepithelial	JJ	O
neoplasia	NN	O
or	CC	O
cancer	NN	O
detected	VBN	O
at	IN	O
enrollment	NN	O
and	CC	O
at	IN	O
subsequent	JJ	O
screening	VBG	O
examinations	NNS	O
were	VBD	O
calculated	VBN	O
.	.	O

RESULTS	NNP	O
At	IN	O
enrollment	NN	O
,	,	O
the	DT	O
proportion	NN	O
of	IN	O
women	NNS	O
in	IN	O
the	DT	O
intervention	NN	O
group	NN	O
who	WP	O
were	VBD	O
found	VBN	O
to	TO	O
have	VB	O
lesions	NNS	O
of	IN	O
grade	NN	O
2	CD	O
or	CC	O
3	CD	O
cervical	JJ	O
intraepithelial	JJ	O
neoplasia	NN	O
or	CC	O
cancer	NN	O
was	VBD	O
51	CD	O
%	NN	O
greater	JJR	O
(	(	O
95	CD	O
%	NN	O
confidence	NN	O
interval	NN	O
[	NNP	O
CI	NNP	O
]	NNP	O
,	,	O
13	CD	O
to	TO	O
102	CD	O
)	)	O
than	IN	O
the	DT	O
proportion	NN	O
of	IN	O
women	NNS	O
in	IN	O
the	DT	O
control	NN	O
group	NN	O
who	WP	O
were	VBD	O
found	VBN	O
to	TO	O
have	VB	O
such	JJ	O
lesions	NNS	O
.	.	O

At	IN	O
subsequent	JJ	O
screening	VBG	O
examinations	NNS	O
,	,	O
the	DT	O
proportion	NN	O
of	IN	O
women	NNS	O
in	IN	O
the	DT	O
intervention	NN	O
group	NN	O
who	WP	O
were	VBD	O
found	VBN	O
to	TO	O
have	VB	O
grade	VBN	O
2	CD	O
or	CC	O
3	CD	O
lesions	NNS	O
or	CC	O
cancer	NN	O
was	VBD	O
42	CD	O
%	NN	O
less	JJR	O
(	(	O
95	CD	O
%	NN	O
CI	NNP	O
,	,	O
4	CD	O
to	TO	O
64	CD	O
)	)	O
and	CC	O
the	DT	O
proportion	NN	O
with	IN	O
grade	JJ	O
3	CD	O
lesions	NNS	O
or	CC	O
cancer	NN	O
was	VBD	O
47	CD	O
%	NN	O
less	JJR	O
(	(	O
95	CD	O
%	NN	O
CI	NNP	O
,	,	O
2	CD	O
to	TO	O
71	CD	O
)	)	O
than	IN	O
the	DT	O
proportions	NNS	O
of	IN	O
control	NN	O
women	NNS	O
who	WP	O
were	VBD	O
found	VBN	O
to	TO	O
have	VB	O
such	JJ	O
lesions	NNS	O
.	.	O

Women	NNS	O
with	IN	O
persistent	JJ	O
HPV	NNP	O
infection	NN	O
remained	VBD	O
at	IN	O
high	JJ	O
risk	NN	O
for	IN	O
grade	JJ	O
2	CD	O
or	CC	O
3	CD	O
lesions	NNS	O
or	CC	O
cancer	NN	O
after	IN	O
referral	JJ	O
for	IN	O
colposcopy	NN	O
.	.	O

CONCLUSIONS	VB	O
The	DT	O
addition	NN	O
of	IN	O
an	DT	O
HPV	NNP	O
test	NN	O
to	TO	O
the	DT	O
Pap	NNP	O
test	NN	O
to	TO	O
screen	JJ	O
women	NNS	O
in	IN	O
their	PRP$	O
mid-30s	NN	A
for	IN	O
cervical	JJ	O
cancer	NN	O
reduces	VBZ	O
the	DT	O
incidence	NN	O
of	IN	O
grade	NN	O
2	CD	O
or	CC	O
3	CD	O
cervical	JJ	O
intraepithelial	JJ	O
neoplasia	NN	O
or	CC	O
cancer	NN	O
detected	VBN	O
by	IN	O
subsequent	JJ	O
screening	NN	O
examinations	NNS	O
.	.	O

(	(	O
ClinicalTrials.gov	NNP	O
number	NN	O
,	,	O
NCT00479375	NNP	O
[	NNP	O
ClinicalTrials.gov	NNP	O
]	NNP	O
.	.	O

)	)	O
.	.	O

Trachoma	NNP	O
prevalence	NN	O
and	CC	O
associated	VBN	O
risk	NN	O
factors	NNS	O
in	IN	O
the	DT	O
gambia	NN	O
and	CC	O
Tanzania	NNP	O
:	:	O
baseline	NN	O
results	NNS	O
of	IN	O
a	DT	O
cluster	NN	O
randomised	VBN	O
controlled	VBN	O
trial	NN	O
.	.	O

BACKGROUND	NNP	O
Blinding	NNP	O
trachoma	NN	O
,	,	O
caused	VBN	O
by	IN	O
ocular	JJ	O
infection	NN	O
with	IN	O
Chlamydia	NNP	O
trachomatis	NN	O
,	,	O
is	VBZ	O
targeted	VBN	O
for	IN	O
global	JJ	O
elimination	NN	O
by	IN	O
2020	CD	O
.	.	O

Knowledge	NNP	O
of	IN	O
risk	NN	O
factors	NNS	O
can	MD	O
help	VB	O
target	VB	O
control	JJ	O
interventions	NNS	O
.	.	O

METHODOLOGY/PRINCIPAL	NNP	O
FINDINGS	NNP	O
As	IN	O
part	NN	O
of	IN	O
a	DT	O
cluster	NN	O
randomised	VBN	O
controlled	VBN	O
trial	NN	O
,	,	O
we	PRP	O
assessed	VBD	O
the	DT	O
baseline	NN	O
prevalence	NN	O
of	IN	O
,	,	O
and	CC	O
risk	NN	O
factors	NNS	O
for	IN	O
,	,	O
active	JJ	O
trachoma	NN	O
and	CC	O
ocular	JJ	O
C.	NNP	O
trachomatis	NN	O
infection	NN	O
in	IN	O
randomly	RB	O
selected	VBN	O
children	NNS	A
aged	VBN	O
0-5	CD	A
years	NNS	A
from	IN	O
48	CD	O
Gambian	JJ	O
and	CC	O
36	CD	O
Tanzanian	JJ	O
communities	NNS	O
.	.	O

Both	DT	O
children	NNS	O
's	POS	O
eyes	NNS	O
were	VBD	O
examined	VBN	O
according	VBG	O
to	TO	O
the	DT	O
World	NNP	O
Health	NNP	O
Organization	NNP	O
(	(	O
WHO	NNP	O
)	)	O
simplified	VBD	O
grading	VBG	O
system	NN	O
,	,	O
and	CC	O
an	DT	O
ocular	JJ	O
swab	NN	O
was	VBD	O
taken	VBN	O
from	IN	O
each	DT	O
child	NN	O
's	POS	O
right	JJ	O
eye	NN	O
and	CC	O
processed	VBN	O
by	IN	O
Amplicor	NNP	O
polymerase	NN	O
chain	NN	O
reaction	NN	O
to	TO	O
test	VB	O
for	IN	O
the	DT	O
presence	NN	O
of	IN	O
C.	NNP	O
trachomatis	NN	O
DNA	NNP	O
.	.	O

Prevalence	NN	O
of	IN	O
active	JJ	O
trachoma	NN	O
was	VBD	O
6.7	CD	O
%	NN	O
(	(	O
335/5033	CD	O
)	)	O
in	IN	O
The	DT	O
Gambia	NNP	O
and	CC	O
32.3	CD	O
%	NN	O
(	(	O
1008/3122	CD	O
)	)	O
in	IN	O
Tanzania	NNP	O
.	.	O

The	DT	O
countries	NNS	O
'	POS	O
corresponding	VBG	O
Amplicor	NNP	O
positive	JJ	O
prevalences	NNS	O
were	VBD	O
0.8	CD	O
%	NN	O
and	CC	O
21.9	CD	O
%	NN	O
.	.	O

After	IN	O
adjustment	NN	O
,	,	O
risk	NN	O
factors	NNS	O
for	IN	O
follicular	JJ	O
trachoma	NN	O
(	(	O
TF	NNP	O
)	)	O
in	IN	O
both	DT	O
countries	NNS	O
were	VBD	O
ocular	JJ	O
or	CC	O
nasal	JJ	O
discharge	NN	O
,	,	O
a	DT	O
low	JJ	O
level	NN	O
of	IN	O
household	NN	O
head	NN	O
education	NN	O
,	,	O
and	CC	O
being	VBG	O
aged	VBN	O
?	.	O
1	CD	O
year	NN	O
.	.	O

Additional	NNP	O
risk	NN	O
factors	NNS	O
in	IN	O
Tanzania	NNP	O
were	VBD	O
flies	NNS	O
on	IN	O
the	DT	O
child	NN	O
's	POS	O
face	NN	O
,	,	O
being	VBG	O
Amplicor	NNP	O
positive	JJ	O
,	,	O
and	CC	O
crowding	NN	O
(	(	O
the	DT	O
number	NN	O
of	IN	O
children	NNS	O
per	IN	O
household	NN	O
)	)	O
.	.	O

The	DT	O
risk	NN	O
factors	NNS	O
for	IN	O
being	VBG	O
Amplicor	NNP	O
positive	JJ	O
in	IN	O
Tanzania	NNP	O
were	VBD	O
similar	JJ	O
to	TO	O
those	DT	O
for	IN	O
TF	NNP	O
,	,	O
with	IN	O
the	DT	O
exclusion	NN	O
of	IN	O
flies	NNS	O
and	CC	O
crowding	VBG	O
.	.	O

In	IN	O
The	DT	O
Gambia	NNP	O
,	,	O
only	RB	O
ocular	JJ	O
discharge	NN	O
was	VBD	O
associated	VBN	O
with	IN	O
being	VBG	O
Amplicor	NNP	O
positive	JJ	O
.	.	O

CONCLUSIONS/SIGNIFICANCE	NNP	O
These	DT	O
results	NNS	O
indicate	VBP	O
that	IN	O
although	IN	O
the	DT	O
prevalence	NN	O
of	IN	O
active	JJ	O
trachoma	NN	O
and	CC	O
Amplicor	NNP	O
positives	NNS	O
were	VBD	O
very	RB	O
different	JJ	O
between	IN	O
the	DT	O
two	CD	O
countries	NNS	O
,	,	O
the	DT	O
risk	NN	O
factors	NNS	O
for	IN	O
active	JJ	O
trachoma	NN	O
were	VBD	O
similar	JJ	O
but	CC	O
those	DT	O
for	IN	O
being	VBG	O
Amplicor	NNP	O
positive	JJ	O
were	VBD	O
different	JJ	O
.	.	O

The	DT	O
lack	NN	O
of	IN	O
an	DT	O
association	NN	O
between	IN	O
being	VBG	O
Amplicor	NNP	O
positive	JJ	O
and	CC	O
TF	NNP	O
in	IN	O
The	DT	O
Gambia	NNP	O
highlights	VBZ	O
the	DT	O
poor	JJ	O
correlation	NN	O
between	IN	O
the	DT	O
presence	NN	O
of	IN	O
trachoma	JJ	O
clinical	JJ	O
signs	NNS	O
and	CC	O
evidence	NN	O
of	IN	O
C.	NNP	O
trachomatis	NN	O
infection	NN	O
in	IN	O
this	DT	O
setting	NN	O
.	.	O

Only	RB	O
ocular	JJ	O
discharge	NN	O
was	VBD	O
associated	VBN	O
with	IN	O
evidence	NN	O
of	IN	O
C.	NNP	O
trachomatis	NN	O
DNA	NN	O
in	IN	O
The	DT	O
Gambia	NNP	O
,	,	O
suggesting	VBG	O
that	IN	O
at	IN	O
this	DT	O
low	JJ	O
endemicity	NN	O
,	,	O
this	DT	O
may	MD	O
be	VB	O
the	DT	O
most	RBS	O
important	JJ	O
risk	NN	O
factor	NN	O
.	.	O

TRIAL	NNP	O
REGISTRATION	NNP	O
ClinicalTrials.gov	NNP	O
NCT00792922	NNP	O
.	.	O

[	RB	O
Clinical	JJ	O
trial	NN	O
of	IN	O
2	CD	O
tobacco	NN	O
use	NN	O
cessation	NN	O
interventions	NNS	O
in	IN	O
primary	JJ	O
care	NN	O
]	NNP	O
.	.	O

OBJECTIVE	NNP	O
To	TO	O
study	VB	O
the	DT	O
efficacy	NN	O
of	IN	O
two	CD	O
types	NNS	O
of	IN	O
intervention	NN	O
to	TO	O
stop	VB	O
tobacco	NN	O
dependency	NN	O
.	.	O

DESIGN	NNP	O
Randomised	VBD	O
clinical	JJ	O
trial	NN	O
.	.	O

SETTING	NN	O
Primary	NNP	O
care	NN	O
centre	NN	O
.	.	O

PATIENTS	NNP	O
AND	CC	O
OTHER	NNP	O
PARTICIPANTS	NNP	O
Smokers	NNP	C
recruited	VBD	O
from	IN	O
among	IN	O
the	DT	O
health	NN	O
centre	NN	O
users	NNS	O
through	IN	O
the	DT	O
preventive	JJ	O
activities	NNS	O
and	CC	O
health	NN	O
promotion	NN	O
programme	NN	O
.	.	O

INTERVENTIONS	NNP	O
INDEPENDENT	NNP	O
VARIABLE	NNP	O
type	NN	O
of	IN	O
intervention	NN	O
.	.	O

General	JJ	O
variables	NNS	O
:	:	O
age	NN	O
,	,	O
sex	NN	O
,	,	O
marital	JJ	O
status	NN	O
,	,	O
educational	JJ	O
level	NN	O
,	,	O
work	NN	O
situation	NN	O
,	,	O
cohabitation	NN	O
with	IN	O
children	NNS	O
,	,	O
smokers	NNS	O
at	IN	O
home	NN	O
,	,	O
number	NN	O
of	IN	O
years	NNS	O
smoking	VBG	O
,	,	O
type	NN	O
of	IN	O
tobacco	NN	O
.	.	O

There	EX	O
were	VBD	O
two	CD	O
types	NNS	O
of	IN	O
intervention	NN	O
:	:	O
a	DT	O
)	)	O
Minimal	NNP	O
Intervention	NNP	O
(	(	O
MI	NNP	O
)	)	O
.	.	O

b	NN	O
)	)	O
Advanced	NNP	O
Intervention	NNP	O
(	(	O
AI	NNP	O
)	)	O
.	.	O

54	CD	SS
patients	NNS	O
were	VBD	O
included	VBN	O
,	,	O
with	IN	O
6	CD	SS
losses	NNS	O
.	.	O

21	CD	SS
were	VBD	O
assigned	VBN	O
at	IN	O
random	NN	O
to	TO	O
the	DT	O
MI	NNP	O
group	NN	O
and	CC	O
27	CD	SS
to	TO	O
the	DT	O
AI	NNP	O
group	NN	O
.	.	O

Progress	NNP	O
was	VBD	O
measured	VBN	O
at	IN	O
15	CD	O
days	NNS	O
,	,	O
1	CD	O
month	NN	O
,	,	O
3	CD	O
months	NNS	O
,	,	O
6	CD	O
months	NNS	O
and	CC	O
a	DT	O
year	NN	O
.	.	O

RESULTS	NNP	O
In	IN	O
the	DT	O
MI	NNP	O
,	,	O
23.8	CD	O
%	NN	O
were	VBD	O
abstinent	JJ	O
at	IN	O
15	CD	O
days	NNS	O
;	:	O
the	DT	O
same	JJ	O
percentage	NN	O
at	IN	O
one	CD	O
month	NN	O
and	CC	O
3	CD	O
months	NNS	O
;	:	O
19	CD	O
%	NN	O
at	IN	O
6	CD	O
months	NNS	O
;	:	O
and	CC	O
14.3	CD	O
%	NN	O
remained	VBD	O
abstinent	JJ	O
after	IN	O
a	DT	O
year	NN	O
.	.	O

In	IN	O
the	DT	O
AI	NNP	O
,	,	O
51.9	CD	O
%	NN	O
were	VBD	O
abstinent	JJ	O
at	IN	O
15	CD	O
days	NNS	O
;	:	O
48.1	CD	O
%	NN	O
at	IN	O
both	DT	O
one	CD	O
and	CC	O
3	CD	O
months	NNS	O
;	:	O
25.9	CD	O
%	NN	O
at	IN	O
6	CD	O
months	NNS	O
;	:	O
and	CC	O
22.2	CD	O
%	NN	O
were	VBD	O
still	RB	O
not	RB	O
smoking	VBG	O
after	IN	O
a	DT	O
year	NN	O
.	.	O

No	DT	O
significant	JJ	O
differences	NNS	O
between	IN	O
the	DT	O
two	CD	O
interventions	NNS	O
were	VBD	O
found	VBN	O
in	IN	O
any	DT	O
of	IN	O
the	DT	O
observations	NNS	O
.	.	O

CONCLUSIONS	NNP	O
These	DT	O
data	NNS	O
do	VBP	O
not	RB	O
show	VB	O
that	IN	O
one	CD	O
intervention	NN	O
is	VBZ	O
better	RBR	O
than	IN	O
the	DT	O
other	JJ	O
.	.	O

With	IN	O
the	DT	O
passage	NN	O
of	IN	O
time	NN	O
the	DT	O
effect	NN	O
of	IN	O
the	DT	O
intervention	NN	O
decreased	VBN	O
in	IN	O
both	DT	O
groups	NNS	O
.	.	O

Obesity	NN	O
and	CC	O
mortality	NN	O
in	IN	O
men	NNS	O
with	IN	O
locally	RB	C
advanced	JJ	C
prostate	NN	C
cancer	NN	C
:	:	C
analysis	NN	O
of	IN	O
RTOG	NNP	O
85-31	JJ	O
.	.	O

BACKGROUND	NNP	O
Greater	NNP	O
body	NN	O
mass	NN	O
index	NN	O
(	(	O
BMI	NNP	O
)	)	O
is	VBZ	O
associated	VBN	O
with	IN	O
shorter	JJR	O
time	NN	O
to	TO	O
prostate-specific	JJ	O
antigen	NN	O
(	(	O
PSA	NNP	O
)	)	O
failure	NN	O
following	VBG	O
radical	JJ	O
prostatectomy	NN	O
and	CC	O
radiation	NN	O
therapy	NN	O
(	(	O
RT	NNP	O
)	)	O
.	.	O

Whether	NNP	O
BMI	NNP	O
is	VBZ	O
associated	VBN	O
with	IN	O
prostate	JJ	O
cancer-specific	JJ	O
mortality	NN	O
(	(	O
PCSM	NNP	O
)	)	O
was	VBD	O
investigated	VBN	O
in	IN	O
a	DT	O
large	JJ	O
randomized	JJ	O
trial	NN	O
of	IN	O
men	NNS	A
treated	VBN	O
with	IN	O
RT	NNP	O
and	CC	O
androgen	JJ	C
deprivation	NN	C
therapy	NN	C
(	(	C
ADT	NNP	C
)	)	C
for	IN	C
locally	RB	O
advanced	JJ	O
prostate	NN	O
cancer	NN	O
.	.	O

METHODS	NNP	O
Between	NNP	O
1987	CD	O
and	CC	O
1992	CD	O
,	,	O
945	CD	O
eligible	JJ	O
men	NNS	O
with	IN	O
locally	RB	O
advanced	JJ	O
prostate	NN	O
cancer	NN	O
were	VBD	O
enrolled	VBN	O
in	IN	O
a	DT	O
phase	NN	O
3	CD	O
trial	NN	O
(	(	O
RTOG	NNP	O
85-31	CD	O
)	)	O
and	CC	O
randomized	VBN	O
to	TO	O
RT	NNP	O
and	CC	O
immediate	JJ	O
goserelin	NN	O
or	CC	O
RT	NNP	O
alone	RB	O
followed	VBD	O
by	IN	O
goserelin	NN	O
at	IN	O
recurrence	NN	O
.	.	O

Height	NNP	O
and	CC	O
weight	VBN	O
data	NNS	O
were	VBD	O
available	JJ	O
at	IN	O
baseline	NN	O
for	IN	O
788	CD	O
(	(	O
83	CD	O
%	NN	O
)	)	O
subjects	VBZ	O
.	.	O

Cox	NNP	O
regression	NN	O
analyses	NNS	O
were	VBD	O
performed	VBN	O
to	TO	O
evaluate	VB	O
the	DT	O
relations	NNS	O
between	IN	O
BMI	NNP	O
and	CC	O
all-cause	JJ	O
mortality	NN	O
,	,	O
PCSM	NNP	O
,	,	O
and	CC	O
nonprostate	JJ	O
cancer	NN	O
mortality	NN	O
.	.	O

Covariates	NNS	O
included	VBD	O
age	NN	O
,	,	O
race	NN	O
,	,	O
treatment	NN	O
arm	NN	O
,	,	O
history	NN	O
of	IN	O
prostatectomy	NN	O
,	,	O
nodal	JJ	O
involvement	NN	O
,	,	O
Gleason	NNP	O
score	NN	O
,	,	O
clinical	JJ	O
stage	NN	O
,	,	O
and	CC	O
BMI	NNP	O
.	.	O

RESULTS	VB	O
The	DT	O
5-year	JJ	O
PCSM	NNP	O
rate	NN	O
for	IN	O
men	NNS	O
with	IN	O
BMI	NNP	O
<	NNP	O
25	CD	O
kg/m	NN	O
(	(	O
2	CD	O
)	)	O
was	VBD	O
6.5	CD	O
%	NN	O
,	,	O
compared	VBN	O
with	IN	O
13.1	CD	O
%	NN	O
and	CC	O
12.2	CD	O
%	NN	O
in	IN	O
men	NNS	O
with	IN	O
BMI	NNP	O
>	NNP	O
or	CC	O
=25	VB	O
to	TO	O
<	VB	O
30	CD	O
and	CC	O
BMI	NNP	O
>	NNP	O
or	CC	O
=30	NNP	O
,	,	O
respectively	RB	O
(	(	O
Gray	NNP	O
's	POS	O
P	NNP	O
=	NNP	O
.005	NNP	O
)	)	O
.	.	O

In	IN	O
multivariate	NN	O
analyses	NNS	O
,	,	O
greater	JJR	O
BMI	NNP	O
was	VBD	O
significantly	RB	O
associated	VBN	O
with	IN	O
higher	JJR	O
PCSM	NNP	O
(	(	O
for	IN	O
BMI	NNP	O
>	NNP	O
or	CC	O
=25	VB	O
to	TO	O
<	VB	O
30	CD	O
,	,	O
hazard	RB	O
ratio	NN	O
[	NNP	O
HR	NNP	O
]	NNP	O
1.52	CD	O
,	,	O
95	CD	O
%	NN	O
confidence	NN	O
interval	NN	O
[	NNP	O
CI	NNP	O
]	NNP	O
,	,	O
1.02-2.27	JJ	O
,	,	O
P	NNP	O
=	NNP	O
.04	NNP	O
;	:	O
for	IN	O
BMI	NNP	O
>	NNP	O
or	CC	O
=30	NNP	O
,	,	O
HR	NNP	O
1.64	CD	O
,	,	O
95	CD	O
%	NN	O
CI	NNP	O
,	,	O
1.01-2.66	JJ	O
,	,	O
P	NNP	O
=	NNP	O
.04	NNP	O
)	)	O
.	.	O

BMI	NNP	O
was	VBD	O
not	RB	O
associated	VBN	O
with	IN	O
nonprostate	JJ	O
cancer	NN	O
or	CC	O
all-cause	JJ	O
mortality	NN	O
.	.	O

CONCLUSIONS	NNP	O
Greater	NNP	O
baseline	NN	O
BMI	NNP	O
is	VBZ	O
independently	RB	O
associated	VBN	O
with	IN	O
higher	JJR	O
PCSM	NN	O
in	IN	O
men	NNS	O
with	IN	O
locally	RB	O
advanced	JJ	O
prostate	NN	O
cancer	NN	O
.	.	O

Further	JJ	O
studies	NNS	O
are	VBP	O
warranted	VBN	O
to	TO	O
evaluate	VB	O
the	DT	O
mechanism	NN	O
(	(	O
s	NN	O
)	)	O
for	IN	O
increased	VBN	O
cancer-specific	JJ	O
mortality	NN	O
and	CC	O
to	TO	O
assess	VB	O
whether	IN	O
weight	JJ	O
loss	NN	O
after	IN	O
prostate	JJ	O
cancer	NN	O
diagnosis	NN	O
alters	NNS	O
disease	VBP	O
course	NN	O
.	.	O

Parenteral	JJ	O
nutrition	NN	O
and	CC	O
protein	NN	O
sparing	NN	O
after	IN	O
surgery	NN	O
:	:	O
do	VBP	O
we	PRP	O
need	VB	O
glucose	RB	O
?	.	O
Although	IN	O
capable	JJ	O
of	IN	O
inducing	VBG	O
an	DT	O
anabolic	JJ	O
state	NN	O
after	IN	O
surgery	NN	O
,	,	O
parenteral	JJ	O
nutrition	NN	O
,	,	O
including	VBG	O
glucose	NN	O
,	,	O
leads	VBZ	O
to	TO	O
hyperglycemia	VB	O
.	.	O

Even	RB	O
moderate	JJ	O
increases	NNS	O
in	IN	O
blood	NN	O
glucose	NN	O
are	VBP	O
associated	VBN	O
with	IN	O
poor	JJ	O
surgical	JJ	O
outcome	NN	O
.	.	O

We	PRP	O
examined	VBD	O
the	DT	O
hypothesis	NN	O
that	WDT	O
amino	NN	O
acids	NNS	O
,	,	O
in	IN	O
the	DT	O
absence	NN	O
of	IN	O
glucose	JJ	O
supply	NN	O
,	,	O
spare	JJ	O
protein	NN	O
while	IN	O
preventing	VBG	O
hyperglycemia	NN	O
.	.	O

In	IN	O
this	DT	O
prospective	JJ	O
study	NN	O
,	,	O
14	CD	SS
patients	NNS	O
with	IN	O
colonic	JJ	C
cancer	NN	C
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
undergo	VB	O
a	DT	O
6-hour	JJ	O
stable	JJ	O
isotope	NN	O
infusion	NN	O
study	NN	O
(	(	O
3	CD	O
hours	NNS	O
of	IN	O
fasting	VBG	O
followed	VBN	O
by	IN	O
3-hour	JJ	O
infusions	NNS	O
of	IN	O
amino	NN	O
acids	NNS	O
,	,	O
Travasol	NNP	O
[	NNP	O
Baxter	NNP	O
,	,	O
Montreal	NNP	O
,	,	O
Canada	NNP	O
]	VBD	O
10	CD	O
%	NN	O
at	IN	O
0.02	CD	O
mL.kg	NN	O
(	(	O
-1	NNP	O
)	)	O
.min	NNP	O
(	(	O
-1	NNP	O
)	)	O
,	,	O
with	IN	O
or	CC	O
without	IN	O
glucose	JJ	O
at	IN	O
4	CD	O
mg.kg	NN	O
(	(	O
-1	NNP	O
)	)	O
.min	NNP	O
(	(	O
-1	NNP	O
)	)	O
)	)	O
on	IN	O
the	DT	O
second	JJ	O
day	NN	O
after	IN	O
colorectal	JJ	O
surgery	NN	O
.	.	O

Protein	NNP	O
breakdown	NN	O
,	,	O
protein	JJ	O
oxidation	NN	O
,	,	O
protein	JJ	O
balance	NN	O
,	,	O
and	CC	O
glucose	JJ	O
production	NN	O
were	VBD	O
assessed	VBN	O
by	IN	O
stable	JJ	O
isotope	NN	O
tracer	NN	O
kinetics	NNS	O
using	VBG	O
l-	JJ	O
[	JJ	O
1-	JJ	O
(	(	O
13	CD	O
)	)	O
C	NNP	O
]	NNP	O
leucine	NN	O
and	CC	O
[	JJ	O
6,6-	JJ	O
(	(	O
2	CD	O
)	)	O
H2	NNP	O
]	NNP	O
glucose	NN	O
.	.	O

Circulating	VBG	O
concentrations	NNS	O
of	IN	O
glucose	NN	O
,	,	O
cortisol	NN	O
,	,	O
insulin	NN	O
,	,	O
and	CC	O
glucagon	NN	O
were	VBD	O
determined	VBN	O
.	.	O

The	DT	O
administration	NN	O
of	IN	O
amino	JJ	O
acids	NNS	O
increased	VBD	O
protein	JJ	O
balance	NN	O
from	IN	O
-16+/-4	JJ	O
micromol.kg	NN	O
(	(	O
-1	NNP	O
)	)	O
.h	NNP	O
(	(	O
-1	NNP	O
)	)	O
in	IN	O
the	DT	O
fasted	JJ	O
state	NN	O
to	TO	O
16+/-3	JJ	O
micromol.kg	NN	O
(	(	O
-1	NNP	O
)	)	O
.h	NNP	O
(	(	O
-1	NNP	O
)	)	O
.	.	O

Combined	VBN	O
infusion	NN	O
of	IN	O
amino	JJ	O
acids	NNS	O
and	CC	O
glucose	VB	O
increased	JJ	O
protein	NN	O
balance	NN	O
from	IN	O
-17+/-7	JJ	O
to	TO	O
7+/-5	JJ	O
micromol.kg	NN	O
(	(	O
-1	NNP	O
)	)	O
.h	NNP	O
(	(	O
-1	NNP	O
)	)	O
.	.	O

The	DT	O
increase	NN	O
in	IN	O
protein	JJ	O
balance	NN	O
during	IN	O
nutrition	NN	O
was	VBD	O
comparable	JJ	O
in	IN	O
the	DT	O
2	CD	O
groups	NNS	O
(	(	O
P=.07	NNP	O
)	)	O
.	.	O

Combined	VBN	O
administration	NN	O
of	IN	O
amino	JJ	O
acids	NNS	O
and	CC	O
glucose	VB	O
decreased	VBN	O
endogenous	JJ	O
glucose	JJ	O
production	NN	O
(	(	O
P=.001	NNP	O
)	)	O
and	CC	O
stimulated	VBN	O
insulin	NN	O
secretion	NN	O
(	(	O
P=.001	NNP	O
)	)	O
to	TO	O
a	DT	O
greater	JJR	O
extent	NN	O
than	IN	O
the	DT	O
administration	NN	O
of	IN	O
amino	JJ	O
acids	NNS	O
alone	RB	O
.	.	O

Hyperglycemia	NNP	O
(	(	O
blood	NN	O
glucose	NN	O
,	,	O
10.1+/-1.9	JJ	O
micromol/L	NN	O
)	)	O
occurred	VBD	O
only	RB	O
in	IN	O
the	DT	O
presence	NN	O
of	IN	O
glucose	JJ	O
infusion	NN	O
.	.	O

In	IN	O
summary	JJ	O
,	,	O
excluding	VBG	O
glucose	NN	O
from	IN	O
a	DT	O
short-term	JJ	O
feeding	NN	O
protocol	NN	O
does	VBZ	O
not	RB	O
diminish	VB	O
the	DT	O
protein-sparing	JJ	O
effect	NN	O
of	IN	O
amino	NN	O
acids	NNS	O
and	CC	O
avoids	NNS	O
hyperglycemia	NN	O
.	.	O

Severe	NNP	O
enteropathy	NN	O
among	IN	O
patients	NNS	C
with	IN	C
stage	NN	C
II/III	NNP	C
colon	NN	C
cancer	NN	C
treated	VBN	O
on	IN	O
a	DT	O
randomized	JJ	O
trial	NN	O
of	IN	O
bolus	JJ	O
5-fluorouracil/leucovorin	JJ	O
plus	CC	O
or	CC	O
minus	CC	O
oxaliplatin	NN	O
:	:	O
a	DT	O
prospective	JJ	O
analysis	NN	O
.	.	O

BACKGROUND	NNP	O
Cases	NNP	O
of	IN	O
severe	JJ	O
gastrointestinal	JJ	O
toxicity	NN	O
were	VBD	O
monitored	VBN	O
prospectively	RB	O
during	IN	O
NSABP	NNP	O
C-07	NNP	O
,	,	O
a	DT	O
randomized	JJ	O
clinical	JJ	O
trial	NN	O
of	IN	O
adjuvant	JJ	O
therapy	NN	O
for	IN	O
patients	NNS	O
with	IN	O
stage	NN	O
II/III	NNP	O
colon	NN	O
cancer	NN	O
.	.	O

METHODS	NNP	O
Patients	NNPS	O
were	VBD	O
treated	VBN	O
with	IN	O
weekly	JJ	O
bolus	NN	O
5-fluorouracil	JJ	O
(	(	O
5-FU	JJ	O
)	)	O
and	CC	O
leucovorin	$	O
(	(	O
FL	NNP	O
;	:	O
Roswell	NNP	O
Park	NNP	O
Regimen	NNP	O
)	)	O
or	CC	O
the	DT	O
same	JJ	O
regimen	NNS	O
plus	CC	O
oxaliplatin	NN	O
(	(	O
FLOX	NNP	O
)	)	O
.	.	O

RESULTS	NNP	O
Of	IN	O
1857	CD	O
patients	NNS	O
,	,	O
79	CD	O
(	(	O
4.3	CD	O
%	NN	O
)	)	O
developed	VBD	O
a	DT	O
syndrome	NN	O
of	IN	O
bowel	NN	O
wall	NN	O
injury	NN	O
(	(	O
BWI	NNP	O
,	,	O
small	JJ	O
or	CC	O
large	JJ	O
)	)	O
characterized	VBN	O
by	IN	O
hospitalization	NN	O
for	IN	O
the	DT	O
management	NN	O
of	IN	O
severe	JJ	O
diarrhea	NN	O
or	CC	O
dehydration	NN	O
and	CC	O
radiographic	JJ	O
or	CC	O
endoscopic	JJ	O
evidence	NN	O
of	IN	O
bowel	NN	O
wall	NN	O
thickening	NN	O
or	CC	O
ulceration	NN	O
.	.	O

Fifty-one	CD	O
(	(	O
64.6	CD	O
%	NN	O
)	)	O
of	IN	O
these	DT	O
adverse	JJ	O
events	NNS	O
occurred	VBD	O
in	IN	O
patients	NNS	O
treated	VBN	O
with	IN	O
FLOX	NNP	O
and	CC	O
28	CD	O
(	(	O
35.4	CD	O
%	NN	O
)	)	O
in	IN	O
those	DT	O
treated	VBN	O
with	IN	O
FL	NNP	O
(	(	O
P	NNP	O
<	NNP	O
.01	NNP	O
)	)	O
.	.	O

Enteric	JJ	O
sepsis	NN	O
(	(	O
ES	NNP	O
)	)	O
,	,	O
characterized	VBN	O
by	IN	O
grade	NN	O
3	CD	O
or	CC	O
greater	JJR	O
diarrhea	NN	O
and	CC	O
grade	VBD	O
4	CD	O
neutropenia	NN	O
with	IN	O
or	CC	O
without	IN	O
proven	JJ	O
bacteremia	NN	O
occurred	VBD	O
in	IN	O
22	CD	O
patients	NNS	O
treated	VBN	O
with	IN	O
FLOX	NNP	O
,	,	O
versus	NN	O
8	CD	O
in	IN	O
those	DT	O
treated	VBN	O
with	IN	O
FL	NNP	O
(	(	O
P	NNP	O
=	NNP	O
.01	NNP	O
)	)	O
.	.	O

Patients	NNPS	O
>	JJ	O
60	CD	O
years	NNS	O
were	VBD	O
at	IN	O
higher	JJR	O
risk	NN	O
for	IN	O
BWI	NNP	O
after	IN	O
treatment	NN	O
with	IN	O
FLOX	NNP	O
(	(	O
6.7	CD	O
%	NN	O
)	)	O
versus	NN	O
treatment	NN	O
with	IN	O
FL	NNP	O
(	(	O
2.9	CD	O
%	NN	O
,	,	O
P	NNP	O
<	NNP	O
.01	NNP	O
)	)	O
.	.	O

Female	JJ	O
patients	NNS	O
had	VBD	O
a	DT	O
higher	JJR	O
incidence	NN	O
of	IN	O
BWI	NNP	O
with	IN	O
FLOX	NNP	O
(	(	O
9.1	CD	O
%	NN	O
)	)	O
than	IN	O
with	IN	O
FL	NNP	O
(	(	O
3.9	CD	O
%	NN	O
,	,	O
P	NNP	O
<	NNP	O
.01	NNP	O
)	)	O
.	.	O

Severe	JJ	O
gastrointestinal	JJ	O
toxicity	NN	O
usually	RB	O
occurred	VBD	O
during	IN	O
the	DT	O
third	JJ	O
or	CC	O
fourth	JJ	O
week	NN	O
on	IN	O
the	DT	O
first	JJ	O
cycle	NN	O
of	IN	O
therapy	NN	O
,	,	O
required	VBN	O
hospitalization	NN	O
,	,	O
and	CC	O
was	VBD	O
managed	VBN	O
with	IN	O
fluids	NNS	O
,	,	O
antidiarrheals	NNS	O
,	,	O
and	CC	O
antibiotics	NNS	O
.	.	O

There	EX	O
were	VBD	O
5	CD	O
deaths	NNS	O
(	(	O
0.3	CD	O
%	NN	O
)	)	O
due	JJ	O
to	TO	O
enteropathy	VB	O
,	,	O
2	CD	O
related	VBN	O
to	TO	O
ES	NNP	O
and	CC	O
3	CD	O
related	VBN	O
to	TO	O
both	DT	O
BWI	NNP	O
and	CC	O
ES	NNP	O
.	.	O

Seventy-one	CD	O
percent	NN	O
of	IN	O
patients	NNS	O
resumed	VBN	O
treatment	NN	O
with	IN	O
FL	NNP	O
after	IN	O
recovery	NN	O
.	.	O

CONCLUSIONS	NNP	O
Patients	NNPS	O
treated	VBD	O
with	IN	O
adjuvant	JJ	O
FL	NNP	O
should	MD	O
be	VB	O
closely	RB	O
monitored	VBN	O
for	IN	O
diarrhea	NN	O
and	CC	O
aggressively	RB	O
managed	VBN	O
,	,	O
especially	RB	O
if	IN	O
oxaliplatin	VBN	O
has	VBZ	O
been	VBN	O
added	VBN	O
to	TO	O
the	DT	O
regimen	NNS	O
.	.	O

Society	NN	O
.	.	O

Pre-operative	JJ	O
radiochemotherapy	NN	O
for	IN	O
rectal	JJ	O
cancer	NN	O
.	.	O

A	DT	O
prospective	JJ	O
randomized	VBN	O
trial	NN	O
comparing	VBG	O
pre-operative	JJ	O
vs.	FW	O
postoperative	JJ	O
radiochemotherapy	NN	O
in	IN	O
rectal	JJ	O
cancer	NN	O
patients	NNS	O
.	.	O

PURPOSE	VB	O
The	DT	O
aim	NN	O
of	IN	O
the	DT	O
study	NN	O
was	VBD	O
to	TO	O
find	VB	O
out	RP	O
whether	IN	O
pre-operative	JJ	O
radiochemotherapy	NN	O
had	VBD	O
any	DT	O
survival	JJ	O
advantage	NN	O
over	IN	O
postoperative	JJ	O
radiochemotherapy	NN	O
for	IN	O
rectal	JJ	O
carcinoma	NN	O
patients	NNS	O
without	IN	O
distant	JJ	O
metastasis	NN	O
or	CC	O
peritoneal	JJ	O
carcinomatosis	NN	O
.	.	O

MATERIAL	NNP	O
AND	CC	O
METHODS	NNP	O
Between	NNP	O
January	NNP	O
1998	CD	O
and	CC	O
December	NNP	O
2003	CD	O
,	,	O
51	CD	O
rectal	JJ	O
carcinoma	NN	O
patients	NNS	O
without	IN	O
distant	JJ	O
metastasis	NN	O
or	CC	O
peritoneal	JJ	O
carcinomatosis	NN	O
were	VBD	O
randomly	RB	O
divided	VBN	O
into	IN	O
pre-operative	JJ	O
(	(	O
PRE	NNP	O
)	)	O
and	CC	O
postoperative	JJ	O
(	(	O
POST	NNP	O
)	)	O
radiochemotherapy	NN	O
groups	NNS	O
.	.	O

Twenty-six	CD	O
were	VBD	O
assigned	VBN	O
to	TO	O
the	DT	O
PRE	NNP	O
group	NN	O
and	CC	O
were	VBD	O
operated	VBN	O
on	IN	O
5	CD	O
to	TO	O
8	CD	O
weeks	NNS	O
after	IN	O
the	DT	O
completion	NN	O
of	IN	O
radiotherapy	NN	O
.	.	O

The	DT	O
other	JJ	O
25	CD	O
patients	NNS	O
were	VBD	O
operated	VBN	O
on	IN	O
immediately	RB	O
and	CC	O
received	VBD	O
radiotherapy	NN	O
postoperatively	RB	O
2	CD	O
to	TO	O
4	CD	O
weeks	NNS	O
after	IN	O
surgery	NN	O
.	.	O

The	DT	O
patients	NNS	O
were	VBD	O
followed	VBN	O
up	RP	O
for	IN	O
between	IN	O
4	CD	O
to	TO	O
51	CD	O
months	NNS	O
.	.	O

RESULTS	NNP	O
In	IN	O
the	DT	O
PRE	NNP	O
group	NN	O
the	DT	O
rates	NNS	O
of	IN	O
disease-free	JJ	O
survival	NN	O
were	VBD	O
92	CD	O
%	NN	O
,	,	O
70	CD	O
%	NN	O
,	,	O
56	CD	O
%	NN	O
and	CC	O
56	CD	O
%	NN	O
at	IN	O
the	DT	O
end	NN	O
of	IN	O
the	DT	O
1st	CD	O
,	,	O
2nd	CD	O
,	,	O
3rd	CD	O
and	CC	O
4th	CD	O
years	NNS	O
,	,	O
respectively	RB	O
.	.	O

In	IN	O
the	DT	O
POST	NNP	O
group	NN	O
those	DT	O
percentages	NNS	O
were	VBD	O
83	CD	O
%	NN	O
,	,	O
68	CD	O
%	NN	O
,	,	O
51	CD	O
%	NN	O
and	CC	O
51	CD	O
%	NN	O
at	IN	O
the	DT	O
1st	CD	O
,	,	O
2nd	CD	O
,	,	O
3rd	CD	O
and	CC	O
4th	CD	O
years	NNS	O
,	,	O
respectively	RB	O
(	(	O
p	JJ	O
=	NNP	O
0.707	CD	O
)	)	O
.	.	O

One-year	JJ	O
and	CC	O
4-year	JJ	O
overall	JJ	O
survival	NN	O
rates	NNS	O
in	IN	O
the	DT	O
PRE	NNP	O
group	NN	O
were	VBD	O
100	CD	O
%	NN	O
and	CC	O
86	CD	O
%	NN	O
respectively	RB	O
and	CC	O
100	CD	O
%	NN	O
and	CC	O
60	CD	O
%	NN	O
in	IN	O
the	DT	O
POST	NNP	O
group	NN	O
(	(	O
p	JJ	O
=	NNP	O
0.520	CD	O
)	)	O
.	.	O

CONCLUSION	NNP	O
No	NNP	O
statistical	JJ	O
difference	NN	O
was	VBD	O
found	VBN	O
between	IN	O
the	DT	O
survival	JJ	O
rates	NNS	O
of	IN	O
the	DT	O
rectal	JJ	O
carcinoma	NN	O
patients	NNS	O
receiving	VBG	O
radiotherapy	NN	O
either	CC	O
pre-operatively	RB	O
or	CC	O
postoperatively	RB	O
.	.	O

However	RB	O
,	,	O
the	DT	O
disease-free	JJ	O
survival	NN	O
rates	NNS	O
of	IN	O
the	DT	O
PRE	NNP	O
group	NN	O
were	VBD	O
higher	JJR	O
than	IN	O
the	DT	O
POST	NNP	O
group	NN	O
's	POS	O
during	IN	O
each	DT	O
year	NN	O
and	CC	O
overall	JJ	O
survival	NN	O
rates	NNS	O
were	VBD	O
higher	JJR	O
after	IN	O
the	DT	O
third	JJ	O
and	CC	O
fourth	JJ	O
years	NNS	O
.	.	O

We	PRP	O
conclude	VBP	O
that	IN	O
pre-operative	JJ	O
radiotherapy	NN	O
is	VBZ	O
at	IN	O
least	JJS	O
as	RB	O
effective	JJ	O
as	IN	O
postoperative	JJ	O
radiotherapy	NN	O
.	.	O

Effect	NN	O
of	IN	O
negative	JJ	O
air	NN	O
ionization	NN	O
on	IN	O
hyperactive	JJ	C
and	CC	O
autistic	JJ	C
children	NNS	A
.	.	O

Twenty-one	CD	SS
attention	NN	C
deficit	NN	C
disorder	NN	C
with	IN	O
hyperactivity	NN	C
and	CC	O
seven	CD	SS
autistic	JJ	C
children	NNS	A
were	VBD	O
randomly	RB	O
exposed	VBN	O
to	TO	O
negatively	RB	O
ionized	JJ	O
and	CC	O
ambient	JJ	O
atmospheres	NNS	O
under	IN	O
rigorously	RB	O
controlled	VBN	O
experimental	JJ	O
conditions	NNS	O
.	.	O

The	DT	O
negatively	RB	O
ionized	JJ	O
condition	NN	O
did	VBD	O
not	RB	O
significantly	RB	O
affect	JJ	O
measurements	NNS	O
of	IN	O
activity	NN	O
level	NN	O
,	,	O
impulsivity	NN	O
,	,	O
reality	NN	O
orientation	NN	O
,	,	O
destructive/constructiveness	NN	O
,	,	O
attention	NN	O
,	,	O
or	CC	O
task	NN	O
performance	NN	O
.	.	O

Significant	JJ	O
results	NNS	O
might	MD	O
be	VB	O
obtained	VBN	O
if	IN	O
subgroups	NNS	O
of	IN	O
known	JJ	O
hyperserotoninemic	JJ	C
autistic	NN	C
and	CC	O
attention	NN	C
deficit	NN	C
disorder	NN	C
children	NNS	A
were	VBD	O
exposed	VBN	O
to	TO	O
negatively	RB	O
ionized	JJ	O
conditions	NNS	O
.	.	O

Sinemet	NNP	O
CR	NNP	O
in	IN	O
Parkinson	NNP	O
's	POS	O
disease	NN	O
.	.	O

Sinemet	NNP	O
CR	NNP	O
,	,	O
a	DT	O
controlled	JJ	O
release	NN	O
carbidopa/levodopa	NN	O
preparation	NN	O
,	,	O
was	VBD	O
compared	VBN	O
to	TO	O
conventional	JJ	O
carbidopa/levodopa	NN	O
in	IN	O
a	DT	O
double	JJ	O
blind	NN	O
,	,	O
placebo-controlled	JJ	O
trial	NN	O
.	.	O

Comparable	JJ	O
clinical	JJ	O
benefits	NNS	O
and	CC	O
adverse	JJ	O
effects	NNS	O
were	VBD	O
noted	VBN	O
with	IN	O
the	DT	O
two	CD	O
medications	NNS	O
.	.	O

However	RB	O
significantly	RB	O
less	RBR	O
frequent	JJ	O
dosing	NN	O
was	VBD	O
necessary	JJ	O
with	IN	O
Sinemet	NNP	O
CR	NNP	O
.	.	O

Direct	JJ	O
renin	NN	O
inhibition	NN	O
improves	VBZ	O
parasympathetic	JJ	O
function	NN	O
in	IN	O
diabetes	NNS	C
.	.	O

AIM	VB	O
The	DT	O
renin-angiotensin-aldosterone	NN	O
system	NN	O
(	(	O
RAAS	NNP	O
)	)	O
and	CC	O
autonomic	JJ	O
nervous	JJ	O
system	NN	O
regulate	VB	O
the	DT	O
cardiovascular	JJ	O
system	NN	O
.	.	O

Blockade	NN	O
of	IN	O
the	DT	O
RAAS	NNP	O
may	MD	O
slow	VB	O
the	DT	O
progression	NN	O
of	IN	O
end-organ	JJ	O
damage	NN	O
.	.	O

Direct	JJ	O
renin	NN	O
inhibition	NN	O
offers	VBZ	O
a	DT	O
means	NN	O
for	IN	O
blocking	VBG	O
the	DT	O
RAAS	NNP	O
.	.	O

The	DT	O
objective	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
examine	VB	O
the	DT	O
effect	NN	O
of	IN	O
direct	JJ	O
renin	NN	O
inhibition	NN	O
on	IN	O
cardiovascular	JJ	O
autonomic	JJ	O
function	NN	O
.	.	O

METHODS	NNP	O
In	IN	O
this	DT	O
double-blind	NN	O
,	,	O
placebo-controlled	JJ	O
trial	NN	O
,	,	O
60	CD	SS
individuals	NNS	O
with	IN	O
diabetes	NNS	C
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
300	CD	O
mg	NN	O
of	IN	O
aliskiren	NN	O
or	CC	O
placebo	NN	O
once	RB	O
daily	JJ	O
for	IN	O
6	CD	O
weeks	NNS	O
.	.	O

The	DT	O
primary	JJ	O
end	NN	O
point	NN	O
was	VBD	O
a	DT	O
change	NN	O
in	IN	O
tests	NNS	O
of	IN	O
cardiovascular	JJ	O
autonomic	JJ	O
function	NN	O
.	.	O

Autonomic	NNP	O
function	NN	O
was	VBD	O
assessed	VBN	O
by	IN	O
power	NN	O
spectral	JJ	O
analysis	NN	O
and	CC	O
RR-variation	NNP	O
during	IN	O
deep	JJ	O
breathing	NN	O
[	JJ	O
i.e	NN	O
.	.	O

mean	VB	O
circular	JJ	O
resultant	NN	O
(	(	O
MCR	NNP	O
)	)	O
,	,	O
expiration/inspiration	NN	O
(	(	O
E/I	NNP	O
)	)	O
ratio	NN	O
]	NN	O
.	.	O

The	DT	O
MCR	NNP	O
and	CC	O
E/I	NNP	O
ratio	NN	O
assess	NN	O
parasympathetic	JJ	O
function	NN	O
.	.	O

Secondary	JJ	O
measures	NNS	O
included	VBD	O
change	NN	O
in	IN	O
biochemical	JJ	O
parameters	NNS	O
[	VBP	O
e.g	NN	O
.	.	O

plasma	JJ	O
renin	NN	O
activity	NN	O
,	,	O
leptin	NN	O
and	CC	O
interleukin-6	JJ	O
]	NN	O
.	.	O

Change	NN	O
in	IN	O
cardiovascular	JJ	O
autonomic	JJ	O
function	NN	O
and	CC	O
blood	NN	O
analytes	NNS	O
were	VBD	O
analysed	VBN	O
by	IN	O
a	DT	O
mixed	JJ	O
effects	NNS	O
model	NN	O
for	IN	O
repeated	JJ	O
measures	NNS	O
.	.	O

RESULTS	NNP	O
Baseline	NNP	O
characteristics	NNS	O
were	VBD	O
similar	JJ	O
between	IN	O
treatment	NN	O
groups	NNS	O
.	.	O

In	IN	O
response	NN	O
to	TO	O
aliskiren	NNS	O
compared	VBN	O
with	IN	O
placebo	NN	O
,	,	O
blood	NN	O
pressure	NN	O
was	VBD	O
reduced	VBN	O
as	RB	O
well	RB	O
as	IN	O
plasma	JJ	O
renin	NN	O
activity	NN	O
[	VBP	O
from	IN	O
2.4	CD	O
?	.	O
3.8	CD	O
(	(	O
mean	VB	O
?	.	O
standard	JJ	O
deviation	NN	O
)	)	O
to	TO	O
0.5	CD	O
?	.	O
0.4	CD	O
?g/l/h	NN	O
,	,	O
p	NN	O
<	VBD	O
0.001	CD	O
]	NN	O
.	.	O

There	EX	O
was	VBD	O
a	DT	O
significant	JJ	O
interaction	NN	O
(	(	O
aliskiren	VB	O
?	.	O
visit	NN	O
)	)	O
for	IN	O
MCR	NNP	O
(	(	O
p	JJ	O
=	NNP	O
0.003	CD	O
)	)	O
and	CC	O
E/I	NNP	O
ratio	NN	O
(	(	O
p	JJ	O
=	NNP	O
0.003	CD	O
)	)	O
indicating	VBG	O
improvement	NN	O
in	IN	O
MCR	NNP	O
and	CC	O
E/I	NNP	O
ratio	NN	O
for	IN	O
those	DT	O
on	IN	O
aliskiren	NNS	O
.	.	O

MCR	NNP	O
means	VBZ	O
,	,	O
baseline	VB	O
vs.	IN	O
follow-up	JJ	O
,	,	O
were	VBD	O
41.8	CD	O
?	.	O
19.7	CD	O
vs.	IN	O
50.8	CD	O
?	.	O
26.1	CD	O
(	(	O
aliskiren	NN	O
)	)	O
and	CC	O
38.2	CD	O
?	.	O
23.6	CD	O
vs.	IN	O
37.5	CD	O
?	.	O
24.1	CD	O
(	(	O
placebo	NN	O
)	)	O
.	.	O

CONCLUSIONS	NNP	O
Parasympathetic	NNP	O
function	NN	O
(	(	O
i.e	JJ	O
.	.	O

MCR	NNP	O
and	CC	O
E/I	NNP	O
ratio	NN	O
)	)	O
was	VBD	O
enhanced	VBN	O
by	IN	O
downregulation	NN	O
of	IN	O
the	DT	O
RAAS	NNP	O
.	.	O

[	JJ	O
Hemostatic	NNP	O
balance	NN	O
during	IN	O
treatment	NN	O
with	IN	O
the	DT	O
newest	JJS	O
contraceptives	NNS	O
]	RB	O
.	.	O

Thirty-four	CD	SS
healthy	JJ	C
young	JJ	A
women	NNS	A
were	VBD	O
allocated	VBN	O
to	TO	O
12	CD	O
consecutive	JJ	O
cycles	NNS	O
of	IN	O
treatment	NN	O
with	IN	O
monophasic	JJ	O
combinations	NNS	O
of	IN	O
:	:	O
20	CD	O
micrograms	NNS	O
ethinyl	VBP	O
estradiol	NN	O
and	CC	O
150	CD	O
micrograms	NNS	O
desogestrel	NN	O
(	(	O
n	JJ	O
=	NNP	O
15	CD	O
)	)	O
or	CC	O
30	CD	O
micrograms	NNS	O
ethinyl	VBP	O
estradiol	NN	O
and	CC	O
75	CD	O
micrograms	NNS	O
gestodene	NN	O
(	(	O
n	JJ	O
=	NNP	O
19	CD	O
)	)	O
.	.	O

In	IN	O
both	DT	O
groups	NNS	O
plasma	VBP	O
levels	NNS	O
of	IN	O
fibrinogen	NN	O
and	CC	O
factor	NN	O
VII	NNP	O
increased	VBD	O
while	IN	O
the	DT	O
capacity	NN	O
of	IN	O
coagulation	NN	O
inhibition	NN	O
was	VBD	O
affected	VBN	O
by	IN	O
increased	JJ	O
protein	NN	O
C	NNP	O
and	CC	O
decreased	VBN	O
protein	NN	O
S	NNP	O
levels	NNS	O
.	.	O

Increased	VBN	O
fibrinolytic	JJ	O
capacity	NN	O
was	VBD	O
indicated	VBN	O
by	IN	O
elevated	JJ	O
activity	NN	O
and	CC	O
reduced	JJ	O
antigen	NN	O
levels	NNS	O
of	IN	O
tissue	NN	O
plasminogen	NN	O
activator	NN	O
and	CC	O
reduced	JJ	O
activity	NN	O
and	CC	O
concentration	NN	O
of	IN	O
tissue	NN	O
plasminogen	NN	O
activator	NN	O
inhibitor	NN	O
.	.	O

The	DT	O
ratio	NN	O
between	IN	O
thrombin-antithrombin-III-complexes	NNS	O
and	CC	O
fibrin	JJ	O
degradation	NN	O
products	NNS	O
were	VBD	O
unchanged	JJ	O
signifying	VBG	O
no	DT	O
effect	NN	O
of	IN	O
hormonal	JJ	O
intake	NN	O
on	IN	O
the	DT	O
balance	NN	O
between	IN	O
thrombin	JJ	O
formation	NN	O
and	CC	O
fibrin	JJ	O
resolution	NN	O
.	.	O

In	IN	O
conclusion	NN	O
,	,	O
the	DT	O
dynamic	JJ	O
balance	NN	O
between	IN	O
generation	NN	O
and	CC	O
resolution	NN	O
of	IN	O
fibrin	NN	O
was	VBD	O
undisturbed	JJ	O
during	IN	O
treatment	NN	O
with	IN	O
both	DT	O
hormonal	JJ	O
compounds	NNS	O
and	CC	O
our	PRP$	O
findings	NNS	O
do	VBP	O
not	RB	O
provide	VB	O
evidence	NN	O
for	IN	O
increased	VBN	O
risk	NN	O
of	IN	O
thrombosis	NN	O
in	IN	O
normal	JJ	C
women	NNS	SE
.	.	O

Effect	NN	O
of	IN	O
sulfasalazine	NN	O
on	IN	O
inflammation	NN	O
and	CC	O
endothelial	JJ	O
function	NN	O
in	IN	O
patients	NNS	O
with	IN	O
established	VBN	O
coronary	JJ	O
artery	NN	O
disease	NN	O
.	.	O

Inflammation	NNP	O
is	VBZ	O
critical	JJ	O
for	IN	O
atherosclerosis	NN	O
development	NN	O
and	CC	O
may	MD	O
be	VB	O
a	DT	O
target	NN	O
for	IN	O
risk-reduction	NN	O
therapy	NN	O
.	.	O

In	IN	O
experimental	JJ	O
studies	NNS	O
,	,	O
activation	NN	O
of	IN	O
the	DT	O
inflammatory	JJ	O
regulator	NN	O
,	,	O
nuclear	JJ	O
factor	NN	O
kappa	NN	O
B	NNP	O
(	(	O
NFlB	NNP	O
)	)	O
,	,	O
contributes	VBZ	O
to	TO	O
endothelial	JJ	O
activation	NN	O
and	CC	O
reduced	JJ	O
nitric	JJ	O
oxide	NN	O
production	NN	O
.	.	O

We	PRP	O
treated	VBD	O
patients	NNS	O
with	IN	O
coronary	JJ	O
artery	NN	O
disease	NN	O
with	IN	O
sulfasalazine	NN	O
,	,	O
an	DT	O
inhibitor	NN	O
of	IN	O
NF?B	NNP	O
,	,	O
and	CC	O
placebo	NN	O
in	IN	O
a	DT	O
randomized	JJ	O
,	,	O
double-blind	JJ	O
,	,	O
crossover	NN	O
study	NN	O
design	NN	O
.	.	O

Brachial	JJ	O
artery	JJ	O
flow-mediated	JJ	O
dilation	NN	O
(	(	O
FMD	NNP	O
)	)	O
and	CC	O
digital	JJ	O
vascular	JJ	O
function	NN	O
were	VBD	O
measured	VBN	O
at	IN	O
baseline	NN	O
and	CC	O
after	IN	O
each	DT	O
6-week	JJ	O
treatment	NN	O
period	NN	O
.	.	O

Of	IN	O
the	DT	O
53	CD	O
patients	NNS	O
enrolled	VBN	O
in	IN	O
the	DT	O
crossover	NN	O
study	NN	O
,	,	O
32	CD	O
(	(	O
age	NN	O
60	CD	O
?	.	O
10	CD	O
,	,	O
22	CD	O
%	NN	O
female	NN	O
)	)	O
completed	VBD	O
all	PDT	O
the	DT	O
visits	NNS	O
,	,	O
with	IN	O
a	DT	O
high	JJ	O
rate	NN	O
of	IN	O
study	NN	O
withdrawal	NN	O
due	JJ	O
to	TO	O
gastrointestinal	JJ	O
side	NN	O
effects	NNS	O
.	.	O

In	IN	O
a	DT	O
subset	NN	O
of	IN	O
10	CD	O
participants	NNS	O
,	,	O
we	PRP	O
compared	VBN	O
the	DT	O
effects	NNS	O
of	IN	O
4	CD	O
days	NNS	O
of	IN	O
sulfasalazine	JJ	O
treatment	NN	O
(	(	O
n	JJ	O
=	NNP	O
5	CD	O
)	)	O
to	TO	O
no	DT	O
treatment	NN	O
(	(	O
n	JJ	O
=	NNP	O
5	CD	O
)	)	O
on	IN	O
NF?B-regulated	JJ	O
gene	NN	O
expression	NN	O
in	IN	O
peripheral	JJ	O
blood	NN	O
mononuclear	NN	O
cells	NNS	O
.	.	O

Tumor	NNP	O
necrosis	JJ	O
factor	NN	O
?-stimulated	JJ	O
expression	NN	O
of	IN	O
CD69	NNP	O
and	CC	O
NFlB	NNP	O
subunit	VBD	O
p50	NN	O
was	VBD	O
significantly	RB	O
blunted	VBN	O
after	IN	O
4	CD	O
days	NNS	O
of	IN	O
sulfasalazine	JJ	O
treatment	NN	O
but	CC	O
not	RB	O
after	IN	O
no	DT	O
treatment	NN	O
.	.	O

However	RB	O
,	,	O
FMD	NNP	O
and	CC	O
digital	JJ	O
vasodilator	NN	O
response	NN	O
did	VBD	O
not	RB	O
significantly	RB	O
change	VBP	O
from	IN	O
baseline	NN	O
with	IN	O
long-term	JJ	O
sulfasalazine	NN	O
treatment	NN	O
.	.	O

Short-term	JJ	O
sulfasalazine	NN	O
inhibited	VBN	O
NFlB	NNP	O
activity	NN	O
;	:	O
however	RB	O
,	,	O
long-term	JJ	O
treatment	NN	O
was	VBD	O
poorly	RB	O
tolerated	VBN	O
and	CC	O
did	VBD	O
not	RB	O
improve	VB	O
endothelial	JJ	O
function	NN	O
.	.	O

Our	PRP$	O
findings	NNS	O
suggest	VBP	O
that	IN	O
sulfasalazine	JJ	O
therapy	NN	O
is	VBZ	O
not	RB	O
the	DT	O
optimal	JJ	O
anti-inflammatory	JJ	O
treatment	NN	O
for	IN	O
reversing	VBG	O
endothelial	JJ	O
dysfunction	NN	O
in	IN	O
cardiovascular	JJ	O
disease	NN	O
.	.	O

Further	JJ	O
studies	NNS	O
are	VBP	O
warranted	VBN	O
to	TO	O
investigate	VB	O
the	DT	O
potential	NN	O
for	IN	O
NFlB	NNP	O
inhibition	NN	O
to	TO	O
reduce	VB	O
cardiovascular	JJ	O
risk	NN	O
.	.	O

[	JJ	O
Radiotherapy	NNP	O
for	IN	O
choroidal	JJ	O
neovascularization	NN	O
in	IN	O
age-related	JJ	O
macular	JJ	O
degeneration	NN	O
.	.	O

A	DT	O
pilot	NN	O
study	NN	O
using	VBG	O
low-	JJ	O
versus	NN	O
high-dose	JJ	O
photon	NN	O
bean	NN	O
radiation	NN	O
]	NN	O
.	.	O

PURPOSE	NNP	O
Several	JJ	O
pilot	NN	O
studies	NNS	O
have	VBP	O
indicated	VBN	O
that	IN	O
low-dose	JJ	O
radiation	NN	O
therapy	NN	O
might	MD	O
have	VB	O
a	DT	O
beneficial	JJ	O
effect	NN	O
on	IN	O
the	DT	O
course	NN	O
of	IN	O
choroidal	JJ	O
neovascularization	NN	O
(	(	O
CNV	NNP	O
)	)	O
in	IN	O
age-related	JJ	O
macular	JJ	O
degeneration	NN	O
(	(	O
AMD	NNP	O
)	)	O
.	.	O

This	DT	O
study	NN	O
aimed	VBD	O
to	TO	O
ascertain	VB	O
whether	IN	O
such	JJ	O
treatment	NN	O
might	MD	O
halt	VB	O
the	DT	O
progression	NN	O
of	IN	O
neovascular	JJ	O
AMD	NNP	O
and	CC	O
whether	IN	O
a	DT	O
low	JJ	O
or	CC	O
a	DT	O
high	JJ	O
radiation	NN	O
dose	NN	O
should	MD	O
be	VB	O
applied	VBN	O
.	.	O

PATIENTS	VB	O
The	DT	O
patients	NNS	O
comprised	VBD	O
some	DT	O
randomized	VBN	O
to	TO	O
0	CD	O
vs	NNS	O
10	CD	O
vs	NNS	O
36	CD	O
Gy	NNP	O
of	IN	O
radiation	NN	O
and	CC	O
(	(	O
after	IN	O
a	DT	O
change	NN	O
of	IN	O
the	DT	O
study	NN	O
protocol	NN	O
became	VBD	O
necessary	JJ	O
)	)	O
others	NNS	O
who	WP	O
participated	VBD	O
in	IN	O
a	DT	O
prospective	JJ	O
,	,	O
controlled	VBD	O
non-randomized	JJ	O
pilot	NN	O
study	NN	O
.	.	O

Enclosed	VBN	O
were	VBD	O
eyes	NNS	O
with	IN	O
visual	JJ	O
acuity	NN	O
of	IN	O
>	NN	O
or	CC	O
=	VB	O
0.1	CD	O
and	CC	O
<	NNP	O
or	CC	O
=	$	O
0.6	CD	O
revealing	VBG	O
a	DT	O
juxta-subfoveal	JJ	O
CNV	NNP	O
either	NN	O
of	IN	O
the	DT	O
occult	NN	O
type	NN	O
(	(	O
type	JJ	O
1	CD	O
)	)	O
or	CC	O
the	DT	O
classic	JJ	O
type	NN	O
(	(	O
isolated	JJ	O
or	CC	O
as	IN	O
part	NN	O
of	IN	O
a	DT	O
predominantly	RB	O
occult	JJ	O
lesion	NN	O
)	)	O
.	.	O

RESULTS	NNP	O
Eyes	NNP	O
treated	VBD	O
with	IN	O
10	CD	O
Gy	NNP	O
for	IN	O
occult	NN	O
CNV	NNP	O
(	(	O
n	JJ	O
=	NNP	O
12	CD	O
)	)	O
were	VBD	O
subject	JJ	O
to	TO	O
severe	JJ	O
visual	JJ	O
loss	NN	O
in	IN	O
41.6	CD	O
%	NN	O
of	IN	O
the	DT	O
cases	NNS	O
compared	VBN	O
to	TO	O
38.5	CD	O
%	NN	O
in	IN	O
the	DT	O
control	NN	O
group	NN	O
(	(	O
n	JJ	O
=	NNP	O
13	CD	O
)	)	O
at	IN	O
12	CD	O
months	NNS	O
of	IN	O
follow-up	NN	O
.	.	O

For	IN	O
eyes	NNS	O
treated	VBN	O
with	IN	O
10	CD	O
Gy	NNP	O
because	IN	O
of	IN	O
classic	JJ	O
CNV	NNP	O
,	,	O
the	DT	O
corresponding	JJ	O
figures	NNS	O
were	VBD	O
33	CD	O
%	NN	O
(	(	O
n	JJ	O
=	NNP	O
18	CD	O
)	)	O
and	CC	O
57	CD	O
%	NN	O
(	(	O
n	JJ	O
=	NNP	O
14	CD	O
)	)	O
respectively	RB	O
.	.	O

At	IN	O
18	CD	O
months	NNS	O
of	IN	O
follow-up	NN	O
,	,	O
the	DT	O
percentages	NNS	O
were	VBD	O
63	CD	O
%	NN	O
and	CC	O
75	CD	O
%	NN	O
respectively	RB	O
.	.	O

Fluorescein	NNP	O
angiographic	JJ	O
growth	NN	O
of	IN	O
classic	JJ	O
and	CC	O
occult	NN	O
CNV	NNP	O
could	MD	O
not	RB	O
be	VB	O
halted	VBN	O
by	IN	O
10	CD	O
Gy	NNP	O
,	,	O
while	IN	O
a	DT	O
temporary	JJ	O
growth	NN	O
retardation	NN	O
was	VBD	O
observed	VBN	O
in	IN	O
cases	NNS	O
irradiated	VBN	O
with	IN	O
36	CD	O
Gy	NNP	O
.	.	O

CONCLUSION	NNP	O
In	IN	O
the	DT	O
study	NN	O
presented	VBD	O
,	,	O
the	DT	O
natural	JJ	O
course	NN	O
of	IN	O
occult	NN	O
CNV	NNP	O
could	MD	O
not	RB	O
be	VB	O
improved	VBN	O
by	IN	O
irradiation	NN	O
with	IN	O
10	CD	O
or	CC	O
36	CD	O
Gy	NNP	O
.	.	O

In	IN	O
cases	NNS	O
of	IN	O
classic	JJ	O
CNV	NNP	O
,	,	O
low-dose	JJ	O
irradiation	NN	O
with	IN	O
10	CD	O
Gy	NNP	O
postponed	VBD	O
severe	JJ	O
visual	JJ	O
loss	NN	O
by	IN	O
a	DT	O
maximum	NN	O
of	IN	O
18	CD	O
months	NNS	O
.	.	O

A	DT	O
positive	JJ	O
treatment	NN	O
effect	NN	O
was	VBD	O
also	RB	O
observed	VBN	O
in	IN	O
cases	NNS	O
irradiated	VBN	O
with	IN	O
36	CD	O
Gy	NNP	O
;	:	O
however	RB	O
,	,	O
a	DT	O
25	CD	O
%	NN	O
incidence	NN	O
of	IN	O
radiation	NN	O
retinopathy	NN	O
seems	VBZ	O
unacceptable	JJ	O
.	.	O

Preschoolers	NNS	A
acquire	VB	O
general	JJ	O
knowledge	NN	O
by	IN	O
sharing	VBG	O
in	IN	O
pretense	NN	O
.	.	O

Children	NNP	O
acquire	VB	O
general	JJ	O
knowledge	NN	O
about	IN	O
many	JJ	O
kinds	NNS	O
of	IN	O
things	NNS	O
,	,	O
but	CC	O
there	EX	O
are	VBP	O
few	JJ	O
known	VBN	O
means	NNS	O
by	IN	O
which	WDT	O
this	DT	O
knowledge	NN	O
is	VBZ	O
acquired	VBN	O
.	.	O

In	IN	O
this	DT	O
article	NN	O
,	,	O
it	PRP	O
is	VBZ	O
proposed	VBN	O
that	IN	O
children	NNS	O
acquire	VB	O
generic	JJ	O
knowledge	NN	O
by	IN	O
sharing	VBG	O
in	IN	O
pretend	JJ	O
play	NN	O
.	.	O

In	IN	O
Experiment	JJ	O
1	CD	O
,	,	O
twenty-two	JJ	SS
3-	JJ	A
to	TO	A
4-year-olds	NNS	A
watched	VBN	O
pretense	NN	O
in	IN	O
which	WDT	O
a	DT	O
puppet	NN	O
represented	VBD	O
a	DT	O
nerp	NN	O
(	(	O
an	DT	O
unfamiliar	JJ	O
kind	NN	O
of	IN	O
animal	NN	O
)	)	O
.	.	O

For	IN	O
instance	NN	O
,	,	O
in	IN	O
one	CD	O
scenario	NN	O
,	,	O
the	DT	O
nerp	JJ	O
ate	NN	O
and	CC	O
disliked	VBD	O
a	DT	O
carrot	NN	O
.	.	O

When	WRB	O
subsequently	RB	O
asked	VBD	O
generic	JJ	O
questions	NNS	O
about	IN	O
real	JJ	O
nerps	NNS	O
,	,	O
children	NNS	A
's	POS	A
responses	NNS	O
suggested	VBD	O
that	IN	O
they	PRP	O
had	VBD	O
learned	VBN	O
general	JJ	O
facts	NNS	O
(	(	O
e.g.	NN	O
,	,	O
nerps	RB	O
dislike	JJ	O
carrots	NNS	O
)	)	O
.	.	O

In	IN	O
Experiment	JJ	O
2	CD	O
,	,	O
thirty-two	JJ	SS
4-	JJ	A
to	TO	A
5-year-olds	NNS	A
learned	VBN	O
from	IN	O
scenarios	NNS	O
lacking	VBG	O
pretend	JJ	O
speech	NN	O
or	CC	O
sound	JJ	O
effects	NNS	O
.	.	O

The	DT	O
findings	NNS	O
reveal	VBP	O
a	DT	O
long	JJ	O
overlooked	JJ	O
means	NNS	O
by	IN	O
which	WDT	O
children	NNS	A
can	MD	O
acquire	VB	O
generic	JJ	O
knowledge	NN	O
.	.	O

Stress	NNP	O
reduction	NN	O
prolongs	NNS	O
life	NN	O
in	IN	O
women	NNS	SE
with	IN	O
coronary	JJ	C
disease	NN	C
:	:	O
the	DT	O
Stockholm	NNP	O
Women	NNP	O
's	POS	O
Intervention	NNP	O
Trial	NNP	O
for	IN	O
Coronary	NNP	O
Heart	NNP	O
Disease	NNP	O
(	(	O
SWITCHD	NNP	O
)	)	O
.	.	O

BACKGROUND	NNP	O
Psychosocial	NNP	O
stress	NN	O
may	MD	O
increase	VB	O
risk	NN	O
and	CC	O
worsen	JJ	O
prognosis	NN	O
of	IN	O
coronary	JJ	C
heart	NN	C
disease	NN	C
in	IN	O
women	NNS	O
.	.	O

Interventions	NNS	O
that	IN	O
counteract	JJ	O
women	NNS	O
's	POS	O
psychosocial	JJ	O
stress	NN	O
have	VBP	O
not	RB	O
previously	RB	O
been	VBN	O
presented	VBN	O
.	.	O

This	DT	O
study	NN	O
implemented	VBD	O
a	DT	O
stress	JJ	O
reduction	NN	O
program	NN	O
for	IN	O
women	NNS	O
and	CC	O
investigated	VBD	O
its	PRP$	O
ability	NN	O
to	TO	O
improve	VB	O
survival	NN	O
in	IN	O
women	NNS	O
coronary	JJ	O
patients	NNS	O
.	.	O

METHODS	NNP	O
AND	CC	O
RESULTS	NNP	O
Two	CD	SS
hundred	VBD	SS
thirty-seven	JJ	SS
consecutive	JJ	O
women	NNS	O
patients	NNS	O
,	,	O
aged	VBD	O
75	CD	A
years	NNS	A
or	CC	O
younger	JJR	O
,	,	O
hospitalized	VBN	O
for	IN	O
acute	JJ	C
myocardial	JJ	C
infarction	NN	C
,	,	O
coronary	JJ	C
artery	NN	C
bypass	NN	C
grafting	NN	C
,	,	O
or	CC	O
percutaneous	JJ	C
coronary	JJ	C
intervention	NN	C
were	VBD	O
randomized	VBN	O
to	TO	O
a	DT	O
group-based	JJ	O
psychosocial	JJ	O
intervention	NN	O
program	NN	O
or	CC	O
usual	JJ	O
care	NN	O
.	.	O

Initiated	VBN	O
4	CD	O
months	NNS	O
after	IN	O
hospitalization	NN	O
,	,	O
intervention	NN	O
groups	NNS	O
of	IN	O
4	CD	O
to	TO	O
8	CD	O
women	NNS	O
met	VBD	O
for	IN	O
a	DT	O
total	NN	O
of	IN	O
20	CD	O
sessions	NNS	O
that	WDT	O
were	VBD	O
spread	VBN	O
over	IN	O
a	DT	O
year	NN	O
.	.	O

We	PRP	O
provided	VBD	O
education	NN	O
about	IN	O
risk	NN	O
factors	NNS	O
,	,	O
relaxation	NN	O
training	NN	O
techniques	NNS	O
,	,	O
methods	NNS	O
for	IN	O
self-monitoring	NN	O
and	CC	O
cognitive	JJ	O
restructuring	NN	O
,	,	O
with	IN	O
an	DT	O
emphasis	NN	O
on	IN	O
coping	VBG	O
with	IN	O
stress	JJ	O
exposure	NN	O
from	IN	O
family	NN	O
and	CC	O
work	NN	O
,	,	O
and	CC	O
self-care	NN	O
and	CC	O
compliance	NN	O
with	IN	O
clinical	JJ	O
advice	NN	O
.	.	O

From	IN	O
randomization	NN	O
until	IN	O
end	NN	O
of	IN	O
follow-up	NN	O
(	(	O
mean	JJ	O
duration	NN	O
,	,	O
7.1	CD	O
years	NNS	O
)	)	O
,	,	O
25	CD	O
women	NNS	O
(	(	O
20	CD	O
%	NN	O
)	)	O
in	IN	O
the	DT	O
usual	JJ	O
care	NN	O
and	CC	O
8	CD	O
women	NNS	O
(	(	O
7	CD	O
%	NN	O
)	)	O
in	IN	O
the	DT	O
stress	NN	O
reduction	NN	O
died	VBD	O
,	,	O
yielding	VBG	O
an	DT	O
almost	RB	O
3-fold	JJ	O
protective	JJ	O
effect	NN	O
of	IN	O
the	DT	O
intervention	NN	O
(	(	O
odds	NNS	O
ratio	NN	O
,	,	O
0.33	CD	O
;	:	O
95	CD	O
%	NN	O
CI	NNP	O
,	,	O
0.15	CD	O
to	TO	O
0.74	CD	O
;	:	O
P=0.007	NNP	O
)	)	O
.	.	O

Introducing	VBG	O
baseline	JJ	O
measures	NNS	O
of	IN	O
clinical	JJ	O
prognostic	JJ	O
factors	NNS	O
,	,	O
including	VBG	O
use	NN	O
of	IN	O
aspirin	NN	O
,	,	O
beta-blockers	NNS	O
,	,	O
angiotensin-converting	JJ	O
enzyme	NN	O
inhibitors	NNS	O
,	,	O
calcium-channel	JJ	O
blockers	NNS	O
,	,	O
and	CC	O
statins	VBZ	O
into	IN	O
multivariate	NN	O
models	NNS	O
confirmed	VBD	O
the	DT	O
unadjusted	JJ	O
results	NNS	O
(	(	O
P=0.009	NNP	O
)	)	O
.	.	O

CONCLUSIONS	NNP	O
Although	IN	O
mechanisms	NN	O
remain	VBP	O
unclear	JJ	O
,	,	O
a	DT	O
group-based	JJ	O
psychosocial	JJ	O
intervention	NN	O
program	NN	O
for	IN	O
women	NNS	O
with	IN	O
coronary	JJ	C
heart	NN	C
disease	NN	C
may	MD	O
prolong	VB	O
lives	NNS	O
independent	JJ	O
of	IN	O
other	JJ	O
prognostic	JJ	O
factors	NNS	O
.	.	O

Opioid-immune	JJ	O
interactions	NNS	O
in	IN	O
autism	NN	C
:	:	O
behavioural	JJ	O
and	CC	O
immunological	JJ	O
assessment	NN	O
during	IN	O
a	DT	O
double-blind	JJ	O
treatment	NN	O
with	IN	O
naltrexone	NN	O
.	.	O

The	DT	O
emerging	VBG	O
concept	NN	O
of	IN	O
opioid	JJ	O
peptides	NNS	O
as	IN	O
a	DT	O
new	JJ	O
class	NN	O
of	IN	O
chemical	JJ	O
messengers	NNS	O
of	IN	O
the	DT	O
neuroimmune	JJ	O
axis	NN	O
and	CC	O
the	DT	O
presence	NN	O
of	IN	O
a	DT	O
number	NN	O
of	IN	O
immunological	JJ	O
abnormalities	NNS	O
in	IN	O
infantile	JJ	O
autism	NN	O
prompted	VBD	O
us	PRP	O
to	TO	O
correlate	VB	O
biological	JJ	O
(	(	O
hormonal	JJ	O
and	CC	O
immunological	JJ	O
)	)	O
determinations	NNS	O
and	CC	O
behavioural	JJ	O
performances	NNS	O
during	IN	O
treatment	NN	O
with	IN	O
the	DT	O
potent	NN	O
opiate	JJ	O
antagonist	NN	O
,	,	O
naltrexone	NN	O
(	(	O
NAL	NNP	O
)	)	O
.	.	O

Twelve	NNP	SS
autistic	JJ	C
patients	NNS	O
ranging	VBG	O
from	IN	O
7	CD	A
to	TO	A
15	CD	A
years	NNS	A
,	,	O
diagnosed	VBD	O
according	VBG	O
to	TO	O
DSM-III-R	NNP	O
,	,	O
entered	VBD	O
a	DT	O
double-blind	JJ	O
crossover	NN	O
study	NN	O
with	IN	O
NAL	NNP	O
at	IN	O
the	DT	O
doses	NNS	O
of	IN	O
0.5	CD	O
,	,	O
1.0	CD	O
and	CC	O
1.5	CD	O
mg/kg	NN	O
every	DT	O
48	CD	O
hours	NNS	O
.	.	O

The	DT	O
behavioural	JJ	O
evaluation	NN	O
was	VBD	O
conducted	VBN	O
using	VBG	O
the	DT	O
specific	JJ	O
BSE	NNP	O
and	CC	O
CARS	NNP	O
rating	NN	O
scales	NNS	O
NAL	NNP	O
treatment	NN	O
produced	VBD	O
a	DT	O
significant	JJ	O
reduction	NN	O
of	IN	O
the	DT	O
autistic	JJ	O
symptomatology	NN	O
in	IN	O
seven	CD	O
(	(	O
responders	NNS	O
)	)	O
out	IN	O
of	IN	O
12	CD	O
children	NNS	A
.	.	O

The	DT	O
behavioural	JJ	O
improvement	NN	O
was	VBD	O
accompanied	VBN	O
by	IN	O
alterations	NNS	O
in	IN	O
the	DT	O
distribution	NN	O
of	IN	O
the	DT	O
major	JJ	O
lymphocyte	NN	O
subsets	NNS	O
,	,	O
with	IN	O
a	DT	O
significant	JJ	O
increase	NN	O
of	IN	O
the	DT	O
T-helper-inducers	NNP	O
(	(	O
CD4+CD8-	NNP	O
)	)	O
and	CC	O
a	DT	O
significant	JJ	O
reduction	NN	O
of	IN	O
the	DT	O
T-cytotoxic-suppressor	NNP	O
(	(	O
CD4-CD8+	NNP	O
)	)	O
resulting	VBG	O
in	IN	O
a	DT	O
normalization	NN	O
of	IN	O
the	DT	O
CD4/CD8	NNP	O
ratio	NN	O
.	.	O

Changes	NNS	O
in	IN	O
natural	JJ	O
killer	NN	O
cells	NNS	O
and	CC	O
activity	NN	O
were	VBD	O
inversely	RB	O
related	VBN	O
to	TO	O
plasma	VB	O
beta-endorphin	JJ	O
levels	NNS	O
.	.	O

It	PRP	O
is	VBZ	O
suggested	VBN	O
that	IN	O
the	DT	O
mechanisms	NNS	O
underlying	VBG	O
opioid-immune	JJ	O
interactions	NNS	O
are	VBP	O
altered	VBN	O
in	IN	O
this	DT	O
population	NN	O
of	IN	O
autistic	JJ	C
children	NNS	A
and	CC	O
that	DT	O
an	DT	O
immunological	JJ	O
screening	NN	O
may	MD	O
have	VB	O
prognostic	JJ	O
value	NN	O
for	IN	O
the	DT	O
pharmacological	JJ	O
therapy	NN	O
with	IN	O
opiate	JJ	O
antagonists	NNS	O
.	.	O

Superior	JJ	O
survival	NN	O
with	IN	O
capecitabine	JJ	O
plus	CC	O
docetaxel	JJ	O
combination	NN	O
therapy	NN	O
in	IN	O
anthracycline-pretreated	JJ	C
patients	NNS	C
with	IN	C
advanced	JJ	C
breast	NN	C
cancer	NN	C
:	:	O
phase	NN	O
III	NNP	O
trial	NN	O
results	NNS	O
.	.	O

PURPOSE	NNP	O
Docetaxel	NNP	O
and	CC	O
capecitabine	NN	O
,	,	O
a	DT	O
tumor-activated	JJ	O
oral	JJ	O
fluoropyrimidine	NN	O
,	,	O
show	VBP	O
high	JJ	O
single-agent	JJ	O
efficacy	NN	O
in	IN	O
metastatic	JJ	O
breast	NN	O
cancer	NN	O
(	(	O
MBC	NNP	O
)	)	O
and	CC	O
synergy	NN	O
in	IN	O
preclinical	JJ	O
studies	NNS	O
.	.	O

This	DT	O
international	JJ	O
phase	NN	O
III	NNP	O
trial	NN	O
compared	VBN	O
efficacy	NN	O
and	CC	O
tolerability	NN	O
of	IN	O
capecitabine/docetaxel	JJ	O
therapy	NN	O
with	IN	O
single-agent	JJ	O
docetaxel	NN	O
in	IN	O
anthracycline-pretreated	JJ	C
patients	NNS	C
with	IN	C
MBC	NNP	C
.	.	O

PATIENTS	NNP	O
AND	CC	O
METHODS	NNP	O
Patients	NNPS	O
were	VBD	O
randomized	VBN	O
to	TO	O
21-day	JJ	O
cycles	NNS	O
of	IN	O
oral	JJ	O
capecitabine	NN	O
1,250	CD	O
mg/m	NN	O
(	(	O
2	CD	O
)	)	O
twice	RB	O
daily	RB	O
on	IN	O
days	NNS	O
1	CD	O
to	TO	O
14	CD	O
plus	CC	O
docetaxel	JJ	O
75	CD	O
mg/m	NN	O
(	(	O
2	CD	O
)	)	O
on	IN	O
day	NN	O
1	CD	O
(	(	O
n	JJ	O
=	NNP	O
255	CD	O
)	)	O
or	CC	O
to	TO	O
docetaxel	VB	O
100	CD	O
mg/m	NN	O
(	(	O
2	CD	O
)	)	O
on	IN	O
day	NN	O
1	CD	O
(	(	O
n	JJ	O
=	NNP	O
256	CD	O
)	)	O
.	.	O

RESULTS	NNP	O
Capecitabine/docetaxel	NNP	O
resulted	VBD	O
in	IN	O
significantly	RB	O
superior	JJ	O
efficacy	NN	O
in	IN	O
time	NN	O
to	TO	O
disease	VB	O
progression	NN	O
(	(	O
TTP	NNP	O
)	)	O
(	(	O
hazard	JJ	O
ratio	NN	O
,	,	O
0.652	CD	O
;	:	O
95	CD	O
%	NN	O
confidence	NN	O
interval	NN	O
[	NNP	O
CI	NNP	O
]	NNP	O
,	,	O
0.545	CD	O
to	TO	O
0.780	CD	O
;	:	O
P	NNP	O
=.0001	NNP	O
;	:	O
median	JJ	O
,	,	O
6.1	CD	O
v	NN	O
4.2	CD	O
months	NNS	O
)	)	O
,	,	O
overall	JJ	O
survival	NN	O
(	(	O
hazard	JJ	O
ratio	NN	O
,	,	O
0.775	CD	O
;	:	O
95	CD	O
%	NN	O
CI	NNP	O
,	,	O
0.634	CD	O
to	TO	O
0.947	CD	O
;	:	O
P	NNP	O
=.0126	NNP	O
;	:	O
median	JJ	O
,	,	O
14.5	CD	O
v	NN	O
11.5	CD	O
months	NNS	O
)	)	O
,	,	O
and	CC	O
objective	JJ	O
tumor	NN	O
response	NN	O
rate	NN	O
(	(	O
42	CD	O
%	NN	O
v	JJ	O
30	CD	O
%	NN	O
,	,	O
P	NNP	O
=.006	NNP	O
)	)	O
compared	VBN	O
with	IN	O
docetaxel	NN	O
.	.	O

Gastrointestinal	JJ	O
side	NN	O
effects	NNS	O
and	CC	O
hand-foot	JJ	O
syndrome	NN	O
were	VBD	O
more	JJR	O
common	JJ	O
with	IN	O
combination	NN	O
therapy	NN	O
,	,	O
whereas	JJ	O
myalgia	NN	O
,	,	O
arthralgia	NN	O
,	,	O
and	CC	O
neutropenic	JJ	O
fever/sepsis	NN	O
were	VBD	O
more	JJR	O
common	JJ	O
with	IN	O
single-agent	JJ	O
docetaxel	NN	O
.	.	O

More	JJR	O
grade	JJ	O
3	CD	O
adverse	JJ	O
events	NNS	O
occurred	VBD	O
with	IN	O
combination	NN	O
therapy	NN	O
(	(	O
71	CD	O
%	NN	O
v	JJ	O
49	CD	O
%	NN	O
,	,	O
respectively	RB	O
)	)	O
,	,	O
whereas	JJ	O
grade	VBP	O
4	CD	O
events	NNS	O
were	VBD	O
slightly	RB	O
more	RBR	O
common	JJ	O
with	IN	O
docetaxel	NN	O
(	(	O
31	CD	O
%	NN	O
v	JJ	O
25	CD	O
%	NN	O
with	IN	O
combination	NN	O
)	)	O
.	.	O

CONCLUSION	VB	O
The	DT	O
significantly	RB	O
superior	JJ	O
TTP	NNP	O
and	CC	O
survival	NN	O
achieved	VBN	O
with	IN	O
the	DT	O
addition	NN	O
of	IN	O
capecitabine	NN	O
to	TO	O
docetaxel	VB	O
75	CD	O
mg/m	NN	O
(	(	O
2	CD	O
)	)	O
,	,	O
with	IN	O
the	DT	O
manageable	JJ	O
toxicity	NN	O
profile	NN	O
,	,	O
indicate	VBP	O
that	IN	O
this	DT	O
combination	NN	O
provides	VBZ	O
clear	JJ	O
benefits	NNS	O
over	IN	O
single-agent	JJ	O
docetaxel	NN	O
100	CD	O
mg/m	NN	O
(	(	O
2	CD	O
)	)	O
.	.	O

Docetaxel/capecitabine	NNP	O
therapy	NN	O
is	VBZ	O
an	DT	O
important	JJ	O
treatment	NN	O
option	NN	O
for	IN	O
women	NNS	SE
with	IN	O
anthracycline-pretreated	JJ	C
MBC	NNP	C
.	.	O

Fake	NNP	O
bad	JJ	O
test	NN	O
response	NN	O
bias	NN	O
effects	NNS	O
on	IN	O
the	DT	O
test	NN	O
of	IN	O
variables	NNS	O
of	IN	O
attention	NN	O
.	.	O

This	DT	O
study	NN	O
investigated	VBD	O
the	DT	O
effects	NNS	O
of	IN	O
faking	VBG	O
bad	JJ	O
(	(	O
FB	NNP	O
)	)	O
on	IN	O
the	DT	O
Test	NNP	O
of	IN	O
Variables	NNP	O
of	IN	O
Attention	NNP	O
(	(	O
TOVA	NNP	O
)	)	O
using	VBG	O
subjects	NNS	O
randomly	RB	O
placed	VBN	O
into	IN	O
two	CD	O
groups	NNS	O
.	.	O

Subjects	NNS	O
in	IN	O
Group	NNP	O
1	CD	O
took	VBD	O
the	DT	O
TOVA	NNP	O
under	IN	O
normal	JJ	O
conditions	NNS	O
(	(	O
NC	NNP	O
)	)	O
first	RB	O
;	:	O
they	PRP	O
were	VBD	O
then	RB	O
requested	VBN	O
to	TO	O
subtly	RB	O
fake	VB	O
bad	JJ	O
.	.	O

Group	NNP	O
2	CD	O
subjects	NNS	O
took	VBD	O
the	DT	O
TOVA	NNP	O
under	IN	O
the	DT	O
same	JJ	O
fake	JJ	O
bad	JJ	O
instructions	NNS	O
first	RB	O
,	,	O
then	RB	O
took	VBD	O
the	DT	O
test	NN	O
under	IN	O
normal	JJ	O
conditions	NNS	O
the	DT	O
second	JJ	O
time	NN	O
.	.	O

An	DT	O
analysis	NN	O
of	IN	O
the	DT	O
effects	NNS	O
of	IN	O
test	NN	O
order	NN	O
yielded	VBN	O
non-significant	JJ	O
differences	NNS	O
for	IN	O
basic	JJ	O
TOVA	NNP	O
variables	NNS	O
across	IN	O
all	DT	O
four	CD	O
quarters	NNS	O
,	,	O
both	DT	O
halves	NNS	O
and	CC	O
the	DT	O
total	JJ	O
score	NN	O
.	.	O

An	DT	O
analysis	NN	O
for	IN	O
group	NN	O
mean	NN	O
differences	NNS	O
between	IN	O
the	DT	O
NC	NNP	O
and	CC	O
the	DT	O
FB	NNP	O
instructions	NNS	O
yielded	VBD	O
significant	JJ	O
differences	NNS	O
across	IN	O
the	DT	O
basic	JJ	O
TOVA	NNP	O
variables	NNS	O
across	IN	O
the	DT	O
four	CD	O
quarters	NNS	O
,	,	O
two	CD	O
halves	NNS	O
and	CC	O
total	JJ	O
score	NN	O
.	.	O

The	DT	O
FB	NNP	O
group	NN	O
had	VBD	O
excessive	JJ	O
amounts	NNS	O
of	IN	O
omission	NN	O
and	CC	O
commission	NN	O
errors	NNS	O
,	,	O
a	DT	O
greater	JJR	O
response	NN	O
time	NN	O
mean	NN	O
(	(	O
i.e.	FW	O
,	,	O
slower	JJR	O
to	TO	O
respond	VB	O
)	)	O
and	CC	O
had	VBD	O
greater	JJR	O
variance	NN	O
around	IN	O
their	PRP$	O
mean	JJ	O
response	NN	O
time	NN	O
.	.	O

The	DT	O
study	NN	O
affirms	VBZ	O
that	IN	O
the	DT	O
professional	JJ	O
using	VBG	O
the	DT	O
TOVA	NNP	O
needs	VBZ	O
to	TO	O
carefully	RB	O
eliminate	VB	O
a	DT	O
fake	JJ	O
bad	JJ	O
test-taking	NN	O
bias	NN	O
when	WRB	O
subjects	NNS	O
produce	VBP	O
excessive	JJ	O
test	NN	O
results	NNS	O
.	.	O

Changes	NNS	O
of	IN	O
activated	JJ	O
circulating	VBG	O
endothelial	JJ	O
cells	NNS	O
and	CC	O
survivin	NN	O
in	IN	O
patients	NNS	O
with	IN	O
non-small	JJ	O
cell	NN	O
lung	NN	O
cancer	NN	O
after	IN	O
antiangiogenesis	NN	O
therapy	NN	O
.	.	O

BACKGROUND	NNP	O
Although	IN	O
antiangiogenesis	NN	O
therapy	NN	O
plays	VBZ	O
an	DT	O
important	JJ	O
role	NN	O
in	IN	O
anti-neoplastic	JJ	O
treatment	NN	O
with	IN	O
its	PRP$	O
recognized	VBN	O
efficacy	NN	O
and	CC	O
slight	JJ	O
adverse	JJ	O
effect	NN	O
,	,	O
there	EX	O
is	VBZ	O
no	DT	O
prospective	JJ	O
clinical	JJ	O
trial	NN	O
to	TO	O
define	VB	O
ideal	JJ	O
markers	NNS	O
for	IN	O
predicting	VBG	O
efficacy	NN	O
of	IN	O
antiangiogenic	JJ	O
therapy	NN	O
.	.	O

This	DT	O
study	NN	O
was	VBD	O
undertaken	VBN	O
to	TO	O
investigate	VB	O
the	DT	O
changes	NNS	O
of	IN	O
activated	JJ	O
circulating	VBG	O
endothelial	JJ	O
cells	NNS	O
(	(	O
aCECs	NN	O
)	)	O
and	CC	O
survivin	JJ	O
after	IN	O
anti-angiogenesis	JJ	O
therapy	NN	O
and	CC	O
their	PRP$	O
significance	NN	O
in	IN	O
predicting	VBG	O
the	DT	O
efficacy	NN	O
of	IN	O
the	DT	O
therapy	NN	O
.	.	O

METHODS	NNP	O
Patients	NNPS	O
of	IN	O
non-small	JJ	O
cell	NN	O
lung	NN	O
cancer	NN	O
(	(	O
NSCLC	NNP	O
)	)	O
treated	VBD	O
with	IN	O
chemotherapy	NN	O
with	IN	O
or	CC	O
without	IN	O
Endostar	NNP	O
were	VBD	O
observed	VBN	O
.	.	O

The	DT	O
amount	NN	O
of	IN	O
activated	JJ	O
CECs	NNP	O
was	VBD	O
detected	VBN	O
by	IN	O
flow	JJ	O
cytometry	NN	O
,	,	O
and	CC	O
the	DT	O
expression	NN	O
of	IN	O
survivin	NN	O
mRNA	NN	O
was	VBD	O
determined	VBN	O
by	IN	O
real-time	JJ	O
polymerase	NN	O
chain	NN	O
reaction	NN	O
(	(	O
PCR	NNP	O
)	)	O
.	.	O

RESULTS	NNP	O
After	IN	O
treatment	NN	O
,	,	O
the	DT	O
amount	NN	O
of	IN	O
activated	JJ	O
CECs	NNP	O
decreased	VBD	O
significantly	RB	O
in	IN	O
clinical	JJ	O
benefit	NN	O
cases	NNS	O
(	(	O
P	NNP	O
=	VBZ	O
0.021	CD	O
in	IN	O
chemotherapy	NN	O
alone	RB	O
,	,	O
P	NNP	O
=	VBZ	O
0.001	CD	O
in	IN	O
chemotherapy	NN	O
plus	CC	O
Endostar	NNP	O
)	)	O
,	,	O
increased	VBN	O
in	IN	O
disease	NN	O
progressive	JJ	O
cases	NNS	O
(	(	O
P	NNP	O
=	VBZ	O
0.015	CD	O
in	IN	O
chemotherapy	NN	O
alone	RB	O
,	,	O
but	CC	O
P	NNP	O
=	NNP	O
0.293	CD	O
in	IN	O
chemotherapy	NN	O
with	IN	O
Endotatar	NNP	O
)	)	O
.	.	O

After	IN	O
therapy	NN	O
,	,	O
the	DT	O
expression	NN	O
of	IN	O
survivin	JJ	O
mRNA	NN	O
decreased	VBN	O
in	IN	O
clinical	JJ	O
benefit	NN	O
cases	NNS	O
(	(	O
P	NNP	O
=	NNP	O
0.001	CD	O
)	)	O
and	CC	O
increased	VBN	O
in	IN	O
disease	NN	O
progressive	JJ	O
cases	NNS	O
(	(	O
P	NNP	O
=	NNP	O
0.018	CD	O
)	)	O
.	.	O

A	DT	O
positive	JJ	O
correlation	NN	O
was	VBD	O
found	VBN	O
between	IN	O
activated	VBN	O
CECs	NNP	O
and	CC	O
survivin	NN	O
in	IN	O
the	DT	O
chemotherapy	NN	O
group	NN	O
pre-	JJ	O
and	CC	O
post-therapy	JJ	O
(	(	O
P	NNP	O
=	NNP	O
0.001	CD	O
and	CC	O
0.021	CD	O
,	,	O
respectively	RB	O
)	)	O
,	,	O
but	CC	O
only	RB	O
in	IN	O
the	DT	O
chemotherapy	NN	O
with	IN	O
Endostar	NNP	O
group	NN	O
pre-therapy	NN	O
(	(	O
P	NNP	O
=	NNP	O
0.030	CD	O
)	)	O
rather	RB	O
than	IN	O
post-therapy	NN	O
.	.	O

A	DT	O
positive	JJ	O
correlation	NN	O
was	VBD	O
found	VBN	O
between	IN	O
the	DT	O
decreased	VBN	O
activated	VBN	O
CECs	NNP	O
after	IN	O
therapy	NN	O
and	CC	O
time	NN	O
to	TO	O
progression	NN	O
(	(	O
TTP	NNP	O
)	)	O
(	(	O
r	JJ	O
=	NN	O
0.322	CD	O
,	,	O
P	NNP	O
=	NNP	O
0.012	CD	O
)	)	O
;	:	O
a	DT	O
negative	JJ	O
correlation	NN	O
was	VBD	O
found	VBN	O
between	IN	O
the	DT	O
amount	NN	O
of	IN	O
survivin	NN	O
mRNA	NN	O
in	IN	O
serum	JJ	O
post-therapy	NN	O
and	CC	O
TTP	NNP	O
(	(	O
r	NN	O
=	NNP	O
-0.291	NNP	O
,	,	O
P	NNP	O
=	NNP	O
0.048	CD	O
)	)	O
.	.	O

CONCLUSIONS	NNP	O
Activated	NNP	O
CECs	NNP	O
and	CC	O
survivin	NN	O
may	MD	O
be	VB	O
ideal	JJ	O
markers	NNS	O
forecasting	VBG	O
efficacy	NN	O
and	CC	O
prognosis	NN	O
of	IN	O
NSCLC	NNP	O
.	.	O

The	DT	O
former	JJ	O
can	MD	O
reflect	VB	O
more	RBR	O
sensitively	RB	O
antiangiogenic	JJ	O
efficacy	NN	O
and	CC	O
the	DT	O
latter	NN	O
is	VBZ	O
more	RBR	O
sensitive	JJ	O
to	TO	O
shrinkage	VB	O
or	CC	O
swelling	VBG	O
of	IN	O
tumors	NNS	O
.	.	O

Their	PRP$	O
combination	NN	O
can	MD	O
evaluate	VB	O
more	RBR	O
accurately	RB	O
the	DT	O
efficacy	NN	O
of	IN	O
antiangiogenic	JJ	O
therapy	NN	O
of	IN	O
NSCLC	NNP	O
.	.	O

Dexamethasone	NN	O
in	IN	O
salbutamol-treated	JJ	O
inpatients	NNS	O
with	IN	O
acute	JJ	O
bronchiolitis	NN	O
:	:	O
a	DT	O
randomized	NN	O
,	,	O
controlled	VBN	O
trial	NN	O
.	.	O

OBJECTIVE	NN	O
To	TO	O
determine	VB	O
the	DT	O
clinical	JJ	O
benefit	NN	O
of	IN	O
oral	JJ	O
dexamethasone	NN	O
in	IN	O
children	NNS	O
admitted	VBN	O
to	TO	O
the	DT	O
hospital	NN	O
with	IN	O
bronchiolitis	NN	O
treated	VBN	O
with	IN	O
nebulized	JJ	O
salbutamol	NN	O
.	.	O

METHODS	NNP	O
Randomized	NNP	O
,	,	O
double-blind	NN	O
,	,	O
placebo-controlled	JJ	O
trial	NN	O
in	IN	O
the	DT	O
inpatient	JJ	O
wards	NNS	O
of	IN	O
a	DT	O
pediatric	JJ	O
tertiary	NN	O
care	NN	O
hospital	NN	O
.	.	O

The	DT	O
participants	NNS	O
,	,	O
children	NNS	O
aged	VBD	O
6	CD	O
weeks	NNS	O
to	TO	O
15	CD	O
months	NNS	O
,	,	O
admitted	VBN	O
with	IN	O
first-time	JJ	O
wheezing	NN	O
,	,	O
were	VBD	O
eligible	JJ	O
if	IN	O
their	PRP$	O
oxygen	NN	O
saturation	NN	O
was	VBD	O
less	JJR	O
than	IN	O
95	CD	O
%	NN	O
on	IN	O
admission	NN	O
to	TO	O
the	DT	O
hospital	NN	O
and	CC	O
their	PRP$	O
Respiratory	NNP	O
Distress	NNP	O
Assessment	NNP	O
Instrument	NNP	O
(	(	O
RDAI	NNP	O
)	)	O
score	NN	O
was	VBD	O
greater	JJR	O
than	IN	O
6	CD	O
.	.	O

Patients	NNS	O
were	VBD	O
excluded	VBN	O
if	IN	O
they	PRP	O
had	VBD	O
any	DT	O
one	CD	O
of	IN	O
the	DT	O
following	NN	O
:	:	O
an	DT	O
underlying	JJ	O
disease	NN	O
that	WDT	O
might	MD	O
affect	VB	O
cardiopulmonary	JJ	O
status	NN	O
,	,	O
asthma	NN	O
,	,	O
recent	JJ	O
treatment	NN	O
with	IN	O
steroids	NNS	O
(	(	O
within	IN	O
2	CD	O
weeks	NNS	O
)	)	O
,	,	O
or	CC	O
any	DT	O
history	NN	O
of	IN	O
adverse	JJ	O
reaction	NN	O
to	TO	O
steroids	NNS	O
.	.	O

Patients	NNS	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
receive	VB	O
either	DT	O
orally	RB	O
administered	VBN	O
dexamethasone	NN	O
with	IN	O
0.5	CD	O
mg/kg	NNS	O
as	IN	O
the	DT	O
first	JJ	O
dose	NN	O
and	CC	O
0.3	CD	O
mg/kg	NN	O
for	IN	O
the	DT	O
next	JJ	O
2	CD	O
mornings	NNS	O
,	,	O
or	CC	O
an	DT	O
equal	JJ	O
volume	NN	O
of	IN	O
an	DT	O
orally	RB	O
administered	VBN	O
placebo	NN	O
with	IN	O
an	DT	O
identical	JJ	O
appearance	NN	O
.	.	O

All	DT	O
patients	NNS	O
received	VBD	O
nebulized	JJ	O
salbutamol	NN	O
at	IN	O
0.15	CD	O
mg/kg	NN	O
every	DT	O
4	CD	O
hours	NNS	O
for	IN	O
the	DT	O
first	JJ	O
24	CD	O
hours	NNS	O
.	.	O

The	DT	O
primary	JJ	O
outcome	NN	O
measure	NN	O
was	VBD	O
the	DT	O
change	NN	O
from	IN	O
baseline	NN	O
in	IN	O
the	DT	O
RDAI	NNP	O
score	NN	O
at	IN	O
24	CD	O
hours	NNS	O
.	.	O

Secondary	JJ	O
outcome	NN	O
measures	NNS	O
were	VBD	O
oxygen	JJ	O
saturation	NN	O
,	,	O
respiratory	NN	O
rate	NN	O
,	,	O
RDAI	NNP	O
measurement	NN	O
twice	RB	O
daily	RB	O
for	IN	O
the	DT	O
first	JJ	O
4	CD	O
days	NNS	O
,	,	O
and	CC	O
the	DT	O
length	NN	O
of	IN	O
hospitalization	NN	O
.	.	O

RESULTS	NNP	O
At	IN	O
24	CD	O
hours	NNS	O
the	DT	O
mean	JJ	O
change	NN	O
(	(	O
SD	NNP	O
)	)	O
from	IN	O
baseline	NN	O
in	IN	O
the	DT	O
RDAI	NNP	O
score	NN	O
was	VBD	O
1.6	CD	O
(	(	O
2.3	CD	O
)	)	O
in	IN	O
the	DT	O
placebo	NN	O
group	NN	O
(	(	O
n	JJ	O
=	NNP	O
28	CD	O
)	)	O
and	CC	O
1.4	CD	O
(	(	O
2.0	CD	O
)	)	O
in	IN	O
the	DT	O
dexamethasone	NN	O
group	NN	O
(	(	O
n	JJ	O
=	VBZ	O
33	CD	O
;	:	O
p	NN	O
=	VBZ	O
0.74	CD	O
)	)	O
.	.	O

There	EX	O
were	VBD	O
no	DT	O
significant	JJ	O
differences	NNS	O
between	IN	O
the	DT	O
two	CD	O
groups	NNS	O
in	IN	O
change	NN	O
in	IN	O
oxygen	NN	O
saturation	NN	O
,	,	O
respiratory	NN	O
rate	NN	O
,	,	O
and	CC	O
RDAI	NNP	O
score	NN	O
at	IN	O
any	DT	O
assessment	JJ	O
period	NN	O
.	.	O

The	DT	O
median	JJ	O
length	NN	O
of	IN	O
stay	NN	O
(	(	O
95	CD	O
%	NN	O
confidence	NN	O
interval	NN	O
)	)	O
for	IN	O
the	DT	O
placebo	NN	O
group	NN	O
was	VBD	O
48	CD	O
(	(	O
42	CD	O
,	,	O
54	CD	O
)	)	O
hours	NNS	O
compared	VBN	O
with	IN	O
57	CD	O
(	(	O
38	CD	O
,	,	O
76	CD	O
)	)	O
hours	NNS	O
in	IN	O
the	DT	O
dexamethasone	NN	O
group	NN	O
(	(	O
p	JJ	O
=	NNP	O
0.19	CD	O
)	)	O
.	.	O

CONCLUSIONS	NNP	O
Oral	NNP	O
dexamethasone	NN	O
therapy	NN	O
does	VBZ	O
not	RB	O
affect	VB	O
the	DT	O
clinical	JJ	O
course	NN	O
of	IN	O
children	NNS	O
hospitalized	VBN	O
with	IN	O
bronchiolitis	NN	O
and	CC	O
therefore	RB	O
can	MD	O
not	RB	O
be	VB	O
recommended	VBN	O
in	IN	O
this	DT	O
clinical	JJ	O
situation	NN	O
.	.	O

A	DT	O
prospective	JJ	O
randomised	JJ	O
comparison	NN	O
of	IN	O
the	DT	O
dynamic	JJ	C
hip	NN	C
screw	NN	C
and	CC	O
the	DT	O
gamma	NN	C
locking	VBG	C
nail	NN	C
.	.	O

We	PRP	O
made	VBD	O
a	DT	O
randomised	JJ	O
prospective	JJ	O
comparison	NN	O
of	IN	O
the	DT	O
Dynamic	NNP	O
Hip	NNP	O
Screw	NNP	O
and	CC	O
the	DT	O
Gamma	NNP	O
locking	VBG	O
nail	NN	O
for	IN	O
the	DT	O
internal	JJ	O
fixation	NN	O
of	IN	O
200	CD	SS
petrochanteric	JJ	C
femoral	JJ	C
fractures	NNS	C
in	IN	O
elderly	JJ	A
patients	NNS	O
.	.	O

There	EX	O
was	VBD	O
less	RBR	O
intraoperative	JJ	O
blood	NN	O
loss	NN	O
and	CC	O
a	DT	O
lower	JJR	O
rate	NN	O
of	IN	O
wound	NN	O
complications	NNS	O
in	IN	O
the	DT	O
patients	NNS	O
treated	VBN	O
by	IN	O
the	DT	O
Gamma	NNP	O
nail	NN	O
.	.	O

They	PRP	O
had	VBD	O
,	,	O
however	RB	O
,	,	O
a	DT	O
high	JJ	O
incidence	NN	O
of	IN	O
femoral	JJ	O
shaft	NN	O
fracture	NN	O
which	WDT	O
we	PRP	O
relate	VBP	O
in	IN	O
part	NN	O
to	TO	O
implant	VB	O
design	NN	O
.	.	O

We	PRP	O
do	VBP	O
not	RB	O
recommend	VB	O
the	DT	O
use	NN	O
of	IN	O
the	DT	O
Gamma	NNP	O
nail	NN	O
for	IN	O
these	DT	O
fractures	NNS	O
.	.	O

Management	NN	O
of	IN	O
unstable	JJ	C
angina	NN	C
at	IN	O
rest	NN	O
by	IN	O
verapamil	NN	O
.	.	O

A	DT	O
double-blind	JJ	O
cross-over	NN	O
study	NN	O
in	IN	O
coronary	JJ	O
care	NN	O
unit	NN	O
.	.	O

A	NNP	O
therapeutic	JJ	O
trial	NN	O
with	IN	O
verapamil	NN	O
,	,	O
a	DT	O
calcium-antagonist	JJ	O
drug	NN	O
,	,	O
was	VBD	O
performed	VBN	O
in	IN	O
12	CD	SS
patients	NNS	SS
admitted	VBN	O
to	TO	O
our	PRP$	O
coronary	JJ	O
care	NN	O
unit	NN	O
because	IN	O
of	IN	O
frequent	JJ	O
daily	JJ	O
attacks	NNS	O
of	IN	O
angina	NN	C
at	IN	O
rest	NN	O
attributed	VBN	O
to	TO	O
coronary	JJ	C
vasospasm	NN	C
.	.	O

After	IN	O
a	DT	O
48-hour	JJ	O
run-in	JJ	O
period	NN	O
,	,	O
oral	JJ	O
verapamil	NN	O
480	CD	O
mg/day	NN	O
and	CC	O
placebo	NN	O
were	VBD	O
administered	VBN	O
alternately	RB	O
during	IN	O
4	CD	O
randomised	VBD	O
48-hour	CD	O
periods	NNS	O
.	.	O

Transient	NNP	O
ischaemic	JJ	O
attacks	NNS	O
with	IN	O
ST	NNP	O
segment	NN	O
elevation	NN	O
or	CC	O
depression	NN	O
,	,	O
with	IN	O
or	CC	O
without	IN	O
pain	NN	O
,	,	O
were	VBD	O
documented	VBN	O
by	IN	O
continuous	JJ	O
electrocardiographic	JJ	O
monitoring	NN	O
.	.	O

The	DT	O
number	NN	O
of	IN	O
attacks	NNS	O
during	IN	O
the	DT	O
run-in	JJ	O
and	CC	O
2	CD	O
placebo	NN	O
periods	NNS	O
were	VBD	O
128	CD	O
,	,	O
123	CD	O
,	,	O
and	CC	O
130	CD	O
,	,	O
respectively	RB	O
,	,	O
and	CC	O
31	CD	O
and	CC	O
23	CD	O
during	IN	O
the	DT	O
2	CD	O
treatment	NN	O
periods	NNS	O
(	(	O
P	NNP	O
less	JJR	O
than	IN	O
0.006	CD	O
and	CC	O
P	NNP	O
less	JJR	O
than	IN	O
0.003	CD	O
)	)	O
.	.	O

This	DT	O
drug	NN	O
therefore	RB	O
appears	VBZ	O
to	TO	O
be	VB	O
effective	JJ	O
in	IN	O
the	DT	O
management	NN	O
of	IN	O
patients	NNS	O
with	IN	O
frequent	JJ	O
attacks	NNS	O
of	IN	O
angina	NN	C
at	IN	O
rest	NN	O
.	.	O

Rizatriptan	NNP	O
5	CD	O
mg	NN	O
for	IN	O
the	DT	O
acute	JJ	O
treatment	NN	O
of	IN	O
migraine	NN	C
in	IN	O
adolescents	NNS	A
:	:	O
a	DT	O
randomized	JJ	O
,	,	O
double-blind	JJ	O
,	,	O
placebo-controlled	JJ	O
study	NN	O
.	.	O

OBJECTIVE	NNP	O
To	TO	O
investigate	VB	O
the	DT	O
tolerability	NN	O
and	CC	O
efficacy	NN	O
of	IN	O
rizatriptan	JJ	O
5	CD	O
mg	NN	O
in	IN	O
adolescent	JJ	O
migraineurs	NNS	O
.	.	O

METHODS	NNP	O
Randomized	NNP	O
,	,	O
double-blind	NN	O
,	,	O
placebo-controlled	JJ	O
study	NN	O
.	.	O

Patients	NNS	O
aged	VBD	O
12	CD	A
to	TO	A
17	CD	A
years	NNS	A
received	VBD	O
rizatriptan	JJ	O
5	CD	O
mg	NN	O
(	(	O
n	JJ	O
=	NNP	O
149	CD	SS
)	)	O
or	CC	O
placebo	NN	O
(	(	O
n	JJ	O
=	NNP	O
147	CD	SS
)	)	O
for	IN	O
a	DT	O
moderate	JJ	O
or	CC	O
severe	JJ	O
headache	NN	O
and	CC	O
for	IN	O
up	RB	O
to	TO	O
two	CD	O
recurrences	NNS	O
.	.	O

Headache	NNP	O
severity	NN	O
,	,	O
presence	NN	O
or	CC	O
absence	NN	O
of	IN	O
associated	VBN	O
symptoms	NNS	O
,	,	O
and	CC	O
functional	JJ	O
disability	NN	O
were	VBD	O
assessed	VBN	O
over	IN	O
a	DT	O
4-hour	JJ	O
postdose	JJ	O
period	NN	O
,	,	O
and	CC	O
any	DT	O
adverse	JJ	O
events	NNS	O
were	VBD	O
recorded	VBN	O
.	.	O

The	DT	O
primary	JJ	O
efficacy	NN	O
measure	NN	O
was	VBD	O
pain-free	JJ	O
status	NN	O
at	IN	O
2	CD	O
hours	NNS	O
postdose	RB	O
.	.	O

RESULTS	NNP	O
Rizatriptan	NNP	O
5	CD	O
mg	NN	O
was	VBD	O
well	RB	O
tolerated	VBN	O
.	.	O

The	DT	O
most	RBS	O
commonly	RB	O
reported	VBD	O
adverse	JJ	O
events	NNS	O
(	(	O
all	DT	O
with	IN	O
incidence	NN	O
of	IN	O
5	CD	O
%	NN	O
or	CC	O
less	JJR	O
)	)	O
among	IN	O
patients	NNS	O
receiving	VBG	O
rizatriptan	NNS	O
were	VBD	O
dry	JJ	O
mouth	NN	O
,	,	O
dizziness	NN	O
,	,	O
asthenia/fatigue	NN	O
,	,	O
nausea	NN	O
,	,	O
and	CC	O
somnolence	NN	O
.	.	O

The	DT	O
percentage	NN	O
of	IN	O
patients	NNS	O
pain-free	JJ	O
at	IN	O
2	CD	O
hours	NNS	O
was	VBD	O
32	CD	O
%	NN	O
for	IN	O
rizatriptan	JJ	O
5	CD	O
mg	NN	O
versus	NN	O
28	CD	O
%	NN	O
for	IN	O
placebo	NN	O
(	(	O
P=.474	NNP	O
)	)	O
.	.	O

The	DT	O
percentage	NN	O
of	IN	O
patients	NNS	O
with	IN	O
pain	NN	O
relief	NN	O
(	(	O
reduction	NN	O
of	IN	O
predose	JJ	O
pain	NN	O
intensity	NN	O
to	TO	O
mild	VB	O
or	CC	O
none	NN	O
)	)	O
at	IN	O
2	CD	O
hours	NNS	O
was	VBD	O
66	CD	O
%	NN	O
for	IN	O
rizatriptan	JJ	O
versus	NN	O
56	CD	O
%	NN	O
for	IN	O
placebo	NN	O
(	(	O
P=.079	NNP	O
)	)	O
.	.	O

Placebo	NNP	O
response	NN	O
rates	NNS	O
were	VBD	O
higher	JJR	O
than	IN	O
those	DT	O
typically	RB	O
observed	VBN	O
in	IN	O
previous	JJ	O
studies	NNS	O
of	IN	O
rizatriptan	NN	O
in	IN	O
adults	NNS	O
.	.	O

Compared	VBN	O
with	IN	O
placebo	NN	O
,	,	O
rizatriptan	VBP	O
significantly	RB	O
improved	VBN	O
functional	JJ	O
disability	NN	O
at	IN	O
1.5	CD	O
and	CC	O
2	CD	O
hours	NNS	O
,	,	O
and	CC	O
nausea	NN	O
at	IN	O
1	CD	O
and	CC	O
1.5	CD	O
hours	NNS	O
.	.	O

Post	NNP	O
hoc	NN	O
analysis	NN	O
showed	VBD	O
a	DT	O
significant	JJ	O
benefit	NN	O
of	IN	O
rizatriptan	JJ	O
versus	NN	O
placebo	NN	O
in	IN	O
the	DT	O
percentage	NN	O
of	IN	O
patients	NNS	O
who	WP	O
had	VBD	O
pain	NN	O
relief	NN	O
when	WRB	O
their	PRP$	O
migraine	NN	O
attacks	NNS	O
were	VBD	O
treated	VBN	O
on	IN	O
weekends	NNS	O
(	(	O
65	CD	O
%	NN	O
versus	IN	O
36	CD	O
%	NN	O
,	,	O
P=.046	NNP	O
)	)	O
compared	VBN	O
with	IN	O
weekdays	NNS	O
(	(	O
66	CD	O
%	NN	O
versus	IN	O
61	CD	O
%	NN	O
,	,	O
P=.365	NNP	O
)	)	O
,	,	O
and	CC	O
the	DT	O
weekend	NN	O
placebo	NN	O
response	NN	O
rate	NN	O
was	VBD	O
similar	JJ	O
to	TO	O
that	DT	O
seen	VBN	O
in	IN	O
adults	NNS	O
.	.	O

CONCLUSIONS	NNP	O
Rizatriptan	NNP	O
5	CD	O
mg	NN	O
was	VBD	O
well	RB	O
tolerated	VBN	O
and	CC	O
effective	JJ	O
on	IN	O
some	DT	O
measures	NNS	O
when	WRB	O
used	VBN	O
in	IN	O
adolescents	NNS	O
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
a	DT	O
migraine	JJ	O
attack	NN	C
.	.	O

Cholesterol-lowering	JJ	O
effect	NN	O
of	IN	O
stanol	NN	O
ester	NN	O
in	IN	O
a	DT	O
US	NNP	O
population	NN	O
of	IN	O
mildly	RB	C
hypercholesterolemic	JJ	C
men	NNS	SE
and	CC	O
women	NNS	SE
:	:	O
a	DT	O
randomized	NN	O
controlled	VBN	O
trial	NN	O
.	.	O

OBJECTIVE	NN	O
To	TO	O
determine	VB	O
the	DT	O
efficacy	NN	O
of	IN	O
stanol	NN	O
esters	NNS	O
in	IN	O
lowering	VBG	O
cholesterol	NN	O
in	IN	O
a	DT	O
US	NNP	O
population	NN	O
.	.	O

SUBJECTS	NNP	O
AND	NNP	O
METHODS	NNP	O
After	IN	O
a	DT	O
run-in	JJ	O
phase	NN	O
,	,	O
318	CD	SS
subjects	NNS	O
were	VBD	O
randomized	VBN	O
to	TO	O
receive	VB	O
one	CD	O
of	IN	O
the	DT	O
following	JJ	O
margarine-like	JJ	O
spreads	NNS	O
containing	VBG	O
stanol	JJ	O
ester	NN	O
or	CC	O
placebo	NN	O
for	IN	O
8	CD	O
weeks	NNS	O
:	:	O
EU	NNP	O
3	CD	O
G	NNP	O
:	:	O
1	CD	O
g	NN	O
of	IN	O
stanol	NN	O
(	(	O
ester	JJ	O
form	NN	O
)	)	O
per	IN	O
8-g	JJ	O
serving	NN	O
of	IN	O
a	DT	O
European	JJ	O
formula	NN	O
3	CD	O
times	NNS	O
a	DT	O
day	NN	O
;	:	O
US	PRP	O
3	CD	O
G	NNP	O
:	:	O
1	CD	O
g	NN	O
of	IN	O
stanol	NN	O
(	(	O
ester	JJ	O
form	NN	O
)	)	O
per	IN	O
8-g	JJ	O
serving	NN	O
of	IN	O
a	DT	O
US	NNP	O
reformulation	NN	O
3	CD	O
times	NNS	O
a	DT	O
day	NN	O
;	:	O
US	PRP	O
2	CD	O
G	NNP	O
:	:	O
0.67	CD	O
g	NN	O
of	IN	O
stanol	NN	O
(	(	O
ester	JJ	O
form	NN	O
)	)	O
per	IN	O
8-g	JJ	O
serving	NN	O
of	IN	O
a	DT	O
US	NNP	O
reformulation	NN	O
3	CD	O
times	NNS	O
a	DT	O
day	NN	O
;	:	O
or	CC	O
placebo	VB	O
spread	NN	O
.	.	O

RESULTS	JJ	O
Mean	JJ	O
+/-	JJ	O
SD	NNP	O
baseline	NN	O
total	NN	O
cholesterol	NN	O
(	(	O
TC	NNP	O
)	)	O
and	CC	O
low-density	JJ	O
lipoprotein	NN	O
cholesterol	NN	O
(	(	O
LDL-C	NNP	O
)	)	O
levels	NNS	O
were	VBD	O
233+/-20	JJ	O
and	CC	O
153+21	CD	O
mg+/-dL	NN	O
,	,	O
respectively	RB	O
.	.	O

In	IN	O
the	DT	O
US	NNP	O
3	CD	O
G	NNP	O
group	NN	O
,	,	O
3	CD	O
g	JJ	O
daily	NN	O
of	IN	O
stanol	JJ	O
esters	NNS	O
lowered	VBD	O
TC	NNP	O
and	CC	O
LDL-C	NNP	O
levels	NNS	O
by	IN	O
6.4	CD	O
%	NN	O
and	CC	O
10.1	CD	O
%	NN	O
,	,	O
respectively	RB	O
.	.	O

There	EX	O
was	VBD	O
a	DT	O
dose-dependent	JJ	O
response	NN	O
compared	VBN	O
with	IN	O
2	CD	O
g	NNS	O
daily	RB	O
(	(	O
US	PRP	O
2	CD	O
G	NNP	O
)	)	O
.	.	O

Triglyceride	NNP	O
and	CC	O
high-density	NN	O
lipoprotein	NNS	O
cholesterol	NN	O
levels	NNS	O
were	VBD	O
unchanged	JJ	O
.	.	O

The	DT	O
incidence	NN	O
of	IN	O
adverse	JJ	O
effects	NNS	O
was	VBD	O
not	RB	O
different	JJ	O
from	IN	O
placebo	NN	O
.	.	O

Serum	NNP	O
vitamin	VBD	O
A	DT	O
and	CC	O
25-hydroxyvitamin	JJ	O
D	NNP	O
levels	NNS	O
were	VBD	O
not	RB	O
affected	VBN	O
.	.	O

CONCLUSIONS	NNP	O
Stanol	NNP	O
esters	NNS	O
lowered	VBD	O
TC	NNP	O
and	CC	O
LDL-C	NNP	O
levels	NNS	O
in	IN	O
a	DT	O
mildly	RB	C
hypercholesterolemic	JJ	C
US	NNP	O
population	NN	O
without	IN	O
evidence	NN	O
of	IN	O
adverse	JJ	O
effects	NNS	O
.	.	O

It	PRP	O
may	MD	O
be	VB	O
a	DT	O
useful	JJ	O
dietary	JJ	O
adjunct	NN	O
to	TO	O
lower	VB	O
cholesterol	NN	O
.	.	O

[	JJ	O
Rapidity	NNP	O
of	IN	O
pain	NN	O
relief	NN	O
,	,	O
medication	NN	O
requirement	NN	O
and	CC	O
patient	JJ	O
satisfaction	NN	O
with	IN	O
reflux	JJ	O
treatment	NN	O
in	IN	O
the	DT	O
physician	NN	O
's	POS	O
office	NN	O
]	NN	O
.	.	O

Treatment	NN	O
of	IN	O
gastroesophageal	NN	C
reflux	NN	C
disease	NN	C
(	(	O
GERD	NNP	C
)	)	O
with	IN	O
proton	NN	O
pump	NN	O
inhibitors	NNS	O
was	VBD	O
investigated	VBN	O
in	IN	O
three	CD	O
controlled	VBD	O
prospective	JJ	O
,	,	O
randomized	JJ	O
open	JJ	O
studies	NNS	O
.	.	O

Lansoprazole	NNP	O
,	,	O
omeprazole	JJ	O
MUPS	NNP	O
and	CC	O
esomeprazole	NN	O
were	VBD	O
compared	VBN	O
under	IN	O
doctor	NN	O
's	POS	O
office	NN	O
conditions	NNS	O
.	.	O

The	DT	O
outcomes	NNS	O
of	IN	O
interest	NN	O
were	VBD	O
the	DT	O
rapidity	NN	O
of	IN	O
pain	NN	O
relief	NN	O
achieved	VBN	O
with	IN	O
a	DT	O
single	JJ	O
dose	NN	O
,	,	O
effectiveness	NN	O
and	CC	O
patient	JJ	O
satisfaction	NN	O
with	IN	O
on	IN	O
demand	NN	O
therapy	NN	O
.	.	O

In	IN	O
the	DT	O
first	JJ	O
study	NN	O
,	,	O
180	CD	SS
patients	NNS	O
with	IN	O
chronic	JJ	C
and	CC	C
prolonged	JJ	C
episodes	NNS	C
of	IN	C
reflux	NN	C
were	VBD	O
investigated	VBN	O
.	.	O

Time	NN	O
to	TO	O
pain	VB	O
relief	NN	O
following	VBG	O
a	DT	O
single	JJ	O
dose	NN	O
was	VBD	O
1.1	CD	O
+/-	JJ	O
0.8	CD	O
hours	NNS	O
with	IN	O
30	CD	O
mg	NNS	O
lansoprazole	JJ	O
,	,	O
3.0	CD	O
+/-	JJ	O
2.5	CD	O
hours	NNS	O
with	IN	O
20	CD	O
mgomeprazole	JJ	O
MUPS	NNP	O
and	CC	O
2.1	CD	O
+/-	JJ	O
1.2	CD	O
hours	NNS	O
with	IN	O
40	CD	O
mg	NNS	O
esomeprazole	JJ	O
.	.	O

Studies	NNS	O
2	CD	O
and	CC	O
3	CD	O
were	VBD	O
designed	VBN	O
as	IN	O
cross-over	NN	O
studies	NNS	O
intended	VBN	O
to	TO	O
investigate	VB	O
drug	NN	O
consumption	NN	O
.	.	O

In	IN	O
study	NN	O
2	CD	O
,	,	O
the	DT	O
amount	NN	O
of	IN	O
lansoprazole	NN	O
consumed	VBN	O
was	VBD	O
approximately	RB	O
50	CD	O
%	NN	O
less	JJR	O
than	IN	O
that	DT	O
of	IN	O
omeprazole	NN	O
,	,	O
and	CC	O
this	DT	O
translated	VBN	O
to	TO	O
81	CD	O
%	NN	O
patient	JJ	O
satisfaction	NN	O
with	IN	O
lansoprazole	JJ	O
compared	VBN	O
with	IN	O
only	RB	O
9.5	CD	O
%	NN	O
for	IN	O
omeprazole	NN	O
.	.	O

In	IN	O
study	NN	O
3	CD	O
comparing	VBG	O
lansoprazole	NN	O
and	CC	O
esomeprazole	NN	O
,	,	O
consumption	NN	O
of	IN	O
the	DT	O
former	JJ	O
was	VBD	O
85	CD	O
%	NN	O
that	WDT	O
of	IN	O
the	DT	O
latter	NN	O
.	.	O

58	CD	O
%	NN	O
of	IN	O
the	DT	O
patients	NNS	O
opted	VBD	O
to	TO	O
continuetreatment	VB	O
with	IN	O
lansoprazole	NN	O
,	,	O
compared	VBN	O
with	IN	O
only	RB	O
25	CD	O
%	NN	O
in	IN	O
the	DT	O
case	NN	O
of	IN	O
esomeprazole	NN	O
.	.	O

The	DT	O
appreciably	RB	O
greater	JJR	O
patient	JJ	O
satisfaction	NN	O
with	IN	O
lansoprazole	NN	O
was	VBD	O
due	JJ	O
tothe	NN	O
faster	RBR	O
pain	NN	O
relief	NN	O
achieved	VBN	O
with	IN	O
this	DT	O
drug	NN	O
.	.	O

Phase	NNP	O
III	NNP	O
trial	NN	O
comparing	VBG	O
whole-pelvic	JJ	O
versus	NN	O
prostate-only	JJ	O
radiotherapy	NN	O
and	CC	O
neoadjuvant	JJ	O
versus	NN	O
adjuvant	NN	O
combined	VBN	O
androgen	JJ	O
suppression	NN	O
:	:	O
Radiation	NN	O
Therapy	NNP	O
Oncology	NNP	O
Group	NNP	O
9413	CD	O
.	.	O

PURPOSE	VB	O
This	DT	O
trial	NN	O
tested	VBD	O
the	DT	O
hypothesis	NN	O
that	WDT	O
combined	VBD	O
androgen	DT	O
suppression	NN	O
(	(	O
CAS	NNP	O
)	)	O
and	CC	O
whole-pelvic	JJ	O
(	(	O
WP	NNP	O
)	)	O
radiotherapy	NN	O
(	(	O
RT	NNP	O
)	)	O
followed	VBN	O
by	IN	O
a	DT	O
boost	NN	O
to	TO	O
the	DT	O
prostate	NN	O
improves	VBZ	O
progression-free	JJ	O
survival	NN	O
(	(	O
PFS	NNP	O
)	)	O
by	IN	O
10	CD	O
%	NN	O
compared	VBN	O
with	IN	O
CAS	NNP	O
and	CC	O
prostate-only	RB	O
(	(	O
PO	NNP	O
)	)	O
RT	NNP	O
.	.	O

This	DT	O
trial	NN	O
also	RB	O
tested	VBD	O
the	DT	O
hypothesis	NN	O
that	WDT	O
neoadjuvant	JJ	O
and	CC	O
concurrent	JJ	O
hormonal	JJ	O
therapy	NN	O
(	(	O
NCHT	NNP	O
)	)	O
improves	VBZ	O
PFS	NNP	O
compared	VBN	O
with	IN	O
adjuvant	JJ	O
hormonal	JJ	O
therapy	NN	O
(	(	O
AHT	NNP	O
)	)	O
by	IN	O
10	CD	O
%	NN	O
.	.	O

MATERIALS	NNP	O
AND	CC	O
METHODS	NNP	O
Eligibility	NNP	C
included	VBD	C
localized	JJ	C
prostate	NN	C
cancer	NN	C
with	IN	C
an	DT	C
elevated	JJ	C
prostate-specific	JJ	C
antigen	NN	C
(	(	C
PSA	NNP	C
)	)	C
<	VBD	C
or	CC	C
=	$	C
100	CD	C
ng/mL	NN	C
and	CC	C
an	DT	C
estimated	VBN	C
risk	NN	C
of	IN	C
lymph	JJ	C
node	NN	C
(	(	C
LN	NNP	C
)	)	C
involvement	NN	C
of	IN	C
15	CD	C
%	NN	C
.	.	C

Between	NNP	O
April	NNP	O
1	CD	O
,	,	O
1995	CD	O
,	,	O
and	CC	O
June	NNP	O
1	CD	O
,	,	O
1999	CD	O
,	,	O
1,323	CD	O
patients	NNS	O
were	VBD	O
accrued	VBN	O
.	.	O

Patients	NNS	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
WP	NNP	O
+	NNP	O
NCHT	NNP	O
,	,	O
PO	NNP	O
+	NNP	O
NCHT	NNP	O
,	,	O
WP	NNP	O
+	NNP	O
AHT	NNP	O
,	,	O
or	CC	O
PO	NNP	O
+	NNP	O
AHT	NNP	O
.	.	O

Failure	NN	O
for	IN	O
PFS	NNP	O
was	VBD	O
defined	VBN	O
as	IN	O
the	DT	O
first	JJ	O
occurrence	NN	O
of	IN	O
local	JJ	O
,	,	O
regional	JJ	O
,	,	O
or	CC	O
distant	JJ	O
disease	NN	O
;	:	O
PSA	NNP	O
failure	NN	O
;	:	O
or	CC	O
death	NN	O
for	IN	O
any	DT	O
cause	NN	O
.	.	O

RESULTS	NNP	O
With	IN	O
a	DT	O
median	JJ	O
follow-up	NN	O
of	IN	O
59.5	CD	O
months	NNS	O
,	,	O
WP	NNP	O
RT	NNP	O
was	VBD	O
associated	VBN	O
with	IN	O
a	DT	O
4-year	JJ	O
PFS	NNP	O
of	IN	O
54	CD	O
%	NN	O
compared	VBN	O
with	IN	O
47	CD	O
%	NN	O
in	IN	O
patients	NNS	O
treated	VBN	O
with	IN	O
PO	NNP	O
RT	NNP	O
(	(	O
P	NNP	O
=.022	NNP	O
)	)	O
.	.	O

Patients	NNS	O
treated	VBD	O
with	IN	O
NCHT	NNP	O
experienced	VBD	O
a	DT	O
4-year	JJ	O
PFS	NNP	O
of	IN	O
52	CD	O
%	NN	O
versus	IN	O
49	CD	O
%	NN	O
for	IN	O
AHT	NNP	O
(	(	O
P	NNP	O
=.56	NNP	O
)	)	O
.	.	O

When	WRB	O
comparing	VBG	O
all	DT	O
four	CD	O
arms	NNS	O
,	,	O
there	EX	O
was	VBD	O
a	DT	O
progression-free	JJ	O
difference	NN	O
among	IN	O
WP	NNP	O
RT	NNP	O
+	NNP	O
NCHT	NNP	O
,	,	O
PO	NNP	O
RT	NNP	O
+	NNP	O
NCHT	NNP	O
,	,	O
WP	NNP	O
RT	NNP	O
+	NNP	O
AHT	NNP	O
,	,	O
and	CC	O
PO	NNP	O
RT	NNP	O
+	NNP	O
AHT	NNP	O
(	(	O
60	CD	O
%	NN	O
v	JJ	O
44	CD	O
%	NN	O
v	JJ	O
49	CD	O
%	NN	O
v	JJ	O
50	CD	O
%	NN	O
,	,	O
respectively	RB	O
;	:	O
P	NNP	O
=.008	NNP	O
)	)	O
.	.	O

No	UH	O
survival	JJ	O
advantage	NN	O
has	VBZ	O
yet	RB	O
been	VBN	O
seen	VBN	O
.	.	O

CONCLUSION	NNP	O
WP	NNP	O
RT	NNP	O
+	NNP	O
NCHT	NNP	O
improves	VBZ	O
PFS	NNP	O
compared	VBN	O
with	IN	O
PO	NNP	O
RT	NNP	O
and	CC	O
NCHT	NNP	O
or	CC	O
PO	NNP	O
RT	NNP	O
and	CC	O
AHT	NNP	O
,	,	O
and	CC	O
compared	VBN	O
with	IN	O
WP	NNP	O
RT	NNP	O
+	NNP	O
AHT	NNP	O
in	IN	O
patients	NNS	O
with	IN	O
a	DT	O
risk	NN	O
of	IN	O
LN	NNP	O
involvement	NN	O
of	IN	O
15	CD	O
%	NN	O
.	.	O

Scaling	VBG	O
clinical	JJ	O
judgments	NNS	O
of	IN	O
symptom	JJ	O
pathology	NN	O
by	IN	O
means	NNS	O
of	IN	O
the	DT	O
psychophysiological	JJ	O
method	NN	O
of	IN	O
magnitude	NN	O
estimation	NN	O
.	.	O

Summing	VBG	O
scores	NNS	O
across	IN	O
heterogeneous	JJ	O
symptom	NN	O
items	NNS	O
without	IN	O
consideration	NN	O
of	IN	O
their	PRP$	O
differing	JJ	O
psychopathological	JJ	O
significance	NN	O
has	VBZ	O
been	VBN	O
criticized	VBN	O
as	IN	O
producing	VBG	O
an	DT	O
inadequate	JJ	O
picture	NN	O
of	IN	O
an	DT	O
individual	NN	O
's	POS	O
clinical	JJ	O
status	NN	O
.	.	O

The	DT	O
purpose	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
derive	JJ	O
symptom	JJ	O
item	NN	O
weights	NNS	O
representing	VBG	O
clinically	RB	O
judged	VBN	O
seriousness	NN	O
of	IN	O
each	DT	O
symptom	NN	O
through	IN	O
the	DT	O
application	NN	O
of	IN	O
Steven	NNP	O
's	POS	O
psychophysical	JJ	O
method	NN	O
of	IN	O
magnitude	NN	O
estimation	NN	O
.	.	O

A	DT	O
nationwide	JJ	O
sample	NN	O
of	IN	O
129	CD	O
clinicians	NNS	O
rated	VBD	O
the	DT	O
pathological	JJ	O
significance	NN	O
of	IN	O
221	CD	O
symptom	JJ	O
items	NNS	O
in	IN	O
a	DT	O
design	NN	O
such	JJ	O
that	IN	O
every	DT	O
rater	NN	O
rated	VBD	O
121	CD	O
items	NNS	O
,	,	O
21	CD	O
of	IN	O
which	WDT	O
were	VBD	O
rated	VBN	O
by	IN	O
all	DT	O
raters	NNS	O
and	CC	O
100	CD	O
of	IN	O
which	WDT	O
were	VBD	O
rated	VBN	O
only	RB	O
by	IN	O
the	DT	O
A	NNP	O
or	CC	O
B	NNP	O
subgroup	NN	O
to	TO	O
which	WDT	O
each	DT	O
rater	NN	O
was	VBD	O
randomly	RB	O
assigned	VBN	O
.	.	O

Each	DT	O
item	NN	O
was	VBD	O
rated	VBN	O
as	IN	O
to	TO	O
the	DT	O
seriousness	NN	O
of	IN	O
the	DT	O
pathology	NN	O
it	PRP	O
would	MD	O
represent	VB	O
if	IN	O
manifested	VBN	O
by	IN	O
either	CC	O
a	DT	O
boy	NN	O
child	NN	O
,	,	O
girl	JJ	O
child	NN	O
,	,	O
boy	JJ	O
adolescent	NN	O
,	,	O
or	CC	O
girl	JJ	O
adolescent	NN	O
,	,	O
with	IN	O
one-fourth	NN	O
of	IN	O
the	DT	O
raters	NNS	O
assigned	VBD	O
to	TO	O
each	DT	O
condition	NN	O
.	.	O

The	DT	O
results	NNS	O
of	IN	O
211	CD	O
two-way	JJ	O
analyses	NNS	O
of	IN	O
variance	NN	O
revealed	VBD	O
that	IN	O
age	NN	O
and	CC	O
age	NN	O
and	CC	O
sex	NN	O
in	IN	O
interaction	NN	O
,	,	O
but	CC	O
not	RB	O
sex	VB	O
alone	RB	O
,	,	O
significantly	RB	O
influenced	VBD	O
the	DT	O
clinical	JJ	O
ratings	NNS	O
.	.	O

The	DT	O
resulting	VBG	O
magnitude	JJ	O
estimation	NN	O
ratings	NNS	O
of	IN	O
symptom	JJ	O
pathology	NN	O
ranged	VBD	O
from	IN	O
1.0	CD	O
to	TO	O
9.9	CD	O
.	.	O

They	PRP	O
were	VBD	O
demonstrated	VBN	O
to	TO	O
have	VB	O
satisfactoy	VBN	O
reliability	NN	O
and	CC	O
convergent	NN	O
validity	NN	O
and	CC	O
to	TO	O
have	VB	O
the	DT	O
psychophysical	JJ	O
characteristics	NNS	O
of	IN	O
a	DT	O
prothetic	JJ	O
continuum	NN	O
.	.	O

Pethidine	NNP	O
versus	NN	O
tramadol	NN	O
for	IN	O
pain	NN	O
relief	NN	O
during	IN	O
labor	NN	C
.	.	O

OBJECTIVE	UH	O
To	TO	O
evaluate	VB	O
and	CC	O
compare	VB	O
the	DT	O
analgesic	JJ	O
efficacy	NN	O
and	CC	O
adverse	JJ	O
effects	NNS	O
of	IN	O
tramadol	NN	O
and	CC	O
pethidine	NN	O
in	IN	O
labor	NN	O
.	.	O

METHOD	NNP	O
Fifty-nine	NNP	SS
full	JJ	O
term	NN	O
parturients	NNS	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
one	CD	O
of	IN	O
two	CD	O
groups	NNS	O
in	IN	O
active	JJ	C
labor	NN	C
.	.	O

Group	NNP	O
1	CD	O
received	VBD	O
100	CD	O
mg	NNS	O
pethidine	VBP	O
;	:	O
group	NN	O
2	CD	O
,	,	O
100	CD	O
mg	NN	O
tramadol	NN	O
,	,	O
intramuscularly	RB	O
.	.	O

Analgesic	JJ	O
efficacy	NN	O
,	,	O
maternal	JJ	O
side	NN	O
effects	NNS	O
,	,	O
changes	NNS	O
in	IN	O
the	DT	O
blood	NN	O
pressure	NN	O
,	,	O
heart	NN	O
rate	NN	O
,	,	O
and	CC	O
duration	NN	O
of	IN	O
labor	NN	O
were	VBD	O
assessed	VBN	O
.	.	O

RESULT	NNP	O
At	IN	O
30	CD	O
and	CC	O
60	CD	O
min	NNS	O
after	IN	O
drug	NN	O
administration	NN	O
,	,	O
pain	VBP	O
relief	NN	O
was	VBD	O
greater	JJR	O
in	IN	O
the	DT	O
pethidine	NN	O
group	NN	O
than	IN	O
in	IN	O
tramadol	JJ	O
group	NN	O
.	.	O

The	DT	O
incidence	NN	O
of	IN	O
nausea	NN	O
and	CC	O
fatigue	NN	O
was	VBD	O
higher	RBR	O
in	IN	O
the	DT	O
tramadol	NN	O
group	NN	O
.	.	O

Following	VBG	O
drug	NN	O
administration	NN	O
the	DT	O
decrease	NN	O
in	IN	O
systolic	JJ	O
and	CC	O
diastolic	JJ	O
blood	NN	O
pressure	NN	O
and	CC	O
the	DT	O
increase	NN	O
in	IN	O
heart	NN	O
rate	NN	O
were	VBD	O
statistically	RB	O
significant	JJ	O
in	IN	O
both	DT	O
groups	NNS	O
.	.	O

No	DT	O
significant	JJ	O
difference	NN	O
was	VBD	O
found	VBN	O
between	IN	O
the	DT	O
groups	NNS	O
when	WRB	O
compared	VBN	O
for	IN	O
duration	NN	O
of	IN	O
labor	NN	O
and	CC	O
Apgar	NNP	O
scores	NNS	O
.	.	O

None	NN	O
of	IN	O
the	DT	O
neonates	NNS	O
developed	VBD	O
respiratory	JJ	O
depression	NN	O
.	.	O

CONCLUSION	NNP	O
Pethidine	NNP	O
seems	VBZ	O
to	TO	O
be	VB	O
a	DT	O
better	RBR	O
alternative	JJ	O
than	IN	O
tramadol	NN	O
in	IN	O
obstetric	JJ	O
analgesia	NN	O
because	IN	O
of	IN	O
its	PRP$	O
superiority	NN	O
in	IN	O
analgesic	JJ	O
efficacy	NN	O
and	CC	O
low	JJ	O
incidence	NN	O
of	IN	O
maternal	JJ	O
side	NN	O
effects	NNS	O
.	.	O

A	DT	O
comparison	NN	O
of	IN	O
single-dose	JJ	O
cefixime	NN	O
with	IN	O
ceftriaxone	NN	O
as	IN	O
treatment	NN	O
for	IN	O
uncomplicated	JJ	O
gonorrhea	NN	C
.	.	O

The	DT	O
Gonorrhea	NNP	O
Treatment	NNP	O
Study	NNP	O
Group	NNP	O
.	.	O

BACKGROUND	NNP	O
Because	IN	O
of	IN	O
the	DT	O
widespread	JJ	O
existence	NN	O
of	IN	O
Neisseria	NNP	O
gonorrhoeae	NN	O
resistant	NN	O
to	TO	O
penicillin	VB	O
or	CC	O
tetracycline	VB	O
,	,	O
ceftriaxone	NN	O
is	VBZ	O
now	RB	O
recommended	VBN	O
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
gonorrhea	NN	O
.	.	O

There	EX	O
is	VBZ	O
,	,	O
however	RB	O
,	,	O
a	DT	O
need	NN	O
for	IN	O
effective	JJ	O
antibiotics	NNS	O
that	WDT	O
can	MD	O
be	VB	O
administered	VBN	O
orally	RB	O
as	IN	O
an	DT	O
alternative	NN	O
to	TO	O
ceftriaxone	NN	O
,	,	O
which	WDT	O
requires	VBZ	O
intramuscular	JJ	O
administration	NN	O
.	.	O

Cefixime	NNP	O
is	VBZ	O
an	DT	O
orally	RB	O
absorbed	JJ	O
cephalosporin	NN	O
that	WDT	O
is	VBZ	O
active	JJ	O
against	IN	O
resistant	JJ	O
gonococci	NN	O
and	CC	O
has	VBZ	O
pharmacokinetic	JJ	O
activity	NN	O
suitable	JJ	O
for	IN	O
single-dose	JJ	O
administration	NN	O
.	.	O

METHODS	NNP	O
AND	CC	O
RESULTS	NNP	O
In	IN	O
a	DT	O
randomized	JJ	O
,	,	O
unblinded	JJ	O
multicenter	NN	O
study	NN	O
of	IN	O
209	CD	SS
men	NNS	O
and	CC	O
124	CD	SS
women	NNS	O
with	IN	O
uncomplicated	JJ	O
gonorrhea	NN	C
,	,	O
we	PRP	O
compared	VBN	O
three	CD	O
single-dose	JJ	O
treatment	NN	O
regimens	NNS	O
:	:	O
400	CD	O
mg	NN	O
or	CC	O
800	CD	O
mg	NN	O
of	IN	O
cefixime	NN	O
,	,	O
administered	VBN	O
orally	RB	O
,	,	O
and	CC	O
250	CD	O
mg	NN	O
of	IN	O
ceftriaxone	NN	O
administered	VBN	O
intramuscularly	RB	O
.	.	O

The	DT	O
overall	JJ	O
cure	NN	O
rates	NNS	O
were	VBD	O
96	CD	O
percent	NN	O
for	IN	O
the	DT	O
400-mg	JJ	O
dose	NN	O
of	IN	O
cefixime	NN	O
(	(	O
89	CD	O
of	IN	O
93	CD	O
patients	NNS	O
)	)	O
(	(	O
95	CD	O
percent	NN	O
confidence	NN	O
interval	NN	O
,	,	O
93.5	CD	O
percent	NN	O
to	TO	O
97.8	CD	O
percent	NN	O
)	)	O
;	:	O
98	CD	O
percent	NN	O
for	IN	O
the	DT	O
800-mg	JJ	O
dose	NN	O
of	IN	O
cefixime	NN	O
(	(	O
86	CD	O
of	IN	O
88	CD	O
patients	NNS	O
)	)	O
(	(	O
95	CD	O
percent	NN	O
confidence	NN	O
interval	NN	O
,	,	O
94.6	CD	O
percent	NN	O
to	TO	O
100	CD	O
percent	NN	O
)	)	O
;	:	O
and	CC	O
98	CD	O
percent	NN	O
for	IN	O
ceftriaxone	NN	O
(	(	O
92	CD	O
of	IN	O
94	CD	O
patients	NNS	O
)	)	O
(	(	O
95	CD	O
percent	NN	O
confidence	NN	O
interval	NN	O
,	,	O
94.9	CD	O
to	TO	O
100	CD	O
percent	NN	O
)	)	O
.	.	O

The	DT	O
cure	NN	O
rates	NNS	O
were	VBD	O
similar	JJ	O
in	IN	O
men	NNS	O
and	CC	O
women	NNS	O
,	,	O
and	CC	O
pharyngeal	JJ	O
infection	NN	O
was	VBD	O
eradicated	VBN	O
in	IN	O
20	CD	O
of	IN	O
22	CD	O
patients	NNS	O
(	(	O
91	CD	O
percent	NN	O
)	)	O
.	.	O

Thirty-nine	JJ	O
percent	NN	O
of	IN	O
303	CD	O
pretreatment	JJ	O
gonococcal	JJ	O
isolates	NNS	O
had	VBD	O
one	CD	O
or	CC	O
more	JJR	O
types	NNS	O
of	IN	O
antimicrobial	JJ	O
resistance	NN	O
;	:	O
the	DT	O
efficacy	NN	O
of	IN	O
all	DT	O
three	CD	O
regimens	NNS	O
was	VBD	O
independent	JJ	O
of	IN	O
the	DT	O
resistance	NN	O
pattern	NN	O
.	.	O

Chlamydia	NNP	O
trachomatis	NN	O
infection	NN	O
persisted	VBN	O
in	IN	O
at	IN	O
least	JJS	O
half	PDT	O
the	DT	O
patients	NNS	O
infected	VBN	O
in	IN	O
each	DT	O
treatment	NN	O
group	NN	O
.	.	O

All	DT	O
three	CD	O
regimens	NNS	O
were	VBD	O
well	RB	O
tolerated	VBN	O
.	.	O

CONCLUSIONS	NNP	O
In	IN	O
the	DT	O
treatment	NN	O
of	IN	O
uncomplicated	JJ	O
gonorrhea	NN	O
,	,	O
a	DT	O
single	JJ	O
dose	NN	O
of	IN	O
cefixime	NN	O
(	(	O
400	CD	O
or	CC	O
800	CD	O
mg	NN	O
)	)	O
given	VBN	O
orally	RB	O
appears	VBZ	O
to	TO	O
be	VB	O
as	RB	O
effective	JJ	O
as	IN	O
the	DT	O
currently	RB	O
recommended	VBN	O
regimen	NNS	O
of	IN	O
ceftriaxone	NN	O
(	(	O
250	CD	O
mg	NN	O
given	VBN	O
intramuscularly	RB	O
)	)	O
.	.	O

Assessing	VBG	O
drug	NN	O
use	NN	O
prevalence	NN	O
in	IN	O
the	DT	O
workplace	NN	O
:	:	O
a	DT	O
comparison	NN	O
of	IN	O
self-report	JJ	O
methods	NNS	O
and	CC	O
urinalysis	NN	O
.	.	O

A	DT	O
random	JJ	O
sample	NN	O
of	IN	O
800	CD	O
employees	NNS	O
of	IN	O
a	DT	O
steel	NN	O
manufacturing	VBG	O
company	NN	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
one	CD	O
of	IN	O
four	CD	O
self-report	JJ	O
methods	NNS	O
of	IN	O
assessing	VBG	O
illicit	JJ	O
drug	NN	O
use	NN	O
:	:	O
1	CD	O
)	)	O
Individual	NNP	O
interview	NN	O
in	IN	O
the	DT	O
workplace	NN	O
,	,	O
2	CD	O
)	)	O
group-administered	JJ	O
questionnaire	NN	O
in	IN	O
the	DT	O
workplace	NN	O
,	,	O
3	CD	O
)	)	O
telephone	NN	O
interview	NN	O
,	,	O
and	CC	O
4	CD	O
)	)	O
individual	JJ	O
interview	NN	O
off	IN	O
the	DT	O
worksite	NN	O
.	.	O

All	DT	O
621	CD	O
subjects	NNS	O
participating	VBG	O
in	IN	O
the	DT	O
research	NN	O
were	VBD	O
also	RB	O
tested	VBN	O
by	IN	O
urinalysis	NN	O
.	.	O

Rates	NNS	O
of	IN	O
drug	NN	O
use	IN	O
self-report	NN	O
were	VBD	O
highest	JJS	O
in	IN	O
the	DT	O
workplace	NN	O
interview	NN	O
condition	NN	O
and	CC	O
lowest	JJS	O
in	IN	O
the	DT	O
overall	JJ	O
group	NN	O
questionnaire	NN	O
condition	NN	O
.	.	O

Although	IN	O
the	DT	O
overall	JJ	O
prevalence	NN	O
rates	NNS	O
produced	VBN	O
by	IN	O
self-reports	NNS	O
and	CC	O
urinalysis	NN	O
were	VBD	O
similar	JJ	O
,	,	O
there	EX	O
was	VBD	O
little	JJ	O
concordance	NN	O
between	IN	O
urinalysis	NN	O
positives	NNS	O
and	CC	O
self-report	JJ	O
positives	NNS	O
.	.	O

The	DT	O
results	NNS	O
indicated	VBD	O
that	IN	O
self-reports	NNS	O
and	CC	O
urinalysis	NN	O
are	VBP	O
complementary	JJ	O
methods	NNS	O
of	IN	O
drug	NN	O
use	NN	O
assessment	NN	O
,	,	O
and	CC	O
are	VBP	O
best	JJS	O
used	VBN	O
in	IN	O
combination	NN	O
.	.	O

[	JJ	O
Effects	NNS	O
of	IN	O
dujieqing	VBG	O
oral	JJ	O
liquid	NN	O
on	IN	O
the	DT	O
promoter	NN	O
methylation	NN	O
of	IN	O
the	DT	O
MGMT	NNP	O
gene	NN	O
in	IN	O
middle-and-late	JJ	C
stage	NN	C
tumor	NN	C
patients	NNS	O
receiving	VBG	C
chemotherapy	NN	C
]	NN	O
.	.	O

OBJECTIVE	UH	O
To	TO	O
observe	VB	O
the	DT	O
effects	NNS	O
of	IN	O
Dujieqing	VBG	O
Oral	NNP	O
Liquid	NNP	O
(	(	O
DJQ	NNP	O
)	)	O
on	IN	O
the	DT	O
promoter	NN	O
methylation	NN	O
of	IN	O
the	DT	O
O6-methylguanine-DNA	JJ	O
methyltransferase	NN	O
(	(	O
MGMT	NNP	O
)	)	O
gene	NN	O
in	IN	O
the	DT	O
plasma	NN	O
DNA	NNP	O
samples	NNS	O
from	IN	O
middle-and-late	JJ	C
stage	NN	C
tumor	NN	C
patients	NNS	O
receiving	VBG	C
chemotherapy	NN	C
.	.	O

METHODS	NNP	O
Recruited	VBD	O
60	CD	SS
patients	NNS	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
the	DT	O
treatment	NN	O
group	NN	O
(	(	O
treated	VBN	O
by	IN	O
conventional	JJ	O
chemotherapy	NN	O
combined	VBN	O
DJQ	NNP	O
,	,	O
20	CD	O
mL	NN	O
each	DT	O
time	NN	O
,	,	O
three	CD	O
times	NNS	O
daily	RB	O
)	)	O
and	CC	O
the	DT	O
control	NN	O
group	NN	O
(	(	O
treated	VBN	O
by	IN	O
chemotherapy	NN	O
alone	RB	O
)	)	O
,	,	O
30	CD	O
in	IN	O
each	DT	O
group	NN	O
.	.	O

The	DT	O
therapeutic	JJ	O
course	NN	O
was	VBD	O
8	CD	O
weeks	NNS	O
.	.	O

The	DT	O
promoter	NN	O
methylation	NN	O
of	IN	O
the	DT	O
MGMT	NNP	O
gene	NN	O
in	IN	O
the	DT	O
plasma	NN	O
DNA	NNP	O
samples	VBZ	O
form	VB	O
middle-and-late	JJ	C
stage	NN	C
tumor	NN	C
patients	NNS	O
receiving	VBG	C
chemotherapy	NN	C
was	VBD	O
detected	VBN	O
before	IN	O
and	CC	O
after	IN	O
treatment	NN	O
using	VBG	O
nested	JJ	O
methylation-specific	JJ	O
polymerase	NN	O
chain	NN	O
reaction	NN	O
(	(	O
MSP	NNP	O
)	)	O
.	.	O

Meanwhile	RB	O
,	,	O
the	DT	O
peripheral	JJ	O
hemogram	NN	O
was	VBD	O
detected	VBN	O
.	.	O

The	DT	O
clinical	JJ	O
efficacy	NN	O
and	CC	O
toxic/adverse	JJ	O
reactions	NNS	O
were	VBD	O
assessed	VBN	O
using	VBG	O
Karnofsky	NNP	O
performance	NN	O
scale	NN	O
(	(	O
KPS	NNP	O
)	)	O
.	.	O

RESULTS	JJ	O
Results	NNP	O
of	IN	O
the	DT	O
promoter	NN	O
methylation	NN	O
of	IN	O
MGMT	NNP	O
genes	NNS	O
showed	VBD	O
that	IN	O
methylation	NN	O
rate	NN	O
was	VBD	O
20.00	CD	O
%	NN	O
in	IN	O
the	DT	O
treatment	NN	O
group	NN	O
and	CC	O
46.67	CD	O
%	NN	O
in	IN	O
the	DT	O
control	NN	O
group	NN	O
(	(	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
.	.	O

Compared	VBN	O
with	IN	O
before	RB	O
treatment	NN	O
,	,	O
the	DT	O
KPS	NNP	O
was	VBD	O
significantly	RB	O
improved	VBN	O
in	IN	O
the	DT	O
treatment	NN	O
group	NN	O
after	IN	O
treatment	NN	O
,	,	O
while	IN	O
it	PRP	O
significantly	RB	O
decreased	VBD	O
in	IN	O
the	DT	O
control	NN	O
group	NN	O
after	IN	O
treatment	NN	O
(	(	O
both	DT	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
.	.	O

There	EX	O
was	VBD	O
statistical	JJ	O
difference	NN	O
in	IN	O
the	DT	O
KPS	NNP	O
between	IN	O
the	DT	O
two	CD	O
groups	NNS	O
after	IN	O
treatment	NN	O
(	(	O
P	NNP	O
<	NNP	O
0.01	CD	O
)	)	O
.	.	O

The	DT	O
toxic/adverse	JJ	O
reactions	NNS	O
were	VBD	O
milder	VBN	O
in	IN	O
the	DT	O
treatment	NN	O
group	NN	O
than	IN	O
in	IN	O
the	DT	O
control	NN	O
group	NN	O
(	(	O
P	NNP	O
<	NNP	O
0.01	CD	O
)	)	O
.	.	O

CONCLUSIONS	NNP	O
DJQ	NNP	O
showed	VBD	O
efficiency	NN	O
synergism	NN	O
and	CC	O
toxicity	NN	O
reducing	NN	O
effects	NNS	O
,	,	O
but	CC	O
with	IN	O
no	DT	O
effect	NN	O
on	IN	O
the	DT	O
hematopoietic	JJ	O
function	NN	O
of	IN	O
the	DT	O
bone	NN	O
marrow	NN	O
.	.	O

MGMT	NNP	O
gene	NN	O
was	VBD	O
indicated	VBN	O
as	IN	O
DJQ	NNP	O
's	POS	O
target	NN	O
point	NN	O
for	IN	O
efficiency	NN	O
synergism	NN	O
and	CC	O
toxicity	NN	O
reducing	NN	O
.	.	O

The	DT	O
efficiency	NN	O
synergism	NN	O
and	CC	O
toxicity	NN	O
reducing	VBG	O
effects	NNS	O
were	VBD	O
achieved	VBN	O
by	IN	O
regulating	VBG	O
the	DT	O
activities	NNS	O
of	IN	O
MGMT	NNP	O
gene	NN	O
.	.	O

Effect	NN	O
of	IN	O
cervical	JJ	O
spine	NN	O
manipulative	JJ	O
therapy	NN	O
on	IN	O
judo	NN	O
athletes	NNS	O
'	POS	O
grip	NN	O
strength	NN	O
.	.	O

OBJECTIVE	CC	O
The	DT	O
objective	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
perform	VB	O
an	DT	O
investigation	NN	O
evaluating	VBG	O
if	IN	O
cervical	JJ	O
spinal	JJ	O
manipulative	JJ	O
therapy	NN	O
(	(	O
SMT	NNP	O
)	)	O
can	MD	O
increase	VB	O
grip	JJ	O
strength	NN	O
on	IN	O
judo	NN	O
athletes	NNS	O
in	IN	O
a	DT	O
top	JJ	O
10	CD	O
national-ranked	JJ	O
team	NN	O
.	.	O

METHODS	VB	O
A	DT	O
single-blinded	JJ	O
,	,	O
prospective	JJ	O
,	,	O
comparative	JJ	O
,	,	O
pilot	NN	O
,	,	O
randomized	VBN	O
,	,	O
clinical	JJ	O
trial	NN	O
was	VBD	O
performed	VBN	O
with	IN	O
18	CD	SS
athletes	NNS	SS
of	IN	O
both	DT	SE
sexes	NNS	SE
from	IN	O
a	DT	O
judo	NN	O
team	NN	O
currently	RB	O
competing	VBG	O
on	IN	O
a	DT	O
national	JJ	O
level	NN	O
.	.	O

The	DT	O
athletes	NNS	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
2	CD	O
groups	NNS	O
:	:	O
chiropractic	JJ	O
SMT	NNP	O
and	CC	O
sham	NN	O
.	.	O

Three	CD	O
interventions	NNS	O
were	VBD	O
performed	VBN	O
on	IN	O
each	DT	O
of	IN	O
the	DT	O
athletes	NNS	O
at	IN	O
different	JJ	O
time	NN	O
points	NNS	O
.	.	O

Force	NN	O
measurements	NNS	O
were	VBD	O
obtained	VBN	O
by	IN	O
a	DT	O
hydraulic	JJ	O
dynamometer	NN	O
immediately	RB	O
before	IN	O
and	CC	O
after	IN	O
each	DT	O
intervention	NN	O
at	IN	O
the	DT	O
same	JJ	O
period	NN	O
before	IN	O
training	VBG	O
up	RP	O
to	TO	O
3	CD	O
weeks	NNS	O
with	IN	O
at	IN	O
least	JJS	O
36	CD	O
hours	NNS	O
between	IN	O
interventions	NNS	O
.	.	O

RESULTS	NNP	O
Analysis	NNP	O
of	IN	O
grip	NN	O
strength	NN	O
data	NNS	O
revealed	VBD	O
a	DT	O
statistically	RB	O
significant	JJ	O
increase	NN	O
in	IN	O
strength	NN	O
within	IN	O
the	DT	O
treatment	NN	O
group	NN	O
after	IN	O
the	DT	O
first	JJ	O
intervention	NN	O
(	(	O
6.95	CD	O
%	NN	O
right	NN	O
,	,	O
12.61	CD	O
%	NN	O
left	NN	O
)	)	O
as	IN	O
compared	VBN	O
with	IN	O
the	DT	O
second	JJ	O
(	(	O
11.53	CD	O
%	NN	O
right	NN	O
,	,	O
17.02	CD	O
%	NN	O
left	NN	O
)	)	O
and	CC	O
the	DT	O
third	JJ	O
interventions	NNS	O
(	(	O
10.53	CD	O
%	NN	O
right	NN	O
,	,	O
16.81	CD	O
%	NN	O
left	VBD	O
)	)	O
.	.	O

No	DT	O
statistically	RB	O
significant	JJ	O
differences	NNS	O
were	VBD	O
found	VBN	O
in	IN	O
grip	JJ	O
strength	NN	O
comparison	NN	O
within	IN	O
the	DT	O
sham	NN	O
group	NN	O
.	.	O

Overall	JJ	O
differences	NNS	O
in	IN	O
strength	NN	O
were	VBD	O
consistently	RB	O
significant	JJ	O
between	IN	O
the	DT	O
study	NN	O
groups	NNS	O
(	(	O
P	NNP	O
=	NNP	O
.0025	NNP	O
)	)	O
.	.	O

CONCLUSION	VB	O
The	DT	O
present	JJ	O
study	NN	O
suggests	VBZ	O
that	IN	O
the	DT	O
grip	NN	O
strength	NN	O
of	IN	O
national	JJ	O
level	NN	O
judo	NN	O
athletes	NNS	O
receiving	VBG	O
chiropractic	JJ	O
SMT	NNP	O
improved	VBD	O
compared	VBN	O
to	TO	O
those	DT	O
receiving	VBG	O
sham	NN	O
.	.	O

Levobunolol	NNP	O
compared	VBN	O
with	IN	O
timolol	NN	O
:	:	O
a	DT	O
four-year	JJ	O
study	NN	O
.	.	O

Fifty-one	CD	SS
patients	NNS	O
with	IN	O
raised	VBN	C
intraocular	JJ	C
pressure	NN	C
(	(	C
IOP	NNP	C
)	)	C
were	VBD	O
treated	VBN	O
for	IN	O
up	IN	O
to	TO	O
four	CD	O
years	NNS	O
with	IN	O
one	CD	O
of	IN	O
three	CD	O
ophthalmic	JJ	O
solutions	NNS	O
:	:	O
0.5	CD	C
%	NN	C
levobunolol	NN	C
,	,	O
1	CD	C
%	NN	C
levobunolol	NN	C
,	,	O
or	CC	O
0.5	CD	C
%	NN	C
timolol	NN	C
.	.	O

The	DT	O
study	NN	O
was	VBD	O
conducted	VBN	O
as	IN	O
a	DT	O
double-masked	JJ	O
,	,	O
randomised	JJ	O
trial	NN	O
in	IN	O
which	WDT	O
medications	NNS	O
were	VBD	O
administered	VBN	O
twice	RB	O
daily	RB	O
to	TO	O
both	DT	O
eyes	NNS	O
.	.	O

Levobunolol	NNP	O
and	CC	O
timolol	NN	O
were	VBD	O
equally	RB	O
effective	JJ	O
in	IN	O
reducing	VBG	O
overall	JJ	O
mean	JJ	O
IOP	NNP	O
;	:	O
reductions	NNS	O
were	VBD	O
greater	JJR	O
than	IN	O
8.8	CD	O
mmHg	NNS	O
in	IN	O
all	DT	O
three	CD	O
treatment	NN	O
groups	NNS	O
.	.	O

The	DT	O
study	NN	O
showed	VBD	O
levobunolol	NNS	O
to	TO	O
be	VB	O
as	IN	O
safe	JJ	O
and	CC	O
effective	JJ	O
as	IN	O
timolol	NN	O
in	IN	O
the	DT	O
long-term	JJ	O
control	NN	O
of	IN	O
raised	VBN	O
IOP	NNP	C
.	.	O

Acute	NNP	O
pressor	NN	O
and	CC	O
hormonal	JJ	O
effects	NNS	O
of	IN	O
beta-endorphin	NN	O
at	IN	O
high	JJ	O
doses	NNS	O
in	IN	O
healthy	JJ	C
and	CC	C
hypertensive	JJ	C
subjects	NNS	O
:	:	O
role	NN	O
of	IN	O
opioid	JJ	O
receptor	NN	O
agonism	NN	O
.	.	O

CONTEXT	VB	O
The	DT	O
opioid	NN	O
system	NN	O
is	VBZ	O
involved	VBN	O
in	IN	O
blood	NN	O
pressure	NN	O
regulation	NN	O
in	IN	O
both	DT	O
normal	JJ	C
humans	NNS	O
and	CC	O
patients	NNS	O
with	IN	O
essential	JJ	C
hypertension	NN	C
.	.	O

OBJECTIVE	CC	O
The	DT	O
objective	NN	O
of	IN	O
the	DT	O
study	NN	O
was	VBD	O
to	TO	O
investigate	VB	O
the	DT	O
effects	NNS	O
of	IN	O
a	DT	O
high-dose	JJ	O
infusion	NN	O
of	IN	O
beta-endorphin	NN	O
,	,	O
an	DT	O
opioid	JJ	O
peptide	NN	O
,	,	O
on	IN	O
blood	NN	O
pressure	NN	O
and	CC	O
on	IN	O
the	DT	O
hormonal	JJ	O
profile	NN	O
in	IN	O
healthy	JJ	C
subjects	NNS	O
and	CC	O
in	IN	O
hypertensive	JJ	C
patients	NNS	O
and	CC	O
the	DT	O
mediation	NN	O
played	VBN	O
by	IN	O
opioid	JJ	O
receptor	NN	O
agonism	NN	O
.	.	O

DESIGN	NNP	O
,	,	O
SETTING	NNP	O
,	,	O
AND	NNP	O
PARTICIPANTS	NNP	O
According	VBG	O
to	TO	O
a	DT	O
randomized	VBN	O
double-blind	NN	O
design	NN	O
,	,	O
11	CD	SS
healthy	JJ	C
subjects	NNS	O
(	(	O
controls	NNS	O
)	)	O
and	CC	O
12	CD	SS
hypertensive	JJ	O
inpatients	NNS	O
(	(	O
mean	JJ	O
age	NN	O
,	,	O
38.9	CD	A
and	CC	O
40.4	CD	A
yr	NN	O
,	,	O
respectively	RB	O
)	)	O
received	VBD	O
1-h	JJ	O
iv	JJ	O
infusion	NN	O
of	IN	O
beta-endorphin	JJ	O
(	(	O
250	CD	O
mug/h	NN	O
)	)	O
and	CC	O
,	,	O
on	IN	O
another	DT	O
occasion	NN	O
,	,	O
the	DT	O
same	JJ	O
infusion	NN	O
protocol	NN	O
preceded	VBN	O
by	IN	O
the	DT	O
opioid	JJ	O
antagonist	NN	O
naloxone	NN	O
(	(	O
8	CD	O
mg	NN	O
)	)	O
.	.	O

MAIN	NNP	O
OUTCOME	NNP	O
MEASURES	NNP	O
Hemodynamic	NNP	O
and	CC	O
hormonal	JJ	O
measurements	NNS	O
were	VBD	O
performed	VBN	O
at	IN	O
established	VBN	O
times	NNS	O
during	IN	O
the	DT	O
infusion	NN	O
protocols	NNS	O
.	.	O

RESULTS	NNP	O
At	IN	O
baseline	NN	O
,	,	O
circulating	VBG	O
beta-endorphin	JJ	O
,	,	O
norepinephrine	JJ	O
,	,	O
and	CC	O
endothelin-1	NN	O
in	IN	O
hypertensive	JJ	O
patients	NNS	O
were	VBD	O
significantly	RB	O
(	(	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
higher	JJR	O
than	IN	O
in	IN	O
controls	NNS	O
.	.	O

In	IN	O
controls	NNS	O
,	,	O
beta-endorphin	JJ	O
reduced	VBD	O
blood	NN	O
pressure	NN	O
(	(	O
P	NNP	O
<	NNP	O
0.01	CD	O
)	)	O
and	CC	O
circulating	VBG	O
norepinephrine	NN	O
(	(	O
P	NNP	O
<	NNP	O
0.02	CD	O
)	)	O
and	CC	O
increased	VBD	O
plasma	JJ	O
atrial	JJ	O
natriuretic	JJ	O
factor	NN	O
(	(	O
P	NNP	O
<	NNP	O
0.003	CD	O
)	)	O
and	CC	O
GH	NNP	O
(	(	O
P	NNP	O
<	NNP	O
0.0001	CD	O
)	)	O
.	.	O

In	IN	O
hypertensive	JJ	O
patients	NNS	O
,	,	O
beta-endorphin	JJ	O
decreased	JJ	O
systemic	JJ	O
vascular	NN	O
resistance	NN	O
(	(	O
P	NNP	O
<	NNP	O
0.0001	CD	O
)	)	O
,	,	O
blood	NN	O
pressure	NN	O
(	(	O
P	NNP	O
<	NNP	O
0.0001	CD	O
)	)	O
,	,	O
and	CC	O
plasma	JJ	O
norepinephrine	NN	O
(	(	O
P	NNP	O
<	NNP	O
0.0001	CD	O
)	)	O
and	CC	O
endothelin-1	JJ	O
(	(	O
P	NNP	O
<	NNP	O
0.0001	CD	O
)	)	O
and	CC	O
raised	VBD	O
circulating	VBG	O
atrial	JJ	O
natriuretic	JJ	O
factor	NN	O
(	(	O
P	NNP	O
<	NNP	O
0.0001	CD	O
)	)	O
,	,	O
GH	NNP	O
(	(	O
P	NNP	O
<	NNP	O
0.0001	CD	O
)	)	O
,	,	O
and	CC	O
IGF-I	NNP	O
(	(	O
P	NNP	O
<	NNP	O
0.0001	CD	O
)	)	O
.	.	O

These	DT	O
hemodynamic	JJ	O
and	CC	O
hormonal	JJ	O
responses	NNS	O
to	TO	O
beta-endorphin	JJ	O
in	IN	O
hypertensive	JJ	O
patients	NNS	O
were	VBD	O
significantly	RB	O
(	(	O
P	NNP	O
<	NNP	O
0.0001	CD	O
)	)	O
greater	JJR	O
than	IN	O
in	IN	O
controls	NNS	O
but	CC	O
were	VBD	O
annulled	VBN	O
in	IN	O
all	DT	O
individuals	NNS	O
when	WRB	O
naloxone	NN	O
preceded	VBD	O
beta-endorphin	JJ	O
infusion	NN	O
.	.	O

CONCLUSIONS	NNP	O
High	NNP	O
doses	NNS	O
of	IN	O
beta-endorphin	JJ	O
induce	NN	O
hypotensive	NN	O
and	CC	O
beneficial	JJ	O
hormonal	JJ	O
effects	NNS	O
in	IN	O
humans	NNS	O
,	,	O
which	WDT	O
are	VBP	O
enhanced	VBN	O
in	IN	O
essential	JJ	O
hypertension	NN	O
and	CC	O
are	VBP	O
mediated	VBN	O
by	IN	O
opioid	JJ	O
receptors	NNS	O
.	.	O

Ovulation	NN	O
and	CC	O
follicular	JJ	O
development	NN	O
associated	VBN	O
with	IN	O
three	CD	O
low-dose	JJ	O
oral	JJ	O
contraceptives	NNS	O
:	:	O
a	DT	O
randomized	NN	O
controlled	VBN	O
trial	NN	O
.	.	O

OBJECTIVE	UH	O
To	TO	O
address	VB	O
the	DT	O
hypothesis	NN	O
that	WDT	O
multiphasic	JJ	O
oral	JJ	O
contraceptives	NNS	O
(	(	O
OCs	NNP	O
)	)	O
increase	NN	O
rather	RB	O
than	IN	O
decrease	VB	O
the	DT	O
risk	NN	O
of	IN	O
functional	JJ	O
ovarian	JJ	O
cysts	NNS	O
.	.	O

METHODS	NNP	O
In	IN	O
this	DT	O
single-center	NN	O
,	,	O
randomized	VBN	O
controlled	VBD	O
study	NN	O
,	,	O
women	NNS	O
were	VBD	O
assigned	VBN	O
to	TO	O
a	DT	O
multiphasic	JJ	O
pill	NN	O
,	,	O
a	DT	O
lower-dose	JJ	O
monophasic	NN	O
pill	NN	O
,	,	O
a	DT	O
higher-dose	JJ	O
monophasic	NN	O
pill	NN	O
,	,	O
or	CC	O
nonsteroidal	JJ	O
contraception	NN	O
.	.	O

Forty	JJ	O
volunteers	NNS	O
were	VBD	O
randomized	VBN	O
(	(	O
ten	VB	O
each	DT	O
)	)	O
to	TO	O
three	CD	O
different	JJ	O
pill	NN	O
regimens	VBZ	O
or	CC	O
to	TO	O
nonsteroidal	DT	O
contraception	NN	O
.	.	O

During	IN	O
6	CD	O
months	NNS	O
of	IN	O
treatment	NN	O
,	,	O
follicular	JJ	O
development	NN	O
was	VBD	O
measured	VBN	O
by	IN	O
vaginal	JJ	O
ultrasonography	NN	O
and	CC	O
ovulation	NN	O
was	VBD	O
indicated	VBN	O
by	IN	O
serum	NN	O
progesterone	NN	O
levels	NNS	O
.	.	O

RESULTS	VB	O
The	DT	O
relative	JJ	O
risk	NN	O
(	(	O
RR	NNP	O
)	)	O
of	IN	O
developing	VBG	O
a	DT	O
follicular	JJ	O
structure	NN	O
greater	JJR	O
than	IN	O
30	CD	O
mm	NN	O
in	IN	O
diameter	NN	O
during	IN	O
a	DT	O
cycle	NN	O
with	IN	O
the	DT	O
higher-dose	JJ	O
monophasic	NN	O
pill	NN	O
was	VBD	O
0.5	CD	O
(	(	O
95	CD	O
%	NN	O
confidence	NN	O
interval	NN	O
[	NNP	O
CI	NNP	O
]	NNP	O
0.1-1.9	NN	O
;	:	O
P	NNP	O
=	NNP	O
.49	NNP	O
)	)	O
compared	VBN	O
with	IN	O
the	DT	O
multiphasic	NN	O
pill	NN	O
.	.	O

The	DT	O
risk	NN	O
with	IN	O
the	DT	O
lower-dose	JJ	O
monophasic	NN	O
pill	NN	O
was	VBD	O
comparable	JJ	O
to	TO	O
that	DT	O
with	IN	O
the	DT	O
multiphasic	NN	O
pill	NN	O
(	(	O
RR	NNP	O
1.3	CD	O
,	,	O
95	CD	O
%	NN	O
CI	NNP	O
0.5-3.6	CD	O
;	:	O
P	NNP	O
=	NNP	O
.56	NNP	O
)	)	O
.	.	O

With	IN	O
the	DT	O
multiphasic	NN	O
pill	NN	O
,	,	O
the	DT	O
maximum	JJ	O
ovulation	NN	O
rate	NN	O
over	IN	O
60	CD	O
cycles	NNS	O
was	VBD	O
1.7	CD	O
per	IN	O
100	CD	O
cycles	NNS	O
(	(	O
95	CD	O
%	NN	O
CI	NNP	O
0.0-8.9	NN	O
)	)	O
.	.	O

CONCLUSION	VB	O
This	DT	O
multiphasic	JJ	O
pill	NN	O
more	RBR	O
closely	RB	O
resembled	VBN	O
the	DT	O
lower-dose	JJ	O
monophasic	NN	O
pill	NN	O
than	IN	O
the	DT	O
higher-dose	JJ	O
monophasic	NN	O
pill	NN	O
in	IN	O
its	PRP$	O
suppression	NN	O
of	IN	O
follicular	JJ	O
development	NN	O
.	.	O

A	DT	O
good	JJ	O
response	NN	O
to	TO	O
oil	NN	O
with	IN	O
medium-	NN	O
and	CC	O
long-chain	JJ	O
fatty	JJ	O
acids	NNS	O
in	IN	O
body	NN	O
fat	JJ	O
and	CC	O
blood	NN	O
lipid	JJ	O
profiles	NNS	O
of	IN	O
male	JJ	SE
hypertriglyceridemic	JJ	C
subjects	NNS	O
.	.	O

A	DT	O
double	JJ	O
blind	NN	O
clinical	JJ	O
trial	NN	O
was	VBD	O
carried	VBN	O
out	IN	O
to	TO	O
clarify	VB	O
the	DT	O
effects	NNS	O
of	IN	O
oil	NN	O
with	IN	O
medium-	NN	O
and	CC	O
long-chain	JJ	O
triglyceride	NN	O
(	(	O
MLCT	NNP	O
)	)	O
on	IN	O
body	NN	O
fat	JJ	O
and	CC	O
blood	NN	O
lipid	JJ	O
profiles	NNS	O
in	IN	O
hypertriglyceridemic	JJ	O
subjects	NNS	O
.	.	O

One-hundred-and-twelve	JJ	SS
subjects	NNS	O
were	VBD	O
enrolled	VBN	O
and	CC	O
divided	VBN	O
into	IN	O
two	CD	O
groups	NNS	O
;	:	O
those	DT	O
that	IN	O
consumed	VBD	O
MLCT	NNP	O
oil	NN	O
and	CC	O
those	DT	O
that	WDT	O
consumed	VBD	O
long-chain	JJ	O
triglyceride	NN	O
(	(	O
LCT	NNP	O
)	)	O
oil	NN	O
for	IN	O
8	CD	O
weeks	NNS	O
.	.	O

All	DT	O
subjects	NNS	O
were	VBD	O
requested	VBN	O
to	TO	O
consume	VB	O
25-30	JJ	O
g	NN	O
of	IN	O
the	DT	O
oils	NNS	O
daily	RB	O
and	CC	O
maintain	VB	O
a	DT	O
fixed	JJ	O
level	NN	O
of	IN	O
energy	NN	O
intake	NN	O
and	CC	O
exercise	NN	O
.	.	O

Anthropometric	NNP	O
and	CC	O
blood	NN	O
biochemical	JJ	O
parameters	NNS	O
were	VBD	O
measured	VBN	O
when	WRB	O
the	DT	O
study	NN	O
was	VBD	O
initiated	VBN	O
and	CC	O
completed	VBN	O
.	.	O

The	DT	O
LCT	NNP	O
group	NN	O
consisted	VBD	O
of	IN	O
50	CD	SS
subjects	NNS	O
(	(	O
34	CD	SS
men	NNS	SE
and	CC	O
16	CD	SS
women	NNS	SE
)	)	O
,	,	O
while	IN	O
the	DT	O
MLCT	NNP	O
group	NN	O
consisted	VBD	O
of	IN	O
51	CD	SS
subjects	NNS	O
(	(	O
33	CD	SS
men	NNS	SE
and	CC	O
18	CD	SS
women	NNS	SE
)	)	O
who	WP	O
completed	VBD	O
the	DT	O
study	NN	O
.	.	O

Larger	NNP	O
decreases	VBZ	O
in	IN	O
body	NN	O
weight	NN	O
,	,	O
body	NN	O
mass	NN	O
index	NN	O
,	,	O
waist	NN	O
circumference	NN	O
,	,	O
body	NN	O
fat	NN	O
,	,	O
total	JJ	O
fat	JJ	O
area	NN	O
and	CC	O
subcutaneous	JJ	O
fat	JJ	O
area	NN	O
in	IN	O
the	DT	O
abdomen	NNS	O
and	CC	O
serum	NN	O
triglycerides	NNS	O
,	,	O
low-density	NN	O
lipoprotein	NN	O
cholesterol	NN	O
,	,	O
apolipoprotein	NN	O
B	NNP	O
,	,	O
C2	NNP	O
,	,	O
C3	NNP	O
and	CC	O
E	NNP	O
were	VBD	O
observed	VBN	O
in	IN	O
male	JJ	O
subjects	NNS	O
in	IN	O
the	DT	O
MLCT	NNP	O
group	NN	O
than	IN	O
those	DT	O
in	IN	O
the	DT	O
LCT	NNP	O
group	NN	O
.	.	O

However	RB	O
,	,	O
no	DT	O
significant	JJ	O
differences	NNS	O
in	IN	O
these	DT	O
parameters	NNS	O
between	IN	O
the	DT	O
female	JJ	O
subjects	NNS	O
in	IN	O
the	DT	O
two	CD	O
groups	NNS	O
were	VBD	O
observed	VBN	O
.	.	O

Data	NNS	O
from	IN	O
this	DT	O
study	NN	O
indicate	VBP	O
that	IN	O
consumption	NN	O
of	IN	O
medium-and	JJ	O
long-chain	JJ	O
triglycerides	NNS	O
can	MD	O
reduce	VB	O
body	NN	O
weight	NN	O
and	CC	O
body	NN	O
fat	NN	O
and	CC	O
improve	VB	O
blood	NN	O
lipid	JJ	O
profiles	NNS	O
in	IN	O
male	JJ	O
hypertriglyceridemic	JJ	O
subjects	NNS	O
.	.	O

The	DT	O
sequencing	NN	O
of	IN	O
chemotherapy	NN	O
and	CC	O
radiation	NN	O
therapy	NN	O
after	IN	O
conservative	JJ	O
surgery	NN	O
for	IN	O
early-stage	JJ	O
breast	NN	C
cancer	NN	C
.	.	O

BACKGROUND	NNP	O
Patients	NNPS	O
with	IN	O
early-stage	JJ	O
breast	NN	C
cancer	NN	C
who	WP	O
are	VBP	O
at	IN	O
substantial	JJ	O
risk	NN	O
for	IN	O
systemic	JJ	O
metastases	NNS	C
are	VBP	O
increasingly	RB	O
treated	VBN	O
with	IN	O
breast-conserving	JJ	O
therapy	NN	O
and	CC	O
adjuvant	JJ	O
chemotherapy	NN	O
.	.	O

However	RB	O
,	,	O
the	DT	O
optimal	JJ	O
sequencing	NN	O
of	IN	O
chemotherapy	NN	O
and	CC	O
radiation	NN	O
therapy	NN	O
is	VBZ	O
not	RB	O
clear	JJ	O
.	.	O

METHODS	NNP	O
Two	CD	SS
hundred	VBD	SS
forty-four	JJ	SS
patients	NNS	O
with	IN	O
stage	NN	O
I	PRP	O
or	CC	O
II	NNP	O
breast	NN	C
cancer	NN	C
who	WP	O
were	VBD	O
at	IN	O
substantial	JJ	O
risk	NN	O
for	IN	O
distant	JJ	O
metastases	NNS	C
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
receive	VB	O
a	DT	O
12-week	JJ	O
course	NN	O
of	IN	O
chemotherapy	NN	O
either	CC	O
before	IN	O
or	CC	O
after	IN	O
radiation	NN	O
therapy	NN	O
.	.	O

All	DT	O
had	VBD	O
had	VBN	O
breast-conserving	JJ	O
surgery	NN	O
.	.	O

The	DT	O
median	JJ	O
length	NN	O
of	IN	O
follow-up	NN	O
in	IN	O
surviving	VBG	O
patients	NNS	O
was	VBD	O
58	CD	O
months	NNS	O
(	(	O
range	NN	O
,	,	O
10	CD	O
to	TO	O
124	CD	O
)	)	O
.	.	O

RESULTS	VB	O
The	DT	O
five-year	JJ	O
actuarial	JJ	O
rates	NNS	O
of	IN	O
cancer	NN	O
recurrence	NN	O
at	IN	O
any	DT	O
site	NN	O
and	CC	O
of	IN	O
distant	JJ	O
metastases	NNS	O
in	IN	O
the	DT	O
radiotherapy-first	JJ	O
group	NN	O
and	CC	O
the	DT	O
chemotherapy-first	JJ	O
group	NN	O
were	VBD	O
38	CD	O
percent	NN	O
and	CC	O
31	CD	O
percent	NN	O
(	(	O
P	NNP	O
=	NNP	O
0.17	CD	O
)	)	O
and	CC	O
36	CD	O
percent	NN	O
and	CC	O
25	CD	O
percent	NN	O
(	(	O
P	NNP	O
=	NNP	O
0.05	CD	O
)	)	O
,	,	O
respectively	RB	O
.	.	O

Overall	JJ	O
survival	NN	O
was	VBD	O
73	CD	O
percent	NN	O
and	CC	O
81	CD	O
percent	NN	O
(	(	O
P	NNP	O
=	NNP	O
0.11	CD	O
)	)	O
,	,	O
respectively	RB	O
.	.	O

The	DT	O
five-year	JJ	O
crude	NN	O
rates	NNS	O
of	IN	O
first	JJ	O
recurrence	NN	O
according	VBG	O
to	TO	O
site	NN	O
in	IN	O
the	DT	O
radiotherapy-first	JJ	O
and	CC	O
chemotherapy-first	JJ	O
groups	NNS	O
,	,	O
respectively	RB	O
,	,	O
were	VBD	O
5	CD	O
percent	NN	O
and	CC	O
14	CD	O
percent	NN	O
for	IN	O
local	JJ	O
recurrence	NN	O
and	CC	O
32	CD	O
percent	NN	O
and	CC	O
20	CD	O
percent	NN	O
for	IN	O
distant	NN	O
or	CC	O
regional	JJ	O
recurrence	NN	O
or	CC	O
both	DT	O
.	.	O

This	DT	O
difference	NN	O
in	IN	O
the	DT	O
pattern	NN	O
of	IN	O
recurrence	NN	O
was	VBD	O
of	IN	O
borderline	JJ	O
statistical	JJ	O
significance	NN	O
(	(	O
P	NNP	O
=	NNP	O
0.07	CD	O
)	)	O
.	.	O

CONCLUSIONS	VB	O
This	DT	O
study	NN	O
suggests	VBZ	O
that	IN	O
for	IN	O
patients	NNS	O
ar	VBP	O
substantial	JJ	O
risk	NN	O
for	IN	O
systemic	JJ	O
metastases	NNS	C
,	,	O
it	PRP	O
is	VBZ	O
preferable	JJ	O
to	TO	O
give	VB	O
a	DT	O
12-week	JJ	O
course	NN	O
of	IN	O
chemotherapy	NN	O
followed	VBN	O
by	IN	O
radiation	NN	O
therapy	NN	O
,	,	O
rather	RB	O
than	IN	O
radiation	NN	O
therapy	NN	O
followed	VBN	O
by	IN	O
chemotherapy	NN	O
.	.	O

The	DT	O
effects	NNS	O
of	IN	O
orthotic	JJ	O
heel	NN	O
lifts	NNS	O
on	IN	O
Achilles	NNP	O
tendon	NNP	O
force	NN	O
and	CC	O
strain	NN	O
during	IN	O
running	VBG	O
.	.	O

This	DT	O
study	NN	O
assessed	VBD	O
the	DT	O
effects	NNS	O
of	IN	O
orthotic	JJ	O
heel	NN	O
lifts	NNS	O
on	IN	O
Achilles	NNP	O
tendon	NN	O
(	(	O
AT	NNP	O
)	)	O
force	NN	O
and	CC	O
strain	NN	O
during	IN	O
running	VBG	O
.	.	O

Ten	CD	SS
females	NNS	SE
ran	VBD	O
barefoot	NN	O
over	IN	O
a	DT	O
force	NN	O
plate	NN	O
in	IN	O
three	CD	O
conditions	NNS	O
:	:	O
no	DT	O
heel	NN	O
lifts	NNS	O
(	(	O
NHL	NNP	O
)	)	O
,	,	O
with	IN	O
12	CD	O
mm	NNS	O
heel	JJ	O
lifts	NNS	O
(	(	O
12HL	CD	O
)	)	O
and	CC	O
with	IN	O
18	CD	O
mm	NNS	O
heel	JJ	O
lifts	NNS	O
(	(	O
18HL	CD	O
)	)	O
.	.	O

Kinematics	NNS	O
for	IN	O
the	DT	O
right	JJ	O
lower	JJR	O
limb	NN	O
were	VBD	O
collected	VBN	O
(	(	O
200	CD	O
Hz	NNP	O
)	)	O
.	.	O

AT	NNP	O
force	NN	O
was	VBD	O
calculated	VBN	O
from	IN	O
inverse	JJ	O
dynamics	NNS	O
.	.	O

AT	NNP	O
strain	NN	O
was	VBD	O
determined	VBN	O
from	IN	O
kinematics	NNS	O
and	CC	O
ultrasound	JJ	O
images	NNS	O
of	IN	O
medial	JJ	O
gastrocnemius	NN	O
(	(	O
50	CD	O
Hz	NNP	O
)	)	O
.	.	O

Peak	NNP	O
AT	NNP	O
strain	NN	O
was	VBD	O
less	JJR	O
for	IN	O
18HL	CD	O
(	(	O
5.5	CD	O
?	.	O
4.4	CD	O
%	NN	O
)	)	O
than	IN	O
for	IN	O
NHL	NNP	O
(	(	O
7.4	CD	O
?	.	O
4.2	CD	O
%	NN	O
)	)	O
(	(	O
p	JJ	O
=	NNP	O
.029	NNP	O
,	,	O
effect	NN	O
size	NN	O
[	NNP	O
ES	NNP	O
]	NNP	O
=	NNP	O
0.44	CD	O
)	)	O
but	CC	O
not	RB	O
for	IN	O
12HL	CD	O
(	(	O
5.8	CD	O
?	.	O
4.8	CD	O
%	NN	O
)	)	O
versus	NN	O
NHL	NNP	O
(	(	O
ES	NNP	O
=	NNP	O
0.35	CD	O
)	)	O
.	.	O

Peak	NNP	O
AT	NNP	O
force	NN	O
was	VBD	O
significantly	RB	O
(	(	O
p	JJ	O
=	NNP	O
.024	NNP	O
,	,	O
ES	NNP	O
=	NNP	O
0.42	CD	O
)	)	O
less	JJR	O
for	IN	O
18HL	CD	O
(	(	O
2382	CD	O
?	.	O
717	CD	O
N	NNP	O
)	)	O
than	IN	O
for	IN	O
NHL	NNP	O
(	(	O
2710	CD	O
?	.	O
830	CD	O
N	NNP	O
)	)	O
but	CC	O
not	RB	O
for	IN	O
12HL	CD	O
(	(	O
2538	CD	O
?	.	O
823	CD	O
N	NNP	O
,	,	O
ES	NNP	O
=	NNP	O
0.21	CD	O
)	)	O
.	.	O

The	DT	O
18HL	CD	O
reduced	VBD	O
ankle	JJ	O
dorsiflexion	NN	O
but	CC	O
not	RB	O
flexion-extension	JJ	O
ankle	NN	O
moments	NNS	O
and	CC	O
increased	VBD	O
the	DT	O
AT	NNP	O
moment	NN	O
arm	NN	O
compared	VBN	O
with	IN	O
NHL	NNP	O
.	.	O

Thus	NNP	O
,	,	O
18HL	CD	O
reduced	VBN	O
force	NN	O
and	CC	O
strain	NN	O
on	IN	O
the	DT	O
AT	NNP	O
during	IN	O
running	VBG	O
via	IN	O
a	DT	O
reduction	NN	O
in	IN	O
dorsiflexion	NN	O
,	,	O
which	WDT	O
lengthened	VBD	O
the	DT	O
AT	NNP	O
moment	NN	O
arm	NN	O
.	.	O

Therefore	RB	O
,	,	O
heel	NN	O
lifts	NNS	O
could	MD	O
be	VB	O
used	VBN	O
to	TO	O
reduce	VB	O
AT	NNP	O
loading	NN	O
and	CC	O
strain	NN	O
during	IN	O
the	DT	O
rehabilitation	NN	O
of	IN	O
AT	NNP	O
injuries	NNS	O
.	.	O

Etanercept	NNP	O
treatment	NN	O
in	IN	O
adults	NNS	A
with	IN	O
established	VBN	O
rheumatoid	NN	C
arthritis	NN	C
:	:	C
7	CD	O
years	NNS	O
of	IN	O
clinical	JJ	O
experience	NN	O
.	.	O

OBJECTIVE	UH	O
To	TO	O
evaluate	VB	O
safety	NN	O
and	CC	O
efficacy	NN	O
of	IN	O
longterm	JJ	O
etanercept	FW	O
treatment	NN	O
in	IN	O
patients	NNS	O
with	IN	O
disease	NN	O
modifying	VBG	O
antirheumatic	JJ	O
drug	NN	O
(	(	O
DMARD	NNP	O
)	)	O
refractory	NN	C
rheumatoid	JJ	C
arthritis	NN	C
(	(	C
RA	NNP	C
)	)	C
.	.	O

METHODS	NNP	O
Safety	NNP	O
results	NNS	O
are	VBP	O
reported	VBN	O
for	IN	O
714	CD	SS
patients	NNS	O
who	WP	O
received	VBD	O
etanercept	RB	O
in	IN	O
one	CD	O
of	IN	O
7	CD	O
initial	JJ	O
trials	NNS	O
or	CC	O
a	DT	O
longterm	JJ	O
extension	NN	O
.	.	O

Efficacy	NN	O
results	NNS	O
are	VBP	O
reported	VBN	O
for	IN	O
581	CD	SS
patients	NNS	O
who	WP	O
enrolled	VBD	O
in	IN	O
the	DT	O
extension	NN	O
.	.	O

RESULTS	NNP	O
Of	IN	O
the	DT	O
714	CD	SS
patients	NNS	O
enrolled	VBN	O
in	IN	O
the	DT	O
initial	JJ	O
trials	NNS	O
,	,	O
581	CD	SS
(	(	O
81	CD	O
%	NN	O
)	)	O
enrolled	VBN	O
in	IN	O
the	DT	O
extension	NN	O
,	,	O
and	CC	O
388	CD	SS
(	(	O
54	CD	O
%	NN	O
)	)	O
patients	NNS	O
are	VBP	O
continuing	VBG	O
to	TO	O
receive	VB	O
etanercept	JJ	O
therapy	NN	O
.	.	O

The	DT	O
longest	JJS	O
individual	JJ	O
treatment	NN	O
was	VBD	O
8.2	CD	O
years	NNS	O
,	,	O
with	IN	O
3139	CD	O
total	JJ	O
patient-years	NNS	O
of	IN	O
etanercept	JJ	O
exposure	NN	O
.	.	O

Rates	NNS	O
of	IN	O
serious	JJ	O
adverse	JJ	O
events	NNS	O
(	(	O
overall	JJ	O
rate=14.8	NN	O
events/100	IN	O
patient-yrs	NN	O
)	)	O
,	,	O
serious	JJ	O
infections	NNS	O
(	(	O
overall	JJ	O
rate=4.2	NN	O
events/100	IN	O
patient-yrs	NN	O
)	)	O
,	,	O
cancer	NN	O
(	(	O
overall	JJ	O
rate=1.0	NN	O
events/100	IN	O
patient-yrs	NN	O
)	)	O
,	,	O
and	CC	O
deaths	NNS	O
(	(	O
overall	JJ	O
rate=0.7	NN	O
events/100	IN	O
patient-yrs	NN	O
)	)	O
were	VBD	O
stable	JJ	O
each	DT	O
year	NN	O
,	,	O
through	IN	O
8	CD	O
years	NNS	O
of	IN	O
etanercept	JJ	O
exposure	NN	O
.	.	O

For	IN	O
356	CD	SS
patients	NNS	O
who	WP	O
completed	VBD	O
6	CD	O
years	NNS	O
of	IN	O
etanercept	JJ	O
treatment	NN	O
,	,	O
response	NN	O
rates	NNS	O
were	VBD	O
ACR20=73	NNP	O
%	NN	O
,	,	O
ACR50=52	NNP	O
%	NN	O
,	,	O
ACR70=27	NNP	O
%	NN	O
,	,	O
DAS28	NNP	O
CRP	NNP	O
good	JJ	O
response=52	NN	O
%	NN	O
,	,	O
and	CC	O
DAS28	NNP	O
CRP	NNP	O
remission=37	VBZ	O
%	NN	O
of	IN	O
patients	NNS	O
.	.	O

Similar	JJ	O
responses	NNS	O
occurred	VBD	O
in	IN	O
167	CD	SS
patients	NNS	O
who	WP	O
completed	VBD	O
Year	NNP	O
7	CD	O
.	.	O

Doses	NNS	O
of	IN	O
concomitant	JJ	O
methotrexate	NN	O
or	CC	O
corticosteroids	NNS	O
were	VBD	O
reduced	VBN	O
in	IN	O
many	JJ	O
patients	NNS	O
who	WP	O
maintained	VBD	O
clinical	JJ	O
responses	NNS	O
.	.	O

CONCLUSION	VB	O
The	DT	O
safety	NN	O
profile	NN	O
of	IN	O
etanercept	NN	O
was	VBD	O
consistent	JJ	O
over	IN	O
time	NN	O
,	,	O
with	IN	O
rates	NNS	O
of	IN	O
adverse	JJ	O
events	NNS	O
similar	JJ	O
to	TO	O
those	DT	O
reported	VBN	O
for	IN	O
patients	NNS	O
with	IN	O
RA	NNP	C
in	IN	O
general	JJ	O
.	.	O

Durable	JJ	O
clinical	JJ	O
responses	NNS	O
were	VBD	O
observed	VBN	O
in	IN	O
some	DT	O
patients	NNS	O
for	IN	O
7	CD	O
years	NNS	O
or	CC	O
more	JJR	O
.	.	O

The	DT	O
benefit-to-risk	JJ	O
ratio	NN	O
for	IN	O
longterm	JJ	O
etanercept	JJ	O
treatment	NN	O
remains	VBZ	O
highly	RB	O
favorable	JJ	O
.	.	O

LEGO	NNP	O
therapy	NN	O
and	CC	O
the	DT	O
social	JJ	O
use	NN	O
of	IN	O
language	NN	O
programme	NN	O
:	:	O
an	DT	O
evaluation	NN	O
of	IN	O
two	CD	O
social	JJ	O
skills	NNS	O
interventions	NNS	O
for	IN	O
children	NNS	A
with	IN	O
high	JJ	C
functioning	VBG	C
autism	NN	C
and	CC	O
Asperger	NNP	C
Syndrome	NNP	C
.	.	O

LEGO	NNP	O
therapy	NN	O
and	CC	O
the	DT	O
Social	NNP	O
Use	NNP	O
of	IN	O
Language	NNP	O
Programme	NNP	O
(	(	O
SULP	NNP	O
)	)	O
were	VBD	O
evaluated	VBN	O
as	IN	O
social	JJ	O
skills	NNS	O
interventions	NNS	O
for	IN	O
6-11	JJ	A
year	NN	O
olds	NNS	O
with	IN	O
high	JJ	C
functioning	VBG	C
autism	NN	C
and	CC	O
Asperger	NNP	C
Syndrome	NNP	C
.	.	O

Children	NNP	O
were	VBD	O
matched	VBN	O
on	IN	O
CA	NNP	O
,	,	O
IQ	NNP	O
,	,	O
and	CC	O
autistic	JJ	O
symptoms	NNS	O
before	IN	O
being	VBG	O
randomly	RB	O
assigned	VBN	O
to	TO	O
LEGO	NNP	O
or	CC	O
SULP	NNP	O
.	.	O

Therapy	NNP	O
occurred	VBD	O
for	IN	O
1	CD	O
h/week	NN	O
over	IN	O
18	CD	O
weeks	NNS	O
.	.	O

A	DT	O
no-intervention	JJ	O
control	NN	O
group	NN	O
was	VBD	O
also	RB	O
assessed	VBN	O
.	.	O

Results	NNS	O
showed	VBD	O
that	IN	O
the	DT	O
LEGO	NNP	O
therapy	NN	O
group	NN	O
improved	VBD	O
more	JJR	O
than	IN	O
the	DT	O
other	JJ	O
groups	NNS	O
on	IN	O
autism-specific	JJ	O
social	JJ	O
interaction	NN	O
scores	NNS	O
(	(	O
Gilliam	NNP	O
Autism	NNP	O
Rating	NNP	O
Scale	NNP	O
)	)	O
.	.	O

Maladaptive	JJ	O
behaviour	NN	O
decreased	VBD	O
significantly	RB	O
more	RBR	O
in	IN	O
the	DT	O
LEGO	NNP	O
and	CC	O
SULP	NNP	O
groups	NNS	O
compared	VBN	O
to	TO	O
the	DT	O
control	NN	O
group	NN	O
.	.	O

There	EX	O
was	VBD	O
a	DT	O
non-significant	JJ	O
trend	NN	O
for	IN	O
SULP	NNP	O
and	CC	O
LEGO	NNP	O
groups	NNS	O
to	TO	O
improve	VB	O
more	JJR	O
than	IN	O
the	DT	O
no-intervention	JJ	O
group	NN	O
in	IN	O
communication	NN	O
and	CC	O
socialisation	NN	O
skills	NNS	O
.	.	O

[	JJ	O
Comparison	NNP	O
of	IN	O
fracture	NN	O
resistance	NN	O
of	IN	O
pulpless	NN	O
teeth	NNS	O
restored	VBD	O
with	IN	O
fiber	NN	O
reinforced	VBN	O
composite	JJ	O
posts	NNS	O
and	CC	O
three	CD	O
kinds	NNS	O
of	IN	O
resin	NN	O
core	NN	O
material	NN	O
]	NNP	O
.	.	O

OBJECTIVE	NNP	O
To	TO	O
compare	VB	O
the	DT	O
fracture	NN	O
resistances	NNS	O
of	IN	O
pulpless	NN	O
teeth	NNS	O
restored	VBD	O
with	IN	O
FRC	NNP	O
(	(	O
Fiber	NNP	O
Reinforced	NNP	O
Composite	NNP	O
)	)	O
posts	NNS	O
and	CC	O
three	CD	O
kinds	NNS	O
of	IN	O
resin	NN	O
core	NN	O
material	NN	O
.	.	O

METHODS	NNP	O
A	NNP	O
total	NN	O
of	IN	O
42	CD	SS
recently	RB	O
extracted	VBN	O
upper	JJ	O
incisors	NNS	O
were	VBD	O
randomly	RB	O
divided	VBN	O
into	IN	O
3	CD	O
groups	NNS	O
.	.	O

Group	NNP	O
A	NNP	O
was	VBD	O
restored	VBN	O
with	IN	O
prefabricated	JJ	O
glass-fiber	JJ	O
posts	NNS	O
and	CC	O
Artglass	NNP	O
polymer	NN	O
core	NN	O
;	:	O
group	NN	O
B	NNP	O
with	IN	O
prefabricated	JJ	O
glass-fiber	JJ	O
posts	NNS	O
and	CC	O
Charisma	NNP	O
composite	JJ	O
resin	NN	O
core	NN	O
;	:	O
and	CC	O
group	NN	O
C	NNP	O
with	IN	O
prefabricated	JJ	O
glass-fiber	JJ	O
posts	NNS	O
and	CC	O
AB	NNP	O
composite	JJ	O
resin	NN	O
core	NN	O
.	.	O

In	IN	O
every	DT	O
group	NN	O
,	,	O
the	DT	O
core	NN	O
material	NN	O
was	VBD	O
processed	VBN	O
by	IN	O
hot-press	NN	O
and	CC	O
non	JJ	O
hot-press	NN	O
respectively	RB	O
.	.	O

The	DT	O
posts	NNS	O
size	NN	O
and	CC	O
shape	NN	O
were	VBD	O
identical	JJ	O
in	IN	O
the	DT	O
3	CD	O
groups	NNS	O
.	.	O

All	DT	O
teeth	NNS	O
were	VBD	O
fully	RB	O
covered	VBN	O
with	IN	O
polycarbonate	JJ	O
resin	NN	O
crowns	NNS	O
.	.	O

Fracture	NN	O
resistance	NN	O
was	VBD	O
measured	VBN	O
by	IN	O
applying	VBG	O
point	NN	O
force	NN	O
at	IN	O
130	CD	O
degrees	NNS	O
to	TO	O
the	DT	O
long	JJ	O
axis	NN	O
of	IN	O
the	DT	O
teeth	NN	O
on	IN	O
an	DT	O
universal	JJ	O
testing	NN	O
machine	NN	O
.	.	O

RESULTS	JJ	O
Mean	JJ	O
fracture	NN	O
threshold	NN	O
was	VBD	O
505.4	CD	O
N	NNP	O
+/-	JJ	O
42.0	CD	O
N	NNP	O
and	CC	O
564.1	CD	O
N	NNP	O
+/-	JJ	O
41.7	CD	O
N	NNP	O
in	IN	O
group	NN	O
A	NNP	O
,	,	O
411.3	CD	O
N	NNP	O
+/-	JJ	O
23.3	CD	O
N	NNP	O
and	CC	O
315.3	CD	O
N	NNP	O
+/-	JJ	O
19.1	CD	O
N	NNP	O
in	IN	O
group	NN	O
B	NNP	O
and	CC	O
358.4	CD	O
N	NNP	O
+/-	JJ	O
36.1	CD	O
N	NNP	O
and	CC	O
423.4	CD	O
N	NNP	O
+/-	JJ	O
47.5	CD	O
N	NNP	O
in	IN	O
group	NN	O
C.	NNP	O
In	IN	O
all	DT	O
groups	NNS	O
,	,	O
there	EX	O
was	VBD	O
no	DT	O
posts	NNS	O
fracture	NN	O
and	CC	O
polycarbonate	NN	O
resin	NN	O
crowns	NNS	O
fragmentation	NN	O
.	.	O

CONCLUSION	VB	O
The	DT	O
composite	JJ	O
restoration	NN	O
of	IN	O
FRC	NNP	O
posts	NNS	O
combined	VBD	O
with	IN	O
resin	NN	O
core	NN	O
and	CC	O
resin	VB	O
crown	NN	O
can	MD	O
improve	VB	O
the	DT	O
fracture	NN	O
resistance	NN	O
of	IN	O
the	DT	O
pulpless	JJ	O
roots	NNS	O
.	.	O

The	DT	O
strength	NN	O
of	IN	O
resin	NN	O
core	NN	O
material	NN	O
can	MD	O
be	VB	O
increased	VBN	O
by	IN	O
hot-press	JJ	O
methods	NNS	O
.	.	O

Warfarin	NNP	O
versus	NN	O
aspirin	NN	O
for	IN	O
prevention	NN	O
of	IN	O
thromboembolism	NN	O
in	IN	O
atrial	JJ	O
fibrillation	NN	O
:	:	O
Stroke	NNP	O
Prevention	NNP	O
in	IN	O
Atrial	NNP	O
Fibrillation	NNP	O
II	NNP	O
Study	NNP	O
.	.	O

Warfarin	NNP	O
is	VBZ	O
an	DT	O
established	JJ	O
treatment	NN	O
for	IN	O
prevention	NN	O
of	IN	O
ischaemic	JJ	O
stroke	NN	O
in	IN	O
patients	NNS	O
with	IN	O
atrial	JJ	C
fibrillation	NN	C
,	,	O
but	CC	O
the	DT	O
value	NN	O
of	IN	O
this	DT	O
agent	JJ	O
relative	NN	O
to	TO	O
aspirin	VB	O
in	IN	O
unclear	JJ	O
.	.	O

In	IN	O
the	DT	O
first	JJ	O
Stroke	NNP	O
Prevention	NNP	O
in	IN	O
Atrial	NNP	O
Fibrillation	NNP	O
(	(	O
SPAF-I	NNP	O
)	)	O
study	NN	O
,	,	O
direct	JJ	O
comparison	NN	O
of	IN	O
warfarin	NN	O
with	IN	O
aspirin	NN	O
was	VBD	O
limited	VBN	O
by	IN	O
the	DT	O
small	JJ	O
number	NN	O
of	IN	O
thromboembolic	JJ	O
events	NNS	O
.	.	O

SPAF-II	JJ	O
aims	NNS	O
to	TO	O
address	VB	O
this	DT	O
issue	NN	O
and	CC	O
also	RB	O
to	TO	O
assess	VB	O
the	DT	O
differential	JJ	O
effects	NNS	O
of	IN	O
the	DT	O
two	CD	O
treatments	NNS	O
according	VBG	O
to	TO	O
age	NN	O
.	.	O

We	PRP	O
compared	VBN	O
warfarin	NN	O
(	(	O
prothrombin	JJ	O
time	NN	O
ratio	JJ	O
1.3-1.8	JJ	O
,	,	O
international	JJ	O
normalised	JJ	O
ratio	NN	O
2.0-4.5	JJ	O
)	)	O
with	IN	O
aspirin	$	O
325	CD	O
mg	JJ	O
daily	RB	O
for	IN	O
prevention	NN	O
of	IN	O
ischaemic	JJ	O
stroke	NN	O
and	CC	O
systemic	JJ	O
embolism	NN	O
(	(	O
primary	JJ	O
events	NNS	O
)	)	O
in	IN	O
two	CD	O
parallel	NNS	O
randomised	VBD	O
trials	NNS	O
involving	VBG	O
715	CD	SS
patients	NNS	O
aged	VBN	O
75	CD	A
years	NNS	A
or	CC	A
less	JJR	A
and	CC	O
385	CD	SS
patients	NNS	O
older	JJR	A
than	IN	A
75	CD	A
;	:	O
we	PRP	O
sought	VBD	O
reductions	NNS	O
in	IN	O
the	DT	O
absolute	JJ	O
rate	NN	O
of	IN	O
primary	JJ	O
events	NNS	O
by	IN	O
warfarin	NNS	O
compared	VBN	O
with	IN	O
aspirin	NN	O
of	IN	O
2	CD	O
%	NN	O
per	IN	O
year	NN	O
and	CC	O
4	CD	O
%	NN	O
per	IN	O
year	NN	O
,	,	O
respectively	RB	O
.	.	O

In	IN	O
the	DT	O
younger	JJR	O
patients	NNS	O
,	,	O
warfarin	NNS	O
decreased	VBD	O
the	DT	O
absolute	JJ	O
rate	NN	O
of	IN	O
primary	JJ	O
events	NNS	O
by	IN	O
0.7	CD	O
%	NN	O
per	IN	O
year	NN	O
(	(	O
95	CD	O
%	NN	O
CI-0.4	NNP	O
to	TO	O
1.7	CD	O
)	)	O
.	.	O

The	DT	O
primary	JJ	O
event	NN	O
rate	NN	O
per	IN	O
year	NN	O
was	VBD	O
1.3	CD	O
%	NN	O
with	IN	O
warfarin	NN	O
and	CC	O
1.9	CD	O
%	NN	O
with	IN	O
aspirin	NN	O
(	(	O
relative	JJ	O
risk	NN	O
[	NNP	O
RR	NNP	O
]	NNP	O
0.67	CD	O
,	,	O
p	NN	O
=	NNP	O
0.24	CD	O
)	)	O
.	.	O

The	DT	O
absolute	JJ	O
rate	NN	O
of	IN	O
primary	JJ	O
events	NNS	O
in	IN	O
low-risk	JJ	O
younger	NN	O
patients	NNS	O
(	(	O
without	IN	O
hypertension	NN	O
,	,	O
recent	JJ	O
heart	NN	O
failure	NN	O
,	,	O
or	CC	O
previous	JJ	O
thromboembolism	NN	O
)	)	O
on	IN	O
aspirin	NN	O
was	VBD	O
0.5	CD	O
%	NN	O
per	IN	O
year	NN	O
(	(	O
95	CD	O
%	NN	O
CI	NNP	O
0.1	CD	O
to	TO	O
1.9	CD	O
)	)	O
.	.	O

Among	IN	O
older	JJR	O
patients	NNS	O
,	,	O
warfarin	NNS	O
decreased	VBD	O
the	DT	O
absolute	JJ	O
rate	NN	O
of	IN	O
primary	JJ	O
events	NNS	O
by	IN	O
1.2	CD	O
%	NN	O
per	IN	O
year	NN	O
(	(	O
95	CD	O
%	NN	O
CI-1.7	NNP	O
to	TO	O
4.1	CD	O
)	)	O
.	.	O

The	DT	O
primary	JJ	O
event	NN	O
rate	NN	O
per	IN	O
year	NN	O
was	VBD	O
3.6	CD	O
%	NN	O
with	IN	O
warfarin	NN	O
and	CC	O
4.8	CD	O
%	NN	O
with	IN	O
aspirin	NN	O
(	(	O
RR	NNP	O
0.73	CD	O
,	,	O
p	NN	O
=	NNP	O
0.39	CD	O
)	)	O
.	.	O

In	IN	O
this	DT	O
older	JJR	O
group	NN	O
,	,	O
the	DT	O
rate	NN	O
of	IN	O
all	DT	O
stroke	NN	O
with	IN	O
residual	JJ	O
deficit	NN	O
(	(	O
ischaemic	JJ	O
or	CC	O
haemorrhagic	NN	O
)	)	O
was	VBD	O
4.3	CD	O
%	NN	O
per	IN	O
year	NN	O
with	IN	O
aspirin	NN	O
and	CC	O
4.6	CD	O
%	NN	O
per	IN	O
year	NN	O
with	IN	O
warfarin	NN	O
(	(	O
RR	NNP	O
1.1	CD	O
)	)	O
.	.	O

Warfarin	NNP	O
may	MD	O
be	VB	O
more	RBR	O
effective	JJ	O
than	IN	O
aspirin	NN	O
for	IN	O
prevention	NN	O
of	IN	O
ischaemic	JJ	O
stroke	NN	O
in	IN	O
patients	NNS	O
with	IN	O
atrial	JJ	O
fibrillation	NN	O
,	,	O
but	CC	O
the	DT	O
absolute	JJ	O
reduction	NN	O
in	IN	O
stroke	NN	O
rate	NN	O
by	IN	O
warfarin	NN	O
is	VBZ	O
small	JJ	O
.	.	O

Younger	JJR	O
patients	NNS	O
without	IN	O
risk	NN	O
factors	NNS	O
had	VBD	O
a	DT	O
low	JJ	O
rate	NN	O
of	IN	O
stroke	NN	O
when	WRB	O
treated	VBN	O
with	IN	O
aspirin	NN	O
.	.	O

In	IN	O
older	JJR	O
patients	NNS	O
the	DT	O
rate	NN	O
of	IN	O
stroke	NN	O
(	(	O
ischaemic	JJ	O
and	CC	O
haemorrhagic	NN	O
)	)	O
was	VBD	O
substantial	JJ	O
,	,	O
irrespective	NN	O
of	IN	O
which	WDT	O
agent	NN	O
was	VBD	O
given	VBN	O
.	.	O

Patient	JJ	O
age	NN	O
and	CC	O
the	DT	O
inherent	JJ	O
risk	NN	O
of	IN	O
thromboembolism	NN	O
should	MD	O
be	VB	O
considered	VBN	O
in	IN	O
the	DT	O
choice	NN	O
of	IN	O
antithrombotic	JJ	O
prophylaxis	NN	O
for	IN	O
patients	NNS	O
with	IN	O
atrial	JJ	O
fibrillation	NN	O
.	.	O

Effects	NNS	O
of	IN	O
an	DT	O
Internet-based	JJ	O
intervention	NN	O
on	IN	O
plasma	NNS	O
glucose	JJ	O
levels	NNS	O
in	IN	O
patients	NNS	O
with	IN	O
type	JJ	C
2	CD	C
diabetes	NNS	C
.	.	O

This	DT	O
study	NN	O
applied	VBD	O
a	DT	O
12-week	JJ	O
educational	JJ	O
intervention	NN	O
that	WDT	O
used	VBD	O
both	DT	O
the	DT	O
cellular	JJ	O
phone	NN	O
and	CC	O
the	DT	O
Internet	NNP	O
to	TO	O
send	VB	O
short	JJ	O
message	NN	O
service	NN	O
.	.	O

Forty-two	NNP	SS
diabetic	JJ	C
patients	NNS	O
were	VBD	O
asked	VBN	O
to	TO	O
access	NN	O
a	DT	O
Web	NNP	O
site	NN	O
by	IN	O
using	VBG	O
a	DT	O
cellular	JJ	O
phone	NN	O
or	CC	O
wire	NN	O
Internet	NNP	O
and	CC	O
input	VB	O
their	PRP$	O
blood	NN	O
glucose	NN	O
levels	NNS	O
every	DT	O
day	NN	O
.	.	O

Patients	NNS	O
were	VBD	O
sent	VBN	O
the	DT	O
optimal	JJ	O
recommendations	NNS	O
by	IN	O
both	DT	O
the	DT	O
cellular	JJ	O
phone	NN	O
and	CC	O
the	DT	O
Internet	NNP	O
.	.	O

After	IN	O
12	CD	O
weeks	NNS	O
,	,	O
the	DT	O
patients	NNS	O
had	VBD	O
a	DT	O
mean	JJ	O
decrease	NN	O
of	IN	O
28.6	CD	O
mg/dL	NNS	O
in	IN	O
fasting	VBG	O
plasma	NN	O
glucose	NN	O
and	CC	O
78.4	CD	O
mg/dL	NN	O
in	IN	O
2-hour	JJ	O
postprandial	JJ	O
blood	NN	O
sugar	NN	O
levels	NNS	O
and	CC	O
a	DT	O
mean	JJ	O
increase	NN	O
in	IN	O
the	DT	O
care	NN	O
satisfaction	NN	O
score	NN	O
.	.	O

A	DT	O
comparison	NN	O
of	IN	O
the	DT	O
serologic	JJ	O
responses	NNS	O
to	TO	O
oral	JJ	O
and	CC	O
injectable	JJ	O
trivalent	NN	O
poliovirus	NN	O
vaccines	NNS	O
.	.	O

United	NNP	O
States	NNPS	O
children	NNS	A
two	CD	A
months	NNS	A
of	IN	O
age	NN	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
two	CD	O
groups	NNS	O
that	WDT	O
received	VBD	O
either	RB	O
the	DT	O
commercially	RB	O
available	JJ	O
oral	JJ	O
trivalent	NN	O
poliovirus	NN	O
vaccine	NN	O
(	(	O
OPV	NNP	O
)	)	O
or	CC	O
an	DT	O
injectable	JJ	O
(	(	O
inactivated	VBN	O
)	)	O
trivalent	NN	O
poliovirus	NN	O
vaccine	NN	O
(	(	O
IPV	NNP	O
)	)	O
with	IN	O
a	DT	O
confirmed	JJ	O
minimum	JJ	O
D-antigen	NNP	O
content	NN	O
of	IN	O
27	CD	O
,	,	O
3.5	CD	O
,	,	O
and	CC	O
29	CD	O
units	NNS	O
for	IN	O
poliovirus	NN	O
types	NNS	O
1	CD	O
,	,	O
2	CD	O
,	,	O
and	CC	O
3	CD	O
,	,	O
respectively	RB	O
.	.	O

Vaccine	NNP	O
was	VBD	O
given	VBN	O
at	IN	O
two	CD	O
,	,	O
four	CD	O
,	,	O
and	CC	O
18	CD	O
months	NNS	O
of	IN	O
age	NN	O
.	.	O

Sera	NN	O
obtained	VBN	O
from	IN	O
439	CD	SS
children	NNS	A
at	IN	A
two	CD	A
,	,	A
four	CD	A
,	,	A
and	CC	A
six	CD	A
months	NNS	A
of	IN	A
age	NN	A
and	CC	O
from	IN	O
85	CD	SS
children	NNS	A
at	IN	A
18	CD	A
and	CC	A
20	CD	A
months	NNS	A
of	IN	A
age	NN	A
were	VBD	O
examined	VBN	O
for	IN	O
neutralizing	VBG	O
antibodies	NNS	O
.	.	O

The	DT	O
percentage	NN	O
of	IN	O
children	NNS	O
with	IN	O
detectable	JJ	O
antibodies	NNS	O
and	CC	O
the	DT	O
reciprocal	JJ	O
geometric	JJ	O
mean	NN	O
titers	NNS	O
were	VBD	O
similar	JJ	O
for	IN	O
both	DT	O
groups	NNS	O
at	IN	O
two	CD	O
months	NNS	O
of	IN	O
age	NN	O
for	IN	O
antibodies	NNS	O
to	TO	O
all	DT	O
three	CD	O
poliovirus	NN	O
types	NNS	O
.	.	O

At	IN	O
20	CD	O
months	NNS	O
of	IN	O
age	NN	O
,	,	O
all	DT	O
children	NNS	O
but	CC	O
one	CD	O
had	VBD	O
detectable	JJ	O
antibodies	NNS	O
to	TO	O
all	DT	O
three	CD	O
poliovirus	NN	O
types	NNS	O
.	.	O

Significantly	RB	O
higher	JJR	O
geometric	JJ	O
mean	NN	O
titers	NNS	O
against	IN	O
types	NNS	O
2	CD	O
and	CC	O
3	CD	O
were	VBD	O
noted	VBN	O
at	IN	O
20	CD	O
months	NNS	O
of	IN	O
age	NN	O
for	IN	O
the	DT	O
IPV	NNP	O
group	NN	O
.	.	O

Double-blind	NNP	O
,	,	O
placebo-controlled	JJ	O
study	NN	O
of	IN	O
L-carnosine	NNP	O
supplementation	NN	O
in	IN	O
children	NNS	A
with	IN	O
autistic	JJ	C
spectrum	NN	C
disorders	NNS	C
.	.	O

L-Carnosine	NNP	O
,	,	O
a	DT	O
dipeptide	NN	O
,	,	O
can	MD	O
enhance	VB	O
frontal	JJ	O
lobe	NN	O
function	NN	O
or	CC	O
be	VB	O
neuroprotective	JJ	O
.	.	O

It	PRP	O
can	MD	O
also	RB	O
correlate	VB	O
with	IN	O
gamma-aminobutyric	JJ	O
acid	NN	O
(	(	O
GABA	NNP	O
)	)	O
-homocarnosine	NN	O
interaction	NN	O
,	,	O
with	IN	O
possible	JJ	O
anticonvulsive	JJ	O
effects	NNS	O
.	.	O

We	PRP	O
investigated	VBD	O
31	CD	O
children	NNS	O
with	IN	O
autistic	JJ	O
spectrum	NN	O
disorders	NNS	O
in	IN	O
an	DT	O
8-week	JJ	O
,	,	O
double-blinded	JJ	O
study	NN	O
to	TO	O
determine	VB	O
if	IN	O
800	CD	O
mg	JJ	O
L-carnosine	JJ	O
daily	NN	O
would	MD	O
result	VB	O
in	IN	O
observable	JJ	O
changes	NNS	O
versus	VBP	O
placebo	NN	O
.	.	O

Outcome	CC	O
measures	NNS	O
were	VBD	O
the	DT	O
Childhood	NNP	O
Autism	NNP	O
Rating	NNP	O
Scale	NNP	O
,	,	O
the	DT	O
Gilliam	NNP	O
Autism	NNP	O
Rating	NNP	O
Scale	NNP	O
,	,	O
the	DT	O
Expressive	NNP	O
and	CC	O
Receptive	NNP	O
One-Word	NNP	O
Picture	NNP	O
Vocabulary	NNP	O
tests	NNS	O
,	,	O
and	CC	O
Clinical	NNP	O
Global	NNP	O
Impressions	NNP	O
of	IN	O
Change	NNP	O
.	.	O

Children	NNP	O
on	IN	O
placebo	NN	O
did	VBD	O
not	RB	O
show	VB	O
statistically	RB	O
significant	JJ	O
changes	NNS	O
.	.	O

After	IN	O
8	CD	O
weeks	NNS	O
on	IN	O
L-carnosine	NNP	O
,	,	O
children	NNS	O
showed	VBD	O
statistically	RB	O
significant	JJ	O
improvements	NNS	O
on	IN	O
the	DT	O
Gilliam	NNP	O
Autism	NNP	O
Rating	NNP	O
Scale	NNP	O
(	(	O
total	JJ	O
score	NN	O
and	CC	O
the	DT	O
Behavior	NNP	O
,	,	O
Socialization	NNP	O
,	,	O
and	CC	O
Communication	NNP	O
subscales	NNS	O
)	)	O
and	CC	O
the	DT	O
Receptive	JJ	O
One-Word	NNP	O
Picture	NNP	O
Vocabulary	NNP	O
test	NN	O
(	(	O
all	DT	O
P	NNP	O
<	NNP	O
.05	NNP	O
)	)	O
.	.	O

Improved	VBN	O
trends	NNS	O
were	VBD	O
noted	VBN	O
on	IN	O
other	JJ	O
outcome	JJ	O
measures	NNS	O
.	.	O

Although	IN	O
the	DT	O
mechanism	NN	O
of	IN	O
action	NN	O
of	IN	O
L-carnosine	NNP	O
is	VBZ	O
not	RB	O
well	RB	O
understood	RB	O
,	,	O
it	PRP	O
may	MD	O
enhance	VB	O
neurologic	JJ	O
function	NN	O
,	,	O
perhaps	RB	O
in	IN	O
the	DT	O
enterorhinal	JJ	O
or	CC	O
temporal	JJ	O
cortex	NN	O
.	.	O

Randomized	VBN	O
trial	NN	O
of	IN	O
combination	NN	O
chemotherapy	NN	O
in	IN	O
hormone-resistant	JJ	O
metastatic	JJ	O
prostate	NN	O
carcinoma	NN	O
.	.	O

A	DT	O
prospective	JJ	O
randomized	NN	O
study	NN	O
was	VBD	O
conducted	VBN	O
in	IN	O
51	CD	O
patients	NNS	O
with	IN	O
stage	JJ	O
D	NNP	O
hormone-resistant	JJ	O
prostatic	JJ	O
carcinoma	NN	O
,	,	O
comparing	VBG	O
a	DT	O
combination	NN	O
of	IN	O
doxorubicin	NN	O
and	CC	O
lomustine	NN	O
(	(	O
DC	NNP	O
)	)	O
with	IN	O
cyclophosphamide	NN	O
and	CC	O
5-FU	JJ	O
(	(	O
CF	NNP	O
)	)	O
.	.	O

Patients	NNS	O
were	VBD	O
assessed	VBN	O
objectively	RB	O
(	(	O
employing	VBG	O
National	NNP	O
Prostate	NNP	O
Cancer	NNP	O
Project	NNP	O
criteria	NNS	O
)	)	O
and	CC	O
subjectively	RB	O
(	(	O
using	VBG	O
a	DT	O
numerical	JJ	O
scoring	NN	O
scheme	NN	O
)	)	O
.	.	O

Each	DT	O
regimen	NN	O
was	VBD	O
well	RB	O
tolerated	VBN	O
with	IN	O
acceptable	JJ	O
levels	NNS	O
of	IN	O
myelosuppression	NN	O
.	.	O

The	DT	O
objective	JJ	O
partial	JJ	O
response	NN	O
rate	NN	O
was	VBD	O
57	CD	O
%	NN	O
for	IN	O
DC	NNP	O
and	CC	O
8	CD	O
%	NN	O
for	IN	O
CF	NNP	O
.	.	O

Objective	NNP	O
stabilization	NN	O
occurred	VBD	O
,	,	O
respectively	RB	O
,	,	O
in	IN	O
14	CD	O
%	NN	O
and	CC	O
44	CD	O
%	NN	O
of	IN	O
the	DT	O
patients	NNS	O
.	.	O

Similarly	RB	O
,	,	O
DC	NNP	O
demonstrated	VBD	O
a	DT	O
significantly	RB	O
superior	JJ	O
subjective	JJ	O
response	NN	O
rate	NN	O
(	(	O
partial	JJ	O
plus	CC	O
complete	JJ	O
)	)	O
of	IN	O
82	CD	O
%	NN	O
,	,	O
compared	VBN	O
to	TO	O
48	CD	O
%	NN	O
for	IN	O
CF	NNP	O
.	.	O

Patients	NNS	O
with	IN	O
poor	JJ	O
initial	JJ	O
performance	NN	O
status	NN	O
or	CC	O
liver	VB	O
involvement	NN	O
had	VBD	O
significantly	RB	O
lower	JJR	O
response	NN	O
rates	NNS	O
and	CC	O
reduced	JJ	O
survival	NN	O
.	.	O

Overall	JJ	O
,	,	O
there	EX	O
was	VBD	O
no	DT	O
significant	JJ	O
difference	NN	O
in	IN	O
survival	NN	O
between	IN	O
the	DT	O
two	CD	O
arms	NNS	O
,	,	O
reflecting	VBG	O
the	DT	O
similarity	NN	O
between	IN	O
DC	NNP	O
and	CC	O
CF	NNP	O
in	IN	O
total	JJ	O
objective	JJ	O
response	NN	O
rate	NN	O
(	(	O
partial	JJ	O
response	NN	O
plus	CC	O
stable	JJ	O
disease	NN	O
)	)	O
.	.	O

DC	NNP	O
provided	VBD	O
superior	JJ	O
palliation	NN	O
and	CC	O
was	VBD	O
well	RB	O
tolerated	VBN	O
by	IN	O
an	DT	O
essentially	RB	O
geriatric	JJ	O
population	NN	O
.	.	O

Modest	NNP	O
antihypertensive	JJ	O
effect	NN	O
of	IN	O
epanolol	NN	O
,	,	O
a	DT	O
beta	NN	O
1-selective	JJ	O
receptor	NN	O
blocker	NN	O
with	IN	O
beta	NN	O
1	CD	O
agonist	NN	O
activity	NN	O
:	:	O
an	DT	O
acute	NN	O
and	CC	O
long-term	JJ	O
hemodynamic	NN	O
study	NN	O
at	IN	O
rest	NN	O
and	CC	O
during	IN	O
exercise	NN	O
and	CC	O
double	JJ	O
crossover	NN	O
comparison	NN	O
with	IN	O
atenolol	NN	O
on	IN	O
ambulatory	JJ	O
blood	NN	O
pressure	NN	O
.	.	O

Beta-blockers	NNS	O
with	IN	O
less	JJR	O
cardiodepressive	JJ	O
effect	NN	O
than	IN	O
traditional	JJ	O
nonselective	JJ	O
beta	NN	O
(	(	O
1+2	CD	O
)	)	O
-blocking	VBG	O
agents	NNS	O
could	MD	O
be	VB	O
useful	JJ	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
hypertension	NN	O
,	,	O
provided	VBD	O
the	DT	O
reduction	NN	O
in	IN	O
blood	NN	O
pressure	NN	O
was	VBD	O
satisfactory	JJ	O
.	.	O

Epanolol	NNP	O
,	,	O
a	DT	O
selective	JJ	O
beta	NN	O
1-receptor	JJ	O
blocker	NN	O
with	IN	O
intrinsic	JJ	O
sympathomimetic	JJ	O
activity	NN	O
,	,	O
induced	VBD	O
a	DT	O
fall	NN	O
in	IN	O
intraarterial	JJ	O
pressure	NN	O
of	IN	O
8	CD	O
%	NN	O
at	IN	O
rest	NN	O
sitting	VBG	O
and	CC	O
11	CD	O
%	NN	O
during	IN	O
100	CD	O
W	NNP	O
bicycle	NN	O
exercise	NN	O
after	IN	O
the	DT	O
first	JJ	O
dose	NN	O
of	IN	O
200	CD	O
mg	NNS	O
in	IN	O
12	CD	C
patients	NNS	C
with	IN	C
essential	JJ	C
hypertension	NN	C
.	.	C

Heart	NNP	O
rate	NN	O
,	,	O
stroke	VBD	O
index	NN	O
,	,	O
and	CC	O
cardiac	JJ	O
index	NN	O
initially	RB	O
fell	VBD	O
by	IN	O
14	CD	O
%	NN	O
,	,	O
11	CD	O
%	NN	O
,	,	O
and	CC	O
23	CD	O
%	NN	O
,	,	O
respectively	RB	O
.	.	O

The	DT	O
total	JJ	O
peripheral	JJ	O
resistance	NN	O
index	NN	O
increased	VBD	O
by	IN	O
21	CD	O
%	NN	O
after	IN	O
2	CD	O
hours	NNS	O
,	,	O
and	CC	O
then	RB	O
reverted	VBD	O
towards	IN	O
the	DT	O
pretreatment	NN	O
level	NN	O
.	.	O

After	IN	O
10	CD	O
months	NNS	O
of	IN	O
epanolol	JJ	O
treatment	NN	O
(	(	O
mean	JJ	O
300	CD	O
mg/day	NN	O
)	)	O
,	,	O
the	DT	O
reduction	NN	O
in	IN	O
arterial	JJ	O
pressure	NN	O
was	VBD	O
5	CD	O
%	NN	O
at	IN	O
rest	NN	O
and	CC	O
10	CD	O
%	NN	O
during	IN	O
exercise	NN	O
.	.	O

Cardiac	NNP	O
index	NN	O
and	CC	O
heart	NN	O
rate	NN	O
were	VBD	O
still	RB	O
reduced	VBN	O
14-21	CD	O
%	NN	O
,	,	O
while	IN	O
total	JJ	O
peripheral	JJ	O
resistance	NN	O
was	VBD	O
unchanged	JJ	O
or	CC	O
slightly	RB	O
increased	VBN	O
(	(	O
2-10	CD	O
%	NN	O
)	)	O
.	.	O

Twenty-four	JJ	O
hour	NN	O
ambulatory	NN	O
blood	NN	O
pressure	NN	O
was	VBD	O
higher	JJR	O
on	IN	O
epanolol	NN	O
(	(	O
300	CD	O
mg/day	NN	O
)	)	O
than	IN	O
on	IN	O
atenolol	NN	O
(	(	O
150	CD	O
mg/day	NN	O
)	)	O
treatment	NN	O
(	(	O
137/97	CD	O
vs.	FW	O
128/91	CD	O
mmHg	NN	O
)	)	O
.	.	O

Thus	RB	O
,	,	O
the	DT	O
achieved	VBN	O
blood	NN	O
pressure	NN	O
reduction	NN	O
induced	VBN	O
by	IN	O
epanolol	NN	O
was	VBD	O
moderate	JJ	O
,	,	O
while	IN	O
other	JJ	O
characteristics	NNS	O
of	IN	O
beta-receptor	NN	O
blockade	NN	O
,	,	O
in	IN	O
particular	JJ	O
,	,	O
the	DT	O
reduction	NN	O
of	IN	O
heart	NN	O
rate	NN	O
and	CC	O
cardiac	JJ	O
output	NN	O
,	,	O
were	VBD	O
maintained	VBN	O
.	.	O

This	DT	O
suggests	VBZ	O
that	IN	O
the	DT	O
compound	NN	O
may	MD	O
be	VB	O
useful	JJ	O
for	IN	O
other	JJ	O
cardiovascular	JJ	C
disorders	NNS	C
,	,	O
e.g.	NN	O
,	,	O
angina	JJ	O
pectoris	NN	O
in	IN	O
patients	NNS	O
without	IN	O
hypertension	NN	C
or	CC	O
cardiac	JJ	C
arrhythmia	NN	C
.	.	O

Assessment	NN	O
in	IN	O
multisite	JJ	O
randomized	JJ	O
clinical	JJ	O
trials	NNS	O
of	IN	O
patients	NNS	O
with	IN	O
autistic	JJ	C
disorder	NN	C
:	:	O
the	DT	O
Autism	NNP	O
RUPP	NNP	O
Network	NNP	O
.	.	O

Research	NNP	O
Units	VBZ	O
on	IN	O
Pediatric	NNP	O
Psychopharmacology	NNP	O
.	.	O

Assessment	NNP	O
of	IN	O
autistic	JJ	O
disorder	NN	O
(	(	O
autism	NN	O
)	)	O
symptoms	NNS	O
,	,	O
primary	JJ	O
and	CC	O
secondary	JJ	O
,	,	O
poses	VBZ	O
more	RBR	O
challenging	JJ	O
problems	NNS	O
than	IN	O
ordinarily	RB	O
found	VBN	O
in	IN	O
multisite	JJ	O
randomized	JJ	O
clinical	JJ	O
trial	NN	O
(	(	O
RCT	NNP	O
)	)	O
assessments	NNS	O
.	.	O

For	IN	O
example	NN	O
,	,	O
subjects	NNS	O
may	MD	O
be	VB	O
uncommunicative	JJ	O
and	CC	O
extremely	RB	O
heterogeneous	JJ	O
in	IN	O
problem	NN	O
presentation	NN	O
,	,	O
and	CC	O
current	JJ	O
pharmacological	JJ	O
treatments	NNS	O
are	VBP	O
not	RB	O
likely	JJ	O
to	TO	O
alter	VB	O
most	JJS	O
core	NN	O
features	NNS	O
of	IN	O
autism	NN	O
.	.	O

The	DT	O
Autism	NNP	O
Research	NNP	O
Units	NNP	O
on	IN	O
Pediatric	NNP	O
Psychopharmacology	NNP	O
(	(	O
RUPP	NNP	O
Autism	NNP	O
Network	NNP	O
)	)	O
resolved	VBD	O
some	DT	O
of	IN	O
these	DT	O
problems	NNS	O
during	IN	O
the	DT	O
design	NN	O
of	IN	O
a	DT	O
risperidone	NN	O
RCT	NNP	O
in	IN	O
children/adolescents	NNS	A
.	.	O

The	DT	O
inappropriateness	NN	O
of	IN	O
the	DT	O
usual	JJ	O
anchors	NNS	O
for	IN	O
a	DT	O
Clinical	JJ	O
Global	NNP	O
Impression	NNP	O
of	IN	O
Severity	NNP	O
(	(	O
CGI-S	NNP	O
)	)	O
was	VBD	O
resolved	VBN	O
by	IN	O
defining	VBG	O
uncomplicated	JJ	O
autism	NN	C
without	IN	O
secondary	JJ	O
symptoms	NNS	O
as	IN	O
a	DT	O
CGI-S	NNP	O
of	IN	O
3	CD	O
,	,	O
mildly	RB	O
ill	JJ	O
.	.	O

The	DT	O
communication	NN	O
problems	NNS	O
,	,	O
compromising	VBG	O
use	NN	O
of	IN	O
the	DT	O
patient	NN	O
as	IN	O
an	DT	O
informant	NN	O
,	,	O
were	VBD	O
addressed	VBN	O
by	IN	O
several	JJ	O
strategies	NNS	O
,	,	O
including	VBG	O
careful	JJ	O
questioning	NN	O
of	IN	O
care	NN	O
providers	NNS	O
,	,	O
rating	NN	O
scales	NNS	O
,	,	O
laboratory	NN	O
tests	NNS	O
,	,	O
and	CC	O
physical	JJ	O
exams	NN	O
.	.	O

The	DT	O
broad	JJ	O
subject	JJ	O
heterogeneity	NN	O
requires	VBZ	O
outcome	JJ	O
measures	NNS	O
sensitive	JJ	O
to	TO	O
individual	JJ	O
change	NN	O
over	IN	O
a	DT	O
wide	JJ	O
spectrum	NN	O
of	IN	O
treatment	NN	O
response	NN	O
and	CC	O
side	NN	O
effects	NNS	O
.	.	O

The	DT	O
problems	NNS	O
of	IN	O
neuropsychologically	RB	O
testing	VBG	O
nonverbal	JJ	O
,	,	O
lower	JJR	O
functioning	NN	O
,	,	O
sometimes	RB	O
noncompliant	JJ	O
subjects	NNS	O
requires	VBZ	O
careful	JJ	O
instrument	JJ	O
selection/adaptation	NN	O
and	CC	O
flexible	JJ	O
administration	NN	O
techniques	NNS	O
.	.	O

The	DT	O
problems	NNS	O
of	IN	O
assessing	VBG	O
low-end	JJ	O
IQs	NNP	O
,	,	O
neglected	VBN	O
by	IN	O
most	JJS	O
standardized	JJ	O
test	NN	O
developers	NNS	O
,	,	O
was	VBD	O
resolved	VBN	O
by	IN	O
an	DT	O
algorithm	NN	O
of	IN	O
test	NN	O
hierarchy	NN	O
.	.	O

Scarcity	NN	O
of	IN	O
other	JJ	O
autism-adapted	JJ	O
cognitive	NN	O
and	CC	O
neuropsychological	JJ	O
tests	NNS	O
and	CC	O
lack	NN	O
of	IN	O
standardization	NN	O
required	VBN	O
development	NN	O
of	IN	O
a	DT	O
new	JJ	O
,	,	O
specially	RB	O
adapted	VBN	O
battery	NN	O
.	.	O

Reliability	NN	O
on	IN	O
the	DT	O
Autism	NNP	O
Diagnostic	NNP	O
Interview	NNP	O
(	(	O
currently	RB	O
the	DT	O
most	RBS	O
valid	JJ	O
diagnostic	JJ	O
instrument	NN	O
)	)	O
and	CC	O
other	JJ	O
clinician	JJ	O
instruments	NNS	O
required	VBN	O
extensive	JJ	O
cross-site	JJ	O
training	NN	O
(	(	O
in-person	JJ	O
,	,	O
videotape	NN	O
,	,	O
and	CC	O
teleconference	NN	O
sessions	NNS	O
)	)	O
.	.	O

Definition	NN	O
of	IN	O
a	DT	O
treatment	NN	O
responder	NN	O
required	VBN	O
focus	NN	O
on	IN	O
individually	RB	O
relevant	JJ	O
target	NN	O
symptoms	NNS	O
,	,	O
synthesis	NN	O
of	IN	O
possible	JJ	O
modest	JJ	O
improvements	NNS	O
in	IN	O
many	JJ	O
domains	NNS	O
,	,	O
and	CC	O
acceptance	NN	O
of	IN	O
attainable	JJ	O
though	IN	O
imperfect	JJ	O
goals	NNS	O
.	.	O

The	DT	O
assessment	NN	O
strategy	NN	O
developed	VBD	O
is	VBZ	O
implemented	VBN	O
in	IN	O
a	DT	O
RCT	NNP	O
of	IN	O
risperidone	NN	O
(	(	O
McDougle	NNP	O
et	RB	O
al.	RB	O
,	,	O
2000	CD	O
)	)	O
for	IN	O
which	WDT	O
the	DT	O
design	NN	O
and	CC	O
other	JJ	O
methodological	JJ	O
challenges	NNS	O
are	VBP	O
described	VBN	O
elsewhere	RB	O
(	(	O
Scahill	NNP	O
et	VBZ	O
al.	RB	O
,	,	O
2000	CD	O
)	)	O
.	.	O

Some	DT	O
of	IN	O
these	DT	O
problems	NNS	O
and	CC	O
solutions	NNS	O
are	VBP	O
partially	RB	O
shared	VBN	O
with	IN	O
RCTs	NNP	O
of	IN	O
other	JJ	O
treatments	NNS	O
and	CC	O
other	JJ	O
disorders	NNS	O
.	.	O

Dietary	NNP	O
lignan	NN	O
and	CC	O
proanthocyanidin	NN	O
consumption	NN	O
and	CC	O
colorectal	JJ	C
adenoma	NN	C
recurrence	NN	C
in	IN	O
the	DT	O
Polyp	NNP	O
Prevention	NNP	O
Trial	NNP	O
.	.	O

Lignans	NNPS	O
and	CC	O
proanthocyanidins	NNS	O
are	VBP	O
plant	NN	O
polyphenols	NNS	O
that	WDT	O
have	VBP	O
shown	VBN	O
protective	JJ	O
properties	NNS	O
against	IN	O
colorectal	JJ	C
neoplasms	NNS	C
in	IN	O
some	DT	O
human	JJ	O
studies	NNS	O
.	.	O

Using	VBG	O
logistic	JJ	O
regression	NN	O
,	,	O
we	PRP	O
estimated	VBD	O
odds	NNS	O
ratios	NNS	O
(	(	O
ORs	NNP	O
)	)	O
and	CC	O
95	CD	O
%	NN	O
confidence	NN	O
intervals	NNS	O
(	(	O
CIs	NNP	O
)	)	O
to	TO	O
prospectively	RB	O
evaluate	VB	O
the	DT	O
association	NN	O
between	IN	O
lignan	NN	O
and	CC	O
proanthocyanidin	JJ	O
intake	NN	O
,	,	O
estimated	VBN	O
from	IN	O
databases	NNS	O
linked	VBN	O
to	TO	O
a	DT	O
food	NN	O
frequency	NN	O
questionnaire	NN	O
,	,	O
and	CC	O
adenoma	JJ	O
recurrence	NN	O
in	IN	O
1,859	CD	O
participants	NNS	O
of	IN	O
the	DT	O
Polyp	NNP	O
Prevention	NNP	O
Trial	NNP	O
.	.	O

Overall	NNP	O
,	,	O
individual	NN	O
or	CC	O
total	JJ	O
lignans	NNS	O
or	CC	O
proanthocyanidins	NNS	O
were	VBD	O
not	RB	O
associated	VBN	O
with	IN	O
colorectal	JJ	O
adenoma	NN	O
recurrence	NN	O
.	.	O

However	RB	O
,	,	O
in	IN	O
sex-specific	JJ	O
analyses	NNS	O
,	,	O
total	JJ	O
lignan	JJ	O
intake	NN	O
was	VBD	O
positively	RB	O
associated	VBN	O
with	IN	O
any	DT	O
adenoma	JJ	O
recurrence	NN	O
in	IN	O
women	NNS	O
(	(	O
highest	JJS	O
vs.	NN	O
lowest	JJS	O
lignan	JJ	O
intake	NN	O
quartile	NN	O
OR	NNP	O
=	VBZ	O
2.07	CD	O
,	,	O
95	CD	O
%	NN	O
CI	NNP	O
:	:	O
1.22-3.52	JJ	O
,	,	O
p	JJ	O
trend	NN	O
=	VBZ	O
0.004	CD	O
)	)	O
but	CC	O
not	RB	O
in	IN	O
men	NNS	O
(	(	O
p	JJ	O
interaction	NN	O
=	NNP	O
0.04	CD	O
)	)	O
.	.	O

To	TO	O
conclude	VB	O
,	,	O
dietary	JJ	O
lignan	NN	O
and	CC	O
proanthocyanidin	NN	O
consumption	NN	O
were	VBD	O
not	RB	O
generally	RB	O
related	VBN	O
to	TO	O
colorectal	JJ	O
adenoma	JJ	O
recurrence	NN	O
;	:	O
however	RB	O
,	,	O
high	JJ	O
lignan	NNS	O
intake	VBP	O
may	MD	O
increase	VB	O
the	DT	O
risk	NN	O
of	IN	O
adenoma	JJ	O
recurrence	NN	O
in	IN	O
women	NNS	SE
.	.	SE

